<SEC-DOCUMENT>0000200406-25-000038.txt : 20250213
<SEC-HEADER>0000200406-25-000038.hdr.sgml : 20250213
<ACCEPTANCE-DATETIME>20250213160739
ACCESSION NUMBER:		0000200406-25-000038
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		168
CONFORMED PERIOD OF REPORT:	20241229
FILED AS OF DATE:		20250213
DATE AS OF CHANGE:		20250213

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1229

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03215
		FILM NUMBER:		25620252

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>jnj-20241229.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:a7478940-65f4-4b69-a475-f625bf9a358e,g:8ea82ba0-2a78-4425-b720-89454b578aab,d:4b4bd2fffa0147e7914e1841a5c21924-->
<html xmlns:srt="http://fasb.org/srt/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:jnj="http://www.jnj.com/20241229" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>jnj-20241229</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-46">0000200406</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-47">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-48">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-49">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-50">Johnson &amp; Johnson</ix:nonNumeric><ix:nonNumeric contextRef="c-10" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-539">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-11" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-540">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-10" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-541">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-11" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-542">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-11" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-543">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-10" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-544">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-10" name="us-gaap:SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration" id="f-579">http://fasb.org/us-gaap/2024#AccountsPayableCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-11" name="us-gaap:SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration" id="f-580">http://fasb.org/us-gaap/2024#AccountsPayableCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-107" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="f-767">P25Y</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-905">http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-12" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-906">http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-2949">http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="jnj-20241229.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="employee"><xbrli:measure>jnj:Employee</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>jnj:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:unit id="stockbasedcompensationplans"><xbrli:measure>jnj:StockBasedCompensationPlans</xbrli:measure></xbrli:unit><xbrli:unit id="segment2"><xbrli:measure>jnj:segment</xbrli:measure></xbrli:unit><xbrli:unit id="claimant"><xbrli:measure>jnj:claimant</xbrli:measure></xbrli:unit><xbrli:unit id="cases"><xbrli:measure>jnj:cases</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.150NotesDueNovember2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A3.20NotesDueNovember2032Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A3.350NotesDueNovember2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A3.550NotesDueNovember2044Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-02-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">jnj:KenvueIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-08</xbrli:startDate><xbrli:endDate>2023-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">jnj:KenvueIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-08</xbrli:startDate><xbrli:endDate>2023-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">jnj:KenvueIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">jnj:JohnsonJohnsonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-08</xbrli:startDate><xbrli:endDate>2023-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">jnj:KenvueIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">jnj:JohnsonJohnsonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">jnj:KenvueIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-23</xbrli:startDate><xbrli:endDate>2023-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">jnj:KenvueIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">jnj:JohnsonJohnsonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-23</xbrli:startDate><xbrli:endDate>2023-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">jnj:YellowJerseyTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">jnj:OtherSovereignSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">jnj:OtherSovereignSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-30</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-30</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-05-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-15</xbrli:startDate><xbrli:endDate>2024-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-05-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-17</xbrli:startDate><xbrli:endDate>2024-05-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ProteologixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A055NotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A055NotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.80DebenturesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.80DebenturesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A130NotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A130NotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.90DebenturesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.90DebenturesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.20DebenturesDue2032Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.20DebenturesDue2032Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95DebenturesDue2034Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95DebenturesDue2034Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.35DebenturesDue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.35DebenturesDue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55DebenturesDue2044Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55DebenturesDue2044Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.25DebenturesDue2054Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.25DebenturesDue2054Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:QualifiedPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:QualifiedPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:NonQualifiedPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:NonQualifiedPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:FundedPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:FundedPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:UnfundedPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:UnfundedPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-02</xbrli:startDate><xbrli:endDate>2025-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">jnj:December172018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">jnj:A2022LongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-471"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-473"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-475"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-476"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-477"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-478"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-479"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-483"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-484"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-485"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-488"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-489"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-491"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-495"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-496"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-498"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-499"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-500"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-534"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-537"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-539"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-540"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-542"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-544"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-545"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-547"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-548"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-553"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-555"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-556"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-557"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-558"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-559"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-560"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-561"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-562"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-563"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-564"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-565"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-566"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-570"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-571"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-573"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-574"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-577"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-580"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-581"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-582"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-583"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-584"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-585"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-586"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-587"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-588"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-589"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-590"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-591"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-592"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-593"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-595"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-596"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-597"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-598"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-599"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-600"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-613"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-624"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TECVAYLIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TECVAYLIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TECVAYLIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TECVAYLIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TECVAYLIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-631"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TECVAYLIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-632"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TECVAYLIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-633"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TECVAYLIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-634"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TECVAYLIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-635"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-638"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-639"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-640"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-641"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-642"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-643"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-644"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-645"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-646"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-647"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-648"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-649"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-650"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-651"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-652"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-653"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-654"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-655"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-656"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-657"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-658"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-659"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-661"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-662"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-663"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-664"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-665"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-666"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-668"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-669"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-670"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-671"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-672"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-673"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-674"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-675"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-676"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-677"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-678"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-679"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-680"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherPulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-681"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherPulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-682"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherPulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-683"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherPulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-684"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherPulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-685"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherPulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-686"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherPulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-687"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherPulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-688"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherPulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-689"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-690"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-691"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-692"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-693"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-694"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-695"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-696"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-697"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-698"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-699"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-700"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-705"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-707"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-708"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-711"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-716"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-722"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-724"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-725"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-732"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ELECTROPHYSIOLOGYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-733"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ELECTROPHYSIOLOGYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-734"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ELECTROPHYSIOLOGYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-735"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ELECTROPHYSIOLOGYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-736"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ELECTROPHYSIOLOGYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-737"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ELECTROPHYSIOLOGYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-738"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ELECTROPHYSIOLOGYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-739"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ELECTROPHYSIOLOGYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-740"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ELECTROPHYSIOLOGYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-741"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AbiomedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-742"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AbiomedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-743"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AbiomedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-744"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AbiomedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-745"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AbiomedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-746"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AbiomedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-747"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AbiomedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-748"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AbiomedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-749"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AbiomedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-750"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-751"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-752"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-753"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-754"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-755"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-756"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-757"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-758"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-759"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherCardiovascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-760"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherCardiovascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-761"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherCardiovascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-762"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherCardiovascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-763"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherCardiovascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-764"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherCardiovascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-765"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherCardiovascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-766"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherCardiovascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-767"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherCardiovascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-768"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-769"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-770"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-771"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-772"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-773"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-774"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-775"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-776"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-777"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-778"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-779"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-780"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-781"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-782"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-783"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-784"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-785"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-786"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-787"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-788"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-789"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-790"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-791"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-792"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-793"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-794"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-795"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-796"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-797"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-798"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-799"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-800"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-809"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-810"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-812"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-813"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-817"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-818"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-819"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-820"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-822"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-824"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-826"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-827"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-829"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-832"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-833"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-834"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-835"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-836"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-837"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-838"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-839"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-840"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-841"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-842"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-843"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-844"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-845"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-846"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-847"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-848"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-849"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-850"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-851"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-852"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-853"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-854"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-855"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-856"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-857"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-858"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-859"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-860"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-861"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-862"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-863"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-864"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-865"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-866"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-867"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-868"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-869"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-870"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-871"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-872"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-873"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-874"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-875"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-876"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-877"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-878"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-879"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-880"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-881"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-882"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-883"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-884"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-885"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-886"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-887"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-888"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-889"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-890"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-891"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-892"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-893"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-894"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-895"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-896"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-897"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-898"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-899"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-900"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-902"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-903"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-904"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-905"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-906"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-907"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-909"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-911"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-912"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-914"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-916"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-917"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-918"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-919"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-920"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-921"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-922"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-923"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-924"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-925"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-926"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-928"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-929"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-931"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-932"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-933"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-934"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-935"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-936"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-937"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-938"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-939"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-940"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-941"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-942"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:VWaveLtd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-943"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-944"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:LaminarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-945"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-946"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-947"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-948"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-949"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-950"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:IntraCellularTherapiesInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-951"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:IntraCellularTherapiesInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-952"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ProteologixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-20</xbrli:startDate><xbrli:endDate>2024-06-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-953"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ProteologixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-954"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ProteologixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-955"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ProteologixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-956"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ProteologixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-957"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-958"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-959"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-960"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-961"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-31</xbrli:startDate><xbrli:endDate>2024-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-962"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-963"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-964"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AmbrxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-965"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AmbrxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-966"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AmbrxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-967"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AmbrxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-968"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-969"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-22</xbrli:startDate><xbrli:endDate>2022-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-970"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jnj:NonTradeableContingentValueRightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-22</xbrli:startDate><xbrli:endDate>2022-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-971"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-972"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ImpellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-973"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ClassIRecommendationForImpellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-974"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-975"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-976"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-977"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-978"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">jnj:VWaveLtd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-08</xbrli:startDate><xbrli:endDate>2024-10-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-979"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">jnj:VWaveLtd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-08</xbrli:startDate><xbrli:endDate>2024-10-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-980"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">jnj:VWaveLtd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-981"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">jnj:YellowJerseyTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-11</xbrli:startDate><xbrli:endDate>2024-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-982"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">jnj:YellowJerseyTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-983"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">jnj:LaminarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-984"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">jnj:LaminarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-985"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:AcclarentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-986"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:PonvoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-987"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:InghamVsJohnsonJohnsonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-988"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:InghamVsJohnsonJohnsonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-989"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:InghamVsJohnsonJohnsonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-990"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-991"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-992"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-20</xbrli:startDate><xbrli:endDate>2024-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-993"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:MesotheliomaAndStateClaimsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-994"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-30</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-995"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-996"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-997"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-998"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-999"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AsrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1000"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PinnacleAcetabularCupSystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PelvicMeshesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RisperdalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1004"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ElmironMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1005"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:DePuyASRU.S.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1008"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1009"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1010"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:RDRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1011"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:RDRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1012"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:RDRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1013"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:OrthopaedicsRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:OrthopaedicsRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1015"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:OrthopaedicsRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1016"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:OrthopaedicsRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1017"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:OrthopaedicsRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1018"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:CostsOfGoodsAndServicesSoldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:CostsOfGoodsAndServicesSoldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:CostsOfGoodsAndServicesSoldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">jnj:KenvueIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-23</xbrli:startDate><xbrli:endDate>2023-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1025"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">jnj:KenvueIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-23</xbrli:startDate><xbrli:endDate>2023-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-08-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1027"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">jnj:KenvueIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">jnj:JohnsonJohnsonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1028"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">jnj:KenvueIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">jnj:JohnsonJohnsonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:ConsumerHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1030"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:ConsumerHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-23</xbrli:startDate><xbrli:endDate>2023-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">jnj:KenvueIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:ConsumerHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">jnj:JohnsonJohnsonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1032"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-23</xbrli:startDate><xbrli:endDate>2023-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1033"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-23</xbrli:startDate><xbrli:endDate>2023-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1034"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-23</xbrli:startDate><xbrli:endDate>2023-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1035"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-30</xbrli:startDate><xbrli:endDate>2024-12-29</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.016%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:11pt;font-weight:700;line-height:110%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:11pt;font-weight:700;line-height:110%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:11pt;font-weight:700;line-height:110%">Washington,&#160;D.C. 20549</span></div><div style="margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.994%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:11pt;font-weight:700;line-height:110%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.419%"><tr><td style="width:1.0%"/><td style="width:2.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="f-2">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:130%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:9pt;font-weight:700;line-height:110%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December 29</ix:nonNumeric>, 2024</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:9pt;font-weight:700;line-height:110%">or</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:2.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Transition Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></div><div><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:9pt;font-weight:700;line-height:115%">for the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:9pt;font-weight:700;line-height:110%">Commission file number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">1-3215</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:110%">Johnson &amp; Johnson</span><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:110%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:9pt;font-weight:700;line-height:110%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.624%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.489%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">New Jersey</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">22-1024240</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:700;line-height:130%">(State of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:700;line-height:130%">(I.R.S. Employer Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:110%">One Johnson&#160;&amp; Johnson Plaza</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:110%">New Brunswick, New Jersey</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">08933</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:700;line-height:130%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:700;line-height:130%">(Zip Code)</span></td></tr></table></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">One Johnson &amp; Johnson Plaza</ix:nonNumeric> </span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">New Brunswick</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-11">New Jersey</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">08933</ix:nonNumeric> </span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">732</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">524-0400</ix:nonNumeric> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.971%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:100%">SECURITIES REGISTERED PURSUANT TO SECTION&#160;12(b) OF THE ACT</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:41.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:700;line-height:130%">Title of each class</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:700;line-height:130%">Trading Symbol</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:18pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:700;line-height:130%">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-15">Common Stock, Par Value $1.00</ix:nonNumeric></span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-16">JNJ</ix:nonNumeric></span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-18">1.150% Notes Due November 2028</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-19">JNJ28</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 19pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-4" name="dei:Security12bTitle" id="f-21">3.20% Notes Due November 2032</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-4" name="dei:TradingSymbol" id="f-22">JNJ32</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 19pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-4" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-23">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-5" name="dei:Security12bTitle" id="f-24">1.650% Notes Due May 2035</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-5" name="dei:TradingSymbol" id="f-25">JNJ35</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 19pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-5" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-26">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-6" name="dei:Security12bTitle" id="f-27">3.350% Notes Due November 2036</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-6" name="dei:TradingSymbol" id="f-28">JNJ36A</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 19pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-6" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-29">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-7" name="dei:Security12bTitle" id="f-30">3.550% Notes Due November 2044</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-7" name="dei:TradingSymbol" id="f-31">JNJ44</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 19pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-7" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-32">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-33">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#254;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">o</span></div><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Exchange Act.&#160;&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">o</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-34">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#254;</span></div><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Exchange Act during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-35">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#254;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">o</span></div><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-36">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#254;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">o</span></div><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange&#160; Act.</span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.003%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.003%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-37">Large accelerated filer</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%">&#9745;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%">Non-accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-38">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-39">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">o</span></div><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes&#160;<ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-40">&#9745;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">o</span></div><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">o</span></div><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-41">o</ix:nonNumeric></span></div><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#9744;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-42">&#254;</ix:nonNumeric></span></div><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">The aggregate market value of the Common Stock held by non-affiliates computed by reference to the price at which the Common Stock was last sold as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter was approximately $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-9" name="dei:EntityPublicFloat" scale="9" id="f-43">352</ix:nonFraction> billion.</span></div><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">On February 6, 2025, there were <ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-44">2,407,616,693</ix:nonFraction> shares of Common Stock outstanding.</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-45" escape="true"><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:110%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.153%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%">Part III:</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%">Portions of the registrant&#8217;s proxy statement for its 2025 annual meeting of shareholders to be filed within 120&#160;days after the close of the registrant&#8217;s fiscal year (the &#8220;Proxy Statement&#8221;), are incorporated by reference to this report on Form 10-K (this &#8220;Report&#8221;).</span></div></td></tr></table></div></ix:nonNumeric><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_7"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.078%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.110%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Item</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Page</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #eb1700;padding:0 1pt"/></tr><tr><td colspan="12" style="border-top:0.5pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_13">P</a><a style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_13">art</a><a style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_13">&#160;I</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_16">1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_19">General</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_19">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_22">Segments of business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_22">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_25">Geographic areas</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_25">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_28">Raw materials</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_28">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_31">Patents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_31">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_34">Trademarks</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_37">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_37">Seasonality</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_37">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_40">Competition</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_40">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_43">Environment</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_43">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_46">Regulation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_46">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_49">Employees and human capital management</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_49">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_52">Available information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_52">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_55">1A.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_55">Risk factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_55">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_58">1B.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_58">Unresolved staff comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_58">17</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_61">1C.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_61">Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_61">17</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_64">2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_64">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_64">18</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_67">3</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_67">Legal proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_67">18</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_70">4</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_70">Mine safety disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_70">18</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_73">Executive officers of the registrant</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_73">19</a></span></div></td></tr><tr style="height:3pt"><td colspan="12" style="border-bottom:0.5pt solid #eb1700;padding:0 1pt"/></tr><tr><td colspan="12" style="border-top:0.5pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_76">P</a><a style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_76">art</a><a style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_76">&#160;II</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_79">5</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_79">Market for </a><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_79">r</a><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_79">egistrant&#8217;s </a><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_79">c</a><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_79">ommon </a><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_79">e</a><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_79">quity, </a><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_79">r</a><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_79">elated </a><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_79">s</a><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_79">tockholder </a><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_79">m</a><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_79">atters and </a><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_79">i</a><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_79">ssuer </a><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_79">p</a><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_79">urchases of </a><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_79">e</a><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_79">quity&#160;</a><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_79">s</a><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_79">ecurities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_79">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_82">6</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_82">(Reserved)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_82">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_88">7</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_88">Management&#8217;s discussion and analysis of results of operations and financial condition</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_88">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_109">7A.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_109">Quantitative and qualitative disclosures about market risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_109">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_112">8</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_112">Financial statements and supplementary data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_112">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_250">9</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_250">Changes in and disagreements with accountants on accounting and financial disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_250">113</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_253">9A.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_253">Controls and procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_253">113</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_256">9B.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_256">Other information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_256">113</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_259">9C.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_259">Disclosure</a><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_259"> regarding foreign jurisdictions that prevent inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_259">113</a></span></div></td></tr><tr style="height:3pt"><td colspan="12" style="border-bottom:0.5pt solid #eb1700;padding:0 1pt"/></tr><tr><td colspan="12" style="border-top:0.5pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_262">P</a><a style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_262">art</a><a style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_262">&#160;III</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_265">10</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_265">Directors, executive officers and corporate governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_265">114</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_268">11</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_268">Executive compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_268">114</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_271">12</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_271">Security ownership of certain beneficial owners and management and related stockholder matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_271">114</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_274">13</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_274">Certain relationships and related transactions, and director independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_274">115</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_277">14</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_277">Principal accountant fees and services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_277">115</a></span></div></td></tr><tr style="height:3pt"><td colspan="12" style="border-bottom:0.5pt solid #eb1700;padding:0 1pt"/></tr><tr><td colspan="12" style="border-top:0.5pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_280">P</a><a style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_280">art</a><a style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_280">&#160;IV</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_283">15</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_283">Exhibits and financial statement schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_283">116</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_286">16</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_286">Form 10-K summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_286">116</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_289">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_289">117</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_292">Exhibit&#160;index</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_292">119</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_10"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cautionary note regarding forward-looking statements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">This Annual Report on Form 10-K and Johnson &amp; Johnson&#8217;s other publicly available documents contain &#8220;forward-looking statements&#8221; within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson &amp; Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect management&#8217;s assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;will,&#8221; &#8220;anticipates,&#8221; &#8220;estimates&#8221; and other words of similar meaning in conjunction with, among other things: discussions of future operations; expected operating results and financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives, including associated cost savings and other benefits; the Company&#8217;s strategy for growth; product development activities; regulatory approvals; market position and expenditures.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they&#160;are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Company&#8217;s control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Company&#8217;s actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include, but are not limited to:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:130%">Risks related to product development, market success and competition</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company&#8217;s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success; </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Challenges to the Company&#8217;s ability to secure and maintain adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products and resulting revenue and market share losses;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Increasingly aggressive and frequent challenges to the Company&#8217;s patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors;&#160;and</span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Allegations that the Company&#8217;s products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company&#8217;s ability to sell the products in question and require the payment of money damages and future royalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:130%">Risks related to product liability, litigation and regulatory activity</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Product efficacy or safety concerns, whether or not based on scientific evidence, potentially resulting in product withdrawals, recalls, regulatory action on the part of the United States Food and Drug Administration (U.S. FDA) (or international counterparts), declining sales, reputational damage, increased litigation expense and share price impact;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">The impact, including declining sales and reputational damage, of significant litigation or government action adverse to the&#160;Company, including product liability claims and allegations related to pharmaceutical marketing practices and contracting strategies;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">The impact of an adverse judgment or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, product liability, personal injury claims, securities class actions, government investigations, employment and other legal proceedings;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Increased scrutiny of the healthcare industry by government agencies and state attorneys general resulting in investigations and prosecutions, which carry the risk of significant civil and criminal penalties, including, but not limited to, debarment from government business; </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Failure to meet compliance obligations in compliance agreements with governments or government agencies, which could result in significant sanctions;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Potential changes to applicable laws and regulations affecting United States and international operations, including relating to: approval of new products; licensing and patent rights; sales and promotion of healthcare products; access to, and reimbursement and pricing for, healthcare products and services; environmental protection; and sourcing of raw materials;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Compliance with local regulations and laws that may restrict the Company&#8217;s ability to manufacture or sell its products in relevant markets, including requirements to comply with medical device reporting regulations and other requirements such as the European Union&#8217;s Medical Devices Regulation;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Changes in domestic and international tax laws and regulations, increasing audit scrutiny by tax authorities around the world may cause exposures to additional tax liabilities potentially in excess of existing reserves; and</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">The issuance of new or revised accounting standards by the Financial Accounting Standards Board and regulations by the Securities and Exchange Commission.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:130%">Risks related to the Company&#8217;s strategic initiatives and healthcare market trends</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payors of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints; </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Challenges to the Company&#8217;s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company, including the divestment of Kenvue Inc., may not be realized or may take longer to realize than expected; and</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:130%">Risks related to economic conditions, financial markets and operating internationally</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">The impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation, and the impact of such changes on raw material prices, supply chains market volatility and the pace of product development;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal&#160;systems; </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">The impact of global public health crises and pandemics;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Changes to global climate, extreme weather and natural disasters that could affect demand for the Company&#8217;s products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company&#8217;s products and operations; </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">The impact of global or economic changes or events, including global tensions and war; and</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">The impact of armed conflicts and terrorist attacks in the United States and other parts of the world, including social and economic disruptions and instability of financial and other markets.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:130%">Risks related to supply chain and operations</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Difficulties and delays in manufacturing, internally, through third-party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Interruptions and breaches of the Company&#8217;s information technology systems or those of the Company&#8217;s vendors, which could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action; </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Company&#8217;s products; and</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">The potential that the expected benefits and opportunities related to restructuring actions may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Investors also should carefully read the risk factors described in Item 1A of this Annual Report on Form 10-K for a description of certain risks that could, among other things, cause the Company&#8217;s actual results to differ materially from those expressed in its forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above and in Item 1A to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_13"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:26pt"><span style="color:#eb1700;font-family:'Johnson Display Medium',sans-serif;font-size:26pt;font-weight:400;line-height:120%">Part&#160;I</span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_16"></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Item 1. Business</span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_19"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">General</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Johnson&#160;&amp; Johnson and its subsidiaries (the Company) have approximately 138,100&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. Johnson&#160;&amp; Johnson is a holding company, with operating companies conducting business in virtually all countries of the world. The Company&#8217;s primary focus is products related to human health and well-being. Johnson&#160;&amp; Johnson was incorporated in the State of New Jersey in&#160;1887.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Chief Operating Decision Maker (CODM) is the Company's Chief Executive Officer (Principal Executive Officer). The Executive Committee is Johnson &amp; Johnson&#8217;s senior leadership team responsible for setting the strategy and priorities of the Company and driving accountability at all levels. Within the strategic parameters provided by the Executive Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies. </span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_22"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Segments of business</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company is organized into two business segments: Innovative Medicine and MedTech. Additional information required by this item is incorporated herein by reference to the narrative and tabular descriptions of segments and operating results under: Item 7. Management&#8217;s discussion and analysis of results of operations and financial condition of this Report; and Note&#160;17 Segments of business and geographic areas of the notes to consolidated financial statements included in Item 8 of this&#160;Report.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Innovative Medicine</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Innovative Medicine segment is focused on the following therapeutic areas: Immunology (e.g., rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis), Infectious Diseases (e.g.,&#160;HIV/AIDS), Neuroscience (e.g., mood disorders, neurodegenerative disorders and schizophrenia), Oncology (e.g., prostate cancer, hematologic malignancies, lung cancer and bladder cancer), Cardiovascular and Metabolism (e.g., thrombosis, diabetes and macular degeneration) and Pulmonary Hypertension (e.g., Pulmonary Arterial Hypertension). Medicines in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. Key products in the Innovative Medicine segment include: REMICADE (infliximab), a treatment for a number of immune-mediated inflammatory diseases; SIMPONI (golimumab), a subcutaneous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; SIMPONI ARIA (golimumab), an intravenous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis and active polyarticular juvenile idiopathic arthritis (pJIA) in people 2 years of age and older; STELARA (ustekinumab), a treatment for adults and children with moderate to severe plaque psoriasis, for adults with active psoriatic arthritis, for adults with moderately to severely active Crohn's disease and treatment of moderately to severely active ulcerative colitis; TREMFYA (guselkumab), a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis and ulcerative colitis; EDURANT (rilpivirine), PREZISTA (darunavir) and PREZCOBIX/REZOLSTA (darunavir/cobicistat), antiretroviral medicines for the treatment of human immunodeficiency virus (HIV) in combination with other antiretroviral products and SYMTUZA (darunavir/cobicistat/emtricitabine/tenofovir alafenamide), a once-daily single tablet regimen for the treatment of HIV; CONCERTA (methylphenidate HCl) extended-release tablets CII, a treatment for attention deficit hyperactivity disorder; INVEGA SUSTENNA/XEPLION (paliperidone palmitate), for the treatment of schizophrenia and schizoaffective disorder in adults; INVEGA TRINZA/TREVICTA (paliperidone palmitate), for the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA for at least four months; SPRAVATO (Esketamine), a nasal spray, used along with an oral antidepressant, to treat adults with treatment-resistant depression (TRD) and depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions; CARVYKTI (ciltacabtagene autoleucel), a chimeric antigen receptor (CAR)-T-cell therapy for the treatment of patients with relapsed/refractory multiple </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">1</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">myeloma; ZYTIGA (abiraterone acetate), a treatment for patients with prostate cancer; ERLEADA (apalutamide), a&#160;next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer; IMBRUVICA (ibrutinib), a&#160;treatment for certain B-cell malignancies, or blood cancers and chronic graft versus host disease; DARZALEX (daratumumab), a treatment for multiple myeloma; DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a treatment for multiple myeloma and light chain (AL) Amyloidosis; TECVAYLI (teclistamab-cqyv), a ready-to-use bispecific antibody for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy; XARELTO (rivaroxaban), an oral anticoagulant for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery, to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the treatment and reduction of risk of recurrence of DVT and PE to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) and peripheral artery disease (PAD), for the treatment and secondary prevention of thromboembolism in pediatric patients, and for thromboprophylaxis in pediatric patients following the Fontan procedure; OPSUMIT (macitentan) as monotherapy or in combination, indicated for the long-term treatment of pulmonary arterial hypertension (PAH); UPTRAVI (selexipag), the only approved oral and intravenous, selective IP receptor agonist targeting a prostacyclin pathway in PAH. Many of these medicines were developed in collaboration with strategic partners or are licensed from other companies and maintain active lifecycle development&#160;programs.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">MedTech</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The MedTech segment includes a broad portfolio of products used in the cardiovascular, orthopaedics, surgery, and vision categories. The Cardiovascular (previously referred to as Interventional solutions) portfolio includes electrophysiology products to treat heart rhythm disorders, the heart recovery portfolio (Abiomed) which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock, circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD), and neurovascular care that treats hemorrhagic and ischemic stroke. The Orthopaedics portfolio includes products and enabling technologies that support hips, knees, trauma, spine, sports, and others. The Surgery portfolios include advanced and general surgery technologies, as well as solutions that focus on breast aesthetics and reconstruction (Mentor). Vision products include ACUVUE brand contact lenses and TECNIS intraocular lenses for cataract surgery. These products are distributed to wholesalers, hospitals, and retailers and are used predominantly in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics.</span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_25"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Geographic areas</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company conducts business in virtually all countries of the world with the primary focus on products related to human health and well-being. The products made and sold in the international business include many of those described above under Segments of Business&#160;&#8211; Innovative Medicine and MedTech. However, the principal markets, products and methods of distribution in the international business vary with the country and the culture. The products sold in the international business include those developed in the U.S. and by subsidiaries abroad.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Investments and activities in some countries outside the U.S. are subject to higher risks than comparable U.S.&#160;activities because the investment and commercial climate may be influenced by financial instability in international economies, restrictive economic policies and political and legal system uncertainties.</span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_28"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Raw materials</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Raw materials essential to the Company's business are generally readily available from multiple sources. Where there are exceptions, the temporary unavailability of those raw materials would not likely have a material adverse effect on the financial results of the Company.</span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_31"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Patents</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company's subsidiaries have made a practice of obtaining patent protection on their products and processes where possible. They own, or are licensed under, a significant number of patents in the U.S. and other countries relating to their products, product uses, formulations and manufacturing processes, which in the aggregate are believed to be of material importance to the Company in the operation of its businesses. The Company&#8217;s subsidiaries face patent challenges from third parties, including challenges seeking to manufacture and market generic and biosimilar versions of the Company's key pharmaceutical products prior to expiration of the applicable patents covering those products. Significant legal proceedings </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">and claims involving the Company's patent and other intellectual property are described in Note 19 Legal proceedings&#8212;Intellectual property of the Notes to Consolidated Financial Statements included in Item 8 of this Report.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Sales of the Company&#8217;s largest product, collectively DARZALEX (daratumumab) and DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), accounted for approximately 13.1% of the Company's total revenues for fiscal 2024. Accordingly, the patents related to these products are believed to be material to the Company. Genmab A/S owns two patent families related to DARZALEX, and Janssen Biotech, Inc. has an exclusive license to those patent families. The two patent families both expire in the United States in 2029, and in Europe, compound/use patent protection in select countries extends to 2031/2032. Janssen Biotech, Inc. owns a separate patent portfolio related to DARZALEX FASPRO.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Sales of the Company&#8217;s second largest product, STELARA (ustekinumab) accounted for approximately 11.7% of the Company's total revenues for fiscal 2024. According to patent settlement and license agreements, the Company expects continued launches of biosimilar versions of STELARA in Europe and the United States in 2025 which will impact the Company&#8217;s sales of&#160;STELARA.</span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_34"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Trademarks</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company&#8217;s subsidiaries have made a practice of selling their products under trademarks and of obtaining protection for these trademarks by all available means. These trademarks are protected by registration in the U.S. and other countries where such products are marketed. The Company considers these trademarks in the aggregate to be of material importance in the operation of its businesses.</span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_37"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Seasonality</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Worldwide sales do not reflect any significant degree of seasonality; however, spending has typically been heavier in the fourth quarter of each year than in other quarters. This reflects increased spending decisions, principally for advertising and research and development activity.</span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_40"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In all of their product lines, the Company's subsidiaries compete with companies both locally and globally. Competition exists in&#160;all product lines without regard to the number and size of the competing companies involved. Competition in research, both&#160;internally and externally sourced, involving the development and the improvement of new and existing products and processes, is particularly significant. The development of new and innovative products, as well as protecting the underlying intellectual property of the Company&#8217;s product portfolio, is important to the Company's success in all areas of its business. The&#160;competitive environment requires substantial investments in continuing research. </span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_43"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Environment</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company is subject to a variety of environmental laws and regulations in the United States and other jurisdictions. The Company believes that its operations comply in all material respects with applicable environmental laws and regulations. The Company&#8217;s compliance with these requirements is not expected to have a material effect upon its capital expenditures, cash flows, earnings or competitive position.</span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_46"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Regulation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company&#8217;s businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation and enforcement. The Company is subject to costly and complex U.S. and foreign laws and governmental regulations, and any adverse regulatory action may materially adversely affect the Company's financial condition and business operations. In the U.S., the pharmaceutical product and medical technology industries have long been subject to regulation by various federal and state agencies, primarily as to product safety, efficacy, manufacturing, advertising, labeling and safety reporting. The exercise of broad regulatory powers by the U.S. Food and Drug Administration (the U.S. FDA) continues to result in increases in the amounts of testing and documentation required for U.S. FDA approval of new drugs and devices and a corresponding increase in the expense of product introduction. Similar trends are also evident in major markets outside of the U.S. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">3</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The medical device regulatory framework and the evolving privacy, data localization, and emerging cyber security laws and regulations around the world are examples of such increased regulation. Within the U.S., an increasing number of U.S. States have enacted comprehensive privacy laws, and federal regulators (e.g., the U.S. FDA, FTC and HHS) continue to stress the intersection of health and privacy as a compliance and enforcement priority. In the EU, multiple directives and laws (including NIS2, EHDS, the Data Act, the Cyber Resilience Act, and the AI Act) are rapidly changing privacy and cybersecurity compliance requirements while introducing new enforcement risks. In addition, China has introduced broad personal information protection and data security regulations, with more anticipated, thereby increasing China&#8217;s scrutiny of company compliance and data transfer practices. With other jurisdictions enacting similar privacy laws, local data protection authorities will force greater accountability on the collection, access and use of personal data in the healthcare industry. These laws can also restrict transfers of data across borders, potentially impacting how data-driven health care solutions are developed and deployed globally in a compliant manner. Moreover, as a result of the broad scale release and availability of Artificial Intelligence (AI) technologies such as generative AI, a global trend towards more comprehensive and nuanced regulation to ensure the ethical use, privacy, and security of AI is underway that includes standards for transparency, accountability, and fairness, which will require compliance developments or enhancements. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The regulatory agencies under whose purview the Company operates have administrative powers that may subject it to actions such as product withdrawals, recalls, seizure of products and other civil and criminal sanctions. In some cases, the Company&#8217;s subsidiaries may deem it advisable to initiate product recalls regardless of whether it has been required or directed to.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The U.S. FDA and regulatory agencies around the globe are also increasing their enforcement activities. If the U.S. FDA were to conclude that we are not in compliance with applicable laws or regulations, or that any of our pharmaceutical products or medical technologies are ineffective or pose an unreasonable safety risk, the U.S. FDA could ban such products, detain or seize adulterated or misbranded products, order a recall, repair, replacement, or refund of such products, withdraw approval for such products, refuse to grant pending applications for marketing authorization or require certificates of foreign governments for exports, and/or require us to notify health professionals and others that the products present unreasonable risks of substantial harm to the public health. The U.S. FDA may also assess civil or criminal penalties against us, our officers or employees and impose operating restrictions on a company-wide basis, or enjoin and/or restrain certain conduct resulting in violations of applicable law. The U.S. FDA may also recommend prosecution to the U.S. Department of Justice. Any adverse regulatory action, depending on its magnitude, may restrict us from effectively marketing and selling our products and limit our ability to obtain future clearances, classifications or approvals, and could result in a substantial modification to our business practices and operations. Equivalent enforcement mechanisms exist in different countries in which we conduct business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The costs of human healthcare have been and continue to be a subject of study, investigation and regulation by governmental agencies and legislative bodies around the world. In the U.S., attention has been focused by states, regulatory agencies and Congress on prices, profits, overutilization and the quality and costs of healthcare generally. Laws and regulations have been enacted to require adherence to strict compliance standards and prevent fraud and abuse in the healthcare industry. There is increased focus on interactions and financial relationships between healthcare companies and healthcare providers. Various state and federal transparency laws and regulations require disclosures of payments and other transfers of value made to certain healthcare practitioners, including physicians, teaching hospitals, and certain non-physician practitioners. Federal and foreign laws governing international business practices require strict compliance with anti-bribery standards and certain prohibitions with respect to payments to any foreign government official. Payors and Pharmacy Benefit Managers (PBMs) are a potent force in the marketplace, and increased attention is being paid to the impact of PBM practices on healthcare cost and access in the U.S.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:126%">Our business has been and continues to be affected by federal and state legislation that alters the pricing, coverage, and reimbursement landscape. At the federal level, in August 2022, President Biden signed into law the Inflation Reduction Act (IRA), which includes provisions that effectively authorize the government to establish prices for certain high-spend single-source drugs and biologics reimbursed by the Medicare program, starting in 2026 for Medicare Part D drugs and 2028 for Medicare Part B drugs. On August 29, 2023, the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) published the first &#8220;Selected Drug&#8221; list, which includes XARELTO and STELARA as well as IMBRUVICA, which is developed in collaboration and co-commercialized in the U.S. with Pharmacyclics LLC, an AbbVie company. The Selected Drug list also included other medicines targeting disease states that are prevalent in the Medicare population. Although CMS published an explanation for how it determined prices for selected drugs in December 2024, uncertainty remains as to the methodology used to determine these prices. The IRA specifies a ceiling price but not a minimum price for selected drugs and does not require CMS to use a specific framework for determining selected drug prices. In any event, we anticipate that the selected products will be subjected to a government-established price for the Medicare population beginning in 2026.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:126%">The IRA also contains provisions that impose rebates if certain prices increase at a rate that outpaces the rate of inflation, beginning October 1, 2022, for Medicare Part D drugs and January 1, 2023, for Medicare Part B drugs. Separate IRA provisions redesign the Medicare Part D benefit in various ways, including by shifting a greater portion of costs to manufacturers within certain coverage phases and replacing the Part D coverage gap discount program with a new manufacturer discounting program. Failure to comply with IRA provisions may subject manufacturers to various penalties, including civil monetary&#160;penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:126%">In July 2023, Janssen Pharmaceuticals, Inc. (Janssen) filed litigation against the U.S. Department of Health and Human Services as well as the Centers for Medicare and Medicaid Services challenging the constitutionality of the IRA's Medicare Drug Price Negotiation Program. The litigation requests a declaration that the IRA violates Janssen&#8217;s rights under the First Amendment and the Fifth Amendment to the Constitution and therefore that Janssen is not subject to the IRA&#8217;s mandatory pricing scheme. The impact of the IRA on our business and the broader pharmaceutical industry remains uncertain, as litigation filed by Janssen and other pharmaceutical companies remains ongoing and while CMS has publicly announced the maximum fair price for each of the selected drugs, implementation of the program is still in progress. In April 2024, Janssen appealed the district court&#8217;s denial of its summary judgment motion to the Third Circuit.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:126%">Additionally, we expect continued scrutiny on drug pricing and government price reporting from Congress, agencies, and other bodies at the federal and state levels, which may result in additional regulations or other mechanisms to increase pricing transparency and controls. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:126%">There are a number of additional bills pending in Congress and healthcare reform proposals at the state level that would affect drug pricing, including in the Medicare and Medicaid programs. This changing legal landscape has both positive and negative impacts on the U.S. healthcare industry with much remaining uncertain as to how various provisions of federal and state law, and potential modification or repeal of these laws, will ultimately affect the industry. The IRA and any other federal or state legislative change could affect the pricing and market conditions for our products.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:126%">In addition, business practices in the healthcare industry have come under increased scrutiny, particularly in the U.S., by government agencies and state attorneys general, and resulting investigations and prosecutions carry the risk of significant civil and criminal penalties. Of note is the increased enforcement activity by data protection authorities in various jurisdictions, particularly in the European Union, where significant fines have been levied on companies for data breaches, violations of privacy requirements, and unlawful cross-border data transfers. In the U.S., the Federal Trade Commission has stepped up enforcement of data privacy with several significant settlements (including settlements concerning the downstream sharing of personal information and use and disclosure of personal health data) and there have been a material increase in class-action lawsuits linked to the collection and use of biometric data and use of tracking technologies.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:126%">Further, the Company relies on global supply chains, and production and distribution processes, that are complex, and subject to increasing regulatory requirements that may affect sourcing, supply and pricing of materials used in the Company's products. These processes also are subject to complex and lengthy regulatory approvals.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">5</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_49"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Employees and human capital management</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">As of December&#160;29, 2024 and December 31, 2023 the number of employees was approximately:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.173%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employees</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">139,800&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">134,400&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Full-time equivalent (FTE) positions</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">138,100&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">131,900&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:4.55pt;font-weight:400;line-height:130%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.93pt">&#8220;Employee&#8221; is defined as an individual working full-time or part-time, excluding fixed term employees, interns and co-op employees. Employee data may not include full population from more recently acquired companies and individuals on long-term disability are excluded. Contingent workers, contractors and subcontractors are also excluded. Shockwave has been included in the fiscal 2024 headcount in the above table.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:4.55pt;font-weight:400;line-height:130%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.88pt">FTE represents the total number of full-time equivalent positions and does not reflect the total number of individual employees as some work part-time.</span></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Employees by region (in percentages)</span></div><div style="text-align:center"><img src="jnj-20241229_g2.jpg" alt="632" style="height:222px;margin-bottom:5pt;vertical-align:text-bottom;width:301px"/></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Strategy</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company believes that its employees are critical to its continued success and are an essential element of its long-term strategy. Management is responsible for ensuring that its policies and processes reflect and reinforce the Company's desired corporate culture, including policies and processes related to strategy, risk management, and ethics and compliance. The Company&#8217;s human capital management strategy is built on three fundamental focus areas:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Attracting and recruiting top talent</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Developing and retaining top talent</span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Empowering and inspiring talent</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Underpinning these focus areas are ongoing efforts to cultivate and foster a culture built on innovation, health, well-being and safety, inclusion and belonging where the Company's employees are encouraged to succeed both professionally and personally while helping the Company achieve its business goals.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Culture and employee engagement</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">At Johnson &amp; Johnson, employees are guided by Our Credo, which sets forth the Company's responsibilities to patients, consumers, customers, healthcare professionals, employees, communities and shareholders. Employees worldwide must adhere to the Company&#8217;s Code of Business Conduct, which sets fundamental requirements and serves as a foundation for the Company policies, procedures and guidelines, all of which provide additional guidance on expected employee behaviors in every market where it operates. The Company conducts global surveys that offer its employees the ability to provide feedback and valuable insight to help address potential human resources risks and identify opportunities to improve. In 2024, 94% of global employees across 73 countries participated in Our Credo Survey which was offered in 36 languages.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Growth and development</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">To lead in the changing healthcare landscape, it is crucial that the Company continue to attract and retain top talent. In 2024, the Company's voluntary turnover rate was 6.3%. The Company believes that its employees must be equipped with the right knowledge and skills and be provided with opportunities to grow and develop in their careers. Accordingly, professional development programs and educational resources are available to all employees. The Company's objective is to foster a learning culture that helps shape each person&#8217;s unique career path while creating a robust pipeline of talent to deliver on the Company&#8217;s long-term strategies. In furtherance of this objective, the Company deploys a global approach to ensure development is for everyone, regardless of where they are on their career journey. To prioritize learning, the Company recently held Johnson &amp; Johnson's second Global Learning Day. Employees were encouraged to set aside a full day to explore skill-building courses on J&amp;J Learn, the new state-of-the-art learning platform.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Our workforce</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">As stated in Our Credo, we are responsible to our employees who work with us throughout the world. The Company is committed to cultivating, fostering and advancing an inclusive, credo-based work environment for employees that recognizes and rewards based on merit. The Company is dedicated to the values in Our Credo and strives to meet the needs of its employees and stakeholders through compliance with law and the following evidence based strategies:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Sustain a global workforce of individuals with many different backgrounds, abilities, cultures and perspectives </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Maintain a work environment where each person&#8217;s dignity is respected and they have an opportunity to advance based on their merit</span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Drive innovation and growth with our business to serve markets around the world </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Our approach with respect to our workforce is guided by applicable laws, internal and external insights, global best practices and employee feedback.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Compensation and benefits</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">As part of the Company's total rewards philosophy, the Company offers competitive compensation and benefits to attract and retain top talent. The Company is committed to fair treatment in its compensation and benefits for employees at all levels. The Company observes legal minimum wage provisions and exceeds them where possible. The Company's total rewards offerings include an array of programs to support its employees' well-being, including annual performance incentive opportunities, pension and retirement savings programs, health and welfare benefits, paid time off, leave programs, flexible work schedules and employee assistance programs. </span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Health, wellness and safety</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company&#8217;s investment in employee health, well-being and safety is built on its conviction that advancing health for humanity starts with advancing the health of its employees. With the right awareness, focus, practices and tools, the Company works to ensure that all its employees around the world, as well as contingent workers, contractors and visitors to the Company's sites, can work safely. The Company has continuously expanded health and well-being programs throughout the Company and across the globe, incorporating new thinking and technologies to keep its offerings best-in-class and to help employees achieve their personal health goals. The programs and practices the Company provides&#8212;physical, mental, emotional and financial&#8212;help promote holistic employee health. The Company continues to address our employees needs through J&amp;J Flex, a hybrid model that empowers the Company&#8217;s office-based employees to find a balance of in-person and remote work, while preserving the Company's culture and need for face-to-face engagement and leadership. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">7</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_52"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Available information</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company&#8217;s main corporate website address is </span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">www.jnj.com</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">. The Company makes its SEC filings available on the Company&#8217;s website at </span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">www.investor.jnj.com/financials/sec-filings</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">, as soon as reasonably practicable after having been electronically filed or furnished to the SEC. The Company's SEC filings are also available at the SEC&#8217;s website at </span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">www.sec.gov</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Investors and the public should note that the Company also announces information through its press releases and media statements at </span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">www.jnj.com/mediacenter</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">, </span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">investor.jnj.com</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> and</span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> www.factsabouttalc.com</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">. We use these websites to communicate with investors and the public about our products, litigation and other matters. It is possible that the information we post to these websites could be deemed to be material information. Therefore, we encourage investors and others interested in the Company to review the information posted to these websites in conjunction with </span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">www.jnj.com</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">, the Company's SEC filings, press releases, public conference calls and webcasts.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In addition, the Restated Certificate of Incorporation, as amended, Amended and Restated By-Laws, the written charters of the Audit Committee, the Compensation&#160;&amp; Benefits Committee, the Nominating&#160;&amp; Corporate Governance Committee, the Regulatory Compliance &amp; Sustainability Committee, and the Science &amp; Technology Committee of the Board of Directors, and the Company&#8217;s Principles of Corporate Governance, Code of Business Conduct (for employees), Code of Business Conduct&#160;&amp; Ethics for Members of the Board of Directors and Executive Officers, and other corporate governance materials are available on the Company's website at </span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">www.investor.jnj.com/governance/corporate-governance-overview</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%"> </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">and will be provided without charge to any shareholder submitting a written request, as provided above. The information on </span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">www.jnj.com</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">,</span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> investor.jnj.com </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">and</span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> www.factsabouttalc.com</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> is not, and will not be deemed, a part of this Report or incorporated into any other filings the Company makes with the SEC.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_55"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Item 1A. Risk factors</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:129%">An investment in the Company&#8217;s common stock or debt securities involves risks and uncertainties. The Company seeks to identify, manage and mitigate risks to our business, but uncertainties and risks are difficult to predict and many are outside of the Company&#8217;s control and cannot therefore be eliminated. In addition to the other information in this report and the Company&#8217;s other filings with the SEC, investors should consider carefully the factors set forth below. Investors should be aware that it is not possible to predict or identify all such factors and that the following is not meant to be a complete discussion of all potential risks or uncertainties. If known or unknown risks or uncertainties materialize, the Company&#8217;s business, results of operations or financial condition could be adversely affected, potentially in a material way.</span></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:129%">Risks related to our business, industry and operations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:129%">The Company&#8217;s businesses operate in highly competitive product markets and competitive pressures could adversely affect the Company&#8217;s earnings.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:129%">The Company faces substantial competition in its two operating segments and in all geographic markets. The Company&#8217;s businesses compete with companies of all sizes on the basis of cost-effectiveness, technological innovations, intellectual property rights, product performance, real or perceived product advantages, pricing and availability and rate of reimbursement. The Company also competes with other market participants in securing rights to acquisitions, collaborations and licensing agreements with third parties. Competition for rights to product candidates and technologies may result in significant investment and acquisition costs and onerous agreement terms for the Company. Competitors&#8217; development of more effective or less costly products, and/or their ability to secure patent and other intellectual property rights and successfully market products ahead of the Company, could negatively impact sales of the Company&#8217;s existing products as well as its ability to bring new products to market despite significant prior investment in the related product development. The Company may also experience operational and financial risk in connection with acquisitions if we are unable to fully identify potential risks and liabilities associated with acquired businesses or products, successfully integrate operations and employees, and successfully identify and realize synergies with existing businesses while containing acquisition-related strain on our management, operations and financial resources.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:129%">For the Company&#8217;s Innovative Medicine businesses, loss of patent exclusivity for a product often is followed by a substantial reduction in sales as competitors gain regulatory approval for generic, biosimilar and other competing products and enter the market. For the Company&#8217;s MedTech businesses, technological innovation, product quality, reputation and customer service are especially important to competitiveness. Development by other companies of new or improved products, processes and technologies could threaten to make the Company&#8217;s products or technologies less desirable, less economical or obsolete. The Company&#8217;s business and operations will be negatively impacted if we are unable to introduce new products or technological advances that are safe, more effective, more effectively marketed or otherwise outperform those of our competitors. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:129%">Interruptions and delays in manufacturing operations could adversely affect the Company&#8217;s business, sales and&#160;reputation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:129%">The Company&#8217;s manufacturing of products requires the timely delivery of sufficient amounts of complex, high-quality components and materials. The Company&#8217;s subsidiaries operate 64 manufacturing facilities as well as sourcing from thousands of suppliers around the world. The Company has in the past, and may in the future, face unanticipated interruptions and delays in manufacturing through its internal or external supply chain. Manufacturing disruptions can occur for many reasons including regulatory action, production quality deviations or safety issues, labor disputes, labor shortages, site-specific incidents (such as fires), natural disasters such as hurricanes and other severe weather events, raw material shortages, lack of available inspectors, political unrest, terrorist attacks and epidemics or pandemics. Such delays and difficulties in manufacturing can result in product shortages, declines in sales and reputational impact as well as significant remediation and related costs associated with addressing the&#160;shortage. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:129%">The Company relies on third parties to manufacture and supply certain of our products. Any failure by or loss of a third-party manufacturer or supplier could result in delays and increased costs, which may adversely affect our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:129%">The Company relies on third parties to manufacture and supply certain of our raw materials, component parts and products. We depend on these third-party manufacturers to allocate to us a portion of their manufacturing capacity sufficient to meet our needs, to produce products of acceptable quality and at acceptable manufacturing yields and to deliver those products to us on a timely basis and at acceptable prices. However, we cannot guarantee that these third-party manufacturers will be able to meet our near-term or long-term manufacturing requirements, which could result in lost sales and have an adverse effect on our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">9</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:127%">Other risks associated with our reliance on third parties to manufacture these products include reliance on the third party for regulatory compliance and quality assurance, misappropriation of the Company&#8217;s intellectual property, limited ability to manage our inventory, possible breach of the manufacturing agreement by the third party and the possible termination or nonrenewal of the manufacturing agreement by the third party at a time that is costly or inconvenient for us. Moreover, if any of our third-party manufacturers suffers any damage to facilities, loses benefits under material agreements, experiences power outages, encounters financial difficulties, is unable to secure necessary raw materials from its suppliers or suffers any other reduction in efficiency, the Company may experience significant business disruption. In the event of any such disruption, the Company would need to seek and source other qualified third-party manufacturers, likely resulting in further delays and increased costs which could affect our business adversely.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:127%">Counterfeit versions of our products could harm our patients and have a negative impact on our revenues, earnings, reputation and business. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:127%">Our industry continues to be challenged by the vulnerability of distribution channels to illegal counterfeiting and the presence of counterfeit products in a growing number of markets and over the Internet. Third parties may illegally distribute and sell counterfeit versions of our products, which do not meet our rigorous manufacturing and testing standards. To distributors and patients, counterfeit products may be visually indistinguishable from the authentic version. Counterfeit medicines pose a risk to patient health and safety because of the conditions under which they are manufactured &#8211; often in unregulated, unlicensed, uninspected and unsanitary sites &#8211; as well as the lack of regulation of their contents.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:127%">The industry&#8217;s failure to mitigate the threat of counterfeit medicines could adversely impact our business and reputation by impacting patient confidence in our authentic products, potentially resulting in lost sales, product recalls, and an increased threat of litigation. In addition, diversion of our products from their authorized market into other channels may result in reduced revenues and negatively affect our profitability.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:127%">Global health crises, pandemics, epidemics, or other outbreaks could adversely disrupt or impact certain aspects of the Company&#8217;s business, results of operations and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:127%">We are subject to risks associated with global health crises, epidemics, pandemics and other outbreaks (such incident(s), a health crisis or health crises). The spread of health crises have caused and may cause the Company to modify its business practices, and take further actions as may be required by government authorities or as the Company determines are in the best interests of our patients, customers, employees and business partners under such circumstances. Impacts to the Company have included and may include adverse impacts to results of operations and financial condition, including lower sales and reduced customer demand and usage of certain of our products. While the Company has robust business continuity plans in place across our global supply chain network designed to help mitigate the impact of health crises, these efforts may not completely prevent our business from being adversely affected in the event of a health crisis. Health crises could adversely impact the Company&#8217;s operations, including, among other things, our manufacturing operations, supply chain, third-party suppliers, sales and marketing, and clinical trial operations. Any of these factors could adversely affect the Company&#8217;s business, financial results, and global economic conditions generally.</span></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Risks related to government regulation and legal proceedings</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:127%">Global sales in the Company&#8217;s Innovative Medicine and MedTech segments may be negatively impacted by healthcare reforms and increasing pricing pressures.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:127%">Sales of the Company&#8217;s Innovative Medicine and MedTech products are significantly affected by reimbursements by third-party payors such as government healthcare programs, private insurance plans and managed care organizations. As part of various efforts to contain healthcare costs, these payors are putting downward pressure on prices at which products will be reimbursed. In the U.S., increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, in part due to continued consolidation among healthcare providers, could result in further pricing pressures. In addition, recent legislation and ongoing political scrutiny on pricing, coverage and reimbursement could result in additional pricing pressures. Specifically, the Inflation Reduction Act of 2022 (IRA) has changed Medicare Part D benefit design and has subjected certain of the Company's products to government-established pricing beginning in 2026 and may subject additional products in the future. Failure to adhere to the government's interpretations of the law pending ongoing litigation may expose the Company to penalties. In addition, change to Medicare Part D could have a negative impact on U.S. Innovative Medicine sales. Further, increased third-party utilization of the 340B Federal Drug Discount Program from expanded interpretations of the statute and program abuse may have a negative impact on the Company's financial performance. Outside the U.S., numerous major markets, including the EU, United Kingdom, Japan and China, have pervasive government involvement in funding healthcare and, in that regard, directly or indirectly impose price controls, limit access to, or reimbursement for, the Company&#8217;s products, or reduce the value of its intellectual property&#160;protection. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">We are subject to an increasing number of costly and complex governmental regulations in the countries in which operations are conducted which may materially adversely affect the Company&#8217;s financial condition and business&#160;operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">As described in Item 1. Business, the Company is subject to an increasing number of extensive government laws and regulations, investigations and legal action by national, state and local government agencies in the U.S. and other countries in which it operates. For example, changes to the U.S. FDA&#8217;s timing or requirements for approval or clearance of our products may have a negative impact on our ability to bring new products to market. New and changing laws, regulations, executive orders and other directives may also impose deadlines on the Company, or its third-party suppliers, manufacturers or other partners and providers, for which there may be insufficient time to implement changes to comply with such new regulations and may result in manufacturing delays or other supply chain constraints. If the Company is unable to identify ways to mitigate these delays or constraints, there may be an adverse effect on sales and access to our products. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">The Company is subject to significant legal proceedings that can result in significant expenses, fines and reputational&#160;damage.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In the ordinary course of business, Johnson &amp; Johnson and its subsidiaries are subject to numerous claims and lawsuits involving various issues such as product liability, patent disputes and claims that their product sales, marketing and pricing practices violate various antitrust, unfair trade practices and/or consumer protection laws. The Company&#8217;s more significant legal proceedings are described in Note 19 Legal proceedings under Notes to the Consolidated Financial Statements included in Item 8 of this Report. Litigation, in general, and securities, derivative action, class action and multi-district litigation, in particular, can be expensive and disruptive. Some of these matters may include thousands of plaintiffs, may involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. For example, the Company is a defendant in numerous lawsuits arising out of the use of body powders containing talc, primarily JOHNSON&#8217;S Baby Powder. While the Company believes it has substantial defenses in these matters, it is not feasible to predict the ultimate outcome of litigation. The Company has been and could in the future be required to pay significant amounts as a result of settlements or judgments in these matters, potentially in excess of accruals, including matters where the Company could be held jointly and severally liable among other defendants. The resolution of, or increase in accruals for, one or more of these matters in any reporting period could have a material adverse effect on the Company&#8217;s results of operations and cash flows for that period. The Company does not purchase third-party product liability insurance; however, the Company utilizes a wholly owned captive insurance company subject to certain limits.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Product reliability, safety and effectiveness concerns can have significant negative impacts on sales and results of operations, lead to litigation and cause reputational damage.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Product concerns, whether raised internally or by litigants, regulators or consumer advocates, and whether or not based on scientific evidence, can result in safety alerts, product recalls, governmental investigations, regulatory action on the part of the U.S. FDA (or its counterpart in other countries), private claims and lawsuits, payment of fines and settlements, declining sales and reputational damage. These circumstances can also result in damage to brand image, brand equity and consumer trust in the Company&#8217;s products. Product recalls have in the past, and could in the future, prompt government investigations and inspections, the shutdown of manufacturing facilities, continued product shortages and related sales declines, significant remediation costs, reputational damage, possible civil penalties and criminal prosecution. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">The Company faces significant regulatory scrutiny, which imposes significant compliance costs and exposes the Company to government investigations, legal actions and penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The rapid increase in new government laws and regulations imposes significant compliance costs to the Company and a failure of the Company to timely implement changes to comply with these new laws may expose the Company to investigations, legal actions or penalties. Regulatory issues regarding compliance with current Good Manufacturing Practices (cGMP) (and comparable quality regulations in foreign countries) by manufacturers of drugs and devices can lead to fines and penalties, product recalls, product shortages, interruptions in production, delays in new product approvals and litigation. In addition, the marketing, pricing and sale of the Company&#8217;s products are subject to regulation, investigations and legal actions including under the Federal Food, Drug, and Cosmetic Act, the Medicaid Rebate Program, federal and state false claims acts, state unfair trade practices acts and consumer protection laws. Scrutiny of healthcare industry business practices by government agencies and state attorneys general in the U.S., and any resulting investigations and prosecutions, carry risk of significant civil and criminal penalties including, but not limited to, debarment from participation in government healthcare programs. Any such debarment could have a material adverse effect on the Company&#8217;s business and results of operations. The most significant current investigations and litigation brought by government agencies are described in Note 19 Legal proceedings&#8212;Government proceedings under Notes to the Consolidated Financial Statements included in Item 8 of this Report. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">11</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Changes in tax laws or exposures to additional tax liabilities could negatively impact the Company&#8217;s operating results.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Changes in tax laws or regulations around the world, including in the U.S. and as led by the Organization for Economic Cooperation and Development, such as the enactment by certain EU and non-EU countries, and the anticipated enactment by additional countries, of a global minimum tax, could negatively impact the Company&#8217;s effective tax rate and results of operations. A change in statutory tax rate or certain international tax provisions in any country would result in the revaluation of the Company&#8217;s deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted. This change would result in an expense or benefit recorded to the Company&#8217;s Consolidated Statement of Earnings. The Company closely monitors these proposals as they arise in the countries where it operates. Changes to tax laws or regulations may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">See Note 8 Income taxes under Notes to the Consolidated Financial Statements included in Item 8 of this Report for additional&#160;information. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company conducts business and files tax returns in numerous countries and is addressing tax audits and disputes with many tax authorities. In connection with various government initiatives, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries. The Company regularly assesses the likely outcomes of its tax audits and disputes to determine the appropriateness of its tax reserves. However, any tax authority could take a position on tax treatment that is contrary to the Company&#8217;s expectations, which could result in tax liabilities in excess of reserves.</span></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Risks related to our intellectual property</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">The Company faces increased challenges to intellectual property rights central to its business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company owns or licenses a significant number of patents and other proprietary rights relating to its products and manufacturing processes. These rights are essential to the Company&#8217;s businesses and the inability of the Company to secure and maintain these rights may have a detrimental impact on the Company&#8217;s financial results. Public policy, both within and outside the U.S., has become increasingly unfavorable toward intellectual property rights. The Company cannot be certain that it will secure and maintain adequate patent protection for new products and technologies in the United States and other important markets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Competitors routinely challenge the validity or extent of the Company&#8217;s owned or licensed patents and proprietary rights through litigation, interferences, oppositions and other proceedings, such as inter partes review (IPR) proceedings before the United States Patent &amp; Trademark Office (USPTO). These proceedings absorb resources and can be protracted as well as unpredictable. In addition, others may claim the Company has infringed their intellectual property rights, including copyrights, patents, or trademarks, and/or has misappropriated their trade secrets, any of which could result in an injunction and/or the need to pay past damages and future royalties and adversely affect the competitive position and sales of our products. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has faced increasing patent challenges from third parties seeking to manufacture and market generic and biosimilar versions of the Company&#8217;s key pharmaceutical products prior to expiration of the applicable patents covering those products. In the event the Company is not successful in defending its patents against such challenges, or upon the &#8220;at-risk&#8221; launch by the generic or biosimilar firm of its product, the Company can lose a major portion of revenues for the referenced product in a very short period of time. Current legal proceedings involving the Company&#8217;s patents and other intellectual property rights are described in Note 19 Legal proceedings&#8212;Intellectual property under Notes to the Consolidated Financial Statements included in Item 8 of this Report.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">12</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Risks related to product development, regulatory approval and&#160;commercialization</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Significant challenges or delays in the Company&#8217;s innovation, development and implementation of new products, technologies and indications could have an adverse impact on the Company&#8217;s long-term success.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The Company&#8217;s continued growth and success depends on its ability to innovate and develop new and differentiated products and services that address the evolving healthcare needs of patients, providers and consumers. Development of successful products and technologies is also necessary to offset revenue losses when the Company&#8217;s existing products lose market share due to various factors such as competition and loss of patent exclusivity. New products introduced within the past five years accounted for approximately 25% of 2024 sales. The Company cannot be certain when or whether it will be able to develop, license or otherwise acquire companies, products and technologies, whether particular product candidates will be granted regulatory approval, and, if approved, whether the products will be commercially successful.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The Company pursues product development through internal research and development as well as through collaborations, acquisitions, joint ventures and licensing or other arrangements with third parties. In all of these contexts, developing new products, particularly pharmaceutical and biotechnology products and medical devices, requires significant investment of resources over many years. Only a very few biopharmaceutical research and development programs result in commercially viable products. The process depends on many factors including the ability to: discern patients&#8217; and healthcare providers&#8217; future needs; develop promising new compounds, strategies and technologies; achieve successful clinical trial results; secure effective intellectual property protection; obtain regulatory approvals on a timely basis; and, if and when they reach the market, successfully differentiate the Company&#8217;s products from competing products and approaches to treatment. Moreover, the development and regulatory approval of new products may be delayed due to limits on federal agency budgets or personnel, including reductions to the U.S. FDA&#8217;s budget, employees, and operations, which may lead to slower response times and longer review periods. After approval, new products or enhancements to existing products may not be accepted quickly or significantly in the marketplace due to product and price competition, changes in customer preferences or healthcare purchasing patterns, resistance by healthcare providers or uncertainty over third-party reimbursement. Even following initial regulatory approval, the success of a product can be adversely impacted by safety and efficacy findings in larger real-world patient populations, as well as market entry of competitive products.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The Company leverages the use of data science, machine learning and other forms of AI and emerging technologies across varying parts of its business and operations, and the introduction and incorporation of AI may result in unintended consequences or other new or expanded risks and liabilities. AI technology is continuously evolving, and the AI technologies we develop and adopt may become obsolete earlier than planned. Our investments in these technologies may not result in the benefits we anticipate or enable us to obtain or maintain a competitive advantage. The application of AI in our business is emerging and evolving alongside new laws and regulations that may entail significant costs or ultimately limit our ability to continue the use of these technologies. These technologies also carry inherent risks related to data privacy and security further described below.</span></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Risks related to financial and economic market conditions</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:125%">The Company faces a variety of financial, economic, legal, social and political risks associated with conducting business&#160;internationally.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The Company&#8217;s extensive operations and business activity throughout the world are accompanied by certain financial, economic, legal, social and political risks, including those listed below.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:125%">Foreign currency exchange</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">: In fiscal 2024, approximately 43% of the Company&#8217;s sales occurred outside of the U.S., with approximately 23% in Europe, 5% in the Western Hemisphere, excluding the U.S., and 15% in the Asia-Pacific and Africa region. Changes in non-U.S. currencies relative to the U.S. dollar impact the Company&#8217;s revenues and expenses. While the Company uses financial instruments to mitigate the impact of fluctuations in currency exchange rates on its cash flows, unhedged exposures continue to be subject to currency fluctuations. In addition, the weakening or strengthening of the U.S. dollar may result in significant favorable or unfavorable translation effects when the operating results of the Company&#8217;s non-U.S. business activity are translated into U.S. dollars. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:125%">Inflation and currency devaluation risks</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">: The Company faces challenges in maintaining profitability of operations in economies experiencing high inflation rates. Specifically, the Company has accounted for operations in Argentina, Turkey, Venezuela and Egypt (beginning in the fiscal fourth quarter of 2024) as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. While the Company strives to maintain profit margins in these areas through cost reduction programs, productivity improvements and periodic price increases, it might experience operating losses as a result of continued inflation. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">13</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In addition, the impact of currency devaluations in countries experiencing high inflation rates or significant currency exchange fluctuations could negatively impact the Company&#8217;s operating results. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%">Illegal importation of pharmaceutical products</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">: The illegal importation of pharmaceutical products from countries where government price controls or other market dynamics result in lower prices may adversely affect the Company&#8217;s sales and profitability in the U.S. and other countries in which the Company operates. With the exception of limited quantities of prescription drugs for personal use, foreign imports of pharmaceutical products are illegal under current U.S. law. However, the volume of illegal imports continues to rise as the ability of patients and other customers to obtain the lower-priced imports has grown significantly.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%">Anti-bribery and other regulations</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">: The Company is subject to various federal and foreign laws that govern its international business practices with respect to payments to government officials. Those laws include the U.S. Foreign Corrupt Practices Act (FCPA), which prohibits U.S. publicly traded companies from promising, offering, or giving anything of value to foreign officials with the corrupt intent of influencing the foreign official for the purpose of helping the Company obtain or retain business or gain any improper advantage. The Company&#8217;s business is heavily regulated and therefore involves significant interaction with foreign officials. Also, in many countries outside the U.S., the healthcare providers who prescribe human pharmaceuticals are employed by the government and the purchasers of human pharmaceuticals are government entities; therefore, the Company&#8217;s interactions with these prescribers and purchasers are subject to regulation under the FCPA. In addition to the U.S. application and enforcement of the FCPA, various jurisdictions in which the Company operates have laws and regulations, including the U.K. Bribery Act 2010, aimed at preventing and penalizing corrupt and anticompetitive behavior. Enforcement activities under these laws could subject the Company to additional administrative and legal proceedings and actions, which could include claims for civil penalties, criminal sanctions, and administrative remedies, including exclusion from healthcare programs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%">Other financial, economic, legal, social and political risks</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">. Other risks inherent in conducting business globally include:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">local and regional economic environments and policies in the markets that we serve, including interest rates, monetary policy, inflation, economic growth, recession, commodity prices, and currency controls or other limitations on the ability to expatriate cash; </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">protective economic policies taken by governments, such as trade protection measures, increased antitrust reporting requirements and enforcement activity, and import/export licensing&#160;requirements; </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">compliance with local regulations and laws including, in some countries, regulatory requirements restricting the Company&#8217;s ability to manufacture or sell its products in the relevant market; </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">diminished protection of intellectual property and contractual rights in certain jurisdictions;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">potential nationalization or expropriation of the Company&#8217;s foreign assets; </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">political or social upheavals, economic instability, repression, or human rights issues; and </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">geopolitical events, including natural disasters, disruptions to markets due to war, armed conflict, terrorism, epidemics or&#160;pandemics.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Due to the international nature of the Company's business, geopolitical or economic changes or events, including global tensions and war, could adversely affect our business, results of operations or financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">As described above, the Company has extensive operations and business activity throughout the world. Global tensions, conflict and/or war among any of the countries in which we conduct business or distribute our products may result in foreign currency volatility, decreased demand for our products in affected countries, and challenges to our global supply chain related to increased costs of materials and other inputs for our products and suppliers. Most recently, we have experienced, and expect to continue to experience, impacts to the Company's business resulting from the Russia-Ukraine war, rising conflict in the Middle East as well as increasing tensions between the U.S. and China. In response to heightened conflict, such as the Russia-Ukraine war, governments may impose export controls and broad financial and economic sanctions. Our business and operations may be further impacted by the imposition of tariffs, trade protection measures or other policies adopted by any country that favor domestic companies and technologies over foreign competitors. Additional sanctions or other measures may be imposed by the global community, including but not limited to limitations on our ability to file, prosecute and maintain patents, trademarks and other intellectual property rights. Furthermore, in some countries, such as in Russia, action may be taken that allows companies and individuals to exploit inventions owned by patent holders from the United States and many other countries without consent or compensation and we may not be able to prevent third parties from practicing the Company's inventions in Russia or from selling or importing products in and into Russia. In addition, the U.S. government recently announced tariffs on products manufactured in several jurisdictions, including China, Mexico and Canada, and has </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">made announcements regarding the potential imposition of tariffs on other jurisdictions. While certain of the announced tariffs  have been delayed, the U.S. government may in the future pause, reimpose or increase tariffs, and countries subject to such tariffs have and in the future may impose reciprocal tariffs or other restrictive trade measures in response. Any of these actions could increase uncertainties and associated risks relating to the Company&#8217;s global&#160;operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Weak financial performance, failure to maintain a satisfactory credit rating or disruptions in the financial markets could adversely affect our liquidity, capital position, borrowing costs and access to capital markets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">We currently maintain investment grade credit ratings with Moody&#8217;s Investors Service and Standard &amp; Poor&#8217;s Ratings Services. Rating agencies routinely evaluate us, and their ratings of our long-term and short-term debt are based on a number of factors. Any downgrade of our credit ratings by a credit rating agency, whether as a result of our actions or factors which are beyond our control, can increase the cost of borrowing under any indebtedness we may incur, reduce market capacity for our commercial paper or require the posting of additional collateral under our derivative contracts. There can be no assurance that we will be able to maintain our credit ratings, and any additional actual or anticipated changes or downgrades in our credit ratings, including any announcement that our ratings are under review for a downgrade, may have a negative impact on our liquidity, capital position and access to capital markets. </span></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Other risks</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Our business depends on our ability to recruit and retain talented and highly skilled employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Our continued growth requires us to recruit and retain talented employees representing many different backgrounds, experiences, and skill sets. The market for highly skilled workers and leaders in our industry is extremely competitive and our ability to compete depends on our ability to hire, develop and motivate highly skilled personnel in all areas of our organization. Maintaining our brand and reputation, as well as a credo-based work environment enables us to attract top talent. If we are less successful in our recruiting efforts, or if we cannot retain highly skilled workers and key leaders, our ability to develop and deliver successful products and services may be adversely affected. In addition, effective succession planning is important to our long-term success. Any unsuccessful implementation of our succession plans or failure to ensure effective transfer of knowledge and smooth transitions involving key employees could adversely affect our business, financial condition, or results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Climate change or legal, regulatory or market measures to address climate change may negatively affect our business and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Climate change resulting from increased concentrations of carbon dioxide and other greenhouse gases in the atmosphere could present risks to our operations, including an adverse impact on global temperatures, weather patterns and the frequency and severity of extreme weather and natural disasters. Natural disasters and extreme weather conditions, such as a hurricane, tornado, earthquake, wildfire or flooding, may pose physical risks to our facilities and disrupt the operation of our supply chain. The impacts of the changing climate on water resources may result in water scarcity, limiting our ability to access sufficient high-quality water in certain locations, which may increase operational costs. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Concern over climate change may also result in new or additional legal or regulatory requirements designed to reduce greenhouse gas emissions and/or mitigate the effects of climate change on the environment. If such laws or regulations are more stringent than current legal or regulatory obligations, we may experience disruption in, or an increase in the costs associated with sourcing, manufacturing and distribution of our products, which may adversely affect our business, results of operations or financial condition. Further, the impacts of climate change have an influence on customer preferences, and failure to provide climate-friendly products could potentially result in loss of market share.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">An information security incident, including a cybersecurity breach, could have a negative impact on the Company&#8217;s business or reputation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">To meet business objectives, the Company relies on both internal information technology (IT) systems and networks, and those of third parties and their vendors, to process and store sensitive data (including confidential research, business plans, financial information, intellectual property, and personal data that may be subject to legal protection) to ensure the continuity of the Company&#8217;s supply chain and operations, and as part of many of the products we deliver to customers. The extensive range of information security and cybersecurity threats, which affect companies globally, pose a persistent risk to the security and availability of these systems and networks, including to customer products that are connected to or rely on such systems and networks, and the confidentiality, integrity, and availability of the Company&#8217;s sensitive data. The Company assesses these threats, responds to attacks and breaches that it has experienced, and makes investments to increase internal protection, detection, and response capabilities, as well as ensure the Company&#8217;s third-party providers have required capabilities and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">15</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">controls, to address this risk. Because of the frequently changing attack techniques, along with the increased volume and sophistication of the attacks, there is the potential for the Company to be adversely impacted. This impact could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action. Also, increasing use of AI could increase these risks. The Company maintains cybersecurity insurance in the event of an information security or cyber incident; however, the coverage may not be sufficient to cover all financial, legal, business or reputational losses.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">As a result of increased global tensions, the Company expects there will continue to be, an increased risk of information security or cybersecurity incidents, including cyberattacks perpetrated by adversaries of countries where the Company maintains operations. Given the potential sophistication of these attacks, the Company may not be able to address the threat of information security or cybersecurity incidents proactively or implement adequate preventative measures and we may not be able to detect and address any such disruption or security breach promptly, or at all, which could adversely affect customers that use our products, our business, results of operations or financial condition. Moreover, these threats could also impact our third-party partners resulting in compromise of the Company's IT systems, networks and data which could negatively affect the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">A breach of privacy laws or unauthorized access, loss or misuse of personal data could have a negative impact on the Company&#8217;s business or reputation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company is subject to privacy and data protection laws and regulations across the globe that impose broad compliance obligations on the collection, possession, use, storage, access, disclosure, transfer, deletion and protection of personal data. Breach of the requirements of these laws and regulations could result in substantial fines, penalties, governmental actions, private right of actions, including class actions, and damage to our reputation and business. New privacy laws are expected globally, together with greater privacy enforcement by governmental authorities globally, particularly on data localization requirements and data transfers including international data flows. The Company has established privacy compliance programs and controls with which our businesses worldwide are required to comply. However, with many technology and data-driven initiatives evolving across the Company, involving multiple vendors and third parties, there are threats that could impact our business operations and research activities, including potential risks of unauthorized access and loss of personal data as well as legislative actions imposing limitations and controls on the use and sharing of personal data as well as on cross border data&#160;flows.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">16</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_58"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Item 1B. Unresolved staff comments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Not applicable.</span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_61"></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Item 1C. Cybersecurity</span></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Risk management and strategy</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-51" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-52" escape="true">The Company has documented cybersecurity policies and standards, assesses risks from cybersecurity threats, and monitors information systems for potential cybersecurity issues. To protect the Company&#8217;s information systems from cybersecurity threats, the Company uses various security tools supporting protection, detection, and response capabilities. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-53">The Company maintains a cybersecurity incident response plan to help ensure a timely, consistent response to actual or attempted cybersecurity incidents impacting the Company.</ix:nonNumeric></ix:nonNumeric> </span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-55"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-54">The Company also identifies and assesses third-party risks within the enterprise, and through the Company's use of third-party service providers, across a range of areas including data security and supply chain through a structured third-party risk management program.</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company maintains a formal information security training program for all employees that includes training on matters such as phishing and email security best practices. Employees are also required to complete mandatory training on data privacy.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">To evaluate and enhance its cybersecurity program, the Company periodically utilizes third-party experts to undertake maturity assessments of the Company&#8217;s information security program.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-56">To date, the Company is not aware of any cybersecurity incident that has had or is reasonably likely to have a material impact on the Company&#8217;s business or operations; however, because of the frequently changing attack techniques, along with the increased volume and sophistication of the attacks, there is the potential for the Company to be adversely impacted.</ix:nonNumeric> This impact could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action. Refer to the risk factor captioned An information security incident, including a cybersecurity breach, could have a negative impact to the Company&#8217;s business or reputation in Part I, Item 1A. Risk factors for additional description of cybersecurity risks and potential related impacts on the Company.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-57" escape="true"><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Governance - management&#8217;s responsibility</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-58" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company takes a risk-based approach to cybersecurity and has implemented cybersecurity controls designed to address cybersecurity threats and risks. The <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-59">Chief Information Officer (CIO), who is a member of the Company&#8217;s Executive Committee, and the Chief Information Security Officer (CISO)</ix:nonNumeric> are responsible for assessing and managing cybersecurity risks, including security incident detection, response, and recovery.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company&#8217;s CISO, in coordination with the CIO, is responsible for leading the Company&#8217;s cybersecurity program and management of cybersecurity risk. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-60" escape="true">The current CISO has over twenty-five years of experience in information security, and his background includes technical experience, strategy and architecture focused roles, cyber and threat experience, and various leadership roles.</ix:nonNumeric></span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-61" escape="true"><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Governance - board oversight</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-63" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-62" escape="true">The Company&#8217;s <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-64">Board of Directors</ix:nonNumeric> oversees the overall risk management process, including cybersecurity risks, directly and through its committees. The Regulatory Compliance &amp; Sustainability Committee (RCSC) of the board is primarily responsible for oversight of risk from cybersecurity threats and oversees compliance with applicable laws, regulations and Company policies related to, among others, privacy and cybersecurity.</ix:nonNumeric></ix:nonNumeric> </span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-65" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">RCSC meetings include discussions of specific risk areas throughout the year including, among others, those relating to cybersecurity. The CISO provides quarterly updates each year to RCSC on cybersecurity matters. These reports include an overview of the cybersecurity threat landscape, key cybersecurity initiatives to improve the Company&#8217;s risk posture, changes in the legal and regulatory landscape relative to cybersecurity, and overviews of certain cybersecurity incidents that have occurred within the Company and within the industry.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">17</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_64"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company's subsidiaries operate 64 manufacturing facilities occupying approximately 9.6&#160;million square feet of floor space. The manufacturing facilities are used by the industry segments of the Company&#8217;s business approximately as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.359%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Segment</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Square Feet<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Innovative Medicine</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,696</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MedTech</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,911</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,607</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Within the U.S., four facilities are used by the Innovative Medicine segment and 19 by the MedTech segment. Outside of the U.S., 14 facilities are used by the Innovative Medicine segment and 27 by the MedTech segment. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The locations of the manufacturing facilities by major geographic areas of the world are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.359%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Geographic Area</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Facilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Square Feet<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">United States</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,892</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Europe</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,521</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Western Hemisphere, excluding U.S.&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">898</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Africa, Asia and Pacific</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,296</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,607</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In addition to the manufacturing facilities discussed above, the Company maintains numerous office and warehouse facilities throughout the world. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company's subsidiaries generally seek to own, rather than lease, their manufacturing facilities, although some, principally in non-U.S. locations, are leased. Office and warehouse facilities are often leased. The Company also engages contract&#160;manufacturers.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company is committed to maintaining all of its properties in good operating condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Segment information on additions to property, plant and equipment is contained in Note&#160;17 Segments of business and geographic areas of the Notes to Consolidated Financial Statements included in Item 8 of this Report.</span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_67"></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Item 3. Legal proceedings</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The information called for by this item is incorporated herein by reference to the information set forth in Note&#160;19 Legal proceedings of the Notes to Consolidated Financial Statements included in Item 8 of this Report.</span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_70"></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Item 4. Mine safety disclosures</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">18</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_73"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Executive officers of the registrant</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Listed below are the executive officers of the Company. There are no family relationships between any of the executive officers, and there is no arrangement or understanding between any executive officer and any other person pursuant to which the executive officer was selected. At the annual meeting of the Board of Directors, the executive officers are elected by the Board to hold office for one year and until their respective successors are elected and qualified, or until earlier resignation or&#160;removal.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.043%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:7.2pt"><img src="jnj-20241229_g3.jpg" alt="05_PRO013333_pic_J&amp;J_directors_BroadhurstV.jpg" style="height:76px;margin-bottom:5pt;vertical-align:text-bottom;width:76px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:11pt;font-weight:700;line-height:130%">Vanessa Broadhurst, 56</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Johnson Display Medium',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Member, Executive Committee; Executive Vice President, Global Corporate&#160;Affairs</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-right:7.2pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:130%">Ms. V. Broadhurst was named Executive Vice President, Global Corporate Affairs and appointed to the Executive Committee in 2022. Ms. Broadhurst rejoined the Company in 2017 and was appointed Company Group Chairman, Global Commercial Strategy Organization in 2018. From 2013 to 2017, she held General Manager roles at Amgen in Inflammation &amp; Cardiovascular, and Cardiovascular &amp; Bone. Prior to her roles at Amgen, she served in various leadership roles at the Company from 2005-2013.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:7.2pt"><img src="jnj-20241229_g4.jpg" alt="05_PRO013333_pic_J&amp;J_directors_DuatoJ.jpg" style="height:76px;margin-bottom:5pt;vertical-align:text-bottom;width:76px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:11pt;font-weight:700;line-height:130%">Joaquin Duato, 62</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Johnson Display Medium',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Chairman of the Board; Chief Executive Officer</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-right:7.2pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:130%">Mr. J. Duato became Chairman of the Board of Directors in 2023 subsequent to his appointments as Chief Executive Officer and Director in 2022. Mr. Duato was appointed to the Executive Committee in 2016 when he was named Executive Vice President, Worldwide Chairman, Pharmaceuticals and subsequently served as Vice Chairman of the Executive Committee. Mr. Duato first joined the Company in 1989 with Janssen-Farmaceutica S.A. (Spain), a subsidiary of the Company, and held executive positions of increasing responsibility in all business sectors and across multiple geographies and functions.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:7.2pt"><img src="jnj-20241229_g5.jpg" alt="05_PRO013333_pic_J&amp;J_directors_ForminardE.jpg" style="height:76px;margin-bottom:5pt;vertical-align:text-bottom;width:76px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:11pt;font-weight:700;line-height:130%">Elizabeth Forminard, 54</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Johnson Display Medium',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Member, Executive Committee; Executive Vice President, Chief Legal Officer</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-right:7.2pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:130%">Ms. E. Forminard was appointed Executive Vice President, Chief Legal Officer and a member of the Executive Committee in 2022. Ms. Forminard joined the Company in 2006, serving in roles of increasing responsibility including General Counsel Medical Devices &amp; Diagnostics, General Counsel Consumer Group &amp; Supply Chain, Worldwide Vice President Corporate Governance, and in her immediate past role as General Counsel Pharmaceuticals.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt 0 8.2pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:7.2pt"><img src="jnj-20241229_g6.jpg" alt="05_PRO013333_pic_J&amp;J_directors_MulhollandK.jpg" style="height:76px;margin-bottom:5pt;vertical-align:text-bottom;width:76px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:11pt;font-weight:700;line-height:130%">Kristen Mulholland, 58</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Johnson Display Medium',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Member, Executive Committee; Executive Vice President, Chief Human Resources&#160;Officer</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-right:7.2pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:130%">Ms. K. Mulholland was appointed Executive Vice President, Chief Human Resources Officer and appointed to the Executive Committee in 2024. She joined the company in 2005 and has held HR leadership positions across the full breadth of the company including MedTech, Innovative Medicines, our Corporate Functions and Corporate HR&#160;Services including Performance and Development and most recently, Global Total&#160;Rewards.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:7.2pt"><img src="jnj-20241229_g7.jpg" alt="05_PRO013333_pic_J&amp;J_directors_ReedJ.jpg" style="height:76px;margin-bottom:5pt;vertical-align:text-bottom;width:76px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:11pt;font-weight:700;line-height:130%">John C. Reed, M.D., Ph.D., 66</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Johnson Display Medium',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Member, Executive Committee; Executive Vice President, Innovative Medicine, R&amp;D</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-right:7.2pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:130%">Dr. J. C. Reed joined the Company in 2023 as Executive Vice President, Innovative Medicine, R&amp;D and a member of the Executive Committee. Prior to joining the Company, Dr. Reed held executive leadership positions at Sanofi (2018-2022) and Roche (2013-2018), serving on their respective executive committees. He also served as CEO of Sanford-Burnham Medical Research Institute (now Sanford Burnham Prebys) where he established multiple therapeutic area-aligned research centers and platform technology centers.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="border-bottom:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #959595;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">19</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.043%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:7.2pt"><img src="jnj-20241229_g8.jpg" alt="05_PRO013333_pic_J&amp;J_directors_SchmidT.jpg" style="height:76px;margin-bottom:5pt;vertical-align:text-bottom;width:76px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:11pt;font-weight:700;line-height:130%">Tim Schmid, 55</span></div><div><span style="color:#000000;font-family:'Johnson Display Medium',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Member, Executive Committee; Executive Vice President, Worldwide Chairman, MedTech</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-right:7.2pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:130%">Mr. T. Schmid was appointed Executive Vice President, Worldwide Chairman, MedTech and a member of the Executive Committee in 2023. He joined the Company in 1993 and has served in leadership positions throughout Johnson &amp; Johnson MedTech, including Chief Strategic Customer Officer and President of Ethicon, and most recently served as Company Group Chairman MedTech Asia Pacific from 2018-2023.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:7.2pt"><img src="jnj-20241229_g9.jpg" alt="05_PRO013333_pic_J&amp;J_directors_SwansonJ.jpg" style="height:76px;margin-bottom:5pt;vertical-align:text-bottom;width:76px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:11pt;font-weight:700;line-height:130%">James Swanson, 59</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Johnson Display Medium',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Member, Executive Committee; Executive Vice President, Chief Information Officer</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-right:7.2pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:130%">Mr. J. Swanson was appointed Executive Vice President, Chief Information Officer and a member of the Executive Committee in 2022. He rejoined the Company in 2019 as Chief Information Officer of Johnson &amp; Johnson from Bayer Crop Science, where he served as a member of the Executive Leadership Team and as Chief Information Officer and Head of Digital Transformation. From 1996 to 2005, Mr. Swanson held positions of increasing responsibility at the Company, including Project Manager, Director IT, Sr. Director IT and Vice President, Chief Information Officer.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:7.2pt"><img src="jnj-20241229_g10.jpg" alt="05_PRO013333_pic_J&amp;J_directors_TaubertJ.jpg" style="height:76px;margin-bottom:5pt;vertical-align:text-bottom;width:76px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-right:7.2pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:11pt;font-weight:700;line-height:130%">Jennifer L. Taubert, 61</span></div><div style="padding-right:7.2pt"><span style="color:#000000;font-family:'Johnson Display Medium',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Member, Executive Committee; Executive Vice President, Worldwide Chairman, Innovative&#160;Medicine</span></div><div style="margin-top:6pt;padding-right:7.2pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:130%">Ms. J. L. Taubert was appointed Executive Vice President, Worldwide Chairman, Innovative Medicine (formerly Pharmaceuticals) and a member of the Executive Committee in 2018. She joined the Company in 2005 as Worldwide Vice President and held several executive positions of increasing responsibility in the Pharmaceuticals sector, including Company Group Chairman, North America, and Company Group Chairman, The Americas from 2012-2018.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:7.2pt"><img src="jnj-20241229_g11.jpg" alt="05_PRO013333_pic_J&amp;J_directors_WengelK.jpg" style="height:76px;margin-bottom:5pt;vertical-align:text-bottom;width:76px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:11pt;font-weight:700;line-height:130%">Kathryn E. Wengel, 59</span></div><div style="margin-bottom:6pt;padding-right:7.2pt"><span style="color:#000000;font-family:'Johnson Display Medium',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Member, Executive Committee; Executive Vice President, Chief Technical Operations &amp; Risk&#160;Officer</span></div><div style="margin-top:6pt;padding-right:7.2pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:130%">Ms. K. E. Wengel was appointed Executive Vice President, Chief Technical Operations &amp; Risk Officer in 2023, subsequent to her appointment to the Executive Committee in 2018 when she was named as Executive Vice President, Chief Global Supply Chain Officer. Ms. Wengel first joined the Company in 1988 as Project Engineer and Engineering Supervisor at Janssen, a subsidiary of the Company. During her tenure with the Company, she has held a variety of strategic leadership and executive positions, including in roles within operations, quality, engineering, new products, information technology, and other technical and business functions.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:7.2pt"><img src="jnj-20241229_g12.jpg" alt="05_PRO013333_pic_J&amp;J_directors_WolkJ.jpg" style="height:76px;margin-bottom:5pt;vertical-align:text-bottom;width:76px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:11pt;font-weight:700;line-height:130%">Joseph J. Wolk, 58</span></div><div><span style="color:#000000;font-family:'Johnson Display Medium',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Member, Executive Committee; Executive Vice President, Chief Financial Officer</span></div><div style="margin-top:6pt;padding-right:7.2pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:130%">Mr. J. J. Wolk was appointed Executive Vice President, Chief Financial Officer and a member of the Executive Committee in 2018. He first joined the Company in 1998 as Finance Manager, Business Development for Ortho-McNeil, a subsidiary of the Company. During his tenure at the Company, he has held a variety of senior leadership roles in several segments and functions across the Company's subsidiaries, including Vice President, Finance and Chief Financial Officer of the Janssen Pharmaceutical Companies, and Vice President, Investor Relations.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">20</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_76"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:26pt"><span style="color:#eb1700;font-family:'Johnson Display Medium',sans-serif;font-size:26pt;font-weight:400;line-height:120%">Part&#160;II</span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_79"></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Item 5. Market for registrant&#8217;s common equity, related stockholder matters and issuer purchases of equity securities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">As of February 6, 2025, there were 114,147 record holders of common stock of the Company. Additional information called for by this item is incorporated herein by reference to the following sections of this Report: Note&#160;16 &#8220;Common Stock, Stock Option Plans and Stock Compensation Agreements&#8221; of the Notes to Consolidated Financial Statements included in Item 8; and&#160;Item 12 &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#160;&#8211; Equity Compensation Plan Information.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Issuer purchases of equity securities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table provides information with respect to common stock purchases by the Company during the fiscal fourth quarter of 2024. Common stock purchases on the open market are made as part of a systematic plan to meet the needs of the Company&#8217;s compensation programs. The repurchases below also include the stock-for-stock option exercises that settled in the fiscal fourth quarter.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.539%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total Number</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of Shares</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Purchased</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Avg. Price<br/>Paid Per<br/>Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total Number of Shares (or<br/>Units) Purchased as Part<br/>of&#160;Publicly Announced<br/>Plans&#160;or Programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maximum Number (or Approximate<br/>Dollar Value) of Shares (or Units)<br/>that May Yet Be Purchased Under<br/>the Plans or Programs</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">September 30, 2024 through October 27, 2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">621,412</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$163.13</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">October 28, 2024 through November 24, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">831,866</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$158.98</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">November 25, 2024 through December 29, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">150,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$152.96</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,603,278</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">During the fiscal fourth quarter of 2024, the Company repurchased an aggregate of 1,603,278 shares of Johnson &amp; Johnson Common Stock in open-market transactions, all of which were purchased as part of a systematic plan to meet the needs of the Company&#8217;s compensation programs. </span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_82"></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Item 6. Reserved</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">21</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_88"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s discussion and analysis of results of operations and financial condition</span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_91"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Organization and business segments</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Description of the company and business segments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Johnson&#160;&amp; Johnson and its subsidiaries (the Company) have approximately 138,100&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The Company conducts business in virtually all countries of the world with the primary focus on products related to human health and well-being.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company is organized into two business segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on the following therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolism. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the Orthopaedic, Surgery, Cardiovascular (previously referred to as Interventional Solutions) and Vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Chief Operating Decision Maker (CODM) is the Company's Chief Executive Officer (Principal Executive Officer).The Executive Committee is Johnson &amp; Johnson&#8217;s senior leadership team responsible for setting the strategy and priorities of the Company and driving accountability at all levels. Within the strategic parameters provided by the Executive Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In all of its product lines, the Company competes with other companies both locally and globally, throughout the world. Competition exists in all product lines without regard to the number and size of the competing companies involved. Competition in research, involving the development and the improvement of new and existing products and processes, is&#160;particularly significant. The development of new and innovative products, as well as protecting the underlying intellectual property of the Company's product portfolio, is important to the Company&#8217;s success in all areas of its business. The competitive environment requires substantial investments in continuing research. </span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Management&#8217;s objectives</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">With Our Credo as the foundation, the Company &#8239;believes health is everything. The Company's strength in healthcare innovation empowers us to build a&#8239;world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and&#8239;solutions are personal. Through the Company's expertise in Innovative Medicine and MedTech, the Company is uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">New products introduced within the past five years accounted for approximately 25% of 2024 sales. In 2024, $17.2 billion was invested in research and development reflecting management&#8217;s commitment to create life-enhancing innovations and to create value through partnerships that will profoundly impact of health for&#160;humanity. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Our approximately 138,100 employees are critical drivers of the Company&#8217;s success. Employees are empowered and inspired to lead with Our Credo and purpose as guides. This allows every employee to use the Company&#8217;s reach and size to advance the Company&#8217;s purpose, and to also lead with agility and urgency. Leveraging the extensive resources across the enterprise enables the Company to innovate and execute with excellence. This ensures the Company can remain focused on addressing the unmet needs of society every day and invest for an enduring impact, ultimately delivering value to its patients, consumers and healthcare professionals, employees, communities and shareholders.</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:30.476%"></div><div style="display:inline-block;max-width:4.285%;min-width:3.785%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:30.476%"></div><div style="display:inline-block;max-width:4.285%;min-width:3.785%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:30.478%"></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">22</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:30.476%"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Research &amp; <br/>development</span></div><div style="padding-left:36pt;padding-right:36pt;text-align:center;text-indent:36pt"><img src="jnj-20241229_g13.jpg" alt="3895" style="height:182px;margin-bottom:5pt;vertical-align:text-bottom;width:180px"/></div></div><div style="display:inline-block;max-width:4.285%;min-width:3.785%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:30.476%"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Acquisitions* <br/>(net of cash acquired)</span></div><div style="padding-left:7.2pt;padding-right:7.2pt;text-align:center;text-indent:-14.4pt"><img src="jnj-20241229_g14.jpg" alt="3938" style="height:182px;margin-bottom:5pt;vertical-align:text-bottom;width:180px"/></div></div><div style="display:inline-block;max-width:4.285%;min-width:3.785%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:30.478%"><div style="padding-left:7.2pt;padding-right:7.2pt;text-align:center;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Dividends paid <br/>per share</span></div><div style="text-align:center"><img src="jnj-20241229_g15.jpg" alt="4102" style="height:182px;margin-bottom:5pt;vertical-align:text-bottom;width:181px"/></div></div></div><div style="padding-left:187.2pt;padding-right:187.2pt;text-align:center;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">*&#160;&#160;&#160;&#160;Includes business combinations and asset acquisitions</span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_94"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Results of operations</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Analysis of consolidated sales</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">For discussion on results of operations and financial condition pertaining to the fiscal years 2023 and 2022 see the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2023, Item 7. Management's discussion and analysis of results of operations and financial condition. Prior periods disclosed herein were recast to reflect the continuing operations of the Company. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In 2024, worldwide sales increased 4.3% to $88.8&#160;billion as compared to an increase of 6.5% in 2023. These sales changes consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.132%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.210%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales increase/(decrease) due to:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Volume</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.9&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">6.8&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(1.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(0.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">4.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">%</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">6.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The net impact of acquisitions and divestitures on the worldwide sales growth was a positive impact of 0.5% in 2024 and a positive impact of 1.5% in 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Sales by U.S.&#160;companies were $50.3&#160;billion in 2024 and $46.4&#160;billion in 2023. This represents increases of 8.3% in 2024 and&#160;10.6% in 2023. In the fiscal 2024, acquisitions and divestitures had a net positive impact of 0.7% on the U.S. operational sales growth. Sales by international companies were $38.5&#160;billion in 2024 and $38.7&#160;billion in 2023. This represents a decrease of 0.5% in 2024 and an increase of 1.9% in 2023. In fiscal 2024, acquisitions and divestitures had a net positive impact of 0.2% on the international operational sales growth. In fiscal 2024, the impact of the Covid-19 Vaccine sales decline on the international operational sales was a negative 2.6%.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The five-year compound annual growth rates for worldwide, U.S.&#160;and international sales were 5.4%, 6.8% and 3.8%, respectively. The ten-year compound annual growth rates for worldwide, U.S.&#160;and international sales were 4.0%, 5.4% and&#160;2.5%, respectively.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">23</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In 2024, sales by companies in Europe experienced a decline of 1.0% as compared to the prior year, which included an operational decline of 0.6% and a negative currency impact of 0.4%. In fiscal 2024, the net impact of the Covid-19 Vaccine on the European regions change in operational sales was a negative 4.7%. Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth of 3.6% as compared to the prior year, which included operational growth of 20.4%, and a negative currency impact of 16.8%. Sales by companies in the Asia-Pacific, Africa region experienced a decline of 1.2% as compared to the prior year, including operational growth of 2.3% offset by a negative currency impact of 3.5%.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In 2024, the Company utilized three wholesalers distributing products for both segments that represented approximately 20.5%, 15.6% and 12.3% of the total gross revenues. In 2023, the Company had three wholesalers distributing products for both segments that represented approximately 18.2%, 15.1% and 14.2% of the total gross revenues. </span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.857%"><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:130%">2024 Sales by geographic region (in billions)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><img src="jnj-20241229_g16.jpg" alt="2384" style="height:240px;margin-bottom:5pt;vertical-align:text-bottom;width:356px"/></div></div><div style="display:inline-block;max-width:4.285%;min-width:3.285%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.858%"><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:130%">2024 Sales by segment (in billions)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><img src="jnj-20241229_g17.jpg" alt="2422" style="height:240px;margin-bottom:5pt;vertical-align:text-bottom;width:320px"/></div></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Note: values may have been rounded</span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_97"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Analysis of sales by business segments</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Innovative Medicine segment</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Innovative Medicine segment sales in 2024 were $57.0 billion, an increase of 4.0% from 2023, which included operational growth of 5.7% and a negative currency impact of 1.7%. U.S.&#160;sales were $34.0 billion, an increase of 9.0%. International sales were $23.0 billion, a decrease of 2.5%, which included operational growth of 1.3% offset by a negative currency impact of 3.8%. In&#160;2024, acquisitions and divestitures had a net negative impact of 0.1% on the operational sales growth of the worldwide Innovative Medicine segment. In fiscal 2024, the net impact of the Covid-19 Vaccine on the total Innovative Medicine and International change in operational sales was a negative 1.8% and 4.2%, respectively.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Major Innovative Medicine therapeutic area sales:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.361%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operations<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Currency<br/>Change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Immunology</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$17,828</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$18,052</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">0.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1.6)</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">REMICADE</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,605</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,839</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SIMPONI/SIMPONI ARIA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,190</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,197</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">STELARA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,361</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,858</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TREMFYA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,670</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,147</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other Immunology</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(74.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(74.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Infectious Diseases</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,396</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,418</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(23.1)</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(22.7)</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(0.4)</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">COVID-19 VACCINE</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">198</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,117</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(82.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(82.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EDURANT/rilpivirine</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,272</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,150</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,712</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,854</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other Infectious Diseases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">214</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">297</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(27.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(25.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Neuroscience</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,115</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,140</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(0.4)</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1.7)</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">CONCERTA/methylphenidate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">641</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">783</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(15.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,222</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,115</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SPRAVATO</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,077</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">689</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other Neuroscience</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,175</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,553</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(24.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(20.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Oncology</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">20,781</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">17,661</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">17.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">19.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(2.1)</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">CARVYKTI</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">963</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">92.7</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">92.7</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.0</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">DARZALEX</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,670</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,744</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ERLEADA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,999</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,387</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">IMBRUVICA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,038</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,264</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TECVAYLI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">549</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">395</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ZYTIGA /abiraterone acetate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">631</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">887</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(28.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(25.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other Oncology</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">931</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">484</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">92.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">94.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Pulmonary Hypertension </span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,282</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,815</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">12.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1.8)</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">OPSUMIT</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,184</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,973</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">UPTRAVI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,817</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,582</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other Pulmonary Hypertension</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">281</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">260</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,562</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,671</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(3.0)</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(2.6)</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(0.4)</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">XARELTO</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,373</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,365</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,189</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,306</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Innovative Medicine Sales</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$56,964</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">54,759</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1.7)</span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">25</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Immunology products sales were $17.8 billion in 2024, representing a decrease of 1.2% as compared to the prior year. The decline of STELARA (ustekinumab) sales was driven by share loss primarily due to European biosimilar entrants. Lower sales of REMICADE (infliximab) was due to continued biosimilar competition. The growth of TREMFYA</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(guselkumab) was due to market growth and share gains.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Sales of STELARA in the United States were approximately $6.7 billion in fiscal 2024. Third parties have filed abbreviated Biologics License Applications with the FDA seeking approval to market biosimilar versions of STELARA. The Company has settled certain litigation under the Biosimilar Price Competition and Innovation Act of 2009. According to patent settlement and license agreements, the Company expects continued launches of biosimilar versions of STELARA in Europe and the United States in 2025 which will impact the Company&#8217;s sales of STELARA.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Biosimilar versions of REMICADE have been introduced in the United States and certain markets outside the United States and additional competitors continue to enter the market. Continued infliximab biosimilar competition will result in a further reduction in sales of REMICADE.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Infectious disease products sales were $3.4 billion in 2024, a decline of 23.1% as compared to the prior year primarily driven by a decline in COVID-19 vaccine revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Neuroscience products sales were $7.1 billion in 2024, representing a decrease of 0.4% as compared to the prior year primarily driven by a decline in Other Neuroscience. The decline was partially offset by the growth of SPRAVATO (esketamine) driven by the ongoing launch and increased physician and patient demand. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Oncology products achieved sales of $20.8 billion in 2024, representing an increase of 17.7% as compared to the prior year. Strong sales of DARZALEX (daratumumab) were driven by continued share gains and market growth. Growth of ERLEADA (apalutamide) was primarily due to continued share gains and market growth. Sales of CARVYKTI (ciltacabtagene autoleucel) were driven by continued share gains, capacity expansion and manufacturing efficiencies. Additionally, sales from the ongoing launches of TECVAYLI (teclistamab-cqyv), TALVEY (talquetamab-tgvs) and RYBREVANT (amivantamab), included in Other Oncology, contributed to the growth. Growth was partially offset by ZYTIGA (abiraterone acetate) due to loss of exclusivity and IMBRUVICA (ibrutinib) due to global competitive pressures. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Pulmonary Hypertension products sales were $4.3 billion, representing an increase of 12.3% as compared to the prior year. Sales growth of both OPSUMIT (macitentan) and UPTRAVI (selexipag) was driven by market growth and share gains. Growth in Other Pulmonary Hypertension was driven by OPSYNVI (macitentan/tadalafil). </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Cardiovascular/Metabolism/Other products sales were $3.6 billion, a decline of 3.0% as compared to the prior year driven by declines in Other. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company maintains a policy that no end customer will be permitted direct delivery of product to a location other than the billing location. This policy impacts contract pharmacy transactions involving non-grantee 340B covered entities for most of the Company&#8217;s drugs, subject to multiple exceptions. Both grantee and non-grantee covered entities can maintain certain contract pharmacy arrangements under policy exceptions. The Company has been and will continue to offer 340B discounts to covered entities on all of its covered outpatient drugs, and it believes its policy will improve its ability to identify inappropriate duplicate discounts and diversion prohibited by the 340B statute. The 340B Drug Pricing Program is a U.S. federal government program requiring drug manufacturers to provide significant discounts on covered outpatient drugs to covered&#160;entities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">26</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">During 2024, the Company advanced its pipeline with several regulatory submissions and approvals for new drugs and additional indications for existing drugs as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Product Name<br/>(Chemical Name)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Indication</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US<br/>Approval</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">EU<br/>Approval</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US<br/>Filing</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">EU<br/>Filing</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BALVERSA (erdafitinib)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma and Selected Fibroblast Growth Factor Receptor Gene Alterations&#160;(THOR)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">CARVYKTI (ciltacabtagene autoleucel)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Treatment for Relapsed and Refactor multiple myeloma with 1-3 PL (CARTITUDE-4)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">DARZALEX (daratumumab)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Treatment for frontline multiple myeloma transplant eligible (PERSEUS)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">DARZALEX (daratumumab)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Treatment for frontline multiple myeloma transplant ineligible (CEPHEUS)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">DARZALEX (daratumumab)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Treatment as subcutaneous monotherapy for high-risk smoldering multiple myeloma (AQUILA)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EDURANT (rilpivirine)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Treatment for pediatric patients (2-12 years old) with&#160;HIV</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">IMBRUVICA (ibrutinib)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Treatment for frontline MCL (Triangle)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">nipocalimab</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Treatment for Generalized Myasthenia Gravis</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">OPSUMIT (macitentan)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Treatment for pediatric pulmonary arterial hypertension (TOMORROW)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">OPSYNVI (macitentan/tadalafil STCT)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Treatment for pulmonary arterial hypertension</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">REKAMBYS</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Treatment for Adolescents HIV</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">RYBREVANT (amivantamab)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In Combination with Chemotherapy for the First-Line Treatment of Adult Patients with Advanced Non-Small Cell Lung Cancer with Activating EGFR Exon 20 Insertion Mutations (PAPILLON)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">RYBREVANT (amivantamab)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Treatment for subcutaneous (PALOMA-3)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">RYBREVANT / LAZCLUZE</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Treatment for Non-Small Cell Lung Cancer (MARIPOSA)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">RYBREVANT</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Treatment for Non-Small Cell Lung Cancer 2L (MARIPOSA-2)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SIMPONI (golimumab)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Treatment of Patients with Pediatric Ulcerative Colitis</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SPRAVATO (esketamine) monotherapy</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Treatment of Patients with Treatment Resistant Depression (TRD4005)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">STELARA (ustekinumab)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Treatment of Patients with Pediatric Crohn's Disease</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TREMFYA (guselkumab)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Treatment of Patients with Ulcerative Colitis (QUASAR)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TREMFYA (guselkumab)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Subcutaneous Induction for treatment of patients with Ulcerative Colitis (ASTRO)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TREMFYA (guselkumab)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Subcutaneous Induction for treatment of patients with Crohn's Disease (GRAVITI)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TREMFYA (guselkumab)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Treatment of Patients with Crohn's Disease (GALAXI)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TREMFYA (guselkumab)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Treatment of Patients with Pediatric Psoriasis</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">UPTRAVI (selexipag)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Treatment of Patients with Pediatric Pulmonary Arterial Hypertension (SALTO)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:130%">&#8226;</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">27</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">MedTech segment</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The MedTech segment sales in 2024 were $31.9 billion, an increase of 4.8% from 2023, which included operational growth of 6.2% and a negative currency impact of 1.4%. U.S.&#160;sales were $16.3 billion, an increase of 6.9% as compared to the prior year. International sales were $15.5 billion, an increase of 2.6% as compared to the prior year, which included operational growth of 5.4% and a negative currency impact of 2.8%. In 2024, the net impact of acquisitions and divestitures on the MedTech segment worldwide operational sales growth was a positive 1.5% primarily related to the Shockwave acquisition. </span></div><div style="margin-bottom:4pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Major MedTech franchise sales:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.013%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operations<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Currency<br/>Change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Surgery</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$9,845</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10,037</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1.9)</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">0.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(2.0)</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Advanced</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,488&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,671&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,358&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,366&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Orthopaedics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9,158</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,942</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Hips</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,638&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,560&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Knees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,545&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,456&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trauma</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,049&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,979&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Spine, Sports &amp; Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,926&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,947&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cardiovascular </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,707</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6,350</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">21.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">22.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Electrophysiology</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,267&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,688&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Abiomed</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,496&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,306&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shockwave </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">564&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other Cardiovascular</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">380&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">356&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Vision</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,146</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,072</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contact Lenses/Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,733&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,702&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Surgical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,413&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,370&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total MedTech Sales</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$31,857</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">30,400</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1.4)</span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">Previously referred to as Interventional Solutions</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Acquired on May 31, 2024</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">*&#160;&#160;&#160;&#160;Percentage greater than 100% or not meaningful</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Surgery franchise sales were $9.8 billion in 2024, representing a decrease of 1.9% from 2023. The decline in Advanced Surgery was primarily due to China volume-based procurement across all platforms and competitive pressures in Energy and Endocutters. This was partially offset by the strength of the portfolio and commercial execution in Biosurgery as well as the strength of new products in Endocutters. Growth in General Surgery was primarily driven by technology penetration and benefits from the differentiated Wound Closure portfolio as well as increased procedure volume. This growth was offset by the negative impact of currency and the Acclarent&#160;divestiture.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Orthopaedics franchise sales were $9.2 billion in 2024, representing an increase of 2.4% from 2023. The fiscal 2024 includes a one-time revenue recognition timing change related to certain products across all Orthopaedic platforms in the U.S. which positively impacted the worldwide Orthopaedics franchise growth as well as the negative impact from the near-term revenue disruption related to the previously announced Orthopaedics restructuring. The growth in Hips reflects continued strength of the portfolio primarily in the Anterior approach, and global procedure growth. The growth in Knees was primarily driven by the ATTUNE portfolio, pull through related to the VELYS Robotic assisted solution and global procedure growth. Growth in Trauma was driven by the adoption of recently launched products. The decline in Spine, Sports &amp; Other was primarily driven by competitive pressures and impacts from China volume-based procurement. This was partially offset by growth in the U.S. market.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">28</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Cardiovascular franchise, which includes sales from Shockwave Medical (Shockwave) acquired on May 31, 2024, achieved sales of $7.7 billion in 2024, representing an increase of 21.4% from 2023. Electrophysiology growth was driven by global procedure growth, new product performance and commercial execution. This was partially offset by the impacts of volume-based procurement in China and competitive pressures in Pulsed Field Ablation catheters in the U.S. Abiomed sales reflect the strength of all major commercialized regions driven by the continued adoption of Impella 5.5 and Impella RP. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Vision franchise achieved sales of $5.1 billion in 2024, representing an increase of 1.5% from 2023. Contact Lenses/Other growth was primarily driven by price actions, continued strong performance in the ACUVUE OASYS 1-Day family of products (including recent launches), impacts from a one-time change in contract shipping terms in the U.S. and lapping of prior year impacts of Russian sanctions partially offset by U.S. distributor stocking dynamics. Surgical growth was primarily driven by the continued strength of recent innovations and commercial execution partially offset by China volume-based procurement and competitive pressures in the U.S. </span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_100"></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Analysis of consolidated earnings before provision for taxes on income</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Consolidated earnings before provision for taxes on income was $16.7 billion and $15.1 billion for the years 2024 and 2023, respectively. As a percent to sales, consolidated earnings before provision for taxes on income was 18.8% and 17.7%, in 2024 and 2023, respectively.</span></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Earnings before provision for taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><img src="jnj-20241229_g18.jpg" alt="364" style="height:182px;margin-bottom:5pt;vertical-align:text-bottom;width:182px"/></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(Dollars in billions. Percentages in chart are as a percent to total sales)</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Cost of products sold and selling, marketing and administrative expenses:</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.857%"><div style="margin-bottom:6pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Cost of products sold</span></div><div style="margin-bottom:6pt;margin-top:14pt;text-align:center"><img src="jnj-20241229_g19.jpg" alt="538" style="height:182px;margin-bottom:5pt;vertical-align:text-bottom;width:182px"/></div></div><div style="display:inline-block;max-width:4.285%;min-width:3.285%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.858%"><div style="margin-bottom:6pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Selling, marketing &amp; administrative</span></div><div style="margin-bottom:6pt;margin-top:14pt;text-align:center"><img src="jnj-20241229_g20.jpg" alt="576" style="height:182px;margin-bottom:5pt;vertical-align:text-bottom;width:182px"/></div></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(Dollars in billions. Percentages in chart are as a percent to total sales)</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">29</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Cost of products sold:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Cost of products sold decreased as a percent to sales driven by:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Lower one-time COVID-19 vaccine supply network related exit costs in 2024 ($0 in 2024 versus $0.2 billion 2023) in the Innovative Medicine business</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Prior year restructuring related excess inventory costs in the MedTech business </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">partially offset by</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">The fair value Inventory step-up of $0.4 billion related to the business combination accounting associated with Shockwave </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The intangible asset amortization expense included in cost of products sold was $4.5 billion for both fiscal years 2024 and&#160;2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Selling, Marketing and Administrative expense:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Selling, Marketing and Administrative Expenses increased as a percent to sales driven by:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Increased commercial investment in the Innovative Medicine business</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">partially offset by</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Optimization efforts related to the residual costs associated with the Kenvue separation </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Research and Development expense:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Research and development expense by segment of business was as follows:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% of Sales*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% of Sales*</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Innovative Medicine</span></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$13,529&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"/><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23.8&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$11,963&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"/><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.8&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MedTech</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3,703&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3,122&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total research and development expense</span></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$17,232</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">19.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$15,085</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">17.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Percent increase/(decrease) over the prior year</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*As a percent to segment sales </span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Research and development activities represent a significant part of the Company's business. These expenditures relate to the processes of discovering, testing and developing new products, upfront payments and developmental milestones, improving existing products, as well as ensuring product efficacy and regulatory compliance prior to launch. The Company remains committed to investing in research and development with the aim of delivering high quality and innovative products. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Research and Development increased as a percent to sales primarily driven by:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Acquired in-process research &amp; development expense of $1.25 billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition) and pipeline advancement in the Innovative Medicine business</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Acquired in-process research &amp; development expense of $0.5 billion from the V-Wave acquisition in the MedTech business</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">In-Process Research and Development Impairments (IPR&amp;D): </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In the fiscal year 2024, the Company recorded a charge of approximately $0.2&#160;billion associated with the M710 (biosimilar) asset acquired as part of the acquisition of Momenta Pharmaceuticals in 2020. There was also a partial impairment of this asset for $0.2 billion in the fiscal 2023. This asset is now fully impaired.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Other (Income) Expense, Net:</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;Other (income) expense, net is the account where the Company records gains and losses related to the sale and write-down of certain investments in equity securities held by Johnson &amp; Johnson Innovation - JJDC, Inc. (JJDC), changes in the fair value of securities, investment (income)/loss related to employee benefit programs, gains and losses on divestitures, certain transactional currency gains and losses, acquisition and divestiture related costs, litigation accruals and settlements, as well as royalty income.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">30</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Other (income)&#160;expense, net for the fiscal year 2024 reflected less expense of $1.9 billion as compared to the prior year primarily due to the following:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Billions)(Income)/Expense</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Litigation related</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$5.5</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.9</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.4)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acquisition, Integration and Divestiture related</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in the fair value of securities</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">COVID-19 vaccine manufacturing exit related costs</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Monetization of royalty rights</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.0</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee benefit plan related</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.9)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.4)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.8)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.6)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Other (Income) Expense, Net</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$4.7</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6.6</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1.9)</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">The fiscal years 2024 and 2023 include charges primarily for talc matters (See Note&#160;19 to the Consolidated Financial Statements for more details). The&#160;fiscal year 2023 includes favorable intellectual property related litigation settlements of approximately $0.3 billion.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">The fiscal year 2024 is primarily related to the acquisition of Shockwave. The fiscal year 2023 is primarily related to the impairment of Ponvory and one-time integration costs related to the acquisition of Abiomed. </span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt">The fiscal year 2024 includes the loss of $0.4 billion on the completion of the debt for equity exchange of the retained stake in Kenvue. The fiscal year 2023 includes $0.4 billion related to the unfavorable change in the fair value of the remaining stake in Kenvue and $0.4 billion related to the partial impairment of Idorsia convertible debt and the change in the fair value of the Idorsia equity securities held.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Interest (Income) Expense:</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;Interest income in the fiscal years 2024 and 2023 was $1.3 billion. Interest expense in the fiscal years 2024 and 2023 was $0.8 billion. Cash, cash equivalents and marketable securities totaled $24.5&#160;billion at the end of 2024, and averaged $23.7&#160;billion as compared to the cash, cash equivalents and marketable securities total of $22.9&#160;billion and $22.6&#160;billion average balance in 2023. The total debt balance at the end of 2024 was $36.6&#160;billion with an average debt balance of $33.0&#160;billion as compared to $29.3&#160;billion at the end of 2023 and an average debt balance of $34.5 billion. The higher debt balance was due to the senior unsecured notes issued by the Company in the fiscal second quarter of 2024. The net proceeds from this offering were used to fund the Shockwave acquisition which closed on May 31, 2024 and for general corporate purposes. </span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Income before tax by segment</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Income (loss) before tax by segment of business were as follows:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.078%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.721%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.429%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Income Before Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Segment Sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Percent of Segment<br/>Sales</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Innovative Medicine</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$18,919</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">18,246</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">56,964</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">54,759</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">33.2&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">%</span></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">33.3&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MedTech</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3,740</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,669</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">31,857</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">30,400</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">11.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">15.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Segment earnings before tax</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">22,659</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">22,915</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">88,821</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">85,159</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">25.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">26.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: Expenses not allocated to segments</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5,972</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7,853</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide income before tax</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$16,687</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">15,062</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">88,821</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">85,159</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">18.8&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">%</span></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">17.7&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">See Note&#160;17 to the Consolidated Financial Statements for more details.</span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. The fiscal years 2024 and 2023&#160;include charges for talc matters of approximately $5.1 billion and $7.0&#160;billion, respectively. The fiscal 2024 includes a loss of approximately $0.4 billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock. The&#160;fiscal&#160;year 2023 includes an approximately $0.4 billion unfavorable change in the fair value of the retained stake in Kenvue.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">31</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Innovative Medicine segment:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In 2024, the Innovative Medicine segment income before tax as a percent to sales was 33.2% versus 33.3% in 2023.&#160;The decrease in the income before tax as a percent of sales was primarily driven by the following:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Acquired in-process research and development expense of $1.25 billion to secure the global rights to the NM26 bispecific&#160;antibody</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Litigation expense of $0.4 billion in 2024, primarily related to Risperdal Gynecomastia, versus favorable litigation related items of $0.1 billion in 2023</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Increased research and development to advance the pipeline</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Increased commercial investment in selling and marketing expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">partially offset by </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Monetization of royalty rights of $0.3 billion in 2024</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Lower one-time COVID-19 Vaccine related exit costs of $0.1 billion in 2024 versus $0.7 billion in 2023</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Lower amortization expense of $0.2 billion in 2024 versus 2023 </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Restructuring charges of $0.1 billion in 2024 versus $0.5 billion in 2023</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">A gain of $0.1 billion in 2024 as compared to a loss of $0.4 billion in 2023 related to changes in the fair value of securities</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">MedTech segment:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In 2024, the MedTech segment income before tax as a percent to sales was 11.7% versus 15.4% in 2023. The decrease in the income before tax as a percent to sales was primarily driven by the following:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Acquisition and integration related costs of $1.0 billion in 2024 (primarily related to the Shockwave acquisition) versus $0.2 billion in 2023 related to Abiomed</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Acquired in-process research and development expense of $0.5 billion from the V-Wave acquisition in 2024</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Higher amortization expense of $0.2 billion in 2024 related to Shockwave</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">partially offset by</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">A gain of $0.2 billion related to the Acclarent divestiture in 2024</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">Restructuring related charge of $0.2 billion in 2024 versus $0.3 billion in 2023</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Restructuring:</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;In the fiscal year 2023, the Company completed a prioritization of its research and development (R&amp;D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&amp;D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The pre-tax restructuring charge of approximately $0.1 billion in the fiscal year 2024 was recorded in Restructuring on the Consolidated Statement of Earnings, and included the termination of partnered and non-partnered development program costs, asset impairments and asset divestments. The pre-tax restructuring charge of approximately $0.5 billion in the fiscal year 2023, of which $449 million was recorded in Restructuring and $30 million was recorded in Cost of products sold on the Consolidated Statement of Earnings, and included the termination of partnered and non-partnered program costs and asset impairments. Total project costs of approximately $0.6&#160;billion have been recorded since the restructuring was announced. The program was completed in the fiscal fourth quarter of 2024.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">32</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In the fiscal year 2023, the Company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense of $0.2 billion in the fiscal year 2024, of which $132 million was recorded in Restructuring and $35 million was recorded in Cost of products sold on the Consolidated Statement of Earnings, primarily included costs related to market and product exits. The pre-tax restructuring expense of $0.3 billion in the fiscal year 2023, of which $40 million was recorded in Restructuring and $279 million was recorded in Cost of products sold on the Consolidated Statement of Earnings, primarily included inventory and instrument charges related to market and product exits. Total project costs of approximately $0.5&#160;billion have been recorded since the restructuring was announced. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">See Note&#160;20 to the Consolidated Financial Statements for additional details related to the restructuring programs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Provision for Taxes on Income:</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;The worldwide effective income tax rate from continuing operations was 15.7% in 2024 and 11.5% in 2023. For discussion related to the fiscal year 2024 provision for taxes refer to Note&#160;8 to the Consolidated Financial&#160;Statements. </span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On December 15, 2022, the European Union (EU) Member States formally adopted the EU&#8217;s Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development (OECD) Pillar Two Framework that was supported by over 130 countries worldwide. Several EU and non-EU countries have enacted Pillar Two legislation with an initial effective date of January 1, 2024, with other aspects of the law effective in 2025 or later. In the fiscal year 2024, the net impact of Pillar Two legislation was less than 1.0% to the Company&#8217;s effective tax rate. While countries continue to enact new provisions or issue new regulations, based on current guidance, the Company expects the net impact of Pillar Two in fiscal year 2025 to be up to 1.0% to the Company&#8217;s effective tax rate.</span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_103"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Liquidity and capital resources</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Liquidity&#160;&amp; cash flows</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Cash and cash equivalents were $24.1&#160;billion at the end of 2024 as compared to $21.9&#160;billion at the end of 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The primary sources and uses of cash that contributed to the $2.2&#160;billion increase were:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.204%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in billions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$21.9</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Q4 2023 Cash and cash equivalents balance</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24.3</span></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">cash generated from operating activities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18.6)</span></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">net cash used by investing activities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.1)</span></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">net cash used by financing activities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.4)</span></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">effect of exchange rate and rounding</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$24.1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Q4 2024 Cash and cash equivalents balance</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In addition, the Company had $0.4 billion in marketable securities at the end of fiscal year 2024 and $1.1 billion at the end of fiscal year 2023. See Note&#160;1 to the Consolidated Financial Statements for additional details on cash, cash equivalents and marketable securities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Cash flow from operations of $24.3&#160;billion was the result of:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.204%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars In billions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$14.1</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Net Earnings</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.4</span></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation, asset write-downs and charges for acquired in-process research and development assets partially offset by net gain on sale of assets/businesses and the deferred tax provision</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.7</span></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">a decrease in other current and non-current assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.6</span></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">an increase in accounts payable and accrued liabilities </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.5)</span></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">an increase in accounts receivable and inventories </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$24.3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Cash flow from operations</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">33</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Cash flow used for investing activities of $18.6 billion was primarily due to:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.204%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in billions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(4.4)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">additions to property, plant and equipment</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(15.1)</span></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">acquisitions, net of cash acquired</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.7</span></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">proceeds from the disposal of assets/businesses, net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.8)</span></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">acquired in-process research and development assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.7</span></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">net sales of investments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.5</span></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">credit support agreements activity, net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.2)</span></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">other (including capitalized licenses and milestones)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(18.6)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash used for investing activities</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Cash flow used for financing activities of $3.1 billion was primarily due to: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.204%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in billions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$(11.8)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">dividends to shareholders </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(2.4)</span></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">repurchase of common stock</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">11.0</span></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">net proceeds from short and long-term debt</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.8</span></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">proceeds from stock options exercised/employee withholding tax on stock awards, net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.3</span></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">credit support agreements activity, net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(1.0)</span></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">settlement of convertible debt acquired from Shockwave</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$(3.1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Net cash used for financing activities</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table summarizes cash taxes paid net of refunds: </span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Federal </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$3,815</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,722</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,158</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. State and Local taxes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">341</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">236</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">216</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total U.S.</span></td><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$4,156</span></td><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,958</span></td><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,374</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total Foreign</span></td><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,558</span></td><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,616</span></td><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,849</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total cash taxes paid net of refunds</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$6,714</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$8,574</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$5,223</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">Includes TCJA foreign undistributed earnings payments of $2.0 billion in fiscal year 2024, $1.5 billion in fiscal year 2023 and $0.8 billion in fiscal year 2022</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">As of December&#160;29, 2024, the Company's notes payable and long-term debt was in excess of cash, cash equivalents and marketable securities. As of December&#160;29, 2024, the net debt position was $12.1 billion as compared to the prior year of $6.4 billion. The debt balance at the end of 2024 was $36.6 billion as compared to $29.3 billion in 2023. In the fiscal second quarter of 2024, the Company issued senior unsecured notes for a total of $6.7 billion. For additional details on borrowings, see Note 7 to the Consolidated Financial Statements. The net proceeds from this offering were used to fund the Shockwave acquisition which closed on May 31, 2024, and for general corporate purposes. Considering recent market conditions, the Company has re-evaluated its operating cash flows and liquidity profile and does not foresee any significant incremental risk. The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs, including the Company's remaining balance to be paid on the agreement to settle opioid litigation for approximately $1.5 billion and the approximately $11.6 billion ($13.5 billion nominal) reserve for talc matters (See Note 19 to the Consolidated Financial Statements for additional details). In addition, the Company monitors the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of 198,734,444 shares of its common stock, par value $0.01 per share (the Kenvue Common Stock), at an initial public offering of $22.00 per share for net proceeds of $4.2&#160;billion. The excess of the net proceeds from the IPO over the net book value of the Johnson &amp; Johnson </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">34</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">divested interest was $2.5 billion and was recorded to additional paid-in capital. As of the closing of the IPO, Johnson &amp;&#160;Johnson owned approximately 89.6% of the total outstanding shares of Kenvue Common Stock and at July 2, 2023, the non-controlling interest of $1.3&#160;billion associated with Kenvue was reflected in equity attributable to non-controlling interests in the consolidated balance sheet. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On August 23, 2023, Johnson &amp; Johnson completed the disposition of an additional 80.1% ownership of Kenvue Common Stock through an exchange offer, which resulted in Johnson &amp; Johnson acquiring 190,955,436 shares of the Company&#8217;s common stock in exchange for 1,533,830,450 shares of Kenvue Common Stock. The $31.4 billion of Johnson &amp; Johnson common stock received in the exchange offer is recorded in Treasury stock. Following the exchange offer, the Company owned 9.5% of the total outstanding shares of Kenvue Common Stock that was recorded in other assets within continuing operations at the fair market value of $4.3 billion as of August 23, 2023 and $3.9 billion as of December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Johnson &amp; Johnson divested net assets of $11.6 billion as of August 23, 2023, and the accumulated other comprehensive loss attributable to the Consumer Health business at that date was $4.3 billion. Additionally, at the date of the exchange offer, Johnson &amp; Johnson decreased the non-controlling interest by $1.2 billion to record the deconsolidation of Kenvue. This&#160;resulted in a gain on the exchange offer of $21.0 billion that was recorded in Net earnings from discontinued operations, net of taxes in the consolidated statements of earnings for the fiscal third quarter of 2023. This one-time gain includes a gain&#160;of $2.8 billion on the Kenvue Common Stock retained by Johnson &amp; Johnson. The gain on the exchange offer qualifies as a tax-free transaction for U.S. federal income tax purposes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On May 15, 2024, the Company issued $3.6&#160;billion aggregate principal amount of commercial paper and received $3.6&#160;billion of net cash proceeds to be used for general corporate purposes. On May 17, 2024, the Company completed a Debt-for-Equity Exchange of its remaining 182,329,550 shares of Kenvue Common Stock for the outstanding Commercial Paper. Upon completion of the Debt-for-Equity Exchange, the Commercial Paper was satisfied and discharged and the Company no longer owns any shares of Kenvue Common Stock. This exchange resulted in a loss of approximately $0.4 billion recorded in Other (income) expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table summarizes the Company&#8217;s material contractual obligations and their aggregate maturities as of December&#160;29, 2024: To satisfy these obligations, the Company intends to use cash from operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.251%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Tax Legislation<br/>(TCJA)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Debt Obligations</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Interest on<br/>Debt Obligations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,536</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,749</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,075</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,360</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,999</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,030</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,029</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,385</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,406</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,275</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">977</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,252</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2029</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,444</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">922</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,366</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">After 2029</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,548</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,921</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,469</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$2,536</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">32,400</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13,946</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">48,882</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">For tax matters, see Note&#160;8 to the Consolidated Financial Statements. For the proposed talc settlement payments, see Note 19 to the Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">35</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Financing and market risk</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company uses financial instruments to manage the impact of foreign exchange rate changes on cash flows. Accordingly, the Company enters into forward foreign exchange contracts to protect the value of certain foreign currency assets and liabilities and to hedge future foreign currency transactions primarily related to product costs. Gains or losses on these contracts are offset by the gains or losses on the underlying transactions. A 10% appreciation of the U.S.&#160;Dollar from the December&#160;29, 2024 market rates would increase the unrealized value of the Company&#8217;s forward contracts by $0.2 billion. Conversely, a 10% depreciation of the U.S.&#160;Dollar from the December&#160;29, 2024 market rates would decrease the unrealized value of the Company&#8217;s forward contracts by $0.2&#160;billion. In either scenario, the gain or loss on the forward contract would be offset by the gain or loss on the underlying transaction, and therefore, would have no impact on future anticipated earnings and cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company hedges the exposure to fluctuations in currency exchange rates, and the effect on certain assets and liabilities in foreign currency, by entering into currency swap contracts. A 1% change in the spread between U.S.&#160;and foreign interest rates on the Company&#8217;s interest rate sensitive financial instruments would either increase or decrease the unrealized value of the Company&#8217;s swap contracts by approximately $1.5 billion. In either scenario, at maturity, the gain or loss on the swap contract would be offset by the gain or loss on the underlying transaction, and therefore, would have no impact on future anticipated cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company does not enter into financial instruments for trading or speculative purposes. Further, the Company has a policy of only entering into contracts with parties that have at least an investment grade credit rating. The counterparties to these contracts are major financial institutions and there is no significant concentration of exposure with any one counterparty. Management believes the risk of loss is remote. The Company entered into credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. See Note&#160;6 to the Consolidated Financial Statements for additional details on credit support agreements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company invests in both fixed rate and floating rate interest earning securities which carry a degree of interest rate risk. The fair market value of fixed rate securities may be adversely impacted due to a rise in interest rates, while floating rate securities may produce less income than predicted if interest rates fall. A 1% (100 basis points) change in spread on the Company&#8217;s interest rate sensitive investments would either increase or decrease the unrealized value of cash equivalents and current marketable securities by less than $8.0 million. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has access to substantial sources of funds at numerous banks worldwide. In June 2024, the Company secured a new 364-day Credit Facility of $10&#160;billion, which expires on June&#160;25, 2025. Interest charged on borrowings under the credit line agreement is based on either Secured Overnight Financing Rate (SOFR) Reference Rate or other applicable market rate as allowed plus applicable margins. Commitment fees under the agreement are not material.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Total borrowings at the end of 2024 and 2023 were $36.6&#160;billion and $29.3&#160;billion, respectively. The increase in the borrowings was due to the issuance of new debt in 2024. In 2024, net debt (cash and current marketable securities, net of debt) was $12.1&#160;billion compared to net debt of $6.4 billion in 2023. Total debt represented 34.0% of total capital (shareholders&#8217; equity and total debt) in 2024 and 30.0% of total capital in 2023. Shareholders&#8217; equity per share at the end of 2024 was $29.70 compared to $28.57 at year-end 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">A summary of borrowings can be found in Note&#160;7 to the Consolidated Financial Statements.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company increased its dividend in 2024 for the 62</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">nd</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;consecutive year. Cash dividends paid were $4.91 per share in 2024 and $4.70 per share in 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On January 2, 2025, the Board of Directors declared a regular cash dividend of $1.24 per share, payable on March 4, 2025 to shareholders of record as of February 18, 2025.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">36</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_106"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Other information</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Critical accounting policies and estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Management&#8217;s discussion and analysis of results of operations and financial condition are based on the Company&#8217;s consolidated financial statements that have been prepared in accordance with accounting principles generally accepted in the U.S.&#160;(GAAP). The preparation of these financial statements requires that management make estimates and assumptions that affect the amounts reported for revenues, expenses, assets, liabilities and other related disclosures. Actual results may or may not differ from these estimates. The Company believes that the understanding of certain key accounting policies and estimates are essential in achieving more insight into the Company&#8217;s operating results and financial condition. These key accounting policies include revenue recognition, income taxes, legal and self-insurance contingencies, valuation of long-lived assets, assumptions used to determine the amounts recorded for pensions and other employee benefit plans and accounting for stock based awards.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Revenue Recognition:</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns, discounts to customers and governmental clawback provisions are accounted for as variable consideration and recorded as a reduction in sales.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates and discounts are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Sales returns are estimated and recorded based on historical sales and returns information. Products that have lost patent exclusivity, or that otherwise exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. In accordance with the Company&#8217;s accounting policies, the Company generally issues credit to customers for returned goods. The Company&#8217;s sales returns reserves are accounted for in accordance with the U.S.&#160;GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Innovative Medicine segment are almost exclusively not resalable. Sales returns for certain franchises in the MedTech segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during the fiscal years&#160;2024, 2023 and 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Promotional programs, such as product listing allowances are recorded in the same period as related sales and include volume-based sales incentive programs. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements of certain products, which are included in sales to customers. Profit-share payments were less than 2.0% of the total revenues in fiscal year 2024 and 2023, respectively, and less than 3.0% of the total revenues in the fiscal year 2022 and are included in sales to customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In addition, the Company enters into collaboration arrangements that contain multiple revenue generating activities. Amounts due from collaborative partners for these arrangements are recognized as each activity is performed or delivered, based on the relative selling price. Upfront fees received as part of these arrangements are deferred and recognized over the performance period. See Note&#160;1 to the Consolidated Financial Statements for additional disclosures on collaborations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Reasonably likely changes to assumptions used to calculate the accruals for rebates, returns and promotions are not anticipated to have a material effect on the financial statements. The Company currently discloses the impact of changes to assumptions in the quarterly or annual filing in which there is a material financial statement impact.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">37</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Below are tables that show the progression of accrued rebates, returns, promotions, reserve for doubtful accounts and reserve for cash discounts by segment of business for the fiscal years ended December&#160;29, 2024 and December&#160;31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Innovative Medicine segment</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.114%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:14.4pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Balance at</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Beginning</span></div><div style="padding-left:14.4pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">of Period</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Accruals</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Payments/</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Credits</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Balance at</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">End of</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">Period</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:130%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued rebates </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$14,661</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52,786</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(51,667)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,780</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued returns</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">634</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">845</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(355)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,124</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued promotions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$15,301</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">53,634</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(52,028)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">16,907</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reserve for doubtful accounts</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reserve for cash discounts</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">111</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,493</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,495)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">109</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$15,445</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">55,141</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(53,529)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">17,057</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued rebates </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$12,289</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47,523</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(45,151)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,661</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued returns</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">649</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">332</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(347)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">634</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued promotions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$12,939</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">47,867</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(45,505)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15,301</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reserve for doubtful accounts</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reserve for cash discounts</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">110</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,386</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,385)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">111</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$13,093</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">49,253</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(46,901)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15,445</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:4.55pt;font-weight:400;line-height:130%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.93pt">Includes reserve for customer rebates of $187&#160;million at December&#160;29, 2024 and $165&#160;million at December&#160;31, 2023, recorded as a contra&#160;asset. </span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:4.55pt;font-weight:400;line-height:130%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.88pt">Includes prior period adjustments</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">38</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:130%">MedTech segment</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.114%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at<br/>Beginning of<br/>Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accruals</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Payments/<br/>Credits</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at<br/>End of<br/>Period</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued rebates</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1,455</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,955</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,986)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,424</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued returns</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">125</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">543</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(550)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">118</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued promotions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(65)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$1,605</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6,560</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(6,601)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,564</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reserve for doubtful accounts</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">133</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(38)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">126</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reserve for cash discounts</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">92</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(91)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$1,743</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6,683</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(6,730)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,696</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued rebates</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1,470</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,241</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,256)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,455</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued returns</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">134</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">555</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(564)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">125</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued promotions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(92)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$1,647</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6,870</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(6,912)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,605</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reserve for doubtful accounts</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">125</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(25)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reserve for cash discounts</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">96</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(100)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$1,781</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6,999</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(7,037)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,743</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:4.55pt;font-weight:400;line-height:130%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.93pt">Includes reserve for customer rebates of $704&#160;million at December&#160;29, 2024 and $740&#160;million at December&#160;31, 2023, recorded as a contra&#160;asset.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Income Taxes:</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP, which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January&#160;1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the tax effect of this repatriation would be approximately $0.5 billion under currently enacted tax laws and regulations and at current currency exchange rates. This amount does not include the possible benefit of U.S. foreign tax credits, which may substantially offset this cost.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">See Note 1 and Note 8 to the Consolidated Financial Statements for further information regarding income taxes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Legal and Self Insurance Contingencies:&#160;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company records accruals for various contingencies, including legal proceedings and product liability claims as these arise in the normal course of business. The accruals are based on management&#8217;s judgment as to the probability of losses and, where applicable, actuarially determined estimates. The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company follows the provisions of U.S.&#160;GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">39</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">See Notes 1 and 19 to the Consolidated Financial Statements for further information regarding product liability and legal&#160;proceedings.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Long-Lived and Intangible Assets:</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;The Company assesses changes, both qualitatively and quantitatively, in economic conditions and makes assumptions regarding estimated future cash flows in evaluating the value of the Company&#8217;s property, plant and equipment, goodwill and intangible assets. As these assumptions and estimates may change over time, it may or may not be necessary for the Company to record impairment charges.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Employee Benefit Plans:</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. These plans are based on assumptions for the discount rate, expected return on plan assets, mortality rates, expected salary increases, healthcare cost trend rates and attrition rates. See Note&#160;10 to the Consolidated Financial Statements for further details on these rates.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Stock Based Compensation:</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;The Company recognizes compensation expense associated with the issuance of equity instruments to employees for their services. Based on the type of equity instrument, the fair value is estimated on the date of grant using either the Black-Scholes option valuation model or a combination of both the Black-Scholes option valuation model and Monte Carlo valuation model, and is expensed in the financial statements over the service period. The input assumptions used in determining fair value are the expected life, expected volatility, risk-free rate and expected dividend yield. For performance share units, the fair market value is calculated for the two component goals at the date of grant: adjusted operational earnings per share and relative total shareholder return. The fair values for the earnings per share goal of each performance share unit was estimated on the date of grant using the fair market value of the shares at the time of the award, discounted for dividends, which are not paid on the performance share units during the vesting period.&#160;The fair value for the relative total shareholder return goal of each performance share unit was estimated on the date of grant using the Monte Carlo valuation model. See Note&#160;16 to the Consolidated Financial Statements for additional information.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">New accounting pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Refer to Note&#160;1 to the Consolidated Financial Statements for recently adopted accounting pronouncements and recently issued accounting pronouncements not yet adopted as of December&#160;29, 2024.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">40</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Economic and market factors</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company is aware that its products are used in an environment where, for more than a decade, policymakers, consumers and businesses have expressed concerns about the rising cost of healthcare. In response to these concerns, the Company has a long-standing policy of pricing products responsibly. For the period 2014&#160;- 2024, in the U.S., the weighted average compound annual growth rate of the Company&#8217;s net price increases for healthcare products (prescription and over-the-counter drugs, hospital and professional products) was below the U.S.&#160;Consumer Price Index (CPI).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company operates in certain countries where the economic conditions continue to present significant challenges. The Company continues to monitor these situations and take appropriate actions. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate. The Company has accounted for operations in Argentina, Venezuela, Turkey and Egypt (beginning in the fiscal fourth quarter of 2024) as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. This did not have a material impact to the Company's results in the period. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In July 2023, Janssen Pharmaceuticals, Inc. (Janssen) filed litigation against the U.S. Department of Health and Human Services as well as the Centers for Medicare and Medicaid Services challenging the constitutionality of the IRA's Medicare Drug Price Negotiation Program. The litigation requests a declaration that the IRA violates Janssen&#8217;s rights under the First Amendment and the Fifth Amendment to the Constitution and therefore that Janssen is not subject to the IRA&#8217;s mandatory pricing scheme. The impact of the IRA on our business and the broader pharmaceutical industry remains uncertain, as litigation filed by Janssen and other pharmaceutical companies remains ongoing and while CMS has publicly announced the maximum fair price for each of the selected drugs, implementation of the program is still in progress. In April 2024, Janssen appealed the district court&#8217;s denial of its summary judgment motion to the Third Circuit.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Russia-Ukraine War</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Although the long-term implications of Russia&#8217;s invasion of Ukraine are difficult to predict at this time, the financial impact of the conflict in the fiscal year 2024, including accounts receivable or inventory reserves, was not material. As of and for each of the fiscal years ending December 29, 2024 and December 31, 2023, the business of the Company&#8217;s Russian subsidiaries represented less than 1% of the Company&#8217;s consolidated assets and revenues. The Company does not maintain Ukraine subsidiaries subsequent to the Kenvue separation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In March of 2022, the Company took steps to suspend all advertising, enrollment in clinical trials, and any additional investment in Russia. The Company continues to supply products relied upon by patients for healthcare purposes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Conflict in the Middle East</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Although the long-term implications of the conflict in the Middle East are difficult to predict at this time, the financial impact of the conflict in the fiscal year 2024, including accounts receivable or inventory reserves, was not material. As of and for each of the fiscal years ending December 29, 2024 and December 31, 2023, the business of the Company&#8217;s Israel subsidiaries represented 1% of the Company&#8217;s consolidated assets and represented less than 1% of revenues.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company is exposed to fluctuations in currency exchange rates. A 1% change in the value of the U.S.&#160;Dollar as compared to all foreign currencies in which the Company had sales, income or expense in 2024 would have increased or decreased the translation of foreign sales by approximately $0.4&#160;billion and net income by approximately $0.1&#160;billion.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates. In connection with various government initiatives, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries. A change in statutory tax rate in any country would result in the revaluation of the Company&#8217;s deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted.&#160;This change would result in an expense or benefit recorded to the Company&#8217;s Consolidated Statement of Earnings.&#160;The Company closely monitors these proposals as they arise in the countries where it operates. Changes to the statutory tax rate may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company faces various worldwide healthcare changes that may continue to result in pricing pressures that include healthcare cost containment and government legislation relating to sales, promotions, pricing and reimbursement of healthcare&#160;products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">41</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Changes in the behavior and spending patterns of purchasers of healthcare products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and foregoing healthcare insurance coverage may continue to impact the Company&#8217;s businesses.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The Company also operates in an environment increasingly hostile to intellectual property rights. Firms have filed Abbreviated New Drug Applications or Biosimilar Biological Product Applications with the U.S. FDA or otherwise challenged the coverage and/or validity of the Company's patents, seeking to market generic or biosimilar forms of many of the Company&#8217;s key pharmaceutical products prior to expiration of the applicable patents covering those products. In the event the Company is not successful in defending the patent claims challenged in the resulting lawsuits, generic or biosimilar versions of the products at issue will be introduced to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset. There is also a risk that one or more competitors could launch a generic or biosimilar version of the product at issue following regulatory approval even though one or more valid patents are in place.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Legal proceedings</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Johnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability, intellectual property, commercial, employment, indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. As of December&#160;29, 2024, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25, Contingencies. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">See Note&#160;19 to the Consolidated Financial Statements included in Item 8 of this report for further information regarding legal&#160;proceedings.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Common stock</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company&#8217;s Common Stock is listed on the New York Stock Exchange under the symbol JNJ. As of February 6, 2025, there were 114,147 record holders of Common Stock of the Company. </span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_109"></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Item 7A. Quantitative and qualitative disclosures about market&#160;risk</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The information called for by this item is incorporated herein by reference to Item 7. Management&#8217;s discussion and analysis of results of operations and financial condition&#160;- Liquidity and capital resources - Financing and market risk of this Report; and Note&#160;1 Summary of significant accounting policies&#160;- Financial instruments of the Notes to Consolidated Financial Statements included in Item 8 of this Report.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">42</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_112"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:112%">Item 8. Financial statements and supplementary data</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Index to audited Consolidated Financial Statements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.501%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.299%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_118">Consolidated balance sheets</a></span></div></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_118">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_124">Consolidated statements of earnings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_124">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_127">Consolidated statements of comprehensive income </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_127">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_133">Consolidated statements of equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_133">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_139">Consolidated statements of cash flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_139">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_142">Notes to consolidated financial statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_142">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_238">Report of independent registered public accounting firm</a><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_238"> (PCAOB ID </a><ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-66">238</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_238">107</a></span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_241">Management&#8217;s report on internal control over financial reporting</a></span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><a style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:none" href="#i4b4bd2fffa0147e7914e1841a5c21924_241">110</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">43</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_118"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Johnson &amp; Johnson and subsidiaries consolidated balance sheets </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br/>At December&#160;29, 2024 and December&#160;31, 2023 <br/>(Dollars in Millions Except Share and Per Share Amounts) (Note&#160;1)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.173%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Current assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Cash and cash equivalents (Notes&#160;1 and 2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-67">24,105</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-68">21,859</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Marketable securities (Notes&#160;1 and 2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="f-69">417</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-70">1,068</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Accounts receivable trade, less allowances $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="f-71">167</ix:nonFraction> (2023, $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="f-72">166</ix:nonFraction>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-73">14,842</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-74">14,873</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Inventories (Notes&#160;1 and 3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-75">12,444</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-76">11,181</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Prepaid expenses and other receivables</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-77">4,085</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-78">4,514</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Total current assets</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-79">55,893</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-80">53,495</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Property, plant and equipment, net (Notes&#160;1 and 4)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-81">20,518</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-82">19,898</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Intangible assets, net (Notes&#160;1 and 5)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-83">37,618</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-84">34,175</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill (Notes&#160;1 and 5)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-85">44,200</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-86">36,558</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Deferred taxes on income (Note 8)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-87">10,461</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-88">9,279</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-89">11,414</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-90">14,153</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Total assets</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-91">180,104</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-92">167,558</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Liabilities and Shareholders&#8217; Equity</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Current liabilities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Loans and notes payable (Note&#160;7)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-93">5,983</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-94">3,451</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-95">10,311</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-96">9,632</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Accrued liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-97">8,549</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-98">10,212</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Accrued rebates, returns and promotions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="jnj:AccruedRebatesReturnsAndPromotions" format="ixt:num-dot-decimal" scale="6" id="f-99">17,580</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="jnj:AccruedRebatesReturnsAndPromotions" format="ixt:num-dot-decimal" scale="6" id="f-100">16,001</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Accrued compensation and employee related obligations</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-101">4,126</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-102">3,993</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Accrued taxes on income (Note 8)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-103">3,772</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-104">2,993</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Total current liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-105">50,321</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-106">46,282</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Long-term debt (Note&#160;7)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-107">30,651</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-108">25,881</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Deferred taxes on income (Note 8)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="f-109">2,448</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="f-110">3,193</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Employee related obligations (Notes&#160;9 and 10)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-111">7,255</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-112">7,149</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Long-term taxes payable (Note 1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="f-113">390</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-114">2,881</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-115">17,549</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-116">13,398</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Total liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-117">108,614</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-118">98,784</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Commitments and Contingencies (Note 19)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-10" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-119"></ix:nonFraction></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-11" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-120"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Shareholders&#8217; equity</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Preferred stock&#160;&#8212; without par value (authorized and unissued <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-121"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-122">2,000,000</ix:nonFraction></ix:nonFraction>&#160;shares)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-123">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-124">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Common stock&#160;&#8212; par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-125"><ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-126">1.00</ix:nonFraction></ix:nonFraction> per share (Note&#160;12) (authorized <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-127"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-128">4,320,000,000</ix:nonFraction></ix:nonFraction>&#160;shares; issued <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-129"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-130">3,119,843,000</ix:nonFraction></ix:nonFraction>&#160;shares)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="f-131">3,120</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="f-132">3,120</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss) (Note&#160;13)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-133">11,741</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-134">12,527</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Retained earnings and Additional-paid-in-capital</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-135">155,791</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-136">153,843</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Less: common stock held in treasury, at cost (Note&#160;12) (<ix:nonFraction unitRef="shares" contextRef="c-10" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-137">712,921,000</ix:nonFraction>&#160;shares and <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-138">712,765,000</ix:nonFraction>&#160;shares)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="f-139">75,680</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="f-140">75,662</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Total shareholders&#8217; equity</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-141">71,490</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-142">68,774</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Total liabilities and shareholders&#8217; equity</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-143">180,104</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-144">167,558</ix:nonFraction></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">See Notes to Consolidated Financial Statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">44</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_124"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Johnson &amp; Johnson and subsidiaries consolidated statements of&#160;earnings</span><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br/></span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars and Shares in Millions Except Per Share Amounts) (Note&#160;1)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.310%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Sales to customers</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-145">88,821</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-146">85,159</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-147">79,990</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of products sold</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-148">27,471</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-149">26,553</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-150">24,596</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="f-151">61,350</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="f-152">58,606</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="f-153">55,394</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, marketing and administrative expenses</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-154">22,869</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-155">21,512</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-156">20,246</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development expense</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-157">17,232</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-158">15,085</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-159">14,135</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In-process research and development impairments</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="jnj:ResearchAndDevelopmentInProcess1" scale="6" id="f-160">211</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="jnj:ResearchAndDevelopmentInProcess1" scale="6" id="f-161">313</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="jnj:ResearchAndDevelopmentInProcess1" scale="6" id="f-162">783</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="6" id="f-163">1,332</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="6" id="f-164">1,261</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-165">490</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest expense, net of portion capitalized (Note&#160;4)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InterestExpenseNonoperating" scale="6" id="f-166">755</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:InterestExpenseNonoperating" scale="6" id="f-167">772</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:InterestExpenseNonoperating" scale="6" id="f-168">276</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (income) expense, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-169">4,694</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-170">6,634</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-171">810</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restructuring (Note 20)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-172">234</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-173">489</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-174">275</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Earnings before provision for taxes on income</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-175">16,687</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-176">15,062</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-177">19,359</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for taxes on income (Note&#160;8)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-178">2,621</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-179">1,736</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-180">2,989</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net earnings from continuing operations</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-181">14,066</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-182">13,326</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-183">16,370</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net earnings from discontinued operations, net of tax (Note 21)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="6" id="f-184">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="6" id="f-185">21,827</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="6" id="f-186">1,571</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net earnings</span></div></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-187">14,066</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-188">35,153</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-189">17,941</ix:nonFraction></span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net earnings per share (Notes 1 and 15)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Continuing operations - basic</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-190">5.84</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-191">5.26</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-192">6.23</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discontinued operations - basic</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="f-193">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="f-194">8.62</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="f-195">0.60</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total net earnings per share - basic</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-196">5.84</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-197">13.88</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-198">6.83</ix:nonFraction></span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Continuing operations - diluted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-199">5.79</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-200">5.20</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-201">6.14</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discontinued operations - diluted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="f-202">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" id="f-203">8.52</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" id="f-204">0.59</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total net earnings per share - diluted</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-205">5.79</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-206">13.72</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-207">6.73</ix:nonFraction></span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Average shares outstanding (Notes 1 and 15)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Basic</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="f-208">2,407.3</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="f-209">2,533.5</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="f-210">2,625.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Diluted</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-211">2,429.4</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-212">2,560.4</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-213">2,663.9</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%">See Notes to Consolidated Financial Statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">45</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_127"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Johnson &amp; Johnson and subsidiaries consolidated statements of comprehensive income</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br/>(Dollars in Millions) (Note&#160;1)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.310%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net earnings </span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-214">14,066</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-215">35,153</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-216">17,941</ix:nonFraction></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency translation</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="f-217">1,708</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="f-218">3,221</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="f-219">1,796</ix:nonFraction>)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unrealized holding gain (loss) arising during period</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="f-220">2</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="f-221">26</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="f-222">24</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reclassifications to earnings</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="f-223">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="f-224">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="f-225">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net change</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="f-226">2</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="f-227">26</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="f-228">24</ix:nonFraction>)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee benefit plans:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior service credit (cost), net of amortization</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" scale="6" id="f-229">154</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" scale="6" id="f-230">149</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" scale="6" id="f-231">160</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gain (loss), net of amortization</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" scale="6" id="f-232">541</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" format="ixt:num-dot-decimal" scale="6" id="f-233">1,183</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" format="ixt:num-dot-decimal" scale="6" id="f-234">1,854</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consumer settlement/ curtailment</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax" format="ixt:fixed-zero" scale="6" id="f-235">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax" scale="6" id="f-236">23</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax" format="ixt:fixed-zero" scale="6" id="f-237">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of exchange rates</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" scale="6" id="f-238">62</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" scale="6" id="f-239">90</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" scale="6" id="f-240">111</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net change</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="f-241">449</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-242">1,399</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-243">1,805</ix:nonFraction></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Derivatives &amp; hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unrealized gain (loss) arising during period</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="f-244">511</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="f-245">422</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="f-246">454</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reclassifications to earnings</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="f-247">862</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="f-248">569</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="f-249">348</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net change</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="f-250">1,373</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="f-251">147</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="f-252">106</ix:nonFraction></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive income (loss)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-253">786</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-254">4,741</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-255">91</ix:nonFraction></span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Comprehensive income </span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-256">14,852</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-257">30,412</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-258">18,032</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The tax cost/(benefit) effects in other comprehensive income for the fiscal years 2024, 2023 and 2022 respectively: Foreign Currency Translation; $(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-8" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="9" id="f-259">1.1</ix:nonFraction>) billion, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="f-260">797</ix:nonFraction> million and $(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="f-261">460</ix:nonFraction>) million; Employee Benefit Plans: $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="f-262">86</ix:nonFraction> million, $(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="f-263">289</ix:nonFraction>) million and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="f-264">461</ix:nonFraction> million, Derivatives &amp; Hedges: $(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="f-265">365</ix:nonFraction>) million, $(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="f-266">39</ix:nonFraction>) million and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="f-267">30</ix:nonFraction> million.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%">See Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%">Amounts presented for 2023 and 2022 have not been recast to exclude discontinued operations</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">46</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_133"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Johnson &amp; Johnson and subsidiaries consolidated statements of&#160;equity</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br/>(Dollars in Millions) (Note&#160;1)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.467%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Retained<br/>Earnings and<br/>Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common<br/>Stock<br/>Issued<br/>Amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Treasury<br/>Stock<br/>Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Balance, January 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-268">74,023</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-269">123,060</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-270">13,058</ix:nonFraction>)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-271">3,120</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-272">39,099</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net earnings </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-273">17,941</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-274">17,941</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-275">4.45</ix:nonFraction> per share)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-276">11,682</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-277">11,682</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee compensation and stock option plans</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="6" id="f-278">2,466</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-279">974</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="6" id="f-280">3,440</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repurchase of common stock</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-281">6,035</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-282">6,035</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-283">91</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-284">91</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Balance, January 1, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-285">76,804</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-286">128,345</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-287">12,967</ix:nonFraction>)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-288">3,120</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-289">41,694</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net earnings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-290">35,153</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-291">35,153</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-292">4.70</ix:nonFraction> per share)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-293">11,770</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-294">11,770</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee compensation and stock option plans</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="6" id="f-295">2,193</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-296">336</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="6" id="f-297">2,529</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repurchase of common stock</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-298">5,054</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-299">5,054</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="f-300">25</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="f-301">25</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Kenvue Separation /IPO (Note 21)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" format="ixt:num-dot-decimal" scale="6" id="f-302">23,786</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" format="ixt:num-dot-decimal" scale="6" id="f-303">2,451</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" format="ixt:num-dot-decimal" scale="6" id="f-304">5,181</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" sign="-" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" format="ixt:num-dot-decimal" scale="6" id="f-305">31,418</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-306">4,741</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-307">4,741</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Balance, December 31, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-308">68,774</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-309">153,843</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-310">12,527</ix:nonFraction>)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-311">3,120</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-312">75,662</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net earnings </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-313">14,066</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-314">14,066</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-315">4.91</ix:nonFraction> per share)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-316">11,823</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-317">11,823</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee compensation and stock option plans</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="6" id="f-318">2,094</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-319">295</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="6" id="f-320">2,389</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repurchase of common stock</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-321">2,407</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-322">2,407</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-323">786</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-324">786</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Balance, December 29, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-325">71,490</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-326">155,791</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-327">11,741</ix:nonFraction>)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-328">3,120</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-329">75,680</ix:nonFraction>)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%">See Notes to Consolidated Financial Statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">47</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_139"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Johnson &amp; Johnson and subsidiaries consolidated statements of cash&#160;flows</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br/>(Dollars in Millions) (Note 1)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.310%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash flows from operating activities</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net earnings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-330">14,066</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-331">35,153</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-332">17,941</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjustments to reconcile net earnings to cash flows from operating activities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization of property and intangibles</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-333">7,339</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-334">7,486</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-335">6,970</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock based compensation</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="f-336">1,176</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="f-337">1,162</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="f-338">1,138</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Asset write-downs</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="f-339">405</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="f-340">1,295</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="f-341">1,216</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Charges for acquired in-process research and development assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-342">1,841</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-343">483</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="6" id="f-344">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Gain on Kenvue separation</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" format="ixt:fixed-zero" scale="6" id="f-345">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-346">20,984</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" format="ixt:fixed-zero" scale="6" id="f-347">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net gain on sale of assets/businesses</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="f-348">226</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="f-349">117</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="f-350">380</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred tax provision</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-351">2,183</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-352">4,194</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-353">1,663</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Credit losses and accounts receivable allowances</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="f-354">11</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="6" id="f-355">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="f-356">17</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in assets and liabilities, net of effects from acquisitions and divestitures:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increase in accounts receivable</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-357">406</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-358">624</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="f-359">1,290</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increase in inventories</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="6" id="f-360">1,128</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="6" id="f-361">1,323</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="6" id="f-362">2,527</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increase in accounts payable and accrued liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-363">1,621</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-364">2,346</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-365">1,098</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Decrease/(Increase) in other current and non-current assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="6" id="f-366">1,717</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="6" id="f-367">3,480</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="f-368">687</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increase/(Decrease) in other current and non-current liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="f-369">33</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-370">5,588</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-371">1,979</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash flows from operating activities</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-372">24,266</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-373">22,791</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-374">21,194</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash flows from investing activities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions to property, plant and equipment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-375">4,424</ix:nonFraction>)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-376">4,543</ix:nonFraction>)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-377">4,009</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proceeds from the disposal of assets/businesses, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="f-378">675</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="f-379">358</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="f-380">543</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acquisitions, net of cash acquired (Note&#160;18)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="f-381">15,146</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="f-382">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="f-383">17,652</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Acquired in-process research and development assets (Note 18)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="jnj:PaymentsToAcquiredInProcessResearchAndDevelopmentAssets" format="ixt:num-dot-decimal" scale="6" id="f-384">1,783</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="jnj:PaymentsToAcquiredInProcessResearchAndDevelopmentAssets" scale="6" id="f-385">470</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="jnj:PaymentsToAcquiredInProcessResearchAndDevelopmentAssets" format="ixt:fixed-zero" scale="6" id="f-386">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchases of investments</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="f-387">1,726</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="f-388">10,906</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="f-389">32,384</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales of investments</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="6" id="f-390">2,462</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="6" id="f-391">19,390</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="6" id="f-392">41,609</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Credit support agreements activity, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-393">1,517</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-394">2,963</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" scale="6" id="f-395">249</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (including capitalized licenses and milestones)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-396">174</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-397">12</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-398">229</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash (used by)/from investing activities</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-399">18,599</ix:nonFraction>)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-400">878</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-401">12,371</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash flows from financing activities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividends to shareholders</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsOfOrdinaryDividends" format="ixt:num-dot-decimal" scale="6" id="f-402">11,823</ix:nonFraction>)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:PaymentsOfOrdinaryDividends" format="ixt:num-dot-decimal" scale="6" id="f-403">11,770</ix:nonFraction>)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:PaymentsOfOrdinaryDividends" format="ixt:num-dot-decimal" scale="6" id="f-404">11,682</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repurchase of common stock</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-405">2,432</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-406">5,054</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-407">6,035</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proceeds from short-term debt</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-408">15,277</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-409">13,743</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-410">16,134</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayment of short-term debt</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-411">9,463</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-412">22,973</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-413">6,550</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proceeds from long-term debt, net of issuance costs</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-414">6,660</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="f-415">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="f-416">2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayment of long-term debt</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-417">1,453</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-418">1,551</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-419">2,134</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" scale="6" id="f-420">838</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-421">1,094</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-422">1,329</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Credit support agreements activity, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" scale="6" id="f-423">272</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" scale="6" id="f-424">219</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" scale="6" id="f-425">28</ix:nonFraction>)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">48</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.310%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Settlement of convertible debt acquired from Shockwave</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="jnj:SettlementOfConvertibleDebtAcquiredFromShockwave" scale="6" id="f-426">970</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="jnj:SettlementOfConvertibleDebtAcquiredFromShockwave" format="ixt:fixed-zero" scale="6" id="f-427">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="jnj:SettlementOfConvertibleDebtAcquiredFromShockwave" format="ixt:fixed-zero" scale="6" id="f-428">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Proceeds of short and long-term debt, net of issuance cost, related to the debt that transferred to Kenvue at separation</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="jnj:ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation" format="ixt:fixed-zero" scale="6" id="f-429">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="jnj:ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation" format="ixt:num-dot-decimal" scale="6" id="f-430">8,047</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="jnj:ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation" format="ixt:fixed-zero" scale="6" id="f-431">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Proceeds from Kenvue initial public offering</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:fixed-zero" scale="6" id="f-432">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="f-433">4,241</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:fixed-zero" scale="6" id="f-434">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Cash transferred to Kenvue at separation</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="jnj:PaymentsMadeInBusinessSeparation" format="ixt:fixed-zero" scale="6" id="f-435">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="jnj:PaymentsMadeInBusinessSeparation" format="ixt:num-dot-decimal" scale="6" id="f-436">1,114</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="jnj:PaymentsMadeInBusinessSeparation" format="ixt:fixed-zero" scale="6" id="f-437">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-438">38</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-439">269</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-440">93</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash used by financing activities</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-441">3,132</ix:nonFraction>)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-442">15,825</ix:nonFraction>)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-443">8,871</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-444">289</ix:nonFraction>)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-445">112</ix:nonFraction>)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-446">312</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increase/(Decrease) in cash and cash equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="f-447">2,246</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="f-448">7,732</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-449">360</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Cash and cash equivalents from continuing operations, beginning of period</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="jnj:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-450">21,859</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-6" name="jnj:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-451">12,889</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="jnj:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-452">13,309</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents from discontinued operations, beginning of period</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="f-453">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-454">1,238</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-455">1,178</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents, beginning of year (Note&#160;1)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-456">21,859</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-457">14,127</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-458">14,487</ix:nonFraction></span></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Cash and cash equivalents from continuing operations, end of period</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="jnj:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-459">24,105</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="jnj:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-460">21,859</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-6" name="jnj:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-461">12,889</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents from discontinued operations, end of period</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="f-462">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="f-463">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-464">1,238</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash and cash equivalents, end of year (Note&#160;1)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-465">24,105</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-466">21,859</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-467">14,127</ix:nonFraction></span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Supplemental cash flow data</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash paid during the year for:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="6" id="f-468">1,990</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="6" id="f-469">1,836</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:InterestPaid" scale="6" id="f-470">982</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest, net of amount capitalized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="f-471">1,911</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="f-472">1,766</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="f-473">933</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income taxes, inclusive of discontinued operations</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="f-474">6,714</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="f-475">8,574</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="f-476">5,223</ix:nonFraction></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Supplemental schedule of non-cash investing and financing activities</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Treasury stock issued for employee compensation and stock option plans, net of cash proceeds/ employee withholding tax on stock awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" format="ixt:num-dot-decimal" scale="6" id="f-477">1,551</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" format="ixt:num-dot-decimal" scale="6" id="f-478">1,435</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" format="ixt:num-dot-decimal" scale="6" id="f-479">2,114</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Acquisitions</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value of assets acquired</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="f-480">16,091</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" format="ixt:fixed-zero" scale="6" id="f-481">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="f-482">18,710</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value of liabilities assumed</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="6" id="f-483">1,632</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" format="ixt:fixed-zero" scale="6" id="f-484">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="6" id="f-485">1,058</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash paid for acquisitions (Note 18)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="6" id="f-486">14,459</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" format="ixt:fixed-zero" scale="6" id="f-487">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="6" id="f-488">17,652</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%">See Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%">Amounts presented for 2023 and 2022 have not been recast to exclude discontinued operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">49</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_142"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_145"></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">1.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-489" continuedAt="f-489-1" escape="true">Summary of significant accounting policies</ix:nonNumeric></span></div><ix:continuation id="f-489-1" continuedAt="f-489-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-490" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The consolidated financial statements include the accounts of Johnson&#160;&amp; Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Description of the company</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has approximately <ix:nonFraction unitRef="employee" contextRef="c-1" decimals="0" name="jnj:NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" format="ixt:num-dot-decimal" scale="0" id="f-491">138,100</ix:nonFraction>&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Kenvue IPO/separation and discontinued operations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="c-41" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-492">198,734,444</ix:nonFraction> shares of its common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-42" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-493">0.01</ix:nonFraction> per share (the &#8220;Kenvue Common Stock&#8221;), at an initial public offering of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-42" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-494">22.00</ix:nonFraction> per share for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-8" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="9" id="f-495">4.2</ix:nonFraction>&#160;billion. The excess of the net proceeds from the IPO over the net book value of the Johnson &amp; Johnson divested interest was $<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-8" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" format="ixt:num-dot-decimal" scale="9" id="f-496">2.5</ix:nonFraction>&#160;billion and was recorded to additional paid-in capital. As of the closing of the IPO, Johnson &amp; Johnson owned approximately <ix:nonFraction unitRef="number" contextRef="c-44" decimals="3" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" scale="-2" id="f-497">89.6</ix:nonFraction>% of the total outstanding shares of Kenvue Common Stock and at July 2, 2023, the <br/>non-controlling interest of $<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-8" name="us-gaap:CommonStockValueOutstanding" format="ixt:num-dot-decimal" scale="9" id="f-498">1.3</ix:nonFraction>&#160;billion associated with Kenvue was reflected in equity attributable to non-controlling interests in the consolidated balance sheet in the fiscal second quarter of 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On August 23, 2023, Johnson &amp; Johnson completed the disposition of an additional <ix:nonFraction unitRef="number" contextRef="c-46" decimals="3" name="jnj:OwnershipPercentageSplitOffPercent" scale="-2" id="f-499">80.1</ix:nonFraction>% ownership of the shares of Kenvue through an exchange offer. Following the exchange offer, the Company owned <ix:nonFraction unitRef="number" contextRef="c-47" decimals="3" name="jnj:ExchangeOfStockPercentageOwnershipAfterTransaction" scale="-2" id="f-500">9.5</ix:nonFraction>% of the shares of Kenvue which were accounted for as an equity investment carried at fair value within continuing operations. The historical results of the Consumer Health business (which previously represented the Consumer Health business segment) are reflected as discontinued operations in the Company&#8217;s Consolidated Financial Statements through the date of the exchange offer (see Note 21 for additional details). Unless otherwise indicated, the information in the notes to the Consolidated Financial Statements refer only to Johnson &amp; Johnson&#8217;s continuing operations. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In the fiscal second quarter of 2024 the Company completed a debt for equity exchange of the retained stake in Kenvue. Upon completion of the debt for equity exchange, the Company no longer owns any shares of Kenvue Common Stock.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-501" continuedAt="f-501-1" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Business segments</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:continuation id="f-501-1">The Company is organized into <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-502">two</ix:nonFraction> business segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on the following therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolic. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the Orthopaedic, Surgery, Cardiovascular (previously referred to as Interventional Solutions) and Vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-503" continuedAt="f-503-1" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">New accounting standards</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently adopted accounting standards</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">ASU 2023-07: Segment Reporting (Topic 280) &#8211; Improvements to Reportable Segment Disclosures</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company adopted the standard in the fiscal year 2024, which requires expanded annual and interim disclosures for significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. The standard was applied retrospectively to all periods presented in the financial statements. As this accounting standard only impacts disclosures, it did not have a material impact on the Company&#8217;s Consolidated Financial Statements. See Note 17 for the required disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">50</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-489-2" continuedAt="f-489-3"><ix:continuation id="f-503-1" continuedAt="f-503-2"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently issued accounting standards</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not adopted as of December 29, 2024</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">ASU 2024-03: Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures (Subtopic&#160;220-40): Disaggregation of Income Statement Expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">This update requires disclosure of disaggregated information about certain income statement expense line items on an annual and interim basis. This update will be effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. As this accounting standard only impacts disclosures, it will not have a material impact on the Company&#8217;s Consolidated Financial Statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">ASU 2023-09: Income Taxes (Topic 740) - Improvements to Income Tax Disclosures</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:continuation id="f-503-2">This update standardizes categories for the effective tax rate reconciliation, requires disaggregation of income taxes and additional income tax-related disclosures. This update is required to be effective for the Company for fiscal periods beginning after December 15, 2024. As this accounting standard only impacts disclosures, it will not have a material impact on the Company&#8217;s Consolidated Financial Statements.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-504" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating. The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="jnj:MinimumCollateralValueasaPercentReverseRepurchaseAgreement" scale="-2" id="f-505">102</ix:nonFraction>% of their value. The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="jnj:MinimumCollateralValueasaPercentReverseRepurchaseAgreement" scale="-2" id="f-506">102</ix:nonFraction>% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentPolicyTextBlock" id="f-507" continuedAt="f-507-1" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Investments</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:continuation id="f-507-1">Investments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets; otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required.</ix:continuation>&#160;</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-508" continuedAt="f-508-1" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Property, plant and equipment and depreciation</span></div><ix:nonNumeric contextRef="c-1" name="jnj:EstimatedUsefulLivesOfAssetsTableTextBlock" id="f-509" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Building and building equipment</span></div></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-48" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-510">30</ix:nonNumeric>&#160;years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Land and leasehold improvements</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-49" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-511">10</ix:nonNumeric>&#160;- <ix:nonNumeric contextRef="c-50" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-512">20</ix:nonNumeric>&#160;years</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Machinery and equipment</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-51" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-513">2</ix:nonNumeric>&#160;- <ix:nonNumeric contextRef="c-52" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-514">13</ix:nonNumeric>&#160;years</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from <ix:nonNumeric contextRef="c-53" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-515">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c-54" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-516">8</ix:nonNumeric>&#160;years.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">51</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-489-3" continuedAt="f-489-4"><ix:continuation id="f-508-1"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset&#8217;s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-517" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between <ix:nonNumeric contextRef="c-55" name="jnj:RevenuePerformanceObligationPaymentTerms" format="ixt-sec:durday" id="f-518">30</ix:nonNumeric> to <ix:nonNumeric contextRef="c-56" name="jnj:RevenuePerformanceObligationPaymentTerms" format="ixt-sec:durday" id="f-519">90</ix:nonNumeric> days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns, discounts to customers and governmental clawback provisions are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued rebates, returns, and promotions on the consolidated balance sheet.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates and discounts are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A&#160;significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily the Managed Care, Medicare and Medicaid programs, which amounted to $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-8" name="jnj:AccruedRebatesReturnsAndPromotions" scale="9" id="f-520">12.3</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-8" name="jnj:AccruedRebatesReturnsAndPromotions" scale="9" id="f-521">11.5</ix:nonFraction> billion as of December&#160;29, 2024 and December&#160;31, 2023, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Sales returns are estimated and recorded based on historical sales and returns information. Products that have lost patent exclusivity, or that otherwise exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. In accordance with the Company&#8217;s accounting policies, the Company generally issues credit to customers for returned goods. The Company&#8217;s sales returns reserves are accounted for in accordance with the U.S.&#160;GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Innovative Medicine segment are almost exclusively not resalable. Sales returns for certain franchises in the MedTech segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately <ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="jnj:SalesReturnReserve" scale="-2" id="f-522"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="jnj:SalesReturnReserve" scale="-2" id="f-523"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="jnj:SalesReturnReserve" scale="-2" id="f-524">1.0</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of annual net trade sales during each of the fiscal years&#160;2024,&#160;2023 and 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Promotional programs, such as product listing allowances are recorded in the same period as related sales and include <br/>volume-based sales incentive programs. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements of certain products, which are included in sales to customers. Profit-share payments were less than <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="jnj:ProfitLossPercentToSales" scale="-2" id="f-525"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="jnj:ProfitLossPercentToSales" scale="-2" id="f-526">2.0</ix:nonFraction></ix:nonFraction>% of the total revenues in the fiscal year 2024 and 2023, respectively, and less than <ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="jnj:ProfitLossPercentToSales" scale="-2" id="f-527">3.0</ix:nonFraction>% of total revenues in the fiscal year 2022 and are included in sales to customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">See Note 17 to the Consolidated Financial Statements for further disaggregation of revenue.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ShippingAndHandlingCostPolicyTextBlock" id="f-528" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Shipping and handling</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Shipping and handling costs incurred were $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-8" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="9" id="f-529">0.9</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-8" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="9" id="f-530">0.9</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-8" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="9" id="f-531">0.8</ix:nonFraction> billion in fiscal years 2024, 2023 and 2022, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than <ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="jnj:ShippingandHandlingCostsasaPercentofSales" scale="-2" id="f-532"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="jnj:ShippingandHandlingCostsasaPercentofSales" scale="-2" id="f-533"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="jnj:ShippingandHandlingCostsasaPercentofSales" scale="-2" id="f-534">1.0</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of sales to customers for all periods presented.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-535" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">52</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-489-4" continuedAt="f-489-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="f-536" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Intangible assets and goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The authoritative literature on U.S.&#160;GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2024 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. In-process research and development purchased as part of a business combination is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset. If warranted the purchased in-process research and development could be written off or partially impaired depending on the underlying&#160;program.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Intangible assets that have finite useful lives continue to be amortized over their useful lives and are reviewed for impairment when warranted by economic conditions. See Note&#160;5 for further details on Intangible Assets and Goodwill.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativesPolicyTextBlock" id="f-537" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">As required by U.S.&#160;GAAP, all derivative instruments are recorded on the balance sheet at fair value. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level&#160;1 having the highest priority and Level&#160;3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge&#160;transaction.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1)&#160;minimize foreign currency exposure&#8217;s impact on the Company&#8217;s financial performance; (2)&#160;protect the Company&#8217;s cash flow from adverse movements in foreign exchange rates; (3)&#160;ensure the appropriateness of financial instruments; and (4)&#160;manage the enterprise risk associated with financial institutions. See Note&#160;6 for additional information on Financial Instruments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-538" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in <span style="-sec-ix-hidden:f-539"><span style="-sec-ix-hidden:f-540">Other assets</span></span>, <span style="-sec-ix-hidden:f-541"><span style="-sec-ix-hidden:f-542">Accrued liabilities</span></span>, and <span style="-sec-ix-hidden:f-543"><span style="-sec-ix-hidden:f-544">Other liabilities</span></span> on the consolidated balance sheet. The ROU Assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Commitments under finance leases are not significant, and are included in Property, plant and equipment, Loans and notes payable, and Long-term debt on the consolidated balance sheet.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The&#160;ROU asset pertaining to leases from continuing operations was $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-8" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="9" id="f-545">1.1</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-8" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="9" id="f-546">1.0</ix:nonFraction>&#160;billion in fiscal years 2024 and 2023, respectively. The lease liability from continuing operations was $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-8" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="9" id="f-547">1.2</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-8" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="9" id="f-548">1.1</ix:nonFraction>&#160;billion in fiscal years 2024 and 2023, respectively. The operating lease costs from continuing operations were $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-8" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="9" id="f-549"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-8" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="9" id="f-550"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-8" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="9" id="f-551">0.2</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;billion in fiscal years 2024, 2023 and 2022. Cash&#160;paid for amounts included in the measurement of lease liabilities from continuing operations were $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-8" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="9" id="f-552"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-8" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="9" id="f-553"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-8" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="9" id="f-554">0.2</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;billion in fiscal years 2024, 2023 and 2022.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">53</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-489-5" continuedAt="f-489-6"><ix:nonNumeric contextRef="c-1" name="jnj:ProductLiabilityPolicyTextBlock" id="f-555" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product liability</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-556" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Research and development</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Research and development expenses are expensed as incurred in accordance with ASC 730, Research&#160;and Development. Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company&#8217;s operations. In general, the income statement presentation for these collaborations is as follows:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.453%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.157%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Nature/Type of Collaboration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Statement of Earnings Presentation</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Third-party sale of product &amp; profit share payments received</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Sales to customers</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Royalties/milestones paid to collaborative partner (post-regulatory approval)*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Cost of products sold</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Royalties received from collaborative partner</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Other income (expense), net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Upfront payments&#160;&amp; milestones paid to collaborative partner (pre-regulatory approval)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Research and development expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Research and development payments to collaborative&#160;partner</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Research and development expense</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Research and development payments received from collaborative partner or government entity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Reduction of Research and development expense</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">*&#160;&#160;&#160;&#160;Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">For all years presented, there was no individual project that represented greater than <ix:nonFraction unitRef="number" contextRef="c-62" decimals="INF" name="jnj:ConcentrationRiskThresholdPercentage" scale="-2" id="f-557"><ix:nonFraction unitRef="number" contextRef="c-63" decimals="INF" name="jnj:ConcentrationRiskThresholdPercentage" scale="-2" id="f-558"><ix:nonFraction unitRef="number" contextRef="c-64" decimals="INF" name="jnj:ConcentrationRiskThresholdPercentage" scale="-2" id="f-559">5</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the total annual consolidated research and development expense other than the acquired in-process research &amp; development expense of $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-6" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="9" id="f-560">1.25</ix:nonFraction>&#160;billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition) in fiscal year 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO, co-developed with Bayer HealthCare AG, IMBRUVICA, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company and CARVYKTI, licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX, licensed from Genmab A/S.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">54</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-489-6" continuedAt="f-489-7"><ix:nonNumeric contextRef="c-1" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="f-561" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Advertising</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-8" name="us-gaap:AdvertisingExpense" scale="9" id="f-562">0.6</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-8" name="us-gaap:AdvertisingExpense" scale="9" id="f-563">0.5</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-8" name="us-gaap:AdvertisingExpense" scale="9" id="f-564">0.7</ix:nonFraction> billion in fiscal years 2024, 2023 and 2022, respectively.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-565" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Income taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from <ix:nonFraction unitRef="number" contextRef="c-66" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-566">35</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-67" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-567">21</ix:nonFraction>%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of <ix:nonFraction unitRef="number" contextRef="c-67" decimals="3" name="jnj:TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" scale="-2" id="f-568">15.5</ix:nonFraction>% and all other earnings were taxed at a rate of <ix:nonFraction unitRef="number" contextRef="c-67" decimals="3" name="jnj:TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" scale="-2" id="f-569">8.0</ix:nonFraction>%. This tax is payable over <ix:nonNumeric contextRef="c-1" name="jnj:TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsPaymentPeriod" format="ixt-sec:duryear" id="f-570">8</ix:nonNumeric> years and will not accrue interest. These payments began in fiscal year 2018 and will continue through 2025. The final payment of $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-8" name="jnj:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="9" id="f-571">2.5</ix:nonFraction>&#160;billion will be made in fiscal year 2025. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI). GILTI is described as the excess of a U.S. shareholder&#8217;s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., &#8220;period cost&#8221;) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to affect the amount of GILTI inclusion in future years upon reversal (i.e., &#8220;deferred method&#8221;). The Company has elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The&#160;Company estimates that the tax effect of this repatriation would be approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-8" name="us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings" scale="9" id="f-572">0.5</ix:nonFraction> billion under currently enacted tax laws and regulations and at current currency exchange rates. This amount does not include the possible benefit of U.S. foreign tax credits, which may substantially offset this cost.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">See Note 8 to the Consolidated Financial Statements for further information regarding income taxes.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-573" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net earnings per share</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-574" continuedAt="f-574-1" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.&#160;requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">55</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-489-7"><ix:continuation id="f-574-1"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company follows the provisions of U.S.&#160;GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="jnj:SupplierFinanceProgramPolicyTextBlock" id="f-575" continuedAt="f-575-1" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Supplier finance program obligations</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:continuation id="f-575-1">The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide participating suppliers the ability to finance payment obligations from the Company with the third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The&#160;Company&#8217;s obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment&#160;terms of <ix:nonNumeric contextRef="c-10" name="us-gaap:SupplierFinanceProgramPaymentTimingPeriod" format="ixt-sec:durday" id="f-576">90</ix:nonNumeric> days), are not affected by a participating supplier&#8217;s decision to participate in the program.</ix:continuation> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Confirmed obligations under the program as of December&#160;29, 2024, and December&#160;31, 2023, were $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-8" name="us-gaap:SupplierFinanceProgramObligationCurrent" format="ixt:num-dot-decimal" scale="9" id="f-577">0.8</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-8" name="us-gaap:SupplierFinanceProgramObligationCurrent" format="ixt:num-dot-decimal" scale="9" id="f-578">0.7</ix:nonFraction>&#160;billion, respectively. The&#160;obligations are presented as <span style="-sec-ix-hidden:f-579"><span style="-sec-ix-hidden:f-580">Accounts payable</span></span> on the Consolidated Balance Sheets.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SupplierFinanceProgramTableTextBlock" id="f-581" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The rollforward of the Company's valid obligations under the program were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Confirmed obligations - beginning of the year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:SupplierFinanceProgramObligationCurrent" scale="6" id="f-582">704</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Invoices confirmed during the year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:SupplierFinanceProgramObligationIncrease" format="ixt:num-dot-decimal" scale="6" id="f-583">3,048</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Confirmed invoices paid during the year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:SupplierFinanceProgramObligationDecreaseSettlement" format="ixt:num-dot-decimal" scale="6" id="f-584">2,964</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Confirmed obligations - end of the year</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:SupplierFinanceProgramObligationCurrent" scale="6" id="f-585">788</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="jnj:FiscalPeriodPolicyTextBlock" id="f-586" escape="true"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Annual closing date</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52&#160;weeks, but every five or six years the fiscal year consists of 53&#160;weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">56</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_151"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">2.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="f-587" continuedAt="f-587-1" escape="true">Cash, cash equivalents and current marketable securities</ix:nonNumeric></span></div><ix:continuation id="f-587-1" continuedAt="f-587-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="f-588" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">At the end of the fiscal year 2024 and 2023, cash, cash equivalents and current marketable securities comprised:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.072%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.209%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.875%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr style="height:35pt"><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying<br/>&#160;Amount</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrecognized<br/>Gain</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>&#160;Fair Value</span></td><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash &amp; Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current<br/> Marketable<br/> Securities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="f-589">2,918</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="6" id="f-590">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="f-591">2,918</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-592">2,918</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="f-593">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-U.S. Sovereign Securities</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="f-594">120</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="6" id="f-595">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="f-596">120</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="f-597">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="f-598">120</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="f-599">7,100</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="6" id="f-600">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="f-601">7,100</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-602">7,100</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="f-603">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="f-604">6,123</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="6" id="f-605">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="f-606">6,123</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-607">6,123</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="f-608">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Time deposits</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="f-609">1,045</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="6" id="f-610">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="f-611">1,045</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-612">1,045</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="f-613">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="f-614">17,306</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="6" id="f-615">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="f-616">17,306</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-617">17,186</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="f-618">120</ix:nonFraction></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Gov't Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-619">6,815</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-620">1</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-621">6,816</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-622">6,796</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="f-623">20</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other Sovereign Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-624">176</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-625">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-626">176</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-627">83</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="f-628">93</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate and other debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-629">224</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-630">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-631">224</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-632">40</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="f-633">184</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal available for sale</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-634">7,215</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-635">1</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-636">7,216</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-637">6,919</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="f-638">297</ix:nonFraction></span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:64.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total cash, cash equivalents and current marketable securities</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-639">24,105</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="f-640">417</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.072%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.875%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr style="height:35pt"><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrecognized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated Fair Value</span></td><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="f-641">3,340</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="f-642">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="f-643">3,340</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-644">3,340</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="f-645">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-U.S. Sovereign Securities</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="f-646">522</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="f-647">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="f-648">522</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-649">174</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="f-650">348</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="f-651">4,377</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="f-652">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="f-653">4,377</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-654">4,377</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="f-655">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="f-656">338</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="f-657">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="f-658">338</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-659">189</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="f-660">149</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="f-661">4,814</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="f-662">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="f-663">4,814</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-664">4,814</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="f-665">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Time deposits</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="f-666">662</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="f-667">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="f-668">662</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-669">662</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="f-670">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="f-671">14,053</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="f-672">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="f-673">14,053</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-674">13,556</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="f-675">497</ix:nonFraction></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Gov't Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-676">8,562</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-677">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-678">8,562</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-679">8,259</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="f-680">303</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Gov't Agencies</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-681">71</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-682">1</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-683">70</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="f-684">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="f-685">70</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other Sovereign Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-686">5</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-687">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-688">5</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-689">1</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="f-690">4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate and other debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-691">237</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-89" xsi:nil="true" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" id="f-692"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-693">237</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-694">43</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="f-695">194</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal available for sale</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-696">8,875</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-697">1</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-698">8,874</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-699">8,303</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="f-700">571</ix:nonFraction></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:64.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total cash, cash equivalents and current marketable securities</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-701">21,859</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-702">1,068</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. </span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive&#160;income.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Fair value of government securities and obligations and corporate debt securities were estimated using quoted broker prices and significant other observable inputs.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">57</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-587-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-703" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The contractual maturities of the available for sale debt securities at December&#160;29, 2024 are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.834%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due within one year</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-704">7,204</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="f-705">7,205</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due after one year through five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="f-706">11</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="f-707">11</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due after five years through ten years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" format="ixt:fixed-zero" scale="6" id="f-708">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="6" id="f-709">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total debt securities</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-710">7,215</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" format="ixt:num-dot-decimal" scale="6" id="f-711">7,216</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company invests its excess cash in both deposits with major banks throughout the world and other high-quality money market instruments. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.</span></div></ix:continuation><div id="i4b4bd2fffa0147e7914e1841a5c21924_154"></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">3.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryDisclosureTextBlock" id="f-712" continuedAt="f-712-1" escape="true">Inventories</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-713" escape="true"><ix:continuation id="f-712-1"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">At the end of fiscal years 2024 and 2023, inventories comprised:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.685%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Raw materials and supplies</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="f-714">2,337</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="f-715">2,355</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goods in process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="f-716">2,815</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="f-717">1,952</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="f-718">7,292</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="f-719">6,874</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total inventories</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-720">12,444</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-721">11,181</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:nonNumeric><div id="i4b4bd2fffa0147e7914e1841a5c21924_157"></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">4.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-722" continuedAt="f-722-1" escape="true">Property, plant and equipment</ix:nonNumeric></span></div><ix:continuation id="f-722-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-723" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">At the end of fiscal years 2024 and 2023, property, plant and equipment at cost and accumulated depreciation were:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.685%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Land and land improvements</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-724">718</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-725">795</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Buildings and building equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="f-726">12,317</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="f-727">12,375</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="f-728">29,444</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="f-729">28,979</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Construction in progress</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="f-730">6,289</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="f-731">5,627</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total property, plant and equipment, gross</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="f-732">48,768</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="f-733">47,776</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-734">28,250</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-735">27,878</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total property, plant and equipment, net</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-736">20,518</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-737">19,898</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company capitalizes interest expense as part of the cost of construction of facilities and equipment. Interest expense capitalized in fiscal years 2024, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InterestCostsCapitalized" scale="6" id="f-738">79</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:InterestCostsCapitalized" scale="6" id="f-739">70</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:InterestCostsCapitalized" scale="6" id="f-740">49</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Depreciation expense, including the amortization of capitalized interest in fiscal years 2024, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-8" name="jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" scale="9" id="f-741">2.8</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-8" name="jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" scale="9" id="f-742">2.6</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-8" name="jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" scale="9" id="f-743">2.4</ix:nonFraction> billion, respectively. </span></div><div style="margin-bottom:40pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Upon retirement or other disposal of property, plant and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds are recorded in earnings.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">58</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_160"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">5.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-744" continuedAt="f-744-1" escape="true">Intangible assets and goodwill</ix:nonNumeric></span></div><ix:continuation id="f-744-1"><ix:nonNumeric contextRef="c-1" name="jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" id="f-745" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">At the end of fiscal years 2024 and 2023, the gross and net amounts of intangible assets were:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Intangible assets with definite lives:</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents and trademarks&#160;&#8212; gross</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-746">44,695</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-747">40,417</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-748">26,124</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-749">24,808</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents and trademarks&#160;&#8212; net</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-750">18,571</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-751">15,609</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Customer relationships and other intangibles&#160;&#8212; gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-752">20,310</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-753">20,322</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-754">13,544</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-755">12,685</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Customer relationships and other intangibles&#160;&#8212; net</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-756">6,766</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-757">7,637</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trademarks</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-758">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-759">1,714</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchased in-process research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-760">12,281</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-761">9,215</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-762">12,281</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-763">10,929</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets&#160;&#8212; net</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-764">37,618</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-765">34,175</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:125%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:9.29pt">In September 2024, the Company announced changes to its MedTech brand identity and the $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="9" id="f-766">1.7</ix:nonFraction>&#160;billion of trademarks associated with the DePuy Synthes business were reclassified from indefinite lived to definite lived and will be amortized over a <span style="-sec-ix-hidden:f-767">25&#160;year</span> period.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:125%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.09pt">The majority is comprised of customer relationships</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-768" continuedAt="f-768-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Goodwill as of December&#160;29, 2024 and December&#160;31, 2023, as allocated by segment of business, was as follows:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.575%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Innovative <br/>Medicine</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MedTech</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill at January 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-769">10,184</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-770">25,863</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-771">36,047</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill, related to acquisitions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="f-772">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="f-773">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="f-774">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill, related to divestitures</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="f-775">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="f-776">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="f-777">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Currency translation/other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="f-778">223</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="f-779">288</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="f-780">511</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill at December 31, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-781">10,407</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-782">26,151</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-783">36,558</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill, related to acquisitions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="f-784">640</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="f-785">7,569</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="f-786">8,209</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill, related to divestitures</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="f-787">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="f-788">56</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="f-789">56</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Currency translation/other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="f-790">355</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="f-791">156</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="f-792">511</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill at December 29, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-793">10,692</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-794">33,508</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-795">44,200</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:continuation id="f-768-1">*&#160;&#160;&#160;&#160;Includes purchase price allocation adjustments for Abiomed</ix:continuation> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The weighted average amortization period for patents and trademarks is approximately <ix:nonNumeric contextRef="c-99" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-796">12</ix:nonNumeric> years. The weighted average amortization period for customer relationships and other intangible assets is approximately <ix:nonNumeric contextRef="c-101" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-797">18</ix:nonNumeric> years. The amortization expense of amortizable assets included in Cost of products sold was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" scale="9" id="f-798">4.5</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" scale="9" id="f-799">4.5</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" scale="9" id="f-800">3.9</ix:nonFraction> billion before tax, for the fiscal years ended December&#160;29, 2024, December&#160;31, 2023 and January&#160;1, 2023, respectively. Intangible asset write-downs are included in Other (income) expense, net.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="f-801" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The estimated amortization expense related to intangible assets for approved products, before tax, for the five succeeding years is approximately:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:18.302%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.302%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.302%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.302%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.308%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:13pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2027</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2028</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2029</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="f-802">4,000</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="f-803">3,400</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="f-804">2,800</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="f-805">2,200</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="6" id="f-806">2,200</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">See Note 18 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">59</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_163"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">6.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-807" continuedAt="f-807-1" escape="true">Fair value measurements</ix:nonNumeric></span></div><ix:continuation id="f-807-1" continuedAt="f-807-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany products and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of December&#160;29, 2024 and December&#160;31, 2023, the total amount of cash collateral paid by the Company under the CSA amounted to $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-8" name="us-gaap:CollateralAlreadyPostedAggregateFairValue" scale="9" id="f-808">2.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-8" name="us-gaap:CollateralAlreadyPostedAggregateFairValue" scale="9" id="f-809">4.0</ix:nonFraction> billion net respectively, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of December&#160;29, 2024, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-810">45.1</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-811">40.5</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-812">9.0</ix:nonFraction> billion, respectively. As of December&#160;31, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-813">42.9</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-814">39.7</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-8" name="us-gaap:DerivativeNotionalAmount" scale="9" id="f-815">10.0</ix:nonFraction> billion, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. Cash exchanged for derivatives is primarily in cash flows from operating activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings.&#160;Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted through the currency translation account within accumulated other comprehensive income.&#160;The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If&#160;and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company designated its Euro denominated notes with due dates ranging from 2024 to 2044 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">As of December&#160;29, 2024, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-8" sign="-" name="us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax" scale="9" id="f-816">1.7</ix:nonFraction> billion&#160;after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note&#160;13. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the <ix:nonNumeric contextRef="c-1" name="us-gaap:DescriptionOfReclassificationOfCashFlowHedgeGainLoss" id="f-817">next 12 months</ix:nonNumeric> as a result of transactions that are expected to occur over that period. The&#160;maximum length of time over which the Company is hedging transaction exposure is <ix:nonNumeric contextRef="c-1" name="us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge" format="ixt-sec:durmonth" id="f-818">18</ix:nonNumeric> months, excluding interest rate contracts and net investment hedges. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">60</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="f-819" continuedAt="f-819-1" escape="true"><ix:continuation id="f-807-2" continuedAt="f-807-3"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended December&#160;29, 2024 and December&#160;31, 2023, net of tax:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.775%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.108%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.084%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.084%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.679%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.388%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost of<br/>Products<br/>&#160;Sold</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">R&amp;D<br/>&#160;Expense</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Interest<br/>(Income)<br/>&#160;Expense</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other<br/>(Income)<br/>Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost of<br/>Products<br/>Sold</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">R&amp;D<br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Interest<br/>(Income)<br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other<br/>(Income)<br/>Expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Interest rate swaps contracts:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Hedged items</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="f-820">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="f-821">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="f-822">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="f-823">64</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="f-824">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="f-825">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="f-826">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="f-827">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="f-828">168</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="f-829">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="f-830">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="f-831">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="f-832">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="f-833">64</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="f-834">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="f-835">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="f-836">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="f-837">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="f-838">168</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="f-839">&#8212;</ix:nonFraction></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="f-840">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="f-841">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="f-842">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="f-843">148</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="f-844">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="f-845">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="f-846">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="f-847">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="f-848">130</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="f-849">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) recognized in AOCI</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="f-850">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="f-851">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="f-852">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="f-853">148</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="f-854">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="f-855">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="f-856">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="f-857">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="f-858">130</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="f-859">&#8212;</ix:nonFraction></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Forward foreign exchange contracts:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="f-860">2</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="f-861">426</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="f-862">33</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="f-863">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="f-864">6</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="f-865">7</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="f-866">186</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="f-867">37</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="f-868">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="f-869">8</ix:nonFraction></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) recognized in AOCI</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="f-870">7</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="f-871">156</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="f-872">80</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="f-873">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="f-874">21</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="f-875">10</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="f-876">447</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="f-877">18</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="f-878">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="f-879">9</ix:nonFraction></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="f-880">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="f-881">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="f-882">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="f-883">247</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="f-884">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="f-885">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="f-886">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="f-887">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="f-888">275</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="f-889">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) recognized in AOCI</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="f-890">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="f-891">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="f-892">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="f-893">597</ix:nonFraction>)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="f-894">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="f-895">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="f-896">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="f-897">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="f-898">156</ix:nonFraction>)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="f-899">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">61</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-807-3" continuedAt="f-807-4"><ix:continuation id="f-819-1"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">As of December&#160;29, 2024 and December&#160;31, 2023, the following amounts were recorded on the consolidated balance sheet related to cumulative basis adjustment for fair value hedges:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Line item in the Consolidated Balance Sheet<br/>in which the hedged item is included</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Amount of the Hedged Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cumulative Amount of Fair Value Hedging<br/>Adjustment Included in the Carrying<br/>Amount of the Hedged Liability</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term Debt</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="f-900">7,935</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="f-901">8,862</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-6" sign="-" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="f-902">1,132</ix:nonFraction>)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-6" sign="-" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="f-903">1,216</ix:nonFraction>)</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="f-904" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended <br/>December&#160;29, 2024 and December&#160;31, 2023:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.138%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.229%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Location of Gain /(Loss)<br/>Recognized in Income on<br/>Derivative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Foreign Exchange Contracts</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-905"><span style="-sec-ix-hidden:f-906">Other (income) expense</span></span></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="f-907">8</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="f-908">60</ix:nonFraction>)</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" id="f-909" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table is the effect of net investment hedges for the fiscal years ended December&#160;29, 2024 and <br/>December&#160;31, 2023:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.231%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain/(Loss)<br/>Recognized In<br/>Accumulated OCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Location of Gain or<br/>(Loss) Reclassified<br/>from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain/(Loss)<br/>Reclassified from<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Debt</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="f-910">282</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="f-911">131</ix:nonFraction>)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Interest (income) expense</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="f-912">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="f-913">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cross Currency interest rate&#160;swaps</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="f-914">955</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="f-915">642</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Interest (income) expense</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="f-916">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="f-917">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company measures equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="f-918" continuedAt="f-918-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table is a summary of the activity related to equity investments for the fiscal years ended December&#160;29, 2024 and December&#160;31, 2023:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.792%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.334%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.658%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Changes in Fair</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value Reflected in</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Income</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales/</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Purchases/</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-Current<br/>Other Assets</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity Investments with readily determinable value *</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-919">4,473</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-6" sign="-" name="us-gaap:EquityFairValueAdjustment" scale="6" id="f-920">17</ix:nonFraction>)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-6" sign="-" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="f-921">4,005</ix:nonFraction>)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="f-922">451</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-923">451</ix:nonFraction></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity Investments without readily determinable value</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="f-924">696</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-6" sign="-" name="us-gaap:EquityFairValueAdjustment" scale="6" id="f-925">197</ix:nonFraction>)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-6" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" scale="6" id="f-926">274</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="f-927">773</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-928">773</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">62</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-807-4" continuedAt="f-807-5"><ix:continuation id="f-918-1"><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.792%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.334%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.658%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Changes in Fair</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value Reflected in</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Income</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales/</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Purchases/</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-Current<br/>Other Assets</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Equity Investments with readily determinable value *</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="f-929">576</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-6" sign="-" name="us-gaap:EquityFairValueAdjustment" scale="6" id="f-930">368</ix:nonFraction>)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-6" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="f-931">4,265</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-932">4,473</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-933">4,473</ix:nonFraction></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Equity Investments without readily determinable value</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="f-934">613</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-6" name="us-gaap:EquityFairValueAdjustment" scale="6" id="f-935">1</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-6" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" scale="6" id="f-936">82</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="f-937">696</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-938">696</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">Recorded in Other Income/Expense</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Other includes impact of currency</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">*&#160;&#160;&#160;&#160;The December 31, 2023 balance includes the <ix:nonFraction unitRef="number" contextRef="c-47" decimals="3" name="jnj:ExchangeOfStockPercentageOwnershipAfterTransaction" scale="-2" id="f-939">9.5</ix:nonFraction>% remaining stake in Kenvue. A debt-for-equity exchange was completed in the fiscal second quarter of 2024.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On May 15, 2024, the Company issued $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-8" name="us-gaap:CommercialPaper" scale="9" id="f-940">3.6</ix:nonFraction> billion aggregate principal amount of commercial paper and received $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-8" name="us-gaap:ProceedsFromIssuanceOfCommercialPaper" format="ixt:num-dot-decimal" scale="9" id="f-941">3.6</ix:nonFraction>&#160;billion of net cash proceeds to be used for general corporate purposes. On May 17, 2024, the Company completed a Debt-for-Equity Exchange of its remaining <ix:nonFraction unitRef="shares" contextRef="c-186" decimals="INF" name="jnj:DebtForEquityExchangeSharesExchanged" format="ixt:num-dot-decimal" scale="0" id="f-942">182,329,550</ix:nonFraction> shares of Kenvue Common Stock for the outstanding Commercial Paper. Upon completion of the Debt-for-Equity Exchange, the Commercial Paper was satisfied and discharged, and the Company no longer owns any shares of Kenvue Common Stock. This exchange resulted in a loss of approximately $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-8" name="jnj:DebtForEquityExchangeLossOnSharesExchanged" format="ixt:num-dot-decimal" scale="9" id="f-943">0.4</ix:nonFraction>&#160;billion recorded in Other (income) expense. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">For the fiscal years ended December&#160;29, 2024 and December&#160;31, 2023 for equity investments without readily determinable market values, $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-6" sign="-" name="jnj:EquityFairValueAdjustmentImpairmentLoss" scale="6" id="f-944">171</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-6" sign="-" name="jnj:EquityFairValueAdjustmentImpairmentLoss" scale="6" id="f-945">1</ix:nonFraction> million, respectively, of the changes in fair value reflected in net income were the result of impairments. There were impacts of $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-6" sign="-" name="jnj:EquityFairValueAdjustmentChangeinObservablePrices" scale="6" id="f-946">26</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-6" name="jnj:EquityFairValueAdjustmentChangeinObservablePrices" scale="6" id="f-947">27</ix:nonFraction> million, respectively, of changes in the fair value reflected in net income due to changes in observable prices and gains on the disposal of investments. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level&#160;1 having the highest priority and Level&#160;3 having the lowest.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S.&#160;Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#8217;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level&#160;1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following three levels of inputs are used to measure fair value:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Level&#160;1&#160;&#8212; Quoted prices in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Level&#160;2&#160;&#8212; Significant other observable inputs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Level&#160;3&#160;&#8212; Significant unobservable inputs.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">63</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="f-948" continuedAt="f-948-1" escape="true"><ix:continuation id="f-807-5" continuedAt="f-807-6"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of the fiscal year ended December&#160;29, 2024 and December&#160;31, 2023 were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.895%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forward foreign exchange contracts </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="f-949">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="f-950">660</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="f-951">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="f-952">660</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="f-953">539</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest rate contracts</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="f-954">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-955">1,484</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="f-956">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-957">1,484</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="f-958">988</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="f-959">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-960">2,144</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="f-961">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-962">2,144</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-963">1,527</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forward foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="f-964">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="f-965">794</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="f-966">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="f-967">794</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="f-968">624</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest rate contracts</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="f-969">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-970">3,753</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="f-971">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-972">3,753</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-973">5,338</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="f-974">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-975">4,547</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="f-976">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-977">4,547</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-978">5,962</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forward foreign exchange contracts </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="f-979">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="f-980">50</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="f-981">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="f-982">50</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="f-983">64</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forward foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" format="ixt:fixed-zero" scale="6" id="f-984">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="f-985">17</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" format="ixt:fixed-zero" scale="6" id="f-986">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="f-987">17</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="f-988">75</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Available For Sale Other Investments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity investments</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-989">451</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="f-990">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="f-991">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-992">451</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="f-993">4,473</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Debt securities</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-994">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-995">7,216</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-996">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-997">7,216</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-998">8,874</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contingent Consideration</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-999">1,217</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-1000">1,217</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-1001">1,092</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.065%"><tr><td style="width:1.0%"/><td style="width:64.302%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.895%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.139%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total Gross Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="6" id="f-1002">2,194</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="6" id="f-1003">1,591</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Credit Support Agreements (CSA)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" format="ixt:num-dot-decimal" scale="6" id="f-1004">2,172</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" format="ixt:num-dot-decimal" scale="6" id="f-1005">1,575</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="jnj:DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" id="f-1006"><ix:nonNumeric contextRef="c-12" name="jnj:DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" id="f-1007">Total Net Asset</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="f-1008">22</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="f-1009">16</ix:nonFraction></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total Gross Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="f-1010">4,564</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="f-1011">6,037</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Credit Support Agreements (CSA)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" format="ixt:num-dot-decimal" scale="6" id="f-1012">4,412</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" format="ixt:num-dot-decimal" scale="6" id="f-1013">5,604</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-12" name="jnj:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" id="f-1014"><ix:nonNumeric contextRef="c-1" name="jnj:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" id="f-1015">Total Net Liabilities</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="f-1016">152</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="f-1017">433</ix:nonFraction></span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">64</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-807-6"><ix:continuation id="f-948-1" continuedAt="f-948-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Summarized information about changes in liabilities for contingent consideration is as follows:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning Balance</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="f-1018">1,092</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="f-1019">1,120</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="f-1020">533</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Changes in estimated fair value </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" scale="6" id="f-1021">88</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" scale="6" id="f-1022">29</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" scale="6" id="f-1023">194</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Additions</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="f-1024">112</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:fixed-zero" scale="6" id="f-1025">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="f-1026">792</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Payments/Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="f-1027">75</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="f-1028">57</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="f-1029">11</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Ending Balance</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="f-1030">1,217</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="f-1031">1,092</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="f-1032">1,120</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">2023 assets and liabilities are all classified as Level&#160;2 with the exception of equity investments of $<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="f-1033">4,473</ix:nonFraction> million, which are classified as Level&#160;1 and contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-1034">1,092</ix:nonFraction> million, classified as Level 3.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Includes cross currency interest rate swaps and interest rate swaps.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt">Classified as non-current other assets.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.89pt">Classified as cash equivalents and current marketable securities.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.99pt">Includes $<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-1035">1,217</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-1036">1,092</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-1037">1,116</ix:nonFraction> million, classified as non-current other liabilities as of December&#160;29, 2024, <br/>December&#160;31, 2023 and January&#160;1, 2023, respectively. Includes $<ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-1038">4</ix:nonFraction>&#160;million classified as current liabilities as of January&#160;1, 2023.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><ix:continuation id="f-948-2" continuedAt="f-948-3"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></ix:continuation><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt"><ix:continuation id="f-948-3">In fiscal year 2024, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-1039">105</ix:nonFraction>&#160;million of contingent consideration related to Proteologix. In fiscal year 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-1040">704</ix:nonFraction>&#160;million of contingent consideration related to Abiomed.</ix:continuation> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">See Notes&#160;2 and 7 for financial assets and liabilities held at carrying amount on the Consolidated Balance Sheet.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">65</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_169"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">7.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-1041" continuedAt="f-1041-1" escape="true">Borrowings</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-1042" continuedAt="f-1042-1" escape="true"><ix:continuation id="f-1041-1" continuedAt="f-1041-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The components of long-term debt are as follows:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.275%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.275%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.275%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.778%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Effective<br/>Rate<br/>%</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Effective<br/>Rate<br/>%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-209" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1043">0.650</ix:nonFraction>% Notes due 2024 </span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-210" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-1044">750</ix:nonFraction>MM Euro <ix:nonFraction unitRef="number" contextRef="c-210" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="f-1045">1.1090</ix:nonFraction>)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="f-1046">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-209" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="f-1047">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1048">831</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-210" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1049">0.68</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-211" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1050">5.50</ix:nonFraction>%&#160;Notes due 2024 </span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="gbp" contextRef="c-212" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-1051">500</ix:nonFraction>MM GBP <ix:nonFraction unitRef="number" contextRef="c-212" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="f-1052">1.2756</ix:nonFraction>)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="f-1053">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-211" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="f-1054">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1055">637</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-212" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1056">6.75</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-213" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1057">2.625</ix:nonFraction>% Notes due 2025</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1058">750</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-213" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1059">2.63</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1060">750</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-214" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1061">2.63</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-215" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1062">0.55</ix:nonFraction>% Notes due 2025</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1063">999</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-215" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1064">0.57</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1065">950</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-216" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1066">0.57</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-217" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1067">2.46</ix:nonFraction>% Notes due 2026</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-1068">1,999</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-217" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1069">2.47</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-1070">1,997</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-218" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1071">2.47</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-219" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1072">2.95</ix:nonFraction>% Notes due 2027</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1073">927</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-219" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1074">2.96</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1075">900</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-220" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1076">2.96</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-221" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1077">0.95</ix:nonFraction>% Notes due 2027</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-1078">1,458</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-221" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1079">0.96</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-1080">1,419</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-222" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1081">0.96</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-223" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1082">1.150</ix:nonFraction>% Notes due 2028<br/>(<ix:nonFraction unitRef="eur" contextRef="c-223" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-1083">750</ix:nonFraction>MM Euro <ix:nonFraction unitRef="number" contextRef="c-223" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="f-1084">1.0401</ix:nonFraction>)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/(<ix:nonFraction unitRef="eur" contextRef="c-224" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-1085">750</ix:nonFraction>MM Euro <ix:nonFraction unitRef="number" contextRef="c-224" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="f-1086">1.1090</ix:nonFraction>)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1087">777</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-223" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1088">1.21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1089">828</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-224" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1090">1.21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-225" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1091">2.90</ix:nonFraction>%&#160;Notes due 2028</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-1092">1,498</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-225" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1093">2.91</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-1094">1,497</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-226" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1095">2.91</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-227" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1096">6.95</ix:nonFraction>%&#160;Notes due 2029</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1097">298</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-227" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1098">7.14</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1099">298</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-228" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1100">7.14</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-229" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1101">4.80</ix:nonFraction>% Debentures due 2029</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-1102">1,146</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-229" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1103">4.83</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="f-1104">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-230" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="f-1105">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1106">1.30</ix:nonFraction>% Notes due 2030</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-1107">1,646</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-231" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1108">1.30</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-1109">1,630</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-232" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1110">1.30</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-233" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1111">4.90</ix:nonFraction>% Debentures due 2031</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-1112">1,145</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-233" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1113">4.92</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="f-1114">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-234" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="f-1115">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-235" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1116">3.20</ix:nonFraction>% Debenture due 2032</span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-235" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-1117">700</ix:nonFraction>M EUR <ix:nonFraction unitRef="number" contextRef="c-235" decimals="4" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="f-1118">1.0401</ix:nonFraction>)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1119">725</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-235" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1120">3.21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="f-1121">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-236" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="f-1122">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-237" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1123">4.95</ix:nonFraction>%&#160;Debentures due 2033</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1124">499</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-237" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1125">4.95</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1126">499</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-238" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1127">4.95</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-239" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1128">4.375</ix:nonFraction>% Notes due 2033</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1129">854</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-239" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1130">4.24</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1131">854</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-240" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1132">4.24</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-241" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1133">4.95</ix:nonFraction>% Debentures due 2034</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1134">846</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-241" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1135">4.96</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="f-1136">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-242" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="f-1137">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-243" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1138">1.650</ix:nonFraction>% Notes due 2035<br/>(<ix:nonFraction unitRef="eur" contextRef="c-243" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="f-1139">1.5</ix:nonFraction>B Euro <ix:nonFraction unitRef="number" contextRef="c-243" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="f-1140">1.0401</ix:nonFraction>)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/(<ix:nonFraction unitRef="eur" contextRef="c-244" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="f-1141">1.5</ix:nonFraction>B Euro <ix:nonFraction unitRef="number" contextRef="c-244" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="f-1142">1.1090</ix:nonFraction>)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-1143">1,550</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-243" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1144">1.68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-1145">1,652</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-244" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1146">1.68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-245" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1147">3.35</ix:nonFraction>% Debentures due 2036 </span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-245" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-1148">800</ix:nonFraction>MM EUR <ix:nonFraction unitRef="number" contextRef="c-245" decimals="4" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="f-1149">1.0401</ix:nonFraction>)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1150">827</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-245" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1151">3.37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="f-1152">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-246" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="f-1153">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-247" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1154">3.587</ix:nonFraction>% Notes due 2036</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1155">869</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-247" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1156">3.59</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1157">864</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-248" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1158">3.59</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-249" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1159">5.95</ix:nonFraction>%&#160;Notes due 2037</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1160">994</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-249" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1161">5.99</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1162">994</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-250" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1163">5.99</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-251" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1164">3.625</ix:nonFraction>% Notes due 2037</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-1165">1,358</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-251" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1166">3.64</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-1167">1,357</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-252" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1168">3.64</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-253" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1169">5.85</ix:nonFraction>%&#160;Debentures due 2038</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1170">697</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-253" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1171">5.85</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1172">697</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-254" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1173">5.85</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-255" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1174">3.40</ix:nonFraction>%&#160;Notes due 2038</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1175">993</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-255" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1176">3.42</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1177">993</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-256" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1178">3.42</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-257" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1179">4.50</ix:nonFraction>%&#160;Debentures due 2040</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1180">541</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-257" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1181">4.63</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1182">541</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-258" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1183">4.63</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-259" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1184">2.10</ix:nonFraction>% Notes due 2040</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1185">845</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-259" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1186">2.14</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1187">849</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-260" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1188">2.14</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-261" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1189">4.85</ix:nonFraction>% Notes due 2041</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1190">297</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-261" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1191">4.89</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1192">297</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-262" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1193">4.89</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-263" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1194">4.50</ix:nonFraction>% Notes due 2043</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1195">496</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-263" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1196">4.52</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1197">496</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-264" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1198">4.52</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-265" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1199">3.55</ix:nonFraction>% Debentures due 2044</span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-265" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="f-1200">1</ix:nonFraction>B EUR <ix:nonFraction unitRef="number" contextRef="c-265" decimals="4" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="f-1201">1.0401</ix:nonFraction>)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-1202">1,030</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-265" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1203">3.58</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="f-1204">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-266" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="f-1205">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-267" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1206">3.73</ix:nonFraction>% Notes due 2046</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-1207">1,978</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-267" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1208">3.74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-1209">1,977</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-268" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1210">3.74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-269" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1211">3.75</ix:nonFraction>% Notes due 2047</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1212">822</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-269" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1213">3.76</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1214">832</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-270" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1215">3.76</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-271" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1216">3.500</ix:nonFraction>% Notes due 2048</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1217">744</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-271" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1218">3.52</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1219">743</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-272" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1220">3.52</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-273" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1221">2.250</ix:nonFraction>% Notes due 2050</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1222">808</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-273" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1223">2.29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1224">826</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-274" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1225">2.29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">66</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-1041-2"><ix:continuation id="f-1042-1"><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.275%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.275%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.275%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.778%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-275" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1226">5.25</ix:nonFraction>% Debentures due 2054</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1227">843</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-275" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1228">5.26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="f-1229">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-276" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="f-1230">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-277" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1231">2.450</ix:nonFraction>% Notes due 2060</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-1232">1,058</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-277" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1233">2.49</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-1234">1,073</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-278" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1235">2.49</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1236">83</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-279" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="f-1237">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-1238">69</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-280" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="f-1239">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-1240">32,400</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-10" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1241">3.36</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-1242">27,350</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-11" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1243">2.98</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less current portion</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1244">1,749</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1245">1,469</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total long-term debt</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1246">30,651</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1247">25,881</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">Weighted average effective rate.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Translation rate at December&#160;29, 2024.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt">Translation rate at December&#160;31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.89pt">The excess of the carrying value over the fair value of debt was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-8" name="jnj:ExcessOfCarryingValueOverFairValueOfDebt" scale="9" id="f-1248">2.0</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-8" name="jnj:ExcessOfFairValueOverCarryingValueOfDebt" scale="9" id="f-1249">1.0</ix:nonFraction> billion at the end of fiscal year 2024 and fiscal year 2023, respectively.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Fair value of the long-term debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has access to substantial sources of funds at numerous banks worldwide. In June 2024, the Company secured a new 364-day Credit Facility of $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-9" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="f-1250">10</ix:nonFraction> billion, which expires on&#160;June 25, 2025. Interest charged on borrowings under the credit line agreement is based on either the Term SOFR Reference Rate or other applicable market rates&#160;as allowed under the terms of the agreement, plus applicable margins. Commitment fees under the agreements are not&#160;material.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Throughout fiscal years 2024 and 2023, the Company continued to have access to liquidity through the commercial paper&#160;market. Short-term borrowings and the current portion of long-term debt amounted to approximately $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-8" name="us-gaap:DebtCurrent" scale="9" id="f-1251">6.0</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-8" name="us-gaap:DebtCurrent" scale="9" id="f-1252">3.5</ix:nonFraction> billion at the end of fiscal years 2024 and 2023, respectively. The current portion of the long-term debt was $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-8" name="us-gaap:LongTermCommercialPaperCurrent" scale="9" id="f-1253">1.7</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-8" name="us-gaap:LongTermCommercialPaperCurrent" scale="9" id="f-1254">1.5</ix:nonFraction> billion in 2024 and 2023, respectively, and the remainder is commercial paper and local borrowing by international&#160;subsidiaries.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The current debt balance as of December&#160;29, 2024 includes $<ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-8" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="9" id="f-1255">4.1</ix:nonFraction>&#160;billion of commercial paper which has a weighted average interest rate of <ix:nonFraction unitRef="number" contextRef="c-281" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="f-1256">4.46</ix:nonFraction>% and a weighted average maturity of approximately <ix:nonNumeric contextRef="c-282" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-1257">two months</ix:nonNumeric>. The current debt balance as of December&#160;31, 2023 includes $<ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-8" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="9" id="f-1258">2.0</ix:nonFraction>&#160;billion of commercial paper which has a weighted average interest rate of <ix:nonFraction unitRef="number" contextRef="c-283" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="f-1259">5.37</ix:nonFraction>% and a weighted average maturity of approximately <ix:nonNumeric contextRef="c-284" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-1260">two months</ix:nonNumeric>.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-1261" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Aggregate maturities of long-term debt obligations commencing in 2025 are:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.826%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2027</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2028</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2029</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">After 2029</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="f-1262">1,749</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="6" id="f-1263">1,999</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="6" id="f-1264">2,385</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="6" id="f-1265">2,275</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="6" id="f-1266">1,444</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="f-1267">22,548</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i4b4bd2fffa0147e7914e1841a5c21924_175"></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">8.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1268" continuedAt="f-1268-1" escape="true">Income taxes</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-1269" escape="true"><ix:continuation id="f-1268-1" continuedAt="f-1268-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The provision for taxes on income on continuing operations consists of:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Currently payable:</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. taxes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1270">2,200</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1271">2,705</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1272">2,274</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International taxes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1273">2,604</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1274">3,090</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1275">2,295</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total currently payable</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1276">4,804</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1277">5,795</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1278">4,569</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Deferred:</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. taxes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1279">2,539</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1280">3,440</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1281">1,990</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International taxes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="f-1282">356</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="f-1283">619</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="f-1284">410</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total deferred</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="jnj:DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-1285">2,183</ix:nonFraction>)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="jnj:DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-1286">4,059</ix:nonFraction>)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="jnj:DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-1287">1,580</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Provision for taxes on income</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1288">2,621</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1289">1,736</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1290">2,989</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">67</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-1268-2" continuedAt="f-1268-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-1291" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">A comparison of income tax expense at the U.S.&#160;statutory rate of <ix:nonFraction unitRef="number" contextRef="c-12" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1292"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1293">21</ix:nonFraction></ix:nonFraction>% in fiscal years 2024, 2023 and 2022, to the Company&#8217;s effective tax rate is as follows:</span></div><div style="margin-bottom:4pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.&#160;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="f-1294">458</ix:nonFraction>)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="f-1295">2,033</ix:nonFraction>)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="f-1296">4,606</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="f-1297">17,145</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="f-1298">17,095</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="f-1299">14,753</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Earnings before taxes on income:</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1300">16,687</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1301">15,062</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1302">19,359</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax rates:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. statutory rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1303">21.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1304">21.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1305">21.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International operations</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1306">5.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1307">8.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1308">5.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. tax settlements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation" scale="-2" id="f-1309">1.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" sign="-" name="jnj:EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation" scale="-2" id="f-1310">3.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation" format="ixt:fixed-zero" scale="-2" id="f-1311">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. taxes on international income</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" scale="-2" id="f-1312">2.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" sign="-" name="jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" scale="-2" id="f-1313">0.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" sign="-" name="jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" scale="-2" id="f-1314">1.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. state taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1315">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1316">1.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1317">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax benefits on share-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1318">0.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1319">0.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1320">1.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1321">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1322">1.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1323">1.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effective Rate</span></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1324">15.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1325">11.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1326">15.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">International operations reflect the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland, and Belgium, which is a favorable impact on the effective tax rate as compared with the U.S. statutory&#160;rate. </span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Includes the net impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code as well as related foreign tax credits.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">The fiscal year 2024 effective tax rate increased <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" scale="-2" id="f-1327">4.2</ix:nonFraction>% as compared to the fiscal year 2023 effective tax rate. The primary drivers of this change are discussed below.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">In fiscal year 2024, The Company had more income in higher tax jurisdictions compared to fiscal year 2023, primarily in the U.S. where the Company recorded a charge of approximately $<ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="f-1328">5.1</ix:nonFraction>&#160;billion in the fiscal year of 2024 versus approximately $<ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="f-1329">7.0</ix:nonFraction>&#160;billion in the fiscal year of 2023, both for the talc matters in the United States. Both charges were recorded at an effective U.S. tax rate of approximately 21% (for further information see Note 19 to the Consolidated Financial Statements). </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">Additionally in the fiscal year 2024, the effective tax rate was unfavorably impacted by legislative changes that went into effect for Pillar Two in some of the Company's foreign jurisdictions which are reflected in International operations on the Company&#8217;s effective tax rate reconciliation. Also in fiscal year 2024, the Company generated incremental U.S. foreign tax credits related to income sourced and taxed outside the United States and is reflected in U.S. taxes on international income on the Company&#8217;s effective tax rate reconciliation. In 2024, the Company finalized multi-year transfer pricing agreements with the U.S. Internal Revenue Service (IRS) and certain other foreign jurisdictions. The U.S portion of the agreements were partially offset by the related tax adjustments in the foreign jurisdictions which are reflected in U.S tax settlements and International operations, respectively, on the Company&#8217;s effective rate reconciliation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">The fiscal year 2023 effective tax rate decreased <ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" sign="-" name="jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" scale="-2" id="f-1330">3.9</ix:nonFraction>% as compared to the fiscal year 2022 effective tax rate as the Company recorded certain non-recurring favorable tax items in fiscal year 2023 when compared to the prior fiscal year.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">In the fiscal fourth quarter of 2023, the Company settled the U.S. Internal Revenue Service audit for tax years 2013 through 2016 which resulted in a favorable impact to the rate of <ix:nonFraction unitRef="number" contextRef="c-287" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" scale="-2" id="f-1331">3.0</ix:nonFraction>%. This settlement was partially offset by the Company recording a $<ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-8" name="us-gaap:IncomeTaxReconciliationTaxCreditsForeign" format="ixt:num-dot-decimal" scale="9" id="f-1332">0.4</ix:nonFraction>&#160;billion decrease in expected U.S. foreign tax credits, an unfavorable effective rate impact of <ix:nonFraction unitRef="number" contextRef="c-287" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" scale="-2" id="f-1333">2.6</ix:nonFraction>%, which has been reflected as a current tax expense in U.S. taxes on international income on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">In the fiscal year 2023, the Company had certain non-recurring impacts as a result of legislative tax elections made in certain international subsidiaries which resulted in a change in the Company&#8217;s tax basis in certain assets resulting in deferred tax re-measurements. The net impact of these non-recurring items is a net benefit of <ix:nonFraction unitRef="number" contextRef="c-288" decimals="3" name="jnj:EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" scale="-2" id="f-1334">3.4</ix:nonFraction>% to the Company&#8217;s annual effective tax rate, comprised of the following items:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:128%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%;padding-left:7.83pt">approximately $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="jnj:DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" format="ixt:num-dot-decimal" scale="9" id="f-1335">0.3</ix:nonFraction>&#160;billion of tax benefit on local deferred tax assets to record the remeasurement of the increased tax basis, this benefit has been reflected as International operations on the Company&#8217;s effective tax rate reconciliation. This&#160;benefit was offset by approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-8" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount" format="ixt:num-dot-decimal" scale="9" id="f-1336">0.1</ix:nonFraction>&#160;billion of U.S. deferred tax expense on the GILTI deferred tax liability resulting from the remeasurement of these deferred tax assets. This has been reflected in the &#8220;U.S. tax on international income&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">68</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-1268-3" continuedAt="f-1268-4"><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">approximately $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="jnj:IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" format="ixt:num-dot-decimal" scale="9" id="f-1337">0.3</ix:nonFraction>&#160;billion of U.S. deferred tax benefit on the GILTI deferred tax related to an election made by an international subsidiary resulting in a decrease in local deferred tax assets. This has been reflected in the U.S. taxes on international income on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company also had lower income in higher tax jurisdictions vs. fiscal year 2022, primarily in the U.S. where the Company recorded an approximately $<ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="f-1338">7.0</ix:nonFraction>&#160;billion charge related to talc matters in the United States at an effective tax rate of <ix:nonFraction unitRef="number" contextRef="c-289" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="f-1339">21.1</ix:nonFraction>% (for further information see Note 19 to the Consolidated Financial Statements).</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-1340" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Temporary differences and carryforwards at the end of fiscal years 2024 and 2023 were as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt;padding-right:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.292%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024 Deferred Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023 Deferred Tax</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Asset</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Asset</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee related obligations</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" scale="6" id="f-1341">372</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" scale="6" id="f-1342">586</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock based compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="f-1343">717</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="f-1344">686</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation of property, plant and equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="f-1345">833</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="f-1346">902</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill and intangibles</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1347">3,261</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1348">1,252</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">R&amp;D capitalized for tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="jnj:DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" format="ixt:num-dot-decimal" scale="6" id="f-1349">4,398</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="jnj:DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" format="ixt:num-dot-decimal" scale="6" id="f-1350">3,595</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reserves&#160;&amp; liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="6" id="f-1351">4,444</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="6" id="f-1352">3,816</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory related</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:DeferredTaxAssetsInventory" scale="6" id="f-1353">371</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:DeferredTaxAssetsInventory" scale="6" id="f-1354">359</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating loss carryforwards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1355">2,298</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1356">2,145</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Undistributed foreign earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="jnj:DeferredTaxAssetsUndistributedForeignEarnings" format="ixt:num-dot-decimal" scale="6" id="f-1357">1,931</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" format="ixt:num-dot-decimal" scale="6" id="f-1358">1,492</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="jnj:DeferredTaxAssetsUndistributedForeignEarnings" format="ixt:num-dot-decimal" scale="6" id="f-1359">1,801</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" format="ixt:num-dot-decimal" scale="6" id="f-1360">1,695</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global intangible low-taxed income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="jnj:DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" format="ixt:num-dot-decimal" scale="6" id="f-1361">1,589</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="jnj:DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" format="ixt:num-dot-decimal" scale="6" id="f-1362">2,731</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Miscellaneous international</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="6" id="f-1363">1,212</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="f-1364">831</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Miscellaneous U.S.&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="jnj:DeferredTaxAssetsOtherDomestic" format="ixt:num-dot-decimal" scale="6" id="f-1365">1,083</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="jnj:DeferredTaxLiabilitiesOtherDomestic" scale="6" id="f-1366">4</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total deferred income taxes</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1367">16,826</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1368">7,175</ix:nonFraction>)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1369">13,819</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1370">6,584</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Valuation allowances</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1371">1,638</ix:nonFraction>)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1372">1,149</ix:nonFraction>)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total deferred income taxes net of valuation allowances</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-1373">15,188</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1374">7,175</ix:nonFraction>)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-1375">12,670</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1376">6,584</ix:nonFraction>)</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has wholly-owned international subsidiaries that have cumulative net losses. The Company believes that it is more likely than not that these subsidiaries will generate future taxable income sufficient to partially utilize these deferred tax assets. In certain jurisdictions, valuation allowances have been recorded against deferred tax assets for loss carryforwards that are not more likely than not to be realized. The net operating loss carryforwards for these international subsidiaries that do not have an indefinite carryforward period will begin to expire in 2025 for various amounts.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="f-1377" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table summarizes the activity related to valuation allowances for continuing operations:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.429%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning of year</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1378">1,149</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="f-1379">775</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="jnj:ValuationAllowanceDeferredTaxAssetsProvision" scale="6" id="f-1380">451</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="jnj:ValuationAllowanceDeferredTaxAssetsProvision" scale="6" id="f-1381">355</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Utilization</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="jnj:ValuationAllowanceDeferredTaxAssetsUtilization" format="ixt:fixed-zero" scale="6" id="f-1382">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="jnj:ValuationAllowanceDeferredTaxAssetsUtilization" scale="6" id="f-1383">116</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency translation</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="jnj:ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslation" scale="6" id="f-1384">46</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="jnj:ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslation" scale="6" id="f-1385">25</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net acquisitions / (dispositions/liquidations)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="jnj:ValuationAllowanceDeferredTaxAssetsAcquisitionsDispositions" scale="6" id="f-1386">84</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="jnj:ValuationAllowanceDeferredTaxAssetsAcquisitionsDispositions" scale="6" id="f-1387">110</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">End of year</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1388">1,638</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1389">1,149</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">69</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-1268-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-1390" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table summarizes the activity related to unrecognized tax benefits for continuing operations:</span></div><div style="margin-bottom:6pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning of year</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-1391">2,485</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-1392">3,716</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-1393">3,210</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increases related to current year tax positions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="f-1394">176</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="f-1395">239</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="f-1396">523</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increases related to prior period tax positions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-1397">129</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-1398">244</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-1399">143</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Decreases related to prior period tax positions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-1400">147</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-1401">781</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-1402">148</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Settlements</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="f-1403">583</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="f-1404">880</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="f-1405">1</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lapse of statute of limitations</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="f-1406">40</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="f-1407">53</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="f-1408">11</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">End of year</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-1409">2,020</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-1410">2,485</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-1411">3,716</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">As of December&#160;29, 2024 the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-8" name="us-gaap:UnrecognizedTaxBenefits" scale="9" id="f-1412">2.0</ix:nonFraction> billion of unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress with a number of tax authorities. With respect to the United States, the Internal Revenue Service (IRS) has completed its audit for the tax years through 2016 and has commenced the audit for tax years 2017 through 2020. The Company recently finalized multi-year transfer pricing agreements with the IRS and certain other foreign jurisdictions in the fiscal fourth quarter of 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In other major jurisdictions where the Company conducts business, the years that remain open to tax audits go back to the year 2013. The Company believes it is possible that some tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions. The Company anticipates a change in uncertain tax positions of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="f-1413">200</ix:nonFraction>&#160;million in certain jurisdictions in the next twelve months due to the expected expiration of the statute of limitations. However, generally the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments, audit settlements, or changes in uncertain tax positions. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company classifies liabilities for unrecognized tax benefits and related interest and penalties as long-term liabilities. Interest expense and penalties related to unrecognized tax benefits are classified as income tax expense. The Company recognized after tax interest expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" scale="6" id="f-1414">217</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" scale="6" id="f-1415">99</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" scale="6" id="f-1416">136</ix:nonFraction> million in fiscal years 2024, 2023 and 2022, respectively. The total amount of accrued interest was $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" format="ixt:num-dot-decimal" scale="6" id="f-1417">274</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" scale="6" id="f-1418">264</ix:nonFraction> million in fiscal years 2024 and 2023,&#160;respectively.</span></div></ix:continuation><div id="i4b4bd2fffa0147e7914e1841a5c21924_181"></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">9.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CompensationRelatedCostsGeneralTextBlock" id="f-1419" continuedAt="f-1419-1" escape="true">Employee related obligations</ix:nonNumeric></span></div><ix:continuation id="f-1419-1"><ix:nonNumeric contextRef="c-1" name="jnj:EmployeeRelatedObligationsTableTextBlock" id="f-1420" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">At the end of fiscal 2024 and fiscal 2023, employee related obligations recorded on the Consolidated Balance Sheets were:</span></div><div style="margin-bottom:6pt;margin-top:7pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.685%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pension benefits</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1421">2,968</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1422">3,129</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Postretirement benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1423">1,920</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1424">1,963</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Postemployment benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1425">2,910</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1426">2,527</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent" scale="6" id="f-1427">49</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent" scale="6" id="f-1428">68</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total employee obligations</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="jnj:EmployeeObligations" format="ixt:num-dot-decimal" scale="6" id="f-1429">7,847</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="jnj:EmployeeObligations" format="ixt:num-dot-decimal" scale="6" id="f-1430">7,687</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less current benefits payable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="f-1431">592</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="f-1432">538</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee related obligations&#160;&#8212; non-current</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1433">7,255</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1434">7,149</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Prepaid employee related obligations of $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1435">6,046</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1436">4,992</ix:nonFraction> million for 2024 and 2023, respectively, are included in Other assets on the Consolidated Balance Sheets.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">70</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_184"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">10.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="f-1437" continuedAt="f-1437-1" escape="true">Pensions and other benefit plans</ix:nonNumeric></span></div><ix:continuation id="f-1437-1" continuedAt="f-1437-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. The Company also provides post-retirement benefits, primarily healthcare, to all eligible U.S.&#160;retired employees and their dependents.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Many international employees are covered by government-sponsored programs and the cost to the Company is not significant.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In the U.S., non-union pension benefits for employees hired before January 1, 2015 are primarily based on the employee&#8217;s compensation during the last <ix:nonNumeric contextRef="c-290" name="jnj:EmployeeCompensationPeriod" format="ixt-sec:durwordsen" id="f-1438">five years</ix:nonNumeric> before retirement and the number of years of service (the Final Average Pay formula). U.S. pension benefits for employees hired after 2014, are calculated using a different formula based on employee compensation over total years of service (the Retirement Value formula).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees, regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits accrued under the Final Average Pay formula for service before January 1, 2026. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">International subsidiaries have plans under which funds are deposited with trustees, annuities are purchased under group contracts, or reserves are provided.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company does not fund retiree healthcare benefits in advance and has the right to modify these plans in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In 2024 and 2023 the Company used December 31, 2024 and December 31, 2023, respectively, as the measurement date for all U.S.&#160;and international retirement and other benefit plans.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="f-1439" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans for 2024, 2023 and 2022 include the following components:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service cost</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-1440">948</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-1441">893</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:num-dot-decimal" scale="6" id="f-1442">1,319</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-1443">277</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-1444">264</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-1445">320</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" format="ixt:num-dot-decimal" scale="6" id="f-1446">1,402</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" format="ixt:num-dot-decimal" scale="6" id="f-1447">1,437</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-1448">908</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-1449">209</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-1450">214</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-1451">104</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected return on plan assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1452">2,560</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1453">2,716</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1454">2,756</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="f-1455">7</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="f-1456">7</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="f-1457">8</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of prior service cost </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="f-1458">184</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="f-1459">184</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="f-1460">184</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="f-1461">2</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="f-1462">2</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="f-1463">5</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recognized actuarial losses (gains)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="f-1464">174</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="f-1465">199</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="f-1466">650</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="f-1467">53</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="f-1468">23</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="f-1469">122</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Curtailments and settlements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="f-1470">2</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="f-1471">93</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="f-1472">1</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" format="ixt:fixed-zero" scale="6" id="f-1473">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="f-1474">5</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" format="ixt:fixed-zero" scale="6" id="f-1475">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net periodic benefit cost (credit)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-1476">222</ix:nonFraction>)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-1477">676</ix:nonFraction>)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-1478">62</ix:nonFraction>)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-1479">530</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-1480">487</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-1481">533</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, Selling, marketing and administrative expenses, and Net earnings from discontinued operations, net of taxes if related to the separation of Kenvue. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings, with the exception of certain amounts for curtailments and settlements, which are reported in Net earnings from discontinued operations, net of taxes if related to the separation of Kenvue (as noted above).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Unrecognized gains and losses for the U.S.&#160;pension plans are amortized over the average remaining future service for each plan. For plans with no active employees, they are amortized over the average life expectancy. The amortization of gains and losses for the other U.S.&#160;benefit plans is determined by using a <ix:nonFraction unitRef="number" contextRef="c-10" decimals="2" name="jnj:PercentageOfCorridorOfGreaterOfMarketValueOfAssets" scale="-2" id="f-1482">10</ix:nonFraction>% corridor of the greater of the market value of assets or the accumulated postretirement benefit obligation. Total unamortized gains and losses in excess of the corridor are amortized over the average remaining future service.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Prior service costs/benefits for the U.S.&#160;pension plans are amortized over the average remaining future service of plan participants at the time of the plan amendment. Prior service cost/benefit for the other U.S.&#160;benefit plans is amortized over the average remaining service to full eligibility age of plan participants at the time of the plan amendment.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">71</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-1437-2" continuedAt="f-1437-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock" id="f-1483" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table represents the weighted-average actuarial assumptions:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Worldwide Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Net Periodic Benefit Cost</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service cost discount rate</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-291" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-1484">4.39</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-292" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-1485">4.85</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-293" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-1486">2.46</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-294" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-1487">5.09</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-295" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-1488">5.40</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-296" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-1489">2.59</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest cost discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-291" decimals="4" name="jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-1490">4.95</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-292" decimals="4" name="jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-1491">5.25</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-293" decimals="4" name="jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-1492">2.80</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-294" decimals="4" name="jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-1493">5.12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-295" decimals="4" name="jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-1494">5.43</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-296" decimals="4" name="jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="f-1495">2.64</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Rate of increase in compensation levels</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-291" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="f-1496">3.70</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-292" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="f-1497">3.71</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-293" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="f-1498">4.02</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-294" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="f-1499">4.22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-295" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="f-1500">4.22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-296" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="f-1501">4.21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected long-term rate of return on plan assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-291" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="f-1502">7.25</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-292" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="f-1503">7.21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-293" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="f-1504">7.25</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Benefit Obligation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-297" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-1505">4.95</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-298" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-1506">4.58</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-299" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-1507">5.01</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-300" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-1508">5.54</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-301" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-1509">5.11</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-302" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-1510">5.42</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Rate of increase in compensation levels</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-297" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="f-1511">3.70</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-298" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="f-1512">3.69</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-299" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="f-1513">4.00</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-300" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="f-1514">4.22</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-301" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="f-1515">4.22</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-302" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="f-1516">4.21</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company&#8217;s discount rates are determined by considering current yield curves representing high quality, long-term fixed income instruments. The resulting discount rates are consistent with the duration of plan liabilities. The Company's methodology in determining service and interest cost uses duration specific spot rates along that yield curve to the plans' liability cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The expected rates of return on plan asset assumptions represent the Company's assessment of long-term returns on diversified investment portfolios globally. The assessment is determined using projections from external financial sources, long-term historical averages, actual returns by asset class and the various asset class allocations by market. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock" id="f-1517" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table displays the assumed healthcare cost trend rates, for all individuals:</span></div><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.685%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Healthcare Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Healthcare cost trend rate assumed for next year</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-10" decimals="4" name="us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" scale="-2" id="f-1518">9.33</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-11" decimals="4" name="us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" scale="-2" id="f-1519">13.90</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Rate to which the cost trend rate is assumed to decline (ultimate trend)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-10" decimals="4" name="us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1" scale="-2" id="f-1520">4.02</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-11" decimals="4" name="us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1" scale="-2" id="f-1521">4.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Year the rate reaches the ultimate trend rate</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" id="f-1522">2048</ix:nonNumeric>&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-12" name="us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" id="f-1523">2048</ix:nonNumeric>&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNetFundedStatusTableTextBlock" id="f-1524" continuedAt="f-1524-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2024 and 2023 for the Company&#8217;s defined benefit retirement plans and other post-retirement plans:</span></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.084%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.084%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.084%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change in Benefit Obligation</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Projected benefit obligation&#160;&#8212; beginning of year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1525">31,744</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1526">29,390</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1527">4,108</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1528">4,192</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-1529">948</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-1530">893</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-1531">277</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-1532">264</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" format="ixt:num-dot-decimal" scale="6" id="f-1533">1,402</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" format="ixt:num-dot-decimal" scale="6" id="f-1534">1,437</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-1535">209</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-1536">214</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Plan participant contributions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" scale="6" id="f-1537">75</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" scale="6" id="f-1538">73</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" format="ixt:fixed-zero" scale="6" id="f-1539">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" format="ixt:fixed-zero" scale="6" id="f-1540">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amendments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAmendments" format="ixt:fixed-zero" scale="6" id="f-1541">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPlanAmendments" scale="6" id="f-1542">6</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAmendments" format="ixt:fixed-zero" scale="6" id="f-1543">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAmendments" format="ixt:fixed-zero" scale="6" id="f-1544">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Actuarial (gains) losses</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-1545">1,245</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-1546">2,068</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="f-1547">398</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="f-1548">469</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Divestitures&#160;&amp; acquisitions</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" name="jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="f-1549">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" scale="6" id="f-1550">352</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="f-1551">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" scale="6" id="f-1552">1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Curtailments, settlements&#160;&amp; restructuring</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" name="jnj:CurtailmentsAndSettlementsAndRestructuring" scale="6" id="f-1553">121</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" name="jnj:CurtailmentsAndSettlementsAndRestructuring" scale="6" id="f-1554">238</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="jnj:CurtailmentsAndSettlementsAndRestructuring" format="ixt:fixed-zero" scale="6" id="f-1555">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="jnj:CurtailmentsAndSettlementsAndRestructuring" scale="6" id="f-1556">332</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Benefits paid from plan</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" format="ixt:num-dot-decimal" scale="6" id="f-1557">1,801</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" format="ixt:num-dot-decimal" scale="6" id="f-1558">2,122</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="f-1559">556</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="f-1560">702</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of exchange rates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="f-1561">685</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="f-1562">601</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="f-1563">11</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="f-1564">2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Projected benefit obligation&#160;&#8212; end of year</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1565">30,317</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1566">31,744</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1567">4,425</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1568">4,108</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">72</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-1524-1"><ix:continuation id="f-1437-3" continuedAt="f-1437-4"><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.084%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.084%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.084%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change in Plan Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Plan assets at fair value&#160;&#8212; beginning of year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1569">33,607</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1570">31,496</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-1571">86</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-1572">78</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Actual return (loss) on plan assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1573">2,113</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1574">3,951</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="f-1575">15</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="f-1576">16</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Company contributions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="f-1577">229</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="f-1578">268</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="f-1579">548</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="f-1580">694</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Plan participant contributions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" scale="6" id="f-1581">75</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" scale="6" id="f-1582">73</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" format="ixt:fixed-zero" scale="6" id="f-1583">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" format="ixt:fixed-zero" scale="6" id="f-1584">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Settlements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="f-1585">114</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="f-1586">176</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" format="ixt:fixed-zero" scale="6" id="f-1587">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" format="ixt:fixed-zero" scale="6" id="f-1588">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Divestitures &amp; acquisitions</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" name="jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="f-1589">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" scale="6" id="f-1590">509</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="f-1591">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="f-1592">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Benefits paid from plan assets</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" format="ixt:num-dot-decimal" scale="6" id="f-1593">1,801</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" format="ixt:num-dot-decimal" scale="6" id="f-1594">2,122</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="f-1595">556</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="f-1596">702</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of exchange rates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="f-1597">714</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="f-1598">626</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="f-1599">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="f-1600">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Plan assets at fair value&#160;&#8212; end of year</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1601">33,395</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1602">33,607</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-1603">93</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-1604">86</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Funded status &#8212; end of year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="f-1605">3,078</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="f-1606">1,863</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="f-1607">4,332</ix:nonFraction>)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="f-1608">4,022</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amounts Recognized in the Company&#8217;s Balance Sheet consist of the&#160;following:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1609">6,046</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1610">4,992</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1611">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1612">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="f-1613">136</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="f-1614">119</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="f-1615">453</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="f-1616">416</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1617">2,832</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1618">3,010</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1619">3,879</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1620">3,606</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total recognized in the consolidated balance sheet&#160;&#8212; end of year</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" format="ixt:num-dot-decimal" scale="6" id="f-1621">3,078</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" format="ixt:num-dot-decimal" scale="6" id="f-1622">1,863</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" format="ixt:num-dot-decimal" scale="6" id="f-1623">4,332</ix:nonFraction>)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" format="ixt:num-dot-decimal" scale="6" id="f-1624">4,022</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amounts Recognized in Accumulated Other Comprehensive Income consist&#160;of the following:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net actuarial loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-1625">3,903</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-1626">4,962</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" scale="6" id="f-1627">691</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" scale="6" id="f-1628">354</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior service cost (credit)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-1629">1,051</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-1630">1,236</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="f-1631">4</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="f-1632">6</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unrecognized net transition obligation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1633">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1634">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1635">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-301" xsi:nil="true" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" id="f-1636"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total before tax effects</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-1637">2,852</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-1638">3,726</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="f-1639">687</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="f-1640">348</ix:nonFraction></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Benefit Obligations&#160;&#8212; end of year</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1641">28,883</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1642">30,139</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">The actuarial (gains)/losses for retirement plans in 2024 and 2023 were primarily driven by changes in the discount rates. </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Driven by the Kenvue separation.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt">The fiscal years 2024 and 2023 includes approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="jnj:DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract" scale="6" id="f-1643">400</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="jnj:DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract" format="ixt:num-dot-decimal" scale="6" id="f-1644">800</ix:nonFraction>&#160;million, respectively, transferred to a group annuity contract issued by a third-party insurer for the U.S. Salaried Pension&#160;Plan.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive&#160;Income</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net periodic benefit cost (credit)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-1645">222</ix:nonFraction>)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-1646">676</ix:nonFraction>)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-1647">530</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-1648">487</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net actuarial (gain) loss</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="f-1649">807</ix:nonFraction>)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="f-1650">711</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="f-1651">389</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="f-1652">136</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of net actuarial loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="f-1653">172</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="f-1654">199</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="f-1655">53</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="f-1656">22</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior service cost (credit)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1657">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="f-1658">2</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1659">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1660">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of prior service (cost) credit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="f-1661">184</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="f-1662">185</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="f-1663">2</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="f-1664">2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of exchange rates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" sign="-" name="jnj:EffectOfExchangeRates" scale="6" id="f-1665">79</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" name="jnj:EffectOfExchangeRates" scale="6" id="f-1666">103</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="jnj:EffectOfExchangeRates" scale="6" id="f-1667">1</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="jnj:EffectOfExchangeRates" format="ixt:fixed-zero" scale="6" id="f-1668">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total loss/(income) recognized in other comprehensive income, before tax</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="f-1669">874</ix:nonFraction>)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-1670">1,195</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="f-1671">339</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="f-1672">116</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total recognized in net periodic benefit cost and other comprehensive&#160;income</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" sign="-" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-1673">1,096</ix:nonFraction>)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" scale="6" id="f-1674">519</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" scale="6" id="f-1675">869</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" scale="6" id="f-1676">603</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">73</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-1437-4" continuedAt="f-1437-5"><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company plans to continue to fund its U.S. Qualified Plans to comply with the Pension Protection Act of 2006. International Plans are funded in accordance with local regulations. Additional discretionary contributions are made when deemed appropriate to meet the long-term obligations of the plans. For certain plans, funding is not a common practice, as funding provides no economic benefit. Consequently, the Company has several pension plans that are not funded. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In 2024, the Company contributed $<ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-6" name="us-gaap:PensionContributions" scale="6" id="f-1677">122</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-6" name="us-gaap:PensionContributions" scale="6" id="f-1678">107</ix:nonFraction> million to its U.S.&#160;and international pension plans, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="jnj:InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" id="f-1679" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table displays the funded status of the Company's U.S. Qualified &amp; Non-Qualified pension plans and international funded and unfunded pension plans at December&#160;31, 2024 and December&#160;31, 2023, respectively:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.685%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.679%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.679%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.679%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.679%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.688%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">International Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Qualified Plans</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-Qualified Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Funded Plans</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unfunded Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Plan Assets</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1680">22,250</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1681">22,298</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-1682">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-1683">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1684">11,145</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1685">11,309</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-1686">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-1687">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Projected Benefit Obligation</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1688">18,146</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1689">19,152</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1690">1,990</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1691">2,037</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1692">10,069</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1693">10,431</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="f-1694">112</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="f-1695">124</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated Benefit Obligation</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1696">17,726</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1697">18,557</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1698">1,949</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1699">1,982</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1700">9,115</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1701">9,498</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="6" id="f-1702">93</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="6" id="f-1703">102</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Over (Under) Funded Status</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Projected Benefit Obligation</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="f-1704">4,104</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="f-1705">3,146</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="f-1706">1,990</ix:nonFraction>)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="f-1707">2,037</ix:nonFraction>)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="f-1708">1,076</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="f-1709">878</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="f-1710">112</ix:nonFraction>)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="f-1711">124</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated Benefit Obligation</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-6" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" format="ixt:num-dot-decimal" scale="6" id="f-1712">4,524</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-6" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" format="ixt:num-dot-decimal" scale="6" id="f-1713">3,741</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" format="ixt:num-dot-decimal" scale="6" id="f-1714">1,949</ix:nonFraction>)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" format="ixt:num-dot-decimal" scale="6" id="f-1715">1,982</ix:nonFraction>)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-6" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" format="ixt:num-dot-decimal" scale="6" id="f-1716">2,030</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-6" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" format="ixt:num-dot-decimal" scale="6" id="f-1717">1,811</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" scale="6" id="f-1718">93</ix:nonFraction>)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" scale="6" id="f-1719">102</ix:nonFraction>)</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Plans with accumulated benefit obligations in excess of plan assets have an accumulated benefit obligation, projected benefit obligation and plan assets of $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-8" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="9" id="f-1720">5.8</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-8" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" scale="9" id="f-1721">6.1</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-8" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="9" id="f-1722">3.2</ix:nonFraction> billion, respectively, at the end of 2024, and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-8" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="9" id="f-1723">5.8</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-8" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" scale="9" id="f-1724">6.1</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-8" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="9" id="f-1725">3.1</ix:nonFraction> billion, respectively, at the end of 2023.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock" id="f-1726" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table displays the projected future benefit payments from the Company&#8217;s retirement and other benefit plans:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.286%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2028</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2029</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2030-2034</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Projected future benefit payments</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Retirement plans</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="f-1727">1,480</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" format="ixt:num-dot-decimal" scale="6" id="f-1728">1,503</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" format="ixt:num-dot-decimal" scale="6" id="f-1729">1,604</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" format="ixt:num-dot-decimal" scale="6" id="f-1730">1,702</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" format="ixt:num-dot-decimal" scale="6" id="f-1731">1,797</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" format="ixt:num-dot-decimal" scale="6" id="f-1732">10,401</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other benefit plans&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="f-1733">464</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="f-1734">478</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="f-1735">432</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="f-1736">445</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="f-1737">462</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" format="ixt:num-dot-decimal" scale="6" id="f-1738">2,537</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="jnj:ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" id="f-1739" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table displays the projected future minimum contributions to the unfunded retirement plans. These amounts do not include any discretionary contributions that the Company may elect to make in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.286%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2028</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2029</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2030-2034</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Projected future contributions</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" scale="6" id="f-1740">133</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" scale="6" id="f-1741">135</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" scale="6" id="f-1742">140</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" scale="6" id="f-1743">145</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" scale="6" id="f-1744">150</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" scale="6" id="f-1745">815</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Each pension plan is overseen by a local committee or board that is responsible for the overall administration and investment of&#160;the pension plans. In determining investment policies, strategies and goals, each committee or board considers factors including, local pension rules and regulations; local tax regulations; availability of investment vehicles (separate accounts, commingled accounts, insurance funds, etc.); funded status of the plans; ratio of actives to retirees; duration of liabilities; and&#160;other relevant factors including: diversification, liquidity of local markets and liquidity of base currency. A majority of the Company&#8217;s pension funds are open to new entrants and are expected to be on-going plans. Permitted investments are primarily liquid and/or listed, with little reliance on illiquid and non-traditional investments such as hedge funds.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">74</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-1437-5" continuedAt="f-1437-6"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock" id="f-1746" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company&#8217;s retirement plan asset allocation at the end of 2024 and 2023 and target allocations for 2025 are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Percent of<br/>Plan Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Target<br/>Allocation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Worldwide Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity securities</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-313" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-1747">55</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-314" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-1748">58</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-313" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-1749">54</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-315" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-1750">45</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-316" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-1751">42</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-315" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-1752">46</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total plan assets</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-10" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-1753">100</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-11" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="f-1754">100</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-10" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-1755">100</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Determination of fair value of plan assets</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Plan has an established and well-documented process for determining fair values. Fair value is based upon quoted market prices, where available. If listed prices or quotes are not available, fair value is based upon models that primarily use, as inputs, market-based or independently sourced market parameters, including yield curves, interest rates, volatilities, equity or debt prices, foreign exchange rates and credit curves.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">While the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Valuation hierarchy</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described in the table below with Level&#160;1 having the highest priority and Level&#160;3 having the lowest.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Net Asset Value (NAV) is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">A financial instrument&#8217;s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Following is a description of the valuation methodologies used for the investments measured at fair value.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%;padding-left:7.83pt">Short-term investment funds</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;&#8212; Cash and quoted short-term instruments are valued at the closing price or the amount held on deposit by the custodian bank. Other investments are through investment vehicles valued using the NAV provided by the administrator of the fund. The NAV is a quoted price in a market that is not active and classified as Level&#160;2.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%;padding-left:7.83pt">Government and agency securities</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;&#8212; A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified within Level&#160;1 of the valuation hierarchy. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows. When quoted market prices for a security are not available in an active market, they are classified as Level&#160;2.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%;padding-left:7.83pt">Debt instruments</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;&#8212; A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified as Level&#160;1. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows and are classified as Level&#160;2. Level&#160;3 debt instruments are priced based on unobservable inputs.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%;padding-left:7.83pt">Equity securities</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;&#8212; Equity securities are valued at the closing price reported on the major market on which the individual securities are traded. Substantially all equity securities are classified within Level&#160;1 of the valuation hierarchy.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%;padding-left:7.83pt">Commingled funds</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;&#8212; These investment vehicles are valued using the NAV provided by the fund administrator. Assets in the Level&#160;2 category have a quoted market price.</span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%;padding-left:7.83pt">Other assets</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;&#8212; Other assets are represented primarily by limited partnerships. These investment vehicles are valued using the NAV provided by the fund administrator. Other assets that are exchange listed and actively traded are classified as Level&#160;1, while inactively traded assets are classified as Level&#160;2. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">75</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-1437-6" continuedAt="f-1437-7"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" id="f-1756" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table sets forth the Retirement Plans' investments measured at fair value as of December&#160;31, 2024 and December&#160;31, 2023:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Inputs</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Investments<br/>Measured at Net<br/>Asset Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term investment funds</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-1757">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-1758">12</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-1759">511</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-1760">829</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-321" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-1761">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-1762">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-1763">511</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-1764">841</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Government and agency securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-1765">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-1766">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1767">7,885</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1768">5,985</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-1769">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-1770">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-331" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1771">7,885</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-332" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1772">5,985</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Debt instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-333" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-1773">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-334" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-1774">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-335" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1775">2,321</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-336" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1776">3,899</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-337" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-1777">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-338" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-1778">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1779">2,321</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1780">3,899</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-341" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1781">7,144</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-342" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1782">7,764</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-343" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-1783">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-1784">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-1785">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-346" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-1786">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1787">7,144</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1788">7,764</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commingled funds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-1789">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-1790">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1791">5,004</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1792">4,967</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-353" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-1793">37</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-354" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-1794">43</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-355" decimals="-6" name="jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1795">6,190</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-356" decimals="-6" name="jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1796">6,672</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-355" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1797">11,231</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-356" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1798">11,682</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-357" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-1799">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-358" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="f-1800">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-1801">88</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-360" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-1802">49</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-361" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-1803">128</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-362" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-1804">92</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-363" decimals="-6" name="jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1805">4,087</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-6" name="jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1806">3,295</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-363" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1807">4,303</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1808">3,436</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Investments at fair value</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1809">7,144</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1810">7,776</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1811">15,809</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-368" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1812">15,729</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-369" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-1813">165</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-370" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-1814">135</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-371" decimals="-6" name="jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1815">10,277</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-372" decimals="-6" name="jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1816">9,967</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-371" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1817">33,395</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-372" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1818">33,607</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">The activity for the Level 3 assets is not significant for all years presented.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company's Other Benefit Plans are unfunded except for U.S.&#160;commingled funds (Level 2) of $<ix:nonFraction unitRef="usd" contextRef="c-373" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-1819">93</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-374" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-1820">86</ix:nonFraction> million at December&#160;31, 2024 and December&#160;31, 2023, respectively. </span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:continuation id="f-1437-7">The fair value of Johnson&#160;&amp; Johnson Common Stock directly held in plan assets was $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="jnj:FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" scale="6" id="f-1821">13</ix:nonFraction> million at December&#160;31, 2024 and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="jnj:FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" scale="6" id="f-1822">14</ix:nonFraction> million at December&#160;31, 2023.</ix:continuation> </span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_190"></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">11.&#160;<ix:nonNumeric contextRef="c-1" name="jnj:SavingsPlanTextBlock" id="f-1823" continuedAt="f-1823-1" escape="true">Savings plan</ix:nonNumeric></span></div><ix:continuation id="f-1823-1"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has voluntary 401(k) savings plans designed to enhance the existing retirement programs covering eligible employees. The Company matches a percentage of each employee&#8217;s contributions consistent with the provisions of the plan for which the employee is eligible. Total Company matching contributions to the plans were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-1824">282</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-1825">263</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-1826">257</ix:nonFraction> million in fiscal years 2024, 2023 and 2022, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">76</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_193"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">12.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:TreasuryStockTextBlock" id="f-1827" continuedAt="f-1827-1" escape="true">Capital and treasury stock</ix:nonNumeric></span></div><ix:continuation id="f-1827-1"><ix:nonNumeric contextRef="c-1" name="jnj:ChangesInTreasuryStockTableTextBlock" id="f-1828" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Changes in treasury stock were:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.685%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Treasury Stock</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Amounts in Millions Except Treasury Stock Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at January 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-1829">490,878</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="f-1830">39,099</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee compensation and stock option plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:num-dot-decimal" scale="3" id="f-1831">20,007</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:num-dot-decimal" scale="6" id="f-1832">3,440</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repurchase of common stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="f-1833">35,375</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-1834">6,035</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at January 1, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-1835">506,246</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="f-1836">41,694</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee compensation and stock option plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:num-dot-decimal" scale="3" id="f-1837">15,521</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:num-dot-decimal" scale="6" id="f-1838">2,529</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repurchase of common stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="f-1839">31,085</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="jnj:TreasuryStockValueAcquiredCostMethodNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-1840">5,079</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Kenvue share exchange (Note 21)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-1841">190,955</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="f-1842">31,418</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at December 31, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-1843">712,765</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="f-1844">75,662</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee compensation and stock option plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:num-dot-decimal" scale="3" id="f-1845">15,027</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:num-dot-decimal" scale="6" id="f-1846">2,389</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repurchase of common stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="f-1847">15,183</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-6" name="jnj:TreasuryStockValueAcquiredCostMethodNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-1848">2,407</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at December 29, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-1849">712,921</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="f-1850">75,680</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Aggregate shares of common stock issued were approximately <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1851"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1852"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1853">3,119,843,000</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;shares at the end of fiscal years 2024, 2023 and 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Cash dividends paid were $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-1854">4.91</ix:nonFraction> per share in fiscal year 2024, compared with dividends of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-1855">4.70</ix:nonFraction> per share in fiscal year 2023, and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-1856">4.45</ix:nonFraction> per share in fiscal year 2022. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On January 2, 2025, the Board of Directors declared a regular cash dividend of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-375" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-1857">1.24</ix:nonFraction> per share, payable on March 4, 2025 to shareholders of record as of February 18, 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On September 14, 2022, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $<ix:nonFraction unitRef="usd" contextRef="c-376" decimals="-8" name="srt:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="f-1858">5.0</ix:nonFraction> billion of the Company's shares of common stock. The repurchase program was completed during the fiscal first quarter of 2023.</span></div></ix:continuation><div id="i4b4bd2fffa0147e7914e1841a5c21924_199"></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">13.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="f-1859" continuedAt="f-1859-1" escape="true">Accumulated other comprehensive income (loss)</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="f-1860" escape="true"><ix:continuation id="f-1859-1" continuedAt="f-1859-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Components of other comprehensive income (loss) consist of the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.334%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Foreign<br/>Currency<br/>Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain/<br/>(Loss) On<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Employee<br/>Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain/<br/>(Loss) On<br/>Derivatives<br/>&amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total<br/>Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">January 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(<ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1861">10,017</ix:nonFraction>)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1862">3</ix:nonFraction>)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1863">2,702</ix:nonFraction>)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1864">336</ix:nonFraction>)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1865">13,058</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net 2022 changes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-1866">1,796</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1867">24</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-383" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-1868">1,805</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1869">106</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1870">91</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">January 1, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1871">11,813</ix:nonFraction>)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1872">27</ix:nonFraction>)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1873">897</ix:nonFraction>)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-388" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1874">230</ix:nonFraction>)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1875">12,967</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net 2023 changes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-389" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-1876">3,221</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-390" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1877">26</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-391" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-1878">1,399</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1879">147</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-1880">4,741</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Kenvue Separation/IPO</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-389" decimals="-6" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" format="ixt:num-dot-decimal" scale="6" id="f-1881">4,885</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-391" decimals="-6" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" scale="6" id="f-1882">296</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-6" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" format="ixt:num-dot-decimal" scale="6" id="f-1883">5,181</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 31, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1884">10,149</ix:nonFraction>)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1885">1</ix:nonFraction>)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-395" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1886">2,000</ix:nonFraction>)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-396" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1887">377</ix:nonFraction>)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1888">12,527</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net 2024 changes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-397" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-1889">1,708</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-398" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1890">2</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-399" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1891">449</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-1892">1,373</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1893">786</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(<ix:nonFraction unitRef="usd" contextRef="c-401" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1894">8,441</ix:nonFraction>)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-402" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1895">1</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-403" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1896">1,551</ix:nonFraction>)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-404" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1897">1,750</ix:nonFraction>)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1898">11,741</ix:nonFraction>)</span></td></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">77</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-1859-2" continuedAt="f-1859-3"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For&#160;additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Details on reclassifications out of Accumulated Other Comprehensive Income:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 10 for additional details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Gain/(Loss) On Derivatives &amp; Hedges - reclassifications to earnings are recorded in the same account as the hedged transaction. See Note 6 for additional details.</span></div></ix:continuation><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"><ix:continuation id="f-1859-3">*&#160;&#160;&#160;&#160;Includes impact of curtailments and settlements in connection with separation from Kenvue.</ix:continuation> </span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_202"></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">14.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyDisclosureTextBlock" id="f-1899" continuedAt="f-1899-1" escape="true">International currency translation</ix:nonNumeric></span></div><ix:continuation id="f-1899-1"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">For translation of its subsidiaries operating in non-U.S.&#160;Dollar currencies, the Company has determined that the local currencies of its international subsidiaries are the functional currencies except those in highly inflationary economies, which are defined as those which have had compound cumulative rates of inflation of 100% or more during the past three years, or where a substantial portion of its cash flows are not in the local currency. For the majority of the Company's subsidiaries the local currency is the functional currency. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive income. The other current and non-current assets line within the Statement of Cash flows includes the impact of foreign currency translation. This equity account includes the results of translating certain balance sheet assets and liabilities at current exchange rates and some accounts at historical rates, except for those located in highly inflationary economies (Argentina, Turkey and Venezuela). Beginning in the fiscal fourth quarter of 2024, the Company also accounted for operations in Egypt as highly inflationary. The translation of balance sheet accounts for highly inflationary economies are reflected in the operating results.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">A rollforward of the changes during fiscal years 2024, 2023 and 2022 for foreign currency translation adjustments is included in Note&#160;13. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Net currency transaction gains and losses included in Other (income) expense were losses of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="f-1900">214</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="f-1901">366</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="f-1902">286</ix:nonFraction> million in fiscal years 2024, 2023 and 2022, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">78</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_205"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">15.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-1903" continuedAt="f-1903-1" escape="true">Earnings per share</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-1904" escape="true"><ix:continuation id="f-1903-1"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended December&#160;29, 2024, December&#160;31, 2023 and January&#160;1, 2023:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.096%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In Millions Except Per Share Amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net earnings per share from continuing operations</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-1905">5.84</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-1906">5.26</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-1907">6.23</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net earnings per share from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="f-1908">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="f-1909">8.62</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="f-1910">0.60</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total net earnings per share - basic</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1911">5.84</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1912">13.88</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1913">6.83</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Average shares outstanding&#160;&#8212; basic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="f-1914">2,407.3</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="f-1915">2,533.5</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="f-1916">2,625.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1917">77.7</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1918">94.1</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1919">140.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: shares repurchased under treasury stock method</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="f-1920">55.6</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="f-1921">67.2</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="f-1922">101.4</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjusted average shares outstanding&#160;&#8212; diluted</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-1923">2,429.4</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-1924">2,560.4</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-1925">2,663.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted net earnings per share from continuing operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-1926">5.79</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-1927">5.20</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-1928">6.14</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted net earnings per share from discontinuing operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="f-1929">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" id="f-1930">8.52</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" id="f-1931">0.59</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total net earnings per share - diluted</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1932">5.79</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1933">13.72</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1934">6.73</ix:nonFraction></span></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Shares in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The diluted net earnings per share calculation excluded the following number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Company&#8217;s stock. </span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="2" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="f-1935">54.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="2" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="f-1936">43.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-405" decimals="2" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="f-1937">0.0</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:nonNumeric><div id="i4b4bd2fffa0147e7914e1841a5c21924_211"></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">16.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-1938" continuedAt="f-1938-1" escape="true">Common stock, stock option plans and stock compensation agreements</ix:nonNumeric></span></div><ix:continuation id="f-1938-1" continuedAt="f-1938-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">At December&#160;29, 2024, the Company had <ix:nonFraction unitRef="stockbasedcompensationplans" contextRef="c-10" decimals="0" name="jnj:NumberOfStockBasedCompensationPlans" format="ixt-sec:numwordsen" scale="0" id="f-1939">one</ix:nonFraction> active stock-based compensation plan, the 2022 Long-Term Incentive Plan. The shares outstanding are for contracts under the Company's 2012 Long-Term Incentive Plan and 2022 Long-Term Incentive Plan. The 2012 Long-Term Incentive Plan expired on April 26, 2022. All awards (stock options, restricted shares units and performance share units) granted subsequent to that date were under the 2022 Long-Term Incentive Plan. Under the 2022 Long-Term Incentive Plan, the Company may issue up to <ix:nonFraction unitRef="shares" contextRef="c-406" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-1940">150</ix:nonFraction>&#160;million shares of common stock, of which up to <ix:nonFraction unitRef="shares" contextRef="c-406" decimals="-6" name="jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights" format="ixt:num-dot-decimal" scale="6" id="f-1941">110</ix:nonFraction>&#160;million shares of common stock may be issued subject to stock options or stock appreciation rights and up to <ix:nonFraction unitRef="shares" contextRef="c-406" decimals="-6" name="jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards" format="ixt:num-dot-decimal" scale="6" id="f-1942">40</ix:nonFraction>&#160;million shares of common stock may be issued subject to full value awards. Awards will generally be counted on a 1-for-1 basis against the share reserve, provided that if more than <ix:nonFraction unitRef="shares" contextRef="c-406" decimals="-6" name="jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards" format="ixt:num-dot-decimal" scale="6" id="f-1943">40</ix:nonFraction>&#160;million full value awards are granted, each full value award in excess of <ix:nonFraction unitRef="shares" contextRef="c-406" decimals="-6" name="jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess" format="ixt:num-dot-decimal" scale="6" id="f-1944">40</ix:nonFraction>&#160;million will be counted on a 5-for-1 basis against the share reserve. Shares available for future grants under the 2022 Long-Term Incentive Plan were <ix:nonFraction unitRef="shares" contextRef="c-406" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="f-1945">111</ix:nonFraction> million at the end of fiscal&#160;year&#160;2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The compensation cost that has been charged against income for these plans was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-1946">1,176</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-1947">1,087</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-1948">1,028</ix:nonFraction> million for fiscal years 2024, 2023 and 2022, respectively. The total income tax benefit recognized in the income statement for share-based compensation costs was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1949">251</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1950">221</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1951">177</ix:nonFraction> million for fiscal years 2024, 2023 and 2022, respectively. The Company also recognized additional income tax benefits of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-1952">94</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-1953">126</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-1954">267</ix:nonFraction>&#160;million for fiscal years 2024, 2023 and 2022, respectively, for which options were exercised or restricted shares were vested. The total unrecognized compensation cost was $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-1955">1,002</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-1956">907</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-1957">866</ix:nonFraction> million for fiscal years 2024, 2023 and 2022, respectively. The weighted average period for this cost to be recognized was <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1958">1.81</ix:nonNumeric>&#160;years, <ix:nonNumeric contextRef="c-12" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1959">1.80</ix:nonNumeric>&#160;years and <ix:nonNumeric contextRef="c-13" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1960">1.80</ix:nonNumeric>&#160;years for fiscal years 2024, 2023, and 2022, respectively. Share-based compensation costs capitalized as part of inventory were insignificant in all periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company settles employee benefit equity issuances with treasury shares. Treasury shares are replenished through market purchases throughout the year for the number of shares used to settle employee benefit equity issuances. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">79</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-1938-2" continuedAt="f-1938-3"><div style="margin-bottom:6pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Stock options</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Stock options expire <ix:nonNumeric contextRef="c-407" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-1961">10</ix:nonNumeric> years&#160;from the date of grant and vest over service periods that range from <ix:nonNumeric contextRef="c-408" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="f-1962">6</ix:nonNumeric> months to <ix:nonNumeric contextRef="c-409" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="f-1963">4</ix:nonNumeric> years. Options granted under the 2012 Long-Term Incentive Plan were granted at the average of the high and low prices of the Company&#8217;s Common Stock on the New York Stock Exchange on the date of grant. Options granted under the 2022 Long-Term incentive Plan were granted at the closing price of the Company&#8217;s Common Stock on the New York Stock Exchange on the date of grant.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. For 2024, 2023, and 2022 grants, expected volatility represents a blended rate of 10-year weekly historical overall volatility rate, and a 5-week average implied volatility rate based on at-the-money traded Johnson&#160;&amp; Johnson options with a life of 2&#160;years. For all grants, historical data is used to determine the expected life of the option. The risk-free rate was based on the U.S.&#160;Treasury yield curve in effect at the time of grant.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-1964" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The average fair value of options granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1965">27.67</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1966">27.85</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1967">23.23</ix:nonFraction>, in fiscal years 2024, 2023 and 2022, respectively. The fair value was estimated based on the weighted average assumptions of:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1968">4.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1969">3.74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1970">1.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1971">17.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1972">17.69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1973">18.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1974">7.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-12" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1975">7.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-13" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1976">7.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-1977">3.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-1978">2.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-1979">2.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-1980" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">A summary of option activity under the Plan as of December&#160;29, 2024, is presented below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value<br/>(Dollars in Millions) </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shares at December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-1981">112,238</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1982">139.88</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-1983">2,239</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1984">13,917</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1985">157.92</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-1986">10,771</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1987">107.06</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1988">2,755</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-1989">162.45</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Shares at December 29, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-1990">112,629</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1991">144.69</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-1992">1,129</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The total intrinsic value of options exercised was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-1993">560</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-1994">729</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-1995">1,228</ix:nonFraction> million in fiscal years 2024, 2023 and 2022, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">80</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-1938-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="f-1996" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table summarizes stock options outstanding and exercisable at December&#160;29, 2024:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercisable</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise Price Range</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average Life</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-410" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1997">100.06</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="c-410" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1998">101.87</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-411" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="f-1999">13,016</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-410" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-2000">0.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-411" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-2001">101.29</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-411" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="3" id="f-2002">13,016</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-411" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-2003">101.29</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-412" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-2004">115.67</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="c-412" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-2005">129.51</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-413" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="f-2006">18,252</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-412" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-2007">2.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-413" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-2008">122.49</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-413" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="3" id="f-2009">18,252</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-413" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-2010">122.49</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-414" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-2011">131.94</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="c-414" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-2012">151.41</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-415" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="f-2013">25,624</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-414" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-2014">4.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-415" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-2015">142.87</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-415" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="3" id="f-2016">25,624</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-415" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-2017">142.87</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-416" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-2018">157.92</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="c-416" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-2019">162.75</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-417" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="f-2020">26,391</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-416" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-2021">8.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-417" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-2022">160.33</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-417" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="3" id="f-2023">4,269</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-417" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-2024">162.75</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-418" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-2025">164.62</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="c-418" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-2026">165.89</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-419" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="f-2027">29,346</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-418" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-2028">6.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-419" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-2029">165.29</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-419" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="3" id="f-2030">13,522</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-419" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-2031">164.64</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="f-2032">112,629</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-2033">5.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-2034">144.69</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="3" id="f-2035">74,683</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-2036">135.72</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">Average contractual life remaining in years.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Stock options outstanding at December&#160;31, 2023 and January&#160;1, 2023 were <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="f-2037">112,238</ix:nonFraction> and an average life of <ix:nonNumeric contextRef="c-12" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-2038">5.5</ix:nonNumeric> years and <ix:nonFraction unitRef="shares" contextRef="c-22" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="f-2039">118,672</ix:nonFraction> and an average life of <ix:nonNumeric contextRef="c-13" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-2040">5.8</ix:nonNumeric>&#160;years, respectively. Stock options exercisable at December&#160;31, 2023 and January&#160;1, 2023 were <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="f-2041">66,998</ix:nonFraction> at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-2042">123.39</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-22" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="f-2043">63,661</ix:nonFraction> at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-22" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-2044">113.06</ix:nonFraction>, respectively. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restricted share units and performance share units</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company grants restricted share units which vest over service periods that range from <ix:nonNumeric contextRef="c-420" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="f-2045">6</ix:nonNumeric> months to <ix:nonNumeric contextRef="c-421" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="f-2046">3</ix:nonNumeric> years. The Company also grants performance share units, which are paid in shares of Johnson &amp; Johnson Common Stock after the end of a <ix:nonNumeric contextRef="c-422" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-2047">three-year</ix:nonNumeric> performance period. Performance shares were granted with two equally-weighted goals that directly align with or help drive long-term total shareholder return: adjusted operational earnings per share and relative total shareholder return. The&#160;number of shares actually earned at the end of the <ix:nonNumeric contextRef="c-422" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-2048">three-year</ix:nonNumeric> period will vary, based only on actual performance, from <ix:nonFraction unitRef="number" contextRef="c-423" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-2049">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-424" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-2050">200</ix:nonFraction>% of the target number of performance share units granted. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="f-2051" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">A summary of the restricted share units and performance share units activity under the Plans as of December&#160;29, 2024 is presented below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>Performance Share Units</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shares at December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-425" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-2052">12,938</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-426" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-2053">2,037</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-427" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-2054">6,331</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-422" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-2055">906</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-427" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-2056">5,454</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-422" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-2057">808</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Canceled/forfeited/adjusted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-427" decimals="-3" name="jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" scale="3" id="f-2058">774</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-422" decimals="-3" name="jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" scale="3" id="f-2059">122</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shares at December 29, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-428" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-2060">13,041</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-429" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-2061">2,013</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The average fair value of the restricted share units granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-427" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-2062">147.51</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-430" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-2063">152.63</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-431" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-2064">153.67</ix:nonFraction> in fiscal years 2024, 2023 and 2022, respectively, using the fair market value at the date of grant. The fair value of restricted share units was discounted for dividends, which are not paid on the restricted share units during the vesting period. The fair value of restricted share units issued was $<ix:nonFraction unitRef="usd" contextRef="c-427" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-2065">833</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-430" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-2066">605</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-431" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-2067">591</ix:nonFraction> million in 2024, 2023 and 2022, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The weighted average fair value of the performance share units granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-422" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-2068">133.76</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-432" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-2069">145.17</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-433" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-2070">170.46</ix:nonFraction> in fiscal years 2024, 2023 and 2022, calculated using the weighted average fair market value for each of the component goals at the date of&#160;grant.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The fair values for the earnings per share goals of each performance share unit were estimated on the date of grant using the fair market value of the shares at the time of the award discounted for dividends, which are not paid on the performance share units during the vesting period.&#160;The fair value for the relative total shareholder return goal of each performance share unit was estimated on the date of grant using the Monte Carlo valuation model.&#160;The fair value of performance share units issued was $<ix:nonFraction unitRef="usd" contextRef="c-422" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-2071">146</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-432" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-2072">140</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-433" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-2073">94</ix:nonFraction> million in fiscal years 2024, 2023 and 2022, respectively.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">81</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_217"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">17.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-2074" continuedAt="f-2074-1" escape="true">Segments of business and geographic areas</ix:nonNumeric></span></div><ix:continuation id="f-2074-1" continuedAt="f-2074-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Following the separation of the Consumer Health business in the fiscal third quarter of 2023, the Company is now organized into <ix:nonFraction unitRef="segment2" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-2075">two</ix:nonFraction> reportable segments: Innovative Medicine and MedTech. The segment results have been recast for all periods to reflect the continuing operations of the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company&#8217;s chief operating decision maker (CODM) is the Chief Executive Officer (Principal Executive Officer). For the Innovative Medicine and MedTech segments, the CODM uses segment income before tax to allocate resources (including employees, financial, and capital resources) for each segment predominantly in the annual forecasting process. The CODM considers planning-to-actual variances on a quarterly basis to assess performance and make decisions about allocating resources to the segments. </span></div><ix:nonNumeric contextRef="c-1" name="jnj:SalesBySegmentOfBusinessTableTextBlock" id="f-2076" continuedAt="f-2076-1" escape="true"><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;24 vs. &#8217;23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;23 vs. &#8217;22</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">INNOVATIVE MEDICINE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-434" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2077">11,355</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-435" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2078">11,539</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-436" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2079">11,036</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-434" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2080">1.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-435" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2081">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-437" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2082">6,473</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-438" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2083">6,513</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-439" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2084">5,899</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-437" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2085">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-438" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2086">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2087">17,828</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2088">18,052</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2089">16,935</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-440" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2090">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-441" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2091">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">REMICADE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2092">1,009</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2093">1,143</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-445" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2094">1,417</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-443" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2095">11.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-444" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2096">19.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Exports</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-446" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2097">98</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-447" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2098">147</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-448" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2099">204</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-446" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2100">33.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-447" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2101">28.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-449" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2102">497</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-450" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2103">549</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-451" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2104">722</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-449" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2105">9.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-450" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2106">23.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-452" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2107">1,605</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-453" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2108">1,839</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-454" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2109">2,343</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-452" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2110">12.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-453" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2111">21.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-455" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2112">1,082</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-456" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2113">1,124</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-457" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2114">1,166</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-455" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2115">3.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-456" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2116">3.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-458" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2117">1,108</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2118">1,073</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-460" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2119">1,017</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-458" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2120">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-459" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2121">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2122">2,190</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-462" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2123">2,197</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-463" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2124">2,184</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-461" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2125">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-462" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2126">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">STELARA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-464" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2127">6,720</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-465" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2128">6,966</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-466" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2129">6,388</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-464" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2130">3.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-465" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2131">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-467" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2132">3,641</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-468" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2133">3,892</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-469" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2134">3,335</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-467" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2135">6.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-468" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2136">16.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-470" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2137">10,361</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-471" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2138">10,858</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-472" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2139">9,723</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-470" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2140">4.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-471" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2141">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">TREMFYA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-473" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2142">2,443</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-474" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2143">2,147</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-475" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2144">1,844</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-473" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2145">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-474" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2146">16.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-476" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2147">1,227</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-477" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2148">999</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-478" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2149">824</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-476" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2150">22.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-477" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2151">21.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-479" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2152">3,670</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-480" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2153">3,147</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-481" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2154">2,668</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-479" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2155">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-480" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2156">17.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER IMMUNOLOGY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-482" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2157">3</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-483" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2158">11</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-484" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2159">17</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-482" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2160">74.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-483" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2161">33.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-485" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2162">0</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-486" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2163">0</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2164">0</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-485" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" format="ixt:fixed-zero" scale="-2" id="f-2165">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-488" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2166">3</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2167">11</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2168">17</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-488" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2169">74.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-489" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2170">33.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Infectious Diseases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2171">1,354</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-492" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2172">1,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-493" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2173">1,680</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-491" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2174">9.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-492" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2175">10.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-494" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2176">2,042</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-495" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2177">2,918</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-496" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2178">3,769</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-494" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2179">30.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-495" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2180">22.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-497" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2181">3,396</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-498" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2182">4,418</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-499" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2183">5,449</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-497" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2184">23.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-498" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2185">18.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">COVID-19 VACCINE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-500" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2186">0</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-501" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2187">0</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-502" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2188">120</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-500" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" format="ixt:fixed-zero" scale="-2" id="f-2189">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-503" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2190">198</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-504" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2191">1,117</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-505" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2192">2,059</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-503" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2193">82.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-504" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2194">45.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">82</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-2076-1" continuedAt="f-2076-2"><ix:continuation id="f-2074-2" continuedAt="f-2074-3"><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;24 vs. &#8217;23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;23 vs. &#8217;22</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-506" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2195">198</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-507" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2196">1,117</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-508" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2197">2,179</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-506" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2198">82.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-507" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2199">48.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">EDURANT / rilpivirine</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-509" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2200">31</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-510" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2201">35</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-511" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2202">36</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-509" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2203">10.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-510" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2204">3.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2205">1,241</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-513" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2206">1,115</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-514" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2207">972</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-512" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2208">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-513" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2209">14.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-515" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2210">1,272</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-516" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2211">1,150</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-517" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2212">1,008</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-515" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2213">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-516" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2214">14.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">PREZISTA / PREZCOBIX</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> /</span></div><div style="padding-left:12pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">REZOLSTA / SYMTUZA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-518" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2215">1,311</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-519" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2216">1,446</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-520" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2217">1,494</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-518" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2218">9.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-519" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2219">3.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-521" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2220">401</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-522" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2221">408</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-523" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2222">449</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-521" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2223">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-522" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2224">9.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-524" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2225">1,712</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-525" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2226">1,854</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-526" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2227">1,943</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-524" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2228">7.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-525" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2229">4.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER INFECTIOUS DISEASES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-527" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2230">11</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-528" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2231">19</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-529" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2232">30</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-527" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2233">41.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-528" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2234">34.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-530" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2235">203</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-531" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2236">278</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-532" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2237">289</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-530" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2238">26.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-531" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2239">3.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-533" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2240">214</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-534" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2241">297</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-535" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2242">318</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-533" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2243">27.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-534" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2244">6.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-536" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2245">4,398</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-537" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2246">4,065</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-538" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2247">3,570</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-536" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2248">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-537" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2249">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-539" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2250">2,718</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-540" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2251">3,076</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-541" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2252">3,323</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-539" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2253">11.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-540" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2254">7.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-542" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2255">7,115</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2256">7,140</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-544" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2257">6,893</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-542" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2258">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-543" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2259">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">CONCERTA / methylphenidate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-545" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2260">134</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-546" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2261">230</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-547" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2262">151</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-545" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2263">41.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-546" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2264">52.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-548" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2265">507</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2266">554</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2267">493</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-548" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2268">8.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-549" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2269">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2270">641</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2271">783</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-553" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2272">644</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-551" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2273">18.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-552" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2274">21.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-554" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2275">3,125</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-555" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2276">2,897</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-556" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2277">2,714</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-554" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2278">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-555" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2279">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-557" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2280">1,097</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-558" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2281">1,218</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-559" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2282">1,426</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-557" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2283">9.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-558" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2284">14.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-560" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2285">4,222</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-561" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2286">4,115</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-562" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2287">4,140</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-560" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2288">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-561" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2289">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">SPRAVATO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-563" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2290">929</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-564" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2291">589</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-565" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2292">328</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-563" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2293">57.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-564" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2294">79.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-566" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2295">148</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2296">100</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2297">46</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-566" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2298">48.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2299">1,077</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2300">689</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-571" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2301">374</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-569" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2302">56.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-570" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2303">84.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER NEUROSCIENCE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-572" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2304">210</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-573" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2305">349</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-574" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2306">376</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-572" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2307">39.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-573" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2308">7.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-575" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2309">965</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-576" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2310">1,204</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-577" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2311">1,358</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-575" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2312">19.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-576" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2313">11.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-578" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2314">1,175</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-579" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2315">1,553</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-580" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2316">1,734</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-578" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2317">24.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="number" contextRef="c-579" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2318">10.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-581" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2319">10,854</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-582" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2320">8,462</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-583" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2321">6,930</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-581" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2322">28.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-582" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2323">22.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-584" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2324">9,926</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-585" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2325">9,199</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-586" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2326">9,052</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-584" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2327">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-585" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2328">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-587" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2329">20,781</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-588" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2330">17,661</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-589" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2331">15,983</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-587" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2332">17.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-588" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2333">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">CARVYKTI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-590" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2334">869</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-591" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2335">469</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-592" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2336">133</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-590" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2337">85.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-593" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2338">94</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-594" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2339">30</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-595" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-2340">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">83</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-2076-2" continuedAt="f-2076-3"><ix:continuation id="f-2074-3" continuedAt="f-2074-4"><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;24 vs. &#8217;23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;23 vs. &#8217;22</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-596" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2341">963</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-597" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2342">500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-598" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2343">133</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-596" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2344">92.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">DARZALEX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-599" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2345">6,588</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-600" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2346">5,277</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-601" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2347">4,210</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-599" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2348">24.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-600" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2349">25.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-602" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2350">5,082</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-603" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2351">4,467</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-604" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2352">3,767</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-602" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2353">13.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-603" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2354">18.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-605" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2355">11,670</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-606" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2356">9,744</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-607" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2357">7,977</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-605" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2358">19.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-606" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2359">22.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">ERLEADA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-608" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2360">1,282</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2361">1,065</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2362">968</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-608" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2363">20.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-609" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2364">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-611" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2365">1,717</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-612" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2366">1,322</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-613" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2367">913</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-611" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2368">29.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-612" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2369">44.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-614" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2370">2,999</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-615" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2371">2,387</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2372">1,881</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-614" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2373">25.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-615" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2374">26.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">IMBRUVICA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2375">1,020</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-618" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2376">1,051</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-619" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2377">1,390</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-617" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2378">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-618" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2379">24.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2380">2,018</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2381">2,214</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2382">2,394</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-620" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2383">8.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-621" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2384">7.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-623" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2385">3,038</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-624" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2386">3,264</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-625" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2387">3,784</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-623" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2388">6.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-624" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2389">13.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">TECVAYLI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-626" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2390">418</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-627" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2391">334</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-628" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2392">12</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-626" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2393">25.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-629" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2394">131</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2395">61</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-631" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2396">3</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-632" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2397">549</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-633" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2398">395</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-634" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2399">15</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-632" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2400">38.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">ZYTIGA /abiraterone acetate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-635" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2401">34</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-636" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2402">50</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-637" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2403">74</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-635" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2404">32.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-636" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2405">32.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-638" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2406">597</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-639" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2407">837</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-640" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2408">1,696</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-638" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2409">28.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-639" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2410">50.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-641" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2411">631</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-642" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2412">887</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-643" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2413">1,770</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-641" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2414">28.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-642" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2415">49.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER ONCOLOGY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-644" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2416">643</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-645" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2417">215</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-646" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2418">144</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-645" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2419">49.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-647" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2420">288</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-648" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2421">269</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-649" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2422">280</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-647" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2423">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-648" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2424">3.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-650" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2425">931</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-651" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2426">484</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-652" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2427">423</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-650" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2428">92.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-651" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2429">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-653" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2430">3,143</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-654" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2431">2,697</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-655" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2432">2,346</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-653" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2433">16.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-654" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2434">15.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-656" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2435">1,140</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-657" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2436">1,117</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-658" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2437">1,071</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-656" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2438">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-657" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2439">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-659" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2440">4,282</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-660" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2441">3,815</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-661" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2442">3,417</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-659" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2443">12.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-660" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2444">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:underline">OPSUMIT</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-662" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2445">1,520</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-663" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2446">1,292</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-664" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2447">1,132</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-662" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2448">17.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-663" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2449">14.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-665" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2450">664</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-666" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2451">681</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-667" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2452">651</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-665" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2453">2.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-666" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2454">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-668" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2455">2,184</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-669" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2456">1,973</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-670" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2457">1,783</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-668" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2458">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-669" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2459">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">UPTRAVI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-671" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2460">1,511</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-672" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2461">1,326</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-673" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2462">1,104</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-671" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2463">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-672" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2464">20.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-674" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2465">307</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-675" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2466">255</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-676" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2467">218</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-674" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2468">20.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-675" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2469">17.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-677" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2470">1,817</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-678" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2471">1,582</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-679" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2472">1,322</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-677" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2473">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-678" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2474">19.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER PULMONARY HYPERTENSION</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-680" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2475">112</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-681" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2476">79</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-682" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2477">110</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-680" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2478">41.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-681" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2479">28.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-683" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2480">169</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-684" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2481">182</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-685" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2482">202</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-683" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2483">6.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-684" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2484">10.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-686" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2485">281</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-687" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2486">260</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-688" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2487">313</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-686" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2488">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-687" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2489">16.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">84</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-2076-3" continuedAt="f-2076-4"><ix:continuation id="f-2074-4" continuedAt="f-2074-5"><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;24 vs. &#8217;23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;23 vs. &#8217;22</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-689" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2490">2,866</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-690" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2491">2,906</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-691" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2492">3,042</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-689" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2493">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-690" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2494">4.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-692" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2495">696</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-693" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2496">765</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-694" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2497">845</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-692" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2498">9.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-693" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2499">9.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-695" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2500">3,562</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-696" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2501">3,671</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-697" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2502">3,887</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-695" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2503">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-696" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2504">5.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">XARELTO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-698" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2505">2,373</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-699" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2506">2,365</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-700" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2507">2,473</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-698" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2508">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-699" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2509">4.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-701" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-2510">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-702" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-2511">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-703" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-2512">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-701" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" format="ixt:fixed-zero" scale="-2" id="f-2513">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-702" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" format="ixt:fixed-zero" scale="-2" id="f-2514">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-704" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2515">2,373</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-705" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2516">2,365</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-706" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2517">2,473</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-704" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2518">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-705" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2519">4.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-707" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2520">494</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-708" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2521">541</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-709" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2522">569</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-707" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2523">8.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-708" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2524">5.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-710" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2525">696</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-711" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2526">765</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-712" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2527">845</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-710" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2528">9.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-711" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2529">9.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-713" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2530">1,189</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-714" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2531">1,306</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-715" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2532">1,414</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-713" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2533">8.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-714" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2534">7.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TOTAL INNOVATIVE MEDICINE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-716" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2535">33,970</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-717" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2536">31,169</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-718" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2537">28,604</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-716" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2538">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-717" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2539">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-719" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2540">22,994</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2541">23,590</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-721" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2542">23,959</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-719" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2543">2.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-720" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2544">1.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2545">56,964</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2546">54,759</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-722" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2547">52,563</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-114" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2548">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-110" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2549">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">MEDTECH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cardiovascular </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-723" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2550">4,513</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-724" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2551">3,633</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-725" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2552">2,169</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-723" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2553">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-724" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2554">67.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-726" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2555">3,194</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-727" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2556">2,717</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2557">2,131</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-726" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2558">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-727" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2559">27.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-729" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2560">7,707</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2561">6,350</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-731" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2562">4,300</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-729" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2563">21.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-730" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2564">47.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">ELECTROPHYSIOLOGY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-732" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2565">2,738</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-733" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2566">2,458</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-734" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2567">2,036</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-732" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2568">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-733" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2569">20.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-735" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2570">2,529</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-736" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2571">2,230</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-737" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2572">1,901</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-735" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2573">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-736" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2574">17.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-738" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2575">5,267</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-739" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2576">4,688</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-740" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2577">3,937</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-738" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2578">12.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-739" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2579">19.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">ABIOMED</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-741" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2580">1,213</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-742" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2581">1,066</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-743" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2582">31</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-741" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2583">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-744" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2584">284</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-745" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2585">240</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-746" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-2586">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-744" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2587">18.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-747" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2588">1,496</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-748" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2589">1,306</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-749" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2590">31</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-747" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2591">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">SHOCKWAVE</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-750" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2592">442</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-751" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-2593">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-752" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-2594">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-753" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2595">122</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-754" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-2596">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-755" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-2597">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-756" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2598">564</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-757" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-2599">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-758" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-2600">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER CARDIOVASCULAR</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-759" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2601">120</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-760" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2602">109</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-761" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2603">102</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-759" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2604">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-760" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2605">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-762" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2606">260</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-763" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2607">247</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-764" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2608">230</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-762" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2609">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-763" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2610">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-765" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2611">380</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-766" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2612">356</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-767" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2613">332</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-765" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2614">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-766" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2615">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-768" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2616">5,689</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-769" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2617">5,525</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-770" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2618">5,321</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-768" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2619">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-769" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2620">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-771" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2621">3,470</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-772" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2622">3,417</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-773" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2623">3,267</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-771" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2624">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-772" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2625">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-774" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2626">9,158</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-775" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2627">8,942</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-776" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2628">8,587</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-774" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2629">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-775" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2630">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">85</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-2076-4" continuedAt="f-2076-5"><ix:continuation id="f-2074-5" continuedAt="f-2074-6"><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;24 vs. &#8217;23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;23 vs. &#8217;22</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">HIPS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-777" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2631">1,057</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-778" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2632">996</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-779" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2633">943</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-777" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2634">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-778" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2635">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-780" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2636">581</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-781" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2637">564</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-782" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2638">571</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-780" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2639">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-781" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2640">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-783" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2641">1,638</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-784" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2642">1,560</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-785" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2643">1,514</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-783" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2644">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-784" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2645">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">KNEES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-786" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2646">922</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-787" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2647">896</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-788" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2648">851</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-786" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2649">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-787" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2650">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-789" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2651">623</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-790" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2652">559</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-791" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2653">508</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-789" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2654">11.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-790" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2655">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-792" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2656">1,545</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-793" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2657">1,456</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-794" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2658">1,359</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-792" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2659">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-793" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2660">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">TRAUMA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-795" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2661">2,013</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-796" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2662">1,949</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-797" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2663">1,882</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-795" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2664">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-796" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2665">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-798" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2666">1,036</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-799" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2667">1,030</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-800" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2668">989</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-798" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2669">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-799" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2670">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-801" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2671">3,049</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-802" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2672">2,979</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-803" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2673">2,871</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-801" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2674">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-802" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2675">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-804" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2676">1,696</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-805" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2677">1,684</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-806" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2678">1,645</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-804" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2679">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-805" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2680">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-807" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2681">1,230</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-808" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2682">1,263</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2683">1,198</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-807" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2684">2.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-808" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2685">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2686">2,926</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2687">2,947</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2688">2,843</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-810" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2689">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-811" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2690">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-813" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2691">4,003</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-814" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2692">4,031</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-815" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2693">3,897</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-813" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2694">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-814" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2695">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-816" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2696">5,842</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-817" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2697">6,006</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-818" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2698">5,793</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-816" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2699">2.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-817" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2700">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-819" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2701">9,845</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-820" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2702">10,037</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-821" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2703">9,690</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-819" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2704">1.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-820" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2705">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">ADVANCED</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-822" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2706">1,838</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-823" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2707">1,833</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-824" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2708">1,784</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-822" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2709">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-823" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2710">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-825" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2711">2,650</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-826" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2712">2,837</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-827" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2713">2,785</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-825" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2714">6.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-826" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2715">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-828" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2716">4,488</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-829" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2717">4,671</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-830" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2718">4,569</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-828" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2719">3.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-829" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2720">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">GENERAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-831" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2721">2,165</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-832" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2722">2,198</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-833" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2723">2,113</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-831" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2724">1.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-832" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2725">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-834" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2726">3,192</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-835" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2727">3,168</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-836" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2728">3,008</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-834" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2729">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-835" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2730">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-837" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2731">5,358</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-838" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2732">5,366</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-839" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2733">5,121</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-837" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2734">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-838" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2735">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-840" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2736">2,128</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-841" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2737">2,086</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-842" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2738">1,990</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-840" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2739">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-841" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2740">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-843" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2741">3,018</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-844" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2742">2,986</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-845" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2743">2,859</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-843" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2744">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-844" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2745">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-846" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2746">5,146</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-847" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2747">5,072</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-848" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2748">4,849</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-846" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2749">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-847" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2750">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">CONTACT LENSES / OTHER</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-849" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2751">1,684</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-850" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2752">1,626</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-851" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2753">1,522</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-849" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2754">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-850" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2755">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-852" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2756">2,049</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-853" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2757">2,076</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-854" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2758">2,022</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-852" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2759">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-853" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2760">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-855" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2761">3,733</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-856" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2762">3,702</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-857" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2763">3,543</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-855" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2764">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-856" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2765">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">SURGICAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-858" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2766">444</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-859" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2767">460</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-860" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2768">468</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-858" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2769">3.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-859" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2770">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-861" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2771">969</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-862" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2772">910</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-863" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2773">837</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-861" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2774">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-862" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2775">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-864" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2776">1,413</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-865" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2777">1,370</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-866" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2778">1,306</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-864" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2779">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-865" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2780">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">86</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-2074-6" continuedAt="f-2074-7"><ix:continuation id="f-2076-5"><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;24 vs. &#8217;23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;23 vs. &#8217;22</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TOTAL MEDTECH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-867" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2781">16,332</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-868" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2782">15,275</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-869" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2783">13,377</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-867" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2784">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-868" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2785">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-870" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2786">15,525</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-871" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2787">15,125</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-872" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2788">14,050</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-870" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2789">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-871" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2790">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2791">31,857</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2792">30,400</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-873" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2793">27,427</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-115" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2794">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-111" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2795">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WORLDWIDE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-874" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2796">50,302</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-875" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2797">46,444</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-876" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2798">41,981</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-874" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2799">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-875" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2800">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-877" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2801">38,519</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-878" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2802">38,715</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-879" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2803">38,009</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-877" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2804">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-878" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2805">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2806">88,821</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2807">85,159</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2808">79,990</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2809">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="f-2810">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">*&#160;&#160;&#160;&#160;percentage greater than 100% or not meaningful</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">Previously referred to as Interventional Solutions</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Acquired on December 22, 2022</span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt">Acquired on May 31, 2024</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="f-2811" escape="true"><div style="margin-bottom:4pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.679%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.679%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.084%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.275%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.679%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.042%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.275%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.679%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.750%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Income Before Tax by Segment</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024 </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="9" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023 </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="9" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022 </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Innovative<br/>Medicine</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MedTech</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Innovative<br/>Medicine</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MedTech</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Innovative<br/>Medicine</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MedTech</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales to customers</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-880" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2812">56,964</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-881" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2813">31,857</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-882" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2814">54,759</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-883" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2815">30,400</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-884" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2816">52,563</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-885" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2817">27,427</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of products sold</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-880" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-2818">14,036</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-881" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-2819">13,345</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-882" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-2820">13,715</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-883" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-2821">12,722</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-884" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-2822">14,066</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-885" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-2823">10,397</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, marketing and administrative </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-880" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-2824">10,906</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-881" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-2825">10,812</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-882" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-2826">9,842</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-883" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-2827">10,476</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-884" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-2828">9,714</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-885" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-2829">9,537</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-880" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-2830">13,529</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-881" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-2831">3,703</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-882" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-2832">11,963</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-883" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-2833">3,122</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-884" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-2834">11,642</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-885" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-2835">2,493</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other segment items </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-880" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-2836">426</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-881" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-2837">257</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-882" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-2838">993</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-883" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-2839">589</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-884" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-2840">1,494</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-885" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-2841">553</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Segment income before tax</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-880" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2842">18,919</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-881" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2843">3,740</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-886" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2844">22,659</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-882" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2845">18,246</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-883" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2846">4,669</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-887" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2847">22,915</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-884" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2848">15,647</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-885" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2849">4,447</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-888" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2850">20,094</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: Expense not allocated to segments </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="6" id="f-2851">5,972</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="6" id="f-2852">7,853</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-2853">735</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2854">16,687</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2855">15,062</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2856">19,359</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-2857" continuedAt="f-2857-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.644%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identifiable Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Innovative Medicine</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-889" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2858">57,070</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-890" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2859">58,324</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MedTech</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-891" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2860">84,322</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-892" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2861">74,710</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-893" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2862">141,392</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-894" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2863">133,034</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General corporate </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-895" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2864">38,712</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-896" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2865">34,524</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2866">180,104</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2867">167,558</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">87</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-2074-7" continuedAt="f-2074-8"><ix:continuation id="f-2857-1"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additions to Property,<br/>Plant &amp; Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Depreciation and<br/>Amortization</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Innovative Medicine</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-880" decimals="-6" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="6" id="f-2868">1,710</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-882" decimals="-6" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="6" id="f-2869">1,653</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-884" decimals="-6" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="6" id="f-2870">1,374</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-880" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2871">3,760</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-882" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2872">3,847</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-884" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2873">3,687</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MedTech</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-881" decimals="-6" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="6" id="f-2874">2,443</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-883" decimals="-6" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="6" id="f-2875">2,372</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-885" decimals="-6" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="6" id="f-2876">2,120</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-881" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2877">3,237</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-883" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2878">2,943</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-885" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2879">2,302</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Segments total</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-897" decimals="-6" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="6" id="f-2880">4,153</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-898" decimals="-6" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="6" id="f-2881">4,025</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-899" decimals="-6" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="6" id="f-2882">3,494</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-897" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2883">6,997</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-898" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2884">6,790</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-899" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2885">5,989</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-900" decimals="-6" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:fixed-zero" scale="6" id="f-2886">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-901" decimals="-6" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" scale="6" id="f-2887">162</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-902" decimals="-6" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" scale="6" id="f-2888">303</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-900" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:fixed-zero" scale="6" id="f-2889">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-901" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-2890">383</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-902" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-2891">641</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-903" decimals="-6" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" scale="6" id="f-2892">271</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-904" decimals="-6" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" scale="6" id="f-2893">356</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-905" decimals="-6" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" scale="6" id="f-2894">212</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-903" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-2895">342</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-904" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-2896">313</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-905" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-2897">340</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="6" id="f-2898">4,424</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="6" id="f-2899">4,543</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="6" id="f-2900">4,009</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2901">7,339</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2902">7,486</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2903">6,970</ix:nonFraction></span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" id="f-2904" continuedAt="f-2904-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.989%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.467%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Long-Lived Assets </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">United States</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-906" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2905">50,302</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-907" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2906">46,444</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-908" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2907">41,981</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-909" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-2908">70,670</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-910" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-2909">54,832</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-911" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2910">20,212</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-912" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2911">20,410</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-913" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2912">20,664</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-914" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-2913">27,267</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-915" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-2914">31,616</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Western Hemisphere excluding U.S.&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-916" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2915">4,714</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-917" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2916">4,549</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-918" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2917">4,108</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-919" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-2918">1,728</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-920" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-2919">1,491</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Asia-Pacific, Africa</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-921" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2920">13,593</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-922" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2921">13,756</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-923" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2922">13,237</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-924" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-2923">1,454</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-925" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-2924">1,500</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Segments total</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-886" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2925">88,821</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-887" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2926">85,159</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-888" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2927">79,990</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-926" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-2928">101,119</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-927" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-2929">89,439</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-895" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-2930">1,217</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-896" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-2931">1,192</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other non long-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-928" decimals="-6" name="jnj:OtherNonLongLivedAssets" format="ixt:num-dot-decimal" scale="6" id="f-2932">77,768</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-929" decimals="-6" name="jnj:OtherNonLongLivedAssets" format="ixt:num-dot-decimal" scale="6" id="f-2933">76,927</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2934">88,821</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2935">85,159</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2936">79,990</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2937">180,104</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2938">167,558</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">See Note&#160;1 for a description of the segments in which the Company operates. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Export sales are not significant. In fiscal year 2024, the Company utilized three wholesalers distributing products for both segments that represented approximately <ix:nonFraction unitRef="number" contextRef="c-930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-2939">20.5</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-931" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-2940">15.6</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-932" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-2941">12.3</ix:nonFraction>% of the total gross revenues. In fiscal year 2023, the Company had three wholesalers distributing products for both segments that represented approximately <ix:nonFraction unitRef="number" contextRef="c-933" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-2942">18.2</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-934" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-2943">15.1</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-935" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-2944">14.2</ix:nonFraction>% of the total gross revenues. In fiscal year 2022, the Company had three wholesalers distributing products for all <ix:nonFraction unitRef="segment" contextRef="c-13" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-2945">three</ix:nonFraction> segments that represented approximately <ix:nonFraction unitRef="number" contextRef="c-936" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-2946">18.9</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-937" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-2947">15.0</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="c-938" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-2948">13.8</ix:nonFraction>% of the total gross revenues. </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.64pt"><span style="-sec-ix-hidden:f-2949">Other segment expenses</span> for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:7.29pt">Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal years 2024 and 2023 include charges for talc matters of approximately $<ix:nonFraction unitRef="usd" contextRef="c-939" decimals="-8" name="us-gaap:LossContingencyLossInPeriod" format="ixt:num-dot-decimal" scale="9" id="f-2950">5.1</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="c-940" decimals="-8" name="us-gaap:LossContingencyLossInPeriod" format="ixt:num-dot-decimal" scale="9" id="f-2951">7</ix:nonFraction>&#160;billion, respectively (See Note 19, Legal proceedings, for additional details). The fiscal year 2024 includes a loss of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-8" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="9" id="f-2952">0.4</ix:nonFraction>&#160;billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock. The fiscal year 2023 includes the unfavorable change in the fair value of the retained stake in Kenvue of approximately $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-8" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="9" id="f-2953">0.4</ix:nonFraction>&#160;billion.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:7.19pt">Innovative Medicine segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">Acquired in-process research &amp; development expense of $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-6" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="9" id="f-2954">1.25</ix:nonFraction>&#160;billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition)</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">Monetization of royalty rights of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromRoyaltiesReceived" format="ixt:num-dot-decimal" scale="9" id="f-2955">0.3</ix:nonFraction>&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="f-2956">0.3</ix:nonFraction>&#160;billion primarily related to Risperdal Gynecomastia</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">An intangible asset impairment charge of approximately $<ix:nonFraction unitRef="usd" contextRef="c-941" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="f-2957">0.2</ix:nonFraction>&#160;billion associated with the M710 (biosimilar) asset acquired as part of the acquisition of Momenta Pharmaceuticals in 2020.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="c-880" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="f-2958">0.1</ix:nonFraction>&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">One-time COVID-19 Vaccine manufacturing exit related costs of $<ix:nonFraction unitRef="usd" contextRef="c-880" decimals="-8" name="us-gaap:SuppliesExpense" format="ixt:num-dot-decimal" scale="9" id="f-2959">0.1</ix:nonFraction>&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">Favorable changes in the fair value of securities of $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-8" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:num-dot-decimal" scale="9" id="f-2960">0.1</ix:nonFraction>&#160;billion</span></div><div style="padding-left:14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">MedTech segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">Acquisition and integration related costs of $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-8" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="9" id="f-2961">1.0</ix:nonFraction>&#160;billion primarily related to the acquisition of Shockwave </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">88</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-2904-1"><ix:continuation id="f-2074-8"><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt">Acquired in-process research and development expense of $<ix:nonFraction unitRef="usd" contextRef="c-942" decimals="-8" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="9" id="f-2962">0.5</ix:nonFraction>&#160;billion from the V-Wave acquisition</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt">A gain of $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-8" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="9" id="f-2963">0.2</ix:nonFraction>&#160;billion related to the Acclarent divestiture</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt">A Medical Device Regulation charge of $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-8" name="jnj:RegulationCharge" format="ixt:num-dot-decimal" scale="9" id="f-2964">0.2</ix:nonFraction>&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="c-881" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="f-2965">0.2</ix:nonFraction>&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.07pt">Innovative Medicine segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">One-time COVID-19 Vaccine manufacturing exit related costs of $<ix:nonFraction unitRef="usd" contextRef="c-882" decimals="-8" name="us-gaap:SuppliesExpense" format="ixt:num-dot-decimal" scale="9" id="f-2966">0.7</ix:nonFraction>&#160;billion </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="c-882" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="f-2967">0.5</ix:nonFraction>&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Unfavorable changes in the fair value of securities of $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-8" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:num-dot-decimal" scale="9" id="f-2968">0.4</ix:nonFraction>&#160;billion </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Favorable litigation related items of $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-8" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="9" id="f-2969">0.1</ix:nonFraction>&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Loss on divestiture of $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-8" sign="-" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="9" id="f-2970">0.2</ix:nonFraction>&#160;billion. </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">An intangible asset impairment charge of approximately $<ix:nonFraction unitRef="usd" contextRef="c-943" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="f-2971">0.2</ix:nonFraction>&#160;billion related to market dynamics associated with a non-strategic asset (M710) acquired as part of the acquisition of Momenta Pharmaceuticals in 2020.</span></div><div style="padding-left:14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:112%">MedTech segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Acquired in-process research and development expense of $<ix:nonFraction unitRef="usd" contextRef="c-944" decimals="-8" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="9" id="f-2972">0.4</ix:nonFraction>&#160;billion related to the Laminar acquisition in 2023</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="c-883" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="f-2973">0.3</ix:nonFraction>&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Acquisition and integration related costs of $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-8" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="9" id="f-2974">0.2</ix:nonFraction>&#160;billion primarily related to the acquisition of Abiomed</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">A Medical Device Regulation charge of $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-8" name="jnj:RegulationCharge" format="ixt:num-dot-decimal" scale="9" id="f-2975">0.3</ix:nonFraction>&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Income from litigation settlements of $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-8" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="9" id="f-2976">0.1</ix:nonFraction>&#160;billion</span></div><div style="padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:7.17pt">Innovative Medicine segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">One-time COVID-19 Vaccine manufacturing exit related costs of $<ix:nonFraction unitRef="usd" contextRef="c-884" decimals="-8" name="us-gaap:SuppliesExpense" format="ixt:num-dot-decimal" scale="9" id="f-2977">1.5</ix:nonFraction>&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">An intangible asset impairment charge of approximately $<ix:nonFraction unitRef="usd" contextRef="c-945" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="f-2978">0.8</ix:nonFraction>&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="c-722" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="f-2979">0.1</ix:nonFraction>&#160;billion </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Unfavorable changes in the fair value of securities of $<ix:nonFraction unitRef="usd" contextRef="c-722" decimals="-8" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:num-dot-decimal" scale="9" id="f-2980">0.7</ix:nonFraction>&#160;billion </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="c-722" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="f-2981">0.1</ix:nonFraction>&#160;billion </span></div><div style="padding-left:14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:112%">MedTech segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="c-873" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="f-2982">0.6</ix:nonFraction>&#160;billion primarily for pelvic mesh related costs</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="c-873" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="f-2983">0.3</ix:nonFraction>&#160;billion </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Acquisition and integration related costs of $<ix:nonFraction unitRef="usd" contextRef="c-873" decimals="-8" name="us-gaap:AcquisitionCosts" format="ixt:num-dot-decimal" scale="9" id="f-2984">0.3</ix:nonFraction>&#160;billion primarily related to the acquisition of Abiomed</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt">A Medical Device Regulation charge of $<ix:nonFraction unitRef="usd" contextRef="c-873" decimals="-8" name="jnj:RegulationCharge" format="ixt:num-dot-decimal" scale="9" id="f-2985">0.3</ix:nonFraction>&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">   General corporate includes cash, cash equivalents, marketable securities and other corporate assets. </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.64pt">Long-lived assets include property, plant and equipment, net for fiscal years 2024, and 2023 of $<ix:nonFraction unitRef="usd" contextRef="c-946" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-2986">20,518</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-947" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-2987">19,898</ix:nonFraction>, respectively, and intangible assets and goodwill, net for fiscal years 2024 and 2023 of $<ix:nonFraction unitRef="usd" contextRef="c-948" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-2988">81,818</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-949" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-2989">70,733</ix:nonFraction>, respectively.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">89</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_220"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">18.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-2990" continuedAt="f-2990-1" escape="true">Acquisitions and divestitures</ix:nonNumeric></span></div><ix:continuation id="f-2990-1" continuedAt="f-2990-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Subsequent to the fiscal year end 2024, the Company announced it has entered into a definitive agreement to acquire Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, for $<ix:nonFraction unitRef="usdPerShare" contextRef="c-950" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="f-2991">132.00</ix:nonFraction> per share in cash for a total equity value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-951" decimals="-8" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="9" id="f-2992">14.6</ix:nonFraction>&#160;billion. The Company expects to fund the transaction through a combination of cash on hand and debt. The closing of the transaction is expected to occur later this year subject to applicable regulatory approvals, approval by Intra-Cellular Therapies&#8217; stockholders and other customary closing conditions for a transaction of this type. The results of operations will be included in the Innovative Medicine segment beginning on the acquisition date.</span></div><div><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Business combinations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Acquisitions of a business are accounted for as business combinations applying the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed are recorded at their respective fair values as of the acquisition date in the Company&#8217;s consolidated financial statements. The excess of the purchase price over the fair value of the acquired net assets, where applicable, is recorded as goodwill. The results of operations of these acquisitions have been included in the Company&#8217;s financial statements from their respective dates of acquisition. </span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">During the fiscal year 2024, certain businesses were acquired for $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="f-2993">15.1</ix:nonFraction>&#160;billion, net of cash acquired. The fiscal year 2024 acquisitions primarily included; Ambrx Biopharma, Inc., Shockwave Medical Inc., and Proteologix, Inc. The remaining acquisitions were not material.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On June 20, 2024, the Company completed the acquisition of Proteologix, Inc., a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for approximately $<ix:nonFraction unitRef="usd" contextRef="c-952" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="9" id="f-2994">0.8</ix:nonFraction>&#160;billion net of cash acquired, with potential for an additional milestone payment. The results of operations are included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $<ix:nonFraction unitRef="usd" contextRef="c-953" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="9" id="f-2995">1.2</ix:nonFraction>&#160;billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&amp;D, for $<ix:nonFraction unitRef="usd" contextRef="c-953" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="f-2996">0.9</ix:nonFraction>&#160;billion, goodwill for $<ix:nonFraction unitRef="usd" contextRef="c-952" decimals="-8" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="9" id="f-2997">0.3</ix:nonFraction>&#160;billion, and $<ix:nonFraction unitRef="usd" contextRef="c-953" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="9" id="f-2998">0.3</ix:nonFraction>&#160;billion of liabilities assumed which included $<ix:nonFraction unitRef="usd" contextRef="c-953" decimals="-8" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="9" id="f-2999">0.1</ix:nonFraction>&#160;billion related to a contingent consideration. The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period. A probability of success factor ranging from <ix:nonFraction unitRef="number" contextRef="c-954" decimals="2" name="jnj:BusinessCombinationProbabilityOfSuccessFactor" scale="-2" id="f-3000">30</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-955" decimals="2" name="jnj:BusinessCombinationProbabilityOfSuccessFactor" scale="-2" id="f-3001">45</ix:nonFraction>% was used in the fair value calculation to reflect inherent regulatory and commercial risk of the IPR&amp;D. The discount rate applied was approximately <ix:nonFraction unitRef="number" contextRef="c-953" decimals="3" name="jnj:BusinessAcquisitionDiscountRate" scale="-2" id="f-3002">16</ix:nonFraction>%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. Acquisition related costs before tax for the fiscal 2024 were <ix:nonFraction unitRef="usd" contextRef="c-956" decimals="-8" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:fixed-zero" scale="0" id="f-3003">not</ix:nonFraction> material. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On May 31, 2024, the Company completed the acquisition of Shockwave Medical Inc. (SWAV)(Shockwave), a leading, first-to-market provider of innovative intravascular lithotripsy (IVL) technology for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD) in an all-cash merger transaction. The Company acquired all the outstanding shares of Shockwave&#8217;s common stock for $<ix:nonFraction unitRef="usdPerShare" contextRef="c-957" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="f-3004">335.00</ix:nonFraction> per share through a merger of Shockwave with a subsidiary of the Company. The results of operations were included in the MedTech segment as of the acquisition date.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">90</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-2990-2" continuedAt="f-2990-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="f-3005" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Details of the fair value amounts recognized for assets acquired and liabilities assumed as of the purchase date and at the end of fiscal year 2024, which includes measurement period adjustments, are included in the table below. As the acquisition occurred in May 2024, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Billions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">May 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Assets acquired:</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-957" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="9" id="f-3006">1.1</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-958" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="9" id="f-3007">1.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-957" decimals="-8" name="us-gaap:Goodwill" scale="9" id="f-3008">7.5</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-958" decimals="-8" name="us-gaap:Goodwill" scale="9" id="f-3009">7.6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortizable intangibles</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-957" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="9" id="f-3010">5.3</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-958" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="9" id="f-3011">5.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">IPR&amp;D</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-957" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="9" id="f-3012">0.6</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-958" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="9" id="f-3013">0.6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-957" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="9" id="f-3014">0.5</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-958" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="9" id="f-3015">0.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-957" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="9" id="f-3016">0.5</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-958" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="9" id="f-3017">0.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total assets acquired</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-957" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="9" id="f-3018">15.5</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-958" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="9" id="f-3019">15.5</ix:nonFraction></span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Liabilities assumed:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-957" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="9" id="f-3020">1.5</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-958" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="9" id="f-3021">1.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Notes payable*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-957" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" scale="9" id="f-3022">1.0</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-958" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" scale="9" id="f-3023">1.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued liabilities**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-957" decimals="-8" name="jnj:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" scale="9" id="f-3024">0.4</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-958" decimals="-8" name="jnj:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" scale="9" id="f-3025">0.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total liabilities assumed</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-957" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="9" id="f-3026">2.9</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-958" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="9" id="f-3027">2.9</ix:nonFraction></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net assets acquired</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-957" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="9" id="f-3028">12.6</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-958" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="9" id="f-3029">12.6</ix:nonFraction></span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net assets acquired as of May 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-957" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="9" id="f-3030">12.6</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: Cash acquired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-957" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="9" id="f-3031">1.1</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity awards settled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-959" decimals="-8" name="jnj:BusinessCombinationSettlementOfEquityAwards" scale="9" id="f-3032">0.6</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Settlement of Note payable*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-959" decimals="-8" name="jnj:BusinessCombinationSettlementOfNotesPayable" scale="9" id="f-3033">1.0</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total enterprise value as of June 30, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-960" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="9" id="f-3034">13.1</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">*&#160;&#160;&#160;&#160;Represents the convertible debt which was subsequently paid in the fiscal second quarter of 2024.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">**&#160;&#160;&#160;&#160;Includes $<ix:nonFraction unitRef="usd" contextRef="c-961" decimals="-8" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="9" id="f-3035">0.2</ix:nonFraction>&#160;billion of equity awards</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. Acquisition related costs before tax for the fiscal 2024 were $<ix:nonFraction unitRef="usd" contextRef="c-962" decimals="-8" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="9" id="f-3036">0.9</ix:nonFraction>&#160;billion of which $<ix:nonFraction unitRef="usd" contextRef="c-962" decimals="-8" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss" format="ixt:num-dot-decimal" scale="9" id="f-3037">0.4</ix:nonFraction>&#160;billion was related to the fair value of the inventory step-up and was recorded in Cost of products sold and $<ix:nonFraction unitRef="usd" contextRef="c-962" decimals="-8" name="jnj:BusinessCombinationAcquisitionRelatedCostsEquityAwards" format="ixt:num-dot-decimal" scale="9" id="f-3038">0.5</ix:nonFraction>&#160;billion primarily related to equity awards and was recorded in Other (income) expense. The amortizable intangible assets were primarily comprised of already in-market CAD and PAD IVL products with the average weighted lives of <ix:nonNumeric contextRef="c-961" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-3039">14</ix:nonNumeric> years. The IPR&amp;D assets were valued for technology programs for unapproved products. The value of the IPR&amp;D was calculated using a probability-adjusted cash flow projection discounted for the risk inherent in such projects with the weighted average probability of success factors of approximately <ix:nonFraction unitRef="number" contextRef="c-963" decimals="2" name="jnj:BusinessCombinationProbabilityOfSuccessFactor" scale="-2" id="f-3040">50</ix:nonFraction>%. The discount rate applied was <ix:nonFraction unitRef="number" contextRef="c-957" decimals="3" name="jnj:BusinessAcquisitionDiscountRate" scale="-2" id="f-3041">9.0</ix:nonFraction>%.</span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On March 7, 2024, the Company completed the acquisition of Ambrx Biopharma, Inc., (Ambrx), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-964" decimals="-8" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="9" id="f-3042">2.0</ix:nonFraction>&#160;billion, or $<ix:nonFraction unitRef="usd" contextRef="c-964" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="9" id="f-3043">1.8</ix:nonFraction>&#160;billion net of cash acquired. The Company acquired all of the outstanding shares of Ambrx&#8217;s common stock for $<ix:nonFraction unitRef="usdPerShare" contextRef="c-965" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="f-3044">28.00</ix:nonFraction> per share through a merger of Ambrx with a subsidiary of the Company. The results of operations were included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $<ix:nonFraction unitRef="usd" contextRef="c-965" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="9" id="f-3045">2.3</ix:nonFraction>&#160;billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&amp;D, for $<ix:nonFraction unitRef="usd" contextRef="c-965" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="f-3046">1.9</ix:nonFraction>&#160;billion, goodwill for $<ix:nonFraction unitRef="usd" contextRef="c-964" decimals="-8" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="9" id="f-3047">0.3</ix:nonFraction>&#160;billion and liabilities assumed of $<ix:nonFraction unitRef="usd" contextRef="c-965" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="9" id="f-3048">0.5</ix:nonFraction>&#160;billion, which includes deferred taxes of $<ix:nonFraction unitRef="usd" contextRef="c-965" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="9" id="f-3049">0.4</ix:nonFraction>&#160;billion. The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period. A probability of success factor ranging from <ix:nonFraction unitRef="number" contextRef="c-966" decimals="2" name="jnj:BusinessCombinationProbabilityOfSuccessFactor" scale="-2" id="f-3050">40</ix:nonFraction>% to </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">91</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-2990-3" continuedAt="f-2990-4"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="number" contextRef="c-967" decimals="2" name="jnj:BusinessCombinationProbabilityOfSuccessFactor" scale="-2" id="f-3051">70</ix:nonFraction>% was used in the fair value calculation to reflect inherent regulatory and commercial risk of the IPR&amp;D. The discount rate applied was approximately <ix:nonFraction unitRef="number" contextRef="c-965" decimals="3" name="jnj:BusinessAcquisitionDiscountRate" scale="-2" id="f-3052">17</ix:nonFraction>%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. Acquisition related costs before tax for the fiscal year 2024 were not material.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">During the fiscal year 2023, the Company did not make any acquisitions that qualified as a business combination. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">During the fiscal year 2022, certain businesses were acquired for $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="f-3053">17.7</ix:nonFraction>&#160;billion, net of cash acquired. The fiscal year 2022 acquisitions primarily included Abiomed, Inc. (Abiomed). The remaining acquisitions were not material.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On December 22, 2022, the Company completed the acquisition of Abiomed, a leading, first-to-market provider of cardiovascular medical technology with a first-in-kind portfolio for the treatment of coronary artery disease and heart failure which also has an extensive innovation pipeline of life-saving technologies. The transaction broadens the Company&#8217;s position as a growing cardiovascular innovator, advancing the standard of care in heart failure and recovery, one of healthcare&#8217;s largest areas of unmet need. The results of operations were included in the MedTech segment as of the date of the acquisition. The acquisition was completed through a tender offer for all outstanding shares. The consideration paid in the acquisition consisted of an upfront payment of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-968" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="f-3054">380.00</ix:nonFraction> per share in cash, amounting to $<ix:nonFraction unitRef="usd" contextRef="c-969" decimals="-8" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="9" id="f-3055">17.1</ix:nonFraction>&#160;billion, net of cash acquired, as well as a non-tradeable contingent value right (&#8220;CVR&#8221;) entitling the holder to receive up to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-970" decimals="2" name="jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight" scale="0" id="f-3056">35.00</ix:nonFraction> per share in cash (which with respect to the CVRs total approximately $<ix:nonFraction unitRef="usd" contextRef="c-970" decimals="-8" name="jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight" format="ixt:num-dot-decimal" scale="9" id="f-3057">1.6</ix:nonFraction>&#160;billion in the aggregate) if certain commercial and clinical milestones are achieved. The corresponding enterprise value (without taking into account the CVRs) of approximately $<ix:nonFraction unitRef="usd" contextRef="c-968" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="9" id="f-3058">16.5</ix:nonFraction>&#160;billion includes cash, cash equivalents and marketable securities acquired.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The milestones of the CVR consist of:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">a.</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.65pt">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-968" decimals="2" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="f-3059">17.50</ix:nonFraction> per share, payable if net sales for Abiomed products exceeds $<ix:nonFraction unitRef="usd" contextRef="c-970" decimals="-8" name="jnj:RevenuesContingentConsideration" format="ixt:num-dot-decimal" scale="9" id="f-3060">3.7</ix:nonFraction>&#160;billion during Johnson &amp; Johnson&#8217;s fiscal second quarter of 2027 through fiscal first quarter of 2028, or if this threshold is not met during this period and is subsequently met during any rolling four quarter period up to the end of Johnson &amp; Johnson&#8217;s fiscal first quarter of 2029, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-971" decimals="2" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="f-3061">8.75</ix:nonFraction> per&#160;share;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">b.</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.23pt">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-972" decimals="2" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="f-3062">7.50</ix:nonFraction> per share payable upon FDA premarket application approval of the use of Impella&#174; products in ST-elevated myocardial infarction (STEMI) patients without cardiogenic shock by January 1, 2028; and</span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">c.</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.49pt">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-973" decimals="2" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="f-3063">10.00</ix:nonFraction> per share payable upon the first publication of a Class I recommendation for the use of Impella&#174; products in high risk PCI or STEMI with or without cardiogenic shock within four years from their respective clinical endpoint publication dates, but in all cases no later than December 31, 2029.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">During the fiscal fourth quarter of 2023, the Company finalized the purchase price allocation. In fiscal 2023, there were purchase price allocation adjustments netting to approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-8" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="9" id="f-3064">0.2</ix:nonFraction>&#160;billion with an offsetting increase to goodwill. The fair value of the acquisition was allocated to assets acquired of $<ix:nonFraction unitRef="usd" contextRef="c-974" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="9" id="f-3065">20.1</ix:nonFraction>&#160;billion (net of $<ix:nonFraction unitRef="usd" contextRef="c-975" decimals="-8" name="us-gaap:CashAcquiredFromAcquisition" format="ixt:num-dot-decimal" scale="9" id="f-3066">0.3</ix:nonFraction>&#160;billion cash acquired), primarily to goodwill for $<ix:nonFraction unitRef="usd" contextRef="c-975" decimals="-8" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="9" id="f-3067">11.1</ix:nonFraction>&#160;billion, amortizable intangible assets for $<ix:nonFraction unitRef="usd" contextRef="c-975" decimals="-8" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="9" id="f-3068">6.6</ix:nonFraction>&#160;billion, IPR&amp;D for $<ix:nonFraction unitRef="usd" contextRef="c-975" decimals="-8" name="jnj:ResearchAndDevelopmentInProcess1" format="ixt:num-dot-decimal" scale="9" id="f-3069">1.1</ix:nonFraction>&#160;billion, marketable securities of $<ix:nonFraction unitRef="usd" contextRef="c-974" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" format="ixt:num-dot-decimal" scale="9" id="f-3070">0.6</ix:nonFraction>&#160;billion and liabilities assumed of $<ix:nonFraction unitRef="usd" contextRef="c-974" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="9" id="f-3071">3.0</ix:nonFraction>&#160;billion, which includes the fair value of the contingent consideration mentioned above for $<ix:nonFraction unitRef="usd" contextRef="c-974" decimals="-8" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="9" id="f-3072">0.7</ix:nonFraction>&#160;billion and deferred taxes of $<ix:nonFraction unitRef="usd" contextRef="c-974" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="9" id="f-3073">2.0</ix:nonFraction>&#160;billion. The goodwill is primarily attributable to the commercial acceleration and expansion of the portfolio and is not expected to be deductible for tax purposes. The contingent consideration was recorded in Other Liabilities and adjusted to fair value through the fiscal year end 2024 on the Consolidated Balance Sheet.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The amortizable intangible assets were primarily comprised of already in-market products of the Impella&#174; platform with an average weighted life of <ix:nonNumeric contextRef="c-971" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-3074">14</ix:nonNumeric> years. The IPR&amp;D assets were valued for technology programs for unapproved products. The value of the IPR&amp;D was calculated using probability-adjusted cash flow projections discounted for the risk inherent in such projects. The probability of success factor ranged from <ix:nonFraction unitRef="number" contextRef="c-976" decimals="2" name="jnj:BusinessCombinationProbabilityOfSuccessFactor" scale="-2" id="f-3075">52</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-977" decimals="2" name="jnj:BusinessCombinationProbabilityOfSuccessFactor" scale="-2" id="f-3076">70</ix:nonFraction>%. The discount rate applied was <ix:nonFraction unitRef="number" contextRef="c-968" decimals="3" name="jnj:BusinessAcquisitionDiscountRate" scale="-2" id="f-3077">9.5</ix:nonFraction>%. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In the fiscal years 2024, 2023 and 2022, the Company recorded acquisition related costs before tax of approximately $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-8" name="us-gaap:AcquisitionCosts" format="ixt:num-dot-decimal" scale="9" id="f-3078">0.3</ix:nonFraction>&#160;billion, $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-8" name="us-gaap:AcquisitionCosts" format="ixt:num-dot-decimal" scale="9" id="f-3079">0.2</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-8" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="9" id="f-3080">0.3</ix:nonFraction>&#160;billion, which was primarily recorded in Other (income)/expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In accordance with U.S.&#160;GAAP standards related to business combinations, and goodwill and other intangible assets, supplemental pro forma information for fiscal years 2024, 2023 and 2022 is not provided, as the impact of the aforementioned acquisitions did not have a material effect on the Company&#8217;s results of operations.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">92</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-2990-4"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Asset acquisitions</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Acquired In-process research and development (IPR&amp;D) in an asset acquisition is immediately expensed as research and development expense in the Company's consolidated financial statements. Milestone payments incurred prior to regulatory approval are expensed as research and development expense when the milestone event occurs.</span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The fiscal year 2024 asset acquisitions expensed as research and development included V-Wave Ltd. and the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition). The remaining activity was not material.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On October 8, 2024, the Company completed the acquisition of V-Wave Ltd, a privately-held company focused on developing innovative treatment options for patients with heart failure, for an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-978" decimals="-8" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="9" id="f-3081">0.6</ix:nonFraction>&#160;billion, with the potential for additional regulatory and commercial milestone payments up to approximately $<ix:nonFraction unitRef="usd" contextRef="c-979" decimals="-8" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="9" id="f-3082">1.1</ix:nonFraction>&#160;billion. The Company recorded an IPR&amp;D charge of approximately $<ix:nonFraction unitRef="usd" contextRef="c-980" decimals="-8" name="jnj:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="f-3083">0.5</ix:nonFraction>&#160;billion, net of a gain recorded on the Company's existing investment in V-Wave and the results of operations are included in the MedTech segment as of the acquisition date. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On July 11, 2024, the Company completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics AG, to secure the global rights to NM26, a novel, investigational first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD), in an all-cash transaction for approximately $<ix:nonFraction unitRef="usd" contextRef="c-981" decimals="-7" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="9" id="f-3084">1.25</ix:nonFraction>&#160;billion. The Company recorded an IPR&amp;D charge of approximately $<ix:nonFraction unitRef="usd" contextRef="c-982" decimals="-7" name="jnj:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="f-3085">1.25</ix:nonFraction>&#160;billion, and the results of operations are included in the Innovative Medicine segment as of the acquisition date.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The fiscal year 2023 asset acquisitions expensed as research and development included Laminar Inc. The remaining activity was not material.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">During the fiscal year 2023, the Company completed the acquisition of Laminar Inc., a privately-held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib), for an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-983" decimals="-8" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="9" id="f-3086">0.4</ix:nonFraction>&#160;billion. The Company recorded an IPR&amp;D charge of approximately $<ix:nonFraction unitRef="usd" contextRef="c-984" decimals="-8" name="jnj:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="f-3087">0.4</ix:nonFraction>&#160;billion and the results of operations are included in the MedTech segment as of the acquisition date. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">There were no significant asset acquisitions in 2022.</span></div><div><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Divestitures</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">During the fiscal year 2024, the Company completed the divestiture of Acclarent resulting in approximately $<ix:nonFraction unitRef="usd" contextRef="c-985" decimals="-8" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="9" id="f-3088">0.3</ix:nonFraction>&#160;billion in proceeds and the divestiture of Ponvory outside of the U.S. resulting in approximately $<ix:nonFraction unitRef="usd" contextRef="c-986" decimals="-8" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="9" id="f-3089">0.2</ix:nonFraction>&#160;billion in proceeds. All other divestitures were not material.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">During the fiscal year 2023, the Company executed divestitures resulting in approximately $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="9" id="f-3090">0.2</ix:nonFraction>&#160;billion in proceeds resulting in gains or losses that were not material. At fiscal year end 2023, the Company held assets, primarily intangibles, on its Consolidated Balance Sheet of approximately $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup" format="ixt:num-dot-decimal" scale="9" id="f-3091">0.3</ix:nonFraction>&#160;billion, primarily related to Acclarent and Ponvory, that were subsequently divested in fiscal 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">During fiscal year 2022, the Company did <ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-8" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:fixed-zero" scale="0" id="f-3092">not</ix:nonFraction> make any material divestitures.</span></div></ix:continuation><div id="i4b4bd2fffa0147e7914e1841a5c21924_223"></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">19.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="f-3093" continuedAt="f-3093-1" escape="true">Legal proceedings</ix:nonNumeric></span></div><ix:continuation id="f-3093-1" continuedAt="f-3093-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Johnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of December 29, 2024, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">93</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-3093-2" continuedAt="f-3093-3"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In the Company&#8217;s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company&#8217;s balance sheet, is not expected to have a material adverse effect on the Company&#8217;s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company&#8217;s results of operations and cash flows for that period.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Matters concerning talc</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">A significant number of personal injury claims alleging that talc causes cancer have been asserted against the Company and its affiliates arising out of the use of body powders containing talc, primarily JOHNSON&#8217;S Baby Powder. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In talc cases that have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $<ix:nonFraction unitRef="usd" contextRef="c-987" decimals="-8" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="9" id="f-3094">4.7</ix:nonFraction>&#160;billion in Ingham v. Johnson &amp; Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $<ix:nonFraction unitRef="usd" contextRef="c-988" decimals="-8" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="9" id="f-3095">2.1</ix:nonFraction>&#160;billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied, and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $<ix:nonFraction unitRef="usd" contextRef="c-989" decimals="-8" name="us-gaap:LossContingencyDamagesPaidValue" format="ixt:num-dot-decimal" scale="9" id="f-3096">2.5</ix:nonFraction>&#160;billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company&#8217;s confidence in the safety of its talc products, in certain circumstances the Company has settled cases. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In June 2014, the Mississippi Attorney General filed a complaint against the Company alleging violation of the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers&#8217; use of talc contained in JOHNSON&#8217;S Baby Powder and JOHNSON&#8217;S Shower to Shower (a product divested in 2012). The Company has reached an agreement to resolve this matter. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The Company has reached an agreement to resolve this matter. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Forty-two states and the District of Columbia commenced a joint investigation into the Company&#8217;s marketing of its talcum powder products. In January 2024, the Company reached an agreement in principle with the multi-state group of state Attorneys General, subject to ongoing negotiation of non-monetary terms. In June 2024, the settlements were finalized. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In October 2021, Johnson &amp; Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&amp;M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor&#8217;s direct parent, Johnson &amp; Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI&#8217;s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers&#8217; compensation statute or act (the Talc-Related Liabilities).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In October 2021, notwithstanding the Company&#8217;s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under Chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). All litigation against LTL, Old JJCI, New JJCI, the Company, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties) was stayed. The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions in March 2022. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss the LTL Bankruptcy Case and the extension of the stay to the Protected Parties. On January 30, 2023, the Third Circuit reversed the Bankruptcy Court&#8217;s ruling and remanded to the Bankruptcy Court to dismiss the LTL bankruptcy. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">94</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-3093-3" continuedAt="f-3093-4"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to all parties and returning the talc litigation to the tort system. LTL re-filed in the United States Bankruptcy Court for the District of New Jersey seeking relief under Chapter 11 of the Bankruptcy Code (the LTL 2 Bankruptcy Case). As a result of the new filing, all talc claims against LTL were again automatically stayed pursuant to section 362 of the Bankruptcy Code. Additionally, the New Jersey Bankruptcy Court issued a temporary restraining order staying all litigation as to LTL, Old JJCI, New JJCI, the Company, identified retailers, and certain other parties (the New Protected Parties). </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Also in April 2023, the New Jersey Bankruptcy Court issued a decision that granted limited injunctive relief to the Company and the New Protected Parties (the LTL 2 Preliminary Injunction). The LTL 2 Preliminary Injunction remained in force until late August 2023, following the Bankruptcy Court&#8217;s extension of the initial LTL 2 Preliminary Injunction in June 2023. Under the LTL 2 Preliminary Injunction, except for those cases filed in the federal court ovarian cancer multi-district litigation, discovery in all personal injury and wrongful death matters was permitted to proceed. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Furthermore, in April 2023, the Talc Claimants' Committee filed a motion to dismiss the LTL 2 Bankruptcy followed by similar motions from other claimants. Hearings on the motions to dismiss occurred in June 2023. In July 2023, the court dismissed the LTL 2 Bankruptcy case and, the same day, the Company stated its intent to appeal the decision and to continue its efforts to obtain a resolution of the talc claims. In September 2023, the Bankruptcy Court entered an order granting LTL leave to seek a direct appeal to the Third Circuit Court of Appeals. In October 2023, the Third Circuit granted LTL&#8217;s petition for a direct appeal. In July 2024, the Third Circuit issued a non-precedential opinion affirming the Bankruptcy Court's decision to dismiss the LTL Bankruptcy case.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In October 2023, the Company stated that it was pursuing the following four parallel and alternative pathways to achieve a comprehensive and final resolution of the talc claims: (i) the appeal of the LTL 2 dismissal decision; (ii) pursuing a consensual &#8220;prepackaged&#8221; bankruptcy case, as &#8220;strongly encouraged&#8221; by the Bankruptcy Court in its dismissal decision; (iii) aggressively litigating the talc claims in the tort system; and (iv) pursuing affirmative claims against experts for false and defamatory narratives regarding the Company&#8217;s talc powder products. In December 2023, LTL changed its state of formation to Texas and its name to LLT Management LLC ("LLT").</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Following the dismissal of LTL 2, new lawsuits were filed, cases across the country that had been stayed were reactivated, and trials have commenced. The majority of the cases are pending in federal court, organized in a multi-district litigation (MDL) in the United States District Court for the District of New Jersey. In the MDL, case-specific discovery proceeded. The MDL proceedings have been stayed by order of the bankruptcy court in the Red River Bankruptcy case discussed below. In March 2024, the court granted the Company's motion for a renewed Daubert hearing prior to the trial. The briefing on the renewed Daubert issues was completed in August 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In May 2024, the Company commenced a <ix:nonNumeric contextRef="c-990" name="jnj:LossContingencySolicitationPeriod" format="ixt-sec:durwordsen" id="f-3097">three-month</ix:nonNumeric> solicitation period of its proposed consensual &#8220;prepackaged&#8221; Chapter 11 bankruptcy plan (the &#8220;Proposed Plan&#8221;) for the comprehensive and final resolution of all current and future claims related to cosmetic talc in the United States, excluding claims related to mesothelioma or State consumer protection claims, in exchange for the payment by the Company of present value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-990" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="9" id="f-3098">6.475</ix:nonFraction>&#160;billion payable over <ix:nonNumeric contextRef="c-990" name="jnj:LossContingencyPaymentPeriod" format="ixt-sec:duryear" id="f-3099">25</ix:nonNumeric> years (nominal value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-990" decimals="-8" name="jnj:LossContingencyDamagesSoughtNominalValue" format="ixt:num-dot-decimal" scale="9" id="f-3100">8.0</ix:nonFraction>&#160;billion, discounted at a rate of <ix:nonFraction unitRef="number" contextRef="c-991" decimals="3" name="jnj:LossContingencyDiscountRate" scale="-2" id="f-3101">4.4</ix:nonFraction>%). The claims encompassed by the Proposed Plan constitute <ix:nonFraction unitRef="number" contextRef="c-990" decimals="4" name="jnj:TotalClaimsAgainstCompanyPercent" scale="-2" id="f-3102">99.75</ix:nonFraction>% of pending lawsuits against the Company relating to its talc powder products. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In August 2024, LLT engaged in a restructuring that resulted in the creation of three new Texas limited liability companies: (a) Red River Talc, LLC ("Red River"); (b) Pecos River Talc LLC ("Pecos River"); and (3) New Holdco (Texas) LLC. As a result of this restructuring, all claims related to ovarian and other gynecological cancers were separated and allocated to Red River, and mesothelioma, governmental unit and certain other claims were allocated to Pecos River.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In September 2024, while reiterating the Company's continued confidence in the safety of its talc products, Red River filed a voluntary petition with the United States Bankruptcy Court for the Southern District of Texas, seeking relief under Chapter 11 of the Bankruptcy Code (the Red River Bankruptcy Case), in furtherance of the Company's consensual "prepackaged" Proposed Plan. Red River also filed a motion for a temporary restraining order, seeking to extend the automatic stay to additional non-debtor entities. Prior to filing, the initial proposed plan was amended to, among other things, increase the proposed resolution by $<ix:nonFraction unitRef="usd" contextRef="c-992" decimals="-7" name="jnj:LossContingencyDamagesSoughtValueIncrease" format="ixt:num-dot-decimal" scale="9" id="f-3103">1.75</ix:nonFraction>&#160;billion.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">95</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-3093-4" continuedAt="f-3093-5"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Shortly after Red River filed its Chapter 11 petition, the U.S. Trustee's office filed a motion to transfer venue in the New Jersey Bankruptcy Court, and thereafter, a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. A coalition of six plaintiff law firms also filed a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. In September 2024, the Texas Bankruptcy Court entered a temporary order enjoining the commencement or prosecution of all claims against Red River and certain non-debtor entities, including the Company, until October 11, 2024. The temporary order was extended in October 2024 and again in December 2024. The commencement and prosecution of all claims against Red River and certain non-debtor entities are currently enjoined until March 15, 2025. Also in September 2024, the New Jersey Bankruptcy Court denied the U.S. Trustee's motion to transfer venue without prejudice. In October 2024, the Texas Bankruptcy Court denied the motion to transfer venue from Texas to New Jersey Bankruptcy Court. A consolidated hearing to address, among other things, the motions to dismiss and plan confirmation is currently scheduled to begin on February&#160;18,&#160;2025. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Mesothelioma and State consumer protection claims are being addressed outside the Proposed Plan. The Company separately has resolved <ix:nonFraction unitRef="number" contextRef="c-993" decimals="2" name="jnj:LossContingencyClaimsSettledPercent" scale="-2" id="f-3104">95</ix:nonFraction>% of the mesothelioma lawsuits filed to date and has resolved the State claims.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">To account for these settlements and the contemplated comprehensive resolution through the Proposed Plan, the Company recorded a cumulative incremental charge of approximately $<ix:nonFraction unitRef="usd" contextRef="c-994" decimals="-8" name="us-gaap:LossContingencyAccrualProvision" format="ixt:num-dot-decimal" scale="9" id="f-3105">5.0</ix:nonFraction>&#160;billion, through the fourth fiscal quarter 2024. As of December 29, 2024, the total present value of the reserve is approximately $<ix:nonFraction unitRef="usd" contextRef="c-995" decimals="-8" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="9" id="f-3106">11.6</ix:nonFraction>&#160;billion (or nominal value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-995" decimals="-8" name="jnj:LossContingencyAccrualNominalValue" format="ixt:num-dot-decimal" scale="9" id="f-3107">13.5</ix:nonFraction>&#160;billion), net of payments made in fiscal 2024. Approximately ten percent of the reserve is recorded as a current liability. The recorded amount remains the Company's best estimate of probable loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In February 2019, the Company&#8217;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition for relief under Chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#8217;s potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In its bankruptcy, Imerys proposed a Chapter 11 plan (the Imerys Plan) that contemplated all talc-related claims against it being channeled to a trust along with its alleged indemnification rights against the Company. Following confirmation and consummation of the plan, the trust would pay talc claims pursuant to proposed trust distribution procedures (the TDP) and then seek indemnification from the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In February 2021, Cyprus Mines Corporation (Cyprus), which had owned certain Imerys talc mines, filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan (the Cyprus Plan). The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain affiliated parties. Cyprus also asserts it has claims for indemnity against the Company arising out of talc personal injury claims. Under the Cyprus Plan, Cyprus would also contribute its alleged indemnification rights to the trust. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In September 2023, Imerys and Cyprus filed amended plans of reorganization. The amended plans contemplate a similar construct as the prior Imerys and Cyprus Plans, including all talc claims against Imerys and Cyprus (and certain other protected parties) being channeled to a trust along with Imerys&#8217;s and Cyprus&#8217;s alleged indemnification rights against the Company. The Company opposed both plans on the basis that the plans inflated Imerys&#8217;s and Cyprus&#8217;s liability for talc claims and had the potential effect of imposing those inflated liabilities on the Company through the Company&#8217;s alleged indemnification&#160;obligations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In July 2024, the Company, Imerys, and Cyprus and certain of their affiliates (including their parent entities), and the tort claimants' committees and future claimants' representatives appointed in their respective Chapter 11 cases entered into a global settlement agreement (the Imerys Settlement Agreement) to resolve their ongoing disputes, including disputes raised in the Imerys and Cyprus bankruptcies. In August 2024, Imerys and Cyprus filed amended Chapter 11 plans and disclosure statements incorporating the terms of the settlement with the Company. In October 2024, the Imerys Bankruptcy Court entered an order approving the Imerys Settlement Agreement (the Settlement Order). The effectiveness of certain provisions of the settlement, including mutual releases, are subject to certain conditions, including the Imerys and Cyprus Plans being accepted by a sufficient number and amount of voting creditors to be confirmed under the Bankruptcy Code. Certain insurers have appealed the Settlement Order and sought a stay of the order pending appeal, which the Court denied on January 13, 2025.  The briefing of the appeal in the District Court is scheduled to be completed in April 2025. On January 5, 2025, Imerys and Cyprus each filed a certification of voting results, indicating that their respective plan had been accepted by each voting class of creditors. A joint confirmation hearing for the plans is scheduled for April 2025.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">96</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-3093-5" continuedAt="f-3093-6"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S Baby Powder, and that purchasers of the Company&#8217;s shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. The case was stayed in May 2022 pursuant to the LTL Bankruptcy Case and was reopened in May 2023. In December 2023, the Court granted Plaintiff&#8217;s motion for class certification. In January 2024, Defendants filed a petition with the Third Circuit under Federal Rule of Civil Procedure 23(f) for permission to appeal the Court&#8217;s order granting class certification, and in February 2024, the Third Circuit granted Defendants' petition. In February 2024, fact discovery closed, the Court ordered the parties to mediate, and stayed the case pending mediation. In May 2024, the parties participated in an unsuccessful mediation. In June 2024, at the parties' request, the Court lifted the stay for certain limited discovery, but otherwise kept the stay in place pending a decision from the Third Circuit on the 23(f) petition. Briefing on the 23(f) petition was completed in September 2024. In January 2025, the Third Circuit listed the appeal for oral argument in March 2025.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:129%">Matters concerning opioids</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">Beginning in 2014 and continuing to the present, the Company and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to <ix:nonFraction unitRef="claimant" contextRef="c-996" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="f-3108">3,500</ix:nonFraction> lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children born with Neonatal Abstinence Syndrome (NAS); hospitals; and health insurers/payors. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">To date, the Company and JPI have litigated two of the cases to judgment and have prevailed in both, either at trial or on&#160;appeal. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">In July 2021, the Company announced finalization of an agreement to settle the state and subdivision claims for up to $<ix:nonFraction unitRef="usd" contextRef="c-997" decimals="-8" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="9" id="f-3109">5.0</ix:nonFraction>&#160;billion. Approximately <ix:nonFraction unitRef="number" contextRef="c-997" decimals="2" name="jnj:LossContingencyAccrualPaymentPercentage" scale="-2" id="f-3110">70</ix:nonFraction>% of the all-in settlement was paid by the end of fiscal fourth quarter 2024. A few government entities opted out of the settlement. In September 2024, the Company reached an agreement to resolve the hospital cases.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">The Company and JPI continue to defend the cases brought by the remaining government entity litigants as well as the cases brought by private litigants. In total, there are approximately 35 remaining opioid cases against the Company and JPI in various state courts, 390 remaining cases in the Ohio multi-district litigation (MDL), and 4 additional cases in other federal courts.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate Janssen Inc., and many other industry members, in Canada. That action was certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada in January 2025. Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. The proposed class action in Quebec on behalf of residents diagnosed with opioid use disorder was authorized to proceed against Janssen Inc. and other industry members in April 2024; and leave to appeal was denied in October 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">Starting in November 2019, a series of shareholder derivative complaints were filed against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches. As of September 2024, all the complaints had been dismissed, and all appeals&#160;exhausted.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product liability</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25, Contingencies. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">97</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-3093-6" continuedAt="f-3093-7"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock" id="f-3111" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The table below contains the most significant of these cases and provides the approximate number of plaintiffs in the United States with direct claims in pending lawsuits regarding injuries allegedly due to the relevant product or product category as of December&#160;29, 2024:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.340%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.419%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Product or product category</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of plaintiffs </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Body powders containing talc, primarily JOHNSON&#8217;S Baby Powder</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="claimant" contextRef="c-998" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="f-3112">62,830</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="claimant" contextRef="c-999" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="f-3113">60</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PINNACLE Acetabular Cup System</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="claimant" contextRef="c-1000" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="f-3114">910</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pelvic meshes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="claimant" contextRef="c-1001" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="f-3115">5,990</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ETHICON PHYSIOMESH Flexible Composite Mesh</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="claimant" contextRef="c-1002" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="f-3116">130</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">RISPERDAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="claimant" contextRef="c-1003" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="f-3117">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ELMIRON</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="claimant" contextRef="c-1004" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="f-3118">2,170</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. There may be additional claims that have not yet been filed.</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MedTech</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DePuy ASR XL Acetabular System and ASR Hip Resurfacing System</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Ireland, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States. This settlement program has resolved more than <ix:nonFraction unitRef="claimant" contextRef="c-1005" decimals="0" name="jnj:Numberofpatientsinsettlement" format="ixt:num-dot-decimal" scale="0" id="f-3119">10,000</ix:nonFraction> claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">DePuy PINNACLE Acetabular Cup System </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Ethicon Pelvic Mesh </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicon&#8217;s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company&#8217;s accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon&#8217;s pelvic mesh devices have been commenced in </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">98</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-3093-7" continuedAt="f-3093-8"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, and Ireland, and class actions in Israel, Australia, Canada and South Africa. The vast majority of these actions are now resolved. The Company has established accruals with respect to product liability litigation associated with Ethicon&#8217;s pelvic mesh products.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Ethicon Physiomesh</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately <ix:nonFraction unitRef="cases" contextRef="c-1006" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:num-dot-decimal" scale="0" id="f-3120">3,600</ix:nonFraction> Physiomesh cases (covering approximately <ix:nonFraction unitRef="claimant" contextRef="c-1006" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="f-3121">4,300</ix:nonFraction> plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes <ix:nonFraction unitRef="cases" contextRef="c-1007" decimals="0" name="jnj:LossContingencyNumberOfClaimsWithinSettlementAgreement" format="ixt:num-dot-decimal" scale="0" id="f-3122">3,729</ix:nonFraction> cases in the MDL and MCL. Other than a small number of cases still pending in the MDL, all Physiomesh matters in the United States have been resolved or are undergoing formal review for purposes of settlement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Claims have also been filed against Ethicon and the Company alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Ethicon and the Company also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In October 2022, an agreement in principle, subject to various conditions, was reached to settle the majority of the pending cases involving Proceed, Proceed Ventral Patch, Prolene Hernia System and related multi-layered mesh products, as well as a number of unfiled claims. All litigation activities in the two New Jersey MCLs are stayed pending effectuation of the proposed settlement. Future cases that are filed in the New Jersey MCLs will be subject to docket control orders requiring early expert reports and discovery requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has established accruals with respect to product liability litigation associated with Ethicon Physiomesh Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Innovative Medicine</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">RISPERDAL</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and the Company arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. The Company continues to defend RISPERDAL product liability lawsuits, and continues to evaluate potential costs related to those claims. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $<ix:nonFraction unitRef="usd" contextRef="c-1008" decimals="-8" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="9" id="f-3123">8.0</ix:nonFraction>&#160;billion of punitive damages related to one plaintiff, which the trial judge reduced to $<ix:nonFraction unitRef="usd" contextRef="c-1009" decimals="-5" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="f-3124">6.8</ix:nonFraction>&#160;million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company's accruals.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ELMIRON</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">99</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-3093-8" continuedAt="f-3093-9"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Jersey (MDL). In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. The Company continues to defend ELMIRON product liability lawsuits and continues to evaluate potential costs related to those claims. All U.S. based ELMIRON matters have been resolved or are undergoing formal review for purposes of settlement. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Intellectual property</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Certain subsidiaries of the Company are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the scope and/or validity of patents that relate to various products and allegations that certain of the Company&#8217;s products infringe the intellectual property rights of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. </span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Innovative Medicine - litigation against filers of abbreviated new drug applications (ANDAs)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company&#8217;s subsidiaries have brought lawsuits against generic companies that have filed ANDAs with the U.S. FDA (or similar lawsuits outside of the United States) seeking to market generic versions of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These lawsuits typically include allegations of non-infringement and/or invalidity of patents listed in FDA&#8217;s publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations&#8221; (commonly known as the Orange Book). In each of these lawsuits, the Company&#8217;s subsidiaries are seeking an order enjoining the defendant from marketing a generic version of a product before the expiration of the relevant patents (Orange Book Listed Patents). In the event the Company&#8217;s subsidiaries are not successful in an action, or any automatic statutory stay expires before the court rulings are obtained, the generic companies involved would have the ability, upon regulatory approval, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company&#8217;s subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Inter Partes Review (IPR) process with the United States Patent and Trademark Office (USPTO), created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits to challenge the applicable patents.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">XARELTO</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning in March 2021, Janssen Pharmaceuticals, Inc.; Bayer Pharma AG; Bayer AG; and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddy&#8217;s Laboratories, Inc.; Dr. Reddy&#8217;s Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mankind Pharma Limited; Apotex Inc.; Apotex Corp.; Auson Pharmaceuticals Inc.; Shanghai Auson Pharmaceuticals Co. Ltd.; Cipla Ltd.; Cipla USA Inc.; InvaGen Pharmaceuticals, Inc.; Prinston Pharmaceuticals, Inc.; Ascent Pharmaceuticals, Inc.; and Hetero Labs Limited. In October 2024, the Company entered into a confidential settlement agreement with Auson Pharmaceuticals Inc. and Shanghai Auson Pharmaceuticals Co., Ltd. and the case was dismissed. In November 2024, the Company entered into confidential settlement agreements with Ascent Pharmaceuticals Inc. that resulted in dismissal of litigation against Ascent Pharmaceuticals, Inc. and Hetero Labs Limited. In January 2025, the Company entered into a confidential settlement agreement with Prinston Pharmaceutical, Inc. (as to U.S. Patent No. 9,539,218). The following U.S. patents are included in one or more cases: 9,539,218 and 10,828,310. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">U.S. Patent No. 10,828,310 was also under consideration by the USPTO in an IPR proceeding. In July 2023, the USPTO issued a final written decision finding the claims of the patent invalid. In September 2023, Bayer Pharma AG filed an appeal to the U.S. Court of Appeals for the Federal Circuit.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">INVEGA SUSTENNA </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">100</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-3093-9" continuedAt="f-3093-10"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; Accord Healthcare, Inc.; Qilu Pharmaceutical Co. Ltd.; and Qilu Pharma Inc. The following U.S. patent is included in one or more cases: 9,439,906. In October 2020, the district court issued a decision in the case against Teva Pharmaceuticals USA, Inc., finding that United States Patent No. 9,439,906 is not invalid. Teva previously stipulated to infringement. Teva appealed the decision, and, in April 2024, the United States Court of Appeals for the Federal Circuit vacated and remanded the case to the district court for further proceedings. In November 2024, the district court issued its decision on remand, finding that United States Patent No. 9,439,906 is not invalid. Teva appealed to the Court of Appeals for the Federal Circuit, and oral argument is scheduled for April 2025. In February 2024, the district court issued a decision in the case against Tolmar Inc. finding that United States Patent No. 9,439,906 is not invalid. Tolmar previously stipulated to infringement. Tolmar has appealed the&#160;decision.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning in February 2018, Janssen Inc. and Janssen Pharmaceutica NV initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the listed patent. The following entities are named defendants: Pharmascience Inc. and Apotex Inc. The following Canadian patent is included in one or more cases: 2,655,335. In June 2024, the Supreme Court dismissed the Apotex case. In September 2024, the Supreme Court granted Pharmascience's motion to appeal the Federal Court's decision that the 2,655,335 Patent is not invalid.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">INVEGA TRINZA </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning in September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp; Development, LLC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA TRINZA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Mylan Laboratories Limited; Mylan Pharmaceuticals Inc.; and Mylan Institutional LLC. The following U.S. patent is included in one or more cases: 10,143,693. In May 2023, the District Court issued a decision finding that Mylan&#8217;s proposed generic product infringes the asserted patent and that the patent is not invalid. Mylan has appealed the decision. Oral argument before the Court of Appeals for the Federal Circuit was held in February 2025.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SYMTUZA </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning in November 2021, Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company, Gilead Sciences, Inc. and Gilead Sciences Ireland UC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SYMTUZA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; MSN Laboratories Private Ltd.; MSN Life Sciences Private Ltd.; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 10,039,718 and 10,786,518. A trial is scheduled to begin in February 2025.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ERLEADA </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning in May 2022, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc. (collectively, Janssen), Sloan Kettering Institute for Cancer Research (SKI) and The Regents of the University of California filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of ERLEADA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Zydus Worldwide DMCC; Zydus Pharmaceuticals (USA), Inc.; Zydus Lifesciences Limited; Hetero Labs Limited Unit V; and Hetero USA, Inc. The following U.S. patents are included in one or more cases: 9,481,663; 9,884,054; 10,052,314 (which reissued as RE49,353); 10,702,508; 10,849,888; 8,445,507; 8,802,689; 9,388,159; 9,987,261; RE49,353; and 11,963,952. In October 2024, Janssen, The Regents of the University of California, SKI, Hetero Labs Limited Unit V, and Hetero USA, Inc. entered into a confidential settlement, and the case was dismissed. In November 2024, Janssen, The Regents of the University of California, Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA), Inc., and Zydus Lifesciences Limited entered into confidential settlements, and the cases were dismissed. </span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SPRAVATO </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning in May 2023, Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SPRAVATO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sandoz </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">101</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-3093-10" continuedAt="f-3093-11"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Inc.; Hikma Pharmaceuticals Inc. USA; Hikma Pharmaceuticals PLC; and Alkem Laboratories Ltd. The following U.S. patents are included in one or more cases: 10,869,844; 11,173,134; 11,311,500; and 11,446,260. </span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">INVOKANA </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning in January 2024, Janssen Inc. and Mitsubishi Tanabe Pharma Corporation initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who filed ANDSs seeking approval to market generic versions of INVOKANA before expiration of the listed patents. The following entities are named defendants: Jamp Pharma Corporation and Apotex Inc. The following Canadian patents are included in one or more cases: 2,534,024 and 2,671,357. Trial in the Jamp action is scheduled for September 2025, and trial in the Apotex action is scheduled for December 2025.</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MedTech </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In March 2016, Abiomed, Inc. (Abiomed) filed a declaratory judgment action against Maquet Cardiovascular LLC (Maquet) in U.S. District Court for the District of Massachusetts seeking a declaration that the Impella does not infringe certain Maquet patents, currently U.S. Patent Nos. 7,022,100 (&#8217;100); 8,888,728; 9,327,068; 9,545,468; 9,561,314; and 9,597,437. Maquet counterclaimed for infringement of each of those patents. After claim construction, Maquet alleged infringement of only the &#8217;100 patent. In September 2021, the court granted Abiomed&#8217;s motion for summary judgment of non-infringement of the &#8217;100 patent, and in September 2023, the district court entered final judgment in favor of Abiomed on all patents-in-suit. Maquet&#160;appealed.</span></div><div><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:142%">Government proceedings</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Like other companies in the pharmaceutical and medical technologies industries, the Company and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:130%">MedTech</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In July 2018, the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp; Johnson do Brasil Ind&#250;stria e Com&#233;rcio de Produtos para Sa&#250;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice (DOJ) and the United States Securities and Exchange Commission. The Company has been informed DOJ has closed its investigation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In July 2023, the DOJ issued Civil Investigative Demands to the Company, Johnson &amp; Johnson Surgical Vision, Inc., and Johnson &amp; Johnson Vision Care, Inc. (collectively, J&amp;J Vision) in connection with a civil investigation under the False Claims Act relating to free or discounted intraocular lenses and equipment used in eye surgery, such as phacoemulsification and laser systems. J&amp;J Vision has begun producing documents and information responsive to the Civil Investigative Demands. J&amp;J Vision is in ongoing discussions with the DOJ regarding its inquiry.</span></div><div><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Innovative Medicine</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and trial commenced in May 2024. On June 13, 2024, a jury found no liability regarding the anti-kickback violations but found liability for a portion of the off-label promotion claims. The Company is pursuing post-trial briefing challenging the verdict on the off-label claims.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">102</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-3093-11" continuedAt="f-3093-12"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">General litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the Company&#8217;s agreement to implement remediation activities at designated hazardous waste sites or to reimburse the government or third parties for the costs they have incurred in performing remediation as such&#160;sites.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Court&#8217;s decision. In June 2023, defendants filed a petition for a writ of certiorari to the United States Supreme Court. In June 2024, the Supreme Court vacated the D.C. Circuit's decision and remanded the case to the D.C. Circuit. Oral argument was held in November 2024. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In February 2024, a putative class action was filed against the Company, the Pension &amp; Benefits Committee of Johnson &amp; Johnson (Committee), and certain named officers and employees, in United States District Court for the District of New Jersey. In May 2024, the plaintiff filed an amended complaint against the Company and the Committee. The complaint alleges that defendants breached fiduciary duties under the Employee Retirement Income Security Act (ERISA) by allegedly mismanaging the Company&#8217;s prescription-drug benefits program. The complaint seeks damages and other relief. In January 2025, the Court granted in part and denied in part defendants&#8217; motion to dismiss.</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MedTech</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#8217;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants&#8217; motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial occurred in January 2024. In September 2024, the court found liability with respect to certain claims and no liability with respect to other claims. The Company has appealed the decision. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc (BWI) in the United States District Court for the Central District of California. The complaint alleges that certain of BWI's business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. Trial is scheduled for April 2025. </span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Innovative Medicine</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to the Company and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssen&#8217;s REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand. Janssen is in ongoing discussions with the FTC staff regarding its inquiry. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In February 2022, the United States Federal Trade Commission (FTC) issued Civil Investigative Demands to Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether advertising practices for REMICADE violate federal law. Janssen has produced documents and information responsive to the Civil Investigative Demands. In January 2025, the FTC Bureau of Consumer Protection informed Janssen that it was closing its investigation.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">103</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-3093-12" continuedAt="f-3093-13"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In September 2024, the district court granted plaintiff's motion for class certification. Trial is scheduled for March 2026.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">In December 2023, a putative class action lawsuit was filed against the Company and Janssen Biotech Inc. (collectively Janssen) in the United States District Court for the Eastern District of Virginia. The complaint alleges that Janssen violated federal and state antitrust laws and other state laws by delaying biosimilar competition with STELARA through Janssen's enforcement of patent rights covering STELARA. The complaint seeks damages and other relief. In February 2024, plaintiffs filed an amended complaint, which Janssen moved to dismiss in March 2024. In August 2024, the court granted in part and denied in part Janssen's motion to dismiss. </span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%"><ix:continuation id="f-3093-13">In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc., Janssen Research &amp; Development, LLC, and Johnson &amp; Johnson (collectively, Janssen) were served with a qui tam complaint on behalf of the United States, certain states, and the District of Columbia. The complaint alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct sales and reimbursement programs. At this time, the federal and state governments have declined to intervene. In December 2021, the United States District Court for the District of New Jersey denied Janssen's motion to dismiss.</ix:continuation> </span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_229"></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">20.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-3125" continuedAt="f-3125-1" escape="true">Restructuring</ix:nonNumeric></span></div><ix:continuation id="f-3125-1" continuedAt="f-3125-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">In fiscal 2023, the Company commenced restructuring actions within its Innovative Medicine and MedTech segments. The amounts and details of the current year programs are included below.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">In fiscal 2023, the Company completed a prioritization of its research and development (R&amp;D) investment within its Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within certain therapeutic areas. The R&amp;D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. Pre-tax Restructuring expenses of $<ix:nonFraction unitRef="usd" contextRef="c-1010" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="f-3126">0.1</ix:nonFraction>&#160;billion in the fiscal year 2024, included the termination of partnered and non-partnered development program costs, asset impairments and asset divestments. Pre-tax Restructuring expenses of $<ix:nonFraction unitRef="usd" contextRef="c-1011" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="f-3127">0.5</ix:nonFraction>&#160;billion in the fiscal year 2023, included the termination of partnered and non-partnered development program costs and asset impairments. Total project costs of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1012" decimals="-8" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="9" id="f-3128">0.6</ix:nonFraction>&#160;billion have been recorded since the restructuring was announced. The program was completed in the fiscal fourth quarter of 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense of $<ix:nonFraction unitRef="usd" contextRef="c-1013" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="f-3129">0.2</ix:nonFraction>&#160;billion in the fiscal year 2024 primarily included costs related to market and product exits. The pre-tax restructuring expense of $<ix:nonFraction unitRef="usd" contextRef="c-1014" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="f-3130">0.3</ix:nonFraction>&#160;billion in the fiscal year 2023 primarily included inventory and instrument charges related to market and product exits. Total project costs of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1015" decimals="-8" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="9" id="f-3131">0.5</ix:nonFraction>&#160;billion have been recorded since the restructuring was announced. The estimated costs of the total program are between $<ix:nonFraction unitRef="usd" contextRef="c-1016" decimals="-8" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="9" id="f-3132">0.7</ix:nonFraction>&#160;billion - $<ix:nonFraction unitRef="usd" contextRef="c-1017" decimals="-8" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="9" id="f-3133">0.8</ix:nonFraction>&#160;billion and is expected to be completed by the end of fiscal year 2025.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="f-3134" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The following table summarizes the restructuring expenses for the fiscal years 2024 and 2023:</span></div><div style="margin-bottom:4pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.173%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Pre-tax Dollars in Millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Innovative Medicine Segment</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-880" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-3135">102</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-882" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-3136">479</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MedTech Segment</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-881" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-3137">167</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-883" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-3138">319</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total Programs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-886" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-3139">269</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-887" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-3140">798</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">The fiscal year of 2024 included $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-3141">102</ix:nonFraction>&#160;million in Restructuring on the Consolidated Statement of Earnings. The fiscal year of 2023 included $<ix:nonFraction unitRef="usd" contextRef="c-1018" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-3142">449</ix:nonFraction>&#160;million in Restructuring and $<ix:nonFraction unitRef="usd" contextRef="c-1019" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-3143">30</ix:nonFraction>&#160;million in Cost of products sold on the Consolidated Statement of Earnings.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">The fiscal year of 2024 included $<ix:nonFraction unitRef="usd" contextRef="c-1020" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-3144">132</ix:nonFraction>&#160;million in Restructuring and $<ix:nonFraction unitRef="usd" contextRef="c-1021" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-3145">35</ix:nonFraction>&#160;million in Cost of products sold on the Consolidated Statement of Earnings. The fiscal year of 2023 Included $<ix:nonFraction unitRef="usd" contextRef="c-1022" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-3146">40</ix:nonFraction>&#160;million in Restructuring and $<ix:nonFraction unitRef="usd" contextRef="c-1023" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-3147">279</ix:nonFraction>&#160;million in Cost of products sold on the Consolidated Statement of Earnings.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:continuation id="f-3125-2">Restructuring reserves as of December 29, 2024 and December 31, 2023 were insignificant.</ix:continuation> </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">104</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_232"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">21.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="f-3148" continuedAt="f-3148-1" escape="true">Kenvue separation and discontinued operations</ix:nonNumeric></span></div><ix:continuation id="f-3148-1" continuedAt="f-3148-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The results of the Consumer Health business (previously reported as a separate business segment) have been reflected as discontinued operations in the Company&#8217;s consolidated statements of earnings as Net earnings from discontinued operations, net of taxes through August 23, 2023, the date of the exchange offer. Prior periods have been recast to reflect this&#160;presentation. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On May 15, 2024, the Company issued $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-8" name="us-gaap:CommercialPaper" format="ixt:num-dot-decimal" scale="9" id="f-3149">3.6</ix:nonFraction>&#160;billion aggregate principal amount of commercial paper and received $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-8" name="us-gaap:ProceedsFromIssuanceOfCommercialPaper" format="ixt:num-dot-decimal" scale="9" id="f-3150">3.6</ix:nonFraction>&#160;billion of net cash proceeds to be used for general corporate purposes. On May 17, 2024, the Company completed a Debt-for-Equity Exchange of its remaining <ix:nonFraction unitRef="shares" contextRef="c-186" decimals="INF" name="jnj:DebtForEquityExchangeSharesExchanged" format="ixt:num-dot-decimal" scale="0" id="f-3151">182,329,550</ix:nonFraction> shares of Kenvue Common Stock for the outstanding Commercial Paper. Upon completion of the Debt-for-Equity Exchange, the Commercial Paper was satisfied and discharged and the Company no longer owns any shares of Kenvue Common Stock. This exchange resulted in a loss of approximately $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-8" name="jnj:DebtForEquityExchangeLossOnSharesExchanged" format="ixt:num-dot-decimal" scale="9" id="f-3152">0.4</ix:nonFraction>&#160;billion recorded in Other (income) expense. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="c-41" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-3153">198,734,444</ix:nonFraction> shares of its common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-42" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-3154">0.01</ix:nonFraction> per share (the &#8220;Kenvue Common Stock&#8221;), at an initial public offering of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-42" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-3155">22.00</ix:nonFraction> per share for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-8" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="9" id="f-3156">4.2</ix:nonFraction>&#160;billion. The excess of the net proceeds from the IPO over the net book value of the Johnson &amp; Johnson divested interest was $<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-8" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" format="ixt:num-dot-decimal" scale="9" id="f-3157">2.5</ix:nonFraction>&#160;billion and was recorded to additional paid-in capital. As of the closing of the IPO, Johnson &amp; Johnson owned approximately <ix:nonFraction unitRef="number" contextRef="c-44" decimals="3" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" scale="-2" id="f-3158">89.6</ix:nonFraction>% of the total outstanding shares of Kenvue Common Stock and at July 2, 2023, the non-controlling interest of $<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-8" name="us-gaap:CommonStockValueOutstanding" format="ixt:num-dot-decimal" scale="9" id="f-3159">1.3</ix:nonFraction>&#160;billion associated with Kenvue was reflected in equity attributable to non-controlling interests in the consolidated balance sheet in the fiscal second quarter of 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On August 23, 2023, Johnson &amp; Johnson completed the disposition of an additional <ix:nonFraction unitRef="number" contextRef="c-46" decimals="3" name="jnj:OwnershipPercentageSplitOffPercent" scale="-2" id="f-3160">80.1</ix:nonFraction>% ownership of Kenvue Common Stock through an exchange offer, which resulted in Johnson &amp; Johnson acquiring <ix:nonFraction unitRef="shares" contextRef="c-1024" decimals="0" name="jnj:StockIssuedDuringPeriodSharesExchangeOffer" format="ixt:num-dot-decimal" scale="0" id="f-3161">190,955,436</ix:nonFraction> shares of the Company&#8217;s common stock in exchange for <ix:nonFraction unitRef="shares" contextRef="c-1025" decimals="0" name="jnj:StockIssuedDuringPeriodSharesExchangeOffer" format="ixt:num-dot-decimal" scale="0" id="f-3162">1,533,830,450</ix:nonFraction> shares of Kenvue Common Stock. The $<ix:nonFraction unitRef="usd" contextRef="c-1026" decimals="-8" name="jnj:ExchangeOfStockCommonStockValueReceived" format="ixt:num-dot-decimal" scale="9" id="f-3163">31.4</ix:nonFraction>&#160;billion of Johnson &amp; Johnson common stock received in the exchange offer is recorded in Treasury stock. Following the exchange offer, the Company owned <ix:nonFraction unitRef="number" contextRef="c-47" decimals="3" name="jnj:ExchangeOfStockPercentageOwnershipAfterTransaction" scale="-2" id="f-3164">9.5</ix:nonFraction>% of the total outstanding shares of Kenvue Common Stock that was recorded in other assets within continuing operations at the fair market value of $<ix:nonFraction unitRef="usd" contextRef="c-1027" decimals="-8" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="9" id="f-3165">4.3</ix:nonFraction>&#160;billion as of August 23, 2023. Subsequent changes are reflected in other income/expense and amounted to $<ix:nonFraction unitRef="usd" contextRef="c-1028" decimals="-8" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="9" id="f-3166">0.4</ix:nonFraction>&#160;billion expense through December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Johnson &amp; Johnson divested net assets of $<ix:nonFraction unitRef="usd" contextRef="c-1029" decimals="-8" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:num-dot-decimal" scale="9" id="f-3167">11.6</ix:nonFraction>&#160;billion as of August 23, 2023, and the accumulated other comprehensive loss attributable to the Consumer Health business at that date was $<ix:nonFraction unitRef="usd" contextRef="c-1029" decimals="-8" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="9" id="f-3168">4.3</ix:nonFraction>&#160;billion. Additionally, at the date of the exchange offer, Johnson &amp; Johnson decreased the non-controlling interest by $<ix:nonFraction unitRef="usd" contextRef="c-1030" decimals="-8" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" format="ixt:num-dot-decimal" scale="9" id="f-3169">1.2</ix:nonFraction>&#160;billion to record the deconsolidation of Kenvue. This resulted in a non-cash gain on the exchange offer of $<ix:nonFraction unitRef="usd" contextRef="c-1029" decimals="-8" name="jnj:NoncashOrPartNoncashTransactionGainOnExchangeOfStock" format="ixt:num-dot-decimal" scale="9" id="f-3170">21.0</ix:nonFraction>&#160;billion that was recorded in Net earnings from discontinued operations, net of taxes in the consolidated statements of earnings for the fiscal third quarter of 2023. This one-time gain includes a gain of $<ix:nonFraction unitRef="usd" contextRef="c-1031" decimals="-8" name="jnj:NoncashOrPartNoncashTransactionGainOnExchangeOfStock" format="ixt:num-dot-decimal" scale="9" id="f-3171">2.8</ix:nonFraction>&#160;billion on the Kenvue Common Stock retained by Johnson &amp; Johnson. The gain on the exchange offer qualifies as a tax-free transaction for U.S. federal income tax purposes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Also in connection with the separation, Johnson &amp; Johnson and Kenvue entered into a separation agreement and also entered into various other agreements that provide for certain transactions to effect the transfer of the assets and liabilities of the Consumer Health business to Kenvue and to govern various interim and ongoing relationships between Kenvue and Johnson &amp; Johnson following the completion of the Kenvue IPO, including transition services agreements (TSAs), transition manufacturing agreements (TMAs), trademark agreements, intellectual property agreements, an employee matters agreement, and a tax matters agreement. Under the TSAs, Johnson &amp; Johnson will provide Kenvue various services and, similarly, Kenvue will provide Johnson &amp; Johnson various services. The provision of services under the TSAs generally will terminate within <ix:nonNumeric contextRef="c-1032" name="jnj:DiscontinuedOperationsTransitionServiceAgreementTerm" format="ixt-sec:durmonth" id="f-3172">24</ix:nonNumeric> months following the Kenvue IPO. Additionally, Johnson &amp; Johnson and Kenvue entered into TMAs pursuant to which Johnson &amp; Johnson will manufacture and supply to Kenvue certain products and, similarly, Kenvue will manufacture and supply to Johnson &amp; Johnson certain products. The terms of the TMAs range in initial duration from <ix:nonNumeric contextRef="c-1033" name="jnj:DiscontinuedOperationTransitionManufacturingAgreementTerm" format="ixt-sec:durmonth" id="f-3173">3</ix:nonNumeric> months to <ix:nonNumeric contextRef="c-1034" name="jnj:DiscontinuedOperationTransitionManufacturingAgreementTerm" format="ixt-sec:duryear" id="f-3174">5</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Amounts related to the TSAs and TMAs included in the consolidated statements of earnings were immaterial for both fiscal years 2024 and 2023. Additionally, the amounts due to and from Kenvue for the above agreements was not material as of December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The results of the Consumer Health business (previously reported as a separate business segment), as well as the associated gain, have been reflected as discontinued operations in the Company&#8217;s consolidated statements of earnings as Net earnings from discontinued operations, net of taxes. As a result of the separation of Kenvue, Johnson &amp; Johnson incurred separation costs of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="jnj:DiscontinuedOperationsSeparationCostsIncurred" format="ixt:num-dot-decimal" scale="6" id="f-3175">145</ix:nonFraction>&#160;million in the fiscal year 2024, which was included in Net Earnings and incurred separation costs of $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="jnj:DiscontinuedOperationsSeparationCostsIncurred" format="ixt:num-dot-decimal" scale="6" id="f-3176">986</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-405" decimals="-6" name="jnj:DiscontinuedOperationsSeparationCostsIncurred" format="ixt:num-dot-decimal" scale="6" id="f-3177">1,089</ix:nonFraction>&#160;million in the fiscal years 2023 and 2022, respectively, which were included in Net earnings from discontinued operations, net of taxes. These costs were primarily related to external advisory, legal, accounting, contractor and other </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">105</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-3148-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">incremental costs directly related to separation activities. In the fiscal 2022, as part of the planned separation of the Company&#8217;s Consumer Health business, the Company recognized approximately $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-8" name="jnj:DiscontinuedOperationIncrementalTaxCost" format="ixt:num-dot-decimal" scale="9" id="f-3178">0.5</ix:nonFraction>&#160;billion in net incremental tax costs. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="f-3179" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Details of Net Earnings from Discontinued Operations, net of taxes are as follows:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.280%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.765%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;2023</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales to customers</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="f-3180">10,036</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="f-3181">14,953</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of products sold</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="6" id="f-3182">4,369</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="6" id="f-3183">6,494</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-3184">5,667</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-3185">8,459</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, marketing and administrative expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-3186">3,085</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-3187">4,519</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="jnj:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" scale="6" id="f-3188">258</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="jnj:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" scale="6" id="f-3189">468</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest Income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome" scale="6" id="f-3190">117</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome" format="ixt:fixed-zero" scale="6" id="f-3191">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest expense, net of portion capitalized</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" scale="6" id="f-3192">199</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" format="ixt:fixed-zero" scale="6" id="f-3193">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (income) expense, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="jnj:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-3194">1,092</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="jnj:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-3195">1,060</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Gain) on separation of Kenvue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-3196">20,984</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" format="ixt:fixed-zero" scale="6" id="f-3197">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restructuring</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="jnj:DisposalGroupIncludingDiscontinuedOperationRestructuringExpense" format="ixt:fixed-zero" scale="6" id="f-3198">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="jnj:DisposalGroupIncludingDiscontinuedOperationRestructuringExpense" scale="6" id="f-3199">46</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Earnings from Discontinued Operations Before Provision for Taxes on Income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="6" id="f-3200">22,134</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="6" id="f-3201">2,366</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for taxes on income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="6" id="f-3202">307</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="6" id="f-3203">795</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net earnings from Discontinued Operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-3204">21,827</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-3205">1,571</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">The Company ceased consolidating the results of the Consumer Health business on August 23, 2023, the date of the exchange offer, but continued to reflect any separation costs incurred as part of discontinued operations through the end of the fiscal fourth quarter.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table presents depreciation, amortization and capital expenditures of the discontinued operations related to&#160;Kenvue:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.173%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;2023</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and Amortization</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" scale="6" id="f-3206">383</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" scale="6" id="f-3207">641</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditures</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:CapitalExpenditureDiscontinuedOperations" scale="6" id="f-3208">162</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:CapitalExpenditureDiscontinuedOperations" scale="6" id="f-3209">303</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">106</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_238"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">To the Board of Directors and Shareholders of Johnson &amp; Johnson</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">We have audited the accompanying consolidated balance sheets of Johnson &amp; Johnson and its subsidiaries (the &#8220;Company&#8221;) as of December 29, 2024 and December 31, 2023, and the related consolidated statements of earnings, of comprehensive income, of equity and of cash flows for each of the three fiscal years in the period ended December 29, 2024, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). We also have audited the Company's internal control over financial reporting as of December 29, 2024, based on criteria established in </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%">Internal Control - Integrated Framework</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 29, 2024 and December 31, 2023, and the results of its operations and its cash flows for each of the three fiscal years in the period ended December 29, 2024 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 29, 2024, based on criteria established in </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%">Internal Control - Integrated Framework</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> (2013) issued by the COSO.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Basis for Opinions</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s report on internal control over financial reporting. Our responsibility is to express opinions on the Company&#8217;s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">As described in Management&#8217;s report on internal control over financial reporting, management has excluded Shockwave Medical, Inc., (&#8220;Shockwave&#8221;) from its assessment of internal control over financial reporting as of December 29, 2024 because it was acquired by the Company in a purchase business combination during 2024. We have also excluded Shockwave from our audit of internal control over financial reporting. Shockwave is a wholly-owned subsidiary whose total assets and total sales excluded from management&#8217;s assessment and our audit of internal control over financial reporting represent less than 1% of each of the related consolidated financial statement amounts as of and for the fiscal year ended December 29, 2024.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">107</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">U.S. Innovative Medicine Rebate Reserves &#8211; Managed Care, Medicare and Medicaid</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">As described in Note 1 to the consolidated financial statements, the Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied. Rebates and discounts provided to customers are accounted for as variable consideration and recorded as a reduction in sales. The liability for such rebates and discounts is recognized within Accrued rebates, returns, and promotions on the consolidated balance sheet. A significant portion of the liability related to rebates is from the sale of pharmaceutical products within the U.S., primarily the Managed Care, Medicare and Medicaid programs, which amounted to $12.3 billion as of December 29, 2024. For significant rebate programs, which include the U.S. Managed Care, Medicare and Medicaid rebate programs, rebates and discounts estimated by management are based on contractual terms, historical experience, patient outcomes, trend analysis, and projected market conditions in the various markets served. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The principal considerations for our determination that performing procedures relating to U.S. Innovative Medicine rebate reserves - Managed Care, Medicare and Medicaid is a critical audit matter are (i) the significant judgment by management due to the significant measurement uncertainty when developing the estimate of these reserves and (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating the assumptions related to contractual terms, historical experience, patient outcomes, trend analysis, and projected market conditions in the U.S. pharmaceutical market. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management&#8217;s estimate of the U.S. Innovative Medicine rebate reserves - Managed Care, Medicare and Medicaid, including controls over the assumptions used to estimate these rebates. These procedures also included, among others (i) developing an independent estimate of the rebates by utilizing third party information on price and market conditions in the U.S. pharmaceutical market, the terms of the specific rebate programs, and the historical experience and trend analysis of actual rebate claims paid; (ii) testing, on a sample basis, rebate claims processed by the Company, including evaluating those claims for consistency with the contractual and mandated terms of the Company&#8217;s rebate arrangements; and (iii) comparing the independent estimates to management&#8217;s estimates to evaluate the reasonableness of management&#8217;s estimates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">108</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Litigation Contingencies &#8211; Talc</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">As described in Notes 1 and 19 to the consolidated financial statements, the Company records accruals for loss contingencies associated with legal matters, including talc, when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. To the extent adverse awards, judgments, or verdicts have been rendered against the Company, management does not record an accrual until a loss is determined to be probable and can be reasonably estimated. For these matters, management is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors, including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. Management continues to believe that the Company has strong legal grounds to contest the talc verdicts it has appealed. Notwithstanding management&#8217;s confidence in the safety of the Company&#8217;s talc products, in certain circumstances the Company has settled cases. In May 2024, the Company proposed a consensual &#8220;prepackaged&#8221; Chapter 11 bankruptcy plan (the &#8220;Proposed Plan&#8221;) for the final resolution of all current and future claims related to cosmetic talc in the United States, excluding claims related to mesothelioma or State consumer protection claims. In September 2024, the Company&#8217;s subsidiary Red River Talc, LLC filed a voluntary petition, seeking relief under Chapter 11 of the Bankruptcy Code, in furtherance of the Company&#8217;s consensual &#8220;prepackaged&#8221; Proposed Plan. As of December 29, 2024, the total present value of the reserve to resolve the talc claims is approximately $11.6 billion, of which approximately ten percent is recorded as a current liability. The recorded amount remains the Company's best estimate of probable loss. The Company is unable to estimate the possible loss or range of loss beyond the amounts accrued.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The principal considerations for our determination that performing procedures relating to the litigation contingencies - talc is a critical audit matter are (i) the significant judgment by management when assessing the likelihood of a loss being incurred for the remaining unresolved talc claims, when determining whether a reasonable estimate of the loss or range of loss for the remaining unresolved talc claims can be made, and when determining the timing of settlement payments for the remaining unresolved talc claims, and (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating audit evidence related to management&#8217;s assessment of the loss contingencies associated with the talc litigation. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management&#8217;s assessment of the litigation contingencies &#8211; talc, including controls over determining whether a loss is probable and whether the amount of loss can be reasonably estimated, as well as financial statement disclosures. These procedures also included, among others (i) gaining an understanding of the Company&#8217;s process around the accounting and reporting for the talc litigation; (ii) obtaining and evaluating certain executed settlement agreements related to the talc litigation; (iii) discussing the status of significant known actual and potential litigation and settlements activity with the Company&#8217;s in-house legal counsel, as well as external counsel when deemed necessary; (iv) obtaining and evaluating the letters of audit inquiry with internal and external legal counsel related to the talc litigation; (v) evaluating the reasonableness of management&#8217;s assessment regarding whether an unfavorable outcome is reasonably possible or probable and reasonably estimable; and (vi) evaluating the sufficiency of the Company&#8217;s litigation contingencies disclosures.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">/s/</span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"> <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-3210">PricewaterhouseCoopers LLP</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-3211">Florham Park, New Jersey</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">February 13, 2025</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">We have served as the Company&#8217;s auditor since at least 1920. We have not been able to determine the specific year we began serving as auditor of the Company.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">109</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_241"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Management&#8217;s report on internal control over financial reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Under Section&#160;404 of the Sarbanes-Oxley Act of 2002, management is required to assess the effectiveness of the Company&#8217;s internal control over financial reporting as of the end of each fiscal year and report, based on that assessment, whether the Company&#8217;s internal control over financial reporting is effective.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting. The Company&#8217;s internal control over financial reporting is designed to provide reasonable assurance as to the reliability of the Company&#8217;s financial reporting and the preparation of external financial statements in accordance with generally accepted accounting principles.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Internal controls over financial reporting, no matter how well designed, have inherent limitations. Therefore, internal control over financial reporting determined to be effective can provide only reasonable assurance with respect to financial statement preparation and may not prevent or detect all misstatements. Moreover, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company&#8217;s management has assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December&#160;29, 2024. In making this assessment, the Company used the criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in &#8220;Internal Control-Integrated Framework (2013).&#8221; These criteria are in the areas of control environment, risk assessment, control activities, information and communication, and monitoring. The Company&#8217;s assessment included extensive documenting, evaluating and testing the design and operating effectiveness of its internal controls over financial reporting.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company acquired Shockwave Medical, Inc. (Shockwave), in a business combination in May 2024. Shockwave&#8217;s total assets, excluding intangible assets and goodwill, and total sales represented less than 1% of each of the related consolidated financial statement amounts as of and for the fiscal year ended December 29, 2024. As the acquisition occurred in the fiscal year 2024, the scope of the Company's assessment of the design and effectiveness of internal control over financial reporting for the fiscal year 2024 excluded the above mentioned acquisition. This exclusion is in accordance with the SEC's general guidance that an assessment of a recently acquired business may be omitted from the scope in the year of acquisition. </span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Based on the Company&#8217;s processes and assessment, as described above, management has concluded that, as of December&#160;29, 2024, the Company&#8217;s internal control over financial reporting was effective.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The effectiveness of the Company&#8217;s internal control over financial reporting as of December&#160;29, 2024 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report, which appears&#160;herein.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.049%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/</span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> J. Duato</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/</span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> J. J. Wolk</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Joaquin Duato</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Joseph J. Wolk</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Chairman, Board of Directors</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Executive Vice President, Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">110</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_247"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:26pt"><span style="color:#eb1700;font-family:'Johnson Display Medium',sans-serif;font-size:26pt;font-weight:400;line-height:120%">Shareholder return performance graphs</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Set forth below are line graphs comparing the cumulative total shareholder return on the Company&#8217;s Common Stock for periods of five years and ten years ending December&#160;31, 2024, against the cumulative total return of the Standard&#160;&amp; Poor&#8217;s 500 Stock Index, the Standard&#160;&amp; Poor&#8217;s Pharmaceutical Index and the Standard&#160;&amp; Poor&#8217;s Healthcare Equipment Index. The graphs and tables assume that $100 was invested on December&#160;31, 2019 and December&#160;31, 2014 in each of the Company&#8217;s Common Stock, the Standard&#160;&amp; Poor&#8217;s 500 Stock Index, the Standard&#160;&amp; Poor&#8217;s Pharmaceutical Index and the Standard&#160;&amp; Poor&#8217;s Healthcare Equipment Index and that all dividends were reinvested.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:130%">5 Year Shareholder Return Performance J&amp;J vs. Indices</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:50.000%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.928%"><tr><td style="width:1.0%"/><td style="width:10.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.284%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><img src="jnj-20241229_g21.jpg" alt="icon-legend_red.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:15px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:130%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Johnson &amp; Johnson</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><img src="jnj-20241229_g22.jpg" alt="icon-legend_black.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:15px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:130%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">S&amp;P 500 Index</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><img src="jnj-20241229_g23.jpg" alt="icon-legend_darkgray.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:15px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:130%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">S&amp;P Pharmaceutical Index</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><img src="jnj-20241229_g24.jpg" alt="icon-legend_gray.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:15px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:130%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">S&amp;P Healthcare Equipment Index</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.583%"><tr><td style="width:1.0%"/><td style="width:60.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.149%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5-year CAGR</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">J&amp;J</span></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:130%">2.6&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">S&amp;P 500</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:130%">14.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">S&amp;P Pharm</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:130%">9.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S&amp;P H/C Equip</span></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.6&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr></table></div></div><div style="display:inline-block;max-width:0.000%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:50.000%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><img src="jnj-20241229_g25.jpg" alt="763" style="height:211px;margin-bottom:5pt;vertical-align:text-bottom;width:432px"/></div></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.179%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Johnson &amp; Johnson</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$100.00</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$110.85</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$123.54</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$130.91</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$119.65</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$113.91</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">S&amp;P 500 Index</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$100.00</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$118.39</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$152.36</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$124.75</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$157.52</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$196.90</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">S&amp;P Pharmaceutical Index</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$100.00</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$107.53</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$135.34</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$146.78</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$147.27</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$159.35</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">S&amp;P Healthcare Equipment Index</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$100.00</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$117.63</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$140.40</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$113.92</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$124.22</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$137.81</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">111</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:130%">10 Year Shareholder Return Performance J&amp;J vs. Indices</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:50.000%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.928%"><tr><td style="width:1.0%"/><td style="width:10.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.284%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><img src="jnj-20241229_g21.jpg" alt="icon-legend_red.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:15px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:130%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">Johnson &amp; Johnson</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><img src="jnj-20241229_g22.jpg" alt="icon-legend_black.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:15px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:130%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">S&amp;P 500 Index</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><img src="jnj-20241229_g23.jpg" alt="icon-legend_darkgray.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:15px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:130%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">S&amp;P Pharmaceutical Index</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><img src="jnj-20241229_g24.jpg" alt="icon-legend_gray.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:15px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:130%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">S&amp;P Healthcare Equipment Index</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.583%"><tr><td style="width:1.0%"/><td style="width:60.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.149%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10-year CAGR</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:120%">J&amp;J</span></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:130%">6.2&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S&amp;P 500</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:130%">13.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S&amp;P Pharm</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:130%">8.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:130%">%</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S&amp;P H/C Equip</span></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11.8&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td></tr></table></div></div><div style="display:inline-block;max-width:0.000%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:50.000%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><img src="jnj-20241229_g26.jpg" alt="837" style="height:211px;margin-bottom:5pt;vertical-align:text-bottom;width:432px"/></div></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.199%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2015</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2016</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2017</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Johnson &amp; Johnson</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$100.00</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$101.16</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$116.66</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$145.13</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$137.67</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$159.99</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$177.35</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$197.66</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$209.45</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$191.43</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$182.25</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S&amp;P 500 Index</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$100.00</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$101.37</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$113.48</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$138.25</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$132.18</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$173.81</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$205.78</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$264.82</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$216.83</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$273.79</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$342.24</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S&amp;P Pharmaceutical Index</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$100.00</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$105.79</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$104.13</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$117.22</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$126.71</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$145.83</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$156.80</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$197.36</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$214.04</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$214.75</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$232.38</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S&amp;P Healthcare Equipment&#160;Index</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$100.00</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$105.97</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$112.85</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$147.71</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$171.70</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$222.04</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$261.19</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$311.74</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$252.95</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$275.82</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$306.00</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">112</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_250"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Item 9. Changes in and disagreements with accountants on accounting and financial disclosure</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Not applicable.</span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_253"></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Item 9A. Controls and procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%">Disclosure controls and procedures. </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">At the end of the period covered by this Report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Company&#8217;s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Joaquin Duato, Chairman and Chief Executive Officer, and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs.&#160;Duato and Wolk concluded that, as of the end of the period covered by this Report, the Company&#8217;s disclosure controls and procedures were effective.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%">Reports on internal control over financial reporting. </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The information called for by this item is incorporated herein by reference to Management&#8217;s report on internal control over financial reporting, and the attestation regarding internal controls over financial reporting included in the report of independent registered public accounting firm included in Item 8 of this Report.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%">Changes in internal control over financial reporting. </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">During the fiscal quarter ended December&#160;29, 2024, there were no changes in the Company&#8217;s internal control over financial reporting identified in connection with the evaluation required under Rules&#160;13a-15 and 15d-15 under the Exchange Act that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. The Company continues to monitor and assess the effectiveness of the design and operation of its disclosure controls and procedures. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company is implementing a multi-year, enterprise-wide initiative to integrate, simplify and standardize processes and systems for the human resources, information technology, procurement, supply chain and finance functions. These are enhancements to support the growth of the Company&#8217;s financial shared service capabilities and standardize financial systems. This initiative is not in response to any identified deficiency or weakness in the Company&#8217;s internal control over financial reporting. In response to this initiative, the Company has and will continue to align and streamline the design and operation of its financial control environment.</span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_256"></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Item 9B. Other information</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%">Securities trading plans of Directors and Executive Officers</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">. During the fiscal fourth quarter of 2024, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) informed us of the <ix:nonNumeric contextRef="c-1035" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-3212"><ix:nonNumeric contextRef="c-1035" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-3213">adoption</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-1035" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-3214"><ix:nonNumeric contextRef="c-1035" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-3215">termination</ix:nonNumeric></ix:nonNumeric> of a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; each as defined in Item 408 of Regulation S-K.</span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_259"></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Item 9C. Disclosure regarding foreign jurisdictions that prevent inspections</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">113</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_262"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:26pt"><span style="color:#eb1700;font-family:'Johnson Display Medium',sans-serif;font-size:26pt;font-weight:400;line-height:120%">Part&#160;III</span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_265"></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Item 10. Directors, executive officers and corporate&#160;governance</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The information called for by this item is incorporated herein by reference to the discussion of the Audit Committee under the caption Item 1. Election of Directors - Board committees; and the material under the captions Item 1. Election of Directors and, if applicable, Delinquent Section&#160;16(a) reporting in the Proxy Statement; and the material under the caption &#8220;Executive Officers of the Registrant&#8221; in Part&#160;I of this Report.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company&#8217;s Code of Business Conduct, which covers all employees (including the Chief Executive Officer, Chief Financial Officer and Controller), meets the requirements of the SEC rules promulgated under Section&#160;406 of the Sarbanes-Oxley Act of 2002. The Code of Business Conduct is available on the Company&#8217;s website at </span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">www.jnj.com/code-of-business-conduct</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">, and copies are available to shareholders without charge upon written request to the Secretary at the Company&#8217;s principal executive offices. Any substantive amendment to the Code of Business Conduct or any waiver of the Code granted to the Chief Executive Officer, the Chief Financial Officer or the Controller will be posted on the Company&#8217;s website at </span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">www.jnj.com/code-of-business-conduct</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> within five business days (and retained on the website for at least one year).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In addition, the Company has adopted a Code of Business Conduct&#160;&amp; Ethics for Members of the Board of Directors and Executive Officers. The Code of Business Conduct&#160;&amp; Ethics for Members of the Board of Directors and Executive Officers is available on the Company&#8217;s website at </span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">www.investor.jnj.com/governance/corporate-governance-overview/code-of-business-conduct--ethics</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">, and copies are available to shareholders without charge upon written request to the Secretary at the Company&#8217;s principal executive offices. Any substantive amendment to the Code or any waiver of the Code granted to any member of the Board of Directors or any executive officer will be posted on the Company&#8217;s website at </span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">www.investor.jnj.com/governance/corporate-governance-overview/code-of-business-conduct--ethics</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> within five business days (and retained on the website for at least one year).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In addition to the prohibition on insider trading for all employees covered in our Code of Business Conduct, the Company has <ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-3216">adopted</ix:nonNumeric> an insider trading policy governing the purchase, sale and other dispositions of its securities by directors, officers and certain other insiders that is reasonably designed to promote compliance with insider trading laws, rules and regulations and any applicable listing standards. A copy of this policy is filed with this Annual Report on Form 10-K as Exhibit 19.</span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_268"></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Item 11. Executive compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The information called for by this item is incorporated herein by reference to the material under the captions Item 1. Election of Directors &#8211; Director compensation, and Item 2. Compensation Committee report, Compensation discussion and analysis and Executive compensation tables in the Proxy Statement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The material incorporated herein by reference to the material under the caption Compensation Committee report in the Proxy Statement shall be deemed furnished, and not filed, in this Report and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, as a result of this furnishing, except to the extent that the Company specifically incorporates it by reference.</span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_271"></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Item 12. Security ownership of certain beneficial owners and management and related stockholder matters</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The information called for by this item is incorporated herein by reference to the material under the caption Stock ownership in the Proxy Statement; and Note&#160;16 Common stock, stock option plans and stock compensation agreements of the Notes to Consolidated Financial Statements in Item 8 of this Report.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">114</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Equity compensation plan information</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table provides certain information as of December&#160;29, 2024 concerning the shares of the Company&#8217;s Common Stock that may be issued under existing equity compensation plans.</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.941%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Plan Category</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Securities to<br/>be Issued Upon<br/>Exercise of<br/>Outstanding<br/>Options and Rights</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise Price of<br/>Outstanding<br/>Options<br/>and Rights</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Securities</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining Available for</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Future Issuance Under</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Equity Compensation</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Plans</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)(3)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity Compensation Plans Approved by Security Holders</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">127,682,644</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$127.63</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">111,042,139</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity Compensation Plans Not Approved by Security Holders</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">127,682,644</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$127.63</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">111,042,139</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">Included in this category are the following equity compensation plans which have been approved by the Company&#8217;s shareholders: 2012 Long-Term Incentive Plan and 2022 Long-Term Incentive Plan.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">This column excludes shares reflected under the column &#8220;Number of Securities to be Issued Upon Exercise of Outstanding Options and&#160;Rights.&#8221;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt">The 2012 Long-Term Incentive Plan expired April 26, 2022. All options and restricted shares granted subsequent to that date were under the 2022 Long-Term Incentive Plan.</span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_274"></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Item 13. Certain relationships and related transactions, and director independence</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The information called for by this item is incorporated herein by reference to the material under the captions Item 1. Election of Directors&#160;- Related person transactions &amp; Director independence in the Proxy Statement.</span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_277"></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Item 14. Principal accountant fees and services</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The information called for by this item is incorporated herein by reference to the material under the caption Item 3. Ratification of appointment of independent registered public accounting firm in the Proxy Statement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">115</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_280"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:26pt"><span style="color:#eb1700;font-family:'Johnson Display Medium',sans-serif;font-size:26pt;font-weight:400;line-height:120%">Part&#160;IV</span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_283"></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Item 15. Exhibits and financial statement schedules</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following documents are filed as part of this report:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%;padding-left:9.06pt">Financial Statements</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Consolidated balance sheets at end of fiscal years 2024 and 2023</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Consolidated statements of earnings for fiscal years 2024, 2023 and 2022</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Consolidated statements of comprehensive income for Fiscal Years 2024, 2023 and 2022</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Consolidated statements of equity for fiscal years 2024, 2023 and 2022</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Consolidated statements of cash flows for fiscal years 2024, 2023 and 2022</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Report of independent registered public accounting firm</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">All schedules are omitted because they are not applicable or the required information is included in the financial statements or&#160;notes.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%;padding-left:6.99pt">Exhibits&#160;required to be filed by item&#160;60l of regulation&#160;S-K</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The information called for by this item is incorporated herein by reference to the Exhibit&#160;Index in this Report.</span></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_286"></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Item 16. Form 10-K summary</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Registrants may voluntarily include a summary of information required by Form 10-K under this Item 16. The Company has elected not to include such summary information.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">116</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_289"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Pursuant to the requirements of Section&#160;13 of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.428%"><div style="margin-bottom:6pt;margin-top:13pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Date: February&#160;13, 2025</span></div></div><div style="display:inline-block;max-width:7.142%;min-width:6.142%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.430%"><div style="margin-bottom:6pt;margin-top:13pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.307%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">JOHNSON&#160;&amp; JOHNSON</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(Registrant)</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">By&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">/s/&#160;&#160;</span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">J. Duato</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">J. Duato</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, Chairman of the Board</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">and Chief Executive Officer</span></div></td></tr></table></div></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.632%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.483%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.585%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/ </span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">J. Duato</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Chairman of the Board</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">February 13, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">J. Duato</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Chief Executive Officer <br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/ </span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">J. J. Wolk</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Chief Financial Officer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">February 13, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">J. J. Wolk</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/ </span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">R. J. Decker Jr.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Controller and Chief Accounting Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">February 13, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">R. J. Decker Jr.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/ </span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">D. Adamczyk</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">February 13, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">D. Adamczyk</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/ </span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">M. C. Beckerle</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">February 13, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">M. C. Beckerle</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/ </span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">J. A. Doudna</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">February 13, 2025</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">J. A. Doudna</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">117</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.483%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.483%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.734%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/ </span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">M. A. Hewson</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">February 13, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">M. A. Hewson</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/</span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> P. A. Johnson</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">February 13, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">P. A. Johnson</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/</span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> H. Joly</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">February 13, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">H. Joly</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/</span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> M. B. McClellan</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">February 13, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">M. B. McClellan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/ </span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">A. M. Mulcahy</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">February 13, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">A. M. Mulcahy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/ </span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">M. A. Weinberger</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">February 13, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">M. A. Weinberger</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/</span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> N. Y. West</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">February 13, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">N. Y. West</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/ </span><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">E. A. Woods</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">February 13, 2025</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">E. A. Woods</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">118</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><div id="i4b4bd2fffa0147e7914e1841a5c21924_292"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Exhibit index</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.734%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reg. S-K<br/>Exhibit Table<br/>Item No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description<br/>of Exhibit</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000119312522274491/d395813dex21.htm">2(i)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Agreement and Plan of Merger, dated as of October 31, 2022, by and among Johnson &amp; Johnson, Athos Merger Sub, Inc. and ABIOMED, Inc. &#8211; Incorporated herein by reference to Exhibit 2.1 of the Registrant&#8217;s Form 8-K Current Report filed November 1, 2022.&#8224;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040616000071/exhibit3i-restatedcertific.htm">3(i)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restated Certificate of Incorporation effective February 19, 2016&#160;&#8212; Incorporated herein by reference to Exhibit 3(i) of the Registrant&#8217;s Form 10-K Annual Report for the fiscal year ended January 3, 2016.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040620000034/ex31amendmenttocoi.htm">3(ii)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certificate of Amendment to the Certificate of Incorporation of Johnson &amp; Johnson effective April 30, 2020 &#8212; Incorporated herein by reference to Exhibit 3.1 of the Registrant's Form 8-K Current Report filed April&#160;29,&#160;2020.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040620000039/ex31amendmenttoby-laws.htm">3(iii)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amended and Restated By-Laws of the Company, as amended effective April 25, 2024&#160;&#8212; Incorporated herein by reference to Exhibit 3.1 of the Registrant&#8217;s Form 8-K Current Report filed April 29, 2024.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Upon the request of the Securities and Exchange Commission, the Registrant will furnish a copy of all instruments defining the rights of holders of long-term debt of the Registrant.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="ex4b-descriptionofcapitals.htm">4(b)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 &#8212; Filed with this document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4(c)**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indenture, dated as of September 15, 1987 &#8211; Incorporated herein by reference to Exhibit 4(a) to the Registrant&#8217;s Form S-3 Registration Statement filed on October 11, 1994</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4(d)**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">First Supplemental Indenture, dated as of September 1, 1990 &#8211; Incorporated herein by reference to Exhibit 4(b) to the Registrant&#8217;s Form S-3 Registration Statement filed on October 11, 1994</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000119312517339898/d493870dex41.htm">4(e)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Second Supplemental Indenture, dated as of November 9, 2017 &#8211; Incorporated herein by reference to Exhibit 4.1 to the Registrant&#8217;s Form 8-K Current Report filed on November 13, 2017 </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000119312512113826/d282627ddef14a.htm#appa282627_1a">10(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2012 Long-Term Incentive Plan &#8212; Incorporated herein by reference to Appendix A of the Registrant&#8217;s Proxy Statement filed on March 15, 2012.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040612000081/a20121q10-qex102stockoptio.htm">10(b)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Form of Stock Option Certificate under the 2012 Long-Term Incentive Plan &#8212; Incorporated herein by reference to Exhibit 10.2 of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter ended April 1, 2012.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040618000019/a1q10q04-01x18.htm#s3C6148D0187A71703C38F6BC707F77D0">10(</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040618000019/a1q10q04-01x18.htm#s3C6148D0187A71703C38F6BC707F77D0">c</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040618000019/a1q10q04-01x18.htm#s3C6148D0187A71703C38F6BC707F77D0">)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global NonQualified Stock Option Award Agreement under the 2012 Long-Term Incentive Plan&#160;&#8212; Incorporated herein by reference to Exhibit 10.1 of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter ended April 1, 2018.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040618000019/a1q10q04-01x18.htm#s3C6148D0187A71703C38F6BC707F77D0">10(</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040618000019/a1q10q04-01x18.htm#s3C6148D0187A71703C38F6BC707F77D0">d</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040618000019/a1q10q04-01x18.htm#s3C6148D0187A71703C38F6BC707F77D0">)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global Restricted Share Unit Award Agreement under the 2012 Long-Term Incentive Plan&#160;&#8212; Incorporated herein by reference to Exhibit 10.2 of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter ended April&#160;1, 2018.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040618000019/a1q10q04-01x18.htm#s3C6148D0187A71703C38F6BC707F77D0">10(e)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global Performance Share Unit Award Agreement under the 2012 Long-Term Incentive Plan&#160;&#8212; Incorporated herein by reference to Exhibit 10.3 of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter ended April&#160;1, 2018.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040624000013/ex10h-reed2023rsugrantagre.htm">10(f)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global Restricted Share Unit Award Agreement granted to John Reed on May 1, 2023 under the 2022 Long-Term Incentive Plan&#160;&#8212; Incorporated herein by reference to Exhibit 10(h) of the Registrant&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2023*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000095012304003155/y94471exv10wg.txt">10(</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000095012304003155/y94471exv10wg.txt">g</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000095012304003155/y94471exv10wg.txt">)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Domestic Deferred Compensation (Certificate of Extra Compensation) Plan&#160;&#8212; Incorporated herein by reference to Exhibit 10(g) of the Registrant&#8217;s Form 10-K Annual Report for the year ended December&#160;28,&#160;2003.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000095012309003187/y74152exv10wj.htm">10(h)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amendments to the Certificate of Extra Compensation Plan effective as of January 1, 2009&#160;&#8212; Incorporated herein by reference to Exhibit 10(j) of the Registrant&#8217;s Form 10-K Annual Report for the year ended December 28, 2008.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040613000038/a2012123010-k.htm#s7BFB06AF8539B9C7765893045AA1C343">10(i)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amended and Restated Deferred Fee Plan for Directors&#160;(Amended as of January 17, 2012) &#8212; Incorporated herein by reference to Exhibit 10(k) of the Registrant's Form 10-K Annual Report for the fiscal year ended January 1, 2012.*</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">119</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.734%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reg. S-K<br/>Exhibit Table<br/>Item No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description<br/>of Exhibit</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040612000140/exhibit101.htm">10(</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040612000140/exhibit101.htm">j</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040612000140/exhibit101.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Johnson &amp; Johnson Executive Income Deferral Plan Amended and Restated Effective January 1, 2010&#160;&#8212; Incorporated herein by reference to Exhibit 10.1 of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter ended September 30, 2012.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040623000016/jnj-20230101.htm#i51a46167ef364951bf70ae9d6493776c_286">10(</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040623000016/jnj-20230101.htm#i51a46167ef364951bf70ae9d6493776c_286">k</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040623000016/jnj-20230101.htm#i51a46167ef364951bf70ae9d6493776c_286">)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Johnson &amp; Johnson Excess Savings Plan (amended and restated as of January 1, 2022)&#160;&#8212; Incorporated herein by reference to Exhibit 10(l) of the Registrant&#8217;s Form 10-K Annual Report for the fiscal year ended January 1, 2023.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040621000008/ex31-jjexcessplanx2020rest.htm">10(</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040621000008/ex31-jjexcessplanx2020rest.htm">l</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040621000008/ex31-jjexcessplanx2020rest.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Excess Benefit Plan of Johnson &amp; Johnson and Affiliated Companies (amended and restated as of January 1, 2020) &#8212; incorporated by reference to Exhibit 10(m) of the Registrant&#8217;s Form 10-K Annual Report for the fiscal year ended January 3, 2021.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10(m)**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Executive Life Plan Agreement&#160;&#8212; Incorporated herein by reference to Exhibit 10(i) of the Registrant&#8217;s Form 10-K Annual Report for the fiscal year ended January 3, 1993.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040615000019/a201510-q1qexhibit101execu.htm">10(</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040615000019/a201510-q1qexhibit101execu.htm">n</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040615000019/a201510-q1qexhibit101execu.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Executive Life Plan Agreement&#160;Closure Letter &#8212; Incorporated herein by reference to Exhibit 10.1 of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter ended March 29, 2015.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040622000026/a2022jnjproxy.htm">10(</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040622000026/a2022jnjproxy.htm">o</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040622000026/a2022jnjproxy.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2022 Long-Term Incentive Plan &#8212; Incorporated by reference to Appendix A of the Registrant&#8217;s Proxy Statement filed on March 16, 2022.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040614000097/a201410-q3qexhibit101sever.htm">10(</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040614000097/a201410-q3qexhibit101sever.htm">p</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040614000097/a201410-q3qexhibit101sever.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Severance Pay Plan of Johnson &amp; Johnson and U.S. Affiliated Companies, Amended and Restated as of October 1, 2014 &#8212; Incorporated herein by reference to Exhibit 10.1 of the Registrant's Form 10-Q Quarterly Report for the quarter ended September 28, 2014.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040615000044/exhibit101severancepayplan.htm">10(</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040615000044/exhibit101severancepayplan.htm">q</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040615000044/exhibit101severancepayplan.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">First Amendment to the Severance Pay Plan of Johnson &amp; Johnson and U.S. Affiliated Companies (as amended and restated effective October 1, 2014) &#8212; Incorporated herein by reference to Exhibit 10.1 of the Registrant's Form 10-Q Quarterly Report for the quarter ended June 28, 2015.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040616000071/exhibit10x-secondamendment.htm">10(</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040616000071/exhibit10x-secondamendment.htm">r</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040616000071/exhibit10x-secondamendment.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Second Amendment to the Severance Pay Plan of Johnson &amp; Johnson and U.S. Affiliated Companies (as amended and restated effective October 1, 2014) &#8212; Incorporated herein by reference to Exhibit 10(x) of the Registrant's Form 10-K Annual Report for the fiscal year ended January 3, 2016.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000119312522311072/d428734dex101.htm">10(</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000119312522311072/d428734dex101.htm">s</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000119312522311072/d428734dex101.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contingent Value Rights Agreement, dated as of December 22, 2022, by and between Johnson &amp; Johnson and American Stock Transfer &amp; Trust Company, LLC &#8211; Incorporated herein by reference to Exhibit 10.1 of the Registrant&#8217;s Form 8-K Current Report filed December 22, 2022.&#8224;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000119312523138287/d301195dex104.htm">10(</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000119312523138287/d301195dex104.htm">t</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000119312523138287/d301195dex104.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intellectual Property Agreement, dated as of May 3, 2023, by and between Johnson &amp; Johnson and Kenvue&#160;Inc. &#8212; Incorporated herein by reference to Exhibit 10.4 of the Registrant's Form 8-K Current Report filed May 8, 2023.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000119312523138287/d301195dex105.htm">10(</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000119312523138287/d301195dex105.htm">u</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000119312523138287/d301195dex105.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trademark Phase-Out License Agreement, dated as of April 3, 2023, by and between Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Inc. &#8212; Incorporated herein by reference to Exhibit 10.5 of the Registrant's Form 8-K Current Report filed May 8, 2023.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/200406/000020040623000105/jnj-20231121.htm">1</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/200406/000020040623000105/jnj-20231121.htm">0</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/200406/000020040623000105/jnj-20231121.htm">(</a>v)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Johnson &amp; Johnson Deferred Compensation Plan &#8212; Incorporated herein by reference to Exhibit 10.1 of the Registrant's Form 8-K Current Report filed November 27, 2023.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040623000056/exhibit101-2022ltipxformps.htm">10(</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040623000056/exhibit101-2022ltipxformps.htm">w</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040623000056/exhibit101-2022ltipxformps.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global Performance Share Unit Award Agreement under the Johnson &amp; Johnson 2022 Long-Term Incentive Plan &#8212; Incorporated herein by reference to Exhibit 10.1 of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter year ended April 2, 2023.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040623000056/exhibit102-2022ltipformrsu.htm">10(</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040623000056/exhibit102-2022ltipformrsu.htm">x</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040623000056/exhibit102-2022ltipformrsu.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global Restricted Share Unit Award Agreement under the Johnson &amp; Johnson 2022 Long-Term Incentive Plan &#8212; Incorporated herein by reference to Exhibit 10.2 of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter year ended April 2, 2023.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040623000056/exhibit103-2022ltipformsto.htm">10(</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040623000056/exhibit103-2022ltipformsto.htm">y</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040623000056/exhibit103-2022ltipformsto.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global Nonqualified Stock Option Award Agreement under the Johnson &amp; Johnson 2022 Long-Term Incentive Plan &#8212; Incorporated herein by reference to Exhibit 10.3 of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter year ended April 2, 2023.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040623000102/exhibit101-amendmentonetot.htm">10(</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040623000102/exhibit101-amendmentonetot.htm">z</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040623000102/exhibit101-amendmentonetot.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amendment One to the Johnson &amp; Johnson Excess Savings Plan (amended and restated effective as of January 1, 2022) &#8212; Incorporated herein by reference to Exhibit 10.1 of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter ended October 1, 2023.*</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">120</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span><img src="jnj-20241229_g1.jpg" alt="Jhonson&amp;Jhonson.jpg" style="height:12px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"/><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:700;line-height:130%">&#160;</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.734%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reg. S-K<br/>Exhibit Table<br/>Item No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description<br/>of Exhibit</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040623000102/exhibit102-johnsonjohnsone.htm">10(a</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040623000102/exhibit102-johnsonjohnsone.htm">a</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040623000102/exhibit102-johnsonjohnsone.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Johnson &amp; Johnson Executive Incentive Plan (Amended as of September 7, 2023) &#8212; Incorporated herein by reference to Exhibit 10.2 of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter ended October&#160;1,&#160;2023.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="ex10ab-executivecashsevera.htm">10(a</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="ex10ab-executivecashsevera.htm">b</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="ex10ab-executivecashsevera.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Johnson &amp; Johnson Executive Officer Cash Severance Policy &#8212; Filed with this document.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040624000013/ex19-johnsonjohnsonstocktr.htm">19</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Johnson &amp; Johnson Stock Trading Policy for Directors, Executive Officers and Insiders (Amended as of April 27, 2023) &#8212; Incorporated herein by reference to Exhibit 19 of the Registrant&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2023.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="ex21-subsidiariesxform10xk.htm">21</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subsidiaries &#8212; Filed with this document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="ex23-pwcconsentxform10xkx2.htm">23</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consent of Independent Registered Public Accounting Firm&#160;&#8212; Filed with this document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="ex311-302certofceoxform10x.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act&#160;&#8212; Filed with this&#160;document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="ex312-302certofcfoxform10x.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act&#160;&#8212; Filed with this&#160;document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="ex321-906certofceoxform10x.htm">32.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act&#160;&#8212; Furnished with this document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="ex322-906certofcfoxform10x.htm">32.2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act&#160;&#8212; Furnished with this document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/200406/000020040624000013/ex97-johnsonjohnsonclawbac.htm">97</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Johnson &amp; Johnson Clawback Policy (effective as of August 8, 2023) &#8212; Incorporated herein by reference to<br/>Exhibit 97 of the Registrant&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2023.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exhibit 101:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EX-101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EX-101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EX-101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EX-101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EX-101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EX-101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Document</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exhibit 104:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cover Page Interactive Data File&#8211;&#8211;the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.895%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management contract or compensatory plan.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Paper filing.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain exhibits and schedules have been omitted pursuant to Item 601(b)(2)(ii) or 601(b)(10)(iv) of Regulation S-K, as&#160;applicable.</span></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">A copy of any of the Exhibits listed above will be provided without charge to any shareholder submitting a written request specifying the desired exhibit(s) to the Secretary at the principal executive offices of the Company. Pursuant to Item 601(b)(4)(iii)(A) of Regulation S-K, the Company has not filed as exhibits to this Form 10-K certain long-term debt instruments, under which the total amount of securities authorized does not exceed 10% of the total assets of the Company and its subsidiaries on a consolidated basis. The Company hereby agrees to furnish a copy of any such instrument to the SEC upon&#160;request.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.947%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2024 Annual Report</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">121</span></div></td></tr></table></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.B
<SEQUENCE>2
<FILENAME>ex4b-descriptionofcapitals.htm
<DESCRIPTION>EX-4.B
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ia18bb51eb0434baba016e5422a36cbd8_41"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4(b)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Capital Stock</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary of the capital stock of Johnson &#38; Johnson (&#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) does not purport to be complete and is subject in all respects to applicable New Jersey law, the Johnson &#38; Johnson restated certificate of incorporation, as amended, and the Johnson &#38; Johnson by-laws.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total authorized shares of capital stock of Johnson &#38; Johnson consist of (1) 4,320,000,000 shares of common stock, par value $1.00 per share, and (2) 2,000,000 shares of preferred stock, without par value. As of the date of this filing, no shares of Johnson &#38; Johnson preferred stock were issued and outstanding.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Johnson &#38; Johnson board of directors is authorized to provide for the issuance from time to time of Johnson &#38; Johnson preferred stock in series and, as to each series, to fix the designation&#59; the dividend rate and the preferences, if any, which dividends on that series will have compared to any other class or series of capital stock of Johnson &#38; Johnson&#59; the voting rights, if any&#59; the liquidation preferences, if any&#59; the conversion privileges, if any, and the redemption price or prices and the other terms of redemption, if any, applicable to that series. Cumulative dividends, dividend preferences and conversion, exchange and redemption provisions, to the extent that some or all of these features may be present when shares of Johnson &#38; Johnson preferred stock are issued, could have an adverse effect on the availability of earnings for distribution to the holders of Johnson &#38; Johnson common stock or for other corporate purposes.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Board of Directors</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Johnson &#38; Johnson restated certificate of incorporation and the Johnson &#38; Johnson by-laws provide that the total number of Johnson &#38; Johnson directors will be not less than nine nor more than 18, as determined by the Johnson &#38; Johnson board from time to time.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All directors are elected at each annual meeting of shareholders to serve until the next annual meeting. The Johnson &#38; Johnson by-laws do not provide for cumulative voting in the election of directors.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dividends</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Johnson &#38; Johnson restated certificate of incorporation, as amended, provides that the Johnson &#38; Johnson board of directors may from time to time declare dividends on its outstanding shares in accordance with New Jersey law.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Voting Rights</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each holder of Johnson &#38; Johnson common stock is entitled to one vote for each share held of record and may not cumulate votes for the election of directors.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liquidation Rights</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a liquidation, dissolution or winding-up of Johnson &#38; Johnson, each share of Johnson &#38; Johnson common stock will be entitled to receive an equal share in our net assets that remain after paying all liabilities and the liquidation preferences of any preferred stock.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">WEIL&#58;&#92;100244599&#92;4&#92;54966.0187</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Preemptive Rights</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Johnson &#38; Johnson common stock have no preemptive rights to purchase, subscribe for or otherwise acquire any common stock or preferred stock or other securities.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Merger or Consolidation</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under New Jersey law, the completion of a merger or consolidation of a New Jersey corporation organized prior to January 1, 1969, such as Johnson &#38; Johnson, requires the approval of such corporation&#8217;s board of directors and the affirmative vote of two-thirds of the votes cast by the holders of shares of the corporation entitled to vote thereon&#59; provided that no such approval and vote are required if such corporation is the surviving corporation and&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">such corporation&#8217;s certificate of incorporation is not amended&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the shareholders of the surviving corporation whose shares were outstanding immediately before the effective date of the merger will hold the same number of shares, with identical designations, preferences, limitations, and rights, immediately after&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the number of voting shares and participation shares outstanding after the merger will not exceed by more than 40% the total number of voting or participating shares of the surviving corporation before the merger.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, a sale of all or substantially all of such corporation&#8217;s assets other than in the ordinary course of business, or a voluntary dissolution of such corporation, requires the approval of such corporation&#8217;s board of directors and the affirmative vote of two-thirds of the votes cast by the holders of shares of such corporation entitled to vote thereon.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Business Combinations</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under New Jersey law, no New Jersey corporation may engage in any &#8220;business combination&#8221; with any interested shareholder (generally, a 10% or greater shareholder) for a period of five years following such interested shareholder&#8217;s stock acquisition, unless such business combination is approved by the board of directors of such corporation prior to the stock acquisition.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under New Jersey law, &#8220;business combination&#8221; includes&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">any merger or consolidation of a resident domestic corporation or one of its subsidiaries&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:100%">o</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:12pt">with an interested shareholder&#59; or</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:100%">o</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:12pt">with any corporation which is, or would be after such merger or consolidation, an affiliate or associate of an interested shareholder.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">any transfer or other disposition to or with an interested shareholder or any affiliate or associate of an interested shareholder of at least 10% of (1) the assets, (2) the outstanding shares or (3) the earning power or income on a consolidated basis, of such resident domestic corporation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">other specified self-dealing transactions between such resident domestic corporation and an interested shareholder or any affiliate or associate thereof.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, no resident domestic corporation may engage, at any time, in any business combination with any interested shareholder of such corporation other than&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">a business combination approved by the board of directors of such corporation prior to the stock acquisition&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">a business combination approved by the affirmative vote of the holders of two-thirds of the voting stock not beneficially owned by such interested shareholder at a meeting called for such purpose&#59; or</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">WEIL&#58;&#92;100244599&#92;4&#92;54966.0187</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">a business combination in which the interested shareholder meets certain fair price criteria.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Debt Securities&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.150% Notes due 2028</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.200% Notes due 2032</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.650% Notes due 2035</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.350% Notes due 2036</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.550% Notes due 2044</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes (as defined below) are our unsecured obligations and were issued under an Indenture dated as of September 15, 1987, between us and The Bank of New York Mellon Trust Company, N.A. (as successor to BNY Midwest Trust Company, which succeeded Harris Trust and Savings Bank), as trustee (the &#8220;Trustee&#8221;), as amended by a First Supplemental Indenture dated as of September 1, 1990 and, solely with respect to the 2032 notes, the 2036 notes and the 2044 notes (each, as hereinafter defined), a Second Supplemental Indenture dated as of November 9, 2017 (collectively, the &#8220;Indenture&#8221;). The 1.150% notes due 2028, the 3.200% notes due 2032, 1.650% notes due 2035, the 3.350% notes due 2036 and the 3.550% notes due 2044 are sometimes respectively referred to herein as the &#8220;2028 notes,&#8221; the &#8220;2032 notes,&#8221; the &#8220;2035 notes,&#8221; the &#8220;2036 notes&#8221; and the &#8220;2044 notes.&#8221; The 2028 notes, the 2032 notes, the 2035 notes, the 2036 notes and the 2044 notes are sometimes collectively referred to herein as the &#8220;notes.&#8221; This summary is subject to and qualified in its entirety by reference to all of the provisions of the Indenture and the notes, including definitions of certain terms used in the Indenture and the notes. The Indenture has been incorporated by reference as an exhibit to the Annual Report on Form 10-K to which this exhibit is a part. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued &#8364;750,000,000 aggregate principal amount of the 2028 notes on May 20, 2016. The 2028 notes will mature on November 20, 2028. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued &#8364;700,000,000 aggregate principal amount of the 2032 notes on May 20, 2024. The 2032 notes will mature on June 1, 2032. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued &#8364;1,500,000,000 aggregate principal amount of the 2035 notes on May 20, 2016. The 2035 notes will mature on May 20, 2035. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued &#8364;800,000,000 aggregate principal amount of the 2036 notes on May 20, 2024. The 2036 notes will mature on June 1, 2036. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued &#8364;1,000,000,000 aggregate principal amount of the 2044 notes on May 20, 2024. The 2044 notes will mature on June 1, 2044.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes of each series were issued only in book-entry form, in minimum denominations of &#8364;100,000 and integral multiples of &#8364;1,000 above that amount, through the facilities of Euroclear Bank S.A.&#47;N.V., as operator of the Euroclear System (&#8220;Euroclear&#8221;), and Clearstream Banking, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">soci&#233;t&#233; anonyme</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;Clearstream&#8221;), and sales in book-entry form are effected only through participants in Euroclear or Clearstream. The notes do not have the benefit of a sinking fund.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest on the Notes</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on the 2028 notes is payable annually on November 20 of each year to the holders of the 2028 notes at the close of business the November 5 preceding such interest payment date. Interest on the 2035 notes is payable annually on May 20 of each year to the holders of the 2035 notes at the close of business the May 5 preceding such interest payment date. Interest on the 2032 notes, the 2036 notes and the 2044 notes is payable annually on June 1 of each year to the holders of each of the 2032 notes, the 2036 notes and the 2044 notes at the close of business the May 15 preceding such interest payment date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">WEIL&#58;&#92;100244599&#92;4&#92;54966.0187</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2028 notes bear interest at the rate of 1.150% per annum, the 2032 notes bear interest at the rate of 3.200% per annum, the 2035 notes bear interest at the rate of 1.650% per annum, the 2036 notes bear interest at the rate of 3.350% per annum and the 2044 notes bear interest at the rate of 3.550% per annum. Interest on the notes is computed on the basis of the actual number of days in the period for which interest is being calculated and the actual number of days from and including the last date on which interest was paid on the notes, to but excluding the next scheduled interest payment date. This payment convention is referred to as ACTUAL&#47;ACTUAL (ICMA) as defined in the rulebook of the International Capital Market Association.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuance in Euro</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All payments of interest and principal, including payments made upon any redemption of the notes, are payable in euro. If the euro becomes unavailable to us due to the imposition of exchange controls or other circumstances beyond our control or if the euro is no longer being used by the then member states of the European Monetary Union that have adopted the euro as their currency or for the settlement of transactions by public institutions of or within the international banking community, then all payments in respect of the notes will be made in U.S. dollars until the euro is again available to us or so used. The amount payable on any date in euro is converted into U.S. dollars at the rate mandated by the U.S. Federal Reserve Board as of the close of business on the second business day prior to the relevant payment date or, in the event the U.S. Federal Reserve Board has not mandated a rate of conversion, on the basis of the most recent euro&#47;U.S. dollar exchange rate available on or prior to the second business day prior to the relevant payment date, as reported by Bloomberg. Any payment in respect of the notes so made in U.S. dollars does not constitute an event of default under the notes or the indenture governing the notes. Neither the trustee nor any paying agent has any responsibility for any calculation or conversion in connection with the forgoing.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Business Day</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term &#8220;business day&#8221; means any day, other than a Saturday or Sunday, (1) that is not a day on which banking institutions in The City of New York or London are authorized or required by law, regulation or executive order to close and (2) on which the Trans-European Automated Real-time Gross Settlement Express Transfer system (the TARGET2 system), or any successor thereto, is open.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Paying Agent and Registrar</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bank of New York Mellon (London Branch) is paying agent for the notes, and The Bank of New York Mellon Trust Company, N.A. acts as security registrar for the notes. We may at any time designate additional paying agents or rescind the designations or approve a change in the offices where they act.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the case of the 2028 notes and the 2035 notes, to the extent permitted by law, we maintain a paying agent that is not required to withhold or deduct tax pursuant to European Council Directive 2003&#47;48&#47;EC on the taxation of savings income or any law implementing or complying with, or introduced in order to conform to, such European Council Directive.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Optional Redemption</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may, at our option, redeem the notes at any time prior to the applicable Par Call Date, either in whole or in part, at a redemption price equal to the greater of the following amounts, plus, in each case, accrued and unpaid interest thereon to, but not including, the redemption date&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">100% of the principal amount of the notes to be redeemed&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the date of redemption), discounted to the date of redemption on an annual basis (ACTUAL&#47;ACTUAL (ICMA)) at the applicable Comparable Government Bond Rate (as defined below), plus 20 basis points in the case of each of the 2028 notes and the 2035 notes and 15 basis points in the case of each of the 2032 notes, the 2036 notes and the 2044 notes. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">WEIL&#58;&#92;100244599&#92;4&#92;54966.0187</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time on or after the applicable Par Call Date, the notes may be redeemed in whole or in part, at our option, at a redemption price equal to 100% of the principal amount of notes to be redeemed, plus accrued and unpaid interest to, but excluding, the date of redemption.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Installments of interest on notes being redeemed that are due and payable on interest payment dates falling on or prior to a redemption date are payable on the interest payment date to the holders as of the close of business on the relevant regular record date according to the notes and the indenture.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Comparable Government Bond&#8221; means, in relation to any Comparable Government Bond Rate calculation, at the discretion of an independent investment bank selected by us, a German government bond whose maturity is closest to the maturity of the notes being redeemed, or if such independent investment bank in its discretion determines that such similar bond is not in issue, such other German government bond as such independent investment bank may, with the advice of three brokers of, and&#47;or market makers in, German government bonds selected by us, determine to be appropriate for determining the Comparable Government Bond Rate.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Comparable Government Bond Rate&#8221; means, (i) with respect to the 2028 notes and the 2035 notes, the price, expressed as a percentage (rounded to three decimal places, with 0.0005 being rounded upwards), at which the gross redemption yield on the notes, if they were to be purchased at such price on the third business day prior to the date fixed for redemption, would be equal to the gross redemption yield on such business day of the Comparable Government Bond on the basis of the middle market price of the Comparable Government Bond prevailing at 11&#58;00 a.m. (London time) on such business day as determined by an independent investment bank selected by us and (ii) with respect to the 2032 notes, the 2036 notes and the 2044 notes, the yield to maturity, expressed as a&#160;percentage (rounded to three decimal places, 0.0005 being rounded upwards), on the third business day prior to the date fixed for redemption, of the applicable Comparable Government Bond on the basis of the middle market price of such Comparable Government Bond prevailing at 11&#58;00&#160;a.m. (London time) on such business day as determined by an independent investment bank selected by us. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Par Call Date&#8221; means (i) August 20, 2028 (three months prior to the maturity date of such notes), in the case of the 2028 notes&#59; (ii) March 1, 2032 (three months prior to the maturity date of such notes), in the case of the 2032 notes&#59; (iii) February 20, 2035 (three months prior to the maturity date of such notes), in the case of the 2035 notes&#59; (iv) March 1, 2036 (three months prior to the maturity date of such notes), in the case of the 2036 notes&#59; and (v) March 1, 2044 (three months prior to the maturity date of such notes), in the case of the 2044 notes.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notice of any redemption will be delivered (or otherwise transmitted in accordance with the depositary&#8217;s procedures) in the case of the 2028 notes and the 2035 notes, at least 30 days, and in the case of the 2032 notes, the 2036 notes and the 2044 notes, at least 15 days, but in any case not more than 60 days before the redemption date to each holder of notes to be redeemed. In the case of the 2032 notes, the 2036 notes and the 2035 notes, any redemption or notice may, at our discretion, be subject to one or more conditions precedent and, at our discretion, the redemption date may be delayed until such time as any or all such conditions shall be satisfied (or waived by us in our sole discretion) or the redemption date may not occur and such notice may be rescinded if all such conditions precedent included at our discretion shall not have been satisfied (or waived by us in our sole discretion). Once notice of redemption is delivered, the notes called for redemption will become due and payable on the redemption date and at the applicable redemption price, plus accrued and unpaid interest to the redemption date, subject to, in the case of the 2032 notes, the 2036 notes and the 2035 notes conditions precedent, if any, that we specify in the notice of redemption.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If less than all of the notes of a series are to be redeemed, the notes of such series to be redeemed will be selected in accordance with applicable depositary procedures or such method as the Trustee may deem fair and appropriate&#59; provided, however, that no notes of a principal amount of &#8364;100,000 or less shall be redeemed in part. Unless we default in payment of the redemption price, on and after the redemption date interest will cease to accrue on the notes or portions thereof called for redemption. On or before the redemption date, we will deposit with the paying agent (or the Trustee) money sufficient to pay the redemption price of and accrued interest on the notes to be redeemed on that date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">WEIL&#58;&#92;100244599&#92;4&#92;54966.0187</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes of each series are also subject to redemption prior to maturity if certain changes in U.S. tax law occur. If such changes occur, the notes may be redeemed at a redemption price of 100% of their principal amount plus accrued and unpaid interest to the date of redemption. See &#8220;&#8212;Redemption for Tax Reasons.&#8221;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Payment of Additional Amounts</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the exceptions and limitations set forth below, we will pay as additional interest on the notes such additional amounts as are necessary in order that the net payment by us or a paying agent of the principal of and interest on the notes to a holder who is not a United States person (as defined below), after deduction for any present or future tax, assessment or other governmental charge of the United States or a political subdivision or taxing authority of or in the United States, imposed by withholding with respect to the payment, will not be less than the amount provided in the Notes to be then due and payable&#59; provided, however, that the foregoing obligation to pay additional amounts shall not apply&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.84pt">to any tax, assessment or other governmental charge that is imposed or withheld solely by reason of the holder, or a fiduciary, settlor, beneficiary, member or shareholder of the holder if the holder is an estate, trust, partnership or corporation, or a person holding a power over an estate or trust administered by a fiduciary holder, being considered as&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">being or having been present or engaged in a trade or business in the United States or having had a permanent establishment in the United States&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">having a current or former relationship with the United States, including a relationship as a citizen or resident of the United States&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">being or having been a foreign or domestic personal holding company, a passive foreign investment company or a controlled foreign corporation with respect to the United States or a corporation that has accumulated earnings to avoid United States federal income tax&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">being or having been a &#8220;10-percent shareholder&#8221; of us as defined in section 871(h)(3) of the United States Internal Revenue Code or any successor provision&#59; or</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">being a bank receiving payments on an extension of credit made pursuant to a loan agreement entered into the ordinary course of its trade or business&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.84pt">to any holder that is not the sole beneficial owner of the notes, or a portion of the notes, or that is a fiduciary or partnership, but only to the extent that a beneficiary or settlor with respect to the fiduciary, a beneficial owner or member of the partnership would not have been entitled to the payment of an additional amount had the beneficiary, settlor, beneficial owner or member received directly its beneficial or distributive share of the payment&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.84pt">to any tax, assessment or other governmental charge that is imposed or otherwise withheld solely by reason of a failure of the holder or any other person to comply with certification, identification or information reporting requirements concerning the nationality, residence, identity or connection with the United States of the holder or beneficial owner of the Notes, if compliance is required by statute, by regulation of the United States Treasury Department or by an applicable income tax treaty to which the United States is a party as a precondition to exemption from such tax, assessment or other governmental charge&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.84pt">to any tax, assessment or other governmental charge that is imposed otherwise than by withholding by us or a paying agent from the payment&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.84pt">to any tax, assessment or other governmental charge that is imposed or withheld solely by reason of a change in law, regulation, or administrative or judicial interpretation that becomes effective after the payment becomes due or is duly provided for, whichever occurs later&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.84pt">to any estate, inheritance, gift, sales, excise, transfer, wealth or personal property tax or similar tax, assessment or other governmental charge&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">WEIL&#58;&#92;100244599&#92;4&#92;54966.0187</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.84pt">to any tax, assessment or other governmental charge any paying agent (which term may include us) must withhold from any payment of principal of or interest on any note, if such payment can be made without such withholding by any other paying agent&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.84pt">to any tax, assessment or governmental charge that would not have been so imposed or withheld but for the presentation by the holder of a note for payment on a date more than 30 days after the date on which such payment became due and payable or the date on which payment thereof is duly provided for, whichever occurs later&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.84pt">any withholding or deduction pursuant to an agreement described in Section 1471(b) of the Code or otherwise imposed pursuant to Sections 1471 through 1474 of the Code (or any regulations or agreements thereunder or official interpretations thereof) or any intergovernmental agreement between the United States and another jurisdiction facilitating the implementation thereof (or any law implementing such an intergovernmental agreement)&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.84pt">in the case of any combination of the above items.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes are subject in all cases to any tax, fiscal or other law or regulation or administrative or judicial interpretation applicable to the notes. Except as specifically provided under this heading &#8220;&#8212;Payment of Additional Amounts&#8221; and under the heading &#8220;&#8212;Redemption for Tax Reasons,&#8221; we are not required to make any payment for any tax, assessment or other governmental charge imposed by any government or a political subdivision or taxing authority of or in any government or political subdivision.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not pay additional amounts on any note&#58;</font></div><div style="margin-bottom:12pt;padding-left:74.25pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in the case of the 2028 notes and the 2035 notes, where withholding or deduction is imposed on a payment and is required to be made pursuant to European Union Directive 2003&#47;48&#47;EC or any law implementing or complying with, or introduced in order to conform to, that Directive, or</font></div><div style="margin-bottom:12pt;padding-left:74.25pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">presented for payment by or on behalf of a beneficial owner who would have been able to avoid the withholding or deduction by presenting the relevant global note to another paying agent in a Member State of the EU.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used under this heading &#8220;&#8212;Payment of Additional Amounts&#8221; and under the heading &#8220;&#8212;Redemption for Tax Reasons&#8221;, the term &#8220;United States&#8221; means the United States of America (including the states and the District of Columbia) and its territories, possessions and other areas subject to its jurisdiction, &#8220;United States person&#8221; means any individual who is a citizen or resident of the United States, a corporation, partnership or other entity created or organized in or under the laws of the United States, any state of the United States or the District of Columbia (other than a partnership that is not treated as a United States person under any applicable Treasury regulations), or any estate or trust the income of which is subject to United States federal income taxation regardless of its source.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption for Tax Reasons</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If, as a result of any change in, or amendment to, the laws (or any regulations or rulings promulgated under the laws) of the United States (or any political subdivision or taxing authority of or in the United States), or any change in, or amendments to, an official position regarding the application or interpretation of such laws, regulations or rulings, which change or amendment is announced or becomes effective on or after the date of the prospectus supplement covering the offer and sale of the applicable series of notes, we become or, based upon a written opinion of independent counsel selected by us, will become obligated to pay additional amounts as described herein under the heading &#8220;&#8212;Payment of Additional Amounts&#8221; with respect to the notes, then we may at our option redeem, in whole, but not in part, the notes on not less than 30 nor more than 60 days prior notice, at a redemption price equal to 100% of their principal amount, together with interest accrued but unpaid on those notes to the date fixed for redemption.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Further Issues</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">WEIL&#58;&#92;100244599&#92;4&#92;54966.0187</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may from time to time, without notice to, or the consent of, the registered holders of any series of notes, create and issue further notes equal in rank to the notes in all respects (or in all respects except for the payment of interest accruing prior to the issue date of the further notes or except for the first payment of interest following the issue date of the further notes). These further notes may be consolidated and form a single series with the applicable existing series of notes and will have the same terms as to status, redemption or otherwise as that existing series of notes.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Book-Entry&#59; Delivery and Form&#59; Global Notes</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained the information in this section concerning Clearstream and Euroclear and their book-entry systems and procedures from sources that we believe to be reliable. We take no responsibility for an accurate portrayal of this information. In addition, the description of the clearing systems in this section reflects our understanding of the rules and procedures of Clearstream and Euroclear as they are currently in effect. Those clearing systems could change their rules and procedures at any time. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes were initially represented by one or more fully registered global notes. Each such global note was deposited with, or on behalf of, a common depositary and registered in the name of the nominee of the common depositary for the accounts of Clearstream and Euroclear. Except as set forth below, the global notes may be transferred, in whole and not in part, only to Euroclear or Clearstream or their respective nominees. Interests in the global notes may be held in Europe through Clearstream or Euroclear, either as a participant in such systems or indirectly through organizations that are participants in such systems. Clearstream and Euroclear hold interests in the global notes on behalf of their respective participating organizations or customers through customers&#8217; securities accounts in Clearstream&#8217;s or Euroclear&#8217;s names on the books of their respective depositaries. Book-entry interests in the notes and all transfers relating to the notes are reflected in the book-entry records of Clearstream and Euroclear.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distribution of the notes is cleared through Clearstream and Euroclear. The secondary market trading of book-entry interests in the notes takes place through Clearstream and Euroclear participants and settle in same-day funds. Owners of book-entry interests in the notes receive payments relating to their notes in euro, with certain exceptions.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clearstream and Euroclear have established electronic securities and payment transfer, processing, depositary and custodial links among themselves and others, either directly or through custodians and depositaries. These links allow the notes to be issued, held and transferred among the clearing systems without the physical transfer of certificates. Special procedures to facilitate clearance and settlement have been established among these clearing systems to trade securities across borders in the secondary market.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The policies of Clearstream and Euroclear govern payments, transfers, exchanges and other matters relating to an investor&#8217;s interest in the notes held by them. We have no responsibility for any aspect of the records kept by Clearstream or Euroclear or any of their direct or indirect participants. We also do not supervise these systems in any way.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clearstream and Euroclear and their participants perform these clearance and settlement functions under agreements they have made with one another or with their customers. They are not obligated to perform or continue to perform these procedures and may modify them or discontinue them at any time.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With certain exceptions, owners of beneficial interests in the notes are not entitled to have the notes registered in their names, do not receive and are not entitled to receive physical delivery of the notes in definitive form and are not considered the owners or holders of the notes under the indenture, including for purposes of receiving any reports delivered by us or the trustee pursuant to the indenture. Accordingly, each person owning a beneficial interest in a note must rely on the procedures of the depositary and, if such person is not a participant, on the procedures of the participant through which such person owns its interest, in order to exercise any rights of a holder of notes.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notices</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">WEIL&#58;&#92;100244599&#92;4&#92;54966.0187</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notices to holders of the notes are sent to such holders. Any notice shall be deemed to have been given on the date of mailing. So long as the notes are represented by a global security deposited with The Bank of New York Mellon (London Branch), or any successor thereto, as the common depositary for Clearstream and Euroclear, notices to holders may be given by delivery to Clearstream and Euroclear, and such notices shall be deemed to be given on the date of delivery to Clearstream and Euroclear. The trustee will transmit notices to each registered holder&#8217;s last known address as it appears in the security register that the trustee maintains. The trustee will only transmit these notices to the registered holder of the notes. Holders of notes will not receive notices regarding the notes directly from us unless we reissue the notes to the holders in fully certificated form.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amendment and Waiver</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than amendments not adverse to holders of the debt securities, amendments of the Indenture or the debt securities may be made with the consent of the holders of a majority in principal amount of the debt securities affected (acting as one class). Waivers of compliance with any provision of the Indenture or the debt securities with respect to any series of debt securities may be made only with the consent of the holders of a majority in principal amount of the debt securities of that series. The consent of all holders of affected debt securities will be required to&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.84pt">make any debt security payable in a currency not specified or described in the debt security&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.84pt">change the stated maturity of any debt security&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.84pt">reduce the principal amount of any debt security&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.84pt">reduce the rate or change the time of payment of interest on any debt security&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.84pt">reduce the amount of debt securities whose holders must consent to an amendment or waiver&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.84pt">impair the right to institute suit for the payment of principal of any debt security or interest on any debt security.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of a majority in aggregate principal amount of debt securities affected may waive any past default under the Indenture and its consequences, except a default (1) in the payment of the principal of or interest on any debt securities, or (2) in respect of a provision that cannot be waived or amended without the consent of all holders of debt securities affected.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Events of Default</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Events of Default with respect to any series of debt securities under the Indenture will include&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.84pt">default in payment of any principal of that series&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.84pt">default in the payment of any installment of interest on such series and continuance of that default for a period of 30 days&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.84pt">default in the performance of any other covenant in the Indenture or in the debt securities and continuance of the default for a period of 90 days after we receive notice of the default from the Trustee or the holders of at least 25% in principal amount of debt securities of the series&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.84pt">certain events of bankruptcy, insolvency or reorganization in respect of Johnson &#38; Johnson.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Trustee may withhold notice to the holders of a series of debt securities of any default (except in the payment of principal of or interest on the series of debt securities) if it considers withholding of notice to be in the interest of holders of the debt securities. Not all Events of Default with respect to a particular series of debt securities issued under the Indenture necessarily constitute Events of Default with respect to any other series of debt securities.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">WEIL&#58;&#92;100244599&#92;4&#92;54966.0187</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the occurrence of an Event of Default with respect to a series of debt securities, the Trustee or the holders of at least 25% in principal amount of debt securities of that series then outstanding may declare the principal (or, in the case of debt securities sold at an original issue discount, the amount specified in the terms thereof) and accrued interest thereon to be due and payable immediately.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within 120 days after the end of each fiscal year, an officer of Johnson &#38; Johnson must inform the Trustee whether he or she knows of any default, describing any default and the status thereof. Subject to provisions relating to its duties in case of default, the Trustee is under no obligation to exercise any of its rights or powers under the Indenture at the direction of any holders of debt securities unless the Trustee shall have received a satisfactory indemnity.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Governing Law</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Indenture and the notes are governed by, and construed in accordance with, the laws of the State of New York.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">WEIL&#58;&#92;100244599&#92;4&#92;54966.0187</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.AB
<SEQUENCE>3
<FILENAME>ex10ab-executivecashsevera.htm
<DESCRIPTION>EX-10.AB
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ib00497952627456c806fc7e8827653b8_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt;margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:11pt;font-weight:400;line-height:134%">Exhibit 10(ab)</font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:134%">JOHNSON &#38; JOHNSON</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:134%">EXECUTIVE OFFICER CASH SEVERANCE POLICY</font></div><div style="margin-bottom:8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:134%">Johnson &#38; Johnson (the &#8220;Company&#8221;) will not enter into any new employment agreement, severance agreement or separation agreement with any Executive Officer of the Company, or establish any new severance plan or policy covering any Executive Officer of the Company, in each case that provides for Cash Severance Benefits exceeding 2.99 times the sum of the Executive Officer&#8217;s Base Salary and Target Bonus, without seeking stockholder ratification of such agreement, plan or policy. </font></div><div style="margin-bottom:8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:134%">Pre-existing agreements and arrangements assumed by the Company in the context of a corporate transaction are not subject to this policy.</font></div><div style="margin-bottom:8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:134%">The Compensation &#38; Benefits Committee of the Company&#8217;s Board of Directors shall administer and make all determinations regarding the interpretation of the provisions of this Executive Officer Cash Severance Policy (this &#8220;Policy&#8221;). </font></div><div style="margin-bottom:8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:134%">For purposes of this Policy&#58;</font></div><div style="margin-bottom:8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:134%">&#8220;Base Salary&#8221; means the Executive Officer&#8217;s annualized base salary in effect immediately prior to the Executive Officer&#8217;s termination date, excluding any overtime, bonus or incentive compensation.</font></div><div style="margin-bottom:8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:134%">&#8220;Cash Severance Benefits&#8221; means cash payments&#58; (i) in respect of the termination of the Executive Officer&#8217;s employment&#894; (ii) to secure an agreement not to compete with the Company&#894; or (iii) to offset any tax liability in respect of any of the foregoing. For the avoidance of doubt, &#8220;Cash Severance Benefits&#8221; do not include </font></div><div style="margin-bottom:8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:134%">(a) the grant, payment, vesting, acceleration or other handling of long-term incentive awards granted under the Company&#8217;s equity-based compensation plans, including without limitation the Johnson &#38; Johnson 2022 Long-Term Incentive Plan or any predecessor or successor plans, </font></div><div style="margin-bottom:8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:134%">(b) payment of deferred compensation, earned retirement benefits or other vested employee benefits, in each case consistent with normal practices, provided under the Company&#8217;s qualified or nonqualified retirement plans or employee benefit plans, </font></div><div style="margin-bottom:8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:134%">(c) the provision of perquisites, insurance, disability, health and welfare plan coverage, outplacement or retraining and other non-cash benefits generally available to similarly-situated employees, </font></div><div style="margin-bottom:8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:134%">(d) any notice pay or interest required to be paid pursuant to the terms of any Company plan or policy between the termination date and the payment date, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt;margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:11pt;font-weight:400;line-height:134%">Exhibit 10(ab)</font></div></div><div style="margin-bottom:8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:134%">(e) any unpaid bonus for any previously completed performance period required to be paid pursuant to the terms of any Company plan or policy, </font></div><div style="margin-bottom:8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:134%">(f) accrued but unpaid base salary or vacation pay through the termination date and reimbursement for any expenses validly incurred prior to the termination date, or </font></div><div style="margin-bottom:8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:134%">(g) any payment in respect of the Executive Officer&#8217;s bonus for the year of termination (prorated based on the Executive Officer&#8217;s completed service during the annual performance period).</font></div><div style="margin-bottom:8pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:134%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:134%;text-decoration:underline">Executive Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:134%">&#8221; means any &#8220;officer&#8221; of the Company within the meaning of Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended. </font></div><div style="margin-bottom:8pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:134%">&#8220;Target Bonus&#8221; means the Executive Officer&#8217;s target annual incentive bonus in effect immediately prior to the Executive Officer&#8217;s termination date for the year of termination, provided that if no target annual incentive bonus has been established for such year, &#8220;Target Bonus&#8221; means the Executive Officer&#8217;s target annual incentive bonus in effect for the year immediately preceding the year of termination.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>4
<FILENAME>ex21-subsidiariesxform10xk.htm
<DESCRIPTION>EX-21
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i4c146623da7e4dc88da657fe5d6259f7_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT&#160;21</font></div><div style="text-align:center"><font style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SUBSIDIARIES</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson&#160;&#38; Johnson, a New Jersey corporation, had the U.S. and international subsidiaries shown below as of December&#160;29,&#160;2024. Johnson &#38; Johnson is not a subsidiary of any other entity. </font></div><div><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of Subsidiary</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Subsidiaries&#58;</font></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ABD&#160;Holding&#160;Company,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ABIOMED&#160;COMMERCIAL,&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ABIOMED&#160;R&#38;D,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ABIOMED,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actelion&#160;Pharmaceuticals&#160;US,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Albany&#160;Street&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New&#160;Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ALZA&#160;Corporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ambrx&#160;Biopharma,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ambrx,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO&#160;Development,&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO&#160;Manufacturing&#160;USA,&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO&#160;Sales&#160;and&#160;Service,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO&#160;Spain&#160;Holdings,&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Anakuria&#160;Therapeutics,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AorTx,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aragon&#160;Pharmaceuticals,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia&#160;Pacific&#160;Holdings,&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New&#160;Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Atrionix,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AUB&#160;Holdings&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Auris&#160;Health,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BeneVir&#160;BioPharm,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biosense&#160;Webster,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Breethe,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cerenovus,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New&#160;Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coherex&#160;Medical,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoTherix&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CRES&#160;Holdings,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CrossRoads&#160;Extremity&#160;Systems,&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CSATS,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Washington</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy&#160;Mitek,&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Massachusetts</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy&#160;Orthopaedics,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy&#160;Products,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy&#160;Spine,&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ohio</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy&#160;Synthes&#160;Institute,&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy&#160;Synthes&#160;Products,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy&#160;Synthes&#160;Sales,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Massachusetts</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy&#160;Synthes,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dutch&#160;Holding&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ECL7,&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon&#160;Endo-Surgery,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ohio</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon&#160;Endo-Surgery,&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon&#160;US,&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New&#160;Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hansen&#160;Medical&#160;International,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hansen&#160;Medical,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">I.D.&#160;Acquisition&#160;Corp.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New&#160;Jersey</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of Subsidiary</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Biotech,&#160;Inc.</font></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Global&#160;Services,&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New&#160;Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Oncology,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Ortho&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Pharmaceuticals,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Products,&#160;LP</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New&#160;Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Research&#160;&#38;&#160;Development,&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New&#160;Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Scientific&#160;Affairs,&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New&#160;Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Supply&#160;Group,&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag&#160;Manufacturing,&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jevco&#160;Holding,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New&#160;Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJHC,&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNJ&#160;International&#160;Investment&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL&#160;(Russia)&#160;HoldCo&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New&#160;Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;(Middle&#160;East)&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New&#160;Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;(Singapore)&#160;HoldCo&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Enterprise&#160;Innovation&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Finance&#160;Corporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New&#160;Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Gateway,&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New&#160;Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Health&#160;Care&#160;Systems&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New&#160;Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Holdco&#160;(NA)&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New&#160;Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Innovation&#160;-&#160;JJDC,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Innovation&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;International</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New&#160;Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Medical&#160;Devices&#160;&#38;&#160;Diagnostics&#160;Group&#160;-&#160;Latin&#160;America,&#160;L.L.C.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;S.E.,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New&#160;Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Services,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New&#160;Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Surgical&#160;Vision,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Urban&#160;Renewal&#160;Associates</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New&#160;Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Vision&#160;Care,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JOM&#160;Pharmaceutical&#160;Services,&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laminar,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical&#160;Device&#160;Business&#160;Services,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical&#160;Devices&#160;&#38;&#160;Diagnostics&#160;Global&#160;Services,&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MegaDyne&#160;Medical&#160;Products,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Utah</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mentor&#160;Partnership&#160;Holding&#160;Company&#160;I,&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mentor&#160;Texas&#160;GP&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mentor&#160;Texas&#160;L.P.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mentor&#160;Worldwide&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Middlesex&#160;Assurance&#160;Company&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vermont</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Momenta&#160;Pharmaceuticals,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands&#160;Holding&#160;Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NeuWave&#160;Medical,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NuVera&#160;Medical,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OMJ&#160;Pharmaceuticals,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Omrix&#160;Biopharmaceuticals,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ortho&#160;Biologics&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ortho&#160;Biotech&#160;Holding&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patient&#160;Service&#160;Center&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patriot&#160;Pharmaceuticals,&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pecos&#160;River&#160;Talc&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Princeton&#160;Laboratories,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Propel&#160;Merger&#160;Sub,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of Subsidiary</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prosidyan,&#160;Inc.</font></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proteologix&#160;US&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proteologix,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSC&#160;Holding&#160;Co&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSC&#160;Pass&#160;Co&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pulsar&#160;Vascular,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Red&#160;River&#160;Talc&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Regency&#160;Urban&#160;Renewal&#160;Associates</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New&#160;Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty&#160;A&#38;M&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">North&#160;Carolina</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rutan&#160;Realty&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New&#160;Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Scios&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Serotiny,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shockwave&#160;Medical,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SterilMed,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes&#160;USA&#160;Products,&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes&#160;USA,&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TalCo&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TARIS&#160;Biomedical&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TearScience,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The&#160;Anspach&#160;Effort,&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tibotec,&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Torax&#160;Medical,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Verb&#160;Surgical&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">V-Wave&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">WH4110&#160;Development&#160;Company,&#160;L.L.C.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Georgia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Wolverine&#160;Merger&#160;Subsidiary,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of Subsidiary</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International Subsidiaries&#58;</font></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ABIOMED&#160;AUSTRALIA&#160;PTY&#160;LTD</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Abiomed&#160;Europe&#160;GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Abiomed&#160;Japan&#160;K.K.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ABIOMED&#160;SARL</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ABIOMED&#160;SINGAPORE&#160;PTE.&#160;LTD.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ABIOMED,&#160;LTD.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United&#160;Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actelion&#160;Pharmaceuticals&#160;Ltd</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actelion&#160;Pharmaceuticals&#160;Trading&#160;(Shanghai)&#160;Co.,&#160;Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actelion&#160;Treasury&#160;Unlimited&#160;Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AIS&#160;GmbH&#160;Aachen&#160;Innovative&#160;Solutions</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ambrx&#160;Australia&#160;Pty&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ambrx&#160;Biopharma&#160;Cayman,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cayman&#160;Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO&#160;(Hangzhou)&#160;Co.,&#160;Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO&#160;(Shanghai)&#160;Medical&#160;Devices&#160;Trading&#160;Co.,&#160;Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO&#160;ASIA&#160;LIMITED</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong&#160;Kong</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO&#160;Australia&#160;Pty&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO&#160;Canada&#160;Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO&#160;Denmark&#160;ApS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO&#160;France</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO&#160;Germany&#160;GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO&#160;Groningen&#160;B.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO&#160;International&#160;Holdings&#160;Unlimited&#160;Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO&#160;Ireland</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cayman&#160;Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO&#160;Italy&#160;SRL</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Italy</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of Subsidiary</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO&#160;Japan&#160;K.K.</font></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO&#160;Netherlands&#160;BV</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO&#160;Norway&#160;AS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Norway</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO&#160;Puerto&#160;Rico&#160;Manufacturing,&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cayman&#160;Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO&#160;Singapore&#160;Pte.&#160;Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO&#160;Switzerland&#160;GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO&#160;United&#160;Kingdom,&#160;Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United&#160;Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO&#160;Uppsala&#160;AB</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Apsis</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arterica Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B-Balloon&#160;Ltd</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Berna&#160;Rhein&#160;B.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biosense&#160;Webster&#160;(Israel)&#160;Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CathWorks Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ChromaGenics&#160;B.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cilag&#160;AG</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cilag&#160;GmbH&#160;International</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cilag&#160;Holding&#160;AG</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cilag&#160;Holding&#160;Treasury&#160;Unlimited&#160;Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cilag-Biotech,&#160;S.L.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cordis&#160;de&#160;Mexico,&#160;S.A.&#160;de&#160;C.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corimmun&#160;GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy&#160;Hellas&#160;SA</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Greece</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy&#160;International&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United&#160;Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy&#160;Ireland&#160;Unlimited&#160;Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy&#160;Mexico,&#160;S.A.&#160;de&#160;C.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ECP&#160;Entwicklungsgesellschaft&#160;mbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EES&#160;Holdings&#160;de&#160;Mexico,&#160;S.&#160;de&#160;R.L.&#160;de&#160;C.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EES,&#160;S.A.&#160;de&#160;C.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EIT&#160;Emerging&#160;Implant&#160;Technologies&#160;GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon&#160;Endo-Surgery&#160;(Europe)&#160;GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon&#160;Sarl</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon&#160;Women's&#160;Health&#160;&#38;&#160;Urology&#160;Sarl</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethnor&#160;(Proprietary)&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South&#160;Africa</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethnor&#160;del&#160;Istmo&#160;S.A.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Panama</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finsbury&#160;(Development)&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United&#160;Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finsbury&#160;(Instruments)&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United&#160;Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finsbury&#160;Medical&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United&#160;Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finsbury&#160;Orthopaedics&#160;International&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United&#160;Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finsbury&#160;Orthopaedics&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United&#160;Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FMS&#160;Future&#160;Medical&#160;System&#160;SA</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GATT&#160;Technologies&#160;B.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Genesis&#160;Shockwave&#160;Private&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GH&#160;Biotech&#160;Holdings&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of Subsidiary</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GMED&#160;Healthcare&#160;BV</font></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Guangzhou&#160;Bioseal&#160;Biotech&#160;Co.,&#160;Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hansen&#160;Medical&#160;Deutschland&#160;GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hansen&#160;Medical&#160;UK&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United&#160;Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Healthcare&#160;Services&#160;(Shanghai)&#160;Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Innomedic&#160;Gesellschaft&#160;f&#252;r&#160;innovative&#160;Medizintechnik&#160;und&#160;Informatik&#160;mbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intratech Medical Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J&#160;&#38;&#160;J&#160;Company&#160;West&#160;Africa&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nigeria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J&#38;J&#160;Argentina&#160;S.A.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Argentina</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J&#38;J&#160;Pension&#160;Trustees&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United&#160;Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J&#38;J&#160;Productos&#160;Medicos&#160;&#38;&#160;Farmaceuticos&#160;del&#160;Peru&#160;S.A.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Peru</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J.C.&#160;General&#160;Services&#160;BV</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Biologics&#160;B.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Cilag&#160;Farmaceutica&#160;S.A.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Argentina</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Cilag&#160;S.p.A.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Cilag&#160;SPA</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Algeria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Cilag,&#160;C.A.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Venezuela,&#160;Bolivarian&#160; Republic&#160;of</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Egypt&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Egypt</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Farmaceutica&#160;Portugal&#160;Lda</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;France&#160;Treasury&#160;Unlimited&#160;Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Irish&#160;Finance&#160;Unlimited&#160;Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Japan&#160;Treasury&#160;Unlimited&#160;Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Korea&#160;Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea,&#160;Republic&#160;of</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Mexico&#160;Treasury&#160;Unlimited&#160;Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Pharmaceutica&#160;(Proprietary)&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South&#160;Africa</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Pharmaceutica&#160;NV</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Pharmaceutical&#160;K.K.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Pharmaceutical&#160;Sciences&#160;Unlimited&#160;Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Pharmaceutical&#160;Unlimited&#160;Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Sciences&#160;Ireland&#160;Unlimited&#160;Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Vaccines&#160;&#38;&#160;Prevention&#160;B.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen&#160;Vaccines&#160;Corp.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea,&#160;Republic&#160;of</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag&#160;(New&#160;Zealand)&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New&#160;Zealand</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag&#160;A&#47;S</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag&#160;AG</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag&#160;Aktiebolag</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag&#160;AS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Norway</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag&#160;B.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag&#160;d.o.o.&#160;Beograd</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Serbia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag&#160;de&#160;Mexico&#160;S.&#160;de&#160;R.L.&#160;de&#160;C.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag&#160;Farmaceutica&#160;Lda.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Portugal</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of Subsidiary</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag&#160;Farmaceutica&#160;Ltda.</font></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag&#160;GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag&#160;International&#160;NV</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag&#160;Kft.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hungary</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thailand</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United&#160;Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag&#160;NV</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag&#160;OY</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag&#160;Pharma&#160;GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag&#160;Pharmaceutical&#160;Single&#160;Member&#160;S.A.C.I.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Greece</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag&#160;Polska,&#160;Sp.&#160;z&#160;o.o.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Poland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag&#160;Pty&#160;Ltd</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag&#160;S.A.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Colombia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag&#160;s.r.o.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Czech&#160;Republic</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag,&#160;S.A.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag,&#160;S.A.&#160;de&#160;C.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Pharma,&#160;S.L.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J-C&#160;Health&#160;Care&#160;Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJ&#160;Surgical&#160;Vision&#160;Spain,&#160;S.L.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJC&#160;Acquisition&#160;Company&#160;B.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJSV&#160;Belgium&#160;BV</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJSV&#160;Manufacturing&#160;Malaysia&#160;SDN.&#160;BHD.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Malaysia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJSV&#160;Norden&#160;AB</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJSV&#160;Produtos&#160;Oticos&#160;Ltda.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNJ&#160;Global&#160;Business&#160;Services&#160;s.r.o.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Czech&#160;Republic</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNJ&#160;Holding&#160;EMEA&#160;B.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL&#160;Russia&#160;HoldCo&#160;1&#160;Pte.&#160;Ltd</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL&#160;Russia&#160;HoldCo&#160;2&#160;Pte.&#160;Ltd</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;(Angola),&#160;Limitada</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Angola</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;(Australia)&#160;Pty&#160;Ltd</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;(Canada)&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;(China)&#160;Investment&#160;Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;(Ecuador)&#160;S.A.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ecuador</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;(Hong&#160;Kong)&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong&#160;Kong</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;(Ireland)&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;(Kenya)&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kenya</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;(Mozambique),&#160;Limitada</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mozambique</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;(Namibia)&#160;(Proprietary)&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Namibia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;(New&#160;Zealand)&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New&#160;Zealand</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;(Philippines),&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Philippines</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;(Private)&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zimbabwe</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;(Trinidad)&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trinidad&#160;and&#160;Tobago</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;(Vietnam)&#160;Co.,&#160;Ltd</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vietnam</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of Subsidiary</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;AB</font></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;AG</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Bulgaria&#160;EOOD</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bulgaria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;d.o.o.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Slovenia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;de&#160;Chile&#160;S.A.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chile</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;de&#160;Mexico,&#160;S.A.&#160;de&#160;C.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;de&#160;Uruguay&#160;S.A.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Uruguay</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;do&#160;Brasil&#160;Industria&#160;E&#160;Comercio&#160;de&#160;Produtos&#160;Para&#160;Saude&#160;Ltda.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Dominicana,&#160;S.A.S.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dominican&#160;Republic</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;European&#160;Treasury&#160;Unlimited&#160;Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Finance&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United&#160;Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Financial&#160;Services&#160;GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;for&#160;Export&#160;and&#160;Import&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Egypt</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;GT,&#160;Sociedad&#160;An&#243;nima</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Guatemala</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Healthcare&#160;SPC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kuwait</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Hemisferica&#160;S.A.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Puerto&#160;Rico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Holding&#160;GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Holdings&#160;(Austria)&#160;GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Innovation&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United&#160;Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;International&#160;(Singapore)&#160;Pte.&#160;Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;International&#160;Financial&#160;Services&#160;Unlimited&#160;Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Irish&#160;Finance&#160;Company&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;K.K.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Kazakhstan&#160;Limited&#160;Liability&#160;Partnership</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kazakhstan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Kft.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hungary</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Russian&#160;Federation</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Management&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United&#160;Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Medical&#160;(China)&#160;Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Medical&#160;(Proprietary)&#160;Ltd</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South&#160;Africa</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Medical&#160;(Shanghai)&#160;Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Medical&#160;(Suzhou)&#160;Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Medical&#160;B.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Medical&#160;GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Medical&#160;Greece&#160;Single&#160;Member&#160;S.A.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Greece</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Medical&#160;Korea&#160;Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea,&#160;Republic&#160;of</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Medical&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United&#160;Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Medical&#160;Mexico,&#160;S.A.&#160;de&#160;C.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Medical&#160;NV</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Medical&#160;Products&#160;GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Medical&#160;Pty&#160;Ltd</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Medical&#160;S.A.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Argentina</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Medical&#160;S.p.A.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Medical&#160;SAS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of Subsidiary</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Medical&#160;Saudi&#160;Arabia&#160;Limited</font></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Saudi&#160;Arabia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Medical&#160;Taiwan&#160;Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taiwan&#160;(Province&#160;of&#160; China)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Medical,&#160;S.A.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Venezuela,&#160;Bolivarian&#160; Republic&#160;of</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Medikal&#160;Sanayi&#160;ve&#160;Ticaret&#160;Limited&#160;Sirketi</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;MedTech&#160;(Thailand)&#160;Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thailand</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Medtech&#160;Colombia&#160;S.A.S.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Colombia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Medtech&#160;CR&#160;Limitada</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Costa&#160;Rica</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;MENA&#160;RHQ&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Saudi&#160;Arabia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Middle&#160;East&#160;FZ-LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United&#160;Arab&#160;Emirates</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Morocco&#160;Societe&#160;Anonyme</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Morocco</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Nordic&#160;AB</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Pakistan&#160;(Private)&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pakistan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Pharmaceutical&#160;Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Poland&#160;Sp.&#160;z&#160;o.o.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Poland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Private&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Romania&#160;S.R.L.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Romania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;S.E.&#160;d.o.o.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Croatia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;SDN.&#160;BHD.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Malaysia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Surgical&#160;Vision&#160;India&#160;Private&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Taiwan&#160;Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taiwan&#160;(Province&#160;of&#160; China)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Trading&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Saudi&#160;Arabia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;UK&#160;Treasury&#160;Company&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United&#160;Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Ukraine&#160;II&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ukraine</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Vision&#160;Care&#160;(Australia)&#160;Pty&#160;Ltd</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Vision&#160;Care&#160;(Shanghai)&#160;Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Vision&#160;Care&#160;Ireland&#160;Unlimited&#160;Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson&#160;Vision&#160;Korea,&#160;Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea,&#160;Republic&#160;of</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson,&#160;Lda</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson,&#160;S.A.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson,&#160;s.r.o.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Czech&#160;Republic</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson,&#160;s.r.o.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Slovakia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson&#160;&#38;&#160;Johnson,&#160;s.r.o.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JTNL&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Russian&#160;Federation</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">La&#160;Concha&#160;Land&#160;Investment&#160;Corporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Philippines</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil&#160;Panama,&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Panama</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medos&#160;International&#160;Sarl</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medos&#160;Sarl</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Menlo&#160;Care&#160;De&#160;Mexico,&#160;S.A.&#160;de&#160;C.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mentor&#160;B.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mentor&#160;Medical&#160;Systems&#160;B.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neovasc&#160;(UK)&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United&#160;Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neovasc&#160;Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neovasc&#160;Medical&#160;Ltd</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of Subsidiary</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neovasc&#160;Tiara&#160;Inc.</font></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuravi&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Obtech&#160;Medical&#160;Mexico,&#160;S.A.&#160;de&#160;C.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OBTECH&#160;Medical&#160;Sarl</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OMJ&#160;Holding&#160;GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Omrix&#160;Biopharmaceuticals&#160;Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Omrix&#160;Biopharmaceuticals&#160;NV</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orthospin&#160;Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orthotaxy</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">preCARDIA</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proleader&#160;S.A.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Uruguay</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Protembis GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proteologix&#160;Australia&#160;Pty&#160;Ltd</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PT&#160;Johnson&#160;and&#160;Johnson&#160;Indonesia&#160;Two</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indonesia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RespiVert&#160;Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United&#160;Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Serhum&#160;S.A.&#160;de&#160;C.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shockwave&#160;Medical&#160;France&#160;SaRL</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ShockWave&#160;Medical&#160;GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shockwave&#160;Medical&#160;India&#160;Private&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shockwave&#160;Medical&#160;Ireland&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shockwave&#160;Medical&#160;Italy&#160;S.R.L.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shockwave&#160;Medical&#160;Japan&#160;KK</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shockwave&#160;Medical&#160;Portugal,&#160;Unipessoal&#160;Lda.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shockwave&#160;Medical&#160;UK&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United&#160;Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spectrum&#160;Vision&#160;Limited&#160;Liability&#160;Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ukraine</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spectrum&#160;Vision&#160;Limited&#160;Liability&#160;Partnership</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kazakhstan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical&#160;Process&#160;Institute&#160;Deutschland&#160;GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Swav&#160;CR,&#160;Sociedad&#160;de&#160;Responsabilidad&#160;Limitada</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Costa&#160;Rica</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SWAV&#160;Medical&#160;Spain,&#160;S.L.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes&#160;Costa&#160;Rica&#160;S.C.R.,&#160;Limitada</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Costa&#160;Rica</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SYNTHES&#160;GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes&#160;GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes&#160;Holding&#160;AG</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes&#160;Holding&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United&#160;Arab&#160;Emirates</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SYNTHES&#160;Medical&#160;Immobilien&#160;GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes&#160;Medical&#160;Surgical&#160;Equipment&#160;&#38;&#160;Instruments&#160;Trading&#160;LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United&#160;Arab&#160;Emirates</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes&#160;Produktions&#160;GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes&#160;S.M.P.,&#160;S.&#160;de&#160;R.L.&#160;de&#160;C.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes&#160;Tuttlingen&#160;GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">UAB&#160;&#34;Johnson&#160;&#38;&#160;Johnson&#34;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lithuania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vision&#160;Care&#160;Finance&#160;Unlimited&#160;Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">V-Wave&#160;(Australia)&#160;Pty&#160;Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">V-Wave&#160;Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of Subsidiary</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xian&#160;Janssen&#160;Pharmaceutical&#160;Ltd.</font></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XO1&#160;Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United&#160;Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Yellow&#160;Jersey&#160;Therapeutics&#160;AG</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>5
<FILENAME>ex23-pwcconsentxform10xkx2.htm
<DESCRIPTION>EX-23
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i6bdf547aa150487aadb3d768c972a0b1_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT&#160;23</font></div><div style="margin-top:19pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-264596, 333-211250, 333-181092, and 333-129542) and Form S-3 (No. 333-269836) of Johnson &#38; Johnson of our report dated February 13, 2025 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#47;s&#47;PricewaterhouseCoopers LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Florham Park, New Jersey </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">February 13, 2025</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>ex311-302certofceoxform10x.htm
<DESCRIPTION>EX-31.1 CEO
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i1d9e64f280654296bb2c44ccd2598a3a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;31.1</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joaquin Duato, certify that&#58;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;I have reviewed this Annual Report on Form 10-K for the fiscal year ended December&#160;29, 2024 (the &#8220;report&#8221;) of Johnson &#38; Johnson (the &#8220;Company&#8221;)&#59;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;The Company&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the Company and have&#58;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(c) Evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(d) Disclosed in this report any change in the Company&#8217;s internal control over financial reporting that occurred during the Company&#8217;s most recent fiscal quarter (the Company&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;The Company&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit committee of the Company&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joaquin Duato</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joaquin Duato</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;13, 2025</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>ex312-302certofcfoxform10x.htm
<DESCRIPTION>EX-31.2 CFO
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i2bf65906191840bb8efc1792b294a915_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 31.2</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joseph J. Wolk certify that&#58;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;I have reviewed this Annual Report on Form 10-K for the fiscal year ended December&#160;29, 2024 (the &#8220;report&#8221;) of Johnson &#38; Johnson (the &#8220;Company&#8221;)&#59;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;The Company&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the Company and have&#58;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(c) Evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(d) Disclosed in this report any change in the Company&#8217;s internal control over financial reporting that occurred during the Company&#8217;s most recent fiscal quarter (the Company&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;The Company&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit committee of the Company&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph J. Wolk</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph J. Wolk</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;13, 2025 </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>ex321-906certofceoxform10x.htm
<DESCRIPTION>EX-32.1 CEO
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i078575c62cc4473aade8c91d2f326737_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1</font></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT</font></div><div style="margin-top:6pt;text-indent:15.75pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The undersigned, Joaquin Duato, the Chief Executive Officer of Johnson &#38; Johnson, a New Jersey corporation (the &#8220;Company&#8221;), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge&#58;</font></div><div style="margin-top:6pt;text-indent:15.75pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.14pt">the Company's Annual Report on Form 10-K for the fiscal year ended December&#160;29, 2024 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.83pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joaquin Duato</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joaquin Duato</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; February&#160;13, 2025</font></div><div style="margin-top:6pt;text-indent:15.75pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification is being furnished to the SEC with this Report on Form 10-K pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section.</font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>ex322-906certofcfoxform10x.htm
<DESCRIPTION>EX-32.2 CFO
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i5e7283eb69a34aadb8aef2dc4498952b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:right"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT</font></div><div style="margin-top:6pt;text-indent:15.75pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The undersigned, Joseph J. Wolk, the Chief Financial Officer of Johnson &#38; Johnson, a New Jersey corporation (the &#8220;Company&#8221;), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge&#58;</font></div><div style="margin-top:6pt;text-indent:15.75pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.14pt">the Company's Annual Report on Form 10-K for the fiscal year ended December&#160;29, 2024 (the &#8220;Report&#34;) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.83pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph J. Wolk</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#eb1700;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph J. Wolk&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; February&#160;13, 2025</font></div><div style="margin-top:6pt;text-indent:15.75pt"><font style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification is being furnished to the SEC with this Report on Form 10-K pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>jnj-20241229.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:a7478940-65f4-4b69-a475-f625bf9a358e,g:8ea82ba0-2a78-4425-b720-89454b578aab-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:jnj="http://www.jnj.com/20241229" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.jnj.com/20241229">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20241229_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20241229_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20241229_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20241229_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.jnj.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.jnj.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEarnings" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings">
        <link:definition>9952153 - Statement - Consolidated Statements of Earnings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>9952154 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncomeParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical">
        <link:definition>9952155 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquity" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity">
        <link:definition>9952156 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquityParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical">
        <link:definition>9952157 - Statement - Consolidated Statements of Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>9952158 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Summaryofsignificantaccountingpolicies" roleURI="http://www.jnj.com/role/Summaryofsignificantaccountingpolicies">
        <link:definition>9952159 - Disclosure - Summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Cashcashequivalentsandcurrentmarketablesecurities" roleURI="http://www.jnj.com/role/Cashcashequivalentsandcurrentmarketablesecurities">
        <link:definition>9952160 - Disclosure - Cash, cash equivalents and current marketable securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.jnj.com/role/Inventories">
        <link:definition>9952161 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Propertyplantandequipment" roleURI="http://www.jnj.com/role/Propertyplantandequipment">
        <link:definition>9952162 - Disclosure - Property, plant and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Intangibleassetsandgoodwill" roleURI="http://www.jnj.com/role/Intangibleassetsandgoodwill">
        <link:definition>9952163 - Disclosure - Intangible assets and goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Fairvaluemeasurements" roleURI="http://www.jnj.com/role/Fairvaluemeasurements">
        <link:definition>9952164 - Disclosure - Fair value measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Borrowings" roleURI="http://www.jnj.com/role/Borrowings">
        <link:definition>9952165 - Disclosure - Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Incometaxes" roleURI="http://www.jnj.com/role/Incometaxes">
        <link:definition>9952166 - Disclosure - Income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Employeerelatedobligations" roleURI="http://www.jnj.com/role/Employeerelatedobligations">
        <link:definition>9952167 - Disclosure - Employee related obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Pensionsandotherbenefitplans" roleURI="http://www.jnj.com/role/Pensionsandotherbenefitplans">
        <link:definition>9952168 - Disclosure - Pensions and other benefit plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Savingsplan" roleURI="http://www.jnj.com/role/Savingsplan">
        <link:definition>9952169 - Disclosure - Savings plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Capitalandtreasurystock" roleURI="http://www.jnj.com/role/Capitalandtreasurystock">
        <link:definition>9952170 - Disclosure - Capital and treasury stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Accumulatedothercomprehensiveincomeloss" roleURI="http://www.jnj.com/role/Accumulatedothercomprehensiveincomeloss">
        <link:definition>9952171 - Disclosure - Accumulated other comprehensive income (loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Internationalcurrencytranslation" roleURI="http://www.jnj.com/role/Internationalcurrencytranslation">
        <link:definition>9952172 - Disclosure - International currency translation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Earningspershare" roleURI="http://www.jnj.com/role/Earningspershare">
        <link:definition>9952173 - Disclosure - Earnings per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Commonstockstockoptionplansandstockcompensationagreements" roleURI="http://www.jnj.com/role/Commonstockstockoptionplansandstockcompensationagreements">
        <link:definition>9952174 - Disclosure - Common stock, stock option plans and stock compensation agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Segmentsofbusinessandgeographicareas" roleURI="http://www.jnj.com/role/Segmentsofbusinessandgeographicareas">
        <link:definition>9952175 - Disclosure - Segments of business and geographic areas</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitionsanddivestitures" roleURI="http://www.jnj.com/role/Acquisitionsanddivestitures">
        <link:definition>9952176 - Disclosure - Acquisitions and divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Legalproceedings" roleURI="http://www.jnj.com/role/Legalproceedings">
        <link:definition>9952177 - Disclosure - Legal proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuring" roleURI="http://www.jnj.com/role/Restructuring">
        <link:definition>9952178 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Kenvueseparationanddiscontinuedoperations" roleURI="http://www.jnj.com/role/Kenvueseparationanddiscontinuedoperations">
        <link:definition>9952179 - Disclosure - Kenvue separation and discontinued operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesPolicies" roleURI="http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesTables" roleURI="http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesTables">
        <link:definition>9955512 - Disclosure - Summary of significant accounting policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashcashequivalentsandcurrentmarketablesecuritiesTables" roleURI="http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesTables">
        <link:definition>9955513 - Disclosure - Cash, cash equivalents and current marketable securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.jnj.com/role/InventoriesTables">
        <link:definition>9955514 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentTables" roleURI="http://www.jnj.com/role/PropertyplantandequipmentTables">
        <link:definition>9955515 - Disclosure - Property, plant and equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsandgoodwillTables" roleURI="http://www.jnj.com/role/IntangibleassetsandgoodwillTables">
        <link:definition>9955516 - Disclosure - Intangible assets and goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsTables" roleURI="http://www.jnj.com/role/FairvaluemeasurementsTables">
        <link:definition>9955517 - Disclosure - Fair value measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsTables" roleURI="http://www.jnj.com/role/BorrowingsTables">
        <link:definition>9955518 - Disclosure - Borrowings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesTables" roleURI="http://www.jnj.com/role/IncometaxesTables">
        <link:definition>9955519 - Disclosure - Income taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeerelatedobligationsTables" roleURI="http://www.jnj.com/role/EmployeerelatedobligationsTables">
        <link:definition>9955520 - Disclosure - Employee related obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandotherbenefitplansTables" roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansTables">
        <link:definition>9955521 - Disclosure - Pensions and other benefit plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalandtreasurystockTables" roleURI="http://www.jnj.com/role/CapitalandtreasurystockTables">
        <link:definition>9955522 - Disclosure - Capital and treasury stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedothercomprehensiveincomelossTables" roleURI="http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossTables">
        <link:definition>9955523 - Disclosure - Accumulated other comprehensive income (loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningspershareTables" roleURI="http://www.jnj.com/role/EarningspershareTables">
        <link:definition>9955524 - Disclosure - Earnings per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonstockstockoptionplansandstockcompensationagreementsTables" roleURI="http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsTables">
        <link:definition>9955525 - Disclosure - Common stock, stock option plans and stock compensation agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofbusinessandgeographicareasTables" roleURI="http://www.jnj.com/role/SegmentsofbusinessandgeographicareasTables">
        <link:definition>9955526 - Disclosure - Segments of business and geographic areas (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsanddivestituresTables" roleURI="http://www.jnj.com/role/AcquisitionsanddivestituresTables">
        <link:definition>9955527 - Disclosure - Acquisitions and divestitures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalproceedingsTables" roleURI="http://www.jnj.com/role/LegalproceedingsTables">
        <link:definition>9955528 - Disclosure - Legal proceedings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringTables" roleURI="http://www.jnj.com/role/RestructuringTables">
        <link:definition>9955529 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="KenvueseparationanddiscontinuedoperationsTables" roleURI="http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsTables">
        <link:definition>9955530 - Disclosure - Kenvue separation and discontinued operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesNarrativeDetails" roleURI="http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails">
        <link:definition>9955531 - Disclosure - Summary of significant accounting policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails" roleURI="http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails">
        <link:definition>9955532 - Disclosure - Summary of significant accounting policies - Estimated Useful Lives of Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesSupplierFinanceProgramDetails" roleURI="http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesSupplierFinanceProgramDetails">
        <link:definition>9955533 - Disclosure - Summary of significant accounting policies - Supplier Finance Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" roleURI="http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails">
        <link:definition>9955534 - Disclosure - Cash, cash equivalents and current marketable securities - Cash and Cash Equivalent Composition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails" roleURI="http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails">
        <link:definition>9955535 - Disclosure - Cash, cash equivalents and current marketable securities - Contractual Maturities of Available for Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.jnj.com/role/InventoriesDetails">
        <link:definition>9955536 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" roleURI="http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails">
        <link:definition>9955537 - Disclosure - Property, plant and equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentNarrativeDetails" roleURI="http://www.jnj.com/role/PropertyplantandequipmentNarrativeDetails">
        <link:definition>9955538 - Disclosure - Property, plant and equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails" roleURI="http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails">
        <link:definition>9955539 - Disclosure - Intangible assets and goodwil - Schedule of Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsandgoodwillGoodwillDetails" roleURI="http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails">
        <link:definition>9955540 - Disclosure - Intangible assets and goodwill - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsandgoodwillNarrativeDetails" roleURI="http://www.jnj.com/role/IntangibleassetsandgoodwillNarrativeDetails">
        <link:definition>9955541 - Disclosure - Intangible assets and goodwill - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsandgoodwillEstimatedAmortizationofIntangibleAssetsDetails" roleURI="http://www.jnj.com/role/IntangibleassetsandgoodwillEstimatedAmortizationofIntangibleAssetsDetails">
        <link:definition>9955542 - Disclosure - Intangible assets and goodwill - Estimated Amortization of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsNarrativeDetails" roleURI="http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails">
        <link:definition>9955543 - Disclosure - Fair value measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsSummaryofDerivativeActivityDetails" roleURI="http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails">
        <link:definition>9955544 - Disclosure - Fair value measurements - Summary of Derivative Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails" roleURI="http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails">
        <link:definition>9955545 - Disclosure - Fair value measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" roleURI="http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails">
        <link:definition>9955546 - Disclosure - Fair value measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails" roleURI="http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails">
        <link:definition>9955547 - Disclosure - Fair value measurements - Schedule of Effect of Net Investment Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" roleURI="http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails">
        <link:definition>9955548 - Disclosure - Fair value measurements - Summary of Activity Related to Equity Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" roleURI="http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails">
        <link:definition>9955549 - Disclosure - Fair value measurements - Financial Assets and Liabilities at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsScheduleofLongtermDebtInstrumentsDetails" roleURI="http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails">
        <link:definition>9955550 - Disclosure - Borrowings - Schedule of Long-term Debt Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsNarrativeDetails" roleURI="http://www.jnj.com/role/BorrowingsNarrativeDetails">
        <link:definition>9955551 - Disclosure - Borrowings - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsAggregateMaturitiesofLongTermObligationsDetails" roleURI="http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails">
        <link:definition>9955552 - Disclosure - Borrowings - Aggregate Maturities of Long Term Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesProvisionforIncomeTaxesDetails" roleURI="http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails">
        <link:definition>9955553 - Disclosure - Income taxes - Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" roleURI="http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails">
        <link:definition>9955554 - Disclosure - Income taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesNarrativeDetails" roleURI="http://www.jnj.com/role/IncometaxesNarrativeDetails">
        <link:definition>9955555 - Disclosure - Income taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesTemporaryDifferencesandCarryforwardsDetails" roleURI="http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails">
        <link:definition>9955556 - Disclosure - Income taxes - Temporary Differences and Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesValuationAllowanceActivityDetails" roleURI="http://www.jnj.com/role/IncometaxesValuationAllowanceActivityDetails">
        <link:definition>9955557 - Disclosure - Income taxes - Valuation Allowance Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" roleURI="http://www.jnj.com/role/IncometaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails">
        <link:definition>9955558 - Disclosure - Income taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeerelatedobligationsEmployeeRelatedObligationsDetails" roleURI="http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails">
        <link:definition>9955559 - Disclosure - Employee related obligations - Employee Related Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeerelatedobligationsEmployeeRelatedObligationsDetails_1" roleURI="http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails_1">
        <link:definition>9955559 - Disclosure - Employee related obligations - Employee Related Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeerelatedobligationsNarrativeDetails" roleURI="http://www.jnj.com/role/EmployeerelatedobligationsNarrativeDetails">
        <link:definition>9955560 - Disclosure - Employee related obligations - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandotherbenefitplansNarrativeDetails" roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails">
        <link:definition>9955561 - Disclosure - Pensions and other benefit plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails" roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails">
        <link:definition>9955562 - Disclosure - Pensions and other benefit plans - Components of Net Periodic Benefit Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails">
        <link:definition>9955563 - Disclosure - Pensions and other benefit plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandotherbenefitplansAssumedHealthCareCostTrendRatesDetails" roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansAssumedHealthCareCostTrendRatesDetails">
        <link:definition>9955564 - Disclosure - Pensions and other benefit plans - Assumed Health Care Cost Trend Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails">
        <link:definition>9955565 - Disclosure - Pensions and other benefit plans - Schedule of Net Funded Status (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails">
        <link:definition>9955566 - Disclosure - Pensions and other benefit plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails" roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails">
        <link:definition>9955567 - Disclosure - Pensions and other benefit plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandotherbenefitplansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails" roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails">
        <link:definition>9955568 - Disclosure - Pensions and other benefit plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandotherbenefitplansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails" roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails">
        <link:definition>9955569 - Disclosure - Pensions and other benefit plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails" roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails">
        <link:definition>9955570 - Disclosure - Pensions and other benefit plans - Schedule of Defined Benefit Plans Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SavingsplanDetails" roleURI="http://www.jnj.com/role/SavingsplanDetails">
        <link:definition>9955571 - Disclosure - Savings plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalandtreasurystockChangesinTreasuryStockDetails" roleURI="http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails">
        <link:definition>9955572 - Disclosure - Capital and treasury stock - Changes in Treasury Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalandtreasurystockNarrativeDetails" roleURI="http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails">
        <link:definition>9955573 - Disclosure - Capital and treasury stock - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedothercomprehensiveincomelossDetails" roleURI="http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails">
        <link:definition>9955574 - Disclosure - Accumulated other comprehensive income (loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InternationalcurrencytranslationDetails" roleURI="http://www.jnj.com/role/InternationalcurrencytranslationDetails">
        <link:definition>9955575 - Disclosure - International currency translation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" roleURI="http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails">
        <link:definition>9955576 - Disclosure - Earnings per share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningspershareNarrativeDetails" roleURI="http://www.jnj.com/role/EarningspershareNarrativeDetails">
        <link:definition>9955577 - Disclosure - Earnings per share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails" roleURI="http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails">
        <link:definition>9955578 - Disclosure - Common stock, stock option plans and stock compensation agreements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonstockstockoptionplansandstockcompensationagreementsScheduleValuationAssumptionsDetails" roleURI="http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsScheduleValuationAssumptionsDetails">
        <link:definition>9955579 - Disclosure - Common stock, stock option plans and stock compensation agreements - Schedule Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails" roleURI="http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails">
        <link:definition>9955580 - Disclosure - Common stock, stock option plans and stock compensation agreements - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails" roleURI="http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails">
        <link:definition>9955581 - Disclosure - Common stock, stock option plans and stock compensation agreements - Summary of Options Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails" roleURI="http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails">
        <link:definition>9955582 - Disclosure - Common stock, stock option plans and stock compensation agreements - Summary of Restricted Share Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails">
        <link:definition>9955583 - Disclosure - Segments of Business and Geographic Areas - Sales by Segment of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails">
        <link:definition>9955584 - Disclosure - Segments of Business and Geographic Areas - Income Before Tax by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails">
        <link:definition>9955585 - Disclosure - Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails">
        <link:definition>9955586 - Disclosure - Segments of Business and Geographic Areas - Schedule of Segment Reporting By Geographic Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsanddivestituresNarrativeDetails" roleURI="http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails">
        <link:definition>9955587 - Disclosure - Acquisitions and divestitures - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsanddivestituresDetails" roleURI="http://www.jnj.com/role/AcquisitionsanddivestituresDetails">
        <link:definition>9955588 - Disclosure - Acquisitions and divestitures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalproceedingsNarrativeDetails" roleURI="http://www.jnj.com/role/LegalproceedingsNarrativeDetails">
        <link:definition>9955589 - Disclosure - Legal proceedings - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalproceedingsProductLiabilitiesDetails" roleURI="http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails">
        <link:definition>9955590 - Disclosure - Legal proceedings - Product Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringNarrativeDetails" roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails">
        <link:definition>9955591 - Disclosure - Restructuring - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringScheduleofRestructuringReserveDetails" roleURI="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails">
        <link:definition>9955592 - Disclosure - Restructuring - Schedule of Restructuring Reserve (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="KenvueseparationanddiscontinuedoperationsDetailsDetails" roleURI="http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails">
        <link:definition>9955593 - Disclosure - Kenvue separation and discontinued operations - Details (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails" roleURI="http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails">
        <link:definition>9955594 - Disclosure - Kenvue separation and discontinued operations - Net Earnings from Discontinued Operation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="KenvueseparationanddiscontinuedoperationsDepreciationandAmortizationofDiscontinuedOperationDetails" roleURI="http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDepreciationandAmortizationofDiscontinuedOperationDetails">
        <link:definition>9955595 - Disclosure - Kenvue separation and discontinued operations - Depreciation and Amortization of Discontinued Operation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="jnj_A1.150NotesDue2028Member" abstract="true" name="A1.150NotesDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A1.650NotesDue2035Member" abstract="true" name="A1.650NotesDue2035Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A1.150NotesDueNovember2028Member" abstract="true" name="A1.150NotesDueNovember2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.20NotesDueNovember2032Member" abstract="true" name="A3.20NotesDueNovember2032Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.350NotesDueNovember2036Member" abstract="true" name="A3.350NotesDueNovember2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.550NotesDueNovember2044Member" abstract="true" name="A3.550NotesDueNovember2044Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_AccruedRebatesReturnsAndPromotions" abstract="false" name="AccruedRebatesReturnsAndPromotions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ResearchAndDevelopmentInProcess1" abstract="false" name="ResearchAndDevelopmentInProcess1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" abstract="false" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" abstract="false" name="OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" abstract="false" name="OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_PaymentsToAcquiredInProcessResearchAndDevelopmentAssets" abstract="false" name="PaymentsToAcquiredInProcessResearchAndDevelopmentAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" abstract="false" name="ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" abstract="false" name="ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" abstract="false" name="ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_SettlementOfConvertibleDebtAcquiredFromShockwave" abstract="false" name="SettlementOfConvertibleDebtAcquiredFromShockwave" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation" abstract="false" name="ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_PaymentsMadeInBusinessSeparation" abstract="false" name="PaymentsMadeInBusinessSeparation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_CashPaidDuringTheYearAbstract" abstract="true" name="CashPaidDuringTheYearAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" abstract="false" name="TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_SavingsPlanAbstract" abstract="true" name="SavingsPlanAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_SavingsPlanTextBlock" abstract="false" name="SavingsPlanTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="jnj_ProductLiabilityPolicyTextBlock" abstract="false" name="ProductLiabilityPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="jnj_SupplierFinanceProgramPolicyTextBlock" abstract="false" name="SupplierFinanceProgramPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_FiscalPeriodPolicyTextBlock" abstract="false" name="FiscalPeriodPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="jnj_EstimatedUsefulLivesOfAssetsTableTextBlock" abstract="false" name="EstimatedUsefulLivesOfAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" abstract="false" name="ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="jnj_EmployeeRelatedObligationsTableTextBlock" abstract="false" name="EmployeeRelatedObligationsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" abstract="false" name="InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" abstract="false" name="ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="jnj_ChangesInTreasuryStockTableTextBlock" abstract="false" name="ChangesInTreasuryStockTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="jnj_SalesBySegmentOfBusinessTableTextBlock" abstract="false" name="SalesBySegmentOfBusinessTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="jnj_ConcentrationOfCreditRiskTable" abstract="true" name="ConcentrationOfCreditRiskTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="jnj_PharmaceuticalMember" abstract="true" name="PharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_KenvueIncMember" abstract="true" name="KenvueIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_JohnsonJohnsonMember" abstract="true" name="JohnsonJohnsonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_YellowJerseyTherapeuticsMember" abstract="true" name="YellowJerseyTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ConcentrationOfCreditRiskLineItems" abstract="true" name="ConcentrationOfCreditRiskLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" abstract="false" name="NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_OwnershipPercentageSplitOffPercent" abstract="false" name="OwnershipPercentageSplitOffPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_ExchangeOfStockPercentageOwnershipAfterTransaction" abstract="false" name="ExchangeOfStockPercentageOwnershipAfterTransaction" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement" abstract="false" name="MinimumCollateralValueasaPercentReverseRepurchaseAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jnj_RevenuePerformanceObligationPaymentTerms" abstract="false" name="RevenuePerformanceObligationPaymentTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jnj_SalesReturnReserve" abstract="false" name="SalesReturnReserve" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jnj_ProfitLossPercentToSales" abstract="false" name="ProfitLossPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jnj_ShippingandHandlingCostsasaPercentofSales" abstract="false" name="ShippingandHandlingCostsasaPercentofSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jnj_ConcentrationRiskThresholdPercentage" abstract="false" name="ConcentrationRiskThresholdPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" abstract="false" name="TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" abstract="false" name="TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jnj_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsPaymentPeriod" abstract="false" name="TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" abstract="false" name="TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_LandAndLeaseholdImprovementsMember" abstract="true" name="LandAndLeaseholdImprovementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_OtherSovereignSecuritiesMember" abstract="true" name="OtherSovereignSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" abstract="false" name="DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" abstract="true" name="ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="jnj_PatentsAndTrademarksMember" abstract="true" name="PatentsAndTrademarksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_PurchasedInProcessResearchAndDevelopmentMember" abstract="true" name="PurchasedInProcessResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" abstract="true" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_InnovativeMedicineMember" abstract="true" name="InnovativeMedicineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_MedTechMember" abstract="true" name="MedTechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" abstract="true" name="EquityInvestmentswithoutReadilyDeterminableValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_DebtForEquityExchangeSharesExchanged" abstract="false" name="DebtForEquityExchangeSharesExchanged" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jnj_DebtForEquityExchangeLossOnSharesExchanged" abstract="false" name="DebtForEquityExchangeLossOnSharesExchanged" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_EquityFairValueAdjustmentImpairmentLoss" abstract="false" name="EquityFairValueAdjustmentImpairmentLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_EquityFairValueAdjustmentChangeinObservablePrices" abstract="false" name="EquityFairValueAdjustmentChangeinObservablePrices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_InterestIncomeExpenseNetMember" abstract="true" name="InterestIncomeExpenseNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_OtherIncomeExpenseNetMember" abstract="true" name="OtherIncomeExpenseNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_EquityInvestmentswithReadilyDeterminableValueMember" abstract="true" name="EquityInvestmentswithReadilyDeterminableValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_EquityInvestmentRollForward" abstract="true" name="EquityInvestmentRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" abstract="false" name="EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_AbiomedMember" abstract="true" name="AbiomedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_ProteologixMember" abstract="true" name="ProteologixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" abstract="false" name="DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" abstract="false" name="DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" abstract="false" name="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_A0.650NotesDue2024Member" abstract="true" name="A0.650NotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A5.50NotesDue2024Member" abstract="true" name="A5.50NotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A2.625Notesdue2025Member" abstract="true" name="A2.625Notesdue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A055NotesDue2025Member" abstract="true" name="A055NotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A2.45Notesdue2026Member" abstract="true" name="A2.45Notesdue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A2.95Notesdue2027Member" abstract="true" name="A2.95Notesdue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A095NotesDue2027Member" abstract="true" name="A095NotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A2.900Notesdue2028Member" abstract="true" name="A2.900Notesdue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A6.95Notesdue2029Member" abstract="true" name="A6.95Notesdue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A4.80DebenturesDue2029Member" abstract="true" name="A4.80DebenturesDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A130NotesDue2030Member" abstract="true" name="A130NotesDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A4.90DebenturesDue2031Member" abstract="true" name="A4.90DebenturesDue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.20DebenturesDue2032Member" abstract="true" name="A3.20DebenturesDue2032Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A4.95Debenturesdue2033Member" abstract="true" name="A4.95Debenturesdue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A4.375Notesdue2033Member" abstract="true" name="A4.375Notesdue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A4.95DebenturesDue2034Member" abstract="true" name="A4.95DebenturesDue2034Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.35DebenturesDue2036Member" abstract="true" name="A3.35DebenturesDue2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.55Notesdue2036Member" abstract="true" name="A3.55Notesdue2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A5.95Notesdue2037Member" abstract="true" name="A5.95Notesdue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A3.625Notesdue2037Member" abstract="true" name="A3.625Notesdue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A5.85Debenturesdue2038Member" abstract="true" name="A5.85Debenturesdue2038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A3.400Notesdue2038Member" abstract="true" name="A3.400Notesdue2038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A4.50Debenturesdue2040Member" abstract="true" name="A4.50Debenturesdue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A210NotesDue2040Member" abstract="true" name="A210NotesDue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A4.85Notesdue2041Member" abstract="true" name="A4.85Notesdue2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A4.50Notesdue2043Member" abstract="true" name="A4.50Notesdue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A3.55DebenturesDue2044Member" abstract="true" name="A3.55DebenturesDue2044Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.70Notesdue2046Member" abstract="true" name="A3.70Notesdue2046Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A3.75Notesdue2047Member" abstract="true" name="A3.75Notesdue2047Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A3.500Notesdue2048Member" abstract="true" name="A3.500Notesdue2048Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A2250NotesDue2050Member" abstract="true" name="A2250NotesDue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A5.25DebenturesDue2054Member" abstract="true" name="A5.25DebenturesDue2054Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2450NotesDue2060Member" abstract="true" name="A2450NotesDue2060Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_ExcessOfCarryingValueOverFairValueOfDebt" abstract="false" name="ExcessOfCarryingValueOverFairValueOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ExcessOfFairValueOverCarryingValueOfDebt" abstract="false" name="ExcessOfFairValueOverCarryingValueOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations" abstract="false" name="DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" abstract="true" name="ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation" abstract="false" name="EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" abstract="false" name="EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jnj_TalcMember" abstract="true" name="TalcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_RisperdalMember" abstract="true" name="RisperdalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_ConsumerMember" abstract="true" name="ConsumerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" abstract="false" name="EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" abstract="false" name="DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" abstract="false" name="IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" abstract="false" name="DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DeferredTaxAssetsUndistributedForeignEarnings" abstract="false" name="DeferredTaxAssetsUndistributedForeignEarnings" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DeferredTaxAssetsOtherDomestic" abstract="false" name="DeferredTaxAssetsOtherDomestic" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" abstract="false" name="DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DeferredTaxLiabilitiesOtherDomestic" abstract="false" name="DeferredTaxLiabilitiesOtherDomestic" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ValuationAllowanceRollForward" abstract="true" name="ValuationAllowanceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_ValuationAllowanceDeferredTaxAssetsProvision" abstract="false" name="ValuationAllowanceDeferredTaxAssetsProvision" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ValuationAllowanceDeferredTaxAssetsUtilization" abstract="false" name="ValuationAllowanceDeferredTaxAssetsUtilization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslation" abstract="false" name="ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ValuationAllowanceDeferredTaxAssetsAcquisitionsDispositions" abstract="false" name="ValuationAllowanceDeferredTaxAssetsAcquisitionsDispositions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_EmployeeObligations" abstract="false" name="EmployeeObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_CommingledFundsMember" abstract="true" name="CommingledFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_EmployeeCompensationPeriod" abstract="false" name="EmployeeCompensationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets" abstract="false" name="PercentageOfCorridorOfGreaterOfMarketValueOfAssets" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" abstract="false" name="FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" abstract="false" name="DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" abstract="false" name="DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_CurtailmentsAndSettlementsAndRestructuring" abstract="false" name="CurtailmentsAndSettlementsAndRestructuring" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" abstract="false" name="DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract" abstract="false" name="DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_EffectOfExchangeRates" abstract="false" name="EffectOfExchangeRates" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_QualifiedPlansMember" abstract="true" name="QualifiedPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_NonQualifiedPlansMember" abstract="true" name="NonQualifiedPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_FundedPlansMember" abstract="true" name="FundedPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_UnfundedPlansMember" abstract="true" name="UnfundedPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanOverUnderFundedStatusABO" abstract="false" name="DefinedBenefitPlanOverUnderFundedStatusABO" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" abstract="false" name="DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" abstract="false" name="DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" abstract="false" name="DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" abstract="false" name="DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" abstract="false" name="DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" abstract="false" name="DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ShortTermInvestmentFundsMember" abstract="true" name="ShortTermInvestmentFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" abstract="false" name="DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ChangesinTreasuryStockSharesOutstandingRollForward" abstract="true" name="ChangesinTreasuryStockSharesOutstandingRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_ChangesInTreasuryStockRollForward" abstract="true" name="ChangesInTreasuryStockRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_TreasuryStockValueAcquiredCostMethodNetOfTax" abstract="false" name="TreasuryStockValueAcquiredCostMethodNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_December172018ShareRepurchaseProgramMember" abstract="true" name="December172018ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" abstract="false" name="SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jnj_A2022LongTermIncentivePlanMember" abstract="true" name="A2022LongTermIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_NumberOfStockBasedCompensationPlans" abstract="false" name="NumberOfStockBasedCompensationPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jnj_ExercisePriceRangeOneMember" abstract="true" name="ExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_ExercisePriceRangeTwoMember" abstract="true" name="ExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_ExercisePriceRangeThreeMember" abstract="true" name="ExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_ExercisePriceRangeFourMember" abstract="true" name="ExercisePriceRangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_ExercisePriceRangeFiveMember" abstract="true" name="ExercisePriceRangeFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" abstract="true" name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jnj_UNITEDSTATESExportsMember" abstract="true" name="UNITEDSTATESExportsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_RemicadeMember" abstract="true" name="RemicadeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_SimponiSimponiAriaMember" abstract="true" name="SimponiSimponiAriaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_StelaraMember" abstract="true" name="StelaraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_TremfyaMember" abstract="true" name="TremfyaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_OtherImmunologyMember" abstract="true" name="OtherImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_COVID19Member" abstract="true" name="COVID19Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_EDURANTrilpivirineMember" abstract="true" name="EDURANTrilpivirineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" abstract="true" name="PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_OtherInfectiousDiseasesMember" abstract="true" name="OtherInfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_CONCERTAMethylphenidateMember" abstract="true" name="CONCERTAMethylphenidateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" abstract="true" name="INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_SPRAVATOMember" abstract="true" name="SPRAVATOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OTHERNEUROSCIENCEMember" abstract="true" name="OTHERNEUROSCIENCEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_CARVYKTIMember" abstract="true" name="CARVYKTIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DARZALEXMember" abstract="true" name="DARZALEXMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_ErleadaMember" abstract="true" name="ErleadaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_IMBRUVICAMember" abstract="true" name="IMBRUVICAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_TECVAYLIMember" abstract="true" name="TECVAYLIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ZYTIGAMember" abstract="true" name="ZYTIGAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_OtherOncologyMember" abstract="true" name="OtherOncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_OPSUMITMember" abstract="true" name="OPSUMITMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_UPTRAVIMember" abstract="true" name="UPTRAVIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_OtherPulmonaryHypertensionMember" abstract="true" name="OtherPulmonaryHypertensionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_XareltoMember" abstract="true" name="XareltoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_OtherMember" abstract="true" name="OtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_ELECTROPHYSIOLOGYMember" abstract="true" name="ELECTROPHYSIOLOGYMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ShockwaveMedicalInc.Member" abstract="true" name="ShockwaveMedicalInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherCardiovascularMember" abstract="true" name="OtherCardiovascularMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_HIPSMember" abstract="true" name="HIPSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_KNEESMember" abstract="true" name="KNEESMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_TRAUMAMember" abstract="true" name="TRAUMAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_SPINESPORTSOTHERMember" abstract="true" name="SPINESPORTSOTHERMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_ADVANCEDMember" abstract="true" name="ADVANCEDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_GENERALMember" abstract="true" name="GENERALMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_CONTACTLENSESOTHERMember" abstract="true" name="CONTACTLENSESOTHERMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_SURGICALMember" abstract="true" name="SURGICALMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_ImmunologyMember" abstract="true" name="ImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_InfectiousDiseasesMember" abstract="true" name="InfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_NeuroscienceMember" abstract="true" name="NeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_OncologyMember" abstract="true" name="OncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_PulmonaryHypertensionMember" abstract="true" name="PulmonaryHypertensionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_CardiovascularMetabolismOtherMember" abstract="true" name="CardiovascularMetabolismOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_CardiovascularMember" abstract="true" name="CardiovascularMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_OrthopaedicsMember" abstract="true" name="OrthopaedicsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_SurgeryMember" abstract="true" name="SurgeryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_VisionMember" abstract="true" name="VisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_PercentageChangeInSalesBySegmentOfBusiness" abstract="false" name="PercentageChangeInSalesBySegmentOfBusiness" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jnj_SegmentsTotalMember" abstract="true" name="SegmentsTotalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_GeneralCorporateMember" abstract="true" name="GeneralCorporateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_LaminarMember" abstract="true" name="LaminarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_MomentaMember" abstract="true" name="MomentaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_VWaveLtd.Member" abstract="true" name="VWaveLtd.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_BabyPowderMember" abstract="true" name="BabyPowderMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_RegulationCharge" abstract="false" name="RegulationCharge" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_WesternHemisphereExcludingUSMember" abstract="true" name="WesternHemisphereExcludingUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_AsiaPacificAfricaMember" abstract="true" name="AsiaPacificAfricaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_Wholesaler1Member" abstract="true" name="Wholesaler1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_Wholesaler2Member" abstract="true" name="Wholesaler2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_Wholesaler3Member" abstract="true" name="Wholesaler3Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_WholesalerConcentrationRiskMember" abstract="true" name="WholesalerConcentrationRiskMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_BermekimabMember" abstract="true" name="BermekimabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_OtherNonLongLivedAssets" abstract="false" name="OtherNonLongLivedAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_IntraCellularTherapiesInc.Member" abstract="true" name="IntraCellularTherapiesInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_AmbrxMember" abstract="true" name="AmbrxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_NonTradeableContingentValueRightMember" abstract="true" name="NonTradeableContingentValueRightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_ImpellaMember" abstract="true" name="ImpellaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_ClassIRecommendationForImpellaMember" abstract="true" name="ClassIRecommendationForImpellaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_AcclarentMember" abstract="true" name="AcclarentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PonvoryMember" abstract="true" name="PonvoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_BusinessCombinationProbabilityOfSuccessFactor" abstract="false" name="BusinessCombinationProbabilityOfSuccessFactor" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jnj_BusinessAcquisitionDiscountRate" abstract="false" name="BusinessAcquisitionDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jnj_BusinessCombinationAcquisitionRelatedCostsEquityAwards" abstract="false" name="BusinessCombinationAcquisitionRelatedCostsEquityAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_RevenuesContingentConsideration" abstract="false" name="RevenuesContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill" abstract="false" name="AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_BusinessCombinationSettlementOfEquityAwards" abstract="false" name="BusinessCombinationSettlementOfEquityAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_BusinessCombinationSettlementOfNotesPayable" abstract="false" name="BusinessCombinationSettlementOfNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DePuyASRU.S.Member" abstract="true" name="DePuyASRU.S.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_InghamVsJohnsonJohnsonMember" abstract="true" name="InghamVsJohnsonJohnsonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_MesotheliomaAndStateClaimsMember" abstract="true" name="MesotheliomaAndStateClaimsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OpioidMember" abstract="true" name="OpioidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_PhysiomeshMember" abstract="true" name="PhysiomeshMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_LitigationSettlementByCompaniesAxis" abstract="true" name="LitigationSettlementByCompaniesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="jnj_LitigationSettlementByCompaniesDomain" abstract="true" name="LitigationSettlementByCompaniesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_LegalProceedingTextualsAbstract" abstract="true" name="LegalProceedingTextualsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_LossContingencyPaymentPeriod" abstract="false" name="LossContingencyPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jnj_LossContingencySolicitationPeriod" abstract="false" name="LossContingencySolicitationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jnj_LossContingencyDamagesSoughtNominalValue" abstract="false" name="LossContingencyDamagesSoughtNominalValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_LossContingencyDiscountRate" abstract="false" name="LossContingencyDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="jnj_TotalClaimsAgainstCompanyPercent" abstract="false" name="TotalClaimsAgainstCompanyPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_LossContingencyDamagesSoughtValueIncrease" abstract="false" name="LossContingencyDamagesSoughtValueIncrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_LossContingencyClaimsSettledPercent" abstract="false" name="LossContingencyClaimsSettledPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_LossContingencyAccrualNominalValue" abstract="false" name="LossContingencyAccrualNominalValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ProductLiabilityContingencyNumberOfClaimant" abstract="false" name="ProductLiabilityContingencyNumberOfClaimant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_LossContingencyAccrualPaymentPercentage" abstract="false" name="LossContingencyAccrualPaymentPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_Numberofpatientsinsettlement" abstract="false" name="Numberofpatientsinsettlement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" abstract="false" name="LossContingencyNumberOfClaimsWithinSettlementAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_AsrMember" abstract="false" name="AsrMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_PinnacleAcetabularCupSystemMember" abstract="false" name="PinnacleAcetabularCupSystemMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_PelvicMeshesMember" abstract="false" name="PelvicMeshesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_ElmironMember" abstract="true" name="ElmironMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_RDRestructuringPlanMember" abstract="true" name="RDRestructuringPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OrthopaedicsRestructuringPlanMember" abstract="true" name="OrthopaedicsRestructuringPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CostsOfGoodsAndServicesSoldMember" abstract="true" name="CostsOfGoodsAndServicesSoldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ConsumerHealthMember" abstract="true" name="ConsumerHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_StockIssuedDuringPeriodSharesExchangeOffer" abstract="false" name="StockIssuedDuringPeriodSharesExchangeOffer" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jnj_ExchangeOfStockCommonStockValueReceived" abstract="false" name="ExchangeOfStockCommonStockValueReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_NoncashOrPartNoncashTransactionGainOnExchangeOfStock" abstract="false" name="NoncashOrPartNoncashTransactionGainOnExchangeOfStock" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DiscontinuedOperationsTransitionServiceAgreementTerm" abstract="false" name="DiscontinuedOperationsTransitionServiceAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jnj_DiscontinuedOperationTransitionManufacturingAgreementTerm" abstract="false" name="DiscontinuedOperationTransitionManufacturingAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jnj_DiscontinuedOperationsSeparationCostsIncurred" abstract="false" name="DiscontinuedOperationsSeparationCostsIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DiscontinuedOperationIncrementalTaxCost" abstract="false" name="DiscontinuedOperationIncrementalTaxCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DisposalGroupIncludingDiscontinuedOperationRestructuringExpense" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationRestructuringExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>jnj-20241229_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:a7478940-65f4-4b69-a475-f625bf9a358e,g:8ea82ba0-2a78-4425-b720-89454b578aab-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="jnj-20241229.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_67632f5a-3f06-4350-8df3-dcd9c00610e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_6e317195-b698-400e-8d5e-4088d3c07323" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_67632f5a-3f06-4350-8df3-dcd9c00610e4" xlink:to="loc_us-gaap_PreferredStockValue_6e317195-b698-400e-8d5e-4088d3c07323" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b3f9aba4-ab37-4728-96ed-04aadc0c86a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_67632f5a-3f06-4350-8df3-dcd9c00610e4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b3f9aba4-ab37-4728-96ed-04aadc0c86a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6cb21155-9841-4743-a8e2-d5af432b5a39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_67632f5a-3f06-4350-8df3-dcd9c00610e4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6cb21155-9841-4743-a8e2-d5af432b5a39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5f8321cc-5044-49bc-8fa7-5fe1dc077cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_67632f5a-3f06-4350-8df3-dcd9c00610e4" xlink:to="loc_us-gaap_CommonStockValue_5f8321cc-5044-49bc-8fa7-5fe1dc077cb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_2b769ebd-e5e2-408e-acaa-54279b408069" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_67632f5a-3f06-4350-8df3-dcd9c00610e4" xlink:to="loc_us-gaap_TreasuryStockValue_2b769ebd-e5e2-408e-acaa-54279b408069" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9c6aee29-01b4-4c6e-8897-423aee12e9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7b1a1d07-10fe-4fff-897d-a6d1da515d34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9c6aee29-01b4-4c6e-8897-423aee12e9f2" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7b1a1d07-10fe-4fff-897d-a6d1da515d34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_b5f61ce0-98a0-40ae-a27a-72166a470df0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9c6aee29-01b4-4c6e-8897-423aee12e9f2" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_b5f61ce0-98a0-40ae-a27a-72166a470df0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c5aed568-3980-4f42-b405-62b7779f7f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9c6aee29-01b4-4c6e-8897-423aee12e9f2" xlink:to="loc_us-gaap_LiabilitiesCurrent_c5aed568-3980-4f42-b405-62b7779f7f6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c345ac3b-b9f9-4323-8c93-73850355831d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9c6aee29-01b4-4c6e-8897-423aee12e9f2" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c345ac3b-b9f9-4323-8c93-73850355831d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_1a0a8bef-1b27-4eb1-9706-c8d73a5b13c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9c6aee29-01b4-4c6e-8897-423aee12e9f2" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_1a0a8bef-1b27-4eb1-9706-c8d73a5b13c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_46f4d248-3d31-4f12-8ba8-3c512fcd25f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9c6aee29-01b4-4c6e-8897-423aee12e9f2" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_46f4d248-3d31-4f12-8ba8-3c512fcd25f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a0b5d4bb-a611-4a5e-aa4c-13fe4f9bc12c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_37f4cecf-3854-4cf9-8283-4b4d047854f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a0b5d4bb-a611-4a5e-aa4c-13fe4f9bc12c" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_37f4cecf-3854-4cf9-8283-4b4d047854f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions_2fdf248e-eb46-472c-b9bc-2dabafc74ecc" xlink:href="jnj-20241229.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a0b5d4bb-a611-4a5e-aa4c-13fe4f9bc12c" xlink:to="loc_jnj_AccruedRebatesReturnsAndPromotions_2fdf248e-eb46-472c-b9bc-2dabafc74ecc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ced3c8d8-8a87-4970-9714-c566f5d74cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a0b5d4bb-a611-4a5e-aa4c-13fe4f9bc12c" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ced3c8d8-8a87-4970-9714-c566f5d74cf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f1731ec8-bc13-44d1-80ee-f878e020b17f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a0b5d4bb-a611-4a5e-aa4c-13fe4f9bc12c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f1731ec8-bc13-44d1-80ee-f878e020b17f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f1506986-73d4-41a9-a389-62d152b940a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a0b5d4bb-a611-4a5e-aa4c-13fe4f9bc12c" xlink:to="loc_us-gaap_AccountsPayableCurrent_f1506986-73d4-41a9-a389-62d152b940a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_7b224f0d-a57b-4e73-854b-b4ca2b54e6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a0b5d4bb-a611-4a5e-aa4c-13fe4f9bc12c" xlink:to="loc_us-gaap_ShortTermBorrowings_7b224f0d-a57b-4e73-854b-b4ca2b54e6f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_309f7bbb-5138-41d5-afe9-4cc41328e567" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_65a59639-40e7-4aeb-b763-994d6acbe31d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_309f7bbb-5138-41d5-afe9-4cc41328e567" xlink:to="loc_us-gaap_AssetsCurrent_65a59639-40e7-4aeb-b763-994d6acbe31d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_154106ff-f791-400c-b4f2-190660737e82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_309f7bbb-5138-41d5-afe9-4cc41328e567" xlink:to="loc_us-gaap_Goodwill_154106ff-f791-400c-b4f2-190660737e82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_e53c7f44-c5a6-452f-a05a-2999990fb85c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_309f7bbb-5138-41d5-afe9-4cc41328e567" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_e53c7f44-c5a6-452f-a05a-2999990fb85c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6dd8a954-49db-4971-9c16-d60d625dc4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_309f7bbb-5138-41d5-afe9-4cc41328e567" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6dd8a954-49db-4971-9c16-d60d625dc4c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d8d80861-0076-4b43-a9bf-c62aaf022261" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_309f7bbb-5138-41d5-afe9-4cc41328e567" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d8d80861-0076-4b43-a9bf-c62aaf022261" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3bf2cd5a-daa0-47de-a952-d1ee33042f86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_309f7bbb-5138-41d5-afe9-4cc41328e567" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3bf2cd5a-daa0-47de-a952-d1ee33042f86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6618d246-3584-4801-997e-1cb5f9dfd86e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_02b4346a-0205-4ce2-a619-90c3dcb08f73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6618d246-3584-4801-997e-1cb5f9dfd86e" xlink:to="loc_us-gaap_InventoryNet_02b4346a-0205-4ce2-a619-90c3dcb08f73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_56c116b1-c30e-4506-94c4-727693e2c58f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6618d246-3584-4801-997e-1cb5f9dfd86e" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_56c116b1-c30e-4506-94c4-727693e2c58f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_11742d5a-c57d-4584-94ee-d4caf80c618a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6618d246-3584-4801-997e-1cb5f9dfd86e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_11742d5a-c57d-4584-94ee-d4caf80c618a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9d332b1f-7f05-4ebc-8c7d-1a7d471e403c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6618d246-3584-4801-997e-1cb5f9dfd86e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9d332b1f-7f05-4ebc-8c7d-1a7d471e403c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_eecfb231-57e8-4c11-b89c-bedbc1fe980c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6618d246-3584-4801-997e-1cb5f9dfd86e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_eecfb231-57e8-4c11-b89c-bedbc1fe980c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cad50e8e-1a56-46bb-b8e7-3daa3224a994" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_977a283e-be25-4424-83ff-c894df646866" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cad50e8e-1a56-46bb-b8e7-3daa3224a994" xlink:to="loc_us-gaap_Liabilities_977a283e-be25-4424-83ff-c894df646866" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_79829356-8fa6-4ee4-8a87-c3c657120d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cad50e8e-1a56-46bb-b8e7-3daa3224a994" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_79829356-8fa6-4ee4-8a87-c3c657120d8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_724c42a3-8774-467c-b3ce-5402178c0e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cad50e8e-1a56-46bb-b8e7-3daa3224a994" xlink:to="loc_us-gaap_CommitmentsAndContingencies_724c42a3-8774-467c-b3ce-5402178c0e5c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="jnj-20241229.xsd#ConsolidatedStatementsofEarnings"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_89cadd06-5d31-4e56-8dff-0448e0933be7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_e7576e81-de1a-46e8-992c-2d5e7a87e825" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_89cadd06-5d31-4e56-8dff-0448e0933be7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_e7576e81-de1a-46e8-992c-2d5e7a87e825" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_c6971dd8-572c-4592-800a-c0b13cf9d9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_89cadd06-5d31-4e56-8dff-0448e0933be7" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_c6971dd8-572c-4592-800a-c0b13cf9d9bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3e9cb41a-3898-4a42-b32e-32791dbc440f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_cc484a0c-6e7d-4018-8970-25212c7db1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_3e9cb41a-3898-4a42-b32e-32791dbc440f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_cc484a0c-6e7d-4018-8970-25212c7db1f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_179a9f0a-c1ee-4271-bc0a-7c6a77d8b246" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_3e9cb41a-3898-4a42-b32e-32791dbc440f" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_179a9f0a-c1ee-4271-bc0a-7c6a77d8b246" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_100d2d66-5ebe-493b-af65-0481ca8147fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_5e109761-09ca-4dea-83ee-810c9521328d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_100d2d66-5ebe-493b-af65-0481ca8147fd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_5e109761-09ca-4dea-83ee-810c9521328d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_e36855b9-9f97-4a88-ac65-25316fae3c43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_100d2d66-5ebe-493b-af65-0481ca8147fd" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_e36855b9-9f97-4a88-ac65-25316fae3c43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_c83d8af3-fc3a-444a-bef9-09cbfa186b10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_dd992b6a-3a0d-4f2a-bac6-f7cec97c5915" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_c83d8af3-fc3a-444a-bef9-09cbfa186b10" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_dd992b6a-3a0d-4f2a-bac6-f7cec97c5915" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5013a1a1-9121-4255-999e-7e240bc5b32d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_c83d8af3-fc3a-444a-bef9-09cbfa186b10" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5013a1a1-9121-4255-999e-7e240bc5b32d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_a6d4a622-3b9e-404d-8f1a-a28c4e56ec19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93c5cd3d-e638-4a1f-88df-31c6751f4d01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_a6d4a622-3b9e-404d-8f1a-a28c4e56ec19" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93c5cd3d-e638-4a1f-88df-31c6751f4d01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9a9d0e0a-89fd-4e29-baf4-4ceb1a1f45a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_a6d4a622-3b9e-404d-8f1a-a28c4e56ec19" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9a9d0e0a-89fd-4e29-baf4-4ceb1a1f45a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f104f079-70db-46d6-be98-74f8b6722adf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_da2440ba-355a-4888-aa9c-54f42cd68141" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f104f079-70db-46d6-be98-74f8b6722adf" xlink:to="loc_us-gaap_GrossProfit_da2440ba-355a-4888-aa9c-54f42cd68141" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_43f0b0ad-c0cd-408b-8339-a0c28c52773a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f104f079-70db-46d6-be98-74f8b6722adf" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_43f0b0ad-c0cd-408b-8339-a0c28c52773a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_af682663-dfab-4415-80d5-e100d905cf91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f104f079-70db-46d6-be98-74f8b6722adf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_af682663-dfab-4415-80d5-e100d905cf91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentInProcess1_873ffdf7-cd36-44b7-9544-3db7b121e2ca" xlink:href="jnj-20241229.xsd#jnj_ResearchAndDevelopmentInProcess1"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f104f079-70db-46d6-be98-74f8b6722adf" xlink:to="loc_jnj_ResearchAndDevelopmentInProcess1_873ffdf7-cd36-44b7-9544-3db7b121e2ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_e94b853a-e609-4dd3-af18-0d358dbfff00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f104f079-70db-46d6-be98-74f8b6722adf" xlink:to="loc_us-gaap_InvestmentIncomeInterest_e94b853a-e609-4dd3-af18-0d358dbfff00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_c4565926-8416-420e-a8a5-6339955bf5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f104f079-70db-46d6-be98-74f8b6722adf" xlink:to="loc_us-gaap_InterestExpenseNonoperating_c4565926-8416-420e-a8a5-6339955bf5d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_91d7552e-637c-49aa-8b2a-68615eee5d86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f104f079-70db-46d6-be98-74f8b6722adf" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_91d7552e-637c-49aa-8b2a-68615eee5d86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_44114328-cd56-4a11-9704-dbe0e71dea3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f104f079-70db-46d6-be98-74f8b6722adf" xlink:to="loc_us-gaap_RestructuringCharges_44114328-cd56-4a11-9704-dbe0e71dea3f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20241229.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0372937d-1c34-4cc1-b852-cdd843ad4588" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_277375e7-67f1-44a0-97a1-fa274c7e6e80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0372937d-1c34-4cc1-b852-cdd843ad4588" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_277375e7-67f1-44a0-97a1-fa274c7e6e80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6959f5e4-6eb1-4cb6-bb19-cac773d190de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0372937d-1c34-4cc1-b852-cdd843ad4588" xlink:to="loc_us-gaap_NetIncomeLoss_6959f5e4-6eb1-4cb6-bb19-cac773d190de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_f9a9016a-15ca-4e8b-b071-c4c190d13273" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax_21309269-329f-432e-959e-ca7b5819bf91" xlink:href="jnj-20241229.xsd#jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_f9a9016a-15ca-4e8b-b071-c4c190d13273" xlink:to="loc_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax_21309269-329f-432e-959e-ca7b5819bf91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_8e34d9b6-da11-4851-8ad2-182d769bc0dd" xlink:href="jnj-20241229.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_f9a9016a-15ca-4e8b-b071-c4c190d13273" xlink:to="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_8e34d9b6-da11-4851-8ad2-182d769bc0dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax_1bba9eec-cd6b-48e9-8d97-378a087aca02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_f9a9016a-15ca-4e8b-b071-c4c190d13273" xlink:to="loc_us-gaap_OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax_1bba9eec-cd6b-48e9-8d97-378a087aca02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_bd118f5d-3cf7-40e0-bb7f-d500952dc1c0" xlink:href="jnj-20241229.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_f9a9016a-15ca-4e8b-b071-c4c190d13273" xlink:to="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_bd118f5d-3cf7-40e0-bb7f-d500952dc1c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_7941168c-9daf-4055-9408-93a5a9196c20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_b400f305-bfa2-4a27-8b16-d55f9ef78d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_7941168c-9daf-4055-9408-93a5a9196c20" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_b400f305-bfa2-4a27-8b16-d55f9ef78d2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_518e6fcd-b647-4af9-bea8-09667fe1a809" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_7941168c-9daf-4055-9408-93a5a9196c20" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_518e6fcd-b647-4af9-bea8-09667fe1a809" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0fddaf03-57fb-4650-af76-47517cf139ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f8c8ef0b-84ee-4eb0-931c-fe3d1a6ab03c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0fddaf03-57fb-4650-af76-47517cf139ba" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f8c8ef0b-84ee-4eb0-931c-fe3d1a6ab03c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_39c38835-ba36-4b59-ab51-4df8c5bf3cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0fddaf03-57fb-4650-af76-47517cf139ba" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_39c38835-ba36-4b59-ab51-4df8c5bf3cc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2146684e-7d80-48a4-b4ee-c25084d1f36a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_31b31417-d123-45c1-b4a1-a813f754f63a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2146684e-7d80-48a4-b4ee-c25084d1f36a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_31b31417-d123-45c1-b4a1-a813f754f63a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_fd819a61-fc5a-4581-b74b-1b07829e9464" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2146684e-7d80-48a4-b4ee-c25084d1f36a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_fd819a61-fc5a-4581-b74b-1b07829e9464" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4a54bd1e-6ada-4f7d-a999-492a20433780" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2146684e-7d80-48a4-b4ee-c25084d1f36a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4a54bd1e-6ada-4f7d-a999-492a20433780" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_cda1f347-b38c-4b94-943c-5b17efeff207" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2146684e-7d80-48a4-b4ee-c25084d1f36a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_cda1f347-b38c-4b94-943c-5b17efeff207" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="jnj-20241229.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_e2627b3f-171c-4a93-97f1-f3627ca960d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_27076749-f3ee-46a9-803e-7b93507b09d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_e2627b3f-171c-4a93-97f1-f3627ca960d9" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_27076749-f3ee-46a9-803e-7b93507b09d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_0bf1e282-592e-48c5-803d-c67af4cae500" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_e2627b3f-171c-4a93-97f1-f3627ca960d9" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_0bf1e282-592e-48c5-803d-c67af4cae500" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8e8310b3-7146-4d5f-8c47-1ca048325a73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e33aa80d-d24b-46ae-84d6-92290fe60d46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8e8310b3-7146-4d5f-8c47-1ca048325a73" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e33aa80d-d24b-46ae-84d6-92290fe60d46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_04053c7a-449f-42f8-be3f-ddd711beea08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8e8310b3-7146-4d5f-8c47-1ca048325a73" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_04053c7a-449f-42f8-be3f-ddd711beea08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_2afba4b4-be61-4e64-8a3d-a1529fcd2078" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8e8310b3-7146-4d5f-8c47-1ca048325a73" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_2afba4b4-be61-4e64-8a3d-a1529fcd2078" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_1af2fe02-fbd4-46dd-9c17-e4e3a7f70989" xlink:href="jnj-20241229.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8e8310b3-7146-4d5f-8c47-1ca048325a73" xlink:to="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_1af2fe02-fbd4-46dd-9c17-e4e3a7f70989" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_814a576b-66e5-4f79-b48b-41e85f49e2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8e8310b3-7146-4d5f-8c47-1ca048325a73" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_814a576b-66e5-4f79-b48b-41e85f49e2f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation_d75a9071-92dc-422a-97de-e5119f929f9d" xlink:href="jnj-20241229.xsd#jnj_ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8e8310b3-7146-4d5f-8c47-1ca048325a73" xlink:to="loc_jnj_ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation_d75a9071-92dc-422a-97de-e5119f929f9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3f4a4cee-0578-4a65-bc40-39a922b38bde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8e8310b3-7146-4d5f-8c47-1ca048325a73" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3f4a4cee-0578-4a65-bc40-39a922b38bde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_abc746c2-0588-452d-8c2c-d20dd536a6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8e8310b3-7146-4d5f-8c47-1ca048325a73" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_abc746c2-0588-452d-8c2c-d20dd536a6f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_fc3fb95e-5b40-4a19-87f0-67178242a132" xlink:href="jnj-20241229.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8e8310b3-7146-4d5f-8c47-1ca048325a73" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_fc3fb95e-5b40-4a19-87f0-67178242a132" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_f20e2e3b-8268-46fd-bf1c-766d6b64156f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8e8310b3-7146-4d5f-8c47-1ca048325a73" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_f20e2e3b-8268-46fd-bf1c-766d6b64156f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PaymentsMadeInBusinessSeparation_0a364266-1fbc-4fe7-aa1a-928244ae5c3f" xlink:href="jnj-20241229.xsd#jnj_PaymentsMadeInBusinessSeparation"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8e8310b3-7146-4d5f-8c47-1ca048325a73" xlink:to="loc_jnj_PaymentsMadeInBusinessSeparation_0a364266-1fbc-4fe7-aa1a-928244ae5c3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_d5593291-dea2-4c8c-a7b6-f2f368b8f1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8e8310b3-7146-4d5f-8c47-1ca048325a73" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_d5593291-dea2-4c8c-a7b6-f2f368b8f1b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SettlementOfConvertibleDebtAcquiredFromShockwave_0b9b03fe-997d-4ee4-a9c4-9848ed701706" xlink:href="jnj-20241229.xsd#jnj_SettlementOfConvertibleDebtAcquiredFromShockwave"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8e8310b3-7146-4d5f-8c47-1ca048325a73" xlink:to="loc_jnj_SettlementOfConvertibleDebtAcquiredFromShockwave_0b9b03fe-997d-4ee4-a9c4-9848ed701706" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dc264cd5-1528-4def-b6dc-608bd02517e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ca1a52f5-ba1a-4d2a-936c-357bdea37f73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dc264cd5-1528-4def-b6dc-608bd02517e3" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ca1a52f5-ba1a-4d2a-936c-357bdea37f73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_24c7cb66-9bce-4b64-a67d-e44eb40692aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dc264cd5-1528-4def-b6dc-608bd02517e3" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_24c7cb66-9bce-4b64-a67d-e44eb40692aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_b446cbea-d343-4480-9801-5a063b9dc79a" xlink:href="jnj-20241229.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dc264cd5-1528-4def-b6dc-608bd02517e3" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_b446cbea-d343-4480-9801-5a063b9dc79a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_0f12c7fc-fd27-42e0-b4e7-8d6d3591a5ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dc264cd5-1528-4def-b6dc-608bd02517e3" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_0f12c7fc-fd27-42e0-b4e7-8d6d3591a5ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PaymentsToAcquiredInProcessResearchAndDevelopmentAssets_e65b8322-816b-4a3d-8fd9-957fd98a145e" xlink:href="jnj-20241229.xsd#jnj_PaymentsToAcquiredInProcessResearchAndDevelopmentAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dc264cd5-1528-4def-b6dc-608bd02517e3" xlink:to="loc_jnj_PaymentsToAcquiredInProcessResearchAndDevelopmentAssets_e65b8322-816b-4a3d-8fd9-957fd98a145e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_db1fc4cf-8796-4fb0-bdb1-c6a4071618d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dc264cd5-1528-4def-b6dc-608bd02517e3" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_db1fc4cf-8796-4fb0-bdb1-c6a4071618d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_c252f0f9-2b66-4af1-b2b5-c606a37a1bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dc264cd5-1528-4def-b6dc-608bd02517e3" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_c252f0f9-2b66-4af1-b2b5-c606a37a1bb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_6f6b85fa-5aa5-4bd2-82d0-0b53c7b6d5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dc264cd5-1528-4def-b6dc-608bd02517e3" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_6f6b85fa-5aa5-4bd2-82d0-0b53c7b6d5d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dfa173e0-7a28-4a11-bad9-f18a72f86c43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2163ebc2-2500-4f32-831f-23fcbcdcf1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dfa173e0-7a28-4a11-bad9-f18a72f86c43" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2163ebc2-2500-4f32-831f-23fcbcdcf1d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6205b69a-3fd8-46ca-b893-b23808e21d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dfa173e0-7a28-4a11-bad9-f18a72f86c43" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6205b69a-3fd8-46ca-b893-b23808e21d5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0d1ee957-6ab1-4a49-9ceb-8715ddd78c32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dfa173e0-7a28-4a11-bad9-f18a72f86c43" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0d1ee957-6ab1-4a49-9ceb-8715ddd78c32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_334c6fdd-742b-4b13-b9ee-1c7aa819f27d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dfa173e0-7a28-4a11-bad9-f18a72f86c43" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_334c6fdd-742b-4b13-b9ee-1c7aa819f27d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2103fc05-38c2-434a-aa81-bd179c2a922e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_74f8aecd-a83d-4d1d-b16a-3a5d9ca6ffc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2103fc05-38c2-434a-aa81-bd179c2a922e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_74f8aecd-a83d-4d1d-b16a-3a5d9ca6ffc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_96f21541-a6ba-4b86-bc75-6128faf58ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2103fc05-38c2-434a-aa81-bd179c2a922e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_96f21541-a6ba-4b86-bc75-6128faf58ac2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_24725f1e-33a5-40be-97ab-a1902f19abfe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2103fc05-38c2-434a-aa81-bd179c2a922e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_24725f1e-33a5-40be-97ab-a1902f19abfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_67f8007f-ee68-4963-866f-83e08820c4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2103fc05-38c2-434a-aa81-bd179c2a922e" xlink:to="loc_us-gaap_ShareBasedCompensation_67f8007f-ee68-4963-866f-83e08820c4ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_5fc2ca6f-ef9f-42d4-bff6-519b7ed141c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2103fc05-38c2-434a-aa81-bd179c2a922e" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_5fc2ca6f-ef9f-42d4-bff6-519b7ed141c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_39a3ad8d-0afa-4d99-995f-d130ff1f49db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2103fc05-38c2-434a-aa81-bd179c2a922e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_39a3ad8d-0afa-4d99-995f-d130ff1f49db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_8cac04de-351d-4780-aada-5c2d7656a18a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2103fc05-38c2-434a-aa81-bd179c2a922e" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_8cac04de-351d-4780-aada-5c2d7656a18a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_86a3695b-f7ee-43da-95c4-c876d0c644d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2103fc05-38c2-434a-aa81-bd179c2a922e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_86a3695b-f7ee-43da-95c4-c876d0c644d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_cd2ae78d-8825-42f5-bbfa-a282f6bc9fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2103fc05-38c2-434a-aa81-bd179c2a922e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_cd2ae78d-8825-42f5-bbfa-a282f6bc9fe5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_fb2633d6-2b8f-43c7-ab56-b565e9655a24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2103fc05-38c2-434a-aa81-bd179c2a922e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_fb2633d6-2b8f-43c7-ab56-b565e9655a24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_86a389bf-54a6-4cff-b0c7-25db2db5fda1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2103fc05-38c2-434a-aa81-bd179c2a922e" xlink:to="loc_us-gaap_NetIncomeLoss_86a389bf-54a6-4cff-b0c7-25db2db5fda1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_a94c4016-0ab6-43df-8415-2156886e6881" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2103fc05-38c2-434a-aa81-bd179c2a922e" xlink:to="loc_us-gaap_AssetImpairmentCharges_a94c4016-0ab6-43df-8415-2156886e6881" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3ad21e13-f178-4467-8946-59112878c33f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2103fc05-38c2-434a-aa81-bd179c2a922e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3ad21e13-f178-4467-8946-59112878c33f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_dde10c37-5808-4a09-8641-09d6cbc205cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2103fc05-38c2-434a-aa81-bd179c2a922e" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_dde10c37-5808-4a09-8641-09d6cbc205cf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_baabb704-2077-4d54-9a4a-fcd392276ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_4d964a80-9f8b-4e23-8525-2d1876728f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_baabb704-2077-4d54-9a4a-fcd392276ccf" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_4d964a80-9f8b-4e23-8525-2d1876728f8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_054814d4-552e-460a-ba3f-666e3bef9cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_baabb704-2077-4d54-9a4a-fcd392276ccf" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_054814d4-552e-460a-ba3f-666e3bef9cb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_c2548d82-423b-43fa-a840-c986210567eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_baabb704-2077-4d54-9a4a-fcd392276ccf" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_c2548d82-423b-43fa-a840-c986210567eb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5a0a3ee6-5944-41a4-aa1e-6d5978dfa053" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7b83db3b-07d8-4be9-8bd6-0eecae7461ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5a0a3ee6-5944-41a4-aa1e-6d5978dfa053" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_7b83db3b-07d8-4be9-8bd6-0eecae7461ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ffdf4c2e-dc4a-4105-9d86-df93257ae4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5a0a3ee6-5944-41a4-aa1e-6d5978dfa053" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ffdf4c2e-dc4a-4105-9d86-df93257ae4f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c32e6677-0d24-4d72-95a2-ee4319947df3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2c9d2be4-8f14-4fdf-a458-b5387ef39842" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c32e6677-0d24-4d72-95a2-ee4319947df3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2c9d2be4-8f14-4fdf-a458-b5387ef39842" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6c76cc60-2067-4eef-ab97-d20d7766c674" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c32e6677-0d24-4d72-95a2-ee4319947df3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6c76cc60-2067-4eef-ab97-d20d7766c674" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1cf6050b-2bfc-4817-8c5b-8e814c3e5896" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_032503d5-1eac-4c3d-b0b0-95f6254b77be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1cf6050b-2bfc-4817-8c5b-8e814c3e5896" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_032503d5-1eac-4c3d-b0b0-95f6254b77be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a9e32752-1397-4cc7-a2b3-89d938de6fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1cf6050b-2bfc-4817-8c5b-8e814c3e5896" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a9e32752-1397-4cc7-a2b3-89d938de6fb7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_60f0a2b1-d250-4da6-b348-24a0d842423e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_c317a115-62aa-4dc7-822d-e62a4ecb53e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssets_60f0a2b1-d250-4da6-b348-24a0d842423e" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_c317a115-62aa-4dc7-822d-e62a4ecb53e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_91cb317c-75e6-4873-9bba-34e8c668166e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssets_60f0a2b1-d250-4da6-b348-24a0d842423e" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_91cb317c-75e6-4873-9bba-34e8c668166e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_a4e8213c-7cb1-4de8-9b7c-34665fc472ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_92329c44-9e09-4acc-a237-b86286fde588" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_a4e8213c-7cb1-4de8-9b7c-34665fc472ce" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_92329c44-9e09-4acc-a237-b86286fde588" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_970c853b-f2c4-4fb9-8f49-0b3906f17e74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_a4e8213c-7cb1-4de8-9b7c-34665fc472ce" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_970c853b-f2c4-4fb9-8f49-0b3906f17e74" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#BorrowingsScheduleofLongtermDebtInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_05393aa2-c513-449e-9de6-e7bd42926d05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_21f8031c-47f0-4032-be3b-971253a15324" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_05393aa2-c513-449e-9de6-e7bd42926d05" xlink:to="loc_us-gaap_LongTermDebtCurrent_21f8031c-47f0-4032-be3b-971253a15324" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_fe263934-bfe3-4722-a5f9-bf1f757ebd06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_05393aa2-c513-449e-9de6-e7bd42926d05" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_fe263934-bfe3-4722-a5f9-bf1f757ebd06" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#IncometaxesProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_376a10d7-6911-44aa-80b6-d999a6d70ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations_4c2e6a14-b3b2-4549-85c7-a3b9118d94b3" xlink:href="jnj-20241229.xsd#jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_376a10d7-6911-44aa-80b6-d999a6d70ff1" xlink:to="loc_jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations_4c2e6a14-b3b2-4549-85c7-a3b9118d94b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d986bda0-6150-4465-b972-85a6bd2b2ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_376a10d7-6911-44aa-80b6-d999a6d70ff1" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d986bda0-6150-4465-b972-85a6bd2b2ad0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b0ddb4d6-7e8a-4b88-bffb-0ec9f8165a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_aca51db9-8e38-4230-ab5b-d1838264c06a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b0ddb4d6-7e8a-4b88-bffb-0ec9f8165a9e" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_aca51db9-8e38-4230-ab5b-d1838264c06a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_8ba4e757-dbec-435f-a04e-bfaae83a17de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b0ddb4d6-7e8a-4b88-bffb-0ec9f8165a9e" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_8ba4e757-dbec-435f-a04e-bfaae83a17de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations_d34c3035-157a-4e76-bcd6-ffecd4c60382" xlink:href="jnj-20241229.xsd#jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_320ed23e-5f24-489f-b3e0-1287df16e638" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations_d34c3035-157a-4e76-bcd6-ffecd4c60382" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_320ed23e-5f24-489f-b3e0-1287df16e638" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_9f5597ad-3304-4feb-84a6-b55cc80201b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations_d34c3035-157a-4e76-bcd6-ffecd4c60382" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_9f5597ad-3304-4feb-84a6-b55cc80201b1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9eae9a21-e0fa-44d6-928c-2bb344f0c803" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_05eea5ee-da9b-4b31-a0c6-57a2381f43b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9eae9a21-e0fa-44d6-928c-2bb344f0c803" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_05eea5ee-da9b-4b31-a0c6-57a2381f43b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_ced8f7b4-9c9e-44e4-9cfe-f20dc456ef2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9eae9a21-e0fa-44d6-928c-2bb344f0c803" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_ced8f7b4-9c9e-44e4-9cfe-f20dc456ef2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_33cdc0f6-df26-496c-8f84-b602d84d91a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_e3a4f771-8c13-4810-985e-a6e9a4e34c87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_33cdc0f6-df26-496c-8f84-b602d84d91a8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_e3a4f771-8c13-4810-985e-a6e9a4e34c87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_6ef5a415-572e-4fdd-b58e-d341a47559ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_33cdc0f6-df26-496c-8f84-b602d84d91a8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_6ef5a415-572e-4fdd-b58e-d341a47559ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation_4b5af55e-1173-45dd-aad4-02f7dbde95a8" xlink:href="jnj-20241229.xsd#jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_33cdc0f6-df26-496c-8f84-b602d84d91a8" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation_4b5af55e-1173-45dd-aad4-02f7dbde95a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f9e501ec-99d4-4295-9612-017f3d5d9872" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_33cdc0f6-df26-496c-8f84-b602d84d91a8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f9e501ec-99d4-4295-9612-017f3d5d9872" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome_b4dcd0b0-6679-4759-a1ad-5927e8d40cba" xlink:href="jnj-20241229.xsd#jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_33cdc0f6-df26-496c-8f84-b602d84d91a8" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome_b4dcd0b0-6679-4759-a1ad-5927e8d40cba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_23199026-a3d5-4c2a-b297-5dff7eb1407a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_33cdc0f6-df26-496c-8f84-b602d84d91a8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_23199026-a3d5-4c2a-b297-5dff7eb1407a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_c0733920-13b1-453c-a2e8-d3a9272f15bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_33cdc0f6-df26-496c-8f84-b602d84d91a8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_c0733920-13b1-453c-a2e8-d3a9272f15bd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#IncometaxesTemporaryDifferencesandCarryforwardsDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_cd732e58-7cfe-4601-92f2-30ba1aa9ac13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_902da763-2a5f-4940-87e5-4b56c3d33d96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_cd732e58-7cfe-4601-92f2-30ba1aa9ac13" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_902da763-2a5f-4940-87e5-4b56c3d33d96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b30653a0-c6ce-4fac-8b1a-55334c68cb0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_cd732e58-7cfe-4601-92f2-30ba1aa9ac13" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b30653a0-c6ce-4fac-8b1a-55334c68cb0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_cab90678-bd82-4454-89cd-e5b4ca505016" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_317bc811-273b-4d02-b621-dcca52b5b6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cab90678-bd82-4454-89cd-e5b4ca505016" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_317bc811-273b-4d02-b621-dcca52b5b6d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_02b9da87-d1ed-49ab-a205-561709732dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cab90678-bd82-4454-89cd-e5b4ca505016" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_02b9da87-d1ed-49ab-a205-561709732dfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_60ee9741-b33c-4348-a23e-e381cb18890f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cab90678-bd82-4454-89cd-e5b4ca505016" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_60ee9741-b33c-4348-a23e-e381cb18890f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f14a033e-c01d-41cc-a9dc-fc9e2962a027" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cab90678-bd82-4454-89cd-e5b4ca505016" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f14a033e-c01d-41cc-a9dc-fc9e2962a027" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsUndistributedForeignEarnings_63435c9a-1896-49b2-994c-db629f6fb9cb" xlink:href="jnj-20241229.xsd#jnj_DeferredTaxAssetsUndistributedForeignEarnings"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cab90678-bd82-4454-89cd-e5b4ca505016" xlink:to="loc_jnj_DeferredTaxAssetsUndistributedForeignEarnings_63435c9a-1896-49b2-994c-db629f6fb9cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0ad9a975-52a4-4856-ab9e-a033f35a29f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cab90678-bd82-4454-89cd-e5b4ca505016" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0ad9a975-52a4-4856-ab9e-a033f35a29f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_03961d5b-b9ad-4a66-b473-32c34af9fbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cab90678-bd82-4454-89cd-e5b4ca505016" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_03961d5b-b9ad-4a66-b473-32c34af9fbf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsOtherDomestic_111d5873-572c-4e2c-96ef-e009eb5e4085" xlink:href="jnj-20241229.xsd#jnj_DeferredTaxAssetsOtherDomestic"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cab90678-bd82-4454-89cd-e5b4ca505016" xlink:to="loc_jnj_DeferredTaxAssetsOtherDomestic_111d5873-572c-4e2c-96ef-e009eb5e4085" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized_6b501b5d-29e1-4276-bbc9-699ae6f7e58e" xlink:href="jnj-20241229.xsd#jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cab90678-bd82-4454-89cd-e5b4ca505016" xlink:to="loc_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized_6b501b5d-29e1-4276-bbc9-699ae6f7e58e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_35c037d6-35cc-49d3-bd92-68fead1d94f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxLiabilitiesOtherDomestic_476cc876-2e80-452c-bca5-e1ca519740cc" xlink:href="jnj-20241229.xsd#jnj_DeferredTaxLiabilitiesOtherDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_35c037d6-35cc-49d3-bd92-68fead1d94f6" xlink:to="loc_jnj_DeferredTaxLiabilitiesOtherDomestic_476cc876-2e80-452c-bca5-e1ca519740cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_e18b9107-2c69-419d-9673-1ea93af32dda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_35c037d6-35cc-49d3-bd92-68fead1d94f6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_e18b9107-2c69-419d-9673-1ea93af32dda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome_17eb386f-82e3-4c93-a32c-aed7058f73e8" xlink:href="jnj-20241229.xsd#jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_35c037d6-35cc-49d3-bd92-68fead1d94f6" xlink:to="loc_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome_17eb386f-82e3-4c93-a32c-aed7058f73e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_072cc53c-483e-4690-9c84-48240f9f2700" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_35c037d6-35cc-49d3-bd92-68fead1d94f6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_072cc53c-483e-4690-9c84-48240f9f2700" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_e5b390d7-e794-48c7-9316-b10718164de0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_35c037d6-35cc-49d3-bd92-68fead1d94f6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_e5b390d7-e794-48c7-9316-b10718164de0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#EmployeerelatedobligationsEmployeeRelatedObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeObligations_bedf2187-7cdd-4594-bc01-d66c09309f95" xlink:href="jnj-20241229.xsd#jnj_EmployeeObligations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_856faba2-9cd3-4bc9-821a-8a2f071a4d13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_EmployeeObligations_bedf2187-7cdd-4594-bc01-d66c09309f95" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_856faba2-9cd3-4bc9-821a-8a2f071a4d13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent_918926a7-d27a-420d-b75b-0300d3ec4850" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_EmployeeObligations_bedf2187-7cdd-4594-bc01-d66c09309f95" xlink:to="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent_918926a7-d27a-420d-b75b-0300d3ec4850" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_99aadc48-479d-4b74-84be-5794293e2629" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_EmployeeObligations_bedf2187-7cdd-4594-bc01-d66c09309f95" xlink:to="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_99aadc48-479d-4b74-84be-5794293e2629" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_4d272dd3-d5fd-43d1-a7bd-a4a8cd199a62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_EmployeeObligations_bedf2187-7cdd-4594-bc01-d66c09309f95" xlink:to="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_4d272dd3-d5fd-43d1-a7bd-a4a8cd199a62" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails_1" xlink:type="simple" xlink:href="jnj-20241229.xsd#EmployeerelatedobligationsEmployeeRelatedObligationsDetails_1"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeObligations_0bee5d02-a12a-4c69-8575-cabea9aeb85a" xlink:href="jnj-20241229.xsd#jnj_EmployeeObligations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_ad269ff4-0e07-4f41-84f3-d966051b3c88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_EmployeeObligations_0bee5d02-a12a-4c69-8575-cabea9aeb85a" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_ad269ff4-0e07-4f41-84f3-d966051b3c88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_b5dbca95-bcb0-4b1a-9439-897dc38ab7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_EmployeeObligations_0bee5d02-a12a-4c69-8575-cabea9aeb85a" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_b5dbca95-bcb0-4b1a-9439-897dc38ab7ba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e2833a03-b64c-4399-8433-01bad87365d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_6b41a82c-cc80-491e-b6e0-82d4e729e005" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e2833a03-b64c-4399-8433-01bad87365d6" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_6b41a82c-cc80-491e-b6e0-82d4e729e005" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_1e51b667-5ff8-4d3c-9ffb-b80b645e7dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e2833a03-b64c-4399-8433-01bad87365d6" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_1e51b667-5ff8-4d3c-9ffb-b80b645e7dfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_54a0c739-e6f2-4fcd-9829-3c1933bfe46e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e2833a03-b64c-4399-8433-01bad87365d6" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_54a0c739-e6f2-4fcd-9829-3c1933bfe46e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_1b8d92de-0236-4a3d-b110-e08f740389cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e2833a03-b64c-4399-8433-01bad87365d6" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_1b8d92de-0236-4a3d-b110-e08f740389cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_aaeaeeec-99e3-4110-b546-c7bd219e9ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e2833a03-b64c-4399-8433-01bad87365d6" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_aaeaeeec-99e3-4110-b546-c7bd219e9ab2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_13e164af-bbe9-48eb-84a8-14c33459af17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e2833a03-b64c-4399-8433-01bad87365d6" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_13e164af-bbe9-48eb-84a8-14c33459af17" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_71c742cf-5839-40c4-a893-4ee1c99775af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_c18612bc-5949-4d6c-9a6a-e7c4cbf16ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_71c742cf-5839-40c4-a893-4ee1c99775af" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_c18612bc-5949-4d6c-9a6a-e7c4cbf16ca3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_8ef2f13a-e8b8-41d0-856d-24d752c484bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_71c742cf-5839-40c4-a893-4ee1c99775af" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_8ef2f13a-e8b8-41d0-856d-24d752c484bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_57bba430-f53a-42fd-8650-65119f6b2a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_71c742cf-5839-40c4-a893-4ee1c99775af" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_57bba430-f53a-42fd-8650-65119f6b2a4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_8f3ecf5d-7880-4d97-bc41-79845f8ba84c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_bf0b6b3d-27c4-4d44-bd9b-21dd6339d3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_8f3ecf5d-7880-4d97-bc41-79845f8ba84c" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_bf0b6b3d-27c4-4d44-bd9b-21dd6339d3fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_c35a7926-898b-4c9b-bd89-dcd6df82ce76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_8f3ecf5d-7880-4d97-bc41-79845f8ba84c" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_c35a7926-898b-4c9b-bd89-dcd6df82ce76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_4bba883a-d934-4583-b12c-21b46ae4acdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_d64438a8-6800-492e-9993-c5a350685f59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_4bba883a-d934-4583-b12c-21b46ae4acdd" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_d64438a8-6800-492e-9993-c5a350685f59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_1483bc7e-03e7-4473-97ce-c5585b0b4d43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_4bba883a-d934-4583-b12c-21b46ae4acdd" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_1483bc7e-03e7-4473-97ce-c5585b0b4d43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_ce8525ae-fe5c-407b-8fef-5861d9e588e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_4bba883a-d934-4583-b12c-21b46ae4acdd" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_ce8525ae-fe5c-407b-8fef-5861d9e588e9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dd214781-723a-4ef3-bc4c-9da1c16315dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3beafb8c-a806-4901-a746-48beea2f1808" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dd214781-723a-4ef3-bc4c-9da1c16315dc" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3beafb8c-a806-4901-a746-48beea2f1808" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c7f01041-a77f-48a9-bd38-fbabde421428" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dd214781-723a-4ef3-bc4c-9da1c16315dc" xlink:to="loc_us-gaap_EarningsPerShareBasic_c7f01041-a77f-48a9-bd38-fbabde421428" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5fbecd26-41e0-48dc-a1d6-5554c78b7dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dd214781-723a-4ef3-bc4c-9da1c16315dc" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5fbecd26-41e0-48dc-a1d6-5554c78b7dc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_7bfc13d6-3370-4450-8daa-454039628d8f" xlink:href="jnj-20241229.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dd214781-723a-4ef3-bc4c-9da1c16315dc" xlink:to="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_7bfc13d6-3370-4450-8daa-454039628d8f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsanddivestituresDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#AcquisitionsanddivestituresDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/AcquisitionsanddivestituresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_c2b01f35-eb06-42df-a5da-a6b0ffaf815e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_8f21a0ae-014d-4654-93e4-48edb9cbcc96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_c2b01f35-eb06-42df-a5da-a6b0ffaf815e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_8f21a0ae-014d-4654-93e4-48edb9cbcc96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_5e1a5d9a-259f-4e86-b906-20e08a906321" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_c2b01f35-eb06-42df-a5da-a6b0ffaf815e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_5e1a5d9a-259f-4e86-b906-20e08a906321" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_8e6893b0-b448-415c-8249-3da4b6f7d86e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_c2b01f35-eb06-42df-a5da-a6b0ffaf815e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_8e6893b0-b448-415c-8249-3da4b6f7d86e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5b8c5fac-4f35-42a5-b993-588fa60b393c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_c2b01f35-eb06-42df-a5da-a6b0ffaf815e" xlink:to="loc_us-gaap_Goodwill_5b8c5fac-4f35-42a5-b993-588fa60b393c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_9c93b1d5-13aa-41b9-845a-cd66d495c70d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_c2b01f35-eb06-42df-a5da-a6b0ffaf815e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_9c93b1d5-13aa-41b9-845a-cd66d495c70d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3c6c616a-9f11-4f6d-8065-78415f1ddacd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_c2b01f35-eb06-42df-a5da-a6b0ffaf815e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3c6c616a-9f11-4f6d-8065-78415f1ddacd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_10c7abf3-5822-4849-ab5c-c294040d8eac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_fa2306c7-3560-463c-a9e2-2172fee88ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_10c7abf3-5822-4849-ab5c-c294040d8eac" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_fa2306c7-3560-463c-a9e2-2172fee88ae6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_5cca61a9-8d3f-4006-9e03-a276a34606a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_10c7abf3-5822-4849-ab5c-c294040d8eac" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_5cca61a9-8d3f-4006-9e03-a276a34606a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_7f043d60-8406-49ec-9514-883f31aa864f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_69ffdf1d-8b5b-4268-ad76-cee84d0fd584" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_7f043d60-8406-49ec-9514-883f31aa864f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_69ffdf1d-8b5b-4268-ad76-cee84d0fd584" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_8676a71b-a277-4b9b-8618-9ab2f8a837db" xlink:href="jnj-20241229.xsd#jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_7f043d60-8406-49ec-9514-883f31aa864f" xlink:to="loc_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_8676a71b-a277-4b9b-8618-9ab2f8a837db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_d7958ad6-d1de-49a1-9975-62a7061d7647" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_7f043d60-8406-49ec-9514-883f31aa864f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_d7958ad6-d1de-49a1-9975-62a7061d7647" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_6344f873-dc73-49d0-8bf2-70d7e6746316" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_421fd82b-4e7c-4db4-a43d-cc34f2741d86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_6344f873-dc73-49d0-8bf2-70d7e6746316" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_421fd82b-4e7c-4db4-a43d-cc34f2741d86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_f96e049f-30fe-4a7c-85e4-d75de8fff109" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_6344f873-dc73-49d0-8bf2-70d7e6746316" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_f96e049f-30fe-4a7c-85e4-d75de8fff109" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_34e7888c-38e0-4eba-b1cc-602ee9fb4fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_75716b7c-2ee0-4b89-8a18-c32d4046e434" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_34e7888c-38e0-4eba-b1cc-602ee9fb4fcf" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_75716b7c-2ee0-4b89-8a18-c32d4046e434" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_4c79a06f-a459-423d-8fbc-3728e73ad73c" xlink:href="jnj-20241229.xsd#jnj_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_34e7888c-38e0-4eba-b1cc-602ee9fb4fcf" xlink:to="loc_jnj_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_4c79a06f-a459-423d-8fbc-3728e73ad73c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_21e8d159-8054-4357-b907-4e3dbac9d353" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_34e7888c-38e0-4eba-b1cc-602ee9fb4fcf" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_21e8d159-8054-4357-b907-4e3dbac9d353" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_9c074911-6681-45aa-96f9-138658c026dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_34e7888c-38e0-4eba-b1cc-602ee9fb4fcf" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_9c074911-6681-45aa-96f9-138658c026dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DisposalGroupIncludingDiscontinuedOperationRestructuringExpense_a52d37d0-872a-4cc7-a343-f6920752e8c0" xlink:href="jnj-20241229.xsd#jnj_DisposalGroupIncludingDiscontinuedOperationRestructuringExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_34e7888c-38e0-4eba-b1cc-602ee9fb4fcf" xlink:to="loc_jnj_DisposalGroupIncludingDiscontinuedOperationRestructuringExpense_a52d37d0-872a-4cc7-a343-f6920752e8c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_6473e088-3dc4-44e5-956c-bcffa80e17a0" xlink:href="jnj-20241229.xsd#jnj_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_34e7888c-38e0-4eba-b1cc-602ee9fb4fcf" xlink:to="loc_jnj_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_6473e088-3dc4-44e5-956c-bcffa80e17a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_848b1714-504f-47e0-ad86-1a9333cd4a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_34e7888c-38e0-4eba-b1cc-602ee9fb4fcf" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_848b1714-504f-47e0-ad86-1a9333cd4a8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_7644d302-a83d-4e6f-beeb-cc55d3b07464" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_34e7888c-38e0-4eba-b1cc-602ee9fb4fcf" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_7644d302-a83d-4e6f-beeb-cc55d3b07464" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>jnj-20241229_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:a7478940-65f4-4b69-a475-f625bf9a358e,g:8ea82ba0-2a78-4425-b720-89454b578aab-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CoverPage" xlink:type="simple" xlink:href="jnj-20241229.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_ad2db268-4c12-48bf-816e-216d20845b48" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_DocumentInformationTable_ad2db268-4c12-48bf-816e-216d20845b48" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e77ddcfe-21b1-40ef-a2a5-44e48f6138db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_ad2db268-4c12-48bf-816e-216d20845b48" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e77ddcfe-21b1-40ef-a2a5-44e48f6138db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e77ddcfe-21b1-40ef-a2a5-44e48f6138db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e77ddcfe-21b1-40ef-a2a5-44e48f6138db" xlink:to="loc_us-gaap_ClassOfStockDomain_e77ddcfe-21b1-40ef-a2a5-44e48f6138db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4bb2db90-b53c-4948-9f22-f96ac1ae62ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e77ddcfe-21b1-40ef-a2a5-44e48f6138db" xlink:to="loc_us-gaap_ClassOfStockDomain_4bb2db90-b53c-4948-9f22-f96ac1ae62ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_272ba4e6-2120-4c8b-ab09-e2fae3a8a53d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4bb2db90-b53c-4948-9f22-f96ac1ae62ad" xlink:to="loc_us-gaap_CommonStockMember_272ba4e6-2120-4c8b-ab09-e2fae3a8a53d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_9ab6d285-95c9-49fd-be3c-6b5a1732a70f" xlink:href="jnj-20241229.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4bb2db90-b53c-4948-9f22-f96ac1ae62ad" xlink:to="loc_jnj_A1.150NotesDue2028Member_9ab6d285-95c9-49fd-be3c-6b5a1732a70f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_577f126c-ee11-49d0-8573-5fac71c9d589" xlink:href="jnj-20241229.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4bb2db90-b53c-4948-9f22-f96ac1ae62ad" xlink:to="loc_jnj_A1.650NotesDue2035Member_577f126c-ee11-49d0-8573-5fac71c9d589" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDueNovember2028Member_31c4509a-671a-4150-a42a-10c5408256ba" xlink:href="jnj-20241229.xsd#jnj_A1.150NotesDueNovember2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4bb2db90-b53c-4948-9f22-f96ac1ae62ad" xlink:to="loc_jnj_A1.150NotesDueNovember2028Member_31c4509a-671a-4150-a42a-10c5408256ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.20NotesDueNovember2032Member_fe1658b9-8f00-4c41-ad5d-26ee1fec2e8e" xlink:href="jnj-20241229.xsd#jnj_A3.20NotesDueNovember2032Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4bb2db90-b53c-4948-9f22-f96ac1ae62ad" xlink:to="loc_jnj_A3.20NotesDueNovember2032Member_fe1658b9-8f00-4c41-ad5d-26ee1fec2e8e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.350NotesDueNovember2036Member_ef3be304-ca08-4834-b96d-0a5d28d332fb" xlink:href="jnj-20241229.xsd#jnj_A3.350NotesDueNovember2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4bb2db90-b53c-4948-9f22-f96ac1ae62ad" xlink:to="loc_jnj_A3.350NotesDueNovember2036Member_ef3be304-ca08-4834-b96d-0a5d28d332fb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.550NotesDueNovember2044Member_a08976d1-1d77-4611-b112-4971d3f5c5de" xlink:href="jnj-20241229.xsd#jnj_A3.550NotesDueNovember2044Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4bb2db90-b53c-4948-9f22-f96ac1ae62ad" xlink:to="loc_jnj_A3.550NotesDueNovember2044Member_a08976d1-1d77-4611-b112-4971d3f5c5de" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_474ddfa9-5f4f-45db-a1ed-073589a1ed2c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_DocumentType_474ddfa9-5f4f-45db-a1ed-073589a1ed2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_c05658b5-148e-4fcd-a1d6-cbc9e35b6ece" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_DocumentAnnualReport_c05658b5-148e-4fcd-a1d6-cbc9e35b6ece" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_69662f74-d37d-42b1-963c-b55ad26b6b98" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_DocumentPeriodEndDate_69662f74-d37d-42b1-963c-b55ad26b6b98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e46ca3ef-f7c3-4bf1-8b33-01f31d98802c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_DocumentTransitionReport_e46ca3ef-f7c3-4bf1-8b33-01f31d98802c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8d2ff0a2-f482-4efb-8452-c6f451d77617" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityFileNumber_8d2ff0a2-f482-4efb-8452-c6f451d77617" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1c0356b9-cb1f-43ab-80be-8f5303d566cc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityRegistrantName_1c0356b9-cb1f-43ab-80be-8f5303d566cc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8d615fe8-aae3-48e9-a992-cd42d1951191" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8d615fe8-aae3-48e9-a992-cd42d1951191" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_fb8e12f6-3ef4-46c6-a0bf-08ab0d60ed04" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityTaxIdentificationNumber_fb8e12f6-3ef4-46c6-a0bf-08ab0d60ed04" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_9c19d5a0-aca8-4353-ab78-a6c4d0ebed57" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityAddressAddressLine1_9c19d5a0-aca8-4353-ab78-a6c4d0ebed57" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4118559e-a605-4d89-8580-1b7262d3b5d2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityAddressCityOrTown_4118559e-a605-4d89-8580-1b7262d3b5d2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_450b9977-4fc4-4311-ad5f-c825396522b8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityAddressStateOrProvince_450b9977-4fc4-4311-ad5f-c825396522b8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ecab23c2-6b29-4a06-b227-eb7ae659c27c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityAddressPostalZipCode_ecab23c2-6b29-4a06-b227-eb7ae659c27c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_eb4562da-017a-44d2-9f25-c773155e0202" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_CityAreaCode_eb4562da-017a-44d2-9f25-c773155e0202" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_7ee8bc97-643b-48f2-979f-fd70643677c6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_LocalPhoneNumber_7ee8bc97-643b-48f2-979f-fd70643677c6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_adea6b98-8891-459f-ba27-35dfb8b91d2f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_Security12bTitle_adea6b98-8891-459f-ba27-35dfb8b91d2f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b15f6ecb-6a79-45f4-ab0c-27b163f8c384" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_TradingSymbol_b15f6ecb-6a79-45f4-ab0c-27b163f8c384" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_de3b6b8d-0065-4298-b01b-1d139ba43042" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_SecurityExchangeName_de3b6b8d-0065-4298-b01b-1d139ba43042" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_44efa598-c0bf-4f78-a759-27786e59d6d3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_44efa598-c0bf-4f78-a759-27786e59d6d3" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_44855fd2-c732-4bbf-be7e-f3baa524d597" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityVoluntaryFilers_44855fd2-c732-4bbf-be7e-f3baa524d597" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_eb3f77c1-2838-46cf-a9d6-8829726b32aa" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityCurrentReportingStatus_eb3f77c1-2838-46cf-a9d6-8829726b32aa" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f0a83b6a-5b73-4b5b-a54e-33be1dbc2d16" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityInteractiveDataCurrent_f0a83b6a-5b73-4b5b-a54e-33be1dbc2d16" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_59f07b33-84b6-4643-af06-9ec60878d90b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityFilerCategory_59f07b33-84b6-4643-af06-9ec60878d90b" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_7e805808-3f5f-4a97-9e72-d7510c0f3065" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityEmergingGrowthCompany_7e805808-3f5f-4a97-9e72-d7510c0f3065" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_99442933-9f3d-46a6-8cad-fbd974d65a51" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntitySmallBusiness_99442933-9f3d-46a6-8cad-fbd974d65a51" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_93f48adb-4b91-4b11-965b-6892cbfcd391" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_IcfrAuditorAttestationFlag_93f48adb-4b91-4b11-965b-6892cbfcd391" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_3d693882-8e6f-4531-8d2d-585e4c395f62" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_3d693882-8e6f-4531-8d2d-585e4c395f62" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_6cd75a24-5cab-4af7-8558-d20e31409b75" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityShellCompany_6cd75a24-5cab-4af7-8558-d20e31409b75" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_593ac1af-aae7-44b5-9d6f-eef002c04bfb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityPublicFloat_593ac1af-aae7-44b5-9d6f-eef002c04bfb" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_443e3634-9ac4-49d5-b850-efa6e7ac7d98" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_443e3634-9ac4-49d5-b850-efa6e7ac7d98" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_540be2f5-4ab5-46f5-8ea1-937852a7aeb9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_540be2f5-4ab5-46f5-8ea1-937852a7aeb9" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_516d8060-b1ef-4d2a-9c71-a57e74b3f502" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityCentralIndexKey_516d8060-b1ef-4d2a-9c71-a57e74b3f502" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_1a773b95-3bfa-4567-a2bb-8fc9fee48491" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_CurrentFiscalYearEndDate_1a773b95-3bfa-4567-a2bb-8fc9fee48491" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_c60c6825-047f-42bf-ad3a-e11ae2b365b5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_DocumentFiscalYearFocus_c60c6825-047f-42bf-ad3a-e11ae2b365b5" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_cc32f880-0192-443f-be6d-912fbe31616c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_cc32f880-0192-443f-be6d-912fbe31616c" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e7e816d8-da5f-4402-8691-1b4bbd4f02ac" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_AmendmentFlag_e7e816d8-da5f-4402-8691-1b4bbd4f02ac" xlink:type="arc" order="34"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="jnj-20241229.xsd#ConsolidatedStatementsofEquity"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7646ef72-c15b-4842-89d1-266fb52a0a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0c2c1a95-0f3c-4b92-b0ec-b566700d6d01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7646ef72-c15b-4842-89d1-266fb52a0a2d" xlink:to="loc_us-gaap_StatementTable_0c2c1a95-0f3c-4b92-b0ec-b566700d6d01" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_79a32450-2f26-4f7a-a513-e37ca9c2600d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0c2c1a95-0f3c-4b92-b0ec-b566700d6d01" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_79a32450-2f26-4f7a-a513-e37ca9c2600d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_79a32450-2f26-4f7a-a513-e37ca9c2600d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_79a32450-2f26-4f7a-a513-e37ca9c2600d" xlink:to="loc_us-gaap_EquityComponentDomain_79a32450-2f26-4f7a-a513-e37ca9c2600d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6895d23a-4014-493f-853c-1a53457fcdca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_79a32450-2f26-4f7a-a513-e37ca9c2600d" xlink:to="loc_us-gaap_EquityComponentDomain_6895d23a-4014-493f-853c-1a53457fcdca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e6dc5aba-0ec7-4fdd-856b-4424884d27ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6895d23a-4014-493f-853c-1a53457fcdca" xlink:to="loc_us-gaap_RetainedEarningsMember_e6dc5aba-0ec7-4fdd-856b-4424884d27ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_58edf495-383a-4287-8908-10f6f776d8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6895d23a-4014-493f-853c-1a53457fcdca" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_58edf495-383a-4287-8908-10f6f776d8d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9e85fcbb-b190-4e4d-87a7-da14abc49b21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6895d23a-4014-493f-853c-1a53457fcdca" xlink:to="loc_us-gaap_CommonStockMember_9e85fcbb-b190-4e4d-87a7-da14abc49b21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_e55b4177-50f4-49d5-bbec-12d7694e4bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6895d23a-4014-493f-853c-1a53457fcdca" xlink:to="loc_us-gaap_TreasuryStockCommonMember_e55b4177-50f4-49d5-bbec-12d7694e4bcf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b14528f7-d46e-4668-8b4a-16f0a4810204" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7646ef72-c15b-4842-89d1-266fb52a0a2d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b14528f7-d46e-4668-8b4a-16f0a4810204" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cf35e243-c110-4bcc-8701-f0f418c68a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7646ef72-c15b-4842-89d1-266fb52a0a2d" xlink:to="loc_us-gaap_NetIncomeLoss_cf35e243-c110-4bcc-8701-f0f418c68a7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_d77b15f8-7f4f-4353-a526-e4dccf728a48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7646ef72-c15b-4842-89d1-266fb52a0a2d" xlink:to="loc_us-gaap_DividendsCommonStockCash_d77b15f8-7f4f-4353-a526-e4dccf728a48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f8a76e8e-b843-4aaf-84db-a8226091cf2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7646ef72-c15b-4842-89d1-266fb52a0a2d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f8a76e8e-b843-4aaf-84db-a8226091cf2e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_bcf2eb47-287e-4ac9-99b1-14356d0cb748" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7646ef72-c15b-4842-89d1-266fb52a0a2d" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_bcf2eb47-287e-4ac9-99b1-14356d0cb748" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_64c412c8-6a2a-4bee-99bc-4b57eebd8f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7646ef72-c15b-4842-89d1-266fb52a0a2d" xlink:to="loc_us-gaap_StockholdersEquityOther_64c412c8-6a2a-4bee-99bc-4b57eebd8f8b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_c6eac08f-8686-43b7-b064-543f8bf2ac5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7646ef72-c15b-4842-89d1-266fb52a0a2d" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_c6eac08f-8686-43b7-b064-543f8bf2ac5c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d5342f42-b594-4e75-9483-05bb982e0eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7646ef72-c15b-4842-89d1-266fb52a0a2d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d5342f42-b594-4e75-9483-05bb982e0eb2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e6b31ddb-4a6d-43f8-bfe2-7479ba4a3b96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#SummaryofsignificantaccountingpoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:href="jnj-20241229.xsd#jnj_ConcentrationOfCreditRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationOfCreditRiskTable_320ee46f-fd3a-4e54-83c3-19aad6a7bc29" xlink:href="jnj-20241229.xsd#jnj_ConcentrationOfCreditRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_ConcentrationOfCreditRiskTable_320ee46f-fd3a-4e54-83c3-19aad6a7bc29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ef3746d6-6a9f-4223-ae6c-23b7b0227b30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_320ee46f-fd3a-4e54-83c3-19aad6a7bc29" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ef3746d6-6a9f-4223-ae6c-23b7b0227b30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ef3746d6-6a9f-4223-ae6c-23b7b0227b30_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ef3746d6-6a9f-4223-ae6c-23b7b0227b30" xlink:to="loc_us-gaap_SegmentDomain_ef3746d6-6a9f-4223-ae6c-23b7b0227b30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_156dfe1e-224e-4f5f-9717-6aa4baa9946f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ef3746d6-6a9f-4223-ae6c-23b7b0227b30" xlink:to="loc_us-gaap_SegmentDomain_156dfe1e-224e-4f5f-9717-6aa4baa9946f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_d86b9543-7d54-4864-8b55-ef44143b6668" xlink:href="jnj-20241229.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_156dfe1e-224e-4f5f-9717-6aa4baa9946f" xlink:to="loc_jnj_PharmaceuticalMember_d86b9543-7d54-4864-8b55-ef44143b6668" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_84b33693-e977-4341-8715-fcec340f81f8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_320ee46f-fd3a-4e54-83c3-19aad6a7bc29" xlink:to="loc_srt_ProductOrServiceAxis_84b33693-e977-4341-8715-fcec340f81f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_84b33693-e977-4341-8715-fcec340f81f8_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_84b33693-e977-4341-8715-fcec340f81f8" xlink:to="loc_srt_ProductsAndServicesDomain_84b33693-e977-4341-8715-fcec340f81f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f04df2d5-6e67-42d8-8e25-100f1a1ff7d2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_84b33693-e977-4341-8715-fcec340f81f8" xlink:to="loc_srt_ProductsAndServicesDomain_f04df2d5-6e67-42d8-8e25-100f1a1ff7d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_e9f5812e-2e25-4887-9dab-174a63ae88c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f04df2d5-6e67-42d8-8e25-100f1a1ff7d2" xlink:to="loc_us-gaap_ShippingAndHandlingMember_e9f5812e-2e25-4887-9dab-174a63ae88c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f72ab68c-5117-4f6f-93b6-c72ed2bd252a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_320ee46f-fd3a-4e54-83c3-19aad6a7bc29" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f72ab68c-5117-4f6f-93b6-c72ed2bd252a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f72ab68c-5117-4f6f-93b6-c72ed2bd252a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f72ab68c-5117-4f6f-93b6-c72ed2bd252a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f72ab68c-5117-4f6f-93b6-c72ed2bd252a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4d603d2e-fa47-41b8-9f47-bcd0c70bf379" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f72ab68c-5117-4f6f-93b6-c72ed2bd252a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4d603d2e-fa47-41b8-9f47-bcd0c70bf379" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2b5aad78-62ec-41d1-b73f-a00f959cd9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4d603d2e-fa47-41b8-9f47-bcd0c70bf379" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2b5aad78-62ec-41d1-b73f-a00f959cd9b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3f3e4f60-734c-4b32-9415-8b67631347a8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_320ee46f-fd3a-4e54-83c3-19aad6a7bc29" xlink:to="loc_srt_RangeAxis_3f3e4f60-734c-4b32-9415-8b67631347a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3f3e4f60-734c-4b32-9415-8b67631347a8_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3f3e4f60-734c-4b32-9415-8b67631347a8" xlink:to="loc_srt_RangeMember_3f3e4f60-734c-4b32-9415-8b67631347a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0306beaf-3022-4f4a-ae5f-641b9503d3d0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3f3e4f60-734c-4b32-9415-8b67631347a8" xlink:to="loc_srt_RangeMember_0306beaf-3022-4f4a-ae5f-641b9503d3d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0a2a2754-c258-4cc2-976f-ae516042282f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0306beaf-3022-4f4a-ae5f-641b9503d3d0" xlink:to="loc_srt_MinimumMember_0a2a2754-c258-4cc2-976f-ae516042282f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_09f735a8-50a8-4bca-979c-0af5a331116e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0306beaf-3022-4f4a-ae5f-641b9503d3d0" xlink:to="loc_srt_MaximumMember_09f735a8-50a8-4bca-979c-0af5a331116e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0898cc60-d33a-4f67-9e04-40a9309a8788" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_320ee46f-fd3a-4e54-83c3-19aad6a7bc29" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0898cc60-d33a-4f67-9e04-40a9309a8788" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0898cc60-d33a-4f67-9e04-40a9309a8788_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0898cc60-d33a-4f67-9e04-40a9309a8788" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0898cc60-d33a-4f67-9e04-40a9309a8788_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_34a5efa0-101c-4cf5-a382-563b97ad3658" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0898cc60-d33a-4f67-9e04-40a9309a8788" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_34a5efa0-101c-4cf5-a382-563b97ad3658" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_6892da83-def5-429b-aefe-26b4af211dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_34a5efa0-101c-4cf5-a382-563b97ad3658" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_6892da83-def5-429b-aefe-26b4af211dc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_8b18c924-2414-4407-b1ff-eaf348f7f492" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_320ee46f-fd3a-4e54-83c3-19aad6a7bc29" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_8b18c924-2414-4407-b1ff-eaf348f7f492" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_8b18c924-2414-4407-b1ff-eaf348f7f492_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8b18c924-2414-4407-b1ff-eaf348f7f492" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_8b18c924-2414-4407-b1ff-eaf348f7f492_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_833dc7e0-c4c0-4595-a644-4b9344625503" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8b18c924-2414-4407-b1ff-eaf348f7f492" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_833dc7e0-c4c0-4595-a644-4b9344625503" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_0873c504-6941-4035-951a-f276ca011559" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_833dc7e0-c4c0-4595-a644-4b9344625503" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_0873c504-6941-4035-951a-f276ca011559" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_62bc16a2-b511-47e8-bd15-edc167f7d5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_320ee46f-fd3a-4e54-83c3-19aad6a7bc29" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_62bc16a2-b511-47e8-bd15-edc167f7d5a7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_62bc16a2-b511-47e8-bd15-edc167f7d5a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_62bc16a2-b511-47e8-bd15-edc167f7d5a7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_62bc16a2-b511-47e8-bd15-edc167f7d5a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3236e0bf-4834-4021-9f59-a25609add569" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_62bc16a2-b511-47e8-bd15-edc167f7d5a7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3236e0bf-4834-4021-9f59-a25609add569" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_eef957d6-9ac3-4dfd-b361-b4def30011ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3236e0bf-4834-4021-9f59-a25609add569" xlink:to="loc_us-gaap_IPOMember_eef957d6-9ac3-4dfd-b361-b4def30011ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6cd900ac-75f4-4c02-a68c-48aec3e765c0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_320ee46f-fd3a-4e54-83c3-19aad6a7bc29" xlink:to="loc_dei_LegalEntityAxis_6cd900ac-75f4-4c02-a68c-48aec3e765c0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6cd900ac-75f4-4c02-a68c-48aec3e765c0_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_6cd900ac-75f4-4c02-a68c-48aec3e765c0" xlink:to="loc_dei_EntityDomain_6cd900ac-75f4-4c02-a68c-48aec3e765c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3d0200dd-a080-4ddc-8592-d4a8ce8dee79" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_6cd900ac-75f4-4c02-a68c-48aec3e765c0" xlink:to="loc_dei_EntityDomain_3d0200dd-a080-4ddc-8592-d4a8ce8dee79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KenvueIncMember_6cf316bb-8845-4391-830a-a7c425939d0a" xlink:href="jnj-20241229.xsd#jnj_KenvueIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3d0200dd-a080-4ddc-8592-d4a8ce8dee79" xlink:to="loc_jnj_KenvueIncMember_6cf316bb-8845-4391-830a-a7c425939d0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_JohnsonJohnsonMember_a5f13a87-a780-4277-95e3-f2eb65163c82" xlink:href="jnj-20241229.xsd#jnj_JohnsonJohnsonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3d0200dd-a080-4ddc-8592-d4a8ce8dee79" xlink:to="loc_jnj_JohnsonJohnsonMember_a5f13a87-a780-4277-95e3-f2eb65163c82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_0bab7da9-7016-4cb0-94b1-fbbaf667aae0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_320ee46f-fd3a-4e54-83c3-19aad6a7bc29" xlink:to="loc_srt_OwnershipAxis_0bab7da9-7016-4cb0-94b1-fbbaf667aae0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_0bab7da9-7016-4cb0-94b1-fbbaf667aae0_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_0bab7da9-7016-4cb0-94b1-fbbaf667aae0" xlink:to="loc_srt_OwnershipDomain_0bab7da9-7016-4cb0-94b1-fbbaf667aae0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_9e21e66b-a034-42c9-9958-108405dfe213" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_0bab7da9-7016-4cb0-94b1-fbbaf667aae0" xlink:to="loc_srt_OwnershipDomain_9e21e66b-a034-42c9-9958-108405dfe213" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KenvueIncMember_43da6dd0-5f45-4ed4-9f81-a68fc9e8bd13" xlink:href="jnj-20241229.xsd#jnj_KenvueIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_9e21e66b-a034-42c9-9958-108405dfe213" xlink:to="loc_jnj_KenvueIncMember_43da6dd0-5f45-4ed4-9f81-a68fc9e8bd13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_222e226f-ef5e-4861-8635-338a27be2e44" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_320ee46f-fd3a-4e54-83c3-19aad6a7bc29" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_222e226f-ef5e-4861-8635-338a27be2e44" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_222e226f-ef5e-4861-8635-338a27be2e44_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_222e226f-ef5e-4861-8635-338a27be2e44" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_222e226f-ef5e-4861-8635-338a27be2e44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_61cde546-99d6-4960-9cfb-7e12eb0391ed" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_222e226f-ef5e-4861-8635-338a27be2e44" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_61cde546-99d6-4960-9cfb-7e12eb0391ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KenvueIncMember_3712ffb4-217c-4f3b-aaa5-2576661aa2a6" xlink:href="jnj-20241229.xsd#jnj_KenvueIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_61cde546-99d6-4960-9cfb-7e12eb0391ed" xlink:to="loc_jnj_KenvueIncMember_3712ffb4-217c-4f3b-aaa5-2576661aa2a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_96f9f02f-b7b2-4e30-a721-2d4a367f648f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_320ee46f-fd3a-4e54-83c3-19aad6a7bc29" xlink:to="loc_us-gaap_AssetAcquisitionAxis_96f9f02f-b7b2-4e30-a721-2d4a367f648f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_96f9f02f-b7b2-4e30-a721-2d4a367f648f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_96f9f02f-b7b2-4e30-a721-2d4a367f648f" xlink:to="loc_us-gaap_AssetAcquisitionDomain_96f9f02f-b7b2-4e30-a721-2d4a367f648f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_717a1112-5276-486b-a39b-bdbddfe47cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_96f9f02f-b7b2-4e30-a721-2d4a367f648f" xlink:to="loc_us-gaap_AssetAcquisitionDomain_717a1112-5276-486b-a39b-bdbddfe47cc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_YellowJerseyTherapeuticsMember_ac5712a0-1956-441d-b5fc-a2eb7bd977a3" xlink:href="jnj-20241229.xsd#jnj_YellowJerseyTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_717a1112-5276-486b-a39b-bdbddfe47cc8" xlink:to="loc_jnj_YellowJerseyTherapeuticsMember_ac5712a0-1956-441d-b5fc-a2eb7bd977a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide_2833127a-80d2-4afc-b99b-12b1b9498c43" xlink:href="jnj-20241229.xsd#jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide_2833127a-80d2-4afc-b99b-12b1b9498c43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_eaeb2bfc-f2fc-4bf0-869a-93fc40d5fe9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_eaeb2bfc-f2fc-4bf0-869a-93fc40d5fe9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_96e96c76-2d76-4f16-bffb-e61c0adbbd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_96e96c76-2d76-4f16-bffb-e61c0adbbd8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_3db88235-0610-4e9f-904d-091354e63ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_3db88235-0610-4e9f-904d-091354e63ce5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_d07538d4-cc67-4f59-84a0-f079797f7eef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_d07538d4-cc67-4f59-84a0-f079797f7eef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_7a2356c0-3d3f-4b7a-8159-e28b096feb37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_7a2356c0-3d3f-4b7a-8159-e28b096feb37" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_d89b0244-2fc9-4c89-be57-f802ceaba90b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_d89b0244-2fc9-4c89-be57-f802ceaba90b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_109887ef-9360-4af5-805f-7542f6fda62f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_CommonStockValueOutstanding_109887ef-9360-4af5-805f-7542f6fda62f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OwnershipPercentageSplitOffPercent_365a6772-9cce-4f0b-9d3b-16390c8c4e6f" xlink:href="jnj-20241229.xsd#jnj_OwnershipPercentageSplitOffPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_OwnershipPercentageSplitOffPercent_365a6772-9cce-4f0b-9d3b-16390c8c4e6f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExchangeOfStockPercentageOwnershipAfterTransaction_07bca1d5-5bcb-4f41-8f32-bf9db6113028" xlink:href="jnj-20241229.xsd#jnj_ExchangeOfStockPercentageOwnershipAfterTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_ExchangeOfStockPercentageOwnershipAfterTransaction_07bca1d5-5bcb-4f41-8f32-bf9db6113028" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_369f1312-5a60-4190-a31e-5b7ec9f40e17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_NumberOfReportableSegments_369f1312-5a60-4190-a31e-5b7ec9f40e17" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationCurrent_1fe98302-4a06-4e76-b2a6-a948baa5b8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_SupplierFinanceProgramObligationCurrent_1fe98302-4a06-4e76-b2a6-a948baa5b8bc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration_70d4a7ea-2202-4673-896d-e83042e96d54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration_70d4a7ea-2202-4673-896d-e83042e96d54" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement_e59d1987-68b8-408e-a88f-13d41d796264" xlink:href="jnj-20241229.xsd#jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement_e59d1987-68b8-408e-a88f-13d41d796264" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f3406898-a5c0-43b3-83c4-2c09ad02a8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f3406898-a5c0-43b3-83c4-2c09ad02a8ea" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RevenuePerformanceObligationPaymentTerms_c492dda8-3d96-4782-892b-44cbe234c9bd" xlink:href="jnj-20241229.xsd#jnj_RevenuePerformanceObligationPaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_RevenuePerformanceObligationPaymentTerms_c492dda8-3d96-4782-892b-44cbe234c9bd" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions_20707d8a-b043-4cf5-8b93-a0a8eab3226d" xlink:href="jnj-20241229.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_AccruedRebatesReturnsAndPromotions_20707d8a-b043-4cf5-8b93-a0a8eab3226d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesReturnReserve_5e39725c-9c5f-49b9-95a2-fa527dd27897" xlink:href="jnj-20241229.xsd#jnj_SalesReturnReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_SalesReturnReserve_5e39725c-9c5f-49b9-95a2-fa527dd27897" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProfitLossPercentToSales_715ad4c0-6b9f-48b8-b741-886a432be7dc" xlink:href="jnj-20241229.xsd#jnj_ProfitLossPercentToSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_ProfitLossPercentToSales_715ad4c0-6b9f-48b8-b741-886a432be7dc" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5c1005bd-7565-4547-a9e6-ecaaf186cc00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5c1005bd-7565-4547-a9e6-ecaaf186cc00" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShippingandHandlingCostsasaPercentofSales_27a3c90a-b38b-4318-b557-a1e26571f358" xlink:href="jnj-20241229.xsd#jnj_ShippingandHandlingCostsasaPercentofSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_ShippingandHandlingCostsasaPercentofSales_27a3c90a-b38b-4318-b557-a1e26571f358" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_c65cc2bd-30cc-4fb3-a6a8-dc1185f94772" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_c65cc2bd-30cc-4fb3-a6a8-dc1185f94772" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_70a8957e-ffbd-482f-a939-d2c91bc31ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_70a8957e-ffbd-482f-a939-d2c91bc31ff1" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_bd56176d-83eb-41e3-8ceb-22b89f71d399" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_bd56176d-83eb-41e3-8ceb-22b89f71d399" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3da7799c-5578-4e4f-b346-9c928547c318" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3da7799c-5578-4e4f-b346-9c928547c318" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_075e715f-1e2f-4435-ba61-d892965e9226" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_OperatingLeaseLiability_075e715f-1e2f-4435-ba61-d892965e9226" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_7cc1e3fa-6894-41b1-89dd-dba5ed97c166" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_OperatingLeaseCost_7cc1e3fa-6894-41b1-89dd-dba5ed97c166" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_40167cf2-8566-496d-8a64-caa3ba66a849" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_OperatingLeasePayments_40167cf2-8566-496d-8a64-caa3ba66a849" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationRiskThresholdPercentage_ed9d0afb-25d8-49ec-8079-395ffb07250f" xlink:href="jnj-20241229.xsd#jnj_ConcentrationRiskThresholdPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_ConcentrationRiskThresholdPercentage_ed9d0afb-25d8-49ec-8079-395ffb07250f" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_36d47c84-efbb-4c5d-9ad6-5106cfc53a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_AdvertisingExpense_36d47c84-efbb-4c5d-9ad6-5106cfc53a6c" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_b603ac13-fbc9-4062-82ae-e493c7a14387" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_b603ac13-fbc9-4062-82ae-e493c7a14387" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent_2b8fa6b6-66e0-40c0-adc1-f0723a34f582" xlink:href="jnj-20241229.xsd#jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent_2b8fa6b6-66e0-40c0-adc1-f0723a34f582" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent_ea16f4fb-47fe-4756-82cf-af58f13a9179" xlink:href="jnj-20241229.xsd#jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent_ea16f4fb-47fe-4756-82cf-af58f13a9179" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsPaymentPeriod_acfe25cb-7fb0-4878-8b16-9b892cc792f6" xlink:href="jnj-20241229.xsd#jnj_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsPaymentPeriod_acfe25cb-7fb0-4878-8b16-9b892cc792f6" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent_986b035f-e703-4e5c-839d-93ea2be24b43" xlink:href="jnj-20241229.xsd#jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent_986b035f-e703-4e5c-839d-93ea2be24b43" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_20643de8-9d93-46db-b310-8b6baa358d24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_20643de8-9d93-46db-b310-8b6baa358d24" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a5ea6c82-6352-4db4-a773-fed5fb4cbd2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a5ea6c82-6352-4db4-a773-fed5fb4cbd2e" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationCurrent_9260a671-05d2-4b79-abda-d1f734a43b13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligationCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramPaymentTimingPeriod_777b70d4-2fa8-44b7-ac33-a0cd62aa38e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramPaymentTimingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_SupplierFinanceProgramPaymentTimingPeriod_777b70d4-2fa8-44b7-ac33-a0cd62aa38e5" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_88a611ff-e504-44dc-abaa-e63b27089ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_88a611ff-e504-44dc-abaa-e63b27089ff7" xlink:type="arc" order="39"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a033eeda-88c6-426e-9068-12a32c30c5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_87422850-e242-47d0-a767-89570da1f5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a033eeda-88c6-426e-9068-12a32c30c5f4" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_87422850-e242-47d0-a767-89570da1f5a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a241505e-2233-48c2-b0f2-fcca38c35e29" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_87422850-e242-47d0-a767-89570da1f5a8" xlink:to="loc_srt_RangeAxis_a241505e-2233-48c2-b0f2-fcca38c35e29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a241505e-2233-48c2-b0f2-fcca38c35e29_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a241505e-2233-48c2-b0f2-fcca38c35e29" xlink:to="loc_srt_RangeMember_a241505e-2233-48c2-b0f2-fcca38c35e29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_618d8d60-954b-43cb-9c77-ae0467878b8d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a241505e-2233-48c2-b0f2-fcca38c35e29" xlink:to="loc_srt_RangeMember_618d8d60-954b-43cb-9c77-ae0467878b8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e16f7724-4e79-452d-96fc-fc8b98748466" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_618d8d60-954b-43cb-9c77-ae0467878b8d" xlink:to="loc_srt_MinimumMember_e16f7724-4e79-452d-96fc-fc8b98748466" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_12ddbd71-f37b-4e91-aa79-aac916b77268" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_618d8d60-954b-43cb-9c77-ae0467878b8d" xlink:to="loc_srt_MaximumMember_12ddbd71-f37b-4e91-aa79-aac916b77268" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fcc6eaf4-0e5e-4d17-97c2-80ac9e99e365" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_87422850-e242-47d0-a767-89570da1f5a8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fcc6eaf4-0e5e-4d17-97c2-80ac9e99e365" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fcc6eaf4-0e5e-4d17-97c2-80ac9e99e365_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fcc6eaf4-0e5e-4d17-97c2-80ac9e99e365" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fcc6eaf4-0e5e-4d17-97c2-80ac9e99e365_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0510ebd6-862e-4d77-944d-9608b291d8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fcc6eaf4-0e5e-4d17-97c2-80ac9e99e365" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0510ebd6-862e-4d77-944d-9608b291d8f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_751e0102-40c8-4de7-9809-588ed4097a73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0510ebd6-862e-4d77-944d-9608b291d8f3" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_751e0102-40c8-4de7-9809-588ed4097a73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LandAndLeaseholdImprovementsMember_29b95507-79e4-4ae9-9e3f-6e48534d87a4" xlink:href="jnj-20241229.xsd#jnj_LandAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0510ebd6-862e-4d77-944d-9608b291d8f3" xlink:to="loc_jnj_LandAndLeaseholdImprovementsMember_29b95507-79e4-4ae9-9e3f-6e48534d87a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_3f2342ff-5331-405e-b018-1a42638d6eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0510ebd6-862e-4d77-944d-9608b291d8f3" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_3f2342ff-5331-405e-b018-1a42638d6eb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7e57cae0-5806-4293-8c56-5ddbba83e07e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a033eeda-88c6-426e-9068-12a32c30c5f4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7e57cae0-5806-4293-8c56-5ddbba83e07e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_8eca1bfa-d4ac-424a-a8d6-6224755df3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4037a68d-e8b1-4364-9e83-011c20a16f72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_8eca1bfa-d4ac-424a-a8d6-6224755df3bf" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4037a68d-e8b1-4364-9e83-011c20a16f72" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_27863df8-865d-4ddf-ad42-41c74afdd200" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4037a68d-e8b1-4364-9e83-011c20a16f72" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_27863df8-865d-4ddf-ad42-41c74afdd200" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_27863df8-865d-4ddf-ad42-41c74afdd200_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_27863df8-865d-4ddf-ad42-41c74afdd200" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_27863df8-865d-4ddf-ad42-41c74afdd200_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_b3e0a658-21be-4b13-bb6e-41c2cdff2175" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_27863df8-865d-4ddf-ad42-41c74afdd200" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_b3e0a658-21be-4b13-bb6e-41c2cdff2175" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember_e3d8cda5-464a-49ca-8152-43b5f0f7ad4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_b3e0a658-21be-4b13-bb6e-41c2cdff2175" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesMember_e3d8cda5-464a-49ca-8152-43b5f0f7ad4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_911305a5-3388-4c05-9d86-79129aefb6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_b3e0a658-21be-4b13-bb6e-41c2cdff2175" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_911305a5-3388-4c05-9d86-79129aefb6c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8f8c547a-730b-4a18-b6e8-287daaa1b548" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4037a68d-e8b1-4364-9e83-011c20a16f72" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8f8c547a-730b-4a18-b6e8-287daaa1b548" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8f8c547a-730b-4a18-b6e8-287daaa1b548_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8f8c547a-730b-4a18-b6e8-287daaa1b548" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8f8c547a-730b-4a18-b6e8-287daaa1b548_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01e23d99-e8ba-47a4-8b58-26673faba0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8f8c547a-730b-4a18-b6e8-287daaa1b548" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01e23d99-e8ba-47a4-8b58-26673faba0e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_d140b678-1585-4671-99ce-c850284971d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01e23d99-e8ba-47a4-8b58-26673faba0e3" xlink:to="loc_us-gaap_CashMember_d140b678-1585-4671-99ce-c850284971d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_9ed66445-7984-458e-ab6c-f66412a82a33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01e23d99-e8ba-47a4-8b58-26673faba0e3" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_9ed66445-7984-458e-ab6c-f66412a82a33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_a4eab89e-eedc-4efd-9d16-c27e9737f13f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01e23d99-e8ba-47a4-8b58-26673faba0e3" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_a4eab89e-eedc-4efd-9d16-c27e9737f13f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_90262701-e62c-4d16-b864-484059523ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01e23d99-e8ba-47a4-8b58-26673faba0e3" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_90262701-e62c-4d16-b864-484059523ea1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_e8f0d55e-e23a-47af-ba1b-792da1c8b4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01e23d99-e8ba-47a4-8b58-26673faba0e3" xlink:to="loc_us-gaap_MoneyMarketFundsMember_e8f0d55e-e23a-47af-ba1b-792da1c8b4e9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_e9d868af-da4a-4ad9-82ce-7d5d2d7359a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01e23d99-e8ba-47a4-8b58-26673faba0e3" xlink:to="loc_us-gaap_BankTimeDepositsMember_e9d868af-da4a-4ad9-82ce-7d5d2d7359a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_35fa7579-5f45-489f-9577-8b74557c38b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01e23d99-e8ba-47a4-8b58-26673faba0e3" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_35fa7579-5f45-489f-9577-8b74557c38b1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d93d2aee-b99e-41d5-9f32-6d0db55e1582" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01e23d99-e8ba-47a4-8b58-26673faba0e3" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d93d2aee-b99e-41d5-9f32-6d0db55e1582" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherSovereignSecuritiesMember_552da266-c7d5-45ca-967b-7d330fe36b63" xlink:href="jnj-20241229.xsd#jnj_OtherSovereignSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01e23d99-e8ba-47a4-8b58-26673faba0e3" xlink:to="loc_jnj_OtherSovereignSecuritiesMember_552da266-c7d5-45ca-967b-7d330fe36b63" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_4957fb59-ec4a-4803-801b-25c0a36c6435" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_8eca1bfa-d4ac-424a-a8d6-6224755df3bf" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_4957fb59-ec4a-4803-801b-25c0a36c6435" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_33f2e5eb-2c85-4283-a142-8f9a2d01052b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_4957fb59-ec4a-4803-801b-25c0a36c6435" xlink:to="loc_us-gaap_HeldToMaturitySecurities_33f2e5eb-2c85-4283-a142-8f9a2d01052b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_798a5fe3-3713-42cb-b2d6-24eb90fa51d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_4957fb59-ec4a-4803-801b-25c0a36c6435" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_798a5fe3-3713-42cb-b2d6-24eb90fa51d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_d6e910a1-75ac-4ac7-b181-11524c452ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_4957fb59-ec4a-4803-801b-25c0a36c6435" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_d6e910a1-75ac-4ac7-b181-11524c452ee3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b70bcf65-05fb-4004-a67c-5f94cdd12927" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_4957fb59-ec4a-4803-801b-25c0a36c6435" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b70bcf65-05fb-4004-a67c-5f94cdd12927" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_278be3f6-c1e4-4b00-bce0-8a2288a9d692" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_4957fb59-ec4a-4803-801b-25c0a36c6435" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_278be3f6-c1e4-4b00-bce0-8a2288a9d692" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_30cc061d-398a-4678-a34d-847acf1041ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_4957fb59-ec4a-4803-801b-25c0a36c6435" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_30cc061d-398a-4678-a34d-847acf1041ed" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_219ed067-41ed-4e31-a6f1-dc3a50c760f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_4957fb59-ec4a-4803-801b-25c0a36c6435" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_219ed067-41ed-4e31-a6f1-dc3a50c760f9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0d92e80e-fd2d-43c0-8564-800aea64c9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_4957fb59-ec4a-4803-801b-25c0a36c6435" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0d92e80e-fd2d-43c0-8564-800aea64c9f5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a4d2c379-d924-4127-a3c4-f9e1d9164486" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_4957fb59-ec4a-4803-801b-25c0a36c6435" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a4d2c379-d924-4127-a3c4-f9e1d9164486" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_1684ece0-85e7-43ef-8164-7cca8f28cbda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_4957fb59-ec4a-4803-801b-25c0a36c6435" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_1684ece0-85e7-43ef-8164-7cca8f28cbda" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e4766893-561a-45c2-8a64-7093d24b9093" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d57924e1-6362-42f1-9b9a-98279f7b99f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e4766893-561a-45c2-8a64-7093d24b9093" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d57924e1-6362-42f1-9b9a-98279f7b99f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e5175cf8-c38a-4504-86dc-d94e4d1d8a42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d57924e1-6362-42f1-9b9a-98279f7b99f0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e5175cf8-c38a-4504-86dc-d94e4d1d8a42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e5175cf8-c38a-4504-86dc-d94e4d1d8a42_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e5175cf8-c38a-4504-86dc-d94e4d1d8a42" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e5175cf8-c38a-4504-86dc-d94e4d1d8a42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_26561d73-7a54-454a-8d4e-a940115e1e72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e5175cf8-c38a-4504-86dc-d94e4d1d8a42" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_26561d73-7a54-454a-8d4e-a940115e1e72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LandAndLeaseholdImprovementsMember_0cbeabf5-b06e-4a73-b722-a205f7b48170" xlink:href="jnj-20241229.xsd#jnj_LandAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_26561d73-7a54-454a-8d4e-a940115e1e72" xlink:to="loc_jnj_LandAndLeaseholdImprovementsMember_0cbeabf5-b06e-4a73-b722-a205f7b48170" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_ff247409-cf9e-4317-ace0-7f86656eed2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_26561d73-7a54-454a-8d4e-a940115e1e72" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_ff247409-cf9e-4317-ace0-7f86656eed2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_24c40446-71cb-45c7-8d0b-ad3f4289442e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_26561d73-7a54-454a-8d4e-a940115e1e72" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_24c40446-71cb-45c7-8d0b-ad3f4289442e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_2051bf15-a184-4afc-9a12-dd003c379910" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_26561d73-7a54-454a-8d4e-a940115e1e72" xlink:to="loc_us-gaap_ConstructionInProgressMember_2051bf15-a184-4afc-9a12-dd003c379910" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_965710c0-118a-407d-bbdc-5aad844ed495" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e4766893-561a-45c2-8a64-7093d24b9093" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_965710c0-118a-407d-bbdc-5aad844ed495" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_151a8e0f-8cd3-48d7-8514-d37db1003d62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e4766893-561a-45c2-8a64-7093d24b9093" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_151a8e0f-8cd3-48d7-8514-d37db1003d62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_43d1a22d-a38a-47b0-92e1-3efe9024e3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e4766893-561a-45c2-8a64-7093d24b9093" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_43d1a22d-a38a-47b0-92e1-3efe9024e3e5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_842c47d1-95aa-4a5a-9a9a-99a9d73ca376" xlink:href="jnj-20241229.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_e4e387ef-06c3-4012-b751-0fc61e5be577" xlink:href="jnj-20241229.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_842c47d1-95aa-4a5a-9a9a-99a9d73ca376" xlink:to="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_e4e387ef-06c3-4012-b751-0fc61e5be577" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_89266570-a750-459d-90ee-cf2522ad14d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_e4e387ef-06c3-4012-b751-0fc61e5be577" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_89266570-a750-459d-90ee-cf2522ad14d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89266570-a750-459d-90ee-cf2522ad14d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_89266570-a750-459d-90ee-cf2522ad14d2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89266570-a750-459d-90ee-cf2522ad14d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eb941a64-cac7-4ebe-93fc-d37b9fb7cac5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_89266570-a750-459d-90ee-cf2522ad14d2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eb941a64-cac7-4ebe-93fc-d37b9fb7cac5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_f1ffd67e-b7d4-46b0-8762-7bbb57eb8ae8" xlink:href="jnj-20241229.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eb941a64-cac7-4ebe-93fc-d37b9fb7cac5" xlink:to="loc_jnj_PatentsAndTrademarksMember_f1ffd67e-b7d4-46b0-8762-7bbb57eb8ae8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_f9e526f5-2fdd-4679-b270-0a9e3fe55e93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eb941a64-cac7-4ebe-93fc-d37b9fb7cac5" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_f9e526f5-2fdd-4679-b270-0a9e3fe55e93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_2a15d081-e396-45f6-97c2-e122fd9eccf5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eb941a64-cac7-4ebe-93fc-d37b9fb7cac5" xlink:to="loc_us-gaap_TrademarksMember_2a15d081-e396-45f6-97c2-e122fd9eccf5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8368751b-bae5-4a67-b4f5-75a471bb0249" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_e4e387ef-06c3-4012-b751-0fc61e5be577" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8368751b-bae5-4a67-b4f5-75a471bb0249" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8368751b-bae5-4a67-b4f5-75a471bb0249_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8368751b-bae5-4a67-b4f5-75a471bb0249" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8368751b-bae5-4a67-b4f5-75a471bb0249_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c6ab608a-1501-4093-af35-15b02138b831" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8368751b-bae5-4a67-b4f5-75a471bb0249" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c6ab608a-1501-4093-af35-15b02138b831" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_2985527f-e4e0-42ba-95d3-c6d0af25ce3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c6ab608a-1501-4093-af35-15b02138b831" xlink:to="loc_us-gaap_TrademarksMember_2985527f-e4e0-42ba-95d3-c6d0af25ce3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_54aea8ac-1b4e-4497-9a48-a8b27701ce26" xlink:href="jnj-20241229.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c6ab608a-1501-4093-af35-15b02138b831" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_54aea8ac-1b4e-4497-9a48-a8b27701ce26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b8245cd9-5566-4eb6-962f-cece48aae586" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_842c47d1-95aa-4a5a-9a9a-99a9d73ca376" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b8245cd9-5566-4eb6-962f-cece48aae586" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_e7b70673-7eb2-4367-ad49-32997e823df7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b8245cd9-5566-4eb6-962f-cece48aae586" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_e7b70673-7eb2-4367-ad49-32997e823df7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e3fd8be2-5eda-4a18-ac97-95b5ec5d323e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_e7b70673-7eb2-4367-ad49-32997e823df7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e3fd8be2-5eda-4a18-ac97-95b5ec5d323e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2e8db78d-ce6d-4a92-9e45-e9b3dd08f0af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_e7b70673-7eb2-4367-ad49-32997e823df7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2e8db78d-ce6d-4a92-9e45-e9b3dd08f0af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7897864f-b516-4b34-b6a1-5cd98fc02d32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_e7b70673-7eb2-4367-ad49-32997e823df7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7897864f-b516-4b34-b6a1-5cd98fc02d32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_48bb8058-ff03-4370-ad55-327a0ab88522" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b8245cd9-5566-4eb6-962f-cece48aae586" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_48bb8058-ff03-4370-ad55-327a0ab88522" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1657d761-8155-45e8-af7d-15172317fd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_48bb8058-ff03-4370-ad55-327a0ab88522" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1657d761-8155-45e8-af7d-15172317fd6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a6243a07-f755-4284-8efc-d64d5ecba83c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_48bb8058-ff03-4370-ad55-327a0ab88522" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a6243a07-f755-4284-8efc-d64d5ecba83c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_dc4a7636-869a-4142-8b5f-7a1f8700589e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_842c47d1-95aa-4a5a-9a9a-99a9d73ca376" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_dc4a7636-869a-4142-8b5f-7a1f8700589e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#IntangibleassetsandgoodwillGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_2082881e-38cd-4d31-bae6-111504bbb26b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_535bd772-c331-4ba8-8118-55726a0b6867" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_2082881e-38cd-4d31-bae6-111504bbb26b" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_535bd772-c331-4ba8-8118-55726a0b6867" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7aeace2c-e708-43e0-903a-043892a85a25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_535bd772-c331-4ba8-8118-55726a0b6867" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7aeace2c-e708-43e0-903a-043892a85a25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7aeace2c-e708-43e0-903a-043892a85a25_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7aeace2c-e708-43e0-903a-043892a85a25" xlink:to="loc_us-gaap_SegmentDomain_7aeace2c-e708-43e0-903a-043892a85a25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_08a84def-83d1-480d-88cd-158842bda448" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7aeace2c-e708-43e0-903a-043892a85a25" xlink:to="loc_us-gaap_SegmentDomain_08a84def-83d1-480d-88cd-158842bda448" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InnovativeMedicineMember_e99cf5e8-589b-47a3-871d-5c1d768bf983" xlink:href="jnj-20241229.xsd#jnj_InnovativeMedicineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_08a84def-83d1-480d-88cd-158842bda448" xlink:to="loc_jnj_InnovativeMedicineMember_e99cf5e8-589b-47a3-871d-5c1d768bf983" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedTechMember_6b0834f3-4483-44b7-bd6a-35fb8ffdf448" xlink:href="jnj-20241229.xsd#jnj_MedTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_08a84def-83d1-480d-88cd-158842bda448" xlink:to="loc_jnj_MedTechMember_6b0834f3-4483-44b7-bd6a-35fb8ffdf448" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_c200e3d3-9cf0-4172-b859-dcf7bce0d71a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_2082881e-38cd-4d31-bae6-111504bbb26b" xlink:to="loc_us-gaap_GoodwillRollForward_c200e3d3-9cf0-4172-b859-dcf7bce0d71a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3324220e-1427-44c4-86ec-d7dd743e964e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_c200e3d3-9cf0-4172-b859-dcf7bce0d71a" xlink:to="loc_us-gaap_Goodwill_3324220e-1427-44c4-86ec-d7dd743e964e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_8f30d96d-568f-4101-b47b-cfe413cc2f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_c200e3d3-9cf0-4172-b859-dcf7bce0d71a" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_8f30d96d-568f-4101-b47b-cfe413cc2f2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_2577ebc3-1ee8-490a-8639-b07874340abd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_c200e3d3-9cf0-4172-b859-dcf7bce0d71a" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_2577ebc3-1ee8-490a-8639-b07874340abd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_ccf00040-3f51-4dc3-8a51-73a7a1ff89c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_c200e3d3-9cf0-4172-b859-dcf7bce0d71a" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_ccf00040-3f51-4dc3-8a51-73a7a1ff89c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_acb1b3c8-6f07-43ab-9460-acb13d634284" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleassetsandgoodwillNarrativeDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#IntangibleassetsandgoodwillNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleassetsandgoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d2bf8f93-a322-4fa6-8a27-5af9278615b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_30a7e6b3-c11f-4348-a7b6-b46c6ff93c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d2bf8f93-a322-4fa6-8a27-5af9278615b9" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_30a7e6b3-c11f-4348-a7b6-b46c6ff93c1d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b6eeaebb-6871-4aa4-840c-e22b4095bbe5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_30a7e6b3-c11f-4348-a7b6-b46c6ff93c1d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b6eeaebb-6871-4aa4-840c-e22b4095bbe5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6eeaebb-6871-4aa4-840c-e22b4095bbe5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b6eeaebb-6871-4aa4-840c-e22b4095bbe5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b6eeaebb-6871-4aa4-840c-e22b4095bbe5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a451343a-707d-4879-8764-459305f9b1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b6eeaebb-6871-4aa4-840c-e22b4095bbe5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a451343a-707d-4879-8764-459305f9b1a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_d7fbf96f-d683-4618-808c-145ec0758ccb" xlink:href="jnj-20241229.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a451343a-707d-4879-8764-459305f9b1a0" xlink:to="loc_jnj_PatentsAndTrademarksMember_d7fbf96f-d683-4618-808c-145ec0758ccb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_96394ea0-cb70-44dd-82a4-2d2272c5a3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a451343a-707d-4879-8764-459305f9b1a0" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_96394ea0-cb70-44dd-82a4-2d2272c5a3dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_5f125d23-dc85-497a-904d-3b48330ab977" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d2bf8f93-a322-4fa6-8a27-5af9278615b9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_5f125d23-dc85-497a-904d-3b48330ab977" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_71f811ca-56ad-496b-be81-a71294d7bedf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d2bf8f93-a322-4fa6-8a27-5af9278615b9" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_71f811ca-56ad-496b-be81-a71294d7bedf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#FairvaluemeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_679e5074-08bb-4dbe-a78e-95f0e823bc77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_bb571d2d-84a4-4ff7-aa4d-f3b5f9c23903" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_679e5074-08bb-4dbe-a78e-95f0e823bc77" xlink:to="loc_us-gaap_DerivativeTable_bb571d2d-84a4-4ff7-aa4d-f3b5f9c23903" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_11997007-fa5a-4a64-baa8-91b915383a28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_bb571d2d-84a4-4ff7-aa4d-f3b5f9c23903" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_11997007-fa5a-4a64-baa8-91b915383a28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_11997007-fa5a-4a64-baa8-91b915383a28_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_11997007-fa5a-4a64-baa8-91b915383a28" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_11997007-fa5a-4a64-baa8-91b915383a28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e17e828b-ac47-43a9-b344-3853b9da896c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_11997007-fa5a-4a64-baa8-91b915383a28" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e17e828b-ac47-43a9-b344-3853b9da896c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_cbd13d0d-3a28-4732-9588-28ea6135089f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e17e828b-ac47-43a9-b344-3853b9da896c" xlink:to="loc_us-gaap_EquitySecuritiesMember_cbd13d0d-3a28-4732-9588-28ea6135089f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_e0bdd1df-9c82-4a53-98cc-d8268351cc55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_bb571d2d-84a4-4ff7-aa4d-f3b5f9c23903" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_e0bdd1df-9c82-4a53-98cc-d8268351cc55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_e0bdd1df-9c82-4a53-98cc-d8268351cc55_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_e0bdd1df-9c82-4a53-98cc-d8268351cc55" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_e0bdd1df-9c82-4a53-98cc-d8268351cc55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_9080e20c-8d81-4dc7-b611-44d87fdc4838" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_e0bdd1df-9c82-4a53-98cc-d8268351cc55" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_9080e20c-8d81-4dc7-b611-44d87fdc4838" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_9ae54ce6-75b7-4b77-b246-8bf08e672d7c" xlink:href="jnj-20241229.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_9080e20c-8d81-4dc7-b611-44d87fdc4838" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_9ae54ce6-75b7-4b77-b246-8bf08e672d7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_f995a9b1-86f7-4bf3-b787-868d6abd56c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_bb571d2d-84a4-4ff7-aa4d-f3b5f9c23903" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_f995a9b1-86f7-4bf3-b787-868d6abd56c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f995a9b1-86f7-4bf3-b787-868d6abd56c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f995a9b1-86f7-4bf3-b787-868d6abd56c9" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f995a9b1-86f7-4bf3-b787-868d6abd56c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_41d51984-8818-4400-b0b2-65327e41deb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f995a9b1-86f7-4bf3-b787-868d6abd56c9" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_41d51984-8818-4400-b0b2-65327e41deb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_b781e610-cab0-48ba-9e83-56476b361024" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_41d51984-8818-4400-b0b2-65327e41deb2" xlink:to="loc_us-gaap_ForeignExchangeContractMember_b781e610-cab0-48ba-9e83-56476b361024" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_77d92969-2473-4b31-ac28-327663932353" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_41d51984-8818-4400-b0b2-65327e41deb2" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_77d92969-2473-4b31-ac28-327663932353" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_a70d4b8c-9209-457a-8598-5a930e76a6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_41d51984-8818-4400-b0b2-65327e41deb2" xlink:to="loc_us-gaap_InterestRateSwapMember_a70d4b8c-9209-457a-8598-5a930e76a6d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_25fb479d-1d11-4145-b1f4-2d030540a23c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_679e5074-08bb-4dbe-a78e-95f0e823bc77" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_25fb479d-1d11-4145-b1f4-2d030540a23c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_1e7be673-05d8-4246-963d-bc545180aa26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_679e5074-08bb-4dbe-a78e-95f0e823bc77" xlink:to="loc_us-gaap_DerivativeNotionalAmount_1e7be673-05d8-4246-963d-bc545180aa26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_75ea850c-03c9-407b-9021-e4722f844980" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_679e5074-08bb-4dbe-a78e-95f0e823bc77" xlink:to="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_75ea850c-03c9-407b-9021-e4722f844980" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_570edcc9-5f26-48f9-8020-ebf96a04ad6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_679e5074-08bb-4dbe-a78e-95f0e823bc77" xlink:to="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_570edcc9-5f26-48f9-8020-ebf96a04ad6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_5afd7a83-824f-42fc-b38d-025ea3a4fb58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_679e5074-08bb-4dbe-a78e-95f0e823bc77" xlink:to="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_5afd7a83-824f-42fc-b38d-025ea3a4fb58" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_53c0c27b-1b0c-439a-80ce-d42ae8d244d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaper"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_679e5074-08bb-4dbe-a78e-95f0e823bc77" xlink:to="loc_us-gaap_CommercialPaper_53c0c27b-1b0c-439a-80ce-d42ae8d244d7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommercialPaper_dfa9a9c7-1633-4eed-a713-c9bd3a079a64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommercialPaper"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_679e5074-08bb-4dbe-a78e-95f0e823bc77" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommercialPaper_dfa9a9c7-1633-4eed-a713-c9bd3a079a64" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DebtForEquityExchangeSharesExchanged_035270e5-2daa-4ba2-8e72-ac11b77d67e9" xlink:href="jnj-20241229.xsd#jnj_DebtForEquityExchangeSharesExchanged"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_679e5074-08bb-4dbe-a78e-95f0e823bc77" xlink:to="loc_jnj_DebtForEquityExchangeSharesExchanged_035270e5-2daa-4ba2-8e72-ac11b77d67e9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DebtForEquityExchangeLossOnSharesExchanged_b4ec95c0-ac3d-4494-9dfc-b789fa544e4c" xlink:href="jnj-20241229.xsd#jnj_DebtForEquityExchangeLossOnSharesExchanged"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_679e5074-08bb-4dbe-a78e-95f0e823bc77" xlink:to="loc_jnj_DebtForEquityExchangeLossOnSharesExchanged_b4ec95c0-ac3d-4494-9dfc-b789fa544e4c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_248cf153-d3c6-4735-9ddd-99a3df4d9657" xlink:href="jnj-20241229.xsd#jnj_EquityFairValueAdjustmentImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_679e5074-08bb-4dbe-a78e-95f0e823bc77" xlink:to="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_248cf153-d3c6-4735-9ddd-99a3df4d9657" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentChangeinObservablePrices_4fab64d3-6450-45a7-9e81-9aa25082765c" xlink:href="jnj-20241229.xsd#jnj_EquityFairValueAdjustmentChangeinObservablePrices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_679e5074-08bb-4dbe-a78e-95f0e823bc77" xlink:to="loc_jnj_EquityFairValueAdjustmentChangeinObservablePrices_4fab64d3-6450-45a7-9e81-9aa25082765c" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#FairvaluemeasurementsSummaryofDerivativeActivityDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_53447a15-e848-404f-84c8-372186b2af8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_99b8879a-6f31-486a-be83-8cc98dcc21ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_53447a15-e848-404f-84c8-372186b2af8b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_99b8879a-6f31-486a-be83-8cc98dcc21ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a2613a57-ab0d-4fe8-a77c-4281b6075209" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_99b8879a-6f31-486a-be83-8cc98dcc21ad" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a2613a57-ab0d-4fe8-a77c-4281b6075209" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a2613a57-ab0d-4fe8-a77c-4281b6075209_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a2613a57-ab0d-4fe8-a77c-4281b6075209" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a2613a57-ab0d-4fe8-a77c-4281b6075209_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ca9f8ade-a893-4b85-8b77-15a7114b5953" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a2613a57-ab0d-4fe8-a77c-4281b6075209" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ca9f8ade-a893-4b85-8b77-15a7114b5953" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_fa657276-db53-4f75-b3c3-52b91247c058" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ca9f8ade-a893-4b85-8b77-15a7114b5953" xlink:to="loc_us-gaap_SalesMember_fa657276-db53-4f75-b3c3-52b91247c058" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_d33d83d3-a888-4b8b-996b-37e9f48aa975" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ca9f8ade-a893-4b85-8b77-15a7114b5953" xlink:to="loc_us-gaap_CostOfSalesMember_d33d83d3-a888-4b8b-996b-37e9f48aa975" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8c2b9e12-7401-48ba-bc49-07a5c40e49e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ca9f8ade-a893-4b85-8b77-15a7114b5953" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8c2b9e12-7401-48ba-bc49-07a5c40e49e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember_e8253cc5-2c55-4c6f-9f1a-0d0ce1e76eb5" xlink:href="jnj-20241229.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ca9f8ade-a893-4b85-8b77-15a7114b5953" xlink:to="loc_jnj_InterestIncomeExpenseNetMember_e8253cc5-2c55-4c6f-9f1a-0d0ce1e76eb5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_972c035f-736e-4276-9cfb-7fd906c64fb6" xlink:href="jnj-20241229.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ca9f8ade-a893-4b85-8b77-15a7114b5953" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_972c035f-736e-4276-9cfb-7fd906c64fb6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_9e5ce314-72a7-4fa8-b76d-45a988fb665e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_99b8879a-6f31-486a-be83-8cc98dcc21ad" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_9e5ce314-72a7-4fa8-b76d-45a988fb665e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9e5ce314-72a7-4fa8-b76d-45a988fb665e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9e5ce314-72a7-4fa8-b76d-45a988fb665e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9e5ce314-72a7-4fa8-b76d-45a988fb665e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c6a81c63-2845-4653-87ce-83f933b6ce7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9e5ce314-72a7-4fa8-b76d-45a988fb665e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c6a81c63-2845-4653-87ce-83f933b6ce7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_be3e62ce-e903-4830-9c5c-76616cef3a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c6a81c63-2845-4653-87ce-83f933b6ce7d" xlink:to="loc_us-gaap_InterestRateSwapMember_be3e62ce-e903-4830-9c5c-76616cef3a3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_37d10a18-519b-454b-a67c-476cf3444f05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c6a81c63-2845-4653-87ce-83f933b6ce7d" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_37d10a18-519b-454b-a67c-476cf3444f05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_186cc0e7-de8f-42f5-b3bd-b4d0a2ebda3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c6a81c63-2845-4653-87ce-83f933b6ce7d" xlink:to="loc_us-gaap_ForeignExchangeContractMember_186cc0e7-de8f-42f5-b3bd-b4d0a2ebda3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_599f8daf-a848-4ac3-9a38-720ad80d1a37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_99b8879a-6f31-486a-be83-8cc98dcc21ad" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_599f8daf-a848-4ac3-9a38-720ad80d1a37" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_599f8daf-a848-4ac3-9a38-720ad80d1a37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_599f8daf-a848-4ac3-9a38-720ad80d1a37" xlink:to="loc_us-gaap_HedgingRelationshipDomain_599f8daf-a848-4ac3-9a38-720ad80d1a37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_4324958b-18e9-4c28-bc8c-106fb49e32c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_599f8daf-a848-4ac3-9a38-720ad80d1a37" xlink:to="loc_us-gaap_HedgingRelationshipDomain_4324958b-18e9-4c28-bc8c-106fb49e32c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_a9a954f0-fa90-4826-a836-14be9029f186" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_4324958b-18e9-4c28-bc8c-106fb49e32c3" xlink:to="loc_us-gaap_FairValueHedgingMember_a9a954f0-fa90-4826-a836-14be9029f186" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_9267fe68-37b6-4d1c-9695-5950a71b0fae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_4324958b-18e9-4c28-bc8c-106fb49e32c3" xlink:to="loc_us-gaap_CashFlowHedgingMember_9267fe68-37b6-4d1c-9695-5950a71b0fae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_1806e5c0-31d8-4281-9c80-58864f40c6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_53447a15-e848-404f-84c8-372186b2af8b" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_1806e5c0-31d8-4281-9c80-58864f40c6f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_2db8d4bc-11ab-4f29-bc26-7e5d0b4e9467" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_53447a15-e848-404f-84c8-372186b2af8b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_2db8d4bc-11ab-4f29-bc26-7e5d0b4e9467" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_b05be443-552e-4b5d-a37b-0f0ce6407350" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_53447a15-e848-404f-84c8-372186b2af8b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_b05be443-552e-4b5d-a37b-0f0ce6407350" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_28b52dfc-6876-4410-a41d-8b351f3fe6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_53447a15-e848-404f-84c8-372186b2af8b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_28b52dfc-6876-4410-a41d-8b351f3fe6c8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_05b46884-12f4-4306-beb2-2d0d84114768" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_df17d42d-16e3-45b7-a3e3-9749f6a7ca6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_05b46884-12f4-4306-beb2-2d0d84114768" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_df17d42d-16e3-45b7-a3e3-9749f6a7ca6a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_803b83c7-75b1-418c-87a6-240cfa4c88cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_df17d42d-16e3-45b7-a3e3-9749f6a7ca6a" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_803b83c7-75b1-418c-87a6-240cfa4c88cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_803b83c7-75b1-418c-87a6-240cfa4c88cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_803b83c7-75b1-418c-87a6-240cfa4c88cc" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_803b83c7-75b1-418c-87a6-240cfa4c88cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c012fe9d-c03d-4b29-8744-24d6601b5dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_803b83c7-75b1-418c-87a6-240cfa4c88cc" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c012fe9d-c03d-4b29-8744-24d6601b5dfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_4a487b08-f449-416e-8d78-825bc1c42a67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c012fe9d-c03d-4b29-8744-24d6601b5dfa" xlink:to="loc_us-gaap_LongTermDebtMember_4a487b08-f449-416e-8d78-825bc1c42a67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_250489db-b9d8-47c4-ac27-a2f229a310d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_df17d42d-16e3-45b7-a3e3-9749f6a7ca6a" xlink:to="loc_us-gaap_HedgingDesignationAxis_250489db-b9d8-47c4-ac27-a2f229a310d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_250489db-b9d8-47c4-ac27-a2f229a310d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_250489db-b9d8-47c4-ac27-a2f229a310d6" xlink:to="loc_us-gaap_HedgingDesignationDomain_250489db-b9d8-47c4-ac27-a2f229a310d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_c4d7941a-3c3b-40df-ab21-87c672122375" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_250489db-b9d8-47c4-ac27-a2f229a310d6" xlink:to="loc_us-gaap_HedgingDesignationDomain_c4d7941a-3c3b-40df-ab21-87c672122375" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_550f6662-8671-4caa-a8f6-73c2465c3b65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_c4d7941a-3c3b-40df-ab21-87c672122375" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_550f6662-8671-4caa-a8f6-73c2465c3b65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_dafd8db1-fa5a-4045-a756-c2ddc14d8f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_05b46884-12f4-4306-beb2-2d0d84114768" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_dafd8db1-fa5a-4045-a756-c2ddc14d8f8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_8d209bf2-f063-46c9-a235-4d3e9cbe9c34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_05b46884-12f4-4306-beb2-2d0d84114768" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_8d209bf2-f063-46c9-a235-4d3e9cbe9c34" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_65ac2f4a-baa0-494f-8ce2-02711a1dcdaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_cb7c90e9-7913-48b8-b7da-b42a5b303ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_65ac2f4a-baa0-494f-8ce2-02711a1dcdaf" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_cb7c90e9-7913-48b8-b7da-b42a5b303ff9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3c550990-0559-40ac-a0ae-bb8f5771e7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_cb7c90e9-7913-48b8-b7da-b42a5b303ff9" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3c550990-0559-40ac-a0ae-bb8f5771e7b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3c550990-0559-40ac-a0ae-bb8f5771e7b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3c550990-0559-40ac-a0ae-bb8f5771e7b3" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3c550990-0559-40ac-a0ae-bb8f5771e7b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7436d28c-71e4-45fa-b7b2-c6ec50924b96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3c550990-0559-40ac-a0ae-bb8f5771e7b3" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7436d28c-71e4-45fa-b7b2-c6ec50924b96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_5621ed2e-9c3b-4b1b-9891-52493686be58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7436d28c-71e4-45fa-b7b2-c6ec50924b96" xlink:to="loc_us-gaap_ForeignExchangeContractMember_5621ed2e-9c3b-4b1b-9891-52493686be58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_e9476217-3669-4ca7-bcd8-85d7a8235432" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_cb7c90e9-7913-48b8-b7da-b42a5b303ff9" xlink:to="loc_us-gaap_HedgingDesignationAxis_e9476217-3669-4ca7-bcd8-85d7a8235432" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e9476217-3669-4ca7-bcd8-85d7a8235432_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_e9476217-3669-4ca7-bcd8-85d7a8235432" xlink:to="loc_us-gaap_HedgingDesignationDomain_e9476217-3669-4ca7-bcd8-85d7a8235432_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_8920a678-ba59-4057-80e5-1a992a2491a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_e9476217-3669-4ca7-bcd8-85d7a8235432" xlink:to="loc_us-gaap_HedgingDesignationDomain_8920a678-ba59-4057-80e5-1a992a2491a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_c8d1bf06-2953-4c4d-bcd7-77da3a651450" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_8920a678-ba59-4057-80e5-1a992a2491a3" xlink:to="loc_us-gaap_NondesignatedMember_c8d1bf06-2953-4c4d-bcd7-77da3a651450" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_a6705a5d-856e-4d84-be6e-2316696217d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_65ac2f4a-baa0-494f-8ce2-02711a1dcdaf" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_a6705a5d-856e-4d84-be6e-2316696217d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_4b939bcf-e35b-4472-967a-5c2f8bf5dbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_65ac2f4a-baa0-494f-8ce2-02711a1dcdaf" xlink:to="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_4b939bcf-e35b-4472-967a-5c2f8bf5dbb6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_04c02064-6178-4478-9f4c-2637741abdf2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_38113d6b-776c-469b-a62b-7c0ac3196f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_04c02064-6178-4478-9f4c-2637741abdf2" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_38113d6b-776c-469b-a62b-7c0ac3196f2f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f91eafec-041e-4196-8317-869bc735a5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_38113d6b-776c-469b-a62b-7c0ac3196f2f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f91eafec-041e-4196-8317-869bc735a5c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f91eafec-041e-4196-8317-869bc735a5c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f91eafec-041e-4196-8317-869bc735a5c2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f91eafec-041e-4196-8317-869bc735a5c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d65cef0d-bfa5-4dee-82e6-6a198b781a73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f91eafec-041e-4196-8317-869bc735a5c2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d65cef0d-bfa5-4dee-82e6-6a198b781a73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_d937e28e-efe9-4adf-987c-a1e782f0c112" xlink:href="jnj-20241229.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d65cef0d-bfa5-4dee-82e6-6a198b781a73" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_d937e28e-efe9-4adf-987c-a1e782f0c112" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6ced0c18-7154-4d81-b4e9-a4797eacfa04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_38113d6b-776c-469b-a62b-7c0ac3196f2f" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6ced0c18-7154-4d81-b4e9-a4797eacfa04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6ced0c18-7154-4d81-b4e9-a4797eacfa04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6ced0c18-7154-4d81-b4e9-a4797eacfa04" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6ced0c18-7154-4d81-b4e9-a4797eacfa04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_50635f5c-5bc3-49af-9ecb-eb7cef1d29f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6ced0c18-7154-4d81-b4e9-a4797eacfa04" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_50635f5c-5bc3-49af-9ecb-eb7cef1d29f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_dc3e6957-aefa-4edf-8386-b79e93da2b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_50635f5c-5bc3-49af-9ecb-eb7cef1d29f2" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_dc3e6957-aefa-4edf-8386-b79e93da2b7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_9c8b5703-f797-4cd9-8927-9af24d542ded" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_04c02064-6178-4478-9f4c-2637741abdf2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_9c8b5703-f797-4cd9-8927-9af24d542ded" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_c0ebba23-7794-44c7-a020-413eb55e04cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_04c02064-6178-4478-9f4c-2637741abdf2" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_c0ebba23-7794-44c7-a020-413eb55e04cf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_a8146088-740b-4e6b-ab96-de38b18556d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_be0e00d7-ee56-4201-b9ba-59409db083ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_a8146088-740b-4e6b-ab96-de38b18556d4" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_be0e00d7-ee56-4201-b9ba-59409db083ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_8f6d8266-9e97-41ee-8764-2333ddc79b43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_be0e00d7-ee56-4201-b9ba-59409db083ec" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_8f6d8266-9e97-41ee-8764-2333ddc79b43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8f6d8266-9e97-41ee-8764-2333ddc79b43_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_8f6d8266-9e97-41ee-8764-2333ddc79b43" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8f6d8266-9e97-41ee-8764-2333ddc79b43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_bc524987-17df-48ba-8bb8-90e440ce0e33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_8f6d8266-9e97-41ee-8764-2333ddc79b43" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_bc524987-17df-48ba-8bb8-90e440ce0e33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_e4f93cc1-6280-4793-a875-21025bbd5cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_bc524987-17df-48ba-8bb8-90e440ce0e33" xlink:to="loc_us-gaap_EquitySecuritiesMember_e4f93cc1-6280-4793-a875-21025bbd5cb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_16acfebd-c896-462a-9e4e-b722e7ccb335" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_be0e00d7-ee56-4201-b9ba-59409db083ec" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_16acfebd-c896-462a-9e4e-b722e7ccb335" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_16acfebd-c896-462a-9e4e-b722e7ccb335_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_16acfebd-c896-462a-9e4e-b722e7ccb335" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_16acfebd-c896-462a-9e4e-b722e7ccb335_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_9d6f7439-81cc-45a5-8faa-5fc056db0403" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_16acfebd-c896-462a-9e4e-b722e7ccb335" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_9d6f7439-81cc-45a5-8faa-5fc056db0403" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_885ace64-c7a8-4262-9021-629359e6baa1" xlink:href="jnj-20241229.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_9d6f7439-81cc-45a5-8faa-5fc056db0403" xlink:to="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_885ace64-c7a8-4262-9021-629359e6baa1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_b747112d-14e6-4c80-95e4-5e9f240bd340" xlink:href="jnj-20241229.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_9d6f7439-81cc-45a5-8faa-5fc056db0403" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_b747112d-14e6-4c80-95e4-5e9f240bd340" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_6f269a1d-2554-42b2-b43c-8f34067b2d83" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_be0e00d7-ee56-4201-b9ba-59409db083ec" xlink:to="loc_srt_OwnershipAxis_6f269a1d-2554-42b2-b43c-8f34067b2d83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_6f269a1d-2554-42b2-b43c-8f34067b2d83_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_6f269a1d-2554-42b2-b43c-8f34067b2d83" xlink:to="loc_srt_OwnershipDomain_6f269a1d-2554-42b2-b43c-8f34067b2d83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_9ece6131-34cb-4ca5-a57b-c3c7e6fad633" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_6f269a1d-2554-42b2-b43c-8f34067b2d83" xlink:to="loc_srt_OwnershipDomain_9ece6131-34cb-4ca5-a57b-c3c7e6fad633" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KenvueIncMember_9577eaa4-f4ae-44f9-8c9f-b64d3492137a" xlink:href="jnj-20241229.xsd#jnj_KenvueIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_9ece6131-34cb-4ca5-a57b-c3c7e6fad633" xlink:to="loc_jnj_KenvueIncMember_9577eaa4-f4ae-44f9-8c9f-b64d3492137a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_18bc0523-8f9e-4575-88f8-53c2c9d10446" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_be0e00d7-ee56-4201-b9ba-59409db083ec" xlink:to="loc_dei_LegalEntityAxis_18bc0523-8f9e-4575-88f8-53c2c9d10446" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_18bc0523-8f9e-4575-88f8-53c2c9d10446_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_18bc0523-8f9e-4575-88f8-53c2c9d10446" xlink:to="loc_dei_EntityDomain_18bc0523-8f9e-4575-88f8-53c2c9d10446_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6d04e9e1-7ad6-485c-8984-4156be56f063" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_18bc0523-8f9e-4575-88f8-53c2c9d10446" xlink:to="loc_dei_EntityDomain_6d04e9e1-7ad6-485c-8984-4156be56f063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_JohnsonJohnsonMember_61b615f9-7b1b-4177-bbb5-ac8ead3a9b83" xlink:href="jnj-20241229.xsd#jnj_JohnsonJohnsonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6d04e9e1-7ad6-485c-8984-4156be56f063" xlink:to="loc_jnj_JohnsonJohnsonMember_61b615f9-7b1b-4177-bbb5-ac8ead3a9b83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward_de0953c8-b245-4ef2-988b-a9f9ea0ba3e6" xlink:href="jnj-20241229.xsd#jnj_EquityInvestmentRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_a8146088-740b-4e6b-ab96-de38b18556d4" xlink:to="loc_jnj_EquityInvestmentRollForward_de0953c8-b245-4ef2-988b-a9f9ea0ba3e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_f9519454-df6d-470d-a636-8e6262e6c43b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_de0953c8-b245-4ef2-988b-a9f9ea0ba3e6" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_f9519454-df6d-470d-a636-8e6262e6c43b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_00e47e20-9e6d-4c46-9e79-b80ae211cff5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_de0953c8-b245-4ef2-988b-a9f9ea0ba3e6" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_00e47e20-9e6d-4c46-9e79-b80ae211cff5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_0d2de39f-0b4b-4463-9e28-bf6781055a09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_de0953c8-b245-4ef2-988b-a9f9ea0ba3e6" xlink:to="loc_us-gaap_EquityFairValueAdjustment_0d2de39f-0b4b-4463-9e28-bf6781055a09" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_8c8b7d6e-d129-4ebc-b6bc-498ad20bfbc1" xlink:href="jnj-20241229.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_de0953c8-b245-4ef2-988b-a9f9ea0ba3e6" xlink:to="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_8c8b7d6e-d129-4ebc-b6bc-498ad20bfbc1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7ed7973b-a95b-4ada-9545-91629c0f4963" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_de0953c8-b245-4ef2-988b-a9f9ea0ba3e6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7ed7973b-a95b-4ada-9545-91629c0f4963" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExchangeOfStockPercentageOwnershipAfterTransaction_2aa8b591-99a0-4344-812a-85c050360915" xlink:href="jnj-20241229.xsd#jnj_ExchangeOfStockPercentageOwnershipAfterTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_a8146088-740b-4e6b-ab96-de38b18556d4" xlink:to="loc_jnj_ExchangeOfStockPercentageOwnershipAfterTransaction_2aa8b591-99a0-4344-812a-85c050360915" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_695f9c43-0848-460a-ad92-f444a32657af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_a8146088-740b-4e6b-ab96-de38b18556d4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_695f9c43-0848-460a-ad92-f444a32657af" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_082494df-6433-44f9-b6e1-3d09c4e6c8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_082494df-6433-44f9-b6e1-3d09c4e6c8f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_64e4b834-4c21-42c1-bb8d-03f5c2838943" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_082494df-6433-44f9-b6e1-3d09c4e6c8f3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_64e4b834-4c21-42c1-bb8d-03f5c2838943" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_64e4b834-4c21-42c1-bb8d-03f5c2838943_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_64e4b834-4c21-42c1-bb8d-03f5c2838943" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_64e4b834-4c21-42c1-bb8d-03f5c2838943_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3ddfa970-0fbe-4f29-9274-c99f55292e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_64e4b834-4c21-42c1-bb8d-03f5c2838943" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3ddfa970-0fbe-4f29-9274-c99f55292e3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_b1402339-6297-45b2-a64a-ecb26a23b054" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3ddfa970-0fbe-4f29-9274-c99f55292e3e" xlink:to="loc_us-gaap_ForeignExchangeContractMember_b1402339-6297-45b2-a64a-ecb26a23b054" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_864f224a-f23f-4b50-b3ee-9bfd8f2e483b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3ddfa970-0fbe-4f29-9274-c99f55292e3e" xlink:to="loc_us-gaap_InterestRateContractMember_864f224a-f23f-4b50-b3ee-9bfd8f2e483b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_98440dba-9fca-4588-9195-62a2f2726678" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_082494df-6433-44f9-b6e1-3d09c4e6c8f3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_98440dba-9fca-4588-9195-62a2f2726678" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_98440dba-9fca-4588-9195-62a2f2726678_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_98440dba-9fca-4588-9195-62a2f2726678" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_98440dba-9fca-4588-9195-62a2f2726678_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d681b796-6a14-4fec-a5c0-617e995d5c30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_98440dba-9fca-4588-9195-62a2f2726678" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d681b796-6a14-4fec-a5c0-617e995d5c30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ba745f7d-11f1-4afa-af78-ed08974d3826" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d681b796-6a14-4fec-a5c0-617e995d5c30" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ba745f7d-11f1-4afa-af78-ed08974d3826" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b44a6656-74e8-4050-9540-c7b779afa09b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d681b796-6a14-4fec-a5c0-617e995d5c30" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b44a6656-74e8-4050-9540-c7b779afa09b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_cb61c78f-9225-4a93-b73c-c7998d3cc51d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d681b796-6a14-4fec-a5c0-617e995d5c30" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_cb61c78f-9225-4a93-b73c-c7998d3cc51d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_84453810-8b84-484c-bfde-61154601fc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_082494df-6433-44f9-b6e1-3d09c4e6c8f3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_84453810-8b84-484c-bfde-61154601fc4c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84453810-8b84-484c-bfde-61154601fc4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_84453810-8b84-484c-bfde-61154601fc4c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84453810-8b84-484c-bfde-61154601fc4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_24c988f9-6dd6-4c33-bafa-0056594e7846" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_84453810-8b84-484c-bfde-61154601fc4c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_24c988f9-6dd6-4c33-bafa-0056594e7846" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AbiomedMember_1f94ec51-d77a-4ac0-a333-43c9867a8fc7" xlink:href="jnj-20241229.xsd#jnj_AbiomedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_24c988f9-6dd6-4c33-bafa-0056594e7846" xlink:to="loc_jnj_AbiomedMember_1f94ec51-d77a-4ac0-a333-43c9867a8fc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProteologixMember_cb156df0-73a9-4071-9c9e-3468f8926889" xlink:href="jnj-20241229.xsd#jnj_ProteologixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_24c988f9-6dd6-4c33-bafa-0056594e7846" xlink:to="loc_jnj_ProteologixMember_cb156df0-73a9-4071-9c9e-3468f8926889" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_fd80d00f-9a65-4f33-b0e4-f3098aba05ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_082494df-6433-44f9-b6e1-3d09c4e6c8f3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_fd80d00f-9a65-4f33-b0e4-f3098aba05ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_fd80d00f-9a65-4f33-b0e4-f3098aba05ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_fd80d00f-9a65-4f33-b0e4-f3098aba05ab" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_fd80d00f-9a65-4f33-b0e4-f3098aba05ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_27c158c1-14f0-4405-a1c4-e922d80ad950" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_fd80d00f-9a65-4f33-b0e4-f3098aba05ab" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_27c158c1-14f0-4405-a1c4-e922d80ad950" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_210c0808-d833-439e-91b4-586ac51951c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_27c158c1-14f0-4405-a1c4-e922d80ad950" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_210c0808-d833-439e-91b4-586ac51951c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_1d5f20d7-70b9-4e59-9241-9b450fc9a3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_27c158c1-14f0-4405-a1c4-e922d80ad950" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_1d5f20d7-70b9-4e59-9241-9b450fc9a3bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract_81f323ab-b38f-43c3-a902-97cf5f967891" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:to="loc_us-gaap_DerivativeInstrumentDetailAbstract_81f323ab-b38f-43c3-a902-97cf5f967891" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_b86389f7-83ef-47a1-bf98-54113f1bb3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_81f323ab-b38f-43c3-a902-97cf5f967891" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_b86389f7-83ef-47a1-bf98-54113f1bb3c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_e00124bc-8e6a-4161-bb53-7595e2c89873" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_81f323ab-b38f-43c3-a902-97cf5f967891" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_e00124bc-8e6a-4161-bb53-7595e2c89873" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_6313d7eb-7b1c-4682-a066-b92208528e82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_81f323ab-b38f-43c3-a902-97cf5f967891" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_6313d7eb-7b1c-4682-a066-b92208528e82" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_ce2fec22-891f-4677-ad5f-5ee4a378c1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_81f323ab-b38f-43c3-a902-97cf5f967891" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_ce2fec22-891f-4677-ad5f-5ee4a378c1bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_335bea12-9d6c-4e05-81bc-30f3733d47e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_81f323ab-b38f-43c3-a902-97cf5f967891" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_335bea12-9d6c-4e05-81bc-30f3733d47e5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1b31d6f0-da5e-4a09-af7c-864b9f7efa71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_81f323ab-b38f-43c3-a902-97cf5f967891" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1b31d6f0-da5e-4a09-af7c-864b9f7efa71" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_21cac2e8-3186-4d14-a60b-1189e404ebec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_81f323ab-b38f-43c3-a902-97cf5f967891" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_21cac2e8-3186-4d14-a60b-1189e404ebec" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_ccb7849d-ef02-4037-86ff-0dc68a3c7f20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_ccb7849d-ef02-4037-86ff-0dc68a3c7f20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_3e0e6fcd-6018-44a5-a3bf-116a5c1081da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_3e0e6fcd-6018-44a5-a3bf-116a5c1081da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_0f94f123-5942-4140-9628-2dfaeaa659cb" xlink:href="jnj-20241229.xsd#jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:to="loc_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_0f94f123-5942-4140-9628-2dfaeaa659cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_ffa5583a-adb2-4a12-9157-3804e80e8795" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:to="loc_us-gaap_DerivativeAssets_ffa5583a-adb2-4a12-9157-3804e80e8795" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_1206c46b-0cde-4254-ba8c-66e734f6f8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_1206c46b-0cde-4254-ba8c-66e734f6f8b6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_b9ff9554-a83a-4da9-bb25-77bb5599a084" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_b9ff9554-a83a-4da9-bb25-77bb5599a084" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_f2dfd7b6-5136-46eb-b674-7c723327a48e" xlink:href="jnj-20241229.xsd#jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:to="loc_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_f2dfd7b6-5136-46eb-b674-7c723327a48e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_46033153-a936-46c4-9d80-f7364d36a4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:to="loc_us-gaap_DerivativeLiabilities_46033153-a936-46c4-9d80-f7364d36a4a2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_116d6b72-00d1-4b22-9da3-d444d45b74ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_116d6b72-00d1-4b22-9da3-d444d45b74ae" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_710eb685-aae0-4dc0-9e44-2ed0a2cf0b1d" xlink:href="jnj-20241229.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:to="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_710eb685-aae0-4dc0-9e44-2ed0a2cf0b1d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_6ffc8a59-f9d6-43f4-bd78-bd567d5361f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_6ffc8a59-f9d6-43f4-bd78-bd567d5361f9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_ec12b859-7745-47ec-a382-b4ed6b434fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_ec12b859-7745-47ec-a382-b4ed6b434fc0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6ac5f5c2-167f-4ba9-b9b6-9a4560fc7a65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#BorrowingsScheduleofLongtermDebtInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7342e7b3-e34c-42ba-af5f-3ec0741d8f50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_30ab6076-9fa2-4bc1-aabe-655f1451a1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7342e7b3-e34c-42ba-af5f-3ec0741d8f50" xlink:to="loc_us-gaap_DebtInstrumentTable_30ab6076-9fa2-4bc1-aabe-655f1451a1bb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9e8e80dc-fa77-4c05-8235-5ad88d9eee1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_30ab6076-9fa2-4bc1-aabe-655f1451a1bb" xlink:to="loc_us-gaap_DebtInstrumentAxis_9e8e80dc-fa77-4c05-8235-5ad88d9eee1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9e8e80dc-fa77-4c05-8235-5ad88d9eee1a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9e8e80dc-fa77-4c05-8235-5ad88d9eee1a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9e8e80dc-fa77-4c05-8235-5ad88d9eee1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9e8e80dc-fa77-4c05-8235-5ad88d9eee1a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_ddb06495-c6ae-4cf2-b081-fa23fd1b03fc" xlink:href="jnj-20241229.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A0.650NotesDue2024Member_ddb06495-c6ae-4cf2-b081-fa23fd1b03fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_b3519391-2985-44a1-828b-1845c769bb70" xlink:href="jnj-20241229.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A5.50NotesDue2024Member_b3519391-2985-44a1-828b-1845c769bb70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member_23aea600-f56f-43df-9971-e60cb695a45c" xlink:href="jnj-20241229.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A2.625Notesdue2025Member_23aea600-f56f-43df-9971-e60cb695a45c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A055NotesDue2025Member_e2b8b2ee-10fb-4088-a6e1-0ea9b4a9e8a4" xlink:href="jnj-20241229.xsd#jnj_A055NotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A055NotesDue2025Member_e2b8b2ee-10fb-4088-a6e1-0ea9b4a9e8a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member_08defe6c-4cc8-4c54-8832-cc3bc7c91878" xlink:href="jnj-20241229.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A2.45Notesdue2026Member_08defe6c-4cc8-4c54-8832-cc3bc7c91878" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member_113068ab-1b39-4057-aa36-ccae47b537a2" xlink:href="jnj-20241229.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A2.95Notesdue2027Member_113068ab-1b39-4057-aa36-ccae47b537a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member_f1c75a64-ee39-4a15-ba0b-ce9b7695a674" xlink:href="jnj-20241229.xsd#jnj_A095NotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A095NotesDue2027Member_f1c75a64-ee39-4a15-ba0b-ce9b7695a674" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_f995958b-d7ea-4281-8780-78502fee2b21" xlink:href="jnj-20241229.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A1.150NotesDue2028Member_f995958b-d7ea-4281-8780-78502fee2b21" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member_e523a76a-464f-4b4d-9e99-627f0a960ca1" xlink:href="jnj-20241229.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A2.900Notesdue2028Member_e523a76a-464f-4b4d-9e99-627f0a960ca1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member_44f7cbde-2dcc-43d8-8764-323edd13edcd" xlink:href="jnj-20241229.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A6.95Notesdue2029Member_44f7cbde-2dcc-43d8-8764-323edd13edcd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.80DebenturesDue2029Member_ee0bdfc6-8918-4cf6-9c16-e10678c9782c" xlink:href="jnj-20241229.xsd#jnj_A4.80DebenturesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A4.80DebenturesDue2029Member_ee0bdfc6-8918-4cf6-9c16-e10678c9782c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A130NotesDue2030Member_1fd8787d-c695-4a7a-8bd2-1365d0fcb892" xlink:href="jnj-20241229.xsd#jnj_A130NotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A130NotesDue2030Member_1fd8787d-c695-4a7a-8bd2-1365d0fcb892" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.90DebenturesDue2031Member_2461f5c3-36d3-4a7c-852b-651f3b13c435" xlink:href="jnj-20241229.xsd#jnj_A4.90DebenturesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A4.90DebenturesDue2031Member_2461f5c3-36d3-4a7c-852b-651f3b13c435" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.20DebenturesDue2032Member_4a857285-0555-478b-9075-5c9ff5ac6774" xlink:href="jnj-20241229.xsd#jnj_A3.20DebenturesDue2032Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A3.20DebenturesDue2032Member_4a857285-0555-478b-9075-5c9ff5ac6774" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member_c4b185e5-1a39-420e-a2f9-2f13ec8fc2ab" xlink:href="jnj-20241229.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A4.95Debenturesdue2033Member_c4b185e5-1a39-420e-a2f9-2f13ec8fc2ab" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member_62b55efd-3049-4849-bc6c-dd8d9176f7b5" xlink:href="jnj-20241229.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A4.375Notesdue2033Member_62b55efd-3049-4849-bc6c-dd8d9176f7b5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95DebenturesDue2034Member_1bded869-0d8f-4818-8926-28a6ef49d85e" xlink:href="jnj-20241229.xsd#jnj_A4.95DebenturesDue2034Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A4.95DebenturesDue2034Member_1bded869-0d8f-4818-8926-28a6ef49d85e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_fd0abd93-d26c-4877-88e8-e7bcd7a2dc4b" xlink:href="jnj-20241229.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A1.650NotesDue2035Member_fd0abd93-d26c-4877-88e8-e7bcd7a2dc4b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.35DebenturesDue2036Member_47499b25-89bb-4d50-a7ca-321c3b7ae7e1" xlink:href="jnj-20241229.xsd#jnj_A3.35DebenturesDue2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A3.35DebenturesDue2036Member_47499b25-89bb-4d50-a7ca-321c3b7ae7e1" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member_d206906d-7431-4f8c-a2d2-f67b8e4bd0e2" xlink:href="jnj-20241229.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A3.55Notesdue2036Member_d206906d-7431-4f8c-a2d2-f67b8e4bd0e2" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member_d50ebbbb-bc00-4199-94f4-7a9b4f213b2b" xlink:href="jnj-20241229.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A5.95Notesdue2037Member_d50ebbbb-bc00-4199-94f4-7a9b4f213b2b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member_c73cf064-a63d-4b9f-a305-c4d8a0a939f3" xlink:href="jnj-20241229.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A3.625Notesdue2037Member_c73cf064-a63d-4b9f-a305-c4d8a0a939f3" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member_dc1c4fc0-47ec-49d4-95a5-6109520990ad" xlink:href="jnj-20241229.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A5.85Debenturesdue2038Member_dc1c4fc0-47ec-49d4-95a5-6109520990ad" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member_91c66c65-9191-45d3-9d3a-42494ad1ab03" xlink:href="jnj-20241229.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A3.400Notesdue2038Member_91c66c65-9191-45d3-9d3a-42494ad1ab03" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member_5e21244b-b595-40d0-b67b-7a2796572237" xlink:href="jnj-20241229.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A4.50Debenturesdue2040Member_5e21244b-b595-40d0-b67b-7a2796572237" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member_a29d63e2-ced5-415d-bd4c-fb0f44aaa73c" xlink:href="jnj-20241229.xsd#jnj_A210NotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A210NotesDue2040Member_a29d63e2-ced5-415d-bd4c-fb0f44aaa73c" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member_bb2f1680-3192-4f0a-9aec-fd0a48d00a68" xlink:href="jnj-20241229.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A4.85Notesdue2041Member_bb2f1680-3192-4f0a-9aec-fd0a48d00a68" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member_c05377f0-8af6-4168-be68-25cd6bf8b55c" xlink:href="jnj-20241229.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A4.50Notesdue2043Member_c05377f0-8af6-4168-be68-25cd6bf8b55c" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55DebenturesDue2044Member_fa78378c-a797-459a-b653-7467d3473a76" xlink:href="jnj-20241229.xsd#jnj_A3.55DebenturesDue2044Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A3.55DebenturesDue2044Member_fa78378c-a797-459a-b653-7467d3473a76" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member_6f3c2e93-2df6-4a61-9cac-824f0c2d005c" xlink:href="jnj-20241229.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A3.70Notesdue2046Member_6f3c2e93-2df6-4a61-9cac-824f0c2d005c" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member_c5dbff0c-5e4f-49d1-a77a-cae422967bf1" xlink:href="jnj-20241229.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A3.75Notesdue2047Member_c5dbff0c-5e4f-49d1-a77a-cae422967bf1" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member_0707d223-dcfa-45af-a13e-5a60328fd0c6" xlink:href="jnj-20241229.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A3.500Notesdue2048Member_0707d223-dcfa-45af-a13e-5a60328fd0c6" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member_c2494f71-a7ab-4c29-acef-3a9f99e99158" xlink:href="jnj-20241229.xsd#jnj_A2250NotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A2250NotesDue2050Member_c2494f71-a7ab-4c29-acef-3a9f99e99158" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.25DebenturesDue2054Member_693f3622-4906-470f-860e-076193713896" xlink:href="jnj-20241229.xsd#jnj_A5.25DebenturesDue2054Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A5.25DebenturesDue2054Member_693f3622-4906-470f-860e-076193713896" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member_6e68a061-1b29-47b4-9ad1-a59b5970e9c3" xlink:href="jnj-20241229.xsd#jnj_A2450NotesDue2060Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A2450NotesDue2060Member_6e68a061-1b29-47b4-9ad1-a59b5970e9c3" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_18245d42-4018-4067-baa1-711ff154e760" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_18245d42-4018-4067-baa1-711ff154e760" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_092012b7-797b-4c29-924b-3fce9b278e19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7342e7b3-e34c-42ba-af5f-3ec0741d8f50" xlink:to="loc_us-gaap_LongTermDebt_092012b7-797b-4c29-924b-3fce9b278e19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_81299db6-f169-4120-956b-b01fb7a8f1de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7342e7b3-e34c-42ba-af5f-3ec0741d8f50" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_81299db6-f169-4120-956b-b01fb7a8f1de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_c39ee766-c292-4832-8f0c-07ae9603c5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7342e7b3-e34c-42ba-af5f-3ec0741d8f50" xlink:to="loc_us-gaap_LongTermDebtCurrent_c39ee766-c292-4832-8f0c-07ae9603c5cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c1cb5b85-4709-4828-b59a-755d535d76ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7342e7b3-e34c-42ba-af5f-3ec0741d8f50" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c1cb5b85-4709-4828-b59a-755d535d76ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5272e9f5-25d4-4bc8-8a64-ed76da6877c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7342e7b3-e34c-42ba-af5f-3ec0741d8f50" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5272e9f5-25d4-4bc8-8a64-ed76da6877c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1a10e121-3185-461c-97b5-69c81df9a04b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7342e7b3-e34c-42ba-af5f-3ec0741d8f50" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1a10e121-3185-461c-97b5-69c81df9a04b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_4078dde7-3411-4c79-a5ea-00fce936159f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7342e7b3-e34c-42ba-af5f-3ec0741d8f50" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_4078dde7-3411-4c79-a5ea-00fce936159f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfCarryingValueOverFairValueOfDebt_dcbef719-7d34-49de-a463-32ca7ea3f357" xlink:href="jnj-20241229.xsd#jnj_ExcessOfCarryingValueOverFairValueOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7342e7b3-e34c-42ba-af5f-3ec0741d8f50" xlink:to="loc_jnj_ExcessOfCarryingValueOverFairValueOfDebt_dcbef719-7d34-49de-a463-32ca7ea3f357" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_815db8e0-bc97-41e4-b717-5acc92dbba49" xlink:href="jnj-20241229.xsd#jnj_ExcessOfFairValueOverCarryingValueOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7342e7b3-e34c-42ba-af5f-3ec0741d8f50" xlink:to="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_815db8e0-bc97-41e4-b717-5acc92dbba49" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#BorrowingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/BorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_75bc8461-adec-4b8b-86fd-8ce08ffd37e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_3cc927f4-5ba4-46bd-b487-af39e91de945" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_75bc8461-adec-4b8b-86fd-8ce08ffd37e1" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_3cc927f4-5ba4-46bd-b487-af39e91de945" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_4f2fa663-794c-4635-a522-793ab0947c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_3cc927f4-5ba4-46bd-b487-af39e91de945" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_4f2fa663-794c-4635-a522-793ab0947c4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_4f2fa663-794c-4635-a522-793ab0947c4d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_4f2fa663-794c-4635-a522-793ab0947c4d" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_4f2fa663-794c-4635-a522-793ab0947c4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_31003d2a-29e6-430a-9c7f-60b0d43f7d55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_4f2fa663-794c-4635-a522-793ab0947c4d" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_31003d2a-29e6-430a-9c7f-60b0d43f7d55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_53bccbe7-fc06-4804-bf0e-a613ca4c2dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_31003d2a-29e6-430a-9c7f-60b0d43f7d55" xlink:to="loc_us-gaap_CommercialPaperMember_53bccbe7-fc06-4804-bf0e-a613ca4c2dc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a22609e0-16f2-4cf7-a456-cb055ec7e85e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_75bc8461-adec-4b8b-86fd-8ce08ffd37e1" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a22609e0-16f2-4cf7-a456-cb055ec7e85e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_886cd81e-aa60-47f4-84bc-6aaa96e80df1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_75bc8461-adec-4b8b-86fd-8ce08ffd37e1" xlink:to="loc_us-gaap_DebtCurrent_886cd81e-aa60-47f4-84bc-6aaa96e80df1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermCommercialPaperCurrent_bce49df1-e53b-4bbc-9941-7d84b21a57db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermCommercialPaperCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_75bc8461-adec-4b8b-86fd-8ce08ffd37e1" xlink:to="loc_us-gaap_LongTermCommercialPaperCurrent_bce49df1-e53b-4bbc-9941-7d84b21a57db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_003a52b0-c5e2-4a3f-a450-78d4af579ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_75bc8461-adec-4b8b-86fd-8ce08ffd37e1" xlink:to="loc_us-gaap_ShortTermBorrowings_003a52b0-c5e2-4a3f-a450-78d4af579ba7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_1bfd6829-aedb-4a1c-a8ce-ae6cbd7ecc37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_75bc8461-adec-4b8b-86fd-8ce08ffd37e1" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_1bfd6829-aedb-4a1c-a8ce-ae6cbd7ecc37" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_46b91baf-fc84-4c42-9ab7-01ed87f0343f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_75bc8461-adec-4b8b-86fd-8ce08ffd37e1" xlink:to="loc_us-gaap_DebtInstrumentTerm_46b91baf-fc84-4c42-9ab7-01ed87f0343f" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncometaxesNarrativeDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#IncometaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IncometaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_f6bfa6fb-1090-4b78-85d1-1044e70f8146" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_f6bfa6fb-1090-4b78-85d1-1044e70f8146" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_895ab97b-52cb-4241-8904-d2f4819e4849" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_f6bfa6fb-1090-4b78-85d1-1044e70f8146" xlink:to="loc_srt_LitigationCaseAxis_895ab97b-52cb-4241-8904-d2f4819e4849" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_895ab97b-52cb-4241-8904-d2f4819e4849_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_895ab97b-52cb-4241-8904-d2f4819e4849" xlink:to="loc_srt_LitigationCaseTypeDomain_895ab97b-52cb-4241-8904-d2f4819e4849_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e2b69826-f59b-4bbb-90ed-1aafcc30b2c9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_895ab97b-52cb-4241-8904-d2f4819e4849" xlink:to="loc_srt_LitigationCaseTypeDomain_e2b69826-f59b-4bbb-90ed-1aafcc30b2c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_36285c25-e391-418e-b0a3-7bb4c63c12d9" xlink:href="jnj-20241229.xsd#jnj_TalcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e2b69826-f59b-4bbb-90ed-1aafcc30b2c9" xlink:to="loc_jnj_TalcMember_36285c25-e391-418e-b0a3-7bb4c63c12d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_aaae11f2-c94c-4b13-a7e2-c9a7e756499c" xlink:href="jnj-20241229.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e2b69826-f59b-4bbb-90ed-1aafcc30b2c9" xlink:to="loc_jnj_RisperdalMember_aaae11f2-c94c-4b13-a7e2-c9a7e756499c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_78a3179f-3448-4ee8-b005-14002ff11e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_f6bfa6fb-1090-4b78-85d1-1044e70f8146" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_78a3179f-3448-4ee8-b005-14002ff11e4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_78a3179f-3448-4ee8-b005-14002ff11e4a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_78a3179f-3448-4ee8-b005-14002ff11e4a" xlink:to="loc_us-gaap_SegmentDomain_78a3179f-3448-4ee8-b005-14002ff11e4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2da56eef-5459-4d25-9ab4-4d1b7628e36f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_78a3179f-3448-4ee8-b005-14002ff11e4a" xlink:to="loc_us-gaap_SegmentDomain_2da56eef-5459-4d25-9ab4-4d1b7628e36f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_68cad141-e89e-4576-9261-e083546ca811" xlink:href="jnj-20241229.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2da56eef-5459-4d25-9ab4-4d1b7628e36f" xlink:to="loc_jnj_ConsumerMember_68cad141-e89e-4576-9261-e083546ca811" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_27353d54-99e2-4ba7-8b8a-8c1ec86d7682" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_f6bfa6fb-1090-4b78-85d1-1044e70f8146" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_27353d54-99e2-4ba7-8b8a-8c1ec86d7682" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_27353d54-99e2-4ba7-8b8a-8c1ec86d7682_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_27353d54-99e2-4ba7-8b8a-8c1ec86d7682" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_27353d54-99e2-4ba7-8b8a-8c1ec86d7682_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d9451539-868c-424a-afc1-dd2488389cef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_27353d54-99e2-4ba7-8b8a-8c1ec86d7682" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d9451539-868c-424a-afc1-dd2488389cef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ef01b064-d8af-4a2b-86d5-ac2c7a29bab6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_f6bfa6fb-1090-4b78-85d1-1044e70f8146" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ef01b064-d8af-4a2b-86d5-ac2c7a29bab6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ef01b064-d8af-4a2b-86d5-ac2c7a29bab6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ef01b064-d8af-4a2b-86d5-ac2c7a29bab6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ef01b064-d8af-4a2b-86d5-ac2c7a29bab6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8b0ea607-b47d-40d6-b128-104314647a36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ef01b064-d8af-4a2b-86d5-ac2c7a29bab6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8b0ea607-b47d-40d6-b128-104314647a36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_cc367d7c-98f2-4e7f-bfba-73c7c1db20a9" xlink:href="jnj-20241229.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8b0ea607-b47d-40d6-b128-104314647a36" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_cc367d7c-98f2-4e7f-bfba-73c7c1db20a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_958853f4-5dc6-4a6a-8be5-cc21edbc91e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_f6bfa6fb-1090-4b78-85d1-1044e70f8146" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_958853f4-5dc6-4a6a-8be5-cc21edbc91e4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_958853f4-5dc6-4a6a-8be5-cc21edbc91e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_958853f4-5dc6-4a6a-8be5-cc21edbc91e4" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_958853f4-5dc6-4a6a-8be5-cc21edbc91e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f4712a46-74ef-4dce-b1d5-2dbfc7624c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_958853f4-5dc6-4a6a-8be5-cc21edbc91e4" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f4712a46-74ef-4dce-b1d5-2dbfc7624c0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_9144ca4d-2eb8-44b9-bf51-3a3b729e76cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f4712a46-74ef-4dce-b1d5-2dbfc7624c0f" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_9144ca4d-2eb8-44b9-bf51-3a3b729e76cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_42ca964f-996e-4b05-82fb-692b68e4de66" xlink:href="jnj-20241229.xsd#jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_42ca964f-996e-4b05-82fb-692b68e4de66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_6a4aa4aa-4582-43e5-8098-b6faf2c1fd3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_6a4aa4aa-4582-43e5-8098-b6faf2c1fd3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_98991976-2bb1-4401-ae84-927b4fe8da25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_98991976-2bb1-4401-ae84-927b4fe8da25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent_06cbe9f9-daaf-415a-b31d-0a0b686d3dfd" xlink:href="jnj-20241229.xsd#jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent_06cbe9f9-daaf-415a-b31d-0a0b686d3dfd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_c75773cb-4c47-447f-94f5-de1bb21b3fd4" xlink:href="jnj-20241229.xsd#jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_c75773cb-4c47-447f-94f5-de1bb21b3fd4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount_f3bb41e1-7d11-4fea-a2a0-85213abf1073" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount_f3bb41e1-7d11-4fea-a2a0-85213abf1073" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI_1836e46e-58c2-4760-a904-cc70f6797db0" xlink:href="jnj-20241229.xsd#jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI_1836e46e-58c2-4760-a904-cc70f6797db0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_dca37bf2-9540-424d-aa59-f5bbe76326df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_us-gaap_LitigationSettlementExpense_dca37bf2-9540-424d-aa59-f5bbe76326df" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_d995841d-9bf3-462a-a749-66e193cfed59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_d995841d-9bf3-462a-a749-66e193cfed59" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_780f0cd3-b0a4-4a6b-82e8-47d620790b76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_780f0cd3-b0a4-4a6b-82e8-47d620790b76" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_70666475-533c-4ba4-ad0a-39c628d33846" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_70666475-533c-4ba4-ad0a-39c628d33846" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_2a423bd6-0b91-4ea0-9834-d2e55cfdbe91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_2a423bd6-0b91-4ea0-9834-d2e55cfdbe91" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_f48e0c52-3189-4160-a774-69db54b4e430" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_f48e0c52-3189-4160-a774-69db54b4e430" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_5980f43e-9523-4357-94d2-0cc7cc307b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_5980f43e-9523-4357-94d2-0cc7cc307b7f" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#PensionsandotherbenefitplansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4c3f04ef-3be9-47cc-95ee-e09abedb382c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5e6a60e5-3eb1-4e7c-b5c4-75dce25f22c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4c3f04ef-3be9-47cc-95ee-e09abedb382c" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5e6a60e5-3eb1-4e7c-b5c4-75dce25f22c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b1464b21-cf91-419b-be4e-0c7355a39d2a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5e6a60e5-3eb1-4e7c-b5c4-75dce25f22c3" xlink:to="loc_srt_RangeAxis_b1464b21-cf91-419b-be4e-0c7355a39d2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b1464b21-cf91-419b-be4e-0c7355a39d2a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b1464b21-cf91-419b-be4e-0c7355a39d2a" xlink:to="loc_srt_RangeMember_b1464b21-cf91-419b-be4e-0c7355a39d2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1f9a5722-fe30-4e0e-aa91-c647d37a43a8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b1464b21-cf91-419b-be4e-0c7355a39d2a" xlink:to="loc_srt_RangeMember_1f9a5722-fe30-4e0e-aa91-c647d37a43a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_64d5b68a-86ec-4700-b1d2-c82f8480f65c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1f9a5722-fe30-4e0e-aa91-c647d37a43a8" xlink:to="loc_srt_MaximumMember_64d5b68a-86ec-4700-b1d2-c82f8480f65c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_54f29874-a595-40c0-b1d5-29738b05670b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5e6a60e5-3eb1-4e7c-b5c4-75dce25f22c3" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_54f29874-a595-40c0-b1d5-29738b05670b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_54f29874-a595-40c0-b1d5-29738b05670b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_54f29874-a595-40c0-b1d5-29738b05670b" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_54f29874-a595-40c0-b1d5-29738b05670b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_a5c23835-3f7b-4784-91bd-315786eb1201" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_54f29874-a595-40c0-b1d5-29738b05670b" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_a5c23835-3f7b-4784-91bd-315786eb1201" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CommingledFundsMember_f505b627-3c35-4fd4-b806-37773a5f9079" xlink:href="jnj-20241229.xsd#jnj_CommingledFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a5c23835-3f7b-4784-91bd-315786eb1201" xlink:to="loc_jnj_CommingledFundsMember_f505b627-3c35-4fd4-b806-37773a5f9079" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_faf53a19-a1ae-4ac1-967c-d1d8ac461637" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5e6a60e5-3eb1-4e7c-b5c4-75dce25f22c3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_faf53a19-a1ae-4ac1-967c-d1d8ac461637" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_faf53a19-a1ae-4ac1-967c-d1d8ac461637_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_faf53a19-a1ae-4ac1-967c-d1d8ac461637" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_faf53a19-a1ae-4ac1-967c-d1d8ac461637_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2c01f42b-c0fc-4d30-9246-ec4eb910e446" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_faf53a19-a1ae-4ac1-967c-d1d8ac461637" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2c01f42b-c0fc-4d30-9246-ec4eb910e446" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9e5e007c-90f3-40b0-8ae0-74339c0e88d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2c01f42b-c0fc-4d30-9246-ec4eb910e446" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9e5e007c-90f3-40b0-8ae0-74339c0e88d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_5aeafa9b-e7fc-42c4-9f26-4c738a054702" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5e6a60e5-3eb1-4e7c-b5c4-75dce25f22c3" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_5aeafa9b-e7fc-42c4-9f26-4c738a054702" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_5aeafa9b-e7fc-42c4-9f26-4c738a054702_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_5aeafa9b-e7fc-42c4-9f26-4c738a054702" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_5aeafa9b-e7fc-42c4-9f26-4c738a054702_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_d9062ee2-9dca-4a9e-9668-ee30e419e5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_5aeafa9b-e7fc-42c4-9f26-4c738a054702" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_d9062ee2-9dca-4a9e-9668-ee30e419e5b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_3268c9f5-d623-4335-b557-aa9ef79f60f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_d9062ee2-9dca-4a9e-9668-ee30e419e5b8" xlink:to="loc_us-gaap_DomesticPlanMember_3268c9f5-d623-4335-b557-aa9ef79f60f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_33f77635-c408-4935-b49a-e2da6eeb3941" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_3268c9f5-d623-4335-b557-aa9ef79f60f3" xlink:to="loc_country_US_33f77635-c408-4935-b49a-e2da6eeb3941" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_e31af6da-175d-4f09-8de7-f05814987591" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_d9062ee2-9dca-4a9e-9668-ee30e419e5b8" xlink:to="loc_us-gaap_ForeignPlanMember_e31af6da-175d-4f09-8de7-f05814987591" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_05dfbf7e-f207-4253-a776-e6d2c084788e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5e6a60e5-3eb1-4e7c-b5c4-75dce25f22c3" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_05dfbf7e-f207-4253-a776-e6d2c084788e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_05dfbf7e-f207-4253-a776-e6d2c084788e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_05dfbf7e-f207-4253-a776-e6d2c084788e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_05dfbf7e-f207-4253-a776-e6d2c084788e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_068a710a-a0dd-4e61-aa4f-9af0a36917b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_05dfbf7e-f207-4253-a776-e6d2c084788e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_068a710a-a0dd-4e61-aa4f-9af0a36917b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_d38e1002-7b22-461a-b26e-ca0add7ed3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_068a710a-a0dd-4e61-aa4f-9af0a36917b2" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_d38e1002-7b22-461a-b26e-ca0add7ed3fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_09581ee7-c1b6-4193-9012-5edde88b61aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_068a710a-a0dd-4e61-aa4f-9af0a36917b2" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_09581ee7-c1b6-4193-9012-5edde88b61aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeCompensationPeriod_bd97257f-ad2b-452f-b8ad-f64188cb2e0d" xlink:href="jnj-20241229.xsd#jnj_EmployeeCompensationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4c3f04ef-3be9-47cc-95ee-e09abedb382c" xlink:to="loc_jnj_EmployeeCompensationPeriod_bd97257f-ad2b-452f-b8ad-f64188cb2e0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets_248e993e-b256-4c29-a82f-585a1007c753" xlink:href="jnj-20241229.xsd#jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4c3f04ef-3be9-47cc-95ee-e09abedb382c" xlink:to="loc_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets_248e993e-b256-4c29-a82f-585a1007c753" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions_6803f4c4-890e-4ad5-befb-6ccec1d7001a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4c3f04ef-3be9-47cc-95ee-e09abedb382c" xlink:to="loc_us-gaap_PensionContributions_6803f4c4-890e-4ad5-befb-6ccec1d7001a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_b7566ab8-9cca-40a0-a9ec-b1c077f221f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4c3f04ef-3be9-47cc-95ee-e09abedb382c" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_b7566ab8-9cca-40a0-a9ec-b1c077f221f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_85d11e9a-d93f-4c49-be71-9a646eca34f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4c3f04ef-3be9-47cc-95ee-e09abedb382c" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_85d11e9a-d93f-4c49-be71-9a646eca34f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_e3c28ada-180b-49f7-90cf-046233b505f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4c3f04ef-3be9-47cc-95ee-e09abedb382c" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_e3c28ada-180b-49f7-90cf-046233b505f6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_8c5de8b5-ee8f-4d2a-a70e-d1a70f16a872" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4c3f04ef-3be9-47cc-95ee-e09abedb382c" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_8c5de8b5-ee8f-4d2a-a70e-d1a70f16a872" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets_7386524f-2668-477a-8c4f-e9bc9e1d0ccd" xlink:href="jnj-20241229.xsd#jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4c3f04ef-3be9-47cc-95ee-e09abedb382c" xlink:to="loc_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets_7386524f-2668-477a-8c4f-e9bc9e1d0ccd" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_513c7f83-bb93-4e19-90f3-0d8918240bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1205e2d8-06e6-4386-94d2-769d8ef49b71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_513c7f83-bb93-4e19-90f3-0d8918240bb5" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1205e2d8-06e6-4386-94d2-769d8ef49b71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_e32ea0c1-13b3-4729-8389-fb1cdcce851a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1205e2d8-06e6-4386-94d2-769d8ef49b71" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_e32ea0c1-13b3-4729-8389-fb1cdcce851a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_e32ea0c1-13b3-4729-8389-fb1cdcce851a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_e32ea0c1-13b3-4729-8389-fb1cdcce851a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_e32ea0c1-13b3-4729-8389-fb1cdcce851a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_ed1611eb-53b7-4bd8-836b-3022b451c909" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_e32ea0c1-13b3-4729-8389-fb1cdcce851a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_ed1611eb-53b7-4bd8-836b-3022b451c909" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_4533e683-884c-4792-9e8f-4494a4e92975" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_ed1611eb-53b7-4bd8-836b-3022b451c909" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_4533e683-884c-4792-9e8f-4494a4e92975" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_a8221675-f87f-47ca-91ba-4a4f75d3525a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_ed1611eb-53b7-4bd8-836b-3022b451c909" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_a8221675-f87f-47ca-91ba-4a4f75d3525a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_eb097104-cb75-4aef-91d7-54d4af0d6896" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_513c7f83-bb93-4e19-90f3-0d8918240bb5" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_eb097104-cb75-4aef-91d7-54d4af0d6896" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_a5f48ec4-5422-475c-8cef-81ae8412d546" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_513c7f83-bb93-4e19-90f3-0d8918240bb5" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_a5f48ec4-5422-475c-8cef-81ae8412d546" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_f2217b0d-6584-4804-9a3f-079c1418d003" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_513c7f83-bb93-4e19-90f3-0d8918240bb5" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_f2217b0d-6584-4804-9a3f-079c1418d003" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_e001341d-eed7-4145-bb65-9f57d4605251" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_513c7f83-bb93-4e19-90f3-0d8918240bb5" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_e001341d-eed7-4145-bb65-9f57d4605251" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_16b9da3f-ba10-4fa2-a25e-a721033b1fea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_513c7f83-bb93-4e19-90f3-0d8918240bb5" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_16b9da3f-ba10-4fa2-a25e-a721033b1fea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_a962cc98-a8d2-4026-ae60-61f1983d2390" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_513c7f83-bb93-4e19-90f3-0d8918240bb5" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_a962cc98-a8d2-4026-ae60-61f1983d2390" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_855c0944-ccbf-4bcf-b74d-5dee59751822" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_513c7f83-bb93-4e19-90f3-0d8918240bb5" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_855c0944-ccbf-4bcf-b74d-5dee59751822" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_47833c7b-fd26-42d5-977e-b319e1d6e7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_921ca349-dc7e-41e4-8e88-39c441e92fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_47833c7b-fd26-42d5-977e-b319e1d6e7cb" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_921ca349-dc7e-41e4-8e88-39c441e92fd9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_a0f93744-3412-4327-81df-0875aae29787" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_921ca349-dc7e-41e4-8e88-39c441e92fd9" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_a0f93744-3412-4327-81df-0875aae29787" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_a0f93744-3412-4327-81df-0875aae29787_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a0f93744-3412-4327-81df-0875aae29787" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_a0f93744-3412-4327-81df-0875aae29787_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_1154e64a-7988-4f4f-bf25-7222e368dab4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a0f93744-3412-4327-81df-0875aae29787" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_1154e64a-7988-4f4f-bf25-7222e368dab4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_03f48f94-37b4-4fb3-9374-cb1c029eef75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1154e64a-7988-4f4f-bf25-7222e368dab4" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_03f48f94-37b4-4fb3-9374-cb1c029eef75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_7e555f50-4d6c-42b6-b47f-8d2976c87864" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1154e64a-7988-4f4f-bf25-7222e368dab4" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_7e555f50-4d6c-42b6-b47f-8d2976c87864" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_b7b03fae-2e0b-434f-a489-8f39c1c28eed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_47833c7b-fd26-42d5-977e-b319e1d6e7cb" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_b7b03fae-2e0b-434f-a489-8f39c1c28eed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_114aa32d-79fe-48f9-b358-86ae4a417098" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_b7b03fae-2e0b-434f-a489-8f39c1c28eed" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_114aa32d-79fe-48f9-b358-86ae4a417098" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_6dc2db91-aed9-4191-8737-e8cad69298d3" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_b7b03fae-2e0b-434f-a489-8f39c1c28eed" xlink:to="loc_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_6dc2db91-aed9-4191-8737-e8cad69298d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_c374e5c3-e4f0-4a51-9711-3802940dad99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_b7b03fae-2e0b-434f-a489-8f39c1c28eed" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_c374e5c3-e4f0-4a51-9711-3802940dad99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_16371e79-06c9-45ac-b372-c244da52fe73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_b7b03fae-2e0b-434f-a489-8f39c1c28eed" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_16371e79-06c9-45ac-b372-c244da52fe73" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_65f9a721-0357-496f-896d-c871932f16b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_47833c7b-fd26-42d5-977e-b319e1d6e7cb" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_65f9a721-0357-496f-896d-c871932f16b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_1d75c4d7-9505-4dff-9ceb-4a2dba37b8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_65f9a721-0357-496f-896d-c871932f16b8" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_1d75c4d7-9505-4dff-9ceb-4a2dba37b8c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_482eeddd-319a-42d9-8baf-c94d75bb1b84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_65f9a721-0357-496f-896d-c871932f16b8" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_482eeddd-319a-42d9-8baf-c94d75bb1b84" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e436275d-5bf2-40f0-a327-28e4eb2cae05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_143dafdc-4390-4c3a-bca4-adedcff126f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e436275d-5bf2-40f0-a327-28e4eb2cae05" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_143dafdc-4390-4c3a-bca4-adedcff126f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_a12cea89-6a12-4936-b565-1571ad3b56d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_143dafdc-4390-4c3a-bca4-adedcff126f1" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_a12cea89-6a12-4936-b565-1571ad3b56d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_a12cea89-6a12-4936-b565-1571ad3b56d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a12cea89-6a12-4936-b565-1571ad3b56d5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_a12cea89-6a12-4936-b565-1571ad3b56d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_dba0bae9-92b6-466d-9eb3-6f2c7d2f13a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a12cea89-6a12-4936-b565-1571ad3b56d5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_dba0bae9-92b6-466d-9eb3-6f2c7d2f13a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_1c07db74-2118-4f9b-af31-e27f3f49af58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_dba0bae9-92b6-466d-9eb3-6f2c7d2f13a5" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_1c07db74-2118-4f9b-af31-e27f3f49af58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_2b154d47-0a1d-451d-8e31-1164a730f3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_dba0bae9-92b6-466d-9eb3-6f2c7d2f13a5" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_2b154d47-0a1d-451d-8e31-1164a730f3f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_6342a166-37c0-4075-b5df-3dd0dd3ee5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e436275d-5bf2-40f0-a327-28e4eb2cae05" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_6342a166-37c0-4075-b5df-3dd0dd3ee5c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_5d4689e8-dbf8-4e05-bb51-a7f4e439db59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_6342a166-37c0-4075-b5df-3dd0dd3ee5c4" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_5d4689e8-dbf8-4e05-bb51-a7f4e439db59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_5fffca5b-ea61-481c-86a3-ae7e39c78b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_6342a166-37c0-4075-b5df-3dd0dd3ee5c4" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_5fffca5b-ea61-481c-86a3-ae7e39c78b2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_c029428c-52eb-4182-906a-6d1fd68cafa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_6342a166-37c0-4075-b5df-3dd0dd3ee5c4" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_c029428c-52eb-4182-906a-6d1fd68cafa2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_a774fcea-d621-443b-a59b-f87af806f365" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_6342a166-37c0-4075-b5df-3dd0dd3ee5c4" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_a774fcea-d621-443b-a59b-f87af806f365" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments_840879c4-c55d-45a1-a03c-a87d2cfb2d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_6342a166-37c0-4075-b5df-3dd0dd3ee5c4" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAmendments_840879c4-c55d-45a1-a03c-a87d2cfb2d1b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_61c6a2b0-835d-4280-8a4c-16dbb7d303f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_6342a166-37c0-4075-b5df-3dd0dd3ee5c4" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_61c6a2b0-835d-4280-8a4c-16dbb7d303f4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease_9eeac8ff-9395-4810-8bc1-71ff648007f8" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_6342a166-37c0-4075-b5df-3dd0dd3ee5c4" xlink:to="loc_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease_9eeac8ff-9395-4810-8bc1-71ff648007f8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CurtailmentsAndSettlementsAndRestructuring_63bf79b3-43cf-41ed-be9c-ce9fbf407cbe" xlink:href="jnj-20241229.xsd#jnj_CurtailmentsAndSettlementsAndRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_6342a166-37c0-4075-b5df-3dd0dd3ee5c4" xlink:to="loc_jnj_CurtailmentsAndSettlementsAndRestructuring_63bf79b3-43cf-41ed-be9c-ce9fbf407cbe" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_2a4b1e3d-53fb-4a25-893e-48d953399cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_6342a166-37c0-4075-b5df-3dd0dd3ee5c4" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_2a4b1e3d-53fb-4a25-893e-48d953399cfa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_b42b6b73-ecaf-437d-b7ab-ffa5e586d483" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_6342a166-37c0-4075-b5df-3dd0dd3ee5c4" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_b42b6b73-ecaf-437d-b7ab-ffa5e586d483" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_8c3af9b8-c88e-41ce-8272-eff237d22385" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_fcd0f491-2891-499e-bfe7-61fbe768be31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e436275d-5bf2-40f0-a327-28e4eb2cae05" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_fcd0f491-2891-499e-bfe7-61fbe768be31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_cc9172eb-f3cd-4273-9e99-c3ab93adc639" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_fcd0f491-2891-499e-bfe7-61fbe768be31" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_cc9172eb-f3cd-4273-9e99-c3ab93adc639" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_ef02c053-b006-4527-b52e-3be2fe061af8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_fcd0f491-2891-499e-bfe7-61fbe768be31" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_ef02c053-b006-4527-b52e-3be2fe061af8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_6c07af88-9950-46d0-8269-9b50c26405d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_fcd0f491-2891-499e-bfe7-61fbe768be31" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_6c07af88-9950-46d0-8269-9b50c26405d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_9df28503-825d-470f-aa7a-dc4f343a693d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_fcd0f491-2891-499e-bfe7-61fbe768be31" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_9df28503-825d-470f-aa7a-dc4f343a693d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_f8b95c24-081e-4f2b-8da6-4912ed680569" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_fcd0f491-2891-499e-bfe7-61fbe768be31" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_f8b95c24-081e-4f2b-8da6-4912ed680569" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease_bf090919-a5a8-4bca-9ec1-b24043cd16c5" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_fcd0f491-2891-499e-bfe7-61fbe768be31" xlink:to="loc_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease_bf090919-a5a8-4bca-9ec1-b24043cd16c5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_8905cfe9-b90e-47e4-addf-9aa89dd15464" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_fcd0f491-2891-499e-bfe7-61fbe768be31" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_8905cfe9-b90e-47e4-addf-9aa89dd15464" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_4b7b06e4-9639-40cb-a942-893f3d4dac67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_fcd0f491-2891-499e-bfe7-61fbe768be31" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_4b7b06e4-9639-40cb-a942-893f3d4dac67" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b259ec30-9430-41a7-9d5f-9430fd8ff313" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_26522b05-326d-4113-9309-c82c0eeaa3af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_fcd0f491-2891-499e-bfe7-61fbe768be31" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_26522b05-326d-4113-9309-c82c0eeaa3af" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_932db230-d2f0-46fa-84fa-2f3370ab3a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e436275d-5bf2-40f0-a327-28e4eb2cae05" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_932db230-d2f0-46fa-84fa-2f3370ab3a4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_31c6554f-47ad-4113-bbd9-511c62ce58f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_932db230-d2f0-46fa-84fa-2f3370ab3a4a" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_31c6554f-47ad-4113-bbd9-511c62ce58f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_51626111-05aa-4b83-baaf-445f4c48fb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_932db230-d2f0-46fa-84fa-2f3370ab3a4a" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_51626111-05aa-4b83-baaf-445f4c48fb4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_48293fa6-a2a1-4a8c-9ae5-5f40b0914891" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_932db230-d2f0-46fa-84fa-2f3370ab3a4a" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_48293fa6-a2a1-4a8c-9ae5-5f40b0914891" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_9e39e2b9-1e03-45b8-ab3b-84504bfc2897" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_932db230-d2f0-46fa-84fa-2f3370ab3a4a" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_9e39e2b9-1e03-45b8-ab3b-84504bfc2897" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_35c97b95-e4a9-4db6-a838-ff7e6d59391c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e436275d-5bf2-40f0-a327-28e4eb2cae05" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_35c97b95-e4a9-4db6-a838-ff7e6d59391c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_280f1ff1-6467-45bf-9dd9-5f088763b855" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_35c97b95-e4a9-4db6-a838-ff7e6d59391c" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_280f1ff1-6467-45bf-9dd9-5f088763b855" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_b1efaf07-207c-4515-b2ab-4f4e85f4ab15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_35c97b95-e4a9-4db6-a838-ff7e6d59391c" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_b1efaf07-207c-4515-b2ab-4f4e85f4ab15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_8ef4a942-85f8-437e-a9df-0c3377c4c843" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_35c97b95-e4a9-4db6-a838-ff7e6d59391c" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_8ef4a942-85f8-437e-a9df-0c3377c4c843" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_9432fa49-d5e0-4149-a098-51dadd885cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_35c97b95-e4a9-4db6-a838-ff7e6d59391c" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_9432fa49-d5e0-4149-a098-51dadd885cc4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_4c54f02a-218b-43d5-b2fb-08f74e52f303" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_35c97b95-e4a9-4db6-a838-ff7e6d59391c" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_4c54f02a-218b-43d5-b2fb-08f74e52f303" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract_0e1cefb4-fc13-4ca7-a35d-15526721cd9e" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_35c97b95-e4a9-4db6-a838-ff7e6d59391c" xlink:to="loc_jnj_DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract_0e1cefb4-fc13-4ca7-a35d-15526721cd9e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_8791f08c-f092-4938-be74-15d9073485b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e436275d-5bf2-40f0-a327-28e4eb2cae05" xlink:to="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_8791f08c-f092-4938-be74-15d9073485b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_a28decc5-2538-4ad4-82a5-162e725e89f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_8791f08c-f092-4938-be74-15d9073485b5" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_a28decc5-2538-4ad4-82a5-162e725e89f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_aef9be59-4361-46b7-9aa0-8e799251b2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_8791f08c-f092-4938-be74-15d9073485b5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_aef9be59-4361-46b7-9aa0-8e799251b2e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_2f7ef138-9f6f-4edd-9ef2-ed0ff69f3dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_8791f08c-f092-4938-be74-15d9073485b5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_2f7ef138-9f6f-4edd-9ef2-ed0ff69f3dd4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_f42dcac7-b7fe-422e-a77c-b4c132bff459" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_8791f08c-f092-4938-be74-15d9073485b5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_f42dcac7-b7fe-422e-a77c-b4c132bff459" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_6503f148-336c-4105-9e87-999f47c5678b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_8791f08c-f092-4938-be74-15d9073485b5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_6503f148-336c-4105-9e87-999f47c5678b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectOfExchangeRates_a5b9521d-623e-4536-96ac-1dcbfeb9a356" xlink:href="jnj-20241229.xsd#jnj_EffectOfExchangeRates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_8791f08c-f092-4938-be74-15d9073485b5" xlink:to="loc_jnj_EffectOfExchangeRates_a5b9521d-623e-4536-96ac-1dcbfeb9a356" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_c0b8afd1-4f0e-48ae-a8c7-6abe1098cd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_8791f08c-f092-4938-be74-15d9073485b5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_c0b8afd1-4f0e-48ae-a8c7-6abe1098cd4d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_a36d621b-9c1d-430e-804a-bbfa01f61ade" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_8791f08c-f092-4938-be74-15d9073485b5" xlink:to="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_a36d621b-9c1d-430e-804a-bbfa01f61ade" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_93042a1b-521e-43a6-9899-ed52b3bb3e78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7cd79564-e08d-463a-8469-bfe7d4a9539d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_93042a1b-521e-43a6-9899-ed52b3bb3e78" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7cd79564-e08d-463a-8469-bfe7d4a9539d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_47a9b8ae-7822-48f7-b6ac-755c9071d429" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7cd79564-e08d-463a-8469-bfe7d4a9539d" xlink:to="loc_us-gaap_PlanNameAxis_47a9b8ae-7822-48f7-b6ac-755c9071d429" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_47a9b8ae-7822-48f7-b6ac-755c9071d429_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_47a9b8ae-7822-48f7-b6ac-755c9071d429" xlink:to="loc_us-gaap_PlanNameDomain_47a9b8ae-7822-48f7-b6ac-755c9071d429_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d8cdc2bf-2e11-472a-bf4f-d66c6b0d8643" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_47a9b8ae-7822-48f7-b6ac-755c9071d429" xlink:to="loc_us-gaap_PlanNameDomain_d8cdc2bf-2e11-472a-bf4f-d66c6b0d8643" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_QualifiedPlansMember_a8fb1bf7-2a96-418c-8b12-e8157efe60fc" xlink:href="jnj-20241229.xsd#jnj_QualifiedPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d8cdc2bf-2e11-472a-bf4f-d66c6b0d8643" xlink:to="loc_jnj_QualifiedPlansMember_a8fb1bf7-2a96-418c-8b12-e8157efe60fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NonQualifiedPlansMember_f1cc4459-d49b-4862-9cb7-53cdad98abf0" xlink:href="jnj-20241229.xsd#jnj_NonQualifiedPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d8cdc2bf-2e11-472a-bf4f-d66c6b0d8643" xlink:to="loc_jnj_NonQualifiedPlansMember_f1cc4459-d49b-4862-9cb7-53cdad98abf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FundedPlansMember_0298675f-b446-4887-8c04-c7381586e169" xlink:href="jnj-20241229.xsd#jnj_FundedPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d8cdc2bf-2e11-472a-bf4f-d66c6b0d8643" xlink:to="loc_jnj_FundedPlansMember_0298675f-b446-4887-8c04-c7381586e169" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UnfundedPlansMember_c7736ba7-1739-4ca7-b784-005a98e8117a" xlink:href="jnj-20241229.xsd#jnj_UnfundedPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d8cdc2bf-2e11-472a-bf4f-d66c6b0d8643" xlink:to="loc_jnj_UnfundedPlansMember_c7736ba7-1739-4ca7-b784-005a98e8117a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_ef8b031c-5ced-4fc3-81d8-c107cdf53c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7cd79564-e08d-463a-8469-bfe7d4a9539d" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_ef8b031c-5ced-4fc3-81d8-c107cdf53c1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_ef8b031c-5ced-4fc3-81d8-c107cdf53c1f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_ef8b031c-5ced-4fc3-81d8-c107cdf53c1f" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_ef8b031c-5ced-4fc3-81d8-c107cdf53c1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_ccf6a7f1-06bd-47ad-a709-2d0811c97121" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_ef8b031c-5ced-4fc3-81d8-c107cdf53c1f" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_ccf6a7f1-06bd-47ad-a709-2d0811c97121" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_d1f28ad1-a4ad-40a7-b8ab-22c9cc533675" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_ccf6a7f1-06bd-47ad-a709-2d0811c97121" xlink:to="loc_us-gaap_DomesticPlanMember_d1f28ad1-a4ad-40a7-b8ab-22c9cc533675" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0e6023d9-a426-434e-93a3-6b7133c1c8f6" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_d1f28ad1-a4ad-40a7-b8ab-22c9cc533675" xlink:to="loc_country_US_0e6023d9-a426-434e-93a3-6b7133c1c8f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_b37fe484-fb32-49be-90db-47a6321babb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_ccf6a7f1-06bd-47ad-a709-2d0811c97121" xlink:to="loc_us-gaap_ForeignPlanMember_b37fe484-fb32-49be-90db-47a6321babb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b202ac7c-292c-4270-97dc-87e2ea63b3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_93042a1b-521e-43a6-9899-ed52b3bb3e78" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b202ac7c-292c-4270-97dc-87e2ea63b3c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_5b858e80-9057-48c8-85d1-9dd845c02132" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_93042a1b-521e-43a6-9899-ed52b3bb3e78" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_5b858e80-9057-48c8-85d1-9dd845c02132" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_e8f8cb44-63e8-4aff-89cf-927edcef2709" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_93042a1b-521e-43a6-9899-ed52b3bb3e78" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_e8f8cb44-63e8-4aff-89cf-927edcef2709" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_629c1031-9100-452a-a1fa-9d32f0448b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_93042a1b-521e-43a6-9899-ed52b3bb3e78" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_629c1031-9100-452a-a1fa-9d32f0448b4b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanOverUnderFundedStatusABO_1f4299c3-d7e4-4c65-add7-50385a8ad787" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanOverUnderFundedStatusABO"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_93042a1b-521e-43a6-9899-ed52b3bb3e78" xlink:to="loc_jnj_DefinedBenefitPlanOverUnderFundedStatusABO_1f4299c3-d7e4-4c65-add7-50385a8ad787" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6a789ecc-4ba7-439c-8c6d-30395368aa26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_aa12424f-03e1-4714-bcd9-23fbcd47547d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6a789ecc-4ba7-439c-8c6d-30395368aa26" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_aa12424f-03e1-4714-bcd9-23fbcd47547d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_876b745d-67a0-43cb-b737-4bdab08f2e27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_aa12424f-03e1-4714-bcd9-23fbcd47547d" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_876b745d-67a0-43cb-b737-4bdab08f2e27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_876b745d-67a0-43cb-b737-4bdab08f2e27_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_876b745d-67a0-43cb-b737-4bdab08f2e27" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_876b745d-67a0-43cb-b737-4bdab08f2e27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_5cc8af25-588b-440a-922f-31f5c322e08b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_876b745d-67a0-43cb-b737-4bdab08f2e27" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_5cc8af25-588b-440a-922f-31f5c322e08b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_7d7fc5b3-5825-4932-b9b7-5548ad82970f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_5cc8af25-588b-440a-922f-31f5c322e08b" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_7d7fc5b3-5825-4932-b9b7-5548ad82970f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_1655fc4f-9082-4d5a-a02a-0f925de7a8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_5cc8af25-588b-440a-922f-31f5c322e08b" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_1655fc4f-9082-4d5a-a02a-0f925de7a8fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_928a5a3c-e997-4254-943e-c2caf30fd83e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6a789ecc-4ba7-439c-8c6d-30395368aa26" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_928a5a3c-e997-4254-943e-c2caf30fd83e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_1a09ee3a-50b7-4bf2-84dd-b83d162ba570" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6a789ecc-4ba7-439c-8c6d-30395368aa26" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_1a09ee3a-50b7-4bf2-84dd-b83d162ba570" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_c18116c6-aa9d-47a5-9f09-8e1e9a25f904" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6a789ecc-4ba7-439c-8c6d-30395368aa26" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_c18116c6-aa9d-47a5-9f09-8e1e9a25f904" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_bb7c4ee0-0c13-46bf-9a7a-6265531aa9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6a789ecc-4ba7-439c-8c6d-30395368aa26" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_bb7c4ee0-0c13-46bf-9a7a-6265531aa9c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_834a947a-55f0-4831-9c77-14f60749c6de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6a789ecc-4ba7-439c-8c6d-30395368aa26" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_834a947a-55f0-4831-9c77-14f60749c6de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_dfba9510-ce60-4dec-82eb-a36fff587ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6a789ecc-4ba7-439c-8c6d-30395368aa26" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_dfba9510-ce60-4dec-82eb-a36fff587ffb" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#PensionsandotherbenefitplansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandotherbenefitplansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3b1f3961-0b64-4ef0-858d-bfa5766c6daf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_533e387d-ede7-46df-888d-860065e9f39c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3b1f3961-0b64-4ef0-858d-bfa5766c6daf" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_533e387d-ede7-46df-888d-860065e9f39c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_fc28ed99-82ae-4917-90f0-75ca146e3c69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_533e387d-ede7-46df-888d-860065e9f39c" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_fc28ed99-82ae-4917-90f0-75ca146e3c69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_fc28ed99-82ae-4917-90f0-75ca146e3c69_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_fc28ed99-82ae-4917-90f0-75ca146e3c69" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_fc28ed99-82ae-4917-90f0-75ca146e3c69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_c80ba231-cfca-439f-8ca0-249fad51bba8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_fc28ed99-82ae-4917-90f0-75ca146e3c69" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_c80ba231-cfca-439f-8ca0-249fad51bba8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_9c4ffc4a-025c-4988-b5a3-acada0a5f0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c80ba231-cfca-439f-8ca0-249fad51bba8" xlink:to="loc_us-gaap_EquitySecuritiesMember_9c4ffc4a-025c-4988-b5a3-acada0a5f0e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_3ccc52f3-65af-4674-824b-d2b4b71c7513" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c80ba231-cfca-439f-8ca0-249fad51bba8" xlink:to="loc_us-gaap_DebtSecuritiesMember_3ccc52f3-65af-4674-824b-d2b4b71c7513" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_8029a65e-eca4-4473-9680-95fc9832bcf0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3b1f3961-0b64-4ef0-858d-bfa5766c6daf" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_8029a65e-eca4-4473-9680-95fc9832bcf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_66366f13-2b4a-4335-9a28-7f147f7a17bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3b1f3961-0b64-4ef0-858d-bfa5766c6daf" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_66366f13-2b4a-4335-9a28-7f147f7a17bf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_efe136dc-ab44-4884-aa6e-26dd25108140" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_05966f34-4071-4968-97c1-f41db29d34bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_efe136dc-ab44-4884-aa6e-26dd25108140" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_05966f34-4071-4968-97c1-f41db29d34bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fb32334e-6524-4982-8303-30367932f404" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_05966f34-4071-4968-97c1-f41db29d34bf" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fb32334e-6524-4982-8303-30367932f404" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_fb32334e-6524-4982-8303-30367932f404_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fb32334e-6524-4982-8303-30367932f404" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_fb32334e-6524-4982-8303-30367932f404_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d6a5957-c3e6-4f53-a30d-0e00242e7810" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fb32334e-6524-4982-8303-30367932f404" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d6a5957-c3e6-4f53-a30d-0e00242e7810" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ec355861-0239-463e-b420-eb774673c625" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d6a5957-c3e6-4f53-a30d-0e00242e7810" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ec355861-0239-463e-b420-eb774673c625" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_e98c61a0-3203-4f6e-a54a-ebf517829182" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_05966f34-4071-4968-97c1-f41db29d34bf" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_e98c61a0-3203-4f6e-a54a-ebf517829182" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_e98c61a0-3203-4f6e-a54a-ebf517829182_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_e98c61a0-3203-4f6e-a54a-ebf517829182" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_e98c61a0-3203-4f6e-a54a-ebf517829182_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_ce352f3f-521d-456b-944d-675ce9e5ae15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_e98c61a0-3203-4f6e-a54a-ebf517829182" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_ce352f3f-521d-456b-944d-675ce9e5ae15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_6b2324b1-4a47-4202-b95b-8c954f8f8416" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_ce352f3f-521d-456b-944d-675ce9e5ae15" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_6b2324b1-4a47-4202-b95b-8c954f8f8416" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_8d834994-217a-4be5-819e-628a2fbfbff0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_05966f34-4071-4968-97c1-f41db29d34bf" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_8d834994-217a-4be5-819e-628a2fbfbff0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_8d834994-217a-4be5-819e-628a2fbfbff0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_8d834994-217a-4be5-819e-628a2fbfbff0" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_8d834994-217a-4be5-819e-628a2fbfbff0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_b59ef042-a82f-49d5-aee4-5bb40e0459a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_8d834994-217a-4be5-819e-628a2fbfbff0" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_b59ef042-a82f-49d5-aee4-5bb40e0459a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShortTermInvestmentFundsMember_a59f00db-eb59-4ae1-a4f8-87f69a1a30f1" xlink:href="jnj-20241229.xsd#jnj_ShortTermInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_b59ef042-a82f-49d5-aee4-5bb40e0459a8" xlink:to="loc_jnj_ShortTermInvestmentFundsMember_a59f00db-eb59-4ae1-a4f8-87f69a1a30f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_7d9c859a-e91e-444e-b4c4-3e89e18b1d11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_b59ef042-a82f-49d5-aee4-5bb40e0459a8" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_7d9c859a-e91e-444e-b4c4-3e89e18b1d11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_31eaad75-a123-46c8-b971-37b53a316561" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_b59ef042-a82f-49d5-aee4-5bb40e0459a8" xlink:to="loc_us-gaap_DebtSecuritiesMember_31eaad75-a123-46c8-b971-37b53a316561" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_88fcc9f8-638d-420c-9c88-e1768d2fa78f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_b59ef042-a82f-49d5-aee4-5bb40e0459a8" xlink:to="loc_us-gaap_EquitySecuritiesMember_88fcc9f8-638d-420c-9c88-e1768d2fa78f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CommingledFundsMember_8651b744-3e5d-4661-aed0-55c568976cc8" xlink:href="jnj-20241229.xsd#jnj_CommingledFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_b59ef042-a82f-49d5-aee4-5bb40e0459a8" xlink:to="loc_jnj_CommingledFundsMember_8651b744-3e5d-4661-aed0-55c568976cc8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_34ab9da7-7d88-471e-b44d-ed83ebd6fcd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_b59ef042-a82f-49d5-aee4-5bb40e0459a8" xlink:to="loc_us-gaap_OtherAssetsMember_34ab9da7-7d88-471e-b44d-ed83ebd6fcd1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b79539bc-ff5d-4c46-9846-1e8b3a3b587e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_05966f34-4071-4968-97c1-f41db29d34bf" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b79539bc-ff5d-4c46-9846-1e8b3a3b587e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b79539bc-ff5d-4c46-9846-1e8b3a3b587e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b79539bc-ff5d-4c46-9846-1e8b3a3b587e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b79539bc-ff5d-4c46-9846-1e8b3a3b587e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4af8ad35-4b81-4445-916e-9567bf9464f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b79539bc-ff5d-4c46-9846-1e8b3a3b587e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4af8ad35-4b81-4445-916e-9567bf9464f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6f9935e2-6edf-4440-9b0c-badf5f719f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4af8ad35-4b81-4445-916e-9567bf9464f0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6f9935e2-6edf-4440-9b0c-badf5f719f3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_85378f31-a3da-4044-8cf1-8c2515aa14b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4af8ad35-4b81-4445-916e-9567bf9464f0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_85378f31-a3da-4044-8cf1-8c2515aa14b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e5062211-f8e7-4b70-856b-5a4d6c3dd983" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4af8ad35-4b81-4445-916e-9567bf9464f0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e5062211-f8e7-4b70-856b-5a4d6c3dd983" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b40b8763-a9f2-4b2c-814c-bd7f83f6d4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_efe136dc-ab44-4884-aa6e-26dd25108140" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b40b8763-a9f2-4b2c-814c-bd7f83f6d4bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets_965470d4-e749-4418-b9fd-0b386815aacb" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_efe136dc-ab44-4884-aa6e-26dd25108140" xlink:to="loc_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets_965470d4-e749-4418-b9fd-0b386815aacb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#CapitalandtreasurystockChangesinTreasuryStockDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_d2d3971a-97a0-4763-9028-57b8a546e56a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_30398b28-159c-48a4-863a-fe0abd7fd24b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_d2d3971a-97a0-4763-9028-57b8a546e56a" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_30398b28-159c-48a4-863a-fe0abd7fd24b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9f67aeff-e3f3-4e52-a7e7-069e4fe88883" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_30398b28-159c-48a4-863a-fe0abd7fd24b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9f67aeff-e3f3-4e52-a7e7-069e4fe88883" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9f67aeff-e3f3-4e52-a7e7-069e4fe88883_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9f67aeff-e3f3-4e52-a7e7-069e4fe88883" xlink:to="loc_us-gaap_EquityComponentDomain_9f67aeff-e3f3-4e52-a7e7-069e4fe88883_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_86aa7033-d068-45fc-8018-6c5fd84781d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9f67aeff-e3f3-4e52-a7e7-069e4fe88883" xlink:to="loc_us-gaap_EquityComponentDomain_86aa7033-d068-45fc-8018-6c5fd84781d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_8bbfedd2-17a2-4f96-bfc8-5b15e3200a20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_86aa7033-d068-45fc-8018-6c5fd84781d4" xlink:to="loc_us-gaap_TreasuryStockCommonMember_8bbfedd2-17a2-4f96-bfc8-5b15e3200a20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_61cd1813-89f0-4528-b5d0-ca58c0eb188e" xlink:href="jnj-20241229.xsd#jnj_ChangesinTreasuryStockSharesOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_d2d3971a-97a0-4763-9028-57b8a546e56a" xlink:to="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_61cd1813-89f0-4528-b5d0-ca58c0eb188e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_40624334-03f4-4863-a72a-7a320422c5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_61cd1813-89f0-4528-b5d0-ca58c0eb188e" xlink:to="loc_us-gaap_TreasuryStockCommonShares_40624334-03f4-4863-a72a-7a320422c5f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_2a2195e8-e20f-428f-b289-28aa3222ba66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_61cd1813-89f0-4528-b5d0-ca58c0eb188e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_2a2195e8-e20f-428f-b289-28aa3222ba66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_fdbf181a-a52f-49e8-a908-17cc7d7c2688" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_61cd1813-89f0-4528-b5d0-ca58c0eb188e" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_fdbf181a-a52f-49e8-a908-17cc7d7c2688" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_e746361c-0852-4093-887a-8f5ba00e16c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesInTreasuryStockRollForward_e5d6cd47-a0fe-4fca-9bed-18cf4a61cb23" xlink:href="jnj-20241229.xsd#jnj_ChangesInTreasuryStockRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_d2d3971a-97a0-4763-9028-57b8a546e56a" xlink:to="loc_jnj_ChangesInTreasuryStockRollForward_e5d6cd47-a0fe-4fca-9bed-18cf4a61cb23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_399b1073-6599-402d-91a7-b05ad1b57052" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_e5d6cd47-a0fe-4fca-9bed-18cf4a61cb23" xlink:to="loc_us-gaap_TreasuryStockValue_399b1073-6599-402d-91a7-b05ad1b57052" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_c885e3e1-6966-49d8-8dfd-96ca7632d886" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_e5d6cd47-a0fe-4fca-9bed-18cf4a61cb23" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_c885e3e1-6966-49d8-8dfd-96ca7632d886" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_5f273c38-0a85-4cff-95e5-76ab5ced5313" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_e5d6cd47-a0fe-4fca-9bed-18cf4a61cb23" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_5f273c38-0a85-4cff-95e5-76ab5ced5313" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TreasuryStockValueAcquiredCostMethodNetOfTax_fdc4fadb-808d-41ea-b18f-aa27672eda1c" xlink:href="jnj-20241229.xsd#jnj_TreasuryStockValueAcquiredCostMethodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_e5d6cd47-a0fe-4fca-9bed-18cf4a61cb23" xlink:to="loc_jnj_TreasuryStockValueAcquiredCostMethodNetOfTax_fdc4fadb-808d-41ea-b18f-aa27672eda1c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_806eb623-906e-4440-8a57-f4aff476b21e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#CapitalandtreasurystockNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_f681f9d3-6f96-457c-82d6-fd8e847548fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_26fb16d5-64e4-4026-b41b-b749a209f693" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_f681f9d3-6f96-457c-82d6-fd8e847548fb" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_26fb16d5-64e4-4026-b41b-b749a209f693" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis_0d796308-f293-4637-b421-0a7c54f20a0c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_26fb16d5-64e4-4026-b41b-b749a209f693" xlink:to="loc_srt_ShareRepurchaseProgramAxis_0d796308-f293-4637-b421-0a7c54f20a0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_0d796308-f293-4637-b421-0a7c54f20a0c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ShareRepurchaseProgramAxis_0d796308-f293-4637-b421-0a7c54f20a0c" xlink:to="loc_srt_ShareRepurchaseProgramDomain_0d796308-f293-4637-b421-0a7c54f20a0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_aa2e83c8-24ff-419a-8b85-18e0d3c85624" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ShareRepurchaseProgramAxis_0d796308-f293-4637-b421-0a7c54f20a0c" xlink:to="loc_srt_ShareRepurchaseProgramDomain_aa2e83c8-24ff-419a-8b85-18e0d3c85624" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_December172018ShareRepurchaseProgramMember_623980f3-6669-4169-8c7b-b68827e2c547" xlink:href="jnj-20241229.xsd#jnj_December172018ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ShareRepurchaseProgramDomain_aa2e83c8-24ff-419a-8b85-18e0d3c85624" xlink:to="loc_jnj_December172018ShareRepurchaseProgramMember_623980f3-6669-4169-8c7b-b68827e2c547" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_381fe001-5852-4783-a3ed-bb116cc04023" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_26fb16d5-64e4-4026-b41b-b749a209f693" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_381fe001-5852-4783-a3ed-bb116cc04023" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_381fe001-5852-4783-a3ed-bb116cc04023_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_381fe001-5852-4783-a3ed-bb116cc04023" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_381fe001-5852-4783-a3ed-bb116cc04023_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6463eb34-4327-42b1-89c3-c04710007ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_381fe001-5852-4783-a3ed-bb116cc04023" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6463eb34-4327-42b1-89c3-c04710007ed4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_eec99664-25ce-4ceb-bf99-e8eb06e94f21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6463eb34-4327-42b1-89c3-c04710007ed4" xlink:to="loc_us-gaap_SubsequentEventMember_eec99664-25ce-4ceb-bf99-e8eb06e94f21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e039d5b5-06c5-4b90-a2fa-3f191fa51267" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_f681f9d3-6f96-457c-82d6-fd8e847548fb" xlink:to="loc_us-gaap_CommonStockSharesIssued_e039d5b5-06c5-4b90-a2fa-3f191fa51267" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_48f23865-b22d-4798-baaf-203d68f65dab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_f681f9d3-6f96-457c-82d6-fd8e847548fb" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_48f23865-b22d-4798-baaf-203d68f65dab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_51fdb8f7-edf5-4e51-b596-c27504e29cba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_f681f9d3-6f96-457c-82d6-fd8e847548fb" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_51fdb8f7-edf5-4e51-b596-c27504e29cba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_a0d02798-f2fc-421a-b3e5-cfb67e1a97aa" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_f681f9d3-6f96-457c-82d6-fd8e847548fb" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_a0d02798-f2fc-421a-b3e5-cfb67e1a97aa" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#AccumulatedothercomprehensiveincomelossDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_3e06d236-2084-460c-bdd8-ddb9216c59cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_a6316efc-2b8f-43ad-8e09-04b566f5ef69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_3e06d236-2084-460c-bdd8-ddb9216c59cb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_a6316efc-2b8f-43ad-8e09-04b566f5ef69" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_77ed07b9-8057-4053-9b1f-b103a72b4f42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_a6316efc-2b8f-43ad-8e09-04b566f5ef69" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_77ed07b9-8057-4053-9b1f-b103a72b4f42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_77ed07b9-8057-4053-9b1f-b103a72b4f42_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_77ed07b9-8057-4053-9b1f-b103a72b4f42" xlink:to="loc_us-gaap_EquityComponentDomain_77ed07b9-8057-4053-9b1f-b103a72b4f42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dfcf608c-aae6-40db-b451-c740ff8f8179" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_77ed07b9-8057-4053-9b1f-b103a72b4f42" xlink:to="loc_us-gaap_EquityComponentDomain_dfcf608c-aae6-40db-b451-c740ff8f8179" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_73c44b54-2faa-48b2-987c-11d7ccdd2934" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dfcf608c-aae6-40db-b451-c740ff8f8179" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_73c44b54-2faa-48b2-987c-11d7ccdd2934" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_280a6611-453c-4c86-9a08-e7870b3ec2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dfcf608c-aae6-40db-b451-c740ff8f8179" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_280a6611-453c-4c86-9a08-e7870b3ec2b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_676c0a03-27ff-4271-9cbb-23005f42f707" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dfcf608c-aae6-40db-b451-c740ff8f8179" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_676c0a03-27ff-4271-9cbb-23005f42f707" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e9da48cf-35f6-4d5e-8c5e-2249a8b93575" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dfcf608c-aae6-40db-b451-c740ff8f8179" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e9da48cf-35f6-4d5e-8c5e-2249a8b93575" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_eb8a3cbd-9dc9-41c7-af1b-6623d44d9c64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dfcf608c-aae6-40db-b451-c740ff8f8179" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_eb8a3cbd-9dc9-41c7-af1b-6623d44d9c64" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_09ab1a70-832d-425b-9843-440091140d75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_3e06d236-2084-460c-bdd8-ddb9216c59cb" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_09ab1a70-832d-425b-9843-440091140d75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c1f71fe3-6213-45c1-9dd1-7c84af1ccf76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_09ab1a70-832d-425b-9843-440091140d75" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c1f71fe3-6213-45c1-9dd1-7c84af1ccf76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_59e6109e-8036-49b5-acfe-5a7250a9acc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_09ab1a70-832d-425b-9843-440091140d75" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_59e6109e-8036-49b5-acfe-5a7250a9acc2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_8970f3a8-6489-4f9c-8170-5c4e78dd514b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_09ab1a70-832d-425b-9843-440091140d75" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_8970f3a8-6489-4f9c-8170-5c4e78dd514b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e5d5d02d-34a4-4194-9f94-f2e1aabcbd63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ef45e920-56b6-436f-af5a-6f65dc010398" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ef45e920-56b6-436f-af5a-6f65dc010398" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis_c71b3e11-2d29-4fec-a0a2-16ba9a1f3362" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ef45e920-56b6-436f-af5a-6f65dc010398" xlink:to="loc_srt_ShareRepurchaseProgramAxis_c71b3e11-2d29-4fec-a0a2-16ba9a1f3362" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_c71b3e11-2d29-4fec-a0a2-16ba9a1f3362_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ShareRepurchaseProgramAxis_c71b3e11-2d29-4fec-a0a2-16ba9a1f3362" xlink:to="loc_srt_ShareRepurchaseProgramDomain_c71b3e11-2d29-4fec-a0a2-16ba9a1f3362_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_723c50c4-b5fa-4f96-85af-1f5835b6b1fd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ShareRepurchaseProgramAxis_c71b3e11-2d29-4fec-a0a2-16ba9a1f3362" xlink:to="loc_srt_ShareRepurchaseProgramDomain_723c50c4-b5fa-4f96-85af-1f5835b6b1fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2022LongTermIncentivePlanMember_33b49579-6cf2-454a-9ab2-b9e9ecefc878" xlink:href="jnj-20241229.xsd#jnj_A2022LongTermIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ShareRepurchaseProgramDomain_723c50c4-b5fa-4f96-85af-1f5835b6b1fd" xlink:to="loc_jnj_A2022LongTermIncentivePlanMember_33b49579-6cf2-454a-9ab2-b9e9ecefc878" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e48f0945-7a6c-43e5-9082-ab69b253d92a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ef45e920-56b6-436f-af5a-6f65dc010398" xlink:to="loc_srt_RangeAxis_e48f0945-7a6c-43e5-9082-ab69b253d92a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e48f0945-7a6c-43e5-9082-ab69b253d92a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e48f0945-7a6c-43e5-9082-ab69b253d92a" xlink:to="loc_srt_RangeMember_e48f0945-7a6c-43e5-9082-ab69b253d92a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e30f2bc9-2f29-40e3-a2ae-76be3bcae3cf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e48f0945-7a6c-43e5-9082-ab69b253d92a" xlink:to="loc_srt_RangeMember_e30f2bc9-2f29-40e3-a2ae-76be3bcae3cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c6008e79-3d8c-4638-9224-91afc1729bfd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e30f2bc9-2f29-40e3-a2ae-76be3bcae3cf" xlink:to="loc_srt_MinimumMember_c6008e79-3d8c-4638-9224-91afc1729bfd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_31dc330f-c04e-461b-a34d-450fd0237f10" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e30f2bc9-2f29-40e3-a2ae-76be3bcae3cf" xlink:to="loc_srt_MaximumMember_31dc330f-c04e-461b-a34d-450fd0237f10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a48b8269-c5be-42fd-954a-ceac4d27b322" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ef45e920-56b6-436f-af5a-6f65dc010398" xlink:to="loc_us-gaap_AwardTypeAxis_a48b8269-c5be-42fd-954a-ceac4d27b322" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a48b8269-c5be-42fd-954a-ceac4d27b322_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a48b8269-c5be-42fd-954a-ceac4d27b322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a48b8269-c5be-42fd-954a-ceac4d27b322_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9084fa15-525b-47b4-9d75-818b089899b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a48b8269-c5be-42fd-954a-ceac4d27b322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9084fa15-525b-47b4-9d75-818b089899b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_72790b1b-13fb-43f2-b4ff-fd24b32abf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9084fa15-525b-47b4-9d75-818b089899b9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_72790b1b-13fb-43f2-b4ff-fd24b32abf8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1204ba01-ba4b-4c8c-a15b-91af8f33daad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9084fa15-525b-47b4-9d75-818b089899b9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1204ba01-ba4b-4c8c-a15b-91af8f33daad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_19fe34e9-9e46-4b93-ae37-b2d7a4617176" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9084fa15-525b-47b4-9d75-818b089899b9" xlink:to="loc_us-gaap_PerformanceSharesMember_19fe34e9-9e46-4b93-ae37-b2d7a4617176" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfStockBasedCompensationPlans_0c57569d-8b0f-4a94-a651-ef8c670fc4f3" xlink:href="jnj-20241229.xsd#jnj_NumberOfStockBasedCompensationPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_jnj_NumberOfStockBasedCompensationPlans_0c57569d-8b0f-4a94-a651-ef8c670fc4f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6b0b47a4-8c48-4f6f-baf0-4b8372f208c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6b0b47a4-8c48-4f6f-baf0-4b8372f208c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights_8b771403-0e30-4215-98ed-15780d8f45fb" xlink:href="jnj-20241229.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights_8b771403-0e30-4215-98ed-15780d8f45fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards_d61f6619-0558-46d0-9fa1-4d02ada01b08" xlink:href="jnj-20241229.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards_d61f6619-0558-46d0-9fa1-4d02ada01b08" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess_e9bbcc11-133b-4c50-95b6-4373200a3da2" xlink:href="jnj-20241229.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess_e9bbcc11-133b-4c50-95b6-4373200a3da2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_60864624-a2da-421f-acf5-7d3d53251cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_60864624-a2da-421f-acf5-7d3d53251cf1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_15a32732-be14-4907-888b-947193761d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_15a32732-be14-4907-888b-947193761d0e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_78e95dbe-f68c-4382-8451-a8c1e8aab44a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_78e95dbe-f68c-4382-8451-a8c1e8aab44a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_b9fdb90e-ba12-4e21-a9e7-fd88139ffa24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_b9fdb90e-ba12-4e21-a9e7-fd88139ffa24" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7263721d-d348-48b4-b105-47a936185a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7263721d-d348-48b4-b105-47a936185a9d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2158ee15-18d0-47b2-ad3a-50035ba495ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2158ee15-18d0-47b2-ad3a-50035ba495ac" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a1aa0c60-1889-4207-8767-f4715389edcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a1aa0c60-1889-4207-8767-f4715389edcc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d31782da-baed-4c13-92ea-04a3a9f6ab54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d31782da-baed-4c13-92ea-04a3a9f6ab54" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_38d54a7e-f016-4204-806c-dfde00c7eb96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_38d54a7e-f016-4204-806c-dfde00c7eb96" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_30acd071-e8bc-4e4f-833f-c62415d66dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_30acd071-e8bc-4e4f-833f-c62415d66dd6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_5fb4d1fd-f345-4753-b308-e5ac9dd102f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_5fb4d1fd-f345-4753-b308-e5ac9dd102f7" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_9dee99b0-c17d-46fd-aa69-f9c551018ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_9dee99b0-c17d-46fd-aa69-f9c551018ed3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c64becf9-5343-43bb-8c59-64d6bb1d2829" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c64becf9-5343-43bb-8c59-64d6bb1d2829" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2df34e72-de53-441d-93d7-6dd34ce189d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2df34e72-de53-441d-93d7-6dd34ce189d8" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e0564529-9d6e-497e-90a1-4e1074faa3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e0564529-9d6e-497e-90a1-4e1074faa3fe" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c2ebd97a-5d93-4c00-9289-aec83d8505e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c2ebd97a-5d93-4c00-9289-aec83d8505e3" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_fe9ab0d8-a88f-4932-8007-c116ce90c818" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_fe9ab0d8-a88f-4932-8007-c116ce90c818" xlink:type="arc" order="21"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_595fc303-5ca5-49f2-ac88-f13faa586bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_606d27d7-f882-4fc4-aee4-8ef0dee5dffc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_595fc303-5ca5-49f2-ac88-f13faa586bf0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_606d27d7-f882-4fc4-aee4-8ef0dee5dffc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_21d5029f-5ab7-4292-8b02-b927a5b1fd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_606d27d7-f882-4fc4-aee4-8ef0dee5dffc" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_21d5029f-5ab7-4292-8b02-b927a5b1fd9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_21d5029f-5ab7-4292-8b02-b927a5b1fd9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_21d5029f-5ab7-4292-8b02-b927a5b1fd9a" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_21d5029f-5ab7-4292-8b02-b927a5b1fd9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_05ae0d6d-9810-4ede-b1c5-ac12da7510c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_21d5029f-5ab7-4292-8b02-b927a5b1fd9a" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_05ae0d6d-9810-4ede-b1c5-ac12da7510c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeOneMember_827bee08-ff60-406d-bbdf-1f342bb55d71" xlink:href="jnj-20241229.xsd#jnj_ExercisePriceRangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_05ae0d6d-9810-4ede-b1c5-ac12da7510c2" xlink:to="loc_jnj_ExercisePriceRangeOneMember_827bee08-ff60-406d-bbdf-1f342bb55d71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeTwoMember_d6edb3e2-d6e3-4342-a630-89a8bd50e543" xlink:href="jnj-20241229.xsd#jnj_ExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_05ae0d6d-9810-4ede-b1c5-ac12da7510c2" xlink:to="loc_jnj_ExercisePriceRangeTwoMember_d6edb3e2-d6e3-4342-a630-89a8bd50e543" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeThreeMember_27436ecb-cb50-44fa-868b-a5ab5cee4d6a" xlink:href="jnj-20241229.xsd#jnj_ExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_05ae0d6d-9810-4ede-b1c5-ac12da7510c2" xlink:to="loc_jnj_ExercisePriceRangeThreeMember_27436ecb-cb50-44fa-868b-a5ab5cee4d6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeFourMember_97938884-63fc-40e8-9563-67f4ca7e187f" xlink:href="jnj-20241229.xsd#jnj_ExercisePriceRangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_05ae0d6d-9810-4ede-b1c5-ac12da7510c2" xlink:to="loc_jnj_ExercisePriceRangeFourMember_97938884-63fc-40e8-9563-67f4ca7e187f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeFiveMember_bb4be895-c3b2-4518-a1ac-cef88390d079" xlink:href="jnj-20241229.xsd#jnj_ExercisePriceRangeFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_05ae0d6d-9810-4ede-b1c5-ac12da7510c2" xlink:to="loc_jnj_ExercisePriceRangeFiveMember_bb4be895-c3b2-4518-a1ac-cef88390d079" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_286ff43a-7d66-4471-9584-3ae21f013416" xlink:href="jnj-20241229.xsd#jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_595fc303-5ca5-49f2-ac88-f13faa586bf0" xlink:to="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_286ff43a-7d66-4471-9584-3ae21f013416" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_9e9f7689-c5f4-456d-92ac-71d213c846f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_286ff43a-7d66-4471-9584-3ae21f013416" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_9e9f7689-c5f4-456d-92ac-71d213c846f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_41cfc87d-47e8-4c15-8379-d762837fbbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_286ff43a-7d66-4471-9584-3ae21f013416" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_41cfc87d-47e8-4c15-8379-d762837fbbdd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_78f5dac7-7fea-4278-9c97-6aefa3cab258" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_286ff43a-7d66-4471-9584-3ae21f013416" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_78f5dac7-7fea-4278-9c97-6aefa3cab258" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_0fb9c95b-18ad-48e1-b7aa-5bf2157196b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_286ff43a-7d66-4471-9584-3ae21f013416" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_0fb9c95b-18ad-48e1-b7aa-5bf2157196b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_23540958-079d-4106-8123-21a62c23569f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_286ff43a-7d66-4471-9584-3ae21f013416" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_23540958-079d-4106-8123-21a62c23569f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_d1a5260d-f21b-475b-9a78-aee0a420de3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_286ff43a-7d66-4471-9584-3ae21f013416" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_d1a5260d-f21b-475b-9a78-aee0a420de3b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_040db937-efa1-433c-b675-2d4a04dfdfe8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_286ff43a-7d66-4471-9584-3ae21f013416" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_040db937-efa1-433c-b675-2d4a04dfdfe8" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f584fad6-dec5-4ed3-9ce1-562c45a4c79e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84c0c7ef-ae68-42fc-a2aa-62c327df5c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f584fad6-dec5-4ed3-9ce1-562c45a4c79e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84c0c7ef-ae68-42fc-a2aa-62c327df5c1d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_46297835-8c14-4c94-a11b-6aa5ca4f02d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84c0c7ef-ae68-42fc-a2aa-62c327df5c1d" xlink:to="loc_us-gaap_AwardTypeAxis_46297835-8c14-4c94-a11b-6aa5ca4f02d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46297835-8c14-4c94-a11b-6aa5ca4f02d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_46297835-8c14-4c94-a11b-6aa5ca4f02d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46297835-8c14-4c94-a11b-6aa5ca4f02d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9fa68b88-d112-4947-8289-ffe112c03833" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_46297835-8c14-4c94-a11b-6aa5ca4f02d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9fa68b88-d112-4947-8289-ffe112c03833" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ec8d2fdd-0ede-42a9-a91d-e6fcfdc358ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9fa68b88-d112-4947-8289-ffe112c03833" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ec8d2fdd-0ede-42a9-a91d-e6fcfdc358ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_82f247dd-c888-4877-b863-bec08ec90fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9fa68b88-d112-4947-8289-ffe112c03833" xlink:to="loc_us-gaap_PerformanceSharesMember_82f247dd-c888-4877-b863-bec08ec90fa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fb3ff400-7a06-431c-bbd4-42c6b958cd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f584fad6-dec5-4ed3-9ce1-562c45a4c79e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fb3ff400-7a06-431c-bbd4-42c6b958cd0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2aba5915-86c2-46bd-88ba-6507f8a39b19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fb3ff400-7a06-431c-bbd4-42c6b958cd0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2aba5915-86c2-46bd-88ba-6507f8a39b19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_83719a20-b37f-4094-8917-39c38106737b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2aba5915-86c2-46bd-88ba-6507f8a39b19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_83719a20-b37f-4094-8917-39c38106737b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_68ddff93-4637-42d0-8b7e-e37f96f71d22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2aba5915-86c2-46bd-88ba-6507f8a39b19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_68ddff93-4637-42d0-8b7e-e37f96f71d22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cad50e76-6b08-4f6b-aa58-7fa63a8f3df9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2aba5915-86c2-46bd-88ba-6507f8a39b19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cad50e76-6b08-4f6b-aa58-7fa63a8f3df9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod_b6d5369b-598e-4ed1-a862-98cb6635fd3c" xlink:href="jnj-20241229.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2aba5915-86c2-46bd-88ba-6507f8a39b19" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod_b6d5369b-598e-4ed1-a862-98cb6635fd3c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b818f15f-30d7-4a1c-b176-fc028c5c2427" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_68606b45-2f3d-488d-b443-55d34606e159" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_75795e21-9881-4130-80f4-43db580e1970" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_68606b45-2f3d-488d-b443-55d34606e159" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_75795e21-9881-4130-80f4-43db580e1970" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_28de42f8-f13e-42fa-872f-9c30e4b7694b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_75795e21-9881-4130-80f4-43db580e1970" xlink:to="loc_srt_StatementGeographicalAxis_28de42f8-f13e-42fa-872f-9c30e4b7694b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_28de42f8-f13e-42fa-872f-9c30e4b7694b_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_28de42f8-f13e-42fa-872f-9c30e4b7694b" xlink:to="loc_srt_SegmentGeographicalDomain_28de42f8-f13e-42fa-872f-9c30e4b7694b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6897f804-8f61-4af3-8113-498eaa16b106" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_28de42f8-f13e-42fa-872f-9c30e4b7694b" xlink:to="loc_srt_SegmentGeographicalDomain_6897f804-8f61-4af3-8113-498eaa16b106" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_dc01e787-cd33-4f6b-9c58-f7386fa696c7" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6897f804-8f61-4af3-8113-498eaa16b106" xlink:to="loc_country_US_dc01e787-cd33-4f6b-9c58-f7386fa696c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_e7f4c96c-76ca-4cd1-be89-78555c4601ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6897f804-8f61-4af3-8113-498eaa16b106" xlink:to="loc_us-gaap_NonUsMember_e7f4c96c-76ca-4cd1-be89-78555c4601ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember_e825d01f-f971-4d49-8701-ff1e2c5185b8" xlink:href="jnj-20241229.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6897f804-8f61-4af3-8113-498eaa16b106" xlink:to="loc_jnj_UNITEDSTATESExportsMember_e825d01f-f971-4d49-8701-ff1e2c5185b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0b0df187-78e2-4874-9991-714047008112" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_75795e21-9881-4130-80f4-43db580e1970" xlink:to="loc_srt_ProductOrServiceAxis_0b0df187-78e2-4874-9991-714047008112" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0b0df187-78e2-4874-9991-714047008112_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0b0df187-78e2-4874-9991-714047008112" xlink:to="loc_srt_ProductsAndServicesDomain_0b0df187-78e2-4874-9991-714047008112_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0b0df187-78e2-4874-9991-714047008112" xlink:to="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember_707fe9f1-4e35-4318-b08d-a222d5d37220" xlink:href="jnj-20241229.xsd#jnj_RemicadeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_RemicadeMember_707fe9f1-4e35-4318-b08d-a222d5d37220" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember_fbccec94-c186-4cd8-ab4a-2cc0a1a5ad04" xlink:href="jnj-20241229.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_SimponiSimponiAriaMember_fbccec94-c186-4cd8-ab4a-2cc0a1a5ad04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember_9acd35d7-62bc-410f-9544-aaf497652800" xlink:href="jnj-20241229.xsd#jnj_StelaraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_StelaraMember_9acd35d7-62bc-410f-9544-aaf497652800" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember_49cb3e3b-aa3c-4e62-90a4-0adee6c5230f" xlink:href="jnj-20241229.xsd#jnj_TremfyaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_TremfyaMember_49cb3e3b-aa3c-4e62-90a4-0adee6c5230f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember_65942f08-ef46-4d35-8ba5-b13490a124ed" xlink:href="jnj-20241229.xsd#jnj_OtherImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_OtherImmunologyMember_65942f08-ef46-4d35-8ba5-b13490a124ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_COVID19Member_deba68b0-7c24-4c36-a7b5-934656b4f2ab" xlink:href="jnj-20241229.xsd#jnj_COVID19Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_COVID19Member_deba68b0-7c24-4c36-a7b5-934656b4f2ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember_cd033215-a317-4105-a593-8c4f5c9c0d18" xlink:href="jnj-20241229.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_EDURANTrilpivirineMember_cd033215-a317-4105-a593-8c4f5c9c0d18" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_9d5494a1-1f6a-4ae8-87ea-d4802413c334" xlink:href="jnj-20241229.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_9d5494a1-1f6a-4ae8-87ea-d4802413c334" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember_724475ad-f544-4878-b51e-b2faf5c866ca" xlink:href="jnj-20241229.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_OtherInfectiousDiseasesMember_724475ad-f544-4878-b51e-b2faf5c866ca" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember_e040eb29-7032-4baa-b881-8e488853c2c5" xlink:href="jnj-20241229.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_CONCERTAMethylphenidateMember_e040eb29-7032-4baa-b881-8e488853c2c5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_b1bfd636-6e53-41fe-84b7-534e30c8b128" xlink:href="jnj-20241229.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_b1bfd636-6e53-41fe-84b7-534e30c8b128" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPRAVATOMember_5529826d-74ca-4b3e-9cf8-73b583d772cf" xlink:href="jnj-20241229.xsd#jnj_SPRAVATOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_SPRAVATOMember_5529826d-74ca-4b3e-9cf8-73b583d772cf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember_37dabb40-f9f3-42ae-af5f-102d3a5b9f80" xlink:href="jnj-20241229.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_OTHERNEUROSCIENCEMember_37dabb40-f9f3-42ae-af5f-102d3a5b9f80" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CARVYKTIMember_ad990165-1f1a-4dec-8431-8d885ea71684" xlink:href="jnj-20241229.xsd#jnj_CARVYKTIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_CARVYKTIMember_ad990165-1f1a-4dec-8431-8d885ea71684" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember_e1d99711-df4e-4ca5-adb6-afe3d4892c47" xlink:href="jnj-20241229.xsd#jnj_DARZALEXMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_DARZALEXMember_e1d99711-df4e-4ca5-adb6-afe3d4892c47" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ErleadaMember_c67c6849-bfbc-4076-9c3d-c6eb9fe921fe" xlink:href="jnj-20241229.xsd#jnj_ErleadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_ErleadaMember_c67c6849-bfbc-4076-9c3d-c6eb9fe921fe" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember_adc755b9-5672-4620-b4a3-2510615730ed" xlink:href="jnj-20241229.xsd#jnj_IMBRUVICAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_IMBRUVICAMember_adc755b9-5672-4620-b4a3-2510615730ed" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TECVAYLIMember_6608d7fd-222f-4df1-9bb2-d324ce1713ee" xlink:href="jnj-20241229.xsd#jnj_TECVAYLIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_TECVAYLIMember_6608d7fd-222f-4df1-9bb2-d324ce1713ee" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember_e91026ce-3e9e-4ea4-8103-a7963510f944" xlink:href="jnj-20241229.xsd#jnj_ZYTIGAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_ZYTIGAMember_e91026ce-3e9e-4ea4-8103-a7963510f944" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember_efd48a56-be35-4783-8b2e-7c1084c2a2f2" xlink:href="jnj-20241229.xsd#jnj_OtherOncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_OtherOncologyMember_efd48a56-be35-4783-8b2e-7c1084c2a2f2" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember_4fb49b42-f188-46f9-813e-163b64ec5df6" xlink:href="jnj-20241229.xsd#jnj_OPSUMITMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_OPSUMITMember_4fb49b42-f188-46f9-813e-163b64ec5df6" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember_a46044c4-dfc6-4f07-a360-b9e584468d39" xlink:href="jnj-20241229.xsd#jnj_UPTRAVIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_UPTRAVIMember_a46044c4-dfc6-4f07-a360-b9e584468d39" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherPulmonaryHypertensionMember_aea1fb86-81f8-4a47-97d7-80b4359c42f4" xlink:href="jnj-20241229.xsd#jnj_OtherPulmonaryHypertensionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_OtherPulmonaryHypertensionMember_aea1fb86-81f8-4a47-97d7-80b4359c42f4" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_c928499a-3ce1-4b17-935c-d8d4f5b68e80" xlink:href="jnj-20241229.xsd#jnj_XareltoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_XareltoMember_c928499a-3ce1-4b17-935c-d8d4f5b68e80" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember_fb2deb2b-a0bd-4de7-8ca1-93f961021254" xlink:href="jnj-20241229.xsd#jnj_OtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_OtherMember_fb2deb2b-a0bd-4de7-8ca1-93f961021254" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ELECTROPHYSIOLOGYMember_c634eadc-9054-4119-95c6-91c10dc44553" xlink:href="jnj-20241229.xsd#jnj_ELECTROPHYSIOLOGYMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_ELECTROPHYSIOLOGYMember_c634eadc-9054-4119-95c6-91c10dc44553" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AbiomedMember_bde2142d-9e70-4519-9787-05da5122f444" xlink:href="jnj-20241229.xsd#jnj_AbiomedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_AbiomedMember_bde2142d-9e70-4519-9787-05da5122f444" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShockwaveMedicalInc.Member_a15c615b-419d-44cc-8f1b-ccc5ebf3ed70" xlink:href="jnj-20241229.xsd#jnj_ShockwaveMedicalInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_ShockwaveMedicalInc.Member_a15c615b-419d-44cc-8f1b-ccc5ebf3ed70" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherCardiovascularMember_60ac0bca-ff35-40c9-be77-99138df9abb5" xlink:href="jnj-20241229.xsd#jnj_OtherCardiovascularMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_OtherCardiovascularMember_60ac0bca-ff35-40c9-be77-99138df9abb5" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember_321bc145-3bdc-4648-8e52-6ee1f43330e0" xlink:href="jnj-20241229.xsd#jnj_HIPSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_HIPSMember_321bc145-3bdc-4648-8e52-6ee1f43330e0" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember_7a979e07-2931-426f-be09-d9f277cf01f0" xlink:href="jnj-20241229.xsd#jnj_KNEESMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_KNEESMember_7a979e07-2931-426f-be09-d9f277cf01f0" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember_5b5f49d5-bc86-4c55-ae0d-29970a881866" xlink:href="jnj-20241229.xsd#jnj_TRAUMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_TRAUMAMember_5b5f49d5-bc86-4c55-ae0d-29970a881866" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINESPORTSOTHERMember_15288009-197d-4414-9f6c-4dcb0f76633a" xlink:href="jnj-20241229.xsd#jnj_SPINESPORTSOTHERMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_SPINESPORTSOTHERMember_15288009-197d-4414-9f6c-4dcb0f76633a" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember_66b663c2-bd75-411e-8a15-2adcd76c6900" xlink:href="jnj-20241229.xsd#jnj_ADVANCEDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_ADVANCEDMember_66b663c2-bd75-411e-8a15-2adcd76c6900" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember_a9af3c43-9add-47e7-8428-9d4d95720230" xlink:href="jnj-20241229.xsd#jnj_GENERALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_GENERALMember_a9af3c43-9add-47e7-8428-9d4d95720230" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember_44610129-5751-4476-9619-9de23806bf70" xlink:href="jnj-20241229.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_CONTACTLENSESOTHERMember_44610129-5751-4476-9619-9de23806bf70" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember_c1fb667c-bf70-4983-bf84-ff4d4147cad8" xlink:href="jnj-20241229.xsd#jnj_SURGICALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_SURGICALMember_c1fb667c-bf70-4983-bf84-ff4d4147cad8" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_38994f47-a33c-42ed-bd4e-858e25eb4226" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_75795e21-9881-4130-80f4-43db580e1970" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_38994f47-a33c-42ed-bd4e-858e25eb4226" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_38994f47-a33c-42ed-bd4e-858e25eb4226_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_38994f47-a33c-42ed-bd4e-858e25eb4226" xlink:to="loc_us-gaap_SegmentDomain_38994f47-a33c-42ed-bd4e-858e25eb4226_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c790d59b-cdc3-4dd9-b0bf-3153b5a504b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_38994f47-a33c-42ed-bd4e-858e25eb4226" xlink:to="loc_us-gaap_SegmentDomain_c790d59b-cdc3-4dd9-b0bf-3153b5a504b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InnovativeMedicineMember_07db87e0-76fb-4abe-9f7b-68ecce4e32b4" xlink:href="jnj-20241229.xsd#jnj_InnovativeMedicineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c790d59b-cdc3-4dd9-b0bf-3153b5a504b5" xlink:to="loc_jnj_InnovativeMedicineMember_07db87e0-76fb-4abe-9f7b-68ecce4e32b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedTechMember_615846d2-8241-4ca3-882f-6d60c31bd913" xlink:href="jnj-20241229.xsd#jnj_MedTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c790d59b-cdc3-4dd9-b0bf-3153b5a504b5" xlink:to="loc_jnj_MedTechMember_615846d2-8241-4ca3-882f-6d60c31bd913" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_2f4b6c41-dfbc-4cc4-842c-1a1819e3d844" xlink:href="jnj-20241229.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c790d59b-cdc3-4dd9-b0bf-3153b5a504b5" xlink:to="loc_jnj_PharmaceuticalMember_2f4b6c41-dfbc-4cc4-842c-1a1819e3d844" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_adfbc886-d4cb-4a78-982c-d6cd32277ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_75795e21-9881-4130-80f4-43db580e1970" xlink:to="loc_us-gaap_SubsegmentsAxis_adfbc886-d4cb-4a78-982c-d6cd32277ea0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_adfbc886-d4cb-4a78-982c-d6cd32277ea0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_adfbc886-d4cb-4a78-982c-d6cd32277ea0" xlink:to="loc_us-gaap_SubsegmentsDomain_adfbc886-d4cb-4a78-982c-d6cd32277ea0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_85f8336c-a3d1-410d-a10e-a46c30db5b58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_adfbc886-d4cb-4a78-982c-d6cd32277ea0" xlink:to="loc_us-gaap_SubsegmentsDomain_85f8336c-a3d1-410d-a10e-a46c30db5b58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember_af0b1b94-9526-43cf-9a35-84b57bca1216" xlink:href="jnj-20241229.xsd#jnj_ImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_85f8336c-a3d1-410d-a10e-a46c30db5b58" xlink:to="loc_jnj_ImmunologyMember_af0b1b94-9526-43cf-9a35-84b57bca1216" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember_bd981507-f7cf-4404-8c81-4b76ec3d2f01" xlink:href="jnj-20241229.xsd#jnj_InfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_85f8336c-a3d1-410d-a10e-a46c30db5b58" xlink:to="loc_jnj_InfectiousDiseasesMember_bd981507-f7cf-4404-8c81-4b76ec3d2f01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember_0ac29c51-7d9d-4cf9-86c8-41b784bc259d" xlink:href="jnj-20241229.xsd#jnj_NeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_85f8336c-a3d1-410d-a10e-a46c30db5b58" xlink:to="loc_jnj_NeuroscienceMember_0ac29c51-7d9d-4cf9-86c8-41b784bc259d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember_672d73b2-edad-491f-bf7d-bda917076c44" xlink:href="jnj-20241229.xsd#jnj_OncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_85f8336c-a3d1-410d-a10e-a46c30db5b58" xlink:to="loc_jnj_OncologyMember_672d73b2-edad-491f-bf7d-bda917076c44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember_b43b88f6-6ec3-407f-bb2e-6f7f17cd3fd2" xlink:href="jnj-20241229.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_85f8336c-a3d1-410d-a10e-a46c30db5b58" xlink:to="loc_jnj_PulmonaryHypertensionMember_b43b88f6-6ec3-407f-bb2e-6f7f17cd3fd2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember_33b00413-7d8a-4e5b-ba7a-327d5b45bfe2" xlink:href="jnj-20241229.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_85f8336c-a3d1-410d-a10e-a46c30db5b58" xlink:to="loc_jnj_CardiovascularMetabolismOtherMember_33b00413-7d8a-4e5b-ba7a-327d5b45bfe2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMember_c7fd3374-aee2-4974-ac41-5577001708a7" xlink:href="jnj-20241229.xsd#jnj_CardiovascularMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_85f8336c-a3d1-410d-a10e-a46c30db5b58" xlink:to="loc_jnj_CardiovascularMember_c7fd3374-aee2-4974-ac41-5577001708a7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember_d25d3219-2276-4731-9455-379e71a77d34" xlink:href="jnj-20241229.xsd#jnj_OrthopaedicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_85f8336c-a3d1-410d-a10e-a46c30db5b58" xlink:to="loc_jnj_OrthopaedicsMember_d25d3219-2276-4731-9455-379e71a77d34" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember_a5885a3f-c570-447d-8727-b2854394bf20" xlink:href="jnj-20241229.xsd#jnj_SurgeryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_85f8336c-a3d1-410d-a10e-a46c30db5b58" xlink:to="loc_jnj_SurgeryMember_a5885a3f-c570-447d-8727-b2854394bf20" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember_b283d033-3f7b-47be-bcf6-a1f7e7d9bfa9" xlink:href="jnj-20241229.xsd#jnj_VisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_85f8336c-a3d1-410d-a10e-a46c30db5b58" xlink:to="loc_jnj_VisionMember_b283d033-3f7b-47be-bcf6-a1f7e7d9bfa9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_f96c9b2d-3895-4ddf-af7b-370565c15ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_68606b45-2f3d-488d-b443-55d34606e159" xlink:to="loc_us-gaap_NumberOfOperatingSegments_f96c9b2d-3895-4ddf-af7b-370565c15ae6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_33c30aab-a309-4492-b133-5154e5c81901" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_68606b45-2f3d-488d-b443-55d34606e159" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_33c30aab-a309-4492-b133-5154e5c81901" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_8e58ecba-70c5-4bf7-ba60-2f18e17a9071" xlink:href="jnj-20241229.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_68606b45-2f3d-488d-b443-55d34606e159" xlink:to="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_8e58ecba-70c5-4bf7-ba60-2f18e17a9071" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_3beca50b-5d8c-48ce-a342-92646f8c6886" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_33a524ff-0078-4109-8933-0b5d838fdb94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_3beca50b-5d8c-48ce-a342-92646f8c6886" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_33a524ff-0078-4109-8933-0b5d838fdb94" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_36994773-3915-47ef-98b6-c7940aa08d63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_33a524ff-0078-4109-8933-0b5d838fdb94" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_36994773-3915-47ef-98b6-c7940aa08d63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_36994773-3915-47ef-98b6-c7940aa08d63_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_36994773-3915-47ef-98b6-c7940aa08d63" xlink:to="loc_us-gaap_SegmentDomain_36994773-3915-47ef-98b6-c7940aa08d63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4f3f51ca-311b-4240-b03b-4ebc23c2267a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_36994773-3915-47ef-98b6-c7940aa08d63" xlink:to="loc_us-gaap_SegmentDomain_4f3f51ca-311b-4240-b03b-4ebc23c2267a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InnovativeMedicineMember_187f9dee-976d-4e14-a7f2-d02b22a8d29d" xlink:href="jnj-20241229.xsd#jnj_InnovativeMedicineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4f3f51ca-311b-4240-b03b-4ebc23c2267a" xlink:to="loc_jnj_InnovativeMedicineMember_187f9dee-976d-4e14-a7f2-d02b22a8d29d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedTechMember_d517a4d3-fbc7-487f-96a7-651de2ac5891" xlink:href="jnj-20241229.xsd#jnj_MedTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4f3f51ca-311b-4240-b03b-4ebc23c2267a" xlink:to="loc_jnj_MedTechMember_d517a4d3-fbc7-487f-96a7-651de2ac5891" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_f4968e0e-0721-4765-906a-cda00992c42f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_33a524ff-0078-4109-8933-0b5d838fdb94" xlink:to="loc_srt_ConsolidationItemsAxis_f4968e0e-0721-4765-906a-cda00992c42f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_f4968e0e-0721-4765-906a-cda00992c42f_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_f4968e0e-0721-4765-906a-cda00992c42f" xlink:to="loc_srt_ConsolidationItemsDomain_f4968e0e-0721-4765-906a-cda00992c42f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_9a6ffaa7-d0d2-4089-9d82-c36046b877a3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_f4968e0e-0721-4765-906a-cda00992c42f" xlink:to="loc_srt_ConsolidationItemsDomain_9a6ffaa7-d0d2-4089-9d82-c36046b877a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_79424a96-8dc9-445a-a0e2-4793f6718735" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_9a6ffaa7-d0d2-4089-9d82-c36046b877a3" xlink:to="loc_us-gaap_OperatingSegmentsMember_79424a96-8dc9-445a-a0e2-4793f6718735" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_909501fd-d7be-44ec-a5c8-11ff1c5c5244" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_3beca50b-5d8c-48ce-a342-92646f8c6886" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_909501fd-d7be-44ec-a5c8-11ff1c5c5244" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_05fb43c6-638b-4d7c-9ed8-6905b412be68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_3beca50b-5d8c-48ce-a342-92646f8c6886" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_05fb43c6-638b-4d7c-9ed8-6905b412be68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3983107b-12de-404e-a8f0-f6633d585e58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_3beca50b-5d8c-48ce-a342-92646f8c6886" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3983107b-12de-404e-a8f0-f6633d585e58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ffe928ba-6668-4148-9576-1dd194b6245f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_3beca50b-5d8c-48ce-a342-92646f8c6886" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ffe928ba-6668-4148-9576-1dd194b6245f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_430103da-f2db-4315-9d1e-640d95d44cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_3beca50b-5d8c-48ce-a342-92646f8c6886" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_430103da-f2db-4315-9d1e-640d95d44cdf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d2e407fd-73dd-4597-b2eb-8e1f661e9406" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_3beca50b-5d8c-48ce-a342-92646f8c6886" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d2e407fd-73dd-4597-b2eb-8e1f661e9406" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_02efe3ba-1176-4d92-9576-6cc91acf12ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_3beca50b-5d8c-48ce-a342-92646f8c6886" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_02efe3ba-1176-4d92-9576-6cc91acf12ba" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5c0bee9b-4425-454d-b1a2-2d7f931430a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5c0bee9b-4425-454d-b1a2-2d7f931430a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_e1ebdb1a-0141-425f-87f5-1fabab4b9652" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5c0bee9b-4425-454d-b1a2-2d7f931430a3" xlink:to="loc_srt_ConsolidationItemsAxis_e1ebdb1a-0141-425f-87f5-1fabab4b9652" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e1ebdb1a-0141-425f-87f5-1fabab4b9652_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_e1ebdb1a-0141-425f-87f5-1fabab4b9652" xlink:to="loc_srt_ConsolidationItemsDomain_e1ebdb1a-0141-425f-87f5-1fabab4b9652_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_2e50adba-2ef9-4140-ba4d-fc99bdf5898b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_e1ebdb1a-0141-425f-87f5-1fabab4b9652" xlink:to="loc_srt_ConsolidationItemsDomain_2e50adba-2ef9-4140-ba4d-fc99bdf5898b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_f3791601-143c-4acf-a384-a8783b73f1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_2e50adba-2ef9-4140-ba4d-fc99bdf5898b" xlink:to="loc_us-gaap_OperatingSegmentsMember_f3791601-143c-4acf-a384-a8783b73f1f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_bb2faebd-2b00-43e2-9236-2092b39b08ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_2e50adba-2ef9-4140-ba4d-fc99bdf5898b" xlink:to="loc_us-gaap_CorporateNonSegmentMember_bb2faebd-2b00-43e2-9236-2092b39b08ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_553809d8-d03b-4590-9c8d-8a815c0a1ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5c0bee9b-4425-454d-b1a2-2d7f931430a3" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_553809d8-d03b-4590-9c8d-8a815c0a1ff5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_553809d8-d03b-4590-9c8d-8a815c0a1ff5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_553809d8-d03b-4590-9c8d-8a815c0a1ff5" xlink:to="loc_us-gaap_SegmentDomain_553809d8-d03b-4590-9c8d-8a815c0a1ff5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ad13768c-faec-423c-a65c-a2d5944af33d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_553809d8-d03b-4590-9c8d-8a815c0a1ff5" xlink:to="loc_us-gaap_SegmentDomain_ad13768c-faec-423c-a65c-a2d5944af33d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InnovativeMedicineMember_d803a676-b1dc-46bc-a77a-1edd2c5c81f6" xlink:href="jnj-20241229.xsd#jnj_InnovativeMedicineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ad13768c-faec-423c-a65c-a2d5944af33d" xlink:to="loc_jnj_InnovativeMedicineMember_d803a676-b1dc-46bc-a77a-1edd2c5c81f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedTechMember_a90e8e6a-e917-44a9-8c0c-282621a45114" xlink:href="jnj-20241229.xsd#jnj_MedTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ad13768c-faec-423c-a65c-a2d5944af33d" xlink:to="loc_jnj_MedTechMember_a90e8e6a-e917-44a9-8c0c-282621a45114" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SegmentsTotalMember_587c2c41-72b6-4b0d-abee-b97ab02d38c7" xlink:href="jnj-20241229.xsd#jnj_SegmentsTotalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ad13768c-faec-423c-a65c-a2d5944af33d" xlink:to="loc_jnj_SegmentsTotalMember_587c2c41-72b6-4b0d-abee-b97ab02d38c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_29a54fca-e0d2-444e-86e1-a864ce2f1516" xlink:href="jnj-20241229.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ad13768c-faec-423c-a65c-a2d5944af33d" xlink:to="loc_jnj_ConsumerMember_29a54fca-e0d2-444e-86e1-a864ce2f1516" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GeneralCorporateMember_7ef84d0e-2513-4756-8beb-66201a60ab06" xlink:href="jnj-20241229.xsd#jnj_GeneralCorporateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ad13768c-faec-423c-a65c-a2d5944af33d" xlink:to="loc_jnj_GeneralCorporateMember_7ef84d0e-2513-4756-8beb-66201a60ab06" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1ef5edaf-95ab-4e9d-b17f-b88143dbfea0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5c0bee9b-4425-454d-b1a2-2d7f931430a3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1ef5edaf-95ab-4e9d-b17f-b88143dbfea0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1ef5edaf-95ab-4e9d-b17f-b88143dbfea0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1ef5edaf-95ab-4e9d-b17f-b88143dbfea0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1ef5edaf-95ab-4e9d-b17f-b88143dbfea0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bbe8075f-1798-4afe-9e79-b388d77d8002" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1ef5edaf-95ab-4e9d-b17f-b88143dbfea0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bbe8075f-1798-4afe-9e79-b388d77d8002" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LaminarMember_71330d5d-1dd1-48ae-9416-7f75868f3904" xlink:href="jnj-20241229.xsd#jnj_LaminarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bbe8075f-1798-4afe-9e79-b388d77d8002" xlink:to="loc_jnj_LaminarMember_71330d5d-1dd1-48ae-9416-7f75868f3904" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MomentaMember_e911903a-ce15-4960-8c68-3bdfc2ed55b0" xlink:href="jnj-20241229.xsd#jnj_MomentaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bbe8075f-1798-4afe-9e79-b388d77d8002" xlink:to="loc_jnj_MomentaMember_e911903a-ce15-4960-8c68-3bdfc2ed55b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VWaveLtd.Member_f2bcdd88-5c76-47fc-b30e-c692388c6d9c" xlink:href="jnj-20241229.xsd#jnj_VWaveLtd.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bbe8075f-1798-4afe-9e79-b388d77d8002" xlink:to="loc_jnj_VWaveLtd.Member_f2bcdd88-5c76-47fc-b30e-c692388c6d9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_c0a631f1-39ac-4611-a2c6-04e836f745a3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5c0bee9b-4425-454d-b1a2-2d7f931430a3" xlink:to="loc_srt_LitigationCaseAxis_c0a631f1-39ac-4611-a2c6-04e836f745a3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c0a631f1-39ac-4611-a2c6-04e836f745a3_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_c0a631f1-39ac-4611-a2c6-04e836f745a3" xlink:to="loc_srt_LitigationCaseTypeDomain_c0a631f1-39ac-4611-a2c6-04e836f745a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_13effff6-6038-4bed-8e96-72897488bdde" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_c0a631f1-39ac-4611-a2c6-04e836f745a3" xlink:to="loc_srt_LitigationCaseTypeDomain_13effff6-6038-4bed-8e96-72897488bdde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember_1c77681e-7f13-409f-8bb8-10ea421717f9" xlink:href="jnj-20241229.xsd#jnj_BabyPowderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_13effff6-6038-4bed-8e96-72897488bdde" xlink:to="loc_jnj_BabyPowderMember_1c77681e-7f13-409f-8bb8-10ea421717f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ab17a9a4-d5f9-4d01-9beb-ca69cb89d618" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5c0bee9b-4425-454d-b1a2-2d7f931430a3" xlink:to="loc_srt_ProductOrServiceAxis_ab17a9a4-d5f9-4d01-9beb-ca69cb89d618" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ab17a9a4-d5f9-4d01-9beb-ca69cb89d618_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ab17a9a4-d5f9-4d01-9beb-ca69cb89d618" xlink:to="loc_srt_ProductsAndServicesDomain_ab17a9a4-d5f9-4d01-9beb-ca69cb89d618_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_21c8fb01-4b69-4975-ba4a-63a974e9ee67" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ab17a9a4-d5f9-4d01-9beb-ca69cb89d618" xlink:to="loc_srt_ProductsAndServicesDomain_21c8fb01-4b69-4975-ba4a-63a974e9ee67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_871667ab-0b30-4f6a-b24c-91c89ea2509c" xlink:href="jnj-20241229.xsd#jnj_TalcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_21c8fb01-4b69-4975-ba4a-63a974e9ee67" xlink:to="loc_jnj_TalcMember_871667ab-0b30-4f6a-b24c-91c89ea2509c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_37a9cd65-1267-445b-9485-0ac85a9dcce4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5c0bee9b-4425-454d-b1a2-2d7f931430a3" xlink:to="loc_us-gaap_AssetAcquisitionAxis_37a9cd65-1267-445b-9485-0ac85a9dcce4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_37a9cd65-1267-445b-9485-0ac85a9dcce4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_37a9cd65-1267-445b-9485-0ac85a9dcce4" xlink:to="loc_us-gaap_AssetAcquisitionDomain_37a9cd65-1267-445b-9485-0ac85a9dcce4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_9ad0d36a-b144-4284-b881-c6a710e85e73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_37a9cd65-1267-445b-9485-0ac85a9dcce4" xlink:to="loc_us-gaap_AssetAcquisitionDomain_9ad0d36a-b144-4284-b881-c6a710e85e73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_YellowJerseyTherapeuticsMember_60c22c62-cdc9-4a3a-8827-c499dc857052" xlink:href="jnj-20241229.xsd#jnj_YellowJerseyTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_9ad0d36a-b144-4284-b881-c6a710e85e73" xlink:to="loc_jnj_YellowJerseyTherapeuticsMember_60c22c62-cdc9-4a3a-8827-c499dc857052" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a86c6b21-1c48-480e-96a2-db1d90b099c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a86c6b21-1c48-480e-96a2-db1d90b099c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_53e5d688-6356-409f-97c7-06f0fddd85fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_53e5d688-6356-409f-97c7-06f0fddd85fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_da448694-53d8-4a1a-af2d-8309f284b78e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_Assets_da448694-53d8-4a1a-af2d-8309f284b78e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentExpenditureAdditionToLongLivedAssets_b13b0b06-a53e-4ff6-b606-da982765cb72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentExpenditureAdditionToLongLivedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_SegmentExpenditureAdditionToLongLivedAssets_b13b0b06-a53e-4ff6-b606-da982765cb72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_779dd7a1-2bb1-4374-bb37-bf3d7aef0533" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_779dd7a1-2bb1-4374-bb37-bf3d7aef0533" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_8973f8ea-7823-493b-b626-bd0444cff930" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_8973f8ea-7823-493b-b626-bd0444cff930" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyLossInPeriod_d469c5fc-089f-4a04-b024-155f62d01ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyLossInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_LossContingencyLossInPeriod_d469c5fc-089f-4a04-b024-155f62d01ca4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_11f21d81-a319-44f0-8f0a-a340b34977ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_11f21d81-a319-44f0-8f0a-a340b34977ea" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived_f94a4e53-7e3c-441c-be41-2e99ba7860df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_ProceedsFromRoyaltiesReceived_f94a4e53-7e3c-441c-be41-2e99ba7860df" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_cde433da-bd3a-4b17-9512-cbed15849f72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_RestructuringCharges_cde433da-bd3a-4b17-9512-cbed15849f72" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b6eb9aa1-c4d3-486a-a275-e4b67fe3f0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b6eb9aa1-c4d3-486a-a275-e4b67fe3f0c7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_3a5c674b-81c5-4642-b094-f51beaa440cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_3a5c674b-81c5-4642-b094-f51beaa440cf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RegulationCharge_ac71f720-5261-47d4-bc99-9c1e7b657c5c" xlink:href="jnj-20241229.xsd#jnj_RegulationCharge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_jnj_RegulationCharge_ac71f720-5261-47d4-bc99-9c1e7b657c5c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_8a44f9e0-9a88-4abc-908f-428940ad0e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_LitigationSettlementExpense_8a44f9e0-9a88-4abc-908f-428940ad0e2e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_fd444baf-6516-4da3-acf1-fb176de4359f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SuppliesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_SuppliesExpense_fd444baf-6516-4da3-acf1-fb176de4359f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9b2f313d-8a29-4c68-8f0c-b7a8a7a68521" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9b2f313d-8a29-4c68-8f0c-b7a8a7a68521" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c630d95f-caa6-440f-8ae4-b00a2aca1412" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c630d95f-caa6-440f-8ae4-b00a2aca1412" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_8741c49f-0261-4c05-83a0-8c7ec7a3adc7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c630d95f-caa6-440f-8ae4-b00a2aca1412" xlink:to="loc_srt_ConsolidationItemsAxis_8741c49f-0261-4c05-83a0-8c7ec7a3adc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_8741c49f-0261-4c05-83a0-8c7ec7a3adc7_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_8741c49f-0261-4c05-83a0-8c7ec7a3adc7" xlink:to="loc_srt_ConsolidationItemsDomain_8741c49f-0261-4c05-83a0-8c7ec7a3adc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_f2fddc2f-7ae3-4705-83df-55c97eac3896" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_8741c49f-0261-4c05-83a0-8c7ec7a3adc7" xlink:to="loc_srt_ConsolidationItemsDomain_f2fddc2f-7ae3-4705-83df-55c97eac3896" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_8dfc59a7-8e8e-4847-90b7-20e94fcc57bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_f2fddc2f-7ae3-4705-83df-55c97eac3896" xlink:to="loc_us-gaap_OperatingSegmentsMember_8dfc59a7-8e8e-4847-90b7-20e94fcc57bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_63caaa70-6ccd-40cc-8241-39b0ef3127cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_f2fddc2f-7ae3-4705-83df-55c97eac3896" xlink:to="loc_us-gaap_CorporateNonSegmentMember_63caaa70-6ccd-40cc-8241-39b0ef3127cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bbd5773d-537d-4153-9ffc-72f4a3ea9ed4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c630d95f-caa6-440f-8ae4-b00a2aca1412" xlink:to="loc_srt_StatementGeographicalAxis_bbd5773d-537d-4153-9ffc-72f4a3ea9ed4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_bbd5773d-537d-4153-9ffc-72f4a3ea9ed4_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_bbd5773d-537d-4153-9ffc-72f4a3ea9ed4" xlink:to="loc_srt_SegmentGeographicalDomain_bbd5773d-537d-4153-9ffc-72f4a3ea9ed4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_28f309ea-8f88-4dea-8d88-b2f19214c730" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_bbd5773d-537d-4153-9ffc-72f4a3ea9ed4" xlink:to="loc_srt_SegmentGeographicalDomain_28f309ea-8f88-4dea-8d88-b2f19214c730" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_322f9f14-799b-4070-af17-12c1ac5a4591" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_28f309ea-8f88-4dea-8d88-b2f19214c730" xlink:to="loc_country_US_322f9f14-799b-4070-af17-12c1ac5a4591" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_0ad005d5-d8dd-456a-befe-a8ccfaf33ada" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_28f309ea-8f88-4dea-8d88-b2f19214c730" xlink:to="loc_srt_EuropeMember_0ad005d5-d8dd-456a-befe-a8ccfaf33ada" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember_ebac6384-754c-42d8-8c04-7e16ac8188db" xlink:href="jnj-20241229.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_28f309ea-8f88-4dea-8d88-b2f19214c730" xlink:to="loc_jnj_WesternHemisphereExcludingUSMember_ebac6384-754c-42d8-8c04-7e16ac8188db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember_a07d8f1a-e437-4d64-9ad3-ce7c1d85739c" xlink:href="jnj-20241229.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_28f309ea-8f88-4dea-8d88-b2f19214c730" xlink:to="loc_jnj_AsiaPacificAfricaMember_a07d8f1a-e437-4d64-9ad3-ce7c1d85739c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_33d3bd71-34cb-4281-a705-cb388f45827c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c630d95f-caa6-440f-8ae4-b00a2aca1412" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_33d3bd71-34cb-4281-a705-cb388f45827c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_33d3bd71-34cb-4281-a705-cb388f45827c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_33d3bd71-34cb-4281-a705-cb388f45827c" xlink:to="loc_us-gaap_SegmentDomain_33d3bd71-34cb-4281-a705-cb388f45827c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dcf96286-5f52-4166-b36d-dff31df165f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_33d3bd71-34cb-4281-a705-cb388f45827c" xlink:to="loc_us-gaap_SegmentDomain_dcf96286-5f52-4166-b36d-dff31df165f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GeneralCorporateMember_88aa6063-58f7-4f14-9802-df87bc3d26b2" xlink:href="jnj-20241229.xsd#jnj_GeneralCorporateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_dcf96286-5f52-4166-b36d-dff31df165f6" xlink:to="loc_jnj_GeneralCorporateMember_88aa6063-58f7-4f14-9802-df87bc3d26b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InnovativeMedicineMember_33eed12f-b93f-411c-a7d6-868c99618424" xlink:href="jnj-20241229.xsd#jnj_InnovativeMedicineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_dcf96286-5f52-4166-b36d-dff31df165f6" xlink:to="loc_jnj_InnovativeMedicineMember_33eed12f-b93f-411c-a7d6-868c99618424" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedTechMember_dbdd96a0-cc4d-4f2b-8b4e-fc6196d254b0" xlink:href="jnj-20241229.xsd#jnj_MedTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_dcf96286-5f52-4166-b36d-dff31df165f6" xlink:to="loc_jnj_MedTechMember_dbdd96a0-cc4d-4f2b-8b4e-fc6196d254b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_a36b8579-2d8b-4a98-ac7c-1a26bae62657" xlink:href="jnj-20241229.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_dcf96286-5f52-4166-b36d-dff31df165f6" xlink:to="loc_jnj_PharmaceuticalMember_a36b8579-2d8b-4a98-ac7c-1a26bae62657" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_71c77fbd-77b1-49b7-987e-f410d872d4e6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c630d95f-caa6-440f-8ae4-b00a2aca1412" xlink:to="loc_srt_MajorCustomersAxis_71c77fbd-77b1-49b7-987e-f410d872d4e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_71c77fbd-77b1-49b7-987e-f410d872d4e6_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_71c77fbd-77b1-49b7-987e-f410d872d4e6" xlink:to="loc_srt_NameOfMajorCustomerDomain_71c77fbd-77b1-49b7-987e-f410d872d4e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_85bedc3f-c828-463b-9cc3-f4381d13dba2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_71c77fbd-77b1-49b7-987e-f410d872d4e6" xlink:to="loc_srt_NameOfMajorCustomerDomain_85bedc3f-c828-463b-9cc3-f4381d13dba2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler1Member_473810f1-98e7-4332-b893-b0ad4fea5be9" xlink:href="jnj-20241229.xsd#jnj_Wholesaler1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_85bedc3f-c828-463b-9cc3-f4381d13dba2" xlink:to="loc_jnj_Wholesaler1Member_473810f1-98e7-4332-b893-b0ad4fea5be9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler2Member_c326e2ac-9b86-41ca-9240-17a13955e607" xlink:href="jnj-20241229.xsd#jnj_Wholesaler2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_85bedc3f-c828-463b-9cc3-f4381d13dba2" xlink:to="loc_jnj_Wholesaler2Member_c326e2ac-9b86-41ca-9240-17a13955e607" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler3Member_24d802ba-b464-4475-9a67-d868066113aa" xlink:href="jnj-20241229.xsd#jnj_Wholesaler3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_85bedc3f-c828-463b-9cc3-f4381d13dba2" xlink:to="loc_jnj_Wholesaler3Member_24d802ba-b464-4475-9a67-d868066113aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_65f69077-88ea-4e0f-98a0-57e934303d55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c630d95f-caa6-440f-8ae4-b00a2aca1412" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_65f69077-88ea-4e0f-98a0-57e934303d55" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_65f69077-88ea-4e0f-98a0-57e934303d55_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_65f69077-88ea-4e0f-98a0-57e934303d55" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_65f69077-88ea-4e0f-98a0-57e934303d55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d54844c8-dad3-412c-bf8f-34cfff2297fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_65f69077-88ea-4e0f-98a0-57e934303d55" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d54844c8-dad3-412c-bf8f-34cfff2297fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_a6dc62ee-9700-4b82-a321-3ae8bc4f8adc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d54844c8-dad3-412c-bf8f-34cfff2297fc" xlink:to="loc_us-gaap_SalesRevenueNetMember_a6dc62ee-9700-4b82-a321-3ae8bc4f8adc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_9f31fb18-fcf0-4e75-a7d5-a8793310c04e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c630d95f-caa6-440f-8ae4-b00a2aca1412" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_9f31fb18-fcf0-4e75-a7d5-a8793310c04e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_9f31fb18-fcf0-4e75-a7d5-a8793310c04e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_9f31fb18-fcf0-4e75-a7d5-a8793310c04e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_9f31fb18-fcf0-4e75-a7d5-a8793310c04e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5632799c-aa4e-4418-9189-4b10387685d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_9f31fb18-fcf0-4e75-a7d5-a8793310c04e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5632799c-aa4e-4418-9189-4b10387685d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WholesalerConcentrationRiskMember_22e4ea07-2e98-40ae-b308-679f27e93041" xlink:href="jnj-20241229.xsd#jnj_WholesalerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_5632799c-aa4e-4418-9189-4b10387685d9" xlink:to="loc_jnj_WholesalerConcentrationRiskMember_22e4ea07-2e98-40ae-b308-679f27e93041" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_7f261b8e-f05b-4293-8966-0bd875c73177" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c630d95f-caa6-440f-8ae4-b00a2aca1412" xlink:to="loc_srt_LitigationCaseAxis_7f261b8e-f05b-4293-8966-0bd875c73177" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_7f261b8e-f05b-4293-8966-0bd875c73177_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_7f261b8e-f05b-4293-8966-0bd875c73177" xlink:to="loc_srt_LitigationCaseTypeDomain_7f261b8e-f05b-4293-8966-0bd875c73177_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_0394a5bf-a6cb-463a-8904-79368c90bcc1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_7f261b8e-f05b-4293-8966-0bd875c73177" xlink:to="loc_srt_LitigationCaseTypeDomain_0394a5bf-a6cb-463a-8904-79368c90bcc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember_6dc4a127-4762-432d-8310-82618521d5e4" xlink:href="jnj-20241229.xsd#jnj_BabyPowderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0394a5bf-a6cb-463a-8904-79368c90bcc1" xlink:to="loc_jnj_BabyPowderMember_6dc4a127-4762-432d-8310-82618521d5e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0a00a3ec-cef3-4dc1-b816-270ac6dbea7c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c630d95f-caa6-440f-8ae4-b00a2aca1412" xlink:to="loc_srt_ProductOrServiceAxis_0a00a3ec-cef3-4dc1-b816-270ac6dbea7c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0a00a3ec-cef3-4dc1-b816-270ac6dbea7c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0a00a3ec-cef3-4dc1-b816-270ac6dbea7c" xlink:to="loc_srt_ProductsAndServicesDomain_0a00a3ec-cef3-4dc1-b816-270ac6dbea7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1b007d85-a63b-421b-be85-301b01ad5c7c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0a00a3ec-cef3-4dc1-b816-270ac6dbea7c" xlink:to="loc_srt_ProductsAndServicesDomain_1b007d85-a63b-421b-be85-301b01ad5c7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_b9ee26b4-a69d-495d-b41c-8c8f2f634917" xlink:href="jnj-20241229.xsd#jnj_TalcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1b007d85-a63b-421b-be85-301b01ad5c7c" xlink:to="loc_jnj_TalcMember_b9ee26b4-a69d-495d-b41c-8c8f2f634917" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4aeb341d-6c2b-42ef-b326-f621165e1de6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c630d95f-caa6-440f-8ae4-b00a2aca1412" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4aeb341d-6c2b-42ef-b326-f621165e1de6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4aeb341d-6c2b-42ef-b326-f621165e1de6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4aeb341d-6c2b-42ef-b326-f621165e1de6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4aeb341d-6c2b-42ef-b326-f621165e1de6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9f5f3917-9c9e-48bf-a343-a75cd27627e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4aeb341d-6c2b-42ef-b326-f621165e1de6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9f5f3917-9c9e-48bf-a343-a75cd27627e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MomentaMember_297eec50-85f7-4ffb-9893-35ab2628a88a" xlink:href="jnj-20241229.xsd#jnj_MomentaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9f5f3917-9c9e-48bf-a343-a75cd27627e8" xlink:to="loc_jnj_MomentaMember_297eec50-85f7-4ffb-9893-35ab2628a88a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_6c6cd960-eadf-4ceb-a450-90184cc0abdf" xlink:href="jnj-20241229.xsd#jnj_BermekimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9f5f3917-9c9e-48bf-a343-a75cd27627e8" xlink:to="loc_jnj_BermekimabMember_6c6cd960-eadf-4ceb-a450-90184cc0abdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_40975445-a1fe-4dba-ad26-07711919b8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c630d95f-caa6-440f-8ae4-b00a2aca1412" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_40975445-a1fe-4dba-ad26-07711919b8a7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_40975445-a1fe-4dba-ad26-07711919b8a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_40975445-a1fe-4dba-ad26-07711919b8a7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_40975445-a1fe-4dba-ad26-07711919b8a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cc164b41-ffff-4ed1-b841-71adc4cfadfe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_40975445-a1fe-4dba-ad26-07711919b8a7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cc164b41-ffff-4ed1-b841-71adc4cfadfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_e1b42d65-79c5-430c-b335-fc8bf2282ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cc164b41-ffff-4ed1-b841-71adc4cfadfe" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_e1b42d65-79c5-430c-b335-fc8bf2282ceb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2e9a913e-a203-4276-bcbc-1cdcb870a291" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c630d95f-caa6-440f-8ae4-b00a2aca1412" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2e9a913e-a203-4276-bcbc-1cdcb870a291" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2e9a913e-a203-4276-bcbc-1cdcb870a291_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2e9a913e-a203-4276-bcbc-1cdcb870a291" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2e9a913e-a203-4276-bcbc-1cdcb870a291_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7932a357-0f58-43d4-a3e2-d0b7a205bcd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2e9a913e-a203-4276-bcbc-1cdcb870a291" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7932a357-0f58-43d4-a3e2-d0b7a205bcd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember_7e04d3f6-66d9-49e7-95b4-b6db35af43ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7932a357-0f58-43d4-a3e2-d0b7a205bcd5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentMember_7e04d3f6-66d9-49e7-95b4-b6db35af43ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_48fe5add-dfe5-4f05-8a7b-6a8649bb10cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7932a357-0f58-43d4-a3e2-d0b7a205bcd5" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_48fe5add-dfe5-4f05-8a7b-6a8649bb10cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6482bb05-4c87-4587-a362-7090f8ff4733" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6482bb05-4c87-4587-a362-7090f8ff4733" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_2c04fa66-c70e-4ec0-9fdf-a2d49bb351cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_NoncurrentAssets_2c04fa66-c70e-4ec0-9fdf-a2d49bb351cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_2de2441f-19f3-4daf-b40e-a1b785e7b8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_2de2441f-19f3-4daf-b40e-a1b785e7b8dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonLongLivedAssets_5eb1fd4c-fe8f-4d8f-b0c1-6074035d3a81" xlink:href="jnj-20241229.xsd#jnj_OtherNonLongLivedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_jnj_OtherNonLongLivedAssets_5eb1fd4c-fe8f-4d8f-b0c1-6074035d3a81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_873410cb-d0c3-4aba-ba6d-e4e981c2c0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_Assets_873410cb-d0c3-4aba-ba6d-e4e981c2c0ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b908567c-56be-4af2-b986-ae78548ddd3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b908567c-56be-4af2-b986-ae78548ddd3e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_3a055d66-548d-478d-bc58-4201a1136923" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_NumberOfOperatingSegments_3a055d66-548d-478d-bc58-4201a1136923" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyLossInPeriod_cf03d51d-b174-4d93-97f4-ce428926534d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyLossInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_LossContingencyLossInPeriod_cf03d51d-b174-4d93-97f4-ce428926534d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_59fb67c5-243a-4d41-beaf-51faea121d93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_59fb67c5-243a-4d41-beaf-51faea121d93" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_b4e5b0b3-b285-4ddf-b353-fb321bddecde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SuppliesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_SuppliesExpense_b4e5b0b3-b285-4ddf-b353-fb321bddecde" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_8c56270f-c296-46b9-afe6-cbb8b30debdc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_RestructuringCharges_8c56270f-c296-46b9-afe6-cbb8b30debdc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_3237b000-d3d9-4d7e-b833-b9071abc5815" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_3237b000-d3d9-4d7e-b833-b9071abc5815" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_6fd08082-be5d-44f2-a3ce-be0595c711a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_6fd08082-be5d-44f2-a3ce-be0595c711a6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_910e1ed8-4c9f-4b2d-9c8f-840b28221333" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_910e1ed8-4c9f-4b2d-9c8f-840b28221333" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_e681d6cf-f0d8-4850-8fe5-6ce73bb44117" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_e681d6cf-f0d8-4850-8fe5-6ce73bb44117" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquisitionCosts_271a3ded-644a-43a1-a4c2-1b0d5258fdca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquisitionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_AcquisitionCosts_271a3ded-644a-43a1-a4c2-1b0d5258fdca" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RegulationCharge_a2f7f529-bb46-4147-ac41-5e0fd3473ef4" xlink:href="jnj-20241229.xsd#jnj_RegulationCharge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_jnj_RegulationCharge_a2f7f529-bb46-4147-ac41-5e0fd3473ef4" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_e71c5fd4-8def-4e0c-bbbe-af3ac9997e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_LitigationSettlementExpense_e71c5fd4-8def-4e0c-bbbe-af3ac9997e6d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentInProcess1_9f9e5555-c23c-4c84-828f-2e42d5ba9b40" xlink:href="jnj-20241229.xsd#jnj_ResearchAndDevelopmentInProcess1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_jnj_ResearchAndDevelopmentInProcess1_9f9e5555-c23c-4c84-828f-2e42d5ba9b40" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_6021ee74-5fe8-46c4-aca3-55a9a3cd12e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_6021ee74-5fe8-46c4-aca3-55a9a3cd12e2" xlink:type="arc" order="19"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#AcquisitionsanddivestituresNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54774428-3abb-43b2-85e8-bb4805809cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54774428-3abb-43b2-85e8-bb4805809cc0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dbc0db2b-3502-48a9-9fdb-041bc6d41463" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54774428-3abb-43b2-85e8-bb4805809cc0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dbc0db2b-3502-48a9-9fdb-041bc6d41463" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dbc0db2b-3502-48a9-9fdb-041bc6d41463_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dbc0db2b-3502-48a9-9fdb-041bc6d41463" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dbc0db2b-3502-48a9-9fdb-041bc6d41463_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7a407c0d-1e0c-4cab-a6e9-c0adc62e8e98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dbc0db2b-3502-48a9-9fdb-041bc6d41463" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7a407c0d-1e0c-4cab-a6e9-c0adc62e8e98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IntraCellularTherapiesInc.Member_bfc55020-85d8-4d94-8f17-936b0c214a4d" xlink:href="jnj-20241229.xsd#jnj_IntraCellularTherapiesInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7a407c0d-1e0c-4cab-a6e9-c0adc62e8e98" xlink:to="loc_jnj_IntraCellularTherapiesInc.Member_bfc55020-85d8-4d94-8f17-936b0c214a4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AmbrxMember_9d9d8e3f-ff4e-4764-87f7-857292fe5d42" xlink:href="jnj-20241229.xsd#jnj_AmbrxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7a407c0d-1e0c-4cab-a6e9-c0adc62e8e98" xlink:to="loc_jnj_AmbrxMember_9d9d8e3f-ff4e-4764-87f7-857292fe5d42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AbiomedMember_ad39807b-a556-4500-ba64-955a25d552e7" xlink:href="jnj-20241229.xsd#jnj_AbiomedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7a407c0d-1e0c-4cab-a6e9-c0adc62e8e98" xlink:to="loc_jnj_AbiomedMember_ad39807b-a556-4500-ba64-955a25d552e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProteologixMember_d3c32c88-bacc-425e-9966-2678f7dce0eb" xlink:href="jnj-20241229.xsd#jnj_ProteologixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7a407c0d-1e0c-4cab-a6e9-c0adc62e8e98" xlink:to="loc_jnj_ProteologixMember_d3c32c88-bacc-425e-9966-2678f7dce0eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShockwaveMedicalInc.Member_ea214221-5770-46ab-8879-32f6f60f8b68" xlink:href="jnj-20241229.xsd#jnj_ShockwaveMedicalInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7a407c0d-1e0c-4cab-a6e9-c0adc62e8e98" xlink:to="loc_jnj_ShockwaveMedicalInc.Member_ea214221-5770-46ab-8879-32f6f60f8b68" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2110c786-56b9-4d1e-95d9-7cfd56f1b7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54774428-3abb-43b2-85e8-bb4805809cc0" xlink:to="loc_us-gaap_AwardTypeAxis_2110c786-56b9-4d1e-95d9-7cfd56f1b7d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2110c786-56b9-4d1e-95d9-7cfd56f1b7d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2110c786-56b9-4d1e-95d9-7cfd56f1b7d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2110c786-56b9-4d1e-95d9-7cfd56f1b7d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d611f546-84fa-4ec3-8130-82d9f5cb8eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2110c786-56b9-4d1e-95d9-7cfd56f1b7d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d611f546-84fa-4ec3-8130-82d9f5cb8eb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NonTradeableContingentValueRightMember_50ef8cfb-45b0-4070-8d9a-a3ac06b1bb65" xlink:href="jnj-20241229.xsd#jnj_NonTradeableContingentValueRightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d611f546-84fa-4ec3-8130-82d9f5cb8eb5" xlink:to="loc_jnj_NonTradeableContingentValueRightMember_50ef8cfb-45b0-4070-8d9a-a3ac06b1bb65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1a0528b1-d49f-4c7e-aa79-c5062038a322" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54774428-3abb-43b2-85e8-bb4805809cc0" xlink:to="loc_srt_ProductOrServiceAxis_1a0528b1-d49f-4c7e-aa79-c5062038a322" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1a0528b1-d49f-4c7e-aa79-c5062038a322_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1a0528b1-d49f-4c7e-aa79-c5062038a322" xlink:to="loc_srt_ProductsAndServicesDomain_1a0528b1-d49f-4c7e-aa79-c5062038a322_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8b51e424-4496-4aa8-8737-c922bff076ba" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1a0528b1-d49f-4c7e-aa79-c5062038a322" xlink:to="loc_srt_ProductsAndServicesDomain_8b51e424-4496-4aa8-8737-c922bff076ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImpellaMember_50ed3c39-832a-4b7b-b81c-a065c67f6353" xlink:href="jnj-20241229.xsd#jnj_ImpellaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8b51e424-4496-4aa8-8737-c922bff076ba" xlink:to="loc_jnj_ImpellaMember_50ed3c39-832a-4b7b-b81c-a065c67f6353" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ClassIRecommendationForImpellaMember_af511b61-fa61-4aed-8a94-8a26a65d1f0e" xlink:href="jnj-20241229.xsd#jnj_ClassIRecommendationForImpellaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8b51e424-4496-4aa8-8737-c922bff076ba" xlink:to="loc_jnj_ClassIRecommendationForImpellaMember_af511b61-fa61-4aed-8a94-8a26a65d1f0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bdf67248-fa1f-4c42-afe9-058a068e76c5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54774428-3abb-43b2-85e8-bb4805809cc0" xlink:to="loc_srt_RangeAxis_bdf67248-fa1f-4c42-afe9-058a068e76c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bdf67248-fa1f-4c42-afe9-058a068e76c5_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bdf67248-fa1f-4c42-afe9-058a068e76c5" xlink:to="loc_srt_RangeMember_bdf67248-fa1f-4c42-afe9-058a068e76c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0df9fdb0-774d-432b-b455-e5290ead7cd5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bdf67248-fa1f-4c42-afe9-058a068e76c5" xlink:to="loc_srt_RangeMember_0df9fdb0-774d-432b-b455-e5290ead7cd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a0fd23a7-94fc-40cc-a057-e1e52d632835" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0df9fdb0-774d-432b-b455-e5290ead7cd5" xlink:to="loc_srt_MinimumMember_a0fd23a7-94fc-40cc-a057-e1e52d632835" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7be4c5af-e7c3-4ef0-b945-c76d28139592" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0df9fdb0-774d-432b-b455-e5290ead7cd5" xlink:to="loc_srt_MaximumMember_7be4c5af-e7c3-4ef0-b945-c76d28139592" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_11fbc227-5398-44f9-aa69-015f68a24a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54774428-3abb-43b2-85e8-bb4805809cc0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_11fbc227-5398-44f9-aa69-015f68a24a8d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_11fbc227-5398-44f9-aa69-015f68a24a8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_11fbc227-5398-44f9-aa69-015f68a24a8d" xlink:to="loc_us-gaap_SegmentDomain_11fbc227-5398-44f9-aa69-015f68a24a8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fb8dfcbb-ae28-4d74-a6bd-1421a6b566da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_11fbc227-5398-44f9-aa69-015f68a24a8d" xlink:to="loc_us-gaap_SegmentDomain_fb8dfcbb-ae28-4d74-a6bd-1421a6b566da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedTechMember_68764d95-7d9b-4284-bb8f-12a0b952353c" xlink:href="jnj-20241229.xsd#jnj_MedTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_fb8dfcbb-ae28-4d74-a6bd-1421a6b566da" xlink:to="loc_jnj_MedTechMember_68764d95-7d9b-4284-bb8f-12a0b952353c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_b0fd238c-9bda-4ca0-aeb0-97b38cff4355" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54774428-3abb-43b2-85e8-bb4805809cc0" xlink:to="loc_us-gaap_AssetAcquisitionAxis_b0fd238c-9bda-4ca0-aeb0-97b38cff4355" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_b0fd238c-9bda-4ca0-aeb0-97b38cff4355_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_b0fd238c-9bda-4ca0-aeb0-97b38cff4355" xlink:to="loc_us-gaap_AssetAcquisitionDomain_b0fd238c-9bda-4ca0-aeb0-97b38cff4355_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_7ade26bb-446e-40d8-8ef8-4f5c4387dfaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_b0fd238c-9bda-4ca0-aeb0-97b38cff4355" xlink:to="loc_us-gaap_AssetAcquisitionDomain_7ade26bb-446e-40d8-8ef8-4f5c4387dfaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VWaveLtd.Member_365be1ff-53dc-428d-a872-79324ac8c196" xlink:href="jnj-20241229.xsd#jnj_VWaveLtd.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_7ade26bb-446e-40d8-8ef8-4f5c4387dfaf" xlink:to="loc_jnj_VWaveLtd.Member_365be1ff-53dc-428d-a872-79324ac8c196" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_YellowJerseyTherapeuticsMember_d54f39dc-6f65-42c3-a333-c8cf6ec2871d" xlink:href="jnj-20241229.xsd#jnj_YellowJerseyTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_7ade26bb-446e-40d8-8ef8-4f5c4387dfaf" xlink:to="loc_jnj_YellowJerseyTherapeuticsMember_d54f39dc-6f65-42c3-a333-c8cf6ec2871d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LaminarMember_89e23a4b-583c-4d9c-b7fd-2a3f2c8dbc3b" xlink:href="jnj-20241229.xsd#jnj_LaminarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_7ade26bb-446e-40d8-8ef8-4f5c4387dfaf" xlink:to="loc_jnj_LaminarMember_89e23a4b-583c-4d9c-b7fd-2a3f2c8dbc3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_398cd435-6c9d-4de1-9129-40790aa0a94f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54774428-3abb-43b2-85e8-bb4805809cc0" xlink:to="loc_srt_StatementScenarioAxis_398cd435-6c9d-4de1-9129-40790aa0a94f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_398cd435-6c9d-4de1-9129-40790aa0a94f_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_398cd435-6c9d-4de1-9129-40790aa0a94f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_398cd435-6c9d-4de1-9129-40790aa0a94f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2c784572-ae83-427d-9a6b-1c6aab9631eb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_398cd435-6c9d-4de1-9129-40790aa0a94f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2c784572-ae83-427d-9a6b-1c6aab9631eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_13484551-8ade-41a7-aba6-d3fbb69f007d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_2c784572-ae83-427d-9a6b-1c6aab9631eb" xlink:to="loc_srt_ScenarioForecastMember_13484551-8ade-41a7-aba6-d3fbb69f007d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_129111b2-755d-449c-865a-92faa4352193" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54774428-3abb-43b2-85e8-bb4805809cc0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_129111b2-755d-449c-865a-92faa4352193" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_129111b2-755d-449c-865a-92faa4352193_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_129111b2-755d-449c-865a-92faa4352193" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_129111b2-755d-449c-865a-92faa4352193_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0c563c41-0555-4655-9319-7a8a82226a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_129111b2-755d-449c-865a-92faa4352193" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0c563c41-0555-4655-9319-7a8a82226a3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AcclarentMember_fcf8637f-3bad-43ea-a035-461934dad4c8" xlink:href="jnj-20241229.xsd#jnj_AcclarentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0c563c41-0555-4655-9319-7a8a82226a3a" xlink:to="loc_jnj_AcclarentMember_fcf8637f-3bad-43ea-a035-461934dad4c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PonvoryMember_9b3bc2be-165a-43c4-93ba-806df2bb419f" xlink:href="jnj-20241229.xsd#jnj_PonvoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0c563c41-0555-4655-9319-7a8a82226a3a" xlink:to="loc_jnj_PonvoryMember_9b3bc2be-165a-43c4-93ba-806df2bb419f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_7516a3a4-2a8f-4ce4-a4f8-e833975e0b85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_7516a3a4-2a8f-4ce4-a4f8-e833975e0b85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_eb268843-ca22-4a4f-b953-205df918e437" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_eb268843-ca22-4a4f-b953-205df918e437" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_b4e95ff0-92ad-4a90-912a-df0be20e39fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_b4e95ff0-92ad-4a90-912a-df0be20e39fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_39492d53-91c1-4d6e-a056-6fb71dbe9cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_39492d53-91c1-4d6e-a056-6fb71dbe9cb5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a951f277-4bf0-4e5a-812d-57678ed11f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a951f277-4bf0-4e5a-812d-57678ed11f4a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_2d9ca2fd-d95d-432e-ab8b-901ff9bea442" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_2d9ca2fd-d95d-432e-ab8b-901ff9bea442" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_f47fe42f-75d2-4dcb-ab0e-717d8a576ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_f47fe42f-75d2-4dcb-ab0e-717d8a576ad0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_7c45f03c-96ea-4b8d-b542-0a39559b8162" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_7c45f03c-96ea-4b8d-b542-0a39559b8162" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7a055add-3e54-4784-849d-1546f07c5e92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7a055add-3e54-4784-849d-1546f07c5e92" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor_1d46a24b-7de6-4ab1-a6fb-253f959c75d2" xlink:href="jnj-20241229.xsd#jnj_BusinessCombinationProbabilityOfSuccessFactor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor_1d46a24b-7de6-4ab1-a6fb-253f959c75d2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessAcquisitionDiscountRate_ad36c372-69e2-4e4b-86ba-274aa15d9eea" xlink:href="jnj-20241229.xsd#jnj_BusinessAcquisitionDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_jnj_BusinessAcquisitionDiscountRate_ad36c372-69e2-4e4b-86ba-274aa15d9eea" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_1cae34c7-4880-4859-9cbc-1c9301ce9cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_1cae34c7-4880-4859-9cbc-1c9301ce9cf1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss_cf7802c7-09f7-4ee1-94e4-acd14ff98ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss_cf7802c7-09f7-4ee1-94e4-acd14ff98ebd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationAcquisitionRelatedCostsEquityAwards_2b830a0d-c716-4fcf-909c-fdc727bea7dd" xlink:href="jnj-20241229.xsd#jnj_BusinessCombinationAcquisitionRelatedCostsEquityAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_jnj_BusinessCombinationAcquisitionRelatedCostsEquityAwards_2b830a0d-c716-4fcf-909c-fdc727bea7dd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_1778651a-ee8e-48d2-8d7e-31b629f4788f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_1778651a-ee8e-48d2-8d7e-31b629f4788f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight_bbef3ed1-58b7-403f-b051-f4c6cece7c4d" xlink:href="jnj-20241229.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight_bbef3ed1-58b7-403f-b051-f4c6cece7c4d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight_64a7ca1c-3605-4d10-8909-6054dab20301" xlink:href="jnj-20241229.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight_64a7ca1c-3605-4d10-8909-6054dab20301" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c0f3db88-5429-47c8-aec1-11a870456b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c0f3db88-5429-47c8-aec1-11a870456b9a" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableAmountPerShare_db5c44d1-835f-4dba-8ea6-27d7866641f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPayableAmountPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_DividendsPayableAmountPerShare_db5c44d1-835f-4dba-8ea6-27d7866641f9" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RevenuesContingentConsideration_6a33025f-765e-458a-b903-4ea4657d86ad" xlink:href="jnj-20241229.xsd#jnj_RevenuesContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_jnj_RevenuesContingentConsideration_6a33025f-765e-458a-b903-4ea4657d86ad" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_ed457371-f456-4ae2-b970-c79f68d4e27c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_ed457371-f456-4ae2-b970-c79f68d4e27c" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_b3a4f590-ba6a-4993-a1cf-280ed734c408" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_b3a4f590-ba6a-4993-a1cf-280ed734c408" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentInProcess1_27ecbd54-52b5-4bf2-8a77-68529693ef71" xlink:href="jnj-20241229.xsd#jnj_ResearchAndDevelopmentInProcess1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_jnj_ResearchAndDevelopmentInProcess1_27ecbd54-52b5-4bf2-8a77-68529693ef71" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_cbc8e63b-6e3c-409a-9a49-5b514430f099" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_cbc8e63b-6e3c-409a-9a49-5b514430f099" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a4bf4ef2-e616-4901-a2bc-0aecff0fd818" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a4bf4ef2-e616-4901-a2bc-0aecff0fd818" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1efeb97e-31fc-4e89-9e68-84cd4661a4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1efeb97e-31fc-4e89-9e68-84cd4661a4bb" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_1045e06b-a5f6-481f-86d7-160fa76e7576" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_1045e06b-a5f6-481f-86d7-160fa76e7576" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquisitionCosts_9dd48566-c380-4a6a-8a66-60bc069dbd80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquisitionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_AcquisitionCosts_9dd48566-c380-4a6a-8a66-60bc069dbd80" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_c87f440b-9d13-47ac-ab67-8f93c2c2877a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_c87f440b-9d13-47ac-ab67-8f93c2c2877a" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill_ce5421b1-471a-41cc-aa78-3f0d2b169529" xlink:href="jnj-20241229.xsd#jnj_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_jnj_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill_ce5421b1-471a-41cc-aa78-3f0d2b169529" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_f46e9973-d963-44e3-8cd9-08b1e703e152" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_f46e9973-d963-44e3-8cd9-08b1e703e152" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_22d70269-6c92-401f-a5af-ccb7cdf32516" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_22d70269-6c92-401f-a5af-ccb7cdf32516" xlink:type="arc" order="31"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsanddivestituresDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#AcquisitionsanddivestituresDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/AcquisitionsanddivestituresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_141cb0ee-b0b2-427b-b245-0da0b19234e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d74a5106-a91a-4b9b-8bbe-73a8ac7857d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_141cb0ee-b0b2-427b-b245-0da0b19234e0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d74a5106-a91a-4b9b-8bbe-73a8ac7857d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5b1e0f6c-f744-4c9f-9171-cc696a8df4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d74a5106-a91a-4b9b-8bbe-73a8ac7857d6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5b1e0f6c-f744-4c9f-9171-cc696a8df4ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5b1e0f6c-f744-4c9f-9171-cc696a8df4ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5b1e0f6c-f744-4c9f-9171-cc696a8df4ff" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5b1e0f6c-f744-4c9f-9171-cc696a8df4ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31d789ce-0d43-4d04-8f40-9e353e637334" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5b1e0f6c-f744-4c9f-9171-cc696a8df4ff" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31d789ce-0d43-4d04-8f40-9e353e637334" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShockwaveMedicalInc.Member_79f8c95a-1715-43d0-8e35-9d1b06c3f18e" xlink:href="jnj-20241229.xsd#jnj_ShockwaveMedicalInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31d789ce-0d43-4d04-8f40-9e353e637334" xlink:to="loc_jnj_ShockwaveMedicalInc.Member_79f8c95a-1715-43d0-8e35-9d1b06c3f18e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_0fcebeca-6271-4dd3-87ad-47138ef8b8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_141cb0ee-b0b2-427b-b245-0da0b19234e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_0fcebeca-6271-4dd3-87ad-47138ef8b8dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6d999bec-4d59-4853-9c01-c38445ccc5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_0fcebeca-6271-4dd3-87ad-47138ef8b8dd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6d999bec-4d59-4853-9c01-c38445ccc5d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0b392e60-9719-44bc-991a-e3a5e302845e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_0fcebeca-6271-4dd3-87ad-47138ef8b8dd" xlink:to="loc_us-gaap_Goodwill_0b392e60-9719-44bc-991a-e3a5e302845e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_e876de16-844d-494d-9122-6267d3798250" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_0fcebeca-6271-4dd3-87ad-47138ef8b8dd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_e876de16-844d-494d-9122-6267d3798250" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_75e17cf5-9457-48e5-9d81-d1f5cf51c0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_0fcebeca-6271-4dd3-87ad-47138ef8b8dd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_75e17cf5-9457-48e5-9d81-d1f5cf51c0f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_022ecec2-2beb-43c3-b89e-39caa1795ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_0fcebeca-6271-4dd3-87ad-47138ef8b8dd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_022ecec2-2beb-43c3-b89e-39caa1795ae0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_cde6adaa-e862-40a9-98e4-464ee6e64dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_0fcebeca-6271-4dd3-87ad-47138ef8b8dd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_cde6adaa-e862-40a9-98e4-464ee6e64dd4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_779c4475-b11b-4dd2-94a7-7a20ce1144a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_0fcebeca-6271-4dd3-87ad-47138ef8b8dd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_779c4475-b11b-4dd2-94a7-7a20ce1144a1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4a0e78aa-b3b2-4289-b9d9-a1cfe86252cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_141cb0ee-b0b2-427b-b245-0da0b19234e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4a0e78aa-b3b2-4289-b9d9-a1cfe86252cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_99d22bbe-1dad-455d-bae2-54f578c97e47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4a0e78aa-b3b2-4289-b9d9-a1cfe86252cb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_99d22bbe-1dad-455d-bae2-54f578c97e47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_a2289227-e53b-4b30-a7c8-122a811415aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4a0e78aa-b3b2-4289-b9d9-a1cfe86252cb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_a2289227-e53b-4b30-a7c8-122a811415aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_385eaacd-a2ce-4d57-bb03-1ed81f431be9" xlink:href="jnj-20241229.xsd#jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4a0e78aa-b3b2-4289-b9d9-a1cfe86252cb" xlink:to="loc_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_385eaacd-a2ce-4d57-bb03-1ed81f431be9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_589a5415-7b19-4ae6-a5db-d9295cdcaae0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4a0e78aa-b3b2-4289-b9d9-a1cfe86252cb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_589a5415-7b19-4ae6-a5db-d9295cdcaae0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0e71c4de-1b0d-4eea-b608-afbeb887bc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_141cb0ee-b0b2-427b-b245-0da0b19234e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0e71c4de-1b0d-4eea-b608-afbeb887bc9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6b8dfde6-600a-4f5a-9a09-825822e07055" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationSettlementOfEquityAwards_8a7c55fd-03e0-4970-bc1b-fa2df0272a16" xlink:href="jnj-20241229.xsd#jnj_BusinessCombinationSettlementOfEquityAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_141cb0ee-b0b2-427b-b245-0da0b19234e0" xlink:to="loc_jnj_BusinessCombinationSettlementOfEquityAwards_8a7c55fd-03e0-4970-bc1b-fa2df0272a16" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationSettlementOfNotesPayable_a391c6fb-7078-4b31-9fc9-f0956de5769f" xlink:href="jnj-20241229.xsd#jnj_BusinessCombinationSettlementOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_141cb0ee-b0b2-427b-b245-0da0b19234e0" xlink:to="loc_jnj_BusinessCombinationSettlementOfNotesPayable_a391c6fb-7078-4b31-9fc9-f0956de5769f" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalproceedingsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#LegalproceedingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/LegalproceedingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_ce157f2f-d760-40ac-9bf4-0e45e2f6e31e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_36f9f607-99d3-47e0-ac87-48e1994f539e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_ce157f2f-d760-40ac-9bf4-0e45e2f6e31e" xlink:to="loc_us-gaap_LossContingenciesTable_36f9f607-99d3-47e0-ac87-48e1994f539e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_865cb276-fd22-4955-ad4f-33d35581e791" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_36f9f607-99d3-47e0-ac87-48e1994f539e" xlink:to="loc_srt_LitigationCaseAxis_865cb276-fd22-4955-ad4f-33d35581e791" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_865cb276-fd22-4955-ad4f-33d35581e791_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_865cb276-fd22-4955-ad4f-33d35581e791" xlink:to="loc_srt_LitigationCaseTypeDomain_865cb276-fd22-4955-ad4f-33d35581e791_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c277515a-30ea-4b0f-8671-7652552bc54f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_865cb276-fd22-4955-ad4f-33d35581e791" xlink:to="loc_srt_LitigationCaseTypeDomain_c277515a-30ea-4b0f-8671-7652552bc54f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member_89690888-3790-4ab5-b276-e0ff93be6a63" xlink:href="jnj-20241229.xsd#jnj_DePuyASRU.S.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_c277515a-30ea-4b0f-8671-7652552bc54f" xlink:to="loc_jnj_DePuyASRU.S.Member_89690888-3790-4ab5-b276-e0ff93be6a63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_b91b11b8-1b67-4c4b-9484-d30bfada6fb2" xlink:href="jnj-20241229.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_c277515a-30ea-4b0f-8671-7652552bc54f" xlink:to="loc_jnj_RisperdalMember_b91b11b8-1b67-4c4b-9484-d30bfada6fb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember_bf78d625-d262-4d0e-be00-55ad2bb19414" xlink:href="jnj-20241229.xsd#jnj_BabyPowderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_c277515a-30ea-4b0f-8671-7652552bc54f" xlink:to="loc_jnj_BabyPowderMember_bf78d625-d262-4d0e-be00-55ad2bb19414" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InghamVsJohnsonJohnsonMember_c9b6e6b6-2c0e-4ea8-85e2-3ecd4373de55" xlink:href="jnj-20241229.xsd#jnj_InghamVsJohnsonJohnsonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_c277515a-30ea-4b0f-8671-7652552bc54f" xlink:to="loc_jnj_InghamVsJohnsonJohnsonMember_c9b6e6b6-2c0e-4ea8-85e2-3ecd4373de55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_c262b47f-fe6b-4f47-9b63-ce013ec497d6" xlink:href="jnj-20241229.xsd#jnj_TalcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_c277515a-30ea-4b0f-8671-7652552bc54f" xlink:to="loc_jnj_TalcMember_c262b47f-fe6b-4f47-9b63-ce013ec497d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MesotheliomaAndStateClaimsMember_ff03f9db-a96a-4ad1-a902-ab0680e60f32" xlink:href="jnj-20241229.xsd#jnj_MesotheliomaAndStateClaimsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_c277515a-30ea-4b0f-8671-7652552bc54f" xlink:to="loc_jnj_MesotheliomaAndStateClaimsMember_ff03f9db-a96a-4ad1-a902-ab0680e60f32" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_8e3cdf27-4a0e-462b-83fc-e1621e34bb33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_36f9f607-99d3-47e0-ac87-48e1994f539e" xlink:to="loc_us-gaap_LitigationStatusAxis_8e3cdf27-4a0e-462b-83fc-e1621e34bb33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_8e3cdf27-4a0e-462b-83fc-e1621e34bb33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_8e3cdf27-4a0e-462b-83fc-e1621e34bb33" xlink:to="loc_us-gaap_LitigationStatusDomain_8e3cdf27-4a0e-462b-83fc-e1621e34bb33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_97c8bab2-25b8-4a4f-a082-27a71a3a5746" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_8e3cdf27-4a0e-462b-83fc-e1621e34bb33" xlink:to="loc_us-gaap_LitigationStatusDomain_97c8bab2-25b8-4a4f-a082-27a71a3a5746" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_f4769c56-23f8-4bbb-9e7e-795dd27e15c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_97c8bab2-25b8-4a4f-a082-27a71a3a5746" xlink:to="loc_us-gaap_SettledLitigationMember_f4769c56-23f8-4bbb-9e7e-795dd27e15c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember_f7f264f7-cf57-437c-8993-55dfbecdd64b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_JudicialRulingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_97c8bab2-25b8-4a4f-a082-27a71a3a5746" xlink:to="loc_us-gaap_JudicialRulingMember_f7f264f7-cf57-437c-8993-55dfbecdd64b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_f4fcfdb4-877b-4401-b99c-fae272cf5262" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_97c8bab2-25b8-4a4f-a082-27a71a3a5746" xlink:to="loc_us-gaap_PendingLitigationMember_f4fcfdb4-877b-4401-b99c-fae272cf5262" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_492b104c-987a-40e2-bd93-ce0edb91c92a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_36f9f607-99d3-47e0-ac87-48e1994f539e" xlink:to="loc_srt_ProductOrServiceAxis_492b104c-987a-40e2-bd93-ce0edb91c92a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_492b104c-987a-40e2-bd93-ce0edb91c92a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_492b104c-987a-40e2-bd93-ce0edb91c92a" xlink:to="loc_srt_ProductsAndServicesDomain_492b104c-987a-40e2-bd93-ce0edb91c92a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e4fbd921-634d-46ed-9959-b7d4545288e9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_492b104c-987a-40e2-bd93-ce0edb91c92a" xlink:to="loc_srt_ProductsAndServicesDomain_e4fbd921-634d-46ed-9959-b7d4545288e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_865ae58a-862e-4958-a606-c5a654f62342" xlink:href="jnj-20241229.xsd#jnj_TalcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e4fbd921-634d-46ed-9959-b7d4545288e9" xlink:to="loc_jnj_TalcMember_865ae58a-862e-4958-a606-c5a654f62342" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpioidMember_b93fdbea-4736-4cd5-9bf4-cbdad5766a28" xlink:href="jnj-20241229.xsd#jnj_OpioidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e4fbd921-634d-46ed-9959-b7d4545288e9" xlink:to="loc_jnj_OpioidMember_b93fdbea-4736-4cd5-9bf4-cbdad5766a28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember_37bf955b-f1c1-449d-8ae8-6d0f2f20d870" xlink:href="jnj-20241229.xsd#jnj_PhysiomeshMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e4fbd921-634d-46ed-9959-b7d4545288e9" xlink:to="loc_jnj_PhysiomeshMember_37bf955b-f1c1-449d-8ae8-6d0f2f20d870" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesAxis_6ec00df4-69fb-47fb-9261-393c7d78a06d" xlink:href="jnj-20241229.xsd#jnj_LitigationSettlementByCompaniesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_36f9f607-99d3-47e0-ac87-48e1994f539e" xlink:to="loc_jnj_LitigationSettlementByCompaniesAxis_6ec00df4-69fb-47fb-9261-393c7d78a06d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain_6ec00df4-69fb-47fb-9261-393c7d78a06d_default" xlink:href="jnj-20241229.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis_6ec00df4-69fb-47fb-9261-393c7d78a06d" xlink:to="loc_jnj_LitigationSettlementByCompaniesDomain_6ec00df4-69fb-47fb-9261-393c7d78a06d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain_b4a1c846-970d-4469-a372-c29dff0ac9e3" xlink:href="jnj-20241229.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis_6ec00df4-69fb-47fb-9261-393c7d78a06d" xlink:to="loc_jnj_LitigationSettlementByCompaniesDomain_b4a1c846-970d-4469-a372-c29dff0ac9e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_b31300d2-aec5-4fd0-bf11-afe5deb372ee" xlink:href="jnj-20241229.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LitigationSettlementByCompaniesDomain_b4a1c846-970d-4469-a372-c29dff0ac9e3" xlink:to="loc_jnj_RisperdalMember_b31300d2-aec5-4fd0-bf11-afe5deb372ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:href="jnj-20241229.xsd#jnj_LegalProceedingTextualsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ce157f2f-d760-40ac-9bf4-0e45e2f6e31e" xlink:to="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_cb0d773b-6c5a-40f7-9317-dfaee6d5dd20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_cb0d773b-6c5a-40f7-9317-dfaee6d5dd20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_ddf97f95-2858-4f5c-989e-03b2c5cdde56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesPaidValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_us-gaap_LossContingencyDamagesPaidValue_ddf97f95-2858-4f5c-989e-03b2c5cdde56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyPaymentPeriod_49c586b7-4bb8-4a7e-a5ac-a32063d79459" xlink:href="jnj-20241229.xsd#jnj_LossContingencyPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_jnj_LossContingencyPaymentPeriod_49c586b7-4bb8-4a7e-a5ac-a32063d79459" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencySolicitationPeriod_dbca34f1-eccb-4efa-9a28-ea79ccaba706" xlink:href="jnj-20241229.xsd#jnj_LossContingencySolicitationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_jnj_LossContingencySolicitationPeriod_dbca34f1-eccb-4efa-9a28-ea79ccaba706" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_c1774bfe-bbfd-4eef-ba38-823cfd990bca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_c1774bfe-bbfd-4eef-ba38-823cfd990bca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyDamagesSoughtNominalValue_507086da-a009-48c2-b65b-ed4089e97701" xlink:href="jnj-20241229.xsd#jnj_LossContingencyDamagesSoughtNominalValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_jnj_LossContingencyDamagesSoughtNominalValue_507086da-a009-48c2-b65b-ed4089e97701" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyDiscountRate_927c11f4-d53d-4b76-bc45-5c91bc73e888" xlink:href="jnj-20241229.xsd#jnj_LossContingencyDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_jnj_LossContingencyDiscountRate_927c11f4-d53d-4b76-bc45-5c91bc73e888" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TotalClaimsAgainstCompanyPercent_fb3ff78b-8416-47dc-9faa-f765b2d48018" xlink:href="jnj-20241229.xsd#jnj_TotalClaimsAgainstCompanyPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_jnj_TotalClaimsAgainstCompanyPercent_fb3ff78b-8416-47dc-9faa-f765b2d48018" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyDamagesSoughtValueIncrease_59307d92-1159-49c0-b48c-d9cbdefbca51" xlink:href="jnj-20241229.xsd#jnj_LossContingencyDamagesSoughtValueIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_jnj_LossContingencyDamagesSoughtValueIncrease_59307d92-1159-49c0-b48c-d9cbdefbca51" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyClaimsSettledPercent_0147728e-d646-4dc0-b4c7-8eb9201c5a02" xlink:href="jnj-20241229.xsd#jnj_LossContingencyClaimsSettledPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_jnj_LossContingencyClaimsSettledPercent_0147728e-d646-4dc0-b4c7-8eb9201c5a02" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_5a354d7b-9474-49fc-9f31-05a1074deeeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_5a354d7b-9474-49fc-9f31-05a1074deeeb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyAccrualNominalValue_92074917-6fa8-4bac-b019-e1c7ae4b310a" xlink:href="jnj-20241229.xsd#jnj_LossContingencyAccrualNominalValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_jnj_LossContingencyAccrualNominalValue_92074917-6fa8-4bac-b019-e1c7ae4b310a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_6e431a91-8681-4ca5-b9c2-62efeee0eb93" xlink:href="jnj-20241229.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_6e431a91-8681-4ca5-b9c2-62efeee0eb93" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_abfa2e5b-0234-4bd2-aae3-a1da943a9fab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_abfa2e5b-0234-4bd2-aae3-a1da943a9fab" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyAccrualPaymentPercentage_c1319114-4a2a-4adf-9999-69a13be1f72f" xlink:href="jnj-20241229.xsd#jnj_LossContingencyAccrualPaymentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_jnj_LossContingencyAccrualPaymentPercentage_c1319114-4a2a-4adf-9999-69a13be1f72f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_2e1556e0-87dd-446c-a7dc-1023e229c443" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_2e1556e0-87dd-446c-a7dc-1023e229c443" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement_567820cb-2622-426a-bbe8-f7d2207097fe" xlink:href="jnj-20241229.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_jnj_Numberofpatientsinsettlement_567820cb-2622-426a-bbe8-f7d2207097fe" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_7cb68e8e-3353-4475-9287-96011eb32a5a" xlink:href="jnj-20241229.xsd#jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_7cb68e8e-3353-4475-9287-96011eb32a5a" xlink:type="arc" order="18"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#LegalproceedingsProductLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_7c70f7b2-7356-4e05-aaa6-4af46519e5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_3a615421-bc7f-4793-80f3-ed877a0e48ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_7c70f7b2-7356-4e05-aaa6-4af46519e5d4" xlink:to="loc_us-gaap_LossContingenciesTable_3a615421-bc7f-4793-80f3-ed877a0e48ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_72611f4d-5b86-4419-b436-957eb6dca8fb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_3a615421-bc7f-4793-80f3-ed877a0e48ef" xlink:to="loc_srt_ProductOrServiceAxis_72611f4d-5b86-4419-b436-957eb6dca8fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_72611f4d-5b86-4419-b436-957eb6dca8fb_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_72611f4d-5b86-4419-b436-957eb6dca8fb" xlink:to="loc_srt_ProductsAndServicesDomain_72611f4d-5b86-4419-b436-957eb6dca8fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_47622451-4440-47d5-a993-4a7d7d4689fa" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_72611f4d-5b86-4419-b436-957eb6dca8fb" xlink:to="loc_srt_ProductsAndServicesDomain_47622451-4440-47d5-a993-4a7d7d4689fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_7fd45463-8bfa-4657-a7cf-1d998c5fc556" xlink:href="jnj-20241229.xsd#jnj_TalcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_47622451-4440-47d5-a993-4a7d7d4689fa" xlink:to="loc_jnj_TalcMember_7fd45463-8bfa-4657-a7cf-1d998c5fc556" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember_d1287ab5-a23d-45fe-9065-56c6b81bd4dd" xlink:href="jnj-20241229.xsd#jnj_AsrMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_47622451-4440-47d5-a993-4a7d7d4689fa" xlink:to="loc_jnj_AsrMember_d1287ab5-a23d-45fe-9065-56c6b81bd4dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember_eaf2587f-9c0f-4506-9b3f-0e80ae57ab94" xlink:href="jnj-20241229.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_47622451-4440-47d5-a993-4a7d7d4689fa" xlink:to="loc_jnj_PinnacleAcetabularCupSystemMember_eaf2587f-9c0f-4506-9b3f-0e80ae57ab94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember_7a9543a4-ac69-4355-9924-0bd52f970ff5" xlink:href="jnj-20241229.xsd#jnj_PelvicMeshesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_47622451-4440-47d5-a993-4a7d7d4689fa" xlink:to="loc_jnj_PelvicMeshesMember_7a9543a4-ac69-4355-9924-0bd52f970ff5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember_9830f3b2-5cac-48f7-8156-ebc32cc29cdd" xlink:href="jnj-20241229.xsd#jnj_PhysiomeshMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_47622451-4440-47d5-a993-4a7d7d4689fa" xlink:to="loc_jnj_PhysiomeshMember_9830f3b2-5cac-48f7-8156-ebc32cc29cdd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_debfbf00-2833-47ed-b7a5-df0bf4b12660" xlink:href="jnj-20241229.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_47622451-4440-47d5-a993-4a7d7d4689fa" xlink:to="loc_jnj_RisperdalMember_debfbf00-2833-47ed-b7a5-df0bf4b12660" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ElmironMember_6781ec63-6788-48dc-b6b2-6e9e1dfe275f" xlink:href="jnj-20241229.xsd#jnj_ElmironMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_47622451-4440-47d5-a993-4a7d7d4689fa" xlink:to="loc_jnj_ElmironMember_6781ec63-6788-48dc-b6b2-6e9e1dfe275f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_e121c872-d397-4a09-bc2e-002bec1d7e9f" xlink:href="jnj-20241229.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7c70f7b2-7356-4e05-aaa6-4af46519e5d4" xlink:to="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_e121c872-d397-4a09-bc2e-002bec1d7e9f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#RestructuringNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_21602c87-826c-4889-aa84-65a3e5677071" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b18a1275-3a48-4e87-93bf-d1ea91482446" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_21602c87-826c-4889-aa84-65a3e5677071" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b18a1275-3a48-4e87-93bf-d1ea91482446" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_6ec14e69-fe8b-4186-9665-a1fd445a8434" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b18a1275-3a48-4e87-93bf-d1ea91482446" xlink:to="loc_us-gaap_RestructuringPlanAxis_6ec14e69-fe8b-4186-9665-a1fd445a8434" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_6ec14e69-fe8b-4186-9665-a1fd445a8434_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_6ec14e69-fe8b-4186-9665-a1fd445a8434" xlink:to="loc_us-gaap_RestructuringPlanDomain_6ec14e69-fe8b-4186-9665-a1fd445a8434_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_f48b6a3e-0c47-46f8-a73c-78a77caee60a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_6ec14e69-fe8b-4186-9665-a1fd445a8434" xlink:to="loc_us-gaap_RestructuringPlanDomain_f48b6a3e-0c47-46f8-a73c-78a77caee60a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RDRestructuringPlanMember_9d1bcfa9-89bd-4d3f-bcd5-f5d38797e313" xlink:href="jnj-20241229.xsd#jnj_RDRestructuringPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_f48b6a3e-0c47-46f8-a73c-78a77caee60a" xlink:to="loc_jnj_RDRestructuringPlanMember_9d1bcfa9-89bd-4d3f-bcd5-f5d38797e313" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsRestructuringPlanMember_f7cf3816-bdd6-4487-8dff-47725b51f7f1" xlink:href="jnj-20241229.xsd#jnj_OrthopaedicsRestructuringPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_f48b6a3e-0c47-46f8-a73c-78a77caee60a" xlink:to="loc_jnj_OrthopaedicsRestructuringPlanMember_f7cf3816-bdd6-4487-8dff-47725b51f7f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2f1b9761-d5c4-447a-91c6-713977940d44" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b18a1275-3a48-4e87-93bf-d1ea91482446" xlink:to="loc_srt_RangeAxis_2f1b9761-d5c4-447a-91c6-713977940d44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2f1b9761-d5c4-447a-91c6-713977940d44_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2f1b9761-d5c4-447a-91c6-713977940d44" xlink:to="loc_srt_RangeMember_2f1b9761-d5c4-447a-91c6-713977940d44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d0971921-edb2-4cdb-8fcc-dc16f91442f1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2f1b9761-d5c4-447a-91c6-713977940d44" xlink:to="loc_srt_RangeMember_d0971921-edb2-4cdb-8fcc-dc16f91442f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1b3ef1c2-a073-4e5f-b125-a0be47d28e95" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d0971921-edb2-4cdb-8fcc-dc16f91442f1" xlink:to="loc_srt_MinimumMember_1b3ef1c2-a073-4e5f-b125-a0be47d28e95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c38a9bdb-f4b3-4dbc-813f-4b105b85850c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d0971921-edb2-4cdb-8fcc-dc16f91442f1" xlink:to="loc_srt_MaximumMember_c38a9bdb-f4b3-4dbc-813f-4b105b85850c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3269dffe-3f9f-4f19-b25c-e8ee0e22aedd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b18a1275-3a48-4e87-93bf-d1ea91482446" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3269dffe-3f9f-4f19-b25c-e8ee0e22aedd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3269dffe-3f9f-4f19-b25c-e8ee0e22aedd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3269dffe-3f9f-4f19-b25c-e8ee0e22aedd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3269dffe-3f9f-4f19-b25c-e8ee0e22aedd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_27ef59d8-8d93-4360-9256-74f90762f3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3269dffe-3f9f-4f19-b25c-e8ee0e22aedd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_27ef59d8-8d93-4360-9256-74f90762f3f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_2903b596-ff80-4b92-9798-4f1faafbe42f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_27ef59d8-8d93-4360-9256-74f90762f3f6" xlink:to="loc_us-gaap_RestructuringChargesMember_2903b596-ff80-4b92-9798-4f1faafbe42f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9109a97e-c9cd-44d5-8f33-a1d10d760b71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b18a1275-3a48-4e87-93bf-d1ea91482446" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9109a97e-c9cd-44d5-8f33-a1d10d760b71" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9109a97e-c9cd-44d5-8f33-a1d10d760b71_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9109a97e-c9cd-44d5-8f33-a1d10d760b71" xlink:to="loc_us-gaap_SegmentDomain_9109a97e-c9cd-44d5-8f33-a1d10d760b71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4ad4c14f-1495-4472-9ae6-63a18387eca5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9109a97e-c9cd-44d5-8f33-a1d10d760b71" xlink:to="loc_us-gaap_SegmentDomain_4ad4c14f-1495-4472-9ae6-63a18387eca5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedTechMember_9a3cfe6d-6513-442b-8f90-ffb667309e1b" xlink:href="jnj-20241229.xsd#jnj_MedTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4ad4c14f-1495-4472-9ae6-63a18387eca5" xlink:to="loc_jnj_MedTechMember_9a3cfe6d-6513-442b-8f90-ffb667309e1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_fe1b9546-54b7-4bdf-9eb3-f46affe09269" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_21602c87-826c-4889-aa84-65a3e5677071" xlink:to="loc_us-gaap_RestructuringCharges_fe1b9546-54b7-4bdf-9eb3-f46affe09269" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_bf2cfe5d-65b6-4ff0-a0e8-8e0a25c6de2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_21602c87-826c-4889-aa84-65a3e5677071" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_bf2cfe5d-65b6-4ff0-a0e8-8e0a25c6de2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_49f80f0b-4bc5-4b9e-9dfc-afe63cf896d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_21602c87-826c-4889-aa84-65a3e5677071" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_49f80f0b-4bc5-4b9e-9dfc-afe63cf896d0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#RestructuringScheduleofRestructuringReserveDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_200539d9-881e-4e1f-9e4e-e82ba9fc3820" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_03889022-f37a-49a4-9241-7b7be60b9ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_200539d9-881e-4e1f-9e4e-e82ba9fc3820" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_03889022-f37a-49a4-9241-7b7be60b9ab7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3f10ce95-cc11-40ec-9686-ebb1233eac44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_03889022-f37a-49a4-9241-7b7be60b9ab7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3f10ce95-cc11-40ec-9686-ebb1233eac44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3f10ce95-cc11-40ec-9686-ebb1233eac44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3f10ce95-cc11-40ec-9686-ebb1233eac44" xlink:to="loc_us-gaap_SegmentDomain_3f10ce95-cc11-40ec-9686-ebb1233eac44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3e65a21d-b29f-44fb-b175-45cee80099e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3f10ce95-cc11-40ec-9686-ebb1233eac44" xlink:to="loc_us-gaap_SegmentDomain_3e65a21d-b29f-44fb-b175-45cee80099e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InnovativeMedicineMember_ef88620e-cdea-4503-b085-fc98d3886e12" xlink:href="jnj-20241229.xsd#jnj_InnovativeMedicineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3e65a21d-b29f-44fb-b175-45cee80099e9" xlink:to="loc_jnj_InnovativeMedicineMember_ef88620e-cdea-4503-b085-fc98d3886e12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedTechMember_41b4a6ef-6972-45f4-833c-d8b0124ec5bb" xlink:href="jnj-20241229.xsd#jnj_MedTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3e65a21d-b29f-44fb-b175-45cee80099e9" xlink:to="loc_jnj_MedTechMember_41b4a6ef-6972-45f4-833c-d8b0124ec5bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_05227b1e-37a5-4a34-b180-e16c2bc4e1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_03889022-f37a-49a4-9241-7b7be60b9ab7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_05227b1e-37a5-4a34-b180-e16c2bc4e1d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_05227b1e-37a5-4a34-b180-e16c2bc4e1d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_05227b1e-37a5-4a34-b180-e16c2bc4e1d6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_05227b1e-37a5-4a34-b180-e16c2bc4e1d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_efbcdcb5-98f7-47ec-a8c5-daf26dd11840" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_05227b1e-37a5-4a34-b180-e16c2bc4e1d6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_efbcdcb5-98f7-47ec-a8c5-daf26dd11840" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_095534b0-0e75-4343-8661-5a36307f623a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_efbcdcb5-98f7-47ec-a8c5-daf26dd11840" xlink:to="loc_us-gaap_RestructuringChargesMember_095534b0-0e75-4343-8661-5a36307f623a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CostsOfGoodsAndServicesSoldMember_9da0a3a6-b779-4b99-89df-6d25dded9e55" xlink:href="jnj-20241229.xsd#jnj_CostsOfGoodsAndServicesSoldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_efbcdcb5-98f7-47ec-a8c5-daf26dd11840" xlink:to="loc_jnj_CostsOfGoodsAndServicesSoldMember_9da0a3a6-b779-4b99-89df-6d25dded9e55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_a7b628b7-6d79-41f5-8149-f1fc8c0a6926" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_03889022-f37a-49a4-9241-7b7be60b9ab7" xlink:to="loc_srt_ConsolidationItemsAxis_a7b628b7-6d79-41f5-8149-f1fc8c0a6926" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a7b628b7-6d79-41f5-8149-f1fc8c0a6926_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_a7b628b7-6d79-41f5-8149-f1fc8c0a6926" xlink:to="loc_srt_ConsolidationItemsDomain_a7b628b7-6d79-41f5-8149-f1fc8c0a6926_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_8a99ee63-57b2-409e-9ec7-0e444cbdf8d4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_a7b628b7-6d79-41f5-8149-f1fc8c0a6926" xlink:to="loc_srt_ConsolidationItemsDomain_8a99ee63-57b2-409e-9ec7-0e444cbdf8d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_f03abdac-874e-4ef6-83b6-0cf688ae84f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_8a99ee63-57b2-409e-9ec7-0e444cbdf8d4" xlink:to="loc_us-gaap_OperatingSegmentsMember_f03abdac-874e-4ef6-83b6-0cf688ae84f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_01222f17-803d-4810-802d-bd42b0594bac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_03889022-f37a-49a4-9241-7b7be60b9ab7" xlink:to="loc_us-gaap_RestructuringPlanAxis_01222f17-803d-4810-802d-bd42b0594bac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_01222f17-803d-4810-802d-bd42b0594bac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_01222f17-803d-4810-802d-bd42b0594bac" xlink:to="loc_us-gaap_RestructuringPlanDomain_01222f17-803d-4810-802d-bd42b0594bac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_5390b1ce-5a84-4c21-9994-498a8f52b217" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_01222f17-803d-4810-802d-bd42b0594bac" xlink:to="loc_us-gaap_RestructuringPlanDomain_5390b1ce-5a84-4c21-9994-498a8f52b217" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RDRestructuringPlanMember_b8fd49e3-12fd-4d52-b907-1ea6f8db9929" xlink:href="jnj-20241229.xsd#jnj_RDRestructuringPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_5390b1ce-5a84-4c21-9994-498a8f52b217" xlink:to="loc_jnj_RDRestructuringPlanMember_b8fd49e3-12fd-4d52-b907-1ea6f8db9929" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_075f01f9-8018-4e37-a57a-522a183a8990" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_200539d9-881e-4e1f-9e4e-e82ba9fc3820" xlink:to="loc_us-gaap_RestructuringReserveRollForward_075f01f9-8018-4e37-a57a-522a183a8990" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_a32ca1bb-d46d-4831-9bf1-1843fcd2fd43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_075f01f9-8018-4e37-a57a-522a183a8990" xlink:to="loc_us-gaap_RestructuringCharges_a32ca1bb-d46d-4831-9bf1-1843fcd2fd43" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#KenvueseparationanddiscontinuedoperationsDetailsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1628b5f3-834c-4c57-b949-03f4b66bfbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1628b5f3-834c-4c57-b949-03f4b66bfbe2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_77557dec-2223-4880-9d91-2888ca62ea51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1628b5f3-834c-4c57-b949-03f4b66bfbe2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_77557dec-2223-4880-9d91-2888ca62ea51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_77557dec-2223-4880-9d91-2888ca62ea51_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_77557dec-2223-4880-9d91-2888ca62ea51" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_77557dec-2223-4880-9d91-2888ca62ea51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5bd9a416-fee5-487e-b215-18c9d9efa664" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_77557dec-2223-4880-9d91-2888ca62ea51" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5bd9a416-fee5-487e-b215-18c9d9efa664" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_96d221cf-6443-4e5d-89cc-aee8135a5974" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5bd9a416-fee5-487e-b215-18c9d9efa664" xlink:to="loc_us-gaap_IPOMember_96d221cf-6443-4e5d-89cc-aee8135a5974" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_99ee4db4-ed5f-4628-8877-22911775eb8f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1628b5f3-834c-4c57-b949-03f4b66bfbe2" xlink:to="loc_dei_LegalEntityAxis_99ee4db4-ed5f-4628-8877-22911775eb8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_99ee4db4-ed5f-4628-8877-22911775eb8f_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_99ee4db4-ed5f-4628-8877-22911775eb8f" xlink:to="loc_dei_EntityDomain_99ee4db4-ed5f-4628-8877-22911775eb8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_99fe87ba-973e-466e-8a03-3233d4247803" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_99ee4db4-ed5f-4628-8877-22911775eb8f" xlink:to="loc_dei_EntityDomain_99fe87ba-973e-466e-8a03-3233d4247803" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KenvueIncMember_e6ed5156-f803-4836-b187-152c243b3421" xlink:href="jnj-20241229.xsd#jnj_KenvueIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_99fe87ba-973e-466e-8a03-3233d4247803" xlink:to="loc_jnj_KenvueIncMember_e6ed5156-f803-4836-b187-152c243b3421" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_JohnsonJohnsonMember_3774f8e7-f538-4226-8597-2477ae53b857" xlink:href="jnj-20241229.xsd#jnj_JohnsonJohnsonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_99fe87ba-973e-466e-8a03-3233d4247803" xlink:to="loc_jnj_JohnsonJohnsonMember_3774f8e7-f538-4226-8597-2477ae53b857" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_727e5bb5-a5f5-4ae8-b761-34c5798b4737" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1628b5f3-834c-4c57-b949-03f4b66bfbe2" xlink:to="loc_srt_OwnershipAxis_727e5bb5-a5f5-4ae8-b761-34c5798b4737" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_727e5bb5-a5f5-4ae8-b761-34c5798b4737_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_727e5bb5-a5f5-4ae8-b761-34c5798b4737" xlink:to="loc_srt_OwnershipDomain_727e5bb5-a5f5-4ae8-b761-34c5798b4737_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_d08cdcaf-cdd0-4f7c-9b44-7dac9b2db155" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_727e5bb5-a5f5-4ae8-b761-34c5798b4737" xlink:to="loc_srt_OwnershipDomain_d08cdcaf-cdd0-4f7c-9b44-7dac9b2db155" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KenvueIncMember_3d6f2054-cf89-4138-ac2e-7deba549ab90" xlink:href="jnj-20241229.xsd#jnj_KenvueIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_d08cdcaf-cdd0-4f7c-9b44-7dac9b2db155" xlink:to="loc_jnj_KenvueIncMember_3d6f2054-cf89-4138-ac2e-7deba549ab90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_87a8dd33-3d6f-4379-b6e0-c65bcafe3ee0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1628b5f3-834c-4c57-b949-03f4b66bfbe2" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_87a8dd33-3d6f-4379-b6e0-c65bcafe3ee0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_87a8dd33-3d6f-4379-b6e0-c65bcafe3ee0_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_87a8dd33-3d6f-4379-b6e0-c65bcafe3ee0" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_87a8dd33-3d6f-4379-b6e0-c65bcafe3ee0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_bd2679c9-a455-42de-b67a-25e8f27aa1d0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_87a8dd33-3d6f-4379-b6e0-c65bcafe3ee0" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_bd2679c9-a455-42de-b67a-25e8f27aa1d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KenvueIncMember_340cef10-2132-4410-98bc-64d1eaea1dfe" xlink:href="jnj-20241229.xsd#jnj_KenvueIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_bd2679c9-a455-42de-b67a-25e8f27aa1d0" xlink:to="loc_jnj_KenvueIncMember_340cef10-2132-4410-98bc-64d1eaea1dfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f993ef70-9146-4369-9a62-d2c5024e7f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1628b5f3-834c-4c57-b949-03f4b66bfbe2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f993ef70-9146-4369-9a62-d2c5024e7f5d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f993ef70-9146-4369-9a62-d2c5024e7f5d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f993ef70-9146-4369-9a62-d2c5024e7f5d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f993ef70-9146-4369-9a62-d2c5024e7f5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a2ee22a2-c7ec-4c17-977c-0c5fb69b2abf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f993ef70-9146-4369-9a62-d2c5024e7f5d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a2ee22a2-c7ec-4c17-977c-0c5fb69b2abf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerHealthMember_235551f8-2e15-4765-b4f1-b8d5c4917d1f" xlink:href="jnj-20241229.xsd#jnj_ConsumerHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a2ee22a2-c7ec-4c17-977c-0c5fb69b2abf" xlink:to="loc_jnj_ConsumerHealthMember_235551f8-2e15-4765-b4f1-b8d5c4917d1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f386ed1f-94bd-40fd-89b2-a28fc1b759bd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1628b5f3-834c-4c57-b949-03f4b66bfbe2" xlink:to="loc_srt_RangeAxis_f386ed1f-94bd-40fd-89b2-a28fc1b759bd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f386ed1f-94bd-40fd-89b2-a28fc1b759bd_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f386ed1f-94bd-40fd-89b2-a28fc1b759bd" xlink:to="loc_srt_RangeMember_f386ed1f-94bd-40fd-89b2-a28fc1b759bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fb4ed207-97ca-4055-929c-e01d7d0f6301" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f386ed1f-94bd-40fd-89b2-a28fc1b759bd" xlink:to="loc_srt_RangeMember_fb4ed207-97ca-4055-929c-e01d7d0f6301" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_16101bb3-802f-4e6b-8b4f-586acc33dee6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fb4ed207-97ca-4055-929c-e01d7d0f6301" xlink:to="loc_srt_MinimumMember_16101bb3-802f-4e6b-8b4f-586acc33dee6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a06fe3b0-9db7-4166-8a5a-722f216fa748" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fb4ed207-97ca-4055-929c-e01d7d0f6301" xlink:to="loc_srt_MaximumMember_a06fe3b0-9db7-4166-8a5a-722f216fa748" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_f4d1534a-5620-4657-b179-18a822896a68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaper"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_us-gaap_CommercialPaper_f4d1534a-5620-4657-b179-18a822896a68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommercialPaper_8225cad2-5be6-4e36-a822-890ae37f1e02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommercialPaper"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommercialPaper_8225cad2-5be6-4e36-a822-890ae37f1e02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DebtForEquityExchangeSharesExchanged_4fba3983-bbc6-4749-afd0-a646b911e0d8" xlink:href="jnj-20241229.xsd#jnj_DebtForEquityExchangeSharesExchanged"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_jnj_DebtForEquityExchangeSharesExchanged_4fba3983-bbc6-4749-afd0-a646b911e0d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DebtForEquityExchangeLossOnSharesExchanged_ca7f255f-6c38-4611-9528-a6f9b4f45405" xlink:href="jnj-20241229.xsd#jnj_DebtForEquityExchangeLossOnSharesExchanged"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_jnj_DebtForEquityExchangeLossOnSharesExchanged_ca7f255f-6c38-4611-9528-a6f9b4f45405" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_33db3c33-4530-4ec9-97c8-0819f1dadc44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_33db3c33-4530-4ec9-97c8-0819f1dadc44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7096b43a-a84a-42db-b3ba-186979faae07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7096b43a-a84a-42db-b3ba-186979faae07" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_a5ed7e1a-c71d-43dd-8f43-8d8c4a987dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_a5ed7e1a-c71d-43dd-8f43-8d8c4a987dd5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_78665b94-ac0a-4e8d-8a2c-79e7679a1a81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_78665b94-ac0a-4e8d-8a2c-79e7679a1a81" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_2bd86bac-05c2-428c-a091-ec861fa399a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_2bd86bac-05c2-428c-a091-ec861fa399a5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_b98639fb-dac7-47ec-a8c4-0792dff0e3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_b98639fb-dac7-47ec-a8c4-0792dff0e3dd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_1db584c1-de68-44f5-b6bf-67549ff78001" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_us-gaap_CommonStockValueOutstanding_1db584c1-de68-44f5-b6bf-67549ff78001" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OwnershipPercentageSplitOffPercent_fc2f1161-c189-4d50-a652-582f663e291d" xlink:href="jnj-20241229.xsd#jnj_OwnershipPercentageSplitOffPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_jnj_OwnershipPercentageSplitOffPercent_fc2f1161-c189-4d50-a652-582f663e291d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StockIssuedDuringPeriodSharesExchangeOffer_a6bb05d3-5eec-4475-8036-299ef748008d" xlink:href="jnj-20241229.xsd#jnj_StockIssuedDuringPeriodSharesExchangeOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_jnj_StockIssuedDuringPeriodSharesExchangeOffer_a6bb05d3-5eec-4475-8036-299ef748008d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExchangeOfStockCommonStockValueReceived_ddf4317b-0781-46b9-853d-2c532beaaa53" xlink:href="jnj-20241229.xsd#jnj_ExchangeOfStockCommonStockValueReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_jnj_ExchangeOfStockCommonStockValueReceived_ddf4317b-0781-46b9-853d-2c532beaaa53" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExchangeOfStockPercentageOwnershipAfterTransaction_225c668b-415a-41f9-9459-ca6601bab3bd" xlink:href="jnj-20241229.xsd#jnj_ExchangeOfStockPercentageOwnershipAfterTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_jnj_ExchangeOfStockPercentageOwnershipAfterTransaction_225c668b-415a-41f9-9459-ca6601bab3bd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_03fa09d9-c70a-457b-93e6-3a91c353828d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_03fa09d9-c70a-457b-93e6-3a91c353828d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_3bd2d166-db83-4365-a358-79d7af62e5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_3bd2d166-db83-4365-a358-79d7af62e5c3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fc924a2c-419c-4064-aa5d-177b5e9736d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fc924a2c-419c-4064-aa5d-177b5e9736d3" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_4cb6fd54-6434-45d4-aa4f-40c4306f38c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_4cb6fd54-6434-45d4-aa4f-40c4306f38c2" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NoncashOrPartNoncashTransactionGainOnExchangeOfStock_453da82f-5d9f-407e-aa03-af816fac154f" xlink:href="jnj-20241229.xsd#jnj_NoncashOrPartNoncashTransactionGainOnExchangeOfStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_jnj_NoncashOrPartNoncashTransactionGainOnExchangeOfStock_453da82f-5d9f-407e-aa03-af816fac154f" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DiscontinuedOperationsTransitionServiceAgreementTerm_6764db4b-b8a3-4c27-8256-fd80075b0d1d" xlink:href="jnj-20241229.xsd#jnj_DiscontinuedOperationsTransitionServiceAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_jnj_DiscontinuedOperationsTransitionServiceAgreementTerm_6764db4b-b8a3-4c27-8256-fd80075b0d1d" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DiscontinuedOperationTransitionManufacturingAgreementTerm_a9a7e01f-afb7-431d-8eef-693f8a4f4976" xlink:href="jnj-20241229.xsd#jnj_DiscontinuedOperationTransitionManufacturingAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_jnj_DiscontinuedOperationTransitionManufacturingAgreementTerm_a9a7e01f-afb7-431d-8eef-693f8a4f4976" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DiscontinuedOperationsSeparationCostsIncurred_f5cb87f5-5f6f-4f41-a7ae-72d1b95c2877" xlink:href="jnj-20241229.xsd#jnj_DiscontinuedOperationsSeparationCostsIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_jnj_DiscontinuedOperationsSeparationCostsIncurred_f5cb87f5-5f6f-4f41-a7ae-72d1b95c2877" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DiscontinuedOperationIncrementalTaxCost_cccf510a-fe2c-47b4-b9e9-53dfcaf9859c" xlink:href="jnj-20241229.xsd#jnj_DiscontinuedOperationIncrementalTaxCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_jnj_DiscontinuedOperationIncrementalTaxCost_cccf510a-fe2c-47b4-b9e9-53dfcaf9859c" xlink:type="arc" order="23"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="101"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="42"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>jnj-20241229_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:a7478940-65f4-4b69-a475-f625bf9a358e,g:8ea82ba0-2a78-4425-b720-89454b578aab-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ForeignCurrencyDisclosureTextBlock_222f3194-5710-4e8b-90d0-5adf88834a29_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International currency translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_fbb4ff30-d4ec-4d98-89a3-a8cd15239236_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government and agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_1e284fba-e36a-4c05-a4c5-763297800665_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_423c7896-ae0a-47ed-8f3f-0bc70d9da6d8_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net earnings to cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BabyPowderMember_cb743b37-de9a-4139-a5a1-62477149419b_terseLabel_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Baby Powder</link:label>
    <link:label id="lab_jnj_BabyPowderMember_label_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Baby Powder [Member]</link:label>
    <link:label id="lab_jnj_BabyPowderMember_documentation_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Baby Powder [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember" xlink:href="jnj-20241229.xsd#jnj_BabyPowderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BabyPowderMember" xlink:to="lab_jnj_BabyPowderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_ebaf9fa1-997c-4c18-8344-370dd156e6b8_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DebtForEquityExchangeSharesExchanged_93e7cf7c-98f4-409b-a736-a08deef1b2a7_terseLabel_en-US" xlink:label="lab_jnj_DebtForEquityExchangeSharesExchanged" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt for equity exchange, shares exchanged (in shares)</link:label>
    <link:label id="lab_jnj_DebtForEquityExchangeSharesExchanged_label_en-US" xlink:label="lab_jnj_DebtForEquityExchangeSharesExchanged" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt For Equity Exchange, Shares Exchanged</link:label>
    <link:label id="lab_jnj_DebtForEquityExchangeSharesExchanged_documentation_en-US" xlink:label="lab_jnj_DebtForEquityExchangeSharesExchanged" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt For Equity Exchange, Shares Exchanged</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DebtForEquityExchangeSharesExchanged" xlink:href="jnj-20241229.xsd#jnj_DebtForEquityExchangeSharesExchanged"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DebtForEquityExchangeSharesExchanged" xlink:to="lab_jnj_DebtForEquityExchangeSharesExchanged" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationCurrent_b18aedc6-497d-40c4-97c5-38b787de9a0b_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier finance program, obligation, current</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationCurrent_af9da0a7-b700-42c8-ad82-8bcd0a610546_periodStartLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Confirmed obligations - beginning of the year</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationCurrent_9abc4d30-c96b-41a9-a740-620f6b1d1be1_periodEndLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Confirmed obligations - end of the year</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationCurrent_label_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Finance Program, Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierFinanceProgramObligationCurrent" xlink:to="lab_us-gaap_SupplierFinanceProgramObligationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyDamagesSoughtNominalValue_0974f637-6d17-4ba6-8525-88d84fb3106d_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyDamagesSoughtNominalValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Damages sought, nominal value</link:label>
    <link:label id="lab_jnj_LossContingencyDamagesSoughtNominalValue_label_en-US" xlink:label="lab_jnj_LossContingencyDamagesSoughtNominalValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Sought, Nominal Value</link:label>
    <link:label id="lab_jnj_LossContingencyDamagesSoughtNominalValue_documentation_en-US" xlink:label="lab_jnj_LossContingencyDamagesSoughtNominalValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Sought, Nominal Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyDamagesSoughtNominalValue" xlink:href="jnj-20241229.xsd#jnj_LossContingencyDamagesSoughtNominalValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyDamagesSoughtNominalValue" xlink:to="lab_jnj_LossContingencyDamagesSoughtNominalValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_cb462a2d-4f9e-4c6c-997e-811ea766e8ae_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DeferredTaxAssetsUndistributedForeignEarnings_318cd3aa-4396-4626-be3a-9d4d3caee02c_terseLabel_en-US" xlink:label="lab_jnj_DeferredTaxAssetsUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undistributed foreign earnings</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsUndistributedForeignEarnings_label_en-US" xlink:label="lab_jnj_DeferredTaxAssetsUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Undistributed Foreign Earnings</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsUndistributedForeignEarnings_documentation_en-US" xlink:label="lab_jnj_DeferredTaxAssetsUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Undistributed Foreign Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsUndistributedForeignEarnings" xlink:href="jnj-20241229.xsd#jnj_DeferredTaxAssetsUndistributedForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DeferredTaxAssetsUndistributedForeignEarnings" xlink:to="lab_jnj_DeferredTaxAssetsUndistributedForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0d2e896b-ea55-4881-9609-e5b32b419584_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Increase/(Decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.550NotesDueNovember2044Member_2e8b0d99-5a0e-413c-b042-434fc0192a4f_terseLabel_en-US" xlink:label="lab_jnj_A3.550NotesDueNovember2044Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.550% Notes Due November 2044</link:label>
    <link:label id="lab_jnj_A3.550NotesDueNovember2044Member_label_en-US" xlink:label="lab_jnj_A3.550NotesDueNovember2044Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.550% Notes Due November 2044 [Member]</link:label>
    <link:label id="lab_jnj_A3.550NotesDueNovember2044Member_documentation_en-US" xlink:label="lab_jnj_A3.550NotesDueNovember2044Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">3.550% Notes Due November 2044</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.550NotesDueNovember2044Member" xlink:href="jnj-20241229.xsd#jnj_A3.550NotesDueNovember2044Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.550NotesDueNovember2044Member" xlink:to="lab_jnj_A3.550NotesDueNovember2044Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_cc5cdf99-e1b4-4bf4-8986-eddc3df6364d_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ConsumerMember_e7125f36-94f1-44a5-8089-47f69579c248_terseLabel_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consumer Health</link:label>
    <link:label id="lab_jnj_ConsumerMember_label_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consumer [Member]</link:label>
    <link:label id="lab_jnj_ConsumerMember_documentation_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consumer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember" xlink:href="jnj-20241229.xsd#jnj_ConsumerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ConsumerMember" xlink:to="lab_jnj_ConsumerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExercisePriceRangeFiveMember_ad64182c-0986-4bec-9e41-c78c21ee7e90_terseLabel_en-US" xlink:label="lab_jnj_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$164.62 - $165.89</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeFiveMember_label_en-US" xlink:label="lab_jnj_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeFiveMember_documentation_en-US" xlink:label="lab_jnj_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeFiveMember" xlink:href="jnj-20241229.xsd#jnj_ExercisePriceRangeFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExercisePriceRangeFiveMember" xlink:to="lab_jnj_ExercisePriceRangeFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_0b322246-7479-4a54-b5a3-2097b6821566_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International Plans</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_ca7cb1d1-3291-45ff-9a23-7e5cb595a733_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory related</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_184fc9e7-a992-47b8-9bba-a598ae549e4b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_dc4222de-fd21-4672-9747-06e9ea987307_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_4ee7a21c-c47e-41a3-bc78-92ce167bdf31_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_50cf252b-abc5-4104-904a-0a408f38e962_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ADVANCEDMember_2fae0431-986b-4446-b2b0-da0311f5fc6a_terseLabel_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ADVANCED</link:label>
    <link:label id="lab_jnj_ADVANCEDMember_label_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ADVANCED [Member]</link:label>
    <link:label id="lab_jnj_ADVANCEDMember_documentation_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ADVANCED [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember" xlink:href="jnj-20241229.xsd#jnj_ADVANCEDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ADVANCEDMember" xlink:to="lab_jnj_ADVANCEDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_070a0c71-fc83-45bb-9443-0895737d006d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_9b4eca49-cefe-4428-a1cd-4c39d82d1c71_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Gross Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets_0d75ac84-be36-4d73-b86f-4ee568608474_terseLabel_en-US" xlink:label="lab_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of company's common stock directly held in plan assets</link:label>
    <link:label id="lab_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets_label_en-US" xlink:label="lab_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Company's Common Stock Directly Held In Plan Assets</link:label>
    <link:label id="lab_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets_documentation_en-US" xlink:label="lab_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of company's common stock directly held in plan assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" xlink:href="jnj-20241229.xsd#jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" xlink:to="lab_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_8f6e5fff-2008-4cf2-b067-f407f583d53b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total income tax benefit recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable_af7b1404-fd1d-4522-b501-2e77f12bb747_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Investment Not Readily Marketable [Table]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Investment Not Readily Marketable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermCommercialPaperCurrent_ca561895-25c8-44c0-9b84-1359a2dffe10_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermCommercialPaperCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowed under the commercial paper program</link:label>
    <link:label id="lab_us-gaap_LongTermCommercialPaperCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermCommercialPaperCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Commercial Paper, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermCommercialPaperCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermCommercialPaperCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermCommercialPaperCurrent" xlink:to="lab_us-gaap_LongTermCommercialPaperCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_c5c0805b-0c43-41ad-b895-68b05a168d12_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash dividend (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_e97a337f-7140-4cfa-91ab-f9b3370d389e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_7b748fc5-59ec-4ef9-8b32-fdd5d89724aa_verboseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Allowances for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_JudicialRulingMember_e883fe0f-1223-47b5-921b-89ebdecdc42f_terseLabel_en-US" xlink:label="lab_us-gaap_JudicialRulingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Judicial Ruling</link:label>
    <link:label id="lab_us-gaap_JudicialRulingMember_label_en-US" xlink:label="lab_us-gaap_JudicialRulingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Judicial Ruling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_JudicialRulingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_JudicialRulingMember" xlink:to="lab_us-gaap_JudicialRulingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d63ddb38-0ee0-4cb9-952c-847d6e2a47fc_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_f838cae4-a597-4687-bf14-0fb02f283cd4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives &amp; hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6fb2b998-e49a-4343-9b68-e30674ee31fe_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Increase in accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.20NotesDueNovember2032Member_6867887d-bfc2-4467-a95a-88dcc5f0763a_terseLabel_en-US" xlink:label="lab_jnj_A3.20NotesDueNovember2032Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.20% Notes Due November 2032</link:label>
    <link:label id="lab_jnj_A3.20NotesDueNovember2032Member_label_en-US" xlink:label="lab_jnj_A3.20NotesDueNovember2032Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.20% Notes Due November 2032 [Member]</link:label>
    <link:label id="lab_jnj_A3.20NotesDueNovember2032Member_documentation_en-US" xlink:label="lab_jnj_A3.20NotesDueNovember2032Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">3.20% Notes Due November 2032</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.20NotesDueNovember2032Member" xlink:href="jnj-20241229.xsd#jnj_A3.20NotesDueNovember2032Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.20NotesDueNovember2032Member" xlink:to="lab_jnj_A3.20NotesDueNovember2032Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_0a03e065-18d2-4221-89f5-7ac770930676_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Equity securities, FV-NI, gain (loss)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_57706353-a010-4abc-99ba-b531add45d47_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities, FV-NI, gain (loss)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_49ca07ba-6462-41f1-b2d5-389943debbed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred net losses (gains) on derivatives included in accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_label_en-US" xlink:label="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:to="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_57642fcb-32b0-4fda-8a6c-d7f64757c9bc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_6e62cce7-976d-4ce5-bd93-55b631408a64_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_f0ae8c53-b5dc-4f26-a029-9deebb56d61a_terseLabel_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CONTACT LENSES/OTHER</link:label>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_label_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CONTACT LENSES/OTHER [Member]</link:label>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_documentation_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CONTACT LENSES/OTHER [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember" xlink:href="jnj-20241229.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CONTACTLENSESOTHERMember" xlink:to="lab_jnj_CONTACTLENSESOTHERMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_6dd14cf2-9b47-45e3-ae93-2e98e586d24c_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_25fe9973-bd3f-46d7-a9bd-3c365ffd33d0_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8ef3c635-62df-458a-8eea-82e181876be9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized holding gain (loss) arising during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized_c10102b0-67e7-4947-bba8-ce36860bf7f0_terseLabel_en-US" xlink:label="lab_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">R&amp;D capitalized for tax</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized_label_en-US" xlink:label="lab_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets International Research And Development Capitalized</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized_documentation_en-US" xlink:label="lab_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax assets international research and development capitalized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" xlink:href="jnj-20241229.xsd#jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" xlink:to="lab_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease_0ea99e52-32b3-4528-9f6a-c21c01c6d544_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divestitures &amp; acquisitions</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Business Combination and Divestiture, Increase (Decrease)</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Business Combination and Divestiture, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" xlink:to="lab_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_59a62b6e-2332-4ec8-96cc-f8ae8f034ad1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain/(Loss) Recognized In Income on Derivative</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_e441c18f-a467-4f74-9e89-0e5e0ea1271b_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_HIPSMember_27f132f8-3130-4acf-88a0-417cf6f0b479_terseLabel_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">HIPS</link:label>
    <link:label id="lab_jnj_HIPSMember_label_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">HIPS [Member]</link:label>
    <link:label id="lab_jnj_HIPSMember_documentation_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">HIPS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember" xlink:href="jnj-20241229.xsd#jnj_HIPSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_HIPSMember" xlink:to="lab_jnj_HIPSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_fe35ac3e-f920-449d-83aa-e5cab63739c3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_UnfundedPlansMember_b8b46a31-7e4d-4adb-b9ef-4030fc45b406_terseLabel_en-US" xlink:label="lab_jnj_UnfundedPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unfunded Plans</link:label>
    <link:label id="lab_jnj_UnfundedPlansMember_label_en-US" xlink:label="lab_jnj_UnfundedPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unfunded Plans [Member]</link:label>
    <link:label id="lab_jnj_UnfundedPlansMember_documentation_en-US" xlink:label="lab_jnj_UnfundedPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unfunded plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UnfundedPlansMember" xlink:href="jnj-20241229.xsd#jnj_UnfundedPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_UnfundedPlansMember" xlink:to="lab_jnj_UnfundedPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_0f89ad34-b10e-461f-a4c0-5fe1273e4040_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_5c325b1c-878c-4a7c-8fda-53ca665e0a71_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of pending claims</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ConcentrationOfCreditRiskTable_0302f807-f330-448e-a583-63295792165a_terseLabel_en-US" xlink:label="lab_jnj_ConcentrationOfCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk [Table]</link:label>
    <link:label id="lab_jnj_ConcentrationOfCreditRiskTable_label_en-US" xlink:label="lab_jnj_ConcentrationOfCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk [Table]</link:label>
    <link:label id="lab_jnj_ConcentrationOfCreditRiskTable_documentation_en-US" xlink:label="lab_jnj_ConcentrationOfCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationOfCreditRiskTable" xlink:href="jnj-20241229.xsd#jnj_ConcentrationOfCreditRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable" xlink:to="lab_jnj_ConcentrationOfCreditRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_3ab0b511-2a07-484e-a11c-c9bb6fdf7fdc_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_192dae83-8095-46d0-9fb4-6ffc8bbbada2_verboseLabel_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">1.650% Notes Due May 2035</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_3683d93b-8516-4664-8cae-3332c81a2805_terseLabel_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.650% Notes due 2035&#8232;(1.5B Euro 1.0401)(2)/(1.5B Euro 1.1090)(3)</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_label_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.650% Notes Due 2035 [Member]</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_documentation_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1.650% Notes Due 2035 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member" xlink:href="jnj-20241229.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1.650NotesDue2035Member" xlink:to="lab_jnj_A1.650NotesDue2035Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_027e1d9c-08d5-4e31-848f-de61c6c65422_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_3696004f-1323-4808-b335-f85313889d9e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NonTradeableContingentValueRightMember_d4315e84-3705-4119-8969-88502070e577_terseLabel_en-US" xlink:label="lab_jnj_NonTradeableContingentValueRightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Tradeable Contingent Value Right</link:label>
    <link:label id="lab_jnj_NonTradeableContingentValueRightMember_label_en-US" xlink:label="lab_jnj_NonTradeableContingentValueRightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Tradeable Contingent Value Right [Member]</link:label>
    <link:label id="lab_jnj_NonTradeableContingentValueRightMember_documentation_en-US" xlink:label="lab_jnj_NonTradeableContingentValueRightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Tradeable Contingent Value Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NonTradeableContingentValueRightMember" xlink:href="jnj-20241229.xsd#jnj_NonTradeableContingentValueRightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NonTradeableContingentValueRightMember" xlink:to="lab_jnj_NonTradeableContingentValueRightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_VWaveLtd.Member_baee84c0-2278-4578-a59a-7b437702f544_terseLabel_en-US" xlink:label="lab_jnj_VWaveLtd.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">V-Wave Ltd.</link:label>
    <link:label id="lab_jnj_VWaveLtd.Member_label_en-US" xlink:label="lab_jnj_VWaveLtd.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">V-Wave Ltd. [Member]</link:label>
    <link:label id="lab_jnj_VWaveLtd.Member_documentation_en-US" xlink:label="lab_jnj_VWaveLtd.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">V-Wave Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VWaveLtd.Member" xlink:href="jnj-20241229.xsd#jnj_VWaveLtd.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_VWaveLtd.Member" xlink:to="lab_jnj_VWaveLtd.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_511bcf5b-8c4a-4623-928e-b28d25e28900_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S. Plans</link:label>
    <link:label id="lab_country_US_6d3e3247-9d1b-48ac-806d-bdd60c2e93a0_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetAbstract_1d9bd962-23c6-4b36-8926-42411a465f4e_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract" xlink:to="lab_us-gaap_InventoryNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_e580dd63-5269-468d-a197-d3f791d72036_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1a7d292d-9f30-4937-9e23-723c320249a3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets, noncurrent</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WholesalerConcentrationRiskMember_b5949c1f-f30a-4ab1-bb4b-ed98288d3392_terseLabel_en-US" xlink:label="lab_jnj_WholesalerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Wholesaler Concentration Risk</link:label>
    <link:label id="lab_jnj_WholesalerConcentrationRiskMember_label_en-US" xlink:label="lab_jnj_WholesalerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Wholesaler Concentration Risk [Member]</link:label>
    <link:label id="lab_jnj_WholesalerConcentrationRiskMember_documentation_en-US" xlink:label="lab_jnj_WholesalerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Wholesaler Concentration Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WholesalerConcentrationRiskMember" xlink:href="jnj-20241229.xsd#jnj_WholesalerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WholesalerConcentrationRiskMember" xlink:to="lab_jnj_WholesalerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight_5824d396-949f-4a25-96a4-0c753bca279b_terseLabel_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-tradeable contingent value right (in dollars per share)</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight_label_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares, Non-Tradeable Contingent Value Right</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight_documentation_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares, Non-Tradeable Contingent Value Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight" xlink:href="jnj-20241229.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight" xlink:to="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_d15f7c85-95df-43dc-9b93-7082fabf5bab_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finite lived intangible assets gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_923c2aa3-9217-4d44-bd2c-be05f56ef8b7_terseLabel_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit support agreements activity, net</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_label_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_documentation_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:href="jnj-20241229.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:to="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_22eb4a65-041d-460f-bd48-d2d2b4b8d6d9_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of claims within settlement agreement</link:label>
    <link:label id="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_label_en-US" xlink:label="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number of Claims within Settlement Agreement</link:label>
    <link:label id="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_documentation_en-US" xlink:label="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number of Claims within Settlement Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:href="jnj-20241229.xsd#jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:to="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentRollForward_dba10e05-e5cc-409e-9f80-21683d73f8bd_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:label id="lab_jnj_EquityInvestmentRollForward_label_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:label id="lab_jnj_EquityInvestmentRollForward_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward" xlink:href="jnj-20241229.xsd#jnj_EquityInvestmentRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentRollForward" xlink:to="lab_jnj_EquityInvestmentRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c0d87f34-fd2d-49f5-8b17-0bf26883ed40_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax rates:</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_be3ae592-069c-4d91-8e5f-41259bd574ca_terseLabel_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OTHER NEUROSCIENCE</link:label>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_label_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OTHER NEUROSCIENCE [Member]</link:label>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_documentation_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OTHER NEUROSCIENCE [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember" xlink:href="jnj-20241229.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OTHERNEUROSCIENCEMember" xlink:to="lab_jnj_OTHERNEUROSCIENCEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_be7cd86c-05a3-416a-9604-38c801de9a7e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_18df46c6-3545-438e-afaa-fdf283cb3117_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_588b1076-ee35-413d-a717-dfc552525537_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_786b1774-9644-4cca-92cd-c501808e228a_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PhysiomeshMember_3a9bbb73-8c93-4787-84f1-e6715451b5e7_terseLabel_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Physiomesh</link:label>
    <link:label id="lab_jnj_PhysiomeshMember_label_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Physiomesh [Member]</link:label>
    <link:label id="lab_jnj_PhysiomeshMember_documentation_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Physiomesh [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember" xlink:href="jnj-20241229.xsd#jnj_PhysiomeshMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PhysiomeshMember" xlink:to="lab_jnj_PhysiomeshMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_f73b346a-948a-4e8a-bc84-486bfb409609_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A055NotesDue2025Member_36553657-79fb-4768-958d-5e592e5b7410_terseLabel_en-US" xlink:label="lab_jnj_A055NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.55% Notes due 2025</link:label>
    <link:label id="lab_jnj_A055NotesDue2025Member_label_en-US" xlink:label="lab_jnj_A055NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.55% Notes due 2025 [Member]</link:label>
    <link:label id="lab_jnj_A055NotesDue2025Member_documentation_en-US" xlink:label="lab_jnj_A055NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">0.55% Notes due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A055NotesDue2025Member" xlink:href="jnj-20241229.xsd#jnj_A055NotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A055NotesDue2025Member" xlink:to="lab_jnj_A055NotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_e9fc91a7-9ea8-4626-a793-977f5920e3a4_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsMember" xlink:to="lab_us-gaap_RepurchaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_412fc99f-52f9-4937-89cd-f76f5e9583cf_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net periodic benefit cost (credit)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_c5531302-2c24-4efe-87bb-aa2dc68fda56_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net periodic benefit cost (credit)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_49dd2962-c79c-4089-bddb-5f5b9af920f6_terseLabel_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">6.95%&#160;Notes due 2029</link:label>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_label_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">6.95% Notes due 2029 [Member]</link:label>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_documentation_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">6.95% Notes due 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member" xlink:href="jnj-20241229.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A6.95Notesdue2029Member" xlink:to="lab_jnj_A6.95Notesdue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_bf9fa14e-8c42-4d5b-9f68-bdfa440be5d9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_0ec4add4-ac7e-4c95-b43f-7c27cff6fd1f_negatedLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Fair value of liabilities assumed</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_cb71b524-218e-4ba3-bd22-3b8b60619172_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_d7daa266-68ad-48d2-9bb4-055826c62ec7_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExcessOfCarryingValueOverFairValueOfDebt_256e4f9d-4204-4d75-8075-181e88f04335_terseLabel_en-US" xlink:label="lab_jnj_ExcessOfCarryingValueOverFairValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Excess of carrying value over fair value of debt</link:label>
    <link:label id="lab_jnj_ExcessOfCarryingValueOverFairValueOfDebt_label_en-US" xlink:label="lab_jnj_ExcessOfCarryingValueOverFairValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Excess Of Carrying Value Over Fair Value Of Debt</link:label>
    <link:label id="lab_jnj_ExcessOfCarryingValueOverFairValueOfDebt_documentation_en-US" xlink:label="lab_jnj_ExcessOfCarryingValueOverFairValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Excess Of Carrying Value Over Fair Value Of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfCarryingValueOverFairValueOfDebt" xlink:href="jnj-20241229.xsd#jnj_ExcessOfCarryingValueOverFairValueOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExcessOfCarryingValueOverFairValueOfDebt" xlink:to="lab_jnj_ExcessOfCarryingValueOverFairValueOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_d4ae2ed2-1123-4b6d-b051-2c93ba456de7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from divestiture of brands</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_bc6af9b1-03d9-4fe8-868a-a180a36fcfee_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan with accumulated benefit obligation in excess of plan assets, plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_15a76d30-2831-481e-9d6f-d19414b6354c_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Investments with readily determinable value</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_label_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Investments with Readily Determinable Value [Member]</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Investments with Readily Determinable Value [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:href="jnj-20241229.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:to="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_cf3c5c9b-ae2b-4eda-8fb0-c571bb1af4e1_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_7bfd2dd9-bfac-434b-bd28-f277d253b44b_terseLabel_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Western Hemisphere excluding U.S.&#160;</link:label>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_label_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Western Hemisphere, excluding U.S. [Member]</link:label>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_documentation_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Western Hemisphere, excluding U.S. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember" xlink:href="jnj-20241229.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WesternHemisphereExcludingUSMember" xlink:to="lab_jnj_WesternHemisphereExcludingUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_599dbb5f-8b56-45b5-b025-70fbb21b3484_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ErleadaMember_fc3a8e08-fc40-4e13-83bd-4a42c44af07d_terseLabel_en-US" xlink:label="lab_jnj_ErleadaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ERLEADA</link:label>
    <link:label id="lab_jnj_ErleadaMember_label_en-US" xlink:label="lab_jnj_ErleadaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erleada [Member]</link:label>
    <link:label id="lab_jnj_ErleadaMember_documentation_en-US" xlink:label="lab_jnj_ErleadaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Erleada</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ErleadaMember" xlink:href="jnj-20241229.xsd#jnj_ErleadaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ErleadaMember" xlink:to="lab_jnj_ErleadaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_e254c3dc-0f70-4341-85dc-da2751af466c_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ccf4a14-7b2a-4f98-9852-951091cc55d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1_adc8af30-2e8b-448d-89d6-bd2a7d3de9c9_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency exchange rate, translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Exchange Rate, Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_8f78428f-2a97-4e54-9ced-208020185290_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_873a4a7d-0a1d-4772-a24f-e1a42a6ed890_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected long-term rate of return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.55DebenturesDue2044Member_673322df-d701-4997-83a0-14f8384f3c89_terseLabel_en-US" xlink:label="lab_jnj_A3.55DebenturesDue2044Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.55% Debentures due 2044</link:label>
    <link:label id="lab_jnj_A3.55DebenturesDue2044Member_label_en-US" xlink:label="lab_jnj_A3.55DebenturesDue2044Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.55% Debentures due 2044 [Member]</link:label>
    <link:label id="lab_jnj_A3.55DebenturesDue2044Member_documentation_en-US" xlink:label="lab_jnj_A3.55DebenturesDue2044Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">3.55% Debentures due 2044</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55DebenturesDue2044Member" xlink:href="jnj-20241229.xsd#jnj_A3.55DebenturesDue2044Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.55DebenturesDue2044Member" xlink:to="lab_jnj_A3.55DebenturesDue2044Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_62545a60-8635-4ab3-9d7a-8b24afbbbfa7_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_db0718b8-49ad-475c-9b40-8684d04c4ef5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DiscontinuedOperationsTransitionServiceAgreementTerm_abcbc602-5280-4055-b6f1-870a947144da_terseLabel_en-US" xlink:label="lab_jnj_DiscontinuedOperationsTransitionServiceAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transition service agreement, term</link:label>
    <link:label id="lab_jnj_DiscontinuedOperationsTransitionServiceAgreementTerm_label_en-US" xlink:label="lab_jnj_DiscontinuedOperationsTransitionServiceAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations, Transition Service Agreement, Term</link:label>
    <link:label id="lab_jnj_DiscontinuedOperationsTransitionServiceAgreementTerm_documentation_en-US" xlink:label="lab_jnj_DiscontinuedOperationsTransitionServiceAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Discontinued Operations, Transition Service Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DiscontinuedOperationsTransitionServiceAgreementTerm" xlink:href="jnj-20241229.xsd#jnj_DiscontinuedOperationsTransitionServiceAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DiscontinuedOperationsTransitionServiceAgreementTerm" xlink:to="lab_jnj_DiscontinuedOperationsTransitionServiceAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_YellowJerseyTherapeuticsMember_fbab3145-b4ea-4a66-8836-049569a86032_terseLabel_en-US" xlink:label="lab_jnj_YellowJerseyTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Yellow Jersey Therapeutics</link:label>
    <link:label id="lab_jnj_YellowJerseyTherapeuticsMember_label_en-US" xlink:label="lab_jnj_YellowJerseyTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Yellow Jersey Therapeutics [Member]</link:label>
    <link:label id="lab_jnj_YellowJerseyTherapeuticsMember_documentation_en-US" xlink:label="lab_jnj_YellowJerseyTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Yellow Jersey Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_YellowJerseyTherapeuticsMember" xlink:href="jnj-20241229.xsd#jnj_YellowJerseyTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_YellowJerseyTherapeuticsMember" xlink:to="lab_jnj_YellowJerseyTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock_39291216-06fd-48c9-878b-b86c2a1c436d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effect of Net Investment Hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_d5ee4a50-97b9-467d-acde-0199dd2abf00_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslation_ccfa1bc1-0f4e-4cb4-ae65-ef13bff2bbb4_terseLabel_en-US" xlink:label="lab_jnj_ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_jnj_ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslation_label_en-US" xlink:label="lab_jnj_ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Foreign Currency Translation</link:label>
    <link:label id="lab_jnj_ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslation_documentation_en-US" xlink:label="lab_jnj_ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Foreign Currency Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslation" xlink:href="jnj-20241229.xsd#jnj_ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslation" xlink:to="lab_jnj_ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_36655469-b25c-4559-8d4a-a1e765b7d63f_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_32bca09d-8b46-4be7-b959-1facbb195dd0_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Goodwill beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_2b6fd9be-52c5-42b4-b07e-024c5f5ac531_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Goodwill end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f67a1e18-cd2f-48ab-bf59-71fb7dfb6ac6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_037a163a-4b75-4a71-82da-4751fad388db_terseLabel_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_526ce2f9-4b65-41a3-969b-84e63acd7e92_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExercisePriceRangeOneMember_168ab1b5-a29f-47e9-8b00-77a6cc363061_terseLabel_en-US" xlink:label="lab_jnj_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$100.06 - $101.87</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeOneMember_label_en-US" xlink:label="lab_jnj_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range One Member</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeOneMember_documentation_en-US" xlink:label="lab_jnj_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise price range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeOneMember" xlink:href="jnj-20241229.xsd#jnj_ExercisePriceRangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExercisePriceRangeOneMember" xlink:to="lab_jnj_ExercisePriceRangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DePuyASRU.S.Member_2a53b1d6-c32e-4aea-bfe3-31a08c752d54_terseLabel_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DePuy ASR U.S.</link:label>
    <link:label id="lab_jnj_DePuyASRU.S.Member_label_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DePuy ASR U.S. [Member]</link:label>
    <link:label id="lab_jnj_DePuyASRU.S.Member_documentation_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">DePuy ASR U.S. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member" xlink:href="jnj-20241229.xsd#jnj_DePuyASRU.S.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DePuyASRU.S.Member" xlink:to="lab_jnj_DePuyASRU.S.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A095NotesDue2027Member_961198f2-41a7-46bc-8909-196b1c3e6c15_terseLabel_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.95% Notes due 2027</link:label>
    <link:label id="lab_jnj_A095NotesDue2027Member_label_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.95% Notes due 2027 [Member]</link:label>
    <link:label id="lab_jnj_A095NotesDue2027Member_documentation_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">0.95% Notes due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member" xlink:href="jnj-20241229.xsd#jnj_A095NotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A095NotesDue2027Member" xlink:to="lab_jnj_A095NotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_18a0e569-eae8-4939-a12c-040819d3dbd2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_d6e55949-c394-4b65-99f2-15648e8e741b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityFairValueAdjustment_01659adb-592d-4b49-9142-9a6571f60c64_terseLabel_en-US" xlink:label="lab_us-gaap_EquityFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity, fair value adjustment</link:label>
    <link:label id="lab_us-gaap_EquityFairValueAdjustment_label_en-US" xlink:label="lab_us-gaap_EquityFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityFairValueAdjustment" xlink:to="lab_us-gaap_EquityFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_c3da8bf5-fd97-4741-95c4-d05b5679e640_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_97a3a5e5-8647-4019-8e84-7d713a40f5db_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_2123c11c-f35a-44c2-9522-3fcc8f837b5d_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued taxes on income</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_612a6fb6-438e-4255-b8b0-c98e02c436c6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_MesotheliomaAndStateClaimsMember_ce7b10da-b9c2-46f6-97f3-965e6a833bff_terseLabel_en-US" xlink:label="lab_jnj_MesotheliomaAndStateClaimsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mesothelioma and State Claims</link:label>
    <link:label id="lab_jnj_MesotheliomaAndStateClaimsMember_label_en-US" xlink:label="lab_jnj_MesotheliomaAndStateClaimsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mesothelioma and State Claims [Member]</link:label>
    <link:label id="lab_jnj_MesotheliomaAndStateClaimsMember_documentation_en-US" xlink:label="lab_jnj_MesotheliomaAndStateClaimsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mesothelioma and State Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MesotheliomaAndStateClaimsMember" xlink:href="jnj-20241229.xsd#jnj_MesotheliomaAndStateClaimsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_MesotheliomaAndStateClaimsMember" xlink:to="lab_jnj_MesotheliomaAndStateClaimsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_0db528b2-b5b9-403c-8cd1-bf54c190b8f3_terseLabel_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.375% Notes due 2033</link:label>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_label_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">4.375% Notes due 2033 [Member]</link:label>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_documentation_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">4.375% Notes due 2033 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member" xlink:href="jnj-20241229.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.375Notesdue2033Member" xlink:to="lab_jnj_A4.375Notesdue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_30aedd05-5c3b-46d1-b001-8c30f463dffa_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_0186713b-cf75-4d93-888c-a69ced1e8918_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred income taxes net of valuation allowances</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_0073f7b0-6ca9-4e2e-9bfc-d1b60610b00e_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.80DebenturesDue2029Member_d3824e12-70c2-4ae0-8fd8-7a34cb8141be_terseLabel_en-US" xlink:label="lab_jnj_A4.80DebenturesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.80% Debentures due 2029</link:label>
    <link:label id="lab_jnj_A4.80DebenturesDue2029Member_label_en-US" xlink:label="lab_jnj_A4.80DebenturesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">4.80% Debentures due 2029 [Member]</link:label>
    <link:label id="lab_jnj_A4.80DebenturesDue2029Member_documentation_en-US" xlink:label="lab_jnj_A4.80DebenturesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">4.80% Debentures due 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.80DebenturesDue2029Member" xlink:href="jnj-20241229.xsd#jnj_A4.80DebenturesDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.80DebenturesDue2029Member" xlink:to="lab_jnj_A4.80DebenturesDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_8478f2da-1d0b-4945-9bf8-a88e7210d433_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_b2aa7374-7edd-4c06-b812-fe05ee29a7ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_475be2ec-ac2d-4464-bfca-d652b395d173_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goods in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock_76fb8d6c-2b90-4fbc-bd9a-5648079c9b80_terseLabel_en-US" xlink:label="lab_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans</link:label>
    <link:label id="lab_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock_label_en-US" xlink:label="lab_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Estimated Future Employer Contributions [Table Text Block]</link:label>
    <link:label id="lab_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock_documentation_en-US" xlink:label="lab_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of estimated future employer contributions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" xlink:href="jnj-20241229.xsd#jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" xlink:to="lab_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_6032e836-1a74-4198-90f2-3729324dffe1_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_9866742d-f6de-4e38-857a-59333c679fc5_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_a34f8945-abe9-41ef-bf4c-dfd831e484c6_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_aa33c14a-2831-4306-806c-5d3b53a7f20f_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SalesReturnReserve_764af4a3-9914-4548-a3bf-442ed91103a0_terseLabel_en-US" xlink:label="lab_jnj_SalesReturnReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales return reserve (as a percent)</link:label>
    <link:label id="lab_jnj_SalesReturnReserve_label_en-US" xlink:label="lab_jnj_SalesReturnReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Return Reserve</link:label>
    <link:label id="lab_jnj_SalesReturnReserve_documentation_en-US" xlink:label="lab_jnj_SalesReturnReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales return reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesReturnReserve" xlink:href="jnj-20241229.xsd#jnj_SalesReturnReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SalesReturnReserve" xlink:to="lab_jnj_SalesReturnReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_7d1231fe-3d92-458b-b22a-db9a680ebc46_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash dividends paid (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncurrentAssets_ac6cbf3c-0464-410d-9a5f-96f97407b356_terseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets" xlink:to="lab_us-gaap_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a773dc65-6066-4ac7-ad6e-8cf345f43a2f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options average price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_74ad23ea-cd8f-4cd4-b335-3c44ca559e50_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_495e34a8-8961-4996-abc7-94e336616a02_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SupplierFinanceProgramPolicyTextBlock_813d481b-abbc-4905-adf3-a8a9cf169b08_terseLabel_en-US" xlink:label="lab_jnj_SupplierFinanceProgramPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier finance program obligations</link:label>
    <link:label id="lab_jnj_SupplierFinanceProgramPolicyTextBlock_label_en-US" xlink:label="lab_jnj_SupplierFinanceProgramPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Finance Program [Policy Text Block]</link:label>
    <link:label id="lab_jnj_SupplierFinanceProgramPolicyTextBlock_documentation_en-US" xlink:label="lab_jnj_SupplierFinanceProgramPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplier Finance Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplierFinanceProgramPolicyTextBlock" xlink:href="jnj-20241229.xsd#jnj_SupplierFinanceProgramPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SupplierFinanceProgramPolicyTextBlock" xlink:to="lab_jnj_SupplierFinanceProgramPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5cca1bcd-68b2-4399-a36a-ad382e5adf64_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average useful life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b88b3042-54a3-440e-8662-1cf369784460_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_871af87d-30c4-4a8b-bf1e-1a7bd5fe1562_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill_14159473-415e-45e7-8212-c8f89f50ad38_terseLabel_en-US" xlink:label="lab_jnj_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPR&amp;D charge</link:label>
    <link:label id="lab_jnj_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_jnj_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Recognized Identifiable Assets Acquired, Intangible Assets, Other than Goodwill</link:label>
    <link:label id="lab_jnj_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill_documentation_en-US" xlink:label="lab_jnj_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Recognized Identifiable Assets Acquired, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill" xlink:href="jnj-20241229.xsd#jnj_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill" xlink:to="lab_jnj_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_00788df7-ca64-4e61-a987-2ea8d5000051_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation/other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0c561678-d22d-4136-984a-19831ebb8836_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights_f7786e98-840b-4fa2-8440-2e85e0263e9d_terseLabel_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued subject to stock options or stock appreciation rights (in shares)</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights_label_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Stock Options Or Stock Appreciation Rights</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights_documentation_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Stock Options Or Stock Appreciation Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights" xlink:href="jnj-20241229.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights" xlink:to="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NoncashOrPartNoncashTransactionGainOnExchangeOfStock_36d54c0b-d94c-4d5a-98d1-9df3073ea8c8_terseLabel_en-US" xlink:label="lab_jnj_NoncashOrPartNoncashTransactionGainOnExchangeOfStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncash gain on exchange offer</link:label>
    <link:label id="lab_jnj_NoncashOrPartNoncashTransactionGainOnExchangeOfStock_label_en-US" xlink:label="lab_jnj_NoncashOrPartNoncashTransactionGainOnExchangeOfStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Or Part Noncash Transaction, Gain On Exchange Of Stock</link:label>
    <link:label id="lab_jnj_NoncashOrPartNoncashTransactionGainOnExchangeOfStock_documentation_en-US" xlink:label="lab_jnj_NoncashOrPartNoncashTransactionGainOnExchangeOfStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash Or Part Noncash Transaction, Gain On Exchange Of Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NoncashOrPartNoncashTransactionGainOnExchangeOfStock" xlink:href="jnj-20241229.xsd#jnj_NoncashOrPartNoncashTransactionGainOnExchangeOfStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NoncashOrPartNoncashTransactionGainOnExchangeOfStock" xlink:to="lab_jnj_NoncashOrPartNoncashTransactionGainOnExchangeOfStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_c07a673a-6e56-4e1f-93a8-3b0b40d6869f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_b2fc0872-96b9-44c5-b940-d11ace85594c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3a89f930-8e69-45a4-8af5-04515232738e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LandAndLeaseholdImprovementsMember_07aa8752-68e1-4c42-b30d-4233e1a487be_terseLabel_en-US" xlink:label="lab_jnj_LandAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land and leasehold improvements</link:label>
    <link:label id="lab_jnj_LandAndLeaseholdImprovementsMember_label_en-US" xlink:label="lab_jnj_LandAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land And Leasehold Improvements [Member]</link:label>
    <link:label id="lab_jnj_LandAndLeaseholdImprovementsMember_documentation_en-US" xlink:label="lab_jnj_LandAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Land and leasehold improvements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LandAndLeaseholdImprovementsMember" xlink:href="jnj-20241229.xsd#jnj_LandAndLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LandAndLeaseholdImprovementsMember" xlink:to="lab_jnj_LandAndLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo_5a453cbd-149b-420e-a54a-7f7195286831_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Expected Future Benefit Contribution In Year Two</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined benefit plan expected future benefit contribution in year two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" xlink:to="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_b0df3f15-e579-4c43-88de-66dd79655b6a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior service cost (credit)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_d3964ff0-63bf-4247-adb6-ae5d9414c521_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan participant contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Plan Participant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_865a338d-8613-484e-9272-ca767b578405_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bde6dd82-f30e-42c3-b5bd-9191c7a1928b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_5f43c3bc-d4c1-4a17-b749-4058c1c226e7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">R&amp;D Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7b92b91c-8d48-40de-9e61-3961d7cd043f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_733abd97-af32-4342-8c41-65e67b812d2e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Lapse of statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_02bfd5f3-8a57-4b41-92d9-5c8df61f6f67_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3fa39d39-c55d-400a-bc24-da92560a5d02_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_71616023-b527-416a-b36c-2c544df4759b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ad6c5cc2-dcc2-42ab-a98b-191e58d0d9ab_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Average shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_5c6e8e2a-09c9-4a0f-9de5-c65604d65bca_negatedTerseLabel_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prior service credit (cost), net of amortization</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_label_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_documentation_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:href="jnj-20241229.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:to="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_63d677fa-62e7-4797-b905-5b997a967710_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-tax restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_e3493470-2794-4005-a52c-4a28532762fc_terseLabel_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA</link:label>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_label_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]</link:label>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_documentation_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:href="jnj-20241229.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:to="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DisposalGroupIncludingDiscontinuedOperationRestructuringExpense_e3a1ca59-f8fa-4657-bccd-3b332516d34c_terseLabel_en-US" xlink:label="lab_jnj_DisposalGroupIncludingDiscontinuedOperationRestructuringExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_jnj_DisposalGroupIncludingDiscontinuedOperationRestructuringExpense_label_en-US" xlink:label="lab_jnj_DisposalGroupIncludingDiscontinuedOperationRestructuringExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Restructuring Expense</link:label>
    <link:label id="lab_jnj_DisposalGroupIncludingDiscontinuedOperationRestructuringExpense_documentation_en-US" xlink:label="lab_jnj_DisposalGroupIncludingDiscontinuedOperationRestructuringExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Restructuring Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DisposalGroupIncludingDiscontinuedOperationRestructuringExpense" xlink:href="jnj-20241229.xsd#jnj_DisposalGroupIncludingDiscontinuedOperationRestructuringExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DisposalGroupIncludingDiscontinuedOperationRestructuringExpense" xlink:to="lab_jnj_DisposalGroupIncludingDiscontinuedOperationRestructuringExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyPaymentPeriod_08f58fcb-8df9-497a-be9e-13732c70db0d_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency, payment period</link:label>
    <link:label id="lab_jnj_LossContingencyPaymentPeriod_label_en-US" xlink:label="lab_jnj_LossContingencyPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Payment Period</link:label>
    <link:label id="lab_jnj_LossContingencyPaymentPeriod_documentation_en-US" xlink:label="lab_jnj_LossContingencyPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyPaymentPeriod" xlink:href="jnj-20241229.xsd#jnj_LossContingencyPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyPaymentPeriod" xlink:to="lab_jnj_LossContingencyPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_559b54e2-17f9-4e41-b5cd-feb262133442_terseLabel_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pinnacle Acetabular Cup System</link:label>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_label_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pinnacle Acetabular Cup System [Member]</link:label>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_documentation_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pinnacle Acetabular cup system.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember" xlink:href="jnj-20241229.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PinnacleAcetabularCupSystemMember" xlink:to="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_190100d0-6624-428d-b92b-50d860b17ad6_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income reported for tax purposes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount_3c7b2938-d540-4372-b83c-f20dcb343868_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation, GILTI, amount</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, GILTI, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_1ed1c7a7-ae5b-45b1-a46f-4e8fa72b01d5_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Less: common stock held in treasury, at cost (Note&#160;12) (712,921,000&#160;shares and 712,765,000&#160;shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_505551ca-3240-42ae-9631-c99f5343bd8d_periodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock, Balance</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_201bee25-937b-401f-8cfd-f9f0ca274be1_periodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock, Ending Balance</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9262b9ca-1ecc-4cc0-8262-a015ba18440c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DiscontinuedOperationsSeparationCostsIncurred_40dfd50b-07ff-4151-bd89-65e63ffb3999_terseLabel_en-US" xlink:label="lab_jnj_DiscontinuedOperationsSeparationCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Separation costs incurred</link:label>
    <link:label id="lab_jnj_DiscontinuedOperationsSeparationCostsIncurred_label_en-US" xlink:label="lab_jnj_DiscontinuedOperationsSeparationCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations, Separation Costs Incurred</link:label>
    <link:label id="lab_jnj_DiscontinuedOperationsSeparationCostsIncurred_documentation_en-US" xlink:label="lab_jnj_DiscontinuedOperationsSeparationCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Discontinued Operations, Separation Costs Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DiscontinuedOperationsSeparationCostsIncurred" xlink:href="jnj-20241229.xsd#jnj_DiscontinuedOperationsSeparationCostsIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DiscontinuedOperationsSeparationCostsIncurred" xlink:to="lab_jnj_DiscontinuedOperationsSeparationCostsIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_5a358165-d8be-494d-937a-8899846873f4_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales to customers</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_91d0f179-3871-4f47-b19a-a2ff1af0a86d_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_381de365-7fbe-433d-b6be-42cef3a77349_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_2d97dbf0-4b53-4106-895b-02e0c407be94_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_528c8989-26f8-4fd9-b5a7-beb4aa45fde8_terseLabel_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.50%&#160;Debentures due 2040</link:label>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_label_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">4.50% Debentures due 2040 [Member]</link:label>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_documentation_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">4.50% Debentures due 2040 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member" xlink:href="jnj-20241229.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.50Debenturesdue2040Member" xlink:to="lab_jnj_A4.50Debenturesdue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_c7e64ee6-8597-470c-830d-0e117e441cf2_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, marketing and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_7e4f7006-87fd-46c4-a1be-2d47f1645f98_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Matching contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_b634fcc7-ea0e-4d1f-bf77-da6a06f6e944_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Products Sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_Wholesaler3Member_c17430ec-fe45-499e-9244-1620177a5c74_terseLabel_en-US" xlink:label="lab_jnj_Wholesaler3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Wholesaler 3</link:label>
    <link:label id="lab_jnj_Wholesaler3Member_label_en-US" xlink:label="lab_jnj_Wholesaler3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Wholesaler 3 [Member]</link:label>
    <link:label id="lab_jnj_Wholesaler3Member_documentation_en-US" xlink:label="lab_jnj_Wholesaler3Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Wholesaler 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler3Member" xlink:href="jnj-20241229.xsd#jnj_Wholesaler3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_Wholesaler3Member" xlink:to="lab_jnj_Wholesaler3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_72797d88-f621-4980-afe2-6f019d5093ce_terseLabel_en-US" xlink:label="lab_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, tax basis increase of certain assets due to reorganization</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_label_en-US" xlink:label="lab_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Basis Increase of Certain Assets due to Reorganization</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_documentation_en-US" xlink:label="lab_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Basis Increase of Certain Assets due to Reorganization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" xlink:href="jnj-20241229.xsd#jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" xlink:to="lab_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f9a7236d-3fe3-4038-bf55-4762d28186c0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized for issuance under long-term incentive plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_aa203ae1-a797-4537-ac71-87c54803188b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyAccrualNominalValue_903c417a-a1d6-4bab-bf46-002da8e05d24_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyAccrualNominalValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrual, nominal value</link:label>
    <link:label id="lab_jnj_LossContingencyAccrualNominalValue_label_en-US" xlink:label="lab_jnj_LossContingencyAccrualNominalValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual, Nominal Value</link:label>
    <link:label id="lab_jnj_LossContingencyAccrualNominalValue_documentation_en-US" xlink:label="lab_jnj_LossContingencyAccrualNominalValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual, Nominal Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyAccrualNominalValue" xlink:href="jnj-20241229.xsd#jnj_LossContingencyAccrualNominalValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyAccrualNominalValue" xlink:to="lab_jnj_LossContingencyAccrualNominalValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_6b93ba0e-0ec6-4b84-8153-57b85e11a7f9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationIncrease_913da7bc-1ea2-45bf-99e3-cf442be0cbf5_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Invoices confirmed during the year</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationIncrease_label_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Finance Program, Obligation, Addition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierFinanceProgramObligationIncrease" xlink:to="lab_us-gaap_SupplierFinanceProgramObligationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_fd604a1b-1f4f-4405-b7b5-5fb173733560_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition related costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_d9832684-8f6d-4cf7-8f79-798c814b75e9_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Employee compensation and stock option plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_6ced83f2-f442-4459-8325-30c8090698cb_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_d534feb6-5f30-4a5a-a305-bf783da8c17b_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential shares exercisable under stock option plans (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShippingandHandlingCostsasaPercentofSales_31a53d91-0b70-44d4-9475-78034284ca01_terseLabel_en-US" xlink:label="lab_jnj_ShippingandHandlingCostsasaPercentofSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shipping and handling costs as a percent of sales</link:label>
    <link:label id="lab_jnj_ShippingandHandlingCostsasaPercentofSales_label_en-US" xlink:label="lab_jnj_ShippingandHandlingCostsasaPercentofSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shipping and Handling Costs as a Percent of Sales</link:label>
    <link:label id="lab_jnj_ShippingandHandlingCostsasaPercentofSales_documentation_en-US" xlink:label="lab_jnj_ShippingandHandlingCostsasaPercentofSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shipping and Handling Costs as a Percent of Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShippingandHandlingCostsasaPercentofSales" xlink:href="jnj-20241229.xsd#jnj_ShippingandHandlingCostsasaPercentofSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShippingandHandlingCostsasaPercentofSales" xlink:to="lab_jnj_ShippingandHandlingCostsasaPercentofSales" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_f34138b7-e421-48c8-9da9-6ce858de69c2_terseLabel_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Simponi/Simponi Aria</link:label>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_label_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Simponi/Simponi Aria [Member]</link:label>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_documentation_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Simponi/Simponi Aria [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember" xlink:href="jnj-20241229.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SimponiSimponiAriaMember" xlink:to="lab_jnj_SimponiSimponiAriaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_a6318af7-2b4f-4d78-80a9-38f6a2e918f0_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_d9f7a050-4774-44fd-b866-267e6c6f5407_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_f5e11cea-5180-4425-9ca4-2c2bb45768af_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_a4eec48f-81b5-446d-a7eb-181e599baf44_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Severance Charges and Associated Spending</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_d34ec6bf-352a-43b0-a839-fd49e17f8f62_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain/ (Loss) On Securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d47b8272-7348-4b62-b28e-2689d65d41c4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_1bba7be9-2fe5-4c01-826c-945a0a1e223c_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_57cac426-4f15-43a7-a3a0-a8ee3817c03d_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_594d7e47-4c04-4a79-aa9f-188d41073663_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b8364bb2-8ee5-4942-904a-22d2b9a3502d_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5e5c7143-4eae-4210-8777-c110db2dc978_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_914942a3-65a6-484b-a485-b513cd29099b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_0409a693-488f-4e75-a8b3-de0f869a63f4_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldtomaturitySecuritiesMember_0cf9932d-7aa1-45ee-b571-fe4743f0bc49_terseLabel_en-US" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity Securities</link:label>
    <link:label id="lab_us-gaap_HeldtomaturitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Held-to-Maturity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldtomaturitySecuritiesMember" xlink:to="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ff277aef-e57b-4432-94e3-82346190ab04_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_be71e5f4-41bd-483c-896c-6b52bddabf66_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_969bd0ee-08e3-48b3-8638-518517151e86_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_XareltoMember_36f31b01-6fe4-449e-b3b1-7635751f3a80_terseLabel_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">XARELTO</link:label>
    <link:label id="lab_jnj_XareltoMember_label_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Xarelto [Member]</link:label>
    <link:label id="lab_jnj_XareltoMember_documentation_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Xarelto [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember" xlink:href="jnj-20241229.xsd#jnj_XareltoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_XareltoMember" xlink:to="lab_jnj_XareltoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_a4b5d442-1be2-468f-8ba1-3b62a17104d3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Actuarial (gains) losses</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_5b467412-d764-45bc-b2bc-f8b522b0abd4_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree_1df8af76-e508-4fb5-a0d9-8fc93ae42eec_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Expected Future Benefit Contribution In Year Three</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined benefit plan expected future benefit contribution in year three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" xlink:to="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_dfc22114-eb82-4d2a-aeea-ecf8f6bcdebe_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents from discontinued operations, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_7cc1f2ca-b796-4c94-8396-78661fd0648a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents from discontinued operations, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fa9cd59d-5cd7-48b2-95f3-dfccb033b74d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1f2088aa-4c98-4460-98aa-e51f61cb5cb5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying Amount, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_017e3d41-dc74-4bdc-9f3d-7abaec2aeee2_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableAmountPerShare_f2e2f31a-c188-4b80-a3e5-7cf1eb463704_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableAmountPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends payable, amount per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DividendsPayableAmountPerShare_label_en-US" xlink:label="lab_us-gaap_DividendsPayableAmountPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends Payable, Amount Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableAmountPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPayableAmountPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableAmountPerShare" xlink:to="lab_us-gaap_DividendsPayableAmountPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_359cbc08-5feb-4766-8298-f89f593000ee_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_3864c1bc-6507-44d4-bc76-e704af7278e7_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_6be9db09-61d9-4e0f-b86a-a9fc763c3386_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding number of Options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierFinanceProgramPaymentTimingPeriod_f2b3008b-056c-4c41-b4aa-e97b36ecd2c0_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramPaymentTimingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier finance program, payment timing, period</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramPaymentTimingPeriod_label_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramPaymentTimingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Finance Program, Payment Timing, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramPaymentTimingPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramPaymentTimingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierFinanceProgramPaymentTimingPeriod" xlink:to="lab_us-gaap_SupplierFinanceProgramPaymentTimingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_b274ae56-7151-4742-b93b-a07dabc07086_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Finite lived intangible assets net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_370a07f2-52e7-47fa-9047-907d92e26128_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_4ec368b9-435e-40db-8f05-98b48ed8f650_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) related to litigation settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) from Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_e509c6bb-29e9-4720-9622-fbff1ec304bc_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c085a672-3053-494d-901a-f18478bc4281_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_d99cb909-48b0-4239-bc71-9273f9af6ddb_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ZYTIGAMember_91b25fd7-6a21-4992-bf3e-f59f01b830fd_terseLabel_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ZYTIGA/abiraterone acetate</link:label>
    <link:label id="lab_jnj_ZYTIGAMember_label_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZYTIGA [Member]</link:label>
    <link:label id="lab_jnj_ZYTIGAMember_documentation_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ZYTIGA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember" xlink:href="jnj-20241229.xsd#jnj_ZYTIGAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ZYTIGAMember" xlink:to="lab_jnj_ZYTIGAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2af7b3b5-acec-4250-b454-803268cfb8e7_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Earnings before provision for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_181fdc81-5fea-490d-9499-1d6e4cf313b3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings before provision for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_31c50b5d-67d2-4345-8957-669ed7d3e2c4_verboseLabel_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets and Goodwill</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_label_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_documentation_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:href="jnj-20241229.xsd#jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:to="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_ccbde859-703e-4ec2-88ac-a33a697ea46b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_d2a61ed1-7b24-452d-a1e4-d66c03016cb7_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_95403df7-915f-457f-983b-215ca9f0fdc8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherNonLongLivedAssets_6167b257-a395-4168-a9ea-f197871cde7b_terseLabel_en-US" xlink:label="lab_jnj_OtherNonLongLivedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non long-lived assets</link:label>
    <link:label id="lab_jnj_OtherNonLongLivedAssets_label_en-US" xlink:label="lab_jnj_OtherNonLongLivedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Non Long Lived Assets</link:label>
    <link:label id="lab_jnj_OtherNonLongLivedAssets_documentation_en-US" xlink:label="lab_jnj_OtherNonLongLivedAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other non long lived assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonLongLivedAssets" xlink:href="jnj-20241229.xsd#jnj_OtherNonLongLivedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherNonLongLivedAssets" xlink:to="lab_jnj_OtherNonLongLivedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_9b87d844-0c8c-4224-af98-fc270f82d27e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kenvue Separation /IPO</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Spinoff Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:to="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract_72e2b322-50e5-45c2-9349-b75930848c07_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_641137d7-e8a4-465f-a351-2223ef0c6b0e_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Investments without readily determinable value</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_label_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Investments without Readily Determinable Value [Member]</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Investments without Readily Determinable Value [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:href="jnj-20241229.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:to="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight_4d7a4669-01cf-4956-b290-6ad2b6801adf_terseLabel_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-tradeable contingent value right</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight_label_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Tradeable Contingent Value Right</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight_documentation_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Tradeable Contingent Value Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight" xlink:href="jnj-20241229.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight" xlink:to="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_3d6799fc-f9ef-436f-b85c-14e3c899de38_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_c2728747-77be-4c24-8d42-8000b0ca1e15_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_81a4fe96-e8fb-4a66-a7af-e79012fe9369_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_904c79c4-a148-482b-954c-c946e6fa87ff_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_12618d61-7ae6-4cd3-9795-1ef8ca2d557f_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of prior service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_df302866-748f-4387-af1d-400c403f69f3_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_2a929675-a5e4-417f-aef4-245034897abd_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted net earnings per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_c8081c1d-b0ac-4449-a29f-6be49abb68d7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Asset Amortization Expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_d078513d-fe0e-4ed9-8c4d-7813b2ace154_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_7f0a483d-7c2b-4ace-9819-7921c67aa36f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.&#160;</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_47416bf1-ac87-48f7-af6e-86d365f1c5c4_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total currently payable</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_bea40fc5-a3bd-4784-9713-22425715ade9_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_acf00d07-fc9e-4dcc-80ab-3216242881a7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SurgeryMember_2da99b89-eae0-4dbe-b047-96f5b7082134_terseLabel_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Surgery</link:label>
    <link:label id="lab_jnj_SurgeryMember_label_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Surgery [Member]</link:label>
    <link:label id="lab_jnj_SurgeryMember_documentation_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Surgery [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember" xlink:href="jnj-20241229.xsd#jnj_SurgeryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SurgeryMember" xlink:to="lab_jnj_SurgeryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_89fb9f44-97e2-4a1a-bd33-204b24b42352_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_5bf5e484-c0c4-4689-866e-0a81b4b25a0d_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency transaction gain (loss), before tax</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_1dd22103-0d00-4bef-b286-14c6d95c7b78_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_11c11d9f-0cf7-4b1d-9398-5f49dc0b42fd_terseLabel_en-US" xlink:label="lab_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Asset, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</link:label>
    <link:label id="lab_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_label_en-US" xlink:label="lab_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</link:label>
    <link:label id="lab_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_documentation_en-US" xlink:label="lab_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Asset, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:href="jnj-20241229.xsd#jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:to="lab_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_6c042f22-9d2c-4a43-8af2-2ce3879a8a91_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EmployeeCompensationPeriod_2dab66db-2ce1-48b2-9739-d1ecb35d2515_terseLabel_en-US" xlink:label="lab_jnj_EmployeeCompensationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement plan benefits employee compensation period</link:label>
    <link:label id="lab_jnj_EmployeeCompensationPeriod_label_en-US" xlink:label="lab_jnj_EmployeeCompensationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Compensation Period</link:label>
    <link:label id="lab_jnj_EmployeeCompensationPeriod_documentation_en-US" xlink:label="lab_jnj_EmployeeCompensationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Compensation Period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeCompensationPeriod" xlink:href="jnj-20241229.xsd#jnj_EmployeeCompensationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EmployeeCompensationPeriod" xlink:to="lab_jnj_EmployeeCompensationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations_de71ec7c-cca7-4fbb-a4ba-f4bcce48e7a8_totalLabel_en-US" xlink:label="lab_jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred</link:label>
    <link:label id="lab_jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations_label_en-US" xlink:label="lab_jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Net Of Discontinued Operations</link:label>
    <link:label id="lab_jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations_documentation_en-US" xlink:label="lab_jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Net Of Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations" xlink:href="jnj-20241229.xsd#jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations" xlink:to="lab_jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ElmironMember_2c9d3cf0-790e-4de4-8c8c-035b7efb60de_terseLabel_en-US" xlink:label="lab_jnj_ElmironMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Elmiron</link:label>
    <link:label id="lab_jnj_ElmironMember_label_en-US" xlink:label="lab_jnj_ElmironMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Elmiron [Member]</link:label>
    <link:label id="lab_jnj_ElmironMember_documentation_en-US" xlink:label="lab_jnj_ElmironMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Elmiron</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ElmironMember" xlink:href="jnj-20241229.xsd#jnj_ElmironMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ElmironMember" xlink:to="lab_jnj_ElmironMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_448ba083-52a7-42f5-a1c1-ef94220440b1_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, period increase (decrease)</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_3efb925d-c0e0-46e2-95e6-357aa19781f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of RSU or PSU units settled</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_9857d7a0-91f2-4ba7-8661-32c051c4fda0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_80562f1b-81a0-4f06-91db-5419fc54f000_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8a51def5-9912-415c-9acc-192008db2f37_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Provision for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_ad9495e8-c9dd-4ccd-ad1f-c7564d020ff8_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_e2f64bf4-b70e-414d-8364-21c29bfc87f7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_74725e83-1980-447e-b344-6a0fe6b7f321_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_b86c9ba5-5753-4db8-b2d8-f76e80715ae4_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Net Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_57f84974-afb4-40ef-9ade-5449b1bfb2f5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of gain or (loss) recognized in AOCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_40c9db77-0090-49e1-98fa-d4cfd66db18e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average period for total compensation cost not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4bf1b383-a83a-4be2-a5c6-e3bd31c32821_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sales to customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_91abb943-e3bb-430f-b1e1-de453127a12f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales to Customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_94f1c061-5fe7-442a-914b-fd6af19663f1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RDRestructuringPlanMember_d04e717c-1569-47d2-86e0-2102bcfd0aca_terseLabel_en-US" xlink:label="lab_jnj_RDRestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">R&amp;D Restructuring Plan</link:label>
    <link:label id="lab_jnj_RDRestructuringPlanMember_label_en-US" xlink:label="lab_jnj_RDRestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">R&amp;D Restructuring Plan [Member]</link:label>
    <link:label id="lab_jnj_RDRestructuringPlanMember_documentation_en-US" xlink:label="lab_jnj_RDRestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">R&amp;D Restructuring Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RDRestructuringPlanMember" xlink:href="jnj-20241229.xsd#jnj_RDRestructuringPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RDRestructuringPlanMember" xlink:to="lab_jnj_RDRestructuringPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_f0003edf-a726-4a22-b5c0-b93aeb3890d3_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_42795804-443a-4950-ac02-7ef73177edcd_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used by)/from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PaymentsToAcquiredInProcessResearchAndDevelopmentAssets_51f881f7-fe87-444b-94a9-9f0484682af7_negatedTerseLabel_en-US" xlink:label="lab_jnj_PaymentsToAcquiredInProcessResearchAndDevelopmentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of in-process research and development assets</link:label>
    <link:label id="lab_jnj_PaymentsToAcquiredInProcessResearchAndDevelopmentAssets_label_en-US" xlink:label="lab_jnj_PaymentsToAcquiredInProcessResearchAndDevelopmentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments To Acquired In-Process Research And Development Assets</link:label>
    <link:label id="lab_jnj_PaymentsToAcquiredInProcessResearchAndDevelopmentAssets_documentation_en-US" xlink:label="lab_jnj_PaymentsToAcquiredInProcessResearchAndDevelopmentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments To Acquired In-Process Research And Development Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PaymentsToAcquiredInProcessResearchAndDevelopmentAssets" xlink:href="jnj-20241229.xsd#jnj_PaymentsToAcquiredInProcessResearchAndDevelopmentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PaymentsToAcquiredInProcessResearchAndDevelopmentAssets" xlink:to="lab_jnj_PaymentsToAcquiredInProcessResearchAndDevelopmentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_5f5e0b8b-6446-43a3-9e96-045c0bb9bb53_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_db188808-df7a-4c73-bd9b-3ecc7704a81f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_822f1c41-d0e1-4d7a-b437-9472f0f201aa_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_4c54a3e9-2a3e-4b37-be38-cfb9936ddbdc_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefits on share-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_VisionMember_2d20bae0-fdaf-43c1-9b3b-125c932c83eb_terseLabel_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vision</link:label>
    <link:label id="lab_jnj_VisionMember_label_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vision [Member]</link:label>
    <link:label id="lab_jnj_VisionMember_documentation_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vision[Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember" xlink:href="jnj-20241229.xsd#jnj_VisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_VisionMember" xlink:to="lab_jnj_VisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_511da348-7c8a-4841-b949-b30de7de1eb6_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and employee related obligations</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LaminarMember_9f2d1952-69f4-4139-bd23-6ddda77001d7_terseLabel_en-US" xlink:label="lab_jnj_LaminarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laminar</link:label>
    <link:label id="lab_jnj_LaminarMember_label_en-US" xlink:label="lab_jnj_LaminarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laminar [Member]</link:label>
    <link:label id="lab_jnj_LaminarMember_documentation_en-US" xlink:label="lab_jnj_LaminarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laminar</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LaminarMember" xlink:href="jnj-20241229.xsd#jnj_LaminarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LaminarMember" xlink:to="lab_jnj_LaminarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2022LongTermIncentivePlanMember_7c7f1097-4985-40ec-8eda-af84a5dd2fcb_terseLabel_en-US" xlink:label="lab_jnj_A2022LongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022 Long-Term Incentive Plan</link:label>
    <link:label id="lab_jnj_A2022LongTermIncentivePlanMember_label_en-US" xlink:label="lab_jnj_A2022LongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2022 Long-Term Incentive Plan [Member]</link:label>
    <link:label id="lab_jnj_A2022LongTermIncentivePlanMember_documentation_en-US" xlink:label="lab_jnj_A2022LongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2022 Long-Term Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2022LongTermIncentivePlanMember" xlink:href="jnj-20241229.xsd#jnj_A2022LongTermIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2022LongTermIncentivePlanMember" xlink:to="lab_jnj_A2022LongTermIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_f5d155b1-744c-4ab5-89ed-112388b1275d_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour_f2750c25-8397-468d-9adf-7dc191ca9d3b_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Expected Future Benefit Contribution In Year Four</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined benefit plan expected future benefit contribution in year four.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" xlink:to="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_0834cc39-c4e5-4fe3-9038-60a080689290_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, noncurrent</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ea955bf6-8e65-47a1-a875-74ad718e90fb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_ed419921-5770-459c-b503-ff47c211a687_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_e9a55dd6-70d0-4165-9d6b-7d6ef0524d45_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_fbb22728-f30a-4787-af41-d6d93c48c6ff_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_406c9dae-af43-4206-a0b6-ed66c2f78f51_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_96e8f6e0-33fa-40b6-b8e1-4af9d102fe45_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI_2e578745-5123-46f2-8d0b-214bb815be4c_terseLabel_en-US" xlink:label="lab_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in deferred tax liabilities, global intangible low-taxed income (GILTI)</link:label>
    <link:label id="lab_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI_label_en-US" xlink:label="lab_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Tax Liabilities, Global Intangible Low-Taxed Income (GILTI)</link:label>
    <link:label id="lab_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI_documentation_en-US" xlink:label="lab_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Tax Liabilities, Global Intangible Low-Taxed Income (GILTI)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" xlink:href="jnj-20241229.xsd#jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" xlink:to="lab_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_GENERALMember_85803d42-ee26-47db-85d8-0488095118a3_terseLabel_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GENERAL</link:label>
    <link:label id="lab_jnj_GENERALMember_label_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GENERAL [Member]</link:label>
    <link:label id="lab_jnj_GENERALMember_documentation_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GENERAL [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember" xlink:href="jnj-20241229.xsd#jnj_GENERALMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_GENERALMember" xlink:to="lab_jnj_GENERALMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_dd089d9b-d51d-4be4-8b17-8acb7fbd069f_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_6dfe837e-c311-4d72-9b89-4f0af1cbe314_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, value</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_fb43bc57-643a-493b-87c7-1afb2a4e502c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, net of portion capitalized</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_eea01574-c947-410b-b016-570730d10453_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain/ (Loss) On Derivatives &amp; Hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_f3bf4c48-7249-47b7-8780-47289dd1fc5e_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Gov't Agencies</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_e3668694-c5bc-49cc-a701-653429fc7361_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic net earnings per share from discontinued operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_1d32aaff-0898-43d7-97c2-831fcd547d69_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average assumptions of fair value of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_57205ff4-e2fc-405f-a6fc-d75c04a1a537_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShortTermInvestmentFundsMember_1a9965d7-2fd9-4f52-966e-7861eebd8340_terseLabel_en-US" xlink:label="lab_jnj_ShortTermInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investment funds</link:label>
    <link:label id="lab_jnj_ShortTermInvestmentFundsMember_label_en-US" xlink:label="lab_jnj_ShortTermInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short Term Investment Funds [Member]</link:label>
    <link:label id="lab_jnj_ShortTermInvestmentFundsMember_documentation_en-US" xlink:label="lab_jnj_ShortTermInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short term investment funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShortTermInvestmentFundsMember" xlink:href="jnj-20241229.xsd#jnj_ShortTermInvestmentFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShortTermInvestmentFundsMember" xlink:to="lab_jnj_ShortTermInvestmentFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_7e035d80-e25e-411f-b314-a0c083423c8c_terseLabel_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_label_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain" xlink:to="lab_us-gaap_PlanAssetCategoriesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_9c8f56d5-0a74-425a-b951-633ce9fe0c70_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_9805b823-f4ab-4ca3-b942-962c1e7923cb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumed Health Care Cost Trend Rates</link:label>
    <link:label id="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Health Care Cost Trend Rates [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_776afa11-a202-4869-b8ee-b65036da4217_terseLabel_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_label_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_ce3c2411-69dd-43e4-ba5c-e6bcd7aafaf0_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization of prior service (cost) credit</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2547af0f-7b99-4aff-91a4-20c364dedccc_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6d4452d6-f173-465c-8444-b37919c52d28_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Shareholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_75f7bf6d-7a13-4cbc-8e53-b3249a348687_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of Net Periodic Benefit Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EmployeeObligations_a2fd9680-73c3-45d3-9667-dcb8ba06ca62_totalLabel_en-US" xlink:label="lab_jnj_EmployeeObligations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total employee obligations</link:label>
    <link:label id="lab_jnj_EmployeeObligations_label_en-US" xlink:label="lab_jnj_EmployeeObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Obligations</link:label>
    <link:label id="lab_jnj_EmployeeObligations_documentation_en-US" xlink:label="lab_jnj_EmployeeObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total employee obligations current and non current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeObligations" xlink:href="jnj-20241229.xsd#jnj_EmployeeObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EmployeeObligations" xlink:to="lab_jnj_EmployeeObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ResearchAndDevelopmentInProcess1_922a7311-0c17-4635-842a-fbddd0356ce2_verboseLabel_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentInProcess1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development impairments</link:label>
    <link:label id="lab_jnj_ResearchAndDevelopmentInProcess1_ed8ebf12-8e9d-490b-a6aa-9a0b25a30764_terseLabel_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentInProcess1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development in process</link:label>
    <link:label id="lab_jnj_ResearchAndDevelopmentInProcess1_label_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentInProcess1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development In Process1</link:label>
    <link:label id="lab_jnj_ResearchAndDevelopmentInProcess1_documentation_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentInProcess1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development In Process1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentInProcess1" xlink:href="jnj-20241229.xsd#jnj_ResearchAndDevelopmentInProcess1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ResearchAndDevelopmentInProcess1" xlink:to="lab_jnj_ResearchAndDevelopmentInProcess1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateContractMember_3ae20d81-8faa-49cc-801b-7d1dd57e6756_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate swaps contracts:</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember" xlink:to="lab_us-gaap_InterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyDamagesSoughtValueIncrease_3ebc22e3-a237-4e99-a3f7-408dd857f9ae_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyDamagesSoughtValueIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in damages sought</link:label>
    <link:label id="lab_jnj_LossContingencyDamagesSoughtValueIncrease_label_en-US" xlink:label="lab_jnj_LossContingencyDamagesSoughtValueIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Sought, Value, Increase</link:label>
    <link:label id="lab_jnj_LossContingencyDamagesSoughtValueIncrease_documentation_en-US" xlink:label="lab_jnj_LossContingencyDamagesSoughtValueIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Sought, Value, Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyDamagesSoughtValueIncrease" xlink:href="jnj-20241229.xsd#jnj_LossContingencyDamagesSoughtValueIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyDamagesSoughtValueIncrease" xlink:to="lab_jnj_LossContingencyDamagesSoughtValueIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_fc8315ed-b319-486e-8e8f-a5fa65d09f5d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Equity Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d6c42a33-37a8-4986-ba44-8106f29e7a0f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_aa83fee1-5c20-4fba-a325-4b23840fef66_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options exercise price beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_47581cc9-9f10-48d5-a1bb-fc80fbe6f026_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options exercise price end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_1c0e32b0-696f-49bc-85b9-e3d274f1efd8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_6a86fda9-8124-4575-816b-bab3450d1a83_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ImmunologyMember_1b1284d6-7960-4c32-9626-5f21b75139e6_terseLabel_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Immunology</link:label>
    <link:label id="lab_jnj_ImmunologyMember_label_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Immunology [Member]</link:label>
    <link:label id="lab_jnj_ImmunologyMember_documentation_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember" xlink:href="jnj-20241229.xsd#jnj_ImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ImmunologyMember" xlink:to="lab_jnj_ImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_23b1b67e-6a0c-4f40-b7f6-02149742681d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5e59fc73-e010-4e6a-8293-14f249bf75e7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_ebf03eb7-4ed5-4a0b-ad96-a229685c5f34_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_3c73166c-e5ed-4b27-bbfd-9145efb1b137_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_927c9538-477e-41ea-9167-5ab00d442630_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAmendments_5d247dc8-10d9-465a-98ea-a71b343cde01_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAmendments_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyClaimsSettledPercent_88fafb49-7458-43b1-9d16-286706d99a7f_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyClaimsSettledPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Claims settled, percent</link:label>
    <link:label id="lab_jnj_LossContingencyClaimsSettledPercent_label_en-US" xlink:label="lab_jnj_LossContingencyClaimsSettledPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Claims Settled, Percent</link:label>
    <link:label id="lab_jnj_LossContingencyClaimsSettledPercent_documentation_en-US" xlink:label="lab_jnj_LossContingencyClaimsSettledPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Claims Settled, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyClaimsSettledPercent" xlink:href="jnj-20241229.xsd#jnj_LossContingencyClaimsSettledPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyClaimsSettledPercent" xlink:to="lab_jnj_LossContingencyClaimsSettledPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_c965ac58-d701-43c1-bba9-6cd420c35930_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_85b6dd84-0ffa-47bf-bb9a-a81d27a46b6e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InnovativeMedicineMember_bd7a191d-570b-4099-8835-743000eeb977_terseLabel_en-US" xlink:label="lab_jnj_InnovativeMedicineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Innovative Medicine</link:label>
    <link:label id="lab_jnj_InnovativeMedicineMember_label_en-US" xlink:label="lab_jnj_InnovativeMedicineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Innovative Medicine [Member]</link:label>
    <link:label id="lab_jnj_InnovativeMedicineMember_documentation_en-US" xlink:label="lab_jnj_InnovativeMedicineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Innovative Medicine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InnovativeMedicineMember" xlink:href="jnj-20241229.xsd#jnj_InnovativeMedicineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InnovativeMedicineMember" xlink:to="lab_jnj_InnovativeMedicineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_b1d9ce0b-075b-4a4c-956a-65779e15f669_terseLabel_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:href="jnj-20241229.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_745c4fde-a55f-4153-9f98-66a42ff3dcae_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) arising during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_4391cedc-7992-45e4-8631-6a129090ee57_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of gain or (loss) recognized in AOCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b2e52499-b2b4-4483-a513-739028482ee3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average fair value of RSU's and PSU's granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_6a9e2ff0-d01f-40a7-b0e9-cdc679564ade_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_f0edaf9c-011a-4cda-a690-c228e2a242d1_terseLabel_en-US" xlink:label="lab_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_label_en-US" xlink:label="lab_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities</link:label>
    <link:label id="lab_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_documentation_en-US" xlink:label="lab_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:href="jnj-20241229.xsd#jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:to="lab_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_ca3b8a05-8bbd-45ae-9c7b-cf8e12b12b0e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_ff871c05-d2b0-4e7d-a296-61fdf5bd2a58_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_f7d6b429-d914-4f73-80f9-b4977456b4b0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Debt Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDebtSecuritiesMember" xlink:to="lab_us-gaap_OtherDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProfitLossPercentToSales_2027e5a3-42a3-460a-8c21-366758f3ac75_terseLabel_en-US" xlink:label="lab_jnj_ProfitLossPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of profit share payments (less than)</link:label>
    <link:label id="lab_jnj_ProfitLossPercentToSales_label_en-US" xlink:label="lab_jnj_ProfitLossPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Loss Percent To Sales</link:label>
    <link:label id="lab_jnj_ProfitLossPercentToSales_documentation_en-US" xlink:label="lab_jnj_ProfitLossPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profit loss percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProfitLossPercentToSales" xlink:href="jnj-20241229.xsd#jnj_ProfitLossPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProfitLossPercentToSales" xlink:to="lab_jnj_ProfitLossPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_d295cd1d-58f3-4f9a-8587-cfd672e995c8_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExercisePriceRangeFourMember_aceb59ff-5aa6-48e2-8cac-1d67bb832cdc_terseLabel_en-US" xlink:label="lab_jnj_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$157.92 - $162.75</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeFourMember_label_en-US" xlink:label="lab_jnj_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeFourMember_documentation_en-US" xlink:label="lab_jnj_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeFourMember" xlink:href="jnj-20241229.xsd#jnj_ExercisePriceRangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExercisePriceRangeFourMember" xlink:to="lab_jnj_ExercisePriceRangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_55d4b048-f907-401f-a218-071861e48541_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_cdb1245c-5ba8-4a4a-98ba-5fe5c4e9ec39_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_7b885002-d288-43f2-a770-b614f041e14f_terseLabel_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.650% Notes due 2024 (750MM Euro 1.1090)(3)</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_label_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.650% Notes Due 2024 [Member]</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_documentation_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">0.650% Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member" xlink:href="jnj-20241229.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A0.650NotesDue2024Member" xlink:to="lab_jnj_A0.650NotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationDecreaseSettlement_72d47372-287e-4f58-8618-3c10f14c58c8_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationDecreaseSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Confirmed invoices paid during the year</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationDecreaseSettlement_label_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationDecreaseSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Finance Program, Obligation, Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationDecreaseSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligationDecreaseSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierFinanceProgramObligationDecreaseSettlement" xlink:to="lab_us-gaap_SupplierFinanceProgramObligationDecreaseSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_99c6c59d-fb69-4d19-bd2a-1fac9ed76ef3_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Funded status - end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_21ad4c7e-5de3-4236-b169-8f92df8206c4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Projected Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Funded (Unfunded) Status of Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1eb0c30b-e91b-4633-8ef7-5e55624099fd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor_6d452e2c-5d13-45cb-abf3-e0975f3a64ae_terseLabel_en-US" xlink:label="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Probability of success factor</link:label>
    <link:label id="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor_label_en-US" xlink:label="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Probability Of Success Factor</link:label>
    <link:label id="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor_documentation_en-US" xlink:label="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Probability Of Success Factor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:href="jnj-20241229.xsd#jnj_BusinessCombinationProbabilityOfSuccessFactor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:to="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6babce09-ecae-428a-81be-728f1450aa31_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_4595ab0b-5f3a-417e-9450-9dec13144adf_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total before tax effects</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_6ebb50a5-6030-49fa-a14a-e2624b5d8ff2_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5d105890-60a9-40f2-97be-962d7bf3a21b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_529a2e8d-72ad-4638-90df-580b49a7a739_terseLabel_en-US" xlink:label="lab_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding and exercisable</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_label_en-US" xlink:label="lab_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Abstract]</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_documentation_en-US" xlink:label="lab_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation shares authorized under stock option plans by exercise price range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" xlink:href="jnj-20241229.xsd#jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" xlink:to="lab_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_eedf9596-c6ee-47d1-8495-6e74720c98f0_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Projected benefit obligation - beginning of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_15f2e782-4182-400d-adf4-02d4c6d4ea2e_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Projected benefit obligation - end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_bce43d88-924f-4a84-b51c-2a268f0ba136_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Projected Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_580488e4-8c1f-431c-9561-6f29dfe2d041_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpenditureDiscontinuedOperations_322d0e97-32ad-492a-a75b-b0174cc45c46_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_CapitalExpenditureDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditure, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:to="lab_us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_c0245830-f5af-4ab1-b984-8d9f7e5095b3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Dividends to shareholders</link:label>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Ordinary Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfOrdinaryDividends" xlink:to="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OPSUMITMember_d055a471-6bb7-497a-b655-a3e1041048e2_terseLabel_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OPSUMIT</link:label>
    <link:label id="lab_jnj_OPSUMITMember_label_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OPSUMIT [Member]</link:label>
    <link:label id="lab_jnj_OPSUMITMember_documentation_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OPSUMIT [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember" xlink:href="jnj-20241229.xsd#jnj_OPSUMITMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OPSUMITMember" xlink:to="lab_jnj_OPSUMITMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_9c8f1565-48d7-4ad3-9895-264dbeb7434a_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_69553e78-a9f9-4f77-a598-7b89336d675c_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and current marketable securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_71b8580e-1e04-4d9f-992f-8d947fc31fb2_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Gross Profit (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_31c849a5-0a40-4afe-9796-f418f35e320e_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted net earnings per share from discontinuing operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_af2d9e74-3978-4c12-b9b9-8e9039a1da09_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_5f69c46a-289c-433d-a5f5-91ccfb9639f9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities assumed:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_970eaf7f-c6a3-46d8-8add-cad4a0886a59_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowances</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_6a02a45e-a15d-4610-a383-cf3f4d6d4b03_periodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning of year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0c22d651-32c6-4c23-98a0-6d7fef86f274_periodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">End of year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_445e50c7-f999-40a3-9381-8a58982fef24_terseLabel_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.90%&#160;Notes due 2028</link:label>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_label_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.900% Notes due 2028 [Member]</link:label>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_documentation_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2.900% Notes due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member" xlink:href="jnj-20241229.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.900Notesdue2028Member" xlink:to="lab_jnj_A2.900Notesdue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_717c9ce5-652b-489c-acc3-f2b734412f4d_terseLabel_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UNITED STATES Exports</link:label>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_label_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES Exports [Member]</link:label>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_documentation_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">UNITED STATES Exports [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember" xlink:href="jnj-20241229.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_UNITEDSTATESExportsMember" xlink:to="lab_jnj_UNITEDSTATESExportsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_9d4896c7-3a8f-48d9-a5ee-908bdf08b0d8_terseLabel_en-US" xlink:label="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]</link:label>
    <link:label id="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_label_en-US" xlink:label="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract" xlink:to="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_df5d785d-c59f-4214-a467-641666e704b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of option activity under the Plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f1abf8b1-d026-483e-8ca2-42dbdc1f1b98_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities, net of effects from acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome_28315555-c2a6-407e-b0ab-9a6b3c106ed9_terseLabel_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. taxes on international income</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome_label_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation Related To Domestic Tax On International Income</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome_documentation_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation related to domestic tax on international income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" xlink:href="jnj-20241229.xsd#jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" xlink:to="lab_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_76bdc485-3731-46f2-bcce-851553863260_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum length of time for hedging transaction exposure</link:label>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_label_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Length of Time, Foreign Currency Cash Flow Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:to="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_3f19aa9b-3d90-42d3-9df8-12d94171817b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying Amount of the Hedged Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_a4709be3-4d7f-4991-b3b6-2c9ab24a77a3_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total Gross Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_3f17640a-3726-4818-a31f-a6efba9350b7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt_7787e16c-c2a9-4ea6-b513-985e87591eb3_terseLabel_en-US" xlink:label="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Excess of fair value over carrying value of debt</link:label>
    <link:label id="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt_label_en-US" xlink:label="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Excess Of Fair Value Over Carrying Value Of Debt</link:label>
    <link:label id="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt_documentation_en-US" xlink:label="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Excess of fair value over carrying value of debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:href="jnj-20241229.xsd#jnj_ExcessOfFairValueOverCarryingValueOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:to="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_f6f76681-ee68-4d57-bc6a-fe7cb6b0e15b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f2d0426b-66ba-47cd-9c5c-ae34b102c7ff_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_6ce9a2b1-3d11-4f35-91bf-4f2585042bf3_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_35c6dad0-beac-4727-8bda-043ae467e28e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_1047866f-07be-4e74-9793-20613d43cf00_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Par Value $1.00</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_8b102e25-632d-4b5f-9b65-502338430cd8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock Issued Amount</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_bb7cb2cb-2369-4d0f-a2e7-6ed4fdd589b4_terseLabel_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.95%&#160;Debentures due 2033</link:label>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_label_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">4.95% Debentures due 2033 [Member]</link:label>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_documentation_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">4.95% Debentures due 2033 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member" xlink:href="jnj-20241229.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.95Debenturesdue2033Member" xlink:to="lab_jnj_A4.95Debenturesdue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_KNEESMember_41ca581b-725a-46d4-91a3-14c08d81e7ef_terseLabel_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">KNEES</link:label>
    <link:label id="lab_jnj_KNEESMember_label_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">KNEES [Member]</link:label>
    <link:label id="lab_jnj_KNEESMember_documentation_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">KNEES [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember" xlink:href="jnj-20241229.xsd#jnj_KNEESMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_KNEESMember" xlink:to="lab_jnj_KNEESMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43d5d5b1-c842-48ce-ab0d-4a781e5f149c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_76f21f7a-62ab-418f-bf4e-c25e7f468059_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanOverUnderFundedStatusABO_cf1a21b3-0af9-41e8-b0fd-2000eb3b4619_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanOverUnderFundedStatusABO" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Benefit Obligation</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanOverUnderFundedStatusABO_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanOverUnderFundedStatusABO" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Over (Under) Funded Status ABO</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanOverUnderFundedStatusABO_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanOverUnderFundedStatusABO" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined benefit plan over (under) funded status ABO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanOverUnderFundedStatusABO" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanOverUnderFundedStatusABO"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanOverUnderFundedStatusABO" xlink:to="lab_jnj_DefinedBenefitPlanOverUnderFundedStatusABO" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_c6533a96-9447-48ff-b721-288c615c8721_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_2dbf778f-c2d1-4678-967a-1ad52e3c20fa_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives designated as hedging instruments : Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments in Hedges, Assets, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:to="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2d50624d-35fd-496d-86f3-34560ab057ad_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_8ba68103-9922-407d-8179-a4db7b71d3a5_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation contingency</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_88a8ba6b-ae51-48fe-a67f-6b5839a70245_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_20c4940f-0257-468a-97f4-08530c0e1fb7_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Expense not allocated to segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:to="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_47f919c0-65fd-4183-95c2-41bd1dd589e2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherSovereignSecuritiesMember_4937234f-cc68-4dde-bb1b-4de515edc51a_terseLabel_en-US" xlink:label="lab_jnj_OtherSovereignSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Sovereign Securities</link:label>
    <link:label id="lab_jnj_OtherSovereignSecuritiesMember_label_en-US" xlink:label="lab_jnj_OtherSovereignSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Sovereign Securities [Member]</link:label>
    <link:label id="lab_jnj_OtherSovereignSecuritiesMember_documentation_en-US" xlink:label="lab_jnj_OtherSovereignSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Sovereign Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherSovereignSecuritiesMember" xlink:href="jnj-20241229.xsd#jnj_OtherSovereignSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherSovereignSecuritiesMember" xlink:to="lab_jnj_OtherSovereignSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_a893b163-88bd-4010-86e8-81c792fecc08_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsPaymentPeriod_a75c04ca-f249-41dd-9f11-a41a2c948eac_terseLabel_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TCJA, transition tax for accumulated foreign earnings, payment period</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsPaymentPeriod_label_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Payment Period</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsPaymentPeriod_documentation_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsPaymentPeriod" xlink:href="jnj-20241229.xsd#jnj_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsPaymentPeriod" xlink:to="lab_jnj_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5cfe2927-6fab-4692-97eb-890307c18bf7_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_b15b9d8b-5c2d-479c-a608-d477802799b9_terseLabel_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product liability contingency, number of claimants</link:label>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_label_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Liability Contingency Number Of Claimant</link:label>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_documentation_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product liability contingency number of claimant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:href="jnj-20241229.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:to="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_c0bffdb7-bf28-4f2a-9dd7-0dbec7b2e475_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_8a57817c-cc31-4053-ab87-6c9602986870_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_5a870efe-0bca-456f-8c27-3461d2088a79_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Segments of business and geographic areas</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SPRAVATOMember_f57056f9-e690-4e15-a1a4-056f4d9bc44f_terseLabel_en-US" xlink:label="lab_jnj_SPRAVATOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SPRAVATO</link:label>
    <link:label id="lab_jnj_SPRAVATOMember_label_en-US" xlink:label="lab_jnj_SPRAVATOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SPRAVATO [Member]</link:label>
    <link:label id="lab_jnj_SPRAVATOMember_documentation_en-US" xlink:label="lab_jnj_SPRAVATOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SPRAVATO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPRAVATOMember" xlink:href="jnj-20241229.xsd#jnj_SPRAVATOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SPRAVATOMember" xlink:to="lab_jnj_SPRAVATOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fe8666c9-ffdd-436d-a675-0e4547b13c79_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee compensation and stock option plans</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_5dc69e41-e89d-4ca0-9f56-e72270f7439e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_52dd46d2-35fc-4002-a48a-0e2806228385_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_52bfca38-107c-417f-aa62-8ea68178c1ed_terseLabel_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.40%&#160;Notes due 2038</link:label>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_label_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.400% Notes due 2038 [Member]</link:label>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_documentation_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">3.400% Notes due 2038 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member" xlink:href="jnj-20241229.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.400Notesdue2038Member" xlink:to="lab_jnj_A3.400Notesdue2038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_88c814f7-3e56-4d26-86d4-7491024e038e_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyLossInPeriod_e9770076-adbe-4eed-80a8-fd567d06b953_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyLossInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency, loss in period</link:label>
    <link:label id="lab_us-gaap_LossContingencyLossInPeriod_label_en-US" xlink:label="lab_us-gaap_LossContingencyLossInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Loss in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyLossInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyLossInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyLossInPeriod" xlink:to="lab_us-gaap_LossContingencyLossInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_a7d6881a-6c0f-4327-b4e8-9e430e8c48d6_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_aa1bee30-063b-4a9d-839d-530b029d16ae_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_0e933068-9303-4a4a-9b8a-b8e708c9e4f6_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">End of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_300fad10-6a8c-4164-b6c7-e9052bfdc48c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_bda172dd-ce9e-4140-b219-301d0c144107_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for taxes on income</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencySolicitationPeriod_59c38dfe-81f7-4e38-97a5-2e8614645b3b_terseLabel_en-US" xlink:label="lab_jnj_LossContingencySolicitationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Solicitation period</link:label>
    <link:label id="lab_jnj_LossContingencySolicitationPeriod_label_en-US" xlink:label="lab_jnj_LossContingencySolicitationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Solicitation Period</link:label>
    <link:label id="lab_jnj_LossContingencySolicitationPeriod_documentation_en-US" xlink:label="lab_jnj_LossContingencySolicitationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Solicitation Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencySolicitationPeriod" xlink:href="jnj-20241229.xsd#jnj_LossContingencySolicitationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencySolicitationPeriod" xlink:to="lab_jnj_LossContingencySolicitationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_f6783f67-78ed-4dcd-b939-46733ea484d9_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_29311bb1-fcee-43cf-b259-2f456784bdb6_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_f406ed95-f851-45f3-801f-6c1d84b4134f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_1fd687dc-0e62-45b6-b5e5-6a9286e384f0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_446e2381-1b77-4eef-8390-00e41709984f_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives not designated as hedging instruments : Assets</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:to="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_51b9118f-4325-4e9a-9c58-1345151e3ead_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_14a2f2fd-b738-4994-8070-ab2fbf73c4a4_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_87c423d4-04b4-418c-b2a3-27eeb4bd5e52_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Undistributed foreign earnings</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Undistributed Foreign Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_80dd72d7-0552-4fa9-8599-40a432858512_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_4f8e352c-0e7d-4cf1-9760-7bef8f9422ea_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2fe2f329-cbf4-4f12-a9a0-1b52e84ee89d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_01f9ea36-01eb-4816-8c05-c8d1217a33f6_terseLabel_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.50%&#160;Notes due 2024 (500MM GBP 1.2756)(3)</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_label_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">5.50% Notes Due 2024 [Member]</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_documentation_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">5.50% Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member" xlink:href="jnj-20241229.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.50NotesDue2024Member" xlink:to="lab_jnj_A5.50NotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_7e12fa14-860e-40b2-99eb-e64e332fb826_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_6d2cb3a1-7698-43ec-8e1a-ce6ba1086262_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_b14ed6ba-0c4d-4f61-b766-377e24de5973_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_d46c20c5-68f7-4e8a-974d-8e8cf72d9ad3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RisperdalMember_3d0f4014-a762-47f2-8a3f-a17e6dad045e_terseLabel_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risperdal</link:label>
    <link:label id="lab_jnj_RisperdalMember_label_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risperdal [Member]</link:label>
    <link:label id="lab_jnj_RisperdalMember_documentation_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Risperdal.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember" xlink:href="jnj-20241229.xsd#jnj_RisperdalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RisperdalMember" xlink:to="lab_jnj_RisperdalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_7a6c7f0d-899c-42fe-a66d-6652976be33b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_704c8877-461d-4a6f-9aa1-520d3bda03a6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_792023d3-0104-448e-986f-a1491fc8d0cd_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings and Additional-paid-in-capital</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_2b3e1905-328e-4cd3-8450-27d0ad2a7792_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest Income</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_135e00de-47e8-4aa2-ad14-e204e7c3eb44_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_a391def1-6f5e-4c16-b687-c4c7a348363e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Increase in inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTranslationAbstract_406a233b-d267-499b-b369-03ef34e17ec3_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTranslationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation [Abstract]</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTranslationAbstract_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTranslationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTranslationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTranslationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTranslationAbstract" xlink:to="lab_us-gaap_ForeignCurrencyTranslationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_e662f260-27e3-4a22-b4cd-4212d99c732c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherOncologyMember_32f81ee0-52f8-4851-8a16-791790fe6aeb_terseLabel_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Oncology</link:label>
    <link:label id="lab_jnj_OtherOncologyMember_label_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:label id="lab_jnj_OtherOncologyMember_documentation_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember" xlink:href="jnj-20241229.xsd#jnj_OtherOncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherOncologyMember" xlink:to="lab_jnj_OtherOncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_e9545f95-b7ff-467b-a064-f10f91d93986_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_3b274ae2-b5be-495e-a723-f72fda88d596_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_39975cdf-36b4-49b3-8230-e0049a906fa9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred compensation</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Liability, Current and Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest_3664356a-9df7-4380-90bd-1fda9c438fb7_terseLabel_en-US" xlink:label="lab_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense, including the amortization of capitalized interest</link:label>
    <link:label id="lab_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest_label_en-US" xlink:label="lab_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation Expense Including Amortization Of Capitalized Interest</link:label>
    <link:label id="lab_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest_documentation_en-US" xlink:label="lab_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Depreciation expense including the amortization of capitalized interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" xlink:href="jnj-20241229.xsd#jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" xlink:to="lab_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_7525a861-5e65-4e48-bcae-f81799b062b9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Periodic Benefit Cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_8850b61f-695b-42ea-90f6-9616e55111c3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash dividends paid</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_9aca45ea-a9ca-4854-8add-d39212580d11_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaper_a45726d2-3084-40ed-bcee-8db122de3691_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaper_label_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaper"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaper" xlink:to="lab_us-gaap_CommercialPaper" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_bd8ec343-52d0-4e07-aa92-e9998850d0b5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan participant contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.20DebenturesDue2032Member_1bc36e0a-dc0b-435d-ba0d-8a41a1621f1e_terseLabel_en-US" xlink:label="lab_jnj_A3.20DebenturesDue2032Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.20% Debentures due 2032</link:label>
    <link:label id="lab_jnj_A3.20DebenturesDue2032Member_label_en-US" xlink:label="lab_jnj_A3.20DebenturesDue2032Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.20% Debentures due 2032 [Member]</link:label>
    <link:label id="lab_jnj_A3.20DebenturesDue2032Member_documentation_en-US" xlink:label="lab_jnj_A3.20DebenturesDue2032Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">3.20% Debentures due 2032</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.20DebenturesDue2032Member" xlink:href="jnj-20241229.xsd#jnj_A3.20DebenturesDue2032Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.20DebenturesDue2032Member" xlink:to="lab_jnj_A3.20DebenturesDue2032Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome_9375ebfe-7063-4862-86ea-a433b30ce91f_negatedTerseLabel_en-US" xlink:label="lab_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Global intangible low-taxed income</link:label>
    <link:label id="lab_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome_label_en-US" xlink:label="lab_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liability, Global Intangible Low-Taxed Income</link:label>
    <link:label id="lab_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome_documentation_en-US" xlink:label="lab_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liability, Global Intangible Low-Taxed Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" xlink:href="jnj-20241229.xsd#jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" xlink:to="lab_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_61622dc2-5138-45ba-9cce-d372d9a23145_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_c743e3af-dc42-49ac-8891-b3efcfd906ff_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actual return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BermekimabMember_e82cb967-42f2-4dd5-aec8-1edbe12f48e7_terseLabel_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">bermekimab</link:label>
    <link:label id="lab_jnj_BermekimabMember_label_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bermekimab [Member]</link:label>
    <link:label id="lab_jnj_BermekimabMember_documentation_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">bermekimab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember" xlink:href="jnj-20241229.xsd#jnj_BermekimabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BermekimabMember" xlink:to="lab_jnj_BermekimabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_519d808a-ff70-4a0b-9831-bcc7f74c40ec_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f61b113f-9ff4-4407-969f-6bc5bd84fec3_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_548f278d-71be-454a-a9e4-4df972ce6f31_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2fd9c7e2-aacd-4f69-a362-9a84d3962bd1_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8281106-bb1e-4dd5-add2-36958b56be3c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_3397bc92-0ab2-4a18-afde-3e0bcb9aa993_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_2565f77a-c72b-4fcd-b94b-a396e42da31c_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from short-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_3094ce47-25d0-4cfd-b016-4cf87b150c39_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments/Other</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_a7692537-ee13-4556-83cc-d73bad0d23b5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_6261400a-4a22-43da-b619-548ce64ec8da_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_079e10f3-1157-4479-9642-2db77d6b7f87_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ChangesInTreasuryStockRollForward_b916d02a-4773-4dce-b22e-b12ecc4b2a9a_terseLabel_en-US" xlink:label="lab_jnj_ChangesInTreasuryStockRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in treasury stock</link:label>
    <link:label id="lab_jnj_ChangesInTreasuryStockRollForward_label_en-US" xlink:label="lab_jnj_ChangesInTreasuryStockRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes In Treasury Stock [Roll Forward]</link:label>
    <link:label id="lab_jnj_ChangesInTreasuryStockRollForward_documentation_en-US" xlink:label="lab_jnj_ChangesInTreasuryStockRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Changes in treasury stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesInTreasuryStockRollForward" xlink:href="jnj-20241229.xsd#jnj_ChangesInTreasuryStockRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward" xlink:to="lab_jnj_ChangesInTreasuryStockRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.95DebenturesDue2034Member_7a9a8230-5eb3-4ae9-9420-d7d382f1fc27_terseLabel_en-US" xlink:label="lab_jnj_A4.95DebenturesDue2034Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.95% Debentures due 2034</link:label>
    <link:label id="lab_jnj_A4.95DebenturesDue2034Member_label_en-US" xlink:label="lab_jnj_A4.95DebenturesDue2034Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">4.95% Debentures due 2034 [Member]</link:label>
    <link:label id="lab_jnj_A4.95DebenturesDue2034Member_documentation_en-US" xlink:label="lab_jnj_A4.95DebenturesDue2034Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">4.95% Debentures due 2034</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95DebenturesDue2034Member" xlink:href="jnj-20241229.xsd#jnj_A4.95DebenturesDue2034Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.95DebenturesDue2034Member" xlink:to="lab_jnj_A4.95DebenturesDue2034Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_bf1629e5-c18e-4f11-bca0-14ee517fc45a_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_57bd1036-ed24-4ece-bb82-67b48bf89b06_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash &amp; Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_db3addfa-68fc-461c-aeb1-7640efc2a127_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_69ab8e2e-172a-48b0-bf1d-29edce14c057_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other (including capitalized licenses and milestones)</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExercisePriceRangeTwoMember_c47f37e0-9c7c-4695-b4b9-b0cae342dc53_terseLabel_en-US" xlink:label="lab_jnj_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$115.67 - $129.51</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_jnj_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeTwoMember_documentation_en-US" xlink:label="lab_jnj_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeTwoMember" xlink:href="jnj-20241229.xsd#jnj_ExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExercisePriceRangeTwoMember" xlink:to="lab_jnj_ExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock_e83add20-8810-48c6-8b16-21da0a59706e_terseLabel_en-US" xlink:label="lab_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Useful Lives of Assets</link:label>
    <link:label id="lab_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock_label_en-US" xlink:label="lab_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Useful Lives Of Assets [Table Text Block]</link:label>
    <link:label id="lab_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock_documentation_en-US" xlink:label="lab_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated useful lives of the assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:href="jnj-20241229.xsd#jnj_EstimatedUsefulLivesOfAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:to="lab_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_97e5a14d-4798-4ea9-a18c-fa54606793c1_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_b6e8124e-0a14-4ffb-8666-78008482f791_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currently payable:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_99e55fd8-2c52-46b5-b438-4c147d48d206_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_8cd1e71e-fd32-4fbc-951e-be833e9f80a1_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NonQualifiedPlansMember_8660c13b-5ca2-49a5-a7a9-52daf9fe9839_terseLabel_en-US" xlink:label="lab_jnj_NonQualifiedPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Qualified Plans</link:label>
    <link:label id="lab_jnj_NonQualifiedPlansMember_label_en-US" xlink:label="lab_jnj_NonQualifiedPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Qualified Plans [Member]</link:label>
    <link:label id="lab_jnj_NonQualifiedPlansMember_documentation_en-US" xlink:label="lab_jnj_NonQualifiedPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non qualified plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NonQualifiedPlansMember" xlink:href="jnj-20241229.xsd#jnj_NonQualifiedPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NonQualifiedPlansMember" xlink:to="lab_jnj_NonQualifiedPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_3ee64b29-3653-48f2-a598-139e57038094_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful lives of the assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_38c2ab89-f14b-44d5-b693-4c9fb0053e07_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive_7d90e6f3-987d-410e-ad9c-477721c223a3_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Expected Future Benefit Contribution In Year Five</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined benefit plan expected future benefit contribution in year five.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" xlink:to="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_6b59ad43-48f3-45b6-abe2-c927f5a86904_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_9c5a4061-4288-4627-b751-6760c2d14588_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of assets acquired</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_ba20f6a2-5078-40e7-8156-72012e031701_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash acquired from acquisition</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_GeneralCorporateMember_c1cdc7b8-c861-42c9-9e64-9e77a62ddfda_terseLabel_en-US" xlink:label="lab_jnj_GeneralCorporateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General Corporate</link:label>
    <link:label id="lab_jnj_GeneralCorporateMember_label_en-US" xlink:label="lab_jnj_GeneralCorporateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General Corporate [Member]</link:label>
    <link:label id="lab_jnj_GeneralCorporateMember_documentation_en-US" xlink:label="lab_jnj_GeneralCorporateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General corporate member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GeneralCorporateMember" xlink:href="jnj-20241229.xsd#jnj_GeneralCorporateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_GeneralCorporateMember" xlink:to="lab_jnj_GeneralCorporateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExchangeOfStockCommonStockValueReceived_0006b517-981e-4c4b-b350-23e3bcc2b5b4_terseLabel_en-US" xlink:label="lab_jnj_ExchangeOfStockCommonStockValueReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock received in exchange offer</link:label>
    <link:label id="lab_jnj_ExchangeOfStockCommonStockValueReceived_label_en-US" xlink:label="lab_jnj_ExchangeOfStockCommonStockValueReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exchange Of Stock, Common Stock, Value, Received</link:label>
    <link:label id="lab_jnj_ExchangeOfStockCommonStockValueReceived_documentation_en-US" xlink:label="lab_jnj_ExchangeOfStockCommonStockValueReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exchange Of Stock, Common Stock, Value, Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExchangeOfStockCommonStockValueReceived" xlink:href="jnj-20241229.xsd#jnj_ExchangeOfStockCommonStockValueReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExchangeOfStockCommonStockValueReceived" xlink:to="lab_jnj_ExchangeOfStockCommonStockValueReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_a01e9db5-138e-4f09-895b-bb077676cfc8_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_35ba3c76-82b7-4f66-b26b-4047214ba0bf_terseLabel_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.85% Notes due 2041</link:label>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_label_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">4.85% Notes due 2041 [Member]</link:label>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_documentation_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">4.85% Notes due 2041 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member" xlink:href="jnj-20241229.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.85Notesdue2041Member" xlink:to="lab_jnj_A4.85Notesdue2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_3101e452-c182-42d3-940d-71c66f7c47e2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rates</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent_e3d8ba72-ba95-469c-80b5-1e7f07d0c857_terseLabel_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate reconciliation, net increase (decrease) in tax rate, percent</link:label>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent_label_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Tax Rate Reconciliation, Net Increase (Decrease) In Tax Rate, Percent</link:label>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent_documentation_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Tax Rate Reconciliation, Net Increase (Decrease) In Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" xlink:href="jnj-20241229.xsd#jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" xlink:to="lab_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b1489b12-1ed6-4b14-8142-69561a9a7e83_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_b5584e2e-f5e3-43c3-b392-571a117b75c4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Projected benefit obligation, unfunded plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_c14e179a-9654-4fb5-86f7-04f53a833b70_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_715d8462-65e3-43bf-86e3-3e9905de242f_verboseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Identifiable Assets</link:label>
    <link:label id="lab_us-gaap_Assets_526e79a3-40bd-42aa-9c89-844697ab545a_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_4b136999-a30f-49d6-a6f5-c0707473832a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension benefits</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability, Defined Benefit Pension Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:to="lab_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_ce49658a-2cc8-4884-8bff-3fc3c678bc21_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_2fce18f2-7559-4c2a-9722-f713b07dd674_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_63f72b0b-94ae-467a-b092-939938b20c10_terseLabel_en-US" xlink:label="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total recognized in net periodic benefit cost and other comprehensive&#160;income</link:label>
    <link:label id="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:to="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_60c06ad2-7a90-4f3d-ad7e-41e5ba3996d6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_734a73cf-c14c-4520-b200-778f4f0c61db_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Additions to property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss_232c2d8b-2370-4c44-b32f-97636d7129eb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity interest in acquiree, remeasurement loss</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_f1995d66-7775-4caa-bd2c-4f832aa52d42_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_0ca3f8a7-7037-4c6b-adbf-3d1c7f624ad3_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital and treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_label_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockTextBlock" xlink:to="lab_us-gaap_TreasuryStockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_3ab3fcdc-c315-4149-98e0-684d190c1e50_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_7ce52dba-3fd8-45aa-8e1a-aa89f9cd3536_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications to earnings</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5ce2c409-7c03-4fca-a66c-b1f3bbf19b89_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesPaidValue_7b30874e-7900-4860-a782-61efa1a836c1_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesPaidValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency, damages paid, value</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesPaidValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesPaidValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Paid, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesPaidValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesPaidValue" xlink:to="lab_us-gaap_LossContingencyDamagesPaidValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_c49fc810-9a59-4eb9-9364-076cd28997c8_totalLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash paid for acquisitions (Note 18)</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TRAUMAMember_67101e71-2bca-4a68-a9a0-203cb729d73d_terseLabel_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TRAUMA</link:label>
    <link:label id="lab_jnj_TRAUMAMember_label_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TRAUMA [Member]</link:label>
    <link:label id="lab_jnj_TRAUMAMember_documentation_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TRAUMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember" xlink:href="jnj-20241229.xsd#jnj_TRAUMAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TRAUMAMember" xlink:to="lab_jnj_TRAUMAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DiscontinuedOperationIncrementalTaxCost_0ea55405-e7df-43f6-b994-095cdab3e23c_terseLabel_en-US" xlink:label="lab_jnj_DiscontinuedOperationIncrementalTaxCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incremental tax cost</link:label>
    <link:label id="lab_jnj_DiscontinuedOperationIncrementalTaxCost_label_en-US" xlink:label="lab_jnj_DiscontinuedOperationIncrementalTaxCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Incremental Tax Cost</link:label>
    <link:label id="lab_jnj_DiscontinuedOperationIncrementalTaxCost_documentation_en-US" xlink:label="lab_jnj_DiscontinuedOperationIncrementalTaxCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Incremental Tax Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DiscontinuedOperationIncrementalTaxCost" xlink:href="jnj-20241229.xsd#jnj_DiscontinuedOperationIncrementalTaxCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DiscontinuedOperationIncrementalTaxCost" xlink:to="lab_jnj_DiscontinuedOperationIncrementalTaxCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_032eedcd-d5b2-4acf-9b3f-eb30ffc2775a_terseLabel_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (Income) Expense</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_label_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income Expense Net [Member]</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_documentation_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Income Expense Net [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember" xlink:href="jnj-20241229.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherIncomeExpenseNetMember" xlink:to="lab_jnj_OtherIncomeExpenseNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_0f6f101c-6e9d-4a9b-921b-6d152299065c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.35DebenturesDue2036Member_9f8cf0d9-8325-4385-8ee1-3fed3abaa4da_terseLabel_en-US" xlink:label="lab_jnj_A3.35DebenturesDue2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.35% Debentures due 2036</link:label>
    <link:label id="lab_jnj_A3.35DebenturesDue2036Member_label_en-US" xlink:label="lab_jnj_A3.35DebenturesDue2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.35% Debentures due 2036 [Member]</link:label>
    <link:label id="lab_jnj_A3.35DebenturesDue2036Member_documentation_en-US" xlink:label="lab_jnj_A3.35DebenturesDue2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">3.35% Debentures due 2036</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.35DebenturesDue2036Member" xlink:href="jnj-20241229.xsd#jnj_A3.35DebenturesDue2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.35DebenturesDue2036Member" xlink:to="lab_jnj_A3.35DebenturesDue2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7c9d1f8c-73f4-4cf5-a523-096b2ad436aa_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets acquired:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FundedPlansMember_948f6abf-b6a3-45d8-ab8f-3c62a4f6116b_terseLabel_en-US" xlink:label="lab_jnj_FundedPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Funded Plans</link:label>
    <link:label id="lab_jnj_FundedPlansMember_label_en-US" xlink:label="lab_jnj_FundedPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Funded Plans [Member]</link:label>
    <link:label id="lab_jnj_FundedPlansMember_documentation_en-US" xlink:label="lab_jnj_FundedPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Funded plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FundedPlansMember" xlink:href="jnj-20241229.xsd#jnj_FundedPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FundedPlansMember" xlink:to="lab_jnj_FundedPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_2abdacdd-5190-47e3-a56a-57e04a692355_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_dcee5bee-8483-44d4-9b6e-65dabd3628dd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_84568536-c853-4902-89be-49a0fcdb3203_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_7b72a351-51c7-4b18-8bc2-ad110a80484c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_eb3c3676-d0b3-42f5-b3f4-c53476981055_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_40942c88-4961-4175-b10d-707050fdf2fb_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ImpellaMember_632e8d46-d8dd-4a07-be55-9c90f3a24f1a_terseLabel_en-US" xlink:label="lab_jnj_ImpellaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impella</link:label>
    <link:label id="lab_jnj_ImpellaMember_label_en-US" xlink:label="lab_jnj_ImpellaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impella [Member]</link:label>
    <link:label id="lab_jnj_ImpellaMember_documentation_en-US" xlink:label="lab_jnj_ImpellaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Impella</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImpellaMember" xlink:href="jnj-20241229.xsd#jnj_ImpellaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ImpellaMember" xlink:to="lab_jnj_ImpellaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ConsumerHealthMember_834e323e-ab4b-4979-b69a-f84c508cd8e8_terseLabel_en-US" xlink:label="lab_jnj_ConsumerHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consumer Health Business</link:label>
    <link:label id="lab_jnj_ConsumerHealthMember_label_en-US" xlink:label="lab_jnj_ConsumerHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consumer Health [Member]</link:label>
    <link:label id="lab_jnj_ConsumerHealthMember_documentation_en-US" xlink:label="lab_jnj_ConsumerHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consumer Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerHealthMember" xlink:href="jnj-20241229.xsd#jnj_ConsumerHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ConsumerHealthMember" xlink:to="lab_jnj_ConsumerHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_e505b0f3-62b9-4451-bfff-bea9c31202cb_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029-2033</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets_0422b64c-eea3-4443-982b-0b2f5ea8ca54_terseLabel_en-US" xlink:label="lab_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of corridor of greater of market value of assets</link:label>
    <link:label id="lab_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets_label_en-US" xlink:label="lab_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Corridor Of Greater Of Market Value Of Assets</link:label>
    <link:label id="lab_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets_documentation_en-US" xlink:label="lab_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of corridor of greater of market value of assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets" xlink:href="jnj-20241229.xsd#jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets" xlink:to="lab_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_a0853aeb-41a8-48c9-94fe-dfaff17b328b_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity, unrecognized gain</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_fe2ca8c3-ada3-4e41-8e70-1a846c1bd59b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company' Retirement Plan Asset Allocation and Target Allocations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Allocation of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_aa4b950b-1b57-44fb-b13a-9581cc88856d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-Sale Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_2db27431-85c1-44df-a27c-6fe499517f52_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_a86c0adf-f151-4565-84bd-4fb3f5267ae6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_f55db469-e28b-44b7-ae03-d1987c405dca_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_32c52774-25d4-4b0f-a47b-50b3253a7b1d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_270976bb-3081-496e-8453-234abf34dc5d_terseLabel_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_label_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_44f2880c-6ab3-49cf-a8e5-91ea741a1014_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. taxes</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_35ac8a95-5c1f-48b2-b936-ca6e5e19fae9_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets with indefinite lives:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c44c23e3-af71-47b4-92c7-e7216349363c_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_81eb3ca6-d098-4b11-bbc3-fdedb5bba247_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesDomain_9db0bd76-a2ca-4084-8bea-0a11e4a95fd3_terseLabel_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Settlement By Companies</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesDomain_label_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement By Companies [Domain]</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesDomain_documentation_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation settlement by companies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain" xlink:href="jnj-20241229.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LitigationSettlementByCompaniesDomain" xlink:to="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_56102b8a-c44c-4615-ae7c-5547d7e48739_terseLabel_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CONCERTA/Methylphenidate</link:label>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_label_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CONCERTA/Methylphenidate [Member]</link:label>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_documentation_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CONCERTA/Methylphenidate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember" xlink:href="jnj-20241229.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CONCERTAMethylphenidateMember" xlink:to="lab_jnj_CONCERTAMethylphenidateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_StelaraMember_6b6520bb-980f-401f-89c9-1c6b05c29469_terseLabel_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stelara</link:label>
    <link:label id="lab_jnj_StelaraMember_label_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stelara [Member]</link:label>
    <link:label id="lab_jnj_StelaraMember_documentation_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stelara [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember" xlink:href="jnj-20241229.xsd#jnj_StelaraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_StelaraMember" xlink:to="lab_jnj_StelaraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_e958111e-23f7-491e-8faa-f1f3f2f9d427_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_d4101ba8-86d6-41b7-a6e9-efde8a2ee11c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Expected Benefit Payments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OrthopaedicsMember_dac965ab-2b8f-4d8f-b335-c1eb2efe1c37_terseLabel_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Orthopaedics</link:label>
    <link:label id="lab_jnj_OrthopaedicsMember_label_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Orthopaedics [Member]</link:label>
    <link:label id="lab_jnj_OrthopaedicsMember_documentation_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Orthopaedics [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember" xlink:href="jnj-20241229.xsd#jnj_OrthopaedicsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OrthopaedicsMember" xlink:to="lab_jnj_OrthopaedicsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ELECTROPHYSIOLOGYMember_fb0a0be6-4cce-430f-b8e6-ccff14f12795_terseLabel_en-US" xlink:label="lab_jnj_ELECTROPHYSIOLOGYMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ELECTROPHYSIOLOGY</link:label>
    <link:label id="lab_jnj_ELECTROPHYSIOLOGYMember_label_en-US" xlink:label="lab_jnj_ELECTROPHYSIOLOGYMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ELECTROPHYSIOLOGY [Member]</link:label>
    <link:label id="lab_jnj_ELECTROPHYSIOLOGYMember_documentation_en-US" xlink:label="lab_jnj_ELECTROPHYSIOLOGYMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ELECTROPHYSIOLOGY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ELECTROPHYSIOLOGYMember" xlink:href="jnj-20241229.xsd#jnj_ELECTROPHYSIOLOGYMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ELECTROPHYSIOLOGYMember" xlink:to="lab_jnj_ELECTROPHYSIOLOGYMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_5336f8c9-bcb5-4960-9b0d-d71c7d90c1f4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decreases related to prior period tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_97c5af47-81e8-44a6-81a1-15ea0f58f891_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExchangeOfStockPercentageOwnershipAfterTransaction_3cae42f9-a876-4319-8f45-6a8dac1f3601_terseLabel_en-US" xlink:label="lab_jnj_ExchangeOfStockPercentageOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage ownership after transaction</link:label>
    <link:label id="lab_jnj_ExchangeOfStockPercentageOwnershipAfterTransaction_label_en-US" xlink:label="lab_jnj_ExchangeOfStockPercentageOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exchange of Stock, Percentage Ownership After Transaction</link:label>
    <link:label id="lab_jnj_ExchangeOfStockPercentageOwnershipAfterTransaction_documentation_en-US" xlink:label="lab_jnj_ExchangeOfStockPercentageOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exchange of Stock, Percentage Ownership After Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExchangeOfStockPercentageOwnershipAfterTransaction" xlink:href="jnj-20241229.xsd#jnj_ExchangeOfStockPercentageOwnershipAfterTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExchangeOfStockPercentageOwnershipAfterTransaction" xlink:to="lab_jnj_ExchangeOfStockPercentageOwnershipAfterTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_4418dfd4-5dbf-43fc-922a-beb5a4023d29_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in foreign tax credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CurtailmentsAndSettlementsAndRestructuring_a5bfec92-31de-490f-8d3a-94201c6af1bb_negatedTerseLabel_en-US" xlink:label="lab_jnj_CurtailmentsAndSettlementsAndRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Curtailments, settlements&#160;&amp; restructuring</link:label>
    <link:label id="lab_jnj_CurtailmentsAndSettlementsAndRestructuring_label_en-US" xlink:label="lab_jnj_CurtailmentsAndSettlementsAndRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Curtailments And Settlements And Restructuring</link:label>
    <link:label id="lab_jnj_CurtailmentsAndSettlementsAndRestructuring_documentation_en-US" xlink:label="lab_jnj_CurtailmentsAndSettlementsAndRestructuring" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of increase or decrease related to curtailments, settlements and restructuring.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CurtailmentsAndSettlementsAndRestructuring" xlink:href="jnj-20241229.xsd#jnj_CurtailmentsAndSettlementsAndRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CurtailmentsAndSettlementsAndRestructuring" xlink:to="lab_jnj_CurtailmentsAndSettlementsAndRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_e4e94605-8ec9-4d67-9ec0-2b43d001f4ed_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted net earnings per share from continuing operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_c9c1d283-2790-4ff5-88d7-c1fb67251a36_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_f4a5b243-c58e-49ee-9403-abcfef9ad183_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Goodwill, related to divestitures</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_bb3a4025-e458-4d48-874c-b8e6923bbb45_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications to earnings</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_8fd03cbe-9557-42d3-baba-0b4e574c7d34_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of gain or (loss) reclassified from AOCI into income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_34b81ee4-9285-413e-9c62-115b2c6ea1c9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_e6b0793c-4194-47e6-815a-b8f7d3b26453_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case Type [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_59c63d29-5247-49eb-9e05-e117eaba03fd_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1e2bcf2c-64d8-40c5-8819-95b179d3d4bd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cc8bf4ff-d63a-487b-bd0f-298999255752_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b3e65f57-3458-4de1-b429-2c3d5b61f07e_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average shares outstanding&#160;&#8212; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_52ffbfb0-2433-4047-af4e-2aa1d89d9cd9_terseLabel_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asia-Pacific, Africa</link:label>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_label_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asia-Pacific, Africa [Member]</link:label>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_documentation_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asia-Pacific, Africa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember" xlink:href="jnj-20241229.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AsiaPacificAfricaMember" xlink:to="lab_jnj_AsiaPacificAfricaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_131cb38a-ed7f-454f-b0e7-782239f63a57_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the disposal of assets/businesses, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_cd87afcc-923f-44fe-9f35-214fd189baa8_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3754f2ba-fa15-4833-8b6c-dfc5c3e6abd6_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_33104224-23bb-497c-b2a4-cc7844e2b79f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cbabfbcf-1ed1-4843-825d-f59c918f90f9_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_7d7f52af-c54c-442e-97f8-2221d3936b88_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized gain (loss)</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_f4707dcf-00f7-470f-9c80-b8d6f0657793_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Target Allocation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Target Allocation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_c1e330a8-2ecf-4cd2-aeef-08a0739b6747_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_3aa4c149-e993-45a3-8d22-5309a902a64e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and Amortization</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_88e06b5b-cfb7-4b10-8b58-b173dcdfce3d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year the rate reaches the ultimate trend rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:to="lab_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_8ea40021-d73c-417c-aa36-9a92ea141ee4_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_c7de0b0a-a155-4c0c-bbc4-056f514aea65_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Revenue, Net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9cda2289-637b-489e-8047-247494bfd036_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Options canceled/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SegmentsTotalMember_66f8647a-2951-4315-82e3-ade612b6ebe6_terseLabel_en-US" xlink:label="lab_jnj_SegmentsTotalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments Total</link:label>
    <link:label id="lab_jnj_SegmentsTotalMember_label_en-US" xlink:label="lab_jnj_SegmentsTotalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments Total [Member]</link:label>
    <link:label id="lab_jnj_SegmentsTotalMember_documentation_en-US" xlink:label="lab_jnj_SegmentsTotalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Segments Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SegmentsTotalMember" xlink:href="jnj-20241229.xsd#jnj_SegmentsTotalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SegmentsTotalMember" xlink:to="lab_jnj_SegmentsTotalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_cf12f2fb-d2f0-48f4-bc5f-0036a45b7f0b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_d50cd543-dc58-4410-b695-32fa0d19cad9_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collateral paid</link:label>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_label_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collateral Already Posted, Aggregate Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:to="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_28bef77e-bb30-4f14-a86d-3a0b5b18cc86_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_e440b9e5-6ace-4bc0-942c-2abc2d08123f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable number of Options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ValuationAllowanceDeferredTaxAssetsUtilization_f42ccf31-6b5d-4d51-b006-76c7e6d258b3_terseLabel_en-US" xlink:label="lab_jnj_ValuationAllowanceDeferredTaxAssetsUtilization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Utilization</link:label>
    <link:label id="lab_jnj_ValuationAllowanceDeferredTaxAssetsUtilization_label_en-US" xlink:label="lab_jnj_ValuationAllowanceDeferredTaxAssetsUtilization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Assets, Utilization</link:label>
    <link:label id="lab_jnj_ValuationAllowanceDeferredTaxAssetsUtilization_documentation_en-US" xlink:label="lab_jnj_ValuationAllowanceDeferredTaxAssetsUtilization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Assets, Utilization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ValuationAllowanceDeferredTaxAssetsUtilization" xlink:href="jnj-20241229.xsd#jnj_ValuationAllowanceDeferredTaxAssetsUtilization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ValuationAllowanceDeferredTaxAssetsUtilization" xlink:to="lab_jnj_ValuationAllowanceDeferredTaxAssetsUtilization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_5f809787-1fb4-41f6-9b17-807fd43ed98c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill, related to acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_18a25358-a66f-4ac9-89ad-719d365f8de0_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentExpenditureAdditionToLongLivedAssets_c38c0fbc-ee90-4f20-b268-a04102dc33a0_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions to Property, Plant &amp; Equipment</link:label>
    <link:label id="lab_us-gaap_SegmentExpenditureAdditionToLongLivedAssets_label_en-US" xlink:label="lab_us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment, Expenditure, Addition to Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentExpenditureAdditionToLongLivedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:to="lab_us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_dec8acde-ecf4-4aaf-83f3-ae410cd39351_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale, unrecognized loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_b73bf3c5-7324-4e92-ad14-9979bd231ce4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_5420997a-7ac4-4f11-837d-ea727c6599bb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent Composition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fcdddb3d-9950-49e8-a1c6-a9376650a966_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_dd8272af-492d-4952-b3f6-eccef8400082_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_fc7ba508-ee00-4612-bc4e-1b2d3a0b40a8_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt instruments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_fcd679ca-804d-456b-8cf6-235e9b4b0be0_terseLabel_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in estimated fair value</link:label>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_label_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</link:label>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_documentation_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:href="jnj-20241229.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:to="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DARZALEXMember_98448069-0937-423d-9ff9-ae6956abc882_terseLabel_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DARZALEX</link:label>
    <link:label id="lab_jnj_DARZALEXMember_label_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DARZALEX [Member]</link:label>
    <link:label id="lab_jnj_DARZALEXMember_documentation_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">DARZALEX [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember" xlink:href="jnj-20241229.xsd#jnj_DARZALEXMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DARZALEXMember" xlink:to="lab_jnj_DARZALEXMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BusinessCombinationSettlementOfNotesPayable_b88518c9-e281-4e78-adcb-a780af436779_terseLabel_en-US" xlink:label="lab_jnj_BusinessCombinationSettlementOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement of notes payable</link:label>
    <link:label id="lab_jnj_BusinessCombinationSettlementOfNotesPayable_label_en-US" xlink:label="lab_jnj_BusinessCombinationSettlementOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Settlement Of Notes Payable</link:label>
    <link:label id="lab_jnj_BusinessCombinationSettlementOfNotesPayable_documentation_en-US" xlink:label="lab_jnj_BusinessCombinationSettlementOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Settlement Of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationSettlementOfNotesPayable" xlink:href="jnj-20241229.xsd#jnj_BusinessCombinationSettlementOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BusinessCombinationSettlementOfNotesPayable" xlink:to="lab_jnj_BusinessCombinationSettlementOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_34cc6131-e171-4076-a011-c54adb98fa83_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1.150NotesDueNovember2028Member_d449e9fb-7262-4d8b-8181-2ad2e7e54797_terseLabel_en-US" xlink:label="lab_jnj_A1.150NotesDueNovember2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.150% Notes Due November 2028</link:label>
    <link:label id="lab_jnj_A1.150NotesDueNovember2028Member_label_en-US" xlink:label="lab_jnj_A1.150NotesDueNovember2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.150% Notes Due November 2028 [Member]</link:label>
    <link:label id="lab_jnj_A1.150NotesDueNovember2028Member_documentation_en-US" xlink:label="lab_jnj_A1.150NotesDueNovember2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1.150% Notes Due November 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDueNovember2028Member" xlink:href="jnj-20241229.xsd#jnj_A1.150NotesDueNovember2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1.150NotesDueNovember2028Member" xlink:to="lab_jnj_A1.150NotesDueNovember2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5ba38838-61c1-4284-a107-23732dd6e5c8_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e61b2a51-015a-4d55-a941-03ada539369e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMember_ba98f798-b341-482b-bb63-bf20ff440d8b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMember_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMember" xlink:to="lab_us-gaap_LongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AmbrxMember_2b4f31b8-a757-4b5c-82cf-a42f417c3eaa_terseLabel_en-US" xlink:label="lab_jnj_AmbrxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ambrx</link:label>
    <link:label id="lab_jnj_AmbrxMember_label_en-US" xlink:label="lab_jnj_AmbrxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ambrx [Member]</link:label>
    <link:label id="lab_jnj_AmbrxMember_documentation_en-US" xlink:label="lab_jnj_AmbrxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ambrx</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AmbrxMember" xlink:href="jnj-20241229.xsd#jnj_AmbrxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AmbrxMember" xlink:to="lab_jnj_AmbrxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_72e0ef69-4202-46c8-88e1-db162aa6cb9b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_7565fed4-d2b9-4a8f-b033-f5bd42eb2384_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill, measurement period adjustment</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Measurement Period Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_bea48802-8d30-4d31-a81c-ef5dfe8a60a2_terseLabel_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.75% Notes due 2047</link:label>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_label_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.75% Notes due 2047 [Member]</link:label>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_documentation_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">3.75% Notes due 2047 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member" xlink:href="jnj-20241229.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.75Notesdue2047Member" xlink:to="lab_jnj_A3.75Notesdue2047Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_73ab2b99-5513-40cf-ac95-2df300012329_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProteologixMember_71f2bde1-f426-4373-b0e2-50b3a15b8514_terseLabel_en-US" xlink:label="lab_jnj_ProteologixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proteologix</link:label>
    <link:label id="lab_jnj_ProteologixMember_label_en-US" xlink:label="lab_jnj_ProteologixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proteologix [Member]</link:label>
    <link:label id="lab_jnj_ProteologixMember_documentation_en-US" xlink:label="lab_jnj_ProteologixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proteologix</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProteologixMember" xlink:href="jnj-20241229.xsd#jnj_ProteologixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProteologixMember" xlink:to="lab_jnj_ProteologixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e40b4f18-7f3e-4d56-b3bc-f72e72771921_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_dbe34612-7a99-4ad9-b0b9-b6b5c8b0dc9f_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Assets and Liabilities at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock_4c0d041d-b8cc-4a48-83b7-6959fb11701c_terseLabel_en-US" xlink:label="lab_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Information Related to the Benefit Obligation and the Fair Value of Plan Assets</link:label>
    <link:label id="lab_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Information Related To Benefit Obligation And Fair Value Of Plan Assets [Table Text Block]</link:label>
    <link:label id="lab_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock_documentation_en-US" xlink:label="lab_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the benefit obligation and the fair value of plan assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" xlink:href="jnj-20241229.xsd#jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_35468d4c-64e5-491e-ae5d-52fa67010f28_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_ed805472-3975-496e-9ffe-b638df976096_negatedTerseLabel_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: shares repurchased under treasury stock method (in shares)</link:label>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_label_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Which Could Be Repurchased Under Treasury Stock Method</link:label>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_documentation_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:href="jnj-20241229.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:to="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_0fe2ff3e-84e9-4ff1-8d0f-e7d993862986_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rate of increase in compensation levels</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6660c049-8aa2-47e5-b5ab-b101c7a38247_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_355df4ef-e96f-4a80-b2b9-ace9fcb406ad_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Legal proceedings</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_570d606c-7932-4dd1-ba68-ea4f592558c7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_2513c909-37e8-49ea-acef-74560e7fc2c4_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_7dfe422e-e7ef-4b32-a4ae-44d8ac9a10e6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_97c3548d-4650-4103-a30c-1d4798255881_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future grants under long-term incentive plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_d91c9702-5684-4338-9aab-a23b007029bb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Benefits paid from plan</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_9e950db4-36af-4fbd-8791-93d0d4f71b76_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherCardiovascularMember_5b981c6c-a6f6-4b32-b67c-e7ad51b964ce_terseLabel_en-US" xlink:label="lab_jnj_OtherCardiovascularMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">other cardiovascular</link:label>
    <link:label id="lab_jnj_OtherCardiovascularMember_label_en-US" xlink:label="lab_jnj_OtherCardiovascularMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">other cardiovascular [Member]</link:label>
    <link:label id="lab_jnj_OtherCardiovascularMember_documentation_en-US" xlink:label="lab_jnj_OtherCardiovascularMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">other cardiovascular</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherCardiovascularMember" xlink:href="jnj-20241229.xsd#jnj_OtherCardiovascularMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherCardiovascularMember" xlink:to="lab_jnj_OtherCardiovascularMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_b7f0820c-ba47-4ac6-be59-feee01d5fc5d_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_3ba73fcc-4305-4880-8727-190b323771f7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_573a78b5-3141-45b3-a9c2-88815c51b351_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b7adf335-28f9-4fd8-ba83-d8d7481bd204_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_fe3a6a17-53fb-46e5-bff3-f6123fd99065_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_f11ad4a2-92d6-40b0-82f2-ea9ce1cc7237_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_56022f9a-6474-4474-aa32-768c92bb5d16_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases related to prior period tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_69208fc2-bf0c-41a2-8543-1988b7023bdd_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_b0692153-0d8c-4145-965f-4babb3d195f8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International taxes</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_ea4e064d-34be-40d9-bb38-2b83d9172cc0_terseLabel_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Postemployment benefits</link:label>
    <link:label id="lab_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Postemployment Benefits Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent" xlink:to="lab_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_94c62741-dcce-4113-b978-05ec113a146f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rate to which the cost trend rate is assumed to decline (ultimate trend)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Ultimate Health Care Cost Trend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:to="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_b4038974-500a-46dc-925d-5d5457f07f0c_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_f0c52ae4-0268-44b2-b3e0-62c113e12099_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rate of increase in compensation levels</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A130NotesDue2030Member_8767a218-f44f-46bd-8e15-cc37590a3b5f_terseLabel_en-US" xlink:label="lab_jnj_A130NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.30% Notes due 2030</link:label>
    <link:label id="lab_jnj_A130NotesDue2030Member_label_en-US" xlink:label="lab_jnj_A130NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.30% Notes due 2030 [Member]</link:label>
    <link:label id="lab_jnj_A130NotesDue2030Member_documentation_en-US" xlink:label="lab_jnj_A130NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1.30% Notes due 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A130NotesDue2030Member" xlink:href="jnj-20241229.xsd#jnj_A130NotesDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A130NotesDue2030Member" xlink:to="lab_jnj_A130NotesDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_536d8c57-f9a7-4fd9-a15a-bf15a45f9c7b_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock Amount</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_3f022991-5774-4476-b059-ddc375c11db3_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of basic net earnings per share to diluted net earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_740454f5-7f57-4ecd-9cf3-fabaab2c0b5e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_December172018ShareRepurchaseProgramMember_89f5ebe7-29cb-46b1-a5ce-30dd4bbe6c28_terseLabel_en-US" xlink:label="lab_jnj_December172018ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 17, 2018 Share Repurchase Program</link:label>
    <link:label id="lab_jnj_December172018ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_jnj_December172018ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 17, 2018 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_jnj_December172018ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_jnj_December172018ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">December 17, 2018 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_December172018ShareRepurchaseProgramMember" xlink:href="jnj-20241229.xsd#jnj_December172018ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_December172018ShareRepurchaseProgramMember" xlink:to="lab_jnj_December172018ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_4aafd77c-27e8-4c27-8783-c7dfd3b25263_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_91709c57-a9ac-4e0e-a8a8-9faf196f379d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Damages awarded</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_6b5dce3a-1842-4487-a155-367959e03b55_terseLabel_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_label_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_documentation_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement" xlink:href="jnj-20241229.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_Numberofpatientsinsettlement" xlink:to="lab_jnj_Numberofpatientsinsettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_6b3f874c-8c1a-4cf7-93ca-0f8ba5d65aa6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_8a2297f3-2548-4b9a-93c2-bedb16ef7411_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_a236aca2-20c5-4a2a-af8c-1d9b47d1ecf5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</link:label>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_label_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Excluded Component, Gain (Loss), Recognized in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:to="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ChangesInTreasuryStockTableTextBlock_64b1e988-e9f9-470e-92b9-14ee9e098da4_terseLabel_en-US" xlink:label="lab_jnj_ChangesInTreasuryStockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in Treasury Stock</link:label>
    <link:label id="lab_jnj_ChangesInTreasuryStockTableTextBlock_label_en-US" xlink:label="lab_jnj_ChangesInTreasuryStockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes In Treasury Stock [Table Text Block]</link:label>
    <link:label id="lab_jnj_ChangesInTreasuryStockTableTextBlock_documentation_en-US" xlink:label="lab_jnj_ChangesInTreasuryStockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Changes in treasury stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesInTreasuryStockTableTextBlock" xlink:href="jnj-20241229.xsd#jnj_ChangesInTreasuryStockTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ChangesInTreasuryStockTableTextBlock" xlink:to="lab_jnj_ChangesInTreasuryStockTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_103686ff-7240-4c01-97ff-26c1fd663e97_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0543bf33-bc66-4cbb-9e48-ad096d8bda62_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1ab90536-7c32-4bad-9e9c-99733495c355_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_14e1ed6d-5a6d-4f8e-b96d-720bad0447a8_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying Amount, held-to-maturity</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecurities" xlink:to="lab_us-gaap_HeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_76dbd7ed-a951-4a55-97c7-19f0b07d11f1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_ab183ed8-5c8d-4589-a211-3814d823468e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain/(Loss) Recognized In Accumulated OCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AbiomedMember_6a272b8d-4dc0-471a-87b4-ba3dd8dae790_terseLabel_en-US" xlink:label="lab_jnj_AbiomedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Abiomed</link:label>
    <link:label id="lab_jnj_AbiomedMember_label_en-US" xlink:label="lab_jnj_AbiomedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Abiomed [Member]</link:label>
    <link:label id="lab_jnj_AbiomedMember_documentation_en-US" xlink:label="lab_jnj_AbiomedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Abiomed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AbiomedMember" xlink:href="jnj-20241229.xsd#jnj_AbiomedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AbiomedMember" xlink:to="lab_jnj_AbiomedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_fdaf059f-fca1-42dd-9a76-9c8e2318b0cf_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Employee compensation and stock option plans (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ValuationAllowanceDeferredTaxAssetsAcquisitionsDispositions_493a0fbf-4a92-433c-9bc3-b62fad297953_terseLabel_en-US" xlink:label="lab_jnj_ValuationAllowanceDeferredTaxAssetsAcquisitionsDispositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net acquisitions / (dispositions/liquidations)</link:label>
    <link:label id="lab_jnj_ValuationAllowanceDeferredTaxAssetsAcquisitionsDispositions_label_en-US" xlink:label="lab_jnj_ValuationAllowanceDeferredTaxAssetsAcquisitionsDispositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Assets, Acquisitions (Dispositions)</link:label>
    <link:label id="lab_jnj_ValuationAllowanceDeferredTaxAssetsAcquisitionsDispositions_documentation_en-US" xlink:label="lab_jnj_ValuationAllowanceDeferredTaxAssetsAcquisitionsDispositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Assets, Acquisitions (Dispositions)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ValuationAllowanceDeferredTaxAssetsAcquisitionsDispositions" xlink:href="jnj-20241229.xsd#jnj_ValuationAllowanceDeferredTaxAssetsAcquisitionsDispositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ValuationAllowanceDeferredTaxAssetsAcquisitionsDispositions" xlink:to="lab_jnj_ValuationAllowanceDeferredTaxAssetsAcquisitionsDispositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_4ef632a8-fac3-4a72-92ff-0bd8adfa7e39_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net actuarial loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_cdebd5a7-ecd4-4dfd-be0c-2542a34e6a34_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionContributions_4f745c7e-1a95-44c9-b69a-5a104f200dd4_terseLabel_en-US" xlink:label="lab_us-gaap_PensionContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contribution to pension plans</link:label>
    <link:label id="lab_us-gaap_PensionContributions_label_en-US" xlink:label="lab_us-gaap_PensionContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Pension Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionContributions" xlink:to="lab_us-gaap_PensionContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_ab4c0482-e19a-4fb1-9794-dff6dc5cb535_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity interests issued and issuable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8d8b6456-ff00-4f25-84b8-62034636433e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectOfExchangeRates_61305e37-bb9f-4770-af7b-963b84796d1e_terseLabel_en-US" xlink:label="lab_jnj_EffectOfExchangeRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rates</link:label>
    <link:label id="lab_jnj_EffectOfExchangeRates_label_en-US" xlink:label="lab_jnj_EffectOfExchangeRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect Of Exchange Rates</link:label>
    <link:label id="lab_jnj_EffectOfExchangeRates_documentation_en-US" xlink:label="lab_jnj_EffectOfExchangeRates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effect Of Exchange Rates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectOfExchangeRates" xlink:href="jnj-20241229.xsd#jnj_EffectOfExchangeRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectOfExchangeRates" xlink:to="lab_jnj_EffectOfExchangeRates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_52643e79-b0e8-49c0-8c21-8064d1c254d3_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental schedule of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_4dccca85-6715-4bda-93eb-4b2597496f24_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">(Gain) on separation of Kenvue</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_8f9dc381-e880-49e6-b4a2-c763b669edfa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repatriation of foreign earnings amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:to="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_b7b9e4db-52d9-4a3f-aa84-28221940eaeb_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_a21ab416-6be0-45df-ae90-067429f28dc0_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on divestiture</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration_3b3d6437-8429-4e41-afc3-c915438136c9_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_8e1a9072-61c3-4764-af22-39fab997c976_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount reserved for settlement</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_dc408d99-deb7-4f10-abb6-a6acfdbd18ba_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_881fb006-84e6-4cf3-a7d6-2dda3f3b56e8_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_7d4d599f-5539-4086-937a-93f5294106e7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net earnings from Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRoyaltiesReceived_fee023b6-0451-45f1-88d0-329c9cac132a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Royalties Received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRoyaltiesReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Royalties Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRoyaltiesReceived" xlink:to="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations_21531157-5934-4523-a085-11d02afd8447_periodStartLabel_en-US" xlink:label="lab_jnj_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents from continuing operations, beginning of period</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations_9cf7b874-9adf-432e-88af-be0b7a147a13_periodEndLabel_en-US" xlink:label="lab_jnj_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents from continuing operations, end of period</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations_label_en-US" xlink:label="lab_jnj_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations_documentation_en-US" xlink:label="lab_jnj_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations" xlink:href="jnj-20241229.xsd#jnj_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations" xlink:to="lab_jnj_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_194fe85e-b136-4f04-9e3d-aa0417bb52d3_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior service cost (credit)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_664007a7-1b9e-41cf-a0b6-9f4b55d7b8ae_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_823b07f7-acdd-4f96-b41a-ef63f2dc9ea3_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_e1a2f2c4-276d-44b6-b6bd-85c681b077b8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt, weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_1ea8ef2d-f109-45ff-964e-7be4f0c4a89d_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_COVID19Member_072b24d4-eccf-4af5-97d5-e050d1b2b7a2_terseLabel_en-US" xlink:label="lab_jnj_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COVID-19</link:label>
    <link:label id="lab_jnj_COVID19Member_label_en-US" xlink:label="lab_jnj_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">COVID-19 [Member]</link:label>
    <link:label id="lab_jnj_COVID19Member_documentation_en-US" xlink:label="lab_jnj_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_COVID19Member" xlink:href="jnj-20241229.xsd#jnj_COVID19Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_COVID19Member" xlink:to="lab_jnj_COVID19Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a98ef58d-5068-4cec-87f1-0d73f1b07b56_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total compensation cost not yet recognized for option</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_f52e65ae-4d4d-482e-8f5d-3360cb6fc682_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net actuarial (gain) loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_9ce92283-21b0-481c-80b0-41f1c5c87e59_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International taxes</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_f415365b-be90-4932-ad76-f29ca7a44a1a_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds_e18f5e56-3f70-46aa-b41e-87b3e41a5a28_terseLabel_en-US" xlink:label="lab_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock issued for employee compensation and stock option plans, net of cash proceeds/ employee withholding tax on stock awards</link:label>
    <link:label id="lab_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds_label_en-US" xlink:label="lab_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock Issued For Employee Compensation And Stock Option Plans Net Of Cash Proceeds</link:label>
    <link:label id="lab_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds_documentation_en-US" xlink:label="lab_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Treasury stock issued for employee compensation and stock option plans, net of cash proceeds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" xlink:href="jnj-20241229.xsd#jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" xlink:to="lab_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_ffcf48ae-9272-4503-bfd5-130f62be7b9a_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent_d6fa00ee-2c38-4777-bcec-7cc16e859d3d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Postretirement benefits</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability, Other Postretirement Defined Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c497a6ce-d64c-4adf-a800-aff5e6e4fdba_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_StockIssuedDuringPeriodSharesExchangeOffer_9ae32b81-b267-496c-a185-d62f6a770a72_terseLabel_en-US" xlink:label="lab_jnj_StockIssuedDuringPeriodSharesExchangeOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued in exchange offer (in shares)</link:label>
    <link:label id="lab_jnj_StockIssuedDuringPeriodSharesExchangeOffer_label_en-US" xlink:label="lab_jnj_StockIssuedDuringPeriodSharesExchangeOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Exchange Offer</link:label>
    <link:label id="lab_jnj_StockIssuedDuringPeriodSharesExchangeOffer_documentation_en-US" xlink:label="lab_jnj_StockIssuedDuringPeriodSharesExchangeOffer" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Exchange Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StockIssuedDuringPeriodSharesExchangeOffer" xlink:href="jnj-20241229.xsd#jnj_StockIssuedDuringPeriodSharesExchangeOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_StockIssuedDuringPeriodSharesExchangeOffer" xlink:to="lab_jnj_StockIssuedDuringPeriodSharesExchangeOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_d83b96dc-a27a-49b3-9185-720f0d237c74_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net earnings from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_f222431c-0f8a-4867-9bdb-75e7f158d21c_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_a11974f6-bffb-4123-84ee-bd6cf21b888b_periodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock, beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_10addc9b-62d3-4c0a-8e18-906971397464_periodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock, ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_709fd767-a43a-4b19-8ffb-cf8bf5a6e0c0_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, interest on income taxes accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaid_4a90447a-0820-4484-9034-572706274d5f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaid_label_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid" xlink:to="lab_us-gaap_InterestPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_09f85140-0d98-4aa7-93ee-04f4a21c7b0b_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_bbb48ef7-c423-4080-991e-7a910a527323_terseLabel_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA</link:label>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_label_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]</link:label>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_documentation_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:href="jnj-20241229.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:to="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_6d9ace1e-cdc0-47c2-bfeb-a7fbb9bcaac0_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_3530ec53-d28b-45fa-aaa5-5bcbd202f6c6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_1e88c731-e0c3-487d-8815-b7a69c0a3cbd_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_d690e4d1-5a78-4df7-8070-8be02e521e6e_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_9228182b-9e9d-4a98-bcd3-d435ca84a467_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials and Supplies, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6691476d-4e48-49e1-a775-376274196fd8_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_fd64ee87-411f-4cce-b9c1-586f9c45c743_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercised, average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent_d24cde78-74b3-494c-82a5-80f020ed64e3_terseLabel_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TCJA, undistributed foreign earnings percent related to cash and cash equivalents</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent_label_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Cash And Cash Equivalents, Tax Rate, Percent</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent_documentation_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Cash And Cash Equivalents, Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" xlink:href="jnj-20241229.xsd#jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" xlink:to="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_d38b2367-c676-417b-8b8e-e37d964a371f_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_Wholesaler1Member_78c7433c-3574-47e0-8abd-ab5ca2f7986f_terseLabel_en-US" xlink:label="lab_jnj_Wholesaler1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Wholesaler 1</link:label>
    <link:label id="lab_jnj_Wholesaler1Member_label_en-US" xlink:label="lab_jnj_Wholesaler1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Wholesaler 1 [Member]</link:label>
    <link:label id="lab_jnj_Wholesaler1Member_documentation_en-US" xlink:label="lab_jnj_Wholesaler1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Wholesaler 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler1Member" xlink:href="jnj-20241229.xsd#jnj_Wholesaler1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_Wholesaler1Member" xlink:to="lab_jnj_Wholesaler1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NumberOfStockBasedCompensationPlans_054d1991-0955-4714-8d3c-85ed67057444_terseLabel_en-US" xlink:label="lab_jnj_NumberOfStockBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of stock-based compensation plans</link:label>
    <link:label id="lab_jnj_NumberOfStockBasedCompensationPlans_label_en-US" xlink:label="lab_jnj_NumberOfStockBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Stock Based Compensation Plans</link:label>
    <link:label id="lab_jnj_NumberOfStockBasedCompensationPlans_documentation_en-US" xlink:label="lab_jnj_NumberOfStockBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of stock-based compensation plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfStockBasedCompensationPlans" xlink:href="jnj-20241229.xsd#jnj_NumberOfStockBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NumberOfStockBasedCompensationPlans" xlink:to="lab_jnj_NumberOfStockBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_ae60de0d-c532-4608-a287-9a0e0dd558e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loans and notes payable</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_f030a33a-92b8-48e2-8755-bfa79e2c7ed5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Loans and notes payable</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_5ab0efe6-882d-4aff-8e25-caf07b8203e9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_a8d8cda4-145a-48dd-b726-a8de88a7e3bd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual Maturities of Available for Sale Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_892533f7-76b9-4e94-a66d-4fdec8037c2c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charges for acquired in-process research and development assets</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsGeneralTextBlock_5d4bae48-0817-4e0f-9a43-cbfe1a9c6a34_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee related obligations</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsGeneralTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Related Costs, General [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsGeneralTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_fbe5bf2c-9fcb-450a-b388-26fed12f593e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_884be782-5c04-4bd1-a2bb-00a0009831f7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_040fc945-94a2-4a44-98ff-9e0591376d09_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_b8c8c9a6-b3d5-4d07-bb80-0f9c081f9ffa_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMember_7c3c2ce8-9ea2-4af4-b737-42e0690ce0db_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_949228b2-98bc-425a-9222-e515bd455efc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of net actuarial loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_0fc34d8f-a72f-449e-81e4-87b636c3b2e1_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_d0bbd909-c89a-4826-9f4e-e5c551666147_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk (as a percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_efb617f7-388e-4eb2-826e-43c476de5cdb_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowing capacity under credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BusinessAcquisitionDiscountRate_84a5137b-01d5-413e-ab5f-f0d35ad80aff_terseLabel_en-US" xlink:label="lab_jnj_BusinessAcquisitionDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_jnj_BusinessAcquisitionDiscountRate_label_en-US" xlink:label="lab_jnj_BusinessAcquisitionDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Discount Rate</link:label>
    <link:label id="lab_jnj_BusinessAcquisitionDiscountRate_documentation_en-US" xlink:label="lab_jnj_BusinessAcquisitionDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Acquisition, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessAcquisitionDiscountRate" xlink:href="jnj-20241229.xsd#jnj_BusinessAcquisitionDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BusinessAcquisitionDiscountRate" xlink:to="lab_jnj_BusinessAcquisitionDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis_04de2574-129b-4afa-805c-4834551db385_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Investment Not Readily Marketable [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Investment Not Readily Marketable [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_c9280f6f-d19b-4635-84f4-26e247e39f07_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net assets divested</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_aa7a603c-90d8-46c8-98b6-8dcb22cd8462_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Net Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f0296bdc-ee28-4b9f-9bb1-b83b08938c9c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_ec8cd8d7-a267-43f6-aff7-fb4ed08b2530_terseLabel_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cardiovascular/Metabolism/Other</link:label>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_label_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cardiovascular/Metabolism/Other [Member]</link:label>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_documentation_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cardiovascular/Metabolism/Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember" xlink:href="jnj-20241229.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CardiovascularMetabolismOtherMember" xlink:to="lab_jnj_CardiovascularMetabolismOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_227acc17-1ff9-47d1-9a1e-dc6e7433c1ee_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_54aba99b-466e-464f-ad3b-81fd76de3c77_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f86e2ed4-48c8-449d-b6b4-b33493c9d455_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_99162305-2c9a-42eb-a430-ae80a792a519_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions, net of cash acquired (Note 18)</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LegalProceedingTextualsAbstract_e1f8adc0-f4c2-4be8-98eb-3158868c79a8_terseLabel_en-US" xlink:label="lab_jnj_LegalProceedingTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Proceeding (Textuals)</link:label>
    <link:label id="lab_jnj_LegalProceedingTextualsAbstract_label_en-US" xlink:label="lab_jnj_LegalProceedingTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Proceeding (Textuals) [Abstract]</link:label>
    <link:label id="lab_jnj_LegalProceedingTextualsAbstract_documentation_en-US" xlink:label="lab_jnj_LegalProceedingTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Legal Proceeding Textuals Abstract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalProceedingTextualsAbstract" xlink:href="jnj-20241229.xsd#jnj_LegalProceedingTextualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LegalProceedingTextualsAbstract" xlink:to="lab_jnj_LegalProceedingTextualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_f63a5dde-ec6c-47d4-bb40-daa3fdfff07c_verboseLabel_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued rebates, returns and promotions</link:label>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_label_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Rebates Returns And Promotions</link:label>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_documentation_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions" xlink:href="jnj-20241229.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AccruedRebatesReturnsAndPromotions" xlink:to="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_1b5fc0dd-f63e-46a6-8d96-234984d97954_verboseLabel_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Purchased in-process research and development</link:label>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_645a2b6c-4ab8-4625-9411-847828b7efd2_terseLabel_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchased in-process research and development(1)</link:label>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchased In-Process Research And Development [Member]</link:label>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchased In-Process Research And Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:href="jnj-20241229.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:to="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_3c50edeb-8d0a-446f-bc13-582432598560_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Payment for Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_8b719233-ef89-4595-9968-47191af7dc27_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_f2b52a52-a14d-4280-bb7c-76565bb1a5b7_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Recognized actuarial losses (gains)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_4f794f48-aa0b-46cf-be7d-3dd2cfbea02c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_14fd8ba8-d740-40e5-a859-5b0116c09396_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_2a6916b1-5d09-4ad7-9ed7-5f09683cbe55_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_8fa89540-0e33-41a3-beec-12977c5b180f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, net of portion capitalized</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_a242c619-82c1-419d-8513-0b41d969404d_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2e9f2932-f011-46d2-8ad5-7363b3710dd0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_1fd62b89-dfff-4893-878c-3e16c248a04e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_85f76e8a-7321-4e1c-be48-24471e507671_terseLabel_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.587% Notes due 2036</link:label>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_label_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.55% Notes due 2036 [Member]</link:label>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_documentation_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">3.55% Notes due 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member" xlink:href="jnj-20241229.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.55Notesdue2036Member" xlink:to="lab_jnj_A3.55Notesdue2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne_78633beb-bf55-4e61-a027-48d43a2f5720_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Expected Future Benefit Contribution In Year One</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined benefit plan expected future benefit contribution in year one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" xlink:to="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_b9d71763-1a43-446d-b804-a464832cd7c4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of options, tax benefit</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Exercise of Option, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TalcMember_1a306e1a-42ad-401c-81c6-3c79bcc3c698_terseLabel_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Talc</link:label>
    <link:label id="lab_jnj_TalcMember_label_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Talc [Member]</link:label>
    <link:label id="lab_jnj_TalcMember_documentation_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Talc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember" xlink:href="jnj-20241229.xsd#jnj_TalcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TalcMember" xlink:to="lab_jnj_TalcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OrthopaedicsRestructuringPlanMember_27986aef-ec67-46e6-82b6-113aa3894b4e_terseLabel_en-US" xlink:label="lab_jnj_OrthopaedicsRestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Orthopaedics Restructuring Plan</link:label>
    <link:label id="lab_jnj_OrthopaedicsRestructuringPlanMember_label_en-US" xlink:label="lab_jnj_OrthopaedicsRestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Orthopaedics Restructuring Plan [Member]</link:label>
    <link:label id="lab_jnj_OrthopaedicsRestructuringPlanMember_documentation_en-US" xlink:label="lab_jnj_OrthopaedicsRestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Orthopaedics Restructuring Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsRestructuringPlanMember" xlink:href="jnj-20241229.xsd#jnj_OrthopaedicsRestructuringPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OrthopaedicsRestructuringPlanMember" xlink:to="lab_jnj_OrthopaedicsRestructuringPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_7cface60-1597-4eac-ac9a-3272ad6e53a5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term borrowings and the current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_45c37568-1424-4335-b34b-9059d58c8c5f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_8b6d4e0b-56e6-448a-9570-cfb41a56f415_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable trade, less allowances $167 (2023, $166)</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_2c107d86-951f-41bc-9bd6-800b3bdf046e_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest cost discount rate</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:to="lab_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_a2261f1c-975f-46c0-98c6-c8b2b40d7904_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a182a92a-bea4-4a23-a96a-9552a8b65782_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase/(Decrease) in other current and non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_38992533-c079-4f74-b131-7321a5e3de6f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset write-downs</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_45af3389-3392-4305-847c-df0973431245_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_9526401b-8a9c-411f-b0f0-5bd553d0d4ff_terseLabel_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.85%&#160;Debentures due 2038</link:label>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_label_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">5.85% Debentures due 2038 [Member]</link:label>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_documentation_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">5.85% Debentures due 2038 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member" xlink:href="jnj-20241229.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.85Debenturesdue2038Member" xlink:to="lab_jnj_A5.85Debenturesdue2038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_88dc08e5-8d9d-43e3-8504-e83fab54bda3_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Plan Assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_0cd22496-ff73-4e17-a491-a15154945f79_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Plan assets at fair value&#160;&#8212; beginning of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_a5d6c241-5647-4479-b8b3-da373de6b541_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Plan assets at fair value&#160;- End of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_b57eb281-fe49-43e8-8171-5862925c90ea_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After 2029</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PelvicMeshesMember_95746ed1-cc8a-4594-b88e-051a11e1f4a2_terseLabel_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pelvic Meshes</link:label>
    <link:label id="lab_jnj_PelvicMeshesMember_label_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pelvic Meshes [Member]</link:label>
    <link:label id="lab_jnj_PelvicMeshesMember_documentation_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pelvic meshes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember" xlink:href="jnj-20241229.xsd#jnj_PelvicMeshesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PelvicMeshesMember" xlink:to="lab_jnj_PelvicMeshesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_f4f46db8-8ca9-4b61-8d01-0f2ebd085fe2_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_5974a9f9-470f-49c8-b120-bd20a2164ac8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_3d772599-f013-49ad-a545-6de75a6103aa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Employee benefits</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_8f9a4b3c-e404-4218-a84d-8e517deb591f_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesMember_c3461dbd-4952-4e20-8b1b-7a897b29fad3_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesMember_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesMember" xlink:to="lab_us-gaap_RestructuringChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EmployeeRelatedObligationsTableTextBlock_0f9a5645-2259-44fe-a3d7-99086ada000f_terseLabel_en-US" xlink:label="lab_jnj_EmployeeRelatedObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Related Obligations</link:label>
    <link:label id="lab_jnj_EmployeeRelatedObligationsTableTextBlock_label_en-US" xlink:label="lab_jnj_EmployeeRelatedObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Related Obligations [Table Text Block]</link:label>
    <link:label id="lab_jnj_EmployeeRelatedObligationsTableTextBlock_documentation_en-US" xlink:label="lab_jnj_EmployeeRelatedObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee related obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeRelatedObligationsTableTextBlock" xlink:href="jnj-20241229.xsd#jnj_EmployeeRelatedObligationsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EmployeeRelatedObligationsTableTextBlock" xlink:to="lab_jnj_EmployeeRelatedObligationsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_739a8db1-29a8-45f2-a08a-5c5a47f74c16_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price Range, Minimum (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_f41e5ddb-1f90-455a-8fad-aacad5460f74_terseLabel_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.46% Notes due 2026</link:label>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_label_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.45% Notes due 2026 [Member]</link:label>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_documentation_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2.45% Notes due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member" xlink:href="jnj-20241229.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.45Notesdue2026Member" xlink:to="lab_jnj_A2.45Notesdue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_ceae6bb7-0004-45f6-8358-a93176a5e2e7_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized gain (loss) on investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Realized Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:to="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_266a659d-6f12-41d9-9556-698bb4898809_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShockwaveMedicalInc.Member_67d9c533-626e-4a97-bd80-c1a679cb5cd7_terseLabel_en-US" xlink:label="lab_jnj_ShockwaveMedicalInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shockwave Medical, Inc.</link:label>
    <link:label id="lab_jnj_ShockwaveMedicalInc.Member_label_en-US" xlink:label="lab_jnj_ShockwaveMedicalInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shockwave Medical, Inc. [Member]</link:label>
    <link:label id="lab_jnj_ShockwaveMedicalInc.Member_documentation_en-US" xlink:label="lab_jnj_ShockwaveMedicalInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shockwave Medical, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShockwaveMedicalInc.Member" xlink:href="jnj-20241229.xsd#jnj_ShockwaveMedicalInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShockwaveMedicalInc.Member" xlink:to="lab_jnj_ShockwaveMedicalInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f49eead3-4cb3-4179-b234-c5dd9ee16e0d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentDetailAbstract_240390d7-aad2-40a0-8036-deb946e94fe0_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial assets and liabilities at fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentDetailAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument Detail [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c5df102d-e139-48cf-9b11-c773a9b0162a_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_982b960b-0506-449b-a935-b8e8414fa94d_terseLabel_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.50% Notes due 2043</link:label>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_label_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">4.50% Notes due 2043 [Member]</link:label>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_documentation_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">4.50% Notes due 2043 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member" xlink:href="jnj-20241229.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.50Notesdue2043Member" xlink:to="lab_jnj_A4.50Notesdue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_e930919d-73d6-48d4-a9aa-6fc204cb510f_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense of amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_9bd10156-a757-4b0e-a21b-174adf8883bf_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-US</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_3b718dbc-6e8a-44ed-9473-fa1a798e1ab0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Investment Not Readily Marketable [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Investment Not Readily Marketable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_688ef029-717a-4b2c-8f6e-dd716dc85daf_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_63747d47-fd8e-4bc5-a4a1-4cdab2f72837_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity investments, increase (decrease) from acquisition (sale) during period</link:label>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_label_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</link:label>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:href="jnj-20241229.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:to="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_9923ac12-b30e-46f6-b401-03b03af1ecd2_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions and divestitures</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_f4525a6e-29b9-49c4-ab39-5884bfaf70f7_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RegulationCharge_c75640d7-af65-405e-8a8e-7e01ca273c23_terseLabel_en-US" xlink:label="lab_jnj_RegulationCharge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regulation charge</link:label>
    <link:label id="lab_jnj_RegulationCharge_label_en-US" xlink:label="lab_jnj_RegulationCharge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulation charge</link:label>
    <link:label id="lab_jnj_RegulationCharge_documentation_en-US" xlink:label="lab_jnj_RegulationCharge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regulation charge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RegulationCharge" xlink:href="jnj-20241229.xsd#jnj_RegulationCharge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RegulationCharge" xlink:to="lab_jnj_RegulationCharge" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IntraCellularTherapiesInc.Member_137d3cb8-93c3-4475-b16c-ed376c181082_terseLabel_en-US" xlink:label="lab_jnj_IntraCellularTherapiesInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intra-Cellular Therapies, Inc.</link:label>
    <link:label id="lab_jnj_IntraCellularTherapiesInc.Member_label_en-US" xlink:label="lab_jnj_IntraCellularTherapiesInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intra-Cellular Therapies, Inc. [Member]</link:label>
    <link:label id="lab_jnj_IntraCellularTherapiesInc.Member_documentation_en-US" xlink:label="lab_jnj_IntraCellularTherapiesInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intra-Cellular Therapies, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IntraCellularTherapiesInc.Member" xlink:href="jnj-20241229.xsd#jnj_IntraCellularTherapiesInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IntraCellularTherapiesInc.Member" xlink:to="lab_jnj_IntraCellularTherapiesInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80a839a4-0494-4e81-881d-f054c2444b03_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_f34d557d-8274-44d5-a868-5589db1d3461_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_85af9f55-2b35-4e15-b054-a2464d6f04bb_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Less: Cash acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2843d6a3-bb61-4353-8b8d-6ddd615aa089_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_6932126b-b112-4a17-a110-efab8bca8755_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee related obligations</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_dcb5d4e5-eb45-48d6-a234-fc66798ca07d_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee related obligations&#160;&#8212; non-current</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_d55bff52-5132-4d5a-aad5-4c2ef3f9af21_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability, Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_54ea1c6c-7e8f-4c02-881e-207f8e87e609_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred taxes on income</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6f12a504-5810-4e51-b0f0-1b1302e1163e_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_08d945ea-a766-420c-b3c8-446545cdad6b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a56d3949-1250-46d7-9d72-ae7dd9dc7959_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other assets assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquisitionCosts_e0b97f73-4b80-4043-a7b2-cac86b3af3e9_terseLabel_en-US" xlink:label="lab_us-gaap_AcquisitionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition costs, period cost</link:label>
    <link:label id="lab_us-gaap_AcquisitionCosts_label_en-US" xlink:label="lab_us-gaap_AcquisitionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oil and Gas, Full Cost Method, Capitalized Cost Excluded from Amortization, Acquisition Cost, Period Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquisitionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquisitionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquisitionCosts" xlink:to="lab_us-gaap_AcquisitionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_376156a8-fc4b-44b7-b90d-f8937703ff8a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesAxis_b20a8d16-2861-40a3-8e78-2ab2dd9c4e65_terseLabel_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Settlement By Companies</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesAxis_label_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement By Companies [Axis]</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesAxis_documentation_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation settlement by companies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesAxis" xlink:href="jnj-20241229.xsd#jnj_LitigationSettlementByCompaniesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis" xlink:to="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_c42ed52c-5aad-4d6e-9c96-216e75fcbb41_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Pensions and other benefit plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PharmaceuticalMember_33038661-9d3d-45c7-b6e4-3c03ba83b024_verboseLabel_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Pharmaceutical</link:label>
    <link:label id="lab_jnj_PharmaceuticalMember_adc6e770-9f75-4902-bdb5-c15b58a1dd0f_terseLabel_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pharmaceutical</link:label>
    <link:label id="lab_jnj_PharmaceuticalMember_label_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pharmaceutical [Member]</link:label>
    <link:label id="lab_jnj_PharmaceuticalMember_documentation_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pharmaceutical.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember" xlink:href="jnj-20241229.xsd#jnj_PharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PharmaceuticalMember" xlink:to="lab_jnj_PharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_e9f8ac95-cb29-4f49-8c3f-ec53925cfed5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_13f9d7c3-ee9f-4e17-b2dc-238532eaf1ed_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLineItems" xlink:to="lab_us-gaap_ShortTermDebtLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e387db14-4918-4bb4-ac1a-be935f6cfc1a_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New accounting standards and Recently issued accounting standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_47e558c2-e3e5-436c-aaa3-2ba3a97dbea4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_85ba7a31-af13-4dd6-9b0a-d1d54ef59ff0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_af0fbb8a-8d2d-49a3-a358-cc53d0144ab1_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_1df9127a-df2c-41f8-95f5-e17c3925cbf5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_a1e21a47-5a10-432e-a5a0-5444b96ee1bd_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2a3dc781-3f8b-4a3d-a91a-7c4f22bbb607_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net earnings from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SavingsPlanTextBlock_247e1783-1650-4f31-a9e7-9f6561a10d67_terseLabel_en-US" xlink:label="lab_jnj_SavingsPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Savings plan</link:label>
    <link:label id="lab_jnj_SavingsPlanTextBlock_label_en-US" xlink:label="lab_jnj_SavingsPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Savings Plan [Text Block]</link:label>
    <link:label id="lab_jnj_SavingsPlanTextBlock_documentation_en-US" xlink:label="lab_jnj_SavingsPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Savings Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SavingsPlanTextBlock" xlink:href="jnj-20241229.xsd#jnj_SavingsPlanTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SavingsPlanTextBlock" xlink:to="lab_jnj_SavingsPlanTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_f473b46b-29d5-41ac-ae97-c15f2619c280_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SPINESPORTSOTHERMember_c398f82d-194d-405e-8edf-a634fbb8fcdf_terseLabel_en-US" xlink:label="lab_jnj_SPINESPORTSOTHERMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SPINE,SPORTS &amp; OTHER</link:label>
    <link:label id="lab_jnj_SPINESPORTSOTHERMember_label_en-US" xlink:label="lab_jnj_SPINESPORTSOTHERMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SPINE, SPORTS &amp; OTHER [Member]</link:label>
    <link:label id="lab_jnj_SPINESPORTSOTHERMember_documentation_en-US" xlink:label="lab_jnj_SPINESPORTSOTHERMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SPINE &amp; OTHER [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINESPORTSOTHERMember" xlink:href="jnj-20241229.xsd#jnj_SPINESPORTSOTHERMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SPINESPORTSOTHERMember" xlink:to="lab_jnj_SPINESPORTSOTHERMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_f54aefea-cfb7-44e7-9316-ac638adff61e_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_8b4acf05-2042-4ba9-9979-a51c31061fb2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes, inclusive of discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_a4ac87f2-386b-4b20-91a1-1ded213a54d6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee benefit plans:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RemicadeMember_cea00a8a-0d31-43dc-be80-33ce601dff56_terseLabel_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remicade</link:label>
    <link:label id="lab_jnj_RemicadeMember_label_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remicade [Member]</link:label>
    <link:label id="lab_jnj_RemicadeMember_documentation_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Remicade [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember" xlink:href="jnj-20241229.xsd#jnj_RemicadeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RemicadeMember" xlink:to="lab_jnj_RemicadeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_755d1353-a32e-4ba6-9cba-74ee3a4a231e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_7ec8dcbf-fd35-42f3-af76-aa489c504e2d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TremfyaMember_f592857f-00c3-4841-a713-47d2da9a97cf_terseLabel_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tremfya</link:label>
    <link:label id="lab_jnj_TremfyaMember_label_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tremfya [Member]</link:label>
    <link:label id="lab_jnj_TremfyaMember_documentation_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tremfaya</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember" xlink:href="jnj-20241229.xsd#jnj_TremfyaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TremfyaMember" xlink:to="lab_jnj_TremfyaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_959dd769-b9ee-4d1a-ae9a-e217320bc199_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_18b16a42-5196-4044-84dc-379611e3bb72_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Restricted Share Units</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_59441009-a1ac-4a63-b414-30a068c30419_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred income taxes net of valuation allowances</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherPulmonaryHypertensionMember_13fe5163-218c-4300-bf74-9bcb325c1985_terseLabel_en-US" xlink:label="lab_jnj_OtherPulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Pulmonary Hypertension</link:label>
    <link:label id="lab_jnj_OtherPulmonaryHypertensionMember_label_en-US" xlink:label="lab_jnj_OtherPulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Pulmonary Hypertension [Member]</link:label>
    <link:label id="lab_jnj_OtherPulmonaryHypertensionMember_documentation_en-US" xlink:label="lab_jnj_OtherPulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Pulmonary Hypertension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherPulmonaryHypertensionMember" xlink:href="jnj-20241229.xsd#jnj_OtherPulmonaryHypertensionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherPulmonaryHypertensionMember" xlink:to="lab_jnj_OtherPulmonaryHypertensionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_c721aacf-914f-4b68-92eb-eafca7048180_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NeuroscienceMember_4402a822-900a-4f52-bf7d-09ced362c9c2_terseLabel_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Neuroscience</link:label>
    <link:label id="lab_jnj_NeuroscienceMember_label_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:label id="lab_jnj_NeuroscienceMember_documentation_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember" xlink:href="jnj-20241229.xsd#jnj_NeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NeuroscienceMember" xlink:to="lab_jnj_NeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TECVAYLIMember_be279b22-26f9-40cd-9304-31b11eff1916_terseLabel_en-US" xlink:label="lab_jnj_TECVAYLIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TECVAYLI</link:label>
    <link:label id="lab_jnj_TECVAYLIMember_label_en-US" xlink:label="lab_jnj_TECVAYLIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TECVAYLI [Member]</link:label>
    <link:label id="lab_jnj_TECVAYLIMember_documentation_en-US" xlink:label="lab_jnj_TECVAYLIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TECVAYLI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TECVAYLIMember" xlink:href="jnj-20241229.xsd#jnj_TECVAYLIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TECVAYLIMember" xlink:to="lab_jnj_TECVAYLIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_ff425379-73a5-4980-8362-5959af144213_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in foreign tax credits, percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_90ba5e74-7858-41c2-bf10-f4fcd58b0e20_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stated interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_7b8c7aa7-437e-4d60-b83f-9b04259e6ce8_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item, Corporate Nonsegment</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExercisePriceRangeThreeMember_9b31b4a7-5912-4df6-b612-361a7ad423ab_terseLabel_en-US" xlink:label="lab_jnj_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$131.94 - $151.41</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_jnj_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeThreeMember_documentation_en-US" xlink:label="lab_jnj_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeThreeMember" xlink:href="jnj-20241229.xsd#jnj_ExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExercisePriceRangeThreeMember" xlink:to="lab_jnj_ExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_6c4e4b82-4bb6-4f51-9ddc-df31cf4d2157_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow data</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_b0c4362a-bf77-4aee-8a16-e4fa86096178_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities, fair market value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_041c8ebb-5f23-456a-9bc6-65525395e48a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_fe3488b6-bb6b-4683-b728-7595639c6707_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Derivative Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsAbstract_38548177-9382-498d-a654-78ff3e825215_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Related Costs [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Related Costs [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract" xlink:to="lab_us-gaap_CompensationRelatedCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation_cc1ed5ba-db31-4218-9cbd-50c39116cf83_terseLabel_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. tax settlements</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation_label_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Consumer Health Separation</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation_documentation_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Consumer Health Separation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation" xlink:href="jnj-20241229.xsd#jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation" xlink:to="lab_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_a22a1da0-5d67-4ed3-a0e5-4601e3d39852_terseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense capitalized</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized" xlink:to="lab_us-gaap_InterestCostsCapitalized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_86a71804-c2d3-4f35-81f5-14521a0596b1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement_ad1436f1-6ce9-4913-a2e0-db0495095b48_terseLabel_en-US" xlink:label="lab_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum reverse repurchase agreement collateral (as a percent)</link:label>
    <link:label id="lab_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement_label_en-US" xlink:label="lab_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Collateral Value as a Percent, Reverse Repurchase Agreement</link:label>
    <link:label id="lab_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement_documentation_en-US" xlink:label="lab_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum Collateral Value as a Percent, Reverse Repurchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement" xlink:href="jnj-20241229.xsd#jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement" xlink:to="lab_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_561f47f9-7faa-45fc-9610-afccf3575d70_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_40ba2d78-196d-40fa-9985-ebe6931bf822_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective Rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_01ca5e54-c1f8-4790-9c6f-7442eaa0f8ef_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_d33ef4a5-154d-4a08-aef3-0a2479d288e6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_0be2f209-639f-4e6c-a0e4-de62d417a7e2_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_48cf076e-2575-4ecb-bf8e-c5f1928d97c0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.90DebenturesDue2031Member_cacba0ac-0f73-42e1-bee9-8957e5ab94c8_terseLabel_en-US" xlink:label="lab_jnj_A4.90DebenturesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.90% Debentures due 2031</link:label>
    <link:label id="lab_jnj_A4.90DebenturesDue2031Member_label_en-US" xlink:label="lab_jnj_A4.90DebenturesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">4.90% Debentures due 2031 [Member]</link:label>
    <link:label id="lab_jnj_A4.90DebenturesDue2031Member_documentation_en-US" xlink:label="lab_jnj_A4.90DebenturesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">4.90% Debentures due 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.90DebenturesDue2031Member" xlink:href="jnj-20241229.xsd#jnj_A4.90DebenturesDue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.90DebenturesDue2031Member" xlink:to="lab_jnj_A4.90DebenturesDue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_bf692bb7-60f5-4e10-ad59-ed87a92728e2_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_ddd4d385-9bad-4de5-88d1-8eb0a45b415a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_9780e902-698f-46ae-89d9-57106ffc91ec_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage ownership after transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Percentage of Ownership after Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CostsOfGoodsAndServicesSoldMember_20297133-b3f6-425a-b178-6c66c7b8a7bd_terseLabel_en-US" xlink:label="lab_jnj_CostsOfGoodsAndServicesSoldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs of Goods and Services Sold</link:label>
    <link:label id="lab_jnj_CostsOfGoodsAndServicesSoldMember_label_en-US" xlink:label="lab_jnj_CostsOfGoodsAndServicesSoldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs of Goods and Services Sold [Member]</link:label>
    <link:label id="lab_jnj_CostsOfGoodsAndServicesSoldMember_documentation_en-US" xlink:label="lab_jnj_CostsOfGoodsAndServicesSoldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Costs of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CostsOfGoodsAndServicesSoldMember" xlink:href="jnj-20241229.xsd#jnj_CostsOfGoodsAndServicesSoldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CostsOfGoodsAndServicesSoldMember" xlink:to="lab_jnj_CostsOfGoodsAndServicesSoldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_c0881131-ab93-4ba4-b296-819f2a1cd889_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AuditorInformationAbstract_label_en-US" xlink:label="lab_jnj_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_jnj_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_jnj_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AuditorInformationAbstract" xlink:href="jnj-20241229.xsd#jnj_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AuditorInformationAbstract" xlink:to="lab_jnj_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_a0d2afbb-ed2d-442e-8c00-bd457805830a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ab246adb-7cbe-4ab4-8d0b-2b47d18a6ea0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InghamVsJohnsonJohnsonMember_6a28f5a5-fd60-457e-9621-4844b4e9f66c_terseLabel_en-US" xlink:label="lab_jnj_InghamVsJohnsonJohnsonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ingham vs. Johnson &amp; Johnson</link:label>
    <link:label id="lab_jnj_InghamVsJohnsonJohnsonMember_label_en-US" xlink:label="lab_jnj_InghamVsJohnsonJohnsonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ingham vs. Johnson &amp; Johnson [Member]</link:label>
    <link:label id="lab_jnj_InghamVsJohnsonJohnsonMember_documentation_en-US" xlink:label="lab_jnj_InghamVsJohnsonJohnsonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ingham vs. Johnson &amp; Johnson</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InghamVsJohnsonJohnsonMember" xlink:href="jnj-20241229.xsd#jnj_InghamVsJohnsonJohnsonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InghamVsJohnsonJohnsonMember" xlink:to="lab_jnj_InghamVsJohnsonJohnsonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_c3d11aca-f9bf-4808-897f-6e7022dfc9c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shipping and Handling</link:label>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_label_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shipping and Handling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShippingAndHandlingMember" xlink:to="lab_us-gaap_ShippingAndHandlingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_7b261d2a-4c9f-49e6-83b5-d8f6c3623934_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Maturities of Long Term Obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_b3457564-184b-49f8-88e6-8a9a47884999_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_62489f3a-106d-4e84-914c-009d61a3ca62_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Building and building equipment</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f7db98a8-9041-476d-ba89-ecfd117ffbf0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyDiscountRate_8987d12a-4809-4222-9634-b24019cac2c4_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bankruptcy loss contingency, discount rate</link:label>
    <link:label id="lab_jnj_LossContingencyDiscountRate_label_en-US" xlink:label="lab_jnj_LossContingencyDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Discount Rate</link:label>
    <link:label id="lab_jnj_LossContingencyDiscountRate_documentation_en-US" xlink:label="lab_jnj_LossContingencyDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyDiscountRate" xlink:href="jnj-20241229.xsd#jnj_LossContingencyDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyDiscountRate" xlink:to="lab_jnj_LossContingencyDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_72ab6374-d237-4d7a-86dc-9365f0f83986_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options canceled/forfeited, average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_3f9dd9c6-c448-4b22-9102-6a0ca7c07866_terseLabel_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.500% Notes due 2048</link:label>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_label_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.500% Notes due 2048 [Member]</link:label>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_documentation_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">3.500% Notes due 2048 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member" xlink:href="jnj-20241229.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.500Notesdue2048Member" xlink:to="lab_jnj_A3.500Notesdue2048Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_624e318f-3558-4abf-8378-c62eace6933f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CardiovascularMember_654f7fb4-da8e-4fd5-a591-3eb90bd70d7f_terseLabel_en-US" xlink:label="lab_jnj_CardiovascularMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cardiovascular</link:label>
    <link:label id="lab_jnj_CardiovascularMember_label_en-US" xlink:label="lab_jnj_CardiovascularMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cardiovascular [Member]</link:label>
    <link:label id="lab_jnj_CardiovascularMember_documentation_en-US" xlink:label="lab_jnj_CardiovascularMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cardiovascular [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMember" xlink:href="jnj-20241229.xsd#jnj_CardiovascularMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CardiovascularMember" xlink:to="lab_jnj_CardiovascularMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4fa669de-6c86-437c-b534-245b2292acde_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_055c1394-6d60-470c-86b8-111c27cfcc69_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_0d0a8c90-dabf-4792-91af-7e40d5ff2f96_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_352bddb3-dfe7-4075-95c1-11321a729de0_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_71938755-0a35-4a0b-9565-86b40144eb07_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_10c14ca6-c962-4532-befa-bbf5bbccb253_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityFairValueAdjustmentImpairmentLoss_ffc59d7e-64d1-4de1-9d6d-50a06fdb9be1_terseLabel_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity, fair value adjustment, impairment loss</link:label>
    <link:label id="lab_jnj_EquityFairValueAdjustmentImpairmentLoss_label_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Fair Value Adjustment, Impairment Loss</link:label>
    <link:label id="lab_jnj_EquityFairValueAdjustmentImpairmentLoss_documentation_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity, Fair Value Adjustment, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:href="jnj-20241229.xsd#jnj_EquityFairValueAdjustmentImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:to="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_bb7d3a77-5c6c-4dda-a9ab-b8021898027e_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_bba405e4-bd03-48f2-ba47-353b4c4564c1_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_bd1f208a-37c0-4bd4-a971-7a9e12538785_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Benefits paid from plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7dcbf767-090f-47ea-badf-1c850fb3ca46_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment at Cost and Accumulated Depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_0e818199-29c1-41e2-9776-a054078dd996_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter_787cebd2-75d4-4c2f-a29e-223244a82ec4_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029-2033</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Expected Future Benefit Contribution In Five Fiscal Years Thereafter</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined benefit plan expected future benefit contribution in five fiscal years thereafter.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" xlink:to="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e98d2807-79a3-4c77-8b8c-c7783d4d1ee1_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c5a4126b-c6bb-4563-81c2-1c4f89012f46_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_99c81e84-08d0-4f5f-b890-154734686c38_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_27047912-d47e-4a97-9648-02260c4bdda7_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software Development</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_133f9bdc-5c02-44be-aee9-c526e9c7a268_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_46dbd8b2-7552-4fa0-9fe7-4ae3caf1eac5_negatedTerseLabel_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss), net of amortization</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_label_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_documentation_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:href="jnj-20241229.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:to="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_0784d016-709b-4d9a-b164-c1810c0fd811_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Investment Not Readily Marketable, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Investment Not Readily Marketable, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_d1493d40-9fa5-4638-8d63-cbf19abde9e0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_b0f4fe67-f5f0-4e67-baaa-7236019b8dba_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_570b89ee-0017-44cf-92a3-30f75ebba7e6_verboseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Credit losses and accounts receivable allowances</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_2285995d-4084-481a-8907-d4109bcb8080_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_5b348c44-f0c1-45d0-9a18-7f01a61388bb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_5ea11a30-f56a-42ac-afb6-fe1f830105c7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9d40b4d2-5469-4d29-b319-a6430a3ce966_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_68b54854-ace1-4e4d-9dfc-f69a0a5f4ad8_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, marketing and administrative expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BusinessCombinationAcquisitionRelatedCostsEquityAwards_91776121-8324-4063-aa08-c0503747a37b_terseLabel_en-US" xlink:label="lab_jnj_BusinessCombinationAcquisitionRelatedCostsEquityAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity awards</link:label>
    <link:label id="lab_jnj_BusinessCombinationAcquisitionRelatedCostsEquityAwards_label_en-US" xlink:label="lab_jnj_BusinessCombinationAcquisitionRelatedCostsEquityAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Acquisition Related Costs, Equity Awards</link:label>
    <link:label id="lab_jnj_BusinessCombinationAcquisitionRelatedCostsEquityAwards_documentation_en-US" xlink:label="lab_jnj_BusinessCombinationAcquisitionRelatedCostsEquityAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Acquisition Related Costs, Equity Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationAcquisitionRelatedCostsEquityAwards" xlink:href="jnj-20241229.xsd#jnj_BusinessCombinationAcquisitionRelatedCostsEquityAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BusinessCombinationAcquisitionRelatedCostsEquityAwards" xlink:to="lab_jnj_BusinessCombinationAcquisitionRelatedCostsEquityAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0ff2b34b-f5ba-44e2-b18f-3aa9df2e8d3a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary Differences and Carryforwards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_c4f98630-aadf-4eb0-bca9-a350623e00ff_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Healthcare cost trend rate assumed for next year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_68c2adc4-41aa-4c94-8971-a5b12cf68303_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_dc36a37e-64e8-472f-9eea-3ac5458b46df_terseLabel_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit support agreements activity, net</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_label_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_documentation_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:href="jnj-20241229.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:to="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_bf0d7c8c-b760-4f36-9f5d-d9d1180028db_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total loss/(income) recognized in other comprehensive income, before tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_9cf9bfc7-0146-400d-bf74-cbae7966fcbb_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_d7074458-589e-4ca6-8cc5-d8cef42a5587_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic net earnings per share from continuing operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_f02da525-1709-4264-afda-8c7cd51593e6_verboseLabel_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">1.150% Notes Due November 2028</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_3dc145aa-cde2-42ff-8d6f-c023a5d32409_terseLabel_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.150% Notes due 2028&#8232;(750MM Euro 1.0401)(2)/(750MM Euro 1.1090)(3)</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_label_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.150% Notes Due 2028 [Member]</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_documentation_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1.150% Notes Due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member" xlink:href="jnj-20241229.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1.150NotesDue2028Member" xlink:to="lab_jnj_A1.150NotesDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_79587bd0-221e-43e0-833c-c7be0b8a460c_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_8c86fe92-9635-4bc0-b97e-42dc340a93ed_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_70d54a01-c7b1-4275-9db2-2327e534618d_terseLabel_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EDURANT/rilpivirine</link:label>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_label_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">EDURANT/rilpivirine [Member]</link:label>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_documentation_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">EDURANT/rilpivirine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember" xlink:href="jnj-20241229.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EDURANTrilpivirineMember" xlink:to="lab_jnj_EDURANTrilpivirineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_73db43e1-5095-442f-a57a-2d0e61a15b32_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_778fb713-6e47-44e0-b818-692a20dea84b_negatedTerseLabel_en-US" xlink:label="lab_jnj_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_jnj_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_label_en-US" xlink:label="lab_jnj_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Income (Expense), Net</link:label>
    <link:label id="lab_jnj_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_documentation_en-US" xlink:label="lab_jnj_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:href="jnj-20241229.xsd#jnj_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:to="lab_jnj_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_f773e110-29e0-446b-aead-94c2754bc4ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity, unrecognized loss</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RevenuePerformanceObligationPaymentTerms_e18f6b39-9b23-4878-a2d7-c4a9c95c9195_terseLabel_en-US" xlink:label="lab_jnj_RevenuePerformanceObligationPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, performance obligation, payment terms</link:label>
    <link:label id="lab_jnj_RevenuePerformanceObligationPaymentTerms_label_en-US" xlink:label="lab_jnj_RevenuePerformanceObligationPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Performance Obligation, Payment Terms</link:label>
    <link:label id="lab_jnj_RevenuePerformanceObligationPaymentTerms_documentation_en-US" xlink:label="lab_jnj_RevenuePerformanceObligationPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Performance Obligation, Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RevenuePerformanceObligationPaymentTerms" xlink:href="jnj-20241229.xsd#jnj_RevenuePerformanceObligationPaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RevenuePerformanceObligationPaymentTerms" xlink:to="lab_jnj_RevenuePerformanceObligationPaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_4a0ba2c1-cf5a-45fa-948c-e6fc8f58a59c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_eab8676f-24e8-4891-9be8-7e5fb159cc37_terseLabel_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation, increase (decrease), percent</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_label_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_documentation_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:href="jnj-20241229.xsd#jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:to="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_bd08a0ec-3689-411e-80cb-e4dba4dd52c7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rates</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_48adb127-650e-4e48-a8a4-1b4a3706efab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_9dae5eb5-bf1d-4ff7-88a5-ba74d161d0f2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_955a90ba-794f-4787-b97e-3b7f90841ff5_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Benefit Plans</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_902c1bbf-a4fa-4c66-8c52-b6be0038f8f4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other benefit plans&#160;</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent_090c2cfc-f77f-4d53-8a15-19c9d2f25796_terseLabel_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TCJA, undistributed foreign earnings percent related to earnings other than cash and cash equivalents</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent_label_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Other Than Cash And Cash Equivalents, Tax Rate, Percent</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent_documentation_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Other Than Cash And Cash Equivalents, Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" xlink:href="jnj-20241229.xsd#jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" xlink:to="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_4ad585b3-9b74-4d74-8b0d-4451d119dc28_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net gain on sale of assets/businesses</link:label>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_6f50996f-e434-4111-8eff-59569072e132_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_09b0ea5d-ab71-48c2-b517-3c2569ea1aba_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_e6b73c68-8185-4a46-bc50-29ff061ccc2a_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total intangible assets - net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IMBRUVICAMember_404af651-b1c6-4831-945a-bbb4cca9fa4b_terseLabel_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IMBRUVICA</link:label>
    <link:label id="lab_jnj_IMBRUVICAMember_label_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IMBRUVICA [Member]</link:label>
    <link:label id="lab_jnj_IMBRUVICAMember_documentation_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">IMBRUVICA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember" xlink:href="jnj-20241229.xsd#jnj_IMBRUVICAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IMBRUVICAMember" xlink:to="lab_jnj_IMBRUVICAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2250NotesDue2050Member_c152a494-5e3c-462f-9d62-f16beaae8762_terseLabel_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.250% Notes due 2050</link:label>
    <link:label id="lab_jnj_A2250NotesDue2050Member_label_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.250% Notes due 2050 [Member]</link:label>
    <link:label id="lab_jnj_A2250NotesDue2050Member_documentation_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2.250% Notes due 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member" xlink:href="jnj-20241229.xsd#jnj_A2250NotesDue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2250NotesDue2050Member" xlink:to="lab_jnj_A2250NotesDue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8c81f1e1-7477-4e14-abf7-c1605f150da3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale, unrealized gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5f9fe742-ba25-4344-a4fc-4cd127db3801_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_05776d58-e917-46a0-b5fe-2e5f27288fe0_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_c42d1ac3-a3b3-42aa-aec8-e1ab45e85d0e_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less current benefits payable</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_bf39548e-4109-4fed-a338-2ee50e5447d3_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability, Defined Benefit Plan, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PaymentsMadeInBusinessSeparation_47c8832a-acd4-474c-9d9e-01104ff17592_negatedTerseLabel_en-US" xlink:label="lab_jnj_PaymentsMadeInBusinessSeparation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash transferred to Kenvue at separation</link:label>
    <link:label id="lab_jnj_PaymentsMadeInBusinessSeparation_label_en-US" xlink:label="lab_jnj_PaymentsMadeInBusinessSeparation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Made In Business Separation</link:label>
    <link:label id="lab_jnj_PaymentsMadeInBusinessSeparation_documentation_en-US" xlink:label="lab_jnj_PaymentsMadeInBusinessSeparation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments Made In Business Separation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PaymentsMadeInBusinessSeparation" xlink:href="jnj-20241229.xsd#jnj_PaymentsMadeInBusinessSeparation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PaymentsMadeInBusinessSeparation" xlink:to="lab_jnj_PaymentsMadeInBusinessSeparation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ec583ceb-6518-4b0f-b2a5-3fcef3d00205_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_777e86ed-0bb9-48e4-99cf-f48a6735a41c_terseLabel_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_label_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_documentation_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:href="jnj-20241229.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:to="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_57d56fd2-d491-4c3b-8bfb-3b3e9f243a03_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_f68f9e99-a089-49aa-ba01-832457e19ae3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Loss Contingencies by Contingency</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Loss Contingencies by Contingency [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:to="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TotalClaimsAgainstCompanyPercent_97aa1563-196c-455d-bcc9-dce7e3b5909f_terseLabel_en-US" xlink:label="lab_jnj_TotalClaimsAgainstCompanyPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total claims against company, percent</link:label>
    <link:label id="lab_jnj_TotalClaimsAgainstCompanyPercent_label_en-US" xlink:label="lab_jnj_TotalClaimsAgainstCompanyPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Claims Against Company, Percent</link:label>
    <link:label id="lab_jnj_TotalClaimsAgainstCompanyPercent_documentation_en-US" xlink:label="lab_jnj_TotalClaimsAgainstCompanyPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Claims Against Company, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TotalClaimsAgainstCompanyPercent" xlink:href="jnj-20241229.xsd#jnj_TotalClaimsAgainstCompanyPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TotalClaimsAgainstCompanyPercent" xlink:to="lab_jnj_TotalClaimsAgainstCompanyPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1501ee86-1719-4085-8839-34b01d9c9b98_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_908cd49d-d04c-4c1c-a999-97d57d8f48fb_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_09a84a0c-2cf4-45b1-b629-38555df814a7_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_c59637a3-ef77-436a-a733-07af7ddd13f5_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred taxes on income</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_69d15061-251e-4399-b2cb-cc0ce3f8a264_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bbf124c3-f1f6-4552-b114-f3ff32a58e77_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess_54bf9673-0059-41f4-9168-0e67b80dffce_terseLabel_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares subject to full value award, excess (in shares)</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess_label_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Full Value Awards, Excess</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess_documentation_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Full Value Awards, Excess</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess" xlink:href="jnj-20241229.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess" xlink:to="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_238e072c-6e7f-457d-9f12-f5cd398fb471_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_208cf20b-d3b4-4bb0-a9e6-260b66d9dea0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International operations</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_cec3e3ec-e956-4c08-b98e-50c16ed5020c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Decrease/(Increase) in other current and non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_Wholesaler2Member_71d0655e-310f-42dd-9c28-da8c5f6807b3_terseLabel_en-US" xlink:label="lab_jnj_Wholesaler2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Wholesaler 2</link:label>
    <link:label id="lab_jnj_Wholesaler2Member_label_en-US" xlink:label="lab_jnj_Wholesaler2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Wholesaler 2 [Member]</link:label>
    <link:label id="lab_jnj_Wholesaler2Member_documentation_en-US" xlink:label="lab_jnj_Wholesaler2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Wholesaler 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler2Member" xlink:href="jnj-20241229.xsd#jnj_Wholesaler2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_Wholesaler2Member" xlink:to="lab_jnj_Wholesaler2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_1088ec20-c859-4d95-ac7c-4c8beacb9a23_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortizable intangibles</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_29f39b99-cea2-41bd-85a7-fd4fa1af73b2_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AsrMember_6b4092c8-8a46-4f08-8151-f2fc07b5e790_terseLabel_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASR</link:label>
    <link:label id="lab_jnj_AsrMember_label_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ASR [Member]</link:label>
    <link:label id="lab_jnj_AsrMember_documentation_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ASR.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember" xlink:href="jnj-20241229.xsd#jnj_AsrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AsrMember" xlink:to="lab_jnj_AsrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d99f949f-83a2-4790-ba4a-e7c02dbae6ce_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. taxes</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ShareRepurchaseProgramDomain_b7927e9e-6421-4bff-be4a-dac5d1ab5cd7_terseLabel_en-US" xlink:label="lab_srt_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_srt_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_srt_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ShareRepurchaseProgramDomain" xlink:to="lab_srt_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6d51c986-ed02-4095-bbe4-cd2187dc65c4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ValuationAllowanceDeferredTaxAssetsProvision_22e65b1b-375a-4ccb-8867-e11fdc68ba2d_terseLabel_en-US" xlink:label="lab_jnj_ValuationAllowanceDeferredTaxAssetsProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision</link:label>
    <link:label id="lab_jnj_ValuationAllowanceDeferredTaxAssetsProvision_label_en-US" xlink:label="lab_jnj_ValuationAllowanceDeferredTaxAssetsProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Assets, Provision</link:label>
    <link:label id="lab_jnj_ValuationAllowanceDeferredTaxAssetsProvision_documentation_en-US" xlink:label="lab_jnj_ValuationAllowanceDeferredTaxAssetsProvision" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Assets, Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ValuationAllowanceDeferredTaxAssetsProvision" xlink:href="jnj-20241229.xsd#jnj_ValuationAllowanceDeferredTaxAssetsProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ValuationAllowanceDeferredTaxAssetsProvision" xlink:to="lab_jnj_ValuationAllowanceDeferredTaxAssetsProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AcclarentMember_180a3fd5-c724-4c45-9e12-12aebf2b6028_terseLabel_en-US" xlink:label="lab_jnj_AcclarentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acclarent</link:label>
    <link:label id="lab_jnj_AcclarentMember_label_en-US" xlink:label="lab_jnj_AcclarentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acclarent [Member]</link:label>
    <link:label id="lab_jnj_AcclarentMember_documentation_en-US" xlink:label="lab_jnj_AcclarentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acclarent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AcclarentMember" xlink:href="jnj-20241229.xsd#jnj_AcclarentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AcclarentMember" xlink:to="lab_jnj_AcclarentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_1f2ff9c7-b20f-43e1-a0f0-7417f2a481fd_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax_08e75ec0-6191-4735-865e-7931068b0ca7_negatedTerseLabel_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rates</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax_label_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), pension and other, effects of exchange rate net of tax</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax_documentation_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">other comprehensive income loss, pension and other , effects of exchange rate net of tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" xlink:href="jnj-20241229.xsd#jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" xlink:to="lab_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_aa29b7f4-6c5e-4e71-bb68-846e67e62d1c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives designated as hedging instruments : Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments in Hedges, Liabilities, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:to="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_d7cb5931-5d6b-4175-993a-5217215a7f60_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases related to current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6e08e8f2-727a-4ae1-b216-baf38871a21a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease_991db4e6-a42b-4eb0-b917-e071d2581f00_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divestitures &amp; acquisitions</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Business Combination and Divestiture, Increase (Decrease)</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Business Combination and Divestiture, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" xlink:to="lab_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_58122468-fa2a-4a87-bb8c-c89a4db0f1ec_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_ab3a6f8a-c6d7-4ff2-bcf2-55851b01da96_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9dab8655-299f-4b5c-bc5d-ae46cfb1ca8f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_cdba5b89-0742-4660-be5f-a3acfca091e0_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_348d94f7-1e18-4fc7-a455-64e9a89d39ef_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_c77a2cb1-a775-4eb3-8193-a123a07cc1b7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_563bb487-a60b-4dca-ac55-11d219144628_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CARVYKTIMember_1e4630e8-2962-4d5e-a599-3406ebdf75ac_terseLabel_en-US" xlink:label="lab_jnj_CARVYKTIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CARVYKTI</link:label>
    <link:label id="lab_jnj_CARVYKTIMember_label_en-US" xlink:label="lab_jnj_CARVYKTIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CARVYKTI [Member]</link:label>
    <link:label id="lab_jnj_CARVYKTIMember_documentation_en-US" xlink:label="lab_jnj_CARVYKTIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CARVYKTI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CARVYKTIMember" xlink:href="jnj-20241229.xsd#jnj_CARVYKTIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CARVYKTIMember" xlink:to="lab_jnj_CARVYKTIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c110de2a-b475-4ffe-9107-b2f931aa1c75_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TreasuryStockValueAcquiredCostMethodNetOfTax_949b54d1-7f6e-435a-90a2-02a3fc10dbd4_terseLabel_en-US" xlink:label="lab_jnj_TreasuryStockValueAcquiredCostMethodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_jnj_TreasuryStockValueAcquiredCostMethodNetOfTax_label_en-US" xlink:label="lab_jnj_TreasuryStockValueAcquiredCostMethodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method, Net Of Tax</link:label>
    <link:label id="lab_jnj_TreasuryStockValueAcquiredCostMethodNetOfTax_documentation_en-US" xlink:label="lab_jnj_TreasuryStockValueAcquiredCostMethodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method, Net Of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TreasuryStockValueAcquiredCostMethodNetOfTax" xlink:href="jnj-20241229.xsd#jnj_TreasuryStockValueAcquiredCostMethodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TreasuryStockValueAcquiredCostMethodNetOfTax" xlink:to="lab_jnj_TreasuryStockValueAcquiredCostMethodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_a93f7dd1-f914-4a6a-8a43-a128b8cce002_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated benefit obligation unfunded plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_039e2035-86c5-4479-82ff-bb7dd5530ad7_terseLabel_en-US" xlink:label="lab_jnj_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_jnj_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_jnj_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Research and Development Expense</link:label>
    <link:label id="lab_jnj_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_jnj_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:href="jnj-20241229.xsd#jnj_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:to="lab_jnj_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_82a85b3a-eb83-4df9-aaa5-c6c28ffb166d_terseLabel_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-U.S. Sovereign Securities</link:label>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sovereign Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SovereignDebtSecuritiesMember" xlink:to="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_3248838b-9694-4a22-a125-6b2ecb06c523_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_0b3558f2-71c7-46fa-b09e-1891f6a6f403_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total recognized in the consolidated balance sheet&#160;&#8212; end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_266ea04b-156a-4123-ba0d-ed9a57f433fa_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_label_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable" xlink:to="lab_us-gaap_ClassOfTreasuryStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.350NotesDueNovember2036Member_ba76e0d1-a190-490e-b485-4d5769d44429_terseLabel_en-US" xlink:label="lab_jnj_A3.350NotesDueNovember2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.350% Notes Due November 2036</link:label>
    <link:label id="lab_jnj_A3.350NotesDueNovember2036Member_label_en-US" xlink:label="lab_jnj_A3.350NotesDueNovember2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.350% Notes Due November 2036 [Member]</link:label>
    <link:label id="lab_jnj_A3.350NotesDueNovember2036Member_documentation_en-US" xlink:label="lab_jnj_A3.350NotesDueNovember2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">3.350% Notes Due November 2036</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.350NotesDueNovember2036Member" xlink:href="jnj-20241229.xsd#jnj_A3.350NotesDueNovember2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.350NotesDueNovember2036Member" xlink:to="lab_jnj_A3.350NotesDueNovember2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ClassIRecommendationForImpellaMember_aaa1d751-b69d-491e-a2f8-ce6a4daae6e3_terseLabel_en-US" xlink:label="lab_jnj_ClassIRecommendationForImpellaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class I Recommendation For Impella</link:label>
    <link:label id="lab_jnj_ClassIRecommendationForImpellaMember_label_en-US" xlink:label="lab_jnj_ClassIRecommendationForImpellaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class I Recommendation For Impella [Member]</link:label>
    <link:label id="lab_jnj_ClassIRecommendationForImpellaMember_documentation_en-US" xlink:label="lab_jnj_ClassIRecommendationForImpellaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class I Recommendation For Impella</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ClassIRecommendationForImpellaMember" xlink:href="jnj-20241229.xsd#jnj_ClassIRecommendationForImpellaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ClassIRecommendationForImpellaMember" xlink:to="lab_jnj_ClassIRecommendationForImpellaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1b984d18-23c6-4ed1-b742-c8708ee45517_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock option average life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_3959be3e-ab4c-46b3-988f-2429b6780504_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Average Life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_e2f16ad3-4427-4bc5-979d-a439c7ff26b0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives &amp; hedges:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_82dfe47d-3713-4488-b37c-d5b48c7b6163_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_44bc1c3c-5dd2-427c-931a-ad9d95c15ca2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_1802277c-50aa-4e9e-aad1-2844db84ea64_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock_1521da14-5a1a-4151-9777-b3f5fc86c66c_terseLabel_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shipping and handling</link:label>
    <link:label id="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shipping and Handling Cost, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:to="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_4e88777b-7418-4358-8e39-1423e19b09ee_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ConcentrationOfCreditRiskLineItems_0067d02b-46f2-4a18-86e4-8d7f19057783_terseLabel_en-US" xlink:label="lab_jnj_ConcentrationOfCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk [Line Items]</link:label>
    <link:label id="lab_jnj_ConcentrationOfCreditRiskLineItems_label_en-US" xlink:label="lab_jnj_ConcentrationOfCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk [Line Items]</link:label>
    <link:label id="lab_jnj_ConcentrationOfCreditRiskLineItems_documentation_en-US" xlink:label="lab_jnj_ConcentrationOfCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration of credit risk.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationOfCreditRiskLineItems" xlink:href="jnj-20241229.xsd#jnj_ConcentrationOfCreditRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems" xlink:to="lab_jnj_ConcentrationOfCreditRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_0af43d52-ac95-4a4e-8c5a-2fc298c02b22_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_792aaba7-332e-4df1-b3b4-9da072841aca_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_0a6a5342-db73-410a-8d2c-6835aca5f8f0_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_d063f5f0-2558-47de-9c28-405cd1d843d3_totalLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Earnings from Discontinued Operations Before Provision for Taxes on Income</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_5065dba4-5034-4dbc-bcb3-e8a66a3c08fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effect of Derivatives not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_0067da74-84d8-4c26-9003-6a85dbd711cc_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest, net of amount capitalized</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_7c9db021-68b0-469a-85ce-b7ea3da36719_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_539520eb-9a69-4499-9fa6-93dd72d53ae1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DebtForEquityExchangeLossOnSharesExchanged_bccf9b85-0673-4f1f-a133-695f7b270ed5_terseLabel_en-US" xlink:label="lab_jnj_DebtForEquityExchangeLossOnSharesExchanged" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on shares exchanged</link:label>
    <link:label id="lab_jnj_DebtForEquityExchangeLossOnSharesExchanged_label_en-US" xlink:label="lab_jnj_DebtForEquityExchangeLossOnSharesExchanged" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt For Equity Exchange, Loss On Shares Exchanged</link:label>
    <link:label id="lab_jnj_DebtForEquityExchangeLossOnSharesExchanged_documentation_en-US" xlink:label="lab_jnj_DebtForEquityExchangeLossOnSharesExchanged" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt For Equity Exchange, Loss On Shares Exchanged</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DebtForEquityExchangeLossOnSharesExchanged" xlink:href="jnj-20241229.xsd#jnj_DebtForEquityExchangeLossOnSharesExchanged"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DebtForEquityExchangeLossOnSharesExchanged" xlink:to="lab_jnj_DebtForEquityExchangeLossOnSharesExchanged" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_895a7e38-7739-414c-8eba-42debeef1071_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_4c4e0bbb-92d6-4fc1-b532-025b73ab3936_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_5b082f67-a076-4228-89d1-7d0843eea1ee_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation, tax settlement, percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_254052c4-f14d-4f1a-ab94-a25b2ee28db5_terseLabel_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Sales by Segment of Business</link:label>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_label_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales By Segment Of Business [Table Text Block]</link:label>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_documentation_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales by segment of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:href="jnj-20241229.xsd#jnj_SalesBySegmentOfBusinessTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:to="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_039b0ce9-dafb-4272-8f4b-db929fc94a7e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_1bd258dd-2933-457b-906e-b8ee2aa10835_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, interest on income tax expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_99394380-861e-4b90-bbbc-36d0b5db63a5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_b0cbd1db-c703-48ca-8577-fc60b3cb1398_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_1cb0f9ba-b6af-4e3e-ad21-1a6c1699f1ff_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_1659e95f-5de0-4835-a6cf-1b1a95bed5ef_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c3f400f7-d82d-4b84-946e-d241050bc169_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average fair value of option granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyAccrualPaymentPercentage_f7966c42-eb3a-4b44-b226-63304540298b_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyAccrualPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency accrual, payment percentage</link:label>
    <link:label id="lab_jnj_LossContingencyAccrualPaymentPercentage_label_en-US" xlink:label="lab_jnj_LossContingencyAccrualPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss contingency accrual, payment percentage</link:label>
    <link:label id="lab_jnj_LossContingencyAccrualPaymentPercentage_documentation_en-US" xlink:label="lab_jnj_LossContingencyAccrualPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss contingency accrual, payment percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyAccrualPaymentPercentage" xlink:href="jnj-20241229.xsd#jnj_LossContingencyAccrualPaymentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyAccrualPaymentPercentage" xlink:to="lab_jnj_LossContingencyAccrualPaymentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_f0acdcd3-db16-4684-bee3-d3281357270a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_d8892e2b-1c81-484e-9c86-6c3e1eff8984_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities without readily determinable fair value, amount</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_b8c886dd-e494-422e-8f8f-39da88d03a4a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_dfbde716-433d-4b9e-88e8-9c813fbde0a1_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_54d6f447-6844-45cd-8941-e8d4f3fddc18_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Customer relationships and other intangible assets</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_11d420c1-5338-46ba-a8bb-7885b52fb7e3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract_2f9d3bf6-6032-4270-8156-c1170e7e46c4_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transferred to group annuity contract</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Transferred To Group Annuity Contract</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Transferred To Group Annuity Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract" xlink:to="lab_jnj_DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_d3786934-7497-4b28-a819-831741873065_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time deposits</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_573aa0dd-62b5-4bca-8cb2-7a62ecabc9b0_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProductLiabilityPolicyTextBlock_cfac5d2a-b187-4590-b815-27a88e5ef378_terseLabel_en-US" xlink:label="lab_jnj_ProductLiabilityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product liability</link:label>
    <link:label id="lab_jnj_ProductLiabilityPolicyTextBlock_label_en-US" xlink:label="lab_jnj_ProductLiabilityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Liability [Policy Text Block]</link:label>
    <link:label id="lab_jnj_ProductLiabilityPolicyTextBlock_documentation_en-US" xlink:label="lab_jnj_ProductLiabilityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityPolicyTextBlock" xlink:href="jnj-20241229.xsd#jnj_ProductLiabilityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProductLiabilityPolicyTextBlock" xlink:to="lab_jnj_ProductLiabilityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_6e8887c5-90b2-4acd-b4ad-446966f5762c_terseLabel_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.73% Notes due 2046</link:label>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_label_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.70% Notes due 2046 [Member]</link:label>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_documentation_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">3.70% Notes due 2046 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member" xlink:href="jnj-20241229.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.70Notesdue2046Member" xlink:to="lab_jnj_A3.70Notesdue2046Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityFairValueAdjustmentChangeinObservablePrices_8083c862-b6e1-4359-b6c1-d9d391352d97_terseLabel_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentChangeinObservablePrices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity, fair value adjustment, change in observable prices</link:label>
    <link:label id="lab_jnj_EquityFairValueAdjustmentChangeinObservablePrices_label_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentChangeinObservablePrices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Fair Value Adjustment, Change in Observable Prices</link:label>
    <link:label id="lab_jnj_EquityFairValueAdjustmentChangeinObservablePrices_documentation_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentChangeinObservablePrices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity, Fair Value Adjustment, Change in Observable Prices</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentChangeinObservablePrices" xlink:href="jnj-20241229.xsd#jnj_EquityFairValueAdjustmentChangeinObservablePrices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityFairValueAdjustmentChangeinObservablePrices" xlink:to="lab_jnj_EquityFairValueAdjustmentChangeinObservablePrices" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DeferredTaxAssetsOtherDomestic_287f6911-3dc3-4e6d-97f9-7df29edb6283_terseLabel_en-US" xlink:label="lab_jnj_DeferredTaxAssetsOtherDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Miscellaneous U.S.&#160;</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsOtherDomestic_label_en-US" xlink:label="lab_jnj_DeferredTaxAssetsOtherDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Other Domestic</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsOtherDomestic_documentation_en-US" xlink:label="lab_jnj_DeferredTaxAssetsOtherDomestic" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax assets other domestic.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsOtherDomestic" xlink:href="jnj-20241229.xsd#jnj_DeferredTaxAssetsOtherDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DeferredTaxAssetsOtherDomestic" xlink:to="lab_jnj_DeferredTaxAssetsOtherDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ConcentrationRiskThresholdPercentage_ecd3aa93-b60f-412c-8ca3-b16c43476e9a_terseLabel_en-US" xlink:label="lab_jnj_ConcentrationRiskThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk, threshold percentage (as a percent)</link:label>
    <link:label id="lab_jnj_ConcentrationRiskThresholdPercentage_label_en-US" xlink:label="lab_jnj_ConcentrationRiskThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Threshold Percentage</link:label>
    <link:label id="lab_jnj_ConcentrationRiskThresholdPercentage_documentation_en-US" xlink:label="lab_jnj_ConcentrationRiskThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration Risk, Threshold Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationRiskThresholdPercentage" xlink:href="jnj-20241229.xsd#jnj_ConcentrationRiskThresholdPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ConcentrationRiskThresholdPercentage" xlink:to="lab_jnj_ConcentrationRiskThresholdPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_6dfcc02a-01ae-4241-b451-cdcef4669861_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Plan</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierFinanceProgramTableTextBlock_46f1cba0-e3a5-4d98-936d-f10a67ec3661_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier Finance Program</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramTableTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Finance Program [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierFinanceProgramTableTextBlock" xlink:to="lab_us-gaap_SupplierFinanceProgramTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_8b0afa77-8981-4c91-b18d-c27874c11050_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_6b24b7e2-16d1-40b9-8f0d-6620ac14bc39_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_83345a23-20fe-4e51-aebe-918531859086_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_dbc368d2-fe98-4948-a76b-5bc8e81e22a9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserves&#160;&amp; liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BusinessCombinationSettlementOfEquityAwards_c2cded4f-96b6-407b-9635-d7a6768e938d_terseLabel_en-US" xlink:label="lab_jnj_BusinessCombinationSettlementOfEquityAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity awards settled</link:label>
    <link:label id="lab_jnj_BusinessCombinationSettlementOfEquityAwards_label_en-US" xlink:label="lab_jnj_BusinessCombinationSettlementOfEquityAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Settlement Of Equity Awards</link:label>
    <link:label id="lab_jnj_BusinessCombinationSettlementOfEquityAwards_documentation_en-US" xlink:label="lab_jnj_BusinessCombinationSettlementOfEquityAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Settlement Of Equity Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationSettlementOfEquityAwards" xlink:href="jnj-20241229.xsd#jnj_BusinessCombinationSettlementOfEquityAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BusinessCombinationSettlementOfEquityAwards" xlink:to="lab_jnj_BusinessCombinationSettlementOfEquityAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_692def70-ccf3-47e6-bf2f-b35590f1a528_terseLabel_en-US" xlink:label="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of reclassification of cash flow hedge gain (loss)</link:label>
    <link:label id="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_label_en-US" xlink:label="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of Reclassification of Cash Flow Hedge Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:to="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_a72bea0a-9163-42d9-aa38-745cf73d78f0_terseLabel_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patents And Trademarks</link:label>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_label_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patents And Trademarks [Member]</link:label>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_documentation_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Patents And Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember" xlink:href="jnj-20241229.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PatentsAndTrademarksMember" xlink:to="lab_jnj_PatentsAndTrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c7d0bf7c-f2bb-4b8f-a6c2-54c1780b0733_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_4665f2a6-6363-48e7-9b40-89bc569cf512_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to acquire businesses, gross</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_MedTechMember_1751507b-1312-4835-ac0b-cfdca6764701_terseLabel_en-US" xlink:label="lab_jnj_MedTechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MedTech</link:label>
    <link:label id="lab_jnj_MedTechMember_221ad7ac-8aa8-4c52-b97e-385cc5162210_verboseLabel_en-US" xlink:label="lab_jnj_MedTechMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">MedTech</link:label>
    <link:label id="lab_jnj_MedTechMember_label_en-US" xlink:label="lab_jnj_MedTechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MedTech [Member]</link:label>
    <link:label id="lab_jnj_MedTechMember_documentation_en-US" xlink:label="lab_jnj_MedTechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MedTech [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedTechMember" xlink:href="jnj-20241229.xsd#jnj_MedTechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_MedTechMember" xlink:to="lab_jnj_MedTechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_56ab9614-6037-422c-ac9c-b41d353523cb_terseLabel_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.625% Notes due 2037</link:label>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_label_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.625% Notes due 2037 [Member]</link:label>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_documentation_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">3.625% Notes due 2037 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member" xlink:href="jnj-20241229.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.625Notesdue2037Member" xlink:to="lab_jnj_A3.625Notesdue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_bde3aa95-f00d-4a6e-83ae-1db878e27008_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization of property and intangibles</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_d52f4f86-137a-451f-9bfd-a00a3918bf6f_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and Amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_07855723-ef01-46db-84de-1db5fff2b043_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherImmunologyMember_58f263d7-fea4-493e-a6f9-7ef089330351_terseLabel_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Immunology</link:label>
    <link:label id="lab_jnj_OtherImmunologyMember_label_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:label id="lab_jnj_OtherImmunologyMember_documentation_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember" xlink:href="jnj-20241229.xsd#jnj_OtherImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherImmunologyMember" xlink:to="lab_jnj_OtherImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_4a65c684-4576-49b9-a920-8b7262a40b1f_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid employee related obligations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_448be97d-0243-40b0-b6fe-fe1cd10f9de1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FiscalPeriodPolicyTextBlock_9bc41d0c-b6b7-4a9a-ae9e-521aa212abd8_terseLabel_en-US" xlink:label="lab_jnj_FiscalPeriodPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual closing date</link:label>
    <link:label id="lab_jnj_FiscalPeriodPolicyTextBlock_label_en-US" xlink:label="lab_jnj_FiscalPeriodPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fiscal Period [Policy Text Block]</link:label>
    <link:label id="lab_jnj_FiscalPeriodPolicyTextBlock_documentation_en-US" xlink:label="lab_jnj_FiscalPeriodPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fiscal period policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiscalPeriodPolicyTextBlock" xlink:href="jnj-20241229.xsd#jnj_FiscalPeriodPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FiscalPeriodPolicyTextBlock" xlink:to="lab_jnj_FiscalPeriodPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_9662e243-1ddf-493a-838f-c8ac7afe9ea4_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_6f572d9f-6e21-41c6-890f-e68564937a3c_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CommingledFundsMember_6d740b3e-2efe-45cb-98fe-f6f98a3df9f2_terseLabel_en-US" xlink:label="lab_jnj_CommingledFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commingled funds</link:label>
    <link:label id="lab_jnj_CommingledFundsMember_label_en-US" xlink:label="lab_jnj_CommingledFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commingled Funds [Member]</link:label>
    <link:label id="lab_jnj_CommingledFundsMember_documentation_en-US" xlink:label="lab_jnj_CommingledFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commingled funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CommingledFundsMember" xlink:href="jnj-20241229.xsd#jnj_CommingledFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CommingledFundsMember" xlink:to="lab_jnj_CommingledFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentMember_79b01de1-8da6-4feb-bf99-60b49a6dbaa4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentMember" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_06abf19a-e9c3-47f4-84a2-e95780259255_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_623af2bc-a150-401c-8e1e-905bc89d5afd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c19cd362-b704-4014-bec7-637cccb36222_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_cde368b8-d0bb-4bb1-b42f-1e6d3540fa58_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_94431c6e-f4f8-4e85-a4bc-f3a269f61444_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_676a6e04-30d8-4a79-94b2-ca60d260f6d2_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock&#160;&#8212; par value $1.00 per share (Note&#160;12) (authorized 4,320,000,000&#160;shares; issued 3,119,843,000&#160;shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PonvoryMember_4dc62f64-c6a5-4343-a916-76d8dff581a9_terseLabel_en-US" xlink:label="lab_jnj_PonvoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ponvory</link:label>
    <link:label id="lab_jnj_PonvoryMember_label_en-US" xlink:label="lab_jnj_PonvoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ponvory [Member]</link:label>
    <link:label id="lab_jnj_PonvoryMember_documentation_en-US" xlink:label="lab_jnj_PonvoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ponvory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PonvoryMember" xlink:href="jnj-20241229.xsd#jnj_PonvoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PonvoryMember" xlink:to="lab_jnj_PonvoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_a2966fac-1e53-4240-b918-52eeed3b4e85_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_d57eaf7e-3008-40cd-acc8-558395ee8917_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_37e36078-38a4-4983-a68c-64b70aef30ac_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain/(Loss) Reclassified from Accumulated OCI Into Income</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_d73bdfde-c158-4c32-a386-ec02cb938881_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts Recognized in the Company&#8217;s Balance Sheet consist of the&#160;following:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6cb16403-2f6c-46c9-88e3-38558d5f5673_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RevenuesContingentConsideration_c8b608a2-caeb-4264-8f6e-71cb7060e9d1_terseLabel_en-US" xlink:label="lab_jnj_RevenuesContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_jnj_RevenuesContingentConsideration_label_en-US" xlink:label="lab_jnj_RevenuesContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues, Contingent Consideration</link:label>
    <link:label id="lab_jnj_RevenuesContingentConsideration_documentation_en-US" xlink:label="lab_jnj_RevenuesContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues, Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RevenuesContingentConsideration" xlink:href="jnj-20241229.xsd#jnj_RevenuesContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RevenuesContingentConsideration" xlink:to="lab_jnj_RevenuesContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_aef021cd-d3ab-4969-9fb6-15ed141e87b6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. state taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_f17d8170-b734-4fdc-b04d-c31bec032853_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Miscellaneous international</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_faa4bc25-5c7d-4c95-9290-8e7bb1a73b1f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation_0740285d-8a23-4e56-a16c-104a34f2c573_terseLabel_en-US" xlink:label="lab_jnj_ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds of short and long-term debt, net of issuance cost, related to the debt that transferred to Kenvue at separation</link:label>
    <link:label id="lab_jnj_ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation_label_en-US" xlink:label="lab_jnj_ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance Of Long-Term Debt, Transferred In Business Separation</link:label>
    <link:label id="lab_jnj_ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation_documentation_en-US" xlink:label="lab_jnj_ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance Of Long-Term Debt, Transferred In Business Separation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation" xlink:href="jnj-20241229.xsd#jnj_ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation" xlink:to="lab_jnj_ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_08bd2705-e6f5-442c-868c-b128f7a8dcc1_verboseLabel_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</link:label>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_label_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</link:label>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_documentation_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:href="jnj-20241229.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:to="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_13f9a25d-4722-4d96-9f2e-3a44783b8e85_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets, excluding goodwill</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent_182428cc-cc6c-4d7d-a1ea-9e1202d39f0d_terseLabel_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TJCA , provisional liability, non-current</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent_label_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability, Noncurrent</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent_documentation_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" xlink:href="jnj-20241229.xsd#jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" xlink:to="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_90b06fb3-a35e-4e62-a72d-645d881693e3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_f41d443f-503c-4bc7-b327-3760aa87f5d2_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_92e0372d-82e6-4418-a876-5a86191dd908_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock&#160;&#8212; without par value (authorized and unissued 2,000,000&#160;shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_e36f800b-dc8a-409c-96e4-1c0fb13a0442_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_e2766471-4e38-42ea-83b5-f884d3e7bc7e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_2d5df0c2-d935-44fd-8d6a-0e57f9a2ebe6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate maturities of long-term obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_979fb75a-2fa7-4365-b8b1-f01fa9d8cd5d_terseLabel_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.95% Notes due 2027</link:label>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_label_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.95% Notes due 2027 [Member]</link:label>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_documentation_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2.95% Notes due 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member" xlink:href="jnj-20241229.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.95Notesdue2027Member" xlink:to="lab_jnj_A2.95Notesdue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b532d68e-4327-4406-97bc-abb59280f60a_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_42f118ba-be30-429a-8be3-7b9489b0309e_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic net earnings per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_93ab116c-94c5-4a93-88e8-935c8e82696f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2e6f418b-c623-4ccf-8470-21e7e537dbfb_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_JohnsonJohnsonMember_7fe3dcf2-9ed6-44ac-8c9e-18df52729ecc_terseLabel_en-US" xlink:label="lab_jnj_JohnsonJohnsonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Johnson &amp; Johnson</link:label>
    <link:label id="lab_jnj_JohnsonJohnsonMember_label_en-US" xlink:label="lab_jnj_JohnsonJohnsonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Johnson &amp; Johnson [Member]</link:label>
    <link:label id="lab_jnj_JohnsonJohnsonMember_documentation_en-US" xlink:label="lab_jnj_JohnsonJohnsonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Johnson &amp; Johnson</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_JohnsonJohnsonMember" xlink:href="jnj-20241229.xsd#jnj_JohnsonJohnsonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_JohnsonJohnsonMember" xlink:to="lab_jnj_JohnsonJohnsonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide_67a73f02-b14e-45d5-ba41-12d7c73e5137_terseLabel_en-US" xlink:label="lab_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of employees</link:label>
    <link:label id="lab_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide_label_en-US" xlink:label="lab_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Employees Engaged In Company Activities Worldwide</link:label>
    <link:label id="lab_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide_documentation_en-US" xlink:label="lab_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of employees engaged in company activities worldwide.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" xlink:href="jnj-20241229.xsd#jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" xlink:to="lab_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OpioidMember_7d750bb9-fff3-45c3-9823-dd27d8d50370_terseLabel_en-US" xlink:label="lab_jnj_OpioidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Opioid</link:label>
    <link:label id="lab_jnj_OpioidMember_label_en-US" xlink:label="lab_jnj_OpioidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">opioid [Member]</link:label>
    <link:label id="lab_jnj_OpioidMember_documentation_en-US" xlink:label="lab_jnj_OpioidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Opioid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpioidMember" xlink:href="jnj-20241229.xsd#jnj_OpioidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OpioidMember" xlink:to="lab_jnj_OpioidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_c4009555-01b3-4b9d-b82e-131851c7e492_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_613e3c9e-506e-41a2-8e17-952a29350717_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_dbd06dfb-0ab1-47b1-9035-0900f82bb1df_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2450NotesDue2060Member_3c4540a8-eaec-465b-9f96-1f9cdcba7d2c_terseLabel_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.450% Notes due 2060</link:label>
    <link:label id="lab_jnj_A2450NotesDue2060Member_label_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.450% Notes due 2060 [Member]</link:label>
    <link:label id="lab_jnj_A2450NotesDue2060Member_documentation_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2.450% Notes due 2060</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member" xlink:href="jnj-20241229.xsd#jnj_A2450NotesDue2060Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2450NotesDue2060Member" xlink:to="lab_jnj_A2450NotesDue2060Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_5251a9cc-bdb5-4a5f-91fe-678f709d1d1c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of Plan Assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_3c97a511-0925-46b0-8c61-c7d7d1c5931a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_a71b03d4-1e0e-4154-ae64-041906a54e55_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment and depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_06c7d258-5414-4beb-a7cd-1a03e4f988dd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_b4908b53-e69b-4fa9-8a43-4c5b46efee37_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets with definite lives:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_901c0b62-3e6e-4573-8f18-0939b0d3aec7_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ShareRepurchaseProgramAxis_0f8e573c-9745-4fbb-ab14-5647d061298b_terseLabel_en-US" xlink:label="lab_srt_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_srt_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_srt_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ShareRepurchaseProgramAxis" xlink:to="lab_srt_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommercialPaper_3186c619-5ea1-4b5b-909e-b7485241c58c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommercialPaper" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of commercial paper</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommercialPaper_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommercialPaper" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Commercial Paper</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommercialPaper" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommercialPaper"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommercialPaper" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommercialPaper" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2cfc262a-a71e-4111-a053-e504f5721570_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherMember_08a37f5b-9b43-44e4-a68c-2f0d4cd8674c_terseLabel_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_jnj_OtherMember_label_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_jnj_OtherMember_documentation_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember" xlink:href="jnj-20241229.xsd#jnj_OtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherMember" xlink:to="lab_jnj_OtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0870e8f9-770e-4393-8ccb-f319ded3c393_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_cfeda475-2a09-4df6-8262-c0b3c1dd312f_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Gov't Securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_cb728cd6-21ec-448b-b375-4730964dd71f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized net transition obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Transition Asset (Obligation), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_f0721995-dda8-4243-9c69-7754331456ec_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value, held-to-maturity</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_8690c5d7-b9b4-4d9e-acb5-80c4f5368d5c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Credit Support Agreements (CSA)</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, Asset Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_8613856b-1327-47e8-8e0a-43ae4b60b49b_terseLabel_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest (Income) Expense</link:label>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_label_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income Expense Net Member</link:label>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_documentation_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Income Expense Net Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember" xlink:href="jnj-20241229.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InterestIncomeExpenseNetMember" xlink:to="lab_jnj_InterestIncomeExpenseNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CashPaidDuringTheYearAbstract_09b9a3a8-1e4f-4727-bbb4-296aef8bb88f_terseLabel_en-US" xlink:label="lab_jnj_CashPaidDuringTheYearAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid during the year for:</link:label>
    <link:label id="lab_jnj_CashPaidDuringTheYearAbstract_label_en-US" xlink:label="lab_jnj_CashPaidDuringTheYearAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Paid During The Year [Abstract]</link:label>
    <link:label id="lab_jnj_CashPaidDuringTheYearAbstract_documentation_en-US" xlink:label="lab_jnj_CashPaidDuringTheYearAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Paid During The Year [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashPaidDuringTheYearAbstract" xlink:href="jnj-20241229.xsd#jnj_CashPaidDuringTheYearAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CashPaidDuringTheYearAbstract" xlink:to="lab_jnj_CashPaidDuringTheYearAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets_6e4a7659-2dc6-4279-8c72-33671e11702f_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments Measured at Net Asset Value</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Alternative Investments, Fair Value of Plan Assets</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Alternative Investments, Fair Value of Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" xlink:to="lab_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax_9b30f10e-8005-4203-ae3f-04952bd9f071_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Consumer settlement/ curtailment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Adjustment for Settlement or Curtailment Gain (Loss), Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod_d19445cc-0ad9-453b-823a-8632dfb29daf_negatedTerseLabel_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Canceled/forfeited/adjusted (in shares)</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod_label_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Canceled, Forfeited and Adjusted During the Period</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod_documentation_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Canceled, Forfeited and Adjusted During the Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" xlink:href="jnj-20241229.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" xlink:to="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_2863d35b-c87b-4518-852d-4ec715444dbe_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service cost discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_379379b0-eeb6-49ac-9666-85f2c27c192e_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayment of short-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_0637e896-bc8b-4556-bdbb-84f17e07267e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Kenvue Separation/IPO</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_c317541b-bcc1-4ded-9a2a-96238ac5db67_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Decrease from Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:to="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5d60610a-a6ec-4030-9d5e-4df3b82c7671_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, stock option plans and stock compensation agreements</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_71a660a1-f51b-40a3-8512-55119a38b732_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OncologyMember_c4caed47-f53d-4723-bd19-9cd8b3e8573e_terseLabel_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oncology</link:label>
    <link:label id="lab_jnj_OncologyMember_label_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_jnj_OncologyMember_documentation_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember" xlink:href="jnj-20241229.xsd#jnj_OncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OncologyMember" xlink:to="lab_jnj_OncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a18676e9-4448-41d8-85ac-7a80ee1fce24_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_dd9554f7-ac9f-43f9-acdb-701e9936eb14_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from long-term debt, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_e9142073-65cb-450d-86cf-53c481767d05_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7489df1f-1c09-4b0d-81e5-2dc7658dee14_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_QualifiedPlansMember_c3bae8cb-5646-404d-9261-4c12339c99e9_terseLabel_en-US" xlink:label="lab_jnj_QualifiedPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Qualified Plans</link:label>
    <link:label id="lab_jnj_QualifiedPlansMember_label_en-US" xlink:label="lab_jnj_QualifiedPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Qualified Plans [Member]</link:label>
    <link:label id="lab_jnj_QualifiedPlansMember_documentation_en-US" xlink:label="lab_jnj_QualifiedPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Qualified plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_QualifiedPlansMember" xlink:href="jnj-20241229.xsd#jnj_QualifiedPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_QualifiedPlansMember" xlink:to="lab_jnj_QualifiedPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2109da54-4c64-488d-b2e9-b66dc029ddbf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_c600d522-1512-4d09-a18d-ac19cd40be73_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Curtailments and settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_5664fb82-0672-4911-aee5-12e881d01ec2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Credit Support Agreements (CSA)</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, Liability Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:to="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_283785c8-d80d-49ec-a1db-fae72d3735d0_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation cost charged for Long term incentive plan</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_b946737f-c1eb-47d8-956d-fc2b7b30596f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kenvue separation and discontinued operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SavingsPlanAbstract_27328b6a-f21b-4e34-a2cb-9d33267ade83_terseLabel_en-US" xlink:label="lab_jnj_SavingsPlanAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Savings Plan [Abstract]</link:label>
    <link:label id="lab_jnj_SavingsPlanAbstract_label_en-US" xlink:label="lab_jnj_SavingsPlanAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Savings Plan [Abstract]</link:label>
    <link:label id="lab_jnj_SavingsPlanAbstract_documentation_en-US" xlink:label="lab_jnj_SavingsPlanAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Savings Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SavingsPlanAbstract" xlink:href="jnj-20241229.xsd#jnj_SavingsPlanAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SavingsPlanAbstract" xlink:to="lab_jnj_SavingsPlanAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9047e281-044b-455e-824b-4e3952549db8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted, average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_316230b6-2e2c-4e66-be30-aa486ae2a8e4_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_2ffe8e06-d656-4b10-9346-67573e660ac7_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Product Liability Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_efa220af-86ed-4c96-9b93-9ad12589d96e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_fbb788f3-53f4-43ec-aa36-513430ac853e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_49b55d53-7ebd-45ca-82d3-55600478eadb_terseLabel_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.95%&#160;Notes due 2037</link:label>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_label_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">5.95% Notes due 2037 [Member]</link:label>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_documentation_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">5.95% Notes due 2037 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member" xlink:href="jnj-20241229.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.95Notesdue2037Member" xlink:to="lab_jnj_A5.95Notesdue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_bf8a7858-ee9b-45e5-92a1-9dd285d22866_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_ecd0f5c6-f35a-41c6-aae7-729c9dca7243_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_97ab20c1-e2ca-48c6-9629-4ea580def2b4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_a5c4fd59-bb27-4a21-8cb4-51c3cd6af590_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee related obligations</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_b0442e81-cc66-484e-889c-c76502828b8f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_c04816c1-a5e3-4dea-9e5f-7c64d98c6105_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Project Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_2bc63a69-71c0-4507-b455-14686f265cc1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_3417fcff-afb0-4528-af5f-db8098311d1a_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_b2037199-d2f2-4a99-9b55-573a231d2a20_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_f8d2432d-be5f-4110-878a-9457726974ce_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A210NotesDue2040Member_10478833-4d11-4eba-bbdd-22198da7bbd0_terseLabel_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.10% Notes due 2040</link:label>
    <link:label id="lab_jnj_A210NotesDue2040Member_label_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.10% Notes due 2040 [Member]</link:label>
    <link:label id="lab_jnj_A210NotesDue2040Member_documentation_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2.10% Notes due 2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member" xlink:href="jnj-20241229.xsd#jnj_A210NotesDue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A210NotesDue2040Member" xlink:to="lab_jnj_A210NotesDue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_33823291-d173-499a-9d47-329783668c48_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8c196e7f-6653-4e4c-b621-2a136a28fb17_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_8d49dcb2-d01e-4f38-bf02-7c60650b4fe6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualProvision_8df5b6f8-881a-40fc-a5fe-5a86785f1438_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incremental charges</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualProvision_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual, Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualProvision" xlink:to="lab_us-gaap_LossContingencyAccrualProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_KenvueIncMember_eadda514-40ab-4e69-8c91-5abbba475e14_terseLabel_en-US" xlink:label="lab_jnj_KenvueIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kenvue Inc.</link:label>
    <link:label id="lab_jnj_KenvueIncMember_label_en-US" xlink:label="lab_jnj_KenvueIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kenvue Inc. [Member]</link:label>
    <link:label id="lab_jnj_KenvueIncMember_documentation_en-US" xlink:label="lab_jnj_KenvueIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kenvue Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KenvueIncMember" xlink:href="jnj-20241229.xsd#jnj_KenvueIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_KenvueIncMember" xlink:to="lab_jnj_KenvueIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SURGICALMember_252c1ea0-a1ef-4096-8bdd-8da6ec326e8c_terseLabel_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SURGICAL</link:label>
    <link:label id="lab_jnj_SURGICALMember_label_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SURGICAL [Member]</link:label>
    <link:label id="lab_jnj_SURGICALMember_documentation_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SURGICAL [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember" xlink:href="jnj-20241229.xsd#jnj_SURGICALMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SURGICALMember" xlink:to="lab_jnj_SURGICALMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_29ec5773-9a44-4eb3-84bc-ecc3c4057170_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_5b18c3d3-32b2-49e1-babb-a2f3b23d8443_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net Funded Status</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Net Funded Status [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNetFundedStatusTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_f3bd2b11-8dc1-4dca-8460-54efbbc117df_verboseLabel_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cross currency interest rate swaps</link:label>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_8c62605e-dbf8-4d59-9b0a-bb4377f3590f_terseLabel_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cross currency interest rate swaps contracts:</link:label>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cross Currency Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:to="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_12a566f0-be0d-4b79-97eb-b4a7a1790d49_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4588636e-4e70-4e96-9d10-2531550604c5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_8aee6ff8-fefb-4ff8-9405-b757ce3e4959_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InfectiousDiseasesMember_c3c52f6a-e281-4dd2-8b99-9ef8e0c6157c_terseLabel_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Infectious Diseases</link:label>
    <link:label id="lab_jnj_InfectiousDiseasesMember_label_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Infectious Diseases [Member]</link:label>
    <link:label id="lab_jnj_InfectiousDiseasesMember_documentation_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Infectious Diseases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember" xlink:href="jnj-20241229.xsd#jnj_InfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InfectiousDiseasesMember" xlink:to="lab_jnj_InfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards_87492571-f0e8-4abd-ac1a-c3f3075e8e1a_terseLabel_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares subject to full value awards (in shares)</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards_label_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Full Value Awards</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards_documentation_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Full Value Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards" xlink:href="jnj-20241229.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards" xlink:to="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_8d6e5dce-c39e-40a9-9af8-ec586ab000b5_terseLabel_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pulmonary Hypertension</link:label>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_label_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pulmonary Hypertension [Member]</link:label>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_documentation_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pulmonary Hypertension [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember" xlink:href="jnj-20241229.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PulmonaryHypertensionMember" xlink:to="lab_jnj_PulmonaryHypertensionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_ace65c00-ae38-4b8c-8c35-8443f3bde8cb_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_4ee9caf5-7dd4-4f5f-a5a1-0e0a74035f1b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0fb3ff76-bde3-48df-a44d-55de16db75e2_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other receivables</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OwnershipPercentageSplitOffPercent_1bb8dfad-7072-4905-ad37-2edb71355a8b_terseLabel_en-US" xlink:label="lab_jnj_OwnershipPercentageSplitOffPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Split-off percentage</link:label>
    <link:label id="lab_jnj_OwnershipPercentageSplitOffPercent_label_en-US" xlink:label="lab_jnj_OwnershipPercentageSplitOffPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership Percentage, Split-Off Percent</link:label>
    <link:label id="lab_jnj_OwnershipPercentageSplitOffPercent_documentation_en-US" xlink:label="lab_jnj_OwnershipPercentageSplitOffPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ownership Percentage, Split-Off Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OwnershipPercentageSplitOffPercent" xlink:href="jnj-20241229.xsd#jnj_OwnershipPercentageSplitOffPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OwnershipPercentageSplitOffPercent" xlink:to="lab_jnj_OwnershipPercentageSplitOffPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_20b63b63-b5d9-4185-aa10-9c28594b96e2_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_bb32138b-ef18-4d10-8128-4d651dfd5964_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forward foreign exchange contracts:</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_803c8190-8905-4962-b082-9f70619e89c8_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_8de2649e-a480-47b2-8418-095bf5fec3eb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset, held-for-sale, not part of disposal group</link:label>
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_label_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset, Held-for-Sale, Not Part of Disposal Group</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" xlink:to="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_MomentaMember_6a1af8f3-3629-4964-bdd1-848b76ad0e8a_terseLabel_en-US" xlink:label="lab_jnj_MomentaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Momenta</link:label>
    <link:label id="lab_jnj_MomentaMember_label_en-US" xlink:label="lab_jnj_MomentaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Momenta [Member]</link:label>
    <link:label id="lab_jnj_MomentaMember_documentation_en-US" xlink:label="lab_jnj_MomentaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Momenta</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MomentaMember" xlink:href="jnj-20241229.xsd#jnj_MomentaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_MomentaMember" xlink:to="lab_jnj_MomentaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_b697aeb0-a2cf-43c2-a064-6c0a27d5d311_terseLabel_en-US" xlink:label="lab_jnj_ChangesinTreasuryStockSharesOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in Treasury Stock Shares Outstanding [Roll Forward]</link:label>
    <link:label id="lab_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_label_en-US" xlink:label="lab_jnj_ChangesinTreasuryStockSharesOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in Treasury Stock Shares Outstanding [Roll Forward]</link:label>
    <link:label id="lab_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_documentation_en-US" xlink:label="lab_jnj_ChangesinTreasuryStockSharesOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Changes in Treasury Stock Shares Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward" xlink:href="jnj-20241229.xsd#jnj_ChangesinTreasuryStockSharesOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward" xlink:to="lab_jnj_ChangesinTreasuryStockSharesOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DeferredTaxLiabilitiesOtherDomestic_b16bb958-eea4-4462-a9f3-fdbd6336ec38_negatedTerseLabel_en-US" xlink:label="lab_jnj_DeferredTaxLiabilitiesOtherDomestic" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Miscellaneous U.S.&#160;</link:label>
    <link:label id="lab_jnj_DeferredTaxLiabilitiesOtherDomestic_label_en-US" xlink:label="lab_jnj_DeferredTaxLiabilitiesOtherDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Other Domestic</link:label>
    <link:label id="lab_jnj_DeferredTaxLiabilitiesOtherDomestic_documentation_en-US" xlink:label="lab_jnj_DeferredTaxLiabilitiesOtherDomestic" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Other Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxLiabilitiesOtherDomestic" xlink:href="jnj-20241229.xsd#jnj_DeferredTaxLiabilitiesOtherDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DeferredTaxLiabilitiesOtherDomestic" xlink:to="lab_jnj_DeferredTaxLiabilitiesOtherDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_e1d24000-0832-472d-be92-c78ea5f49a4e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SuppliesExpense_174028e1-df36-4c61-b6d7-12779d37fe4a_terseLabel_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplies expense</link:label>
    <link:label id="lab_us-gaap_SuppliesExpense_label_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplies Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SuppliesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SuppliesExpense" xlink:to="lab_us-gaap_SuppliesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_908c7ac5-5017-4437-a21d-083c6b6c1358_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives not designated as hedging instruments : Liabilities</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:to="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_dd1e33f8-f3f4-4d94-9b65-7713a87b85a2_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_eb415eea-3cbb-4da6-98ad-604c7561fc39_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_63d51914-354c-4547-aa69-2388d582ed57_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings and Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_c85ff21b-e916-4291-8281-c377f2d2cad6_terseLabel_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">% Change</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_label_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Change In Sales By Segment Of Business</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_documentation_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage change in sales by segment of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:href="jnj-20241229.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:to="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_2005c2b1-50e0-4b97-b949-edf3a830fecf_terseLabel_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.625% Notes due 2025</link:label>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_label_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.625 Notes due 2025 [Member]</link:label>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_documentation_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2.625 Notes due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member" xlink:href="jnj-20241229.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.625Notesdue2025Member" xlink:to="lab_jnj_A2.625Notesdue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_dcd0f7b8-824e-4125-a53b-b551d1a2e96f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Kenvue initial public offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_c7089f4d-158e-4793-ba3e-ded20a035161_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_4f29e5cf-2593-44b6-82a9-2059cc0f5b55_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ValuationAllowanceRollForward_8e038f76-a5d2-4660-a5eb-db0d29edfac6_terseLabel_en-US" xlink:label="lab_jnj_ValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowance [Roll Forward]</link:label>
    <link:label id="lab_jnj_ValuationAllowanceRollForward_label_en-US" xlink:label="lab_jnj_ValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance [Roll Forward]</link:label>
    <link:label id="lab_jnj_ValuationAllowanceRollForward_documentation_en-US" xlink:label="lab_jnj_ValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ValuationAllowanceRollForward" xlink:href="jnj-20241229.xsd#jnj_ValuationAllowanceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ValuationAllowanceRollForward" xlink:to="lab_jnj_ValuationAllowanceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_a0e28187-b019-4463-86f7-b5875cc79fa5_terseLabel_en-US" xlink:label="lab_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract</link:label>
    <link:label id="lab_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_label_en-US" xlink:label="lab_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract</link:label>
    <link:label id="lab_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_documentation_en-US" xlink:label="lab_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Comparison of income tax expense at the Statutory rate and Company's tax rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" xlink:href="jnj-20241229.xsd#jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" xlink:to="lab_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_f886c4bd-1061-432a-a13c-62ef07d1d4ce_terseLabel_en-US" xlink:label="lab_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Liability, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</link:label>
    <link:label id="lab_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_label_en-US" xlink:label="lab_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</link:label>
    <link:label id="lab_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_documentation_en-US" xlink:label="lab_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Liability, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:href="jnj-20241229.xsd#jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:to="lab_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_53cf8dbc-d1dd-43b6-91b3-9b06b0296707_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price Range, Maximum (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_29da3133-d795-4328-8e48-43a60757d062_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation expense</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Fee Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.25DebenturesDue2054Member_db894986-98ca-4f5b-837c-a4af1575aede_terseLabel_en-US" xlink:label="lab_jnj_A5.25DebenturesDue2054Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.25% Debentures due 2054</link:label>
    <link:label id="lab_jnj_A5.25DebenturesDue2054Member_label_en-US" xlink:label="lab_jnj_A5.25DebenturesDue2054Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">5.25% Debentures due 2054 [Member]</link:label>
    <link:label id="lab_jnj_A5.25DebenturesDue2054Member_documentation_en-US" xlink:label="lab_jnj_A5.25DebenturesDue2054Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">5.25% Debentures due 2054</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.25DebenturesDue2054Member" xlink:href="jnj-20241229.xsd#jnj_A5.25DebenturesDue2054Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.25DebenturesDue2054Member" xlink:to="lab_jnj_A5.25DebenturesDue2054Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_UPTRAVIMember_f669a74d-4858-4a55-b1dd-2ece7681ae01_terseLabel_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UPTRAVI</link:label>
    <link:label id="lab_jnj_UPTRAVIMember_label_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UPTRAVI [Member]</link:label>
    <link:label id="lab_jnj_UPTRAVIMember_documentation_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">UPTRAVI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember" xlink:href="jnj-20241229.xsd#jnj_UPTRAVIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_UPTRAVIMember" xlink:to="lab_jnj_UPTRAVIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_2afe514b-f329-417e-ae75-8888c61a910e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_e33efe8c-219f-4e8a-bb47-f5aeba39c760_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DiscontinuedOperationTransitionManufacturingAgreementTerm_81e4050b-0ab8-4ca1-841a-332e5e9e7462_terseLabel_en-US" xlink:label="lab_jnj_DiscontinuedOperationTransitionManufacturingAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transition manufacturing agreement, term</link:label>
    <link:label id="lab_jnj_DiscontinuedOperationTransitionManufacturingAgreementTerm_label_en-US" xlink:label="lab_jnj_DiscontinuedOperationTransitionManufacturingAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Transition Manufacturing Agreement, Term</link:label>
    <link:label id="lab_jnj_DiscontinuedOperationTransitionManufacturingAgreementTerm_documentation_en-US" xlink:label="lab_jnj_DiscontinuedOperationTransitionManufacturingAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Transition Manufacturing Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DiscontinuedOperationTransitionManufacturingAgreementTerm" xlink:href="jnj-20241229.xsd#jnj_DiscontinuedOperationTransitionManufacturingAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DiscontinuedOperationTransitionManufacturingAgreementTerm" xlink:to="lab_jnj_DiscontinuedOperationTransitionManufacturingAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationRollForward_c960a368-b300-4cb2-ba6f-43e04674d628_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier Finance Program, Obligation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationRollForward_label_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Finance Program, Obligation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierFinanceProgramObligationRollForward" xlink:to="lab_us-gaap_SupplierFinanceProgramObligationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_50a79fed-9760-476d-9827-ea37fc059183_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_c4561340-15a6-4c29-8a11-d09ab9148ee6_terseLabel_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Infectious Diseases</link:label>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_label_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Infectious Diseases [Member]</link:label>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_documentation_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Infectious Diseases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember" xlink:href="jnj-20241229.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherInfectiousDiseasesMember" xlink:to="lab_jnj_OtherInfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_92639122-9dbc-4633-ba0c-06c3908e75e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_bad273fb-48bd-46c5-93ef-59e2e5ddd8b2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SettlementOfConvertibleDebtAcquiredFromShockwave_af44f0c1-cf0a-47bd-9309-8de931d788c1_negatedTerseLabel_en-US" xlink:label="lab_jnj_SettlementOfConvertibleDebtAcquiredFromShockwave" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Settlement of convertible debt acquired from Shockwave</link:label>
    <link:label id="lab_jnj_SettlementOfConvertibleDebtAcquiredFromShockwave_label_en-US" xlink:label="lab_jnj_SettlementOfConvertibleDebtAcquiredFromShockwave" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settlement of convertible debt acquired from Shockwave</link:label>
    <link:label id="lab_jnj_SettlementOfConvertibleDebtAcquiredFromShockwave_documentation_en-US" xlink:label="lab_jnj_SettlementOfConvertibleDebtAcquiredFromShockwave" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Settlement of convertible debt acquired from Shockwave</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SettlementOfConvertibleDebtAcquiredFromShockwave" xlink:href="jnj-20241229.xsd#jnj_SettlementOfConvertibleDebtAcquiredFromShockwave"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SettlementOfConvertibleDebtAcquiredFromShockwave" xlink:to="lab_jnj_SettlementOfConvertibleDebtAcquiredFromShockwave" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>jnj-20241229_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:a7478940-65f4-4b69-a475-f625bf9a358e,g:8ea82ba0-2a78-4425-b720-89454b578aab-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.jnj.com/role/CoverPage" xlink:type="simple" xlink:href="jnj-20241229.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_81fa6e76-f4bb-41d9-ac46-234f421b4da7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_ad2db268-4c12-48bf-816e-216d20845b48" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81fa6e76-f4bb-41d9-ac46-234f421b4da7" xlink:to="loc_dei_DocumentInformationTable_ad2db268-4c12-48bf-816e-216d20845b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e77ddcfe-21b1-40ef-a2a5-44e48f6138db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_ad2db268-4c12-48bf-816e-216d20845b48" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e77ddcfe-21b1-40ef-a2a5-44e48f6138db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4bb2db90-b53c-4948-9f22-f96ac1ae62ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e77ddcfe-21b1-40ef-a2a5-44e48f6138db" xlink:to="loc_us-gaap_ClassOfStockDomain_4bb2db90-b53c-4948-9f22-f96ac1ae62ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_272ba4e6-2120-4c8b-ab09-e2fae3a8a53d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4bb2db90-b53c-4948-9f22-f96ac1ae62ad" xlink:to="loc_us-gaap_CommonStockMember_272ba4e6-2120-4c8b-ab09-e2fae3a8a53d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_9ab6d285-95c9-49fd-be3c-6b5a1732a70f" xlink:href="jnj-20241229.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4bb2db90-b53c-4948-9f22-f96ac1ae62ad" xlink:to="loc_jnj_A1.150NotesDue2028Member_9ab6d285-95c9-49fd-be3c-6b5a1732a70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_577f126c-ee11-49d0-8573-5fac71c9d589" xlink:href="jnj-20241229.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4bb2db90-b53c-4948-9f22-f96ac1ae62ad" xlink:to="loc_jnj_A1.650NotesDue2035Member_577f126c-ee11-49d0-8573-5fac71c9d589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDueNovember2028Member_31c4509a-671a-4150-a42a-10c5408256ba" xlink:href="jnj-20241229.xsd#jnj_A1.150NotesDueNovember2028Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4bb2db90-b53c-4948-9f22-f96ac1ae62ad" xlink:to="loc_jnj_A1.150NotesDueNovember2028Member_31c4509a-671a-4150-a42a-10c5408256ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.20NotesDueNovember2032Member_fe1658b9-8f00-4c41-ad5d-26ee1fec2e8e" xlink:href="jnj-20241229.xsd#jnj_A3.20NotesDueNovember2032Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4bb2db90-b53c-4948-9f22-f96ac1ae62ad" xlink:to="loc_jnj_A3.20NotesDueNovember2032Member_fe1658b9-8f00-4c41-ad5d-26ee1fec2e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.350NotesDueNovember2036Member_ef3be304-ca08-4834-b96d-0a5d28d332fb" xlink:href="jnj-20241229.xsd#jnj_A3.350NotesDueNovember2036Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4bb2db90-b53c-4948-9f22-f96ac1ae62ad" xlink:to="loc_jnj_A3.350NotesDueNovember2036Member_ef3be304-ca08-4834-b96d-0a5d28d332fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.550NotesDueNovember2044Member_a08976d1-1d77-4611-b112-4971d3f5c5de" xlink:href="jnj-20241229.xsd#jnj_A3.550NotesDueNovember2044Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4bb2db90-b53c-4948-9f22-f96ac1ae62ad" xlink:to="loc_jnj_A3.550NotesDueNovember2044Member_a08976d1-1d77-4611-b112-4971d3f5c5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_ad2db268-4c12-48bf-816e-216d20845b48" xlink:to="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_474ddfa9-5f4f-45db-a1ed-073589a1ed2c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_DocumentType_474ddfa9-5f4f-45db-a1ed-073589a1ed2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_c05658b5-148e-4fcd-a1d6-cbc9e35b6ece" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_DocumentAnnualReport_c05658b5-148e-4fcd-a1d6-cbc9e35b6ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_69662f74-d37d-42b1-963c-b55ad26b6b98" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_DocumentPeriodEndDate_69662f74-d37d-42b1-963c-b55ad26b6b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e46ca3ef-f7c3-4bf1-8b33-01f31d98802c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_DocumentTransitionReport_e46ca3ef-f7c3-4bf1-8b33-01f31d98802c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8d2ff0a2-f482-4efb-8452-c6f451d77617" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityFileNumber_8d2ff0a2-f482-4efb-8452-c6f451d77617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1c0356b9-cb1f-43ab-80be-8f5303d566cc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityRegistrantName_1c0356b9-cb1f-43ab-80be-8f5303d566cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8d615fe8-aae3-48e9-a992-cd42d1951191" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8d615fe8-aae3-48e9-a992-cd42d1951191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_fb8e12f6-3ef4-46c6-a0bf-08ab0d60ed04" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityTaxIdentificationNumber_fb8e12f6-3ef4-46c6-a0bf-08ab0d60ed04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_9c19d5a0-aca8-4353-ab78-a6c4d0ebed57" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityAddressAddressLine1_9c19d5a0-aca8-4353-ab78-a6c4d0ebed57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4118559e-a605-4d89-8580-1b7262d3b5d2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityAddressCityOrTown_4118559e-a605-4d89-8580-1b7262d3b5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_450b9977-4fc4-4311-ad5f-c825396522b8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityAddressStateOrProvince_450b9977-4fc4-4311-ad5f-c825396522b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ecab23c2-6b29-4a06-b227-eb7ae659c27c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityAddressPostalZipCode_ecab23c2-6b29-4a06-b227-eb7ae659c27c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_eb4562da-017a-44d2-9f25-c773155e0202" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_CityAreaCode_eb4562da-017a-44d2-9f25-c773155e0202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_7ee8bc97-643b-48f2-979f-fd70643677c6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_LocalPhoneNumber_7ee8bc97-643b-48f2-979f-fd70643677c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_adea6b98-8891-459f-ba27-35dfb8b91d2f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_Security12bTitle_adea6b98-8891-459f-ba27-35dfb8b91d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b15f6ecb-6a79-45f4-ab0c-27b163f8c384" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_TradingSymbol_b15f6ecb-6a79-45f4-ab0c-27b163f8c384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_de3b6b8d-0065-4298-b01b-1d139ba43042" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_SecurityExchangeName_de3b6b8d-0065-4298-b01b-1d139ba43042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_44efa598-c0bf-4f78-a759-27786e59d6d3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_44efa598-c0bf-4f78-a759-27786e59d6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_44855fd2-c732-4bbf-be7e-f3baa524d597" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityVoluntaryFilers_44855fd2-c732-4bbf-be7e-f3baa524d597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_eb3f77c1-2838-46cf-a9d6-8829726b32aa" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityCurrentReportingStatus_eb3f77c1-2838-46cf-a9d6-8829726b32aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f0a83b6a-5b73-4b5b-a54e-33be1dbc2d16" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityInteractiveDataCurrent_f0a83b6a-5b73-4b5b-a54e-33be1dbc2d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_59f07b33-84b6-4643-af06-9ec60878d90b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityFilerCategory_59f07b33-84b6-4643-af06-9ec60878d90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_7e805808-3f5f-4a97-9e72-d7510c0f3065" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityEmergingGrowthCompany_7e805808-3f5f-4a97-9e72-d7510c0f3065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_99442933-9f3d-46a6-8cad-fbd974d65a51" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntitySmallBusiness_99442933-9f3d-46a6-8cad-fbd974d65a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_93f48adb-4b91-4b11-965b-6892cbfcd391" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_IcfrAuditorAttestationFlag_93f48adb-4b91-4b11-965b-6892cbfcd391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_3d693882-8e6f-4531-8d2d-585e4c395f62" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_3d693882-8e6f-4531-8d2d-585e4c395f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_6cd75a24-5cab-4af7-8558-d20e31409b75" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityShellCompany_6cd75a24-5cab-4af7-8558-d20e31409b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_593ac1af-aae7-44b5-9d6f-eef002c04bfb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityPublicFloat_593ac1af-aae7-44b5-9d6f-eef002c04bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_443e3634-9ac4-49d5-b850-efa6e7ac7d98" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_443e3634-9ac4-49d5-b850-efa6e7ac7d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_540be2f5-4ab5-46f5-8ea1-937852a7aeb9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_540be2f5-4ab5-46f5-8ea1-937852a7aeb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_516d8060-b1ef-4d2a-9c71-a57e74b3f502" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_EntityCentralIndexKey_516d8060-b1ef-4d2a-9c71-a57e74b3f502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_1a773b95-3bfa-4567-a2bb-8fc9fee48491" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_CurrentFiscalYearEndDate_1a773b95-3bfa-4567-a2bb-8fc9fee48491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_c60c6825-047f-42bf-ad3a-e11ae2b365b5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_DocumentFiscalYearFocus_c60c6825-047f-42bf-ad3a-e11ae2b365b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_cc32f880-0192-443f-be6d-912fbe31616c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_cc32f880-0192-443f-be6d-912fbe31616c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e7e816d8-da5f-4402-8691-1b4bbd4f02ac" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_24fffa5b-d500-4d10-ae04-ed20bffaa0c4" xlink:to="loc_dei_AmendmentFlag_e7e816d8-da5f-4402-8691-1b4bbd4f02ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AuditInformation" xlink:type="simple" xlink:href="jnj-20241229.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AuditorInformationAbstract_cee43583-d959-40a9-9ffa-7d9c64c641e2" xlink:href="jnj-20241229.xsd#jnj_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_c37d7289-17a8-4c39-bae3-6866f96fabc2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_AuditorInformationAbstract_cee43583-d959-40a9-9ffa-7d9c64c641e2" xlink:to="loc_dei_AuditorName_c37d7289-17a8-4c39-bae3-6866f96fabc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_0678faf8-6ffd-428a-b7d9-714bdc67c443" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_AuditorInformationAbstract_cee43583-d959-40a9-9ffa-7d9c64c641e2" xlink:to="loc_dei_AuditorLocation_0678faf8-6ffd-428a-b7d9-714bdc67c443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_4b614b11-5177-476b-806e-a5c2c919ad69" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_AuditorInformationAbstract_cee43583-d959-40a9-9ffa-7d9c64c641e2" xlink:to="loc_dei_AuditorFirmId_4b614b11-5177-476b-806e-a5c2c919ad69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="jnj-20241229.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_41a3872a-0fc4-4405-a35a-4b7acba4f03a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_87b5672d-78c8-42d7-ad3b-334c2aa02729" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_41a3872a-0fc4-4405-a35a-4b7acba4f03a" xlink:to="loc_us-gaap_AssetsAbstract_87b5672d-78c8-42d7-ad3b-334c2aa02729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_ea25cab2-7ace-4b81-a412-ee79b8dc2926" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_87b5672d-78c8-42d7-ad3b-334c2aa02729" xlink:to="loc_us-gaap_AssetsCurrentAbstract_ea25cab2-7ace-4b81-a412-ee79b8dc2926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_58f3c6f6-4ad4-4116-bc40-02d193d78653" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ea25cab2-7ace-4b81-a412-ee79b8dc2926" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_58f3c6f6-4ad4-4116-bc40-02d193d78653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_89ce7af6-ec33-432b-a81d-50948a107bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ea25cab2-7ace-4b81-a412-ee79b8dc2926" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_89ce7af6-ec33-432b-a81d-50948a107bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_84b54a93-ebca-4ef8-92a4-08e5365d7329" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ea25cab2-7ace-4b81-a412-ee79b8dc2926" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_84b54a93-ebca-4ef8-92a4-08e5365d7329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_11c9e553-86dc-4fd8-b5f7-1728b46f7aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ea25cab2-7ace-4b81-a412-ee79b8dc2926" xlink:to="loc_us-gaap_InventoryNet_11c9e553-86dc-4fd8-b5f7-1728b46f7aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d0cd3abe-d9d6-4fff-aba8-9912145f8136" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ea25cab2-7ace-4b81-a412-ee79b8dc2926" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d0cd3abe-d9d6-4fff-aba8-9912145f8136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_63a6e48e-9761-459f-8638-a616be16136f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ea25cab2-7ace-4b81-a412-ee79b8dc2926" xlink:to="loc_us-gaap_AssetsCurrent_63a6e48e-9761-459f-8638-a616be16136f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_726cab8c-c48c-498a-9a20-4b2703d8ff66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_87b5672d-78c8-42d7-ad3b-334c2aa02729" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_726cab8c-c48c-498a-9a20-4b2703d8ff66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3e75480a-1ec9-4acf-84c4-a7ab26ea0192" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_87b5672d-78c8-42d7-ad3b-334c2aa02729" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3e75480a-1ec9-4acf-84c4-a7ab26ea0192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_fe0e2f18-32de-4d92-9245-9e6cbd2b8571" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_87b5672d-78c8-42d7-ad3b-334c2aa02729" xlink:to="loc_us-gaap_Goodwill_fe0e2f18-32de-4d92-9245-9e6cbd2b8571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_715d9ea3-cfe5-40c7-b61c-4ae07888b9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_87b5672d-78c8-42d7-ad3b-334c2aa02729" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_715d9ea3-cfe5-40c7-b61c-4ae07888b9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3642544e-b05c-497d-a7aa-2081eae04e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_87b5672d-78c8-42d7-ad3b-334c2aa02729" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3642544e-b05c-497d-a7aa-2081eae04e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a3633aa0-991d-4654-a2ba-bc8568625083" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_87b5672d-78c8-42d7-ad3b-334c2aa02729" xlink:to="loc_us-gaap_Assets_a3633aa0-991d-4654-a2ba-bc8568625083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39c96e1a-b32a-4510-ab7f-c4aa4585daae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_41a3872a-0fc4-4405-a35a-4b7acba4f03a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39c96e1a-b32a-4510-ab7f-c4aa4585daae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_b1126b49-2659-4a0a-b18c-a27fa5c58745" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39c96e1a-b32a-4510-ab7f-c4aa4585daae" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_b1126b49-2659-4a0a-b18c-a27fa5c58745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_131ff6e4-06b0-494c-84ed-2ae5b41ca66f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b1126b49-2659-4a0a-b18c-a27fa5c58745" xlink:to="loc_us-gaap_ShortTermBorrowings_131ff6e4-06b0-494c-84ed-2ae5b41ca66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a64ac73e-edee-4f59-9d84-5fdc05b162d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b1126b49-2659-4a0a-b18c-a27fa5c58745" xlink:to="loc_us-gaap_AccountsPayableCurrent_a64ac73e-edee-4f59-9d84-5fdc05b162d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_31f2d936-181f-4a65-a012-b926c713bcba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b1126b49-2659-4a0a-b18c-a27fa5c58745" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_31f2d936-181f-4a65-a012-b926c713bcba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions_1b0fc1ad-8268-4fe7-b111-255241c9a045" xlink:href="jnj-20241229.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b1126b49-2659-4a0a-b18c-a27fa5c58745" xlink:to="loc_jnj_AccruedRebatesReturnsAndPromotions_1b0fc1ad-8268-4fe7-b111-255241c9a045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0d208ecc-c47d-4c7b-a608-40de0eb754d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b1126b49-2659-4a0a-b18c-a27fa5c58745" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0d208ecc-c47d-4c7b-a608-40de0eb754d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_a6f6447b-c8e7-44cf-9319-a2b6bf065d26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b1126b49-2659-4a0a-b18c-a27fa5c58745" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_a6f6447b-c8e7-44cf-9319-a2b6bf065d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_64af7af9-7450-4d95-9f52-f702758395da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b1126b49-2659-4a0a-b18c-a27fa5c58745" xlink:to="loc_us-gaap_LiabilitiesCurrent_64af7af9-7450-4d95-9f52-f702758395da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1e7e0788-2962-4b7e-9e62-e72f29c20aef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39c96e1a-b32a-4510-ab7f-c4aa4585daae" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1e7e0788-2962-4b7e-9e62-e72f29c20aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_73dceae0-3cee-4e75-a257-485e0ff4989e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39c96e1a-b32a-4510-ab7f-c4aa4585daae" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_73dceae0-3cee-4e75-a257-485e0ff4989e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_8b9b1052-3d61-4676-b830-eb16f8ac63bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39c96e1a-b32a-4510-ab7f-c4aa4585daae" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_8b9b1052-3d61-4676-b830-eb16f8ac63bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_01a71d3a-abb9-4dc0-b044-3fd6344f8818" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39c96e1a-b32a-4510-ab7f-c4aa4585daae" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_01a71d3a-abb9-4dc0-b044-3fd6344f8818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8e83082f-05a1-427d-9e4f-66067312bf2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39c96e1a-b32a-4510-ab7f-c4aa4585daae" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8e83082f-05a1-427d-9e4f-66067312bf2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_38939c22-c5b7-48de-88e4-87a2ec0e0bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39c96e1a-b32a-4510-ab7f-c4aa4585daae" xlink:to="loc_us-gaap_Liabilities_38939c22-c5b7-48de-88e4-87a2ec0e0bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b1fe5d67-937a-492e-86e8-11dae3e9af0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39c96e1a-b32a-4510-ab7f-c4aa4585daae" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b1fe5d67-937a-492e-86e8-11dae3e9af0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_38bb88f5-2f09-423f-bd94-dce17898aaed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39c96e1a-b32a-4510-ab7f-c4aa4585daae" xlink:to="loc_us-gaap_StockholdersEquityAbstract_38bb88f5-2f09-423f-bd94-dce17898aaed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_d2d27c05-961c-4744-8070-a304bc566da3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_38bb88f5-2f09-423f-bd94-dce17898aaed" xlink:to="loc_us-gaap_PreferredStockValue_d2d27c05-961c-4744-8070-a304bc566da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a7272681-1e53-40ef-b353-58aa8abf5b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_38bb88f5-2f09-423f-bd94-dce17898aaed" xlink:to="loc_us-gaap_CommonStockValue_a7272681-1e53-40ef-b353-58aa8abf5b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_14c29667-4299-4a20-91cc-ae38f7c942bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_38bb88f5-2f09-423f-bd94-dce17898aaed" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_14c29667-4299-4a20-91cc-ae38f7c942bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1200daaa-16de-4b1b-9928-3b414059f957" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_38bb88f5-2f09-423f-bd94-dce17898aaed" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1200daaa-16de-4b1b-9928-3b414059f957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_821f196e-df25-4123-8805-06d46e68e1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_38bb88f5-2f09-423f-bd94-dce17898aaed" xlink:to="loc_us-gaap_TreasuryStockValue_821f196e-df25-4123-8805-06d46e68e1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0ac3d4f8-3677-47a4-ae0c-aec2505b617d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_38bb88f5-2f09-423f-bd94-dce17898aaed" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0ac3d4f8-3677-47a4-ae0c-aec2505b617d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_85ed24b6-4701-484d-a420-be34862ab6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39c96e1a-b32a-4510-ab7f-c4aa4585daae" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_85ed24b6-4701-484d-a420-be34862ab6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="jnj-20241229.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c0b38483-dcc4-4efc-a4c7-93cc8319d92d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_d93e1339-fc6c-4a3c-b6e7-59faf653b0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c0b38483-dcc4-4efc-a4c7-93cc8319d92d" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_d93e1339-fc6c-4a3c-b6e7-59faf653b0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_291d46a1-c34e-4f52-9305-e7ba91b15d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c0b38483-dcc4-4efc-a4c7-93cc8319d92d" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_291d46a1-c34e-4f52-9305-e7ba91b15d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_3e497536-e639-4b38-8641-83f7219612bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c0b38483-dcc4-4efc-a4c7-93cc8319d92d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_3e497536-e639-4b38-8641-83f7219612bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6d5fba99-2265-42f0-a297-692f45b1184e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c0b38483-dcc4-4efc-a4c7-93cc8319d92d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6d5fba99-2265-42f0-a297-692f45b1184e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d47ca6da-8d56-4dc9-a7c9-eb11b8f346d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c0b38483-dcc4-4efc-a4c7-93cc8319d92d" xlink:to="loc_us-gaap_CommonStockSharesIssued_d47ca6da-8d56-4dc9-a7c9-eb11b8f346d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_71320982-fa56-4e40-a14a-bc618ac5e320" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c0b38483-dcc4-4efc-a4c7-93cc8319d92d" xlink:to="loc_us-gaap_TreasuryStockCommonShares_71320982-fa56-4e40-a14a-bc618ac5e320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="jnj-20241229.xsd#ConsolidatedStatementsofEarnings"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_e0bc24fa-6a82-4355-aee6-21a039ca76dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6b007e08-c3d5-491d-9dc7-f33a089c6e02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0bc24fa-6a82-4355-aee6-21a039ca76dd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6b007e08-c3d5-491d-9dc7-f33a089c6e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8b271f7a-9f1d-4a03-9eac-230618b69a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0bc24fa-6a82-4355-aee6-21a039ca76dd" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8b271f7a-9f1d-4a03-9eac-230618b69a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_5eb4c559-3d26-4dae-874f-54870f524421" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0bc24fa-6a82-4355-aee6-21a039ca76dd" xlink:to="loc_us-gaap_GrossProfit_5eb4c559-3d26-4dae-874f-54870f524421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f7bb115c-31de-4f8c-a965-db198aabcd5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0bc24fa-6a82-4355-aee6-21a039ca76dd" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f7bb115c-31de-4f8c-a965-db198aabcd5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_a8e86861-a42f-4ec9-b210-cc1fefe0e97e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0bc24fa-6a82-4355-aee6-21a039ca76dd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_a8e86861-a42f-4ec9-b210-cc1fefe0e97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentInProcess1_f265ed88-b14d-4e74-8e57-3d7d47359fe1" xlink:href="jnj-20241229.xsd#jnj_ResearchAndDevelopmentInProcess1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0bc24fa-6a82-4355-aee6-21a039ca76dd" xlink:to="loc_jnj_ResearchAndDevelopmentInProcess1_f265ed88-b14d-4e74-8e57-3d7d47359fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_52c0a256-c4d8-49f6-9772-390552ef28dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0bc24fa-6a82-4355-aee6-21a039ca76dd" xlink:to="loc_us-gaap_InvestmentIncomeInterest_52c0a256-c4d8-49f6-9772-390552ef28dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_43648f91-5174-46a7-8221-05fd332824f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0bc24fa-6a82-4355-aee6-21a039ca76dd" xlink:to="loc_us-gaap_InterestExpenseNonoperating_43648f91-5174-46a7-8221-05fd332824f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c0096919-58b4-4ba6-8001-c3d2a2989b80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0bc24fa-6a82-4355-aee6-21a039ca76dd" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c0096919-58b4-4ba6-8001-c3d2a2989b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_5ba89e9b-b615-4804-9591-78d5b92eb566" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0bc24fa-6a82-4355-aee6-21a039ca76dd" xlink:to="loc_us-gaap_RestructuringCharges_5ba89e9b-b615-4804-9591-78d5b92eb566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_57c3f8cf-7ea2-48dd-9414-721745dfb0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0bc24fa-6a82-4355-aee6-21a039ca76dd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_57c3f8cf-7ea2-48dd-9414-721745dfb0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_00e64ce0-6922-4994-9fe2-99279ed42c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0bc24fa-6a82-4355-aee6-21a039ca76dd" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_00e64ce0-6922-4994-9fe2-99279ed42c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_1317f933-ba9d-46ca-af38-63ff2bf0c5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0bc24fa-6a82-4355-aee6-21a039ca76dd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_1317f933-ba9d-46ca-af38-63ff2bf0c5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_e3f3a4af-0a33-485f-a66a-21a775118be8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0bc24fa-6a82-4355-aee6-21a039ca76dd" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_e3f3a4af-0a33-485f-a66a-21a775118be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7d0a634b-5674-470c-bf91-9cf09b380657" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0bc24fa-6a82-4355-aee6-21a039ca76dd" xlink:to="loc_us-gaap_NetIncomeLoss_7d0a634b-5674-470c-bf91-9cf09b380657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2fbb0a4d-59b8-4618-bd8b-5be98e9c2277" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0bc24fa-6a82-4355-aee6-21a039ca76dd" xlink:to="loc_us-gaap_EarningsPerShareAbstract_2fbb0a4d-59b8-4618-bd8b-5be98e9c2277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_5aaf0a87-1df9-4cd8-8673-5adcafa4d5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2fbb0a4d-59b8-4618-bd8b-5be98e9c2277" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_5aaf0a87-1df9-4cd8-8673-5adcafa4d5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_4716a724-6adb-4f56-937b-36ffb3cd5532" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2fbb0a4d-59b8-4618-bd8b-5be98e9c2277" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_4716a724-6adb-4f56-937b-36ffb3cd5532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_25122b7b-4c66-40cc-8ebe-133509fcc29e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2fbb0a4d-59b8-4618-bd8b-5be98e9c2277" xlink:to="loc_us-gaap_EarningsPerShareBasic_25122b7b-4c66-40cc-8ebe-133509fcc29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_e7f81dff-c8aa-4793-a256-cd37e58a3649" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2fbb0a4d-59b8-4618-bd8b-5be98e9c2277" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_e7f81dff-c8aa-4793-a256-cd37e58a3649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_fb4fd977-7a61-41d6-bea7-cb0e04597515" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2fbb0a4d-59b8-4618-bd8b-5be98e9c2277" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_fb4fd977-7a61-41d6-bea7-cb0e04597515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e4723eb5-8f15-460c-af30-4767c9ab11a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2fbb0a4d-59b8-4618-bd8b-5be98e9c2277" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e4723eb5-8f15-460c-af30-4767c9ab11a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_fb721d9e-9248-4d3a-be4a-76f3e39ff66a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0bc24fa-6a82-4355-aee6-21a039ca76dd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_fb721d9e-9248-4d3a-be4a-76f3e39ff66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b3d375ff-3274-42f5-a82a-071ee32d8330" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_fb721d9e-9248-4d3a-be4a-76f3e39ff66a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b3d375ff-3274-42f5-a82a-071ee32d8330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_81df9f0d-d982-4138-b645-8d59ae011bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_fb721d9e-9248-4d3a-be4a-76f3e39ff66a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_81df9f0d-d982-4138-b645-8d59ae011bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20241229.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e46122ed-4e98-4e50-957b-f57881816104" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e6dd841e-ea08-41e7-952a-e45acf07401d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e46122ed-4e98-4e50-957b-f57881816104" xlink:to="loc_us-gaap_NetIncomeLoss_e6dd841e-ea08-41e7-952a-e45acf07401d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4dc2929b-b463-4ca9-980f-ba989d8aa3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e46122ed-4e98-4e50-957b-f57881816104" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4dc2929b-b463-4ca9-980f-ba989d8aa3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_06e34b28-ef4a-4e5e-9eb5-5e017aa6fb97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4dc2929b-b463-4ca9-980f-ba989d8aa3ca" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_06e34b28-ef4a-4e5e-9eb5-5e017aa6fb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_ee36cd19-a102-482a-b87e-627655c08d47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4dc2929b-b463-4ca9-980f-ba989d8aa3ca" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_ee36cd19-a102-482a-b87e-627655c08d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_da841e81-790e-4d8b-82f9-5641ab028a93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_ee36cd19-a102-482a-b87e-627655c08d47" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_da841e81-790e-4d8b-82f9-5641ab028a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_70147200-2b4a-40f9-906b-9023303a7ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_ee36cd19-a102-482a-b87e-627655c08d47" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_70147200-2b4a-40f9-906b-9023303a7ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7aa8041b-a9ab-4baf-9358-88626572d2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_ee36cd19-a102-482a-b87e-627655c08d47" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7aa8041b-a9ab-4baf-9358-88626572d2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_625c1274-7d91-4a8f-a967-a56aeafdd159" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4dc2929b-b463-4ca9-980f-ba989d8aa3ca" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_625c1274-7d91-4a8f-a967-a56aeafdd159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_e955a153-c20b-4475-a3d4-34938dd5c66c" xlink:href="jnj-20241229.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_625c1274-7d91-4a8f-a967-a56aeafdd159" xlink:to="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_e955a153-c20b-4475-a3d4-34938dd5c66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_24af3a49-28f7-46d8-8ed1-f2d973945ae2" xlink:href="jnj-20241229.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_625c1274-7d91-4a8f-a967-a56aeafdd159" xlink:to="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_24af3a49-28f7-46d8-8ed1-f2d973945ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax_2ec01233-5160-4e02-80db-ae76131d28f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_625c1274-7d91-4a8f-a967-a56aeafdd159" xlink:to="loc_us-gaap_OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax_2ec01233-5160-4e02-80db-ae76131d28f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax_afd04d90-d46c-4a59-baec-1018f8d09473" xlink:href="jnj-20241229.xsd#jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_625c1274-7d91-4a8f-a967-a56aeafdd159" xlink:to="loc_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax_afd04d90-d46c-4a59-baec-1018f8d09473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_8692f3fd-0904-46fd-adc8-9fbf30b479b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_625c1274-7d91-4a8f-a967-a56aeafdd159" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_8692f3fd-0904-46fd-adc8-9fbf30b479b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_c4aa7462-02a5-4df7-bff7-5533ac89563d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4dc2929b-b463-4ca9-980f-ba989d8aa3ca" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_c4aa7462-02a5-4df7-bff7-5533ac89563d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_4976bf9c-cc55-42d4-a3bf-ff5cf612ed82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_c4aa7462-02a5-4df7-bff7-5533ac89563d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_4976bf9c-cc55-42d4-a3bf-ff5cf612ed82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_17d2d040-975d-4f36-9cce-db4ea44294c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_c4aa7462-02a5-4df7-bff7-5533ac89563d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_17d2d040-975d-4f36-9cce-db4ea44294c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_976d9383-c5e7-409b-8810-50504d7ef0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_c4aa7462-02a5-4df7-bff7-5533ac89563d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_976d9383-c5e7-409b-8810-50504d7ef0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a868a4fb-d5d3-49f2-92e7-1580b57c2971" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e46122ed-4e98-4e50-957b-f57881816104" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a868a4fb-d5d3-49f2-92e7-1580b57c2971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f485aff6-0d95-4b8b-af34-7966faab6309" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e46122ed-4e98-4e50-957b-f57881816104" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f485aff6-0d95-4b8b-af34-7966faab6309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="jnj-20241229.xsd#ConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_94569a07-625e-4b33-95bd-46c2b99e202f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_0f2a70f5-4f37-4893-875d-e4fb2a35f30d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_94569a07-625e-4b33-95bd-46c2b99e202f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_0f2a70f5-4f37-4893-875d-e4fb2a35f30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_96c280ce-1996-478f-bf96-d5e54a6d705b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_94569a07-625e-4b33-95bd-46c2b99e202f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_96c280ce-1996-478f-bf96-d5e54a6d705b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_35bab3c7-3e9a-47d9-8141-54e8bc29b87d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_94569a07-625e-4b33-95bd-46c2b99e202f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_35bab3c7-3e9a-47d9-8141-54e8bc29b87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="jnj-20241229.xsd#ConsolidatedStatementsofEquity"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_6777e9d8-de78-4721-a174-f18a6869daa4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0c2c1a95-0f3c-4b92-b0ec-b566700d6d01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_6777e9d8-de78-4721-a174-f18a6869daa4" xlink:to="loc_us-gaap_StatementTable_0c2c1a95-0f3c-4b92-b0ec-b566700d6d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_79a32450-2f26-4f7a-a513-e37ca9c2600d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0c2c1a95-0f3c-4b92-b0ec-b566700d6d01" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_79a32450-2f26-4f7a-a513-e37ca9c2600d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6895d23a-4014-493f-853c-1a53457fcdca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_79a32450-2f26-4f7a-a513-e37ca9c2600d" xlink:to="loc_us-gaap_EquityComponentDomain_6895d23a-4014-493f-853c-1a53457fcdca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e6dc5aba-0ec7-4fdd-856b-4424884d27ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6895d23a-4014-493f-853c-1a53457fcdca" xlink:to="loc_us-gaap_RetainedEarningsMember_e6dc5aba-0ec7-4fdd-856b-4424884d27ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_58edf495-383a-4287-8908-10f6f776d8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6895d23a-4014-493f-853c-1a53457fcdca" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_58edf495-383a-4287-8908-10f6f776d8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9e85fcbb-b190-4e4d-87a7-da14abc49b21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6895d23a-4014-493f-853c-1a53457fcdca" xlink:to="loc_us-gaap_CommonStockMember_9e85fcbb-b190-4e4d-87a7-da14abc49b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_e55b4177-50f4-49d5-bbec-12d7694e4bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6895d23a-4014-493f-853c-1a53457fcdca" xlink:to="loc_us-gaap_TreasuryStockCommonMember_e55b4177-50f4-49d5-bbec-12d7694e4bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7646ef72-c15b-4842-89d1-266fb52a0a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0c2c1a95-0f3c-4b92-b0ec-b566700d6d01" xlink:to="loc_us-gaap_StatementLineItems_7646ef72-c15b-4842-89d1-266fb52a0a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b14528f7-d46e-4668-8b4a-16f0a4810204" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7646ef72-c15b-4842-89d1-266fb52a0a2d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b14528f7-d46e-4668-8b4a-16f0a4810204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cf35e243-c110-4bcc-8701-f0f418c68a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7646ef72-c15b-4842-89d1-266fb52a0a2d" xlink:to="loc_us-gaap_NetIncomeLoss_cf35e243-c110-4bcc-8701-f0f418c68a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_d77b15f8-7f4f-4353-a526-e4dccf728a48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7646ef72-c15b-4842-89d1-266fb52a0a2d" xlink:to="loc_us-gaap_DividendsCommonStockCash_d77b15f8-7f4f-4353-a526-e4dccf728a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f8a76e8e-b843-4aaf-84db-a8226091cf2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7646ef72-c15b-4842-89d1-266fb52a0a2d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f8a76e8e-b843-4aaf-84db-a8226091cf2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_bcf2eb47-287e-4ac9-99b1-14356d0cb748" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7646ef72-c15b-4842-89d1-266fb52a0a2d" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_bcf2eb47-287e-4ac9-99b1-14356d0cb748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_64c412c8-6a2a-4bee-99bc-4b57eebd8f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7646ef72-c15b-4842-89d1-266fb52a0a2d" xlink:to="loc_us-gaap_StockholdersEquityOther_64c412c8-6a2a-4bee-99bc-4b57eebd8f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_c6eac08f-8686-43b7-b064-543f8bf2ac5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7646ef72-c15b-4842-89d1-266fb52a0a2d" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_c6eac08f-8686-43b7-b064-543f8bf2ac5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d5342f42-b594-4e75-9483-05bb982e0eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7646ef72-c15b-4842-89d1-266fb52a0a2d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d5342f42-b594-4e75-9483-05bb982e0eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e6b31ddb-4a6d-43f8-bfe2-7479ba4a3b96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7646ef72-c15b-4842-89d1-266fb52a0a2d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e6b31ddb-4a6d-43f8-bfe2-7479ba4a3b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="simple" xlink:href="jnj-20241229.xsd#ConsolidatedStatementsofEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_40a8b8b1-29c8-4cf5-96ce-1e6397cb45b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_bf0e5348-866a-4025-9cae-fe1b40ca4dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_40a8b8b1-29c8-4cf5-96ce-1e6397cb45b6" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_bf0e5348-866a-4025-9cae-fe1b40ca4dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="jnj-20241229.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_3d4e1ba8-e7c5-423f-8b67-4711365a8c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3f3bfee0-bdc0-455a-a8ae-6724fa736184" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d4e1ba8-e7c5-423f-8b67-4711365a8c7a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3f3bfee0-bdc0-455a-a8ae-6724fa736184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c7827392-4c4e-4c05-81ae-e4f5aa8abe11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3f3bfee0-bdc0-455a-a8ae-6724fa736184" xlink:to="loc_us-gaap_NetIncomeLoss_c7827392-4c4e-4c05-81ae-e4f5aa8abe11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f89b8b6-a9e5-484f-95e0-becf5f0cc900" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3f3bfee0-bdc0-455a-a8ae-6724fa736184" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f89b8b6-a9e5-484f-95e0-becf5f0cc900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5a26d49c-55f4-468c-99ae-0d6ef02e3ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f89b8b6-a9e5-484f-95e0-becf5f0cc900" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5a26d49c-55f4-468c-99ae-0d6ef02e3ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_bb58f00f-e2e1-455a-85a5-5146e6df3ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f89b8b6-a9e5-484f-95e0-becf5f0cc900" xlink:to="loc_us-gaap_ShareBasedCompensation_bb58f00f-e2e1-455a-85a5-5146e6df3ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_9f367a1d-7c03-4c86-9aca-d5562b492959" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f89b8b6-a9e5-484f-95e0-becf5f0cc900" xlink:to="loc_us-gaap_AssetImpairmentCharges_9f367a1d-7c03-4c86-9aca-d5562b492959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_874f895c-c22d-441d-9d75-b1adf66da94a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f89b8b6-a9e5-484f-95e0-becf5f0cc900" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_874f895c-c22d-441d-9d75-b1adf66da94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_28d6c32e-d995-4434-83aa-e65688a3f80e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f89b8b6-a9e5-484f-95e0-becf5f0cc900" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_28d6c32e-d995-4434-83aa-e65688a3f80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_8d69e3f8-a297-4542-9c77-164c7092881f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f89b8b6-a9e5-484f-95e0-becf5f0cc900" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_8d69e3f8-a297-4542-9c77-164c7092881f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f56ccbf6-43e3-4d12-b180-8f6d8066a863" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f89b8b6-a9e5-484f-95e0-becf5f0cc900" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f56ccbf6-43e3-4d12-b180-8f6d8066a863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_7a5e41d4-99cd-4c62-a0d8-4d214df1cf10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f89b8b6-a9e5-484f-95e0-becf5f0cc900" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_7a5e41d4-99cd-4c62-a0d8-4d214df1cf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2d409d5d-6a6a-4ae5-b902-45d7b0ddd096" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3f3bfee0-bdc0-455a-a8ae-6724fa736184" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2d409d5d-6a6a-4ae5-b902-45d7b0ddd096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2a8fef64-1a1e-4a5a-890a-c12e0d6009b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2d409d5d-6a6a-4ae5-b902-45d7b0ddd096" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2a8fef64-1a1e-4a5a-890a-c12e0d6009b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_0af178af-0293-4895-bd9d-507fe0aa4c84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2d409d5d-6a6a-4ae5-b902-45d7b0ddd096" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_0af178af-0293-4895-bd9d-507fe0aa4c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_06e4858d-3685-4731-819f-d826f9c1d6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2d409d5d-6a6a-4ae5-b902-45d7b0ddd096" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_06e4858d-3685-4731-819f-d826f9c1d6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_863bbf01-1722-4437-a821-867f2b63c6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2d409d5d-6a6a-4ae5-b902-45d7b0ddd096" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_863bbf01-1722-4437-a821-867f2b63c6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_62c1f948-f633-43a9-a82d-c9d7319b40c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2d409d5d-6a6a-4ae5-b902-45d7b0ddd096" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_62c1f948-f633-43a9-a82d-c9d7319b40c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb77e569-6459-43cc-8714-93944225c29b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2d409d5d-6a6a-4ae5-b902-45d7b0ddd096" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb77e569-6459-43cc-8714-93944225c29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88b1fef5-79a4-436a-986b-dfdd85ea326e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d4e1ba8-e7c5-423f-8b67-4711365a8c7a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88b1fef5-79a4-436a-986b-dfdd85ea326e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2cf4f399-c5ac-42d9-a3c1-27efe05a8b63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88b1fef5-79a4-436a-986b-dfdd85ea326e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2cf4f399-c5ac-42d9-a3c1-27efe05a8b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_20c86471-d350-4fde-a728-338b45b205db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88b1fef5-79a4-436a-986b-dfdd85ea326e" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_20c86471-d350-4fde-a728-338b45b205db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_214928c7-8211-4838-ba6e-11ca7adf32c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88b1fef5-79a4-436a-986b-dfdd85ea326e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_214928c7-8211-4838-ba6e-11ca7adf32c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PaymentsToAcquiredInProcessResearchAndDevelopmentAssets_6403c92e-2944-4cdc-b69b-d3072cdddf11" xlink:href="jnj-20241229.xsd#jnj_PaymentsToAcquiredInProcessResearchAndDevelopmentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88b1fef5-79a4-436a-986b-dfdd85ea326e" xlink:to="loc_jnj_PaymentsToAcquiredInProcessResearchAndDevelopmentAssets_6403c92e-2944-4cdc-b69b-d3072cdddf11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_a4b2b7a7-5bb0-4e26-8d2f-dc07af39c85c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88b1fef5-79a4-436a-986b-dfdd85ea326e" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_a4b2b7a7-5bb0-4e26-8d2f-dc07af39c85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_109e7b42-c97e-4a90-8c4c-614231b9fefd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88b1fef5-79a4-436a-986b-dfdd85ea326e" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_109e7b42-c97e-4a90-8c4c-614231b9fefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_5d296163-d845-48a9-b590-1096dc2ed9ae" xlink:href="jnj-20241229.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88b1fef5-79a4-436a-986b-dfdd85ea326e" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_5d296163-d845-48a9-b590-1096dc2ed9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_e62c79ff-3bbc-4a86-a036-c482f88d8835" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88b1fef5-79a4-436a-986b-dfdd85ea326e" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_e62c79ff-3bbc-4a86-a036-c482f88d8835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_713f706a-1098-4caf-a386-52637d3fef6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88b1fef5-79a4-436a-986b-dfdd85ea326e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_713f706a-1098-4caf-a386-52637d3fef6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4fa6b293-d62b-472e-a834-94a72509b8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d4e1ba8-e7c5-423f-8b67-4711365a8c7a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4fa6b293-d62b-472e-a834-94a72509b8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_8f073955-daa1-4609-a071-5d5218eea96b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4fa6b293-d62b-472e-a834-94a72509b8d2" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_8f073955-daa1-4609-a071-5d5218eea96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f1184646-7496-4624-bab7-628400f701c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4fa6b293-d62b-472e-a834-94a72509b8d2" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f1184646-7496-4624-bab7-628400f701c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_30825f55-2811-4837-8006-d9d95f6c6364" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4fa6b293-d62b-472e-a834-94a72509b8d2" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_30825f55-2811-4837-8006-d9d95f6c6364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_c1a08346-f39f-47c6-a6b7-d9e88032554a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4fa6b293-d62b-472e-a834-94a72509b8d2" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_c1a08346-f39f-47c6-a6b7-d9e88032554a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c0f2f111-aa83-4818-8b36-12b8c05b965e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4fa6b293-d62b-472e-a834-94a72509b8d2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c0f2f111-aa83-4818-8b36-12b8c05b965e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_70f2a0fd-6a67-4ae3-8d00-38c51fa3afef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4fa6b293-d62b-472e-a834-94a72509b8d2" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_70f2a0fd-6a67-4ae3-8d00-38c51fa3afef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_6a74f38f-8229-404d-8b54-031a423781f1" xlink:href="jnj-20241229.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4fa6b293-d62b-472e-a834-94a72509b8d2" xlink:to="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_6a74f38f-8229-404d-8b54-031a423781f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_e8cccf79-9e94-49f8-b304-990ae2dc5b87" xlink:href="jnj-20241229.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4fa6b293-d62b-472e-a834-94a72509b8d2" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_e8cccf79-9e94-49f8-b304-990ae2dc5b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SettlementOfConvertibleDebtAcquiredFromShockwave_6beb2db2-b5bb-4abf-8a4d-d16f47a8b53c" xlink:href="jnj-20241229.xsd#jnj_SettlementOfConvertibleDebtAcquiredFromShockwave"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4fa6b293-d62b-472e-a834-94a72509b8d2" xlink:to="loc_jnj_SettlementOfConvertibleDebtAcquiredFromShockwave_6beb2db2-b5bb-4abf-8a4d-d16f47a8b53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation_4b68483f-7ce8-48de-8025-713ac285bd61" xlink:href="jnj-20241229.xsd#jnj_ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4fa6b293-d62b-472e-a834-94a72509b8d2" xlink:to="loc_jnj_ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation_4b68483f-7ce8-48de-8025-713ac285bd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0e403c6f-f5d6-450c-a7d1-17d8a8140a15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4fa6b293-d62b-472e-a834-94a72509b8d2" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0e403c6f-f5d6-450c-a7d1-17d8a8140a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PaymentsMadeInBusinessSeparation_5f6a494b-6fd2-4a8f-afd1-25ec278b7baf" xlink:href="jnj-20241229.xsd#jnj_PaymentsMadeInBusinessSeparation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4fa6b293-d62b-472e-a834-94a72509b8d2" xlink:to="loc_jnj_PaymentsMadeInBusinessSeparation_5f6a494b-6fd2-4a8f-afd1-25ec278b7baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_d1c6864c-c5aa-4f18-b1c0-99c0f0fad6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4fa6b293-d62b-472e-a834-94a72509b8d2" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_d1c6864c-c5aa-4f18-b1c0-99c0f0fad6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff55576e-24cd-4d4f-bea6-e23f494d846a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4fa6b293-d62b-472e-a834-94a72509b8d2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff55576e-24cd-4d4f-bea6-e23f494d846a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d40e6d47-86f5-4fc9-9342-c23c4c8276aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d4e1ba8-e7c5-423f-8b67-4711365a8c7a" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d40e6d47-86f5-4fc9-9342-c23c4c8276aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5afdc34e-24df-4eee-bc51-632b754ef9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d4e1ba8-e7c5-423f-8b67-4711365a8c7a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5afdc34e-24df-4eee-bc51-632b754ef9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations_6d49ce98-0c13-460d-9ceb-ffd428b2e28e" xlink:href="jnj-20241229.xsd#jnj_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d4e1ba8-e7c5-423f-8b67-4711365a8c7a" xlink:to="loc_jnj_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations_6d49ce98-0c13-460d-9ceb-ffd428b2e28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_f6ea7287-faf0-4deb-91be-2b61802eb8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d4e1ba8-e7c5-423f-8b67-4711365a8c7a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_f6ea7287-faf0-4deb-91be-2b61802eb8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f9512908-5964-4165-a41f-4562342c691f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d4e1ba8-e7c5-423f-8b67-4711365a8c7a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f9512908-5964-4165-a41f-4562342c691f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations_0b416b8e-4920-436b-8809-2f46bbbf7b3e" xlink:href="jnj-20241229.xsd#jnj_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d4e1ba8-e7c5-423f-8b67-4711365a8c7a" xlink:to="loc_jnj_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations_0b416b8e-4920-436b-8809-2f46bbbf7b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_daf8f3a6-3306-4913-af73-554690255446" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d4e1ba8-e7c5-423f-8b67-4711365a8c7a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_daf8f3a6-3306-4913-af73-554690255446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ad6149ec-74b1-440a-b0a2-9eee0013e8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d4e1ba8-e7c5-423f-8b67-4711365a8c7a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ad6149ec-74b1-440a-b0a2-9eee0013e8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_31f025fd-ca66-4173-b3ec-718c3614a819" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d4e1ba8-e7c5-423f-8b67-4711365a8c7a" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_31f025fd-ca66-4173-b3ec-718c3614a819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashPaidDuringTheYearAbstract_c8d3d4d8-14ae-4629-a6f0-5ebde4d7fe4b" xlink:href="jnj-20241229.xsd#jnj_CashPaidDuringTheYearAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_31f025fd-ca66-4173-b3ec-718c3614a819" xlink:to="loc_jnj_CashPaidDuringTheYearAbstract_c8d3d4d8-14ae-4629-a6f0-5ebde4d7fe4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_15d0a838-f0d2-441c-9a6c-7790561b0bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_CashPaidDuringTheYearAbstract_c8d3d4d8-14ae-4629-a6f0-5ebde4d7fe4b" xlink:to="loc_us-gaap_InterestPaid_15d0a838-f0d2-441c-9a6c-7790561b0bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_7677367a-15d4-4742-b3b6-b17f0f54006b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_CashPaidDuringTheYearAbstract_c8d3d4d8-14ae-4629-a6f0-5ebde4d7fe4b" xlink:to="loc_us-gaap_InterestPaidNet_7677367a-15d4-4742-b3b6-b17f0f54006b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_0143e623-5c6e-40d4-99c9-9dfc52111327" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_CashPaidDuringTheYearAbstract_c8d3d4d8-14ae-4629-a6f0-5ebde4d7fe4b" xlink:to="loc_us-gaap_IncomeTaxesPaid_0143e623-5c6e-40d4-99c9-9dfc52111327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_cf33b48b-f344-4339-af37-413899aaa444" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d4e1ba8-e7c5-423f-8b67-4711365a8c7a" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_cf33b48b-f344-4339-af37-413899aaa444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds_27de85ce-44c4-4ff6-85d5-eb821e2f84ca" xlink:href="jnj-20241229.xsd#jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_cf33b48b-f344-4339-af37-413899aaa444" xlink:to="loc_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds_27de85ce-44c4-4ff6-85d5-eb821e2f84ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_27e8f514-37b3-4b31-9610-d8f930d6f381" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d4e1ba8-e7c5-423f-8b67-4711365a8c7a" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_27e8f514-37b3-4b31-9610-d8f930d6f381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_8923e997-864a-43a6-a8c1-fd99f7981476" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_27e8f514-37b3-4b31-9610-d8f930d6f381" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_8923e997-864a-43a6-a8c1-fd99f7981476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_e0287fe0-35f2-43b7-8349-e94f5b612231" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_27e8f514-37b3-4b31-9610-d8f930d6f381" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_e0287fe0-35f2-43b7-8349-e94f5b612231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_032aed97-2f62-4997-8d5d-c67678528e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_27e8f514-37b3-4b31-9610-d8f930d6f381" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_032aed97-2f62-4997-8d5d-c67678528e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Summaryofsignificantaccountingpolicies" xlink:type="simple" xlink:href="jnj-20241229.xsd#Summaryofsignificantaccountingpolicies"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Summaryofsignificantaccountingpolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f1295e72-b3dd-4e29-a760-91afe80b08b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8e71e173-7ac3-4818-988c-145811a3e0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f1295e72-b3dd-4e29-a760-91afe80b08b0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8e71e173-7ac3-4818-988c-145811a3e0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Cashcashequivalentsandcurrentmarketablesecurities" xlink:type="simple" xlink:href="jnj-20241229.xsd#Cashcashequivalentsandcurrentmarketablesecurities"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Cashcashequivalentsandcurrentmarketablesecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_e9e09c7e-ad78-4c00-ba05-7b7a727b60ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_3b54ed0c-e84c-4c2e-b02a-c28bdc8caff5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_e9e09c7e-ad78-4c00-ba05-7b7a727b60ec" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_3b54ed0c-e84c-4c2e-b02a-c28bdc8caff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Inventories" xlink:type="simple" xlink:href="jnj-20241229.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_24651226-ee41-45c3-8872-628ba8402369" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_d0ed756c-77bc-49be-9ef3-2fa79e445c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_24651226-ee41-45c3-8872-628ba8402369" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_d0ed756c-77bc-49be-9ef3-2fa79e445c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Propertyplantandequipment" xlink:type="simple" xlink:href="jnj-20241229.xsd#Propertyplantandequipment"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Propertyplantandequipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_072f9baf-c6ac-447d-b6c5-81d0eae52307" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_873a07be-a66c-4632-9576-c78d83a10046" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_072f9baf-c6ac-447d-b6c5-81d0eae52307" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_873a07be-a66c-4632-9576-c78d83a10046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Intangibleassetsandgoodwill" xlink:type="simple" xlink:href="jnj-20241229.xsd#Intangibleassetsandgoodwill"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Intangibleassetsandgoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bcea285e-72ec-4ab0-a035-088c1e6f98a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_97ef1f53-0c2f-4929-a36c-97046924bb58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bcea285e-72ec-4ab0-a035-088c1e6f98a5" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_97ef1f53-0c2f-4929-a36c-97046924bb58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Fairvaluemeasurements" xlink:type="simple" xlink:href="jnj-20241229.xsd#Fairvaluemeasurements"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Fairvaluemeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f20d1048-2c6f-475e-a4e2-ded315cb0c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_c766395b-f4ff-4601-8cd0-12f5f7233566" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f20d1048-2c6f-475e-a4e2-ded315cb0c1a" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_c766395b-f4ff-4601-8cd0-12f5f7233566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Borrowings" xlink:type="simple" xlink:href="jnj-20241229.xsd#Borrowings"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Borrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4045cf9a-b604-407a-a6b9-ae93cb567718" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_7e8f99f3-f28d-4ef0-a08c-509581347ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4045cf9a-b604-407a-a6b9-ae93cb567718" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_7e8f99f3-f28d-4ef0-a08c-509581347ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Incometaxes" xlink:type="simple" xlink:href="jnj-20241229.xsd#Incometaxes"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Incometaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9fe6fd61-8de3-4915-b743-dbe184b3bc49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_f7576388-1175-4457-9cb0-985132dc7122" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9fe6fd61-8de3-4915-b743-dbe184b3bc49" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_f7576388-1175-4457-9cb0-985132dc7122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Employeerelatedobligations" xlink:type="simple" xlink:href="jnj-20241229.xsd#Employeerelatedobligations"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Employeerelatedobligations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_7be77ce0-eaa7-4288-b22e-45175fa044aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsGeneralTextBlock_a251e619-aed7-4994-b62b-752005b3fe7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsGeneralTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_7be77ce0-eaa7-4288-b22e-45175fa044aa" xlink:to="loc_us-gaap_CompensationRelatedCostsGeneralTextBlock_a251e619-aed7-4994-b62b-752005b3fe7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Pensionsandotherbenefitplans" xlink:type="simple" xlink:href="jnj-20241229.xsd#Pensionsandotherbenefitplans"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Pensionsandotherbenefitplans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9491d12c-a420-4ec2-8ac8-ec7f8812a966" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_4134d22a-5f97-46aa-9e2f-20ed6093a1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9491d12c-a420-4ec2-8ac8-ec7f8812a966" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_4134d22a-5f97-46aa-9e2f-20ed6093a1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Savingsplan" xlink:type="simple" xlink:href="jnj-20241229.xsd#Savingsplan"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Savingsplan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SavingsPlanAbstract_ca38e69b-955c-4438-a6ec-dcae182844d1" xlink:href="jnj-20241229.xsd#jnj_SavingsPlanAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SavingsPlanTextBlock_84cbe7e4-2b87-47d0-aef1-ded9f645ff51" xlink:href="jnj-20241229.xsd#jnj_SavingsPlanTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_SavingsPlanAbstract_ca38e69b-955c-4438-a6ec-dcae182844d1" xlink:to="loc_jnj_SavingsPlanTextBlock_84cbe7e4-2b87-47d0-aef1-ded9f645ff51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Capitalandtreasurystock" xlink:type="simple" xlink:href="jnj-20241229.xsd#Capitalandtreasurystock"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Capitalandtreasurystock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_48d3904b-bfbd-4e1a-a5a9-3e5d4655a595" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock_6eb6a80f-5f5d-4bbc-8033-57dd63a4921d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_48d3904b-bfbd-4e1a-a5a9-3e5d4655a595" xlink:to="loc_us-gaap_TreasuryStockTextBlock_6eb6a80f-5f5d-4bbc-8033-57dd63a4921d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Accumulatedothercomprehensiveincomeloss" xlink:type="simple" xlink:href="jnj-20241229.xsd#Accumulatedothercomprehensiveincomeloss"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Accumulatedothercomprehensiveincomeloss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d7a932c2-a4c5-4c8b-a385-62309d35565a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_da84abb4-4938-432e-8aa7-6cfed9ee751e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d7a932c2-a4c5-4c8b-a385-62309d35565a" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_da84abb4-4938-432e-8aa7-6cfed9ee751e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Internationalcurrencytranslation" xlink:type="simple" xlink:href="jnj-20241229.xsd#Internationalcurrencytranslation"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Internationalcurrencytranslation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTranslationAbstract_9e87f295-0fa4-458b-8dba-b13038ad36fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTranslationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDisclosureTextBlock_418213d7-6a2b-4b40-8aa6-5228933fd06d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignCurrencyTranslationAbstract_9e87f295-0fa4-458b-8dba-b13038ad36fc" xlink:to="loc_us-gaap_ForeignCurrencyDisclosureTextBlock_418213d7-6a2b-4b40-8aa6-5228933fd06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Earningspershare" xlink:type="simple" xlink:href="jnj-20241229.xsd#Earningspershare"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Earningspershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7a2e1287-b9d4-442f-a7cd-026af9b59b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_b1d4bf2a-0c8a-474d-84d9-15235dff5230" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7a2e1287-b9d4-442f-a7cd-026af9b59b3d" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_b1d4bf2a-0c8a-474d-84d9-15235dff5230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Commonstockstockoptionplansandstockcompensationagreements" xlink:type="simple" xlink:href="jnj-20241229.xsd#Commonstockstockoptionplansandstockcompensationagreements"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Commonstockstockoptionplansandstockcompensationagreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5c522f00-cf8e-483b-bd79-abb86f70ca86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8e4496a2-5ca1-4ccc-9cfc-dca75214088e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5c522f00-cf8e-483b-bd79-abb86f70ca86" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8e4496a2-5ca1-4ccc-9cfc-dca75214088e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Segmentsofbusinessandgeographicareas" xlink:type="simple" xlink:href="jnj-20241229.xsd#Segmentsofbusinessandgeographicareas"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Segmentsofbusinessandgeographicareas" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_591bf6ee-5b5d-4254-a3fc-ecadff8915e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_00f26db4-7c5f-44e0-9c94-6604c501894c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_591bf6ee-5b5d-4254-a3fc-ecadff8915e9" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_00f26db4-7c5f-44e0-9c94-6604c501894c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Acquisitionsanddivestitures" xlink:type="simple" xlink:href="jnj-20241229.xsd#Acquisitionsanddivestitures"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Acquisitionsanddivestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_3a107e69-2a65-4e22-8473-6040a3b1d574" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_fd8c21d2-3af5-47d9-a568-620d2b1d7158" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_3a107e69-2a65-4e22-8473-6040a3b1d574" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_fd8c21d2-3af5-47d9-a568-620d2b1d7158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Legalproceedings" xlink:type="simple" xlink:href="jnj-20241229.xsd#Legalproceedings"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Legalproceedings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_aa831150-2647-4e3e-bf4d-2a55d1e03028" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_8dc7ea8e-0961-40e7-8db7-8abde95b13b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_aa831150-2647-4e3e-bf4d-2a55d1e03028" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_8dc7ea8e-0961-40e7-8db7-8abde95b13b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Restructuring" xlink:type="simple" xlink:href="jnj-20241229.xsd#Restructuring"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Restructuring" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e324b212-88df-48a8-9b87-5596939ee57a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_2b6883d8-e2c2-404c-a885-01ad4f4c7cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e324b212-88df-48a8-9b87-5596939ee57a" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_2b6883d8-e2c2-404c-a885-01ad4f4c7cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Kenvueseparationanddiscontinuedoperations" xlink:type="simple" xlink:href="jnj-20241229.xsd#Kenvueseparationanddiscontinuedoperations"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Kenvueseparationanddiscontinuedoperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6a26a2eb-dcd7-4026-8cad-8181078d5a10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_abc61013-6bab-41e1-8851-eae096c6cc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6a26a2eb-dcd7-4026-8cad-8181078d5a10" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_abc61013-6bab-41e1-8851-eae096c6cc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="jnj-20241229.xsd#SummaryofsignificantaccountingpoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3f687a63-66e2-444d-88c2-eb8c7c849975" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_c8de35bb-b4d9-488b-bb63-fb2d0d6b0369" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3f687a63-66e2-444d-88c2-eb8c7c849975" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_c8de35bb-b4d9-488b-bb63-fb2d0d6b0369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_fdda9da1-8886-40cd-a353-55283756fe9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3f687a63-66e2-444d-88c2-eb8c7c849975" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_fdda9da1-8886-40cd-a353-55283756fe9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_dac88452-beee-49b8-ad81-e093c11b7359" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3f687a63-66e2-444d-88c2-eb8c7c849975" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_dac88452-beee-49b8-ad81-e093c11b7359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4c34b81f-1b0a-44b0-8587-92fb0f3f2d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3f687a63-66e2-444d-88c2-eb8c7c849975" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4c34b81f-1b0a-44b0-8587-92fb0f3f2d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_1ed26c01-ce38-463a-bcb1-c12c18a176d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3f687a63-66e2-444d-88c2-eb8c7c849975" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_1ed26c01-ce38-463a-bcb1-c12c18a176d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ef8828d7-36d5-4acb-925b-c2c44b99e6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3f687a63-66e2-444d-88c2-eb8c7c849975" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ef8828d7-36d5-4acb-925b-c2c44b99e6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_b0878b52-8aff-4f5e-9fe5-82f2fca75088" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3f687a63-66e2-444d-88c2-eb8c7c849975" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_b0878b52-8aff-4f5e-9fe5-82f2fca75088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock_72211b86-1d4e-4af1-916a-eccb2def8ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3f687a63-66e2-444d-88c2-eb8c7c849975" xlink:to="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock_72211b86-1d4e-4af1-916a-eccb2def8ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_92f8285e-e7e2-4bf6-b395-8e2066743449" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3f687a63-66e2-444d-88c2-eb8c7c849975" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_92f8285e-e7e2-4bf6-b395-8e2066743449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_c0d3f68d-b5ac-427a-b741-88a2298ba1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3f687a63-66e2-444d-88c2-eb8c7c849975" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_c0d3f68d-b5ac-427a-b741-88a2298ba1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_cf42bb91-3083-42c0-b5c0-1129a6454d73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3f687a63-66e2-444d-88c2-eb8c7c849975" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_cf42bb91-3083-42c0-b5c0-1129a6454d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_5842a6e0-efdd-40c6-81ed-afca6ae449bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3f687a63-66e2-444d-88c2-eb8c7c849975" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_5842a6e0-efdd-40c6-81ed-afca6ae449bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityPolicyTextBlock_2e6a9687-5a2a-4491-ae23-380f3b410379" xlink:href="jnj-20241229.xsd#jnj_ProductLiabilityPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3f687a63-66e2-444d-88c2-eb8c7c849975" xlink:to="loc_jnj_ProductLiabilityPolicyTextBlock_2e6a9687-5a2a-4491-ae23-380f3b410379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_4190fb94-74c4-4d45-af05-f024b29536f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3f687a63-66e2-444d-88c2-eb8c7c849975" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_4190fb94-74c4-4d45-af05-f024b29536f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_71bae7e2-1485-4542-8019-81eb74f45e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3f687a63-66e2-444d-88c2-eb8c7c849975" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_71bae7e2-1485-4542-8019-81eb74f45e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_3e0a5406-44d9-4b92-b3f5-56e6aa5255cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3f687a63-66e2-444d-88c2-eb8c7c849975" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_3e0a5406-44d9-4b92-b3f5-56e6aa5255cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_a26b1a89-60e0-441f-b682-c31e398ff6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3f687a63-66e2-444d-88c2-eb8c7c849975" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_a26b1a89-60e0-441f-b682-c31e398ff6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_7dc854bd-c388-4443-8c71-e088bafaca65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3f687a63-66e2-444d-88c2-eb8c7c849975" xlink:to="loc_us-gaap_UseOfEstimates_7dc854bd-c388-4443-8c71-e088bafaca65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplierFinanceProgramPolicyTextBlock_454c3692-3638-4adc-9657-304f32c84091" xlink:href="jnj-20241229.xsd#jnj_SupplierFinanceProgramPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3f687a63-66e2-444d-88c2-eb8c7c849975" xlink:to="loc_jnj_SupplierFinanceProgramPolicyTextBlock_454c3692-3638-4adc-9657-304f32c84091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiscalPeriodPolicyTextBlock_33ea609d-45e8-45e6-a16e-7d2119ced70b" xlink:href="jnj-20241229.xsd#jnj_FiscalPeriodPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3f687a63-66e2-444d-88c2-eb8c7c849975" xlink:to="loc_jnj_FiscalPeriodPolicyTextBlock_33ea609d-45e8-45e6-a16e-7d2119ced70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesTables" xlink:type="simple" xlink:href="jnj-20241229.xsd#SummaryofsignificantaccountingpoliciesTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7a772c84-e3d3-4bd0-8704-6111cac833dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock_573ef0e7-c9fc-481c-831e-b07b63cb6946" xlink:href="jnj-20241229.xsd#jnj_EstimatedUsefulLivesOfAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a772c84-e3d3-4bd0-8704-6111cac833dc" xlink:to="loc_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock_573ef0e7-c9fc-481c-831e-b07b63cb6946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramTableTextBlock_80d271c9-1e4a-4f2b-8218-8b3102013542" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a772c84-e3d3-4bd0-8704-6111cac833dc" xlink:to="loc_us-gaap_SupplierFinanceProgramTableTextBlock_80d271c9-1e4a-4f2b-8218-8b3102013542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesTables" xlink:type="simple" xlink:href="jnj-20241229.xsd#CashcashequivalentsandcurrentmarketablesecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_385ad7f8-6107-4363-9ae9-9391a4c8df7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_ed2443b7-3267-4a25-9eb6-7f4f528c0f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_385ad7f8-6107-4363-9ae9-9391a4c8df7c" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_ed2443b7-3267-4a25-9eb6-7f4f528c0f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_a651eb42-b9d1-4f50-8494-2ad2623e64c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_385ad7f8-6107-4363-9ae9-9391a4c8df7c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_a651eb42-b9d1-4f50-8494-2ad2623e64c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesTables" xlink:type="simple" xlink:href="jnj-20241229.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_5507fdd3-de57-4d24-9fac-7c568eac7dad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9dad6f25-6b17-4710-9760-dabb9d132ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5507fdd3-de57-4d24-9fac-7c568eac7dad" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9dad6f25-6b17-4710-9760-dabb9d132ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyplantandequipmentTables" xlink:type="simple" xlink:href="jnj-20241229.xsd#PropertyplantandequipmentTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PropertyplantandequipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_733d7c2a-f46d-4cc0-9964-787eb4fd9f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_71f802b3-0874-471a-be23-819fb5dd1a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_733d7c2a-f46d-4cc0-9964-787eb4fd9f5b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_71f802b3-0874-471a-be23-819fb5dd1a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleassetsandgoodwillTables" xlink:type="simple" xlink:href="jnj-20241229.xsd#IntangibleassetsandgoodwillTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleassetsandgoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5d9a56ce-6161-4edd-a814-3f7219e7b839" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_26c4b1a2-8684-4f5b-89a5-3be484d0e007" xlink:href="jnj-20241229.xsd#jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5d9a56ce-6161-4edd-a814-3f7219e7b839" xlink:to="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_26c4b1a2-8684-4f5b-89a5-3be484d0e007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_7ea41283-13ee-407a-ab08-3f108141cfa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5d9a56ce-6161-4edd-a814-3f7219e7b839" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_7ea41283-13ee-407a-ab08-3f108141cfa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_fdcb3bd2-1701-419c-86f8-ea548100f584" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5d9a56ce-6161-4edd-a814-3f7219e7b839" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_fdcb3bd2-1701-419c-86f8-ea548100f584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairvaluemeasurementsTables" xlink:type="simple" xlink:href="jnj-20241229.xsd#FairvaluemeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairvaluemeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4d3498a2-eeee-41a7-993b-9ac8f5cee883" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_472f1836-81d6-44a0-9f46-74abcc12a1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4d3498a2-eeee-41a7-993b-9ac8f5cee883" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_472f1836-81d6-44a0-9f46-74abcc12a1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_f999f56f-3648-4812-9b66-b9a39446cc59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4d3498a2-eeee-41a7-993b-9ac8f5cee883" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_f999f56f-3648-4812-9b66-b9a39446cc59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock_1c19311d-685b-4cd9-b7e0-b989e564c4ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4d3498a2-eeee-41a7-993b-9ac8f5cee883" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock_1c19311d-685b-4cd9-b7e0-b989e564c4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_20dccab7-5d06-4572-8034-77d04971a264" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4d3498a2-eeee-41a7-993b-9ac8f5cee883" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_20dccab7-5d06-4572-8034-77d04971a264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_b31b06b8-8918-48c0-b5f7-d3e56d3b0e18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4d3498a2-eeee-41a7-993b-9ac8f5cee883" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_b31b06b8-8918-48c0-b5f7-d3e56d3b0e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsTables" xlink:type="simple" xlink:href="jnj-20241229.xsd#BorrowingsTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/BorrowingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_27b21a5d-11c4-4c6c-8ece-8b40290893be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_325ec3bc-5f98-4042-92cb-f0ecdad662e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_27b21a5d-11c4-4c6c-8ece-8b40290893be" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_325ec3bc-5f98-4042-92cb-f0ecdad662e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_c4215a2d-0232-4892-9f74-5041c467cc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_27b21a5d-11c4-4c6c-8ece-8b40290893be" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_c4215a2d-0232-4892-9f74-5041c467cc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncometaxesTables" xlink:type="simple" xlink:href="jnj-20241229.xsd#IncometaxesTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncometaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_cca3547c-0a77-4c51-b77e-18f0c5145712" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1b0fd346-e343-4194-b5ec-0237f3b805f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cca3547c-0a77-4c51-b77e-18f0c5145712" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1b0fd346-e343-4194-b5ec-0237f3b805f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_afe52e2d-7ecd-4825-8511-9a675c38b89e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cca3547c-0a77-4c51-b77e-18f0c5145712" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_afe52e2d-7ecd-4825-8511-9a675c38b89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e855eb21-b570-4fbe-8461-ba11de22971f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cca3547c-0a77-4c51-b77e-18f0c5145712" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e855eb21-b570-4fbe-8461-ba11de22971f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_7a75f55d-b867-48a5-b2c9-01c8dfedb2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cca3547c-0a77-4c51-b77e-18f0c5145712" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_7a75f55d-b867-48a5-b2c9-01c8dfedb2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_eab9a68f-d73d-4e09-8cfe-d2f5dd70a443" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cca3547c-0a77-4c51-b77e-18f0c5145712" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_eab9a68f-d73d-4e09-8cfe-d2f5dd70a443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeerelatedobligationsTables" xlink:type="simple" xlink:href="jnj-20241229.xsd#EmployeerelatedobligationsTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EmployeerelatedobligationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_343af798-189a-4135-b206-ff8b174e04c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeRelatedObligationsTableTextBlock_ee7d8ba9-62e9-43b9-8c98-51072023f643" xlink:href="jnj-20241229.xsd#jnj_EmployeeRelatedObligationsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_343af798-189a-4135-b206-ff8b174e04c3" xlink:to="loc_jnj_EmployeeRelatedObligationsTableTextBlock_ee7d8ba9-62e9-43b9-8c98-51072023f643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansTables" xlink:type="simple" xlink:href="jnj-20241229.xsd#PensionsandotherbenefitplansTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandotherbenefitplansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1b3be28f-5b46-43b9-8af7-413e7538393b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_ce4f20c2-f6b7-47d8-a290-70256a591ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1b3be28f-5b46-43b9-8af7-413e7538393b" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_ce4f20c2-f6b7-47d8-a290-70256a591ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_0493d9e0-894c-41dd-9482-62006840140b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1b3be28f-5b46-43b9-8af7-413e7538393b" xlink:to="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_0493d9e0-894c-41dd-9482-62006840140b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_837e00c2-2284-430f-b174-2a5b693b7e17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1b3be28f-5b46-43b9-8af7-413e7538393b" xlink:to="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_837e00c2-2284-430f-b174-2a5b693b7e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_781317ec-22bc-48db-94ae-2ea6fa7f06f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNetFundedStatusTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1b3be28f-5b46-43b9-8af7-413e7538393b" xlink:to="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_781317ec-22bc-48db-94ae-2ea6fa7f06f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock_d75620af-c9e7-4488-ae27-08c3731f82c9" xlink:href="jnj-20241229.xsd#jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1b3be28f-5b46-43b9-8af7-413e7538393b" xlink:to="loc_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock_d75620af-c9e7-4488-ae27-08c3731f82c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_cc0ecda8-2643-45cd-a1f4-3f1ff8732389" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1b3be28f-5b46-43b9-8af7-413e7538393b" xlink:to="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_cc0ecda8-2643-45cd-a1f4-3f1ff8732389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock_b3fc64d9-c1dc-454c-a631-3c24c62f4e18" xlink:href="jnj-20241229.xsd#jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1b3be28f-5b46-43b9-8af7-413e7538393b" xlink:to="loc_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock_b3fc64d9-c1dc-454c-a631-3c24c62f4e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_9bacdfaa-9075-4792-81eb-9232face0f98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1b3be28f-5b46-43b9-8af7-413e7538393b" xlink:to="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_9bacdfaa-9075-4792-81eb-9232face0f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_22b48279-fd56-44e8-944f-4da9a30ad31c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1b3be28f-5b46-43b9-8af7-413e7538393b" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_22b48279-fd56-44e8-944f-4da9a30ad31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandtreasurystockTables" xlink:type="simple" xlink:href="jnj-20241229.xsd#CapitalandtreasurystockTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CapitalandtreasurystockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_bd83a8b5-5e07-4e27-b3aa-9294f8aeadc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesInTreasuryStockTableTextBlock_0a91ce10-233d-425d-8a48-e3e82be23bd5" xlink:href="jnj-20241229.xsd#jnj_ChangesInTreasuryStockTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bd83a8b5-5e07-4e27-b3aa-9294f8aeadc4" xlink:to="loc_jnj_ChangesInTreasuryStockTableTextBlock_0a91ce10-233d-425d-8a48-e3e82be23bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossTables" xlink:type="simple" xlink:href="jnj-20241229.xsd#AccumulatedothercomprehensiveincomelossTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_54f8340c-ad99-40f4-a109-657a13fc0dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_d58a6e07-01c6-459b-a992-6d4d5b6844e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_54f8340c-ad99-40f4-a109-657a13fc0dc2" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_d58a6e07-01c6-459b-a992-6d4d5b6844e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningspershareTables" xlink:type="simple" xlink:href="jnj-20241229.xsd#EarningspershareTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningspershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_48d4e219-0f51-4ed6-8d53-8360a502dfaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_49cc8774-d510-4fc8-ba81-e0c9e50f35e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_48d4e219-0f51-4ed6-8d53-8360a502dfaf" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_49cc8774-d510-4fc8-ba81-e0c9e50f35e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsTables" xlink:type="simple" xlink:href="jnj-20241229.xsd#CommonstockstockoptionplansandstockcompensationagreementsTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4c299b59-23f2-418c-9459-26fd42d5f0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_64836730-1d36-407e-bbe6-ef4bb93b517c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4c299b59-23f2-418c-9459-26fd42d5f0cc" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_64836730-1d36-407e-bbe6-ef4bb93b517c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a7907b02-408d-4c5c-892c-bde3518e581b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4c299b59-23f2-418c-9459-26fd42d5f0cc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a7907b02-408d-4c5c-892c-bde3518e581b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_894cfbbb-216f-47a0-b878-45be1a6814ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4c299b59-23f2-418c-9459-26fd42d5f0cc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_894cfbbb-216f-47a0-b878-45be1a6814ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_807b9f62-f85a-4849-a71b-5083cbe098a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4c299b59-23f2-418c-9459-26fd42d5f0cc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_807b9f62-f85a-4849-a71b-5083cbe098a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofbusinessandgeographicareasTables" xlink:type="simple" xlink:href="jnj-20241229.xsd#SegmentsofbusinessandgeographicareasTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofbusinessandgeographicareasTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ff75467e-4e1f-4148-af11-57dfee9cb10d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesBySegmentOfBusinessTableTextBlock_77bfea02-8c4a-4cfc-ac33-5b18eb496633" xlink:href="jnj-20241229.xsd#jnj_SalesBySegmentOfBusinessTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ff75467e-4e1f-4148-af11-57dfee9cb10d" xlink:to="loc_jnj_SalesBySegmentOfBusinessTableTextBlock_77bfea02-8c4a-4cfc-ac33-5b18eb496633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_8555d484-9031-46aa-9b76-7f4abe580d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ff75467e-4e1f-4148-af11-57dfee9cb10d" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_8555d484-9031-46aa-9b76-7f4abe580d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_f7c79471-8561-481f-935d-060163cbbe03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ff75467e-4e1f-4148-af11-57dfee9cb10d" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_f7c79471-8561-481f-935d-060163cbbe03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_f6b1ffc3-29f1-4970-abfa-51c4f1d6347b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ff75467e-4e1f-4148-af11-57dfee9cb10d" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_f6b1ffc3-29f1-4970-abfa-51c4f1d6347b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsanddivestituresTables" xlink:type="simple" xlink:href="jnj-20241229.xsd#AcquisitionsanddivestituresTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AcquisitionsanddivestituresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1d2f29a0-d361-40b7-90e8-7dec231f8929" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_c79a7dad-1c14-4693-a359-16337192ed4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1d2f29a0-d361-40b7-90e8-7dec231f8929" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_c79a7dad-1c14-4693-a359-16337192ed4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalproceedingsTables" xlink:type="simple" xlink:href="jnj-20241229.xsd#LegalproceedingsTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/LegalproceedingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1c857dfc-1fd6-43f2-aeba-3df1852aaf5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_9abed772-6516-4802-a549-8dd13f286e63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1c857dfc-1fd6-43f2-aeba-3df1852aaf5f" xlink:to="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_9abed772-6516-4802-a549-8dd13f286e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringTables" xlink:type="simple" xlink:href="jnj-20241229.xsd#RestructuringTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/RestructuringTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ff473385-18ef-4f7b-9366-bc4e2d7b8c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_799c35f0-5424-4f10-80c9-f7708dc2d621" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ff473385-18ef-4f7b-9366-bc4e2d7b8c1b" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_799c35f0-5424-4f10-80c9-f7708dc2d621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsTables" xlink:type="simple" xlink:href="jnj-20241229.xsd#KenvueseparationanddiscontinuedoperationsTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0ae7bf4a-c7a0-4a60-ad0c-fc2314958e83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_2b659cec-13d4-4402-aa73-71d57164c9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0ae7bf4a-c7a0-4a60-ad0c-fc2314958e83" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_2b659cec-13d4-4402-aa73-71d57164c9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#SummaryofsignificantaccountingpoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_975727c6-4831-49a1-8512-909de893ca4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationOfCreditRiskTable_320ee46f-fd3a-4e54-83c3-19aad6a7bc29" xlink:href="jnj-20241229.xsd#jnj_ConcentrationOfCreditRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_975727c6-4831-49a1-8512-909de893ca4a" xlink:to="loc_jnj_ConcentrationOfCreditRiskTable_320ee46f-fd3a-4e54-83c3-19aad6a7bc29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ef3746d6-6a9f-4223-ae6c-23b7b0227b30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_320ee46f-fd3a-4e54-83c3-19aad6a7bc29" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ef3746d6-6a9f-4223-ae6c-23b7b0227b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_156dfe1e-224e-4f5f-9717-6aa4baa9946f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ef3746d6-6a9f-4223-ae6c-23b7b0227b30" xlink:to="loc_us-gaap_SegmentDomain_156dfe1e-224e-4f5f-9717-6aa4baa9946f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_d86b9543-7d54-4864-8b55-ef44143b6668" xlink:href="jnj-20241229.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_156dfe1e-224e-4f5f-9717-6aa4baa9946f" xlink:to="loc_jnj_PharmaceuticalMember_d86b9543-7d54-4864-8b55-ef44143b6668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_84b33693-e977-4341-8715-fcec340f81f8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_320ee46f-fd3a-4e54-83c3-19aad6a7bc29" xlink:to="loc_srt_ProductOrServiceAxis_84b33693-e977-4341-8715-fcec340f81f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f04df2d5-6e67-42d8-8e25-100f1a1ff7d2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_84b33693-e977-4341-8715-fcec340f81f8" xlink:to="loc_srt_ProductsAndServicesDomain_f04df2d5-6e67-42d8-8e25-100f1a1ff7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_e9f5812e-2e25-4887-9dab-174a63ae88c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f04df2d5-6e67-42d8-8e25-100f1a1ff7d2" xlink:to="loc_us-gaap_ShippingAndHandlingMember_e9f5812e-2e25-4887-9dab-174a63ae88c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f72ab68c-5117-4f6f-93b6-c72ed2bd252a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_320ee46f-fd3a-4e54-83c3-19aad6a7bc29" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f72ab68c-5117-4f6f-93b6-c72ed2bd252a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4d603d2e-fa47-41b8-9f47-bcd0c70bf379" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f72ab68c-5117-4f6f-93b6-c72ed2bd252a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4d603d2e-fa47-41b8-9f47-bcd0c70bf379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2b5aad78-62ec-41d1-b73f-a00f959cd9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4d603d2e-fa47-41b8-9f47-bcd0c70bf379" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2b5aad78-62ec-41d1-b73f-a00f959cd9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3f3e4f60-734c-4b32-9415-8b67631347a8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_320ee46f-fd3a-4e54-83c3-19aad6a7bc29" xlink:to="loc_srt_RangeAxis_3f3e4f60-734c-4b32-9415-8b67631347a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0306beaf-3022-4f4a-ae5f-641b9503d3d0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3f3e4f60-734c-4b32-9415-8b67631347a8" xlink:to="loc_srt_RangeMember_0306beaf-3022-4f4a-ae5f-641b9503d3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0a2a2754-c258-4cc2-976f-ae516042282f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0306beaf-3022-4f4a-ae5f-641b9503d3d0" xlink:to="loc_srt_MinimumMember_0a2a2754-c258-4cc2-976f-ae516042282f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_09f735a8-50a8-4bca-979c-0af5a331116e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0306beaf-3022-4f4a-ae5f-641b9503d3d0" xlink:to="loc_srt_MaximumMember_09f735a8-50a8-4bca-979c-0af5a331116e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0898cc60-d33a-4f67-9e04-40a9309a8788" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_320ee46f-fd3a-4e54-83c3-19aad6a7bc29" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0898cc60-d33a-4f67-9e04-40a9309a8788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_34a5efa0-101c-4cf5-a382-563b97ad3658" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0898cc60-d33a-4f67-9e04-40a9309a8788" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_34a5efa0-101c-4cf5-a382-563b97ad3658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_6892da83-def5-429b-aefe-26b4af211dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_34a5efa0-101c-4cf5-a382-563b97ad3658" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_6892da83-def5-429b-aefe-26b4af211dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_8b18c924-2414-4407-b1ff-eaf348f7f492" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_320ee46f-fd3a-4e54-83c3-19aad6a7bc29" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_8b18c924-2414-4407-b1ff-eaf348f7f492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_833dc7e0-c4c0-4595-a644-4b9344625503" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8b18c924-2414-4407-b1ff-eaf348f7f492" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_833dc7e0-c4c0-4595-a644-4b9344625503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_0873c504-6941-4035-951a-f276ca011559" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_833dc7e0-c4c0-4595-a644-4b9344625503" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_0873c504-6941-4035-951a-f276ca011559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_62bc16a2-b511-47e8-bd15-edc167f7d5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_320ee46f-fd3a-4e54-83c3-19aad6a7bc29" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_62bc16a2-b511-47e8-bd15-edc167f7d5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3236e0bf-4834-4021-9f59-a25609add569" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_62bc16a2-b511-47e8-bd15-edc167f7d5a7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3236e0bf-4834-4021-9f59-a25609add569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_eef957d6-9ac3-4dfd-b361-b4def30011ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3236e0bf-4834-4021-9f59-a25609add569" xlink:to="loc_us-gaap_IPOMember_eef957d6-9ac3-4dfd-b361-b4def30011ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6cd900ac-75f4-4c02-a68c-48aec3e765c0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_320ee46f-fd3a-4e54-83c3-19aad6a7bc29" xlink:to="loc_dei_LegalEntityAxis_6cd900ac-75f4-4c02-a68c-48aec3e765c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3d0200dd-a080-4ddc-8592-d4a8ce8dee79" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_6cd900ac-75f4-4c02-a68c-48aec3e765c0" xlink:to="loc_dei_EntityDomain_3d0200dd-a080-4ddc-8592-d4a8ce8dee79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KenvueIncMember_6cf316bb-8845-4391-830a-a7c425939d0a" xlink:href="jnj-20241229.xsd#jnj_KenvueIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3d0200dd-a080-4ddc-8592-d4a8ce8dee79" xlink:to="loc_jnj_KenvueIncMember_6cf316bb-8845-4391-830a-a7c425939d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_JohnsonJohnsonMember_a5f13a87-a780-4277-95e3-f2eb65163c82" xlink:href="jnj-20241229.xsd#jnj_JohnsonJohnsonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3d0200dd-a080-4ddc-8592-d4a8ce8dee79" xlink:to="loc_jnj_JohnsonJohnsonMember_a5f13a87-a780-4277-95e3-f2eb65163c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_0bab7da9-7016-4cb0-94b1-fbbaf667aae0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_320ee46f-fd3a-4e54-83c3-19aad6a7bc29" xlink:to="loc_srt_OwnershipAxis_0bab7da9-7016-4cb0-94b1-fbbaf667aae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_9e21e66b-a034-42c9-9958-108405dfe213" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_0bab7da9-7016-4cb0-94b1-fbbaf667aae0" xlink:to="loc_srt_OwnershipDomain_9e21e66b-a034-42c9-9958-108405dfe213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KenvueIncMember_43da6dd0-5f45-4ed4-9f81-a68fc9e8bd13" xlink:href="jnj-20241229.xsd#jnj_KenvueIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_9e21e66b-a034-42c9-9958-108405dfe213" xlink:to="loc_jnj_KenvueIncMember_43da6dd0-5f45-4ed4-9f81-a68fc9e8bd13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_222e226f-ef5e-4861-8635-338a27be2e44" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_320ee46f-fd3a-4e54-83c3-19aad6a7bc29" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_222e226f-ef5e-4861-8635-338a27be2e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_61cde546-99d6-4960-9cfb-7e12eb0391ed" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_222e226f-ef5e-4861-8635-338a27be2e44" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_61cde546-99d6-4960-9cfb-7e12eb0391ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KenvueIncMember_3712ffb4-217c-4f3b-aaa5-2576661aa2a6" xlink:href="jnj-20241229.xsd#jnj_KenvueIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_61cde546-99d6-4960-9cfb-7e12eb0391ed" xlink:to="loc_jnj_KenvueIncMember_3712ffb4-217c-4f3b-aaa5-2576661aa2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_96f9f02f-b7b2-4e30-a721-2d4a367f648f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_320ee46f-fd3a-4e54-83c3-19aad6a7bc29" xlink:to="loc_us-gaap_AssetAcquisitionAxis_96f9f02f-b7b2-4e30-a721-2d4a367f648f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_717a1112-5276-486b-a39b-bdbddfe47cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_96f9f02f-b7b2-4e30-a721-2d4a367f648f" xlink:to="loc_us-gaap_AssetAcquisitionDomain_717a1112-5276-486b-a39b-bdbddfe47cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_YellowJerseyTherapeuticsMember_ac5712a0-1956-441d-b5fc-a2eb7bd977a3" xlink:href="jnj-20241229.xsd#jnj_YellowJerseyTherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_717a1112-5276-486b-a39b-bdbddfe47cc8" xlink:to="loc_jnj_YellowJerseyTherapeuticsMember_ac5712a0-1956-441d-b5fc-a2eb7bd977a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:href="jnj-20241229.xsd#jnj_ConcentrationOfCreditRiskLineItems"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_320ee46f-fd3a-4e54-83c3-19aad6a7bc29" xlink:to="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide_2833127a-80d2-4afc-b99b-12b1b9498c43" xlink:href="jnj-20241229.xsd#jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide_2833127a-80d2-4afc-b99b-12b1b9498c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_eaeb2bfc-f2fc-4bf0-869a-93fc40d5fe9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_eaeb2bfc-f2fc-4bf0-869a-93fc40d5fe9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_96e96c76-2d76-4f16-bffb-e61c0adbbd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_96e96c76-2d76-4f16-bffb-e61c0adbbd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_3db88235-0610-4e9f-904d-091354e63ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_3db88235-0610-4e9f-904d-091354e63ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_d07538d4-cc67-4f59-84a0-f079797f7eef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_d07538d4-cc67-4f59-84a0-f079797f7eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_7a2356c0-3d3f-4b7a-8159-e28b096feb37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_7a2356c0-3d3f-4b7a-8159-e28b096feb37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_d89b0244-2fc9-4c89-be57-f802ceaba90b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_d89b0244-2fc9-4c89-be57-f802ceaba90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_109887ef-9360-4af5-805f-7542f6fda62f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_CommonStockValueOutstanding_109887ef-9360-4af5-805f-7542f6fda62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OwnershipPercentageSplitOffPercent_365a6772-9cce-4f0b-9d3b-16390c8c4e6f" xlink:href="jnj-20241229.xsd#jnj_OwnershipPercentageSplitOffPercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_OwnershipPercentageSplitOffPercent_365a6772-9cce-4f0b-9d3b-16390c8c4e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExchangeOfStockPercentageOwnershipAfterTransaction_07bca1d5-5bcb-4f41-8f32-bf9db6113028" xlink:href="jnj-20241229.xsd#jnj_ExchangeOfStockPercentageOwnershipAfterTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_ExchangeOfStockPercentageOwnershipAfterTransaction_07bca1d5-5bcb-4f41-8f32-bf9db6113028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_369f1312-5a60-4190-a31e-5b7ec9f40e17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_NumberOfReportableSegments_369f1312-5a60-4190-a31e-5b7ec9f40e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationCurrent_1fe98302-4a06-4e76-b2a6-a948baa5b8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligationCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_SupplierFinanceProgramObligationCurrent_1fe98302-4a06-4e76-b2a6-a948baa5b8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration_70d4a7ea-2202-4673-896d-e83042e96d54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration_70d4a7ea-2202-4673-896d-e83042e96d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement_e59d1987-68b8-408e-a88f-13d41d796264" xlink:href="jnj-20241229.xsd#jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement_e59d1987-68b8-408e-a88f-13d41d796264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f3406898-a5c0-43b3-83c4-2c09ad02a8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f3406898-a5c0-43b3-83c4-2c09ad02a8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RevenuePerformanceObligationPaymentTerms_c492dda8-3d96-4782-892b-44cbe234c9bd" xlink:href="jnj-20241229.xsd#jnj_RevenuePerformanceObligationPaymentTerms"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_RevenuePerformanceObligationPaymentTerms_c492dda8-3d96-4782-892b-44cbe234c9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions_20707d8a-b043-4cf5-8b93-a0a8eab3226d" xlink:href="jnj-20241229.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_AccruedRebatesReturnsAndPromotions_20707d8a-b043-4cf5-8b93-a0a8eab3226d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesReturnReserve_5e39725c-9c5f-49b9-95a2-fa527dd27897" xlink:href="jnj-20241229.xsd#jnj_SalesReturnReserve"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_SalesReturnReserve_5e39725c-9c5f-49b9-95a2-fa527dd27897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProfitLossPercentToSales_715ad4c0-6b9f-48b8-b741-886a432be7dc" xlink:href="jnj-20241229.xsd#jnj_ProfitLossPercentToSales"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_ProfitLossPercentToSales_715ad4c0-6b9f-48b8-b741-886a432be7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5c1005bd-7565-4547-a9e6-ecaaf186cc00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5c1005bd-7565-4547-a9e6-ecaaf186cc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShippingandHandlingCostsasaPercentofSales_27a3c90a-b38b-4318-b557-a1e26571f358" xlink:href="jnj-20241229.xsd#jnj_ShippingandHandlingCostsasaPercentofSales"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_ShippingandHandlingCostsasaPercentofSales_27a3c90a-b38b-4318-b557-a1e26571f358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_c65cc2bd-30cc-4fb3-a6a8-dc1185f94772" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_c65cc2bd-30cc-4fb3-a6a8-dc1185f94772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_70a8957e-ffbd-482f-a939-d2c91bc31ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_70a8957e-ffbd-482f-a939-d2c91bc31ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_bd56176d-83eb-41e3-8ceb-22b89f71d399" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_bd56176d-83eb-41e3-8ceb-22b89f71d399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3da7799c-5578-4e4f-b346-9c928547c318" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3da7799c-5578-4e4f-b346-9c928547c318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_075e715f-1e2f-4435-ba61-d892965e9226" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_OperatingLeaseLiability_075e715f-1e2f-4435-ba61-d892965e9226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_7cc1e3fa-6894-41b1-89dd-dba5ed97c166" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_OperatingLeaseCost_7cc1e3fa-6894-41b1-89dd-dba5ed97c166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_40167cf2-8566-496d-8a64-caa3ba66a849" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_OperatingLeasePayments_40167cf2-8566-496d-8a64-caa3ba66a849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationRiskThresholdPercentage_ed9d0afb-25d8-49ec-8079-395ffb07250f" xlink:href="jnj-20241229.xsd#jnj_ConcentrationRiskThresholdPercentage"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_ConcentrationRiskThresholdPercentage_ed9d0afb-25d8-49ec-8079-395ffb07250f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_36d47c84-efbb-4c5d-9ad6-5106cfc53a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_AdvertisingExpense_36d47c84-efbb-4c5d-9ad6-5106cfc53a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_b603ac13-fbc9-4062-82ae-e493c7a14387" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_b603ac13-fbc9-4062-82ae-e493c7a14387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent_2b8fa6b6-66e0-40c0-adc1-f0723a34f582" xlink:href="jnj-20241229.xsd#jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent_2b8fa6b6-66e0-40c0-adc1-f0723a34f582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent_ea16f4fb-47fe-4756-82cf-af58f13a9179" xlink:href="jnj-20241229.xsd#jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent_ea16f4fb-47fe-4756-82cf-af58f13a9179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsPaymentPeriod_acfe25cb-7fb0-4878-8b16-9b892cc792f6" xlink:href="jnj-20241229.xsd#jnj_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsPaymentPeriod"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsPaymentPeriod_acfe25cb-7fb0-4878-8b16-9b892cc792f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent_986b035f-e703-4e5c-839d-93ea2be24b43" xlink:href="jnj-20241229.xsd#jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent_986b035f-e703-4e5c-839d-93ea2be24b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_20643de8-9d93-46db-b310-8b6baa358d24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_20643de8-9d93-46db-b310-8b6baa358d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a5ea6c82-6352-4db4-a773-fed5fb4cbd2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a5ea6c82-6352-4db4-a773-fed5fb4cbd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationCurrent_9260a671-05d2-4b79-abda-d1f734a43b13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligationCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramPaymentTimingPeriod_777b70d4-2fa8-44b7-ac33-a0cd62aa38e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramPaymentTimingPeriod"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_SupplierFinanceProgramPaymentTimingPeriod_777b70d4-2fa8-44b7-ac33-a0cd62aa38e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_88a611ff-e504-44dc-abaa-e63b27089ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_6d32a2a7-db06-466c-a276-c0630f165b45" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_88a611ff-e504-44dc-abaa-e63b27089ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_05d8a83c-d6fb-4c24-ba10-46bbc98a3e11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_87422850-e242-47d0-a767-89570da1f5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05d8a83c-d6fb-4c24-ba10-46bbc98a3e11" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_87422850-e242-47d0-a767-89570da1f5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a241505e-2233-48c2-b0f2-fcca38c35e29" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_87422850-e242-47d0-a767-89570da1f5a8" xlink:to="loc_srt_RangeAxis_a241505e-2233-48c2-b0f2-fcca38c35e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_618d8d60-954b-43cb-9c77-ae0467878b8d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a241505e-2233-48c2-b0f2-fcca38c35e29" xlink:to="loc_srt_RangeMember_618d8d60-954b-43cb-9c77-ae0467878b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e16f7724-4e79-452d-96fc-fc8b98748466" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_618d8d60-954b-43cb-9c77-ae0467878b8d" xlink:to="loc_srt_MinimumMember_e16f7724-4e79-452d-96fc-fc8b98748466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_12ddbd71-f37b-4e91-aa79-aac916b77268" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_618d8d60-954b-43cb-9c77-ae0467878b8d" xlink:to="loc_srt_MaximumMember_12ddbd71-f37b-4e91-aa79-aac916b77268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fcc6eaf4-0e5e-4d17-97c2-80ac9e99e365" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_87422850-e242-47d0-a767-89570da1f5a8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fcc6eaf4-0e5e-4d17-97c2-80ac9e99e365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0510ebd6-862e-4d77-944d-9608b291d8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fcc6eaf4-0e5e-4d17-97c2-80ac9e99e365" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0510ebd6-862e-4d77-944d-9608b291d8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_751e0102-40c8-4de7-9809-588ed4097a73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0510ebd6-862e-4d77-944d-9608b291d8f3" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_751e0102-40c8-4de7-9809-588ed4097a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LandAndLeaseholdImprovementsMember_29b95507-79e4-4ae9-9e3f-6e48534d87a4" xlink:href="jnj-20241229.xsd#jnj_LandAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0510ebd6-862e-4d77-944d-9608b291d8f3" xlink:to="loc_jnj_LandAndLeaseholdImprovementsMember_29b95507-79e4-4ae9-9e3f-6e48534d87a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_3f2342ff-5331-405e-b018-1a42638d6eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0510ebd6-862e-4d77-944d-9608b291d8f3" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_3f2342ff-5331-405e-b018-1a42638d6eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a033eeda-88c6-426e-9068-12a32c30c5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_87422850-e242-47d0-a767-89570da1f5a8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a033eeda-88c6-426e-9068-12a32c30c5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7e57cae0-5806-4293-8c56-5ddbba83e07e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a033eeda-88c6-426e-9068-12a32c30c5f4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7e57cae0-5806-4293-8c56-5ddbba83e07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesSupplierFinanceProgramDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#SummaryofsignificantaccountingpoliciesSupplierFinanceProgramDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesSupplierFinanceProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_12c97ff7-c911-42c0-89cc-b80d2d96ef60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationRollForward_7dfdbb83-8814-4e68-a17e-4479a964353d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12c97ff7-c911-42c0-89cc-b80d2d96ef60" xlink:to="loc_us-gaap_SupplierFinanceProgramObligationRollForward_7dfdbb83-8814-4e68-a17e-4479a964353d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationCurrent_79870552-e7d5-4f9f-bc3d-59c40bf9fe84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligationCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplierFinanceProgramObligationRollForward_7dfdbb83-8814-4e68-a17e-4479a964353d" xlink:to="loc_us-gaap_SupplierFinanceProgramObligationCurrent_79870552-e7d5-4f9f-bc3d-59c40bf9fe84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationIncrease_54d57c89-0d46-4797-83dd-ef8f8c236449" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligationIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplierFinanceProgramObligationRollForward_7dfdbb83-8814-4e68-a17e-4479a964353d" xlink:to="loc_us-gaap_SupplierFinanceProgramObligationIncrease_54d57c89-0d46-4797-83dd-ef8f8c236449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationDecreaseSettlement_81c75538-2840-4689-9a79-cd074379e5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligationDecreaseSettlement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplierFinanceProgramObligationRollForward_7dfdbb83-8814-4e68-a17e-4479a964353d" xlink:to="loc_us-gaap_SupplierFinanceProgramObligationDecreaseSettlement_81c75538-2840-4689-9a79-cd074379e5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationCurrent_5b0c5047-75ef-407d-b8c1-4ea40bcedfbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplierFinanceProgramObligationCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplierFinanceProgramObligationRollForward_7dfdbb83-8814-4e68-a17e-4479a964353d" xlink:to="loc_us-gaap_SupplierFinanceProgramObligationCurrent_5b0c5047-75ef-407d-b8c1-4ea40bcedfbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_58318248-02ea-4fe1-9506-5de212b7f047" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4037a68d-e8b1-4364-9e83-011c20a16f72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_58318248-02ea-4fe1-9506-5de212b7f047" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4037a68d-e8b1-4364-9e83-011c20a16f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_27863df8-865d-4ddf-ad42-41c74afdd200" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4037a68d-e8b1-4364-9e83-011c20a16f72" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_27863df8-865d-4ddf-ad42-41c74afdd200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_b3e0a658-21be-4b13-bb6e-41c2cdff2175" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_27863df8-865d-4ddf-ad42-41c74afdd200" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_b3e0a658-21be-4b13-bb6e-41c2cdff2175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember_e3d8cda5-464a-49ca-8152-43b5f0f7ad4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_b3e0a658-21be-4b13-bb6e-41c2cdff2175" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesMember_e3d8cda5-464a-49ca-8152-43b5f0f7ad4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_911305a5-3388-4c05-9d86-79129aefb6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_b3e0a658-21be-4b13-bb6e-41c2cdff2175" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_911305a5-3388-4c05-9d86-79129aefb6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8f8c547a-730b-4a18-b6e8-287daaa1b548" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4037a68d-e8b1-4364-9e83-011c20a16f72" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8f8c547a-730b-4a18-b6e8-287daaa1b548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01e23d99-e8ba-47a4-8b58-26673faba0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8f8c547a-730b-4a18-b6e8-287daaa1b548" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01e23d99-e8ba-47a4-8b58-26673faba0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_d140b678-1585-4671-99ce-c850284971d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01e23d99-e8ba-47a4-8b58-26673faba0e3" xlink:to="loc_us-gaap_CashMember_d140b678-1585-4671-99ce-c850284971d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_9ed66445-7984-458e-ab6c-f66412a82a33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01e23d99-e8ba-47a4-8b58-26673faba0e3" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_9ed66445-7984-458e-ab6c-f66412a82a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_a4eab89e-eedc-4efd-9d16-c27e9737f13f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01e23d99-e8ba-47a4-8b58-26673faba0e3" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_a4eab89e-eedc-4efd-9d16-c27e9737f13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_90262701-e62c-4d16-b864-484059523ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01e23d99-e8ba-47a4-8b58-26673faba0e3" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_90262701-e62c-4d16-b864-484059523ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_e8f0d55e-e23a-47af-ba1b-792da1c8b4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01e23d99-e8ba-47a4-8b58-26673faba0e3" xlink:to="loc_us-gaap_MoneyMarketFundsMember_e8f0d55e-e23a-47af-ba1b-792da1c8b4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_e9d868af-da4a-4ad9-82ce-7d5d2d7359a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01e23d99-e8ba-47a4-8b58-26673faba0e3" xlink:to="loc_us-gaap_BankTimeDepositsMember_e9d868af-da4a-4ad9-82ce-7d5d2d7359a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_35fa7579-5f45-489f-9577-8b74557c38b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01e23d99-e8ba-47a4-8b58-26673faba0e3" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_35fa7579-5f45-489f-9577-8b74557c38b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d93d2aee-b99e-41d5-9f32-6d0db55e1582" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01e23d99-e8ba-47a4-8b58-26673faba0e3" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d93d2aee-b99e-41d5-9f32-6d0db55e1582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherSovereignSecuritiesMember_552da266-c7d5-45ca-967b-7d330fe36b63" xlink:href="jnj-20241229.xsd#jnj_OtherSovereignSecuritiesMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01e23d99-e8ba-47a4-8b58-26673faba0e3" xlink:to="loc_jnj_OtherSovereignSecuritiesMember_552da266-c7d5-45ca-967b-7d330fe36b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_8eca1bfa-d4ac-424a-a8d6-6224755df3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4037a68d-e8b1-4364-9e83-011c20a16f72" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_8eca1bfa-d4ac-424a-a8d6-6224755df3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_4957fb59-ec4a-4803-801b-25c0a36c6435" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_8eca1bfa-d4ac-424a-a8d6-6224755df3bf" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_4957fb59-ec4a-4803-801b-25c0a36c6435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_33f2e5eb-2c85-4283-a142-8f9a2d01052b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_4957fb59-ec4a-4803-801b-25c0a36c6435" xlink:to="loc_us-gaap_HeldToMaturitySecurities_33f2e5eb-2c85-4283-a142-8f9a2d01052b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_798a5fe3-3713-42cb-b2d6-24eb90fa51d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_4957fb59-ec4a-4803-801b-25c0a36c6435" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_798a5fe3-3713-42cb-b2d6-24eb90fa51d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_d6e910a1-75ac-4ac7-b181-11524c452ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_4957fb59-ec4a-4803-801b-25c0a36c6435" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_d6e910a1-75ac-4ac7-b181-11524c452ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b70bcf65-05fb-4004-a67c-5f94cdd12927" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_4957fb59-ec4a-4803-801b-25c0a36c6435" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b70bcf65-05fb-4004-a67c-5f94cdd12927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_278be3f6-c1e4-4b00-bce0-8a2288a9d692" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_4957fb59-ec4a-4803-801b-25c0a36c6435" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_278be3f6-c1e4-4b00-bce0-8a2288a9d692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_30cc061d-398a-4678-a34d-847acf1041ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_4957fb59-ec4a-4803-801b-25c0a36c6435" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_30cc061d-398a-4678-a34d-847acf1041ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_219ed067-41ed-4e31-a6f1-dc3a50c760f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_4957fb59-ec4a-4803-801b-25c0a36c6435" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_219ed067-41ed-4e31-a6f1-dc3a50c760f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0d92e80e-fd2d-43c0-8564-800aea64c9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_4957fb59-ec4a-4803-801b-25c0a36c6435" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0d92e80e-fd2d-43c0-8564-800aea64c9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a4d2c379-d924-4127-a3c4-f9e1d9164486" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_4957fb59-ec4a-4803-801b-25c0a36c6435" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a4d2c379-d924-4127-a3c4-f9e1d9164486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_1684ece0-85e7-43ef-8164-7cca8f28cbda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_4957fb59-ec4a-4803-801b-25c0a36c6435" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_1684ece0-85e7-43ef-8164-7cca8f28cbda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_53774b2e-838f-4713-b201-fb4e74a472cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_e4168f90-b5c3-4f89-9bf4-9a3aa85fdfc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_53774b2e-838f-4713-b201-fb4e74a472cc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_e4168f90-b5c3-4f89-9bf4-9a3aa85fdfc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_84eaed6c-c5e7-4260-bbd0-0ab2542d4493" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_e4168f90-b5c3-4f89-9bf4-9a3aa85fdfc1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_84eaed6c-c5e7-4260-bbd0-0ab2542d4493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_23f73567-5274-43a7-a58c-fd18a8d70796" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_e4168f90-b5c3-4f89-9bf4-9a3aa85fdfc1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_23f73567-5274-43a7-a58c-fd18a8d70796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_2feec980-a3e1-467a-ba13-dc1eafa5740c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_e4168f90-b5c3-4f89-9bf4-9a3aa85fdfc1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_2feec980-a3e1-467a-ba13-dc1eafa5740c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_af5bf9f1-5d98-4713-93f6-233d4de7ef8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_e4168f90-b5c3-4f89-9bf4-9a3aa85fdfc1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_af5bf9f1-5d98-4713-93f6-233d4de7ef8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_00df317b-c19c-4fb7-ab21-7c498697082f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_53774b2e-838f-4713-b201-fb4e74a472cc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_00df317b-c19c-4fb7-ab21-7c498697082f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7e37f65d-dc9d-4f60-8fce-f408fb274899" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_00df317b-c19c-4fb7-ab21-7c498697082f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7e37f65d-dc9d-4f60-8fce-f408fb274899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_a0afddb6-dacf-47e9-9a3f-72bbbf833ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_00df317b-c19c-4fb7-ab21-7c498697082f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_a0afddb6-dacf-47e9-9a3f-72bbbf833ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_03266a8a-9e6a-4213-9859-d3019b004036" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_00df317b-c19c-4fb7-ab21-7c498697082f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_03266a8a-9e6a-4213-9859-d3019b004036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_4e5ad281-92ad-4e55-afcf-08c5d25d9b33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_00df317b-c19c-4fb7-ab21-7c498697082f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_4e5ad281-92ad-4e55-afcf-08c5d25d9b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_7956f4b0-a414-471e-a7cc-1103daa375c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract_09049dfa-bfb9-446c-ae00-4175df938078" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_7956f4b0-a414-471e-a7cc-1103daa375c8" xlink:to="loc_us-gaap_InventoryNetAbstract_09049dfa-bfb9-446c-ae00-4175df938078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_62381c44-850e-4a87-92c4-5f305d3e1345" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_09049dfa-bfb9-446c-ae00-4175df938078" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_62381c44-850e-4a87-92c4-5f305d3e1345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_9665efd7-01d8-4a7e-a3cb-a224d39b81f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_09049dfa-bfb9-446c-ae00-4175df938078" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_9665efd7-01d8-4a7e-a3cb-a224d39b81f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_ddee67b5-ef34-4d9e-8ba4-f8ec305c3ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_09049dfa-bfb9-446c-ae00-4175df938078" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_ddee67b5-ef34-4d9e-8ba4-f8ec305c3ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_eed0fe50-ff11-4ce3-93a6-123e15094501" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_09049dfa-bfb9-446c-ae00-4175df938078" xlink:to="loc_us-gaap_InventoryNet_eed0fe50-ff11-4ce3-93a6-123e15094501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_84f0c673-1d70-4063-8d58-a626d9aa52b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d57924e1-6362-42f1-9b9a-98279f7b99f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_84f0c673-1d70-4063-8d58-a626d9aa52b5" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d57924e1-6362-42f1-9b9a-98279f7b99f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e5175cf8-c38a-4504-86dc-d94e4d1d8a42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d57924e1-6362-42f1-9b9a-98279f7b99f0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e5175cf8-c38a-4504-86dc-d94e4d1d8a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_26561d73-7a54-454a-8d4e-a940115e1e72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e5175cf8-c38a-4504-86dc-d94e4d1d8a42" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_26561d73-7a54-454a-8d4e-a940115e1e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LandAndLeaseholdImprovementsMember_0cbeabf5-b06e-4a73-b722-a205f7b48170" xlink:href="jnj-20241229.xsd#jnj_LandAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_26561d73-7a54-454a-8d4e-a940115e1e72" xlink:to="loc_jnj_LandAndLeaseholdImprovementsMember_0cbeabf5-b06e-4a73-b722-a205f7b48170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_ff247409-cf9e-4317-ace0-7f86656eed2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_26561d73-7a54-454a-8d4e-a940115e1e72" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_ff247409-cf9e-4317-ace0-7f86656eed2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_24c40446-71cb-45c7-8d0b-ad3f4289442e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_26561d73-7a54-454a-8d4e-a940115e1e72" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_24c40446-71cb-45c7-8d0b-ad3f4289442e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_2051bf15-a184-4afc-9a12-dd003c379910" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_26561d73-7a54-454a-8d4e-a940115e1e72" xlink:to="loc_us-gaap_ConstructionInProgressMember_2051bf15-a184-4afc-9a12-dd003c379910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e4766893-561a-45c2-8a64-7093d24b9093" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d57924e1-6362-42f1-9b9a-98279f7b99f0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e4766893-561a-45c2-8a64-7093d24b9093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_965710c0-118a-407d-bbdc-5aad844ed495" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e4766893-561a-45c2-8a64-7093d24b9093" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_965710c0-118a-407d-bbdc-5aad844ed495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_151a8e0f-8cd3-48d7-8514-d37db1003d62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e4766893-561a-45c2-8a64-7093d24b9093" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_151a8e0f-8cd3-48d7-8514-d37db1003d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_43d1a22d-a38a-47b0-92e1-3efe9024e3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e4766893-561a-45c2-8a64-7093d24b9093" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_43d1a22d-a38a-47b0-92e1-3efe9024e3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyplantandequipmentNarrativeDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#PropertyplantandequipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PropertyplantandequipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_85a6a319-a5a2-41a8-b326-4b4658ade996" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_a2d3876c-eb34-4ba8-baca-528742f15ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_85a6a319-a5a2-41a8-b326-4b4658ade996" xlink:to="loc_us-gaap_InterestCostsCapitalized_a2d3876c-eb34-4ba8-baca-528742f15ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest_0bc3ee21-d691-43f9-9383-7e47050227ec" xlink:href="jnj-20241229.xsd#jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_85a6a319-a5a2-41a8-b326-4b4658ade996" xlink:to="loc_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest_0bc3ee21-d691-43f9-9383-7e47050227ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e5056f80-2071-47be-9608-2a552b38c48c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_e4e387ef-06c3-4012-b751-0fc61e5be577" xlink:href="jnj-20241229.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e5056f80-2071-47be-9608-2a552b38c48c" xlink:to="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_e4e387ef-06c3-4012-b751-0fc61e5be577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_89266570-a750-459d-90ee-cf2522ad14d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_e4e387ef-06c3-4012-b751-0fc61e5be577" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_89266570-a750-459d-90ee-cf2522ad14d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eb941a64-cac7-4ebe-93fc-d37b9fb7cac5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_89266570-a750-459d-90ee-cf2522ad14d2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eb941a64-cac7-4ebe-93fc-d37b9fb7cac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_f1ffd67e-b7d4-46b0-8762-7bbb57eb8ae8" xlink:href="jnj-20241229.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eb941a64-cac7-4ebe-93fc-d37b9fb7cac5" xlink:to="loc_jnj_PatentsAndTrademarksMember_f1ffd67e-b7d4-46b0-8762-7bbb57eb8ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_f9e526f5-2fdd-4679-b270-0a9e3fe55e93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eb941a64-cac7-4ebe-93fc-d37b9fb7cac5" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_f9e526f5-2fdd-4679-b270-0a9e3fe55e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_2a15d081-e396-45f6-97c2-e122fd9eccf5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eb941a64-cac7-4ebe-93fc-d37b9fb7cac5" xlink:to="loc_us-gaap_TrademarksMember_2a15d081-e396-45f6-97c2-e122fd9eccf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8368751b-bae5-4a67-b4f5-75a471bb0249" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_e4e387ef-06c3-4012-b751-0fc61e5be577" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8368751b-bae5-4a67-b4f5-75a471bb0249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c6ab608a-1501-4093-af35-15b02138b831" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8368751b-bae5-4a67-b4f5-75a471bb0249" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c6ab608a-1501-4093-af35-15b02138b831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_2985527f-e4e0-42ba-95d3-c6d0af25ce3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c6ab608a-1501-4093-af35-15b02138b831" xlink:to="loc_us-gaap_TrademarksMember_2985527f-e4e0-42ba-95d3-c6d0af25ce3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_54aea8ac-1b4e-4497-9a48-a8b27701ce26" xlink:href="jnj-20241229.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c6ab608a-1501-4093-af35-15b02138b831" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_54aea8ac-1b4e-4497-9a48-a8b27701ce26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_842c47d1-95aa-4a5a-9a9a-99a9d73ca376" xlink:href="jnj-20241229.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_e4e387ef-06c3-4012-b751-0fc61e5be577" xlink:to="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_842c47d1-95aa-4a5a-9a9a-99a9d73ca376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b8245cd9-5566-4eb6-962f-cece48aae586" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_842c47d1-95aa-4a5a-9a9a-99a9d73ca376" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b8245cd9-5566-4eb6-962f-cece48aae586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_e7b70673-7eb2-4367-ad49-32997e823df7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b8245cd9-5566-4eb6-962f-cece48aae586" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_e7b70673-7eb2-4367-ad49-32997e823df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e3fd8be2-5eda-4a18-ac97-95b5ec5d323e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_e7b70673-7eb2-4367-ad49-32997e823df7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e3fd8be2-5eda-4a18-ac97-95b5ec5d323e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2e8db78d-ce6d-4a92-9e45-e9b3dd08f0af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_e7b70673-7eb2-4367-ad49-32997e823df7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2e8db78d-ce6d-4a92-9e45-e9b3dd08f0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7897864f-b516-4b34-b6a1-5cd98fc02d32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_e7b70673-7eb2-4367-ad49-32997e823df7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7897864f-b516-4b34-b6a1-5cd98fc02d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_48bb8058-ff03-4370-ad55-327a0ab88522" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b8245cd9-5566-4eb6-962f-cece48aae586" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_48bb8058-ff03-4370-ad55-327a0ab88522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1657d761-8155-45e8-af7d-15172317fd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_48bb8058-ff03-4370-ad55-327a0ab88522" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1657d761-8155-45e8-af7d-15172317fd6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a6243a07-f755-4284-8efc-d64d5ecba83c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_48bb8058-ff03-4370-ad55-327a0ab88522" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a6243a07-f755-4284-8efc-d64d5ecba83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_dc4a7636-869a-4142-8b5f-7a1f8700589e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_842c47d1-95aa-4a5a-9a9a-99a9d73ca376" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_dc4a7636-869a-4142-8b5f-7a1f8700589e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#IntangibleassetsandgoodwillGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_aabb04f4-2ded-4878-800e-7225fc70b979" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_535bd772-c331-4ba8-8118-55726a0b6867" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_aabb04f4-2ded-4878-800e-7225fc70b979" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_535bd772-c331-4ba8-8118-55726a0b6867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7aeace2c-e708-43e0-903a-043892a85a25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_535bd772-c331-4ba8-8118-55726a0b6867" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7aeace2c-e708-43e0-903a-043892a85a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_08a84def-83d1-480d-88cd-158842bda448" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7aeace2c-e708-43e0-903a-043892a85a25" xlink:to="loc_us-gaap_SegmentDomain_08a84def-83d1-480d-88cd-158842bda448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InnovativeMedicineMember_e99cf5e8-589b-47a3-871d-5c1d768bf983" xlink:href="jnj-20241229.xsd#jnj_InnovativeMedicineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_08a84def-83d1-480d-88cd-158842bda448" xlink:to="loc_jnj_InnovativeMedicineMember_e99cf5e8-589b-47a3-871d-5c1d768bf983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedTechMember_6b0834f3-4483-44b7-bd6a-35fb8ffdf448" xlink:href="jnj-20241229.xsd#jnj_MedTechMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_08a84def-83d1-480d-88cd-158842bda448" xlink:to="loc_jnj_MedTechMember_6b0834f3-4483-44b7-bd6a-35fb8ffdf448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_2082881e-38cd-4d31-bae6-111504bbb26b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_535bd772-c331-4ba8-8118-55726a0b6867" xlink:to="loc_us-gaap_GoodwillLineItems_2082881e-38cd-4d31-bae6-111504bbb26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_c200e3d3-9cf0-4172-b859-dcf7bce0d71a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_2082881e-38cd-4d31-bae6-111504bbb26b" xlink:to="loc_us-gaap_GoodwillRollForward_c200e3d3-9cf0-4172-b859-dcf7bce0d71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3324220e-1427-44c4-86ec-d7dd743e964e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_c200e3d3-9cf0-4172-b859-dcf7bce0d71a" xlink:to="loc_us-gaap_Goodwill_3324220e-1427-44c4-86ec-d7dd743e964e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_8f30d96d-568f-4101-b47b-cfe413cc2f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_c200e3d3-9cf0-4172-b859-dcf7bce0d71a" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_8f30d96d-568f-4101-b47b-cfe413cc2f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_2577ebc3-1ee8-490a-8639-b07874340abd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_c200e3d3-9cf0-4172-b859-dcf7bce0d71a" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_2577ebc3-1ee8-490a-8639-b07874340abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_ccf00040-3f51-4dc3-8a51-73a7a1ff89c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_c200e3d3-9cf0-4172-b859-dcf7bce0d71a" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_ccf00040-3f51-4dc3-8a51-73a7a1ff89c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_acb1b3c8-6f07-43ab-9460-acb13d634284" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_c200e3d3-9cf0-4172-b859-dcf7bce0d71a" xlink:to="loc_us-gaap_Goodwill_acb1b3c8-6f07-43ab-9460-acb13d634284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleassetsandgoodwillNarrativeDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#IntangibleassetsandgoodwillNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleassetsandgoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_915c3823-659b-4ddb-92d8-27a55ffecf9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_30a7e6b3-c11f-4348-a7b6-b46c6ff93c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_915c3823-659b-4ddb-92d8-27a55ffecf9c" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_30a7e6b3-c11f-4348-a7b6-b46c6ff93c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b6eeaebb-6871-4aa4-840c-e22b4095bbe5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_30a7e6b3-c11f-4348-a7b6-b46c6ff93c1d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b6eeaebb-6871-4aa4-840c-e22b4095bbe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a451343a-707d-4879-8764-459305f9b1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b6eeaebb-6871-4aa4-840c-e22b4095bbe5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a451343a-707d-4879-8764-459305f9b1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_d7fbf96f-d683-4618-808c-145ec0758ccb" xlink:href="jnj-20241229.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a451343a-707d-4879-8764-459305f9b1a0" xlink:to="loc_jnj_PatentsAndTrademarksMember_d7fbf96f-d683-4618-808c-145ec0758ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_96394ea0-cb70-44dd-82a4-2d2272c5a3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a451343a-707d-4879-8764-459305f9b1a0" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_96394ea0-cb70-44dd-82a4-2d2272c5a3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d2bf8f93-a322-4fa6-8a27-5af9278615b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_30a7e6b3-c11f-4348-a7b6-b46c6ff93c1d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d2bf8f93-a322-4fa6-8a27-5af9278615b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_5f125d23-dc85-497a-904d-3b48330ab977" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d2bf8f93-a322-4fa6-8a27-5af9278615b9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_5f125d23-dc85-497a-904d-3b48330ab977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_71f811ca-56ad-496b-be81-a71294d7bedf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d2bf8f93-a322-4fa6-8a27-5af9278615b9" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_71f811ca-56ad-496b-be81-a71294d7bedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleassetsandgoodwillEstimatedAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#IntangibleassetsandgoodwillEstimatedAmortizationofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleassetsandgoodwillEstimatedAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_32351c30-7bfe-41e5-a591-1425fb0c0eba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e3c56c3b-a2a6-4326-bea9-54bd51ef4408" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_32351c30-7bfe-41e5-a591-1425fb0c0eba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e3c56c3b-a2a6-4326-bea9-54bd51ef4408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_8f485ad5-9051-49d4-8491-d0871f2f8035" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_32351c30-7bfe-41e5-a591-1425fb0c0eba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_8f485ad5-9051-49d4-8491-d0871f2f8035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_205f8471-223f-4501-8ff5-ac93592d11a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_32351c30-7bfe-41e5-a591-1425fb0c0eba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_205f8471-223f-4501-8ff5-ac93592d11a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_5a1ec3a1-3586-4f74-998b-3c3383c15235" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_32351c30-7bfe-41e5-a591-1425fb0c0eba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_5a1ec3a1-3586-4f74-998b-3c3383c15235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0764808e-1cd9-45aa-8ebc-ae58ef3b72cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_32351c30-7bfe-41e5-a591-1425fb0c0eba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0764808e-1cd9-45aa-8ebc-ae58ef3b72cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#FairvaluemeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ba18b34c-d120-45a2-9213-9e9cf3e23cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_bb571d2d-84a4-4ff7-aa4d-f3b5f9c23903" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ba18b34c-d120-45a2-9213-9e9cf3e23cc0" xlink:to="loc_us-gaap_DerivativeTable_bb571d2d-84a4-4ff7-aa4d-f3b5f9c23903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_11997007-fa5a-4a64-baa8-91b915383a28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_bb571d2d-84a4-4ff7-aa4d-f3b5f9c23903" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_11997007-fa5a-4a64-baa8-91b915383a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e17e828b-ac47-43a9-b344-3853b9da896c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_11997007-fa5a-4a64-baa8-91b915383a28" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e17e828b-ac47-43a9-b344-3853b9da896c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_cbd13d0d-3a28-4732-9588-28ea6135089f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e17e828b-ac47-43a9-b344-3853b9da896c" xlink:to="loc_us-gaap_EquitySecuritiesMember_cbd13d0d-3a28-4732-9588-28ea6135089f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_e0bdd1df-9c82-4a53-98cc-d8268351cc55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_bb571d2d-84a4-4ff7-aa4d-f3b5f9c23903" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_e0bdd1df-9c82-4a53-98cc-d8268351cc55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_9080e20c-8d81-4dc7-b611-44d87fdc4838" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_e0bdd1df-9c82-4a53-98cc-d8268351cc55" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_9080e20c-8d81-4dc7-b611-44d87fdc4838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_9ae54ce6-75b7-4b77-b246-8bf08e672d7c" xlink:href="jnj-20241229.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_9080e20c-8d81-4dc7-b611-44d87fdc4838" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_9ae54ce6-75b7-4b77-b246-8bf08e672d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_f995a9b1-86f7-4bf3-b787-868d6abd56c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_bb571d2d-84a4-4ff7-aa4d-f3b5f9c23903" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_f995a9b1-86f7-4bf3-b787-868d6abd56c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_41d51984-8818-4400-b0b2-65327e41deb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f995a9b1-86f7-4bf3-b787-868d6abd56c9" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_41d51984-8818-4400-b0b2-65327e41deb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_b781e610-cab0-48ba-9e83-56476b361024" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_41d51984-8818-4400-b0b2-65327e41deb2" xlink:to="loc_us-gaap_ForeignExchangeContractMember_b781e610-cab0-48ba-9e83-56476b361024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_77d92969-2473-4b31-ac28-327663932353" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_41d51984-8818-4400-b0b2-65327e41deb2" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_77d92969-2473-4b31-ac28-327663932353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_a70d4b8c-9209-457a-8598-5a930e76a6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_41d51984-8818-4400-b0b2-65327e41deb2" xlink:to="loc_us-gaap_InterestRateSwapMember_a70d4b8c-9209-457a-8598-5a930e76a6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_679e5074-08bb-4dbe-a78e-95f0e823bc77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_bb571d2d-84a4-4ff7-aa4d-f3b5f9c23903" xlink:to="loc_us-gaap_DerivativeLineItems_679e5074-08bb-4dbe-a78e-95f0e823bc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_25fb479d-1d11-4145-b1f4-2d030540a23c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_679e5074-08bb-4dbe-a78e-95f0e823bc77" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_25fb479d-1d11-4145-b1f4-2d030540a23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_1e7be673-05d8-4246-963d-bc545180aa26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_679e5074-08bb-4dbe-a78e-95f0e823bc77" xlink:to="loc_us-gaap_DerivativeNotionalAmount_1e7be673-05d8-4246-963d-bc545180aa26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_75ea850c-03c9-407b-9021-e4722f844980" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_679e5074-08bb-4dbe-a78e-95f0e823bc77" xlink:to="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_75ea850c-03c9-407b-9021-e4722f844980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_570edcc9-5f26-48f9-8020-ebf96a04ad6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_679e5074-08bb-4dbe-a78e-95f0e823bc77" xlink:to="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_570edcc9-5f26-48f9-8020-ebf96a04ad6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_5afd7a83-824f-42fc-b38d-025ea3a4fb58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_679e5074-08bb-4dbe-a78e-95f0e823bc77" xlink:to="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_5afd7a83-824f-42fc-b38d-025ea3a4fb58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_53c0c27b-1b0c-439a-80ce-d42ae8d244d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaper"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_679e5074-08bb-4dbe-a78e-95f0e823bc77" xlink:to="loc_us-gaap_CommercialPaper_53c0c27b-1b0c-439a-80ce-d42ae8d244d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommercialPaper_dfa9a9c7-1633-4eed-a713-c9bd3a079a64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommercialPaper"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_679e5074-08bb-4dbe-a78e-95f0e823bc77" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommercialPaper_dfa9a9c7-1633-4eed-a713-c9bd3a079a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DebtForEquityExchangeSharesExchanged_035270e5-2daa-4ba2-8e72-ac11b77d67e9" xlink:href="jnj-20241229.xsd#jnj_DebtForEquityExchangeSharesExchanged"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_679e5074-08bb-4dbe-a78e-95f0e823bc77" xlink:to="loc_jnj_DebtForEquityExchangeSharesExchanged_035270e5-2daa-4ba2-8e72-ac11b77d67e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DebtForEquityExchangeLossOnSharesExchanged_b4ec95c0-ac3d-4494-9dfc-b789fa544e4c" xlink:href="jnj-20241229.xsd#jnj_DebtForEquityExchangeLossOnSharesExchanged"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_679e5074-08bb-4dbe-a78e-95f0e823bc77" xlink:to="loc_jnj_DebtForEquityExchangeLossOnSharesExchanged_b4ec95c0-ac3d-4494-9dfc-b789fa544e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_248cf153-d3c6-4735-9ddd-99a3df4d9657" xlink:href="jnj-20241229.xsd#jnj_EquityFairValueAdjustmentImpairmentLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_679e5074-08bb-4dbe-a78e-95f0e823bc77" xlink:to="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_248cf153-d3c6-4735-9ddd-99a3df4d9657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentChangeinObservablePrices_4fab64d3-6450-45a7-9e81-9aa25082765c" xlink:href="jnj-20241229.xsd#jnj_EquityFairValueAdjustmentChangeinObservablePrices"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_679e5074-08bb-4dbe-a78e-95f0e823bc77" xlink:to="loc_jnj_EquityFairValueAdjustmentChangeinObservablePrices_4fab64d3-6450-45a7-9e81-9aa25082765c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#FairvaluemeasurementsSummaryofDerivativeActivityDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_283f9398-36b3-4db6-bc2c-4125270237b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_99b8879a-6f31-486a-be83-8cc98dcc21ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_283f9398-36b3-4db6-bc2c-4125270237b7" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_99b8879a-6f31-486a-be83-8cc98dcc21ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a2613a57-ab0d-4fe8-a77c-4281b6075209" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_99b8879a-6f31-486a-be83-8cc98dcc21ad" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a2613a57-ab0d-4fe8-a77c-4281b6075209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ca9f8ade-a893-4b85-8b77-15a7114b5953" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a2613a57-ab0d-4fe8-a77c-4281b6075209" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ca9f8ade-a893-4b85-8b77-15a7114b5953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_fa657276-db53-4f75-b3c3-52b91247c058" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ca9f8ade-a893-4b85-8b77-15a7114b5953" xlink:to="loc_us-gaap_SalesMember_fa657276-db53-4f75-b3c3-52b91247c058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_d33d83d3-a888-4b8b-996b-37e9f48aa975" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ca9f8ade-a893-4b85-8b77-15a7114b5953" xlink:to="loc_us-gaap_CostOfSalesMember_d33d83d3-a888-4b8b-996b-37e9f48aa975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8c2b9e12-7401-48ba-bc49-07a5c40e49e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ca9f8ade-a893-4b85-8b77-15a7114b5953" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8c2b9e12-7401-48ba-bc49-07a5c40e49e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember_e8253cc5-2c55-4c6f-9f1a-0d0ce1e76eb5" xlink:href="jnj-20241229.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ca9f8ade-a893-4b85-8b77-15a7114b5953" xlink:to="loc_jnj_InterestIncomeExpenseNetMember_e8253cc5-2c55-4c6f-9f1a-0d0ce1e76eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_972c035f-736e-4276-9cfb-7fd906c64fb6" xlink:href="jnj-20241229.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ca9f8ade-a893-4b85-8b77-15a7114b5953" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_972c035f-736e-4276-9cfb-7fd906c64fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_9e5ce314-72a7-4fa8-b76d-45a988fb665e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_99b8879a-6f31-486a-be83-8cc98dcc21ad" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_9e5ce314-72a7-4fa8-b76d-45a988fb665e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c6a81c63-2845-4653-87ce-83f933b6ce7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9e5ce314-72a7-4fa8-b76d-45a988fb665e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c6a81c63-2845-4653-87ce-83f933b6ce7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_be3e62ce-e903-4830-9c5c-76616cef3a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c6a81c63-2845-4653-87ce-83f933b6ce7d" xlink:to="loc_us-gaap_InterestRateSwapMember_be3e62ce-e903-4830-9c5c-76616cef3a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_37d10a18-519b-454b-a67c-476cf3444f05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c6a81c63-2845-4653-87ce-83f933b6ce7d" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_37d10a18-519b-454b-a67c-476cf3444f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_186cc0e7-de8f-42f5-b3bd-b4d0a2ebda3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c6a81c63-2845-4653-87ce-83f933b6ce7d" xlink:to="loc_us-gaap_ForeignExchangeContractMember_186cc0e7-de8f-42f5-b3bd-b4d0a2ebda3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_599f8daf-a848-4ac3-9a38-720ad80d1a37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_99b8879a-6f31-486a-be83-8cc98dcc21ad" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_599f8daf-a848-4ac3-9a38-720ad80d1a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_4324958b-18e9-4c28-bc8c-106fb49e32c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_599f8daf-a848-4ac3-9a38-720ad80d1a37" xlink:to="loc_us-gaap_HedgingRelationshipDomain_4324958b-18e9-4c28-bc8c-106fb49e32c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_a9a954f0-fa90-4826-a836-14be9029f186" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_4324958b-18e9-4c28-bc8c-106fb49e32c3" xlink:to="loc_us-gaap_FairValueHedgingMember_a9a954f0-fa90-4826-a836-14be9029f186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_9267fe68-37b6-4d1c-9695-5950a71b0fae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_4324958b-18e9-4c28-bc8c-106fb49e32c3" xlink:to="loc_us-gaap_CashFlowHedgingMember_9267fe68-37b6-4d1c-9695-5950a71b0fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_53447a15-e848-404f-84c8-372186b2af8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_99b8879a-6f31-486a-be83-8cc98dcc21ad" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_53447a15-e848-404f-84c8-372186b2af8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_1806e5c0-31d8-4281-9c80-58864f40c6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_53447a15-e848-404f-84c8-372186b2af8b" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_1806e5c0-31d8-4281-9c80-58864f40c6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_2db8d4bc-11ab-4f29-bc26-7e5d0b4e9467" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_53447a15-e848-404f-84c8-372186b2af8b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_2db8d4bc-11ab-4f29-bc26-7e5d0b4e9467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_b05be443-552e-4b5d-a37b-0f0ce6407350" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_53447a15-e848-404f-84c8-372186b2af8b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_b05be443-552e-4b5d-a37b-0f0ce6407350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_28b52dfc-6876-4410-a41d-8b351f3fe6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_53447a15-e848-404f-84c8-372186b2af8b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_28b52dfc-6876-4410-a41d-8b351f3fe6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9502cad4-6674-4dd9-a88d-a16c3418b595" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_df17d42d-16e3-45b7-a3e3-9749f6a7ca6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9502cad4-6674-4dd9-a88d-a16c3418b595" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_df17d42d-16e3-45b7-a3e3-9749f6a7ca6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_803b83c7-75b1-418c-87a6-240cfa4c88cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_df17d42d-16e3-45b7-a3e3-9749f6a7ca6a" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_803b83c7-75b1-418c-87a6-240cfa4c88cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c012fe9d-c03d-4b29-8744-24d6601b5dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_803b83c7-75b1-418c-87a6-240cfa4c88cc" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c012fe9d-c03d-4b29-8744-24d6601b5dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_4a487b08-f449-416e-8d78-825bc1c42a67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c012fe9d-c03d-4b29-8744-24d6601b5dfa" xlink:to="loc_us-gaap_LongTermDebtMember_4a487b08-f449-416e-8d78-825bc1c42a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_250489db-b9d8-47c4-ac27-a2f229a310d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_df17d42d-16e3-45b7-a3e3-9749f6a7ca6a" xlink:to="loc_us-gaap_HedgingDesignationAxis_250489db-b9d8-47c4-ac27-a2f229a310d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_c4d7941a-3c3b-40df-ab21-87c672122375" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_250489db-b9d8-47c4-ac27-a2f229a310d6" xlink:to="loc_us-gaap_HedgingDesignationDomain_c4d7941a-3c3b-40df-ab21-87c672122375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_550f6662-8671-4caa-a8f6-73c2465c3b65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_c4d7941a-3c3b-40df-ab21-87c672122375" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_550f6662-8671-4caa-a8f6-73c2465c3b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_05b46884-12f4-4306-beb2-2d0d84114768" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_df17d42d-16e3-45b7-a3e3-9749f6a7ca6a" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_05b46884-12f4-4306-beb2-2d0d84114768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_dafd8db1-fa5a-4045-a756-c2ddc14d8f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_05b46884-12f4-4306-beb2-2d0d84114768" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_dafd8db1-fa5a-4045-a756-c2ddc14d8f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_8d209bf2-f063-46c9-a235-4d3e9cbe9c34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_05b46884-12f4-4306-beb2-2d0d84114768" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_8d209bf2-f063-46c9-a235-4d3e9cbe9c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_659e6536-a85a-4f42-871e-91b79a0b3702" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_cb7c90e9-7913-48b8-b7da-b42a5b303ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_659e6536-a85a-4f42-871e-91b79a0b3702" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_cb7c90e9-7913-48b8-b7da-b42a5b303ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3c550990-0559-40ac-a0ae-bb8f5771e7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_cb7c90e9-7913-48b8-b7da-b42a5b303ff9" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3c550990-0559-40ac-a0ae-bb8f5771e7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7436d28c-71e4-45fa-b7b2-c6ec50924b96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3c550990-0559-40ac-a0ae-bb8f5771e7b3" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7436d28c-71e4-45fa-b7b2-c6ec50924b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_5621ed2e-9c3b-4b1b-9891-52493686be58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7436d28c-71e4-45fa-b7b2-c6ec50924b96" xlink:to="loc_us-gaap_ForeignExchangeContractMember_5621ed2e-9c3b-4b1b-9891-52493686be58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_e9476217-3669-4ca7-bcd8-85d7a8235432" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_cb7c90e9-7913-48b8-b7da-b42a5b303ff9" xlink:to="loc_us-gaap_HedgingDesignationAxis_e9476217-3669-4ca7-bcd8-85d7a8235432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_8920a678-ba59-4057-80e5-1a992a2491a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_e9476217-3669-4ca7-bcd8-85d7a8235432" xlink:to="loc_us-gaap_HedgingDesignationDomain_8920a678-ba59-4057-80e5-1a992a2491a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_c8d1bf06-2953-4c4d-bcd7-77da3a651450" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_8920a678-ba59-4057-80e5-1a992a2491a3" xlink:to="loc_us-gaap_NondesignatedMember_c8d1bf06-2953-4c4d-bcd7-77da3a651450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_65ac2f4a-baa0-494f-8ce2-02711a1dcdaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_cb7c90e9-7913-48b8-b7da-b42a5b303ff9" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_65ac2f4a-baa0-494f-8ce2-02711a1dcdaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_a6705a5d-856e-4d84-be6e-2316696217d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_65ac2f4a-baa0-494f-8ce2-02711a1dcdaf" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_a6705a5d-856e-4d84-be6e-2316696217d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_4b939bcf-e35b-4472-967a-5c2f8bf5dbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_65ac2f4a-baa0-494f-8ce2-02711a1dcdaf" xlink:to="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_4b939bcf-e35b-4472-967a-5c2f8bf5dbb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ad0ea08b-6440-4e36-9fe3-e8ce6f6ae08b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_38113d6b-776c-469b-a62b-7c0ac3196f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ad0ea08b-6440-4e36-9fe3-e8ce6f6ae08b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_38113d6b-776c-469b-a62b-7c0ac3196f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f91eafec-041e-4196-8317-869bc735a5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_38113d6b-776c-469b-a62b-7c0ac3196f2f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f91eafec-041e-4196-8317-869bc735a5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d65cef0d-bfa5-4dee-82e6-6a198b781a73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f91eafec-041e-4196-8317-869bc735a5c2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d65cef0d-bfa5-4dee-82e6-6a198b781a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_d937e28e-efe9-4adf-987c-a1e782f0c112" xlink:href="jnj-20241229.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d65cef0d-bfa5-4dee-82e6-6a198b781a73" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_d937e28e-efe9-4adf-987c-a1e782f0c112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6ced0c18-7154-4d81-b4e9-a4797eacfa04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_38113d6b-776c-469b-a62b-7c0ac3196f2f" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6ced0c18-7154-4d81-b4e9-a4797eacfa04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_50635f5c-5bc3-49af-9ecb-eb7cef1d29f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6ced0c18-7154-4d81-b4e9-a4797eacfa04" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_50635f5c-5bc3-49af-9ecb-eb7cef1d29f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_dc3e6957-aefa-4edf-8386-b79e93da2b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_50635f5c-5bc3-49af-9ecb-eb7cef1d29f2" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_dc3e6957-aefa-4edf-8386-b79e93da2b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_04c02064-6178-4478-9f4c-2637741abdf2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_38113d6b-776c-469b-a62b-7c0ac3196f2f" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_04c02064-6178-4478-9f4c-2637741abdf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_9c8b5703-f797-4cd9-8927-9af24d542ded" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_04c02064-6178-4478-9f4c-2637741abdf2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_9c8b5703-f797-4cd9-8927-9af24d542ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_c0ebba23-7794-44c7-a020-413eb55e04cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_04c02064-6178-4478-9f4c-2637741abdf2" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_c0ebba23-7794-44c7-a020-413eb55e04cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_adb538f9-5701-4b4b-81c6-9cd5f8f0ef65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_be0e00d7-ee56-4201-b9ba-59409db083ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_adb538f9-5701-4b4b-81c6-9cd5f8f0ef65" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_be0e00d7-ee56-4201-b9ba-59409db083ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_8f6d8266-9e97-41ee-8764-2333ddc79b43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_be0e00d7-ee56-4201-b9ba-59409db083ec" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_8f6d8266-9e97-41ee-8764-2333ddc79b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_bc524987-17df-48ba-8bb8-90e440ce0e33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_8f6d8266-9e97-41ee-8764-2333ddc79b43" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_bc524987-17df-48ba-8bb8-90e440ce0e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_e4f93cc1-6280-4793-a875-21025bbd5cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_bc524987-17df-48ba-8bb8-90e440ce0e33" xlink:to="loc_us-gaap_EquitySecuritiesMember_e4f93cc1-6280-4793-a875-21025bbd5cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_16acfebd-c896-462a-9e4e-b722e7ccb335" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_be0e00d7-ee56-4201-b9ba-59409db083ec" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_16acfebd-c896-462a-9e4e-b722e7ccb335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_9d6f7439-81cc-45a5-8faa-5fc056db0403" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_16acfebd-c896-462a-9e4e-b722e7ccb335" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_9d6f7439-81cc-45a5-8faa-5fc056db0403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_885ace64-c7a8-4262-9021-629359e6baa1" xlink:href="jnj-20241229.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_9d6f7439-81cc-45a5-8faa-5fc056db0403" xlink:to="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_885ace64-c7a8-4262-9021-629359e6baa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_b747112d-14e6-4c80-95e4-5e9f240bd340" xlink:href="jnj-20241229.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_9d6f7439-81cc-45a5-8faa-5fc056db0403" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_b747112d-14e6-4c80-95e4-5e9f240bd340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_6f269a1d-2554-42b2-b43c-8f34067b2d83" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_be0e00d7-ee56-4201-b9ba-59409db083ec" xlink:to="loc_srt_OwnershipAxis_6f269a1d-2554-42b2-b43c-8f34067b2d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_9ece6131-34cb-4ca5-a57b-c3c7e6fad633" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_6f269a1d-2554-42b2-b43c-8f34067b2d83" xlink:to="loc_srt_OwnershipDomain_9ece6131-34cb-4ca5-a57b-c3c7e6fad633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KenvueIncMember_9577eaa4-f4ae-44f9-8c9f-b64d3492137a" xlink:href="jnj-20241229.xsd#jnj_KenvueIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_9ece6131-34cb-4ca5-a57b-c3c7e6fad633" xlink:to="loc_jnj_KenvueIncMember_9577eaa4-f4ae-44f9-8c9f-b64d3492137a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_18bc0523-8f9e-4575-88f8-53c2c9d10446" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_be0e00d7-ee56-4201-b9ba-59409db083ec" xlink:to="loc_dei_LegalEntityAxis_18bc0523-8f9e-4575-88f8-53c2c9d10446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6d04e9e1-7ad6-485c-8984-4156be56f063" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_18bc0523-8f9e-4575-88f8-53c2c9d10446" xlink:to="loc_dei_EntityDomain_6d04e9e1-7ad6-485c-8984-4156be56f063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_JohnsonJohnsonMember_61b615f9-7b1b-4177-bbb5-ac8ead3a9b83" xlink:href="jnj-20241229.xsd#jnj_JohnsonJohnsonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6d04e9e1-7ad6-485c-8984-4156be56f063" xlink:to="loc_jnj_JohnsonJohnsonMember_61b615f9-7b1b-4177-bbb5-ac8ead3a9b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_a8146088-740b-4e6b-ab96-de38b18556d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_be0e00d7-ee56-4201-b9ba-59409db083ec" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_a8146088-740b-4e6b-ab96-de38b18556d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward_de0953c8-b245-4ef2-988b-a9f9ea0ba3e6" xlink:href="jnj-20241229.xsd#jnj_EquityInvestmentRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_a8146088-740b-4e6b-ab96-de38b18556d4" xlink:to="loc_jnj_EquityInvestmentRollForward_de0953c8-b245-4ef2-988b-a9f9ea0ba3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_f9519454-df6d-470d-a636-8e6262e6c43b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_de0953c8-b245-4ef2-988b-a9f9ea0ba3e6" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_f9519454-df6d-470d-a636-8e6262e6c43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_00e47e20-9e6d-4c46-9e79-b80ae211cff5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_de0953c8-b245-4ef2-988b-a9f9ea0ba3e6" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_00e47e20-9e6d-4c46-9e79-b80ae211cff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_0d2de39f-0b4b-4463-9e28-bf6781055a09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_de0953c8-b245-4ef2-988b-a9f9ea0ba3e6" xlink:to="loc_us-gaap_EquityFairValueAdjustment_0d2de39f-0b4b-4463-9e28-bf6781055a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_8c8b7d6e-d129-4ebc-b6bc-498ad20bfbc1" xlink:href="jnj-20241229.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_de0953c8-b245-4ef2-988b-a9f9ea0ba3e6" xlink:to="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_8c8b7d6e-d129-4ebc-b6bc-498ad20bfbc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7ed7973b-a95b-4ada-9545-91629c0f4963" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_de0953c8-b245-4ef2-988b-a9f9ea0ba3e6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7ed7973b-a95b-4ada-9545-91629c0f4963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExchangeOfStockPercentageOwnershipAfterTransaction_2aa8b591-99a0-4344-812a-85c050360915" xlink:href="jnj-20241229.xsd#jnj_ExchangeOfStockPercentageOwnershipAfterTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_a8146088-740b-4e6b-ab96-de38b18556d4" xlink:to="loc_jnj_ExchangeOfStockPercentageOwnershipAfterTransaction_2aa8b591-99a0-4344-812a-85c050360915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_695f9c43-0848-460a-ad92-f444a32657af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_a8146088-740b-4e6b-ab96-de38b18556d4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_695f9c43-0848-460a-ad92-f444a32657af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3cf479cb-c912-426b-bc99-bf63e6e73d89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_082494df-6433-44f9-b6e1-3d09c4e6c8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3cf479cb-c912-426b-bc99-bf63e6e73d89" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_082494df-6433-44f9-b6e1-3d09c4e6c8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_64e4b834-4c21-42c1-bb8d-03f5c2838943" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_082494df-6433-44f9-b6e1-3d09c4e6c8f3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_64e4b834-4c21-42c1-bb8d-03f5c2838943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3ddfa970-0fbe-4f29-9274-c99f55292e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_64e4b834-4c21-42c1-bb8d-03f5c2838943" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3ddfa970-0fbe-4f29-9274-c99f55292e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_b1402339-6297-45b2-a64a-ecb26a23b054" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3ddfa970-0fbe-4f29-9274-c99f55292e3e" xlink:to="loc_us-gaap_ForeignExchangeContractMember_b1402339-6297-45b2-a64a-ecb26a23b054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_864f224a-f23f-4b50-b3ee-9bfd8f2e483b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3ddfa970-0fbe-4f29-9274-c99f55292e3e" xlink:to="loc_us-gaap_InterestRateContractMember_864f224a-f23f-4b50-b3ee-9bfd8f2e483b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_98440dba-9fca-4588-9195-62a2f2726678" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_082494df-6433-44f9-b6e1-3d09c4e6c8f3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_98440dba-9fca-4588-9195-62a2f2726678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d681b796-6a14-4fec-a5c0-617e995d5c30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_98440dba-9fca-4588-9195-62a2f2726678" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d681b796-6a14-4fec-a5c0-617e995d5c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ba745f7d-11f1-4afa-af78-ed08974d3826" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d681b796-6a14-4fec-a5c0-617e995d5c30" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ba745f7d-11f1-4afa-af78-ed08974d3826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b44a6656-74e8-4050-9540-c7b779afa09b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d681b796-6a14-4fec-a5c0-617e995d5c30" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b44a6656-74e8-4050-9540-c7b779afa09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_cb61c78f-9225-4a93-b73c-c7998d3cc51d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d681b796-6a14-4fec-a5c0-617e995d5c30" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_cb61c78f-9225-4a93-b73c-c7998d3cc51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_84453810-8b84-484c-bfde-61154601fc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_082494df-6433-44f9-b6e1-3d09c4e6c8f3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_84453810-8b84-484c-bfde-61154601fc4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_24c988f9-6dd6-4c33-bafa-0056594e7846" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_84453810-8b84-484c-bfde-61154601fc4c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_24c988f9-6dd6-4c33-bafa-0056594e7846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AbiomedMember_1f94ec51-d77a-4ac0-a333-43c9867a8fc7" xlink:href="jnj-20241229.xsd#jnj_AbiomedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_24c988f9-6dd6-4c33-bafa-0056594e7846" xlink:to="loc_jnj_AbiomedMember_1f94ec51-d77a-4ac0-a333-43c9867a8fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProteologixMember_cb156df0-73a9-4071-9c9e-3468f8926889" xlink:href="jnj-20241229.xsd#jnj_ProteologixMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_24c988f9-6dd6-4c33-bafa-0056594e7846" xlink:to="loc_jnj_ProteologixMember_cb156df0-73a9-4071-9c9e-3468f8926889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_fd80d00f-9a65-4f33-b0e4-f3098aba05ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_082494df-6433-44f9-b6e1-3d09c4e6c8f3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_fd80d00f-9a65-4f33-b0e4-f3098aba05ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_27c158c1-14f0-4405-a1c4-e922d80ad950" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_fd80d00f-9a65-4f33-b0e4-f3098aba05ab" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_27c158c1-14f0-4405-a1c4-e922d80ad950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_210c0808-d833-439e-91b4-586ac51951c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_27c158c1-14f0-4405-a1c4-e922d80ad950" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_210c0808-d833-439e-91b4-586ac51951c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_1d5f20d7-70b9-4e59-9241-9b450fc9a3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_27c158c1-14f0-4405-a1c4-e922d80ad950" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_1d5f20d7-70b9-4e59-9241-9b450fc9a3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_082494df-6433-44f9-b6e1-3d09c4e6c8f3" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract_81f323ab-b38f-43c3-a902-97cf5f967891" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:to="loc_us-gaap_DerivativeInstrumentDetailAbstract_81f323ab-b38f-43c3-a902-97cf5f967891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_b86389f7-83ef-47a1-bf98-54113f1bb3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_81f323ab-b38f-43c3-a902-97cf5f967891" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_b86389f7-83ef-47a1-bf98-54113f1bb3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_e00124bc-8e6a-4161-bb53-7595e2c89873" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_81f323ab-b38f-43c3-a902-97cf5f967891" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_e00124bc-8e6a-4161-bb53-7595e2c89873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_6313d7eb-7b1c-4682-a066-b92208528e82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_81f323ab-b38f-43c3-a902-97cf5f967891" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_6313d7eb-7b1c-4682-a066-b92208528e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_ce2fec22-891f-4677-ad5f-5ee4a378c1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_81f323ab-b38f-43c3-a902-97cf5f967891" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_ce2fec22-891f-4677-ad5f-5ee4a378c1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_335bea12-9d6c-4e05-81bc-30f3733d47e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_81f323ab-b38f-43c3-a902-97cf5f967891" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_335bea12-9d6c-4e05-81bc-30f3733d47e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1b31d6f0-da5e-4a09-af7c-864b9f7efa71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_81f323ab-b38f-43c3-a902-97cf5f967891" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1b31d6f0-da5e-4a09-af7c-864b9f7efa71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_21cac2e8-3186-4d14-a60b-1189e404ebec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_81f323ab-b38f-43c3-a902-97cf5f967891" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_21cac2e8-3186-4d14-a60b-1189e404ebec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_ccb7849d-ef02-4037-86ff-0dc68a3c7f20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_ccb7849d-ef02-4037-86ff-0dc68a3c7f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_3e0e6fcd-6018-44a5-a3bf-116a5c1081da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_3e0e6fcd-6018-44a5-a3bf-116a5c1081da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_0f94f123-5942-4140-9628-2dfaeaa659cb" xlink:href="jnj-20241229.xsd#jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:to="loc_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_0f94f123-5942-4140-9628-2dfaeaa659cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_ffa5583a-adb2-4a12-9157-3804e80e8795" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:to="loc_us-gaap_DerivativeAssets_ffa5583a-adb2-4a12-9157-3804e80e8795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_1206c46b-0cde-4254-ba8c-66e734f6f8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_1206c46b-0cde-4254-ba8c-66e734f6f8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_b9ff9554-a83a-4da9-bb25-77bb5599a084" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_b9ff9554-a83a-4da9-bb25-77bb5599a084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_f2dfd7b6-5136-46eb-b674-7c723327a48e" xlink:href="jnj-20241229.xsd#jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:to="loc_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_f2dfd7b6-5136-46eb-b674-7c723327a48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_46033153-a936-46c4-9d80-f7364d36a4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:to="loc_us-gaap_DerivativeLiabilities_46033153-a936-46c4-9d80-f7364d36a4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_116d6b72-00d1-4b22-9da3-d444d45b74ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_116d6b72-00d1-4b22-9da3-d444d45b74ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_710eb685-aae0-4dc0-9e44-2ed0a2cf0b1d" xlink:href="jnj-20241229.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:to="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_710eb685-aae0-4dc0-9e44-2ed0a2cf0b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_6ffc8a59-f9d6-43f4-bd78-bd567d5361f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_6ffc8a59-f9d6-43f4-bd78-bd567d5361f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_ec12b859-7745-47ec-a382-b4ed6b434fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_ec12b859-7745-47ec-a382-b4ed6b434fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6ac5f5c2-167f-4ba9-b9b6-9a4560fc7a65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ad82c682-6fd0-440e-a478-2059f8d99ca6" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6ac5f5c2-167f-4ba9-b9b6-9a4560fc7a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#BorrowingsScheduleofLongtermDebtInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_786716a5-4d25-487a-a7cb-4f782643252f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_30ab6076-9fa2-4bc1-aabe-655f1451a1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_786716a5-4d25-487a-a7cb-4f782643252f" xlink:to="loc_us-gaap_DebtInstrumentTable_30ab6076-9fa2-4bc1-aabe-655f1451a1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9e8e80dc-fa77-4c05-8235-5ad88d9eee1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_30ab6076-9fa2-4bc1-aabe-655f1451a1bb" xlink:to="loc_us-gaap_DebtInstrumentAxis_9e8e80dc-fa77-4c05-8235-5ad88d9eee1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9e8e80dc-fa77-4c05-8235-5ad88d9eee1a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_ddb06495-c6ae-4cf2-b081-fa23fd1b03fc" xlink:href="jnj-20241229.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A0.650NotesDue2024Member_ddb06495-c6ae-4cf2-b081-fa23fd1b03fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_b3519391-2985-44a1-828b-1845c769bb70" xlink:href="jnj-20241229.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A5.50NotesDue2024Member_b3519391-2985-44a1-828b-1845c769bb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member_23aea600-f56f-43df-9971-e60cb695a45c" xlink:href="jnj-20241229.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A2.625Notesdue2025Member_23aea600-f56f-43df-9971-e60cb695a45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A055NotesDue2025Member_e2b8b2ee-10fb-4088-a6e1-0ea9b4a9e8a4" xlink:href="jnj-20241229.xsd#jnj_A055NotesDue2025Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A055NotesDue2025Member_e2b8b2ee-10fb-4088-a6e1-0ea9b4a9e8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member_08defe6c-4cc8-4c54-8832-cc3bc7c91878" xlink:href="jnj-20241229.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A2.45Notesdue2026Member_08defe6c-4cc8-4c54-8832-cc3bc7c91878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member_113068ab-1b39-4057-aa36-ccae47b537a2" xlink:href="jnj-20241229.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A2.95Notesdue2027Member_113068ab-1b39-4057-aa36-ccae47b537a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member_f1c75a64-ee39-4a15-ba0b-ce9b7695a674" xlink:href="jnj-20241229.xsd#jnj_A095NotesDue2027Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A095NotesDue2027Member_f1c75a64-ee39-4a15-ba0b-ce9b7695a674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_f995958b-d7ea-4281-8780-78502fee2b21" xlink:href="jnj-20241229.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A1.150NotesDue2028Member_f995958b-d7ea-4281-8780-78502fee2b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member_e523a76a-464f-4b4d-9e99-627f0a960ca1" xlink:href="jnj-20241229.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A2.900Notesdue2028Member_e523a76a-464f-4b4d-9e99-627f0a960ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member_44f7cbde-2dcc-43d8-8764-323edd13edcd" xlink:href="jnj-20241229.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A6.95Notesdue2029Member_44f7cbde-2dcc-43d8-8764-323edd13edcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.80DebenturesDue2029Member_ee0bdfc6-8918-4cf6-9c16-e10678c9782c" xlink:href="jnj-20241229.xsd#jnj_A4.80DebenturesDue2029Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A4.80DebenturesDue2029Member_ee0bdfc6-8918-4cf6-9c16-e10678c9782c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A130NotesDue2030Member_1fd8787d-c695-4a7a-8bd2-1365d0fcb892" xlink:href="jnj-20241229.xsd#jnj_A130NotesDue2030Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A130NotesDue2030Member_1fd8787d-c695-4a7a-8bd2-1365d0fcb892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.90DebenturesDue2031Member_2461f5c3-36d3-4a7c-852b-651f3b13c435" xlink:href="jnj-20241229.xsd#jnj_A4.90DebenturesDue2031Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A4.90DebenturesDue2031Member_2461f5c3-36d3-4a7c-852b-651f3b13c435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.20DebenturesDue2032Member_4a857285-0555-478b-9075-5c9ff5ac6774" xlink:href="jnj-20241229.xsd#jnj_A3.20DebenturesDue2032Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A3.20DebenturesDue2032Member_4a857285-0555-478b-9075-5c9ff5ac6774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member_c4b185e5-1a39-420e-a2f9-2f13ec8fc2ab" xlink:href="jnj-20241229.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A4.95Debenturesdue2033Member_c4b185e5-1a39-420e-a2f9-2f13ec8fc2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member_62b55efd-3049-4849-bc6c-dd8d9176f7b5" xlink:href="jnj-20241229.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A4.375Notesdue2033Member_62b55efd-3049-4849-bc6c-dd8d9176f7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95DebenturesDue2034Member_1bded869-0d8f-4818-8926-28a6ef49d85e" xlink:href="jnj-20241229.xsd#jnj_A4.95DebenturesDue2034Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A4.95DebenturesDue2034Member_1bded869-0d8f-4818-8926-28a6ef49d85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_fd0abd93-d26c-4877-88e8-e7bcd7a2dc4b" xlink:href="jnj-20241229.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A1.650NotesDue2035Member_fd0abd93-d26c-4877-88e8-e7bcd7a2dc4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.35DebenturesDue2036Member_47499b25-89bb-4d50-a7ca-321c3b7ae7e1" xlink:href="jnj-20241229.xsd#jnj_A3.35DebenturesDue2036Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A3.35DebenturesDue2036Member_47499b25-89bb-4d50-a7ca-321c3b7ae7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member_d206906d-7431-4f8c-a2d2-f67b8e4bd0e2" xlink:href="jnj-20241229.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A3.55Notesdue2036Member_d206906d-7431-4f8c-a2d2-f67b8e4bd0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member_d50ebbbb-bc00-4199-94f4-7a9b4f213b2b" xlink:href="jnj-20241229.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A5.95Notesdue2037Member_d50ebbbb-bc00-4199-94f4-7a9b4f213b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member_c73cf064-a63d-4b9f-a305-c4d8a0a939f3" xlink:href="jnj-20241229.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A3.625Notesdue2037Member_c73cf064-a63d-4b9f-a305-c4d8a0a939f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member_dc1c4fc0-47ec-49d4-95a5-6109520990ad" xlink:href="jnj-20241229.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A5.85Debenturesdue2038Member_dc1c4fc0-47ec-49d4-95a5-6109520990ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member_91c66c65-9191-45d3-9d3a-42494ad1ab03" xlink:href="jnj-20241229.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A3.400Notesdue2038Member_91c66c65-9191-45d3-9d3a-42494ad1ab03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member_5e21244b-b595-40d0-b67b-7a2796572237" xlink:href="jnj-20241229.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A4.50Debenturesdue2040Member_5e21244b-b595-40d0-b67b-7a2796572237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member_a29d63e2-ced5-415d-bd4c-fb0f44aaa73c" xlink:href="jnj-20241229.xsd#jnj_A210NotesDue2040Member"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A210NotesDue2040Member_a29d63e2-ced5-415d-bd4c-fb0f44aaa73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member_bb2f1680-3192-4f0a-9aec-fd0a48d00a68" xlink:href="jnj-20241229.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A4.85Notesdue2041Member_bb2f1680-3192-4f0a-9aec-fd0a48d00a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member_c05377f0-8af6-4168-be68-25cd6bf8b55c" xlink:href="jnj-20241229.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A4.50Notesdue2043Member_c05377f0-8af6-4168-be68-25cd6bf8b55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55DebenturesDue2044Member_fa78378c-a797-459a-b653-7467d3473a76" xlink:href="jnj-20241229.xsd#jnj_A3.55DebenturesDue2044Member"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A3.55DebenturesDue2044Member_fa78378c-a797-459a-b653-7467d3473a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member_6f3c2e93-2df6-4a61-9cac-824f0c2d005c" xlink:href="jnj-20241229.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A3.70Notesdue2046Member_6f3c2e93-2df6-4a61-9cac-824f0c2d005c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member_c5dbff0c-5e4f-49d1-a77a-cae422967bf1" xlink:href="jnj-20241229.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A3.75Notesdue2047Member_c5dbff0c-5e4f-49d1-a77a-cae422967bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member_0707d223-dcfa-45af-a13e-5a60328fd0c6" xlink:href="jnj-20241229.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A3.500Notesdue2048Member_0707d223-dcfa-45af-a13e-5a60328fd0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member_c2494f71-a7ab-4c29-acef-3a9f99e99158" xlink:href="jnj-20241229.xsd#jnj_A2250NotesDue2050Member"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A2250NotesDue2050Member_c2494f71-a7ab-4c29-acef-3a9f99e99158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.25DebenturesDue2054Member_693f3622-4906-470f-860e-076193713896" xlink:href="jnj-20241229.xsd#jnj_A5.25DebenturesDue2054Member"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A5.25DebenturesDue2054Member_693f3622-4906-470f-860e-076193713896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member_6e68a061-1b29-47b4-9ad1-a59b5970e9c3" xlink:href="jnj-20241229.xsd#jnj_A2450NotesDue2060Member"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_jnj_A2450NotesDue2060Member_6e68a061-1b29-47b4-9ad1-a59b5970e9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_18245d42-4018-4067-baa1-711ff154e760" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52fb9105-0d19-425e-b774-8f9ab58ade1d" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_18245d42-4018-4067-baa1-711ff154e760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7342e7b3-e34c-42ba-af5f-3ec0741d8f50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_30ab6076-9fa2-4bc1-aabe-655f1451a1bb" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7342e7b3-e34c-42ba-af5f-3ec0741d8f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_092012b7-797b-4c29-924b-3fce9b278e19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7342e7b3-e34c-42ba-af5f-3ec0741d8f50" xlink:to="loc_us-gaap_LongTermDebt_092012b7-797b-4c29-924b-3fce9b278e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_81299db6-f169-4120-956b-b01fb7a8f1de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7342e7b3-e34c-42ba-af5f-3ec0741d8f50" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_81299db6-f169-4120-956b-b01fb7a8f1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_c39ee766-c292-4832-8f0c-07ae9603c5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7342e7b3-e34c-42ba-af5f-3ec0741d8f50" xlink:to="loc_us-gaap_LongTermDebtCurrent_c39ee766-c292-4832-8f0c-07ae9603c5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c1cb5b85-4709-4828-b59a-755d535d76ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7342e7b3-e34c-42ba-af5f-3ec0741d8f50" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c1cb5b85-4709-4828-b59a-755d535d76ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5272e9f5-25d4-4bc8-8a64-ed76da6877c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7342e7b3-e34c-42ba-af5f-3ec0741d8f50" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5272e9f5-25d4-4bc8-8a64-ed76da6877c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1a10e121-3185-461c-97b5-69c81df9a04b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7342e7b3-e34c-42ba-af5f-3ec0741d8f50" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1a10e121-3185-461c-97b5-69c81df9a04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_4078dde7-3411-4c79-a5ea-00fce936159f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7342e7b3-e34c-42ba-af5f-3ec0741d8f50" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_4078dde7-3411-4c79-a5ea-00fce936159f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfCarryingValueOverFairValueOfDebt_dcbef719-7d34-49de-a463-32ca7ea3f357" xlink:href="jnj-20241229.xsd#jnj_ExcessOfCarryingValueOverFairValueOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7342e7b3-e34c-42ba-af5f-3ec0741d8f50" xlink:to="loc_jnj_ExcessOfCarryingValueOverFairValueOfDebt_dcbef719-7d34-49de-a463-32ca7ea3f357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_815db8e0-bc97-41e4-b717-5acc92dbba49" xlink:href="jnj-20241229.xsd#jnj_ExcessOfFairValueOverCarryingValueOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7342e7b3-e34c-42ba-af5f-3ec0741d8f50" xlink:to="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_815db8e0-bc97-41e4-b717-5acc92dbba49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#BorrowingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/BorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8bfed550-918f-4193-98ef-3c8baeb933b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_3cc927f4-5ba4-46bd-b487-af39e91de945" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8bfed550-918f-4193-98ef-3c8baeb933b3" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_3cc927f4-5ba4-46bd-b487-af39e91de945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_4f2fa663-794c-4635-a522-793ab0947c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_3cc927f4-5ba4-46bd-b487-af39e91de945" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_4f2fa663-794c-4635-a522-793ab0947c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_31003d2a-29e6-430a-9c7f-60b0d43f7d55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_4f2fa663-794c-4635-a522-793ab0947c4d" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_31003d2a-29e6-430a-9c7f-60b0d43f7d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_53bccbe7-fc06-4804-bf0e-a613ca4c2dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_31003d2a-29e6-430a-9c7f-60b0d43f7d55" xlink:to="loc_us-gaap_CommercialPaperMember_53bccbe7-fc06-4804-bf0e-a613ca4c2dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_75bc8461-adec-4b8b-86fd-8ce08ffd37e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_3cc927f4-5ba4-46bd-b487-af39e91de945" xlink:to="loc_us-gaap_ShortTermDebtLineItems_75bc8461-adec-4b8b-86fd-8ce08ffd37e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a22609e0-16f2-4cf7-a456-cb055ec7e85e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_75bc8461-adec-4b8b-86fd-8ce08ffd37e1" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a22609e0-16f2-4cf7-a456-cb055ec7e85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_886cd81e-aa60-47f4-84bc-6aaa96e80df1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_75bc8461-adec-4b8b-86fd-8ce08ffd37e1" xlink:to="loc_us-gaap_DebtCurrent_886cd81e-aa60-47f4-84bc-6aaa96e80df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermCommercialPaperCurrent_bce49df1-e53b-4bbc-9941-7d84b21a57db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermCommercialPaperCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_75bc8461-adec-4b8b-86fd-8ce08ffd37e1" xlink:to="loc_us-gaap_LongTermCommercialPaperCurrent_bce49df1-e53b-4bbc-9941-7d84b21a57db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_003a52b0-c5e2-4a3f-a450-78d4af579ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_75bc8461-adec-4b8b-86fd-8ce08ffd37e1" xlink:to="loc_us-gaap_ShortTermBorrowings_003a52b0-c5e2-4a3f-a450-78d4af579ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_1bfd6829-aedb-4a1c-a8ce-ae6cbd7ecc37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_75bc8461-adec-4b8b-86fd-8ce08ffd37e1" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_1bfd6829-aedb-4a1c-a8ce-ae6cbd7ecc37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_46b91baf-fc84-4c42-9ab7-01ed87f0343f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_75bc8461-adec-4b8b-86fd-8ce08ffd37e1" xlink:to="loc_us-gaap_DebtInstrumentTerm_46b91baf-fc84-4c42-9ab7-01ed87f0343f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#BorrowingsAggregateMaturitiesofLongTermObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e05f27c9-6e7d-4f62-9507-363a796f746c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_73ae6352-b41e-48eb-9c98-7dd78566ffa8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e05f27c9-6e7d-4f62-9507-363a796f746c" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_73ae6352-b41e-48eb-9c98-7dd78566ffa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_df06ad67-0148-4204-be5a-c01073b5ef66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_73ae6352-b41e-48eb-9c98-7dd78566ffa8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_df06ad67-0148-4204-be5a-c01073b5ef66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0897c4e1-d4e6-42b0-b113-1187c950d10e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_73ae6352-b41e-48eb-9c98-7dd78566ffa8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0897c4e1-d4e6-42b0-b113-1187c950d10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_80d6368d-f69f-444c-b1bd-317a287e2752" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_73ae6352-b41e-48eb-9c98-7dd78566ffa8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_80d6368d-f69f-444c-b1bd-317a287e2752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_ee24bfe8-c17a-4e70-852c-7bc51abb158e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_73ae6352-b41e-48eb-9c98-7dd78566ffa8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_ee24bfe8-c17a-4e70-852c-7bc51abb158e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_0ea75de9-6d38-490f-a282-9c10f36174d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_73ae6352-b41e-48eb-9c98-7dd78566ffa8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_0ea75de9-6d38-490f-a282-9c10f36174d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_394e3e97-5559-491f-9a71-4be541958dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_73ae6352-b41e-48eb-9c98-7dd78566ffa8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_394e3e97-5559-491f-9a71-4be541958dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#IncometaxesProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2cae95fe-ec29-4dc3-93e0-9fbf49f96209" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_4d9ca62f-9504-45c1-9029-470b9254e88d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2cae95fe-ec29-4dc3-93e0-9fbf49f96209" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_4d9ca62f-9504-45c1-9029-470b9254e88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_f28cfcef-81ab-45df-b140-173235bbe7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_4d9ca62f-9504-45c1-9029-470b9254e88d" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_f28cfcef-81ab-45df-b140-173235bbe7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_77f98eb1-9204-4e49-9777-089b88910bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_4d9ca62f-9504-45c1-9029-470b9254e88d" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_77f98eb1-9204-4e49-9777-089b88910bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_86b401f5-9970-41fc-b67f-5b5e3a3ee8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_4d9ca62f-9504-45c1-9029-470b9254e88d" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_86b401f5-9970-41fc-b67f-5b5e3a3ee8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e33237a5-fd75-407f-b85f-1cb809af4aed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2cae95fe-ec29-4dc3-93e0-9fbf49f96209" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e33237a5-fd75-407f-b85f-1cb809af4aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ffc44bf0-348c-4f95-b05d-9cb0d40e4c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e33237a5-fd75-407f-b85f-1cb809af4aed" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ffc44bf0-348c-4f95-b05d-9cb0d40e4c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_06067c9f-82dc-45dd-bc09-d405a26147b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e33237a5-fd75-407f-b85f-1cb809af4aed" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_06067c9f-82dc-45dd-bc09-d405a26147b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations_ea785b59-b72e-4d81-918d-6dea9392e4e2" xlink:href="jnj-20241229.xsd#jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e33237a5-fd75-407f-b85f-1cb809af4aed" xlink:to="loc_jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations_ea785b59-b72e-4d81-918d-6dea9392e4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_003428d5-e598-416f-abcf-c01181f915f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2cae95fe-ec29-4dc3-93e0-9fbf49f96209" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_003428d5-e598-416f-abcf-c01181f915f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_41a2a4dd-e70d-4e1f-8eff-17e2504c1206" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_9be59ddb-3c4e-4087-a4f2-b240a66a420c" xlink:href="jnj-20241229.xsd#jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_41a2a4dd-e70d-4e1f-8eff-17e2504c1206" xlink:to="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_9be59ddb-3c4e-4087-a4f2-b240a66a420c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_33c450bb-5d34-4d9a-8b8e-8ac0d6c93c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_9be59ddb-3c4e-4087-a4f2-b240a66a420c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_33c450bb-5d34-4d9a-8b8e-8ac0d6c93c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_aba5ea79-4ce4-4fcd-8e0f-13653d0b726c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_9be59ddb-3c4e-4087-a4f2-b240a66a420c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_aba5ea79-4ce4-4fcd-8e0f-13653d0b726c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dc759cbf-89b3-4b6d-ad4c-f55c55847a08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_9be59ddb-3c4e-4087-a4f2-b240a66a420c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dc759cbf-89b3-4b6d-ad4c-f55c55847a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_6765bcf9-931c-42e7-92e6-4ded1ed207b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_9be59ddb-3c4e-4087-a4f2-b240a66a420c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_6765bcf9-931c-42e7-92e6-4ded1ed207b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_66a84db6-6a41-4b93-8c69-871e441695c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_6765bcf9-931c-42e7-92e6-4ded1ed207b0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_66a84db6-6a41-4b93-8c69-871e441695c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_72e7c2a2-7ee6-46e8-812d-28f1eb49c6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_6765bcf9-931c-42e7-92e6-4ded1ed207b0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_72e7c2a2-7ee6-46e8-812d-28f1eb49c6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation_808c3083-06a3-420e-b5e2-3dc5193e5378" xlink:href="jnj-20241229.xsd#jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_6765bcf9-931c-42e7-92e6-4ded1ed207b0" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation_808c3083-06a3-420e-b5e2-3dc5193e5378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome_93eb09e6-89c0-4da9-b197-93a0f1968f66" xlink:href="jnj-20241229.xsd#jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_6765bcf9-931c-42e7-92e6-4ded1ed207b0" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome_93eb09e6-89c0-4da9-b197-93a0f1968f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8bb4a83c-2112-4427-8fe8-a8b42a700685" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_6765bcf9-931c-42e7-92e6-4ded1ed207b0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8bb4a83c-2112-4427-8fe8-a8b42a700685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_334e3dc3-36c8-4ba1-af2d-c6e37e81920d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_6765bcf9-931c-42e7-92e6-4ded1ed207b0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_334e3dc3-36c8-4ba1-af2d-c6e37e81920d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_58163e3b-8aaf-418c-9406-c77c11261d51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_6765bcf9-931c-42e7-92e6-4ded1ed207b0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_58163e3b-8aaf-418c-9406-c77c11261d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_94108738-e2ec-49e7-8866-d1a12749b624" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_6765bcf9-931c-42e7-92e6-4ded1ed207b0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_94108738-e2ec-49e7-8866-d1a12749b624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncometaxesNarrativeDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#IncometaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncometaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_50f48b71-6af1-4d96-9096-36dbf0711612" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_f6bfa6fb-1090-4b78-85d1-1044e70f8146" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_50f48b71-6af1-4d96-9096-36dbf0711612" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_f6bfa6fb-1090-4b78-85d1-1044e70f8146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_895ab97b-52cb-4241-8904-d2f4819e4849" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_f6bfa6fb-1090-4b78-85d1-1044e70f8146" xlink:to="loc_srt_LitigationCaseAxis_895ab97b-52cb-4241-8904-d2f4819e4849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e2b69826-f59b-4bbb-90ed-1aafcc30b2c9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_895ab97b-52cb-4241-8904-d2f4819e4849" xlink:to="loc_srt_LitigationCaseTypeDomain_e2b69826-f59b-4bbb-90ed-1aafcc30b2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_36285c25-e391-418e-b0a3-7bb4c63c12d9" xlink:href="jnj-20241229.xsd#jnj_TalcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e2b69826-f59b-4bbb-90ed-1aafcc30b2c9" xlink:to="loc_jnj_TalcMember_36285c25-e391-418e-b0a3-7bb4c63c12d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_aaae11f2-c94c-4b13-a7e2-c9a7e756499c" xlink:href="jnj-20241229.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e2b69826-f59b-4bbb-90ed-1aafcc30b2c9" xlink:to="loc_jnj_RisperdalMember_aaae11f2-c94c-4b13-a7e2-c9a7e756499c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_78a3179f-3448-4ee8-b005-14002ff11e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_f6bfa6fb-1090-4b78-85d1-1044e70f8146" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_78a3179f-3448-4ee8-b005-14002ff11e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2da56eef-5459-4d25-9ab4-4d1b7628e36f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_78a3179f-3448-4ee8-b005-14002ff11e4a" xlink:to="loc_us-gaap_SegmentDomain_2da56eef-5459-4d25-9ab4-4d1b7628e36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_68cad141-e89e-4576-9261-e083546ca811" xlink:href="jnj-20241229.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2da56eef-5459-4d25-9ab4-4d1b7628e36f" xlink:to="loc_jnj_ConsumerMember_68cad141-e89e-4576-9261-e083546ca811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_27353d54-99e2-4ba7-8b8a-8c1ec86d7682" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_f6bfa6fb-1090-4b78-85d1-1044e70f8146" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_27353d54-99e2-4ba7-8b8a-8c1ec86d7682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d9451539-868c-424a-afc1-dd2488389cef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_27353d54-99e2-4ba7-8b8a-8c1ec86d7682" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d9451539-868c-424a-afc1-dd2488389cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ef01b064-d8af-4a2b-86d5-ac2c7a29bab6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_f6bfa6fb-1090-4b78-85d1-1044e70f8146" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ef01b064-d8af-4a2b-86d5-ac2c7a29bab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8b0ea607-b47d-40d6-b128-104314647a36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ef01b064-d8af-4a2b-86d5-ac2c7a29bab6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8b0ea607-b47d-40d6-b128-104314647a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_cc367d7c-98f2-4e7f-bfba-73c7c1db20a9" xlink:href="jnj-20241229.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8b0ea607-b47d-40d6-b128-104314647a36" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_cc367d7c-98f2-4e7f-bfba-73c7c1db20a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_958853f4-5dc6-4a6a-8be5-cc21edbc91e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_f6bfa6fb-1090-4b78-85d1-1044e70f8146" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_958853f4-5dc6-4a6a-8be5-cc21edbc91e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f4712a46-74ef-4dce-b1d5-2dbfc7624c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_958853f4-5dc6-4a6a-8be5-cc21edbc91e4" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f4712a46-74ef-4dce-b1d5-2dbfc7624c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_9144ca4d-2eb8-44b9-bf51-3a3b729e76cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f4712a46-74ef-4dce-b1d5-2dbfc7624c0f" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_9144ca4d-2eb8-44b9-bf51-3a3b729e76cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_f6bfa6fb-1090-4b78-85d1-1044e70f8146" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_42ca964f-996e-4b05-82fb-692b68e4de66" xlink:href="jnj-20241229.xsd#jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_42ca964f-996e-4b05-82fb-692b68e4de66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_6a4aa4aa-4582-43e5-8098-b6faf2c1fd3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_6a4aa4aa-4582-43e5-8098-b6faf2c1fd3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_98991976-2bb1-4401-ae84-927b4fe8da25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_98991976-2bb1-4401-ae84-927b4fe8da25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent_06cbe9f9-daaf-415a-b31d-0a0b686d3dfd" xlink:href="jnj-20241229.xsd#jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent_06cbe9f9-daaf-415a-b31d-0a0b686d3dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_c75773cb-4c47-447f-94f5-de1bb21b3fd4" xlink:href="jnj-20241229.xsd#jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_c75773cb-4c47-447f-94f5-de1bb21b3fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount_f3bb41e1-7d11-4fea-a2a0-85213abf1073" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount_f3bb41e1-7d11-4fea-a2a0-85213abf1073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI_1836e46e-58c2-4760-a904-cc70f6797db0" xlink:href="jnj-20241229.xsd#jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI_1836e46e-58c2-4760-a904-cc70f6797db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_dca37bf2-9540-424d-aa59-f5bbe76326df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_us-gaap_LitigationSettlementExpense_dca37bf2-9540-424d-aa59-f5bbe76326df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_d995841d-9bf3-462a-a749-66e193cfed59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_d995841d-9bf3-462a-a749-66e193cfed59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_780f0cd3-b0a4-4a6b-82e8-47d620790b76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_780f0cd3-b0a4-4a6b-82e8-47d620790b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_70666475-533c-4ba4-ad0a-39c628d33846" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_70666475-533c-4ba4-ad0a-39c628d33846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_2a423bd6-0b91-4ea0-9834-d2e55cfdbe91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_2a423bd6-0b91-4ea0-9834-d2e55cfdbe91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_f48e0c52-3189-4160-a774-69db54b4e430" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_f48e0c52-3189-4160-a774-69db54b4e430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_5980f43e-9523-4357-94d2-0cc7cc307b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_89e74bad-54fb-4442-a81b-346622db5275" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_5980f43e-9523-4357-94d2-0cc7cc307b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#IncometaxesTemporaryDifferencesandCarryforwardsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7f950c78-1c48-46d0-a65e-a8f988954902" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2ba7debf-969f-4b69-a00c-766519523678" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7f950c78-1c48-46d0-a65e-a8f988954902" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2ba7debf-969f-4b69-a00c-766519523678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_e05e1e07-02a2-44db-895d-23f3f347756c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2ba7debf-969f-4b69-a00c-766519523678" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_e05e1e07-02a2-44db-895d-23f3f347756c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_b7f9d5bc-bd86-468a-8c6b-6747bfd4a0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e05e1e07-02a2-44db-895d-23f3f347756c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_b7f9d5bc-bd86-468a-8c6b-6747bfd4a0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_a027ef3b-d64f-42d7-adcb-8a112dfb0efe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e05e1e07-02a2-44db-895d-23f3f347756c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_a027ef3b-d64f-42d7-adcb-8a112dfb0efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized_3e9217d1-4267-4f93-8550-fef5e5a7f25c" xlink:href="jnj-20241229.xsd#jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e05e1e07-02a2-44db-895d-23f3f347756c" xlink:to="loc_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized_3e9217d1-4267-4f93-8550-fef5e5a7f25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_ebb537e0-a8f9-4f20-8fdf-d9549e09455b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e05e1e07-02a2-44db-895d-23f3f347756c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_ebb537e0-a8f9-4f20-8fdf-d9549e09455b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_44d4efad-b4bc-40b0-bbaf-a21bd3c4a450" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e05e1e07-02a2-44db-895d-23f3f347756c" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_44d4efad-b4bc-40b0-bbaf-a21bd3c4a450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ae90d825-1708-4367-a3d5-d51822bece42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e05e1e07-02a2-44db-895d-23f3f347756c" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ae90d825-1708-4367-a3d5-d51822bece42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsUndistributedForeignEarnings_8d75abd7-1e14-4803-bc53-e68a9d036ad5" xlink:href="jnj-20241229.xsd#jnj_DeferredTaxAssetsUndistributedForeignEarnings"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e05e1e07-02a2-44db-895d-23f3f347756c" xlink:to="loc_jnj_DeferredTaxAssetsUndistributedForeignEarnings_8d75abd7-1e14-4803-bc53-e68a9d036ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_933d5779-0df5-4a84-b0fd-b024ea1be104" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e05e1e07-02a2-44db-895d-23f3f347756c" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_933d5779-0df5-4a84-b0fd-b024ea1be104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsOtherDomestic_b4b19c56-21a5-4528-aa6b-e29ffe5f5dc1" xlink:href="jnj-20241229.xsd#jnj_DeferredTaxAssetsOtherDomestic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e05e1e07-02a2-44db-895d-23f3f347756c" xlink:to="loc_jnj_DeferredTaxAssetsOtherDomestic_b4b19c56-21a5-4528-aa6b-e29ffe5f5dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_15b75bc0-c158-4cc5-8d46-6efa1fd088b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e05e1e07-02a2-44db-895d-23f3f347756c" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_15b75bc0-c158-4cc5-8d46-6efa1fd088b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e6adba2b-f003-4383-9ae6-52a7f07612a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e05e1e07-02a2-44db-895d-23f3f347756c" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e6adba2b-f003-4383-9ae6-52a7f07612a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_754ba634-722f-43a5-b7d2-55a23ddf12bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e05e1e07-02a2-44db-895d-23f3f347756c" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_754ba634-722f-43a5-b7d2-55a23ddf12bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_20efb536-1773-484d-94bc-d6c4f9fd75ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2ba7debf-969f-4b69-a00c-766519523678" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_20efb536-1773-484d-94bc-d6c4f9fd75ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_0803d902-5f53-47cc-b253-6431ed82f854" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_20efb536-1773-484d-94bc-d6c4f9fd75ca" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_0803d902-5f53-47cc-b253-6431ed82f854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_b6839a03-b932-4029-b63e-c077ad726cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_20efb536-1773-484d-94bc-d6c4f9fd75ca" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_b6839a03-b932-4029-b63e-c077ad726cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_493e6b0d-3bcd-42bf-afae-51b7b31c9f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_20efb536-1773-484d-94bc-d6c4f9fd75ca" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_493e6b0d-3bcd-42bf-afae-51b7b31c9f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome_b92911b9-375d-48c5-9a52-5322a19fe22e" xlink:href="jnj-20241229.xsd#jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_20efb536-1773-484d-94bc-d6c4f9fd75ca" xlink:to="loc_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome_b92911b9-375d-48c5-9a52-5322a19fe22e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxLiabilitiesOtherDomestic_9d5455f4-b80c-4cd3-ad26-467737b53d70" xlink:href="jnj-20241229.xsd#jnj_DeferredTaxLiabilitiesOtherDomestic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_20efb536-1773-484d-94bc-d6c4f9fd75ca" xlink:to="loc_jnj_DeferredTaxLiabilitiesOtherDomestic_9d5455f4-b80c-4cd3-ad26-467737b53d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_a50c22b4-549f-45a6-b94e-32aba71151c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_20efb536-1773-484d-94bc-d6c4f9fd75ca" xlink:to="loc_us-gaap_DeferredTaxLiabilities_a50c22b4-549f-45a6-b94e-32aba71151c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncometaxesValuationAllowanceActivityDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#IncometaxesValuationAllowanceActivityDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncometaxesValuationAllowanceActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_989feb52-8ec8-43c9-bcde-2f859e25ddb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ValuationAllowanceRollForward_0094e26e-9258-46b6-b8b4-3a8ce662b143" xlink:href="jnj-20241229.xsd#jnj_ValuationAllowanceRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_989feb52-8ec8-43c9-bcde-2f859e25ddb7" xlink:to="loc_jnj_ValuationAllowanceRollForward_0094e26e-9258-46b6-b8b4-3a8ce662b143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7332e5c6-8efa-4d65-a949-b1b33c35660f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ValuationAllowanceRollForward_0094e26e-9258-46b6-b8b4-3a8ce662b143" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7332e5c6-8efa-4d65-a949-b1b33c35660f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ValuationAllowanceDeferredTaxAssetsProvision_50563d0a-97b8-4092-a666-c85a4f733393" xlink:href="jnj-20241229.xsd#jnj_ValuationAllowanceDeferredTaxAssetsProvision"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ValuationAllowanceRollForward_0094e26e-9258-46b6-b8b4-3a8ce662b143" xlink:to="loc_jnj_ValuationAllowanceDeferredTaxAssetsProvision_50563d0a-97b8-4092-a666-c85a4f733393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ValuationAllowanceDeferredTaxAssetsUtilization_2d3a1b8a-ad90-4820-936e-c44af75885ea" xlink:href="jnj-20241229.xsd#jnj_ValuationAllowanceDeferredTaxAssetsUtilization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ValuationAllowanceRollForward_0094e26e-9258-46b6-b8b4-3a8ce662b143" xlink:to="loc_jnj_ValuationAllowanceDeferredTaxAssetsUtilization_2d3a1b8a-ad90-4820-936e-c44af75885ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslation_96b8e58b-792d-4571-9ae3-c191ac06b4cb" xlink:href="jnj-20241229.xsd#jnj_ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ValuationAllowanceRollForward_0094e26e-9258-46b6-b8b4-3a8ce662b143" xlink:to="loc_jnj_ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslation_96b8e58b-792d-4571-9ae3-c191ac06b4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ValuationAllowanceDeferredTaxAssetsAcquisitionsDispositions_411dc718-9b13-4554-ab79-3a80c2a83db8" xlink:href="jnj-20241229.xsd#jnj_ValuationAllowanceDeferredTaxAssetsAcquisitionsDispositions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ValuationAllowanceRollForward_0094e26e-9258-46b6-b8b4-3a8ce662b143" xlink:to="loc_jnj_ValuationAllowanceDeferredTaxAssetsAcquisitionsDispositions_411dc718-9b13-4554-ab79-3a80c2a83db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4a24b132-a306-435f-a1f0-3ad01d3b4871" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ValuationAllowanceRollForward_0094e26e-9258-46b6-b8b4-3a8ce662b143" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4a24b132-a306-435f-a1f0-3ad01d3b4871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncometaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#IncometaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncometaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_cea17cf9-3bd1-4fc7-8594-b6440e82b2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c059e172-4683-457d-906d-fe0a0612b59c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cea17cf9-3bd1-4fc7-8594-b6440e82b2f4" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c059e172-4683-457d-906d-fe0a0612b59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e9364adf-c49a-43e5-8dab-9d9bb33cb832" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c059e172-4683-457d-906d-fe0a0612b59c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e9364adf-c49a-43e5-8dab-9d9bb33cb832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_42091c90-8080-40ee-b4bc-77202cae3e43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c059e172-4683-457d-906d-fe0a0612b59c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_42091c90-8080-40ee-b4bc-77202cae3e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_2715de9a-b534-4a4c-a3ba-ab98ddced26c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c059e172-4683-457d-906d-fe0a0612b59c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_2715de9a-b534-4a4c-a3ba-ab98ddced26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_d438ba91-6184-4b2c-b94e-b45a4bbff6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c059e172-4683-457d-906d-fe0a0612b59c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_d438ba91-6184-4b2c-b94e-b45a4bbff6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_1cbb6d44-249e-47f5-ac83-0d83f23660f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c059e172-4683-457d-906d-fe0a0612b59c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_1cbb6d44-249e-47f5-ac83-0d83f23660f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_bf56419a-be90-495b-b556-e1d802eeadf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c059e172-4683-457d-906d-fe0a0612b59c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_bf56419a-be90-495b-b556-e1d802eeadf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_3736f424-c8d3-4ed3-9c50-df73014a4a25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c059e172-4683-457d-906d-fe0a0612b59c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_3736f424-c8d3-4ed3-9c50-df73014a4a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#EmployeerelatedobligationsEmployeeRelatedObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_27ef19a2-b88e-4828-b663-e4d5185b866e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_05178256-0909-4742-8714-e963758a2bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_27ef19a2-b88e-4828-b663-e4d5185b866e" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_05178256-0909-4742-8714-e963758a2bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_f4a6af1e-49fa-4cf0-9c0b-ba922c4f4ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_05178256-0909-4742-8714-e963758a2bc7" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_f4a6af1e-49fa-4cf0-9c0b-ba922c4f4ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent_ff57e358-41cd-4ccd-ad78-3986a013aa67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_05178256-0909-4742-8714-e963758a2bc7" xlink:to="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent_ff57e358-41cd-4ccd-ad78-3986a013aa67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_1c461f48-4c6f-44cc-8d31-fcb90261f9de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_05178256-0909-4742-8714-e963758a2bc7" xlink:to="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_1c461f48-4c6f-44cc-8d31-fcb90261f9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_0e7d5aa1-f32d-4c5c-a25d-0fedcb2af82f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_05178256-0909-4742-8714-e963758a2bc7" xlink:to="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_0e7d5aa1-f32d-4c5c-a25d-0fedcb2af82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeObligations_f580f146-1d38-4315-b3cd-a5e61b9bc712" xlink:href="jnj-20241229.xsd#jnj_EmployeeObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_05178256-0909-4742-8714-e963758a2bc7" xlink:to="loc_jnj_EmployeeObligations_f580f146-1d38-4315-b3cd-a5e61b9bc712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_a9b475d1-93fb-48e1-b217-ff7d9e58cf52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_05178256-0909-4742-8714-e963758a2bc7" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_a9b475d1-93fb-48e1-b217-ff7d9e58cf52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_4fb1ffb6-526c-4098-bf6d-25af212a0b31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_05178256-0909-4742-8714-e963758a2bc7" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_4fb1ffb6-526c-4098-bf6d-25af212a0b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeerelatedobligationsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#EmployeerelatedobligationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EmployeerelatedobligationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_00a79bc2-d4f4-4a9e-abc0-bdadf80cfb74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_5581c3be-c53a-4984-9eaa-8c313240609e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_00a79bc2-d4f4-4a9e-abc0-bdadf80cfb74" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_5581c3be-c53a-4984-9eaa-8c313240609e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#PensionsandotherbenefitplansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_df61bef3-18cd-4d35-a7a9-816c7818534f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5e6a60e5-3eb1-4e7c-b5c4-75dce25f22c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_df61bef3-18cd-4d35-a7a9-816c7818534f" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5e6a60e5-3eb1-4e7c-b5c4-75dce25f22c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b1464b21-cf91-419b-be4e-0c7355a39d2a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5e6a60e5-3eb1-4e7c-b5c4-75dce25f22c3" xlink:to="loc_srt_RangeAxis_b1464b21-cf91-419b-be4e-0c7355a39d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1f9a5722-fe30-4e0e-aa91-c647d37a43a8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b1464b21-cf91-419b-be4e-0c7355a39d2a" xlink:to="loc_srt_RangeMember_1f9a5722-fe30-4e0e-aa91-c647d37a43a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_64d5b68a-86ec-4700-b1d2-c82f8480f65c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1f9a5722-fe30-4e0e-aa91-c647d37a43a8" xlink:to="loc_srt_MaximumMember_64d5b68a-86ec-4700-b1d2-c82f8480f65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_54f29874-a595-40c0-b1d5-29738b05670b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5e6a60e5-3eb1-4e7c-b5c4-75dce25f22c3" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_54f29874-a595-40c0-b1d5-29738b05670b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_a5c23835-3f7b-4784-91bd-315786eb1201" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_54f29874-a595-40c0-b1d5-29738b05670b" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_a5c23835-3f7b-4784-91bd-315786eb1201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CommingledFundsMember_f505b627-3c35-4fd4-b806-37773a5f9079" xlink:href="jnj-20241229.xsd#jnj_CommingledFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a5c23835-3f7b-4784-91bd-315786eb1201" xlink:to="loc_jnj_CommingledFundsMember_f505b627-3c35-4fd4-b806-37773a5f9079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_faf53a19-a1ae-4ac1-967c-d1d8ac461637" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5e6a60e5-3eb1-4e7c-b5c4-75dce25f22c3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_faf53a19-a1ae-4ac1-967c-d1d8ac461637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2c01f42b-c0fc-4d30-9246-ec4eb910e446" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_faf53a19-a1ae-4ac1-967c-d1d8ac461637" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2c01f42b-c0fc-4d30-9246-ec4eb910e446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9e5e007c-90f3-40b0-8ae0-74339c0e88d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2c01f42b-c0fc-4d30-9246-ec4eb910e446" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9e5e007c-90f3-40b0-8ae0-74339c0e88d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_5aeafa9b-e7fc-42c4-9f26-4c738a054702" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5e6a60e5-3eb1-4e7c-b5c4-75dce25f22c3" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_5aeafa9b-e7fc-42c4-9f26-4c738a054702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_d9062ee2-9dca-4a9e-9668-ee30e419e5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_5aeafa9b-e7fc-42c4-9f26-4c738a054702" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_d9062ee2-9dca-4a9e-9668-ee30e419e5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_3268c9f5-d623-4335-b557-aa9ef79f60f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_d9062ee2-9dca-4a9e-9668-ee30e419e5b8" xlink:to="loc_us-gaap_DomesticPlanMember_3268c9f5-d623-4335-b557-aa9ef79f60f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_33f77635-c408-4935-b49a-e2da6eeb3941" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_3268c9f5-d623-4335-b557-aa9ef79f60f3" xlink:to="loc_country_US_33f77635-c408-4935-b49a-e2da6eeb3941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_e31af6da-175d-4f09-8de7-f05814987591" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_d9062ee2-9dca-4a9e-9668-ee30e419e5b8" xlink:to="loc_us-gaap_ForeignPlanMember_e31af6da-175d-4f09-8de7-f05814987591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_05dfbf7e-f207-4253-a776-e6d2c084788e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5e6a60e5-3eb1-4e7c-b5c4-75dce25f22c3" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_05dfbf7e-f207-4253-a776-e6d2c084788e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_068a710a-a0dd-4e61-aa4f-9af0a36917b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_05dfbf7e-f207-4253-a776-e6d2c084788e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_068a710a-a0dd-4e61-aa4f-9af0a36917b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_d38e1002-7b22-461a-b26e-ca0add7ed3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_068a710a-a0dd-4e61-aa4f-9af0a36917b2" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_d38e1002-7b22-461a-b26e-ca0add7ed3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_09581ee7-c1b6-4193-9012-5edde88b61aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_068a710a-a0dd-4e61-aa4f-9af0a36917b2" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_09581ee7-c1b6-4193-9012-5edde88b61aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4c3f04ef-3be9-47cc-95ee-e09abedb382c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5e6a60e5-3eb1-4e7c-b5c4-75dce25f22c3" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4c3f04ef-3be9-47cc-95ee-e09abedb382c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeCompensationPeriod_bd97257f-ad2b-452f-b8ad-f64188cb2e0d" xlink:href="jnj-20241229.xsd#jnj_EmployeeCompensationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4c3f04ef-3be9-47cc-95ee-e09abedb382c" xlink:to="loc_jnj_EmployeeCompensationPeriod_bd97257f-ad2b-452f-b8ad-f64188cb2e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets_248e993e-b256-4c29-a82f-585a1007c753" xlink:href="jnj-20241229.xsd#jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4c3f04ef-3be9-47cc-95ee-e09abedb382c" xlink:to="loc_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets_248e993e-b256-4c29-a82f-585a1007c753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions_6803f4c4-890e-4ad5-befb-6ccec1d7001a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionContributions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4c3f04ef-3be9-47cc-95ee-e09abedb382c" xlink:to="loc_us-gaap_PensionContributions_6803f4c4-890e-4ad5-befb-6ccec1d7001a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_b7566ab8-9cca-40a0-a9ec-b1c077f221f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4c3f04ef-3be9-47cc-95ee-e09abedb382c" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_b7566ab8-9cca-40a0-a9ec-b1c077f221f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_85d11e9a-d93f-4c49-be71-9a646eca34f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4c3f04ef-3be9-47cc-95ee-e09abedb382c" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_85d11e9a-d93f-4c49-be71-9a646eca34f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_e3c28ada-180b-49f7-90cf-046233b505f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4c3f04ef-3be9-47cc-95ee-e09abedb382c" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_e3c28ada-180b-49f7-90cf-046233b505f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_8c5de8b5-ee8f-4d2a-a70e-d1a70f16a872" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4c3f04ef-3be9-47cc-95ee-e09abedb382c" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_8c5de8b5-ee8f-4d2a-a70e-d1a70f16a872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets_7386524f-2668-477a-8c4f-e9bc9e1d0ccd" xlink:href="jnj-20241229.xsd#jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4c3f04ef-3be9-47cc-95ee-e09abedb382c" xlink:to="loc_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets_7386524f-2668-477a-8c4f-e9bc9e1d0ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_381e44a8-98e8-4e78-bc23-345ab8305f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1205e2d8-06e6-4386-94d2-769d8ef49b71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_381e44a8-98e8-4e78-bc23-345ab8305f1c" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1205e2d8-06e6-4386-94d2-769d8ef49b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_e32ea0c1-13b3-4729-8389-fb1cdcce851a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1205e2d8-06e6-4386-94d2-769d8ef49b71" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_e32ea0c1-13b3-4729-8389-fb1cdcce851a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_ed1611eb-53b7-4bd8-836b-3022b451c909" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_e32ea0c1-13b3-4729-8389-fb1cdcce851a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_ed1611eb-53b7-4bd8-836b-3022b451c909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_4533e683-884c-4792-9e8f-4494a4e92975" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_ed1611eb-53b7-4bd8-836b-3022b451c909" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_4533e683-884c-4792-9e8f-4494a4e92975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_a8221675-f87f-47ca-91ba-4a4f75d3525a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_ed1611eb-53b7-4bd8-836b-3022b451c909" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_a8221675-f87f-47ca-91ba-4a4f75d3525a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_513c7f83-bb93-4e19-90f3-0d8918240bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1205e2d8-06e6-4386-94d2-769d8ef49b71" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_513c7f83-bb93-4e19-90f3-0d8918240bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_eb097104-cb75-4aef-91d7-54d4af0d6896" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_513c7f83-bb93-4e19-90f3-0d8918240bb5" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_eb097104-cb75-4aef-91d7-54d4af0d6896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_a5f48ec4-5422-475c-8cef-81ae8412d546" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_513c7f83-bb93-4e19-90f3-0d8918240bb5" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_a5f48ec4-5422-475c-8cef-81ae8412d546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_f2217b0d-6584-4804-9a3f-079c1418d003" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_513c7f83-bb93-4e19-90f3-0d8918240bb5" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_f2217b0d-6584-4804-9a3f-079c1418d003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_e001341d-eed7-4145-bb65-9f57d4605251" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_513c7f83-bb93-4e19-90f3-0d8918240bb5" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_e001341d-eed7-4145-bb65-9f57d4605251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_16b9da3f-ba10-4fa2-a25e-a721033b1fea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_513c7f83-bb93-4e19-90f3-0d8918240bb5" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_16b9da3f-ba10-4fa2-a25e-a721033b1fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_a962cc98-a8d2-4026-ae60-61f1983d2390" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_513c7f83-bb93-4e19-90f3-0d8918240bb5" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_a962cc98-a8d2-4026-ae60-61f1983d2390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_855c0944-ccbf-4bcf-b74d-5dee59751822" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_513c7f83-bb93-4e19-90f3-0d8918240bb5" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_855c0944-ccbf-4bcf-b74d-5dee59751822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_809f677c-4ac4-480e-878a-fc07fa89821d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_921ca349-dc7e-41e4-8e88-39c441e92fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_809f677c-4ac4-480e-878a-fc07fa89821d" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_921ca349-dc7e-41e4-8e88-39c441e92fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_a0f93744-3412-4327-81df-0875aae29787" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_921ca349-dc7e-41e4-8e88-39c441e92fd9" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_a0f93744-3412-4327-81df-0875aae29787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_1154e64a-7988-4f4f-bf25-7222e368dab4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a0f93744-3412-4327-81df-0875aae29787" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_1154e64a-7988-4f4f-bf25-7222e368dab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_03f48f94-37b4-4fb3-9374-cb1c029eef75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1154e64a-7988-4f4f-bf25-7222e368dab4" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_03f48f94-37b4-4fb3-9374-cb1c029eef75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_7e555f50-4d6c-42b6-b47f-8d2976c87864" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1154e64a-7988-4f4f-bf25-7222e368dab4" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_7e555f50-4d6c-42b6-b47f-8d2976c87864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_47833c7b-fd26-42d5-977e-b319e1d6e7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_921ca349-dc7e-41e4-8e88-39c441e92fd9" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_47833c7b-fd26-42d5-977e-b319e1d6e7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_b7b03fae-2e0b-434f-a489-8f39c1c28eed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_47833c7b-fd26-42d5-977e-b319e1d6e7cb" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_b7b03fae-2e0b-434f-a489-8f39c1c28eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_114aa32d-79fe-48f9-b358-86ae4a417098" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_b7b03fae-2e0b-434f-a489-8f39c1c28eed" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_114aa32d-79fe-48f9-b358-86ae4a417098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_6dc2db91-aed9-4191-8737-e8cad69298d3" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_b7b03fae-2e0b-434f-a489-8f39c1c28eed" xlink:to="loc_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_6dc2db91-aed9-4191-8737-e8cad69298d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_c374e5c3-e4f0-4a51-9711-3802940dad99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_b7b03fae-2e0b-434f-a489-8f39c1c28eed" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_c374e5c3-e4f0-4a51-9711-3802940dad99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_16371e79-06c9-45ac-b372-c244da52fe73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_b7b03fae-2e0b-434f-a489-8f39c1c28eed" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_16371e79-06c9-45ac-b372-c244da52fe73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_65f9a721-0357-496f-896d-c871932f16b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_47833c7b-fd26-42d5-977e-b319e1d6e7cb" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_65f9a721-0357-496f-896d-c871932f16b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_1d75c4d7-9505-4dff-9ceb-4a2dba37b8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_65f9a721-0357-496f-896d-c871932f16b8" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_1d75c4d7-9505-4dff-9ceb-4a2dba37b8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_482eeddd-319a-42d9-8baf-c94d75bb1b84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_65f9a721-0357-496f-896d-c871932f16b8" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_482eeddd-319a-42d9-8baf-c94d75bb1b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansAssumedHealthCareCostTrendRatesDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#PensionsandotherbenefitplansAssumedHealthCareCostTrendRatesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandotherbenefitplansAssumedHealthCareCostTrendRatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_bb50ae04-40df-40ea-b421-d1f3f5557bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract_3c1b0b20-1df4-41f7-9526-90c7c5b8fa16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_bb50ae04-40df-40ea-b421-d1f3f5557bd6" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract_3c1b0b20-1df4-41f7-9526-90c7c5b8fa16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_83d751ad-e5b4-4520-a91d-2572141cc24b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract_3c1b0b20-1df4-41f7-9526-90c7c5b8fa16" xlink:to="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_83d751ad-e5b4-4520-a91d-2572141cc24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_224bf262-cdfd-4992-87b4-b28e27a67331" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract_3c1b0b20-1df4-41f7-9526-90c7c5b8fa16" xlink:to="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_224bf262-cdfd-4992-87b4-b28e27a67331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_fed88842-7b14-4529-8c82-be6d57439b11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract_3c1b0b20-1df4-41f7-9526-90c7c5b8fa16" xlink:to="loc_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_fed88842-7b14-4529-8c82-be6d57439b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b9e6ce68-b4c0-4e96-b828-47a28c3d683c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_143dafdc-4390-4c3a-bca4-adedcff126f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b9e6ce68-b4c0-4e96-b828-47a28c3d683c" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_143dafdc-4390-4c3a-bca4-adedcff126f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_a12cea89-6a12-4936-b565-1571ad3b56d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_143dafdc-4390-4c3a-bca4-adedcff126f1" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_a12cea89-6a12-4936-b565-1571ad3b56d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_dba0bae9-92b6-466d-9eb3-6f2c7d2f13a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a12cea89-6a12-4936-b565-1571ad3b56d5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_dba0bae9-92b6-466d-9eb3-6f2c7d2f13a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_1c07db74-2118-4f9b-af31-e27f3f49af58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_dba0bae9-92b6-466d-9eb3-6f2c7d2f13a5" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_1c07db74-2118-4f9b-af31-e27f3f49af58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_2b154d47-0a1d-451d-8e31-1164a730f3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_dba0bae9-92b6-466d-9eb3-6f2c7d2f13a5" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_2b154d47-0a1d-451d-8e31-1164a730f3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e436275d-5bf2-40f0-a327-28e4eb2cae05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_143dafdc-4390-4c3a-bca4-adedcff126f1" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e436275d-5bf2-40f0-a327-28e4eb2cae05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_6342a166-37c0-4075-b5df-3dd0dd3ee5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e436275d-5bf2-40f0-a327-28e4eb2cae05" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_6342a166-37c0-4075-b5df-3dd0dd3ee5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_5d4689e8-dbf8-4e05-bb51-a7f4e439db59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_6342a166-37c0-4075-b5df-3dd0dd3ee5c4" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_5d4689e8-dbf8-4e05-bb51-a7f4e439db59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_5fffca5b-ea61-481c-86a3-ae7e39c78b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_6342a166-37c0-4075-b5df-3dd0dd3ee5c4" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_5fffca5b-ea61-481c-86a3-ae7e39c78b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_c029428c-52eb-4182-906a-6d1fd68cafa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_6342a166-37c0-4075-b5df-3dd0dd3ee5c4" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_c029428c-52eb-4182-906a-6d1fd68cafa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_a774fcea-d621-443b-a59b-f87af806f365" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_6342a166-37c0-4075-b5df-3dd0dd3ee5c4" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_a774fcea-d621-443b-a59b-f87af806f365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments_840879c4-c55d-45a1-a03c-a87d2cfb2d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_6342a166-37c0-4075-b5df-3dd0dd3ee5c4" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAmendments_840879c4-c55d-45a1-a03c-a87d2cfb2d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_61c6a2b0-835d-4280-8a4c-16dbb7d303f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_6342a166-37c0-4075-b5df-3dd0dd3ee5c4" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_61c6a2b0-835d-4280-8a4c-16dbb7d303f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease_9eeac8ff-9395-4810-8bc1-71ff648007f8" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_6342a166-37c0-4075-b5df-3dd0dd3ee5c4" xlink:to="loc_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease_9eeac8ff-9395-4810-8bc1-71ff648007f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CurtailmentsAndSettlementsAndRestructuring_63bf79b3-43cf-41ed-be9c-ce9fbf407cbe" xlink:href="jnj-20241229.xsd#jnj_CurtailmentsAndSettlementsAndRestructuring"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_6342a166-37c0-4075-b5df-3dd0dd3ee5c4" xlink:to="loc_jnj_CurtailmentsAndSettlementsAndRestructuring_63bf79b3-43cf-41ed-be9c-ce9fbf407cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_2a4b1e3d-53fb-4a25-893e-48d953399cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_6342a166-37c0-4075-b5df-3dd0dd3ee5c4" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_2a4b1e3d-53fb-4a25-893e-48d953399cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_b42b6b73-ecaf-437d-b7ab-ffa5e586d483" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_6342a166-37c0-4075-b5df-3dd0dd3ee5c4" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_b42b6b73-ecaf-437d-b7ab-ffa5e586d483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_8c3af9b8-c88e-41ce-8272-eff237d22385" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_6342a166-37c0-4075-b5df-3dd0dd3ee5c4" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_8c3af9b8-c88e-41ce-8272-eff237d22385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_fcd0f491-2891-499e-bfe7-61fbe768be31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e436275d-5bf2-40f0-a327-28e4eb2cae05" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_fcd0f491-2891-499e-bfe7-61fbe768be31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_cc9172eb-f3cd-4273-9e99-c3ab93adc639" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_fcd0f491-2891-499e-bfe7-61fbe768be31" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_cc9172eb-f3cd-4273-9e99-c3ab93adc639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_ef02c053-b006-4527-b52e-3be2fe061af8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_fcd0f491-2891-499e-bfe7-61fbe768be31" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_ef02c053-b006-4527-b52e-3be2fe061af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_6c07af88-9950-46d0-8269-9b50c26405d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_fcd0f491-2891-499e-bfe7-61fbe768be31" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_6c07af88-9950-46d0-8269-9b50c26405d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_9df28503-825d-470f-aa7a-dc4f343a693d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_fcd0f491-2891-499e-bfe7-61fbe768be31" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_9df28503-825d-470f-aa7a-dc4f343a693d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_f8b95c24-081e-4f2b-8da6-4912ed680569" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_fcd0f491-2891-499e-bfe7-61fbe768be31" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_f8b95c24-081e-4f2b-8da6-4912ed680569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease_bf090919-a5a8-4bca-9ec1-b24043cd16c5" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_fcd0f491-2891-499e-bfe7-61fbe768be31" xlink:to="loc_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease_bf090919-a5a8-4bca-9ec1-b24043cd16c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_8905cfe9-b90e-47e4-addf-9aa89dd15464" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_fcd0f491-2891-499e-bfe7-61fbe768be31" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_8905cfe9-b90e-47e4-addf-9aa89dd15464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_4b7b06e4-9639-40cb-a942-893f3d4dac67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_fcd0f491-2891-499e-bfe7-61fbe768be31" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_4b7b06e4-9639-40cb-a942-893f3d4dac67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b259ec30-9430-41a7-9d5f-9430fd8ff313" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_fcd0f491-2891-499e-bfe7-61fbe768be31" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b259ec30-9430-41a7-9d5f-9430fd8ff313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_26522b05-326d-4113-9309-c82c0eeaa3af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_fcd0f491-2891-499e-bfe7-61fbe768be31" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_26522b05-326d-4113-9309-c82c0eeaa3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_932db230-d2f0-46fa-84fa-2f3370ab3a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e436275d-5bf2-40f0-a327-28e4eb2cae05" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_932db230-d2f0-46fa-84fa-2f3370ab3a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_31c6554f-47ad-4113-bbd9-511c62ce58f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_932db230-d2f0-46fa-84fa-2f3370ab3a4a" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_31c6554f-47ad-4113-bbd9-511c62ce58f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_51626111-05aa-4b83-baaf-445f4c48fb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_932db230-d2f0-46fa-84fa-2f3370ab3a4a" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_51626111-05aa-4b83-baaf-445f4c48fb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_48293fa6-a2a1-4a8c-9ae5-5f40b0914891" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_932db230-d2f0-46fa-84fa-2f3370ab3a4a" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_48293fa6-a2a1-4a8c-9ae5-5f40b0914891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_9e39e2b9-1e03-45b8-ab3b-84504bfc2897" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_932db230-d2f0-46fa-84fa-2f3370ab3a4a" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_9e39e2b9-1e03-45b8-ab3b-84504bfc2897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_35c97b95-e4a9-4db6-a838-ff7e6d59391c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e436275d-5bf2-40f0-a327-28e4eb2cae05" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_35c97b95-e4a9-4db6-a838-ff7e6d59391c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_280f1ff1-6467-45bf-9dd9-5f088763b855" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_35c97b95-e4a9-4db6-a838-ff7e6d59391c" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_280f1ff1-6467-45bf-9dd9-5f088763b855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_b1efaf07-207c-4515-b2ab-4f4e85f4ab15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_35c97b95-e4a9-4db6-a838-ff7e6d59391c" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_b1efaf07-207c-4515-b2ab-4f4e85f4ab15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_8ef4a942-85f8-437e-a9df-0c3377c4c843" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_35c97b95-e4a9-4db6-a838-ff7e6d59391c" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_8ef4a942-85f8-437e-a9df-0c3377c4c843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_9432fa49-d5e0-4149-a098-51dadd885cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_35c97b95-e4a9-4db6-a838-ff7e6d59391c" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_9432fa49-d5e0-4149-a098-51dadd885cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_4c54f02a-218b-43d5-b2fb-08f74e52f303" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_35c97b95-e4a9-4db6-a838-ff7e6d59391c" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_4c54f02a-218b-43d5-b2fb-08f74e52f303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract_0e1cefb4-fc13-4ca7-a35d-15526721cd9e" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_35c97b95-e4a9-4db6-a838-ff7e6d59391c" xlink:to="loc_jnj_DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract_0e1cefb4-fc13-4ca7-a35d-15526721cd9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_8791f08c-f092-4938-be74-15d9073485b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e436275d-5bf2-40f0-a327-28e4eb2cae05" xlink:to="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_8791f08c-f092-4938-be74-15d9073485b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_a28decc5-2538-4ad4-82a5-162e725e89f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_8791f08c-f092-4938-be74-15d9073485b5" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_a28decc5-2538-4ad4-82a5-162e725e89f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_aef9be59-4361-46b7-9aa0-8e799251b2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_8791f08c-f092-4938-be74-15d9073485b5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_aef9be59-4361-46b7-9aa0-8e799251b2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_2f7ef138-9f6f-4edd-9ef2-ed0ff69f3dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_8791f08c-f092-4938-be74-15d9073485b5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_2f7ef138-9f6f-4edd-9ef2-ed0ff69f3dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_f42dcac7-b7fe-422e-a77c-b4c132bff459" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_8791f08c-f092-4938-be74-15d9073485b5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_f42dcac7-b7fe-422e-a77c-b4c132bff459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_6503f148-336c-4105-9e87-999f47c5678b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_8791f08c-f092-4938-be74-15d9073485b5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_6503f148-336c-4105-9e87-999f47c5678b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectOfExchangeRates_a5b9521d-623e-4536-96ac-1dcbfeb9a356" xlink:href="jnj-20241229.xsd#jnj_EffectOfExchangeRates"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_8791f08c-f092-4938-be74-15d9073485b5" xlink:to="loc_jnj_EffectOfExchangeRates_a5b9521d-623e-4536-96ac-1dcbfeb9a356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_c0b8afd1-4f0e-48ae-a8c7-6abe1098cd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_8791f08c-f092-4938-be74-15d9073485b5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_c0b8afd1-4f0e-48ae-a8c7-6abe1098cd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_a36d621b-9c1d-430e-804a-bbfa01f61ade" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_8791f08c-f092-4938-be74-15d9073485b5" xlink:to="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_a36d621b-9c1d-430e-804a-bbfa01f61ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_01e89896-7651-4ef3-90f3-793a2d8f1686" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7cd79564-e08d-463a-8469-bfe7d4a9539d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_01e89896-7651-4ef3-90f3-793a2d8f1686" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7cd79564-e08d-463a-8469-bfe7d4a9539d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_47a9b8ae-7822-48f7-b6ac-755c9071d429" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7cd79564-e08d-463a-8469-bfe7d4a9539d" xlink:to="loc_us-gaap_PlanNameAxis_47a9b8ae-7822-48f7-b6ac-755c9071d429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d8cdc2bf-2e11-472a-bf4f-d66c6b0d8643" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_47a9b8ae-7822-48f7-b6ac-755c9071d429" xlink:to="loc_us-gaap_PlanNameDomain_d8cdc2bf-2e11-472a-bf4f-d66c6b0d8643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_QualifiedPlansMember_a8fb1bf7-2a96-418c-8b12-e8157efe60fc" xlink:href="jnj-20241229.xsd#jnj_QualifiedPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d8cdc2bf-2e11-472a-bf4f-d66c6b0d8643" xlink:to="loc_jnj_QualifiedPlansMember_a8fb1bf7-2a96-418c-8b12-e8157efe60fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NonQualifiedPlansMember_f1cc4459-d49b-4862-9cb7-53cdad98abf0" xlink:href="jnj-20241229.xsd#jnj_NonQualifiedPlansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d8cdc2bf-2e11-472a-bf4f-d66c6b0d8643" xlink:to="loc_jnj_NonQualifiedPlansMember_f1cc4459-d49b-4862-9cb7-53cdad98abf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FundedPlansMember_0298675f-b446-4887-8c04-c7381586e169" xlink:href="jnj-20241229.xsd#jnj_FundedPlansMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d8cdc2bf-2e11-472a-bf4f-d66c6b0d8643" xlink:to="loc_jnj_FundedPlansMember_0298675f-b446-4887-8c04-c7381586e169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UnfundedPlansMember_c7736ba7-1739-4ca7-b784-005a98e8117a" xlink:href="jnj-20241229.xsd#jnj_UnfundedPlansMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d8cdc2bf-2e11-472a-bf4f-d66c6b0d8643" xlink:to="loc_jnj_UnfundedPlansMember_c7736ba7-1739-4ca7-b784-005a98e8117a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_ef8b031c-5ced-4fc3-81d8-c107cdf53c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7cd79564-e08d-463a-8469-bfe7d4a9539d" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_ef8b031c-5ced-4fc3-81d8-c107cdf53c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_ccf6a7f1-06bd-47ad-a709-2d0811c97121" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_ef8b031c-5ced-4fc3-81d8-c107cdf53c1f" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_ccf6a7f1-06bd-47ad-a709-2d0811c97121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_d1f28ad1-a4ad-40a7-b8ab-22c9cc533675" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_ccf6a7f1-06bd-47ad-a709-2d0811c97121" xlink:to="loc_us-gaap_DomesticPlanMember_d1f28ad1-a4ad-40a7-b8ab-22c9cc533675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0e6023d9-a426-434e-93a3-6b7133c1c8f6" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_d1f28ad1-a4ad-40a7-b8ab-22c9cc533675" xlink:to="loc_country_US_0e6023d9-a426-434e-93a3-6b7133c1c8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_b37fe484-fb32-49be-90db-47a6321babb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_ccf6a7f1-06bd-47ad-a709-2d0811c97121" xlink:to="loc_us-gaap_ForeignPlanMember_b37fe484-fb32-49be-90db-47a6321babb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_93042a1b-521e-43a6-9899-ed52b3bb3e78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7cd79564-e08d-463a-8469-bfe7d4a9539d" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_93042a1b-521e-43a6-9899-ed52b3bb3e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b202ac7c-292c-4270-97dc-87e2ea63b3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_93042a1b-521e-43a6-9899-ed52b3bb3e78" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b202ac7c-292c-4270-97dc-87e2ea63b3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_5b858e80-9057-48c8-85d1-9dd845c02132" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_93042a1b-521e-43a6-9899-ed52b3bb3e78" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_5b858e80-9057-48c8-85d1-9dd845c02132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_e8f8cb44-63e8-4aff-89cf-927edcef2709" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_93042a1b-521e-43a6-9899-ed52b3bb3e78" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_e8f8cb44-63e8-4aff-89cf-927edcef2709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_629c1031-9100-452a-a1fa-9d32f0448b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_93042a1b-521e-43a6-9899-ed52b3bb3e78" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_629c1031-9100-452a-a1fa-9d32f0448b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanOverUnderFundedStatusABO_1f4299c3-d7e4-4c65-add7-50385a8ad787" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanOverUnderFundedStatusABO"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_93042a1b-521e-43a6-9899-ed52b3bb3e78" xlink:to="loc_jnj_DefinedBenefitPlanOverUnderFundedStatusABO_1f4299c3-d7e4-4c65-add7-50385a8ad787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_59b1791c-ef1a-4726-a2b0-8042f81cd612" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_aa12424f-03e1-4714-bcd9-23fbcd47547d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_59b1791c-ef1a-4726-a2b0-8042f81cd612" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_aa12424f-03e1-4714-bcd9-23fbcd47547d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_876b745d-67a0-43cb-b737-4bdab08f2e27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_aa12424f-03e1-4714-bcd9-23fbcd47547d" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_876b745d-67a0-43cb-b737-4bdab08f2e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_5cc8af25-588b-440a-922f-31f5c322e08b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_876b745d-67a0-43cb-b737-4bdab08f2e27" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_5cc8af25-588b-440a-922f-31f5c322e08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_7d7fc5b3-5825-4932-b9b7-5548ad82970f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_5cc8af25-588b-440a-922f-31f5c322e08b" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_7d7fc5b3-5825-4932-b9b7-5548ad82970f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_1655fc4f-9082-4d5a-a02a-0f925de7a8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_5cc8af25-588b-440a-922f-31f5c322e08b" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_1655fc4f-9082-4d5a-a02a-0f925de7a8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6a789ecc-4ba7-439c-8c6d-30395368aa26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_aa12424f-03e1-4714-bcd9-23fbcd47547d" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6a789ecc-4ba7-439c-8c6d-30395368aa26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_928a5a3c-e997-4254-943e-c2caf30fd83e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6a789ecc-4ba7-439c-8c6d-30395368aa26" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_928a5a3c-e997-4254-943e-c2caf30fd83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_1a09ee3a-50b7-4bf2-84dd-b83d162ba570" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6a789ecc-4ba7-439c-8c6d-30395368aa26" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_1a09ee3a-50b7-4bf2-84dd-b83d162ba570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_c18116c6-aa9d-47a5-9f09-8e1e9a25f904" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6a789ecc-4ba7-439c-8c6d-30395368aa26" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_c18116c6-aa9d-47a5-9f09-8e1e9a25f904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_bb7c4ee0-0c13-46bf-9a7a-6265531aa9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6a789ecc-4ba7-439c-8c6d-30395368aa26" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_bb7c4ee0-0c13-46bf-9a7a-6265531aa9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_834a947a-55f0-4831-9c77-14f60749c6de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6a789ecc-4ba7-439c-8c6d-30395368aa26" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_834a947a-55f0-4831-9c77-14f60749c6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_dfba9510-ce60-4dec-82eb-a36fff587ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6a789ecc-4ba7-439c-8c6d-30395368aa26" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_dfba9510-ce60-4dec-82eb-a36fff587ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#PensionsandotherbenefitplansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d3fd9b0-cf0c-4382-92a2-1ffb520ddeef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne_d24fe24f-ad1e-49ca-92ed-8d7d790399ec" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d3fd9b0-cf0c-4382-92a2-1ffb520ddeef" xlink:to="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne_d24fe24f-ad1e-49ca-92ed-8d7d790399ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo_15705088-2623-47b2-ac94-05e403196f67" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d3fd9b0-cf0c-4382-92a2-1ffb520ddeef" xlink:to="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo_15705088-2623-47b2-ac94-05e403196f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree_44c9367a-344e-4c5a-9b76-863b7acb446d" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d3fd9b0-cf0c-4382-92a2-1ffb520ddeef" xlink:to="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree_44c9367a-344e-4c5a-9b76-863b7acb446d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour_c891def6-5ce5-4c59-ada8-3fdc9f5c404d" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d3fd9b0-cf0c-4382-92a2-1ffb520ddeef" xlink:to="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour_c891def6-5ce5-4c59-ada8-3fdc9f5c404d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive_5bdcc854-b836-4444-a140-99b62664bf7e" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d3fd9b0-cf0c-4382-92a2-1ffb520ddeef" xlink:to="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive_5bdcc854-b836-4444-a140-99b62664bf7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter_25c7d34a-5a61-46d9-bf6d-21cc0c903385" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d3fd9b0-cf0c-4382-92a2-1ffb520ddeef" xlink:to="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter_25c7d34a-5a61-46d9-bf6d-21cc0c903385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#PensionsandotherbenefitplansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandotherbenefitplansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0626ac89-2bdb-4a75-8893-4c012211b90b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_533e387d-ede7-46df-888d-860065e9f39c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0626ac89-2bdb-4a75-8893-4c012211b90b" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_533e387d-ede7-46df-888d-860065e9f39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_fc28ed99-82ae-4917-90f0-75ca146e3c69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_533e387d-ede7-46df-888d-860065e9f39c" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_fc28ed99-82ae-4917-90f0-75ca146e3c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_c80ba231-cfca-439f-8ca0-249fad51bba8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_fc28ed99-82ae-4917-90f0-75ca146e3c69" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_c80ba231-cfca-439f-8ca0-249fad51bba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_9c4ffc4a-025c-4988-b5a3-acada0a5f0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c80ba231-cfca-439f-8ca0-249fad51bba8" xlink:to="loc_us-gaap_EquitySecuritiesMember_9c4ffc4a-025c-4988-b5a3-acada0a5f0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_3ccc52f3-65af-4674-824b-d2b4b71c7513" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c80ba231-cfca-439f-8ca0-249fad51bba8" xlink:to="loc_us-gaap_DebtSecuritiesMember_3ccc52f3-65af-4674-824b-d2b4b71c7513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3b1f3961-0b64-4ef0-858d-bfa5766c6daf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_533e387d-ede7-46df-888d-860065e9f39c" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3b1f3961-0b64-4ef0-858d-bfa5766c6daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_8029a65e-eca4-4473-9680-95fc9832bcf0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3b1f3961-0b64-4ef0-858d-bfa5766c6daf" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_8029a65e-eca4-4473-9680-95fc9832bcf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_66366f13-2b4a-4335-9a28-7f147f7a17bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3b1f3961-0b64-4ef0-858d-bfa5766c6daf" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_66366f13-2b4a-4335-9a28-7f147f7a17bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_52c2ce2a-e7cb-4fd6-9f62-a96c93a393de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_05966f34-4071-4968-97c1-f41db29d34bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_52c2ce2a-e7cb-4fd6-9f62-a96c93a393de" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_05966f34-4071-4968-97c1-f41db29d34bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fb32334e-6524-4982-8303-30367932f404" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_05966f34-4071-4968-97c1-f41db29d34bf" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fb32334e-6524-4982-8303-30367932f404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d6a5957-c3e6-4f53-a30d-0e00242e7810" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fb32334e-6524-4982-8303-30367932f404" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d6a5957-c3e6-4f53-a30d-0e00242e7810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ec355861-0239-463e-b420-eb774673c625" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d6a5957-c3e6-4f53-a30d-0e00242e7810" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ec355861-0239-463e-b420-eb774673c625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_e98c61a0-3203-4f6e-a54a-ebf517829182" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_05966f34-4071-4968-97c1-f41db29d34bf" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_e98c61a0-3203-4f6e-a54a-ebf517829182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_ce352f3f-521d-456b-944d-675ce9e5ae15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_e98c61a0-3203-4f6e-a54a-ebf517829182" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_ce352f3f-521d-456b-944d-675ce9e5ae15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_6b2324b1-4a47-4202-b95b-8c954f8f8416" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_ce352f3f-521d-456b-944d-675ce9e5ae15" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_6b2324b1-4a47-4202-b95b-8c954f8f8416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_8d834994-217a-4be5-819e-628a2fbfbff0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_05966f34-4071-4968-97c1-f41db29d34bf" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_8d834994-217a-4be5-819e-628a2fbfbff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_b59ef042-a82f-49d5-aee4-5bb40e0459a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_8d834994-217a-4be5-819e-628a2fbfbff0" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_b59ef042-a82f-49d5-aee4-5bb40e0459a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShortTermInvestmentFundsMember_a59f00db-eb59-4ae1-a4f8-87f69a1a30f1" xlink:href="jnj-20241229.xsd#jnj_ShortTermInvestmentFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_b59ef042-a82f-49d5-aee4-5bb40e0459a8" xlink:to="loc_jnj_ShortTermInvestmentFundsMember_a59f00db-eb59-4ae1-a4f8-87f69a1a30f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_7d9c859a-e91e-444e-b4c4-3e89e18b1d11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_b59ef042-a82f-49d5-aee4-5bb40e0459a8" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_7d9c859a-e91e-444e-b4c4-3e89e18b1d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_31eaad75-a123-46c8-b971-37b53a316561" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_b59ef042-a82f-49d5-aee4-5bb40e0459a8" xlink:to="loc_us-gaap_DebtSecuritiesMember_31eaad75-a123-46c8-b971-37b53a316561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_88fcc9f8-638d-420c-9c88-e1768d2fa78f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_b59ef042-a82f-49d5-aee4-5bb40e0459a8" xlink:to="loc_us-gaap_EquitySecuritiesMember_88fcc9f8-638d-420c-9c88-e1768d2fa78f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CommingledFundsMember_8651b744-3e5d-4661-aed0-55c568976cc8" xlink:href="jnj-20241229.xsd#jnj_CommingledFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_b59ef042-a82f-49d5-aee4-5bb40e0459a8" xlink:to="loc_jnj_CommingledFundsMember_8651b744-3e5d-4661-aed0-55c568976cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_34ab9da7-7d88-471e-b44d-ed83ebd6fcd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_b59ef042-a82f-49d5-aee4-5bb40e0459a8" xlink:to="loc_us-gaap_OtherAssetsMember_34ab9da7-7d88-471e-b44d-ed83ebd6fcd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b79539bc-ff5d-4c46-9846-1e8b3a3b587e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_05966f34-4071-4968-97c1-f41db29d34bf" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b79539bc-ff5d-4c46-9846-1e8b3a3b587e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4af8ad35-4b81-4445-916e-9567bf9464f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b79539bc-ff5d-4c46-9846-1e8b3a3b587e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4af8ad35-4b81-4445-916e-9567bf9464f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6f9935e2-6edf-4440-9b0c-badf5f719f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4af8ad35-4b81-4445-916e-9567bf9464f0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6f9935e2-6edf-4440-9b0c-badf5f719f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_85378f31-a3da-4044-8cf1-8c2515aa14b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4af8ad35-4b81-4445-916e-9567bf9464f0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_85378f31-a3da-4044-8cf1-8c2515aa14b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e5062211-f8e7-4b70-856b-5a4d6c3dd983" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4af8ad35-4b81-4445-916e-9567bf9464f0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e5062211-f8e7-4b70-856b-5a4d6c3dd983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_efe136dc-ab44-4884-aa6e-26dd25108140" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_05966f34-4071-4968-97c1-f41db29d34bf" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_efe136dc-ab44-4884-aa6e-26dd25108140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b40b8763-a9f2-4b2c-814c-bd7f83f6d4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_efe136dc-ab44-4884-aa6e-26dd25108140" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b40b8763-a9f2-4b2c-814c-bd7f83f6d4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets_965470d4-e749-4418-b9fd-0b386815aacb" xlink:href="jnj-20241229.xsd#jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_efe136dc-ab44-4884-aa6e-26dd25108140" xlink:to="loc_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets_965470d4-e749-4418-b9fd-0b386815aacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SavingsplanDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#SavingsplanDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SavingsplanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SavingsPlanAbstract_8a17be1f-8514-43c4-8ba1-7bdd3a6b7543" xlink:href="jnj-20241229.xsd#jnj_SavingsPlanAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_cd350373-3b82-4ba5-9bce-adb2bd7f0bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_SavingsPlanAbstract_8a17be1f-8514-43c4-8ba1-7bdd3a6b7543" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_cd350373-3b82-4ba5-9bce-adb2bd7f0bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#CapitalandtreasurystockChangesinTreasuryStockDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ade13f05-500a-4adc-b7dd-5572d3497a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_30398b28-159c-48a4-863a-fe0abd7fd24b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ade13f05-500a-4adc-b7dd-5572d3497a8a" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_30398b28-159c-48a4-863a-fe0abd7fd24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9f67aeff-e3f3-4e52-a7e7-069e4fe88883" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_30398b28-159c-48a4-863a-fe0abd7fd24b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9f67aeff-e3f3-4e52-a7e7-069e4fe88883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_86aa7033-d068-45fc-8018-6c5fd84781d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9f67aeff-e3f3-4e52-a7e7-069e4fe88883" xlink:to="loc_us-gaap_EquityComponentDomain_86aa7033-d068-45fc-8018-6c5fd84781d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_8bbfedd2-17a2-4f96-bfc8-5b15e3200a20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_86aa7033-d068-45fc-8018-6c5fd84781d4" xlink:to="loc_us-gaap_TreasuryStockCommonMember_8bbfedd2-17a2-4f96-bfc8-5b15e3200a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_d2d3971a-97a0-4763-9028-57b8a546e56a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_30398b28-159c-48a4-863a-fe0abd7fd24b" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_d2d3971a-97a0-4763-9028-57b8a546e56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_61cd1813-89f0-4528-b5d0-ca58c0eb188e" xlink:href="jnj-20241229.xsd#jnj_ChangesinTreasuryStockSharesOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_d2d3971a-97a0-4763-9028-57b8a546e56a" xlink:to="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_61cd1813-89f0-4528-b5d0-ca58c0eb188e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_40624334-03f4-4863-a72a-7a320422c5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_61cd1813-89f0-4528-b5d0-ca58c0eb188e" xlink:to="loc_us-gaap_TreasuryStockCommonShares_40624334-03f4-4863-a72a-7a320422c5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_2a2195e8-e20f-428f-b289-28aa3222ba66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_61cd1813-89f0-4528-b5d0-ca58c0eb188e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_2a2195e8-e20f-428f-b289-28aa3222ba66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_fdbf181a-a52f-49e8-a908-17cc7d7c2688" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_61cd1813-89f0-4528-b5d0-ca58c0eb188e" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_fdbf181a-a52f-49e8-a908-17cc7d7c2688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_e746361c-0852-4093-887a-8f5ba00e16c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_61cd1813-89f0-4528-b5d0-ca58c0eb188e" xlink:to="loc_us-gaap_TreasuryStockCommonShares_e746361c-0852-4093-887a-8f5ba00e16c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesInTreasuryStockRollForward_e5d6cd47-a0fe-4fca-9bed-18cf4a61cb23" xlink:href="jnj-20241229.xsd#jnj_ChangesInTreasuryStockRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_d2d3971a-97a0-4763-9028-57b8a546e56a" xlink:to="loc_jnj_ChangesInTreasuryStockRollForward_e5d6cd47-a0fe-4fca-9bed-18cf4a61cb23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_399b1073-6599-402d-91a7-b05ad1b57052" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_e5d6cd47-a0fe-4fca-9bed-18cf4a61cb23" xlink:to="loc_us-gaap_TreasuryStockValue_399b1073-6599-402d-91a7-b05ad1b57052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_c885e3e1-6966-49d8-8dfd-96ca7632d886" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_e5d6cd47-a0fe-4fca-9bed-18cf4a61cb23" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_c885e3e1-6966-49d8-8dfd-96ca7632d886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_5f273c38-0a85-4cff-95e5-76ab5ced5313" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_e5d6cd47-a0fe-4fca-9bed-18cf4a61cb23" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_5f273c38-0a85-4cff-95e5-76ab5ced5313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TreasuryStockValueAcquiredCostMethodNetOfTax_fdc4fadb-808d-41ea-b18f-aa27672eda1c" xlink:href="jnj-20241229.xsd#jnj_TreasuryStockValueAcquiredCostMethodNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_e5d6cd47-a0fe-4fca-9bed-18cf4a61cb23" xlink:to="loc_jnj_TreasuryStockValueAcquiredCostMethodNetOfTax_fdc4fadb-808d-41ea-b18f-aa27672eda1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_806eb623-906e-4440-8a57-f4aff476b21e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_e5d6cd47-a0fe-4fca-9bed-18cf4a61cb23" xlink:to="loc_us-gaap_TreasuryStockValue_806eb623-906e-4440-8a57-f4aff476b21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#CapitalandtreasurystockNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_64cb4035-6c3e-4cdd-95d1-0029992b783d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_26fb16d5-64e4-4026-b41b-b749a209f693" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_64cb4035-6c3e-4cdd-95d1-0029992b783d" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_26fb16d5-64e4-4026-b41b-b749a209f693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis_0d796308-f293-4637-b421-0a7c54f20a0c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_26fb16d5-64e4-4026-b41b-b749a209f693" xlink:to="loc_srt_ShareRepurchaseProgramAxis_0d796308-f293-4637-b421-0a7c54f20a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_aa2e83c8-24ff-419a-8b85-18e0d3c85624" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramAxis_0d796308-f293-4637-b421-0a7c54f20a0c" xlink:to="loc_srt_ShareRepurchaseProgramDomain_aa2e83c8-24ff-419a-8b85-18e0d3c85624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_December172018ShareRepurchaseProgramMember_623980f3-6669-4169-8c7b-b68827e2c547" xlink:href="jnj-20241229.xsd#jnj_December172018ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramDomain_aa2e83c8-24ff-419a-8b85-18e0d3c85624" xlink:to="loc_jnj_December172018ShareRepurchaseProgramMember_623980f3-6669-4169-8c7b-b68827e2c547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_381fe001-5852-4783-a3ed-bb116cc04023" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_26fb16d5-64e4-4026-b41b-b749a209f693" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_381fe001-5852-4783-a3ed-bb116cc04023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6463eb34-4327-42b1-89c3-c04710007ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_381fe001-5852-4783-a3ed-bb116cc04023" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6463eb34-4327-42b1-89c3-c04710007ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_eec99664-25ce-4ceb-bf99-e8eb06e94f21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6463eb34-4327-42b1-89c3-c04710007ed4" xlink:to="loc_us-gaap_SubsequentEventMember_eec99664-25ce-4ceb-bf99-e8eb06e94f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_f681f9d3-6f96-457c-82d6-fd8e847548fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_26fb16d5-64e4-4026-b41b-b749a209f693" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_f681f9d3-6f96-457c-82d6-fd8e847548fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e039d5b5-06c5-4b90-a2fa-3f191fa51267" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_f681f9d3-6f96-457c-82d6-fd8e847548fb" xlink:to="loc_us-gaap_CommonStockSharesIssued_e039d5b5-06c5-4b90-a2fa-3f191fa51267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_48f23865-b22d-4798-baaf-203d68f65dab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_f681f9d3-6f96-457c-82d6-fd8e847548fb" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_48f23865-b22d-4798-baaf-203d68f65dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_51fdb8f7-edf5-4e51-b596-c27504e29cba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_f681f9d3-6f96-457c-82d6-fd8e847548fb" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_51fdb8f7-edf5-4e51-b596-c27504e29cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_a0d02798-f2fc-421a-b3e5-cfb67e1a97aa" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_f681f9d3-6f96-457c-82d6-fd8e847548fb" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_a0d02798-f2fc-421a-b3e5-cfb67e1a97aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#AccumulatedothercomprehensiveincomelossDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_65417a9b-7697-4d44-ae6f-7b8c896c6325" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_a6316efc-2b8f-43ad-8e09-04b566f5ef69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_65417a9b-7697-4d44-ae6f-7b8c896c6325" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_a6316efc-2b8f-43ad-8e09-04b566f5ef69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_77ed07b9-8057-4053-9b1f-b103a72b4f42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_a6316efc-2b8f-43ad-8e09-04b566f5ef69" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_77ed07b9-8057-4053-9b1f-b103a72b4f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dfcf608c-aae6-40db-b451-c740ff8f8179" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_77ed07b9-8057-4053-9b1f-b103a72b4f42" xlink:to="loc_us-gaap_EquityComponentDomain_dfcf608c-aae6-40db-b451-c740ff8f8179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_73c44b54-2faa-48b2-987c-11d7ccdd2934" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dfcf608c-aae6-40db-b451-c740ff8f8179" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_73c44b54-2faa-48b2-987c-11d7ccdd2934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_280a6611-453c-4c86-9a08-e7870b3ec2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dfcf608c-aae6-40db-b451-c740ff8f8179" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_280a6611-453c-4c86-9a08-e7870b3ec2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_676c0a03-27ff-4271-9cbb-23005f42f707" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dfcf608c-aae6-40db-b451-c740ff8f8179" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_676c0a03-27ff-4271-9cbb-23005f42f707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e9da48cf-35f6-4d5e-8c5e-2249a8b93575" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dfcf608c-aae6-40db-b451-c740ff8f8179" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e9da48cf-35f6-4d5e-8c5e-2249a8b93575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_eb8a3cbd-9dc9-41c7-af1b-6623d44d9c64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dfcf608c-aae6-40db-b451-c740ff8f8179" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_eb8a3cbd-9dc9-41c7-af1b-6623d44d9c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_3e06d236-2084-460c-bdd8-ddb9216c59cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_a6316efc-2b8f-43ad-8e09-04b566f5ef69" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_3e06d236-2084-460c-bdd8-ddb9216c59cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_09ab1a70-832d-425b-9843-440091140d75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_3e06d236-2084-460c-bdd8-ddb9216c59cb" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_09ab1a70-832d-425b-9843-440091140d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c1f71fe3-6213-45c1-9dd1-7c84af1ccf76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_09ab1a70-832d-425b-9843-440091140d75" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c1f71fe3-6213-45c1-9dd1-7c84af1ccf76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_59e6109e-8036-49b5-acfe-5a7250a9acc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_09ab1a70-832d-425b-9843-440091140d75" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_59e6109e-8036-49b5-acfe-5a7250a9acc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_8970f3a8-6489-4f9c-8170-5c4e78dd514b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_09ab1a70-832d-425b-9843-440091140d75" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_8970f3a8-6489-4f9c-8170-5c4e78dd514b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e5d5d02d-34a4-4194-9f94-f2e1aabcbd63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_09ab1a70-832d-425b-9843-440091140d75" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e5d5d02d-34a4-4194-9f94-f2e1aabcbd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InternationalcurrencytranslationDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#InternationalcurrencytranslationDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/InternationalcurrencytranslationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTranslationAbstract_e1befc2d-84af-45da-8100-40ba34eda1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTranslationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ecb8d02f-42d2-4f6d-85da-d15e1b97627c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignCurrencyTranslationAbstract_e1befc2d-84af-45da-8100-40ba34eda1d2" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ecb8d02f-42d2-4f6d-85da-d15e1b97627c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ba7ef0ec-4830-47a3-842e-307e018eb561" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_9bd0a0f3-f9b8-4aaf-b7bf-a12d3c5f1f29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ba7ef0ec-4830-47a3-842e-307e018eb561" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_9bd0a0f3-f9b8-4aaf-b7bf-a12d3c5f1f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b5b9aab2-51d7-43cd-b6af-8fa4e79ba0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_9bd0a0f3-f9b8-4aaf-b7bf-a12d3c5f1f29" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b5b9aab2-51d7-43cd-b6af-8fa4e79ba0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_b52401a9-8122-4039-becb-b3fabbec7c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_9bd0a0f3-f9b8-4aaf-b7bf-a12d3c5f1f29" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_b52401a9-8122-4039-becb-b3fabbec7c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d545cff5-0a62-48f8-8c49-5f961f9d17dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_9bd0a0f3-f9b8-4aaf-b7bf-a12d3c5f1f29" xlink:to="loc_us-gaap_EarningsPerShareBasic_d545cff5-0a62-48f8-8c49-5f961f9d17dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_524341c7-3905-4fc7-a653-5b18fbdb7334" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_9bd0a0f3-f9b8-4aaf-b7bf-a12d3c5f1f29" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_524341c7-3905-4fc7-a653-5b18fbdb7334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_450c0b56-452e-4947-b5fb-849b9f56b3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_9bd0a0f3-f9b8-4aaf-b7bf-a12d3c5f1f29" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_450c0b56-452e-4947-b5fb-849b9f56b3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_44a9391d-d997-474e-808c-184f6e650b48" xlink:href="jnj-20241229.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_9bd0a0f3-f9b8-4aaf-b7bf-a12d3c5f1f29" xlink:to="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_44a9391d-d997-474e-808c-184f6e650b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_31426a9a-84fc-49a0-a5b6-7d433f9cb98d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_9bd0a0f3-f9b8-4aaf-b7bf-a12d3c5f1f29" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_31426a9a-84fc-49a0-a5b6-7d433f9cb98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_5a9722b3-46a7-49db-afaa-b3e58d17843a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_9bd0a0f3-f9b8-4aaf-b7bf-a12d3c5f1f29" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_5a9722b3-46a7-49db-afaa-b3e58d17843a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_88f4cf2e-7259-495a-8ddd-039445df4866" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_9bd0a0f3-f9b8-4aaf-b7bf-a12d3c5f1f29" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_88f4cf2e-7259-495a-8ddd-039445df4866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c92dd258-6bff-4228-8079-de74834da6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_9bd0a0f3-f9b8-4aaf-b7bf-a12d3c5f1f29" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c92dd258-6bff-4228-8079-de74834da6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0f71aa51-d24b-40d5-b00d-f84ad653d70f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ba7ef0ec-4830-47a3-842e-307e018eb561" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0f71aa51-d24b-40d5-b00d-f84ad653d70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningspershareNarrativeDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#EarningspershareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningspershareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_506034d7-ac64-499b-b549-6f1be607d684" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e1f56603-32c9-4202-9b02-56e9f5907960" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_506034d7-ac64-499b-b549-6f1be607d684" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e1f56603-32c9-4202-9b02-56e9f5907960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1bb1acef-f3f9-412c-a833-ada648620445" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ef45e920-56b6-436f-af5a-6f65dc010398" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1bb1acef-f3f9-412c-a833-ada648620445" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ef45e920-56b6-436f-af5a-6f65dc010398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis_c71b3e11-2d29-4fec-a0a2-16ba9a1f3362" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ef45e920-56b6-436f-af5a-6f65dc010398" xlink:to="loc_srt_ShareRepurchaseProgramAxis_c71b3e11-2d29-4fec-a0a2-16ba9a1f3362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_723c50c4-b5fa-4f96-85af-1f5835b6b1fd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramAxis_c71b3e11-2d29-4fec-a0a2-16ba9a1f3362" xlink:to="loc_srt_ShareRepurchaseProgramDomain_723c50c4-b5fa-4f96-85af-1f5835b6b1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2022LongTermIncentivePlanMember_33b49579-6cf2-454a-9ab2-b9e9ecefc878" xlink:href="jnj-20241229.xsd#jnj_A2022LongTermIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramDomain_723c50c4-b5fa-4f96-85af-1f5835b6b1fd" xlink:to="loc_jnj_A2022LongTermIncentivePlanMember_33b49579-6cf2-454a-9ab2-b9e9ecefc878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e48f0945-7a6c-43e5-9082-ab69b253d92a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ef45e920-56b6-436f-af5a-6f65dc010398" xlink:to="loc_srt_RangeAxis_e48f0945-7a6c-43e5-9082-ab69b253d92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e30f2bc9-2f29-40e3-a2ae-76be3bcae3cf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e48f0945-7a6c-43e5-9082-ab69b253d92a" xlink:to="loc_srt_RangeMember_e30f2bc9-2f29-40e3-a2ae-76be3bcae3cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c6008e79-3d8c-4638-9224-91afc1729bfd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e30f2bc9-2f29-40e3-a2ae-76be3bcae3cf" xlink:to="loc_srt_MinimumMember_c6008e79-3d8c-4638-9224-91afc1729bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_31dc330f-c04e-461b-a34d-450fd0237f10" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e30f2bc9-2f29-40e3-a2ae-76be3bcae3cf" xlink:to="loc_srt_MaximumMember_31dc330f-c04e-461b-a34d-450fd0237f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a48b8269-c5be-42fd-954a-ceac4d27b322" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ef45e920-56b6-436f-af5a-6f65dc010398" xlink:to="loc_us-gaap_AwardTypeAxis_a48b8269-c5be-42fd-954a-ceac4d27b322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9084fa15-525b-47b4-9d75-818b089899b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a48b8269-c5be-42fd-954a-ceac4d27b322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9084fa15-525b-47b4-9d75-818b089899b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_72790b1b-13fb-43f2-b4ff-fd24b32abf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9084fa15-525b-47b4-9d75-818b089899b9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_72790b1b-13fb-43f2-b4ff-fd24b32abf8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1204ba01-ba4b-4c8c-a15b-91af8f33daad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9084fa15-525b-47b4-9d75-818b089899b9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1204ba01-ba4b-4c8c-a15b-91af8f33daad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_19fe34e9-9e46-4b93-ae37-b2d7a4617176" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9084fa15-525b-47b4-9d75-818b089899b9" xlink:to="loc_us-gaap_PerformanceSharesMember_19fe34e9-9e46-4b93-ae37-b2d7a4617176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ef45e920-56b6-436f-af5a-6f65dc010398" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfStockBasedCompensationPlans_0c57569d-8b0f-4a94-a651-ef8c670fc4f3" xlink:href="jnj-20241229.xsd#jnj_NumberOfStockBasedCompensationPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_jnj_NumberOfStockBasedCompensationPlans_0c57569d-8b0f-4a94-a651-ef8c670fc4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6b0b47a4-8c48-4f6f-baf0-4b8372f208c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6b0b47a4-8c48-4f6f-baf0-4b8372f208c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights_8b771403-0e30-4215-98ed-15780d8f45fb" xlink:href="jnj-20241229.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights_8b771403-0e30-4215-98ed-15780d8f45fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards_d61f6619-0558-46d0-9fa1-4d02ada01b08" xlink:href="jnj-20241229.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards_d61f6619-0558-46d0-9fa1-4d02ada01b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess_e9bbcc11-133b-4c50-95b6-4373200a3da2" xlink:href="jnj-20241229.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess_e9bbcc11-133b-4c50-95b6-4373200a3da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_60864624-a2da-421f-acf5-7d3d53251cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_60864624-a2da-421f-acf5-7d3d53251cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_15a32732-be14-4907-888b-947193761d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_15a32732-be14-4907-888b-947193761d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_78e95dbe-f68c-4382-8451-a8c1e8aab44a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_78e95dbe-f68c-4382-8451-a8c1e8aab44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_b9fdb90e-ba12-4e21-a9e7-fd88139ffa24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_b9fdb90e-ba12-4e21-a9e7-fd88139ffa24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7263721d-d348-48b4-b105-47a936185a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7263721d-d348-48b4-b105-47a936185a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2158ee15-18d0-47b2-ad3a-50035ba495ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2158ee15-18d0-47b2-ad3a-50035ba495ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a1aa0c60-1889-4207-8767-f4715389edcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a1aa0c60-1889-4207-8767-f4715389edcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d31782da-baed-4c13-92ea-04a3a9f6ab54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d31782da-baed-4c13-92ea-04a3a9f6ab54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_38d54a7e-f016-4204-806c-dfde00c7eb96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_38d54a7e-f016-4204-806c-dfde00c7eb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_30acd071-e8bc-4e4f-833f-c62415d66dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_30acd071-e8bc-4e4f-833f-c62415d66dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_5fb4d1fd-f345-4753-b308-e5ac9dd102f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_5fb4d1fd-f345-4753-b308-e5ac9dd102f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_9dee99b0-c17d-46fd-aa69-f9c551018ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_9dee99b0-c17d-46fd-aa69-f9c551018ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c64becf9-5343-43bb-8c59-64d6bb1d2829" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c64becf9-5343-43bb-8c59-64d6bb1d2829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2df34e72-de53-441d-93d7-6dd34ce189d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2df34e72-de53-441d-93d7-6dd34ce189d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e0564529-9d6e-497e-90a1-4e1074faa3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e0564529-9d6e-497e-90a1-4e1074faa3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c2ebd97a-5d93-4c00-9289-aec83d8505e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c2ebd97a-5d93-4c00-9289-aec83d8505e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_fe9ab0d8-a88f-4932-8007-c116ce90c818" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_deb83434-9468-4161-a89d-b2846f1cb116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_fe9ab0d8-a88f-4932-8007-c116ce90c818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsScheduleValuationAssumptionsDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#CommonstockstockoptionplansandstockcompensationagreementsScheduleValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsScheduleValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ac5f2833-c84f-4c46-9029-6c5fc7c52946" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_585303c9-a9ce-4cc7-a558-c2cd7f0f5662" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ac5f2833-c84f-4c46-9029-6c5fc7c52946" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_585303c9-a9ce-4cc7-a558-c2cd7f0f5662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ab9daa37-daab-42b9-b2bc-8a73261dc783" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_585303c9-a9ce-4cc7-a558-c2cd7f0f5662" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ab9daa37-daab-42b9-b2bc-8a73261dc783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e44b03f1-40df-4f73-87c7-bc27fe8ae85f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_585303c9-a9ce-4cc7-a558-c2cd7f0f5662" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e44b03f1-40df-4f73-87c7-bc27fe8ae85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a1487f91-4066-495f-a832-34be60548c99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_585303c9-a9ce-4cc7-a558-c2cd7f0f5662" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a1487f91-4066-495f-a832-34be60548c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9ade125d-c281-425e-8da4-e5b09a3be067" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_585303c9-a9ce-4cc7-a558-c2cd7f0f5662" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9ade125d-c281-425e-8da4-e5b09a3be067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_446e381a-9f63-4c9e-ba0f-9684c758edf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2a4453bd-31f4-45ff-aefd-217cee33bf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_446e381a-9f63-4c9e-ba0f-9684c758edf7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2a4453bd-31f4-45ff-aefd-217cee33bf8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0f36eaa1-5b19-4acc-b03a-70c118015cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2a4453bd-31f4-45ff-aefd-217cee33bf8b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0f36eaa1-5b19-4acc-b03a-70c118015cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4d97fcb4-f089-4ea6-a132-9db737f54bde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0f36eaa1-5b19-4acc-b03a-70c118015cb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4d97fcb4-f089-4ea6-a132-9db737f54bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9dbe8c26-b8e5-4c2a-88b1-316586b68a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0f36eaa1-5b19-4acc-b03a-70c118015cb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9dbe8c26-b8e5-4c2a-88b1-316586b68a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12b31ac3-34b6-4182-a5e9-2ab7b6bebf5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0f36eaa1-5b19-4acc-b03a-70c118015cb3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12b31ac3-34b6-4182-a5e9-2ab7b6bebf5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_63126074-f9fd-4c4c-8c87-da7346306d78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0f36eaa1-5b19-4acc-b03a-70c118015cb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_63126074-f9fd-4c4c-8c87-da7346306d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9dbaf7d3-9d4a-444d-aaf5-650e60b6dddd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0f36eaa1-5b19-4acc-b03a-70c118015cb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9dbaf7d3-9d4a-444d-aaf5-650e60b6dddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8958da8f-6959-420e-9adf-df015a538cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2a4453bd-31f4-45ff-aefd-217cee33bf8b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8958da8f-6959-420e-9adf-df015a538cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4b62d417-57bc-4db4-ad7d-5d3a88a574bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8958da8f-6959-420e-9adf-df015a538cbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4b62d417-57bc-4db4-ad7d-5d3a88a574bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b5a57da4-0796-46de-8ac8-8f3acde61603" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8958da8f-6959-420e-9adf-df015a538cbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b5a57da4-0796-46de-8ac8-8f3acde61603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f77db0ca-84a0-4c0f-9a10-e7efb84b9f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8958da8f-6959-420e-9adf-df015a538cbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f77db0ca-84a0-4c0f-9a10-e7efb84b9f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5294bf93-e2ed-4f1e-853c-73703d85a2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8958da8f-6959-420e-9adf-df015a538cbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5294bf93-e2ed-4f1e-853c-73703d85a2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3f2597a6-b4b9-4885-8275-93ab2afcb654" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8958da8f-6959-420e-9adf-df015a538cbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3f2597a6-b4b9-4885-8275-93ab2afcb654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c40e0c3d-cc20-4fb7-9ef4-c52a817fbc53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8958da8f-6959-420e-9adf-df015a538cbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c40e0c3d-cc20-4fb7-9ef4-c52a817fbc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e755dac7-0dc6-4c15-99b1-69129ed3f7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_606d27d7-f882-4fc4-aee4-8ef0dee5dffc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e755dac7-0dc6-4c15-99b1-69129ed3f7f4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_606d27d7-f882-4fc4-aee4-8ef0dee5dffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_21d5029f-5ab7-4292-8b02-b927a5b1fd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_606d27d7-f882-4fc4-aee4-8ef0dee5dffc" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_21d5029f-5ab7-4292-8b02-b927a5b1fd9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_05ae0d6d-9810-4ede-b1c5-ac12da7510c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_21d5029f-5ab7-4292-8b02-b927a5b1fd9a" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_05ae0d6d-9810-4ede-b1c5-ac12da7510c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeOneMember_827bee08-ff60-406d-bbdf-1f342bb55d71" xlink:href="jnj-20241229.xsd#jnj_ExercisePriceRangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_05ae0d6d-9810-4ede-b1c5-ac12da7510c2" xlink:to="loc_jnj_ExercisePriceRangeOneMember_827bee08-ff60-406d-bbdf-1f342bb55d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeTwoMember_d6edb3e2-d6e3-4342-a630-89a8bd50e543" xlink:href="jnj-20241229.xsd#jnj_ExercisePriceRangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_05ae0d6d-9810-4ede-b1c5-ac12da7510c2" xlink:to="loc_jnj_ExercisePriceRangeTwoMember_d6edb3e2-d6e3-4342-a630-89a8bd50e543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeThreeMember_27436ecb-cb50-44fa-868b-a5ab5cee4d6a" xlink:href="jnj-20241229.xsd#jnj_ExercisePriceRangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_05ae0d6d-9810-4ede-b1c5-ac12da7510c2" xlink:to="loc_jnj_ExercisePriceRangeThreeMember_27436ecb-cb50-44fa-868b-a5ab5cee4d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeFourMember_97938884-63fc-40e8-9563-67f4ca7e187f" xlink:href="jnj-20241229.xsd#jnj_ExercisePriceRangeFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_05ae0d6d-9810-4ede-b1c5-ac12da7510c2" xlink:to="loc_jnj_ExercisePriceRangeFourMember_97938884-63fc-40e8-9563-67f4ca7e187f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeFiveMember_bb4be895-c3b2-4518-a1ac-cef88390d079" xlink:href="jnj-20241229.xsd#jnj_ExercisePriceRangeFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_05ae0d6d-9810-4ede-b1c5-ac12da7510c2" xlink:to="loc_jnj_ExercisePriceRangeFiveMember_bb4be895-c3b2-4518-a1ac-cef88390d079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_595fc303-5ca5-49f2-ac88-f13faa586bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_606d27d7-f882-4fc4-aee4-8ef0dee5dffc" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_595fc303-5ca5-49f2-ac88-f13faa586bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_286ff43a-7d66-4471-9584-3ae21f013416" xlink:href="jnj-20241229.xsd#jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_595fc303-5ca5-49f2-ac88-f13faa586bf0" xlink:to="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_286ff43a-7d66-4471-9584-3ae21f013416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_9e9f7689-c5f4-456d-92ac-71d213c846f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_286ff43a-7d66-4471-9584-3ae21f013416" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_9e9f7689-c5f4-456d-92ac-71d213c846f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_41cfc87d-47e8-4c15-8379-d762837fbbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_286ff43a-7d66-4471-9584-3ae21f013416" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_41cfc87d-47e8-4c15-8379-d762837fbbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_78f5dac7-7fea-4278-9c97-6aefa3cab258" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_286ff43a-7d66-4471-9584-3ae21f013416" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_78f5dac7-7fea-4278-9c97-6aefa3cab258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_0fb9c95b-18ad-48e1-b7aa-5bf2157196b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_286ff43a-7d66-4471-9584-3ae21f013416" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_0fb9c95b-18ad-48e1-b7aa-5bf2157196b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_23540958-079d-4106-8123-21a62c23569f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_286ff43a-7d66-4471-9584-3ae21f013416" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_23540958-079d-4106-8123-21a62c23569f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_d1a5260d-f21b-475b-9a78-aee0a420de3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_286ff43a-7d66-4471-9584-3ae21f013416" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_d1a5260d-f21b-475b-9a78-aee0a420de3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_040db937-efa1-433c-b675-2d4a04dfdfe8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_286ff43a-7d66-4471-9584-3ae21f013416" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_040db937-efa1-433c-b675-2d4a04dfdfe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fdfd26a9-6312-4415-8093-b72d779c0b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84c0c7ef-ae68-42fc-a2aa-62c327df5c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fdfd26a9-6312-4415-8093-b72d779c0b8c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84c0c7ef-ae68-42fc-a2aa-62c327df5c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_46297835-8c14-4c94-a11b-6aa5ca4f02d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84c0c7ef-ae68-42fc-a2aa-62c327df5c1d" xlink:to="loc_us-gaap_AwardTypeAxis_46297835-8c14-4c94-a11b-6aa5ca4f02d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9fa68b88-d112-4947-8289-ffe112c03833" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_46297835-8c14-4c94-a11b-6aa5ca4f02d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9fa68b88-d112-4947-8289-ffe112c03833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ec8d2fdd-0ede-42a9-a91d-e6fcfdc358ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9fa68b88-d112-4947-8289-ffe112c03833" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ec8d2fdd-0ede-42a9-a91d-e6fcfdc358ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_82f247dd-c888-4877-b863-bec08ec90fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9fa68b88-d112-4947-8289-ffe112c03833" xlink:to="loc_us-gaap_PerformanceSharesMember_82f247dd-c888-4877-b863-bec08ec90fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f584fad6-dec5-4ed3-9ce1-562c45a4c79e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84c0c7ef-ae68-42fc-a2aa-62c327df5c1d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f584fad6-dec5-4ed3-9ce1-562c45a4c79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fb3ff400-7a06-431c-bbd4-42c6b958cd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f584fad6-dec5-4ed3-9ce1-562c45a4c79e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fb3ff400-7a06-431c-bbd4-42c6b958cd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2aba5915-86c2-46bd-88ba-6507f8a39b19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fb3ff400-7a06-431c-bbd4-42c6b958cd0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2aba5915-86c2-46bd-88ba-6507f8a39b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_83719a20-b37f-4094-8917-39c38106737b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2aba5915-86c2-46bd-88ba-6507f8a39b19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_83719a20-b37f-4094-8917-39c38106737b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_68ddff93-4637-42d0-8b7e-e37f96f71d22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2aba5915-86c2-46bd-88ba-6507f8a39b19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_68ddff93-4637-42d0-8b7e-e37f96f71d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cad50e76-6b08-4f6b-aa58-7fa63a8f3df9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2aba5915-86c2-46bd-88ba-6507f8a39b19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cad50e76-6b08-4f6b-aa58-7fa63a8f3df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod_b6d5369b-598e-4ed1-a862-98cb6635fd3c" xlink:href="jnj-20241229.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2aba5915-86c2-46bd-88ba-6507f8a39b19" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod_b6d5369b-598e-4ed1-a862-98cb6635fd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b818f15f-30d7-4a1c-b176-fc028c5c2427" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2aba5915-86c2-46bd-88ba-6507f8a39b19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b818f15f-30d7-4a1c-b176-fc028c5c2427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ac9000d7-db2b-4952-b9d2-edb69d2892bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_75795e21-9881-4130-80f4-43db580e1970" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ac9000d7-db2b-4952-b9d2-edb69d2892bb" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_75795e21-9881-4130-80f4-43db580e1970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_28de42f8-f13e-42fa-872f-9c30e4b7694b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_75795e21-9881-4130-80f4-43db580e1970" xlink:to="loc_srt_StatementGeographicalAxis_28de42f8-f13e-42fa-872f-9c30e4b7694b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6897f804-8f61-4af3-8113-498eaa16b106" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_28de42f8-f13e-42fa-872f-9c30e4b7694b" xlink:to="loc_srt_SegmentGeographicalDomain_6897f804-8f61-4af3-8113-498eaa16b106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_dc01e787-cd33-4f6b-9c58-f7386fa696c7" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6897f804-8f61-4af3-8113-498eaa16b106" xlink:to="loc_country_US_dc01e787-cd33-4f6b-9c58-f7386fa696c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_e7f4c96c-76ca-4cd1-be89-78555c4601ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6897f804-8f61-4af3-8113-498eaa16b106" xlink:to="loc_us-gaap_NonUsMember_e7f4c96c-76ca-4cd1-be89-78555c4601ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember_e825d01f-f971-4d49-8701-ff1e2c5185b8" xlink:href="jnj-20241229.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6897f804-8f61-4af3-8113-498eaa16b106" xlink:to="loc_jnj_UNITEDSTATESExportsMember_e825d01f-f971-4d49-8701-ff1e2c5185b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0b0df187-78e2-4874-9991-714047008112" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_75795e21-9881-4130-80f4-43db580e1970" xlink:to="loc_srt_ProductOrServiceAxis_0b0df187-78e2-4874-9991-714047008112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0b0df187-78e2-4874-9991-714047008112" xlink:to="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember_707fe9f1-4e35-4318-b08d-a222d5d37220" xlink:href="jnj-20241229.xsd#jnj_RemicadeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_RemicadeMember_707fe9f1-4e35-4318-b08d-a222d5d37220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember_fbccec94-c186-4cd8-ab4a-2cc0a1a5ad04" xlink:href="jnj-20241229.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_SimponiSimponiAriaMember_fbccec94-c186-4cd8-ab4a-2cc0a1a5ad04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember_9acd35d7-62bc-410f-9544-aaf497652800" xlink:href="jnj-20241229.xsd#jnj_StelaraMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_StelaraMember_9acd35d7-62bc-410f-9544-aaf497652800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember_49cb3e3b-aa3c-4e62-90a4-0adee6c5230f" xlink:href="jnj-20241229.xsd#jnj_TremfyaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_TremfyaMember_49cb3e3b-aa3c-4e62-90a4-0adee6c5230f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember_65942f08-ef46-4d35-8ba5-b13490a124ed" xlink:href="jnj-20241229.xsd#jnj_OtherImmunologyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_OtherImmunologyMember_65942f08-ef46-4d35-8ba5-b13490a124ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_COVID19Member_deba68b0-7c24-4c36-a7b5-934656b4f2ab" xlink:href="jnj-20241229.xsd#jnj_COVID19Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_COVID19Member_deba68b0-7c24-4c36-a7b5-934656b4f2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember_cd033215-a317-4105-a593-8c4f5c9c0d18" xlink:href="jnj-20241229.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_EDURANTrilpivirineMember_cd033215-a317-4105-a593-8c4f5c9c0d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_9d5494a1-1f6a-4ae8-87ea-d4802413c334" xlink:href="jnj-20241229.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_9d5494a1-1f6a-4ae8-87ea-d4802413c334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember_724475ad-f544-4878-b51e-b2faf5c866ca" xlink:href="jnj-20241229.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_OtherInfectiousDiseasesMember_724475ad-f544-4878-b51e-b2faf5c866ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember_e040eb29-7032-4baa-b881-8e488853c2c5" xlink:href="jnj-20241229.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_CONCERTAMethylphenidateMember_e040eb29-7032-4baa-b881-8e488853c2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_b1bfd636-6e53-41fe-84b7-534e30c8b128" xlink:href="jnj-20241229.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_b1bfd636-6e53-41fe-84b7-534e30c8b128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPRAVATOMember_5529826d-74ca-4b3e-9cf8-73b583d772cf" xlink:href="jnj-20241229.xsd#jnj_SPRAVATOMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_SPRAVATOMember_5529826d-74ca-4b3e-9cf8-73b583d772cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember_37dabb40-f9f3-42ae-af5f-102d3a5b9f80" xlink:href="jnj-20241229.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_OTHERNEUROSCIENCEMember_37dabb40-f9f3-42ae-af5f-102d3a5b9f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CARVYKTIMember_ad990165-1f1a-4dec-8431-8d885ea71684" xlink:href="jnj-20241229.xsd#jnj_CARVYKTIMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_CARVYKTIMember_ad990165-1f1a-4dec-8431-8d885ea71684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember_e1d99711-df4e-4ca5-adb6-afe3d4892c47" xlink:href="jnj-20241229.xsd#jnj_DARZALEXMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_DARZALEXMember_e1d99711-df4e-4ca5-adb6-afe3d4892c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ErleadaMember_c67c6849-bfbc-4076-9c3d-c6eb9fe921fe" xlink:href="jnj-20241229.xsd#jnj_ErleadaMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_ErleadaMember_c67c6849-bfbc-4076-9c3d-c6eb9fe921fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember_adc755b9-5672-4620-b4a3-2510615730ed" xlink:href="jnj-20241229.xsd#jnj_IMBRUVICAMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_IMBRUVICAMember_adc755b9-5672-4620-b4a3-2510615730ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TECVAYLIMember_6608d7fd-222f-4df1-9bb2-d324ce1713ee" xlink:href="jnj-20241229.xsd#jnj_TECVAYLIMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_TECVAYLIMember_6608d7fd-222f-4df1-9bb2-d324ce1713ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember_e91026ce-3e9e-4ea4-8103-a7963510f944" xlink:href="jnj-20241229.xsd#jnj_ZYTIGAMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_ZYTIGAMember_e91026ce-3e9e-4ea4-8103-a7963510f944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember_efd48a56-be35-4783-8b2e-7c1084c2a2f2" xlink:href="jnj-20241229.xsd#jnj_OtherOncologyMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_OtherOncologyMember_efd48a56-be35-4783-8b2e-7c1084c2a2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember_4fb49b42-f188-46f9-813e-163b64ec5df6" xlink:href="jnj-20241229.xsd#jnj_OPSUMITMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_OPSUMITMember_4fb49b42-f188-46f9-813e-163b64ec5df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember_a46044c4-dfc6-4f07-a360-b9e584468d39" xlink:href="jnj-20241229.xsd#jnj_UPTRAVIMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_UPTRAVIMember_a46044c4-dfc6-4f07-a360-b9e584468d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherPulmonaryHypertensionMember_aea1fb86-81f8-4a47-97d7-80b4359c42f4" xlink:href="jnj-20241229.xsd#jnj_OtherPulmonaryHypertensionMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_OtherPulmonaryHypertensionMember_aea1fb86-81f8-4a47-97d7-80b4359c42f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_c928499a-3ce1-4b17-935c-d8d4f5b68e80" xlink:href="jnj-20241229.xsd#jnj_XareltoMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_XareltoMember_c928499a-3ce1-4b17-935c-d8d4f5b68e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember_fb2deb2b-a0bd-4de7-8ca1-93f961021254" xlink:href="jnj-20241229.xsd#jnj_OtherMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_OtherMember_fb2deb2b-a0bd-4de7-8ca1-93f961021254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ELECTROPHYSIOLOGYMember_c634eadc-9054-4119-95c6-91c10dc44553" xlink:href="jnj-20241229.xsd#jnj_ELECTROPHYSIOLOGYMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_ELECTROPHYSIOLOGYMember_c634eadc-9054-4119-95c6-91c10dc44553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AbiomedMember_bde2142d-9e70-4519-9787-05da5122f444" xlink:href="jnj-20241229.xsd#jnj_AbiomedMember"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_AbiomedMember_bde2142d-9e70-4519-9787-05da5122f444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShockwaveMedicalInc.Member_a15c615b-419d-44cc-8f1b-ccc5ebf3ed70" xlink:href="jnj-20241229.xsd#jnj_ShockwaveMedicalInc.Member"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_ShockwaveMedicalInc.Member_a15c615b-419d-44cc-8f1b-ccc5ebf3ed70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherCardiovascularMember_60ac0bca-ff35-40c9-be77-99138df9abb5" xlink:href="jnj-20241229.xsd#jnj_OtherCardiovascularMember"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_OtherCardiovascularMember_60ac0bca-ff35-40c9-be77-99138df9abb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember_321bc145-3bdc-4648-8e52-6ee1f43330e0" xlink:href="jnj-20241229.xsd#jnj_HIPSMember"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_HIPSMember_321bc145-3bdc-4648-8e52-6ee1f43330e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember_7a979e07-2931-426f-be09-d9f277cf01f0" xlink:href="jnj-20241229.xsd#jnj_KNEESMember"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_KNEESMember_7a979e07-2931-426f-be09-d9f277cf01f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember_5b5f49d5-bc86-4c55-ae0d-29970a881866" xlink:href="jnj-20241229.xsd#jnj_TRAUMAMember"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_TRAUMAMember_5b5f49d5-bc86-4c55-ae0d-29970a881866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINESPORTSOTHERMember_15288009-197d-4414-9f6c-4dcb0f76633a" xlink:href="jnj-20241229.xsd#jnj_SPINESPORTSOTHERMember"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_SPINESPORTSOTHERMember_15288009-197d-4414-9f6c-4dcb0f76633a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember_66b663c2-bd75-411e-8a15-2adcd76c6900" xlink:href="jnj-20241229.xsd#jnj_ADVANCEDMember"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_ADVANCEDMember_66b663c2-bd75-411e-8a15-2adcd76c6900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember_a9af3c43-9add-47e7-8428-9d4d95720230" xlink:href="jnj-20241229.xsd#jnj_GENERALMember"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_GENERALMember_a9af3c43-9add-47e7-8428-9d4d95720230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember_44610129-5751-4476-9619-9de23806bf70" xlink:href="jnj-20241229.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_CONTACTLENSESOTHERMember_44610129-5751-4476-9619-9de23806bf70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember_c1fb667c-bf70-4983-bf84-ff4d4147cad8" xlink:href="jnj-20241229.xsd#jnj_SURGICALMember"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a657347-f495-4f3e-ae6c-2b9ab2da4701" xlink:to="loc_jnj_SURGICALMember_c1fb667c-bf70-4983-bf84-ff4d4147cad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_38994f47-a33c-42ed-bd4e-858e25eb4226" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_75795e21-9881-4130-80f4-43db580e1970" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_38994f47-a33c-42ed-bd4e-858e25eb4226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c790d59b-cdc3-4dd9-b0bf-3153b5a504b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_38994f47-a33c-42ed-bd4e-858e25eb4226" xlink:to="loc_us-gaap_SegmentDomain_c790d59b-cdc3-4dd9-b0bf-3153b5a504b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InnovativeMedicineMember_07db87e0-76fb-4abe-9f7b-68ecce4e32b4" xlink:href="jnj-20241229.xsd#jnj_InnovativeMedicineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c790d59b-cdc3-4dd9-b0bf-3153b5a504b5" xlink:to="loc_jnj_InnovativeMedicineMember_07db87e0-76fb-4abe-9f7b-68ecce4e32b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedTechMember_615846d2-8241-4ca3-882f-6d60c31bd913" xlink:href="jnj-20241229.xsd#jnj_MedTechMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c790d59b-cdc3-4dd9-b0bf-3153b5a504b5" xlink:to="loc_jnj_MedTechMember_615846d2-8241-4ca3-882f-6d60c31bd913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_2f4b6c41-dfbc-4cc4-842c-1a1819e3d844" xlink:href="jnj-20241229.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c790d59b-cdc3-4dd9-b0bf-3153b5a504b5" xlink:to="loc_jnj_PharmaceuticalMember_2f4b6c41-dfbc-4cc4-842c-1a1819e3d844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_adfbc886-d4cb-4a78-982c-d6cd32277ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_75795e21-9881-4130-80f4-43db580e1970" xlink:to="loc_us-gaap_SubsegmentsAxis_adfbc886-d4cb-4a78-982c-d6cd32277ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_85f8336c-a3d1-410d-a10e-a46c30db5b58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_adfbc886-d4cb-4a78-982c-d6cd32277ea0" xlink:to="loc_us-gaap_SubsegmentsDomain_85f8336c-a3d1-410d-a10e-a46c30db5b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember_af0b1b94-9526-43cf-9a35-84b57bca1216" xlink:href="jnj-20241229.xsd#jnj_ImmunologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_85f8336c-a3d1-410d-a10e-a46c30db5b58" xlink:to="loc_jnj_ImmunologyMember_af0b1b94-9526-43cf-9a35-84b57bca1216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember_bd981507-f7cf-4404-8c81-4b76ec3d2f01" xlink:href="jnj-20241229.xsd#jnj_InfectiousDiseasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_85f8336c-a3d1-410d-a10e-a46c30db5b58" xlink:to="loc_jnj_InfectiousDiseasesMember_bd981507-f7cf-4404-8c81-4b76ec3d2f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember_0ac29c51-7d9d-4cf9-86c8-41b784bc259d" xlink:href="jnj-20241229.xsd#jnj_NeuroscienceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_85f8336c-a3d1-410d-a10e-a46c30db5b58" xlink:to="loc_jnj_NeuroscienceMember_0ac29c51-7d9d-4cf9-86c8-41b784bc259d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember_672d73b2-edad-491f-bf7d-bda917076c44" xlink:href="jnj-20241229.xsd#jnj_OncologyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_85f8336c-a3d1-410d-a10e-a46c30db5b58" xlink:to="loc_jnj_OncologyMember_672d73b2-edad-491f-bf7d-bda917076c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember_b43b88f6-6ec3-407f-bb2e-6f7f17cd3fd2" xlink:href="jnj-20241229.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_85f8336c-a3d1-410d-a10e-a46c30db5b58" xlink:to="loc_jnj_PulmonaryHypertensionMember_b43b88f6-6ec3-407f-bb2e-6f7f17cd3fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember_33b00413-7d8a-4e5b-ba7a-327d5b45bfe2" xlink:href="jnj-20241229.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_85f8336c-a3d1-410d-a10e-a46c30db5b58" xlink:to="loc_jnj_CardiovascularMetabolismOtherMember_33b00413-7d8a-4e5b-ba7a-327d5b45bfe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMember_c7fd3374-aee2-4974-ac41-5577001708a7" xlink:href="jnj-20241229.xsd#jnj_CardiovascularMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_85f8336c-a3d1-410d-a10e-a46c30db5b58" xlink:to="loc_jnj_CardiovascularMember_c7fd3374-aee2-4974-ac41-5577001708a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember_d25d3219-2276-4731-9455-379e71a77d34" xlink:href="jnj-20241229.xsd#jnj_OrthopaedicsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_85f8336c-a3d1-410d-a10e-a46c30db5b58" xlink:to="loc_jnj_OrthopaedicsMember_d25d3219-2276-4731-9455-379e71a77d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember_a5885a3f-c570-447d-8727-b2854394bf20" xlink:href="jnj-20241229.xsd#jnj_SurgeryMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_85f8336c-a3d1-410d-a10e-a46c30db5b58" xlink:to="loc_jnj_SurgeryMember_a5885a3f-c570-447d-8727-b2854394bf20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember_b283d033-3f7b-47be-bcf6-a1f7e7d9bfa9" xlink:href="jnj-20241229.xsd#jnj_VisionMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_85f8336c-a3d1-410d-a10e-a46c30db5b58" xlink:to="loc_jnj_VisionMember_b283d033-3f7b-47be-bcf6-a1f7e7d9bfa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_68606b45-2f3d-488d-b443-55d34606e159" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_75795e21-9881-4130-80f4-43db580e1970" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_68606b45-2f3d-488d-b443-55d34606e159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_f96c9b2d-3895-4ddf-af7b-370565c15ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_68606b45-2f3d-488d-b443-55d34606e159" xlink:to="loc_us-gaap_NumberOfOperatingSegments_f96c9b2d-3895-4ddf-af7b-370565c15ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_33c30aab-a309-4492-b133-5154e5c81901" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_68606b45-2f3d-488d-b443-55d34606e159" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_33c30aab-a309-4492-b133-5154e5c81901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_8e58ecba-70c5-4bf7-ba60-2f18e17a9071" xlink:href="jnj-20241229.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_68606b45-2f3d-488d-b443-55d34606e159" xlink:to="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_8e58ecba-70c5-4bf7-ba60-2f18e17a9071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_56566019-47d7-4590-893d-659e538ccece" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_33a524ff-0078-4109-8933-0b5d838fdb94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_56566019-47d7-4590-893d-659e538ccece" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_33a524ff-0078-4109-8933-0b5d838fdb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_36994773-3915-47ef-98b6-c7940aa08d63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_33a524ff-0078-4109-8933-0b5d838fdb94" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_36994773-3915-47ef-98b6-c7940aa08d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4f3f51ca-311b-4240-b03b-4ebc23c2267a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_36994773-3915-47ef-98b6-c7940aa08d63" xlink:to="loc_us-gaap_SegmentDomain_4f3f51ca-311b-4240-b03b-4ebc23c2267a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InnovativeMedicineMember_187f9dee-976d-4e14-a7f2-d02b22a8d29d" xlink:href="jnj-20241229.xsd#jnj_InnovativeMedicineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4f3f51ca-311b-4240-b03b-4ebc23c2267a" xlink:to="loc_jnj_InnovativeMedicineMember_187f9dee-976d-4e14-a7f2-d02b22a8d29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedTechMember_d517a4d3-fbc7-487f-96a7-651de2ac5891" xlink:href="jnj-20241229.xsd#jnj_MedTechMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4f3f51ca-311b-4240-b03b-4ebc23c2267a" xlink:to="loc_jnj_MedTechMember_d517a4d3-fbc7-487f-96a7-651de2ac5891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_f4968e0e-0721-4765-906a-cda00992c42f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_33a524ff-0078-4109-8933-0b5d838fdb94" xlink:to="loc_srt_ConsolidationItemsAxis_f4968e0e-0721-4765-906a-cda00992c42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_9a6ffaa7-d0d2-4089-9d82-c36046b877a3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_f4968e0e-0721-4765-906a-cda00992c42f" xlink:to="loc_srt_ConsolidationItemsDomain_9a6ffaa7-d0d2-4089-9d82-c36046b877a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_79424a96-8dc9-445a-a0e2-4793f6718735" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_9a6ffaa7-d0d2-4089-9d82-c36046b877a3" xlink:to="loc_us-gaap_OperatingSegmentsMember_79424a96-8dc9-445a-a0e2-4793f6718735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_3beca50b-5d8c-48ce-a342-92646f8c6886" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_33a524ff-0078-4109-8933-0b5d838fdb94" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_3beca50b-5d8c-48ce-a342-92646f8c6886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_909501fd-d7be-44ec-a5c8-11ff1c5c5244" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_3beca50b-5d8c-48ce-a342-92646f8c6886" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_909501fd-d7be-44ec-a5c8-11ff1c5c5244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_05fb43c6-638b-4d7c-9ed8-6905b412be68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_3beca50b-5d8c-48ce-a342-92646f8c6886" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_05fb43c6-638b-4d7c-9ed8-6905b412be68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3983107b-12de-404e-a8f0-f6633d585e58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_3beca50b-5d8c-48ce-a342-92646f8c6886" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3983107b-12de-404e-a8f0-f6633d585e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ffe928ba-6668-4148-9576-1dd194b6245f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_3beca50b-5d8c-48ce-a342-92646f8c6886" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ffe928ba-6668-4148-9576-1dd194b6245f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_430103da-f2db-4315-9d1e-640d95d44cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_3beca50b-5d8c-48ce-a342-92646f8c6886" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_430103da-f2db-4315-9d1e-640d95d44cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d2e407fd-73dd-4597-b2eb-8e1f661e9406" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_3beca50b-5d8c-48ce-a342-92646f8c6886" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d2e407fd-73dd-4597-b2eb-8e1f661e9406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_02efe3ba-1176-4d92-9576-6cc91acf12ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_3beca50b-5d8c-48ce-a342-92646f8c6886" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_02efe3ba-1176-4d92-9576-6cc91acf12ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_28d1b6e1-83a1-44ae-900b-6f19052542e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5c0bee9b-4425-454d-b1a2-2d7f931430a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_28d1b6e1-83a1-44ae-900b-6f19052542e4" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5c0bee9b-4425-454d-b1a2-2d7f931430a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_e1ebdb1a-0141-425f-87f5-1fabab4b9652" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5c0bee9b-4425-454d-b1a2-2d7f931430a3" xlink:to="loc_srt_ConsolidationItemsAxis_e1ebdb1a-0141-425f-87f5-1fabab4b9652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_2e50adba-2ef9-4140-ba4d-fc99bdf5898b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_e1ebdb1a-0141-425f-87f5-1fabab4b9652" xlink:to="loc_srt_ConsolidationItemsDomain_2e50adba-2ef9-4140-ba4d-fc99bdf5898b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_f3791601-143c-4acf-a384-a8783b73f1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_2e50adba-2ef9-4140-ba4d-fc99bdf5898b" xlink:to="loc_us-gaap_OperatingSegmentsMember_f3791601-143c-4acf-a384-a8783b73f1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_bb2faebd-2b00-43e2-9236-2092b39b08ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_2e50adba-2ef9-4140-ba4d-fc99bdf5898b" xlink:to="loc_us-gaap_CorporateNonSegmentMember_bb2faebd-2b00-43e2-9236-2092b39b08ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_553809d8-d03b-4590-9c8d-8a815c0a1ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5c0bee9b-4425-454d-b1a2-2d7f931430a3" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_553809d8-d03b-4590-9c8d-8a815c0a1ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ad13768c-faec-423c-a65c-a2d5944af33d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_553809d8-d03b-4590-9c8d-8a815c0a1ff5" xlink:to="loc_us-gaap_SegmentDomain_ad13768c-faec-423c-a65c-a2d5944af33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InnovativeMedicineMember_d803a676-b1dc-46bc-a77a-1edd2c5c81f6" xlink:href="jnj-20241229.xsd#jnj_InnovativeMedicineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ad13768c-faec-423c-a65c-a2d5944af33d" xlink:to="loc_jnj_InnovativeMedicineMember_d803a676-b1dc-46bc-a77a-1edd2c5c81f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedTechMember_a90e8e6a-e917-44a9-8c0c-282621a45114" xlink:href="jnj-20241229.xsd#jnj_MedTechMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ad13768c-faec-423c-a65c-a2d5944af33d" xlink:to="loc_jnj_MedTechMember_a90e8e6a-e917-44a9-8c0c-282621a45114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SegmentsTotalMember_587c2c41-72b6-4b0d-abee-b97ab02d38c7" xlink:href="jnj-20241229.xsd#jnj_SegmentsTotalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ad13768c-faec-423c-a65c-a2d5944af33d" xlink:to="loc_jnj_SegmentsTotalMember_587c2c41-72b6-4b0d-abee-b97ab02d38c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_29a54fca-e0d2-444e-86e1-a864ce2f1516" xlink:href="jnj-20241229.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ad13768c-faec-423c-a65c-a2d5944af33d" xlink:to="loc_jnj_ConsumerMember_29a54fca-e0d2-444e-86e1-a864ce2f1516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GeneralCorporateMember_7ef84d0e-2513-4756-8beb-66201a60ab06" xlink:href="jnj-20241229.xsd#jnj_GeneralCorporateMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ad13768c-faec-423c-a65c-a2d5944af33d" xlink:to="loc_jnj_GeneralCorporateMember_7ef84d0e-2513-4756-8beb-66201a60ab06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1ef5edaf-95ab-4e9d-b17f-b88143dbfea0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5c0bee9b-4425-454d-b1a2-2d7f931430a3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1ef5edaf-95ab-4e9d-b17f-b88143dbfea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bbe8075f-1798-4afe-9e79-b388d77d8002" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1ef5edaf-95ab-4e9d-b17f-b88143dbfea0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bbe8075f-1798-4afe-9e79-b388d77d8002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LaminarMember_71330d5d-1dd1-48ae-9416-7f75868f3904" xlink:href="jnj-20241229.xsd#jnj_LaminarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bbe8075f-1798-4afe-9e79-b388d77d8002" xlink:to="loc_jnj_LaminarMember_71330d5d-1dd1-48ae-9416-7f75868f3904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MomentaMember_e911903a-ce15-4960-8c68-3bdfc2ed55b0" xlink:href="jnj-20241229.xsd#jnj_MomentaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bbe8075f-1798-4afe-9e79-b388d77d8002" xlink:to="loc_jnj_MomentaMember_e911903a-ce15-4960-8c68-3bdfc2ed55b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VWaveLtd.Member_f2bcdd88-5c76-47fc-b30e-c692388c6d9c" xlink:href="jnj-20241229.xsd#jnj_VWaveLtd.Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bbe8075f-1798-4afe-9e79-b388d77d8002" xlink:to="loc_jnj_VWaveLtd.Member_f2bcdd88-5c76-47fc-b30e-c692388c6d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_c0a631f1-39ac-4611-a2c6-04e836f745a3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5c0bee9b-4425-454d-b1a2-2d7f931430a3" xlink:to="loc_srt_LitigationCaseAxis_c0a631f1-39ac-4611-a2c6-04e836f745a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_13effff6-6038-4bed-8e96-72897488bdde" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_c0a631f1-39ac-4611-a2c6-04e836f745a3" xlink:to="loc_srt_LitigationCaseTypeDomain_13effff6-6038-4bed-8e96-72897488bdde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember_1c77681e-7f13-409f-8bb8-10ea421717f9" xlink:href="jnj-20241229.xsd#jnj_BabyPowderMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_13effff6-6038-4bed-8e96-72897488bdde" xlink:to="loc_jnj_BabyPowderMember_1c77681e-7f13-409f-8bb8-10ea421717f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ab17a9a4-d5f9-4d01-9beb-ca69cb89d618" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5c0bee9b-4425-454d-b1a2-2d7f931430a3" xlink:to="loc_srt_ProductOrServiceAxis_ab17a9a4-d5f9-4d01-9beb-ca69cb89d618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_21c8fb01-4b69-4975-ba4a-63a974e9ee67" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ab17a9a4-d5f9-4d01-9beb-ca69cb89d618" xlink:to="loc_srt_ProductsAndServicesDomain_21c8fb01-4b69-4975-ba4a-63a974e9ee67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_871667ab-0b30-4f6a-b24c-91c89ea2509c" xlink:href="jnj-20241229.xsd#jnj_TalcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_21c8fb01-4b69-4975-ba4a-63a974e9ee67" xlink:to="loc_jnj_TalcMember_871667ab-0b30-4f6a-b24c-91c89ea2509c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_37a9cd65-1267-445b-9485-0ac85a9dcce4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5c0bee9b-4425-454d-b1a2-2d7f931430a3" xlink:to="loc_us-gaap_AssetAcquisitionAxis_37a9cd65-1267-445b-9485-0ac85a9dcce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_9ad0d36a-b144-4284-b881-c6a710e85e73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_37a9cd65-1267-445b-9485-0ac85a9dcce4" xlink:to="loc_us-gaap_AssetAcquisitionDomain_9ad0d36a-b144-4284-b881-c6a710e85e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_YellowJerseyTherapeuticsMember_60c22c62-cdc9-4a3a-8827-c499dc857052" xlink:href="jnj-20241229.xsd#jnj_YellowJerseyTherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_9ad0d36a-b144-4284-b881-c6a710e85e73" xlink:to="loc_jnj_YellowJerseyTherapeuticsMember_60c22c62-cdc9-4a3a-8827-c499dc857052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5c0bee9b-4425-454d-b1a2-2d7f931430a3" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a86c6b21-1c48-480e-96a2-db1d90b099c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a86c6b21-1c48-480e-96a2-db1d90b099c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_53e5d688-6356-409f-97c7-06f0fddd85fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_53e5d688-6356-409f-97c7-06f0fddd85fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_da448694-53d8-4a1a-af2d-8309f284b78e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_Assets_da448694-53d8-4a1a-af2d-8309f284b78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentExpenditureAdditionToLongLivedAssets_b13b0b06-a53e-4ff6-b606-da982765cb72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentExpenditureAdditionToLongLivedAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_SegmentExpenditureAdditionToLongLivedAssets_b13b0b06-a53e-4ff6-b606-da982765cb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_779dd7a1-2bb1-4374-bb37-bf3d7aef0533" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_779dd7a1-2bb1-4374-bb37-bf3d7aef0533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_8973f8ea-7823-493b-b626-bd0444cff930" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_8973f8ea-7823-493b-b626-bd0444cff930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyLossInPeriod_d469c5fc-089f-4a04-b024-155f62d01ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyLossInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_LossContingencyLossInPeriod_d469c5fc-089f-4a04-b024-155f62d01ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_11f21d81-a319-44f0-8f0a-a340b34977ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_11f21d81-a319-44f0-8f0a-a340b34977ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived_f94a4e53-7e3c-441c-be41-2e99ba7860df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_ProceedsFromRoyaltiesReceived_f94a4e53-7e3c-441c-be41-2e99ba7860df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_cde433da-bd3a-4b17-9512-cbed15849f72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_RestructuringCharges_cde433da-bd3a-4b17-9512-cbed15849f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b6eb9aa1-c4d3-486a-a275-e4b67fe3f0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b6eb9aa1-c4d3-486a-a275-e4b67fe3f0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_3a5c674b-81c5-4642-b094-f51beaa440cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_3a5c674b-81c5-4642-b094-f51beaa440cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RegulationCharge_ac71f720-5261-47d4-bc99-9c1e7b657c5c" xlink:href="jnj-20241229.xsd#jnj_RegulationCharge"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_jnj_RegulationCharge_ac71f720-5261-47d4-bc99-9c1e7b657c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_8a44f9e0-9a88-4abc-908f-428940ad0e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_LitigationSettlementExpense_8a44f9e0-9a88-4abc-908f-428940ad0e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_fd444baf-6516-4da3-acf1-fb176de4359f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SuppliesExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_SuppliesExpense_fd444baf-6516-4da3-acf1-fb176de4359f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9b2f313d-8a29-4c68-8f0c-b7a8a7a68521" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4402e083-4648-47ce-93b9-1399298d06c1" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9b2f313d-8a29-4c68-8f0c-b7a8a7a68521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_0c2985e1-619e-450d-a26f-8d6acb5fab1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c630d95f-caa6-440f-8ae4-b00a2aca1412" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0c2985e1-619e-450d-a26f-8d6acb5fab1a" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c630d95f-caa6-440f-8ae4-b00a2aca1412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_8741c49f-0261-4c05-83a0-8c7ec7a3adc7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c630d95f-caa6-440f-8ae4-b00a2aca1412" xlink:to="loc_srt_ConsolidationItemsAxis_8741c49f-0261-4c05-83a0-8c7ec7a3adc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_f2fddc2f-7ae3-4705-83df-55c97eac3896" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_8741c49f-0261-4c05-83a0-8c7ec7a3adc7" xlink:to="loc_srt_ConsolidationItemsDomain_f2fddc2f-7ae3-4705-83df-55c97eac3896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_8dfc59a7-8e8e-4847-90b7-20e94fcc57bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_f2fddc2f-7ae3-4705-83df-55c97eac3896" xlink:to="loc_us-gaap_OperatingSegmentsMember_8dfc59a7-8e8e-4847-90b7-20e94fcc57bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_63caaa70-6ccd-40cc-8241-39b0ef3127cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_f2fddc2f-7ae3-4705-83df-55c97eac3896" xlink:to="loc_us-gaap_CorporateNonSegmentMember_63caaa70-6ccd-40cc-8241-39b0ef3127cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bbd5773d-537d-4153-9ffc-72f4a3ea9ed4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c630d95f-caa6-440f-8ae4-b00a2aca1412" xlink:to="loc_srt_StatementGeographicalAxis_bbd5773d-537d-4153-9ffc-72f4a3ea9ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_28f309ea-8f88-4dea-8d88-b2f19214c730" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_bbd5773d-537d-4153-9ffc-72f4a3ea9ed4" xlink:to="loc_srt_SegmentGeographicalDomain_28f309ea-8f88-4dea-8d88-b2f19214c730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_322f9f14-799b-4070-af17-12c1ac5a4591" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_28f309ea-8f88-4dea-8d88-b2f19214c730" xlink:to="loc_country_US_322f9f14-799b-4070-af17-12c1ac5a4591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_0ad005d5-d8dd-456a-befe-a8ccfaf33ada" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_28f309ea-8f88-4dea-8d88-b2f19214c730" xlink:to="loc_srt_EuropeMember_0ad005d5-d8dd-456a-befe-a8ccfaf33ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember_ebac6384-754c-42d8-8c04-7e16ac8188db" xlink:href="jnj-20241229.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_28f309ea-8f88-4dea-8d88-b2f19214c730" xlink:to="loc_jnj_WesternHemisphereExcludingUSMember_ebac6384-754c-42d8-8c04-7e16ac8188db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember_a07d8f1a-e437-4d64-9ad3-ce7c1d85739c" xlink:href="jnj-20241229.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_28f309ea-8f88-4dea-8d88-b2f19214c730" xlink:to="loc_jnj_AsiaPacificAfricaMember_a07d8f1a-e437-4d64-9ad3-ce7c1d85739c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_33d3bd71-34cb-4281-a705-cb388f45827c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c630d95f-caa6-440f-8ae4-b00a2aca1412" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_33d3bd71-34cb-4281-a705-cb388f45827c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dcf96286-5f52-4166-b36d-dff31df165f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_33d3bd71-34cb-4281-a705-cb388f45827c" xlink:to="loc_us-gaap_SegmentDomain_dcf96286-5f52-4166-b36d-dff31df165f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GeneralCorporateMember_88aa6063-58f7-4f14-9802-df87bc3d26b2" xlink:href="jnj-20241229.xsd#jnj_GeneralCorporateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_dcf96286-5f52-4166-b36d-dff31df165f6" xlink:to="loc_jnj_GeneralCorporateMember_88aa6063-58f7-4f14-9802-df87bc3d26b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InnovativeMedicineMember_33eed12f-b93f-411c-a7d6-868c99618424" xlink:href="jnj-20241229.xsd#jnj_InnovativeMedicineMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_dcf96286-5f52-4166-b36d-dff31df165f6" xlink:to="loc_jnj_InnovativeMedicineMember_33eed12f-b93f-411c-a7d6-868c99618424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedTechMember_dbdd96a0-cc4d-4f2b-8b4e-fc6196d254b0" xlink:href="jnj-20241229.xsd#jnj_MedTechMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_dcf96286-5f52-4166-b36d-dff31df165f6" xlink:to="loc_jnj_MedTechMember_dbdd96a0-cc4d-4f2b-8b4e-fc6196d254b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_a36b8579-2d8b-4a98-ac7c-1a26bae62657" xlink:href="jnj-20241229.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_dcf96286-5f52-4166-b36d-dff31df165f6" xlink:to="loc_jnj_PharmaceuticalMember_a36b8579-2d8b-4a98-ac7c-1a26bae62657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_71c77fbd-77b1-49b7-987e-f410d872d4e6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c630d95f-caa6-440f-8ae4-b00a2aca1412" xlink:to="loc_srt_MajorCustomersAxis_71c77fbd-77b1-49b7-987e-f410d872d4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_85bedc3f-c828-463b-9cc3-f4381d13dba2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_71c77fbd-77b1-49b7-987e-f410d872d4e6" xlink:to="loc_srt_NameOfMajorCustomerDomain_85bedc3f-c828-463b-9cc3-f4381d13dba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler1Member_473810f1-98e7-4332-b893-b0ad4fea5be9" xlink:href="jnj-20241229.xsd#jnj_Wholesaler1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_85bedc3f-c828-463b-9cc3-f4381d13dba2" xlink:to="loc_jnj_Wholesaler1Member_473810f1-98e7-4332-b893-b0ad4fea5be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler2Member_c326e2ac-9b86-41ca-9240-17a13955e607" xlink:href="jnj-20241229.xsd#jnj_Wholesaler2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_85bedc3f-c828-463b-9cc3-f4381d13dba2" xlink:to="loc_jnj_Wholesaler2Member_c326e2ac-9b86-41ca-9240-17a13955e607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler3Member_24d802ba-b464-4475-9a67-d868066113aa" xlink:href="jnj-20241229.xsd#jnj_Wholesaler3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_85bedc3f-c828-463b-9cc3-f4381d13dba2" xlink:to="loc_jnj_Wholesaler3Member_24d802ba-b464-4475-9a67-d868066113aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_65f69077-88ea-4e0f-98a0-57e934303d55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c630d95f-caa6-440f-8ae4-b00a2aca1412" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_65f69077-88ea-4e0f-98a0-57e934303d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d54844c8-dad3-412c-bf8f-34cfff2297fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_65f69077-88ea-4e0f-98a0-57e934303d55" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d54844c8-dad3-412c-bf8f-34cfff2297fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_a6dc62ee-9700-4b82-a321-3ae8bc4f8adc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d54844c8-dad3-412c-bf8f-34cfff2297fc" xlink:to="loc_us-gaap_SalesRevenueNetMember_a6dc62ee-9700-4b82-a321-3ae8bc4f8adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_9f31fb18-fcf0-4e75-a7d5-a8793310c04e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c630d95f-caa6-440f-8ae4-b00a2aca1412" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_9f31fb18-fcf0-4e75-a7d5-a8793310c04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5632799c-aa4e-4418-9189-4b10387685d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_9f31fb18-fcf0-4e75-a7d5-a8793310c04e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5632799c-aa4e-4418-9189-4b10387685d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WholesalerConcentrationRiskMember_22e4ea07-2e98-40ae-b308-679f27e93041" xlink:href="jnj-20241229.xsd#jnj_WholesalerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_5632799c-aa4e-4418-9189-4b10387685d9" xlink:to="loc_jnj_WholesalerConcentrationRiskMember_22e4ea07-2e98-40ae-b308-679f27e93041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_7f261b8e-f05b-4293-8966-0bd875c73177" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c630d95f-caa6-440f-8ae4-b00a2aca1412" xlink:to="loc_srt_LitigationCaseAxis_7f261b8e-f05b-4293-8966-0bd875c73177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_0394a5bf-a6cb-463a-8904-79368c90bcc1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_7f261b8e-f05b-4293-8966-0bd875c73177" xlink:to="loc_srt_LitigationCaseTypeDomain_0394a5bf-a6cb-463a-8904-79368c90bcc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember_6dc4a127-4762-432d-8310-82618521d5e4" xlink:href="jnj-20241229.xsd#jnj_BabyPowderMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0394a5bf-a6cb-463a-8904-79368c90bcc1" xlink:to="loc_jnj_BabyPowderMember_6dc4a127-4762-432d-8310-82618521d5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0a00a3ec-cef3-4dc1-b816-270ac6dbea7c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c630d95f-caa6-440f-8ae4-b00a2aca1412" xlink:to="loc_srt_ProductOrServiceAxis_0a00a3ec-cef3-4dc1-b816-270ac6dbea7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1b007d85-a63b-421b-be85-301b01ad5c7c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0a00a3ec-cef3-4dc1-b816-270ac6dbea7c" xlink:to="loc_srt_ProductsAndServicesDomain_1b007d85-a63b-421b-be85-301b01ad5c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_b9ee26b4-a69d-495d-b41c-8c8f2f634917" xlink:href="jnj-20241229.xsd#jnj_TalcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1b007d85-a63b-421b-be85-301b01ad5c7c" xlink:to="loc_jnj_TalcMember_b9ee26b4-a69d-495d-b41c-8c8f2f634917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4aeb341d-6c2b-42ef-b326-f621165e1de6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c630d95f-caa6-440f-8ae4-b00a2aca1412" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4aeb341d-6c2b-42ef-b326-f621165e1de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9f5f3917-9c9e-48bf-a343-a75cd27627e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4aeb341d-6c2b-42ef-b326-f621165e1de6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9f5f3917-9c9e-48bf-a343-a75cd27627e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MomentaMember_297eec50-85f7-4ffb-9893-35ab2628a88a" xlink:href="jnj-20241229.xsd#jnj_MomentaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9f5f3917-9c9e-48bf-a343-a75cd27627e8" xlink:to="loc_jnj_MomentaMember_297eec50-85f7-4ffb-9893-35ab2628a88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_6c6cd960-eadf-4ceb-a450-90184cc0abdf" xlink:href="jnj-20241229.xsd#jnj_BermekimabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9f5f3917-9c9e-48bf-a343-a75cd27627e8" xlink:to="loc_jnj_BermekimabMember_6c6cd960-eadf-4ceb-a450-90184cc0abdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_40975445-a1fe-4dba-ad26-07711919b8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c630d95f-caa6-440f-8ae4-b00a2aca1412" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_40975445-a1fe-4dba-ad26-07711919b8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cc164b41-ffff-4ed1-b841-71adc4cfadfe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_40975445-a1fe-4dba-ad26-07711919b8a7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cc164b41-ffff-4ed1-b841-71adc4cfadfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_e1b42d65-79c5-430c-b335-fc8bf2282ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cc164b41-ffff-4ed1-b841-71adc4cfadfe" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_e1b42d65-79c5-430c-b335-fc8bf2282ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2e9a913e-a203-4276-bcbc-1cdcb870a291" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c630d95f-caa6-440f-8ae4-b00a2aca1412" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2e9a913e-a203-4276-bcbc-1cdcb870a291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7932a357-0f58-43d4-a3e2-d0b7a205bcd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2e9a913e-a203-4276-bcbc-1cdcb870a291" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7932a357-0f58-43d4-a3e2-d0b7a205bcd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember_7e04d3f6-66d9-49e7-95b4-b6db35af43ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7932a357-0f58-43d4-a3e2-d0b7a205bcd5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentMember_7e04d3f6-66d9-49e7-95b4-b6db35af43ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_48fe5add-dfe5-4f05-8a7b-6a8649bb10cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7932a357-0f58-43d4-a3e2-d0b7a205bcd5" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_48fe5add-dfe5-4f05-8a7b-6a8649bb10cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c630d95f-caa6-440f-8ae4-b00a2aca1412" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6482bb05-4c87-4587-a362-7090f8ff4733" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6482bb05-4c87-4587-a362-7090f8ff4733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_2c04fa66-c70e-4ec0-9fdf-a2d49bb351cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_NoncurrentAssets_2c04fa66-c70e-4ec0-9fdf-a2d49bb351cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_2de2441f-19f3-4daf-b40e-a1b785e7b8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_2de2441f-19f3-4daf-b40e-a1b785e7b8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonLongLivedAssets_5eb1fd4c-fe8f-4d8f-b0c1-6074035d3a81" xlink:href="jnj-20241229.xsd#jnj_OtherNonLongLivedAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_jnj_OtherNonLongLivedAssets_5eb1fd4c-fe8f-4d8f-b0c1-6074035d3a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_873410cb-d0c3-4aba-ba6d-e4e981c2c0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_Assets_873410cb-d0c3-4aba-ba6d-e4e981c2c0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b908567c-56be-4af2-b986-ae78548ddd3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b908567c-56be-4af2-b986-ae78548ddd3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_3a055d66-548d-478d-bc58-4201a1136923" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_NumberOfOperatingSegments_3a055d66-548d-478d-bc58-4201a1136923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyLossInPeriod_cf03d51d-b174-4d93-97f4-ce428926534d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyLossInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_LossContingencyLossInPeriod_cf03d51d-b174-4d93-97f4-ce428926534d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_59fb67c5-243a-4d41-beaf-51faea121d93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_59fb67c5-243a-4d41-beaf-51faea121d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_b4e5b0b3-b285-4ddf-b353-fb321bddecde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SuppliesExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_SuppliesExpense_b4e5b0b3-b285-4ddf-b353-fb321bddecde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_8c56270f-c296-46b9-afe6-cbb8b30debdc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_RestructuringCharges_8c56270f-c296-46b9-afe6-cbb8b30debdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_3237b000-d3d9-4d7e-b833-b9071abc5815" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_3237b000-d3d9-4d7e-b833-b9071abc5815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_6fd08082-be5d-44f2-a3ce-be0595c711a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_6fd08082-be5d-44f2-a3ce-be0595c711a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_910e1ed8-4c9f-4b2d-9c8f-840b28221333" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_910e1ed8-4c9f-4b2d-9c8f-840b28221333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_e681d6cf-f0d8-4850-8fe5-6ce73bb44117" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_e681d6cf-f0d8-4850-8fe5-6ce73bb44117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquisitionCosts_271a3ded-644a-43a1-a4c2-1b0d5258fdca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquisitionCosts"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_AcquisitionCosts_271a3ded-644a-43a1-a4c2-1b0d5258fdca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RegulationCharge_a2f7f529-bb46-4147-ac41-5e0fd3473ef4" xlink:href="jnj-20241229.xsd#jnj_RegulationCharge"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_jnj_RegulationCharge_a2f7f529-bb46-4147-ac41-5e0fd3473ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_e71c5fd4-8def-4e0c-bbbe-af3ac9997e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_LitigationSettlementExpense_e71c5fd4-8def-4e0c-bbbe-af3ac9997e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentInProcess1_9f9e5555-c23c-4c84-828f-2e42d5ba9b40" xlink:href="jnj-20241229.xsd#jnj_ResearchAndDevelopmentInProcess1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_jnj_ResearchAndDevelopmentInProcess1_9f9e5555-c23c-4c84-828f-2e42d5ba9b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_6021ee74-5fe8-46c4-aca3-55a9a3cd12e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c4fa6ed3-c8b6-4c21-8836-6a16d3ba9626" xlink:to="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_6021ee74-5fe8-46c4-aca3-55a9a3cd12e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#AcquisitionsanddivestituresNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4d6bfcde-7d8c-4d01-8ec2-cfe7ce97adcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54774428-3abb-43b2-85e8-bb4805809cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4d6bfcde-7d8c-4d01-8ec2-cfe7ce97adcc" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54774428-3abb-43b2-85e8-bb4805809cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dbc0db2b-3502-48a9-9fdb-041bc6d41463" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54774428-3abb-43b2-85e8-bb4805809cc0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dbc0db2b-3502-48a9-9fdb-041bc6d41463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7a407c0d-1e0c-4cab-a6e9-c0adc62e8e98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dbc0db2b-3502-48a9-9fdb-041bc6d41463" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7a407c0d-1e0c-4cab-a6e9-c0adc62e8e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IntraCellularTherapiesInc.Member_bfc55020-85d8-4d94-8f17-936b0c214a4d" xlink:href="jnj-20241229.xsd#jnj_IntraCellularTherapiesInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7a407c0d-1e0c-4cab-a6e9-c0adc62e8e98" xlink:to="loc_jnj_IntraCellularTherapiesInc.Member_bfc55020-85d8-4d94-8f17-936b0c214a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AmbrxMember_9d9d8e3f-ff4e-4764-87f7-857292fe5d42" xlink:href="jnj-20241229.xsd#jnj_AmbrxMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7a407c0d-1e0c-4cab-a6e9-c0adc62e8e98" xlink:to="loc_jnj_AmbrxMember_9d9d8e3f-ff4e-4764-87f7-857292fe5d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AbiomedMember_ad39807b-a556-4500-ba64-955a25d552e7" xlink:href="jnj-20241229.xsd#jnj_AbiomedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7a407c0d-1e0c-4cab-a6e9-c0adc62e8e98" xlink:to="loc_jnj_AbiomedMember_ad39807b-a556-4500-ba64-955a25d552e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProteologixMember_d3c32c88-bacc-425e-9966-2678f7dce0eb" xlink:href="jnj-20241229.xsd#jnj_ProteologixMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7a407c0d-1e0c-4cab-a6e9-c0adc62e8e98" xlink:to="loc_jnj_ProteologixMember_d3c32c88-bacc-425e-9966-2678f7dce0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShockwaveMedicalInc.Member_ea214221-5770-46ab-8879-32f6f60f8b68" xlink:href="jnj-20241229.xsd#jnj_ShockwaveMedicalInc.Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7a407c0d-1e0c-4cab-a6e9-c0adc62e8e98" xlink:to="loc_jnj_ShockwaveMedicalInc.Member_ea214221-5770-46ab-8879-32f6f60f8b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2110c786-56b9-4d1e-95d9-7cfd56f1b7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54774428-3abb-43b2-85e8-bb4805809cc0" xlink:to="loc_us-gaap_AwardTypeAxis_2110c786-56b9-4d1e-95d9-7cfd56f1b7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d611f546-84fa-4ec3-8130-82d9f5cb8eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2110c786-56b9-4d1e-95d9-7cfd56f1b7d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d611f546-84fa-4ec3-8130-82d9f5cb8eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NonTradeableContingentValueRightMember_50ef8cfb-45b0-4070-8d9a-a3ac06b1bb65" xlink:href="jnj-20241229.xsd#jnj_NonTradeableContingentValueRightMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d611f546-84fa-4ec3-8130-82d9f5cb8eb5" xlink:to="loc_jnj_NonTradeableContingentValueRightMember_50ef8cfb-45b0-4070-8d9a-a3ac06b1bb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1a0528b1-d49f-4c7e-aa79-c5062038a322" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54774428-3abb-43b2-85e8-bb4805809cc0" xlink:to="loc_srt_ProductOrServiceAxis_1a0528b1-d49f-4c7e-aa79-c5062038a322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8b51e424-4496-4aa8-8737-c922bff076ba" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1a0528b1-d49f-4c7e-aa79-c5062038a322" xlink:to="loc_srt_ProductsAndServicesDomain_8b51e424-4496-4aa8-8737-c922bff076ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImpellaMember_50ed3c39-832a-4b7b-b81c-a065c67f6353" xlink:href="jnj-20241229.xsd#jnj_ImpellaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8b51e424-4496-4aa8-8737-c922bff076ba" xlink:to="loc_jnj_ImpellaMember_50ed3c39-832a-4b7b-b81c-a065c67f6353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ClassIRecommendationForImpellaMember_af511b61-fa61-4aed-8a94-8a26a65d1f0e" xlink:href="jnj-20241229.xsd#jnj_ClassIRecommendationForImpellaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8b51e424-4496-4aa8-8737-c922bff076ba" xlink:to="loc_jnj_ClassIRecommendationForImpellaMember_af511b61-fa61-4aed-8a94-8a26a65d1f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bdf67248-fa1f-4c42-afe9-058a068e76c5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54774428-3abb-43b2-85e8-bb4805809cc0" xlink:to="loc_srt_RangeAxis_bdf67248-fa1f-4c42-afe9-058a068e76c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0df9fdb0-774d-432b-b455-e5290ead7cd5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bdf67248-fa1f-4c42-afe9-058a068e76c5" xlink:to="loc_srt_RangeMember_0df9fdb0-774d-432b-b455-e5290ead7cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a0fd23a7-94fc-40cc-a057-e1e52d632835" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0df9fdb0-774d-432b-b455-e5290ead7cd5" xlink:to="loc_srt_MinimumMember_a0fd23a7-94fc-40cc-a057-e1e52d632835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7be4c5af-e7c3-4ef0-b945-c76d28139592" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0df9fdb0-774d-432b-b455-e5290ead7cd5" xlink:to="loc_srt_MaximumMember_7be4c5af-e7c3-4ef0-b945-c76d28139592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_11fbc227-5398-44f9-aa69-015f68a24a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54774428-3abb-43b2-85e8-bb4805809cc0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_11fbc227-5398-44f9-aa69-015f68a24a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fb8dfcbb-ae28-4d74-a6bd-1421a6b566da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_11fbc227-5398-44f9-aa69-015f68a24a8d" xlink:to="loc_us-gaap_SegmentDomain_fb8dfcbb-ae28-4d74-a6bd-1421a6b566da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedTechMember_68764d95-7d9b-4284-bb8f-12a0b952353c" xlink:href="jnj-20241229.xsd#jnj_MedTechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_fb8dfcbb-ae28-4d74-a6bd-1421a6b566da" xlink:to="loc_jnj_MedTechMember_68764d95-7d9b-4284-bb8f-12a0b952353c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_b0fd238c-9bda-4ca0-aeb0-97b38cff4355" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54774428-3abb-43b2-85e8-bb4805809cc0" xlink:to="loc_us-gaap_AssetAcquisitionAxis_b0fd238c-9bda-4ca0-aeb0-97b38cff4355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_7ade26bb-446e-40d8-8ef8-4f5c4387dfaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_b0fd238c-9bda-4ca0-aeb0-97b38cff4355" xlink:to="loc_us-gaap_AssetAcquisitionDomain_7ade26bb-446e-40d8-8ef8-4f5c4387dfaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VWaveLtd.Member_365be1ff-53dc-428d-a872-79324ac8c196" xlink:href="jnj-20241229.xsd#jnj_VWaveLtd.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_7ade26bb-446e-40d8-8ef8-4f5c4387dfaf" xlink:to="loc_jnj_VWaveLtd.Member_365be1ff-53dc-428d-a872-79324ac8c196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_YellowJerseyTherapeuticsMember_d54f39dc-6f65-42c3-a333-c8cf6ec2871d" xlink:href="jnj-20241229.xsd#jnj_YellowJerseyTherapeuticsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_7ade26bb-446e-40d8-8ef8-4f5c4387dfaf" xlink:to="loc_jnj_YellowJerseyTherapeuticsMember_d54f39dc-6f65-42c3-a333-c8cf6ec2871d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LaminarMember_89e23a4b-583c-4d9c-b7fd-2a3f2c8dbc3b" xlink:href="jnj-20241229.xsd#jnj_LaminarMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_7ade26bb-446e-40d8-8ef8-4f5c4387dfaf" xlink:to="loc_jnj_LaminarMember_89e23a4b-583c-4d9c-b7fd-2a3f2c8dbc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_398cd435-6c9d-4de1-9129-40790aa0a94f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54774428-3abb-43b2-85e8-bb4805809cc0" xlink:to="loc_srt_StatementScenarioAxis_398cd435-6c9d-4de1-9129-40790aa0a94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2c784572-ae83-427d-9a6b-1c6aab9631eb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_398cd435-6c9d-4de1-9129-40790aa0a94f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2c784572-ae83-427d-9a6b-1c6aab9631eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_13484551-8ade-41a7-aba6-d3fbb69f007d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_2c784572-ae83-427d-9a6b-1c6aab9631eb" xlink:to="loc_srt_ScenarioForecastMember_13484551-8ade-41a7-aba6-d3fbb69f007d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_129111b2-755d-449c-865a-92faa4352193" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54774428-3abb-43b2-85e8-bb4805809cc0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_129111b2-755d-449c-865a-92faa4352193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0c563c41-0555-4655-9319-7a8a82226a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_129111b2-755d-449c-865a-92faa4352193" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0c563c41-0555-4655-9319-7a8a82226a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AcclarentMember_fcf8637f-3bad-43ea-a035-461934dad4c8" xlink:href="jnj-20241229.xsd#jnj_AcclarentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0c563c41-0555-4655-9319-7a8a82226a3a" xlink:to="loc_jnj_AcclarentMember_fcf8637f-3bad-43ea-a035-461934dad4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PonvoryMember_9b3bc2be-165a-43c4-93ba-806df2bb419f" xlink:href="jnj-20241229.xsd#jnj_PonvoryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0c563c41-0555-4655-9319-7a8a82226a3a" xlink:to="loc_jnj_PonvoryMember_9b3bc2be-165a-43c4-93ba-806df2bb419f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54774428-3abb-43b2-85e8-bb4805809cc0" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_7516a3a4-2a8f-4ce4-a4f8-e833975e0b85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_7516a3a4-2a8f-4ce4-a4f8-e833975e0b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_eb268843-ca22-4a4f-b953-205df918e437" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_eb268843-ca22-4a4f-b953-205df918e437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_b4e95ff0-92ad-4a90-912a-df0be20e39fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_b4e95ff0-92ad-4a90-912a-df0be20e39fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_39492d53-91c1-4d6e-a056-6fb71dbe9cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_39492d53-91c1-4d6e-a056-6fb71dbe9cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a951f277-4bf0-4e5a-812d-57678ed11f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a951f277-4bf0-4e5a-812d-57678ed11f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_2d9ca2fd-d95d-432e-ab8b-901ff9bea442" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_2d9ca2fd-d95d-432e-ab8b-901ff9bea442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_f47fe42f-75d2-4dcb-ab0e-717d8a576ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_f47fe42f-75d2-4dcb-ab0e-717d8a576ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_7c45f03c-96ea-4b8d-b542-0a39559b8162" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_7c45f03c-96ea-4b8d-b542-0a39559b8162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7a055add-3e54-4784-849d-1546f07c5e92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7a055add-3e54-4784-849d-1546f07c5e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor_1d46a24b-7de6-4ab1-a6fb-253f959c75d2" xlink:href="jnj-20241229.xsd#jnj_BusinessCombinationProbabilityOfSuccessFactor"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor_1d46a24b-7de6-4ab1-a6fb-253f959c75d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessAcquisitionDiscountRate_ad36c372-69e2-4e4b-86ba-274aa15d9eea" xlink:href="jnj-20241229.xsd#jnj_BusinessAcquisitionDiscountRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_jnj_BusinessAcquisitionDiscountRate_ad36c372-69e2-4e4b-86ba-274aa15d9eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_1cae34c7-4880-4859-9cbc-1c9301ce9cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_1cae34c7-4880-4859-9cbc-1c9301ce9cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss_cf7802c7-09f7-4ee1-94e4-acd14ff98ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss_cf7802c7-09f7-4ee1-94e4-acd14ff98ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationAcquisitionRelatedCostsEquityAwards_2b830a0d-c716-4fcf-909c-fdc727bea7dd" xlink:href="jnj-20241229.xsd#jnj_BusinessCombinationAcquisitionRelatedCostsEquityAwards"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_jnj_BusinessCombinationAcquisitionRelatedCostsEquityAwards_2b830a0d-c716-4fcf-909c-fdc727bea7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_1778651a-ee8e-48d2-8d7e-31b629f4788f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_1778651a-ee8e-48d2-8d7e-31b629f4788f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight_bbef3ed1-58b7-403f-b051-f4c6cece7c4d" xlink:href="jnj-20241229.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight_bbef3ed1-58b7-403f-b051-f4c6cece7c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight_64a7ca1c-3605-4d10-8909-6054dab20301" xlink:href="jnj-20241229.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight_64a7ca1c-3605-4d10-8909-6054dab20301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c0f3db88-5429-47c8-aec1-11a870456b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c0f3db88-5429-47c8-aec1-11a870456b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableAmountPerShare_db5c44d1-835f-4dba-8ea6-27d7866641f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPayableAmountPerShare"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_DividendsPayableAmountPerShare_db5c44d1-835f-4dba-8ea6-27d7866641f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RevenuesContingentConsideration_6a33025f-765e-458a-b903-4ea4657d86ad" xlink:href="jnj-20241229.xsd#jnj_RevenuesContingentConsideration"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_jnj_RevenuesContingentConsideration_6a33025f-765e-458a-b903-4ea4657d86ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_ed457371-f456-4ae2-b970-c79f68d4e27c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_ed457371-f456-4ae2-b970-c79f68d4e27c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_b3a4f590-ba6a-4993-a1cf-280ed734c408" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_b3a4f590-ba6a-4993-a1cf-280ed734c408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentInProcess1_27ecbd54-52b5-4bf2-8a77-68529693ef71" xlink:href="jnj-20241229.xsd#jnj_ResearchAndDevelopmentInProcess1"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_jnj_ResearchAndDevelopmentInProcess1_27ecbd54-52b5-4bf2-8a77-68529693ef71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_cbc8e63b-6e3c-409a-9a49-5b514430f099" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_cbc8e63b-6e3c-409a-9a49-5b514430f099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a4bf4ef2-e616-4901-a2bc-0aecff0fd818" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a4bf4ef2-e616-4901-a2bc-0aecff0fd818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1efeb97e-31fc-4e89-9e68-84cd4661a4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1efeb97e-31fc-4e89-9e68-84cd4661a4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_1045e06b-a5f6-481f-86d7-160fa76e7576" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_1045e06b-a5f6-481f-86d7-160fa76e7576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquisitionCosts_9dd48566-c380-4a6a-8a66-60bc069dbd80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquisitionCosts"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_AcquisitionCosts_9dd48566-c380-4a6a-8a66-60bc069dbd80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_c87f440b-9d13-47ac-ab67-8f93c2c2877a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_c87f440b-9d13-47ac-ab67-8f93c2c2877a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill_ce5421b1-471a-41cc-aa78-3f0d2b169529" xlink:href="jnj-20241229.xsd#jnj_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_jnj_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill_ce5421b1-471a-41cc-aa78-3f0d2b169529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_f46e9973-d963-44e3-8cd9-08b1e703e152" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_f46e9973-d963-44e3-8cd9-08b1e703e152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_22d70269-6c92-401f-a5af-ccb7cdf32516" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b2df87ab-c588-4630-b5e7-47dccbf3e61a" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_22d70269-6c92-401f-a5af-ccb7cdf32516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsanddivestituresDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#AcquisitionsanddivestituresDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AcquisitionsanddivestituresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_614ce675-57f6-41bf-bad0-d4636f1ac65d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d74a5106-a91a-4b9b-8bbe-73a8ac7857d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_614ce675-57f6-41bf-bad0-d4636f1ac65d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d74a5106-a91a-4b9b-8bbe-73a8ac7857d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5b1e0f6c-f744-4c9f-9171-cc696a8df4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d74a5106-a91a-4b9b-8bbe-73a8ac7857d6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5b1e0f6c-f744-4c9f-9171-cc696a8df4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31d789ce-0d43-4d04-8f40-9e353e637334" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5b1e0f6c-f744-4c9f-9171-cc696a8df4ff" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31d789ce-0d43-4d04-8f40-9e353e637334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShockwaveMedicalInc.Member_79f8c95a-1715-43d0-8e35-9d1b06c3f18e" xlink:href="jnj-20241229.xsd#jnj_ShockwaveMedicalInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31d789ce-0d43-4d04-8f40-9e353e637334" xlink:to="loc_jnj_ShockwaveMedicalInc.Member_79f8c95a-1715-43d0-8e35-9d1b06c3f18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_141cb0ee-b0b2-427b-b245-0da0b19234e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d74a5106-a91a-4b9b-8bbe-73a8ac7857d6" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_141cb0ee-b0b2-427b-b245-0da0b19234e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_0fcebeca-6271-4dd3-87ad-47138ef8b8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_141cb0ee-b0b2-427b-b245-0da0b19234e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_0fcebeca-6271-4dd3-87ad-47138ef8b8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6d999bec-4d59-4853-9c01-c38445ccc5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_0fcebeca-6271-4dd3-87ad-47138ef8b8dd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6d999bec-4d59-4853-9c01-c38445ccc5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0b392e60-9719-44bc-991a-e3a5e302845e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_0fcebeca-6271-4dd3-87ad-47138ef8b8dd" xlink:to="loc_us-gaap_Goodwill_0b392e60-9719-44bc-991a-e3a5e302845e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_e876de16-844d-494d-9122-6267d3798250" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_0fcebeca-6271-4dd3-87ad-47138ef8b8dd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_e876de16-844d-494d-9122-6267d3798250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_75e17cf5-9457-48e5-9d81-d1f5cf51c0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_0fcebeca-6271-4dd3-87ad-47138ef8b8dd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_75e17cf5-9457-48e5-9d81-d1f5cf51c0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_022ecec2-2beb-43c3-b89e-39caa1795ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_0fcebeca-6271-4dd3-87ad-47138ef8b8dd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_022ecec2-2beb-43c3-b89e-39caa1795ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_cde6adaa-e862-40a9-98e4-464ee6e64dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_0fcebeca-6271-4dd3-87ad-47138ef8b8dd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_cde6adaa-e862-40a9-98e4-464ee6e64dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_779c4475-b11b-4dd2-94a7-7a20ce1144a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_0fcebeca-6271-4dd3-87ad-47138ef8b8dd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_779c4475-b11b-4dd2-94a7-7a20ce1144a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4a0e78aa-b3b2-4289-b9d9-a1cfe86252cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_141cb0ee-b0b2-427b-b245-0da0b19234e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4a0e78aa-b3b2-4289-b9d9-a1cfe86252cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_99d22bbe-1dad-455d-bae2-54f578c97e47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4a0e78aa-b3b2-4289-b9d9-a1cfe86252cb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_99d22bbe-1dad-455d-bae2-54f578c97e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_a2289227-e53b-4b30-a7c8-122a811415aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4a0e78aa-b3b2-4289-b9d9-a1cfe86252cb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_a2289227-e53b-4b30-a7c8-122a811415aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_385eaacd-a2ce-4d57-bb03-1ed81f431be9" xlink:href="jnj-20241229.xsd#jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4a0e78aa-b3b2-4289-b9d9-a1cfe86252cb" xlink:to="loc_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_385eaacd-a2ce-4d57-bb03-1ed81f431be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_589a5415-7b19-4ae6-a5db-d9295cdcaae0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4a0e78aa-b3b2-4289-b9d9-a1cfe86252cb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_589a5415-7b19-4ae6-a5db-d9295cdcaae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0e71c4de-1b0d-4eea-b608-afbeb887bc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_141cb0ee-b0b2-427b-b245-0da0b19234e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0e71c4de-1b0d-4eea-b608-afbeb887bc9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6b8dfde6-600a-4f5a-9a09-825822e07055" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_141cb0ee-b0b2-427b-b245-0da0b19234e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6b8dfde6-600a-4f5a-9a09-825822e07055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationSettlementOfEquityAwards_8a7c55fd-03e0-4970-bc1b-fa2df0272a16" xlink:href="jnj-20241229.xsd#jnj_BusinessCombinationSettlementOfEquityAwards"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_141cb0ee-b0b2-427b-b245-0da0b19234e0" xlink:to="loc_jnj_BusinessCombinationSettlementOfEquityAwards_8a7c55fd-03e0-4970-bc1b-fa2df0272a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationSettlementOfNotesPayable_a391c6fb-7078-4b31-9fc9-f0956de5769f" xlink:href="jnj-20241229.xsd#jnj_BusinessCombinationSettlementOfNotesPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_141cb0ee-b0b2-427b-b245-0da0b19234e0" xlink:to="loc_jnj_BusinessCombinationSettlementOfNotesPayable_a391c6fb-7078-4b31-9fc9-f0956de5769f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalproceedingsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#LegalproceedingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/LegalproceedingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ba9bf6b4-d43c-422e-a04b-974d3af97975" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_36f9f607-99d3-47e0-ac87-48e1994f539e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ba9bf6b4-d43c-422e-a04b-974d3af97975" xlink:to="loc_us-gaap_LossContingenciesTable_36f9f607-99d3-47e0-ac87-48e1994f539e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_865cb276-fd22-4955-ad4f-33d35581e791" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_36f9f607-99d3-47e0-ac87-48e1994f539e" xlink:to="loc_srt_LitigationCaseAxis_865cb276-fd22-4955-ad4f-33d35581e791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c277515a-30ea-4b0f-8671-7652552bc54f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_865cb276-fd22-4955-ad4f-33d35581e791" xlink:to="loc_srt_LitigationCaseTypeDomain_c277515a-30ea-4b0f-8671-7652552bc54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member_89690888-3790-4ab5-b276-e0ff93be6a63" xlink:href="jnj-20241229.xsd#jnj_DePuyASRU.S.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_c277515a-30ea-4b0f-8671-7652552bc54f" xlink:to="loc_jnj_DePuyASRU.S.Member_89690888-3790-4ab5-b276-e0ff93be6a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_b91b11b8-1b67-4c4b-9484-d30bfada6fb2" xlink:href="jnj-20241229.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_c277515a-30ea-4b0f-8671-7652552bc54f" xlink:to="loc_jnj_RisperdalMember_b91b11b8-1b67-4c4b-9484-d30bfada6fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember_bf78d625-d262-4d0e-be00-55ad2bb19414" xlink:href="jnj-20241229.xsd#jnj_BabyPowderMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_c277515a-30ea-4b0f-8671-7652552bc54f" xlink:to="loc_jnj_BabyPowderMember_bf78d625-d262-4d0e-be00-55ad2bb19414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InghamVsJohnsonJohnsonMember_c9b6e6b6-2c0e-4ea8-85e2-3ecd4373de55" xlink:href="jnj-20241229.xsd#jnj_InghamVsJohnsonJohnsonMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_c277515a-30ea-4b0f-8671-7652552bc54f" xlink:to="loc_jnj_InghamVsJohnsonJohnsonMember_c9b6e6b6-2c0e-4ea8-85e2-3ecd4373de55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_c262b47f-fe6b-4f47-9b63-ce013ec497d6" xlink:href="jnj-20241229.xsd#jnj_TalcMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_c277515a-30ea-4b0f-8671-7652552bc54f" xlink:to="loc_jnj_TalcMember_c262b47f-fe6b-4f47-9b63-ce013ec497d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MesotheliomaAndStateClaimsMember_ff03f9db-a96a-4ad1-a902-ab0680e60f32" xlink:href="jnj-20241229.xsd#jnj_MesotheliomaAndStateClaimsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_c277515a-30ea-4b0f-8671-7652552bc54f" xlink:to="loc_jnj_MesotheliomaAndStateClaimsMember_ff03f9db-a96a-4ad1-a902-ab0680e60f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_8e3cdf27-4a0e-462b-83fc-e1621e34bb33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_36f9f607-99d3-47e0-ac87-48e1994f539e" xlink:to="loc_us-gaap_LitigationStatusAxis_8e3cdf27-4a0e-462b-83fc-e1621e34bb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_97c8bab2-25b8-4a4f-a082-27a71a3a5746" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_8e3cdf27-4a0e-462b-83fc-e1621e34bb33" xlink:to="loc_us-gaap_LitigationStatusDomain_97c8bab2-25b8-4a4f-a082-27a71a3a5746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_f4769c56-23f8-4bbb-9e7e-795dd27e15c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_97c8bab2-25b8-4a4f-a082-27a71a3a5746" xlink:to="loc_us-gaap_SettledLitigationMember_f4769c56-23f8-4bbb-9e7e-795dd27e15c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember_f7f264f7-cf57-437c-8993-55dfbecdd64b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_JudicialRulingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_97c8bab2-25b8-4a4f-a082-27a71a3a5746" xlink:to="loc_us-gaap_JudicialRulingMember_f7f264f7-cf57-437c-8993-55dfbecdd64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_f4fcfdb4-877b-4401-b99c-fae272cf5262" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_97c8bab2-25b8-4a4f-a082-27a71a3a5746" xlink:to="loc_us-gaap_PendingLitigationMember_f4fcfdb4-877b-4401-b99c-fae272cf5262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_492b104c-987a-40e2-bd93-ce0edb91c92a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_36f9f607-99d3-47e0-ac87-48e1994f539e" xlink:to="loc_srt_ProductOrServiceAxis_492b104c-987a-40e2-bd93-ce0edb91c92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e4fbd921-634d-46ed-9959-b7d4545288e9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_492b104c-987a-40e2-bd93-ce0edb91c92a" xlink:to="loc_srt_ProductsAndServicesDomain_e4fbd921-634d-46ed-9959-b7d4545288e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_865ae58a-862e-4958-a606-c5a654f62342" xlink:href="jnj-20241229.xsd#jnj_TalcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e4fbd921-634d-46ed-9959-b7d4545288e9" xlink:to="loc_jnj_TalcMember_865ae58a-862e-4958-a606-c5a654f62342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpioidMember_b93fdbea-4736-4cd5-9bf4-cbdad5766a28" xlink:href="jnj-20241229.xsd#jnj_OpioidMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e4fbd921-634d-46ed-9959-b7d4545288e9" xlink:to="loc_jnj_OpioidMember_b93fdbea-4736-4cd5-9bf4-cbdad5766a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember_37bf955b-f1c1-449d-8ae8-6d0f2f20d870" xlink:href="jnj-20241229.xsd#jnj_PhysiomeshMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e4fbd921-634d-46ed-9959-b7d4545288e9" xlink:to="loc_jnj_PhysiomeshMember_37bf955b-f1c1-449d-8ae8-6d0f2f20d870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesAxis_6ec00df4-69fb-47fb-9261-393c7d78a06d" xlink:href="jnj-20241229.xsd#jnj_LitigationSettlementByCompaniesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_36f9f607-99d3-47e0-ac87-48e1994f539e" xlink:to="loc_jnj_LitigationSettlementByCompaniesAxis_6ec00df4-69fb-47fb-9261-393c7d78a06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain_b4a1c846-970d-4469-a372-c29dff0ac9e3" xlink:href="jnj-20241229.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis_6ec00df4-69fb-47fb-9261-393c7d78a06d" xlink:to="loc_jnj_LitigationSettlementByCompaniesDomain_b4a1c846-970d-4469-a372-c29dff0ac9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_b31300d2-aec5-4fd0-bf11-afe5deb372ee" xlink:href="jnj-20241229.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LitigationSettlementByCompaniesDomain_b4a1c846-970d-4469-a372-c29dff0ac9e3" xlink:to="loc_jnj_RisperdalMember_b31300d2-aec5-4fd0-bf11-afe5deb372ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_ce157f2f-d760-40ac-9bf4-0e45e2f6e31e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_36f9f607-99d3-47e0-ac87-48e1994f539e" xlink:to="loc_us-gaap_LossContingenciesLineItems_ce157f2f-d760-40ac-9bf4-0e45e2f6e31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:href="jnj-20241229.xsd#jnj_LegalProceedingTextualsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ce157f2f-d760-40ac-9bf4-0e45e2f6e31e" xlink:to="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_cb0d773b-6c5a-40f7-9317-dfaee6d5dd20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_cb0d773b-6c5a-40f7-9317-dfaee6d5dd20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_ddf97f95-2858-4f5c-989e-03b2c5cdde56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesPaidValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_us-gaap_LossContingencyDamagesPaidValue_ddf97f95-2858-4f5c-989e-03b2c5cdde56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyPaymentPeriod_49c586b7-4bb8-4a7e-a5ac-a32063d79459" xlink:href="jnj-20241229.xsd#jnj_LossContingencyPaymentPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_jnj_LossContingencyPaymentPeriod_49c586b7-4bb8-4a7e-a5ac-a32063d79459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencySolicitationPeriod_dbca34f1-eccb-4efa-9a28-ea79ccaba706" xlink:href="jnj-20241229.xsd#jnj_LossContingencySolicitationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_jnj_LossContingencySolicitationPeriod_dbca34f1-eccb-4efa-9a28-ea79ccaba706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_c1774bfe-bbfd-4eef-ba38-823cfd990bca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_c1774bfe-bbfd-4eef-ba38-823cfd990bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyDamagesSoughtNominalValue_507086da-a009-48c2-b65b-ed4089e97701" xlink:href="jnj-20241229.xsd#jnj_LossContingencyDamagesSoughtNominalValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_jnj_LossContingencyDamagesSoughtNominalValue_507086da-a009-48c2-b65b-ed4089e97701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyDiscountRate_927c11f4-d53d-4b76-bc45-5c91bc73e888" xlink:href="jnj-20241229.xsd#jnj_LossContingencyDiscountRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_jnj_LossContingencyDiscountRate_927c11f4-d53d-4b76-bc45-5c91bc73e888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TotalClaimsAgainstCompanyPercent_fb3ff78b-8416-47dc-9faa-f765b2d48018" xlink:href="jnj-20241229.xsd#jnj_TotalClaimsAgainstCompanyPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_jnj_TotalClaimsAgainstCompanyPercent_fb3ff78b-8416-47dc-9faa-f765b2d48018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyDamagesSoughtValueIncrease_59307d92-1159-49c0-b48c-d9cbdefbca51" xlink:href="jnj-20241229.xsd#jnj_LossContingencyDamagesSoughtValueIncrease"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_jnj_LossContingencyDamagesSoughtValueIncrease_59307d92-1159-49c0-b48c-d9cbdefbca51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyClaimsSettledPercent_0147728e-d646-4dc0-b4c7-8eb9201c5a02" xlink:href="jnj-20241229.xsd#jnj_LossContingencyClaimsSettledPercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_jnj_LossContingencyClaimsSettledPercent_0147728e-d646-4dc0-b4c7-8eb9201c5a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_5a354d7b-9474-49fc-9f31-05a1074deeeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_5a354d7b-9474-49fc-9f31-05a1074deeeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyAccrualNominalValue_92074917-6fa8-4bac-b019-e1c7ae4b310a" xlink:href="jnj-20241229.xsd#jnj_LossContingencyAccrualNominalValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_jnj_LossContingencyAccrualNominalValue_92074917-6fa8-4bac-b019-e1c7ae4b310a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_6e431a91-8681-4ca5-b9c2-62efeee0eb93" xlink:href="jnj-20241229.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_6e431a91-8681-4ca5-b9c2-62efeee0eb93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_abfa2e5b-0234-4bd2-aae3-a1da943a9fab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_abfa2e5b-0234-4bd2-aae3-a1da943a9fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyAccrualPaymentPercentage_c1319114-4a2a-4adf-9999-69a13be1f72f" xlink:href="jnj-20241229.xsd#jnj_LossContingencyAccrualPaymentPercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_jnj_LossContingencyAccrualPaymentPercentage_c1319114-4a2a-4adf-9999-69a13be1f72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_2e1556e0-87dd-446c-a7dc-1023e229c443" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_2e1556e0-87dd-446c-a7dc-1023e229c443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement_567820cb-2622-426a-bbe8-f7d2207097fe" xlink:href="jnj-20241229.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_jnj_Numberofpatientsinsettlement_567820cb-2622-426a-bbe8-f7d2207097fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_7cb68e8e-3353-4475-9287-96011eb32a5a" xlink:href="jnj-20241229.xsd#jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_51c42e24-3a0f-4c4e-ad4c-44e1faa999f6" xlink:to="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_7cb68e8e-3353-4475-9287-96011eb32a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#LegalproceedingsProductLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2d03b1a4-8973-4b32-951e-e49d9df111b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_3a615421-bc7f-4793-80f3-ed877a0e48ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2d03b1a4-8973-4b32-951e-e49d9df111b2" xlink:to="loc_us-gaap_LossContingenciesTable_3a615421-bc7f-4793-80f3-ed877a0e48ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_72611f4d-5b86-4419-b436-957eb6dca8fb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_3a615421-bc7f-4793-80f3-ed877a0e48ef" xlink:to="loc_srt_ProductOrServiceAxis_72611f4d-5b86-4419-b436-957eb6dca8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_47622451-4440-47d5-a993-4a7d7d4689fa" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_72611f4d-5b86-4419-b436-957eb6dca8fb" xlink:to="loc_srt_ProductsAndServicesDomain_47622451-4440-47d5-a993-4a7d7d4689fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_7fd45463-8bfa-4657-a7cf-1d998c5fc556" xlink:href="jnj-20241229.xsd#jnj_TalcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_47622451-4440-47d5-a993-4a7d7d4689fa" xlink:to="loc_jnj_TalcMember_7fd45463-8bfa-4657-a7cf-1d998c5fc556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember_d1287ab5-a23d-45fe-9065-56c6b81bd4dd" xlink:href="jnj-20241229.xsd#jnj_AsrMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_47622451-4440-47d5-a993-4a7d7d4689fa" xlink:to="loc_jnj_AsrMember_d1287ab5-a23d-45fe-9065-56c6b81bd4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember_eaf2587f-9c0f-4506-9b3f-0e80ae57ab94" xlink:href="jnj-20241229.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_47622451-4440-47d5-a993-4a7d7d4689fa" xlink:to="loc_jnj_PinnacleAcetabularCupSystemMember_eaf2587f-9c0f-4506-9b3f-0e80ae57ab94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember_7a9543a4-ac69-4355-9924-0bd52f970ff5" xlink:href="jnj-20241229.xsd#jnj_PelvicMeshesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_47622451-4440-47d5-a993-4a7d7d4689fa" xlink:to="loc_jnj_PelvicMeshesMember_7a9543a4-ac69-4355-9924-0bd52f970ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember_9830f3b2-5cac-48f7-8156-ebc32cc29cdd" xlink:href="jnj-20241229.xsd#jnj_PhysiomeshMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_47622451-4440-47d5-a993-4a7d7d4689fa" xlink:to="loc_jnj_PhysiomeshMember_9830f3b2-5cac-48f7-8156-ebc32cc29cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_debfbf00-2833-47ed-b7a5-df0bf4b12660" xlink:href="jnj-20241229.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_47622451-4440-47d5-a993-4a7d7d4689fa" xlink:to="loc_jnj_RisperdalMember_debfbf00-2833-47ed-b7a5-df0bf4b12660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ElmironMember_6781ec63-6788-48dc-b6b2-6e9e1dfe275f" xlink:href="jnj-20241229.xsd#jnj_ElmironMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_47622451-4440-47d5-a993-4a7d7d4689fa" xlink:to="loc_jnj_ElmironMember_6781ec63-6788-48dc-b6b2-6e9e1dfe275f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_7c70f7b2-7356-4e05-aaa6-4af46519e5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_3a615421-bc7f-4793-80f3-ed877a0e48ef" xlink:to="loc_us-gaap_LossContingenciesLineItems_7c70f7b2-7356-4e05-aaa6-4af46519e5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_e121c872-d397-4a09-bc2e-002bec1d7e9f" xlink:href="jnj-20241229.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7c70f7b2-7356-4e05-aaa6-4af46519e5d4" xlink:to="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_e121c872-d397-4a09-bc2e-002bec1d7e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#RestructuringNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0872bb49-f50e-4392-b5a2-14a51ed79596" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b18a1275-3a48-4e87-93bf-d1ea91482446" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0872bb49-f50e-4392-b5a2-14a51ed79596" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b18a1275-3a48-4e87-93bf-d1ea91482446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_6ec14e69-fe8b-4186-9665-a1fd445a8434" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b18a1275-3a48-4e87-93bf-d1ea91482446" xlink:to="loc_us-gaap_RestructuringPlanAxis_6ec14e69-fe8b-4186-9665-a1fd445a8434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_f48b6a3e-0c47-46f8-a73c-78a77caee60a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_6ec14e69-fe8b-4186-9665-a1fd445a8434" xlink:to="loc_us-gaap_RestructuringPlanDomain_f48b6a3e-0c47-46f8-a73c-78a77caee60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RDRestructuringPlanMember_9d1bcfa9-89bd-4d3f-bcd5-f5d38797e313" xlink:href="jnj-20241229.xsd#jnj_RDRestructuringPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_f48b6a3e-0c47-46f8-a73c-78a77caee60a" xlink:to="loc_jnj_RDRestructuringPlanMember_9d1bcfa9-89bd-4d3f-bcd5-f5d38797e313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsRestructuringPlanMember_f7cf3816-bdd6-4487-8dff-47725b51f7f1" xlink:href="jnj-20241229.xsd#jnj_OrthopaedicsRestructuringPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_f48b6a3e-0c47-46f8-a73c-78a77caee60a" xlink:to="loc_jnj_OrthopaedicsRestructuringPlanMember_f7cf3816-bdd6-4487-8dff-47725b51f7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2f1b9761-d5c4-447a-91c6-713977940d44" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b18a1275-3a48-4e87-93bf-d1ea91482446" xlink:to="loc_srt_RangeAxis_2f1b9761-d5c4-447a-91c6-713977940d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d0971921-edb2-4cdb-8fcc-dc16f91442f1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2f1b9761-d5c4-447a-91c6-713977940d44" xlink:to="loc_srt_RangeMember_d0971921-edb2-4cdb-8fcc-dc16f91442f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1b3ef1c2-a073-4e5f-b125-a0be47d28e95" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d0971921-edb2-4cdb-8fcc-dc16f91442f1" xlink:to="loc_srt_MinimumMember_1b3ef1c2-a073-4e5f-b125-a0be47d28e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c38a9bdb-f4b3-4dbc-813f-4b105b85850c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d0971921-edb2-4cdb-8fcc-dc16f91442f1" xlink:to="loc_srt_MaximumMember_c38a9bdb-f4b3-4dbc-813f-4b105b85850c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3269dffe-3f9f-4f19-b25c-e8ee0e22aedd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b18a1275-3a48-4e87-93bf-d1ea91482446" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3269dffe-3f9f-4f19-b25c-e8ee0e22aedd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_27ef59d8-8d93-4360-9256-74f90762f3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3269dffe-3f9f-4f19-b25c-e8ee0e22aedd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_27ef59d8-8d93-4360-9256-74f90762f3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_2903b596-ff80-4b92-9798-4f1faafbe42f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_27ef59d8-8d93-4360-9256-74f90762f3f6" xlink:to="loc_us-gaap_RestructuringChargesMember_2903b596-ff80-4b92-9798-4f1faafbe42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9109a97e-c9cd-44d5-8f33-a1d10d760b71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b18a1275-3a48-4e87-93bf-d1ea91482446" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9109a97e-c9cd-44d5-8f33-a1d10d760b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4ad4c14f-1495-4472-9ae6-63a18387eca5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9109a97e-c9cd-44d5-8f33-a1d10d760b71" xlink:to="loc_us-gaap_SegmentDomain_4ad4c14f-1495-4472-9ae6-63a18387eca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedTechMember_9a3cfe6d-6513-442b-8f90-ffb667309e1b" xlink:href="jnj-20241229.xsd#jnj_MedTechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4ad4c14f-1495-4472-9ae6-63a18387eca5" xlink:to="loc_jnj_MedTechMember_9a3cfe6d-6513-442b-8f90-ffb667309e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_21602c87-826c-4889-aa84-65a3e5677071" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b18a1275-3a48-4e87-93bf-d1ea91482446" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_21602c87-826c-4889-aa84-65a3e5677071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_fe1b9546-54b7-4bdf-9eb3-f46affe09269" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_21602c87-826c-4889-aa84-65a3e5677071" xlink:to="loc_us-gaap_RestructuringCharges_fe1b9546-54b7-4bdf-9eb3-f46affe09269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_bf2cfe5d-65b6-4ff0-a0e8-8e0a25c6de2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_21602c87-826c-4889-aa84-65a3e5677071" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_bf2cfe5d-65b6-4ff0-a0e8-8e0a25c6de2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_49f80f0b-4bc5-4b9e-9dfc-afe63cf896d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_21602c87-826c-4889-aa84-65a3e5677071" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_49f80f0b-4bc5-4b9e-9dfc-afe63cf896d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#RestructuringScheduleofRestructuringReserveDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6c58b563-3b9e-4c7e-ae28-91e2ddcc5f18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_03889022-f37a-49a4-9241-7b7be60b9ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6c58b563-3b9e-4c7e-ae28-91e2ddcc5f18" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_03889022-f37a-49a4-9241-7b7be60b9ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3f10ce95-cc11-40ec-9686-ebb1233eac44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_03889022-f37a-49a4-9241-7b7be60b9ab7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3f10ce95-cc11-40ec-9686-ebb1233eac44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3e65a21d-b29f-44fb-b175-45cee80099e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3f10ce95-cc11-40ec-9686-ebb1233eac44" xlink:to="loc_us-gaap_SegmentDomain_3e65a21d-b29f-44fb-b175-45cee80099e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InnovativeMedicineMember_ef88620e-cdea-4503-b085-fc98d3886e12" xlink:href="jnj-20241229.xsd#jnj_InnovativeMedicineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3e65a21d-b29f-44fb-b175-45cee80099e9" xlink:to="loc_jnj_InnovativeMedicineMember_ef88620e-cdea-4503-b085-fc98d3886e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedTechMember_41b4a6ef-6972-45f4-833c-d8b0124ec5bb" xlink:href="jnj-20241229.xsd#jnj_MedTechMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3e65a21d-b29f-44fb-b175-45cee80099e9" xlink:to="loc_jnj_MedTechMember_41b4a6ef-6972-45f4-833c-d8b0124ec5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_05227b1e-37a5-4a34-b180-e16c2bc4e1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_03889022-f37a-49a4-9241-7b7be60b9ab7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_05227b1e-37a5-4a34-b180-e16c2bc4e1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_efbcdcb5-98f7-47ec-a8c5-daf26dd11840" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_05227b1e-37a5-4a34-b180-e16c2bc4e1d6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_efbcdcb5-98f7-47ec-a8c5-daf26dd11840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_095534b0-0e75-4343-8661-5a36307f623a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_efbcdcb5-98f7-47ec-a8c5-daf26dd11840" xlink:to="loc_us-gaap_RestructuringChargesMember_095534b0-0e75-4343-8661-5a36307f623a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CostsOfGoodsAndServicesSoldMember_9da0a3a6-b779-4b99-89df-6d25dded9e55" xlink:href="jnj-20241229.xsd#jnj_CostsOfGoodsAndServicesSoldMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_efbcdcb5-98f7-47ec-a8c5-daf26dd11840" xlink:to="loc_jnj_CostsOfGoodsAndServicesSoldMember_9da0a3a6-b779-4b99-89df-6d25dded9e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_a7b628b7-6d79-41f5-8149-f1fc8c0a6926" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_03889022-f37a-49a4-9241-7b7be60b9ab7" xlink:to="loc_srt_ConsolidationItemsAxis_a7b628b7-6d79-41f5-8149-f1fc8c0a6926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_8a99ee63-57b2-409e-9ec7-0e444cbdf8d4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_a7b628b7-6d79-41f5-8149-f1fc8c0a6926" xlink:to="loc_srt_ConsolidationItemsDomain_8a99ee63-57b2-409e-9ec7-0e444cbdf8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_f03abdac-874e-4ef6-83b6-0cf688ae84f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_8a99ee63-57b2-409e-9ec7-0e444cbdf8d4" xlink:to="loc_us-gaap_OperatingSegmentsMember_f03abdac-874e-4ef6-83b6-0cf688ae84f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_01222f17-803d-4810-802d-bd42b0594bac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_03889022-f37a-49a4-9241-7b7be60b9ab7" xlink:to="loc_us-gaap_RestructuringPlanAxis_01222f17-803d-4810-802d-bd42b0594bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_5390b1ce-5a84-4c21-9994-498a8f52b217" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_01222f17-803d-4810-802d-bd42b0594bac" xlink:to="loc_us-gaap_RestructuringPlanDomain_5390b1ce-5a84-4c21-9994-498a8f52b217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RDRestructuringPlanMember_b8fd49e3-12fd-4d52-b907-1ea6f8db9929" xlink:href="jnj-20241229.xsd#jnj_RDRestructuringPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_5390b1ce-5a84-4c21-9994-498a8f52b217" xlink:to="loc_jnj_RDRestructuringPlanMember_b8fd49e3-12fd-4d52-b907-1ea6f8db9929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_200539d9-881e-4e1f-9e4e-e82ba9fc3820" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_03889022-f37a-49a4-9241-7b7be60b9ab7" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_200539d9-881e-4e1f-9e4e-e82ba9fc3820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_075f01f9-8018-4e37-a57a-522a183a8990" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_200539d9-881e-4e1f-9e4e-e82ba9fc3820" xlink:to="loc_us-gaap_RestructuringReserveRollForward_075f01f9-8018-4e37-a57a-522a183a8990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_a32ca1bb-d46d-4831-9bf1-1843fcd2fd43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_075f01f9-8018-4e37-a57a-522a183a8990" xlink:to="loc_us-gaap_RestructuringCharges_a32ca1bb-d46d-4831-9bf1-1843fcd2fd43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#KenvueseparationanddiscontinuedoperationsDetailsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_644959d7-cf84-4826-b81f-d6bb527cf21d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1628b5f3-834c-4c57-b949-03f4b66bfbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_644959d7-cf84-4826-b81f-d6bb527cf21d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1628b5f3-834c-4c57-b949-03f4b66bfbe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_77557dec-2223-4880-9d91-2888ca62ea51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1628b5f3-834c-4c57-b949-03f4b66bfbe2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_77557dec-2223-4880-9d91-2888ca62ea51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5bd9a416-fee5-487e-b215-18c9d9efa664" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_77557dec-2223-4880-9d91-2888ca62ea51" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5bd9a416-fee5-487e-b215-18c9d9efa664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_96d221cf-6443-4e5d-89cc-aee8135a5974" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5bd9a416-fee5-487e-b215-18c9d9efa664" xlink:to="loc_us-gaap_IPOMember_96d221cf-6443-4e5d-89cc-aee8135a5974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_99ee4db4-ed5f-4628-8877-22911775eb8f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1628b5f3-834c-4c57-b949-03f4b66bfbe2" xlink:to="loc_dei_LegalEntityAxis_99ee4db4-ed5f-4628-8877-22911775eb8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_99fe87ba-973e-466e-8a03-3233d4247803" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_99ee4db4-ed5f-4628-8877-22911775eb8f" xlink:to="loc_dei_EntityDomain_99fe87ba-973e-466e-8a03-3233d4247803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KenvueIncMember_e6ed5156-f803-4836-b187-152c243b3421" xlink:href="jnj-20241229.xsd#jnj_KenvueIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_99fe87ba-973e-466e-8a03-3233d4247803" xlink:to="loc_jnj_KenvueIncMember_e6ed5156-f803-4836-b187-152c243b3421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_JohnsonJohnsonMember_3774f8e7-f538-4226-8597-2477ae53b857" xlink:href="jnj-20241229.xsd#jnj_JohnsonJohnsonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_99fe87ba-973e-466e-8a03-3233d4247803" xlink:to="loc_jnj_JohnsonJohnsonMember_3774f8e7-f538-4226-8597-2477ae53b857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_727e5bb5-a5f5-4ae8-b761-34c5798b4737" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1628b5f3-834c-4c57-b949-03f4b66bfbe2" xlink:to="loc_srt_OwnershipAxis_727e5bb5-a5f5-4ae8-b761-34c5798b4737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_d08cdcaf-cdd0-4f7c-9b44-7dac9b2db155" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_727e5bb5-a5f5-4ae8-b761-34c5798b4737" xlink:to="loc_srt_OwnershipDomain_d08cdcaf-cdd0-4f7c-9b44-7dac9b2db155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KenvueIncMember_3d6f2054-cf89-4138-ac2e-7deba549ab90" xlink:href="jnj-20241229.xsd#jnj_KenvueIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_d08cdcaf-cdd0-4f7c-9b44-7dac9b2db155" xlink:to="loc_jnj_KenvueIncMember_3d6f2054-cf89-4138-ac2e-7deba549ab90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_87a8dd33-3d6f-4379-b6e0-c65bcafe3ee0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1628b5f3-834c-4c57-b949-03f4b66bfbe2" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_87a8dd33-3d6f-4379-b6e0-c65bcafe3ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_bd2679c9-a455-42de-b67a-25e8f27aa1d0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_87a8dd33-3d6f-4379-b6e0-c65bcafe3ee0" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_bd2679c9-a455-42de-b67a-25e8f27aa1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KenvueIncMember_340cef10-2132-4410-98bc-64d1eaea1dfe" xlink:href="jnj-20241229.xsd#jnj_KenvueIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_bd2679c9-a455-42de-b67a-25e8f27aa1d0" xlink:to="loc_jnj_KenvueIncMember_340cef10-2132-4410-98bc-64d1eaea1dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f993ef70-9146-4369-9a62-d2c5024e7f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1628b5f3-834c-4c57-b949-03f4b66bfbe2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f993ef70-9146-4369-9a62-d2c5024e7f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a2ee22a2-c7ec-4c17-977c-0c5fb69b2abf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f993ef70-9146-4369-9a62-d2c5024e7f5d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a2ee22a2-c7ec-4c17-977c-0c5fb69b2abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerHealthMember_235551f8-2e15-4765-b4f1-b8d5c4917d1f" xlink:href="jnj-20241229.xsd#jnj_ConsumerHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a2ee22a2-c7ec-4c17-977c-0c5fb69b2abf" xlink:to="loc_jnj_ConsumerHealthMember_235551f8-2e15-4765-b4f1-b8d5c4917d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f386ed1f-94bd-40fd-89b2-a28fc1b759bd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1628b5f3-834c-4c57-b949-03f4b66bfbe2" xlink:to="loc_srt_RangeAxis_f386ed1f-94bd-40fd-89b2-a28fc1b759bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fb4ed207-97ca-4055-929c-e01d7d0f6301" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f386ed1f-94bd-40fd-89b2-a28fc1b759bd" xlink:to="loc_srt_RangeMember_fb4ed207-97ca-4055-929c-e01d7d0f6301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_16101bb3-802f-4e6b-8b4f-586acc33dee6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fb4ed207-97ca-4055-929c-e01d7d0f6301" xlink:to="loc_srt_MinimumMember_16101bb3-802f-4e6b-8b4f-586acc33dee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a06fe3b0-9db7-4166-8a5a-722f216fa748" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fb4ed207-97ca-4055-929c-e01d7d0f6301" xlink:to="loc_srt_MaximumMember_a06fe3b0-9db7-4166-8a5a-722f216fa748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1628b5f3-834c-4c57-b949-03f4b66bfbe2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_f4d1534a-5620-4657-b179-18a822896a68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaper"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_us-gaap_CommercialPaper_f4d1534a-5620-4657-b179-18a822896a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommercialPaper_8225cad2-5be6-4e36-a822-890ae37f1e02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommercialPaper"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommercialPaper_8225cad2-5be6-4e36-a822-890ae37f1e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DebtForEquityExchangeSharesExchanged_4fba3983-bbc6-4749-afd0-a646b911e0d8" xlink:href="jnj-20241229.xsd#jnj_DebtForEquityExchangeSharesExchanged"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_jnj_DebtForEquityExchangeSharesExchanged_4fba3983-bbc6-4749-afd0-a646b911e0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DebtForEquityExchangeLossOnSharesExchanged_ca7f255f-6c38-4611-9528-a6f9b4f45405" xlink:href="jnj-20241229.xsd#jnj_DebtForEquityExchangeLossOnSharesExchanged"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_jnj_DebtForEquityExchangeLossOnSharesExchanged_ca7f255f-6c38-4611-9528-a6f9b4f45405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_33db3c33-4530-4ec9-97c8-0819f1dadc44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_33db3c33-4530-4ec9-97c8-0819f1dadc44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7096b43a-a84a-42db-b3ba-186979faae07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7096b43a-a84a-42db-b3ba-186979faae07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_a5ed7e1a-c71d-43dd-8f43-8d8c4a987dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_a5ed7e1a-c71d-43dd-8f43-8d8c4a987dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_78665b94-ac0a-4e8d-8a2c-79e7679a1a81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_78665b94-ac0a-4e8d-8a2c-79e7679a1a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_2bd86bac-05c2-428c-a091-ec861fa399a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_2bd86bac-05c2-428c-a091-ec861fa399a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_b98639fb-dac7-47ec-a8c4-0792dff0e3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_b98639fb-dac7-47ec-a8c4-0792dff0e3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_1db584c1-de68-44f5-b6bf-67549ff78001" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_us-gaap_CommonStockValueOutstanding_1db584c1-de68-44f5-b6bf-67549ff78001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OwnershipPercentageSplitOffPercent_fc2f1161-c189-4d50-a652-582f663e291d" xlink:href="jnj-20241229.xsd#jnj_OwnershipPercentageSplitOffPercent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_jnj_OwnershipPercentageSplitOffPercent_fc2f1161-c189-4d50-a652-582f663e291d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StockIssuedDuringPeriodSharesExchangeOffer_a6bb05d3-5eec-4475-8036-299ef748008d" xlink:href="jnj-20241229.xsd#jnj_StockIssuedDuringPeriodSharesExchangeOffer"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_jnj_StockIssuedDuringPeriodSharesExchangeOffer_a6bb05d3-5eec-4475-8036-299ef748008d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExchangeOfStockCommonStockValueReceived_ddf4317b-0781-46b9-853d-2c532beaaa53" xlink:href="jnj-20241229.xsd#jnj_ExchangeOfStockCommonStockValueReceived"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_jnj_ExchangeOfStockCommonStockValueReceived_ddf4317b-0781-46b9-853d-2c532beaaa53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExchangeOfStockPercentageOwnershipAfterTransaction_225c668b-415a-41f9-9459-ca6601bab3bd" xlink:href="jnj-20241229.xsd#jnj_ExchangeOfStockPercentageOwnershipAfterTransaction"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_jnj_ExchangeOfStockPercentageOwnershipAfterTransaction_225c668b-415a-41f9-9459-ca6601bab3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_03fa09d9-c70a-457b-93e6-3a91c353828d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_03fa09d9-c70a-457b-93e6-3a91c353828d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_3bd2d166-db83-4365-a358-79d7af62e5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_3bd2d166-db83-4365-a358-79d7af62e5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fc924a2c-419c-4064-aa5d-177b5e9736d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fc924a2c-419c-4064-aa5d-177b5e9736d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_4cb6fd54-6434-45d4-aa4f-40c4306f38c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_4cb6fd54-6434-45d4-aa4f-40c4306f38c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NoncashOrPartNoncashTransactionGainOnExchangeOfStock_453da82f-5d9f-407e-aa03-af816fac154f" xlink:href="jnj-20241229.xsd#jnj_NoncashOrPartNoncashTransactionGainOnExchangeOfStock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_jnj_NoncashOrPartNoncashTransactionGainOnExchangeOfStock_453da82f-5d9f-407e-aa03-af816fac154f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DiscontinuedOperationsTransitionServiceAgreementTerm_6764db4b-b8a3-4c27-8256-fd80075b0d1d" xlink:href="jnj-20241229.xsd#jnj_DiscontinuedOperationsTransitionServiceAgreementTerm"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_jnj_DiscontinuedOperationsTransitionServiceAgreementTerm_6764db4b-b8a3-4c27-8256-fd80075b0d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DiscontinuedOperationTransitionManufacturingAgreementTerm_a9a7e01f-afb7-431d-8eef-693f8a4f4976" xlink:href="jnj-20241229.xsd#jnj_DiscontinuedOperationTransitionManufacturingAgreementTerm"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_jnj_DiscontinuedOperationTransitionManufacturingAgreementTerm_a9a7e01f-afb7-431d-8eef-693f8a4f4976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DiscontinuedOperationsSeparationCostsIncurred_f5cb87f5-5f6f-4f41-a7ae-72d1b95c2877" xlink:href="jnj-20241229.xsd#jnj_DiscontinuedOperationsSeparationCostsIncurred"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_jnj_DiscontinuedOperationsSeparationCostsIncurred_f5cb87f5-5f6f-4f41-a7ae-72d1b95c2877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DiscontinuedOperationIncrementalTaxCost_cccf510a-fe2c-47b4-b9e9-53dfcaf9859c" xlink:href="jnj-20241229.xsd#jnj_DiscontinuedOperationIncrementalTaxCost"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_afb69423-85de-43e9-8adf-b58735611cc3" xlink:to="loc_jnj_DiscontinuedOperationIncrementalTaxCost_cccf510a-fe2c-47b4-b9e9-53dfcaf9859c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c59fc7a2-7c90-4851-a8f6-925a594248c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_e5d15789-0ff5-4ff1-a067-9b1e60d3488e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c59fc7a2-7c90-4851-a8f6-925a594248c7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_e5d15789-0ff5-4ff1-a067-9b1e60d3488e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_064ac84a-4d97-488c-a110-4c4c41113013" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c59fc7a2-7c90-4851-a8f6-925a594248c7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_064ac84a-4d97-488c-a110-4c4c41113013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_1bdc48f3-782c-465f-87a0-54a09f35c268" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c59fc7a2-7c90-4851-a8f6-925a594248c7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_1bdc48f3-782c-465f-87a0-54a09f35c268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_2a8e197f-6fc4-4ac5-b4ec-1bc3e9e1f6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c59fc7a2-7c90-4851-a8f6-925a594248c7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_2a8e197f-6fc4-4ac5-b4ec-1bc3e9e1f6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_a2fbbaa6-d273-4244-8188-8678b171a424" xlink:href="jnj-20241229.xsd#jnj_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c59fc7a2-7c90-4851-a8f6-925a594248c7" xlink:to="loc_jnj_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_a2fbbaa6-d273-4244-8188-8678b171a424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_c4fccf3f-dc60-4159-9249-119035828653" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c59fc7a2-7c90-4851-a8f6-925a594248c7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_c4fccf3f-dc60-4159-9249-119035828653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_35e58ae9-074b-4a4d-9735-7e8e8f0ad6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c59fc7a2-7c90-4851-a8f6-925a594248c7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_35e58ae9-074b-4a4d-9735-7e8e8f0ad6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_7da2bce6-56e7-442d-93d9-934742ec543d" xlink:href="jnj-20241229.xsd#jnj_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c59fc7a2-7c90-4851-a8f6-925a594248c7" xlink:to="loc_jnj_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_7da2bce6-56e7-442d-93d9-934742ec543d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_86e43e45-f008-4248-911f-64c298b6ab39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c59fc7a2-7c90-4851-a8f6-925a594248c7" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_86e43e45-f008-4248-911f-64c298b6ab39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DisposalGroupIncludingDiscontinuedOperationRestructuringExpense_40c1a9a5-2efc-4918-973d-e31f507e3bc1" xlink:href="jnj-20241229.xsd#jnj_DisposalGroupIncludingDiscontinuedOperationRestructuringExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c59fc7a2-7c90-4851-a8f6-925a594248c7" xlink:to="loc_jnj_DisposalGroupIncludingDiscontinuedOperationRestructuringExpense_40c1a9a5-2efc-4918-973d-e31f507e3bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_418a31c6-9d20-4803-9a1d-65bf8b04936e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c59fc7a2-7c90-4851-a8f6-925a594248c7" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_418a31c6-9d20-4803-9a1d-65bf8b04936e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_77c42cbf-3f55-4b6d-aaf8-30587adb7cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c59fc7a2-7c90-4851-a8f6-925a594248c7" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_77c42cbf-3f55-4b6d-aaf8-30587adb7cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_43e0cd85-4e31-44dd-9c98-085694fa1e64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c59fc7a2-7c90-4851-a8f6-925a594248c7" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_43e0cd85-4e31-44dd-9c98-085694fa1e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDepreciationandAmortizationofDiscontinuedOperationDetails" xlink:type="simple" xlink:href="jnj-20241229.xsd#KenvueseparationanddiscontinuedoperationsDepreciationandAmortizationofDiscontinuedOperationDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDepreciationandAmortizationofDiscontinuedOperationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_92d9db56-1192-41eb-9aad-c238c026cfb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_80644c43-1d6d-4e42-ba72-8a6d48856882" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_92d9db56-1192-41eb-9aad-c238c026cfb6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_80644c43-1d6d-4e42-ba72-8a6d48856882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpenditureDiscontinuedOperations_b25eb615-d095-48cf-a0f6-5e9e0547ccc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_92d9db56-1192-41eb-9aad-c238c026cfb6" xlink:to="loc_us-gaap_CapitalExpenditureDiscontinuedOperations_b25eb615-d095-48cf-a0f6-5e9e0547ccc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>jnj-20241229_g1.jpg
<TEXT>
begin 644 jnj-20241229_g1.jpg
M_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B '
MS@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M]M8  0    #3+4A0("
M                     !%C<')T   !4    #-D97-C   !A    &QW='!T
M   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B
M6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3
M (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T96-H   $
M,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT
M     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N
M>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$              !)S
M4D="($E%0S8Q.38V+3(N,0
M                            6%E:(        /-1  $    !%LQ865H@
M                     %A96B        !OH@  ./4   .06%E:(
M &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,         %DE%
M0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W
M+FEE8RYC:
M          !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="
M(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M            9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET
M:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W
M:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M             '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>
M 5A96B       $P)5@!0    5Q_G;65A<P         !
M         H\    "<VEG(     !#4E0@8W5R=@        0     !0 *  \
M%  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ? "!
M (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .  Y0#K /
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M_)C]*?VZ_DO^W/]M____[@ A061O8F4 9$     ! P 0 P(#!@
M     /_; (0  @(" @(" @(" @," @(#! ," @,$!00$! 0$!08%!04%!04&
M!@<'" <'!@D)"@H)"0P,# P,# P,# P,# P,# $# P,%! 4)!@8)#0H)"@T/
M#@X.#@\/# P,# P/#PP,# P,# \,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,_\( $0@ 70,Y P$1  (1 0,1 ?_$ ,    ,  @,! 0$            )
M"@<(! 4& 0(# 0$                     $   !@(" @(" @(# 0     $
M!08'" D  Q X 0(V-R 64#48&4!@H!01  (" 0($ P,'!P8*!P4)  $" P0%
M$08 (1('$#$302((43(4M!6U=F%Q0B,6AG<@@3-UQ;904F*RTK,D=)0U,)&"
M--25%V#ADI8XH;'1<J)3DR4F$@$                   "@_]H # ,! 0(1
M Q$   !_@                                'X/*'J#^P
M                          $;QM84Z@   &O9(,4"#>0
M       %-B#S;PTT'<#JP   !((D L-,X    $L1Y0K(
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M.:<HZPP*>@,V'T ,=&,C/1W '!..=L!UY_,[0
M                                              /_V@ ( 0(  04
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MR,ET[/\ M/\ _]H " $" @8_ !P?_]H " $# @8_ !P?_]H " $! 08_ /\
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M=FY:!(CHO+U'0$$[5[6; H&AMK:E7T*YD(:>S,[&2Q:L. .J6>1F=SH!J=
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MN3P@:C]5/+&9(_,_,8<?3+G8>E#-T='10S.=H1:=1;^AIY&&/75CSZ==-!Y
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)%U!!_P#:K__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>jnj-20241229_g10.jpg
<TEXT>
begin 644 jnj-20241229_g10.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^(,6$E#0U]04D]&24Q%  $!   ,2$QI
M;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#
M('-21T(                  /;6  $     TRU(4" @
M                                               18W!R=    5
M   S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@
M A@    49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD
M9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4
M;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P
M  @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W
M;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y
M-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                     %A96B
M      #S40 !     1;,6%E:(                     !865H@
M;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /
MA   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M     !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                    9&5S8P         N245#(#8Q
M.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M       N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="                             &1E<V,         +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M     "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M
M,BXQ                                  !V:65W       3I/X %%\N
M !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M         0                        */     G-I9R      0U)4(&-U
M<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\
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M[D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?
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M^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X $T%D;V)E &0
M     04  DE$_]L A  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0$! 0$"
M @$" @," @(" P,# P,# P,# P,# P,# P,# P,# P,$! 0$! 0$! 0$! 0$
M! 0$! 0$! 3_P  1" #H .@# 1$  A$! Q$!_\0!H@    8" P$
M    !P@&!00) PH" 0 + 0  !@,! 0$            &!00#!P(( 0D "@L0
M  (! P0! P," P,# @8)=0$" P01!1(&(0<3(@ (,11!,B,5"5%"%F$D,Q=2
M<8$88I$E0Z&Q\"8T<@H9P=$U)^%3-H+QDJ)$5'-%1C='8RA55E<:LL+2XO)D
M@W23A&6CL\/3XRDX9O-U*CDZ2$E*6%E:9VAI:G9W>'EZA8:'B(F*E)66EYB9
MFJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8V=KDY>;GZ.GJ]/7V]_CY^A$
M @$# @0$ P4$! 0&!@5M 0(#$00A$@4Q!@ B$T%1!S)A%'$(0H$CD152H6(6
M,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V160G"G.#DT9TPM+B\E5E=58W
MA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=79CAVAI:FML;6YO9G=X>7I[?'
MU^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H
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MO7)8/,_8T\V2A=:J#9&8R=,=45#@%6.IKJ=6)>L9$?1)3>P#S3OA24;;;MW
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M 42222223<D\DD_4D_U]O=,]=>_=>Z][]U[KWOW7NO>_=>ZIF_GF_*";X_\
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M2?J2?R3[?Z8ZZ]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7S@_YO?=LG;/S6^5>^'
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MCJ8'CE57@D0.5]0X'(O[KX\9611\2G(^=>BY]NGM[I!*HTD&E//&#7SZ&/\
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MJ2AP/6^Y-TFG=?M(::KS%)*:4S-I4TLU;4TB,3IU!6OI]9N#41YKF., U)
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M6XVY@;:1=0ID?[%>COY'/"MPXIT8%+D",.MM)!!\:K?T:QR3^![$<]T'L_#
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MC(G->U%U!#%R:^5$8@CSK4=![W$\5.1]V1&IJ6,&GF#(HH?DW ]:MDF1R;=
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M/G]YNWOA%2[D^1G1@6HR.6ZP6&+*]Z]>4#?Y^GI,1004[]M;=IWD(CDQ5/\
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MQ>Z?R1CDJ][=QXVKH]W5^-)IWDEVEU%Y*/>61GJ*:I6:GDRG\$QE5$&\=82
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MT*/V7L:LVYO6NH\>I#0TE56U%$K 7A87!?BN9X?[*4@>GE^SAUNO6N#\@O\
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0[KWOW7NO>_=>Z][]U[K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>jnj-20241229_g11.jpg
<TEXT>
begin 644 jnj-20241229_g11.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !]     $  0'T     0 !_^(,6$E#0U]04D]&24Q%  $!   ,2$QI
M;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#
M('-21T(                  /;6  $     TRU(4" @
M                                               18W!R=    5
M   S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@
M A@    49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD
M9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4
M;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P
M  @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W
M;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y
M-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                     %A96B
M      #S40 !     1;,6%E:(                     !865H@
M;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /
MA   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M     !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                    9&5S8P         N245#(#8Q
M.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M       N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="                             &1E<V,         +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M     "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M
M,BXQ                                  !V:65W       3I/X %%\N
M !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M         0                        */     G-I9R      0U)4(&-U
M<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\
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M[D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?
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M^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X $T%D;V)E &0
M     04  DE$_]L A  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0$! 0$"
M @$" @," @(" P,# P,# P,# P,# P,# P,# P,# P,$! 0$! 0$! 0$! 0$
M! 0$! 0$! 3_P  1" &# 8,# 1$  A$! Q$!_\0!H@    8" P$
M    !P@&!00) PH" 0 + 0  !@,! 0$            &!00#!P(( 0D "@L0
M  (! P0! P," P,# @8)=0$" P01!1(&(0<3(@ (,11!,B,5"5%"%F$D,Q=2
M<8$88I$E0Z&Q\"8T<@H9P=$U)^%3-H+QDJ)$5'-%1C='8RA55E<:LL+2XO)D
M@W23A&6CL\/3XRDX9O-U*CDZ2$E*6%E:9VAI:G9W>'EZA8:'B(F*E)66EYB9
MFJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8V=KDY>;GZ.GJ]/7V]_CY^A$
M @$# @0$ P4$! 0&!@5M 0(#$00A$@4Q!@ B$T%1!S)A%'$(0H$CD152H6(6
M,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V160G"G.#DT9TPM+B\E5E=58W
MA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=79CAVAI:FML;6YO9G=X>7I[?'
MU^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H
M# ,!  (1 Q$ /P#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4&KR>/H
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MH*Y^TNU<=0U:/&4,<U12[LI<71+%"8M++3Z:AV93I N"'[BW6P+R1W1FJ*_
M74\* $$TZ-(BM\RP3V_@C@H!TD>I-:5KU?'TA\C,CVW&M4/C_B6KHXYQ13;)
M[)V7F:LT.AFF6*IHZ^&/,T23O<Q("=3!'C!(!8M]^N/'6&;9)6 J%9-*M2GH
M34BO#IR\V.)(I!'O4?D&60-QQ0 ^1_U<.K".K>T<UMDP4F/DW#A*01>:JP&Y
M4CRL%-KE]9AJX&D:EIJ>20A]($<>KDJ.!(.Q<V2P,L"R2! *M'/5J#Y'C_DZ
M V]<M0R*TDJ*9N ,- 3Z$@8/^&GSZ.WM7M3$Y\T]-5Q28^KG!$,CE9*"LTDZ
MGI:Z,FG(6W*D@J>";\>Y-V_?[.^TJ"5<\-7!O]*>!ZCR^V6ZL@SX:(9)'$?:
M.(Z%4$$ @@@@$$&X(/(((X((]GO1-UW[]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NNP2"""00;@C@@CZ$'^OOW7NA'VYO,Q^.AS$A9.$AKVN63
M^BU1^K)^-?U']J_)#;)YCJZO3!X=">"& 92"" 00;@@\@@C@@CVWT[UW[]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z0VY]UIC@]#CG62O/IEE #)1BW(Y!5Z@WX'(7\\\>
M[JM<GAU1FI@<>@B=WD=I)&9W=B[NY+,[,;LS,;EF8GD^W>FNN/OW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z)/\C_EUB^L-OU5)UU!C=Y;JG-=
M1OD5R]!3[?VF]&ZPUM?E*B;RK6U%"&U)!&K1EP/*RKPP-YFYM@V.U9K6'ZBZ
M)*A4*T4CB6)/EZ="GE_EMMVN0EW.((  Q+!B6!X 4'GUJ[]^[\J=Z5NY<O1U
M,>Y-]U\TE7F^SMVQOD)LOG+)38ZC3%+#%3^01!(86BCB9XXB1' @56QXW#=)
M=UD:YOG>24MJ+D]U?):#"@#%33J=[#;/W=&(K4QQ1A $! (K_%G)(SCR/0";
M'Z2W+O'(U>6J,I6[FS^6K*/'5NY<M-4SSKA<1!3U64Q6)Q\E.(<33-DZF)):
M*E6\D<&@2*-3^T$DSF"O:JZOMH!_,_+Y]&R+"QD+2:Y3IK(V->,KGX03QIT?
MW9'3^W>N\#_?K);>BJ-LT, J4W!D)/M\34*)I8Y8:;)T5/5X6DG\R%6B:LJ)
MDDYDGL#[)I9U1OJ1 SP-2C9[OD!Z_+HP,!G001+6<5"Z1A#\OZ(]>@5[7^9W
M0%'!/@\56_P3*U5%(LL='+NF&11.8XH<K V)S='65F$I?%YH/L))ZHRG5$E3
MK$/M3!<;G>T:VVW1:U(9JCUH!G*T\^K_ $=K9 F^N0]X*:DK0T(RX/ U]1C\
M^M>#NU<]O7LW(;7SL\N_4K:4U.,S^5R462G&-:U77Y^CSLPEFJZ6MDB:2I9I
MJAFF*J(UD=XEE#8&*67B_P!G+&VEA4BM*^5?MI@= ;=(7FN7L702(*%"^=*G
M)T,,@$\<G.//H*L%C]L;&@R&WLCA:D4-8T6/R]?5;CAH!EUQE<:FGAGBR2I,
M<'2U2>5*705EF5'D *QJ#2>>]O"'63(.  1@CY?B'1:L,=G&4$.F&M#(S $Y
MKIH?PU_GT:_K"7H;?4N+QF.VW!/DJ!G:.CHYZC$9ZHD#_P"4YR6DQE7'6Q5/
MK"M4TEX88T36A)N0KN*[G;%GF=Q$:?->'#A0?F>/2^WDM+TA;7LE PO EOXA
M3NK\QY=68]7]+P5+TM;24%')B4:CBCJ]W0P;OVC5:5$'AS61GB6LQ\,,S+&^
M1%9!%#(X6?0S)K#IL[RZ1RDM)&!*4P#Z5'"@\^CB*]CCCTS(1&N'J-3$CC0_
M,\/EU;)LCX<[ W3@J:M@Q>Z^D]Y0S4S46[.M-[[ABVDM<)EEIZR*IQ=:<7B,
MG%51K)&N0QXEFIF\8J&4ZO9E:V4DT,<<LSPW*_Z(!J3TH'K49\CY<.D4V[B(
M^*B036H_T(L-=?5E(XTXT./Y=#?AMC?)[J&0TV6S=3WAMJC>(R5?W$6)W[CE
MC.J&FKH9%5JJ5U?4DHDJZ>LN '5N 77-CS'M4XE60W5H3P0T=3^>6'[?2O2Q
M-RY<W6,QO#]+=+Q+"J$'T;U^WHW?67:N(RU+5T(DR'BCD$>3H,SB9</DJ&O8
M'[Z@S6'>1),7G,:X"RU*)'%4:6DC\P*DB_8^8C+1'<D YQH8'T*FE"/6F?GT
M'=XY>$"--"HC'%:D/K!ID'.*9SY=&GP&^LQL[Q3R3U.=VC-)KDH?$TV1P$,V
MI_N:2J*JV1Q_EN/'PR7_ -2#ID_:^8)+55%P[269X&E63[?-A_@ZC;<]B2>K
MQ*J77 T.&/EC@N/.N>C)87-XS<&/@RF(JX:RCJ4#QR1."5N+Z)4OKAF3Z,C@
M,I%B/8[@GBN8EFA<-&<@CH%2Q202-%*A#@T(/3K[>Z;Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NEKMG=4F+*T5<SRXX\(UBTE(Q-[H/U/"
M2>5_'U7\@T9:Y''JZM3!X=#!')'-&DL3K)%(H>.1"&1T875E8<$$>VNG>N?O
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7ND-NO<XQR/CJ%[U\B@2RK:U&C '@\WJ'4\#^R#?ZV]W5:Y/#JC
M-3 X]!"26)9B22222;DD\DDGDDGV[TUUU[]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KB[I&K/(RHB*SN[D*B(@NS.[6554<DD_3W[AU[JJ7Y-?,&HS,
M-5A^I=S28O:NW\O/3;GW72>"*'/G'-5TV5Q\.3G!:BV]CI8':KG@*R@Q*K$Q
MN8VC[F3FR.VB=;&Y 1&I(X%>'$#Y?,=#K8N6'EEB:^MR6<51":4]"?GZ ]:^
M':_R;W'W1E9=E]621TFS*/*9"/(;LFADCBK6IT$CTFW:6E@F3)U-=+*7C^X9
M8("@=@S"1HH4O+V;<926&F(L6CKQ->'V#J6[:Q@M5#TJX4([?TEXZ0>)_P!0
MZ8=L=9SYG-_W?Q'DKY*NIH:2,32RR42T%;%Y&KZ^H=ZNHURRAW;0RSU$H221
M@2(_9(Q822(&'BC)QBAX_P"QT>HC*DDP92CCL!R0/L_"U./#Y]"5\K>^^J_@
MOU]BJO/[>HMW;KRV/E&P.NZHU2XJNP4#)!/O7LBGQ,D>9786.S<R)18F#3D=
MTY2>3RO!14U3.AA8;)<;Q-HC5:J,(:!7'D#6@ '')\OL!I/?P6T(#'57(/F@
M_%@5+,3@ 9H?M(URNZ?G)V'\K-R2U_:L^1W;AXJ@P8W#5\51BMN8.@TPQ/!B
ML)@<CX=N4,2,(Z>*F#PT],J!02"?8QM^5Y-J<W"71-SDUK6G&@56&D4'&E,]
M!T[U'=L\"6=(Z@&H %,:B6!J>[[<=1#U?D)ACUQZYS^'-NR/%G$YF7(Y!]L4
M6,J:**E;;V<::6LH:99*2LH:RFEG\9CBCJ$%N%;-VOZDDHC$NCXT"J')K74M
M-)(XUIQJ/L6M8RT5(G[%E&I6!(0!@HT'+<0RLIJ*4:@Z.'UWT;2Y/:*;XWM4
M_:XW;-?O+(P555-'(Z;-R[_Q$4#+%*M10S&M'DD>56ABI'5A:5M!+TG5Y'2!
MCWJJG(IJ X_;QX>O1NNWO+J\;L"$R1EB*^%6I&/GPKT1/LU,3G,GEJB?)9>@
MHADZBKIZ7+R.LDE+D9:AH*:DHX*.%8*!!3J$C*HPL6NU^3ZWN9853PEU&E#\
MR,$_;T';^"(R2:Y"JZJA9%-2#D4 &.F+;&P#N-(VP6Z]O5FB:EEBVMDY:_%2
M9*>+TQ3X?.S4R"AR-.>!4>:EC#'T\W'M)<[R;8LMS:/&3CQ!1@*_Q**BA'D<
M]:M]K%VM8+F J*'PG5L^A#<0?,&O5L/PB^67971_8>+V;V!39C,8\5-'*=K[
MGR+8?>.$IYG6EJLKM;>Z09"AS6/=5C9QDS4Q5D:%3+3V!8-W<D$##=K)PP [
MC'55)&<@X4_( ?8>C9$O)!]'<,QD-!IG%745 JI%"X]*UH,=;?'1>Y-N[WP4
M.[NO\I@THJMX9,O0X?!P8*CR<$J* V3VU33R+A\_4!PU0M+"V/J)#Y$#,RL!
M#M=TE] ES$Z!VRX  K7^C_%ZT^WH);G9O8W4L<T;5'"O"GJ3Z=&Q."HJU7C2
M*!ZRG*H*'RJE&\,T0,[4" &LQE>@-Y*=KK.5!]!!'LY-H'!9%HZ\$KZ^:^8(
MXD>?1.;C4KI+)521WD8 \@WEGAC\^@[WSTA@^SA]W49/(8'=%#1+'C-Z8-?M
ML_0M2P-!21UT9>'[^E 01RT[+IECN%T$^RB^Y<MMW<S&1X[U%HLL?::C )'G
MGC7''HTL^8+C:HA;B)9+-VJT<G=5?Q -]G#SZ ;8/=.=Z=W/2]-_(.DDH9JJ
MO7&[#[%IZ:HGP>YDK&$])"N41?L BV8"&H>"L@C0HRRJ5D]EFT\P76TW";1S
M"NFXU:(9J$*_I5OA%?V]&6Z[+;;A;'=-C=7LJ#Q(P1J0UX4XG_/^SHZE/19+
M:V0FW=LN1*JGJX:9LWMTRS)BJZ*HD/\ N;I%B/BCKXM(42@+'*OIDM(+F5;"
M^DMI1/;MJ@8 /'FE:_&OE4#^7SZC:_L8IX9XIP1*C562@KPPI]!_E^71@-L[
MGQ>YJ$5..JXYWC/BJHM+Q3T\ZW5XIZ>54FA<,IX*@$<CCV/;6[@NXEDAD#*?
M3_5CH%W-M-:R&.:,J?*O2D]J>D_7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]TLMK;F;$RBCK'9L;*W!Y8TDC'_.(.286/ZU'_!AS<&CK7(X]
M75J8/#H9%97571E='4,C*0RLK"ZLI'!4@W!]M=.]<O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TE=T;B7#4XA@*MD:A3
MX5-B((S<&HD4@@V(L@/ZC_@#[LJU^SJC-3AQZ!-W>1VDD9G=V+N[DLSLQNS,
MQN69B>3[>Z:ZX^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZZ9E4$L0H
M"EB2; *OZB2> !?W[KW5-ORJ^867[ K<UUGU9ELMMO8-$^8PV[]W86>*FW7O
M.:CJ(*2LP6V"9(*_;>(D:*H@EK[K-+$WD30@4R1SS-S(_?9V4A6 $K(ZGN8_
MPKYJ.-3^SH?;%RZJ".ZO0&N#I=(B*@*:]Y\CY4'[>J)^^-X9G?V:AZKVO%%@
M=EX#"T-/GTIJ>:EP+_<N\F+PZT-*T4E5@*."EDJGIPRR92J"?<E( P$,;A='
M<)Y8@^B-<$8IG(  \AZ]2I;6WT4:27"AB<Y-3_IC_2]/+TZ3&P=G5>6R&/V)
MM6GA@J<W'3XV@J<H(I)H9*9DUU.2BBC6FI<=7GR!]"K%K5 %TJJ*@4*I\-%I
MKPM37[*GRKT9=I5V)J M0:_+C\B>K.NN>N=K=;X;+UF0A3'XS!X"?/;DJ9M!
MJ\3AJ:DEGI<<U7-)&XRM531M4R696URA5;60/;;*(C(9EI3XCP/R7[3U>%?&
M:*VMVU,U2",@^9)(\A3C^WK5 ^5&Y^Q_G+\G-YY^KF.-VO1YA&VM3>*>C@PF
M%Q6)2GVOCZ)W1*@XS$4%7.BWDLU35SO_ &A[&VV;A:[9MQ=F5)I 2P)K1:G%
M*U\AY8Z8_<USN^X"UB!2&/)?A0@>1^=:<<UZ,CT#\ ML9,4M1N6:M_B--6T1
MQU% BU;97'5>0J8882[:JK+/1Y1)J25@)!$)E5WTKJ!%><PR2LZJ]5I4@8+5
M'X1Z-C@/V="F'E""-*2U$F<D8"_,GS7RKT>W:'Q_3!P_PG%8#$U4>=W%C/XA
M7Y>FJ/XICIL;3;DWIF,K0T50IJJR9*G"?:U+D:?(QB8ZE8D/7UU*ZS0"X72)
M2BOQTBF%[<4_GT)(-KCM[B8A 8W4,S<0VJF01P-:=/B=.M6=;G;&W,=]KE\U
MDJ?%R0U--4U8J_LJ'-YW+9BIJ92M(RI49VB2*#0S2$AD_384:X@-O D@/CB4
M*ISWE1GAP X#UZM/MK*9%H-2I1F/F&X"GG0FOVCJOSO7X;Y#&5,<.9J6S%/C
MJ>(;@R$JR25>4S!@I3-^WXDJ:NHD$<$=455?%?2ET+>Q#!NZVKRHDOZF#3)I
M7-*\!3_B\]%5URX9T4"4F)5'B%A5F^WS->'RZ+%'U'DMDUTM3FNI<.F =UF%
M35[ASV$S+@6>.'&0+6+A((EU:1Y(TL]E9HQ8>ZW.X+N"46_/C_A#!0GIW$9)
MKTE&Q3PR>(-H_P 6Q4ZBIQZ>0 '#YXZL+Z6ZSVAV#MVDBJ4K=S;9IZ^.'3F$
M8;UZ]R<DD-ZW;F:<U.6QHHW=9!'YZFCE /$8O[ 5S=7%O<O!)%1V.EO#.H$8
M\N'\J^N>C*:"-8T6/X0:IXE-2?(,<C.?M^75V7QNPO8G161.U9R,U3B-C255
M(M;C*#=-.(UDILK''1A8,!NU:>-EGGCC-/F(A:5&FA-[6=WNFQW;R6T8: G4
MT1)SBNI6_"].'DW UZ)=UM]NW6V2.Y;3(3I63BV/)_56/[/+JXC9N\L1O;$4
MV3J&:CRC(B34>0EIX3.QYIDJQ ]I:NEG0&*=K1L.%=2WB,O[-OEKO%I'<!BE
MP3\#D!OM^T=19NFTW&UW4L7:]LHJ605 KQ&<$'H:,<\C03RUB"6.DD$\E12
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M%W<1ZFH#$AI2AJ-9K@T\AYGJGGM+>,&SJ"CZ^Q%;%-N6J@AR.Y,C1PM).ZU
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M:[W['I]J8[=6]1+#)A]ITL6TMNI(UJJMR7B;^-9X1-JC,,E4@):[%E@8"_E
M]L7FXO;VUYN$9!BC @C!R6)&6'R)\^C7:-F-[);6)0+<%_%:2N*#@I\J_+CU
M5OAJQ]S;EKL_6M+7Y')9.26H6:1Y31RPSQQPE!,6DJXX::F5E6X\K\FVH^XW
M"SW#QM*E68@R U\_.OF<]9%6T*V5K#;@@!5%/4G%01Y =''V?AFJ*J>JJ96:
MG,4C&B/-8 U4@-4[Z6@@)J!XPQ)&H6 ^GL_@L'AD.NI4F@'G3U/^3I+<W/Z9
M52-?J/\ !\\=&YV/BDJJE3 :CPQ0P20P21 4\9\LOWR&?4I>H0'Z,+ZSI((-
M_8DLXPK!B2$KE3PI7/YTZ#]U+5-+BC^O^#H?\#CZ UPDHRD=) ZFA#Z$+-=W
M8HJV4S4_();@:K W'L\@2)IBT8_2!J@QP_S]$LLK(55N!.2>A"I8DEDF)8^,
MR!SZE)8Z@0+*^H@2H;'DM;V8HL;^+J;LKJP?]7GTDF!)H!D\.EEC=<K/(JEG
M&A669!&@B0A'4:@9!(P6]K<_6_M=;!I'UOD5Q44QP_F.B^91H89T\.G]*>$R
M2:WC-$=.F,_H+: Q5>0""P /^M[4N8R6ROA^GD.D60PI6OKU%R^UZ'-4CXVK
M$9$KET\;QI+XEA7R^IK,D,0MI-S<G@\>T-]90WD+6\PPQJH&#Z&ORZ6PWLL#
M"1<@<:_Y.@-R>R\EUODYLQCJ6KJ,-**"GS4<4<<]2<=%(9HJZ?3*TC5.'D)E
M07MIN-=POL/&RFV>99[<'Z=0%8<:*#6O^U_8.EEW]+OUD]M<.IN:$HIJ/M6O
MGJ].CL;/K4R^,CI1]O5T>2IHLC1NDQ$5>I@5ZQ:=^%\U5$PFAM8%E(')%Q]9
MLDT>A3VN-:FHS49(^?F/GU NZ6TME=R53X/TR&QIS2A'F/\  .L&X]K_ '\$
MF-R#S5D5J>:"I2I>AK9&I'5L9FL=E(6'V.5HY%\0*V:.6X8:'(/IK;Q$,4I)
MID,#0XX,#Y,!_/IF.?1(6BC4,1H/H0>*G^C7IGQF3R2-/C\R\D=;0F.2BR4X
MC89N@EIXY:&ND,"Q1F13KAJXK'QS)J!*N+-1S,'99^V5?,\&]#C^?SZK<01$
M!HE.AL:0<H1Q&>/"HIY=2(=V0&IGI[>.M92:RF8OIK% ""II$!O)4PI;RVY,
M9!L2OMZ#<%9S$PTSC)6O$>5/4^9Z3O8RQJ)58-$W:#\_G7A\N@V[6VCANV-I
M[@Z_W$R-CLYC3]G53Z?+CLO"@JL161ZPIDB@J8@#^I3:P')!9W:SCWBQFM)>
M[4N#_"PRI^>1TJVF[DVG<$N(J KVTK\2'XA4_:?SX=%2^+?:>X,KB]T?'/L'
M'BD[>Z+2GBT?=_=8G>&R3D\ECL#G\5620P2 5-)3G]F34:1'BU%E<:2#9-SD
MNHY-GO8Z;C:H.UB"&2I (I]GGY4Z$/,&VQVS)NUF%:RNS4,G^AOC&>!Z'G[R
M"0U< E8!W2&+6#]S2QB;6<56*[Z!44DQ$E-,1:0$*"#?V96UXUM*QUD"M1ZB
MGD?V8Z#\]LLT;H4&  WI]H]:^?SZ,_U1ON+*T<.W\K6,<W )A3)-$8WJ:6G-
MBY;U 3VY*DWX-N![F#8MWBW&W0:_U@,CY>O49[QMLEG,SB(B$F@/S].AJ]G_
M $2]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2EVOFCA\BIE
M8BCJM,-4/P@O^W4?Z\+,;_[23[JRU'SZLK4/RZ'($$ @@@BX(Y!!^A!_(/MG
MI[KOW[KW7O?NO=>]^Z]U[W[KW7O?NO=0LC718VBJ*V?_ #=/&7M>Q=R0L<:_
M[5)(0H_U_>P*FG6B:"IZ+Y5U4U;4SU=0VJ:HD:5SS8%CPJ@DV1!PH_  'M\"
M@ITQQR>H_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NDSO#=V"V+MW([
MGW'70T&+QT:F22614,T\KK%2TD 8CR5-5.ZHBCZD_P! 3[9GGCMHGFF8!%XD
M].P0R7$JQ1*2Y\AUKB]\=\9SOKL;([MR-H-K89),1AZ&F1TBEA$BU%(KZY"L
MM1'(S5#$@!84C1_4SL<?>9.8I-XNI)CBT1O#51Z<:X\Z]31L>RV^W60@J6F?
M2[\ :Y[1\NBT[KW(<D*C Q%Y8#24@A0:P(J)A:H-2HU!70\I'?F1U#6]2>P@
M9?$JK4/FM*X'GCH3M (2!H*%A@U_;\CU/P&(J)A!!"9:**&D\E94 ZYOM97C
M?&4T,LCW$LPC)50 &E!U\1V9QY@@\-/+TZHT+2RZBQT8H>ESC<2VY*TTU-#)
M145)3)Y)?,'ACT500Q5$L95!=G$"KJ(:S:;:S[1O6=P.'1E&5BC+#(ID'T'^
M?HU^8CDVULBAQF+0TU;E*>.BHYA#%'4)0&5%S.941+Z*AD !TDA%;ZDGA?>A
MXK2.WC)UL-)(XTKW,/\ 53I'92K+=/<R?V(.%;AC@I^5<=56?)KMQ]R;IQ/6
MN+R$"X3912EK$I ? :BFE>M9)=!_<:KBBBA !8QP0ES=I#8);G.7;Z.-:PPK
MV^A'SIYCRZEWEO;1!2\GS<3$.R>2TX"G'/SZ3NT99IJJF/W$9:8HLM0X1"DO
MG66>K,*+=&TM(220%?20+$CVEA0=K>&/]7^;H=&8NSM4$GT_GT?+9_GI:6.:
MGFIW!C*FF "3I(TD<S,Q#AI5F$1D5;773_M0]G8%%25&U,:8_P!7RZ0LX9F5
ME IP;S^S/1P=A*)H::19321($>HADEIS),[LLK31-"NB191$&NH-[V)!X]F=
MJ/$T%E[?,'HHNZD''$TQY4_/H<:*E%[&)5EC=YU,2.L$0=[(L<!)?2B/=[W!
M() ]G$:**!> SCRZ);D%U)\P0!\\9Z6=+"?#I58?-3M3@N#96C02>(R,.)ET
MN;6^I'^%RJI@!:"A%:>?V],%AK;4<4Q7_)TM<?.GBD"AB"H9W-U 8*%=D%M.
MI0?J0./Z^S-6UI1#D#-?\G17*'UDEAH]/]7SZ=:.L6I$D/VHC2&5?W20UU50
M&L#:]U(M_0^W(W5ZJ(L+QK_DZK*FFH!Q3'2OI*2"K(64:BLD.IP"NF,$?MF4
M#2(WM?GZV]J?!232Q^('B./V?9T6R.T0DHU$(S7@>GBLQ]#D<94THEC4G04,
MC*N@D*P743^V&TE;']7(/U]WG@CFA9&/E3_B^DZ7,D,JR(.VM?\ !GI(]?J*
M*KKMEQ+IK2U1F-LH+P"3Q>2KEPU$FKT/YF<Q+?5=PJV''M+MJM5[%!2=5,D0
M'F!4Z1_F_9T3\W6R,L6[T!@9?"E] QH-53Q/#[.AABK8\YB3/3?OO3H/OZ=E
M0?95$AUO41Q(S.L4Z:5=U-F-F!NI/LY603PJZ+W@58#\)^8XTZCV6 V[L)"
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M#(8Y99Z*)BS,MC+$+GD G>R<R/ME['.H+1+V,A/$5X_[7_!TGW?9A>V;6TE
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MJ4&I)5UCD:AE*FIA#)Z?N(KZXRI-W4WM[0;A$)H&!HQ&:_+Y?,=/6;%6)!*
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M.36U^1J-6H^,1X^*>>+'P")])A^WQJHMKZ]=V8EF8FVZH$,4,)H% 4GUP/\
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M4H17&?7J&>=MTY'FA:ZV+=X9MS4#QK:U*2J5J/U&=&*K5N 'R!S4"T/9W8&
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MAU>&6=+=ED8BO!@"0#^8Z,.7>=6W9+BULMDNO$D:L*3CZ<*:#4P\0U= "":
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M>D@@@S,FXL3/E,)24%:ZUE7C5D2D7(9]9)5-(&$[6U#3(= +RFTU1>+=E"Q
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M>-EN0?::'?[*S!6=##+&:,K5/VFBUH <>8'6I-FNIB7299$<U1E SZ CU/\
M/K#DNZME;R@CJ84P^XH:D/+%4XW/4M!K$9;7*E#+00Y&1T)(8!2P)]5^1[M-
MN5G>'66253P*N%_9BIITC2RFBPP>,U\U+5->! IIZ!'>\N%S4LLU!MC)9D/
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MB=O#E);2 Q RQ^0\U]/SZ5^U]J5$<M-3U E7+334U?5QR1"4QPS4-0*&G&H
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MF'Q-'4O$/"]=1T BG@/C3PD/2O+5E/&K+J8$<_@#V(;&ZF0NHCC5R *G\?\
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M.=-00>I,VZ^,;5U@$ %6\LXZ/UL_*Q92BIE#R)4B*&*G#!7TO(R>(^F]A$P
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M,D9@(D>:)54""G=8T4QB_D4\"YN#F*:K^$5^$5:GI\OLZ#]Y#HHX:H-:?/\
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MV-=)1RY*"HHZ6#(TN'=9U2#*;<K1'D:1(])DIJJI"N_B11D#>P?3/)<D+X;
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M$J*S +C*'&PU^"WYM^.HC$]/73PRTDK".2G%KL:VGMM=2)_C\J!S@A&.FGY
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M",1%6D9=>FWC.HDD_A6YO3':V<"*A7BV551BI/&HI^9Z+;QX+57FN)JR5II
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MRLP%<*M\^T>4771TN-_8ACJ$D!EJ'==.D1L2HCF6&SG,;HLS47X225/'NK0
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M#^:6]$IMQPBDD?%['^2&=J:FNWMB5E$II</2=EX^";<E'/.4B-:,M&/#!2Q
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M2AHYIJO#=>X/$JF3D$HH\=M_<>X:FDQ.:IP\"SP883+)2Y.665_!!+'(P"Q
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M7&9C?VS>R-M5V?S2;3K5VCMC.4F&VULFMQPBBJ\S5TU7N84V5QV2SV BHZK
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M/C*T2'M2W.PP71OH]=_<S/"UA,REH*:@):Q,Z90M&59DR6(4BC&*OJ#S;O\
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M2O#I,S!FE<@MX9!( !!4XIYD&OG@] 9A\;2YW,)B:BER+U<&IX\/-4C&9_\
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M(/V7\%W#F\A_"\1!A]Q;;CEEFF@J(JBKEA3[D,QY]!<0Z6BC?N90NB)02:<
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M;'4-)E\[BO+:94CIYH6D51Z60FFZH&O9?TVC3"K$XTE0%!(.*5J:_GU:W4K
M-3AG_$WE7CBOR/21Q]/E=B4NWL_E\329G9N\,;NBJV8^3B6OQO@QTU=M3+S-
M0QU'\6I,CBLTLB(D\B3Q5<2N@,:W*:.1K>DC]T#:C&PS2G'YX/KTXA$7AR
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M(DU:R(S-:G2ZE;1VM-<D12L4Y0*TK/Q&D&HT#&JI!SC..O2*KN7E[@"&CXT
M(XX\S_JIU$W'VP^19J[;E/MC:F;RL-%69R7K_&5N*Q6,JJS"UV%W#BL96Y6J
MK,[N')[LQ=2ASU;+5"FJJEE2&FA6FCE]II+XS(XB")*]#((UTI7S"U)))\ZG
M[ .G5A9)=3R,RTT@'@ >..''S_GT"JUL.,K9Y%I(FJJ=J>%H74U5*DT$R_Y/
M5%-?WL<TD'Z-1#HJW)^OLM658G?5'Y #I5J* Z*5X?E\_7H0((ZK^Z$.0>MK
M\= <M48C'T.&I,?_ !'*8?'4,&;W!3562EK15T-#BQF;I"U/+#-.0S2W3T+>
M\6S/XS!:T 2@)%,AO*@)ZH#'KC5E)4URU,&E>WTX^?0]]0=N=T_&FEW!W'T!
MV/G.K]WT$FRZ'+Y?95:U/29K9N>.0$>*WA6YW^);<W=5RUM-3SSXF3%5>.!G
MGE29'N"4;KM%CN=@Z;C9I/!J4$$952.*N<@^1 /F>CS:=[W;86N)-IOGM;AP
MC2.A.EPN0'0U# &AX>75XW6_\\GJKM[8:=&?S"OBU7[L_BE/-@,WVCT_5;>R
M>W\HE324U!2[DQW6V=KZ"+$YRCH*MS6/B,]+_EFJ2EHUC<0K#^]>TB3W,T^S
M7YCE\35%'<+A6Q0I,"=)'D#45H#4=3;L'OC) T'[VVRDS*%EN+5@R2 @AB\3
M4(!!JVDD\=.FH'0[_'GY_=0?&W>4W2V#[9V7\A_COGL)#MSKON7.1;^Q>[NH
M]NS;XQN]JOJSNK8&?,$:_P!P,'/NR@PF5H<324=(^::>HJ:VF\4./"&Z<L;N
ML#V7,&TBVN_THFW!EDG66)6<: >Z.OZ@#4H\0:22.M%!$5IO6P"ZDYFY#WA9
M+769I]B4Q6[1R%=)E!.ERL:K6,C4* *PK7JY?='56RM^X'%;RVCF:K(;/R.2
MW'0]<[SK]N9J+ [OHL3E),#//AOX[2X_<T>%JFBCJH3'+5Q&&HIIE5%E1FB&
M_P!IU>&6;0[DQVK,#ID5"4UH7[RITU)!(&I0<FG4]\M<YP[DK3V9\27PT>\M
ME*ZH/%&M$D$99->:5--0%:#AT%4&Q]VXHG'U^5I*6M2CIXHY*^I1H1CDFC>'
M*15>1CFIZH(2BB9'62)M2O<$^T7@W\3RQ32A;A5$8#Y!7!U FM<>G#H2W6X[
M:R*R(?#+5;0&J&X4-,C_  'I18_'96#[):C'8\K40%ZN"CR"Q 3RRA):FE40
ME6,S1*7>%F4JX!"+S[3%+I'B,:1L')#A"33["/,^8'Y],2W0D64QRFJ >7$&
MG^"O2VBPM &<U])3XZ=YTM13U$$TK134QE H!Z*/$K* 9'=C^X-0'(!#A%I+
M'/;R3!)]5/#D\@1^&@H*G-3T5K>W0=B2[0<0RBE3Z>IS@]+N;+;7VEM*HW57
M;IP.SMK5:[LP%)ONEDJWR0W'L[:&9W/D,#MVCH=N;JJ:K.U$&)J/ME_AU1)4
MR4L[4E-6M!,D0JVS:E6#Q_K8+>Q9?#%[)(J!)!1=(J''>U%U:&TDZM) )$;<
MX\[1;;>C9Q9RW',.A94LXT=ET2-@MI*CX2:#6I8T 8%A4!:.LK\G2U_>&_H5
MV;UC%MC9>[MF;#WM5Y/ XKJV+#;$AP6YNP]\9'<.9EQU'O7.[9D:()%!2Q8J
MDI2SHM=4U3A]76[>WL=KV^4V\<<=((Y%>-BFFDKA!0EBBE%9G*M5PRDZ>K\O
M<L3['%>[IOTD9W\N\LMS,#K@C<EA'K<G$2L02JI56TMJ IU2[\LOYMW4R/5;
M8Z#V_7=CUU;0BNP_86]=>S>N9**NEK8\;D=NXXSMNO>6/J8J+RK,(L3 \8!$
MC)<^Y.V+V9W?=_\ &][O([;;3$7$>3<5-20#4H%(X_BSQZ W,7OELVS))%R[
M!)N&Y*X422'1; "@!#=S.0>%55:"@]>J"NS^\]V5T.1W1N/=%-29?L7K3<%7
MN7(31S>'*8/*Y[(4])MRJV6U1D8H1!E=LPMCXZ-J:DH8#!5,KU6N1\AMIVW:
MN6=LCL-LB6*,6U>[N9L\6-22:\!Y=8U<Q<P;OS+N;;IN=WXEVS5JH(5%J*J%
M)- /E@G/GU6_M3- ULM;/]O-DY*V2OE:MKZK'TTBW0&F"0QM1/%/*Z*\;J04
M//I6WLM@>K$FA8G4:DC\L8SPX=%@(</K.22:U(Z,I%L_$U.UJ&;"9O[K<!JS
M%FMDX'%Y.+(8F835LM!6XZDG67#[UPSRT@;(1Q!)J*HFA:)'&LH($MD-O$4G
MU$$ZH@#VGB#0C2XKQXD=)9)'8D*NAZ ]I&EA\B,\/Y]+/ 4&;P]7A\%N6KV]
M5;93)G=YQ.=AK]U=0;DG I<)5?QW;&)GIL]L7<U7D*0XUIEDHZZHF<()(H07
M]J85G21(9VC,*MXIB<$QL3C(%#&S<.(K]G3#&)58#4'(TAA0Z:@U)&:GT)K3
MIBG7)J9(]O)D=JT.]LSD\K'MC>>1DJ=I5VV</5L**AH=UTZSYBL_@V5I)HHO
MOZ9YXM,=Y) [2%J1IT+)$CJ6<MX<IJNFN K<2%/K4].0B@4,X8FB$C\1_I#R
M/ITI::BW#G\1VEOS!Y#!86"K3'4NY>L:S I5;=W3D]U9V6G;%;&P]#!6ILE<
M5BZ&KK9ZU9X1C$A=J?QW4!X179BO;N&F@JJ/&XJI+X[*?#@5KY=5EFA\18G5
ME8$.*94'R!/S].I6V]];[RM71-N#.UNY=NXO^*8['47:-'-N?&;8RV_,11XO
M/09K*)))EXDFVI31S4U72Z1YZ2GE62)06&X[J>657D82+33^OW$-0 U(R:+2
MG$?/J[+(/TT)0%Z@* : C'Q \>GW?M7!AMO85Y-IS;2VUE-ZTNX-I5%4L>:Z
M8W_6;>3%X#/T/CC%558\[@I\;%6:%RM0/NZF:%@L3*RJ+ED$%O.UL8D:0.JG
M,+4PRAOB76!45/$GIN(.#/$TH-&H6([J_P 1' T^SH&\WUGO"KARF>QF,PV;
M@?%[:W/69+KRK@S5)C6W]DJM/[NU6%IZRDK<978"MI)Z>HBC!^R6))=7@99&
M*YMNO 'F$'8=+:H^X=Y(TTK^'_,>GHY5?6%EU/J H0 ?V4%.@^FR^4HHIJ>I
MS>Z\0%AH\DL>0V_730UM!4U DQ\RK5Q(?X745-$95F1G1WBU*QTBR+6T0D0S
M.@J&.I.(\CD5I7IT$/72.!S3R/H:>8ZNE_E-?RFOE+_,[RN6/6U9M'&],;QR
M64V'WOW[NC;E97T/6NV,4VU=V5";9@GE%'NWL7>$]4M+38JGEBJXDC,]5-0T
MK_<%0]TMG9/*K0RR7(,; CN"C\7H*G%<'&//INCN[-XC*!C'F",CAP]>OIZ?
M"+X)_'#^7STIB>C?C=LFGVW@*=EKMS[FKUI*S?/8FXF\K5&Y]][B@I*.3,Y-
MFG=*>)4AHL=3%::C@IZ9$B4/2S23.7D:I_P?(?+IS%304S6@Z.'[:Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW6JQ_.8_P"$Y^QOEG@=[=W_  FQV!ZM^0N3
MW#FNS=Y=505=#M/KCO;?$FU),+'F8JS[=<?L[L6K:F@*/4LNWLA4M,]4M!45
MM;E7.[3>'C@-I<ZFAUF0.I[PVC0*_P 0  ^S^73+0*2[**.5TU_.M?V]?.8^
M5?QT[-Z6W_GME=C;'WWUQV]UOEX-H;OV?V!@JS&YN6MP6"IJFKR-!72O68:L
MI$6:(4$-#45%--CFIZBGD>*16+EW;B=!=VVLRU&6%0V.*GA4<-/6D+* KGRQ
M\O+_ %'H)-E[@A:A:)EQ\U/6)44-(V9"2TV RM=3_8UV)J(:F'[1*/<--.#!
M6-H:AKHUD66)FU'5I/IC[M+(!I4R<$)_#]C#S\C]O3FA&.DN03YKY?;\CT,%
M+E*_(4&4VS24M7G'FQN,FRU5/MB6L_N3@-JU>4W%F:[$I1E*^CI*-9F-9&8Y
MH:I)II'76L;>S%9VT20(&8X)QA56I-*<1\LUZI)&'=6))(\R32GG05X](NH-
M;6T>*I,UD-."QU=19.''4-1"TE.*N6DGJCB9! 4@.1%.AJHU!D%27NJR!S[;
MTZ] G:D*L)&4"AP> P#W#JCL3$SA #2E:BA/S]*=#[N_L78^-['SN6Z_P.T*
M;8VYFRF?Q/7\&W:Z2@P<.9V_]GO#K7<$L(CW9G**&IGE$V+.3-%$KT3R2%'9
M?9C<75E'=71MEC:RE)>.( D4(!,;8U'32ISB@STTT,]PD2.=+BC'0 :,O K4
M$9''R/3!NRHJ^T::GS&VSE,YV=U]MBJHLS@]M[1>FS^Z^M]E8S^)8#MS)3XI
M<CAVSNTL!%]OG(ZB7SI%3J[^<Q2NE+F1[LI=1QD[E%%218U-71143$C!91QK
MDTR,=>B2&*(1!Z6[$A V:U))6OVU_P G2>W7MOL#=D$G9><S=1NS*-B<)+VH
MJ[>IMMS;"BJZ6CQVRZK/YC&4U)MS^[N[L.M*:'+4L=.]9,Q24M(P9T<\5]/J
MOYY@S%09SI"E"0"NJ@"@,/,#Y'/3L,L"(T*:@ 2%#=Q8Y^!B3P\P?R%.D=E_
M#38ZFFI*^+)KD: +7STF%:)<?EL55340QM+6_:Q4F1<4SPU$LM&=$OG7R%I%
M8^VK@_I J2P88.GCGRX _ET_"2(1I-00%8TX?+/GZ]/FT\G1TF17%Y/:F+WO
M79*/ T>(HLS/E(,+@\I59J@R%9EJN.AR%+335>8IJ5J0Q3,],()G;PEP'5Z%
MHCK@DC621U CJ<(W$DT-*D X/29XWU(5DII>O 4H0*UJ.G#-XO-5.%S8R52T
MTNVL3!@: 5ZY5,5AY("DM!AMNU==$*(U"8V%FCQTS/Y$\TRQLBAPS,7\-XV;
M 6@!!"B@QI]3\C]O2O42S&E6X4/\N/E3HJVT]\G'5L,.3I*BHH7B\#0XBMDP
M\TU0M+/%12U$E/=)56L>-I0%1G0$:@;$$L-T:JDM?#IIHE!Y&E?(YIUI:*:@
M?;^72^QW:6; JX<@:R=HE@H:S'S5=,8Y5C6-(R[*D3U;44T*F%Y)&EC NKDW
M'M2ETY#++4T 5EKQIP.*9'D>(]>K-HD$C%14\* 8KZ5%?G]N>/1Q.I/YCOR@
MZ3V['M3K?OWM/KW:>$P.0Q& V]2YO)YK X&CR>8QF7R5'MS'9^7=6W=G297)
MX^*6HJL724T]1%']O(_B=E!3O&P\N<P:/WWM$4HC73&[ A@,DIJ6I +'5CSI
M7H\V+F/>^6I)I>7]TELWE \<0D!9&7X79:$%@/4='PVY_/-^6^)VXC54W279
M6.FR'\.R63S?5V>3,2R_;TU7')F9MF9':]"6GHZ;S0SK3-7>82F9Y+! ";GV
M9Y!EC:2T6Z@C=C58I2X5OB)[P3W<<=2?;^__ #]#HBEDLKN10!KN+<H2!CXH
MWSCY'[!T9O ?\*"M^8S;AJMW=#]*225NX\748[')O'LSKRJR>.,5?2YC/8VH
MRM%GZ)4H*V*"FG*S/,VJ3]HE"P*9?8W84@K!S#=)"90Z),B+6@HS(RE?L-?\
M-.CB#[PN\*ZSWG+-H9@AC(CDE4D&IJ00RX/#K'N3_A0IOG<^ K8=K_&[JG:"
M0?85GGE[&R>\JRHK8<]0Y"OQ67QOVFTY\[M_<>-AEQU1'&XGIJ.L>=O(T8C:
M]E[*;'$JR3<P3*JRER(DC\1@6KH+DDZ?(YKIJ.D6[>^N\WUE<VUML,$9FB>,
MNTQETAE*U1*)H85XYSZ=$I[7_FL][=K]K;Z[3PV?VIMC=_8F]-P=AXG:&%V[
ME]X87J/>N]MR)D<G1=+[,W7N7=^V:66J./IYQGJK'S9J*LFD^R6EXL.)?;OE
M.Y*0R"1]NU&62QC.F,RL::EC0 UTU[@0V?ET -F]R.8N78F;:?IH=X*!!N4D
M0EN!2@"JSG0J*H\PS5S48(+#OCNO/]J]NY3=&7W_ -E;IP&V,^NZ]O9+Y%]E
M[IR5>8-OS4F;EVD:S*2E&R>Y<Y2^*FBQ^/BFD:?Q,="LP&6W;?LMA>R/MVW0
MP6J$.-:*A.BA"$@ DEAQXGSZ"6[;SO>Y +N6ZW-XS]I,TC,!J^)@A8JM22:
M4^70 [VW14;OW+O'=N;R.*6NW)FZ_<61V_M&B&!H,*^?R<U55XK 8FC26#!T
M<,\KQP"22.GIT+$@ZF]J+FX\:XGNI95)<EPB8"!CP'\/2 $F,0*20@"@G\7R
M^SR^701]H[PQ$M+E<=@<5'B:/.55.Z8]IQ6-04./:U-#%52RU56SLMO,[2)]
MQ*I=D T*I9>S1"-DCC +\3Q_GGJ]&U'410<*>7R_+IAZZDA6.*GDID+5:Z)5
MKLPF#IWHHZX5$T]/65E.\1%0J-3%8'0ZW4LQMI]MV3 :5*G.*DTQJ\J_/&.M
ME6TZA0_(_P";HU&W\#USOW[NFV[)V/AWQK5&:FH:^GVU3Y3#[<;(4,+T4N/J
M(<7A-S[JS&=R@CBR%/58U*>BIF>6%Y'L@@A@M;QY$MVN%90'*MI5@*BOH"2?
M3RX])F<!PT@45)R,B@%: 9Z66Z.L-Q3[6S.XZ7!U^X=T[E[$RF%5J/)Y#=^<
MJMH;3H,7'%MK>D-+%/2Y^NR-=F<<T.1A>O..J/MXXY6C4Z+O8W'T4EPMM(6D
MF*5%22BC <>9]"*D>N.MAXWFH)%4 >9_BX4'S^?#Y=('$5/VQJU[*V]N6IQ>
M$>?!99H_XACLWU__  C,+2;@QFY\33PMD-O;FIZA8J?[E(W5A(LLJ2 E?=([
MD-$OUBS-H'AJ1QCI6HD7BIKY]6\!D=BND1DUD4UKZ$CR_+RX_/IUQ.,RN*K<
M5F\1B<GNW"[IEASF0AZTW#6YO*4S5M=78W#56>VYAVI9-P5<&(%3',B0K,9F
MF=9Q$6"66-HZRZ&DMW/ZAMVK0<!V@Y%./F,]4:19" "/CR&!!(^5<&GE3H5N
MOLWU]O/<^RL!N/)8O:%/MRDDW%!V/@/XK04F6VOAMDY.AQV/RNV,1)AJ:CKY
M\=!1/E*_&20Y+)K3-$:MV99?9A#]%>O LT@65$+>(OFM"$!7@!D5(R?,],L9
MT/AR'7 2 *4Q0DG41FI_S=!Y1[8CQOW^[=D9+KC>E%DL#6U4O6F9K,_0;CPN
M[9,M-@DQV(VA)5)D,]FMJ8.II\[12R&HIZJG3Q5/GF25)$36S1)).C6\L)HW
MAL6#!Z\ /+2*-4\>&>KQR!IZ&-EF(*5Q0+3#?,^E*_/I-8:LVQ48+=&ZLE%A
M8-W989G;V$JLSDL[LW-T,FV=O8H[AW3M#<.QX,=293-Y@QQ8VDI*VEGIO'4S
MI-H_6C*F-H9KF6,"5B54EC&10 ,59!W5X<"./#IYB*")&I(/Q4J<9\A0 ^AS
MZ=;2/\J'_A-GV[\LLSM;O_Y;U6\NC?B[-583<VW^N:B2N;LKMW"X^EQU;M.B
MVE_>RG.X>N>K7-36M-5Y:C6NR$4RMC8&I9X<DA;N.X*DKQVDA*X'<=:BE*!2
MV: UXCS/58X$")J-6XGB,^I&*]?08Z@Z=ZMZ!ZWVIU!TML/;76G6>Q\=_"]K
M[,VEC8<7AL73//-5U<PAB'DK,GE,A4S5==6U#RUE?6SRU-3++/+)(Q S%F+,
M<DU/2@YST)/O77NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJV_
MYBO\J?X@?S-^OO[J?(;8QIM[X;'U5+U_W=LLTV#[7Z_GG#.B8W/_ &T\6<V\
MU0VN?#92*LQDS$N(DG"3(]'<31 JDA"$U*UQ7UIZ]:H*@D5Z^;A_,]_D0_,O
M^4EFLUV_B-OUO?GQP9<ABJ[NS9.T(<SL^AVGEJ&DI*T=T[&K/[PU7759/D:Q
MH#]XE3@I"U.U)DWJ]<,"N&ZC@8S0K5R"KHX!4@C/EZ_GYBG6G4/AABN".(^?
M51&RHX]P44\\V>I\!!M>E4X?(YR//C;^ZE J,A%UP=Q;>IWFQF\LGC87BQ;3
ME!E($,(F22(:SJS <H3)X<*9#.6"O^(Q!EP&886O$>?2>8S*A9LL*#4H_82!
MP^?0S[XVS@\E%N+LK9^S\QD>OY\)A=S5VXNXM\X[*5-)5=CK45-/@,3CMNU>
MWLQNC.8W+_=PA52NKA68]YZI8XPY)C=6L162\M;:3Z'2LGBW+#MUBNA54@M0
MX&"<9ZI%.JU626,3DFL8X'/EYUID]*BGK<'N+JX[8W?N^OJ-L;O@Q6ZML]QT
M&PLK)'UG\@]GX&;9%)U77Y2GIY:>NINV]C8JG3(F*H$S5,M)6RQ-'!+&5=O%
M'/MSVDDJ*DC"XCO!&Q$<X73X!('^CCB/4 D>B>1WCNTDB>@4>'+&QR5SW*>/
M;Y>1%>@-Q-/7;5W+MZ@HIMY8G=F&D>CW%MY*C)[:W5-E&R=5!N#KK;L./Q\F
M:I3N?;U><<LL\-EK)9[QF%O450>+;W%N1)('&)42H;C1XU R=2DT/#YTZ4DQ
MM%(K !*50GA0Y#GTZ<L3!$LO8._,/']YBMLYN?!Q;>[5S<-+6S[6R\N7VRV.
MSJ8D4.-S66Z\QE7C/N_%/##13+%)XPILG@%47=PNIK?QC'HG:G;FBR$=K/&M
M*YI^?3P+F2-%0, IDJ!@ <?]ZZ;8L-O/--M7#-2;O@VG509?);4I,!M_,Y:B
MJ,9BBPWCFMH4F0I:"CRT>/R@D@KJI)'-+)^VS%43VT(KEGBM=$BQ&OAT4T('
MQ,F,BN"1PX=4,T!C2XR5KVB,T"U.0=1_P]"7M;:FXL]MU\1M/;6PMO83'=@;
M;3,[YS>3HJ+(;0RN79\WMC,YG=I>+<6%V!CX<8OW=;+1/')7*Z1.LD\$),;6
MSN7A%O!9QK$L@=Y)"%T&FI2[$U5".)I\L$CK1N% D=9 2*J <U^8 &6^60?3
MH><UF<QO[#[SQ5/3=582;;NZ\,G8N],WN#=&XMB83)[=Q67P$F(V#3Z<EA,C
MM"LVW]SF<9D:2ADS,?WCPQR?:K(P7732WJWL*+;HT;@S2,Q,8TBA$9QVD&H_
M%Z^O3$2FW*,\Y.JBJ*9H227H16G $\!PZI^WMBJ7 [MSM!CIS48^+(S2XJJ:
M%Z9Y<?/(:BCF6'R2>,K$P6Q8\CW'5S&(9Y40U4'M/R\NC(BE*'_)UBBJL353
M/)/-+CUJ(1]Q%3Q:P)P49Q#=2B1S/%J!)!5V-N./=@T;5))6HR!Z_P"SUHT\
MC0'I8T&#GFGQ\7FI'>I3$JWV%6)0/N:]H):*I\K_ +;3TA+HR@D,.+W'M2L;
M,Z(SK0Z1@X-3P)\O\_6ZK1@.(X_YO3I4T&,@,6\:!I\MF8L3DZG)I-@H*84\
M&)Q#M25V2EK04IRKQO"EXW$A1SQ<^U2* MTC,S*K:JI3@,5KP\Q\^MBE5Q5C
MZ>0\^ESGZ:E_T>=75D]=NFKJ:W%[ZP]:7>CR6*H%I=S+-C),%039"3,XBII*
M7*O-7BH@A2LDG5]3FX]NSQJ+7;W8L6:-U-0& &O&GS!'$^O2='!>="U45J B
MH]#FM*]0Z7:V,R&!VW'C]F[FR64SD5722Y.'!8:H>KR-)FZO%X&?"44*5F2H
MZ6>IJ5I999U2"IJ]42\Q7]^BMXFCC#6TFIC0.J@YKC[/GT\U4BD=0-'XF?@/
MLIPZ$O8G5.Z\QN*J@PNRZC 187&YK/0GL[<#X6FJH\92YYAC,K#AOLJI\C-!
MA9A'+310T<%7$KR20AA99M]G/).PAM]#)4ZI6(!(_":'TK0C%:=,22HD<<A;
M])S0,<\?.F>'Y]*#&=897%MNB;<-3TUM7*TV#R]-!C:[<=+VAG\G2STM71U5
M/@Z/:TV:P^/R4\0-329!ZF%DI[3%D ?VH2RF;ZF21((Y%!H';66J""  3^1'
MY];:2&,B.5R/5E!/E4<.%>D'MR;;46!SO\4V-'NW(53I)2+D)*#;&U<2M-2K
M#3YBII:25LMN&LBJ3,R4PK%@FDAC\JOH90E@\(0NTEJ&8N!I- HH!W-FI^6:
M>O7G?462)Q0T(IP_(]%7W_G9<WN:MF%70U-)2.*>@_AF.3%XV.&)(U(I:)88
M2FJ1"7=T#2278_7V'[V4RSMW J,#2* 8\ATXBZ$5 Q*CA7H2MIYO$8? ;DQD
M[T9K=Q;8_A4^0:AK,K+@XJK)T>9JJFDH)$>CNTD"171%,<9<AKG4%UK+%%'*
MC'O>/16A;14U+4STX14"C4(\AY_['V=+C:T$$..@K*/%92IKSEF3"YS%Y^K.
MWVQRT%5CJ+(8O^'U%1N#%;H.X4C9*>MAJ,:R!P\37!]K+<TA5D$FK7_:!NTK
M2@H14JY;B&JM/*O3!5A^%6\Q49!]<?ZO7H3MZ;WS>%JHJ#&4^XZ3:*T\FZ,%
MLK<&ZZ&LK]J[NW=%3*^X=H9W"3+BJVGR5/)3U34ZU,!-2!(R^5/%&OEO[F+4
MD#R"VIK$;L-2N<$J1VFO&A/\^F8[8-K,H1F!.HXH:C&?E\CT(5!D]N;^H<AE
M<KOFIQV^,QG<QAL?G*[*YBJ[/>7 ;6PE+M\=[X/-QMM_)];[;AQ[JN8H <K3
M7CNLL-,J>UZ&WOHM<MUINW<HM 1(6"K3Z@'M,8\BHU<.FVD:$E(P?#)!!8U
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MDA14(?4$=.43-CLI)U_E-P=[[3V9OC?C4?7/4&2H=OX/=31Y#=.U=P[*WKN
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A=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>jnj-20241229_g12.jpg
<TEXT>
begin 644 jnj-20241229_g12.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !]     $  0'T     0 !_^(,6$E#0U]04D]&24Q%  $!   ,2$QI
M;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#
M('-21T(                  /;6  $     TRU(4" @
M                                               18W!R=    5
M   S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@
M A@    49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD
M9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4
M;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P
M  @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W
M;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y
M-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                     %A96B
M      #S40 !     1;,6%E:(                     !865H@
M;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /
MA   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M     !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                    9&5S8P         N245#(#8Q
M.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M       N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="                             &1E<V,         +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M     "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M
M,BXQ                                  !V:65W       3I/X %%\N
M !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M         0                        */     G-I9R      0U)4(&-U
M<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\
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M[D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?
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M^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X $T%D;V)E &0
M     04  DE$_]L A  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0$! 0$"
M @$" @," @(" P,# P,# P,# P,# P,# P,# P,# P,$! 0$! 0$! 0$! 0$
M! 0$! 0$! 3_P  1" &# 8,# 1$  A$! Q$!_\0!H@    8" P$
M    !P@&!00) PH" 0 + 0  !@,! 0$            &!00#!P(( 0D "@L0
M  (! P0! P," P,# @8)=0$" P01!1(&(0<3(@ (,11!,B,5"5%"%F$D,Q=2
M<8$88I$E0Z&Q\"8T<@H9P=$U)^%3-H+QDJ)$5'-%1C='8RA55E<:LL+2XO)D
M@W23A&6CL\/3XRDX9O-U*CDZ2$E*6%E:9VAI:G9W>'EZA8:'B(F*E)66EYB9
MFJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8V=KDY>;GZ.GJ]/7V]_CY^A$
M @$# @0$ P4$! 0&!@5M 0(#$00A$@4Q!@ B$T%1!S)A%'$(0H$CD152H6(6
M,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V160G"G.#DT9TPM+B\E5E=58W
MA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=79CAVAI:FML;6YO9G=X>7I[?'
MU^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H
M# ,!  (1 Q$ /P#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4&KR>/H
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MDEIY,G5_W=S(>><4\5/2M&9:AAQ)4*AK4TP#_D!_PC'5X] 8 -IC]6Q2GEG
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MCQLGXWD\L0Q]35M3L:6FK'2*-EKSI215JS'-20%/KIX5_P!5:=%O@2*%8!5
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M,,$M*ZJJ/+,Q96\\A_48HQ#91<EF"V!%S[#5U=,JR!#3R_U?/H>65F-,-:5
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M 9;1U>REYSDXX?Y_SZEFP@"P"G$Y/\ORQT*NV:#[2CKHR::40-,U:]+ZH_%
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M\'\NF;<51/%27,/[GC(B2)H98XHD0G4\WI= BK;0HM=AS86]I;YF2$DU+4H
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MMCQ3SFGGD<1P5&B1PRJ5+-P2L$I''2>E%H ;F -6FH</Y?SZ^8?MO;R5._\
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ML,59+09G$5%!7TM)&K4U1.M#-B:Z5:F R12_L2$-YL]O)5D30&X+I%#]F?\
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M7>Y7**JP01Z<DEJL:UH* 4%!Y_Y./069/YS9/IS;-:N>P.4WI68O(U5'6Y/
M9; 1[FR60A2OJZB3^![IK,=D\30UK4Y$<=-CV\$<#'46&J59'MUM-.1&&B2M
M*D$_;G@.BV]W">*-6FD5VQV#LJ*8P!1CFE1Q/0$;,^3?RN^2^]<EANO<;3=9
M[;H:>+(Y&EW,T&?R4-+5UIIZ:..3&28>@GR,=0DI5TAI9IE>S&4(LWM^ZL=J
MBB1)&\1A@!33\SQITBL[O>99C)H$:##%U#_[4&M:#\J8Z,_U7V'W)M*@I=J=
MU;:HYZ2EJJS'T>^<!GZ;/5\\"R2(T^]<)DMQUNXJ*8U,,@2K5JD522J)UIS
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MO:;'+2T1M'65TM?+&L$4CPPO,5$LT,9:9$MZ*VTH^S_".E^V?[FP?G_QT]:
M^-R?WJ24./$.-BW%OC;N%?[* RU%!#N7$8VGBAI6&EH1,E70_:R(IB,RWN\>
MK4$Y!2IXL%K3APKT.(:=BG"DBI^T?[/_ !?4+;>.BR6<KTI*6FQ\*5G\.I8H
M)JN80,4FL&JZC55ULYDB;RM):1I7))+,00+NMPJ2RO4TK7\A3J6=@M-=K$F
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MU[W[KW0Z_P 9_P!J_P"8;_C/U3_DK_?<>V*'TZ>U?X*] ]FY3-F,I(?[5?5
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ME,>'>HE2H*T3O&0)9D@F6:1D()U4TBN'#/9GTCD%+^P'</XJ$$#&1Z#J6MM
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M!N.OKEBBH.QZ+!Q15LYGRTRUDB5%9,"H +O.7]MV:U>7;H2A:0:A4D9K09X
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M^R;==;INMK:6<>J>5M*"M. +9)P!05K_ ,5TFWW<['9-LN-QW>?P["!5:>0
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M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2P^W_R#Q\_\>?\
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MH!HHX_X.J5MSXZ)LK2S4T17S4MF0!&<-"^D%FA"Q&-]0 L ; _GV)+NQ5KF
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M5DE@L4]+-36E#3(SLT9=%AB&FVD,P2';V<NO&AS3R^1_P=*5W")2!P<G%?\
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MZ?7'_%](6MPIU Y\\'AT["GB<Z4USFRDA] 5E!0']1,3SDH5^A!U V-UTJ0
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M$80TBL\(6(D.S1!=,0A;]L,Q41$JX!))YXX!/NNG6Y)44X^76U#%0-6:4/\
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M1U9!^T#YCT^?#_!UDJ(]/CAF0K(Y9O&UB '#(&;22C RC2""5+@@&Z^W'!^
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M" \:X\C_ +/4"*13(%"Z0S#0CLRJ7+JLHC$ES(Y%B&N186_!M<,,4P*^?[
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MZASS[2RO@5K7C7_5QX=5IJH:4]1^?7T(O^$^G\L<_#3H*?Y$=KX!J#Y'_)#
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M.1W=NGK3:^]X,Q']PM.\^6R\-;+#312BD>.=ZW*:[>KW'B.RTU,HKIJ?Q&I
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M=>Z][]U[K2P_X4!_RB#LW+[K^?7QOV^J[/W!7-D_DML'%1:1M?.92H;[KN'
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M429S?^ZLW4P4M)&'KMR5<\5)3I&L5#CJ>FI8P(X%]Q[+*SRM(6U5X'A@<.
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M7 &3TKV_;&O)% :D R[>?V"OF?SIQSU]+_JCJKK[H[K?9?475.U\;LOKOK[
M4.VMI[:Q2.M+C<701Z5\DTSS5>0R-9,SU%965,DM76U<LE142232R2-B9>7E
MSN%U<7MY,9+J5B[NW$D_X!Z 8 P,=#I$2-%CC4! * #R'0@^TW5NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NHE?04.5H:W&9.BI,E
MC<E25%!D<=7T\-90U]#60O3U=%6TE0DE/54E53R,DD;JR.C%6!!(][5F1E96
M(8&H(X@^HZ]UH*_SI/Y/.2^%^Y\G\AOC_AYJ[XH[OS2?>8>%YJ_(=$;ERY6-
M=NY1ZB6:OR&P\U7LPPV1)D>F8KCJP^44U579.>W//:;]#'L^Y,!O<:DAS@3*
M/,4_&!\0\_B'F #MYVUH7^IA_P!QB<C^$_YB?V?LZUZJBE0321NB1^1U&B/Q
MM)(EU2)7()0QEH?4&U:B;G3<:I4TDD * *UQQ\J>7^K_  AXD=U')'D*_P"?
MIGK::QA1F9R%+,OI'#@% '8(1&X5R>6 _'-@6)QITAA^7^H#CU>%5I6F:\>D
M+FZ&"LHJNCF!,&02>CD#'R!A41-'+JO^Y$I6PU*QX( %O99=Q)+'+"X&EP5/
MG@X/3RG1('!X9_9TBMLS&LVYA9JA5-534S8O(".RG[[!3SXF<RO%(=4D\,"3
M,2$:3[AF+/9B"K:I6EVVS>0ZI5!BD;A5XB8VX>9TU^=?/IJ\0I=2(J]I[QBN
M&&H?YORQT^_PQ51G)(&I6/"D*$LK,QL+-J:W 7BQY)T^S+Z<-ENDAE(8$<>F
MB;&(J"P"W9HV?2JN\7J.HZ02"=0"G_B?;+VPH#3Y?ET^LY[AQ_;_ )>H<]&;
M$D.23XW(C()%F#,5U M<FP%A_7D^VI(JC-:5]/\ BNGHIP/BX'A_J^729KJ)
M"I9HP?&RRB7Q&[KJ;R(\DED5I$<@"WI-K^RZ2(_P^5:_Y.GU?.K/&E!TT-2/
MK-U:/4HUJ"05,;,5!;ZQKX^0^D7%S]+'VE,1&2/MI_J].E!9=)S^?6*'&ZY>
M%**/*-((=PI76KI8% 62WTX(XL/PSX.IJMY]65N #<?]7VXZ55!0+"T+(CO#
MY60R&Z!E]$L8)+MZX]?"?4G4?I?VK2$*5 J1_J_U?MZ]4A3GHP75V9FV7O7K
MO?M,R4M1L+LGKCL"F9F4^%]C[XV[N@M&_#:U;$-=@!;A1^JWMW=+%;K:-PBT
MBCP./^,GK=A,([J%G-65JBGJ3U]-_=T<2Y/,P0W^V_BN0-.R^H&G-7+XP#I9
M"!'8W^A'O%1#V(3QH.I%&&)_P]4^_P Y7M:FZ(_EP_)/=LJ5]5D]U[;HNI]K
MQT*Z_L\KVAD*?:<^:J+JX6+ 8.LK*TMZB33A0+L/=RRZDU-2IX_S_;T\&94G
M=0:JA_GVC_#UHE_&[;^4R.&W!N;:-'V1FTZIJ:?=]735VUJ7)=>;=P==7P[>
MES/8^1P^3H]SK+DY*FBIJ'1DJ6!\K6TL)FBEBI4JC^QA+KXH:0LK@!"N.ZM"
M6->YB.%,^9Q3H.7,E6$3:0#45![J@ F@\P!Q\^CQU?S4V#U9V'E]\?)#I?'[
MQW]VC@3FX*W$]3;?ZOIMM4&9R51'#D]OXK:.^,_BFQ]1--)20T/V<&.I(Z>>
MF:CFI?M?MQ%%N=OM0MH;F:>.A)_1!;4 =)'<PH=0(J /Y5)<+-YU;P=)4&E'
M.0:$YIG\0/'_  TZMJ_E.X?8._\ ^8)\9<E7YGNW8.Y5I.U=^;BPN]]]P[GV
MAVI#LGK?;_86R>ML%CEJAE:&CW#E\W%N/,9"MQM"V3I<32XII!4U%2F12<SR
M3GQ+L2LMM*!X:!44=VI6/:6% :BH->%:8Z5;91Y&C8#6A )J3BE1Q S\^'H>
MMXV@S 2.0I)K=Y7=BSZV-P&5F;\E@U[_ )O[ <G'!^70@^5.@5[+G>HAD:.Y
M=O392#<@FU[&[$@_D#^@]U49J3CSZ>BP]":?/_5Y4ZTC/Y]G:TNY>^^E^GJ>
MJ+0;;7/=BYJ(:9%$B@[9V^T\>H'A:[(.I;3^DVY%_<B>V]H;C?)[L@E(45<>
MK5.?L '2?F.81[;96JTK([.:^B@*O[23U3A MZ15",@NJ"6&(O'I8E#&517%
MG0,NK2P<FQO>YR.ATA8Z+0\,#M4^I]2>H_E!T_'Z5QY?+[.H=3$59@I8*Q:[
MJNL1^1#+&?UBU3>Q5@&T1\\$%3<QL"..>[(K@\"?G7@.FV*:AFG#CCILG=3=
MRX9424ERMT#J TD;-$#-+(K J78,1]"WO;-158>66#4/YL1Q/R\N'5&*\-1K
M4?ZAPZ]!-(I5Q/*JLA9=;%5MXV"J6U2F50 R?1A=O3I(N&A(=5#6AS0U^>?L
M'D.KPD')/R_U?/IZ%8?0D8ND*>*TZD'4RW#Q$%G$D/C(6Q!#6M<<%:'6@&,&
ME#Y?Y:^?[.JL&+.U?+_5^SI_\6)AC22<Y"&JTUL]3FZ=9,O!CJ"B7S+))M2G
MI*>OEHTFD_RFHII*S(T_A>5J5X9(U5^26*"-=9HQ)HXJ0 !4 H!4?,BI'\-"
M.DA64R.V"N#I IG PQ/'Y&@X9ZCSI-3O&*E*5WJ*5*S'U&/J%K\7F:%YM$64
MQ633_)LKBZF06$D2@*^I)DBF70K:R$G6QTR!=2TR"#P8'*Z3Y'[:YQTI.D]@
MK2N0<4^5.-?]7#J'"CS3:E96C^A$2Q@/JU!I7TEB%8,5*@%EN=;+P/=HZEF;
MB/.G^$FO _M^SAUZ5Q1(P*>>:^1\O]5/MX].N2KEQ.#GDCDA6MR%2*''Q,]/
M,ZB%(IY*Z:FF>64+3*X6(O$JMHFT/%(@#O22((SI>C$T %#GCP.0!QKBI\QT
MR3D*HX @_GT@L=2&-%2.4B.%&10LLQFM3(WK+"*-S*AO<EG//TN3[21*!BIH
M/F:X_GCKU:@TS\OMIZ<>G^.A"M>)':0&0QTZP.0FB%&5Y#*@5)+V:]M+&_J-
MB?=S13BORI]G\NG-/;J*9S4&O[.I45$N@*YTJVLZ6'*%PQ+*DH9D%P =6H+<
MD\@^[AM2E3PK2C>7^7JGAL"'H!FIITXZ!&J((PGB"0LRE-1)LHCD%E,94 J=
M2@^D?BX]JEPJC3Y4_P!7GUIZZ:_.N/4^7^K[*]9:P1R1R+#J\R2-8 H3):<-
M&K2^2%U]3'A0/T^G\A?3!67!S^7[*],*SK12N?/S^WHU'PF^$W<OSQ[UP/2/
M3V/BC>J\&6WEO3)154VUNN-CT;"'*[HW#4TKN[1Q^5*:DI499,A5S10+I9C(
M@6YDW^PY9VZ7<;QJBM(XP>YW(-%7R^T^0R>C&RM9KV81*.VG>2,#\L9]/\W#
MZ5?PW^(74'P@Z(VIT-TUB%H\+A8QD-R;@J(Q_'M_;TK*6D@S^]]S5'DE>?+Y
MJ2D0",.8:.ECBI8 L$,:+B5ON]WW,&XS;E?O61L*H^%%'PHH]!^TFI.2>AU!
M"EO$L48[1^T_,]&F]D_3O7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]TG=W;2VOO[:^X-D[VV_B-U;0W7B*_ ;EVWGJ&
MGR>&SF%RE/)29#&9/'U:24]71U=-*R.CJ00?;L$\UM-%<6\K).C!D=30@C((
M(X$=:90P*L 5."#UH/?S?OY,^[OA-F<YWQTA39'=WQ2SV6#3*KU>2W+TA7Y"
M14H\#NZ274:W9]76S?;8O.L9)6D>.CKRE2T%17Y1\@>XMMS#"NV;H1'OJKB@
M 68*/B7- _FRTSQ7%0H)W;:)+5Q<6P+6Q(!'$K4_\=_U'U.O[44Z1!W2*[$W
MT,MWU"RG7(Q30 A4DAPQ8V4@$@R5*Z@5I^713_I#_J)STCZ^F5R[2*K:@Q10
MP72(QK$;K'HF(*@W&G20/[7'M!,FH'U^7^KAU9"#Q'^K\^@OPM.:3,;WPJK&
MS4F5Q&Z*12L:LL&XJ8XW+.$:2-U2.NI*=6164F1Q<,0M@WMX:.]W>PJ25D2Y
M Q0"9=#?/XHQ4>I]>E-VH\*WF- 60QU\SI.H<!Z$G_+TN? )4#&-7BD9A(R,
MOE"L@9P5'B$D4<EN& _H#I.KV(D'GY'_ %9X=$NDEB!\(ZC21:VDDD(9F0%7
M-RB^-410KR.QLD6E038V07]0'MP+JU,P\O\ 5Z^73;-2E!FO^?\ U?GTUR4)
MM('BL'46*E"H*"YN^H'4C,3ZN3>X-R;,/%4,I3R^7^'Y<>GF-%4TX>>?]6>F
MFHQHF4DHT:EUC!U%K>=CK=WO&ZZ&L!R-7'/UND>WU@>0X _;^SA_J^=XYM)J
M> ^T'\NF+^&J%",BQKY#$Z*GEC1E4HX=BB67T\%KD?4E;@>T36III8>=#Y_Y
MO]7ITM\4$T \A3/[/M_U<>H<=&Q(;Q@%(PAE("C5$/%)RH,0#*C* &](:_/U
M]H_ *E3IS2E:?ETJ4]AH?3TZ=H$86NQ?2ZLKHRDRNC1R1L)@5,9T!P&'I;58
M7_+ZH*5IP\^FBS@@'U_PBO0F"DGK=M9Z"EC62:;!YFDAF9+QF4T,T<,T6H$F
M2&.4V*$:> ;D>S98C+;.J+G214\*4_R ];21#-$[5^(8_P!6.OI1=<;UCW]U
M-U'O6.193OCJ+J?>@E!+JTF[NN-L;EG?62"ZF;*-=C;5:_U/O#N:/P9IX?X)
M&3_>6(_R=2@E:*W$$ UZI*_X4)?*' ](_!:HZ2IJC'U'97RSS\G7>V<3-#25
MN0QFP-LU.,RO96]H*2H6>HAGACJ*' 4%2D9=,CFTDC<-3R,OH4620JX[1G_5
M\Z\/G3KTDQBC=Q\14I^WXORT_P"3K7*^+W7^P-L[*ZY?(97L<XW-4U=5?++%
MXG$G'5% U!M%:W;NU4\E7D)Z:E_NY44E9>:EQ+Q9&L*:9_!'5,/MCM5.F>5S
MJ8*%)H6UZ@#I74*]OK05K7&>@=>7+!IT6,'03I&<BE<D8X^E<"O''10?D#34
MNX^RMW;R;84^<VAUQT[N+^*4TJYJ'%;8R6\-O-LCK&HR&9AKJ>?^(X[),V6Q
MOW50XRLV-T3K4(\Z2M<PQPI>Q4C+Q10N7)J#5AV$D4H:Y'D2*<.MV3F6 +XV
MF1Y0$X'X2"0!FHI@^8K7JTKXH;][7P72/PW[QV?DMM;63I+Y [Q3KKN"OQ,]
M5/2[V79PR</578]=CL;GLW!LS>>>R46!R,1:HFQ])E(:Z&G)R#SA:8[?<-I2
M/Q--SX061S7X*LH)KP72:T'I\AU8.]O<RS"K*6JL8(RQ(^$5 '#UZWO>N>VM
MN=M]5];=V]?S2?W#[=Z^VGV/M17FBJ'I,/NW!TV5CQ5144TT]/45N FGDH*E
MXF>-JFEDTDBWN-9(WB:2.5:2(Q5@?4&A_GT*(V$@1D-:BH_P]<MVYG_<1/5R
M.#X:66=KDC]$3LMV(Y)*CVQJ U \*=+(4U4SW XZ^==_,![)/;_S]^06X8ZE
M9\7M'+XSK?%2,S3"VV:,SY<06M#&PS63G!Y8DI]#?B</:VQ*V,ER5-99"X;@
M*< *_P"E6O\ DZ#O-<JB\2'4/T46.GS JV/],:= "JJICY>\85V82!U$I3GQ
MPDHT4(Y)8>LW) )L1-><$2=O$'-*C%0OY\?^+Z""Y/J?0?Y^FFJ(60,C!4*W
MD1+,@&I62)4O&?(C!];(RCFUC:WNLC /J#FM=1J:Y\OM/H!UN@(*LHTCS_U<
M*]-<QB)\KCQI<![S2"-M3%8H49-(2:12+L5#+SQ]#[9= _$T%>!-:?YV/\NF
MI**:4(8C'^KTZYAG'A57"?Y09)'$:B16TB&G6*0R/$TDDK&_I:T?''%]?J4$
M@- #5B>(/EFM"3Z9I^SK<>A:"AU' IPQBOV=.E-_G&5F1HRJ2>( JJ2B4JSZ
M9'35$"Q'H==5KD<6]^CDR5D4DTJ!7U(/G2I/GZ =*6 *56@IYC_4>GE75I2T
M#>&:*7S0)KG1(5@O)#(KJ8:ZFJ(G;6DT9$D9("$6Y55$K%%-1\^%!DG&1D8(
MSTG=&45TZA_L?[/41ZC(TL;8U(DEV_7>6KS6)D>&".#+U5,ZP[OVO+XFBV_N
MC[AXOOI*8PPY6&Z55)*W[GMMUD&@1I6W9M31>A-:2H?P,#\5,/7*DYZ82,@@
MZU\2E 3Z"G8>)9?0&ND\".GO"4,DH2FDCB>HE21$FG1@@C%,[UE4S"&22BHZ
M6!7EEJ#K\,09F]*LQ,$B"* [YX5X4Q7''/S-:5^77F=6)8+@>7J<?[&.H.<2
M/+9/7!]R:&A"4.+(UR"*A6:H$DLBEY88JNLJ5>:HT?M25C2LFD-;W28 R !Z
MJ!@C/$U/VFO\ZTZJBZF8A:9R?G_JQGRIUDAH7",XAE-TC=55V==$DDD/D1E5
M+"(N2R7_ %N>%'(:DU!:A32E?ETHC #T<CY_R/SZF_9,TC2/3J!Y%=E-931M
M/&?MO$^L)INR2%U(8G5R"=18:*D@MI%:YR/RZ=U E0 :GS%3P/\ +IRGA,<)
M,OB"H(FL)A)$_D4EV6._D!M<BUPS7TDCCVIUE5_4R,?/IJM2P!:N0/E^WK!)
M!I0LOV[F^F6+7++81M%(BQA@RLAD0-Q;4Q!N;:BX74 &H_/]OSZ9=2VM48_;
M]O\ J_V/+HW?PK^$/>?SM[@HNH>EL)0UDT,4&2WOO3,I51;)Z[V^TXA;<6Z,
MG1K*%UE+4E'$DE76SDI!$VEWC#_,7,NV\M6#[AN,HSVQQ+EI&]%%?3))P//-
M.E%E8S7<GA(M%XE_(#R_/C]O[>OHP_!7X*=*? /I7'=2=1XU:O)UBT61['['
MR-'!#NOLS=<%.T+YK-21--]EBZ+RR1XO%QR/38VG=E4R3RU-148E\R<R;CS/
MN+W]^]%';%$OP1K_  J/7U/$G)\@!Q;6T5K$(HACS)XD^IZ.E[#_ $HZ][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[IKS>#PNYL-E=N[DQ&+W!M_.X^LQ.;P6;Q])E<-F,5D('I:_&97&
M5\4]%D,?74LK1S0S(\<L;%6!!(]WCDDAD26*1EE4AE92001D$$9!!Z\17!X=
M:27\W?\ D2[EZ-?<_P D_AG@\KNOI*".MW#O[IZC-7E=W=2TD/DJLEF-J2,]
M1E]V==T\+.TL1,N1PD*F21JBC666FR-Y#]SH=P6#9^8&5-RPD5P:!9?(!SP6
M0^1X,?0X(3W/92KFYM 2E:LGI\U]1\O+R^6KA54^@6DB0C4&NJI%)'*J^1%A
M1!'=08PQ5'"*=))4%09;E"!02,'\C^S'1 L;,=0./]7V] A5QMC>W,530$I_
M>C;.7P$ABY\M:*:3+T,?K,3L)\EC8T968W$C!M8)C8&.WTW,UF-0TW,$D-*5
MJU/%7C3-8Z>?'SX$PGCUV3JJ@E"K<:8':3Y^1Z$"B"K11,*9T;40@D22G(1G
M:5O\ZT3Q2!K*"RWO(1;DDBR(J(U*I3)I_A\^B1DDCKJ)+<#_ *O/'62*G,@=
M2$5I%?S:M36D:12Q4%'<"RVU*22HTWL6 4QHK&OGYUZ2R/0K@T\_\./]7\NH
M;Q*CV)B8RLNBS1&RG7)/.8DC86T26"C^C&QOS6@$A'E_J\OS/5@VH:J9XY_U
M#ILFI3$&B9#HB1R"&\2(2;NKZN+)8ZM)NH"_D7#)B;*Z<#\J9^?5FH-!J"33
MUSU$:C*PLR".(,T<[M*)'5!*!,$T%;J%8'46/)0BQ'J+)BP< +EC7/'/Y?GT
M\TB H:D^6/V<>F66DT5#NC/*%9)8HE*D*[JXNY9=/E$D:WOR2;"W(!=+;,)#
MFIP0!_L^?^KY=+(YE8+52!3S!_R=9:&C970JH44XU.TBM)I0'4H"$LVI0JA.
M-0T6%S8BL,-#4 8XUZM+*&[3Y_ZO/H9MHPB--!OI*,"R-'ILJ"( $"[1IK#"
MS:'#6#6) /K-='9P\J_E\OV])A56+< /+^?6]G_+RW8^X_@5\*LS63Q15#?&
MGK' 5,]9,L,$$^R,.VP:J>LGG<I!!3#:+/,[-:)%8LPTD^\.=]B\'?-YBI0K
M=28IZO7A^?4N6K5MK<!OP 5^P4ZTB?GI\N,A\^?G_P!C]\X-QE>ENC,75XGH
MG$Y--6.R'4O3K;NJ<+7143U5-%%+V[OF/(;LKXB9Y9*2I*!2E-&J5LHI4D26
M)PLH*2*6R3WZ0 ""..<U!"U/1=?R+(&B*ED:L>/2E23YC[<<>CLSX?*83!4F
MV\5OS:F1I?E+B:_M/M&CP&+GBI-J9[$82GBI]EQX: 8#&"JPN;Q8KBE/!+C:
M;&9;'LA@99(:>3K" *S0,WAB(E!(RU)).IB134.& *&HS4=!67PR"=!T\:$@
M4Q3!KG'VU^WJM+Y!8^EVWMC<FX:'-23_ .DBIW%1[RVS1R4%?2XC"T==N>@V
M;I;&55:VEEH8ZI9I1!&OW)@5M+1L2O>HX]=Q)([-&Z%& # #0>W/PN3Q'IPP
M>GK$N1&410ZL&4^?<,CU'I_Q71K?Y=U9CZGK/"8NBJCO7>R=TU5=FN@*F*I7
M&9_;6&AHES5=&:6KPD,E-@JJ2@RHQXD-2DRM5TU=15E31Q^Z;%/6*_BE&@Z9
M Q  T-6J!3FH?N4B@I_24T55=1LTD&ACH[=+ UK6O%3Z4!XYKY4).W1_)J[%
MDW!\*L]U)4U-ST=OK-_W!PU=4P3;DVSTWV3G]SY+:VSMRQ0U$DV/RVP]_;;W
M3C5BDBB3[ 49A:H@T5,@6YJM3:[E')I[)8Q^96F?6A4KQR?MQT;;5/K21-56
M1Z$TX>?EC]A('#CT<+Y-=D4?5_1F_-ZY644]%M_;6:R-2Q-@(L?CJBLF"@GT
MC1%P?^*^PN1J.E?B)HOVG@/V]"6R ,PDKVKW-\@,U_+KYONVLYD=X9#<.^,L
MQ?,;XW/N+=]>XN]3)4[IR=7F6TJPD-0D)JEC+:5T:--[ #WE)RAM_P"[]GL8
M53"H*5X?/'XO\_4;[I,UY>SRDDEV)QQJ?7TQT((<?;A0\=] :2,M(5(76KAY
MI075O(HO<.EFLOTL!O4Z NL:B.Y5)U$#U)KI'_%]%N@$@T(H?R^6/]5.F.ID
M;4K71F?2KR<(RZE\:G0D<2^-@@"QJ0I# FU[A,>\JY%*TX&G'TQ\/S\^M&10
MI7C3/[/SZA2$:E<B?RQ?4*H1H"6!5?[2B,*I9K$DZK\@V9IS0TJ=0%: 4IPX
M#_+U5"6457!QQ_//4V)A'"%82&T9 8-94U%F<H"K!4)C 8L 6O8 V][5O#T(
M')\Q3@/GZLV .KDQE:L@QC_5Z=9*1@VA;M(Q!4:S$JC3^A1(TH=4U.2M@Q+V
MYMS[<0,Y0:?+2 :5R<"OJQX_D.O=HXOGY?ZN Z>(:AE4^;4&C"-HE!:3R.6U
MJ-#*L86#ZC2O,;*0S7'M2L;=Q=:D, 1ZFOPK3%!Z_+K8D)JGF.%/(>IZD1NL
M;QJC?=1-+<",$2O.PC=Y6/ATR1K#J4$L.2"20![<B!=:NP\+5DCBQ\@/4 5_
M;TW(YC(S5J?L'J>E%55'\*Q+&+QI-5"6*@EE0F-H*:56R60B6KI"@19[4Z20
MU ((JHS&VJQW<NL:,*:6!P*X'KQ _.AXU'3:FC_$&QGU!/V?;_@STP4WKC2%
M(HT4^,^-!52179$C3QQK(LI;TC\C5SPUP2RKAE%./IG_ (O_ #]*HZU8TSZX
M\NGJ+R))&6,B*',9>**13'42D+3ZJ=V>3142$:RH10YU'3J'M\$D+5FI7/$Y
M\OGQZHPJ"RT_V/YYZS0>)"7$KS'6&O&NB[.-<K:"SMID=P;2C3X[74J;>Z'2
M7[6J/*GS_P!7GUY =!#-W8K\O]7RZZ+HT8TLZ/\ YI]=F4L#&%A=33I)$[D*
M6]5V+<@$ >WF"&.H)#\#7\L?;U7NKDU4Y&?Y\>K'OY=_\LGO;^8=V)_"=BX^
MKV7U%M[(0P]C=W9S&S5&V-L1&GCJ7P^$1S2KN_?%;0R1^#&TLBO%'/%-5R4T
M#K.0?S7SAMG*UL6N#XE\PK#; C4U<:FXZ4^9&> !/2VPL);E]2XC![G_ ,WF
M34_E_+KZ%?Q&^'G17PEZDQ73W1.U8\+AZ8)5;AW)7K256\]^YZS_ '&YM[9Z
MGI*)LQEIFE81J(XJ6CA(@I88($2-<6]\WW<N8;Z3<-RFU2G"J,(B^2HOD/YG
MB23GH70016\8BB6BC^9]3\^C1>R?I[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNM:?^:C_ ""MD?(Q=S=Y_#JBV]UGWC4PY#*[FZJ<TV"ZQ[9R$BO/456+*K%C
M]A[[R3:OW&"X6OJF5ZA:.62IKWE_DSW0NMJCCVGF M/MGPI-\4D0X '_ 'Y&
M/3XE'PU "]$>X;,EP3-;$)/Q(\F]?L)]?/S]>M WY7=:]B_'SLO%8'M#9>ZM
MA;[ZZW=2'<6U-U8VJQ&:QE11UL%?(C1U.EZBER%+3F2"I5FAJH2LT;&-T+2;
MO]];O'LV_P"WW2R6\<R2B1#5=(92^0>- 0>!'H#T3P0R!KFVG33(RE--/6H&
M?MX>7V].4J0TU=DL?"ZF.BKJJ*FD=;**?3:GE$7V=(_A>B\3QE8H8]##QJ8B
M#[&244S1:LAB/E]H!IY4\OY4Z*&#FFH8I7U/YG[>I4:V2.18+DQ2+>-V=5LL
M<R$$F2,R(AU*!]78<$D KHF%-0'RQ\N'YT_U5Z+I>!(RO'/^JO7"HC;RH]BS
M2: 7D*QH_P!8Y(S*RF18T9@XD=M7))4D#5HM^H"1GC]OEY=.A*IPH.%:=1IJ
M='8$W/FCEL(5,LA8WA15\ADLWG4"S.6(:^F[:3Z5EJ& XCRS\OG_ (>F5C;4
MPD!IY>GK_J_R]81CE8)*$.I&(D:<L!Y ;Q2 1,"H5VT-].!8"][74!E#?,<?
MVX]:\/\ -7KS!RP45KYT]*_9_J]>H,F/)K(T-@A5X@(XE2UCJB=%E4DWGB !
M]1%B;#Z>T<R 2BK8-0<?F /S\^G;=S*#4'5C/V<?]7SZFT>,;[@R^.^G3)Y%
M"$(Q>[&2201Q"11.FE% )(N/5;VW&B(PXZ2*_GY^5//I3H9@6/ 'S^7#CT(V
MWHUAFB1[*FA7!97J5"HZ0Z3!J=+RDKZ5)#7Y#6]FL"J#4UI3'[?\W7@ 0=)S
M4D@TK_JSU>MO[Y6U7Q__ .$\V!RV"SO\(WYOK#[]^*_7U?!,T%?197?_ ,A>
MYL;N?(T&GQRBIV]T]B\[4HR-&()%B964@$8B\XIHYPYA"M2ET2#08KIS3ABM
M?RZD_;W(VBT9LMX5//)X<?/K7=^%G7P;.XGL"FZYK=];2Z9RD/:_;5%*GCP[
M]:4T&X]K;?V[FLG2S4-;AX-PYJMI,?)KKJ989LQ3^.HI:AXGF:VZ%7N(EAJC
M%C'K./C-$X TH,_G\LE-Y+@AF^+X5_TN6\\_.GIY]7!XGJ//;ORN2V%C]F8'
M;M?\F,E4]F[6RO\ $VHUP_7>"P!>7#YJKJS-+2T$38G+0T=(*^JJLA5T-*35
M7*2U$G0*T4>4,AC[ Q%2360$J..GR8D>1I2A'0<FD)H5(T $$+@# .3\A_A^
M=>J^/G5D$R^#S^^E3$X3'[WR>!ZZGV]B(<+3IA\CLC=^_,=D:J#$4=-A(UHZ
MG'I4>+QT:10U,4+2U*5D[1J1[X@A@,8,8@<B-N%0'5"Q0,Q8TI\515JBHX=+
M+ DR'269E4L*\#0\":4XFE/(>O'IU_EBY&M.[>L<)AMRKUKN'!;PWOVIM_LV
MKRL^#I8H\+28#&K@ZO(8ZN3(45?EL9)#+1U-+XJ^GJ'4$5GBID@*=C=XC.OT
MP9/#8 D$EU9^QB"2M%9<8J,U.!1=>%&;NJ=6& X#M[EX5R#^?IUL-_R>-[X_
M ?)[<NSL745*U?;7QB[&D[%Q0J(UV]1]D=7]Z;?SM%D=NT%'5R8FC-=AZK<(
MFC@AI'CE::/P^**.>?W.L"26UK=KP\8J,#"L@*BO%JT'Q $&OV]/;-))]3(C
M !0@ID\:FN#P'V8_/'0X_P ]+N8[.^&G9F#H:CPU>Y,90;(H$$YC:JS7868H
M=L)2#QE#Y(L'49"J!N;+2,>?H07M-M]1NEA$5K^J*C[/7[33]O0KE8V]A>W
M- 8RB_:V/Y GK3BVS1&@H*2A6&*$14D*M%J;QBQ12P+6,+QOI5-+,H*V/UYR
MPVZV,$,,#U%$ (;\JT]!7S..HRDD#N7#*03@C^5?G3I7R.S+"G[UY0CK-$@#
MH_U\PC"Q232*A_59=(:VH$>S<,=.B,_ID"NG'V5\W(_+CQZ;8U-,5_EGID#'
M5+,BZTTAI@JDF-K.= ATQH)">#:P2X&MKD!D&2KM0:!\7RIYD4 KF@ X=,:>
M!KD_ZL?[/4 :9%4HH5=3SR L9=2DZXD5X2'9C/&H)*G2$_-K^T[%BQJ5'XCJ
M-< XK3B*TQQ_+I20J"N:'  _GQZSNVE%COIE\31/.DNJ#U?5WJ0#YV2.P !M
M'9@1R3[\"Q8.K?JE:5K3!XU]!G@.M&@H-';\\Y_S]9(&8!&@8!R MU?QH\6D
MC3,$DFBCBTK90UAI6Y/)(NI(*^'4$X!&*CA@<*?,_MZ;_&U *<?]7[.G%YWB
M1GE"N(="K3F(HH(0 >*-I A5A8227<6YT@:@%)D(41U 9:H /+'X17)\B?+K
MR#(/&N37S]*].&/C%5,L4;*D\I2G:>6HI_!+/*2J:)ZAXJ6F'DLHDF=(T502
MUB/;ENN<BA QG"\?7BQK1?G]O6FI5F<5QDCB0?(4_P!7[.N%?519*OFFIE,%
M%3BGIZ:.%0!XZ50L,DSR4L$X$B$./+KD+NP9R;>T]RQ=G%2(A04'R]3I!P/7
MB>MJNC2E<D^>/\IZG1^-Z35+_$/U%4TB%5=YA=V\@:)K6C"!18"]S8>[1HAA
M+=W[:9/\^G'HKI$I[J<1TZ16C5(UJ)TUW$#^2("229/&JA?X@\I1$N"[)<$F
MS'5[?K'COH> S_F/5267 -?7_41U.91Y2SS6$2.?!_$%'[;2PR30%HUG65GO
MK"< 2*NKTVM<#N8EO*E-7\OG_GZ;?40K!!J-/P_ZJ=;%_P#+'_D'=I_)B;;_
M '/\M*;.]0] SK2Y;!;.M+A^U>U<:Q2>B>*":):G9&SLD!YOXA4HE=5PL&HJ
M<13QUT<3\X>YEIM EV_972XW/@THS'$?M&'<>@P#QS4='MCM3SA9+I2L5<(1
M0G[?0?S^SSW>^K>J^N>DM@;8ZLZEV;@=@=>[-QL>*VWM3;=#'08O&TBN\TKZ
M%U35=?7U4LE15U<[RU5;52R3SR232.[8[WEY=;A<S7E[.TMU(=3NYJ2?\PX
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MJ8I5LYYB<4P1FD*,%TR1R!G-[%B +-SI]HF8CXTKJ%0?.GJ*\:^IZ4J#0#%
M,BOG\^HLLX$S$DO,&:)9)!I2-0XU2*[J%?4TFGU#7;40/J/;=/CU@$KYU[1G
MB?XC4\/M].J*2H;2:U/#@?R'EPZ<XG>-+NH!EC06=3J:2Z!5*E8XGE9]*E?2
M6U7 47(5I)3+5)IY 5/H/15R!ZGIM0F1Y>?R_P _4D,6?P* =!\K*O#"/TAW
MF9TB32Y4^,LK,=1(MI!][#1NVFII_1XG&:#@ /4C/6R0 ' J/VTI\O\ BNGU
MIUI**JG0^.>MBEQM*OW)IIX:.9%&12&GCJJ:1:*JAE%'Z4GCF1ZN-A&T:$NR
MT57C#9(%-)X5&12H-?*M"/B''IM9%8HQ7 /IZ''D1\^/H>H*I#H%GA;]O1I"
MR%DDC.B0M).5F\NJ[O\ V3S_ $%V@B^'0L":4_U>?^K]KM.\OJ%>('V^HZ<X
M5IQI9!&Y9H?WGBC\<"7*3K%&P$GA\K%P5%M)X9>1[4J$$?:V<?[/\^M-&2U7
MXG_+T;+XN?$COSYD;T@ZU^/'5F;WWFM-)'F\I14<5%M7:6,D%1'_ !+>F\J_
MPX';-"(H6\35,Z35$J&.".:=TB*'=]_V;8K0W.ZW*11THJ\7<@<$45))]> X
MFG'JT-E<7,@6!"0#QK@<./\ F_9UNU_RY/Y#70GQ&DPG:7?3X/Y!_(.BEILG
M03UF.:7J;K?*0%)(9=D;:R=+3ON'-4,Z!XLUEJ=94D1):2CH) 2V/'-GN/N.
M^M+:[:&M=K." :2./Z97"@C\*X]21T*K/;(;;2[]\_\ $?+[*]7Y^XUZ,^O>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NL%5
M2TM=2U-#74U/64593S4M91U4,=12U5+41M#44U33S*\4]//$Y5T8%64D$$'W
ML$J0RFA&01U[K7J^>7_">#XQ?)1\YO[XYU5)\8^VL@]1D*G#8;&"JZ2W9D7$
MTY7*[)HO!4;*J*VK\2FKP;I201JS-C:B1M0DWEOW.W;:?#MMV4WEB, L:2J/
MD^=8'HV3_$.BB[VB"?4\/Z<Q\P,?F/\ -3YUZT[?F/\ RX/EO\&\P]+W]U7G
M:#;%35#&8GM/:A;<W56XI)3/#2_8;XHH%IJ.LK@CM%C\U%09C0HD^T/.J<MC
MYIV+F% VW7P,U*M _;(O^U/Q >9&H>A/0:N;.[M0WU*G3P#C*G[33'YTZ(Q&
MO@TQN5U*I.B)):@_<AC$8VC<2*68LR:$#>IM3 V74?XIC'V?ZO/_ (OIL%4&
MG%:5_P!7IUD9='EBC\C",M&&>9?&"$C1- !C ".%TE2JZ5 -E*^WT#$/Q]*?
MY>DC98GC3K"J-:(,OJUNE2T3/;6H>..%9I@BC3*P)4,"'?@KR?;%.UCG5Y_X
M./RZ<0 .BAL8_P!7EUEB#R)&TFD%8(R&F=38J&OIBC,(:%@Z'TMRNDL>6;W:
M(]E& I3S_P '3C*=8;S'2BP95I3/&E=/I=O)'2QK$95C ;U"$0S!E(568L]M
M%[D<L8VI(KIKI^7^7_5Y=)IAK#4P:5P.B4]Q9#*;Y[7S.!J:-\G68/"5/4VQ
ML;(\?VL=?5R9?(;?I3)5O+'+/63;KR-4YTI,LM=Z6,A37C!SS#&.<.8XT0F:
M2<H!Y>(VG12A:I*_8>ZGVC';Y)/W78O)( J(&8_T5K7TIG[>'5FG6F]MS[ I
MM[=Y8+";*H,-C9=D_#/>>U\E)@JW/PUE5N'/8K.[RH]O;JJ,IF=N_P 0P=3D
MV7)8BD@_N_6K$8:K"33X^"8HLRC7<2M"(PS*NE!2IC3030ZFJ6&HDXU$@"G;
MU0DH /$>0@,^MA6@8U K0*0 =('&E"?7JS#8>^<)MJ?;71>]N^J$]6?'C8.+
MWGTQN:F&1.'INQ-T4M6<KMNH&9..7;E9F<V:/"5\U#34L%-F*5Y_OIZ6-*J4
M?V<IEMYKF"T'U<I$4@!%2GDV#WZ15AFNDTXFG17+K$@5V[0U5&?V#'$F@../
M'@.JTOD!M+</:^8VI79:DW?NOLS=65@WMVU2YNAKGKL[0X"#<VW<SO3(TNXY
M:6DJ:B,U-955F/\ X=4U&1I<;!7N:@25LD0?WBWB4^)#$QC340%IIT*JO2@[
MN ;4315'"E#TK@DD4R([J$H K?BK4BI-:<=-/,FH].A+Z0V]FL-T53UTU;AM
MK]2_,#MJAPN5QT";?S&]=CQ;?VO24;U$\%)E*G>.!SS;BJHIL0LD$>-S$U5(
MK25]11RQ4E]I6WC:27P@+B,&1:DZ1K.%J68D 5K4EJ4J0#G4S2"B:VT :":+
M5J4S04 S3R )KZ84'2G9,F ^<?Q!?"M19K<$ORUHH<1NR%:>,YK;.<VS68#'
MPX\XV$;?K\=35F^,E))+CJN5*B69A(LKPR5$K',?A_N_PBU9%*C!.FE34@-W
M>7F*TI4#R4[/I%U&331JR//(\^/^KSZ*I\Y-^)V=\YN[Z^GK(Z_$["RN)Z?P
MTWD5UML2A2EW',)K>/5+O*LR,A_LECS>WL0>V]F8K9KKO621SIIDLOR\N'^#
MY=/\R3&2X6)5!""F?(\3_/H):1HRCZPZ1^)&8LQ$@5%&B+QLD[)$I'J92 ;?
M6][S-$42(Z: ?#49S2M IR37B?M],A0%I" RDBGI\_EU)E5 $4LC$7$$@E/)
M3]R0TYD)6ZHHN&TE2/J+&_M+"C%>T&A(-1Y5I7XGIGT'3A6/-*$TP",_['3-
M/KE 5&BD3A4+(@=9%T:WT$^0!B %(U<@FY L6IJM4*U232G$\?VDCT&/GU1&
M0X(-5SGAZ>?SZB&=!="2QUL\%KE&\6J,@$$K(LTXD*LVOD AC=;)>PLQ"$J"
M2-1!^6:<37@/]0=K(@HS#41Z?GC[.H:@WT"9-!58P@CM ]M)C!FC)9(]1)8#
MR(NAC9>;:T#4ND'Q*=H(J3\Z#"]4UO4]OG4Z?]6>I2^1")1I5"3=M):G#V\D
MANH*I.OK*,; :O40187+F&HXBH##\.K^DWYG_4.M( S:N'^KR'3C0>>1_P!N
M$M-*Q5%N\R:&&H,S4[FI:)I2#($-Y!^&L %%FQ+ZFCK7))]!YZN*I7C09QTW
M,0 =3KX8/GY9]?7Y]<Y\CYYS%%)&U)CE-+3%6AF60^,^>6010"%IZN5C(9H4
MC+Z@6743>K35D(:2JC'EQIY\:?E_AZ=:)M*UJ3GUZ&/J7IWM7O;=E-UYTOUU
MO7M#>F5/EI]M;/VYGMRY8TIEAIY*NMCQ]*8L=CX'E0SU4JQT]*&#221JM_;%
M[N%CMUN\U]=QQ0#B\K4_+RJ?D,^G3L4+SA!#$6?Y?ZJ4IZ];4_P0_P"$S.X,
M@<1V'\\]\/MRAF2"M'Q_ZKS"3YR4J&5*3?W95&\V)Q>D1Z9J/ I6R2Q2!ERE
M/*K+[B'?O=<1+):\N0ZFX&YE&/M2,Y/R+4_TIZ/;?9@=+W38XZ!_E/R^7[>M
MM;IWI'J/X^[&QG6O2G7FUNM-CX@7I-O[4Q<..II:AD2.;)9*=0U=FLS6"-34
M5U9+/65+C5+*[<^X:OMPO=SN'N[^Z>:X;B[FI^P>@^0P.CM$2-0D:!4'  4'
M0I>T?5^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NFK.X'![HPV3V[N;#8K<6W\W15&,S."SN.H\OA
MLOCJN-H:O'Y/%Y"&HHJ^BJHF*R12H\;J2""/=XY)(G22)RLBFJLIH0?4$9!Z
M\17!X=4&?+[_ (3G_"CO]LCN?H[^*?%+L2H%3-"=B4,.?ZHK*NH(<MD.K\E5
MT:8F %=*18'(X:EC5W+02DBTD;'[H[_M82&_TWEJ/]^XD'V2 &O^V#'Y]%5U
MM%K<=RC1)2@*\/E5>%/LIUK"?*/^1)_,'^,!R.3H^JCWWL6D&J3>70DE=OJ6
M:GT!_+D=@S4=)V+C?MZ61EJI(L14TL3(W^4O&/(TP['[C\K[J4C-W]+<'!CN
M>T5SP>I0_*I!/I7H.W6S7L 9T'B+ZKQ_,<?V=4[UM#7XVKGQ^0H<AC,EC))X
M*RDR5+)1Y"CG@J)164\]/4QPUJ3TDD)5T>,*&!4CT$*. R-&7C8,A4$,.!KZ
M'T_ET5OJ[-=0ZFA!XC_+_+J+$TI<6$$1;R<C4I1"GE"A7C#,TWIT:D8!V/I:
M_-(06-*@9/R\J^G^KTZ522#PP:8I3I7;>**\4C%&$=0E/.L@D 9 KVC9"\3>
M3PTZAC;2K@,+J!<VM!P+-5-6?R_V!_L](96 -%6GG^WY=$NR$-%#WAOF:MS<
MF.&-S^0WI0R05%-3K0[LP+;;VKM2*KH<F)HJZ897*M#XXE5B^136T<2S XO<
M]J%YKYCBDN0D37#RJ "3XB1J@!%<%N%<TK4^G0PL]9L;4Q0:F"A#4_A)))%0
M>'^3H[G2_P#='$U?7>\LEUIO3L>+K+8&ZNQ?ECU_GY\SMZ'-YC)X_%;KP^2%
M+E:W&56(JZ[ 8*@HY9Z/554.=J_-##21STP]AVW+".1E8H"@1&P"&)\ABE=0
M^=017-.G97(E,9%=3CU&*9SQ(%/V'SI7HU&QMJ=D8#:W4W0F>Q6Q=F8CY3[N
MS/=G5/<&[Z^FHJ'&8O';XKH:"LK,K5R4.!QNS!N3,5R;J:.N$%+/M>.I>>IA
MQT<;B&WO5CDI(VN2VBT,JU[LTT_L84-*Y.*&O21TUMJ6JZV\Z>6.->&/\'GT
M][W[#J=\X/N;L_/=E4V![UZ\\'277?7&W-LT>+S^^-J86BPE;,<544>%R&+R
MNZ\!L7%4$%4KO%4YZARY?[;(30U<TBQ9!=);AX"T4IU2.6KI)-#7((7AG@,#
M I5.J+!J6%E&D444(K6I^P9K7_#7A/AR^S>L]R;BW=L+8FZ-S[$ZYZQJ]N]H
MX_.5N5$.PNV-S5%/D)<Y@*.JR>"&/KZ[<&X:ZOV_--4U02DH_#7M4)++02J(
MF9HQ:3E-3M^D.%5H0 U*UR!Y@G@!Y]:E605= 0006R/+B%KQJ*\!7SZ)CENU
M*#X]?*7XQ[GS%?CLG@?C9OGJ7>T\^/22H@JJ;&[SGR>0P8CJ*MJ&486"I@II
M9H8(:LY(SK*H.B"G(.89#/$86D'BT!55TFNIE-217.:T)Q\/J.C#:]*W$;^$
M0@:C5\M-?+\N/GQZ*CL:KRN;&1W7GIYJK/[IS.8W1G*AM3-55^=KI\OE*FH\
MH*J?OZIRQ;]8/!OQ[EOE"P-KM5C&%"U%-(-6SQ'R^WTZ+-QN6ENIGXEF+$GA
MDX_XKH9(I0H1M ]+!5GB;QQNH8-Y2T)]'@X4*!=C?42"!['7:&-/@':--!45
MR%IP /$^?2)"Y4?QDD]W^K]@ZXM*(R\L[,;(@TL(D,TC.P93)XM'V[3 @*I#
M.Q!'XOX.$4*/Q8%//R-#P KQ/^QTT4<R94T' 9]>F>ID"LP4-,P 5EE9XF5%
M=K&H\C:HH4T%8[GCC4W!THI)0@/<0*:1IQC_ "#Y^?5J,6!7Y5)^WJ%)*0XB
ME02K$JR1R$$$J'*1D.!J1_6-*F[-]>-7M+'H+A:$H!@K@_8/3CQ\_P ^GY'8
MJ&IYT-3C[<=8D]0!UIX(XR5^BKJ=M*M$@#1S)R5(U/;^G-O:ED' *?#7X@#0
M?FV:_.E>FHVK4TS@CS/[/+KO4VM(T#JZ,DDHLA:0)/',H5"%4,\ZQ@D,H4CG
MD$^ZE>Y00=50W#_ IIY^9ZL) -51Y4X_X33^71]_BM_+B^;/R_19_C_\?-Z[
MGP%4"L'86:HTV-UDTOBF$TYW]NP8K:];-24L+-HHJNIR"5$L#I!("58EW+FG
M9=BBD%[N<:S#/A*=3DYIVK5LT^+ %?//3T.WSW933$WAG\1PM*^7K7Y5QY];
M,?PR_P"$M.U]M-C=V?-_NN;?612I6LJ>H^DILE@]H.P"2?;YSLC,T.-W1EZ:
MI:61)X,?B\/)&54Q5C \1)N?NE=L)(]GM=%?]&FRU?4("5K]I;[.A"FU1&GC
M&M/(8'[>/[*=;0?0GQIZ#^+NS(^O_C[U-LKJC:H\#UE%M/$0TE;FZFF1XH,C
MNC/3&HW!NS+QQ2,GWN3JJNK*'29"./<9[AN>X;K-]1N-Y)--Y%S6GR4<%'R
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MT\.$5]3D_P ^'Y=6D0PQ4\44$$4<$$$:0PPPHL<4,4:A(XHHT"I''&B@*H
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-U[KWOW7NO>_=>Z__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>jnj-20241229_g13.jpg
<TEXT>
begin 644 jnj-20241229_g13.jpg
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MSQMKMG&TDVC>'?%5M<W1C7[TJQ*^Z2,9&74%1GDU[+0 4444 %%%% !1110
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M:_6BOS>_9HT378?^#FG]IG6_[,GBM9_@+X;CMKV6V;R7D'V+@-P&(QR <\4
M?,/[/'Q?^%_Q1_:<_:X^-^N_\$</$7[4FK7O[1NK:=!XAB\!:/?6.F:+I5M;
M6%O%!=:F<RSMY,CFVMU8A?++%2ZBOTA_X)3?M ?L&?M)? #4_'_["'P0TKX;
M6=OXDGTWQSX%A\$VOA_4=%UJ!566WU"TME"B=5V#=E@5P-V595^;/V4O^"\?
MP?\ @!X;\4_ W_@L*N@? +XR>%?%6I+?Z#I?@K4[?2-=LC,7@U'3&5;C[2DH
M;DB1G=AO PXK+_X):>.9O@!X,_;3_P""Q/QA^&'BSPM\,/B3XZG\7^$?#UUH
M+QZM>:%IUO/G4Q9MM,;79E+*'*YV%RP0B0@'O?\ P6=_91\9_'+]DWXC?$WP
M[^V5\6OAY:^$OA-X@N;GPOX UJUM+#73%93SA;SS+:29E;9Y;".2/,;$=3FK
M'_! #_E#3^SW_P!B%'_Z/FKHOC=^T)X(_;(_X([?$3]H[X0:;K"Z'X[^ 'B'
M4M#M-7TXP7OERZ3<[4>(%L/GCY2RMP59@03A_P#!!#3M0TG_ (([? #3=5L9
MK:XA\"(LL%Q$4=#Y\W!4\@_6@#Z\HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ^)?CC_R5_Q)_P!A>;_T(URM=5\<?^2O^)/^PO-_
MZ$:Y6M%L9A1110 4444 %%%% !7TS^Q!_P B'J__ &%__:25\S5],_L0?\B'
MJ_\ V%__ &DE)[#6Y[71114%A1110 4444 %%%% !15?4]5L-'MOM>HS^7'N
M"[MI/)^@-9__  GWA/\ Z"W_ ) D_P#B: NC8HK'_P"$^\)_]!;_ ,@2?_$T
M?\)]X3_Z"W_D"3_XFG9BNC3N+*SNWCDNK2*5H7WQ-)&&*-ZC/0^]2,JNI1U!
M!&""."*R/^$^\)_]!;_R!)_\31_PGWA/_H+?^0)/_B:+,+HUT1(T$<:!5485
M0, #TI:Q_P#A/O"?_06_\@2?_$T?\)]X3_Z"W_D"3_XFBS"Z-BBL?_A/O"?_
M $%O_($G_P 33H?''A>XF2"+5,N[!5'D/R3P/X:+,=T:U%%%( HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /B7XX_\ )7_$G_87F_\ 0C7*UU7Q
MQ_Y*_P")/^PO-_Z$:Y6M%L9A1110 4444 %%%% !7TS^Q!_R(>K_ /87_P#:
M25\S5],_L0?\B'J__87_ /:24GL-;GM=%%%06%%%% !1110 4444 <_\2_\
MD7!_U\K_ "->?UZ!\2_^1<'_ %\K_(UY_5QV(>X4444Q!1110 4444 %6='_
M .0M:_\ 7RG_ *$*K59T?_D+6O\ U\I_Z$* 6YZO11169H%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!\2_''_DK_B3_L+S?^A&N5KJOCC_ ,E?
M\2?]A>;_ -"-<K6BV,PHHHH **** "BBB@ KZ9_8@_Y$/5_^PO\ ^TDKYFKZ
M9_8@_P"1#U?_ +"__M)*3V&MSVNBBBH+"BBB@ HHHH **** .?\ B7_R+@_Z
M^5_D:\_KT#XE_P#(N#_KY7^1KS^KCL0]PHHHIB"BBB@ HHHH *LZ/_R%K7_K
MY3_T(56JSH__ "%K7_KY3_T(4 MSU>BBBLS0**** "BBB@ HHHH *\(^,O[:
ME[\/?VR?A]^QC\/_ (+ZCXLUCQ1H=WXD\9:U'JT%G9^#_#L$@M_[0G,O-PTE
MRRQ)!'AB!(^0$PWN]?GM_P %L?AQ\"?#&O\ A[]HWQ5_P51A_96\4:MX/U+P
M-J&LRZ-::JWBGP_<21SW%G':3,)%EBDPZ74'SPF<_P!]: +O['?_  6J^(W[
M3GQ6^']]XO\ V'M3\&?!?XU^(M6T3X+?%6?QG;7<NLW=C'=3*+S35B66Q6YB
MLKIHB7?F(#YE825]^5^4W[&7Q'_X)8?%;]KC]G'X%?LX_P#!3;2O%OA7X)^#
MVL/A%\&+/0)8[C4?$<>G7D%UK5Y>M$OGN+%YF6':BK(\K@C(0_JS0 4444 %
M%%% !1110!\2_''_ )*_XD_["\W_ *$:Y6NJ^./_ "5_Q)_V%YO_ $(URM:+
M8S"BBB@ HHHH **** "OIG]B#_D0]7_["_\ [22OF:OIG]B#_D0]7_["_P#[
M22D]AK<]KHHHJ"PHHHH **** "BBB@#G_B7_ ,BX/^OE?Y&O/Z] ^)?_ "+@
M_P"OE?Y&O/ZN.Q#W"BBBF(**** "BBB@ JSH_P#R%K7_ *^4_P#0A5:K.C_\
MA:U_Z^4_]"% +<]7HHHK,T"BBB@ HHHH **** "OSA_X*=:K;_ C_@IM\,?V
MJ=6_X)M_%?\ :*TZ'X2:GX?N+;P1\.TURV\-SOJ,-Q%>PF1MBW;*LT3J0C>5
M(K+)PT;_ */5\+_\%!/&W[6_[1'[>G@+_@F;^S/^TY<?!32]3^&.I>/O'7CW
M1]+ANM8O[2WOX+&+3-/,WRP/YDIEDE'S!-N#@%9 !?V2/^"@G@WXS_M#^'/A
MGI?_  19_:&^%<^J2W"Q^/O&OP5L]*TO2MEM+(6GNHYF:(.$,2D [GE5?XJ^
MYZ_.KP'IG[9O_!,7]N'X)? OXC?MY^)OCS\-?CKJNJ^'WTOXCZ?;'7?#VI6F
MFRWT5];7<(#W%NPA,4L<@VQAU89+<?HK0 4444 %%%% !1110!\2_''_ )*_
MXD_["\W_ *$:Y6NJ^./_ "5_Q)_V%YO_ $(URM:+8S"BBB@ HHHH **** "O
MIG]B#_D0]7_["_\ [22OF:OIG]B#_D0]7_["_P#[22D]AK<]KHHHJ"PHHHH
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M1#U?_L+_ /M)*^9J^F?V(/\ D0]7_P"PO_[22D]AK<]KHHHJ"PHHHH ****
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M_$;Z;H^C:1%=):)DQ@R3S23OM"J<H #M8%B@!S?P/_X(JZA\,OVG_A[^T_\
M%7_@I)\?_BQ>_#74+Z]\.:!\1O$5K>V$<]U83V4C[1 K*?+G;E6!RHSQD5]Q
MU\>?LR_$W_@N+K_QRT'2/VL_V8/@+H'P]FDG'B/5_!_C6_N]2MU%O(8C#%*H
M1R9A$K9Z*S'J!7V'0 4444 %%%% !1110!\2_''_ )*_XD_["\W_ *$:Y6NJ
M^./_ "5_Q)_V%YO_ $(URM:+8S"BBB@ HHHH **** "OIG]B#_D0]7_["_\
M[22OF:OIG]B#_D0]7_["_P#[22D]AK<]KHHHJ"PHHHH **** "BBB@#G_B7_
M ,BX/^OE?Y&O/Z] ^)?_ "+@_P"OE?Y&O/ZN.Q#W"BBBF(**** "BBB@ JSH
M_P#R%K7_ *^4_P#0A5:K.C_\A:U_Z^4_]"% +<]7HHHK,T"BBB@ HHHH ***
M* ,_Q;XL\-> _"NI^.?&FNVNEZ/HNGS7^K:G>S".&TMH8S)+-(QX5$168D\
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M59T?_D+6O_7RG_H0H!;GJ]%%%9F@4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'Q+\<?^2O^)/\ L+S?^A&N5KJOCC_R5_Q)_P!A>;_T(URM:+8S
M"BBB@ HHHH **** "OIG]B#_ )$/5_\ L+_^TDKYFKZ9_8@_Y$/5_P#L+_\
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M_P"AM\=_^%E<_P"-'_#O?X)_]#;X[_\ "RN?\:]THH \+_X=[_!/_H;?'?\
MX65S_C1_P[W^"?\ T-OCO_PLKG_&O=** /"_^'>_P3_Z&WQW_P"%E<_XT?\
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MO=** //O@S^S7X"^!FIWNK>$-9\0W4E_ L4RZUKDMVJJ&R"H<_*<]Q7H-%%
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MOX;:UX>^)WCBQ4&TO]<U([8?#RS#B>6U5FN9%4LL+OL;:Y +?^#?KR?B;/\
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MO+N R=A^6OT0HH **** "BBB@ HHHH **** "BBB@ H.<<444 ?E5I'['_\
MP7PU;]JF;]L+XY_#K]E?XA^*],FD3X<V7B'QWX@72_ MJX 9=-M(]/"+<N!^
M\O9?,N& "AT0;*^A?VG_ -B']K+_ (*.?L ?\*I_:LU;P%\/?C1H/C&U\4^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/%%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>jnj-20241229_g14.jpg
<TEXT>
begin 644 jnj-20241229_g14.jpg
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M)M91')J%W--';6ML'(.P23S1*7PVQ2S;3MP0#V>BOS.\>?M'_P#!P/\  O\
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M1110 4444 %%%% !1110 4444 %%%% 'Q+\<?^2O^)/^PO-_Z$:Y6NJ^./\
MR5_Q)_V%YO\ T(URM:+8S"BBB@ HHHH **** "OIG]B#_D0]7_["_P#[22OF
M:OIG]B#_ )$/5_\ L+_^TDI/8:W/:Z***@L**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5&2P!_:R@ HHHH **** "BBB@#XE^./_ "5_Q)_V%YO_ $(URM=5\<?^2O\
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MH ^)?CC_ ,E?\2?]A>;_ -"-<K75?''_ )*_XD_["\W_ *$:Y6M%L9A1110
M4444 %%%% !7TS^Q!_R(>K_]A?\ ]I)7S-7TS^Q!_P B'J__ &%__:24GL-;
MGM=%%%06%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %?GM_P %XM8^%\NK?L_?#G]J7]J_4?A7\#O$_C[4K?XGW&A^
M*CI%YJACTR233H'FC_>_8_M0"S[ 0OFQ,VP+YL?Z$U^;GQD^*/\ P6-^-K1Z
M+\7/^" WP6\<:=IMW(^E+XL^,VCWR1$_+YJ)<6SB-F4#..>U 'F7P!_9K_X-
MLM&^._@G6/@U_P %"?[7\86GB[39O"FE?\-&7EY]MU);J-K6#R&N")]\P1?+
M((?=MP<U^N%?F/\ !3P1^WC:_&7PE<^*?^#<;]G'P=I<?B>P;4O%VC^.?#\M
MWH< N(S)?0)%9J[RPKF5%0ABR  @X-?IQ0 4444 %%%% !1110!\2_''_DK_
M (D_["\W_H1KE:ZKXX_\E?\ $G_87F_]"-<K6BV,PHHHH **** "BBB@ KZ9
M_8@_Y$/5_P#L+_\ M)*^9J^F?V(/^1#U?_L+_P#M)*3V&MSVNBBBH+"BBB@
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M-<K75?''_DK_ (D_["\W_H1KE:T6QF%%%% !1110 4444 %?3/[$'_(AZO\
M]A?_ -I)7S-7TS^Q!_R(>K_]A?\ ]I)2>PUN>UT445!84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'Q+\<?^2O^)/\ L+S?^A&N5KJOCC_R5_Q)_P!A>;_T(URM
M:+8S"BBB@ HHHH **** "OIG]B#_ )$/5_\ L+_^TDKYFKZ9_8@_Y$/5_P#L
M+_\ M)*3V&MSVNBBBH+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^)?CC_ ,E?
M\2?]A>;_ -"-<K75?''_ )*_XD_["\W_ *$:Y6M%L9A1110 4444 %%%% !7
MTS^Q!_R(>K_]A?\ ]I)7S-7TS^Q!_P B'J__ &%__:24GL-;GM=%%%06%%%%
M !1110 4444 %%%% !117PG^T]^WI^V;\8_V\]5_X)I_\$Q]$\"6GB+P-X9M
M=<^+WQ.^(]O<W6G^'$NP&M-/M[6V=&GO)8V27+ML",>,JQ4 ^[**^&/V,OV_
MOVNO"G[=>H?\$O?^"EWACP4GQ N_!Y\5?#3X@_#R.XATGQ=IB2-'/$UO<,SV
M]Y$4=F4':5CD("@(TOW-))'#&TLLBJBJ2S,<  =230 M%?F+^R)^UY_P<$?M
M^? 73/VM?V<]._8ZT;P'XMU+5#X1L?&VE>*QJGV"VU"XM(I+C[-<M%N<0;P5
M(!# [5SM'Z _LVK^THGP4T-?VOIO TGQ&"3_ /"2/\-HKQ-$+>?)Y/V87K-.
M!Y'D[MY/[S?CY<4 =S1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+/\ H+?^0(__ (FGRL7,CTBBO-_^$^\6?]!;_P @1_\ Q-'_  GWBS_H+?\
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MN?\ &C_AWO\ !/\ Z&WQW_X65S_C7NE% 'A?_#O?X)_]#;X[_P#"RN?\:/\
MAWO\$_\ H;?'?_A97/\ C7NE% 'A?_#O?X)_]#;X[_\ "RN?\:/^'>_P3_Z&
MWQW_ .%E<_XU[I10!X7_ ,.]_@G_ -#;X[_\+*Y_QH_X=[_!/_H;?'?_ (65
MS_C7NE% 'A?_  [W^"?_ $-OCO\ \+*Y_P :/^'>_P $_P#H;?'?_A97/^->
MZ44 >%_\.]_@G_T-OCO_ ,+*Y_QH_P"'>_P3_P"AM\=_^%E<_P"->Z44 >%_
M\.]_@G_T-OCO_P +*Y_QH_X=[_!/_H;?'?\ X65S_C7NE% 'A?\ P[W^"?\
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M\8OV?X4N_"_[-?PVUKP]\3O'%BH-I?ZYJ1VP^'EF'$\MJK-<R*I987?8VUR
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MX+J_\$KO GCG4? VO_M3PM_8^J_V9K/B+3O"FK7FA:?>;PA@FU:WM'LHV#$
MEI@JG[Q%>._\$W/!FF_M>?M__M;?M^?#NTN[#X-_$_3M'\#^$==T]WM3XPET
MVUDMK_6;=EP3$DC&""Y7/F .RD%2*H_\% -"\8?\$Z?^"<^N?\$\/V)O^"=G
MB/QI\,)OA/JNG7?CE]7AGT_PW'?-=I=3WMLB27U\\*R-=,(879PP&0<D 'Z0
M:3JVE:_I5KKNA:G;WMC>VZ3V=Y:3+)%/$ZADD1U)#*RD$,"00015BO#O^"9W
MA[X:^$?^">GP5\)?![XLQ>._#&D_#/1[+1?&$,;1IJT,5I'&)Q&_S0@E3^Z;
MYH\;&Y4U[C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5\A_\%:/A+_P5-^/'@/0OA/_ ,$Z_&_@+PSH^IR3?\+'U;Q#XCOM+U:>U!CV
M6=A<VMK.;995,PDG4+,HV>4R$EJ^O** /B#]@KX5?\%4OV;[CP;\!=>_9>_9
M8\#?!O1B\.HVGPW\5Z[/J-O$4=O,B2ZM52>9YMK223.6?<[LS,<GG=-_9$_X
M*,_\$^?VEOB[X^_X)X^"_AI\1?AI\;?%TOC#4O!/CKQ3<Z)>>%_$MPBI>W4$
MT5O-'<VLY1)&C(5UVJBX"EG_ $!HH ^*/V7_ -AO]LO]CW]E7XQ?$'P1XS^'
MWBS]J;XR^*+GQ7K^MZVMW;^&+?4Y2D4-E%L1K@V5I;AA%N7>[9W;0V%\+_91
M_9(_X+O?LN:[K_Q4G^%'[+/CGXG>,F5O&OQ3\9?$+Q#/J^JJIRELACT]([.S
MCX$=I;I'"@4?*6RQ_4NB@#YG^*?_  2J_8>_; U73/C5^V[^Q]X!\4_$JZ\/
M6-MXDU,)/-$L\<(#PPNS(S0HY<(64,5P2 :\'_8J_P"""7[.7[+?_!2#XR?M
M6O\ L^?#^V\'W=YX3N_V?['29;AKSPI/::;+#JLAC=52$S73)(NUY=P&3L/R
MU^B%% !1110 4444 %%%% !1110 4444 %!SCBBB@#\JM(_8_P#^"^&K?M4S
M?MA?'/X=?LK_ !#\5Z9-(GPYLO$/COQ NE^!;5P RZ;:1Z>$6Y<#]Y>R^9<,
M %#H@V5]"_M/_L0_M9?\%'/V /\ A5/[5FK> OA[\:-!\8VOBGP!X@^'5W>:
MCI6C:MI\OF6%P3=QQRMN5I8I!M^5925W$ '[0HH _.SXK?LE_P#!5+_@I7!X
M*_9[_P""@O@KX0> /A1X;\5:=KOQ&?X?^*;W5KSQ[+82":&S@AGMHEL+*295
M>3S'>4!$"G@YT/\ @JW^RI_P5G_:^^+6F_#WX'CX/7_[/]G:13:_X%\5>,M7
MTFZ\7WG5H-3EL;5W:P0XQ;12HLO/G%UP@_0.B@#Y/_9D\%_\%-_$VAZ[\"_V
MO?AS\#_AS\/9_ %SH_AN]^ 7BG5DU32;EEC@@%NL]M#':QQ0-,R/&0T<D<.T
M8R1XMX(^%/\ P7M^#?[,$W["VGZ%\&/B&\&C7>A:'^T#XJ^(FIQ79L9 Z175
M_IC6<TL]XD3\[9V1F099N2WZ,T4 >._\$_?V1=&_8,_8Q^'?[(FA>)Y=:B\#
M>'DL9]8FA\LWMPSO-/,$R?+5II)&5,G:I"Y.,GV*BB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
(* "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>jnj-20241229_g15.jpg
<TEXT>
begin 644 jnj-20241229_g15.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@!
M; %J P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP3X9L=#T=)F!D-O:P)"C.0!N<A 6;NQ)[UUU% !1110 4444 %%%% !1110
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M-:?]>L?_ *"*F142S1114E!1110 4444 %%%% '(R_%3RY6C_L+.UB,_:O\
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MHH **** "BBB@#R.Z_X^9/\ KH?YU'4EU_Q\R?\ 70_SJ.M#,**** "BBB@
MHHHH *]=M?\ CVC_ .N8_E7D5>NVO_'M'_US'\JF141]%%%24%%%% !1110
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MY#-W_P!?4G_H1JK5K6O^0S=_]?4G_H1JK6AF%%%% !1110 4444 %??>B_\
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M56K6M?\ (9N_^OJ3_P!"-5:T,PHHHH **** "BBB@ K[[T7_ ) UI_UZQ_\
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M** "BBB@ HHHH \CNO\ CYD_ZZ'^=1U)=?\ 'S)_UT/\ZCK0S"BBB@ HHHH
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MZ$:JU:UK_D,W?_7U)_Z$:JUH9A1110 4444 %%%% !7WWHO_ "!K3_KUC_\
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M/_H;?'?_ (65S_C1_P .]_@G_P!#;X[_ /"RN?\ &O=** /"_P#AWO\ !/\
MZ&WQW_X65S_C1_P[W^"?_0V^._\ PLKG_&O=** /"_\ AWO\$_\ H;?'?_A9
M7/\ C1_P[W^"?_0V^.__  LKG_&O=** /"_^'>_P3_Z&WQW_ .%E<_XT?\.]
M_@G_ -#;X[_\+*Y_QKW2B@#PO_AWO\$_^AM\=_\ A97/^-'_  [W^"?_ $-O
MCO\ \+*Y_P :]THH \+_ .'>_P $_P#H;?'?_A97/^-'_#O?X)_]#;X[_P#"
MRN?\:]THH \+_P"'>_P3_P"AM\=_^%E<_P"-'_#O?X)_]#;X[_\ "RN?\:]T
MHH \+_X=[_!/_H;?'?\ X65S_C1_P[W^"?\ T-OCO_PLKG_&O=** /"_^'>_
MP3_Z&WQW_P"%E<_XT?\ #O?X)_\ 0V^._P#PLKG_ !KW2B@#PO\ X=[_  3_
M .AM\=_^%E<_XT?\.]_@G_T-OCO_ ,+*Y_QKW2B@#PO_ (=[_!/_ *&WQW_X
M65S_ (UV?P9_9K\!? S4[W5O"&L^(;J2_@6*9=:UR6[55#9!4.?E.>XKT&B@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\,_:U_P""DO[%O[#VN:1X
M1_:/^,Z:5K^OV[W&C>&-(T.^UC5;J!"0TZV>GP3SB(%6'FL@3*L-V0<>YUXA
M9_LI_LT? #]IWXF?\%)/$NOSV/B3Q/X0LM/\4:]XCU>,:?HND:='N(@WJ/LD
M3;!+-ERK,@;@YR =5^R[^UK^SC^VE\+(OC3^R]\6=,\8>&Y;J2U>^T\21O;7
M*8+V\\,JI+;S*&4F*5$<!E.,,"?#_%/_  71_P""5?@SXIW7PE\0_M::=%=Z
M?K8T?4M<BT'4I="LM0W;?LTVKQVQL(G!X.Z<!2"&(/%?&'PJ\1_$KP5^P;_P
M44_X*H?"+1=1\*>&?C.VJ:S\'(GMGM)Y;*TTR6T7Q&D1 :+[7+*URA8!F$2N
M00RD_6_['/[*_P #[W_@@_X#_9MNO".FOX4\2?LZ6;:S;M;)Y=S/?:2MS<W;
M#'^L:XF>??U#D,"" : /I?X\?M(? C]F+X1:A\>_C]\5-'\*^#]+A22[U_5+
MH+!AR!&J8R97<D!$0,SD@*"37F'[*O\ P53_ &#OVT?B%>?"/]G[XY_;O%EE
MI_V]_#&O>&]2T34)K/./M,-OJ5O!)/%R"7C#!=PW8S7RM_P2)_9O\"?\%(O^
M".W['GQ"_:INM;U2Z^%6JKKGAVR74-MM=76CZA>6%@UW&ZL+A$@A3 ..IYY-
M;_Q[73OVSO\ @N]\![/]GZ%+V+]EK2?$NH_&7QI8*##83ZM8K:V.@&9>'N6*
MO-)#D^7&S'AMPH ^^?'GCOP;\+O!.K_$GXB>);/1M T'39M0UG5]0G$<%G:P
MH9)99&/"JJJ23Z"N=_9P_:1^"/[77P8T;]H7]G/Q];^*/!OB#[1_8^NVMO-%
M'<^1<2VTN%F1'&V:&5.5'*$C(P3\>?&7Q%I'_!6O]JZ^_9:LM?ME_9N^#/B*
M(_%V^-VJQ?$'Q3;LLL7AR,YQ)86;B.:\/(DF$<&,*S56_P"#6^^LI?\ @AK\
M$K&*\B:>(^)C)"L@+H#XFU7!(ZB@#]!**** "BBB@ HHHH **** "BBB@ KQ
M+]K;_@HO^QO^PY>Z-H?[2?QDCT?6?$222:#X:TO1KW5M5U!$SODCLK"&:<Q@
M@@R% @((+#!KVVO%4_9'_9R^%/[6?C/_ (*1^)-7N;;Q9JG@.#0M9UG7]6C&
MG:-HUH?/?R=Z@6J%E\V5B^TE2QQR: -_]E;]L/\ 9H_;;^&C?%W]EKXNZ=XO
MT&*^DLKNXLXY89K*Z3!>WN+>=$FMI0&4^7*B-AE.,$&O&/B!_P %RO\ @EE\
M+_BKJ'PA\9?M76$%_HVL#2=<U:V\/ZE<Z+I5^6V_9KK58;9K*WD#?*P>8;""
M'VFOD+X#>+/'NC_ C_@I)_P5Z^!^DWOA[P=\4M N=2^"[&V:V:_70M O+=O$
M<49 98[NY<SJ[!6<1%B,%2?J/_@EA^RU\$M9_P""''PA^ &I^$].F\,^/?@7
MI]UXIM9+=62\GU?3UN;V63(^9S+<R$L>00.>!@ ^F?C)^T1\#?V>_@[J'[0/
MQJ^*NB>'/!6EV:75YXEU*^5;58G($95QGS"Y9514W,Y90H)(!\G_ &6_^"L7
M[ ?[97Q*D^#7P$^/'VSQ8-..H6_AS7_#.IZ)>WMF.?M%M%J5M US'CYBT0;
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G HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>jnj-20241229_g16.jpg
<TEXT>
begin 644 jnj-20241229_g16.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]H_P5XYB6$22+X6\2VM[+$.X>&)S+&P[AT4\UZ8LL3NT:2 LN-R@\C/3([4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBL,@X901R!5_1]'TCP]I%KH&@:7;6-A8VR6]E96<"Q0V\**%2-$4!455  4
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M"^(#Z3N_LN3QGX2L]2:T#'+"-KB-R@/<# ..: /FW_@@WX.^#?A']DCQE+\
M_C[>?$CPQJ_QK\3ZA:^(V\&C0]/,[SQK<QZ9 LLD;Z?]H25XI8VV'S&4 %#7
MVS6=X3\(^%/ /AFQ\%^!?#&G:+HVF6RV^FZ3I-E';6UI"HPL<448"1H!P%4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0!SWQ4UX^'O M]=QOMEEC\B'UW/\N1]!D_A7SY7J?[1VM$#3O#T;]=UQ*O\
MXZO_ +/7EE !1110 4444 %%%% !1110 4444 %%%=A\&_ Z^+?$?VR_AW65
MCB28$<2/_"GZ9/L,=Z .V^"GPZ'A_3AXHU>#_3;N/]PC#F&(_P F;OZ#CUKO
MJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /QA_X.K_
M /@B?:_M*_"R^_X*0?LU^$@?B'X*TP-\0M)L(/G\1:+"G_'V%4?/<VB#)/5[
M=2N288D/\T-?W]R1QRQM%*@96!#*PR"#V-?R+?\ !R7_ ,$I(?\ @FE^W%/X
MB^%GATVGPI^*/GZSX)2%/W.F7 8?;=+' P(9)%>,=!#/$N6*,: /SMHHHH *
M*** "BBB@ HHHH **** "BBB@#^US_@C'^ULW[;G_!,CX0?M 7^IM=ZO>>$H
M=.\2S.X+-JEB6LKMF'52\MNTH!_AE4\@U]05^&G_  9+_M,GQ%\ _B_^R/JU
M^&F\+>)[3Q-H\4K_ #&VOX?L]PJ?[*2V4+$<#=<YZDU^Y= !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 444C,J*7<X &23VH \&^,^JG5?B%>A7
MREL%@3VVCD?]]%JY6K.L7[:KJUUJ;DYN;AY3G_:8G^M5J "BBB@ HHHH ***
M* "BBB@ HHHH 559F"JI))P !UKZ&^'/A2/P?X4MM+,8$[+YMV?61AR/PX'X
M5Y'\&O#@\0^.;=IH]T%D#<2Y'!*_='_?1'X U[S0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %?'?\ P76_X)UV7_!2S_@G5XR^
M#.C:*ESXUT* ^(OAU,%'F+J]JCLMNI["XB,ML<\#SPW5!C[$HH _@%FAFMYG
MM[B)HY$8JZ.N"I'!!!Z&FU][_P#!RC^Q#!^Q'_P5=\=:9X9T86?A;XB!/&GA
MA(U C1+UW^U1*!PH2]CNE5!]V/R^,$5\$4 %%%% !1110 4444 %%%% !111
M0!^F?_!I5\?G^#7_  6#\/\ @>XN_+L_B5X0U?P[,DCXC:5(1J,&>VXR6"HI
MZYDQW-?UDU_#/_P3M^-$O[.W[>OP:^."WIMXO#'Q-T2_O9-V ;5+V+ST)]&B
M,BGV8U_<M"8_+"Q,2J_+R?3CO]* '52\2>)/#W@WP[?^+_%NN6FF:5I5E+>:
MGJ5_<+#!:6\2%Y)I)&(5$5%+,Q(  )-7:^>?^"LG[.?Q2_:V_P"";WQC_9S^
M"=RJ>*_%7@JXMM#B>X$(NYE*RBU+L0J"8(8<L0H\WYB!DT ?F%^W#_P=N_ [
MPG^VO\*=!_9!^)&J:U\(-'UFZC^-5_'X)1GU6VWPB'^S6NF24[0)\MB,'*E2
MU?K#^Q%^WQ^RK_P42^#B?'+]DSXI6_B714N3:ZC$8'M[O3;H*&-O<V\H#Q/@
M@C(VL"&0LI!/\J'PH_:;L_V,_C%^R]\'?VY?V(]6\)67[/GCC7[[QW;WGAD#
M4?%EGJ5U#(XGL[Q8DF>)8S"&:0H\(B48V_-^]_\ P;T_!'_@D1X4\#?$/]HC
M_@E7\7_%FL6/BZ_@B\<:%XLU()+H4L33S6]NUGY,7DJBSS+')\X9 P$C[6-
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M17V3\)O^#?'_ (+.?&G3UU/P?_P3\\;6<;=%\6-::!)^,>IS6[C\17NGA/\
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MX2Z/813_ !R_X*[>"=-NUP;JS\$_#V[UV/W5)OM,)/LQC_"OL@DDY)R3U-%
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M3/\ K+N)?U)_I7:5PO[0C;? T0]=1C'_ (X] 'BM%%% !1110 4444 %%%%
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MOY\2O^":VGZQ)/\ %#PS\;+O]FWP^+A\2ZB-0U4+:N .?+?2;F14('S"'V-
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M+\,9O'_QX?QIX*\7>'=,@+:);S+*C:=+??9YC!"QE"R PB+]VCED* K^H/\
MP= :CX-_93_X((^"OV7?A5XKO]8T'6O$7ACPGH5[?:BMY<7VF65O)>PRO,H
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M_NZJ.E>*/#.NZA?Z3HGB*QO+K2IU@U2VM+M))+.4J'"2JI)C8J0P#8."#T-
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M1^S#^S5I_B[Q+\3/BMI]CI=EX(G\)7"R:5<-=02MYLI4Q3.GED1BW:4O)LX
M)8;7[1__  1A_:;\7?\ !K%\,_V2D\&WEY\6?A=<_P#">)X2A0O=R2SW>HW%
MQIJJ,EIX[75)1Y2Y+RVX1<EA7["^$OV<?V>? 'B=O&W@3X#^#-$UEMV[5](\
M+VEM='=][,L<8?GOSS79T ?A;^S)_P '6O[)?P*_X)7:!\(/''AGQA#\>? '
MP\B\)VOA3^P6\F]U.SM19VUTUR6"QQDQQR2JVV1&\Q5C?"ENP_X(#?!?Q?\
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M;-!U31M+\:_$"?6O!.D:M$\<AL#9VT)O%C?!2.:2)BN0-RQB095U9OU=HHH
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MZQI?@CXA?L7#P/9>.7T]_L*ZC<7]PKPK+]UI4CE$A0'.!F@"E=?\%R?CE:_
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M 'S-KVG'2-<O-*(Q]FNI(O\ OEB/Z54KK?C;I/\ 9?Q!NI%7"7<:3I^(P?\
MQY37)4 %%%% !1110 4444 %%%% !1110!U?P9\2+X=\<0).^V&]'V:4D\ L
M1M/_ 'T /H37O-?+BLR,'1B"#D$'D&OH;X<^+$\8^%+?56<&=1Y5VH[2+U/X
M\'\: -VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOZ1/<SW6I_8TA$@AGDGGD,:,P"KL7SAM)?['HH **** "BBB@ HHHH ****
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MAVZ']JZA$1/(C<VL)X)]F;H/09/'%?,= !1110 4444 %%%% !1110 4444
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M??#8WNIW'Q*U2W_=6N;?3=P^](1\[CZ*=O\ P(^E?0M !1110 4444 %%%%
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M_!([P/\ L@W_ ("CT#XJIX?L_B#XZ>'3M"T^/2+N2W$]D50A8F2,J&&W; [
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M"/Q[T 8-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_%'Q!\4_B5J.D++H=SX<BE.C-:WUO=R>4T$LCSN7@$0945?+D=G*8V']@?\
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M'3KFSUJ.UB$T\#RZ?=W'V.Z6)@Y@G"' (SN*JP!]545^<O["O[:7[ W[#?\
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M7*KS'[.!T/OT/Z4 <K1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ]OQ.:T_ 'PZ\+_#71%T/PS8[%.#/</S).W]YV[_ $Z#L!6[0 4444 %%%%
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MX(_86^$^E2SZS;:L\EAX"L(F%[;N9+>=2L7R/$[%D*XV$DK@FO=** "BBB@
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L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>jnj-20241229_g17.jpg
<TEXT>
begin 644 jnj-20241229_g17.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\)O"/C'PEJF@66K>#UU_PQ;74,5G<0130/%'-&PBS&8B  ,8'H*_#K_@X/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7EUJ%W)?7L[2S3.7ED<\LQ.2:BH **** "BBB@ HHHH **** "BBB@ HHHH
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M7]D>#QI,+XEU&79P>?+7!8_^@C_@5>)T %%%% !1110 4444 %%%% !1110
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MJ&;+?99<R1$_1O-0>T8H ^DJ*** "BBB@ HHHH **** "BBB@ HHHH ****
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MN6P"LX',1/99 -I[ [6_A%?EC=6MS8W4EE>V[PS0R%)HI%*LC X*D'H0>,4
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MMYFH:=!_:>E87+>? "VT>[IYB?\  Z /ROHHHH **** "BBB@ HHHH ****
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M -"K]4*_)W]D.9H/VG? KIU/B2V7\"V#_.OUBH **** "BBB@ HHHH ****
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M&C #CA7EGC(/UQ$P_$U]^T %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ/Q'>@#Z#HIEM<P7EM'=VT@>.5 \;CHRD9!I] !1110 4444 %%%% !1110
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M1?%&C6WB'PYJMO?6-Y$);6[M90\<J'HRL."*MT %%%% !1110 4444 %%%%
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M[)#[(S4 >LT4BLKJ'1@01D$'K2T %%%% !1110 444V22.&-III%1$4EF8X
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MC1Q':VUO([R;=K-.D:%G^4_T-6MM;V5M'9VD0CBAC"1(HX50, #\* )****
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M#'Q([]ED:W4?F'/\JY_7?^"O-J(F3PS\#9&<_=EOM=  ^JI"<_\ ?0KXGHH
M^E/&'_!4S]H[7XGMO#=AH&A*?N36E@TTR_C,[(?^^*\9^('Q[^,_Q3#1_$#X
MFZSJ<+G)M)[UA!GU$2X0?@M<C10 4444 %%%% !1110 4444 %%%% !1110
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M)'P[\#ZM<1&*;5_#/A&TM+MXSUC,Z1B38?[N['M7KM% &7XU\$>"_B3X4O\
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M(U"(H55&  , "H=+TS3M$TV#1]'L8;6TM85BMK:WC")%&HPJJHX     J>@
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M  !T ':GT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ,N+>WN[=[6Z@26*5"DD<BAE92,$$'@@CM7PG^VQ_P3[N
MO!S7?Q9^!.D23Z1EI=5\/VZEGL>YDA'5HO5.J=1E?N_=]% 'XKT5]]?MA?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPR;6)]DWUX?XD\)>*O!NHG2/%_AK4-*NUZVVHV;P2#_@+@&@#/HHHH ****
M"BBB@ HHHH **** "BBB@ HJWHN@:[XEOTTKP[HMW?W4GW+:RMFED;Z*H)->
MU?#/_@G5^TW\1/+NK_PK#X<LWP?M'B"?RGQW_<J&D!]F5?K0!X56MX-\!^-?
MB)K*>'_ GA6_U>]?I;Z?:M*P']X[1\H]S@"ON_X3_P#!*_X.^%?*U#XH>(;[
MQ/=+@M:QDVEIGTVH3(WUW@'TKZ-\'>!/!GP]T=/#_@7PM8:19)TMM/M5B4GU
M.T?,?4G)- 'Q/\#_ /@E7XPUWR=:^.OB5=%MCACH^E.LUTP]'EYCC/\ N^9^
M%?87PG^!OPK^"&C?V)\,_!UKIR,H%Q<JN^>XQWDE;+/ZX)P.P%=910 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
9HHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>jnj-20241229_g18.jpg
<TEXT>
begin 644 jnj-20241229_g18.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG>)_%,=U)X9\.7VL00W^KI;(LERUK;NPDN!$C*TAC5MBL"V 17YV_P#!*'X
M?\$^/C!^T@/V_O\ @G3^UGH-H=1^#&G>%?BE\+_ EI#;Q3:F%W+JUW Q5[>X
M!555C  S12-N8R29\IOOV6_&'[+O_!R5^RQHWB_]K[XJ_%R36/AMXON8KSXH
M:S;73Z;MTZ\0QVR6UO!'$KX!;Y26*C)X% 'ZB_M$_M9_LQ_LC^%[?QI^T]\?
M/"7@+3+R8PV-UXIUV&S^UR  E(5D8-,P!!*H&(')&*O? C]HWX!?M0^!D^)?
M[.7QF\,^.= :8PG5O"VM0WL"2@ M$[1,VR0 C*-AAD9%?D1X;_:\_95\8_\
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M<72JW[PD0N%P&H _6965U#HP((R"#P12TBJJJ%50 !@ #I2T %%%% !1110
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M-?PQ_9XU3XAV_B3Q?\5/',?A;1=$\(:E8WL^G7#9!N;Z,W"/!;HX",P5WWN
M$/. #Z*HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L7QO\ $+P?
M\.--BU?QGJ_V.WFG$,4GV>23<^"V,1JQ'"GGIQ6U7C'[;O\ R3C2_P#L-K_Z
M)EH$]$=-_P -3_ ?_H>__*7=?_&J/^&I_@/_ -#W_P"4NZ_^-5\>45?*B>9G
MV'_PU/\  ?\ Z'O_ ,I=U_\ &J/^&I_@/_T/?_E+NO\ XU7QY11RH.9GV'_P
MU/\  ?\ Z'O_ ,I=U_\ &J/^&I_@/_T/?_E+NO\ XU7QY11RH.9GV'_PU/\
M ?\ Z'O_ ,I=U_\ &J/^&I_@/_T/?_E+NO\ XU7QY11RH.9GV'_PU/\  ?\
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M?;U%%%9F@4444 %%%% !1110 51\3?\ (NWW_7J__H)J]5'Q-_R+M]_UZO\
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MH%%%% !1110 4444 %4?$W_(NWW_ %ZO_P"@FKU4?$W_ "+M]_UZO_Z"::W
M\MHHHJS,**** "BBB@ HHHH **** /5M#_Y MG_UZQ_^@BK55=#_ .0+9_\
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M:'_R!;/_ *]8_P#T$5:JKH?_ "!;/_KUC_\ 015JLRUL%%%% PHHHH ****
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M110 51\3?\B[??\ 7J__ *":O51\3?\ (NWW_7J__H)IK<#RVBBBK,PHHHH
M**^-?^"D_P#P7!_8^_X)E_$#PI\*OBM<7VO^(]?OH6UC1_#I22?0-+<X:_N%
M)_%(1\\@#$8 !/U;\,OB;\/_ (S_  _TCXJ_"KQ?8Z_X<U^QCO-'UC3)Q)!=
M0.,JZL/R(."""" 011<#=HHHH **** /5M#_ .0+9_\ 7K'_ .@BK55=#_Y
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M;3*ZEP""'0Y&./I3ZZ;X,?\ )6_#7_8;MO\ T8M +<]XU[_@G+_P3U\4[O\
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MH?\ 9F_Z'_XI_P#AQ[W_ !H_X=#_ +,W_0__ !3_ /#CWO\ C7U-10!\L_\
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M:_!*QBO(FGB/B8R0K("Z ^)M5P2.HH _02BBB@ HHHH **** "BBB@ HHHH
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MX?\ @]?C1<V=_:>/_&?A2XGG35H&U2YN+2,RS)&SB.W>W3F-<&,CD#)^X**
M"BBB@ HHHH **** "BBB@ HHHH **** "OD__@K#\,?^"HGQH^%^A_"S_@FU
MXY\"^%XM6N+A?B)KWB77[S3M42R'D^7;:;/;VMQ]G>4&X62?:)(@L9B(8EE^
ML** /A3]@SX._P#!5O\ 9?'@_P" L_[+?[*O@KX1:9=[=:B\!>+]?N-36)LF
M6X3[5:@7-T[X9Y)Y"SDEF8FL^Z_9"_X*$_L(?M<?%KXY_P#!/#P?\.?B'X ^
M.6N)XD\3?#_QUXGN=$NO#_B0IY=Q?6MS%;SI/!<8$DL;@/N"A, 9/WW10!\5
M_LG_ +#_ .V+^RC\"OC?\=;?Q7\/O%7[4_QNUQ_$.L7M_P#;(/"]C=QQ"#3]
M-1E4W+V5I"6"L5$CEB#@8(\$_9;_ &1?^"\?[-OC+Q!\;=:^%_[+/Q ^*GB\
M!/%7Q1\9?$#Q!+J=U;A]T=C;K%IZ16-E&<;+6W1(_E#,'8;J_4^B@#XS_:6^
M '_!3>Z^*WP@_;7_ &<OB!X5N?&OACP0VB_%?X'ZUXOU*U\(Z^]PB233V$RQ
MOY-S#<;Q'/- 6DB$88KL*/D_ W]D3]M_]H#_ (*)>%O^"BG[=WAWP)X"A^&O
M@G4=!^'7PW\"^(Y]:G^T:@0MW>W]]);P(W[L;$BB0CHQ(*G?]Q44 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>jnj-20241229_g19.jpg
<TEXT>
begin 644 jnj-20241229_g19.jpg
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M]H%[X\O[S1O/G^(NE:> %L;B2.Y3R5D3#>;F;YTCD*LRYKY]_P""\_[._P
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MM7%[;W+WEM'.B2310Q0>0964=(P.#BOT^I%554*H  & !VI: "BBB@ HHHH
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M?^AM6M63X&_Y%6T_W6_]#:M:LRUL%%%% PHHHH **** "BBB@ HHHH ****
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MZ* /@#_A^UXW?YX?^")'[<10\H9/@O$K$=LC[9P?;M1_P_7\=_\ 2$?]M_\
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MH&%%%% !1110 4444 %%%% !1110 5\[_MT?\A#PU_UQNOYQ5]$5\[_MT?\
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M^15N/]Y/_0Q6U6+\0?\ D5;C_>3_ -#%-;B>QYS1115D!1110 4444 %%%%
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M_P"AM\=_^%E<_P"->Z44 >%_\.]_@G_T-OCO_P +*Y_QH_X=[_!/_H;?'?\
MX65S_C7NE% 'A?\ P[W^"?\ T-OCO_PLKG_&C_AWO\$_^AM\=_\ A97/^->Z
M44 >%_\ #O?X)_\ 0V^._P#PLKG_ !H_X=[_  3_ .AM\=_^%E<_XU[I10!X
M7_P[W^"?_0V^._\ PLKG_&C_ (=[_!/_ *&WQW_X65S_ (U[I10!X7_P[W^"
M?_0V^.__  LKG_&C_AWO\$_^AM\=_P#A97/^->Z44 >%_P##O?X)_P#0V^._
M_"RN?\:/^'>_P3_Z&WQW_P"%E<_XU[I10!X7_P .]_@G_P!#;X[_ /"RN?\
M&C_AWO\ !/\ Z&WQW_X65S_C7NE% 'A?_#O?X)_]#;X[_P#"RN?\:/\ AWO\
M$_\ H;?'?_A97/\ C7NE% 'A?_#O?X)_]#;X[_\ "RN?\:/^'>_P3_Z&WQW_
M .%E<_XU[I10!X7_ ,.]_@G_ -#;X[_\+*Y_QH_X=[_!/_H;?'?_ (65S_C7
MNE% 'A?_  [W^"?_ $-OCO\ \+*Y_P :/^'>_P $_P#H;?'?_A97/^->Z44
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M')J>B@ HHHH **** "BBB@ HHHH **** "O#/VM?^"DO[%O[#VN:1X1_:/\
MC.FE:_K]N]QHWAC2-#OM8U6Z@0D-.MGI\$\XB!5AYK($RK#=D''N=>(6?[*?
M[-'P _:=^)G_  4D\2Z_/8^)/$_A"RT_Q1KWB/5XQI^BZ1IT>XB#>H^R1-L$
MLV7*LR!N#G(!U7[+O[6O[./[:7PLB^-/[+WQ9TSQAX;ENI+5[[3Q)&]M<I@O
M;SPRJDMO,H928I41P&4XPP)\/\4_\%T?^"5?@SXIW7PE\0_M::=%=Z?K8T?4
MM<BT'4I="LM0W;?LTVKQVQL(G!X.Z<!2"&(/%?&'PJ\1_$KP5^P;_P %%/\
M@JA\(M%U'PIX9^,[:IK/P<B>V>TGELK33);1?$:1$!HOM<LK7*%@&81*Y!#*
M3];_ +'/[*_P/O?^"#_@/]FVZ\(Z:_A3Q)^SI9MK-NULGEW,]]I*W-S=L,?Z
MQKB9Y]_4.0P((!H ^E_CQ^TA\"/V8OA%J'Q[^/WQ4T?PKX/TN%)+O7]4N@L&
M'($:IC)E=R0$1 S.2 H)->8?LJ_\%4_V#OVT?B%>?"/]G[XY_;O%EEI_V]_#
M&O>&]2T34)K/./M,-OJ5O!)/%R"7C#!=PW8S7RM_P2)_9O\  G_!2+_@CM^Q
MY\0OVJ;K6]4NOA5JJZYX=LEU#;;75UH^H7EA8-=QNK"X1((4P#CJ>>36_P#'
MM=._;._X+O? >S_9^A2]B_9:TGQ+J/QE\:6"@PV$^K6*VMCH!F7A[EBKS20Y
M/EQLQX;<* /OGQYX[\&_"[P3J_Q)^(GB6ST;0-!TV;4-9U?4)Q'!9VL*&266
M1CPJJJDD^@KG?V</VD?@C^UU\&-&_:%_9S\?6_BCP;X@^T?V/KMK;S11W/D7
M$MM+A9D1QMFAE3E1RA(R,$_'GQE\1:1_P5K_ &KK[]EJRU^V7]F[X,^(HC\7
M;XW:K%\0?%-NRRQ>'(SG$EA9N(YKP\B281P8PK-5;_@UOOK*7_@AK\$K&*\B
M:>(^)C)"L@+H#XFU7!(ZB@#]!**** "BBB@ HHHH **** "BBB@ HHHH *X7
M]HW]ICX"?LC?"F^^-_[27Q2TKPAX6TYTCN-6U:4A6E<X2*-%!>:5CG;'&K.V
M#A3BNZKR']I?]B3X)?M9_$'X7?$3XQQ:K=S?"+QB/%'A;3;>^"64NI*FR*6Y
MA9&$WE\LG*E6)(/)% '/_LG_ /!4+]AK]MGQMJ?PQ_9X^-PU#Q3I%D+V^\+:
MYX=U'1=3%H6"BY2UU*W@EEARR?O$5E&]0Q!(%1?M9?\ !4S]A;]B7QM9?#']
MH3XVFR\47^GG4(?#&@^'=1UK48[,$@W4MMIUO/)!#PV))%53M."2#7SGXZ73
MOVS?^"_WPI\:?L_PI>:-^RSX-\36OQ>\:6"YM9M3UBU%M9^'3,.)KBWR]V\8
M+"+>0VUSMIG_  0G$/Q4^-_[;/[4/C&W2?QEJ?[6>O\ A":_G7=<0Z-HT%K%
MI]IN/(2-)G7:,#*].* /MKX _M*? ;]J7X0:=\?/V?/BII'BOP?JD3R6>O:7
M<YA^0D2*X8!HG0@AT<*Z$$, :\"T7_@NG_P2F\0?$NT^%VE?M=:8]SJ&M'2-
M/UZ30=2CT&[O]VW[/%K#VPT^1L\ K.5/8DU\[_L/?!/PCXP_X*&?\%*O^">"
MSZAI?PRU^]\+:E-9>'+K[(UC=>(M E?56@901%),<<@<>7T]-3_@L?\ "OX.
M?"S_ ()7^&_^"-7[-G@N'7O&_P 1;#1_!GP?\$$)+=>79W-M)/K%T54>5%;Q
M0O/-=E0OF-DD;R0 ?:W[5W[:_P"R[^Q#X,L?'?[4'Q<LO#%GJU^+'1;9K6>[
MO=4N2,^3:VEK')<7+X(RL4;$9&<9K%_9)_X**_L=_MPZAK>@?LX?%X:KK?AI
M8V\0^&=6T2]TC5=.23[DDME?PPSB,]!($*$D -S6/X\_8N^&NE^,/ ?[8>N^
M$-<^('Q0^!OPXU#3/!%K'JPC&HS266R8)',?*2ZN"@C$S$8W@,VT5\D?L@?$
MKQ?^T9_P7<U#XZ_M0?!74/@%XXTS]GIO#G@CX6^(9OM6H^+=..J"ZNM5:^MT
M^QR1P/MB6UCEEE4DR-M"XH _3RBBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "OS@_X*._L??\%??VMOVHD_L+P[\!?%?[/OAV>WN?#OPM\:
M>,-8L(=>O46.076MQVEF_P!M6.<.8[4R?9L*C21R,*_1^B@#Y=^#?PT_;M_:
M)^%'Q$_9Z_X*9?"CX+Z1X+\5>$)=!L+7X0^(-2NI9;>ZAFM[J.47MO&L0$3I
MY93.#G@8%?-W@O\ 9/\ ^"Y/PC_9"/\ P2\\"ZK\%[_PA9^'Y/"?AK]H&_U^
M_BU33?#90P1^9HZVY#W\-J?+C*SB(%(]Q."Q_3.B@#X9_:=_8I_;Z^"/[ ?P
MU_81_P""07CCP9X7LO#ND1Z+XH\5^,=8N;'5?L$4:!GL9;>UN%ANKES.TDY3
M,1?=$ Q#)F_L'_!#_@K-^RC!X2^!=E^RY^RIX2^%MKK"2>*)/"/C7Q#=ZO-%
M(X-U>;[JU'VR]<98RSR%G;&YJ^^** /DSQ#_ ,$)_P#@D-XKU^^\4^(_V!O
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M%'QE\0/$$NIW5N'W1V-NL6GI%8V49QLM;=$C^4,P=ANK]3Z* /C/]I;X ?\
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04 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>jnj-20241229_g2.jpg
<TEXT>
begin 644 jnj-20241229_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%C4?'D'AHZW9:/J>LZC)?W.E:II-P8IXHKJ7][+:21I*560G88X]@0,X+_\
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MV.T0-/=2,ZQ06T08@&66:2.),D+ND&2!DC\6_@Q_P6B_X.3/^"JD_B+XL?\
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M6]6:V@_?26=W;F0O+'DQO+-N\L>63^]E% '\X7[>7_!4O_@J5_P< ?"S3O\
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MX.$1D/BRT\0VTNF! VTM]J5S%C<0,[L9XKX%_P""E(_9/\4?\%1OA]X>U?\
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M0^%&D-\7[+P?X1\41?%5[16\1MJ=QJVGPR3/J)'VB0>3,T2HSE41(@H'E)M
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M#@@@@@C@@U^?GQD_X* _!;]NK]B?]H6R^/O["7QRT7X):%\++K77\4Z]H_\
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MJR'^$_H?UKE:* 3:/J#PUXHT7Q=I::OH=X)8FX8=&C;NK#L:T*^9?!WC36_
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MDDDUMT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTGQOHD>M:5)C/RS0L?FB?NI_Q[BM:OFWX>^.]1\ Z\NI6Q9[>3"WEMGB1/\
MXH=0?Z$U]$Z1JUAKNF0ZOI=P);>XC#QN.X_H1T([&H:L;1E=%FBBBD4%%%%
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M845S_P +?$/_  DW@33]1DDW2I#Y,Y)YWI\I)^N ?QKH*S.A:A1110 4444
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M-25>09HG/K]TC_V:O5Z\W_:6C!\*6$O<:AC\XV_PIK<F?PGB]%%%68A1110
M4444 %%%% !7TC\+93-\/-(<G.+)%_+C^E?-U?17P=+-\-=)+?\ /%O_ $-J
MF1<-SIJ***DU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I)$61&C8<,"#2T4 ?C-<0O
M;SO;R?>C<JWU!Q3*W/B?HQ\.?$KQ#X>88-AKEW;D>FR9U_I6'70<84444 %%
M%% !1110 5])?\$M=4CL?VCKVRD;_C]\+7,2#U8302?R0U\VUZU^PUXL3P?^
MU/X1O9I=L5W>O82#/WC/$\2#_OMT/X4I:HJ+M)'ZA4445@=04444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7FO[3$P7PUIUOW>^+#\$(_K7I5>0_
MM-ZB'U'2M)5^8X9)F7_>(4'_ ,<--;DS^$\MHHHJS$**** "BBB@ HHHH *^
MC?A&FSX;Z2N/^7;/YL37SE7TS\/[;[)X&T>W(P1IL)8>Y0$_J:F1<-S7HHHJ
M34**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#\K_ -LCPVWA3]J'QMIC+CS=;>\'
MTN%6X_\ :M>9U])?\%1?!YT+]H:V\311GR]<T&"5WQUEB9HF'X(L9_&OFVMU
ML<LE:3"BBBF2%%%% !1110 5;T'6K_PWKEEXBTJ7R[JPNX[FV?\ NR(P93^8
M%5** /V(\$>+-,\>>#=*\:Z,^ZUU;3X;N#G.%D0, ?<9P?<5J5\R_P#!,+XP
M)XQ^#UU\+]2NPU_X7N3]G1CRUG,2Z'WVOYB^PV#N*^FJP:L['7%W5PHHHI#"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYZ^-.N#7/B)?-&V8[4BVC_
M . #YO\ QXM7N7C+Q%!X4\,WFO3D?Z/"3&I_B<\*/Q8BOF2::6XF>XGD+/(Q
M9V/4DG)-5$SF^@VBBBJ,PHHHH **** "BBB@!T,3SRK!$N6=@JCU)KZIL;1+
M"QAL8_NPQ+&OT Q7S?\ #C2VUGQWI5@%R#>H[CU5#O;]%-?2M3(TIH****DT
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ^4?\ @J[X$?5?AGX<^(=O&2VC:M):
M3[1TBN$!W'V#PJ/J]?"-?K#^TS\-G^+?P&\3^ [>'?<W>F-)8H!RUQ$1+$/Q
M=%'T)K\GB"#@BM8/0YZJM*X44459F%%%% !1110 4444 >B_LK_'"Y^ 'QGT
MOQTSN=.=OLFM0H,^9:2$;^.Y4A7 [E .]?JCI^H6.K6$&J:9=QSVUS"LMO/$
MP99$8 JP(Z@@@@U^--?;G_!-?]J6+4]-3]G?QSJ6+JU5F\,7$S?ZZ(99K;)_
MB7ED]5R.-H!B:ZFM.5G8^P****R-PHHHH **** "BBB@ HHHH **** "BBB@
M HHKQ7]N#]M[X;_L/?#2V\<>,[&35-1U*^6VT;P_:W*QS7I!!F<$@[4C0[BQ
M&-Q1>"XH!NQ/^T3XV6^U"+P9839CM2);PJ>LA'RK^ .?JWM7F5,^%_Q)^$G[
M5OA2;XI_LY^-6UN//F:SH-YA-4TR1LDB:+)+#.<.N5;'REL$T\@@X(P1U%6C
M"5VPHHHIB"BBB@ HHHH **** /0OV<='-[XRN-6=,I969PWH[G _\=#U[=7!
M_L\Z#_9?@AM5D3$FH7#."1_ ORJ/S#'\:[RH>YM%6B%%%%(H**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ K\M/VROA._P 'OVAM?\.P6_EV-[<'4=*PN%^SSDN%
M7V1]\?\ VSK]2Z^6?^"HOP8?Q5\-M/\ C!H]KNN_#<ODZCM7EK.5@ Q]=DFW
MCL)'/:J@[,SJ*\3X)HHHK8YPHHHH **** "BBB@ J?3-3U'1=2M]8TB^EMKN
MUF66VN8'*O%(IRK*1R"" 0:@HH _27]B_P#;$T?]H3PXGA7Q7<PVOC#3X!]K
M@R%74$ _U\0]?[Z#[IY'!X]WK\;] U_6_"NM6OB/PWJD]E?V4RRVMW;2%7B<
M=""*^^?V2/\ @H%X9^*\-KX!^+MU;Z3XFP(X+UL1VNI'H,'I%*?[A^5C]WKM
M&4HVU1O"I?1GTO1114&H4444 %%%% !1110 4444 %%%>)?ME_MZ? []BOP@
M=6\?:LM_KUU"6T;PI83*;R];D!B.?)BR.96&."%#-A2!L=7^TW^TS\+?V4/A
M3??%CXJZP(+2V'EV=E$0;C4+@@E+>%2?F=L?10"S$*":_"7]K3]JCXD?M@?&
M2_\ BY\1;G9YI\G2-*BD+0Z9: DI!'GKC)+-@%F+,<9P)?VLOVN_C!^V-\2Y
M?B'\5-7_ '46Z/1M$M6(M-,@)SY<2D]3@;G/S.0,G  'EU6E8QE*YT'PO^*W
MQ&^"OC2T^(GPJ\8WVA:U8MFWO[";:P'=&'1T/0HP*L.""*_2/]E7_@J1\'/V
MEEMO ?[2YL/ _CB0+%:^*81Y>DZL_0>>"?\ 19#ZD[">=R_+'7Y>44Q)V/W*
M\3>$]<\)7HL]9M-@<9@G0[HYE_O(PX8<CW&><5FU^=?[&'_!4;XK?LU6=O\
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MC*VC,JD+ZH_/:BIK^POM*OIM,U.SEM[FWE:.XMYXRCQNIP593R"",$&H:U,
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MYBOR2,27'VN-;ERPQ)(6W?>-?2M% 'XXZ?\ \&Z/_!0KXV?#WX<?L2_MR_\
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M.OQ'X0\(_M/^+]<L-3\=QWK^&+'0_"=]JLMV+3RO/^6TBD*[1/&<'J"2.AH
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MOE7L(QVCNHYX_P#@%>SU^5__  ;:^)_B=^SWXE_:"_X)8?'[X?1>"_$GPO\
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MO+*+4O#=MK=W\6OBMIDR!X9-+TM)(K"&=/XX;BX-Q RG@[D_#])J_+7X:?\
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M"?%;XS_$+1O"GAG2#X^?5?$'B'4H[2SLU?3+>-#)-*0B NZ*,D9+ =37J?\
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MQ?\ !N%_P3?T_5-4U/PY-\5]%_MG5KC4[^UT+XNZO9P/=3OODD$44RJ"3[=
M!VK[THH ^9O"/_!)G]DKPC^R#XX_8>)\:ZQX#^(=TT_B2'Q'XYOM0O7+) I6
M*ZGD:2%,6\9VJ0,[CU8UTO[0/_!.+]DW]J']D/1?V'/C5X!GU;X>^'[;28-)
MT\ZE+'<6ZZ<J);$3H0^[RTV,V<LKN#]XU[I10!Y%^TY^P]^SS^UU9_#W3OC+
MX8NI[?X7^.].\7^#H-,OWM$M-3L0PMV81X#QJ'(\L_*>..*\K_:V_P""+W[$
M_P"VC^T(?VH_B];>-[/QHWAV'0WU7PEX]O\ 2"]C%(TBQ$6TBY&]B3GJ0N>@
MKZQHH ^6_P!E/_@D+^RK^QO\4F^,/P?\4_$Z;6#I5QIX'B;XG:GJMNL4VW<P
M@N973>-HVOC([=:]1_8W_8V^ _[!OP*L?V=OV<_#MUIWARQO[N^QJ&HR7=S<
M7-S,TTLLTTI+R.6;&2>%51T%>IT4 >2K^Q/\ X?VTF_;\L-"OK3XDS>!O^$1
MOM1M=3D2VO=+$_VA8YK<'9(XD"$2$;@(T&<*!7K5%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!G>*?"'A3QOI+Z#XR\-V.JV4
MGW[74+5)D)]<," ??J*\"^)O_!,?X!^,O,O/!-SJ/A:[;)5;24W%MGU,4IW?
M@KJ/:OHZBFFUL)Q3W/SU^('_  2^^/\ X8WW'@W4-(\20+G8EO<_9IR/=)L(
M/P<UXUXR^ OQJ^'V]O&7PLUVPC3[US-ILAA_"0 H?P-?K?15*;,W2B?C'3?^
M"L>KPZ5X+^ GPH52LFF?#A]:D7'3^T9@?SS;-7Z^^)?A)\*_&6X^+?AMH.IL
M_P!Y[_2(96SZY92<^]>?_&S]@7]D7]HG5++6OC!\&K75;O3=*BTVPGCU&[M6
M@M(RYCA7[/*F%4NQ ]Z'.X*FT?S\45^V.J?\$1_V M0G\ZT\"Z[8KS^ZM?$U
MP5_\B%S^M9DG_!"G]A9RQ6+Q@N<X"^(5X_.*CF0<DC\8:*_:K3?^"'G[!-CM
M^U>%_$E[@\_:?$LHSSGGRPOTKJ_#/_!(C_@GKX7D$\'[/D%Y*#]_4]=O[@'_
M ( \Y3_QVCF0<C/PJKI_ /P2^,GQ5E6'X8_"?Q)XA9FP/[$T2>Z /N8T('U/
M2OWY\&_L=_LH?#Z6.Z\&?LW>"-/GB_U=W#X8MC./^VA0O^M>C11101+!!&J(
MBA41%P% Z #M2YA^S/Q-^$?_  15_;H^)WE76O>#M*\'V<F")_$^JJK[>_[F
MW$L@/LZK^'6OK#X&?\$ /@MX8>+5/C]\5-6\4SJ0S:9HT0T^T]U9\O+(/=6C
M-?H)12NRE!(X3X+_ +,?[/W[.^GG3O@K\(]$\/;HPDMS968-S,H[23OF63_@
M3&N[HHI%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>jnj-20241229_g20.jpg
<TEXT>
begin 644 jnj-20241229_g20.jpg
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M^*.N2W_C#Q_XX^'NKPZEXNUCRI)I+J]O)[=8XU"K((XMPCC!PN69F< ^@_\
M@O!KOQG\-?\ !(/X]:U\ 9K^+Q)#X(?;-IA83Q6#3PKJ$B%?F4K9&Z;<.0 2
M,8KY>\0?#K_@C#JO_!ON\?AKPY\*+CP[<?!,#1KFTMK%]8E\2-IV(0C*/M#:
ML;XJNW_6F8E2,$BOJ?1_^"DEK^UG\+OVD_#?[!GPVU#7?B;\"-1U'P\?#_C[
M0I+73]:UJ!)MEO$RR@RQ2M"\8W-$P+(6"JZL?SE^'O[;O_!%'PU\"!\7OAM^
MP%X9T;]MZ\\.RV$/P:\+?!R_AU?3O&KP&)A:VSP-':0BX/FK*K;UA.,F7*$
M^\_^#=S]I+Q]^U3_ ,$??@]\2_BEK=QJ?B"STZ]T/4=2NY"\MTNGWUQ:02.Y
MY=S;PP[F.2S;B22<U]L5\P?\$9OV,?$__!/_ /X)H?"K]ESQZL2^)-$T6:\\
M3QPRB18=1O;J:]G@WK\K^4]P8=PX(B!&0<U]/T %%%% !1110 4444 %%%%
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M_P"H!_Y-?_8T?\+7_P"H!_Y-?_8T6871V%%<?_PM?_J ?^37_P!C1_PM?_J
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MO6/_ -!%6JJZ'_R!;/\ Z]8__015JLRUL%%%% PHHHH **** "BBB@ HHHH
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M@3H!D\LS'"JBY9F(5020*^$FMM1_X+#_ !5\,_%#X]RVW@?]F?P5K<6M^#?
M7B"]B@UCXBZC%DV^I:E;LV;33DR6BM7_ 'DV=\@"LH%,A&__ ,%D/COXBC^
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MYL;>:Z^@ HHHH *Z;X,?\E;\-?\ 8;MO_1BUS-=-\&/^2M^&O^PW;?\ HQ:
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M%V^_Z]7_ /035ZJ/B;_D7;[_ *]7_P#0336X'EM%%%69A1110!\:_P#!2?\
MX(??L??\%-/B!X4^*OQ6M[[0/$>@7T*ZQK'AT)'/K^EH<M87#$?@DP^>,%@,
M@@#ZM^&7PR^'_P &/A_I'PJ^%7A"QT#PYH%C'9Z/H^F0"."U@085%4?F2<DD
MDDDDFMVBBP!1110 4444 >K:'_R!;/\ Z]8__015JJNA_P#(%L_^O6/_ -!%
M6JS+6P4444#"BBB@ HHHH **** "BBB@ HHHH *\8_;=_P"2<:7_ -AM?_1,
MM>SUXQ^V[_R3C2_^PVO_ *)EIK<3V/F*BBBK("BBB@ HHHH **** "NF^#'_
M "5OPU_V&[;_ -&+7,UTWP8_Y*WX:_[#=M_Z,6@%N?;U%%%9F@4444 %%%%
M!1110 51\3?\B[??]>K_ /H)J]5'Q-_R+M]_UZO_ .@FFMP/+:***LS"BBB@
M HHHH **** "BBB@#U;0_P#D"V?_ %ZQ_P#H(JU570_^0+9_]>L?_H(JU69:
MV"BBB@84444 %%%% !1110 4444 %%%% !7C'[;O_).-+_[#:_\ HF6O9Z\8
M_;=_Y)QI?_8;7_T3+36XGL?,5%%%60%%%% !1110 4444 %=-\&/^2M^&O\
ML-VW_HQ:YFNF^#'_ "5OPU_V&[;_ -&+0"W/MZBBBLS0**** "BBB@ HHHH
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M%V^_Z]7_ /035ZJ/B;_D7;[_ *]7_P#0336X'EM%%%69A1110 4444 %%%%
M!1110!ZMH?\ R!;/_KUC_P#015JJNA_\@6S_ .O6/_T$5:K,M;!1110,****
M "BBB@ HHHH \V_:1_9;^'G[4FB:;H'Q#USQ)8PZ5=/<6[^&]?FL'9F7:0[1
M'+C'8]Z\B_X=#_LS?]#_ /%/_P ./>_XU]344 ?+/_#H?]F;_H?_ (I_^''O
M?\:/^'0_[,W_ $/_ ,4__#CWO^-?4U% 'RS_ ,.A_P!F;_H?_BG_ .''O?\
M&C_AT/\ LS?]#_\ %/\ \./>_P"-?4U% 'RS_P .A_V9O^A_^*?_ (<>]_QH
M_P"'0_[,W_0__%/_ ,./>_XU]344 ?+/_#H?]F;_ *'_ .*?_AQ[W_&C_AT/
M^S-_T/\ \4__  X][_C7U-10!\L_\.A_V9O^A_\ BG_X<>]_QH_X=#_LS?\
M0_\ Q3_\./>_XU]344 ?+/\ PZ'_ &9O^A_^*?\ X<>]_P :/^'0_P"S-_T/
M_P 4_P#PX][_ (U]344 ?+/_  Z'_9F_Z'_XI_\ AQ[W_&C_ (=#_LS?]#_\
M4_\ PX][_C7U-10!\L_\.A_V9O\ H?\ XI_^''O?\:/^'0_[,W_0_P#Q3_\
M#CWO^-?4U% 'RS_PZ'_9F_Z'_P"*?_AQ[W_&C_AT/^S-_P!#_P#%/_PX][_C
M7U-10!\L_P##H?\ 9F_Z'_XI_P#AQ[W_ !H_X=#_ +,W_0__ !3_ /#CWO\
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M *'_ .*?_AQ[W_&C_AT/^S-_T/\ \4__  X][_C7U-10!\L_\.A_V9O^A_\
MBG_X<>]_QH_X=#_LS?\ 0_\ Q3_\./>_XU]344 ?+/\ PZ'_ &9O^A_^*?\
MX<>]_P :/^'0_P"S-_T/_P 4_P#PX][_ (U]344 ?+/_  Z'_9F_Z'_XI_\
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M_CQ^TA\"/V8OA%J'Q[^/WQ4T?PKX/TN%)+O7]4N@L&'($:IC)E=R0$1 S.2
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MGUJ?[1J!"W=[?WTEO C?NQL2*)".C$@J=_W%10 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
)10 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>jnj-20241229_g21.jpg
<TEXT>
begin 644 jnj-20241229_g21.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X
M @ )  8 ,0  86-S<$U31E0     245#('-21T(                  /;6
M  $     TRU(4" @
M                   18W!R=    5     S9&5S8P   80   !L=W1P=
M ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    48EA9
M6@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&
M=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#
M   ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=
M  !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD
M &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2<U)'
M0B!)14,V,3DV-BTR+C$
M                         %A96B        #S40 !     1;,6%E:(
M                  !865H@        ;Z(  #CU   #D%A96B        !B
MF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)14,@
M:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI
M96,N8V@
M        9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C
M;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N,2!$
M969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M         &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO
M;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN
M9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M          !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@    %8
M65H@      !,"58 4    %<?YVUE87,          0
M      */     G-I9R      0U)4(&-U<G8        $      4 "@ / !0
M&0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"&
M (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .4 ZP#P /8
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MQ1KL&Q0;.QMC&XH;LAO:' (<*AQ2''L<HQS,'/4='AU''7 =F1W#'>P>%AY
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M ?_$ *P  0 !!0                 ( P4&!PH! 0 " @,!
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.;W_V?.;J82RS:96__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>jnj-20241229_g22.jpg
<TEXT>
begin 644 jnj-20241229_g22.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^$P+FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI
M2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN
M<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@.2XQ+6,P,#$@-SDN
M-C<U9#!F-RP@,C R,R\P-B\Q,2TQ.3HR,3HQ-B @(" @(" @(CX*(" @/')D
M9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R
M+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R
M9R]D8R]E;&5M96YT<R\Q+C$O(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM;&YS
M.GAM<$=);6<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+VEM9R\B
M"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @
M(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z
M:6QL=7-T<F%T;W(](FAT=' Z+R]N<RYA9&]B92YC;VTO:6QL=7-T<F%T;W(O
M,2XP+R(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N
M8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]J<&5G
M/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @
M/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M
M9&5F875L="(^:6-O;BUL96=E;F1?8FQA8VL\+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @(" \
M>&UP.DUE=&%D871A1&%T93XR,#(T+3 Q+3$Q5# X.C0T.C$T*S X.C P/"]X
M;7 Z365T861A=&%$871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R
M-"TP,2TQ,50P,#HT-#HQ-%H\+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \
M>&UP.D-R96%T941A=&4^,C R-"TP,2TQ,50P.#HT-#HQ-"LP.#HP,#PO>&UP
M.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^061O8F4@
M26QL=7-T<F%T;W(@,C@N," H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*
M(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F.D%L
M=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U-CPO
M>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z:&5I
M9VAT/C(X/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @/'AM
M<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @(" @
M(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%0DQ!
M17-!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!04)!
M0DQ!04%!045!)B-X03M!445S04%!04%104(O*TE-5T5L1%$Q.5%5:SE'4U5X
M1D%!14)!04%-4T5X<&)M.$-%04%!8E<U,&-L2DA1:4)95U9O9T(X-$%!9T%*
M)B-X03M!05E!35%!05E73GIC13%44FQ104%!04%3559$24A.4U(P24%!04%!
M04%!04%!04%!04%!05!B5T%!14%!04%!,'DQ255#06=!04%!)B-X03M!04%!
M04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!
M04%!04%!04%!05)9,T)Y9$%!04%604%!04%Z)B-X03M:1U9Z67=!04%944%!
M04)S9#-2=V1!04%!9D%!04%!55EM='=D04%!06=104%!055C;&A:5V=!04%H
M9T%!04%56C%H6E=G04%!:7=!)B-X03M!04%566QH6E=G04%!:T%!04%!55I'
M,75:04%!06Q104%!0G=:1S%K6D%!04%S44%!04-)9&Y6;%I!04%!,'=!04%#
M1V1M;&QD=T%!)B-X03M!.5%!04%!:V)(5G1A44%!02]G04%!055B5U9H8W=!
M04)!=T%!04%K9$=6:F%!04%"1$%!04%!36-L4E-1=T%!0D1W04%!9TU:,5)3
M)B-X03M1=T%!0D1W04%!9TU9;%)347=!04)$=T%!06=-9$=6-&1!04%!04)$
M8C-"-6-M;&YA2%%G2T=-<$E$135/5&=G4T=6,V)'5C!D0S%1)B-X03M95TYR
M65A*:TE%3G9B6$)H8FYK04%'4FQC,DU!04%!04%!04%%;DY34C!)9U-55D1.
M:D4U3FI9=$UI-'A!04%!04%!04%!04%!04%3)B-X03MC,4I(46E"2E)533)-
M5&LR3FDP>4QJ14%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!
M04%!04%!04%!04%!04%!04%!)B-X03M!04%!04%!04%!04%!1FA:5VE!04%!
M04%!041Z55%!0D%!04%!4F)-5T9L84E!04%!04%!04%!04%!04%!04%!04%"
M65=6;V=!04%!)B-X03M!04%!8C9)04%$:C%!04%$:T9H6E=I04%!04%!04%"
M:6U104%T-%5!04)J85=&;&%)04%!04%!04%#4V=!04%0:$%!071S.6M:6$YJ
M)B-X03M!04%!04%!04%"6DI254UG84A2,&-$;W9,,V0S9'DU<%I73759,F=!
M04%!04%!04%!04%!04):2E)536=A2%(P8T1O=DPS9#-D>35P)B-X03M:5TUU
M63)G04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!
M04%!04%!04%!04%!04%!04%!05I'5GI9=T%!)B-X03M!04%!04%!=5-55D1)
M1%EX3U19,DQ4275-4T)%6E=::&17>#!)1DI(46E":F(R>'9D6$EG8S-":%DR
M56=,4T)Z56MD0T%!04%!04%!)B-X03M!04%!04%!=5-55D1)1%EX3U19,DQ4
M275-4T)%6E=::&17>#!)1DI(46E":F(R>'9D6$EG8S-":%DR56=,4T)Z56MD
M0T%!04%!04%!)B-X03M!04%!04%!04%!04%!04%!04%!04%'4FQC,DU!04%!
M04%!04%,1DIL6FU6>5I7-6I:4T)785=6,V%7-6Y)14YV8FU2<&1';'9B:4)P
M)B-X03MB:4)*4E5-,DU4:S).:3!Y3&I%04%!04%!04%!04%!04%#>%-:5UIL
M8VU6=5DR56=6;6QL9#)L=5IY0D1B,C5K85A2<&(R-&=A5S1G)B-X03M3559$
M3FI%-4YJ671-:31X04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!
M04(R85=6,T%!04%!04%4<% T049&.'5!0D10)B-X03M&04%$-V-W04)"34Q!
M04YC;F=!04%!1EE75F]G04%!04%!0DU#5EE!54%!04%&8V8U,C%L65A-04%!
M04%!04%!05%!04%!04%!04%!)B-X03M!04%!04%!04%!04%!04M004%!04%N
M3G!:>4%!04%!05$Q2E5)1TXQ8VY904%!04%!04%%04%!04%!54%#9T%004)1
M04=1065!0TU!)B-X03M+04%T041)04YW03=!14%!4E%"2T%%.$%604):048T
M05EW0F]!1S!!8V=",T%(=T%G44-'04ES06M!0U9!2F]!;G=#:T%+:T%R9T-Y
M)B-X03M!3&-!=D%$0D%-64%Y=T1104Y503)W1&=!3U5!-G=$=T%064$K=T5"
M05%C0D11151!4FM"2'=%;$%3<T)-9T4T050T0E)11DU!5DE")B-X03M7449G
M05=C0F)G1C%!6'="9W='3$%:24)M9T=H06%K0G-11S5!8T5">5%(4D%D:T(T
M44AP069)0BMG241!9W=#1D%)9$%I64-,=TDT)B-X03M!:T5#4W=*54%L,$-:
M=TIX06YO0VA!2T]!<&=#;V=+<T%R64-W44Q,07150S1!3')!=E5$04%-3$%X
M641)44UT07IG1%%W3E!!,6]$)B-X03M:9TYY03,T1&EG3U=!-DE$<F=/-D$X
M8T0P=U!G02MW1"M144="0DU%24%1=$)$<T5305)60D=-16-14BM"27=%;6=3
M;T),645X0514)B-X03M"3T5%.$%4*T)1,$9(055R0E1O1E-15EE"5V-&9'=7
M1T):649P9U<Q0F-51C%16&Q"9EE'0F=95T)I8T=.=UI)0FQK1V%G6C=";W='
M)B-X03MN46%V0G-!1S!18FI"=E5(0G=C6D)Y<TA046100C)%2&1!94="-6M(
M<D%E+T(Y24@U468T0T%S24AW9WE#15E)5V=H=4-)24EL9VEQ)B-X03M#3#1)
M,&=J;D-0<TI%06ML0U1O2E1W;&M#6&M*:G=M:T-B;TIZ=VYL0V9S2T51;VY#
M:C!+5D%P<4-O14MM07%U0W-52S-!<GI#=W-,)B-X03M)9W,U0S%%3&%1=4%#
M-6=,<T%V24,K14PK47=31$-O35%W>&-$2%5-:F=Y;D1-04TR47IZ1%$P3DIG
M,4%$5F].9$$R3T1A:TYW=S-E)B-X03M$9F=/17<T=41K:T]:034O1'!S3W1G
M-U-$=3100U$X;$0P15!89SDV1#594'-W+U!$*W=10U)!;45%35%94D(K14IS
M47521%A%4%52)B-X03M%>$5X154X4F)21TU%86]2>5)(;T5G8U-*:$I&16U1
M4VA"2VI%<TU3-'A-1$5Y3511>$YJ131-5'!"4$9%*U550FA1;D9%:U5A:%-,
M)B-X03M&2S!5>FA4=T92259.0E971EAG5FUX5SE&94%707A9;49K:U=B0F%0
M1G))5S%H8C9&>#!845)D;$8T:UAR:&931B]C64=X:$%'1U59)B-X03MI:&EV
M1TY562MH:V='555:87AM4D=B8UHS4F]%1VEO8552<#-'<#1A>%)R<T=X46)/
M>'1J1S1O8G-H=F%(04EC2VAX4TA(<V-O>'I-)B-X03M(4%5D2&@Q2$A8061M
M4C-$2&5W949H-4%(;6]E;$(V*TAU:V9%>#@K2#)K9FQ"*R](*V]G1E-"0DE'
M=V=M0T1%25!!:$A#1DE)6%5H)B-X03MO4TA/269S:4IY2E9);TEI<GE,9$EW
M;VI/0TYM2351:G=I4'=*0CAK5%-2.$I+<VLR:55*2E1G;&%#5UA*8V-L.7E9
M;DIL8VUH>6$S)B-X03M*=6=N1T-D2DHS;VYQ>69C2T$P;U!Y:'A+2TEO,4-K
M1TM49W!A>6UD2V1!<4%I;S%+;6=Q;7ER4$MW27).:71P2S4P<C!3=T9,1&MS
M)B-X03MB:7EI3$YC=$1#,4),6%ET<7DS:$QH67540S9#3')C=3=I.&M,,6]V
M:U,O2$PO-'=.5$)S34M1=S)Z15--56]X9VI'-DUF27E+:DIJ)B-X03M-<'-Y
M,41-3DTP67IF>D\T32]%,$MZ4FQ.2C0P,D155$Y5,#%H>EA#3F8P,DYZ6GE.
M<30R-E1C:TXR03-N1&983T)1-%5$:4U/36<U)B-X03M"5&Q#3U@X-79$;C5/
M:EDV9$1Q>4]U.#=,5'1R3S9O-S9$=VY01U4X<$1Z:E!323E95#)H4&5!*TE$
M-6=0<4$K-$0X:% R12]O:B]I)B-X03M10TY!6D5#;5%/9$)+549Q46%X0C=K
M27=1;DI#=%5,,U%Z<$1F55!!4D%.15(P4TM2335&16M65E):<$8S:UEI4FUD
M1W$P8G=2>E9()B-X03ME,&9!4T%625,P:5)33F1*2%5L:E-A;$HX16\S4VXQ
M2WA%<TU3,4Y,;6MV:51#<$UC:WDV5%%*3E-K,E149'A/2E4U=51R9%!!13E*
M)B-X03M4-4Y0,U9!;E5(1E%U,45'559"4FTQ2&U5:D939D9,2%5X3E18,4]Q
M52]:55%L4U!63G162T96,59C2E=$,5IC5G%L5SDQ9$56-4I8)B-X03LT1F=V
M5T@Q67DQ:V%75VQ:=49O2%=L6F%P;'(Q5S!68FQ6=FQ81%9C:&QZ5UA39&1E
M1C-*6&AP96)&-CE8=SEF658K>EE!5F=6,D-Q)B-X03M94'AH5#)':5EF5FE3
M5TMC679":E$R3UA9*W1K44=355I/;&Q05U=36F5D;5!785-:=6AN4%=E5%HK
M;&]0,FE784]X<%$R;6%A9D9Q)B-X03M31W%F879D<E0R=6YA+SES5C)Y=F)1
M:'191S(U8FA*=6$R-T5B>#5V94<O4F-#='=H;D1G8U1P>&Q82'=C:W1Y<&Y-
M0F,Q,7IU2%%5)B-X03MD2$(P>DA5;V195C$T6%DK9'!T,BM(9%=D-TXT15AH
M=65->#5+;FU*965D-E)N<6QE=U(W63-V0V9#1CAG6'IH9E5&.6]8-$)F;4HK
M)B-X03MW;CAJ9C12+S590DAG2VE"0V]&<F=C,D--24M39W931%8T3S9H0C)%
M9TE4:FA5949Q-%E/:&Y+1S$T8S=H-2M)0DEH<&E--DI--&U:)B-X03MI9C9+
M6DER2VEZ0TQL;W8X:D=/37EO,'AJ6FE.+S0U;6IS-E!.;RME:T%A46)P1%=K
M5"M2<4I)4FMN<5,T-4Y.:S=A54E*4TML4%-6)B-X03M8-5A*;&I35VXU8TML
M,U=8-$IH36U,:5I*2FU1;69Y86%*<E9M,$MB<C5W8VY);6,Y-3%K;F1+95%*
M-G5N>#)F:34O-F]';6<R2T9()B-X03MO8F%I2G%+5V]W86ID<5!M<$9A:W@V
M531P86UM1W%A3'!V,FYB<69G<49+;WA+:S-Q86UQ2$MQ4'%W2W)D879P<D9Y
M<S!+,45R8FEU)B-X03M,839H<GAA=FDW04%S2%=W-G)&9W-D87E3-TQ#<WII
M>G)R46QT2GDQ13=72W1G1S)E8F)W=#)I,S1,:%IU3D<U4W)N0W5J=39T8G-U
M)B-X03MU-F4X26)Y8G925SEJ-S1+=F]3*R\W.39V+UA!8TU$<W=79D(T.$IF
M=W1V1%=-4%5X1DA%>G-63'AC:D=2<V)$>#!(2'8X9SEY3'I*)B-X03M/<VTU
M>6IJ2W0X<S)Y-V)-3F-Y,7I46$YT8S0R>G)B4$XX*S0P1&Y1=71%.#!B-U-0
M.4Q",#!45'AT4DHQ37965'184C%L6%<R3F1C)B-X03LQ*T196DYJ;S)7>EHX
M9' R,G9V8F=.=T8S27)D14XR5S-H>F5O=#AP,S8O9TYU0SDT551H>D]*5#1T
M=FI9*U!R-4A0:R]/5T4U9S-M)B-X03ML=6-F-39N;TUU:3@V56)P,$]P8C9U
M6')C3W8W-TEB=$5E,F,W:6IU=$\Y03<X>G=74$1L.%A,>"\O2TTX>&YZ<"]1
M,#E-3#%54%AE)B-X03LY;3,R*R]E2RM";C1Q4&LT*V-F-E8O<FXK,V8X0B]Y
M62]3;CEU=C5,+W1Z+V)F+R\O*S1!1&M&:V(R2FQ!1U1!04%!04%F+V)!25%!
M)B-X03M"9U%%0D%514)G549"9VM'0E%92D-W9T="9V=,1$%O2T-W;TM$0D%-
M1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(>#AF)B-X03M(>#AF
M2'@X9DAW14A"=V-.1$$P645"05E':%521E)O9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF)B-X03M(>#AF2'@X9DAX.&9(
M>#AF2'@X9B\X04%%46=!2$%%04%W15)!04E205%-4D%F+T5!84E!04%!2$%1
M14)!445!04%!04%!04%!05%&)B-X03M!=TE'05%!2$-!:TM#=T5!06=)1$%1
M14)!445!04%!04%!04%!44%#07=11D)G8TE#46],14%!0T%1341!9U%#0F=C
M1$)!24=!;DU")B-X03M!9TU20D%!1DE227A15D5'13)%:6-9155-<$=H0GA7
M>%%I4$)5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#3E51;FLV3WI.:&15
M)B-X03M:2%1$,'5)24IO34I#:&=::$I21E)Q4S!6=$Y62T)R>30O4$4Q3U0P
M6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD-&58)B-X03MP-V9(
M,2MF,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L<&59;5IQ8FY*,F5N-4MJ<$M7
M;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%)B-X03M"45E%0T%-1&)114%!
M:$5$0D-%4TU514954DYH26=:>&=:17EO8DAW1DU(4C133D-&5DII8W9%>DI$
M4D1G:&%357E7:5DW3$-",U!3)B-X03M.94I%9WAD56MW9TI#:&=:2FI:1D=I
M9&MD1E4S.'%/>G=Y9W P*U!Z:$I3:W1-5%4U4%)L9%E75G!B6$8Q95@Q4FQ:
M;61O85=P<F)')B-X03LQ=6(R4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI
M-'E.:F\K1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+;7%Q-GET<G$K=B]A
M)B-X03M!07=$05%!0T5135)!1#A!4%!Z*R]0-U9.3#%39GEL-5-N1G908FIH
M<75Q<'9):V@V=U%(;W!59F)F<41S2T59<$%F3FPO<65P86I/)B-X03MB:E5,
M=6$X=4=*3%1816I3=5-E=%=C:S1P43)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU
M>%8R2W5X5C)+=7A6,DMU>%8R2W5X5G-%9S%()B-X03M81E=E9FPO*V1(;FIY
M8F9X4&(S,'0Y<%E99E=.2W5:1VMH9% R9VY,:UEM<#!:9G!Q3G-6<#EQ*U5V
M3D=L*V%F3'1J<C)L<U=S-S90)B-X03MM9V%N2D="2W9'.4LO16IG<69C67-5
M,WA6,DMU>%8R2W5X5C)+=7A6,DMU>%8K8T=Q,VPQ939P95AT,U@V,V-Z>518
M2$QR-FMJ;&YR)B-X03LO<VII>5%U2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=G)0+VY%3S=U6E!),G)7>C%-
M)B-X03M%1V]K=VMM;T)K:&HU2U K0D(K;D9"93=9;V1I<G-69&ER<U9D:7)S
M5F1I<G-69D98-2]F;&1Q2&Q(>F)D86QB=TTS;#-6<&YU3%,T)B-X03M55E-+
M4U%L;G0S4#=*5FEE1F5Q*S1.1FM(;&5+=7A6,DMU>%8R2W5X5C)+=7A6,DMU
M>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6)B-X03M%-F)P=6]A;F9W869P
M.79*9#-T>31J9W0T;$Q/-TAS04U69F1F-5!E450U2#AI,F5J5$97,4-2;75T
M4UI$5E1C4V="9T0S0TMQ<%AV)B-X03M3=4Q&;75+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMO2%A0,$@K:6)N.4\O5G8P5'=0,78V-W<K<CA0*TQ052M#;GIX5C@V
M83$O,$M"*VM*)B-X03MA."MD5#9N,4PY265J>7%A.&%F0B]W04(X3TMD,$0O
M,6E"+WDK9CA!8W=X6&0S+U=)2"],-2\S34U6,V0O=T)99V8X04PU+S--358S
M)B-X03MD+S%I0B]Y*V8Y>D1&9#-F.5EG9CAV;B]!2$U-5C-D+S%I0B]Y*V8Y
M>D1&9#-F.$%724@O04,K9CEZ1$9D,V8Y66=F.'9N+V-W>%AD)B-X03LS+U=)
M2"],-2]W0GI$1F0S9CE99V8X=FXO8W=X6&0S+T%&:4(O=T%V;B]C=WA89#,O
M5TE(+TPU+S--358S9"\Q:4(O>2MF.$%C=WA8)B-X03MD,R]724@O3#4O,TU-
M5C-D+W="66=F.$%,-2\S34U6,V0O,6E"+WDK9CEZ1$9D,V8Y66=F.'9N+T%(
M34U6,V0O,6E"+WDK9CEZ1$9D)B-X03LS9CA!5TE(+T%#*V8Y>D1&9#-R,S53
M+SAQ4C139CAQ*RMP+U=U4#<O05!V4')V1'9Y*W,O=BM&9CEJ:7(P;D9$<U9D
M:7)S5F1I<G-6)B-X03MD:7)S5F1I<G-69B\R43T]/"]X;7!'26UG.FEM86=E
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z
M06QT/@H@(" @(" @(" \+WAM<#I4:'5M8FYA:6QS/@H@(" @(" @(" \>&UP
M34TZ26YS=&%N8V5)1#YX;7 N:6ED.C=D-64W-64Y+3DP9C M9&0T,BUB,C,W
M+3@U-V4U-&(P-3(Y.3PO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM
M<$U-.D1O8W5M96YT240^>&UP+F1I9#IA,S4S9F0P,BTU.#9C+38X-# M8C-D
M.2UB93AB.#!B93%F,V,\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX
M;7!-33I/<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q
M.3$T03@U.3!$,S$U,#A#.#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@
M(" @(" @(" \>&UP34TZ4F5N9&ET:6]N0VQA<W,^<')O;V8Z<&1F/"]X;7!-
M33I296YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F
M.FEN<W1A;F-E240^=75I9#HX8V0U8CDY,BTX864P+30S9F4M.3DU-RUA868R
M,34Y,3)F-38\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E
M9CID;V-U;65N=$E$/GAM<"YD:60Z,&(V9F-C8F4M8C-C9"TQ,C0Y+6$Y-6,M
M-V-B,3,V-C9A.31C/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \
M<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q
M,3DQ-$$X-3DP1#,Q-3 X0S@\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*
M(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/G!R;V]F.G!D9CPO
M<W12968Z<F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#PO>&UP34TZ1&5R:79E
M9$9R;VT^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \
M<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.FEN<W1A;F-E240^>&UP+FEI9#IA,S1F,69B82TS938T+65E-# M8F,S9"UF
M,&$V9C4V-3<T,V(\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IW:&5N/C(P,C0M,#$M,3%4,#@Z,S@Z,C$K,#@Z,# \+W-T
M179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G
M96YT/D%D;V)E($EL;'5S=')A=&]R(#(W+C @*%=I;F1O=W,I/"]S=$5V=#IS
M;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E
M9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T
M179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E
M240^>&UP+FEI9#HW9#5E-S5E.2TY,&8P+61D-#(M8C(S-RTX-3=E-31B,#4R
M.3D\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,C0M,#$M,3%4,#@Z-#0Z,30K,#@Z,# \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M($EL;'5S=')A=&]R(#(X+C @*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G
M96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V
M=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @
M(" @(#QI;&QU<W1R871O<CI3=&%R='5P4')O9FEL93Y0<FEN=#PO:6QL=7-T
M<F%T;W(Z4W1A<G1U<%!R;V9I;&4^"B @(" @(" @(#QI;&QU<W1R871O<CI#
M<F5A=&]R4W5B5&]O;#Y!25)O8FEN/"]I;&QU<W1R871O<CI#<F5A=&]R4W5B
M5&]O;#X*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R
M>2 Q-RXP,#PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_^(,6$E#0U]04D]&24Q%  $!
M   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0
M    245#('-21T(                  /;6  $     TRU(4" @
M                                                       18W!R
M=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4
M<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN9    E0
M  !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0
M _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U12
M0P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y
M.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@
M245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M
M %A96B        #S40 !     1;,6%E:(                     !865H@
M        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M             !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                            9&5S8P         N
M245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="                             &1E<V,
M+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M             "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#
M-C$Y-C8M,BXQ                                  !V:65W       3
MI/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?
MYVUE87,          0                        */     G-I9R
M0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $
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M P,# P,# P,#_\  $0@ "0 Y P$1  (1 0,1 ?_$ '$  0 " P
M       )"@8("P$!  ,!                  $" P00   $! 8!! ,
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7)CTY?9M9E\XLKW8O!6_"?CKBQ+B?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>jnj-20241229_g23.jpg
<TEXT>
begin 644 jnj-20241229_g23.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M
M   18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=
M @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN
M9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D
M;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P
M  @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@
M*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M$G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR
M+C$
M         %A96B        #S40 !     1;,6%E:(
M  !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:
M(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI
M96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                                    9&5S8P
M       N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C
M;VQO=7(@<W!A8V4@+2!S4D="                             &1E<V,
M        +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV
M-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@
M:6X@245#-C$Y-C8M,BXQ                                  !V:65W
M       3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58
M4    %<?YVUE87,          0                        */     G-I
M9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M #(
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M(@LY"U$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-)@U
M#5H-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/
MLP_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%
M$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5
M-!56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA
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M.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/> ^(#Y@/J ^X#\A/V$_HC_B0"-
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M P,# P,# P,# P,# P,#_\  $0@ "@ Z P$1  (1 0,1 ?_$ ($  0$  P$
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>jnj-20241229_g24.jpg
<TEXT>
begin 644 jnj-20241229_g24.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M('-21T(                  /;6  $     TRU(4" @
M                                               18W!R=    5
M   S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@
M A@    49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD
M9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4
M;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P
M  @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W
M;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y
M-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                     %A96B
M      #S40 !     1;,6%E:(                     !865H@
M;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /
MA   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M     !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                    9&5S8P         N245#(#8Q
M.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M       N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="                             &1E<V,         +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M     "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M
M,BXQ                                  !V:65W       3I/X %%\N
M !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M         0                        */     G-I9R      0U)4(&-U
M<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\
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M[D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?
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M^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X #D%D;V)E &3
M     ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$" @(! @(#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,#_\  $0@ "@ Z P$1  (1 0,1 ?_$ 'X  0 " P                 '
M" ,$"@$! 0$!                  $" Q    ,$!P0'"0           0(%
M  ,$!A$S--065@<28I:8\$%D-38W.#)2$U.#DU5E%Q$  P " @(#
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@&U VV#]%MJA[#;:TEC[5\O?H9L7!<O[%1T^@W(I__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>jnj-20241229_g25.jpg
<TEXT>
begin 644 jnj-20241229_g25.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@!
MI@-@ P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HKR3]K3]NO\ 90_8;\/Z5XB_:@^,%IX;&OWC6GA_
M38[&YO\ 4-5F4 LEK96<<MQ<%=R[C'&P7>NXC<,M_9&_;O\ V3OVZ_#6J^)_
MV6_C!:>)4T"]%GX@TY[&YL=0TF<AML=U9W<<5Q;EMK[2\8#;&VD[3@ ]=HKY
M9^/G_!:?_@FA^S/\5]5^"WQ;_:5BM]>\/21Q^*$T?PSJFJ6N@._"K?W5E;2P
M6;9X*RNI7^(*.:^B=-^*'PVUGX;1?&32O'^C7'A&?1AJ\/B>+4XCI[Z>8O-^
MUBXW>7Y/E_/YF[;MYSB@#=HKY2^$'_!;K_@F!\=?BUI/P6^''[4-M/K/B*_:
MQ\+W.I>&]3L-.UVY5MAALK^ZMH[6Z?=A56.5B[$!-V:^K: "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** /'_$W[%?P,\0?MIZ'_P %!/%3:E/XV\)^ KGPMHBW
M6H*=-T^SFG:>:Y2$K^[N2&>,S!AF)BI! &/C']D'Q'-\9?\ @HI^UI_P59^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOASX9^&FC:I_9*Z=,(A+J\NHQR333R##/"C0J 0RD;L*_P"%?_!;'XN>'O\
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MS]GKP'\(M5N5GNO"O@S2]'N9D;*R26UI%"S ]P2A- '9T444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<%^TY^TU\$_P!C
MSX&^(?VC/VAO'%MX>\)^&;(W.I:A<'+,>B0Q(.99I&*HD:Y9V8 #F@#%_;7_
M &T_@#_P3_\ V===_:<_:1\7+I7A[1(L1PQX:ZU.[8'RK*UC)'FSR$$*N0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 444V>>&VA>YN9ECCC4M)([ *
MJ@9))/0"@"OK>MZ-X:T:[\1^(]6MM/T_3[62YO[^]G6*&VAC4L\DCL0J(J@L
M6)  !)K^7'_@XA_X+Y>*O^"E/Q%D_8R_8]U34$^#6E:LD$D]A&XN/'>H)(!'
M*R ;C:+)CR(,9=L2N-WEI%V__!RC_P '"MS^USKFJ?L"_L1^,7'PNT^[-OXV
M\7:9,0?%]RC<VT#+UL$8?>'%PXR/W:J9/J[_ (-HO^#>1/V<].T;_@H5^W)X
M(!^(-Y"MW\.O!&J6_/AB%AE+^ZC8<7S*<I&?^/=3D_OCB$ [_P#X-OO^#?+3
M_P!@[PK8?MH_M?\ A6&X^-&MV._0="NXPZ^"K.5,%<<C[?(A(D?_ )9*QB7D
MR%OUTHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KC-;_:$^#7AWXYZ'^S3K/CRU@\=>)-#N]9T3PX8Y#-<V-LZ)/."%
M**JM(@^9@22< X..SK\IO /[%_[-_P"Q;_P<@_"WPK^S?X$NM#LM<_9MUZ]U
M1+SQ)J&IO/.NH",-YE]<3.H"J!M5@O?&230!]F_M2_\ !63]@+]C7XBGX0_'
MOX\&S\41:<NH7^@:!X8U/6[O3K,X(N+N/3;:<VD9!#!IMF5((R*]8^&?[1GP
M'^,?P1M/VD_AE\7- UCP#?:5)J4'BZUU)/L(M8PQEE>5B!$(]CB0/M,91@X4
MJ0/R5_X(\?M3?ME>++?]H_XD?LE?L2Z5\3/'/B/]H;Q%J'Q)\:>-_'J:!:Q*
MD@BT_0K5_LUQ+<O!;IN"D1PP+<H-Y,A"\7^TE\6O@%??\$$_'OPJ_98^$GB3
MX0/XH_:@@\$_&WX>ZMKS7EQX5UBXU2W?5;*&<'8+5ECB5?*5(RDSKL!+B@#]
M)?A!_P %NO\ @F!\=?BUI/P6^''[4-M/K/B*_:Q\+W.I>&]3L-.UVY5MAALK
M^ZMH[6Z?=A56.5B[$!-V:^K:^&/^"^OP0^&(_P""*'Q4\+Z3X8LM)M/A[X5L
MM4\#C3X1#_8=SIT\#6C6I7!@953R@4P=CLO1B*^K/V7/'/B'XG_LR_#KXE>+
MO^0MXB\":1J>IY7;_I$]E%+)QV^=VXH [NBBB@ HHHH **** "BBB@ HHHH
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M6MVL;QJT<0D82E\/OPT:_*I]* /H6BBB@ HHHH **** "BBB@ HHHH ****
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M,3[EH _L:HKXH_X)$_\ !<W]DS_@K/X'2P\&:@GA+XG:?9B7Q)\-=7O%-U&
M!ON+.3"B\ML_QJ Z9'F(FY=WVO0 4444 %%%% !1110 4444 %%%% !1110
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M[ WP#UC]I#]IOQ[!H7AS24VH.'N=1N6!,=I:Q9!GGDP0J#H S,5168?RI_\
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M+3[8;'[*MY=R;)[N[\S8 4C#K'&0>F_;&_:@^%?[0G_!M3\)K7X?76MRZ/\
M#6Z^%>D?%/\ MCPO?:=!'##'9),%:ZAC6Z@\X18FB+Q-\I#'(K]D/VE/@5X7
M_:A_9X\<_LV^-M4O['1O'WA'4?#VJWNE.BW,%O>6SV\CQ&1702!9"5+*PR!D
M$<5S*?L3? G5/V(M._X)_?$'0YO%/P]LOAY9>#KBVUF0>?>V-K:QVT<CO$$V
MSXB2021A"L@#)M(& #P__@X/U+PO:?\ !%[X_P!WXFF@^QR^"5CMVE8;6N)+
MNW6VQZDS-%M]\5]%?LD:7XIT3]E+X8Z-XY29=;M/A[HL&L+<9\P726,*RAL\
M[MX;/O7RQX3_ ."'/AJXE\(^!?VA_P!NCXS_ !;^%GP^U2UO_!_PH\;:E8'3
M1+:D&T74);>UCGU.. A2D<S[,HH8,N5/W30 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7QM_P6*_X+/?L[?\ !(WX+_V]XSEA\1?$;7;5SX'^'MK=!9[YQE?M
M-P1DV]HC<-(1EB"B!F!V\;_P6_\ ^"[WP0_X)+?#1O"/A_[#XL^,^O6!?PMX
M*\_,=BC9"ZAJ!0AHK<$';&"))V4JNU0\D?\ /E^PU^P5^W]_P<4_ML:W\3O'
M_CC4KJSN-22X^)?Q6UN O:Z5"?N6MO&-J-+L&V&TCVJB@9\N-2P *'P6^!__
M  4B_P"#D[]O[4/$FN:_-JNI74D<GBKQ??0NFB^#=*WMY<,: XC11O$-LAWR
MOO8DGS91_4I_P3:_X)H_LS?\$NOV?+7X#?LZ>&\22[)_%'BF^C4ZCX@O0N#<
M7#@=!DA(E^2-20HR6+='^PY^PM^SA_P3O_9^TK]G#]F/P/'I&B:>/,O;R7#W
MNKW94"2\NY@ 9IGP,G 50%1%1%51[!0 45G^)?%/A_PAIC:QXDU6*TMU_BD/
M+'T4#EC[#)KPKXF_M.Z]XB,FC^!4DTZS;*M=D_Z1*/;'^K'TY]QTII7$VD>I
M?$KXX^#OAPCVDT_VW40/EL+9QE3_ +;=$'Z^U>%>(O&_Q.^.6N)I,,4TZLV8
M-,LE(BC']YO7']YCQ["MGX:_LW>*?&;IK7BYY=,L9#O/F#_2)P><A3]W/]YO
MR->]>$?!/ACP-IHTKPSI4=M'QYC@9>4^K,>6/\NU/1"U9XU%^R-KA\+-=3>(
MH1J_#):!?W(&/N%^N[WQ@=.>M<EX2\>?$/X&>(9-)NK65$5_]+TJ[SL?_:4]
MB1T9>#QU%>@_M%_\% OV3/V6;V70_BW\6;2'68X@YT#38GN[WD94-'$#Y61R
M#(4!&#GFOA7]J3_@NAX,^(5F^@?!W]G5IA&W^BZ]XKO1'+&,\[8+<G&?>4CU
M6A78.R/TM^'?Q1\*_$K3OM>A7>V>-0;FQF($L1]QW'^T./QXKE?C7^V5^RY^
MSNDB_&'XWZ#I%S$,MIGVOS[W\+:$/*?KMQ7P]^SS^TQ\/_VI?!][;:7#<V-^
MEH8M;T>25U>-) 5)25,;D/(# AAW"\5X_??\$BV\?_%J.P\"_&?2] \/WS%W
M?Q"DTL]NY/\ JT*#;-G)P7>,]B6/).4.8^@?C=_P<$_"+0/.TSX!?!_5O$4Z
MY5-3U^=;"VSV98U\R21?9O+-?)?Q-_X*L_\ !0K]IC5_^$3\(>,KS1EO6*P:
M%\/=,>&9_99%WW)./23'M7W/\$?^"$?[(WP[\G4/BGJNN>.[Y,%X[VY-C9$C
MN(;<B3\&E8'TZY^M/AE\&/A'\&-(_L'X2_#30_#EH5 >+1M,BM_,QW<HH+GW
M8DT72'9GXU_"K_@D/^W]^T-J?_"4>,_"A\-QWK[[C5_'FIM'<2'N6A'F7&['
M]]%SZ^G.?\%1/^"*'_!0W]FKX!)\7OV*O$6C?$VXTZV>3Q;X?M/#LB:O;(.?
M.L(C,ZWJ@9W1[1+P"B/DA?W=HI7861_+)_P1#_X.+IOV$_B8_P -_P!MWX5:
M7XC\):KJ!67QWIGAFVB\1>''8X;<8XU:\M@<[H3B5 6*%L"(_P!.7P6^-GPD
M_:+^&.D?&?X%_$/2O%7A77K47&DZYHUVLT%PAX/(^ZRD%61L,C JP!! _./_
M (+9?\&TGP"_X*.P:I^T!^S:-,^'?QJ=&FN+U8/+TGQ1)C.V_CC!,4Y/2[C4
ML<GS%E^4I^''[(_[=W_!3C_@W7_:PU7X3^*?"6IZ3##?*WC;X3>+';^S=9B^
MZ+JW=2RH[*O[N]MRP8*N?-0%"AG]AE%?,/\ P3%_X*V_LB?\%6/A/_PGG[/7
MB[[+K^G0(?%?@+5Y$35=$D/'SQ@_O8"W"7$>4;H=KAD7Z>H **** "BBB@ H
MHHH **** "BHKV]LM,LIM1U&[BM[>WB:2>>>0(D:*,LS,>   22> !7\\/\
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M%B]&@:7!+;V<S[8=,L<L\WLY'+_3@>W>NN^&/[+#R>7K'Q)E*KPR:7!)R?\
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M]@FSTG]K3]M#1]/\1_&B2-;C1=$8I<6'@O(R-AY6>^'\4XRD1^6+.#*_ZWT
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M;]OW<?WAQ],XKL?A)^TY%<>5X>^),JQR<+#JH7"M[2@=/]X<>H'6OF'XH_\
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MXQ5\[?#'_@VX_:*USRY_BW\>?"7AV)\%HM'M;C4YD'H0X@3/T<CWKZ)^&/\
MP;G_ +(?ACR[KXF?$GQGXIG3&^&.Y@L+9_7*1QM(/PEI?7_$3,?X6'A1CWE:
M_P"+?_I)7^KOT8N&?]\S*OCZBWC3347Z.,(+_P JL_&G_@I/X0_9'_X* ?M
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MZ*_%3X,_\'$G[7G@FT33/BWX)\+^-8T !OFMFT^\8^K& ^2?H(E^M>W^$O\
M@N3\,_C#ML/%WCC5O!4\G!M[BRV0;CV$\&XX]Y-M>_EW&W#F8V2K*$NT_=_'
MX?Q/SKB;P#\4>&>:<\"Z]-?:H/VB_P# 5:HEZP1^EVM^)_#GAJ'S_$&NVEDN
M,@W-PJ9^@)R?PKA/$G[4GPVT8-%I!NM4E'"_9X=D>?=GP<>X!KPWX1>";_\
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MA ?<XZGW-6Z*F]RK(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\0>\&\\_Y$O%<(-[1K*";\O>E1?_ )+\C]^:*_GX'[07_!8']E\8U_QC\:=
M@MA\J^*;.^GMD4?W1>H\>WZ<5V?@'_@OY_P4)\'[%\1:[X4\5!>&_MWPRD9;
M\;-H.:TI^)&51ER8FC4IOS2?ZI_@<^)^BSQC4I>VRG'8;$PZ.,Y)O_R64?\
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MNA\S[#_5+Z/'A]KG>8SS3$1WIT?@O_VY*UT]U*OZQW/R$^%&N?M!:]XL&B_
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M#,7D^'M!M+)<8/V:W5"WU(&3^-:%*X[=SQ#PY^R QVR^+?%P']Z#3H?Y._\
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M_@MG_P %+/AE=_V5K_Q8@U?[.=KV/B;PQ:EU/HS)''*?Q:OWOK&\7_#OX?\
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M:VMA;Q%KG5M1E7<B@<LTC8"#UQ@5X?\ '7_@L%^P!\!?.L]5^.5KXDU&'/\
MQ*_!D1U)V(ZKYL9\A3VPTJG/T-<>+S# X"GSXBI&"_O-+\]SV<EX;S_B/$>P
MRO"U*\^U.$I6];)V7F[(]P\"?!CP%\/U2?2=)$]XHYO[O#RY]1QA/^ @5U=?
MDM\=O^#DOQ=?>=IG[-G[/MEIZ<B+5_&5ZUQ(1Z_9K<HJ,/>5QGL>_P N:_\
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MHNG0:/HVGP6EI:PK%:VMM$L<<,:C"HJJ %4   #@ 5/117J'R 4444 %%%%
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MI.O/JY.R?W:_?)GBYU])OC:OA_JF18>C@**V5."E)+M>2Y/NIQ9XMX3^-O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV:?"JRQ8\JZU/3_M\Z'U$MT9'!]P<UZ_96-EIMI'8:=9Q6\$2[8H8(PB(/0
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MJ/\ A ?^"@G_ $7_ ,"?^$I)_P#%4 >Z45X7_P (#_P4$_Z+_P"!/_"4D_\
MBJ/^$!_X*"?]%_\  G_A*2?_ !5 'NE%>%_\(#_P4$_Z+_X$_P#"4D_^*H_X
M0'_@H)_T7_P)_P"$I)_\50![I17A?_" _P#!03_HO_@3_P )23_XJC_A ?\
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M ,"?^$I)_P#%4 >Z45X7_P (#_P4$_Z+_P"!/_"4D_\ BJ/^$!_X*"?]%_\
M G_A*2?_ !5 'NE%>%_\(#_P4$_Z+_X$_P#"4D_^*H_X0'_@H)_T7_P)_P"$
MI)_\50![I17A?_" _P#!03_HO_@3_P )23_XJC_A ?\ @H)_T7_P)_X2DG_Q
M5 'NE%>%_P#" _\ !03_ *+_ .!/_"4D_P#BJ/\ A ?^"@G_ $7_ ,"?^$I)
M_P#%4 >Z45X7_P (#_P4$_Z+_P"!/_"4D_\ BJ/^$!_X*"?]%_\  G_A*2?_
M !5 'NE%>%_\(#_P4$_Z+_X$_P#"4D_^*H_X0'_@H)_T7_P)_P"$I)_\50![
MI17A?_" _P#!03_HO_@3_P )23_XJC_A ?\ @H)_T7_P)_X2DG_Q5 'NE%>%
M_P#" _\ !03_ *+_ .!/_"4D_P#BJ/\ A ?^"@G_ $7_ ,"?^$I)_P#%4 >Z
M45X7_P (#_P4$_Z+_P"!/_"4D_\ BJ/^$!_X*"?]%_\  G_A*2?_ !5 'NE%
M>%_\(#_P4$_Z+_X$_P#"4D_^*H_X0'_@H)_T7_P)_P"$I)_\50![I17A?_"
M_P#!03_HO_@3_P )23_XJC_A ?\ @H)_T7_P)_X2DG_Q5 'NE%>%_P#" _\
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M,^ OB5J]SJ?CCX:^ ]1L!ITEU<_\?4NGR7-K)+I;3?Q^2V.RA5"J/?\ 3_V
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MH6D?"[X::GHR:;=Z)X5T.P^Q6<DUD@ LGN-QD-N1E B]F!(!]^4444 %%%%
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M\*S>/_"7PQ^,VI?"OX5>!=4U2Y32=#M]*AB%W?1V\4B*US=/.CF9\NH 52H
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M#OA+JNB_$7QWX@\!77AF#QK=74B&RL(;>ZBAFO/L[KYQE:/:FW;D?)N_3*@
MHHHH **** "BBB@ HHHH ^,?CK_P2?L/VV?VY_$7QJ_;TUO3_B#\'=+\+6.G
M?";X2O?WL5GI=\1NU#4;V"-DBGN'?Y8W)?$; $ HA'S%^P]^T#K7[!G[._\
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MB&P^"_BWP;;Z9_PBDHUZ^8SJ[0)>.TZ_OML[%<7&4 7;7Z2T %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
A110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>jnj-20241229_g26.jpg
<TEXT>
begin 644 jnj-20241229_g26.jpg
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]C?]F/6KC4OA5X!ULVUJ=)+2CQ=K^3"UT@3/FQ1EFAMPN=^Z20$B5 OZ)_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7HVGPVMO$,1PP(%4?@/YU9I-W&E8****0PHHHH **** "BBB@#S7]I3]C?\
M94_;%\.VGA7]J;]GOPEX]LM/D:334\3:)%=/9.P 9H9&&^$L  2A&0!G-6_V
M=_V5?V:_V2?!TOP__9C^!?A;P'H]Q<>?=6/A?18;-;F;&/,E,:@ROCC<Y)P
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M;7$8>&5#PRG_ #T[58J2@HHHH **** "BBB@ HHHH **** "BBOS;_X./_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ Y;\3@^E>FV&GV&EVB6&F645O!&,1PP1A%4>P' J:BIO<JU@K\6_P#@YO\
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MQ7\0-&L&CAMO%US>I?)=VT+$/Y$4L,$>TE6DC1_]69,+]^44 ?FY\9/V4O\
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M$4L]_K%RE[XV\6R6['3/"&BJ^U(H8]V%55S'!;AMTCY+-_K90 =!_P $I/\
M@F9^U%_P7Y_;AUWXM_'3QGK4WA--:&J_%[XDW?,T\DAW"PM21L^TR*-J*!Y=
MO$H;;M6.-_ZSO@K\%_A=^SK\*- ^!WP4\%67AWPKX8TV.PT/1M/CVQ6T*#@<
MY+,3EF=B6=F9F)9B3RO[&7[''P'_ &"OV=?#W[,7[.?A-=*\.>'[;:'?#7.H
M7+8,UY<R #S9Y6&YFP!T50JJJCU*@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]O[]JW6O^$)\%^([[18;]C';>'/AY8RQSS9_A\Q-]RY(X(#A3S\M?7?[/O\
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M??V^_P!D#]F99K?XO?';0[*_@!W:-9W'VN^W=E,$.YTR>,N%'O7P_P#M ?\
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M=[4^?[I./G8_5;X]_P#!PJ46?3?V;_@HL:\B+6_&ES^HM8&X]03-]5KX@_:
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MDO>Z)T(@^\W\>T HWZAZ?IVGZ180:5I5C#:VMM"L5M;6\02.*-1A451@*H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%,CNK:6>2UBN(VEB
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M'YSYEI\&?V;T7KY5_P")]:)^F8(%'_HVJLS.Z/TYKX5_X*/?\%@O"O[/PO\
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M<Q>,?C?<)\.M&NW\Z:;7T-QJUP&.2PM0P*,3G/G/&P/.UJ_6S]F?]AS]EO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQRS0>'/$GA_PNDAVK'X?\/1NV#V#79G.?<8/IBN3_P"-K7[5?_18?$=G<?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7YI^#[?Q-=_\%X/VP[7P5YG]LR_LR>'DTGR3\_VHQ2B+;[[]N* .W7_@KO\
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M>%_\(#_P4$_Z+_X$_P#"4D_^*H_X0'_@H)_T7_P)_P"$I)_\50![I17A?_"
M_P#!03_HO_@3_P )23_XJC_A ?\ @H)_T7_P)_X2DG_Q5 'NE%>%_P#" _\
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M ?\ @H)_T7_P)_X2DG_Q5 'NE%>%_P#" _\ !03_ *+_ .!/_"4D_P#BJ/\
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M9H[:6XC628GRHV<!GP,G [X'- #Z**;'-#*SI%*K&-ML@5L[3@'!]#@@_B*
M'44R>>"UA:XN9DCC09=W8 */4D]*<K*ZAT8%2,@@\$4 +1110 444V*:&XC$
ML$JNIZ,C9!_&@!U%,GNK:U"M=7$<8=PB&1P-S'H!GJ3Z4^@ HIHFA,S6XE4R
M*H9D#<@'(!(]#@_D:=0 4444 %%%-$T)F-N)5,BJ&9-W(!R <>AP?R- #J*"
M0!DFF6US;7D"W-I<)+&XRDD;AE8>Q'6@!]%-DFAAV^=*J;F"KN;&2>@'O3J
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M_P#P4GU7X/>)O '@GXP3>%])\!:+XQTA]-U35[?2+![>;5KBSDQ) DKN!")
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M/ITNG_VD8-0T^^LI(S.J@P7#VOE+/S'AR<X!H \S^(7PB_X(T>#? _A?P5\
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M\=_B9IO@W6]+T36/V:M%TS0/&=SHTPTU]16[)\M)RGE221Y#-&&+ #D5\_\
M_!-']J;X/_\ !/+]A"?]AC]N7]A?XN#XM6-_K$?CO0]/^"NH^(H_B3=SWMQ*
M+R&^@@DM]1$T<D:;YY5&5VYVJ#0!]F?\$0M)_:FT7_@EE\(++]LK5=3O/'AT
M&:6ZFUR[\^^%@]W.^GK<R9)>8636P;<=PQALL&-?5M?'/_!!C]GCX^_LP?\
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M$K(%@5XT6\F<[Y)UW-E<JRY(K[EK\GO^"A__  42^+?[0GQ^\3_L3:]^RO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>jnj-20241229_g3.jpg
<TEXT>
begin 644 jnj-20241229_g3.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !]     $  0'T     0 !_^(,6$E#0U]04D]&24Q%  $!   ,2$QI
M;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#
M('-21T(                  /;6  $     TRU(4" @
M                                               18W!R=    5
M   S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@
M A@    49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD
M9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4
M;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P
M  @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W
M;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y
M-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                     %A96B
M      #S40 !     1;,6%E:(                     !865H@
M;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /
MA   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M     !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                    9&5S8P         N245#(#8Q
M.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M       N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="                             &1E<V,         +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M     "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M
M,BXQ                                  !V:65W       3I/X %%\N
M !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M         0                        */     G-I9R      0U)4(&-U
M<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\
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M[D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?
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M^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X $T%D;V)E &0
M     04  DE$_]L A  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0$! 0$"
M @$" @," @(" P,# P,# P,# P,# P,# P,# P,# P,$! 0$! 0$! 0$! 0$
M! 0$! 0$! 3_P  1" &# 8,# 1$  A$! Q$!_\0!H@    8" P$
M    !P@&!00) PH" 0 + 0  !@,! 0$            &!00#!P(( 0D "@L0
M  (! P0! P," P,# @8)=0$" P01!1(&(0<3(@ (,11!,B,5"5%"%F$D,Q=2
M<8$88I$E0Z&Q\"8T<@H9P=$U)^%3-H+QDJ)$5'-%1C='8RA55E<:LL+2XO)D
M@W23A&6CL\/3XRDX9O-U*CDZ2$E*6%E:9VAI:G9W>'EZA8:'B(F*E)66EYB9
MFJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8V=KDY>;GZ.GJ]/7V]_CY^A$
M @$# @0$ P4$! 0&!@5M 0(#$00A$@4Q!@ B$T%1!S)A%'$(0H$CD152H6(6
M,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V160G"G.#DT9TPM+B\E5E=58W
MA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=79CAVAI:FML;6YO9G=X>7I[?'
MU^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H
M# ,!  (1 Q$ /P#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4&KR>/H
M?O*VFIR!?1)*HD(_VF($R-]?P#[V 3P'6B0./28J]]X>"XITJ:QOP4C\,7^Q
M:<I(/^2#[L$/52X\ND]4]@UK7%)04T(^@,[R5##_ !]'VZWM^.?]C[V$]3U7
M6?(=,D^\=P37 K1"I_LP00);\<.8VE'_ "5[MH7K6MO7ILES>8F-Y,I7M^;"
MJF5;\\Z$=5OS_3WO2OIUK4?7J"U14/\ KGF?BWJE=N/Z<L>.??J#TZU6O'K#
M[WU[KWOW7NN:RR)^B1TYOZ79>?Z\$<^_4'IU[J9'E,G#_FLC71_\$JYU^O)X
M60?7WJ@].MU/KTY0[JS\%M.2F<?TF2&>X_H3-&[<_P"!O[UH7TZWJ;UZ>*??
MV7CL)X*.I7\G1)#(?^0DD\8_Y(]Z*#R/6]9Z?J7L&A>PK*&HIR?JT+I4H#_4
MZO X'^L#[J4/EU8./,=*:CW'A:ZP@R$ =OI',33R$_ZE5G$9=O\ @M_=2".(
MZMJ7UZ>_>NM]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U&JJVDH8C-65$5/&+^J5PNHC\(#ZG;_  GW[C@=:) XGI$9'?U'#J
M3&T[U;?0337@@!_JJ6,T@_P(3W<(?/JA?T'2)KMU9NON'K&IXS_NFCO3I8_4
M%E)F8'^C.?=PBCJA8GSZ3Q)))))))))-R2>223R23[MUKKKW[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3
ME19?)XXC[.MJ(5!OX@^N$G^I@DUPD_ZZ^]$ \1UL$C@>EIC^P)TTIDZ19EX!
MGI#XY+?DM#(3&['_  9!_A[H4]#U8.?,=+O'9W%90 4E7&TI%S3R?M5 L+G]
MI[,UOR5N/\?=""./3@8'@>G?WKK?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U"KLC
M18V+SUM1'3Q\VUDEW(_LQQJ#)(W^"@^]@$\.M$@9/0<Y;?LTFJ'$0^!.1]W4
M*KS'_&*'U11_Z[:[C\ ^W GKTV7)X=(&HJJBKE::JGEJ)6^LDKL[6_ !8FRC
M\ <#W< #AU0DGCU@]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO==@D
M$$$@@@@@V((Y!!'((/OW7NE;BMY97'E8YV_B%,+#QU#'S*!Q^W4V9P?^#AQ_
M0#W0H#PZL&(Z$O$[DQ>7LD$WBJ2.:6HM'-_CXS<I,/\ @I)M]0/;94CCTX&!
M^WI_]ZZMU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7%W2-6>1E1$4L[NP554"Y9F) 50/J3[]U[H/<WOF*$O3X=5
MGD%U:LD!\"'Z'P1FQF(/]HV7C@,#[<">9Z;+^G09U574ULS5%7/)43-]7E8L
M0+DA5'T1!?A18#\#VX !PZ;XY/4?W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=<6945G=E1$4LS,0JJJB[,S&P55 N2?I[]U[HK?;/SB^&W1&1
M_@O<?RFZ!ZVSWAJ:@;<W;VOLK$[E-/1P25%5.NW)\R,XT,$41+,*<J#9;ZB
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M-''#5S?<1T6&Q.)A :"EGGADBH<;CZ>9UM&1)425+>)+R60,T)!Z,@A()(H
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M=-!0[TZQW%5!8C?*;/S@DI<3EZZ)5BGR6)DQ^4>)0AG*\>S&"Z=0="]M?/\
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M\,+:5ECU>-6"-$ZNJ)*@5Y(9$%A=B "0!];$5Q:Z:D@'R-!Z'U].CRUN"V@
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M,L 5),"L[1R)<7O8G5];_7V8K  =2O7S_P!@_GT@%P48G0=0/G_A'KUMI_\
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M'D/E_L=.!0AP/MQ_L^?01[I^X^V:2G#,%TM!$OJDD+@&1;WU)X5) "W56O\
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MG%*D>=*4_P O7'[R;QP1Q:"JRS$"X(;7&(99]/Z(T@I(EC#<6 )'U/NPKD,
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M-?6E?Y_ZAU:/L;(5-7@J&0PU)C\3S4JH68BD*PN(U13(]4R(-&@E2_CUEM3
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MA]H;)W=DY34-14E5M.HSE-0;NP.2J32U?BP>9VM55M)5R+!(/LZMBH:P'M9
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M7L65)O-]*U9)E8UR7P?]Z! J?Y]%DFT[<*+!;(J_PCA3[""*>GITH>L_C?\
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M6.?3E<5H"?\ 9Z2F2(LU?BH,CRZCPX&2G((B:06)(\"! &YD;ZLMK?I()O\
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M6L)/Y>=)[N;!PN:>I(H.H*YPB>WLK4(14R8'R56J:<:4_GT67 5,L<=-%&2
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MR5G:W77WT$$4D-1N_$T E,3*6*?Q:C6/60\CJ1-&+"QUKR6NE;;HS.&C&C4
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MZO)=0_(CKYMFI8J5(U0$_=3U32,2\NB2*&,1>3@-'>*ZC2I!)N3?V6$EF/\
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ML7G>6+P/.DL24]2NEE8*2/S]26;8[?NV>&0G6O< <D*:4_F.CS=T2/?[2ZB
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M*)X8N+R-(6]-N")/\+^UL$@ 8UP>D%\A9XP%.H^?RZ#K(Q06EA@4B!%$='Y
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M9-FO7MYUAE.%.!P_R^?1^NF.TJW9V[Z2M2:)J66>!YT<&6-=$S,MS'JLSJX
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MI?XS$T\L +T[JZL\44*G1#)&L/J?Q>75-%J32&*HB.VJY+ ^U\<6H D8]/\
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M<+WJZ)Y2W'5_JSUD=LI\>SC8Y#(/YCI'R87)[3SE9/C0'@U7GI6) "D^0Z+
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MK9E#>:9V+2TT/F,0, LT5[@H2$*Z;<$E0EO2"M5X^M>('^K'2K;P^LZO@!X
M<#CSZ!>HR%%&9\C52K!%0N[!2 KRO&#^\SLJH8YK$!E-KBU^-1(6:,(\S8"G
MAYG_ (ORZ/G644C4$ZADCR^7VCJH[Y7_ "CQ^V$W'F<?-#-G)HJG;&WH$J6#
M"JKY'K,I63"ZZ8J6CBAUZ0=6FQ/]4-E;2;C=:2I$9JSGY5_R\.G[J>/;+9/]
M^$]J_.G$_8,]5T=";2RFX,_4;VRE-4Y>LFYQS_N214DU7YG22-*D/JJZEHD$
MCDC4MP;)Q[5[Y=1J%L+<@1I0/C)('RI@?X>F]ELY75MQNNZ5O@KY DFM#YGJ
MK3^=!1R4^XND*6HIH&D2MWPE55([/'53-1;75GT7956*,J."0;$D<D>Y5]F#
M5M^-<Z8L?F_4(_>!J(.5P1V^+,:_[2/_ "=5$[;I/XEB,]$TBI)C*:DG1@-*
M211UU/3Q3$N=:L\I5=(NWY/'N:IETO&P&*FO6/%N=<<JDY%/\/42H@UPUDYN
MK5*S5 U#3:;RTL4R,0;E'/J'  +<>]CR4<!CIQP3K8\3G_!TQY>G:4LVDWGE
M$XXTLCO&L4G-OH'%N#^?=C@]-E234^9)ZA4(-ZLH1JC@DC4. R.8GBU"1+V9
M0K#CZV)((]U:AT@^O^?IZ$T+T]*?X.GV"6+]IU0I33>C7S*E-(J(2E0R#R(G
MJ)1V4*5L&Y^J5R0&7BX%:#B>/#_+3HQC*G20M(F-*G(!]":8^1/Y^?0]=9[R
MW!M1C3FFBW)M&MR%'+FMO35(CTUE."*;(4-79GPV;IX&84U4%:&3F.021EHR
M5LT4H 84\@?]7E\NCJV>YMS75JC/%3_JP0.!_P G5DNR-W[7R.QJ_96S-Q9[
M$8C=,^+JNP<%)!%3S02T^32JQ@KJ,29"=\;6U$@5LG1^6GEAD:&: S+YIJ*\
MUN:1M^F3P\CY_P ^C3_%KY0&:C4IZ%:GS'F#Z^76X1_PGMZIV3LKHONO<N,W
M7M[<79V_>SL7+V!3XC(55368C#[=P]1C\+)5X^LAAEQ%-N;-5>6R%(D8,4<4
MRT[-Y::6-#ZPE6:)G (D)[@>(^W[>@%S'#);7,<;#](+VL!AC7-/L_;UL7C@
M ?[UP/\ 8#\>S7H,=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T)O7
MM'QD*]A]3'1Q-_K?O3C_ 'F/VVYX#IQ!Q/0E^V^G.O>_=>Z+SEZ(X[)UM'8A
M8:AQ%?ZF%_W("?\ $PNI]O@U /3!%"1TV^]]:Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NJ>/YQ-=/D>B-N]?P5-#0S]D[SGQ$55D,D<;#18WK'8>_N^,_65OCR6
M+GJ,+7S]8XO&5""41/'D66571M#I+DDKC!K3HTVOMG#TKIS_ )!_/KY=>,R=
M%!@*K(S:9]PYC[NDH&JF9FI\744GAR.:J861#_%)9:O[>BM8JR2NUSI]H)>!
M(4^@SZ<>A$IUJ"6HW'\O7_(.G+:+K2U'CIB[UM:BPTB(3$[>)C+*RRW"P#5I
MO+<:;FQ!%_99+(QJ7I@_LZ,8,=H^(BG[.C#C"?PN2FJZB&FJ9Q20Q2EJN&:H
ME:H4E3]Q+3B.FH$!9W81PQQHH-KJC$J<L[&@]?L_XOHW2B#52N/*E?\ BNLN
M[-]5&XUQ.T-K5:9>NJZ-::NS>1%J$Q-61O/5Q^.,5=+LS&M9B3X9*]P$10C/
MK,+.T$;&244/DOSIY^5?\&>D%U>>*PMX6!U8U'A3U_TO[*]!-VAO"@>&AZ]V
M573?W-PKTD4K37F;,5E-%)5UE;4SP%8LC6Y7,5$U3YY44+%))P%L MJ#K<FA
MH:>6>%?6@&!\^D,FA52!)*@-D@5!'&GS+'B3Y5^70&M11XZNUSR-*\-0DU6_
M.HU,LIDBI"S:7+4GFTLH%E;A?I[=$AD30@ J**/E05/Y]%KQ+%)KUUHU2?*I
M.!^7G\^DA#$8?XV6'Z)6CC#<JSBL<)H(N75 ][\7 _VYB37PP#Z?X.BC20T@
MIP8C^=.I.-8-*J.Q*R%*=FOPC3G0C%3I^CD?[?WMC133[?V=7C%6 / XZ3U2
MW[U(^ED\58BS7&I$>&H2,R,20"&4W%^!^/;IR#3TZ3,:LH(X'_+U:1U-7-%2
M4E+Y&",(RIN/TN =0L2I"GD#_'CW#NYQYD<#-,=9%\MO2)(M1TTZ'2;;<>2'
MD4%JB0Z6C)99I2K+(50#T@LI.E>5/TX/)(TNBO'@/,<.A8]D)<T);I!9?9-5
MC:@9'&^6EF5FT"-0"Z'R QNC621'5#J4\'D?7VK@OU;LDX>IZ*;K;'B<2Q A
MN%1_EZ6>U<_'410P5W^XJOCC6*&M5'?&SN6U)%4A0]13:]/ 0%;CFWU]ZGB5
MM1/<I/#_ "CIRUN"-(9]#@88?#^?F/RZ/MT_VW5[:,6,SJ-68BMI_LKAS-$D
MW+4\]+5QRLGDAGG;3Z=-OJ%*^P=N&U*[-);TKQ*\#^SJ1]IWLQ^''<KV8S6M
M?SKY]6O?'?L":>>GUSPU]/%%2VJ+H/+X8GN9'D=XDD6G=47A2S,S:K@^PC<0
MM&Y.@@^8/V]#J&[BN8:*<\,?M^?GU9]M_L5S0(L2*]2:9(_*L'EB]3J#H:&]
MG4MH:.QT @K<Z;O0WDH 6@].B:>R1G)+'3JKQI_J]:]<9-^2-6+4C(F:B;Q^
M<1212)3U"*]YA,UOMX]#+;5#J1Q8V)(.Y97 !$A+<?S_ ,'3L-LFDJ8P",?:
M/3Y_/J)N#N2CI(&3[]9)&,@B>><*-,":G:*+08ETJY92&6-2Q :_ 1S7LY%"
M[$5_XK'3\&WQ\1&.%2!\_4_EGJNWY2_,VCVO@)=M[:RM-59FN$HFE@EDG6DX
M$*O+!32J:R+2ZMX;@2,.75;M[6;=M]UN!9IRT=JIQ7\9\P ?\/\ +HOW"^M]
MK5TC57OCA1Y*/5OV\//[.J;J!-Q=P[XIJS,/5MB**=9(:29];3B*1Y355&DK
M%%)//I<PI<,;\M^KV(+NXCVZV:*WHLC"AIP'^4_+HCL+>;=KY9;GNB'!?+_8
MSDCSZM1ZLVS2[?QU*ZPR+21Q$)<(AGDG2,RU,MT8,1&2D*Z39':Y.HV 4C-)
M([2$U/0Z2,I&J# ' =4/_P \+#0XO-]'9>*)IHQF][4,B*$EI-=3C<354DDS
MZT9:BJ@IGU@"X$5M1(XG'V9<>-OL50',<9^>&:OY"HZQS^\%&39<KS@8$\JG
MTRBD5^9T_P NJ2<'*U/&&E 5:VG?7%*I E@I:V&28,%L0C>DBY!8KQ^3[G24
M5'6-]H=)(K0,,_8"">GN:FB&.FE9O)'39BFA60KZC25=33J9"[ 6+Q4H*ZK
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M(1:M<ISJ-0/,YR3Y#_!TELBIFB2%=,4$#$-&DCRNZZ4(022+Y) 6N2Y _'^
M"Z,D9-:GU_U8Z+9SJ 5:!16@_P"+S_J_+J+3,J4F0J6=2?&T:HH#D/3Q:D0
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M%&TQ!Y3=2DZ(ZT^T^9^P="SM>KRM;1UF19S#4U-;),]72F"DGIRT(FJI8I'
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MDL9W?V9B&I=P4L+S];;2R$)CFVZM5 8CO;.TD@5H=R5-'*T>,I7 ;'P2-42
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MVQTM1]6;<R^U-VX"J@KJ)ZF@8S4LZF11)J51#!:6LT:NB5!-:D\/E^76B0H
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M!_Q?0HBLF:Z2(X#>9^?#_5Y]!#FL;.F0K:505/E,A2QT3T^HSM$(756LJ $
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M%T622+^I!07 _K[V!D?ZN/7F4 >HZ4M.IX(92%%B H 5-.D(ZZ3_ %LH(M<
MV^OMY< ?Y.J>O1X_Y=7;E/T5\[OAOV_554E+C-F_)3J]<U.H\;G;V\]P1=>;
MJ\S!@J1C;F\JIF9C8JO(*W]LWB![2==->PFGS&1_@Z?A;42*G\_\G7U!.S^M
MZ:O2>?'C354SR*KJH4LT+L+6']38^XRFB4AU/Q+BO1JCD@-7!\N@)VMG:K$9
M)\1DA)%)&VDJ]_JK6.B]Q8\'VDPI*$4/^QT_Z&O;YCUQT.5-*E0@D0V8\^C\
M@V(/];7_ -C_ +?W4@#\O7K5>X@C/3C'.UK G4OY)MJ"_2Y_U7!L?;;=P!'Q
M]7!XYQUQJ]WPX>E5Y%>6H>04])21V^XJ:ER2E/&";!S8EB>$0%CP/>UD!!H>
M_A^?6PC%@*T'J?(>O6#%35,CR5^2F$U?52>60IS!3*;&.GI0U],,"66_ZF)+
M'D^WHEI5SESY_P"3K3.#11A!C[?F?GT\5%<=))8G@\6XY'X _J?;A8*!U4!1
M6F.D\3)6.0+^,'Z\CZ_[P3?VV:N0:8X=;Q0D<!T_T%-'3AIYK($74Q-K 6Y+
M7YLO^]>WE0!:$]O39)-0//'3:M4<Y6><DKCJ5B*96_3,RW#36/U!MQ[JOZA_
MH# IYGJQ[!0_$>D#VK65E5MC-T.-9T!QM93^5/U:Y8'0V;@W53;_ (W[4C^&
MOV],J:,",#KYXO\ .4P%)M+YKC:F.B$7\%Z%ZB>>-0;_ '>9KM]YF0LP8*TL
MJUJ.?I^K\F_L;;$P^C9BU:R'_ .D]^>]<YT#CZ9/54#,X9?%H;U<DZCI9?21
MI ]!X ^G&J_]?9Z,\.D 9:D%<4ZY0W4WOSJ4V71I0GGT&)!?R#ZBY)L#[N..
M!U4TS08ZA9.B2OB*1N(ZN N\=1<7 0:FBF7ZO [*+@$-JL18^ZR $8-#Z_ZO
M+K8:AKY>8ZA)HEB,)")4HI$]+Y%80RJMB\3,5$NM;.LG"F_'-P&Z CAGKQ8U
MJ#_J_P"*Z36ZI%@VSE:N !---)&\A*A=9LL8"C2RNS_0<<B_M/=]MK*ZXHIX
M?9TX@U%36HU ']O1;\)7M3^)0T;Q_=LTB3O:%E:=XW^X(%@K(A!-_2 ?S[BZ
M_C9Y0_\ 1X?LX?MZ&FW.J(!QHU>.*$GC^0Z&'8^YY\+)29%:F5'F:6FC</''
M]L*6-Z.!HV#!X8Z&CKYW!:UWM:X!/L@EBU3:2, 5QYU_XH=":VN3#$-+45CG
MA^$8^R@)Z-E-@:>JVCA=R[>KT?.[ER&8RTHK%J:AJ9J:*GS,^8FK'!%#08+'
M2M52SRD2-4+3QD"24(&7D;Q'1D)C I4'C4TI3S).,?,^72YHE:UCN(W'BN23
MJ_(U^0 S^SUZ47PV_EP=_?S"_D%B^B_C?MN2>N4TF=WSV9N:&OH-@]<[,>L=
M:O>N]LK'25$RM4U"O!24,*RY'(U2&.&)BLSQG%E#)=4 7N'[!_L=!?<YH[-=
M3G@13U;.<=?4E_EW?R[.@OY;/0]#TSTKB_O\UEI*3.=L=JY:BIH=Z=N;WCIC
M!-N#<$L+3?88F@$LD.(Q$4KTF*I'*J9:B6JJJD8C@!Z"G0%FF:>1G;S-0/3H
M^WOW377O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=-&?V_@=UX/+[8W3A,1N7;6X<;6X;/[>S^-H\Q@\Y
MA\E3R4F1Q67Q.1AJ:#)8VOI)7BF@FC>*6-BK*02/>P2""#0CKW6A3_.;_P"$
M[VY^B:O<?R8^"VU<WOGHR6HFS._>CL7)69/>O3\,M2DE;EMJS,,AF-U]6TB2
M.]0H2;+8&G4RRO44:35-*8_O+]%O'8#2"2Y] *YZ?@C^HEBA5:R,P55&*DFE
M*^5?^*ZU6=Y;=H=OP4N.RN<VQ25$$,E150TU><YGQ$70?Y:E)72OBS'(7CBI
M&>:MJM +)&C ^P3N&^27K2+:K(8>!;@"1Y*:"H]3P\NI"M-DCL &NA")Q4Z0
MVI@/G0DU]!D^O1?<M28>-JT826HK*<!C/DT@BH#+1NRB2%J=::)J6G+N%$21
M\O( 68M[*4>5RBN /1>.?7[?G7RZ=D6W748R:_B? J">' 4'RZ!+*5=17RYJ
MHHJ(_84!2BHHY")O(\55&E;.EE!D<A_41?TZ;6L?8LL[1HH(M7]H>YS2GE@?
MET#+V^$T\^E?TE.A!Y8.6_VW^;I,2T\;EWA6=3'(D>G3P+J7IS?@@QH"MB+@
MKR+\^U@4^G2#4O%<>5/EUD#S01FGE4NC(D9+M(&C43)*OC(-R&T@6X"W)'/N
MKBGEU[55?Z/#IZQ--#43:I4CGC5TC598],@0.DC:C>[*-(X)/^)Y]U1J.@/"
MO3@!*L<8X=&IP<.,6&F^WE5&?P:GDF"V"A0NKR-=1&MQI) 0'ZVY]BZ'PP%5
M3_/]G\NB\@9!]>GR,"9WF&KQ(R+2ZF4LJ@W:J8,;*)4!T!N;<\,19]17(X>7
M31!\O^+ZE0^6ZD*TBR:)V( ;4)"0797\>EF"W_P)_/MP TX_;U0FIIZ8Z?Z?
M5I+60:"$<ZF2ZJ021&NA'++;_"PM8^[TZU3AT_1U%=3TTE7BV\>3I8ON\5*+
MAX\M27J,=*& XD@K(HW4BX5@/Q[V2*'T(ZO&:'/ ]?71Z4[,I>[>@^DNY*5H
M9:;MGJ#K;LB-H7\D3/O79>$W#.%<<-HJLA(I/^J4CW&EROA7,Z G#4/^7^?1
MI'E :C_5_L=);?6RH,E(:ZD58J^G.L,HTF5/J5NH!NI^G''^M[1RHK '\0Z>
M0TXY!QTQ;8RDL9%+4$B6%FCD5^#=;<'\_7VF/%JGI]A3SQTM\IDJ/%T$N1JI
M=$,2*=0NSN[%4CBBC4%I9I97"QHHU.[  7]MG%*]>XD #->D7C*:KR5>^;R:
M&.LG7QT=&2"N,HR5M%Z?0U94!09W_J BG2HOI$J[L0:GJ[LJJJJ:H,U]?/\
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MW ,\.O?8,]8W)^A"*SE[:"/VWTHI4)S>X7F_T(/OW'K5*"F?GU"J-2 -XRR
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M'  X_/\ 7VXB:22P%3Z?X.MN*@  @ X)QQZSI&TTESP">#Q>YX L;#G\\^W
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2OW7NO>_=>Z][]U[KWOW7NO_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>jnj-20241229_g4.jpg
<TEXT>
begin 644 jnj-20241229_g4.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !]     $  0'T     0 !_^(,6$E#0U]04D]&24Q%  $!   ,2$QI
M;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#
M('-21T(                  /;6  $     TRU(4" @
M                                               18W!R=    5
M   S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@
M A@    49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD
M9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4
M;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P
M  @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W
M;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y
M-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                     %A96B
M      #S40 !     1;,6%E:(                     !865H@
M;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /
MA   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M     !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                    9&5S8P         N245#(#8Q
M.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M       N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="                             &1E<V,         +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M     "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M
M,BXQ                                  !V:65W       3I/X %%\N
M !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M         0                        */     G-I9R      0U)4(&-U
M<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\
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M[D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?
M2 5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,<DRZ30)-2DV33=Q.
M)4YN3K=/ $])3Y-/W5 G4'%0NU$&45!1FU'F4C%2?%+'4Q-37U.J4_940E2/
M5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8RUD:66E9N%H'6E9:IEKU6T5;
ME5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S8 5@5V"J8/QA3V&B8?5B26*<
M8O!C0V.78^MD0&249.EE/6629>=F/6:29NAG/6>39^EH/VB6:.QI0VF::?%J
M2&J?:O=K3VNG:_]L5VRO;0AM8&VY;A)N:V[$;QYO>&_1<"MPAG#@<3IQE7'P
M<DMRIG,!<UUSN'04='!TS'4H=85UX78^=IMV^'=6=[-X$7AN>,QY*GF)>>=Z
M1GJE>P1[8WO"?"%\@7SA?4%]H7X!?F)^PG\C?X1_Y8!'@*B!"H%K@<V",(*2
M@O2#5X.ZA!V$@(3CA4>%JX8.AG*&UX<[AY^(!(AIB,Z),XF9B?Z*9(K*BS"+
MEHO\C&.,RHTQC9B-_XYFCLZ/-H^>D :0;I#6D3^1J)(1DGJ2XY--D[:4()2*
ME/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R::)K5FT*;KYP<G(F<]YUDG=*>
M0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:DQZ4XI:FF&J:+IOVG;J?@
MJ%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:OB[  L'6PZK%@L=:R
M2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;
MO16]C[X*OH2^_[]ZO_7 <,#LP6?!X\)?PMO#6,/4Q%'$SL5+Q<C&1L;#QT''
MO\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XVSK;/-\^XT#G0NM$\T;[2/]+!
MTT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9\=IVVOO;@-P%W(K=$-V6WAS>
MHM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;
MZN7K<.O[[(;M$>V<[BCNM.] [\SP6/#E\7+Q__*,\QGSI_0T],+U4/7>]FWV
M^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X $T%D;V)E &0
M     04  DE$_]L A  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0$! 0$"
M @$" @," @(" P,# P,# P,# P,# P,# P,# P,# P,$! 0$! 0$! 0$! 0$
M! 0$! 0$! 3_P  1" &# 8,# 1$  A$! Q$!_\0!H@    8" P$
M    !P@&!00) PH" 0 + 0  !@,! 0$            &!00#!P(( 0D "@L0
M  (! P0! P," P,# @8)=0$" P01!1(&(0<3(@ (,11!,B,5"5%"%F$D,Q=2
M<8$88I$E0Z&Q\"8T<@H9P=$U)^%3-H+QDJ)$5'-%1C='8RA55E<:LL+2XO)D
M@W23A&6CL\/3XRDX9O-U*CDZ2$E*6%E:9VAI:G9W>'EZA8:'B(F*E)66EYB9
MFJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8V=KDY>;GZ.GJ]/7V]_CY^A$
M @$# @0$ P4$! 0&!@5M 0(#$00A$@4Q!@ B$T%1!S)A%'$(0H$CD152H6(6
M,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V160G"G.#DT9TPM+B\E5E=58W
MA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=79CAVAI:FML;6YO9G=X>7I[?'
MU^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H
M# ,!  (1 Q$ /P#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4&KR>/H
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M3%7SSR54J NYR;9#$2QQ2RU$"J-*4JQA@[<@J"[%S]=EDK8*4J <FOS.//\
METGE]O+ *2NX.&)P:"GV9]/M].C"[*^<-'FVH(=P]>UF-_;U9JNQ6X,3718M
M&8M#D)*"H>GF7'5%.I;B:22)U*2 6U$ZM^>+-V1+BU=">)4@@?/C6G1'<\A7
M<7B&"^C:GPA@P)_.E*_RZ,MMGOGJS=-TI-UT&/J3D_X1#1YR1,14UE:41T7'
MK6,B9"&4/Z)(6='TD@D"_L16N][9=C].Z4-JT@/VDGY5I7\N@Q=[#NMF?U+-
MBNG460:@!\R*T(^?0N0S0U$234\L<\,BZHY8766*13]&21"R,I_J#[-000"#
M4=%!!4D,*'T/63WOK77O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=3*
M'(5>-G6IHIWAE7ZZ3Z76]]$B&ZR(?Z$'WH@'B.O<,CH7<!NVERVBFJM%)7G@
M)>T%0?\ FPS$D.?]023_ $)]M,I'V=.AP?MZ5_NO5^O>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[I*[BW13X93!"%J,BRW6&]XX 0"LE0001<&X0<M_@.?
M=E6OV=49J8\^@;K*VIKZAZJKF>::0\LQ^@_"(H]*(M^ + >W0*8'37')ZB^]
M]>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@&[V^1G7/Q]V
MG4;JWE49')-%+'34VWMKT:YC<%;53ZUA1*-)HHZ6$NA5I9WCC!(%R2 2^_W*
MUVZ'QKAC2M %R2?\GY]&>V;3=[K.(+=0,5+-A0/M\_RZI7^1O\U'>V[<CE-A
M=98N;86RLMBI]NY/?<F/S4FY,'E-R2XTX#+NU318U,7!C:.5Q5"'S.'>5"T<
MD2A@%NG.S,'BM$TH017\7'B/($#[>I$V?D:&-EFO6,DBD$*/@K3AYZOY=%NR
MV.R&=S&'W[G=_;HW'OG;:8V@%1/E,ID,%555=-5[H;<,M-D?)5X],=]W/%4Q
M,\L(@"$+^@>P->[G<7#UN)F8$G-233C3[.A[:;9;6\86"%5CIP4 ?+\ST*^Q
M::GEV;3YK+WV[3S52YB:7)2)5335)JJBKP&V9Q3:JC(T^*H)_*9 JE]2HR 1
MD^RII58"0,1\R?V#HV6#PSH"ZCPH/YGTX]<:ZC.2ITR%,,IC*>IFFR;4)FMD
M*3 BFDAPF)F$0GG&9R]8&F](,$$"L[^OUE%+<C4<T;SK\_\ +TNBLV.BJJ1Y
M'Y^?\NGJNQU554U/BX*^AQ!K8!%,8J+[VNI\=BTD,[1BID J:MII?%I*-'3C
MU<Z0GM,;QG^&F#CB>E0V_0I8^0R?MZ#.N3'S9"&@S&/RTQQ:(<?AX91744E'
M)&T[U.82DK(_'%4K$HUU,D6I6$7H-E]N1W@+4,@5JY'R_P _539, S1)5#C4
M?7Y=,F[,A+@X"88JY\S--3^':U0WW65JFID6;'U%?C,0XQ57/#$K+CZ&:1Z4
M2<U$,UM)5FY5?BDXX Z3FQ+Y"=HJ2WE\^/G_ (/ET.>VNQJ.EI\=55D*29J*
MAI:R7%;@HYJG,4L533*:WR-D:>."FR]*LQ5Y8)(Z9=3*(]&FQC#?* #K#,.
M-32O'CPZ([C;F->(C)I530?R\CT/F!^1W:?6NW:R/8=5LV@P5"&K0,G4?QC&
M4DDE,L\U-7XV:LQV444E]4TE--'#'!R@:0-<1[?S)NU@JQ6TD8M@:Z7[AD<.
M(89].@UN/+.T;DYENXIOJ2*:D[>!XUH5-?G4UZ/MT[\RNL^P<?MS'[BS6'P>
M],GCW:OH\=-)D<$<E1HQR H<A3-6BGH&$9D@>I= \3+ZBYT^Y$VSFW;+Q88[
MB817;#(.%U>8!/\ EZC7=>4-SL7FDMX6EM :J?Q4/"H]?LZ.##+'/%%/"ZR0
MS1I+%(INLD<BAT=3^592"/8I!! (..@F002",C!ZR>]]:Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z[!((()!!N".""/H0?Z^_=>Z$?;F\S'XZ',2%DX2&
MO:Y9/Z+5'ZLGXU_4?VK\D-LGF.KJ],'AT)X(8!E(((!!!N"#R"".""/;?3O7
M?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[I#;GW6F.#T..=9*\^F64 ,E&+<CD%7J#?@<A
M?SSQ[NJUR>'5&:F!QZ")W>1VDD9G=V+N[DLSLQNS,QN69B>3[=Z:ZX^_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KHFW^^X'%^3^![]U[HE/RE
M^2V/ZUVW!%M'<^"J*Z2LEI=Q5&*KZ3*9+;]&(HY#.(()S#32B%F8FH:(  6;
M58$/;UO L85\"13*30@9(_(>?0DV'96O[@_40MX0%5K@$_:>JX5[&V7D,]55
MV[,;1YK"5T$\N3I24J:^.@W"LL>2JLM1U?\ $(,_MK,&H(J()TF@6M"/&P0A
MQ'MQ?1O.9KBKU(KZY\Z<"/D>!ZDZ#;YDC2*%:.HHO#RX 4X$>1].LU!TCMN@
MS[[JV'/B]R4[TM,HV5N#(24^ULYAJBA6@K!#1YB#+X:AB>(64B=TI:M;21Q
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M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5=/S)^5F"V=M#<6RMF9:&KWC/&E*U.LM
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M2QEEN135-2\_@:652OB)*.2+D?7V(+#<4CHLK#2!Y"IK\B?GY=![<]J:X4O
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M>/\ G'4JHQ^)G:.,J9%1'0T\LBJIU'2Q ;7S_@"+?['WIO#+JI8&F*$T_/\
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M%B!92+G\>U'B@K0'/S_U4Z2Z2&!/PUIC_!THQ$\DCB*1 \RTBQ6]"R+3"P5
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M<(E4L./#CTA,C"U-)+/I<>8'Q.C@Z:=V#2QA=+:)HW*LWU+$"Y/U]HY4T.[
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MNO>_=>Z][]U[KWOW7NL-3/%2T\]3.Q6&GAEGF8 DK%"C22, OJ)"*?IS[T<
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M*#R'2JJHZ3'TQC\FBCC(FAANJQH5&A66- P$RMR2H!!%[\^U<]LL,1HM(QP
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M*IY(Z*.)(Q3DA!X9B R@Q1I<$ *URWYM[,]LA8/W-\5>@KO,FJ)F45*MQ/\
MD^WI<YVG2GJ)*TQ)*+)!*JLS.RQ2:AXF<M&/$&U<&[<W'M/ND#!S(#G@0#_J
M'5+&4/"L=2&I4'A2OKY]1Y*W!4FK)5-?2T$3*H:IGF2&(>,^,&:9],:1K(P%
MS_:-N/:-"(91+0!OG\NGUBOID$$4!DIY**G.<#C7I%[@Q&.W$D]'C,C2&IDC
M62*9")8Y77]Y)XX]2)4QQN@8^-@UUN#Q[?D*W*GPF6OR_P /V]'%G-/9*LMW
M;.(^!\J>5#Z$_/H*MN9#+T.4FV[N*GCCR-+$\554JK)19.&5F5)X5!*SQU<0
M^C E7)##FY+X7=9'BF2DGF?4=""YCMY8DN;5JV[&JK@E3Z'TH>AAHL'2M'#+
MCYZBE\(ACB0S22,JKZHA$WDNLD'T!4_0:1]![-(U "M$Y%. 'E_FZ#\U]+&7
MCN8E;54D^7H:X\_GTV9;9E+#.,MCA2P[@2[LZQ6@R%.FH'[Z&,CS3*C<2M^X
M=1#$J;!#?V2D?4(1]2,G^D!ZCS(]>KVNZO(#!*K&S.!4FJD_PL?+Y</3.>D%
MN+%??0C+8VG$&XJ%98:FDFECME:>GD;305;65&9!ZX&(+H#HOI/!%.BSQA]%
M)EK@TS3R/^3HQAF\%O!E<FU>A##\)/XA_E_S]%&[-HL1FZJ#>T%6^(RU12U,
M&9>BA=#E/M8RB19&.16,=9#->%IG1I FI"&4W]ER2*[%R0'^72EHY(2+?26B
M5L5\A\J>7GU7;WGDZ;&9VB'J>;5)"'>G1JPU=0D5(GACIPB3F7S1I'"-"-Y-
M36(][LLW#^5,G_5PI3IZ]S:(!2AQBO\ Q?21^6.%[&VFWQKZLVW55-9!+M26
MORE/04K38+9N1^\2&:L2GID:3(9CPUDVF>H=Y&F=I&T*L:^S7:YH2NX7,U6;
M4 @^7' ]#BIZ:L(O$JJ($4-0L>)H!Y^0X@#JR7IGKK$[9Z4PU3N:EKJG!IFM
MO8S^%PPO/796""KAJX:6"A=3]U6Y:N@": ?6T@U%B0/;Z64NXN%928Y'6-4'
M%B3PIQ))('3]_>"QN-,,JH(XFE,K&BH IJQ/ :5J2>KW^L-KU&T-D83$Y HV
M9ECGR^X'0AHVW!G*F;+9E(6L+TE-75CPP#C3!&B@ "WO,WEO:%V'8]MVI35H
MHP'/JY[G/V%B:?+KGCS9OC<Q\Q;IN]"(I9*1*>(C0!(P?F$45]34]+[V>=!W
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[I=?<G[7RW-_[B_;7Y^G\8^SM]?\ 4\?[ZWMO_H+J]?\ CO2+J&UU
M$[\>N:5N/IZG8\?7CGW<<!U0YSUA][Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U1=_/DZ8SNY/C;LOY%[4
MHZRNROQHW-E:_=D-#')/40]2]D4F.P&]LR*:&*22:GVOG,5@\G6.=,=-BJ2L
MG=@L1N!^?-I?<MI26,$O"^H@>:G!_80#]E>I2]I]]CVG?Y;29@L=W'H5C@"1
M:E1_M@6 ^9'6F])5.<EV%NZ2(A,0H:&.$R1JDE!1T<(5"1Q&9I&8@?5A].?<
M2+IAM[&U'QR'/GYGJ<EU2[CN5Y3L3 _(#HQ?0^Z(HZ>EFD<+#'/#4S1-ZH*R
M9HC.U;(PO,'IF"L5CU6U$'FQ!;?0@F5J9 Q\OE^?4E<L2ZH0M<U_;@FOY=7>
M]2=J187&4M=DS-"X6.82U#^C[CQAU#23+(13!)M-QRR< AN"&FA#-G&>'0HN
MHFD%$'<1_AX](;>ORD[$[FW14;#Z8IJ;!T=%.]#N#?=9"U918BL1C#5)B:*2
M1J+.;@T\ ,8XZ>ZAR3Z28):K BR3GL/X1Q/^8=)XXK>T0UE#R"NHG@/11ZFO
MY#SZ!GO'HS96T.L]S5V1R.3W+O3*XFLK*W*Y6L>NSU=D85;S2R5%2;"%)'#Q
MPPB.*-2%1.+>[VET6EC*+H4$#' 5_P!CI*;IITF9Q2( BOKCHR7QS^2.V<#\
M95QU%74PRNWMG)0TN.J&\2I+%"JQ3(\>F297U%C<W;5;D#V'[NUG-].D@(<N
M6!'SK_AZ0S%9S%.,I3N ^6/\G08?RRNTAFMS[FQF4G7^+5>2GRT22MICKJQY
M:HU4KTZ7_;:>I93IX"J+@GV97<'@WUNI'Z90*"/4>1KZCIB*7Z_;Y)CQ1J-0
M9(KQ_*G^#K84VU4R25$:Q20 )1""II:&0%46F8%GD:P:)Y'NMK E5Y%_9JL9
M4J%H!3@#Y#H-W#(%D9Z_%568>9X #I0[FR5/-'%%]Q#'3RZ&EEC4VCF$:@B>
MP72V@_3ZZ3?_ %T-^H)J6 CK4G_/TQ8*R*[!"9!6@)\JUQ_JX]8*O:U!EL12
MFNH()J!*>!S22!)J:2,:E EC):.76"&TN#_C[3_#%J,0*CAYU%>/2^WW.2WG
M9(IB)B2 >!!QP]/RZJT^7':.[/C%V'M[?&PDR^0VIDB8M^;0%33C%U7BF2"A
MSNU:!X9%P^>BAD:.=8BL-4JH62XU>WH[5;E?J;8^%+P(4=K$>H]2/,4]>I+V
M62VW/9Y(=U0-+6D;K7Q " 2&)^- ?(U(SGH5<-\C-H]L87#;TVY6#(M!2P5C
M&,QT]5X)V$4ZU$",ZQS+XR9 + 21GZ>R>[4+-5U(F5L@_L.?RZ+(;!K&26W6
M0&V?"GB#3(_F?V=&)VIV)%EX(G$\-/'.BR?>(ZI%>;Z!@W!D1UMJX4$_['VO
MA9)(^UJ'I-=;<HRREFR I^72_J-RT\DGA!=2ZAQ+J+$L"J>A@0#ZK<?D>T=[
M-I!@I\ZU_+'ET7Q;8T:AV-:8I3\\](#-NLM1)FH!:2FD?S U$HCGIC$4:>*G
MTE2\#7*HPN!>UOI["]R^F3Q@.!R*\13B!\NE2"@-JQ.DC&.!K@$^51T4#L^G
MB_B.8R$T<TV*RE/!.3321/2_=D2PFI*<25"SBH61PA $T8:UP;E+.?$9CP8^
M6>/^'HVB#> D>JCI@5K7[/\ -\NJFL_E%W/W-C,15SM+AMGY67*Y9HHY97C7
M&U*$B=8(I))JPU(41*BO=6$9]90@XM[<QVLK8UN-(^P_['22YD\62-%!HHU4
M_P G5SN$P*[@@HJ_,[5H=LUE3CL9#@,;ET:HW'3XFIG:>BDW+Y5ECQV4KX;R
M_:*\CTR\2,7X"W;EELHIVU!=0'S_ &](+8?43A%9G )9R,"ORIZ?X>CT;!ZK
MQ>>W#T_!54]*V(V)!D>R:RBC*/%4;CC,>'V>LZJ )(J2JJ*G(1GZ"IH8B/H0
M9E]L]FAW#=;.]D4-%:Q&X]097.B,_.@#,/F >H5]W>9;C;-EW:PMY"LM[.ME
M7@?"C4234]-19%/JI(Z/)[R)ZQ1Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I^\W^X_1=?^+#X;?G_C
MY_N+?7]7Y_UO=?/\_P#)U;R_+_+TP^[=5Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[IKS>$PVYL+E]N
M;BQ6.SNW]P8O(83.X3+T=/D<3F<-E:26@R>*RF/JXY:6NQV1HIWAGAE1HY8G
M96!!(]Z95=65@"I%"#YCJR.\3I)&Y612&5@:$$9!!\B#U\\/N+K#:.T8OEOA
M-CXF7&['V[WAW5LC9&*^_P CEY<5LO:G<VX-J;1QBYK*U-5D,CX=OXB&)9:J
M:6HD50TKL;N<8M[GB@YH:VMQI@AD=4'D *_F:>O69/+D4UQRI;WEVVJZFA26
M1J %BP%3C )KT%?0^*EDR])0213)CZ>:26C>$J\TE0L\C+&JZBDID9"=(!0V
M -[>T-Y=H0RZP9,5!]/^*Z&G+A:+LTT0'M)^T]'JJ#O?L.MKNN<!GJ[;.(HJ
M*"MWGE:<01[BA2MHY8TQ=#)*H*U]5$@>HEA0/!#(&C&HW#=J;>-4G9 S5[1Y
M8\^A#?WTD(58GH#AF''/D/0^I_9GK+L3=S=:5F$QE'#3B+"2+2TE'!3L*L4@
M#4V0ER<<3.HDIIPHC*HTD\M_-R.5ERJS*23DY)/^3[>B?][ *T _LR?+^?\
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M+68\(,8 ]1]Y%%HG>""T2Y TY#R4T<RJ4IWD),BW-K$$K%C#-]F :])&MUC
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MO3V^7-/*+6^WJ40J_(('(Y L'.91&UG&LHJA:G0UY'9TW*>2,]ZQU_GUKO\
MP_[4BQ^Z#&S/24695:R?&A5C>CG\ZO74T7ZE-.MF#\A=+!N./<(\T[:659E
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M1'Q;?WINO*T>P8YZN.IJ(.N=D0?W/Z\IWC&N1#48>A^_T>E0:]UN&8^YJN%
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MV[V+W#O*MW)V;V)OOMC?:ZH,YOSL/=N:WAN"4SB25L%B\AGJ^NDQ&!HS(?\
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M.?!* JG4+,T0<  L6NW)MZP/K;VA8D=4HQ;I>8&A@I\?F*F>-?/)3TTMV\1
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MOP!S[31,5;N/'TZJ<@T&1_J_;T)N=:5-FY"H;0$.)J*:9Y:FGAELN.JXE;0
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MK*^)CC:"..HR,O\ !13O!DL_2"C\K))',)*>@]0,=II-+: "H1VMXR[EJD@
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M4?AD=B6F72Y.D?I)%97"R.#)0DDT'^KS\NO1J2M% K09IU9E_+S_ ):_??\
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MKH(:*HGAJS+B:=OLH74)3TT@5Y-:9J#QRB.6:)Y)D$@"^I=174=.CJ8 (PT
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MAJ0U/2PBID?(//)052*S^Q(AJ?J-6F1J*X'D1@*OEZDG_!T5I$J^ %8 I6F
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M5O>I]?T45/$I4TU:/4<*YIZUQUO]/ZA_@K05TZZ_YOV9]>AOP'^A'1)_'/\
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7]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>jnj-20241229_g5.jpg
<TEXT>
begin 644 jnj-20241229_g5.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !]     $  0'T     0 !_^(,6$E#0U]04D]&24Q%  $!   ,2$QI
M;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#
M('-21T(                  /;6  $     TRU(4" @
M                                               18W!R=    5
M   S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@
M A@    49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD
M9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4
M;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P
M  @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W
M;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y
M-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                     %A96B
M      #S40 !     1;,6%E:(                     !865H@
M;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /
MA   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M     !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                    9&5S8P         N245#(#8Q
M.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M       N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="                             &1E<V,         +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M     "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M
M,BXQ                                  !V:65W       3I/X %%\N
M !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M         0                        */     G-I9R      0U)4(&-U
M<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\
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M[D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?
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M^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X $T%D;V)E &0
M     04  DE$_]L A  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0$! 0$"
M @$" @," @(" P,# P,# P,# P,# P,# P,# P,# P,$! 0$! 0$! 0$! 0$
M! 0$! 0$! 3_P  1" &# 8,# 1$  A$! Q$!_\0!H@    8" P$
M    !P@&!00) PH" 0 + 0  !@,! 0$            &!00#!P(( 0D "@L0
M  (! P0! P," P,# @8)=0$" P01!1(&(0<3(@ (,11!,B,5"5%"%F$D,Q=2
M<8$88I$E0Z&Q\"8T<@H9P=$U)^%3-H+QDJ)$5'-%1C='8RA55E<:LL+2XO)D
M@W23A&6CL\/3XRDX9O-U*CDZ2$E*6%E:9VAI:G9W>'EZA8:'B(F*E)66EYB9
MFJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8V=KDY>;GZ.GJ]/7V]_CY^A$
M @$# @0$ P4$! 0&!@5M 0(#$00A$@4Q!@ B$T%1!S)A%'$(0H$CD152H6(6
M,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V160G"G.#DT9TPM+B\E5E=58W
MA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=79CAVAI:FML;6YO9G=X>7I[?'
MU^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H
M# ,!  (1 Q$ /P#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4&KR>/H
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M&J#?:Q9!XZ,((?N:J7762L2PV]HI^@U*OF6D))^7Q''R_/IZ)IIGK=HTV*C
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MJKK*N:.FI:6F@1I9ZBIJ)F2&""&-2SNQ"JH))M[]UX DT SUIZ_SQ?YB6:[
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M^0\>&GQ&2IGDGCHT%30.U'%-2PRM52U=?C(:IIRR:24AD0 !S[U9S!)0Q!"
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M=53M]/LSTTI9RH\N'Y?ZO\W0I09.E@I$J(Y*[5"YH(8I8:9GR64A0$RC55I
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M1TN&^[:"255*?VXXS$X*,DP\22NQC*I-^1QZ39@ H]F$,-=)-/L_R?MZ13W
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M<VT^*TYVDCIS#"]:E'2,:FG<,?N*6HH9(F?5('=92]6_$I_:/7\N'1.WAP.
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M5U-/1E\-5U4U0D/VDVJEJDDGHJNE%32N]+54]'%,GM9I]EN.TF7;V/=C*@U
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MB!A12P%<CSX5_+HTVV,1-OKM3&XAHII8I)*1LC3TJB*.#$8REHF@IGT#2<9
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MS+6,GW4E*BFGA5I"J(H):-7&K2Q*C23ZII*("6:IH*5-:<. Z3/;B*SC EH
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M2)'21U$*4^/42%2CSQXR*..=Y6+L8QH 5^0ES5<!8[:SBKI9M1/^EX_S./\
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MMFUI+;JK#QY"1J) TM&,DZ6K4'M/#UZ'+9O\^/Y6;8W!@,!VCU;T/D*:AR>
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M&W73074>L PF@8C[*5_PX]?V=%U];>);G5B0 Z2.!_+R_*O6XK_*.WO4;[^
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M]58JI2)X7R=5)E$H"RL(X]4D4$>N)"DAIAI6?4TC+(W/KU'W%^_W9.Z2"M=
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MAN_.XK"XO#XBKAF:&HQ>%>J9A#)$L\:(9Z@463;=:?1R75]#-$,^%&=2 ^>
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M6D//*J!J%F=AJ*D#YG_..FY8%"T1>VOR_.G5]OP*G$'QRV/C)X8::=GS"ND
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M]D]@4='$YQM-MFKPN\LSM+K>KPM343UU+14M/-@L>J122&."FKZ)::;2J1E
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ML 8&-_7^"[A;Z&^B@ _7CVM8*T:D 9Q4?X>BF*62WE,:DFA)7/'_  T^8Z1
MVC-2SR>,4U11\Z!50QO60N95;]NK2 .JQ! Z&PD5M0)8N3[3+')054:?.M*_
MZA_JX]&7CHZ#]0B0YJ#0?[S7SK3[*>G3Z</+I>)?M&=HE.FJIBA&MPIDCGIU
M,;&0!=:31.1S];D>[LI.I  01P(I^=?\XZ2!M+AJG2#Y'&/D<_F#TT5^$>(&
M:JH(XI5]<5702J6!12%,D<4&-=E_4?0KGDCE;CV67%OAB\0!K@@_YJ?ZO/HU
MLKCN 2>J<&5AZ^E2P_;3]O1;^X<30[TVMD:"N\-#4TT$LE%543O3UN-KJ?R?
M95]#54\BU-/5)(J@2 78Z3<V/L+;@H+>(I 9<8_E_J_GT)K/_%Y%9 64XSD$
M'B#7_!Y=:P/=^.@FW3N_"Y#)9#:G86'_ (SD<!NG"XV#)8C.Y;;PJ]V4Z9_:
MU-+054&?^TQE0L;XD3P9 U;P_8B73-(<[(D4ACU\&.?3Y\,C[?SIT3\P^)#%
M,T \2.E0I-&%>&DFNK-,&GR;I)_'SY]8C"4]%MSLG=W4N5VS0Y"OJ)5W;ORM
MQ6QZW(56&FP.W=OYB'=VU]N5_6>2K\9524=+N"JB&VLS2U[8S-5F+JONJFO'
MEWRT]Y"1!"7EP.P=S"E25(/D1W =U1J 84 @6;FR&WFCENDDAA%068!@*8 8
M $=U1I/P^1*D&IX.M.JJ?IG&XZDZ?W[N&KZCW+DZW<FW-BY3&14F]=K8^J:K
MHHL/B:F3(+M/=?\ <:*MI*89"FJ*F/+X>.:+Q5'\0_B,P,W9[GZBDPT7B*%9
MU)[B,%B#Q+9K@9P0*!0(]G6Q-FW@N7MI&+HLE"%5SJ""E2%%.W)'F"2:D><)
MNG.5<,^.@QU;C-QPU*8W/[;IZZOI\7EJMZ*FR32X[ 9NFRF-PU=+2T<&2P\]
M/'1RU/C>-)H*JGJ(I"<.7 CS0^OR_P !'^ST:RQ1H3+QIYT%?3)'Q*:^=?SZ
M8=_8#&[D?*=EXT(<=65F.S/<$E/1Q4V0BB#T<5!WEMC%1093&Y2BKH8EH-X4
M\,LE%/ \\]7#.8ZUHW1'+([2"C&E'!%,'\7IQ].#9Z023B%?#8%5K5"O$$?Z
M&?\ )7RQZ=5C;[R>:I*NICWWMBIJMSX>NS^V*_<VUI%EPF;AHLF,9BJVA7(9
M*AK<=0Y!<3!!5T;R_>T%9"B:W\BR2/>$L4P2*8A<'NXC]G&F?D1TXLIEB9C"
M"2*@ FE?]D_;3I1[7WT=F=A8'=N(QV]]WX[<&'V-@L(=C5,6PMVP;OGP="D'
M6&]J#(QZ:&3=M+3R-C<DZP5D$TDL#&6-X!5#R&!D2TD2<O(H7,7F:YH1G@:>
M?&I''H'S.CFX1HUCU%R!**T'D2#@D$5^SACK>VZ"3><72'4</8RB/?\ 3]<[
M-IMZQ*]%*L&Z:?;]!#G8%GQP%!4+#DDD420VBDMJ4 $ 3W9&4VEOXXI-H&L8
MP:9&,=8]7_A?6W7@&L/B-I.>%<<<]"Y[5=).O>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NEU]R?M?+<W_N+]M?GZ?QC[.WU_P!3Q_OK
M>V_^@NKU_P".](NH;743OQZYI6X^GJ=CQ]>.?=QP'5#G/6'WOKW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U17\K*;=&SM[]DS[;D:#.8+/
MG>5%#-]IX:>FR.UM]4>WZX4V5J(\;D,;E\Q)!%4TDDL<4PJI""&4PR1IS*?!
MO)1_0J,>I/\ F_GT/^7]%Q';AJ::Z6R?EG&<#\\=$W^2%%19WL7:&:Q66CP>
MPMX=0]EX'=>.Q!F.8P.:AP&6WEMO<F+IJAHJC)4>-W(T;UE'/3S4\U319"FJ
M;#A@II42+IJH8YKY5&13_+Z5Z%,#RQDQR99:&.GG0@5KPJ!2@/E0]5A_)_;<
M6<Z>RD60R GJ\MMS%YS^+4'FSE!3GKW=4U32>: SR5TTD&WMQ-1QN*EJQ\=Z
M9DEE$-B:&4I=E>VK K3 X9&?\'KY]'L\.J(JJD(&#'CC\)Q7C7)],]4*=];8
MS6)K8\CDL55QI+C6UU=,5K\49JN2&/-5]-68R&IIJ6BJ:M046=:9I#4&P)O8
M:;=*KQA4>M*<>/RX\?Y]!J_A\.740:<#Z?/]OY=!%MC$M!OJ#%2JL4F2:CDC
MA\QFFI_XVV.K3%))]M2I#5R4_P"\$%BBLO\ 3A1=D?2^)Z#_  5'2FP4&>-3
MYXS\R">C^= ;LJW.5I9Q*D<&X,E1X^$^N.GQE!7>&"&".36R4T,9]3@%I&X(
M(Y(,W6V59$<<64$_;3B?F>I%Y<N'9BI':LA"CY>GV#JV[J#(4(S>.AK(0S32
MTE0D<I$2&F]*Q)(0J- OF8D$A&TE+<JOL'RG$@XBM/\ 8'4T[5'2BBH8J#]@
M^SUZN.Z6W06\GW+PLAJ/(L@A9:9:>+QQ0Q1E29Z=:Z6,LG(5U#@:K+<ND8K*
M*@]'%U;A55D8A?,5R?\ )T<6#<<=28TB)5#3-*JL)+R(DKEIXDBOY98) 1H.
MD6!;5I!LZ#5N'^KUZ)?!(K4]U:?RX?*O0&]F[@H,5B)JW*U4%/3I23B2%G14
M:I2*.1*=XI6"2)40AR0I,>D_0WX<*A2-0P0,#)Z4*:N HKGB/YFOR/\ @ZH3
M^6'<>8WU7G:NP<55UK/&E?5Y6LJ?!%C,+3R3M7S/JE9:2DOI*@D25$H1 &92
M?9Q86$+N9IV(BKV@"NHC_ .F-PNI((VM+) 9F'>3@*/,UX_YSPZ$?^4]BZ7(
M]D[HFR)DJU9M=,\M4YFAA2T4,BP:E?RPM*S1F_D]3,BV2_M9ND86:VATT0_%
M3\^BO:'I;7TRDD^( M:G'I]G6SS0XZ/$8]:Z$1+XPC).ZEFEJ1(SM$Q(.AI(
MH0?1P'C)/H'*<0^#%K5: ''G_JK3IQI?J9A;$G."H]"./SR?YXST\54)-)2Y
M21F65W4LGK?QHPU1*RL[:R$&DV^K78_7BUS;H(XYQ4$T_+IF*4+-/:"GA@&A
MQFG$CT]?LH.F:?,U>W:5<XY@FQ*5!5J<1R2^5YIO%3I$8P9EED-](;TV(-CS
M9LNR(K:<*,U\_M(\^J"!+_5#4B<K4$$5 '$YQ3UZ7&V-W;6W?2Q5^&R$#I,J
M:4$T-0%=O6\""G9W1H0OJU+;4_%Q8E9:SV]ROB0N1_1.:?($'-*?SZ)K_;=P
MVYBEQ%4#S&#]IK09)Q\A]O2DEQ<BLOAEU+Y64.-$IE"QNZCQVTK&&0$E;L>0
M+^U_@D >?_%8Z1)>*0=:4-*TX4S3CZYQ7'#ISIL>L:QO,!K!94(&B*0V%20Q
M8BWE N HN0"#>URHBA50ID-/3\\_SZ1373,76/@1GS(_#_+_ &<=,>Z*:G>'
M28VU%" J,X# !]9!1AS+8@G\@\GVAW.-&C*Z:$?YC^6>C+9I9!(>\4KFOY?X
M/^*Z*GO*B\'WBRQ"TJ2I9O1$OJ,T &C2T,=F'Z?J!<?FX)NX%:H<>7G^W_4>
MA[;R"B$/YUQUJN_,_,46V^W-\YM0D:[?6*:I-/(OD*Q^&.L\:Q,BI6?9RS+Y
M Z7+AD.LJ/9GLD+![8*H+:P:'S\\_;Y]%O,,BC;KSQ'95\$@D<17%1\QY<.M
M;_MYYHJNA;%U;8O(I!20RU4@C%-E*9J-J.N.36%8X9?XPE.(ZA'14J +N5<%
MS,^SD1,0ZZHM)P.(S44^S^7SZQDWR%KA0J/ID-*MY$9!K2GQ>?\ DZ.1_+V^
M57;'465S73N(R_EZ_P"PHUEVKA,C$^ZMI;-[.P#'+8U7P$T]%15AW10>7&5
MQ+4-7/3U<31$5$9\99SAMEMN%K%=:-4\1#.&P7CR#W99=/$5J*@UQQ4<H7ES
M8WK;?* MO("B,AJ(VP0144;5@-05X4SUL/\ 7O>\':6+K\=/L;%U.X*>J@S<
MF'R.?W!-FEQ DR69QNX=G;D>9JV;&"H@JZ>GI*N3_(ZZAE6EJ"L$/DB*YLM*
MD)%J!&& R&%<8\Z9^S\QU)\;TD[KHA:?#04(-!4CAQXG'G4=*[(]R5FWLACL
MMC6H=C[<PE8N0QV0KZU*^U+DBM!O?&;BFR$$A6LQ=6LF3@ABGJ<5/#$1"?\
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M@7M?WN/N8 U].D;,NL%2.((I_GZU(?E!M_(;I[M[ P3RO#B)LWAMI+#Y!RU
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MZ+W2U@ZT[VV'NV6Z46/W/1XW<TJHP\6,RX? 9/(Q:M6I6IJY:UUOK5HY2NH
M!C%X_P!X;+N%BN7,1:,?TD[E'VXI^SI-;2C:N8=JOR?T5F6.0_T'[&-?EJU?
MD?SOUV7613I243N9)XY)4,LC)(IEBIA1OZ%_::+13V _#$F_U!B5SH;4!@C_
M  _SZR1VZ741&WQ5I^=/]CH\OQ\WB-KYS%S^6T=0U-23:UTQ)-,\;TK%@Z*
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M,1GB,9 5:BIS\OV G_#T7&AV_5Y2#+[>Q%?C-MYR/<6.R75^X,OD%Q..EW+
MLN>I:63/3F.'"U.2W12PXJ'(U#4U/23R44OEA+B1C".<*%E.HEE*R!0*@>1
MKF@S3TKQZ#=TDCEX@J]C@QD\"37!\Q4XKY&G#JV/XWRQ96+(YFAQE-/EI:&+
M;W;>R#7T,NTX]WT2QQ;IEIJB23&QNV9:CU;?HJ2:6JQDM8SUM&BPTQ :W231
M<N='8_<JTH ":GS./09_8!4YVVUDDMXSXK#P^TDU+&@HI.*U &6H 1\R>KH^
MO^DCDIJ+>E-/F<%E<CB(<#4?QW"T<>)W;25<-,^,VOVABH(4VSO.CQE13"3
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M82"H?2VI%821B0RZ=#A S$_;:P-14%2M[:K'V73G)J2<^>/]5.GE1$12I '
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M5?MI)Y:^:7;U91^61_)'3X\[>J9UBJ)J<Z:BNCJ*",.8B4HI9Y0CL0BQH+@
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MQU/LS!X_:%+:NKX:JFRF?DCJ4CFS>ZZ^6L>CQ7G<*ZK%4,)YE.OQK32"^J)
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M7(]?0G[/Y]-^6[&PN,ISDJJHITB)E'E,H6GLL>I1-4!B/(H4ZA=>."/>@[.
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MV4FV*G=>TLO4438N.@J]Z-18.G,TF=PM)-BMP9;,KMY9?*BQ456S2E4569B
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MHTL43:Y Q<1.P<+,);A"VJ,GTGD^R]+@,U)>!/''^K\^CF**XB'B6V"!]O\
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MMK+UV1K,&M<N-S&1H=P)A,Q@L=E,5),C*)H:M8"R/4PI _E":YN%@0,023P
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MY]1G#>75M_N/<NF:]K$9Z%O%XO'83&8_#8BBI<;B<30TN-QF.HH4IZ.@Q]#
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MHS +8Z_J/J+)W&DE36GGG_5Y=>H*G'R'24KL>&C;TH$5;("T*-')XG:S/J+
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M0JAN;Z1Q0&@/V</Y=68@T\J\.FY]'D;UE3$C&1V 4L-<211.D$ABC2S\,-1
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MZ=(7MI0AE#%08GB:10\P# /%.UV)AD;TLR@7<:2UF"H4P#Q^SS_S]:)9#7R
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MR"!+=N88K35;V1#W'FW%5/\ E/\ +_!T8P6A/=(*+Z>9^WTZ^@OT_P!.]7=
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MAVQ1'[?)+\=.I,S3UFY*AUD:1*3L?M.D-5AL0ZF(+44>WOXE)/!+>/+4LBE
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M>!<'\NOHNQT%33J8$HAX8:LP1*L$FNCGK9'OX8R[/5PR3:&:$E=48>X'ZO>
M3)I!$<1,=0%P<%CY9JP)H:&F*_;UG8DJ,>Z;]335C44;0/7@#2M#G-/LZS/)
M! $C8HTM,DLTM,5E2&*.H6$Q9"%3(5*1F-UL=/D6XNK\>VEDTZ IJZU.DX&<
MA@"?D1\Q\^G5C:0,Q!T.0 P(K4$U0F@XU'K0^HZBY6K=HD>2:*-(XH(/,!3P
MJ\4"%YIQ)4_;05,4.I5ED5&)B4!;EC9V9I-*.6% H%: <.)S0&E:$^G7K=$9
MC'X9H6+:<G)P%[=1%:8SQ.>'0>[F@IY&CG@CI*F>)8D1FIXO/3APTL0>0O\
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MFB_OAE-NIA>QZ>GI(?MZ>DH>T-J38'L7'44<-E\%/E(H6")=3H32_#=7%O\
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MQKD^""/FJ,S?[7K56IJ>-8:>DB18 D*,FD.46,1E8!*RE-,(BBTDZ@RVU%B
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M]=]&GT:?8=W*M,_O2O\ P^FG\J8Z70<!_9?\V^ML#;?_ ![N _XLO_%EQ?\
MQ[?_ ![O_ &#_BP?]67_ )5?^;&GV%F^)N/'SX_G\^E/3U[KU[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>jnj-20241229_g6.jpg
<TEXT>
begin 644 jnj-20241229_g6.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !]     $  0'T     0 !_^(,6$E#0U]04D]&24Q%  $!   ,2$QI
M;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#
M('-21T(                  /;6  $     TRU(4" @
M                                               18W!R=    5
M   S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@
M A@    49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD
M9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4
M;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P
M  @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W
M;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y
M-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                     %A96B
M      #S40 !     1;,6%E:(                     !865H@
M;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /
MA   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M     !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                    9&5S8P         N245#(#8Q
M.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M       N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="                             &1E<V,         +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M     "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M
M,BXQ                                  !V:65W       3I/X %%\N
M !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M         0                        */     G-I9R      0U)4(&-U
M<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\
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M[D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?
M2 5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,<DRZ30)-2DV33=Q.
M)4YN3K=/ $])3Y-/W5 G4'%0NU$&45!1FU'F4C%2?%+'4Q-37U.J4_940E2/
M5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8RUD:66E9N%H'6E9:IEKU6T5;
ME5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S8 5@5V"J8/QA3V&B8?5B26*<
M8O!C0V.78^MD0&249.EE/6629>=F/6:29NAG/6>39^EH/VB6:.QI0VF::?%J
M2&J?:O=K3VNG:_]L5VRO;0AM8&VY;A)N:V[$;QYO>&_1<"MPAG#@<3IQE7'P
M<DMRIG,!<UUSN'04='!TS'4H=85UX78^=IMV^'=6=[-X$7AN>,QY*GF)>>=Z
M1GJE>P1[8WO"?"%\@7SA?4%]H7X!?F)^PG\C?X1_Y8!'@*B!"H%K@<V",(*2
M@O2#5X.ZA!V$@(3CA4>%JX8.AG*&UX<[AY^(!(AIB,Z),XF9B?Z*9(K*BS"+
MEHO\C&.,RHTQC9B-_XYFCLZ/-H^>D :0;I#6D3^1J)(1DGJ2XY--D[:4()2*
ME/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R::)K5FT*;KYP<G(F<]YUDG=*>
M0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:DQZ4XI:FF&J:+IOVG;J?@
MJ%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:OB[  L'6PZK%@L=:R
M2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;
MO16]C[X*OH2^_[]ZO_7 <,#LP6?!X\)?PMO#6,/4Q%'$SL5+Q<C&1L;#QT''
MO\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XVSK;/-\^XT#G0NM$\T;[2/]+!
MTT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9\=IVVOO;@-P%W(K=$-V6WAS>
MHM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;
MZN7K<.O[[(;M$>V<[BCNM.] [\SP6/#E\7+Q__*,\QGSI_0T],+U4/7>]FWV
M^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X $T%D;V)E &0
M     04  DE$_]L A  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0$! 0$"
M @$" @," @(" P,# P,# P,# P,# P,# P,# P,# P,$! 0$! 0$! 0$! 0$
M! 0$! 0$! 3_P  1" &# 8,# 1$  A$! Q$!_\0!H@    8" P$
M    !P@&!00) PH" 0 + 0  !@,! 0$            &!00#!P(( 0D "@L0
M  (! P0! P," P,# @8)=0$" P01!1(&(0<3(@ (,11!,B,5"5%"%F$D,Q=2
M<8$88I$E0Z&Q\"8T<@H9P=$U)^%3-H+QDJ)$5'-%1C='8RA55E<:LL+2XO)D
M@W23A&6CL\/3XRDX9O-U*CDZ2$E*6%E:9VAI:G9W>'EZA8:'B(F*E)66EYB9
MFJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8V=KDY>;GZ.GJ]/7V]_CY^A$
M @$# @0$ P4$! 0&!@5M 0(#$00A$@4Q!@ B$T%1!S)A%'$(0H$CD152H6(6
M,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V160G"G.#DT9TPM+B\E5E=58W
MA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=79CAVAI:FML;6YO9G=X>7I[?'
MU^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H
M# ,!  (1 Q$ /P#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4&KR>/H
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MF=605M/8JS:V60ZKJEO96PM"/X3Q ]10BO3$EDB@^(2#3##(/H#CC\^KX?\
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M9GP.^8-?03U4&6I?BGWA-C8Z:>&*>MJ*[:LV'TTBR-Y"^.@KY*F5T&I(DLK
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MG'XC?W<G:&["F'V?MO*UU%4+04M/#7YO+)25#T=%+#!+-&EEN=!T1IJDI7T
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MY:.U9:5,ON;:\.R9:"*F*X;86=I\O09"2 1UD-5Y<G'6S8W*4$T0;[*HTQ5
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MQQ]/\_67*5V9W1D&R%+E*G(U[*T!%-]W)E)XW61R(ZN63[BKA2)6^KMH!
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MB9...6U1RP4>N6Q6Y%PJVO\ 0'GBX/\ A[=1M)#EA_MNGM+:20.T^73[3Y:
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M3UH2>VOQ5'A9C!(H' )_UO99):+"*1YTGRSYUZ6EW9V+*RN>(;%/LZJ/^?\
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M*9%35E/KYD?Y>@AN]HK(&7NIA6'^!CYCR'6R_09""M\ZQ2I*U/*8);>EXY5
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M4$61BQTD]'09&6"9Y)(JFJ$XF='"OJ:Q4$D>R,DF0!> /$>@^71_))V!3BH
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MH>6;*&W0F4DM0F1V"K\U48J/G_+SZ <O-%R;F1(+*BBH"*I=O*C.14*3_".
MXGIZVQ\B/YD'RER>.PVWL/W;6XHSP$T.R\%'UULV>GJ7B\596[FR5.NZ<C!0
M<-JE;TQW5BRL ?3GEZPB,?U$1ET_""78^?EC]O5[.YWZ[;QS:2QQ>;2:8DR?
MPEJN:'Y#H\5#M_YF?'ZI.Z,QM\RUB8]8JC>4N>W/2Q-CJ69JZ;'3;0H:.OCK
M*6IJG*I75$(B U%D34&]AEVVV[;55E\P< Y%#Q('0OB:?P@I>.9/Q$DU]10\
M?\O1F/\ 23M?Y3](G=^.HZF6CR*U2[CQT\%3%4X7)XC_ "/-XBHHJF"FJXZA
M*ZG90DD4<IIY4<CU$DLN+.3;Y&4UJ2'&1E?(@BHX'/3:21S&)U-8Z$$$4S7*
MGTIUJ,_S#.HJC8^[8*U:8Q8RJGFQQG\8BU')/59+'$H':YI2DL*E?3:/3]5/
MN:_;^^^HMS5ZN,4^S!'V4-?MZQ]]R]M2SN.U>T^?^FJ5/Y''5>FW,=_%":0.
MPJ'4RT^DV,TR*R34I=00LLBJ&0MP2+'^ON1[AG450?:/EZ]1/:!')20'C4=/
MF0 Q-1C&K1"$R<<U*1=HPTL 'AJ@\;CPU2!]$D;_ %96#"^D^T)5Y8I-(.M:
M&G^3YCHU+B&6$NPH]0:_+SKY'I9[7P#5.0I?M*R!'G"*DDS30PN8B;1U'A65
M?NXF9E68*?(ITN#^GV2W-V70I(N17AQ_XKSIY=&UM;!3KC(!\R<?MIY_/H>\
MZE?MW;]7D(ZK)4OC=*2HQ=?2#(XFIBU@^; Y:E8I1-]T.4E6%5 _"-I]I(*O
MB@->'R^T'T^72^=0JE\U]"./S'V]!9NNHHS7X3=RTV.I8<M-$N8I: 5,%/.T
M@$=1.M.09*>DIVA=VCY"U ;02A4!?-%KB.G#$$C[17A]O#HI$@29J_V=0"?*
MF ?V='A^ ?8^=^/W\P7H;>(W5%A]A;V[3Q>V=W56-K*W&;7R6U>P9J[:=95R
M5$2"&CP5.,ZM>)PRMC%-]48# ;VV_C9HM8TS5TL*@>8K7YBM/GY=)MPM)5\9
M!1H<LI )!XTI\N'7U(^N<G69K#XW*96EAHLY)M_ P;BI89HJA:'/I1Z\ACEJ
M(@/N8X-2R1N0-<4J,.&]CB(EJ-P-,] *8!:J#5:FGV>O0C^WND_7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO="WL"L\N/JJ)C=J2H$B GZ15*D@ ?X
M2QN3_P &]M.,UZ=0X(Z7ONG5^D5ONK\&'2G!]594QH1_S:AO.Q_V$B)_M_=T
M&>J.<4Z!SV[TUU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U7E_,0HJRGZSQ
M>Z:_9!W=U[A:BNC["R^.P=-N+/=7T,E*U3A.Y*?%305->^*ZRR],*VMEQT-5
M6P4KR.:>6F$Y1'=@A0].T<?.GS_+HQVXKXC)KHY^&IH#_1K\^M1[YN=[=!;P
M^/\ V5C(\94];]T34U!N?K[<& W=5[@DKM[KNB.LW7ALGB\L\,>#Z[WM@,S_
M !G"18J=?#601SZ5B0P$.7=S;M&VI:2\5(]?3[.A7;P7 D4+*#'P8$4QY4]2
M"*'JEO#_ # ^0&WNL7ZCINS8J_:&3R4F9&'W)LG;FY)Y-Q5V-FQ3U\>[Y\4-
MT5#-3-IH14U-2U*41(UTJA]H$W.8*$TJ5XG5Y?.O2Z2QC)U$$S4H--17Y4Z*
M%)L88R6IRVYY5RM32SP9*CQU"Z_P_(9 S&6FDS%;D4AFFEFK)UFEA$:,%4JQ
M4@)[JFX1L[I$*FA4M_F\J4ZO](VE6FKI%&TD4X>1KGCU'Q-+/NC<K8>2H@J*
M>GH=S[CR51&SI2T1@I9*ZOJJ9_0\K4ZIXX2;:IG '!'M+<.MM"9@E6+*B@^>
MK 'R]?RZ40PF:7PRU0%:1B,4"BIIU#J]E55;M/\ CN-I!+(_DER]33R1I446
M/IT2H>&6G*Z:NIJJ70CLNE@&;4=1O[>M[[P;Q89G-30(#PKPKYT%<CIN:S66
MT$\,=<U<BE:<:?,D8Z"6=_/)5UOD@FIT:D14IN*K'SU%6289*8D)XF5O3HU
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M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TY8>H^TRN/J+V$59 7_'[9D59!?\
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M]8I_I0W\B>@/: VM^D>K^RO A/H-97C\P >KO^E*<PUC4C.Q290!)+(8VC,
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MQ*T,*Z3_ *H<G_!!=N7?3FA[NC">(&* @=RC3C[>CS[B@FJ9Q42%3 J!7E4
M)%&#<^D7+J38\\_[S[+)HV(U%<#%?G_GZM::(U*"NJAX_P"'I@@W[@J!Z<5P
MJ:*(.(WJPK&CBD1_!#]Q+I_:20FQ_P 6 '/LH0?3R,[U91FHX"O3QM)Y@RH
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M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TX:E^VM?G^'Z;?[5_%==O^2>?=?/\_\
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MY32J\,1>_/!"\M_3W17#UQPZ\5*TJ>GN)- %M.@KQ<"ZD&P%Q8A;<G\ <^[
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M%(!-V^GO4Y!C"D]S$#^=?\G5D-&!/ 'KY-&S8&VKBJG/Y%Z=Z_9VUWRTU)*
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M &L3J (+[E2<@_X.O*,U-:=/=-M^KI]4BN9BSE_+)X_(@-[)$FF-$0#\6O\
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M\? ]97Y%W<"XI*&"24\V]-S[0W-Q. ^J0T]3PI\_RZ,[:"-T1PA9SVA?5B:
M?F<=:86X.MLG\D._^]/DKN.BKZW,=R]F[BWCC*>JBDBI(MK1FGP&P,+2RL4\
MF*QNRL-0ZWN )IF"@#WBKS%O\F[[O=S+709"%X_",#/#AUFIR]R]%R]LFW6"
MT\2.,>)Y]Y&IOR#$XZ2FY>GVQE>L4-)&SI)&5^TA5@&9F96"D!9%22ZF0BP4
M7-S[+X)CE2Q^5>'1LRAAG[*],64ZASM9C9IJ:&1HUB:>0I<AU@5G++(5C)18
M1(1RH YX^GM8EP@=E\^DD\9 "U%#Z_LZMIZCHZ/:W36%IRB1PTF&IZBJ9&1)
MY5E 54II ]HE!;7Y"ID4'Z7Y]A:YD,EQ*0]'+5_U?9UJ8DR(#6M*#TX=&&^,
M?QCJOD1N";=6ZY:VBZFQ-0J11TU7_#LIN>8R:Y,93UVEY:+$+:TE5$K5,K,4
MB*>I_<L\C<CR;RJ[INE4VDXC05#3&N<_AC_I#XL@>O44<_>X,>PEMIVDJ^]D
M5D=A580?E^*3S /P\37AT=[L+;/3.T,*O8.2V]@L'T+U,:O!;#ZRVE045%6]
MX=ATWDBJE6KC1*FIVM39!32U%9(TLN0:"5GF%/&=<Z0VMI80BVLK98;2,=V@
M #[%]2?GYY]>H&:^W&^E?Q[IY]TF.II9&+>&I/GZ>M!0#RR>BB]P_./<.XML
M;@P/2%#DZ_LS>F,C&1W-D,-]KMSJ?&5>,7%C$X6ADA02YC X\/!104]Z2.1?
MN7:S"-@A>/?[S<FW!T[:A/8,U!'P5\@?,\3T=6NRQ6066\/ZGX:'+'CJ/V_L
M'V]$>Z1V0VWYL9B<G*U6U/+:JEJF,]14R(Q>HJ*VHD+--4SRL6=FU,S$DWO[
M%=G%]+;K&U*T_9Z?LZ;OYO%D+\%/EQZK._FH?S)N]OA/\H>K=B_"[L>OZCWO
MLS;M!V;V]F\6M+F-O;UK-\4[Q;3ZUW_L3("7;NZ]J8_:](N0J(JN(5,=771-
M#)"41PKC0,6H_$^>17_/]AKT&-QG9A%$5!([J^>?*OI\NK*/@C_PJFZ*[(I<
M+LC^8!UZ?CAOB0043]X]:4F;WCT!F:HDI]]N?;(&0[#ZH$A(,A"YO&0W)\\:
MC2'P60T)%/0G_ W^0_[UT5!N-145\O3K:*ZR[/ZQ[KV9CNRNF.Q=C=L=>Y>.
M*7%;TZUW1A=Y;8JUEC64*<E@ZNL@I:Q5<"2"?PU,1]+HK7'NX88J""> /G]G
MD?M'5@0U*&OV=+?R,"ZNA8H Y,08@*?I>]C<_P"%Q;W:O&HZWU#D9;OXB AT
MDZ>5/ /(_!!)_P!;VVV"12G7NH$4=15U)BB#R2:EB@AC!?R2W!TB^GEW('O?
M!:D=OKU[KYMO\\;Y"'Y"?S*OE#F:3(_?[2ZHSN#^-^S?MZF:>DFPW2^,&'W#
M/22(YIQ%E.Q,CF))O&?&S(H^H/NT8TPI449B6/Y]-L1J.<#'V>OY]5L]5;4.
M[/[Z;ARU4V/V[LO$4<4C0R8Z')9O<NY*AZ/!X#;<64#4>4RT%)1U60G@NLJ4
ME*TB<V]OPL%?)()! ^WUZ8D-14# (K]G3!VQG$)J:>1P9$7Q.0[$B2!%AFE-
MR"ADF#\@#@\^]25+,33C3'6EH)#3TZ+%190154D;$ $D![_J9C>['Z *!;CV
ME 9\&N//I1@"HR>EO1NLNEC9T:Q*\6OIM=O\ ?\ ;_ZWNH!K2AQTX#12PX]/
MT,0*JJC45+L"BV5#I&EM().D 'GZ_P"/M\ #ATP23DGI3T&&2H2&G58Y#*P&
MEOTR/(UY51@/UZK'_"US]#[=XJ N:<>DIXT(ITG,CCFW%V'BMMK%Y(<+%3)-
M'$K/JKZ]ON'"W #:(C&A-EY!/%_=!W2 L_P_Y13ITC],Z10L<T\J=6A=:XR+
M:U'1T0BIU4I&DL*^-1'+JTK$P?T3+53AD8-J"DC^I(>I44KJ^?K^SK>$51Y^
MO5KW3E%C*+"TE7.M/ !15%951&GDFB1M,4,<%3%S++.JOZPH$<MD N06%'R4
M'^:@'V_E_FZ7P$A2^DU!J"<YIQX='M^+_P 5MT?,KMN'8^':KQFP]O245;VE
MOVE*Z-M;9AR52T6$QDTZ&&IW7N":*:/&QE)4B/EJ)$:.!_:::58(PQXGX:>?
MV_(5ZT[*_!: '@?\!X=;?>P]B;1ZQV;MSK_8>#HMM[0VGBZ?#X+"T",L%'1T
MX)U/)(TE15UM5,SS5-3,\E155$CS2N\KNY)F9G8LQJQXGJG2M]UZ]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UT0&!5@"""""+@@\
M$$'@@CW[KW0.[JVR<7(U=1+?'2N-2"Y:DD8\(;W)A=OTG\?I/X)=5JX/'IIE
MID<.D5[OU3KY?O\ PHN[*J^R?YNOR?HIJW[O%]983I+IO *&$BTM#A^K-N;\
MSM)&0241-W=@Y$..+2:A[<BIW-7-:'IX$@+3@!U2S04^J15]-ENS'Z7 -P&(
M]O<,CIMFKT\> 22Z> B@V4'E5^MR3]0#[LN>/6T%3PQU8A\ N@-L[SW9EOD;
MW)B17_&[XV9K#Y/.8F?7$O=7>$L?\6ZKZ P;^A*Z*MKX8LWNDJUJ';E&R2>N
MLA5E$$#7$FD?V2Y<_P"3[3T^H"]QII&:>=>G'Y9?-;.[KWCO&:AR]'NWM/>E
M=F,AO?>\+)48'9V1SM=)65>)VO#'_N/R>?IJ618C,J+38B1"E/K<:U6W5TL9
M*1?'2F. 'IYY_P '5#(M*:<>OV_/JW+_ (33?S1H_CMV]-\"^^]S5"=(?)+=
M_P#%>B]V;@KY:B@ZD^1F<=:>IVQ55=5*'Q>R>_IC%"[!F@I-TQ4\Q117U,JE
M2N8Y-8),9/<!_J_9\ZCSZ\""<'/6_P!225"*U+/Y5>)WCD1M0DC>,Z'CD7^Q
M)$ZZ2/P>/9H &JR@4I7]OGZ=5+'4 /7AU+HUB.J&+_*:>0B67TZ9::H8EBQN
M%!CE(]1']K_7]T<%3JX-_A_V>G!4X)Z?:=44%+ *% _-K7_V/]?K[3N3@_/J
MS+D!14T_P=$J^=&\*WK[XS]OU>#C9MT[RP5/U!LU$9M<VZ>WJ^'8] BA61BT
M.*RE;4D@@JD#'\>PKSG?/MO+VYW,5/&,3+&//4]$%/LU5^5.AW[;;8-VYMV:
MTDS;+.+B;_20@R-^TJ!^?5.&,V)#LO8>&QJU$<E8N*BIE7&QQR17@IEI(J83
MO=8:.EA()8#C@L?>+H@=(8RS5QY9K]IZS%:5)IY6"T6N WSS7HOF<V@U14S>
M6FCD92)*V>$^5O'"MXDCD8J)"?']%(O>XL/?@2I-!\O]7SZTU*U-<FG\^E_5
M[7Q.-ZUSV1GCIVJYJ'[.F@4@.S5(0I#+8:T::%B&1OJ 3[;82%'<5KZ5Z8-'
MNXHB3X0[B:<?V\>G+8^-RNY<?B*:*C=\'#7P[8H:6EE:5MQ92<1Q28C"P1PA
MDI::8Q1U<GU)_:0W+$#GD/D1>8;D;QN47^ZB!Z#B/&<<5!_@0_&?]J,UI&WN
M%SDG+\;[982:M\F36#Y01G@[>KN*Z!Y?$<4ZNPVWC8]D=58;9-'B*JE:F-,V
MX*;;\E/1#)4B%#D,/+E6#3T9K6'A9J,'QQW56%[^\DPJP:4B15@"Z4510 #@
M . 6G =8N&22ZGED8EG:I+R&IJ?,^9/J>@C[;V5N#=]!29?=;4D+- ,;MG;&
M,@^UPFT\# GB%%BZ-!H$H@5(3+IUR$_4#CVEN0SP%:47@/\ 5Q->C.PDABD
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MW#V)T-O$2ZJS([ W+54M!GHUDU?;;NVK6QS[)W92SO\ YR.NQE0I6]F%[BI
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MF-S_ +$^_=>&01T+NS7QBSQ1\HWH7QSLJF7Z%C'>RW*<"YL"??AQSPZV31:
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MGB?/J11J!44\H"AWBUH);B.-&6RF0)8M:P/)_LGZ>ZR*: +GSKTRM*L#6O\
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M$<<4:QI4?;RF:1YYYX[DH5"ZA900NH>Z2AEDHW >?Y?M'2Z!E\-S0D4I^?\
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M^%$,.X(2D<A$CK2O"A!.O2-7M])4;C@_/HT@NK>0G4^EO(-\OY='T^+79?\
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MPZEDA39&\0=EU3%@'D2*]CK#:%@+?YOB]OK_ (>U4-0*=5/'Y^?3-63K$)9
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M#G^HM[3.2.!I]G^7JZK7-<=)B:3RRZRH-XV15$?$DA)9F( + QL.3P6M_MO
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KNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>jnj-20241229_g7.jpg
<TEXT>
begin 644 jnj-20241229_g7.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !]     $  0'T     0 !_^(,6$E#0U]04D]&24Q%  $!   ,2$QI
M;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#
M('-21T(                  /;6  $     TRU(4" @
M                                               18W!R=    5
M   S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@
M A@    49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD
M9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4
M;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P
M  @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W
M;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y
M-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                     %A96B
M      #S40 !     1;,6%E:(                     !865H@
M;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /
MA   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M     !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                    9&5S8P         N245#(#8Q
M.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M       N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="                             &1E<V,         +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M     "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M
M,BXQ                                  !V:65W       3I/X %%\N
M !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M         0                        */     G-I9R      0U)4(&-U
M<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\
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M[D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?
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M^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X $T%D;V)E &0
M     04  DE$_]L A  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0$! 0$"
M @$" @," @(" P,# P,# P,# P,# P,# P,# P,# P,$! 0$! 0$! 0$! 0$
M! 0$! 0$! 3_P  1" &# 8,# 1$  A$! Q$!_\0!H@    8" P$
M    !P@&!00) PH" 0 + 0  !@,! 0$            &!00#!P(( 0D "@L0
M  (! P0! P," P,# @8)=0$" P01!1(&(0<3(@ (,11!,B,5"5%"%F$D,Q=2
M<8$88I$E0Z&Q\"8T<@H9P=$U)^%3-H+QDJ)$5'-%1C='8RA55E<:LL+2XO)D
M@W23A&6CL\/3XRDX9O-U*CDZ2$E*6%E:9VAI:G9W>'EZA8:'B(F*E)66EYB9
MFJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8V=KDY>;GZ.GJ]/7V]_CY^A$
M @$# @0$ P4$! 0&!@5M 0(#$00A$@4Q!@ B$T%1!S)A%'$(0H$CD152H6(6
M,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V160G"G.#DT9TPM+B\E5E=58W
MA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=79CAVAI:FML;6YO9G=X>7I[?'
MU^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H
M# ,!  (1 Q$ /P#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4&KR>/H
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M>]^Z]U[W[KW7O?NO=>]^Z]U,H<A5XV=:FBG>&5?KI/I=;WT2(;K(A_H0?>B
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MC&R97,Y7.K"^/JF:.2CBJ&;252Y5?3)*$B0@BN3Y?(?GT?;7!+;&2:9"M0
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ME<+!BJ<-3Q)#M_%5V?WCG\\-*M5Y&MR&+IZ"&1F$*??+"L8$;>Z(J!"P-&(
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M]5*:J22LD@B.NH5J: KIEO[W_7&SA*"=F[R%!6E3ZTKY>53\SY=>;D&>2-C
MZAE4D@@TXD@'U/G3[!Y]$J[6V?VQUGFWH\O1;H$M;34F5J8X'AILKFTD16ER
MNZ,[JEK(&K"7ABPF-,:4T"H)BY%V%.V[GM6X1+(EPA/ 5K0?(+_/4>/ET"=Y
MY=WG;96$ENY73J+ #-?,D9K7&D</GT!VS^Z.P>N<_'D,/$NT,A2:6I32;JWG
M2O)64]1J@1$QM748ZFKJ-;Z XC3AB5YL3Z7;;.]A&ERR$_$$'IZX:A^708BW
M.^L)@%C 48(J2*_8<'JU+8/RCA^1V+DIM[4.'QG9]32TE&,KALK%MW=V\6HZ
M 8ZCGJ8*^IJ=C;L:6@@FB<,JK5V1)%BD*R^PY/:/8RMI8R0U(P.W]H[D*X_V
M>A597Z;C%HD(CF(TJ#@_X2&4^0Z"7<.6W+L#*U^[\979O<&/H%@\ QNW\CCZ
MS&I6LU!%0YX4]=4-4XZ">.1!154=8T$D/W"3>)2?:ZSN$DTI4!_,D@\,FGS/
MRX^G1=?PRVS,5^#A0#\LGT/\NKP/Y0W\V/?737:/5_QJ[LJ,OD>G^SFKJ;9L
MM,^%JL?L;(UT_P!Q)7?>U]?'F)*6AR\DR9*"-((6C9ZN!)9%D$@LVR_EA=8V
M):W)T_Z4GA@XI^?0%WK;TO0\PCTWE*@_Q >6/.@QUNS(Z2(DD;*Z2(KHZFZL
MC@,K*?RK W'L7] +KE[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NEEM;<S8F44=8[-C96X/+&DD8_YQ!R3"Q_6H_X,.;@T=:Y''JZM3!X=#(K*
MZJZ,KHZAD92&5E875E(X*D&X/MKIWKE[]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NDKNC<2X:G$,!5LC4*?"IL1!&;@U$
MBD$&Q%D!_4?\ ?=E6OV=49J<./0)N[R.TDC,[NQ=W<EF=F-V9F-RS,3R?;W3
M77'W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW73,%4L?HH)/^P_XGW[A
MU[CUIK?\*@OD7G8WZ]^/F)S\L="V"BW;D-HQUIIZ?*9'*3Y2AI,GE((GCDJ,
M?B:+'OH5F,4U541HZA48DGNY"TRQ'A2M?Y<.A)ML:1VC.M/&=J?D.M'ELZ_W
M+TE=23STCN(:J&0+K5 &$JQP:EB#Q&1F4#D,.#]0:B'2 0W=Q'5C(265EQTN
M:2APS4D4^.R?V]<:K&U4N.RTT0IJFMQ,*+35.&J9I?&8JM2I\,FF2GE)7Z,K
M>V2[,3J!X$5'^7IV-$J=+4\Z?YO\W2^VIA\C75B2C(MBJN&IC?%9*(BH5<K#
M5I.^-J:.H>FR%"7CDM+%(DT:LBGU #VCFF2)"S"JTR/.GKBO1E:VLC,!CY$Y
MZL2ZAP=+GJ7<:TE' ^;,.->IQ5#5>/'PP0U5159O:53+KJJI-OY6>>2KQLQ#
MQX^H)C+ )H]AF\O])B EP?,X-?)@/6@ST-=LVMVK6/T+-Y >AXX)X'JP/JGJ
M(U"29;&#<64PK2ELWB*VFH6W#MH8VG6499\+Y(*NLIJ44:F2LIY-5)-J*>AB
MOL%[AO*JSQZP&7T/$<?]7\^I#V_8F_3#+53337@2?*H\_3^70_;9V37[UKDD
M3:U5193'&2BINPX*BAGQ&]]NY"CEQ-5BYZ>"E,N..3QKM0SBO:2.:!K2+'(L
M<B@Z_P"8-(UPD^.IH<\?*A\CCH>[?RVKJT5RJ^$>X!AD$9J",@K\NA^ZJZ>H
MZ*FHL&YR\$L-<?X/2Y1%GDQ4L3H\%'_$*'4KU"S4;F.1D9C*!?5Y'!"-SOK2
M Z6*4_//0GCV6" EV5'< "@Q4<*CA\J]&VI_C1BLIN'#;KV]B(VS%++7&98@
MZT9Q>6J#/D:,0SQ+#$D5<C+-&1K#$-IMITH9MZN9%IJ+*3_J/RIUN/:[=  Z
M*E  "/EP]?+_ #=")M;XS[6@DJ4?"4[8B+(8NL*$F #(X?74"K!IV!J*Z&24
MJI^DL:7OR![30;E<J'+$E?4_ZL_9T[=6R+H '?3@,\>''KAO+XU4#8J&EQZ1
M4<*UE4]).:A$T1R/KH%25:1YJAEJ:DDL8P!^HV(][>^D8ER>W-*?YN/252=9
M#+5Z $4_V<8Z#ZA^->#PV'_@^6C_ (W3"LGGKIYJ-X:;(9=JI%6.21P:O["D
MTQZ7:5Y&2)!8*EB4W.Z/XF7-*4_+_!T>VL:O&/TZ$]U"1YBOYG'0([_^(6!W
M-7Y.HJ,9CZS(7DI9I<M11-234,:IX,92T-1&OV^/<*+R1N9Y$C0%N!=39\RW
M5E(1"6'=6H.:_/UZ?FVFTO(ZSA<K@<1\Z_,^9\NJC/D9\'=Y;2BFJ-D-58W#
M/7E<?54TC4\V+E-*YDQ>,!K&Q$8J999-$E5!K-] *\EI'V?W$C=U6\J^D4/'
MCYDTS0>=,=1UOGMRER7>Q6BMD**5% <"N*'Y]5*[DVWO+J^LRV.[/Z[QN6Q6
M4J<>!N?$8:/&[SV]DHZI*V@RT%5@TQ]'#G:>>*,RS?LI,B,H=F-_<OV&\6N[
M11R6-Y5BIJKFJL*9 U5:E/MXYZ@S<N6[_996AW"Q/A@]KJ""I\JC@#^SY'H>
M.KM]9'<F0?8=+52_WPK:BKH*RH>C2IP>]L\L%(:.OP0BGR=7FMPU-'31ZZD5
M<=6#9XZ9U,T4FKB)+=O%%/"I@J?A&<'A10>&/SZ:M9/J5\%RPE.!J_$?EQ%?
MY]+;>V'W5A:2ES#PU&V\_M&LJ*^@J<:N2HMXT%?59"@EQ6YL5)C(Q5T5%55<
M.I*D(J1S1:!%8Z/:NTFD#T#EE-,^6 ?YCI/=V85&++1UJ,\:GCCK8=_E'_S^
M]V;][*ZV^#GRNV-EMQ=B[CW#)LGK7NG:=;%F*G<;K33U=!B]ZX!(A)65U)#3
M2@Y*CE#M $6:D$D<DT@WVW<9F"12KK4\&'$9I0C_ "_\7U&V[[3"#-<PN(V%
M24/ TXZ3Y&GEPXY'#K;P1E=5=#=6 93_ %!%P>>?8AXY'04X8/7+W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO="!L_<OVCIBJ^3_)9&M2S.>*>
M1C_FF)X$$C'@_16_P/#;KYCCU=6I@\.A8]M].]>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=-68RL&'H9*R;U,/1!#>S3SL"4C!YL.+
ML?PH)Y^GO8%33K1-!7H!JVLJ*^IFJZIS)-,Y9C^!^%1!SI1%X _ 'MX"F!TQ
MQR>HOO?7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z9MPY?%X#!9G
M-YNJIZ'#XC%9#*92LJYTIJ6EQV/I)JNMJ:BHD(C@A@IH69G8@*!>_NK$*"3U
M>-69U5?B)H/MZ^4Q_-0^5N^OF?\ (S._(W+UN%PF-W?C:?']=[,H<E]QE-D=
M<XFLR=+M+$[L%-,T<.[MPXHC)Y-%17I:JH:.30;("G2K.TCFI)R/2G^;^?0G
MIX<*Q1'(%,_;G_#^75>NT=MY//(]2?'4?9Z%KWJW'V4,1&E:B3)S^"!)I'8$
M L&N+AB ?;4TB)@X4X!'K]G5H(F=37XJ?:!TMZ78KRF"3,5-#]K41?MM102R
MBL362GA>G<TM7+JNI;U%>>.!<KN=P2'4J5U#^1^?1O8[;XI!9AH)]#G[.C+]
M<[+R=;*E#BX"\$ZT]+*T\IK*%$B8*DU5C:^&:DKI8U8   .!:Y)%O8.W#=HX
M%,LCT<5-.%?4 C('4@[1R]+=.L4<54- 6/ #UH>)ZM2^/O1E&*S'BBH)TRU#
M!5RRY2A>3'X^5ZG2-(I*VH$&-0%58-"ZQ"PNMB;P_P Q<U7$KG2P%3@$]U!]
MGIU.W+W*5G;Q*"E=(R0,$^>#4BO'&.K/=I[$5Z".?(K74^ZJ6.-:#-XV5:>=
M322:$DR@+P/5PR%#=76:&H+$$( H]@N;F"=QW']8<&K_ *J'H9G8[:/0(XE\
M CO7/G3AY?X*="SM39-/D:FOILGB:D0Y1IQ+)3-44=-%4R)YYZO(4N/G^VH*
M>9U\:@*&5[$<\$LFNI95)<5#8Q^W_)T;00"!4\*0:5(H& )_(D<>C9[ V7C:
M6>CB6GD@EI(J-3&C0M*\!!>F+U"(LD*R*@96T^K2=0'Y1*:U4UH/+IBY355S
MIU5)]*'SZ.+@<?#3TTL)$=JV1:F:.:35]'2,)&@8->:X)0DAEOQP?:Z*$$$$
M#-*U^W_+T3%V))7BHH*>1]?RZ=8Z6ECDR-%%&^-\=2$*%SXV*QZXPSL#%]O*
M%N&!#$?Z]O;_ (:5F11ISG/^K'34FO1%(3J)%<?ZN.>FBKHZR3[!"K/35LZ4
M]!]N 7I)70R0QS/$MTB9P^EF// N/I[12I+^F*U5CI4+Y$^1ZO"L#F9OQHNI
M]7F.!H/,CT'V]8:[;=15B1<H\+PT\X\,42ND\C!-(G=Y LD83U,5 (9?I[9:
MQ+N1.W8#BF/S]:=.QW,<-#;J0Y&2<@9X =(_-;,IJ@4DD6,IJEZ5[P%WE,!+
MNO\ DQ602UAE<#6NDV1@"MO>I;&$::1BM<4)I]F<]7CO;A"_ZY"$9H!7SS_#
M]O[.@8WEM;$Y&EK8\K%2DU"+'-0B@@DBR-/*Y22FF>M2;R2HP %A&I(L>?:-
MXXX3JKWX(%>/1A!-,RH4!:,<23P/EP\OV]5]=S?"_KSMS!5^)K:%<?63TTL>
M,>EAK"(TG$@,$"^1 *162TU-*W[RL2I5PMCC9]]N]KN%N8)BO E3P.?+T/Y=
M-;IMEMO%L;>^B5A33XF P^7S!ZU\>XOC_NCXR;GPV6FQ]5BZG#5$&*I=XTM$
M\FWJ["QU;)#C*ZDG^WC;*QQRO#39"I9)_"QITJ(*I(YC/FQ\Q1[W!+&,DC5H
MK1AYDBG 5X@8\Z$8ZQ^Y@Y3.T71=%(B5BA(RI!H0I_R$Y\JUZ.IV%MJNWEUQ
ML[?6R*[,9V+=.'QU!CMN[JR+1;EHHTH$FR%)LC?V:HJB3=V"FCD<)C,K&]33
M,$#/*07)M;7$8\/0X#KAU .A6'RK@U].B6>S>2!Q)$M0!2F#GS\S7[?V]5-[
MXVE5]=;G_OAUYO#=76.\L#D1G=KY(UU;MG=>T*J"?[W%Y["9;:V6J:W!Y6BJ
MX25?&3E4<7C\9#1@6V5X6*B11ZZT)X^?I_GZ!&Y;:J%]!)\BCCR_G_FZ^C5_
M*=^>.ROGI\2=C;QH=S5&6[AZUPFV.N/D3A<NE)3;@Q?:F*VY0?Q/<,L-$L=#
M7;:[!T-EL3D*55IJB&:2!E@JZ6LI*8?6-RES"I#5< !J\?M_/J+-QM'M+EU*
M4C8DI3A3T_+JS3VLZ0=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW0N[-W#]]",96/>LITO!(Y]53 G]DD_JFA'U_++S^&/MIUID<.G4:N#QZ
M7?NG5^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZXNZQHTCLJ(BL[N
MQ 554$LS$\!5 N3[]U[H"MR9M\U7M(I84=/JBI(S<>B_JF8?B28BY_H !^/;
MRB@^?3#&IZ3WNW6NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[JB'^>?\],7\6NCZ'JG$8W:6]MR]M8[+G?\ LG.91HA#U&::JQTBYNFHZREK
M:'![YW#:@>5B!68^BR,$(:471#>2D 1*:,>)]!_L]&VV0!B]PZDJE OI4_YO
M\O7S<LS)-N;<^2RD"XU*3)9"O:F@I:>6DP6.%35RU#4. AK3654>.I9YRL*V
M<VLJZF)/M#4!: FOF?/AY]'-"SZL"AI\JCHP<6!P>&VOBL;DJ%*_(7A>3'9-
M'BI6AJ4:9&CQ$ (25TN5DJ)!,% NHN/9#=74@=FC:@\B./SST>6=H).UA5N)
M_P!@=9-M;=^]JY:ZH2-*:36D$$7[<,5-:Z0+"RW$^H !5X_-B1R'+VY(5C6K
MG_57[.AKM>U@L&DPG"GR_P _1X^GMMM4"EHQ"<;#%DM*Q*5-1-''31R/3J&*
M@SJ[ZEEY"7("\>XRYAOC'XDH;6Q7RX#-*_9U,/+5A58X]&E0V!Y\.'5U?2&&
MQ%#C4J-,-3DZZF@61IT642(D9$_CC61D5(D.H #B2Y)^@]PY?3LTK%L4X#_/
MU,%LA\*, 4&D9'1NMJ;5KDCI!Y(J6.1*A*,G68XZ>,$R39#RHLU3,C2%W6-B
M 7X-[^T*(S&OK7/2EYD[C0D"E0/\GE^WH=\!M2"BJ(I,?1RU!K/"DL4\5E=6
M 5Y9)VNE0\?C8K&5M>Q)N 2I1&(T*I.>'^KTZ+Y;HH&9W *U->-/E3B*UX]&
M,V9CH!%.\"PUSRNXDJ[QTQD"M"@-2MA*[*L9A 06%@#8\^U$$:!F3B.)/#&/
MVUX=%L\VLH6.FF*<<_+Y>?0Z8J@IJ6FE5?M1*[QV64+IEE5FE$H4OYDT%AI*
M\7 !^OLRAC158#B?7_5BG2"25B1EJ<?L'^ UZG24,U2Y:K2-X&BUR0:1*^M9
M%CC24QPLPC5G)*@!C]?Q[4"%W)#@:*9''Y"O$]->(JCL)#5H#7'KCI08_#E:
M80-1QM.@70*<2F.1(@4:65#9HE"DN"6NWUXO;VOCV_\ 3TM#64< M:>A^S'#
MI#)=(KZA+2.O%J<?*GJ?+KG6[9<PDQP4]8RV21PAAF\;Z=*"-AHD5;WN>3:U
M_K[I<;2ZI555Z#)H0:?+U'5$W&-Y &8I7AFHQT@J[;=50":E221UFF\J)<O3
MNXA9H_&S6?0S7+G5>]K#Z@DD]A-$&09!-?4<,=&"7J2E7*@$+3Y\?/H%,MB/
M#+-4S+)X5*NU284FCA50S- 5D5P!9C:YN%/)^@]D0B(9F?X1FO1R)P45(P-1
MQIJ14GSZ!C.8EZ7(U,E,[S4=<$JS3-"0**8BT<4,GD13(&174_I96())'M+/
M&4<&,U4Y^SHSMYU,0204=>T&OQ#U^SR/IT6+Y&=*4?;.S,E%B((Z7?IARBXR
M=8,?D\-NW&S4Z'+8#-;?R$;T&2?[$2%1(OEF*W4$@^Q3R[NCVDJ48BC5P0/L
MH>((^WHFWFT2]MY890/"*Z26'P_;Q!#?R/5 Z39S8.1SO2M;1346V6DS=7%L
M:G.1;;^4\$2U%1-UC+3UU74[;SD&:ITK?X>DHB@<L8P5 B6;=MNX[O\ Q@2U
M9B%8GB#_ $^%<8KY]0SN>VM82M;-!HH#0C@1\LU'K3RZ+9V;2Q9Z-<#E2V;B
M@IXLO@<W7T=/09O/8ZO::8QYO[6IAH)<]0UD;PFK@>%ZF4%9!Y+DBVR<(WB0
M\"=++Y C_(?0_ECH ;I"=31R97#*<U(_R_RZM=_X38[_ -]=2?/[>_4M+BY\
M]LGY$].YBLWDVT)_XQCME;BZHJ3G-E;@[ %314\V%2FH\QEL/%+2S2P25V=@
MCE5W9)(QWLTQ\8(M=!!!!%.&:CU'EU&O,5L#;&0@54@@U]<%:>IX_EUOG>Q1
MT".O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K-3U$U+/%4P.
M8YH762-U^H93<?ZX/T(^A''OQ%13KW0]X3+19G'Q5:663_-U,0-_%.H&M?ZZ
M&OJ7^JD?F_M@BAIT^#45Z=_>NM]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=!WOG-F&)</3O:2=1)6,IY2"]XX+CD&8B[?3T@#D-[<0>9Z;<^705^W.F^O>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM#7_A4O/BF^
M8/5V)QG\$H]S9'HO;%9N#+12U,F??;^-W?OH8#$UU,KK2_PP5]575-+>[B=)
M2RV9+E-X?UB/.@Z$^U?[A#YN1_@ZUI]C45/BL[%724=5GLQ J^$9VK\U**I_
M73ROBHI8Y&,$#,RH\JI&!<@\V+YR2A%: CR]/MZ,[5=,BMQSBO2WEK&R%=6U
M AQQ7[B2>2MI @DED94,O[U,KQ01*590BG0>/J>?82O)CKT!L#@.AIMT'9J"
M"O0H[7226,5$<*F/5#"@8:(8W(.EH  $93%?R+P5 X^OL+;A.JMH+4.>''YU
M]#Z=#_;+<L@- :D8/ ?9Z]'_ .E]OM4>MY9JF=T+51<H%2>%1(#&XC9UG:)U
M.L:%*^DW ]Q3OMR&DH/AX@9X?\7]O4J[%!X0!9JL!D_YNK0>D*<T<T$RM#+/
M+3,2]/(*DQ4XL/'4Q65&C:,EP4-P+_X7 VXJ PH"!3^?4@V573/GD>75D^TJ
M&.6<2PTT0)HX',TLC5?B@D!'DIX@#X 0VN2+TLS!3IMP$T,3DAE7RSY_LZI,
M0D>FM26(QC/I_F/0];?Q]-!0K$ZU-3*D<0AFDEE1:B<*TD<D+!K! 7(/"A ;
M?BY,[:(4 8,2!Q/^'_5PZ(+Z1RSD:0#6H &!PS_JST*NUJ22'[:E26-:DK*L
M$J) %$4=1:: R,J%U#<ZSH(/)%B/9BML/@ JY.D'Y#I!XE=3$=II4?E@T_XO
MTZ&/$XF%(YV>DDJJAI%A>>1HY(X],H9Y$'HET@@?T! %O9O:64,:L6AU25"U
M.:>?VXZ17%TS2*!)I0?A .<</0=")243&)QX098IH7CDC*J]Y-0))8$2 1>H
M,W"\@\^Q'!:QLK%D[P05(XYK^T4_9T13W 5T(D["I!!K3%/V9Q3SZ?:+'.39
M@D;,P6(I)(49"3K((4,"S#\GU"UK#VLAM#YK05QZ4]>BVYNUQI)-!4@@5!_U
M?LZ?)\8$1P)7*,%U@+''#"S#]+32:YVE;CT@E0!_KV=FLP":M4$4^7[>/1=%
M>%F4E "*TXDD>M!04_GTALK@I0'D1EU#7%]%C/CD4%)A$A-GC!NNDI?Z7YL2
M*ZVN32[K0C@1P-#YT^7V]"&SW",E$:M./KD>53_L] )O' +4)5-]OX6E+QI>
M-FIWD2)_6(I"NB&L5R&%F**; :;$ F]L#61M!5C7[#CCGUZ%5I<T9!6N03ZC
M/#[1T FX\>]-5*AI&_:A$9A2TJ2TI037C\DBRLAB#*C"[7](/I]A^6,]R%,C
MT]#T=VTBD!C)0DGNX4/#\OGT'^8P8K,7)-2W2I:1:F@E5_%/#54;1RT,K1NO
M[-1&\*L& ^NH ^H$L0Q>&VL#Y=."XI(8Y!V4HP(J,\:'S!X=5Y?(WXQXCLJM
MH.R<!BJ;![JI,[1YC(U>/*P4K[EAKO)65DL3)]OC:J:FN\D8%JUE9+B3QLTC
M\M7KT,9>B$:&^8/#\_3]G08WNS@TL*:V6K+_ ! 4_:P]?09ZKO\ D?T)+N&'
M>V=VWAJW!Q;4J:2AFQ&!FQM/7]>4^;H_O*TT..JZ=)]S=8[\RZS32E]34=4P
M>Z:]7N7MJN!IC1^\>K5S3A]A'^JG4-[Q9Q]QJ?%H=)6F?.GV>O07_P NG=N]
M]H_,?I*BV+*_5W8M1V=M#8M'F,+)]QA,YG,WD5H,M@L]@F$\]9M_,[/BKJ7-
MT9+2(TE+5T\H:/S <[;JCN(#',22P*^HJ?/U!ZC3<XT:SO%N(^T(=0XY7-17
M@13KZ,'N0>HFZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z4NU\T</D5,K$4=5IAJA^$%_VZC_7A9C?_:2?=66H^?5E:A^70Y @@$$$
M$7!'((/T(/Y!]L]/==^_=>Z][]U[KWOW7NO>_=>Z][]U[J%D:Z+&T516S_YN
MGC+VO8NY(6.-?]JDD(4?Z_O8%33K1-!4]%\JZJ:MJ9ZNH;5-42-*YYL"QX50
M2;(@X4?@ #V^!04Z8XY/4?W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7R__P";+\C]\]]_-SY!=F[_ $QIK</OG<76'66)C>-V
MVGU;UWF\KA=I01TT@6&AJ<I!$V5K)9C-43Y#)/9(T6.&(AF8R2,_E7_BAT,8
M4$%O%#&#J !-/4Y)ZJKH*S+UE6E*3*D<9EFK8J8K!+D:ABI9:FK9_,U.EU2P
M.IW?1]. 7WDBK&:_%P'^KUZ,[")Y774*8J1ZG_5_/H8<'CUI*"2YD:.!!)XD
M+:_N2R^1)%/#MYF/TX.D\#\@N[FU28%*\3\NI$V^ 10X-1QIZ>O1C^K:,5E&
MBN4,1K(S#"(]3-+S+)H;2R11Q@ OP?\ #^GL%;Y*8W+@=VGC_(?GT.]BA\2)
M*Y75_L]6"]74B0RT<?B?QU$L"5"1RB1DB$>M)ZB=/3/%(WI-@0 0"2;CW&NY
M'6ZFH^$T/Y\*=2=MPT&G"M*CJT7H1<9#6PS%XPK/]I/ 5I9C+! B^=H@6CE@
MD@F/[<CG4%8\&P]ARZ)0@L*_ZL<>A7&'\(* <<"/7JPW9R4T0@J<7/'#CHR[
M9:%:<5%',T:&%Z5:AVA^QEAJ9UF$Y\CLZBUQ<^Z6S@G^% *L*8^SRIZUZ8G,
MCKX<PK+^ UH17-:9K4"E,8Z,-@8J:ICR8<2P-2I#&L,R6F\<Y$*S4DP5Y9Z.
M5H=.MM(N/J1[.;9%+2@FA%!0\:'%1ZC_ %9Z(+KQ$$&00QK4<*C-&%:!L\.A
M.P='2HT7FE6I$LZEHYHJA2J+'$JJ%91JCF*JS$MZF _%O9E'&G;JH5KD&O\
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M20Y7%TU7'!/20O(D%91"3PU"W_SZ/P!91+EE)XMK!)6H90?Y=8];K"+?<;R
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MGHL;*[P15#$@3APC(D<A(3M+![^5N\A?Z(R:C@/F>/V<,GH=7M]'8H-04O\
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M=GE$3OJU>["];:K5F@A26.21C(8Z%U6@*D$&H'$8'I7IVWMDW3=8#=R2(\2
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M2YB9O&TE2\FH6-]1-P;V+,EY"RB*WD4,0-.!Z5^RIKT<)82J_CW4!,8/<%+
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M0P-!J!7AZD>G0/VM7_>$MTVKT.KB#@ ^N0.!Z G'9RAK-L15,L]*]504U11
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M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U4O\
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MM)H5)'ZDU/2)3@_QE/GUM+(B1(D<:+''&JI'&BA$1$ 5415 55518 < >\N
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MXFL["G>H8H\L,-3GL+2T@8D"26I1@--O9E[?6C[USEM2D$Q+,)V] (N\?D2
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MZLH[:(,G_)_/JOITHI38L;W) 8VX!+W)(L/U$_7V\QR1UOJ%*=8:R_5@=*V
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MN2&B=N!8D&_-B++W-1H/^JO[.D3"F:\.C8[=RD\,$>L@J>4A-DNK<DL6)4.
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MT8X X@?,\*5_;Z5Z;MQ;9C6/'X-)6JIJP 5C$B:GHX'*R,KURED$\]"C-/R
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M.<L\S5.:?ZOY]?/>_P"%"%)35O\ ,*WK0#QEZ?XW?':&I#I9Q5-@]Q5<>ME
M)8021FYL;<?ZZ?=],D[4.-# _;XLAZ/MM)-K0CS/^3AUKY;:W1NS9&Z]M[XV
M9N3-[.WQLG/XG=.SMX;<R,^&W-M/=.VZJ.MPFXL!E*7QSX_+8VK@5HY%_58J
MX9692&9(U=2K#'\P?EZ=+JFO'Y=;;'QA_P"%:G<6VJ7;6V/EU\7MM]I1T%-1
M4.X>T>C=U+L3>63IZ6 03[A?JO=]+6;+RF?KGC\M3#2[BP- TSN:>&GCT0*A
M>TD%2A!]!YG_ "=4*H<BH_GUM!_"K^;;\#?GNE%BNB>[<52=EU-,L]5T;V;
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MI3Y<.A4M=6L"AX?ZOMZE;/SDL%7]M+4K41^+_-SR1-&:F.5FD-'&^B(::5F
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M+;&5DJY*BMK]@9S)2,N"R;,S4KR+C:T^<4E3D1%97HN%$4I_6 X^H_S]6XC
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M$Y#.;;J!*K8_)S30PI==-/DB7D8C5=6CJXV*\$@FU[>_6GZ?CQ$=RM4?8?\
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J>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>jnj-20241229_g8.jpg
<TEXT>
begin 644 jnj-20241229_g8.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !]     $  0'T     0 !_^(,6$E#0U]04D]&24Q%  $!   ,2$QI
M;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#
M('-21T(                  /;6  $     TRU(4" @
M                                               18W!R=    5
M   S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@
M A@    49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD
M9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4
M;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P
M  @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W
M;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y
M-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                     %A96B
M      #S40 !     1;,6%E:(                     !865H@
M;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /
MA   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M     !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                    9&5S8P         N245#(#8Q
M.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M       N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="                             &1E<V,         +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M     "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M
M,BXQ                                  !V:65W       3I/X %%\N
M !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M         0                        */     G-I9R      0U)4(&-U
M<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\
M5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #!
M ,8 RP#0 -4 VP#@ .4 ZP#P /8 ^P$! 0<!#0$3 1D!'P$E 2L!,@$X 3X!
M10%, 5(!60%@ 6<!;@%U 7P!@P&+ 9(!F@&A :D!L0&Y <$!R0'1 =D!X0'I
M ?(!^@(# @P"% (= B8"+P(X D$"2P)4 ET"9P)Q GH"A *. I@"H@*L K8"
MP0++ M4"X +K O4#  ,+ Q8#(0,M S@#0P-/ UH#9@-R WX#B@.6 Z(#K@.Z
M \<#TP/@ ^P#^00&!!,$( 0M!#L$2 15!&,$<01^!(P$F@2H!+8$Q 33!.$$
M\ 3^!0T%' 4K!3H%2058!6<%=P6&!98%I@6U!<4%U07E!?8&!@86!B<&-P9(
M!ED&:@9[!HP&G0:O!L &T0;C!O4'!P<9!RL'/0=/!V$'= >&!YD'K >_!]('
MY0?X" L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)$ DE"3H)3PED"7D)CPFD
M";H)SPGE"?L*$0HG"CT*5 IJ"H$*F JN"L4*W KS"PL+(@LY"U$+:0N "Y@+
ML O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-)@U #5H-= V.#:D-PPW>
M#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0"1 F$$,0
M81!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#
M$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7@5FQ6]%> 6
M Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA &&48BABO&-48^AD@
M&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:' (<*AQ2''L<
MHQS,'/4='AU''7 =F1W#'>P>%AY 'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!
M(&P@F"#$(/ A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D
M321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G&"=))WHGJR?<* TH/RAQ
M**(HU"D&*3@I:RF=*= J BHU*F@JFRK/*P(K-BMI*YTKT2P%+#DL;BRB+-<M
M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP-3!L,*0PVS$2,4HQ@C&Z
M,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43-4TUAS7"-?TV-S9R-JXV
MZ3<D-V WG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z=#JR.N\[+3MK.ZH[Z#PG
M/&4\I#SC/2(]83VA/> ^(#Y@/J ^X#\A/V$_HC_B0"- 9$"F0.=!*4%J0:Q!
M[D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?
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M^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X $T%D;V)E &0
M     04  DE$_]L A  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0$! 0$"
M @$" @," @(" P,# P,# P,# P,# P,# P,# P,# P,$! 0$! 0$! 0$! 0$
M! 0$! 0$! 3_P  1" &# 8,# 1$  A$! Q$!_\0!H@    8" P$
M    !P@&!00) PH" 0 + 0  !@,! 0$            &!00#!P(( 0D "@L0
M  (! P0! P," P,# @8)=0$" P01!1(&(0<3(@ (,11!,B,5"5%"%F$D,Q=2
M<8$88I$E0Z&Q\"8T<@H9P=$U)^%3-H+QDJ)$5'-%1C='8RA55E<:LL+2XO)D
M@W23A&6CL\/3XRDX9O-U*CDZ2$E*6%E:9VAI:G9W>'EZA8:'B(F*E)66EYB9
MFJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8V=KDY>;GZ.GJ]/7V]_CY^A$
M @$# @0$ P4$! 0&!@5M 0(#$00A$@4Q!@ B$T%1!S)A%'$(0H$CD152H6(6
M,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V160G"G.#DT9TPM+B\E5E=58W
MA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=79CAVAI:FML;6YO9G=X>7I[?'
MU^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H
M# ,!  (1 Q$ /P#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4&KR>/H
M?O*VFIR!?1)*HD(_VF($R-]?P#[V 3P'6B0./28J]]X>"XITJ:QOP4C\,7^Q
M:<I(/^2#[L$/52X\ND]4]@UK7%)04T(^@,[R5##_ !]'VZWM^.?]C[V$]3U7
M6?(=,D^\=P37 K1"I_LP00);\<.8VE'_ "5[MH7K6MO7ILES>8F-Y,I7M^;"
MJF5;\\Z$=5OS_3WO2OIUK4?7J"U14/\ KGF?BWJE=N/Z<L>.??J#TZU6O'K#
M[WU[KWOW7NN:RR)^B1TYOZ79>?Z\$<^_4'IU[J9'E,G#_FLC71_\$JYU^O)X
M60?7WJ@].MU/KTY0[JS\%M.2F<?TF2&>X_H3-&[<_P"!O[UH7TZWJ;UZ>*??
MV7CL)X*.I7\G1)#(?^0DD\8_Y(]Z*#R/6]9Z?J7L&A>PK*&HIR?JT+I4H#_4
MZO X'^L#[J4/EU8./,=*:CW'A:ZP@R$ =OI',33R$_ZE5G$9=O\ @M_=2".(
MZMJ7UZ>_>NM]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U&JJVDH8C-65$5/&+^J5PNHC\(#ZG;_  GW[C@=:) XGI$9'?U'#J
M3&T[U;?0337@@!_JJ6,T@_P(3W<(?/JA?T'2)KMU9NON'K&IXS_NFCO3I8_4
M%E)F8'^C.?=PBCJA8GSZ3Q)))))))))-R2>223R23[MUKKKW[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3
ME19?)XXC[.MJ(5!OX@^N$G^I@DUPD_ZZ^]$ \1UL$C@>EIC^P)TTIDZ19EX!
MGI#XY+?DM#(3&['_  9!_A[H4]#U8.?,=+O'9W%90 4E7&TI%S3R?M5 L+G]
MI[,UOR5N/\?=""./3@8'@>G?WKK?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U"KLC
M18V+SUM1'3Q\VUDEW(_LQQJ#)(W^"@^]@$\.M$@9/0<Y;?LTFJ'$0^!.1]W4
M*KS'_&*'U11_Z[:[C\ ^W GKTV7)X=(&HJJBKE::JGEJ)6^LDKL[6_ !8FRC
M\ <#W< #AU0DGCU@]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO==@D
M$$$@@@@@V((Y!!'((/OW7NE;BMY97'E8YV_B%,+#QU#'S*!Q^W4V9P?^#AQ_
M0#W0H#PZL&(Z$O$[DQ>7LD$WBJ2.:6HM'-_CXS<I,/\ @I)M]0/;94CCTX&!
M^WI_]ZZMU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7%W2-6>1E1$4L[NP554"Y9F) 50/J3[]U[H/<WOF*$O3X=5
MGD%U:LD!\"'Z'P1FQF(/]HV7C@,#[<">9Z;+^G09U574ULS5%7/)43-]7E8L
M0+DA5'T1!?A18#\#VX !PZ;XY/4?W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]T@.Q^U^K>G=OMNWMSLG8/5FU4J(J1]S=C;QV[LC;ZU<
MXD:"E;,[FR.,QPJ9Q$Q2/R:FTFP-C[H\L<0K)(JC^D0.G8H)IVTPQ,[<:*"?
M\'1/L?\ S6?Y:64SDVW:+YV_%:3)0$J[R]U;%I<2Y$ABM3[@J\Q!@*LEQQXJ
ME[KZOT\^V?K+6M/'7_)^WATH.WWH%?IF^P<?V<>CL[-WMLSL7;F,WCU]N[;&
M^MHYJ U.&W3LW/XK<^W,M3B1XC48S.82KKL97P"6-EUQ2NNI2+W!]OHZ2#4C
MAE]0:])I(I86*31LC^C @_L/2G]VZ;Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z[!((()!!N".""/H0?P1[]U[I;87>M;0Z(,CKKZ
M46'D)O61+_A(Q G _HYO_M7X]T*5X=75R./#H5*#(T>3@%113I/&>&T\/&W^
MHEC-GC;_  (Y^HX]MD$<>G 0>'4WWKK?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=-65S%#AX/-6269K^&!+-/.P^HC0D<"_+&RC\GD>]
M@$\.M$@<>@=S>Y*_-.5D;[>C#7CI(F.C@\-,W!FD']38#\ >W0H'V],EB>D]
M[MUKKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NHU964F/I*FOKZJGH
MJ&C@EJJRLJYHZ:EI::!&EGJ*BHF9(H8(8U+,[$*JBY-O>B0H))H!UL L0J@E
MC@ =:XOS@_X4)=2=9T69V3\,:?9G='9N/W#D=N5N^-^Y:'"]-8DXZ,BIR&W9
MJ;/X;+]IU K=,*P4%104H5S,:M@GAD#]YOL<>J.T :0&FIOA_*AJ>A/8<MS2
M4EO@R14KI6NKSX]I _F?EUJI=H?*3YG;\W5G-Z]B?,'Y ;>&[=Q9;<DU+M+N
M7OC;'7F%J,E5#(/C=F25&^\UL>GPJ5%28J3$SIBZ"C\9IZ>LA1$C >-]<N79
MIF)/')IGTSV]'?TEM$$$,*"GJ.[\_P"(_82?ET7"HVEV5NW+Y7<&8IMN]I9Y
MYO+FZO/5>>Q^_*ZJ:1$DI8*[<,^7R.4R&0:9##-503PSER8)Y255TC2PA]-3
MJ.,^OV]+ECN" 3'KBXC. /D"/]7SZC4]-M_/QQXG=?4FS9LK5RU$.-Q.[<#3
M]<[AKX4+PKC,'V/M4XG 9RM2H2]ZR'$&1@X\R^J[Z7#QGMD(4^8R/V4KU1[:
MW?4=)!'VJ1_/2?LIUBVSULVV<U64/6^Z]T]:YZ2HJ:NLV9E\MG=C[FHE2.HB
M>OI<CBO\FKI\6Z?:BIH)8?)J>*2636H]J#,KC5+W8H&&13_"!TFT3P8B9AZ+
M720#\L#HVFV?FU_,*Z4RE(G6?S%^10S6 JPM!@=W=H;@[3VUE9J8+6(<939V
MLW+MC=-0M'#.LV.R%%N!X:>(MIB\<E/2O+=S !X;AU'R)S]H-?\ !]G2=H8S
M5+NTCDKYE0K#C^(9/VC_ &>K/^E/^%+_ ,XMO5N)I.T.E>CN\,#'04]/40F7
M.]$[\K:E(X4;(UO8M#7;\ZRJ*F:2.421IM/"TK2'4C1(K1JLCY@FBH+I 13B
MHR?3%<?/C]G2*38;6<$VK,&\A44_G7\@6'V];,GP*_FM_&/YZ05.U]L5N2ZC
M[\P<3ON?X[]J5>#QO8 AI8KUVXM@56.R5;@^UMAQ3HZ_Q7"S3/2KH7(TV/GD
M6G]B"TO[:\C5X9 :BM*_ZO\ 5\N@[=V$]JS!D)4$YI0\>)'E7'J,TK4$"S;V
MLZ0]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4RAR%7C9UJ:
M*=X95^ND^EUO?1(ANLB'^A!]Z(!XCKW#(Z%W ;MI<MHIJK125YX"7M!4'_FP
MS$D.?]023_0GVTRD?9TZ'!^WI7^Z]7Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NDKN+=%/AE,$(6HR++=8;WC@! *R5!!!%P;A!RW^ Y]V5:_9U1FICS
MZ!NLK:FOJ'JJN9YII#RS'Z#\(BCTHBWX L![= I@=-<<GJ+[WU[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJF?EO_.@^#WQ7&\=JQ=ET'<G=&V8Z
MNACZLZN:;/P4VZ(9Y:$X+>W95/3R];=?SXBN0ME::OR?\9HZ:.1HL?4S".GD
M*KO>+*U#+XFN8<$3.?2O#_5PZ.+/8[^["R&/PX/-WQCY#B:^6*?/K2_^>G\S
M;?\ \Z]X9.7OKMS)[5ZM2:''8WX[=/;UK8>K<30T%29*"OR$,4V>F[0W?+4,
M99<SD,930.A"4M+2J/'&&;J]O+QP_@-I\E)*H/R(R?F?V="^RV^WV^BK<HB^
M;T!D-<'NQ0?*E/MR213%Y;XWR4M.NR=EU6[):"6#[N;=-7E=R[IKTHIS45<6
M/;-Y#K/"8RDK8JHH:>CI*L"&(:V60ZP@:*[8T-$4YH"*?+R;]AZ6N;4C3]1+
M(.%:5IZ_PT'[>H]3V!)M"-4VOUKFZ'$5<;+-5XS;J28S)4=+ R539)=D[CH8
MZJ)XI29RXECC) ,GIM[LMN9"29U#>:E@#_,4ZOKC!4M$Q3^(*U/Y$T/KU+VQ
M\D.O):C'4E5@_P"[%7BJNGB@,<-<QP4C%C49#:U=#54F3P:BH:-JG'5QRM/*
M8P8IH&:19DTUE<HE(DJ*?(\/]7ETKBN+1V_M*&O BG^3-.C_ &(JO]+&WI]Q
M8S"[&[O3(S5^,WEUUDTI-L;WR5;452T]'1[>["@HJVJPVX,Y4R0#!9/*T60Q
M]3D&CI*FGQ<BTM=.7HP+*DK-'(::7R1^>>%!FG >HKT]-9L$,T<>NW6NI5^+
MADJ*&IKD#%?4=!;UY)TYV929_K'=67R4=;0)D:GJ3=>6P^2V1NO;68Q%%+6Y
MOJ;LS;RY/);AP^\<'D,?41^:*MRLB*G^3R5,4BTJ/S":UD&DU4UK0 ^>.'D?
MY<>DB4NH%D5U$B@&A;##T!(P2,\/*C>O47,]:X,SQ+GH()5S^2JL5A.R]LY&
MBV_64^Y<8K_P6GW#D98(]O5M'DJ37]M75XFK<1,&204^-<U=,HM[NH<M4"E2
M#7 ]1Q_9TGN;=4%2#KX!AFI.*$"@KZ$<:>N.@DRVRLL^[&VYNFK=*R;&KC!N
M=\;7;<S>%[%::KGI4[4Q61BR=3LS/5&3Q\T,U<*>JP]=E%DDDJ7EJ9HZ9UYE
MTBAH 1@GB"!\-./KC/3,4#@T$=-6 P!IJ'\51VDT(H1\ATG=V[IH8J#"U^\=
MDTM?!B4Q;[KVBM (11RS5-;B#O\ V3()):S:T\&?PE9!EH(FTX;,1+-CW>DJ
MXA-N*W=&,EM/WFM&X^AH?6E?MITYKBDHEQ"?#X'%"HX8(R">(].MC;^6=_./
M[!Z6V_USU!O[-5GR,^.T39/'[>W)FLON#-?*CK>'(9.-Z#:>>R6Z]QU=#VO@
M-IU4DU+CZ6*9\^M \%-2?>&"FH?9O9\RM"X@W!-('%J<!^1X>F.B;<.5GD7Z
MBQ;745.<GCDBG'US6OEQ/6VET3WYU)\E>N,-VMTKO3%;WV;F"U.]50.T.3P&
M;IX*>;*;3W?@JI8<QM#>F :J2/(XC(PTV0H9CHFB1K#V,8I8YD62)@4/IT"I
MH9;>0QRH0X]>AA]N=-=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UV
M"0002"#<$<$$?0@_U]^Z]T(^W-YF/QT.8D+)PD->URR?T6J/U9/QK^H_M7Y(
M;9/,=75Z8/#H3P0P#*000""#<$'D$$<$$>V^G>N_?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW2&W/NM,<'H<<ZR5Y],LH 9*,6Y'(*O4&_ Y"_GGCW=5KD\.J,U,#CT$3N
M\CM)(S.[L7=W)9G9C=F9C<LS$\GV[TUUQ]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW6J5_.G_ )U&W,%MW?GP^^(]=@-Y[GR5)4[7[I[N-9B<
MOLC8T-8YI*_8.PX$S$%'O+?+B.6'*UE8T.!PZWIUEK<BM134!#N=_&4>UC-:
MBC$'^0_R_P"?@)-JVR6-UNIX6UBA1"#^UO/[ /M.,'357K[<V?AI:_)14U70
M1K)2T9;'U^=B@BI4CDJ)!#BXJ7;6/C@2159::.RNP];.Q(#9GA@Q& I_9_A)
M)Z%26UQ<$&=B1ZM4C\@,="=M7KR7%'&U"[8S^X,E64<58F,I</LRFDR4!J(E
MI4Q0AW7C\A-3Q#]V?UJ5C&HEK%0C-RTG^B "M*U/^;I7]'#'&S2J:9KVXX>N
MH=#K)M_K3--@\9FLOV-LG?9FH?X12;EVE!19=I0[HM#B:;<5;A9MPTA2J3PT
M>-EER,L;#[&GK"T8D]XL@5@R54G)!J*_SI_GX]56WA8IX%R-?X4IFG^$\,TK
M\J])K*;KIMDM4X7<.V\-N/(82N$FY!M^&OPVY\!&M554;;AQ5-545'5YS%T5
M54-3Y'&YF-<UA*[1=FIIRL-&4-@/0D'2#\)^7R.,4QTHA90QK'50<T/=PX\*
M$?//7>2VQT;V!CTR.Z-E5#4$]33KD-Q;9K4P^\<)21T[A<SC*B.ER*U6,CI,
MBL]1054%2*J >>&E66*561I>7UJQ$,@*_P #4(/[>'I4'[2>GY-M@G.H*RN,
M^(OI\QP/S_EZ=(0=5]G]!]E8^LQ4M9N;$34LE-'54--5,-Q;5JL;)2+/G\+&
M:C3!D=OQK. #/"9X&,+OH+GWUD-W&0:*>-#CYT'E_P 7T\(;BU?#$C*U4GT\
M_P O\'F.ARWADL?W]A'[ H*B/#?)79/VZ;ESE+225-!WA1[.DQJ87<FY,*8E
M6M[/V_2X]359(-Y\RSSPUD4LR1S-5)_")BD8F+\)\P*?#7A3T_V>MK9B1FDM
MUHU3J0?#7B6%<@GS'#C@=3>O=_UL*;GP.4AAK-E;WVY0UU0,JJ97&#(8ZH@$
M&,RT$T"20PQ21T+?;1I%+&M++40>*<*165JZ9-7>#Q''U)'\_EPXYZW%$P$D
M3(2A& 14<<#-/.GS_9U)RF-R^W\1@MV[%S-7F'VEC\'0R?;5U/+E*OKIH*FN
MQ6)K<ZU.M5)6==*8::BJZEN<0[8VJAE7#*L]S(D@9931APX_8:?*IK3RS3K2
M6DZ$$(&A<9)())\J^O#)IF@)S7H%M_8AMT[(R,YV_P#:T[ZZG#[CQ<$&(FQ6
MY,SAZ+^&SS8RF(@H,1F*W:F#@GCIDC./GG:J+5)2=@LLKJ/6L+L0:FGG7AQ/
MF:U_+I'>[9(H:YCC_3TK^1!)''-*'[!Z]%5V;N>KV\*\E(JNCR^)@:MQZS38
M^(Y*EHY$JZHF&45^'R\F(507AN(:M8]:R44CI(_.BRD$ !AP/'\O3C7_ (OK
M5LSQ T^$T( QG_9'^JG5H/\ +Z_FE]K?!3M+<.^=F0T78%+O6GP>+WYMC?61
MR.!H^TL)'6S28&7=>2Q#5_\ ">P]JM+/28K<ZXVO9(JYJ6II98I1I4V%W/M\
MIDA-8#AHSP^T>G_%](]RVZVW6)TG.FZ4DI(  <^3>M>%?LZWWOY??S\Z;_F(
M=$T/</5PJMN[@Q53!M[M?JC.U=-4[LZJWQ]E#6RX/)U%(L=+G,#E*25:O"YJ
ME04F6H'5PL-3'54E,.;6ZBNXA)&P^8].HXOK&:PF,4JFGX6]1_/(\Q_DH>CS
M^U/2+KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z6NV=U28LK
M15S/+CCPC6+24C$WN@_4\))Y7\?5?R#1EKD<>KJU,'AT,$<D<T:2Q.LD4BAX
MY$(9'1A=65AP01[:Z=ZY^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z0VZ]SC'(^.H7O7R*!+*MK4:, >#
MS>H=3P/[(-_K;W=5KD\.J,U,#CT$))8EF))))))N23R22>22?;O3777OW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZTTOYZ'\\/(562W!\)/@KV
M!20TE(U=@?DU\E-MY6:#$X>H9I:*LZ4ZRWCB3/4RYU-$B[DRV'2IFI7_ -Q5
M'(*P9 T17?W'Z;1QRT/F1Q_+_4/7A@G6V6^F96> M*#@' 7YG^D/G@4X:OAT
M]:S<VV<,U/D)I,YFS1QP18Y%2GQ6&HZ_Q0R0M@J(SR*AGE1=*?Y1(T?[KLKD
M)[(4LGD.A  .%<D\<U/^K\^A+]=#!0R+J/HO#^>3^P]"KUAOO<.1J):^AV36
M::AX:&EGH<N)+FCA28Y"LQ%>V03*XJBFIHY!Y)H8IZEG(+(#%*6;G:VMH )+
MI3)Q((I3\_(GH[VV[N;S,5H1'@ J:UR?+-0*>O\ LG9Z[;N"HACQ]=MC;F<Q
MC2F'[*AQ%%MB?+4#@31XW+I@J3'XNOQSQHAT?PVF>%XDD22.2+V"[_=]LMV7
M_&]++4FI)'Y<37["?LZ'%ER[N%VO^X1(/FH"DUSYXX5\NEXG7.<::7&9/:.X
M:?;V;:EBK<?09^&DEBJUBJ?M:VMQHQ%1@,O44CRB/5-%2>>G"Q2.([I,Q'S+
M:R+V7*D*"<?,^5<C_5^3T_*-U&RA[)JU J5K_@Z$&MZLWM7T^.Q^\_MMT5>#
M-/CMOYC=>%J]O[GJ<"*?QXK R[HIONC45%+#.\E'-4335=*T<-.\DF-;P0L2
M<P6Y;]-FR.X USZTJ,?9Y?/BNM>4YR6+6RK(#4&N".- 3P)'\\'!Z5>Q/B1N
M+*5&-K<=1S4*2I71YRBT5,#S8^I@GGK8'F@H7HI*B$31UF.--IJ8*BF@F#1W
M/W"23F%#K73W4PQX5'#B0<TH?SZ.X.3I"8R:!=52/.F?M_+[!7YBCM+XV=Q[
M/WK29*AI\9D=J544--54Q:HIS@XLK4TTT-?0/.#-C\54K!6?=TU-IIDJ'JQ*
ML0E63VVVY03VYI)1P<5/'C_,&F?LX]7DV*2TN@?"#)IIJ X?;Y4IY<,GACH0
M<=\$8-Q5M3_!<%7X'.BEWG)EJ5ZIZRGI<]EVR\U!34%;# [1X_$PP0?=EI))
MJAIE'IU&[\&[:=$<C$UX$<* >E>/KP'^1#-L#('GCH :MI(X$G@?RR#QS\NA
M#SO\OB>GVEA:#"T=0<EEL10Y&JK:VIBI:S')78NB&2GQ4JTZ.L]9N*MJ:N2B
M6;7%CXF52T;*4:CW65KDEM)2O$8^P>A('\^E(Y8C>U4D/XU2*4X'YG)I7Y</
MGT__ /#>U?292MRVT*%<3-5TC+E=OUV(8;?JMLFFRTE/A<M 7K(:?=<V+RAE
MEE@C: /,'N!=/;IW.8QFI8TKGTX>?3D7+=O')DC3P*GSH3PJ/7ATK=A_$C [
M+?%T^Y,/#54$>.H,'N:BSL#4>-3<=?5Y2MI:JGK9?/#D=KT,F9CI9()HXJC[
M>24&;2K!BR]W*0A)2X"J::M5*5P#CYT^7GT(=OY8M90\8C)=EU:3W:J9(H?0
M<*9Z(S\M_P"47*T%=NGX]8ZLGW)AXVGR76L\]1++N')28R"JR62P#HDE31T]
M/&T%%]N[F03*P#)&(F<^VSF61'6&]S$3373*YX'A45Z!6]\B+"C7.V5H%KX=
M<-]A\JC@.J#,SMC/;=RSX+<>+K-K9['Y-\'FJ#,0U6,R%.8JI:5VDAE2GK*:
M2GKG>72@#!UL#H%F'$4J.@='U)2JTR/\/4:/$Z2-&ZE9 =+!J@CJPS^67\XN
MV?A5\Q>NM\[0WKBL'L/L'-]>X?O'9^7%10]?[IZ]W)G9Z#=U-N*&G%/3XW(;
M1>HR.?VYF(D=\'E9)%)?%5^8I:LZVVY:W*E!^F6*GT(%,_;0_P"#HAWBUCNT
M>-AWA ZTX@FH(^PD5_R]?3LVENS;6_-K[>WKLW.8O<VT]V8;&[AVWN'"5U+D
M\1FL)EZ2*NQN3QN0HI9Z2LHJRDG5XY(W9&5@03[&*LKJ&4U4\#U';HT;,CJ0
MX-"#TH?>^J]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2RVM
MN9L3**.L=FQLK<'EC22,?\X@Y)A8_K4?\&'-P:.M<CCU=6I@\.AD5E=5=&5T
M=0R,I#*RL+JRD<%2#<'VUT[UR]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW25W1N)<-3B& JV1J%/A4V(@C-P:B12"#8B
MR _J/^ /NRK7[.J,U.''H$W=Y':21F=W8N[N2S.S&[,S&Y9F)Y/M[IKKC[]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM?C^?K_ #1\'\(OC]7=
M"=?YC.1?)SY'[-W+AMFU.VII,?5]8[)K()<'FNS*K-I%+)1YA9ZAJ/!4M-IK
M:FO)F66FBII)U17EPL*%:]Q_P?ZO]7"IEM]J9&$[XC#4%?,C)_(?YOF1\YZ:
MI3%P8W^\,U77FAIT>BP],SUDP9/'3T,,Z3:J6CHX(TTB1M"(FI4$C<*0QPO)
M)4TH<U-!Y?ZL#H]EFXT!KY_[/2FZUV%4=EYA:^9<M!AZ6M--&\U32NF3J<AI
MFJZ.C@C5JVBGJZ.>_EU'QP6"N9F0JQNNYIM4 %09R*CY4\SZBO[3\J]&&P[+
M+OEWH!*VZD!VXU)-0B^C$?L&>-.KE.HOC?\ =T(A@@CQL$.-,E0WFC$&,IJ2
M*-%D_=5E^]F2)O! X,=%''=CK])@??.:'>5A$"WF2?,G)^=/4^9X8ZR4Y>Y.
MABACB6B1A17'"GGGBQ\@?A^W'5A'5W3N&IFJ:>>D2H6BCIS)XR\TTS3*/\GE
MC#1/%$CZ0)95(D>2]BJ:7CJ[N[J60L[G4?SI]AZE*UVRUB4*BT49KY]'+VUU
MQL[%TT:PXBGB@IU.JC*11S,T<<99OV(8PZJ-0!9C(Z@E[$7*87DQ/Q$>M/\
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M8+++KCD!!:/R1D,22!JOI!7V@FMVU:API0@</E_EZ,[>Y33I(!;B">/#]O\
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M;'BXO';JI !H1FHIY=([B65TS%@D C[:X-*>7#H3X$IJF*.IU>1$.MFE>.)
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M/V5%/\/2 IL54L'@G\-1%40?>0Z(_ T5$]33S5&/JG CBJ&H:I"$F2SO&1J
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MC25DGAE8B$I)**6.JDKH1HC=@TDZLT1#,@&C@@D ?<F.G)Q_Q?0VVX$-3/\
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M25.N%85:%I&K (D #W+25#O(LCW<EHR1P4*LFO%$!GN(R"K5K3CJQ3CQ]?\
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MTQTLTSJBH  I=G0CMY >?^7H8[8"\L2FM"P%!Q_+HR. Q\L%. "(EE0.M/3
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M&*]70T/0S>VNG>@I[!J=5;04@/$-,\Y _#5$FCG\7TT_'^O_ (^W$'$]-/Q
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M1VCLW=NU*9L]B\)24=9/CJE(9J";*1T].?MVACR>-Q$XI9JNIHXICI.E(@5
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MVI2Y 1+)1XY</-D(A24BO&$---7?=,)=.@M:_P!+B%+ZZ<M;HH&K0'8>I/\
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M>6LK:N6II<'2/#%&\>+\DS4$56T:-')FJKR+-(O^;1=);4Q/L>65I#;F*.)
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MNH#/G\OL_;T=>FH:2AID2GHH*;( P0J*7Q)3PPJ0D9F\1NH9""L:Z"JL0O!
M!:4T:D)[2<5Z1>.TQ)>8M!ENX9)^5?\ #GAGJ525!8UD7!JIH32+(TH"PI#=
ME$9F],DE2Z^.S2)J%EUE0P]I[=0OB%E)8X'IZ_MZO<11ND7^^U.J@'&N,TX
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MJ+\(%20/*GSZ,=TE@HJ+KO&YRH@,\FY\WF\K23I/)'%/C:6884M)4"-@3/\
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M[]U[KWOW7NO>_=>Z1W8NQ=O]H]?;ZZSW92_>[5[$V;N?8NY:,VM5[?W=A*[
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MNE:L=-5RJ>058-I8 GW9H]4Z2^3(0Q]#J.G[<$_Y.DBSF*WFM6KK62JC.1I
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M)]S&,A0PS+K2Z20*M.Z*;K'.38L3=7:1:83C_5P_P_X.M2S:KA%/'R/I7/\
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M<5AK;MXY-//_ %>?[.D1#TCD,F%8JM>( _:,G(/KW<<]#1"%:&%Y8A$2Q)0
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MV+V%E_+3;$ZZP?E*ALENK-H$ED-HZ.ACJ:N0K# [ 2;;:3;C<Q6<+4+=SO\
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ML+TV=JXED==53%3235]2ZJX26#PQKX'ITE:P8N8P60$%CI>%E9H=3Q*1\_\
M5CIPW5Z]0LC#RQT+^WX=ZYB=(5?)S0S3(RJ\D<<,<#LT,*2%)5CI]1IR-;EO
M*/T+92/?GO+*V4A%15] .O+:W=PU&9F8^I/1B]M=!97/JIW7D:V*!X=45+33
M-!1!;JD@J:B-8ZVZ  EM*J;6M=K$AN-]EF8I9QA5_B;C_L=&D&UQ0*LD[:V'
M%1P_;Y]"]MWHS9-!5-%A]O8ZKK(9X/--7)5/2TDU.=4F0J$=9*EH]47[<ZR*
M:@$B);+K6BS2%0\\Q8^2DU_ETX/$E9HK5 BTRXIP/E7U_H\?7HQVS]M8G:+K
MC,!!-F=Q9F.*FJ*RA@)J:J6H I!B\93X^%]%.RL&6FB>1B=!];'VXAN;Z9+>
M*,M(WPH@/V4 ''C_ (/+I1(MO96DL]W*D-FAU/)*0*Z>X,[,< $8& ,]6 ]/
M?"G)[AEH]R=T&IPVWEC5J3KNCDCI,YG*>6-E/]\<E2/))MW'30R%7QM#*M7(
MK:9)H!KB>3N7N10ACNMX]*K OGC\9!Q_I0?M.*=0-SI[R?IS[;RC0L:A[YZT
M6A_T%336:C^T84_A4X86.TV.Q^)Q]%B<104.)Q6+HX:#%XK&4E/C\9C*"FC$
M5+0X^@I$CIJ*CIX[*D<:JBCZ?GW*\<<<2)'$@6,  !0 !3%*8ZQRDEEGDDGG
ME9YG)9G<EF8DU+,3DDGC7B>/33D:FDHJ.JKLC6T6+Q]!2U5=D<EDZN&@QN,Q
M]#!)5U^2R-=4O'2T6/H*2%YIIY&$<42,S$ $^UB5.D!2S$@!5R23@  9))-
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M'$X'(/3BDV9E-NYS;F%VYN>:EG24#=N1RGW:41#^2EQQ:H"130>=?80AW9W
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M5*D>HDL%B\?ZA^3[]XL?AZ,8[>@[A2G&O1QNK.B8JZ-)JQI6*U#3HTAE2FJ
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M55]C'8^5-SWK1-I\*Q-*S2#!']!<%_MPOSKCH%<T>X7+O)\+6KO]1NZ@Z;.
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M5(UV/^)]ISG/3X% !U*]^ZWU[W[KW7O?NO=>]^Z]TP;DQ/\ %\7- @!J8O\
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M&'UM[VH8**$<<T]<?MZV:!V[2,8)I7K U-#301/(66[>&!B_^2"1Y))!J$!
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M=;Z][]U[KWOW7NO>_=>Z][]U[KWOW7NH61H(,G1ST50+QSIIU#]4;CF.5/\
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M:& 5\TI12OC6*X"$JK*&TA>*RN;J=8+:W=YB:!4!)/V#J5Q?V=A:27U]<)'
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MMI^FJVH\K[\1C/\ +IK54C2.NOMQ(596',J-JUL5>15>) "RJ3)&A:Y&F-@
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MA@9U8*R<E @GW>@:.SB.FE \N 1G(7XCQKG3TY'9EVU7$F:"JJ?/[13Y<*]
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M /3@ -(XN2/^(X%_]A[;S7JU/GUGA8!O]CQ^#_2_X'U]T;SKUKKGG-R8C:>
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M^Z28T@#_ #\//JZ8!)XUZAQB)D]5,ZB0.K1I(FD2K9)# 4;QM"S%M)N0J@L
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ME;:EJYX8XXR))GBCB*H>-;Z2JDL([\\WX^EK^T$Y_ETO@%3@?;T!=;25^_\
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MT,:C6HKJ/#[#\LX/'TQPI]3HU:V.@MI%/YG]O0(5TE5$\M.UXYZ:0@4]0?\
M*EK$$D4D$L1?S+,L>I&2]U_LE@UE*)M0JI'</7U]/6O1@A#Z65JBF:?9CKT:
M,"-0CA+-$K2% T,@FTQJTN@LT4@"FUF4LB@_4L/;*&AI3T'3C5H<^1_E7^76
M/(:H_%,)D4Q,IDO+&HG6,:FT$%+^ L=)Y;7<7N />FD#TKY>GGUM$*U&GRZB
M31C6S1Q"TD*:$IYV>10JQS1EGC",6%]!MJT$$FQN35M))%.VG#_5\NK9%37N
MK_JX]2EM%%#JK&'@D0%&41I*9'6>0BTAA>.21U5"&%EU$%1ZO>W TA2V0?\
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M4<KQ+X=)E)FC",LIFUG3J9E!:Q"D>V54?">.3GIUY,'[?\-,=1:@)-(7.@2
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M*9_:>A:Q&.H]")+!%)+8M<(I<ZCP;A>%YO\ @W/MIY'P:GK8 '&O0I8?%P(
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M)FCHLA'0Y#QC4U.H^IK'>V]TJF*2K>:G!'Y?YJ]-^$Z'([?49Z!ZDI M*>.
MNFY!(+'C\\$!?][^OOSFI^?3ZJ ,=<Z.-"2@74[&P53=R+@!5&KEBQ  '/\
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MU^WAYT!/2B#QPM%%($(:" TI:G=6:)JM*F&!?L5KJN-&,<822(5)IY(4%/\
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<WOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>jnj-20241229_g9.jpg
<TEXT>
begin 644 jnj-20241229_g9.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !]     $  0'T     0 !_^(,6$E#0U]04D]&24Q%  $!   ,2$QI
M;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#
M('-21T(                  /;6  $     TRU(4" @
M                                               18W!R=    5
M   S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@
M A@    49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD
M9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4
M;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P
M  @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W
M;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y
M-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                     %A96B
M      #S40 !     1;,6%E:(                     !865H@
M;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /
MA   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M     !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                    9&5S8P         N245#(#8Q
M.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M       N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="                             &1E<V,         +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M     "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M
M,BXQ                                  !V:65W       3I/X %%\N
M !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M         0                        */     G-I9R      0U)4(&-U
M<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\
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M[D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?
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M^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X $T%D;V)E &0
M     04  DE$_]L A  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0$! 0$"
M @$" @," @(" P,# P,# P,# P,# P,# P,# P,# P,$! 0$! 0$! 0$! 0$
M! 0$! 0$! 3_P  1" &# 8,# 1$  A$! Q$!_\0!H@    8" P$
M    !P@&!00) PH" 0 + 0  !@,! 0$            &!00#!P(( 0D "@L0
M  (! P0! P," P,# @8)=0$" P01!1(&(0<3(@ (,11!,B,5"5%"%F$D,Q=2
M<8$88I$E0Z&Q\"8T<@H9P=$U)^%3-H+QDJ)$5'-%1C='8RA55E<:LL+2XO)D
M@W23A&6CL\/3XRDX9O-U*CDZ2$E*6%E:9VAI:G9W>'EZA8:'B(F*E)66EYB9
MFJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8V=KDY>;GZ.GJ]/7V]_CY^A$
M @$# @0$ P4$! 0&!@5M 0(#$00A$@4Q!@ B$T%1!S)A%'$(0H$CD152H6(6
M,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V160G"G.#DT9TPM+B\E5E=58W
MA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=79CAVAI:FML;6YO9G=X>7I[?'
MU^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H
M# ,!  (1 Q$ /P#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4&KR>/H
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MNQU*. +EKL 0?];D>[/&R'0IK05K_L]75PRZF45./GU GQ8T.ZHJNW)(*@2
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MP!F8ZAGSKCI#/I45''T_S4Z%[%4PC1'>:_B#%?V_'=19$U(#RK$W0?2PN?\
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M2A>%5$2WN=&F*\,D@]"HT;64-SJ_V!]JD'<"?]7^K'25&(04_/\ GZYZU/\
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MHB4L,YJ6% >( '[>E1>01Q>E;^:$%Q*'*_O+I5N#RRZN5Y/]1[-BIC5>WN+
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M(DL5MZB?P/9//;.R$N17R&<?/Y8X_/IZ*Y"2#PZD>;#S^7[>'^ST&F= )ED
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MN_\ I%!9_P#C /7RHOD=M]\%VOG9C%)#2YMJ;<=#9I+2X[+'[JC*K(BL!-"
M&4C3&UU%]/ ;Y>O%N]N0(U2I9#7U%17_ "]#7GBV>VYANY7CTK*1,@'\+=P
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MI3I%>  QY$9\O^+ZMO\ CW1?);,P5.<H]TX2FP= 9Z]Z;;.:7<%%4/+%#/\
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M\$J0(L;*J.?)4N/4WJ;(#E=-&VV.<::''V5_:?\ )UC[SE<E]WW)2:'MIY\
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MMW-O5T^U>NMOICQ6UU0$I*S$XL3RTU%202U-1$S1 ZCF[YUM+RK33"18X^Q
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MK+O>\W&W0L#9K(0ODQ(6IS_IL \ !UD?R3M:<N\OQ+<Q_KO"CRMF@)-0 /\
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MIU;C-]PG)87+R; WM5MXZG)T&.HJZ@S%2(&+Q9_;U8\%!FH9XA;SK)3Y%44
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M+4>%F^\-34X:G.,^XW!E6IP"(J/ 4E2=4O\ F9:HQHK.S\ZLX;RV$=Q* OU
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M15$C4T@#7=!50P&:,@L/U1WT-<C4?:!I*$\*'_5PZ*'(!.O4%'"F?V'_ #]
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MC;+/4*PH>.D,58<>%#G@>H]O.2^8-BN[F;;;*:ZV^8 ^'$4$T+5R%+-&LL1
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M9#"[,HMJPY/%_P!Y&H*G.-!492:NHU6"!(X%,M3*K!P$=@7_ $[VAGGN[A/
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M+:=+6_N/]A;2?^!&OR7^OZM?-O;5?\->G:'_ (S3I.;^I_'EX)P/34T:7/\
M62&21&_VT>CW9#@CJK\>D-[OU3KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBX?+SXT;,^8?QK[?^-F_
M)7H<%VIM*HPU-G(:85E7M+=-!4TN=V/OC'4;5%(E7D]C;TQ5!EZ:%Y$BFFHE
MCD/C9@6;B%;B&6!_A84\_P#)0]*K&[DL;N"[B^-&U>7YC((R/EU\UNBVUNWI
M;M/L/I[M;%?P'L#K/=FZ^O=]XND=YZ*AW3M"NJ<165]!4U4=.U7@\F:=:O'U
M10#(XNHCG6RRJ&A'?K"6VGDC ^$TSYBO ?G^SK(OE[<H+F-)LF*1*BGV8)K_
M #Z$';&>EVWEYZV.,!ZVM6<5-(4EIQ74;J1''$FI#1U%-&C"R$"07N >"B2(
M31!">&*'C]O[>CR.X:"?6G$FN/\ 5D?X>K2.@.SZ:J,*?=ULB555C<-5E)?*
M]=2U])*YR$,4",\+C)C0?&\?CK-!#A 4]@^[@,+JE35344^7\^/4D[7?/-:Z
MVRY!H?\ /Y?;TKJSJZ#(;DBW-C6B#2"'^)BF3R2/'4-_N%K8Y';QK!6U$],L
M$MD &B8NJL -13*%T5ICN!XT/F/]6.CI2) CCB12OS].AJV)#2X*GI9:MIH-
MQ;;JUHZS&.Y_B<DY\DU3CI)9'EJEKJ/[,O3QK$9&:%CXSY(O,DE56975OU%]
M./S'F<4_ETNC,A!%!X3#CY>@^7GG[?MZ&C YSKVBU5T-=1& )/65=16R'"/
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M6GJ#7EY6H,MC:&6;'I45%#KR&/:/&TU168:DJ8T1J8*K/,MT1'T(S$J( 5;
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MIZ26%+F$U1J?N$J8Q3J!RWL,<:"-OUAQJ>/']GRZ2IS%N\SNTU%A-:!5-10
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MM73R;@W1N/<60J<CGMT9^:1:B3(5^2RE7+/4.Y4/([N@146R:636S,Q-3GI
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M_=)'9CQJ>.?G_EZ1L'+ZF.#G_4>G/(JE5*\L\,Y-4*G[M)*<^5HU+TJI$B<
M(@654TZFCU-RP(]LL173IS_J_P!7SZ;-2:ZJXQZ?\7TTU&*I345\T=1-/2HS
M).R&-%C=JRGI4CE2J@IE6*K2C0@1:RD[I(-0CM[V"PS3%*XQ^7RZT *"ASY4
M\NF6LP%8IJ*A):>>,1T<5$HBDE>>*IGHJN+7&RU-.0M/,'-B;QE%"BS > #
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M?,Q<2R?T3W <*]!B^VI[(ZHID=!@JIJ5^8]5^7$?/K8/>,J=+#3H .@$$!7
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M>) ?#)*FERI/O9H01J&KC0]:K3(/\Z?ET#GRBJ98M@T%!-/43'([RV[HJ9#
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MW7FZJGQV.A)]=74(6M&&8-HFHA0>/'Y#S)^0_GPK4]5&/L\L?ZO]7SZ^;?\
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M$*;S4TM.(\.IC+TY+T\ZOYHE56C@5"J^IFT" RL3C@<]>((4@@?+_8^WISI
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MWIM**IQ&W))Q528>MP[3T=/CZXM*SQ+3R!K]U6.Y\P[AM4YG>:W+,(1*5$Q
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M)+3-((:J&"IIXYO3-$E2HG5)DL-$Z+(!(#]&O[BR9!6A^($@TX&GI\O3H#.
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M-F=C]MT-%EI27DR=%G^WM][CQ5;,2/77SX?*PM5'Z&IUD>G3[:WB[6[:*Z5
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+[W[KW7O?NO=?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052291043712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Feb. 06, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 29,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-3215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Johnson & Johnson<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-1024240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Johnson & Johnson Plaza<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Brunswick<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">524-0400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,407,616,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:110%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.153%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%">Part III:</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%">Portions of the registrant&#8217;s proxy statement for its 2025 annual meeting of shareholders to be filed within 120&#160;days after the close of the registrant&#8217;s fiscal year (the &#8220;Proxy Statement&#8221;), are incorporated by reference to this report on Form 10-K (this &#8220;Report&#8221;).</span></div></td></tr></table></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000200406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, Par Value $1.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes Due May 2035</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.650% Notes Due May 2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDueNovember2028Member', window );">1.150% Notes Due November 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.150% Notes Due November 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A3.20NotesDueNovember2032Member', window );">3.20% Notes Due November 2032</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">3.20% Notes Due November 2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A3.350NotesDueNovember2036Member', window );">3.350% Notes Due November 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">3.350% Notes Due November 2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ36A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A3.550NotesDueNovember2044Member', window );">3.550% Notes Due November 2044</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">3.550% Notes Due November 2044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDueNovember2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDueNovember2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A3.20NotesDueNovember2032Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A3.20NotesDueNovember2032Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A3.350NotesDueNovember2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A3.350NotesDueNovember2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A3.550NotesDueNovember2044Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A3.550NotesDueNovember2044Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052291097488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Florham Park, New Jersey<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052289073536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 24,105<span></span>
</td>
<td class="nump">$ 21,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">417<span></span>
</td>
<td class="nump">1,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable trade, less allowances $167 (2023, $166)</a></td>
<td class="nump">14,842<span></span>
</td>
<td class="nump">14,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">12,444<span></span>
</td>
<td class="nump">11,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other receivables</a></td>
<td class="nump">4,085<span></span>
</td>
<td class="nump">4,514<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">55,893<span></span>
</td>
<td class="nump">53,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">20,518<span></span>
</td>
<td class="nump">19,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">37,618<span></span>
</td>
<td class="nump">34,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">44,200<span></span>
</td>
<td class="nump">36,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred taxes on income</a></td>
<td class="nump">10,461<span></span>
</td>
<td class="nump">9,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">11,414<span></span>
</td>
<td class="nump">14,153<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">180,104<span></span>
</td>
<td class="nump">167,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Loans and notes payable</a></td>
<td class="nump">5,983<span></span>
</td>
<td class="nump">3,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">10,311<span></span>
</td>
<td class="nump">9,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">8,549<span></span>
</td>
<td class="nump">10,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_AccruedRebatesReturnsAndPromotions', window );">Accrued rebates, returns and promotions</a></td>
<td class="nump">17,580<span></span>
</td>
<td class="nump">16,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee related obligations</a></td>
<td class="nump">4,126<span></span>
</td>
<td class="nump">3,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued taxes on income</a></td>
<td class="nump">3,772<span></span>
</td>
<td class="nump">2,993<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">50,321<span></span>
</td>
<td class="nump">46,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">30,651<span></span>
</td>
<td class="nump">25,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred taxes on income</a></td>
<td class="nump">2,448<span></span>
</td>
<td class="nump">3,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Employee related obligations</a></td>
<td class="nump">7,255<span></span>
</td>
<td class="nump">7,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Long-term taxes payable</a></td>
<td class="nump">390<span></span>
</td>
<td class="nump">2,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">17,549<span></span>
</td>
<td class="nump">13,398<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">108,614<span></span>
</td>
<td class="nump">98,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock&#160;&#8212; without par value (authorized and unissued 2,000,000&#160;shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#160;&#8212; par value $1.00 per share (Note&#160;12) (authorized 4,320,000,000&#160;shares; issued 3,119,843,000&#160;shares)</a></td>
<td class="nump">3,120<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(11,741)<span></span>
</td>
<td class="num">(12,527)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings and Additional-paid-in-capital</a></td>
<td class="nump">155,791<span></span>
</td>
<td class="nump">153,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Less: common stock held in treasury, at cost (Note&#160;12) (712,921,000&#160;shares and 712,765,000&#160;shares)</a></td>
<td class="nump">75,680<span></span>
</td>
<td class="nump">75,662<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">71,490<span></span>
</td>
<td class="nump">68,774<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 180,104<span></span>
</td>
<td class="nump">$ 167,558<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_AccruedRebatesReturnsAndPromotions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_AccruedRebatesReturnsAndPromotions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052289620864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowances for doubtful accounts</a></td>
<td class="nump">$ 167<span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in usd per share)</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">4,320,000,000<span></span>
</td>
<td class="nump">4,320,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">3,119,843,000<span></span>
</td>
<td class="nump">3,119,843,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">712,921,000<span></span>
</td>
<td class="nump">712,765,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052291025728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Earnings - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 88,821<span></span>
</td>
<td class="nump">$ 85,159<span></span>
</td>
<td class="nump">$ 79,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">27,471<span></span>
</td>
<td class="nump">26,553<span></span>
</td>
<td class="nump">24,596<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">61,350<span></span>
</td>
<td class="nump">58,606<span></span>
</td>
<td class="nump">55,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, marketing and administrative expenses</a></td>
<td class="nump">22,869<span></span>
</td>
<td class="nump">21,512<span></span>
</td>
<td class="nump">20,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="nump">17,232<span></span>
</td>
<td class="nump">15,085<span></span>
</td>
<td class="nump">14,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ResearchAndDevelopmentInProcess1', window );">In-process research and development impairments</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="nump">783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(1,332)<span></span>
</td>
<td class="num">(1,261)<span></span>
</td>
<td class="num">(490)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense, net of portion capitalized</a></td>
<td class="nump">755<span></span>
</td>
<td class="nump">772<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="nump">4,694<span></span>
</td>
<td class="nump">6,634<span></span>
</td>
<td class="nump">810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">489<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">16,687<span></span>
</td>
<td class="nump">15,062<span></span>
</td>
<td class="nump">19,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for taxes on income</a></td>
<td class="nump">2,621<span></span>
</td>
<td class="nump">1,736<span></span>
</td>
<td class="nump">2,989<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net earnings from continuing operations</a></td>
<td class="nump">14,066<span></span>
</td>
<td class="nump">13,326<span></span>
</td>
<td class="nump">16,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net earnings from discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,827<span></span>
</td>
<td class="nump">1,571<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 14,066<span></span>
</td>
<td class="nump">$ 35,153<span></span>
</td>
<td class="nump">$ 17,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic net earnings per share from continuing operations (in dollars per share)</a></td>
<td class="nump">$ 5.84<span></span>
</td>
<td class="nump">$ 5.26<span></span>
</td>
<td class="nump">$ 6.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare', window );">Basic net earnings per share from discontinued operations (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8.62<span></span>
</td>
<td class="nump">0.60<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">5.84<span></span>
</td>
<td class="nump">13.88<span></span>
</td>
<td class="nump">6.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted net earnings per share from continuing operations (in dollars per share)</a></td>
<td class="nump">5.79<span></span>
</td>
<td class="nump">5.20<span></span>
</td>
<td class="nump">6.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare', window );">Diluted net earnings per share from discontinuing operations (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8.52<span></span>
</td>
<td class="nump">0.59<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 5.79<span></span>
</td>
<td class="nump">$ 13.72<span></span>
</td>
<td class="nump">$ 6.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">2,407.3<span></span>
</td>
<td class="nump">2,533.5<span></span>
</td>
<td class="nump">2,625.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">2,429.4<span></span>
</td>
<td class="nump">2,560.4<span></span>
</td>
<td class="nump">2,663.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ResearchAndDevelopmentInProcess1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development In Process1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ResearchAndDevelopmentInProcess1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052289593520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 14,066<span></span>
</td>
<td class="nump">$ 35,153<span></span>
</td>
<td class="nump">$ 17,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax', window );">Foreign currency translation</a></td>
<td class="nump">1,708<span></span>
</td>
<td class="num">(3,221)<span></span>
</td>
<td class="num">(1,796)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) arising during period</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassifications to earnings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net change</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Employee benefit plans:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax', window );">Prior service credit (cost), net of amortization</a></td>
<td class="num">(154)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="num">(160)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax', window );">Gain (loss), net of amortization</a></td>
<td class="nump">541<span></span>
</td>
<td class="num">(1,183)<span></span>
</td>
<td class="nump">1,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax', window );">Consumer settlement/ curtailment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax', window );">Effect of exchange rates</a></td>
<td class="nump">62<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net change</a></td>
<td class="nump">449<span></span>
</td>
<td class="num">(1,399)<span></span>
</td>
<td class="nump">1,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Derivatives &amp; hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Unrealized gain (loss) arising during period</a></td>
<td class="num">(511)<span></span>
</td>
<td class="nump">422<span></span>
</td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Reclassifications to earnings</a></td>
<td class="num">(862)<span></span>
</td>
<td class="num">(569)<span></span>
</td>
<td class="num">(348)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net change</a></td>
<td class="num">(1,373)<span></span>
</td>
<td class="num">(147)<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">786<span></span>
</td>
<td class="num">(4,741)<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">$ 14,852<span></span>
</td>
<td class="nump">$ 30,412<span></span>
</td>
<td class="nump">$ 18,032<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>other comprehensive income loss, pension and other , effects of exchange rate net of tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) for increase (decrease) to other comprehensive income from settlement and curtailment gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052283518880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation</a></td>
<td class="num">$ (1,100)<span></span>
</td>
<td class="nump">$ 797<span></span>
</td>
<td class="num">$ (460)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax', window );">Employee benefits</a></td>
<td class="nump">86<span></span>
</td>
<td class="num">(289)<span></span>
</td>
<td class="nump">461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax', window );">Derivatives &amp; hedges</a></td>
<td class="num">$ (365)<span></span>
</td>
<td class="num">$ (39)<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052288201664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Retained Earnings and Additional paid-in capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Common Stock Issued Amount</div></th>
<th class="th"><div>Treasury Stock Amount</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Jan. 02, 2022</a></td>
<td class="nump">$ 74,023<span></span>
</td>
<td class="nump">$ 123,060<span></span>
</td>
<td class="num">$ (13,058)<span></span>
</td>
<td class="nump">$ 3,120<span></span>
</td>
<td class="num">$ (39,099)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">17,941<span></span>
</td>
<td class="nump">17,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(11,682)<span></span>
</td>
<td class="num">(11,682)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Employee compensation and stock option plans</a></td>
<td class="nump">2,466<span></span>
</td>
<td class="num">(974)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(6,035)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,035)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Jan. 01, 2023</a></td>
<td class="nump">76,804<span></span>
</td>
<td class="nump">128,345<span></span>
</td>
<td class="num">(12,967)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(41,694)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">35,153<span></span>
</td>
<td class="nump">35,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(11,770)<span></span>
</td>
<td class="num">(11,770)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Employee compensation and stock option plans</a></td>
<td class="nump">2,193<span></span>
</td>
<td class="num">(336)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(5,054)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,054)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Kenvue Separation /IPO</a></td>
<td class="num">(23,786)<span></span>
</td>
<td class="nump">2,451<span></span>
</td>
<td class="nump">5,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,418)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(4,741)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,741)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2023</a></td>
<td class="nump">68,774<span></span>
</td>
<td class="nump">153,843<span></span>
</td>
<td class="num">(12,527)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(75,662)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">14,066<span></span>
</td>
<td class="nump">14,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(11,823)<span></span>
</td>
<td class="num">(11,823)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Employee compensation and stock option plans</a></td>
<td class="nump">2,094<span></span>
</td>
<td class="num">(295)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(2,407)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,407)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 29, 2024</a></td>
<td class="nump">$ 71,490<span></span>
</td>
<td class="nump">$ 155,791<span></span>
</td>
<td class="num">$ (11,741)<span></span>
</td>
<td class="nump">$ 3,120<span></span>
</td>
<td class="num">$ (75,680)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSpinoffTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 60<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481423/505-60-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSpinoffTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052289682288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Cash dividends paid (in dollars per share)</a></td>
<td class="nump">$ 4.91<span></span>
</td>
<td class="nump">$ 4.70<span></span>
</td>
<td class="nump">$ 4.45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052288433056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 14,066<span></span>
</td>
<td class="nump">$ 35,153<span></span>
</td>
<td class="nump">$ 17,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net earnings to cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization of property and intangibles</a></td>
<td class="nump">7,339<span></span>
</td>
<td class="nump">7,486<span></span>
</td>
<td class="nump">6,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">1,176<span></span>
</td>
<td class="nump">1,162<span></span>
</td>
<td class="nump">1,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset write-downs</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">1,295<span></span>
</td>
<td class="nump">1,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Charges for acquired in-process research and development assets</a></td>
<td class="nump">1,841<span></span>
</td>
<td class="nump">483<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">(Gain) on separation of Kenvue</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(20,984)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Net gain on sale of assets/businesses</a></td>
<td class="num">(226)<span></span>
</td>
<td class="num">(117)<span></span>
</td>
<td class="num">(380)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax provision</a></td>
<td class="num">(2,183)<span></span>
</td>
<td class="num">(4,194)<span></span>
</td>
<td class="num">(1,663)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Credit losses and accounts receivable allowances</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities, net of effects from acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable</a></td>
<td class="num">(406)<span></span>
</td>
<td class="num">(624)<span></span>
</td>
<td class="num">(1,290)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="num">(1,128)<span></span>
</td>
<td class="num">(1,323)<span></span>
</td>
<td class="num">(2,527)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase in accounts payable and accrued liabilities</a></td>
<td class="nump">1,621<span></span>
</td>
<td class="nump">2,346<span></span>
</td>
<td class="nump">1,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Decrease/(Increase) in other current and non-current assets</a></td>
<td class="nump">1,717<span></span>
</td>
<td class="num">(3,480)<span></span>
</td>
<td class="nump">687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Increase/(Decrease) in other current and non-current liabilities</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">5,588<span></span>
</td>
<td class="num">(1,979)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows from operating activities</a></td>
<td class="nump">24,266<span></span>
</td>
<td class="nump">22,791<span></span>
</td>
<td class="nump">21,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property, plant and equipment</a></td>
<td class="num">(4,424)<span></span>
</td>
<td class="num">(4,543)<span></span>
</td>
<td class="num">(4,009)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from the disposal of assets/businesses, net</a></td>
<td class="nump">675<span></span>
</td>
<td class="nump">358<span></span>
</td>
<td class="nump">543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, net of cash acquired</a></td>
<td class="num">(15,146)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(17,652)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PaymentsToAcquiredInProcessResearchAndDevelopmentAssets', window );">Purchases of in-process research and development assets</a></td>
<td class="num">(1,783)<span></span>
</td>
<td class="num">(470)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(1,726)<span></span>
</td>
<td class="num">(10,906)<span></span>
</td>
<td class="num">(32,384)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Sales of investments</a></td>
<td class="nump">2,462<span></span>
</td>
<td class="nump">19,390<span></span>
</td>
<td class="nump">41,609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities', window );">Credit support agreements activity, net</a></td>
<td class="nump">1,517<span></span>
</td>
<td class="num">(2,963)<span></span>
</td>
<td class="num">(249)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other (including capitalized licenses and milestones)</a></td>
<td class="num">(174)<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="num">(229)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used by)/from investing activities</a></td>
<td class="num">(18,599)<span></span>
</td>
<td class="nump">878<span></span>
</td>
<td class="num">(12,371)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfOrdinaryDividends', window );">Dividends to shareholders</a></td>
<td class="num">(11,823)<span></span>
</td>
<td class="num">(11,770)<span></span>
</td>
<td class="num">(11,682)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(2,432)<span></span>
</td>
<td class="num">(5,054)<span></span>
</td>
<td class="num">(6,035)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term debt</a></td>
<td class="nump">15,277<span></span>
</td>
<td class="nump">13,743<span></span>
</td>
<td class="nump">16,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of short-term debt</a></td>
<td class="num">(9,463)<span></span>
</td>
<td class="num">(22,973)<span></span>
</td>
<td class="num">(6,550)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt, net of issuance costs</a></td>
<td class="nump">6,660<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="num">(1,453)<span></span>
</td>
<td class="num">(1,551)<span></span>
</td>
<td class="num">(2,134)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits', window );">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</a></td>
<td class="nump">838<span></span>
</td>
<td class="nump">1,094<span></span>
</td>
<td class="nump">1,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities', window );">Credit support agreements activity, net</a></td>
<td class="nump">272<span></span>
</td>
<td class="num">(219)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_SettlementOfConvertibleDebtAcquiredFromShockwave', window );">Settlement of convertible debt acquired from Shockwave</a></td>
<td class="num">(970)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation', window );">Proceeds of short and long-term debt, net of issuance cost, related to the debt that transferred to Kenvue at separation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,047<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Kenvue initial public offering</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,241<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PaymentsMadeInBusinessSeparation', window );">Cash transferred to Kenvue at separation</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,114)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(269)<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used by financing activities</a></td>
<td class="num">(3,132)<span></span>
</td>
<td class="num">(15,825)<span></span>
</td>
<td class="num">(8,871)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(289)<span></span>
</td>
<td class="num">(112)<span></span>
</td>
<td class="num">(312)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase/(Decrease) in cash and cash equivalents</a></td>
<td class="nump">2,246<span></span>
</td>
<td class="nump">7,732<span></span>
</td>
<td class="num">(360)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations', window );">Cash and cash equivalents from continuing operations, beginning of period</a></td>
<td class="nump">21,859<span></span>
</td>
<td class="nump">12,889<span></span>
</td>
<td class="nump">13,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents from discontinued operations, beginning of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,238<span></span>
</td>
<td class="nump">1,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">21,859<span></span>
</td>
<td class="nump">14,127<span></span>
</td>
<td class="nump">14,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations', window );">Cash and cash equivalents from continuing operations, end of period</a></td>
<td class="nump">24,105<span></span>
</td>
<td class="nump">21,859<span></span>
</td>
<td class="nump">12,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents from discontinued operations, end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">24,105<span></span>
</td>
<td class="nump">21,859<span></span>
</td>
<td class="nump">14,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_CashPaidDuringTheYearAbstract', window );"><strong>Cash paid during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest</a></td>
<td class="nump">1,990<span></span>
</td>
<td class="nump">1,836<span></span>
</td>
<td class="nump">982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest, net of amount capitalized</a></td>
<td class="nump">1,911<span></span>
</td>
<td class="nump">1,766<span></span>
</td>
<td class="nump">933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes, inclusive of discontinued operations</a></td>
<td class="nump">6,714<span></span>
</td>
<td class="nump">8,574<span></span>
</td>
<td class="nump">5,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds', window );">Treasury stock issued for employee compensation and stock option plans, net of cash proceeds/ employee withholding tax on stock awards</a></td>
<td class="nump">1,551<span></span>
</td>
<td class="nump">1,435<span></span>
</td>
<td class="nump">2,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1', window );">Fair value of assets acquired</a></td>
<td class="nump">16,091<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Fair value of liabilities assumed</a></td>
<td class="num">(1,632)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,058)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1', window );">Net cash paid for acquisitions (Note 18)</a></td>
<td class="nump">$ 14,459<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 17,652<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CashPaidDuringTheYearAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Paid During The Year [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CashPaidDuringTheYearAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PaymentsMadeInBusinessSeparation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments Made In Business Separation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PaymentsMadeInBusinessSeparation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PaymentsToAcquiredInProcessResearchAndDevelopmentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquired In-Process Research And Development Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PaymentsToAcquiredInProcessResearchAndDevelopmentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Long-Term Debt, Transferred In Business Separation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SettlementOfConvertibleDebtAcquiredFromShockwave">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement of convertible debt acquired from Shockwave</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SettlementOfConvertibleDebtAcquiredFromShockwave</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury stock issued for employee compensation and stock option plans, net of cash proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfOrdinaryDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfOrdinaryDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052288775232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text">Summary of significant accounting policies<div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The consolidated financial statements include the accounts of Johnson&#160;&amp; Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Description of the company</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has approximately 138,100&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Kenvue IPO/separation and discontinued operations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of 198,734,444 shares of its common stock, par value $0.01 per share (the &#8220;Kenvue Common Stock&#8221;), at an initial public offering of $22.00 per share for net proceeds of $4.2&#160;billion. The excess of the net proceeds from the IPO over the net book value of the Johnson &amp; Johnson divested interest was $2.5&#160;billion and was recorded to additional paid-in capital. As of the closing of the IPO, Johnson &amp; Johnson owned approximately 89.6% of the total outstanding shares of Kenvue Common Stock and at July 2, 2023, the <br/>non-controlling interest of $1.3&#160;billion associated with Kenvue was reflected in equity attributable to non-controlling interests in the consolidated balance sheet in the fiscal second quarter of 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On August 23, 2023, Johnson &amp; Johnson completed the disposition of an additional 80.1% ownership of the shares of Kenvue through an exchange offer. Following the exchange offer, the Company owned 9.5% of the shares of Kenvue which were accounted for as an equity investment carried at fair value within continuing operations. The historical results of the Consumer Health business (which previously represented the Consumer Health business segment) are reflected as discontinued operations in the Company&#8217;s Consolidated Financial Statements through the date of the exchange offer (see Note 21 for additional details). Unless otherwise indicated, the information in the notes to the Consolidated Financial Statements refer only to Johnson &amp; Johnson&#8217;s continuing operations. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In the fiscal second quarter of 2024 the Company completed a debt for equity exchange of the retained stake in Kenvue. Upon completion of the debt for equity exchange, the Company no longer owns any shares of Kenvue Common Stock.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Business segments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company is organized into two business segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on the following therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolic. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the Orthopaedic, Surgery, Cardiovascular (previously referred to as Interventional Solutions) and Vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">New accounting standards</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently adopted accounting standards</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">ASU 2023-07: Segment Reporting (Topic 280) &#8211; Improvements to Reportable Segment Disclosures</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company adopted the standard in the fiscal year 2024, which requires expanded annual and interim disclosures for significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. The standard was applied retrospectively to all periods presented in the financial statements. As this accounting standard only impacts disclosures, it did not have a material impact on the Company&#8217;s Consolidated Financial Statements. See Note 17 for the required disclosures.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently issued accounting standards</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not adopted as of December 29, 2024</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">ASU 2024-03: Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures (Subtopic&#160;220-40): Disaggregation of Income Statement Expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">This update requires disclosure of disaggregated information about certain income statement expense line items on an annual and interim basis. This update will be effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. As this accounting standard only impacts disclosures, it will not have a material impact on the Company&#8217;s Consolidated Financial Statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">ASU 2023-09: Income Taxes (Topic 740) - Improvements to Income Tax Disclosures</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">This update standardizes categories for the effective tax rate reconciliation, requires disaggregation of income taxes and additional income tax-related disclosures. This update is required to be effective for the Company for fiscal periods beginning after December 15, 2024. As this accounting standard only impacts disclosures, it will not have a material impact on the Company&#8217;s Consolidated Financial Statements. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating. The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value. The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Investments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets; otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required.&#160;</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Property, plant and equipment and depreciation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Building and building equipment</span></div></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">30&#160;years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Land and leasehold improvements</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">10&#160;- 20&#160;years</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Machinery and equipment</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2&#160;- 13&#160;years</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8&#160;years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset&#8217;s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns, discounts to customers and governmental clawback provisions are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued rebates, returns, and promotions on the consolidated balance sheet.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates and discounts are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A&#160;significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily the Managed Care, Medicare and Medicaid programs, which amounted to $12.3 billion and $11.5 billion as of December&#160;29, 2024 and December&#160;31, 2023, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Sales returns are estimated and recorded based on historical sales and returns information. Products that have lost patent exclusivity, or that otherwise exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. In accordance with the Company&#8217;s accounting policies, the Company generally issues credit to customers for returned goods. The Company&#8217;s sales returns reserves are accounted for in accordance with the U.S.&#160;GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Innovative Medicine segment are almost exclusively not resalable. Sales returns for certain franchises in the MedTech segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during each of the fiscal years&#160;2024,&#160;2023 and 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Promotional programs, such as product listing allowances are recorded in the same period as related sales and include <br/>volume-based sales incentive programs. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements of certain products, which are included in sales to customers. Profit-share payments were less than 2.0% of the total revenues in the fiscal year 2024 and 2023, respectively, and less than 3.0% of total revenues in the fiscal year 2022 and are included in sales to customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">See Note 17 to the Consolidated Financial Statements for further disaggregation of revenue.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Shipping and handling</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Shipping and handling costs incurred were $0.9 billion, $0.9 billion and $0.8 billion in fiscal years 2024, 2023 and 2022, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 1.0% of sales to customers for all periods presented.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Intangible assets and goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The authoritative literature on U.S.&#160;GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2024 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. In-process research and development purchased as part of a business combination is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset. If warranted the purchased in-process research and development could be written off or partially impaired depending on the underlying&#160;program.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Intangible assets that have finite useful lives continue to be amortized over their useful lives and are reviewed for impairment when warranted by economic conditions. See Note&#160;5 for further details on Intangible Assets and Goodwill.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">As required by U.S.&#160;GAAP, all derivative instruments are recorded on the balance sheet at fair value. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level&#160;1 having the highest priority and Level&#160;3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge&#160;transaction.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1)&#160;minimize foreign currency exposure&#8217;s impact on the Company&#8217;s financial performance; (2)&#160;protect the Company&#8217;s cash flow from adverse movements in foreign exchange rates; (3)&#160;ensure the appropriateness of financial instruments; and (4)&#160;manage the enterprise risk associated with financial institutions. See Note&#160;6 for additional information on Financial Instruments.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in <span style="-sec-ix-hidden:f-539"><span style="-sec-ix-hidden:f-540">Other assets</span></span>, <span style="-sec-ix-hidden:f-541"><span style="-sec-ix-hidden:f-542">Accrued liabilities</span></span>, and <span style="-sec-ix-hidden:f-543"><span style="-sec-ix-hidden:f-544">Other liabilities</span></span> on the consolidated balance sheet. The ROU Assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Commitments under finance leases are not significant, and are included in Property, plant and equipment, Loans and notes payable, and Long-term debt on the consolidated balance sheet.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The&#160;ROU asset pertaining to leases from continuing operations was $1.1&#160;billion and $1.0&#160;billion in fiscal years 2024 and 2023, respectively. The lease liability from continuing operations was $1.2&#160;billion and $1.1&#160;billion in fiscal years 2024 and 2023, respectively. The operating lease costs from continuing operations were $0.2&#160;billion in fiscal years 2024, 2023 and 2022. Cash&#160;paid for amounts included in the measurement of lease liabilities from continuing operations were $0.2&#160;billion in fiscal years 2024, 2023 and 2022.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product liability</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Research and development</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Research and development expenses are expensed as incurred in accordance with ASC 730, Research&#160;and Development. Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company&#8217;s operations. In general, the income statement presentation for these collaborations is as follows:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.453%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.157%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Nature/Type of Collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Statement of Earnings Presentation</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Third-party sale of product &amp; profit share payments received</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Sales to customers</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Royalties/milestones paid to collaborative partner (post-regulatory approval)*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Cost of products sold</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Royalties received from collaborative partner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Other income (expense), net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Upfront payments&#160;&amp; milestones paid to collaborative partner (pre-regulatory approval)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Research and development expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Research and development payments to collaborative&#160;partner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Research and development expense</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Research and development payments received from collaborative partner or government entity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Reduction of Research and development expense</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">*&#160;&#160;&#160;&#160;Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense other than the acquired in-process research &amp; development expense of $1.25&#160;billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition) in fiscal year 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO, co-developed with Bayer HealthCare AG, IMBRUVICA, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company and CARVYKTI, licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX, licensed from Genmab A/S.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Advertising</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $0.6 billion, $0.5 billion and $0.7 billion in fiscal years 2024, 2023 and 2022, respectively.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Income taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from 35% to 21%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of 15.5% and all other earnings were taxed at a rate of 8.0%. This tax is payable over 8 years and will not accrue interest. These payments began in fiscal year 2018 and will continue through 2025. The final payment of $2.5&#160;billion will be made in fiscal year 2025. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI). GILTI is described as the excess of a U.S. shareholder&#8217;s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., &#8220;period cost&#8221;) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to affect the amount of GILTI inclusion in future years upon reversal (i.e., &#8220;deferred method&#8221;). The Company has elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The&#160;Company estimates that the tax effect of this repatriation would be approximately $0.5 billion under currently enacted tax laws and regulations and at current currency exchange rates. This amount does not include the possible benefit of U.S. foreign tax credits, which may substantially offset this cost.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">See Note 8 to the Consolidated Financial Statements for further information regarding income taxes.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net earnings per share</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.&#160;requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company follows the provisions of U.S.&#160;GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Supplier finance program obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide participating suppliers the ability to finance payment obligations from the Company with the third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The&#160;Company&#8217;s obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment&#160;terms of 90 days), are not affected by a participating supplier&#8217;s decision to participate in the program. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Confirmed obligations under the program as of December&#160;29, 2024, and December&#160;31, 2023, were $0.8&#160;billion and $0.7&#160;billion, respectively. The&#160;obligations are presented as <span style="-sec-ix-hidden:f-579"><span style="-sec-ix-hidden:f-580">Accounts payable</span></span> on the Consolidated Balance Sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The rollforward of the Company's valid obligations under the program were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Confirmed obligations - beginning of the year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$704</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Invoices confirmed during the year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3,048</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Confirmed invoices paid during the year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2,964</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Confirmed obligations - end of the year</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$788</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Annual closing date</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52&#160;weeks, but every five or six years the fiscal year consists of 53&#160;weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052287266000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, cash equivalents and current marketable securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash, cash equivalents and current marketable securities</a></td>
<td class="text">Cash, cash equivalents and current marketable securities<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">At the end of the fiscal year 2024 and 2023, cash, cash equivalents and current marketable securities comprised:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.875%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr style="height:35pt"><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying<br/>&#160;Amount</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrecognized<br/>Gain</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>&#160;Fair Value</span></td><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash &amp; Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current<br/> Marketable<br/> Securities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,918</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,918</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,918</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-U.S. Sovereign Securities</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,100</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,100</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,100</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,123</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,123</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,123</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Time deposits</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,045</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,045</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,045</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$17,306</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">17,306</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">17,186</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">120</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Gov't Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$6,815</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,816</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,796</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other Sovereign Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">176</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">176</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">93</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate and other debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">224</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">224</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">184</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal available for sale</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$7,215</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,216</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6,919</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">297</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:64.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total cash, cash equivalents and current marketable securities</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$24,105</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">417</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.875%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr style="height:35pt"><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrecognized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated Fair Value</span></td><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$3,340</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,340</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,340</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-U.S. Sovereign Securities</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">522</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">522</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">174</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">348</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,377</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,377</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,377</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">338</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">338</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">189</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">149</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,814</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,814</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,814</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Time deposits</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">662</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">662</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">662</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14,053</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14,053</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13,556</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">497</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Gov't Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$8,562</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,562</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,259</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">303</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Gov't Agencies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other Sovereign Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate and other debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">237</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">237</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">194</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal available for sale</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$8,875</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,874</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,303</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">571</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:64.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total cash, cash equivalents and current marketable securities</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$21,859</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,068</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. </span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive&#160;income.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Fair value of government securities and obligations and corporate debt securities were estimated using quoted broker prices and significant other observable inputs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The contractual maturities of the available for sale debt securities at December&#160;29, 2024 are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due within one year</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$7,204</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7,205</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due after one year through five years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">11</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due after five years through ten years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total debt securities</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$7,215</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">7,216</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company invests its excess cash in both deposits with major banks throughout the world and other high-quality money market instruments. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052290763824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">At the end of fiscal years 2024 and 2023, inventories comprised:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Raw materials and supplies</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,337</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,355</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goods in process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,815</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,952</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,292</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,874</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total inventories</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$12,444</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">11,181</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052291383136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, plant and equipment</a></td>
<td class="text">Property, plant and equipment<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">At the end of fiscal years 2024 and 2023, property, plant and equipment at cost and accumulated depreciation were:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Land and land improvements</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$718</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">795</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Buildings and building equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,317</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,375</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,444</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,979</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Construction in progress</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,289</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,627</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total property, plant and equipment, gross</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$48,768</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">47,776</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,250</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,878</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total property, plant and equipment, net</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$20,518</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">19,898</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company capitalizes interest expense as part of the cost of construction of facilities and equipment. Interest expense capitalized in fiscal years 2024, 2023 and 2022 was $79 million, $70 million and $49 million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Depreciation expense, including the amortization of capitalized interest in fiscal years 2024, 2023 and 2022 was $2.8 billion, $2.6 billion and $2.4 billion, respectively. </span></div><div style="margin-bottom:40pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Upon retirement or other disposal of property, plant and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds are recorded in earnings.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052289532608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets and goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible assets and goodwill</a></td>
<td class="text">Intangible assets and goodwill<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">At the end of fiscal years 2024 and 2023, the gross and net amounts of intangible assets were:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Intangible assets with definite lives:</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents and trademarks&#160;&#8212; gross</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$44,695</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">40,417</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(26,124)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(24,808)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents and trademarks&#160;&#8212; net</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$18,571</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">15,609</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Customer relationships and other intangibles&#160;&#8212; gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$20,310</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">20,322</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(13,544)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(12,685)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Customer relationships and other intangibles&#160;&#8212; net</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$6,766</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">7,637</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trademarks</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,714</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchased in-process research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">12,281</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">9,215</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$12,281</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">10,929</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets&#160;&#8212; net</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$37,618</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">34,175</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:125%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:9.29pt">In September 2024, the Company announced changes to its MedTech brand identity and the $1.7&#160;billion of trademarks associated with the DePuy Synthes business were reclassified from indefinite lived to definite lived and will be amortized over a <span style="-sec-ix-hidden:f-767">25&#160;year</span> period.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:125%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.09pt">The majority is comprised of customer relationships</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Goodwill as of December&#160;29, 2024 and December&#160;31, 2023, as allocated by segment of business, was as follows:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.575%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Innovative <br/>Medicine</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MedTech</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill at January 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$10,184</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,863</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,047</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill, related to acquisitions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill, related to divestitures</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Currency translation/other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">223</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">288</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">511</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill at December 31, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,407</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,151</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,558</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill, related to acquisitions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">640</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,569</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,209</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill, related to divestitures</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(56)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(56)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Currency translation/other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(355)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(156)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(511)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill at December 29, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$10,692</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,508</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,200</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">*&#160;&#160;&#160;&#160;Includes purchase price allocation adjustments for Abiomed </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The weighted average amortization period for patents and trademarks is approximately 12 years. The weighted average amortization period for customer relationships and other intangible assets is approximately 18 years. The amortization expense of amortizable assets included in Cost of products sold was $4.5 billion, $4.5 billion and $3.9 billion before tax, for the fiscal years ended December&#160;29, 2024, December&#160;31, 2023 and January&#160;1, 2023, respectively. Intangible asset write-downs are included in Other (income) expense, net.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The estimated amortization expense related to intangible assets for approved products, before tax, for the five succeeding years is approximately:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:18.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:13pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2027</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2028</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2029</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$4,000</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,400</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,800</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,200</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,200</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">See Note 18 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052284172384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value measurements</a></td>
<td class="text">Fair value measurements<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany products and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of December&#160;29, 2024 and December&#160;31, 2023, the total amount of cash collateral paid by the Company under the CSA amounted to $2.2 billion and $4.0 billion net respectively, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of December&#160;29, 2024, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $45.1 billion, $40.5 billion and $9.0 billion, respectively. As of December&#160;31, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $42.9 billion, $39.7 billion and $10.0 billion, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. Cash exchanged for derivatives is primarily in cash flows from operating activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings.&#160;Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted through the currency translation account within accumulated other comprehensive income.&#160;The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If&#160;and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company designated its Euro denominated notes with due dates ranging from 2024 to 2044 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">As of December&#160;29, 2024, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $1.7 billion&#160;after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note&#160;13. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The&#160;maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedges. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended December&#160;29, 2024 and December&#160;31, 2023, net of tax:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.388%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost of<br/>Products<br/>&#160;Sold</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">R&amp;D<br/>&#160;Expense</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Interest<br/>(Income)<br/>&#160;Expense</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other<br/>(Income)<br/>Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost of<br/>Products<br/>Sold</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">R&amp;D<br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Interest<br/>(Income)<br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other<br/>(Income)<br/>Expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Interest rate swaps contracts:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Hedged items</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">168</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(64)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(168)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">148</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">130</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) recognized in AOCI</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">148</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">130</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Forward foreign exchange contracts:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">426</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">186</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(37)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) recognized in AOCI</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(156)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">80</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">447</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">247</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">275</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) recognized in AOCI</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(597)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(156)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">As of December&#160;29, 2024 and December&#160;31, 2023, the following amounts were recorded on the consolidated balance sheet related to cumulative basis adjustment for fair value hedges:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.230%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Line item in the Consolidated Balance Sheet<br/>in which the hedged item is included</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Amount of the Hedged Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cumulative Amount of Fair Value Hedging<br/>Adjustment Included in the Carrying<br/>Amount of the Hedged Liability</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term Debt</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$7,935</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$8,862</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(1,132)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(1,216)</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended <br/>December&#160;29, 2024 and December&#160;31, 2023:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.138%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.179%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Location of Gain /(Loss)<br/>Recognized in Income on<br/>Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Foreign Exchange Contracts</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-905"><span style="-sec-ix-hidden:f-906">Other (income) expense</span></span></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$8</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(60)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table is the effect of net investment hedges for the fiscal years ended December&#160;29, 2024 and <br/>December&#160;31, 2023:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain/(Loss)<br/>Recognized In<br/>Accumulated OCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Location of Gain or<br/>(Loss) Reclassified<br/>from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain/(Loss)<br/>Reclassified from<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Debt</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$282</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(131)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Interest (income) expense</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cross Currency interest rate&#160;swaps</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$955</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">642</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Interest (income) expense</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company measures equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table is a summary of the activity related to equity investments for the fiscal years ended December&#160;29, 2024 and December&#160;31, 2023:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Changes in Fair</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value Reflected in</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Income</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales/</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Purchases/</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-Current<br/>Other Assets</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity Investments with readily determinable value *</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$4,473</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(17)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,005)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">451</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">451</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity Investments without readily determinable value</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$696</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(197)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">274</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">773</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">773</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Changes in Fair</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value Reflected in</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Income</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales/</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Purchases/</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-Current<br/>Other Assets</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Equity Investments with readily determinable value *</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$576</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(368)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,265</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,473</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,473</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Equity Investments without readily determinable value</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$613</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">696</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">696</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">Recorded in Other Income/Expense</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Other includes impact of currency</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">*&#160;&#160;&#160;&#160;The December 31, 2023 balance includes the 9.5% remaining stake in Kenvue. A debt-for-equity exchange was completed in the fiscal second quarter of 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On May 15, 2024, the Company issued $3.6 billion aggregate principal amount of commercial paper and received $3.6&#160;billion of net cash proceeds to be used for general corporate purposes. On May 17, 2024, the Company completed a Debt-for-Equity Exchange of its remaining 182,329,550 shares of Kenvue Common Stock for the outstanding Commercial Paper. Upon completion of the Debt-for-Equity Exchange, the Commercial Paper was satisfied and discharged, and the Company no longer owns any shares of Kenvue Common Stock. This exchange resulted in a loss of approximately $0.4&#160;billion recorded in Other (income) expense. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">For the fiscal years ended December&#160;29, 2024 and December&#160;31, 2023 for equity investments without readily determinable market values, $171 million and $1 million, respectively, of the changes in fair value reflected in net income were the result of impairments. There were impacts of $26 million and $27 million, respectively, of changes in the fair value reflected in net income due to changes in observable prices and gains on the disposal of investments. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level&#160;1 having the highest priority and Level&#160;3 having the lowest.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S.&#160;Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#8217;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level&#160;1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following three levels of inputs are used to measure fair value:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Level&#160;1&#160;&#8212; Quoted prices in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Level&#160;2&#160;&#8212; Significant other observable inputs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Level&#160;3&#160;&#8212; Significant unobservable inputs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of the fiscal year ended December&#160;29, 2024 and December&#160;31, 2023 were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forward foreign exchange contracts </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">660</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">660</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">539</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest rate contracts</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,484</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,484</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">988</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$&#8212;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,144</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,144</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,527</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forward foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">794</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">794</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">624</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest rate contracts</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,753</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,753</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,338</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$&#8212;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,547</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,547</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,962</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forward foreign exchange contracts </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forward foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Available For Sale Other Investments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity investments</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">451</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">451</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,473</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Debt securities</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,216</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,216</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,874</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contingent Consideration</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,217</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,217</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,092</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.065%"><tr><td style="width:1.0%"></td><td style="width:64.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.895%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total Gross Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,194</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,591</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Credit Support Agreements (CSA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,172)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,575)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total Net Asset</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total Gross Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,564</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,037</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Credit Support Agreements (CSA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,412)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,604)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total Net Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$152</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">433</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Summarized information about changes in liabilities for contingent consideration is as follows:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning Balance</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$1,092</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,120</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">533</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Changes in estimated fair value </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">88</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(194)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Additions</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">112</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">792</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Payments/Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(75)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(57)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(11)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Ending Balance</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$1,217</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,092</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,120</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">2023 assets and liabilities are all classified as Level&#160;2 with the exception of equity investments of $4,473 million, which are classified as Level&#160;1 and contingent consideration of $1,092 million, classified as Level 3.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Includes cross currency interest rate swaps and interest rate swaps.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt">Classified as non-current other assets.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.89pt">Classified as cash equivalents and current marketable securities.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.99pt">Includes $1,217 million, $1,092 million and $1,116 million, classified as non-current other liabilities as of December&#160;29, 2024, <br/>December&#160;31, 2023 and January&#160;1, 2023, respectively. Includes $4&#160;million classified as current liabilities as of January&#160;1, 2023.</span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt">In fiscal year 2024, the Company recorded $105&#160;million of contingent consideration related to Proteologix. In fiscal year 2022, the Company recorded $704&#160;million of contingent consideration related to Abiomed. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">See Notes&#160;2 and 7 for financial assets and liabilities held at carrying amount on the Consolidated Balance Sheet.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052288443168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowings</a></td>
<td class="text">Borrowings<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The components of long-term debt are as follows:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.155%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.778%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Effective<br/>Rate<br/>%</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Effective<br/>Rate<br/>%</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.650% Notes due 2024 </span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(750MM Euro 1.1090)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$&#8212;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$831</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.68&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.50%&#160;Notes due 2024 </span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(500MM GBP 1.2756)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">637</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">6.75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.625% Notes due 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">750</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">750</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.55% Notes due 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">999</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">950</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.46% Notes due 2026</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,999</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.47&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,997</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.47&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.95% Notes due 2027</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">927</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">900</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.95% Notes due 2027</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,458</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,419</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.150% Notes due 2028<br/>(750MM Euro 1.0401)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/(750MM Euro 1.1090)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">777</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">828</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.90%&#160;Notes due 2028</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,498</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.91&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,497</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.91&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.95%&#160;Notes due 2029</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">298</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7.14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">298</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7.14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.80% Debentures due 2029</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,146</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.30% Notes due 2030</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,646</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,630</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.90% Debentures due 2031</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,145</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.92&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.20% Debenture due 2032</span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(700M EUR 1.0401)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">725</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.95%&#160;Debentures due 2033</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">499</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">499</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.375% Notes due 2033</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">854</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">854</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.95% Debentures due 2034</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">846</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.650% Notes due 2035<br/>(1.5B Euro 1.0401)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/(1.5B Euro 1.1090)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,550</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,652</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.35% Debentures due 2036 </span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(800MM EUR 1.0401)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">827</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.587% Notes due 2036</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">869</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">864</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.95%&#160;Notes due 2037</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">994</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">994</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.625% Notes due 2037</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,358</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,357</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.85%&#160;Debentures due 2038</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">697</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">697</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.40%&#160;Notes due 2038</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">993</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">993</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.50%&#160;Debentures due 2040</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">541</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">541</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.10% Notes due 2040</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">845</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">849</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.85% Notes due 2041</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">297</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">297</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.50% Notes due 2043</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">496</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">496</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.55% Debentures due 2044</span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1B EUR 1.0401)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,030</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.73% Notes due 2046</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,978</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,977</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.75% Notes due 2047</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">822</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">832</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.500% Notes due 2048</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">744</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">743</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.250% Notes due 2050</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">808</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">826</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.155%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.778%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.25% Debentures due 2054</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">843</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.450% Notes due 2060</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,058</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,073</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">83</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">69</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">32,400</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">3.36</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">27,350</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">2.98</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less current portion</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,749</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,469</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total long-term debt</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$30,651</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$25,881</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">Weighted average effective rate.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Translation rate at December&#160;29, 2024.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt">Translation rate at December&#160;31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.89pt">The excess of the carrying value over the fair value of debt was $2.0 billion and $1.0 billion at the end of fiscal year 2024 and fiscal year 2023, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Fair value of the long-term debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has access to substantial sources of funds at numerous banks worldwide. In June 2024, the Company secured a new 364-day Credit Facility of $10 billion, which expires on&#160;June 25, 2025. Interest charged on borrowings under the credit line agreement is based on either the Term SOFR Reference Rate or other applicable market rates&#160;as allowed under the terms of the agreement, plus applicable margins. Commitment fees under the agreements are not&#160;material.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Throughout fiscal years 2024 and 2023, the Company continued to have access to liquidity through the commercial paper&#160;market. Short-term borrowings and the current portion of long-term debt amounted to approximately $6.0 billion and $3.5 billion at the end of fiscal years 2024 and 2023, respectively. The current portion of the long-term debt was $1.7 billion and $1.5 billion in 2024 and 2023, respectively, and the remainder is commercial paper and local borrowing by international&#160;subsidiaries.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The current debt balance as of December&#160;29, 2024 includes $4.1&#160;billion of commercial paper which has a weighted average interest rate of 4.46% and a weighted average maturity of approximately two months. The current debt balance as of December&#160;31, 2023 includes $2.0&#160;billion of commercial paper which has a weighted average interest rate of 5.37% and a weighted average maturity of approximately two months.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Aggregate maturities of long-term debt obligations commencing in 2025 are:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.826%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2027</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2028</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2029</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">After 2029</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1,749</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,999</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,385</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,275</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,444</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,548</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052290297184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text">Income taxes<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The provision for taxes on income on continuing operations consists of:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Currently payable:</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. taxes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,200</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,705</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,274</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International taxes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,604</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,090</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,295</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total currently payable</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,804</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,795</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,569</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Deferred:</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. taxes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,539)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,440)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,990)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International taxes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">356</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(619)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">410</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total deferred</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,183)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,059)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,580)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Provision for taxes on income</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$2,621</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,736</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,989</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">A comparison of income tax expense at the U.S.&#160;statutory rate of 21% in fiscal years 2024, 2023 and 2022, to the Company&#8217;s effective tax rate is as follows:</span></div><div style="margin-bottom:4pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.&#160;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(458)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,033)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,606</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,145</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,095</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,753</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Earnings before taxes on income:</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$16,687</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,062</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,359</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax rates:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. statutory rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International operations</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. tax settlements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. taxes on international income</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. state taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax benefits on share-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effective Rate</span></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15.7&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.5&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15.4&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">International operations reflect the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland, and Belgium, which is a favorable impact on the effective tax rate as compared with the U.S. statutory&#160;rate. </span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Includes the net impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code as well as related foreign tax credits.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">The fiscal year 2024 effective tax rate increased 4.2% as compared to the fiscal year 2023 effective tax rate. The primary drivers of this change are discussed below.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">In fiscal year 2024, The Company had more income in higher tax jurisdictions compared to fiscal year 2023, primarily in the U.S. where the Company recorded a charge of approximately $5.1&#160;billion in the fiscal year of 2024 versus approximately $7.0&#160;billion in the fiscal year of 2023, both for the talc matters in the United States. Both charges were recorded at an effective U.S. tax rate of approximately 21% (for further information see Note 19 to the Consolidated Financial Statements). </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">Additionally in the fiscal year 2024, the effective tax rate was unfavorably impacted by legislative changes that went into effect for Pillar Two in some of the Company's foreign jurisdictions which are reflected in International operations on the Company&#8217;s effective tax rate reconciliation. Also in fiscal year 2024, the Company generated incremental U.S. foreign tax credits related to income sourced and taxed outside the United States and is reflected in U.S. taxes on international income on the Company&#8217;s effective tax rate reconciliation. In 2024, the Company finalized multi-year transfer pricing agreements with the U.S. Internal Revenue Service (IRS) and certain other foreign jurisdictions. The U.S portion of the agreements were partially offset by the related tax adjustments in the foreign jurisdictions which are reflected in U.S tax settlements and International operations, respectively, on the Company&#8217;s effective rate reconciliation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">The fiscal year 2023 effective tax rate decreased 3.9% as compared to the fiscal year 2022 effective tax rate as the Company recorded certain non-recurring favorable tax items in fiscal year 2023 when compared to the prior fiscal year.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">In the fiscal fourth quarter of 2023, the Company settled the U.S. Internal Revenue Service audit for tax years 2013 through 2016 which resulted in a favorable impact to the rate of 3.0%. This settlement was partially offset by the Company recording a $0.4&#160;billion decrease in expected U.S. foreign tax credits, an unfavorable effective rate impact of 2.6%, which has been reflected as a current tax expense in U.S. taxes on international income on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">In the fiscal year 2023, the Company had certain non-recurring impacts as a result of legislative tax elections made in certain international subsidiaries which resulted in a change in the Company&#8217;s tax basis in certain assets resulting in deferred tax re-measurements. The net impact of these non-recurring items is a net benefit of 3.4% to the Company&#8217;s annual effective tax rate, comprised of the following items:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:128%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%;padding-left:7.83pt">approximately $0.3&#160;billion of tax benefit on local deferred tax assets to record the remeasurement of the increased tax basis, this benefit has been reflected as International operations on the Company&#8217;s effective tax rate reconciliation. This&#160;benefit was offset by approximately $0.1&#160;billion of U.S. deferred tax expense on the GILTI deferred tax liability resulting from the remeasurement of these deferred tax assets. This has been reflected in the &#8220;U.S. tax on international income&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">approximately $0.3&#160;billion of U.S. deferred tax benefit on the GILTI deferred tax related to an election made by an international subsidiary resulting in a decrease in local deferred tax assets. This has been reflected in the U.S. taxes on international income on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company also had lower income in higher tax jurisdictions vs. fiscal year 2022, primarily in the U.S. where the Company recorded an approximately $7.0&#160;billion charge related to talc matters in the United States at an effective tax rate of 21.1% (for further information see Note 19 to the Consolidated Financial Statements).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Temporary differences and carryforwards at the end of fiscal years 2024 and 2023 were as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt;padding-right:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.292%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024 Deferred Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023 Deferred Tax</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Asset</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Asset</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee related obligations</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$372</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">586</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock based compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">717</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">686</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation of property, plant and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(833)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(902)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill and intangibles</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,261)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,252)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">R&amp;D capitalized for tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,398</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,595</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reserves&#160;&amp; liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,444</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,816</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory related</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">371</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">359</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating loss carryforwards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,298</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,145</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Undistributed foreign earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,931</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,492)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,801</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,695)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global intangible low-taxed income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,589)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,731)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Miscellaneous international</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,212</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">831</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Miscellaneous U.S.&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,083</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total deferred income taxes</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,826</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,175)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,819</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,584)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Valuation allowances</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,638)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,149)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total deferred income taxes net of valuation allowances</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15,188</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(7,175)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">12,670</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(6,584)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has wholly-owned international subsidiaries that have cumulative net losses. The Company believes that it is more likely than not that these subsidiaries will generate future taxable income sufficient to partially utilize these deferred tax assets. In certain jurisdictions, valuation allowances have been recorded against deferred tax assets for loss carryforwards that are not more likely than not to be realized. The net operating loss carryforwards for these international subsidiaries that do not have an indefinite carryforward period will begin to expire in 2025 for various amounts.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table summarizes the activity related to valuation allowances for continuing operations:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning of year</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1,149</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">775</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">451</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">355</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Utilization</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(116)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency translation</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(46)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net acquisitions / (dispositions/liquidations)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">84</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">110</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">End of year</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$1,638</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$1,149</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table summarizes the activity related to unrecognized tax benefits for continuing operations:</span></div><div style="margin-bottom:6pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning of year</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,485</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,716</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,210</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increases related to current year tax positions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">176</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">239</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">523</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increases related to prior period tax positions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">129</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">244</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">143</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Decreases related to prior period tax positions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(147)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(781)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(148)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Settlements</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(583)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(880)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lapse of statute of limitations</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(40)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(53)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">End of year</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$2,020</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,485</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,716</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">As of December&#160;29, 2024 the Company had approximately $2.0 billion of unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress with a number of tax authorities. With respect to the United States, the Internal Revenue Service (IRS) has completed its audit for the tax years through 2016 and has commenced the audit for tax years 2017 through 2020. The Company recently finalized multi-year transfer pricing agreements with the IRS and certain other foreign jurisdictions in the fiscal fourth quarter of 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In other major jurisdictions where the Company conducts business, the years that remain open to tax audits go back to the year 2013. The Company believes it is possible that some tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions. The Company anticipates a change in uncertain tax positions of approximately $200&#160;million in certain jurisdictions in the next twelve months due to the expected expiration of the statute of limitations. However, generally the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments, audit settlements, or changes in uncertain tax positions. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company classifies liabilities for unrecognized tax benefits and related interest and penalties as long-term liabilities. Interest expense and penalties related to unrecognized tax benefits are classified as income tax expense. The Company recognized after tax interest expense of $217 million, $99 million and $136 million in fiscal years 2024, 2023 and 2022, respectively. The total amount of accrued interest was $274&#160;million and $264 million in fiscal years 2024 and 2023,&#160;respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052378422192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee related obligations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Compensation Related Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsGeneralTextBlock', window );">Employee related obligations</a></td>
<td class="text">Employee related obligations<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">At the end of fiscal 2024 and fiscal 2023, employee related obligations recorded on the Consolidated Balance Sheets were:</span></div><div style="margin-bottom:6pt;margin-top:7pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pension benefits</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,968</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,129</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Postretirement benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,920</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,963</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Postemployment benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,910</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,527</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">68</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total employee obligations</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,847</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,687</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less current benefits payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">592</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">538</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee related obligations&#160;&#8212; non-current</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$7,255</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,149</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Prepaid employee related obligations of $6,046 million and $4,992 million for 2024 and 2023, respectively, are included in Other assets on the Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsGeneralTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation costs, including compensated absences accruals, compensated absences liability, deferred compensation arrangements and income statement compensation items. Deferred compensation arrangements may include a description of an arrangement with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares (units) issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 710<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482969/710-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsGeneralTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052284750096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and other benefit plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pensions and other benefit plans</a></td>
<td class="text">Pensions and other benefit plans<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. The Company also provides post-retirement benefits, primarily healthcare, to all eligible U.S.&#160;retired employees and their dependents.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Many international employees are covered by government-sponsored programs and the cost to the Company is not significant.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In the U.S., non-union pension benefits for employees hired before January 1, 2015 are primarily based on the employee&#8217;s compensation during the last five years before retirement and the number of years of service (the Final Average Pay formula). U.S. pension benefits for employees hired after 2014, are calculated using a different formula based on employee compensation over total years of service (the Retirement Value formula).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees, regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits accrued under the Final Average Pay formula for service before January 1, 2026. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">International subsidiaries have plans under which funds are deposited with trustees, annuities are purchased under group contracts, or reserves are provided.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company does not fund retiree healthcare benefits in advance and has the right to modify these plans in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In 2024 and 2023 the Company used December 31, 2024 and December 31, 2023, respectively, as the measurement date for all U.S.&#160;and international retirement and other benefit plans.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans for 2024, 2023 and 2022 include the following components:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service cost</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$948</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">893</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,319</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">277</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">264</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">320</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,402</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,437</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">908</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">209</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">214</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,560)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,716)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,756)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of prior service cost </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(184)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(184)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(184)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recognized actuarial losses (gains)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">174</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(199)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">650</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">122</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Curtailments and settlements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">93</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net periodic benefit cost (credit)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$(222)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(676)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(62)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">530</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">487</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">533</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, Selling, marketing and administrative expenses, and Net earnings from discontinued operations, net of taxes if related to the separation of Kenvue. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings, with the exception of certain amounts for curtailments and settlements, which are reported in Net earnings from discontinued operations, net of taxes if related to the separation of Kenvue (as noted above).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Unrecognized gains and losses for the U.S.&#160;pension plans are amortized over the average remaining future service for each plan. For plans with no active employees, they are amortized over the average life expectancy. The amortization of gains and losses for the other U.S.&#160;benefit plans is determined by using a 10% corridor of the greater of the market value of assets or the accumulated postretirement benefit obligation. Total unamortized gains and losses in excess of the corridor are amortized over the average remaining future service.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Prior service costs/benefits for the U.S.&#160;pension plans are amortized over the average remaining future service of plan participants at the time of the plan amendment. Prior service cost/benefit for the other U.S.&#160;benefit plans is amortized over the average remaining service to full eligibility age of plan participants at the time of the plan amendment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table represents the weighted-average actuarial assumptions:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Worldwide Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Net Periodic Benefit Cost</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service cost discount rate</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.39&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.85&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.46&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.09&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.40&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.59&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest cost discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.80&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Rate of increase in compensation levels</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.02&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected long-term rate of return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Benefit Obligation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.95&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.58&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.01&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.54&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.11&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.42&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Rate of increase in compensation levels</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.70&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.69&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.00&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.22&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.22&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.21&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company&#8217;s discount rates are determined by considering current yield curves representing high quality, long-term fixed income instruments. The resulting discount rates are consistent with the duration of plan liabilities. The Company's methodology in determining service and interest cost uses duration specific spot rates along that yield curve to the plans' liability cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The expected rates of return on plan asset assumptions represent the Company's assessment of long-term returns on diversified investment portfolios globally. The assessment is determined using projections from external financial sources, long-term historical averages, actual returns by asset class and the various asset class allocations by market. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table displays the assumed healthcare cost trend rates, for all individuals:</span></div><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Healthcare Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Healthcare cost trend rate assumed for next year</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.33&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.90&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Rate to which the cost trend rate is assumed to decline (ultimate trend)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.02&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Year the rate reaches the ultimate trend rate</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2048&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2048&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2024 and 2023 for the Company&#8217;s defined benefit retirement plans and other post-retirement plans:</span></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change in Benefit Obligation</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Projected benefit obligation&#160;&#8212; beginning of year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$31,744</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,390</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,108</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,192</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">948</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">893</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">277</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">264</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,402</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,437</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">209</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">214</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Plan participant contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amendments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Actuarial (gains) losses</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,245)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,068</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">398</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">469</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Divestitures&#160;&amp; acquisitions</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(352)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Curtailments, settlements&#160;&amp; restructuring</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(121)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(238)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(332)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Benefits paid from plan</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,801)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,122)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(556)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(702)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of exchange rates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(685)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">601</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Projected benefit obligation&#160;&#8212; end of year</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$30,317</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">31,744</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,425</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,108</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change in Plan Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Plan assets at fair value&#160;&#8212; beginning of year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$33,607</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,496</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">86</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">78</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Actual return (loss) on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,113</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,951</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Company contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">229</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">268</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">548</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">694</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Plan participant contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Settlements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(114)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(176)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Divestitures &amp; acquisitions</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(509)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Benefits paid from plan assets</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,801)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,122)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(556)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(702)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of exchange rates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(714)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">626</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Plan assets at fair value&#160;&#8212; end of year</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$33,395</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">33,607</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">93</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">86</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Funded status &#8212; end of year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$3,078</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,863</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4,332)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4,022)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amounts Recognized in the Company&#8217;s Balance Sheet consist of the&#160;following:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$6,046</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,992</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(136)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(119)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(453)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(416)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,832)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,010)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,879)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,606)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total recognized in the consolidated balance sheet&#160;&#8212; end of year</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$3,078</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,863</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4,332)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4,022)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amounts Recognized in Accumulated Other Comprehensive Income consist&#160;of the following:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net actuarial loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$3,903</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,962</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">691</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">354</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior service cost (credit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,051)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,236)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unrecognized net transition obligation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total before tax effects</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$2,852</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,726</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">687</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">348</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Benefit Obligations&#160;&#8212; end of year</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$28,883</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">30,139</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">The actuarial (gains)/losses for retirement plans in 2024 and 2023 were primarily driven by changes in the discount rates. </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Driven by the Kenvue separation.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt">The fiscal years 2024 and 2023 includes approximately $400 million and $800&#160;million, respectively, transferred to a group annuity contract issued by a third-party insurer for the U.S. Salaried Pension&#160;Plan.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive&#160;Income</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net periodic benefit cost (credit)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(222)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(676)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">530</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">487</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net actuarial (gain) loss</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(807)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">711</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">389</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">136</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of net actuarial loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(172)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">199</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(53)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(22)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior service cost (credit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of prior service (cost) credit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">184</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">185</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of exchange rates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(79)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">103</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total loss/(income) recognized in other comprehensive income, before tax</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$(874)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,195</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">339</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">116</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total recognized in net periodic benefit cost and other comprehensive&#160;income</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$(1,096)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">519</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">869</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">603</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company plans to continue to fund its U.S. Qualified Plans to comply with the Pension Protection Act of 2006. International Plans are funded in accordance with local regulations. Additional discretionary contributions are made when deemed appropriate to meet the long-term obligations of the plans. For certain plans, funding is not a common practice, as funding provides no economic benefit. Consequently, the Company has several pension plans that are not funded. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In 2024, the Company contributed $122 million and $107 million to its U.S.&#160;and international pension plans, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table displays the funded status of the Company's U.S. Qualified &amp; Non-Qualified pension plans and international funded and unfunded pension plans at December&#160;31, 2024 and December&#160;31, 2023, respectively:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.685%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">International Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Qualified Plans</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-Qualified Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Funded Plans</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unfunded Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Plan Assets</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$22,250</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,298</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,145</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,309</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Projected Benefit Obligation</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,146</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,152</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,990</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,037</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,069</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,431</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">112</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">124</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated Benefit Obligation</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,726</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,557</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,949</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,982</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,115</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,498</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">93</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">102</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Over (Under) Funded Status</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Projected Benefit Obligation</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$4,104</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,146</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,990)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,037)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,076</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">878</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(112)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(124)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated Benefit Obligation</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,524</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,741</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,949)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,982)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,030</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,811</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(93)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(102)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Plans with accumulated benefit obligations in excess of plan assets have an accumulated benefit obligation, projected benefit obligation and plan assets of $5.8 billion, $6.1 billion and $3.2 billion, respectively, at the end of 2024, and $5.8 billion, $6.1 billion and $3.1 billion, respectively, at the end of 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table displays the projected future benefit payments from the Company&#8217;s retirement and other benefit plans:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.286%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2030-2034</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Projected future benefit payments</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Retirement plans</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1,480</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,503</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,604</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,702</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,797</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,401</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other benefit plans&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$464</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">478</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">432</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">445</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">462</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,537</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table displays the projected future minimum contributions to the unfunded retirement plans. These amounts do not include any discretionary contributions that the Company may elect to make in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.286%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2030-2034</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Projected future contributions</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$133</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">135</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">140</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">145</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">150</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">815</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Each pension plan is overseen by a local committee or board that is responsible for the overall administration and investment of&#160;the pension plans. In determining investment policies, strategies and goals, each committee or board considers factors including, local pension rules and regulations; local tax regulations; availability of investment vehicles (separate accounts, commingled accounts, insurance funds, etc.); funded status of the plans; ratio of actives to retirees; duration of liabilities; and&#160;other relevant factors including: diversification, liquidity of local markets and liquidity of base currency. A majority of the Company&#8217;s pension funds are open to new entrants and are expected to be on-going plans. Permitted investments are primarily liquid and/or listed, with little reliance on illiquid and non-traditional investments such as hedge funds.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company&#8217;s retirement plan asset allocation at the end of 2024 and 2023 and target allocations for 2025 are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Percent of<br/>Plan Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Target<br/>Allocation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Worldwide Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity securities</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total plan assets</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Determination of fair value of plan assets</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Plan has an established and well-documented process for determining fair values. Fair value is based upon quoted market prices, where available. If listed prices or quotes are not available, fair value is based upon models that primarily use, as inputs, market-based or independently sourced market parameters, including yield curves, interest rates, volatilities, equity or debt prices, foreign exchange rates and credit curves.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">While the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Valuation hierarchy</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described in the table below with Level&#160;1 having the highest priority and Level&#160;3 having the lowest.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Net Asset Value (NAV) is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">A financial instrument&#8217;s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Following is a description of the valuation methodologies used for the investments measured at fair value.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%;padding-left:7.83pt">Short-term investment funds</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;&#8212; Cash and quoted short-term instruments are valued at the closing price or the amount held on deposit by the custodian bank. Other investments are through investment vehicles valued using the NAV provided by the administrator of the fund. The NAV is a quoted price in a market that is not active and classified as Level&#160;2.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%;padding-left:7.83pt">Government and agency securities</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;&#8212; A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified within Level&#160;1 of the valuation hierarchy. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows. When quoted market prices for a security are not available in an active market, they are classified as Level&#160;2.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%;padding-left:7.83pt">Debt instruments</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;&#8212; A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified as Level&#160;1. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows and are classified as Level&#160;2. Level&#160;3 debt instruments are priced based on unobservable inputs.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%;padding-left:7.83pt">Equity securities</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;&#8212; Equity securities are valued at the closing price reported on the major market on which the individual securities are traded. Substantially all equity securities are classified within Level&#160;1 of the valuation hierarchy.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%;padding-left:7.83pt">Commingled funds</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;&#8212; These investment vehicles are valued using the NAV provided by the fund administrator. Assets in the Level&#160;2 category have a quoted market price.</span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%;padding-left:7.83pt">Other assets</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;&#8212; Other assets are represented primarily by limited partnerships. These investment vehicles are valued using the NAV provided by the fund administrator. Other assets that are exchange listed and actively traded are classified as Level&#160;1, while inactively traded assets are classified as Level&#160;2. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table sets forth the Retirement Plans' investments measured at fair value as of December&#160;31, 2024 and December&#160;31, 2023:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Inputs</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Investments<br/>Measured at Net<br/>Asset Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term investment funds</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$&#8212;&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">511</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">829</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">511</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">841</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Government and agency securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,885</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,985</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,885</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,985</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Debt instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,321</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,899</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,321</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,899</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,144</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,764</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,144</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,764</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commingled funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,004</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,967</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,190</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,672</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,231</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,682</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">88</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">128</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">92</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,087</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,295</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,303</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,436</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Investments at fair value</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$7,144</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,776</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15,809</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15,729</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">165</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">135</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10,277</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9,967</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">33,395</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">33,607</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">The activity for the Level 3 assets is not significant for all years presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company's Other Benefit Plans are unfunded except for U.S.&#160;commingled funds (Level 2) of $93 million and $86 million at December&#160;31, 2024 and December&#160;31, 2023, respectively. </span></div>The fair value of Johnson&#160;&amp; Johnson Common Stock directly held in plan assets was $13 million at December&#160;31, 2024 and $14 million at December&#160;31, 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052291556352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Savings plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_SavingsPlanAbstract', window );"><strong>Savings Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_SavingsPlanTextBlock', window );">Savings plan</a></td>
<td class="text">Savings plan<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has voluntary 401(k) savings plans designed to enhance the existing retirement programs covering eligible employees. The Company matches a percentage of each employee&#8217;s contributions consistent with the provisions of the plan for which the employee is eligible. Total Company matching contributions to the plans were $282 million, $263 million and $257 million in fiscal years 2024, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SavingsPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Savings Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SavingsPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SavingsPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Savings Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SavingsPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052284750096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital and treasury stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockTextBlock', window );">Capital and treasury stock</a></td>
<td class="text">Capital and treasury stock<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Changes in treasury stock were:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Treasury Stock</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Amounts in Millions Except Treasury Stock Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at January 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">490,878</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$39,099</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee compensation and stock option plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(20,007)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,440)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repurchase of common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35,375</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,035</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at January 1, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">506,246</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,694</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee compensation and stock option plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(15,521)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,529)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repurchase of common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,085</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,079</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Kenvue share exchange (Note 21)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">190,955&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">31,418</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at December 31, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">712,765</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75,662</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee compensation and stock option plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(15,027)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,389)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repurchase of common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,183</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,407</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at December 29, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">712,921</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$75,680</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Aggregate shares of common stock issued were approximately 3,119,843,000&#160;shares at the end of fiscal years 2024, 2023 and 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Cash dividends paid were $4.91 per share in fiscal year 2024, compared with dividends of $4.70 per share in fiscal year 2023, and $4.45 per share in fiscal year 2022. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On January 2, 2025, the Board of Directors declared a regular cash dividend of $1.24 per share, payable on March 4, 2025 to shareholders of record as of February 18, 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On September 14, 2022, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company's shares of common stock. The repurchase program was completed during the fiscal first quarter of 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052291379136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated other comprehensive income (loss)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="text">Accumulated other comprehensive income (loss)<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Components of other comprehensive income (loss) consist of the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Foreign<br/>Currency<br/>Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain/<br/>(Loss) On<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Employee<br/>Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain/<br/>(Loss) On<br/>Derivatives<br/>&amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total<br/>Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">January 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(10,017)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,702)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(336)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(13,058)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net 2022 changes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,796)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(24)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,805</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">91</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">January 1, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11,813)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(27)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(897)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(230)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12,967)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net 2023 changes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,221)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,399)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(147)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,741)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Kenvue Separation/IPO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,885</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">296</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,181</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 31, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10,149)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,000)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(377)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12,527)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net 2024 changes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,708</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,373)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">786</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(8,441)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,551)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,750)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11,741)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For&#160;additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Details on reclassifications out of Accumulated Other Comprehensive Income:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 10 for additional details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Gain/(Loss) On Derivatives &amp; Hedges - reclassifications to earnings are recorded in the same account as the hedged transaction. See Note 6 for additional details.</span></div>*&#160;&#160;&#160;&#160;Includes impact of curtailments and settlements in connection with separation from Kenvue.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/220/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052378509024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>International currency translation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTranslationAbstract', window );"><strong>Foreign Currency Translation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDisclosureTextBlock', window );">International currency translation</a></td>
<td class="text">International currency translation<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">For translation of its subsidiaries operating in non-U.S.&#160;Dollar currencies, the Company has determined that the local currencies of its international subsidiaries are the functional currencies except those in highly inflationary economies, which are defined as those which have had compound cumulative rates of inflation of 100% or more during the past three years, or where a substantial portion of its cash flows are not in the local currency. For the majority of the Company's subsidiaries the local currency is the functional currency. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive income. The other current and non-current assets line within the Statement of Cash flows includes the impact of foreign currency translation. This equity account includes the results of translating certain balance sheet assets and liabilities at current exchange rates and some accounts at historical rates, except for those located in highly inflationary economies (Argentina, Turkey and Venezuela). Beginning in the fiscal fourth quarter of 2024, the Company also accounted for operations in Egypt as highly inflationary. The translation of balance sheet accounts for highly inflationary economies are reflected in the operating results.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">A rollforward of the changes during fiscal years 2024, 2023 and 2022 for foreign currency translation adjustments is included in Note&#160;13. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Net currency transaction gains and losses included in Other (income) expense were losses of $214 million, $366 million and $286 million in fiscal years 2024, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for foreign currency transactions and translation. This may include description of foreign currency transactions, foreign currency gains and losses, explanation of change in cumulative translation adjustment, description of effect of subsequent foreign currency exchange rate change, cumulative translation adjustment movement, foreign currency translation adjustment by component movement, translation adjustment for net investment hedge movement, adjustment for long-term intercompany transactions, schedule of long-term intercompany balances and any other foreign currency transactions and translation related items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-13<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-16<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479424/830-30-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTranslationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTranslationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052284803536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per share</a></td>
<td class="text">Earnings per share<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended December&#160;29, 2024, December&#160;31, 2023 and January&#160;1, 2023:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.096%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In Millions Except Per Share Amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net earnings per share from continuing operations</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$5.84&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.26</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.23</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net earnings per share from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.62</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.60</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total net earnings per share - basic</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.84</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.88</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.83</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Average shares outstanding&#160;&#8212; basic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,407.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,533.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,625.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">77.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">94.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">140.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: shares repurchased under treasury stock method</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(55.6)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(67.2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(101.4)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjusted average shares outstanding&#160;&#8212; diluted</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,429.4</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,560.4</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,663.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted net earnings per share from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.14</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted net earnings per share from discontinuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.52</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.59</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total net earnings per share - diluted</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$5.79&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.72</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.73</span></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Shares in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The diluted net earnings per share calculation excluded the following number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Company&#8217;s stock. </span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54.1&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43.0&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.0</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052289533632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common stock, stock option plans and stock compensation agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Common stock, stock option plans and stock compensation agreements</a></td>
<td class="text">Common stock, stock option plans and stock compensation agreements<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">At December&#160;29, 2024, the Company had one active stock-based compensation plan, the 2022 Long-Term Incentive Plan. The shares outstanding are for contracts under the Company's 2012 Long-Term Incentive Plan and 2022 Long-Term Incentive Plan. The 2012 Long-Term Incentive Plan expired on April 26, 2022. All awards (stock options, restricted shares units and performance share units) granted subsequent to that date were under the 2022 Long-Term Incentive Plan. Under the 2022 Long-Term Incentive Plan, the Company may issue up to 150&#160;million shares of common stock, of which up to 110&#160;million shares of common stock may be issued subject to stock options or stock appreciation rights and up to 40&#160;million shares of common stock may be issued subject to full value awards. Awards will generally be counted on a 1-for-1 basis against the share reserve, provided that if more than 40&#160;million full value awards are granted, each full value award in excess of 40&#160;million will be counted on a 5-for-1 basis against the share reserve. Shares available for future grants under the 2022 Long-Term Incentive Plan were 111 million at the end of fiscal&#160;year&#160;2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The compensation cost that has been charged against income for these plans was $1,176 million, $1,087 million and $1,028 million for fiscal years 2024, 2023 and 2022, respectively. The total income tax benefit recognized in the income statement for share-based compensation costs was $251 million, $221 million and $177 million for fiscal years 2024, 2023 and 2022, respectively. The Company also recognized additional income tax benefits of $94&#160;million, $126&#160;million and $267&#160;million for fiscal years 2024, 2023 and 2022, respectively, for which options were exercised or restricted shares were vested. The total unrecognized compensation cost was $1,002 million, $907 million and $866 million for fiscal years 2024, 2023 and 2022, respectively. The weighted average period for this cost to be recognized was 1.81&#160;years, 1.80&#160;years and 1.80&#160;years for fiscal years 2024, 2023, and 2022, respectively. Share-based compensation costs capitalized as part of inventory were insignificant in all periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company settles employee benefit equity issuances with treasury shares. Treasury shares are replenished through market purchases throughout the year for the number of shares used to settle employee benefit equity issuances. </span></div><div style="margin-bottom:6pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Stock options</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Stock options expire 10 years&#160;from the date of grant and vest over service periods that range from 6 months to 4 years. Options granted under the 2012 Long-Term Incentive Plan were granted at the average of the high and low prices of the Company&#8217;s Common Stock on the New York Stock Exchange on the date of grant. Options granted under the 2022 Long-Term incentive Plan were granted at the closing price of the Company&#8217;s Common Stock on the New York Stock Exchange on the date of grant.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. For 2024, 2023, and 2022 grants, expected volatility represents a blended rate of 10-year weekly historical overall volatility rate, and a 5-week average implied volatility rate based on at-the-money traded Johnson&#160;&amp; Johnson options with a life of 2&#160;years. For all grants, historical data is used to determine the expected life of the option. The risk-free rate was based on the U.S.&#160;Treasury yield curve in effect at the time of grant.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The average fair value of options granted was $27.67, $27.85 and $23.23, in fiscal years 2024, 2023 and 2022, respectively. The fair value was estimated based on the weighted average assumptions of:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.15&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.74&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.98&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.10&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.90&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.70&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">A summary of option activity under the Plan as of December&#160;29, 2024, is presented below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value<br/>(Dollars in Millions) </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shares at December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">112,238</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$139.88</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,239</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,917</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">157.92</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10,771)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">107.06</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,755)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">162.45</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Shares at December 29, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">112,629</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$144.69</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$1,129</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The total intrinsic value of options exercised was $560 million, $729 million and $1,228 million in fiscal years 2024, 2023 and 2022, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table summarizes stock options outstanding and exercisable at December&#160;29, 2024:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercisable</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise Price Range</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average Life</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$100.06 - $101.87</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,016</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.8</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$101.29</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,016</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$101.29</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$115.67 - $129.51</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,252</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">122.49</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,252</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">122.49</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$131.94 - $151.41</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,624</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142.87</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,624</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142.87</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$157.92 - $162.75</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,391</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">160.33</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,269</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">162.75</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$164.62 - $165.89</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,346</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">165.29</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,522</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">164.64</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">112,629</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5.3</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$144.69</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">74,683</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$135.72</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">Average contractual life remaining in years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Stock options outstanding at December&#160;31, 2023 and January&#160;1, 2023 were 112,238 and an average life of 5.5 years and 118,672 and an average life of 5.8&#160;years, respectively. Stock options exercisable at December&#160;31, 2023 and January&#160;1, 2023 were 66,998 at an average price of $123.39 and 63,661 at an average price of $113.06, respectively. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restricted share units and performance share units</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company grants restricted share units which vest over service periods that range from 6 months to 3 years. The Company also grants performance share units, which are paid in shares of Johnson &amp; Johnson Common Stock after the end of a three-year performance period. Performance shares were granted with two equally-weighted goals that directly align with or help drive long-term total shareholder return: adjusted operational earnings per share and relative total shareholder return. The&#160;number of shares actually earned at the end of the three-year period will vary, based only on actual performance, from 0% to 200% of the target number of performance share units granted. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">A summary of the restricted share units and performance share units activity under the Plans as of December&#160;29, 2024 is presented below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>Performance Share Units</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shares at December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,938</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,037</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,331</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">906</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,454)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(808)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Canceled/forfeited/adjusted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(774)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(122)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shares at December 29, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,041</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,013</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The average fair value of the restricted share units granted was $147.51, $152.63 and $153.67 in fiscal years 2024, 2023 and 2022, respectively, using the fair market value at the date of grant. The fair value of restricted share units was discounted for dividends, which are not paid on the restricted share units during the vesting period. The fair value of restricted share units issued was $833 million, $605 million and $591 million in 2024, 2023 and 2022, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The weighted average fair value of the performance share units granted was $133.76, $145.17 and $170.46 in fiscal years 2024, 2023 and 2022, calculated using the weighted average fair market value for each of the component goals at the date of&#160;grant.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The fair values for the earnings per share goals of each performance share unit were estimated on the date of grant using the fair market value of the shares at the time of the award discounted for dividends, which are not paid on the performance share units during the vesting period.&#160;The fair value for the relative total shareholder return goal of each performance share unit was estimated on the date of grant using the Monte Carlo valuation model.&#160;The fair value of performance share units issued was $146 million, $140 million and $94 million in fiscal years 2024, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052291491744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of business and geographic areas<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments of business and geographic areas</a></td>
<td class="text">Segments of business and geographic areas<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Following the separation of the Consumer Health business in the fiscal third quarter of 2023, the Company is now organized into two reportable segments: Innovative Medicine and MedTech. The segment results have been recast for all periods to reflect the continuing operations of the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company&#8217;s chief operating decision maker (CODM) is the Chief Executive Officer (Principal Executive Officer). For the Innovative Medicine and MedTech segments, the CODM uses segment income before tax to allocate resources (including employees, financial, and capital resources) for each segment predominantly in the annual forecasting process. The CODM considers planning-to-actual variances on a quarterly basis to assess performance and make decisions about allocating resources to the segments. </span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;24 vs. &#8217;23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;23 vs. &#8217;22</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">INNOVATIVE MEDICINE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$11,355</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,539</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,473</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,513</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,899</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,828</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,052</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,935</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">REMICADE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,009</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,143</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,417</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(19.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Exports</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">98</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">147</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">204</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(33.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(28.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">497</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">549</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">722</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(23.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,605</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,839</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,343</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(21.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,082</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,124</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,166</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,108</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,073</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,190</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,197</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,184</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">STELARA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,720</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,966</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,388</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,641</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,892</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,335</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,361</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,858</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,723</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">TREMFYA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,443</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,147</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,844</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,227</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">999</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">824</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,670</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,147</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,668</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER IMMUNOLOGY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(74.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(33.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(74.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(33.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Infectious Diseases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,354</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,680</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,042</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,918</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,769</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(30.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(22.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,396</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,418</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,449</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(23.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">COVID-19 VACCINE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">120</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">198</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,117</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2,059</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(82.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(45.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;24 vs. &#8217;23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;23 vs. &#8217;22</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">198</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,117</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2,179</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(82.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(48.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">EDURANT / rilpivirine</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">35</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">36</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(10.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,241</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,115</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">972</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">14.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,272</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,150</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,008</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">14.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">PREZISTA / PREZCOBIX</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> /</span></div><div style="padding-left:12pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">REZOLSTA / SYMTUZA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,311</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,446</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,494</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">401</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">408</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">449</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(9.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,712</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,854</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,943</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER INFECTIOUS DISEASES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(41.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(34.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">203</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">278</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">289</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(26.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">214</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">297</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">318</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(27.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(6.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,398</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,065</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3,570</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2,718</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3,076</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3,323</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(11.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7,115</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7,140</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">6,893</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">CONCERTA / methylphenidate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">134</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">230</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">151</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(41.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">52.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">507</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">554</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">493</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(8.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">641</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">783</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">644</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(18.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">21.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3,125</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2,897</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2,714</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,097</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,218</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,426</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(9.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(14.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,222</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,115</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,140</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">SPRAVATO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">929</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">589</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">328</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">57.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">79.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">148</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">100</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">46</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">48.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,077</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">689</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">374</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">56.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">84.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER NEUROSCIENCE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">210</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">349</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">376</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(39.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(7.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">965</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,204</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,358</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(19.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(11.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,175</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,553</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,734</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(24.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(10.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">10,854</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">8,462</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">6,930</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">28.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">22.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">9,926</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">9,199</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">9,052</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">20,781</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">17,661</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">15,983</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">17.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">CARVYKTI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">869</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">469</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">133</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">85.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">94</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;24 vs. &#8217;23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;23 vs. &#8217;22</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">963</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">133</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">92.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">DARZALEX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,588</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,277</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,210</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,082</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,467</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,767</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,670</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,744</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,977</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">ERLEADA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,282</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,065</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">968</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,717</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,322</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">913</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,999</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,387</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,881</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">IMBRUVICA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,051</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,390</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(24.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,214</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,394</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,038</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,264</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,784</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(13.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">TECVAYLI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">418</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">334</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">131</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">549</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">395</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">ZYTIGA /abiraterone acetate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(32.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(32.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">597</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">837</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,696</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(28.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(50.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">631</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">887</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,770</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(28.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(49.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER ONCOLOGY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">643</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">215</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">144</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">288</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">269</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">280</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">931</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">484</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">423</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">92.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,143</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,697</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,346</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,140</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,117</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,071</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,282</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,815</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,417</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:underline">OPSUMIT</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,520</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,292</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,132</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">664</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">681</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">651</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,184</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,973</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,783</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">UPTRAVI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,511</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,326</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,104</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">307</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">255</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">218</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,817</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,582</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,322</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER PULMONARY HYPERTENSION</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">112</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">110</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(28.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">169</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">182</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">202</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">281</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">260</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">313</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(16.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;24 vs. &#8217;23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;23 vs. &#8217;22</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,866</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,906</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,042</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">696</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">765</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">845</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,562</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,671</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,887</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">XARELTO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,373</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,365</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,473</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,373</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,365</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,473</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">494</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">541</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">569</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">696</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">765</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">845</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,189</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,306</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,414</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TOTAL INNOVATIVE MEDICINE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,970</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,169</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,604</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,994</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,590</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,959</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56,964</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54,759</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52,563</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">MEDTECH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cardiovascular </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,513</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,633</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,169</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">67.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,194</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,717</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,131</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,707</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,350</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,300</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">ELECTROPHYSIOLOGY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,738</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,458</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,529</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,230</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,901</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,267</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,688</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,937</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">ABIOMED</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,213</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,066</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">284</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">240</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,496</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,306</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">SHOCKWAVE</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">442</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">122</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">564</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER CARDIOVASCULAR</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">109</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">102</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">260</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">247</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">230</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">380</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">356</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">332</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,689</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,525</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,321</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,470</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,417</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,267</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,158</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,942</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,587</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;24 vs. &#8217;23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;23 vs. &#8217;22</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">HIPS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,057</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">996</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">943</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">581</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">564</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">571</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,638</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,560</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,514</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">KNEES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">922</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">896</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">851</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">623</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">559</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">508</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,545</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,456</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,359</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">TRAUMA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,013</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,949</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,882</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">989</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,049</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,979</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,871</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,696</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,684</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,645</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,230</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,263</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,198</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,926</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,947</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,843</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,003</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,897</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,842</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,006</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,793</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,845</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,037</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,690</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">ADVANCED</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,838</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,833</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,784</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,650</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,837</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,785</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,488</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,671</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,569</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">GENERAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,165</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,198</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,113</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,192</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,168</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,008</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,358</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,366</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,121</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,128</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,086</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,990</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,986</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,859</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,146</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,072</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,849</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">CONTACT LENSES / OTHER</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,684</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,626</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,522</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,049</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,076</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,733</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,702</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,543</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">SURGICAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">444</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">460</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">468</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">969</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">910</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">837</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,413</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,370</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,306</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;24 vs. &#8217;23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;23 vs. &#8217;22</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TOTAL MEDTECH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,332</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,275</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,377</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,525</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,125</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,857</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,400</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,427</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WORLDWIDE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,302</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,444</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,981</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,519</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,715</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,009</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$88,821</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">85,159</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79,990</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">*&#160;&#160;&#160;&#160;percentage greater than 100% or not meaningful</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">Previously referred to as Interventional Solutions</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Acquired on December 22, 2022</span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt">Acquired on May 31, 2024</span></div><div style="margin-bottom:4pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.750%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Income Before Tax by Segment</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024 </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="9" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023 </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="9" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022 </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Innovative<br/>Medicine</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MedTech</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Innovative<br/>Medicine</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MedTech</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Innovative<br/>Medicine</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MedTech</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales to customers</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$56,964</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,857</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54,759</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,400</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52,563</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,427</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of products sold</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,036</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,345</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,715</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,722</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,066</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,397</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, marketing and administrative </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,906</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,812</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,842</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,476</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,714</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,537</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,529</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,703</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,963</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,122</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,642</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,493</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other segment items </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(426)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">257</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">993</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(589)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,494</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">553</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Segment income before tax</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$18,919</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,740</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,659</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,246</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,669</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,915</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,647</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,447</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,094</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: Expense not allocated to segments </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,972</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,853</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">735</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$16,687</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15,062</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">19,359</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.644%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identifiable Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Innovative Medicine</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$57,070</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,324</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MedTech</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">84,322</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74,710</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">141,392</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">133,034</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General corporate </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,712</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34,524</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$180,104</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">167,558</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additions to Property,<br/>Plant &amp; Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Depreciation and<br/>Amortization</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Innovative Medicine</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1,710</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,653</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,374</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$3,760</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,847</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,687</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MedTech</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,443</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,372</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,120</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,237</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,943</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,302</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Segments total</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,153</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,025</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,494</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,997</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,790</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,989</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">162</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">303</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">383</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">641</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">271</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">356</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">212</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">342</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">313</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">340</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$4,424</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,543</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,009</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$7,339</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,486</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6,970</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.989%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.467%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Long-Lived Assets </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">United States</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$50,302</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,444</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,981</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$70,670</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54,832</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,212</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,410</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,664</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,267</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,616</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Western Hemisphere excluding U.S.&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,714</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,549</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,108</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,728</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,491</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Asia-Pacific, Africa</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,593</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,756</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,237</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,454</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,500</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Segments total</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">88,821</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">85,159</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79,990</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101,119</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">89,439</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,217</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,192</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other non long-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">77,768</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">76,927</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$88,821</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">85,159</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">79,990</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$180,104</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">167,558</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">See Note&#160;1 for a description of the segments in which the Company operates. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Export sales are not significant. In fiscal year 2024, the Company utilized three wholesalers distributing products for both segments that represented approximately 20.5%, 15.6% and 12.3% of the total gross revenues. In fiscal year 2023, the Company had three wholesalers distributing products for both segments that represented approximately 18.2%, 15.1% and 14.2% of the total gross revenues. In fiscal year 2022, the Company had three wholesalers distributing products for all three segments that represented approximately 18.9%, 15.0%, and 13.8% of the total gross revenues. </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.64pt"><span style="-sec-ix-hidden:f-2949">Other segment expenses</span> for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:7.29pt">Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal years 2024 and 2023 include charges for talc matters of approximately $5.1&#160;billion and $7&#160;billion, respectively (See Note 19, Legal proceedings, for additional details). The fiscal year 2024 includes a loss of approximately $0.4&#160;billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock. The fiscal year 2023 includes the unfavorable change in the fair value of the retained stake in Kenvue of approximately $0.4&#160;billion.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:7.19pt">Innovative Medicine segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">Acquired in-process research &amp; development expense of $1.25&#160;billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition)</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">Monetization of royalty rights of $0.3&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">Litigation expense of $0.3&#160;billion primarily related to Risperdal Gynecomastia</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">An intangible asset impairment charge of approximately $0.2&#160;billion associated with the M710 (biosimilar) asset acquired as part of the acquisition of Momenta Pharmaceuticals in 2020.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">A restructuring related charge of $0.1&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">One-time COVID-19 Vaccine manufacturing exit related costs of $0.1&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">Favorable changes in the fair value of securities of $0.1&#160;billion</span></div><div style="padding-left:14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">MedTech segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">Acquisition and integration related costs of $1.0&#160;billion primarily related to the acquisition of Shockwave </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt">Acquired in-process research and development expense of $0.5&#160;billion from the V-Wave acquisition</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt">A gain of $0.2&#160;billion related to the Acclarent divestiture</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt">A Medical Device Regulation charge of $0.2&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt">A restructuring related charge of $0.2&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.07pt">Innovative Medicine segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">One-time COVID-19 Vaccine manufacturing exit related costs of $0.7&#160;billion </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">A restructuring related charge of $0.5&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Unfavorable changes in the fair value of securities of $0.4&#160;billion </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Favorable litigation related items of $0.1&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Loss on divestiture of $0.2&#160;billion. </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">An intangible asset impairment charge of approximately $0.2&#160;billion related to market dynamics associated with a non-strategic asset (M710) acquired as part of the acquisition of Momenta Pharmaceuticals in 2020.</span></div><div style="padding-left:14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:112%">MedTech segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Acquired in-process research and development expense of $0.4&#160;billion related to the Laminar acquisition in 2023</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">A restructuring related charge of $0.3&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Acquisition and integration related costs of $0.2&#160;billion primarily related to the acquisition of Abiomed</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">A Medical Device Regulation charge of $0.3&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Income from litigation settlements of $0.1&#160;billion</span></div><div style="padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:7.17pt">Innovative Medicine segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">One-time COVID-19 Vaccine manufacturing exit related costs of $1.5&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">An intangible asset impairment charge of approximately $0.8&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Litigation expense of $0.1&#160;billion </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Unfavorable changes in the fair value of securities of $0.7&#160;billion </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">A restructuring related charge of $0.1&#160;billion </span></div><div style="padding-left:14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:112%">MedTech segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Litigation expense of $0.6&#160;billion primarily for pelvic mesh related costs</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">A restructuring related charge of $0.3&#160;billion </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Acquisition and integration related costs of $0.3&#160;billion primarily related to the acquisition of Abiomed</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt">A Medical Device Regulation charge of $0.3&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">   General corporate includes cash, cash equivalents, marketable securities and other corporate assets. </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.64pt">Long-lived assets include property, plant and equipment, net for fiscal years 2024, and 2023 of $20,518 and $19,898, respectively, and intangible assets and goodwill, net for fiscal years 2024 and 2023 of $81,818 and $70,733, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052378500800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and divestitures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions and divestitures</a></td>
<td class="text">Acquisitions and divestitures<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Subsequent to the fiscal year end 2024, the Company announced it has entered into a definitive agreement to acquire Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, for $132.00 per share in cash for a total equity value of approximately $14.6&#160;billion. The Company expects to fund the transaction through a combination of cash on hand and debt. The closing of the transaction is expected to occur later this year subject to applicable regulatory approvals, approval by Intra-Cellular Therapies&#8217; stockholders and other customary closing conditions for a transaction of this type. The results of operations will be included in the Innovative Medicine segment beginning on the acquisition date.</span></div><div><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Business combinations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Acquisitions of a business are accounted for as business combinations applying the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed are recorded at their respective fair values as of the acquisition date in the Company&#8217;s consolidated financial statements. The excess of the purchase price over the fair value of the acquired net assets, where applicable, is recorded as goodwill. The results of operations of these acquisitions have been included in the Company&#8217;s financial statements from their respective dates of acquisition. </span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">During the fiscal year 2024, certain businesses were acquired for $15.1&#160;billion, net of cash acquired. The fiscal year 2024 acquisitions primarily included; Ambrx Biopharma, Inc., Shockwave Medical Inc., and Proteologix, Inc. The remaining acquisitions were not material.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On June 20, 2024, the Company completed the acquisition of Proteologix, Inc., a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for approximately $0.8&#160;billion net of cash acquired, with potential for an additional milestone payment. The results of operations are included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $1.2&#160;billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&amp;D, for $0.9&#160;billion, goodwill for $0.3&#160;billion, and $0.3&#160;billion of liabilities assumed which included $0.1&#160;billion related to a contingent consideration. The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period. A probability of success factor ranging from 30% to 45% was used in the fair value calculation to reflect inherent regulatory and commercial risk of the IPR&amp;D. The discount rate applied was approximately 16%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. Acquisition related costs before tax for the fiscal 2024 were not material. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On May 31, 2024, the Company completed the acquisition of Shockwave Medical Inc. (SWAV)(Shockwave), a leading, first-to-market provider of innovative intravascular lithotripsy (IVL) technology for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD) in an all-cash merger transaction. The Company acquired all the outstanding shares of Shockwave&#8217;s common stock for $335.00 per share through a merger of Shockwave with a subsidiary of the Company. The results of operations were included in the MedTech segment as of the acquisition date.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Details of the fair value amounts recognized for assets acquired and liabilities assumed as of the purchase date and at the end of fiscal year 2024, which includes measurement period adjustments, are included in the table below. As the acquisition occurred in May 2024, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Billions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">May 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Assets acquired:</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$1.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortizable intangibles</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">IPR&amp;D</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.4</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total assets acquired</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$15.5</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$15.5</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Liabilities assumed:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred taxes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$1.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$1.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Notes payable*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued liabilities**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.4</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total liabilities assumed</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$2.9</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$2.9</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net assets acquired</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$12.6</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$12.6</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net assets acquired as of May 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$12.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: Cash acquired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity awards settled</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Settlement of Note payable*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total enterprise value as of June 30, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$13.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">*&#160;&#160;&#160;&#160;Represents the convertible debt which was subsequently paid in the fiscal second quarter of 2024.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">**&#160;&#160;&#160;&#160;Includes $0.2&#160;billion of equity awards</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. Acquisition related costs before tax for the fiscal 2024 were $0.9&#160;billion of which $0.4&#160;billion was related to the fair value of the inventory step-up and was recorded in Cost of products sold and $0.5&#160;billion primarily related to equity awards and was recorded in Other (income) expense. The amortizable intangible assets were primarily comprised of already in-market CAD and PAD IVL products with the average weighted lives of 14 years. The IPR&amp;D assets were valued for technology programs for unapproved products. The value of the IPR&amp;D was calculated using a probability-adjusted cash flow projection discounted for the risk inherent in such projects with the weighted average probability of success factors of approximately 50%. The discount rate applied was 9.0%.</span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On March 7, 2024, the Company completed the acquisition of Ambrx Biopharma, Inc., (Ambrx), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of approximately $2.0&#160;billion, or $1.8&#160;billion net of cash acquired. The Company acquired all of the outstanding shares of Ambrx&#8217;s common stock for $28.00 per share through a merger of Ambrx with a subsidiary of the Company. The results of operations were included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $2.3&#160;billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&amp;D, for $1.9&#160;billion, goodwill for $0.3&#160;billion and liabilities assumed of $0.5&#160;billion, which includes deferred taxes of $0.4&#160;billion. The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period. A probability of success factor ranging from 40% to </span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">70% was used in the fair value calculation to reflect inherent regulatory and commercial risk of the IPR&amp;D. The discount rate applied was approximately 17%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. Acquisition related costs before tax for the fiscal year 2024 were not material.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">During the fiscal year 2023, the Company did not make any acquisitions that qualified as a business combination. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">During the fiscal year 2022, certain businesses were acquired for $17.7&#160;billion, net of cash acquired. The fiscal year 2022 acquisitions primarily included Abiomed, Inc. (Abiomed). The remaining acquisitions were not material.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On December 22, 2022, the Company completed the acquisition of Abiomed, a leading, first-to-market provider of cardiovascular medical technology with a first-in-kind portfolio for the treatment of coronary artery disease and heart failure which also has an extensive innovation pipeline of life-saving technologies. The transaction broadens the Company&#8217;s position as a growing cardiovascular innovator, advancing the standard of care in heart failure and recovery, one of healthcare&#8217;s largest areas of unmet need. The results of operations were included in the MedTech segment as of the date of the acquisition. The acquisition was completed through a tender offer for all outstanding shares. The consideration paid in the acquisition consisted of an upfront payment of $380.00 per share in cash, amounting to $17.1&#160;billion, net of cash acquired, as well as a non-tradeable contingent value right (&#8220;CVR&#8221;) entitling the holder to receive up to $35.00 per share in cash (which with respect to the CVRs total approximately $1.6&#160;billion in the aggregate) if certain commercial and clinical milestones are achieved. The corresponding enterprise value (without taking into account the CVRs) of approximately $16.5&#160;billion includes cash, cash equivalents and marketable securities acquired.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The milestones of the CVR consist of:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">a.</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.65pt">$17.50 per share, payable if net sales for Abiomed products exceeds $3.7&#160;billion during Johnson &amp; Johnson&#8217;s fiscal second quarter of 2027 through fiscal first quarter of 2028, or if this threshold is not met during this period and is subsequently met during any rolling four quarter period up to the end of Johnson &amp; Johnson&#8217;s fiscal first quarter of 2029, $8.75 per&#160;share;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">b.</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.23pt">$7.50 per share payable upon FDA premarket application approval of the use of Impella&#174; products in ST-elevated myocardial infarction (STEMI) patients without cardiogenic shock by January 1, 2028; and</span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">c.</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.49pt">$10.00 per share payable upon the first publication of a Class I recommendation for the use of Impella&#174; products in high risk PCI or STEMI with or without cardiogenic shock within four years from their respective clinical endpoint publication dates, but in all cases no later than December 31, 2029.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">During the fiscal fourth quarter of 2023, the Company finalized the purchase price allocation. In fiscal 2023, there were purchase price allocation adjustments netting to approximately $0.2&#160;billion with an offsetting increase to goodwill. The fair value of the acquisition was allocated to assets acquired of $20.1&#160;billion (net of $0.3&#160;billion cash acquired), primarily to goodwill for $11.1&#160;billion, amortizable intangible assets for $6.6&#160;billion, IPR&amp;D for $1.1&#160;billion, marketable securities of $0.6&#160;billion and liabilities assumed of $3.0&#160;billion, which includes the fair value of the contingent consideration mentioned above for $0.7&#160;billion and deferred taxes of $2.0&#160;billion. The goodwill is primarily attributable to the commercial acceleration and expansion of the portfolio and is not expected to be deductible for tax purposes. The contingent consideration was recorded in Other Liabilities and adjusted to fair value through the fiscal year end 2024 on the Consolidated Balance Sheet.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The amortizable intangible assets were primarily comprised of already in-market products of the Impella&#174; platform with an average weighted life of 14 years. The IPR&amp;D assets were valued for technology programs for unapproved products. The value of the IPR&amp;D was calculated using probability-adjusted cash flow projections discounted for the risk inherent in such projects. The probability of success factor ranged from 52% to 70%. The discount rate applied was 9.5%. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In the fiscal years 2024, 2023 and 2022, the Company recorded acquisition related costs before tax of approximately $0.3&#160;billion, $0.2&#160;billion and $0.3&#160;billion, which was primarily recorded in Other (income)/expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In accordance with U.S.&#160;GAAP standards related to business combinations, and goodwill and other intangible assets, supplemental pro forma information for fiscal years 2024, 2023 and 2022 is not provided, as the impact of the aforementioned acquisitions did not have a material effect on the Company&#8217;s results of operations.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Asset acquisitions</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Acquired In-process research and development (IPR&amp;D) in an asset acquisition is immediately expensed as research and development expense in the Company's consolidated financial statements. Milestone payments incurred prior to regulatory approval are expensed as research and development expense when the milestone event occurs.</span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The fiscal year 2024 asset acquisitions expensed as research and development included V-Wave Ltd. and the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition). The remaining activity was not material.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On October 8, 2024, the Company completed the acquisition of V-Wave Ltd, a privately-held company focused on developing innovative treatment options for patients with heart failure, for an upfront payment of $0.6&#160;billion, with the potential for additional regulatory and commercial milestone payments up to approximately $1.1&#160;billion. The Company recorded an IPR&amp;D charge of approximately $0.5&#160;billion, net of a gain recorded on the Company's existing investment in V-Wave and the results of operations are included in the MedTech segment as of the acquisition date. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On July 11, 2024, the Company completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics AG, to secure the global rights to NM26, a novel, investigational first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD), in an all-cash transaction for approximately $1.25&#160;billion. The Company recorded an IPR&amp;D charge of approximately $1.25&#160;billion, and the results of operations are included in the Innovative Medicine segment as of the acquisition date.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The fiscal year 2023 asset acquisitions expensed as research and development included Laminar Inc. The remaining activity was not material.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">During the fiscal year 2023, the Company completed the acquisition of Laminar Inc., a privately-held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib), for an upfront payment of $0.4&#160;billion. The Company recorded an IPR&amp;D charge of approximately $0.4&#160;billion and the results of operations are included in the MedTech segment as of the acquisition date. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">There were no significant asset acquisitions in 2022.</span></div><div><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Divestitures</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">During the fiscal year 2024, the Company completed the divestiture of Acclarent resulting in approximately $0.3&#160;billion in proceeds and the divestiture of Ponvory outside of the U.S. resulting in approximately $0.2&#160;billion in proceeds. All other divestitures were not material.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">During the fiscal year 2023, the Company executed divestitures resulting in approximately $0.2&#160;billion in proceeds resulting in gains or losses that were not material. At fiscal year end 2023, the Company held assets, primarily intangibles, on its Consolidated Balance Sheet of approximately $0.3&#160;billion, primarily related to Acclarent and Ponvory, that were subsequently divested in fiscal 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">During fiscal year 2022, the Company did not make any material divestitures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052287246032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal proceedings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal proceedings</a></td>
<td class="text">Legal proceedings<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Johnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of December 29, 2024, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In the Company&#8217;s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company&#8217;s balance sheet, is not expected to have a material adverse effect on the Company&#8217;s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company&#8217;s results of operations and cash flows for that period.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Matters concerning talc</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">A significant number of personal injury claims alleging that talc causes cancer have been asserted against the Company and its affiliates arising out of the use of body powders containing talc, primarily JOHNSON&#8217;S Baby Powder. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In talc cases that have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7&#160;billion in Ingham v. Johnson &amp; Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $2.1&#160;billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied, and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $2.5&#160;billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company&#8217;s confidence in the safety of its talc products, in certain circumstances the Company has settled cases. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In June 2014, the Mississippi Attorney General filed a complaint against the Company alleging violation of the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers&#8217; use of talc contained in JOHNSON&#8217;S Baby Powder and JOHNSON&#8217;S Shower to Shower (a product divested in 2012). The Company has reached an agreement to resolve this matter. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The Company has reached an agreement to resolve this matter. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Forty-two states and the District of Columbia commenced a joint investigation into the Company&#8217;s marketing of its talcum powder products. In January 2024, the Company reached an agreement in principle with the multi-state group of state Attorneys General, subject to ongoing negotiation of non-monetary terms. In June 2024, the settlements were finalized. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In October 2021, Johnson &amp; Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&amp;M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor&#8217;s direct parent, Johnson &amp; Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI&#8217;s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers&#8217; compensation statute or act (the Talc-Related Liabilities).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In October 2021, notwithstanding the Company&#8217;s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under Chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). All litigation against LTL, Old JJCI, New JJCI, the Company, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties) was stayed. The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions in March 2022. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss the LTL Bankruptcy Case and the extension of the stay to the Protected Parties. On January 30, 2023, the Third Circuit reversed the Bankruptcy Court&#8217;s ruling and remanded to the Bankruptcy Court to dismiss the LTL bankruptcy. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to all parties and returning the talc litigation to the tort system. LTL re-filed in the United States Bankruptcy Court for the District of New Jersey seeking relief under Chapter 11 of the Bankruptcy Code (the LTL 2 Bankruptcy Case). As a result of the new filing, all talc claims against LTL were again automatically stayed pursuant to section 362 of the Bankruptcy Code. Additionally, the New Jersey Bankruptcy Court issued a temporary restraining order staying all litigation as to LTL, Old JJCI, New JJCI, the Company, identified retailers, and certain other parties (the New Protected Parties). </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Also in April 2023, the New Jersey Bankruptcy Court issued a decision that granted limited injunctive relief to the Company and the New Protected Parties (the LTL 2 Preliminary Injunction). The LTL 2 Preliminary Injunction remained in force until late August 2023, following the Bankruptcy Court&#8217;s extension of the initial LTL 2 Preliminary Injunction in June 2023. Under the LTL 2 Preliminary Injunction, except for those cases filed in the federal court ovarian cancer multi-district litigation, discovery in all personal injury and wrongful death matters was permitted to proceed. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Furthermore, in April 2023, the Talc Claimants' Committee filed a motion to dismiss the LTL 2 Bankruptcy followed by similar motions from other claimants. Hearings on the motions to dismiss occurred in June 2023. In July 2023, the court dismissed the LTL 2 Bankruptcy case and, the same day, the Company stated its intent to appeal the decision and to continue its efforts to obtain a resolution of the talc claims. In September 2023, the Bankruptcy Court entered an order granting LTL leave to seek a direct appeal to the Third Circuit Court of Appeals. In October 2023, the Third Circuit granted LTL&#8217;s petition for a direct appeal. In July 2024, the Third Circuit issued a non-precedential opinion affirming the Bankruptcy Court's decision to dismiss the LTL Bankruptcy case.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In October 2023, the Company stated that it was pursuing the following four parallel and alternative pathways to achieve a comprehensive and final resolution of the talc claims: (i) the appeal of the LTL 2 dismissal decision; (ii) pursuing a consensual &#8220;prepackaged&#8221; bankruptcy case, as &#8220;strongly encouraged&#8221; by the Bankruptcy Court in its dismissal decision; (iii) aggressively litigating the talc claims in the tort system; and (iv) pursuing affirmative claims against experts for false and defamatory narratives regarding the Company&#8217;s talc powder products. In December 2023, LTL changed its state of formation to Texas and its name to LLT Management LLC ("LLT").</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Following the dismissal of LTL 2, new lawsuits were filed, cases across the country that had been stayed were reactivated, and trials have commenced. The majority of the cases are pending in federal court, organized in a multi-district litigation (MDL) in the United States District Court for the District of New Jersey. In the MDL, case-specific discovery proceeded. The MDL proceedings have been stayed by order of the bankruptcy court in the Red River Bankruptcy case discussed below. In March 2024, the court granted the Company's motion for a renewed Daubert hearing prior to the trial. The briefing on the renewed Daubert issues was completed in August 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In May 2024, the Company commenced a three-month solicitation period of its proposed consensual &#8220;prepackaged&#8221; Chapter 11 bankruptcy plan (the &#8220;Proposed Plan&#8221;) for the comprehensive and final resolution of all current and future claims related to cosmetic talc in the United States, excluding claims related to mesothelioma or State consumer protection claims, in exchange for the payment by the Company of present value of approximately $6.475&#160;billion payable over 25 years (nominal value of approximately $8.0&#160;billion, discounted at a rate of 4.4%). The claims encompassed by the Proposed Plan constitute 99.75% of pending lawsuits against the Company relating to its talc powder products. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In August 2024, LLT engaged in a restructuring that resulted in the creation of three new Texas limited liability companies: (a) Red River Talc, LLC ("Red River"); (b) Pecos River Talc LLC ("Pecos River"); and (3) New Holdco (Texas) LLC. As a result of this restructuring, all claims related to ovarian and other gynecological cancers were separated and allocated to Red River, and mesothelioma, governmental unit and certain other claims were allocated to Pecos River.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In September 2024, while reiterating the Company's continued confidence in the safety of its talc products, Red River filed a voluntary petition with the United States Bankruptcy Court for the Southern District of Texas, seeking relief under Chapter 11 of the Bankruptcy Code (the Red River Bankruptcy Case), in furtherance of the Company's consensual "prepackaged" Proposed Plan. Red River also filed a motion for a temporary restraining order, seeking to extend the automatic stay to additional non-debtor entities. Prior to filing, the initial proposed plan was amended to, among other things, increase the proposed resolution by $1.75&#160;billion.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Shortly after Red River filed its Chapter 11 petition, the U.S. Trustee's office filed a motion to transfer venue in the New Jersey Bankruptcy Court, and thereafter, a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. A coalition of six plaintiff law firms also filed a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. In September 2024, the Texas Bankruptcy Court entered a temporary order enjoining the commencement or prosecution of all claims against Red River and certain non-debtor entities, including the Company, until October 11, 2024. The temporary order was extended in October 2024 and again in December 2024. The commencement and prosecution of all claims against Red River and certain non-debtor entities are currently enjoined until March 15, 2025. Also in September 2024, the New Jersey Bankruptcy Court denied the U.S. Trustee's motion to transfer venue without prejudice. In October 2024, the Texas Bankruptcy Court denied the motion to transfer venue from Texas to New Jersey Bankruptcy Court. A consolidated hearing to address, among other things, the motions to dismiss and plan confirmation is currently scheduled to begin on February&#160;18,&#160;2025. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Mesothelioma and State consumer protection claims are being addressed outside the Proposed Plan. The Company separately has resolved 95% of the mesothelioma lawsuits filed to date and has resolved the State claims.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">To account for these settlements and the contemplated comprehensive resolution through the Proposed Plan, the Company recorded a cumulative incremental charge of approximately $5.0&#160;billion, through the fourth fiscal quarter 2024. As of December 29, 2024, the total present value of the reserve is approximately $11.6&#160;billion (or nominal value of approximately $13.5&#160;billion), net of payments made in fiscal 2024. Approximately ten percent of the reserve is recorded as a current liability. The recorded amount remains the Company's best estimate of probable loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In February 2019, the Company&#8217;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition for relief under Chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#8217;s potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In its bankruptcy, Imerys proposed a Chapter 11 plan (the Imerys Plan) that contemplated all talc-related claims against it being channeled to a trust along with its alleged indemnification rights against the Company. Following confirmation and consummation of the plan, the trust would pay talc claims pursuant to proposed trust distribution procedures (the TDP) and then seek indemnification from the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In February 2021, Cyprus Mines Corporation (Cyprus), which had owned certain Imerys talc mines, filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan (the Cyprus Plan). The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain affiliated parties. Cyprus also asserts it has claims for indemnity against the Company arising out of talc personal injury claims. Under the Cyprus Plan, Cyprus would also contribute its alleged indemnification rights to the trust. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In September 2023, Imerys and Cyprus filed amended plans of reorganization. The amended plans contemplate a similar construct as the prior Imerys and Cyprus Plans, including all talc claims against Imerys and Cyprus (and certain other protected parties) being channeled to a trust along with Imerys&#8217;s and Cyprus&#8217;s alleged indemnification rights against the Company. The Company opposed both plans on the basis that the plans inflated Imerys&#8217;s and Cyprus&#8217;s liability for talc claims and had the potential effect of imposing those inflated liabilities on the Company through the Company&#8217;s alleged indemnification&#160;obligations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In July 2024, the Company, Imerys, and Cyprus and certain of their affiliates (including their parent entities), and the tort claimants' committees and future claimants' representatives appointed in their respective Chapter 11 cases entered into a global settlement agreement (the Imerys Settlement Agreement) to resolve their ongoing disputes, including disputes raised in the Imerys and Cyprus bankruptcies. In August 2024, Imerys and Cyprus filed amended Chapter 11 plans and disclosure statements incorporating the terms of the settlement with the Company. In October 2024, the Imerys Bankruptcy Court entered an order approving the Imerys Settlement Agreement (the Settlement Order). The effectiveness of certain provisions of the settlement, including mutual releases, are subject to certain conditions, including the Imerys and Cyprus Plans being accepted by a sufficient number and amount of voting creditors to be confirmed under the Bankruptcy Code. Certain insurers have appealed the Settlement Order and sought a stay of the order pending appeal, which the Court denied on January 13, 2025.  The briefing of the appeal in the District Court is scheduled to be completed in April 2025. On January 5, 2025, Imerys and Cyprus each filed a certification of voting results, indicating that their respective plan had been accepted by each voting class of creditors. A joint confirmation hearing for the plans is scheduled for April 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S Baby Powder, and that purchasers of the Company&#8217;s shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. The case was stayed in May 2022 pursuant to the LTL Bankruptcy Case and was reopened in May 2023. In December 2023, the Court granted Plaintiff&#8217;s motion for class certification. In January 2024, Defendants filed a petition with the Third Circuit under Federal Rule of Civil Procedure 23(f) for permission to appeal the Court&#8217;s order granting class certification, and in February 2024, the Third Circuit granted Defendants' petition. In February 2024, fact discovery closed, the Court ordered the parties to mediate, and stayed the case pending mediation. In May 2024, the parties participated in an unsuccessful mediation. In June 2024, at the parties' request, the Court lifted the stay for certain limited discovery, but otherwise kept the stay in place pending a decision from the Third Circuit on the 23(f) petition. Briefing on the 23(f) petition was completed in September 2024. In January 2025, the Third Circuit listed the appeal for oral argument in March 2025.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:129%">Matters concerning opioids</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">Beginning in 2014 and continuing to the present, the Company and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children born with Neonatal Abstinence Syndrome (NAS); hospitals; and health insurers/payors. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">To date, the Company and JPI have litigated two of the cases to judgment and have prevailed in both, either at trial or on&#160;appeal. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">In July 2021, the Company announced finalization of an agreement to settle the state and subdivision claims for up to $5.0&#160;billion. Approximately 70% of the all-in settlement was paid by the end of fiscal fourth quarter 2024. A few government entities opted out of the settlement. In September 2024, the Company reached an agreement to resolve the hospital cases.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">The Company and JPI continue to defend the cases brought by the remaining government entity litigants as well as the cases brought by private litigants. In total, there are approximately 35 remaining opioid cases against the Company and JPI in various state courts, 390 remaining cases in the Ohio multi-district litigation (MDL), and 4 additional cases in other federal courts.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate Janssen Inc., and many other industry members, in Canada. That action was certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada in January 2025. Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. The proposed class action in Quebec on behalf of residents diagnosed with opioid use disorder was authorized to proceed against Janssen Inc. and other industry members in April 2024; and leave to appeal was denied in October 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">Starting in November 2019, a series of shareholder derivative complaints were filed against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches. As of September 2024, all the complaints had been dismissed, and all appeals&#160;exhausted.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product liability</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25, Contingencies. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The table below contains the most significant of these cases and provides the approximate number of plaintiffs in the United States with direct claims in pending lawsuits regarding injuries allegedly due to the relevant product or product category as of December&#160;29, 2024:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.419%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Product or product category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of plaintiffs </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Body powders containing talc, primarily JOHNSON&#8217;S Baby Powder</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62,830&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PINNACLE Acetabular Cup System</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">910&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pelvic meshes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,990&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ETHICON PHYSIOMESH Flexible Composite Mesh</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">130&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">RISPERDAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ELMIRON</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,170&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. There may be additional claims that have not yet been filed.</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MedTech</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DePuy ASR XL Acetabular System and ASR Hip Resurfacing System</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Ireland, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">DePuy PINNACLE Acetabular Cup System </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Ethicon Pelvic Mesh </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicon&#8217;s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company&#8217;s accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon&#8217;s pelvic mesh devices have been commenced in </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, and Ireland, and class actions in Israel, Australia, Canada and South Africa. The vast majority of these actions are now resolved. The Company has established accruals with respect to product liability litigation associated with Ethicon&#8217;s pelvic mesh products.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Ethicon Physiomesh</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. Other than a small number of cases still pending in the MDL, all Physiomesh matters in the United States have been resolved or are undergoing formal review for purposes of settlement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Claims have also been filed against Ethicon and the Company alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Ethicon and the Company also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In October 2022, an agreement in principle, subject to various conditions, was reached to settle the majority of the pending cases involving Proceed, Proceed Ventral Patch, Prolene Hernia System and related multi-layered mesh products, as well as a number of unfiled claims. All litigation activities in the two New Jersey MCLs are stayed pending effectuation of the proposed settlement. Future cases that are filed in the New Jersey MCLs will be subject to docket control orders requiring early expert reports and discovery requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has established accruals with respect to product liability litigation associated with Ethicon Physiomesh Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Innovative Medicine</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">RISPERDAL</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and the Company arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. The Company continues to defend RISPERDAL product liability lawsuits, and continues to evaluate potential costs related to those claims. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0&#160;billion of punitive damages related to one plaintiff, which the trial judge reduced to $6.8&#160;million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company's accruals.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ELMIRON</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Jersey (MDL). In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. The Company continues to defend ELMIRON product liability lawsuits and continues to evaluate potential costs related to those claims. All U.S. based ELMIRON matters have been resolved or are undergoing formal review for purposes of settlement. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Intellectual property</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Certain subsidiaries of the Company are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the scope and/or validity of patents that relate to various products and allegations that certain of the Company&#8217;s products infringe the intellectual property rights of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. </span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Innovative Medicine - litigation against filers of abbreviated new drug applications (ANDAs)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company&#8217;s subsidiaries have brought lawsuits against generic companies that have filed ANDAs with the U.S. FDA (or similar lawsuits outside of the United States) seeking to market generic versions of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These lawsuits typically include allegations of non-infringement and/or invalidity of patents listed in FDA&#8217;s publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations&#8221; (commonly known as the Orange Book). In each of these lawsuits, the Company&#8217;s subsidiaries are seeking an order enjoining the defendant from marketing a generic version of a product before the expiration of the relevant patents (Orange Book Listed Patents). In the event the Company&#8217;s subsidiaries are not successful in an action, or any automatic statutory stay expires before the court rulings are obtained, the generic companies involved would have the ability, upon regulatory approval, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company&#8217;s subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Inter Partes Review (IPR) process with the United States Patent and Trademark Office (USPTO), created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits to challenge the applicable patents.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">XARELTO</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning in March 2021, Janssen Pharmaceuticals, Inc.; Bayer Pharma AG; Bayer AG; and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddy&#8217;s Laboratories, Inc.; Dr. Reddy&#8217;s Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mankind Pharma Limited; Apotex Inc.; Apotex Corp.; Auson Pharmaceuticals Inc.; Shanghai Auson Pharmaceuticals Co. Ltd.; Cipla Ltd.; Cipla USA Inc.; InvaGen Pharmaceuticals, Inc.; Prinston Pharmaceuticals, Inc.; Ascent Pharmaceuticals, Inc.; and Hetero Labs Limited. In October 2024, the Company entered into a confidential settlement agreement with Auson Pharmaceuticals Inc. and Shanghai Auson Pharmaceuticals Co., Ltd. and the case was dismissed. In November 2024, the Company entered into confidential settlement agreements with Ascent Pharmaceuticals Inc. that resulted in dismissal of litigation against Ascent Pharmaceuticals, Inc. and Hetero Labs Limited. In January 2025, the Company entered into a confidential settlement agreement with Prinston Pharmaceutical, Inc. (as to U.S. Patent No. 9,539,218). The following U.S. patents are included in one or more cases: 9,539,218 and 10,828,310. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">U.S. Patent No. 10,828,310 was also under consideration by the USPTO in an IPR proceeding. In July 2023, the USPTO issued a final written decision finding the claims of the patent invalid. In September 2023, Bayer Pharma AG filed an appeal to the U.S. Court of Appeals for the Federal Circuit.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">INVEGA SUSTENNA </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; Accord Healthcare, Inc.; Qilu Pharmaceutical Co. Ltd.; and Qilu Pharma Inc. The following U.S. patent is included in one or more cases: 9,439,906. In October 2020, the district court issued a decision in the case against Teva Pharmaceuticals USA, Inc., finding that United States Patent No. 9,439,906 is not invalid. Teva previously stipulated to infringement. Teva appealed the decision, and, in April 2024, the United States Court of Appeals for the Federal Circuit vacated and remanded the case to the district court for further proceedings. In November 2024, the district court issued its decision on remand, finding that United States Patent No. 9,439,906 is not invalid. Teva appealed to the Court of Appeals for the Federal Circuit, and oral argument is scheduled for April 2025. In February 2024, the district court issued a decision in the case against Tolmar Inc. finding that United States Patent No. 9,439,906 is not invalid. Tolmar previously stipulated to infringement. Tolmar has appealed the&#160;decision.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning in February 2018, Janssen Inc. and Janssen Pharmaceutica NV initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the listed patent. The following entities are named defendants: Pharmascience Inc. and Apotex Inc. The following Canadian patent is included in one or more cases: 2,655,335. In June 2024, the Supreme Court dismissed the Apotex case. In September 2024, the Supreme Court granted Pharmascience's motion to appeal the Federal Court's decision that the 2,655,335 Patent is not invalid.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">INVEGA TRINZA </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning in September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp; Development, LLC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA TRINZA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Mylan Laboratories Limited; Mylan Pharmaceuticals Inc.; and Mylan Institutional LLC. The following U.S. patent is included in one or more cases: 10,143,693. In May 2023, the District Court issued a decision finding that Mylan&#8217;s proposed generic product infringes the asserted patent and that the patent is not invalid. Mylan has appealed the decision. Oral argument before the Court of Appeals for the Federal Circuit was held in February 2025.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SYMTUZA </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning in November 2021, Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company, Gilead Sciences, Inc. and Gilead Sciences Ireland UC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SYMTUZA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; MSN Laboratories Private Ltd.; MSN Life Sciences Private Ltd.; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 10,039,718 and 10,786,518. A trial is scheduled to begin in February 2025.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ERLEADA </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning in May 2022, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc. (collectively, Janssen), Sloan Kettering Institute for Cancer Research (SKI) and The Regents of the University of California filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of ERLEADA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Zydus Worldwide DMCC; Zydus Pharmaceuticals (USA), Inc.; Zydus Lifesciences Limited; Hetero Labs Limited Unit V; and Hetero USA, Inc. The following U.S. patents are included in one or more cases: 9,481,663; 9,884,054; 10,052,314 (which reissued as RE49,353); 10,702,508; 10,849,888; 8,445,507; 8,802,689; 9,388,159; 9,987,261; RE49,353; and 11,963,952. In October 2024, Janssen, The Regents of the University of California, SKI, Hetero Labs Limited Unit V, and Hetero USA, Inc. entered into a confidential settlement, and the case was dismissed. In November 2024, Janssen, The Regents of the University of California, Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA), Inc., and Zydus Lifesciences Limited entered into confidential settlements, and the cases were dismissed. </span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SPRAVATO </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning in May 2023, Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SPRAVATO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sandoz </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Inc.; Hikma Pharmaceuticals Inc. USA; Hikma Pharmaceuticals PLC; and Alkem Laboratories Ltd. The following U.S. patents are included in one or more cases: 10,869,844; 11,173,134; 11,311,500; and 11,446,260. </span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">INVOKANA </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning in January 2024, Janssen Inc. and Mitsubishi Tanabe Pharma Corporation initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who filed ANDSs seeking approval to market generic versions of INVOKANA before expiration of the listed patents. The following entities are named defendants: Jamp Pharma Corporation and Apotex Inc. The following Canadian patents are included in one or more cases: 2,534,024 and 2,671,357. Trial in the Jamp action is scheduled for September 2025, and trial in the Apotex action is scheduled for December 2025.</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MedTech </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In March 2016, Abiomed, Inc. (Abiomed) filed a declaratory judgment action against Maquet Cardiovascular LLC (Maquet) in U.S. District Court for the District of Massachusetts seeking a declaration that the Impella does not infringe certain Maquet patents, currently U.S. Patent Nos. 7,022,100 (&#8217;100); 8,888,728; 9,327,068; 9,545,468; 9,561,314; and 9,597,437. Maquet counterclaimed for infringement of each of those patents. After claim construction, Maquet alleged infringement of only the &#8217;100 patent. In September 2021, the court granted Abiomed&#8217;s motion for summary judgment of non-infringement of the &#8217;100 patent, and in September 2023, the district court entered final judgment in favor of Abiomed on all patents-in-suit. Maquet&#160;appealed.</span></div><div><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:142%">Government proceedings</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Like other companies in the pharmaceutical and medical technologies industries, the Company and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:130%">MedTech</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In July 2018, the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp; Johnson do Brasil Ind&#250;stria e Com&#233;rcio de Produtos para Sa&#250;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice (DOJ) and the United States Securities and Exchange Commission. The Company has been informed DOJ has closed its investigation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In July 2023, the DOJ issued Civil Investigative Demands to the Company, Johnson &amp; Johnson Surgical Vision, Inc., and Johnson &amp; Johnson Vision Care, Inc. (collectively, J&amp;J Vision) in connection with a civil investigation under the False Claims Act relating to free or discounted intraocular lenses and equipment used in eye surgery, such as phacoemulsification and laser systems. J&amp;J Vision has begun producing documents and information responsive to the Civil Investigative Demands. J&amp;J Vision is in ongoing discussions with the DOJ regarding its inquiry.</span></div><div><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Innovative Medicine</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and trial commenced in May 2024. On June 13, 2024, a jury found no liability regarding the anti-kickback violations but found liability for a portion of the off-label promotion claims. The Company is pursuing post-trial briefing challenging the verdict on the off-label claims.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">General litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the Company&#8217;s agreement to implement remediation activities at designated hazardous waste sites or to reimburse the government or third parties for the costs they have incurred in performing remediation as such&#160;sites.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Court&#8217;s decision. In June 2023, defendants filed a petition for a writ of certiorari to the United States Supreme Court. In June 2024, the Supreme Court vacated the D.C. Circuit's decision and remanded the case to the D.C. Circuit. Oral argument was held in November 2024. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In February 2024, a putative class action was filed against the Company, the Pension &amp; Benefits Committee of Johnson &amp; Johnson (Committee), and certain named officers and employees, in United States District Court for the District of New Jersey. In May 2024, the plaintiff filed an amended complaint against the Company and the Committee. The complaint alleges that defendants breached fiduciary duties under the Employee Retirement Income Security Act (ERISA) by allegedly mismanaging the Company&#8217;s prescription-drug benefits program. The complaint seeks damages and other relief. In January 2025, the Court granted in part and denied in part defendants&#8217; motion to dismiss.</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MedTech</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#8217;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants&#8217; motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial occurred in January 2024. In September 2024, the court found liability with respect to certain claims and no liability with respect to other claims. The Company has appealed the decision. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc (BWI) in the United States District Court for the Central District of California. The complaint alleges that certain of BWI's business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. Trial is scheduled for April 2025. </span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Innovative Medicine</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to the Company and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssen&#8217;s REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand. Janssen is in ongoing discussions with the FTC staff regarding its inquiry. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In February 2022, the United States Federal Trade Commission (FTC) issued Civil Investigative Demands to Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether advertising practices for REMICADE violate federal law. Janssen has produced documents and information responsive to the Civil Investigative Demands. In January 2025, the FTC Bureau of Consumer Protection informed Janssen that it was closing its investigation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In September 2024, the district court granted plaintiff's motion for class certification. Trial is scheduled for March 2026.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">In December 2023, a putative class action lawsuit was filed against the Company and Janssen Biotech Inc. (collectively Janssen) in the United States District Court for the Eastern District of Virginia. The complaint alleges that Janssen violated federal and state antitrust laws and other state laws by delaying biosimilar competition with STELARA through Janssen's enforcement of patent rights covering STELARA. The complaint seeks damages and other relief. In February 2024, plaintiffs filed an amended complaint, which Janssen moved to dismiss in March 2024. In August 2024, the court granted in part and denied in part Janssen's motion to dismiss. </span></div>In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc., Janssen Research &amp; Development, LLC, and Johnson &amp; Johnson (collectively, Janssen) were served with a qui tam complaint on behalf of the United States, certain states, and the District of Columbia. The complaint alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct sales and reimbursement programs. At this time, the federal and state governments have declined to intervene. In December 2021, the United States District Court for the District of New Jersey denied Janssen's motion to dismiss.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052287784864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text">Restructuring<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">In fiscal 2023, the Company commenced restructuring actions within its Innovative Medicine and MedTech segments. The amounts and details of the current year programs are included below.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">In fiscal 2023, the Company completed a prioritization of its research and development (R&amp;D) investment within its Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within certain therapeutic areas. The R&amp;D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. Pre-tax Restructuring expenses of $0.1&#160;billion in the fiscal year 2024, included the termination of partnered and non-partnered development program costs, asset impairments and asset divestments. Pre-tax Restructuring expenses of $0.5&#160;billion in the fiscal year 2023, included the termination of partnered and non-partnered development program costs and asset impairments. Total project costs of approximately $0.6&#160;billion have been recorded since the restructuring was announced. The program was completed in the fiscal fourth quarter of 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense of $0.2&#160;billion in the fiscal year 2024 primarily included costs related to market and product exits. The pre-tax restructuring expense of $0.3&#160;billion in the fiscal year 2023 primarily included inventory and instrument charges related to market and product exits. Total project costs of approximately $0.5&#160;billion have been recorded since the restructuring was announced. The estimated costs of the total program are between $0.7&#160;billion - $0.8&#160;billion and is expected to be completed by the end of fiscal year 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The following table summarizes the restructuring expenses for the fiscal years 2024 and 2023:</span></div><div style="margin-bottom:4pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.173%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Pre-tax Dollars in Millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Innovative Medicine Segment</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$102</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">479</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MedTech Segment</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">167</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">319</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total Programs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$269</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$798</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">The fiscal year of 2024 included $102&#160;million in Restructuring on the Consolidated Statement of Earnings. The fiscal year of 2023 included $449&#160;million in Restructuring and $30&#160;million in Cost of products sold on the Consolidated Statement of Earnings.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">The fiscal year of 2024 included $132&#160;million in Restructuring and $35&#160;million in Cost of products sold on the Consolidated Statement of Earnings. The fiscal year of 2023 Included $40&#160;million in Restructuring and $279&#160;million in Cost of products sold on the Consolidated Statement of Earnings.</span></div>Restructuring reserves as of December 29, 2024 and December 31, 2023 were insignificant.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052291510992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Kenvue separation and discontinued operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Kenvue separation and discontinued operations</a></td>
<td class="text">Kenvue separation and discontinued operations<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The results of the Consumer Health business (previously reported as a separate business segment) have been reflected as discontinued operations in the Company&#8217;s consolidated statements of earnings as Net earnings from discontinued operations, net of taxes through August 23, 2023, the date of the exchange offer. Prior periods have been recast to reflect this&#160;presentation. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On May 15, 2024, the Company issued $3.6&#160;billion aggregate principal amount of commercial paper and received $3.6&#160;billion of net cash proceeds to be used for general corporate purposes. On May 17, 2024, the Company completed a Debt-for-Equity Exchange of its remaining 182,329,550 shares of Kenvue Common Stock for the outstanding Commercial Paper. Upon completion of the Debt-for-Equity Exchange, the Commercial Paper was satisfied and discharged and the Company no longer owns any shares of Kenvue Common Stock. This exchange resulted in a loss of approximately $0.4&#160;billion recorded in Other (income) expense. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of 198,734,444 shares of its common stock, par value $0.01 per share (the &#8220;Kenvue Common Stock&#8221;), at an initial public offering of $22.00 per share for net proceeds of $4.2&#160;billion. The excess of the net proceeds from the IPO over the net book value of the Johnson &amp; Johnson divested interest was $2.5&#160;billion and was recorded to additional paid-in capital. As of the closing of the IPO, Johnson &amp; Johnson owned approximately 89.6% of the total outstanding shares of Kenvue Common Stock and at July 2, 2023, the non-controlling interest of $1.3&#160;billion associated with Kenvue was reflected in equity attributable to non-controlling interests in the consolidated balance sheet in the fiscal second quarter of 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On August 23, 2023, Johnson &amp; Johnson completed the disposition of an additional 80.1% ownership of Kenvue Common Stock through an exchange offer, which resulted in Johnson &amp; Johnson acquiring 190,955,436 shares of the Company&#8217;s common stock in exchange for 1,533,830,450 shares of Kenvue Common Stock. The $31.4&#160;billion of Johnson &amp; Johnson common stock received in the exchange offer is recorded in Treasury stock. Following the exchange offer, the Company owned 9.5% of the total outstanding shares of Kenvue Common Stock that was recorded in other assets within continuing operations at the fair market value of $4.3&#160;billion as of August 23, 2023. Subsequent changes are reflected in other income/expense and amounted to $0.4&#160;billion expense through December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Johnson &amp; Johnson divested net assets of $11.6&#160;billion as of August 23, 2023, and the accumulated other comprehensive loss attributable to the Consumer Health business at that date was $4.3&#160;billion. Additionally, at the date of the exchange offer, Johnson &amp; Johnson decreased the non-controlling interest by $1.2&#160;billion to record the deconsolidation of Kenvue. This resulted in a non-cash gain on the exchange offer of $21.0&#160;billion that was recorded in Net earnings from discontinued operations, net of taxes in the consolidated statements of earnings for the fiscal third quarter of 2023. This one-time gain includes a gain of $2.8&#160;billion on the Kenvue Common Stock retained by Johnson &amp; Johnson. The gain on the exchange offer qualifies as a tax-free transaction for U.S. federal income tax purposes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Also in connection with the separation, Johnson &amp; Johnson and Kenvue entered into a separation agreement and also entered into various other agreements that provide for certain transactions to effect the transfer of the assets and liabilities of the Consumer Health business to Kenvue and to govern various interim and ongoing relationships between Kenvue and Johnson &amp; Johnson following the completion of the Kenvue IPO, including transition services agreements (TSAs), transition manufacturing agreements (TMAs), trademark agreements, intellectual property agreements, an employee matters agreement, and a tax matters agreement. Under the TSAs, Johnson &amp; Johnson will provide Kenvue various services and, similarly, Kenvue will provide Johnson &amp; Johnson various services. The provision of services under the TSAs generally will terminate within 24 months following the Kenvue IPO. Additionally, Johnson &amp; Johnson and Kenvue entered into TMAs pursuant to which Johnson &amp; Johnson will manufacture and supply to Kenvue certain products and, similarly, Kenvue will manufacture and supply to Johnson &amp; Johnson certain products. The terms of the TMAs range in initial duration from 3 months to 5 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Amounts related to the TSAs and TMAs included in the consolidated statements of earnings were immaterial for both fiscal years 2024 and 2023. Additionally, the amounts due to and from Kenvue for the above agreements was not material as of December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The results of the Consumer Health business (previously reported as a separate business segment), as well as the associated gain, have been reflected as discontinued operations in the Company&#8217;s consolidated statements of earnings as Net earnings from discontinued operations, net of taxes. As a result of the separation of Kenvue, Johnson &amp; Johnson incurred separation costs of $145&#160;million in the fiscal year 2024, which was included in Net Earnings and incurred separation costs of $986&#160;million and $1,089&#160;million in the fiscal years 2023 and 2022, respectively, which were included in Net earnings from discontinued operations, net of taxes. These costs were primarily related to external advisory, legal, accounting, contractor and other </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">incremental costs directly related to separation activities. In the fiscal 2022, as part of the planned separation of the Company&#8217;s Consumer Health business, the Company recognized approximately $0.5&#160;billion in net incremental tax costs. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Details of Net Earnings from Discontinued Operations, net of taxes are as follows:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.280%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.765%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;2023</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales to customers</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$10,036</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">14,953</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of products sold</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,369</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">6,494</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5,667</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">8,459</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, marketing and administrative expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3,085</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,519</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">258</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">468</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest Income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(117)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest expense, net of portion capitalized</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">199</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (income) expense, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,092</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,060</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Gain) on separation of Kenvue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(20,984)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restructuring</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">46</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Earnings from Discontinued Operations Before Provision for Taxes on Income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">22,134</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2,366</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for taxes on income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">307</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">795</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net earnings from Discontinued Operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$21,827</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">1,571</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">The Company ceased consolidating the results of the Consumer Health business on August 23, 2023, the date of the exchange offer, but continued to reflect any separation costs incurred as part of discontinued operations through the end of the fiscal fourth quarter.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table presents depreciation, amortization and capital expenditures of the discontinued operations related to&#160;Kenvue:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.173%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;2023</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and Amortization</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$383</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">641</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditures</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$162</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">303</span></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052289534160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 14,066<span></span>
</td>
<td class="nump">$ 35,153<span></span>
</td>
<td class="nump">$ 17,941<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052290900128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052288443168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052288748736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has documented cybersecurity policies and standards, assesses risks from cybersecurity threats, and monitors information systems for potential cybersecurity issues. To protect the Company&#8217;s information systems from cybersecurity threats, the Company uses various security tools supporting protection, detection, and response capabilities. The Company maintains a cybersecurity incident response plan to help ensure a timely, consistent response to actual or attempted cybersecurity incidents impacting the Company. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company also identifies and assesses third-party risks within the enterprise, and through the Company's use of third-party service providers, across a range of areas including data security and supply chain through a structured third-party risk management program. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company maintains a formal information security training program for all employees that includes training on matters such as phishing and email security best practices. Employees are also required to complete mandatory training on data privacy.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">To evaluate and enhance its cybersecurity program, the Company periodically utilizes third-party experts to undertake maturity assessments of the Company&#8217;s information security program.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">To date, the Company is not aware of any cybersecurity incident that has had or is reasonably likely to have a material impact on the Company&#8217;s business or operations; however, because of the frequently changing attack techniques, along with the increased volume and sophistication of the attacks, there is the potential for the Company to be adversely impacted. This impact could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action. Refer to the risk factor captioned An information security incident, including a cybersecurity breach, could have a negative impact to the Company&#8217;s business or reputation in Part I, Item 1A. Risk factors for additional description of cybersecurity risks and potential related impacts on the Company.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">The Company has documented cybersecurity policies and standards, assesses risks from cybersecurity threats, and monitors information systems for potential cybersecurity issues. To protect the Company&#8217;s information systems from cybersecurity threats, the Company uses various security tools supporting protection, detection, and response capabilities. The Company maintains a cybersecurity incident response plan to help ensure a timely, consistent response to actual or attempted cybersecurity incidents impacting the Company.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Governance - board oversight</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company&#8217;s Board of Directors oversees the overall risk management process, including cybersecurity risks, directly and through its committees. The Regulatory Compliance &amp; Sustainability Committee (RCSC) of the board is primarily responsible for oversight of risk from cybersecurity threats and oversees compliance with applicable laws, regulations and Company policies related to, among others, privacy and cybersecurity. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">RCSC meetings include discussions of specific risk areas throughout the year including, among others, those relating to cybersecurity. The CISO provides quarterly updates each year to RCSC on cybersecurity matters. These reports include an overview of the cybersecurity threat landscape, key cybersecurity initiatives to improve the Company&#8217;s risk posture, changes in the legal and regulatory landscape relative to cybersecurity, and overviews of certain cybersecurity incidents that have occurred within the Company and within the industry.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The Company&#8217;s Board of Directors oversees the overall risk management process, including cybersecurity risks, directly and through its committees. The Regulatory Compliance &amp; Sustainability Committee (RCSC) of the board is primarily responsible for oversight of risk from cybersecurity threats and oversees compliance with applicable laws, regulations and Company policies related to, among others, privacy and cybersecurity.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">RCSC meetings include discussions of specific risk areas throughout the year including, among others, those relating to cybersecurity. The CISO provides quarterly updates each year to RCSC on cybersecurity matters. These reports include an overview of the cybersecurity threat landscape, key cybersecurity initiatives to improve the Company&#8217;s risk posture, changes in the legal and regulatory landscape relative to cybersecurity, and overviews of certain cybersecurity incidents that have occurred within the Company and within the industry.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Governance - management&#8217;s responsibility</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company takes a risk-based approach to cybersecurity and has implemented cybersecurity controls designed to address cybersecurity threats and risks. The Chief Information Officer (CIO), who is a member of the Company&#8217;s Executive Committee, and the Chief Information Security Officer (CISO) are responsible for assessing and managing cybersecurity risks, including security incident detection, response, and recovery.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company&#8217;s CISO, in coordination with the CIO, is responsible for leading the Company&#8217;s cybersecurity program and management of cybersecurity risk. The current CISO has over twenty-five years of experience in information security, and his background includes technical experience, strategy and architecture focused roles, cyber and threat experience, and various leadership roles.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company takes a risk-based approach to cybersecurity and has implemented cybersecurity controls designed to address cybersecurity threats and risks. The Chief Information Officer (CIO), who is a member of the Company&#8217;s Executive Committee, and the Chief Information Security Officer (CISO) are responsible for assessing and managing cybersecurity risks, including security incident detection, response, and recovery.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">The current CISO has over twenty-five years of experience in information security, and his background includes technical experience, strategy and architecture focused roles, cyber and threat experience, and various leadership roles.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">The Company&#8217;s Board of Directors oversees the overall risk management process, including cybersecurity risks, directly and through its committees. The Regulatory Compliance &amp; Sustainability Committee (RCSC) of the board is primarily responsible for oversight of risk from cybersecurity threats and oversees compliance with applicable laws, regulations and Company policies related to, among others, privacy and cybersecurity.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052283476832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The consolidated financial statements include the accounts of Johnson&#160;&amp; Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Business segments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Business segments</span></div>The Company is organized into two business segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on the following therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolic. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the Orthopaedic, Surgery, Cardiovascular (previously referred to as Interventional Solutions) and Vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting standards and Recently issued accounting standards</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">New accounting standards</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently adopted accounting standards</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">ASU 2023-07: Segment Reporting (Topic 280) &#8211; Improvements to Reportable Segment Disclosures</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company adopted the standard in the fiscal year 2024, which requires expanded annual and interim disclosures for significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. The standard was applied retrospectively to all periods presented in the financial statements. As this accounting standard only impacts disclosures, it did not have a material impact on the Company&#8217;s Consolidated Financial Statements. See Note 17 for the required disclosures.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently issued accounting standards</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not adopted as of December 29, 2024</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">ASU 2024-03: Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures (Subtopic&#160;220-40): Disaggregation of Income Statement Expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">This update requires disclosure of disaggregated information about certain income statement expense line items on an annual and interim basis. This update will be effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. As this accounting standard only impacts disclosures, it will not have a material impact on the Company&#8217;s Consolidated Financial Statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">ASU 2023-09: Income Taxes (Topic 740) - Improvements to Income Tax Disclosures</span></div>This update standardizes categories for the effective tax rate reconciliation, requires disaggregation of income taxes and additional income tax-related disclosures. This update is required to be effective for the Company for fiscal periods beginning after December 15, 2024. As this accounting standard only impacts disclosures, it will not have a material impact on the Company&#8217;s Consolidated Financial Statements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash equivalents</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating. The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value. The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Investments</span></div>Investments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets; otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, plant and equipment and depreciation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Property, plant and equipment and depreciation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Building and building equipment</span></div></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">30&#160;years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Land and leasehold improvements</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">10&#160;- 20&#160;years</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Machinery and equipment</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2&#160;- 13&#160;years</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8&#160;years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset&#8217;s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns, discounts to customers and governmental clawback provisions are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued rebates, returns, and promotions on the consolidated balance sheet.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates and discounts are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A&#160;significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily the Managed Care, Medicare and Medicaid programs, which amounted to $12.3 billion and $11.5 billion as of December&#160;29, 2024 and December&#160;31, 2023, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Sales returns are estimated and recorded based on historical sales and returns information. Products that have lost patent exclusivity, or that otherwise exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. In accordance with the Company&#8217;s accounting policies, the Company generally issues credit to customers for returned goods. The Company&#8217;s sales returns reserves are accounted for in accordance with the U.S.&#160;GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Innovative Medicine segment are almost exclusively not resalable. Sales returns for certain franchises in the MedTech segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during each of the fiscal years&#160;2024,&#160;2023 and 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Promotional programs, such as product listing allowances are recorded in the same period as related sales and include <br/>volume-based sales incentive programs. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements of certain products, which are included in sales to customers. Profit-share payments were less than 2.0% of the total revenues in the fiscal year 2024 and 2023, respectively, and less than 3.0% of total revenues in the fiscal year 2022 and are included in sales to customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">See Note 17 to the Consolidated Financial Statements for further disaggregation of revenue.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock', window );">Shipping and handling</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Shipping and handling</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Shipping and handling costs incurred were $0.9 billion, $0.9 billion and $0.8 billion in fiscal years 2024, 2023 and 2022, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 1.0% of sales to customers for all periods presented.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible assets and goodwill</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Intangible assets and goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The authoritative literature on U.S.&#160;GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2024 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. In-process research and development purchased as part of a business combination is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset. If warranted the purchased in-process research and development could be written off or partially impaired depending on the underlying&#160;program.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Intangible assets that have finite useful lives continue to be amortized over their useful lives and are reviewed for impairment when warranted by economic conditions. See Note&#160;5 for further details on Intangible Assets and Goodwill.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Financial instruments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">As required by U.S.&#160;GAAP, all derivative instruments are recorded on the balance sheet at fair value. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level&#160;1 having the highest priority and Level&#160;3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge&#160;transaction.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1)&#160;minimize foreign currency exposure&#8217;s impact on the Company&#8217;s financial performance; (2)&#160;protect the Company&#8217;s cash flow from adverse movements in foreign exchange rates; (3)&#160;ensure the appropriateness of financial instruments; and (4)&#160;manage the enterprise risk associated with financial institutions. See Note&#160;6 for additional information on Financial Instruments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in <span style="-sec-ix-hidden:f-539"><span style="-sec-ix-hidden:f-540">Other assets</span></span>, <span style="-sec-ix-hidden:f-541"><span style="-sec-ix-hidden:f-542">Accrued liabilities</span></span>, and <span style="-sec-ix-hidden:f-543"><span style="-sec-ix-hidden:f-544">Other liabilities</span></span> on the consolidated balance sheet. The ROU Assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Commitments under finance leases are not significant, and are included in Property, plant and equipment, Loans and notes payable, and Long-term debt on the consolidated balance sheet.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The&#160;ROU asset pertaining to leases from continuing operations was $1.1&#160;billion and $1.0&#160;billion in fiscal years 2024 and 2023, respectively. The lease liability from continuing operations was $1.2&#160;billion and $1.1&#160;billion in fiscal years 2024 and 2023, respectively. The operating lease costs from continuing operations were $0.2&#160;billion in fiscal years 2024, 2023 and 2022. Cash&#160;paid for amounts included in the measurement of lease liabilities from continuing operations were $0.2&#160;billion in fiscal years 2024, 2023 and 2022.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityPolicyTextBlock', window );">Product liability</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product liability</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Research and development</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Research and development expenses are expensed as incurred in accordance with ASC 730, Research&#160;and Development. Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company&#8217;s operations. In general, the income statement presentation for these collaborations is as follows:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.453%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.157%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Nature/Type of Collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Statement of Earnings Presentation</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Third-party sale of product &amp; profit share payments received</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Sales to customers</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Royalties/milestones paid to collaborative partner (post-regulatory approval)*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Cost of products sold</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Royalties received from collaborative partner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Other income (expense), net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Upfront payments&#160;&amp; milestones paid to collaborative partner (pre-regulatory approval)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Research and development expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Research and development payments to collaborative&#160;partner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Research and development expense</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Research and development payments received from collaborative partner or government entity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Reduction of Research and development expense</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">*&#160;&#160;&#160;&#160;Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense other than the acquired in-process research &amp; development expense of $1.25&#160;billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition) in fiscal year 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO, co-developed with Bayer HealthCare AG, IMBRUVICA, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company and CARVYKTI, licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX, licensed from Genmab A/S.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Advertising</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $0.6 billion, $0.5 billion and $0.7 billion in fiscal years 2024, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Income taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from 35% to 21%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of 15.5% and all other earnings were taxed at a rate of 8.0%. This tax is payable over 8 years and will not accrue interest. These payments began in fiscal year 2018 and will continue through 2025. The final payment of $2.5&#160;billion will be made in fiscal year 2025. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI). GILTI is described as the excess of a U.S. shareholder&#8217;s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., &#8220;period cost&#8221;) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to affect the amount of GILTI inclusion in future years upon reversal (i.e., &#8220;deferred method&#8221;). The Company has elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The&#160;Company estimates that the tax effect of this repatriation would be approximately $0.5 billion under currently enacted tax laws and regulations and at current currency exchange rates. This amount does not include the possible benefit of U.S. foreign tax credits, which may substantially offset this cost.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net earnings per share</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net earnings per share</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.&#160;requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company follows the provisions of U.S.&#160;GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_SupplierFinanceProgramPolicyTextBlock', window );">Supplier finance program obligations</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Supplier finance program obligations</span></div>The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide participating suppliers the ability to finance payment obligations from the Company with the third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The&#160;Company&#8217;s obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment&#160;terms of 90 days), are not affected by a participating supplier&#8217;s decision to participate in the program.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_FiscalPeriodPolicyTextBlock', window );">Annual closing date</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Annual closing date</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52&#160;weeks, but every five or six years the fiscal year consists of 53&#160;weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FiscalPeriodPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FiscalPeriodPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProductLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProductLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SupplierFinanceProgramPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplier Finance Program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SupplierFinanceProgramPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShippingAndHandlingCostPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052291560800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock', window );">Estimated Useful Lives of Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Building and building equipment</span></div></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">30&#160;years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Land and leasehold improvements</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">10&#160;- 20&#160;years</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Machinery and equipment</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2&#160;- 13&#160;years</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramTableTextBlock', window );">Supplier Finance Program</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The rollforward of the Company's valid obligations under the program were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Confirmed obligations - beginning of the year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$704</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Invoices confirmed during the year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3,048</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Confirmed invoices paid during the year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2,964</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Confirmed obligations - end of the year</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$788</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated useful lives of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EstimatedUsefulLivesOfAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplier finance program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477128/405-50-55-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052378494368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, cash equivalents and current marketable securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Cash and Cash Equivalent Composition</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">At the end of the fiscal year 2024 and 2023, cash, cash equivalents and current marketable securities comprised:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.875%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr style="height:35pt"><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying<br/>&#160;Amount</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrecognized<br/>Gain</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>&#160;Fair Value</span></td><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash &amp; Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current<br/> Marketable<br/> Securities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,918</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,918</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,918</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-U.S. Sovereign Securities</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,100</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,100</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,100</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,123</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,123</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,123</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Time deposits</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,045</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,045</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,045</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$17,306</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">17,306</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">17,186</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">120</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Gov't Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$6,815</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,816</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,796</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other Sovereign Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">176</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">176</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">93</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate and other debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">224</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">224</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">184</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal available for sale</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$7,215</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,216</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6,919</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">297</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:64.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total cash, cash equivalents and current marketable securities</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$24,105</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">417</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.875%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr style="height:35pt"><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrecognized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated Fair Value</span></td><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$3,340</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,340</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,340</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-U.S. Sovereign Securities</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">522</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">522</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">174</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">348</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,377</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,377</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,377</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">338</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">338</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">189</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">149</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,814</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,814</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,814</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Time deposits</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">662</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">662</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">662</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14,053</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14,053</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13,556</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">497</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Gov't Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$8,562</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,562</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,259</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">303</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Gov't Agencies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other Sovereign Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate and other debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">237</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">237</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">194</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal available for sale</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$8,875</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,874</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,303</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">571</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:64.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total cash, cash equivalents and current marketable securities</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$21,859</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,068</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. </span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive&#160;income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Contractual Maturities of Available for Sale Securities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The contractual maturities of the available for sale debt securities at December&#160;29, 2024 are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due within one year</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$7,204</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7,205</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due after one year through five years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">11</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due after five years through ten years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total debt securities</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$7,215</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">7,216</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052291561296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">At the end of fiscal years 2024 and 2023, inventories comprised:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Raw materials and supplies</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,337</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,355</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goods in process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,815</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,952</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,292</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,874</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total inventories</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$12,444</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">11,181</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052287246032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment at Cost and Accumulated Depreciation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">At the end of fiscal years 2024 and 2023, property, plant and equipment at cost and accumulated depreciation were:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Land and land improvements</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$718</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">795</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Buildings and building equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,317</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,375</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,444</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,979</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Construction in progress</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,289</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,627</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total property, plant and equipment, gross</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$48,768</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">47,776</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,250</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,878</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total property, plant and equipment, net</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$20,518</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">19,898</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052289033088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets and goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock', window );">Schedule of Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">At the end of fiscal years 2024 and 2023, the gross and net amounts of intangible assets were:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Intangible assets with definite lives:</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents and trademarks&#160;&#8212; gross</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$44,695</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">40,417</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(26,124)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(24,808)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents and trademarks&#160;&#8212; net</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$18,571</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">15,609</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Customer relationships and other intangibles&#160;&#8212; gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$20,310</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">20,322</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(13,544)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(12,685)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Customer relationships and other intangibles&#160;&#8212; net</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$6,766</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">7,637</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trademarks</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,714</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchased in-process research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">12,281</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">9,215</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$12,281</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">10,929</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets&#160;&#8212; net</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$37,618</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">34,175</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:125%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:9.29pt">In September 2024, the Company announced changes to its MedTech brand identity and the $1.7&#160;billion of trademarks associated with the DePuy Synthes business were reclassified from indefinite lived to definite lived and will be amortized over a <span style="-sec-ix-hidden:f-767">25&#160;year</span> period.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:125%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.09pt">The majority is comprised of customer relationships</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Goodwill</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Goodwill as of December&#160;29, 2024 and December&#160;31, 2023, as allocated by segment of business, was as follows:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.575%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Innovative <br/>Medicine</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MedTech</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill at January 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$10,184</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,863</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,047</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill, related to acquisitions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill, related to divestitures</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Currency translation/other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">223</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">288</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">511</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill at December 31, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,407</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,151</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,558</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill, related to acquisitions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">640</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,569</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,209</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill, related to divestitures</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(56)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(56)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Currency translation/other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(355)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(156)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(511)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill at December 29, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$10,692</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,508</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,200</span></td></tr></table></div>*&#160;&#160;&#160;&#160;Includes purchase price allocation adjustments for Abiomed<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Intangible Asset Amortization Expense</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The estimated amortization expense related to intangible assets for approved products, before tax, for the five succeeding years is approximately:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:18.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:13pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2027</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2028</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2029</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$4,000</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,400</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,800</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,200</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,200</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052288476368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of Derivative Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended December&#160;29, 2024 and December&#160;31, 2023, net of tax:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.388%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost of<br/>Products<br/>&#160;Sold</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">R&amp;D<br/>&#160;Expense</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Interest<br/>(Income)<br/>&#160;Expense</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other<br/>(Income)<br/>Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost of<br/>Products<br/>Sold</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">R&amp;D<br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Interest<br/>(Income)<br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other<br/>(Income)<br/>Expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Interest rate swaps contracts:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Hedged items</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">168</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(64)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(168)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">148</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">130</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) recognized in AOCI</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">148</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">130</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Forward foreign exchange contracts:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">426</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">186</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(37)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) recognized in AOCI</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(156)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">80</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">447</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">247</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">275</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) recognized in AOCI</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(597)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(156)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">As of December&#160;29, 2024 and December&#160;31, 2023, the following amounts were recorded on the consolidated balance sheet related to cumulative basis adjustment for fair value hedges:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.230%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Line item in the Consolidated Balance Sheet<br/>in which the hedged item is included</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Amount of the Hedged Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cumulative Amount of Fair Value Hedging<br/>Adjustment Included in the Carrying<br/>Amount of the Hedged Liability</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term Debt</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$7,935</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$8,862</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(1,132)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(1,216)</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Effect of Derivatives not Designated as Hedging Instruments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended <br/>December&#160;29, 2024 and December&#160;31, 2023:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.138%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.179%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Location of Gain /(Loss)<br/>Recognized in Income on<br/>Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Foreign Exchange Contracts</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-905"><span style="-sec-ix-hidden:f-906">Other (income) expense</span></span></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$8</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(60)</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Effect of Net Investment Hedges</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table is the effect of net investment hedges for the fiscal years ended December&#160;29, 2024 and <br/>December&#160;31, 2023:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain/(Loss)<br/>Recognized In<br/>Accumulated OCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Location of Gain or<br/>(Loss) Reclassified<br/>from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain/(Loss)<br/>Reclassified from<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Debt</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$282</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(131)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Interest (income) expense</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cross Currency interest rate&#160;swaps</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$955</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">642</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Interest (income) expense</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Activity Related to Equity Investments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table is a summary of the activity related to equity investments for the fiscal years ended December&#160;29, 2024 and December&#160;31, 2023:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Changes in Fair</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value Reflected in</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Income</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales/</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Purchases/</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-Current<br/>Other Assets</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity Investments with readily determinable value *</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$4,473</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(17)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,005)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">451</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">451</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity Investments without readily determinable value</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$696</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(197)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">274</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">773</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">773</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Changes in Fair</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value Reflected in</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Income</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales/</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Purchases/</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-Current<br/>Other Assets</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Equity Investments with readily determinable value *</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$576</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(368)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,265</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,473</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,473</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Equity Investments without readily determinable value</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$613</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">696</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">696</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">Recorded in Other Income/Expense</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Other includes impact of currency</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">*&#160;&#160;&#160;&#160;The December 31, 2023 balance includes the 9.5% remaining stake in Kenvue. A debt-for-equity exchange was completed in the fiscal second quarter of 2024.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Financial Assets and Liabilities at Fair Value</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of the fiscal year ended December&#160;29, 2024 and December&#160;31, 2023 were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forward foreign exchange contracts </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">660</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">660</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">539</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest rate contracts</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,484</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,484</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">988</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$&#8212;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,144</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,144</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,527</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forward foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">794</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">794</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">624</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest rate contracts</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,753</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,753</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,338</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$&#8212;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,547</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,547</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,962</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forward foreign exchange contracts </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forward foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Available For Sale Other Investments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity investments</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">451</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">451</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,473</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Debt securities</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,216</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,216</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,874</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contingent Consideration</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,217</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,217</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,092</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.065%"><tr><td style="width:1.0%"></td><td style="width:64.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.895%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total Gross Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,194</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,591</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Credit Support Agreements (CSA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,172)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,575)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total Net Asset</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total Gross Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,564</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,037</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Credit Support Agreements (CSA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,412)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,604)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total Net Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$152</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">433</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Summarized information about changes in liabilities for contingent consideration is as follows:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning Balance</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$1,092</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,120</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">533</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Changes in estimated fair value </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">88</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(194)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Additions</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">112</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">792</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Payments/Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(75)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(57)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(11)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Ending Balance</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$1,217</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,092</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,120</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">2023 assets and liabilities are all classified as Level&#160;2 with the exception of equity investments of $4,473 million, which are classified as Level&#160;1 and contingent consideration of $1,092 million, classified as Level 3.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Includes cross currency interest rate swaps and interest rate swaps.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt">Classified as non-current other assets.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.89pt">Classified as cash equivalents and current marketable securities.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.99pt">Includes $1,217 million, $1,092 million and $1,116 million, classified as non-current other liabilities as of December&#160;29, 2024, <br/>December&#160;31, 2023 and January&#160;1, 2023, respectively. Includes $4&#160;million classified as current liabilities as of January&#160;1, 2023.</span></div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span>In fiscal year 2024, the Company recorded $105&#160;million of contingent consideration related to Proteologix. In fiscal year 2022, the Company recorded $704&#160;million of contingent consideration related to Abiomed.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CC<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052287810576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt Instruments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The components of long-term debt are as follows:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.155%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.778%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Effective<br/>Rate<br/>%</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Effective<br/>Rate<br/>%</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.650% Notes due 2024 </span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(750MM Euro 1.1090)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$&#8212;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$831</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.68&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.50%&#160;Notes due 2024 </span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(500MM GBP 1.2756)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">637</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">6.75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.625% Notes due 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">750</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">750</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.55% Notes due 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">999</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">950</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.46% Notes due 2026</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,999</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.47&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,997</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.47&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.95% Notes due 2027</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">927</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">900</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.95% Notes due 2027</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,458</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,419</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.150% Notes due 2028<br/>(750MM Euro 1.0401)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/(750MM Euro 1.1090)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">777</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">828</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.90%&#160;Notes due 2028</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,498</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.91&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,497</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.91&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.95%&#160;Notes due 2029</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">298</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7.14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">298</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7.14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.80% Debentures due 2029</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,146</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.30% Notes due 2030</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,646</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,630</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.90% Debentures due 2031</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,145</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.92&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.20% Debenture due 2032</span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(700M EUR 1.0401)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">725</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.95%&#160;Debentures due 2033</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">499</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">499</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.375% Notes due 2033</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">854</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">854</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.95% Debentures due 2034</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">846</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.650% Notes due 2035<br/>(1.5B Euro 1.0401)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/(1.5B Euro 1.1090)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,550</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,652</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.35% Debentures due 2036 </span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(800MM EUR 1.0401)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">827</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.587% Notes due 2036</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">869</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">864</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.95%&#160;Notes due 2037</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">994</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">994</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.625% Notes due 2037</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,358</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,357</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.85%&#160;Debentures due 2038</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">697</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">697</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.40%&#160;Notes due 2038</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">993</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">993</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.50%&#160;Debentures due 2040</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">541</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">541</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.10% Notes due 2040</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">845</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">849</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.85% Notes due 2041</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">297</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">297</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.50% Notes due 2043</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">496</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">496</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.55% Debentures due 2044</span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1B EUR 1.0401)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,030</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.73% Notes due 2046</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,978</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,977</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.75% Notes due 2047</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">822</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">832</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.500% Notes due 2048</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">744</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">743</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.250% Notes due 2050</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">808</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">826</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.155%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.778%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.25% Debentures due 2054</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">843</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.450% Notes due 2060</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,058</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,073</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">83</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">69</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">32,400</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">3.36</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">27,350</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">2.98</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less current portion</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,749</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,469</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total long-term debt</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$30,651</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$25,881</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">Weighted average effective rate.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Translation rate at December&#160;29, 2024.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt">Translation rate at December&#160;31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.89pt">The excess of the carrying value over the fair value of debt was $2.0 billion and $1.0 billion at the end of fiscal year 2024 and fiscal year 2023, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Aggregate Maturities of Long Term Obligations</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Aggregate maturities of long-term debt obligations commencing in 2025 are:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.826%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2027</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2028</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2029</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">After 2029</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1,749</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,999</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,385</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,275</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,444</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,548</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052290140352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Provision for Income Taxes</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The provision for taxes on income on continuing operations consists of:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Currently payable:</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. taxes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,200</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,705</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,274</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International taxes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,604</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,090</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,295</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total currently payable</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,804</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,795</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,569</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Deferred:</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. taxes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,539)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,440)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,990)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International taxes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">356</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(619)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">410</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total deferred</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,183)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,059)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,580)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Provision for taxes on income</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$2,621</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,736</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,989</span></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">A comparison of income tax expense at the U.S.&#160;statutory rate of 21% in fiscal years 2024, 2023 and 2022, to the Company&#8217;s effective tax rate is as follows:</span></div><div style="margin-bottom:4pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.&#160;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(458)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,033)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,606</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,145</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,095</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,753</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Earnings before taxes on income:</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$16,687</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,062</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,359</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax rates:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. statutory rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International operations</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. tax settlements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. taxes on international income</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. state taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax benefits on share-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effective Rate</span></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15.7&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.5&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15.4&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">International operations reflect the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland, and Belgium, which is a favorable impact on the effective tax rate as compared with the U.S. statutory&#160;rate. </span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Includes the net impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code as well as related foreign tax credits.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Temporary Differences and Carryforwards</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Temporary differences and carryforwards at the end of fiscal years 2024 and 2023 were as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt;padding-right:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.292%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024 Deferred Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023 Deferred Tax</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Asset</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Asset</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee related obligations</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$372</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">586</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock based compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">717</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">686</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation of property, plant and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(833)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(902)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill and intangibles</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,261)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,252)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">R&amp;D capitalized for tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,398</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,595</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reserves&#160;&amp; liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,444</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,816</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory related</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">371</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">359</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating loss carryforwards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,298</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,145</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Undistributed foreign earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,931</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,492)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,801</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,695)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global intangible low-taxed income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,589)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,731)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Miscellaneous international</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,212</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">831</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Miscellaneous U.S.&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,083</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total deferred income taxes</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,826</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,175)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,819</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,584)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Valuation allowances</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,638)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,149)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total deferred income taxes net of valuation allowances</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15,188</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(7,175)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">12,670</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(6,584)</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of Valuation Allowance</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table summarizes the activity related to valuation allowances for continuing operations:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning of year</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1,149</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">775</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">451</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">355</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Utilization</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(116)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency translation</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(46)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net acquisitions / (dispositions/liquidations)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">84</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">110</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">End of year</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$1,638</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$1,149</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table summarizes the activity related to unrecognized tax benefits for continuing operations:</span></div><div style="margin-bottom:6pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning of year</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,485</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,716</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,210</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increases related to current year tax positions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">176</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">239</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">523</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increases related to prior period tax positions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">129</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">244</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">143</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Decreases related to prior period tax positions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(147)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(781)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(148)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Settlements</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(583)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(880)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lapse of statute of limitations</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(40)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(53)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">End of year</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$2,020</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,485</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,716</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052291558560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee related obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Compensation Related Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EmployeeRelatedObligationsTableTextBlock', window );">Employee Related Obligations</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">At the end of fiscal 2024 and fiscal 2023, employee related obligations recorded on the Consolidated Balance Sheets were:</span></div><div style="margin-bottom:6pt;margin-top:7pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pension benefits</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,968</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,129</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Postretirement benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,920</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,963</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Postemployment benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,910</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,527</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">68</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total employee obligations</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,847</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,687</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less current benefits payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">592</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">538</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee related obligations&#160;&#8212; non-current</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$7,255</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,149</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EmployeeRelatedObligationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee related obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EmployeeRelatedObligationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052288743728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and other benefit plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Components of Net Periodic Benefit Cost</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans for 2024, 2023 and 2022 include the following components:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service cost</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$948</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">893</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,319</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">277</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">264</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">320</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,402</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,437</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">908</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">209</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">214</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,560)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,716)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,756)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of prior service cost </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(184)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(184)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(184)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recognized actuarial losses (gains)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">174</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(199)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">650</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">122</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Curtailments and settlements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">93</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net periodic benefit cost (credit)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$(222)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(676)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(62)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">530</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">487</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">533</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table represents the weighted-average actuarial assumptions:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Worldwide Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Net Periodic Benefit Cost</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service cost discount rate</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.39&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.85&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.46&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.09&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.40&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.59&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest cost discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.80&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Rate of increase in compensation levels</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.02&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected long-term rate of return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Benefit Obligation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.95&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.58&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.01&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.54&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.11&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.42&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Rate of increase in compensation levels</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.70&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.69&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.00&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.22&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.22&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.21&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock', window );">Assumed Health Care Cost Trend Rates</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table displays the assumed healthcare cost trend rates, for all individuals:</span></div><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Healthcare Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Healthcare cost trend rate assumed for next year</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.33&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.90&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Rate to which the cost trend rate is assumed to decline (ultimate trend)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.02&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Year the rate reaches the ultimate trend rate</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2048&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2048&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetFundedStatusTableTextBlock', window );">Schedule of Net Funded Status</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2024 and 2023 for the Company&#8217;s defined benefit retirement plans and other post-retirement plans:</span></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change in Benefit Obligation</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Projected benefit obligation&#160;&#8212; beginning of year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$31,744</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,390</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,108</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,192</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">948</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">893</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">277</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">264</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,402</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,437</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">209</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">214</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Plan participant contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amendments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Actuarial (gains) losses</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,245)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,068</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">398</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">469</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Divestitures&#160;&amp; acquisitions</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(352)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Curtailments, settlements&#160;&amp; restructuring</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(121)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(238)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(332)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Benefits paid from plan</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,801)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,122)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(556)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(702)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of exchange rates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(685)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">601</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Projected benefit obligation&#160;&#8212; end of year</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$30,317</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">31,744</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,425</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,108</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change in Plan Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Plan assets at fair value&#160;&#8212; beginning of year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$33,607</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,496</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">86</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">78</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Actual return (loss) on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,113</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,951</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Company contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">229</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">268</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">548</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">694</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Plan participant contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Settlements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(114)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(176)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Divestitures &amp; acquisitions</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(509)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Benefits paid from plan assets</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,801)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,122)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(556)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(702)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of exchange rates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(714)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">626</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Plan assets at fair value&#160;&#8212; end of year</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$33,395</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">33,607</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">93</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">86</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Funded status &#8212; end of year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$3,078</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,863</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4,332)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4,022)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amounts Recognized in the Company&#8217;s Balance Sheet consist of the&#160;following:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$6,046</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,992</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(136)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(119)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(453)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(416)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,832)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,010)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,879)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,606)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total recognized in the consolidated balance sheet&#160;&#8212; end of year</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$3,078</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,863</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4,332)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4,022)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amounts Recognized in Accumulated Other Comprehensive Income consist&#160;of the following:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net actuarial loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$3,903</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,962</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">691</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">354</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior service cost (credit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,051)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,236)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unrecognized net transition obligation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total before tax effects</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$2,852</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,726</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">687</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">348</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Benefit Obligations&#160;&#8212; end of year</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$28,883</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">30,139</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">The actuarial (gains)/losses for retirement plans in 2024 and 2023 were primarily driven by changes in the discount rates. </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Driven by the Kenvue separation.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt">The fiscal years 2024 and 2023 includes approximately $400 million and $800&#160;million, respectively, transferred to a group annuity contract issued by a third-party insurer for the U.S. Salaried Pension&#160;Plan.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive&#160;Income</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net periodic benefit cost (credit)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(222)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(676)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">530</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">487</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net actuarial (gain) loss</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(807)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">711</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">389</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">136</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of net actuarial loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(172)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">199</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(53)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(22)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior service cost (credit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of prior service (cost) credit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">184</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">185</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of exchange rates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(79)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">103</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total loss/(income) recognized in other comprehensive income, before tax</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$(874)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,195</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">339</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">116</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total recognized in net periodic benefit cost and other comprehensive&#160;income</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$(1,096)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">519</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">869</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">603</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock', window );">Information Related to the Benefit Obligation and the Fair Value of Plan Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table displays the funded status of the Company's U.S. Qualified &amp; Non-Qualified pension plans and international funded and unfunded pension plans at December&#160;31, 2024 and December&#160;31, 2023, respectively:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.685%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">International Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Qualified Plans</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-Qualified Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Funded Plans</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unfunded Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Plan Assets</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$22,250</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,298</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,145</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,309</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Projected Benefit Obligation</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,146</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,152</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,990</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,037</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,069</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,431</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">112</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">124</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated Benefit Obligation</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,726</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,557</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,949</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,982</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,115</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,498</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">93</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">102</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Over (Under) Funded Status</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Projected Benefit Obligation</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$4,104</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,146</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,990)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,037)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,076</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">878</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(112)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(124)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated Benefit Obligation</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,524</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,741</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,949)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,982)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,030</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,811</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(93)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(102)</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock', window );">Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table displays the projected future benefit payments from the Company&#8217;s retirement and other benefit plans:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.286%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2030-2034</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Projected future benefit payments</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Retirement plans</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1,480</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,503</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,604</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,702</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,797</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,401</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other benefit plans&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$464</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">478</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">432</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">445</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">462</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,537</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock', window );">Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table displays the projected future minimum contributions to the unfunded retirement plans. These amounts do not include any discretionary contributions that the Company may elect to make in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.286%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2030-2034</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Projected future contributions</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$133</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">135</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">140</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">145</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">150</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">815</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock', window );">Company' Retirement Plan Asset Allocation and Target Allocations</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company&#8217;s retirement plan asset allocation at the end of 2024 and 2023 and target allocations for 2025 are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Percent of<br/>Plan Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Target<br/>Allocation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Worldwide Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity securities</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total plan assets</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock', window );">Schedule of Defined Benefit Plans Disclosures</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table sets forth the Retirement Plans' investments measured at fair value as of December&#160;31, 2024 and December&#160;31, 2023:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Inputs</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Investments<br/>Measured at Net<br/>Asset Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term investment funds</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$&#8212;&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">511</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">829</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">511</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">841</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Government and agency securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,885</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,985</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,885</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,985</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Debt instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,321</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,899</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,321</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,899</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,144</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,764</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,144</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,764</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commingled funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,004</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,967</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,190</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,672</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,231</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,682</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">88</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">128</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">92</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,087</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,295</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,303</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,436</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Investments at fair value</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$7,144</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,776</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15,809</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15,729</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">165</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">135</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10,277</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9,967</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">33,395</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">33,607</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">The activity for the Level 3 assets is not significant for all years presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information related to the benefit obligation and the fair value of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of estimated future employer contributions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Subparagraph (d)(5)<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Subparagraph (f)<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the assumed health care cost trend rates for the next year used to measure the expected cost of benefits covered by the plans, including the ultimate trend rate(s) and when that rate is expected to be achieved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Subparagraph (l)<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Subparagraph (h)<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetFundedStatusTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of net funded status of pension plans and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetFundedStatusTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052287787904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital and treasury stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ChangesInTreasuryStockTableTextBlock', window );">Changes in Treasury Stock</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Changes in treasury stock were:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Treasury Stock</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Amounts in Millions Except Treasury Stock Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at January 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">490,878</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$39,099</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee compensation and stock option plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(20,007)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,440)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repurchase of common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35,375</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,035</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at January 1, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">506,246</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,694</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee compensation and stock option plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(15,521)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,529)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repurchase of common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,085</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,079</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Kenvue share exchange (Note 21)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">190,955&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">31,418</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at December 31, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">712,765</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75,662</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee compensation and stock option plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(15,027)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,389)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repurchase of common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,183</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,407</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at December 29, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">712,921</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$75,680</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ChangesInTreasuryStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ChangesInTreasuryStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052378422192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated other comprehensive income (loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Components of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Components of other comprehensive income (loss) consist of the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Foreign<br/>Currency<br/>Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain/<br/>(Loss) On<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Employee<br/>Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain/<br/>(Loss) On<br/>Derivatives<br/>&amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total<br/>Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">January 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(10,017)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,702)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(336)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(13,058)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net 2022 changes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,796)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(24)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,805</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">91</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">January 1, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11,813)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(27)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(897)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(230)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12,967)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net 2023 changes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,221)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,399)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(147)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,741)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Kenvue Separation/IPO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,885</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">296</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,181</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 31, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10,149)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,000)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(377)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12,527)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net 2024 changes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,708</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,373)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">786</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(8,441)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,551)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,750)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11,741)</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052288629808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended December&#160;29, 2024, December&#160;31, 2023 and January&#160;1, 2023:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.096%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In Millions Except Per Share Amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net earnings per share from continuing operations</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$5.84&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.26</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.23</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net earnings per share from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.62</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.60</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total net earnings per share - basic</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.84</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.88</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.83</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Average shares outstanding&#160;&#8212; basic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,407.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,533.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,625.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">77.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">94.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">140.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: shares repurchased under treasury stock method</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(55.6)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(67.2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(101.4)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjusted average shares outstanding&#160;&#8212; diluted</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,429.4</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,560.4</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,663.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted net earnings per share from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.14</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted net earnings per share from discontinuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.52</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.59</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total net earnings per share - diluted</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$5.79&#160;</span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.72</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.73</span></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Shares in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The diluted net earnings per share calculation excluded the following number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Company&#8217;s stock. </span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54.1&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43.0&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.0</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052378556624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common stock, stock option plans and stock compensation agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule Valuation Assumptions</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The average fair value of options granted was $27.67, $27.85 and $23.23, in fiscal years 2024, 2023 and 2022, respectively. The fair value was estimated based on the weighted average assumptions of:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.15&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.74&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.98&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.10&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.90&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.70&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">A summary of option activity under the Plan as of December&#160;29, 2024, is presented below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value<br/>(Dollars in Millions) </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shares at December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">112,238</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$139.88</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,239</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,917</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">157.92</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10,771)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">107.06</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,755)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">162.45</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Shares at December 29, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">112,629</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$144.69</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$1,129</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of Options Outstanding</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table summarizes stock options outstanding and exercisable at December&#160;29, 2024:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercisable</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise Price Range</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average Life</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$100.06 - $101.87</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,016</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.8</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$101.29</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,016</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$101.29</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$115.67 - $129.51</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,252</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">122.49</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,252</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">122.49</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$131.94 - $151.41</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,624</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142.87</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,624</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142.87</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$157.92 - $162.75</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,391</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">160.33</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,269</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">162.75</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$164.62 - $165.89</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,346</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">165.29</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,522</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">164.64</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">112,629</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5.3</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$144.69</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">74,683</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$135.72</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">Average contractual life remaining in years.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of Restricted Share Units</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">A summary of the restricted share units and performance share units activity under the Plans as of December&#160;29, 2024 is presented below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>Performance Share Units</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shares at December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,938</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,037</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,331</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">906</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,454)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(808)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Canceled/forfeited/adjusted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(774)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(122)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shares at December 29, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,041</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,013</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052290991216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of business and geographic areas (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_SalesBySegmentOfBusinessTableTextBlock', window );">Schedule of Sales by Segment of Business</a></td>
<td class="text"><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;24 vs. &#8217;23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;23 vs. &#8217;22</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">INNOVATIVE MEDICINE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$11,355</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,539</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,473</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,513</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,899</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,828</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,052</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,935</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">REMICADE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,009</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,143</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,417</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(19.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Exports</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">98</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">147</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">204</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(33.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(28.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">497</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">549</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">722</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(23.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,605</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,839</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,343</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(21.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,082</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,124</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,166</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,108</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,073</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,190</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,197</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,184</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">STELARA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,720</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,966</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,388</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,641</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,892</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,335</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,361</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,858</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,723</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">TREMFYA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,443</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,147</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,844</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,227</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">999</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">824</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,670</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,147</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,668</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER IMMUNOLOGY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(74.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(33.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(74.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(33.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Infectious Diseases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,354</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,680</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,042</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,918</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,769</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(30.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(22.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,396</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,418</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,449</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(23.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">COVID-19 VACCINE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">120</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">198</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,117</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2,059</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(82.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(45.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;24 vs. &#8217;23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;23 vs. &#8217;22</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">198</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,117</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2,179</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(82.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(48.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">EDURANT / rilpivirine</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">35</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">36</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(10.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,241</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,115</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">972</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">14.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,272</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,150</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,008</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">14.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">PREZISTA / PREZCOBIX</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> /</span></div><div style="padding-left:12pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">REZOLSTA / SYMTUZA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,311</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,446</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,494</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">401</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">408</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">449</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(9.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,712</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,854</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,943</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER INFECTIOUS DISEASES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(41.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(34.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">203</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">278</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">289</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(26.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">214</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">297</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">318</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(27.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(6.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,398</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,065</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3,570</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2,718</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3,076</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3,323</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(11.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7,115</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7,140</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">6,893</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">CONCERTA / methylphenidate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">134</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">230</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">151</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(41.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">52.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">507</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">554</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">493</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(8.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">641</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">783</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">644</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(18.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">21.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3,125</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2,897</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2,714</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,097</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,218</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,426</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(9.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(14.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,222</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,115</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,140</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">SPRAVATO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">929</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">589</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">328</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">57.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">79.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">148</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">100</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">46</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">48.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,077</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">689</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">374</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">56.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">84.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER NEUROSCIENCE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">210</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">349</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">376</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(39.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(7.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">965</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,204</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,358</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(19.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(11.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,175</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,553</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,734</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(24.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(10.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">10,854</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">8,462</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">6,930</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">28.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">22.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">9,926</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">9,199</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">9,052</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">20,781</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">17,661</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">15,983</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">17.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">CARVYKTI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">869</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">469</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">133</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">85.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">94</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;24 vs. &#8217;23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;23 vs. &#8217;22</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">963</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">133</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">92.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">DARZALEX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,588</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,277</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,210</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,082</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,467</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,767</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,670</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,744</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,977</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">ERLEADA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,282</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,065</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">968</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,717</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,322</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">913</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,999</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,387</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,881</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">IMBRUVICA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,051</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,390</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(24.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,214</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,394</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,038</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,264</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,784</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(13.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">TECVAYLI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">418</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">334</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">131</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">549</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">395</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">ZYTIGA /abiraterone acetate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(32.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(32.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">597</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">837</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,696</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(28.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(50.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">631</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">887</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,770</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(28.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(49.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER ONCOLOGY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">643</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">215</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">144</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">288</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">269</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">280</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">931</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">484</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">423</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">92.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,143</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,697</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,346</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,140</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,117</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,071</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,282</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,815</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,417</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:underline">OPSUMIT</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,520</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,292</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,132</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">664</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">681</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">651</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,184</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,973</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,783</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">UPTRAVI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,511</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,326</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,104</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">307</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">255</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">218</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,817</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,582</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,322</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER PULMONARY HYPERTENSION</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">112</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">110</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(28.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">169</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">182</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">202</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">281</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">260</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">313</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(16.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;24 vs. &#8217;23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;23 vs. &#8217;22</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,866</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,906</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,042</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">696</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">765</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">845</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,562</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,671</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,887</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">XARELTO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,373</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,365</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,473</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,373</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,365</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,473</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">494</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">541</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">569</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">696</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">765</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">845</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,189</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,306</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,414</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TOTAL INNOVATIVE MEDICINE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,970</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,169</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,604</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,994</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,590</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,959</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56,964</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54,759</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52,563</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">MEDTECH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cardiovascular </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,513</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,633</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,169</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">67.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,194</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,717</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,131</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,707</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,350</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,300</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">ELECTROPHYSIOLOGY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,738</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,458</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,529</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,230</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,901</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,267</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,688</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,937</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">ABIOMED</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,213</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,066</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">284</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">240</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,496</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,306</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">SHOCKWAVE</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">442</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">122</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">564</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER CARDIOVASCULAR</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">109</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">102</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">260</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">247</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">230</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">380</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">356</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">332</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,689</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,525</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,321</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,470</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,417</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,267</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,158</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,942</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,587</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;24 vs. &#8217;23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;23 vs. &#8217;22</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">HIPS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,057</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">996</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">943</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">581</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">564</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">571</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,638</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,560</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,514</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">KNEES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">922</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">896</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">851</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">623</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">559</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">508</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,545</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,456</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,359</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">TRAUMA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,013</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,949</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,882</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">989</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,049</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,979</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,871</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,696</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,684</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,645</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,230</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,263</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,198</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,926</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,947</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,843</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,003</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,897</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,842</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,006</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,793</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,845</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,037</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,690</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">ADVANCED</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,838</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,833</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,784</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,650</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,837</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,785</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,488</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,671</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,569</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">GENERAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,165</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,198</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,113</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,192</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,168</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,008</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,358</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,366</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,121</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,128</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,086</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,990</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,986</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,859</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,146</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,072</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,849</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">CONTACT LENSES / OTHER</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,684</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,626</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,522</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,049</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,076</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,733</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,702</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,543</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">SURGICAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">444</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">460</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">468</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">969</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">910</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">837</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,413</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,370</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,306</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;24 vs. &#8217;23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8217;23 vs. &#8217;22</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TOTAL MEDTECH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,332</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,275</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,377</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,525</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,125</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,857</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,400</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,427</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WORLDWIDE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,302</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,444</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,981</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,519</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,715</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,009</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$88,821</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">85,159</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79,990</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">*&#160;&#160;&#160;&#160;percentage greater than 100% or not meaningful</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">Previously referred to as Interventional Solutions</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Acquired on December 22, 2022</span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt">Acquired on May 31, 2024</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Operating Profit (Loss) from Segments to Consolidated</a></td>
<td class="text"><div style="margin-bottom:4pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.750%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Income Before Tax by Segment</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024 </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="9" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023 </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="9" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022 </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Innovative<br/>Medicine</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MedTech</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Innovative<br/>Medicine</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MedTech</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Innovative<br/>Medicine</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MedTech</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales to customers</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$56,964</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,857</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54,759</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,400</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52,563</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,427</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of products sold</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,036</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,345</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,715</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,722</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,066</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,397</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, marketing and administrative </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,906</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,812</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,842</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,476</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,714</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,537</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,529</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,703</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,963</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,122</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,642</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,493</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other segment items </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(426)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">257</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">993</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(589)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,494</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">553</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Segment income before tax</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$18,919</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,740</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,659</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,246</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,669</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,915</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,647</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,447</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,094</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: Expense not allocated to segments </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,972</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,853</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">735</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$16,687</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15,062</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">19,359</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.644%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identifiable Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Innovative Medicine</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$57,070</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,324</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MedTech</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">84,322</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74,710</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">141,392</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">133,034</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General corporate </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,712</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34,524</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$180,104</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">167,558</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additions to Property,<br/>Plant &amp; Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Depreciation and<br/>Amortization</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Innovative Medicine</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1,710</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,653</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,374</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$3,760</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,847</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,687</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MedTech</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,443</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,372</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,120</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,237</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,943</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,302</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Segments total</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,153</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,025</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,494</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,997</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,790</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,989</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">162</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">303</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">383</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">641</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">271</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">356</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">212</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">342</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">313</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">340</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$4,424</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,543</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,009</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$7,339</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,486</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6,970</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.989%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.467%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Long-Lived Assets </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">United States</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$50,302</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,444</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,981</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$70,670</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54,832</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,212</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,410</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,664</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,267</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,616</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Western Hemisphere excluding U.S.&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,714</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,549</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,108</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,728</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,491</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Asia-Pacific, Africa</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,593</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,756</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,237</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,454</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,500</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Segments total</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">88,821</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">85,159</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79,990</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101,119</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">89,439</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,217</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,192</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other non long-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">77,768</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">76,927</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$88,821</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">85,159</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">79,990</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$180,104</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">167,558</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">See Note&#160;1 for a description of the segments in which the Company operates. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Export sales are not significant. In fiscal year 2024, the Company utilized three wholesalers distributing products for both segments that represented approximately 20.5%, 15.6% and 12.3% of the total gross revenues. In fiscal year 2023, the Company had three wholesalers distributing products for both segments that represented approximately 18.2%, 15.1% and 14.2% of the total gross revenues. In fiscal year 2022, the Company had three wholesalers distributing products for all three segments that represented approximately 18.9%, 15.0%, and 13.8% of the total gross revenues. </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.64pt"><span style="-sec-ix-hidden:f-2949">Other segment expenses</span> for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:7.29pt">Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal years 2024 and 2023 include charges for talc matters of approximately $5.1&#160;billion and $7&#160;billion, respectively (See Note 19, Legal proceedings, for additional details). The fiscal year 2024 includes a loss of approximately $0.4&#160;billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock. The fiscal year 2023 includes the unfavorable change in the fair value of the retained stake in Kenvue of approximately $0.4&#160;billion.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:7.19pt">Innovative Medicine segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">Acquired in-process research &amp; development expense of $1.25&#160;billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition)</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">Monetization of royalty rights of $0.3&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">Litigation expense of $0.3&#160;billion primarily related to Risperdal Gynecomastia</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">An intangible asset impairment charge of approximately $0.2&#160;billion associated with the M710 (biosimilar) asset acquired as part of the acquisition of Momenta Pharmaceuticals in 2020.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">A restructuring related charge of $0.1&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">One-time COVID-19 Vaccine manufacturing exit related costs of $0.1&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">Favorable changes in the fair value of securities of $0.1&#160;billion</span></div><div style="padding-left:14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">MedTech segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">Acquisition and integration related costs of $1.0&#160;billion primarily related to the acquisition of Shockwave </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt">Acquired in-process research and development expense of $0.5&#160;billion from the V-Wave acquisition</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt">A gain of $0.2&#160;billion related to the Acclarent divestiture</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt">A Medical Device Regulation charge of $0.2&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt">A restructuring related charge of $0.2&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.07pt">Innovative Medicine segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">One-time COVID-19 Vaccine manufacturing exit related costs of $0.7&#160;billion </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">A restructuring related charge of $0.5&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Unfavorable changes in the fair value of securities of $0.4&#160;billion </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Favorable litigation related items of $0.1&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Loss on divestiture of $0.2&#160;billion. </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">An intangible asset impairment charge of approximately $0.2&#160;billion related to market dynamics associated with a non-strategic asset (M710) acquired as part of the acquisition of Momenta Pharmaceuticals in 2020.</span></div><div style="padding-left:14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:112%">MedTech segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Acquired in-process research and development expense of $0.4&#160;billion related to the Laminar acquisition in 2023</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">A restructuring related charge of $0.3&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Acquisition and integration related costs of $0.2&#160;billion primarily related to the acquisition of Abiomed</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">A Medical Device Regulation charge of $0.3&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Income from litigation settlements of $0.1&#160;billion</span></div><div style="padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:7.17pt">Innovative Medicine segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">One-time COVID-19 Vaccine manufacturing exit related costs of $1.5&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">An intangible asset impairment charge of approximately $0.8&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Litigation expense of $0.1&#160;billion </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Unfavorable changes in the fair value of securities of $0.7&#160;billion </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">A restructuring related charge of $0.1&#160;billion </span></div><div style="padding-left:14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:112%">MedTech segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Litigation expense of $0.6&#160;billion primarily for pelvic mesh related costs</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">A restructuring related charge of $0.3&#160;billion </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Acquisition and integration related costs of $0.3&#160;billion primarily related to the acquisition of Abiomed</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt">A Medical Device Regulation charge of $0.3&#160;billion</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">   General corporate includes cash, cash equivalents, marketable securities and other corporate assets. </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.64pt">Long-lived assets include property, plant and equipment, net for fiscal years 2024, and 2023 of $20,518 and $19,898, respectively, and intangible assets and goodwill, net for fiscal years 2024 and 2023 of $81,818 and $70,733, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SalesBySegmentOfBusinessTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales by segment of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SalesBySegmentOfBusinessTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052290764608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and divestitures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Details of the fair value amounts recognized for assets acquired and liabilities assumed as of the purchase date and at the end of fiscal year 2024, which includes measurement period adjustments, are included in the table below. As the acquisition occurred in May 2024, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Billions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">May 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Assets acquired:</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$1.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortizable intangibles</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">IPR&amp;D</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.4</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total assets acquired</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$15.5</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$15.5</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Liabilities assumed:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred taxes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$1.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$1.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Notes payable*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued liabilities**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.4</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total liabilities assumed</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$2.9</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$2.9</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net assets acquired</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$12.6</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$12.6</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net assets acquired as of May 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$12.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: Cash acquired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity awards settled</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Settlement of Note payable*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total enterprise value as of June 30, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$13.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">*&#160;&#160;&#160;&#160;Represents the convertible debt which was subsequently paid in the fiscal second quarter of 2024.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">**&#160;&#160;&#160;&#160;Includes $0.2&#160;billion of equity awards</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052415272400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal proceedings (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock', window );">Schedule of Loss Contingencies by Contingency</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The table below contains the most significant of these cases and provides the approximate number of plaintiffs in the United States with direct claims in pending lawsuits regarding injuries allegedly due to the relevant product or product category as of December&#160;29, 2024:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.419%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Product or product category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of plaintiffs </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Body powders containing talc, primarily JOHNSON&#8217;S Baby Powder</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62,830&#160;</span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PINNACLE Acetabular Cup System</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">910&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pelvic meshes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,990&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ETHICON PHYSIOMESH Flexible Composite Mesh</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">130&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">RISPERDAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ELMIRON</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,170&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052291513216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Summary of Severance Charges and Associated Spending</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The following table summarizes the restructuring expenses for the fiscal years 2024 and 2023:</span></div><div style="margin-bottom:4pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.173%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Pre-tax Dollars in Millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Innovative Medicine Segment</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$102</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">479</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MedTech Segment</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">167</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">319</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total Programs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$269</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$798</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">The fiscal year of 2024 included $102&#160;million in Restructuring on the Consolidated Statement of Earnings. The fiscal year of 2023 included $449&#160;million in Restructuring and $30&#160;million in Cost of products sold on the Consolidated Statement of Earnings.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">The fiscal year of 2024 included $132&#160;million in Restructuring and $35&#160;million in Cost of products sold on the Consolidated Statement of Earnings. The fiscal year of 2023 Included $40&#160;million in Restructuring and $279&#160;million in Cost of products sold on the Consolidated Statement of Earnings.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052291510000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Kenvue separation and discontinued operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Disposal Groups, Including Discontinued Operations</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Details of Net Earnings from Discontinued Operations, net of taxes are as follows:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.280%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.765%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;2023</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales to customers</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$10,036</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">14,953</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of products sold</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,369</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">6,494</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5,667</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">8,459</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, marketing and administrative expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3,085</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,519</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">258</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">468</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest Income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(117)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest expense, net of portion capitalized</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">199</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (income) expense, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,092</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,060</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Gain) on separation of Kenvue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(20,984)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restructuring</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">46</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Earnings from Discontinued Operations Before Provision for Taxes on Income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">22,134</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2,366</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for taxes on income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">307</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">795</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net earnings from Discontinued Operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$21,827</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">1,571</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">The Company ceased consolidating the results of the Consumer Health business on August 23, 2023, the date of the exchange offer, but continued to reflect any separation costs incurred as part of discontinued operations through the end of the fiscal fourth quarter.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table presents depreciation, amortization and capital expenditures of the discontinued operations related to&#160;Kenvue:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.173%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;2023</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and Amortization</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$383</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">641</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditures</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$162</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">303</span></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5D<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052286450256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Narrative (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 23, 2023</div></th>
<th class="th">
<div>May 08, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 29, 2024 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>Employee </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 02, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
<th class="th">
<div>Jul. 02, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide', window );">Number of employees | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Kenvue initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,241<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Realized gain (loss) on investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of business segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramObligationCurrent', window );">Supplier finance program, obligation, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 788<span></span>
</td>
<td class="nump">$ 704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration', window );">Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accounts Payable, Current<span></span>
</td>
<td class="text">Accounts Payable, Current<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement', window );">Minimum reverse repurchase agreement collateral (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_AccruedRebatesReturnsAndPromotions', window );">Accrued rebates, returns and promotions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,580<span></span>
</td>
<td class="nump">$ 16,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_SalesReturnReserve', window );">Sales return reserve (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProfitLossPercentToSales', window );">Percentage of profit share payments (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,471<span></span>
</td>
<td class="nump">$ 26,553<span></span>
</td>
<td class="nump">$ 24,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShippingandHandlingCostsasaPercentofSales', window );">Shipping and handling costs as a percent of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other assets, noncurrent<span></span>
</td>
<td class="text">Other assets, noncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accrued Liabilities, Current<span></span>
</td>
<td class="text">Accrued Liabilities, Current<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other Liabilities, Noncurrent<span></span>
</td>
<td class="text">Other Liabilities, Noncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent', window );">TCJA, undistributed foreign earnings percent related to cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent', window );">TCJA, undistributed foreign earnings percent related to earnings other than cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsPaymentPeriod', window );">TCJA, transition tax for accumulated foreign earnings, payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent', window );">TJCA , provisional liability, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings', window );">Repatriation of foreign earnings amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, marketing and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,869<span></span>
</td>
<td class="nump">$ 21,512<span></span>
</td>
<td class="nump">$ 20,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramPaymentTimingPeriod', window );">Supplier finance program, payment timing, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=jnj_YellowJerseyTherapeuticsMember', window );">Yellow Jersey Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payments to Acquire in Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=jnj_KenvueIncMember', window );">Kenvue Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_OwnershipPercentageSplitOffPercent', window );">Split-off percentage</a></td>
<td class="nump">80.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=jnj_KenvueIncMember', window );">Kenvue Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=jnj_JohnsonJohnsonMember', window );">Johnson &amp; Johnson | Kenvue Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Percentage ownership after transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ExchangeOfStockPercentageOwnershipAfterTransaction', window );">Percentage ownership after transaction</a></td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Kenvue Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,734,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Kenvue initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_RevenuePerformanceObligationPaymentTerms', window );">Revenue, performance obligation, payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Software Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_RevenuePerformanceObligationPaymentTerms', window );">Revenue, performance obligation, payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Software Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D Expense | Project Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ConcentrationRiskThresholdPercentage', window );">Concentration risk, threshold percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember', window );">Shipping and Handling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, marketing and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_AccruedRebatesReturnsAndPromotions', window );">Accrued rebates, returns and promotions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,300<span></span>
</td>
<td class="nump">$ 11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_AccruedRebatesReturnsAndPromotions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_AccruedRebatesReturnsAndPromotions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ConcentrationOfCreditRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration of credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ConcentrationOfCreditRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ConcentrationRiskThresholdPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Threshold Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ConcentrationRiskThresholdPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ExchangeOfStockPercentageOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange of Stock, Percentage Ownership After Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ExchangeOfStockPercentageOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum Collateral Value as a Percent, Reverse Repurchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of employees engaged in company activities worldwide.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OwnershipPercentageSplitOffPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership Percentage, Split-Off Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OwnershipPercentageSplitOffPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProfitLossPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Profit loss percent to sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProfitLossPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_RevenuePerformanceObligationPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Payment Terms</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_RevenuePerformanceObligationPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SalesReturnReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales return reserve</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SalesReturnReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ShippingandHandlingCostsasaPercentofSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shipping and Handling Costs as a Percent of Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ShippingandHandlingCostsasaPercentofSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Cash And Cash Equivalents, Tax Rate, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Other Than Cash And Cash Equivalents, Tax Rate, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Payment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483385/720-35-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramObligationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation for supplier finance program, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramObligationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes obligation for supplier finance program, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramPaymentTimingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period when payment is expected to be made to finance provider or intermediary in supplier finance program, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramPaymentTimingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=jnj_YellowJerseyTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=jnj_YellowJerseyTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=jnj_KenvueIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=jnj_KenvueIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=jnj_KenvueIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=jnj_KenvueIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=jnj_JohnsonJohnsonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=jnj_JohnsonJohnsonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=jnj_KenvueIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=jnj_KenvueIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052294607792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of significant accounting policies - Estimated Useful Lives of Assets (Details)<br></strong></div></th>
<th class="th"><div>Dec. 29, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Land and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Building and building equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">30 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Land and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">13 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=jnj_LandAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=jnj_LandAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052294535040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Supplier Finance Program (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 29, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramObligationRollForward', window );"><strong>Supplier Finance Program, Obligation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramObligationCurrent', window );">Confirmed obligations - beginning of the year</a></td>
<td class="nump">$ 704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramObligationIncrease', window );">Invoices confirmed during the year</a></td>
<td class="nump">3,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramObligationDecreaseSettlement', window );">Confirmed invoices paid during the year</a></td>
<td class="nump">2,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramObligationCurrent', window );">Confirmed obligations - end of the year</a></td>
<td class="nump">$ 788<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramObligationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation for supplier finance program, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramObligationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramObligationDecreaseSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in obligation for supplier finance program from settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477128/405-50-55-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramObligationDecreaseSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramObligationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in obligation for supplier finance program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477128/405-50-55-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479468/405-50-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramObligationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramObligationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramObligationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052290492560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, cash equivalents and current marketable securities - Cash and Cash Equivalent Composition (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale</a></td>
<td class="nump">$ 7,216<span></span>
</td>
<td class="nump">$ 8,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">24,105<span></span>
</td>
<td class="nump">21,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">417<span></span>
</td>
<td class="nump">1,068<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="nump">17,306<span></span>
</td>
<td class="nump">14,053<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity, unrecognized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Fair value, held-to-maturity</a></td>
<td class="nump">17,306<span></span>
</td>
<td class="nump">14,053<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">17,186<span></span>
</td>
<td class="nump">13,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="nump">2,918<span></span>
</td>
<td class="nump">3,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity, unrecognized gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity, unrecognized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Fair value, held-to-maturity</a></td>
<td class="nump">2,918<span></span>
</td>
<td class="nump">3,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">2,918<span></span>
</td>
<td class="nump">3,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Non-U.S. Sovereign Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity, unrecognized gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity, unrecognized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Fair value, held-to-maturity</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | U.S. Reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="nump">7,100<span></span>
</td>
<td class="nump">4,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity, unrecognized gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity, unrecognized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Fair value, held-to-maturity</a></td>
<td class="nump">7,100<span></span>
</td>
<td class="nump">4,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">7,100<span></span>
</td>
<td class="nump">4,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity, unrecognized gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity, unrecognized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Fair value, held-to-maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="nump">6,123<span></span>
</td>
<td class="nump">4,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity, unrecognized gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity, unrecognized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Fair value, held-to-maturity</a></td>
<td class="nump">6,123<span></span>
</td>
<td class="nump">4,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">6,123<span></span>
</td>
<td class="nump">4,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Time deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="nump">1,045<span></span>
</td>
<td class="nump">662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity, unrecognized gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity, unrecognized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Fair value, held-to-maturity</a></td>
<td class="nump">1,045<span></span>
</td>
<td class="nump">662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">1,045<span></span>
</td>
<td class="nump">662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Carrying Amount, available-for-sale</a></td>
<td class="nump">7,215<span></span>
</td>
<td class="nump">8,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, unrealized gain</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, unrecognized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale</a></td>
<td class="nump">7,216<span></span>
</td>
<td class="nump">8,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">6,919<span></span>
</td>
<td class="nump">8,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">297<span></span>
</td>
<td class="nump">571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Carrying Amount, available-for-sale</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, unrealized gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, unrecognized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | U.S. Gov't Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Carrying Amount, available-for-sale</a></td>
<td class="nump">6,815<span></span>
</td>
<td class="nump">8,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, unrealized gain</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, unrecognized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale</a></td>
<td class="nump">6,816<span></span>
</td>
<td class="nump">8,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">6,796<span></span>
</td>
<td class="nump">8,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | U.S. Gov't Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Carrying Amount, available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, unrecognized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | Other Sovereign Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Carrying Amount, available-for-sale</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, unrealized gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, unrecognized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=jnj_OtherSovereignSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=jnj_OtherSovereignSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052287574768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, cash equivalents and current marketable securities - Contractual Maturities of Available for Sale Securities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 29, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Cost Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due within one year</a></td>
<td class="nump">$ 7,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost', window );">Due after five years through ten years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total debt securities</a></td>
<td class="nump">7,215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due within one year</a></td>
<td class="nump">7,205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Due after five years through ten years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total debt securities</a></td>
<td class="nump">$ 7,216<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052291495888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Summary of Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials and supplies</a></td>
<td class="nump">$ 2,337<span></span>
</td>
<td class="nump">$ 2,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Goods in process</a></td>
<td class="nump">2,815<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">7,292<span></span>
</td>
<td class="nump">6,874<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 12,444<span></span>
</td>
<td class="nump">$ 11,181<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052282349696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, plant and equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment, gross</a></td>
<td class="nump">$ 48,768<span></span>
</td>
<td class="nump">$ 47,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="nump">28,250<span></span>
</td>
<td class="nump">27,878<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property, plant and equipment, net</a></td>
<td class="nump">20,518<span></span>
</td>
<td class="nump">19,898<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=jnj_LandAndLeaseholdImprovementsMember', window );">Land and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment, gross</a></td>
<td class="nump">718<span></span>
</td>
<td class="nump">795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building and building equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment, gross</a></td>
<td class="nump">12,317<span></span>
</td>
<td class="nump">12,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment, gross</a></td>
<td class="nump">29,444<span></span>
</td>
<td class="nump">28,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment, gross</a></td>
<td class="nump">$ 6,289<span></span>
</td>
<td class="nump">$ 5,627<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=jnj_LandAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=jnj_LandAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052288701600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Interest expense capitalized</a></td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest', window );">Depreciation expense, including the amortization of capitalized interest</a></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation expense including the amortization of capitalized interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052290950288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible assets and goodwil - Schedule of Intangible Assets and Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 22, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite lived intangible assets</a></td>
<td class="nump">$ 12,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets - net</a></td>
<td class="nump">37,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite lived intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember', window );">Purchased in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite lived intangible assets</a></td>
<td class="nump">12,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember', window );">Patents And Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets with definite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite lived intangible assets gross</a></td>
<td class="nump">44,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="num">(26,124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,808)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite lived intangible assets net</a></td>
<td class="nump">$ 18,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets useful life</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Customer relationships and other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets with definite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite lived intangible assets gross</a></td>
<td class="nump">$ 20,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="num">(13,544)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,685)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite lived intangible assets net</a></td>
<td class="nump">$ 6,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets useful life</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets with definite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite lived intangible assets gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052289058640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets and goodwill - Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill beginning of period</a></td>
<td class="nump">$ 36,558<span></span>
</td>
<td class="nump">$ 36,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">8,209<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill, related to divestitures</a></td>
<td class="num">(56)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/other</a></td>
<td class="num">(511)<span></span>
</td>
<td class="nump">511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill end of period</a></td>
<td class="nump">44,200<span></span>
</td>
<td class="nump">36,558<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember', window );">Innovative Medicine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill beginning of period</a></td>
<td class="nump">10,407<span></span>
</td>
<td class="nump">10,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">640<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill, related to divestitures</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/other</a></td>
<td class="num">(355)<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill end of period</a></td>
<td class="nump">10,692<span></span>
</td>
<td class="nump">10,407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember', window );">MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill beginning of period</a></td>
<td class="nump">26,151<span></span>
</td>
<td class="nump">25,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">7,569<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill, related to divestitures</a></td>
<td class="num">(56)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/other</a></td>
<td class="num">(156)<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill end of period</a></td>
<td class="nump">$ 33,508<span></span>
</td>
<td class="nump">$ 26,151<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052284668944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets and goodwill - Narrative (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Dec. 22, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of amortizable intangible assets</a></td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember', window );">Patents And Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets useful life</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Customer relationships and other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets useful life</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052282337488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible assets and goodwill - Estimated Amortization of Intangible Assets (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 29, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">3,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">2,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">2,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029</a></td>
<td class="nump">$ 2,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052290111840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 17, 2024</div></th>
<th class="th"><div>May 15, 2024</div></th>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax', window );">Deferred net losses (gains) on derivatives included in accumulated other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss', window );">Description of reclassification of cash flow hedge gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">next 12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge', window );">Maximum length of time for hedging transaction exposure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommercialPaper', window );">Proceeds from issuance of commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DebtForEquityExchangeSharesExchanged', window );">Debt for equity exchange, shares exchanged (in shares)</a></td>
<td class="nump">182,329,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DebtForEquityExchangeLossOnSharesExchanged', window );">Loss on shares exchanged</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,100<span></span>
</td>
<td class="nump">42,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,500<span></span>
</td>
<td class="nump">39,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities | Equity Investments without readily determinable value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityFairValueAdjustmentImpairmentLoss', window );">Equity, fair value adjustment, impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(171)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityFairValueAdjustmentChangeinObservablePrices', window );">Equity, fair value adjustment, change in observable prices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (26)<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DebtForEquityExchangeLossOnSharesExchanged">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt For Equity Exchange, Loss On Shares Exchanged</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DebtForEquityExchangeLossOnSharesExchanged</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DebtForEquityExchangeSharesExchanged">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt For Equity Exchange, Shares Exchanged</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DebtForEquityExchangeSharesExchanged</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityFairValueAdjustmentChangeinObservablePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity, Fair Value Adjustment, Change in Observable Prices</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityFairValueAdjustmentChangeinObservablePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityFairValueAdjustmentImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity, Fair Value Adjustment, Impairment Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityFairValueAdjustmentImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAlreadyPostedAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4H<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAlreadyPostedAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the transactions or other events that will result in the reclassification into earnings of gains or losses reported in accumulated other comprehensive income. May include the time period over which gains or losses will be reclassified to earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum period of hedging exposure to variability in future cash flows for forecasted transaction of foreign currency cash flow hedge, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transaction for payment of variable interest on existing financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 30<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowing by issuing commercial paper.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052287553968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements - Summary of Derivative Activity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">$ 862<span></span>
</td>
<td class="nump">$ 569<span></span>
</td>
<td class="nump">$ 348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="num">(511)<span></span>
</td>
<td class="nump">422<span></span>
</td>
<td class="nump">$ 454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Sales | Interest Rate Swap | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Sales | Cross currency interest rate swaps contracts: | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Sales | Cross currency interest rate swaps contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Sales | Forward foreign exchange contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="num">(7)<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Products Sold | Interest Rate Swap | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Products Sold | Cross currency interest rate swaps contracts: | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Products Sold | Cross currency interest rate swaps contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Products Sold | Forward foreign exchange contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">426<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="num">(156)<span></span>
</td>
<td class="nump">447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D Expense | Interest Rate Swap | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D Expense | Cross currency interest rate swaps contracts: | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D Expense | Cross currency interest rate swaps contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D Expense | Forward foreign exchange contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">33<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">80<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember', window );">Interest (Income) Expense | Interest Rate Swap | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="num">(64)<span></span>
</td>
<td class="num">(168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember', window );">Interest (Income) Expense | Cross currency interest rate swaps contracts: | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember', window );">Interest (Income) Expense | Cross currency interest rate swaps contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="num">(597)<span></span>
</td>
<td class="num">(156)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember', window );">Interest (Income) Expense | Forward foreign exchange contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other (Income) Expense | Interest Rate Swap | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other (Income) Expense | Cross currency interest rate swaps contracts: | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other (Income) Expense | Cross currency interest rate swaps contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other (Income) Expense | Forward foreign exchange contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -SubTopic 20<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480627/815-20-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480627/815-20-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052291038032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Carrying Amount of the Hedged Liability</a></td>
<td class="nump">$ 4,564<span></span>
</td>
<td class="nump">$ 6,037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember', window );">Long-term Debt | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Carrying Amount of the Hedged Liability</a></td>
<td class="nump">7,935<span></span>
</td>
<td class="nump">8,862<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability</a></td>
<td class="num">$ (1,132)<span></span>
</td>
<td class="num">$ (1,216)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4EE<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052287812128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Other (income) expense, net<span></span>
</td>
<td class="text">Other (income) expense, net<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts: | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain/(Loss) Recognized In Income on Derivative</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="num">$ (60)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052290572224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements - Schedule of Effect of Net Investment Hedges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Gain/(Loss) Recognized In Accumulated OCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 282<span></span>
</td>
<td class="num">$ (131)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross currency interest rate swaps contracts:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Gain/(Loss) Recognized In Accumulated OCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 955<span></span>
</td>
<td class="nump">$ 642<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other (Income) Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Gain/(Loss) Reclassified from Accumulated OCI Into Income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other (Income) Expense | Cross currency interest rate swaps contracts:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Gain/(Loss) Reclassified from Accumulated OCI Into Income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480627/815-20-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052291246448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements - Summary of Activity Related to Equity Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 23, 2023</div></th>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,414<span></span>
</td>
<td class="nump">$ 14,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Equity securities, FV-NI, gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=jnj_KenvueIncMember', window );">Kenvue Inc. | Johnson &amp; Johnson</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ExchangeOfStockPercentageOwnershipAfterTransaction', window );">Percentage ownership after transaction</a></td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities | Equity Investments with readily determinable value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">451<span></span>
</td>
<td class="nump">4,473<span></span>
</td>
<td class="nump">$ 576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Equity, fair value adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(368)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod', window );">Equity investments, increase (decrease) from acquisition (sale) during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,005)<span></span>
</td>
<td class="nump">4,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">451<span></span>
</td>
<td class="nump">4,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities | Equity Investments without readily determinable value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity securities without readily determinable fair value, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">773<span></span>
</td>
<td class="nump">696<span></span>
</td>
<td class="nump">$ 613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Equity, fair value adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(197)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod', window );">Equity investments, increase (decrease) from acquisition (sale) during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 773<span></span>
</td>
<td class="nump">$ 696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityInvestmentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Investment [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityInvestmentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ExchangeOfStockPercentageOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange of Stock, Percentage Ownership After Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ExchangeOfStockPercentageOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=jnj_KenvueIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=jnj_KenvueIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=jnj_JohnsonJohnsonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=jnj_JohnsonJohnsonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052286375360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jun. 20, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">$ 2,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">4,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity investments</a></td>
<td class="nump">451<span></span>
</td>
<td class="nump">$ 4,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">7,216<span></span>
</td>
<td class="nump">8,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent Consideration</a></td>
<td class="nump">1,217<span></span>
</td>
<td class="nump">1,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total Gross Assets</a></td>
<td class="nump">2,194<span></span>
</td>
<td class="nump">1,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossLiability', window );">Credit Support Agreements (CSA)</a></td>
<td class="num">$ (2,172)<span></span>
</td>
<td class="num">$ (1,575)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag', window );">Derivative Asset, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</a></td>
<td class="text">Total Net Asset<span></span>
</td>
<td class="text">Total Net Asset<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Total Net Asset</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total Gross Liabilities</a></td>
<td class="nump">4,564<span></span>
</td>
<td class="nump">6,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossAsset', window );">Credit Support Agreements (CSA)</a></td>
<td class="num">$ (4,412)<span></span>
</td>
<td class="num">$ (5,604)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag', window );">Derivative Liability, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</a></td>
<td class="text">Total Net Liabilities<span></span>
</td>
<td class="text">Total Net Liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total Net Liabilities</a></td>
<td class="nump">$ 152<span></span>
</td>
<td class="nump">$ 433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">1,092<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
<td class="nump">$ 533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue', window );">Changes in estimated fair value</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="num">(194)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Additions</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments/Other</a></td>
<td class="num">(75)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">1,217<span></span>
</td>
<td class="nump">1,092<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent Consideration</a></td>
<td class="nump">1,217<span></span>
</td>
<td class="nump">1,092<span></span>
</td>
<td class="nump">1,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember', window );">Abiomed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent Consideration</a></td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_ProteologixMember', window );">Proteologix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent Consideration</a></td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity investments</a></td>
<td class="nump">451<span></span>
</td>
<td class="nump">4,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">2,144<span></span>
</td>
<td class="nump">1,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">4,547<span></span>
</td>
<td class="nump">5,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">7,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent Consideration</a></td>
<td class="nump">1,217<span></span>
</td>
<td class="nump">1,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">660<span></span>
</td>
<td class="nump">539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">794<span></span>
</td>
<td class="nump">624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate swaps contracts:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">1,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">3,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate swaps contracts: | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate swaps contracts: | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">1,484<span></span>
</td>
<td class="nump">988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">3,753<span></span>
</td>
<td class="nump">$ 5,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate swaps contracts: | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Asset, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Liability, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 20<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -SubTopic 20<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 30: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentDetailAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentDetailAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueGrossAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 20<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -SubTopic 20<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueGrossAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all foreign currency derivative assets not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all foreign currency derivative liabilities not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_ProteologixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_ProteologixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052296682480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Schedule of Long-term Debt Instruments (Details)<br> &#8364; in Millions, &#163; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 29, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 29, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 32,400<span></span>
</td>
<td class="nump">$ 27,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.36%<span></span>
</td>
<td class="nump">2.98%<span></span>
</td>
<td class="nump">3.36%<span></span>
</td>
<td class="nump">2.98%<span></span>
</td>
<td class="nump">2.98%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less current portion</a></td>
<td class="nump">$ 1,749<span></span>
</td>
<td class="nump">$ 1,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt</a></td>
<td class="nump">30,651<span></span>
</td>
<td class="nump">25,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ExcessOfCarryingValueOverFairValueOfDebt', window );">Excess of carrying value over fair value of debt</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ExcessOfFairValueOverCarryingValueOfDebt', window );">Excess of fair value over carrying value of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes due 2024 (750MM Euro 1.1090)(3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.68%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.68%<span></span>
</td>
<td class="nump">0.68%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate, translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1090<span></span>
</td>
<td class="nump">1.1090<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member', window );">5.50%&#160;Notes due 2024 (500MM GBP 1.2756)(3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate, translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2756<span></span>
</td>
<td class="nump">1.2756<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member', window );">2.625% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.63%<span></span>
</td>
<td class="nump">2.63%<span></span>
</td>
<td class="nump">2.63%<span></span>
</td>
<td class="nump">2.63%<span></span>
</td>
<td class="nump">2.63%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A055NotesDue2025Member', window );">0.55% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 999<span></span>
</td>
<td class="nump">$ 950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.57%<span></span>
</td>
<td class="nump">0.57%<span></span>
</td>
<td class="nump">0.57%<span></span>
</td>
<td class="nump">0.57%<span></span>
</td>
<td class="nump">0.57%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member', window );">2.46% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,999<span></span>
</td>
<td class="nump">$ 1,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.47%<span></span>
</td>
<td class="nump">2.47%<span></span>
</td>
<td class="nump">2.47%<span></span>
</td>
<td class="nump">2.47%<span></span>
</td>
<td class="nump">2.47%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member', window );">2.95% Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 927<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.96%<span></span>
</td>
<td class="nump">2.96%<span></span>
</td>
<td class="nump">2.96%<span></span>
</td>
<td class="nump">2.96%<span></span>
</td>
<td class="nump">2.96%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member', window );">0.95% Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,458<span></span>
</td>
<td class="nump">$ 1,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.96%<span></span>
</td>
<td class="nump">0.96%<span></span>
</td>
<td class="nump">0.96%<span></span>
</td>
<td class="nump">0.96%<span></span>
</td>
<td class="nump">0.96%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes due 2028&#8232;(750MM Euro 1.0401)(2)/(750MM Euro 1.1090)(3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 777<span></span>
</td>
<td class="nump">$ 828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">1.21%<span></span>
</td>
<td class="nump">1.21%<span></span>
</td>
<td class="nump">1.21%<span></span>
</td>
<td class="nump">1.21%<span></span>
</td>
<td class="nump">1.21%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate, translation</a></td>
<td class="nump">1.0401<span></span>
</td>
<td class="nump">1.1090<span></span>
</td>
<td class="nump">1.0401<span></span>
</td>
<td class="nump">1.1090<span></span>
</td>
<td class="nump">1.1090<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member', window );">2.90%&#160;Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,498<span></span>
</td>
<td class="nump">$ 1,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.91%<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member', window );">6.95%&#160;Notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 298<span></span>
</td>
<td class="nump">$ 298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">7.14%<span></span>
</td>
<td class="nump">7.14%<span></span>
</td>
<td class="nump">7.14%<span></span>
</td>
<td class="nump">7.14%<span></span>
</td>
<td class="nump">7.14%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">6.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.80DebenturesDue2029Member', window );">4.80% Debentures due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,146<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">4.83%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">4.83%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A130NotesDue2030Member', window );">1.30% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,646<span></span>
</td>
<td class="nump">$ 1,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.90DebenturesDue2031Member', window );">4.90% Debentures due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,145<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">4.92%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">4.92%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.20DebenturesDue2032Member', window );">3.20% Debentures due 2032</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 725<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.21%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">3.21%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate, translation</a></td>
<td class="nump">1.0401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member', window );">4.95%&#160;Debentures due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 499<span></span>
</td>
<td class="nump">$ 499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member', window );">4.375% Notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 854<span></span>
</td>
<td class="nump">$ 854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">4.24%<span></span>
</td>
<td class="nump">4.24%<span></span>
</td>
<td class="nump">4.24%<span></span>
</td>
<td class="nump">4.24%<span></span>
</td>
<td class="nump">4.24%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.95DebenturesDue2034Member', window );">4.95% Debentures due 2034</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 846<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">4.96%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">4.96%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes due 2035&#8232;(1.5B Euro 1.0401)(2)/(1.5B Euro 1.1090)(3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,550<span></span>
</td>
<td class="nump">$ 1,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,500<span></span>
</td>
<td class="nump">&#8364; 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate, translation</a></td>
<td class="nump">1.0401<span></span>
</td>
<td class="nump">1.1090<span></span>
</td>
<td class="nump">1.0401<span></span>
</td>
<td class="nump">1.1090<span></span>
</td>
<td class="nump">1.1090<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.35DebenturesDue2036Member', window );">3.35% Debentures due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 827<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.37%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">3.37%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate, translation</a></td>
<td class="nump">1.0401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member', window );">3.587% Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 869<span></span>
</td>
<td class="nump">$ 864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.59%<span></span>
</td>
<td class="nump">3.59%<span></span>
</td>
<td class="nump">3.59%<span></span>
</td>
<td class="nump">3.59%<span></span>
</td>
<td class="nump">3.59%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.587%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.587%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member', window );">5.95%&#160;Notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 994<span></span>
</td>
<td class="nump">$ 994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">5.99%<span></span>
</td>
<td class="nump">5.99%<span></span>
</td>
<td class="nump">5.99%<span></span>
</td>
<td class="nump">5.99%<span></span>
</td>
<td class="nump">5.99%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member', window );">3.625% Notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,358<span></span>
</td>
<td class="nump">$ 1,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.64%<span></span>
</td>
<td class="nump">3.64%<span></span>
</td>
<td class="nump">3.64%<span></span>
</td>
<td class="nump">3.64%<span></span>
</td>
<td class="nump">3.64%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member', window );">5.85%&#160;Debentures due 2038</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 697<span></span>
</td>
<td class="nump">$ 697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">5.85%<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member', window );">3.40%&#160;Notes due 2038</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 993<span></span>
</td>
<td class="nump">$ 993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.42%<span></span>
</td>
<td class="nump">3.42%<span></span>
</td>
<td class="nump">3.42%<span></span>
</td>
<td class="nump">3.42%<span></span>
</td>
<td class="nump">3.42%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member', window );">4.50%&#160;Debentures due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 541<span></span>
</td>
<td class="nump">$ 541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">4.63%<span></span>
</td>
<td class="nump">4.63%<span></span>
</td>
<td class="nump">4.63%<span></span>
</td>
<td class="nump">4.63%<span></span>
</td>
<td class="nump">4.63%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member', window );">2.10% Notes due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 845<span></span>
</td>
<td class="nump">$ 849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.14%<span></span>
</td>
<td class="nump">2.14%<span></span>
</td>
<td class="nump">2.14%<span></span>
</td>
<td class="nump">2.14%<span></span>
</td>
<td class="nump">2.14%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member', window );">4.85% Notes due 2041</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 297<span></span>
</td>
<td class="nump">$ 297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">4.89%<span></span>
</td>
<td class="nump">4.89%<span></span>
</td>
<td class="nump">4.89%<span></span>
</td>
<td class="nump">4.89%<span></span>
</td>
<td class="nump">4.89%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member', window );">4.50% Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 496<span></span>
</td>
<td class="nump">$ 496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">4.52%<span></span>
</td>
<td class="nump">4.52%<span></span>
</td>
<td class="nump">4.52%<span></span>
</td>
<td class="nump">4.52%<span></span>
</td>
<td class="nump">4.52%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.55DebenturesDue2044Member', window );">3.55% Debentures due 2044</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,030<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.58%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">3.58%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate, translation</a></td>
<td class="nump">1.0401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member', window );">3.73% Notes due 2046</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,978<span></span>
</td>
<td class="nump">$ 1,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.74%<span></span>
</td>
<td class="nump">3.74%<span></span>
</td>
<td class="nump">3.74%<span></span>
</td>
<td class="nump">3.74%<span></span>
</td>
<td class="nump">3.74%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member', window );">3.75% Notes due 2047</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 822<span></span>
</td>
<td class="nump">$ 832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.76%<span></span>
</td>
<td class="nump">3.76%<span></span>
</td>
<td class="nump">3.76%<span></span>
</td>
<td class="nump">3.76%<span></span>
</td>
<td class="nump">3.76%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member', window );">3.500% Notes due 2048</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 744<span></span>
</td>
<td class="nump">$ 743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.52%<span></span>
</td>
<td class="nump">3.52%<span></span>
</td>
<td class="nump">3.52%<span></span>
</td>
<td class="nump">3.52%<span></span>
</td>
<td class="nump">3.52%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member', window );">2.250% Notes due 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 808<span></span>
</td>
<td class="nump">$ 826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.29%<span></span>
</td>
<td class="nump">2.29%<span></span>
</td>
<td class="nump">2.29%<span></span>
</td>
<td class="nump">2.29%<span></span>
</td>
<td class="nump">2.29%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.25DebenturesDue2054Member', window );">5.25% Debentures due 2054</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 843<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">5.26%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">5.26%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member', window );">2.450% Notes due 2060</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,058<span></span>
</td>
<td class="nump">$ 1,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.49%<span></span>
</td>
<td class="nump">2.49%<span></span>
</td>
<td class="nump">2.49%<span></span>
</td>
<td class="nump">2.49%<span></span>
</td>
<td class="nump">2.49%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_OtherDebtSecuritiesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ExcessOfCarryingValueOverFairValueOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Excess Of Carrying Value Over Fair Value Of Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ExcessOfCarryingValueOverFairValueOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ExcessOfFairValueOverCarryingValueOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Excess of fair value over carrying value of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ExcessOfFairValueOverCarryingValueOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479424/830-30-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A055NotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A055NotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.80DebenturesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.80DebenturesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A130NotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A130NotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.90DebenturesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.90DebenturesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.20DebenturesDue2032Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.20DebenturesDue2032Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.95DebenturesDue2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.95DebenturesDue2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.35DebenturesDue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.35DebenturesDue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.55DebenturesDue2044Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.55DebenturesDue2044Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.25DebenturesDue2054Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.25DebenturesDue2054Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_OtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_OtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052282392544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Borrowing capacity under credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term borrowings and the current portion of long-term debt</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermCommercialPaperCurrent', window );">Borrowed under the commercial paper program</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Loans and notes payable</a></td>
<td class="nump">5,983<span></span>
</td>
<td class="nump">3,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Loans and notes payable</a></td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Debt, weighted average interest rate</a></td>
<td class="nump">4.46%<span></span>
</td>
<td class="nump">5.37%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">2 months<span></span>
</td>
<td class="text">2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermCommercialPaperCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the current portion of long-term unsecured obligations issued by corporations and other borrowers to investors (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermCommercialPaperCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052378492960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings - Aggregate Maturities of Long Term Obligations (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 29, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Aggregate maturities of long-term obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 1,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2026</a></td>
<td class="nump">1,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2027</a></td>
<td class="nump">2,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2028</a></td>
<td class="nump">2,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2029</a></td>
<td class="nump">1,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">After 2029</a></td>
<td class="nump">$ 22,548<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052284158256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Provision for Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Currently payable:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">U.S. taxes</a></td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="nump">$ 2,705<span></span>
</td>
<td class="nump">$ 2,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">International taxes</a></td>
<td class="nump">2,604<span></span>
</td>
<td class="nump">3,090<span></span>
</td>
<td class="nump">2,295<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total currently payable</a></td>
<td class="nump">4,804<span></span>
</td>
<td class="nump">5,795<span></span>
</td>
<td class="nump">4,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">U.S. taxes</a></td>
<td class="num">(2,539)<span></span>
</td>
<td class="num">(3,440)<span></span>
</td>
<td class="num">(1,990)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">International taxes</a></td>
<td class="nump">356<span></span>
</td>
<td class="num">(619)<span></span>
</td>
<td class="nump">410<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations', window );">Total deferred</a></td>
<td class="num">(2,183)<span></span>
</td>
<td class="num">(4,059)<span></span>
</td>
<td class="num">(1,580)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for taxes on income</a></td>
<td class="nump">$ 2,621<span></span>
</td>
<td class="nump">$ 1,736<span></span>
</td>
<td class="nump">$ 2,989<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Income Tax Expense (Benefit), Net Of Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052290483440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract', window );"><strong>Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S.&#160;</a></td>
<td class="num">$ (458)<span></span>
</td>
<td class="num">$ (2,033)<span></span>
</td>
<td class="nump">$ 4,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">International</a></td>
<td class="nump">17,145<span></span>
</td>
<td class="nump">17,095<span></span>
</td>
<td class="nump">14,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">$ 16,687<span></span>
</td>
<td class="nump">$ 15,062<span></span>
</td>
<td class="nump">$ 19,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Tax rates:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">International operations</a></td>
<td class="num">(5.20%)<span></span>
</td>
<td class="num">(8.10%)<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation', window );">U.S. tax settlements</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome', window );">U.S. taxes on international income</a></td>
<td class="num">(2.60%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">U.S. state taxes</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Tax benefits on share-based compensation</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">All other</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Rate</a></td>
<td class="nump">15.70%<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
<td class="nump">15.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Comparison of income tax expense at the Statutory rate and Company's tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Consumer Health Separation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation related to domestic tax on international income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052288435216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent', window );">Effective income tax rate reconciliation, increase (decrease), percent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="num">(3.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsForeign', window );">Decrease in foreign tax credits</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign', window );">Decrease in foreign tax credits, percent</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization', window );">Deferred tax assets, tax basis increase of certain assets due to reorganization</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount', window );">Effective income tax rate reconciliation, GILTI, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI', window );">Increase (decrease) in deferred tax liabilities, global intangible low-taxed income (GILTI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">2,485<span></span>
</td>
<td class="nump">2,020<span></span>
</td>
<td class="nump">2,485<span></span>
</td>
<td class="nump">$ 3,716<span></span>
</td>
<td class="nump">$ 3,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense', window );">Unrecognized tax benefits, interest on income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Unrecognized tax benefits, interest on income taxes accrued</a></td>
<td class="nump">$ 264<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Unrecognized tax benefits, period increase (decrease)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent', window );">Effective tax rate reconciliation, net increase (decrease) in tax rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_TalcMember', window );">Talc | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements', window );">Effective income tax rate reconciliation, tax settlement, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Basis Increase of Certain Assets due to Reorganization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, Net Increase (Decrease) In Tax Rate, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deferred Tax Liabilities, Global Intangible Low-Taxed Income (GILTI)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense accrued for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_TalcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_TalcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052288815584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income taxes - Temporary Differences and Carryforwards (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits', window );">Employee related obligations</a></td>
<td class="nump">$ 372<span></span>
</td>
<td class="nump">$ 586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">717<span></span>
</td>
<td class="nump">686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized', window );">R&amp;D capitalized for tax</a></td>
<td class="nump">4,398<span></span>
</td>
<td class="nump">3,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Reserves&#160;&amp; liabilities</a></td>
<td class="nump">4,444<span></span>
</td>
<td class="nump">3,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory related</a></td>
<td class="nump">371<span></span>
</td>
<td class="nump">359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">2,298<span></span>
</td>
<td class="nump">2,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DeferredTaxAssetsUndistributedForeignEarnings', window );">Undistributed foreign earnings</a></td>
<td class="nump">1,931<span></span>
</td>
<td class="nump">1,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Miscellaneous international</a></td>
<td class="nump">1,212<span></span>
</td>
<td class="nump">831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DeferredTaxAssetsOtherDomestic', window );">Miscellaneous U.S.&#160;</a></td>
<td class="nump">1,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Income reported for tax purposes</a></td>
<td class="nump">16,826<span></span>
</td>
<td class="nump">13,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowances</a></td>
<td class="num">(1,638)<span></span>
</td>
<td class="num">(1,149)<span></span>
</td>
<td class="num">$ (775)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred income taxes net of valuation allowances</a></td>
<td class="nump">15,188<span></span>
</td>
<td class="nump">12,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation of property, plant and equipment</a></td>
<td class="num">(833)<span></span>
</td>
<td class="num">(902)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Goodwill and intangibles</a></td>
<td class="num">(3,261)<span></span>
</td>
<td class="num">(1,252)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings', window );">Undistributed foreign earnings</a></td>
<td class="num">(1,492)<span></span>
</td>
<td class="num">(1,695)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome', window );">Global intangible low-taxed income</a></td>
<td class="num">(1,589)<span></span>
</td>
<td class="num">(2,731)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DeferredTaxLiabilitiesOtherDomestic', window );">Miscellaneous U.S.&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred income taxes net of valuation allowances</a></td>
<td class="num">$ (7,175)<span></span>
</td>
<td class="num">$ (6,584)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets international research and development capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DeferredTaxAssetsOtherDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets other domestic.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DeferredTaxAssetsOtherDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DeferredTaxAssetsUndistributedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Undistributed Foreign Earnings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DeferredTaxAssetsUndistributedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DeferredTaxLiabilitiesOtherDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Other Domestic</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DeferredTaxLiabilitiesOtherDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liability, Global Intangible Low-Taxed Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052414794128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Valuation Allowance Activity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ValuationAllowanceRollForward', window );"><strong>Valuation Allowance [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Beginning of year</a></td>
<td class="nump">$ 1,149<span></span>
</td>
<td class="nump">$ 775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ValuationAllowanceDeferredTaxAssetsProvision', window );">Provision</a></td>
<td class="nump">451<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ValuationAllowanceDeferredTaxAssetsUtilization', window );">Utilization</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(116)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslation', window );">Foreign currency translation</a></td>
<td class="num">(46)<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ValuationAllowanceDeferredTaxAssetsAcquisitionsDispositions', window );">Net acquisitions / (dispositions/liquidations)</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">End of year</a></td>
<td class="nump">$ 1,638<span></span>
</td>
<td class="nump">$ 1,149<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Asset, Foreign Currency Translation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ValuationAllowanceDeferredTaxAssetsAcquisitionsDispositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Assets, Acquisitions (Dispositions)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ValuationAllowanceDeferredTaxAssetsAcquisitionsDispositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ValuationAllowanceDeferredTaxAssetsProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Assets, Provision</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ValuationAllowanceDeferredTaxAssetsProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ValuationAllowanceDeferredTaxAssetsUtilization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Assets, Utilization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ValuationAllowanceDeferredTaxAssetsUtilization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ValuationAllowanceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ValuationAllowanceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052284113600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Summary of unrecognized tax benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning of year</a></td>
<td class="nump">$ 2,485<span></span>
</td>
<td class="nump">$ 3,716<span></span>
</td>
<td class="nump">$ 3,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to current year tax positions</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="nump">523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases related to prior period tax positions</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decreases related to prior period tax positions</a></td>
<td class="num">(147)<span></span>
</td>
<td class="num">(781)<span></span>
</td>
<td class="num">(148)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="num">(583)<span></span>
</td>
<td class="num">(880)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapse of statute of limitations</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">End of year</a></td>
<td class="nump">$ 2,020<span></span>
</td>
<td class="nump">$ 2,485<span></span>
</td>
<td class="nump">$ 3,716<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052288810160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Employee related obligations - Employee Related Obligations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Employee-related Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities', window );">Pension benefits</a></td>
<td class="nump">$ 2,968<span></span>
</td>
<td class="nump">$ 3,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent', window );">Postretirement benefits</a></td>
<td class="nump">1,920<span></span>
</td>
<td class="nump">1,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent', window );">Postemployment benefits</a></td>
<td class="nump">2,910<span></span>
</td>
<td class="nump">2,527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent', window );">Deferred compensation</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EmployeeObligations', window );">Total employee obligations</a></td>
<td class="nump">7,847<span></span>
</td>
<td class="nump">7,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Less current benefits payable</a></td>
<td class="nump">592<span></span>
</td>
<td class="nump">538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Employee related obligations&#160;&#8212; non-current</a></td>
<td class="nump">$ 7,255<span></span>
</td>
<td class="nump">$ 7,149<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EmployeeObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total employee obligations current and non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EmployeeObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension plan. Excludes other postretirement benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit other postretirement plan. Excludes pension plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount as of the balance sheet date of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 712<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481179/712-10-25-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 712<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481179/712-10-25-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052291510736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Employee related obligations - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Compensation Related Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Prepaid employee related obligations</a></td>
<td class="nump">$ 6,046<span></span>
</td>
<td class="nump">$ 4,992<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052287483728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and other benefit plans - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets', window );">Percentage of corridor of greater of market value of assets</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">Accumulated benefit obligation unfunded plans</a></td>
<td class="nump">$ 5,800<span></span>
</td>
<td class="nump">$ 5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation', window );">Projected benefit obligation, unfunded plans</a></td>
<td class="nump">6,100<span></span>
</td>
<td class="nump">6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Plan with accumulated benefit obligation in excess of plan assets, plan assets</a></td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets', window );">Fair value of company's common stock directly held in plan assets</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Retirement Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">33,395<span></span>
</td>
<td class="nump">33,607<span></span>
</td>
<td class="nump">$ 31,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contribution to pension plans</a></td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contribution to pension plans</a></td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=jnj_CommingledFundsMember', window );">Commingled funds | Level 2 | Other Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Retirement Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EmployeeCompensationPeriod', window );">Retirement plan benefits employee compensation period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EmployeeCompensationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Compensation Period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EmployeeCompensationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of company's common stock directly held in plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of corridor of greater of market value of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=jnj_CommingledFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=jnj_CommingledFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052283355888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and other benefit plans - Components of Net Periodic Benefit Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Retirement Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 948<span></span>
</td>
<td class="nump">$ 893<span></span>
</td>
<td class="nump">$ 1,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">1,402<span></span>
</td>
<td class="nump">1,437<span></span>
</td>
<td class="nump">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(2,560)<span></span>
</td>
<td class="num">(2,716)<span></span>
</td>
<td class="num">(2,756)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost</a></td>
<td class="num">(184)<span></span>
</td>
<td class="num">(184)<span></span>
</td>
<td class="num">(184)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial losses (gains)</a></td>
<td class="nump">174<span></span>
</td>
<td class="num">(199)<span></span>
</td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1', window );">Curtailments and settlements</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost (credit)</a></td>
<td class="num">(222)<span></span>
</td>
<td class="num">(676)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">209<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial losses (gains)</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1', window );">Curtailments and settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost (credit)</a></td>
<td class="nump">$ 530<span></span>
</td>
<td class="nump">$ 487<span></span>
</td>
<td class="nump">$ 533<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052388995328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and other benefit plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Retirement Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Net Periodic Benefit Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Service cost discount rate</a></td>
<td class="nump">4.39%<span></span>
</td>
<td class="nump">4.85%<span></span>
</td>
<td class="nump">2.46%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate', window );">Interest cost discount rate</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of increase in compensation levels</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.71%<span></span>
</td>
<td class="nump">4.02%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected long-term rate of return on plan assets</a></td>
<td class="nump">7.25%<span></span>
</td>
<td class="nump">7.21%<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.58%<span></span>
</td>
<td class="nump">5.01%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Rate of increase in compensation levels</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.69%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Net Periodic Benefit Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Service cost discount rate</a></td>
<td class="nump">5.09%<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
<td class="nump">2.59%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate', window );">Interest cost discount rate</a></td>
<td class="nump">5.12%<span></span>
</td>
<td class="nump">5.43%<span></span>
</td>
<td class="nump">2.64%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of increase in compensation levels</a></td>
<td class="nump">4.22%<span></span>
</td>
<td class="nump">4.22%<span></span>
</td>
<td class="nump">4.21%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">5.54%<span></span>
</td>
<td class="nump">5.11%<span></span>
</td>
<td class="nump">5.42%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Rate of increase in compensation levels</a></td>
<td class="nump">4.22%<span></span>
</td>
<td class="nump">4.22%<span></span>
</td>
<td class="nump">4.21%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052290191632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and other benefit plans - Assumed Health Care Cost Trend Rates (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract', window );"><strong>Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear', window );">Healthcare cost trend rate assumed for next year</a></td>
<td class="nump">9.33%<span></span>
</td>
<td class="nump">13.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1', window );">Rate to which the cost trend rate is assumed to decline (ultimate trend)</a></td>
<td class="nump">4.02%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate', window );">Year the rate reaches the ultimate trend rate</a></td>
<td class="text">2048<span></span>
</td>
<td class="text">2048<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assumed rate, for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ultimate trend rate for health care cost for defined benefit postretirement plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Year ultimate health care cost trend rate is expected to be reached, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052286430704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and other benefit plans - Schedule of Net Funded Status (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts Recognized in the Company&#8217;s Balance Sheet consist of the&#160;following:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Non-current assets</a></td>
<td class="nump">$ 6,046<span></span>
</td>
<td class="nump">$ 4,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(592)<span></span>
</td>
<td class="num">(538)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Non-current liabilities</a></td>
<td class="num">(7,255)<span></span>
</td>
<td class="num">(7,149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract', window );"><strong>Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract', window );">Transferred to group annuity contract</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Retirement Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation - beginning of year</a></td>
<td class="nump">31,744<span></span>
</td>
<td class="nump">29,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">948<span></span>
</td>
<td class="nump">893<span></span>
</td>
<td class="nump">$ 1,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">1,402<span></span>
</td>
<td class="nump">1,437<span></span>
</td>
<td class="nump">908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant', window );">Plan participant contributions</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Amendments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gains) losses</a></td>
<td class="num">(1,245)<span></span>
</td>
<td class="nump">2,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease', window );">Divestitures &amp; acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(352)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_CurtailmentsAndSettlementsAndRestructuring', window );">Curtailments, settlements&#160;&amp; restructuring</a></td>
<td class="num">(121)<span></span>
</td>
<td class="num">(238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid from plan</a></td>
<td class="num">(1,801)<span></span>
</td>
<td class="num">(2,122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Effect of exchange rates</a></td>
<td class="num">(685)<span></span>
</td>
<td class="nump">601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation - end of year</a></td>
<td class="nump">30,317<span></span>
</td>
<td class="nump">31,744<span></span>
</td>
<td class="nump">29,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value&#160;&#8212; beginning of year</a></td>
<td class="nump">33,607<span></span>
</td>
<td class="nump">31,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">2,113<span></span>
</td>
<td class="nump">3,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant', window );">Plan participant contributions</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="num">(114)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease', window );">Divestitures &amp; acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(509)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid from plan assets</a></td>
<td class="num">(1,801)<span></span>
</td>
<td class="num">(2,122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Effect of exchange rates</a></td>
<td class="num">(714)<span></span>
</td>
<td class="nump">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value&#160;- End of year</a></td>
<td class="nump">33,395<span></span>
</td>
<td class="nump">33,607<span></span>
</td>
<td class="nump">31,496<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status - end of year</a></td>
<td class="nump">3,078<span></span>
</td>
<td class="nump">1,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts Recognized in the Company&#8217;s Balance Sheet consist of the&#160;following:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Non-current assets</a></td>
<td class="nump">6,046<span></span>
</td>
<td class="nump">4,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(136)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Non-current liabilities</a></td>
<td class="num">(2,832)<span></span>
</td>
<td class="num">(3,010)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Total recognized in the consolidated balance sheet&#160;&#8212; end of year</a></td>
<td class="nump">3,078<span></span>
</td>
<td class="nump">1,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract', window );"><strong>Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Net actuarial loss</a></td>
<td class="nump">3,903<span></span>
</td>
<td class="nump">4,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Prior service cost (credit)</a></td>
<td class="num">(1,051)<span></span>
</td>
<td class="num">(1,236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax', window );">Unrecognized net transition obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax', window );">Total before tax effects</a></td>
<td class="nump">2,852<span></span>
</td>
<td class="nump">3,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated Benefit Obligation</a></td>
<td class="nump">28,883<span></span>
</td>
<td class="nump">30,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract', window );"><strong>Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost (credit)</a></td>
<td class="num">(222)<span></span>
</td>
<td class="num">(676)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Net actuarial (gain) loss</a></td>
<td class="num">(807)<span></span>
</td>
<td class="nump">711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax', window );">Amortization of net actuarial loss</a></td>
<td class="num">(172)<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Prior service cost (credit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Amortization of prior service (cost) credit</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EffectOfExchangeRates', window );">Effect of exchange rates</a></td>
<td class="num">(79)<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Total loss/(income) recognized in other comprehensive income, before tax</a></td>
<td class="num">(874)<span></span>
</td>
<td class="nump">1,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax', window );">Total recognized in net periodic benefit cost and other comprehensive&#160;income</a></td>
<td class="num">(1,096)<span></span>
</td>
<td class="nump">519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation - beginning of year</a></td>
<td class="nump">4,108<span></span>
</td>
<td class="nump">4,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">209<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant', window );">Plan participant contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Amendments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gains) losses</a></td>
<td class="nump">398<span></span>
</td>
<td class="nump">469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease', window );">Divestitures &amp; acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_CurtailmentsAndSettlementsAndRestructuring', window );">Curtailments, settlements&#160;&amp; restructuring</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(332)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid from plan</a></td>
<td class="num">(556)<span></span>
</td>
<td class="num">(702)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Effect of exchange rates</a></td>
<td class="num">(11)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation - end of year</a></td>
<td class="nump">4,425<span></span>
</td>
<td class="nump">4,108<span></span>
</td>
<td class="nump">4,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value&#160;&#8212; beginning of year</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">548<span></span>
</td>
<td class="nump">694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant', window );">Plan participant contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease', window );">Divestitures &amp; acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid from plan assets</a></td>
<td class="num">(556)<span></span>
</td>
<td class="num">(702)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Effect of exchange rates</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value&#160;- End of year</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status - end of year</a></td>
<td class="num">(4,332)<span></span>
</td>
<td class="num">(4,022)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts Recognized in the Company&#8217;s Balance Sheet consist of the&#160;following:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Non-current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(453)<span></span>
</td>
<td class="num">(416)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Non-current liabilities</a></td>
<td class="num">(3,879)<span></span>
</td>
<td class="num">(3,606)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Total recognized in the consolidated balance sheet&#160;&#8212; end of year</a></td>
<td class="num">(4,332)<span></span>
</td>
<td class="num">(4,022)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract', window );"><strong>Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Net actuarial loss</a></td>
<td class="nump">691<span></span>
</td>
<td class="nump">354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Prior service cost (credit)</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax', window );">Unrecognized net transition obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax', window );">Total before tax effects</a></td>
<td class="nump">687<span></span>
</td>
<td class="nump">348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract', window );"><strong>Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost (credit)</a></td>
<td class="nump">530<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="nump">$ 533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Net actuarial (gain) loss</a></td>
<td class="nump">389<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax', window );">Amortization of net actuarial loss</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Prior service cost (credit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Amortization of prior service (cost) credit</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EffectOfExchangeRates', window );">Effect of exchange rates</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Total loss/(income) recognized in other comprehensive income, before tax</a></td>
<td class="nump">339<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax', window );">Total recognized in net periodic benefit cost and other comprehensive&#160;income</a></td>
<td class="nump">$ 869<span></span>
</td>
<td class="nump">$ 603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CurtailmentsAndSettlementsAndRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase or decrease related to curtailments, settlements and restructuring.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CurtailmentsAndSettlementsAndRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Benefit Obligation, Business Combination and Divestiture, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Benefit Obligation, Transferred To Group Annuity Contract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Plan Assets, Business Combination and Divestiture, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectOfExchangeRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect Of Exchange Rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectOfExchangeRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized in net periodic benefit cost (credit) and other comprehensive (income) loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive income (loss) for transition asset (obligation) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received by defined benefit plan from participant which increase benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAmendments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAmendments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received by defined benefit plan from participant which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(8)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052283226656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pensions and other benefit plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jnj_QualifiedPlansMember', window );">Qualified Plans | U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">$ 22,250<span></span>
</td>
<td class="nump">$ 22,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected Benefit Obligation</a></td>
<td class="nump">18,146<span></span>
</td>
<td class="nump">19,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated Benefit Obligation</a></td>
<td class="nump">17,726<span></span>
</td>
<td class="nump">18,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Projected Benefit Obligation</a></td>
<td class="nump">4,104<span></span>
</td>
<td class="nump">3,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanOverUnderFundedStatusABO', window );">Accumulated Benefit Obligation</a></td>
<td class="nump">4,524<span></span>
</td>
<td class="nump">3,741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jnj_NonQualifiedPlansMember', window );">Non-Qualified Plans | U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected Benefit Obligation</a></td>
<td class="nump">1,990<span></span>
</td>
<td class="nump">2,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated Benefit Obligation</a></td>
<td class="nump">1,949<span></span>
</td>
<td class="nump">1,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Projected Benefit Obligation</a></td>
<td class="num">(1,990)<span></span>
</td>
<td class="num">(2,037)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanOverUnderFundedStatusABO', window );">Accumulated Benefit Obligation</a></td>
<td class="num">(1,949)<span></span>
</td>
<td class="num">(1,982)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jnj_FundedPlansMember', window );">Funded Plans | International Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">11,145<span></span>
</td>
<td class="nump">11,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected Benefit Obligation</a></td>
<td class="nump">10,069<span></span>
</td>
<td class="nump">10,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated Benefit Obligation</a></td>
<td class="nump">9,115<span></span>
</td>
<td class="nump">9,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Projected Benefit Obligation</a></td>
<td class="nump">1,076<span></span>
</td>
<td class="nump">878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanOverUnderFundedStatusABO', window );">Accumulated Benefit Obligation</a></td>
<td class="nump">2,030<span></span>
</td>
<td class="nump">1,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jnj_UnfundedPlansMember', window );">Unfunded Plans | International Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected Benefit Obligation</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated Benefit Obligation</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Projected Benefit Obligation</a></td>
<td class="num">(112)<span></span>
</td>
<td class="num">(124)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanOverUnderFundedStatusABO', window );">Accumulated Benefit Obligation</a></td>
<td class="num">$ (93)<span></span>
</td>
<td class="num">$ (102)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanOverUnderFundedStatusABO">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan over (under) funded status ABO</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanOverUnderFundedStatusABO</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jnj_QualifiedPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jnj_QualifiedPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jnj_NonQualifiedPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jnj_NonQualifiedPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jnj_FundedPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jnj_FundedPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jnj_UnfundedPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jnj_UnfundedPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052287478624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pensions and other benefit plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 29, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Retirement plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2025</a></td>
<td class="nump">1,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2026</a></td>
<td class="nump">1,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2027</a></td>
<td class="nump">1,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2028</a></td>
<td class="nump">1,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2029-2033</a></td>
<td class="nump">10,401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other benefit plans&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2024</a></td>
<td class="nump">464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2025</a></td>
<td class="nump">478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2026</a></td>
<td class="nump">432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2027</a></td>
<td class="nump">445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2028</a></td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2029-2033</a></td>
<td class="nump">$ 2,537<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052283187920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pensions and other benefit plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 29, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne', window );">2024</a></td>
<td class="nump">$ 133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo', window );">2025</a></td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree', window );">2026</a></td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour', window );">2027</a></td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive', window );">2028</a></td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter', window );">2029-2033</a></td>
<td class="nump">$ 815<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan expected future benefit contribution in five fiscal years thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan expected future benefit contribution in year five.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan expected future benefit contribution in year four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan expected future benefit contribution in year one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan expected future benefit contribution in year three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan expected future benefit contribution in year two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052378580496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pensions and other benefit plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)<br></strong></div></th>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Percent of Plan Assets</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target Allocation</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Percent of Plan Assets</a></td>
<td class="nump">55.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target Allocation</a></td>
<td class="nump">54.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DebtSecuritiesMember', window );">Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Percent of Plan Assets</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target Allocation</a></td>
<td class="nump">46.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of actual investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052290167984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pensions and other benefit plans - Schedule of Defined Benefit Plans Disclosures (Details) - Retirement plans - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">$ 33,395<span></span>
</td>
<td class="nump">$ 33,607<span></span>
</td>
<td class="nump">$ 31,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">33,395<span></span>
</td>
<td class="nump">33,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets', window );">Investments Measured at Net Asset Value</a></td>
<td class="nump">10,277<span></span>
</td>
<td class="nump">9,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">7,144<span></span>
</td>
<td class="nump">7,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">15,809<span></span>
</td>
<td class="nump">15,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Short-term investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">511<span></span>
</td>
<td class="nump">841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Short-term investment funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Short-term investment funds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">511<span></span>
</td>
<td class="nump">829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Short-term investment funds | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">7,885<span></span>
</td>
<td class="nump">5,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government and agency securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government and agency securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">7,885<span></span>
</td>
<td class="nump">5,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government and agency securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Debt instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">2,321<span></span>
</td>
<td class="nump">3,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Debt instruments | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Debt instruments | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">2,321<span></span>
</td>
<td class="nump">3,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Debt instruments | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">7,144<span></span>
</td>
<td class="nump">7,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Equity securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">7,144<span></span>
</td>
<td class="nump">7,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Equity securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Equity securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commingled funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">11,231<span></span>
</td>
<td class="nump">11,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets', window );">Investments Measured at Net Asset Value</a></td>
<td class="nump">6,190<span></span>
</td>
<td class="nump">6,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commingled funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commingled funds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">5,004<span></span>
</td>
<td class="nump">4,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commingled funds | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">4,303<span></span>
</td>
<td class="nump">3,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets', window );">Investments Measured at Net Asset Value</a></td>
<td class="nump">4,087<span></span>
</td>
<td class="nump">3,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Other assets | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Other assets | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Other assets | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">$ 128<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Alternative Investments, Fair Value of Plan Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=jnj_ShortTermInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=jnj_ShortTermInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=jnj_CommingledFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=jnj_CommingledFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052288654016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Savings plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_SavingsPlanAbstract', window );"><strong>Savings Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Matching contributions</a></td>
<td class="nump">$ 282<span></span>
</td>
<td class="nump">$ 263<span></span>
</td>
<td class="nump">$ 257<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SavingsPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Savings Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SavingsPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052291243296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital and treasury stock - Changes in Treasury Stock (Details) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ChangesinTreasuryStockSharesOutstandingRollForward', window );"><strong>Changes in Treasury Stock Shares Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, beginning balance (shares)</a></td>
<td class="nump">712,765<span></span>
</td>
<td class="nump">506,246<span></span>
</td>
<td class="nump">490,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Employee compensation and stock option plans (shares)</a></td>
<td class="num">(15,027)<span></span>
</td>
<td class="num">(15,521)<span></span>
</td>
<td class="num">(20,007)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, ending balance (shares)</a></td>
<td class="nump">712,921<span></span>
</td>
<td class="nump">712,765<span></span>
</td>
<td class="nump">506,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ChangesInTreasuryStockRollForward', window );"><strong>Changes in treasury stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury Stock, Balance</a></td>
<td class="nump">$ 75,662<span></span>
</td>
<td class="nump">$ 41,694<span></span>
</td>
<td class="nump">$ 39,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Employee compensation and stock option plans</a></td>
<td class="num">(2,389)<span></span>
</td>
<td class="num">(2,529)<span></span>
</td>
<td class="num">(3,440)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="nump">2,407<span></span>
</td>
<td class="nump">5,054<span></span>
</td>
<td class="nump">6,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury Stock, Ending Balance</a></td>
<td class="nump">$ 75,680<span></span>
</td>
<td class="nump">$ 75,662<span></span>
</td>
<td class="nump">$ 41,694<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Stock Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ChangesinTreasuryStockSharesOutstandingRollForward', window );"><strong>Changes in Treasury Stock Shares Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, beginning balance (shares)</a></td>
<td class="nump">190,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock (shares)</a></td>
<td class="nump">15,183<span></span>
</td>
<td class="nump">31,085<span></span>
</td>
<td class="nump">35,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, ending balance (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ChangesInTreasuryStockRollForward', window );"><strong>Changes in treasury stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury Stock, Balance</a></td>
<td class="nump">$ 31,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="nump">2,407<span></span>
</td>
<td class="nump">$ 5,054<span></span>
</td>
<td class="nump">$ 6,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_TreasuryStockValueAcquiredCostMethodNetOfTax', window );">Repurchase of common stock</a></td>
<td class="nump">$ 2,407<span></span>
</td>
<td class="nump">5,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury Stock, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ChangesInTreasuryStockRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ChangesInTreasuryStockRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ChangesinTreasuryStockSharesOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in Treasury Stock Shares Outstanding [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ChangesinTreasuryStockSharesOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TreasuryStockValueAcquiredCostMethodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury Stock, Value, Acquired, Cost Method, Net Of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TreasuryStockValueAcquiredCostMethodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052291391136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital and treasury stock - Narrative (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Billions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2025</div></th>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Sep. 14, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,119,843<span></span>
</td>
<td class="nump">3,119,843<span></span>
</td>
<td class="nump">3,119,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Cash dividends paid (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.91<span></span>
</td>
<td class="nump">$ 4.70<span></span>
</td>
<td class="nump">$ 4.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividend (in dollars per share)</a></td>
<td class="nump">$ 1.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramAxis=jnj_December172018ShareRepurchaseProgramMember', window );">December 17, 2018 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ShareRepurchaseProgramAxis=jnj_December172018ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ShareRepurchaseProgramAxis=jnj_December172018ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052290111472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated other comprehensive income (loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="nump">$ 68,774<span></span>
</td>
<td class="nump">$ 76,804<span></span>
</td>
<td class="nump">$ 74,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="nump">786<span></span>
</td>
<td class="num">(4,741)<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="nump">71,490<span></span>
</td>
<td class="nump">68,774<span></span>
</td>
<td class="nump">76,804<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(10,149)<span></span>
</td>
<td class="num">(11,813)<span></span>
</td>
<td class="num">(10,017)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="nump">1,708<span></span>
</td>
<td class="num">(3,221)<span></span>
</td>
<td class="num">(1,796)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation', window );">Kenvue Separation/IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,885)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(8,441)<span></span>
</td>
<td class="num">(10,149)<span></span>
</td>
<td class="num">(11,813)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Gain/ (Loss) On Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Employee Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="num">(897)<span></span>
</td>
<td class="num">(2,702)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="nump">449<span></span>
</td>
<td class="num">(1,399)<span></span>
</td>
<td class="nump">1,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation', window );">Kenvue Separation/IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(296)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(1,551)<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="num">(897)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Gain/ (Loss) On Derivatives &amp; Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(377)<span></span>
</td>
<td class="num">(230)<span></span>
</td>
<td class="num">(336)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="num">(1,373)<span></span>
</td>
<td class="num">(147)<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(1,750)<span></span>
</td>
<td class="num">(377)<span></span>
</td>
<td class="num">(230)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(12,527)<span></span>
</td>
<td class="num">(12,967)<span></span>
</td>
<td class="num">(13,058)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="nump">786<span></span>
</td>
<td class="num">(4,741)<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation', window );">Kenvue Separation/IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,181)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">$ (11,741)<span></span>
</td>
<td class="num">$ (12,527)<span></span>
</td>
<td class="num">$ (12,967)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052378562784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>International currency translation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTranslationAbstract', window );"><strong>Foreign Currency Translation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction gain (loss), before tax</a></td>
<td class="num">$ (214)<span></span>
</td>
<td class="num">$ (366)<span></span>
</td>
<td class="num">$ (286)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTranslationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTranslationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052291247472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Reconciliation of basic net earnings per share to diluted net earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic net earnings per share from continuing operations (in dollars per share)</a></td>
<td class="nump">$ 5.84<span></span>
</td>
<td class="nump">$ 5.26<span></span>
</td>
<td class="nump">$ 6.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare', window );">Basic net earnings per share from discontinued operations (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8.62<span></span>
</td>
<td class="nump">0.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net earnings per share (in dollars per share)</a></td>
<td class="nump">$ 5.84<span></span>
</td>
<td class="nump">$ 13.88<span></span>
</td>
<td class="nump">$ 6.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Average shares outstanding&#160;&#8212; basic (in shares)</a></td>
<td class="nump">2,407,300,000<span></span>
</td>
<td class="nump">2,533,500,000<span></span>
</td>
<td class="nump">2,625,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Potential shares exercisable under stock option plans (in shares)</a></td>
<td class="nump">77,700,000<span></span>
</td>
<td class="nump">94,100,000<span></span>
</td>
<td class="nump">140,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod', window );">Less: shares repurchased under treasury stock method (in shares)</a></td>
<td class="num">(55,600,000)<span></span>
</td>
<td class="num">(67,200,000)<span></span>
</td>
<td class="num">(101,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Average shares outstanding - diluted (in shares)</a></td>
<td class="nump">2,429,400,000<span></span>
</td>
<td class="nump">2,560,400,000<span></span>
</td>
<td class="nump">2,663,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted net earnings per share from continuing operations (in dollars per share)</a></td>
<td class="nump">$ 5.79<span></span>
</td>
<td class="nump">$ 5.20<span></span>
</td>
<td class="nump">$ 6.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare', window );">Diluted net earnings per share from discontinuing operations (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8.52<span></span>
</td>
<td class="nump">0.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net earnings per share (in dollars per share)</a></td>
<td class="nump">$ 5.79<span></span>
</td>
<td class="nump">$ 13.72<span></span>
</td>
<td class="nump">$ 6.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">54.1<span></span>
</td>
<td class="nump">43.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052283996672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share - Narrative (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">54.1<span></span>
</td>
<td class="nump">43.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052289092400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common stock, stock option plans and stock compensation agreements - Narrative (Details)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 29, 2024 </div>
<div>USD ($) </div>
<div>StockBasedCompensationPlans </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_NumberOfStockBasedCompensationPlans', window );">Number of stock-based compensation plans | StockBasedCompensationPlans</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost charged for Long term incentive plan | $</a></td>
<td class="nump">$ 1,176<span></span>
</td>
<td class="nump">$ 1,087<span></span>
</td>
<td class="nump">$ 1,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Total income tax benefit recognized | $</a></td>
<td class="nump">251<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Exercise of options, tax benefit | $</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total compensation cost not yet recognized for option | $</a></td>
<td class="nump">$ 1,002<span></span>
</td>
<td class="nump">$ 907<span></span>
</td>
<td class="nump">$ 866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for total compensation cost not yet recognized</a></td>
<td class="text">1 year 9 months 21 days<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Average fair value of option granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 27.67<span></span>
</td>
<td class="nump">$ 27.85<span></span>
</td>
<td class="nump">$ 23.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised | $</a></td>
<td class="nump">$ 560<span></span>
</td>
<td class="nump">$ 729<span></span>
</td>
<td class="nump">$ 1,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Stock options outstanding (in shares) | shares</a></td>
<td class="nump">112,629<span></span>
</td>
<td class="nump">112,238<span></span>
</td>
<td class="nump">118,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Stock option average life</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock options exercisable (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,998<span></span>
</td>
<td class="nump">63,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Stock options average price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123.39<span></span>
</td>
<td class="nump">$ 113.06<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Average fair value of RSU's and PSU's granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 147.51<span></span>
</td>
<td class="nump">$ 152.63<span></span>
</td>
<td class="nump">$ 153.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair Value of RSU or PSU units settled | $</a></td>
<td class="nump">$ 833<span></span>
</td>
<td class="nump">$ 605<span></span>
</td>
<td class="nump">$ 591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Average fair value of RSU's and PSU's granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 133.76<span></span>
</td>
<td class="nump">$ 145.17<span></span>
</td>
<td class="nump">$ 170.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair Value of RSU or PSU units settled | $</a></td>
<td class="nump">$ 146<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramAxis=jnj_A2022LongTermIncentivePlanMember', window );">2022 Long-Term Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance under long-term incentive plan (in shares) | shares</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights', window );">Shares issued subject to stock options or stock appreciation rights (in shares) | shares</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards', window );">Shares subject to full value awards (in shares) | shares</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess', window );">Shares subject to full value award, excess (in shares) | shares</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants under long-term incentive plan | shares</a></td>
<td class="nump">111,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_NumberOfStockBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock-based compensation plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_NumberOfStockBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Full Value Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Full Value Awards, Excess</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Stock Options Or Stock Appreciation Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ShareRepurchaseProgramAxis=jnj_A2022LongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ShareRepurchaseProgramAxis=jnj_A2022LongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052289472880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common stock, stock option plans and stock compensation agreements - Schedule Valuation Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted average assumptions of fair value of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">4.15%<span></span>
</td>
<td class="nump">3.74%<span></span>
</td>
<td class="nump">1.98%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">17.85%<span></span>
</td>
<td class="nump">17.69%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052504199856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common stock, stock option plans and stock compensation agreements - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Outstanding Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding beginning of period (in shares)</a></td>
<td class="nump">112,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted (in shares)</a></td>
<td class="nump">13,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(10,771)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options canceled/forfeited (in shares)</a></td>
<td class="num">(2,755)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding end of period (in shares)</a></td>
<td class="nump">112,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options exercise price beginning of period (in dollars per share)</a></td>
<td class="nump">$ 139.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, average exercise price (in dollars per share)</a></td>
<td class="nump">157.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised, average exercise price (in dollars per share)</a></td>
<td class="nump">107.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options canceled/forfeited, average exercise price (in dollars per share)</a></td>
<td class="nump">162.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options exercise price end of period (in dollars per share)</a></td>
<td class="nump">$ 144.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value</a></td>
<td class="nump">$ 1,129<span></span>
</td>
<td class="nump">$ 2,239<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052288015248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common stock, stock option plans and stock compensation agreements - Summary of Options Outstanding (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract', window );"><strong>Stock options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options (in shares)</a></td>
<td class="nump">112,629<span></span>
</td>
<td class="nump">112,238<span></span>
</td>
<td class="nump">118,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, Average Life</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 144.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options (in shares)</a></td>
<td class="nump">74,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 135.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeOneMember', window );">$100.06 - $101.87</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract', window );"><strong>Stock options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Price Range, Minimum (in dollars per share)</a></td>
<td class="nump">100.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Price Range, Maximum (in dollars per share)</a></td>
<td class="nump">$ 101.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options (in shares)</a></td>
<td class="nump">13,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, Average Life</a></td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 101.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options (in shares)</a></td>
<td class="nump">13,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 101.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeTwoMember', window );">$115.67 - $129.51</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract', window );"><strong>Stock options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Price Range, Minimum (in dollars per share)</a></td>
<td class="nump">115.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Price Range, Maximum (in dollars per share)</a></td>
<td class="nump">$ 129.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options (in shares)</a></td>
<td class="nump">18,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, Average Life</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 122.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options (in shares)</a></td>
<td class="nump">18,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 122.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeThreeMember', window );">$131.94 - $151.41</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract', window );"><strong>Stock options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Price Range, Minimum (in dollars per share)</a></td>
<td class="nump">131.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Price Range, Maximum (in dollars per share)</a></td>
<td class="nump">$ 151.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options (in shares)</a></td>
<td class="nump">25,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, Average Life</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 142.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options (in shares)</a></td>
<td class="nump">25,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 142.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeFourMember', window );">$157.92 - $162.75</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract', window );"><strong>Stock options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Price Range, Minimum (in dollars per share)</a></td>
<td class="nump">157.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Price Range, Maximum (in dollars per share)</a></td>
<td class="nump">$ 162.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options (in shares)</a></td>
<td class="nump">26,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, Average Life</a></td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 160.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options (in shares)</a></td>
<td class="nump">4,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 162.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeFiveMember', window );">$164.62 - $165.89</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract', window );"><strong>Stock options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Price Range, Minimum (in dollars per share)</a></td>
<td class="nump">164.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Price Range, Maximum (in dollars per share)</a></td>
<td class="nump">$ 165.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options (in shares)</a></td>
<td class="nump">29,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, Average Life</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 165.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options (in shares)</a></td>
<td class="nump">13,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 164.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation shares authorized under stock option plans by exercise price range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052288416464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common stock, stock option plans and stock compensation agreements - Summary of Restricted Share Units (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 29, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">12,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">6,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Issued (in shares)</a></td>
<td class="num">(5,454)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod', window );">Canceled/forfeited/adjusted (in shares)</a></td>
<td class="num">(774)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">13,041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">2,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Issued (in shares)</a></td>
<td class="num">(808)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod', window );">Canceled/forfeited/adjusted (in shares)</a></td>
<td class="num">(122)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">2,013<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Canceled, Forfeited and Adjusted During the Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052272792000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Sales by Segment of Business (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 29, 2024 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of segments</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 88,821<span></span>
</td>
<td class="nump">$ 85,159<span></span>
</td>
<td class="nump">$ 79,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember', window );">Innovative Medicine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 56,964<span></span>
</td>
<td class="nump">$ 54,759<span></span>
</td>
<td class="nump">52,563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember', window );">Innovative Medicine | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 17,828<span></span>
</td>
<td class="nump">$ 18,052<span></span>
</td>
<td class="nump">16,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(1.20%)<span></span>
</td>
<td class="nump">6.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember', window );">Innovative Medicine | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,396<span></span>
</td>
<td class="nump">$ 4,418<span></span>
</td>
<td class="nump">5,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(23.10%)<span></span>
</td>
<td class="num">(18.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember', window );">Innovative Medicine | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 7,115<span></span>
</td>
<td class="nump">$ 7,140<span></span>
</td>
<td class="nump">6,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember', window );">Innovative Medicine | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 20,781<span></span>
</td>
<td class="nump">$ 17,661<span></span>
</td>
<td class="nump">15,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">17.70%<span></span>
</td>
<td class="nump">10.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember', window );">Innovative Medicine | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,282<span></span>
</td>
<td class="nump">$ 3,815<span></span>
</td>
<td class="nump">3,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">12.30%<span></span>
</td>
<td class="nump">11.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember', window );">Innovative Medicine | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,562<span></span>
</td>
<td class="nump">$ 3,671<span></span>
</td>
<td class="nump">3,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="num">(5.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember', window );">MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 31,857<span></span>
</td>
<td class="nump">$ 30,400<span></span>
</td>
<td class="nump">27,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">10.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember', window );">MedTech | Cardiovascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 7,707<span></span>
</td>
<td class="nump">$ 6,350<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">21.40%<span></span>
</td>
<td class="nump">47.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember', window );">MedTech | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 9,158<span></span>
</td>
<td class="nump">$ 8,942<span></span>
</td>
<td class="nump">8,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember', window );">MedTech | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 9,845<span></span>
</td>
<td class="nump">$ 10,037<span></span>
</td>
<td class="nump">9,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(1.90%)<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember', window );">MedTech | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 5,146<span></span>
</td>
<td class="nump">$ 5,072<span></span>
</td>
<td class="nump">4,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_RemicadeMember', window );">Remicade | Innovative Medicine | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,605<span></span>
</td>
<td class="nump">$ 1,839<span></span>
</td>
<td class="nump">2,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(12.80%)<span></span>
</td>
<td class="num">(21.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember', window );">Simponi/Simponi Aria | Innovative Medicine | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,190<span></span>
</td>
<td class="nump">$ 2,197<span></span>
</td>
<td class="nump">2,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_StelaraMember', window );">Stelara | Innovative Medicine | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 10,361<span></span>
</td>
<td class="nump">$ 10,858<span></span>
</td>
<td class="nump">9,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(4.60%)<span></span>
</td>
<td class="nump">11.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_TremfyaMember', window );">Tremfya | Innovative Medicine | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,670<span></span>
</td>
<td class="nump">$ 3,147<span></span>
</td>
<td class="nump">2,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">16.60%<span></span>
</td>
<td class="nump">17.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OtherImmunologyMember', window );">Other Immunology | Innovative Medicine | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(74.10%)<span></span>
</td>
<td class="num">(33.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_COVID19Member', window );">COVID-19 | Innovative Medicine | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">$ 1,117<span></span>
</td>
<td class="nump">2,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(82.40%)<span></span>
</td>
<td class="num">(48.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember', window );">EDURANT/rilpivirine | Innovative Medicine | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,272<span></span>
</td>
<td class="nump">$ 1,150<span></span>
</td>
<td class="nump">1,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">10.60%<span></span>
</td>
<td class="nump">14.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember', window );">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Innovative Medicine | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,712<span></span>
</td>
<td class="nump">$ 1,854<span></span>
</td>
<td class="nump">1,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(7.70%)<span></span>
</td>
<td class="num">(4.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember', window );">Other Infectious Diseases | Innovative Medicine | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 214<span></span>
</td>
<td class="nump">$ 297<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(27.60%)<span></span>
</td>
<td class="num">(6.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember', window );">CONCERTA/Methylphenidate | Innovative Medicine | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 641<span></span>
</td>
<td class="nump">$ 783<span></span>
</td>
<td class="nump">644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(18.10%)<span></span>
</td>
<td class="nump">21.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember', window );">INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Innovative Medicine | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,222<span></span>
</td>
<td class="nump">$ 4,115<span></span>
</td>
<td class="nump">4,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_SPRAVATOMember', window );">SPRAVATO | Innovative Medicine | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,077<span></span>
</td>
<td class="nump">$ 689<span></span>
</td>
<td class="nump">374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">56.40%<span></span>
</td>
<td class="nump">84.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember', window );">OTHER NEUROSCIENCE | Innovative Medicine | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,175<span></span>
</td>
<td class="nump">$ 1,553<span></span>
</td>
<td class="nump">1,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(24.30%)<span></span>
</td>
<td class="num">(10.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_CARVYKTIMember', window );">CARVYKTI | Innovative Medicine | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 963<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">92.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_DARZALEXMember', window );">DARZALEX | Innovative Medicine | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 11,670<span></span>
</td>
<td class="nump">$ 9,744<span></span>
</td>
<td class="nump">7,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">19.80%<span></span>
</td>
<td class="nump">22.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_ErleadaMember', window );">ERLEADA | Innovative Medicine | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,999<span></span>
</td>
<td class="nump">$ 2,387<span></span>
</td>
<td class="nump">1,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">25.60%<span></span>
</td>
<td class="nump">26.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_IMBRUVICAMember', window );">IMBRUVICA | Innovative Medicine | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,038<span></span>
</td>
<td class="nump">$ 3,264<span></span>
</td>
<td class="nump">3,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(6.90%)<span></span>
</td>
<td class="num">(13.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_TECVAYLIMember', window );">TECVAYLI | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 549<span></span>
</td>
<td class="nump">$ 395<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">38.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_ZYTIGAMember', window );">ZYTIGA/abiraterone acetate | Innovative Medicine | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 631<span></span>
</td>
<td class="nump">$ 887<span></span>
</td>
<td class="nump">1,770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(28.80%)<span></span>
</td>
<td class="num">(49.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OtherOncologyMember', window );">Other Oncology | Innovative Medicine | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 931<span></span>
</td>
<td class="nump">$ 484<span></span>
</td>
<td class="nump">423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">92.50%<span></span>
</td>
<td class="nump">14.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OPSUMITMember', window );">OPSUMIT | Innovative Medicine | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,184<span></span>
</td>
<td class="nump">$ 1,973<span></span>
</td>
<td class="nump">1,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">10.70%<span></span>
</td>
<td class="nump">10.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_UPTRAVIMember', window );">UPTRAVI | Innovative Medicine | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,817<span></span>
</td>
<td class="nump">$ 1,582<span></span>
</td>
<td class="nump">1,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">14.90%<span></span>
</td>
<td class="nump">19.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OtherPulmonaryHypertensionMember', window );">Other Pulmonary Hypertension | Innovative Medicine | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 281<span></span>
</td>
<td class="nump">$ 260<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">7.90%<span></span>
</td>
<td class="num">(16.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_XareltoMember', window );">XARELTO | Innovative Medicine | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,373<span></span>
</td>
<td class="nump">$ 2,365<span></span>
</td>
<td class="nump">2,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="num">(4.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OtherMember', window );">Other | Innovative Medicine | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,189<span></span>
</td>
<td class="nump">$ 1,306<span></span>
</td>
<td class="nump">1,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(8.90%)<span></span>
</td>
<td class="num">(7.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_ELECTROPHYSIOLOGYMember', window );">ELECTROPHYSIOLOGY | MedTech | Cardiovascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 5,267<span></span>
</td>
<td class="nump">$ 4,688<span></span>
</td>
<td class="nump">3,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">12.30%<span></span>
</td>
<td class="nump">19.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_AbiomedMember', window );">Abiomed | MedTech | Cardiovascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,496<span></span>
</td>
<td class="nump">$ 1,306<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">14.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_ShockwaveMedicalInc.Member', window );">Shockwave Medical, Inc. | MedTech | Cardiovascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 564<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OtherCardiovascularMember', window );">other cardiovascular | MedTech | Cardiovascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 380<span></span>
</td>
<td class="nump">$ 356<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">7.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_HIPSMember', window );">HIPS | MedTech | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,638<span></span>
</td>
<td class="nump">$ 1,560<span></span>
</td>
<td class="nump">1,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_KNEESMember', window );">KNEES | MedTech | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,545<span></span>
</td>
<td class="nump">$ 1,456<span></span>
</td>
<td class="nump">1,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">6.10%<span></span>
</td>
<td class="nump">7.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_TRAUMAMember', window );">TRAUMA | MedTech | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,049<span></span>
</td>
<td class="nump">$ 2,979<span></span>
</td>
<td class="nump">2,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_SPINESPORTSOTHERMember', window );">SPINE,SPORTS &amp; OTHER | MedTech | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,926<span></span>
</td>
<td class="nump">$ 2,947<span></span>
</td>
<td class="nump">2,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_ADVANCEDMember', window );">ADVANCED | MedTech | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,488<span></span>
</td>
<td class="nump">$ 4,671<span></span>
</td>
<td class="nump">4,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(3.90%)<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_GENERALMember', window );">GENERAL | MedTech | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 5,358<span></span>
</td>
<td class="nump">$ 5,366<span></span>
</td>
<td class="nump">5,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember', window );">CONTACT LENSES/OTHER | MedTech | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,733<span></span>
</td>
<td class="nump">$ 3,702<span></span>
</td>
<td class="nump">3,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_SURGICALMember', window );">SURGICAL | MedTech | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,413<span></span>
</td>
<td class="nump">$ 1,370<span></span>
</td>
<td class="nump">1,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 50,302<span></span>
</td>
<td class="nump">$ 46,444<span></span>
</td>
<td class="nump">41,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">8.30%<span></span>
</td>
<td class="nump">10.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Innovative Medicine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 33,970<span></span>
</td>
<td class="nump">$ 31,169<span></span>
</td>
<td class="nump">28,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Innovative Medicine | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 11,355<span></span>
</td>
<td class="nump">$ 11,539<span></span>
</td>
<td class="nump">11,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(1.60%)<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Innovative Medicine | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,354<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">1,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(9.80%)<span></span>
</td>
<td class="num">(10.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Innovative Medicine | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,398<span></span>
</td>
<td class="nump">$ 4,065<span></span>
</td>
<td class="nump">3,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">8.20%<span></span>
</td>
<td class="nump">13.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Innovative Medicine | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 10,854<span></span>
</td>
<td class="nump">$ 8,462<span></span>
</td>
<td class="nump">6,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">28.30%<span></span>
</td>
<td class="nump">22.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Innovative Medicine | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,143<span></span>
</td>
<td class="nump">$ 2,697<span></span>
</td>
<td class="nump">2,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">16.50%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Innovative Medicine | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,866<span></span>
</td>
<td class="nump">$ 2,906<span></span>
</td>
<td class="nump">3,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(1.40%)<span></span>
</td>
<td class="num">(4.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 16,332<span></span>
</td>
<td class="nump">$ 15,275<span></span>
</td>
<td class="nump">13,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">14.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | MedTech | Cardiovascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,513<span></span>
</td>
<td class="nump">$ 3,633<span></span>
</td>
<td class="nump">2,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">24.20%<span></span>
</td>
<td class="nump">67.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | MedTech | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 5,689<span></span>
</td>
<td class="nump">$ 5,525<span></span>
</td>
<td class="nump">5,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | MedTech | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,003<span></span>
</td>
<td class="nump">$ 4,031<span></span>
</td>
<td class="nump">3,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | MedTech | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,128<span></span>
</td>
<td class="nump">$ 2,086<span></span>
</td>
<td class="nump">1,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Remicade | Innovative Medicine | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,009<span></span>
</td>
<td class="nump">$ 1,143<span></span>
</td>
<td class="nump">1,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(11.70%)<span></span>
</td>
<td class="num">(19.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Simponi/Simponi Aria | Innovative Medicine | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,082<span></span>
</td>
<td class="nump">$ 1,124<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(3.80%)<span></span>
</td>
<td class="num">(3.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Stelara | Innovative Medicine | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 6,720<span></span>
</td>
<td class="nump">$ 6,966<span></span>
</td>
<td class="nump">6,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(3.50%)<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Tremfya | Innovative Medicine | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,443<span></span>
</td>
<td class="nump">$ 2,147<span></span>
</td>
<td class="nump">1,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">13.70%<span></span>
</td>
<td class="nump">16.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Other Immunology | Innovative Medicine | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(74.10%)<span></span>
</td>
<td class="num">(33.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | COVID-19 | Innovative Medicine | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | EDURANT/rilpivirine | Innovative Medicine | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(10.00%)<span></span>
</td>
<td class="num">(3.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Innovative Medicine | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,311<span></span>
</td>
<td class="nump">$ 1,446<span></span>
</td>
<td class="nump">1,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(9.40%)<span></span>
</td>
<td class="num">(3.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Other Infectious Diseases | Innovative Medicine | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(41.00%)<span></span>
</td>
<td class="num">(34.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | CONCERTA/Methylphenidate | Innovative Medicine | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 134<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(41.70%)<span></span>
</td>
<td class="nump">52.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Innovative Medicine | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,125<span></span>
</td>
<td class="nump">$ 2,897<span></span>
</td>
<td class="nump">2,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">7.90%<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | SPRAVATO | Innovative Medicine | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 929<span></span>
</td>
<td class="nump">$ 589<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">57.80%<span></span>
</td>
<td class="nump">79.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | OTHER NEUROSCIENCE | Innovative Medicine | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 210<span></span>
</td>
<td class="nump">$ 349<span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(39.80%)<span></span>
</td>
<td class="num">(7.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | CARVYKTI | Innovative Medicine | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 869<span></span>
</td>
<td class="nump">$ 469<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">85.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | DARZALEX | Innovative Medicine | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 6,588<span></span>
</td>
<td class="nump">$ 5,277<span></span>
</td>
<td class="nump">4,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">24.80%<span></span>
</td>
<td class="nump">25.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | ERLEADA | Innovative Medicine | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,282<span></span>
</td>
<td class="nump">$ 1,065<span></span>
</td>
<td class="nump">968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">20.30%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | IMBRUVICA | Innovative Medicine | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,020<span></span>
</td>
<td class="nump">$ 1,051<span></span>
</td>
<td class="nump">1,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="num">(24.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | TECVAYLI | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 418<span></span>
</td>
<td class="nump">$ 334<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">25.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | ZYTIGA/abiraterone acetate | Innovative Medicine | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(32.20%)<span></span>
</td>
<td class="num">(32.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Other Oncology | Innovative Medicine | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 643<span></span>
</td>
<td class="nump">$ 215<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | OPSUMIT | Innovative Medicine | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,520<span></span>
</td>
<td class="nump">$ 1,292<span></span>
</td>
<td class="nump">1,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">17.70%<span></span>
</td>
<td class="nump">14.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | UPTRAVI | Innovative Medicine | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,511<span></span>
</td>
<td class="nump">$ 1,326<span></span>
</td>
<td class="nump">1,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">13.90%<span></span>
</td>
<td class="nump">20.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Other Pulmonary Hypertension | Innovative Medicine | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 112<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">41.80%<span></span>
</td>
<td class="num">(28.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | XARELTO | Innovative Medicine | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,373<span></span>
</td>
<td class="nump">$ 2,365<span></span>
</td>
<td class="nump">2,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="num">(4.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Other | Innovative Medicine | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 494<span></span>
</td>
<td class="nump">$ 541<span></span>
</td>
<td class="nump">569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(8.80%)<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | ELECTROPHYSIOLOGY | MedTech | Cardiovascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,738<span></span>
</td>
<td class="nump">$ 2,458<span></span>
</td>
<td class="nump">2,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">11.40%<span></span>
</td>
<td class="nump">20.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Abiomed | MedTech | Cardiovascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,213<span></span>
</td>
<td class="nump">$ 1,066<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">13.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Shockwave Medical, Inc. | MedTech | Cardiovascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 442<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | other cardiovascular | MedTech | Cardiovascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">10.70%<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | HIPS | MedTech | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,057<span></span>
</td>
<td class="nump">$ 996<span></span>
</td>
<td class="nump">943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">6.20%<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | KNEES | MedTech | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 922<span></span>
</td>
<td class="nump">$ 896<span></span>
</td>
<td class="nump">851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">5.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | TRAUMA | MedTech | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,013<span></span>
</td>
<td class="nump">$ 1,949<span></span>
</td>
<td class="nump">1,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | SPINE,SPORTS &amp; OTHER | MedTech | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,696<span></span>
</td>
<td class="nump">$ 1,684<span></span>
</td>
<td class="nump">1,645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | ADVANCED | MedTech | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,838<span></span>
</td>
<td class="nump">$ 1,833<span></span>
</td>
<td class="nump">1,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | GENERAL | MedTech | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,165<span></span>
</td>
<td class="nump">$ 2,198<span></span>
</td>
<td class="nump">2,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | CONTACT LENSES/OTHER | MedTech | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,684<span></span>
</td>
<td class="nump">$ 1,626<span></span>
</td>
<td class="nump">1,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">6.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | SURGICAL | MedTech | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 444<span></span>
</td>
<td class="nump">$ 460<span></span>
</td>
<td class="nump">468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(3.40%)<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 38,519<span></span>
</td>
<td class="nump">$ 38,715<span></span>
</td>
<td class="nump">38,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Innovative Medicine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 22,994<span></span>
</td>
<td class="nump">$ 23,590<span></span>
</td>
<td class="nump">23,959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(2.50%)<span></span>
</td>
<td class="num">(1.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Innovative Medicine | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 6,473<span></span>
</td>
<td class="nump">$ 6,513<span></span>
</td>
<td class="nump">5,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="nump">10.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Innovative Medicine | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,042<span></span>
</td>
<td class="nump">$ 2,918<span></span>
</td>
<td class="nump">3,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(30.00%)<span></span>
</td>
<td class="num">(22.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Innovative Medicine | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,718<span></span>
</td>
<td class="nump">$ 3,076<span></span>
</td>
<td class="nump">3,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(11.60%)<span></span>
</td>
<td class="num">(7.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Innovative Medicine | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 9,926<span></span>
</td>
<td class="nump">$ 9,199<span></span>
</td>
<td class="nump">9,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">7.90%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Innovative Medicine | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,140<span></span>
</td>
<td class="nump">$ 1,117<span></span>
</td>
<td class="nump">1,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Innovative Medicine | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 696<span></span>
</td>
<td class="nump">$ 765<span></span>
</td>
<td class="nump">845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(9.10%)<span></span>
</td>
<td class="num">(9.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 15,525<span></span>
</td>
<td class="nump">$ 15,125<span></span>
</td>
<td class="nump">14,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">7.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | MedTech | Cardiovascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,194<span></span>
</td>
<td class="nump">$ 2,717<span></span>
</td>
<td class="nump">2,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">17.60%<span></span>
</td>
<td class="nump">27.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | MedTech | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,470<span></span>
</td>
<td class="nump">$ 3,417<span></span>
</td>
<td class="nump">3,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | MedTech | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 5,842<span></span>
</td>
<td class="nump">$ 6,006<span></span>
</td>
<td class="nump">5,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(2.70%)<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | MedTech | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,018<span></span>
</td>
<td class="nump">$ 2,986<span></span>
</td>
<td class="nump">2,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Remicade | Innovative Medicine | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 497<span></span>
</td>
<td class="nump">$ 549<span></span>
</td>
<td class="nump">722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(9.50%)<span></span>
</td>
<td class="num">(23.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Simponi/Simponi Aria | Innovative Medicine | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,108<span></span>
</td>
<td class="nump">$ 1,073<span></span>
</td>
<td class="nump">1,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Stelara | Innovative Medicine | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,641<span></span>
</td>
<td class="nump">$ 3,892<span></span>
</td>
<td class="nump">3,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(6.40%)<span></span>
</td>
<td class="nump">16.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Tremfya | Innovative Medicine | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,227<span></span>
</td>
<td class="nump">$ 999<span></span>
</td>
<td class="nump">824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">22.80%<span></span>
</td>
<td class="nump">21.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Other Immunology | Innovative Medicine | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | COVID-19 | Innovative Medicine | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">$ 1,117<span></span>
</td>
<td class="nump">2,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(82.40%)<span></span>
</td>
<td class="num">(45.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | EDURANT/rilpivirine | Innovative Medicine | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,241<span></span>
</td>
<td class="nump">$ 1,115<span></span>
</td>
<td class="nump">972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">11.20%<span></span>
</td>
<td class="nump">14.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Innovative Medicine | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 401<span></span>
</td>
<td class="nump">$ 408<span></span>
</td>
<td class="nump">449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(1.70%)<span></span>
</td>
<td class="num">(9.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Other Infectious Diseases | Innovative Medicine | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">$ 278<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(26.70%)<span></span>
</td>
<td class="num">(3.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | CONCERTA/Methylphenidate | Innovative Medicine | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 507<span></span>
</td>
<td class="nump">$ 554<span></span>
</td>
<td class="nump">493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(8.40%)<span></span>
</td>
<td class="nump">12.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Innovative Medicine | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,097<span></span>
</td>
<td class="nump">$ 1,218<span></span>
</td>
<td class="nump">1,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(9.90%)<span></span>
</td>
<td class="num">(14.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | SPRAVATO | Innovative Medicine | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">48.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | OTHER NEUROSCIENCE | Innovative Medicine | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 965<span></span>
</td>
<td class="nump">$ 1,204<span></span>
</td>
<td class="nump">1,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(19.80%)<span></span>
</td>
<td class="num">(11.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | CARVYKTI | Innovative Medicine | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | DARZALEX | Innovative Medicine | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 5,082<span></span>
</td>
<td class="nump">$ 4,467<span></span>
</td>
<td class="nump">3,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">13.80%<span></span>
</td>
<td class="nump">18.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | ERLEADA | Innovative Medicine | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,717<span></span>
</td>
<td class="nump">$ 1,322<span></span>
</td>
<td class="nump">913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">29.80%<span></span>
</td>
<td class="nump">44.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | IMBRUVICA | Innovative Medicine | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,018<span></span>
</td>
<td class="nump">$ 2,214<span></span>
</td>
<td class="nump">2,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(8.80%)<span></span>
</td>
<td class="num">(7.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | TECVAYLI | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 131<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | ZYTIGA/abiraterone acetate | Innovative Medicine | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 597<span></span>
</td>
<td class="nump">$ 837<span></span>
</td>
<td class="nump">1,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(28.60%)<span></span>
</td>
<td class="num">(50.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Other Oncology | Innovative Medicine | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 288<span></span>
</td>
<td class="nump">$ 269<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">7.10%<span></span>
</td>
<td class="num">(3.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | OPSUMIT | Innovative Medicine | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 664<span></span>
</td>
<td class="nump">$ 681<span></span>
</td>
<td class="nump">651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(2.40%)<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | UPTRAVI | Innovative Medicine | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 307<span></span>
</td>
<td class="nump">$ 255<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">20.10%<span></span>
</td>
<td class="nump">17.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Other Pulmonary Hypertension | Innovative Medicine | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 169<span></span>
</td>
<td class="nump">$ 182<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(6.90%)<span></span>
</td>
<td class="num">(10.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | XARELTO | Innovative Medicine | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Other | Innovative Medicine | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 696<span></span>
</td>
<td class="nump">$ 765<span></span>
</td>
<td class="nump">845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(9.10%)<span></span>
</td>
<td class="num">(9.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | ELECTROPHYSIOLOGY | MedTech | Cardiovascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,529<span></span>
</td>
<td class="nump">$ 2,230<span></span>
</td>
<td class="nump">1,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">13.40%<span></span>
</td>
<td class="nump">17.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Abiomed | MedTech | Cardiovascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 284<span></span>
</td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">18.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Shockwave Medical, Inc. | MedTech | Cardiovascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | other cardiovascular | MedTech | Cardiovascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 260<span></span>
</td>
<td class="nump">$ 247<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="nump">7.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | HIPS | MedTech | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 581<span></span>
</td>
<td class="nump">$ 564<span></span>
</td>
<td class="nump">571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | KNEES | MedTech | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 623<span></span>
</td>
<td class="nump">$ 559<span></span>
</td>
<td class="nump">508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">11.30%<span></span>
</td>
<td class="nump">10.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | TRAUMA | MedTech | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,036<span></span>
</td>
<td class="nump">$ 1,030<span></span>
</td>
<td class="nump">989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | SPINE,SPORTS &amp; OTHER | MedTech | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,230<span></span>
</td>
<td class="nump">$ 1,263<span></span>
</td>
<td class="nump">1,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(2.60%)<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | ADVANCED | MedTech | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,650<span></span>
</td>
<td class="nump">$ 2,837<span></span>
</td>
<td class="nump">2,785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(6.60%)<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | GENERAL | MedTech | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,192<span></span>
</td>
<td class="nump">$ 3,168<span></span>
</td>
<td class="nump">3,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">5.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | CONTACT LENSES/OTHER | MedTech | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,049<span></span>
</td>
<td class="nump">$ 2,076<span></span>
</td>
<td class="nump">2,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | SURGICAL | MedTech | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 969<span></span>
</td>
<td class="nump">$ 910<span></span>
</td>
<td class="nump">837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">8.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember', window );">UNITED STATES Exports | Remicade | Innovative Medicine | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 98<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">% Change</a></td>
<td class="num">(33.00%)<span></span>
</td>
<td class="num">(28.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageChangeInSalesBySegmentOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage change in sales by segment of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageChangeInSalesBySegmentOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_ImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_ImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_CardiovascularMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_CardiovascularMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_SurgeryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_SurgeryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_VisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_VisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_RemicadeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_RemicadeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_StelaraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_StelaraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TremfyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TremfyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_COVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_COVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SPRAVATOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SPRAVATOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_CARVYKTIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_CARVYKTIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_DARZALEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_DARZALEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ErleadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ErleadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_IMBRUVICAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_IMBRUVICAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TECVAYLIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TECVAYLIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ZYTIGAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ZYTIGAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OPSUMITMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OPSUMITMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_UPTRAVIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_UPTRAVIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherPulmonaryHypertensionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherPulmonaryHypertensionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_XareltoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_XareltoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ELECTROPHYSIOLOGYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ELECTROPHYSIOLOGYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_AbiomedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_AbiomedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ShockwaveMedicalInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ShockwaveMedicalInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherCardiovascularMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherCardiovascularMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_HIPSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_HIPSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_KNEESMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_KNEESMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TRAUMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TRAUMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SPINESPORTSOTHERMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SPINESPORTSOTHERMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ADVANCEDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ADVANCEDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_GENERALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_GENERALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SURGICALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SURGICALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052290566160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Income Before Tax by Segment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 88,821<span></span>
</td>
<td class="nump">$ 85,159<span></span>
</td>
<td class="nump">$ 79,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">27,471<span></span>
</td>
<td class="nump">26,553<span></span>
</td>
<td class="nump">24,596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, marketing and administrative expenses</a></td>
<td class="nump">22,869<span></span>
</td>
<td class="nump">21,512<span></span>
</td>
<td class="nump">20,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="nump">17,232<span></span>
</td>
<td class="nump">15,085<span></span>
</td>
<td class="nump">14,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="num">(4,694)<span></span>
</td>
<td class="num">(6,634)<span></span>
</td>
<td class="num">(810)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">16,687<span></span>
</td>
<td class="nump">15,062<span></span>
</td>
<td class="nump">19,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Less: Expense not allocated to segments</a></td>
<td class="nump">5,972<span></span>
</td>
<td class="nump">7,853<span></span>
</td>
<td class="nump">735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">88,821<span></span>
</td>
<td class="nump">85,159<span></span>
</td>
<td class="nump">79,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">22,659<span></span>
</td>
<td class="nump">22,915<span></span>
</td>
<td class="nump">20,094<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember', window );">Innovative Medicine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">56,964<span></span>
</td>
<td class="nump">54,759<span></span>
</td>
<td class="nump">52,563<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember', window );">Innovative Medicine | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">56,964<span></span>
</td>
<td class="nump">54,759<span></span>
</td>
<td class="nump">52,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">14,036<span></span>
</td>
<td class="nump">13,715<span></span>
</td>
<td class="nump">14,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, marketing and administrative expenses</a></td>
<td class="nump">10,906<span></span>
</td>
<td class="nump">9,842<span></span>
</td>
<td class="nump">9,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="nump">13,529<span></span>
</td>
<td class="nump">11,963<span></span>
</td>
<td class="nump">11,642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="num">(426)<span></span>
</td>
<td class="nump">993<span></span>
</td>
<td class="nump">1,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">18,919<span></span>
</td>
<td class="nump">18,246<span></span>
</td>
<td class="nump">15,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember', window );">MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">31,857<span></span>
</td>
<td class="nump">30,400<span></span>
</td>
<td class="nump">27,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember', window );">MedTech | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">31,857<span></span>
</td>
<td class="nump">30,400<span></span>
</td>
<td class="nump">27,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">13,345<span></span>
</td>
<td class="nump">12,722<span></span>
</td>
<td class="nump">10,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, marketing and administrative expenses</a></td>
<td class="nump">10,812<span></span>
</td>
<td class="nump">10,476<span></span>
</td>
<td class="nump">9,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="nump">3,703<span></span>
</td>
<td class="nump">3,122<span></span>
</td>
<td class="nump">2,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="nump">257<span></span>
</td>
<td class="num">(589)<span></span>
</td>
<td class="nump">553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">$ 3,740<span></span>
</td>
<td class="nump">$ 4,669<span></span>
</td>
<td class="nump">$ 4,447<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052272362800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">$ 16,687<span></span>
</td>
<td class="nump">$ 15,062<span></span>
</td>
<td class="nump">$ 19,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Identifiable Assets</a></td>
<td class="nump">180,104<span></span>
</td>
<td class="nump">167,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets', window );">Additions to Property, Plant &amp; Equipment</a></td>
<td class="nump">4,424<span></span>
</td>
<td class="nump">4,543<span></span>
</td>
<td class="nump">4,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">7,339<span></span>
</td>
<td class="nump">7,486<span></span>
</td>
<td class="nump">6,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Equity securities, FV-NI, gain (loss)</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRoyaltiesReceived', window );">Proceeds from Royalties Received</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">489<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=jnj_YellowJerseyTherapeuticsMember', window );">Yellow Jersey Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payments to Acquire in Process Research and Development</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_BabyPowderMember', window );">Baby Powder | Talc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyLossInPeriod', window );">Loss contingency, loss in period</a></td>
<td class="nump">5,100<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember', window );">Innovative Medicine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring</a></td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (loss) on divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember', window );">Innovative Medicine | Momenta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets, excluding goodwill</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember', window );">MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (loss) on divestiture</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_RegulationCharge', window );">Regulation charge</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember', window );">MedTech | Laminar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payments to Acquire in Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember', window );">MedTech | V-Wave Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payments to Acquire in Process Research and Development</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_SegmentsTotalMember', window );">Segments Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Identifiable Assets</a></td>
<td class="nump">141,392<span></span>
</td>
<td class="nump">133,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets', window );">Additions to Property, Plant &amp; Equipment</a></td>
<td class="nump">4,153<span></span>
</td>
<td class="nump">4,025<span></span>
</td>
<td class="nump">3,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">6,997<span></span>
</td>
<td class="nump">6,790<span></span>
</td>
<td class="nump">5,989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets', window );">Additions to Property, Plant &amp; Equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">383<span></span>
</td>
<td class="nump">641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">22,659<span></span>
</td>
<td class="nump">22,915<span></span>
</td>
<td class="nump">20,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Innovative Medicine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">18,919<span></span>
</td>
<td class="nump">18,246<span></span>
</td>
<td class="nump">15,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Identifiable Assets</a></td>
<td class="nump">57,070<span></span>
</td>
<td class="nump">58,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets', window );">Additions to Property, Plant &amp; Equipment</a></td>
<td class="nump">1,710<span></span>
</td>
<td class="nump">1,653<span></span>
</td>
<td class="nump">1,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">3,760<span></span>
</td>
<td class="nump">3,847<span></span>
</td>
<td class="nump">3,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Supplies expense</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">3,740<span></span>
</td>
<td class="nump">4,669<span></span>
</td>
<td class="nump">4,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Identifiable Assets</a></td>
<td class="nump">84,322<span></span>
</td>
<td class="nump">74,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets', window );">Additions to Property, Plant &amp; Equipment</a></td>
<td class="nump">2,443<span></span>
</td>
<td class="nump">2,372<span></span>
</td>
<td class="nump">2,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">3,237<span></span>
</td>
<td class="nump">2,943<span></span>
</td>
<td class="nump">2,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Segment Reporting, Reconciling Item, Corporate Nonsegment | General Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Identifiable Assets</a></td>
<td class="nump">38,712<span></span>
</td>
<td class="nump">34,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets', window );">Additions to Property, Plant &amp; Equipment</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">356<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">$ 342<span></span>
</td>
<td class="nump">$ 313<span></span>
</td>
<td class="nump">$ 340<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_RegulationCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Regulation charge</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_RegulationCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyLossInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyLossInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRoyaltiesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRoyaltiesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenditure for addition to long-lived assets included in determination of segment assets by chief operating decision maker (CODM) or otherwise regularly provided to CODM. Excludes expenditure for addition to financial instrument, long-term customer relationship of financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentExpenditureAdditionToLongLivedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SuppliesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense associated with supplies that were used during the current accounting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SuppliesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=jnj_YellowJerseyTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=jnj_YellowJerseyTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_BabyPowderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_BabyPowderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TalcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TalcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_MomentaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_MomentaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_LaminarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_LaminarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_VWaveLtd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_VWaveLtd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_SegmentsTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_SegmentsTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_GeneralCorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_GeneralCorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052281468384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Schedule of Segment Reporting By Geographic Area (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 29, 2024 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 88,821<span></span>
</td>
<td class="nump">$ 85,159<span></span>
</td>
<td class="nump">$ 79,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">$ 180,104<span></span>
</td>
<td class="nump">167,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of segments</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Equity securities, FV-NI, gain (loss)</a></td>
<td class="num">$ (400)<span></span>
</td>
<td class="num">(400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">489<span></span>
</td>
<td class="nump">$ 275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (loss) related to litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ResearchAndDevelopmentInProcess1', window );">Research and development in process</a></td>
<td class="nump">$ 211<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="nump">783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Other (income) expense, net<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property, Plant and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">$ 20,518<span></span>
</td>
<td class="nump">19,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">81,818<span></span>
</td>
<td class="nump">70,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember', window );">bermekimab | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets, excluding goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_BabyPowderMember', window );">Baby Powder | Talc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyLossInPeriod', window );">Loss contingency, loss in period</a></td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=jnj_Wholesaler1Member', window );">Wholesaler 1 | Sales Revenue, Net | Wholesaler Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">20.50%<span></span>
</td>
<td class="nump">18.20%<span></span>
</td>
<td class="nump">18.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=jnj_Wholesaler2Member', window );">Wholesaler 2 | Sales Revenue, Net | Wholesaler Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">15.60%<span></span>
</td>
<td class="nump">15.10%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=jnj_Wholesaler3Member', window );">Wholesaler 3 | Sales Revenue, Net | Wholesaler Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">12.30%<span></span>
</td>
<td class="nump">14.20%<span></span>
</td>
<td class="nump">13.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember', window );">Innovative Medicine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 56,964<span></span>
</td>
<td class="nump">$ 54,759<span></span>
</td>
<td class="nump">$ 52,563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring</a></td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized gain (loss)</a></td>
<td class="nump">100<span></span>
</td>
<td class="num">(400)<span></span>
</td>
<td class="num">(700)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (loss) related to litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (loss) on divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember', window );">Innovative Medicine | Momenta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets, excluding goodwill</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember', window );">MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">31,857<span></span>
</td>
<td class="nump">30,400<span></span>
</td>
<td class="nump">27,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (loss) on divestiture</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquisitionCosts', window );">Acquisition costs, period cost</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_RegulationCharge', window );">Regulation charge</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">50,302<span></span>
</td>
<td class="nump">46,444<span></span>
</td>
<td class="nump">41,981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Innovative Medicine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">33,970<span></span>
</td>
<td class="nump">31,169<span></span>
</td>
<td class="nump">28,604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">16,332<span></span>
</td>
<td class="nump">15,275<span></span>
</td>
<td class="nump">13,377<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">88,821<span></span>
</td>
<td class="nump">85,159<span></span>
</td>
<td class="nump">79,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">101,119<span></span>
</td>
<td class="nump">89,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Innovative Medicine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">56,964<span></span>
</td>
<td class="nump">54,759<span></span>
</td>
<td class="nump">52,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">57,070<span></span>
</td>
<td class="nump">58,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Supplies expense</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">31,857<span></span>
</td>
<td class="nump">30,400<span></span>
</td>
<td class="nump">27,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">84,322<span></span>
</td>
<td class="nump">74,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">50,302<span></span>
</td>
<td class="nump">46,444<span></span>
</td>
<td class="nump">41,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">70,670<span></span>
</td>
<td class="nump">54,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">20,212<span></span>
</td>
<td class="nump">20,410<span></span>
</td>
<td class="nump">20,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">27,267<span></span>
</td>
<td class="nump">31,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Western Hemisphere excluding U.S.&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">4,714<span></span>
</td>
<td class="nump">4,549<span></span>
</td>
<td class="nump">4,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">1,728<span></span>
</td>
<td class="nump">1,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Asia-Pacific, Africa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">13,593<span></span>
</td>
<td class="nump">13,756<span></span>
</td>
<td class="nump">$ 13,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">1,454<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Segment Reporting, Reconciling Item, Corporate Nonsegment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_OtherNonLongLivedAssets', window );">Other non long-lived assets</a></td>
<td class="nump">77,768<span></span>
</td>
<td class="nump">76,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Segment Reporting, Reconciling Item, Corporate Nonsegment | General Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">1,217<span></span>
</td>
<td class="nump">1,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">$ 38,712<span></span>
</td>
<td class="nump">$ 34,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherNonLongLivedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other non long lived assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherNonLongLivedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_RegulationCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Regulation charge</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_RegulationCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ResearchAndDevelopmentInProcess1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development In Process1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ResearchAndDevelopmentInProcess1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquisitionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of capitalized acquisition cost incurred during period and excluded from amortization for oil- and gas-producing activities accounted for under full cost method. Excludes exploration and development costs and capitalized interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 932<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477385/932-360-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 932<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(c)(7)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479664/932-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquisitionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of intangible asset. Includes, but is not limited to, finite-lived and indefinite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyLossInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyLossInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SuppliesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense associated with supplies that were used during the current accounting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SuppliesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_BabyPowderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_BabyPowderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TalcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TalcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=jnj_Wholesaler1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=jnj_Wholesaler1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=jnj_WholesalerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=jnj_WholesalerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=jnj_Wholesaler2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=jnj_Wholesaler2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=jnj_Wholesaler3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=jnj_Wholesaler3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_MomentaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_MomentaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_GeneralCorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_GeneralCorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052285239104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and divestitures - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 08, 2024</div></th>
<th class="th"><div>Jul. 11, 2024</div></th>
<th class="th"><div>Jun. 20, 2024</div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>Dec. 22, 2022</div></th>
<th class="th"><div>Feb. 13, 2025</div></th>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,100<span></span>
</td>
<td class="nump">$ 17,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, net of cash acquired (Note 18)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,146<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 17,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,209<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,217<span></span>
</td>
<td class="nump">1,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Dividends payable, amount per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ResearchAndDevelopmentInProcess1', window );">Research and development in process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="nump">783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from divestiture of brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup', window );">Asset, held-for-sale, not part of disposal group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Goodwill, measurement period adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_AcclarentMember', window );">Acclarent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from divestiture of brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_PonvoryMember', window );">Ponvory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from divestiture of brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=jnj_VWaveLtd.Member', window );">V-Wave Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Consideration transferred</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill', window );">IPR&amp;D charge</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=jnj_YellowJerseyTherapeuticsMember', window );">Yellow Jersey Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill', window );">IPR&amp;D charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=jnj_LaminarMember', window );">Laminar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill', window );">IPR&amp;D charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember', window );">MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,569<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquisitionCosts', window );">Acquisition costs, period cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | V-Wave Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Consideration transferred</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_ClassIRecommendationForImpellaMember', window );">Class I Recommendation For Impella</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Dividends payable, amount per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_IntraCellularTherapiesInc.Member', window );">Intra-Cellular Therapies, Inc. | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Acquisition price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Equity interests issued and issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AmbrxMember', window );">Ambrx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Acquisition price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Equity interests issued and issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, net of cash acquired (Note 18)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Other assets assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BusinessAcquisitionDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AmbrxMember', window );">Ambrx | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BusinessCombinationProbabilityOfSuccessFactor', window );">Probability of success factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AmbrxMember', window );">Ambrx | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BusinessCombinationProbabilityOfSuccessFactor', window );">Probability of success factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember', window );">Abiomed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Acquisition price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 380.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Equity interests issued and issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Other assets assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BusinessAcquisitionDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Dividends payable, amount per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired from acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ResearchAndDevelopmentInProcess1', window );">Research and development in process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Marketable securities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember', window );">Abiomed | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BusinessCombinationProbabilityOfSuccessFactor', window );">Probability of success factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember', window );">Abiomed | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BusinessCombinationProbabilityOfSuccessFactor', window );">Probability of success factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember', window );">Abiomed | Impella</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Dividends payable, amount per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember', window );">Abiomed | Non-Tradeable Contingent Value Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight', window );">Non-tradeable contingent value right (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight', window );">Non-tradeable contingent value right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_RevenuesContingentConsideration', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_ProteologixMember', window );">Proteologix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, net of cash acquired (Note 18)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Other assets assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BusinessAcquisitionDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_ProteologixMember', window );">Proteologix | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BusinessCombinationProbabilityOfSuccessFactor', window );">Probability of success factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_ProteologixMember', window );">Proteologix | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BusinessCombinationProbabilityOfSuccessFactor', window );">Probability of success factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_ShockwaveMedicalInc.Member', window );">Shockwave Medical, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Acquisition price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 335.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Equity interests issued and issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Other assets assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BusinessAcquisitionDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss', window );">Equity interest in acquiree, remeasurement loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BusinessCombinationAcquisitionRelatedCostsEquityAwards', window );">Equity awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_ShockwaveMedicalInc.Member', window );">Shockwave Medical, Inc. | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BusinessCombinationProbabilityOfSuccessFactor', window );">Probability of success factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Recognized Identifiable Assets Acquired, Intangible Assets, Other than Goodwill</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_BusinessAcquisitionDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_BusinessAcquisitionDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_BusinessCombinationAcquisitionRelatedCostsEquityAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Acquisition Related Costs, Equity Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_BusinessCombinationAcquisitionRelatedCostsEquityAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_BusinessCombinationProbabilityOfSuccessFactor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Probability Of Success Factor</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_BusinessCombinationProbabilityOfSuccessFactor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ResearchAndDevelopmentInProcess1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development In Process1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ResearchAndDevelopmentInProcess1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_RevenuesContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenues, Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_RevenuesContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Tradeable Contingent Value Right</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Shares, Non-Tradeable Contingent Value Right</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquisitionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of capitalized acquisition cost incurred during period and excluded from amortization for oil- and gas-producing activities accounted for under full cost method. Excludes exploration and development costs and capitalized interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 932<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477385/932-360-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 932<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(c)(7)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479664/932-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquisitionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482309/360-10-15-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In a business combination achieved in stages, this element represents the amount of loss recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableAmountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share amount of a dividend declared, but not paid, as of the financial reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableAmountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from measurement period adjustment of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 16<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_AcclarentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_AcclarentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_PonvoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_PonvoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=jnj_VWaveLtd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=jnj_VWaveLtd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=jnj_YellowJerseyTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=jnj_YellowJerseyTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=jnj_LaminarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=jnj_LaminarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ClassIRecommendationForImpellaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ClassIRecommendationForImpellaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_IntraCellularTherapiesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_IntraCellularTherapiesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AmbrxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AmbrxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ImpellaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ImpellaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=jnj_NonTradeableContingentValueRightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=jnj_NonTradeableContingentValueRightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_ProteologixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_ProteologixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_ShockwaveMedicalInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_ShockwaveMedicalInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052289680800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and divestitures (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2024</div></th>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Jun. 20, 2024</div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,558<span></span>
</td>
<td class="nump">$ 36,047<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_ShockwaveMedicalInc.Member', window );">Shockwave Medical, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Amortizable intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Other assets assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,600<span></span>
</td>
<td class="nump">$ 13,100<span></span>
</td>
<td class="nump">12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Less: Cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BusinessCombinationSettlementOfEquityAwards', window );">Equity awards settled</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BusinessCombinationSettlementOfNotesPayable', window );">Settlement of notes payable</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_BusinessCombinationSettlementOfEquityAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Settlement Of Equity Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_BusinessCombinationSettlementOfEquityAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_BusinessCombinationSettlementOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Settlement Of Notes Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_BusinessCombinationSettlementOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_ShockwaveMedicalInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_ShockwaveMedicalInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052290051696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal proceedings - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 20, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 01, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 29, 2024 </div>
<div>USD ($) </div>
<div>claimant</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>cases</div>
</th>
<th class="th">
<div>Jul. 04, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>cases </div>
<div>claimant</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_TalcMember', window );">Talc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OpioidMember', window );">Opioid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Amount reserved for settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LossContingencyAccrualPaymentPercentage', window );">Loss contingency accrual, payment percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PhysiomeshMember', window );">Physiomesh</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember', window );">Judicial Ruling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 8,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation | Physiomesh</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending claims | cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement', window );">Number of claims within settlement agreement | cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member', window );">DePuy ASR U.S. | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_Numberofpatientsinsettlement', window );">Number of patients in settlement | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_InghamVsJohnsonJohnsonMember', window );">Ingham vs. Johnson &amp; Johnson</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Loss contingency, damages paid, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_TalcMember', window );">Talc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LossContingencyPaymentPeriod', window );">Loss contingency, payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LossContingencySolicitationPeriod', window );">Solicitation period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Litigation contingency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,475.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LossContingencyDamagesSoughtNominalValue', window );">Damages sought, nominal value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LossContingencyDiscountRate', window );">Bankruptcy loss contingency, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_TotalClaimsAgainstCompanyPercent', window );">Total claims against company, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LossContingencyDamagesSoughtValueIncrease', window );">Increase in damages sought</a></td>
<td class="nump">$ 1,750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Incremental charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LossContingencyAccrualNominalValue', window );">Accrual, nominal value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Amount reserved for settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_MesotheliomaAndStateClaimsMember', window );">Mesothelioma and State Claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LossContingencyClaimsSettledPercent', window );">Claims settled, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LegalProceedingTextualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal Proceeding Textuals Abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LegalProceedingTextualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyAccrualNominalValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency Accrual, Nominal Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyAccrualNominalValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyAccrualPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss contingency accrual, payment percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyAccrualPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyClaimsSettledPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Claims Settled, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyClaimsSettledPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyDamagesSoughtNominalValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Damages Sought, Nominal Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyDamagesSoughtNominalValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyDamagesSoughtValueIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Damages Sought, Value, Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyDamagesSoughtValueIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number of Claims within Settlement Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Payment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencySolicitationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Solicitation Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencySolicitationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_Numberofpatientsinsettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of patients in settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_Numberofpatientsinsettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProductLiabilityContingencyNumberOfClaimant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product liability contingency number of claimant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProductLiabilityContingencyNumberOfClaimant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TotalClaimsAgainstCompanyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Claims Against Company, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TotalClaimsAgainstCompanyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesPaidValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages paid to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesPaidValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TalcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TalcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OpioidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OpioidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PhysiomeshMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PhysiomeshMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_InghamVsJohnsonJohnsonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_InghamVsJohnsonJohnsonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_TalcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_TalcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_MesotheliomaAndStateClaimsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_MesotheliomaAndStateClaimsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052284757392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Legal proceedings - Product Liabilities (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 29, 2024 </div>
<div>claimant</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_TalcMember', window );">Talc</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="nump">62,830<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_AsrMember', window );">ASR</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember', window );">Pinnacle Acetabular Cup System</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="nump">910<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PelvicMeshesMember', window );">Pelvic Meshes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="nump">5,990<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PhysiomeshMember', window );">Physiomesh</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_RisperdalMember', window );">Risperdal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_ElmironMember', window );">Elmiron</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="nump">2,170<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProductLiabilityContingencyNumberOfClaimant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product liability contingency number of claimant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProductLiabilityContingencyNumberOfClaimant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TalcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TalcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_AsrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_AsrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PelvicMeshesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PelvicMeshesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PhysiomeshMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PhysiomeshMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_RisperdalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_RisperdalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ElmironMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ElmironMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052295504528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 234<span></span>
</td>
<td class="nump">$ 489<span></span>
</td>
<td class="nump">$ 275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember', window );">MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring Charges | MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_RDRestructuringPlanMember', window );">R&amp;D Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring and Related Cost, Cost Incurred to Date</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_OrthopaedicsRestructuringPlanMember', window );">Orthopaedics Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring and Related Cost, Cost Incurred to Date</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_OrthopaedicsRestructuringPlanMember', window );">Orthopaedics Restructuring Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Pre-tax restructuring charges</a></td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_OrthopaedicsRestructuringPlanMember', window );">Orthopaedics Restructuring Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Pre-tax restructuring charges</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=jnj_RDRestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=jnj_RDRestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=jnj_OrthopaedicsRestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=jnj_OrthopaedicsRestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052283384320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Schedule of Restructuring Reserve (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 234<span></span>
</td>
<td class="nump">$ 489<span></span>
</td>
<td class="nump">$ 275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_RDRestructuringPlanMember', window );">R&amp;D Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember', window );">Innovative Medicine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember', window );">Innovative Medicine | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember', window );">Innovative Medicine | Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember', window );">Innovative Medicine | Costs of Goods and Services Sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember', window );">MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember', window );">MedTech | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember', window );">MedTech | Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember', window );">MedTech | Costs of Goods and Services Sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=jnj_RDRestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=jnj_RDRestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_CostsOfGoodsAndServicesSoldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_CostsOfGoodsAndServicesSoldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052290919808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Kenvue separation and discontinued operations - Details (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 17, 2024</div></th>
<th class="th"><div>May 15, 2024</div></th>
<th class="th"><div>Aug. 23, 2023</div></th>
<th class="th"><div>May 08, 2023</div></th>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jul. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommercialPaper', window );">Proceeds from issuance of commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DebtForEquityExchangeSharesExchanged', window );">Debt for equity exchange, shares exchanged (in shares)</a></td>
<td class="nump">182,329,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DebtForEquityExchangeLossOnSharesExchanged', window );">Loss on shares exchanged</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Kenvue initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,241<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Realized gain (loss) on investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ExchangeOfStockCommonStockValueReceived', window );">Common stock received in exchange offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,741<span></span>
</td>
<td class="nump">12,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DiscontinuedOperationsTransitionServiceAgreementTerm', window );">Transition service agreement, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DiscontinuedOperationsSeparationCostsIncurred', window );">Separation costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="nump">$ 986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DiscontinuedOperationIncrementalTaxCost', window );">Incremental tax cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DiscontinuedOperationTransitionManufacturingAgreementTerm', window );">Transition manufacturing agreement, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DiscontinuedOperationTransitionManufacturingAgreementTerm', window );">Transition manufacturing agreement, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_ConsumerHealthMember', window );">Consumer Health Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Net assets divested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation', window );">Decrease in noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_NoncashOrPartNoncashTransactionGainOnExchangeOfStock', window );">Noncash gain on exchange offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=jnj_KenvueIncMember', window );">Kenvue Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_OwnershipPercentageSplitOffPercent', window );">Split-off percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=jnj_KenvueIncMember', window );">Kenvue Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_StockIssuedDuringPeriodSharesExchangeOffer', window );">Stock issued in exchange offer (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,955,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=jnj_KenvueIncMember', window );">Kenvue Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_StockIssuedDuringPeriodSharesExchangeOffer', window );">Stock issued in exchange offer (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,533,830,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=jnj_JohnsonJohnsonMember', window );">Johnson &amp; Johnson | Kenvue Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Percentage ownership after transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ExchangeOfStockPercentageOwnershipAfterTransaction', window );">Percentage ownership after transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities, fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=jnj_JohnsonJohnsonMember', window );">Johnson &amp; Johnson | Kenvue Inc. | Consumer Health Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_NoncashOrPartNoncashTransactionGainOnExchangeOfStock', window );">Noncash gain on exchange offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Kenvue Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,734,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Kenvue initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DebtForEquityExchangeLossOnSharesExchanged">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt For Equity Exchange, Loss On Shares Exchanged</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DebtForEquityExchangeLossOnSharesExchanged</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DebtForEquityExchangeSharesExchanged">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt For Equity Exchange, Shares Exchanged</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DebtForEquityExchangeSharesExchanged</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DiscontinuedOperationIncrementalTaxCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discontinued Operation, Incremental Tax Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DiscontinuedOperationIncrementalTaxCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DiscontinuedOperationTransitionManufacturingAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discontinued Operation, Transition Manufacturing Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DiscontinuedOperationTransitionManufacturingAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DiscontinuedOperationsSeparationCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discontinued Operations, Separation Costs Incurred</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DiscontinuedOperationsSeparationCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DiscontinuedOperationsTransitionServiceAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discontinued Operations, Transition Service Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DiscontinuedOperationsTransitionServiceAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ExchangeOfStockCommonStockValueReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange Of Stock, Common Stock, Value, Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ExchangeOfStockCommonStockValueReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ExchangeOfStockPercentageOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange of Stock, Percentage Ownership After Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ExchangeOfStockPercentageOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_NoncashOrPartNoncashTransactionGainOnExchangeOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Or Part Noncash Transaction, Gain On Exchange Of Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_NoncashOrPartNoncashTransactionGainOnExchangeOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OwnershipPercentageSplitOffPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership Percentage, Split-Off Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OwnershipPercentageSplitOffPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_StockIssuedDuringPeriodSharesExchangeOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Exchange Offer</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_StockIssuedDuringPeriodSharesExchangeOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowing by issuing commercial paper.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_ConsumerHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_ConsumerHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=jnj_KenvueIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=jnj_KenvueIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=jnj_KenvueIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=jnj_KenvueIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=jnj_KenvueIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=jnj_KenvueIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=jnj_JohnsonJohnsonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=jnj_JohnsonJohnsonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052290427920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Kenvue separation and discontinued operations - Net Earnings from Discontinued Operation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,036<span></span>
</td>
<td class="nump">$ 14,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,369<span></span>
</td>
<td class="nump">6,494<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss', window );">Gross profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,667<span></span>
</td>
<td class="nump">8,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, marketing and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,085<span></span>
</td>
<td class="nump">4,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="nump">468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome', window );">Interest Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(117)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense', window );">Interest expense, net of portion capitalized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet', window );">Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,092<span></span>
</td>
<td class="nump">1,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">(Gain) on separation of Kenvue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(20,984)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DisposalGroupIncludingDiscontinuedOperationRestructuringExpense', window );">Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Earnings from Discontinued Operations Before Provision for Taxes on Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,134<span></span>
</td>
<td class="nump">2,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Provision for taxes on income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">307<span></span>
</td>
<td class="nump">795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest', window );">Net earnings from Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,827<span></span>
</td>
<td class="nump">$ 1,571<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Other Income (Expense), Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Research and Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DisposalGroupIncludingDiscontinuedOperationRestructuringExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Restructuring Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DisposalGroupIncludingDiscontinuedOperationRestructuringExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480781/205-20-S99-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45052289608880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Kenvue separation and discontinued operations - Depreciation and Amortization of Discontinued Operation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">$ 383<span></span>
</td>
<td class="nump">$ 641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpenditureDiscontinuedOperations', window );">Capital expenditures</a></td>
<td class="nump">$ 162<span></span>
</td>
<td class="nump">$ 303<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpenditureDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of capital expenditure attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpenditureDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>162
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M_)K<]Y$55,U]3?.QN?G'==Y'KJ7[[<K>N/O,W8KGUNT-C=9BZ' TS3<#MQP
M__DD/H6FG&3%?W61;Y">'EG.#N^+%8[(94\,_X*P1]*[>OV;'5@?='%!PL9
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M#G.SUE\5[,(U?.D:OMDUW+Y3-Z2TE_".S+RV,QTH;0Q%4[.4ON%WX!L^J&^
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M\ SV>[%!LL)&)142E!%:,83=-)CUQO.1\_<./P14YFS.7"9;K0_.6*73H.N
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MS$-,.K4>--QZ6%@?<O[*$#+K,X7SI8S+SO529G7PC<U\X/S*Y%T-^\^&W\+
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M5/:)*7Y9L4\RT?1!B&,,3(F^M$R,A_6%96+"R(/987=HY^Y7^$FFB"D23=\
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M<Q_D"['+EYNDRC9-JS=#:5G9=2-%*<_S1(P,WD'![P80CK<#3J3W(1!E+'<
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MLS$DC)DV;8UO6K0E-T?-.C6HV8=P-TJN85(":] =ASZH3%9E]E!6B@?>*HJ
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M(3MO^AG( \"_,"W2F1@2%CM&A(-)P&>"+NM<#T) J)P\O2B>G)T7Y^?GRJT
M@X0"W#2LL@8 0>///Q4* %:WNH(-/!R/QA,%4/)X7NC/?[J83L?/98]7_.H-
MODK?3)X?%TIW]\$+JSZ<3D? 0W%JL/&J!D< <#TWIB30'IZ/IFIFJPI0Q'0V
MG^=(5*%<-G[1-FLEB%#-+4SLAZ!=E@W)B_N%O00;[3KB7I!H^%/= ?,_G(X>
M>2"8T!H98=ZT)7,"2*A%(N)&M2U/+$KBQG:Z&JG+ .N\:ISL78 L#H#1W-5(
M[DSF+IZ.'G_EW^T:F%N!EP-JC11"0LT]5"&@@2 _]##1U#,83@1,=]DOP= K
M?,+/]\,4V1#? R;>P&Z\Z@!*)SBX&(\F7]$F6K>R&P_T#HC="E32$F4'J;H2
M>0<.&:GOF@H<-MQ8QS1/OF7(O;PSKIZ.'GUU<)V[E04%=&?:H.]1"P*WH6*#
MM7_I;;<%DB/M43<!\5I0#X2RA;9>%$0[B_ 2)8/T,F^N+,A/"[:K$C$,M+^"
M,?T:./)OK"Z"<CIBX,!>W]JF=T"?UI#QKCVJ#[[JS!*A/2:[ MXDNIH(M#NH
M8D0C".I05B=/GCM:(9C,[X+)O(DFTU.*2 ]/_;9RPJ@C9XSZL8'OIQ-&<&2*
MTG3:5@ZLY<>Z(@F&"=H[ZT!# 0O/<7&FK*W9VT?>$HC!# )%0=(\0NX'%Y !
MT#0U8!/>V<O/8?,'R/F:%UX )M%[,&A6U"^];CN<>4$N8,:'B9J&O<XZVK^P
M5H(F,8J "V1;$-]/N&'A5,#-)HI:8I8/39B+0MVHJH&G+0H%LO;V?K4P4B\&
MO.0R4XJFKUWJVO[*&A'0?]?L\)][!LBJFUN- 8YZ:X"6\#VI'/CPP<Q7+!S[
M!LD4N!)96V1707RJ %J],7T']@,VHW&]];JOFZI9;@N8=D$A%ICJE\!,$"*Y
M0OUH^K9QX"^"W2M R<UE\/N^@MVC<?_;%HC=<7A7$+!7NBTM0.C0@VH%?G#%
MT/$$?RMS0FS8/0D?R!OX$[,>J5]:L P=<Q[1N0(M6( .:H#K-7\(XQO\M&H<
MV0IV!!/O!M3_ A!-\N.(_*@9@LL&Z&+,"IHC-MG!=<&5VC1M!PBU3>9.$;I%
MP-ZUW:K9:*1+H6[Z%I@(T#5 R5&FI4#$6C%_CCW@6UB<A?T&/%L2I&/:TT^6
MHFCRUEA5.A/A&&(09LRPE>,GP2E^I$UL."8@!T\VE.).%E:SK=JLM@Y8#YQR
M\(G[EI@ES%\HLS5J#^IQH3G$+'8.T/\(L7X2F) %!CPY=6W0(T<?LVPVI CV
MC;J\^4AV]F3\Y)FZ$8I=&R01.7(?F@TP^O1B?$QNUF3R'-@=P+GUJKB1T1@D
MA F ]=&]0+\^$V$/"ME%@<&C2'3;%OQS4F>%&,H6E0Q.9#[#'"4YGC5XS^P@
M(Z'MFDR,7Q Y,PW;/!_"^R!@J+A7NA,KM41. ASACJRX3^0<K:Q9> T,>"C-
MG)EF#1JRE:6)K4MOB(TF8!$7\' -HH^A!(:0LCX2T7:@PT M.C'1 0EW'-54
M:.>!IT!=; SE:%AT,4X 8&Q3.A7M<<#<;EA)GAYIACUD9UMD@2;(\ GN"G"^
MX7-)@1[%<5JAP]?BY#S>:\3?;;5'P!UBCB=/B$AL>XBZ90K%*/(N1@N'6/='
M"D:%M\FHO(37UC.@C\^*>/8^/QF?H5T 4V8B2(&C([_CKEJS0D5\:_P+?M@K
M9B#D;KU< O.P4Y R^]%-/^M89*;CD_/Q\;/A: !S!XY7GC,_(,'Z#?DT@>\C
M9O#E,DY''!"=$[ -/3B+8$? FB-[XB*!(SS[*TQV )G-FB))=)5WQ6FFG24.
MC>#<0< !4;TRBP4S)I$P$5I0:&9IZYKB_ 7Z)8$<DT=$CL=%MHCG9Y&?WS75
MDY%Z18)+#$"NF<,)U[:C7,8?9G[:YO\)]T=-^S2PX@?]&9F&E>P38!=ULJ->
MX]"!6HVT\5L#SP@\2'BR;"B?X(4LTJR#65KF+G AY[:RQ#M%QFT#=A5.Z@A6
M"MVB&QV_._&IB$R04RBMB](.^]KAI=1W3'C+L\F76.+\_R75K[1;D9L,0=N.
M1SNO-!CU!9(*%?S*+E< 9&5A>)D$@"PB+,HEPM:W@'^?+VI!JZXYLXRF!5UA
MRCSXP&C3M^"=@^!KY(T!-$3./[@T, FB"<UIG<,1,A][8>C!40-]M-;M)\-N
M \0S,N]H-]7'N59*QH+QY4Q2!(_(2C!BRLBT1 !;N\YV[/*QM6>Z=H >[203
M%,+K9:M+L/C EL );.]S,'BLX\048I!3<I;=NR6F=FJ:*>Z#$-O,*LMBY#!O
MUH*107Q0]!2'%H@ULQ5\J$5?E]ZUA(D=BFI$'^!<-,/1]?4EAJ_X#SDS$%2@
M +:ZH@ )O,O24%(D!-IH*A"-WT>(;W*(WT6(.6 &Z[!&42+A(-XB:D_&4Y_?
M\/F('&5E S/B.YR7HHF<,^S]6#T#Q0-QHW:9T%M^):AQU!+. '?"2X"$RI1+
M29,[UP"A<4C<]3VL0RS ^60_F@<D#'&ICB2@9=DXOH\C@+4J4K8:%0[L;P.1
M^)9+5*5%<6@PH:P%WC3@CO0%:XPVG8!+  .,&5")):(#"XD2F\.@!.MY]I!X
M (TY"!QRI9AO>OP?EE]D-*^UR.TZ(,:O$QE-_\Y?7D$@Q+@BP+:9:+.'+OXT
M>NQK=-)^):(3S5!$A-N7@"3G76LS>)><\Q9-QP"P'!A]"\C#C9P ZY]0_G\@
MJKS]F(V#B2@?6@[S<JJO!Z AM );2-42BV)V!>0?1 P3E_-YOY:*"26DZ.OH
MD+*Y!4.W"VH*I?^69-CKVR3QMDM%/XB$U#V/V3!*Z6SWO(&I'07LLQZIM\3I
MI$]*@X\P(<."BCECT);(1O[U>70L2#4%/0QD(GR3;'!B*=T42S @?,"1Q 8G
M!I&O,2WG>HC#/!SB&7<<G<UT1:4'KO C<^=BC?D$<^<&@+$J1$_ MIQC(1_H
MY]Y1*M)0RC .!G9.N,&G*CT#%DI'-XCR.)CXV19J4^DZ[GT3%BHQ_SIG-^U+
MPUOC)9U4BNL.:"T.OUN-1?H3B@?6IELU)<47Z7JA:A$YO7=FT5>@Q&]CP8JY
MYIEZT=N*TO\(U\Q_B ">C<6]?T,H1)' #-FJ 2U@4[=W,@9'>.I'OP7: 9#M
M=K#?*0R:G,F@S*_B:@>[PQ(/H2#UJ.Y<L^CNM%3YDA(@(0S=01_76XSV]ZZ,
MJ0E#(59/22=.P]?26T$*0":F/&X+G@#"@!]VP2#FPI (_6E*HET%\,LXC* C
M$D<]^!O)X^?P&96EJ='28-J,K!*I^S-DW M&YGZI0(D_J<@T,<$YV>;0*T"=
M!L!XP\[57BP..U_@(,=I435W,/L_$'N>,.:6'3G05&0DR5V)F1<TRH#<9@T1
M$F:]+:NP!C1E6Y GEP@F ;-F[W*+$09,@UY/3.0. /6U,-#I6UPM-:O.,S88
MC83/T2X'-><C&0;"EPQ0T9/YYB102:TR 8328G4"<\'P9G>'A?(P>0@M$A7B
M"\$YD 34+WW#=IU<1U"T<S%25*CW9B!/RU.LXQDF74=*]"HA6D!'8NEZ*I&G
MY+Q&$O:,VV5M0^]#9"!Z_BO9/AY*+"<I5RJU.Q:IQ&5&]A'V1F0[+L9C?03[
M45C*B';4%X1).51_\*Y#$_4\<GG!02%QC(OO42_$@LLG-&M3>798-AAP F7]
MW+E$_,6I9=7,J+RZ)6YC !& ;KO!@ALZ84);4'HPT],QV)NM(XU_2ZE$-BM>
M"EHS0^M5"#) M6#V^A:?=!2? ++638@E^@W]X3'8&B!*S:E\:?=(H2<6BG$*
M  [&^&ZFYY\X\>F"5[!3D+R%.(=<"6QDL:5).@=R/P;8O)_[(AEM@G$6O7WK
M(B>$K.GE?-[VE/.4_8>MX!)QTUYXLGZ:S)Z'HDB"! CM:#.XM4P&(T>UI .3
M6)<K)@65 ?$O#N7(&?-R!LZ^Q01_W;$]QTZ+Z LG:LI;$];\*0*)Z=8; W$J
M%5*P +5$42(TQ,Z,WGO"40+#1KPL8/:.-E2D)5_,][52<MK HN0#]ATZD,14
MADRPKK;..H_LG[EFN[,/'T$B-V!IBP=@U:F]I71;EG"G9&JL%D8.2+I5A-Y4
M:O/1AF^YZ3)1VZQT"W:8*FXH<KY.X[N38/#'T<VH2*)R?,9.*=71  %4XO-&
MGS]8VC%PR-IYP\BQ+@/X<#(=G65M%@\GD[3QXD#&&4>&IV<3W\70FIC0S\UK
M]%QWT<Y%-MDP_+T$9W+CLK)9NNM8%0^$A:&Q>I6P,H6M)QRV8HQ]$KL? OU#
MLQ1(F\X8W?LKL"JKV4$N>J1N2(V), \8.%,>@9L3UF4=*.4UFB";.Q0_8VJG
MPH@0N)P3W2!R$"Y9]),IKPBC8GG??%[9&<3U?=V[/BQ&*09<"V?!S3G?Y%:2
M'U($<27.;C.-@.*]IM=XJTAJ$@:N &)L8)=AZT2;7UEO(@&"%QVSEE3"2C"(
MW[4 K-M!+):E40>ZV*A!RI@D,^<?PH/X1?R^"9U\H"QL*ZG@$L!MHR[G"A,$
MZH1,5.ZR.RY_IT8(-TR]"KB5MB3='.SM,'FZIYLR=U2BFTI5(.<3,IEE6P3"
M8:B-=CN3KK":R] F^-EG\^Q^Z%'%J.\O+]^K96_Y.UYZU_4A1Z;%V HI*P0T
MGX&]=\B7P1'M*68!*\^9XNWE+PI=[FMBH*U5:Q0,+Q%83.2D'$R-5GTX;>J1
M+, P0O3C3%AM6-C/_9TP*41^77!"?29]F%%=8 S,-3Z?'7.15<DDH.#4H!*V
M.9']("F@[L-G*"=P8UJ:$Z2^U$'[Z&C\%7>-41T,&_38Y>*YRYY:!"F!()*:
ME:JX5HU:GJ0;_IB2BF+'A2V66!E*3>BP3[",CO@_D>*,$03O3J^-E$$X>\!6
M-&I)WT*<%EA_<W<2E5KZEM39;O%'&!P8964W&Q_; [W*"C_L?\JQ:@B/J=7M
MX7CTU!O/(OO$QG4\N@@/AM7 /2C.+2I[BXB[-'I'NT:J.VII3MU Y(8-'BPX
M4A=E=I)L=]QX3,>23MZ[73"S26I<N(FILZ.K]A;R.2N)O(Z9KO3O/*7#L>6=
MCUD<I=-KLM28+B#AXY M"5!G6^'9UG4G%G#/?V&MF+,^U# . FCQ=8GL.6!H
M2@H6"3$]#&UMQS@#;PZ-/I6DZT0WABHBV9HP@51]!VN0;@4OVRRP+==(SF)F
M)(P/C1[5=I" &W98^TXW2X"3$"=)@0[[9G$"<L_R9I-%@XSO&^E&ZCL.;@=O
MNU#\CNF$ -I]$Y+%=$T#=DQ9<,0HV!!ZGU"?L','6])#BC-S%'1L>(.-SWR&
M,Q8]LU[2 79WJ:#0 E>T PJW*THP2"2 LP;L4@NU=(<VMNZD-W(PG4?4+C#J
M"Y!0/B-@B)NF @+L;T 7+%B5N/9=B]4CU%X+Q#]%:TPJ2=)@CM-PG[*$@_G>
M45OO$XKH;LI.LF2;;W&5C-!NELZV^0M>97%^S;L?D?7(CX@8 3G>DPA+NFH>
MY:J<&UQQA\E.+J-X?R_2.4K, A9.VY[MPF52KH>U@Y 7I,, 7U8\C_2ES'P)
M<O.L>];$#&O'_)-U4BRSDLIBA-]YN@9-[,N":5$1&]W)YOFLCHYQYW 5+0;A
MA&,/R=+E]8MP8@5<S_4FJ23OR0$(B#T5 GPLO[_D.;I?F8*R 25N 5-<6FR-
M.:F0QR$Z@C' ]M0-!DO@Z\!=(H6;/FF@Y/U0&!&V7;"V?4-S39")?3,[5OY1
M0\J<G.GF<6?I.+0[6%"XBDE:TGL1LU0\\%PQ8 7RGL2%P6RYE)M\520&5/OJ
M744NL" 7$L*:C TQ+8MI"-T-5>:**\?Q\),T(H&5;CCF #>6-K S<EC6GGM&
MKRIVQ) SP"MP(=]'4Y328<5**B"%9Z,$-+YOW2<I$W/[ +HD9KF-';,88/D\
M .FHCCL@=L#T%>6.S[-0=_3NNK.?V6&2R@"V#?LE@5K/U-'D&(]5VC5R%JQI
M )M"JSGZZ1MJF0DQU?W-,;$K4:PF*H'GZFAZC#JV0_NR[[606.8@0)?<!+$.
MM2%T#@6T4%?'33B8^^PX5M6SZF,MAW06^U3=<T+>T?EQ5K-'7,++V("!=$IZ
M#DB4\IE\MTFBCA\/CQRDO7KP7]2ZKR,H(Q ][09=LTE1U?,^*I>8N62E1K4T
MKOQ)CARSR-P=A\;#ZQ9B$'^^3D;"'[=FRPJ80U?T7"4K3A;2D7S8$M/25 />
MY+5(\G5B;8[V[B4>N0WKMC8A&86::4ITI*Y]S/P1%CNZ?O?Q.+57A!CU1C2I
M;V^+A:**$3<, MXQOG@>GVVNDEEX0/H$5KY_8:_:))7M/7,:1VU(@'<V)UAB
MR1+//D<35"8J I*Y?BTS2%'!Q?(>/^=B>U;0I>"<0RTV8,!-LZ9M^:A"N[-Z
MUBX:N@2(98904S6>^<Z;@!W8<WBE*DKK@-,(5K!C$*QO!=(EYBE#;9X2$&_"
MWOB(J8]E&V]T,3G58;(:8WHIZIN(%M^_[\</Z9_C3PJW'1<C4+D"%-N0\PB-
M0GFQ[#/VE3GQ1WBAD7J7<U[HK\W+'-25D]?:J3OGR\3%;(610U1==@1%NIK\
M87YN_9$^V&=>4N,A"U*#E+VHO9 @WS&#<Y%MK1W5I$U[BWY7;#,K?.Z(LP$.
MW!:N=H69]OAX;%V1Y/ZL:4 2?U&?!%GAWI=!Q3GFM!$) Q'G0!S/E1?JUD!
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M%CN7Y&6XP!S=A)![MW)M@G?[O#40NYI7F/S&?/DW)IE8/"@AQ7>4 (7S/06
MN</8[^N> G?C\4\;YK7C =#!?#Q/CI7@9GD/9WCD3\Y9>2UKUJA7V^TNGH;8
M\?>P +A!&-*"@&!%NKIW][C?74EI)ZKW@+ZESCP$9'"L#&]1HW,273B0)86V
M]'+P77CHCA4O42E,L9Q_ )(\[S^P-)*F"->/'0)(JHE$$C\Q'W#G9J#@H,3F
M94HC\CFJ86$+UZGEL&[2@.N'>U<E,SB-,P/XLD1@=@"1;OXK^?X)K>B.%NZ/
MH44VNN/++0;+2%3/YQ*S?I+8S!IOPDI%'0?3"914RWB/2YC\D%\>NE?BRZ'1
M+\!*!L5#D1^$R6(E%CZ)2["PEOCQT34?./3H)DHDD[0-IDUZ8G=%S81":!KN
M@+/GR *(*QX<#F]!R(FBLV#AY"9&!\AD'29.*._<+!:8YJ;-\U48H3/OXH\=
MCDG+UWA$IBVYF!Y#0+R-,VEJC7>)OP"-/-_WA738]]+@34DOG+5.YXF=6L3E
M?#-ZM+7.F\4[^M4-U'U23XUIA_0ME]W4[9F.U==(O;350/T$8"65[X1*6 ]'
M=)66;U>5,(%XBXH4U& ;;W A=\SW4E$[%W4=ML%G3R]]E_9KXN:6XINM?.%-
MP$>7W4S +9.;-MYNG_T>@SGXZPLX" F+9IH3)(DC$'_=(58TX'NS2:[?)-X,
M)U^2?EZZV.A3&BB1C P[RG>LKPM7%XW4J_AN:[C%FRKC>P^+AA/C13Q/GYXM
MX[Q"N%A@V,WB:V.!G[EK'+F,:,&/T@MBBJQN6H1?8 A1=%+"FML PN#02.K*
M;%4PTY@YXNJFCQ91RK&8)[]$P9;;GQ]OTI!T?X3.38S!)_9Z16)V:N% 4TW]
M3[:3BRB"9Y7M!,^\[UQM0%:>R1,:.'Y?O\8,;5;:\2(3R6%W+3>V\'$?[)-X
MKE;-'3HH!4I;W<27_2]>^!=FI@O9<KJI'I4:6R???RI:.<X.2K.G2VE],![:
M.K*;.G9RSO&:.J[/[Y\C7,81:UR'NJH_^#N:^3UO,4.)FN]ZE'7D[BFA#=['
MY-?U 59ZS9V_?2"V?/H+0GX;7,/KZ[1<!B<V)DOSIO>]1&A]=]?O7#"6,9/M
MP*K\\S R>99HB"5>;M'$7[4J^PKS&H(9[BZ07P&@9([HO<%5)\"9<J,)_K:&
MOW"&%!E;,GV -@'H<*,R.D!A:&#;< P+;/3"\@T^>^^&\?QXX#Z&XM"%##Y7
M?'$P.[RW03*!@;N2?#5*4W<Y(]BG$_"-%G0/",$=W4$ZO-L"=)W]TL;XAR*2
MFC)U<1Z]Q/H%56*P?H?PNN,#R#I)[DX5$"AW\/#)^!Q/FS94,I^'=^7$<QAW
M5HS/+Y*YK7^%"J_#T=/BZ>/S@Y!0(W<&P\6%NI1BG?PB"?G7A_0W7EL+YI=U
M8Y()\9X@10,2QMQ@QAULA='TXRDBD0D(=-]ARC?@P:&/AV:>6@C35 L%*(ZC
M_D=3H(OY!.*%A]U1_Z+(WE)NW]G/$B)S O? #&=^!A%_\*Z:6&C)&B?#L6,4
M.+Z(0W(P<^WVI83&14P[S4P<29V)>\8_'NW[1:[3Y)?4UJ9=TN_%.?Z](OY1
MM?!4^9^DN^1?8HO#^??LWNIVB=<@5F8!KX*0/7K %5#_H6LV]+MLLZ;KFC7]
MN3(:9 $'P/>+!OQ-^8 +A!_J^_9_ 5!+ P04    " #L@$U:I94AA>D%  !U
M#P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6RU5VUOVS80_BL'+^A:
M0+7U9DM.DP")TZ[[T*UHVN[#L ^T=+:X2*)#4G:R7[\C*4MRWE9T&V!+/(KW
M_MR1/-D)>:T*1 VW55FKTU&A]>9X,E%9@1538['!FKZLA*R8)E*N)VHCD>66
MJ2HGH>_/)A7C]>CLQ,Y]E&<GHM$EK_&C!-54%9-W%UB*W>DH&.TG/O%UH<W$
MY.QDP]9XA?K+YJ,D:M))R7F%M>*B!HFKT]%Y<'P1F_5VP5>..S48@_%D*<2U
M(7[.3T>^,0A+S+21P.BUQ066I1%$9MRT,D>=2L,X'.^EO[.^DR]+IG ARM]X
MKHO343J"'%>L*?4GL7N/K3]3(R\3I;)/V+FUTV0$6:.TJ%IFLJ#BM7NSVS8.
M X;4?X(A;!E":[=39*V\9)J=G4BQ VE6DS0SL*Y:;C*.UR8I5UK25TY\^FS!
M5.%!1D_ FX9O68FU5L#JG+1+201ID]>HV;)$4$B37'-4)Q--VHV,2=9JNG":
MPB<T!2%\$+4N%+RM<\P/!4S([,[V<&_[1?BLQ$O,QA#./0C],'Y&7M3%(K+R
MHF=B83VW@[>#</Q^OE1:$H+^>,QO)S5^7*JIJF.U81F>CJAL%,HMCLY>_!#,
M_#?/V!QW-L?/2?]/\_?_:()S#;I 0%HH5G:XXBIC)=PADS9W5@@-(B?_N[1D
MHMI(KC _AI>7HBR95,!K^,#+DJI?O7**%DS*.UZOX4LM,1/KFO^%.;Q5FE.!
M8YOY%ZS:O''#1:O3$D>A-P]2>/%#&@;A&W#4X=POHG[]97PUABNQ14DMH8:K
MWL:7P2L(0K];?7]L.3\A<2JDCK=I9%90QP&VEHB5#43B!7[/Y*C#.2HRO&N#
M!*NFSA7,O"",N@6..IS[3(V6FME&**Y;.ST_GO;66>IP[JI9:J$ICT=!XD7^
MK%_L2'H%Z:QW[">Q_5$/PW$T\]* I()YS^B9S&>4)OB5,"(?CV"0#-7,((U@
M'L%"R(V0E$"+$V'9<USJ(3Y"RGZ7.1K'/@1IW#O!MHR7%E2TTX$BW,'+\!4<
M)5YH;31O8^,\F%//2>"SY?INN!Z%,65M"G&0/(W7J,?K>24:$O8$;-\Q+N$K
M*QM\@.!A&]NC^4-OTB"V#N.1%\4]F!QU./?/&)^&8;?:C(,DABA.OP7?L1<E
M2<?LJ,.Y/MGW4VQ41U%?C&8<I',(XOEC51$3ZN*!*D,=SCVLBMFL]\R,AW0'
MI2#V_&E?6RT91-YT.H.8L/-$.:3>="#.4:D73N<0^=&0Z7R-=698DL!:E0PZ
MPK/ETQ>O@73\;843)?8?DPOS;RB8U$N3J37+C&)Z&NNG9.J_+IG 2RD8U(5F
MJ57P'LL<M*#UVBRZHP+:HM(.24Q:C EI"H1I8!4-;=UD0FFKCTZQI9U9T^E5
M ;E1"J7P'B]5)6U4-56A&EL7SQ]Z?C]H]Y6O3(%N;8'NN"Z@J>_I-N:TRCN^
MFJ!J=DQVB[8WN/S8C0X+<R[>(DT3C6/7 9P"8EF;Y-<F#@=&F1PO2[YFYD#<
MAOS):MH1? "[%M,HTX9N&F&(I1379 IMN%DK5Q'2^(IGC%0Z.\72G'5LF'B]
M:>CJ )]I[\_H#&A.4@U!H<V;T=:>#!X!U8/0:J"#'U9+TK$__-EX,T5,)=TR
MU%-'@(5)_ 537 T[YF6;%!/A&MVIQ+1]/S9-GWJT6<!6VOBT_ZX+*9IU02>9
MK9NAK2DPOW[MX--^M<:ZG=F78==I;&G<=[7=?-S68X*WH-RS>H]S\H[^>$LY
M4*Z@R(4E1;_O619L%?M3F+M+?=V90M<S&V^Z,E$)]<5?T"7F]0WEQE13->R9
M!%(M&UM:XP-;J(,#@XTH>79GTEBQ:X.482F*NKQSIA!8*Y09)V>-0*X;!T5=
M4%H+1A&C=XG,%NA !JPERPD\$G.N@?!**L:/'9\G@ZL0:5K;"Y\Y'=+NZ6Y%
MW6QWISQW5ZE^N;N0TBZY-J59XHI8_7$R'8%TESQ':+&Q%RL*.5W3[+"@>S%*
MLX"^KP052TL8!=U-^^QO4$L#!!0    ( .R 35HD>D,Q@ (  '$%   9
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;(U474_;,!3]*U<9FC8I(HF;TM*U
MD5HZ& ]("/;Q,.W!36X:"\?.;(? OY_MM%DG0=E+['M]S_$YCJ_GG50/ND(T
M\%1SH1=!94PSBR*=5UA3?2H;%':EE*JFQH9J&^E&(2T\J.81B>.SJ*9,!-G<
MYVY5-I>MX4S@K0+=UC55SRODLEL$2;!/W+%M95PBRN8-W>(]FF_-K;)1-+ 4
MK$:AF12@L%P$RV2V2EV]+_C.L-,'<W!.-E(^N."Z6 2Q$X0<<^,8J!T>\0(Y
M=T16QN\=9S!LZ8"'\SW[I?=NO6RHQ@O)?[#"5(M@&D"!)6VYN9/=%]SY&3N^
M7'+MO]#UM2,20-YJ(^L=V"JHF>A'^K0[AP/ -'X%0'8 XG7W&WF5:VIH-E>R
M ^6J+9N;>*L>;<4QX7[*O5%VE5F<R:[%(PHC%4,]CXPE=.DHWX%7/9B\ DX(
MW$AA*@V?18'%OP2153+((7LY*W*4<8WY*9#S$$A,TB-\H\'>R/.-WK#W#&NF
M<RYUJQ!^+C?:*'L??KUDN2=,7R9T/3+3#<UQ$=@FT*@>,<C>OTO.XD]'Y*:#
MW/08^UM_X[_!L#1@*@04!<@22NN=<GA&JK0_6:!VP4Y&(; #5"[K1C&-Q0P^
MK"7GKIP)N&&<VP[2'WNLP\$=[>PU-*@8Y=K3Z;9IN&,Y(>%H- '['8_A2LK"
MDS1*YJCM]N$T&4,2GH\)7#+![-4M8.NK)B$Y)W 63B<I?)7&*CX4=Y*0,$U3
M2)(PF28O'79TT 8UJJUO=N>J%:;OB"$[O"?+OHW^EO>/T0U56R8T<"PM-#Z=
MC -0?8/W@9&-;ZJ--+9%_;2R;R(J5V#72RG-/G ;#*]L]@=02P,$%     @
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M-V:O]AZ#:!0QD'1**1B<.IB.QNX+--*&*+1(S_%T+!@W'WK"7Q J\&:;(^G
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MQ\!F94XJ>Q"Q@(DY1C=42TC==UAF$J;P#$$T$5#UZG"2L8>=H*5XO$]5-^5
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MZ[BBD\R_X^\\.VBZQ'I^GZ?Y%E'#>[*F0*Q$O,OD[[7I>30C.Q<V;9[2"BS
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M7RDU(DBY>7BR<[L#]X=0X&LZMORQ7LMU<RVS/-E4/6B<VCU3X __@3[ID]P
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MP"_N^NCXD>?/9ONC V\R'35'=T=+!*7@Y_?G>I?S&4<A%P\4UC&-&"KTGA;
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MB,(^;&B_E'K+#_@M=%GJ#7]<RSB5!2W _TNMR_H+'= \\?GF?U!+ P04
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M=M1,PW1#KQ<:[T#_*ZW=8>$3=._A[#=02P,$%     @ [(!-6NG++E>L%P
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M+0L0%?*SX*$'V<?*B>Q&)BMH1D%.F8"J@5DW]O,MV?M,I6QX[FM<=@;\MU#
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MHK<<2F- ZVM!I\QN8 (<7H?S?P%02P,$%     @ [(!-6J]MQ'5P!   #@H
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M37M2H# :Y/(KY'-)J]I889*%I2RI"W"Q.H?>#8V9TJ0 ][PLJ41)GBJ-ZDC
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MYW[4.'-9R=IF!+=-]JNRB2D$5RK""@KL$D1AHVO8,_"*:LH,NIS(:Z50Y"]
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M!85XAO!04"PB.%,\&%+")LN42A7:TL.MP%DK#O@2"QNA3%5Q"94NX2YQC_C
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ML[=7-W#250:G)1J$I',?V5>GR28# FTGM,-%M2-4B<$!F23993,0GD_:TU%
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MK((V0*)W+/I%V%K=U@G^/(G]:5S&?VP7X<YM-SNT_Z6 #C[C&I,5B[5RV#[
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M&0[YM%"E7&IE!_@&EK+_7MI4?GTJ+C]=7!Y BV*JS7(AH;E$U94FZA)/RLS
MP7 R%$H4INH:,6K)!Q*K6):K,M$RT_]P:C<S6HCS>">+#4J1*"(H$P44:6HK
M[,I6*A?[%^^O#B M:\I4E:".UCXX/AD/1R.Q5 B+H$F!:9%(N^!O)=BLL!,D
MJJN5N)99K>A(N5R6YE;#]%2VPAZGPT=@*LM T9#X;T2K;I>(=9:D-:O! #$%
MV@HK702L%J6IYPL<E+2V3R<P"7BY(+99RVI:N;V3S,!?YI[USG;:^A,A0AQI
MDJ0N108J2RS%EVP$MI[^B26LP>4R@_RGF4(TGT-[E2E7CCOP"A&%EV*ZVJKF
M'W]X/#X^?R80&),O"Y.1<)ED0YKQ$1/9I2$\,47J[=<+.6*!N0*IU6JI'+\P
M:\1S2]\@\972/7D#<8LIJ2O)ZI2-E<5Q"6.^EFRL[U2J$WB/L&K.)C15<UT4
M+#NW6+:^)%*(:2B:6!3IPXJ.SY'^Q32L(Y.120('(J$S/[;]MK,+27M%IZ\?
MG:MJ85+>V.V$14/Q.\*UUYM;X+Q64ERTP?F<<61:PORP&2( OJ]S^KPDT25D
M['A3T;.Z)&&2?9!X9A+OV:3IH6!.ZR()<O46[95-G!769)J6@&WP6)!;P@CP
M 0G;.N6IVX3DX#=?UF6" (,7I4[@2=?,8$Q*APQBKT 2<"P/Q WL245&.R"#
M;WFT8FY,2H:QRW#< ;;#J86?02)3I8H-@UIGO(]7,2M-OBEA$HZSE_:HH7A=
ME\$(XMCLXG*BR@JXK;$@/'_#3 =YN*!U-CP. 6? (@HA(ZQS$EC?O\LSE "_
MU(A@@>=G8I)/RUOQ*@1H%\('XFH!W[Z1P:FPI_N<C.]#:2IE,C/7MS[B.^$3
M_B1&.V<R,X6I!,7.$E(<BM\*\::&EXY'@Y[D1)DA4QS0UJP3+&\<3=D%;%V[
MP+Q064K)IE+)HJ!EJ[Y$,]6D,#W3"=BI]-2DY$8D9YWG(.P0WJ39S)$[%*S7
MIXZU)# :/@XJZ=4(S%=7"[$$-3@%$N0] ()3%PSQ2:XS9'(#62SEB@QKEQV[
M7'7_X+?=Q;VM]/N@7W>#QV66F43ZW+(>AO#,@^/AN+7*UKH*4QS*W)05DC:E
M&L *6<PUO0R>S8Q8HAO[A"B1BLL/'W^4^?+9:Y^L1\,G[0'!V<-7)^U79);Q
M)[1K7XR\6>ADT4H1CS1N!:EG#:\4[2@HDQPI\.G4J\&)#J QTZ@$*,FMA3@O
M,Y^<X]0+([0M6"/!NV4R_1,9TX45LABOVAR6!X3'JH01: ,7G^ 0,W5LK8A'
M6R<<;F=(IA!*26*&!W)T.AD]I'-/SQZR,MGZ_=Z1ZN':">$ !B>&:CPJUK"0
M0B^.CF%"!Y")4MLOP7(:O3GYP&\XK8&@RL=O$KZT:SYT_.BA>Z!1K8ZCE*RJ
M4D_KBHT(Q-D5$-Z<]!F#'JR%]$- CA)U9,U$.K:F.!0_.B7$F=8(WG0"F54E
M;TFC2P.O'\8PH#&/Q%@H:JJP6O%R?JR-O1QV^Z/>.[D2)\??'/3Z8['8O_IC
M\OE@O_F6D7:F9 H+@/OHTE:'E3F$++\@.A&L(RNF#74;-31AO&MI$X9X,*N%
M@<R7=B7V+S^_/1!1) U\5J62;*XNXF4425DNI6&'D"587H78"10^>7W "B K
M7A*(S#;6?* UNN#PF&6''$=A9W.""RU6[$+M%A#!;H@P4U?(T 7Q[Z"][4@O
M0C)Y#LDR?'6QY.3DK%L3M##=4]%1 \=UR=ZLD2G*57 #3]I.&*MZPCCT^@F"
MOE?H?JV %[)F0>3*"+DU!1$"2/-"_Z.!I_?$CYNHC?$@%R0,)[F<Q)I-%-.)
MJ[8G=L51;M";RIR73ZE%!<>SFXY M8TK4MF1-IV(XFW%^0&1&05C@[S;D-P/
M2WWAK&$Z\)&:[/-^,G.*OG/_=5:9D58T4YD!8")Q<P<07$QE5!)/@1 $U?L4
M2NB 7!9RKIH2F2-FFX[HHRCK@ QD,02+UR:#AULBX95+>/:@$Y!@6(G*I[#U
MT.EQ'9E6"D_%!?DELOZQ^_-KB-KGPS/\>P0PV9?TK3A#9J9_39H0(ZRF?Y?%
M-1BA[#+"'O3O-RXBO0+<AZ?B$U?EZUHA6'SF_[[=U,Y3L#13;#.(T_@<1)^Y
M/^\- 76 +B+U)W$\'/&_29*4M>JH^J>?F("6B#[7>3 &3N$_[YOJ)29S#$[=
MW[[OG>-U=.$6OT4:\T)O%I/<?W;="7DCRQ0VKZHJPS<DSBM^'8(S<=EETK'
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MB98:_G01YHTL:LIAKCOW^)GS*#*NM9#48<AA$Q+.LIXVS/!EDHL,J%U<<E:
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M8).T-?\)ZX+7DAJ)![ "HKH&'@1^P,<%($%G@+W&C)-K> P$;*FJ%2PW@S>
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M9F2H "I6UB958'/.Z&4R7W"$3'5&$T;#P,%! ;T ,#)\4(A<,G>G4Q %AGP
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M-PA@2OB0RATH"S8%R6AI!9P 8-ST*2&O&!@K:2E7(%)2 >+6LW;"-<5O*9[
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MNKAQ5W/Z-N@(BX&$#'V7VP\WEB:R>U<JD42[B1AU8G<C,KMM[,EE&%F]A%S
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M[;I%Z'#E-0JM:F:=[7AUU4Q'@]>)U,NB+G*PP1!Z*ZD6PUYV&^G!1+Q@*GN
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M"A8YVK$M.;U+Q0(I23T&^4N?*0 V! MN"W$]+I.#2_TF"<*U5Z0YN#.H/$D
M;0$<WCE'J[NMFQ+.*W&T0,PB=*PBDTY7-T535[[LC!;B'Z60RI)XAOFP$\II
MNYRMHQLO#*5]^*TK@IML)$V%W/5<#640=#H<8N/11"I,:8/YXFN)5!J)X8'
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M965T,S N>&ULM5=M;QHY$/XK%A=5B90&6,@+:8*4EYZ:#]%%2:_WX70?S.X
MON[:6]M Z*^_9^S=!=(DI%+O"ZSM\<PS,\^,[;.%L5_=E,B+QR+7[KPU];X\
M;;==.J5"N@-3DL;*V-A">@SMI.U*2S(+FXJ\G70Z1^U"*MT:GH6Y.SL\,S.?
M*TUW5KA944B[O*3<+,Y;W58]<:\F4\\3[>%9*2?T0/[/\LYBU&ZT9*H@[931
MPM+XO'71/;WLLWP0^*)HX=:^!7LR,N8K#VZR\U:' 5%.J6<-$G]SNJ(\9T6
M\:W2V6I,\L;U[UK[[\%W^#*2CJY,_I?*_/2\==(2&8WE+/?W9O&)*G\.65]J
M<A=^Q2+*]B&<SIPW1;49" JEX[]\K.*PMN&D\\*&I-J0!-S14$!Y+;T<GEFS
M$):EH8T_@JMA-\ IS4EY\!:K"OO\\)Z<M[/4SZS2D[.VATI>:*?5]LNX/7EA
M>S<1MT;[J1,?=4;9IH(VL#2 DAK09?*JQFM*#T0RV!=))^F_HJ_7.-@+^GIO
M<5!(G8E[RJ6G3%PP(917Y,3?%R-(@2'_/!>":*#_O &NFE-7RI3.6R@+1W9.
MK>&[W[I'G0^OP.\W\/NO:=^>GY_8+FZT&"N7RIR#V]L7?DKBRA2EU$N1F@*U
MEB(N=C-BH7H<:.FG2@OE'=1H,Y=<3>*6,I7"9@@L!I\IG0I'$ZA"KQ"?84 6
M9H9!D,C(2Y4[8<;!=CJS%H)B2=**TIJ)E04$+0FETWP&0HD1MXV#;<C+G#BC
M$DJ4L<CI=QEJ'G88,*=%6B"+&.;063)"L7O_3A;EA^L]&)S#[3"YQ=/*.^&-
M&!M4J( =AE,8Y]F)0CF.6U')Q\@%B0FZIH<5.*5IK(**$MKK6*F %.T$KJBH
ME!XA!B]2LHB<7@6I EG/0];*DF9>I1P_6<6^<J_>%M3% "-0:,(J7[(EI<>A
M2<*93"%4CF*ZYC*-+L1TL%L,"C(IBE[IV=,HE\I*;^Q2N*5.EUXA7W-EH7;W
M_N'+GI 9G*NUUJ#VQ90X"EY%HY]NOJSGZ$#<67KOY:/8Y#(]XEQBH+"^TSGH
MBI'*<T931:ZB2Z 6MY+]%:=XV9-%-VWPE])Z398Y! C:Z/>KF77"U(%,D6RW
M+Z1S.#<5>*ALH'S8'F<S53/*O=&'PRT^]/X'']8 K[D!]A@/RQ#]%\RH1&%#
MEIAZ!'4\@3K ?-1@GDI4R8B(S^K46 :)0D@I0-WL*0O)=C7Z OI-9&H-BI=6
M!;T9A[&96932MQG<(LMP.+&O-P>E02P9F\,FB-IBQ=X_H-J4DJO6B;&5.D4]
M4EUGK/))>^/JA3Z2!3==@6N2E;%5CI:AT-A(79^HM:_$C('5#!!$'NHJ]",%
M+6HT"VG4Y/D6@Q(%@@FMM=&R8I!]CD$5@9)M1;!1]A638FYM=2C"J8@U8*O1
MAK[Q=AR];41^#@=W8!V:!UM6FM6'.*=3:2?T5HAOY.WA+^(MUH/6;&4KE&8-
M(U",&^X(F64CL'W<V'[/PY-F&!QW(9AIY>F(ULH!Q J' L1@YTE0#R.@L<EQ
M8H96+4<Y5;=M]1T!_-&AI@'A=O\T42XRAC%QRD[%;MW$KF&"UY'<VXC<[47A
MD-OG#LV'JF9VNWMBI]M)1/]XT!14LYCLB>[1L>AU!U4>[^KC;B<Y&HB=X\%)
MT/#Y":6J3K#B4C!1K#BXV7:K _L*N$VNLI"]!X^_@ +*/DJK(5@Q_D=+O35+
M_?[@94L<O)U>9UW@BJ\)W*TC;YT ANQG('&4WA" WBL!B+ .?RFLER)ULXI4
M9PNBY'CP*R$]=_MNK[V4"D);X?<@GSBXHL9'4S/;/#DOXDMK)1[?J[?H2NA2
M(J<QMJ*J#UO"QC=@''A3AG?7R'B\XL+G%,]FLBR ];$QOAZP@>8A/OP/4$L#
M!!0    ( .R 35K,,H6[: L  -4@   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,Q+GAM;-5:6W/;-A;^*QC7[=@SC"Q2%TNY>,:YM$UWLO'4R>[#SCY )"1A
M0A(L0%IQ?WV_<P!2I",Y:7?W85\L7H!S_<X-]/.=L9_<5JE:?"[RTKTXV=9U
M]?3BPJ5;54@W,I4J\69M;"%KW-K-A:NLDAEO*O*+9#R>7Q12ER=7S_G9C;UZ
M;IHZUZ6ZL<(U12'M_4N5F]V+D_BD??"KWFQK>G!Q];R2&W6KZH_5C<7=14<E
MTX4JG3:EL&K]XN0Z?OIR2NMYP3^TVKG>M2!-5L9\HINWV8N3,0FD<I761$'B
MYTZ]4GE.A"#&;X'F2<>2-O:O6^H_LN[0926=>F7R?^JLWKXX69R(3*UED]>_
MFMW/*N@S(WJIR1W_%3N_=C8[$6GC:E.$S9"@T*7_E9^#'7H;%N,C&Y*P(6&Y
M/2.6\K6LY=5S:W;"TFI0HPM6E7=#.%V24VYKB[<:^^JKOZGRKE'"J4I:Z>U4
M9B+3+C5EK<M&90( \*_<\XL:+&GC11K(O_3DDR/DXT2\ Z&M$V_*3&5# A>0
MM1,X:05^F3Q*\;5*1R)91B(9)]-'Z$TZ TR8WN08O;ZJ[SM5V0QX5QDG<_&3
M-4WEQ+^N5ZZV -*_#UG"\YD>YD/!]=15,E4O3A ]3MD[=7+UPW?Q?/SL$2VF
MG1;3QZC_YV[\+Y(7'[8*\>H0%TZ8M:AQ^PK/FT)9\;.2>;T5J\:!A7/B#,:X
MTZ9Q^3WV5,;6H"5A_I:9VJ]U:H-T4)^+K;S#8Z4X+5!\^SW'Y-%ED*&H9'G_
MPW>+)+Y\Y@36.I/K3-)V5^.'J+/(2MI2EQM'5/^.S-C=KZTICO&)1(FEI+#\
MK!Q8 C2;K;AN-@ACD4P8LOA+LA#3UC;J<[J5Y8;NU\J.Q(W5Q@J0U29S UU3
M"4*U:;7&;NT$HZFL68:1>%^*=_)>Q#,?(%%?<Z&=(Y%/)Z.Y6.D\9T=N-E9M
M2)S*ZC+5%> N"].4K$IJ"G@MU7A828C$?H<@"JGT 2&L)OTAXQ:D3*H4I(>P
M*R4:A\4H(&*C2E@K!UD+5S/3!E=.N;WDEX<DAQQ5KMC/XK5:U4] [<F;WQI=
MWXLW>_L)#?]91<4([A+Q(HDFR!6SV5BXK82A:$T ,T@7$/NV-NDG%H[XH6P!
M"65&NU_M=;\AW4?B8X4-092@,FTZ)E"GPH",V %4#NYR:TWZA$"">)MPVU>\
M-"(WH&6%V7%6NG]<DQ&B#Z#H,.7C$(01!!*D'&^4%3ST6:.H*<3=Z7@T[=P(
MYQJ;^0WO(8D59X"%*=0YB*(5<*ISU:)%M)<CZGNIQ'Y=,VZ:5:Y3#VXRZQFI
M]_;F_7F0C9Z%""5\RC)E3\;+170YF4;3Z;2G,?DW]>HZ4C<"+*VXDSG, #7&
M,<6-7^\94;0GXV<'+,5OXF?GD9#U8_*"ZVF2C,;C'FF""X&]PSDMFHZ2UHHC
MSH%P@G)="ARLYSP2#"',G;+=$FI@@D)AXR]FBT15BA]D43WK[C)$H/..K16L
M4S.N3I/1;!_:P!(][%R*:)19I@F['- Z>P++I[+2M<Q'XKJ3-050@NY!R.B(
M&$ EN7N I\5R-/^^W5L;T![$U>.12$+#(;\T()3T4V9IRB>4=JV!=HR9H#?9
M/AY-]FH[9Q!N9)N=1JT)7+PEVG(!O96/5EG75J^:6JYRDO8HGZZ.#.K&2N:,
M6-]!AQ5KQ#.4=K [M/FMD:AJEN0D;3A\OB@*AZV[#R@N&MR.Z#;U +,];R[&
MH_A[=H=U6UT=,V];E;!Y6'<BL=OJ=#M(&(>%DBD,QZ$1+\?1<C:+II-YSZN'
M:^T^9MGV+6^*I#B:32;18C*.IE]+U#ZP3B=Q+V-AY5'K[9EV12OX:*@]4L\@
M\WW @.,:>^\WC\2/ (/9D<Y?[AU6*A\0R]'L+T= O97U,&XAD.%4#&@K )%@
M38'KFQ .U%[C6GL,2FTQ*-A/@&673I"C^G%"CQX@<21NFY5#:*"E$%Y+D+1J
M&#I>&E\7+D)9\)'+G8-/-8.RTBYJ\8<V7A4K$)G$+>.OY#E*CD%_COBXW\0<
M4B7JBJE,TZ9H<@Y8+SH%EE5;&B[17G%9?)@''FU;V<CXPWT<)]Z>99%)N[C,
M[Z/6(\=[OF/AGZF4<!C"_V@"7-U3 NR*C^\0"3J>K=HGK! N'G6A51AV",R$
M6KB-)#\?C!6NB/%HO&=X"+%_M6\^E&6/=.=MUQ;R+8+"'DBWK*4IU9-:%\KK
M!>3F34;(#GJ21J/%/J5X&0Y%IU4U=E#FOS_L-9^B'C$?!,PU>C_GYQQH_61M
M%3!G9>FD/ZP@S3Z.;D=BK3+NF'VLT>)>RWR=.R-\(BC#*0=7/&*ZG]6.H8NB
M(VBH&$K<2YC]Z.7' XA&EO?A30P'B^^DI>FMS4_M:N<Q@:[@3F<^RZ?*DN7Z
M:O)\H&"4U$<(OPH(X[CUX4Z<<RWA' 25^OI,":)!+TX 1FRHPRH[63EP=,%O
MT5L;"B:K<H]&U$Z'F:7>T<C5(W/8ANM!7?AR- @$N('RH..UI*>OXW00H%/"
MPMYT9Q]NKQWZTMZR0I;-&D9KN.X.UKYKUV:*TGWO9<2:YI2V&^KW+,4<=3R]
M%=0'0&AS#P"B?8-A>J+X#,H0_?(EQJ$R"XTK"7P,9CO$5 >$8(_6$WOMRRP2
M3A<ZEY929MNS]?<>)O^0E \_WN."(SHNS4#@=AI%H\E\H%ZA2T[HOKXF4U'X
MPZNAF_=.?9CI_UR@D>LHFFGHX;G>=V"/F'$/ P]*UU05Q-\#O@TRZ)\U:?VX
M88]3.])//2#N34UFZV*25;*<[/1^I,J:D$VX#$Q:JX+13-PCFU,JX\;!^3CT
M_4/G)Y*-"8>TG?V9&K&#O84N:#2Q) NEHA6R55LTF#^?.# ?7S*&7N54%.3+
M&FX.:"DK$^S95B*Y0JKIQR=5Q=+4HN/O6Y4#[<__^M0LH@4[I /Z#=FUG9.H
M6D7_%\=J/*7*8*C63KUZU74WQX(1&&HLA6!O4VI<VU5.9Z((3<!PF".<A(,I
M'Z;DV3X@2:$WG8)E]A5.R\6\XT2K3^-HO%@^PIQ!.FE!BM$8-J@4?]0@D :A
M&.T/I/I+9@8<G0KR,M4*)1.YEA'7Q:CZ#%C3^"DSY%MC(4BN-C*/J.>FB '?
MB <5.C8W_ORPFQXL0X// XE-IM$_UD,&_5:$=.4.8"3>#LSC[0%_8&T'B@J#
M>3FT_I'A]%B8#0<[ZFTWI?[]B^,.S#G[,Q>8O.2#@+UR5#U9P1'"'@DT9P ,
MX,*..?(EXD%[3+.8;"N2>RK.7N.*T '.[[P0[MQ#Y2SFBT3<REQQNO4?E*B,
MG\;C:(RQ/9YB@I] 27^0TM4-A' FIM%DOA3S:+J<TB<01X?-9JUK,8OF\TNQ
MP+R^%+>*QY$H#)O<GU#7D*&8:OI<0@AMYS\G)H#Y#)1G\5+\"HA)FV[](:@"
MD$W%O68[+2:SA9C.%W!W&'7>^C;X+(XOS_EL+TZ>[=^&;9W%*#%RU/D3+O9=
MO%QV&P^?;_KM",=E0G_G8W'V$_+CN>!V[<M,(\Z2<;1<3/<"0:_:-FVWUCZ=
MSK_-X>*E0CE1XJ;K8:BZ?&#OXR:8 (B/)U.1P$7S!TOK=FD8&B;C2W&YG!W(
M!<<DP'@7+9)+.IFYC!E''_J'\7XF[8V5H3'ZUO)E#AR ?6U"QF0N]K+V/H+P
MD?C##-OEWEY2.%;'VB,)YDKI:=W/+6O36,@>IDI?IGOM()\6A$\PR& *EU13
M>>Q"SP#\_;[_8!9PZ(&&#J/IG9@=DZZ7"SW<OBWD7_<D8=[7?6%.)XN)F$]C
M\>J01*?Q/ %H)H>^2U[T/C7#M1O^H$Y%'[G>?W7NGG;?[*_]I^K]<O_!_YVT
M&PT-<[7&UO'H<G8BK/^([F]J4_&':[1KR%I\N548<RPMP/NU,75[0PRZ_V2X
M^@-02P,$%     @ [(!-6MJ302AD @  ?P8  !D   !X;"]W;W)K<VAE971S
M+W-H965T,S(N>&ULK55K;]HP%/TK5E9-F[3AO* K"Y%*LVJ;Q(2*NGTVR858
M=>S,-M#^^]E.R* +J)KZ)?&]ON?<AYV39"?D@RH!-'JL&%<3K]2Z'F.L\A(J
MH@:B!FYV5D)61!M3KK&J)9#"@2J&0]\?X8I0[J6)\\UEFHB-9I3#7"*UJ2HB
MGZ; Q&[B!=[><4?7I;8.G"8U6<,"]'T]E\;"'4M!*^"*"HXDK";>=3#.8AOO
M GY2V*F#-;*=+(5XL,:W8N+YMB!@D&O+0,QK"S? F"4R9?QN.;TNI04>KO?L
MMZYWT\N2*+@1[!<M=#GQ/GFH@!79,'TG=E^A[6=H^7+!E'NB71,[C#V4;Y06
M50LV%524-V_RV,[A !",3@#"%A ^!YS*$+6 Z*6 N 6X4>.F%3>'C&B2)E+L
MD+31ALTNW# =VK1/N3WVA99FEQJ<3N?D"6T5FH-T5XCG@#*J<B;41@+ZB.X7
M&7IW\1Y=(,K1C#)F#DLE6)O4E@#G;9IIDR8\D28(T4QP72KTA1=0'!-@4W-7
M>+@O?!J>9<P@'Z#PZ@,*_3#N*>CF!? H</"H!YZ=AW\G?(#\7OA1-U%W#)'C
MB_[G&/K&W=#%_716*\:J)CE,/",&"N06O/3MFV#D?^X;U6N29:]$=C3&N!MC
M?(X]_6%T$HCDE*][+VF#'CJT%<1M&L3^:)3@[>$X_HV*AL$P.H[*>K@NK^*@
MBVH:P >?9@5R[21.H5QLN&XN>^?M5/3:B<<S_]2H:R.&?VD::9X1N:9<(08K
M0^D/+DU-LI&[QM"B=@*P%-K(B5N6Y@\!T@:8_940>F_8!-T_)_T#4$L#!!0
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MR"(MX,N-T8@-60Q9']98VDX!=H"IFQ)A A%V&IADNZTLS&U-US9N:\@4 W*
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M62 .^.$0#=2VY/75H * NE-U%= OXS#"CHX8]#+XX_CC)QZ/A^&#QI6I4=^
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M2(2!B'.B!B\33=2M@<BLHOY#7?=+K-NU>:,.67_=:26!5/8KKXKBSF[BEMF
M^+WQ.R0;*%$.N3];45B.NOF_FDUG@Y+6]/QHILOGN$8K6+S%6-[[^.KSX>JS
M+U]]2&I.]!W#05)_\\_)[6%?$':@8KQ =F+#)=FAV*910= VJ:+^PQ$[9OKC
MY:#9\:LZ;T(F6@YQU OX3!ALNG25U2^3GXM*VTWN\4^D\3]K7B+E,TG5(,!:
MD!G@^S()S)#;#YE>NG*6I5'S8G0!RU&8&#3K2(F=RC;L(B?6"+,"6'9O.6F1
M1($>!'D_K>'[,P5;C[=<XV/*4'6F_*UWN!R['E)'P4S,N!>X,%2\C]8PUT0$
MFY(6L='([]JL- ;A2]+Z+"FU,7*[B+Z7H(O+F-XZ-BYM@0O41P(<(1^@U4AL
M3@59[Y3#_\(FN_22'G8A&#JME4;'.#5H>35PK,.9B2D),AT:P [ZQ#X#\8%1
M<Z9:HL?>MV0R0I&<BNK5_JS9U=1EM_6I#1DH%R"Y&"JG28U[_OQ]:2>'+YFM
MB1<18G.P:D;L:KH 1H4KXRN8Y"K2J2$5S,B!><UU;/_'=$J\PS$[?@7C^H[T
MWZAJ^3)0ZLX?PHTZ:CG@#R6W+,2VT6&!]_+F2CVZ.)_D8+^/8*?JW184N-CH
MC04SWH$S$-W?#=8+J>3FN],M)SV&':I'<J,5R'3C;<*=Z/=;7]KC'"^5A_#.
M(%5*R7^ZQ7+KF^.HX15>KL!R-\X!!&X]3WIBA8>&3;!@\\0-"9G39= [OE0I
M-F"J+@,31L#D(V%E-%!SZ!=SKB>FH\$H8)T'/<.BZ#=RRU>0TX=Y& K.':<Y
M$CKC%96D_6N2%+/IK'C90?\1(+NPF(]8UTW5K/8BZMR]T/@C94T3;LA@@J1L
M^Q4*7TG%6*>D ;E"S[CG,C'%J#Y(R#K3(F:VOFTJP+S;-72# C9M3L.Q@EH2
MC4#;R]*.UG?0)8P6,MR4K9%D:=+*A;D,WXFSHRN.G%LC-\?#"_> X!0+R9QP
M0TN'73C^FI$S0R:G!IQD3[Z]+$[$9  *FFS4[S/MJ[M+HH:E5JG ^M:ZKK6+
M7J*C)9BIB30?#U"4G#:('<G_)!%^OJJ^UQ5V-+?^+JU;D^8-<2:[?"LD&#9M
M$F&H%95[D;%TZ1LNN+(EG=F Z_MX^7=(66Z)KM/]1N$J?8-MSNM(NQKE(&G#
M2S500G7<0M*O;I82VPTZ/4GW'%?$Z+3HWG$0G&3V0M<M9G32>1+7.1^)8Q\L
M7M,)_0QY_B^ZT61K!>F)6,O!?5-)"C#G2X_(X9%C@LI)".N>J)\IUW[_K:1\
MKS+QB1=FX:<7/CW])EWG;=II)QV.WB?FYQ5&.2?6+VX.J_?7Q'9P4O<#.[I0
MTQ@]=74"\MV=C2CZT[_!GER7-14ZO!L2%DGZ#N[D*DE-"<E/Y/1/65%[XQGV
MQOO^#-Q;,XKZ1_V NP<$7.Y<]0^ _2F$P[;.>$$04Y; *->IC'T4D;^IUY&4
M!W;;C13V<V-.)!AC@6#E$]L^53]([PC'IJ%SA(0.%L=8OVZH?_K6EF+:?N,$
MONYBGR(V[*57XAZ$RW;<MB5] EG']T?5C>]NU7*]HY"2Y%AYFKEP%,J2LA6Q
MVY=JB(6O%$CW/R6?G==,/[^>/X3QL3L23G+1E'MU\B^#JD3]A$'0GE%R%!&<
M#@)]BO/'[E76/;43I^<C#L:VH?N-L@E_*RI547(AD0HW@%:P M&"_O/R^L6K
MM[^@K3J+@&C><[V'=?]N0!&LL9-:7?XX42]?/[]^]^O+J\O)L749P3,VPA[>
M&W:F]@5$Q4Z]>G5%EXDN%XM?;0B::.;5Y?6O__JOMR\GP'.%>,'QR._<YRNS
MPE#V.7MHZMW-)5Y6GTIN//OM)9I!_-IN+,5^-YP --4@\AP> 2-$KD3JHF6]
MMOGI1%)_?WG]WY>O7OPSV1:IAA]-O=$+=7G_YF@,%N]RSH[?Q[S$D+NS[J[^
MND^>3;;!'92S=#(B"U7$R21NSE(Q_U%#'+Y5D*P8@KQ=TU;ESI;ADAW5@RTY
MLJ8R?+-EHEI=VH8N". =-5-:36O14T5HGY+=3$(V[F'6(?A@V"'XZ,L[!(\>
M<;PC.SM^B54>8>CPO8;1,_[TZ2K[D%7B0R;,IP_ &02>IJP"]5'LZ4_?<.LK
M]73^:6LJ1X.NK_A]*<KH'-[(BVUJ27<X)?+T!WG(ALXHO7J$V2OB,APCYJW)
MBF2#8#"DZ,9FTO78)&T;,X&UYO(&84*N2"BD4STYM*8E%RIQ<*5WR2BJ&VEZ
ML"3NXE,0\0T4M,:AC>CKI)"#8!;@"2]MYYL!0M4(?J)7"MAE3L&(QYL<@O22
MP;D5$"T9=OYCHSLVG#BZ1DQ9D20#KCL.KR)CC#P(E,$:0J!&C!19^/#>T,T+
ME/ZB"\D]_AZS.G(VV H^E?L_!&MA*FMN?<MCD76D.)/F;*DQ9^RI%7YB9M"[
M\%>7LG2,1";)/4U%+]*$U@;9#,4J\_/9([8T[[!5K>1@P@5.HW0%< ^XT#L^
M%&(GL.*NDJL:X68"/L5RU0O;_-0LL'S<J9.W5S]=GLJC.0@I*.!M?@M1#QII
MT.];ZSY<B(R/:=B@*>!+U+O1M@TB0PI;84<]N>P1 AT278*E"]#@]<$VY[,_
M3Y)W? #"3QJ\/YA(-ZAFCYE5<3]Q$SIN0W:!L)&9L+$9>_::WD'\2D4%8<@R
M:2):,NU" D=532$WF4+/R&\]F!/,6K.\O!L'-7CP@XZ?<\V#]U_(N*":I4J\
M9D+ C-F#*1#"OP[#3FR ?M>DQ]/S/\OAXL:Q/B+JF/QVN59.4,,;0IPJY@M<
M1IXJ2.OX"[/20Y-&!Q#!Q"Y*R8:#A7O YX.<'F_%HA<]3RRG[SREC.2AY_L@
M.6-=N2;V-1UPJYRS^.%)> ,B=\:4\I'HCR]?O7T),D#_E:XOTF:E?PX%\^M.
MKA<30U @CGK-M"'/P"$).@N>,V0!(C6VSIJ-\??52$_D$==$[GWPDV[2A8Y;
M)57@F1T)S5+]P^7-<__46+AQQ%4OUM*1:['KH**+JDZJ(MF]JGWL@&M\\82"
M+* A2QSM7>A3^T0-]L+X8=D=WGCA[\1.S71";Y'-SY_*' PDZ9O9TU-)B^&>
MZ> ^Q<XER2EN/HAN0JB'6->EB<M@#<2NYE4_OS'?&A S;2P>E)7CMW_@A/,]
M!83Y;H#?UY'FA\;3GS;,:\>+[ -X#">G2G"SO(<SO+HL]T6]EC4;U*OM_I!.
M0^KX]XT W2 ,:55$J"(W0@[W..ZNI&<GJO<.?4LMHXC(X'HL/KU'][VZ<+%4
MBI_I.Z.'^-#;15ZB4IQBJ\<=F.3%CX&ED5Q->+/N+H2DPDM'X@'SDR'<*!8<
ME-CA3[E4O@\Z+#;B.K4\.I!TJ?OAWE7)#$[CS "_+!N:7:2FYR)1EW+=G+(N
MU#M%BVQU1WV/PV4DM<'WJ[->H]AE+0D6ZC..HHZ#Z29=JF6\QR5,?I=?'CJ;
MXN30@1IP)8/BL<@O]&7A&@N?Q"58[$S\^.B:#QQZ=!,EDDGZ6=/N4;&[HF9"
M<3H-=\#9<V0!Q!4/#H>W(.1$T9W6< ,=HP-DL@ZS1Y1\;Y9+S/73YNEQH6-/
M,,>'/^;'G^SXV23=U%MLIT*;-Q9&?A$@]1Q4=S'V@]Q7Z>6Z!*4(T535*9S8
M[D?BL-G .29&V7G[N:.GNU%)2C$\)FG260[?/:"W%OW=ZFCCINI[6PWT5$!6
M"A].CA.;&="++W$&!T#:7VJAD@ZUB,<7WLAO\PUYU!-(K:MM<.X]DEU3O)<+
M!,3V+05">_GAX_?2YO$&YOSXS<EW+GM89C1Q\)D@2(BWK73/^:<M/O[P- Y"
MAQG="LXI)8Y+?-@ZEJ'@=[--WI@E60K7V9+&>'H,[GT:V)%,#Z]F''@+3OFW
M<J?J19S;&KXK0=T5HY?TPTL=D_B.27JGE_,@X4&784>4+VB&% Q?OT!F)Y;@
MK](GPB99L1LBI\VV:O8FJ)JT[EC8@,+@)ECJ>NU5<"LPV<8E:1_=HE;""JP\
MPLV>AG^WHTE#Z/&, C?D!A_>ZT'),5 ;$+H6U,MG.WD *'B"V4[PK9&#)V7(
M*^'C"4U G]?SLT ;FW9-"2!Y9$3+FUU\AP][;9ZJ=;-#AVJ"0E\W<;)P9YBP
M,%TH<2!1*+AC:^I[J<6*1.A'A3U>PIT?OT9[T]/KS3X!$=J+TE>61A7 'PTV
MQS]>HIT?O_-Z*04@. EZ\!JH.XKN9T.YDTF!U5#', ,DX:DWS^2BB6]Y@VE0
M$ B#%J;SKA(U?[/G18\[IH_$3-7/6/U&74:]=FG\2UZCXU#LP1Q,AWD/0HPO
M*2"3 9:4%L%7Q#](W,)9M3L@7'@(T@4)EJR)"?BLPS#<(\?WJ?B5%PF,"^W&
MXO3S2<P%+$P<22U\(^,?CG+S_>2?OMB8=D7_P <Z!R )_*]@A&^5_T=$+OF?
MSHC#^5\@>:W;E:WQXOL2IIY/'SVXQ[4Y_Z%KMO0/:2R:KFLV].?::/ D< #\
MOFS MLL'7"#\TRK/_@]02P,$%     @ [(!-6EWY>716 P  C@<  !D   !X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL?55M;]LX#/XKA'>X;4!;.T[:9;TD
M0-)NV( 5"-;M[L/A/B@V;0N3)4^2DW6__D@Y=M,MS8?$>GGX\"$I2K.=L=]<
MA>CA1ZVTFT>5]\UU'+NLPEJX"].@IIW"V%IXFMHR=HU%D0>C6L5IDES%M9 Z
M6LS"VMHN9J;U2FI<6W!M70O[L$)E=O-H%/4+GV59>5Z(%[-&E'B/_FNSMC2+
M!Y9<UJB=-!HL%O-H.;I>73(^ /Z6N','8^!(-L9\X\G'?!XE+ @59IX9!'VV
M>(-*,1')^+[GC :7;'@X[MG?A]@IEHUP>&/4/S+WU3R:1I!C(5KE/YO=!]S'
M$P1F1KGP#[L.>YE&D+7.FWIO3 IJJ;NO^+'/PX'!-'G&(-T;I$%WYRBHO!5>
M+&;6[, RFMAX$$(-UB1.:B[*O;>T*\G.+^Z[8H IP,E2RT)F0GM*5F9:[:4N
MH3%*9A(=O/HB-@K=ZUGLR3&;Q]G>R:ISDC[C9)3"G=&^<O!.YY@_)8A)\2 [
M[66OTI.,MYA=0/KV#-(DG9S@&P]I& >^\3-\R\=XUWV\_RXWSELZ-O\=B[CC
MFQSGXU:Z=HW(<!Y1KSBT6XP6?[X8725_G5 [&=1.3K$OWCDOZ4!B#E\=%JV"
M3W2R'==PZ1QZ=TSO:<:UI3:W_N$,&A7JKW/ [ZULJ/]H9A&<#PZ%A\PX?P%?
M*H0;4S="/T#KI9(_28&O&&@%M\(Y^X :?65REI8C92*3(C2CV:(-:!Q":;M0
M5!\*[XH0SC6L6JER+@[KVO231X'C!!Y06 >?&, _A=2JE5$YR+JQY(YQ#D8)
MG-.9V:/O1%:12#K^3^--"30:=Z 3Y;H<RG5Y,KGW;=,H20&_EUKH#(&R75I1
M'RO3:29.NC6*+^.=L'F?IGT=7CK8"B5I>:-D&1+MH*6.ZU+==%YAAY8S"P41
MF1UEEWL(7MW2E),B-=Q)I=CX-3'K0MH:GW*>PP9+J34782^!<P5_O$DF\%%O
MC<RHAME@F[>6H0-N?)9,I@?<LC=IA/P=G9Z]O9H\JP1U_HN&Z?18S>*#.[)&
M6X:7@$52VW?7Y; Z/#;+[HY]A'<OU9VP%+VC,U:0:7+QAHIFN]N_FWC3A!MW
M8SS=WV%8T8.)E@&T7QCC^PD[&)[@Q?]02P,$%     @ [(!-6C.0'P="!0
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M#J3Z5:F^D<E6O9Y<)E(FD;K<8&_+4UJ OZ^21!8WQ*!\7WW^7U!+ P04
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M@7OD%U),M-,Z):2M'U%^$5G?#S-V7P?EKC?Z!=O V1 )25MG7&(&LP8/QH]
M*7MH^&SX_L>!CNKJ:N<G6^'[(P&ES4,C4JH3[(IOPR0AL4-(PGA/#4UQ3)-P
ML0'S-14-: 1';X!L:F!30YKC<*:&,K0[MO>!0X(0<J6129&%JU*D(N98S#$:
MQNKS)82UEDBA 0CV_'!8D]UJ,%)C$XW0C**;0!6ZHMHN,SSL!^'P&N5;7H2(
MUQCVLQ_O7R)'_E&&>2CY(6#2+&E8G3NMAVB4'IR1A$@060F>,A+M3-.)"]UP
MNQ0-4&S*A+T?(HID:2PM=68(KEU5S%,T@7 L">I47+_=;*!:TAE_#*01B. &
MV;C8J(V$,=,P5_\V*R 7:/6O JHZK#(#4S&1KZ05M.8F5'DIW>EFX%JMWTT9
MF:'8JEC$]&SFVLQQI0ZC.H7.2('S82:%+#2#&8IG:4RSF&;73CHP)EV'S4'9
M%JS4]OZB[=UV8:JF"5SLC!C?=UF2I7J'%([908WP_[(Y.,2UK=L'*SZOM;Y1
M&(@&%JO4!K>'RJJHGXNH?V2:HD*QX-PVV,Q4A,WCK-(&4)*4)-E.90'+&HN[
M;WPPB[AS*_I*T%P>YF*WO>KNG/V:)F=!F6447JNMG=J*"A!I*A[BUU &5]78
M*/17801EB7AAD%@US2-.+1*\2455EW9OO*ZX8E?8JJ:*L^MXXFRKF/<E+81-
M#_=(NTBC<"VRV:K:H&R<_2!)7@9!&9<R7<HT0W+-^(Y:-/<< 1N D4^)$[ST
M:SUBPU,-$J>MPZ\T9@"5WHS4DG5U!JM5K2H$"\&2$^%\EW1$DG!"0TA]H2Q/
M#P/4\"RENN+(U$ Y_B/CP@/ (-1AZ0@0#FS>1A%HF&Y/$H>)\HCIZJ[BN@@U
MJJ*A(J$T0C#%'^:9995G"#,<X %HH8\L'I BJ?:.02-Z8NL,BDC8"M%+>&U>
M6T>OKLD7(H)<-X-IQ-]Y<E\23$)0$]M8B"@AH%0+;O+!^E5;!"Z_WV?IHT")
MX./4!**,)=00@T_=]H%"V8P*'BP?/2E24QL.5Q PS&?;+"WWF):485'%88@)
MH#8OR;:?,*38A=GZC.+O$WC($2BS!F7=+6X7[!8>D(487C4017Q:_&B\-.XH
MQ^M4$L6$ZWQO=Z)N3/0=2QB2Q"MLYJK.G#FH\@S70P%A'S1NDD.G1%+"$IH'
M*Q7QBA:<\LDF%>DC.&JR3S0C0G,F"3'--?&/4AM_$QD(P5!3NPT>Z;S$^G(6
M"DG.!P%28NB@)W,Y4NDZ_>G,=1!/-(!32DT0&/# 6,!-CBJJ1>QCJV$%Q"^/
M5*=Y2'D>D-543\EMZB=WLN#YT*EH/O<KFA$@7U<T[RA'MVVF%H*-55S3##Q;
M2&]ZN;W*#55>_B67/OM/H+5P0TXK,0^ER/;9OG+DMC(*J4)(Q)Z@H6H%>E$F
MU<U@3L&N><#C%;0#H-B&LN%3HQ^BSB5[,CA\Z"TJG[5,ROL^X_)9!6[DS5W-
MX/<&G+&K+G8^U75%MU1&)Y0E0V_48-JF12<#-=0!A)MH-,(Q,=5&5% TBPHQ
M#[4<ZA^48YJ*,LBCDVD 1&MX"]:F<R33')%10=6R'")G>G1T=88% ,0]X'A7
M]'%1]GVZAVYF=Y!8-N_W!J9Y/J4RPT3R)LYG@F>!=\$U>;GJH%( " (XHY *
MKN?/L6TJEDX$'5,3!$U/0!'P+:I!Q&,@*D3;F2<0-K#TA'=[C7=[D\[5[O%=
M235!FZ[\)UE,"(#?>E,GR[49IY?CQCQ\FHEG/7S?<+F17#8?5GI<CN'QK,_O
MR'>9\^,^8M'!I@-U!G1J2E&M!EV<X6!V+.087Y^',.L45:1+JK0HSP!W(R\I
MCN@_.)XP>!,%\:>1ST>GIHT2%S9E&CHSX6HF<*VN6(8S80>:VGX,5;_/$CZ&
M21B7I/MN]5F%_D%X)='VHU<3AH:P:/1CZC1KWV\?<<5[,,9[$\*'&'A!D#0'
M<*Z@USIE25HTW^>H<B>P2].PQVQ8QQ<[9(&.<%CL/S'Q#9Y6COVOO(;,DLO%
M#S2\/B>GF@'C,A"-39@:167$;5>SI@RE\]5<>_9;+*E^J%F9)]@E]!2T8."+
MGVU[3\<-8'K)+]..W;8?J%?>K"Z5415*_=I"P!3)63NC^4)K,>J?^WEE=(@0
M@-P!K01"U8;:STP'N+^72"WV]@]1:^0<);FLPRWQY<>E@XG#-5\5W=?DVO#P
M&AYVFRN:Z*9WCE,:U5N-ZM_<(K^N^L;]LH4^^  $4]-H5'W3])_IF9.6AD+\
M!2Y!C2H916/NT]KK0??'SR7'WX2[S@&E4O(8E!L!I'P; G-OPH :;-WKNR1=
M40TAN/R0[,M"-F8_=/B9_8.^6#'J%<@KO;DRZC9*A9K^/_S57MWN("OY_:Z5
MC "F</<&@^D _QIS]4, -CR+<4 :?TL!@)(F/_I;G@0]8QU.=!07=90%7&(]
MNTAWK+!RU--%5O9;Y/595PP=M:3B>L]SWQU[Z%\.0)F)HX.$^1RE0Y;;N0@Y
M2"3;2(19$O2!$!55-46'R6% JZ;!;-1W*HZVHQ,4U@5J56Q@3YG2*S\>$G*1
MU0%2$>@]>+ZB4C,(*)N:V89*/603Y777 ON.<-IP#=BI68H+!(Z3 SO0;$MF
M E6AKQ^>Y+77(>WTB\)[$F7=[:@LNF8ZS$4ZS#O.4G^>E/V;ZJ,^7R_&PM*R
M\TNMF".(TN_1<B9Z1_)'6\W3YC=OE_*77NUP^8.YCXC!,"46\0VFJ@O'.F&9
M_ V:O"G2O?C=URHMBC06ESON ^/3 +S?I @%U0TMT/P2\.)_4$L#!!0    (
M .R 35INW]R#( ,  "<'   9    >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM
M;)55VV[C-A#]E8&Z*!Q B"CJGK4-Q-D4O2!%D&QW'Q9]H.6Q)402M205)W_?
M(66[;N 8W1>)EYDSYW XP^E6JB==(1IX:9M.S[S*F/XJ"'1982OTI>RQHYVU
M5*TP-%6;0/<*Q<HYM4W &4N#5M2=-Y^ZM7LUG\K!-'6']PKTT+9"O2ZPD=N9
M%WK[A8=Z4QF[$,RGO=C@(YJ_^GM%L^" LJI;['0M.U"XGGG7X=4BMO;.X$N-
M6WTT!JMD*>63G?RVFGG,$L(&2V,1!/V>\0:;Q@(1C>\[3.\0TCH>C_?HOSCM
MI&4I--[(YFN],M7,RSU8X5H,C7F0VU]QIR>Q>*5LM/O"=K2-4@_*01O9[IR)
M05MWXU^\[,[AR"%G[SCPG0-WO,= CN4G8<1\JN06E+4F-#MP4ITWD:L[FY1'
MHVBW)C\SOQ%];40#HEN!H:SJ0;T"12V?8/)9+!O4%]/ 4"!K'I0[T,4(RM\!
M#3G<R<Y4&FZ[%:[^"Q 0PP--OJ>YX&<1/V%Y";SP@3,>G\&+#K(CAQ>]@W?[
M?:C-*WR[7FJCZ&;\?4KD"!&?AK#5<J5[4>+,HW+0J)[1F__\4YBRCV<(Q@>"
M\3GT^4TEN@UJJ#OXO$_+HTW+*:+_&^I-AK>H\.H-/DRN6SETQMG?U4U#M4-Y
M?"FQ-V]-'RNA=APK.6BZ0_IBOSBBP$(THBL1A('?13=0W0-W6>00%\S/LQP^
M1(7/B@)NV[Z1KXA0RI9ZCA9CV=+%'-G*WBWT!*AAPIG/6'8!D\B/8W8!#]@/
MJJRH0$&N+41+MJ-CE/A1ED#JLR@Y12ATA")(6.KS.(4X]-,B_D$^8>(G/"0^
MG/[%>3ZAS_($$I]E!?R!W?. H.VI ;Z4+EDP^5,:!(L7TBD526*=XC _ID\U
M@>T2E=T:!60A][,T@2SQTY3_N #&,R<@RL\+(-,PCRB1,<M.,MI7JF-4\! ^
M6$HY.U48P5'S:E%M7(O6%)"NS]C'#JN'5^!Z;'[_FH]/R)U0FYJT-+@F5W:9
M)1ZHL2V/$R-[UPJ7TE!C=<.*7C)4UH#VUY*.?3>Q 0YOX_P?4$L#!!0    (
M .R 35K;WNS!0 ,  -X&   9    >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM
M;)55;6_;-A#^*P=U*.)!B$1*LN34-I"W;=F0-6BZ[<.P#[1\MH1*I$I2<?/O
M=Z1LV062#/L@B4?>/?<<CWPTWRG]Q52(%KZUC32+H+*VNX@B4U;8"G.N.I2T
MLE&Z%99,O8U,IU&L?5#;1#R.IU$K:ADLYW[N02_GJK=-+?%!@^G;5NCG*VS4
M;A&PX##QJ=Y6UDU$RWDGMOB(]H_N09,5C2CKND5I:B5!XV817+*+J]3Y>X<_
M:]R9DS&X2E9*?7'&W7H1Q(X0-EA:AR#H\X37V#0.B&A\W6,&8TH7>#H^H/_D
M:Z=:5L+@M6K^JM>V6@1% &O<B+ZQG]3N%]S7DSF\4C7&OV$W^&99 &5OK&KW
MP<2@K>7P%=_V^W 24,2O!/!] />\AT2>Y8VP8CG7:@?:>1.:&_A2?321JZ5K
MRJ/5M%I3G%U>EF7?]HVPN 9E*]10JI;:6[E]?T*H)=D(9XTR9@)GG\6J03.9
M1Y9R.X2HW.>Y&O+P5_(P#O=*VLK K5SC^GN B$B/S/F!^15_$_$&RW/@LQ!X
MS-,W\))Q)Q*/E[R"=_NUK^TS_'VY,E;38?GGI2('B/1E"'>!+DPG2EP$M(4&
M]1,&R_?OV#3^\ ;!="28OH6^O*;&*(G2&E ;.&W<1]^XZ^\:=^<;]U(-_R?+
M?Q^)4M&LL<Z9?&&C&KKGM=Q>P-D-C84V% #W==/0)21_NDMT4R3\3((1P6W;
M->H9<6]^5E8T\*N0/0D$<-];#C^<L3B,64[G+Z&'AWG,W3B9TILE89P5$_B=
M!,Q[EY606S2T$N8SY\'3";"PB#-@\11F;,1G'C\A3UIF'MKE*&;NS9/8H?-P
M-LU'].2(GH2<LPGPJ4N4S&;..76!:9BGM/ ;RJ<>X1$[H843H.CNX2.D85%D
M\/Y=P1G_0*=W"C^.5A:R@@$=:VQ7M.G)D5X<LM0G\-7'L6.6Y/G +^-'?NG(
MCXJ/"^"0IC-/,*?R\F)ZA#_<'-K=(DP=8^8<L\PEH>C,E\]\,2\=WNA$<UK4
M6Z^LAHY#+^T@/^/L*-Z7@V8=W0?EOQ=Z6TL##6XH-#[/22OUH*:#857G%6RE
M+.FA'U;T T+M'&A]HY0]&"[!^$M;_@M02P,$%     @ [(!-6A<"U<P$!
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M^D3YF'/0O>R==<Z[M0Q8T\;2EF-<7(T38*33#D[P$K7=DWI0]S,15:H(LYH
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M%R P M0A\GJS\HS02!,F / 1Q6H_<0S[E#QN89O1J'=)!N*8JE%>8*-L]K4
M#J%BA%"D+-H<T']HUXTB/[ \)!J=\3BMF1&F!/^PF?9D@1:QUU'#403S%P6_
MG3\/[M>1'0'L7AV!C3IF%YEE2VA8MA >2S4L#YS=0$O"PU%:LK:H_AQQ:H,A
MN4.#^"+YIY9^'? +*HE80 <(..SI1SSD!0D#&@M2?$V_5,&J'&4;QG97?[MR
M.N0<T+AF,8)*0(O*M72N7+C8GM[A4="-D<3&2)0\#A#F$0F19O(H/PKL%_P@
M6/E!\,5^, #_8(=U'.E^EK ]W4AL:-:+/)N\OH"%Q@V(+4:%=ZM'EG!#AP\M
M'7*;%R7Y\F=@]D10+1Y2?AW>;K.4=#1DSYOAXU *<QS8<B:!:!(BO^HNB':2
M'(V'%\-##PQ!W$%L8?6,\.,[2!R3DLI3[Y-96L[!S GX?#1=C,DM3='#&$#K
M1@2@/.X1:#G4BQQL*XU?7\<CT,7(4IW[ GJ52  .9VCR)%!IZ;V;U?,&.[@^
MF#\Y-IO7$4I:RP!+^_AD,R:0LDXW026#0T^I\JFH/*Y5'@3PP5 %P*$.]M%[
M</$]+ADFB;K*N:H"WZH8$; <%>E\F>A@_76T@%T_ 6 /\NE9/IO'V5/CBTFY
M?-Q'E8*7N*CC3IE.,BHQSJHVV$7=PX\AWA-BKF#!VIH,&=\T_1>#U$,!R3X]
MY)@+\P%48T;V]&XAT6&5.5#HN[QZ6 N)!+1":BD S@BP>([1GU/$D@1)IT:B
M^XW%DP7_&W$GML6^66ZUUMVD0#*'.<07RT-BN]MB/\3_18G9:*LE=AJ)45-\
MM<3ZSTF,]*$9_Q5B1[78-EY$;K<=_H[<3)BV$ZDF"VNJ@%F^X-+/)S3(H^#D
M"5[A_N  U:HSJY/393I7/]^Y%X9WAK75#83<T&%9,Q?O%O9:+C1ZB(M)4BL)
M.QHA)ZTJZA+[W%;(,0RH[FI>E'F.@^6?%E10SA-Y2!<C6VNOC"SD<A/(@)E&
M24+Z M^+19HL -^-DRI.I^7)GM"US(VH\$FP2'E(,CX(N)2L2*9+K=).X^2N
MXOL$U57U1!*M*^O&C V>_H=&Y&/0!$X)E22RS$])]KB003/,/*SRT6\'9737
M,G+2178?/\(NS-.:Y4 ]_.8^3@OU&$\7*P$*[CV#O&45_R;CFD5?W&5;2J1#
MR4[Y;$*^%/%;R3&T_]VZY$RSUV(?P7)33M3-O4,%!20[=MK(=98J%P"/%EP'
M.YI,\SOHIN CU>72#%>7VL=X@H1L"OQ4Z5T^!E8^HAA"PO$/8"YY4C%%*@48
M)RLY+_,,5=*_5M5KD3_%4QBS68+R\+AH*<[RM@M,,ZEOVA1]<^B\@':+5(KY
M%6P&%+,88P_OGC*4SK.XK-)XK;6,W@FKIK2O!#.5 D5I(5JJ'>J@^?3:?<HR
M9ZJ+!3^E51V0+IFDMN[2O$QG*?*0DV;N>&FEN%3SN*B6R-E0%3^ZS+E\K*ZQ
M_@PY$$@0$)6@!X3:[;7\M'%5@!H7!>&^W/E:\&-[P].7M_6SY'65 E+K)P7C
MD4!N%F>+^W@Y7?(YK=9SHE(NGYWRQQTO*0^[B6 +^TSV9UHF[5^-^D9OI#%2
M[:1.QP_([;3ME]%RP!3#!Q#%IQAN^46>]ESA7F]V[6:25'.Y#Z]_YN2;JZZ-
M.P&=-+?JYTBQ,QH!8%QK#/( NBLZ[WH.81/@_SQY3$<)LOK)8EHK: LD>L^B
M7X2M]6TM\^=)[$_C,OACN_#V;KO=H_TO!;1YP36F:Q9;RE$W9Y[SJ@N)D=F6
M:7<4W_Z/DMD&N.J&EAH_9?&,1XF[/!>S%G@M+:YDPC @"[9(?2?_,:+[PZ3P
MQQSTV=3C CK(D"!LRE\+Z7X=U/9#V]=QV*:QOI3#.@A$,WS[U:2P+VS3!1;Z
MVD S+%]-D]4/F+:PO-_N_<N)P3G@X7_<6\)#((FS+X*;K&-ALUCE-\QYIUK_
MR/[Q.@A,8(RO3ZQZ(O'VR?*49%PL)G52SV*%AQO+WQAUJGP.USM/I#U9I2A-
M.N<GLNK[=%S$XR233X>+^7PAO>A8M=X/-_QSE;+L8.:7MRF2_M&#19.W5]RW
MG2O#03OKU#]=MTFA@ F?;Z%)[EEQCYZ6#- YK\4;8CQ!6+?.[I)1#//&CR@>
MA"KKXGXJY?>Z5%P5 J/Z*)-_8^]PS2IIOEGKFK^D6^N9^ENO_;MYY3X7__&0
M\ >CTI]+C9[=F7^ /ZB<>3(%&:A94C[LN-!?3'"_D]+_=PB.O>_]_M>J%!S%
M)5R!5ZD^86MRW?+41S"Q87;N,I?6P7JJNE/6EN[DQ5X#;5G"SU<M]/DT)E]@
M)BXHB+84:B>QU5XSP%IW [@S;5N>$]:5/>KV, JWRWIK:8@M_FM^<)KGXT_0
MR@NK;2\6\NG/9K' YCG\]F+M0XWITXV?RLX26(0_"(:>V52I?S6[^G3UF^-.
M_5/;]?#Z!\N7,&@*#IDF][@5[N8=U>7D\@^0I/SP]BZOJGPF;Q\2<&/! ?C^
M/@?5-7]P@=4OL=_\&U!+ P04    " #L@$U:6=;W'7D$  #P"0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970U,BYX;6R-5FU/W#@0_BNC'*I:A+)O0*\45EJ@
MO:,J/02]WH?3?7"2V5VWCAULA^WVU]]C.X2EW:)^B&./Q\^\CWV\,O:+6S)[
M^EHK[4ZRI??-T6#@RB77PN6F88V=N;&U\%C:Q< UED45#]5J,!X.#P>UD#J;
M'D?:E9T>F]8KJ?G*DFOK6MCU*2NS.LE&V3WA6BZ6/A &T^-&+/B&_=_-E<5J
MT*-4LF;MI-%D>7Z2S49'I_N!/S)\DKQR&W,*EA3&? F+B^HD&P:%6''I X+
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MIJP!)C,8D5P*&F7*T< +-ZE0IM8(?P[6QFHJF;\NI:%QTKGLQ+71LZE8BKV
M^L2@WF+0__RI?1]]N1)"YQ1"YQI[/Z&VS&J!H'*8*6/^%\-Z?W:POR3^*OUE
M\6\;!.NJ M:NBR$E#]3O!BQ]*)6Q8'@A><Y3)JT31N<&(:5N:?),];7E&38
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M[7R(]%!/L1!)NWBA.2J4YE:TIMSV^B4G%?,/%.LUQ0M-/Z$T!J5Q%,T4;YV
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M9+*2Y1H>LS2+RX4^4M5GFI?NV5GK0V9Q^Z4$-,N&TMPC.]\[O,0'M!T^E!9
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MM<M19!4*A'*!4[@XI]!%*%<D$[+R$JV0\@*>X [I"5H8Y8J(+HM5<H-#'2M
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M@]E=H>?HU0B A@07[M4(C/9JF/+6S0X0GT"S5V/DRB%1+ICP0TMBQ3R5P,&
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M!5HQP*L\A^SQ%A&ZGQNV\33Q"6^V0DV8R:R$&W2/Q)=RQ>3([% RG*."8UH
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M/ZTO'[O+PS<N[X;HFC.52W3),LBV!7SMI+$3KNV,P[V*":0=%)X=HS (HY:
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M-6,2?4^33$RLM92;!]L6\S5+J;CG&Y:I;Y8\3ZE4F_G*%IN<T449E"8V<9S
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M<T=P1$0:H,]O.%?GG72 <E%K^3]02P,$%     @ [(!-6K)+LMN3 P  WA(
M !D   !X;"]W;W)K<VAE971S+W-H965T-C8N>&ULM9A=;],P%(;_BA4F!!)K
M/IJVVV@KM4L00QN:&(,+Q(77G#86CEUL=QW\>FPG"^V4AA9Y-VWL^'ULGS<Y
ML3U<<_%#Y@ */124R9&7*[4\\WTYRZ' LL.7P/2=.1<%5KHH%KY<"L"9%174
MCX*@[Q>8,&\\M'778CSD*T4)@VN!Y*HHL/@U!<K7(R_T'BL^D46N3(4_'B[Q
M FY W2ZOA2[Y-24C!3!).$,"YB-O$IZEH178%E\(K.7&-3)3N>/\ARE<9",O
M,",""C-E$%C_W<,Y4&I(>AP_*ZA7]VF$F]>/]'=V\GHR=UC".:=?2:;RD7?B
MH0SF>$75)[Y^#]6$>H8WXU3:7[0NVPX&'IJMI.)%)=8C* @K__%#%8@-0=C?
M(8@J0?14$.\0="M!=U]!7 GB?06]2F"G[I=SMX%+L,+CH>!K)$QK33,7-OI6
MK>-%F'E0;I30=XG6J?$%4Y@MR!T%A*4$)1%F&5IPGJT)I>@8?<1"8&,F>I6
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MB,)<(X/.0"\D17F84A847]K3@CNN=-*TESGH-9XP#?3].>?JL6 ZJ(^TQG\
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M9,.2G).4,YTK#G>!T>2"_,&48I9%<N9SPT2B/T+K]T>?G'WX2#X0D9%[D23
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M[V_FZZ7R]B^; ;[-%[\]_SH7_P)02P,$%     @ [(!-6O,Z5NG& P  F \
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MI*>Q*"[D%"^*+_,+)%.N%,_RQP70&(01T-]GG*O-BS&PO18U_A=02P,$%
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MF(30R54-;.-M(D4'+#&.>[RF363P.C,:R!ON>4,G[]>7)"_?I2@C)=.$L_^
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M<Z87<COW.</-W%'KLR;N?HVI'Q]@UTV"H-/,/:BX!ZW<>/.UG8Y!_70D4?\
MJ\%H_PB57/Y>FRA S5SWU"232V'*"[9:K1KTE>M+!^MC;-QEG_TK4W;].ZKP
MP&O"88J2G8L>(JFRDY83(Q>N&3U+@ZW-#>?X\0'*&N#^5$JSF]@ U>=,^@=0
M2P,$%     @ [(!-6J^?"'Y^ P  I0L  !D   !X;"]W;W)K<VAE971S+W-H
M965T.#,N>&ULK5;O;]LV$/U7"*TH6J"-?MJ6,UM ;&U8BP4(DF7[S$AGFRA%
MJB0=)_OK1U**8DNTUJ+]8HG4O<?W[JS3+0Y<?)$[ (6>*LKDTMLI55_ZOBQV
M4&%YP6M@^LF&BPHKO11;7]8"<&E!%?6C()CZ%2;,RQ9V[T9D"[Y7E#"X$4CN
MJPJ+YQ50?EAZH?>R<4NV.V4V_&Q1XRW<@;JO;X1>^1U+22I@DG"&!&R6WE5X
MF8>! =B(OPD<Y-$],E8>./]B%I_*I1<814"A4(8"Z\LCK(%2PZ1U?&U)O>Y,
M SR^?V'_W9K79AZPA#6G_Y!2[99>ZJ$2-GA/U2T__ &MH8GA*SB5]A<=VMC
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M6(,YWZN4FW=6:5# 6R+6*EI@"ZU);4T4^^]7M:N#>5=X-\I-MSON[^1>J]G
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M^U,.AHRW'#LR+9>KM/CV[(>(NN'KFKQ-Y1C..+EM4\A,CD96BV8<I?"S']S
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M/4Z_=C!2?6\3IC&U)6-IZX==85V 8]V8_=J!R6V1D5],&?V4/L%-M@V) L4
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MP"'EGR3VX\,2?/SP"7P 80P^AY0J+C-;R,H4/WN=5W&=58$ZJEB2]05 P0\
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MP1N2J !Y?<N8>#E0[\J+WT86_P%02P,$%     @ [(!-6NWN/R\H P  6 L
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M1CK.?'--_P\P;@(]7VJ-;QUWIM5_I/0?4$L#!!0    ( .R 35J8X!XT_@(
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M9-Y%YP,MTJP1G0N-;6UVN\(O#Y!F ZY'0NB[@>EMRV^9X!]02P,$%     @
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MO]&I6PX/FW"]#U-CI)(_0#1"74Y7I7K5SSEZ34$W'E!H,M\D/P*SG4\!5'-
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MU.?A]8U@>75"_,*$8&EU&5&RID5I(-]O&!.'FW*!]E^)Y;]02P,$%     @
M[(!-6MT^-&L-!   JA4  !D   !X;"]W;W)K<VAE971S+W-H965T.3@N>&UL
MM9A=CZ,V%(;_RA$=53/2- 1"OJ9)I)T VJVZU6BRTUY4O? $)U@#F+%-LM-?
M7]L0\E&"$LE[DV#C]_'Q>;$QGFPI>^,QQ@*^ITG&IU8L1/Y@VWP9XQ3Q#LUQ
M)N^L*$N1D$6VMGG.,(JT*$ULM]L=V"DBF36;Z+HG-IO00B0DPT\,>)&FB'T\
MXH1NIY9C[2J>R3H6JL*>37*TQ@LL7O(G)DMV38E(BC-.: 8,KZ;6)^<A=+1
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M8I26)^?!)EMHBZV9AUJ3$K,F/6XQ 30E]?UVG4+*DW;*%.*B!UYKD%J@$K-
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MVS 4_2M6AB:0H/FD ]9&HLW0F(2$8&P/TQ[<Y+:Q<.S,=EOX][MVTM"B%/'
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M=VT'UGH[Y"[;CNKLEOX"];@JRTUHK*H45^O,$4=;HO7*C#4OKCL*W.>OX/5
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M<VAE970Q,#0N>&ULK59M;]HP$/XK5B9-G=22%P)I.XA4H-,VJ5+5:NUG-[F
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MB*P*77?K=K:]/MS94_-@?H+7BOH6\)^FOI,\4#EGV.<X9$CI]2(L-UF?\_5
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MW1/ZOJV45!@JEL5D;@)X+$B%CMYQ'3I;/,B<AC"V,!U($&NP)K__YOK.'\<
MKZ1L#[=7X?::M$^*Q24)W\%^@YAEF7[#-9B#8#PBM[AJBO5T=RP>A1'?&-')
M;CUQ7<_K#D;V>I>TT9>6I/V*M'\6:2QHIN"71/U#HN[0#6I C29; OD5D'\6
M$'R ")G\-9)_@/3%=8+ K3$U6FW)%%1,P5E,(<U"/)TB&\_6!; SYBLXA/."
M?K_&UFB])=N@8AM<O-4 #X2S-]G@V";SO6&-L=&+EHS#BG'8F#U_F),>9VNZ
M!H$W%_*U7)SD1; 0CE$-KYE*KZ1LC]UUML>_<]&.)+F&/IE/(YXD5$C=54S[
MT5DO;0;[F:@SJ.?69M_:LN]<?=Q+TNL]H>4*J 7C O#"X& 7O!]TAEX=O-&Q
MMN#>%MR[+ U? ]T[1'>"CN/7T1M=:XN^O2JYC5>3AFQ]C1AT#V/@>YU>/:4W
M^]@V!MO[DWO>!:K&>9C8SZ3N'>[V7J_CUY-\LU=MJ;=W*;?Y,C6-L62)J0*L
M)I1@6(B&9$V3U=$,7^KJ[Q]<!T2'H_ &N1U5>&KO5&<IB-@4K;@"^2I31:%6
M]5:%\=24@_9V>%%5/U.!>5F2!!8HZG0"-"V*0K5H*)Z;6N^-*ZP<S>L2BWL0
M>@!^7W"N/AO:0/5WP>1_4$L#!!0    ( .R 35KE<"]TR <  *A#   :
M>&PO=V]R:W-H965T<R]S:&5E=#$P-BYX;6RUG/]OHS88QO\5*ZNFF]01L U)
MNC;2-=RT33M===V7GVGB)NCXD@%I>__]##@Q)M3!XN67)J'XX>7!AN<3'&Y?
MT^Q;OF.L0&]QE.1WDUU1[&^FTWR]8W&06^F>)?P_SVD6!P7_F&VG^3YCP:9J
M%$=3;-O>- ["9+*\K98]9,O;]%!$8<(>,I0?XCC(OM^S*'V]FSB3XX*OX797
ME NFR]M]L&6/K/A[_Y#Q3].3RB:,69*':8(R]GPW^>C<^"XI&U1K_!.RU[SQ
M'I6[\I2FW\H/OV_N)G99$8O8NB@E O[RPE8LBDHE7L=_0G1RVF;9L/G^J/YK
MM?-\9YZ"G*W2Z-]P4^SN)O,)VK#GX! 57]/7WYC8(;?46Z=17OU%KV)=>X+6
MA[Q(8]&85Q"'2?T:O DC&@VP^TX#+!K@5@-G]DX#(AJ0OEN@H@&MG*EWI?+!
M#XI@>9NEKR@KU^9JY9O*S*HUW_TP*8_[8Y'Q_X:\7;%<I7',[>?;67^[KE]0
MNJ\.R3X*DAP%R48L7J<Q[VUY4!^O;<88/_Y%CGY&CW6G0>DS^E*US=&70Y$7
MO&V8;-$'GQ5!&.4_\56OT!3ENR!C^?$E3-!?N_20\Y7SVVG!]ZFL;+H6]=_7
M]>-WZG<P^IPFQ2Y'GY(-VZ@"4V[&R1%\=.0>:Q5]MK807EPC;&/:4="J1W/B
M5,U)1W-?W_R/(+&0W=E<V1MR.KZDTB/OZ#TVCFB.TL91*0\L>V/9.LR#IXAU
M65]+TV[I\HQTD^^#-;N;\%-.SK(7-EG^^(/CV;]TV08IY@.)*9;2DZ54I[YL
M=NWD$#^QK-GQ/_#^7/?LG[HLK:6]2KH\)[\L'0=[>'$[?6F:U;D:)G-U-;]K
MM;DWPZ?5E!UT3SOH]MW!:_3QA67\ H#^#)\[^XA>RD7?69#EB*"X'J7.'&V"
M[UT#?=5/R1-*7;VBG\)"6XOBF'=RS.O=)8Z&?:K'%D,/6;AF5;_8I%%45K#G
M7:;J(YU=I-[4K'E0*;6\=A?15F0ZGH#$%/-F)_-F6O,^R9.0^7B:G8V &?7F
MI.65M@!3KX#$%*_F)Z_F?;VZ'M[3YN<]C;A6X_11NZ<MR=0](#'%O<7)O876
MO2O'MBW;*V.(8SO6?-9EBE;"]*('*>8#B2G6.;8,BO9X24)H [D*JN9#J:F^
M-@*XH^V4]:#]&B1;/J0_ATD8'V*#,2S4Y\U!7/7RUB#65V'L&9":ZAF6GF$#
MSX(W4\_P^8E/G ]4S[15&'L&I*9Z)D' T8;B8;%5:"M)D]C.62<##?E0:JIA
M,N8[O7/^Y1A\04N?.85Y6@EC\X#45/,D0CB]&6)X3A';:H_7,VK2UV3L()":
MZJ!$"D?/%(-BL="^.%Y!(0)*335,8H33FR, LK'8V.4^!\H64&JJA9(N'#U>
M7#F.:WFS*B#CA>4ZG<Y \L *5,V'4E/]DWSA+$;,R*#D :KF0ZFIW\A*]L#:
M##XT(PMU)2-7';TUEO55F'H&I:9Z)KD"FW"%<486ZLKY3YP25,] N0)*3?5,
M<@76<\6@C"RTE6ON'+OM;U/T)1@;-@948 D5N#=47,[(%[2P^'YV=LS*WKM1
M6:]D[.$8G($E9^#^]Q,&QQ:Q+7788HNV8XN^)F,'QX -+&$#ZV%C4%06VA>'
M+2A;0*FIADFVP+W9 B JXXX[%IU]#I0VH-14"R5M8#UM7#G$L1:TBLJN8]'.
MJ*S7,(UTH&H^E)KJGT0-/!\O*F-0! %5\Z'45%\E@F#]/8ZA47EQ'I6KCMX>
MRZ!X :6F3I&0>$%,\,(X*@MUY?PG3@F*9_HJC*= C($71.(%T>/%H*@LM)O7
M7.QZN-W)]"48&S8&6Q#)%J0W6UR.RA>T:/^HK%<R]G ,W""-R4S][V$,CBUB
M6^I$"WQ^%TA?D[&#8\ &D;!!]+ Q*"J3\_E&G<,6E"V@U%3#)%N0WFP!$)5)
MQYV,SCX'2AM0:JJ%DC:(GC9X0)Y9"UQ%90];,[?3&4@X6(&J^5!JJG\2-<AL
MO*A,0!$$5,V'4E-]E0A"]'<[!D9EH:Y$Y:JCM\<R*%Y J:F>2;P@)GAA'I47
MY^<_<4I0/0/%"R@U=;JPQ NJQXMA$X;M\VNN1Q9MMM"78&H8E)IJF&0+VILM
M+D?E"UKS_E%9KV3LX1BX025NT/ZW,@;'%MHQ8<JS+=*>9ZNOR=C!,6"#2MB@
M>M@8%)7I^80IBL_F<.LK,/9KE%]%-'X6T1LM )(R[;B1T76ET!=E;.$8L$$E
M;% ];/!\3"U/)&77FB\ZG8%D@Q6HF@^EIOHG28-ZXR5E"DH@H&H^E)KJJR00
MJK_9,3 I"W4E*5<=O3V60>D"2DWU3-(%-:$+XZ1,.WZ<(4X)JF>@= &EIGHF
MZ8+JZ6)84EZ<)^4%H>TYC_H2C T; RU<B19N;[3H\5,]O9;7/RGKE4P]A%)3
M/92TX?:_DS$XMK@=TZ;XL#V;-JJOR=C!,5C#E:SAZEEC4%)V.Z9-$1>WKPWZ
M$HP-&P,M7(D6;F^T (C*;L>-C/+RVOY>7E^4L86@M#%M/,(@9MFV>A1$CM;I
M(2GJW^Z?EIX>-_&Q>LA":_F]<^/7#XV0,O4S+#X'V3;D_3%BSUS2YB@Q05G]
M6(CZ0Y'NJP<E/*5%D<;5VQT+-BPK5^#_?T[3XOBAW,#IX1S+_P%02P,$%
M  @ [(!-6BTC=5^: P  :@P  !H   !X;"]W;W)K<VAE971S+W-H965T,3 W
M+GAM;-5747/B-A#^*QIWIG,W$V++@($4F DD;?-P/0::WD/G'H2]8#>VY)/D
M</GW7<F.\17LY-J[A[Y@2]9^^^G;U6J9'H1\4#& )I^SE*N9$VN=7[FN"F/(
MF+H4.7#\LA,R8QJ'<N^J7 *+K%&6NK[G!6[&$N[,IW9N)>=34>@TX;"21!59
MQN33 E)QF#G4>9Y8)_M8FPEW/LW9'C:@[_.5Q)%;HT1)!EPE@A,)NYES3:\6
M-# &=L4?"1Q4XYV8K6R%>#"#NVCF>(81I!!J \'P\0A+2%.#A#P^5:!.[=,8
M-M^?T7^VF\?-;)F"I4@_))&.9\[8(1'L6)'JM3C\"M6&A@8O%*FRO^10K?4<
M$A9*BZPR1@99PLLG^UP)T3#P:8N!7QGXEG?IR+*\89K-IU(<B#2K$<V\V*U:
M:R27<!.5C9;X-4$[/5^*+$-QT$_X<%$^B,BM8'G*N"*,1]5T*#+,!<5*-?<2
M *.C%>F131E2(G9D#4K+)-00D4W,))![GN":-S>@69*JMT2964423GZ/1:$0
M7DU=C3LQ?-RP8KTH6?LMK*E/W@FN8T5N>031EP N2E#KX#_KL/ [$6\@O"3^
MY(+XGC^H2'; ]FMY^Q9VT +;E,.*6,FQWMRKM^?VW0EGCNB5RED(,P?/H +Y
M",[\QQ]HX/W40790DQU8]'X+61NPGLGQB"R;P;Z6DO&]#3?9/I'FNA5[LM/7
M!R:C"_*;X+WW9?K<?BH2_43N."I0V$RY(.\+K32&/.%[\N=:I"G!HV4L/Y[3
M8O =M!C66@P[ [> ?<*YX;EE> Y"(&\P9<N\.!NX$BZP<*84/F*23OKCJ?MX
MAD50LP@Z6?R"NIO<><%W<.([Z/?I>=>CVO6HT_6=4L7+GD<GGGO#P7!PWO6X
M=CWN=+TT>J<0N7CI["!! 5P6_86U\&4^XU,^HU$+G4E-9]))Y[;,UU?FP>0T
M#_K>H"48U#N6::^3Q JDO8(-@\V9ZE15S4Z0?WED:.,NH?^K E+1_<9R^$<Y
M_&];0RJ\9O+X7G_4DCO'.XAV7T*OK"(52M/[Q M:G!_O%-I9IE]91RJ0+P[N
MV&NIGO18Q&EW%?\/E82>%O0>]?T61L>"3KLK^M<5$WI:V7V/]O]!PFVT?QG(
MO6UR%?9K!==E)UC/UHWT==D^'I>77?@[)C%G%4EAAZ;>Y0A5D&5C6PZTR&TS
MN14:6U/[&N.? 9!F 7[?":&?!\9!_?=B_C=02P,$%     @ [(!-6FE!@,Y0
M/0  ZJ\" !H   !X;"]W;W)K<VAE971S+W-H965T,3 X+GAM;+6=;7,C-[*E
M_PJC]]X)W@A/BWBIMQF/(^@";YL[:DE!4EIW;^P'MIIN,482M91DCR/VQR^E
M9HE90 (@BP?WP[7=3AQ69;ER$J< /#_^L5K_Z_%FL7CJ_?ON]O[Q'^]NGIX>
M_G9R\GA]L[B;/[Y?/2SN-__FM]7Z;OZT^<?UMY/'A_5B_O5UT-WMB1P,\I.[
M^?+^W4\_OO[9Q?JG'U?/3[?+^\7%NO?X?'<W7__Y\^)V]<<_WHEWS1],EM]N
MGE[^X.2G'Q_FWQ;3Q=/EP\5Z\T\G;RI?EW>+^\?EZKZW7OSVCW=#\3>3#UY'
MO(9<+1=_/)*_[[W<RY?5ZE\O_S#^^H]W@Y=+6MPNKI]>-.:;O_R^J!>WMR]2
MFPOYOUO5=V\_^C*0_GVC_M^O=[^YFR_SQT6]NOU?RZ]/-_]X5[[K?5W\-G^^
M?9JL_OAEL;VC[$7O>G7[^/K_>W]L8P?O>M?/CT^KN^W@S17<+>^__W7^[VTF
MR #E&R"W Z0U0$K/ +4=H/;]!;T=H%\S\_U67O-@YD_SGWY<K_[HK5^B-VHO
M?_.:S-?1F]M?WK\\^.G3>O-OEYMQ3S]-%]\VC_'IL;?ZK??S\^/FWSX^]N;W
M7WL?%JMOZ_G#S?*Z-]S\%_78^VMO.K]=//:^_-G;#FJ-Z9O%TWQY^_A?O?_H
M+>]['Y>WMYOG^OCCR=/F*E]^Z^1Z>T4_?[\BZ;DB(7L?5_=/-X^]T?W7Q=>V
MP,GF]M[N43;W^+,,*IK%]?N>K'[HR8'4O<NIZ?7_X[]ZC]]O@KG >@\Y)5[E
M5"/'R)BPS/^<W[_O#2R9)K6!NU9O3U:]ZJOPD^U-%@^K]=/R_EMO?/^]4+R\
M;__[=!/>&S\M[A[_#_>,OFMK7ONE&OWM\6%^O?C'NTVY>5RL?U^\^^DO_T/D
M@[]S^42*&9!8*Z?Z+:<ZI/[3V?/=E\7ZY;_[[7\]['_?WS7R5XV7POO[3_+'
MD]]I0H*_<FA"W)]3;S_7NLOL[2ZSX%U^?\^?5KWZM?XLUNQ=?M?(R,^692F%
M=:=,5":RJAUEW*BBJJH!?QOYVVWDP=OXSUY],[__MN N_OM((<@O#MX/M+*N
MG@_+,^OR@]?1\3_)XNTNB^!=CN_O5[_/7_['L_=Q\75YO?G7W T'10Y]GY%B
M!B362E[YEKPR88TLD3E%BAF06"NGU5M.*T#UJ)PW/LNK7%OO'Q.E"Z=Z5$X!
MS&26>XJ@&.PZHT'G^K$=^O*75@&QKK\)L^N,];\')GPE'1^8(#V@.+2&]/Y?
M;WQW]WR_NEU]^Y/-0%#RT/_ZH6H&I=9.I]RE4R:L*EMQ5&*1:@:EUD[LKJ,5
MP>9NS]*R%:%50Q2E+.UWDPDK!YGS:BJGNHB\4IFGNNPZ21%N)8/5)3RT+][+
MP7]R4XYZ.]+I6'+[KD =:/OF=PVF"'>8GH)S_]NK&_#\V#/+Q\V<<\$_WZ#V
MP2\(4LV@U-IYW76\(D]9>4!][#:Q2#6#4FLG=M=DBW"7O6?E*9R2HE25VX7'
MC=):E/8;6KA=C=:5I^SL&EX1[/W"92<\M"_5>^&K.Y&AHGQ?\4-->&C7)[OK
M5D6X7>5+T=GB>;UZO%XN[J_Y5 5%#WY5D&H&I=;VVG9MLQPDK$$2U EOC3RD
MFD&IM1.[Z])EN$O?KP9M15I>BA"68U&S47I@U:!M%*U!>5EY)E9RUQ_+8)L8
MK$&1H?W!>^TI0=N1=NNC[-8G_ M=G^*NAY7A'I:O-^?WU]Z95ECPX%<":L:B
MU-K)W#714J>L-4@;MH:J&91:.[&[!ETB+&#I^K9R4)2V!\R$B2+/A?UB9NY,
M*ZM*7[G9-<6RNP\L68=7%(5]"WS<P':"PY?2];'MVE1YL!F\*2X7S[=WJ_OY
M^L_>+W\^+-9/WS_;LNF VL10-8-2:Z=VUSC+E%:QA'K%4#6#4FLG=M> 2X1?
M+%TK6,O2_J[&1*G2;GZ,= UCI47!UQFU:WQ5=[]8L4:PD/8')T^<L)N8\*5T
M?&9JUXJJ+H9Q/5]_76[^_/'Z^7:^/OFX>)I_6=TN'^].SI]N%FLV+U 7&:IF
M4&KM'.^Z9)721590%QFJ9E!J[<22=1$(%UFY]K#*<KO@<%%Y87<VRO6055GZ
M"LZN^U7=+>3(T+YZ/_#,HV(CL_>9Q\D)C^SZ7'<]JPKWK)M*-%M<W[#9@%K&
M4#6#4FMG;=<=JY26L8):QE U@U)K)W;7BRN$9:P8RUB4F3W_X,(&>F ;-LHU
MC66AI:_2[)I?U=TUW@YUOG';W]OX.#&PC>_PI71];+MV5(7;T6T5<=H9]M:A
M+C!4S:#4VNOD=LVP3ND":Z@+#%4S*+5V8G>MMT:XP)KQ=XN!7568J%QE=E'1
MK@NLU<"S.$_O^EO=W076K)<KA;V^AH_3MGUCPI?2]9GM.DX=[CAW->5\_72S
M>IB_S)GXYP;U>J%J!J763B)9>IO2Z]50KQ>J9E!J[<3N^F:-\'JU:^)6(K/_
M1YZ)*BMGN9MVG=XR\\V']*Z5U=V-7LTOY95.1?&L#+:G=.%+Z?K,=LVE#C>7
MNXHR?5Y_6ZS9#T=AC8/_FX>ZN2BU=OYV#:U.Z>9JJ)L+53,HM79B=^VS1KBY
MVO5IJU+;'ZF9*#$8*.=_W%T[M\I]FP>R70>;=;=S(T/[PK?:I<[X%<'.5^KP
M+W1\C-FNR\S"7>:NOEPM?1^+PA*'O@50-8-2:Z=OU]MF*;W;#.K=0M4,2JV=
MV%TGG2&\V\QU93.A[75X7-2@L'N5S/5N=>E;AY?MNMFLNW>;\8MXG44\GCC[
M1DWX4KH^,[*;+-Q?3A9WR^OYU^\K? _?:!!6/_AM@'JW*+5V9G<-;Y;2N\V@
MWBU4S:#4VHG=M=<9PKO-7%-V<P7.6\I$E<K9 <DXMTK[-G+N^MRLNW$;&=H7
M\GWIZV)B*X6%]R-1>&C7)[OK3[-(?[J\>UC=+T^V?^T-U\MYU\($=7^A:@:E
MUMYXN^N=\Y3N;PYU?Z%J!J763NRN+\\1[F_N^KI25):O6_-1]NPJ=]U?*4K-
M%Z9\UR'GW=W?R-#^X+WRU*6<7P,\L#NB\"]T?8J[+C:/=+%/B]OYNFO="8L?
M_'I /6*46CNQNZXZ3^D1YU"/&*IF4&KMQ.YZ^!SA$>?,0M^!LA?ZUFQ8:7O)
M)G==XJJ0GI8H)Z="''$L1'AH7[_/?96'7R LG'*:HK'-=XUM'FYL9^O%W6]_
M=JX\4$,9JF90:NW$[AKM/*6AG$,-9:B:0:FU$[MKV'.$H9PS"W_SPNEXF"BA
MG5?4]9-EGI=\W2EV/7'1W4\N^&6_]K;MVA-7V+/)\*5T/9%FUZ46X2[U=;DO
MJ24=RTWX5PX^M 9J,*/4VAG>M<]%2H.Y@!K,4#6#4FLG=M>:%PB#N6"6_=JO
M*G.\A/T1N6#.EO!\!2]V/7#1W5F.#.T7VKO#.S94*9];9,)#NS[27>]:A'O7
M^OQJ;/XJ*G\5VN_<B?#/'/S60(UHE%H[Q;N>NDAI1!=0(QJJ9E!J[<22P]T0
M1G3!6,R5O32'"W+G)P7C0]/^HGT?N_:XZ.Y#1X;V2^G=\QT;JDM_44K1UA:[
MMK8(M[4C<SD9GLU.ULO;A^7ORW53B8ZI3U _&JIF4&KM4_YVO7>9TH\NH7XT
M5,V@U-J)W77Z)<*/+EVG64C[2WO-10EG-7+I^M%B,/#,SLI=0UUV]Z-+UE46
MMJM<>^*<M8/A2^GZS'8M;AEN<2\FH\_CZ6QX\O(W]?G/XU]/-G]S?OKR1]-/
M'V>7GX?'EJ+P%1S\QD M:I1:._N[]KQ,:5&74(L:JF90:NW$[MK\$F%1E]Q9
M%,(I14Q4F6G[/68.K*A\W^S+73-==C>H(T/[Q?O"TRK%1GJM;1,>V?6Y[EK@
M,MP";\TDM_ <7:2@;C94S:#4VCDGQR(G/1<9>S R]F3D%&U_N6O[2X2;7;H^
MM;OWB0MROMZ7S%$7PM,L5;MVNNIN94>&]F7A_886&YK[BIL)C^SX5*M=%UR%
MN^#Z_*P>33;MT\?%T\V?MP\WB_OEU_F3?T87.UXP_'N'OD%0-8-2:^=ZUZA7
M*9WO"NI\0]4,2JV=V-VTH$(XWY5K:^?V!*=F@HK2,LA-Y9K?N?:L*ZIV[775
MW?V.#'TYI-3G?F^'.AM2[85%X9_H^@QW/7 5.5?Y[&KT8=B;7DYGH[.SX<FO
MHXO3\?G9R6PR/OL\W/QE=#6N9_[I7;0N02UPJ)I!J;53O^O:JY06> 6UP*%J
M!J763NRN_Z\0%GC%'*HLI3VOXZ*<PU%-Y7K@FAZ.VKZ175-==?? *_X0#6E;
M3)&?Z ^\L[CPR*Y/D4!!(HWOQ61X-9R==R\]4'<;JF90:A:HA))*4OK;C3HH
MMU@Y Y.SLDOH* .$R=VHM)<U.B>)<F%Y:2_@::):$[?"TQV)@23WTMWG;L9:
M52C+547_S[DA=E3IV-Z12^O\( D^9!!N<<]GOXPFO;/1Y>1\6H]'FTE;YW(4
M^:G#WQFHQPV3LU)-Z":#E#9WHP[++M3HALE9V27XE '"ZVY4VE_4"GN#&AN6
M9?9\K0EKKU92WII$H"6#[H9W;&Q?:N]ND.A8X3U-WD3&=G[&A#@R"/>]]7!R
M]>F?L[&W1(7.C(^('_X"0=UMF)R57$)!&:0TN!MU6':A%C=,SLHN0:H,$"YW
MH](Z!22WUU%R49ES\&$3U2I.RH< I S 8R" /-ZODD[/A^+[;6\V$2Z0\@+#
M';$93CX/3T>_=JM-:'0@F!V8!!Y(Z8%I\8%@?B 8()B&($@1@AB&($<'%.Z.
M$BZN*K2]4D P%,&B*CQKO06E"!Z#$>1I@.[24$^@XY^9R-5T?GRD\XV0 T>3
MT]'0^!WL<.'!D@/!Z, T[$ *#TQ+#P3C \'\P#0 04H0Q" $&3J@9$P7+DR5
M]N=_P5 $14D /=;=D ;Z&(Z@8-ULF3DD1$]@[MAA:2"!E!(8PP1^_'ER>36N
MNU8>+"\0# Q,0@P4!!DHDC(#!18:B)4S,#DKNZ1;AX #!<,$5 /E] I<F+3)
M[48P[$!5^,X-$00>*(Z@!\;&]G/OP8S1H4)YEQ]%QG9^Q*2KC5 %9Z/Z:OCI
M],4LNKB9;UZ<Z\7ST_)Z?ALK3%BX(%;.P.2LO)+V.BE@4& )@U@Y Y.SLDN:
M>0AE4##\P$P['1$3I2K[T[Y@(8.^HD1:YR,8@X*'!ZK2+:W8EC<)C% 0&J&(
MX @_?YJ-/PQ/YE^6Z_G38KW:O"R;GWL*K8P,%RNLJ8WE$\+DK'23GCPIHE!@
M&858.0.3L[)+9@ 03J%@$(2YLA=(<E&E.WMC0(6B*#P+D00A%8HC4(6QL7WI
MW51;1\?JRL^!3\(T% 1J*")4P^\[39H*U*U$88&&6#D#D[-23)KWI%!#@:4:
M8N4,3,[*+ID%0,B&@H$65FZ)8J)TZ4SS&+2A]IW1)@C:4!S!-FS&.M_=G)4-
M?*!P_?DDZ$)!V(4B B\\OYA>?AS/O$5G?X9SY)<.?TFP+G<2W*$@O$.1%'@H
ML,1#K)R!R5G9)2T_A'HH&)YAZU39)CO<P2:%LS*)P1Z*P@>.%P1[*([@'@H?
MT-#Y^N\+M#>/1*ZF\],C/6X$?GAY,9L,K_Q+C@ZI0EC'&PM'A,FU,TWPB"(I
M'U%@ 8E8.0.3L[)+.GD()%$P_$-1VD<BU6Q89K/GC6 XB9N64'JJ$ $EBB-(
MB8)'( K7'_,$.EN&(U?3^>F1-C:"2_P^#^-K#:(T82&+6#D#D[/23UKOI*!%
M@24M8N4,3,[*+FGT(;1%P8 49>G,T;BHW%D;R> 6E?!U1P2W*([@+0H/2-$^
MJK:._4A?^+?]1\9V?IJDW8UP&'\=3D:G@5UM;8;TR_D \R^KV^7CW<EKD>,S
MAW6YL=Q&F)R5<M*3)T4W"BR[$2MG8')6=LD, ,)O% R:42I[8E;S8;GS48XA
M.$I=^"H403B*(QB.PH-B'#AW$:,]:O\NDB081T$XCB("<OS>2R'+$Q;[B)4S
M,#DKX:193XI^%%CV(U;.P.2L[)*I 83_*!BTHQ#V)MN:#5.N+<,@(#>3/=]2
M)L* %$= (&-C^Z5_*5-LJ/<()A,9VOD)D_XX0HL<G8[JV>3\XI=/T_'YZ?F'
M3YLRM:/1M@L6GS>L_8T%1L+DK/R2ICTI,U)@H9%8.0.3L[)+Y@,0<*1@F)"9
MS!WCB0G3N;ULR B&':DJY=M<0N"1X@AZ9#/6]I.DVS[Q@95S/D 2-*0@;$@1
M@4,.ORPWS^SKP14':W5C29 PN796"0M2)(5!"BP-$BMG8')6=DF##R%""@;V
MN)EV.1LRN#"F(V*@D,JWJ20GO7-^A-&=>XQNYZ-_^$<.?\))>EX"BQ0Q6N3-
MZOI??\R;F=O\]H?-"W3]_M JA<5&8N4,3,[*,NG%DZ(C!98=B94S,#DKNZ2K
MA_ C!4.&S.RM);5@P)".YQV,L6Z#-,\1 .3JU4VY;KUL![^'V X:*F=@<E:*
M20>]!36F>@^QYCF640F3L[)+.OHPK7'O][!TWD-5.GO?N2A[CZ=IHEJ]@O)]
M%2=<2!$!0X:;A8KU=O-J0/_/^9[F&58,JL ):"9RI5T?*T%+B@A;\I?QQ;15
MA\[73S>KA_E+O\ _810A<ILXJ)R!R5D))5WUEM^8J IAR958.0.3L[)+^OPP
MQ''?*K15:4U&<G=#*A>6N5_!MV'MG5]>%Y<0(T4$&1DL1-NQ+R?VT(KB3%H\
M<<Y2Q_"U='YVI$^.@![_>38:'5IKL+TQ5,[ Y*R,DMYX"V=,56NP?C>62PF3
ML[)+6O8PH7'O6I,S1<3U%K@P[?8\V[#V4L#,0U$4! <I(CS(<*TI^*;':7,\
M@;$V)WQMG9\EZ5XC/,?99'CY<7A@\<&N]X#*&9B<E5+216_)BZF*#];ZQD(G
M87+M[!+LI CC%_<M/EN5]LD;[@I>)DQ6#ON]"6NMIBD+GSU+6(\B GL,%I_M
M6.<$>^=SD"?0[NM,Y&HZ/SW2ID:8D-.+\=GHA^G%^60V[?UE?O?P]][W$Z0/
M*D HVF.3/JR[G81%*0B,4FQYBXD*$)8TB94S,#DKNZ1;#T,7]RY FJDL#GR"
M#]/.!H)M6+L ^;B(@A >103Q&"Y X;']@1>-V QU2I)[9TFZ68*&%!%,X]!<
M#<_JD6F5H.GS^MMBS>]'1\$;FTQAW>8D:$E!V)*B3.HV8Q&26#D#D[.R2_KU
M,$UQ[^KC^LA:NZ?C<&%YX:PB*5V_>3-#\\V]"+I11-B-X>H3'MM7_M5Z)6\Z
MNX>OAG^CZ_,DV$<1(3!^&)V-)L/3O8L/"LNX3114SL#DK'22?KI*:C)C(9%8
M.0.3L[)+NO<P+W'?XE.Y[G&F,J?XL&&Y8_Q4KLF<">F;>Q$XHXC0&8/%)S)V
MT_I(7_'9#K6+CW9F8^'?Z/P\22L;P3/6YV>S83WKG8[.IJ/IB3L3NUIZ=WRB
ML(Q-TK .=!)HI"#42%$E=:"Q5$BLG(')6=DE/7L8D+AW(7*M954HQSYAPP9.
MKU"Y#K3*O',P0F,4$1QCN!#QQO+ +:=\H&VXF\C5='YZI(>-(!6GEY,/X]IJ
M>D*E!NLW0^4,3,Y*)VFBJZ1^,Y8"B94S,+E6=B7A0,HP"W'/4M.HM+]B";O4
ML&'*1F"8)JS]L8NL&;;N1I"[Z>XW-V,=S\9&OOH";7O=1*ZF\].3Y'[#'>OE
M_?)I\;4W?3D@U?/@H%XR5L[ Y*P$*I+ E%ZRQ"(=L7(&)F=E5Y/L(KSD1J7-
MZU)VAU)S<3K7SM%\35R;QESY&!:24!1EA*(8KB^\)VQC[&M/H'NZ5^1J.C_
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M*VH&F>@<EE^S4<R6,H:L* ?>CV\$K:B/0"O&QO9+Z9_$Q<;JS'^*;!( HR8
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ME*HRU*KVC55%4,YN4:+FTE3(LBZV#+$GM8X*!B;+[3>+^*Z6ACF P@XFFD0
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M%NLC&?04L'[O[:[/WNXAJ9GN:?CTW?1Y+FX>R%5YG\J*?".?19Z QB#QXMI
M3#6.I68:J&'6CP[9KIVHO+>QF&H<2\TT5G.T[P;I2T66:B0N6D]ED:@90LN:
M;=-6$X:L!.'+MQ&8^19^ 5&Q9X&GNWK/35]SM^\&[XNB*.]$NR)'/LHT2]3/
M8,9(?+QV!E.-8ZF9#FIX]\>';)F8D#Y!5>-8:N::G6;^X(7,']BD[GN]Q92)
M^R#[6@(><@?]!GIR$+@G!Q_T'+==94I5:ZR;3"4.MD6WV+Z73&#S_)O ZJ6P
MCFD:I*<'@7MZ<*DF3M-5@Y)?%[*H86-0IP6H:GRM]K0+1]-^X(1>J/=6>/6Q
M;#LD 5J$"OBH:AQ+S?12 WY #]B/!YBT/D%5XUAJIK&:_8-'5I[G"Y%5G;?E
MK0*K1A33K%V%%MTJ])%JTDF^3%O'IV69WF=Y#CILKSE;_=3D*4'<7=_G^J%1
M/G O3*N6^EDF,S!'5$Y'5>-8:J9KFM.#^)#-$XFRU\9BJG$L-=-8/0,(W#.
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M!8[+#W4Q;U]I^%#4PAG;/Z<\'O.R$1"_/Q9%_?*AN<'J-9H7_P=02P,$%
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M2[Y.D,?^1<@ON1;P$X,K'0V,44V@FD0UA6H:U<RXNYBXI])?(P<>-[9,]N?
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M[\J2N0@^IT61[@Y?WB;Q.LFJ!Y3__SI-B]-?J@&^I-FOAZ?]_O\!4$L#!!0
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MJ28DC #!%#5'C9HCF*@Z8H9GT> Z3BNJ+L<,VF.(<3HW.CMNG!T;G?UU2_.
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MHGDY0)Q?,<9/.^4%FK[5^7]02P,$%     @ [(!-6HKC>K&0#   ZYX  !H
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MYD U%ZIY4,V':@%4HU"-H32U_[JTW=2G[;_7/584HBS((JH/INW/V?7*X*Z
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M\Z%: -4H5&,H36V!O:^VUD?G[O:+3PL15KG<L1!ROV')HYPD//\J=SF>?P>
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M?<_QN<?F9+21ZE'G (8\%5SHL9<;4U[YODYS**CNR1($KBRE*JC!H5KYNE1
M,P<JN!\%P= O*!->,G)SMRH9R<IP)N!6$5T5!55_IL#E9NR%WG;BCJUR8R?\
M9%32%=R#>2AO%8[\EB5C!0C-I" *EF-O$E[-!K;>%7QGL-$[[\1VLI#RT0X^
M9V,OL(* 0VHL \7'&F; N25"&;\;3J_=T@)WW[?L'UWOV,N":IA)_H-E)A][
MEQ[)8$DK;N[DYA,T_3B!J>3:_9)-4QMX)*VTD44#1@4%$_63/C4^[ #"X1%
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M#'KO4)&J0[(>&%FZG%E(@ZGE7G/\KH"R!;B^E-)L!W:#]DN5_ -02P,$%
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
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MYIAC(@O-A2V$,:-%=,A"<^G1(+;&X&@N>X[D,S_=Q /JPO-%?G,DG[GX[#:
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MU3L!]$ZJ=P+HG57O#- [J]X9H'=6O3- [ZQZ9X#>6?7. +VS^6<E0.^L>F>
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M53N\YB=+47?S$U!+ 0(4 Q0    ( .R 35H'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ [(!-6N!@
MZ]ON    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ [(!-6IE<G",0!@  G"<  !,              ( !S $
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #L@$U:;>4\(DX*  "]
M4@  &               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ [(!-6A',]?A" @  R 4  !@              ("!D1(
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( .R 35IFZLZZ
M"@<  ,4=   8              " @0D5  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    " #L@$U:+OY@6?H"  #3"   &
M@(%)'   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ [(!-
M6D7&'U!(!@  ,1P  !@              ("!>1\  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    ( .R 35HN,RVX*P4  !\7   8
M      " @?<E  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M" #L@$U:RZ7?*><"  !$"   &               @(%8*P  >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ [(!-6O0$'90(!@  OR,  !@
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M970Q,BYX;6Q02P$"% ,4    " #L@$U:)'I#,8 "  !Q!0  &0
M    @(%4;P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M .R 35K*_E!QY@,  ' )   9              " @0MR  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ [(!-6H5C:; *!@  %P\  !D
M             ("!*'8  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    " #L@$U:*F]"UC83  #Y/P  &0              @(%I?   >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( .R 35ISE*(WU0<
M ! 4   9              " @=:/  !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ [(!-6EX]?K%6#@  _2D  !D              ("!
MXI<  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #L@$U:
M;A\JFQ(#   ;!P  &0              @(%OI@  >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    ( .R 35KIRRY7K!<  -A(   9
M      " @;BI  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ [(!-6N1-MOG/ @  . 8  !D              ("!F\$  'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #L@$U:J1+<Z50$   I"@
M&0              @(&AQ   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    ( .R 35JO;<1U< 0   X*   9              " @2S)  !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ [(!-6L^>W;FE
M!   20L  !D              ("!T\T  'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    " #L@$U:P0*MN.T#  !+"0  &0
M@(&OT@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( .R
M35HY30E[<PL  #@C   9              " @=/6  !X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @ [(!-6H-<<HRQ%P  <3X  !D
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M=#,Q+GAM;%!+ 0(4 Q0    ( .R 35K:DT$H9 (  '\&   9
M  " @01( 0!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @
M[(!-6KSJ#^U# @  B@8  !D              ("!GTH! 'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q02P$"% ,4    " #L@$U:0'N&01$"  #=!   &0
M            @($930$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4
M Q0    ( .R 35H*5H,0O@D  (PI   9              " @6%/ 0!X;"]W
M;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ [(!-6B'JVYI"(
M9F4  !D              ("!5ED! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q02P$"% ,4    " #L@$U:7?EY=%8#  ".!P  &0              @('/
M>0$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( .R 35HS
MD!\'0@4  "0.   9              " @5Q] 0!X;"]W;W)K<VAE971S+W-H
M965T,S@N>&UL4$L! A0#%     @ [(!-6NE7\&Z. @  >04  !D
M     ("!U8(! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .R 35H'KI'1YP<  *43   9              "
M@=B= 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ [(!-
M6K:PVF'= @  6P8  !D              ("!]J4! 'AL+W=O<FMS:&5E=',O
M<VAE970T-2YX;6Q02P$"% ,4    " #L@$U:;(PCO$D-   5*   &0
M        @($*J0$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0
M   ( .R 35INW]R#( ,  "<'   9              " @8JV 0!X;"]W;W)K
M<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ [(!-6MO>[,%  P  W@8
M !D              ("!X;D! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q0
M2P$"% ,4    " #L@$U:%P+5S 0$  !_"0  &0              @(%8O0$
M>&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( .R 35J9\1$/
M3 4  .X,   9              " @9/! 0!X;"]W;W)K<VAE971S+W-H965T
M-3 N>&UL4$L! A0#%     @ [(!-6N4XZK?@%@  E3T  !D
M ("!%L<! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " #L
M@$U:6=;W'7D$  #P"0  &0              @($MW@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( .R 35IF!;O/?P,  #('   9
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M970U-RYX;6Q02P$"% ,4    " #L@$U:[FF\UJT"  "M!@  &0
M    @('7 P( >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    (
M .R 35K$![ H%@H  '95   9              " @;L& @!X;"]W;W)K<VAE
M971S+W-H965T-3DN>&UL4$L! A0#%     @ [(!-6B-DN>3( @  I@@  !D
M             ("!"!$" 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"
M% ,4    " #L@$U:;]-=M'T"  #,!@  &0              @($'% ( >&PO
M=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( .R 35JH>5-<K0,
M - 1   9              " @;L6 @!X;"]W;W)K<VAE971S+W-H965T-C(N
M>&UL4$L! A0#%     @ [(!-6E.7MXS+ @  H0<  !D              ("!
MGQH" 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " #L@$U:
M9\)JJ,P%  "[+P  &0              @(&A'0( >&PO=V]R:W-H965T<R]S
M:&5E=#8T+GAM;%!+ 0(4 Q0    ( .R 35K28VGL+00  . 2   9
M      " @:0C @!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%
M  @ [(!-6K)+LMN3 P  WA(  !D              ("!""@" 'AL+W=O<FMS
M:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    " #L@$U:.P$E/EX"   )!@
M&0              @('2*P( >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+
M 0(4 Q0    ( .R 35J Y"#""08  /,E   9              " @6<N @!X
M;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ [(!-6ES4OJ3Z
M"0  >VP  !D              ("!IS0" 'AL+W=O<FMS:&5E=',O<VAE970V
M.2YX;6Q02P$"% ,4    " #L@$U:1=U,V@,#   Q"0  &0
M@('8/@( >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( .R
M35KZ-/C2, ,  (<)   9              " @1)" @!X;"]W;W)K<VAE971S
M+W-H965T-S$N>&UL4$L! A0#%     @ [(!-6I^#>?T !   918  !D
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M=#<V+GAM;%!+ 0(4 Q0    ( .R 35I>2KGS:P(  &,&   9
M  " @5UY @!X;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @
M[(!-6F,&S!-D P  90P  !D              ("!_WL" 'AL+W=O<FMS:&5E
M=',O<VAE970W."YX;6Q02P$"% ,4    " #L@$U:K=2/]>0$  "0&0  &0
M            @(&:?P( >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4
M Q0    ( .R 35I:K6EWRP4  "(E   9              " @;6$ @!X;"]W
M;W)K<VAE971S+W-H965T.# N>&UL4$L! A0#%     @ [(!-6NGDVGHD!0
M:A@  !D              ("!MXH" 'AL+W=O<FMS:&5E=',O<VAE970X,2YX
M;6Q02P$"% ,4    " #L@$U:FM WTQ$#  #:"   &0              @($2
MD ( >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    ( .R 35JO
MGPA^?@,  *4+   9              " @5J3 @!X;"]W;W)K<VAE971S+W-H
M965T.#,N>&UL4$L! A0#%     @ [(!-6M<GILL" P  (@D  !D
M     ("!#Y<" 'AL+W=O<FMS:&5E=',O<VAE970X-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .R 35I>88^@W (  ,D'   9              "
M@<ZK @!X;"]W;W)K<VAE971S+W-H965T.#DN>&UL4$L! A0#%     @ [(!-
M6K-C'(>M#0  QF4  !D              ("!X:X" 'AL+W=O<FMS:&5E=',O
M<VAE970Y,"YX;6Q02P$"% ,4    " #L@$U:MD38QZX$   G&0  &0
M        @('%O ( >&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+ 0(4 Q0
M   ( .R 35KM[C\O* ,  %@+   9              " @:K! @!X;"]W;W)K
M<VAE971S+W-H965T.3(N>&UL4$L! A0#%     @ [(!-6H6Y-P65 @  G08
M !D              ("!"<4" 'AL+W=O<FMS:&5E=',O<VAE970Y,RYX;6Q0
M2P$"% ,4    " #L@$U:F. >-/X"  #7#   &0              @('5QP(
M>&PO=V]R:W-H965T<R]S:&5E=#DT+GAM;%!+ 0(4 Q0    ( .R 35HQ*JIG
M @H  &9P   9              " @0K+ @!X;"]W;W)K<VAE971S+W-H965T
M.34N>&UL4$L! A0#%     @ [(!-6@=UN#YN @  =@8  !D
M ("!0]4" 'AL+W=O<FMS:&5E=',O<VAE970Y-BYX;6Q02P$"% ,4    " #L
M@$U:T4FC1JP$  "A&   &0              @('HUP( >&PO=V]R:W-H965T
M<R]S:&5E=#DW+GAM;%!+ 0(4 Q0    ( .R 35K=/C1K#00  *H5   9
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M:&5E=#$P,BYX;6Q02P$"% ,4    " #L@$U:3U?#ZCL)  "]0@  &@
M        @('Y\0( >&PO=V]R:W-H965T<R]S:&5E=#$P,RYX;6Q02P$"% ,4
M    " #L@$U:I5+E= X#  !X"0  &@              @(%L^P( >&PO=V]R
M:W-H965T<R]S:&5E=#$P-"YX;6Q02P$"% ,4    " #L@$U:F [ X/(#   Z
M$   &@              @(&R_@( >&PO=V]R:W-H965T<R]S:&5E=#$P-2YX
M;6Q02P$"% ,4    " #L@$U:Y7 O=,@'  "H0P  &@              @('<
M @, >&PO=V]R:W-H965T<R]S:&5E=#$P-BYX;6Q02P$"% ,4    " #L@$U:
M+2-U7YH#  !J#   &@              @('<"@, >&PO=V]R:W-H965T<R]S
M:&5E=#$P-RYX;6Q02P$"% ,4    " #L@$U::4& SE ]  #JKP( &@
M        @(&N#@, >&PO=V]R:W-H965T<R]S:&5E=#$P."YX;6Q02P$"% ,4
M    " #L@$U:L 5X/\\&  #5)P  &@              @($V3 , >&PO=V]R
M:W-H965T<R]S:&5E=#$P.2YX;6Q02P$"% ,4    " #L@$U: _:)5I *   /
M4   &@              @($]4P, >&PO=V]R:W-H965T<R]S:&5E=#$Q,"YX
M;6Q02P$"% ,4    " #L@$U:- N/3:<-  !2<P  &@              @($%
M7@, >&PO=V]R:W-H965T<R]S:&5E=#$Q,2YX;6Q02P$"% ,4    " #L@$U:
MCQV;/9(8  !D?P$ &@              @('D:P, >&PO=V]R:W-H965T<R]S
M:&5E=#$Q,BYX;6Q02P$"% ,4    " #L@$U:S>2?#*,%  #8*P  &@
M        @(&NA , >&PO=V]R:W-H965T<R]S:&5E=#$Q,RYX;6Q02P$"% ,4
M    " #L@$U:E<K\;&(+  #:G0  &@              @(&)B@, >&PO=V]R
M:W-H965T<R]S:&5E=#$Q-"YX;6Q02P$"% ,4    " #L@$U:..]78$H#  !4
M$   &@              @($CE@, >&PO=V]R:W-H965T<R]S:&5E=#$Q-2YX
M;6Q02P$"% ,4    " #L@$U:UVCXQWP$   1'P  &@              @(&E
MF0, >&PO=V]R:W-H965T<R]S:&5E=#$Q-BYX;6Q02P$"% ,4    " #L@$U:
MK/DM=E$%  ##*@  &@              @(%9G@, >&PO=V]R:W-H965T<R]S
M:&5E=#$Q-RYX;6Q02P$"% ,4    " #L@$U:BN-ZL9 ,  #KG@  &@
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M2P$"% ,4    " #L@$U:;/*&>TP#  !K1@  &@              @ %)Q0,
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #L@$U:@_^P
M6I<"  "+0P  $P              @ '-R , 6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     @ "  $PC  "5RP,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1035</ContextCount>
  <ElementCount>694</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>239</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - Consolidated Statements of Earnings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEarnings</Role>
      <ShortName>Consolidated Statements of Earnings</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Statement - Consolidated Statements of Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Summaryofsignificantaccountingpolicies</Role>
      <ShortName>Summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Cash, cash equivalents and current marketable securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Cashcashequivalentsandcurrentmarketablesecurities</Role>
      <ShortName>Cash, cash equivalents and current marketable securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Property, plant and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Propertyplantandequipment</Role>
      <ShortName>Property, plant and equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Intangible assets and goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Intangibleassetsandgoodwill</Role>
      <ShortName>Intangible assets and goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Fair value measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Fairvaluemeasurements</Role>
      <ShortName>Fair value measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Borrowings</Role>
      <ShortName>Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Incometaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Employee related obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Employeerelatedobligations</Role>
      <ShortName>Employee related obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Pensions and other benefit plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Pensionsandotherbenefitplans</Role>
      <ShortName>Pensions and other benefit plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Savings plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Savingsplan</Role>
      <ShortName>Savings plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Capital and treasury stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Capitalandtreasurystock</Role>
      <ShortName>Capital and treasury stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Accumulated other comprehensive income (loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Accumulatedothercomprehensiveincomeloss</Role>
      <ShortName>Accumulated other comprehensive income (loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - International currency translation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Internationalcurrencytranslation</Role>
      <ShortName>International currency translation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9952173 - Disclosure - Earnings per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Earningspershare</Role>
      <ShortName>Earnings per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9952174 - Disclosure - Common stock, stock option plans and stock compensation agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Commonstockstockoptionplansandstockcompensationagreements</Role>
      <ShortName>Common stock, stock option plans and stock compensation agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9952175 - Disclosure - Segments of business and geographic areas</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Segmentsofbusinessandgeographicareas</Role>
      <ShortName>Segments of business and geographic areas</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9952176 - Disclosure - Acquisitions and divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Acquisitionsanddivestitures</Role>
      <ShortName>Acquisitions and divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9952177 - Disclosure - Legal proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Legalproceedings</Role>
      <ShortName>Legal proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9952178 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9952179 - Disclosure - Kenvue separation and discontinued operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Kenvueseparationanddiscontinuedoperations</Role>
      <ShortName>Kenvue separation and discontinued operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies</Role>
      <ShortName>Summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Summary of significant accounting policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesTables</Role>
      <ShortName>Summary of significant accounting policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Summaryofsignificantaccountingpolicies</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Cash, cash equivalents and current marketable securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesTables</Role>
      <ShortName>Cash, cash equivalents and current marketable securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Cashcashequivalentsandcurrentmarketablesecurities</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Inventories</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Property, plant and equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PropertyplantandequipmentTables</Role>
      <ShortName>Property, plant and equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Propertyplantandequipment</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Intangible assets and goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleassetsandgoodwillTables</Role>
      <ShortName>Intangible assets and goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Intangibleassetsandgoodwill</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Fair value measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairvaluemeasurementsTables</Role>
      <ShortName>Fair value measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Fairvaluemeasurements</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Borrowings (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/BorrowingsTables</Role>
      <ShortName>Borrowings (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Borrowings</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Income taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncometaxesTables</Role>
      <ShortName>Income taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Incometaxes</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Employee related obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EmployeerelatedobligationsTables</Role>
      <ShortName>Employee related obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Employeerelatedobligations</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Pensions and other benefit plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandotherbenefitplansTables</Role>
      <ShortName>Pensions and other benefit plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Pensionsandotherbenefitplans</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Capital and treasury stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CapitalandtreasurystockTables</Role>
      <ShortName>Capital and treasury stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Capitalandtreasurystock</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Accumulated other comprehensive income (loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossTables</Role>
      <ShortName>Accumulated other comprehensive income (loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Accumulatedothercomprehensiveincomeloss</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Earnings per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningspershareTables</Role>
      <ShortName>Earnings per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Earningspershare</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Common stock, stock option plans and stock compensation agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsTables</Role>
      <ShortName>Common stock, stock option plans and stock compensation agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Commonstockstockoptionplansandstockcompensationagreements</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Segments of business and geographic areas (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofbusinessandgeographicareasTables</Role>
      <ShortName>Segments of business and geographic areas (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Segmentsofbusinessandgeographicareas</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Acquisitions and divestitures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AcquisitionsanddivestituresTables</Role>
      <ShortName>Acquisitions and divestitures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Acquisitionsanddivestitures</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Legal proceedings (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/LegalproceedingsTables</Role>
      <ShortName>Legal proceedings (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Legalproceedings</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/RestructuringTables</Role>
      <ShortName>Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Restructuring</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Kenvue separation and discontinued operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsTables</Role>
      <ShortName>Kenvue separation and discontinued operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Kenvueseparationanddiscontinuedoperations</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Summary of significant accounting policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails</Role>
      <ShortName>Summary of significant accounting policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Summary of significant accounting policies - Estimated Useful Lives of Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails</Role>
      <ShortName>Summary of significant accounting policies - Estimated Useful Lives of Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Summary of significant accounting policies - Supplier Finance Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesSupplierFinanceProgramDetails</Role>
      <ShortName>Summary of significant accounting policies - Supplier Finance Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Cash, cash equivalents and current marketable securities - Cash and Cash Equivalent Composition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails</Role>
      <ShortName>Cash, cash equivalents and current marketable securities - Cash and Cash Equivalent Composition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Cash, cash equivalents and current marketable securities - Contractual Maturities of Available for Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails</Role>
      <ShortName>Cash, cash equivalents and current marketable securities - Contractual Maturities of Available for Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/InventoriesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Property, plant and equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails</Role>
      <ShortName>Property, plant and equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Property, plant and equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PropertyplantandequipmentNarrativeDetails</Role>
      <ShortName>Property, plant and equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Intangible assets and goodwil - Schedule of Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails</Role>
      <ShortName>Intangible assets and goodwil - Schedule of Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Intangible assets and goodwill - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails</Role>
      <ShortName>Intangible assets and goodwill - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Intangible assets and goodwill - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleassetsandgoodwillNarrativeDetails</Role>
      <ShortName>Intangible assets and goodwill - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Intangible assets and goodwill - Estimated Amortization of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleassetsandgoodwillEstimatedAmortizationofIntangibleAssetsDetails</Role>
      <ShortName>Intangible assets and goodwill - Estimated Amortization of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Fair value measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails</Role>
      <ShortName>Fair value measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Fair value measurements - Summary of Derivative Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails</Role>
      <ShortName>Fair value measurements - Summary of Derivative Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Fair value measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails</Role>
      <ShortName>Fair value measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Fair value measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails</Role>
      <ShortName>Fair value measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Fair value measurements - Schedule of Effect of Net Investment Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails</Role>
      <ShortName>Fair value measurements - Schedule of Effect of Net Investment Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Fair value measurements - Summary of Activity Related to Equity Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails</Role>
      <ShortName>Fair value measurements - Summary of Activity Related to Equity Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Fair value measurements - Financial Assets and Liabilities at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails</Role>
      <ShortName>Fair value measurements - Financial Assets and Liabilities at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Borrowings - Schedule of Long-term Debt Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails</Role>
      <ShortName>Borrowings - Schedule of Long-term Debt Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Borrowings - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/BorrowingsNarrativeDetails</Role>
      <ShortName>Borrowings - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Borrowings - Aggregate Maturities of Long Term Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails</Role>
      <ShortName>Borrowings - Aggregate Maturities of Long Term Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Income taxes - Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income taxes - Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Income taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails</Role>
      <ShortName>Income taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Income taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncometaxesNarrativeDetails</Role>
      <ShortName>Income taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Income taxes - Temporary Differences and Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails</Role>
      <ShortName>Income taxes - Temporary Differences and Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - Income taxes - Valuation Allowance Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncometaxesValuationAllowanceActivityDetails</Role>
      <ShortName>Income taxes - Valuation Allowance Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - Income taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncometaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - Employee related obligations - Employee Related Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails</Role>
      <ShortName>Employee related obligations - Employee Related Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9955560 - Disclosure - Employee related obligations - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EmployeerelatedobligationsNarrativeDetails</Role>
      <ShortName>Employee related obligations - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9955561 - Disclosure - Pensions and other benefit plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails</Role>
      <ShortName>Pensions and other benefit plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9955562 - Disclosure - Pensions and other benefit plans - Components of Net Periodic Benefit Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails</Role>
      <ShortName>Pensions and other benefit plans - Components of Net Periodic Benefit Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9955563 - Disclosure - Pensions and other benefit plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails</Role>
      <ShortName>Pensions and other benefit plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9955564 - Disclosure - Pensions and other benefit plans - Assumed Health Care Cost Trend Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandotherbenefitplansAssumedHealthCareCostTrendRatesDetails</Role>
      <ShortName>Pensions and other benefit plans - Assumed Health Care Cost Trend Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9955565 - Disclosure - Pensions and other benefit plans - Schedule of Net Funded Status (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails</Role>
      <ShortName>Pensions and other benefit plans - Schedule of Net Funded Status (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9955566 - Disclosure - Pensions and other benefit plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails</Role>
      <ShortName>Pensions and other benefit plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9955567 - Disclosure - Pensions and other benefit plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails</Role>
      <ShortName>Pensions and other benefit plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>9955568 - Disclosure - Pensions and other benefit plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails</Role>
      <ShortName>Pensions and other benefit plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>9955569 - Disclosure - Pensions and other benefit plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandotherbenefitplansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails</Role>
      <ShortName>Pensions and other benefit plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>9955570 - Disclosure - Pensions and other benefit plans - Schedule of Defined Benefit Plans Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails</Role>
      <ShortName>Pensions and other benefit plans - Schedule of Defined Benefit Plans Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>9955571 - Disclosure - Savings plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SavingsplanDetails</Role>
      <ShortName>Savings plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Savingsplan</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>9955572 - Disclosure - Capital and treasury stock - Changes in Treasury Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails</Role>
      <ShortName>Capital and treasury stock - Changes in Treasury Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>9955573 - Disclosure - Capital and treasury stock - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails</Role>
      <ShortName>Capital and treasury stock - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>9955574 - Disclosure - Accumulated other comprehensive income (loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails</Role>
      <ShortName>Accumulated other comprehensive income (loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossTables</ParentRole>
      <Position>99</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>9955575 - Disclosure - International currency translation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/InternationalcurrencytranslationDetails</Role>
      <ShortName>International currency translation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Internationalcurrencytranslation</ParentRole>
      <Position>100</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>9955576 - Disclosure - Earnings per share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails</Role>
      <ShortName>Earnings per share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>9955577 - Disclosure - Earnings per share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningspershareNarrativeDetails</Role>
      <ShortName>Earnings per share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>9955578 - Disclosure - Common stock, stock option plans and stock compensation agreements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails</Role>
      <ShortName>Common stock, stock option plans and stock compensation agreements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsTables</ParentRole>
      <Position>103</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>9955579 - Disclosure - Common stock, stock option plans and stock compensation agreements - Schedule Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsScheduleValuationAssumptionsDetails</Role>
      <ShortName>Common stock, stock option plans and stock compensation agreements - Schedule Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>9955580 - Disclosure - Common stock, stock option plans and stock compensation agreements - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails</Role>
      <ShortName>Common stock, stock option plans and stock compensation agreements - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>9955581 - Disclosure - Common stock, stock option plans and stock compensation agreements - Summary of Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails</Role>
      <ShortName>Common stock, stock option plans and stock compensation agreements - Summary of Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>9955582 - Disclosure - Common stock, stock option plans and stock compensation agreements - Summary of Restricted Share Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails</Role>
      <ShortName>Common stock, stock option plans and stock compensation agreements - Summary of Restricted Share Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>9955583 - Disclosure - Segments of Business and Geographic Areas - Sales by Segment of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Sales by Segment of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>9955584 - Disclosure - Segments of Business and Geographic Areas - Income Before Tax by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Income Before Tax by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>9955585 - Disclosure - Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>9955586 - Disclosure - Segments of Business and Geographic Areas - Schedule of Segment Reporting By Geographic Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Schedule of Segment Reporting By Geographic Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>9955587 - Disclosure - Acquisitions and divestitures - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails</Role>
      <ShortName>Acquisitions and divestitures - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>9955588 - Disclosure - Acquisitions and divestitures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AcquisitionsanddivestituresDetails</Role>
      <ShortName>Acquisitions and divestitures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/AcquisitionsanddivestituresTables</ParentRole>
      <Position>113</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>9955589 - Disclosure - Legal proceedings - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/LegalproceedingsNarrativeDetails</Role>
      <ShortName>Legal proceedings - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>9955590 - Disclosure - Legal proceedings - Product Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails</Role>
      <ShortName>Legal proceedings - Product Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>115</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>9955591 - Disclosure - Restructuring - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/RestructuringNarrativeDetails</Role>
      <ShortName>Restructuring - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>9955592 - Disclosure - Restructuring - Schedule of Restructuring Reserve (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails</Role>
      <ShortName>Restructuring - Schedule of Restructuring Reserve (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>117</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>9955593 - Disclosure - Kenvue separation and discontinued operations - Details (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails</Role>
      <ShortName>Kenvue separation and discontinued operations - Details (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsTables</ParentRole>
      <Position>118</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>9955594 - Disclosure - Kenvue separation and discontinued operations - Net Earnings from Discontinued Operation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails</Role>
      <ShortName>Kenvue separation and discontinued operations - Net Earnings from Discontinued Operation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>119</Position>
    </Report>
    <Report instance="jnj-20241229.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>9955595 - Disclosure - Kenvue separation and discontinued operations - Depreciation and Amortization of Discontinued Operation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDepreciationandAmortizationofDiscontinuedOperationDetails</Role>
      <ShortName>Kenvue separation and discontinued operations - Depreciation and Amortization of Discontinued Operation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>120</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="jnj-20241229.htm">jnj-20241229.htm</File>
    <File>jnj-20241229.xsd</File>
    <File>jnj-20241229_cal.xml</File>
    <File>jnj-20241229_def.xml</File>
    <File>jnj-20241229_lab.xml</File>
    <File>jnj-20241229_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>jnj-20241229_g1.jpg</File>
    <File>jnj-20241229_g10.jpg</File>
    <File>jnj-20241229_g11.jpg</File>
    <File>jnj-20241229_g12.jpg</File>
    <File>jnj-20241229_g13.jpg</File>
    <File>jnj-20241229_g14.jpg</File>
    <File>jnj-20241229_g15.jpg</File>
    <File>jnj-20241229_g16.jpg</File>
    <File>jnj-20241229_g17.jpg</File>
    <File>jnj-20241229_g18.jpg</File>
    <File>jnj-20241229_g19.jpg</File>
    <File>jnj-20241229_g2.jpg</File>
    <File>jnj-20241229_g20.jpg</File>
    <File>jnj-20241229_g21.jpg</File>
    <File>jnj-20241229_g22.jpg</File>
    <File>jnj-20241229_g23.jpg</File>
    <File>jnj-20241229_g24.jpg</File>
    <File>jnj-20241229_g25.jpg</File>
    <File>jnj-20241229_g26.jpg</File>
    <File>jnj-20241229_g3.jpg</File>
    <File>jnj-20241229_g4.jpg</File>
    <File>jnj-20241229_g5.jpg</File>
    <File>jnj-20241229_g6.jpg</File>
    <File>jnj-20241229_g7.jpg</File>
    <File>jnj-20241229_g8.jpg</File>
    <File>jnj-20241229_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="2595">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="53">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>169
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "jnj-20241229.htm": {
   "nsprefix": "jnj",
   "nsuri": "http://www.jnj.com/20241229",
   "dts": {
    "inline": {
     "local": [
      "jnj-20241229.htm"
     ]
    },
    "schema": {
     "local": [
      "jnj-20241229.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "jnj-20241229_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "jnj-20241229_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "jnj-20241229_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "jnj-20241229_pre.xml"
     ]
    }
   },
   "keyStandard": 569,
   "keyCustom": 125,
   "axisStandard": 47,
   "axisCustom": 0,
   "memberStandard": 74,
   "memberCustom": 151,
   "hidden": {
    "total": 17,
    "http://xbrl.sec.gov/dei/2024": 5,
    "http://fasb.org/us-gaap/2024": 12
   },
   "contextCount": 1035,
   "entityCount": 1,
   "segmentCount": 239,
   "elementCount": 1265,
   "unitCount": 12,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 2595,
    "http://xbrl.sec.gov/dei/2024": 53,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 5,
    "http://fasb.org/srt/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://www.jnj.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.jnj.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.jnj.com/role/ConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
     "longName": "9952153 - Statement - Consolidated Statements of Earnings",
     "shortName": "Consolidated Statements of Earnings",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GrossProfit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "longName": "9952154 - Statement - Consolidated Statements of Comprehensive Income",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical",
     "longName": "9952155 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)",
     "shortName": "Consolidated Statements of Comprehensive Income (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEquity",
     "longName": "9952156 - Statement - Consolidated Statements of Equity",
     "shortName": "Consolidated Statements of Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical",
     "longName": "9952157 - Statement - Consolidated Statements of Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R10": {
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "9952158 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.jnj.com/role/Summaryofsignificantaccountingpolicies",
     "longName": "9952159 - Disclosure - Summary of significant accounting policies",
     "shortName": "Summary of significant accounting policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.jnj.com/role/Cashcashequivalentsandcurrentmarketablesecurities",
     "longName": "9952160 - Disclosure - Cash, cash equivalents and current marketable securities",
     "shortName": "Cash, cash equivalents and current marketable securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.jnj.com/role/Inventories",
     "longName": "9952161 - Disclosure - Inventories",
     "shortName": "Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.jnj.com/role/Propertyplantandequipment",
     "longName": "9952162 - Disclosure - Property, plant and equipment",
     "shortName": "Property, plant and equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.jnj.com/role/Intangibleassetsandgoodwill",
     "longName": "9952163 - Disclosure - Intangible assets and goodwill",
     "shortName": "Intangible assets and goodwill",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.jnj.com/role/Fairvaluemeasurements",
     "longName": "9952164 - Disclosure - Fair value measurements",
     "shortName": "Fair value measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.jnj.com/role/Borrowings",
     "longName": "9952165 - Disclosure - Borrowings",
     "shortName": "Borrowings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.jnj.com/role/Incometaxes",
     "longName": "9952166 - Disclosure - Income taxes",
     "shortName": "Income taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.jnj.com/role/Employeerelatedobligations",
     "longName": "9952167 - Disclosure - Employee related obligations",
     "shortName": "Employee related obligations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationRelatedCostsGeneralTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationRelatedCostsGeneralTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.jnj.com/role/Pensionsandotherbenefitplans",
     "longName": "9952168 - Disclosure - Pensions and other benefit plans",
     "shortName": "Pensions and other benefit plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.jnj.com/role/Savingsplan",
     "longName": "9952169 - Disclosure - Savings plan",
     "shortName": "Savings plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "jnj:SavingsPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "jnj:SavingsPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.jnj.com/role/Capitalandtreasurystock",
     "longName": "9952170 - Disclosure - Capital and treasury stock",
     "shortName": "Capital and treasury stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:TreasuryStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:TreasuryStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.jnj.com/role/Accumulatedothercomprehensiveincomeloss",
     "longName": "9952171 - Disclosure - Accumulated other comprehensive income (loss)",
     "shortName": "Accumulated other comprehensive income (loss)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.jnj.com/role/Internationalcurrencytranslation",
     "longName": "9952172 - Disclosure - International currency translation",
     "shortName": "International currency translation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ForeignCurrencyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ForeignCurrencyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.jnj.com/role/Earningspershare",
     "longName": "9952173 - Disclosure - Earnings per share",
     "shortName": "Earnings per share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.jnj.com/role/Commonstockstockoptionplansandstockcompensationagreements",
     "longName": "9952174 - Disclosure - Common stock, stock option plans and stock compensation agreements",
     "shortName": "Common stock, stock option plans and stock compensation agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.jnj.com/role/Segmentsofbusinessandgeographicareas",
     "longName": "9952175 - Disclosure - Segments of business and geographic areas",
     "shortName": "Segments of business and geographic areas",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.jnj.com/role/Acquisitionsanddivestitures",
     "longName": "9952176 - Disclosure - Acquisitions and divestitures",
     "shortName": "Acquisitions and divestitures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.jnj.com/role/Legalproceedings",
     "longName": "9952177 - Disclosure - Legal proceedings",
     "shortName": "Legal proceedings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.jnj.com/role/Restructuring",
     "longName": "9952178 - Disclosure - Restructuring",
     "shortName": "Restructuring",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.jnj.com/role/Kenvueseparationanddiscontinuedoperations",
     "longName": "9952179 - Disclosure - Kenvue separation and discontinued operations",
     "shortName": "Kenvue separation and discontinued operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R33": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1035",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1035",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of significant accounting policies (Policies)",
     "shortName": "Summary of significant accounting policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesTables",
     "longName": "9955512 - Disclosure - Summary of significant accounting policies (Tables)",
     "shortName": "Summary of significant accounting policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "jnj:EstimatedUsefulLivesOfAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "jnj:EstimatedUsefulLivesOfAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesTables",
     "longName": "9955513 - Disclosure - Cash, cash equivalents and current marketable securities (Tables)",
     "shortName": "Cash, cash equivalents and current marketable securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.jnj.com/role/InventoriesTables",
     "longName": "9955514 - Disclosure - Inventories (Tables)",
     "shortName": "Inventories (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.jnj.com/role/PropertyplantandequipmentTables",
     "longName": "9955515 - Disclosure - Property, plant and equipment (Tables)",
     "shortName": "Property, plant and equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.jnj.com/role/IntangibleassetsandgoodwillTables",
     "longName": "9955516 - Disclosure - Intangible assets and goodwill (Tables)",
     "shortName": "Intangible assets and goodwill (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.jnj.com/role/FairvaluemeasurementsTables",
     "longName": "9955517 - Disclosure - Fair value measurements (Tables)",
     "shortName": "Fair value measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.jnj.com/role/BorrowingsTables",
     "longName": "9955518 - Disclosure - Borrowings (Tables)",
     "shortName": "Borrowings (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.jnj.com/role/IncometaxesTables",
     "longName": "9955519 - Disclosure - Income taxes (Tables)",
     "shortName": "Income taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.jnj.com/role/EmployeerelatedobligationsTables",
     "longName": "9955520 - Disclosure - Employee related obligations (Tables)",
     "shortName": "Employee related obligations (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "jnj:EmployeeRelatedObligationsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "jnj:EmployeeRelatedObligationsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.jnj.com/role/PensionsandotherbenefitplansTables",
     "longName": "9955521 - Disclosure - Pensions and other benefit plans (Tables)",
     "shortName": "Pensions and other benefit plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.jnj.com/role/CapitalandtreasurystockTables",
     "longName": "9955522 - Disclosure - Capital and treasury stock (Tables)",
     "shortName": "Capital and treasury stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "jnj:ChangesInTreasuryStockTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "jnj:ChangesInTreasuryStockTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossTables",
     "longName": "9955523 - Disclosure - Accumulated other comprehensive income (loss) (Tables)",
     "shortName": "Accumulated other comprehensive income (loss) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.jnj.com/role/EarningspershareTables",
     "longName": "9955524 - Disclosure - Earnings per share (Tables)",
     "shortName": "Earnings per share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsTables",
     "longName": "9955525 - Disclosure - Common stock, stock option plans and stock compensation agreements (Tables)",
     "shortName": "Common stock, stock option plans and stock compensation agreements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.jnj.com/role/SegmentsofbusinessandgeographicareasTables",
     "longName": "9955526 - Disclosure - Segments of business and geographic areas (Tables)",
     "shortName": "Segments of business and geographic areas (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "jnj:SalesBySegmentOfBusinessTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "jnj:SalesBySegmentOfBusinessTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.jnj.com/role/AcquisitionsanddivestituresTables",
     "longName": "9955527 - Disclosure - Acquisitions and divestitures (Tables)",
     "shortName": "Acquisitions and divestitures (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.jnj.com/role/LegalproceedingsTables",
     "longName": "9955528 - Disclosure - Legal proceedings (Tables)",
     "shortName": "Legal proceedings (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.jnj.com/role/RestructuringTables",
     "longName": "9955529 - Disclosure - Restructuring (Tables)",
     "shortName": "Restructuring (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsTables",
     "longName": "9955530 - Disclosure - Kenvue separation and discontinued operations (Tables)",
     "shortName": "Kenvue separation and discontinued operations (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails",
     "longName": "9955531 - Disclosure - Summary of significant accounting policies - Narrative (Details)",
     "shortName": "Summary of significant accounting policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "jnj:NumberOfEmployeesEngagedInCompanyActivitiesWorldwide",
      "unitRef": "employee",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "jnj:NumberOfEmployeesEngagedInCompanyActivitiesWorldwide",
      "unitRef": "employee",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails",
     "longName": "9955532 - Disclosure - Summary of significant accounting policies - Estimated Useful Lives of Assets (Details)",
     "shortName": "Summary of significant accounting policies - Estimated Useful Lives of Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-49",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "jnj:EstimatedUsefulLivesOfAssetsTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-49",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "jnj:EstimatedUsefulLivesOfAssetsTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesSupplierFinanceProgramDetails",
     "longName": "9955533 - Disclosure - Summary of significant accounting policies - Supplier Finance Program (Details)",
     "shortName": "Summary of significant accounting policies - Supplier Finance Program (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:SupplierFinanceProgramObligationCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SupplierFinanceProgramTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplierFinanceProgramObligationIncrease",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SupplierFinanceProgramTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails",
     "longName": "9955534 - Disclosure - Cash, cash equivalents and current marketable securities - Cash and Cash Equivalent Composition (Details)",
     "shortName": "Cash, cash equivalents and current marketable securities - Cash and Cash Equivalent Composition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-74",
      "name": "us-gaap:HeldToMaturitySecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails",
     "longName": "9955535 - Disclosure - Cash, cash equivalents and current marketable securities - Contractual Maturities of Available for Sale Securities (Details)",
     "shortName": "Cash, cash equivalents and current marketable securities - Contractual Maturities of Available for Sale Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.jnj.com/role/InventoriesDetails",
     "longName": "9955536 - Disclosure - Inventories (Details)",
     "shortName": "Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails",
     "longName": "9955537 - Disclosure - Property, plant and equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details)",
     "shortName": "Property, plant and equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.jnj.com/role/PropertyplantandequipmentNarrativeDetails",
     "longName": "9955538 - Disclosure - Property, plant and equipment - Narrative (Details)",
     "shortName": "Property, plant and equipment - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestCostsCapitalized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestCostsCapitalized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails",
     "longName": "9955539 - Disclosure - Intangible assets and goodwil - Schedule of Intangible Assets and Goodwill (Details)",
     "shortName": "Intangible assets and goodwil - Schedule of Intangible Assets and Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails",
     "longName": "9955540 - Disclosure - Intangible assets and goodwill - Goodwill (Details)",
     "shortName": "Intangible assets and goodwill - Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.jnj.com/role/IntangibleassetsandgoodwillNarrativeDetails",
     "longName": "9955541 - Disclosure - Intangible assets and goodwill - Narrative (Details)",
     "shortName": "Intangible assets and goodwill - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-971",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.jnj.com/role/IntangibleassetsandgoodwillEstimatedAmortizationofIntangibleAssetsDetails",
     "longName": "9955542 - Disclosure - Intangible assets and goodwill - Estimated Amortization of Intangible Assets (Details)",
     "shortName": "Intangible assets and goodwill - Estimated Amortization of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails",
     "longName": "9955543 - Disclosure - Fair value measurements - Narrative (Details)",
     "shortName": "Fair value measurements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails",
     "longName": "9955544 - Disclosure - Fair value measurements - Summary of Derivative Activity (Details)",
     "shortName": "Fair value measurements - Summary of Derivative Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-124",
      "name": "us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails",
     "longName": "9955545 - Disclosure - Fair value measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheets (Details)",
     "shortName": "Fair value measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-164",
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
     "longName": "9955546 - Disclosure - Fair value measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)",
     "shortName": "Fair value measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-166",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-166",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
     "longName": "9955547 - Disclosure - Fair value measurements - Schedule of Effect of Net Investment Hedges (Details)",
     "shortName": "Fair value measurements - Schedule of Effect of Net Investment Hedges (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails",
     "longName": "9955548 - Disclosure - Fair value measurements - Summary of Activity Related to Equity Investments (Details)",
     "shortName": "Fair value measurements - Summary of Activity Related to Equity Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:OtherAssetsNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-176",
      "name": "us-gaap:MarketableSecuritiesNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
     "longName": "9955549 - Disclosure - Fair value measurements - Financial Assets and Liabilities at Fair Value (Details)",
     "shortName": "Fair value measurements - Financial Assets and Liabilities at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails",
     "longName": "9955550 - Disclosure - Borrowings - Schedule of Long-term Debt Instruments (Details)",
     "shortName": "Borrowings - Schedule of Long-term Debt Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.jnj.com/role/BorrowingsNarrativeDetails",
     "longName": "9955551 - Disclosure - Borrowings - Narrative (Details)",
     "shortName": "Borrowings - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-9",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-9",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails",
     "longName": "9955552 - Disclosure - Borrowings - Aggregate Maturities of Long Term Obligations (Details)",
     "shortName": "Borrowings - Aggregate Maturities of Long Term Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails",
     "longName": "9955553 - Disclosure - Income taxes - Provision for Income Taxes (Details)",
     "shortName": "Income taxes - Provision for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails",
     "longName": "9955554 - Disclosure - Income taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details)",
     "shortName": "Income taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.jnj.com/role/IncometaxesNarrativeDetails",
     "longName": "9955555 - Disclosure - Income taxes - Narrative (Details)",
     "shortName": "Income taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-287",
      "name": "jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-287",
      "name": "jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails",
     "longName": "9955556 - Disclosure - Income taxes - Temporary Differences and Carryforwards (Details)",
     "shortName": "Income taxes - Temporary Differences and Carryforwards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.jnj.com/role/IncometaxesValuationAllowanceActivityDetails",
     "longName": "9955557 - Disclosure - Income taxes - Valuation Allowance Activity (Details)",
     "shortName": "Income taxes - Valuation Allowance Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "jnj:ValuationAllowanceDeferredTaxAssetsProvision",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.jnj.com/role/IncometaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails",
     "longName": "9955558 - Disclosure - Income taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)",
     "shortName": "Income taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails",
     "longName": "9955559 - Disclosure - Employee related obligations - Employee Related Obligations (Details)",
     "shortName": "Employee related obligations - Employee Related Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:EmployeeRelatedObligationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:EmployeeRelatedObligationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.jnj.com/role/EmployeerelatedobligationsNarrativeDetails",
     "longName": "9955560 - Disclosure - Employee related obligations - Narrative (Details)",
     "shortName": "Employee related obligations - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R86": {
     "role": "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails",
     "longName": "9955561 - Disclosure - Pensions and other benefit plans - Narrative (Details)",
     "shortName": "Pensions and other benefit plans - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "jnj:PercentageOfCorridorOfGreaterOfMarketValueOfAssets",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "jnj:PercentageOfCorridorOfGreaterOfMarketValueOfAssets",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails",
     "longName": "9955562 - Disclosure - Pensions and other benefit plans - Components of Net Periodic Benefit Cost (Details)",
     "shortName": "Pensions and other benefit plans - Components of Net Periodic Benefit Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-291",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-291",
      "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails",
     "longName": "9955563 - Disclosure - Pensions and other benefit plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)",
     "shortName": "Pensions and other benefit plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-291",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-291",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.jnj.com/role/PensionsandotherbenefitplansAssumedHealthCareCostTrendRatesDetails",
     "longName": "9955564 - Disclosure - Pensions and other benefit plans - Assumed Health Care Cost Trend Rates (Details)",
     "shortName": "Pensions and other benefit plans - Assumed Health Care Cost Trend Rates (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails",
     "longName": "9955565 - Disclosure - Pensions and other benefit plans - Schedule of Net Funded Status (Details)",
     "shortName": "Pensions and other benefit plans - Schedule of Net Funded Status (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "jnj:DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
     "longName": "9955566 - Disclosure - Pensions and other benefit plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details)",
     "shortName": "Pensions and other benefit plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-305",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-305",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails",
     "longName": "9955567 - Disclosure - Pensions and other benefit plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details)",
     "shortName": "Pensions and other benefit plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-297",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-297",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails",
     "longName": "9955568 - Disclosure - Pensions and other benefit plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details)",
     "shortName": "Pensions and other benefit plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.jnj.com/role/PensionsandotherbenefitplansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails",
     "longName": "9955569 - Disclosure - Pensions and other benefit plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)",
     "shortName": "Pensions and other benefit plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails",
     "longName": "9955570 - Disclosure - Pensions and other benefit plans - Schedule of Defined Benefit Plans Disclosures (Details)",
     "shortName": "Pensions and other benefit plans - Schedule of Defined Benefit Plans Disclosures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c-297",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-371",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.jnj.com/role/SavingsplanDetails",
     "longName": "9955571 - Disclosure - Savings plan (Details)",
     "shortName": "Savings plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails",
     "longName": "9955572 - Disclosure - Capital and treasury stock - Changes in Treasury Stock (Details)",
     "shortName": "Capital and treasury stock - Changes in Treasury Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:TreasuryStockCommonShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:ChangesInTreasuryStockTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:TreasuryStockCommonShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:ChangesInTreasuryStockTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails",
     "longName": "9955573 - Disclosure - Capital and treasury stock - Narrative (Details)",
     "shortName": "Capital and treasury stock - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails",
     "longName": "9955574 - Disclosure - Accumulated other comprehensive income (loss) (Details)",
     "shortName": "Accumulated other comprehensive income (loss) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-377",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R100": {
     "role": "http://www.jnj.com/role/InternationalcurrencytranslationDetails",
     "longName": "9955575 - Disclosure - International currency translation (Details)",
     "shortName": "International currency translation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R101": {
     "role": "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails",
     "longName": "9955576 - Disclosure - Earnings per share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details)",
     "shortName": "Earnings per share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsPerBasicShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R102": {
     "role": "http://www.jnj.com/role/EarningspershareNarrativeDetails",
     "longName": "9955577 - Disclosure - Earnings per share - Narrative (Details)",
     "shortName": "Earnings per share - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R103": {
     "role": "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails",
     "longName": "9955578 - Disclosure - Common stock, stock option plans and stock compensation agreements - Narrative (Details)",
     "shortName": "Common stock, stock option plans and stock compensation agreements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "jnj:NumberOfStockBasedCompensationPlans",
      "unitRef": "stockbasedcompensationplans",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "jnj:NumberOfStockBasedCompensationPlans",
      "unitRef": "stockbasedcompensationplans",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R104": {
     "role": "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsScheduleValuationAssumptionsDetails",
     "longName": "9955579 - Disclosure - Common stock, stock option plans and stock compensation agreements - Schedule Valuation Assumptions (Details)",
     "shortName": "Common stock, stock option plans and stock compensation agreements - Schedule Valuation Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R105": {
     "role": "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails",
     "longName": "9955580 - Disclosure - Common stock, stock option plans and stock compensation agreements - Summary of Stock Option Activity (Details)",
     "shortName": "Common stock, stock option plans and stock compensation agreements - Summary of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "105",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R106": {
     "role": "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails",
     "longName": "9955581 - Disclosure - Common stock, stock option plans and stock compensation agreements - Summary of Options Outstanding (Details)",
     "shortName": "Common stock, stock option plans and stock compensation agreements - Summary of Options Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "106",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R107": {
     "role": "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails",
     "longName": "9955582 - Disclosure - Common stock, stock option plans and stock compensation agreements - Summary of Restricted Share Units (Details)",
     "shortName": "Common stock, stock option plans and stock compensation agreements - Summary of Restricted Share Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "107",
     "firstAnchor": {
      "contextRef": "c-425",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-425",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R108": {
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
     "longName": "9955583 - Disclosure - Segments of Business and Geographic Areas - Sales by Segment of Business (Details)",
     "shortName": "Segments of Business and Geographic Areas - Sales by Segment of Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "108",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment2",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "jnj:PercentageChangeInSalesBySegmentOfBusiness",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R109": {
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails",
     "longName": "9955584 - Disclosure - Segments of Business and Geographic Areas - Income Before Tax by Segment (Details)",
     "shortName": "Segments of Business and Geographic Areas - Income Before Tax by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "109",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingOtherItemAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R110": {
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
     "longName": "9955585 - Disclosure - Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details)",
     "shortName": "Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "110",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentExpenditureAdditionToLongLivedAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R111": {
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
     "longName": "9955586 - Disclosure - Segments of Business and Geographic Areas - Schedule of Segment Reporting By Geographic Area (Details)",
     "shortName": "Segments of Business and Geographic Areas - Schedule of Segment Reporting By Geographic Area (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "111",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R112": {
     "role": "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
     "longName": "9955587 - Disclosure - Acquisitions and divestitures - Narrative (Details)",
     "shortName": "Acquisitions and divestitures - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "112",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R113": {
     "role": "http://www.jnj.com/role/AcquisitionsanddivestituresDetails",
     "longName": "9955588 - Disclosure - Acquisitions and divestitures (Details)",
     "shortName": "Acquisitions and divestitures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "113",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-958",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R114": {
     "role": "http://www.jnj.com/role/LegalproceedingsNarrativeDetails",
     "longName": "9955589 - Disclosure - Legal proceedings - Narrative (Details)",
     "shortName": "Legal proceedings - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "114",
     "firstAnchor": {
      "contextRef": "c-998",
      "name": "jnj:ProductLiabilityContingencyNumberOfClaimant",
      "unitRef": "claimant",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-996",
      "name": "jnj:ProductLiabilityContingencyNumberOfClaimant",
      "unitRef": "claimant",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R115": {
     "role": "http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails",
     "longName": "9955590 - Disclosure - Legal proceedings - Product Liabilities (Details)",
     "shortName": "Legal proceedings - Product Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "115",
     "firstAnchor": {
      "contextRef": "c-998",
      "name": "jnj:ProductLiabilityContingencyNumberOfClaimant",
      "unitRef": "claimant",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-999",
      "name": "jnj:ProductLiabilityContingencyNumberOfClaimant",
      "unitRef": "claimant",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R116": {
     "role": "http://www.jnj.com/role/RestructuringNarrativeDetails",
     "longName": "9955591 - Disclosure - Restructuring - Narrative (Details)",
     "shortName": "Restructuring - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "116",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1012",
      "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R117": {
     "role": "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails",
     "longName": "9955592 - Disclosure - Restructuring - Schedule of Restructuring Reserve (Details)",
     "shortName": "Restructuring - Schedule of Restructuring Reserve (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "117",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1018",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R118": {
     "role": "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails",
     "longName": "9955593 - Disclosure - Kenvue separation and discontinued operations - Details (Details)",
     "shortName": "Kenvue separation and discontinued operations - Details (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "118",
     "firstAnchor": {
      "contextRef": "c-184",
      "name": "us-gaap:CommercialPaper",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1026",
      "name": "jnj:ExchangeOfStockCommonStockValueReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "unique": true
     }
    },
    "R119": {
     "role": "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails",
     "longName": "9955594 - Disclosure - Kenvue separation and discontinued operations - Net Earnings from Discontinued Operation (Details)",
     "shortName": "Kenvue separation and discontinued operations - Net Earnings from Discontinued Operation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "119",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    },
    "R120": {
     "role": "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDepreciationandAmortizationofDiscontinuedOperationDetails",
     "longName": "9955595 - Disclosure - Kenvue separation and discontinued operations - Depreciation and Amortization of Discontinued Operation (Details)",
     "shortName": "Kenvue separation and discontinued operations - Depreciation and Amortization of Discontinued Operation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "120",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20241229.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "jnj_A0.650NotesDue2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A0.650NotesDue2024Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.650% Notes due 2024 (750MM Euro 1.1090)(3)",
        "label": "0.650% Notes Due 2024 [Member]",
        "documentation": "0.650% Notes Due 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A055NotesDue2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A055NotesDue2025Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.55% Notes due 2025",
        "label": "0.55% Notes due 2025 [Member]",
        "documentation": "0.55% Notes due 2025"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A095NotesDue2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A095NotesDue2027Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.95% Notes due 2027",
        "label": "0.95% Notes due 2027 [Member]",
        "documentation": "0.95% Notes due 2027"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A1.150NotesDue2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A1.150NotesDue2028Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails",
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "1.150% Notes Due November 2028",
        "terseLabel": "1.150% Notes due 2028\u2028(750MM Euro 1.0401)(2)/(750MM Euro 1.1090)(3)",
        "label": "1.150% Notes Due 2028 [Member]",
        "documentation": "1.150% Notes Due 2028 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A1.150NotesDueNovember2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A1.150NotesDueNovember2028Member",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.150% Notes Due November 2028",
        "label": "1.150% Notes Due November 2028 [Member]",
        "documentation": "1.150% Notes Due November 2028"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A1.650NotesDue2035Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A1.650NotesDue2035Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails",
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "1.650% Notes Due May 2035",
        "terseLabel": "1.650% Notes due 2035\u2028(1.5B Euro 1.0401)(2)/(1.5B Euro 1.1090)(3)",
        "label": "1.650% Notes Due 2035 [Member]",
        "documentation": "1.650% Notes Due 2035 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A130NotesDue2030Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A130NotesDue2030Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.30% Notes due 2030",
        "label": "1.30% Notes due 2030 [Member]",
        "documentation": "1.30% Notes due 2030"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A2.45Notesdue2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A2.45Notesdue2026Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.46% Notes due 2026",
        "label": "2.45% Notes due 2026 [Member]",
        "documentation": "2.45% Notes due 2026 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A2.625Notesdue2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A2.625Notesdue2025Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.625% Notes due 2025",
        "label": "2.625 Notes due 2025 [Member]",
        "documentation": "2.625 Notes due 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A2.900Notesdue2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A2.900Notesdue2028Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.90%\u00a0Notes due 2028",
        "label": "2.900% Notes due 2028 [Member]",
        "documentation": "2.900% Notes due 2028 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A2.95Notesdue2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A2.95Notesdue2027Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.95% Notes due 2027",
        "label": "2.95% Notes due 2027 [Member]",
        "documentation": "2.95% Notes due 2027 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A2022LongTermIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A2022LongTermIncentivePlanMember",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Long-Term Incentive Plan",
        "label": "2022 Long-Term Incentive Plan [Member]",
        "documentation": "2022 Long-Term Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A210NotesDue2040Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A210NotesDue2040Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.10% Notes due 2040",
        "label": "2.10% Notes due 2040 [Member]",
        "documentation": "2.10% Notes due 2040"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A2250NotesDue2050Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A2250NotesDue2050Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.250% Notes due 2050",
        "label": "2.250% Notes due 2050 [Member]",
        "documentation": "2.250% Notes due 2050"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A2450NotesDue2060Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A2450NotesDue2060Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.450% Notes due 2060",
        "label": "2.450% Notes due 2060 [Member]",
        "documentation": "2.450% Notes due 2060"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A3.20DebenturesDue2032Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A3.20DebenturesDue2032Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.20% Debentures due 2032",
        "label": "3.20% Debentures due 2032 [Member]",
        "documentation": "3.20% Debentures due 2032"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A3.20NotesDueNovember2032Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A3.20NotesDueNovember2032Member",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.20% Notes Due November 2032",
        "label": "3.20% Notes Due November 2032 [Member]",
        "documentation": "3.20% Notes Due November 2032"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A3.350NotesDueNovember2036Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A3.350NotesDueNovember2036Member",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.350% Notes Due November 2036",
        "label": "3.350% Notes Due November 2036 [Member]",
        "documentation": "3.350% Notes Due November 2036"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A3.35DebenturesDue2036Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A3.35DebenturesDue2036Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.35% Debentures due 2036",
        "label": "3.35% Debentures due 2036 [Member]",
        "documentation": "3.35% Debentures due 2036"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A3.400Notesdue2038Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A3.400Notesdue2038Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.40%\u00a0Notes due 2038",
        "label": "3.400% Notes due 2038 [Member]",
        "documentation": "3.400% Notes due 2038 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A3.500Notesdue2048Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A3.500Notesdue2048Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.500% Notes due 2048",
        "label": "3.500% Notes due 2048 [Member]",
        "documentation": "3.500% Notes due 2048 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A3.550NotesDueNovember2044Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A3.550NotesDueNovember2044Member",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.550% Notes Due November 2044",
        "label": "3.550% Notes Due November 2044 [Member]",
        "documentation": "3.550% Notes Due November 2044"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A3.55DebenturesDue2044Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A3.55DebenturesDue2044Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.55% Debentures due 2044",
        "label": "3.55% Debentures due 2044 [Member]",
        "documentation": "3.55% Debentures due 2044"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A3.55Notesdue2036Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A3.55Notesdue2036Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.587% Notes due 2036",
        "label": "3.55% Notes due 2036 [Member]",
        "documentation": "3.55% Notes due 2036 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A3.625Notesdue2037Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A3.625Notesdue2037Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.625% Notes due 2037",
        "label": "3.625% Notes due 2037 [Member]",
        "documentation": "3.625% Notes due 2037 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A3.70Notesdue2046Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A3.70Notesdue2046Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.73% Notes due 2046",
        "label": "3.70% Notes due 2046 [Member]",
        "documentation": "3.70% Notes due 2046 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A3.75Notesdue2047Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A3.75Notesdue2047Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.75% Notes due 2047",
        "label": "3.75% Notes due 2047 [Member]",
        "documentation": "3.75% Notes due 2047 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A4.375Notesdue2033Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A4.375Notesdue2033Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.375% Notes due 2033",
        "label": "4.375% Notes due 2033 [Member]",
        "documentation": "4.375% Notes due 2033 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A4.50Debenturesdue2040Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A4.50Debenturesdue2040Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.50%\u00a0Debentures due 2040",
        "label": "4.50% Debentures due 2040 [Member]",
        "documentation": "4.50% Debentures due 2040 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A4.50Notesdue2043Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A4.50Notesdue2043Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.50% Notes due 2043",
        "label": "4.50% Notes due 2043 [Member]",
        "documentation": "4.50% Notes due 2043 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A4.80DebenturesDue2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A4.80DebenturesDue2029Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.80% Debentures due 2029",
        "label": "4.80% Debentures due 2029 [Member]",
        "documentation": "4.80% Debentures due 2029"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A4.85Notesdue2041Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A4.85Notesdue2041Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.85% Notes due 2041",
        "label": "4.85% Notes due 2041 [Member]",
        "documentation": "4.85% Notes due 2041 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A4.90DebenturesDue2031Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A4.90DebenturesDue2031Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.90% Debentures due 2031",
        "label": "4.90% Debentures due 2031 [Member]",
        "documentation": "4.90% Debentures due 2031"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A4.95DebenturesDue2034Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A4.95DebenturesDue2034Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.95% Debentures due 2034",
        "label": "4.95% Debentures due 2034 [Member]",
        "documentation": "4.95% Debentures due 2034"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A4.95Debenturesdue2033Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A4.95Debenturesdue2033Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.95%\u00a0Debentures due 2033",
        "label": "4.95% Debentures due 2033 [Member]",
        "documentation": "4.95% Debentures due 2033 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A5.25DebenturesDue2054Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A5.25DebenturesDue2054Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5.25% Debentures due 2054",
        "label": "5.25% Debentures due 2054 [Member]",
        "documentation": "5.25% Debentures due 2054"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A5.50NotesDue2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A5.50NotesDue2024Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5.50%\u00a0Notes due 2024 (500MM GBP 1.2756)(3)",
        "label": "5.50% Notes Due 2024 [Member]",
        "documentation": "5.50% Notes Due 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A5.85Debenturesdue2038Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A5.85Debenturesdue2038Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5.85%\u00a0Debentures due 2038",
        "label": "5.85% Debentures due 2038 [Member]",
        "documentation": "5.85% Debentures due 2038 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A5.95Notesdue2037Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A5.95Notesdue2037Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5.95%\u00a0Notes due 2037",
        "label": "5.95% Notes due 2037 [Member]",
        "documentation": "5.95% Notes due 2037 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A6.95Notesdue2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "A6.95Notesdue2029Member",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "6.95%\u00a0Notes due 2029",
        "label": "6.95% Notes due 2029 [Member]",
        "documentation": "6.95% Notes due 2029 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ADVANCEDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ADVANCEDMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ADVANCED",
        "label": "ADVANCED [Member]",
        "documentation": "ADVANCED [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_AbiomedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "AbiomedMember",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Abiomed",
        "label": "Abiomed [Member]",
        "documentation": "Abiomed"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_AcclarentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "AcclarentMember",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acclarent",
        "label": "Acclarent [Member]",
        "documentation": "Acclarent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r1219"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts receivable trade, less allowances $167 (2023, $166)",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1438"
     ]
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued taxes on income",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r236"
     ]
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedIncomeTaxesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term taxes payable",
        "label": "Accrued Income Taxes, Noncurrent",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r236"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "jnj_AccruedRebatesReturnsAndPromotions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "AccruedRebatesReturnsAndPromotions",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued rebates, returns and promotions",
        "label": "Accrued Rebates Returns And Promotions",
        "documentation": "Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plans",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8",
      "r21",
      "r41",
      "r173",
      "r1406",
      "r1407",
      "r1408"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r319",
      "r974"
     ]
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain/ (Loss) On Derivatives &amp; Hedges",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r356",
      "r357",
      "r802",
      "r1153",
      "r1406"
     ]
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain/ (Loss) On Securities",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]",
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r342",
      "r343",
      "r346",
      "r356",
      "r357",
      "r1406"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r858",
      "r860",
      "r861",
      "r862",
      "r863",
      "r865"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated other comprehensive income (loss)",
        "negatedTerseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r174",
      "r331",
      "r970",
      "r1011",
      "r1012"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r858",
      "r860",
      "r861",
      "r862",
      "r863",
      "r865"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r21",
      "r41",
      "r812",
      "r815",
      "r882",
      "r1007",
      "r1008",
      "r1406",
      "r1407",
      "r1408",
      "r1424",
      "r1425",
      "r1426",
      "r1428"
     ]
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedTranslationAdjustmentMember",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Translation",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r21",
      "r41",
      "r171",
      "r172",
      "r356",
      "r357",
      "r860",
      "r861",
      "r862",
      "r863",
      "r865",
      "r1406"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average useful life",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r524",
      "r1141"
     ]
    },
    "us-gaap_AcquisitionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AcquisitionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition costs, period cost",
        "label": "Oil and Gas, Full Cost Method, Capitalized Cost Excluded from Amortization, Acquisition Cost, Period Cost",
        "documentation": "Amount of capitalized acquisition cost incurred during period and excluded from amortization for oil- and gas-producing activities accounted for under full cost method. Excludes exploration and development costs and capitalized interest."
       }
      }
     },
     "auth_ref": [
      "r1602",
      "r1603"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1311"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1324"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1324"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1324"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1324"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee compensation and stock option plans",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r706"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Adjustments to reconcile net earnings to cash flows from operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising",
        "label": "Advertising Cost [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising expense",
        "label": "Advertising Expense",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r743",
      "r1201"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1369"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1282",
      "r1293",
      "r1303",
      "r1336"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1285",
      "r1296",
      "r1306",
      "r1339"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1370"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1324"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1331"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r1286",
      "r1297",
      "r1307",
      "r1331",
      "r1340",
      "r1344",
      "r1352"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1350"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation cost charged for Long term incentive plan",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r736",
      "r741"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Allowances for doubtful accounts",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r454",
      "r493"
     ]
    },
    "jnj_AmbrxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "AmbrxMember",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ambrx",
        "label": "Ambrx [Member]",
        "documentation": "Ambrx"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amortization expense of amortizable intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r521",
      "r528",
      "r1175"
     ]
    },
    "us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total recognized in net periodic benefit cost and other comprehensive\u00a0income",
        "label": "Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax",
        "documentation": "Amount recognized in net periodic benefit cost (credit) and other comprehensive (income) loss."
       }
      }
     },
     "auth_ref": [
      "r1189"
     ]
    },
    "us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]",
        "label": "Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.jnj.com/role/EarningspershareNarrativeDetails",
      "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AociLossCashFlowHedgeCumulativeGainLossAfterTax",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred net losses (gains) on derivatives included in accumulated other comprehensive income",
        "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax",
        "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "jnj_AsiaPacificAfricaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "AsiaPacificAfricaMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asia-Pacific, Africa",
        "label": "Asia-Pacific, Africa [Member]",
        "documentation": "Asia-Pacific, Africa [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_AsrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "AsrMember",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASR",
        "label": "ASR [Member]",
        "documentation": "ASR."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Axis]",
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r1562"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration transferred",
        "label": "Asset Acquisition, Consideration Transferred",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r1204",
      "r1563",
      "r1564",
      "r1565"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Domain]",
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r1562"
     ]
    },
    "jnj_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPR&amp;D charge",
        "label": "Asset Acquisition, Recognized Identifiable Assets Acquired, Intangible Assets, Other than Goodwill",
        "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired, Intangible Assets, Other than Goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset write-downs",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r66"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "verboseLabel": "Identifiable Assets",
        "terseLabel": "Assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r249",
      "r323",
      "r370",
      "r407",
      "r415",
      "r440",
      "r444",
      "r490",
      "r571",
      "r572",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r580",
      "r581",
      "r800",
      "r804",
      "r847",
      "r965",
      "r1071",
      "r1166",
      "r1167",
      "r1219",
      "r1256",
      "r1496",
      "r1497",
      "r1593"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r335",
      "r370",
      "r490",
      "r571",
      "r572",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r580",
      "r581",
      "r800",
      "r804",
      "r847",
      "r1219",
      "r1496",
      "r1497",
      "r1593"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsHeldForSaleNotPartOfDisposalGroup",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset, held-for-sale, not part of disposal group",
        "label": "Asset, Held-for-Sale, Not Part of Disposal Group",
        "documentation": "Amount of assets held-for-sale that are not part of a disposal group."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net assets divested",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r129",
      "r143",
      "r202",
      "r312",
      "r313"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.jnj.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r1265",
      "r1266",
      "r1289"
     ]
    },
    "jnj_AuditorInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "AuditorInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Information [Abstract]",
        "documentation": "Auditor Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.jnj.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r1265",
      "r1266",
      "r1289"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.jnj.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r1265",
      "r1266",
      "r1289"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-sale, unrealized gain",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Available-for-sale, unrecognized loss",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying Amount, available-for-sale",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r500",
      "r964"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after five years through ten years",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1450"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after five years through ten years",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r960"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after one year through five years",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1449"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after one year through five years",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r959"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total debt securities",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date."
       }
      }
     },
     "auth_ref": [
      "r1446",
      "r1447",
      "r1607"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total debt securities",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date."
       }
      }
     },
     "auth_ref": [
      "r1446",
      "r1447",
      "r1606"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost Basis",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due within one year",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1448"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due within one year",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r958"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value, available-for-sale",
        "terseLabel": "Debt securities",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r500",
      "r823",
      "r952",
      "r1206",
      "r1210",
      "r1440",
      "r1575",
      "r1576",
      "r1577"
     ]
    },
    "us-gaap_AvailableforsaleSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableforsaleSecuritiesMember",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-sale Securities",
        "label": "Available-for-Sale Securities [Member]",
        "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1347"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1348"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1343"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1343"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1343"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1343"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1343"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1343"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1346"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1345"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1344"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1344"
     ]
    },
    "jnj_BabyPowderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "BabyPowderMember",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Baby Powder",
        "label": "Baby Powder [Member]",
        "documentation": "Baby Powder [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position Location, Balance [Axis]",
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r1614",
      "r1615"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position Location, Balance [Domain]",
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r114",
      "r544",
      "r1614",
      "r1615"
     ]
    },
    "us-gaap_BankTimeDepositsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BankTimeDepositsMember",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Time deposits",
        "label": "Bank Time Deposits [Member]",
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "jnj_BermekimabMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "BermekimabMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "bermekimab",
        "label": "bermekimab [Member]",
        "documentation": "bermekimab"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BuildingAndBuildingImprovementsMember",
     "presentation": [
      "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Building and building equipment",
        "label": "Building and Building Improvements [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails",
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IncometaxesNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r793",
      "r1191",
      "r1194"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails",
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IncometaxesNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r793",
      "r1191",
      "r1194"
     ]
    },
    "jnj_BusinessAcquisitionDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "BusinessAcquisitionDiscountRate",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Business Acquisition, Discount Rate",
        "documentation": "Business Acquisition, Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails",
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionSharePrice",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition price (in dollars per share)",
        "label": "Business Acquisition, Share Price",
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition related costs",
        "label": "Business Combination, Acquisition Related Costs",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "jnj_BusinessCombinationAcquisitionRelatedCostsEquityAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "BusinessCombinationAcquisitionRelatedCostsEquityAwards",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity awards",
        "label": "Business Combination, Acquisition Related Costs, Equity Awards",
        "documentation": "Business Combination, Acquisition Related Costs, Equity Awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity interests issued and issuable",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r96",
      "r796"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration",
        "label": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r226",
      "r797",
      "r825",
      "r826",
      "r827"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.jnj.com/role/Acquisitionsanddivestitures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Acquisitions and divestitures",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r794"
     ]
    },
    "jnj_BusinessCombinationProbabilityOfSuccessFactor": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "BusinessCombinationProbabilityOfSuccessFactor",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Probability of success factor",
        "label": "Business Combination, Probability Of Success Factor",
        "documentation": "Business Combination, Probability Of Success Factor"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails",
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets assumed",
        "totalLabel": "Other assets assumed",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "documentation": "Amount of assets acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets acquired:",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails",
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and equivalents",
        "verboseLabel": "Less: Cash acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities assumed",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities",
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails",
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred taxes",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails",
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets assumed",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortizable intangibles",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "documentation": "The amount of inventory recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails",
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total liabilities assumed",
        "totalLabel": "Total liabilities assumed",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "documentation": "Amount of liabilities assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities assumed:",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes payable",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt",
        "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "jnj_BusinessCombinationSettlementOfEquityAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "BusinessCombinationSettlementOfEquityAwards",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity awards settled",
        "label": "Business Combination, Settlement Of Equity Awards",
        "documentation": "Business Combination, Settlement Of Equity Awards"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_BusinessCombinationSettlementOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "BusinessCombinationSettlementOfNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement of notes payable",
        "label": "Business Combination, Settlement Of Notes Payable",
        "documentation": "Business Combination, Settlement Of Notes Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity interest in acquiree, remeasurement loss",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Loss",
        "documentation": "In a business combination achieved in stages, this element represents the amount of loss recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_CARVYKTIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "CARVYKTIMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CARVYKTI",
        "label": "CARVYKTI [Member]",
        "documentation": "CARVYKTI"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_CONCERTAMethylphenidateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "CONCERTAMethylphenidateMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONCERTA/Methylphenidate",
        "label": "CONCERTA/Methylphenidate [Member]",
        "documentation": "CONCERTA/Methylphenidate [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_CONTACTLENSESOTHERMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "CONTACTLENSESOTHERMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONTACT LENSES/OTHER",
        "label": "CONTACT LENSES/OTHER [Member]",
        "documentation": "CONTACT LENSES/OTHER [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_COVID19Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "COVID19Member",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COVID-19",
        "label": "COVID-19 [Member]",
        "documentation": "COVID-19"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpenditureDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpenditureDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDepreciationandAmortizationofDiscontinuedOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital expenditures",
        "label": "Capital Expenditure, Discontinued Operations",
        "documentation": "Amount of capital expenditure attributable to discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "jnj_CardiovascularMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "CardiovascularMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cardiovascular",
        "label": "Cardiovascular [Member]",
        "documentation": "Cardiovascular [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_CardiovascularMetabolismOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "CardiovascularMetabolismOtherMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cardiovascular/Metabolism/Other",
        "label": "Cardiovascular/Metabolism/Other [Member]",
        "documentation": "Cardiovascular/Metabolism/Other [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAcquiredFromAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash acquired from acquisition",
        "label": "Cash Acquired from Acquisition",
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Abstract]",
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "terseLabel": "Cash &amp; Cash Equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r317",
      "r1146"
     ]
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsLineItems",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Line Items]",
        "label": "Cash and Cash Equivalents [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.jnj.com/role/Cashcashequivalentsandcurrentmarketablesecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and current marketable securities",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r1439"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAbstract",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents, and Short-term Investments [Abstract]",
        "label": "Cash, Cash Equivalents, and Short-Term Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of year",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r190",
      "r367"
     ]
    },
    "jnj_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents from continuing operations, beginning of period",
        "periodEndLabel": "Cash and cash equivalents from continuing operations, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents from discontinued operations, beginning of period",
        "periodEndLabel": "Cash and cash equivalents from discontinued operations, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r190",
      "r367"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase/(Decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r190"
     ]
    },
    "us-gaap_CashFlowHedgingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowHedgingMember",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flow Hedging",
        "label": "Cash Flow Hedging [Member]",
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental schedule of non-cash investing and financing activities",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashMember",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "jnj_CashPaidDuringTheYearAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "CashPaidDuringTheYearAbstract",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid during the year for:",
        "label": "Cash Paid During The Year [Abstract]",
        "documentation": "Cash Paid During The Year [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1322"
     ]
    },
    "jnj_ChangesInTreasuryStockRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ChangesInTreasuryStockRollForward",
     "presentation": [
      "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in treasury stock",
        "label": "Changes In Treasury Stock [Roll Forward]",
        "documentation": "Changes in treasury stock."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ChangesInTreasuryStockTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ChangesInTreasuryStockTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/CapitalandtreasurystockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in Treasury Stock",
        "label": "Changes In Treasury Stock [Table Text Block]",
        "documentation": "Changes in treasury stock."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ChangesinTreasuryStockSharesOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ChangesinTreasuryStockSharesOutstandingRollForward",
     "presentation": [
      "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in Treasury Stock Shares Outstanding [Roll Forward]",
        "label": "Changes in Treasury Stock Shares Outstanding [Roll Forward]",
        "documentation": "Changes in Treasury Stock Shares Outstanding [Roll Forward]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1319"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1317"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ClassIRecommendationForImpellaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ClassIRecommendationForImpellaMember",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class I Recommendation For Impella",
        "label": "Class I Recommendation For Impella [Member]",
        "documentation": "Class I Recommendation For Impella"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r328",
      "r329",
      "r330",
      "r370",
      "r393",
      "r397",
      "r399",
      "r401",
      "r409",
      "r410",
      "r490",
      "r571",
      "r574",
      "r575",
      "r576",
      "r580",
      "r581",
      "r611",
      "r612",
      "r613",
      "r614",
      "r616",
      "r847",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1058",
      "r1080",
      "r1099",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1374",
      "r1418",
      "r1429"
     ]
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfTreasuryStockTable",
     "presentation": [
      "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Treasury Stock [Table]",
        "label": "Class of Treasury Stock [Table]",
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73",
      "r74",
      "r75"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1323"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1323"
     ]
    },
    "us-gaap_CollateralAlreadyPostedAggregateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollateralAlreadyPostedAggregateFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collateral paid",
        "label": "Collateral Already Posted, Aggregate Fair Value",
        "documentation": "The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_CommercialPaper": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommercialPaper",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper",
        "label": "Commercial Paper",
        "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r234",
      "r1609"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r570",
      "r1245",
      "r1246",
      "r1247",
      "r1250"
     ]
    },
    "jnj_CommingledFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "CommingledFundsMember",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commingled funds",
        "label": "Commingled Funds [Member]",
        "documentation": "Commingled funds."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r239",
      "r967",
      "r1057"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockDividendsPerShareCashPaid",
     "presentation": [
      "http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash dividends paid (in dollars per share)",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockDividendsPerShareDeclared",
     "presentation": [
      "http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash dividend (in dollars per share)",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity",
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common Stock, Par Value $1.00",
        "terseLabel": "Common Stock Issued Amount",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1241",
      "r1242",
      "r1243",
      "r1245",
      "r1246",
      "r1247",
      "r1250",
      "r1424",
      "r1425",
      "r1428",
      "r1571",
      "r1646",
      "r1648"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, par value per share (in usd per share)",
        "terseLabel": "Common Stock, Par or Stated Value Per Share",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r1058"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock\u00a0\u2014 par value $1.00 per share (Note\u00a012) (authorized 4,320,000,000\u00a0shares; issued 3,119,843,000\u00a0shares)",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r969",
      "r1219"
     ]
    },
    "us-gaap_CommonStockValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValueOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, value",
        "label": "Common Stock, Value, Outstanding",
        "documentation": "Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r1058"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1328"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1327"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1329"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1326"
     ]
    },
    "jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract",
        "label": "Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract",
        "documentation": "Comparison of income tax expense at the Statutory rate and Company's tax rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Benefits [Abstract]",
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationRelatedCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Related Costs [Abstract]",
        "label": "Compensation Related Costs [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationRelatedCostsGeneralTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsGeneralTextBlock",
     "presentation": [
      "http://www.jnj.com/role/Employeerelatedobligations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee related obligations",
        "label": "Compensation Related Costs, General [Text Block]",
        "documentation": "The entire disclosure for compensation costs, including compensated absences accruals, compensated absences liability, deferred compensation arrangements and income statement compensation items. Deferred compensation arrangements may include a description of an arrangement with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares (units) issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability."
       }
      }
     },
     "auth_ref": [
      "r620",
      "r621"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r227",
      "r351",
      "r353",
      "r359",
      "r954",
      "r980"
     ]
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "presentation": [
      "http://www.jnj.com/role/Accumulatedothercomprehensiveincomeloss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated other comprehensive income (loss)",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r358",
      "r953",
      "r978"
     ]
    },
    "jnj_ConcentrationOfCreditRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ConcentrationOfCreditRiskLineItems",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk [Line Items]",
        "label": "Concentration of Credit Risk [Line Items]",
        "documentation": "Concentration of credit risk."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ConcentrationOfCreditRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ConcentrationOfCreditRiskTable",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk [Table]",
        "label": "Concentration of Credit Risk [Table]",
        "documentation": "Concentration of Credit Risk [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r125",
      "r126",
      "r452",
      "r1129"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r125",
      "r126",
      "r452",
      "r1014",
      "r1129"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r125",
      "r126",
      "r452",
      "r1129",
      "r1384"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk (as a percent)",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r125",
      "r126",
      "r452"
     ]
    },
    "jnj_ConcentrationRiskThresholdPercentage": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ConcentrationRiskThresholdPercentage",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk, threshold percentage (as a percent)",
        "label": "Concentration Risk, Threshold Percentage",
        "documentation": "Concentration Risk, Threshold Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r125",
      "r126",
      "r452",
      "r1129"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Axis]",
        "label": "Consolidation Items [Axis]",
        "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r270",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r374",
      "r407",
      "r417",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r444",
      "r445",
      "r446",
      "r571",
      "r572",
      "r573",
      "r574",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r1166",
      "r1167",
      "r1400",
      "r1401",
      "r1496",
      "r1497"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Domain]",
        "label": "Consolidation Items [Domain]",
        "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r270",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r374",
      "r407",
      "r417",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r444",
      "r445",
      "r446",
      "r571",
      "r572",
      "r573",
      "r574",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r1166",
      "r1167",
      "r1400",
      "r1401",
      "r1496",
      "r1497"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r1154"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ConsumerHealthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ConsumerHealthMember",
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consumer Health Business",
        "label": "Consumer Health [Member]",
        "documentation": "Consumer Health"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ConsumerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ConsumerMember",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consumer Health",
        "label": "Consumer [Member]",
        "documentation": "Consumer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r1187",
      "r1189",
      "r1206",
      "r1220",
      "r1238",
      "r1643"
     ]
    },
    "us-gaap_CorporateNonSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateNonSegmentMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting, Reconciling Item, Corporate Nonsegment",
        "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]",
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r439",
      "r440",
      "r441",
      "r442",
      "r445",
      "r1434"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of products sold",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r917"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Products Sold",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_CostsOfGoodsAndServicesSoldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "CostsOfGoodsAndServicesSoldMember",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs of Goods and Services Sold",
        "label": "Costs of Goods and Services Sold [Member]",
        "documentation": "Costs of Goods and Services Sold"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover page.",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CrossCurrencyInterestRateContractMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CrossCurrencyInterestRateContractMember",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cross currency interest rate swaps",
        "terseLabel": "Cross currency interest rate swaps contracts:",
        "label": "Cross Currency Interest Rate Contract [Member]",
        "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates."
       }
      }
     },
     "auth_ref": [
      "r1507",
      "r1570"
     ]
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. taxes",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1386",
      "r1421",
      "r1557"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International taxes",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1386",
      "r1421"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total currently payable",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r1421"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currently payable:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_CurtailmentsAndSettlementsAndRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "CurtailmentsAndSettlementsAndRestructuring",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Curtailments, settlements\u00a0&amp; restructuring",
        "label": "Curtailments And Settlements And Restructuring",
        "documentation": "The amount of increase or decrease related to curtailments, settlements and restructuring."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1274",
      "r1363"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1274",
      "r1363"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1276",
      "r1365"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1276",
      "r1365"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1278",
      "r1367"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1276",
      "r1365"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1269",
      "r1358"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1270",
      "r1359"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1270",
      "r1359"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r1268",
      "r1357"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1268",
      "r1357"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r1268",
      "r1357"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1271",
      "r1360"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1273",
      "r1362"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1273",
      "r1362"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1274",
      "r1363"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1277",
      "r1366"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1275",
      "r1364"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1272",
      "r1361"
     ]
    },
    "jnj_DARZALEXMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DARZALEXMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DARZALEX",
        "label": "DARZALEX [Member]",
        "documentation": "DARZALEX [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_DePuyASRU.S.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DePuyASRU.S.Member",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DePuy ASR U.S.",
        "label": "DePuy ASR U.S. [Member]",
        "documentation": "DePuy ASR U.S. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term borrowings and the current portion of long-term debt",
        "label": "Debt, Current",
        "documentation": "Amount of debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.jnj.com/role/Borrowings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r369",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r569",
      "r570",
      "r582",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r598",
      "r605",
      "r606",
      "r608",
      "r869"
     ]
    },
    "jnj_DebtForEquityExchangeLossOnSharesExchanged": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DebtForEquityExchangeLossOnSharesExchanged",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on shares exchanged",
        "label": "Debt For Equity Exchange, Loss On Shares Exchanged",
        "documentation": "Debt For Equity Exchange, Loss On Shares Exchanged"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_DebtForEquityExchangeSharesExchanged": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DebtForEquityExchangeSharesExchanged",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt for equity exchange, shares exchanged (in shares)",
        "label": "Debt For Equity Exchange, Shares Exchanged",
        "documentation": "Debt For Equity Exchange, Shares Exchanged"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r151",
      "r152",
      "r235",
      "r238",
      "r374",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r589",
      "r594",
      "r595",
      "r596",
      "r597",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1217",
      "r1419",
      "r1483",
      "r1484",
      "r1485",
      "r1591",
      "r1592"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, face amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r583",
      "r869",
      "r870",
      "r1179",
      "r1180",
      "r1217"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective interest rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r610",
      "r869",
      "r870",
      "r1217"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stated interest rate (as a percent)",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r584"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r589",
      "r594",
      "r595",
      "r596",
      "r597",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r607",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1217",
      "r1419",
      "r1591",
      "r1592"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r374",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r589",
      "r594",
      "r595",
      "r596",
      "r597",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1217",
      "r1419",
      "r1483",
      "r1484",
      "r1485",
      "r1591",
      "r1592"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r69",
      "r70",
      "r127",
      "r210",
      "r211",
      "r374",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r589",
      "r594",
      "r595",
      "r596",
      "r597",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r607",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1217",
      "r1419",
      "r1591",
      "r1592"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, term",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realized gain (loss)",
        "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)",
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1452"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual Maturities of Available for Sale Securities",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1441",
      "r1442",
      "r1443",
      "r1444",
      "r1445",
      "r1446",
      "r1447",
      "r1448",
      "r1449",
      "r1450",
      "r1451",
      "r1452"
     ]
    },
    "us-gaap_DebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesMember",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities",
        "verboseLabel": "Debt instruments",
        "label": "Debt Securities [Member]",
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r1243",
      "r1650"
     ]
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtWeightedAverageInterestRate",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt, weighted average interest rate",
        "label": "Debt, Weighted Average Interest Rate",
        "documentation": "Weighted average interest rate of debt outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_December172018ShareRepurchaseProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "December172018ShareRepurchaseProgramMember",
     "presentation": [
      "http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December 17, 2018 Share Repurchase Program",
        "label": "December 17, 2018 Share Repurchase Program [Member]",
        "documentation": "December 17, 2018 Share Repurchase Program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationLiabilityCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails": {
       "parentTag": "jnj_EmployeeObligations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred compensation",
        "label": "Deferred Compensation Liability, Current and Noncurrent",
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "parentTag": "jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. taxes",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1421",
      "r1556",
      "r1557"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "parentTag": "jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International taxes",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1421",
      "r1556"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred taxes on income",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r750",
      "r751"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax provision",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r267",
      "r1421"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred",
        "label": "Deferred Income Tax Expense (Benefit), Net Of Discontinued Operations",
        "documentation": "Deferred Income Tax Expense (Benefit), Net Of Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred taxes on income",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r750",
      "r751",
      "r966"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income reported for tax purposes",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D capitalized for tax",
        "label": "Deferred Tax Assets International Research And Development Capitalized",
        "documentation": "Deferred tax assets international research and development capitalized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInventory",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory related",
        "label": "Deferred Tax Assets, Inventory",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory."
       }
      }
     },
     "auth_ref": [
      "r1554"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred income taxes net of valuation allowances",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1549"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1554"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Miscellaneous international",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1554"
     ]
    },
    "jnj_DeferredTaxAssetsOtherDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DeferredTaxAssetsOtherDomestic",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Miscellaneous U.S.",
        "label": "Deferred Tax Assets Other Domestic",
        "documentation": "Deferred tax assets other domestic."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets, tax basis increase of certain assets due to reorganization",
        "label": "Deferred Tax Assets, Tax Basis Increase of Certain Assets due to Reorganization",
        "documentation": "Deferred Tax Assets, Tax Basis Increase of Certain Assets due to Reorganization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee related obligations",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1554"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1554"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserves\u00a0&amp; liabilities",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r1554"
     ]
    },
    "jnj_DeferredTaxAssetsUndistributedForeignEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DeferredTaxAssetsUndistributedForeignEarnings",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Undistributed foreign earnings",
        "label": "Deferred Tax Assets, Undistributed Foreign Earnings",
        "documentation": "Deferred Tax Assets, Undistributed Foreign Earnings"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails",
      "http://www.jnj.com/role/IncometaxesValuationAllowanceActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Valuation allowances",
        "periodStartLabel": "Beginning of year",
        "periodEndLabel": "End of year",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred income taxes net of valuation allowances",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1549"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Goodwill and intangibles",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r1554"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability",
        "label": "Deferred Tax Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_DeferredTaxLiabilitiesOtherDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DeferredTaxLiabilitiesOtherDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Miscellaneous U.S.",
        "label": "Deferred Tax Liabilities, Other Domestic",
        "documentation": "Deferred Tax Liabilities, Other Domestic"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Depreciation of property, plant and equipment",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1554"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Undistributed foreign earnings",
        "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences."
       }
      }
     },
     "auth_ref": [
      "r1554"
     ]
    },
    "jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Global intangible low-taxed income",
        "label": "Deferred Tax Liability, Global Intangible Low-Taxed Income",
        "documentation": "Deferred Tax Liability, Global Intangible Low-Taxed Income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails": {
       "parentTag": "jnj_EmployeeObligations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension benefits",
        "label": "Liability, Defined Benefit Pension Plan",
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension plan. Excludes other postretirement benefit plan."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r237"
     ]
    },
    "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAccumulatedBenefitObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Benefit Obligation",
        "label": "Defined Benefit Plan, Accumulated Benefit Obligation",
        "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total before tax effects",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax",
        "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8",
      "r41",
      "r173",
      "r1510"
     ]
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net actuarial loss",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax",
        "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r668"
     ]
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior service cost (credit)",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax",
        "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit)."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r668"
     ]
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized net transition obligation",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Transition Asset (Obligation), before Tax",
        "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for transition asset (obligation) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r41",
      "r668"
     ]
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actual return on plan assets",
        "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)",
        "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses."
       }
      }
     },
     "auth_ref": [
      "r638",
      "r1189"
     ]
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanActuarialGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Actuarial (gains) losses",
        "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)",
        "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments Measured at Net Asset Value",
        "label": "Defined Benefit Plan, Alternative Investments, Fair Value of Plan Assets",
        "documentation": "Defined Benefit Plan, Alternative Investments, Fair Value of Plan Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Recognized actuarial losses (gains)",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r663",
      "r689",
      "r1189",
      "r1190"
     ]
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amortization of prior service cost",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r664",
      "r690",
      "r1189",
      "r1190"
     ]
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total recognized in the consolidated balance sheet\u00a0\u2014 end of year",
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position",
        "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78"
     ]
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts Recognized in the Company\u2019s Balance Sheet consist of the\u00a0following:",
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]",
        "label": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/EmployeerelatedobligationsNarrativeDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid employee related obligations",
        "terseLabel": "Non-current assets",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r623",
      "r624",
      "r646",
      "r1070",
      "r1189",
      "r1608"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansAssumedHealthCareCostTrendRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]",
        "label": "Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate",
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rate of increase in compensation levels",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase",
        "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service cost discount rate",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate",
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected long-term rate of return on plan assets",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets",
        "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r694"
     ]
    },
    "jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest cost discount rate",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate",
        "documentation": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rate of increase in compensation levels",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase",
        "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanBenefitObligation",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Projected benefit obligation - beginning of year",
        "periodEndLabel": "Projected benefit obligation - end of year",
        "terseLabel": "Projected Benefit Obligation",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Benefits paid from plan",
        "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid",
        "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services."
       }
      }
     },
     "auth_ref": [
      "r633",
      "r697"
     ]
    },
    "jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Divestitures &amp; acquisitions",
        "label": "Defined Benefit Plan, Benefit Obligation, Business Combination and Divestiture, Increase (Decrease)",
        "documentation": "Defined Benefit Plan, Benefit Obligation, Business Combination and Divestiture, Increase (Decrease)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan participant contributions",
        "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant",
        "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "jnj_DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transferred to group annuity contract",
        "label": "Defined Benefit Plan, Benefit Obligation, Transferred To Group Annuity Contract",
        "documentation": "Defined Benefit Plan, Benefit Obligation, Transferred To Group Annuity Contract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "label": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "documentation": "Information by defined benefit plan asset investment."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r648",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r675",
      "r1187",
      "r1188",
      "r1189"
     ]
    },
    "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Benefit Obligation",
        "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]",
        "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company contributions",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets."
       }
      }
     },
     "auth_ref": [
      "r640",
      "r650",
      "r693",
      "r1187",
      "r1188",
      "r1189",
      "r1190"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029-2033",
        "label": "Defined Benefit Plan Expected Future Benefit Contribution In Five Fiscal Years Thereafter",
        "documentation": "Defined benefit plan expected future benefit contribution in five fiscal years thereafter."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Defined Benefit Plan Expected Future Benefit Contribution In Year Five",
        "documentation": "Defined benefit plan expected future benefit contribution in year five."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Defined Benefit Plan Expected Future Benefit Contribution In Year Four",
        "documentation": "Defined benefit plan expected future benefit contribution in year four."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Defined Benefit Plan Expected Future Benefit Contribution In Year One",
        "documentation": "Defined benefit plan expected future benefit contribution in year one."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Defined Benefit Plan Expected Future Benefit Contribution In Year Three",
        "documentation": "Defined benefit plan expected future benefit contribution in year three."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Defined Benefit Plan Expected Future Benefit Contribution In Year Two",
        "documentation": "Defined benefit plan expected future benefit contribution in year two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029-2033",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expected return on plan assets",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r662",
      "r688",
      "r1189",
      "r1190"
     ]
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Plan Assets",
        "periodStartLabel": "Plan assets at fair value\u00a0\u2014 beginning of year",
        "periodEndLabel": "Plan assets at fair value\u00a0- End of year",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee."
       }
      }
     },
     "auth_ref": [
      "r637",
      "r648",
      "r650",
      "r651",
      "r1187",
      "r1188",
      "r1189"
     ]
    },
    "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Effect of exchange rates",
        "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)",
        "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanFundedStatusOfPlan",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Funded status - end of year",
        "terseLabel": "Projected Benefit Obligation",
        "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan",
        "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r646",
      "r1189"
     ]
    },
    "us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansAssumedHealthCareCostTrendRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Healthcare cost trend rate assumed for next year",
        "label": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year",
        "documentation": "Assumed rate, for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanInterestCost",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest cost",
        "terseLabel": "Interest cost",
        "label": "Defined Benefit Plan, Interest Cost",
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r629",
      "r661",
      "r687",
      "r1189",
      "r1190"
     ]
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net periodic benefit cost (credit)",
        "terseLabel": "Net periodic benefit cost (credit)",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r685",
      "r1189",
      "r1190"
     ]
    },
    "jnj_DefinedBenefitPlanOverUnderFundedStatusABO": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DefinedBenefitPlanOverUnderFundedStatusABO",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Benefit Obligation",
        "label": "Defined Benefit Plan Over (Under) Funded Status ABO",
        "documentation": "Defined benefit plan over (under) funded status ABO"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated benefit obligation unfunded plans",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation",
        "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets."
       }
      }
     },
     "auth_ref": [
      "r682",
      "r683",
      "r1189"
     ]
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan with accumulated benefit obligation in excess of plan assets, plan assets",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets",
        "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets."
       }
      }
     },
     "auth_ref": [
      "r682",
      "r683",
      "r1189"
     ]
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Projected benefit obligation, unfunded plans",
        "label": "Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation",
        "documentation": "Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets."
       }
      }
     },
     "auth_ref": [
      "r1511"
     ]
    },
    "us-gaap_DefinedBenefitPlanPlanAmendments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanPlanAmendments",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendments",
        "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment",
        "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Benefits paid from plan assets",
        "label": "Defined Benefit Plan, Plan Assets, Benefits Paid",
        "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services."
       }
      }
     },
     "auth_ref": [
      "r642",
      "r1513"
     ]
    },
    "jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Divestitures &amp; acquisitions",
        "label": "Defined Benefit Plan, Plan Assets, Business Combination and Divestiture, Increase (Decrease)",
        "documentation": "Defined Benefit Plan, Plan Assets, Business Combination and Divestiture, Increase (Decrease)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan participant contributions",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant",
        "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets."
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rates",
        "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)",
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Target Allocation",
        "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage",
        "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r1189"
     ]
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Curtailments and settlements",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment",
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment."
       }
      }
     },
     "auth_ref": [
      "r1505",
      "r1508",
      "r1512"
     ]
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanServiceCost",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Service cost",
        "terseLabel": "Service cost",
        "label": "Defined Benefit Plan, Service Cost",
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r627",
      "r660",
      "r686",
      "r1189",
      "r1190"
     ]
    },
    "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanSettlementsPlanAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Settlements",
        "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement",
        "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanUltimateHealthCareCostTrendRate1",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansAssumedHealthCareCostTrendRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rate to which the cost trend rate is assumed to decline (ultimate trend)",
        "label": "Defined Benefit Plan, Ultimate Health Care Cost Trend Rate",
        "documentation": "Ultimate trend rate for health care cost for defined benefit postretirement plan."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanWeightedAverageAssetAllocations",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent of Plan Assets",
        "label": "Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage",
        "documentation": "Percentage of actual investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan."
       }
      }
     },
     "auth_ref": [
      "r1506"
     ]
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Benefit Obligation",
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Periodic Benefit Cost",
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansAssumedHealthCareCostTrendRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year the rate reaches the ultimate trend rate",
        "label": "Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate",
        "documentation": "Year ultimate health care cost trend rate is expected to be reached, in YYYY format."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/SavingsplanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Matching contributions",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization of property and intangibles",
        "terseLabel": "Depreciation and Amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r407",
      "r420",
      "r444",
      "r1166",
      "r1167"
     ]
    },
    "jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DepreciationExpenseIncludingAmortizationOfCapitalizedInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/PropertyplantandequipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense, including the amortization of capitalized interest",
        "label": "Depreciation Expense Including Amortization Of Capitalized Interest",
        "documentation": "Depreciation expense including the amortization of capitalized interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeAssetFairValueGrossLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeAssetFairValueGrossLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "parentTag": "us-gaap_DerivativeAssets",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Credit Support Agreements (CSA)",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, Liability Offset",
        "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r33",
      "r228",
      "r229",
      "r1116",
      "r1117"
     ]
    },
    "jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Asset, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag",
        "label": "Derivative Asset, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag",
        "documentation": "Derivative Asset, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Net Asset",
        "label": "Derivative Asset",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r823",
      "r824",
      "r837",
      "r846",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1064",
      "r1065",
      "r1111",
      "r1114",
      "r1115",
      "r1116",
      "r1118",
      "r1119",
      "r1152",
      "r1206",
      "r1210",
      "r1243",
      "r1575",
      "r1576",
      "r1577",
      "r1647"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Contract [Domain]",
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r1047",
      "r1049",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1111",
      "r1112",
      "r1115",
      "r1118",
      "r1241",
      "r1243",
      "r1578",
      "r1579",
      "r1580",
      "r1581",
      "r1582",
      "r1583",
      "r1585",
      "r1586"
     ]
    },
    "us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeExcludedComponentGainLossRecognizedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing",
        "label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings",
        "documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r1569"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "parentTag": "us-gaap_DerivativeAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Gross Assets",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset",
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r169",
      "r228",
      "r229",
      "r336",
      "r1152"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying Amount of the Hedged Liability",
        "verboseLabel": "Total Gross Liabilities",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r169",
      "r228",
      "r229",
      "r336",
      "r1152"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain/(Loss) Recognized In Income on Derivative",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r1568"
     ]
    },
    "us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative."
       }
      }
     },
     "auth_ref": [
      "r1568"
     ]
    },
    "us-gaap_DerivativeInstrumentDetailAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentDetailAbstract",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial assets and liabilities at fair value",
        "label": "Derivative Instrument Detail [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument [Axis]",
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r115",
      "r117",
      "r230",
      "r1047",
      "r1049",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1111",
      "r1112",
      "r1115",
      "r1118",
      "r1152",
      "r1241",
      "r1243",
      "r1578",
      "r1579",
      "r1580",
      "r1581",
      "r1582",
      "r1583",
      "r1585",
      "r1586"
     ]
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Axis]",
        "label": "Hedging Relationship [Axis]",
        "documentation": "Information by type of hedging relationship."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r111",
      "r115"
     ]
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r111",
      "r115",
      "r117",
      "r122",
      "r123",
      "r808"
     ]
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain/(Loss) Reclassified from Accumulated OCI Into Income",
        "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred",
        "documentation": "The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsInHedgesAssetsAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives designated as hedging instruments : Assets",
        "label": "Derivative Instruments in Hedges, Assets, at Fair Value",
        "documentation": "Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsInHedgesLiabilitiesAtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives designated as hedging instruments : Liabilities",
        "label": "Derivative Instruments in Hedges, Liabilities, at Fair Value",
        "documentation": "Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Net Liabilities",
        "label": "Derivative Liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r823",
      "r824",
      "r837",
      "r846",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1072",
      "r1074",
      "r1075",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1118",
      "r1119",
      "r1152",
      "r1575",
      "r1576",
      "r1577",
      "r1647"
     ]
    },
    "us-gaap_DerivativeLiabilityFairValueGrossAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilityFairValueGrossAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Credit Support Agreements (CSA)",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, Asset Offset",
        "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r33",
      "r228",
      "r229",
      "r1116",
      "r1117",
      "r1151"
     ]
    },
    "jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Liability, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag",
        "label": "Derivative Liability, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag",
        "documentation": "Derivative Liability, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLineItems",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative [Line Items]",
        "label": "Derivative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "us-gaap_DerivativeNotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeNotionalAmount",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative, notional amount",
        "label": "Derivative, Notional Amount",
        "documentation": "Nominal or face amount used to calculate payment on derivative."
       }
      }
     },
     "auth_ref": [
      "r1566",
      "r1567"
     ]
    },
    "us-gaap_DerivativeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeTable",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative [Table]",
        "label": "Derivative [Table]",
        "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r104",
      "r105",
      "r106",
      "r109",
      "r112",
      "r115",
      "r119",
      "r121",
      "r123",
      "r818"
     ]
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesFairValueLineItems",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives, Fair Value [Line Items]",
        "label": "Derivatives, Fair Value [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instruments",
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r104",
      "r105",
      "r109",
      "r120",
      "r373",
      "r388"
     ]
    },
    "us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DescriptionOfReclassificationOfCashFlowHedgeGainLoss",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of reclassification of cash flow hedge gain (loss)",
        "label": "Description of Reclassification of Cash Flow Hedge Gain (Loss)",
        "documentation": "Description of the transactions or other events that will result in the reclassification into earnings of gains or losses reported in accumulated other comprehensive income. May include the time period over which gains or losses will be reclassified to earnings."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DesignatedAsHedgingInstrumentMember",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Designated as Hedging Instrument",
        "label": "Designated as Hedging Instrument [Member]",
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.jnj.com/role/Commonstockstockoptionplansandstockcompensationagreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, stock option plans and stock compensation agreements",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r709",
      "r737",
      "r738",
      "r740",
      "r1198"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "(Gain) on separation of Kenvue",
        "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax",
        "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r132",
      "r134",
      "r145"
     ]
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings from Discontinued Operations Before Provision for Taxes on Income",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r140",
      "r178",
      "r1611"
     ]
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net earnings per share from discontinued operations (in dollars per share)",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share",
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net earnings per share from discontinuing operations (in dollars per share)",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share",
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_DiscontinuedOperationIncrementalTaxCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DiscontinuedOperationIncrementalTaxCost",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental tax cost",
        "label": "Discontinued Operation, Incremental Tax Cost",
        "documentation": "Discontinued Operation, Incremental Tax Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for taxes on income",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r134",
      "r140",
      "r145",
      "r752",
      "r782",
      "r784"
     ]
    },
    "jnj_DiscontinuedOperationTransitionManufacturingAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DiscontinuedOperationTransitionManufacturingAgreementTerm",
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transition manufacturing agreement, term",
        "label": "Discontinued Operation, Transition Manufacturing Agreement, Term",
        "documentation": "Discontinued Operation, Transition Manufacturing Agreement, Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_DiscontinuedOperationsSeparationCostsIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DiscontinuedOperationsSeparationCostsIncurred",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Separation costs incurred",
        "label": "Discontinued Operations, Separation Costs Incurred",
        "documentation": "Discontinued Operations, Separation Costs Incurred"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_DiscontinuedOperationsTransitionServiceAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DiscontinuedOperationsTransitionServiceAgreementTerm",
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transition service agreement, term",
        "label": "Discontinued Operations, Transition Service Agreement, Term",
        "documentation": "Discontinued Operations, Transition Service Agreement, Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of products sold",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r313"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDepreciationandAmortizationofDiscontinuedOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and Amortization",
        "label": "Disposal Group, Including Discontinued Operation, Depreciation and Amortization",
        "documentation": "Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, marketing and administrative expenses",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Disposal Group, Including Discontinued Operation, Gross Profit (Loss)",
        "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r313"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense, net of portion capitalized",
        "label": "Disposal Group, Including Discontinued Operation, Interest Expense",
        "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r38",
      "r141"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest Income",
        "label": "Disposal Group, Including Discontinued Operation, Interest Income",
        "documentation": "Amount of interest income attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "jnj_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other (income) expense, net",
        "label": "Disposal Group, Including Discontinued Operation, Other Income (Expense), Net",
        "documentation": "Disposal Group, Including Discontinued Operation, Other Income (Expense), Net"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expense",
        "label": "Disposal Group, Including Discontinued Operation, Research and Development Expense",
        "documentation": "Disposal Group, Including Discontinued Operation, Research and Development Expense"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_DisposalGroupIncludingDiscontinuedOperationRestructuringExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "DisposalGroupIncludingDiscontinuedOperationRestructuringExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring",
        "label": "Disposal Group, Including Discontinued Operation, Restructuring Expense",
        "documentation": "Disposal Group, Including Discontinued Operation, Restructuring Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales to customers",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r313"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://www.jnj.com/role/Kenvueseparationanddiscontinuedoperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kenvue separation and discontinued operations",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r199"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Domain]",
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r1191",
      "r1194"
     ]
    },
    "us-gaap_DividendsCommonStockCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DividendsCommonStockCash",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash dividends paid",
        "label": "Dividends, Common Stock, Cash",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "us-gaap_DividendsPayableAmountPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DividendsPayableAmountPerShare",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends payable, amount per share (in dollars per share)",
        "label": "Dividends Payable, Amount Per Share",
        "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r1265",
      "r1266",
      "r1289"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r1265",
      "r1266",
      "r1289",
      "r1332"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1310"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r1263"
     ]
    },
    "us-gaap_DomesticPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticPlanMember",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic Plan",
        "label": "Domestic Plan [Member]",
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r1514",
      "r1515",
      "r1516"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1321"
     ]
    },
    "jnj_EDURANTrilpivirineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "EDURANTrilpivirineMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EDURANT/rilpivirine",
        "label": "EDURANT/rilpivirine [Member]",
        "documentation": "EDURANT/rilpivirine [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ELECTROPHYSIOLOGYMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ELECTROPHYSIOLOGYMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ELECTROPHYSIOLOGY",
        "label": "ELECTROPHYSIOLOGY [Member]",
        "documentation": "ELECTROPHYSIOLOGY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net earnings per share",
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "calculation": {
      "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Basic (in dollars per share)",
        "verboseLabel": "Basic net earnings per share (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r391",
      "r393",
      "r399",
      "r400",
      "r401",
      "r406",
      "r791",
      "r799",
      "r820",
      "r821",
      "r955",
      "r981",
      "r1158"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Diluted (in dollars per share)",
        "terseLabel": "Diluted net earnings per share (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r393",
      "r399",
      "r400",
      "r401",
      "r406",
      "r791",
      "r799",
      "r820",
      "r821",
      "r955",
      "r981",
      "r1158"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net earnings per share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r403"
     ]
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareReconciliationAbstract",
     "presentation": [
      "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reconciliation of basic net earnings per share to diluted net earnings per share",
        "label": "Earnings Per Share Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.jnj.com/role/Earningspershare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Earnings per share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r402",
      "r404",
      "r405"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "jnj_EffectOfExchangeRates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "EffectOfExchangeRates",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rates",
        "label": "Effect Of Exchange Rates",
        "documentation": "Effect Of Exchange Rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective Rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r1203"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax rates:",
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r754",
      "r780",
      "r1203"
     ]
    },
    "jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. tax settlements",
        "label": "Effective Income Tax Rate Reconciliation, Consumer Health Separation",
        "documentation": "Effective Income Tax Rate Reconciliation, Consumer Health Separation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International operations",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r755",
      "r758",
      "r1203",
      "r1422",
      "r1544"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationGiltiAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective income tax rate reconciliation, GILTI, amount",
        "label": "Effective Income Tax Rate Reconciliation, GILTI, Amount",
        "documentation": "Amount of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI)."
       }
      }
     },
     "auth_ref": [
      "r1203",
      "r1544",
      "r1546"
     ]
    },
    "jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective income tax rate reconciliation, increase (decrease), percent",
        "label": "Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax benefits on share-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1203",
      "r1422",
      "r1544",
      "r1546"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1203",
      "r1422",
      "r1544",
      "r1545"
     ]
    },
    "jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. taxes on international income",
        "label": "Effective Income Tax Rate Reconciliation Related To Domestic Tax On International Income",
        "documentation": "Effective income tax rate reconciliation related to domestic tax on international income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. state taxes",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r757",
      "r1203",
      "r1422",
      "r1544"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsForeign",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in foreign tax credits, percent",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit."
       }
      }
     },
     "auth_ref": [
      "r1422",
      "r1544",
      "r1546"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective income tax rate reconciliation, tax settlement, percent",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements."
       }
      }
     },
     "auth_ref": [
      "r1422",
      "r1544",
      "r1545"
     ]
    },
    "jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective tax rate reconciliation, net increase (decrease) in tax rate, percent",
        "label": "Effective Tax Rate Reconciliation, Net Increase (Decrease) In Tax Rate, Percent",
        "documentation": "Effective Tax Rate Reconciliation, Net Increase (Decrease) In Tax Rate, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ElmironMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ElmironMember",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Elmiron",
        "label": "Elmiron [Member]",
        "documentation": "Elmiron"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_EmployeeCompensationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "EmployeeCompensationPeriod",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement plan benefits employee compensation period",
        "label": "Employee Compensation Period",
        "documentation": "Employee Compensation Period."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_EmployeeObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "EmployeeObligations",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total employee obligations",
        "label": "Employee Obligations",
        "documentation": "Total employee obligations current and non current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued compensation and employee related obligations",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract",
     "presentation": [
      "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee-related Liabilities [Abstract]",
        "label": "Employee-related Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_EmployeeRelatedObligationsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "EmployeeRelatedObligationsTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/EmployeerelatedobligationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Related Obligations",
        "label": "Employee Related Obligations [Table Text Block]",
        "documentation": "Employee related obligations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total compensation cost not yet recognized for option",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average period for total compensation cost not yet recognized",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total income tax benefit recognized",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of options, tax benefit",
        "label": "Share-Based Payment Arrangement, Exercise of Option, Tax Benefit",
        "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1262"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails",
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1262"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1262"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1372"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1262"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1262"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1262"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1262"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1373"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1315"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1368"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r1368"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1368"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityClassOfTreasuryStockLineItems",
     "presentation": [
      "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity, Class of Treasury Stock [Line Items]",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails",
      "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r309",
      "r355",
      "r356",
      "r357",
      "r375",
      "r376",
      "r377",
      "r379",
      "r384",
      "r386",
      "r388",
      "r408",
      "r491",
      "r492",
      "r536",
      "r617",
      "r778",
      "r779",
      "r788",
      "r789",
      "r790",
      "r792",
      "r798",
      "r799",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r819",
      "r858",
      "r860",
      "r861",
      "r862",
      "r863",
      "r865",
      "r871",
      "r873",
      "r882",
      "r978",
      "r1007",
      "r1008",
      "r1009",
      "r1027",
      "r1099"
     ]
    },
    "us-gaap_EquityFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityFairValueAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity, fair value adjustment",
        "label": "Equity, Fair Value Adjustment",
        "documentation": "Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_EquityFairValueAdjustmentChangeinObservablePrices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "EquityFairValueAdjustmentChangeinObservablePrices",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity, fair value adjustment, change in observable prices",
        "label": "Equity, Fair Value Adjustment, Change in Observable Prices",
        "documentation": "Equity, Fair Value Adjustment, Change in Observable Prices"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_EquityFairValueAdjustmentImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "EquityFairValueAdjustmentImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity, fair value adjustment, impairment loss",
        "label": "Equity, Fair Value Adjustment, Impairment Loss",
        "documentation": "Equity, Fair Value Adjustment, Impairment Loss"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_EquityInvestmentRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "EquityInvestmentRollForward",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Investment [Roll Forward]",
        "label": "Equity Investment [Roll Forward]",
        "documentation": "Equity Investment [Roll Forward]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity investments, increase (decrease) from acquisition (sale) during period",
        "label": "Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period",
        "documentation": "Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_EquityInvestmentswithReadilyDeterminableValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "EquityInvestmentswithReadilyDeterminableValueMember",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Investments with readily determinable value",
        "label": "Equity Investments with Readily Determinable Value [Member]",
        "documentation": "Equity Investments with Readily Determinable Value [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_EquityInvestmentswithoutReadilyDeterminableValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "EquityInvestmentswithoutReadilyDeterminableValueMember",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Investments without readily determinable value",
        "label": "Equity Investments without Readily Determinable Value [Member]",
        "documentation": "Equity Investments without Readily Determinable Value [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]",
        "documentation": "Name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r488",
      "r489",
      "r787",
      "r1376",
      "r1377",
      "r1378",
      "r1558",
      "r1559",
      "r1560",
      "r1561"
     ]
    },
    "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realized gain (loss) on investment",
        "label": "Equity Method Investment, Realized Gain (Loss) on Disposal",
        "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment."
       }
      }
     },
     "auth_ref": [
      "r1410",
      "r1411",
      "r1415"
     ]
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity investments",
        "label": "Equity Securities, FV-NI, Current",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r845",
      "r1148"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities, fair market value",
        "label": "Equity Securities, FV-NI",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r823",
      "r845",
      "r962",
      "r963",
      "r1206",
      "r1237",
      "r1240",
      "r1575",
      "r1576",
      "r1577"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Equity securities, FV-NI, gain (loss)",
        "terseLabel": "Equity securities, FV-NI, gain (loss)",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r983",
      "r1456"
     ]
    },
    "us-gaap_EquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesMember",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities",
        "label": "Equity Securities [Member]",
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r1220",
      "r1251",
      "r1252",
      "r1253",
      "r1650"
     ]
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities without readily determinable fair value, amount",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "documentation": "Amount of investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1325"
     ]
    },
    "jnj_ErleadaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ErleadaMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ERLEADA",
        "label": "Erleada [Member]",
        "documentation": "Erleada"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1282",
      "r1293",
      "r1303",
      "r1336"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r1279",
      "r1290",
      "r1300",
      "r1333"
     ]
    },
    "jnj_EstimatedUsefulLivesOfAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "EstimatedUsefulLivesOfAssetsTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Useful Lives of Assets",
        "label": "Estimated Useful Lives Of Assets [Table Text Block]",
        "documentation": "Estimated useful lives of the assets."
       }
      }
     },
     "auth_ref": []
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EuropeMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Europe",
        "label": "Europe [Member]",
        "documentation": "Continent of Europe."
       }
      }
     },
     "auth_ref": [
      "r1396",
      "r1397",
      "r1398",
      "r1399",
      "r1649",
      "r1651",
      "r1652",
      "r1653"
     ]
    },
    "jnj_ExcessOfCarryingValueOverFairValueOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ExcessOfCarryingValueOverFairValueOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excess of carrying value over fair value of debt",
        "label": "Excess Of Carrying Value Over Fair Value Of Debt",
        "documentation": "Excess Of Carrying Value Over Fair Value Of Debt"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ExcessOfFairValueOverCarryingValueOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ExcessOfFairValueOverCarryingValueOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excess of fair value over carrying value of debt",
        "label": "Excess Of Fair Value Over Carrying Value Of Debt",
        "documentation": "Excess of fair value over carrying value of debt."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ExchangeOfStockCommonStockValueReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ExchangeOfStockCommonStockValueReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock received in exchange offer",
        "label": "Exchange Of Stock, Common Stock, Value, Received",
        "documentation": "Exchange Of Stock, Common Stock, Value, Received"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ExchangeOfStockPercentageOwnershipAfterTransaction": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ExchangeOfStockPercentageOwnershipAfterTransaction",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails",
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage ownership after transaction",
        "label": "Exchange of Stock, Percentage Ownership After Transaction",
        "documentation": "Exchange of Stock, Percentage Ownership After Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1331"
     ]
    },
    "jnj_ExercisePriceRangeFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ExercisePriceRangeFiveMember",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$164.62 - $165.89",
        "label": "Exercise Price Range Five [Member]",
        "documentation": "Exercise Price Range."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ExercisePriceRangeFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ExercisePriceRangeFourMember",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$157.92 - $162.75",
        "label": "Exercise Price Range Four [Member]",
        "documentation": "Exercise Price Range."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ExercisePriceRangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ExercisePriceRangeOneMember",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$100.06 - $101.87",
        "label": "Exercise Price Range One Member",
        "documentation": "Exercise price range."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ExercisePriceRangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ExercisePriceRangeThreeMember",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$131.94 - $151.41",
        "label": "Exercise Price Range Three [Member]",
        "documentation": "Exercise Price Range."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ExercisePriceRangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ExercisePriceRangeTwoMember",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$115.67 - $129.51",
        "label": "Exercise Price Range Two [Member]",
        "documentation": "Exercise Price Range."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Domain]",
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r838",
      "r1208"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Axis]",
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r838",
      "r1208"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r822",
      "r824",
      "r825",
      "r826",
      "r827",
      "r836",
      "r837",
      "r839",
      "r887",
      "r888",
      "r889",
      "r1179",
      "r1180",
      "r1187",
      "r1188",
      "r1189",
      "r1206",
      "r1210"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r823",
      "r824",
      "r825",
      "r827",
      "r1206",
      "r1576",
      "r1587"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.jnj.com/role/Fairvaluemeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r834",
      "r835",
      "r836",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r950",
      "r1206",
      "r1211"
     ]
    },
    "us-gaap_FairValueHedgingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueHedgingMember",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hedging",
        "label": "Fair Value Hedging [Member]",
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r650",
      "r655",
      "r824",
      "r837",
      "r887",
      "r1187",
      "r1188",
      "r1189",
      "r1206"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r650",
      "r655",
      "r824",
      "r825",
      "r837",
      "r888",
      "r1179",
      "r1180",
      "r1187",
      "r1188",
      "r1189",
      "r1206"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r824",
      "r825",
      "r826",
      "r827",
      "r837",
      "r889",
      "r1179",
      "r1180",
      "r1187",
      "r1188",
      "r1189",
      "r1206",
      "r1210"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r823",
      "r824",
      "r825",
      "r827",
      "r1206",
      "r1576",
      "r1587"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments/Other",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r831",
      "r838"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r828",
      "r838"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r822",
      "r824",
      "r825",
      "r826",
      "r827",
      "r836",
      "r837",
      "r839",
      "r887",
      "r888",
      "r889",
      "r1179",
      "r1180",
      "r1187",
      "r1188",
      "r1189",
      "r1206",
      "r1210"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r1206",
      "r1573",
      "r1574",
      "r1575",
      "r1576",
      "r1577",
      "r1587"
     ]
    },
    "jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in estimated fair value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value",
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of company's common stock directly held in plan assets",
        "label": "Fair Value Of Company's Common Stock Directly Held In Plan Assets",
        "documentation": "Fair value of company's common stock directly held in plan assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "documentation": "Disclosure of information about location and fair value of derivative instrument and nonderivative instrument designated as hedging instrument."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r112",
      "r122"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r494",
      "r495",
      "r497",
      "r498",
      "r499",
      "r501",
      "r502",
      "r503",
      "r607",
      "r615",
      "r818",
      "r844",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r979",
      "r1173",
      "r1206",
      "r1208",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1220",
      "r1388",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1393",
      "r1394",
      "r1452",
      "r1453",
      "r1454",
      "r1455",
      "r1572",
      "r1575",
      "r1576",
      "r1577",
      "r1584",
      "r1587"
     ]
    },
    "jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]",
        "documentation": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleassetsandgoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets useful life",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less accumulated amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r507",
      "r527",
      "r1175"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwillEstimatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r1141",
      "r1175"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Asset Amortization Expense",
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwillEstimatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r1141",
      "r1175"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwillEstimatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r1141",
      "r1175"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwillEstimatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r1141",
      "r1175"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwillEstimatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r1141",
      "r1175"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleassetsandgoodwillNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r522",
      "r523",
      "r524",
      "r526",
      "r527",
      "r531",
      "r532",
      "r918",
      "r919",
      "r1141"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finite lived intangible assets gross",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r527",
      "r919",
      "r1175"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r527",
      "r531",
      "r532",
      "r535",
      "r918",
      "r1141",
      "r1175"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleassetsandgoodwillNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r522",
      "r523",
      "r524",
      "r526",
      "r527",
      "r531",
      "r532",
      "r1141"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Finite lived intangible assets net",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r918",
      "r1479"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets with definite lives:",
        "label": "Finite-Lived Intangible Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-lived intangible assets acquired",
        "label": "Finite-Lived Intangible Assets Acquired",
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "jnj_FiscalPeriodPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "FiscalPeriodPolicyTextBlock",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual closing date",
        "label": "Fiscal Period [Policy Text Block]",
        "documentation": "Fiscal period policy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives not designated as hedging instruments : Assets",
        "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value",
        "documentation": "Fair value as of the balance sheet date of all foreign currency derivative assets not designated as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives not designated as hedging instruments : Liabilities",
        "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value",
        "documentation": "Fair value as of the balance sheet date of all foreign currency derivative liabilities not designated as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_ForeignCurrencyDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyDisclosureTextBlock",
     "presentation": [
      "http://www.jnj.com/role/Internationalcurrencytranslation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International currency translation",
        "label": "Foreign Currency Disclosure [Text Block]",
        "documentation": "The entire disclosure for foreign currency transactions and translation. This may include description of foreign currency transactions, foreign currency gains and losses, explanation of change in cumulative translation adjustment, description of effect of subsequent foreign currency exchange rate change, cumulative translation adjustment movement, foreign currency translation adjustment by component movement, translation adjustment for net investment hedge movement, adjustment for long-term intercompany transactions, schedule of long-term intercompany balances and any other foreign currency transactions and translation related items."
       }
      }
     },
     "auth_ref": [
      "r848",
      "r867",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1379"
     ]
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency exchange rate, translation",
        "label": "Foreign Currency Exchange Rate, Translation",
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r867"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/InternationalcurrencytranslationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency transaction gain (loss), before tax",
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r851",
      "r853",
      "r855",
      "r1096"
     ]
    },
    "us-gaap_ForeignCurrencyTranslationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTranslationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Translation [Abstract]",
        "label": "Foreign Currency Translation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignExchangeContractMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignExchangeContractMember",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange contracts",
        "verboseLabel": "Forward foreign exchange contracts:",
        "label": "Foreign Exchange Contract [Member]",
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates."
       }
      }
     },
     "auth_ref": [
      "r1152",
      "r1187",
      "r1205",
      "r1206"
     ]
    },
    "us-gaap_ForeignPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignPlanMember",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International Plans",
        "label": "Foreign Plan [Member]",
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r1514",
      "r1515",
      "r1516"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1286",
      "r1297",
      "r1307",
      "r1340"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1286",
      "r1297",
      "r1307",
      "r1340"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1286",
      "r1297",
      "r1307",
      "r1340"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1286",
      "r1297",
      "r1307",
      "r1340"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1286",
      "r1297",
      "r1307",
      "r1340"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1320"
     ]
    },
    "jnj_FundedPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "FundedPlansMember",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Funded Plans",
        "label": "Funded Plans [Member]",
        "documentation": "Funded plans."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_GENERALMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "GENERALMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GENERAL",
        "label": "GENERAL [Member]",
        "documentation": "GENERAL [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfBusiness",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) on divestiture",
        "label": "Gain (Loss) on Disposition of Business",
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant."
       }
      }
     },
     "auth_ref": [
      "r803",
      "r1415"
     ]
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net gain on sale of assets/businesses",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value."
       }
      }
     },
     "auth_ref": [
      "r1415"
     ]
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossRelatedToLitigationSettlement",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) related to litigation settlement",
        "label": "Gain (Loss) from Litigation Settlement",
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process."
       }
      }
     },
     "auth_ref": [
      "r1166",
      "r1489"
     ]
    },
    "jnj_GeneralCorporateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "GeneralCorporateMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General Corporate",
        "label": "General Corporate [Member]",
        "documentation": "General corporate member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "periodStartLabel": "Goodwill beginning of period",
        "periodEndLabel": "Goodwill end of period",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r508",
      "r951",
      "r1167",
      "r1174",
      "r1207",
      "r1219",
      "r1462",
      "r1469"
     ]
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAcquiredDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill, related to acquisitions",
        "label": "Goodwill, Acquired During Period",
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r1174"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.jnj.com/role/Intangibleassetsandgoodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets and goodwill",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1460",
      "r1472"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets and goodwill",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1460",
      "r1472"
     ]
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Line Items]",
        "label": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r1174"
     ]
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillOtherIncreaseDecrease",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation/other",
        "label": "Goodwill, Other Increase (Decrease)",
        "documentation": "Amount of increase (decrease) of asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized, classified as other."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill, measurement period adjustment",
        "label": "Goodwill, Measurement Period Adjustment",
        "documentation": "Amount of increase (decrease) from measurement period adjustment of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1468"
     ]
    },
    "us-gaap_GoodwillRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillRollForward",
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Roll Forward]",
        "label": "Goodwill [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Goodwill, related to divestitures",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "documentation": "Amount of divestiture of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r1174"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r181",
      "r248",
      "r370",
      "r490",
      "r571",
      "r572",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r580",
      "r581",
      "r847",
      "r1160",
      "r1166",
      "r1431",
      "r1433",
      "r1435",
      "r1436",
      "r1437",
      "r1496"
     ]
    },
    "jnj_HIPSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "HIPSMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "HIPS",
        "label": "HIPS [Member]",
        "documentation": "HIPS [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability",
        "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)",
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_HedgingDesignationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HedgingDesignationAxis",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Axis]",
        "label": "Hedging Designation [Axis]",
        "documentation": "Information by designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r808"
     ]
    },
    "us-gaap_HedgingDesignationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HedgingDesignationDomain",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Domain]",
        "label": "Hedging Designation [Domain]",
        "documentation": "Designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_HedgingRelationshipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HedgingRelationshipDomain",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Domain]",
        "label": "Hedging Relationship [Domain]",
        "documentation": "Nature or intent of a hedge."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_HeldToMaturitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying Amount, held-to-maturity",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss",
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r468",
      "r497",
      "r1458"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Held-to-maturity, unrecognized gain",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain",
        "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r478"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Held-to-maturity, unrecognized loss",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r479"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecuritiesFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value, held-to-maturity",
        "label": "Debt Securities, Held-to-Maturity, Fair Value",
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r477",
      "r824",
      "r836",
      "r952",
      "r964"
     ]
    },
    "us-gaap_HeldtomaturitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldtomaturitySecuritiesMember",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Held-to-maturity Securities",
        "label": "Held-to-Maturity Securities [Member]",
        "documentation": "Investments in debt securities classified as held-to-maturity."
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "jnj_IMBRUVICAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "IMBRUVICAMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IMBRUVICA",
        "label": "IMBRUVICA [Member]",
        "documentation": "IMBRUVICA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "INVEGASUSTENNAXEPLIONTRINZATREVICTAMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA",
        "label": "INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]",
        "documentation": "INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPO",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r1265",
      "r1266",
      "r1289"
     ]
    },
    "jnj_ImmunologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ImmunologyMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Immunology",
        "label": "Immunology [Member]",
        "documentation": "Immunology [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of intangible asset. Includes, but is not limited to, finite-lived and indefinite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets, excluding goodwill",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r521",
      "r533"
     ]
    },
    "jnj_ImpellaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ImpellaMember",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impella",
        "label": "Impella [Member]",
        "documentation": "Impella"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InProcessResearchAndDevelopmentMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In Process Research and Development",
        "label": "In Process Research and Development [Member]",
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process."
       }
      }
     },
     "auth_ref": [
      "r1473",
      "r1474",
      "r1475",
      "r1476",
      "r1477",
      "r1478",
      "r1479",
      "r1480",
      "r1481",
      "r1482"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net earnings from continuing operations",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r177",
      "r195",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r398",
      "r401",
      "r799"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r753"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings before provision for taxes on income",
        "terseLabel": "Earnings before provision for taxes on income",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r242",
      "r248",
      "r956",
      "r976",
      "r1160",
      "r1166",
      "r1431",
      "r1433",
      "r1435",
      "r1436",
      "r1437"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r753"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net earnings per share from continuing operations (in dollars per share)",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r243",
      "r360",
      "r378",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r393",
      "r399",
      "r400",
      "r791",
      "r799",
      "r821",
      "r955",
      "r1612"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net earnings per share from continuing operations (in dollars per share)",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r360",
      "r378",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r393",
      "r399",
      "r400",
      "r401",
      "r799",
      "r821",
      "r955",
      "r1612"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net earnings from Discontinued Operations",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r140",
      "r145",
      "r227"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net earnings from discontinued operations",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r140",
      "r145",
      "r227"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Axis]",
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r1191",
      "r1194"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r26",
      "r37",
      "r129",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r144",
      "r146",
      "r147",
      "r203"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r544",
      "r555",
      "r829",
      "r833",
      "r838",
      "r1004",
      "r1006",
      "r1083",
      "r1141",
      "r1209",
      "r1616"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r555",
      "r829",
      "r833",
      "r838",
      "r1004",
      "r1006",
      "r1083",
      "r1141",
      "r1209",
      "r1616"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Axis]",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r754",
      "r755",
      "r762",
      "r774",
      "r1203",
      "r1553"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Domain]",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r754",
      "r755",
      "r762",
      "r774",
      "r1203",
      "r1553"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.jnj.com/role/Incometaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r746",
      "r754",
      "r759",
      "r760",
      "r761",
      "r768",
      "r773",
      "r781",
      "r783",
      "r785",
      "r786",
      "r1025",
      "r1203"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for taxes on income",
        "totalLabel": "Provision for taxes on income",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r268",
      "r387",
      "r388",
      "r407",
      "r423",
      "r444",
      "r752",
      "r754",
      "r782",
      "r984",
      "r1203"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r748",
      "r749",
      "r768",
      "r769",
      "r772",
      "r776",
      "r1019"
     ]
    },
    "us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationRepatriationOfForeignEarnings",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repatriation of foreign earnings amount",
        "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings."
       }
      }
     },
     "auth_ref": [
      "r1544",
      "r1545"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxCreditsForeign",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in foreign tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit."
       }
      }
     },
     "auth_ref": [
      "r1544",
      "r1546"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes, inclusive of discontinued operations",
        "label": "Income Taxes Paid",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r194",
      "r1417",
      "r1551",
      "r1552"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Increase in accounts payable and accrued liabilities",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Increase in accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in deferred tax liabilities, global intangible low-taxed income (GILTI)",
        "label": "Increase (Decrease) in Deferred Tax Liabilities, Global Intangible Low-Taxed Income (GILTI)",
        "documentation": "Increase (Decrease) in Deferred Tax Liabilities, Global Intangible Low-Taxed Income (GILTI)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Increase in inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Changes in assets and liabilities, net of effects from acquisitions and divestitures:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease/(Increase) in other current and non-current assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Increase/(Decrease) in other current and non-current liabilities",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential shares exercisable under stock option plans (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r395",
      "r396",
      "r401",
      "r708"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Indefinite-lived Intangible Assets by Major Class [Axis]",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r525",
      "r530",
      "r1175"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Indefinite lived intangible assets",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r530",
      "r1175"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets with indefinite lives:",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r525",
      "r530",
      "r1175"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1286",
      "r1297",
      "r1307",
      "r1331",
      "r1340",
      "r1344",
      "r1352"
     ]
    },
    "jnj_InfectiousDiseasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "InfectiousDiseasesMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Infectious Diseases",
        "label": "Infectious Diseases [Member]",
        "documentation": "Infectious Diseases [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InformationByCategoryOfDebtSecurityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InformationByCategoryOfDebtSecurityAxis",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Security Category [Axis]",
        "label": "Debt Security Category [Axis]",
        "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Information Related to the Benefit Obligation and the Fair Value of Plan Assets",
        "label": "Information Related To Benefit Obligation And Fair Value Of Plan Assets [Table Text Block]",
        "documentation": "Information related to the benefit obligation and the fair value of plan assets."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_InghamVsJohnsonJohnsonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "InghamVsJohnsonJohnsonMember",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ingham vs. Johnson &amp; Johnson",
        "label": "Ingham vs. Johnson &amp; Johnson [Member]",
        "documentation": "Ingham vs. Johnson &amp; Johnson"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_InnovativeMedicineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "InnovativeMedicineMember",
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Innovative Medicine",
        "label": "Innovative Medicine [Member]",
        "documentation": "Innovative Medicine"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1350"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1267",
      "r1356"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1267",
      "r1356"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1267",
      "r1356"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets, net",
        "totalLabel": "Total intangible assets - net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r1479",
      "r1480"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets and Goodwill",
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestCostsCapitalized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestCostsCapitalized",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/PropertyplantandequipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense capitalized",
        "label": "Interest Costs Capitalized",
        "documentation": "Amount of interest capitalized during the period."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense, net of portion capitalized",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r1412"
     ]
    },
    "jnj_InterestIncomeExpenseNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "InterestIncomeExpenseNetMember",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest (Income) Expense",
        "label": "Interest Income Expense Net Member",
        "documentation": "Interest Income Expense Net Member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest",
        "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities",
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities."
       }
      }
     },
     "auth_ref": [
      "r1416"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest, net of amount capitalized",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r364",
      "r365"
     ]
    },
    "us-gaap_InterestRateContractMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestRateContractMember",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate swaps contracts:",
        "label": "Interest Rate Contract [Member]",
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate."
       }
      }
     },
     "auth_ref": [
      "r1143",
      "r1152",
      "r1187",
      "r1206"
     ]
    },
    "us-gaap_InterestRateSwapMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestRateSwapMember",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Swap",
        "label": "Interest Rate Swap [Member]",
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period."
       }
      }
     },
     "auth_ref": [
      "r1143",
      "r1248",
      "r1249"
     ]
    },
    "jnj_IntraCellularTherapiesInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "IntraCellularTherapiesInc.Member",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intra-Cellular Therapies, Inc.",
        "label": "Intra-Cellular Therapies, Inc. [Member]",
        "documentation": "Intra-Cellular Therapies, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory Disclosure [Abstract]",
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.jnj.com/role/Inventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventories",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r1149"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.jnj.com/role/InventoriesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventories",
        "totalLabel": "Total inventories",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r1147",
      "r1219"
     ]
    },
    "us-gaap_InventoryNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNetAbstract",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Inventories",
        "label": "Inventory, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r316",
      "r333",
      "r504",
      "r505",
      "r506",
      "r916",
      "r1155"
     ]
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Raw materials and supplies",
        "label": "Inventory, Raw Materials and Supplies, Net of Reserves",
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r1404"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goods in process",
        "label": "Inventory, Work in Process, Net of Reserves",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r1150"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r418",
      "r444",
      "r1166",
      "r1409"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r982",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1104",
      "r1105"
     ]
    },
    "jnj_JohnsonJohnsonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "JohnsonJohnsonMember",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails",
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Johnson &amp; Johnson",
        "label": "Johnson &amp; Johnson [Member]",
        "documentation": "Johnson &amp; Johnson"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_JudicialRulingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "JudicialRulingMember",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Judicial Ruling",
        "label": "Judicial Ruling [Member]",
        "documentation": "Litigation outcome that occurs as a result of judicial intervention, supervision, or approval."
       }
      }
     },
     "auth_ref": [
      "r1489"
     ]
    },
    "jnj_KNEESMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "KNEESMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "KNEES",
        "label": "KNEES [Member]",
        "documentation": "KNEES [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_KenvueIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "KenvueIncMember",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails",
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kenvue Inc.",
        "label": "Kenvue Inc. [Member]",
        "documentation": "Kenvue Inc."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_LaminarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "LaminarMember",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laminar",
        "label": "Laminar [Member]",
        "documentation": "Laminar"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_LandAndLeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "LandAndLeaseholdImprovementsMember",
     "presentation": [
      "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land and leasehold improvements",
        "label": "Land And Leasehold Improvements [Member]",
        "documentation": "Land and leasehold improvements."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails",
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LegalMattersAndContingenciesTextBlock",
     "presentation": [
      "http://www.jnj.com/role/Legalproceedings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Legal proceedings",
        "label": "Legal Matters and Contingencies [Text Block]",
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "jnj_LegalProceedingTextualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "LegalProceedingTextualsAbstract",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Proceeding (Textuals)",
        "label": "Legal Proceeding (Textuals) [Abstract]",
        "documentation": "Legal Proceeding Textuals Abstract."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r151",
      "r152",
      "r153",
      "r156",
      "r157",
      "r158",
      "r159",
      "r370",
      "r490",
      "r571",
      "r572",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r580",
      "r581",
      "r801",
      "r804",
      "r805",
      "r847",
      "r1056",
      "r1159",
      "r1256",
      "r1496",
      "r1593",
      "r1594"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and shareholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r240",
      "r972",
      "r1219",
      "r1420",
      "r1457",
      "r1588"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Liabilities and Shareholders\u2019 Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r315",
      "r370",
      "r490",
      "r571",
      "r572",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r580",
      "r581",
      "r801",
      "r804",
      "r805",
      "r847",
      "r1219",
      "r1496",
      "r1593",
      "r1594"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current liabilities",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowing capacity under credit facility",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r155"
     ]
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesNarrativeDetails",
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Axis]",
        "label": "Litigation Case [Axis]",
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesNarrativeDetails",
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case Type [Domain]",
        "label": "Litigation Case [Domain]",
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_LitigationSettlementByCompaniesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "LitigationSettlementByCompaniesAxis",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Settlement By Companies",
        "label": "Litigation Settlement By Companies [Axis]",
        "documentation": "Litigation settlement by companies."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_LitigationSettlementByCompaniesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "LitigationSettlementByCompaniesDomain",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Settlement By Companies",
        "label": "Litigation Settlement By Companies [Domain]",
        "documentation": "Litigation settlement by companies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LitigationSettlementExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation expense",
        "label": "Litigation Settlement, Fee Expense",
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees."
       }
      }
     },
     "auth_ref": [
      "r1387"
     ]
    },
    "us-gaap_LitigationStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LitigationStatusAxis",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Status [Axis]",
        "label": "Litigation Status [Axis]",
        "documentation": "Information by status of pending, threatened, or settled litigation."
       }
      }
     },
     "auth_ref": [
      "r1483",
      "r1484",
      "r1485",
      "r1489"
     ]
    },
    "us-gaap_LitigationStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LitigationStatusDomain",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Status [Domain]",
        "label": "Litigation Status [Domain]",
        "documentation": "Status of pending, threatened, or settled litigation."
       }
      }
     },
     "auth_ref": [
      "r1483",
      "r1484",
      "r1485",
      "r1489"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermCommercialPaperCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermCommercialPaperCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowed under the commercial paper program",
        "label": "Long-Term Commercial Paper, Current",
        "documentation": "Carrying value as of the balance sheet date of the current portion of long-term unsecured obligations issued by corporations and other borrowers to investors (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152"
     ]
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Long-term debt",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r238",
      "r595",
      "r609",
      "r1179",
      "r1180",
      "r1217",
      "r1610"
     ]
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtByMaturityAbstract",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate maturities of long-term obligations",
        "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less current portion",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After 2029",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r374",
      "r1499"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r374",
      "r600"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Long-Term Debt, Maturity, Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r374",
      "r600"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r374",
      "r600"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r374",
      "r600"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r374",
      "r600"
     ]
    },
    "us-gaap_LongTermDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMember",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt",
        "label": "Long-Term Debt [Member]",
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "verboseLabel": "Total long-term debt",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails",
      "http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r564",
      "r565",
      "r568",
      "r742",
      "r1177",
      "r1490",
      "r1492"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails",
      "http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Product Liability Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r564",
      "r565",
      "r568",
      "r742",
      "r1177",
      "r1490",
      "r1492"
     ]
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount reserved for settlement",
        "label": "Loss Contingency Accrual",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r1375"
     ]
    },
    "jnj_LossContingencyAccrualNominalValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "LossContingencyAccrualNominalValue",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrual, nominal value",
        "label": "Loss Contingency Accrual, Nominal Value",
        "documentation": "Loss Contingency Accrual, Nominal Value"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_LossContingencyAccrualPaymentPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "LossContingencyAccrualPaymentPercentage",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency accrual, payment percentage",
        "label": "Loss contingency accrual, payment percentage",
        "documentation": "Loss contingency accrual, payment percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyAccrualProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyAccrualProvision",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental charges",
        "label": "Loss Contingency Accrual, Provision",
        "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges."
       }
      }
     },
     "auth_ref": [
      "r1489"
     ]
    },
    "jnj_LossContingencyClaimsSettledPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "LossContingencyClaimsSettledPercent",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Claims settled, percent",
        "label": "Loss Contingency, Claims Settled, Percent",
        "documentation": "Loss Contingency, Claims Settled, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyDamagesAwardedValue",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Damages awarded",
        "label": "Loss Contingency, Damages Awarded, Value",
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r1489",
      "r1490",
      "r1492"
     ]
    },
    "us-gaap_LossContingencyDamagesPaidValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyDamagesPaidValue",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency, damages paid, value",
        "label": "Loss Contingency, Damages Paid, Value",
        "documentation": "Amount of damages paid to the plaintiff in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r1489",
      "r1490",
      "r1492"
     ]
    },
    "jnj_LossContingencyDamagesSoughtNominalValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "LossContingencyDamagesSoughtNominalValue",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Damages sought, nominal value",
        "label": "Loss Contingency, Damages Sought, Nominal Value",
        "documentation": "Loss Contingency, Damages Sought, Nominal Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyDamagesSoughtValue",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation contingency",
        "label": "Loss Contingency, Damages Sought, Value",
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r1489",
      "r1490",
      "r1492"
     ]
    },
    "jnj_LossContingencyDamagesSoughtValueIncrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "LossContingencyDamagesSoughtValueIncrease",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in damages sought",
        "label": "Loss Contingency, Damages Sought, Value, Increase",
        "documentation": "Loss Contingency, Damages Sought, Value, Increase"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_LossContingencyDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "LossContingencyDiscountRate",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bankruptcy loss contingency, discount rate",
        "label": "Loss Contingency, Discount Rate",
        "documentation": "Loss Contingency, Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyLossInPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyLossInPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency, loss in period",
        "label": "Loss Contingency, Loss in Period",
        "documentation": "The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates."
       }
      }
     },
     "auth_ref": [
      "r1489"
     ]
    },
    "jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "LossContingencyNumberOfClaimsWithinSettlementAgreement",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of claims within settlement agreement",
        "label": "Loss Contingency, Number of Claims within Settlement Agreement",
        "documentation": "Loss Contingency, Number of Claims within Settlement Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_LossContingencyPaymentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "LossContingencyPaymentPeriod",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency, payment period",
        "label": "Loss Contingency, Payment Period",
        "documentation": "Loss Contingency, Payment Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyPendingClaimsNumber",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of pending claims",
        "label": "Loss Contingency, Pending Claims, Number",
        "documentation": "Number of pending claims pertaining to a loss contingency."
       }
      }
     },
     "auth_ref": [
      "r1490",
      "r1492"
     ]
    },
    "jnj_LossContingencySolicitationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "LossContingencySolicitationPeriod",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Solicitation period",
        "label": "Loss Contingency, Solicitation Period",
        "documentation": "Loss Contingency, Solicitation Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Machinery and equipment",
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r1186",
      "r1230",
      "r1235",
      "r1501",
      "r1613",
      "r1617",
      "r1618",
      "r1620",
      "r1621",
      "r1622",
      "r1623",
      "r1624",
      "r1625",
      "r1626",
      "r1627",
      "r1628",
      "r1629",
      "r1630",
      "r1631",
      "r1632",
      "r1633",
      "r1634",
      "r1635",
      "r1636",
      "r1637",
      "r1638",
      "r1639",
      "r1640",
      "r1641",
      "r1642",
      "r1644",
      "r1645"
     ]
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Marketable securities",
        "terseLabel": "Current Marketable Securities",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1403"
     ]
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities, noncurrent",
        "label": "Marketable Securities, Noncurrent",
        "documentation": "Amount of investment in marketable security, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r1403"
     ]
    },
    "us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MaximumLengthOfTimeForeignCurrencyCashFlowHedge",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum length of time for hedging transaction exposure",
        "label": "Maximum Length of Time, Foreign Currency Cash Flow Hedge",
        "documentation": "Maximum period of hedging exposure to variability in future cash flows for forecasted transaction of foreign currency cash flow hedge, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transaction for payment of variable interest on existing financial instrument."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails",
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r273",
      "r275",
      "r276",
      "r278",
      "r307",
      "r308",
      "r564",
      "r565",
      "r566",
      "r567",
      "r701",
      "r742",
      "r827",
      "r915",
      "r1003",
      "r1005",
      "r1013",
      "r1048",
      "r1049",
      "r1102",
      "r1106",
      "r1108",
      "r1109",
      "r1120",
      "r1139",
      "r1140",
      "r1172",
      "r1183",
      "r1197",
      "r1210",
      "r1211",
      "r1215",
      "r1216",
      "r1231",
      "r1498",
      "r1595",
      "r1596",
      "r1597",
      "r1598",
      "r1599",
      "r1600"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1323"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1323"
     ]
    },
    "jnj_MedTechMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "MedTechMember",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MedTech",
        "verboseLabel": "MedTech",
        "label": "MedTech [Member]",
        "documentation": "MedTech [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_MesotheliomaAndStateClaimsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "MesotheliomaAndStateClaimsMember",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mesothelioma and State Claims",
        "label": "Mesothelioma and State Claims [Member]",
        "documentation": "Mesothelioma and State Claims"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "MinimumCollateralValueasaPercentReverseRepurchaseAgreement",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum reverse repurchase agreement collateral (as a percent)",
        "label": "Minimum Collateral Value as a Percent, Reverse Repurchase Agreement",
        "documentation": "Minimum Collateral Value as a Percent, Reverse Repurchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails",
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r273",
      "r275",
      "r276",
      "r278",
      "r307",
      "r308",
      "r564",
      "r565",
      "r566",
      "r567",
      "r701",
      "r742",
      "r827",
      "r915",
      "r1003",
      "r1005",
      "r1013",
      "r1048",
      "r1049",
      "r1102",
      "r1106",
      "r1108",
      "r1109",
      "r1120",
      "r1139",
      "r1140",
      "r1172",
      "r1183",
      "r1197",
      "r1210",
      "r1211",
      "r1215",
      "r1231",
      "r1498",
      "r1595",
      "r1596",
      "r1597",
      "r1598",
      "r1599",
      "r1600"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1343"
     ]
    },
    "jnj_MomentaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "MomentaMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Momenta",
        "label": "Momenta [Member]",
        "documentation": "Momenta"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1507"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1351"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r1186",
      "r1230",
      "r1235",
      "r1501",
      "r1613",
      "r1617",
      "r1618",
      "r1620",
      "r1621",
      "r1622",
      "r1623",
      "r1624",
      "r1625",
      "r1626",
      "r1627",
      "r1628",
      "r1629",
      "r1630",
      "r1631",
      "r1632",
      "r1633",
      "r1634",
      "r1635",
      "r1636",
      "r1637",
      "r1638",
      "r1639",
      "r1640",
      "r1641",
      "r1642",
      "r1644",
      "r1645"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1324"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used by)/from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flows from operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r191",
      "r195"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flows from operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      },
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net earnings",
        "terseLabel": "Net earnings",
        "verboseLabel": "Net earnings",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r195",
      "r244",
      "r313",
      "r349",
      "r352",
      "r357",
      "r370",
      "r378",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r387",
      "r388",
      "r398",
      "r490",
      "r571",
      "r572",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r580",
      "r581",
      "r791",
      "r799",
      "r821",
      "r847",
      "r977",
      "r1079",
      "r1097",
      "r1098",
      "r1254",
      "r1496"
     ]
    },
    "jnj_NeuroscienceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "NeuroscienceMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Neuroscience",
        "label": "Neuroscience [Member]",
        "documentation": "Neuroscience [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New accounting standards and Recently issued accounting standards",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1323"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r1286",
      "r1297",
      "r1307",
      "r1331",
      "r1340"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1313"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1331"
     ]
    },
    "jnj_NonQualifiedPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "NonQualifiedPlansMember",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Qualified Plans",
        "label": "Non Qualified Plans [Member]",
        "documentation": "Non qualified plans."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1351"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1351"
     ]
    },
    "jnj_NonTradeableContingentValueRightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "NonTradeableContingentValueRightMember",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Tradeable Contingent Value Right",
        "label": "Non-Tradeable Contingent Value Right [Member]",
        "documentation": "Non-Tradeable Contingent Value Right"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonUsMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-US",
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r1649",
      "r1651",
      "r1652",
      "r1653"
     ]
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash paid for acquisitions (Note 18)",
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)",
        "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r51"
     ]
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Acquisitions",
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value of assets acquired",
        "label": "Noncash or Part Noncash Acquisition, Value of Assets Acquired",
        "documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r51"
     ]
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Fair value of liabilities assumed",
        "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed",
        "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r51"
     ]
    },
    "jnj_NoncashOrPartNoncashTransactionGainOnExchangeOfStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "NoncashOrPartNoncashTransactionGainOnExchangeOfStock",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncash gain on exchange offer",
        "label": "Noncash Or Part Noncash Transaction, Gain On Exchange Of Stock",
        "documentation": "Noncash Or Part Noncash Transaction, Gain On Exchange Of Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncontrollingInterestDecreaseFromDeconsolidation",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails",
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Kenvue Separation/IPO",
        "terseLabel": "Decrease in noncontrolling interest",
        "label": "Noncontrolling Interest, Decrease from Deconsolidation",
        "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r71"
     ]
    },
    "us-gaap_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Assets",
        "label": "Long-Lived Assets",
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_NondesignatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NondesignatedMember",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Not Designated as Hedging Instrument",
        "label": "Not Designated as Hedging Instrument [Member]",
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "NumberOfEmployeesEngagedInCompanyActivitiesWorldwide",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of employees",
        "label": "Number Of Employees Engaged In Company Activities Worldwide",
        "documentation": "Number of employees engaged in company activities worldwide."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r1167",
      "r1432"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of business segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r1161",
      "r1171",
      "r1432"
     ]
    },
    "jnj_NumberOfStockBasedCompensationPlans": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "NumberOfStockBasedCompensationPlans",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of stock-based compensation plans",
        "label": "Number Of Stock Based Compensation Plans",
        "documentation": "Number of stock-based compensation plans."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_Numberofpatientsinsettlement": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "Numberofpatientsinsettlement",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of patients in settlement",
        "label": "Number of patients in settlement",
        "documentation": "Number of patients in settlement"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_OPSUMITMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "OPSUMITMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OPSUMIT",
        "label": "OPSUMIT [Member]",
        "documentation": "OPSUMIT [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_OTHERNEUROSCIENCEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "OTHERNEUROSCIENCEMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER NEUROSCIENCE",
        "label": "OTHER NEUROSCIENCE [Member]",
        "documentation": "OTHER NEUROSCIENCE [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_OncologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "OncologyMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oncology",
        "label": "Oncology [Member]",
        "documentation": "Oncology [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease costs",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r879",
      "r1218"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r877",
      "r880"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, right-of-use asset",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segments",
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r445",
      "r1166",
      "r1167"
     ]
    },
    "jnj_OpioidMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "OpioidMember",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opioid",
        "label": "opioid [Member]",
        "documentation": "Opioid"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_OrthopaedicsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "OrthopaedicsMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Orthopaedics",
        "label": "Orthopaedics [Member]",
        "documentation": "Orthopaedics [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_OrthopaedicsRestructuringPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "OrthopaedicsRestructuringPlanMember",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Orthopaedics Restructuring Plan",
        "label": "Orthopaedics Restructuring Plan [Member]",
        "documentation": "Orthopaedics Restructuring Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsMember",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other assets."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r122"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other assets",
        "terseLabel": "Other assets, noncurrent",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "jnj_OtherCardiovascularMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "OtherCardiovascularMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "other cardiovascular",
        "label": "other cardiovascular [Member]",
        "documentation": "other cardiovascular"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities:",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior service cost (credit)",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax",
        "documentation": "Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r174",
      "r667"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee benefit plans:",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives &amp; hedges:",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Consumer settlement/ curtailment",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Adjustment for Settlement or Curtailment Gain (Loss), Tax",
        "documentation": "Amount of tax expense (benefit) for increase (decrease) to other comprehensive income from settlement and curtailment gain (loss) of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r227"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax",
        "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r174",
      "r850",
      "r852",
      "r857"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization of prior service (cost) credit",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax",
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r174",
      "r348",
      "r667"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r342",
      "r344",
      "r978"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r344",
      "r978"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives &amp; hedges",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax",
        "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrealized gain (loss) arising during period",
        "terseLabel": "Amount of gain or (loss) recognized in AOCI",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r344"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reclassifications to earnings",
        "terseLabel": "Amount of gain or (loss) reclassified from AOCI into income",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r347"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of gain or (loss) recognized in AOCI",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax",
        "documentation": "Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r344",
      "r806",
      "r810"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain/(Loss) Recognized In Accumulated OCI",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax",
        "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r344",
      "r806",
      "r807",
      "r810"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9",
      "r854",
      "r864"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive income (loss)",
        "verboseLabel": "Other comprehensive income (loss), net of tax",
        "terseLabel": "Net change",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r32",
      "r350",
      "r353",
      "r358",
      "r384",
      "r858",
      "r859",
      "r865",
      "r953",
      "r978",
      "r1406",
      "r1407"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Effect of exchange rates",
        "label": "Other comprehensive income (loss), pension and other, effects of exchange rate net of tax",
        "documentation": "other comprehensive income loss, pension and other , effects of exchange rate net of tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total loss/(income) recognized in other comprehensive income, before tax",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax",
        "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8",
      "r173",
      "r174",
      "r978",
      "r1189",
      "r1509"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net change",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8",
      "r173",
      "r174",
      "r978"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net actuarial (gain) loss",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax",
        "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174",
      "r214"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Employee benefits",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax",
        "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r173",
      "r227"
     ]
    },
    "jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prior service credit (cost), net of amortization",
        "label": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax",
        "documentation": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reclassifications to earnings",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r174",
      "r348",
      "r485"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of net actuarial loss",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax",
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r174",
      "r348",
      "r667"
     ]
    },
    "jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain (loss), net of amortization",
        "label": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax",
        "documentation": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized holding gain (loss) arising during period",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r344",
      "r485"
     ]
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentLiabilitiesMember",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Current Liabilities",
        "label": "Other Current Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherDebtSecuritiesMember",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Debt Obligations [Member]",
        "documentation": "Investments in debt securities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1459",
      "r1507"
     ]
    },
    "jnj_OtherImmunologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "OtherImmunologyMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Immunology",
        "label": "Other Immunology [Member]",
        "documentation": "Other Immunology [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_OtherIncomeExpenseNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "OtherIncomeExpenseNetMember",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (Income) Expense",
        "label": "Other Income Expense Net [Member]",
        "documentation": "Other Income Expense Net [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_OtherInfectiousDiseasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "OtherInfectiousDiseasesMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Infectious Diseases",
        "label": "Other Infectious Diseases [Member]",
        "documentation": "Other Infectious Diseases [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIntangibleAssetsMember",
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleassetsandgoodwillNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Customer relationships and other intangible assets",
        "terseLabel": "Other Intangible Assets",
        "label": "Other Intangible Assets [Member]",
        "documentation": "Intangible assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r1175",
      "r1473",
      "r1474",
      "r1475",
      "r1476",
      "r1477",
      "r1478",
      "r1479",
      "r1480",
      "r1481",
      "r1482"
     ]
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherInvestmentNotReadilyMarketableAxis",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Investment Not Readily Marketable [Axis]",
        "label": "Other Investment Not Readily Marketable [Axis]",
        "documentation": "Information by investment not readily marketable."
       }
      }
     },
     "auth_ref": [
      "r1604"
     ]
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherInvestmentNotReadilyMarketableLineItems",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Investment Not Readily Marketable [Line Items]",
        "label": "Other Investment Not Readily Marketable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1604"
     ]
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherInvestmentNotReadilyMarketableNameDomain",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Investment Not Readily Marketable, Name [Domain]",
        "label": "Other Investment Not Readily Marketable, Name [Domain]",
        "documentation": "Name of the investment category or actual investment title."
       }
      }
     },
     "auth_ref": [
      "r1604"
     ]
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherInvestmentNotReadilyMarketableTable",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Investment Not Readily Marketable [Table]",
        "label": "Other Investment Not Readily Marketable [Table]",
        "documentation": "Disclosure of information about investment not readily marketable."
       }
      }
     },
     "auth_ref": [
      "r1604"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "jnj_OtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "OtherMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other [Member]",
        "documentation": "Other [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_OtherNonLongLivedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "OtherNonLongLivedAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non long-lived assets",
        "label": "Other Non Long Lived Assets",
        "documentation": "Other non long lived assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncurrentLiabilitiesMember",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Noncurrent Liabilities",
        "label": "Other Noncurrent Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other (income) expense, net",
        "terseLabel": "Other (income) expense, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "jnj_OtherOncologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "OtherOncologyMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Oncology",
        "label": "Other Oncology [Member]",
        "documentation": "Other Oncology [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1323"
     ]
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other Benefit Plans",
        "terseLabel": "Other benefit plans",
        "label": "Other Postretirement Benefits Plan [Member]",
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r670",
      "r672",
      "r673",
      "r675",
      "r678",
      "r681",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r698",
      "r699",
      "r700",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193"
     ]
    },
    "us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails": {
       "parentTag": "jnj_EmployeeObligations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Postretirement benefits",
        "label": "Liability, Other Postretirement Defined Benefit Plan",
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit other postretirement plan. Excludes pension plan."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r237"
     ]
    },
    "jnj_OtherPulmonaryHypertensionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "OtherPulmonaryHypertensionMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Pulmonary Hypertension",
        "label": "Other Pulmonary Hypertension [Member]",
        "documentation": "Other Pulmonary Hypertension"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_OtherSovereignSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "OtherSovereignSecuritiesMember",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Sovereign Securities",
        "label": "Other Sovereign Securities [Member]",
        "documentation": "Other Sovereign Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]",
        "label": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]",
        "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1284",
      "r1295",
      "r1305",
      "r1338"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1287",
      "r1298",
      "r1308",
      "r1341"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1287",
      "r1298",
      "r1308",
      "r1341"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails",
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Axis]",
        "label": "Ownership [Axis]",
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails",
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Domain]",
        "label": "Ownership [Domain]",
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_OwnershipPercentageSplitOffPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "OwnershipPercentageSplitOffPercent",
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Split-off percentage",
        "label": "Ownership Percentage, Split-Off Percent",
        "documentation": "Ownership Percentage, Split-Off Percent"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "PREZISTAPREZCOBIXREZOLSTASYMTUZAMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA",
        "label": "PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]",
        "documentation": "PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_PatentsAndTrademarksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "PatentsAndTrademarksMember",
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleassetsandgoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents And Trademarks",
        "label": "Patents And Trademarks [Member]",
        "documentation": "Patents And Trademarks [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1312"
     ]
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other (including capitalized licenses and milestones)",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1381",
      "r1413"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of common stock",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "jnj_PaymentsMadeInBusinessSeparation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "PaymentsMadeInBusinessSeparation",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash transferred to Kenvue at separation",
        "label": "Payments Made In Business Separation",
        "documentation": "Payments Made In Business Separation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfOrdinaryDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfOrdinaryDividends",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividends to shareholders",
        "label": "Payments of Ordinary Dividends",
        "documentation": "Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments to acquire businesses, gross",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r795"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisitions, net of cash acquired",
        "terseLabel": "Acquisitions, net of cash acquired (Note 18)",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments to Acquire in Process Research and Development",
        "label": "Payments to Acquire in Process Research and Development",
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of investments",
        "label": "Payments to Acquire Investments",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Additions to property, plant and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "jnj_PaymentsToAcquiredInProcessResearchAndDevelopmentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "PaymentsToAcquiredInProcessResearchAndDevelopmentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of in-process research and development assets",
        "label": "Payments To Acquired In-Process Research And Development Assets",
        "documentation": "Payments To Acquired In-Process Research And Development Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1322"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1322"
     ]
    },
    "jnj_PelvicMeshesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "PelvicMeshesMember",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pelvic Meshes",
        "label": "Pelvic Meshes [Member]",
        "documentation": "Pelvic meshes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PendingLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PendingLitigationMember",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pending Litigation",
        "label": "Pending Litigation [Member]",
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process."
       }
      }
     },
     "auth_ref": [
      "r1489"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.jnj.com/role/Pensionsandotherbenefitplans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Pensions and other benefit plans",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r647",
      "r649",
      "r655",
      "r674",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r695",
      "r696",
      "r698",
      "r1189"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails_1": {
       "parentTag": "jnj_EmployeeObligations",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less current benefits payable",
        "negatedLabel": "Current liabilities",
        "label": "Liability, Defined Benefit Plan, Current",
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r623",
      "r624",
      "r646",
      "r1189"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails_1": {
       "parentTag": "jnj_EmployeeObligations",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Employee related obligations",
        "terseLabel": "Employee related obligations\u00a0\u2014 non-current",
        "negatedLabel": "Non-current liabilities",
        "label": "Liability, Defined Benefit Plan, Noncurrent",
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r623",
      "r624",
      "r646",
      "r1189"
     ]
    },
    "us-gaap_PensionContributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionContributions",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contribution to pension plans",
        "label": "Payment for Pension Benefits",
        "documentation": "Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionPlansDefinedBenefitMember",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Retirement Plans",
        "terseLabel": "Retirement plans",
        "label": "Pension Plan [Member]",
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r670",
      "r672",
      "r673",
      "r675",
      "r678",
      "r681",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r698",
      "r699",
      "r703",
      "r1189",
      "r1190",
      "r1194",
      "r1195",
      "r1196"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1331"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1324"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1313"
     ]
    },
    "jnj_PercentageChangeInSalesBySegmentOfBusiness": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "PercentageChangeInSalesBySegmentOfBusiness",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "% Change",
        "label": "Percentage Change In Sales By Segment Of Business",
        "documentation": "Percentage change in sales by segment of business."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "PercentageOfCorridorOfGreaterOfMarketValueOfAssets",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of corridor of greater of market value of assets",
        "label": "Percentage Of Corridor Of Greater Of Market Value Of Assets",
        "documentation": "Percentage of corridor of greater of market value of assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Shares",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_PharmaceuticalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "PharmaceuticalMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Pharmaceutical",
        "terseLabel": "Pharmaceutical",
        "label": "Pharmaceutical [Member]",
        "documentation": "Pharmaceutical."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_PhysiomeshMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "PhysiomeshMember",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails",
      "http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Physiomesh",
        "label": "Physiomesh [Member]",
        "documentation": "Physiomesh [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_PinnacleAcetabularCupSystemMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "PinnacleAcetabularCupSystemMember",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pinnacle Acetabular Cup System",
        "label": "Pinnacle Acetabular Cup System [Member]",
        "documentation": "Pinnacle Acetabular cup system."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanAssetCategoriesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanAssetCategoriesDomain",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "label": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "documentation": "Defined benefit plan asset investment."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r648",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r675",
      "r1187",
      "r1188",
      "r1189"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1517",
      "r1518",
      "r1519",
      "r1520",
      "r1521",
      "r1522",
      "r1523",
      "r1524",
      "r1525",
      "r1526",
      "r1527",
      "r1528",
      "r1529",
      "r1530",
      "r1531",
      "r1532",
      "r1533",
      "r1534",
      "r1535",
      "r1536",
      "r1537",
      "r1538",
      "r1539",
      "r1540",
      "r1541",
      "r1542"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1517",
      "r1518",
      "r1519",
      "r1520",
      "r1521",
      "r1522",
      "r1523",
      "r1524",
      "r1525",
      "r1526",
      "r1527",
      "r1528",
      "r1529",
      "r1530",
      "r1531",
      "r1532",
      "r1533",
      "r1534",
      "r1535",
      "r1536",
      "r1537",
      "r1538",
      "r1539",
      "r1540",
      "r1541",
      "r1542"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1315"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1371"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "jnj_PonvoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "PonvoryMember",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ponvory",
        "label": "Ponvory [Member]",
        "documentation": "Ponvory"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PostemploymentBenefitsLiabilityCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails": {
       "parentTag": "jnj_EmployeeObligations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Postemployment benefits",
        "label": "Postemployment Benefits Liability",
        "documentation": "The carrying amount as of the balance sheet date of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r1503",
      "r1504"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r1058"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock\u00a0\u2014 without par value (authorized and unissued 2,000,000\u00a0shares)",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r968",
      "r1219"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses and other receivables",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1405"
     ]
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from divestiture of brands",
        "label": "Proceeds from Divestiture of Businesses",
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from the exercise of stock options/employee withholding tax on stock awards, net",
        "label": "Proceeds From The Exercise Of Stock Options And Excess Tax Benefits",
        "documentation": "Proceeds From The Exercise Of Stock Options And Excess Tax Benefits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from Kenvue initial public offering",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommercialPaper": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommercialPaper",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of commercial paper",
        "label": "Proceeds from Issuance of Commercial Paper",
        "documentation": "The cash inflow from borrowing by issuing commercial paper."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from long-term debt, net of issuance costs",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r1020"
     ]
    },
    "jnj_ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds of short and long-term debt, net of issuance cost, related to the debt that transferred to Kenvue at separation",
        "label": "Proceeds From Issuance Of Long-Term Debt, Transferred In Business Separation",
        "documentation": "Proceeds From Issuance Of Long-Term Debt, Transferred In Business Separation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1382",
      "r1414"
     ]
    },
    "us-gaap_ProceedsFromRoyaltiesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromRoyaltiesReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from Royalties Received",
        "label": "Proceeds from Royalties Received",
        "documentation": "Cash received for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193"
     ]
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Sales of investments",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from the disposal of assets/businesses, net",
        "label": "Proceeds from Sale of Productive Assets",
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromShortTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from short-term debt",
        "label": "Proceeds from Short-Term Debt",
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit support agreements activity, net",
        "label": "Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities",
        "documentation": "Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit support agreements activity, net",
        "label": "Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities",
        "documentation": "Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductConcentrationRiskMember",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Project Concentration Risk",
        "label": "Product Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "jnj_ProductLiabilityContingencyNumberOfClaimant": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ProductLiabilityContingencyNumberOfClaimant",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails",
      "http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product liability contingency, number of claimants",
        "label": "Product Liability Contingency Number Of Claimant",
        "documentation": "Product liability contingency number of claimant."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ProductLiabilityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ProductLiabilityPolicyTextBlock",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product liability",
        "label": "Product Liability [Policy Text Block]",
        "documentation": "Product liability."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails",
      "http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r305",
      "r448",
      "r917",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1144",
      "r1184",
      "r1229",
      "r1231",
      "r1232",
      "r1236",
      "r1239",
      "r1402",
      "r1493",
      "r1494",
      "r1501",
      "r1613",
      "r1617",
      "r1618",
      "r1619",
      "r1620",
      "r1621",
      "r1622",
      "r1623",
      "r1624",
      "r1625",
      "r1626",
      "r1627",
      "r1628",
      "r1629",
      "r1630",
      "r1631",
      "r1632",
      "r1633",
      "r1634",
      "r1635",
      "r1636",
      "r1637",
      "r1638",
      "r1639",
      "r1640",
      "r1641",
      "r1642",
      "r1644",
      "r1645"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails",
      "http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r305",
      "r448",
      "r917",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1144",
      "r1184",
      "r1229",
      "r1231",
      "r1232",
      "r1236",
      "r1239",
      "r1402",
      "r1493",
      "r1494",
      "r1501",
      "r1613",
      "r1617",
      "r1618",
      "r1619",
      "r1620",
      "r1621",
      "r1622",
      "r1623",
      "r1624",
      "r1625",
      "r1626",
      "r1627",
      "r1628",
      "r1629",
      "r1630",
      "r1631",
      "r1632",
      "r1633",
      "r1634",
      "r1635",
      "r1636",
      "r1637",
      "r1638",
      "r1639",
      "r1640",
      "r1641",
      "r1642",
      "r1644",
      "r1645"
     ]
    },
    "jnj_ProfitLossPercentToSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ProfitLossPercentToSales",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of profit share payments (less than)",
        "label": "Profit Loss Percent To Sales",
        "documentation": "Profit loss percent to sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r881"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.jnj.com/role/Propertyplantandequipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r261",
      "r265",
      "r266"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total property, plant and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r318",
      "r975"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment",
        "label": "Property, Plant and Equipment [Member]",
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property, plant and equipment, net",
        "totalLabel": "Total property, plant and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r881",
      "r961",
      "r975",
      "r1219"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment and depreciation",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r261",
      "r265",
      "r973"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.jnj.com/role/PropertyplantandequipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment at Cost and Accumulated Depreciation",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r881"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful lives of the assets",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ProteologixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ProteologixMember",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proteologix",
        "label": "Proteologix [Member]",
        "documentation": "Proteologix"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Credit losses and accounts receivable allowances",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r496"
     ]
    },
    "jnj_PulmonaryHypertensionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "PulmonaryHypertensionMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pulmonary Hypertension",
        "label": "Pulmonary Hypertension [Member]",
        "documentation": "Pulmonary Hypertension [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_PurchasedInProcessResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "PurchasedInProcessResearchAndDevelopmentMember",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Purchased in-process research and development",
        "terseLabel": "Purchased in-process research and development(1)",
        "label": "Purchased In-Process Research And Development [Member]",
        "documentation": "Purchased In-Process Research And Development [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r1312"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1312"
     ]
    },
    "jnj_QualifiedPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "QualifiedPlansMember",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Qualified Plans",
        "label": "Qualified Plans [Member]",
        "documentation": "Qualified plans."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_RDRestructuringPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "RDRestructuringPlanMember",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D Restructuring Plan",
        "label": "R&amp;D Restructuring Plan [Member]",
        "documentation": "R&amp;D Restructuring Plan"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails",
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r273",
      "r275",
      "r276",
      "r278",
      "r307",
      "r308",
      "r564",
      "r565",
      "r566",
      "r567",
      "r647",
      "r701",
      "r732",
      "r733",
      "r734",
      "r742",
      "r827",
      "r890",
      "r899",
      "r915",
      "r1003",
      "r1005",
      "r1013",
      "r1048",
      "r1049",
      "r1102",
      "r1106",
      "r1108",
      "r1109",
      "r1120",
      "r1139",
      "r1140",
      "r1172",
      "r1183",
      "r1197",
      "r1210",
      "r1211",
      "r1215",
      "r1216",
      "r1231",
      "r1243",
      "r1487",
      "r1498",
      "r1576",
      "r1596",
      "r1597",
      "r1598",
      "r1599",
      "r1600"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails",
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r273",
      "r275",
      "r276",
      "r278",
      "r307",
      "r308",
      "r564",
      "r565",
      "r566",
      "r567",
      "r647",
      "r701",
      "r732",
      "r733",
      "r734",
      "r742",
      "r827",
      "r890",
      "r899",
      "r915",
      "r1003",
      "r1005",
      "r1013",
      "r1048",
      "r1049",
      "r1102",
      "r1106",
      "r1108",
      "r1109",
      "r1120",
      "r1139",
      "r1140",
      "r1172",
      "r1183",
      "r1197",
      "r1210",
      "r1211",
      "r1215",
      "r1216",
      "r1231",
      "r1243",
      "r1487",
      "r1498",
      "r1576",
      "r1596",
      "r1597",
      "r1598",
      "r1599",
      "r1600"
     ]
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofbusinessandgeographicareasTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1279",
      "r1290",
      "r1300",
      "r1333"
     ]
    },
    "jnj_RegulationCharge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "RegulationCharge",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulation charge",
        "label": "Regulation charge",
        "documentation": "Regulation charge"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_RemicadeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "RemicadeMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remicade",
        "label": "Remicade [Member]",
        "documentation": "Remicade [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of long-term debt",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r1023"
     ]
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfShortTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of short-term debt",
        "label": "Repayments of Short-Term Debt",
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_RepurchaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepurchaseAgreementsMember",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Reverse repurchase agreements",
        "label": "Repurchase Agreements [Member]",
        "documentation": "Investments represented by an agreement between the entity and another party for the sale and repurchase of identical or substantially the same securities at a date certain for a specified price. Such agreements are generally short-term in nature."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charges for acquired in-process research and development assets",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r745",
      "r1141",
      "r1166",
      "r1601"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expense",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r1543"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D Expense",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "jnj_ResearchAndDevelopmentInProcess1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ResearchAndDevelopmentInProcess1",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "In-process research and development impairments",
        "terseLabel": "Research and development in process",
        "label": "Research and Development In Process1",
        "documentation": "Research and Development In Process1"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1280",
      "r1291",
      "r1301",
      "r1334"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1281",
      "r1292",
      "r1302",
      "r1335"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1288",
      "r1299",
      "r1309",
      "r1342"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units (RSUs)",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and Related Activities [Abstract]",
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.jnj.com/role/Restructuring"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r552",
      "r554",
      "r557",
      "r562"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and Related Cost, Cost Incurred to Date",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "documentation": "Amount of costs incurred to date for the specified restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r556",
      "r559",
      "r561"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-tax restructuring charges",
        "label": "Restructuring and Related Cost, Expected Cost",
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r556",
      "r559",
      "r561"
     ]
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring",
        "verboseLabel": "Restructuring charges",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r558",
      "r559",
      "r1488"
     ]
    },
    "us-gaap_RestructuringChargesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringChargesMember",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Charges",
        "label": "Restructuring Charges [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r206"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r554",
      "r555",
      "r556",
      "r559",
      "r560",
      "r561"
     ]
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Axis]",
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Domain]",
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserveRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveRollForward",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Reserve [Roll Forward]",
        "label": "Restructuring Reserve [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Retained earnings and Additional-paid-in-capital",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r212",
      "r971",
      "r1010",
      "r1012",
      "r1024",
      "r1059",
      "r1219"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained Earnings and Additional paid-in capital",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r375",
      "r376",
      "r377",
      "r379",
      "r384",
      "r386",
      "r388",
      "r491",
      "r492",
      "r536",
      "r778",
      "r779",
      "r788",
      "r789",
      "r790",
      "r792",
      "r798",
      "r799",
      "r811",
      "r813",
      "r814",
      "r816",
      "r819",
      "r871",
      "r873",
      "r1007",
      "r1009",
      "r1027",
      "r1648"
     ]
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanSponsorLocationAxis",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Sponsor Location [Axis]",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r670",
      "r671",
      "r672",
      "r673",
      "r675",
      "r678",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r1514",
      "r1515",
      "r1516"
     ]
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanSponsorLocationDomain",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Sponsor Location [Domain]",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r670",
      "r671",
      "r672",
      "r673",
      "r675",
      "r678",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r1514",
      "r1515",
      "r1516"
     ]
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanTypeAxis",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Type [Axis]",
        "label": "Retirement Plan Type [Axis]",
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r670",
      "r672",
      "r673",
      "r675",
      "r678",
      "r681",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r698",
      "r699",
      "r700",
      "r703",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196"
     ]
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanTypeDomain",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Type [Domain]",
        "label": "Retirement Plan Type [Domain]",
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r670",
      "r672",
      "r673",
      "r675",
      "r678",
      "r681",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r698",
      "r699",
      "r700",
      "r703",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Sales to customers",
        "terseLabel": "Sales to Customers",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247",
      "r407",
      "r416",
      "r417",
      "r438",
      "r444",
      "r448",
      "r450",
      "r452",
      "r618",
      "r619",
      "r917"
     ]
    },
    "jnj_RevenuePerformanceObligationPaymentTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "RevenuePerformanceObligationPaymentTerms",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, performance obligation, payment terms",
        "label": "Revenue, Performance Obligation, Payment Terms",
        "documentation": "Revenue, Performance Obligation, Payment Terms"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1142",
      "r1156"
     ]
    },
    "jnj_RevenuesContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "RevenuesContingentConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration",
        "label": "Revenues, Contingent Consideration",
        "documentation": "Revenues, Contingent Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_RisperdalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "RisperdalMember",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesNarrativeDetails",
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails",
      "http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risperdal",
        "label": "Risperdal [Member]",
        "documentation": "Risperdal."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1351"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1351"
     ]
    },
    "jnj_SPINESPORTSOTHERMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "SPINESPORTSOTHERMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SPINE,SPORTS &amp; OTHER",
        "label": "SPINE, SPORTS &amp; OTHER [Member]",
        "documentation": "SPINE &amp; OTHER [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_SPRAVATOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "SPRAVATOMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SPRAVATO",
        "label": "SPRAVATO [Member]",
        "documentation": "SPRAVATO"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_SURGICALMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "SURGICALMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SURGICAL",
        "label": "SURGICAL [Member]",
        "documentation": "SURGICAL [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, number of shares issued in transaction (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage ownership after transaction",
        "label": "Sale of Stock, Percentage of Ownership after Transaction",
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock (in USD per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_SalesBySegmentOfBusinessTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "SalesBySegmentOfBusinessTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofbusinessandgeographicareasTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Sales by Segment of Business",
        "label": "Sales By Segment Of Business [Table Text Block]",
        "documentation": "Sales by segment of business."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesMember",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales",
        "label": "Sales [Member]",
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "jnj_SalesReturnReserve": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "SalesReturnReserve",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales return reserve (as a percent)",
        "label": "Sales Return Reserve",
        "documentation": "Sales return reserve"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Revenue, Net",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r1383"
     ]
    },
    "jnj_SavingsPlanAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "SavingsPlanAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Savings Plan [Abstract]",
        "label": "Savings Plan [Abstract]",
        "documentation": "Savings Plan."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_SavingsPlanTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "SavingsPlanTextBlock",
     "presentation": [
      "http://www.jnj.com/role/Savingsplan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Savings plan",
        "label": "Savings Plan [Text Block]",
        "documentation": "Savings Plan."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]",
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r1395",
      "r1427"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r389",
      "r702",
      "r1375",
      "r1427"
     ]
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Components of Accumulated Other Comprehensive Income",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r1589",
      "r1590"
     ]
    },
    "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company' Retirement Plan Asset Allocation and Target Allocations",
        "label": "Schedule of Allocation of Plan Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation",
        "label": "Defined Benefit Plan, Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Activity Related to Equity Investments",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails",
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r793"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalent [Table]",
        "label": "Cash and Cash Equivalent [Table]",
        "documentation": "Disclosure of information about cash and cash equivalent by type. Excludes restricted cash and cash equivalent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalent Composition",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for Income Taxes",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1555"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r69",
      "r70",
      "r127",
      "r210",
      "r211",
      "r1179",
      "r1181",
      "r1423",
      "r1591"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary Differences and Carryforwards",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1549"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan [Table]",
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r79",
      "r80",
      "r81",
      "r82"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table Text Block]",
        "documentation": "Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r79",
      "r80",
      "r81",
      "r82"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effect of Net Investment Hedges",
        "label": "Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Derivative Activity",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r115",
      "r808"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial Assets and Liabilities at Fair Value",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Groups, Including Discontinued Operations",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r26",
      "r37",
      "r129",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r144",
      "r146",
      "r147",
      "r203"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/EarningspershareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1430"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r1203",
      "r1544"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]",
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r488",
      "r489",
      "r787",
      "r1376",
      "r1377",
      "r1378",
      "r1558",
      "r1559",
      "r1560",
      "r1561"
     ]
    },
    "jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans",
        "label": "Schedule Of Estimated Future Employer Contributions [Table Text Block]",
        "documentation": "Schedule of estimated future employer contributions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans",
        "label": "Schedule of Expected Benefit Payments [Table Text Block]",
        "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Intangible Assets and Goodwill",
        "label": "Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]",
        "documentation": "Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable",
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]",
        "label": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]",
        "documentation": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets by Major Class [Table]",
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r527",
      "r531",
      "r532",
      "r535",
      "r918",
      "r1141",
      "r1175"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfGoodwillTable",
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Table]",
        "label": "Goodwill [Table]",
        "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r1174"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill",
        "label": "Schedule of Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r1174",
      "r1461",
      "r1462",
      "r1463",
      "r1464",
      "r1465",
      "r1466",
      "r1467",
      "r1468",
      "r1469",
      "r1470",
      "r1471"
     ]
    },
    "us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfHealthCareCostTrendRatesTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assumed Health Care Cost Trend Rates",
        "label": "Schedule of Health Care Cost Trend Rates [Table Text Block]",
        "documentation": "Tabular disclosure of the assumed health care cost trend rates for the next year used to measure the expected cost of benefits covered by the plans, including the ultimate trend rate(s) and when that rate is expected to be achieved."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/InventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Inventories",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r166",
      "r167",
      "r168"
     ]
    },
    "us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfLossContingenciesByContingencyTextBlock",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Loss Contingencies by Contingency",
        "label": "Schedule of Loss Contingencies by Contingency [Table Text Block]",
        "documentation": "Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r1489",
      "r1491",
      "r1493",
      "r1495"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Maturities of Long Term Obligations",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Components of Net Periodic Benefit Cost",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_ScheduleOfNetFundedStatusTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNetFundedStatusTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Funded Status",
        "label": "Schedule of Net Funded Status [Table Text Block]",
        "documentation": "Tabular disclosure of net funded status of pension plans and/or other employee benefit plans."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/FairvaluemeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effect of Derivatives not Designated as Hedging Instruments",
        "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r1385"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r881"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost [Table]",
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r554",
      "r555",
      "r556",
      "r559",
      "r560",
      "r561"
     ]
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "presentation": [
      "http://www.jnj.com/role/RestructuringTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Severance Charges and Associated Spending",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r205"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofbusinessandgeographicareasTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas",
        "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r175"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r175"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r61"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofbusinessandgeographicareasTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Segment Reporting Information",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r61"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Restricted Share Units",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r222"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r705",
      "r707",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Options Outstanding",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r219"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Valuation Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Short-term Debt [Table]",
        "label": "Short-Term Debt [Table]",
        "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r763",
      "r1202"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1261"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1264"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/IncometaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r249",
      "r407",
      "r412",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r429",
      "r430",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r444",
      "r445",
      "r446",
      "r452",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r535",
      "r556",
      "r561",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r1163",
      "r1166",
      "r1167",
      "r1174",
      "r1234",
      "r1613",
      "r1617",
      "r1618",
      "r1619",
      "r1620",
      "r1621",
      "r1622",
      "r1623",
      "r1624",
      "r1625",
      "r1626",
      "r1627",
      "r1628",
      "r1629",
      "r1630",
      "r1631",
      "r1632",
      "r1633",
      "r1634",
      "r1635",
      "r1636",
      "r1637",
      "r1638",
      "r1639",
      "r1640",
      "r1641",
      "r1642",
      "r1644",
      "r1645"
     ]
    },
    "us-gaap_SegmentExpenditureAdditionToLongLivedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentExpenditureAdditionToLongLivedAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions to Property, Plant &amp; Equipment",
        "label": "Segment, Expenditure, Addition to Long-Lived Assets",
        "documentation": "Amount of expenditure for addition to long-lived assets included in determination of segment assets by chief operating decision maker (CODM) or otherwise regularly provided to CODM. Excludes expenditure for addition to financial instrument, long-term customer relationship of financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r426",
      "r444",
      "r1166",
      "r1167"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r274",
      "r277",
      "r279",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r450",
      "r451",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r1041",
      "r1044",
      "r1046",
      "r1103",
      "r1107",
      "r1110",
      "r1121",
      "r1128",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1145",
      "r1185",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1233",
      "r1243",
      "r1501",
      "r1613",
      "r1617",
      "r1618",
      "r1620",
      "r1621",
      "r1622",
      "r1623",
      "r1624",
      "r1625",
      "r1626",
      "r1627",
      "r1628",
      "r1629",
      "r1630",
      "r1631",
      "r1632",
      "r1633",
      "r1634",
      "r1635",
      "r1636",
      "r1637",
      "r1638",
      "r1639",
      "r1640",
      "r1641",
      "r1642",
      "r1644",
      "r1645"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Abstract]",
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.jnj.com/role/Segmentsofbusinessandgeographicareas"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Segments of business and geographic areas",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r407",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r427",
      "r429",
      "r430",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r448",
      "r449",
      "r452",
      "r1161",
      "r1164",
      "r1165",
      "r1166",
      "r1168",
      "r1170",
      "r1171"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Expense not allocated to segments",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r429",
      "r430",
      "r444",
      "r1166"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business segments",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r447",
      "r450",
      "r1162",
      "r1163",
      "r1169"
     ]
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_SegmentsTotalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "SegmentsTotalMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments Total",
        "label": "Segments Total [Member]",
        "documentation": "Segments Total"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, marketing and administrative expenses",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "us-gaap_SettledLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SettledLitigationMember",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settled Litigation",
        "label": "Settled Litigation [Member]",
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval."
       }
      }
     },
     "auth_ref": [
      "r1489"
     ]
    },
    "jnj_SettlementOfConvertibleDebtAcquiredFromShockwave": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "SettlementOfConvertibleDebtAcquiredFromShockwave",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Settlement of convertible debt acquired from Shockwave",
        "label": "Settlement of convertible debt acquired from Shockwave",
        "documentation": "Settlement of convertible debt acquired from Shockwave"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Award vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r1198"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Canceled/forfeited/adjusted (in shares)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Canceled, Forfeited and Adjusted During the Period",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Canceled, Forfeited and Adjusted During the Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average fair value of RSU's and PSU's granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r721",
      "r722"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Issued (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of RSU or PSU units settled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsScheduleValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average assumptions of fair value of options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsScheduleValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsScheduleValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsScheduleValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r705",
      "r707",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-tradeable contingent value right",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Tradeable Contingent Value Right",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Tradeable Contingent Value Right"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized for issuance under long-term incentive plan (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1200"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for future grants under long-term incentive plan",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of option activity under the Plan",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options average price (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Options canceled/forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r1524"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average fair value of option granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding beginning of period (in shares)",
        "periodEndLabel": "Options outstanding end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r714"
     ]
    },
    "jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares subject to full value awards (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Full Value Awards",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Full Value Awards"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares subject to full value award, excess (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Full Value Awards, Excess",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Full Value Awards, Excess"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued subject to stock options or stock appreciation rights (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Stock Options Or Stock Appreciation Rights",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Stock Options Or Stock Appreciation Rights"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options exercise price beginning of period (in dollars per share)",
        "periodEndLabel": "Options exercise price end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r714"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-tradeable contingent value right (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares, Non-Tradeable Contingent Value Right",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares, Non-Tradeable Contingent Value Right"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercised, average exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options canceled/forfeited, average exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted, average exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options outstanding and exercisable",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Abstract]",
        "documentation": "Share based compensation shares authorized under stock option plans by exercise price range."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Axis]",
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]",
        "label": "Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price Range, Minimum (in dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable number of Options (in shares)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options outstanding (in shares)",
        "terseLabel": "Outstanding number of Options (in shares)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r221"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price Range, Maximum (in dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "srt_ShareRepurchaseProgramAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ShareRepurchaseProgramAxis",
     "presentation": [
      "http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails",
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Axis]",
        "label": "Share Repurchase Program [Axis]",
        "documentation": "Information by share repurchase program."
       }
      }
     },
     "auth_ref": [
      "r1500"
     ]
    },
    "srt_ShareRepurchaseProgramDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ShareRepurchaseProgramDomain",
     "presentation": [
      "http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails",
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Domain]",
        "label": "Share Repurchase Program [Domain]",
        "documentation": "Name of share repurchase program."
       }
      }
     },
     "auth_ref": [
      "r1500"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1517"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1199"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsScheduleValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, Average Exercise Price (in dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Average Exercise Price (in dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r221"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock option average life",
        "terseLabel": "Outstanding, Average Life",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod",
     "calculation": {
      "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: shares repurchased under treasury stock method (in shares)",
        "label": "Shares Which Could Be Repurchased Under Treasury Stock Method",
        "documentation": "Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShippingAndHandlingCostPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShippingAndHandlingCostPolicyTextBlock",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shipping and handling",
        "label": "Shipping and Handling Cost, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShippingAndHandlingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShippingAndHandlingMember",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shipping and Handling",
        "label": "Shipping and Handling [Member]",
        "documentation": "Packing and transport of product."
       }
      }
     },
     "auth_ref": [
      "r1502"
     ]
    },
    "jnj_ShippingandHandlingCostsasaPercentofSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ShippingandHandlingCostsasaPercentofSales",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shipping and handling costs as a percent of sales",
        "label": "Shipping and Handling Costs as a Percent of Sales",
        "documentation": "Shipping and Handling Costs as a Percent of Sales"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ShockwaveMedicalInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ShockwaveMedicalInc.Member",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresDetails",
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shockwave Medical, Inc.",
        "label": "Shockwave Medical, Inc. [Member]",
        "documentation": "Shockwave Medical, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans and notes payable",
        "verboseLabel": "Loans and notes payable",
        "label": "Short-Term Debt",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r235",
      "r1219",
      "r1609"
     ]
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term Debt [Line Items]",
        "label": "Short-Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term Debt, Type [Axis]",
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r1483",
      "r1484",
      "r1485"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term Debt, Type [Domain]",
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r1483",
      "r1484",
      "r1485"
     ]
    },
    "jnj_ShortTermInvestmentFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ShortTermInvestmentFundsMember",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investment funds",
        "label": "Short Term Investment Funds [Member]",
        "documentation": "Short term investment funds."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.jnj.com/role/Summaryofsignificantaccountingpolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of significant accounting policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r368"
     ]
    },
    "jnj_SimponiSimponiAriaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "SimponiSimponiAriaMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Simponi/Simponi Aria",
        "label": "Simponi/Simponi Aria [Member]",
        "documentation": "Simponi/Simponi Aria [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SoftwareDevelopmentMember",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software Development",
        "label": "Software Development [Member]",
        "documentation": "Internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SovereignDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SovereignDebtSecuritiesMember",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-U.S. Sovereign Securities",
        "label": "Sovereign Debt Securities [Member]",
        "documentation": "Debt security issued by foreign government (not within the country of domicile of the entity)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and Local Jurisdiction",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/IncometaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Segments [Axis]",
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r249",
      "r311",
      "r407",
      "r412",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r429",
      "r430",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r444",
      "r445",
      "r446",
      "r452",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r535",
      "r538",
      "r556",
      "r561",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r1163",
      "r1166",
      "r1167",
      "r1174",
      "r1234",
      "r1613",
      "r1617",
      "r1618",
      "r1619",
      "r1620",
      "r1621",
      "r1622",
      "r1623",
      "r1624",
      "r1625",
      "r1626",
      "r1627",
      "r1628",
      "r1629",
      "r1630",
      "r1631",
      "r1632",
      "r1633",
      "r1634",
      "r1635",
      "r1636",
      "r1637",
      "r1638",
      "r1639",
      "r1640",
      "r1641",
      "r1642",
      "r1644",
      "r1645"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r328",
      "r329",
      "r330",
      "r370",
      "r393",
      "r397",
      "r399",
      "r401",
      "r409",
      "r410",
      "r490",
      "r571",
      "r574",
      "r575",
      "r576",
      "r580",
      "r581",
      "r611",
      "r612",
      "r613",
      "r614",
      "r616",
      "r847",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1058",
      "r1080",
      "r1099",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1374",
      "r1418",
      "r1429"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails",
      "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "verboseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r161",
      "r163",
      "r164",
      "r309",
      "r355",
      "r356",
      "r357",
      "r375",
      "r376",
      "r377",
      "r379",
      "r384",
      "r386",
      "r388",
      "r408",
      "r491",
      "r492",
      "r536",
      "r617",
      "r778",
      "r779",
      "r788",
      "r789",
      "r790",
      "r792",
      "r798",
      "r799",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r819",
      "r858",
      "r860",
      "r861",
      "r862",
      "r863",
      "r865",
      "r871",
      "r873",
      "r882",
      "r978",
      "r1007",
      "r1008",
      "r1009",
      "r1027",
      "r1099"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r274",
      "r277",
      "r279",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r450",
      "r451",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r1041",
      "r1044",
      "r1046",
      "r1103",
      "r1107",
      "r1110",
      "r1121",
      "r1128",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1145",
      "r1185",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1233",
      "r1243",
      "r1501",
      "r1613",
      "r1617",
      "r1618",
      "r1620",
      "r1621",
      "r1622",
      "r1623",
      "r1624",
      "r1625",
      "r1626",
      "r1627",
      "r1628",
      "r1629",
      "r1630",
      "r1631",
      "r1632",
      "r1633",
      "r1634",
      "r1635",
      "r1636",
      "r1637",
      "r1638",
      "r1639",
      "r1640",
      "r1641",
      "r1642",
      "r1644",
      "r1645"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376",
      "r377",
      "r408",
      "r873",
      "r917",
      "r1015",
      "r1038",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1058",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1078",
      "r1081",
      "r1082",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1099",
      "r1244"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r389",
      "r702",
      "r1375",
      "r1380",
      "r1427"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376",
      "r377",
      "r408",
      "r453",
      "r873",
      "r917",
      "r1015",
      "r1038",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1058",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1078",
      "r1081",
      "r1082",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1099",
      "r1244"
     ]
    },
    "jnj_StelaraMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "StelaraMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stelara",
        "label": "Stelara [Member]",
        "documentation": "Stelara [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1283",
      "r1294",
      "r1304",
      "r1337"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_StockIssuedDuringPeriodSharesExchangeOffer": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "StockIssuedDuringPeriodSharesExchangeOffer",
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued in exchange offer (in shares)",
        "label": "Stock Issued During Period, Shares, Exchange Offer",
        "documentation": "Stock Issued During Period, Shares, Exchange Offer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Employee compensation and stock option plans (shares)",
        "label": "Stock Issued During Period, Shares, Other",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Options exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r160",
      "r161",
      "r212",
      "r718"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Employee compensation and stock option plans",
        "label": "Stock Issued During Period, Value, Other",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "srt_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock repurchase program, authorized amount",
        "label": "Share Repurchase Program, Authorized, Amount",
        "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r1500"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shareholders\u2019 equity",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders\u2019 equity",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r102",
      "r309",
      "r310",
      "r356",
      "r375",
      "r376",
      "r377",
      "r379",
      "r384",
      "r386",
      "r491",
      "r492",
      "r536",
      "r617",
      "r778",
      "r779",
      "r788",
      "r789",
      "r790",
      "r792",
      "r798",
      "r799",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r819",
      "r858",
      "r860",
      "r865",
      "r872",
      "r882",
      "r1008",
      "r1009",
      "r1026",
      "r1060",
      "r1077",
      "r1100",
      "r1101",
      "r1127",
      "r1255",
      "r1420",
      "r1457",
      "r1588",
      "r1648"
     ]
    },
    "us-gaap_StockholdersEquityNoteSpinoffTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteSpinoffTransaction",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kenvue Separation /IPO",
        "label": "Stockholders' Equity Note, Spinoff Transaction",
        "documentation": "The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_StockholdersEquityOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityOther",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other",
        "label": "Stockholders' Equity, Other",
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsegmentsAxis",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsegments [Axis]",
        "label": "Subsegments [Axis]",
        "documentation": "Information by business subsegments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsegmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsegmentsDomain",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsegments [Domain]",
        "label": "Subsegments [Domain]",
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r883"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r883"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r883"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Valuation Allowance",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r1550"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow data",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplierFinanceProgramObligationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplierFinanceProgramObligationCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesSupplierFinanceProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier finance program, obligation, current",
        "periodStartLabel": "Confirmed obligations - beginning of the year",
        "periodEndLabel": "Confirmed obligations - end of the year",
        "label": "Supplier Finance Program, Obligation, Current",
        "documentation": "Amount of obligation for supplier finance program, classified as current."
       }
      }
     },
     "auth_ref": [
      "r546",
      "r547",
      "r550"
     ]
    },
    "us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]",
        "label": "Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes obligation for supplier finance program, classified as current."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "us-gaap_SupplierFinanceProgramObligationDecreaseSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplierFinanceProgramObligationDecreaseSettlement",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesSupplierFinanceProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Confirmed invoices paid during the year",
        "label": "Supplier Finance Program, Obligation, Settlement",
        "documentation": "Amount of decrease in obligation for supplier finance program from settlement."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r1176"
     ]
    },
    "us-gaap_SupplierFinanceProgramObligationIncrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplierFinanceProgramObligationIncrease",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesSupplierFinanceProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Invoices confirmed during the year",
        "label": "Supplier Finance Program, Obligation, Addition",
        "documentation": "Amount of increase in obligation for supplier finance program."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r1176"
     ]
    },
    "us-gaap_SupplierFinanceProgramObligationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplierFinanceProgramObligationRollForward",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesSupplierFinanceProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier Finance Program, Obligation [Roll Forward]",
        "label": "Supplier Finance Program, Obligation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplierFinanceProgramPaymentTimingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplierFinanceProgramPaymentTimingPeriod",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier finance program, payment timing, period",
        "label": "Supplier Finance Program, Payment Timing, Period",
        "documentation": "Period when payment is expected to be made to finance provider or intermediary in supplier finance program, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "jnj_SupplierFinanceProgramPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "SupplierFinanceProgramPolicyTextBlock",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier finance program obligations",
        "label": "Supplier Finance Program [Policy Text Block]",
        "documentation": "Supplier Finance Program"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplierFinanceProgramTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplierFinanceProgramTableTextBlock",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier Finance Program",
        "label": "Supplier Finance Program [Table Text Block]",
        "documentation": "Tabular disclosure of supplier finance program."
       }
      }
     },
     "auth_ref": [
      "r1176",
      "r1486"
     ]
    },
    "us-gaap_SuppliesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SuppliesExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplies expense",
        "label": "Supplies Expense",
        "documentation": "Amount of expense associated with supplies that were used during the current accounting period."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "jnj_SurgeryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "SurgeryMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Surgery",
        "label": "Surgery [Member]",
        "documentation": "Surgery [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_TECVAYLIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "TECVAYLIMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TECVAYLI",
        "label": "TECVAYLI [Member]",
        "documentation": "TECVAYLI"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_TRAUMAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "TRAUMAMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TRAUMA",
        "label": "TRAUMA [Member]",
        "documentation": "TRAUMA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1330"
     ]
    },
    "jnj_TalcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "TalcMember",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesNarrativeDetails",
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails",
      "http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Talc",
        "label": "Talc [Member]",
        "documentation": "Talc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardLineItems",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Line Items]",
        "label": "Tax Credit Carryforward [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardTable",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Table]",
        "label": "Tax Credit Carryforward [Table]",
        "documentation": "Disclosure of information about tax credit carryforward available to reduce future taxable income. Includes, but is not limited to, description, amount, expiration date, limitation on use, and related deferred tax asset and valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TJCA , provisional liability, non-current",
        "label": "Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability, Noncurrent",
        "documentation": "Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability, Current"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TCJA, undistributed foreign earnings percent related to cash and cash equivalents",
        "label": "Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Cash And Cash Equivalents, Tax Rate, Percent",
        "documentation": "Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Cash And Cash Equivalents, Tax Rate, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TCJA, undistributed foreign earnings percent related to earnings other than cash and cash equivalents",
        "label": "Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Other Than Cash And Cash Equivalents, Tax Rate, Percent",
        "documentation": "Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Other Than Cash And Cash Equivalents, Tax Rate, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsPaymentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsPaymentPeriod",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TCJA, transition tax for accumulated foreign earnings, payment period",
        "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Payment Period",
        "documentation": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Payment Period"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_TotalClaimsAgainstCompanyPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "TotalClaimsAgainstCompanyPercent",
     "presentation": [
      "http://www.jnj.com/role/LegalproceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total claims against company, percent",
        "label": "Total Claims Against Company, Percent",
        "documentation": "Total Claims Against Company, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1322"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1329"
     ]
    },
    "us-gaap_TrademarksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TrademarksMember",
     "presentation": [
      "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trademarks",
        "label": "Trademarks [Member]",
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r1175",
      "r1473",
      "r1474",
      "r1475",
      "r1476",
      "r1477",
      "r1478",
      "r1479",
      "r1480",
      "r1481",
      "r1482"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1350"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1352"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r607",
      "r615",
      "r818",
      "r844",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r979",
      "r1206",
      "r1208",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1220",
      "r1388",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1393",
      "r1394",
      "r1452",
      "r1453",
      "r1454",
      "r1455",
      "r1572",
      "r1575",
      "r1576",
      "r1577",
      "r1584",
      "r1587"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1353"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1354"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1354"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1352"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1352"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1355"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1353"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock Amount",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock (in shares)",
        "periodStartLabel": "Treasury Stock, beginning balance (shares)",
        "periodEndLabel": "Treasury Stock, ending balance (shares)",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock issued for employee compensation and stock option plans, net of cash proceeds/ employee withholding tax on stock awards",
        "label": "Treasury Stock Issued For Employee Compensation And Stock Option Plans Net Of Cash Proceeds",
        "documentation": "Treasury stock issued for employee compensation and stock option plans, net of cash proceeds."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Repurchase of common stock (shares)",
        "label": "Treasury Stock, Shares, Acquired",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r161",
      "r212"
     ]
    },
    "us-gaap_TreasuryStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockTextBlock",
     "presentation": [
      "http://www.jnj.com/role/Capitalandtreasurystock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital and treasury stock",
        "label": "Treasury Stock [Text Block]",
        "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Less: common stock held in treasury, at cost (Note\u00a012) (712,921,000\u00a0shares and 712,765,000\u00a0shares)",
        "periodStartLabel": "Treasury Stock, Balance",
        "periodEndLabel": "Treasury Stock, Ending Balance",
        "label": "Treasury Stock, Value",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r75",
      "r161",
      "r163"
     ]
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repurchase of common stock",
        "terseLabel": "Repurchase of common stock",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r72",
      "r212"
     ]
    },
    "jnj_TreasuryStockValueAcquiredCostMethodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "TreasuryStockValueAcquiredCostMethodNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchase of common stock",
        "label": "Treasury Stock, Value, Acquired, Cost Method, Net Of Tax",
        "documentation": "Treasury Stock, Value, Acquired, Cost Method, Net Of Tax"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_TremfyaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "TremfyaMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tremfya",
        "label": "Tremfya [Member]",
        "documentation": "Tremfaya"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_UNITEDSTATESExportsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "UNITEDSTATESExportsMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "UNITED STATES Exports",
        "label": "UNITED STATES Exports [Member]",
        "documentation": "UNITED STATES Exports [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_UPTRAVIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "UPTRAVIMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "UPTRAVI",
        "label": "UPTRAVI [Member]",
        "documentation": "UPTRAVI [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "U.S. Plans",
        "terseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Gov't Agencies",
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r1157",
      "r1187",
      "r1605"
     ]
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government and agency securities",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r1605"
     ]
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasuryAndGovernmentMember",
     "presentation": [
      "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Gov't Securities",
        "label": "US Treasury and Government [Member]",
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r957",
      "r1187",
      "r1220",
      "r1238",
      "r1643"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1349"
     ]
    },
    "jnj_UnfundedPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "UnfundedPlansMember",
     "presentation": [
      "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unfunded Plans",
        "label": "Unfunded Plans [Member]",
        "documentation": "Unfunded plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesNarrativeDetails",
      "http://www.jnj.com/role/IncometaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "periodStartLabel": "Beginning of year",
        "periodEndLabel": "End of year",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r747",
      "r763",
      "r1202"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decreases related to prior period tax positions",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r764",
      "r1202"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Settlements",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities."
       }
      }
     },
     "auth_ref": [
      "r766",
      "r1202"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases related to current year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r1202"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases related to prior period tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r764",
      "r1202"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits, interest on income taxes accrued",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued",
        "documentation": "Amount of interest expense accrued for an underpayment of income taxes."
       }
      }
     },
     "auth_ref": [
      "r1547"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits, interest on income tax expense",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Expense",
        "documentation": "Amount of interest expense for an underpayment of income taxes."
       }
      }
     },
     "auth_ref": [
      "r1547"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits, period increase (decrease)",
        "label": "Unrecognized Tax Benefits, Period Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns."
       }
      }
     },
     "auth_ref": [
      "r1548"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Lapse of statute of limitations",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r58",
      "r259",
      "r260",
      "r262",
      "r263"
     ]
    },
    "jnj_VWaveLtd.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "VWaveLtd.Member",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "V-Wave Ltd.",
        "label": "V-Wave Ltd. [Member]",
        "documentation": "V-Wave Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslation",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesValuationAllowanceActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation",
        "label": "Valuation Allowance, Deferred Tax Asset, Foreign Currency Translation",
        "documentation": "Valuation Allowance, Deferred Tax Asset, Foreign Currency Translation"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ValuationAllowanceDeferredTaxAssetsAcquisitionsDispositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ValuationAllowanceDeferredTaxAssetsAcquisitionsDispositions",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesValuationAllowanceActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net acquisitions / (dispositions/liquidations)",
        "label": "Valuation Allowance, Deferred Tax Assets, Acquisitions (Dispositions)",
        "documentation": "Valuation Allowance, Deferred Tax Assets, Acquisitions (Dispositions)"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ValuationAllowanceDeferredTaxAssetsProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ValuationAllowanceDeferredTaxAssetsProvision",
     "crdr": "credit",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesValuationAllowanceActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision",
        "label": "Valuation Allowance, Deferred Tax Assets, Provision",
        "documentation": "Valuation Allowance, Deferred Tax Assets, Provision"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ValuationAllowanceDeferredTaxAssetsUtilization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ValuationAllowanceDeferredTaxAssetsUtilization",
     "crdr": "debit",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesValuationAllowanceActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Utilization",
        "label": "Valuation Allowance, Deferred Tax Assets, Utilization",
        "documentation": "Valuation Allowance, Deferred Tax Assets, Utilization"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_ValuationAllowanceRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ValuationAllowanceRollForward",
     "presentation": [
      "http://www.jnj.com/role/IncometaxesValuationAllowanceActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Allowance [Roll Forward]",
        "label": "Valuation Allowance [Roll Forward]",
        "documentation": "Valuation Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_VisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "VisionMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vision",
        "label": "Vision [Member]",
        "documentation": "Vision[Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1318"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Average shares outstanding - diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r401"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Average shares outstanding",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Average shares outstanding\u00a0\u2014 basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r401"
     ]
    },
    "jnj_WesternHemisphereExcludingUSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "WesternHemisphereExcludingUSMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Western Hemisphere excluding U.S.",
        "label": "Western Hemisphere, excluding U.S. [Member]",
        "documentation": "Western Hemisphere, excluding U.S. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_Wholesaler1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "Wholesaler1Member",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wholesaler 1",
        "label": "Wholesaler 1 [Member]",
        "documentation": "Wholesaler 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_Wholesaler2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "Wholesaler2Member",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wholesaler 2",
        "label": "Wholesaler 2 [Member]",
        "documentation": "Wholesaler 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_Wholesaler3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "Wholesaler3Member",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wholesaler 3",
        "label": "Wholesaler 3 [Member]",
        "documentation": "Wholesaler 3 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_WholesalerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "WholesalerConcentrationRiskMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wholesaler Concentration Risk",
        "label": "Wholesaler Concentration Risk [Member]",
        "documentation": "Wholesaler Concentration Risk"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_XareltoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "XareltoMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "XARELTO",
        "label": "Xarelto [Member]",
        "documentation": "Xarelto [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_YellowJerseyTherapeuticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "YellowJerseyTherapeuticsMember",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Yellow Jersey Therapeutics",
        "label": "Yellow Jersey Therapeutics [Member]",
        "documentation": "Yellow Jersey Therapeutics"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1316"
     ]
    },
    "jnj_ZYTIGAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20241229",
     "localname": "ZYTIGAMember",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ZYTIGA/abiraterone acetate",
        "label": "ZYTIGA [Member]",
        "documentation": "ZYTIGA [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "16",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-16"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(j)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(k)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "30",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(2)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(c)(2)",
   "SubTopic": "20",
   "Topic": "860",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-8"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "SubTopic": "20",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-8"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-6"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-7"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-3"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-3"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "60",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481423/505-60-25-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-5"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-18"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4H",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4H"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "25",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-20/tableOfContent"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3B"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-4"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-7"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/220/tableOfContent"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r189": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r190": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r191": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r192": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r193": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r194": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r195": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r196": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r197": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r198": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r199": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r200": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482309/360-10-15-4"
  },
  "r201": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r202": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r203": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r204": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r205": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r206": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r207": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r208": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r209": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r210": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r211": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r212": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r213": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505-30/tableOfContent"
  },
  "r214": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r215": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Subparagraph": "(d)(5)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r216": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r217": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r218": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r219": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r221": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r222": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r223": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r224": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r225": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r226": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1"
  },
  "r227": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r228": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r229": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r230": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r231": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r232": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r233": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r234": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r235": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r236": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r237": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r238": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r239": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r240": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r241": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r242": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r243": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r244": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r245": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479024/942-230-45-1"
  },
  "r246": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r247": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r248": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r249": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r250": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7A"
  },
  "r251": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r252": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r253": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r254": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-8B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480627/815-20-45-1A"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(A)",
   "Publisher": "SEC"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(B)",
   "Publisher": "SEC"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(A)",
   "Publisher": "SEC"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(B)",
   "Publisher": "SEC"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(C)",
   "Publisher": "SEC"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(dd)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-17A"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-4"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482969/710-10-50-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3A"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-4"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480627/815-20-45-3"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-6"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-9"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-3"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-5"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-12"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-21"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-20"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477128/405-50-55-5"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-13"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-14"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-15"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-16"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1347": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1348": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1349": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1350": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1351": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1352": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1353": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1354": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1355": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1356": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1357": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1358": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1359": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1360": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1361": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1362": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1363": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1364": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1365": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1366": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1367": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1368": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1369": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1370": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1371": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1372": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1373": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1374": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1375": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1376": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1377": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1378": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1379": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-3"
  },
  "r1380": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r1381": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r1382": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r1383": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1384": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r1385": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r1386": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1387": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1388": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1389": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1390": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1391": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1392": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1393": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1394": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1395": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "11",
   "Subsection": "03",
   "Publisher": "SEC"
  },
  "r1396": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Subparagraph": "(ii)",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r1397": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r1398": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "1",
   "Publisher": "SEC"
  },
  "r1399": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r1400": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(ii)",
   "Publisher": "SEC"
  },
  "r1401": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)",
   "Publisher": "SEC"
  },
  "r1402": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r1403": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1404": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1405": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1406": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1407": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1408": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1409": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1410": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1411": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1412": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1413": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r1414": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1415": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1416": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r1417": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r1418": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1419": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1420": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1421": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1422": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1423": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1424": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1425": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1426": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1427": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r1428": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1429": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1430": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1431": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1432": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1433": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1434": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1435": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1436": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r1440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1441": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1442": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1443": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1444": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1445": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1446": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1447": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1448": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1449": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1450": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1451": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1452": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1453": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1454": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1455": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1456": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4"
  },
  "r1457": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1458": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r1459": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r1460": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1461": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1462": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1463": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1464": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1465": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1466": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1467": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1468": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1469": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1470": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r1471": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r1472": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1473": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1474": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1475": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1476": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1477": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1478": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1479": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1482": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1483": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1484": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1485": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1486": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r1487": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1488": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r1489": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r1490": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1491": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r1496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r1500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r1501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1502": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "712",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481179/712-10-25-4"
  },
  "r1504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "712",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481179/712-10-25-5"
  },
  "r1505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3A"
  },
  "r1506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r1512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-4"
  },
  "r1514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1"
  },
  "r1515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9"
  },
  "r1517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r1549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r1552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r1553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r1563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r1564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r1565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r1566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r1567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B"
  },
  "r1568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r1570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r1571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r1590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r1591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "932",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479664/932-10-S99-1"
  },
  "r1603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "932",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477385/932-360-S50-1"
  },
  "r1604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r1605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r1607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r1608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r1612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r1613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>170
<FILENAME>0000200406-25-000038-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000200406-25-000038-xbrl.zip
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MB  Q-=K@8RT:]AB?DBN%"Q QL(9%?411"-\V&G(B=/#2B=J.58/4#4M[I34
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MJ T-;TEH._:+[@6DB?T<J0MO+TQTAVXB(5'3@C/?H 6)B:F]-45<4LQ%1%)
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M6O_!/F=(MAGM\42C[9T=0P([1C':B#:3S?AJ:S1?$U%5SRV6*K<HVRQLKR?
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M9C-QG>MI2M$5M7V\?5Q$I,F*7*/#0*M$HL%O4>6EJ0@FH^=P^T'4I,AP910
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M+<V+].YTJ'<1D#?NQBY2D9N&1<>P5090$"[VI";$.P_+WUA#:#:+QR#_V*!
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M'#*AM1>C%G3'AX_N8HH,P'E5>?^4^YKGO6]9U9_^G:]M?M?L?U!+ P04
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M0$!.]6EV[?O1^UN8J8FX[TUHA%>Q2MUL\@G>;_S:3V,[YI/<?U!+ P04
M" #M@$U:V,<"S2L%  !4%P  '@   &5X,S(R+3DP-F-E<G1O9F-F;WAF;W)M
M,3!X+FAT;>U8;6_;-A#^OE_!.5C: )(BR78BOS2 Y]IHLB(98A?=/@V4=(JX
MR*)*4DF\7[\C*;5Q7MH,?4FSS1\,R^0]O)='Q[L;YVI5'(QSH.G!#^,?79>\
MY$F]@E*11 !5D)):LO*,O$U!GA/7;79->;46["Q7)/3#/GG+Q3F[H'9=,57
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MP?1,D98X#H6;.4I4E2A@A9G.1C22X08GJSWHLMK?IOU>HU9BLM_I0EN5;]-
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M]VG((%&F<)6Q,O+BS3^3GTQV#3=7]P.^V^AMC?%:WRMK325O8>>7ZHJRY'
MNYSYB<^T3G;P1A2_S#O^S:6PQTD8*!.KY%MCH<'+9KG,-0)IJ/SF]<#E>'K
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M4<@D?AN!2OS6N,SU9GH;N7N->^$<?XZ'UL$\2MVK@5#-2'C^Q##-X_W#D^V
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M5'W8:/> _7[;6)HZ%O7;4";Y@7J.GSQZCN\_C($4Y>& *T1DPF,)_XZ\4U,
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M[;FN=\="$-(W;L'=W-T>J+RR3]C;YEW:?'N+>8?9ON7FKE>DY#?956F3:DE
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M:C,?'=DY[?B*_"7[=D_G+TN7ODW(.Z?.7B/D=CY"WCG]\SHAM[<7<CL?(:M
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M^Q&<!'KM@IDZ%1H)]&6+:NI47R30ERZ\D;*L2$ L7\BA6(6/@*AK&*!888^
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M0K'Z_IZJ5H1B]2,*U8I6>V23",[JA194O"(X:Q1C4.V*X*Q1L"%EZ8H@IE,
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M45Y+2FZL6%$49:!4XY!>$D"H:JE4HW;V*9.B3)9JC,L^95*0[3J1D@@Y\]S
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M<A/+ I9ANX8=!@;8"A^&^CY]*R4HZT;[N''R=$ZV[>>UXU:MD4L ( ;5V5$
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M%G$OU>Y:A;1[B[EN;*/=N*=H_;BV2;D?\Q5E4N[&L\J->VZ"<K]]FG10[K6
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ML/EHFP<&AU>8P@U$^K2IS-O8^;9YVVU9?'YU]OW;Q>5MW^A=GEW=7%_==/$
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M!3UTY^%=G7156-QK&K.[:W87(.SNWZ:Y&PO;<2JQB%"0+TD397OU9TET(X"
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M:/AC#G%+Z-F 7#\<H^/"JE$ +HS%/YQ_*%J:)Y.8W!IX$-X@]K&M-/9[XC>
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M\T%F@3@)\O_B1(1%X4%"-S_/V=L=6N\VIU)MNQ/>#^<BJ*SI)#GZD]T8Z\B
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MT7($)O=U/';7_]'XIY$?\8ZLPU_-I$+>$C-XIV<'(B.8&4Q?@W.>H1JPR.K
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MH(^@?>5J1\,156DO?)T?L;PVL5_&Y:XUM;D!S8PQ"SGE9N0ZZ<:<X':Q/VJ
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M?.(,.C7EHXG[6)7'? V25]YMC[MJ^Y?_0P!=<W2>6&C4B2,;%^B/0 :?;EO
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M;CR\P9U^BLPV$9DIY CZ-2LIJT 7*%Y#E+C\"5=]3'&*;L<!Q29$H;\<I4,
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M8$]CRIL[F=_MMVW**0H[6,Y04*^KO)6>&OJ,FBD:]+'*AQ^YUC#F<16%RX>
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MQEEK!^MFK7B4<<=S?$0--WN [7&N,T6QT]W(:B$QZU*Y+7K/6!!A3G[,SZ6
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MMV'#S0T;/CFXQ6E>S?S=X-7Z!H*L08]!K:-;&]P3[!]J@LZJ<]-EX]5B[A*
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MK/"9*P]C*@"\C1QL)M-/YFW=M!FWE^*V"+TCL:XQF#L+PSV^CCD@D7%UD-1
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M4TM012A]WM:3K-3&2OSDPT'R"N04]I_[&#1>EB:-'<'46"WZ(X?:$R8,J9G
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M5@T=_AW4T$\M+/+WIJG:VLHQ#AQ^4UKI7X-@6Z^IECJK$RNHJT<0#P;)J?U
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M37>'4(XZ?T>5\UH^>4/0]8V,QL],:?]*4WIAFF&=,["VTZOH%B=X-_AK>9!
MZ"-KCXI#%G$I:_(@L,4>)M/LW*"Z6 $7Q3+9W3],K0CA!YK9O*B6!C0-CG7)
ME!-[PQP6V76FP.M&OO0W3699V8ZM14EEO.C-FQ6&C<8SM+)/K,$YH5\HJX,^
M<FJR8C$= J<]SDTQ8C"UFL*XC_1IMV]H]Y[7"ZN@[/AAN0ZKMES0=&6[:?2>
MUV)>V]G62VMY6\&0L/W)S]1B&S"$4.\M'@N-_\(4Q<Z9L0KMBZ#6=X'0=_7;
M0+[0_:8-1/'*1;5Z 7[HI?FBH@ZF$^8=Z?N0/ )OHM6U[Q$(?E ET.ER@O?-
M9JU2>+PNQU1#8[?&7G\#]'R:_&K:NFJ4^O)M.90/OVL+Z])@,W]:6@F^L"Y%
MKE3))UD]RNT(K?@'@HC';U6V]9^;&>!NX;'+W?2I0&"$JJS\K,5A8-X)>[;L
M>M7V 7EAZ@;\FR@PS_@']_D*/TVK9@[&S$9(R=QYM@=M;$@7X8^H.)K7@72R
MZ\5+J[3-;CFY9*!QEP=VF%W1O(HN$*VWW"(JNY]GV)@T.6WKB:GM>G76Y(%]
M_3F6NI"BIIH/O_7Q7J.1S+E].1=,G<)_@'I\*&7JI%#I?G*U0V/\.+HKB/;@
MX6K%ZQ.L*7ZD2=@K:M7OG*ZT3"A<.WDQRD7F4ZO-K::&VUJV-9T6]_PT,4LK
M[5>7'B\:VLN2#WN=SGM^G8EH0'B/[(5Z88:\'6^RCT#1G;Q]\>8AKF#,:;"N
ML_N#=[K8JW]\./BPCC"BZ8\R.+MKE9%A >99Q[E7&+H J&W1B(BP";%>GJ-K
M%!5$=6((K&KJG'H[94.2]IGGD84&**"(0*[$[$+!LQ&HR.IL9JB 4DJ51EIW
MU#/15"<R\P5M$Y#Y43.JWP:G ^F#NT!?7+DME=N;H=([T*4PV7"ZL@+<FZJZ
M*,,QNO(_#&N4+>V1V['_">U46I6J,?X=&Z687I<:9H*5(K(C*;@WY"+2^+.Y
M60A7E+ [^66U4YHF135D[6\7;$*,6VCX&-#S.RM@P)6%BUSJK*R4(@V H41C
MH+?AJXBTU:[+9LE(53)H[%Q#@])T-CPOSZOBW'1>">8KL9E2^8@>_U&G?R5^
ME\]P1OG8V7>!!8OIM>S \3TO<^G*5$,KXXBR1/#%"-7E).S1+L#ZT>@ D)4+
MUC/A&X.GYUZS>\HMJQ-@ E'\KZX6T-$R[A8(VV+)O%[6BBSLWQ NL!^#3N[R
MO/S#[[938RE5V\[P<^;IV+I!PZ8=#L7BPWZ1\: '2*T8GMA05QRMWDIK'E8E
M3;)&M26"I+"*\:J<BH'!L:)EL; P[=1:(0BEG;JICKA#KZ?'$Z[._N3N=QOE
MXD"&)V_1*]8:)V2:L#EI3QT)PEA88++[1\_.3)';L]VH 6]/%UB EE 'D\BA
M -G/HK9>#3Y5AL::W@+("7LR+Z P6JJN/FMS\ _)N\2[H/)TG+O"?(+U0Y9K
MPJ:'@2&%%IOV31G]@PP0ZQJ-E,B=_B+\1/;'9L;I 'RNX#-OK3:[=RE7:=.;
M&S7*^#5V@- ^F!Z#;N)+9S[A-MJ!4<GWY19^O*AV]=HR_T\+!U%CRFS6R1J9
ME>; 5.A;MS-<SV!-_8@7%=29?<3(;M6Y(35(+84_BMAF!5?-JKJN+E*5;[3O
M, KMR*P D>V%&B6'S=H &Z4$?PU8#2$\Z9]FI+2(9/=FS<+:NW:CEE86-6KQ
M"&-![+WO/?Y?32"1OVVEX>M2\DG_L_MTL)=8.ZG(I3\"RSUV&=;Y\7 +"I'U
MLU61PLTSE4)S2*?;ZL^QV3'E%!$TT@EZC\2B<1\\1U&'@XA!50F]@-0]7^2L
ME3N;[HX45H#5G-O\C3+F(=5ZPR^)C[S@U@QA!R-7"*M7F"XNT8^#Y&7T=9%>
ME#O$9EOG2/P\&.=L5@4"%A>MK>>P+.TAF;2HY8=,L5(@@P\OHM2-$0^R3EOO
MB&JR>)VU!-=R=$Z,:7V?EM>F>DRH7-Z/,9N(D0\OT3JTY=#N]R_$[C916\1N
M"6( YQ29DK;I@6RB]JC6LVCP3T3O(R<IEFB.Q50H4<VG(6P;.WA9#?NBMNX\
MP=I6]LTS\&($ 9!L-*KA?#J#R?H?/C_:5$.BL>-EA5CD?<+MY$MN-5 I7 A\
M!_Y_]MZTN6TD21C^*XA^[1UZ X()\':_,Q%L6>Y1CP^M)'NFY\L$"!1)M$&
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ML-?9NM)ND=S"DC2%EE5..&QXMT,7AFVM*XT=)P1_])HM72^(>8&HM4  M"H
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M^![NX#T)$E*D#P3DT[/)>3@+G".?.P^P$Q <+ AP*P90&Z!+LH$B9_1.*73
M>*%W_I(L>N7![F@%P56$[R@$"_\<&P&^4&NW1PK\PP 3"+<*.US".9U O'&!
M?^*CMCBM/O,8?>K+],YHD^S'DJ&$2[C;UD/'F',\;3\N8H++&'K5.B:Y=.Q)
M]W/+F .,;5NRX+5PA-06Z%Y]\+.?B*((FE4B[5_R(15+52++"6-(O@&I%0!3
M+ODC*"-RX50'*X6!;YELPZ_1PD'B $J-Y+'K)2A%X@#$"V+C2RH _0CAB;S?
M(-DYYD"]A7: >]:E:>A1?2%H,]"/@BG75$FE$'CI3!D>)02Y:_FDNW/5?T?I
MKFM_/:V\-= PCRC\M*Z.57FR"*Q[_N7;Y?LS=23=Z09=N8 D8X"N2L'T,P/I
MX!L6<XP-T!PHZDZV5%OI/ANTO#0VO;>L_86JE[2);L,B[G3JH^!_H/<DYLW-
MU?7XV_CVB]1B/C 4@,YA;U*OQ%^[SLS%,W"12KQJ.?PPH+#F#[YE6#H7\2"]
M+939)EO /Q6I2FB..I8G*-:-N07T:B8RX976?MQL=F+PD-T\4 :/&LXW($SA
MT?@][\?7_QY_O/B7U#)U3P_"A3"GD-H2Y"3:+F5*$1XRQI8B_1KC6TR1EEKZ
M4K=#Q+?)N)FV9G<77CVVA\['U]]^_\?MI=0R+#O0#7T2@,N&$U/"P+49* N[
MV!EDR8#]&59 FEWG#7GYFYUP"IHW]!#2;#JUB/3!8@(S(M8?]H,L0#GUW$4.
M#?/M1C/0I%: /.,#-/3)F?'GP]T;6;H=?_QV\3M\I=M_AHQ_%<SN_#>TC^O?
M?[F^^#;^? N 7%AWX(K@#^ QP+P=FEPI9AOARW14SYJ$04(#*PC:Q+-B"DTK
M9PK-FPA=Y#S!J=@/V(%OW2'PR.J*AJ&"2S3Q0@"V-8D?FMGN)*5O\78<*=D/
M/81HE;AW0Q?G7''=53H1#S_"NYK2>9QW:>5$I )4YI+H0RBU%DC&L+KN<,H1
MS7^D%CA)[(>UU&=O5GSA[8Y21"HQ?6TX>'9-V,[OG_&MR7;>!KJIVSKX&&^J
MA>EL[>K;I'+U+0?(!GNGGZ \8^=TE/9CNCB!HWC.C\%?+="E_;H%D%/ 1;JT
M!/@9J.SU0'+0S ;;/?1AVP!.LIHG  _F+:P 99=I>6!C BQL (N'<BJ".<).
M!TG$_5'))7S JMQ!(/BC#!;?D\_K1R_G+A6W]SUTKI9 ]4"NL"T/3JP;W,6U
MG#O7OL-E'-<YFV$4B#&ITVW_ D_"=F!_R,OD1$\!@0O7)U<SSU4SO7 &NL8/
M)W\POOD%^ ;6TF8H1=F2WJA(OR!#1V]"?DR_>>VEAN[$L(T]H/5#Z1XL,..^
MK'"B!2#2KUYUQ,GUPBT05M*N$2@+6(+@ (:_X8:X+FGQE?VA)H5G 20609M_
M#:Y9;+MQJ)"9!]H'L PVD$^_%CN,7& /'J;/02_9J&_@?6!/P)NF@$^' @_
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M@J <3)!_\J[<'0ZWRL67L;!J!\;^0#T"& \6:*L>2EJ=S>9F0]-% +A%/S8
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M+Z?4\Y,/OED^N-)U5N/YY^[):K??),M4$&_M0=--\E2,E0U#^922#6AL.+<
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M-658L,7F_G8\++3?-"A'BC9"L%UY[,YR0]]^D#PV99['3"EP)=V7+IV >7<
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M2$YB_MPF:HUVLFUN;.@DLE*\+?=.D;\?RZ/Q0F%E T3FV]Z27W]U:;J>;^D
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M805X ]+(A>,Y;K&")P?N,0<[)\15U'\KQ7" S-F//A!@M7<_@5/.=%P7LRT
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MJ0,G0Q3=_$#1.MOW7OKJD*::E>>O@>GSD<TLWR;)0C&J%N9:U.J4J*FE+XG
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MOE%IB<X03['O^H58\8N(N8 =M.!]GZIFH9ZCCX8]2G6#0J_HX%,8/+IZ9GY
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MCD=^1(.4LX7),.X$["!GV3NZ:B5?0(1+#88SAV!342Y9/'XI:PWF[2EFQ<B
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M6@N/4I=P0?LIDU1/;%)J=2<OHI_1+12CJ_Q1>SU9[181E94_:0L\KIXV*B*
M*G]6=2"W>[E.3/1Z\?,.SXO>X<I:;#B"01LA\.B0UA-<HW)F8CXE8>U +51V
MX4R-YBC-4?9TE"8YIDF.>;'D&$W6AJ-:<$YW (99/;1,JPOV=$^MB9>[GG]5
M.:OFA))CNO60!IV.5HMSM#K=FB3)K=Y3UDP(U"PUIB9Q[YH(@;J(@&H+@)/(
MC='D4:=J)D#^6< A&/8'M3@*.@2]=N6NO3:$E=?3KRHG"DXU-Z9;CZ22=BU.
MT5)K$B+H5#QI]D1S8^K!1:K<J4M-'1ZE<D9"L<RK8KDQHK'6^L7J:>;.O  X
M2F)#OE([<KM02EOM0=$=R5JO@01Y29AU7\@FJCTL<G+/<MJ %FU\B/_<V&',
M<DSF!._.^&=[E8I=I?><.=R:TNT6O,S=WYY7^_;D;S@-S)$RH@RJ2]X-/CLM
M(AY6%EV9TY#IX8 G"BQX$S^<S+&EF><KM=][Y/=1AT]YI?<_G_K$?T/C]IXZ
MW;NN)*25@H2&RG"8(:&E9]&$0SY-POP#J(B:MS7=NUDS0_S(,\2'S0SQ9H9X
M'1N18U_J8S2Z7IE_U32WWK'W<SD[4C?-K3?90QO<O_TWMRY-QV%MI6<J2JJX
M*32V*,4/5GJ!UN#$^^FQ7*XS)6V4$6<K_8KK<, 5,A4]=#<0:-.F]MEG/13V
M]UR+T1RW.6X%CUOC:IRF&.?(Q3ARMU>/EHX]>523D[3@*,.:M* !^JIW>\HZ
M%>*H6CT8J->M24U>K]>NB1A0AW46 C4KQ*F)&.C7I!*G7Y/\.DVKM@PXB5H<
MN=^N&O?G'Z4O]_I5RQ;><,G0!Z14+NU^0XX88*66_D#]ZW#4FC2I[=2CSKC5
MJ5S?ZDU>9\5K=$^R%*=J1D+^*48U<1%&E3,/]E"M?YH%-M6M#P#G8E H,E?Y
MDX+!/CR)@X)K,N@4BE%6_JC@&8]RQ=-*ZFS3F/:EUJB<8=@TIFV.TARE285I
M4F$J0&R8"C.H6L!X@Q<E:X4F(Y3_)&!?:KWZI,+T<JJCJV30G% J3.4F'&X(
MT]4F)Z[?K8D8T&HM!&J6"E.33+)!/:19:Z350PA470:<2"I,MQZM7/ORL'*>
MS<9X\TBMG S8&%!N5UP,G&PJ3$TR9&N2T=/2:I(ANYIB54.!4,-4F*JUKM]P
MBKHTI&W7I&9F)]N@:49[6KTV,9=FN,/TX_I" CR"41$)7'M M 9RNU-H:D_M
M0;&>:+9+(]H3Z2):U4:T@W9WIT:T@VY[;XUHG]:'MK]GRBC6 @@@"K"3;O4?
MS'^W?U0_:L2D^C**K02X%4GW6 )GI$=30J0LR"& ;Z:A8U)'0&PFJS_0GT@,
MP9P!07@>\)OTP'2/L&MQLJ$O@7)".R BT9T'<#*F4P:_-I@T8<$]8X[T5;E1
MI%_'XZLH'(&=S' 9V!D\OG0]_"1+!B:#53S&?T-4X./.;$N?6#8P'O,5Z1;>
M?NXNEOA:Y@?6@H@U[TE\6>K1Y/S,T8V 13N9A<C*KL,?\' Y1?H0!B' SICK
MSHQ1RSG\L:W?IWXE+?0'28>#&T%RB@(;*2EEYQ-5&MQS0%'HX%%G#JS SSAA
M#IM:<$JDFQ HP MT :Y(6JY@;>K:M@N C"E$EN[GEC&7ED!5AF=-D' E\1I\
M'B@.OIF[MDF@7##=!^1@ES60+P$\$ 8)V4XM1W<,T&H )< 2_2J]UNH*2,&9
MW<(_O@/]PG+LQY)Q0G'AF.)S.)LN* >OX!7ID^[H,[[6!.0]NX/M!W,0?&GB
MF8.D39'KO1O"81PW )B"_-4E_!A5L<0X/=&A8Y#]Q4\SG+MD'J=8F;OX4P(G
M;#@Y>W282M-:/E.E61KQ:=M =J;E"T(P)9!7V#8Q:I(-R(M4D,2UCSJ0IIZ[
MD)!J+0< [Q XD63"B6^9ENZMB1K<#^)KZ;EWUNJ>^$X081MV@NNR/T.D$=C.
M;[H3ZMX#E]=\1T.^HXA[-N\*6 4$+;TK7AVE/.A/^ WS8FI%:PGHP0J8_0"0
MM!R@2]A3]E3X'L?T\1%4P)83,OP[^GE$M]&+B))=GZWL+R%(1;J<I@D7H&18
M:&D .^@@/N$IR83_Y2]9Z@ I^E?V-? EKH'R0<ZLQMEF@NKGS] 29Q48B06
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M&/B?_V^HJ8.??>F/T)QQ6R66;+"32;0'6-@&EF6T1UF(=Y L-GB2P,8RO"@
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M[UV;VT:2=.&_@M#9V6.?@&@"!&_RKB+4LMVC'K>EUW+/G#U?)D"R**(- AP
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M24<J<-V?L!JV(%_*7_H+S%=A'XPYH1".3XUUS/%<VR:%A;X^O(44.+8QH/-
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M?/.(S$NR4VTUCHM-GR+<VU*N8R<!;];K7*3:W3&H/NK210>3K+=T$"7IM]$
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M;ES<ZD:,3IC# 3OC=9I" R3505@&(W S3$>J2@4;^.R8FHF;"<(!S:WHJ^0
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M1<"30HM2=_*4X,<0*5HB,=R+JG_X7-P;CH,F8%<E6'6YFDAKQU&"Q$'BH(%
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M('"?G\48C%]==X)378I*8.?LLM-7>[OIA=HQ(#.64CX##&" H6K]_1R+ZJ@
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MJ"M\E'=_NT-R\^U+"KH\7]<]+HL.C7\5OCN?;6Q'BD7;HLTVK%![W17J&"4
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MA<A*E2NG$?7D,Z[><8_Q?4(OGIX4Y81P(YK%98@;V1W#[+TAXLWVLI*=)\&
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MP,$4#!H1G5LTQ0U-VND)V[Y.0&&QTZBZKMUK3GH)GG-AZNM _8[:T1OJE^
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M(]=IZR#5';6?,J3M4))="RZ7F7(X&&\[U+/?7>\=2'<C&_[NR-\,A)J#\==
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M5O>IO8?R83=1?IW"/3!JI^>J)O5J+43I4)[J7GJ3>C6-;N,Q%714]R+Z@/H
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M+3)@]HNR\0(LZVVWAK3:\5HV8.V(>;=36;WF?W8>0'XF-XYX?33#_1^N9T_
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M'\3^JF3T8(3D/:W/8.[-8W$1\RH'HD4AX^G2H[E1Z+JY)H_HL7 B)M&2=52
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MJ3&*''<&BWYYQSYK5#?01G)>4$ Y[AR445<IU%>ON16;A=:;!*4UDBT$&[:
M$$(/%!C6!$)PW!\D"%=,P_'I,#W/#\E,L$/!COUN0'5!2!6@V/,B/-J.&PB>
M+RR](" ']SJN0&S?A;<'(V%?+3I*#'H?B$'N!#&8(Y$2PWW*]7Z8YI$BB;GM
M^,(//%N$)R=<@' ZH @DDH@DMO>Y)!2\N1#:/^%3H V643+U5FN?+(@; /C^
M_!^2+KYR7/B0C X4:29N/FU6L/%I<0K26S8ALN \&+_? 0BV_(C9Q2YRUQY0
M,:MF K1A(PE%EL6QX3K"$P$< (^"7$9@;@+ H_"OC8=_3'SO.X!R#8")GAL
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MPR,!62D=D,V.$;--=)W'[QE7$N3'.9B'*.PB Y'%6^$+^$494M:(X,]RH9R
MS'H1@-7-<F'3\P0[>0"6!V O"@>4#_W<MG*IH"L\Y +NPZ_V$Z;Q$%3WHZS-
MS7J]+&5V]S3R5J&0)L?,V:HI@)6/,5+NW=E#A))/)/P\_THPA[9T9;LA@5(J
M#Y5J3:TXIANMA6D7T1I%M';6D.IEI-=?/6]&S^JU[Z'=>CU'UIGIL:C@^8?G
M?__@?F'0K$>%.E*A6<T%UT\D%14:#2()XZ1#2\L9T74+HN*]XSK! FN#4&9P
M&JPI*&)P4@E<CP9-ZG&U^)BXQ@5%@TBR!F,]ORU2IZ*8;<N94R%,)^G0Y!&G
M+C8U*"KI@&_*<HLLPK$J#U6U3CXKIX;N]"ZH10P2YJ(-);-(/EHZI+@?A,H*
M,A8-2AG7%)12*P6E0"=> ]T]?UG:;@CV-+8C66/$[U202LX(4LD90:KXX4-A
MC8^GSC(2OR W;)4519)9%*F9+69L[-KJ"XL'K-:G<(%1WVV7"'O7L1,#V3[P
M*<,!UK+S$!</<?$0%P]Q]6O;/0MQ_4:/ >P%@S^<%9P=/PA-)>*!C\9#7%:.
M)GU4?:'MM+/49RP-E'(Z?7'<->!6LN2F48>U?58/PE"O-\X25\D"Z)/HKZ1Q
M<"W'S)DI3JE'<24-<9UZ912)CW4JC"#UK @R&(+R1F/<@LCX:$\7\*'_?.A&
MX(2828C:60G1!#W9JNJ_[2>"]+,BR ($F4/+R&D.? N2XHU':R48"EBJRZ//
M<UV.4Z)Q3DI41 R,RF:E+M7]Q$_.).2&\2,-QMI0EW-TON).D"L/3)]TG ^%
M1X1Q.=.Z?@SR>F.,C4:<&R9\>3!6S:&1UR2=X_=,,>2&T:L >HVA810I5"WK
MW8V V3&Q=L2[B^6JQX)\E9V$!Q"HY"3,A^(5GMZYE=H[3+Q-( )^7Q+\!0@_
M*N^GGQ]EBM+\H%*+0-;$YCS%G @JBKJ+$0%6/AA#TR@R&(2G*>9J@RXIXI#B
M^6I7I$M62&!3L))#'&JU@G"<.JY $ZU"'.BSMX:F57X6T_4V3)G::R>DHV8P
MBR8D/@E"@?Q<$S>@'>S7MA_&'?%I(AK\/DVZ\3"[S9XZR]T,EJW4'0D?#I^X
M>QT=9Y3*BZ/M\Y4X.TX6GF )Y:1)7O8K6Q"V8PK>[!:310Y8S)'VA0DKEF@T
M++FNG(ATF859L+"T;A@OC *OW-IR8I<EUJ:*8,N= AH\9TVF..9F^3RJD[)X
M;J9):G\Q.6.WD>ER0R/D=&1$0A.DC+)'[1$KG('LS1B#?[A_O$PN_!U;]X=X
MU4G5]?,\@=H8Y5L46SL4XS3#45I&"I,F&*/=I<NX]+2;(5YZ;=9I=_4*KCX=
MQ]L!?H^YBDZ(4\4NL-?O:WB*#R:53_/9< 0>:[R%2<=> -P"_)2CX\=G5!#-
MU&-.%&#*#>VU-3^>0 UOV^-='-]"EL[*<>FU<]];,08/ I*3BPU?T/<=8@,/
MW9DSGP-VW2E*#EB."SN9D/")$)<^'B>ZL5>P46?X(OR<EH2363PW;HH:X/XX
M0#Y[K+V\<QP8)C>3F(U3S,PS9F:OG-EL&15+G-\PU\QSC!1K<E]2H7:043E/
MM#=G]2@$_I3*_#L\S"59MO[Y*(W^6#\.!'L)]L??%QZ^^<_V:OTJ^IU]N\^2
M$NR^$EU+VOHG$L]E 5%\C%J)4B]=W)9Z=7;XVA74H&F5:M"PV/H)E LPK$$O
ML=U'!Q!ZCP=4<*H*357356BJFM4J,7XF._78N?T8O;12&1I]3<$R--31=GT5
ML< \)'2G,S*G?_P&!V)JX^]^1BI<#)S7SQ^QC>B;)>SA2#-&5;N>ZC59*U6]
MAI?12#O]C"HP.WW+22&X3*6:>K4:@Z&-++.IJK N3L-K<DV\4JW[:56\4HU7
MJI73_=-G.VUS'1^MPA+.UL1<5%[Y=,(W<J!F<UB5@U4;F=,MV]/9>0U?[)!V
MC:=N(6S[CAWH [;C:#++?M9C<PO41J968(T9#B4DI#ME)&7H6Q,[(/@$.!ZE
M7TN["JXYT[C\B!++.AVC>7_<8JF4E*?J@[&J#O6\FL<;QU&Y1(:<3(;&<60
MCL2AFE<%> NE(ZG<R*2_OD\4^<N9I$8B\2T9K"I-HUA_I@\E.1VWNB+[Y\QH
MJR-)FL(;EJ6I0U-,!WI_O=URD^IZ5ZG\PA[7(IQ5\ZF0!*9AOT-SJ!F5IN-R
M_)Y5:ZJ"7VQAJ UUL5ZY[?47F[S9!$ 5Q&=Y$NB/7#CK(#'Q;.>\/V5B\DJ$
MQDP\2<Q)7FS:?M!DF@VM2+S0Y!S684X&:./851AVY1YTQ.?6834SH[K :<C,
MP/&2DC+4,MJ3</.P#5'2%-XTVM](-]/NP8N;AQ?QS5=7IQ*6X_7XZ^7B_GIN
M$YU7%:QB%.G8^<70<PKP.7X;LWFK"_ JZ#5P+(V>-R[OADS>4CD)CMM45D*O
MC)^:60E]A]7-9"5\VWK$KT^-:2KM0,[$FRATER++'5>Y!:+E4J;W#["Y\Y/,
M[OY-?&][=HF[L\M$[J&:<NKTRI9 V0Q$42$6142N)7GU!F<Y_.?TSJV'_P(*
MC(6S'0VIWLBVCNDH1V*-&W^Z  &%Y7UWT2A8K"0D-GQ.S<D9^4&67I]:[%8@
MV)P>NVT3K,ZFILEY@[(XSA(XRVF[VSK.I,'8&LIY4WYO*M_A]-S'0M82]Q"T
MY &Z,#?(=208QWAY^9?;N:9EA"N <'%HR8TD1A3I7G6E7J0CTK%&.E@]8#77
M3JS;GI6S"-64K[4^7ZF#L6(,]=9;SG$*.8<0;H% -" 0=2@5&A6SWU.A:.DT
M_ADAZ@X%Z4M)':DQLE"A<\.7=^RS1@6J-I(+E)L?\][)([.@\ZZY%1^6<V:O
M-PE*:R1;"+8/KO! UB%938@?]?0*$WWV;-?U-NX4['HP[]U'$@BA)SB@5'\D
MLV\$3/N)3T?Z(2Z<\'G;^J>D?#.RVU$UFV.T:TFEXQRJ43JNQ [#N*L6M@_<
M.HGQN/2P61* @AH4N,NWY,OF67AX=N&/0)AL @!YP+H%8+\C;*W@S)VX$].!
M"3)#4!Y\@N!#9A0FVZYL\*D'Q"38PAZ]  E,[YR?=PMG!K!_B9LR!F-98UO
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M'Q4OP8XWJPU3[8\S'8 B=);T!10HRV?J8]AQAF!3% 0)IP0%DD]U;S0SITL
M$&B[#'=;7H^6'8"DCJ&/V$EL/LE_U\0J?Z4F/57CLPGDF!Z1\ SM8S,"R(Q,
M4!"'OC/9,%L"G5J[F_:>>X!Q5C/%OH[KJ2(4[ 3RT\*94OI]%CP@#W\DI/82
MF8@IS]T!%X4+W]L\+A+>J/V.55N4(T *4V-$^2B+T$_":L.B>CPJ9K?R )N%
M"2$&M8%<G2 !AVAA6V <EN\)V&J,N=&"M1=&G%_ K$7SC8(H/IGH:7<@[C!:
M$AR188B!A",O$0M(2 .PSC[,&1@0*U1@V <'H.L!MN!>/T]J#B.Y'2$C@M7,
M";:!G:MBO#W7WT[FHQOXW<;W]L(A:"A'QO!LPTXHH!),6$'[ &F)NK4 ;K*H
MJNRXRR+\^%B+WOM?0>(*RI2QUPZN<\+(]<_.4#!.@LTD<&8.J TD\C#$3@NZ
M8"8/01+,-^XTNB5AC0@TRP'7Z)/99LIN_.$AA]%8%'6!4*]:0DCL!9RNS+>;
M[Y>(E5:JA<Z)CWX31!M*+Y1=>SI;HI2WX&E8O@(]9<X?:9YU#R?$;[!(U#/?
M@W+R-R2N-VQ-L "4P_CU/8;;O]D_LTP7[$APPK"*A 8^X"ZT?U*-*9DHY+@L
M"8NJ8 &)?6>)=*-$DA' ]\T>@#XP *%,PHREJ,A:V7?C,7$443K2/ACDH8.A
M'JI51:P46^S)&%=^"":A9>T4#NKAVYD7/R*MKEP4_BT)IKZS9B7N7[>/GT9%
M[WL8B_&TPXHQ&+OP<$&2T?$9+E+Q=B9;X"S:+%F$9J?V1) ZU'_IV1SO!KYG
M!S@%-8/[RO[IK#8K84G<1Q!P^% 'D$/OV)[Q6ZPX+%)UJ-AM(V?P?3F ?62O
M_XV^_?/\&[P[TL[CYI5[,,OL,T%AM8.BF=EH@@%T&"D!]/C:4ZT2 3H6T\B*
M.'[;DIP &(@;:OC$7A[&V\"X@8/%F:-+UPZR0_A!)&O1]1L]X3&E#P)0$Z^:
M$5CSBKIR053#<C&7Z>"A@.45AI"B%(-]0XJG[+68LH=Y=N6JK$\F_U6HC:Z<
ML;9R9K-EU/GAK(EI+.5)/$<F7I/[D@HEW$6)7-'>G-6C$/C3_QG\X?YQAWJ(
M),O6/Q^ET1_KQP&<:B#5_K[ 0]3]L[U:OXI^9]_NLZ0$NZ]$UY*V_HG$<UE
M%,\^[&P>8:E#[F$*!\@&FU/OW,L?=B[56!'XX&ZUIL_S;;[VEUWH,IW/AY&
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MY!2A2I%PAI&)9'0BH:@8!?_R%E4='P6<\-%9+G$T40EGX.G-%XNOE09@MV1
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M^MOG^7O'M=TI2)$OQ*>LYT[)O3O;?1QE7_SFL5RH;[@%U+I?+[WI]QT?PKE
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MND30Y!!SN'1Z9V)UB:5\@(^G>*11@XTFXMT_O!%,601- 5[A$P+V*-"2L'!
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M:;WOVUD>>ZECK'7^T@=CHU#+F.NW6;[8SS0#^ 5M!WD3%DHY):D=._F(F?Q
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M!Z:3!Y^<6;AX*8D4+XF[HFQ'<7>+/0F\Y28\?LM^GJ2>E2=)=[%[A3\C_AW
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MBNU'(I#85R[X=DA&J=FF/<:<W G,F2.18BXQ\I2B2K!#X2V9$HR<,&Z7K:&
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M Q=4[K9#@15R)U,VQW0"F\FR+8)/CX22I;WU6V!6N1?,:H[$A%DG;CP%AD(
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M<8-M]"Y%K7"W:(.QJ91H L,A;@?B\E*S-L3Z8&R)QUI%7X,,^]GWIT\.%M?
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M*)^R69&./>'E5I6SGP,_K.$=0;>Q/C3E4Q-Q;QG7#KS.U8'%"H9#R3CF]N+
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M2&%Q0O58,<QKD.I?212Y9 GF"Y?8)W%7AI#_<J(%/ ]?W,?1P@^2>D<%;*:
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M/:09!8XW<>,I#<D6Z*82;#K3$D&)I>)^$_[E308KACEB9\"&VE9ANT*SPT#
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M9MR]#$@9+06\:"_+^F550/BP)>O#^"%TIHY-R^\L;("4'KH)9=C).X,_V%D
M9QQ:X$ Y5EXFB,.(@@D<$K/J"52NQ<%D0;<5&V8>^/&*'?KV)"DL$1 D:OH#
M=E1/+VK+9!6.-;<AK1(!2#)*Q8;U'%!XIH_4?9)6"4+^HUY:/#67/H@H6O\C
M3+%(J_+0JAT712*0*EN>IRVI$B.#I'6R!$4:;I[=_33OLF)46Q(;57^VX;'H
M"6Y6E#\;E0V'VU9O=HZG G5_E-/OZW2J_TA2*X6F=>_+>U:L"\M[AG4E756
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MK*&)(F>-OK!&VY> 55E#HJS1L:YQ)1;A.UJAB6 A(&]^AS65Z'T?&HD!B>+
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M V*/&Z.X_W5.?:37#3,2!&3ZS?\Y\./5O>?%3O3\!EZ"KR]4(3&I3<S78A"
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M\.1$"UHY-W%$")\#/R+L1+IGU_*R*.HCX0-69O4H!6%7L&'L@- 7,=O9GDQ
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M@&&_$-HQYYN?*Q<.>N-[VPG^:;LQ^32C'79HK]5O>!H@+_T$N_V/S%JM@4"
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MILF"&5V E__ LI5(MJVO'^P0S/LX"(@W>1X)]_#D[WZ0?%E45RN%@5) L ,
M$3["57GD20"Z H&2%^&7)-GY^, #/.O=S7WDF823/B,31?C]!A@VZBH V1+
MADKFBR/^"/SB L.2Z9#5! 5J1<#80!V'P@+S0A]]^KP >_T.)@2+Q0M5=^LE
M80RL:(?"@DSG": [%Z8H+5#J.5YL,_&2D1?)3E7Q>G/EA_0-KV B-J*\N=7\
M8?OR.Q$OXN8G]@,<$W&T_R=7<U<[,C6YF<LG>62I9H>W3TMG.G63,(;NO7&&
MNL.6M;HO'W0P-KPNZ=BZZ/&V'2SN+.="&$RH!G&'-44E6;;^/9=&OZ_F \%V
MH_\9_&/AXYO_9B]7KY-_LV^WMZ0$JZ_%UY*V^H[,<UY"9$ NTF R_UT$&]SG
MY.X!%*8_[JC.],IVG^SG$!>3E21 D.3%N@(S.T'BL*D^!#^.=Z:=EKO,RLU4
M;5,5XTYCBB1\1:;WT?IC?5"[2.:]BT<<OB=;UG-?;))ZB34R#]2VW-2DACV2
M$J*@0B\]#K$R*?U'!*O:^D5(E4.\Y*6'KQTF\5 W4"135T>B<?@T.4=\A:$K
M?$ZEYG1XI)*:P"G=T:TRY^\$=BL)>G/Y"8KWA%EY5(JCX!28Y.SD)KAGU/A&
MY2&EQ.8XJ7(M7%'Q A%YAE7^RP_<*>P.(F2J$WTN69VHR5I0%Q :(*OE?8[M
M%\^Z!((IG(F.A,QU6#NQ:0%3SH'\[L\8/4<AF<0!]6.UNH?DZI03A0OTOGOQ
M\@'=X+M-AI2L!UX^GK;R+_HV,+O0_3LG]+3?G':;Y-\[.6,N&8.QEO>S%^=Y
MU^!CBH?8="#4Z6#\P#FW1<Y5N^!<$S@WG]O,.9=S;H<R-^N00A-CP[6) 0;L
M7,R^%K!OONK"C;%OOZVN<BMZ2QZB:BI1R1UXM9M,Z^!XT,3!N"#^Z.#^.KJ%
M#A&\GFOI!M#6NT!; K3S.?4<[=[O[=H'J"9C'85N(6\N=Z2!TN=MGW9[/*E^
MA+$ZFTZIS8;N52Z9F5-8FZ!^/W9D,0 5=^1V'%];XA>C?<7]89V=B:LRZG-#
MV_/\"G8Q?U2P#_F&/,>&E+K8D"K?D'Q#\@W9R@E97V75^*[LYZYL,)5 DO>%
MD26.ND*]_"V+D=H79BB76M/;)&9_'7$^LYU >,2.V/A7D=)>(^CK' %R-'QE
M86/8N4!"Q,D)%X3%@#\1U[V;^I,8PQW@LU7@8X=P&O"6S6+8$",<">\WE'%"
M&B0_%>(53/?/V,=!6#P]!JE/,-GA";-5TEP#EXR$#[,D4#UY!#,=Z$]9<#M6
M_5H_/<SBL/VVI3\E;E+X:Q,0'X?P&QMS %8QIB6PR=RQW\&+'&]*5@3^XT7P
M=.C'('4V4[8#D%^P;)K/D"01",\.<:>8!_!(Z.?P/= 1DQ?P[T<?P]I9:L)0
M(.R6EY+O84,#H"?  O3_/EG8WIRP'U,()@&9.E$R_$E5R;IFKG\M')?06$K*
M8@_$=0@F<3A12 %C6PGHN?"3; A[!0P&-*'I)%Z2V0*<X$4L98'E<VS  #'G
MK&R:7D)KQX5T+TZ=V0P@@!^QL6&I-)4&B X[-%ZNU@7G4A9FL]S>T1.0HK;C
M"7!"V=[$H0D0813$+ %BXL<N)M&$L8LUZ 0[\U:2E/_;D1))7&E 5CY,'/AF
M"L_4!/2,@O"?:^06#BC-P63Q?$E,B1+/CH$M B>BZ2:8!P/KH*4Z-N(/^!'0
M"@BY<X%GW<U:D6V 0_'G\%***!,ER'V8B0-,9X=QL"T5:?%"@0X54E9.:@UN
MAD7VGY)P$C@/;!C\FL4 P\;QG]@&^ 5'8!J&!#+[D99<I./,%RASDID]T]V3
M>5C)/@RCP;,7)4J0>A]ASU/54/@GW4\O/M[_\^5&YON,9.O]RXI)@C;E/N/"
MV=DL^$^@;V+Z'ZOTZ$V'6(XR9D(IDT0V9*'>"^)ABI@SW?R(*;KXAG !H,&0
M 'X$3\-;1L(E$?6^4+:M ^4GF(((W/07V^T9KGW,BX"=LW?#9HSI6?8@;)-U
M;F4(QQU-N_.BM/1G1E:R/42#+"^*3]^O"Z$Z*$'8AEZE*N,V[;8/)RH]TB33
M;*I=0HHIGA\9@5*2*NHV5?#/Q(BX0UOAE22.S-30=*C6\^J.?=:M_SO)Y3%E
M67]=T62K\GHZVBN0_*XS.0KG-J6,D:D@5;["T1'=H=Z0S8>E*9 M3OP@US$9
M3S>N_%IX8X<+*KT2=3O,3GBCP>"!0UEIFFHF$]</:7HI*J5"PHJLW*ZP0!77
MQ]1EFGR9"L-)'$;^U$'MSO;^& FLK<EN.BH<I'X\7Q3F#R=3B,/T= *ICF;&
MELS-)%O[0;J3D.3L7,6?T/V6K)@M@&IEB:Z82AUJ.]!<8J9?NG L@!1"&H39
M\U+F^^M<^^MGS+#W*)/0/.@Y)E<7Q("<=Y/=@[*P=)#9-OI 1.M3[S+_H3W&
M;(&-\D+SQU.>Q3,7-LDB.1&H&A+#4;TA!=M<@0T[923\BYK1V1V0V%2IJ4PW
MA)>R/WO),'?<X$\RVR(Y];?TSMQ)MM8"J.U>9.7G#??U61>NR 05@71=ST.F
M=F5<"BP9/BVJCD(A7A,1_Y]9^L.=Q:.&MB$559]#P,RU P&,;/0/ A_ H!-J
M&6+M<)1T\/L)"M 9)O!1JA;[+>C\[?6D"Q:XC]S/NS3FHJ<GHH=&FV7.2"YJ
MNA0UV]M NC99LJ[J<6#G;YOLTQUV3$M[H$-R;?/&GO\ 7/:8D!T]$5R G$N
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M\<=+(<S0(81=@MH#G(J1+Q!O87L30C4-\MT)@0)S$,<1; G:+W<5^// 7H9
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M(7!0J,,;P0GA +U$:Z2MCN.9/DR^PT#^\*(];\\@9A$QB(TQ$G0&\:95CSO
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M??V7)-_N!RFH.8VL8QG8#RWF*WA9USH>#JT8.JI,K)^74@+HV"W-'_*%_.$
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M_:/[.><3/R5DWP?)4$:,#^ECHD@?U]? Y,DGGC2>E1.DTH:0-*RD_S!,<D)
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MMLWQRK(096WQBN?(A+2L\0;%MTVVEV5Z6WWVDO7<*/)1*;XEKI+!$Z7441K
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M(1RDZ^EZXFM1(K9[(F9 24(  HHV]S06Z[80: -4<@,&0'L.'95A FV 8%S
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MB;A&63G-(>HL'<3$;V4G;Z+AH+D&#&YKB6L -2Y.+&5$)+D>-<4(^CP3D)A
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MK[SM[L79Q?%[Z_3CQ[,OQQ>G7TZL#R?O3M^>?CPQ(62DZ^EZ(L-1LK9[LF9
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M\O;B_.S3[W]^/CU[?_;;GR9X6KJ>KB>V$\6XN\>X!DB"^)[:YN<A)3.(0!M
M:_/5>8[P"&A,H V@M?GJ/,?A&ELRMCD+86A9")SG4-9Z:/:"QH[SX3S'H:R5
MV$[-FRREOM0 YG  2O&VQT@9$1-H VAM 0C%VXS3F0XFT ;0V@+5QSIRB.VD
M)=KQL**=@$L<.47'!V8O:.RX0"AV7+'6BZ)C8CL9/%%*_:@!K.$ Y.%MYA/;
M"1-H VAM@0\D&#^D?6-$H(4!M+8@@,J>B&N<T6V.=$*T2 ?VC9DQD0[92SWV
M@L:."R)I+U&WF! W.C*NHCHU^^[\*X[@\Q(F)4AO#@?J^)?3LP\G[[0H5)7>
MVZX*58P4JNAZTZYO30).G*UZ(W4#ZA)"!_:P&2E4H0)M #DO= %HQ]=(Y6DA
MT!CDO!(LF4ROZ=1)1ZZTN$;7F2N%V:F3*1P;FOA+EO)?"PBT)L8C"A*2:\"@
M\Y:X!M'IL9 4E3"1Q""3E2 )U12"2$282&*SQ:X'WY+^T7^2=%R*L-^1SCYD
M+GM#L9R.6 Y-'3(,9"P7'J2:Z$&L"BV-Y8@P@^ S#"">AG L:XN(]G(P@3:
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M7!H"WY!<8O4/;]PI7;D$Z5-7<1F3;"FUBSQB6(V"Z><;LM:4&VJ=?=F-2JF
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M,@UTCS*_GR3_/DS@+\>C_OR64G6C<%5W(Y]<B9GKQ097@F,3#&PBQ%/3)YO
M]"$X-J&ZH&U4AVSN+K9IA;MM82AO:@6(&A%!JS=;".0&K"T'>$/5&BK '@#,
M=Q3R)X!K:12$"K / ,N;)H#WMT3C!!P!!!R,UQN$$K*5UF8<9$.8LQ%YW7TN
MRCC(1LK=.AO<;6L4)]8VI)_45O1%%?:UE$INZ&B*&<:$#O0O=/%V[<D\7FP>
M&]HCHIJ'"^;AL+WTKR7SV,H\-N@DHIJ'VJ\5FYIADGF8ZUQ0PC$9W?=\.XKV
MTA67[*(.KX)C%P+L(HC0SOS(+K#="8Y=>*KM:;A-EY<#/N-Y-Y@\549:XZ=V
M.[0Y49=U1PX6=^YZ\"WI'_TG2<>E]NU#ZX^0N>P-;3TAHEOGB5X)BDJ-@4YT
M,!&LD\!8@F H\Q6'MG_WN,)6CQ\V+*T1+:T&+*W;P5J$+W) C(]FY![7U)VA
M<V4R)]QVA^P%X58RW/H,MT[^3HG]LDZ/!1OLEQ!\$8)U%AV4( C44,\G!!$1
MK)-B58(@\"!)B'>?J^C.[E\I\1)T>UP^=X;.E]"Y%'3O<=W<&3H@)PK<QCHD
M?JU[Q$B#MQ;]YOT1(:(0>#)BDRH]69=1UE7)N/986A]%8%U>S;QELBZ#K&M_
MI4JP8P\</V?#X3M9EU'65:=GQ.!TP(E!+[ Y)[-JDEG5Z1)QS(J!68FPWET_
M,BN#S&H/I6&P2P:,U4U=X5?TV5CLJ['0>*.X$B]Y]JO;I/\P3,ZNSY/'9/20
M3'Y-QW<GWZ9).HJ';Q\F$JDDG<CG6_+SOWS_+1G?I/']+2![G";QY +N"]+C
M7X;CJ[_G'DX4)??EBW SB1R*>WD[T_0A.4R%?<&[41@9J#YNHB(ZW=/F>XJZ
MOEOMFW3<D_#7=Z-I[D'\=N*=/_W@^LX;$HC?:K ^2_>G-/>?_(N%-G+1T_7U
MMNG)AG0/@P=^^$@Y8BOSQ"B]>MD6][*J52_KAD6'.M>I-RCKU'OH"P2U 4 9
M5I+^UC'$)/U-;0 :,8JT%FA>"UJM4?_':#"58=CG:3Q-7E0F=[B6IUE+.'(V
M]'W/=[E@D^NMO!*^\U^#Z>TL$3GY=C5\@ &!T%K^?_\B_E9],P_*29W-<D!D
M)'LB1VW0)-!B(WZG)WQ;"!(E-]-&-N@3:+&10-J(:T=AO44"9".U.9L-8@4?
MQZ.KAS1-1M-=N1%AIQ<XMK_I7(@L8#^KA+NAVO3E!A#)4$+8(4=2%FQ*I'WR
M -U9B2!>G^5NX.3H\&]R]LB$TJ8"'%RD-]!DM"#M*J1%S8V[".E%I#<P5[0@
MS132OE]O7D-(+R*]H3+KQ7&'-*4>"VSFDPHY)HP;JK1>#J. 2CO;=S?0%0\]
M?/Q7,@%"F_5[<C>8W-\F:6(EL]7.^J/[N8M,WVBA:1NP#RNG5T_8@4NN"!-H
M S9373\K4*J7ZT] +P)MP(ZH&RBY>"<DH!&!QM[5=+,NSHQ01$2186]-NJKA
MLHA:KL!U/!G$1Y_BJ\'UX,JVCJ]3>5-DQO69L0'[E SZ1W/;BTBR!!-I _8I
MI;4!T@&)>J$B;< ^I;0V0)K:[.$BC;U/*4T)@A"/4GQ,%+&W*:692!0]!U=7
MJCFZ4=0^KSFS YHK[-^;>9U>&-HA0V.*D9V\V$X,V"AEOK03SW8]%%44LI-:
M[,2 ?586='I!9$?4*<M8.X&YC!R5P3:MX]JN2ZN%N5:PP:N\W HBZ3(B6VP2
MTCKT?5XC.RW0]?N]_C 6$=!2QUU$..R@V\RES39,%+$# @Z[X[8;M;P6X6QZ
MFZ26?'QK"%(L0R7%$JLA-<&:Z7KR"74$EBO2T+]&?[U6,T N)R^5_N4@IAG8
M@4],$$PD5_!Y:D622R1]6Z8CU!J"6D.T05*V3@%L'5MZ7& >$9"9F:!<; "#
MAGN8)PQD9B:8F0'T'>YC'E"0F1GA-#<PF'<-58-.SPT=VW6H6U*3;*>2Z6P(
MN'8U'3@1\P/;\S8DK"4Z_=6D[77N:7F*6Y18'\?3)*N#=&%@K%@.X>0J'=RK
MX1Y?6S)7M"8S$M)@9'V]'5S=JE??CN_D#7^WQO<)'(U,NL]ZS@UX^)-O]^-4
M3@BE2AVGB34:RW])*P=.?SR:=JW3D74] 'NPOB=Q:H'0I+WPX _3P5#^8%^^
MF,JA_'H[EM\EOR^=6/W!9)H.+N4G1C?6?3KN/US)X8,!EF-P^SR@T]MX:J70
M7&("TM)]*[Z7G_XF;7&:#+];*\U?VNUEDA:R?KZP>O+E&2 ],RA8IZIGQ/E@
M\O>G)(47XIO$?3+](S9G^Q$4]G>]@N'_:%>_-[?>>Q-PO.!UBZ3M'ZUXU*]^
M>ZSFVX-]<]8M5@_\.)M5*MNWY+H^F4@3R/IPE%D=7[2ZV]@D@^,UCQHPM,-N
M\;!A%X,3-=\;5P973*5W-#BOYML#/JTH&[JJ!L=>9G#Q<+AZ,')#7)]>G'[\
MM7".I0;Q[/I,.1OYFS-B[((_E[[@"GSZ5QGW2/M^&B=G;IADKJJ>IC!.>)/$
MKQEI7TV28K*]RR0):KZW0$V28H8F[VVG61+6?'\0S?%N,93;,$NV#&W$8F@#
M_\R#["/8<WXM)ZB8!=J#45_>Z>NC[+5:0R"O&WI;1$&K>CGPKEO2'6FNF8/[
MU,2@OGM>UJ(NO^'YP0R[?G'@8 DX&GP[NAWTY?"^5IA'L_/;?(9;"?2TG#S)
M-ZME*XEE7"LGO8P*LQ93^6<'(]BZ2*RK6XEK C8AAPJ"OK$U5E\J/S"^2Y1U
MS[[7EI^2RZ-<$A]26!_!QA[E2$.H*3\VD OK(%7?7O*MTG;D:G.5*/N;R#59
MWA=<U9?&.!S?PV5=,L=Y<V1&F&/091$,W/&=S-2E%X&$0OK"\=4,V+DT*C.I
M 723D89B_9S9T#]>Y0:D\+Y9)I\5/M:U+N2"->>])RI+45=#X%BP7;!SN;I=
M6=*33<&+RS5OT;=5TT+EBZ>,X?+R_%XNHK =*,<H&5U]AW^>CN02/1CWM\O#
MH^>5VY/Q?EGTE66OEUEW%?7HU9Y!.!J? ?J3KG\"M73<)[!@ !X_SY)TRXUL
MZWUR(Y%6JT,"AB<7&A5QY7UYY7O]9!H/AI-_%$PCLXS<(.0R9 W!P;T,?W=Y
MY"!_EG];'L*3?S\,IM\_)U=R-81%\-?'CX/?XL$(QK+Z&,H4P>D6M_$6[6!N
M/06GWD\NI_#W1-T)Z$#=QA+/F<_/0]W_%U;<.WECL&9/Y)Q)U C]=S)Z?% ?
MNI/?_'DZOOJ[='CY\_#"ESZ,KN-'.7'!F>0_-QBI=Z[EZF\]QL.'IQM( ;91
M GW4XK_5Y_(??2% ;"\(\2T0(A>VX,*X(2[,52[L=#0:/ZK;MS[(A>9*7C0?
M#T&X<YE(JY#1<OSMR>I?UP0IRSJ1+4+J0'\QU.8GY?N$/_T0,N:_,0&=L,L\
M%6!<R=F:RL6B+%+\*;Z[?S,?*\Z"4EA**BT>_@:"\*?XNPIG+L;Y#4FWF-W-
M>7XSQZ/^N^<;J;Z.P(Z&?.8-2[V*K.3"E:B5]&8XOI1KLCJ_F,R6_X\?F&]=
M#L"OPO:NC!*F@\MQ7[K7/Q,9H7VU_BF#H>2[C-/E@V03^!]DS%J,^<-XE,PZ
M*(.)IN/O\5"ZZ!S JD:[X0SH4Q8ZJ7['Y^J7I+,[3ZX2H,%5-U /'-W_S]Z[
M-C6.96FC?T7!.7T:)@SM&]C.C#<CG)!9134)O$!E3<^7"5G>!E7:DENR(-V_
M_JS+ODKRE:LIQ_1TD[8L::^]]KJO9Q5#O Y_;OGH1?CH#$[M+7/1N@*OEH-F
M+;H"^AG78C(9"I1J7_AAJ_/.T1*\ Z8^_#X!ZMD&[14*LJ0/4NZ7:21 &_OI
M)/2W?/8RRC="MQVL^1#M>NH *,9S'NM7-PN>E<N(I_J!%X-3_3:<X-:E-K_$
M<?\!^&AUUFPA:Q83"3E/.TWC("2>? @GG!+^UJI5O=U>"$8P;(6?[$D"^<IB
M\5-O["<3Y?98^A8_^A;CDGSO$H@X\@.1D;%,:6=PKZI/Y3)L67P!B^>BETKT
M&-Y>B9O;[041EBO[:<<<JEJ=:=O(M O"0UL&>A$&NH"+)B$XB<<7WT]/]FL=
M[[L?D!,Y\J-LX"O&$C_#B>&N.%W#WEO(7-?9>#P$(V]M/=W9\M5;X:NON7A:
M6AY02W48:PT3L#F?G4Y$;V+"9-U[']0<O-#7.,'Y]E?"IXJ@M4-G1]7'<%M)
M8.P5&.>;Z-^(X&X;,'HSYZ9KF5F4?P26O^6<^2/%[T*7Z7.6PBMB!F74"R-Z
MI/4V5_SP8WSVZF<%*ZQ**@V6\*!*;,_KNSCX\>#?BURJ7][]/!O!=@3\[X#2
M09G/-: 6V\J=:&*LMQ@)?@C[D[L/M2H5MEJ_DEQ>-3_Q>VD\S":S?[)$0:7,
M8JM'4"$P,.#0'Z?B@_KC8Q]\R:$__1!&Q$KTHX_NW4L"UW32^&OSB@=5?DW9
MZ2>?++\^@*_^4?R\>= ^K)=^ U*P]/-9=^K4#SK-]MQ;+>A#7+%?<!3V^T/!
MV_+R38/M=HY-9Q>OK]L'^<3KJBU:5Z-*TM.>R1*.;KTT":AM=1\3F+5ZO?._
MM[6#/\>W.YX_!&'QVUV,3Z:PM_R;OW6/9 U6OQ9?UP['/Y%Y7I<0UB:7E)G;
M_WV7F'V_%?N]1/@_]OW!1"0?_.&#/TUQ,;8D 8+(!Q\UX,T>(7'X57O)/S[E
M7IO^.R<WS;3+YGYM9^;7U583E,H[L WDIKZ6;0"/7R.9E"L[6CNRBG6]<\V$
M9\\E'5'5P*)4TB")1V0<?-__ TT!RT9X9Z;JFV5'[Q9\IZ>W0Y5'=A&AGW8Q
M4';IZHS46"8XFK,UNT$P]!&$QP/&$>DDG&2)V'+4"W$4E3#X0P_D1Q@([TK<
M9D-6,FM&-&=R&Z)KF-MS*'-U#FLNP6%;YGDAYGGB4/B"Q,Z3A,*/#E^.@=Y0
M^15MXIKE5\W7*+\J<%WKH-KZRY9?S7*#WI!,J!V]>'9C@=W\V.S&$54A+"A)
M?JKFERUCS6>L)U<V"YCG:91-:PG':LM +\) OQ<JSI\C0U9(N,ZH*7_N5%E[
MF3Z +>>]".>9S.S0U.$I^15.Q.A)&*W<I9=)I)NXK#QO=;9Z__G^C>&J,VI1
MBNR@R3/*JR<+$;6J2_A?3]92O&6B!5;5BQ1L-EZS8+-56S$F"?ST \C0G\);
MAD%:J.7T$>EZ/\6^>G&+_1)$M5TL[]Q[]F+.5Z]BJ=7_2E4LFW.07R93M:
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MT<LMW-?;]+)/=DG2.C@ZQ.4_B]UQ$J+9'?55PU&7[ 1SMQ(ET"&56U(O991
M1?6)H11#W9O"7;C*33H#I@90_ S K%RUN'R>[+\"(1AE(C7BV[%'5I8*1U50
M>XM<3*_/GK9B 8I\J7]IPWI>6T%+6[;R*G)O<A>UJ2PFQ",8H@\!(AXM#A4S
M0BN]KUQ^#%%1.DI%E9QN!^M2]."2>$@VS"#.$OU,^7.V8/#0 Z=0O],RBRQ[
M_4YE74.H]L1L?%3;^=0^:!5%/2Z:=Y98^>-[%&R]-R+8ZHWU!5NK_M0<4:=A
MR7.-6R76,K"KO*\GF.45,H)! 6V93^9"7E_7;V4I.;JG8(D.ASYP5ZOYT4A
ML/"N;_;%4-Q3W'8TC<GCAY^'T<!/F":[US=?OIWNP1N (:$2T&B_<70 I%P8
MP$MB\5=OZOWF1QG&.AAPI/T1)<!Z)L?;9N3@C3!RL_,(1BXO;7X$(V-,=%%D
MP.%D#@^CN!YG/<W%:/M[QT,_3;U3"AN!%Q+U?5VVNA1GWP'-."MT>7R*NHOX
MF-U"^-=L+I8%%J2/J+Q>9T["1#F4Z%YK;PC>;1R'D;L&C#&E%:^7434[QH?
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M[$ &5^0VAK>^E".ZCS>@8L,RW3C!@\-59 ^QKOD;4EH#S N4V'=HH9/%!3L
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MTBZV 'K6]XJYG02S-%Q4Z]\F@B=L4Z-JBAX[CSA@)V7S^$@BM!L3B,0^]=B
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M,&.B681R@XK/=7&U?N^1/^5]^'<66I,;9<TC4M=0U>9!,._@$*=&FFQK@[:
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M=6ZQWED?<+OFO2>MWDKA-1]Q$.7!4--/(P/H8LQ[;L'UOF%%6K 9:IU'7_$
M90][20\\ ]@12S :'FM6YU+WWW 2%U+DTH\$R9QO^'KZ[2P3(1 ^8^#+D5OP
M/.P=4+VIDBOTLZWQ=^2Z1+&Z5OE->4(ZTY_T?1PSA3@;Q9YKIMC]MPIX:#G3
MY< [47.RD<^P%5'U@L/EW-_&Y\81M(OEI]O8K>H7J6D+ 8!*(&CE+X%N_7ML
M1?/@O['!Q68EZ3 N4 .1T@0L(N9([5+=L.!@JU.CM$)Q"6]8%WP!#0MRPY,I
M.TQ6O"O17Y3Z<L7*#Y/_W"M(TQPVO[S.3$4Q.4YL"PH#8'L2\32%3_@@V"=D
M4^%Q0D\.L9<CA=%"9;M\!Y*&R"E4EOIDII61Z/F^^36=LOZ*PIMZ]U<2X:5S
MR/_ >4??0V2ST)<H9!+T2L*8P'-FH4XC\I$29B0Z;YSKV?D =P)[JZ1*PW>A
MSG0IO[',.46Q0^W8W-2G8=*PESE.P!,"XH*O)[MX79K;C.+B"AF9S;I!6>PY
M^:Q?W.F1-9$R WCFS,<;^7_"JTVFI6+>JAXG#) %'5N3F3/J\K@.J-D2,1AR
MT"]T0/8-H+ZTRVD[#?R!V\#/:LN (N7'8M#C&"L0)8":XZ[ZR6CPAP;NIY]P
M!S%A,&/[XS(GVNR3&E%*B]IV7VV1F=\>,G-[B\R\169^)XUDK?)&LO:;[^92
M$$C+1HH-1J"%3N!@).5#Q^3M"E3Z&$&60!HZGDP_=Q0ISA5+$U\,*UX7T5J
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M"4(TQ$6#3:MEJ186&%UR0Y7.<J6,<D5G*UD.^0QTBQSJBXE6ICXV[Y@A[!_
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M^J=0LH9\^0!\AO)._E K)YTI50>(2QC4T5*'R-1)V >I*#:Y) -;C9ZDFNE
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MLU8AR4P,3JW<]4)$#1IJ<B@9IK\89;AP."0?6BC0EH%S$E-> K%$J*K QM*
MYY7=%:C_LQB=[-(TG!1!)X_U)4$7;4]+&5.Z$'-SODU#*146H,JR@4)HD-KN
M(\,Q7=/3?J$V &8)2E]AWTOBZ#N?D E.R8P]>/[/9USPVN4I%WI;Z[Q4[""(
M^.QTL5DS.PP9Y4YOY[C]-#3ZJW]GN")6DXS%!6UN@1+G=P54!'EQ_?7VZ\M:
MY38_NHH7^8K'Y7)K=3IK'N%GF88FIXI\J#(Q;!I*#-1HT#QB,3U5# (44Y>2
MATKW;&EZT_8R*LZ<HTA,)56EE'P&<2,&R6/5!\HU&B2?C!;$H80 ZQQ;]2=S
ML^%W-@^3B;B_N20S2 O2\J_(PS9418ZJ7]DFB:J9 ;(%_I]9Z]#.A\5S2=Q(
MHF.71"!'MA0C!S3NWAJ!S;E*FGEUDH3?,^IZ9KC@LU%O0#L@-@)P;(S^B(G1
M00DYV:*+)7\B1VW!A5RXX8-0?!E!P(* UB4+?.0C>4G0I,J3E^=R9XS1SS$*
MXEEZOO#*W/(O496O(+AB!-H.BD@[X(-946L$4JK%3L'::<^Y^HA,27=KBRL6
M9RACR7P+N$V'H]:4.?<T4Q)] IXFW![[HB3Q\>7"*962.>6<?H5W!TAMPM^[
MR C\E\K%S?75U[<O>==='Q49&,E"PXZ16A(GF-XF!+L<MR[?B/(?7NI;Y#G$
MZ_I-O565";-0^2@!,R.?)BTJCO$0Q+K3F,]A\13A]"/45O@#0!DY6<OG-KD?
MKW@O"\Q2AI!\) &U/%[PN,7 OXBO<;($DD1,#T68!2)T+=C0&#L"Y.]3+TC_
M*O83+C%@!_G\2D(3F!9H./ =X*^"/?7&*#'@+@. HBT!QH]\>C<87!$\8\JH
M*4XY@PU):N)SRS8V#G"WY"6M^(%6Q(@Y?1]$#OQWXL.RN!"2EVQC2^ L\,12
M*314:F4\?TW(0^S^YIV(1:[8>&XA>B:SJ#20O% 4\=R<M8.?0>&>E7YIJ<TM
M6 _2*Y?>%A<V2->T+E6YC<!X3ET<P\8>C1DIO!9*54,)L;W<&,T#,$3O;1!C
M)HJX.V -Z:,;,Q257*18R=!/J9DVPLCUC-@-@]O,<C7WAA,EU;7YIGF$*@!?
MCIUS[ D(0FP+'(0T!Q9)UV)HG25V 8VD?6! Q/#OTBN0"Y"\A5>4F4];!9)*
MZCP!F$L/WL1=B5P,(:(@PB^JV0><%.,P"NPZ)P@C(<@'9OPDRX,]@CH,A"N&
MB!,]Y)=08S%$,-?8W#M+FT6%-DRLHFD':5GP&5>T9N-3)!T@J?*A[BF"I1VD
M'0&:1&WK@J\3!(:_B.G.]LUHAN@S&3<*QLRQV;V0Y"D%,<>SD!8:#"FI/8Y-
MXI3[5B\A=X4US@$X>F,NMG=C%K;2%O84.>A1;-KMU#-_/F @[3.S,(W4PM/W
M:DNY$'&Y^((XH$F'N5:MXR<[NK#7I@&" 9Y-^LLPA5&6!(QBJPO,1!\,(;@X
M+L\'6WH,+R/FMZBK SV5J(A'"I%:<P G>+RMA(":>@Q0G@&2WW.<Q:7W0-.R
M98AX@=\'J NP9 ;1)D0O_R*@P8+QRF@]L]5]3Z&;^'D[L>4S&3QRN-X#^M;^
MQ,/)27 F-_J<(SX314)[*GVGU$D$C.P4A7**.;,I0ZA8AD#% X.=U"%@1</Z
M:OYG*G'?5PEX.4E,(NG*=:,X_[6/<H6#(" _?:_A ?2JN?OZ9^$/%]%[QT#"
MVG$E]R=[9H=),. D<[17BKD4?JI@@*/")?,R"(2ARR,XTC;,]>>S?A"H%-L0
M83+ <:ZU(J(KH#;3+21SW4W*<3P* ,!$ 3W$<H,9.:F)7$=)59Z$(6Z:!\*/
MG(,F-V4@:=GKO+!?H@5/@1 1YJ(  G-IU0"QSQ &?CGE/E+XM1C<"+8C !%A
MK-_A"6>>GXH//5+:![8AX%62L?LIU77LV L3*?;A" &O88VXR'6[2Z!D7T'A
M/5PY/U>9^!Q(*0R32*6V]@F;*!-FY-N;S)X+ZR_OE*(I,W(^^C[X'/*%/=?)
M#3<:$6RMG\Z6I@Q]CEU9YK*,3/P5$+H)HPF_ ); 9>1( A//GN$NP\8S4R(N
M<N5Z"!5@OO-];:&_W\*[4IN]M*",F1L*H@1D.I:PWA,GF/NOTCW-=^KK) 3?
M"K]'I%%M%_QF,M 3!="JP/4S8X&U%W*_".VT2YEP5L!SG2W<_1_,C.D'B4\&
M$?@F9<,%P#63"$E6I&DYAX&K\R,5($]B%V*U :T*'#QOAF%,(.G?(SPV/4Y
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M>8P<E::G%,I\L>N^E/F7I6B%XBVY:I3H *T@8JH4J4J;8XEL1%Y\^>H9^)\
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MO">N:O6!42Z%)T1\2D%9/WZ?:[WBS"EPX6('+J00?(5-/CX/1:BI NVXT7?
M14&J<#TMB7$W W"T@:KX#MS!DUTKD"$C)@03"MA$BMF\;MN8SYGAX'M!*Z"
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M$>UK/0O_+%#!I+*G!F@0X%J& 4-09 ;)3S1Q@'?1& -?&) -/LT"3(R?J.N
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M8+W?V RT*.JPJSA'"0KUF)?\(0KQ% %R+"4#?D-=?,P+%G;9=9F(^!$L%]7
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M#]\V493?3@V?*;^Y(+8/H2=V[U#PY33*HF'ZK+(XBI#[H1G_AOG .C,#&?'
MG-]I.+_A_#)5G%WB_,XK# =.+X%$+;VM=_P@ND.:,8!HX\C@I.'QLLJ=D >7
M %/B N N&5]?B/-*G8P8T)]'#%Q,=WM$XQTS>:Y.G"'K-&*@[F)@U ,=U(&/
M[8[6Z[U:C+K=@<8>[[7VPYT:/H:GZPINAOSN3.$^!CE_H*I-;P;RW39!TH%
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M""T[4"S/C*B%29.3.2I6V-[FH%:66@=L#FVT9&T$F&D,95O34<--R]P4MQ=
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M,/L\E0FC,]+]MG8Q?GFAO[RP[9?(M>(+K0W?W-,@TF_L3GKEMY?_:"F&*+0
M/>D $D#7E-%E$BU9M=2).PGLDQ"N8,_G"X3-<!<RJ?!>XM#!*D=+,<9@,8 6
M=QQ H3+WO7M;JG4O DDW!4"H1AZ?$6#_S*GG8*NT(!HCMK$JTE >?$2\J_CL
M]X@%8&O-F6E/%O@COM1B@8T%E6(#+X*7R>1:TV<A-M$Q0OIB[MNN:<\-1XE/
M)\'2,<$92!#$ $(UD_!,;W,7M]E^>7&5N[&I1P#I<&.(]\R'#S&)T?KL=,;%
M%%3H8!.X$)O 66P<4MS8)ULG:(DN<@]3VYS2>T(O!$B,&=:/XEH"  E0A>74
M1@08]F$WK<0F8X\F@\]:^T\25O& (&#A,OS$!;C4=/FZ@I-A4#^1M4LY)W M
M[4!5OJ?!9C[#(3/8_8Y G?#<+]V:D$P0 1@)?/&>O;]6HKGG<OX06ZYF<X5-
M4Z%=]^G 5D"#G9B?V)^HLT?K,]U[)R?'[R-Y'$ \8N>=;!IU'\V'#H* _&8\
M&AYN68%X0R>>5V//6L _TW#FO/G_4$L#!!0    ( .V 35J,!,F*%BH  &CV
M 0 0    :FYJ+3(P,C0Q,C(Y+GAS9.U]6W,B.=+H^_Z*.GXY>R+6;AO;?8OI
M^0)CNIM=VW  ]UQ>-D25 $T7)59599O]]9]2JAMUDPKP6#WEC9AM \I4WG1+
MI3)_^I^GE6L]8.83ZGTZ.CLY/;*P9U.'>(M/1_?3S\?OC_[GY[_][:?_<WS\
MZ]7XQKJF=KC"7F#U&$8!=JQ'$BRM8(FM7RC[3AZ0-7)1,*=L=7S\LP#KT?6&
MD<4RL#JGG<NX6?PK^XC>7;Q[_^'B]/CMY?SB^&+V]L,QNGAW>3Q_V[F<S3^@
M\\OW^!^+C^\Q>M^9H=/C#GKW_OCBHG-Y/'O7.3WFH)<7L\MW[Q&:":1/_D??
M7N(5LCAKGO_QR?]TM R"]<<W;QX?'T\>ST\H6[SIG)Z>O?GU]F8BFAY%;5WB
M?=]J_31C;MS^_ W\/$,^CIO_X?VQU9I_/K'IBC?N7)QU.A_B=H"%U. EGA\@
MST[P.@$[#C9K[)^5 _'?W\#OT-'I\>G9<>>L *J&[!R?GA^?GV6)=(($+$OA
MY1OYXY&%@H"161C@SUS#UWB.0I>#A-Y_0N22.<$.-Q\7@X%L-<C\'""VP,$=
M6F%_C6Q<+[^?_V99H%"R6E,66%X!:H[\F:#29X$ .[*D\F^HC0)AT]#2CQDJ
MM'^#W<"'3\?PZ>3)=X[>Z/<:^L<+A-:->L["R-ZC;YI04&=#9624@L"GXQCN
M&+XZ/NMPB]B9AG1\-*,AAMN3AM)A4:44%:3X[.]+1C+&&I,1038BHWS,:NHB
M!@ E7#;IT,?VR8(^O+%IZ 5LHS,8RD#B#TV&P3:RC7.,YL=^.&M$PL:)ND_
M=Z; P:1)UW%S^&/G/K'M-.DS;@Y_E/2)/(\& AZ^B;Y;KXDWI_(+_A6,UH_Q
MD!WC>;Q^%!;/:*D]^_#APQOQ*U]J!#!B-J,NKF_\9LWH&K. 8#^[\ H$2X;G
MGX[X<G$<+Q7_7C-\P@F)6Q3P;T\[\#/O /M\I1+LWJ3\Q"A@Y'TZ\KD:7"PE
M9##[#IXW99^#$(_\%9AWT:PI\QP$NS\ZWS9RF_+-0>S0W<7D 7S*?[>(\^FH
M1_F98806G#KX_GX\*-W(B2[3MC'"&&5J@3^?BO^=6<?I">/8$I 6@/[T)@^0
M0Q7ZV!EZ/XN_\^,Z HZ:U #FA*,-MSV22L&B+V,AUHBV&SHD&'APA!*4:$BX
M *(4=&=;T *!E<'0(GGWJ.=3ESAPFKU"+NR%)TN, U_+M*M@:S3PX<-EY^P2
M3'W"98836T]161$N2R)[54;@CQ#C7"UQ0#B=^VAF&Y%231U]-5E_W\+]_UJJ
MMD1:/IWW$?.(MV@ZE$I1*%5U7J>J%*5%YU:,]%5%\QY=<<:6V//) QYX7!]Z
M:[H^-J7B+O05MX7?DAV\*K%,[/M,F(U0*]5[N9]Z7Z?5XISXGY $FWTF58E
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MP?*NLY?30:-49>%('Z.%:Y,8L71E):@M@;M%&NO:_PF)+["!D!V^D/L!";C
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MN"NV%W8L#CR//B!(-7/+5U2;TU6OZ.KV)JB4TS3%]K*>A5PC$^B&'7BPD8\
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M^CNK6]:/CV&://;$"*;]T!O%+R^Q&W\,-]K6&588,8.3M=:,/(-@($KE0*C
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MM7,X%-V^SWB&'F8/?0$TYTQOY22;7@B7V,UK:]?;5^K,RD]A/DXTH!OO6[6
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M2C L2B];IYL/8>"YRC4'QL"CQ#-(1;OB^_6QU\W<^$2,YUD#ES7:Y;'6?>D
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M;6SLO=MR6\>2)GS?3^'?<_NG7>?#CMX]H>-N==N60I*[9^8&48<L$FT02PV
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M#Z,%*D92=\\@:IE >>7 %R&@>!,2#VA$R$^4_6^,P <D?QL1]T%Z=W;6C>>
M?IT;A0-AR7M5:&A^Y+6JY"*$R#R@* %E<$'+YIS?!-&2\E66]&V^]V7F)M%[
MB?4VSVQ7GLEN'CSC/W'-?NMF.'UYCB1]=X')ATB[EM/@=?(TPY(A(LW51!VX
ME2)85NXQZ=<]_\FRV$QH#5_8"TSF.B:I+S!I:PL7)@$BIS7)9P9.6PFZA&1Y
M\ED[OQF1*Y__U(G<7VBWB13MWLC?R)VMB*XIF>1):>8#&,L#*/HR!"4"<):T
M8DYH$\/6;^;M<9XZL>V$>)M@N1?!\B>Q IH4%] *<J-=].!*=3^3XA"RSB ,
M*6/!)-#=%TS98)BG36]#$=YF5^W)KERE>=)<8,,B:4]@"E)@Y"HZJ2!ZDX$%
M35M'EE*4N!F]:\=YZORV$^)M@O6>!.M5V)2ZP$:(O#69 \_6@C*T@41> P+>
M\BR+3CIO^/ZN'>>I$]Q.B+<)-BTBHA_INP-E5<XE>-KY50&E,YGF'$G1K"03
MH/XH4I,H:!WM<)3V'@/=6G@-_9KK.)Z-Q^=A]!X_=9/9(#%=MP4-7#D$55(F
M/-E BLFCU-%@6G%XL@.9UT<](E)W%F9#7^<ZGG<X&7;YU3B_##,<&&^,*%9!
MEC:#$I&#-[0J1:U#%B::Z-L<6'PS[!'1N[LX&[I WRPBDS">SJ5YH7.H3 H2
M"Q2;)*A8.+@H)3!>),_>.=9J-;XQ\A&QO)=0&[I"%=.K\6PX^_IZ.,+?SN?;
MOLNB%!;(@%".-GLL$9S2 I(I2E=3P'"[%\$W1SP"8O<28D/OYPK+>SP93F>D
M9[/?PAD.>&*2_&E/6P,G,T &PL,BDG.F)9-9&Y/V>VM7C7HTQ.XAS(:>SQ6>
M-^/436CAF$]R?A3RHCL?SR9?7W092?<,UP4=A("TF#CT$+PGW<M*9.XUYYXW
MX'HMB*.AOIVH&[M("W@?PY<WF68^+,-%:M_%^E.B0RZ* =I4%/ENR4"@V0)S
M(;)L&&:V7R[,VN&/AOT6XKW-N]V?]V<Y3W ZO?BC3I</?.(^ZT 33,'1LJ0E
MA&A)-TU2F6'$K%MLW"N&/AJ^]Q7K;:Y=,ZY?T(]O)Q^[/\<#Q;G3VB-A8)HF
MZ3PX[1CP:(4164:=13NFKP8^-IYW%.EMEGTSEN=;S-O)NTGW>3A..%":1>]K
M_*TD6FDDGX?1"R0GM/1&"Q'W\ZC7C7YL?.\CW!7QD[VB8]\ >]=-9V'T?X:?
MYE8%IA"%3 ),%!Y48 :B$!8PVH!&^R1L"V-]U=C'QOCN@EW!]UX!L[K6/)M@
M6 ")2M.J$LC!MP&4RJ+&[#4D:R77&AG1M1?#UT<[ DYW%MX*%O<*B]4;-*-W
MI]UXZ>A;1!>3MV"4C.0!% )C?8&2+:./C+7)[,7DS1&/@,V]A+B"T;WB7Q\P
MG4](O;B('X>S>0HQAAI8!><\!Z4)1PRT2$B=R>R/GF=1]F+TYHA'P.A>0ES!
MZ%X!L(^34*\=?OAZ%KO1()*#;C!%,,'2FE_O!I*/ED#8R(TL+DFWGR?\S7!'
MP.7NXEM!Y%[!KJ56O?J23L/X!.?!MXPRFN@R,&;(4!>D8Y'Q"#QSZ6-0DJG]
MMLY5HQX!K7L+<P6[#0)8_XFCT;^/R0/[@&%*.T)^,YV>TY:@%-(L"4^J<155
MJL-MM2>]L\Z@]MEDV< &OF/X(^"[G7A7$-\@@O4?W>A\/ N3^:G)9$J(R/\N
M9,LE*P6H2+ B6H0B8PA:J*Q]B^C5C6&/ANA]Q+F"X 9AJQ?GDPG-=7'"63<4
M<K[/IV2]RT+V' ?AI*NATP*!U(T,!>&M,%&*$!KPO'KTHZ&[@7!7L-X@C/5F
M/,-)2+/A9WP99N$"YZ"PX&BK":"CK0?<-.^@%8*4$7F.262^GYNT;O2C8;V!
M<%>DB30(8\T7G1=AAB?=Y.N K'UF:_J"4]&0%BH)H3 #'I-ASKKLV;K;J=MD
M$%P.>C0<[R[*%=3N%;%:X'EUAI,36F'^,>G^G)V^Z,X^A?%7\M@=TXXYD$63
M_1#(=_=H!62K.4NL2+(G&U"\<O"CH7I_T:Z@?*_PU@+7A[,P&CT_G](TI].!
M]XH< U)!7V0F%0RTG:20H<3LK<I&!]TBG>";08^&XMU%N8+:O>)<;U*9/#O/
M0_K&L]D,I[/Y/%^/PLG RZ)<R)&VCAJLB;RF&=*,C?,BQ9*RW#-AY.ZQCX#H
M1H)=P?=>4;#E7%\/QQ]F9[-7DTDW>=&1P9 NX<ELO"33$!R:FALN.;@L,FBG
M427I=3'[A5+NQW $_#<6] H]:) Q]N$41Z/E#F,2[25!*- ID&Z&8H&<10<T
M491<,1]MB\W[^IA'P/.>@ES!:X/PV;OS.!JFUZ,NS,A6E/7"3ZG):!84^0%
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M$^2H>YZ*:.W$]CVG)Z^,CXKT'HRF;ZRY.:)GB7!/ZERFLU]Q=MKE0:P@HK)
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MW6F8G(6$YS,RK487I[?9F>C)6P2;:253CGQ'%[4&+$IQ\B>-,6X#,V#5LQ_
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M[$D8S6WX, T7&_E[_%Q/6VG9/I_01C_%9R<3G$]O@-IG[IT%XZ(#Q1Q"<*X
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MSD7&YAUMUD-J=U1Z5\Y]#5TH)FTPKE;'CK1"2Z-HXW82&.=)L)J'W[R@U$;
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M+(W*9 C&X&1Z@/# =Z-2C2DZJ"WU^Q3+^>B78<%!3BI8(PTXX\F=F'=\B+J
M#;PXRT@\_G!^W16NHX\N-2?GSG6H_^LLHSZOK-QZ>%_74M;/HE&-M>485THD
MF!/.<03I$CE<6?)Z?&: <ZZ9BC$*T[J0PBT0[2JH+1^]R'S04L=LK8 D:5J*
M%CS:4;DCL]$*$U@TSK2.-]X!Y5#UT?;C]^YR:+O+];%<\/@P"[/Y$Y^?3TDX
MT^F'Q7,71\<V8$@H$J!EKM:V9."9#,"4=%X$IX-HG:.V%M##5SS;@_&;6M1,
M\CW8NA=8+HX!-P'34R[0-T >)LNG(5$W56!O*?=./7/!J5QKVDJRJ)1C&5Q=
M,;EV9&?%')1R3X_R>S)L#L7X-L)M?$/AS7C<?0XS,G1_Q5R[;>)EGV:?2G6M
MR8J-M7FF!&=Y!ITX^=XN%N\V:3!ZU_,/[XCN(?*NL;P:Y[D0DH^83B^ F,B<
M5(5<9N7J?Z*%F$T J4MTI>1RZTU=2=PW#WVJ;.TNF1X6U*7)\+X;C5YWDS_#
M) ^28 QEED#*P\B%)!,B.NTAIV)K0Y]L>>OZ[2M@')[>MH;XOI+M(>7C,LHD
MI5!", 2NA"6E2[4,)2;(-F=+FX8WJG4$Y^&"?7L3<0>Q6TFQQU?W6?KO\^$$
M\\OSR7!\\@XGPRX/7)$L>T-+O7&%)LA(<Y6-D HJ+E,21;0.]:[#<SRL[RWM
M'J*V2VS_.1G.9CA^6\I[G!_3?^QJ'YJW96DJ_DY2'PAM+<8D@2-9!LJS0&HK
M/41F':FM8B&V[G"V%<#CT97V?/1P-KX$>W$],4UJF=F7N/ASD&CVC"D&LF@R
M<C+!=(%^LC+4B')Q/K4.QZT%=#S*L;^\>VCC>74.E2*/,CDPA=7&,2&"5X9!
M_5QF(^O)5*\6P@&.('X+D\G<:^KE#.+6TWL[A%@_CT:G$&L2?*[LY2QB<:4F
MXDLA0)5@:O-/"SH4+ZPS7,?6MT(WP=7NK&+-:(N@JV3!HHD2$N=D"<AZ4<!&
M0^: 2::0:,CS[NWXXCYTASK1:*XK=Q]R-"7DL9Q[;%.T)!K$@#&"<98VC!#(
M"5$L 0H1%?,ZQN:U(Q]Q8:N^%62/\E7;$/4(Z@EM O>O\E4]4+]G8:%=>'L$
MZA:4YI+,3+"U;+1RUM<:.;5ZN9=,%Q]Y:%W8_5&H6</R58?4LFWH.ESYJFQ+
M+-X4R*;&T@UWX)A+P)7&Q*QV*<5[#/JG7KYJ*V(V*U^UC50/7+[*&^D5!@8I
M6O+#5<[@!.F]R$)8D720N;6U_:3+5^VB':UY..AF<RTQ4A<N=!82<G(:E+<!
M/%,99%1.DA$8_<UBQ$>6M7HP[ZPY'7TTB[AV@>WMK:+B \N+XSP%T";0B^)-
MA(B.DV? A5?91LRM[Q^N1W2$:M*0@MX3F5^'X>1S[;M^AF%Z/EFTT6H0/]SL
MN?M%#G? WBAF^!(GPT5>RI7&&.M1,ZN .3)5529_/EB'X'5A]8YA3,V7X14P
M]ET^KAZY""+40IX\"]KV%&U[JA0+9']G*#+2MIJ$]*QU'<T;$ X5V]N7TYNK
MP#Z2?#3Q.GK#_J.^8<^_SA>O*Y^,<^\MJ]=YZDT/58M%QA <>!X]U]+)(%IG
M*-X)YJ%B<7LQ?-.T:"+I/DS0);"E73Q?:O/;\7M,YY.:*O \3(?3W\==G"(M
MQR2(-^-/YS/Z=3=.P]&BK='U65V8[)O,JZ\X7$]S>J" 71O5N4LA'P/O3TFO
MD=>2 BY"2&I^P.PA2J5 .BVCS\%YTSI!Z6GI\WV1P:>ESMO0W8,:UXY?LZ\?
MZB2(&ES&+5+,7&9&7B?)!)25@FP6YT X#(9+S9QO[>:M1O( [MVC8+IK3E-_
M$<C/.)W-F\9U)(20AZ.OOX;)'^0^59]UWMR=Q9QY+N"3$_5NKP3O4H+LA'%2
M\Y1TZZ/8#:$=@^G7!PL]Y&)N /-Z"?D-P/9DW6T%]&%,MEXHWUZM]N2KA^UL
M.]">.8:")7#9S7,*+43#>8W3.UMR4DZV=D(?@7+=8S\]/MW:AJ;&9ZJ+??<*
MZ?3/X>RT.U_"?8DSG)P-QQ7PW&98'OL$U"JA :LC;?71$F*A#+A8F$-C1;8W
M;/B5YZV[C7YXDZE'.KN#<M&#C72UT[^9-Y"OR-\/IW_,WZ'BO0X^<G"F5&Q%
M0K3.TE]=-B%F;5+KM-!U>([!&FHF[QYN%%QA>]&-YW63/M*_O'@M-L'6D\6S
M#M?#&#CM6+Q3/1I1T(,1LQ:CXEES7ZM?.4XNGV(,(HL"C);"(OT68^O"BX=7
MCWM,E(?1CFTDWT? L9O@\&3\ZDLZ#>.32X 7NQQ-D:/A#%*(#)2KC1O0U:;P
MRIHHZ3>B];64M8 .;X2TX^YFZ*^9X'LP+U[4.M8OSB<3'">RC<@$(NOH?9C=
MA&EM]L(;#T)96>O,<@A)N%J?SQCII9"Z]3GLAM".2%/Z(*.?DIB7R#[\&3Y=
MH J6915= B^8!Z5M *>] UI-)4-K@LD]],A8@>2(-**!J'L(Q;WH1O76[22,
MGHTFY#U]?==-:^WRDY,)GM O+D/@ Z%+5-9GX+EZ:%QIB+S4_$4FF58LB.:%
M43<&]Y!J\DN3%(]^>.C5B27?GD1,@,^Z\_%LP-%&K)71F<[T;E2_VAN9(2:M
M-'<LA)M=F!I:H]]B>?KJT$3*/>P7S[HT_*7N;&%Z^GK4_?FOF,D,6G0\(+#_
M(%G57S\KI,H?PY>!U1B<9@F83+2Z,1O!,\$!E16B.*6\:WUE94N(3U]7^N2D
MAQWG)4[39/AID='Z'E,]%AV68;K(<?UF%DOL VT9YD1P=1&&3.OBP3'! .NM
MB\!4R,TS(7;!^?25J7=V>HBE_1J^#,_.SW[!\<GL]&WY.#S#"T=M:8!_ WN@
M0\DVD&/FA"JTAI8$4;H,3-";(8,J4;<^Z]D2XM/7HSXYZ:&FQXON[ PG:1A&
M[\*GVM!0)I8$K8P\TD*II">KG"6$K$1 EX52N74&]@T(3U\%]I'I;8KUOA3/
M^UABGKZFB;^93L_#."$M:#= YA)\\,D"-Y+\<?H']3*%A.1CKCT'?#"M@V<;
M 7OZZM!>_K>5Q.QSP/L2XXS6J,79XC+$]^$TD-.^_%L>,*D%[7::W*W:FR &
M 0ZM@) XC]9F8_'&,=W*X]Q-QGJZE/<BS=MLV^9L5VOF[?@FRJ@P>9UJ82?R
MM,@^5N!SW:"L\R5HI5!M<H2_^8A'R/S^DKW-O]L_G>,JPS/_U_DBE^#-V2?Z
ML/XTMVV%<JEP+2'+9&I>I2:(.==F)#(7E;W1=@/R-QSN:3/?ATQOT^Y[H?W%
M7"6'X[>7J;SO)L.$TX$J(1J5)1BE&2@=;#W5X>!#$)HY88W>/(%GBX&/5!6:
MR'E%9(L=X#+KA_.SLS#YVI4K23U+]%^::>/KK1N,U,.%UVWGU_P*[-49_G09
M7+A212V5LH%K0*<<*$9^HE/)@;2".Q-%**YU1Y_-D/61%W8YRO.OU4$>CD_F
MY5&)XNGI\-/SKV_&1"5>]CGXI4L7=PWN2HA8I%-Y'YTC(QI,J?U.G GUPCAY
MW2EYEU,2/+0N!G*XV1W^>F\S?=TD=>T1J,1CN4Q\QU3G23]!&"Z#MA B(YNR
MU":3UJ;:)Y!'PZP6K'4BY1HX#Y]'^;@4Z-:A>!LB>TF-6 EM625H W ]I6BN
M!?8P.9K-:-Q,/?;@X."*DH(O+F0RFYVO"3Y.@ZN)YYP,7,Y5U+YYMM4#*,@]
M69H/HQ_;B+Z//EQA='D[LP1R:<F%@1S)[57%:H@R2= B>BZ43:SYD=.UX1^B
M>7 S8FZ6-=Y1JGTD7';3V=MR'5"6,KM:\SXXY^K$(OA:E$E:]*5V</>V]>W6
M6R".B>S])-S#._T>IT@//'TVSB_Q,XZZ3W7&K[Y\HH5P><O()5(_Y *L8GR1
M!AR3\L!LT$DQ5/3+QDJP :QC4HO6+#3,<EFTFEMD>BX$< 'K-URF_*(36J:D
M0:3:OCR9 K[P "RSA!RMP7ACD;BC0=^Z48Z![L:R;)AY4I$M>Y.L@N6M2$S6
MCN+2(%DRM$7Y5"+8DCTSR:@2S084KQGB6/AM)<4><D+67BWRJ!-*KL"*8&M1
M1P?1FESCUMXY F9TZ^YPC_NZYJ,.,S2CLI=\R#47#C;!]M=-T*U9W.:NWRX4
M'/HF:#+!\60D"*=H&S2Z]K!-"$X6+V4T"6U_8?VG<!.T-^W81O*'N[\54:(1
M! ,]H]W8248[ITY@C>$$J<@@6Q^5/8G[6UNQM=G]K6U$_8"7/J7-G 7N0//:
MY5JK",'4*)LUJ4BE5&'-(Q-/\M+G/BK2!QD'OS[.G4F)H:7]V,TSL6M0+6:(
M*K,@,.;0_)[?4[H^OH]^M!-\KW;HIJ;\?&?5GAR_' HY?O64.R0)/DA'&RT+
MV;',@^RO5ODV2/]RD;9VD1K3W\/5GQ6P+M[338#UY#G=">KQN$VMF>WZI*6'
M+?!N@$H*Y;6+P!UZ4+460TRUDQ,S)2J/4J36Y[4'UI<=_*@'4Y=MV.BSLO<%
MPF7-!A^\)B,-2O"UT(LP-&MI@*M(7H#PA;;RUB;22B2'MXT:47572>W=Y=R'
M;W7MAN(5*"^,+6AJ'E\TH#)/X(W7H+UFP?+(2F@=^5T)Y%BXWU_*O4;;R%@?
MG6?,+[JS3]V8UL+E4EB+?)^,A_^WMGYZ%29CPCXE&YX9K!=:))^79ZCYZ\DQ
MT,X9511+IK3.\]@1ZD.Z50=(F^V/MKZ*IU>D$SRMNW254'4 *MXU4Z(O33!,
M\24N_GR.A1S,JZL65R4?1(XNJT@O) \15!&>WD]:32WJS*)"KTQK)ZWO.1VE
M_CXJ1>BK)O<=\UM96N)F!8K+B42F(RHE06N!H*+.0 9F!%980J.8E;IU89EF
MX+\[U>V/VKZ:$VPSD<7;=N=TA(M:U$NMQEFR9!1G$!3/X*+4O$@R<E(OE>7;
M3>$O?6U,\YV!L'YO+Z93S.<CO'Z];VX.$80\'+\@B[X;#7.887X>1K4\PX=3
MQ-FT]=7&/6'T<>^QI60.>RF2UDIEG%/ 15&@)#,0,8I:#3 [Q;FRIC^'XT@N
M1>;";58B S<H0=7> $'23]XJ7TRP*9CPX$<81W(I<AM]?<!+D=NHQ&.Y%'E]
M:?KFAHUC,CJ9;&U[42N&N@3.!@."'-L2:,-TJ?6)[EU8OH-#N*U4I^N!PA[\
MME6X+D)_FR#KZ9SM;E0/<]#6AKT-5&(/T1]6.1*C91Y]AL1J?9\H/"%4BA!F
M8Q@GUZZTWED/K13WG*8=6B>VD7@/NO!+-S[YB).S6@/J(I*O@G(V,@=%*4\3
M-0@N6P=.Z)AX4B(TCSW>1G%X%[851UU3 ?<0O+[8.U_B='@ROM)OH9ER/D>(
MOH;4;5*UL0'MA:*0>Q@D9\U;"*Q&\I?)L=;D:$!?#T&XVZ@NWIU-</6;UG,+
MT\,8&RUXNU<5]A!Z?TD[M_$EE:U7/(!,,H)BN4"(@M?$3&,%%T(VOW9]6&6X
MQ\@XI"YL(^M>#N87@# _FUY@O%H1+S9$K5DQQ@APQI)IE4* X(H!*Y-01A-N
MTUH=-H#U8/D:>W)XNT!\4P)Z;5%RF5?T]EID]Y=AB,/1</9UD$/)+I/Y78(.
M]?Q 0[#:0!(Y)ZZR*ZZ_P-]Z;(_VS*5- *\A,3V9M)@OX7R3G7:ML\;-8_>!
MRX+Y6 049L@.,\G36BLUJ"S1ITC_EZV+A^\(]2C5ZQ"TW;FE'>CH[E4IF&;?
M'%2-N]G5HAQN+\K]'>#M Z;78[QF4CKL89[19)\5%2"&P$#Y>IZ=4  3EO/
M<Z)U\:_#O/6^<(HV>88>K.?U/F:L-WTSB52)H*-DLI1#]-'^+@[SMM'7!SS,
MVT8E'LMAWMK;[#*1A>T] Z9U[> 5$@06$&)T15M;>\2UOJ/RG1<?V4J%MBD^
ML@V5AZXJL0FVOXJ/;,WB-N4E=J'@T&IBE319N 0$ATQV7>BUL&2R)X.)P L5
M?7^-/Y]"\9'>M&,;R1^\CH V@F,6"'X>9(H\@G>>@Q;*2^-,Q.8E3Y]2'8&M
MN-NJCL V@C_<>2!Z<MT%MR"-J5?$@H68L@.G:]\_<K>5%(W5X;L]#]S'6FE
MWR'/ S?!]3V?!V[%VZ9G0+L(_9#G@<X+%HPEK0_S#5=;<+7+' _>BT#+( \]
MW>%_U.>!O>C"-K+N00=^Z\;Y,JQWL0$FEWDLS(#PM2QX4K4]>K9@:0V4P6BN
MFM\-6P'C$9WW;<51UU; O9[O+;?/M^.KSW[#V8 FRW30F52[5H[-3D%$^DE(
M3JI?WX'<^B#F7E"/]LBE312O!14'T95+:^IM69A7;U== WM5 __3(5E3K\8D
MN,G\=1J042Y]3 50:C*ME17@C0V@28 N%IWCS;K./>C5'A/X3G3P4!0_EL-
M>L_>C#_CXK+W_+2S_S._-6,>Y&AOTSD?^#J>2DPPH\!PVFY)>QSXHA(((ZU5
M/,1<6GNY1W>")QWG,IM(YH1)H(ROU3$%_36QD"3WIHB#GH(>\PG>-OKZ@"=X
MVZC$8SG!6]?SJGB.@=8Q8(J34403 "?),7,TLV0EV4NI]3+Q??<HW$J!MNA1
MN V1!V\]MPFXOWH4;DWC5CWH=N'@X(J2C4Y8&'GQ)=2T-T1P @V8P+V+UO%@
MO^\>A?WIQS:B;Z@7][7>R5Y:% X!2RWH%W(![VR"P-$Z45CB7-SC1SRQ!D9;
M$;%A Z-MI-AK[&/%H;1)F F  \NUJG$9#K7^%P1EO<602F#]A<B^RQRB?6R0
M9E0>NH'1)MC^RB':FL5MLD1VH>#0.42:&:F+3J!CDJ!\H)424P2,EE9EGH7O
M,6[R%'*(>M..;23?@U9LVC(E)XG&UR[1I*B@D+92)YV!:#UZF8.(MG5'HZ?9
MOV8K/G?L7[,-&4^I7.XXUTI^/KFH+9-0Z-4"E;('YX4%$J5062M1H\EM5:W?
M&3W:4Y]]HH^/2 D.9+I?"O!F#<K7)/]G*2TNN&%^^^+-Q^["(YG.AF?U,_))
MGIUUY^/9Q^XY?IR$\;0@O>9YD!C&&(0DH]33OJ(2O=3$"?FX$J/62!0=--C>
M<&Y'J?:/4C$>Z!ST_.PL3+YVY5DB>0QG7^=>&N99]^J_S^FO5\>#S4]#MQ^Y
MCS/1/>??Z&3T(@"R'.NW;O8>0QZ.OOX:)G_0N.3Z7JE^<%P9YESMRA[)<B!O
M.$1OR'62+G*GM6F>F+,-OB:6R?JQ%K& B P9RQ80M0$E&)GS/@;07C&?(W,2
M6Y=DW!3;H4XH>].;E99":U(>RRGCY27WYU^?3:<X>U$W@$6!N6*R$\:0^5\M
M&%X#FI8V'2&ES#E9'U7KH/Z=8!XJNM</]7<U+]J+@CZ[5\UA37]=[!WY[9CL
M!'+RAN.3YV$ZG/X^[N(4:7\A0;P9?SJ?U<K7XS0<#2_"FE>S6N:3;C"OGH)Z
M?<WI80*"C53G+H5\#+P_);V.J=Z1<A:XS:7>FPG@8B3KG*%2+-$:(7M;,I^$
M/M\3P7QBZKP-W3VH\<)*_U G0=3@]"*XAJIXF1('(QRY6]9+",YJ$)P)'6/6
M*?+&2K@:R>']Y\?!=-><IKYBH.LMF_F+QTU(!6.&Y,A<5D8$>@450K1"H$TI
M2MFZ%MZ&T([:)NR#GKYZ':V'^5LX6QXM; *V)[-O*Z /8\OU0OGV:K4G7WTU
M?=L8M,^F6"4].)X2*!TTN!+HK2N)D9<?F6*M;;!'H%SW&%:/3[>VH:EQWMJM
MZ.:?P]GI!=:7.,/)V7!<T<XMB8O=VCD=:O,X2#;4!I]&T-XOZN;MI?9H8@@W
MC*J5^6P[#'UX*ZI'(KO#L=#09KH3;G<^NP=QM,IR7BNK*Z07JO:$]1H5:/1%
M*!:S5&Q7O;EW].]*==IRT7#)F4YF@[=_CG%RV>K>%&%\X!F$KKDX(@H@]S71
MY F!L5%DM]$614^^MCW1WZZVIEN#'J6UO)]H[^RBN"?'R[2Y#:!L8^UNRO9#
MV+![$K&*SCVDV-?+NURVD/8@+CE(E6(M@Z$A:!LAR631E)#-9E&^QT#H'79C
M?WQN([S&=M^_X_CS><WRN=@/O+860U!05$!0JM!&E'R!:!1M!5YP:<,&>_.-
MQQYNT]U;O%T;V32TM#(.![_@21B]&L]HBU_X)"Z2.2 DJ9HG*-J2E>"* RV3
M2#YSIM2ZF@E33#^==)]_ID<OWC;ZX>I%6S'@4>Z4^PKV-L=J'XX7*)9AA@UP
M;+!1WD_T]5$/NS_N+?ZNH>P:+JNW\)C,%'KD8&FI >4T[1#>T8;!=:T;:&J%
M_$?.X1U;8F\4;B.RQCOBOW6GXVDWOOCC8NDW/!JN:<&WM?*CXM9"C)'VD>1H
M/9+!QYO>R<IM<=6S#[<W[B?EKJ&(>HY#O.]&H]?=Y,\PR31IYDGU'$2A-"@L
M KQS$8(G]0PL!HEF ^;6#/$H(PJ_[)7EU5*H/9S374WSZ@3QMVZ<YI<L9H/B
M-?>*+/)<3 9E689@I &'1AB!)BG9^EK+>D2'TY"FQ'6]2?T !___>6?XZ^I
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MQ/LJ,7IU;^9:TO3%GB@X2\PQ!]G-C1G:#CV/"K0S@:P=K_E-([#-9:4UF![
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M/H0%_EH*IMJ@\#W.$OU9^(PCQX7W.1HHW!##N6#@M8D0&2_1!E=X;MW@>2>
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M75HG=0V^R-?],313>G@,N+O@[3!=TAE=U(#HZGB398,_LA(SI_\4;H*SK</
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MFHOY),[LEXNYBUZ.)1?S9A#F$_VK9<S<61.MTAF,#60UR!0A6DGBBSE$YHI
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M8HA,BLX_!:*$ ,I% =Z1 \%YMBGE++QL'=OOANQ82N=W4N/]5DHK'?00ZMM
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M:9^\!1.P!)E"%'J8U*]G7/GX(O9'(P[U-7?S",K26(FT;!V!NT#'AD,.T88
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MDLF8P!WE,Z)H-I\N'.4W?WPE$X",=N\D9S8"%YFTG2E:O"L,2FU>EK73V+Y
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MNI]A7H0%CB??P[@"/,:$U;XZ+5X%A5J"Q=H,1O$$$16=FNA]#-89UKR_]).
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M4+5/8TP\0@DB%R:L"/>+.+O:=8^]\@"^T2&%W/"<Z #S_62.RP:^IT%ZGNH
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M%WF41F%\?$%_X_,2DRW"J&(AE5J4+6T"5X<!:IU+).\@&]6Z3&<5CH/@O;>
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MX+D7'23//>4Y0*N4U3O-R>3B\Y?YU3'$K56Q(,18%OTQ"L0@'3@A4\G>,UK
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MY_4#]YV?S233NF9Z='X>TAB/$GDA\6(<IJ\NOIY\GY')> 4.0Q':D4'@4_5
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M*D11+AK:0H$E15:5*0Z"E0FL"]:FVLCC?@[]?BG",X,;MJ<'ZPBZ==.KUP]
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MXP 8  M  2P 8&3BXBBO*J$&O$%:7(S8Y:T2\)]P.P> _KRG&:24B(F!_W]
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M Q@ #D (D '4  / "G !?( P( [( (J &J -Z ,F@"5@!S@#'H O\ D( 2*
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MCUI/5$][SU$O6J\PKWUO">\"'P@?$Y]N7Q+?3[Z;?B)^N?X@?V/_[@"R@*"
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M("/_5?;_OA"0$?X7O'8#J#" 'C@/. @5 $,%@:."7GN!SK?X%@ #!X'^&?C
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MJ)_]Z'V7627D_1E\=]!^,:+MAZ5@#3E ^RND9, 'D/]^6[@@7*IJ.O9 EE<
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MTP9:^[A:^;@ >;2B)@;ZHL+79DSB-54=9E(-I$]1)AYK:_\ZX8?D?<G2!L,
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MN>?<_]QW[WW?FC7SK:KNGMK5U;5K]^[GV>=5 $-.6E8:@(*&@F*"8@* YR.
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MUU&AH_]\.5N:_ZV?A(H:N8FKD]O?=7^6)0 '( /H  Y  ) "E  =P R\!7@
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M=T$4PE7*2?[C1P$@B\0B!D$TRX1'-RU[0.7.6-P'IQ<<!"<RZF\G<6O2]PQ
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MG>73@MK(JG4TY.C8.-MIQJ0]B[;O>7H#*L$A]:40YO"9.R3]MGBSQR;T?59
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M6:=3JJ#XDEZ'\2Y;T;^FOE@3=.@_Z?G7RFD8G4,8K][*Y-NO*[D25B-.S6?
MADI^";SZ#'P2OOB57U&:N^M16!I4DT4(<<>2X$>B=+Q%. %-:8-A?<7PKGK
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M2I(_67C/QND<_@J)/BC*Y50U1#TGZ-OAU#R_W"/;71A'P1>%\ ZH8[6M4MD
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M^#M\H!R#^%"] QKF7\:?4D0]D-')+,C^%Z"&=*OG]0,*P_6>+,,SS*2)>98
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M6L#CZ*7V7KS)<%-*N,>TMH$13TH FOE9Q<5J76_V#J&GP+A>2 K4]=Q/Y"^
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M313@E4+^>F,E[VFQW673\EO,E00R\E,A3ZI1V"N1R">@K\JA,9&@P%GNF%4
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MA^G^3OCK:_C._ 29DI=OLS!9R/=)/3SQE-3,TL)>VN(H PO.R8-!SL0_XP!
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MC<D<^+)T[#<_;N!A<U/2MD&:=I\?N58]1%LU>?;#O[BZ_5^!,GX=[[J]0S9
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M. Z&E:.@7=$"/=<^.D[R]5< G*NJB.5[F+-T8B2$0UF8%^NWVXJWQ_4V:NL
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MGK3OJ2\UF":+D"\RN;&R=6(V!SH+75RZRV9B2V'G$!5IA:&AWJHZKXI?97<
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M!*4@*N!#X ]P_M0 0 #H?WX_;&+J0Z2ES=0UU>0@RK*/!0" J: ,=7%%P $
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MCZL,ZF+WZ&X7:Z@7U-6%&NKR7SGQ7VSVO^"OZ_H1^&7W ($9!X S00" #\<
M1'P, &Q<\%@"^C>_*:/I G_N/#VJW;^N^[\ ]+_WBI#TY\,3:O>7=M*:VM16
MWAX^?RW[<UL"2  Z@ T0 "0 )4 ', /L #<@ +P ) !90!%0 [0! \ 4L +L
M 6?  _ %@H P(!*( Y*!#" 7* 3*@"J@#F@$6H%.H <8 $:!26 .6 ;6@1W@
M.W ,7 *W(! (!80%P@>1@*A #" V$#=($"0&D@4I@S1!!B!SD!W(!>0-"@)%
M@.) J:!<4#&H"M0 :@/U@(9!4Z!%T 9H'W0*ND$ (V B$"!0(# B<"(((D@B
M*"%H(Y@@V"&X(P0@O$)(1,A&*$&H06A!Z$$819A#6$?XCG !!L 88"(P#9@=
M+ B6!JN!#<&V8 ]P"#@6G DN =>!V\&#X!GP.O@'^!H1&1$?D1J1'?$%H@*B
M#J(5HCMB"&(\8BYB)6(+8A_B#.(&XC'B/1(6$CD2&Y(P$@1)'\D.R1<I$BD3
MJ0*I&:D?:0YI!^D2&1F9")D)60!9 =D V0$Y$#D>.1^Y'ODC\A3R%O(%"@H*
M"0H;BBB*&HH%BA=*)$H.2@W*!Y1IE!V4*U0,5"I4;E0Y5$-4%]1PU$Q4.&HW
MZC3J+NHM&@X: YHPFAJ:-9H_6A):&5H[V@3:#MHM.BXZ$[HHNC:Z WH8>C9Z
M'7H_^@KZ&08&!BV&$(8&!A3C)48VQEN,(8P-C&M,/$Q63&E,8TQOS$1,&.9'
MS$7,,RPL+$8L"2Q#+"^L1*PJK$]8:UA73_"?<#R!/+%^$OHD[TG+D^DG1]AH
MV S8DMBFV '8F=COL">P?^"@X3#B2.-8X(3@Y.&TX2S@7.#BXW+AJN$ZX\;C
MPG&'<??P4/ 8\63QK/%>X97B?<+;P@?CT^%+XUOA1^"7X??C[Q @$S 10 @<
M".((:@D^$QP3XA'R$NH2^A'F$781KA.!B1B)($1.1$E$C43S1#=/*9Y*/K5Y
M&O.T[NGTTU_$9,02Q#;$L<3UQ'/$-R34)+(DCB0I)*TDJZ2(I*RD&J2^I 6D
M_:0_R C(7I!9D<62-9(MD2.0LY)KD@>2EY*/D5]04%+(4[A1Y%!\HOA!240I
M0>E F4[93;E/A4\E1@6E2J?Z0'5 34@M2>U$G4W=1WU,0TZC0.--4TSSF>:6
MEHE6AS:<MIYVE0Z=3I#.EBZ=KI?NF)Z*7H4^B+Z:?HD!C4&0P9XABV&0X1<C
M$Z,>8Q1C*^,>$S$3A"F J9IIA1F+69S9G;F$>98%F460Q9$EGV62%8&5C]6>
M-8]U@@V!C9\-RI;/-O4,Z9G0,Y=G)<\6V#'9)=E]V*O9-SB(.)0YPCE:.8XX
MZ3D-.5,X!SGOG_,]=WI>]GR9"X]+D2N<JYWKE)N5VXH[CWN6!XM'CB>4YSW/
M"2\;KPUO >\7/GP^%;XHOEZ^W_P"_![\=?S[ O0"Y@)O!!8$"035!>,%AX20
MA*2$0H4ZA:Z%^86]A!N%?[Y@?^'X OYB3X1)Q$:D3&1+E%;40K18=%V,6LQ<
MK$AL79Q&W$*\1'Q3@D["6J)"8E>21=)!LD;R2.JYE(=4L]0O:6'I8.F/,F 9
M>9E8F<^R>+(ZLKFR:W*T<G9RU7+'\GSR@?(?%9 4E!12%!8@%! K2!7D6%%
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MD7Q/?8I*%XYZ&3@E8'+[CR)270]U.!HB6;@@=5(QRLV?[$]^.6]L<*MX3,%
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M[-EB0.7V+'U1;^\#X*[CS8HK8QV5 L+RI+S)4WF+EA?%H/O*B@JW/OGLKBL
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M_3:O[@_=DQ.<35($#DZ2NL?%7>BHOD6C*9 \LE5$YR[XO$'Q5($O8WA<SZF
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M*:9*!XO%2B_V5MNL[I;+@[U>(EZ9IJI$R6ENVNDANE;BMA(9AY25#"M*WS<
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MVCK=3:-E-R M'-#Z$^MKJ-=*>^3U^1JNDCYNK"$FND[3F'EUP)P"A3IN@\J
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M88J2Y1$ZE/;Z!#]GKP+>:5SB%I=\<Q9?%'FS>VMW!D+I]DI;M;B]H-WH%G6
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M4R1Y53LD?SHC0M#L'"4:6.7E8&/++(9-%S#<(_V:.I0?RL7%>9H=9ND5\0(
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M<C6TN51:C"TN-P@?XN<M8BW,^0!9+K1+JRE*&;B]+UO>P3=3LQ_Z&\U_6?-
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M4GP*=VM9O 4U$^T>EQ^"]I*,50Z!<J*(M!.I=I7*DR'UVA> V1+U8_=V?;Y
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M^&#%RD;;U[K-X^%0<8IQ<V1P<"[-666/AOJVPS&-'*4W?G]3Q5;I7[")+;O
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M4IJO35%L4^6A7ADLT\KF*WT-J<17"YI5;Q5($S&^2*04^6<A5>UN]U -KMW
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M0ZXMA=F7;U%ZF[:XE7I#+;1_F9;U/=;Z+5OCA'\U0Y<FKG-C[6OTODP>O]+
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M<S9@%SVE]J*8K&-Z[A$MWMJI6K@%_8:6"AM;(\\0K\^2AEJ-6SF!4<FMH](
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MM1^SMD,3'^3=-RJ!IK[=UX(4)6YCOK=HUE=<<<3_ !( ](-C8W!8:Y*FR7L
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M^*FMKG>=U1$G8Q_3F;3T:$0'ST>T="2XO=Q+\Q'R-K):+\6FA&LV"4# D(*
MZ!,VLU6'YF0YM^*\'+=/25.N<Q.@;/7<'>,-FN [G6G4I8YX5NQ=+,'YW:GG
M,$4<T*>WK*A.\==7-@,*ZILHFS/NM[(YC,],\D0^LMVSS!H.' SL"NR/&PVK
M[XIX?PZB__UVLO<MY:EC'_-46D0D<E)C2.KW@#J7^OSP"Q0M?]D*UV)S%RX;
M-/:7=P=H_[64Z$:#YSED1FV;>*>I^<$/VUAFN4-=X2V/J%Z9C25-:E61)O\B
M6JK3"4+_XV8-8UOF2F^4+LH_'#-P^(BZ^E2&N'^%K^9G(Y?VA2]# >DC+ ZK
M-/O*7=2XK?7[\OI ?>/'H/K;D7,=]):&KHGZO\T%Y;Y9@=H[+\4=Q4Z_V>8X
M7YRP_=+AI^\L2.$>1!J/*6H#B7Y.%8TG.<R+.FIUZ\H3SM8+A?11*[F536HF
MB$5B>[TC<.FDHR'=_R**R9O8CZ\D1HGD&(5.T$U=G9()M04Y9K_9*OLLT/?)
MRHW<_\?(J9*ABSW88.B3-.,+"ZYZJ*:V=+UK2RI%-S!5<X'&0%:FA5 1/-_9
MKSY^Y@T9)2UV,J2[KG*^^"Z(O&R><F+(6%+/)I:S*W9F%@DF!2;DT=3H$_5:
M'L7<Y+B1_FEQC2310R K E>Q,8U<.W/M^:]6?E#Z9MKP7U.YR"<1L5?T_J)*
M7)#G?NH:AAVYLUESW>9M;F,*1<+;1O\!JN8C%6OSWR(C$A8PFM DM:[N@H.X
MA83UC1O.0I!%1*DV>\5(F^)T,HU>'IF3$LOJ@A#/$)L83 B]G+ES]^"$)1Y#
M2SO1L'D';# (]XY@TRCT[9M<WICW6!]R>N4?*:X.C'5P[E)M6&R_<834(M(9
M&2W(>)NO9#!KAG9=SIK%X4?D6K9:ANZI&2Q4Z324A+.?W+,KVQ(?Y.O2%;\,
MEA-%'H;^+ NU?LQ6@X#+@>6E%24/OWCG)E7H7VU,!'B,\[&J0Q>5^QDT(EDY
M'%0/;\HH4Y.*"^[PC;</DWK3"! !6'?M[IA.HF7ISDESV2(MB,3#.XX_HG@U
M5'6GP"M!W=]<PTLX*6==*@.9:B@_UMQUV<(AI7B^\H]; T48W?$*S9,9M8 2
M@M5= HG71Q%UE)>W>-3 !BV0'K?/^$IT,JV\/&FN?XF9QL*B:B(HP?A"J9<7
M".Y+Z>1H1C"$S5+>^.0"?)]Z0'K^?&+D1#7>M.)-\T4^?Y?JA?K@3MT6AJGM
M0>&G<:<D;Y<$B]0@'S@W_RZ(V^0-;D<#0XJ<3T7B[.<:@,6V.(4Y$FL>8SJK
MHJEK=GX?E7\\T.'WAP^)@@?O[MT)=_79IIU#](YK!O1+C&#^$D%$6&,2YX=_
M"F<+8/R+\>A5+UY9FN"D,H04!XA.*0'(-U!ZYZ(6-[W_.^ LY60T>Y989WK%
M-3OXZRCP<NMI5]RAX[>0"Q;)3/I);_;_RY\<'WT9XL<69Y?#(PH&=>XSC&_H
MF!Y5V,M6?Z/0YS'4D^:=>JYJ_U><'.V!PT/SJO=FQ>](&&/.(ZS]W?/<STP8
M)<[*?4YJYH2%\T?\OH[S!@COG&RSW5L*B+2Q9O,YI5 T")B$R#H%QKT[-45^
M) _Z<@ >#"16*!"?W<0^'TGUU7G!.C-&G+>$HI L>04($5N+\=TK"")H=]9[
M#.#7P4H;L6Q(=:E.6;A=:;<#?9 SBYF=0F_D3L,P/G,,J- CZK<TD;R@9K+Y
M25Y5@">2 &O\!_B6P/_6V9K'D*/+LW1RS+&V>^1X;7%M2EM259F?XVW.J-5>
M!3*D<X'0 D[+(07*+CR,)RO1N?PHU6_D@D>SL!88@>BLDL"W4]L6HCKW"TYW
MB>%I((N-03G7B!PLYJ4^Z2&*BZM''6/:6[<UYU\%SL%O#P\9).F%*=V1MG9(
MPH85(GIL]S5==%<TNQT=W!?8-!WH\^/_R40/WE 5FMX.\XL#RK@@L(]_ DW(
MVKH3B5+39NMVC 6B])5)19H'CZ+>9E(F4K]8$Y7L0M."D<G:MOF\M/J5-=PJ
MYQ.26&?GG,;Z,>=#YE8T8\P+\"!@Y+.3]'Y9<2#4!PJ1NJVDT KIAJ(TAPFB
MX581/G:5+2#V.+3,@L]8XA5C]31+(VWIQ;%B7Z]-",YS$<J^F&8)+))5--;1
M6(_4+Q.=A/>(&_FXY[= C.71%F;U>:V10\33(#SZN,Q8N#B$/2"+NOE)+)V4
M?46MUNWSWAR)=X3$]F^<IY1AWU<W:<^\KCT8+&Q:FJB_,6UBNA7%>5]WW\<W
MB%K@:W&:L1>,H!!LQ]<C]C6,]G1,"A<EMM?H_^$K]>Z?C=ND:M]B4SDF],>3
M&6I$=65MA>V151HLL8+J[M;%1+=R.%\6#WXL51@.".0(LCX;3BK75'^[,^-I
M"TR=&!WLP_L'J SVH 1]B-$]-',@'@(KOPM52DGC6),SSF]G<7E2ZTI2E]R8
M]XUZ_[F@3D>X395_8Y4<? A@3%,AHY$C^0=X(;:9"P?#6^/#WILSR@IW]1:9
M#9)A)3B7H*P6#W>9:C#"Q<9)/C4&V1$9GZ@K4U$[D,/OX^B>U\X.SH/E]=38
M>+>DAHAR9<'* DGA:X*7'8##@ \#.G3Z*_IQ7,J;KS%MQ*?GE@^$&J$X?6UE
ML6_@94[;)<65'(RLLRQ0I96?.9K,AFH#I>$-5B*-:(%8S6^=L\K1\]&^3O_X
M!W@[ER6<WI")D(+QYV,$54T4_"'H1$%[^ P&I35,O'>UW+F(/RN75%-(]=$E
M^_U:-MO%,MH?6:G9N<#:FZE@#X, ALNW*>^=#VX88D/:IPUC*Y)<_Y);(G5_
M,I1,0(%><2Q%^G? F(VBU)=UY4%U7:L_OS@G"2-B_3Q<L*;/C]Q6BG@110<9
MA)IU6,9R-$6C9_M*!]_/QX\#AE22M37-#_7*,[HRD]*$')RVRAP@+WUV3$C7
M4M\%LFJKD@HP[V+-TUU@B:=+O3;^A=F"2EM*H<Z_^4WT+<_VX^$O3Z=)5L^=
M0?,*+RU^ 48%\'N]2FN]O1 N-IX16,F! _3%TN"@2@ DDU2!] T_>]I;#Z+1
M(B4DRJR/U?<?@ <5CL'?].EB92+_ '#P>V%T9&*BR&'Q%UTK/C]-KLH'HR^X
MB-IY92#.-&^-Y@*1"C#?I@*1*^07S."#C4IW9)5O37-O7MA 1" 5QFKM\L[=
M?YZN,@ZI1 [&\T#*W@5-[\V.K%)GQHPOZLPO.H*92K5+E?3HXO;31[2(Q?]@
M^MV71J5X-!B^>^!I[O2R#6O$I\]F%HP/%5B%%KMT:U>_5KR8\AWK\'*<&K2L
M/"=R!(/'#DTB"@MAL?6?:0J#,8DU(9E*W69 :?2:$+[GDEHVWD1Y!N4K'/(S
M5I2&1*D\>CRUT=SZH;XQ9DT,Y$$N>^9LND#$]X67P)C%VISFB5%Q2=G/K!PF
M)9$<N(*.@\,29FXA>/(;MSR_<O_7Q=SLR</N!JVWUU"_+FE2DRK6A',3>9H,
MY*BLX)D!(8]L68G;SOSK7RN"M=V5%6M=Z1RR75U"G:!=*D2I-#^3H_F1NO!6
M?3.D9#.M2,9.>U!1))R8S_F-<IB ZEC-+E[#8!O^&DZ.I"Q(\@GL\I2CL3ZG
M/.1Y&K-&LY'X*2AQ7^C8<3SG?<885!-<:K);3^DMML 0&[!]&/6,KSVW@F$Y
MZQA%L)VTG:O#8]# 34GI_/&!:W:HFO/;.YG/YK2$5P\!OAQ^=G86?AQ,\6,6
M^#*:I G^&IKRO%)-(.W*#U479+8F64/.5GY@QK3QP01KS\5>4F5>E5+(W\,+
ML1Q@YD!G.E^T6AK(B.SQGK#HN\8)<B!VU5E11] WVK[F1K,]AS"@@84!I#OD
MH(P-!&O^ UAD<:*YU^5[L5G<'JI*(9@E+J\.---BMJ[D4O/+IJ<K5Y_=LF+\
MF<Z/C]_!E^;&C'MO_@&@Z@/T;Q J-0KKMNU(F&]F'[ST Y55?A:!TN!CZMYR
MU2IS2<>>87:H[D;$IF=9@1JVVJ/-%?E#"WCUP6_2\G6ZCX,);#XAOA'MG#<V
MKYZFQ6[%YY6 E1">Q2G*+Q(7ST=%9WE)49Y="2=&2)>;M]U+;X%NW&%\ED8N
MB6'.HK2R N?/IBP%NA_6O$@ZD".B'QB,IZ[SJ99/^T7<M<Y2M4%S^UL%MFW6
M)F:\VM)4%("Y&Z2$\H\N>UUCO)D^JK+HY:1Y\L@O0-WQ\#+\Y@-/H^\6#VM*
MEM_V6Y@C'ASJ*0\[5>T!E8^4>/Y=;>_T?3321F#4]?]1L6?]CT5BI3@]]]KT
M8=X0@_XY!XW&9E>Y3^W(%GDUN>A>]$?RK9FTN>=#[XS5R>@N.7U=NK#D-@7%
MEQ[%#0NP/MS@E^2Y-2]#74U[)0>:!70@CM1# J-Y\>W+UZ6O$UQ1TLK+ 37S
MPHX(6&S$]#&,550.1IE[=81? I5-S*\L-BCE\-RB*QTS[TY&J4D+PO\!G-)6
M#M7*,6ZCT!O1"K7,;)D=WX\,T)&54]S:S7[_Z<VD5APOIQ]E8?G7@I<95!K+
M4V.0.*X&$-S-H3"*.E7R=D[]=?JFR_VJUYB$3>6!$N=G7=JD@Y!]-;963\/#
M6Y!B$MSA1[, IA@?MV;&0&T1-1ND0(M%]37"C92SHLU&^FLJ77;X%89V'\/!
MIW2%/8BME:E;;34I/A_YBY9\HW>VLY]7?+)/5U;<]6\J&KEOC(?%>VRX]"H!
MC8ZYY3F5HV,.U%>M<(U0_ZOXHQ_GS>Z-\YH#8GRG)6G9-C[$4PX!S97C%5=4
M:O=42Q#)77QN9K'9A5P__#$5]BG,)ULP76$;@M";4"UC?]A$. WA"T-VR]E;
MN*!.6#4T40FMM0.6$CR:<SLN<] 1/4E>%1QEFF!=WT$KKB"[FM-Y!9O,6-ZO
M@M,9#!.%#U\$3G5PNCFQTM&D]XS2E_.2OKQ+AGQ?OF>* YKJ$.36ALAS8D&)
M1]2@4!_[$E,TBFA*A2:.%N6.,*$7 #7*(+$O1M.2;.]0\. @L="?>^>?$*V@
M ^<?*V]S+=U(+S,RN=]4!A,)CT935G./F=4PX-*_F.PG<%AS3"J?=7ST1NH\
MR9<0ZBEN*C/@Q.QF4),ZC/Q8#DT8=<SY:I!I+Z7M0S]L;AD?0_D844CG.P-F
MJJE2LM7\L:*8DW$0 62 D8G.DPDQ^S?'6-PC H0X%="2<!N4?%KMK@F$+KG]
MV5=6I[<C/4[P%L068A+,/-ZX&AXAQYBM"DNK*@90YJV+ZW$["-UPCT#E(?4J
M3R=J*C4&WS>''=).?;OX-TZI)M#6'Q-;RAQ$Y2_(,/TGU)^"<[-W[8Y$$ZQ[
M=3+37;J^?(LG"LF?UR?F*5.[M?W4ZK$B>,?EC4/)A(1]?ILU!/S^??=MKGS\
MZ>^/VO@>?;,*M D^?"](HS61\]4!.5>C4TKN)=<W*O^K,\O,5:M-X "N-"Y[
M)C#AU*J]X5R3EBWKJ9+7I.^<H)4<E3P_SEQ4]L?W\/^=(>ED8GZIII@L>SE9
MBG#%HE'X V15V\GE'GBRH%F3'G2?CPV=<3OY7O&_G (#H,TLC2*%N8R<==)X
M93&<3YA'H$1+HH,I6/3VZK1EY@[R>/D/D"(^7'/77N[R5+9LF-SGG%JGVCZ_
MZ;DX]H<M"XI4-(=U^K1IR<D[NK=N3LYC_0.P^;*6R#2(6%%DJ^1RV/;&<^O-
MD 6)DA4\2(PHO[%M#G<EAZ(UVIZ+Y=@=/7X/VI!Y4CSOLA] Y5'>)[<=_6WZ
MJ@:!]G5%I-LX@ _?5>-JKO#OKO=K_Q':WS_<>-6DJ8PH]2'G#22.0CPP_;RV
M^$G_EQW?#(.2Z+EN>JE(M<HURRG'NDU)A6#G(>AKK$?UNGZ/0.!193*HW8N&
MO;;3ZF4RD21?@)(4HH 'I;D@0Y#4K8&!PZJ.2XS5N'\''UX+;VOE_:U/8\ L
MMA[[_4DX$FEK;OM:"F C9K'9 Z2J__W_L/463E&X4=_W*B A@J1TYQ*2$A+2
M+ V[=$FS=#?2M70*JS0+RR[=("!(E]0"$B+=("TEOK][YIWGF7OF^0NNN:XY
MUSG?S\PYWU.A!H=?5J&K9ZDJDKDS$IZ+;J98D:F:/#WJ5T&:_>@(+P9!_.0!
M!+V&4UN/(9(.?^:,QTM-N<J?I8%N'>(^@B3_WAOK9".*4R3>IUMGFIN$-G(B
M<RI2Q#>,MV>*303Z']VOKAND:\@)>CY[[(M\JA[,278$D,O*-L9^,.?D_-D<
M&6NT!,9:$"H\]P>QI>0353[-YWEY 0FSJK75>QWFI%0FE]V$J27X#_I304N/
M<F3E*&<$- -0NUVHE8GQED?8H;RE="E/>[E=[:FL7?D(#Q LH4Y%W@-?^XUU
MGC:STC/KO>)UDHKX!V#>C\,<&?V<N/HBNO1'JK% ,T$J\V_H[W+M6K-(M!I)
M/KDE*#U1R,P3=8!H8CS%30TNAUITW5XY_@-0B FY,;24E#DP]K]!0-I"/2N-
M690^&VQLI?]HE(*JZ(R*I!CSW=0EM'^;KO:GYGRANOLD_!99^L$A%?RK=>$X
ML&&(; STGH."->7MQW,"Z$.'D+<>&*UORYT[H!;?8-"[\=&<3\?V'I9,2 1_
M8R^F\W3E1SAO: Q<)8A[I CKKT47L5V"[0)05R_[/6YAWCVQ%D5N3&U*H;EQ
M]H.,*FJ=/;[M!6ZE9E42@"T2#ROJ)$%(*4>\1D5;W7T#Q>ZD2FZ%T9#1:\@I
M5U.;,C%1UIL 4L+\[ E[AGH(>D-94P*?K2ZWM:18LV&>GAVTM)(.GF1B+<J!
M>QYZ;B^Y;/QQEWN<;=)_LN2_SZ,*E%);\.5'XGN6]S]?_:409@ONIY0O"XU[
M^(G'_'G:5J%O01I/Z2SOAUWYL&Z?(7[":^$AQVF$C@;FHG@.YT>B0!OX:G>)
MD7[#8X2=/ PMTT6#$[M-I4EE1VYU_= E.SG;PO.B4Z#$*;^TH!RNN@9E'=)7
M.],G0?P#K EKWI.! L7GRJ\;3OF.YU;Y>O\!:&(B@XJJPU[S)[ER=#=)'MEB
M_P,\IWO4[]TS6V9D?>O@.C.IHJ\Q![G*FE&A$Q_>B!5)!C+(BJ2-T-Z)#C\:
M&CZ34)T>Z/HJDD/H2TT0FE<=2OQ1GNL6=:8K4SXE2-^C", ]W9TI^%"!&!3^
M^D'1#88*\&#LAW*5EL B59TIF"*#"JFO)D0\X? $.YC>ZRH40"GF;[G#C_7X
M1BWHYZ#++=/KWR+-C2U'TDWNK >R<T/2]$3(PY21U?-Y_>OR/[6)Q)J:FEBN
M28K?4B21QG&+2IF5V/-SL[T$4,' G#=K,5TG+[_^LE8,#J9*&S>"^H]@32N_
MXUR8+=WX\CF^]K^GZ/NF07C[V8%J[\)U)67A<$7#*/2K@I(Z/0U 251HB!RX
M=_:MXP>H7%DJ$YG'J%42</VJX-K8+JM)/U^3=M?,)KQGG^S8:>T&5DSTCNII
MWO!#Q_/65&?IMYCB+*TD*>\O73,%)6\$]Y7]A(0:U5[^$$,F>EO3M$1"4Z//
M7_!%I#"TW_H:0YB=N@((4OGI@E[4*W#_H,X>R&G)(RUOGW9P5%G&*)]N6B$=
M\%&(P@6$<9S4CV RZ2K!@5IS6WU LP=4SL0GPV&> /PTC[%5FCI_E/LTMXWK
M="?%+&E,&T<QJZD1,VAMH,@'4AV5UZOZ3MI#F39HQXNL^)7TG8$]N9<-DB:
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MVD2/QQQ J];(Y707./M OC?@XCH!*RK 55'S(P/WB:3QZI;9:=5R1K"J/CT
M#H)>6XM3;B[BC L)(;F("SZ$2$HW9ZRN)E<J!!9>2XI>=F4J:<I)AOYDS@K
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ML._I-0QE^P?@@!L;<#D@(W5Q\SB@5,AD%/E-1",P'/1P7]G+37*\]B%$-CO
MUPDV95!X\-#A*K(FW/.;,YU%2(5*F=(?$DI<JY7QZN!=?>O"LE4(&NY;.UD%
M?0)4C852R<^*%3=5R59\;VDDCS\'_8^1>%"Y.$,S^(&SQH=B+J SAD.!4>?4
MP.9@'5U6&=W0J4\^@V^5IW;7153T#U!]W*J4SB!&H8Q-<BXM0=NIQU9?3\I-
MB'?.RG059,[W@^IDX8?1PUW ^(P50^%_B@3??L#.L>QTJ]($O)G-DJ.[)3?L
MN*TR>_4'</'LEV?#B9#Q?!W-<$H(YC-QDV]V"+JK[ZO+F7D&X1@]FVY:BD#
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M48?9OQL7W8T6W6L'XJVPJL3Z8E?A)7G1CC A"E)$N,M)(*)\Q2F[');_!2)
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M>GH)'U\V0;7AI%B\F"%Q/)U+L&_FD_T:"J>02 V[6"WN)_J&^6U$"?_P7ND
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ML< DX>ENR;KI-E?7 -%L+&\0<+A:7/+;[3]<LK9XYP3C6J:FZ=VDX^ KR'H
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MAI+_\%)+10;L;?DH420$,"+,J4*.:6G#M@5+78;_X+=33_L]?SJM)XI?\I
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MV_LH9-:JL../H^["R#OF+PS8@)J (;>X*@EN"+]=<+.6'F)P9FX*&4=:+\H
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MTK*5UYN&1#^_'X5HQZET:3K?4N58,YW:D'9QO2C88>(;JPK32B]4EY0YL9!
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M'I622/.KOI9J%G\YU\H@;$E45E,Z-.3#   %I]A/XX,:%#BUD ^5L)&DQX0
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M#U-@W!4&P*KO',_KO>%RZN@=CU5^9CPDJ"N9<QZ[$N'3L]=R&]U.T=A#*[I
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MV!F8\PF@D%NJ//J]\Q#;\?Y25$?WC(Q;M=T#?@ZV7JKXCE,25O^TY_.B^A-
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MFE2M<ZE.&K)K&-Z:<C.DBU_Y)'@8;2].)*GQ>_D=NMAR[HC)U0/2R2*K&;[
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M:?TLZY<';N:BY0J1JN.K]2S<8P>4SQ>:[;-^_&"]"V'+'#ZRY-:\#)T>6Q=
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M$L;&QJ62K!2$O)=]DVO\Q]R->=D(C5?]"'6"MZ_UE&Q;1R5B1W5IE#59&WA
M/';@H4U292=)Z+BX@WY>;P7+019?\1V%A6SVRZ]&2S/-9.4ART1L,\D]IM9[
MW'Q"M@92*3!A"4ULJ= &M/DH7SXOMHG-ZC[3LL1Q:O5QS3=?Y.1XE3X.?LSA
MD%0P_YI__[5#K"JG+!=*CMB90C&<7QQ8$G)T8/T*R;8*Z7B76U57CE1#S<&O
MZ^&@3Y7@1^% :7%P<JAA9^'91SUD V8RGN+@-.O7F1^B*@';6W*X0Z+=D;?E
MLEO]"K?8B1'WX>*G?G+C5]LO&93CH<8[!ROY[Z)U3\Y'0GXG:7.'IB6G_ZX*
M((H=.XYZL'\EA&_.3>J'@&\@_#5/F)@@FT,_JB)!!.S#=96<RQ%4%!9[1F'O
MW[4S!>)B*R!CYB:,L_;,(,Y>!)X )!#[\*)094W=5>A&5P\H<W &@M/8)A ]
M[SS:;G.B"-]"FFS-RNL$/L[L 'TJ>>/4YBL3VZ4UKDO;P/,P$&,5,X&A>Q*
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M/A.3P1Q%H@Q[DGM1G:6J'Q5 -[XMN21Z4^NT@G_6YJ"U[L, ]YIK!;28Y+;
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MWU8[IH(U6M24 U+D2'S9B@W2]JFSC43!62,Y?/-Z[05)S6_MQ.AC7T16#\R
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M4") P5'<6!C[M-&T*K/<609&(M.Q:V$-RR8!HKEF=ESME:A'R6@><W)R[C-
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M5AT@TU3?GY*Z3*V7-)U&!^3H%2ET"N5WA7$ \BJL6RJH5!/K34"TJ?* 5-)
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M$_DY?Z2V*@9W>1&_O9:%&9[$E",EMG[U#."):99_S[1?F\O/@ Y93]],N*(
MGY_MKKJM7+UL*G>[B;!@.@'WH>T+:Q*K*E6RD<MUDT?_R#"Y-__5VA[\,2CB
MJKJ$H'DT7XW3),*R;?94N[8Z[K%+JO8X,XE*-'U74=<Y.3B?7CI97\M,?"#7
ML!P!VP#IXM*62-R[&1%Z5K><["W0>W&,+KU4DG2^G2][OTC+*/ )K69[<$Y/
M_8)_#C(MR?W9I1:IS'<O>I"N39BVNR02YX"^;*0+DNHU+JQOM8^"H<H2_Z=G
M42M]9-FKWC 5/4,USN!JYN'1)!Q\'8/IJR.+U^6N9B#AV2BT[6'C159*Z.0Q
M\[& @[R;IGQUHGSAN\NOC30(DS'HP+Q <L.RI2EN^+4@P[SNS.AC[*5-@;AB
M^Q\G@[S26:X*!%F-O@'_TI&O,[TL[29;:S/+TT3,;R$AYI:-W,(,2R+F']9A
M)?/2]?.YXCX08;'T?&R='6T[W3H,OQ0=O'QT'@INJ]">Z7[7&Q%\TR'"R"J_
M"XXZ[:&RWWN_/0=I6LX>LTA^]@_I3FS[QAVHNU@A57JF8'KB(%7+1+]1"CNL
M>5WXVS<LW6)>/J#!T4>]W;G5M]J*_.6T^]+N"@0=3G1/^[:%L-Q]6+!^M!WA
M*.CUS&12V$=2!3V>S[A%%3(/N+L830Z5'TA,2+J? 02J6_9JCAH8%3./%CGZ
MB[7.NBG4I]GP= 8!>_9:#X@_8]8O-N?OO)5EV)8]A.JI/4;[TZH1AFL+!XD;
MT-651FQCT"4'P9V.0/-B-^TB$CH^5&!SC;J7&2#N>C94&'\JW(#0NJ[K:BZ'
M7B<%6-K__RDY?=S^-WSO>+I.K4Z6_^EC6ND5DX.[+NF#3]4Y.T^:E5NWT)1B
M6M_]CO]A19B>QL.=OW&XYX/OP02<0$A;XW3B,Y[FEA+B1'_3_Z"C_&K-8GZC
M)JZN0KAUXB(/8Z+4<"N9^)Z,XR(Y<9 RI'7&W:2C2;Q21HB@-.&!6P::1;#I
MGRJ9OIVR\/9^&8T03GF#9Z5\?P9L>WTV4QDX1^V0UK*_SW[]TQBX$"J!1*@&
MHZ-T+I);WOO;Z78J1MM,MZF0SA1^<?Z$:;R7/9R&;V"4M^O:6M[;EI3HZ%&N
MLW>VI]Q(/ RVX$TL;$RH"4HSBA(69G"T<4PQ=<VS+HK_0FN1>T=@FY%G1UA*
MDHNX%[6YBOEJPKN/37L3@78D+/80?E<[=;+7HLOND,]?)'OO\/4D&3O?WO %
M?'I)1"&=+-/XZBVR>/XMNAM!L',(V&(965FON$SQ$ I-N06V587ETE"(;<KD
M<_B3J\L1"H!0(&::?<-<TFZ-U9N1P23U9A78**&C.-F8TA(7/"U &]1.;_);
M:.W47KB$)S'N546PPC>(M6P^Q):0@ZD:;>_5ZHO(T5H(3F>3*Y=JEITBX\6X
M]/B4983J&N( ]@S(R2=<%5]-X651;<O/;21YT<;^V]'.D9/#B.";WON;OUR$
M FVXX=-<.9 K$S9[>!#2H*!1EEB-C!&9C9AHIY3,6EF&?OB][YE@R\>OIU/,
MR&U@<"6\P'$76HXH2)OBX."'>$!DJ295B"S)VMU"#1W)7>,5+\Y,QDO9?Q91
MX8O&ZFSZ^8=,?O P*FJ!.7_0UGL%N>&3@I!CY.<^*7B#[]W]?%NK^H\_:TKA
M%>,D"\54.RI-\L<-4@E")KZ-R\O_4ZN=<=6'8T9[B2=3=:\/0396S4+<> G3
M-CFOA:N3].!84C:Q.Y.L 1VK>2W_E*_\,@ EU!&\K>*$@;_K][G4OYXG][;>
MHD-$:JCG\+&'\SC=#[&[7YN$G$6F+82,XGGIV)[RRS+4@H@))1C\#&N]O7@/
MJ=_RFLEZ>OZIWDT&XE#$ZLA;G-.:AWW_(&!H;L)4&VQOA[X1[S"J*8PYL6/&
M.E] V"[^[3;HF+<NO%B$6HKML06F,=BZ5WO?[,FFJR%!?&_N=/AN:0E)7NQ5
M6S&]Z=S TWS_3@1R]<E\C5CCDN=PK9<&PV^'*?Z6H+GPK7CHQ33#DLD@E2U<
M/:U2,%X;\XCU<'^\DT?W<]SX;ZNQA^0!UY67>X/3,^G4L<U>:MDIXA;,0E-0
MJFJ?PN)P_/#0+UEL_Q=I;QD45QNTZPX0$B!X< _N! L$=QC<!I<$'UR#N[N[
M^PP:W ($]R"#6W 8+'B"#>=]OU-G5^T?>Y]/_G;5JN?'6JOZZNZG[YMD2M/R
M!2"T\QZL*+><M.$UP>TEN4!AH5&]7Y55A BT5G)RHDF9$^08SOR,.EBE&L3*
MBIN$SM'?(QVN*LEZ7SWS&(N3FNF]!7UJT?B^ (/!T%@L(1G>EM#"LW1K%PA=
M,)RC3L)1.]:7JZ,EF3$YZ_7"(+5ITW1I;:&G(KM/^V?_T$CJ6^NBTEVGT4^7
MMS<S($6=2$DM>A@IO6V5_,6$F@;> KN3#&>G$]1T3GMM%;D>B60W(5QKA/#V
MF[N&5N+U<V1UQC)E,2BSM#2.G1$=*K+@&EVN;^ 9(Q#-4L+^5BS)0#[#,&);
M'K9ZY*0(532?? &$/A<$97;9EG;%'+^.32RP#111=V]9_\2<@]/QF9#0/*5*
M47]>J+]PE1MYV.Q.0,!Y7.4OTYH6L*K^$0S[>)E>X_%3ZIAZ_ZC=R6>H-L(S
MAJE2[F**('RG[7Z%$OHL/?R@7%#AS.^ZOEQH>9;!+\I*&!N++">^<A3K%\R/
MU<!J2X2*O?PTJ7USOKUG4_&8#:YZ-6R**N+N?H'OE\<']'BF?VRI#2@A\UEZ
M-G4R_)LB"V%3!V[G^#U\_QFTNF 8VM;Y^#?9-D8TM<G0UVM6>LZLZN@2I^EN
MD<JTI*BZ>C-[,DP"(F;+(9TN=J@JM8;Z\Q_(V[42]LJ1^.=X&=._:X7-'JB/
MM=\'6A]]72S?HO;T="GIO$$M->8=WSWEEHC< R_D^N8+#?YW&N3_2T5V0/.Y
MI7[ZXOGC"\ 6P5;WZTI-[.1?";34VB7JS'L?IS^._Q?3W_][0/4%,&V.FC85
MR$4)YR!HC#,A;NU\P]1QM(-O2!<&/9NJ;H.7Y.^0%9>/G"L?B/7([TK-IGJ(
M%1$?,B1=W5[+S</*$Y?1ZC6Y6E30#N,K/F7TT"2_>^:.ARZ&^T^T'+>VV<P3
M96EKG;.+B56DJ$LDY$-[=G(J\M-XD7:<BX/9Q[G< D2'G[J%IEK'TXH3%*D+
MV$PJSCV;/OH.=<6-L%M ;U@EZ.YO<\&#S73$&F3WE3EU5>#=M'41'FTM6)D
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M#$T^V6RT2!6D/M-MD=.M4)*GU%W._K 87=AU&5L6]>:4Z]2WT*OF]A;Y*)3
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M;9V;Z1QR!_5F'M:;#HC^C6L17FTY5K<YARB;JB*@+*-F]BC35U_*R3W2^9)
M<7$NKI]9VPMD,HKS_]$-@K2-%6;_8@NP/F?^0SQ.]>>4:J>ZLHZ4W838=?]+
MR7*N8]=92M2" U736EJ62=M*BYH*+I!AR,SFL# C>\]U4O9C+KO&-X4OTY<?
MU?YYN\EP86/:(O9 :YQ;JE@Z%O!;;QQZ;*>J10?ZI*("\>5@Q-K*"^#\0-(
M(&9Z_ +0_8M'WL!24L!4DZ'I:#A3&B)!@^>TT/?1%#Y"?=8-P:T"Z)E73'B2
M)1^].801^HLGQSS+ULGV$CTX _Y=8!(;Z,JOG/](3H P9FYM1U]EYE5-!3FC
M @  V1O( ]/-EM[59K]N!H)2&QL%X&Z'F8YA5Q W/80XJ%KI.%;I,-:,5N,
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M>$_0,M=6TEN;LM#KZ^.]H!]YL,HJ5_P/:)(0HAD4UF(DO21^VRM\>Q0\NQ=
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MEJQ)M;(\#T\!'B=7K;0A*5EHA@UN%]WRXG E!=7T\#:T:RIYY:T:!@8#R3.
M0>()Q5E-BQ7]0TUN1> [[AJI[XHL5%*FQBSS:?0.SER8B_GJA',29[)YQVRE
M&R OM^(30GB@[,N;FEZ$^:M9_(H:KB*&BAIZ;T/SAR:9;TFEK=/13$*U5>E<
MQZ:^P/<EPE)M/.@5%*?(KW_0,O3$ ^Z]J 7UMSH\'S(&I-!_+Y,0.H1E=R?]
M:2[^0UUKS=2M3GY0,#+3J_)E5H&._MCZ<TFF@P/'=TB>8FWR"?NV*I4G.<.
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M <H(R)<+2X9#;YS7%U=I1YMT%WU,.[^STRJ3H8L'"E_9RM%K>[22B\&U_,\
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M:N:]?F5$C=^)_4I)= TFA#%O@<XEYS=&;7\\ET9<VJ_^:4PWX:/.X7K]S+>
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MJ1K,X _*EU!XIG-".&].1Q,\PKWZ?<^B1*881UR_"?\=!^G=_;1XCUK3H5Y
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MR_8Z?S)4"\KQ[KB7M[W@4[H".CAY=44OK?K6<674BJ@9?-H-PI-D4Y]2)VV
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M!.-5RK)07Z[K[:S>?@8Y-?,$9$U+G,=D7NGME+GXL=]:)3%I^6M([=MR,A.
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ML!?5=POK(QJ%AUN^!M 8AJPF#4N>4D%2Q#E4A-)N?4O"NR-R*<I*-$31[+X
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M6FT&%*^1ZT.ZI&X%<A2W/FG7K&3)K >;@,T]W+#G]&W*Z!L3#?>!YX=KTBD
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MS.GUY):LL;HB6Q^6P[?P\OQ():#X<X60TAMIBO]9"531]G? \57B#6]#/<<
M]9FZ'C,([UM"D,!%^-+HPD U?J1_;^W*"P$!U[+F0\T,BE\H$ERUM:F[5]Q
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M?$1]IYDA<^M&[Y';:%)*U-?GRL4[NV#2Z:%:];W%]0=,I\6']!'HM=/"Z#.
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M)8TP(L$<FW/$P8KLPF8N)>-/ZYD/CM)L0X^FWTI>9VTI^L@V1\A6B7S)#R%
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M^*1!DC[_I$7-O81D[2<:>VG;N((ARIS5 $AK&]CP+>HM%;33RGL)Q'C(F5M
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M)\54[I+*2F=WPITCZ0-R5WFM%5.,INJ^Q57<NBIL1&(+';^)ZGAL 96[]4V
M=H#_(2-U+Q@?%]KU#=53H%]$LQ^P<W @>1E$U)1M7BDK@O%X-)%38=^)R28W
M#TU?+\W '$B +(.QXZ_F9K]X-W:VR$1)Z&SVX<H351G=-PZ7A6:D__(WVDE5
M#AK8(=O7U?Q6/?6D4/Q"PB[(7#^& T#0&1-E_@\)(^35KGM9(UQC!4?("K')
MS?EUE;?C-!\H*AB/[++?3DV^NO%-:6.<!!!B W/WEUUS4RNMS7ZA-)CZS>O6
M <8$O69UD_.UI]+E:?U%ED\M\7J=_()%QI1TB^;L-<L;HY;3T&^E!;$^E?S
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M#EM[2?REMOVY.^W!B;J/' #4CV@/K7VL<FE'C-=:Y>Y)8>[W@KPD]4(P99P
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MH&2@:*PAXFHTYC\X\C@__P=02P,$%     @ [8!-6LI!.0G9(   _BX  !0
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M7EW?T-C4W/+ZS=O.KH_=/;U]_0,T^LB7T:]CX]\FF+-S\PNL17!I^8==?(
MWQ_KK]HE!=O%_\,'(C_LXN./_O$%*4&AM0;"TKL=1;S#9-2WG!.5W9.1][1.
M3&/K(8:<S^D.<?EUAC1-Y@_3_F+9/V98_/^397\:]N]V#0 K!/A@YPE( 2B
MR\E/T0;^JCS9&<ATI1$:8JTM.B!UG,T'0Q6*S$3K?3"HU[U'C7S5I=;7S\/#
M]_JU=@-G'PW[=WNNIJV,(::AJ/>1C /I2>;Z'_%(G"VW%A+'GD5W3'_N=?VP
MT)YRR_+^Z*7Q4QWV*ZK$F=MVRAT3G=86&!@G&8(:;'^HA5C1_"*&1NAO8#T!
M YD"3EU3YMV$(JQ&RQE\B5F%2GQ,F77PUK+U7YT_[5)2\U__@JB(;:E'(G#Z
ML2,$)+;8_L.\YZ;^4B,S])':M(&>3KG1>S?<1&T^1ONIB0.=^37!+ (/B+^
MKT>3_5-+:Y%0VS!YK*%=);@RK.)JP.<U3&=R6\=E_'RQ=.TW#26E2"&K&*/)
M"L#14O8_4_C ,1X@I,N]AO-G("!Q,EL*Y &-A$J')M*%RL\ZW-Q-[H,-7J8]
M)7Y=AFJ%8D!YTN>!-<^D;R[:>%:J7UK0FD8.9K&"8$,<<>*@&5.%1>4^X '>
MB/B!@7%EY\\OZ2'!1T"W@J$)Y<?4$SKV1L\#0]=?NQ?D>=$_XW0,20(^L2>@
MNKD(UD$<_HSW"JRV;VLT)JAN^O+BAJA2C^!LB;F_FK?U\^)AQNG'RHN7*,<I
MB<3RZ>S"(:] 'B#+ P)1(EC_QLJ>)^7)7;<"I^]M$?JFF-DC;3NR+7=5 B2*
MX0&"3 9E<I3QPH5+YH0ST/6UJ\"'S,_:Y)?^#3F2']2Z(F9$QV?Y-),2 S'\
MZE;JJ:V!@P$Q_I].^&N7>#V$%3."%0LC@AM<DR$5W!9F='-@A3X?UHENE'P1
M%TWM[KC\SMRHHO)4:V&[>KM2DD;6NJDK\ANCXE,:!B@!Z#15,>Y-O "6PDH$
MDX,?V-)@?;"G9]RZ:1V3EYM:/3SV=E8W*6J$ASC%V:C>W[4.%\;VXP%UL1 _
M_CWJ":&!.*A *ZHG*H"%[!'S;+V6!H>5GP.<!J])+?FX+6@E^K)W&B@=UVJ=
M\_)L>+OJWNM<50M8X^>@ $/_%;+"8=*51NGC 33]I!H=9OUW5FKG[08,M4U:
M0N4:HZGBD/$C/X\(SYZPA).>1^3$OO+5G2*XZ##/LM; %L,NJ=.KE<(=Z::<
MQ RTLU*8O8TS PK-QG;'B['/\2N"/P3FK.Y:#/54V5MU]E"([I4<3\I94S_;
M54<></-R^5.T_Q.%'MD^L)7:F[20>E? G9E^-3IPJV68 BNVX>2I4U8N6Q#4
MH"*.$>H585F5!\QF1?* Y@?E<AWCAJY$0H,31X0'Y,WP@ W1:$Y0.AA$B.,!
M\V8\8'33=QYPV:E<HN"#DO.U8F"WHMIB_K;.=5)[SSGO$G^T&9@GH7A 4A&(
MX $6P]"A:0K8C61\Y,$U$!@_RP/>>O;R .7\=YO2=^?7L"%E(A7%11"6[*IY
MP,CAW^^;NKG:3#AE;N;WV[O:4PD7X(#,\#8NHKX\/O5DM\EU'6Z.#:N6KWF=
MLU;\CD/E:SJJ+&4/\OT?(G<N&,;$V,7&VZ0$8[2TH5B-]_%[+8_0V$-Z/L(?
M2R9/A"M[FCW &*WU%Q),W'-#4. 6,)Q?DT#/XLAJL(1!E9'BF<1A%50HXKPJ
M@FF</4H(Q$8WH:3G2\RAKG<7?=/;JG)HZ](C0M->7//U/')",O@1#(NVT'L8
M%I-CZ# LCLS$UZI]JX[L(W\T0@AB'[6[Q ^<SN,\7$?.Z$8&"P_8;%,;$8XS
M==^XQMJQ:S[6/!;M2DGJZ>R1OS4Q\?5@1H-R_+O)=[N< 6E;*I\;!0'C.@HL
MI[:AZ";UE-7CT'H&BX09^[9C,7EA&^DDR>>-Z@FG^G>9FW8K';(6CC/6SD\!
M_A$!LT;2.==Y@#2ASPO#%>W5\71M02[I0.MXP).:X66I4I<*#Z5$6<==0G](
M[%:V).%U<C$/Z$/#^**):T/OAQJ1LVLG> !+@0<,V-I.&CV?BG"TW.W]FU=$
M3)@)KY2)3:@DY;&&EPIT*PJ5_?*XP]F G0ZTP/QTQRZW:OO0+NMUP6J3;HIG
M74>'.3(R< "@_ G@-B+K"NA)1P^(M!!D0D/,1<:W$N5P5MWJ+S[>EVX-U+KF
MKIA_^?B>1O6-V@(?,X,7\BDF%+_+,I[)T*I ;F$D9?(-G4RDZB>-5+Z\T5^3
M=24V->Z3L,;JN/ F -? WHE#@VBF->L.M]3<Y#N%88V0PG^\19Z94BD._(!-
MTN<+6.S9X9=ZW\/CB$>34$]AN.[4E]=?!X:.),ZVRFW*I]@0J->&*T0FE=BV
M.. CA\ 6Q4EVUJJX#8*9L28MYD+)=<:UR(\1GD%"SC>&#U94'LR/]$R(.B+W
M:NBZ+_HVRE<?U$?6\8 X516FPZMA4'?C.!*HW8)U;7+/'![?@8XGF\9J>)9M
M54AP[%)R&9G:H!UJDW&W#R.P2D<?$@L<R:X%L%M973 L-7*\06]ZNP1N,WAU
MY"$'34,B/ /T54MB\@)[YL:<Y$,JFGO]#KU=71JEH"MY453D)0QC_@1?I!+G
M-/<J7@-GSYB9NLX,IHV2SM?*8.._CM5#0$])B*Y1E]RUN<2:.;U[V=<K8TYJ
M9.YL;HS<7HQD[$(L63A,+O( 'UG"LGG0>*T)_D..*+<,14T;ED(%S)Q7#GU2
MC4R# &SRH0]31K';ZLZ.MM[[-&5]0;YA+/U:6960VSE!&/7K! VG+&QA"TQQ
M0%>DAU))Z5J&NNZ3HWL=/RS-G3H\B^B),Z_YFP3H5Q&@H]-0LZX<^'+>,91Y
MC:,ED>C5A"\D\"I4/T<8MWKNWG'23];1$OA#Y.;;)W?S '55$GP&@7OO^IS1
M[U&N]:1GC-QA*2?T2R[(H9VZ3QJ>Q9 GMBZ%34N\"-Q)S#4B\@"QQ?,P"NKQ
M@"MP'M$#) I\4EIXP'EV/6%>G@>\EB8P#0GUL334L@3ABQ@*O!7E4VTXK?MX
M^O/V327JU_-BF8892=J?"\P0+VW>EMY?LUOP6/PV]3(4S9Q!Y I19@6)''LD
M@XAU@.*'E_@=H/4P?AIU2!M*-9]SMI+;]4J@\\93N*S]G6\;:S\F@ XU6CQ@
M-X9S#GZ3.9#<HJKP+%LM]7#K"R''+ZAU#%12JL&0\D='2S5Q[?RXOR?FFN (
M#] D-!)9"K=YP!ZCM[W.S!9H'P^XB)K4-X'.!U\OD6_^!0U^QPST5M<NU%,1
MSH4S%&XB_,?,0V=7AI[UE'4\>.1G.M;.L>,!&:<(O6]Y@(87P>L<4Q^RA#,'
MK<.Y',,]&K5V&O:GP9_^<>O@ 5_T@N'C&^!J(U[B$D%8DG#G ;UO">-[XCQR
M2):R+G[G_FK]^ FU&BF_1L]$[38>\ ;-U.(F?N4!'RZ?)N?WO?L95'6^$?L2
MH+UF:*B>![!M=;X&+?NSU&#%$:XPK%*@SGT.WB7MP?DI&R5^WL;M\'X19C<A
MEI?07X+;OW\PUX1CY1GJ^R@A@X0J3FLTJT_1+E3[(]"+=Z XB26$[Z.H^;7.
MC]ZG\X"UP>CE)0>NZ$&)\.[Q_)1W'W[1J=Y\"S2014$03A*3AY^F-\"YMIR>
M:I0N&Q"-7\>\058M$;I+3."8"L8/L_>$ZYNLU&S5M17$^@BF7Y%9.;VP- 4S
MIZ=@&$.K09D')%,"AN4(=8>]N==K'(NQJ$,,X[S'K07N025T(N*3[>I%^;"!
M_?66-S9L_A8ITBYVAP?$!O#/3$;#UW@$7F8?P+F A%@ZG%QGG1C^=83+>/7N
M"H?X83E_YEWRI^JVH4O13MHU72Z:-YI"?<JJ RY&?U4S]_76C%U"7QM^FM5(
M #63FS #(ZPP4(X-.Z/.OH(D#[I2B0D##32%NE0S_B/31DBIEB*OW9$E7EX5
M=F//GL9D>P^DE.TL%7UML5S^[RD,"U*:$\8#,BET![9$&QPGRJ-P,?\MH'M2
MCV_^&69(A00?Q)+D H$-D_2I=:3LXE]]OL$LJ<JL-$7[@>[/3AB#?G8I:1>8
M!:,.E0>0KD-6-5"IJ>0B' <WX_]@=H_'8<(F3X:/7X/C+-'E9Y?OTFMWS4_1
MV;KK%ZW>(\$-/<48A@8D'L)H83WLIE!O$^1X0$#)#N3Y6\3D:;T:*<:442MF
MY?OE2R927O4G0E*CWI;OG=AC<EV][$V#%0\HZ&90.+(RS<-DRI04^PQ6 A*[
MS=X*=64AA0Q?.M#2[H_,K,$N6G?2JGOTI_1FJ$]3]W>]&]9%?-WGF^DX)SB8
M$.>R2XB;B:+FYJP$V]D68#@M!S93T(V;5RO7_LCNU%.0W4P1.CE?HK^O/T0W
ML:@ZS2\@X;S!!F ZQIF04CM&>D_B^T:LQ'!D%%@T4).A3S>9&J-CTE$K\3LF
MJDG)PW9@>M'@FNB&@>N%M_7F77MZ3\4MRD^N-;!;G7#2NSO)+FQ9YY_3OP(W
MP!$FH9Y0/E-'E.-$,2=-9@-R5C&FOI*+6^X?(;?!_=*>+AOUBS$9K+QZYM6/
MY]KPL.%U!^ "-@RN1T^A&%548C,/2%6VGEI#:SM[E-& +:*9-%+B:^4_ZN%L
M:8,>N0]U[<-"TYYD\Y>.WW-U$5<Z('I\V8Q9[M0=@4[PVM03@;S@;GT>4[+3
M@&"4E;*P8.&=_[9R=HO7IXM*!QLD^#2FUT85G(#O"U/\H]  >K["Y$=EC><*
M\("KXP#\R0E;#(G51;,CP> F^=J=W">0/N?X1UW]"HH(=H25\6%!)16S<E#%
M3?.Y7>")I&TG.7WY$9OJLE.O"<9<4EE8IAC#)3I]P(25QVR9<J;I2^!VP1==
MQ+\E*E:D/B]-'&L@)-\XL^/[CM<>V_M=^@8_VZH9E#UN(SN\D1@36(?/_"=$
M=CHA\##S/*6<DI8+QC)2;<%SI;:T-9:&1/[OO5*6Q^DJ2957UA-/=0DHIOCL
MM:=\&1B+$K;'8SF.W(NU6H'$E;4J<*LE@J)^TN]C'V'*DVFBI="Z@%M#Z<F3
MO0W+SU%&=S95AE:)BIAV7Q 97='WB; '%81)&2"^2N]/I:-:5DJ_U;D]+ PB
MCO2&Z!6)G"@;<+,_=:%O+- @+O8RWA*D4$VFV P%EAYHP [&!D/B3<P"-]AY
M.@]!CP:"5 1%)M@V,N^;(_;I(<WJCA!^?59(V]5/S1TVEQ-&[^@&11T4Z2 ^
M:9D<91\$D:Q'C*P4O!JA3I#@ZY!0;7FOUVJ.;MW0VK:&?%?1Z,Y$R4F]R9$K
MV4HWY <:OF3/95PAV.K,;7TU_+2-R)&VAL1MV3NQ'JP0;BY>*]A< OP>34>M
MPEDR2(T(Q=;'%N'1@05M#]V#KBSEQIBHVT79*IYZLQ;0?HWIVO'?TS.)H'ZA
M-V?@>%U2$.'B2+-&8PMA?<G/8$K4^">)];>&^2:9Q,450><WDG^C/GRA9U[*
M.KK=^AD75Y-:T.<'3%HH\>9;0 6ZV;Z)]@/,HL3(-<+0;"OFKJ#)C4Z/FHQI
MH>A'KVU>:ZB=4.8L]Q"HGS9P+*@.JW#ZO2AJ*8$L-YR,0T87#F$]+(E-4?8A
M]QV*KAEOV974*U4A)-EL_6G H)-B]_T+8K"<1>66X_C8!["NK T_AEGX=W@5
MYG"Z4;K0$+:A49F2QK%:#DTO")3RU,P_T;SB:MNZF8J-=W*!J6-'<D5,&"A(
MM/@!;@NW"%*%X%9'CD"]1T1"NEX<HX_Z)-SV7)P54ZYDZGSXT!$'7XTI29T-
MLV.ASN?>7F)FH,-Z6XCE^HW#X*9-%&;K[DY4,*H_@;KI'(,5J*6JT<U!CGBP
M7^X;LJQ)TEAQZ('U>F_IRC,Z!A-"L<G_I'4$U52KR^B-X\ Y.-9\:ZHTJV"\
M&M>[7%ET=G.:BEW \2UVAI>PA_>Z^#@ _,&S,RP6]SX,NZB!JI'V!%0 LG\8
M6K6&(?**>[P.6O.R4P",G(^UL@-#"]/<7-RTLNWV[M],U$RPKEUW2N"!QH*.
M1X<A1GJ\%[^:J9H1_"!P(/'QC5Z60N5W79/-K^][;9 ZYVIUZ/!#04D;HU$T
M8P;3IP!=.@L;"ZG8Z\#(.BY 1_;)T$,*7[*/@BC;5&B5?P=D9MCE>8YQ8[#A
MC*!T,%AV9TK:_;4?6@<9L"1B;H40[/TV%5-UCG#<H5^ 1DB9VAG-:&<Y@2&T
MH=.OGC_IB= 7"&1E135E9%P*MQ2O]E6Z1KV4I)%G],WPE]$O4_^WK*XF_=96
M!E1N_:45^KT6+-VJS>9>0'VQZ.8!D_H\H"+S:E]P^ ",X/'U/TWP5A'H:$YJ
M E3KNJ0\MSR/^*E43(P\19S*3]EPX8_(V/AS.7 .*B^ X\2]%ZIU@J-/EO_3
MPAGM_'+#7WJS,W"NW8&&HG@ PP'3CVH<5BT T72*[(3++=5[RYJ4Y)WZX0\]
M!KTLCILU'II  *CC92LEI8]N%XV;#9X-8D/B+6P+?!N:L=_>O<4.S&,[85M8
MB>!B\3@CP&L+>(Y!.$CNB AQ.B3YN*=6=25@Y5PE0Z[8/+WE=;%N6.F^WNF6
M2YPU-,*%'$1W+1(<WIO@U!$YM"46Y=H5FA7A&E5NU=$JDS;Q^MV],S)H:?Q[
M"F,7I7^&:M*"%L1Y,I%3)LPBNO%%1B%M#+1D?*<C+PM!R32Q?9.7I_)FK]^L
MO^VRIFU6</^T]CT MY41SNIY#EN+@;I1H@OZR009 @9YX;,,<X@[G<PTK:,@
MS5<'FW1.A'.3W&@?(_;F"$56V]*%[;"I68DWKY[70U=!(DS?HG2<7 'XM6'?
MQY/'>BI>G 5/DE,5R"^J; O<!,/KJ89;'AQ3-E9R$52UQ'VGM8/KR2_'.+*J
M8Y X'[.%E<[$I),,#:M3:5KGR'O35B)?90P-/C;!8%;CVL/4DQVVLS)6)]KX
M//@^OP#\/(' V?W6+Y<6_U9CW/4N_1PS_+]'5JW?;U!SCZ7\B56MG9_[Y.?,
M)_X*)2\%?@Z]9Y,6G^ @\_DS?GX)+SGWWW &J#+S2M%^W/8?3:@1%_&_TZIN
MW.](:OGTYL__>_EM&N#ZKONW&<VUG :/G%Y+V</R/^]C.+QC<-T[BER8I;SN
M)?;FXGZ9%[BNN7 6+LS[=_]19'\9"!0[WT5">WHH"[/$9<E<^;'B#DNY[-S_
MZ#]$_QPP\:^QSO],\O_?.M/__\Q/_Y0PHE*M,-9B)"?;]QY(.=Q3<OSIW<+$
M"D]W.RL_G8JD#8M)ILJ3X[D(&/>2SW)DX.M5M1! MZ,\X#*2,4.()\P;@S,\
M0$*'R"1%Y,?MU(?6S# <H*3A-3R YAL.&1(:7D)BL,\'1R@<W5)"\\O.%(!!
M :,I=:AE%5PT#TB\W@[""J]:!+5X@ 4F#2ZF97"I45[<IRT !P/M,P\0Y 'C
M(<QA2-X5-6+-,1VF$KDK:TUY0/W;,4[PD/:_M/N7=O^0=G,S":AR=%RM<%!T
M==5Y(Z+DD"V!OVG+=_<O54&/5-0>A,_>690;-_PK:?*'G$)64*8<V&90"UI\
M&F\$=:'D*BBB6+\>NFGX@XG0QC;3L1.23<H553+&BH\==;:+-VX 1BBDM=P\
MBH]#/+J"!S2CS_, E5K=ID=#02CA&LOP4JSU@210[WS6W)ZGNHN;KZG[I09@
M;\H9U-KLO+++@'"" FXHFK1EG\(6'V&(3(XR'T:BI /DBR.+L6BW#_KS(8<D
M_-0DTLN"-N_>6F^G-N<LSC\A)A3W>&;@!23^G"V$;_)")="LI_B8[_K!0D]3
MMA5Z58"JRD?RB^]V^DO+SY(/5-V=RFM9.RHNNMJO%BM1"/43&:>0B9 !OIUQ
M?QBN+'Z4I('>Y%HM++UI=P6EUTBC$HG0;;@X2G8)SI:ST]W$5@F^(D&@#I.T
MZ"=Y #EYRI'^/>(9LRB5!P3-R 2>*;R_Y2LV8LA(+_])UZ(J[H%&1KW^L7D^
MUF(=>D"?BIY28(0?X.9"HKC#'3A;:HE+V_3C&MLBKPV5!GGJ>R;#1LOD?"-/
M/4X\LEE0RHN/.@-N\N=(5[4090UGSG]6XI88?L-$WCWV;<?ZIV$T[H'AO1])
M5;)LL]H2O;*^]Z-)PF]>^^PZU)*R1(+$N&P4%DE/GX)Y@) &3&9#AAT>!J(D
MC)"JWTQLO6G%[4_)M\$$VQOV!TS]Q%TDFV4/Y47%A5U:[=+.D6^@H>M;]4$M
MK7@>0$WA >4FYZ<6T$C.WATB29 <Z&+HIM5I.&4\W>-Q^?27_'3USY\E_.<V
M;7Z1<TCX-!7 9[G>Y""XY2A?&/ =Z)AT:!5'#'QS'R0V$B0BM0UY #)PP.?U
M<+^"DU+/MIP]\28A/5T/I<I# K(]!'UJ5& &S+;E."2[,4@<&1V6-9A425'$
MJXW'HR6Q7Z-AYB&JD#C2:'*&\RE]_N$J[XI+&;6T16EY#2*<7_$Z. E0D[V>
M4 >7TE!,?RLULD;>7)'Q-9N1V6Z9."-O&WH;DFJMNA6-+[?7;5]71G')M#[^
M)A?Q<>/?(B\>(!O>0ICXQ = [X9EC3 )1 5"(#9D86;5ZPPP7T^E0;FP!)-;
MSNVF/']*OB5A_)[/[:Y;>"8@F!Y#'*FJ"\8D:+%2B?2JY-Y7%GN4.Y@7N_.A
M-NB]P5+\]RF5&HIV41ME6Q.N?03!CV]",BS;^^SH!XJ,R*RB FR15S<YF*O3
MJ"!PL'MG"%W/8V/U:>#<]-=GL4\>A?A(2K<$E2/BH6UP6Z5 \26"ZJZ3L*L%
MOW#S]W>8-*(&CM>KK@:+[K<;C]J;.':3R%:=A6I7</D]S"=OC@Y<V6*P"YD_
M7$[AR&,@,3+;"7>D"R^&6\TMR!QI/#-YR)9VVPP#VY:A6G-A2YNW$;?"P(O*
M'R:Q74T>2 O^@ K&#'YGV7"3*J:4YUAWP(80&ILH]6FGZNJ.D(C!$FNG[A.[
M)%*#5;3O/[NY:?13J]+A3R\NO"9=0U''$(@ 2!+>3^OOPZHX_<"0(FP!=>P2
M3H?ND'SK>LW&S$!7YG<7ET<?Y.KV6X:IU5./(7:G/[S-,@/EPMC'/ AU-AQW
M(UEF6W*#/*/D>;>1YHZHC$(8;()OV- CN>\&4XOW*_HJ?;RD#'1Q,RFAB'XT
M:XP!QR(,R;[$5);7AK)._;8T<FAEE7QTM>_K-[.A)9L*TNC][U<)9I1.%2G5
MD52961P%5TC,D^JP>L)<N!?.;:P'&^D,O>O!619AG5QJ/E2PVV@K9()Z6.F^
M*L)JTEU"3HL72#\>Z G%;K7GDE 8./8'61PP.C#:FX&AX^\6@,CZ'=,Y,T$X
M[TVW@S7)4'EH:[R/K6*=T-NQ=WS]-ALM'>&SXP*\-L-O$3R@;OM".ZB5/&D/
M.W22B;QLKFC/(#IWE7).+]=L_0:II"V5=DZ<'3QAJT_*D<LHO6DA49XDH/8E
M#M&Y4LNED\S=V.OY@6QZ=E!E,"+G_6RG;^8&>N2*3(V':Z]?BU>4%E5+>>H%
MJROXGK'8@!:%;V=F+@[:41>;;M9$TRYKT7+2??/!>L4!P^Z\E,YMC723I3S!
MA]PN7,?(\=.%+YO_+M__4Y80D'@'(PL2O\T<>75&H9X :J$O<X1H=Y%.F1CP
MR'+5!9QU[/V)KH$$U593B=L>;FUE;PN]UTW(^ZKL+-QCY]I[#6;7R">N]21P
M8];D<!AU.*YZ<?(E6Q>K0OU\R6N-51>-DK+0OZ""33&-R=#L?G1O;N>@N^WZ
MT^W/A[)O?IFKQDQ>A'-7"=Y1'-0YK("+_<MC:N@&APN4E>;&8#5:,<A+C-F;
M$AIAURX!WJ#)Z8?FWM*)*7A.OI-OTW&E](6S I\=:GPEW)U93U+8*Z%^PM.9
MR6)F*AT1O].?P6XBDDV:T;)'01*Z9P'N[1E-M44;;/+*4GV,ZLHJJE:H?WHQ
M5/XBX*1^(O0656;-43C+.MH;R0-2KG*TN3=PX4S3YOTE(^@4_!8PD:ZT$.M\
M>%3O2DO1O:BH,(9&194-;5?!J-X-U,.(@R+O_O(8'O4Z^LGBU+E'WXC*E)#A
M/O8K\PW@]4C:=Q6,=)"WUBW-G&V[L-Y1)_P25S_;\U:Q5 SH38":T(S=^OVM
M+ ]X&Z[@3G"+T2P<2 BALE^TBPU![:P=^ZM6QM!LIPS[O;M/&%0_VN-7?2(C
MJN9%W)L^O#M7\F_X=E58$TS<1UTRV$@X>G!&F(%"S*#$"+&!U(^F(U/FW]QS
M2#;V6LL<OJ!@Q] KCE.*&+299Z2>IN)G6>@MM#CQ-9(G27F$0+A52&:5P:JE
MX5\A&8\(06T>K] (O&& N0&9Z1"W<S=C8GK.L;,BQ,,AZ]V39^NGMXV&O.UL
M4AN<?7ROE Z@ AQW(>\2Y2@P==B8Q9$M10CAVPF,@V@AG!I#I#Y])5A\H!>O
M@6J M^_S1&^.V8WZW8;&IRS,*NR\?=>])6G=G-$6/><@L@/)<*;T.T'B[6PT
MSKT+K\I!($5(/,"?;6I3V,N1H).4@I;M>U-G=E0HWZDT+ITZEJQ8F7+8+68N
MM502?ZYC%U(+>I?SXT'+V^!MBUZ\$-1+6847X6P'SZ+B-D405G[F\#,//+Y5
M>/5TZVI)B<B< <6IXRG"V1DC:PLRMT5=.I$NS["N)X+ZF#I*?SRFS\/A0^T*
MG 76,/BEA 4W%^?,E'%*F>Q[O4:]FM*E_#[0O\:&>+>\;*M:JXDFQ2H@%_$#
M>_#0ZVJ3226V(L>4FV&H+]-:8DG%(#0O+3=^6/)CT>Y^S3F6;>Y>T6GS-MOT
M<.*;9H>G/XT\_BN$P.O_-U!+ P04    " #M@$U:"KIB&=T=  "2*@  %
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MT;2!%N9B8WW*1L:9YY\TP4ZR$OBQ K[!:?\.?K9M./ZE90<7>(FE:['CY[G
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M\=#@D%%,\K_VIWDH[OB_ 5!+ P04    " #M@$U:.U8EH,X=  !7*@  %
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M[HV4#7Z_W3S<3=O"J>*JAX*]>_SV)PU2-H//&G@ZR)1G$V7#B:3-.!S[/@?
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M9&)(6%E1AZ[[%GE[_C#5K(['<8#-&-3:2A('."1+4_LIE,=C8SQ_SI3/^TK
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MWMK@E$&N A!U,K/9^  HE_\>^VC(,L2]CFC7/_2)X;#+V&O7NPY+I4,\6?R
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M67)EM*5DI;BI)%FPW;ZF=!#?*.,MO^!17?G<WK_X;,^;DZ=UY=Y+B)IL#5A
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MZI*N9XXPCW8]"$M\AHG 5GBZLC^WZ3Q)]?=PYUV/R\,MNL!?0,+,Q4F_F %
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M=O0,4Y^Y.OS:Z+SEB![K(-V.ZV'KRU*?+NE;E90^4=/]$.UG0J=K,H.O(%5
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M(!.>DNV391!<?-M,JL-<A)N3*JX'N3B,U@$IR[[N;]]SSDAT2ATZT;.XT^@
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MT= 21CY#U+.3\M<V6_QR]/;@/<$'$U>^O3:/69;>%KI]^ZE,"5.2D]X,E(-
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MQKY"15(&PJUGCT?;B^T9)YM;RXFCR=:Z!!$$*1DIC4:"0/9^>!<2N&[8ZZ:
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M!9$F)4%]Z0(JTDM05$!$1.0E0D@0I L1"RA($4%42NA(#1T4$:7W%!0% B2
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MPLZ.2!<Y&D-6-M>QS#Q7*GZU"O:N(!H&&N<H"PAP+&%EF-9/0B3N@HA%K<;
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M6.S++CKPW <4V@+SX1L_R S\\?=3N]3+ >-Y+/ 'RDH3^GK:%_5'Z#>:+$:
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M9?K'-')G0+Q']EZ(TP9-/P@9:O8@JU+ND>$IF'J'3@26K3NRB6R%H&2I QL
MN&/,VR\/F@1],M4?=2N.UUJH-OE9V:BM/J/A&64B.QH6_?\:GHC+82L!=P#?
M'I?&RY9U2M#LX%X%C]N@'3](7)2(=PCC-. SN^@\IU:'A?K/.;7SL-TJMZUW
M#"!4(]"ZVE^0M$I5<^-P^7QK94Y!EA18+O'6Q;3XEG%29E<)7)ZC0/T:U"5?
M<>^""D\;&;)W&!%IO53<GK>;LS:[(,M6[(5AK5QI4M#7O@1>R,94-"RGX#TA
M'B]90SC8D77MW6+0VWNQTH9NK&$"*Z_?M$GM/^>'1&"<EFT-.+Q$Q6GI!1;"
M?:I5J1N0KWQ+2/F^,EKQ_,(]:M77FO[#F8TC28QL;8+&23F3PCOR';]@G5G;
M?EW>2F/-;J6#')UV+C*[*6%6N0K2Q_6%\VD3YY*L+KV.5ASU&_N5W?N^L>')
M!Y,A!3?L^LZ?$NY_%0D:2T+$$GKS#NCB!6\<.;9ZJD&I1GT#/OR=-\JJ'-VR
M"Z+K4H\E3Y\#$B+!.GF5$X_@]P\,:>_DO()3:D&1!>\*[IMSF;6!;NW1_"?D
ME3K5YJB->PR5ZZ:,?G+1K@E>XI*W?+\,.&4=Y5D("K5L^J(7F2.Y':)94R1+
MD-]'5^*CO?N=Y"<56Z_AK5N5LDJ6_<(73,2P,MG;.(V_C)/88XF<L99]>O6D
M,Q\OQ'TS#X1"-E2)+'KKSNJ>V9_9I[,$GX9TF?;"W3?<C_(LSAHX#M>FZ.*'
MUBZ_C^OM5[8_"&'C:QT0>D!XM[<BM8@PK2MO;W60]8OOZ"YH[1AQO CI0H^O
MR'&>[IX*-6/!AJ\+'-I2'T%+YX-M"M[ZMRI]09GS3>G:N0L\[;%*-K-A69X'
M1J?^[:IY-_6ZNO!GQL*:R\C+N@<8N:$]@\.F@4]&8=#)ZT86E;N@?;S<C//#
MI3(+^\J5KJ;=*E[8S_>I2WA"6EEP*U^XZ?Q(#>OP1SM;I];XJ3F568V-/I$#
M$8^0$B2$%#[0;!&:P);\YJ=^I%+-=_G[L5W0EVRJO-!=@S3V422!;#K10'.N
M5^XK>U;FNWTHA34BYS?SC3$.-Q/U\O*<F_EP-_+6AIUZ1H:;9[6Q0N'C#WKR
M?SV?>\K$+/$TX<K EP&WMC,-'I=J%Y<<;V.:+J\$[P'<>]N])2JHY3F?G)V7
M%2B^D6%^L.])\%1D."6*.C&W% X1K;7%S+HO$.QF8)OW4:NPY#]W06W8HBB!
M__$DTG]I!ZYG!>56%@\4$3H4I.>/'<XECG_.U:2._KA?RT@5WA2]C)G]D*9\
M9LLURG(Y'6'M(D7+;K/LCH#07^<(+R]+:$0+7\66J#:LPD7FHDU@_Y=P';Y.
M$_I0TLH"<M;>Z6NB$DWBZR)$BJWHOZ2$];[[!;-GBO_$+H@;;K#L.2#.M2@)
MJ4'7'N!QI,[6S+WFSS)A1Y8X$^C8+Q/@6N3M%5-4@Q,^5[WO33[XRBXH/H6:
MP.+Z!65L03CD<MZ!88F\BYF?[MS"[8*\Y*6VQ;Q/F8,BKNZ"5@Z]:;5X3D+Z
M;IZ8D6*!$#\\Z1Q (@N_VZ]57O<&$S.DB =H_>C:C^?-1&?GYA"?;P:O?L^U
M8 S9';H&3RJ9 ]/$YR1H*J^;A*WBSR^\82N;:#.32C\>Y<D!9HG/3(1HW$N#
M=D[LP1:GYF%IOH\^CY6Y*,6WL5?Y6F[K45I/#F&[P+&(P"3;)6^Q)_72&O0+
M46N,;]%13\%ER-&_#N4L)J[MOYYK0-/+BZOQWS#]ULXCT@%U#J6 E%GJ.JW/
M6$];1?/X 22P[%D[_>9Z.KA:*<VGW@3[$LU/%U@S4\@DP047<X6HLWEQFTCZ
M]*29TMDTURW?57OKK2,U_O^;0)A9'+&SPM$Y?7F\<%_H'N 'W9[U$*:Z5(^H
M$<X:J^@L]9]3J,4/->O=RKQE^LD ^^?9X&-U8I95A@N32M%LCV/3._V(#X-,
M\0UZ .L]Q[5[AA#'!^;Q,FU9SX*;S:D<G(T=B5TD'+3(T:T;J\-3TT^5M)%I
M(H^.7;GBZE?WY)6TOK;R82D0JYECQPE,.P9_)0\XYI> .D[EWNJ5:<VF-?9W
MZ)>132'=1G](PJ>WOK@73Z^6"C75Z*@^J[+]#M8ZI>#ZAX1L<#.:0* ZK4T,
ML_D[J9?7YBU[$8G'WEH&EIJ_YGC1JG?]PDL&;Z\Z/3(.T#H\F,%SXGO\J",A
M=IO#D+PN (<.>/59>,QU3,R<(480Z.V U_)U8N,;A5->NU^OQTSNA"="=:-T
M/3Z$WPQ25@\_%G=0QU,B/%[1I&Y?3S.#+<SQ#6-,T=V[H,HURB)T99**.$,3
M5( #6!H1FE2N)Q2UJNEY77*JC#68R0^R?$XZ_1ZN]BT\'SR)PR*H%\&3/'0?
M5HJ)Z>^;#]IL;SQ3C%P&MA_A:*IPOX7K+FM1-^KUZ2$>70,+G@<_:+SK/J=4
M;6BN!5.D8I@*$AS;OX\R75Z[ YSAM^P9W MXN#>LUPS*+L^)U@:*YI.*PNJ;
M'IU.(7QP\V!ET3EN38P#NP]#=0(#1W"4=A)^JM.*)C0" P/6^3/^#OE O(>2
M>*:,>?23QO(+GHGGN)=L8J:M9B:9T[N@V/MP(@XN# _(BXL89(H:M^V"JH1V
M0=&OOL#4BA,H;$5@D31<HPDS/;QJ&V*:?O'0Y2L/WERJOR'<IGZ3.QJ>3^ #
MFCIV00=,5(J C789UNN2@N6(.P8[%F\O:3\2Z'=[)6JN>[-9QTBGXE([K\P&
M;AI.'V=QA"0Q;Q?$]0LR94 O!&*E$IAZQ1\S:-I)K]_C&V_U&'OX.VKJ#M8F
MGO_JE)-<4"U( %2A[5&J]#!63"L8!?[2JA3 AM90!SM;U#Y"Q!>E#@>:7M2L
M@M1,&RKK"EO[?W98_3@^CV#*+]+R.JK1<_BJWK;@M(BGGQ "=UX[B" _S\T9
MA&@6];R5:!F)UUVPM/6P/GVO;\,3W.S/LP1)@%/#=T%,L>!N;]@0TY@F10+W
M0$! I'?>->Q\L#C@/K&XFAWSO%!R_,)')=X'SX8\_5ZX+*4EE/O/'?EZ@VE-
M&G"?V@4YC&CZ-E2T5N=<C5^0%M>Q2BM,L+BPS^?6*5X78C%3/)LM($ ]0\\"
MU$F0^#SJN5T0< C>,\B/'MA )G]<:\\U"3*OR7Z389BC.=""GW@5;SKV";@'
M!?EOU"9*0VH0E7NPE%W0:W1OGF#-VJ2#5_8%(( O1O<;566EFU(O"GNB.4QI
MST7,W72EOW7I/.95R/T>I%#\C\J<4](<DJ=A4S%@X7MO\L06.6:_G+5F;)[O
MTLG[5C82(8>U(98LSCJ<K1K34!G6DPW+X/]2F%Y_&KR^0\>!@%ABX!I/8)"O
MUJ)FH4J9UC[&\D_,E/P^9N27O4+_3<*3S0/K,8+XNBKK"I/I!OYCC??M=7 "
MU%"*(3SN;D(7;J\G"DYK?4FR[M?QL$</*F'ZK3P6+':>*AFNI4\U&371LFUW
M0??'2:^?T_;OF8TLJ!BN]9U]J;JE _&Q)]QFCW!]N_AW4=P+W E-,!KOXKAR
MG:2!0S8OMU=7D[_[)"JX,N@\#4K+9O(NE%EJ2.MAX#$#XU&G:C%\9>^YSI3G
M$8DMO:?G)B#=B(O1H+:#//D2.22X@/^< )6%B[\C>TFBMC3R7+CO[+.MR[>M
M?^F]^M>.<O'&<"FEO:K%Z'!P!0\<PS(E("2I=H<I7S;_[TO-8.I"+<X36*E!
MMAX !L]2RS+R"M5< [5G/V@X\)X7R([,1G;>G%6NZ!?M66K 0'>"<! 6!QTO
M$^()U'.#DR>Z\95;W8,'EMT=$I@^&8&8-\"?KA?HX&KO]C_CCV2=/"!*7RH^
MBG:^X4.,!O_88/.W$%E^[/W/?Y^!L#+0QNP^>+5"-0G,R^0&0DEVQN3Z+H$<
M%<V@VB 'J[K@FK/K9YX\<IONKTVUU1T4Y;OUKLB7,<X&ZU+I>#("4,''E)J<
M?#EW70S7&Z5F$?]Q\ONM6,NQ>Y?%Q1X\/+&J_DN :-#^N^#W((:G698JUKY5
M[V+D$(-2+_YI%#2P?<;DB[N'9;#<HR=.CDH:/I5.YUQ?< TU?@0Q'[):\==Q
M@-HX18\#I@4<0PTYC A'\024(2-M *]\<YKW!Z9&F/SI#I6A4AG^T[=]H^,:
MTMQ,JGR/Z%A]4%H@ &IK3#D$@R-#VAWQQ%QW/,6< 64/P$69UC0'\A]95R05
MY%NHS8Z8*YZ==_=T-@?Q5EF''%W/,F06?MC0F=[+V1EF>A<&3WW97%[\90>W
MJ(E9^+FP0):]ZJ8"7]&6#NZ)AA\.PT\/SA<S9>]R;'1D/4>)T5[1;[30=D$/
M:O?FV8UKJ(P/Y+3&+=B: C49I$,OI(>.#<TJ\02LJQQ*?+!W@X,81F"Z!C#/
M0# E@=^9.S; 'JJZV]AK*CIVSV":B0 L=_BZ?L35P70,?]8LUS57Y1/=M\2/
MG]>^S*U4P6IJ&:;H&9JWOO(5ZKIL'B)'XSOW\8RZSQ8O-_CR"<=S?!O+G"=>
MXA!$3"L(TX[8!?DT80'5<8H'0Y-YGL;7#4]R3WM8]3,<)I?L^$JO[%?+3*[C
M*0VL<6;T']+G7?K3)S_Z7F+]K@QHR^[W-F8EXXDO(/LPUZ#)!L<_D!WV S:&
MO[[%7U+SF!U0SM1I*S<,2UKPCQ7>AU6*42=0-DVE[%OR+@QOIKAJ:24:.';>
M?+<!<?;1(:2Z_\^4?ZQB(DBFT!XCC2Q8,41HPUP-FZ5*Z62N&Y;9<#RV07$
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M]QM>+;9:51*4)CX.5'OQ;3,?_/8-+H%]#-,>S.0GX20!-OQ>7F5"3W!*ZW[
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M^P7*55L-?20;/KUXHN\3)>31)^MOX];FH-L1F#9,3)9E6O-Y&MP&L"--!XL
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MR5JHV%N6V<*($S7#FU7>)8?4IU1UO(OG1S(',UT$N:X=N-!U$/(2,@4C7H>
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M@J>X$P>^G;]RG_OV.?9BA6@F*G(Q@-D"*-$.+LX,Z)-I="YO"%4@CF"*GLN
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M[T^7'C1N@DD8Y3:R5-;U;XGL_OQ3#)<IH_#!JS,HUP*/XOEYO*S$\/*"AQC
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M2[9S#TJ+RCC8KZ@4@^VYJ)N!9.+A6WKE:JX[N!TL:7;T3PYB,84M-]TQ*)G
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MUAPX,2C1KO\ICX .EA=AOCEYV]L?^NHA]7WV.&H6H_/FB!4OE2_I#]JD7]4
ML/?NS$,&$,(-9L4">U<ZH,2K_5-Z\)CU!MV;.1[GD?-CJ7Q:/>#7M6@ZB)$
MPTB;<[#VXX-4(S#CP\J]VN[*K%]/)7X)J!U \C@E_'<MOS!@/X4B6OI-]K9^
MHP]F*9>U$"QAO/EQX^]Z[\&NO6  XU9>NWE,UB"$00XP )$/AC++4H1JUQ\K
MXU]J15/?F>[L;8F8/7:3UO#^%= R(S% %</70[D"O9I5']%T1E77UN<.RGOD
ML&S<.V5@L1BJ/F@BS$)@ #5I:Q;$ #*)EH%P).H1_$+U58I73F,CJPQ@+5,,
M($9?>_\;NC2VMBI9'+/>%O'H@8F<?&A'UZ1QE+1W/VPV&4>TA#Z%$2TW)P-:
MLSDK<?R!9^U)"Y$%(S)*8%I^H*D4#RW0(DB+%)._N^B?J)MX'",''!;O!$+L
M38 '#$",SD$5I^50)=1;L]$P+H3VG!6D7S;96:C]R4')R/<G^\:WBDR=6Q7Y
MXN.)WK$T9K+?@$V@R%?&CY"LUB8I\@@]HF')?8%8'WBKH4!E97U@_[6OR^(I
M-^D;:\'VI8-&$DAM)H#2Y<'+#. S2@!QJ&!U3^:M[XV1;1]OJ\25H2VYL5,W
M7UZ7OT(;8[>%14&YD"((0>)3&*2)%Z'Y&V ?27G>3L:=(W8D[(O\X]+:]<F;
M82+"%8(6;,D/O'/>A)Z4=B?;TEY334C3EVC%S"(::@AI!-'YUZ4NJG?:NTC7
MA-@-\7VHEZM37E3BWLCC^QS QO),EZY-[\>Q8CV974\K9DIL%A=)O9_3\.9*
M'EAQ)L*Z1A P2KK\Z$:IQKU67LWFTJ98X"=Z<I-L0'N!O=UK^/,"[176'<(.
M[E<]%U', %H4\.^]Q>KE]!#C,2(%'8'?+NG=:I3Y!]:52\T(/UKQ<P9"ZX\%
M(.L\VJK[3W]IG(-]#:9=]&<F3D_\AWB;D7!^3KGGWO 60^[1!O@#PO!MT8]\
MXP'#?YBPAB5;_.KTFS^%L02CB2E&#:,+I)+1GU/73-C3)"OMB%K)ALV?RH^&
M6Q[@-V)//LF>#MJ3BVG55>BX,0RQ!^^37\<1GNN#O7.V.L228[//&&\%5U=4
M3#UVOY*M@9;/ 'POBC4_"1EOL9I$4A9OW!K3]XC>29&)K^[\N*+?O'&E(CM9
M(=5BWK,P*?-[G%Y9]ZTGR<'#'O]W?HQ:.+Q-67>@\ZE85B03%A?=8F=FA(]M
M=;7MLV5+MI!EV;0>_X8B7H), DO58PR@$M96HB(6(+!!;(QL><A[&]4YS4:]
MP"\T>&F3<!DP0)/5::\^8.]L1G%YOSM[,$M^C-4*X_26PY5ER_$M?>U&4M;:
MM6U9R*W_O>GS@UQ&>X<T0&@R0;&9WHTJ'P_7#R"KLU O#E#][\^%\%#4QJS6
ME;5HJHH5?J?-TST0M5QWSRU)Y?D>M/N!1LW6,)/3+\I>L@03SP"\G36^;T.$
MG -1;:PXHY$-5+G?^N*!\VEWI.Q%!V,>A <];ELK%9AV=>U"^?;O7A,B0QA
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MB93(:)OV*[30/U%6*ZCU$?,'TKCL^C-/R88:,@RL(6+P4*H8CKP\T'24>GY
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M_4F%SU]%/PC2J(.UK$ B88!9V>PKB0<IYH:X,*N+H$,S!'?3^TKZY&0-!Q%
M6C)OYLV9=@=500VN:?340\B!SJ1T=;OCVNAIRG@!_<E>0FT88YYCOPM(2GY
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MRU,!7-IV$OM:UO&B[;'U!IVTHN K2.G".?6^_R$=_1__&BN<OP-02P,$%
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MCJ>L0Q>TM?K-B7I2 '&K]?8"^[")TLG=>L"?)URS!$#[&(6>@?V:2AT7  )
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MB.)&7W^NAKXZ8(=$0#WPC"0 EFYR]7G2((T]0NLDRC6Y<(_P@D>1'3L[EP3
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MO?-]M[QW[[OWOG_.)BMA,K/W_-;:>Z_U6WMV^&/\:4#ZF+6=-2 @* !<A/\
M_E=@TV%OK*</X / 18 _ 5@"@@(_R\]WP9]%6.CG^P9A82%AD0TB(G\147$Q
M6$1%1,0DQ<0E?A;XOXV2$AM_'OQLY']5%=P@)+1!0E1$5.(_7/@M@(R8P!6!
M*T("&H"@C("0C "_'4#"&#?\!9X \,]%0%!(>(.(* Q#$KZ@1AJ&+R0$@]X
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MR]1>PCS!QT Q%5],]Q2&/,0-X0]71B&E TQD;;/]<R<3(NEC]9*:B@: DJ$
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M3H2G7ZX-/VVOM>- FXC+#N=)^ZQ?#FPN0T !!'CV?;/@ [-[%OE ^BD^(.4
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M*(T90>]JHZ:B-\$)FA@'E7DR=916EU&]S0]5A!L\U&O8(7S+"S>6=/JTW@M
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M<5X51!0<;J,X,&=X6-=%@%S/\X'TJ")Y 1H!9!#B"-^,(08?D-0I9#[F;6.
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MG)Z1^>1I5GY!8=&+XI+2E]4UM77U#6\:FSHZN[I[>M_U]0^/?/XR.C8^,;E
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MUON@G_@E.UZ><;-L-,&08V/C7X/[5_B%Y Y+4=K5+TGXA8&CKXU-)BN7V(R
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M5LO*$K1Z,#UO(5N7>FJ[W!5-ORSQ5,):8\A(6#'B'\KX_X &8J:0<J&R\"(
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M?@I=:&RX3E/K!92E2K7^'P<(1 96?S:G@?P[B!C,03 6*:Y>X#/L:%E[#[?
M,AT>U5&PLD-*Q+QFC,!Y\<2Y-J0@N']6ZI=.J)O9C?MWQ_CY#QN2[UG]5"0H
MQ<G,XT;Y#'->UKZ"K.CPY"^NS;),J";T\N#OP\1_$J2.-XYDM_95G(LR\"A\
M@%QLO"+<MG%Y_\YN0?&*B&[= XD73X,/4L:.EM=O=[5GG+_._5JN1":2%Z,U
M-H4G66 G,]0M+2PGYGIU,XY4V#[K%!74V5V.<:BHQL:'N.]<2SIQ_X9O:<4I
MAW$JI.#RQ'_?KFK=6'^^J; %PMIITO!4K_3QJC2;SX%JW^J'6N"^=ZL^A)[E
M\&2+JI,S?%,E-FV%.J+,L69)/0].(.OVMHB[GG"K.^3445S^ %T&LN++PNR>
M6AN(TLQ ,^I5\ H2AZW!)SHY)1O<K,F===6VT#3N.^15;;[O^_[&J[W]3FPC
M[V3F'_)_MBW@<G[]C_CCI\9$KXE.J^:;+]F:&5<]>9<W;L/)GW;6O[0S!G7Y
M*(A(2=N48XIYMS]RP=H(JLGOC]%\6R 08N0H^[\%0M2V1BC]X"4FP$GP\L-V
MOG;Z':33P&DU_/H-HN:C>33"/9P,!;TNW;PR SM?0N" =2-X:YG 0XG3KU8)
MO -?5_3L,FK2[^\+#S)K2.HP.?TR=^W]BEH7J(A3KDBZ_=?>L?3G!TNKH4"U
M<#?3UHS)C5&/C,DE3E6R:;%JOXE,) M';OY]N!GV!K2:H D]3_]DCC#9^?V)
MUJ,C\S#?*%F[RV?@8UVGL:U1&SDFG,G!E3UT5L0H3:W"$4SN#"VDV%&L#]<W
M! T+HY[?D\%1OU-,(5>/0'D26TZTLH#-@<A"\-F>DQI._),K)KGM/X2*J;'?
MW'Z%KHM?./%%LJ/HI^<P5,#.EOSK7(W*7,^DAJ+WTW$TF4 DS&< 6^E\SLF8
M5/2@'ZGA]$@L"?VD^E1ZS$E9PQ-"$55?&"/8VL&.N0G#!8M?W<FXIK;(X?&0
MH""K _[:/)%<YB@;_-,IF!%0<R WBZ9 KX#[),?#ZCE[S)E  I[?/RBDN&]8
MJZ10??]3+RX5MI#5AZD?[CLD'.NYK4 O)_@2'L+J=;H:,;(TFR],(%!D^:>?
MP)>XVA$9)8-K%RRM(QH'WW_=]QS@S+0M<A._\/TLB4!LZ$)&MFK5@O&DLAZ=
M29&Z&Q,-A-?/?%EFQ.[=.\U]5+4S<F_E,'S"CL&=0@J@9#@A61C#2YUMC)./
M#E]M57D0$GJIG,Z9P\4$C![MIKW."=88D,*X6%TT&Z?W_Y_VWC.LJ2Y<&PPB
MTJ1W$()T143I30(J(@(B\ +2C(K4B*BTH"%!D")50$%0B8J*@/0F-806%33T
M$EH25 2))"AA:W;"A/?,-3/G^\ZY9JYK9OY]/U;R:^W]K/8\][W6>N[-,+V[
M212\D'$L:.SBC4?:)]K,"UGO>U.X_*'DAG?3GRF6/ ;OVJ6+_N09PX7M:,T9
M6+:URI?]PTV"1%+4^$K;YX AY*HZ3/M<NZ >_ 5&!.5-+V.FT\V!4I8),&)U
MXI4JG"9RM-O9_LQ-V 11;$%95'ZOB:#;1U,W8?BED!?IE_]U:W4O5UHL/I=%
MO)RI#FPMNIQYNZ[?J^84^VF'1C1,?)#Z^-$OT9+V2QK7 R_EC'#);KR02M*9
MGX3:[W_]FS->^8;*(M*JGITO_:LS$/9)VC.(\O\>R?U'^0?E0NE4'[!6PM&Q
M:7HGF18/GQ2T7,<N98U7BET3_%;C:@/-Q2JB91%POB[M'U"1Z&$??Y/O;PT?
M=I=(_;+785XY>&,ZS])+#X["X)U@P;$,XAT*,$/)4/N+354]NEJN^+6L]H-E
M5]U1/<Z/5EB45_=FA__(H-E&.Q^7$=S_'Y5^OKO,#'*$Y!CVY#E/CARC#7</
MA(D+[O,RO/QSPN*R^=E8'6CWGWT0H706G#Q%LZ.[+S758WH$E^2=?VFM&-VF
M[F_/&8^[ @(_WWO'_]C(>[IWS/=CB^Q&_>E,!64EOM/?;95%'!.#<LMUL W_
M>'V#]8K-$ID/@8NY,UP6P0K[J+IK!ID":\R\%5<D>6<-JC+Q\X(0=WDVAKJI
MV3+D*#)]3OSKAZ/\;:^(_$X_]VX;TO4IB#SRHEPV/LL.:9^Y<\#?P-\;D;R@
M"'0RU/L47Z>^1%9O?)L]S?+,UQ@S]&V><=3$/3J>=">WY$7K=PRY%D<_&S?^
M@/WB?KC_D :]^FW'[:"Q_+4#WH51\4?M4*]J,/@P#+GDKY7>X:<,+_>)\U'9
MO3U3'PDKR_WR;,3'KOT8/!X'B;J+Y,B#DHP+K0>3FC81&?'66M;]BC&$"5OF
MBR&_$9A-Y2.@DE%*L>]>W^NP!,W BD=AQ4+?BQZ.=NS/&%(-OAJ&#E4:.2=[
M+!EMCPKE-G>9,XV5W/_8"8C;DTQ&F L*'WX8S'S\J:RN>.EF3L6IN[>F/ERP
M!O(9_-2:M%>,B#ZBTFH;I\Q4$OY#;L/OC'W@W)?[_!?-E,LW\KZU05_@FJ&@
M7%;UQ5:ZR]H-RE9:\Q>,(F(R29U=B? DUHD=86ZT3RW+978@J.MI)=H=C+(<
M*\?;;\-(=P=\Y^U=6T.#BH@Q01I8V^\0WCO>#SPT+RM%[+AK\7_1J2O]]I)7
MOW["!?,F((>>--#2)EL7@G:L-#?+-1#,/FGN'6"F8,]WUEQF<,0&6@&OKP&E
M">14FB\S8C=XPT0% B0=5D_Z1Z3!?O+5,8/SVY#2,X2&?9+(( W5K0A))-R/
M7O(L:CX&3\FO./KU"G3!\WOO"CQE<[-L+7 ;PN<%/*0+NS0!K@R<RV,"7&RX
MPBXPVB1:1).?ITHK(*_"XN3R-8C02.;7J\<4_@K:.9#C(R@U!+%=^OV8F:4!
M.H"U48TO5_L3830UX.1UA/Z^.[;[O0+TL#S!R;,64"W^%M7<DE7BL.^@6F:!
M!IF+^5%6]"=H8?K3ZE3\0Z_XL1SJP]:(:@NQB[I#F.!%7I.J*M.,=?(VY%1=
M>/-LJIB)Q3:DVY8XGG.&65QD>/KP<SOI?XK_SXU(]Z!B)>0%*M4CV\CM\\]I
M(7Z-O%M"D&@9A@LH7<,1;F!)[XA'<'AZ&2F]5&@R1SMLJWA<5C$V$51>NJV@
M7\V;$JK=8Y2LEN5UZ&O,U]S( LB?95HY-SQ+H S9F9A+ZPG;D.;)=I;ACS9:
M*L%?!Q[Z5Z0L;7]*N(;2^6J3#^JG/-WO'?]J\R4H 78JI*87"F0+D^78\J:9
M,'ICTS9D2889 4IP#5FA+W.$I1A2 S@QE 3+ H$6*,3?TFLN/?:YLKHWIL71
MZ).XG<1 ^VG=)SL9-"+27E_@M%FN&>$H?G8:#E&CS/DP!:^WOX?RN$'V#V89
MK%^H9=AU=G@9'@H9Y<MZ<;E=N=@P[^:Y$N"9V-097482\_8V).E#%S]Z& JU
M$J-#G=FIH-?K.>1L_]^@.Q%OB%16J.3$^N'2%F_ODZJU[JJ7>7;?26<Y<H0N
M<6?$?3ILC8\!QT/KB;TY,ZQ^F +:&'7R3G7'4?I8C\%;@\?&!OJDX*)<\&7
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MSL QL[TWH3DPQ<.I:6BML+^E<84%09ZA+\9()SYO&ECE0ZDE7KOK"0K09QX
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M:*4E&;>;W#CJ%RSO"J]K KA<</?.YV+\ 5-F+_MIES;H/86["B.I=^?WLVR
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MH$1O6(K)86<Q=/%,4H*=VL+WZL$,U%:V1Z^^%7F?"GGJ/49Q9X,*?72X@Q9
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MHC6T'%YI.7Z_5-N8E8)O-\1(N#\M)YO":I=IRY0E[M@-C%@?17KY,%+3..)
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M$*&R]Q52GZS=D^Q6'XH5A?KDWAACG;J(L9HU1G<!A13M'IS"-6L](/S9*I?
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M=K>-<T-68YU],>V(UUZMY^\FQMM6O-^Y>3Q%^\^1<<4ODOQ5=[C&'"Q?00C
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M,, $C1Y8H2^A29;]_EZQ[\=ZE]ZUXM7CGS[XG1Z(/%#=7?#(X-VE+2]&.H7
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MQQXF\17WP=(],>_6"ZI@=+R$XQVF5!8AS,KS*BQS'F'W0IY5"C8<F]A<T6S
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M)W8K2MURNQ!HRIE!#Y>@H>U?8*D;UJCY50SXHL6^4B&PZ -<)")U)S !_!A
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M]G$9?VT**W_P?%BYZ<MPY?;@52)%O".5-:^41&[]\63O\ON"2-Y:^)40$%T
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MFX"\O6/,&_.N[-KYYOP]5_T3+H__[AP\;#TV:WO3T?\!4$L#!!0    ( .V
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MDU[%^.\$SO[_,7"=VLD#<7Q4[SQPUTUXC6@T7*&52K485.2,(')C0460*NO
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MG9Y 5[AZI644*A<;2NNEWL$US+Z#D,-A'W1QJLA5*L-!+2BTP@ZB<J%(2PT
MZ-C<+O-:OAW4G&R%'%;KL'$$FN"H;VS\EJ45VP[U#ZH=,]W"1[?73<4G7PH
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MJ(&]\GU'CK[QP&T7;WGI_P!02P,$%     @ [8!-6G&5FZ>I(0  ^T(  !0
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M,%6[X,C[0;F6CQ@\?H-%#4;A<L!'J*8F%@E0<IW/N6V!#-[PY;R=G4.@6&Z
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MS3AC3(PU-(I-1\6@HB5C1CN_[M:L5TA#&]#H2"0,L80KH3'YI'##;+!M0W%
MG>9]!^_L;49I^)^"=RS<B_G?!KP-&".K>8,H6=W&DCUN+U>\N;B% ',<:?56
MO1ZBY(TSVLZ\'LN;?-5Z[)L?;<!]X-OG1^>#H.\.S]?9BGQW>)V]S7>(5^\$
MY3MTXO=!^3XHWP?E_V50:@9G?N7.KV4[W[GN\57S?_"]_UZ_RU[1O@DRC$OE
M"BTQ'(Z.: W+!8$=3K-.<R;#FH:LG-DQY#1;TD-TVF89HDU.VFIGS38:9-O
MNXKO 8W*3+5U 68;-*M!@[03M&<RS!#KL!J':-KB&'(P1MM0VIBQILT6QD&;
M;-NA1XGO 1U2!%Z0:'$43[6JX5M1D]'A-%F<9MB%PB#H!"V0P^HTHF;0:G0@
MCNW88\COH8/D)%9H7?]!1+I<'BDJLIQIW179CK%;_Y[#YQ2AQK$N12[LXZ6
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MTDARO@C<) 4&V0[\_Q1P5]HM#WU.CYC*QQJIN"67BL!Q*AXS47&+U,[=?+C
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MR)V761&VZMQ5(8/5[3JW4<B(L$[OULF<,P+#N$OA\@B*X2$HZT:<.)X@LVU
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M/1LR8GHYI^<[&TXD *4P)$\$&=A+.HL$58=M JX0D@>ID#X3T2R@&3($A:$
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MN^IEVEVW9SJ?RRK3?BE8:RL70"%#4NTAZ<J286=8SNQH_P:O70''O/1V]>Q
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MLWX'\$>&(D$4G, FW9G%2%^$A&8Z95WDB)4 UJ_BW'K8S_(*+^6@VGYSOB8
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M)_/5UO:$ K0RW?\%EIW^U1*4V/IZQG-O_8*2N1X,!K/?QN17O["2A=3UZR8
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MVH.A"2F!!')&"C,"C*-D1%,&+N39R"<5];%ERLT]Y4JF5ZO.Q[T2O\6X"UG
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M'4 4!G$+PQ^I7'D":TU1'P1T1T.X/3=NJ['G7W>X,-@.'+,Q51]@J>+'S.1
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M3'64$;Z56*LMBT.;O_%]"JZ/V3"MVP=-0Z-"[B9F.W\0KQ00X4[U<F+F@?3
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M&/_]-)-;?D(/*="-G*EN@L53\H'4$H%X?8%,!Z<7%!B\4W&M-WF7Q78^!N*
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M5H\B0T0P$ L9>DP-BV_0]M)5(PBF0]-&BKOG!F?JS..Q6M^NQ+^5^7[:,Q>
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M&NLF7%:1'"/M#9>_^_GFRH8P9BZNZU77,][<WQ]!$XCL0EHV+HX]1:HKSH(
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MEX2T Q4IP>Z#M^)\3Z_?7=K&6![L=#7HA%W8*5!_HP!\OK#&E#Y*9[.>AQ/
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M&^[0][W&C1-Y+(PHA%DM^B?H[XL_X,*=_&#QZ;K&W,$1IFW#A!%<Q/:F^F!
M>%5 Z%RIY[&575%OAC0.G]7@OR[%CK7==<.FKH]R+V;OF^N"EH*&0,-_8*OT
M?]6D^[$7P<$RYOY1YOV(<X'-@KC7 452^&';06N50GMRI!I1'F&PA!<)&ZZ;
MN]HRL2IIW%1&BV??0ICI/_KNM&";#/)0.$ :^Q"F*=C%Y>7=+E_2T\#KZ516
MPK*7$F#*,_<GH3MQ@Y(#2&4+E'%YY:<W%PV2QAL/V1R!K58NM2OQ*7%]TUE"
M"X.H8[2(%%@2$WGYA=<14Y[G*LN#[2I?\WM]Y$>P:B6]CZ[(./ U""<X3V1%
M:+5:OD,];H]S@X3OG9Y_+E?\V<L6^J.7['!O4"_<Z17=Z)D;#/.%J?Z@:)J3
M]+VO*\)6?UV&-WX<P(_N<ON!YGKO>N]S0J*@P#RIV7UEB(&$W,<"Z2\:2;_/
M*F&Z*R=FE7EE^U;TJ[/JSW:H_G9SJ\VQF"D+ ;Z5WF@]XW:!68KI[4<U)S&5
M("CE0R3.G:PU^(%0N]];'M!C&ZS3K:*2\M-C#JY[0&<ULBO@26Z,C^MQ)SZF
M >02[?CNP>+&$Y]4"];.KK_;[/CDO98<[F^,4Z EU-_!/G+%/CS3]2I1,Z!\
MUNMJ1NOS;5?HG(/X;F4$I.G4.(#_:^P.2AJ(M:>2Q.O.838&G7R_(!ZK+PXU
M)=COUCG;O#/97O?MZL>F"6 3#FK9,B47R29,27.Z]PC2#QY3X+ZME\HJ]9X*
M47=MGPK7<I7T^2@^,5TIU*IN>,;Z]QGWMG^=R=VSL-$L2&%<ALT\\&L&7Z[/
M':TCQBC/&A4.SJXU1[CPFA<:8(825#8A8O:G@%U !>,Y.#R*]RN.EYAO>97F
ML7ZUW1U1,LL_)$9^$+OI21[P:_7S(<X&V:C4V;/FZI<,3HHM=.[*\?#AKP[_
M)/5%F^"A^:8S&%YI1$6J(,F/2+4<8)FZZ(EU .?+:LK%CEXI.)&X_6L_6R95
M=.#@VNZ1-50ROD& *:U%?P6).H:^$A,UH3'F]\K,.-=D^NJ;8O*51W-?L[:_
MG6-,I5QY1R4I?J_]AI :13<*SV2M5C4\-\Z# C?\E PR ?M$OP^AW-OI>=(5
MM75I^PTI87BZ#E6JE=)ZU_*)@=2+._-MC9(!D8T(?-M)1 32M=,2<IJ><IEH
M$SH:U*XEJ.NA!_*1E8VQ+9N\[S8]P7AZ#+1V=W#CJ(8#15,+^8/5;E2GAVH-
MCNI.=1[2[*5$X*FJ"J&%,<J$E'J<W9_'@G!&ANZ>_LLK54MNH^<;U]+\LDX(
MPM;E5CU\+["_2Z*<L!!OB;^*T DL<B4-ZL_J'QG)3<P9ZE6X/+5JNX5]G2Z4
M]%$GB^"YP $\,?4'QO2'_G+?.$,D$=29'FM0AE6G^2<T+OCL=MW5G*ALW<!
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M^"G$ NTM"MJ/1O)602Q%+>%O-[M<]H4$5U67=72TV#U.$1[2K9%V/OSZHA/
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MB)@QA1_>(JU(O!#]^#4@0QDK:-1<%AQ_P-0M?)!F=,M9]: V^8[+ @)T.6M
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M*>G+57+:@8T=AE6E(M?JY4@+O-RG]U#RH(9VI=WT1D7%H[6QLYL9^'%\&$)
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M2,D$Z^!?!C\@->6..4[3F(CSM?YF-A-=>/G7X^4HZX9+5L.&3W7-@MPHR_R
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M&U(^0QKS$%LA4D[\0I;632#D%JW9'HV-3V!\5/ATBR)GX0N1;X2FMPU1VC)
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M9"0/<WQWW$"5O1.'#T;;C[C@UX3EOA3S7=#WS )<1)&5UTFDU&-XMB$?Y5[
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MNVWB\X&.\$L?W/?R KY-]FK;7!S=K>8F\8NL#1>MV]!WGF$LJAO)L^#K" J
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MV0EE,Z\#J=R)/"CAKVYYQO*;SKC</W_OEK\Q;_2]^:O\P(963*9[2C:'U@.
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MAFZ-U<B8,-EO7JUL-[S9>/Q9VN/-::V!@1>V*'.5URCY@E81D&Y.CJ6Y<!H
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M%2[ZSY<SS/)O_234-2E-79W>_5WV9UL""  J@ G@ 40 .0 !Z $6@!W@ 00
M44 *D =4 $U #W@#F )6@"W@!+@!WL![( 3X",0 B4 :D 7D R5 )5 #-  M
M0 ?0"PP!8\ TL "L EO  7 "7 *W(! ("80!P@41@2A -" F$#N(%R0,D@(I
M@M1!>B CD"7(#N0*\@8%@CZ"XD!IH!Q0":@:U 3J  V QD%SH#70'N@4= ,'
MAD.'PX,C@Z.%>P''"R<&IP"G"?<:SA+.$<X3+@@N"BX%+A>N'*X>K@-N"&X:
M;A7N .X"#(#1P 1@*C +F!<L 58!ZX,MP$Y@7W X. F<"ZX$-X/[P)/@5? A
M^!H>$1X7GA*>!5X 7A9>"]X4WA'>%SX"/@V^&+X>OAM^$GX-_@3^ 0$#@12!
M"8$?00Y!%\$2P0TA!"$)H1"A#J$'81IA"^$2$1&1 )$.D0=1%E$/T1K1"S$"
M,0.Q"O$;XCCB!N(%$A(2$1(3DA"2"I(QD@M2"%(J4CE2.]($TA;2;V0T9 ID
M=F1I9'UD.^0 Y"3D4N0VY GD'>1;%"P4&A1^%!44,Q0/E&B4?)1FE%&4+91;
M5&Q4.E0A5$U4:]3WJ"FHE:@]J(NH9VAH:-1H?&AJ:# T?[04M,]H_6AK:-?H
M..B,Z!+HK]!=T:/0B]"_H<^AGV%@8-!BB&+H8[A@1&&48'1A+&/\?H;[C/69
MW#.S9W[/TI_5/YMX=HR)@DF#*8;Y!M,3,PGS"^8HYB$6"A8ME@26,98O5CI6
M$]8LU@4V+C8;M@JV+78$=BGV /8N#A(.+8X4CAE.$$X>3A?.!BX8%X(K@6N*
M&XB;C]N#NX6'B$>')X=GC?<1KP)O!.\$'P>?$U\;WQT_';\5?Y4 3$!+($?P
MEB":H(9@AN#F.=ESL>?FS\.>5SZ?>'Y%2$(H2FA.&$Y813A->$-$221%9$,4
M2]1 M$0,3\Q(K$;L1IQ)W$-\2()'(D!B2A).4D,R3PI'RDBJ3NI%FD<Z3'I!
M1DXF0^9 EDK6179(3D N2FY-GD#>1KY'@4LA3 &C2*!HI]BGQ*<4HWQ+F4+9
M37E"14HE2^5*E4,U0G5+34>M11U 746]!$&%\$(L( F03L@)E *J!/6&ED'G
M:5!H>&FL:))I^FBN:.EH=6@_T#;0[M(1TLG1>=*5T2W28]"+T#O2Y])/,2 R
M\#+8,&0PC#'",7(Q6C&F,XXRP3%Q,\&8,IC&F1&8^9CMF'.99UG06<18WK&4
ML:RQ$K JL@:P-K >OX"^T'\1^Z+OQ<-+KI=O7^:_7&##89-G"V!K9CME9V0W
M94]GG^+ X)#F\.-HY/C%R<1ISIG)^8,+ETN)ZP-7)]<]-P^W$W<E]QX/E,>(
MYQ//+"\>KRIO!&\_'P*?.)\?7PO?-3\WOPM_#?]/ 18!&X%2@5U!.D%SP7S!
M#2%J(6.A'*%584IA(^%LX541*A%CD5R1=5&(J)EHH>B.&(.8M5BYV+'X2W$G
M\3KQ*PE^"1^);Y)@21G)<,D1*1PI+:DTJ65I:FE+Z3+I$QDN&2^9;[((L@JR
ML;*S<F1RIG(E<B?R//(^\MT*Z H:"FD*ZXJ,BDZ*S4IP2O)*\4J+RC3*=LH-
M*H"*G$J\RI(JG:JCZE<U1#55M72U;74V=6_U/@U<#4.-4HU+37'-:,T%+7HM
M5ZU.;4SM5]HEVE<ZDCIQ.JNZ+W1]=(?TB/5@>HWZ2/K:^H7Z%P92!HD&6Z^X
M7H6\FGE-]]K]]< ;XC=OW[0:8AH:&WXQ0C#2,2HUNC-6,<XUOC"1,_ED<F(J
M89IL>F F:I9@MF<N9!YGOF,A9!%GL6LI9!EON6<E8I5D=0B3@*7!?EG+6F=9
M7]FHV!39/+[5>5MEBVQK9-MDAV-G8]=M3V[O;C_NP.00XK#JR.^8Z'CBI.!4
MZ QR?NW<Z(+W5$P-N]*[!KNNO1-^E_[NMYNVVQ=W;'<[]V$/1H\PCQU/:<\"
M+W@O4Z].;RKO]]YK/F(^.;X@7Q/?3C^(7Y#?EK^,?_%[U/<V[[\'O R("S@/
MU EL#B(+\@_:")8)+@MY%N(4,OM!X$-6*'PH+'0DC",L->PAW"Q\\./+CTD?
M[R),(P8CV2)3(A^C+*)&HKFC,V,08^QB9F)%8HOCL.,\XS;BE>+K$R@3PA/.
M$PT3!Y(XD[*249-=DU=3%%,:4Z&I,:EW:59IT^GBZ56?2#^%?;K*,,N8R!3-
MK,PBR_J8=9,-R_Z1(Y-3GTN;FY2'F/<N;SM?.[^O@+>@I)"X\&/A?9%=T6JQ
M>G%W"4])22EI:7097)EKV5[YJ_*Q"LF*QDJ6RIPJ@JJ/GX'/KI_WJXVJ9VH4
M:CJ_\'ZIK*6I_52'6Q=>#ZKWJ#]IL&I8;=1K'&^2;^IL%FBN^\KZM:B%JB6]
M%;\UN@VU+:CML=VS_>*;P[?##LN.C4[#SH4NW:ZI;K7ND1Z%GOY>Z=ZN/K&^
M]GZA_I8!_H&F0=[!AB'NH?IAKN&Z[US?ZT:X1^I'>48;Q_C&FL<%Q]LF1"8Z
M)B4G>Z?DIH:FE:?'9[1F?LR^FEW]8?9C=^[MW*_Y=_.W"_Z+"(OA2UA+2<ND
MR[DK#"M5J]RKK6N2:\/K&NL+&Z8;!YO.FW=;0=L8VTD[%#LEN^R[+7O2>V/[
M!OM;!PX'MX<A1]A'GX[ICVM_BOX</M$]V?KE].OQ-.*,Z*SHG/.\\T+U8OG2
M]O+V*OPWT>_B:][KOAN=FYU;MSNDNY1[AOOF!X6'Q4?;Q\?'8P!7S,S>Q!PP
M^UO]@ # R4D^+@!!3V>,_S'!_2>!_X/^B_SI _ZOXO]"\/^,'K\!V,A/%4$@
M&(0-P&&#P-B@QV[04U4+(,*!_Z'004)&1(!' :/"@0"T)S;BGR?_A_!)!$:"
M0P:A *AH6  <" P/ H/_J &'B.(*@@/#8R/@(%(AX5(#R&QX8NP0?!0U<0)C
M*,=S=<?WA":Q-!(YU2>TG$ZH1!WC7'1K&MP!O^)R)36=I:1Y9$SIM;1UB&LZ
M)]9/S0)=XH/,\[YT36XP\%J<N3+R\<O*R3_5:I96,.MW;NX>GL$A'T+#PA,2
MDY)34M/R"PJ+BDM*:^OJ&QJ;FKM[>OOZ!P:GIF=F?\S-;VYM[^SN[9]?7%[]
MOK[!_J,R'#P\&.')((B("+9/*F/#4^$@L"$"U+AB:DCLQGB.R.+O(;'XZCDF
M!!PHU=".<0FGD^=K 9PT<1J$II*_<FMHN8@TN:7,Z%"= ^.E7?[HJV7NJLT3
M%/PWA<\8B!/R:[NG-L\3"^IZIK<NZ&5T+'C?A205UO?.;%]:NGU(+FKHF]VY
MDM6U<@]-*6[L_['[FT].#^81EEK2-#"W=\W(+Z]O[1F>5MH\.+]_\S@/H#^Y
M!PX;C V( "L;*\U7;ZZ.6V=;;ZM<?_H>+'G]>PQ5ZU/W&\#WM#[MTWL?'/E<
M<9%Y$_C^%<-OPI<@021]Z#,A6L:K97*T<)>2<OL.V3LVOVK8H*S(9N!Q!Z86
MJV"SBN8EALTK=54-<6'_D5/-EX\ A<Q"Q='OG?OHUJ +(1V]4S)VE18W^%FX
M6O&BVY=B< :_NE+FU1X!&J_ZX /]A=G" 6>/L,C-09V&[<Y2<X.SD2!7@[-[
MH9_R-ZX5,K/%+&JJCT"E1]9'SX)W&S=.?5$^-X&3%=HMGET_?;RJO*[>'*0-
M4?N&D?&U%\QY/+1@C[:K>KH>%\HD#'0]V$!>4]SA5+K>G+KK(<TN%POQ+ZE4
M*:L>E]\13,:E]IVG4F5NW.!RVBT^ N_;6ZT,E1M*6CW=BU;FW _I J(*_.@D
M8_K]-J'QO2*;T9[T@M$&,YZ^!8?$SS^7YQ07T>V/-6MFBTSMG_!2'("/"S"3
MM9\)]LE;"_4%5WX.I +>W<BP<9[B/A1H.Q*]>P0"5I9D(:'[\\FS1>V>!S[_
MIK?^CS*(2^OC0B!<YI*:OS[>%#@TA]Y1"A?9GP!9OAOO9\+ 87O8L2M3#ON*
MM@+3#6-*7*O^%/LEIIR!=\@J;LC>-SE^8A.T7UTM#H[)JTLV1([3!"8+HJ<(
MU"V,_/+XKAS"^7-,O&]4<.2@<4\?I0&Z.#G!.)6OKI7-_Y[&DXD$AG11D,,#
M:RI5^W7,2AR_D@ EA_B'YMMQX!?96QQ>\J24AV\9G(7*L19O0)DQOS<;-FO9
M<4FJ'P%$L0?R78VQ"Z.=89>O?9:.>J((-*]L&9YSGOI.BWYNNB_ZPM5.8R?2
MMX0,B59&1'J_M[+<O/+_LR]0OT*D(C^.&JB1"7HOZ-$L1A_V$0="(Q]0,5O]
M59[5RA()(?'9WG*FY71+K"K++$TQMO3=F7R8QO,[J/\:_4UX$>5@TGQ@;0(Q
MMS2W4CNMU,.:QKX\[JN P0G(Y&W>"1)XZ1OX@R8T4\CH_Z32/Z!88I0!R)0_
M OC@L?LI;Z_>[!F$+^N]\M#=L5_'Z^SJ4^T;SG:\=>6V1'IX1NHG*C26+<C_
MV80?YY= _//D&C&>\/PHF#4+Z<K&!@_#4^0(B+.] "^8RVY,OG]_Z^EW55GQ
M?]<#CFZRTYG2FI+J(\<=6IIH2190!%7A_*=I[ I]_YF2\T+E@U:FF*OU .B$
MZH8"WJ+7!/,R,CD*##[ZEFE9.'3C0C2M-34S/(WO/*#&X?-&FUFTB4K3!QOA
MMYJ1"'C!']15^'OS@N*_U\)"4]O-7%**>;B;L;3X*P?;9RU55KF;I]"V6W$Y
M.O(B9 D[]@%MT8^A&:GBRS)QVOL&'GN;PW+E+<YS!SDU+?ZC@3,([U@'GN07
M5*?L.?MB?^N1LB0C)!6:EE-S:A-AB6P(PMV*2!+Y^F"$L,@.19\[$PF$@)6/
M(_V6K)XM7DN)]%1RZKIBD(W7.HT.;SBWE#^D<$9-,&U3RAHEAS9 JVIA,M+<
MI:SXV]3NQ6%F[\'R8'=7UD'&U1>W!]1L#HWM>N6=3KMRQ?T@IA0G7<;]&S[Q
M+X!+4[7P8K$@IMR<GB\-Y&C/9+@4Q4(+I(#3#>#[:>#XAC=L/@C]++U8:7<]
M;OVY]/<XOGP_VWSUSQA?X0.0H5AVR*L!PD$4'>1/7 -CMPK;9Z'L_ =[4A]B
MTF<DV]<@6'3@&[[V6YV-)52=#SHZD.AGP?+HD>3*(#4I?A6BM=J37PTW8:;<
M[@MWR#O[O)=S\(Y[W\36IE;^+P1CE^G$8=6UU3-M.0N;WT8*G&>?;T+'8K^U
M,[_-._4@?\JK_..4CKMDWX_E[R838]N6([@V\L.BHC Q.!PL8OPTC$0 +Q=Z
M"GO%)+K\JZ>(^2\MM$MS;'>[1Q'U55SI?L6G:9:,JV:BP"K9^9W%Z;>W+4+*
M8AMQ5HXN^*DW-X2G?-8IZZ;X-")QA39ZV-'DY[*D*MJ:EIQ:T+OFF9];C\ =
MH^4&DH&43H,P\47(Z;5"\X!LS@I)0#+35*N  I,,DS)#EJ-)G\6QY^+;,L),
MFHX-MGD:=';]#Y%Q QZHZB'Y-RZ6B-."J3$P0T7MMBS68I5JD369K.\?ZB C
MM)B?/=,+'%T+JZ0PU5V5GS6P?,SUR.0*^, SE^AU6L-3%.;/!0HZ_,9IQH9V
MA)X>KU$+NCQWM*\1IY]D42E0.>.E&"H].,9,?@1>M$FHRD5=HYR6;?)8KUOH
MD=OF)!ZR3 M_I^LJE!T9ZMET_&HTQ!X/;LJ5KA;$\BFR2<VZQWO0?020I-GF
M]#M5/L %'HSK1%,00#4GUKY+KQ24R](E9>%+ITRJ)FQ9KT;5\^OK;B6:EHSM
M2D:C-E]S+K$20QMZ;2YWRE(Z5;,G+U'] HLO!N"T>FG>+ILPP+:M?^R45<H)
M3B('BN,>$VU%L@I&>:30EM%SDVC!FP&\JJX5$HA%49X^\[<-?#-Z><TW9ZX_
M1QJ&)B='/EMP*Z^.V"KU*%RIR09)I7[3V7 :&U<B=*242Z.+ -O@_G1UX9*A
MO%;-K)1\B]H<(+B/).UE]0AP^&4L8.!@?#GC:%_3?\5T=&>6.C*\N) 6\)'P
M_(NZAHR*6#/3J>-$F_!S>PS_L6X<W6#R%86%8#!5I @6ODB6[.8""U$=;$+9
ML>O2=:;C >8WK%):*GQE>9=W3.Q:'NV NA]Z%:)?C]Z27D9#:R"0N8@W1W2P
MVR"\6S8\!'T$>FM49[:R3]VI2\(3C4->L&X.&X!@6P<3>MRU"%;!/58HJT@W
M[=/*Y2K9[6O*6<.!I4]!\Y:QO4R@_>V81I^TT8J _"N+[21BO<3$@J5TZ2)L
M/2&7A)5:R_* \M8DF:\', J2T-]ZO!Y1\62E=!52)%N&OROK4W];/@*HSW[S
MG7H9L:X>VG7,MQ/>8A)I<3W;WE_^L2B,,L-HK:9UOSTO4!]-_./U]WK&U2B3
M"=Z\XKPD*KR3JC@B<SVR*2?4#Q3&NS6VS>X+LN(K;-,+AW:=/UK3ZTZ\%BJO
M0N962$2<U="CEI9(5 0B%@7\!,3U8DNK^;R5M%YCN+ -1D29.JE-E0%2K<7H
MQ F[+67/( 71?[4U]\V?B5>1\$^-*Y\,MK^FFSCPVHW%F)$4&0O\*0GN=CTF
M(D-KQ%A02!I7TLJ-:SG!N0S(?@2^AYC(.C]DQ_GE",^;0P[WQE;O6YGN9\LN
M_D\E/!HW@MVB+H8 K#HB H-RGA8'.) >(S+EQT"'P*1' #3ZE7'V<#]BJB]+
M=,G<5LE'8EIK^$R):BOE'FD-6Z8 V_X; 7@A6P-<V+AY\7SYYI\_;(QC986*
MWWG]2L=.>/NG[47XP7'S_'HLN\=BVK1F2UT3T40R46CW^J^IB]2WR_9T&I3R
MGORRM,7Q<<_EOV#@ -!/SSZ%$]$YDLKJW2/INWN?/@+!+R][KQX8ZH11U[+W
MGGW5WSLY6,F(].^T&QE;<M5TM;8N_$'"6G!VBV2Q1AS^G+J*CF"M?TI&-8U^
MEQ&[W(#K#$<;%,TMLKE[@Y$+)3XN0&B)]?MFHUSG>9@Y=4A^O9Q(<MO \P@8
M7]'N%F.HZ+3<6KZS=-/6W,@_T]+>&#%@B:\<,'&L_E#+N^CZ"L^!"(<WC\,]
M]_+]T@^W)JXUC<N'D0B32#%R/"J-8#;%7U6I3\%F9\S^]<?A31L;6":J$!ZG
M8Y<.SZ*,5$CWNC$HNR#3W2S\ TET4>K,>"R-9"++NL* &?I8C"<[LBPT' "^
M95.P)O.V< D1%<GFQ-/AY69D#\E^V6!@8CHH)4\UZ3(UTOU"],&SD*US&@,U
MT(,&051\)40W8G+*\1$(W_MN78K 6#0:XGZ!4ZC?7%0R(,1N2D_M##>MQ(PW
M=+4;88Y3P3G>\\J@9\LBA&ACDK EW]HH1[.D@-^R&XKC1_50=>%YCK+-84LC
M+H%H$N<$.1&=FHJ,CJ3$P2V5()7/44Q6WXS?  @:X.95*!@?@;*S/0$^"T!6
M"/;0OS:I]') 4V- PYZ&T_ESG&OJ-PWJWM.F=YDOUQ!"33K$ZO/L?85EABH
M*?W&=7J_K"+Y9NNP/8;I=*Z86]T<G? 02<ND?*TWU#&Y2LR.2[HE;@!^:QAB
MG[=GLXS^V,5(8;/>!+'L!AYN@ D*!MYSJ_U8;9>*7"UV+2%U'-$);RD)T&A!
MD;&$,L7^QD0!DC_?(Z!SM#?Z5F-,U#PGA7B7J8RFX+NZM+\0#:G+,M4KFD<@
MP6/HNQFP9Y)6+@.T[A:\^D0:E17Y+"Z/,O-G389,NMWD$)1M>CA614V%])<9
MS&JN+C2F X&]A&VRE@%=@7.BI;H;?PI_1ND3[+E<]NA->]>D!1Q),":9Q-TC
M8*EVVL@8 11'^9&_"2FDS4PK)4A#CLM-9>B.XRO&T*BDB<D+X.0L1\7Y=#MF
MI(L;.!NA0EB&&ACC.WKANQPYVOESF^Y,8K5^([%-R$WIW52/^;Y?^%;SF<N8
MZD_EZD4M,1.>P;=WJW')N,F58=H,I[JI;-<R8>)$@[\.>]&*5%U>V'H_ @,3
M*(<Y3?J*"?;KX(J;I^E6G>7L_]R&A/C6'Z)Z/U>_J_QFND*7<"!;MO66PNCH
MQM,UK<K#];66%_&G2OZP&<.VWB_?#2/""/048QK2YUI;)Q21>1VW'MX$7-V^
M33)[.2SS?O\$/]'?G"KA'C5&[!'0C<*L\R%P_9<5764'90 */$D +V5T#M+-
MGQI;9B%]N"CJ QN5V1I5E9V>",@Z>CKYP<Y'YK)J */&(ZJR2I&<#&4U!)00
M@ S_5/X)!CQ5@$(-DZUN_VW%^-<,"3N?F935<]X=/:;10CU1] 23Q2@QG6*>
M5:?G9Z/DQV6O,LG4TE)(/9$SEF5@4 NW=ZS'FU\$V)XJ\R8+$P_AI;W*QMM_
M-38D:QAW9U3Q$6 =C9[+_'548C:T:4UGVSHC9!E>49B_]+JLW;(@K8BL[K.2
MH"M<>!1]MO6G3*FU)&9;>"=%TS1##,&I.*DPA:8^>9:*_.8$&0IR:":X*GUG
M1&0;XU3G.O!2R<W,;?O7 $8F._ZXJXRT[7YS/_^DD88B76%ASMQOPGQY[UY/
M:_[<)J'QUYO],P^K[%)R^%Q<5)R3@H?.-Z94?J/[GO@+"Q*F*-@9ZCPX@O=(
M-VW+H:<;YD-"^%P6I;\WLGH\P9?G]I!!DX*.HQ]0AX]B&EKEQ &2=76(<JEQ
ME,^7"*.?PL39178;$]RW-$_33>#:^^YA)#F GY\1+R?[&>EDO0Z/EFS%G3"\
M/65^3B\Q]XF"=&VIIFR'8G ^&X+&YCL4NNBSISU24%T9)?C2<1)U5AR#1LM"
MF$,E,F9&?8-Q/ODW>!;/K*BR+.I=.,-.A*QB9,5\)AX5,L*'KXSH:9O7UX]
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MS26O0#HM1";K0Y^L\#A/L\'CHZU&&X9?YU@#S'CK'MV)N&)*I)-]A4:E>I'
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MXOYG^J);LAB*@?F[7*"0:14G5/1+9H\H:VI8-0-JDKZRLH!;,^D?+&%U/@
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M3^LN48=FQ\3U6\DPE==NYG@+OW:$H=CRF'5:*UZ+.#P[1QL2[*W6(C(4?<3
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M\3.[ND>)_'N$353R;;NQ;"*I::J*=/7[6T"1V>_ X^Q_E8%Y:;[AM[O#$&W
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MKXT(PP":!J/7)_C'1E\ Y/R]G"XFZ98<!LO!P5T,ONY)@/7B%J]+CY>/$$[
M;U;#^5UTG*=[Y=;POI>P#\4IC_7U"12\JR)#GF#+%]YCO)7>\U2,A?YXE6S:
MQ#&L;WL(9%$+'9_LWY^?J8]P-,!Y/A7_A*G(E1 E312 GN-(&9^>)[QD?OJX
M;7W_54E\I]YDA2R/3)UN^'?EYN>0 +IKV6GTQ@(JO[)7638ZRTP49O"3G!OA
M:U/RL<*J[!$"8'X^[NU+Z;2[6@LCUI4/S5A 9PTU1PQ-%F?1F^=85WO@]X:$
MNNOD<748>=GZ29JE/$E%,HRY91OHY RH4V+#<T4J] W5G&TL#C:I:6AVD"],
M[=F ]-16P^;V7S*2=3P97\>A><Z J_GG-^IY.MZY=]XNC<N*MD(?L]3R:,,.
MJ$Z9^_Q)E?.$PG[%KO#/?(JD6F!O]98F,K8_BJ]N];QY(K&8Q1?'-=KO>-8*
M'S+3+COY4LWV^]1\9M\AP62ODE]I.M^1T&JV@7+I7%^WO"[E#2YE'U:)')@N
M3#:,<H]S*<!0ZR/,#HDQ]O0RQ^P5Q/[VK9L:T^O1,@:Z:UK!<UZ>S:V7.?R^
M$5MWU'8\9CQL>0L='S@0FBM;%&Y]&VIIO([Z+/Z"+Z1S#+V%!]Z\^.-B(Y9B
MTR)+*_/F\+&R>SGT1C. *^MG_=82#?4JQ=%*J5S!3P7QR A""A*7.# 3Y2[3
MZN'%MJ]@%<+4HI@W(]YV!A7=9&SH<E; $B:S]-0FB/_R3T=7NAX8(S7HLSA^
MZNYPL++=#NO@KZS_\^G7'>BK5/39BOD2\_N/ 3X73\3B!E_7-06H%E>61 0<
M?V3P5E8ME?[MP?CS;V=[ )UZ6^)>4)Q#%Y\$%H""/_<]_3.A,TJI8_7SZ=*%
MQ2K$KEFBW&-U*!KKE%96G:E\^.WAV'*_,=KNK26UNL2\)Y>8*_2OE=5J'M7,
M':99LLGK]U\'[H;ZZOC^X%^.OWEOJ5H%N]F*JY;]%TUU7#F>=G]5N-N<286?
M?!HHCB,A5)SJ>5UD[:R?_9R=BA&D[MS9@*3_ ([8X6LC+I:$^I10ZW ;)NEA
M\\-]_DXC."QK&W=V<U42+*+XQ14265/Q).0U@F#L7T!4391MLN62+762IP7-
M^S&OH4\T;[L6=F#UC^]6L2,CD<&1X]L)S34[!ZZP)9K+8LX<6_OVQZ$,KRJ@
M+_>$4 ;J.!9>0!R _"_G@TQ*B9O0M<J)&+_TY[]M&FFNKF^OW0_H:%\/*7 ^
MZM-.PO.;^*'/8;;:J63DDE+.>Y\[(>Y NUDN0;Q]$[@XDT_TWLXFARSW 7")
M$7;"7-@ZN2X&]S93V[9),=W\ZJ"(?);Z,ZOJ2UUO]%*'4CM1Z=H2U?QAYG-^
M8T$_/09,FU]<;V)IM#1JSPXF[+S"(KFW5J: QB:,W*&+H:2M@6D:C>!LAQL>
MZ94C(A3(B,WP 6^?R] 5(XGE6CGV* MP3QLM#=J!&<U[EYYM?F[NQ;]+^G 2
M/3>._>E6"I0[CTTU+7JI]U8\K,6\H$93]EZ4_$P@E-)<L3=BL?B$NSYW:53?
MO,^UN"73^&,YGH%\1-,.7N<I\>;1+M>^B^^;V0VRY'06U!4V3 GX8P;;*%1(
M9Z%]3[+VVOA*>&9)N-9/_JF;JYG9X:_EK(3!#'M,KI7GD>M"\M**5IUG:Q9W
M:4'IL,/I5;LLZ)Y84=Z84WSO/K"MQ-,N:+:%3"57[L=2R4L5.VA6P3V?X\$.
MHS";1!0Z1=45>WGH9?:0>*(10CP"U@W.J\.X6HU\\CM@3KXSG[DCGF1D_2+E
M;H%Q^U7TP_6H=T7\\H":W6W-4[RUND)[/S&'=3BN5XX:&ZDY%V&D)Z&"4!<\
M'TM*/LJ>S9"J'V4<CZ*(+#$7E?-6J-0/NQT-!O2JW BS=Z8OR!7/PMZ^DY 0
MS7G^O5L?^34]-?P[_%D4J PT'ME%LB]SD?OQ;=6[#+>9(SI"GC/I$2A?I)>K
MX,9YZCBAFW8PFX/'5?RG7'%XM<0+9Y0RKSM-^"V\F\1VY9D/XP$M. </*]5X
M]=R:])%"R+(OQ^G13S^:C8AEK#6L=9Y+VN[2.A)P<@\A_-K'_V6,]2#)8@#O
M+E\Z"NF/RL_@CGCC^AI!JF_"0=%H(*;Z+E$@#M3Y "@GT#!/16.4#6Y"%W9,
MR439?SN7J!*'"@LUS=];MU;L58J*7R%YN&Z0SC*+M$@LG/,LW-AA?<+!!2*8
M0+T( J1A_(HJ%D/P.<F48OZ]#<W3[1YCO'+CY26'628PG>7C[(!$]A^)X\,H
M_7P*+:M;$L*TW$I-5"]=Q[2@=K$*NF$WFB9UYI. 'N,,<E$K07O(9\?4R2G4
M_6I/IC^*>*VSA?K1*=YTV#=9WMMK<K^_R149/4C&@LQO[-ZK_B9Z7K02KQSC
MBFH^WOO+3W>1R9%J%90KPIGSKEO/!=\$(?I!A,,5GJ=@Z"A]["0=O %LRU'J
MSI#RC2RK8O.N?J1>FC6I*:53#5"QZV.=ZE";=[8C?' @)B@DQ69MREMQVG98
MA"Q744F@13FF",?'[U* F/C "84HGD_GY#HE.JFD;S_>40HJPY_?)FJXI4(E
MF1<0MNX7"U0W8G/3XU?/@F(^;92=]EXN?&G(0KWIVUGTEVT!NVTFU![M>R[D
M-HY #@.=@UKY$-/&&Y)WC"2JMIZAS=51J0VB8OB'>18\,Z<[Y&W]JS\U =^.
M5G5E0_.@NX?W2?\_(O0%#PC'A>11L?&+B'R-L+QB")\&(/1]?1OPV-U5>C30
MEP1_]]U1CE4Q]*;R^/54-C/$7MM)_78Q^JS^ ?":C?LF]*UB;ODVY0[#Q1^=
M__ZX">'3EQT777VYX4>A2>\F.3^YG'>9NK\:'C$P&DB&VL.:0[ [)%NUO34(
M)8U?R+$93''&(DI]] E8WE4VISG(*U?V1:NK4%6(]P5>GEZ$PHYJ]@]JAH]"
MOM?>\W?=: 6YZ?QI<RF(JZ+8^NMGUB*2':A_.LQ!.0F!X/,6VFRRULWX8L@&
MM(!T3Y?5+V48S-YK5.HR%MT^SON]R_<A$8RM9F* /ZHURO&F8:9=D*<LUDAC
M<B.IT EM0"DUJ8.<4@5)LZ7>!P4#%W:UGCL25D:MZ9V0EV8^ /3S]Y/N%CC3
M"M03ISZ$W;<)N6&9A]7\SB!4WV,Q7R'VI0#M#C'D\M^C,)()2.=8BAR2"OM3
MC4HZ?MEIF(@J*75+NB6K8AV@]O)=@*Z\U=[9;O-JS]QMU]:>D)_3:<+$]YAO
M6MBV4:!/W]BJ66SUOZUV/"XO%TINN [2NNJ\0\6G*=0R?71C%VN6)H1G>ZR?
M79'4KWMZ0XSU71 Z!K#H_)&JD0N;R:'3WAM!^00YUI",KO5%\]@9MJ1P?2^Q
MVXJ^'*"K0Y^3:6RY. O\+CI_ AF:5]0YUYJW!IY?-$&+Y);F/L6Q64R261@J
MI\N8$!RX#@X._XOM*W+V*-'P8L9]_8?;UT;**X^]DVMA:]<O:534)"TT&(.A
MU(A"OM*L"J4^B!FXK#@WE].2L(=Z%D^FAOB]49OV/L<<8 );,[G_]FNP;L>K
M.?J>I"A.!:K: :Q-Q?M:^2HKQI.YJC.:YN^3AW*MZ)%"),RE>8R?4^%TA&(?
MT8?N9JLI32MN;"$*1<\G!4?E>7>2T"Q+8)5/:0 %(C<G3P^A+K2F@NS\.T/%
MS(WDRE,AM;_[1I<X'4H6:.,<9&+M YU'DXG>=;CDOY4W<;[(54KOXE?'$61U
M@FU&_2YC:11]U9O&=1;,#P6EQ7M9X=WMD/&%YJDB7%]Z%'Y[ ^_Z+FUTP (/
M#/0IV ?&/P 8)&4Q$IY;>Q6EY=7. U.1Q F+I_UFEUN%%=6(IT_Z]?BG-'^U
MPY*+$(Y 8\[X+G^]YT\XBJO_P^95RUPU""1GG?B<@^47L5(FN_N%Z)G.R=Y<
M_J6&YO+\CC?CVX7F?(')##Z";G#T3-F4<SDF;R<00LK\.!,*2SH/CU1LRA(!
M@2Z[&QY]AI$2E^I7_$8[+I-65Y%=_%*2>.Z3]KSE/,T74RA457%IXKC)%=V5
MR QE+0_":TJ"FN+%I@C,$OLMG8*BN]W<L[1<GNK;8XT;51G1NL4X3QUO(8MC
M'%)A>9J]QJ_2A]?.]X<_MND9B1HS-5"4E3+*+*@![>]1A>J^<Z5*LNGR8<L4
MPH=^:_T[V@*_GAI?^+38-AH$G3DQEBL )?M)FE&[/*O2=,+DR@P3W4B!#]_8
M61<?$UO34KG[LECD[;O#_,+HN.[YSC\&"67@053Q-B]N8W3NZL.<VQ<36^+^
M28_C>&/!,K2BK;N1,%#YO*6!<6OYX^#WXWSG$$N:0\.8AO"\>.\;V(1Z0M%D
M=E"P-GYCF[:YX=@K+#8=642]$[^M(,RZHH1ZTF$SV,K\G4!=)^+[N6&1/DOD
MMI7P^'")%%3DU4*3 KH*ORQ-MK^:8(?V5Q[CKBBF :U*+9.=D594C("7"<:E
M:K$-RNIHR::FI=:-T%0U?K=5.8$])M!$L1S]\DIX'3VX1C#P .!6G&M&,/(,
M0\IZ1&X"B7F^BKF^"7X#06"@"P&WXR*U2_0)G]_,-L8*^)(/"\J2'0Z9Y$;4
MY,CR7AS@HJ-O/^F]XX/STWFLZS8Q.('LO4BDJ]6O NF.+5D;*A]GR4P_B6/S
MR4*)I?2W;J1#E5+0?4UM<:V^]J)XT+ G]8\^)MH94S3VDPS)[H2NM4.118\_
M[[W>:;QM#<TH^$Z<HO6^.)K( D0E#J*UI03I(L$= @;3TPW?;JQ/1@\Q@'=J
MWY*(.:;G2LC5'#BZ>ES^Z=+>$$L 8]/[TMK^V4ETW_L!!E5>54NAV9E-B*50
M \]F_#QY/UZZ6@K+/^PY^CFE"DBL"PSM]475GC$P=Z..P1A\M(MYXMCD X \
M<1!R*]]""\%6E+!D$0D^Q W"1Q]I.<>8M2\?.P@I6_>=21.5J _,73A>8"C>
M59-K7 Q*\Y)(>!90KHE$_MCL1S$.Z==5E#N7VX9I?+=W)OATN#ND.^)P,B;[
M/9NEO0=?Y+.E3QXHT[9==X)FCX:*]M[2-O6BQ'0AB7=]$<04,(YU>GJZH[HD
M[ML$3FTB?P6KW-];;;BL%50LH.@[18/X'ILRB5J&XX%C3HES;)<JOD0%NDE4
MT.GE #.T5CIP7$#&%#)T9A*#['RJ[,6N@F^HQ*GRZTQ+C+0L&:@-@H&Z6/)+
M27F80(_=G8'OT7T*-T%=&8JY@0T,T5*"L<E;595#)9P6NF$B+SI;C(Q A<3\
M3.UO$IB:D2H.1BP4R=XN.6JFYB:R]*#:M* '0/)NK((=@@WD8)9X/N0?_)XL
M5&SVL.LXF>30X@'0'YJ6Q\RWC7*^;SP<+5G,W.'0]"U*Q%KZI*O3/CDEBIH!
M&5![H_AR\U]81Q3RFQLPC1]D4ODR=>W]6YD*=VNB= 2@-=XK$N;&N>JO=S4[
M&?\[S+TDO0]U[-"#<^W"6PK_%>\9KE]VYU'__ %@>Y0@\JHF.J;@TY+ERPFC
M>0F92B=>K#4ZQ^SP2^=8<>_+K\@0X-P#@-F-92T0=AD^\>YPK.*_^W[,AA\
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M&KV3Z)PMMJ@U=.#8#=//<6MH&O$MP;7)9?,N5TQR 3L<T>_1%%7>6ZUEU:I
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M61D:7D12!E>,=7>++:1DP$44:K7)&"Q-R_,DL(4;:*L\5[1:<?CE\=6G*I+
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M"JTBB/ TO_>5--\\\W=5A8X6HD)',G&$7!.\(C%75F),>-K)[=UQMM2V2S;
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M<3="A#V4R><!8'2P.]W-_6JB ^H<2WY??6X4H7JZSCQNF23W3/([2;.U5M:
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MGH9 @\&-IS%'_]^S125FE5XM4RV]9][W6B,4Q@&C'P9+F0TW\][(H&D99 -
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MQIF_?7F&<9-@N[5@:A-4O9A+T[2K3M;T]K>[E2-RD4;=9TVR)".WHYJ-<2T
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M2%C/6;8W;@U^BX=GKACUPN\8Q'-):X+X"GV,(HT#401*%B14-E9GT+!GW^%
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M0%G*@XM=+W_H(@S0L2.\"OY4L35^YSS#.%)5[L1/9^RY96P0K(GUD?$+.C7
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M>2SWLPC.>[G1<A>N&VF],[Z'UZ0S 0 X0;CU+,?_?ZO[WP,F9>3NMJ65>!H
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M.R,HJ@=T@ 9(IPB1)\@X&@!&!8W%,13T?-P0;3FH_%_WH[2I_P)02P,$%
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M #? !SP%G@%2@#R@#&@ 4, 0> Y8 ?: "^ )O  "@1 @ H@!$H$T(!O(!TJ
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MOA9$D<GEV?1/PN1&22I=3L(X;S[Y2@/Y+2$S5T5?+,T!DNJDHWM 4E=(%2P
M@0I/![TTY7,=?MTNC!'!L3D\(B@9Z01]NFCCF)U%ZAPD_Y(??XU$7XR7DT<B
MPH$F%3(BQV\,T7/5?<DNO(R;DD-XB?&-0\4O\.+R'@C;&-]L?4<1GYY/K6N(
M"<F&1Z0WFN@M%V>7\ZJ0J/%E_V"T=E@+S7FLW$3B9YXL:C/]A7&B[/.3'VS
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MS+HE0=XLZ?.0BA@L\U)F$-N&?=W^>6&( SD!(SQ;0[,U5S;$PLWCYYYG:9Z
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MTZXUC(\T7QGYJ:;.J'^A$"QY)DI^M/$67V"TW>?DB.SA_)<;(<Y'%50C?I;
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M2T&XGY./'5W[N\P#2 ?"%7?!3:6M$F2.['95B3N)7 P": @N)49K/ 9VRT9
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M5N]@324<E'I4KHF[7L8VC*,G9RL@9N_UT/"'%6?-(N5N3_I;Z&*U2@@[5G+
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M0K%4JTNF8J!+IBQ$&^XA2R.'U^US&BO%WF#KV>!3>"2!.>&>EXQ+Q-J\86=
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M?/GW]*UOFZ* 1VHE9 ;PJ>C[O:V;I%$F0@7*BC8J2U5S;;L3:<UQ;<:HH(7
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MGE/S>XJ4TS] %LD;>Q+2@!J>HE8E+_$)2DYW,'/JV!!EY9:+T;YGT6(Q$/3
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ME3G/^(?=RVQT,=-JE2X:J,:6'A@VYGJ;LIM[K>^7]Y]V3O]60U>ZFN-5(!/
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M*<)WU$*V)!'6J!JUG&_!7(.2/(CSH/,ANZI:C"-4FE?0)C?)+M^X)1]Z_ K
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M:>5M$,A[B.T,ER(B!/^+6-64)G*6C>F[')\6FAKA=/'#T>12LV<CX=@]#4K
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MR=-/OL$(Z;QV3'303Q**C*KP"N"7C.'-V#*AR;@"T#\J:U6\ E#@]]\%MK?
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MUE\&R#CD_E33MQ*K+3_/#^W^M3;WT4JP>T5?8?2CS?!N?6S!@XBMG9!:/O&
MW" CA-?ND>!ZW.O*ON-" B[1UN/CB%9//W_8<Y^9;V9PC4^1OT\N?FE>JOX#
MO/N/=&I1MR2LVJ]36OO^=*>%_CB(#:@[/.?_=IW\?2F?-3_AF_V'2^GW2?>^
MYI0IOW&_3E3].I[86+7 R]D<TS^E836[^"9S]S@2M(O^!S">K(T!@65^,P_:
M_B6<CU!!!E)P6Z8@/S"J%J:/-M>++)5I\N+MI-C0&JFA:\.F)5J>G!HG!U;=
MH(A$F*OX\98=<'9NG%E1R\;@9RD^.]A:RYA2;X61AU_$P:+V>"WBS\CK:(XP
M"[/7LWZC>=_\W@A"F:7!=9/J&'H>ZJ]7=D.;Y@3)UG7G?X )LO?XK0?K424&
MP-O!<ZU(-0M+O]^"9B_UY>OE6YE4906J:G# 5)&=V&&N<(*7P=$U].:C^7(V
M!7\J!UC!6,0G5;%(^IH)])P%B,D0&L..PLAL\F5T:%V 3I*:;+?TZZ)> )_8
M^.RJNZGZKV;U_ ,\P:+<\; )WT!_QW^ NY4SF=9[KD1?(YU?9U5)P]+I@M@^
M SO!8@1B?ZAD49GRBO;X.C$@3G,FAFDO[1\ >"_>Z^UQG*WXIV?8_J2QP#CA
MOS?0N_SVK74UU!Y<(OZ<M+?UC7F^#&[O0&^=(#>?^1GZ?LF?Y*AYZP4U+>6D
MJJGB"]/:LK&I[^L=2>F3$G&S]C2YUFS;>RDY$#M?R\^*"V:0>*\3(YW3+65N
MD=2S*B[^+L;)>\/WZY7 CQ[#WA?@O.3^MU6#*_N&::]K,L?I)<C$RCX+%OJ9
M<9"M[5Y"3%EO6PO*^*L7Y+5T<83D[NU^I_U2E*W@>7D2A&NGM=X5T7C@[W3Q
M_&Q]#CYV,_+]X96E:)5O7G!3O14L&CNTJM[E\@_@LA"E^73YF^EST/R+2_GT
M7G X0O)VK-U  @VZ>N!5:IJ"]@?:S@]8,3,5A\Y>_KZ[<16W4Z*&4"NOSM/"
M0D4A@VM/1Q;1(P9[H?\ <W*:[&I/(U-]?P[\V7GH"ZJ)VU\7W#]S-Y+4\0!;
MR#JAJRN3(Y*(#8BNS]BO'GM$I%%[ I?WQ'K1L'+]+A:A;A4X7CI"8-K=PQ:^
M^HTVD"".:5UG$PEAI,?A@S3#[U^25CWM6AT*T!^J*WX6L#7AGW,S:-OP5MW=
M[%NQS+V-[?%8\@ ];+#=@%^%-+Q>"FVN2/^Q_]%,/XV.Y!#?XB?,XKGB*F4[
M1<;>"93 -B9'PJ;*W0,,&=<WG)1YN3#V;(4Q;7=&^D=+?C7T+B=3[)6DH:H*
MA[;*R;$_BM&7:++)GV18;GC-K$1F+0(CLR:+(4\R-50VV;4&G"A 180V;NK_
M^M.L\1M%I9X?!".@&M$JPL0'#4H1X16U%QXW@XNORE.+=!^L6(EUH$;91=PI
M.5=N[ASZPC:_'R%>%U8C8,5;M!U/!92\;"6#KL;]%6Y+,4&-TVIJJ[VS9EO\
M4(=H FIL1W-G!J\Z(Q?N<+_(E3=IE&>@+'6'\Q>Q1E4(5'7$X51[+\PH)+WF
MW/B MNGEY&-M@Z^U@UD617.H4;/1]%Y_S"*33 C47XYGG/WIONF<>U*;$9F1
MEJENZTO]T" 2B+KRET]Q/=-5OPCGY_=>SQG-J-%\=-2?+7&12-8\_VE7#(2;
M[/_MIR%'^1L. O'UD1&_:AWHA#_=M</O;?'#>.-)0?I<4XONKP!4.BK)UAYV
MP\\-3U(/_:P%;J5W3AE,90B&2]V4X"4R/Z]$%G WVL8G'(R".>#.U*WW_MH#
M[[:8+,II33*^_H+7\,MTCFW#P<B>#MUK,=6RIO5BT%,0$)9D;/BDX,%2Q)X6
M60DCA[FP!CI5):B1G8WD#V3NN"HNT]<^XHKJ"?=FX#HU2_^^?7ACY4+$ @WC
M5X6L<D<K&S?V@TQO!B7T.F@^BVS3ZQQ0A4AOX@K5JV(@\ 5#%^<FMV/7!\>3
MUSE<B186..#M(OBQ&H D87]06^ S0;: /@>ODS5#Z)FMU?M;U\CEPEIA8]5A
MG%8ZT%/CQOTX8F^&G/\-*P<97>]503#8^3?3,%O8#\NFE<8CQD0FJ(4%G^\@
MCSJYJ&-K_%J&>"&W1@443$6[?!#6C4ZN"]WN,Z"\&V6I6"16ASHK!X/V&=<.
MZI\]M;SY^E;84@K<L3IL/.1;K]^^?POKN]FD-S/PYB23HMN)G\U?8J1^(VN0
M-NF!"'E]F8C3,6.,S*UW82-!^!-_NU=,&H'_!4T?W/W"Z)=IE6";Y?>EMV;-
MO%!^M*-&K:3Y),_7-8-&43#Z88@>J_/K9!;Q6E0UQ=_W0AY@LMQ0+3_C>:46
M:V2M; #:NH>35^_M_L5&3053%AU%821D@<8RK'ND'YMGRYSB=%?/\ E/7_*7
M;PM>NT/+]UU_4V)J<@9U,H4C2^'GK"2]DX?;?)2)U2X"4>RIUL!^=GF_]_)9
M?EM@R;BL^++Z%!CN<8JYEMAO=ZR6XC6:]OH-UP7##>[X/;HE0$L-&0^X"1=[
M)^@K(V6JC3IR%X #6S#8_&Y>0X[6U#YM;:O:LKSC1; U&@50D7\PIY6/DOBL
MRQT_/"%Q$IZ+>16(/Q;@RP!PD:0J<DYB,,4]<X:3L#1,94Y.J8UZO 4T<=1N
MV\419^3%@U/A2B]7MY<0]&)[P26NB&\E,9J!AL37%VIA<_4%&@;>6\H,G@4>
MN_X#W ]_FSJN%#L:O]11-UGQ)ZR@.*.(77/6XM0\9V0RH8\Q:1J_XSF!JOYQ
MB;8I+W,6XJI^*Q5;KJ\3N&& 7325_OW8R%JUXX93:>05YTB!O"4FF9+E<[_+
M=FJ1.>C*Z.:E$O7+"Q$!VI8#V2<)!='9V%?AE'OP,7<++XMT9S(":NEEI\\!
M3<:4AJDZ*23@.-2R=7^&'AXY?#+: ;#-3_LK?..IM+(-U?!K=>ECHR-,3<\A
M[(6$JG\#J[8KW5Q6JLMJRPJ!^?!.L[@YL^!\USC3E<+"P'>2$/J:\OM:BJ,7
M]8C_>:M18DE]*V2A#[U#S+O6=XLKM4(UM>-?*^N?%2IBE^.+Z\UO80H>LIHY
M.V\55T3X]>JS]C^\6H#6#28V<\"N,G=39!7DR<4AZ?_O/L[_O;'*K!%)7<!V
MA+ZU/Y'O3TMXE&*7K;18YDUQTZTV^"E*S;(%"H4 )!FEUEPW2ZLL)+]L>$WD
M6N&T<B_*$U0XMR\#65\%V\70JORP#_!Z=K0W.G&BY/[G4\G<6U)W1,+WWD]/
MEU?[=BWJHS$N] \WAIW^IXU#U <=B/C$IH$R(*618R3?*7]*S?4\!OC7_!A[
M<H8LTMNIJFXK^J)84_MGI\_1U6AW;^1&;IY="6J H@">W"SDLM,ZGHA0@@F]
MG]M^.Y);%G;Y\T53NN_N!Z1N$EJBF3P5BW:.:U.'_P%^O3@\_46=1W7OUSGO
MAT8Y7@E^%,,Q+4+[L?ZQU]^+<OM,RJP^#[/*4^D_?0_W6)Y*6TDG/P\# +X(
MH^#L8*_"X+G.*YZHC6D I@0SB,\7>3FMIJW[B*4,^PK?'^!HF\:#RY9LOG;G
M4%59O2',) YRA!K7H 5*Y33O(N$7GCI(89"$3".=7%VL-7G\!19_%;IMHK\T
MUU.OBR@_E+!J]H?0E>4EB&O-K(WS]#T3XHQ^W_H/4-^)DKA=8%JEQ[(RRTEN
M5%G$ DJ?QP]E@P@Y0>O8ZHHTF+;A:F.+(_K6'%^D<O>'-Q$]LL3:WO;4B^:I
M](YF)CP>N?;[MYOX BL!)BE%C#AHR9Q7!TK*7)C8B#5>]S5)O. V41_)(?-9
M%1<4#/8>-3.@7B],._S)%1,I6,6T(AXW$S@6N\>KKKIL5O4UCO 0G"CW_(QL
MZ4<>T%GF'(]#^R!3\C8S(+)P1-:[&DF-8ZBID=!#%^<M]+6^^#V5[-E["ER/
M.(,MJ/RBGMG_1\Q7UR]-Z['GP47M*R8_<0$T(&UCMA$;%6Z)<WL->GI_@$4/
M?_W-4I%GI0&%O"LPV"5V<C36J/KO$D?BK$E\H3#H?>BFJ5R0?,2F7$I3.B6%
MB0M=7V=X#^?VCEMCOV[=[7'M]_\ R>%O2X4/H&,C,@:T&Y8U3RJ;?5?;19D,
M'@3'4U63<V@\36&XSZE\T:V_!E,J<O)^U?FY1]'*"7K Y5#%;JIQ>$Y"^,$>
M;!Y^:OS<<=O[DP>A8P1RO60<&\DZ/M[Y5-K3M/(DUGPGQ.^@_[;FRS\Z8Z*P
M%&SZ3&$!?? B%N[J\I71ZX&WF<HQ?7YFW/S8=52MV6>1&8J9Z%1Z&=KV6DB7
M?;B4TG_H"CJ-D0-W-($M7&8OPX6NU&JZE-S'/J;M6&2RBUPTGG_[9::54];T
M$G[T=Y;PZT!<]O*3MGI6UJI,UN-C)'WF>TC^:Q*XF*[@;)7-P#L%VCRZ?@_6
MVZF,A[*3&SWW7EW7=C\-6*U,>-;VNQHWHB^JRRZV,H'8K;DM&=D>(/(G#SOD
M>;MWSJGMD#".P4 NN+X LYD E,MR'^@*;IAMCR#:AAJ!"5-I^JQ)QHH%IE/"
M V6Z0NE%8G=FHB:ZG8PI]R=]0G [N9]W]#[^V=W]BMS )GJM2?/3Z-MZPG6L
MEP(OLMB1IBG?+KU"=JE<Z\;KK27.61<[5JLG*85^5B9#82K4C]I6[/WZ?>U=
MT<KD&7%R,1C&JBN-C^0JD]!#\P4=RHQ9#;\YS*O\0A 9FT^/?+#)J:;=/X!$
M=YSD4?BH0MG^26J IUCJ*,I3A_-Y^(M''@%MM-6_FU =\+KZ<]+(A0^9@;NU
M^,9+I"MA=J5B<&!;&%E*Z.>Z_UD^>/GTT?9UZ\],AY05HJF \C"?_7V8F;%1
M'1FMA!6W>MO<R=RIL+#5F4^W5XQ>Y?)'H4HJND,.OT/P]\E5K^&PIO.B_>;*
M+H3_K3G$3N&W)<Z!3,\-?M/G2[3^=MA,AJX+O*_DDN5+6\\$V&^'+!HF"3ZT
M4. OA)8(OTO)GFI3DK@[)_SO80F;3.1M27^_F$5$K#!"QK:;J-A5&/@[O! [
M$#.F!M"-?5P([99/"7VCT67/.5G^I&>3 [4E;&%D'L-W0.D9:!X*W?U/+R=<
M'GI7!_FM^\O*$*.["QZ/=!:\Q<\JD#0_]UU[^M0/M2X1M#@";\74#!YC[NYB
M?DCBNRH<,L&G!K9K#M9]^I*UYR>'Q+9F%S<8/ZX*Q"?(/KBQ954$=]^=6UTM
M)FHUA=YE$SR?R=XV;BUUDIR=:5_4)&MI7-LRRBO%DC\S_*Q:&9+.,\0HQ#W[
M:&@$P'9GPX97SO;=K=11TA(>;(PRHN_=>O"Q+.BZ"Q=_,U)*)U-7JP_$Q_-K
MSQM]6)X];GS%$XU'PGA=J#L]S1';R\*&OVB4QGO\&UC<T(Q#DZ-7V5LIJ#CE
M5E\\/Z_1#'=P@A)?=V^C9RH;$QKX$&_$'!'%E":RPH12Q# C5\NS&<C)IE#!
M%T4\2D5HB4Z4AJY,46%@\#RFLZ"2?W P-_7T-^^'?L.39MZFNO++=S'2&&YS
M*)(W8M57)/WBS?<@K>FV'* _EZ>2HNP=WJMK2'D>A;#FD5+S:$JP>^Q=-(U$
M?!5VN-_@J&$* 4'.]YNX$FU4<$'II4GP+]OKMY0_FS1M;=I4H^]^\R:7,)O)
MEH>\ITD3%#K<^M7!7L^A45ITU[R+S$\WI>IS<@_W.'JCD!(A@KG#;?%DJ4N*
M@HD4:LAM:B>R\N/-J*^&00:E^XWZW\-M.V#CZD>?A/"F8+*#/+UOR_BIU29"
MU?Q#61=,BD5SFS!?Y;=PVSS*:JB89@!805KU18:+*38E0X:$+]HVIQEB\=<.
MP-E;]/>_C(L9!D(E;\/J-_2R'R8G)RVU(EE]8 ]KAKCSVYS9B1LX942AZ^)B
MU"E3%Z<P]^$'+6V )_/-7)I!PPPHYCIV%"=L#+M"*88K<KIL:?A,MT)U[I\=
M]>?\31 T[>NTC@EUTVKBE&\4<A.TSC%ZST?K3\-+^B2!Q'%(,<172;'=@$2Y
MH#/<YK >MA,MBV6MA^JB]3>I%D<'N!,@Z:)\OK6@5AI&?=1&B!WTCXV#@44.
MPCE5D,L;='03*OF:C+ 2#=Z[.CL:IX'PR[IT$;BQ+D*&\EH4R5N6X>*!O9J<
M*54&)M'TC]?#'LWE)U,<%?\#/-:/J#FUT= +3]^^):R/-$2"]13AP>XAF(#X
M.06:)PD4R\#_5+6'-K^$&^]]=MTAMEQ>Z^FQ/M9H#LOR\%@<A*>)+O,9%7[3
M[!\@JO(?P(\*.4;09DS%(1GM[ZG^9J*#L@[MFNT7'79EQ_WU=->V%VNLB"NI
MNG/UR5*UY%8,).3Z^3ID4D6K"06[17C-F(6O49^LLT$BTK^"TB+8'$"2>6QI
M@T=?GWQ"KQGQ1U@#H>&?S_TK?#?'@HV5G/1]6MTEQ)4GP0A-SJ]96LN5,+9H
M.U@6=XYK@H<(.CY% WAZ>Z7H'@4)E)9UOC8-9C9$,7DI'UB8/-\?_HOD +^"
MMDUYM?NQGWFL[%#?''_91%5[BO=?96UR?.7^KL "M&0&KQ)[7+WD'PC?*O\%
M*T\RJ7@?*9P&5J<N#]&..K^X\=\B5 #L5%)XYV."%S57'UP)6JT]\5*+7%(2
M;/!78GXZH<%+>]HM9'F962+9F@Y1J7I)+B389$Z#FWB?X,G*JA,*I.'LVWS)
M_#C7,^]V94KKT4.OTR*ED4_N \[P=^'5D['FLNY).J".(=^2U<)GM?+@^Y,,
M-8VAKT>:D8$.JD-;$*:T!FFN^J/N)BP8=+#MVL*R-K/T'=+^_SV51*_TBPYY
M\,(KQ&R7_?CO#T_W@OF#!T[6?..[H>^[Q,\+/D,+^^Q^[+U@O\UP)VK"8_'=
MW&$B=;-N3%E&+5=UO7I$[[EJ;HG0JF!:6FPR9-H@\/C@YSG3@=5Z^&CR#X[]
M\Z=+!1'?6#ZB+73.@FE^H'556J7'=3-8\(['OZAR[S9(V]=Q4PJO^<SBQ^Z?
MKZ?O]1USHQC1I#M75V?I>":,<&%$RZO.EMK[)E^V$W5\91*D6/SSM5I-8.(B
M 'G@W=3:ZTHZUW%!R+Y=TM$NCW)Z#;6MU#CU+=B;T;N#U(GK,>EKW"G%B77J
M#23PF';%V;A+OT*! O$Q%9E_ ..-F8"N4IFU0#LM >[64BG3M62\3D0.@MK_
MGHJ=+4H0$*[OT;G5#_$W-QBLUSTZ,\O_BG 6[(EAH8.:@4;OPG>8\Q'+N?XN
MY'CX0@UL;3&<\NN5#''C%:.793DTOCR%GP%F;"R4KVR+C4-F.[_6.F9H9( W
MP/<&P(:UNT</%+]1=2J3'FR'#A0'VV'A ?"@<IM'AOV<.!F>C\@Y(*6\+TSJ
M3KZ=H4B8AIZ(.^-=\^55A$SJ:.TL^=[GRV#7E/S"-V4$0$:F!9*?OOW\>= K
MGJ=4+((E/J*C$BZZ9^8_EK99-_L0BFJIARMX1R@/KN?J<'N.>O:/O$ .4$4?
MQGB ^B1"L1=3KLX(?K98:);'J\OE]A/<$C'9]ABD"X*X63)>=WTRA0+#']Q+
M>ZZI]&TLQ%?V+_Q6U:S(^'UO@(C9[G![#6WMIQ);3509\U901$ED$>>;JD+P
MX;"^KNA2GS+HF(X>J;.?J-%DI44-8,O<]6@BV#]>Q1M>:J+3MG@?/JZ&G?G*
M6W"VX<8>P#_U?W"N&]HGFM40].#9D=F(?5TVKXK^&6UOK5/N'0J-:7>*">S@
MI=V4YPW\^T@@*U781$JA$65;PD[HYT<7CT?TR>$WV!23GZ8KL/LNR$V)K^'Z
MCI+)Y!)+9IP'?OF\JV=5::JSG);5G.>#I]*_O_T7_<1N#D%,04#,PO:9HNZ?
MN!7KK/.;SW_@8W6\-OJ99)G"[I:U2^DJ\!J_?FG'QILFAAW*;JGE/7M1G?OD
M9D'L5HE77#<6;+N5.2<[@5*9_P L!\0W+M'ELWY;1U]FM Q1#3.);-D,Z0_3
M@RCV7[VF/5&<:G;U/1X@U]\I><SI0 Z1,(3B#P[63H[L(-U,!N>L[M<*\H=0
MMN?*?"%N]I7E=4-,_78^"[B:O,A$!GT3/A]V@V/A5]-%7/3J-IZWB\>CF>2!
MNO+-RH*0,H.(Y?)"7OQD;+UQ]/X=^SK/#Y?=63JZ_GPMC*%HM9:7QNM@O:^E
MPX/OJS(?F,^QO-,W/1=^02ZJQT^L6#JV+14D2Z]1"K\MM4<4IC'XL*0%L[OO
M8=6+>&Y0G;8NB-&XK4DRXT+BH%8^-4M M&!<M8.#CDZOOCYULK"5#G#S=*<(
MGA1]?SJNJT!#8SFQ7;?P[.:Z?-%[>H<FD7GCVX>^-3?7RY<N3[Y_/)9 UKQ_
M6&43:)3*VC*;_81LVN-Y!5U!4S&SK5]41980HVOZL_GSH^P0 UYZJ3>Y9RV
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MWW@&$5/-'37A]F3T:=)E1EN4;I=@*B/@'^ 3(+QWRFR;X0/W62KIP> YQ#3
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MLGY67<(!Z^E)[&*3/(@I<"SM@D!-BA(9['FXAQ_-Q%_A3;3$^0M5K-0>HS)
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M=#KG2%X(4/M,.B/P6(2G!$LI3Z+X8V)"W"9,@_$ZV$S<0(W(H)W"JYU"-,]
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MVUN;TWO4EV8W@,W)&P#H!G#H BX_[#AV3Y??^O_0&6ZF_P=02P,$%     @
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MT@%9@%Q  : 84 :H#-0$Z@--@39 )R 4Z \, 48!$X&9P%Q@*; 6V KL <*
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MCV0?(SY>?;+\-)DMD5V50YX3E7/[V>[S?*Y<;E,>?5YJ/E*^9_YV@4[!8*%
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M^.>*/$WX_F+:7'&7[\';?S-:_T<%)&5-B:$TO%;2VB=1MX4N;>'W5&+%SL>
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M@V1(OM8HFH;A^6;DZ.#WV>:?U1,QWP)H,=8S#@P.[Z;MV6$CTS-HXFW?9K7
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M>=P,U&EIXT1#@7:JQR*[1F!>2:+R.:*4+K9K(>UB02(,S'N X4O6R7:-O8]
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MT*4?)U]_T*.;?/_J:2@;6^IC7M[ [4_K'9!(--J"\JDINH+=J[&JJC+V">W
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M]HCKV.FF'=ZP*,P(#:^8<<$UW,D,N\)$QU,<DJP4J\;)#4( @T@D<E.*Z1[
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M?\*\6&=N_-*S@]8=B4Z5(+IH2H&RYTF5: 0\S[XP.'!QU<O3H^>IV',^AX<
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MNNJ[SD'P7"9#\Q&O]1/F4MR@^^4V(YTR4NHHT+RQ<#SF]57RN*!M 7F^V"!
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MP3]D=#TV;EG!)T;UD#:[KV F)^&KO7$ ;04+IH+(EF+?Z^1FT\TPX\Z"D_O
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MG5E!R&_HO 5L[5[5/\V )([;G+FTC*NS^U/!CZIWF[!]_;06:H"#8OA=&^Z
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MA=7%I>0XT)C,\QOOG<\#.@]R-['?QW^>!!:FX+V)*C":S=UX:QC6W^(8\H6
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M%T#_59AN\<)NM(&AY0O;N/_3-/ N/X3W2DZ7E5-;A@3@+C8@X6OJ'+?:W!K
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MF@W6:S8H(NJZ _OV M@"W-_'';.\+Y\II,N9U],\[9Q3$O<>2/BLV_#8'1'
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M]'*C>9<<L8,KU?4K5=<U7SH8Z#Q)@UZ3SC2&_&!SLSV94M'M;D_UWQR@(,>
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M8E\6X6@E4"H\*>E(7>2[&P:00:8<MD)<F_J YQ?\?XT,<;+C:;D))38. $]
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ML7;F!>T*^Y3'MIKM/][IT"?0P!^RN"'O*"67G.W@JR+KM<>W(""_(W?)>A/
MOAR+2=B_7:YGEPV>$^]OH)O]S=Y#(L8-R#3DUNB^[N/,82$ZD;!X7Q073K$D
M_0-& ]9B_VJXSE?N!+$G9/,]2*O+7B3[*D2!K1=E_D3]JYSU>P,K"EE2ZV%;
M(MI6#A"4SSB4OMZF,"=1,0T&WIX.UXT-B.9**9!N%EKB; \WKPCY:SP_KBNF
MQGQ-O67>9P82 *H(&U=J&9ON<VD%V?1Q8R;HA--3?%."JVR;M+4EXOR#K0_.
M=65.=DS_V#!@8I:P'-USXDY.?_AZ>KKEG2WDA31.9_JYRL(:O2\7A\1X6ABW
M2U$K0F"CH:=(SGR+9O%7N&IRC46V&I&W=E^B5,QC+3L_?V@\:]H,EX:$]J:@
MTSL@7^%\YD&A-R:%WANC ;[>V<]HS,)($=P8$MHGW$VG0-9.A37,8O?H8E-N
M)>JMWR6MM^J?4<-O&8C%Q@M1:1,\^ !#3_)HB#^=HWTI"BI>7$ -A6!?I!N1
M]L-CME[Y#C<_RUK5-'.I#C2#N1DQ"_"<4'+!D+K74LSYTX[P4[ZW\KA81H**
M#KB-T_3/YQI% 8&=-\"W+=UB/6\/1P]G>K0Y1Q9_TN-XKX_;-0"GWO"\OJI0
M-C'A=QMZHK(9E1@8Q2$@D-X[Z+F<-]+:AVV_=:C "WH$&,D+QA0O<;8EJ[G>
MP$7TL!ZL,R?*5B-7KX/']A)+?V9_(7+XF1JH;WCTQ0J/[:G^YLG2!Q%+([/&
MHE%P0P?8GNZCIOKLZZ8<GK%*@"+6]_8/;8U):QM\U545OKM<S3V'D!GI- (G
M/X%&#SS2J6?$.*%'96-&_M2RU;LD__O! <$00OBB9U-/ZR/@O3/7 [;3J?7^
M3=.9J[/)'7!WD>GJNY2.ZUX(HQ7!UW/,5.G$!9R&7?41X,P(\U8.EZH\V24Z
MNC?XGRWE5.D??BBQ_/6*\)H#]I(^.][N?\/)]\7Z,YVG&!K[)'6$:5%B5L,3
MG.[\O=FB,F/=1'>+\Z5,5,2KIJV1]2UDM1E+O$ "G$9?0V.X.,UP1NI'"6)R
MXLD9,S; 2[ 89TF&9&DV#>+/5'M1'GW'7;;1<*B=VA"P3;4%#_P[YC]Z3FI3
MEE] 1 *Y\UVD[II1Y)_$@$0G[O_L\$KM_.H/^P749UO/ZTIQ%8(!U'7^XY//
M>H^ B**74P*F_238$S\)UF[]9ZV:"^TA:Z6C*@P"1J\K3NW8_%%%(S85+$7(
M9&-5&H<JZL&!/IH4PS$.&?>;4D^;(@<^97#!A?OU.:OR*I;+(@D_<5+&+#S.
MOVUM2!W31-V9]*,Z?;?2B'5\O26*L874TM3.4'37@!+'DL)(7VH0QY EY@E(
MG;VUC]Y0#U;_F?3!ZG/&J:J[0;^8+GU(Y=E.KK>77=;1_0\[]_/0SK;[V#9'
M5)B=>7,FGX&L#MH?O%&>0<":3E*4?!/$BQ7\0BZ1"*K:A&(,U0N)0):R6XVJ
MO11JEIMYF%"7N^V?'LFIC,._&[-6?.&+X#C7?HH!@ULQ%$!57<:Z 1Z 'TU6
MRHTZN&E\7RM4L5Q^XMI]-W&.PC=K$FX2_4?M;,VJBFFMYI/*3SH2.C5+"ZB/
MR[A6\%-YB@058XVX#!'BQ>6OR8L;/];720US:VD(S68GT#2],F--N72['.J[
M$"'^_+BA#=U+=,I>B0%*-T5\JM5YLJ1^KRN4W^.FECI)-\O^VT,R\]TATT<C
M10'*=3X2.-",'7=T&C)#C@#.CS+NN5Y?O,:=>R88Z<S//5L:,H&I1H;W""*/
M\KZ+J;%$!WX.<3?1PIPW\;'AD:%2$MR'L6Q8GU&44B[N_+595&QJ%(]R)"*H
MT<X6G:[PG4;4&-O N0L3PFV&AX^2 *TBL44E<;IOF5K\;/THK!Z8@S\S!3PW
M,\3JFRE[.YE#W-7D/IL&5#O\'5>$%>>XLU=LQIK-D"/"VUQZ,OZ'U5 @:V<F
M&+=4@'=GB#'W#7,M4DHVX,/3>A_D<'B\0!0"QD4I&5?,3MK9Q FWATI%$E8,
M@E[XKMC:DQ:R<]<Q[E/V]2MC(JS82O'GW5L=2Z0@L&.F"\8<]QZJ]O6L_[2/
M^T].-%PCFU.4@,.&7V@&H\63\%I1=]@[#&ZJ/EVJ5/N[SDI<,D\I \=I>WMJ
MMGD_X!F@A;A*82+S2FW37WY%K?GF%J=EMW I((3IF6U)BE_9J;'>;#TJGX4#
M"D?,LEQPM[Y]YD;P,9.)!ANN[?[P0THQ)*338NQ!)(!%232E(K0F VMG9)W/
M/(1UIE0&S'SFE$)=NBCDG[QNB57J=?_&>EH9R]6??+\8C2,;/&$56Y*@.L;6
M\%*B]--0]-8D++$F2@)YDI&2DV=N9DH)_Z)"1^'@'F+^=:SDE_IO8M?#D]<)
M])MQ)L@%S7IHH?GOYW-EK-%C\TB!H0R0>^K4=0P/O<L/BM([KV?LGG:[1F#1
MDV*)<UY5 MOA>AI[P>?^Y4$A>?(BMU)Z*9'IIEP#X$M;]J (N1#!<&0EJJ;F
M/7-YD "*\G-*[/-V3PF%<=TEIZ=@/4/T8<70@N<V9\F7ZXU[P]VM-V_T2["^
MWO6,%%S85DDC@+K:RF@K,;(Q]C>5P VO1+B(5U>\AA&H5< -"Q O;L!BB%;<
M][2W6A5%R@4YF=Q=/RC-8"Z21J[&FH5Q0>QC7*[>(4O[CLPE7]<]#"W=6YPF
MT@U-,/:G3=FQ:_:N]*)I9,L$&1N"!K'PXV5UGHJ4H0)CK(F#P[L)!4'?E!Z?
M(#FG;(N4I%D.@+RKSZ;4'-.&CZ9#@)J0@.<L9=;WRI9QX2.&;SI--%0(C5C(
M!K*D\"RHM7)BJP*M"RN*<\BO0",4L)6,0=)9/H[\)E^-<+<&C-2?GLE/@>'J
M:U;L246,9C]=Q"73MY+1Q0YJ^B :"CUMW&;64!.)4SQT.K32O8?D06ZSL.@K
M^'V'8(?-[$C2DL$$@Z>T1[Z6O3'>4\7<"JB70_4087O."'K#O*HBT^$]-G>*
MEM.%B7^.DA>9&2S/0W?;/&R3!XSIX[EQTL-6KZ2M8(T(5<&19Y;(E]QK]>:D
M8VU;&?DW8<Z>RA _-+7)@8)\^J\2^^T-<&KRII-6M]GFM !UIF6DU/+WJEJ4
M#XW7)!)0 ..R@R&L6ZR[=A#]\Y/)B!R]:]C"GOHN'O'UK6.?OG-@D)4JO($K
M;GCMVU*V67U;@NR;8S&BZ1X \_C[4]!3WUTH<T55\@SH30T]O,^(]TK -L6(
M(2=2\3EOJ2+E<^YEM44<D=.=5\"!T3K?/"]<YDH[(;RU(:QK<O#NX$0P]5W"
MGO;"VWDZF^8&R(Q=W5]1TZJ"89D??W]*(YPVZN #N06W;8NUMBUB\\M9SBU;
M?N['F^:.0IX:0)V=;C?XF5WZ@F%AIH'AS@!!.6JM[(!-<L!?J/%7\6>-;XNB
M,Z6Z9 I(?%OE+T:@4KS,M[A>&3N[LF7:N'O#KN?[.2L_5K4>R,E;3W(;'/]\
M0 IK4]J"#^^;S#XC;G^.LGNE?5>?QODP7=7_9/C@X'+;)R"5]/<>/BLBTCA1
M5R,I75MPJU6%7L@T-B,G0TW[.=:&Z@=]B/ET5'=94:[_Y:&7%0OT,DF<,P4I
M8[A^-DA=UO<'9<4ETJ0B1O2&VMP6I(>=P 9B.'\$Y#O4G7?,K#G;? QF0T8/
MSWW!&X.ILVU=&>N]XM#-(823O% ,27CPO(LV0BQ(]^&EH?OF_P9:6=$22F7Q
MA$2"G67&EZ 2^_F?K%MJSZ:_Q4D<V/-'.600\-C+>[+"(0XJ;^A:EJ=70XM_
M8W:Q(ZR8#0F#QSTKM+,ZI'LO;!_N^*QYR;"@\\/S"-=9Z:5R_W^NF^+R1B[T
M#W+AV5 DU&6HO'K@M^.V!G?1+92_^6Y5E,[ >2(]O?_"*YG=(ZC* "]6P?#]
MC]GQ6ZE2YY$3/$K[(C2@D%\!)1><!_CG\G;%ROH$8XGW@Q,=.%*,$@5_]3^G
M/5QIZWH$9.'9'6HD1.W$^WI&]4]@M@)$@C<@#89![AT I"\=RK^WN3L\"5$G
M+"F)RI#Y\:>X#-%G6SLBP"ADAZ[,KT[[PS?TRP[6GQPD#+00\+S/KQK,-RR<
M6#1S?R[3@QWK2BXP'E_J96"RJ.)807#&G@ICQ1WLL!,_KO 6Z@2W%Y5]+AY@
MD.55H?<\5B0+7GZM1@N(::_"8R_P$*@3H(:^( &XP_C]O*@M .S,^HA$V<"S
M[>F(Q:2L_W\^2U7!JJ@J13[Y4XS$ER^[7J"4ZX'-_E4+V^]C)TYP^?P(T.\I
M4]ME0MSKSOP7[^B9)0;N7:R?HNT[CDZ MK)R7],')4-D9<$Q"8#I(&B%&#)+
M_XXQ'.9R_G^8^GB'*HNJSRF&%V&G7>AIZLI\Q#*)\EWDT0O'9TF)V?Z5Y#X?
M5H174?E@U76A"4I"7:4L!A3]:KUT%G/R]]K_4[&W%='0+7?$?VG+,N^52R*0
M'A6G/:4[W\%W<'SA1&&ES@,IS #_ 6J2/?-KDO[&<@\VICS3=U-#XTJ)=C<S
M"VPZW6A'E:VYO@[B_31E_N!.]TI@1?[9+0+%X]XZGG\V='28W7,S1+W!?BWV
M[>/!!;_!D8$EL5S-44-ZUGBZ,0]/W5\*(?VM][DL,FXC>I%BF\\6?H0:'1L&
M11_L&L\O>%%$K#%7,O$6O-JR'F-PA)DDB5(T(\RAK920"..<DG+H-0LL6>-U
M!J]Y5'8X-^^!'7,]R;N7-J9[G&UE94S;DZV$@,"''[($#,YM$%2#T2V$*Z,;
MXGUASY2A=JJF"Y/V1WK%%4,_(8O;I>+P^[)B-7@^I+'5X=<5M@(XVTE7A@[9
M$,]XB'SI$P)1DW2M3B%=E@/:0,GDV2HZPASHNSUSWE/N2'N9(:7P>B,C0PWJ
M&_44E9H0[W<V#?*]9M]U%X9*'0<UD[]N\II,R$5?GU<>\8JB!YS;#I("O9)5
M:#YWGNDK9PSZ0BOH[M8%V+0]O)X$QMJ^<WY+ X"#M=XQ_?0W\6V*XC<9#I[J
MOVOG[S+K^"=NZFW%YGGHEX69G!])K$:D802(/[G:E9)8QJ-/>$LP$Z)8Z\E\
MLK*&/%* *70_58IBP'O9IEYC,4NE+T;13T]%[Q&,07B7'6-YE;[-'8W^KX.>
MD^ EPCQH_4S.L''II7ZFEMW21O@=WO!V&I:R57\VH.9XPAO'CU"=0K/QH@SS
M"0SZV((S,30"7JRT/77P19]JA>]!:C6W#'8/$ZUJ 1^3HB=3=H)(#C:VK\_K
MOL^WK.AC''/$RQQ1,1SZ$$9<5(R(5"B,1U7<S>NGQ2.@0O!M<XGC1-D5Y#]T
MKED,MCN7=_Z=?N7+LSHSPEBPANE]SVV7 0I+F=)7%'4/:A]F F-IUC 3\8>.
MCJ<!+QX!7)I3$8)J&A8Z/'5M'UYQ"]$11MF3^3V7\R5[X_L[^[T:L5GLAN7
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M$CZ<6R85?+V,-NG_.OE\(_ITUP87PD;K5"!_5F#P0!QA##=728/)?'[X+;5
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M73">("5$Y0"8N'5N8I2!=&8D7H*F2'*'^<V&<7_Z/>QQ@Z*\13,;4N$5A30
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M[QD94XX9'QTPSD^0(A2H+ I)8/ &_'^N:C1I#?V>+L[7&5!9=;>/U_[AQ\[
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MC\7B.%A\JV")Z;E^78+3FL:Q\@<74,"Z'#!Q![@DSV6KAUTB>K->K,30\1<
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M/KQ&G<A^CZ+&SF&PT)?$,_>/K[H<-!21$DC+F56F5]-;&&6"<IDI)-*%NE#
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MN@U'_4J,QB#$W D"KXMLLG9Q09S#OYV.$4F0SS"M(J0,VU0-I)%>VMOOCK+
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MY*^H$G=^F&0X:VMU#A:R4X:HMA-QV[M_YAAT\)\\,"LJU]:LUT<=>(_)U>#
MD%BL3R0,IL<+[VJ%;^Q4)/2BT%B _O7 839%>9F;KXBZ8(VSYTBLNYOAP%48
MRGE9D*;JMS'!A=Q# )*5=*'?C[E[J,$-LF<ZNPCL=:UZ(G[E]]N7FOM("W5G
M2\Z9EO)4@:Y\<87WP5X_ ]AH?Z1V '.*?U@4& Y06!9VM4L)Y_C7.0LL!6A=
MS^SRS:\(M.@-;17O.6%E"EW)7W^R00H5^*ON9=E?_) O3$EJFKTOP"&,!;+(
M^+(@/V),F2+E]+=3].+CQ$ [$QW!^&OYB24625:7"#K&.'+VX>;S#N3X,K.:
M4)V>F&"\.O]LDCJG#WP#:J&",U@^#JEJ+J(MN^/:M89'^DJ (A*2GU)8!_<Z
M4":T)01Q9+D.<JP0E-;&>]_-?<$LBVUIV>RE5;%#&*NRD,-GU+&2Z'H7:,JR
M*3H97C6Q!C!HQK>ZJ15"B)LR-/!H3>^$QZNKE7RYXDMR]$;=T'N%[YI!%-3X
MS::G]6ZU]?5I^B*][ F+02QLCD99AS(^EOPA<3-82!(*2I1*L#3=,(@X!?.'
M>:-*-%S.DXQQNAS#(N)T\O@0>K>NA@>]"&R\?5=]?;DCA:6$]8D"C3&PK35A
M'1+[0;H@L2PO]KXM5I(F!!>25D;:BK'^#"!4KZVK*?4DV7MT';\M:61?0/W\
MR09%1)X:A'!;*<[2E.S#"&S:CRRF86XS6)!#^=[@Z%89C%/E:J)$JT"],,E9
MUU2%IZZ"%B%ZOY>%^>\S)OP,09LI]WX*IB8L)T1<Q?Z()L-#HUL]ZSF3X?R^
M:&1+V)!PA'5[[3&5"S2O39;,:972EX&E <CX&_I@%LU6?[!@0L6N@UF0*;*Z
MU?VUP$,1K<GS("X5Y--,QXSZ%%7U4!Z0F-/KE1N88T>T,N7Z:38@;B(E]H1!
M1V+9FH*Z(W<JR*/V((4>NT.OH9.#Y$T-DVP6RP?]LIT>5>8S%)W30]:(S\1J
MNSYPV#%V/<&KC*8\Z<'!,.<B4YX]5%\W3/OK=P:;2I6RK^.6SD#?V R0O]T(
MT[DA+0@$P?"^E C7CENDUZ$:I;BL662:4L04,HJNL"HRZHZPC,5\ED0'_';]
M0B_V]#5HE?@&@K-,%/T.G]D/WS *E?&M4$N_U=Z7G@ <3 'WW8CWKON&2G[W
MT#H"U49M$PI:9:6V8HE^8@.]J=E +JYYKA$5YDCAW^E![C1$0452NJOT,=5K
M2U"G&"QR-U7'9*.L40X%0Y5(1H;Y@Y6XG ]Z,--,D,UHX5*$=VAMJC3-VQ\5
MT"7Z"DY*B$,*4;+=O#Q!AZL] Y?*70TS;^TXG9Q[I2%;^$R D5155>/2:!H]
M+?OO+;@752LW9=HL245:D.V3=JVL !.M*D?85UK\L8?PG0E@;%VCZAP^[\8]
M-)-.(%EC'DSHBNOQ9I*>OD\HSK J#: F !FZ6Z" 2L3/2OC$ILT"E^%]X\=H
M*#\&\6_=V?&,M2O:$APE=$\&QC\C__WZQ\9-TQW1O+9HBYW>2Y]Z\P +(#6)
MY[2G;AC;A#BR=,) OWY(IG**5LC4FJI0A\1VX03LG8!7\LLZ]\"(\(*3BK@8
M?$(>4Z0[L;NZKNA]^<..P7X+OA8=KYI'K0DW92M#>3<RZ<S__+#;%8S0W;DJ
M*-IYL-3O>GMRK,ES<KJ3=)MO<;_]VY!@,N:2Y[@TDRNS7=_^S/6SMOGY^P:%
M*=\L759U)JW3):%]BK()>O4/Q^2-PN9K!']I/<8,G@$OS^6]\K='*Y5:P.:M
MSGL,DX"]>O&M6M! V8"F>?!ESN_^P$;8G)U=V8B'96'G*5'4Z\0RY>"JM BK
MLJ$WH(9LM?SU]3S6QN:&?+.$/,<B4V8;XG9UR52NGR_"@OG. :"#G( O]ROC
M8K#[_Q:6_UW Z!EPBX<P+"88ROLP0N5UB#YFIODWMJ0HQ^9O^(P9%Z_[.;OU
M-+/.P>T?55W20,^GT9E;VQN0D;T#SP*S[I)+(:GICH6I=(UY!UPMB X:<@U)
MI51A&X$_A4* >3DW# \Y\&Y./ZIQILB<K]+""EQM.G__F.]S[I!%CN?91Q)?
M)->E@B:AR1^E])18:[*K\27;,<%GQP4&:H*M6QY>D27G1<4HM#)@[>)_(3S9
M& F-8U+*!-)A>BT) D*?Z!I*'3[H!C#7XE:NB+BBITWA#C\#D,/R@^PZ:5AQ
MK1;"P[QK*M5RG3_3J*2S"TOWURG;'W T3K;_!F#LW\M8!^2SI(LF!4>M1F4Z
M2$?;%0KO.]XLNMK6*J5RYRH9*68HGR'E@KT5>U"I-JGH7!LJT)'.3FZ$GP$R
M:F]0Q1^NP"<J+D52DNDFXT3L'IA[PJ^Z+]HV"B#THH]T[BL=DB&:>KA(U6F/
MH7VCPFC(PKZEY1_D(816FOP3.-^B^SFYX]K0K((P=NKP:0?D+IS?4ZZN/AE"
M)._*U?FO-_0MQ2A#R\XJ,B#)<F2[KDL\,@SQMJC&<>!##R'A&W#N8MW4>ZP%
MF*?!INL)Z%2Z#$AO?J7<MHAIQ%766R(#J5:;CT*CQL_=0S1#C1M'@7OBA?EK
MS:E2#XO+63J:=-;WB#<A8]K&Q@:-RI\NI IIT-X%Z6(KWV>A\*]D:<D$V 6_
M"5.P3D[A?=H]7Y>V.?HZ/J+K%6!W)2Y,XL*\Y*H]7F4[3G[&&?[G[Z?>P+"-
MI=Z>CB%38Q5]Q7S^"JF@\2:1/3U<;63W5K@^IYX::DA550W;8IY#>8("<T,C
ME9#>1&8=8>&T"D!>#GM0[A)P??8JLA"B_4%66*BZA-9IJ%W* ;M0@+7JP@&5
M[9+IF ]+#(4Z*-C_'+4LSR&MDJ'()?&IGZ'4K*VN_DTAY:%*0K221B2KCGKZ
MZOT"Q&2M*+$F4K8J_VG0D-:T4NRD3E>C@L4J098[MII2_S#TVEHC(%I7BHNO
M(7VR8J"S714I0<(%;F4,1,DMSZZKLRU?A/DS "))'U_MI57.Q:A\<*Q$DY+2
MGEZL6IM9]J/!1N3BCJ[D,7;HR'BXCDLQMMU,JVMRM0^DM_55;RHM2(5R&XL'
MJM0VD,'WA=Z_UZ5Y<A!@\Q)TM<AOD2$4)Q'^AE">>*V0)J%/R6!34ZX*9P94
MJU1IGTM7X/B<-GQH4BN@2VP,+>O4=,^CC\ERC--'X9BD'.<06)Y%(\Q%X:VH
M2;,T80=T4;36'SS8EZO\4@%J8POJ7P>'Z",X4T)6JA\J[@47WYMI?FDF:-C9
MV,:FJ-E]@<2NR(3EXHO1>.7B]J5#[/0W.$4\-.7UKY*DJ'LREZ>]V9T!2W>2
MY'8-F>.*V.]JP39D,CDZRMN\84_+$^Z=2H?:O5;*6',P8J;Q]"%W+OM;2/8V
MWSQ /2M67;5F@H54GU"^70 3RI%6V9&F^:L@\;@IW>5[QW_6(H<,__[-]V:Z
M:DUC&K_:O.['^91:V8Y%W*MV J!-!!>71K8(ZN^06$VJB#ECUEQPCT$K3HV5
M_WQ@&*.BO_?1DLI4T\*[>!LYEE3T']NGXZB'"<9U40E99X1..*739PH'MAX<
MQ!/R4V'TN>=%U4PQ[KXE'ROE$_S7<!LH#VC4%:C4YB>Z@.M^C?[;R^C;? %C
M1*H,' #:)G+?,<61=-?%"'A-B$_ZS12(/1O\2IW9EYUP3)!W8[1/*8]BI5"]
M1E:^/A'%&RW7S8;-34#YGTQVR(*Q*CF\[[C</ AD2BR 3[]8*ZQ&HI[CGYQ%
M*? ME?SK5R.FC0[A2G;$G%FM?K;0BW$Z?\',^1GR9*4#+9L>__V8?R$M>^?;
M?SLFM.1K<GW>LI:R_+:!!+\<[.D@#P$A]TE_\7FD?'B_^<=W*C ?Y8M1JGTP
M=IED?U-WTY"B5:P9ASX>*6P$(+&VYDCY:BD9!)^SI+ TX,/#5BK7J\VF48S*
MJ!$*=]G+]9EV R1FZTDMD=8(S\&&TF0@S882DS7$S<5*]?O6W^<R9,0^XM&V
M_)M=ILII:Q>80WTX+Z3FT_6@ <D9F#P#*'>H=IB7^H'N.N2[OFB.[_26U<HH
M@XYK'&*4>$6I- =?<V\.&ZQ$Q<O0BQ5#C:M)L7BP=/CAL>8WSP#.XG]:.>,R
MG[6['S\>VFX,,2/4=;Z*:$6Z#?@OTP@N/P2IY+.+D*[.ZNG/]?D%P1+)!?/J
M'+)94]A=3GUNF=Z.OQT2M-@YBUEI-:.EISU^5-F55K@O2KJX(,+FO\Q873RG
M>?_QG'_A?W-5U/^'0,URIG\PI<1 N'QZ_F#D8'Z(!(1R@K&NO*&\+KZDMJ*^
MJM"*,L$MSC)=94NM+QV3_O'E?I.A8_%G -:G?UDW59;#:T 2SAIIID!/-;.&
M+"4RW,\(IE]O^YD$EC0Y'$1(4/16 K8LPU3CI6^]5#J(05C4^QQ.83:P\?#>
M+F3Q\7A\'+C"[2W\&> "YEH!303PNL-2;P/*YV:'CAQOO1Y"G)W+'V@6Q4.5
M9D++YFT^)KH^! *U+X,="_?+Q&8?DJ+U]GU-61.,8NGR4LERB1'5Y8K2/TC?
M?BX\;7@=^%!N.^1<O,XAP9V/Q3C=)*6,5Z_^W>4FH 70IXY=$^EB2+ 2Z\1D
MU0)BAOUJ>4*]\;I,B.0LB(O%/K-N[4&,6!7R[K^+?:J%UZZ*'08=ZK5)I$U-
M,_X6SHRD4""TM?6;.("+<9#6A8<91I1**L]5$]3S7M:#7"8,@C5<F+#1X^:6
MH3(52!,B/?W>N[?5>+E"PG.!.;G/ /M:,YH[+)I72.0&O)6V+IVNBBDZU,H'
M'.+,32!?'D"OTH+K>-VO2DX+&+ ^58.$^&26^1V5&^6R 7))K>-"="LJ7G@U
M/+@S;<#0KH%_(<L-O+@R7'Q5&/ZSP!/>>;[=EJ],?KEQNMFHKD#<CB)M7]\M
M0N9OOZF@S>6KRC=B=!1%53^.Q>*)U<'R9WNS_>;#:F]=!DLAC-/U&1#V,ZG1
MC,"U\75LLWYS*U5$8MY?=2P' S)2QX-& ._K!"0=.0D6OV*M;EG9I:L& _\;
MI6L#QJ<^O6E!0[VEJ1]DD9'IBFHP2L5 7<8^(3;#IF%C+=K\>I)DE=)=-#>L
M&]T8W9&X$N@93UH>L<H,)N<U$1J%DMMLEKU< F6Q5B'__)RJ(G5[B)7RKT],
MN*\%U7484PT3C-]$D'3E;EE@Z#J2^:Z+$W.*$'_1L?\9!9,OMFU2UK302!HF
M()*MK9WX5EOI5C4D:(4Q5YNN3)SIH_WV^VW]CPIM];>:S&UJ8T_6/KM\JDQB
MW4D<%N@+6#9G'-'[5;*NFXWZUH6N:D7$D,@02C:;:+KH!&S\]KAJRJ4'XY*_
MPJ:59&.X&6.N5LHZD13;JJPJI_LU*77DA$M6\P),-PHF::!9?!>22BQ) 7=9
M)%1L&'Y1B#5Y4LS*UO*8V!(V2DUDQ<*@S>)BW>,#?N\/TO1F4MK\$G6MFY4Y
MO5(./8X$G80;&E5C(Z$Z2"^R4+N0O1EAC4$>"5+M#VVZF[M@S\^_YEY0"=B+
MR@_&G[[?A=9BW&+M^'@VP5ZP@L6KO/+H)%KOB"F[2;7O(KC<&!3U;Z' <\&.
MB;-.*2F/($V.]E;_\AG0UEG-?6D^4Y:^;>&:] SXOEN'7XCS><Y$^V_VCO10
MP7UR)&N#>5AN,-(S &BQH 0?52='6+YF$$\1<+#G5"I%Q=IUE<W]-Q=7 J-'
M&])-ULS2KLE(6X]0,Y;.HILJM)]BUZ"\F@2+ZC).'P8]F4F^'S>U9F3GY,EV
MXN>>T"$/22Y(][AH0/ETM )QZ8"2"[\,=>D2T@2%"2=%D'"LRD$_ :W+C*.0
M"S=]WXVL/;!D:1)0G&-,7DJ78_'I8S8/\](DIL>[OEI#^TK:@PF6<&1$28.G
MIT<9?D& ['H//A2OD"TVA9>YX9V>:[XQ?7&W"OSS-"C Y3>GF $J@-M#>:.N
M!#LC5:;]2:':%^G-=.V5VH(+*)I?4X^#UM :D/(:^9^=87*4 F:U=75:.VYX
MFH>7%XM)K=!24&I[[)I675E>]?G!JG:I@J1GZX8N89M FUN*V$!:1R!+ M\0
M/<&TG2S31JQX(P:L)V _P""I6 *:J&.MA^KHR .+L'?_!\D;7CCF]D%GWB3]
M^@R@A2Q9I,I8%\.-S0!IRH6NOS*6:-@W=^B[5V0:^T3KN^?<_@QDOK_K-[?U
M^#)X,/W4MT3O!DMXKT&2;M^Z="%D%;*>EGF%K-'&R&:SF4-@KK2P.=-:<FLO
M=_:H?7&FELJ^2$GD_N#\$-#=?/-"INBJ2\FT;Q^,;XEV8M_KTG5/\HYK5<PL
MKGBJQ9I2OJLX#U^L$#9YKU ;QZU(NXU@8;Y2#[I9:F.7Q=GL_6HP8&Y&Y/Y4
M?_4,<!L "CY*",9,1;93P_!OH;U 97]\-;CKV::RP1V=Z7M$S=DF)9)"UP=/
MQF(RI=M_!PD6V5K^N)8%LX8-:FZ<9XXUC;6V=::6O?<81?L?:W%6B=HG0G__
M9Z+W:.$*.0%)[M?7BZ+_?ZW=_S*P*+VWT0\,M+G9L _8;7DL]G ^Y? QW?K:
MXY-IVD#K3F;^6LXT>=K.5\?@EX,+QYYO^HB0%W6"BHW<WTZ["H%T<F^FYH#&
MZI]>_]0#OP$SEH4?5TNJ?L)%+]C+:J^+^LIB??VWE=QB;[JOM2JG5G[A<"@I
MQ;WV//+.S-Q;R\^WM\'C_MO?4Y%\+,UFN+AUK5<"MP(6!A7ENKLDM-6!FWR^
M#SF;?8;/OF0._ P0G(M/=_0S"!,88I;X0QOS;F>(\G#B ^KW+XPJCE,!M3\.
M^M4^[59G#4),KFYU%LD/._5':SGC]K8;F@#(VGC:RN.W>W"8RLK-^$AON 5P
M^3&D'/O4_2H8>S,@ ->(ER6E+C^EG0Y4F9W(H&"*(B6LR1U&(J\L16/@%9"E
M5LZ$3 &DG9&4[3.EBJL!BRM<=0*E*\8,7V4Y+C@<2C;)>M]R;/UA,H=PUZ9D
MKOJ-/=6F>+S+OSIX>/HJ-/_E(:4/E+B1:A#75JM TW3#Q\PA8#)8D*:X"K;W
MW;X?4T=#>;-8ST%"V2?S#)@ZZ; !>Q73D08V!IB4?7\&5'*)3,]IUK'(15U@
MNUUV37)V',K:)O\5F&6R5#'I1 G ^"VX&9;7W21W/(UYT#"D"L7$(%HY;T\(
M?09H+)8.=9NWKCVLYOQ10%/@_Y3H_4JB0U@RB SCYNRTGP9-4R*7*"[(MI[O
M73UJ_NE)(^C/7E*_E(6 9FD^D;&![24&Y&^$1KX<X:A& )*WM\F#4P-6:6D5
MYSVT,)Z#_[( *K2<K$@E"]W%Y53XLGA^)CB)BL1DE\PMH"[4,>:H8I=2:LOO
MP*#/H ?*W7KO_T"Z#X%_='58+&&O;]3*^/0E!E ,HN._!2\G5^",TN#)XF V
MR@G+NX@MA?R"I90=N6V5*:>[E*OL1^+S$5_5CR&3Y?NP:&_(Z1-+9#F"=./C
M9<VS13XX9:B)V\J6&$5X[_O)NIJ]!J\VSE,DA5.4VJW[^GJ3=>N25 F.GL3*
M71Y'%BFE!#%5U!:QQ!/F%_%*B7DOC-+*/P."SG2):3LPYSA3_/&059<UZJ:(
MN]A3Z(XFZ%P?_&V]F.(HI31:T[6IZ9B.JCNZ?V,T&X;=Y/<ENYQ1JNJZL#,_
MUD <*&??8N$(_EPFB7/TPHSN:"8B2Q%F%?R8&M[9G(!CD\W\F=;A&8#YJ'U[
M>K]2+3\U+%=B;P$0T.(#G*GAGO0ZG>,-[YA?FJZ[!GI>;P;GAU0;QN?'-+-(
M23,,KL7T) 69!>6,?I\B6[;SE#">>BMP;M'><H'$SDPZ7YX*!M>OGC1T3S?9
MW8;_?2-P"^2_10K3W=I69W9&D-4TV(2!ZE(RLH25U.4>0;($V0Y9)IQHB\0Q
MXAUR7%&C0BK5B81SNYHZ2VA!=AVG<0EX><ZZ[,F_!Z-Y=D6*0KEM#'!E(^N_
MV4^\*:#Z>(U302(&A41_4OL20&%O=Z#_V8"'\ [2/U11^";NB,QN7/7.%14T
MWO4[XF/?*@'2W=YXK:(%"2<9Q]3\ZRJ5>']DHT\!&57OZ SIT24R(7I2/6PC
M*(V[R$H21:U9)B7&U\+J75V2%7R<G))N*4Q&Z:YY=C@8OWI85/_JT<C_NI;9
MNSE3"7"S/?I4W"VEDH3.4.[LLB).KW=,YI3"MZ"(Q=,I0;+ ..ENPL<5$*DP
MG$NH?0(>OSFSS?U%^!B^G3HW9GT$NNT_[NC@OCXX*+:Y;&RW9FY$@/R("5]L
M8[PMK5HI A28N-NE).]B3R:T%" LO)Z2&1^O,]$L6D]%\/UCUBH<Y<W3H5&A
M%$U'FP.KE!::%'"_?F5QZ-70'DN!,IH(75#H]1]QT3$/;HV #/]5^?Q-VE\%
M\OIB%9MAU3W\N4]K>66U0$9MS:31/8>X&A?WE*Y[HL$3BB\NK;$J"-%2F?2D
M\/6G0AYUYF%0O'0Q9/+,O3AEAU1:(E1M#6M5AJK/S\[_?N'KVU6=\W,NXH '
M6)W*84(!2[\HSG&USQ_J&;ZI"4[?SH"L$+QBUC2,EN39K=G#(NZE\S^0\=C?
M8DCW_JV&.JZ*2&$8"G\[GLS_2WS3_U[@-!=>BK#<P4"XZ&O23<XE66JO/XBG
MY_/^B='WK")K!8/!#(\A(6JTO]8S;#Z2T2A2BUBC2>NQF3!::D4OP$6-29\!
MOV>F;ZAEG/'JIAK8IO W5OKHF(?VZ&0( T>7'X")SP"&1[\#A'PEI(YA@^J,
M)/X/;JR::65^#E6"*><'](=Q/<ZV'\Z-,\>L!I1QH";R%9K[8TEURA[H+G 6
MWF?;6"Z#Q?1DW?T ?5=X\F+I]!&N3[J&W-H6^S#KPR82/;/<XH9^Z5C7$SBA
MBG+BF^A+":WNJLA!D_+E@]*FR<AHCOZA\K79(3[35EJ>#J%91>6;VFJ-K_6_
M/M.G,BQKW1M_2RT&4IR!;YYJKT4/K8VZ2!L%Q%Z* U((QENLF+&C^_>953[V
MXT%K5H%\R1Z$/=UNWDAM'JS,.(,IV3VT<1DY>ELN_]241<+AK8AUBUXH -K<
M4&FCEUB"Z$G&":.7'TO J.[HW$=VPG 7MU83C-\[N[^GR1G,SGJ_.NE\M11@
M6A=<<R!@P'RWML8!KM"#V!61F30@23]LS%!9_ICL]WSD_L;2R$N[H\*:1#A5
M"_A+8& 0UG,F(Q[HV[$E,MOM]VDEPZRALD7(74=M=0]-=18#V^W4P",8NR]*
M<EK(;[%,%0?H765:Z_Y*WJ!  T0?A\9BJO#V]6SB:S9!M0LF-[0@7 NY,<YB
MWJ*@.X8Z\V'*'_DJ;I'^NP(G4UG,)Y* :DT*-PFW#<.ODKH#!K^&WX(-,*=:
M%G/-=0NCKR":*I4HMQ"48O\\P]/S$DJ ZK=&=,R'X+NC@49RE^7X2Q;924E?
M,9MGP-A)R:K?N+I*ECP%15V2!\<U"W/'HB9IKY%U-P.'GLDGAU2#1#M5L@44
M37(=Y*6OTC:105>5/O=W;5A;I]3A175.T01X8BO1=!)XG3<(MZT$B1<*BVXY
MD,1K@B;M#WYOV"PN3^KJHWN%:OTS<<I"44<E..#S-?I95T=.+D>9'$?W4;^%
MYK%(/&2XO+%-%2H8I2<I)J.3.IME?'L:N[EMCVA\#)QY[)O2N]Z%O?U0@O&C
M5QJ3Z;AF9N<B9-DLOT@XIBB=V019/BE?(=-DU-&&J"US$3.!FQF"T[5D$L$]
M#ZA,!I+!AD9617^A89?O(D<=/0-(5B3F!,6? >+B*KFC-^0'CJ^)@^C.:,H(
MQ^O5S>!4&; B_HQ4#>#8W3Z$M6)QKFH6Z6?LRK7*=R,V%0_"7EU'70IYRTZJ
M GK)%*Y9&MDT;:^<H]5DTJSQ'/DAP]# /S]OF\F;0*>7FQ?PZ*0+TK<-(7^#
M_^3=+4Y656I*_QYUK&.ZBL\D<Z\SAPC3N;+V=,6%=YQ&./=&O(P?R.1KOB50
M.GZUT?2\S%7AT''W5G-J?<[!ES"Y[GJG3TZ;4FL#77/6"3867 N&[^=-\\Y[
M0AG/3?8PZ0L!G3EKH9MC'>8)8:J@@5&;XI-/<%C?[\T)30,..!@Q9^QU?8(@
M(FQRPVF>MLY!VB-!\NW'/UA9X&(IU6DCE%N7 F%C!Q_5.#&KMA\:MKBWVB&1
M[(A"O*[5-9!D':1[=X=.P [F(?3EXO"AM69S)+@]0KEXFG.__L"WG_= 9'EG
M8Y4ZK?@N:EM <^,QVVT]$!_/JIBN?_"/H\?,@$9)P[_W2L*9-URJS#%_PK9X
M.=JV^+0H]3N 7,4S1=G,_ QU)<W-1N,X?(L*)%*2NG+:J+HCJ 0_6A5P^-E4
MRA*8L4%CE&S8)0! R[WNXE>'_RI]_W\;D#6V!W[)0#@8/ZP^ _*2$7Y00^"7
M9T#!T"H\X!'M5O3@&9#.FP//? 8L/#P#,HY^_<F2P8#G!#T#ICDOJ*6!1Z>]
MR\^ P,%MK\%G@./V,\#'L/ZQ'I&!^ $S@P'[BY*!]48I,HI#K9?"&:>AO*N(
M1A^OOV20.X05&:Q'?[HVA&Z;\@ &/ O\W@&;*VNF^Q>8LW'[<(=[^ SH SKJ
MW\N<UCT#7-$&-YZ$@=@W5O6:0P-6J:2IR\#U&T2S<4OT4)^DN"3=EO""--UV
M2%#WXU\ZKZSP,#R/H?!_\_^> 8/@FNNG^:;"@5#JU8?%& FNL$+XZ]FT9T"J
MPF7HZ_4=,,:_F.;^CV'=\+X!6$#8[)-,&:*1=F356G%_LOH4KE;\H-Y,QW'O
M!FT2\V?;D GZIVJ]34LK]H17'/NS$!8F(\,!K?][:X8X @;>._^->B()&X*I
M>'4AGH#M*'#\2YG^QY275X)( F[F7--(($8NGP&3_D]C7ZWH_'):*($-_=6?
M]\Y@*%=NU^S[RI:T;YR**.'@LJ(PQ>*@8C)8:LN_'?T]Q)UUZLA5_>ZD9CA9
M>)_Q"%QFW;A?V]"Y96@M9%GW:>\9X/ &@:;S;^@E U>GE)(A!9<R,<^ <KS0
MP*YFT<NSQ;T#XX&^9P#%^2)44@;_$[P3R--R>]<Q^51,B(!7G]Q"AKLP'MFL
M_)Y>2J D5'*0(Q%8J?TO%-BV?!1E-70WC%"\S^\ #U5M:U('2^58A%D)(V[V
M_H47(,)NP$N+-> K,02WX3,@.1@:MH,U%/L,^-@U=-4,0XO]![R6M-X MIT]
MG3X#-"6 <8/-&'_GGN#/@!_PG$?\?NB.4K%2L>W65,?<'[5GP BX^J9*PA(#
MZ2D'OG'V'K?[&4![B8+@&KIV''L&C/_G\ \<*0K!10=U? 9D63^T5O\V'60]
M&)]+/;D%:VM;G?T7Z)OGM?\&4$L#!!0    ( .V 35HGI.8&-VL! '-Z 0 3
M    :FYJ+3(P,C0Q,C(Y7V<V+FIP9[RZ!5@<W[(OVH.[0W!W"QX@N$MP=X*[
M92 X"002!A\<@NO@[I( P=V#$R XP8-SR=[OGK//??M_SGG[WOOJZV_F]U4M
MJ555O595=S_./ZX!.$IRBG( " X$.@>= \#C(<"N;N<*=GUCY^I&S<O)!0A*
M*:K 'P)_".=/"P $@/[G_^,/#'U%:6DS=4TU.<57LD\" ,!0>&7OX@J' P#.
M+F /37DI:GT#0VKD40 .0 60 &X >&WYQDU%2T[[SY"*LM+4;YX: ?^!+F>?
M1G^B*0X%=6IJX/\;X5JZ>8"?U%-_PKQ6UF\LG_"')^ST%NSVAW_\A DL'/]@
M.(0_V.-)P2=,_ ?;_AVS_ZW-W['$'VSE[&+UA/_H[&;E;/4']SSA3UZ>UD\8
M_M43#O.RMW[[A*>?,+V3I[/]$[[ZT]?9^O4; $# ^,,'6UO:/6&N)XSAH:TI
M_81%   %P_8?L,4_8+"U-_C/HJ1=W7P\[&WMP-3,EBS4W$)"@M0*UF^=K,%@
M#O77EHZO/:RHI5V=W5Z[^ # W]?\-\+[8UOJ)R,+< L)"'#P<'+_@Z'^4^%_
MD_[X]N_H3.-O/@,1#?\[[Y^U<\T% ,&+)]O$_CO/(A4 &D,!@'CAWWGTV0"
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MW'F]3$ LTN'A$'DAHZ'1E%,R]',]#Q9=O5U^#XDT/O=$5^'GES$0L%ON+?J
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MGN)2+BI776W;+IBHSO.!1V!;Y]AQ0X2DB;>]]=U2ZA*"QE#\XJU4!<:1:L2
M%@/5XJOI&'[R:X42VOM!M+=I+7SF(\14VCQ'N'1VNHAW[S8F/K_4Z8;%C9=@
M,53/PE;%Q->5J=@"92S?4IG>F>_W7=U/>]HSD*Q>)""[>XW^S'L.?&13N(CM
M#IOGF^%A0X$RL^Y;RF-N0ZR)V%N6-?8)WF2[BMSXNE.0&1S\I)I+6I&##Q,-
M-/:^*+M\XV'SULO&^,&KH:73;69TYCOY3SFEDJ700"D#@SU'MI5"I:22XN+B
M "?])';7-P>I1MTV;^1@(ZI!KO)._!_X)B6^/ )Z8T7^6/C/R>L)Z_EX2(5_
M@H-M$F&P/<<D276^5S?J@P6"G\YHS',"DRQ\9M4AY2M<[EE5X#O=(^)6.2ER
M"!YOGRCFO&E[O]Z8/.,.[.' .;DHJ23,P%Q21+H;ZU.7B7DZB_XG.H6?K40J
M#-A%"W3,9@??#-M['H&2=@Y]_=@Q#0I6X5=ZBGS<LY;%=@_=.+KZJDHU\M%*
M^M6' I\<[M0([/F=?MG32(UN*#K./Z\GA==(#0_D,TUEJ,/Y+*HF&3[:5=]"
M#^.O6\BWGJW"U^ %*H6*W#114:5*>HC00'>W59]"UZ4?*B\"VAEX[<SSY[:B
M:[N3>AR#26'?5-B&Q#_=-^%/YJK&\,B]DW;E%2?U9)D,H-O_M8*1@)U??$;W
M_F_V(5F;+EXCY"\(FM\=[43%\DU0;-@LN%UXBRNON,ZGDZA>YQ$^PB#[/)11
MP=^**X,BK#5 +'IQL%J4$2''5"2H^T$U-8G?4PPXJAP.:!-\Z+X$)_>J;_T8
M4;=PK/(8W[3G<5=FY#%TB]]TGW'WWOCXBV8R,3:@!EI#8_)JZQ&8->(M"L-E
MP,8WI^)R3_,!IRT;?2N5+[C 5=-0)=Z82(DO=3N_"LA)#.N Y&_M\!B0%L.*
M()F=WV(R+"(HZ&L&+F.M[1,2\Q4Q@L#@B RE@(^;B5U50+2(-U56/YA:65N,
M#).)G NE*';G]0IQ>;)92 RJF@&ED9?V^%ADR?!<7>R<_-,QJ-3FI*-=HU2G
M<\$_WB?")4SC2[I#2<1IRF@QO^4=V\KD2NKK,+;@RY4F^%,%;;7T"_XI9: Q
M\N%.YLQ6C>-O,)*]O3T=[)-VGRP&P[8^Q\\3:BWV,TU%--96"M9AYS?G+SX4
M)CKHQ%0F+UZ>*UP TQG\.45G#X$!PJ]K_>1">H>;A4JRF>F*PQJ?17W2D;4-
M@Y$QB)JP]S(PF%)(AC];.SG<((C\<GS1&SB:&JTPKHZGXK_#^T 9FN9=[0>!
MH)AD#STKTF>UJH"%Q=-$^383=&@:1[%?@..^R5ECEL,A317TY6?9JUC2Q*Z1
MCKOO&N+T$TYF0^ O[^Y:7FTV( F$5=1P[.K$+IKU4!?K+OL%D2!Z$77(O@U.
MBO=T'O3^FE.:.A.K.S5?*M!@@%5:8O3="%U*_,,)_+0ZY+PG22'[ZD/(*ZY^
ML7<;,6.EZX_ AZL@KNCAJY'39XYWSP\XALQ2KTY6_$HR0TK?:-I8C)K[CE65
MY@YI:UJZL1/9P=PRJG7(U45I[_/!W_V&CU%9'<CFDYTZ%?D*6T0],(.&MHV#
MBL^)ERY_HUA-HKT/H]JB(R@,^G%S@_M5>(S8$U%M(BXL6>X1T-SST3J0*\S+
MAA'LOVB_J/C+7'/7NKZ1U\*:P#-Z)"JQ2:0Z/R[FNH<\'IUJ-N\!0ZB)S[-"
MGK*B_!4E!09D<*\BLB(Z)RXA3%?WF:ZF(*MDD]C"[LI?9^S_E %MS7/G)/TL
M#=+MGV8YAE7CR+E@RD DD7H,0/?R=Z#?UH;W&1IIGP7/45O;HB<5AH\.3)8'
M;+PLO6PL/89[3@/:ITS<__(4F*"1M*&1V(1* $&::O!/$IV8LZEKJ&=0UT/C
MP"_V\VZF^&)^_?;0.O/*C[B?#Y:_J>V4YBTDZN#,BLR7-[/'#:240=(4=JA?
MP]IJY/&)5HYP#66LO?H D?F[%H'%AF;7 OUI__EKYNO[#A.[Z]/*ZV[_F6M0
M;/_/1V!2UDQ[G;9PP Q^-BX(7= IT'E<:VKK=]GD2/.;^JH?TWPQY-/]-W%X
MB+.SR,:NSQKQ-*BD]K+AP^]NR+IK#1;H=$6=$)7)WP6. A=R!B*AJK;,CH[T
M/G1%-H8TFAJ&]DF:%T+"O<V&;0E3 WOLRG@^(AX_JF58Q>M=PVL-?0,R-$I_
MP(TM(!*Z]UW%C.4DDT K^TVV_3WI+[@YR*;[M_O#":I\F.*IR =\6 )7'BRR
MDXB:@1AK1((7<'8.XC8L$T60,PH98#KGKEU^:S+([<=;3C*VWYKFMJ.3:EO%
MQJ'\O*^^$WXFBFY!H8G[2<^%,3A(I;A)MKJ0HLM"$,*8M"[=?; K,L CT(FN
MJ5G_0VT8-%[;^"(,K96$7-^X'6MYF:"JA_>EG^=D7YAA6!B%]C6YBK6;5V$%
MEB>*4LWSJU(<PTSD3S,_.,@HN3<#P=^$C3"[^'PMW6JQ(4)(GP-]]F2#7)Q;
M.JOSEQ+XC8*88J)V$=)=(OO"^NGLDX0'N,OI4\X'AB^?Z[V:J&6[)_3^K>^<
MU53JB+"A04CUG#V@W?DHUY>]-*<7*1,A(.OG;B4]5VM7BX#S4&--JT.NDIRA
M7MD#14KO\# M@:?&7%_TK;VELR&C?-IST]J233_-Z)/+FL3X4.\0-558H9"L
MK@X+!#+Q<8CO/B^_(<A\W7W&\^J:[@$S+K_6@J'<F^=<:'\ [Q' ,NYE%%\;
M,E.:Q!O)96#0QB...YQ.5/-Q6543BU>T^61'X'"?]_ \W_;8Z?/9U$;I29RF
MWLL9R^+]P,GT P]TI$Y1_!%ZZQ\5:;B;N/V]"HO34=G!%'@%Q/D9'0[N:F?;
M8_E1)!4?-4KYZ$*1;YK BT3=2V \+2N67*5B3//"3Q OJ*\O--A7GZW8>4L7
M%ID4H;GCI?L,P6@E379*@OMT?P ]4K<DJ'ORP8G0Q99,] W3_"9W9W=.25FQ
M#<27!9@12:P'9+70] 9R1*!=)XOCI_-9]DE:9-P_5'D?7#*]T4./0.^_B)EP
MOC5.C*DY/J^!I!DG4?I4OTQVUIM0EM324:20'HM:MM<BO7*L\BWY(*!G$]K5
MLJIOD5A,3Z-F3_ITT#)M3U;\C.*7XZ\@UHM6#?K10B"@9M*QW5WX,X9+!%=+
MV42+3E)4177UVV&:  RFE*^ -JT]@7BBJ;-,PR#=?+KZ_=5IRR@M:B9!)=49
MV-/5B2&4GH>"WH'OM% E<(P3TO S'J2AISY_%ZRCK,=0@BCJ-HZ&T'8RK::"
M\(;^EVTT3S8;&YQ"K9]@2*]Z=J^LH#98T8WC@@([;5-OJ+AVO>&N:;"^=\J:
MM8;5/M6=BQZ53D%VST,_U=S>UF-/:>@5I4*A'%8EB3*B^P -V( 8;=J1_^[C
MUBO*B)\*(R:.F_(85+RS'.U-EQ5S0ZRZG&K.5KN4O@ZO-CTGYR9&")U,A7*S
M"'KERZ+R9LA+WH,!35GVPE^*]F]8D3#HI>/SW8HJL4HIOK6W?5 PP(YCS)[;
M.CT[W^E;^VU"M)9-G%_\[<A)5.<16*)TI=*,?065I/<17G)V0F40H*+A34S4
MB889@&_J;Q3SPV="MHP#J3W$GXO%6#2%;QRKD/+&LH1<WYSC/P+80Q=RISDK
MMT0M1?"<^*(12TTV,1QFBEKR\=_TI!.[9S<H\3&J^J1-X/@\^*(X^-(4_")N
M31 'W''C;[5IHY3(@TJ'<H?2=3\-Y<#(((E,)*?G^SN\=^F=Z5:=?,+!N1$M
M/!,JBXM2[2??(4YBE$J1"QM[## G%9>+'G-FVPA\93T,10HLYTGH1_:M/-P^
M#8SL:/9?(OHSF1)],_X/"VX[J'Z-5TZ&S)"0;_K'MVP]GD'J>IK3#"^_\;UB
MS3O]6FAGA5<8N]IPHDCOX194HU#%M'LPS"460$!(V[0^W>FUU_Z75<CX^]K?
MSQ>$+4HW'P&&N')EWDR63<L'^_ U23I*[ FC.VS,ENO_I_HA$FV<^NN!_@-#
MQ2"RC-B7A(WQ@NM<$O-@:O1+0B2EDV K55>PSXW?/"'?OLRX7C9I0TUN1Z%#
M2Q&/"F^2Y155J SYKHPI< <Z7&-Y/T7NX1OQ/[].^*<'J,PEUGK?84!1QJAU
M:>ZW']S$:7<5EDPB$>2"!ZK"\%KQY8F+'Y2$$:$>0=,] 8TT(-7 E8QP3T'
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MP1@)"%7=/J[A5CX3F:=0GNT'AX6H[V9B445Y05P2LQ7_/^.Q%YG;&A)J[T&
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MQ6@';B!!M"?84TU/5X)?<UJ_&Z13IV0CR7,QS(9A*!Z+@S_8)*#P2_E7(#F
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MUPGI-=H2!4K,3)AQ2J!,P+_">*"*X//PH!#[:_M>-0 -9<%9R^D\71"1XC-
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MVCN;ID%_YIQ((Y#- &H_H$ [N^!05 W^F:G.+\4)R\J2BI+:==M,96849J9
MO.L/=5H1<S(4-A<#$#S@=.E7"@WY&Y*'ON^T1A6RMH 0%WBPL-_A;KK$%J^:
M/"B"!KJLD-6H\1)0T\,(VD.1D'.Q\HWXZ"[JF@B^]JCME;X5"LN7WV E?G"O
MH3 9S3R-(^>*>Y?LBKV;?>;Q_K&1XILMSD3$>V(?JZ[ QF/]D^A7@#O#=LEY
MNWF6]R:,&6J8Z)[$JEH(UM/6.RU) G0XV"?\<>,?_(+3^]1I/EXW89)*<^/\
MW.G;Y*-,6%@)L1 SKTB4D>A*E-4SNHHOXY],JUJ1OGXP6;2ALRSSUS-\N/H"
M-]1* :AWS[Y4>- [J4]$C[&)^,)BAU#D3R9N\1HY"L&D@YJ3.\FHLN5/RPC]
MP<A+@K=ZN>=)?@'8U0CWYH4D_E:,&!:WYB(Y.Q3-I4;9D"]LI\-;I44ER2$@
M0P]#<D]F+<IT"#$LB9>9;T6OMV0C:2.$12&S<OK0C%8]DBEPO3Y<OED.8J)*
MZO#P61SQ.>WI86@Z0Z7=XZ]#<1BLC,FJ>DA:RY[I"#\KG=C.-G"#5=JP(K[
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MH0[OV6U*AWW2U@*E#E2HUCS%WO(YP\EYR"CBMQ]!(G)YD'&]W4H:I,'K8K2
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M?%0DFP_P"B\K*AQS.EHM5E;'5_38M1K4ZH?^W$Z=_CUG23L+UB03%AH^53!
M*]<(LMZ?BL!1MH@O^89'*B\B.;WG.]7^@L=^+E*/V>H[O:LON\ C&"N*W[>V
M#*V_92-A;'5]W,:F.,_LE&AW0I57;.#0Q<A:QGWNX&_S+LDIB>@YHZUC'I1N
M28F%A=*IVNN,C#<<R#;9Q!.A(J6T2F#3[)KH7^%:BJB?QC[=7<]EDSY,$ C+
M_#FQ4R)_OD=H(Z$ 8GY$L#]EY3<T[AUW9!%&CX'.WX=]^UM<PHP6;1?0R,.=
MH-7^6!Q).LG"#.MM?Y8LE*"/M6Z)[U;2HM_C$M_S+:I.?P60>]$/_%FM7#*
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M&ZM+"SNP %T+-.4JSB-)&8V4W01R%;^?[59!XXOO0"PA%P:,V@:>;]7LF-X
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M)LY^W^@!Z>BZIJ1ITV_?D1>[EBU8/!>H[0(4Y:LDA+W?W#!L@.A7V-,O7O0
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MK==>>RD>WF8IO**KS:$,A=VVFN3W<9*S#D4)#)\$CLW037</,MR[=GMP,U\
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M9TIBGE=@:8N:O&C0DMRR5 8C0<KI<,M5IN_]S.K*B?,7*0<*0!7#-W)\:1
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MN45,68DG\>G-3;6-W5R:)OY4(&VP! J>'&TTGBP*GC<*C=/E@.'_?V7KR/G
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M1_WPU#=K J'PN.F'U+6KG$^!Y1"VZ:BLLJ20]]>+#7RGHW[BA#$4CX#[RQ?
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M4JIP19V>O:\%B4=DD1I8M/"928S+IY?:8^=SI<5J84>K3XI0DC?KJ92QM!0
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M*M>@@9C=%:*2 A:NB_$3@Z%E'6:?JJ7/Q1Q&T)^4C33)% N!2[(%R1=/3<\
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M/V4Q2QJ]97SKM^"#-!PJR3U^BM<)'YQYJA?Z]M,D+/)/09]2P>T"Y3!L,Z8
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M,Q?O>-E(U>O\%XXE\L"?_QG+@GU[=OP&^0%X!BJM9SN_Z7E,6YAK:\K\RY9
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M]E7WY)?59'Q4DB/8D+,JWD@G#>Q(<"#:B(P]?0I],A0.K"@G3=M2K> +0E8
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M[]<M/KYX!M@C&YH#K.7(7-:X5'MBP>.]F"7%4^HM+R--Q0LL;2D3"P">]\^
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MC",D8HGON+**AW6NR_B DS3?V8RI6DT4WU:*[8TT5Y+'7CAL< 8#EJLZ^=6
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MTNY@\EN"=M./!I=VZ<86/+$2/?9F\L-TJL1)\I=I4ESB9RN$O?/C(%E)P*E
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M)?D%GLB;$(=PV*K<-AE(!_%_K"@;6BE$W;JCH0\--OU0_0M<WS+ODDY7,%Z
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M !B>TYL_OSYR=%PN41Q:F&79?V4"W1P N_]!=H&N]8?U@TSS1K@(EMVA13K
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M#3+0OG#$;)9M-4.\:,">OR=U+Z";9$ 'MAKF6X*&Z<$%"^4+QX:633SVN\5
MJYMKB.PXPCXIPM;V*WQI87ZX[OPN*<J0!#K7Y\0O_&LB V%*8^KPY?2M/3(0
MH;0P<NX[6/4O<G>R2@^N#G<K(P/YW=OMD0^&B'56;MMU)\=29.#<0FEY,($,
MI'B2%$9.*&C/+_H>=T&9F?J$>L2T:B\NLI"X]7^@V,A3_P-02P,$%     @
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M?W1VL7"T^(-[GO '3ZCE$X8H/N%03UM+KR<\_81I'*".MD_X]Y^^CI:F[@
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M)N ST GT </ .# #+ &KP!:P#QP#E\ M" 1"!*&#<$%$('(0+8@9Q GB!XF
MI$"*('60'L@$9 UR D%!?J!@4"0(!DH#Y8)*036@%E G:! T 5H K8%V0:>@
M&S $C ;& Y."Z<#L8'ZP&%@!K DV!%N#7<&^X/?@&' *. ]< 6X$=X*'P3/@
M5? ^^ ("0% A!!!*""N$'R(!48'H0ZP@;I"WD A(,B0/4@5IA?1#IB"KD /(
M-1P"'"X<!1PKW$LX63@M.',X5[BW<%%P:7 E<(UP/7!3<&MPQW /\.CP)/#,
M\(+P<O"Z\-;P7O"A\,GP1? -\+WP,_!;\)<(" @$"/0(? BR"'H(=@AO$*(0
M,A&J$;XB3"!L(%P@(B(2(3(C"B.J()HB>B"&(J8B5B!V($XB;B'^1D)%(D?B
M1))&TD=R0@I"2D8J0_J"-(FTC72+C(5,BRR(K()L@>R#'(M<@-R*/(:\A7R+
M@HU"CR*,HHEBAQ*(DH)2A=*+LHQRAHJ*2H4J@*J&:HOZ#C4%]1/J .H:ZC4:
M#AH3F@2: 1H4+0:M&.TKV@+:&3HZ.AWZ*W1]= _T&/12]&[T[^B_,7 QV##D
M,"PP C#2,1HQ)C&.,)$Q:3'%,(TP?3&3,>LPQS /L)"QZ+ DL$RQWF*E8[5@
MS6%=8.-B<V"K8#MB1V&780]B[^ @XM#A2.%8X+S'R<?IQMG A>!2XTK@FN,&
MXQ;@]N)NX2'@T>/)X=GA1>)5XGW#.\;'P>?&U\;WQD_';\=?)8 0T!'($3@0
MQ!+4$LP2W#PC?2;VS/)9^+.J9Y//K@B?$[XBM"2,(*PFG"&\(:(@DB*R)XHG
M:B):(88C9B)6(_8BSB+N)3YXCO?\Y7/SYQ'/:Y\ODH!)F$C42=Z0Y).,D%R0
MDI'*D+J0II)VDQZ0$9"](K,C2R3[0K9+CDLN0FY+GDC>0;Y'@4\A1N% D4+1
M0W%,24(I2PFES*7\1GE+14^E115$54VU0HU"S4]M19U(W45]3$-.HT3C1U-.
MLTB+3,M/:T/[D;:?]HJ.GDZ'+HRNB6Z'GI!>CMZ7OIQ^F0&=093!E2&/89H1
M@9&?T9XQDW&<"<S$PV3#E,XTQ@QFYF6V9<YDGF"!9Q%@<6+)8YEC16,58_5D
M+6==8R-@4V0+8FMB.V*G8==GCV?O9W]XP?/"X47!BR4.' YYCB".5HY33B9.
M<\YTSFDN="YIK@"N9JX3;F9N2^XL[GD>7!XEGC">+IY[7CY>-]XJWET^&CX3
MO@R^.7X\?E7^*/X! 7@!<8$ @<\"UX*\@AZ"M8*_7K*^M']9]G)'B%[(4JA
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M>'F!K^_/;)&H1\#@<IK4L?;JF;D%4[D[]-;7[C"]B8E9UX)J964LKBH&8_"
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M1:4N4'WWS=^%Z_0Z0%3(H^AE@05,[C5D#7)8+&;D_*FMN-;>M&_]%NQ4OKB
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MLBWOQ]$"!*:_Y0S;WC$+/0">C1OU3]#[5BFVXTNM'H]>>@EXN!R-G,+)IG^
M8+ QC1F^4I G$#&E2SFD&1OCK1;%JF](H1M:RVQ=7/-, .P&#*!?"<47<]T*
MH[IK(1O1Z*KE?='XSHA'-O]=TQJ#1<"5&X?9&B0L#9RZJ<_BEJMO::FM3L1W
M%)&/HZ16^<Y)I4IRNL._MD1BBK'I>$URY(OAV/,B6_SO3-XDXJ.RQDPU2'X*
M(=6+0@G@O+OTSO6XEECH9 AVSK-OWPP:<2ALG?D@,N CGMY!*<Q.\RI[G,W!
M7WLM43+%MZ+3805ZI;8*O.S%XR]"T_#RV*O]WZ;2"6L<V5L^;V<QB?.I5"+-
MJ5_QEAL]/F-\=OE<7 .V!R9TE3D!GQ2E:"7[\85$"7:SUP+ >XEYY$72"C@@
M"T6^?"Q?]7VEQF1+I'_/P&;)UZVL?;?^\-PQY;(<[VJ33"@V2C+SC7;9I*OR
M\92"*A92D9_G;EN)^CGQ2*&(%O[CX&0 0*(T7!QBM$F8!)[JBAU:N0O*?TIS
MR*@CJMHO$[*J>4X<6W=75)@^W\QE2^Q88>J?EIRLMQ]?;2H?O:ZDR/L)YQ[Z
MK&7VV[> Q+&IR^G05,EO.&[-R\N;;F$()9/@JM=2S[5(BV26]SU1)M_@ZGR!
M ]G]=.!VK6,]BGKN\Y^$-/3'^%6%?RT\J:$=LP?#I)5;8A2. HK%9-7%DFY4
MZX;>)6,\S8A 9UPLA5"D332C1FL"& QYDUZO0L3WTU9+#K$91/3!V:RT4(?[
MQ[,@[_:3VUBEZHZ]^<OX14EY%^;4'5P4+0JID*PGHY- #PHS$"[FA%,(?M.B
M+<1J#;PPED@2I3-RW34Y<:LI+=.@NS4_8=YZ +R4\372^AB#1*-S8V):2P\*
M47HHA'LE5>S->UP>'77YR4T+\BK+8QZ<A,%DI4Z4\%3DC)23Z\EN:1(3<;HF
M0KK0WTO[W'RP)(Q'_X<9S6;6,[AVO8M^9 3:CF<^BSFCVUR(3*>-MV0O85!3
M/Z-H!BH5,:^,9E,!40SYC-SP%;I%JY90EMAYP\"(NY^CC'*?#] &'A5406\"
M"NN!D#%_)4!AL'?$7O:]Q3[)3_7O8;9^6 ,;-EN+HIZ?= @;T&)#PXS669=P
M'0%OV$2N[M3!G)2FP"!<F<2XFO]Y5.SY--V<NHT.6G)H[ &0<.Z&LS@>B*W
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M-^T[H'&+0;.0I-IIZ ;ZHL:@K1Y]6JPX>5\\_:J4E,B.YVK'^8<L%IX&TSP
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M&-LG7L&LC&OSKF,MSH6/?O\@U7'8L;>F%T:E,Y:F]ZP++B6]X%]##V]%U>K
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MV/[G-NLH.D-?E<I\XNKOF\#2@YJ,C[8TI81J^:Y0!H>4VD>MZ[R)1!RP;F"
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M5J?O5C-PI8NI.G7V)KN"P,)Z6YL56]>_=-<EK)1]4VIL7H'S4WI$"W'\=7'
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M^A0C?(;68PO24A_C7+2,X#$+I-V$"X5/S8.B@&0$D3-^RM7"O"L+!U^]02R
MK53\B/7=>P;772*GC& ^'@&,RM@K%5KLL,J<X]$G0=Z-/:BB;'0,.LNF77.]
M)!$V[M-MX>9.RF[IKDH,QN[4)P70U]GW3=C?O-]VBIDLI9&+W&6)W;#=-DZ9
M^Y-R 1P\0]%B'CL\O:(0+#H_XW5PIUY8J!_;^.<2Y&/D071R4]TX=KT*8C"5
M@;YWJQS28=+5UZ2VK7&#J]6:JU]Q96+$>7OWP;NPE'7Y+UHSA,#-*OM;A*^Q
MN01IJH,W9Z;%ESYYS0 VNC JRAH!D93N&R@_FW'W\)_+1LF1LOUZP%H=]K?)
M/>WM6/#5_4C@Q<5[6GVF)/. ?%M3\=)TD53FQOS6]1(O!12!%2VA&?W;D-4'
M /_8.$L:!?P;*M,9W:W:D\+2$HYUMZ834N _N*:D+J=Q6""(=<*<)-W'E5>.
M!J7(]]/&(';%H)9V-I KYI'@E8"82&L7)7$!S:GQ%_RZ3%.)4U0D)&@$-HXM
M(]B[^EE!66"H?G#X$-I(6X5%,,O4J(WS69U6;C;A Z"AD%0N,WY2O'CDKHT,
M:-O+CJVH9?M[ROH3T];KSB=2[0R>B+IHN^(' "^_J$M-F*;'L-Z$?4-"N?I(
MO.GU*RLKOZJL,[_2P1Q# 0\^R-,M!;^I=+>?"Y]CA6KMS[=6DRM^/H<GE72-
MPPL<88.4[O>BH2]HK=Q.8#Z9E%"HMN;KCT*]CDJQ5M2"4)E7']:>XR2?G-[8
MB,'.79?XSE> ++*=RO@,] R2?/[BS75TZ3NU-]JV?XS:=))CK=<OF-;Y3H]$
M359F"9LC"@HROT"JNAD<X&UP <-'JJY\LXOYXXZU S;FQ%WIOE3@HL&)P8GB
M[G4#^NB]D9EF@]@G0K(>/_PMB'7%16?V]YX==W9H/P#RAHQ=<^H-/U/0S7S]
M-L-W%]_ZR?B@7WDLB91([=N :@D["<"7X%SB_+7"T)NMK15[V\?:QY[L3DQP
M@&YQT!_]3^RZ&4PSI:<_])FR3A1I6#5-Q. _G75*#GU^D_X7,Z.*^"24YBU=
MSYY51=8\^@?M!4%@W\O+'PX^NZU/IWL>[W1^-B^ZQFZ,NG=L1V U=[ $^'7*
MDZ<P^*GHM_S((E7[V>6E]KD1_E_B/=M\XY.1ZL(OYC>C:-O3R(K^/:;>V4F'
ME:281G>'VQZ*2"U\J7HX(OJ^<]Y@!W<J::GZ 2 ?D7!>PDB[WWA0_X=>9^N'
MXZ%Y!O.8RZ^-WUL3)TJO/GW\-4M_"$2(/@!^'!V4_8D4,Z/HY-QK?U=33S/W
M+ER)#F8N1 "G;(VWXK<W7EXQ"A 779Y+W8.44*T69I^A?FS3U2>^35-T![ZU
MHV>9](Z%3V7U5KSQF+3:*PR&JL@"O2V5YFK"[V""+$W(M(F]!KP'@"KSNP4"
M@@9YS<N?8@^ K&+5CS4/ %K/:+N2.%'M[;'?-5NA>#WPGDT,.I(O*)*Y(=_3
M5@LG\85.C94SM63Z&JO&LD+5YK?SD?TAQS[6: 3A)*;5W_=E8_X;<9O:9#8&
M]5?J$M#LO:'KMWD>V[ZC=AH64LUG[I3F_-]6.WI2$=Z&8!>PY0O62E&VY$+D
MCS7M0\$/L"0(':D!#U(YL:OQ]R/EX^JCISKA<\/V:D_?TMD'O.7:-"XLSRSR
MD,>+= MU?^2OZU]YI,WY U]'8,Q'=4HB+2&TEE=MSEM2]C'WJ]H6M\3:F; C
MY2:''!+:]"!^**W-N[1\E.C^3-,&>LNS/*-3A;#^/3[ 3PHJY@:N7N O"MM#
M,)K4I6MO=IW9TQ.M^BD1VVFN'35=>]A9B^1_<=_<72G$*?9DC:D\3,9+)OL1
MM,G=<5]*ZDYQ)U?B4C BJLTL204ZV2W]4EA_"2S.HQS=/-G5%.FZJP]#(1PD
M94O,NX"Z,)D$&Z%ZI$;=OBT/.KYD]UV)/J<&FR<;A=J3Y);ZSU[1:+T._STL
MH)"TA^^\>3Z%<8[R1CR!+KH4%F"H"^X6[TV14?P]ZR%12U0/!DLH0CC524$Y
M:4=[1EVZ8QSYW1/JG)G,962X?1LLWT(V< L^9+LRF=3.Y!&]"8\]?Z5!%PH:
M]OTE]!:MNA%7% G<T;M2]P$;$J^]ZS$QRJ=0IAZDC[\Q4W7Q1\F<5XPLN7>U
MG>?!?%I-LA8P;ZZ$@%]_KYM W!$W;*[]#=]+G2:U\N$4Z=>$FGR6Z:IRKY"O
MM< ?(P6O)3[^E-*^/&?[7J__L5?Q'3W[O:^)5(K"&X5!A>\+V50<P>Y7S'_=
MF_]%NK:\M9D^H96#;;:"[P)IDFTX! F'W.+8,+V(@GBVD@B+NS$BO;^/SV6J
M%VAU.[SL:7 \*PD9(MW,A]YSM'1>*B!8[=J.=$YX@Q!7+CL:[2J<;!*<8M*A
M0D9">,E0 ^WO8;KA??*(=Y^?7K*N_SZ ]/"_$'^-;^;+?L7$7%OHU+%T</"*
MR]A? 8^W(S2M,N6&D?@U9,"C.@GL[BXPSNT?BK269O5781CF%\,[Y1'8FQDI
M?#2]MD84%LV_X9E/V/S^K:N&ZU>7NY9'^ROQE<]#:=(6X-),5L&:L2@2GET,
M0FV8-R>_=UHZB4*^%9L==J+T/)I:-37MAR.':G^QWB]-$;QSOGY/(N[(905B
MZ8F 79.:PA8&CF#TO<0D3@^IBU9;9+IK?V[ C90S]!+2J2<.R,NW"U4GZ_K"
M?L :EOXHZ'PH.UHUGYMM#R Y?7!MB4MP@ W"CBT&=7OQ+YK^E8)-4KAJJ5,G
M897VH/17,8<JKAZW[M[*)=LHD51(RD<2/M_<F-<<%AIMI!"DC_B-B%5CX+*E
M!A907:F$P6_J1HP$:&RXM*#<=6G7[O:5F%EJD.I&:(P^K;^?2ATL7]>C91:J
M0O6GD PI_IZ,DI8\61@G6OS5LY\3B\[-M033BE'5&((KU\JY>R]W#L=SF[_#
M%.HR)?YL1[!'DHNQ0V[:-V]X8@TYS?&0S:HD#%1U25^>YN,_,X#!_XCR5J"1
MUC;C6,>OXI4(^0 I/1RZ#8AT$HAW,31KB E[>ZS4*=3\$TD_\Y@EEYA_>U'.
M7>I>(:_?!S<K>SLV="I\&RD&%/+(]7: \T/EM12FS6Z*HK ^F.:3GYVKN* ?
MH;&.K](? +5CTY3OZZUHJ?A\1]_&3*]<GF2DB9G8%"C*N:I_;[0?WU[/31:3
M.IR<3)U&>W_%[-E:=8=FKA*\B(8"6-M;PNF=F\)V',OU^EV%RAS0]3FBE;,2
M4(5DAGY'VE_.1LC'!^6WRG,G:[ ):<I.4P;8=A[7HH&VYX%4+%6+:@PR-(6_
M>;URGN;'J78/9C!H *3ZK2:)>/!Y@5D "9FZEX4U>6^?9-<GX48#Q7'&J)CF
M#5ORQ_VFBGI9SXN8TGIEC%#GHQY;6<N=AO%RN9Y:P;@6)?)%:=/V")A649[^
MWX^!";3^2Z+I;J5)#8=<E0V#.M-<D=GM,M'#%K8""=(!SR..ZJY"6'!QE 1C
MLW&&E_LZQAUN4H&3^FQ10I[C!$4W1B8UF>9^RXCUWJ4KASW-BC<1=2^DIX E
M7D=B0]8G^'D+ATZ_:;W^NP%J.^[W0O=3#X!7OXZRT'[])G^^G7>3%D'M'@"X
M7OBU[]-J:55(STOW_'_.0(9V4C9."I0:4U8908M0==^+Z?^;86U7HP\ D9&D
MC/5>CXNBMRW$B9=J^*:9-]-1B6LHO+W#F4&=/TOYWV9_-LK4UUQY+\^?W!&G
M"C,@EE=+#UK5:U/_O".ZY[LNB,7$(J788FI5DZ]")=^=KSM^_SCU">?=M%E7
M6&ADF=\$!_V)A*:SS69N# 02ID+Q>B<_5'G=<@+4&?JIOOV9P>S3WEJ)<H+H
M25=B'F/_SZ=;0K1]Q,%DHLR-.7)%)U-$]<(-AF5@]U2OR*\?QF'9R6)7W,!H
MI^4"%*]->K(*BBI.9$\Y?&OK?ME4GS6=+EXSF4DVT8I93">K,9\>=,\<)(!(
M*LY9@5+A;[@:EQ?9O=ONV7?XB"FH3,_CF05FQ#:*4!)O\^(]?9UB(Y A&5.$
MJ;M:NDK.1U5\HK;LU>*3.V]C6B-01J[O@3#L:.DP?XSH73CIP>L]QZI\G:J%
MGNO\A#/.#[W?^[QG9X[W^B5%+W]_\$!\M?C5L2/L*XM(7[1Z;9D>4["9ZV7X
M<0E/!TRA^>YY/$)%Y4=M%7M%G$2""6>0_E-MT786\\F[HA+JX;F#1+SGTCE$
MT#.7O1NO[*184FUVS9G15WJY\$_Q"(%GJ)PLS1^PPVT,TSG;7U$2O0YPS[P[
MW8J?U-RXSKY>MTOS*4O_:M>*]N3$1(ZSU[16E^]\&C6J$*W\!))+*8_FS1F@
MMB0"'2LW(R4LXOCM/X-_D.?MR!.J@\F[UB-.;GC'W@_0LL<:5JC9FQ _#;BR
MP/H-E0SO=1]\(H;,-9>*1*&AQY$F8KV@#]K&8K8K*:IX.2#OO6M0>@IT,C##
MOUU:6P'\>CT&Q]>(4'@V0!M>CHNM'2YN?U)Y)9;#''?3@*SE28U$YL.TQ]IA
MD[6:D\^">R$<(>ODRNT*(,$J#*PE0H3]1F!AU4VO6_1KT,D#X*5R([4)^1R^
MB\E?5T:RK.C$\?.7GU9N[>QS(6EH#/8'A@A&I9 @VUJBT7X N?LYYU);?;6\
M'2\%T'<YPA.NL+R'S,;A+*I,?F5_[NG^';\'<N5Z(^*\#OPR<<G#[A_+@&1_
M&X4$?1A:B;.8S"9:K)S8W0^R-2E*,F[)C\]">8EMT6L*+2J7:L_;(IY&P@BO
MGH0QKCXR%_QVUTVL+1<+^598C./YCQ&&<H:JOR#Y\F%$P^&20R+*<([(35CX
M_%</[+93@[J!&6%M/?& BB1(I.E7N*_UP9ZOB:]CI%I^'1AV1@4+%2Y NQ*J
MJ 5J% ]OF+9I-F2/2 ,[?D&+FPT-PAQ=[:+.TR?"B)G?(N<=OD<U5 \R#"3H
M(C#UO96GU3*[XW17;Q>"'$Q9#EX4E/=/Z*S_SL\?6!$$$^D&5N3-,,^/JG/+
MV@"1V200;!L<P4S9Y?Y& WKG"^#_0]I;!L75;MVB32"X6W#71H)#<'>G<0T6
MW%T#! WN[M:-NT.":[!&&TAP)[C+>?=7=;ZZI^ZMNF?O[^^H6FO]6/7,,<=\
MYAQSR<"7S_62]N3@2_VT"UWZB$L\LQZ5!Y6MW;YF@9$9Y2KSC/-%P;Z,Z/7H
M6-2ZHZ%,NVOM\LO/T'$1$0(OW%ZF '4%GL_)O@>0SZ)Z]"H* F;C*J>GZ*3?
MG@)"&!RE8K(OZMZ)!"^89)QU=UFTZ_/^6BL"?#+03ETL,VA'FCFGK:*'Y<4I
M=(C^4G1N2[**'ER862R>)BLU,> I<>0:SB<EEWVLE7GM_;6Y3OAG&(6"'D.>
MAW8'J>@ R7^BRCK%-G4S(C-F*U_9,-S^B7E)Y"<]W::=!:)+0Q.WYJ1Q*'L2
MODSARPCF&Z :&S'M#6"Z(KIGX2<8&M"E*D[)$>AS766O4+R IZ$@L,@$M-?*
M17<Y^.XM$C"KH*C79;$-KAW1IH-<\*2MH.K;-?1YX[)=_S14K"U,BUODK+M9
M_NI-&<<+*K2C9&?H>,+"VI_I')#L(A2K/JS6$L; $)UQO[V6X.-CI,[Y+>+?
MZMJ6\;'CCAT+#Z#]5,)4(# GI0NJA8\"A*=2S_U\]_KQI!7?OVK"WT;WQC))
M.VC.-3[\0XJ,XQ=_ST]EW1I-#0)E'T0,SP;*(ZN:.NR,CY/KBB:T=7:.J[@_
M75*DL\H09RWFH.C 2X^A(]-E#B/$07YOGGQIADTUF\JWS76['3D3%-S+!.&]
M:N1_[2JN?6J3$(6]F\"6T9NCW+8+MA$(VX$;T6OR_PW?X:8?=V62A=K3T:H3
MAM+&R4@@G);U'*%3P[D,-+(64FX$H>_YE2.76+UO&?]>&G8R;MOGL]$R(7F*
M:ANZ2E4!BAU1!/3ZY28TS=<9+*LU.HY9F@B<[>EV=&2VS^.[UG;HPT9'L!TL
M0J9UJ.?R OF-3M"=&!G_!,ZG9Y>X.RMF^PK/3'=>^0'=7+1 ^'$5PY\3Y1**
MZ+7#,<BHOH?]9>F0^DS64;_B."WEK4:X.X*8=GDMUH_U#RE*8]:SK(G:"^].
M&<;_I2AJ>\=V4N* WY;0*AB32#YD?#BTDE @.=W +Q[_;]*B<>#8DRG;U!N@
MO<\Q**A@6/37;],;X>#>MM8WP %[G>G]7_G.B"4-H8OC;)WMPR,OX4"?_?41
MN 5,]T5*__]HUYY=TQL ]9_#A)Z@'Q#T@!974I[ BWDX=8UXFL\3 YP<_KVV
M3/;;RJ%(0U,\67L5%F9A.1>'9B/W"ZIGY_^$=&7<J#G^6% 9:R'&L4+P\$ZL
M0.M+DV%J@7:O [I"6WO8R+MV#.(BVO%2CI>P&O2V=1&CU 5.;N4;HDY(C$[4
M.&KIY^\R6YIP,PTBJV\ M=O7&<<I$OGP<(*O=O.W2U<'3UD(">A)<XW#)ZE(
MMUK_LOV7ZI,&S8V1OR<WQ&H+;4)+KHPVF*##]\3WU 9VOP'R_&QRX6\$VV\+
M7&.;N0_%*K6_/LE3>43:_G.RZ5XGN1J>X B.IORV_:#3K1P$VLD*]$'[4U9W
M#C+&B=HD!@VMK<;,8?H2:I$#&LIF7.RIZ9IK>&<?^QIPIN@4A6C1*%?B5.VO
M&,'N]MV^X5V<@J7T7RG2@"6WF#6PK3-18  ?*H\+"T-ZHV)$8GN\+7"#F3Z[
ML5@,-%QL4;TB;FC4T-,3YHTD^DE28/ODDES9W^;=@L1]\UZ8F*AHH-&^IE.#
M0DRY+1#(&!);R1!'';+MP26CHD0-E9'6)'H>_(K<$]WS<K0$DM9L?K!8>O#(
M<6VYT F1[7P'!QZI$4[(4.F96&]G2PJ#5(_O!C0-,N3G"SZ8T(I(QQH O9@^
M,E:GA<NL+.X&SAWNF5.K&T@E8MVK)<)7G3[I6^/*APJ( Y)VQ,2X%P@#_LD]
M<XD4LT>EH=>7EMO#W:R_6DHM<6T._UQ&H" ;%%>7+!2Z_> 4G>0+K!C*%2ZO
M4;P8QO#QP\Q;<\(=1R&A%P3B!U:0ZVI3&"C?\M-JF^HTZH T$?7*!<&'?TCV
MJK&7*4FFA!)1=NH9KX+-B<5UBFL O RI= _![%$Z_/G,=-8$0!51D^ V<-_$
M'XN&E_$%7J5W@;6VAV:V 2:\X8WLF!%I<SSLD^]JB_Q_/Z,Z.2>]IB\C,A3J
MWOI>FXXFL7I_V,M"'^_[+#9Q0NY$O:#1@\F/HZNA30]O];DH.9VQTB95OJFS
M^@9G*-@TSM&S7>-Z)\'R-D4360GN!X?SN>[N[.O.SPUYZ<_?K%JP@;82,07
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M6!/-79KKU*&9JQP3?+I"&94XL]N5GQ>T3$V%>6:J)H#,LSP(-_5H))B])F\
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M(G7)!9UA;6HZOO0D17P7R9N7DLM(_\@NAD;@^A00X6?I%2O"0!A2FB2=?KG
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MYL]NF[>[\EPL*O'<*[[>,:1Z6/"E>:')M%@)<1).6%/8\)4D9F3<5RS&L+P
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M#6YIC@S__:-;PL-2()[DKG%Q84UEOR?*A'[Z-<9GF)7UI[!Z'I NA/K\MTN
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M,C68<7#EK4?B6;HA\!"N^X<NE<RQL-2&5!AG1&DF+ <8X,8#8_%74S.L*8[
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M ') BY  LHK*^Z7D1K+<Y0+D9>+>CP?<!17(E^J5F3&1[C>@,BH2H1Z[;&0
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M[ID"1J*6K])F7@IH:)D860[^9/%W-+25A9-L[E!>TLCO(7;HC:>,JDODZ)\
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M:#5/6<0I2MY3YHY)*N@!_0F /P%F>@)$(__5+CG2X!#PYJA\Y!.@1V0!A?-
M>W%]=QD(!#?N7R)EBV+Z*XUL!T,)Z?V0X+2QX@^(!WC&;!G"=K., 7\P;\-Y
M<UO[RKM3X7%T;TGK8?Z?3=$NF #31NUM '3SYK04NL5TD#;[(!.J*X+HONYL
MN5NV[))]U=?[Z/?OQ@T.@'M)VYRUS^]Q72M_SND1&+8%'QRNZ<7)OIGL(ZZ[
MF'X"$#P!\MT>A^Y_A6X\9('_<MV<;/2_74"IW:\]/K[\ZYQF%G<28OO'[W$=
MZF+U, "^>1D'GI"?W#N<=GT"^#K4PH.='UU/Z<$EC[K-7LM/@+-CSXW;>O!
M'/D3@+$;%61[B@Y]E-VXJP>/ECT([U\;37OK0?Y?>/?3TO\ 4$L#!!0    (
M .V 35HUO:H;+D ! +A3 0 3    :FYJ+3(P,C0Q,C(Y7V<X+FIP9[RZ!51<
M3[,ONH?!@UMP"*XA:'"W00(,@UMP!H([08(&"1 T0!((#H,EN 8+#.X2-+A#
M"!:<2[YOO7.^<]^YY_^_Y]W[:NTU\UM5+=55W;VK=O?=][LE@$!%$:((@%!
MH!/0"0#<[0-<FG;.'L[N=LXN]/R/GP#"LA!U\#[PAPC^E !  .C_^;];P=&'
MR,F9:4(U%"%J"O<" ,!15H,[.:,0 ("CDX<;5$F67M_ D!YC"$ !L !T@!<
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M>S;ZGY[_37@O F.@8(*P .P'!  *"(P* H/_J(&"CN4)0@&C$J(1H3_"(&8
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ME;:_34'=2!;W25@W]GLS5H/Z0.BL*D_BKY>Q6G:/SJJM80;[(H7>;MZEB7,
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MKLG<G@/A"1]-OXOK&S^RY210:%Y&04 =MY^ZMJI$ !DKL3JW@W0_&EA7 4W
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MVST&FU[CW+6-RXB+B(A[6%126E*<GDCI9V_':)LP'RX/A0 O?]&C:.#5@I@
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MAI]^E._P+/W[Y#A6\6IB#L5:NDU1A Y<O!CUJ/3+^(#^+)].).VG$I^9U+Z
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MS<Q3CRSOS$ZN #5<O1<R*E)YY^#,'4K8.@,&^J_8:SKKY%HR65EP00PIN 1
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M4WA5EW,L15#+>_SX8[*]3CI,FO (8+A1"?OP:W(Q *OQT.?=$4LV:*-UESO
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M728$ 1\!QF&FC#JWCO#1<4P=L=;605J*ILNO]=46G@+YY'XCT*)!&DK+J:2
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M5;KG(M0] &:YX,_,23]OI&X@3X5N.1G-C$TS/?@N2\W?:Q1:V+U%'\ROLRE
M-C.;]-'[_.+T(91,LZER\1_JP8)(]6>=@=%&?((P3:)K8\1$=03R6S'=D>2Q
MX.%*=VA,W72=HYR8GSAZ.<3I>F1A0,#/S_))H ]DLP="\)/3%SPF5D^0I60X
M[I'1Y:W$+<; #@.0N.D_12E+K":Z.]YT/N<%YHE";96HBA67OQ!=B#8IO'Q#
M\@CX;NC\5^Y=_IG9&Q+"IR:M/\L&=_R+WN'K^^3CV7UO)QI2('RE XH\33"N
M3Q=X"HT7[A+1()=/ZWCW@7N5S70.<(4I0SOBIC,$!7NC#LGV%-U;4S=4"ZY9
M3"?XA,IA<^]<HXU@@>3*RD4?).)/7Q[\_1X:\)F[05N^<NFT2@7A<.P>&;U2
MP!?H:%UPY6-L<K"VG)+&+I!03XY9&)[G?*ZWD::U587(+04-WO4)'GCLMYZ4
M2-FM#\=3E51I-GP+3O6O5U[V+]C@ORT<_!HCYCVB9IZ25/37@3W!D)3<TID+
M\V!JM73R]*U'V-R5WII%5)YV)K'&]G[W5<:VOZ8+!@3!))IPX\@\&_Y9[28\
M7RGYHU)R;;X)GM[>[NBR^LXB.4]K>4"'AH]A0S,)"^%9CI3&^S962HV$^W,L
MMPX7X>>,M.D^2\7RL34#R!]5IS*DO"1\12=8\L7/49ZOMY&Q7-6@:/)XK75@
MS8^L?WGJ\_N1"7%KF1YXSBQF%JP3FU:6[L4I6E;KYRLR13_8-\'"<DO@?ANU
MIGUB-;(Q29+G: 1%)55B<="%EG\MY/ON7K$*"DORED>-0Z,RP<AXS#O2U:@P
MNG.1;:%KF"VCCAPYG8SK8O($?ED&Q(!-=L&V48#C(AV:2??:# 9E$E>I)BBX
M!04P(+7$^NW*8N _J[?W8@VL5^F^!U#LRT]_Q\( S@-*GAI0/.\*)O0YQSR\
M+$?F=U7/UAEDIGR-9<N!#LFZ2-A6:WB.LE!>*XRE1!I'=1[I/@(48D4&+P23
MU:2I-@QX0SKK>W/DO3LE&QQ^W:RW/>S  JBD[IZ_\^SZY\DV*I]G6/65 8&Y
M?;O]L.-&FJO]_+.<"XH7AN?-GT<M/'ZRKCBTOVE/\4+^EF(^/#VD76_U?B4T
MU%:6FU@A /XB /3\AE5R@?B&RYQJ\T1&LY*G=R[/V=GV$=#[C[I!UN2N#PVF
MJ)Q3[SWE;VT7Y%;!E%G;D8L-RVND5HB(3&4.^;8/R#O\G=R;I:64-^7E-'[^
M?Y!?'IB+BTGB;JW29EO6^=ZL^KJV:]?V&@%.L.EB#CVHIP>4CW9FH&?9Z'>?
M>5H.6HM'Z#K\0:CAI9V_!MX$U>:ZW]D]^]B5"MZB-NS^V(OXS<Y/4/M[. 94
M50@P<O_6A67TR"*CNJ;)_0$9%;.!]E \#BSX$[Y=URC>&#T?SKCO&Z"GU=I0
M/[HDX:M(7- %%9,*NO(PG)]7;TKYSVT]LLU?OUFX ")-\#'53V<1"I78'-J4
M5&N:!K.0\I]"G;9=]>IV!;%LG42G6R0I+$^M?_#'P+MBW:RQ6TBDSXZ(0W^;
M:K;3)ZM%NE$%1_V$06<'?H$6HFXS.Q/_0Z\&@E]><\71^^+%IZ2F)_\"IU41
MWM%75UUO0@]Z*!>'\?8'WMDC;IZVI3RX]YEC=?:S1(8/J)&_9P@'FG5W%9/J
M]@X&Z[YK@_X'B%7C=MWI0>L_<GK[SQLT#_N':AD4%[DNBV>C_,32G*.B[Q@-
MP;?VW6>61SV% J$<HE]Q'U0+LHSA_<.D4X60\/A21!N28X\Q0Y+X3?@6L<'>
M8H1L&3QA1\)?.TLFJ'+L5^V4GRGY_6AP?E.?:ZI(1T9@.;&C(P$H\H;,H+VL
M\O7<"!92[A/@7^=C9M(UZ.&,3HN()(2'O2;=L\XJ,JM*QF6 UIDEW$HW8<2R
MM)H@6SY^=3B2\HRZ6:2=F=4^!8',]%GVBCJO."$4PJF+RIHF[')XTL_"-)$W
M]"X;W:$,>.9W"7W,Z/#J0F:#I'-H"_WI!T.C><PVC\MBL QOPG9>,;/I;(LX
M+2&!$+(NR]DPHZR^J?,"0+=A== _V'*EXWUQ)J\=TDN6Y0,/)W:]4Y2Y"+DB
MJ7BX=/_HQ-:+WR:JDUN'+/FZ6[-1/=[B^R1_9W( ;*.NJ9.?3C/W95;=0!6_
MC$*]RHRA-8/*ZDL-"^"Y(.X3%ZGL2!OV@>E2-_?+4D?1YW.-V56E,& )M3UB
MUX],JQ)7O:Z'S>-[S[K9^L"">($S;MH$%$S712+P]IJ7X LO&TBL0%5 #X?R
MJ:4QF;V8C]&K7./QM)KC@L_E7JI7UZ-TRKB_6&[.=UH7")SXC)(TRACJB]'4
M=>&LL^6K-#T'B'*<MK -Y$8>9V6*X:^#UV-U1J)\E;H=ND6:I/H9D%*[%8\U
M,D**RF<*;(VO?/I"B:4>^G&G$<[H"%>352P/<8P6XMO+X6ZQW^Z)K=P#V]7O
MF#])QAVA4A9+JL8]:!?S=\+<>+QGW'\ID$CQ6(O/(K57BB$N0V^&S,?LDG3/
M\C(88'8_FM%8<SX!G#R,N66:]"0O([UWD'E<O>^)/FY5?[P&=0AG8^S\Z_G(
MA&CHJA.Y="&N5!>D6K#!'(./R),1JKDO3P)+W(;TFY;SOPG;\Q'V4A=I9=3R
M?6$N!GJV[L5264UR9+9G#CP=[Z:L/X^GQI%T&TKFX1G>,,(U7<A/J3\9X72(
MS"%P[?G^E.'&XU3L=9ZM&Z/[G%@ZJ_U0S5V[+_.ZV)57=0I64E!0F-4;QKNN
M[>A[DC>_'.:'T::'#.K48I.GV%;DY>J:>CI5>"/K%G^WV2R$;,I27[/3&J]Y
M3"!L[4:.N>.K@C.<G[G[VPG_Z0<\B09X<^6.9 P+%]79^&H:,#(II!46[8I,
MZ$.!,[$F_;I)CL+EJQ&#5L-94@K_^.?Z,L=S%8\7XM::%E,8 [:);5SJ0A4W
MF_?FH&5Z7IH@W5S?YC@$RKQX'1'.JV8M#9KY,-&406-I/9*\NJY*D^\ SCP[
M^!LEF^"8FO#, 2MZ[\O2Q.4YP-]DR*/CUW/4F%U)S6I0?%J%@BK!K+IE<[G<
M'VQ$1F#U1]%1*IU:POHXH]+W<Y6I&/=-)6-O(W->YR7T9ON!>NKE"3IS8PW?
M75@MKYV!U$N\Y+X+1JITN;K_(R=4X>LM6';I/C4YKYK@RK4F5H.=WUB1WK ,
M8@+D!PIP9%;G.F/#Q)\,$M[J4=?ON$!;CW9*Z=!M#1E3/@J6I-KUU_'O ^PW
M/&4=9D=+2OVHJ>3<$ DL)PB2E.]/.]]II-&%6-\=U-[I02PQQK9EJ)J1.O#D
MJ1X_]3>M(U3_Q :7AEE+1B##-UJ)^]Z!2H_:Y/3-E"+Q"T.74-<9%Y\V_O$I
MP87N0'T$H42&JS:6)I]Y$,27P]['L^!)65&3+B''+'0@*2FIE#4/?)B$?WAH
M#4=PV<WT-I,FF0H@CR2Y/OTVLOP,9$?[P)ZQ/".X@638_*)BWYM_>^Q)#2H[
MV>*%C)M2ZE,3E,1L#6(D)\;,V\U!'.+16.II]68[F2LT/*,3<1@GQU=4Q/RY
M_#_;X[0<Z; "IR8H/]G9,?=!<^@^DFQ<9HB$J3$X^!KE.7$&IAQS\ .HD;,'
M_>W,0AI>P:K_R#F)%##+#'!ICC9J<VKK5K[QP>)&'%OJ" 4V_M2FUF*U3QNB
MC?T5[?7\Y(DJ!88%:9^NK!)&;AF$-5!J/"I(IT:4&4,U7T>5$O33\:18)#"-
M\4FN[^9+6 U[:A:^6A._AJ/P""68PW<?5)BG4EM!*SCTM2 ->*FB?:<M;)V^
MFR--UCLHI"=J#B^^E.O4>D/4$-_LW^+NP<S(J;!8^G77O+4Q2D<3K*D)5E4+
M.RYRC)+:0I%/XVOPIWOY491HNH<)U#X+]F-\'>'U$J>V.',?N_L8)W1<=BBG
M^DJ=+IJC\4G."%G@TJBO[+;_@L9U??TP1L[(;DC.+'7EC(V7CKNHC,AZ]1/4
MZWHE^E5!U)&.'O]K'U.65*9?ZW(Y/-8_E1"%+^[$#\J#?J+)^O'>0M/U0G&J
M[KJZ$O?30J:+"EQ^A0VMV=/K<"D4NQD==YHZ&O:_$%X4%9!1F1T_YH/PT8L(
M1A"/8H76JD<1=QXDS!$*L02]]KH-IO89*C<0,W;2,-.-L],L5(FL^;5Q&_:]
MX=TF"?FG<*;@<5I.RBEHB\2O^?'&P/*@ XE+=F+VP5Y5HM0D3 R6'_O]VXRB
ME8&?I]9CZ4GR-ML/OD?XH=_:7S!<]\Q' 1'7,,2*.+C\U2\_S-O_N$!+M>&D
M^++A.NX1D'(/?M!^!(2.M+X,E7EG<L4W(U^0,_5A7"N\Q0:"_=!I[*S6RUW(
M*]_5BW=0M1GL]K>GY3_<1?9CU_L3KRS[SX;1-]1B1OK?ZA"J/3#;6(>L(&]&
MO_8_G_>\-0V(M$\A4(7UU0L[FOYLCDH(8>8OV2G_)FN?AQTJFQ5>_!</[I_"
M5U=G$%GUBQ-PB:"/L[H]C :97H:4IS4D/>&,WDV.8_9_)50J>9W*AG8<5W(Z
ML"C&--,LY9;Q8CG9NFR)Q19^^/9;R1":/P)T$HQN#B8LRB)KE/R9*AX!T8Q.
M.)B:H(NWH]N%YE3PUP)>BB(&=R;*+5#"+<D4-)>VTQ]Y8DZ5^3(^6%:&]C]L
MP_5%X0*:_XNTMPJ**VJW13L!$B 0G. 0+-! \ 0(&K1QEP:"-$X@N+O3> ,-
M=()+0^,N04)P"]:X!;= <)>;O>N>4_?6>;CU[_LZ7E;5FG-^8XQOS?6-5&@&
MV2/@V26N,P8.IZ8B38AL@/P=Q0Z6LX)G:2JS1Q4!<D9%;5O+)%M7^/BMLVQ*
M97%AS!VJC!*U#Y8I.I86AF(A(T"?A&"@$D)%'$LS$EM-0?(+W"T:X*MB'0JZ
M#HG^]1*UY"AQIO!2$E@@P_,_H[,^K;_J#H1.OJK2F'K;;J(XI'.F)R;[] Q7
M9Y2P!%Q0:DKX@L^)N$2A,@&Z$SERVL1E\U&BHOL/90'+!6?5L4 CK&=!5&/9
MBG=Q:E2AFZ?%,W>*H9TTVNH*=@Q0H &'?@;[65Y9,EEQ1G<(T+LG_CNQ=O@T
MZ'+7!A]T*V&MG">$GN 9 XG(T\_R:HI)I&E-Y('8:1$4HO$L)/?-B%Z"?OVI
M1T# 1UF$7M,75&+W;/V&W1C)I&-0TPNP>2J2_H0@+2U;TMI,BXBF1_*V#LG+
M#9=S*XHY^&,N3;8L1,3$B17M@8]4B>;<=9E/OXBG-38]*,?G,-GN0^5>8Y#_
M6'"9M*QU%ZE-DCGIA:']-T@T5?CYHO-C7PFX=G+'MNP?UV!9FOZX)7'@9H::
M1ZN([NY?W)QIM.:AKFJJ "_GKV_6[TW$HT?[,FM67G_XF68_3/MNBSQ'9V/#
M(VBR2TUY0%#LPXC0T<";L$3HCYMK5W-.CB25S"1G-:*TZZ.=%XU,AU_#\B*[
M8IHF'_C$K<NS1.A+>)8\L7 Y=5+0569T\"3;W0G9!"::)(2W&*],W3FZ;NBI
MCIH-3#=Z';<3H\ENUDN-P9U)!U1DY]<^J)=;CQYVT)PG#"OEDA+X4Q0PCQCS
MC\Q_\Q55,(!;%+QO&D)9TA<O4G<^)<OI0*;L )BNQCZ+SC-_02R_L[Z\%:;"
MQ&<W"9X\[;P547*L_9'T#%N_1!#HQ/XC=!L\EG!T=M#@VD3)YL+1Y$(X)D7;
M??+K!Z="8F]XEI45L$;4@<<^>4W3P9?>)HM%[\LK[+SZ?W+YIK5%A?-5A!?X
M%_%?HR=;]@\C[/L3+0E?>I+B[!KNW81QA<?([8373_AG02KG=2S,P8[#(&,9
MH_ENKL::5T"5,M3O^!<A?@^C;T5%U!=2/*9BG(+Z&+-[\=E_W!UY$2C?Q5BJ
MBN<)(\B9>F%1Z-KRU*2_OTV-!W-D)EKTGTVZ,[^(^#3A)0BH!T_>)TAP+VQ.
MU)/7,B3IM4(GOMD)'=%9(2>:D6IHP6-YWB\L$!U%.N&"D 'JTL24,:VKNBN+
MB3#>]WIF>[\3[%[#U$LK6AX!1'VS@+.^@_M,\M'&WD%)*"]%KOIB8(&*5\+6
M<P+QPC::VOXG1\I5XO6QPSAJ3,^\UD"K)7H$R*_!I;MFG1<67-,ZQA9$N[O7
MA#XH"D9PU""<M%QH<GBL7.(M_5#18G\_XW0/0P38:YHE O,EG2 G*,[8H-42
MHGF<6E.1K=#X>D [1T0RAYX@F_Y<"_63"R<<S9,X7>;EU(L].CHS?$9XJ+C2
MCCS69O.Z"W@"Q!?73P:+.@]16*E2& N2)8'6?A"8#0W01@9N!,X] G1\/C0T
M*'G:,MJ1+!6U2G"+T_BU8)V234P4LGQ,HGDF_:0$U[BP(-C26Y;Y(SL9!*(,
MB4O?55I1HC9FBZ+A^4&_^E^Q9*.,_;^\$-/9$ED^H-7 <*W-HOZ-?4C?;R>T
M@5]$@/<^LZ*K;&QW/43T1"6/-'RCI]M@6A)']V6?3EM&7^J$E_JW1T#UF*<K
M/Y47.\K34AM@55BRN9T57MXV>Z8C-)M-]K5GJF('D?U:PU#6A-9*Q)(T/N5,
M0)"PKL3P)7%8;]G>TP'AS&M\%]1*]Q'V3V2/QE5[X-;N0:,UE05\;ZX]]X4&
MA48X=J'4:O',"7)N7/9ZI=[UMM.'NJ"AG&ICXS!N,\5O0D7CI1C[NUYT1*2+
M8W0I'QE!$0R1]ED+#6(B'I[_''R.@G^!-!U!&AN8ASZ@\HY$X@&C!Q+ K+AF
MEX?EY6V_Q;\F74I>^4^*];5A. #G$4!?ENU'G[GW%A @SW>)S^:HW;Q<5$XG
MA'W/AGW3=K=ZLI#YDY$[YW#QJ>;Z\E%WCY3-&/&32_BM6-KA =*AB@$##X<2
M(PB80R@N/53AX8KUQQ=^_7WEYV8>?$M>SNSCH/YX%!D@"28:+Z)]R[>3_1_F
M#J>9N 3,#+D&'G(OF&0CCQ-J&V?NU>C_EA]TW+PHG7GX,/'V7P51O?/92FVZ
M\<E,H/\D?.G\PUWZVWGD\LU_$J4)M3$KB0#[I)L7(XNA"M8A7A/ZUA':[)S\
ML@PVFU 9\[(R;-//_CM!4IBFO\^K%!A"/XI<KWO*&VZVLUZ.#BRGY$VD.S;\
MI3T.Z_Q=NG%[XSIS/9"W8FQ&IUHD=RHH)UWV_AV5 05AB?JO;OYL;?S6V1[(
M=Z-YBN(H7YSUHLSF6Y'A"NEEV6TNL"-FJ1&HI."$JI?"K]9D"+5N=S9P.#@<
M+BKA0*>O8V%;@GY \[:I: Z0!LB9,4V@-?OC'+5?+*[,[UNJ%7)L1(+N0[Z)
MR[B1MOK[]@P/LC&;[XG/_Z/U_+\3&8-E!'-1&;:[TPB[>41+>NN#S71('I47
M4CV5^&UB&03]'"6S 6=X>EF,><#EFBD2R..3YJTK&T&!95.'UK^&FG=8CVY.
M?3O+.NY'XQK!P8C/8:<@ _79@0Q;]F(9@8.80M:L=,D1)FQ-A0W3/XUCNC_W
M")OCV:11P:7W\B6&7UC7F/0FU) YYY5I\GW6U@^_>[;@V*5FT3FE4 ,)CRP?
M;_E41H,N-5P"-)-FI]24O]Z%'FLD9D3NJMI0Z<B7TGHIWF]0)\$=H^C5;V%0
M,<W=4S;3'JM(F?#U*#C!1FR0OP4,QSX;65<D<>Z\;TL1!_H247=+D!I@3'YX
MNT+Z0=K"$:]C7E8C48!;=8AT5U9]>*1<64=<@?UN64U?<T,(\*+4[J44?1SP
M8UW)^C]AE%PI+&-:T2<IV!OP2^+8WWZTI7%U^8JK+V/9V]N>PVZSI+!S0I17
M[GCM+ED04\>!2L#%"M4:(Q#SX/ *Y*"L5KV96O!NBVU-$M^WY.X1\#8_\]?F
M7ZSN25[>Q(\$.S,8][P[C@\&M9K<$$>$R"">;> )$$IU,Z/ 5K*WH;]6'%RB
MCN/"0PIEL7\$(-B4R'3=W3\LEA(;]G:\('G Z#O8S=*-3?\R&,+V(Y/&!<!
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M):$@*F%UZ7_GEL-5M,*4Z,0 NC?U U>C+=ZC^!-V;^V2T>3VF)Y'"T@M3(B
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MT9F^CXR%*N2E-S#:E:!XW";E01B38$$/7@[O@9/GEBS6MAW1\U5V&G=X88\
MUDI-EO*VB$W'*L&!\/Z\JZK!8!5^S1W =7:5CYN#X<9*UZ^9>73L]UJ+#:;B
M>$1>41YX9[.T9VMM\/[N&:?XQ[2KV$^N7\1;K*5_5L!;V\\$H3*?"XBO][3
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M^H%9(*4!2K#7E)YR 0XS831S5$ <2[_2,RQ)[O=1([)OQ%N?WYE<B\CM4U7
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M19D8-;E4.0FFOH)7,\Z&#@MU"2DA@X?FJGSP$]L*%T'-K"9Z\0:7RV1CUT?
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M*LPD^J%G<;C(%8 ].U 4\V"$OCP1P(8*$H?"_<O.1[4SB)/9BM^K)U)'LKZ
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M5?4-= V6HEG+B*9UM=#K^SF*Y62)>:=Q*KZ[5^,6"'"=MP-?-+Z[D&40=W#
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M3^)BIIQ82YNM7_!>??X1^C!M>%0O,\QXB$V:K:=ZPCB\_<H&SVJ1LNV5[Q,
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M@YX@VUC5,*7A&RI*O_QHGEO[8"2U/$X8FO4?#S4SNBJA.&&(_QDH$O]]*HV
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M71V@UZ*.AOAA!4.J)H-/&^][+?U$**U <52_UI]<G9,3I-7$-YZH265W(9#
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M "2UO+N/Z[5Z_15@_4+%P4O#+BL\F*ZLO>&L?EC:US\@$7)AL*:FC%W5YR$
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M(M3HIFMB:=)G_2U;!([!Y,Z)<LU2H.=>]4IR:4"_^RS0B4&T9*[UEK>"9 B
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ML&%TOB='G?_W[^_NNX7_!U!+ P04    " #M@$U:EOC3D.P^ 0!L4@$ $P
M &IN:BTR,#(T,3(R.5]G.2YJ<&>\N@54'5&R+MQP< WN?G );L$)<G!W=W<(
M[NX>),'AX 270"#!);A+ @&"$]P#C\S\;^[<]\_,G7?_N_Y:O<[Y5M66VE6[
MJZMV]]/BTSKP0DX:(@W P,+ 7,!< ,#3$<"B8N/LX>QNX^Q"R<7&#O!+0!1!
M1\ ?>O&G!0 #P/SO_Z<?:#H024EC%35E:8B"U+,  -!D%6R=G&%? ("CDX>;
MFHP$I8ZN'B7B.  +( ,(  < F)J[NRBJ2VO\&1(B)4GI_MP(^$]T-?\\^C/-
ML,JJ4%("_W>$9>[BYO&LGLHSYK*P=#=_QN'/V.&-A\L?_LDSQC6S_X-AX?Y@
MMV<%GS'A'VS]5\SRES9_Q6)_L(6CD\4S_J.SBX6CQ1_<]XRCO3PMGS%(X1E'
M>ME:OGG&L\\8[.#I:/N,;_[T=;0T=0< .+0_? ]+<YMGS/Z,T=PTU"2?L1
M(*%9_QTV^SOL8>GM\6=1DLXN/FZVUC8>E SFC)0< @+\E+*6;QPL/3Q854S-
M[4W=+"@EG1U=3)U\ ."O:_X+8?^Q+>6SD7DY!'AY63G9./[.4/]2^&_2']_^
M%9VK_L5G,/AC_\'[1^V<BP" __+9-LG_P3/+!H#6"  @7/X/'K@  #"?_=8R
M\7?KP?^S7VP\/%P$7[Y\\^8-FZVE.=L?@_Z-_LL&_P;]W7QL?X;[FWDH7UM:
MF7HZ>%#^L9NYLX.SIQNENXNIN24EZ_^YB?_;'?^Q'BQJEE:6;I9.SSVTGG>9
MK9/UL[N=+&P];)V=*&V=_ID3_YO=_@_ZZ[Y^)IR21P#7F UX,8$+@([& #@<
M5 !DD/<L@?F;WQ20M8 _=YXVQ<Y?]_U?".;_/2ILTI\?=UOKO_235-.@-/=T
M\_JK[,]M"< #*  F@ L0 >0 #<  L *< !_P"A #I  Y0!G0 '0!(\ <L $<
M 3?@#> /A "10!R0#&0 .4 ^4 )4 +5  ] *= *?@0%@%)@$YH 58!W8!@Z
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M.N5FYK;DSN->Y,'A4>2)XOG"\YN7C]>-MY9WCP_,9\+WCF^!'Y=?A3^>?T@
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MM0 "+.CO$AU$) 1X.&00"BP,@/K,1O@S\]^$SR(0(BP2##* @OH"@(4!P<&
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MNK=]S4/AJ(K[B!QORQYKC-.:*(E;.<_+:Q*P^\)><GZ(.H-,NO#K1D.Z<\K
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MK/3HE3474PVF$;6^Z^QP#R.>,"V6QQ-M&8.HNGV*!"*=$+>2D1[R[?$G-#4
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MQ! =* ?]_-[ W-+M^9.YSE]Z1R-/P6 (S8W%C*EL:)B??7I*6:%: QYC@#_
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MEQ;M-/_:6UGB&BTIJ9G)T^JL ^83TBR-!L* <VSN*?$GWH\9@D]&2F*@XU=
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ME=]8'DC :/LKQ:,M.OH<H:KJSN>L,^08T'D1_$L<5D<R/?#L2U'ZA",QN)!
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M^*;X@MI^!?1$^7<7L@L06] *9*GE1;%:)SZ[ !^<GTFDG)QO:[//+V"O-@L
M(Z!AFR(BW,V[&_DPB"O9"(?3J;PV(U@)VW1<3Q8+P?>,&$-[)M@_%90+9=7$
MIS]WV\[KQ]F;(G<K#GG_ST=(-1A8ZD[9@MRG2"KDP<.,9?EP(^J&J;9$_"%X
MS8M\OTXM/#SZBNBUI;B^]Z_\)[.T?_( T\.+I/^9PJV'/N6@WWIW&DG,@)1
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M';-ZZWC5:%''8]XJ^TI[Q8VN?+L%8]D/=^Z+U$1+PA"U+<7-/?LCT[304D0
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M\NF?=TE9\,,>!AL8:P&O>D4R;*?-2)JDJE-J"MKMGWMC<*UU]T'MXBWOK_D
MYR[.M]<&1_C[X3ZZRA?UA&)K;@8C_&/-ON0&$5!G1D4FC1/VMH\?M3^,7)*V
MRJ0)J.V2Q.B"0]$?D6E(&?6M-'_)-%+ABY$BVM1HFJ0D9G4I(N^DDB1(W=0,
MDY<3G^3097[CQ>V#:)W(%F'X9QWPP"H<=1YC]&OH[C5>XAS4X4TANUA2'[G3
MI^6HZO-\T;C5PUU>!Y.H3AJ-D"GH..5*19M0ZW,%KF<4N+I877'";L+W[30C
MG^JJ9ZFA;UD,J&&ER)_O:[Q$7?!QPQG#63=02CO37Q4U@?VA&6K2#&#A9A$Y
M]QKFY'F^^!<@)';_OQ+,G98C5SWD[70B2Q-;N:\ZL_50&OA=XE/'GT'U#E^B
M9U4K$7F.ET+@ [ZH4SDB2?S"J4,.!"=7M%R"Y:=PTY@>7'DUDJ4#5VLR=?XQ
MYN$A>1R2'<AR2'+\ZXEN!H&PG_JHO-RQA ?9/,O&4-HZ6%[/VCHBP$F0/B*,
M[J=_WFUD*(@@"%^:!?4&V3?YLT:1!%2*?2V!2):4N53JU$TMJ?#+.?4J,E5O
M30,Z=L>_XK\VF"F]_*.VZUHY.&]J%PW/[\AY!'IKMBZOKKW.G,$8Z=P)8TB?
MTK@&(G8*99[W)A.,%-7G6$Z\G#=L&T&:_"X6]UN_N0Z1^+)LC=A7D*R-?6)U
MEVQPKUB&]:#W0<ZV0]5'_^ (W2 )/NM@=Q"8X/A#MMEJX-5C0L"O6@%QP*<K
M0\7]8']UFS_-_LH*].&MA;GGHN]C$UE N.:H NHZ).^AZW3W]6WG(92NJ\;9
M <K<,[_ \Q#+5AB,?GNR9V'N_VR:];^Q?\'_WA-#W/07\.KX]!_TA2R$[ U=
MFJ-W#E/^ N*]7;F'[MJE%K6N^*^9F_X-M9)YIUTTW?%[NQZ2,Y?U5XIFKE%G
MV9<N9?])C?LOH83[CBUGC5+Q1>L-]N;HHU2'6&87$6Y84&7-8SQ8:=_TH>GU
M5,9 H'L*LJB?IGBC5T]O>! 7;+DSGIJA6.TK^.NJIL\C__O'OX"$NX&_@#<Z
M;U^[R+#95GO&7)6=GKPW!^'3SV.P#PA'*!UMBPBEY-OXP'KM)DR%%6HL+&\R
MGL8*C O5VRD^1-[<1AQR#K\8U:]_7/KDND,1M?ER11Q1<H4JG!E[X A);:?B
MCC;N\6G+H'+8X!V+#"_0AY?J%F;H%-F;@AA(^05.&#ZS[JPF$-I$9)/\X4WS
M3E$ )E.O]5UXO1^ZQ!)\_4Y^-;!'ZK[=6&$U(JPZ8!9!9<9"03X-*Y"-0=W)
M694L9[S2BU4W+6+R4H3"$CYSY(E'MJG%&6*Z3CO_ IX<["I^2@E]SD/9\ _O
MYC6/O,U;_?@W'TNRT7CJ:^FV6MN2\"NGEA)SF@+DD@:>;1M-5# RQJGH-@S>
M^O7J";+V$<]?>+?L)I<!%*MNVD5>5M\JH#S1,0[X)9;Y&4R([!B1=R ,!"3-
M5A""C5Z7(_K#("<KT,%RONVJJOY*NS"IA/B<Y'2[%S/WCJ2$-T'S.MB4EJNE
M.##V+*G<ZPP=%/87\#SGA_[9A+Y6^5096*.Z#FBU6IQ<&/LZ\;S7J)*\8Y+9
MS6;BM\KJ?_W<:%<PZPM=B54XX8WY3B0<5(B/1DL$4>,'-E[.G1B_3"A/A?D#
M''S]:Y5EO6^-4AW\2BG6*)S5J1P_/?6IK?9.[:7\$>9 -+B4(>FJ]#V0J5#!
M U!2]&0VZ:M[;PC(BTO;1W]%8.TU@U7L1%=^;;*4%5+ 0ZV!3!/;:K<!.*?T
MC!]'^F4:"*(N=.E?W XSL$D-S2$FSDE+OW;?K6B![%".F$J'/6$IS@6_CGS$
ME@.R*A(SC3: (]2\O*IE$^2G22'IUH):+Y0=0-NU9& 9.;JG)BJ5X7E'R76D
M+1,C_A^0C2HY8!F_*<1D_2OPO5'PLSTY&[A6H*3XJ_!EF="6J"F\DKP!P5NR
MVWAF6; ,AH"-J11U:Y2;&\%&23DPW@56^4:5FB\S->6J0:->H3;9]U+H<TO=
M<[.7D1BF\@]1(OKU)>25?E8S;] %AKZ3G_MPXHJDL:(IGG;SZBAVR_H345&(
MJ^\>M&HS<;=XDN"$0S>HYMZI//\+\%HS=1;#G4S6*TS((-6%VD0\)X]3HW!N
M,J[#\GY]SZN3W^88$U^7"[MN;L?T?ZX1PWK75W*>=W8JSN>"7[SX[DEE;B$,
MA*\23R3*'9]EE^UOGUJ<F%\6;IVJH.18-L@Y+9@V_2-]UM2R3MG-$/ J%U_>
M 0J9@;'?!C N8$N3]C*+?"ICZQQ+[\N]:XDTSNEU4B](J2@9))"02'JF3*@+
MPSDCS^A_G5B41IFDLJEDZ_V:*7&Y)=3ZS3;*);3N>461.J */VQ=PBY_^XM8
MG]XSZQCWO//K,_I ]]F#I+Y#E_T%76^_W?M3<98W3CKK<SG423U.487(3#J&
M@***6Y..<Y1/_P!PY]9!B8W1JJQ?FKFG6YU03&5;X 20*B#P;I3M)$\BB(I/
MA4XT2 #'X56H!A^(O3.$#[J!)AY\F)^GY:\]^3;+T$!NB+\&*X5YW0XFD_"4
M\(#3\[/ERE%Z]1]K,NH_O@,T-/Y2%EQ7H/^(( @-K-N0/CW;D4MC$/6?\_CP
MN)A\.3!"$[A,5%90DL;V92X36=_4\VB@]9:8D44!^<)(FSL[[(]W;##UT/5Z
M<<Q3(+XG;<J:-B-OW?.(^=@!CNU$VZ<1"8'-D_6GJ!W]69?C3CKW?*A28N>J
M./E=Y]E=RZ\/UTK>BQJS5T,I^X&Y4+[[W[,?F@+ZM+45+S YB^4$X]X/B]*,
M_ /@Z %:E%YZ;I!:G'J:OAEPB[F]?&[T]^"$27\]XE A9ZM@.?X$U!)YXU+#
M^)MVQ]?,+WN4\8:2IZ@:.Z+.B.FN2R+I(:U,^9+)F^C_IM;(;!VA.)&JQK?Q
M%Y23(<L*WYD?OI>9"UU@0KK,LO+^ F+1A9L/R..-Y:_$ZNI D[\ H]=P.=>+
MB>U+:V'&TN]T"4M_,"+_(<Q]B1P:BWO)OTG?V_'[:O8[<P#-"P=G4*R@D ?P
MO9%!?9,ZKCJ7K]6?6.^7NCK,9II6KFIZC\T0+Q(9$ [,,-DU6]S,*/U5:HN0
M\'"QOX !V<FRE]\X7)9;OZPI8#:N8T/Y)$P#I[<;IP]V7-#[$MD'3@9'=)U[
MXK,M-Y=!JSNT6_EYBZ(R+4@2(W-IL!ZMJ-[RB6V6P_&Y/*!_=9<QRZFVQ%XQ
MN#IUSI\1>T5@++T*Z_IAM)8[K8F5RTJYUC(1Q'9A@?@+D/A,6Y.=YKRQ50'C
MH6MLL*,0"&=&4DRY%"K2**,(:>4%['_V2R68+=/A,T6I/Y?QLXR,G[\-$(.M
MY.9 W%F:_P+T%:\"ZF$?]V\<"O"#%IVB]?3BNO22TP;/IQK.X-_Z9<F?CCV+
M31\/=*6'U4D3/2>_(&[]^',W11"LK9EVNC:5U/!;;+IEGDOZW[.23)N?;*DK
MR^UW46H2$LPG?!5YE5ZLR11/*QO2#/FU[G-<3M% AN8@G04 6;A*.PGE^<(G
M(%;-= (25O>&VSM*"8PP)IWODAH1%=&$7/C9J9!&!&%/X^XTK([J,"1ZX-V)
M.A@&-Z*#%%46W/*='9<K*-@;7HW!N?F4]8Q2,-^U@X3O^C)Z)--4"_B>RS_Y
MW!6?EGOMOW5P&P#D>3?:GH\Q)?0F^<ATGN)-44O#V(F L@6",&7/K.CE^FOR
M!\0\=9$'YEH* 3B,&O\,89#D*@H]^2P:EU9)!1RN.'_/W32^E1=/V-:RQG($
M'C-5UKZL;I2 ?%][BAZ27I,W^5Q3.B5O1,-!PQK;JH['T:GTB,POM*I[W>!>
M-G\ZPIMY)5Z/B#+]^CKL:]!7$9[0+[@)$D[6O$."S"+:.KHZF&YW&XL8B%ZH
MOXU>]$I%<:H=AXXR3OG3!)YX\!BPVK8LJ"!R+'\HS0LTIU!JT SP^^=PUM ;
M:&>SF4&,N#PS*7#0,LXHD5PO"8T9K^<)*H=3HKJT@P?K90R#(+NV +\SAQHK
MJ<Z$!HGZ:ZMQKS/?5PQB9;(_O-V8LJFL'MZCY>9]X@DAD!SJ.(>,&*E3:\<\
MF%! BA).;W:JNL< +3^>&J5^QM>=&JDB,@58((L4)#M$S#]X*?G>*WEJ,J'A
MCA$M!I6^N/:J+4[]_H[ <#A(*3>O9YS&NB[ 6N#7=NCO0^9C1>R9Z4&!/%U#
MN*D2833F#U:!.1'#HYW<-W&2/R!K![M?!*2NDA"I(G'BFD@:K.ML<2&7M$ZK
M'5:>O-P>JQ.JW9A 3ZD39L/^'YR*BP+=^EPZ7U[KJ;/+G>C^/!MB*$TJ8>?G
M_T3ZB=K$(B3Y8<SL2^4&P7Z_*G#+H%A"EZ$C9[E/3IZMCK;AUU!U <IAJ73V
M_.KK]"TBHF9+K?!8EM#EB=4/(T@$\ 81Z$B0JAW[;"VO*(:2C0.F+#CUD6.O
M$KXS64]1%-CK=^W>1Y<9E3ZH]&CO^I_#ESSQ\FUBN2B>]X/>8<@3WJ-JP#H3
M>LTE" <MYHA4L*F:_KN"1"9F?+2#WM-")6P2*@]#(TD-$/[%IP<5]ZJ3[=Y1
M60[$IHZ2".)KD*,9^:TGAM;%)'OCNN"W5TT7$R;(:#I#J/C1NY]@%\X?\?KY
MR-)4HV$O#%6;IS23KJ7H3[3BIEM-3T5$Z&+C2+V.Y/&U%0E"'T6?CCQ^MW:2
M>[K#'4VWULRHM&PHM1%%0Z>RG ._=C\<2]@>B!52;'C[>'XONS5ZJV3A RRR
MZB+%*,8SKG3!?_=L'NE6."&KDY+.68XATYW6K174T4;K#KE-BC!?+'YK>CG/
M6<O"L+LRS4'\&0X*?"#1"=SFG[P?\PMSG/<57]K,474DTU!@+\+5\]P\D*?3
M8ZQHOJ ;_G'>VS][']1HX6#:6G/1\<1^&;78,$#)Z+*ZXTYUEBH[7(</D9_>
M2G-,&KA,OTB=,(+,&W76A[)."]#%Y&+=19I<=[3EN+>W+G#EZ V?U$^^+1.E
MM+K55!ES$%']3VF#)09;STA5#7=$7NUYB.9I+2@HA+YL*1Y[)D*)EFH1[Z$H
M1"-^4E+Q)@>Y\\]J(QM%M">QJZ'>X^/36)Z:6D<U=Y]1Z@:2RW0 R5^W+33H
M4N%.<5RZQ9W_PXB;_W]!BGOK^G/>K[^ $5<?:XM/]HHV9Y&*?P+FHN!/)YN$
M$P]A+3&5I12 Z4%W4T\<X-()%C[G62FQ^Q\AR-[7ED#KQWEG &Q-S:N.HE'E
MEN)Y8#;^AKR$[;?S-8QMT(]4!,0O-36UR"*EQ,;(4)[,DL'CB%,M6%,ZMG3A
M+1$J)+?Y2=?X,B*E,D2BT"=-USI6G/<"%AD2;YI&RR*_D:H7D5J16USB4Z6B
M&U.+VM!<.8]&[<RJ\ZD_]W[V-KM(H+_).,55GR.F'-EF'91=,":XK3V46=P
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MR&"U^*D<XIM-M:D.@!];Q QT']M;QQOI%3I&RUX TGI\)38Y9P2?XP0[66!
MS/?XPE_P(!YC&,6Y?!:9'24^Z5JRJHU3"@_I?#@VA._2R/M]"I+%E>UM561[
MF4EE9$_1Q*<H9/1N6K,,:D7(6RWGB,A1>V9T^D>U-_WN4ZB<M)XF.M_[!&X^
MO5'^7@_;JVW@*/(V^)/N/NQ$?OT-PWQPER&&4H#X;3AS8FY&(.Z2OJ)6ZD/
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M((JGR%5D),T2UN?>K.;)R5.@X!\8/H&<V5)+YZ_H[)I^S0.5*DIYJ DT=9G
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M8WYL)Y+8P5\-&&73" QQ+@(-*5*-0'56=X8:"A9)"'D@^_9SOW*S!FF4U@L
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M><Z?.O])AM6X%AP.1FAI9YK'1BI"V\OAJ4QE>QLQ'Z/8P-.HZOLF9?$R80U
M)B8T?\ZD[DJ-"J!0AWCD [?5Y:K2"\#[@;"D$;M^;S0F\?!X9L"T1 &S"I*:
M6T7NR&U[='^7JN#5I.IPTC+DW_[-M:B?3_$8XT=ITGS+"G[0>[Z^[X-W08_[
MSJ*JGW]HX&-ZG95*C+$7/)1N51JY^G4=17][L/)P9(-ECVA,FFZ6%>3/MUN$
M=2DJRLRU.WW^E:U%5"6TD*I@_ZH'HTM=FD!R1NU<3HG(.N'PF)]$)^*/(D#@
M&TEQ@"($%#&.-UU3^&I*L*AT[I$J33JP/[>[JLAOU<JDU=?Q4:;XET-E>\V#
MTX[O>M_1(30NB[*3@+Q=[[&Y,^7&:.K7S\#++ND?C%\=VW8 ((M%-G60J*$J
MB0QYT@XRD6T%?#V %,DH".E50MD CWY-/FSM33$^*V\>;AIOP6=.0_+/G[-Q
M()EJY$@VHIS3X@R-N7WP55&JIOOI.]I'A1'0N&[+LX/?*'SQH>XNQR\A;X"-
M7L7,8^M&:R>R,,"T_$:)NU=$P)YZ<0+D30PR!\X,-3CT5M3N*>I^+"7'Y6K.
M0^V@=E%?!ET[HVF93F;KC9+/-;&=+NC-2= $N;N4 7#C(2%"7I=6+2$;<><[
M=SB)MD_][2^ =*H+JE&0TLE/W[ .WSE?>\KR 7"!K<(A >7:F"E\__I900I%
M[8Z+N\B#T*+&1'*1?UA@=JLA)Y(#E59A:*=#$BR XOTHBD$KTF7<J8Z5$KI$
M(0\&G]'AK\>>OBDEQ8%J&=0(D=V9^7GTW%VO=N?F="',F)/+97_RBSV/*N7C
M.M&;'2WU%M4"*BKF3!U,E1??7WSJI8GS3S&CB_P;2RTN:A>;-.@^VN33M4/R
M*A&+@(#HG("J-@?)?^:QK^/UVBF>R?;MAY4_P&QP_?312+^1^TZ@G6-.7;,U
M(23ZX]J\WHCIZ<^8PI\NV,5_S\%)4\.XQBTCKG(=([3;E4=9/4E9#BL%Q10-
MY:^8I $*/VCQQ[=#IJTL=QAC( [W1%]SM^-#02&A))5V<T;#-W<+)JV>'MV3
MJT ^K;/]D1D'"P,BW9OG@[S"HH76V=SHL;.CYQ,_>AXRS\K65Z3$FQZCGTP7
M,P07--/-@"C,8*,1D7QZ.-E1G>*G &%W7J#?B+XBXZ6J,SG+A.F#K2\MG#EA
MPAB>F7(7IWGG0B76B.,UE,/*\Q?P%^4=P2]SKR4*=LQP20WLQ&\$0@Z':-S;
MDUIY:%AVN\_]]W5S.*-ATWN]O8>LJ.&$XNM75%D!O$:+,[#(Y\#_]%T>1 :F
M?JUL]*T]$WWU?D2Z>@&8G'1/PY$UUW<?[PM> +MICUU&&VD2_9.B-FE>8A)^
M2;^M?@C89EN &$!5/I7NIIZ=)@/,(6 -"VX'X34.E/3!LM3&!CT5+NDC)5(S
M2F[,:/9[)UI5&;1.1VCZ02"Z=]?Y^G.%RX%,.@&F,AD=@<!.R:FL0M3;7A#Y
M-^G-6 J781%Q1TBV]]NJ-"X ^,%F50T1$#C^F$/KD]0O+O0"Z'7[8 _\7IZ?
M9:\UJ$C_F;(5*:HX%4Z0:-^X6EU68-"0!580NO8N@^WM[['@!LM=3-1EB?Q>
MK$XW#9!]A&[OY0=)M7<ZB'IEN]& 9%'F_7K52WJ':=-G!<K<BM2UE"E\IC]-
MOK&!H[@+[,0R&L,O.(S!B;*=A(#$GJ0M&VC=%CK$G$=-[)U-4MR?780Z#U=T
M5!NX=E"&4$/.CKHJ%1^5C$2J?F(Z$E$<ZP7DXI*WBL'Z2M1LIZ[( :EYZMPO
MU3JJ E0R[T'/KTCA+1FV!?&;=,$<-7M]0Z"I#PE2D9OJZM(%\*K<E#P/"3-5
MX#ZZ.N7Q#&F,361T(#1.[U4>)FXWV[-C$@EY7N*G8DF5$SH"UXM'OMA\<VO=
M<OI<>&K2]0%=J/CGI$W.X7?4HM5YRN^RYP['A!J102-FSRS3):E<2CL,221D
M,ZSJ]&GTZ9%:Z?WJ6!!I5OD/KR#PC%2O>"K,Q)(TH&I[YKO/^>4Q.)!*+IR+
MTNT)P?/($IU&+%24:822J_"PXU]8_*\"(!#3<#<78F,#V\"OL+7HFY:IXCOM
M!ZFLRQX38@T6<[0)4%T%AI4+VY"0!R+\Q6>Z"UQ>2>3G9>Q;YGP"SD;)<0F5
M(A\5)B^+5,+2$R4U19YT&0<N9ZLEIT=P7]L,JS \_1K:(::UCDBNB=1$?5?7
MNZ^AZ5A1(;D5YXZ67JW%6XH[2SS")4^U)S?B//B0W$9<(.NO\4E@AN65DZ7%
MK"" Z69-!1UIQIK8+'P/D;"N-]39BOF%5DZ$,%.5M,+9VB991F4V(CF/7.?>
MZ<0N7A9:K0D(+7L0^BZ\(DDA,H[%(S>@43(E_Y#W*KA+5%O6"V%SCZK!7KHR
MQB0YKF<A3N#7<E[.Z@(>ZALS^,"E>(,&<?;SB.LAD1J9VC>2YWLU:[%I@$!+
M/W\0RNL#' A]EA-S3<2E<V6:0/Z<J:[_3:CK;<F0.RI&3Y;0O-Z&H*A]@I%8
M)<N=_@N 5?3L<?SA/JRBIOZ*."#ZS_EZW>J'A]>@J72^T/%<C]PDI_5>B**R
M9L=-T\(P&BD@"<,S5N%/H8^MMVR[7)?V[K9A!0?O^P #?U4^E8G?[M>C"[XX
M#E7R'M?#BU[*L!"2BAV[+SN!WQP.'?@8R?_$#/]D.6^-<K& )"9@*0=(P4M:
M:DVG55D36UMI]SJ2G__;OLD6:@[@KW>2*+C.DFO!."BX_\8K'<77)8QX CQ?
M .PJR5W71CVQ60=MU;J./F&+63=;#+N50TY*X[+'(IW+$\9[9GNW-?-^0MT9
MF=9T/8[ZJ=ILX5&TN/US&V]R8^#+6E4XE+!\2=B8E_N%W\E)PO(+X+PT4'&!
MBDXXT-]3Y2[1-D$^<S7#F^N=<7ZYFT^%X^@BHD;=P2 H.*.OI-_8VJ5>Z.>[
MD/$FGOB"-B'G]^C#TT]&5A)I,=E?[J-\  ;:TF6<U %9!/>0Z]W5YC7W.E"D
M?\Z7R(R=1(&""P7]A$V9#U%?E6\QV7_]YWB<X2G^MZI"D G3J6"^S\ KP(_,
MDC?$H1*_3S]A14D58?.4U^D;+J%O$F\:5C'/:6*]TR65,GT-Y\5PE<X!\!A&
ME;$5K5Y031BN+)4AQZ)KK<=]3!0$%K[/].J+C R"_<9]5D:.5P<S8]:J.DU)
M $OW!NIP"I'''RG >V6C0@GUSD>IPU,2LU/TB!']@K]2'?)T&=5%;Y]ENFZ:
M^_)DTPRKL%T,HZ&@0V]AO#:^#DJ"!(Y66WE/0BE34J^]K0(:* Y9I)L99PG0
M5G4FN]O"T%'Y>EXIS24I.>X*RPOL7+T['1\\5I"MC+ZH4EWHXWZXN.MY!>V.
M%++9\V@<''((N+X+8GO?0K#"DVY9]G<\UG7F\PY5\\%R>:+^SEHQ_3?=M@%Y
ML++LH969PQ4><*"SJ%3O<2_%Z.[VV8!,C5#?HY)9U9!G__<IF6$(K3K#6'4Q
M1)_2#%FWL;S,Y;2(6?7;H-ENSRQ(X[TA4\Y9@TI\%.H_ C5  ^,AUM7QP"UZ
M^J;V OA8*>7J4[FZO3D7R%#C?Y.RMQJ:\Z%)V'?[!:!BNKW8_ *(-^B,[M>^
MPNE20I.JK!/>;'3Q<A@">H@8W"TM3L&K.NS'I,AS#-G?*LO*Q/7/<2G%]]7)
M-/Y.J+RLF.R32E'OL0@G0:D/8Z1)AF1BN)G9421H9;FU<"XDR;X6AA),,$LA
MW7EGYI*T1+-W0<,>5!LX6[-VG88^CCQ;&'':<2F*:AO:MUV;<39PZN[(;<&Z
M$<=O+ 45*/)IV7+^!K8V9[II)$YVDXK7H!8ZU?XJM%Q([+9]6S;NC"KW3$V,
M!-H"T-V]5Y7R=>CWRAPMV%Z&"V/5J_&<HV+.Y_-2@^]C-R_V]US:N[/W1PNC
M_[P *,383;ET;?]1BJY#QYK%F:PX@M "Q-:$E;!@X:(O&#P=8ZB*^MF:VR J
M*[@7ITEO>73CI/6"SMYV2FE!-P[>O70IIOGFVDV5816EBG[%\\\; 4N/Z6MU
MX>RX01^FY<KYP'$G8?$SL<8#U5A_P:82^JFL1D]9'4TMT"_R@7%NY6@YYOI2
M++AN]2V&+ /NHJ]]F9GNQV,&8D04S9R8A':Y/SL=/?J<OIPL%9:1^'J_C'C
M#>.%84GO9J.VS^/P[5Z#:U8_=_0BF5WE,V?OS-WSVNIB$IN&C36'5U'OD=+$
MHI<< 4/EL"70$F*+:4#_:4400OUMH]MA^W5*->NU<"-S$OV$R?M8D3>DZ:<
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M%IV:C9<69B381'T:>[7!P?95B.##8@/&<=Q @74W8:&/ H<"$-N_<0^@GSS
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M$^H?PW*W*/"16-=3D1I#>;ZK'VP9J^*%8B:.6KO"W#/-SL&>424CXY<VU:4
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MV^++U(QO4Y4(LQ3E)FR;;\+Z:-6]ZXJAT16) 1?1I\-@1^/5%R;9Q"LK)O:
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M7D5R7T6SK:'*GCGWY.W]\;=H],!XCF2$D/#>-0!.=+=2D^XCD_XG"(PZ=KT
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M)]FD*%$05@ ''IK;F53REMP=SPT5$)BV ](=*6A:ZI/\1][N;:R4:G#0F?.
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M0<W _W<4FISND%I*4R O]J7-J8&TV\E6"G%K45-<DEK>=C0AMX?>\655=M]
M^4T]XS0(OGOQM,^+3BY<T!'8VRO>T5S814\5W'D":9$_F@)0Y:8O2O,P!&-_
M 'G!>"'LX0-"OGBEO][^F@L+>B7-XHN\>,J+>EZ4YRMV?B](9KR\Y6+F9)7X
M]!M_)+Q8I(2@-/4=R!"G$+$D%H8L]B&.*7,#ST\\/]31$P8\3*PXMOP O&(
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M5H9PW#^8 A@]E2$Y #T6SD"'TFV+4LL'^/-$**D["U.@9>8PV$)-RVO0%7_
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M,?O.VS<#LQ"YL4>A(U=_1#B%"4<NI%%,/9?SB">.ZG0?(C3QY/_?;HC>AAZ
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M3,EI0+65"FF9NWES':>!]D4RXT1D#+(5/_SY_//%Y8<N-S'%W$&^"Y-85E]
M*(3$(PYDV/%=-PU2&F+EW,2=H2<VECIB&EEVNY(/Z[/3Y-%311T=D\S!79DT
M\@2-93/;6U.742\1\* 80VE_NS?,E^1WD-&=E+[#5QB6#J(/G*V7_#IM,Z7W
M\J/OI'99.)&#'1JY,*6Q#U% "$P0\J$3)T'D1\Q1+):@175BO7#1G6/9._0
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M'+?8[6.C-\U58#$PYU7?,F7CWCY.9J;^2:^1EL&O)_& ^:\XT&S.@)Y@?==
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MMC7@-,'[FO_$D?3U?=-M8-OMX29?+C_FA0QQ+!C!KB-\!%D0G$+D)!PF:>Q
MSY6GPB-?^ U,5:D/T)E8<S>4P98T^":)@Y:ZQO[@$%;C*MD2 GIZ=Q[AU=6G
M)1#,=*0Q&%I:4$'$ 54W=/=L^DQ!A+[24KG<+ !ZF:9<6K5M/_0[_.,&5VVD
M=2UT9%M4,5^5[4^R:]>*9LNLB>-V&9+487&4^@BFPB"%*$D#&!,W@@Y)O3".
M?<[T:L]:XFMBS2>;'A<RZ_J/>@%36ZBKQ55? 4M-'=HQV'6!D[A*1L N)[*0
M8D%KM3)!MJMEF"P%;VUQ-6N,US*4^Z%@V\/K&W77=W^ZO/E\^?7F^O;BZO+S
MQ667 L=]S(/$@TZ8"(..)2Z,>9!"L00%"6%!A*AR1<<C-*;.3I5409^LN@5S
M#)5QT\V"K'HJYZ68!NELQ^15M]8LR&UFJ9G(KV6DC4@V8* =NW,VXVR$];YA
M-G;IB4T!VL)MF]8A/*(L#BET NP+G1)BF(0.@GY,8\=E/,&15MV0(W2FUC";
M.O"W1C45CZ&C9@Q9D%E3T[P0U^),4Y3*=O7Y/2JO4TG^L*A'J\(?N=QLAG[F
MU04N'[X4^?>,<?;^^6LIMZ4WQ'I;96[,4A32$/H!"B#R99'G%&/A**5>[%/B
MNVZTJ/(*+]4FK3IIK7F\84 ]8,\K0 4G(%WFOY?-EEF^>=FQYK:D ;)J$WX:
MO/1T@(1*,@$Z+F22W1O)",A6OX"MBK"YD6@.@"5UH4%X5@VB#\B^4C$886H]
MLXD)!'%,7"<*(>>^K$OD,X@C-X(LI4'@B?\/_$@O8TV?B<ESV"Y>4>]H1E^F
M16]R/31)J,4<D]E5T^L$4,P!,E=5E@XT;YLQGE/AF:Z7N.*L/HPH$X +_B#[
M['2A&[D;5Q>HWQ9#C^*0N)%L:1\B!!&EPLGQ*(,T<-S8B;GGQ5A/?YW(T?3*
M3'"1KVK/($]!CT?0G)S=X;(-D9KVMC5[)FJ:;D:<]=1>O_.P&KS@C>3OE[8[
MQ425[>W 9;T+K1DWK]1F]B3HCO>1/6U8@PSDA^<R$X.6#UU9>)P00B(?QC3Q
M(8KB",8H=2$/(U?XD2X)N'I&\=[@$\=WMN0T$E+WY1\/&9\BE9[ZV%(RB!&_
MD$PC=?8$"0U3834DU4MH/2+*4(+J_BWS)9P>878G@?38-89&DRQ@^Y OQ1UE
ML]E?JYU%&OG$1S+.BV(,$1?_(3069I$PDE*"G"1TDL6*WTM%=:=1,/HP.:47
M+&E>L!=$U0.BDI2F_7($'D6[Y 1IS>R-'L%_!@W),S LM[[Y,"R5+;/@")5Y
ME_MA45\LXR.7&S2X<8)@VV_!V_9N"0+QOPA&24K$(AW&, EB!@.Y!<P#$B%7
M*>GE.(F)EVKG;1#L-F[Q='K:'$9E?.D^75:]^7A(3),.+(?EU>B_<K+<9LNZ
MUF/6Z[DR*-%0QY7#-\[7;V60\9UN*\-7FJWW-_Q)/*L'7/+M,9/V=>))2A,7
MR\)F.);E5D.((^$#)%&4"K7B<!\K550>)S6Q<JE+L-[P[_).4&RXZ!T9U#,"
M!C!3LP/L(*&G>K8T>T?')M@ 'I?-DD$P0&A6FV!<X'VS0.$.O<G,*5O4I0KN
M'N]_X]5#SK81,X4).G#[Q#.SI@KNLD<9ZF](JTW%(8F'YZ E8?4FWP$YP3>K
ML3P%L0:*#XN[VRE'V7:F#8TYRQ13$*J;6RJ7FJV0'WB:K3A[SU?B0U7W9>+5
M%UYD.<MH^^U%7E8+85>(!3-)8>"E25,2-$X$GFD4I@$7]KA/4YW\"E7",V17
M/+54 6G( BKH@C>T/J:JV5Y)&4\:R"94C@<]ZB&(>,IA'!$",?88#>.4X2#4
ML3\FP=/@>.EKX:EFFTR!DIZR;#D +;&Z>'Y36KIC8_/310W;Q0ALVC:,+@:6
M+!IELK/:-[I@[%L[VO<;1$7"MTGC&K':-4I::QPEC'FRFCR-9!*\$R>R=P*!
M01J0!*?"ATF5-,@ C8F5A23ZC__T#V[H_,N.UYQH! N.@*,0'3E=9+V97TN[
M&QY(3,(C1R36B(^<+KE9@,0, ;U(R;!L0Z&2(W?.%RL99GTG6#)RJ9DM>/X=
M9TNYU?HQ+V3#OUM.UT6=L_*!D^HW7+5_W0H[?\G;OY\_X(J?/\J.Y_\MB\^5
MU7M<9N6"I$F*7<1E.QL/(A80F*1A+%14BA%R" _4"FE,P=S$:NU.FJ& ";9
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M.9 N=\,"D.4WFB-LZJNX H#CQH]=6/3F[TM$SO8@,;!M%%!1-V7LHF-FN=A
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M;]$@/@E.LZ5>F]I\]H I$#M&@_$@IH<5;A_Q<MEE.2R")&&$!"F,21!"%)
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M-\7[LD[2*$Y)+K/R.D='G:_&SIA@.X5V1B\^L03%U>II796?^'>^]+L^#%Z
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MCPCS%,8,Q4(3, X36<733T*7190YR-<Z$:A.>F+5T*NKBYNS'')^W&N51#;
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M3\\?\Z+*_KO=M7UQAJ&^1EJ! 0UYS#T,G80F$&$GA0GC :2AL+T1"P-"L4;
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MF!%(0IY"1 E5MAM*81!$G.0B2'AD[,(\3V[B!=]1O *KEB;X;E[IVA"O\YX
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M&_UOL?J^$>"K>"2MP@=_^7A[8VE]FF)H:#).@(SE&7O P;^"K@BJ9N(*=&R
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M;GD=MN_0[()]?IM,C!W'?5&EJ^.U7(<9'+="4?99O6 Z>'TE6_AG<-Z$BLD
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MXL6A.GV<8]>[Z,.R_%,'/(I;HF/BNT.G$"0(DPQ!AE$&41A02(,PA4D69''
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MY0"8B#=,"#!ZWC[D<5OG\>/JNVA;=GS8K'CO\0H)QFFB;+M(<AV3D400IZF
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M"V?%?>X/./^":W'.YW6 =RG\G[:%<3#+99+R! 8D0Q!%"8$4)R%,XY@)+$7
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M^Q_D01?V5(]_$>M-M:J_*#7^H:QTI/B"<1I&*&$PH237I2QT,5Y*8")%PI#
M@L5&I2SF8GCJH_OFX8%43]I;N!EPKN-5 .UXM[UYFW@&32_Q7L^\V.U=0TYU
M, WH>05_:/J@8\#K]> \6'F[:9R8W9DO+><!__#^<R:Z]FZ=Z^"7- D^EVM1
MO]L(/?_=D3VC>9X$001YE.N:R3*"),L"2-,0R0"%0OW/U*5SBLC$"K>A^C]
M0Q?PC0":,O@I2X+??@/O-U4)PE_"  <__Q1;7,^<1.R\E\<'#G8*;@^"=ST$
M]MZ=DT*;>W9\"._FU7$$P<J]<TZZ$=?.R5=G<^N<8W[HTCG[K$NP8]E]FXQ#
M&\M9%,CM^QN;>,722!$X"V!Y,?O^QN-7_"C3CL&%Y9Q?[Z.,[P<./O_0-1'U
M\7%9B.I#L2**H]NJO*_(PRZDI>].T58!UTILD44<97$6P2C7#8QDDL,\#7,8
MLS"0(6));GD/:<W"Q.OG;;F21?70E/CY7JHC:PT>2<'[ZDSK;P(\"6(9X^0
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MLCH.Q;CNN5A .U5B(YNQ.AB58>3F5;W7+FSUPVX]'Q]MEN4Y*DB_VL8?NJ0
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M0K\9SC#MMF-S6]JCHPJ:4^^05:_EU;M;>UMNZVMO5MX!P^TZ;_5@S,/D;_:
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M]'XF#4_>TG96G^43,'.XIT<5]I[:P?ENR]%/&MDM4]YM!]F6+Z,IB#:S(LX
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MB?4GWF$U16]+TCPY]A02P]O*@7RP;74HFD4"\"D9S9. SY35+A$8*C,H*WA
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MC%ML6B(];ME,!-QYN8Z*6C?%L05QSY"G.$(U2Z ^I98@0G)^I@33-M''.:C
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M(/ 31&D@VO@7UW4A21YG-$ZHB$!N[62 GS4[O0-JW8'H\N^S@&NF:B>##*:
MST,+/C3(1FI7\X- M.<=)60#R]%4(:M%X-U3OPBV5HKPY49^+ K=$FK_ OEU
ML1+7E7@:.VTR76:Z[_V6NO8Y%/WU2JPWY;+MR/^ZI5G70-&\>35SCEKT0W"P
M:D1J1&"VGJ00<;OM24'WV7L4UZNR*NK8_B?"1--E]CZ*\I2R/$0^H2'"),@0
MD5R@2/B4T9R0/ <%-/H(31W;U<;V8D?WPI.*LFZE--1)%X:4N9MQKOP6?L9U
M1W1-U%D385.Y'#H:)\G,[FD,"7O*U1B\WK*]<+%F0O#RDV+PZ^.ZJ+9SKN[#
M.(EEFA+$TI JOT+I19ICJIR+/!$XY"0*&,ROZ*4UN0^QI>SIY^"5FC:J]+ V
MKJ@#.P[W F:V>9V  -N]A]+71/>CZASV'1Z3S%7GX5XZ\_8>'A/WJ/OPZ WN
MP@7Z)./WU9J6HOBF#SZN5\^;JM1&P(HMEFVE@#X%*1:KA_>D7)2[5-2OHJJ6
MC?5['_DY9@*G*(QUJ3632@?X0:)_RE(:Q#Z+<HNV/=-Q;+2)SD[]OVWG_OVO
M>@K*^<ZPHZ=E[SG/"/Z9;O9!#*@^:O>ZC'L-Y]XAZQ?>CGFOYOZBFR[?D6!:
M3]TMRA.Z]8X8??,8@%O 30(&CBG"6SE]7%5JK4O.U6XJ;]=E19;_W^+Y:LW%
M/4F3/(RC% D11 C'<8*RB#'$TX@2[O,P,NN;,4QF8B>L(>RUE"^\AK:GB'N:
MNGG7IP&@AO6H._%A.M!6<E"#J''!K+I%#2P[6^NH<=&Z?:0,KK;,JN/*@ZD6
MI=K_;=O>^R1, NS[I!D:CB-.$$V"',4X8R+!@F6<@++DCDA,O"D[!+<-IX%9
M;\>@F!DSYXD*VX!=*3^.2 G/'NL5Q%4VV#&!>;.[>@4\RM;JO])NRVV[7G]1
MYO[7[^2YS77VTUP$OHQ0$,0IPCC-49[@$(6<IBE/:*I\',BV.TUFXJVW)>II
MJIXF"]MY/=B8[;[S)8;MP&-A)ZAP&Q;*T6[L(3+KCAP6]/6N'+D:7E5R]:CG
MI9<ZIZFVGU_JM*<OZ^7RT[K0QTCW- \2[H?JO9BFRF#E3" :ANJ?(!2,81J2
MW.B]:$1MXGW:TF]2&QL.FBQ(\V*-<<"&=ZUS&&";=XO M4Y*;!%H&HW\H>E[
M+0. ZI5Q0,S+69P"8U??TOL5<32)PUC$@0*8\35FJX@Q%J=;(F-^DT6_-OQS
M'K]NMX3;%VJJ=%4]XRT65.DR(I2Q@4-?.=\\RD(92!8:E\P-$9I8C6G*I]IT
M84"[LB&8QC68*^%ARJM7;IM^;4,  /JU.0+"3EG!OPBP?FT&P@WU:QNZ?;Y^
M;09"'/1K,[G>LI4U*1\O5US_1_<C^$:6.LYX65V1HM"S@>LXYCV501+F(D8L
MR 3",M"5>L1' 18B#E+)<$Q@1[Y&="<__JT'->BL/*9_$'M&@#VPC4",4\H#
M/TJ0X"%&6&BKE68A2E**,RHS/<,(U"7<-80VUJO&[3_(T_-_UI,>O(_30FCF
M?3H'!FC/;K]4KQ&Y\$CE;9EH3JT<MB.'".VJ2;D1S7E;ET-@.&IH#KK93N'^
MNJC:_L!?U9MU4U[^6)3WG$:$<TE0DDF&<!(P1 0-4)I@7R@+D 1F1N 0D8DU
MP9ZDU]#T_M!4@1GA)]$QV_7GR@S;Y&!QP1MZ2!Y'^_<DB5FWZY"0KW?GX+66
M26YMOH;R\;I).'7VQO7JFRCU8*Q+5BV^U67 ]TE.:"9"@8)41Y\RZB-E&G&D
M;"/.1("9'Z?;M!>SG0KDP"*-!;:-:\*ZL'8[%;0[ 72Y8#KJ7M9OMZ?%4G&W
M7H&+;Z&@FVW_*8"T2ZIK&:G[)KT[2+'[R6O@W?'C[1ERF&YGAX2K)#P@]7E3
M\^R@.4K8LUP&7A-R];AZN%Y]TNDD-_)F4Y5<+;SBOZ^^E17_^._JY?)[P<M?
MBE7%KU>W1?&/HC1OLWT6@8G-"=UH >G"!%0WY&C"<SH"VBFLTB4FRDRKVNJ2
MTONE(*NJ*6^_+19J^^E[2^_N4=G=I!">EJ]2NDOO/*W"?J^?E3 <SG?>\QC6
M8K,]"I@NF_4I.#RR<P*G55&0/=79*H7.!J9;/G3^8O!X^L<?>NI4*=2WBXDO
M^BMY]WW=;C.&4QFEPD<Y2[4GE<>(8IHCZC,B(AQR%AN5%(W0F5C[_<\@B'].
M4@]Y_S,(\Y_CP#R(/ 3.>!#=D<@P+;,EZM54O9JLI^A:A-"'I#>/H#M"P2Z
M?@H-1P=]!G(-Q,Z'[IXM=&X@0C=R;G*YA0)2!MZ3]JU^+X7<+']=J!?8C6S:
M:=[I[-Y]?Q"1Z<A.Z*,L"WSE,;($931(4!APXI,X3_W$>!R3.=F)U=..$:_A
MQ*M9T9; ):#7+A!) ^4U"3Y 778:FILM--X?-2>>23^6<] "*+M)4+/4?3OT
M-@UZR^T72[E6;2-G5[H0+/:0:C1?;#Y-"1;P0''"[[88+[WA"_6$/A,]("85
M,0DP1SC-,X0%R1$),H8DB7'B)VD>,?/ATOMU)]:$+25/DP(,EN[(/:S6SI &
MIK>,!(&-E#YFVVZ@=&>=^<9)'S-_,$SZQ)\MS]\W1:'49#/.XX[\:!.;V[[=
M>H3D8K51GO+-LRAJ75I>TK(J"*ON:2*R(,0"^6K?("PE15F2)"C-?#_#62A3
MX-1I:U:F/F1N&%N^>,_D1>N>OP+/ENTQ-HL]SX,<;$.W/+5S?>I)0"U;WKN6
ML9^:2;8-;]Z>.>^/+7L.C[/.Q\C5H;4](_.>9)\-V-'Q]ODKVBFY.C#>4M^6
M-2[$-C*:YR*.)<]0R.(0X83JD(V>.<0"G'*<*>\)E!<S2&UB5=6<[VSW7H<Z
M3&,- V:FE)S! -,[O0A,4)%A)*(CM3%,:U;-8"3VZ\UO=A/\A.H?Q<<5;^._
MK^.]5]\*_H_B=508=D!EN_X<YU-BQ4U/0J[T*8KZL3Y'J=P=2%G#/WX>-0?R
M%L=1DX'N^/SI7/BLCI^LB<YV^G0N+-W#I[/7<M :BRS%=H*$3AU<+Y>B[L)=
MWL@F%:!IP9(Q'H@T$$CR2!DYDC*4Q^HC%5D4B5QFRHD[HVF6&1>0G6F53ZWY
MJ,-UBSW1,[IH&6)K9@]-C!=,D[WJO%7/+=D-(JESAW<L:3BO#> \KRT7#) I
M&G89<O!VK;Q@$ TV^0(N!3^A^KQ>_;\;LES(A>!ZU-O6=<B2Q&=!1%',2#WZ
M,48D)3F*0TYD+D6>1;GI<50/C8D-+T45[<C6PPL!QTU]L(R?+3D0%J8A%$'O
ME9P6Y^%] IL?#SD0W.XL2 /P[QT >I*GJZ.?$9$&SGGZ[ISM4&>$]>X)SMBE
MUK;/LRBJ%[UBU1UBNSTGDN(^$B+!-,Q1E,01TF-#$(GS# 51+N+4CS(_QY"
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M@(47P-B:11*FQ OV]MARXFT1:WAI"OUJ[#KL7'@?%LM-W4-T@M;IMJ X"@>
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MM=;QG'9<V?-N7)G8L@(<X&:.KYF*<(R9W3BWE@>-5<N%]VK$V\7AC#>'8]W
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M%0:!SU'JIW[L2RY#26%==ZU1L&JTZPH'0R?55C:@>RJJPYXTWF55%0NZJ>J
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MIA;K(..G1<G(L@XUWCV*0M1!['L1^S%5=@)*0IHCC., 42FE,B%(SJ) (<Y
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M=X&IPS![NIXB7-06CZ?(KU=BO2D/.UI?/JTWJ\K\3*<?E?%C'2>  &,W#K$
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M<2O$M\:7<+=4S:QOQ=MU72YX7?^V*%<S@7!"(A1#FN3*I\<Y+% 00TRHX*+
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M2(W?% 'F;%,#^#U_JCAMFKM(E=!F2#?A0#'&B(:H@+PH8H@2',.<11%,XJ#
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MAP^]!CN%NF7%N2>B.;QF!XU10+/;>GSA97T:L);=DYUO3G=2"]X:CGW;W'X
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MDC%7@'"I&CBXGL^7?V#Y70="=?*I."M70#E(_"F,<W!X4A GR4RJ$,X)NZ\
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M/DIZ,\HX80G.(*<,0<0$@X0'5*561SA&/)7_V%SCG*4XLE'>T>^;+:T-(UD
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M;=?W\-B3+& C\;H5:O:PFV&Q-614Q<);T=W\SG 48H+"%*:$2^,A87(5\B*
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M/.A\K4]U[_!3N9)?A_]IKE'U0U>=PTU^KN)?;W1>N_KMFJ[*9QT^X-/)=@B
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MZNL%D\0>E]J8F(DTQ@EC''*:4N6AD;8H00%D&,>""2&"C)H=0LT(CGX.;5D
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MJ%2F<9-V@3.901*S#"*44)J0 C.[%(8EO9'W=Y<#L,="[=O9;QD;Z(9U0F!
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M% /?BUX: ,A!/0VMY.G1\#LI'N?RLSK2A657'E'M0@%(J +%N;:,5,PA1HK
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M@LBD-DN_H"\MDX%/>^2FF@L@[AWS^Q\>[\NWN>CCV!'?17"'5$L0 /P.R"-
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M-8K[ N[U"F:?-"VB;^6"/[\M*[Y\7*Q-Y^@9*4@ND,D8D*B .(YC6&2)N0F
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MNKN9YL6UD4.X]V/IJ[P*ZHZ>3<LCJ)F\ %LV09=/L&7T K2L-AW4]]]+RVU
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MQASOQM=><OT%?JQ;A/VRV%V\^-MR;M@SE3\SE>?:HT01C M]SF"<,4@E%;#
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M)EAK6 >:!6"8-TW-P6<%#/\78$^";0!D(\.FE-2( 8P ]2KU#QU1+K8188\
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M#_$80Z8NQW$XQ3?]8(TQQ'MT1,8HA.P4^1_+[:AW:3VW7=6J+JGH>KFQME5
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M%L%N M15)A%\E%KX[J$LUO</=Z).?JHDB'*EXM%J5NZ<8H9QS#D4*$6J3%M
MG.$,ABDG&',O),C,7'.);F1U^7XM %$X0*9,D!=%'ZP:/& EELU?# TXIZNC
M:>&]ELQ-,RWHJJ<YI4;L<,.L**%"7FO)!DL[CGN;L7FUJ'5B>Q1X*UT>J6"[
MC^L0Z*Q=S3JW,P(ME\#W'-J18XC:E:'I%-NTEN@88CTP54<A8J;$N<CG'Z2_
MOGKYAU@L_GM9?%_>"E(52\$_5=5:E'.>42X2Y3J'H3HF2Z5"Q@(K@]4/U6<>
MT>K@>9;2V+9H31LHXO!?BCKHR(.&OIY>/2^P81WI5 R&MJ*U!+35DC9W1U2,
M]!)^O2^>_RJ?T6@7^<-6J9Q_\B0*0IO!;K/KWV!G?=5.[O[1?-LF.D(\SA!*
M8(R1M*4BQB%.D0\%YB@+,\Z9C\VZ: ]0,_G>6G71?K>N5M)[+Z7ON&B&;SWD
M3U7]\BWJ $Z^GW%E9BD-2=+W.0H\YL,H##%$,2608$IA@G%$HR"CB= : ^]8
MCA9JL(EU'>0HN1.5GHGH2 !F"O $[R/T)==@SY&1-41I4I-)@^5] TCG%INF
MQ/NIMNV/UW21WS?->TJRK#)1EH+?%;])H^KI:KE4WG.=E*N:W059RD.:Q3#V
MPD#UB/ @]J,8,M]//)$(%#.M")TK0"-KA1Y]L"K O4(@-6L-H<G/EQA,&O4Z
M6()A1?(:@C5U+X\E\G>_;2'.0%_Z=P6H88(6)WCW.M(W:: \[2K8ME:>9C4,
M^RZ[$]U@1V8'9";LU>Q.*+M=G!T^U[(Z@RS_=9<_BO?B20V]ZDPF'B8X3D,$
M$Y0FTL4.L+0N_13BT$^0CY/0BXTJPX^3&?L5(@D"WE(TK'$X+A8]2_)R9LW4
MNJ(':F8[BB/8C\-,N4J^/TYDVBSY048/TMF'K[8=$=?VAU#C7Q=%M2[[DU*3
MD!"/<Q@'-));4Y50,QK A,2!8(2RE'IF+O00N=%]Z$^;-C(#D]',I:2W4UUQ
M;K9?>XU;MW3!MU&F<NIPZ&Q>W "IB8?'G6?Z<)*<QCWFKM]-6? U6W6U*R\W
MQ2)G+]OO*<L(BWA ()5O58@BU8)%NG4P2 C&(A*9?!'K>G5G:(W\MFVI@T5'
M7M\].">D\WZ70];-]G+']88R^-;0MFN'>DX2^CZ00XG8N3<'WP='74\U&1MP
M/LX]83*_0I.5OLN@>XNYIKH*?TV\+\5*5'PM @_%K<T;"XQQPB*8>M+*0(1Q
M2!'A$*$XC>,L2N) :S[M (V1-9,D&OXGJ,D"21<HPOI;\I1<SBLE!]R:*2-%
M;Y_1\ZZ -L?ZRL<!YW9*QTX"1OKG#&\#>N?4G9/IFS/0^WKFW*7F^J5)!MLF
M>O%_KJN56N%W]:"J?'E-*U$^J^R#FS)GHIIC#X<,QP&DL? A"J-4_L1\R%,>
MIGX8!3Q-=#6/,?6QS_YK/+-^,2O98)J!9GB7JFLL-KC 4PU,?Q^;2_R\3AM5
MCF;:KA/A-H,47/5$^&XCPBTD<#.Z"/65Y*BBM%.?(XC42+=:BV1 ZYH_<S)]
M;,UN7U/;/\3J(+,)19,?O8X+[Z7C7*UR-@]PDL6I[\.0LQ B$7.8)ED*$YX%
MJ> T#K!63L)Y4B-KY]_SBHF%_),HUA7XX]?;7__R'W[L_<WHQ&M(4EHGB8[X
M-SXC; ^:R(\N&Z')4NAH.Q."T8&>(V%8']6U)]%2*&WOI";#A[<8'#FW>HP.
M'ZP-/6#*(S,-1O8.PW3N,%=:!].F57/3ZJ%8\%Z%L6 \)"0-I87I95#*E$',
MB/S5CQD*41*+5"O)7Y?@R IL=P9Z*3',5-I^@Z)7>0S>D J0[@^:?5*TA7I>
MR[D6E9FN.YP4/P,; .#&HJ!=2RSZ>L^U>.RTW\5B,E*!)CP/*$*MQTRF#DV8
MZBM%H_LLN[ZV&E:E'W0A/YXQY@4$>CX1$$G)0HHB'S+.1(;B.,6Q5H+]:1(C
MJ[^.8)U38]B_]5 <PVK,#9.&1EJ?OQ$.^T_SXJJIZB&!:;NGGF3PH$WJZ2LM
MF\JMGYX6N2J?61*)]:8L[DORN#?O#L69SRCQH A)!!%/,4Q#Z4YEOD?B1+ P
M-MN!.D1'WI,=!-!B "T(P]YL.M+3V["N96*VA4^)PV2:HGFS,@.67748TR$Y
M;5LP R$<]/(RN?>"\IDODI5F[GROZV7[.L+4(QE)$HA3U:J!I;Y*'N"0!0E.
M$/-5JTCCRH\!@B/KA2:XL*7?;V%K40,R)#D]O>!2'F8Z84@48Y6$:##JLBYD
MB-STQ2$:S!^M$-&YSV7+V?JOU=5Z]5"4JKSVCZ5\8CTTL^D1J(P3U;&]F8_7
MQ'F_JNCOU8^\FL<T0#01 ?1C+A6&1U.(,X_#. X\PGQ$6>B@K>Q%&,>V/>I6
MHO2@Y>BL:3):@2ULL%:X03.1M$%>6]G5K!YKT*)O3CU C1]\4QP8=K$:8YTU
MS9[773W#,SX+>3MJX>I$(J.V:;T,X4_0BM6)B/7:K;HA9:?3OXC5.U(]2&/Q
M.>>"OWWYHU*]RQL;,E_>7[%5_ER_0N8X#%%$@E!^!3(!D8A\2 05,/5Q%,K_
M4@_'\U6Q(@L]5:U/VD@#;P!H;V0)!#")!*R5#I::-.L@ ++!8*9"#<2JIQG'
M$9:9PE-R4B! AT+)ZHT" O+E+V"#!5R=EYJQ(C07@"/]9D!X4K5E+I!];63Q
M!.OA7;O'9RJ5O?U;.V3TJU") %(++GG;!K6:<VG\Q9@',!,IABA%&)(DIC"B
M# OLBR @1K:A'8R1S;^.8G.(_Q?R^/2W35JRL=JQ%+1F$'ET\1D&F@^S 69-
MX4KW08M*3:EI<-7M+SID3L=_72 9=[/ ;$!,/1CL D$=F1)VR=/,3^N/S(>Y
M%:O5HNZ4?YTUV4YU>_QJS@(F=2K*8!K36#JV:A9['$:0)R1.8BS2$'/=0WL#
MNB-KJ[:!)JEI@:H&H3FBRU2 PTII1+&8::'C8[&V.,!U!EJI-5#&D9;^N?U(
M4K,[OG<G/:-S? L9#!SGFSQMLE-]"Q;[A_LVM]L:AQ4K\]K1O<Z^"K8@595G
M.2/-7Y2%^G%1?/^[X/?B-Y(O53_J>9P&7&2)!QG+0H@2$4.:!1FD823]T,PG
M46 XJ]D<Q-AY EM(:I94N0=*_:UV6C.)"SPH8.!>(@-O%JH'NZG=:+$&NE;C
MN)(UM1EWA+J/1_VM]G 5)%!C K_50OT\*%0+B]%>*L[L10L($UN+]D(ZM!4O
M>)9%:35923VIS,Z[DG#Q2,I_=0=]) FH(!Z!J1]+U17P%!(28IB@B&5)R!.<
M:1V1#I,963FUA(&D#+:D#6J)3\OGO-WGAFLSQ7&<88L"Q@'.#0JHG4C LG;:
M4A)FA=1G&1RJH3Y]\W3ETV<9V*F</G^U;:/BK^(^KU9J$ML7\BCF+.$>S1(&
MLX!2-<8S4S.H Q@AYB?8HUX2:I7!G"(PMO_9-.7=T@2*J&DOXCV9#&L<%YP:
M'BR:,6G1;O@X)Q=T&=Y[X,3-A8^S<]A3^,1U=GY+.Z:KNBO:.<"=RR2JWTIE
M'Z,XCK* J-&#ZD6/10)3BCR(4\JB.&59Y <F/LHY@J._\AORJN,E:0  ND$P
M4UTP*\-P]5D1ZKD8+@5C:A5L9=+2!F][,OEM4";&7H,NHXX\A+/D)O4&=)G?
MM_RU[S.W\G\7_$ZPAZ[K=1+YD8KS^J$?R/T>1I PCT*6<:9BOBCQM/*B#YX\
M\L9N:>F;L+ML!X%/>$(8Q(1@B%@40)HF H8X8BSR8_FY9L^WBQBW:O!V(>OG
M715K=LST4$O&PAW994C? [%FS,[IT&;0R,LXRL2 8[%[_62^Q%&8???A^ 5F
M^DPP/K_B_[PKOA3+&U%\$85*4?JXW%8N:*BNLP\9695M&PRH-[($ 6\^7(,O
M\K^=8>X?BV*U+%::?L-YR0SK :=",=,+AO)PW.=1F_$!QT,^HS55&-]:*.>?
M/,GFU&:PVZSZ-UCU2(N#:-L6*4RZN28QH6GL(]6</U$SXIBT2U(&*?)Y&(51
M$#+MB>BGB(R\KVNJN[VSPL2H:=AQT9Q_@;M@V&S/'N75KE/:<::-6J5=S+QM
MKS0K(9@V2QOD;KA;VO%;IVR7-@A^KU_:\+6V![=/I6!YO;#RYX50/ZA$FV;0
M6O/UHERHWA41S#R/0T1B 7%(!/0YQ0D60>)YAD.5=,B.[CCT0=1)9:1'79TB
M/I7%DRA5JLR2]T8M&>?S:8B81T&&,AQ+OS,A$$5^!E.:<4@\CX2ICVD69V9G
MX6X%;'7VO2?>/NT11*@79W(M&+/W0I_Z#&SHZXO'XI!:GU]GA](:)"<^A-87
MPN&AL\&]=DJX#F'=E$66K^9>@J,H"4(H,L^'*.848L1K71ME6190#X4F!1J]
M9QOM=_,*C)J2TIF2E-GV[O.OMXLMN3+;K U#-\,,&6_((] =[;O^DR?=7D=8
MVM]%QRZQB&VH7+7?U-F/FC6\:4FH'=4X?OO([\%>KTM2*;.B1E!/2S:(79S@
M7"-J<3G3AO$*1;#'9*_9IZ-PQ#!'=H&($\^<+@0QS-1.\.',I>9AAV8JX>/C
M>EDLBON7+N: LR .>0(S01!$:2@@B56W3?EJPFD8>F&D?19RE,+(&Z^=?;DA
MJN]V'Y?'^4##Q5R:[;1]!BT"#,<YU8\N7,RQ76C!G'.CJ,(@5P,AA>/W319/
M&(3=#R8,7VA='[@W:ZZIY_E8E+W!<]6VL\4<D3AB,59CFI-8ZA>:0I(&'L0T
M">* ((_ZF6E8P1##Z#&&FU(\D9P#\?BT*%Z$:"8Y"PZ*S00^\_) 4SDC3$6:
M<"B_KJ%JS^%!&F="JG6?<=_+4B[,NNV-*64+/:^.1+J&-C93L,TEJAMJ&%%.
MAC99TU(X*\JFHU]'6\4@#H>$.BVJM!.!NWI*0_I3EU+:B>=(%:7E@\R-Q8]Y
MQ<CB1I1YP??'1Z64(9][3"H8FD!$4@*)2 6, I^0P \(Y=K3Q@;HC'T"O5RN
MR0*H*6VJ$P+7]M3.B>>\!>F(:3/MT! %#=7+YHL-<:]O53J2@IUMV4KCJ9'&
M4TW>4?=U#;X&K,NANR>S,358Z%N:.I?;V9L;O_?3\FF]JCZ+9[$(6O\EC>-
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M%](DPC%+"&-1&E'%FH%]N]1_^6%M;? >5'O#7VQ$/?<A/^(8 7<R'FU >[J
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MO<AZ>^2,O(S824:'HOW?"5T(];_4![(;]NX];7+ CJO+=O_7UD 8A+U=0K$
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M5VVM"I2XQQ=;OQW9*(@!5W5'8+5*H$8+5*N!/O;!%<#D S1],#X?7[D3L_H
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M$3I1X^)(E) +-WG%_\PU^WVQQM7;<R3=N0LN?(AD5IT&KY,GF90,$4DZ)NK
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ME/!6F"A%" TPLGOU_2K(7EIFM(&D1X&8#W/Z6DCKZ7=\&];A@JU)8<'1:1I
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MV14;&$2]%A9  D"2@^,0R$P HO71Y22\>*C.^'#4W")D6/ <H]N=,#E&S*-
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M\F?'PH:;2_.J=53<6M"L5+%D#3'6QQ(B6^.)L9A:7ZG<2\S (X6:PZ:-U$<
MGRM/\3<ZH#_03\D]-,I@L0(2UW08.R7(3F8.PI@2M0@LB-["KRLJ1I)2;QAS
M'2;@44#D=@;CH J"R)7NGOMFXAZ4,0Y<;>3$36%!.<Y$#\W#6U ^DE#N0/S<
M@>.S*_-@"'_KGH60 );K)D"^V60\%:E1*$E2Y'3.QSIJT#(.A>PV=\FX8%MG
M"I[>W+U_"]<&5H>+=A1U_F^GWZ<9YWFUY0[6^YU)MC9R71S8HDJ=920A:&&
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MH'8U]><V'^0KNJ[=/=HJJE@,1.EIRZ!@QE@E50\]17?3LA><_ N#4Q/!CP!
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MP.IJ)L1M/B2RH!4S))Y:Q1&]H'BU:-"&3'/00NO4&D_WT;(?D%Y:!KV)Y$>
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MAZ-@?%C']QGVU4L!U0BNF1\Q1N]*P;3^..\D6D=]+O&4G+#N+]7'1-50W1(
M3]Q+SC,81\&J2ME#M,A( ,ZC-BHI;/V,JSD3PWK>0YT\/2M[5&B_?5=_?8M?
MNW_11I]-=^UNP7)*(5K0N3Z7T[:^M90*K,U,><N#,*TCR&-I'K9]Z3-@^1E4
M.2KH[MR[]WB+%V?5E1:V.ME)'IF)#ISG]9SJNJL4"UG2OLTR,N2MFPHV9F'8
M/JI#&>E>%3W*<H#7B^5R\4=]:'IP7N3.)XY-ACQ,4ZOY1!C7.U)MPD;!@\[
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M'>^O3/!0J@=N=3$NN/>H\)< \?J[JU?GZ]/%LCZ6^AN=QLLM,71I]=<_W_W
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M2/N-@95UU%&4 KPB+]-%8XWD4MG0(C2[7G":TOD1X['#1-F#_G>P99*9B*&
M9$*0[54! NH"AG:(U[1C9!YT]3L$ 5.[S <JZZZZ#Y#<Q K_;;Z8GU^<7Q$>
M1!"6$)Z$=J!2(N8M09^HYX8I(9P8=%?[A,I_6'1BI1^BLF4+^4VM^/#7;<)]
ML5('!YK1'RJF0(3[.A>[Z" EY]P,:JORE.)O+SK-#5PSQ1\LOPY<R3]6M:IJ
M\[WV3ZDU%;6#[-9QN2R9VQI"YKQ+R=27$?7<*X:B>F0*% M>,A^<=:U=R0%D
M33/?:N1 N+4Z>D9896CG=TL5-); @#.>:J\!#4$Z =K(Z&W(TNAG0]@-6=,&
M*\VA,!1J!^JE ZA]7);-GR3<6_'7SBH;YT4.3D)&XD&)VHV:: 1AH@I%<)Y3
M\W&F#Q'3*:P.5?O=R^$F.N@ 3/?<2%WO.Q>Y2UXH$(IO2PLMU ?,0-Z#5*[8
MHGSKQOR/D#/-Z+SGOQ(^2/P](NG65G-2$NR105*)U3;YM-6,(J:BETH9H77S
MKAV/D-/;]=R!*G\*2@?*OP,H[1)Z/W%T%7PX*Y,F!\!X5=\P2PU>\P!%6),"
MXUSKUFF%QRGJ#%"'*OYGUZF5%CK U,>+N)[G>5A]KYW!WI=M5\WMIC,B)FZ"
M@*@Y,6+10<Q< V;ZMBTVZ]#<:WJ(F&G&<XY=[ME$]#U@Z(;\W\,Y??EI51OS
MIRJR*Z=22(,LEEIC72,4P<$7[2$(;2A4R5F;YA493U(U<45@&_7?!55;772
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MF6Q!$9A*$854R<<\P)@-76\8@$XIMS":M"=&T(N45A>8/V D:[S^@)N+U78
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M#*JGF",976L=(/,CGM&//O^*BQIMTLY\D<_GB^KLA!JB7EV;!(W!)"? 2"U
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MK)BWP;8&VR#".H7;H7!8CJV;B2M WH5%)F:VKTGJZX![N!$^>JV9!>N1_,*
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M4Q#L8O%./N$0/?;Y$P/A<'4M&\MN8OT3Y9\P?=D1;B)S4A6*7)6K?T0+,9L
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M2E_"XO,U0SOK2B+A:#B#%"(#Y>HX7702M%'61$D_$:V;"3Q*4"^ .E;O=R]
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M&P0E>RI0:J^+B8L=7F/<D"V]S*U?I1<^?B'AKJ_^E6=,:D$GNJ9HN(YPC4&
M0RL@),ZCM=E8O)-VOK>T8<A:@^#B>H?+*)+M$2G5VWN_N,M55)B\3K4!-@7"
M%((H\+D>PM;Y$K12J(:4P@Q?<1!J_,FBYG@I=U%2=5.?F__OQ64-S]OSK_3-
M^M4V;A#*I<*UA"R3J56QFEC*N<Z*EKFH[(VV X S<+EA=YWL%& SAH![Q<RK
M+?[GB_?75=Q_K.8)US-50C0J2S!*;U]4V9H&Y^!#$)HY88T>7H&WQ\+#<-3]
MI?GX0C^59ZT?+\[/P^K[LMR(]D6B/TDTC1^Z#EAIE*>O^W+X'(]AA9/%2^]
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M\/ MHD0CB&STC$X!)QE9;)W &L.)A2*#;-W*]XCWAM.\DMY+T\/>&^XC]@[
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M-2:+3SJL'7\JM@=]'=FG _'P^*AL*.5T +S[9\;.F90=)PL;3&T*00O2J9C
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M>N@239M+(SD&%@-Z\/7^AC(F@\<HP121;!:%RS \GGJ^(KB/GG>](KB/T#L
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M4KJHI%R)S4WL\53W=K1Z"C"?6->C)F(/Y?D>L_<6M7*" L9@((A _EAP"7Q
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M$CRC#];+(+(KW+C6'6?W(._8O>-3^H+YZA+?ERT7 .]>M_P<XB5.;,K6:Z,
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M/#CDZ(/0Q;/AA_CL1NLY'#2?&JE[Z_ \L?KK_&HQB=$FA<B K:=BF#K ,=@
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M[LWEIN?\=[P[*;W;.^;W6?5&*\NR K3*T\;!ZWE#R<"B=,95#R(]ZL"U8S/
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M%KIY*?=V4GJM=CMDQVHI]3[!LUEHIDZ$B?4VNQ2U>7[DX'R20"Q8SABSV+R
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MII<E0KOT?*\KV3(3&LD(!KDDC-;@C4)K* 5B4K DN]H#39]82HNE8CVBKX;
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MJK\0&CF&2J(A:UR^$*4E?BC;I-<J!1Y9OM^W^PGW8(=&3?LS&NO)O@;_>L;
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MA7>[V.JRL,HDDH!H1G&K4Q(L40Y"=(38,F^%Y2[' +[BUA& 7]UL_T^_O5]
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MC5).5N00I/:=9JML</(=S\R,C63<<6;&)@QO #=/CV]0''=;ITF9XQ=!D!#
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M;Z%E-G.:/3600T92$A[R3D?\8+3EG)) 1.WZ_6>6T\I H1;.PZU$U"+:;HV
ME(HS;6T YT0J;< ,6&IL:>A$N-'*R&CWC;:^AZ)6%_E+4-J2_\UX<0\(6OLG
M+(GDB"Y-Y-#3(2Z54=(&E+:9%2.!B'L)JR]X=4^\J#&8;"O.1WV]&KQM:N3R
M,LB9F:+>),A$EF0(R\%8I8#X:+0,FE-=HSYTRS'=!Q@I=-![@QT%T!1\;BD7
MX58XZ3,X53)J5)G$94N.IN7E/ISXT&T T&N8V+V1/+M,[-Z$N:U-[$;C7SC*
M- BM& B^&*U!"1CD46E4$N7]X9O'.K%[(RD]-[%[$Y:U,7?Y[HQAXG /Y"E
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MF-S,OC8PF@MTESSZ9(&7@<$.O%,1DDC6T(";M:M]*&Z FKUU/>AQ]]F(Y0T
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M$'7IH?52-FSZN!4$54@ 'G1ZB:(M,! IX)$5VJ<Z;U!W5T,[9FHG+6_&(SP
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M6#\^F?CT8>*H[N(/;IJ9'O\Z;18W3](/*55,.0%L2 :<Q!P8&36?X\8P+&S
M*'>%C8XD9H[%_J*CK6G]^97WZ10XB5 M,1L_]EJ<_7*W24H<8KQ(741WD[ZR
M45!RY[% @"2IM:QE(AJN5 %( C6<FV!\[B:>K[2TLAIW2(D^$#.N0E8J, ?.
M%V8V<B,]O3O7R6 _GS?VWZM.@H(QX;P%&&.2GF] $"TH!+"4TFJ.O6;9"Q6\
M1$Q5L><Z1&<[&S,+CC4(Y"/Y7_5U_/A]JB>SN/L?H[C,N'A-1!P$[UE<D?#
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ML^]^__=\*4H?KB:79_8XM7=@Z#*YR9V@:\><6M-P/DV7\8*!4G">CYXE_>8
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M Q:LA'L(BPV?\QYFE(X4/)!V]%O2K:&*8;.7VSM1J>AUZ<EXO$.7Y"F7^_+
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M+FAT;5!+ 0(4 Q0    ( .V 35K2;'UAP@(  /@'   >              "
M 4$E  !E>#(S+7!W8V-O;G-E;G1X9F]R;3$P>&MX,BYH=&U02P$"% ,4
M" #M@$U:/$,C?@$(  !R)@  '@              @ $_*   97@S,3$M,S R
M8V5R=&]F8V5O>&9O<FTQ,'@N:'1M4$L! A0#%     @ [8!-6CJ0:8#\!P
M<"8  !X              ( !?#   &5X,S$R+3,P,F-E<G1O9F-F;WAF;W)M
M,3!X+FAT;5!+ 0(4 Q0    ( .V 35H\+4MS0@4  )D;   >
M  "  ;0X  !E>#,R,2TY,#9C97)T;V9C96]X9F]R;3$P>"YH=&U02P$"% ,4
M    " #M@$U:V,<"S2L%  !4%P  '@              @ $R/@  97@S,C(M
M.3 V8V5R=&]F8V9O>&9O<FTQ,'@N:'1M4$L! A0#%     @ [8!-6CM1E.82
M+@  )!$! !X              ( !F4,  &5X-&(M9&5S8W)I<'1I;VYO9F-A
M<&ET86QS+FAT;5!+ 0(4 Q0    ( .V 35I#W4*%.M<# /#A-P 0
M      "  >=Q  !J;FHM,C R-#$R,CDN:'1M4$L! A0#%     @ [8!-6HP$
MR8H6*@  :/8! !               ( !3TD$ &IN:BTR,#(T,3(R.2YX<V10
M2P$"% ,4    " #M@$U:@Z]S69DU  !U* ( %               @ &3<P0
M:FYJ+3(P,C0Q,C(Y7V-A;"YX;6Q02P$"% ,4    " #M@$U:9M'R@:;X  "=
MW@H %               @ %>J00 :FYJ+3(P,C0Q,C(Y7V1E9BYX;6Q02P$"
M% ,4    " #M@$U:1H^&Y;Y:   B7P  $P              @ $VH@4 :FYJ
M+3(P,C0Q,C(Y7V<Q+FIP9U!+ 0(4 Q0    ( .V 35I&NUQS:Y<  #:=   4
M              "  27]!0!J;FHM,C R-#$R,CE?9S$P+FIP9U!+ 0(4 Q0
M   ( .V 35JTG.\ =\(! +C0 0 4              "  <*4!@!J;FHM,C R
M-#$R,CE?9S$Q+FIP9U!+ 0(4 Q0    ( .V 35K[P.PN[5(! #UE 0 4
M          "  6M7" !J;FHM,C R-#$R,CE?9S$R+FIP9U!+ 0(4 Q0    (
M .V 35K*03D)V2   /XN   4              "  8JJ"0!J;FHM,C R-#$R
M,CE?9S$S+FIP9U!+ 0(4 Q0    ( .V 35H*NF(9W1T  )(J   4
M      "  97+"0!J;FHM,C R-#$R,CE?9S$T+FIP9U!+ 0(4 Q0    ( .V
M35H[5B6@SAT  %<J   4              "  :3I"0!J;FHM,C R-#$R,CE?
M9S$U+FIP9U!+ 0(4 Q0    ( .V 35H(<Z ,!7$  /2"   4
M  "  :0'"@!J;FHM,C R-#$R,CE?9S$V+FIP9U!+ 0(4 Q0    ( .V 35I1
M>NL:=4T  '!=   4              "  =MX"@!J;FHM,C R-#$R,CE?9S$W
M+FIP9U!+ 0(4 Q0    ( .V 35H0^UCT+"P  !4Z   4              "
M 8+&"@!J;FHM,C R-#$R,CE?9S$X+FIP9U!+ 0(4 Q0    ( .V 35J$^ ('
MNRL  " [   4              "  >#R"@!J;FHM,C R-#$R,CE?9S$Y+FIP
M9U!+ 0(4 Q0    ( .V 35HZ$K*"G7(  ,U_   3              "  <T>
M"P!J;FHM,C R-#$R,CE?9S(N:G!G4$L! A0#%     @ [8!-6EIOM507+P
MO#T  !0              ( !FY$+ &IN:BTR,#(T,3(R.5]G,C N:G!G4$L!
M A0#%     @ [8!-6E02Q.I"&@  0S0  !0              ( !Y, + &IN
M:BTR,#(T,3(R.5]G,C$N:G!G4$L! A0#%     @ [8!-6NU1EW,R(@  !3\
M !0              ( !6-L+ &IN:BTR,#(T,3(R.5]G,C(N:G!G4$L! A0#
M%     @ [8!-6G&5FZ>I(0  ^T(  !0              ( !O/T+ &IN:BTR
M,#(T,3(R.5]G,C,N:G!G4$L! A0#%     @ [8!-6F35F8SX(   .$(  !0
M             ( !EQ\, &IN:BTR,#(T,3(R.5]G,C0N:G!G4$L! A0#%
M  @ [8!-6H8<6_OHE@  ?K$  !0              ( !P4 , &IN:BTR,#(T
M,3(R.5]G,C4N:G!G4$L! A0#%     @ [8!-6L41HY+]J   5L,  !0
M         ( !V]<, &IN:BTR,#(T,3(R.5]G,C8N:G!G4$L! A0#%     @
M[8!-6KU>7OSA6P$ /&L! !,              ( !"H$- &IN:BTR,#(T,3(R
M.5]G,RYJ<&=02P$"% ,4    " #M@$U:-GD;.=(T 0#-2 $ $P
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M,C0Q,C(Y7VQA8BYX;6Q02P$"% ,4    " #M@$U:UHQ^'[UO 0#GS1  %
M            @ '*"1D :FYJ+3(P,C0Q,C(Y7W!R92YX;6Q02P4&     "@
,* "/"@  N7D:

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>jnj-20241229_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:jnj="http://www.jnj.com/20241229"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="jnj-20241229.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.150NotesDueNovember2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A3.20NotesDueNovember2032Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A3.350NotesDueNovember2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A3.550NotesDueNovember2044Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2025-02-06</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">jnj:KenvueIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-08</startDate>
            <endDate>2023-05-08</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">jnj:KenvueIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-08</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2023-05-08</startDate>
            <endDate>2023-05-08</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">jnj:KenvueIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">jnj:JohnsonJohnsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-08</startDate>
            <endDate>2023-05-08</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">jnj:KenvueIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">jnj:JohnsonJohnsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-02</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">jnj:KenvueIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-23</startDate>
            <endDate>2023-08-23</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">jnj:KenvueIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">jnj:JohnsonJohnsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-23</startDate>
            <endDate>2023-08-23</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">jnj:YellowJerseyTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">jnj:OtherSovereignSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">jnj:OtherSovereignSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-30</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-30</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2024-05-15</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2024-05-15</startDate>
            <endDate>2024-05-15</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2024-05-17</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2024-05-17</startDate>
            <endDate>2024-05-17</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ProteologixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A055NotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A055NotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.80DebenturesDue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.80DebenturesDue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A130NotesDue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A130NotesDue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.90DebenturesDue2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.90DebenturesDue2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.20DebenturesDue2032Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.20DebenturesDue2032Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95DebenturesDue2034Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95DebenturesDue2034Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.35DebenturesDue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.35DebenturesDue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55DebenturesDue2044Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55DebenturesDue2044Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.25DebenturesDue2054Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.25DebenturesDue2054Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2023-10-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:QualifiedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:QualifiedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:NonQualifiedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:NonQualifiedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:FundedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:FundedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:UnfundedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:UnfundedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">jnj:December172018ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-14</instant>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">jnj:A2022LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-500">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-548">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-557">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-559">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-564">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-565">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-566">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-573">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-574">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-580">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-584">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-586">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-591">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-592">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-599">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-600">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TECVAYLIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TECVAYLIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TECVAYLIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TECVAYLIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TECVAYLIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-631">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TECVAYLIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-632">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TECVAYLIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-633">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TECVAYLIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-634">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TECVAYLIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-641">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-642">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-643">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-644">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-645">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-647">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-649">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-650">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-652">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-654">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-655">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-657">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-659">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-661">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-662">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-664">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-665">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-666">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-668">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-669">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-670">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-672">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-673">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-674">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-675">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-676">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-677">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-679">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-680">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherPulmonaryHypertensionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-681">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherPulmonaryHypertensionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-682">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherPulmonaryHypertensionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-683">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherPulmonaryHypertensionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-684">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherPulmonaryHypertensionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-685">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherPulmonaryHypertensionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-686">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherPulmonaryHypertensionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherPulmonaryHypertensionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-688">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherPulmonaryHypertensionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-689">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-690">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-691">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-692">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-693">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-695">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-696">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-697">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-698">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-699">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-708">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-709">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-724">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-732">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ELECTROPHYSIOLOGYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-733">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ELECTROPHYSIOLOGYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ELECTROPHYSIOLOGYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-735">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ELECTROPHYSIOLOGYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-736">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ELECTROPHYSIOLOGYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-737">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ELECTROPHYSIOLOGYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-738">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ELECTROPHYSIOLOGYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-739">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ELECTROPHYSIOLOGYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-740">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ELECTROPHYSIOLOGYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-741">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AbiomedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-742">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AbiomedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-743">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AbiomedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-744">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AbiomedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-745">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AbiomedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-746">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AbiomedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-747">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AbiomedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-748">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AbiomedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-749">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AbiomedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-751">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-752">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-753">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-754">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-755">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-756">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-757">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-758">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-759">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherCardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-760">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherCardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-761">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherCardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-762">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherCardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-763">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherCardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-764">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherCardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-765">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherCardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-766">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherCardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-767">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherCardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-768">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-769">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-770">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-771">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-772">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-773">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-774">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-775">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-776">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-777">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-778">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-779">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-780">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-782">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-783">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-784">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-785">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-786">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-787">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-788">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-789">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-790">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-791">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-792">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-793">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-794">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-795">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-796">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-797">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-798">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-799">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-800">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-809">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-813">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-817">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-818">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-819">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-820">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-822">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-824">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-826">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-827">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-829">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-832">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-833">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-834">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-835">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-836">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-837">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-838">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-839">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-840">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-841">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-842">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-844">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-845">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-846">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-847">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-848">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-849">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-850">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-851">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-852">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-853">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-854">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-855">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-856">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-857">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-858">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-859">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-860">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-861">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-862">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-863">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-864">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-865">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-866">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-867">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-868">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-869">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-870">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-871">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-872">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-873">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-874">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-875">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-876">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-877">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-878">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-879">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-880">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-881">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-882">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-883">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-884">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-885">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-886">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-887">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-888">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-889">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-890">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-891">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-892">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-893">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-894">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-895">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-896">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-897">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-898">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-899">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-900">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-902">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-903">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-904">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-906">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-907">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-911">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-912">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-914">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-916">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-917">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-919">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-920">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-921">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-922">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-923">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-924">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-929">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-931">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-932">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-933">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-934">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-935">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-936">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-937">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-938">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-939">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-940">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-941">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-942">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:VWaveLtd.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-943">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-944">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:LaminarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-945">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-946">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-947">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-948">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-949">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-950">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:IntraCellularTherapiesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-13</instant>
        </period>
    </context>
    <context id="c-951">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:IntraCellularTherapiesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-02-13</endDate>
        </period>
    </context>
    <context id="c-952">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ProteologixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-20</startDate>
            <endDate>2024-06-20</endDate>
        </period>
    </context>
    <context id="c-953">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ProteologixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-20</instant>
        </period>
    </context>
    <context id="c-954">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ProteologixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-20</instant>
        </period>
    </context>
    <context id="c-955">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ProteologixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-20</instant>
        </period>
    </context>
    <context id="c-956">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ProteologixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-957">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="c-958">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-959">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-29</endDate>
        </period>
    </context>
    <context id="c-960">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-20</instant>
        </period>
    </context>
    <context id="c-961">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-31</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="c-962">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-963">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:ShockwaveMedicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="c-964">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AmbrxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-965">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AmbrxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-966">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AmbrxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-967">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AmbrxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-968">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="c-969">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="c-970">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jnj:NonTradeableContingentValueRightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="c-971">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="c-972">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ImpellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="c-973">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ClassIRecommendationForImpellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="c-974">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-975">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-976">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="c-977">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="c-978">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">jnj:VWaveLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-08</startDate>
            <endDate>2024-10-08</endDate>
        </period>
    </context>
    <context id="c-979">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">jnj:VWaveLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-08</startDate>
            <endDate>2024-10-08</endDate>
        </period>
    </context>
    <context id="c-980">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">jnj:VWaveLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-08</instant>
        </period>
    </context>
    <context id="c-981">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">jnj:YellowJerseyTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-11</startDate>
            <endDate>2024-07-11</endDate>
        </period>
    </context>
    <context id="c-982">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">jnj:YellowJerseyTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-11</instant>
        </period>
    </context>
    <context id="c-983">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">jnj:LaminarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-984">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">jnj:LaminarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-985">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:AcclarentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-986">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:PonvoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-987">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:InghamVsJohnsonJohnsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="c-988">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:InghamVsJohnsonJohnsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c-989">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:InghamVsJohnsonJohnsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c-990">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-01</endDate>
        </period>
    </context>
    <context id="c-991">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-01</instant>
        </period>
    </context>
    <context id="c-992">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-20</startDate>
            <endDate>2024-09-20</endDate>
        </period>
    </context>
    <context id="c-993">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:MesotheliomaAndStateClaimsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-01</endDate>
        </period>
    </context>
    <context id="c-994">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-30</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-995">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-996">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-997">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-04</instant>
        </period>
    </context>
    <context id="c-998">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-999">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AsrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-1000">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PinnacleAcetabularCupSystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-1001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PelvicMeshesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-1002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-1003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RisperdalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-1004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ElmironMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-1005">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:DePuyASRU.S.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-1006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c-1007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c-1008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="c-1009">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="c-1010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:RDRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-1011">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:RDRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1012">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:RDRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-1013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:OrthopaedicsRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-1014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:OrthopaedicsRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:OrthopaedicsRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-1016">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:OrthopaedicsRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-1017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:OrthopaedicsRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-1018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:CostsOfGoodsAndServicesSoldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:InnovativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-1021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:CostsOfGoodsAndServicesSoldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <context id="c-1022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:CostsOfGoodsAndServicesSoldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">jnj:KenvueIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-23</startDate>
            <endDate>2023-08-23</endDate>
        </period>
    </context>
    <context id="c-1025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">jnj:KenvueIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-23</startDate>
            <endDate>2023-08-23</endDate>
        </period>
    </context>
    <context id="c-1026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2023-08-23</instant>
        </period>
    </context>
    <context id="c-1027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">jnj:KenvueIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">jnj:JohnsonJohnsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-23</instant>
        </period>
    </context>
    <context id="c-1028">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">jnj:KenvueIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">jnj:JohnsonJohnsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-29</instant>
        </period>
    </context>
    <context id="c-1029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:ConsumerHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-23</instant>
        </period>
    </context>
    <context id="c-1030">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:ConsumerHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-23</startDate>
            <endDate>2023-08-23</endDate>
        </period>
    </context>
    <context id="c-1031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">jnj:KenvueIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:ConsumerHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">jnj:JohnsonJohnsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-23</instant>
        </period>
    </context>
    <context id="c-1032">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2023-08-23</startDate>
            <endDate>2023-08-23</endDate>
        </period>
    </context>
    <context id="c-1033">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-23</startDate>
            <endDate>2023-08-23</endDate>
        </period>
    </context>
    <context id="c-1034">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-23</startDate>
            <endDate>2023-08-23</endDate>
        </period>
    </context>
    <context id="c-1035">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2024-09-30</startDate>
            <endDate>2024-12-29</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="employee">
        <measure>jnj:Employee</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>jnj:Segment</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="stockbasedcompensationplans">
        <measure>jnj:StockBasedCompensationPlans</measure>
    </unit>
    <unit id="segment2">
        <measure>jnj:segment</measure>
    </unit>
    <unit id="claimant">
        <measure>jnj:claimant</measure>
    </unit>
    <unit id="cases">
        <measure>jnj:cases</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-46">0000200406</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-47">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-48">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-49">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName contextRef="c-1" id="f-50">Johnson &amp; Johnson</dei:EntityRegistrantName>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-10" id="f-539">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-11" id="f-540">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-10" id="f-541">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-11" id="f-542">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-11" id="f-543">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-10" id="f-544">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration contextRef="c-10" id="f-579">http://fasb.org/us-gaap/2024#AccountsPayableCurrent</us-gaap:SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration contextRef="c-11" id="f-580">http://fasb.org/us-gaap/2024#AccountsPayableCurrent</us-gaap:SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-107" id="f-767">P25Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-1" id="f-905">http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense</us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-12" id="f-906">http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense</us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-1" id="f-2949">http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense</us-gaap:ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-12-29</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-29</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">1-3215</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">NJ</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">22-1024240</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">One Johnson &amp; Johnson Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">New Brunswick</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">08933</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">732</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">524-0400</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-2" id="f-15">Common Stock, Par Value $1.00</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-2" id="f-16">JNJ</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-17">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-3" id="f-18">1.150% Notes Due November 2028</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-19">JNJ28</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-3" id="f-20">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-4" id="f-21">3.20% Notes Due November 2032</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-4" id="f-22">JNJ32</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-4" id="f-23">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-5" id="f-24">1.650% Notes Due May 2035</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-5" id="f-25">JNJ35</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-5" id="f-26">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-6" id="f-27">3.350% Notes Due November 2036</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-6" id="f-28">JNJ36A</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-6" id="f-29">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-7" id="f-30">3.550% Notes Due November 2044</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-7" id="f-31">JNJ44</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-7" id="f-32">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-33">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-34">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-35">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-36">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-37">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-38">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-39">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-40">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-41">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-42">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-8" decimals="-9" id="f-43" unitRef="usd">352000000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-9" decimals="INF" id="f-44" unitRef="shares">2407616693</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-45">&lt;div style="margin-top:4pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:110%"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:93.153%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%"&gt;Part III:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%"&gt;Portions of the registrant&#x2019;s proxy statement for its 2025 annual meeting of shareholders to be filed within 120&#160;days after the close of the registrant&#x2019;s fiscal year (the &#x201c;Proxy Statement&#x201d;), are incorporated by reference to this report on Form 10-K (this &#x201c;Report&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c-1" id="f-51">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company has documented cybersecurity policies and standards, assesses risks from cybersecurity threats, and monitors information systems for potential cybersecurity issues. To protect the Company&#x2019;s information systems from cybersecurity threats, the Company uses various security tools supporting protection, detection, and response capabilities. The Company maintains a cybersecurity incident response plan to help ensure a timely, consistent response to actual or attempted cybersecurity incidents impacting the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company also identifies and assesses third-party risks within the enterprise, and through the Company's use of third-party service providers, across a range of areas including data security and supply chain through a structured third-party risk management program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company maintains a formal information security training program for all employees that includes training on matters such as phishing and email security best practices. Employees are also required to complete mandatory training on data privacy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;To evaluate and enhance its cybersecurity program, the Company periodically utilizes third-party experts to undertake maturity assessments of the Company&#x2019;s information security program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;To date, the Company is not aware of any cybersecurity incident that has had or is reasonably likely to have a material impact on the Company&#x2019;s business or operations; however, because of the frequently changing attack techniques, along with the increased volume and sophistication of the attacks, there is the potential for the Company to be adversely impacted. This impact could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action. Refer to the risk factor captioned An information security incident, including a cybersecurity breach, could have a negative impact to the Company&#x2019;s business or reputation in Part I, Item 1A. Risk factors for additional description of cybersecurity risks and potential related impacts on the Company.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c-1" id="f-52">The Company has documented cybersecurity policies and standards, assesses risks from cybersecurity threats, and monitors information systems for potential cybersecurity issues. To protect the Company&#x2019;s information systems from cybersecurity threats, the Company uses various security tools supporting protection, detection, and response capabilities. The Company maintains a cybersecurity incident response plan to help ensure a timely, consistent response to actual or attempted cybersecurity incidents impacting the Company.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-53">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-55">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c-1" id="f-54">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-56">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c-1" id="f-57">&lt;div style="margin-bottom:6pt;margin-top:16pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt;Governance - management&#x2019;s responsibility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company takes a risk-based approach to cybersecurity and has implemented cybersecurity controls designed to address cybersecurity threats and risks. The Chief Information Officer (CIO), who is a member of the Company&#x2019;s Executive Committee, and the Chief Information Security Officer (CISO) are responsible for assessing and managing cybersecurity risks, including security incident detection, response, and recovery.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company&#x2019;s CISO, in coordination with the CIO, is responsible for leading the Company&#x2019;s cybersecurity program and management of cybersecurity risk. The current CISO has over twenty-five years of experience in information security, and his background includes technical experience, strategy and architecture focused roles, cyber and threat experience, and various leadership roles.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-58">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company takes a risk-based approach to cybersecurity and has implemented cybersecurity controls designed to address cybersecurity threats and risks. The Chief Information Officer (CIO), who is a member of the Company&#x2019;s Executive Committee, and the Chief Information Security Officer (CISO) are responsible for assessing and managing cybersecurity risks, including security incident detection, response, and recovery.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c-1" id="f-59">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c-1" id="f-60">The current CISO has over twenty-five years of experience in information security, and his background includes technical experience, strategy and architecture focused roles, cyber and threat experience, and various leadership roles.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c-1" id="f-61">&lt;div style="margin-bottom:6pt;margin-top:16pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt;Governance - board oversight&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company&#x2019;s Board of Directors oversees the overall risk management process, including cybersecurity risks, directly and through its committees. The Regulatory Compliance &amp;amp; Sustainability Committee (RCSC) of the board is primarily responsible for oversight of risk from cybersecurity threats and oversees compliance with applicable laws, regulations and Company policies related to, among others, privacy and cybersecurity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;RCSC meetings include discussions of specific risk areas throughout the year including, among others, those relating to cybersecurity. The CISO provides quarterly updates each year to RCSC on cybersecurity matters. These reports include an overview of the cybersecurity threat landscape, key cybersecurity initiatives to improve the Company&#x2019;s risk posture, changes in the legal and regulatory landscape relative to cybersecurity, and overviews of certain cybersecurity incidents that have occurred within the Company and within the industry.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-63">The Company&#x2019;s Board of Directors oversees the overall risk management process, including cybersecurity risks, directly and through its committees. The Regulatory Compliance &amp;amp; Sustainability Committee (RCSC) of the board is primarily responsible for oversight of risk from cybersecurity threats and oversees compliance with applicable laws, regulations and Company policies related to, among others, privacy and cybersecurity.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-62">The Company&#x2019;s Board of Directors oversees the overall risk management process, including cybersecurity risks, directly and through its committees. The Regulatory Compliance &amp;amp; Sustainability Committee (RCSC) of the board is primarily responsible for oversight of risk from cybersecurity threats and oversees compliance with applicable laws, regulations and Company policies related to, among others, privacy and cybersecurity.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-64">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-65">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;RCSC meetings include discussions of specific risk areas throughout the year including, among others, those relating to cybersecurity. The CISO provides quarterly updates each year to RCSC on cybersecurity matters. These reports include an overview of the cybersecurity threat landscape, key cybersecurity initiatives to improve the Company&#x2019;s risk posture, changes in the legal and regulatory landscape relative to cybersecurity, and overviews of certain cybersecurity incidents that have occurred within the Company and within the industry.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <dei:AuditorFirmId contextRef="c-1" id="f-66">238</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-10" decimals="-6" id="f-67" unitRef="usd">24105000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-11" decimals="-6" id="f-68" unitRef="usd">21859000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-10" decimals="-6" id="f-69" unitRef="usd">417000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-11" decimals="-6" id="f-70" unitRef="usd">1068000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-10" decimals="-6" id="f-71" unitRef="usd">167000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-11" decimals="-6" id="f-72" unitRef="usd">166000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-10" decimals="-6" id="f-73" unitRef="usd">14842000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-11" decimals="-6" id="f-74" unitRef="usd">14873000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-10" decimals="-6" id="f-75" unitRef="usd">12444000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-11" decimals="-6" id="f-76" unitRef="usd">11181000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-10" decimals="-6" id="f-77" unitRef="usd">4085000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-11" decimals="-6" id="f-78" unitRef="usd">4514000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-10" decimals="-6" id="f-79" unitRef="usd">55893000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-11" decimals="-6" id="f-80" unitRef="usd">53495000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-10" decimals="-6" id="f-81" unitRef="usd">20518000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-11" decimals="-6" id="f-82" unitRef="usd">19898000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-10" decimals="-6" id="f-83" unitRef="usd">37618000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-11" decimals="-6" id="f-84" unitRef="usd">34175000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="c-10" decimals="-6" id="f-85" unitRef="usd">44200000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-11" decimals="-6" id="f-86" unitRef="usd">36558000000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-10" decimals="-6" id="f-87" unitRef="usd">10461000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-11" decimals="-6" id="f-88" unitRef="usd">9279000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-10" decimals="-6" id="f-89" unitRef="usd">11414000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-11" decimals="-6" id="f-90" unitRef="usd">14153000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-10" decimals="-6" id="f-91" unitRef="usd">180104000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-11" decimals="-6" id="f-92" unitRef="usd">167558000000</us-gaap:Assets>
    <us-gaap:ShortTermBorrowings contextRef="c-10" decimals="-6" id="f-93" unitRef="usd">5983000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c-11" decimals="-6" id="f-94" unitRef="usd">3451000000</us-gaap:ShortTermBorrowings>
    <us-gaap:AccountsPayableCurrent contextRef="c-10" decimals="-6" id="f-95" unitRef="usd">10311000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-11" decimals="-6" id="f-96" unitRef="usd">9632000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-10" decimals="-6" id="f-97" unitRef="usd">8549000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-11" decimals="-6" id="f-98" unitRef="usd">10212000000</us-gaap:AccruedLiabilitiesCurrent>
    <jnj:AccruedRebatesReturnsAndPromotions contextRef="c-10" decimals="-6" id="f-99" unitRef="usd">17580000000</jnj:AccruedRebatesReturnsAndPromotions>
    <jnj:AccruedRebatesReturnsAndPromotions contextRef="c-11" decimals="-6" id="f-100" unitRef="usd">16001000000</jnj:AccruedRebatesReturnsAndPromotions>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-10" decimals="-6" id="f-101" unitRef="usd">4126000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-11" decimals="-6" id="f-102" unitRef="usd">3993000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-10" decimals="-6" id="f-103" unitRef="usd">3772000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-11" decimals="-6" id="f-104" unitRef="usd">2993000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-10" decimals="-6" id="f-105" unitRef="usd">50321000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-11" decimals="-6" id="f-106" unitRef="usd">46282000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-10" decimals="-6" id="f-107" unitRef="usd">30651000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-11" decimals="-6" id="f-108" unitRef="usd">25881000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-10" decimals="-6" id="f-109" unitRef="usd">2448000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-11" decimals="-6" id="f-110" unitRef="usd">3193000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent contextRef="c-10" decimals="-6" id="f-111" unitRef="usd">7255000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent contextRef="c-11" decimals="-6" id="f-112" unitRef="usd">7149000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent contextRef="c-10" decimals="-6" id="f-113" unitRef="usd">390000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent contextRef="c-11" decimals="-6" id="f-114" unitRef="usd">2881000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-10" decimals="-6" id="f-115" unitRef="usd">17549000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-11" decimals="-6" id="f-116" unitRef="usd">13398000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-10" decimals="-6" id="f-117" unitRef="usd">108614000000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-11" decimals="-6" id="f-118" unitRef="usd">98784000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-10" id="f-119" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-11" id="f-120" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-10"
      decimals="INF"
      id="f-121"
      unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-11"
      decimals="INF"
      id="f-122"
      unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockValue contextRef="c-10" decimals="-6" id="f-123" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-11" decimals="-6" id="f-124" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-11"
      decimals="INF"
      id="f-125"
      unitRef="usdPerShare">1.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-10"
      decimals="INF"
      id="f-126"
      unitRef="usdPerShare">1.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-11"
      decimals="INF"
      id="f-127"
      unitRef="shares">4320000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-10"
      decimals="INF"
      id="f-128"
      unitRef="shares">4320000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-11" decimals="-3" id="f-129" unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-10" decimals="-3" id="f-130" unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-10" decimals="-6" id="f-131" unitRef="usd">3120000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-11" decimals="-6" id="f-132" unitRef="usd">3120000000</us-gaap:CommonStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-10" decimals="-6" id="f-133" unitRef="usd">-11741000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-11" decimals="-6" id="f-134" unitRef="usd">-12527000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-10" decimals="-6" id="f-135" unitRef="usd">155791000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-11" decimals="-6" id="f-136" unitRef="usd">153843000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares contextRef="c-10" decimals="-3" id="f-137" unitRef="shares">712921000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-11" decimals="-3" id="f-138" unitRef="shares">712765000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue contextRef="c-10" decimals="-6" id="f-139" unitRef="usd">75680000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="c-11" decimals="-6" id="f-140" unitRef="usd">75662000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-10" decimals="-6" id="f-141" unitRef="usd">71490000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-11" decimals="-6" id="f-142" unitRef="usd">68774000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-10" decimals="-6" id="f-143" unitRef="usd">180104000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-11" decimals="-6" id="f-144" unitRef="usd">167558000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-6" id="f-145" unitRef="usd">88821000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-6" id="f-146" unitRef="usd">85159000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-6" id="f-147" unitRef="usd">79990000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-6" id="f-148" unitRef="usd">27471000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-12" decimals="-6" id="f-149" unitRef="usd">26553000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-13" decimals="-6" id="f-150" unitRef="usd">24596000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c-1" decimals="-6" id="f-151" unitRef="usd">61350000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-12" decimals="-6" id="f-152" unitRef="usd">58606000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-13" decimals="-6" id="f-153" unitRef="usd">55394000000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-6" id="f-154" unitRef="usd">22869000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-12" decimals="-6" id="f-155" unitRef="usd">21512000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-13" decimals="-6" id="f-156" unitRef="usd">20246000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-1" decimals="-6" id="f-157" unitRef="usd">17232000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-12" decimals="-6" id="f-158" unitRef="usd">15085000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-13" decimals="-6" id="f-159" unitRef="usd">14135000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <jnj:ResearchAndDevelopmentInProcess1 contextRef="c-1" decimals="-6" id="f-160" unitRef="usd">211000000</jnj:ResearchAndDevelopmentInProcess1>
    <jnj:ResearchAndDevelopmentInProcess1 contextRef="c-12" decimals="-6" id="f-161" unitRef="usd">313000000</jnj:ResearchAndDevelopmentInProcess1>
    <jnj:ResearchAndDevelopmentInProcess1 contextRef="c-13" decimals="-6" id="f-162" unitRef="usd">783000000</jnj:ResearchAndDevelopmentInProcess1>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-6" id="f-163" unitRef="usd">1332000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-12" decimals="-6" id="f-164" unitRef="usd">1261000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-13" decimals="-6" id="f-165" unitRef="usd">490000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-6" id="f-166" unitRef="usd">755000000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-12" decimals="-6" id="f-167" unitRef="usd">772000000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-13" decimals="-6" id="f-168" unitRef="usd">276000000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-6" id="f-169" unitRef="usd">-4694000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-12" decimals="-6" id="f-170" unitRef="usd">-6634000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-13" decimals="-6" id="f-171" unitRef="usd">-810000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-6" id="f-172" unitRef="usd">234000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-12" decimals="-6" id="f-173" unitRef="usd">489000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-13" decimals="-6" id="f-174" unitRef="usd">275000000</us-gaap:RestructuringCharges>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-175" unitRef="usd">16687000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-12" decimals="-6" id="f-176" unitRef="usd">15062000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-13" decimals="-6" id="f-177" unitRef="usd">19359000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-178" unitRef="usd">2621000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-6" id="f-179" unitRef="usd">1736000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-6" id="f-180" unitRef="usd">2989000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-1" decimals="-6" id="f-181" unitRef="usd">14066000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-12" decimals="-6" id="f-182" unitRef="usd">13326000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-13" decimals="-6" id="f-183" unitRef="usd">16370000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-1" decimals="-6" id="f-184" unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-12" decimals="-6" id="f-185" unitRef="usd">21827000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-13" decimals="-6" id="f-186" unitRef="usd">1571000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-6" id="f-187" unitRef="usd">14066000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-6" id="f-188" unitRef="usd">35153000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-6" id="f-189" unitRef="usd">17941000000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-190"
      unitRef="usdPerShare">5.84</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-12"
      decimals="2"
      id="f-191"
      unitRef="usdPerShare">5.26</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-13"
      decimals="2"
      id="f-192"
      unitRef="usdPerShare">6.23</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-193"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="c-12"
      decimals="2"
      id="f-194"
      unitRef="usdPerShare">8.62</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="c-13"
      decimals="2"
      id="f-195"
      unitRef="usdPerShare">0.60</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-196"
      unitRef="usdPerShare">5.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-12"
      decimals="2"
      id="f-197"
      unitRef="usdPerShare">13.88</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-13"
      decimals="2"
      id="f-198"
      unitRef="usdPerShare">6.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-199"
      unitRef="usdPerShare">5.79</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-12"
      decimals="2"
      id="f-200"
      unitRef="usdPerShare">5.20</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-13"
      decimals="2"
      id="f-201"
      unitRef="usdPerShare">6.14</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-202"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="c-12"
      decimals="2"
      id="f-203"
      unitRef="usdPerShare">8.52</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="c-13"
      decimals="2"
      id="f-204"
      unitRef="usdPerShare">0.59</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-205"
      unitRef="usdPerShare">5.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-12"
      decimals="2"
      id="f-206"
      unitRef="usdPerShare">13.72</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-13"
      decimals="2"
      id="f-207"
      unitRef="usdPerShare">6.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-208" unitRef="shares">2407300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-12" decimals="-5" id="f-209" unitRef="shares">2533500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-13" decimals="-5" id="f-210" unitRef="shares">2625200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-211" unitRef="shares">2429400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-12" decimals="-5" id="f-212" unitRef="shares">2560400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-13" decimals="-5" id="f-213" unitRef="shares">2663900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-6" id="f-214" unitRef="usd">14066000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-6" id="f-215" unitRef="usd">35153000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-6" id="f-216" unitRef="usd">17941000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax contextRef="c-1" decimals="-6" id="f-217" unitRef="usd">1708000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax contextRef="c-12" decimals="-6" id="f-218" unitRef="usd">-3221000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax contextRef="c-13" decimals="-6" id="f-219" unitRef="usd">-1796000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-6" id="f-220" unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-12" decimals="-6" id="f-221" unitRef="usd">26000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-13" decimals="-6" id="f-222" unitRef="usd">-24000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="c-1" decimals="-6" id="f-223" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="c-12" decimals="-6" id="f-224" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="c-13" decimals="-6" id="f-225" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="-6" id="f-226" unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-12" decimals="-6" id="f-227" unitRef="usd">26000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-13" decimals="-6" id="f-228" unitRef="usd">-24000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax contextRef="c-1" decimals="-6" id="f-229" unitRef="usd">154000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax contextRef="c-12" decimals="-6" id="f-230" unitRef="usd">149000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax contextRef="c-13" decimals="-6" id="f-231" unitRef="usd">160000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax contextRef="c-1" decimals="-6" id="f-232" unitRef="usd">-541000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax contextRef="c-12" decimals="-6" id="f-233" unitRef="usd">1183000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax contextRef="c-13" decimals="-6" id="f-234" unitRef="usd">-1854000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <us-gaap:OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax contextRef="c-1" decimals="-6" id="f-235" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax>
    <us-gaap:OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax contextRef="c-12" decimals="-6" id="f-236" unitRef="usd">-23000000</us-gaap:OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax>
    <us-gaap:OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax contextRef="c-13" decimals="-6" id="f-237" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax>
    <jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax contextRef="c-1" decimals="-6" id="f-238" unitRef="usd">-62000000</jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax>
    <jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax contextRef="c-12" decimals="-6" id="f-239" unitRef="usd">90000000</jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax>
    <jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax contextRef="c-13" decimals="-6" id="f-240" unitRef="usd">-111000000</jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-1" decimals="-6" id="f-241" unitRef="usd">-449000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-12" decimals="-6" id="f-242" unitRef="usd">1399000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-13" decimals="-6" id="f-243" unitRef="usd">-1805000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-1" decimals="-6" id="f-244" unitRef="usd">-511000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-12" decimals="-6" id="f-245" unitRef="usd">422000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-13" decimals="-6" id="f-246" unitRef="usd">454000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-1" decimals="-6" id="f-247" unitRef="usd">862000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-12" decimals="-6" id="f-248" unitRef="usd">569000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-13" decimals="-6" id="f-249" unitRef="usd">348000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-1" decimals="-6" id="f-250" unitRef="usd">-1373000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-12" decimals="-6" id="f-251" unitRef="usd">-147000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-13" decimals="-6" id="f-252" unitRef="usd">106000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-6" id="f-253" unitRef="usd">786000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-12" decimals="-6" id="f-254" unitRef="usd">-4741000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-13" decimals="-6" id="f-255" unitRef="usd">91000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-256" unitRef="usd">14852000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-12" decimals="-6" id="f-257" unitRef="usd">30412000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-13" decimals="-6" id="f-258" unitRef="usd">18032000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c-1" decimals="-8" id="f-259" unitRef="usd">-1100000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c-12" decimals="-6" id="f-260" unitRef="usd">797000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c-13" decimals="-6" id="f-261" unitRef="usd">-460000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax contextRef="c-1" decimals="-6" id="f-262" unitRef="usd">-86000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax contextRef="c-12" decimals="-6" id="f-263" unitRef="usd">289000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax contextRef="c-13" decimals="-6" id="f-264" unitRef="usd">-461000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax contextRef="c-1" decimals="-6" id="f-265" unitRef="usd">-365000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax contextRef="c-12" decimals="-6" id="f-266" unitRef="usd">-39000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax contextRef="c-13" decimals="-6" id="f-267" unitRef="usd">30000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-14" decimals="-6" id="f-268" unitRef="usd">74023000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-15" decimals="-6" id="f-269" unitRef="usd">123060000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-16" decimals="-6" id="f-270" unitRef="usd">-13058000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-17" decimals="-6" id="f-271" unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-18" decimals="-6" id="f-272" unitRef="usd">-39099000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-6" id="f-273" unitRef="usd">17941000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-19" decimals="-6" id="f-274" unitRef="usd">17941000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-13"
      decimals="INF"
      id="f-275"
      unitRef="usdPerShare">4.45</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash contextRef="c-13" decimals="-6" id="f-276" unitRef="usd">11682000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-19" decimals="-6" id="f-277" unitRef="usd">11682000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="-6" id="f-278" unitRef="usd">2466000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-19" decimals="-6" id="f-279" unitRef="usd">-974000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-20" decimals="-6" id="f-280" unitRef="usd">3440000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-13" decimals="-6" id="f-281" unitRef="usd">6035000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-20" decimals="-6" id="f-282" unitRef="usd">6035000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-13" decimals="-6" id="f-283" unitRef="usd">91000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-21" decimals="-6" id="f-284" unitRef="usd">91000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-22" decimals="-6" id="f-285" unitRef="usd">76804000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-23" decimals="-6" id="f-286" unitRef="usd">128345000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-24" decimals="-6" id="f-287" unitRef="usd">-12967000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-25" decimals="-6" id="f-288" unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-26" decimals="-6" id="f-289" unitRef="usd">-41694000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-6" id="f-290" unitRef="usd">35153000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-6" id="f-291" unitRef="usd">35153000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-12"
      decimals="INF"
      id="f-292"
      unitRef="usdPerShare">4.70</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash contextRef="c-12" decimals="-6" id="f-293" unitRef="usd">11770000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-27" decimals="-6" id="f-294" unitRef="usd">11770000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-12" decimals="-6" id="f-295" unitRef="usd">2193000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-27" decimals="-6" id="f-296" unitRef="usd">-336000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-28" decimals="-6" id="f-297" unitRef="usd">2529000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-12" decimals="-6" id="f-298" unitRef="usd">5054000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-28" decimals="-6" id="f-299" unitRef="usd">5054000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockholdersEquityOther contextRef="c-12" decimals="-6" id="f-300" unitRef="usd">25000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-28" decimals="-6" id="f-301" unitRef="usd">-25000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction contextRef="c-12" decimals="-6" id="f-302" unitRef="usd">-23786000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction contextRef="c-27" decimals="-6" id="f-303" unitRef="usd">2451000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction contextRef="c-29" decimals="-6" id="f-304" unitRef="usd">5181000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction contextRef="c-28" decimals="-6" id="f-305" unitRef="usd">-31418000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-12" decimals="-6" id="f-306" unitRef="usd">-4741000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-29" decimals="-6" id="f-307" unitRef="usd">-4741000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-11" decimals="-6" id="f-308" unitRef="usd">68774000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-30" decimals="-6" id="f-309" unitRef="usd">153843000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-6" id="f-310" unitRef="usd">-12527000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-6" id="f-311" unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-6" id="f-312" unitRef="usd">-75662000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-6" id="f-313" unitRef="usd">14066000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-34" decimals="-6" id="f-314" unitRef="usd">14066000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-1"
      decimals="INF"
      id="f-315"
      unitRef="usdPerShare">4.91</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash contextRef="c-1" decimals="-6" id="f-316" unitRef="usd">11823000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-34" decimals="-6" id="f-317" unitRef="usd">11823000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-6" id="f-318" unitRef="usd">2094000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-34" decimals="-6" id="f-319" unitRef="usd">-295000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-35" decimals="-6" id="f-320" unitRef="usd">2389000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-1" decimals="-6" id="f-321" unitRef="usd">2407000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-35" decimals="-6" id="f-322" unitRef="usd">2407000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-6" id="f-323" unitRef="usd">786000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-36" decimals="-6" id="f-324" unitRef="usd">786000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-10" decimals="-6" id="f-325" unitRef="usd">71490000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-37" decimals="-6" id="f-326" unitRef="usd">155791000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-38" decimals="-6" id="f-327" unitRef="usd">-11741000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-39" decimals="-6" id="f-328" unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-40" decimals="-6" id="f-329" unitRef="usd">-75680000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-6" id="f-330" unitRef="usd">14066000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-6" id="f-331" unitRef="usd">35153000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-6" id="f-332" unitRef="usd">17941000000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-6" id="f-333" unitRef="usd">7339000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-12" decimals="-6" id="f-334" unitRef="usd">7486000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-13" decimals="-6" id="f-335" unitRef="usd">6970000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-6" id="f-336" unitRef="usd">1176000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-12" decimals="-6" id="f-337" unitRef="usd">1162000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-13" decimals="-6" id="f-338" unitRef="usd">1138000000</us-gaap:ShareBasedCompensation>
    <us-gaap:AssetImpairmentCharges contextRef="c-1" decimals="-6" id="f-339" unitRef="usd">405000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-12" decimals="-6" id="f-340" unitRef="usd">1295000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-13" decimals="-6" id="f-341" unitRef="usd">1216000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-6" id="f-342" unitRef="usd">1841000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-12" decimals="-6" id="f-343" unitRef="usd">483000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-13" decimals="-6" id="f-344" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax contextRef="c-1" decimals="-6" id="f-345" unitRef="usd">0</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax contextRef="c-12" decimals="-6" id="f-346" unitRef="usd">20984000000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax contextRef="c-13" decimals="-6" id="f-347" unitRef="usd">0</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges contextRef="c-1" decimals="-6" id="f-348" unitRef="usd">226000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges contextRef="c-12" decimals="-6" id="f-349" unitRef="usd">117000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges contextRef="c-13" decimals="-6" id="f-350" unitRef="usd">380000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-351" unitRef="usd">-2183000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-12" decimals="-6" id="f-352" unitRef="usd">-4194000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-13" decimals="-6" id="f-353" unitRef="usd">-1663000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-1" decimals="-6" id="f-354" unitRef="usd">11000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-12" decimals="-6" id="f-355" unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-13" decimals="-6" id="f-356" unitRef="usd">-17000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-6" id="f-357" unitRef="usd">406000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-12" decimals="-6" id="f-358" unitRef="usd">624000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-13" decimals="-6" id="f-359" unitRef="usd">1290000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-6" id="f-360" unitRef="usd">1128000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-12" decimals="-6" id="f-361" unitRef="usd">1323000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-13" decimals="-6" id="f-362" unitRef="usd">2527000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-6" id="f-363" unitRef="usd">1621000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-12" decimals="-6" id="f-364" unitRef="usd">2346000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-13" decimals="-6" id="f-365" unitRef="usd">1098000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-1" decimals="-6" id="f-366" unitRef="usd">-1717000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-12" decimals="-6" id="f-367" unitRef="usd">3480000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-13" decimals="-6" id="f-368" unitRef="usd">-687000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-1" decimals="-6" id="f-369" unitRef="usd">33000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-12" decimals="-6" id="f-370" unitRef="usd">5588000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-13" decimals="-6" id="f-371" unitRef="usd">-1979000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-6" id="f-372" unitRef="usd">24266000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-12" decimals="-6" id="f-373" unitRef="usd">22791000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-13" decimals="-6" id="f-374" unitRef="usd">21194000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-6" id="f-375" unitRef="usd">4424000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-12" decimals="-6" id="f-376" unitRef="usd">4543000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-13" decimals="-6" id="f-377" unitRef="usd">4009000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="c-1" decimals="-6" id="f-378" unitRef="usd">675000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="c-12" decimals="-6" id="f-379" unitRef="usd">358000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="c-13" decimals="-6" id="f-380" unitRef="usd">543000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-1" decimals="-6" id="f-381" unitRef="usd">15146000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-12" decimals="-6" id="f-382" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-13" decimals="-6" id="f-383" unitRef="usd">17652000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <jnj:PaymentsToAcquiredInProcessResearchAndDevelopmentAssets contextRef="c-1" decimals="-6" id="f-384" unitRef="usd">1783000000</jnj:PaymentsToAcquiredInProcessResearchAndDevelopmentAssets>
    <jnj:PaymentsToAcquiredInProcessResearchAndDevelopmentAssets contextRef="c-12" decimals="-6" id="f-385" unitRef="usd">470000000</jnj:PaymentsToAcquiredInProcessResearchAndDevelopmentAssets>
    <jnj:PaymentsToAcquiredInProcessResearchAndDevelopmentAssets contextRef="c-13" decimals="-6" id="f-386" unitRef="usd">0</jnj:PaymentsToAcquiredInProcessResearchAndDevelopmentAssets>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-1" decimals="-6" id="f-387" unitRef="usd">1726000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-12" decimals="-6" id="f-388" unitRef="usd">10906000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-13" decimals="-6" id="f-389" unitRef="usd">32384000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="c-1" decimals="-6" id="f-390" unitRef="usd">2462000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="c-12" decimals="-6" id="f-391" unitRef="usd">19390000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="c-13" decimals="-6" id="f-392" unitRef="usd">41609000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities contextRef="c-1" decimals="-6" id="f-393" unitRef="usd">1517000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities contextRef="c-12" decimals="-6" id="f-394" unitRef="usd">-2963000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities contextRef="c-13" decimals="-6" id="f-395" unitRef="usd">-249000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-1" decimals="-6" id="f-396" unitRef="usd">174000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-12" decimals="-6" id="f-397" unitRef="usd">-12000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-13" decimals="-6" id="f-398" unitRef="usd">229000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-6" id="f-399" unitRef="usd">-18599000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-12" decimals="-6" id="f-400" unitRef="usd">878000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-13" decimals="-6" id="f-401" unitRef="usd">-12371000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfOrdinaryDividends contextRef="c-1" decimals="-6" id="f-402" unitRef="usd">11823000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsOfOrdinaryDividends contextRef="c-12" decimals="-6" id="f-403" unitRef="usd">11770000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsOfOrdinaryDividends contextRef="c-13" decimals="-6" id="f-404" unitRef="usd">11682000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="-6" id="f-405" unitRef="usd">2432000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-12" decimals="-6" id="f-406" unitRef="usd">5054000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-13" decimals="-6" id="f-407" unitRef="usd">6035000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c-1" decimals="-6" id="f-408" unitRef="usd">15277000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c-12" decimals="-6" id="f-409" unitRef="usd">13743000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c-13" decimals="-6" id="f-410" unitRef="usd">16134000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c-1" decimals="-6" id="f-411" unitRef="usd">9463000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c-12" decimals="-6" id="f-412" unitRef="usd">22973000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c-13" decimals="-6" id="f-413" unitRef="usd">6550000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-1" decimals="-6" id="f-414" unitRef="usd">6660000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-12" decimals="-6" id="f-415" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-13" decimals="-6" id="f-416" unitRef="usd">2000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-6" id="f-417" unitRef="usd">1453000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-12" decimals="-6" id="f-418" unitRef="usd">1551000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-13" decimals="-6" id="f-419" unitRef="usd">2134000000</us-gaap:RepaymentsOfLongTermDebt>
    <jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits contextRef="c-1" decimals="-6" id="f-420" unitRef="usd">838000000</jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits>
    <jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits contextRef="c-12" decimals="-6" id="f-421" unitRef="usd">1094000000</jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits>
    <jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits contextRef="c-13" decimals="-6" id="f-422" unitRef="usd">1329000000</jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities contextRef="c-1" decimals="-6" id="f-423" unitRef="usd">272000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities contextRef="c-12" decimals="-6" id="f-424" unitRef="usd">-219000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities contextRef="c-13" decimals="-6" id="f-425" unitRef="usd">-28000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities>
    <jnj:SettlementOfConvertibleDebtAcquiredFromShockwave contextRef="c-1" decimals="-6" id="f-426" unitRef="usd">970000000</jnj:SettlementOfConvertibleDebtAcquiredFromShockwave>
    <jnj:SettlementOfConvertibleDebtAcquiredFromShockwave contextRef="c-12" decimals="-6" id="f-427" unitRef="usd">0</jnj:SettlementOfConvertibleDebtAcquiredFromShockwave>
    <jnj:SettlementOfConvertibleDebtAcquiredFromShockwave contextRef="c-13" decimals="-6" id="f-428" unitRef="usd">0</jnj:SettlementOfConvertibleDebtAcquiredFromShockwave>
    <jnj:ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation contextRef="c-1" decimals="-6" id="f-429" unitRef="usd">0</jnj:ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation>
    <jnj:ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation contextRef="c-12" decimals="-6" id="f-430" unitRef="usd">8047000000</jnj:ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation>
    <jnj:ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation contextRef="c-13" decimals="-6" id="f-431" unitRef="usd">0</jnj:ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c-1" decimals="-6" id="f-432" unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c-12" decimals="-6" id="f-433" unitRef="usd">4241000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c-13" decimals="-6" id="f-434" unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <jnj:PaymentsMadeInBusinessSeparation contextRef="c-1" decimals="-6" id="f-435" unitRef="usd">0</jnj:PaymentsMadeInBusinessSeparation>
    <jnj:PaymentsMadeInBusinessSeparation contextRef="c-12" decimals="-6" id="f-436" unitRef="usd">1114000000</jnj:PaymentsMadeInBusinessSeparation>
    <jnj:PaymentsMadeInBusinessSeparation contextRef="c-13" decimals="-6" id="f-437" unitRef="usd">0</jnj:PaymentsMadeInBusinessSeparation>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-1" decimals="-6" id="f-438" unitRef="usd">-38000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-12" decimals="-6" id="f-439" unitRef="usd">-269000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-13" decimals="-6" id="f-440" unitRef="usd">93000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-6" id="f-441" unitRef="usd">-3132000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-12" decimals="-6" id="f-442" unitRef="usd">-15825000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-13" decimals="-6" id="f-443" unitRef="usd">-8871000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-6" id="f-444" unitRef="usd">-289000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-12" decimals="-6" id="f-445" unitRef="usd">-112000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-13" decimals="-6" id="f-446" unitRef="usd">-312000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-6" id="f-447" unitRef="usd">2246000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-12" decimals="-6" id="f-448" unitRef="usd">7732000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-13" decimals="-6" id="f-449" unitRef="usd">-360000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <jnj:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations contextRef="c-11" decimals="-6" id="f-450" unitRef="usd">21859000000</jnj:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations>
    <jnj:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations contextRef="c-22" decimals="-6" id="f-451" unitRef="usd">12889000000</jnj:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations>
    <jnj:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations contextRef="c-14" decimals="-6" id="f-452" unitRef="usd">13309000000</jnj:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-11" decimals="-6" id="f-453" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-22" decimals="-6" id="f-454" unitRef="usd">1238000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-14" decimals="-6" id="f-455" unitRef="usd">1178000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-11" decimals="-6" id="f-456" unitRef="usd">21859000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-22" decimals="-6" id="f-457" unitRef="usd">14127000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-14" decimals="-6" id="f-458" unitRef="usd">14487000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <jnj:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations contextRef="c-10" decimals="-6" id="f-459" unitRef="usd">24105000000</jnj:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations>
    <jnj:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations contextRef="c-11" decimals="-6" id="f-460" unitRef="usd">21859000000</jnj:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations>
    <jnj:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations contextRef="c-22" decimals="-6" id="f-461" unitRef="usd">12889000000</jnj:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-10" decimals="-6" id="f-462" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-11" decimals="-6" id="f-463" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-22" decimals="-6" id="f-464" unitRef="usd">1238000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-10" decimals="-6" id="f-465" unitRef="usd">24105000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-11" decimals="-6" id="f-466" unitRef="usd">21859000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-22" decimals="-6" id="f-467" unitRef="usd">14127000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaid contextRef="c-1" decimals="-6" id="f-468" unitRef="usd">1990000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="c-12" decimals="-6" id="f-469" unitRef="usd">1836000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="c-13" decimals="-6" id="f-470" unitRef="usd">982000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-6" id="f-471" unitRef="usd">1911000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-12" decimals="-6" id="f-472" unitRef="usd">1766000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-13" decimals="-6" id="f-473" unitRef="usd">933000000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid contextRef="c-1" decimals="-6" id="f-474" unitRef="usd">6714000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-12" decimals="-6" id="f-475" unitRef="usd">8574000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-13" decimals="-6" id="f-476" unitRef="usd">5223000000</us-gaap:IncomeTaxesPaid>
    <jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds contextRef="c-1" decimals="-6" id="f-477" unitRef="usd">1551000000</jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds>
    <jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds contextRef="c-12" decimals="-6" id="f-478" unitRef="usd">1435000000</jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds>
    <jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds contextRef="c-13" decimals="-6" id="f-479" unitRef="usd">2114000000</jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1 contextRef="c-1" decimals="-6" id="f-480" unitRef="usd">16091000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1 contextRef="c-12" decimals="-6" id="f-481" unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1 contextRef="c-13" decimals="-6" id="f-482" unitRef="usd">18710000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1 contextRef="c-1" decimals="-6" id="f-483" unitRef="usd">1632000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1 contextRef="c-12" decimals="-6" id="f-484" unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1 contextRef="c-13" decimals="-6" id="f-485" unitRef="usd">1058000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1 contextRef="c-1" decimals="-6" id="f-486" unitRef="usd">14459000000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1 contextRef="c-12" decimals="-6" id="f-487" unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1 contextRef="c-13" decimals="-6" id="f-488" unitRef="usd">17652000000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-489">Summary of significant accounting policies&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Principles of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The consolidated financial statements include the accounts of Johnson&#160;&amp;amp; Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Description of the company&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company has approximately 138,100&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Kenvue IPO/separation and discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of 198,734,444 shares of its common stock, par value $0.01 per share (the &#x201c;Kenvue Common Stock&#x201d;), at an initial public offering of $22.00 per share for net proceeds of $4.2&#160;billion. The excess of the net proceeds from the IPO over the net book value of the Johnson &amp;amp; Johnson divested interest was $2.5&#160;billion and was recorded to additional paid-in capital. As of the closing of the IPO, Johnson &amp;amp; Johnson owned approximately 89.6% of the total outstanding shares of Kenvue Common Stock and at July 2, 2023, the &lt;br/&gt;non-controlling interest of $1.3&#160;billion associated with Kenvue was reflected in equity attributable to non-controlling interests in the consolidated balance sheet in the fiscal second quarter of 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;On August 23, 2023, Johnson &amp;amp; Johnson completed the disposition of an additional 80.1% ownership of the shares of Kenvue through an exchange offer. Following the exchange offer, the Company owned 9.5% of the shares of Kenvue which were accounted for as an equity investment carried at fair value within continuing operations. The historical results of the Consumer Health business (which previously represented the Consumer Health business segment) are reflected as discontinued operations in the Company&#x2019;s Consolidated Financial Statements through the date of the exchange offer (see Note 21 for additional details). Unless otherwise indicated, the information in the notes to the Consolidated Financial Statements refer only to Johnson &amp;amp; Johnson&#x2019;s continuing operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In the fiscal second quarter of 2024 the Company completed a debt for equity exchange of the retained stake in Kenvue. Upon completion of the debt for equity exchange, the Company no longer owns any shares of Kenvue Common Stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Business segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company is organized into two business segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on the following therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolic. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the Orthopaedic, Surgery, Cardiovascular (previously referred to as Interventional Solutions) and Vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;New accounting standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently adopted accounting standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;ASU 2023-07: Segment Reporting (Topic 280) &#x2013; Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company adopted the standard in the fiscal year 2024, which requires expanded annual and interim disclosures for significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. The standard was applied retrospectively to all periods presented in the financial statements. As this accounting standard only impacts disclosures, it did not have a material impact on the Company&#x2019;s Consolidated Financial Statements. See Note 17 for the required disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently issued accounting standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Not adopted as of December 29, 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;ASU 2024-03: Income Statement &#x2013; Reporting Comprehensive Income &#x2013; Expense Disaggregation Disclosures (Subtopic&#160;220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;This update requires disclosure of disaggregated information about certain income statement expense line items on an annual and interim basis. This update will be effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. As this accounting standard only impacts disclosures, it will not have a material impact on the Company&#x2019;s Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;ASU 2023-09: Income Taxes (Topic 740) - Improvements to Income Tax Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;This update standardizes categories for the effective tax rate reconciliation, requires disaggregation of income taxes and additional income tax-related disclosures. This update is required to be effective for the Company for fiscal periods beginning after December 15, 2024. As this accounting standard only impacts disclosures, it will not have a material impact on the Company&#x2019;s Consolidated Financial Statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating. The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value. The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Investments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets; otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Property, plant and equipment and depreciation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.789%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Building and building equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;30&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Land and leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;10&#160;- 20&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Machinery and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2&#160;- 13&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8&#160;years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset&#x2019;s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns, discounts to customers and governmental clawback provisions are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued rebates, returns, and promotions on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates and discounts are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A&#160;significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily the Managed Care, Medicare and Medicaid programs, which amounted to $12.3 billion and $11.5 billion as of December&#160;29, 2024 and December&#160;31, 2023, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Sales returns are estimated and recorded based on historical sales and returns information. Products that have lost patent exclusivity, or that otherwise exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. In accordance with the Company&#x2019;s accounting policies, the Company generally issues credit to customers for returned goods. The Company&#x2019;s sales returns reserves are accounted for in accordance with the U.S.&#160;GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Innovative Medicine segment are almost exclusively not resalable. Sales returns for certain franchises in the MedTech segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during each of the fiscal years&#160;2024,&#160;2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Promotional programs, such as product listing allowances are recorded in the same period as related sales and include &lt;br/&gt;volume-based sales incentive programs. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements of certain products, which are included in sales to customers. Profit-share payments were less than 2.0% of the total revenues in the fiscal year 2024 and 2023, respectively, and less than 3.0% of total revenues in the fiscal year 2022 and are included in sales to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;See Note 17 to the Consolidated Financial Statements for further disaggregation of revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Shipping and handling&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Shipping and handling costs incurred were $0.9 billion, $0.9 billion and $0.8 billion in fiscal years 2024, 2023 and 2022, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 1.0% of sales to customers for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Intangible assets and goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The authoritative literature on U.S.&#160;GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2024 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. In-process research and development purchased as part of a business combination is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset. If warranted the purchased in-process research and development could be written off or partially impaired depending on the underlying&#160;program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Intangible assets that have finite useful lives continue to be amortized over their useful lives and are reviewed for impairment when warranted by economic conditions. See Note&#160;5 for further details on Intangible Assets and Goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;As required by U.S.&#160;GAAP, all derivative instruments are recorded on the balance sheet at fair value. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level&#160;1 having the highest priority and Level&#160;3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge&#160;transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1)&#160;minimize foreign currency exposure&#x2019;s impact on the Company&#x2019;s financial performance; (2)&#160;protect the Company&#x2019;s cash flow from adverse movements in foreign exchange rates; (3)&#160;ensure the appropriateness of financial instruments; and (4)&#160;manage the enterprise risk associated with financial institutions. See Note&#160;6 for additional information on Financial Instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in &lt;span style="-sec-ix-hidden:f-539"&gt;&lt;span style="-sec-ix-hidden:f-540"&gt;Other assets&lt;/span&gt;&lt;/span&gt;, &lt;span style="-sec-ix-hidden:f-541"&gt;&lt;span style="-sec-ix-hidden:f-542"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;, and &lt;span style="-sec-ix-hidden:f-543"&gt;&lt;span style="-sec-ix-hidden:f-544"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt; on the consolidated balance sheet. The ROU Assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Commitments under finance leases are not significant, and are included in Property, plant and equipment, Loans and notes payable, and Long-term debt on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The&#160;ROU asset pertaining to leases from continuing operations was $1.1&#160;billion and $1.0&#160;billion in fiscal years 2024 and 2023, respectively. The lease liability from continuing operations was $1.2&#160;billion and $1.1&#160;billion in fiscal years 2024 and 2023, respectively. The operating lease costs from continuing operations were $0.2&#160;billion in fiscal years 2024, 2023 and 2022. Cash&#160;paid for amounts included in the measurement of lease liabilities from continuing operations were $0.2&#160;billion in fiscal years 2024, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Product liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Research and development expenses are expensed as incurred in accordance with ASC 730, Research&#160;and Development. Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company&#x2019;s operations. In general, the income statement presentation for these collaborations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.157%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;Nature/Type of Collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;Statement of Earnings Presentation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Third-party sale of product &amp;amp; profit share payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Sales to customers&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Royalties/milestones paid to collaborative partner (post-regulatory approval)*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Royalties received from collaborative partner&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Upfront payments&#160;&amp;amp; milestones paid to collaborative partner (pre-regulatory approval)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Research and development payments to collaborative&#160;partner&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Research and development payments received from collaborative partner or government entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Reduction of Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;*&#160;&#160;&#160;&#160;Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense other than the acquired in-process research &amp;amp; development expense of $1.25&#160;billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition) in fiscal year 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO, co-developed with Bayer HealthCare AG, IMBRUVICA, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company and CARVYKTI, licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX, licensed from Genmab A/S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Advertising&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $0.6 billion, $0.5 billion and $0.7 billion in fiscal years 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from 35% to 21%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of 15.5% and all other earnings were taxed at a rate of 8.0%. This tax is payable over 8 years and will not accrue interest. These payments began in fiscal year 2018 and will continue through 2025. The final payment of $2.5&#160;billion will be made in fiscal year 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI). GILTI is described as the excess of a U.S. shareholder&#x2019;s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., &#x201c;period cost&#x201d;) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to affect the amount of GILTI inclusion in future years upon reversal (i.e., &#x201c;deferred method&#x201d;). The Company has elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The&#160;Company estimates that the tax effect of this repatriation would be approximately $0.5 billion under currently enacted tax laws and regulations and at current currency exchange rates. This amount does not include the possible benefit of U.S. foreign tax credits, which may substantially offset this cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;See Note 8 to the Consolidated Financial Statements for further information regarding income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Net earnings per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.&#160;requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company follows the provisions of U.S.&#160;GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Supplier finance program obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide participating suppliers the ability to finance payment obligations from the Company with the third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The&#160;Company&#x2019;s obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment&#160;terms of 90 days), are not affected by a participating supplier&#x2019;s decision to participate in the program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Confirmed obligations under the program as of December&#160;29, 2024, and December&#160;31, 2023, were $0.8&#160;billion and $0.7&#160;billion, respectively. The&#160;obligations are presented as &lt;span style="-sec-ix-hidden:f-579"&gt;&lt;span style="-sec-ix-hidden:f-580"&gt;Accounts payable&lt;/span&gt;&lt;/span&gt; on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The rollforward of the Company's valid obligations under the program were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.697%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.139%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Confirmed obligations - beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$704&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Invoices confirmed during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3,048&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Confirmed invoices paid during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2,964&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Confirmed obligations - end of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$788&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Annual closing date&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52&#160;weeks, but every five or six years the fiscal year consists of 53&#160;weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-490">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Principles of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The consolidated financial statements include the accounts of Johnson&#160;&amp;amp; Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <jnj:NumberOfEmployeesEngagedInCompanyActivitiesWorldwide contextRef="c-1" decimals="0" id="f-491" unitRef="employee">138100</jnj:NumberOfEmployeesEngagedInCompanyActivitiesWorldwide>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-41"
      decimals="INF"
      id="f-492"
      unitRef="shares">198734444</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-42"
      decimals="INF"
      id="f-493"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-42"
      decimals="2"
      id="f-494"
      unitRef="usdPerShare">22.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c-41" decimals="-8" id="f-495" unitRef="usd">4200000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal contextRef="c-43" decimals="-8" id="f-496" unitRef="usd">2500000000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction contextRef="c-44" decimals="3" id="f-497" unitRef="number">0.896</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:CommonStockValueOutstanding contextRef="c-45" decimals="-8" id="f-498" unitRef="usd">1300000000</us-gaap:CommonStockValueOutstanding>
    <jnj:OwnershipPercentageSplitOffPercent contextRef="c-46" decimals="3" id="f-499" unitRef="number">0.801</jnj:OwnershipPercentageSplitOffPercent>
    <jnj:ExchangeOfStockPercentageOwnershipAfterTransaction contextRef="c-47" decimals="3" id="f-500" unitRef="number">0.095</jnj:ExchangeOfStockPercentageOwnershipAfterTransaction>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-501">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Business segments&lt;/span&gt;&lt;/div&gt;The Company is organized into two business segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on the following therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolic. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the Orthopaedic, Surgery, Cardiovascular (previously referred to as Interventional Solutions) and Vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-502"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-503">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;New accounting standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently adopted accounting standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;ASU 2023-07: Segment Reporting (Topic 280) &#x2013; Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company adopted the standard in the fiscal year 2024, which requires expanded annual and interim disclosures for significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. The standard was applied retrospectively to all periods presented in the financial statements. As this accounting standard only impacts disclosures, it did not have a material impact on the Company&#x2019;s Consolidated Financial Statements. See Note 17 for the required disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently issued accounting standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Not adopted as of December 29, 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;ASU 2024-03: Income Statement &#x2013; Reporting Comprehensive Income &#x2013; Expense Disaggregation Disclosures (Subtopic&#160;220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;This update requires disclosure of disaggregated information about certain income statement expense line items on an annual and interim basis. This update will be effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. As this accounting standard only impacts disclosures, it will not have a material impact on the Company&#x2019;s Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;ASU 2023-09: Income Taxes (Topic 740) - Improvements to Income Tax Disclosures&lt;/span&gt;&lt;/div&gt;This update standardizes categories for the effective tax rate reconciliation, requires disaggregation of income taxes and additional income tax-related disclosures. This update is required to be effective for the Company for fiscal periods beginning after December 15, 2024. As this accounting standard only impacts disclosures, it will not have a material impact on the Company&#x2019;s Consolidated Financial Statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-504">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating. The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value. The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <jnj:MinimumCollateralValueasaPercentReverseRepurchaseAgreement contextRef="c-1" decimals="INF" id="f-505" unitRef="number">1.02</jnj:MinimumCollateralValueasaPercentReverseRepurchaseAgreement>
    <jnj:MinimumCollateralValueasaPercentReverseRepurchaseAgreement contextRef="c-1" decimals="INF" id="f-506" unitRef="number">1.02</jnj:MinimumCollateralValueasaPercentReverseRepurchaseAgreement>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c-1" id="f-507">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;Investments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets; otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-508">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Property, plant and equipment and depreciation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.789%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Building and building equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;30&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Land and leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;10&#160;- 20&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Machinery and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2&#160;- 13&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8&#160;years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset&#x2019;s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <jnj:EstimatedUsefulLivesOfAssetsTableTextBlock contextRef="c-1" id="f-509">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.789%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Building and building equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;30&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Land and leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;10&#160;- 20&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Machinery and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2&#160;- 13&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</jnj:EstimatedUsefulLivesOfAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-48" id="f-510">P30Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-49" id="f-511">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-50" id="f-512">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-51" id="f-513">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-52" id="f-514">P13Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-53" id="f-515">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-54" id="f-516">P8Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c-1" id="f-517">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns, discounts to customers and governmental clawback provisions are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued rebates, returns, and promotions on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates and discounts are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A&#160;significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily the Managed Care, Medicare and Medicaid programs, which amounted to $12.3 billion and $11.5 billion as of December&#160;29, 2024 and December&#160;31, 2023, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Sales returns are estimated and recorded based on historical sales and returns information. Products that have lost patent exclusivity, or that otherwise exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. In accordance with the Company&#x2019;s accounting policies, the Company generally issues credit to customers for returned goods. The Company&#x2019;s sales returns reserves are accounted for in accordance with the U.S.&#160;GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Innovative Medicine segment are almost exclusively not resalable. Sales returns for certain franchises in the MedTech segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during each of the fiscal years&#160;2024,&#160;2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Promotional programs, such as product listing allowances are recorded in the same period as related sales and include &lt;br/&gt;volume-based sales incentive programs. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements of certain products, which are included in sales to customers. Profit-share payments were less than 2.0% of the total revenues in the fiscal year 2024 and 2023, respectively, and less than 3.0% of total revenues in the fiscal year 2022 and are included in sales to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;See Note 17 to the Consolidated Financial Statements for further disaggregation of revenue.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <jnj:RevenuePerformanceObligationPaymentTerms contextRef="c-55" id="f-518">P30D</jnj:RevenuePerformanceObligationPaymentTerms>
    <jnj:RevenuePerformanceObligationPaymentTerms contextRef="c-56" id="f-519">P90D</jnj:RevenuePerformanceObligationPaymentTerms>
    <jnj:AccruedRebatesReturnsAndPromotions contextRef="c-57" decimals="-8" id="f-520" unitRef="usd">12300000000</jnj:AccruedRebatesReturnsAndPromotions>
    <jnj:AccruedRebatesReturnsAndPromotions contextRef="c-58" decimals="-8" id="f-521" unitRef="usd">11500000000</jnj:AccruedRebatesReturnsAndPromotions>
    <jnj:SalesReturnReserve contextRef="c-12" decimals="3" id="f-522" unitRef="number">0.010</jnj:SalesReturnReserve>
    <jnj:SalesReturnReserve contextRef="c-1" decimals="3" id="f-523" unitRef="number">0.010</jnj:SalesReturnReserve>
    <jnj:SalesReturnReserve contextRef="c-13" decimals="3" id="f-524" unitRef="number">0.010</jnj:SalesReturnReserve>
    <jnj:ProfitLossPercentToSales contextRef="c-1" decimals="3" id="f-525" unitRef="number">0.020</jnj:ProfitLossPercentToSales>
    <jnj:ProfitLossPercentToSales contextRef="c-12" decimals="3" id="f-526" unitRef="number">0.020</jnj:ProfitLossPercentToSales>
    <jnj:ProfitLossPercentToSales contextRef="c-13" decimals="3" id="f-527" unitRef="number">0.030</jnj:ProfitLossPercentToSales>
    <us-gaap:ShippingAndHandlingCostPolicyTextBlock contextRef="c-1" id="f-528">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Shipping and handling&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Shipping and handling costs incurred were $0.9 billion, $0.9 billion and $0.8 billion in fiscal years 2024, 2023 and 2022, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 1.0% of sales to customers for all periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShippingAndHandlingCostPolicyTextBlock>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-59" decimals="-8" id="f-529" unitRef="usd">900000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-60" decimals="-8" id="f-530" unitRef="usd">900000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-61" decimals="-8" id="f-531" unitRef="usd">800000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <jnj:ShippingandHandlingCostsasaPercentofSales contextRef="c-12" decimals="3" id="f-532" unitRef="number">0.010</jnj:ShippingandHandlingCostsasaPercentofSales>
    <jnj:ShippingandHandlingCostsasaPercentofSales contextRef="c-13" decimals="3" id="f-533" unitRef="number">0.010</jnj:ShippingandHandlingCostsasaPercentofSales>
    <jnj:ShippingandHandlingCostsasaPercentofSales contextRef="c-1" decimals="3" id="f-534" unitRef="number">0.010</jnj:ShippingandHandlingCostsasaPercentofSales>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-535">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c-1" id="f-536">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Intangible assets and goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The authoritative literature on U.S.&#160;GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2024 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. In-process research and development purchased as part of a business combination is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset. If warranted the purchased in-process research and development could be written off or partially impaired depending on the underlying&#160;program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Intangible assets that have finite useful lives continue to be amortized over their useful lives and are reviewed for impairment when warranted by economic conditions. See Note&#160;5 for further details on Intangible Assets and Goodwill.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="c-1" id="f-537">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;As required by U.S.&#160;GAAP, all derivative instruments are recorded on the balance sheet at fair value. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level&#160;1 having the highest priority and Level&#160;3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge&#160;transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1)&#160;minimize foreign currency exposure&#x2019;s impact on the Company&#x2019;s financial performance; (2)&#160;protect the Company&#x2019;s cash flow from adverse movements in foreign exchange rates; (3)&#160;ensure the appropriateness of financial instruments; and (4)&#160;manage the enterprise risk associated with financial institutions. See Note&#160;6 for additional information on Financial Instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-538">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in &lt;span style="-sec-ix-hidden:f-539"&gt;&lt;span style="-sec-ix-hidden:f-540"&gt;Other assets&lt;/span&gt;&lt;/span&gt;, &lt;span style="-sec-ix-hidden:f-541"&gt;&lt;span style="-sec-ix-hidden:f-542"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;, and &lt;span style="-sec-ix-hidden:f-543"&gt;&lt;span style="-sec-ix-hidden:f-544"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt; on the consolidated balance sheet. The ROU Assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Commitments under finance leases are not significant, and are included in Property, plant and equipment, Loans and notes payable, and Long-term debt on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The&#160;ROU asset pertaining to leases from continuing operations was $1.1&#160;billion and $1.0&#160;billion in fiscal years 2024 and 2023, respectively. The lease liability from continuing operations was $1.2&#160;billion and $1.1&#160;billion in fiscal years 2024 and 2023, respectively. The operating lease costs from continuing operations were $0.2&#160;billion in fiscal years 2024, 2023 and 2022. Cash&#160;paid for amounts included in the measurement of lease liabilities from continuing operations were $0.2&#160;billion in fiscal years 2024, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-10" decimals="-8" id="f-545" unitRef="usd">1100000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-11" decimals="-8" id="f-546" unitRef="usd">1000000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability contextRef="c-10" decimals="-8" id="f-547" unitRef="usd">1200000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c-11" decimals="-8" id="f-548" unitRef="usd">1100000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseCost contextRef="c-12" decimals="-8" id="f-549" unitRef="usd">200000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-8" id="f-550" unitRef="usd">200000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-13" decimals="-8" id="f-551" unitRef="usd">200000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c-12" decimals="-8" id="f-552" unitRef="usd">200000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-8" id="f-553" unitRef="usd">200000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-13" decimals="-8" id="f-554" unitRef="usd">200000000</us-gaap:OperatingLeasePayments>
    <jnj:ProductLiabilityPolicyTextBlock contextRef="c-1" id="f-555">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Product liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;</jnj:ProductLiabilityPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-556">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Research and development expenses are expensed as incurred in accordance with ASC 730, Research&#160;and Development. Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company&#x2019;s operations. In general, the income statement presentation for these collaborations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.157%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;Nature/Type of Collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;Statement of Earnings Presentation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Third-party sale of product &amp;amp; profit share payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Sales to customers&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Royalties/milestones paid to collaborative partner (post-regulatory approval)*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Royalties received from collaborative partner&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Upfront payments&#160;&amp;amp; milestones paid to collaborative partner (pre-regulatory approval)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Research and development payments to collaborative&#160;partner&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Research and development payments received from collaborative partner or government entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Reduction of Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;*&#160;&#160;&#160;&#160;Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense other than the acquired in-process research &amp;amp; development expense of $1.25&#160;billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition) in fiscal year 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO, co-developed with Bayer HealthCare AG, IMBRUVICA, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company and CARVYKTI, licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX, licensed from Genmab A/S.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <jnj:ConcentrationRiskThresholdPercentage
      contextRef="c-62"
      decimals="INF"
      id="f-557"
      unitRef="number">0.05</jnj:ConcentrationRiskThresholdPercentage>
    <jnj:ConcentrationRiskThresholdPercentage
      contextRef="c-63"
      decimals="INF"
      id="f-558"
      unitRef="number">0.05</jnj:ConcentrationRiskThresholdPercentage>
    <jnj:ConcentrationRiskThresholdPercentage
      contextRef="c-64"
      decimals="INF"
      id="f-559"
      unitRef="number">0.05</jnj:ConcentrationRiskThresholdPercentage>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="c-65" decimals="-6" id="f-560" unitRef="usd">1250000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="c-1" id="f-561">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Advertising&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $0.6 billion, $0.5 billion and $0.7 billion in fiscal years 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense contextRef="c-1" decimals="-8" id="f-562" unitRef="usd">600000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c-12" decimals="-8" id="f-563" unitRef="usd">500000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c-13" decimals="-8" id="f-564" unitRef="usd">700000000</us-gaap:AdvertisingExpense>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-565">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from 35% to 21%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of 15.5% and all other earnings were taxed at a rate of 8.0%. This tax is payable over 8 years and will not accrue interest. These payments began in fiscal year 2018 and will continue through 2025. The final payment of $2.5&#160;billion will be made in fiscal year 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI). GILTI is described as the excess of a U.S. shareholder&#x2019;s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., &#x201c;period cost&#x201d;) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to affect the amount of GILTI inclusion in future years upon reversal (i.e., &#x201c;deferred method&#x201d;). The Company has elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The&#160;Company estimates that the tax effect of this repatriation would be approximately $0.5 billion under currently enacted tax laws and regulations and at current currency exchange rates. This amount does not include the possible benefit of U.S. foreign tax credits, which may substantially offset this cost.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-66"
      decimals="INF"
      id="f-566"
      unitRef="number">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-67"
      decimals="INF"
      id="f-567"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <jnj:TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent contextRef="c-67" decimals="3" id="f-568" unitRef="number">0.155</jnj:TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent>
    <jnj:TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent contextRef="c-67" decimals="3" id="f-569" unitRef="number">0.080</jnj:TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent>
    <jnj:TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsPaymentPeriod contextRef="c-1" id="f-570">P8Y</jnj:TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsPaymentPeriod>
    <jnj:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent contextRef="c-10" decimals="-8" id="f-571" unitRef="usd">2500000000</jnj:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent>
    <us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings contextRef="c-1" decimals="-8" id="f-572" unitRef="usd">500000000</us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-573">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Net earnings per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-574">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.&#160;requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company follows the provisions of U.S.&#160;GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <jnj:SupplierFinanceProgramPolicyTextBlock contextRef="c-1" id="f-575">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Supplier finance program obligations&lt;/span&gt;&lt;/div&gt;The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide participating suppliers the ability to finance payment obligations from the Company with the third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The&#160;Company&#x2019;s obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment&#160;terms of 90 days), are not affected by a participating supplier&#x2019;s decision to participate in the program.</jnj:SupplierFinanceProgramPolicyTextBlock>
    <us-gaap:SupplierFinanceProgramPaymentTimingPeriod contextRef="c-10" id="f-576">P90D</us-gaap:SupplierFinanceProgramPaymentTimingPeriod>
    <us-gaap:SupplierFinanceProgramObligationCurrent contextRef="c-10" decimals="-8" id="f-577" unitRef="usd">800000000</us-gaap:SupplierFinanceProgramObligationCurrent>
    <us-gaap:SupplierFinanceProgramObligationCurrent contextRef="c-11" decimals="-8" id="f-578" unitRef="usd">700000000</us-gaap:SupplierFinanceProgramObligationCurrent>
    <us-gaap:SupplierFinanceProgramTableTextBlock contextRef="c-1" id="f-581">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The rollforward of the Company's valid obligations under the program were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.697%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.139%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Confirmed obligations - beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$704&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Invoices confirmed during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3,048&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Confirmed invoices paid during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2,964&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Confirmed obligations - end of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$788&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplierFinanceProgramTableTextBlock>
    <us-gaap:SupplierFinanceProgramObligationCurrent contextRef="c-11" decimals="-6" id="f-582" unitRef="usd">704000000</us-gaap:SupplierFinanceProgramObligationCurrent>
    <us-gaap:SupplierFinanceProgramObligationIncrease contextRef="c-1" decimals="-6" id="f-583" unitRef="usd">3048000000</us-gaap:SupplierFinanceProgramObligationIncrease>
    <us-gaap:SupplierFinanceProgramObligationDecreaseSettlement contextRef="c-1" decimals="-6" id="f-584" unitRef="usd">2964000000</us-gaap:SupplierFinanceProgramObligationDecreaseSettlement>
    <us-gaap:SupplierFinanceProgramObligationCurrent contextRef="c-10" decimals="-6" id="f-585" unitRef="usd">788000000</us-gaap:SupplierFinanceProgramObligationCurrent>
    <jnj:FiscalPeriodPolicyTextBlock contextRef="c-1" id="f-586">&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Annual closing date&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52&#160;weeks, but every five or six years the fiscal year consists of 53&#160;weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026.&lt;/span&gt;&lt;/div&gt;</jnj:FiscalPeriodPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="c-1" id="f-587">Cash, cash equivalents and current marketable securities&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;At the end of the fiscal year 2024 and 2023, cash, cash equivalents and current marketable securities comprised:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.072%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.209%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.465%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.627%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.875%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Carrying&lt;br/&gt;&#160;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrecognized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;br/&gt;&#160;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cash &amp;amp; Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Current&lt;br/&gt; Marketable&lt;br/&gt; Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$2,918&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,918&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,918&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-U.S. Sovereign Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;120&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;120&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;120&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,123&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,123&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,123&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Subtotal &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$17,306&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;17,306&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;17,186&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;120&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Gov't Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$6,815&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,816&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,796&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other Sovereign Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;176&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;176&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;93&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate and other debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;224&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;224&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;184&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Subtotal available for sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$7,215&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,216&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;6,919&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;297&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total cash, cash equivalents and current marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$24,105&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;417&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.072%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.209%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.465%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.627%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.875%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrecognized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Current Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$3,340&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,340&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,340&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-U.S. Sovereign Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;522&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;522&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;174&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;348&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,377&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,377&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,377&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;338&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;338&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;189&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;149&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,814&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,814&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,814&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;662&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;662&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;662&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Subtotal &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;14,053&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;14,053&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;13,556&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;497&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Gov't Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$8,562&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,562&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,259&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;303&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Gov't Agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;70&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other Sovereign Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate and other debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;237&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;237&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;194&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Subtotal available for sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$8,875&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8,874&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8,303&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;571&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total cash, cash equivalents and current marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$21,859&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,068&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt"&gt;Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt"&gt;Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive&#160;income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Fair value of government securities and obligations and corporate debt securities were estimated using quoted broker prices and significant other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The contractual maturities of the available for sale debt securities at December&#160;29, 2024 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.834%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$7,204&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;7,205&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;$7,215&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;7,216&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company invests its excess cash in both deposits with major banks throughout the world and other high-quality money market instruments. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="c-1" id="f-588">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;At the end of the fiscal year 2024 and 2023, cash, cash equivalents and current marketable securities comprised:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.072%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.209%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.465%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.627%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.875%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Carrying&lt;br/&gt;&#160;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrecognized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;br/&gt;&#160;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cash &amp;amp; Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Current&lt;br/&gt; Marketable&lt;br/&gt; Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$2,918&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,918&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,918&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-U.S. Sovereign Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;120&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;120&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;120&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,123&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,123&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,123&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Subtotal &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$17,306&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;17,306&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;17,186&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;120&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Gov't Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$6,815&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,816&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,796&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other Sovereign Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;176&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;176&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;93&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate and other debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;224&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;224&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;184&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Subtotal available for sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$7,215&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,216&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;6,919&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;297&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total cash, cash equivalents and current marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$24,105&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;417&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.072%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.209%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.465%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.627%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.875%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrecognized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Current Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$3,340&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,340&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,340&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-U.S. Sovereign Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;522&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;522&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;174&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;348&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,377&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,377&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,377&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;338&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;338&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;189&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;149&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,814&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,814&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,814&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;662&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;662&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;662&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Subtotal &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;14,053&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;14,053&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;13,556&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;497&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Gov't Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$8,562&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,562&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,259&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;303&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Gov't Agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;70&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other Sovereign Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate and other debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;237&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;237&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;194&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Subtotal available for sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$8,875&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8,874&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8,303&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;571&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:64.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total cash, cash equivalents and current marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$21,859&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,068&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt"&gt;Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt"&gt;Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive&#160;income.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:HeldToMaturitySecurities contextRef="c-68" decimals="-6" id="f-589" unitRef="usd">2918000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain contextRef="c-68" decimals="-6" id="f-590" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-68" decimals="-6" id="f-591" unitRef="usd">2918000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-68" decimals="-6" id="f-592" unitRef="usd">2918000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-68" decimals="-6" id="f-593" unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities contextRef="c-69" decimals="-6" id="f-594" unitRef="usd">120000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain contextRef="c-69" decimals="-6" id="f-595" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-69" decimals="-6" id="f-596" unitRef="usd">120000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-69" decimals="-6" id="f-597" unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-69" decimals="-6" id="f-598" unitRef="usd">120000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities contextRef="c-70" decimals="-6" id="f-599" unitRef="usd">7100000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain contextRef="c-70" decimals="-6" id="f-600" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-70" decimals="-6" id="f-601" unitRef="usd">7100000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-70" decimals="-6" id="f-602" unitRef="usd">7100000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-70" decimals="-6" id="f-603" unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities contextRef="c-71" decimals="-6" id="f-604" unitRef="usd">6123000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain contextRef="c-72" decimals="-6" id="f-605" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-71" decimals="-6" id="f-606" unitRef="usd">6123000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-71" decimals="-6" id="f-607" unitRef="usd">6123000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-71" decimals="-6" id="f-608" unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities contextRef="c-73" decimals="-6" id="f-609" unitRef="usd">1045000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain contextRef="c-71" decimals="-6" id="f-610" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-73" decimals="-6" id="f-611" unitRef="usd">1045000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-73" decimals="-6" id="f-612" unitRef="usd">1045000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-73" decimals="-6" id="f-613" unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities contextRef="c-74" decimals="-6" id="f-614" unitRef="usd">17306000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain contextRef="c-73" decimals="-6" id="f-615" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-74" decimals="-6" id="f-616" unitRef="usd">17306000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-74" decimals="-6" id="f-617" unitRef="usd">17186000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-74" decimals="-6" id="f-618" unitRef="usd">120000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-75" decimals="-6" id="f-619" unitRef="usd">6815000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-75" decimals="-6" id="f-620" unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-75" decimals="-6" id="f-621" unitRef="usd">6816000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-75" decimals="-6" id="f-622" unitRef="usd">6796000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-75" decimals="-6" id="f-623" unitRef="usd">20000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-76" decimals="-6" id="f-624" unitRef="usd">176000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-76" decimals="-6" id="f-625" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-76" decimals="-6" id="f-626" unitRef="usd">176000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-76" decimals="-6" id="f-627" unitRef="usd">83000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-76" decimals="-6" id="f-628" unitRef="usd">93000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-77" decimals="-6" id="f-629" unitRef="usd">224000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-77" decimals="-6" id="f-630" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-77" decimals="-6" id="f-631" unitRef="usd">224000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-77" decimals="-6" id="f-632" unitRef="usd">40000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-77" decimals="-6" id="f-633" unitRef="usd">184000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-78" decimals="-6" id="f-634" unitRef="usd">7215000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-78" decimals="-6" id="f-635" unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-78" decimals="-6" id="f-636" unitRef="usd">7216000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-78" decimals="-6" id="f-637" unitRef="usd">6919000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-78" decimals="-6" id="f-638" unitRef="usd">297000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-10" decimals="-6" id="f-639" unitRef="usd">24105000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-10" decimals="-6" id="f-640" unitRef="usd">417000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities contextRef="c-79" decimals="-6" id="f-641" unitRef="usd">3340000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss contextRef="c-79" decimals="-6" id="f-642" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-79" decimals="-6" id="f-643" unitRef="usd">3340000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-79" decimals="-6" id="f-644" unitRef="usd">3340000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-79" decimals="-6" id="f-645" unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities contextRef="c-80" decimals="-6" id="f-646" unitRef="usd">522000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss contextRef="c-80" decimals="-6" id="f-647" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-80" decimals="-6" id="f-648" unitRef="usd">522000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-80" decimals="-6" id="f-649" unitRef="usd">174000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-80" decimals="-6" id="f-650" unitRef="usd">348000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities contextRef="c-81" decimals="-6" id="f-651" unitRef="usd">4377000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss contextRef="c-81" decimals="-6" id="f-652" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-81" decimals="-6" id="f-653" unitRef="usd">4377000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-81" decimals="-6" id="f-654" unitRef="usd">4377000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-81" decimals="-6" id="f-655" unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities contextRef="c-82" decimals="-6" id="f-656" unitRef="usd">338000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss contextRef="c-82" decimals="-6" id="f-657" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-82" decimals="-6" id="f-658" unitRef="usd">338000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-82" decimals="-6" id="f-659" unitRef="usd">189000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-82" decimals="-6" id="f-660" unitRef="usd">149000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities contextRef="c-83" decimals="-6" id="f-661" unitRef="usd">4814000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss contextRef="c-83" decimals="-6" id="f-662" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-83" decimals="-6" id="f-663" unitRef="usd">4814000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-83" decimals="-6" id="f-664" unitRef="usd">4814000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-83" decimals="-6" id="f-665" unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities contextRef="c-84" decimals="-6" id="f-666" unitRef="usd">662000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss contextRef="c-84" decimals="-6" id="f-667" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-84" decimals="-6" id="f-668" unitRef="usd">662000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-84" decimals="-6" id="f-669" unitRef="usd">662000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-84" decimals="-6" id="f-670" unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities contextRef="c-85" decimals="-6" id="f-671" unitRef="usd">14053000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss contextRef="c-85" decimals="-6" id="f-672" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-85" decimals="-6" id="f-673" unitRef="usd">14053000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-85" decimals="-6" id="f-674" unitRef="usd">13556000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-85" decimals="-6" id="f-675" unitRef="usd">497000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-86" decimals="-6" id="f-676" unitRef="usd">8562000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-86" decimals="-6" id="f-677" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-86" decimals="-6" id="f-678" unitRef="usd">8562000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-86" decimals="-6" id="f-679" unitRef="usd">8259000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-86" decimals="-6" id="f-680" unitRef="usd">303000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-87" decimals="-6" id="f-681" unitRef="usd">71000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-87" decimals="-6" id="f-682" unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-87" decimals="-6" id="f-683" unitRef="usd">70000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-87" decimals="-6" id="f-684" unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-87" decimals="-6" id="f-685" unitRef="usd">70000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-88" decimals="-6" id="f-686" unitRef="usd">5000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-88" decimals="-6" id="f-687" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-88" decimals="-6" id="f-688" unitRef="usd">5000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-88" decimals="-6" id="f-689" unitRef="usd">1000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-88" decimals="-6" id="f-690" unitRef="usd">4000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-89" decimals="-6" id="f-691" unitRef="usd">237000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-89" id="f-692" unitRef="usd" xsi:nil="true"/>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-89" decimals="-6" id="f-693" unitRef="usd">237000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-89" decimals="-6" id="f-694" unitRef="usd">43000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-89" decimals="-6" id="f-695" unitRef="usd">194000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-90" decimals="-6" id="f-696" unitRef="usd">8875000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-90" decimals="-6" id="f-697" unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-90" decimals="-6" id="f-698" unitRef="usd">8874000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-90" decimals="-6" id="f-699" unitRef="usd">8303000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-90" decimals="-6" id="f-700" unitRef="usd">571000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-11" decimals="-6" id="f-701" unitRef="usd">21859000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-11" decimals="-6" id="f-702" unitRef="usd">1068000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-703">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The contractual maturities of the available for sale debt securities at December&#160;29, 2024 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.834%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$7,204&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;7,205&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;$7,215&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;7,216&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c-10" decimals="-6" id="f-704" unitRef="usd">7204000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-10" decimals="-6" id="f-705" unitRef="usd">7205000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="c-10" decimals="-6" id="f-706" unitRef="usd">11000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c-10" decimals="-6" id="f-707" unitRef="usd">11000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost contextRef="c-10" decimals="-6" id="f-708" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue contextRef="c-10" decimals="-6" id="f-709" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis contextRef="c-10" decimals="-6" id="f-710" unitRef="usd">7215000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate contextRef="c-10" decimals="-6" id="f-711" unitRef="usd">7216000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c-1" id="f-712">Inventories&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;At the end of fiscal years 2024 and 2023, inventories comprised:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.685%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$2,337&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,355&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Goods in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,815&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,952&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,292&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,874&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$12,444&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;11,181&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-713">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;At the end of fiscal years 2024 and 2023, inventories comprised:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.685%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$2,337&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,355&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Goods in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,815&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,952&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,292&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,874&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$12,444&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;11,181&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves contextRef="c-10" decimals="-6" id="f-714" unitRef="usd">2337000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves contextRef="c-11" decimals="-6" id="f-715" unitRef="usd">2355000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-10" decimals="-6" id="f-716" unitRef="usd">2815000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-11" decimals="-6" id="f-717" unitRef="usd">1952000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-10" decimals="-6" id="f-718" unitRef="usd">7292000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-11" decimals="-6" id="f-719" unitRef="usd">6874000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet contextRef="c-10" decimals="-6" id="f-720" unitRef="usd">12444000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-11" decimals="-6" id="f-721" unitRef="usd">11181000000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-722">Property, plant and equipment&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;At the end of fiscal years 2024 and 2023, property, plant and equipment at cost and accumulated depreciation were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.685%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Land and land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$718&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;795&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Buildings and building equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,317&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,375&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;29,444&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;28,979&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,289&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,627&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$48,768&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;47,776&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;28,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;27,878&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$20,518&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;19,898&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company capitalizes interest expense as part of the cost of construction of facilities and equipment. Interest expense capitalized in fiscal years 2024, 2023 and 2022 was $79 million, $70 million and $49 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Depreciation expense, including the amortization of capitalized interest in fiscal years 2024, 2023 and 2022 was $2.8 billion, $2.6 billion and $2.4 billion, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:40pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Upon retirement or other disposal of property, plant and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds are recorded in earnings.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-723">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;At the end of fiscal years 2024 and 2023, property, plant and equipment at cost and accumulated depreciation were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.685%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Land and land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$718&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;795&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Buildings and building equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,317&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,375&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;29,444&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;28,979&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,289&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,627&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$48,768&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;47,776&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;28,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;27,878&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$20,518&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;19,898&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-91" decimals="-6" id="f-724" unitRef="usd">718000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-92" decimals="-6" id="f-725" unitRef="usd">795000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-93" decimals="-6" id="f-726" unitRef="usd">12317000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-94" decimals="-6" id="f-727" unitRef="usd">12375000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-95" decimals="-6" id="f-728" unitRef="usd">29444000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-96" decimals="-6" id="f-729" unitRef="usd">28979000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-97" decimals="-6" id="f-730" unitRef="usd">6289000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-98" decimals="-6" id="f-731" unitRef="usd">5627000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-10" decimals="-6" id="f-732" unitRef="usd">48768000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-11" decimals="-6" id="f-733" unitRef="usd">47776000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-10" decimals="-6" id="f-734" unitRef="usd">28250000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-11" decimals="-6" id="f-735" unitRef="usd">27878000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-10" decimals="-6" id="f-736" unitRef="usd">20518000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-11" decimals="-6" id="f-737" unitRef="usd">19898000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:InterestCostsCapitalized contextRef="c-1" decimals="-6" id="f-738" unitRef="usd">79000000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized contextRef="c-12" decimals="-6" id="f-739" unitRef="usd">70000000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized contextRef="c-13" decimals="-6" id="f-740" unitRef="usd">49000000</us-gaap:InterestCostsCapitalized>
    <jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest contextRef="c-1" decimals="-8" id="f-741" unitRef="usd">2800000000</jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest>
    <jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest contextRef="c-12" decimals="-8" id="f-742" unitRef="usd">2600000000</jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest>
    <jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest contextRef="c-13" decimals="-8" id="f-743" unitRef="usd">2400000000</jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-744">Intangible assets and goodwill&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;At the end of fiscal years 2024 and 2023, the gross and net amounts of intangible assets were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Intangible assets with definite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents and trademarks&#160;&#x2014; gross&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$44,695&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;40,417&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(26,124)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(24,808)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents and trademarks&#160;&#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;$18,571&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;15,609&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Customer relationships and other intangibles&#160;&#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$20,310&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;20,322&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(13,544)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(12,685)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Customer relationships and other intangibles&#160;&#x2014; net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;$6,766&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;7,637&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Intangible assets with indefinite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trademarks&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,714&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Purchased in-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;12,281&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;9,215&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total intangible assets with indefinite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;$12,281&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;10,929&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total intangible assets&#160;&#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;$37,618&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;34,175&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:125%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:9.29pt"&gt;In September 2024, the Company announced changes to its MedTech brand identity and the $1.7&#160;billion of trademarks associated with the DePuy Synthes business were reclassified from indefinite lived to definite lived and will be amortized over a &lt;span style="-sec-ix-hidden:f-767"&gt;25&#160;year&lt;/span&gt; period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:125%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.09pt"&gt;The majority is comprised of customer relationships&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;Goodwill as of December&#160;29, 2024 and December&#160;31, 2023, as allocated by segment of business, was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.465%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.316%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.139%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.575%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Innovative &lt;br/&gt;Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;MedTech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Goodwill at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$10,184&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;25,863&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;36,047&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Goodwill, related to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Goodwill, related to divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Currency translation/other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;223&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;288&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;511&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Goodwill at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,407&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26,151&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;36,558&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Goodwill, related to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;640&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,569&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,209&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Goodwill, related to divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Currency translation/other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(355)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(511)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Goodwill at December 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$10,692&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;33,508&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,200&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;*&#160;&#160;&#160;&#160;Includes purchase price allocation adjustments for Abiomed &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;The weighted average amortization period for patents and trademarks is approximately 12 years. The weighted average amortization period for customer relationships and other intangible assets is approximately 18 years. The amortization expense of amortizable assets included in Cost of products sold was $4.5 billion, $4.5 billion and $3.9 billion before tax, for the fiscal years ended December&#160;29, 2024, December&#160;31, 2023 and January&#160;1, 2023, respectively. Intangible asset write-downs are included in Other (income) expense, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;The estimated amortization expense related to intangible assets for approved products, before tax, for the five succeeding years is approximately:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.302%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.302%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.302%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.302%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.308%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$4,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,200&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;See Note 18 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock contextRef="c-1" id="f-745">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;At the end of fiscal years 2024 and 2023, the gross and net amounts of intangible assets were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Intangible assets with definite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents and trademarks&#160;&#x2014; gross&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$44,695&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;40,417&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(26,124)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(24,808)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents and trademarks&#160;&#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;$18,571&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;15,609&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Customer relationships and other intangibles&#160;&#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$20,310&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;20,322&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(13,544)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(12,685)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Customer relationships and other intangibles&#160;&#x2014; net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;$6,766&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;7,637&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Intangible assets with indefinite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trademarks&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,714&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Purchased in-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;12,281&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;9,215&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total intangible assets with indefinite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;$12,281&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;10,929&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total intangible assets&#160;&#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;$37,618&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;34,175&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:125%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:9.29pt"&gt;In September 2024, the Company announced changes to its MedTech brand identity and the $1.7&#160;billion of trademarks associated with the DePuy Synthes business were reclassified from indefinite lived to definite lived and will be amortized over a &lt;span style="-sec-ix-hidden:f-767"&gt;25&#160;year&lt;/span&gt; period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:125%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.09pt"&gt;The majority is comprised of customer relationships&lt;/span&gt;&lt;/div&gt;</jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-99" decimals="-6" id="f-746" unitRef="usd">44695000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-100" decimals="-6" id="f-747" unitRef="usd">40417000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-99" decimals="-6" id="f-748" unitRef="usd">26124000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-100" decimals="-6" id="f-749" unitRef="usd">24808000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-99" decimals="-6" id="f-750" unitRef="usd">18571000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-100" decimals="-6" id="f-751" unitRef="usd">15609000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-101" decimals="-6" id="f-752" unitRef="usd">20310000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-102" decimals="-6" id="f-753" unitRef="usd">20322000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-101" decimals="-6" id="f-754" unitRef="usd">13544000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-102" decimals="-6" id="f-755" unitRef="usd">12685000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-101" decimals="-6" id="f-756" unitRef="usd">6766000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-102" decimals="-6" id="f-757" unitRef="usd">7637000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-103" decimals="-6" id="f-758" unitRef="usd">0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-104" decimals="-6" id="f-759" unitRef="usd">1714000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-105" decimals="-6" id="f-760" unitRef="usd">12281000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-106" decimals="-6" id="f-761" unitRef="usd">9215000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-10" decimals="-6" id="f-762" unitRef="usd">12281000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-11" decimals="-6" id="f-763" unitRef="usd">10929000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-10" decimals="-6" id="f-764" unitRef="usd">37618000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-11" decimals="-6" id="f-765" unitRef="usd">34175000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-107" decimals="-8" id="f-766" unitRef="usd">1700000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c-1" id="f-768">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;Goodwill as of December&#160;29, 2024 and December&#160;31, 2023, as allocated by segment of business, was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.465%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.316%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.139%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.575%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Innovative &lt;br/&gt;Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;MedTech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Goodwill at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$10,184&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;25,863&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;36,047&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Goodwill, related to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Goodwill, related to divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Currency translation/other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;223&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;288&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;511&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Goodwill at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,407&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26,151&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;36,558&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Goodwill, related to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;640&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,569&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,209&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Goodwill, related to divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Currency translation/other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(355)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(511)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Goodwill at December 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$10,692&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;33,508&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,200&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;*&#160;&#160;&#160;&#160;Includes purchase price allocation adjustments for Abiomed</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="c-108" decimals="-6" id="f-769" unitRef="usd">10184000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-109" decimals="-6" id="f-770" unitRef="usd">25863000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-22" decimals="-6" id="f-771" unitRef="usd">36047000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-110" decimals="-6" id="f-772" unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-111" decimals="-6" id="f-773" unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-12" decimals="-6" id="f-774" unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit contextRef="c-110" decimals="-6" id="f-775" unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit contextRef="c-111" decimals="-6" id="f-776" unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit contextRef="c-12" decimals="-6" id="f-777" unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillOtherIncreaseDecrease contextRef="c-110" decimals="-6" id="f-778" unitRef="usd">223000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease contextRef="c-111" decimals="-6" id="f-779" unitRef="usd">288000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease contextRef="c-12" decimals="-6" id="f-780" unitRef="usd">511000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill contextRef="c-112" decimals="-6" id="f-781" unitRef="usd">10407000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-113" decimals="-6" id="f-782" unitRef="usd">26151000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-11" decimals="-6" id="f-783" unitRef="usd">36558000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-114" decimals="-6" id="f-784" unitRef="usd">640000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-115" decimals="-6" id="f-785" unitRef="usd">7569000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-1" decimals="-6" id="f-786" unitRef="usd">8209000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit contextRef="c-114" decimals="-6" id="f-787" unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit contextRef="c-115" decimals="-6" id="f-788" unitRef="usd">56000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit contextRef="c-1" decimals="-6" id="f-789" unitRef="usd">56000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillOtherIncreaseDecrease contextRef="c-114" decimals="-6" id="f-790" unitRef="usd">-355000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease contextRef="c-115" decimals="-6" id="f-791" unitRef="usd">-156000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease contextRef="c-1" decimals="-6" id="f-792" unitRef="usd">-511000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill contextRef="c-116" decimals="-6" id="f-793" unitRef="usd">10692000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-117" decimals="-6" id="f-794" unitRef="usd">33508000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-10" decimals="-6" id="f-795" unitRef="usd">44200000000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-99" id="f-796">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-101" id="f-797">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-8" id="f-798" unitRef="usd">4500000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-12" decimals="-8" id="f-799" unitRef="usd">4500000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-13" decimals="-8" id="f-800" unitRef="usd">3900000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="c-1" id="f-801">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;The estimated amortization expense related to intangible assets for approved products, before tax, for the five succeeding years is approximately:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.302%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.302%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.302%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.302%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.308%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$4,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,200&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-10" decimals="-6" id="f-802" unitRef="usd">4000000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-10" decimals="-6" id="f-803" unitRef="usd">3400000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-10" decimals="-6" id="f-804" unitRef="usd">2800000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-10" decimals="-6" id="f-805" unitRef="usd">2200000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-10" decimals="-6" id="f-806" unitRef="usd">2200000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-807">Fair value measurements&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany products and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of December&#160;29, 2024 and December&#160;31, 2023, the total amount of cash collateral paid by the Company under the CSA amounted to $2.2 billion and $4.0 billion net respectively, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of December&#160;29, 2024, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $45.1 billion, $40.5 billion and $9.0 billion, respectively. As of December&#160;31, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $42.9 billion, $39.7 billion and $10.0 billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. Cash exchanged for derivatives is primarily in cash flows from operating activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings.&#160;Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted through the currency translation account within accumulated other comprehensive income.&#160;The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If&#160;and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company designated its Euro denominated notes with due dates ranging from 2024 to 2044 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;As of December&#160;29, 2024, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $1.7 billion&#160;after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note&#160;13. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The&#160;maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedges. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended December&#160;29, 2024 and December&#160;31, 2023, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.775%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.108%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.436%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.703%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.388%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost of&lt;br/&gt;Products&lt;br/&gt;&#160;Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;R&amp;amp;D&lt;br/&gt;&#160;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Interest&lt;br/&gt;(Income)&lt;br/&gt;&#160;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Other&lt;br/&gt;(Income)&lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost of&lt;br/&gt;Products&lt;br/&gt;Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;R&amp;amp;D&lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Interest&lt;br/&gt;(Income)&lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Other&lt;br/&gt;(Income)&lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The effects of fair value, net investment and cash flow hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gain (Loss) on fair value hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Hedged items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;168&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gain (Loss) on net investment hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;148&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;130&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;148&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;130&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gain (Loss) on cash flow hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Forward foreign exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;426&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;33&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;186&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;447&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;247&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;275&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(597)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;As of December&#160;29, 2024 and December&#160;31, 2023, the following amounts were recorded on the consolidated balance sheet related to cumulative basis adjustment for fair value hedges:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.126%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.227%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.230%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Line item in the Consolidated Balance Sheet&lt;br/&gt;in which the hedged item is included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Carrying Amount of the Hedged Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cumulative Amount of Fair Value Hedging&lt;br/&gt;Adjustment Included in the Carrying&lt;br/&gt;Amount of the Hedged Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Long-term Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$7,935&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$8,862&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$(1,132)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$(1,216)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended &lt;br/&gt;December&#160;29, 2024 and December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.138%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.179%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Location of Gain /(Loss)&lt;br/&gt;Recognized in Income on&lt;br/&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Foreign Exchange Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-905"&gt;&lt;span style="-sec-ix-hidden:f-906"&gt;Other (income) expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table is the effect of net investment hedges for the fiscal years ended December&#160;29, 2024 and &lt;br/&gt;December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.227%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.161%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Accumulated OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Location of Gain or&lt;br/&gt;(Loss) Reclassified&lt;br/&gt;from Accumulated Other Comprehensive Income Into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gain/(Loss)&lt;br/&gt;Reclassified from&lt;br/&gt;Accumulated OCI&lt;br/&gt;Into Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$282&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cross Currency interest rate&#160;swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$955&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;642&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company measures equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table is a summary of the activity related to equity investments for the fiscal years ended December&#160;29, 2024 and December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.792%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.334%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.658%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Changes in Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value Reflected in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Sales/&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Purchases/&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Non-Current&lt;br/&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Equity Investments with readily determinable value *&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$4,473&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,005)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;451&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;451&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Equity Investments without readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$696&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(197)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;274&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;773&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;773&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.792%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.334%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.658%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Changes in Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value Reflected in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Sales/&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Purchases/&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Non-Current&lt;br/&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Equity Investments with readily determinable value *&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$576&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(368)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,265&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,473&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,473&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Equity Investments without readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$613&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;696&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;696&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt"&gt;Recorded in Other Income/Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt"&gt;Other includes impact of currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;*&#160;&#160;&#160;&#160;The December 31, 2023 balance includes the 9.5% remaining stake in Kenvue. A debt-for-equity exchange was completed in the fiscal second quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;On May 15, 2024, the Company issued $3.6 billion aggregate principal amount of commercial paper and received $3.6&#160;billion of net cash proceeds to be used for general corporate purposes. On May 17, 2024, the Company completed a Debt-for-Equity Exchange of its remaining 182,329,550 shares of Kenvue Common Stock for the outstanding Commercial Paper. Upon completion of the Debt-for-Equity Exchange, the Commercial Paper was satisfied and discharged, and the Company no longer owns any shares of Kenvue Common Stock. This exchange resulted in a loss of approximately $0.4&#160;billion recorded in Other (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;For the fiscal years ended December&#160;29, 2024 and December&#160;31, 2023 for equity investments without readily determinable market values, $171 million and $1 million, respectively, of the changes in fair value reflected in net income were the result of impairments. There were impacts of $26 million and $27 million, respectively, of changes in the fair value reflected in net income due to changes in observable prices and gains on the disposal of investments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level&#160;1 having the highest priority and Level&#160;3 having the lowest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S.&#160;Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#x2019;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level&#160;1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following three levels of inputs are used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Level&#160;1&#160;&#x2014; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Level&#160;2&#160;&#x2014; Significant other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Level&#160;3&#160;&#x2014; Significant unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company&#x2019;s significant financial assets and liabilities measured at fair value as of the fiscal year ended December&#160;29, 2024 and December&#160;31, 2023 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.209%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.894%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.894%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.894%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.894%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.895%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;660&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;660&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;539&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest rate contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,484&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,484&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;988&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,144&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,144&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,527&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Forward foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;794&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;794&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;624&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest rate contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,753&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,753&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,338&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,547&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,547&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,962&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;64&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Forward foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Available For Sale Other Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Equity investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;451&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;451&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,473&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,216&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,216&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,874&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Other Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,217&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,217&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,092&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.065%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.302%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.895%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.558%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.139%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross to Net Derivative Reconciliation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total Gross Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$2,194&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,591&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Credit Support Agreements (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,172)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,575)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total Net Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total Gross Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,564&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,037&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Credit Support Agreements (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,412)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,604)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total Net Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$152&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;433&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Summarized information about changes in liabilities for contingent consideration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$1,092&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,120&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;533&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Changes in estimated fair value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Additions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;112&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;792&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Payments/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Ending Balance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$1,217&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,092&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,120&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt"&gt;2023 assets and liabilities are all classified as Level&#160;2 with the exception of equity investments of $4,473 million, which are classified as Level&#160;1 and contingent consideration of $1,092 million, classified as Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt"&gt;Includes cross currency interest rate swaps and interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt"&gt;Classified as non-current other assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.89pt"&gt;Classified as cash equivalents and current marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.99pt"&gt;Includes $1,217 million, $1,092 million and $1,116 million, classified as non-current other liabilities as of December&#160;29, 2024, &lt;br/&gt;December&#160;31, 2023 and January&#160;1, 2023, respectively. Includes $4&#160;million classified as current liabilities as of January&#160;1, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt"&gt;In fiscal year 2024, the Company recorded $105&#160;million of contingent consideration related to Proteologix. In fiscal year 2022, the Company recorded $704&#160;million of contingent consideration related to Abiomed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;See Notes&#160;2 and 7 for financial assets and liabilities held at carrying amount on the Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CollateralAlreadyPostedAggregateFairValue contextRef="c-118" decimals="-8" id="f-808" unitRef="usd">2200000000</us-gaap:CollateralAlreadyPostedAggregateFairValue>
    <us-gaap:CollateralAlreadyPostedAggregateFairValue contextRef="c-119" decimals="-8" id="f-809" unitRef="usd">4000000000.0</us-gaap:CollateralAlreadyPostedAggregateFairValue>
    <us-gaap:DerivativeNotionalAmount contextRef="c-118" decimals="-8" id="f-810" unitRef="usd">45100000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-120" decimals="-8" id="f-811" unitRef="usd">40500000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-121" decimals="-8" id="f-812" unitRef="usd">9000000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-119" decimals="-8" id="f-813" unitRef="usd">42900000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-122" decimals="-8" id="f-814" unitRef="usd">39700000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-123" decimals="-8" id="f-815" unitRef="usd">10000000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax contextRef="c-10" decimals="-8" id="f-816" unitRef="usd">-1700000000</us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax>
    <us-gaap:DescriptionOfReclassificationOfCashFlowHedgeGainLoss contextRef="c-1" id="f-817">next 12 months</us-gaap:DescriptionOfReclassificationOfCashFlowHedgeGainLoss>
    <us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge contextRef="c-1" id="f-818">P18M</us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock contextRef="c-1" id="f-819">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended December&#160;29, 2024 and December&#160;31, 2023, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.775%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.108%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.436%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.703%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.388%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost of&lt;br/&gt;Products&lt;br/&gt;&#160;Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;R&amp;amp;D&lt;br/&gt;&#160;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Interest&lt;br/&gt;(Income)&lt;br/&gt;&#160;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Other&lt;br/&gt;(Income)&lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost of&lt;br/&gt;Products&lt;br/&gt;Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;R&amp;amp;D&lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Interest&lt;br/&gt;(Income)&lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Other&lt;br/&gt;(Income)&lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The effects of fair value, net investment and cash flow hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gain (Loss) on fair value hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Hedged items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;168&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gain (Loss) on net investment hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;148&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;130&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;148&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;130&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gain (Loss) on cash flow hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Forward foreign exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;426&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;33&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;186&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;447&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;247&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;275&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(597)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;As of December&#160;29, 2024 and December&#160;31, 2023, the following amounts were recorded on the consolidated balance sheet related to cumulative basis adjustment for fair value hedges:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.126%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.227%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.230%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Line item in the Consolidated Balance Sheet&lt;br/&gt;in which the hedged item is included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Carrying Amount of the Hedged Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cumulative Amount of Fair Value Hedging&lt;br/&gt;Adjustment Included in the Carrying&lt;br/&gt;Amount of the Hedged Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Long-term Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$7,935&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$8,862&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$(1,132)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$(1,216)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings contextRef="c-124" decimals="-6" id="f-820" unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings contextRef="c-125" decimals="-6" id="f-821" unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings contextRef="c-126" decimals="-6" id="f-822" unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings contextRef="c-127" decimals="-6" id="f-823" unitRef="usd">64000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings contextRef="c-128" decimals="-6" id="f-824" unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings contextRef="c-129" decimals="-6" id="f-825" unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings contextRef="c-130" decimals="-6" id="f-826" unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings contextRef="c-131" decimals="-6" id="f-827" unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings contextRef="c-132" decimals="-6" id="f-828" unitRef="usd">168000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings contextRef="c-133" decimals="-6" id="f-829" unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax contextRef="c-124" decimals="-6" id="f-830" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax contextRef="c-125" decimals="-6" id="f-831" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax contextRef="c-126" decimals="-6" id="f-832" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax contextRef="c-127" decimals="-6" id="f-833" unitRef="usd">-64000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax contextRef="c-128" decimals="-6" id="f-834" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax contextRef="c-129" decimals="-6" id="f-835" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax contextRef="c-130" decimals="-6" id="f-836" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax contextRef="c-131" decimals="-6" id="f-837" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax contextRef="c-132" decimals="-6" id="f-838" unitRef="usd">-168000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax contextRef="c-133" decimals="-6" id="f-839" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings contextRef="c-134" decimals="-6" id="f-840" unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings contextRef="c-135" decimals="-6" id="f-841" unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings contextRef="c-136" decimals="-6" id="f-842" unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings contextRef="c-137" decimals="-6" id="f-843" unitRef="usd">148000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings contextRef="c-138" decimals="-6" id="f-844" unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings contextRef="c-139" decimals="-6" id="f-845" unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings contextRef="c-140" decimals="-6" id="f-846" unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings contextRef="c-141" decimals="-6" id="f-847" unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings contextRef="c-142" decimals="-6" id="f-848" unitRef="usd">130000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings contextRef="c-143" decimals="-6" id="f-849" unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax contextRef="c-134" decimals="-6" id="f-850" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax contextRef="c-135" decimals="-6" id="f-851" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax contextRef="c-136" decimals="-6" id="f-852" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax contextRef="c-137" decimals="-6" id="f-853" unitRef="usd">148000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax contextRef="c-138" decimals="-6" id="f-854" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax contextRef="c-139" decimals="-6" id="f-855" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax contextRef="c-140" decimals="-6" id="f-856" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax contextRef="c-141" decimals="-6" id="f-857" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax contextRef="c-142" decimals="-6" id="f-858" unitRef="usd">130000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax contextRef="c-143" decimals="-6" id="f-859" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-144" decimals="-6" id="f-860" unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-145" decimals="-6" id="f-861" unitRef="usd">426000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-146" decimals="-6" id="f-862" unitRef="usd">33000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-147" decimals="-6" id="f-863" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-148" decimals="-6" id="f-864" unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-149" decimals="-6" id="f-865" unitRef="usd">7000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-150" decimals="-6" id="f-866" unitRef="usd">186000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-151" decimals="-6" id="f-867" unitRef="usd">-37000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-152" decimals="-6" id="f-868" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-153" decimals="-6" id="f-869" unitRef="usd">8000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-144" decimals="-6" id="f-870" unitRef="usd">-7000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-145" decimals="-6" id="f-871" unitRef="usd">-156000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-146" decimals="-6" id="f-872" unitRef="usd">80000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-147" decimals="-6" id="f-873" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-148" decimals="-6" id="f-874" unitRef="usd">21000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-149" decimals="-6" id="f-875" unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-150" decimals="-6" id="f-876" unitRef="usd">447000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-151" decimals="-6" id="f-877" unitRef="usd">-18000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-152" decimals="-6" id="f-878" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-153" decimals="-6" id="f-879" unitRef="usd">9000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-154" decimals="-6" id="f-880" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-155" decimals="-6" id="f-881" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-156" decimals="-6" id="f-882" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-157" decimals="-6" id="f-883" unitRef="usd">247000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-158" decimals="-6" id="f-884" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-159" decimals="-6" id="f-885" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-160" decimals="-6" id="f-886" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-161" decimals="-6" id="f-887" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-162" decimals="-6" id="f-888" unitRef="usd">275000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-163" decimals="-6" id="f-889" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-154" decimals="-6" id="f-890" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-155" decimals="-6" id="f-891" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-156" decimals="-6" id="f-892" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-157" decimals="-6" id="f-893" unitRef="usd">-597000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-158" decimals="-6" id="f-894" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-159" decimals="-6" id="f-895" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-160" decimals="-6" id="f-896" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-161" decimals="-6" id="f-897" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-162" decimals="-6" id="f-898" unitRef="usd">-156000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-163" decimals="-6" id="f-899" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-164" decimals="-6" id="f-900" unitRef="usd">7935000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-165" decimals="-6" id="f-901" unitRef="usd">8862000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease contextRef="c-164" decimals="-6" id="f-902" unitRef="usd">-1132000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease contextRef="c-165" decimals="-6" id="f-903" unitRef="usd">-1216000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock contextRef="c-1" id="f-904">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended &lt;br/&gt;December&#160;29, 2024 and December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.138%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.179%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Location of Gain /(Loss)&lt;br/&gt;Recognized in Income on&lt;br/&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Foreign Exchange Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-905"&gt;&lt;span style="-sec-ix-hidden:f-906"&gt;Other (income) expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="c-166" decimals="-6" id="f-907" unitRef="usd">8000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="c-167" decimals="-6" id="f-908" unitRef="usd">-60000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-909">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table is the effect of net investment hedges for the fiscal years ended December&#160;29, 2024 and &lt;br/&gt;December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.227%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.161%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Accumulated OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Location of Gain or&lt;br/&gt;(Loss) Reclassified&lt;br/&gt;from Accumulated Other Comprehensive Income Into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gain/(Loss)&lt;br/&gt;Reclassified from&lt;br/&gt;Accumulated OCI&lt;br/&gt;Into Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$282&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cross Currency interest rate&#160;swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$955&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;642&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax contextRef="c-1" decimals="-6" id="f-910" unitRef="usd">282000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax contextRef="c-12" decimals="-6" id="f-911" unitRef="usd">-131000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred contextRef="c-168" decimals="-6" id="f-912" unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred contextRef="c-169" decimals="-6" id="f-913" unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax contextRef="c-170" decimals="-6" id="f-914" unitRef="usd">955000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax contextRef="c-171" decimals="-6" id="f-915" unitRef="usd">642000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred contextRef="c-172" decimals="-6" id="f-916" unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred contextRef="c-173" decimals="-6" id="f-917" unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="c-1" id="f-918">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table is a summary of the activity related to equity investments for the fiscal years ended December&#160;29, 2024 and December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.792%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.334%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.658%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Changes in Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value Reflected in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Sales/&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Purchases/&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Non-Current&lt;br/&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Equity Investments with readily determinable value *&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$4,473&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,005)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;451&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;451&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Equity Investments without readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$696&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(197)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;274&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;773&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;773&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.792%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.334%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.658%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Changes in Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value Reflected in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Sales/&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Purchases/&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Non-Current&lt;br/&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Equity Investments with readily determinable value *&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$576&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(368)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,265&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,473&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,473&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Equity Investments without readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$613&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;696&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;696&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt"&gt;Recorded in Other Income/Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt"&gt;Other includes impact of currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;*&#160;&#160;&#160;&#160;The December 31, 2023 balance includes the 9.5% remaining stake in Kenvue. A debt-for-equity exchange was completed in the fiscal second quarter of 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-174" decimals="-6" id="f-919" unitRef="usd">4473000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:EquityFairValueAdjustment contextRef="c-175" decimals="-6" id="f-920" unitRef="usd">-17000000</us-gaap:EquityFairValueAdjustment>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod contextRef="c-175" decimals="-6" id="f-921" unitRef="usd">-4005000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-176" decimals="-6" id="f-922" unitRef="usd">451000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-176" decimals="-6" id="f-923" unitRef="usd">451000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-177" decimals="-6" id="f-924" unitRef="usd">696000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquityFairValueAdjustment contextRef="c-178" decimals="-6" id="f-925" unitRef="usd">-197000000</us-gaap:EquityFairValueAdjustment>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod contextRef="c-178" decimals="-6" id="f-926" unitRef="usd">274000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-179" decimals="-6" id="f-927" unitRef="usd">773000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-179" decimals="-6" id="f-928" unitRef="usd">773000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-180" decimals="-6" id="f-929" unitRef="usd">576000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:EquityFairValueAdjustment contextRef="c-181" decimals="-6" id="f-930" unitRef="usd">-368000000</us-gaap:EquityFairValueAdjustment>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod contextRef="c-181" decimals="-6" id="f-931" unitRef="usd">4265000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-174" decimals="-6" id="f-932" unitRef="usd">4473000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-174" decimals="-6" id="f-933" unitRef="usd">4473000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-182" decimals="-6" id="f-934" unitRef="usd">613000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquityFairValueAdjustment contextRef="c-183" decimals="-6" id="f-935" unitRef="usd">1000000</us-gaap:EquityFairValueAdjustment>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod contextRef="c-183" decimals="-6" id="f-936" unitRef="usd">82000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-177" decimals="-6" id="f-937" unitRef="usd">696000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-177" decimals="-6" id="f-938" unitRef="usd">696000000</us-gaap:OtherAssetsNoncurrent>
    <jnj:ExchangeOfStockPercentageOwnershipAfterTransaction contextRef="c-47" decimals="3" id="f-939" unitRef="number">0.095</jnj:ExchangeOfStockPercentageOwnershipAfterTransaction>
    <us-gaap:CommercialPaper contextRef="c-184" decimals="-8" id="f-940" unitRef="usd">3600000000</us-gaap:CommercialPaper>
    <us-gaap:ProceedsFromIssuanceOfCommercialPaper contextRef="c-185" decimals="-8" id="f-941" unitRef="usd">3600000000</us-gaap:ProceedsFromIssuanceOfCommercialPaper>
    <jnj:DebtForEquityExchangeSharesExchanged
      contextRef="c-186"
      decimals="INF"
      id="f-942"
      unitRef="shares">182329550</jnj:DebtForEquityExchangeSharesExchanged>
    <jnj:DebtForEquityExchangeLossOnSharesExchanged contextRef="c-187" decimals="-8" id="f-943" unitRef="usd">400000000</jnj:DebtForEquityExchangeLossOnSharesExchanged>
    <jnj:EquityFairValueAdjustmentImpairmentLoss contextRef="c-178" decimals="-6" id="f-944" unitRef="usd">-171000000</jnj:EquityFairValueAdjustmentImpairmentLoss>
    <jnj:EquityFairValueAdjustmentImpairmentLoss contextRef="c-183" decimals="-6" id="f-945" unitRef="usd">-1000000</jnj:EquityFairValueAdjustmentImpairmentLoss>
    <jnj:EquityFairValueAdjustmentChangeinObservablePrices contextRef="c-178" decimals="-6" id="f-946" unitRef="usd">-26000000</jnj:EquityFairValueAdjustmentChangeinObservablePrices>
    <jnj:EquityFairValueAdjustmentChangeinObservablePrices contextRef="c-183" decimals="-6" id="f-947" unitRef="usd">27000000</jnj:EquityFairValueAdjustmentChangeinObservablePrices>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock contextRef="c-1" id="f-948">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company&#x2019;s significant financial assets and liabilities measured at fair value as of the fiscal year ended December&#160;29, 2024 and December&#160;31, 2023 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.209%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.894%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.894%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.894%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.894%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.895%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;660&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;660&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;539&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest rate contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,484&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,484&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;988&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,144&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,144&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,527&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Forward foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;794&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;794&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;624&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest rate contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,753&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,753&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,338&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,547&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,547&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,962&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;64&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Forward foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Available For Sale Other Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Equity investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;451&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;451&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,473&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,216&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,216&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,874&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Other Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,217&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,217&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,092&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.065%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.302%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.895%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.558%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.139%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross to Net Derivative Reconciliation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total Gross Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$2,194&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,591&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Credit Support Agreements (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,172)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,575)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total Net Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total Gross Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,564&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,037&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Credit Support Agreements (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,412)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,604)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total Net Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$152&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;433&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Summarized information about changes in liabilities for contingent consideration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$1,092&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,120&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;533&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Changes in estimated fair value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Additions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;112&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;792&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Payments/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Ending Balance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$1,217&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,092&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,120&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt"&gt;2023 assets and liabilities are all classified as Level&#160;2 with the exception of equity investments of $4,473 million, which are classified as Level&#160;1 and contingent consideration of $1,092 million, classified as Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt"&gt;Includes cross currency interest rate swaps and interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt"&gt;Classified as non-current other assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.89pt"&gt;Classified as cash equivalents and current marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.99pt"&gt;Includes $1,217 million, $1,092 million and $1,116 million, classified as non-current other liabilities as of December&#160;29, 2024, &lt;br/&gt;December&#160;31, 2023 and January&#160;1, 2023, respectively. Includes $4&#160;million classified as current liabilities as of January&#160;1, 2023.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;In fiscal year 2024, the Company recorded $105&#160;million of contingent consideration related to Proteologix. In fiscal year 2022, the Company recorded $704&#160;million of contingent consideration related to Abiomed.</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue contextRef="c-188" decimals="-6" id="f-949" unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue contextRef="c-189" decimals="-6" id="f-950" unitRef="usd">660000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue contextRef="c-190" decimals="-6" id="f-951" unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue contextRef="c-118" decimals="-6" id="f-952" unitRef="usd">660000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue contextRef="c-191" decimals="-6" id="f-953" unitRef="usd">539000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue contextRef="c-192" decimals="-6" id="f-954" unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue contextRef="c-193" decimals="-6" id="f-955" unitRef="usd">1484000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue contextRef="c-194" decimals="-6" id="f-956" unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue contextRef="c-195" decimals="-6" id="f-957" unitRef="usd">1484000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue contextRef="c-196" decimals="-6" id="f-958" unitRef="usd">988000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue contextRef="c-197" decimals="-6" id="f-959" unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue contextRef="c-198" decimals="-6" id="f-960" unitRef="usd">2144000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue contextRef="c-199" decimals="-6" id="f-961" unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue contextRef="c-10" decimals="-6" id="f-962" unitRef="usd">2144000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue contextRef="c-200" decimals="-6" id="f-963" unitRef="usd">1527000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue contextRef="c-188" decimals="-6" id="f-964" unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue contextRef="c-189" decimals="-6" id="f-965" unitRef="usd">794000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue contextRef="c-190" decimals="-6" id="f-966" unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue contextRef="c-118" decimals="-6" id="f-967" unitRef="usd">794000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue contextRef="c-191" decimals="-6" id="f-968" unitRef="usd">624000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue contextRef="c-192" decimals="-6" id="f-969" unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue contextRef="c-193" decimals="-6" id="f-970" unitRef="usd">3753000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue contextRef="c-194" decimals="-6" id="f-971" unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue contextRef="c-195" decimals="-6" id="f-972" unitRef="usd">3753000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue contextRef="c-196" decimals="-6" id="f-973" unitRef="usd">5338000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue contextRef="c-197" decimals="-6" id="f-974" unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue contextRef="c-198" decimals="-6" id="f-975" unitRef="usd">4547000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue contextRef="c-199" decimals="-6" id="f-976" unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue contextRef="c-10" decimals="-6" id="f-977" unitRef="usd">4547000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue contextRef="c-200" decimals="-6" id="f-978" unitRef="usd">5962000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue contextRef="c-188" decimals="-6" id="f-979" unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue contextRef="c-189" decimals="-6" id="f-980" unitRef="usd">50000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue contextRef="c-190" decimals="-6" id="f-981" unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue contextRef="c-118" decimals="-6" id="f-982" unitRef="usd">50000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue contextRef="c-191" decimals="-6" id="f-983" unitRef="usd">64000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue contextRef="c-188" decimals="-6" id="f-984" unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue contextRef="c-189" decimals="-6" id="f-985" unitRef="usd">17000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue contextRef="c-190" decimals="-6" id="f-986" unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue contextRef="c-118" decimals="-6" id="f-987" unitRef="usd">17000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue contextRef="c-191" decimals="-6" id="f-988" unitRef="usd">75000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-197" decimals="-6" id="f-989" unitRef="usd">451000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-198" decimals="-6" id="f-990" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-199" decimals="-6" id="f-991" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-10" decimals="-6" id="f-992" unitRef="usd">451000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-11" decimals="-6" id="f-993" unitRef="usd">4473000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-197" decimals="-6" id="f-994" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-198" decimals="-6" id="f-995" unitRef="usd">7216000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-199" decimals="-6" id="f-996" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-10" decimals="-6" id="f-997" unitRef="usd">7216000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-11" decimals="-6" id="f-998" unitRef="usd">8874000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-199" decimals="-6" id="f-999" unitRef="usd">1217000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-10" decimals="-6" id="f-1000" unitRef="usd">1217000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-11" decimals="-6" id="f-1001" unitRef="usd">1092000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-10" decimals="-6" id="f-1002" unitRef="usd">2194000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-11" decimals="-6" id="f-1003" unitRef="usd">1591000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeAssetFairValueGrossLiability contextRef="c-10" decimals="-6" id="f-1004" unitRef="usd">2172000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssetFairValueGrossLiability contextRef="c-11" decimals="-6" id="f-1005" unitRef="usd">1575000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <jnj:DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag contextRef="c-1" id="f-1006">Total Net Asset</jnj:DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag>
    <jnj:DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag contextRef="c-12" id="f-1007">Total Net Asset</jnj:DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag>
    <us-gaap:DerivativeAssets contextRef="c-10" decimals="-6" id="f-1008" unitRef="usd">22000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-11" decimals="-6" id="f-1009" unitRef="usd">16000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-10" decimals="-6" id="f-1010" unitRef="usd">4564000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-11" decimals="-6" id="f-1011" unitRef="usd">6037000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset contextRef="c-10" decimals="-6" id="f-1012" unitRef="usd">4412000000</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset contextRef="c-11" decimals="-6" id="f-1013" unitRef="usd">5604000000</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <jnj:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag contextRef="c-12" id="f-1014">Total Net Liabilities</jnj:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag>
    <jnj:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag contextRef="c-1" id="f-1015">Total Net Liabilities</jnj:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag>
    <us-gaap:DerivativeLiabilities contextRef="c-10" decimals="-6" id="f-1016" unitRef="usd">152000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-11" decimals="-6" id="f-1017" unitRef="usd">433000000</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-11" decimals="-6" id="f-1018" unitRef="usd">1092000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-22" decimals="-6" id="f-1019" unitRef="usd">1120000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-14" decimals="-6" id="f-1020" unitRef="usd">533000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue contextRef="c-1" decimals="-6" id="f-1021" unitRef="usd">88000000</jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue>
    <jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue contextRef="c-12" decimals="-6" id="f-1022" unitRef="usd">29000000</jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue>
    <jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue contextRef="c-13" decimals="-6" id="f-1023" unitRef="usd">-194000000</jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-1" decimals="-6" id="f-1024" unitRef="usd">112000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-12" decimals="-6" id="f-1025" unitRef="usd">0</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-13" decimals="-6" id="f-1026" unitRef="usd">792000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-1" decimals="-6" id="f-1027" unitRef="usd">75000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-12" decimals="-6" id="f-1028" unitRef="usd">57000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-13" decimals="-6" id="f-1029" unitRef="usd">11000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-10" decimals="-6" id="f-1030" unitRef="usd">1217000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-11" decimals="-6" id="f-1031" unitRef="usd">1092000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-22" decimals="-6" id="f-1032" unitRef="usd">1120000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-201" decimals="-6" id="f-1033" unitRef="usd">4473000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-202" decimals="-6" id="f-1034" unitRef="usd">1092000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-203" decimals="-6" id="f-1035" unitRef="usd">1217000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-204" decimals="-6" id="f-1036" unitRef="usd">1092000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-205" decimals="-6" id="f-1037" unitRef="usd">1116000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-206" decimals="-6" id="f-1038" unitRef="usd">4000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-207" decimals="-6" id="f-1039" unitRef="usd">105000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-208" decimals="-6" id="f-1040" unitRef="usd">704000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-1041">Borrowings&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The components of long-term debt are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Effective&lt;br/&gt;Rate&lt;br/&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Effective&lt;br/&gt;Rate&lt;br/&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.650% Notes due 2024 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(750MM Euro 1.1090)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$831&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.50%&#160;Notes due 2024 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(500MM GBP 1.2756)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;637&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;6.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.625% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;750&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;750&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.55% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;999&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;950&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.46% Notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,999&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,997&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;927&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;900&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,458&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,419&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.150% Notes due 2028&lt;br/&gt;(750MM Euro 1.0401)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;/(750MM Euro 1.1090)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;777&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;828&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.90%&#160;Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,498&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,497&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.95%&#160;Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;298&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;7.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;298&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;7.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.80% Debentures due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,146&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.30% Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,646&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,630&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.90% Debentures due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,145&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.20% Debenture due 2032&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(700M EUR 1.0401)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;725&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.95%&#160;Debentures due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;499&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;499&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.375% Notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;854&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;854&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4.95% Debentures due 2034&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;846&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.650% Notes due 2035&lt;br/&gt;(1.5B Euro 1.0401)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;/(1.5B Euro 1.1090)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,550&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,652&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.35% Debentures due 2036 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(800MM EUR 1.0401)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;827&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.587% Notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;869&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;864&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.95%&#160;Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;994&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;5.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;994&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;5.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.625% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,358&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,357&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.85%&#160;Debentures due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;697&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;5.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;697&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;5.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.40%&#160;Notes due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;993&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;993&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.50%&#160;Debentures due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;541&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;541&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.10% Notes due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;845&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;849&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.85% Notes due 2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;297&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;297&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.50% Notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;496&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;496&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.55% Debentures due 2044&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1B EUR 1.0401)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.73% Notes due 2046&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,978&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,977&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.75% Notes due 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;822&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;832&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.500% Notes due 2048&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;744&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;743&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.250% Notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;808&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;826&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.25% Debentures due 2054&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;843&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;5.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.450% Notes due 2060&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,058&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,073&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;32,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;3.36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;27,350&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;2.98&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,749&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,469&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;$30,651&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;$25,881&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt"&gt;Weighted average effective rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt"&gt;Translation rate at December&#160;29, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt"&gt;Translation rate at December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.89pt"&gt;The excess of the carrying value over the fair value of debt was $2.0 billion and $1.0 billion at the end of fiscal year 2024 and fiscal year 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Fair value of the long-term debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company has access to substantial sources of funds at numerous banks worldwide. In June 2024, the Company secured a new 364-day Credit Facility of $10 billion, which expires on&#160;June 25, 2025. Interest charged on borrowings under the credit line agreement is based on either the Term SOFR Reference Rate or other applicable market rates&#160;as allowed under the terms of the agreement, plus applicable margins. Commitment fees under the agreements are not&#160;material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Throughout fiscal years 2024 and 2023, the Company continued to have access to liquidity through the commercial paper&#160;market. Short-term borrowings and the current portion of long-term debt amounted to approximately $6.0 billion and $3.5 billion at the end of fiscal years 2024 and 2023, respectively. The current portion of the long-term debt was $1.7 billion and $1.5 billion in 2024 and 2023, respectively, and the remainder is commercial paper and local borrowing by international&#160;subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The current debt balance as of December&#160;29, 2024 includes $4.1&#160;billion of commercial paper which has a weighted average interest rate of 4.46% and a weighted average maturity of approximately two months. The current debt balance as of December&#160;31, 2023 includes $2.0&#160;billion of commercial paper which has a weighted average interest rate of 5.37% and a weighted average maturity of approximately two months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Aggregate maturities of long-term debt obligations commencing in 2025 are:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.826%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;After 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$1,749&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,999&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,385&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,275&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,444&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,548&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-1042">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The components of long-term debt are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Effective&lt;br/&gt;Rate&lt;br/&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Effective&lt;br/&gt;Rate&lt;br/&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.650% Notes due 2024 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(750MM Euro 1.1090)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$831&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.50%&#160;Notes due 2024 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(500MM GBP 1.2756)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;637&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;6.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.625% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;750&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;750&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.55% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;999&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;950&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.46% Notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,999&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,997&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;927&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;900&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,458&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,419&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.150% Notes due 2028&lt;br/&gt;(750MM Euro 1.0401)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;/(750MM Euro 1.1090)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;777&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;828&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.90%&#160;Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,498&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,497&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.95%&#160;Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;298&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;7.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;298&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;7.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.80% Debentures due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,146&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.30% Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,646&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,630&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.90% Debentures due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,145&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.20% Debenture due 2032&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(700M EUR 1.0401)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;725&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.95%&#160;Debentures due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;499&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;499&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.375% Notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;854&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;854&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4.95% Debentures due 2034&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;846&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.650% Notes due 2035&lt;br/&gt;(1.5B Euro 1.0401)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;/(1.5B Euro 1.1090)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,550&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,652&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.35% Debentures due 2036 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(800MM EUR 1.0401)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;827&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.587% Notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;869&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;864&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.95%&#160;Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;994&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;5.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;994&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;5.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.625% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,358&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,357&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.85%&#160;Debentures due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;697&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;5.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;697&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;5.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.40%&#160;Notes due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;993&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;993&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.50%&#160;Debentures due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;541&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;541&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.10% Notes due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;845&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;849&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.85% Notes due 2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;297&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;297&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.50% Notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;496&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;496&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.55% Debentures due 2044&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1B EUR 1.0401)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.73% Notes due 2046&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,978&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,977&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.75% Notes due 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;822&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;832&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.500% Notes due 2048&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;744&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;743&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.250% Notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;808&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;826&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.25% Debentures due 2054&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;843&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;5.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.450% Notes due 2060&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,058&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,073&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;32,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;3.36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;27,350&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;2.98&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,749&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,469&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;$30,651&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;$25,881&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt"&gt;Weighted average effective rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt"&gt;Translation rate at December&#160;29, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt"&gt;Translation rate at December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.89pt"&gt;The excess of the carrying value over the fair value of debt was $2.0 billion and $1.0 billion at the end of fiscal year 2024 and fiscal year 2023, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-209"
      decimals="INF"
      id="f-1043"
      unitRef="number">0.00650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-210" decimals="-6" id="f-1044" unitRef="eur">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c-210"
      decimals="INF"
      id="f-1045"
      unitRef="number">1.1090</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebt contextRef="c-209" decimals="-6" id="f-1046" unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-209"
      decimals="4"
      id="f-1047"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-210" decimals="-6" id="f-1048" unitRef="usd">831000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-210"
      decimals="4"
      id="f-1049"
      unitRef="number">0.0068</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-211"
      decimals="INF"
      id="f-1050"
      unitRef="number">0.0550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-212" decimals="-6" id="f-1051" unitRef="gbp">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c-212"
      decimals="INF"
      id="f-1052"
      unitRef="number">1.2756</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebt contextRef="c-211" decimals="-6" id="f-1053" unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-211"
      decimals="4"
      id="f-1054"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-212" decimals="-6" id="f-1055" unitRef="usd">637000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-212"
      decimals="4"
      id="f-1056"
      unitRef="number">0.0675</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-213"
      decimals="INF"
      id="f-1057"
      unitRef="number">0.02625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-213" decimals="-6" id="f-1058" unitRef="usd">750000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-213"
      decimals="4"
      id="f-1059"
      unitRef="number">0.0263</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-214" decimals="-6" id="f-1060" unitRef="usd">750000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-214"
      decimals="4"
      id="f-1061"
      unitRef="number">0.0263</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-215"
      decimals="INF"
      id="f-1062"
      unitRef="number">0.0055</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-215" decimals="-6" id="f-1063" unitRef="usd">999000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-215"
      decimals="4"
      id="f-1064"
      unitRef="number">0.0057</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-216" decimals="-6" id="f-1065" unitRef="usd">950000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-216"
      decimals="4"
      id="f-1066"
      unitRef="number">0.0057</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-217"
      decimals="INF"
      id="f-1067"
      unitRef="number">0.0246</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-217" decimals="-6" id="f-1068" unitRef="usd">1999000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-217"
      decimals="4"
      id="f-1069"
      unitRef="number">0.0247</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-218" decimals="-6" id="f-1070" unitRef="usd">1997000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-218"
      decimals="4"
      id="f-1071"
      unitRef="number">0.0247</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-219"
      decimals="INF"
      id="f-1072"
      unitRef="number">0.0295</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-219" decimals="-6" id="f-1073" unitRef="usd">927000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-219"
      decimals="4"
      id="f-1074"
      unitRef="number">0.0296</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-220" decimals="-6" id="f-1075" unitRef="usd">900000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-220"
      decimals="4"
      id="f-1076"
      unitRef="number">0.0296</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-221"
      decimals="INF"
      id="f-1077"
      unitRef="number">0.0095</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-221" decimals="-6" id="f-1078" unitRef="usd">1458000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-221"
      decimals="4"
      id="f-1079"
      unitRef="number">0.0096</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-222" decimals="-6" id="f-1080" unitRef="usd">1419000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-222"
      decimals="4"
      id="f-1081"
      unitRef="number">0.0096</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-223"
      decimals="INF"
      id="f-1082"
      unitRef="number">0.01150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-223" decimals="-6" id="f-1083" unitRef="eur">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c-223"
      decimals="INF"
      id="f-1084"
      unitRef="number">1.0401</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-224" decimals="-6" id="f-1085" unitRef="eur">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c-224"
      decimals="INF"
      id="f-1086"
      unitRef="number">1.1090</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebt contextRef="c-223" decimals="-6" id="f-1087" unitRef="usd">777000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-223"
      decimals="4"
      id="f-1088"
      unitRef="number">0.0121</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-224" decimals="-6" id="f-1089" unitRef="usd">828000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-224"
      decimals="4"
      id="f-1090"
      unitRef="number">0.0121</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-225"
      decimals="INF"
      id="f-1091"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-225" decimals="-6" id="f-1092" unitRef="usd">1498000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-225"
      decimals="4"
      id="f-1093"
      unitRef="number">0.0291</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-226" decimals="-6" id="f-1094" unitRef="usd">1497000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-226"
      decimals="4"
      id="f-1095"
      unitRef="number">0.0291</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-227"
      decimals="INF"
      id="f-1096"
      unitRef="number">0.0695</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-227" decimals="-6" id="f-1097" unitRef="usd">298000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-227"
      decimals="4"
      id="f-1098"
      unitRef="number">0.0714</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-228" decimals="-6" id="f-1099" unitRef="usd">298000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-228"
      decimals="4"
      id="f-1100"
      unitRef="number">0.0714</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-229"
      decimals="INF"
      id="f-1101"
      unitRef="number">0.0480</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-229" decimals="-6" id="f-1102" unitRef="usd">1146000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-229"
      decimals="4"
      id="f-1103"
      unitRef="number">0.0483</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-230" decimals="-6" id="f-1104" unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-230"
      decimals="4"
      id="f-1105"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-231"
      decimals="INF"
      id="f-1106"
      unitRef="number">0.0130</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-231" decimals="-6" id="f-1107" unitRef="usd">1646000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-231"
      decimals="4"
      id="f-1108"
      unitRef="number">0.0130</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-232" decimals="-6" id="f-1109" unitRef="usd">1630000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-232"
      decimals="4"
      id="f-1110"
      unitRef="number">0.0130</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-233"
      decimals="INF"
      id="f-1111"
      unitRef="number">0.0490</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-233" decimals="-6" id="f-1112" unitRef="usd">1145000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-233"
      decimals="4"
      id="f-1113"
      unitRef="number">0.0492</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-234" decimals="-6" id="f-1114" unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-234"
      decimals="4"
      id="f-1115"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-235"
      decimals="3"
      id="f-1116"
      unitRef="number">0.0320</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-235" decimals="-6" id="f-1117" unitRef="eur">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c-235"
      decimals="4"
      id="f-1118"
      unitRef="number">1.0401</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebt contextRef="c-235" decimals="-6" id="f-1119" unitRef="usd">725000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-235"
      decimals="4"
      id="f-1120"
      unitRef="number">0.0321</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-236" decimals="-6" id="f-1121" unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-236"
      decimals="4"
      id="f-1122"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-237"
      decimals="INF"
      id="f-1123"
      unitRef="number">0.0495</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-237" decimals="-6" id="f-1124" unitRef="usd">499000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-237"
      decimals="4"
      id="f-1125"
      unitRef="number">0.0495</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-238" decimals="-6" id="f-1126" unitRef="usd">499000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-238"
      decimals="4"
      id="f-1127"
      unitRef="number">0.0495</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-239"
      decimals="INF"
      id="f-1128"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-239" decimals="-6" id="f-1129" unitRef="usd">854000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-239"
      decimals="4"
      id="f-1130"
      unitRef="number">0.0424</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-240" decimals="-6" id="f-1131" unitRef="usd">854000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-240"
      decimals="4"
      id="f-1132"
      unitRef="number">0.0424</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-241"
      decimals="INF"
      id="f-1133"
      unitRef="number">0.0495</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-241" decimals="-6" id="f-1134" unitRef="usd">846000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-241"
      decimals="4"
      id="f-1135"
      unitRef="number">0.0496</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-242" decimals="-6" id="f-1136" unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-242"
      decimals="4"
      id="f-1137"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-243"
      decimals="INF"
      id="f-1138"
      unitRef="number">0.01650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-243" decimals="-8" id="f-1139" unitRef="eur">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c-243"
      decimals="INF"
      id="f-1140"
      unitRef="number">1.0401</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-244" decimals="-8" id="f-1141" unitRef="eur">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c-244"
      decimals="INF"
      id="f-1142"
      unitRef="number">1.1090</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebt contextRef="c-243" decimals="-6" id="f-1143" unitRef="usd">1550000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-243"
      decimals="4"
      id="f-1144"
      unitRef="number">0.0168</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-244" decimals="-6" id="f-1145" unitRef="usd">1652000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-244"
      decimals="4"
      id="f-1146"
      unitRef="number">0.0168</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-245"
      decimals="4"
      id="f-1147"
      unitRef="number">0.0335</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-245" decimals="-6" id="f-1148" unitRef="eur">800000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c-245"
      decimals="4"
      id="f-1149"
      unitRef="number">1.0401</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebt contextRef="c-245" decimals="-6" id="f-1150" unitRef="usd">827000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-245"
      decimals="4"
      id="f-1151"
      unitRef="number">0.0337</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-246" decimals="-6" id="f-1152" unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-246"
      decimals="4"
      id="f-1153"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-247"
      decimals="INF"
      id="f-1154"
      unitRef="number">0.03587</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-247" decimals="-6" id="f-1155" unitRef="usd">869000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-247"
      decimals="4"
      id="f-1156"
      unitRef="number">0.0359</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-248" decimals="-6" id="f-1157" unitRef="usd">864000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-248"
      decimals="4"
      id="f-1158"
      unitRef="number">0.0359</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-249"
      decimals="INF"
      id="f-1159"
      unitRef="number">0.0595</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-249" decimals="-6" id="f-1160" unitRef="usd">994000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-249"
      decimals="4"
      id="f-1161"
      unitRef="number">0.0599</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-250" decimals="-6" id="f-1162" unitRef="usd">994000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-250"
      decimals="4"
      id="f-1163"
      unitRef="number">0.0599</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-251"
      decimals="INF"
      id="f-1164"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-251" decimals="-6" id="f-1165" unitRef="usd">1358000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-251"
      decimals="4"
      id="f-1166"
      unitRef="number">0.0364</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-252" decimals="-6" id="f-1167" unitRef="usd">1357000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-252"
      decimals="4"
      id="f-1168"
      unitRef="number">0.0364</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-253"
      decimals="INF"
      id="f-1169"
      unitRef="number">0.0585</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-253" decimals="-6" id="f-1170" unitRef="usd">697000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-253"
      decimals="4"
      id="f-1171"
      unitRef="number">0.0585</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-254" decimals="-6" id="f-1172" unitRef="usd">697000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-254"
      decimals="4"
      id="f-1173"
      unitRef="number">0.0585</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-255"
      decimals="INF"
      id="f-1174"
      unitRef="number">0.0340</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-255" decimals="-6" id="f-1175" unitRef="usd">993000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-255"
      decimals="4"
      id="f-1176"
      unitRef="number">0.0342</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-256" decimals="-6" id="f-1177" unitRef="usd">993000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-256"
      decimals="4"
      id="f-1178"
      unitRef="number">0.0342</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-257"
      decimals="INF"
      id="f-1179"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-257" decimals="-6" id="f-1180" unitRef="usd">541000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-257"
      decimals="4"
      id="f-1181"
      unitRef="number">0.0463</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-258" decimals="-6" id="f-1182" unitRef="usd">541000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-258"
      decimals="4"
      id="f-1183"
      unitRef="number">0.0463</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-259"
      decimals="INF"
      id="f-1184"
      unitRef="number">0.0210</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-259" decimals="-6" id="f-1185" unitRef="usd">845000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-259"
      decimals="4"
      id="f-1186"
      unitRef="number">0.0214</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-260" decimals="-6" id="f-1187" unitRef="usd">849000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-260"
      decimals="4"
      id="f-1188"
      unitRef="number">0.0214</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-261"
      decimals="INF"
      id="f-1189"
      unitRef="number">0.0485</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-261" decimals="-6" id="f-1190" unitRef="usd">297000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-261"
      decimals="4"
      id="f-1191"
      unitRef="number">0.0489</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-262" decimals="-6" id="f-1192" unitRef="usd">297000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-262"
      decimals="4"
      id="f-1193"
      unitRef="number">0.0489</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-263"
      decimals="INF"
      id="f-1194"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-263" decimals="-6" id="f-1195" unitRef="usd">496000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-263"
      decimals="4"
      id="f-1196"
      unitRef="number">0.0452</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-264" decimals="-6" id="f-1197" unitRef="usd">496000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-264"
      decimals="4"
      id="f-1198"
      unitRef="number">0.0452</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-265"
      decimals="4"
      id="f-1199"
      unitRef="number">0.0355</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-265" decimals="-6" id="f-1200" unitRef="eur">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c-265"
      decimals="4"
      id="f-1201"
      unitRef="number">1.0401</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebt contextRef="c-265" decimals="-6" id="f-1202" unitRef="usd">1030000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-265"
      decimals="4"
      id="f-1203"
      unitRef="number">0.0358</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-266" decimals="-6" id="f-1204" unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-266"
      decimals="4"
      id="f-1205"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-267"
      decimals="INF"
      id="f-1206"
      unitRef="number">0.0373</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-267" decimals="-6" id="f-1207" unitRef="usd">1978000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-267"
      decimals="4"
      id="f-1208"
      unitRef="number">0.0374</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-268" decimals="-6" id="f-1209" unitRef="usd">1977000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-268"
      decimals="4"
      id="f-1210"
      unitRef="number">0.0374</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-269"
      decimals="INF"
      id="f-1211"
      unitRef="number">0.0375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-269" decimals="-6" id="f-1212" unitRef="usd">822000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-269"
      decimals="4"
      id="f-1213"
      unitRef="number">0.0376</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-270" decimals="-6" id="f-1214" unitRef="usd">832000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-270"
      decimals="4"
      id="f-1215"
      unitRef="number">0.0376</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-271"
      decimals="INF"
      id="f-1216"
      unitRef="number">0.03500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-271" decimals="-6" id="f-1217" unitRef="usd">744000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-271"
      decimals="4"
      id="f-1218"
      unitRef="number">0.0352</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-272" decimals="-6" id="f-1219" unitRef="usd">743000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-272"
      decimals="4"
      id="f-1220"
      unitRef="number">0.0352</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-273"
      decimals="INF"
      id="f-1221"
      unitRef="number">0.02250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-273" decimals="-6" id="f-1222" unitRef="usd">808000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-273"
      decimals="4"
      id="f-1223"
      unitRef="number">0.0229</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-274" decimals="-6" id="f-1224" unitRef="usd">826000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-274"
      decimals="4"
      id="f-1225"
      unitRef="number">0.0229</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-275"
      decimals="INF"
      id="f-1226"
      unitRef="number">0.0525</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-275" decimals="-6" id="f-1227" unitRef="usd">843000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-275"
      decimals="4"
      id="f-1228"
      unitRef="number">0.0526</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-276" decimals="-6" id="f-1229" unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-276"
      decimals="4"
      id="f-1230"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-277"
      decimals="INF"
      id="f-1231"
      unitRef="number">0.02450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-277" decimals="-6" id="f-1232" unitRef="usd">1058000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-277"
      decimals="4"
      id="f-1233"
      unitRef="number">0.0249</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-278" decimals="-6" id="f-1234" unitRef="usd">1073000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-278"
      decimals="4"
      id="f-1235"
      unitRef="number">0.0249</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-279" decimals="-6" id="f-1236" unitRef="usd">83000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-279"
      decimals="4"
      id="f-1237"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-280" decimals="-6" id="f-1238" unitRef="usd">69000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-280"
      decimals="4"
      id="f-1239"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-10" decimals="-6" id="f-1240" unitRef="usd">32400000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-10" decimals="4" id="f-1241" unitRef="number">0.0336</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt contextRef="c-11" decimals="-6" id="f-1242" unitRef="usd">27350000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-11" decimals="4" id="f-1243" unitRef="number">0.0298</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtCurrent contextRef="c-10" decimals="-6" id="f-1244" unitRef="usd">1749000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-11" decimals="-6" id="f-1245" unitRef="usd">1469000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-10" decimals="-6" id="f-1246" unitRef="usd">30651000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-11" decimals="-6" id="f-1247" unitRef="usd">25881000000</us-gaap:LongTermDebtNoncurrent>
    <jnj:ExcessOfCarryingValueOverFairValueOfDebt contextRef="c-1" decimals="-8" id="f-1248" unitRef="usd">2000000000.0</jnj:ExcessOfCarryingValueOverFairValueOfDebt>
    <jnj:ExcessOfFairValueOverCarryingValueOfDebt contextRef="c-12" decimals="-8" id="f-1249" unitRef="usd">1000000000.0</jnj:ExcessOfFairValueOverCarryingValueOfDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-8" decimals="-9" id="f-1250" unitRef="usd">10000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtCurrent contextRef="c-10" decimals="-8" id="f-1251" unitRef="usd">6000000000.0</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent contextRef="c-11" decimals="-8" id="f-1252" unitRef="usd">3500000000</us-gaap:DebtCurrent>
    <us-gaap:LongTermCommercialPaperCurrent contextRef="c-10" decimals="-8" id="f-1253" unitRef="usd">1700000000</us-gaap:LongTermCommercialPaperCurrent>
    <us-gaap:LongTermCommercialPaperCurrent contextRef="c-11" decimals="-8" id="f-1254" unitRef="usd">1500000000</us-gaap:LongTermCommercialPaperCurrent>
    <us-gaap:ShortTermBorrowings contextRef="c-281" decimals="-8" id="f-1255" unitRef="usd">4100000000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="c-281"
      decimals="4"
      id="f-1256"
      unitRef="number">0.0446</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentTerm contextRef="c-282" id="f-1257">P2M</us-gaap:DebtInstrumentTerm>
    <us-gaap:ShortTermBorrowings contextRef="c-283" decimals="-8" id="f-1258" unitRef="usd">2000000000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="c-283"
      decimals="4"
      id="f-1259"
      unitRef="number">0.0537</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentTerm contextRef="c-284" id="f-1260">P2M</us-gaap:DebtInstrumentTerm>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-1261">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Aggregate maturities of long-term debt obligations commencing in 2025 are:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.826%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;After 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$1,749&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,999&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,385&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,275&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,444&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,548&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-10" decimals="-6" id="f-1262" unitRef="usd">1749000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-10" decimals="-6" id="f-1263" unitRef="usd">1999000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-10" decimals="-6" id="f-1264" unitRef="usd">2385000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c-10" decimals="-6" id="f-1265" unitRef="usd">2275000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="c-10" decimals="-6" id="f-1266" unitRef="usd">1444000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive contextRef="c-10" decimals="-6" id="f-1267" unitRef="usd">22548000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-1268">Income taxes&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The provision for taxes on income on continuing operations consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Currently payable:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$2,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,705&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,274&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,604&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,090&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,295&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total currently payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,804&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,795&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,569&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,539)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,440)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,990)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;356&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(619)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;410&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,183)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,059)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,580)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Provision for taxes on income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$2,621&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,736&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,989&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;A comparison of income tax expense at the U.S.&#160;statutory rate of 21% in fiscal years 2024, 2023 and 2022, to the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$(458)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,033)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,606&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17,145&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17,095&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,753&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Earnings before taxes on income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$16,687&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,062&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19,359&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Tax rates:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. tax settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. taxes on international income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. state taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Tax benefits on share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Effective Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt"&gt;International operations reflect the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland, and Belgium, which is a favorable impact on the effective tax rate as compared with the U.S. statutory&#160;rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt"&gt;Includes the net impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code as well as related foreign tax credits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%"&gt;The fiscal year 2024 effective tax rate increased 4.2% as compared to the fiscal year 2023 effective tax rate. The primary drivers of this change are discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%"&gt;In fiscal year 2024, The Company had more income in higher tax jurisdictions compared to fiscal year 2023, primarily in the U.S. where the Company recorded a charge of approximately $5.1&#160;billion in the fiscal year of 2024 versus approximately $7.0&#160;billion in the fiscal year of 2023, both for the talc matters in the United States. Both charges were recorded at an effective U.S. tax rate of approximately 21% (for further information see Note 19 to the Consolidated Financial Statements). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%"&gt;Additionally in the fiscal year 2024, the effective tax rate was unfavorably impacted by legislative changes that went into effect for Pillar Two in some of the Company's foreign jurisdictions which are reflected in International operations on the Company&#x2019;s effective tax rate reconciliation. Also in fiscal year 2024, the Company generated incremental U.S. foreign tax credits related to income sourced and taxed outside the United States and is reflected in U.S. taxes on international income on the Company&#x2019;s effective tax rate reconciliation. In 2024, the Company finalized multi-year transfer pricing agreements with the U.S. Internal Revenue Service (IRS) and certain other foreign jurisdictions. The U.S portion of the agreements were partially offset by the related tax adjustments in the foreign jurisdictions which are reflected in U.S tax settlements and International operations, respectively, on the Company&#x2019;s effective rate reconciliation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%"&gt;The fiscal year 2023 effective tax rate decreased 3.9% as compared to the fiscal year 2022 effective tax rate as the Company recorded certain non-recurring favorable tax items in fiscal year 2023 when compared to the prior fiscal year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%"&gt;In the fiscal fourth quarter of 2023, the Company settled the U.S. Internal Revenue Service audit for tax years 2013 through 2016 which resulted in a favorable impact to the rate of 3.0%. This settlement was partially offset by the Company recording a $0.4&#160;billion decrease in expected U.S. foreign tax credits, an unfavorable effective rate impact of 2.6%, which has been reflected as a current tax expense in U.S. taxes on international income on the Company&#x2019;s effective tax rate reconciliation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%"&gt;In the fiscal year 2023, the Company had certain non-recurring impacts as a result of legislative tax elections made in certain international subsidiaries which resulted in a change in the Company&#x2019;s tax basis in certain assets resulting in deferred tax re-measurements. The net impact of these non-recurring items is a net benefit of 3.4% to the Company&#x2019;s annual effective tax rate, comprised of the following items:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:128%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%;padding-left:7.83pt"&gt;approximately $0.3&#160;billion of tax benefit on local deferred tax assets to record the remeasurement of the increased tax basis, this benefit has been reflected as International operations on the Company&#x2019;s effective tax rate reconciliation. This&#160;benefit was offset by approximately $0.1&#160;billion of U.S. deferred tax expense on the GILTI deferred tax liability resulting from the remeasurement of these deferred tax assets. This has been reflected in the &#x201c;U.S. tax on international income&#x201d; on the Company&#x2019;s effective tax rate reconciliation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt"&gt;approximately $0.3&#160;billion of U.S. deferred tax benefit on the GILTI deferred tax related to an election made by an international subsidiary resulting in a decrease in local deferred tax assets. This has been reflected in the U.S. taxes on international income on the Company&#x2019;s effective tax rate reconciliation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company also had lower income in higher tax jurisdictions vs. fiscal year 2022, primarily in the U.S. where the Company recorded an approximately $7.0&#160;billion charge related to talc matters in the United States at an effective tax rate of 21.1% (for further information see Note 19 to the Consolidated Financial Statements).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Temporary differences and carryforwards at the end of fiscal years 2024 and 2023 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt;padding-right:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.292%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.236%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024 Deferred Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023 Deferred Tax&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Employee related obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$372&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;586&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;717&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;686&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(833)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(902)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Goodwill and intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,261)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,252)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D capitalized for tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,398&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,595&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Reserves&#160;&amp;amp; liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,444&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,816&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventory related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;371&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;359&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,298&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,145&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Undistributed foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,931&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,492)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,801&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,695)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Global intangible low-taxed income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,589)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,731)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Miscellaneous international&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,212&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;831&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Miscellaneous U.S.&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,083&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,826&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7,175)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,819&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6,584)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Valuation allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,638)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,149)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total deferred income taxes net of valuation allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;15,188&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(7,175)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;12,670&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(6,584)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company has wholly-owned international subsidiaries that have cumulative net losses. The Company believes that it is more likely than not that these subsidiaries will generate future taxable income sufficient to partially utilize these deferred tax assets. In certain jurisdictions, valuation allowances have been recorded against deferred tax assets for loss carryforwards that are not more likely than not to be realized. The net operating loss carryforwards for these international subsidiaries that do not have an indefinite carryforward period will begin to expire in 2025 for various amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table summarizes the activity related to valuation allowances for continuing operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$1,149&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;775&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;451&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;355&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Utilization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net acquisitions / (dispositions/liquidations)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;110&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;End of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$1,638&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$1,149&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table summarizes the activity related to unrecognized tax benefits for continuing operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$2,485&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,716&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,210&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;176&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;239&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;523&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Increases related to prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;129&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;244&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;143&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Decreases related to prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(781)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(583)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(880)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;End of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$2,020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,485&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,716&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;As of December&#160;29, 2024 the Company had approximately $2.0 billion of unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress with a number of tax authorities. With respect to the United States, the Internal Revenue Service (IRS) has completed its audit for the tax years through 2016 and has commenced the audit for tax years 2017 through 2020. The Company recently finalized multi-year transfer pricing agreements with the IRS and certain other foreign jurisdictions in the fiscal fourth quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In other major jurisdictions where the Company conducts business, the years that remain open to tax audits go back to the year 2013. The Company believes it is possible that some tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions. The Company anticipates a change in uncertain tax positions of approximately $200&#160;million in certain jurisdictions in the next twelve months due to the expected expiration of the statute of limitations. However, generally the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments, audit settlements, or changes in uncertain tax positions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company classifies liabilities for unrecognized tax benefits and related interest and penalties as long-term liabilities. Interest expense and penalties related to unrecognized tax benefits are classified as income tax expense. The Company recognized after tax interest expense of $217 million, $99 million and $136 million in fiscal years 2024, 2023 and 2022, respectively. The total amount of accrued interest was $274&#160;million and $264 million in fiscal years 2024 and 2023,&#160;respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-1269">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The provision for taxes on income on continuing operations consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Currently payable:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$2,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,705&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,274&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,604&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,090&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,295&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total currently payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,804&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,795&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,569&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,539)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,440)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,990)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;356&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(619)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;410&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,183)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,059)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,580)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Provision for taxes on income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$2,621&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,736&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,989&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1270" unitRef="usd">2200000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-12" decimals="-6" id="f-1271" unitRef="usd">2705000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-13" decimals="-6" id="f-1272" unitRef="usd">2274000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1273" unitRef="usd">2604000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-12" decimals="-6" id="f-1274" unitRef="usd">3090000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-13" decimals="-6" id="f-1275" unitRef="usd">2295000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1276" unitRef="usd">4804000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-12" decimals="-6" id="f-1277" unitRef="usd">5795000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-13" decimals="-6" id="f-1278" unitRef="usd">4569000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1279" unitRef="usd">-2539000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-12" decimals="-6" id="f-1280" unitRef="usd">-3440000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-13" decimals="-6" id="f-1281" unitRef="usd">-1990000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1282" unitRef="usd">356000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-12" decimals="-6" id="f-1283" unitRef="usd">-619000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-13" decimals="-6" id="f-1284" unitRef="usd">410000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <jnj:DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations contextRef="c-1" decimals="-6" id="f-1285" unitRef="usd">-2183000000</jnj:DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations>
    <jnj:DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations contextRef="c-12" decimals="-6" id="f-1286" unitRef="usd">-4059000000</jnj:DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations>
    <jnj:DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations contextRef="c-13" decimals="-6" id="f-1287" unitRef="usd">-1580000000</jnj:DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1288" unitRef="usd">2621000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-6" id="f-1289" unitRef="usd">1736000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-6" id="f-1290" unitRef="usd">2989000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-1291">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;A comparison of income tax expense at the U.S.&#160;statutory rate of 21% in fiscal years 2024, 2023 and 2022, to the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$(458)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,033)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,606&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17,145&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17,095&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,753&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Earnings before taxes on income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$16,687&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,062&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19,359&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Tax rates:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. tax settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. taxes on international income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. state taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Tax benefits on share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Effective Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt"&gt;International operations reflect the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland, and Belgium, which is a favorable impact on the effective tax rate as compared with the U.S. statutory&#160;rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt"&gt;Includes the net impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code as well as related foreign tax credits.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-12" decimals="2" id="f-1292" unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="2" id="f-1293" unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-6" id="f-1294" unitRef="usd">-458000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-12" decimals="-6" id="f-1295" unitRef="usd">-2033000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-13" decimals="-6" id="f-1296" unitRef="usd">4606000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-6" id="f-1297" unitRef="usd">17145000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-12" decimals="-6" id="f-1298" unitRef="usd">17095000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-13" decimals="-6" id="f-1299" unitRef="usd">14753000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-1300" unitRef="usd">16687000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-12" decimals="-6" id="f-1301" unitRef="usd">15062000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-13" decimals="-6" id="f-1302" unitRef="usd">19359000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="3" id="f-1303" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-12" decimals="3" id="f-1304" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-13" decimals="3" id="f-1305" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="3" id="f-1306" unitRef="number">-0.052</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-12" decimals="3" id="f-1307" unitRef="number">-0.081</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-13" decimals="3" id="f-1308" unitRef="number">-0.050</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <jnj:EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation contextRef="c-1" decimals="3" id="f-1309" unitRef="number">0.010</jnj:EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation>
    <jnj:EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation contextRef="c-12" decimals="3" id="f-1310" unitRef="number">-0.030</jnj:EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation>
    <jnj:EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation contextRef="c-13" decimals="3" id="f-1311" unitRef="number">0</jnj:EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation>
    <jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome contextRef="c-1" decimals="3" id="f-1312" unitRef="number">-0.026</jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome>
    <jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome contextRef="c-12" decimals="3" id="f-1313" unitRef="number">-0.003</jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome>
    <jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome contextRef="c-13" decimals="3" id="f-1314" unitRef="number">-0.011</jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-1315" unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-12" decimals="3" id="f-1316" unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-13" decimals="3" id="f-1317" unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="3" id="f-1318" unitRef="number">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-12" decimals="3" id="f-1319" unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-13" decimals="3" id="f-1320" unitRef="number">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="3" id="f-1321" unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-12" decimals="3" id="f-1322" unitRef="number">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-13" decimals="3" id="f-1323" unitRef="number">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-1324" unitRef="number">0.157</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-12" decimals="3" id="f-1325" unitRef="number">0.115</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-13" decimals="3" id="f-1326" unitRef="number">0.154</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent contextRef="c-1" decimals="3" id="f-1327" unitRef="number">0.042</jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent>
    <us-gaap:LitigationSettlementExpense contextRef="c-285" decimals="-8" id="f-1328" unitRef="usd">5100000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense contextRef="c-286" decimals="-8" id="f-1329" unitRef="usd">7000000000</us-gaap:LitigationSettlementExpense>
    <jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent contextRef="c-12" decimals="3" id="f-1330" unitRef="number">-0.039</jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent>
    <jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent
      contextRef="c-287"
      decimals="3"
      id="f-1331"
      unitRef="number">0.030</jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent>
    <us-gaap:IncomeTaxReconciliationTaxCreditsForeign contextRef="c-287" decimals="-8" id="f-1332" unitRef="usd">400000000</us-gaap:IncomeTaxReconciliationTaxCreditsForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
      contextRef="c-287"
      decimals="3"
      id="f-1333"
      unitRef="number">0.026</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign>
    <jnj:EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent
      contextRef="c-288"
      decimals="3"
      id="f-1334"
      unitRef="number">0.034</jnj:EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent>
    <jnj:DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization contextRef="c-11" decimals="-6" id="f-1335" unitRef="usd">300000000</jnj:DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount contextRef="c-1" decimals="-8" id="f-1336" unitRef="usd">100000000</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount>
    <jnj:IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI contextRef="c-12" decimals="-6" id="f-1337" unitRef="usd">300000000</jnj:IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI>
    <us-gaap:LitigationSettlementExpense contextRef="c-289" decimals="-8" id="f-1338" unitRef="usd">7000000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="c-289"
      decimals="3"
      id="f-1339"
      unitRef="number">0.211</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-1340">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Temporary differences and carryforwards at the end of fiscal years 2024 and 2023 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt;padding-right:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.292%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.236%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024 Deferred Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023 Deferred Tax&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Employee related obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$372&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;586&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;717&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;686&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(833)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(902)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Goodwill and intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,261)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,252)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D capitalized for tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,398&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,595&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Reserves&#160;&amp;amp; liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,444&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,816&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventory related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;371&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;359&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,298&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,145&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Undistributed foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,931&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,492)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,801&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,695)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Global intangible low-taxed income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,589)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,731)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Miscellaneous international&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,212&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;831&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Miscellaneous U.S.&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,083&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,826&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7,175)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,819&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6,584)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Valuation allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,638)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,149)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total deferred income taxes net of valuation allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;15,188&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(7,175)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;12,670&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(6,584)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits contextRef="c-10" decimals="-6" id="f-1341" unitRef="usd">372000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits contextRef="c-11" decimals="-6" id="f-1342" unitRef="usd">586000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-10" decimals="-6" id="f-1343" unitRef="usd">717000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-11" decimals="-6" id="f-1344" unitRef="usd">686000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-10" decimals="-6" id="f-1345" unitRef="usd">833000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-11" decimals="-6" id="f-1346" unitRef="usd">902000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-10" decimals="-6" id="f-1347" unitRef="usd">3261000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-11" decimals="-6" id="f-1348" unitRef="usd">1252000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <jnj:DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized contextRef="c-10" decimals="-6" id="f-1349" unitRef="usd">4398000000</jnj:DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized>
    <jnj:DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized contextRef="c-11" decimals="-6" id="f-1350" unitRef="usd">3595000000</jnj:DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="c-10" decimals="-6" id="f-1351" unitRef="usd">4444000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="c-11" decimals="-6" id="f-1352" unitRef="usd">3816000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c-10" decimals="-6" id="f-1353" unitRef="usd">371000000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c-11" decimals="-6" id="f-1354" unitRef="usd">359000000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-10" decimals="-6" id="f-1355" unitRef="usd">2298000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-11" decimals="-6" id="f-1356" unitRef="usd">2145000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <jnj:DeferredTaxAssetsUndistributedForeignEarnings contextRef="c-10" decimals="-6" id="f-1357" unitRef="usd">1931000000</jnj:DeferredTaxAssetsUndistributedForeignEarnings>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings contextRef="c-10" decimals="-6" id="f-1358" unitRef="usd">1492000000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <jnj:DeferredTaxAssetsUndistributedForeignEarnings contextRef="c-11" decimals="-6" id="f-1359" unitRef="usd">1801000000</jnj:DeferredTaxAssetsUndistributedForeignEarnings>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings contextRef="c-11" decimals="-6" id="f-1360" unitRef="usd">1695000000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <jnj:DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome contextRef="c-10" decimals="-6" id="f-1361" unitRef="usd">1589000000</jnj:DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome>
    <jnj:DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome contextRef="c-11" decimals="-6" id="f-1362" unitRef="usd">2731000000</jnj:DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-10" decimals="-6" id="f-1363" unitRef="usd">1212000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-11" decimals="-6" id="f-1364" unitRef="usd">831000000</us-gaap:DeferredTaxAssetsOther>
    <jnj:DeferredTaxAssetsOtherDomestic contextRef="c-10" decimals="-6" id="f-1365" unitRef="usd">1083000000</jnj:DeferredTaxAssetsOtherDomestic>
    <jnj:DeferredTaxLiabilitiesOtherDomestic contextRef="c-11" decimals="-6" id="f-1366" unitRef="usd">4000000</jnj:DeferredTaxLiabilitiesOtherDomestic>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-10" decimals="-6" id="f-1367" unitRef="usd">16826000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilities contextRef="c-10" decimals="-6" id="f-1368" unitRef="usd">7175000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-11" decimals="-6" id="f-1369" unitRef="usd">13819000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilities contextRef="c-11" decimals="-6" id="f-1370" unitRef="usd">6584000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-10" decimals="-6" id="f-1371" unitRef="usd">1638000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-11" decimals="-6" id="f-1372" unitRef="usd">1149000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-10" decimals="-6" id="f-1373" unitRef="usd">15188000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilities contextRef="c-10" decimals="-6" id="f-1374" unitRef="usd">7175000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-11" decimals="-6" id="f-1375" unitRef="usd">12670000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilities contextRef="c-11" decimals="-6" id="f-1376" unitRef="usd">6584000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="c-1" id="f-1377">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table summarizes the activity related to valuation allowances for continuing operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$1,149&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;775&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;451&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;355&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Utilization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net acquisitions / (dispositions/liquidations)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;110&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;End of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$1,638&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$1,149&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-11" decimals="-6" id="f-1378" unitRef="usd">1149000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-22" decimals="-6" id="f-1379" unitRef="usd">775000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <jnj:ValuationAllowanceDeferredTaxAssetsProvision contextRef="c-1" decimals="-6" id="f-1380" unitRef="usd">451000000</jnj:ValuationAllowanceDeferredTaxAssetsProvision>
    <jnj:ValuationAllowanceDeferredTaxAssetsProvision contextRef="c-12" decimals="-6" id="f-1381" unitRef="usd">355000000</jnj:ValuationAllowanceDeferredTaxAssetsProvision>
    <jnj:ValuationAllowanceDeferredTaxAssetsUtilization contextRef="c-1" decimals="-6" id="f-1382" unitRef="usd">0</jnj:ValuationAllowanceDeferredTaxAssetsUtilization>
    <jnj:ValuationAllowanceDeferredTaxAssetsUtilization contextRef="c-12" decimals="-6" id="f-1383" unitRef="usd">-116000000</jnj:ValuationAllowanceDeferredTaxAssetsUtilization>
    <jnj:ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslation contextRef="c-1" decimals="-6" id="f-1384" unitRef="usd">-46000000</jnj:ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslation>
    <jnj:ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslation contextRef="c-12" decimals="-6" id="f-1385" unitRef="usd">25000000</jnj:ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslation>
    <jnj:ValuationAllowanceDeferredTaxAssetsAcquisitionsDispositions contextRef="c-1" decimals="-6" id="f-1386" unitRef="usd">84000000</jnj:ValuationAllowanceDeferredTaxAssetsAcquisitionsDispositions>
    <jnj:ValuationAllowanceDeferredTaxAssetsAcquisitionsDispositions contextRef="c-12" decimals="-6" id="f-1387" unitRef="usd">110000000</jnj:ValuationAllowanceDeferredTaxAssetsAcquisitionsDispositions>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-10" decimals="-6" id="f-1388" unitRef="usd">1638000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-11" decimals="-6" id="f-1389" unitRef="usd">1149000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-1390">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table summarizes the activity related to unrecognized tax benefits for continuing operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$2,485&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,716&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,210&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;176&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;239&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;523&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Increases related to prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;129&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;244&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;143&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Decreases related to prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(781)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(583)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(880)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;End of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$2,020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,485&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,716&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-11" decimals="-6" id="f-1391" unitRef="usd">2485000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-22" decimals="-6" id="f-1392" unitRef="usd">3716000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-14" decimals="-6" id="f-1393" unitRef="usd">3210000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-6" id="f-1394" unitRef="usd">176000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-12" decimals="-6" id="f-1395" unitRef="usd">239000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-13" decimals="-6" id="f-1396" unitRef="usd">523000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-6" id="f-1397" unitRef="usd">129000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-12" decimals="-6" id="f-1398" unitRef="usd">244000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-13" decimals="-6" id="f-1399" unitRef="usd">143000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-6" id="f-1400" unitRef="usd">147000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-12" decimals="-6" id="f-1401" unitRef="usd">781000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-13" decimals="-6" id="f-1402" unitRef="usd">148000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-1" decimals="-6" id="f-1403" unitRef="usd">583000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-12" decimals="-6" id="f-1404" unitRef="usd">880000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-13" decimals="-6" id="f-1405" unitRef="usd">1000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-1" decimals="-6" id="f-1406" unitRef="usd">40000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-12" decimals="-6" id="f-1407" unitRef="usd">53000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-13" decimals="-6" id="f-1408" unitRef="usd">11000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-10" decimals="-6" id="f-1409" unitRef="usd">2020000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-11" decimals="-6" id="f-1410" unitRef="usd">2485000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-22" decimals="-6" id="f-1411" unitRef="usd">3716000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-10" decimals="-8" id="f-1412" unitRef="usd">2000000000.0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease contextRef="c-1" decimals="-6" id="f-1413" unitRef="usd">200000000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense contextRef="c-1" decimals="-6" id="f-1414" unitRef="usd">217000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense contextRef="c-12" decimals="-6" id="f-1415" unitRef="usd">99000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense contextRef="c-13" decimals="-6" id="f-1416" unitRef="usd">136000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued contextRef="c-10" decimals="-6" id="f-1417" unitRef="usd">274000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued contextRef="c-11" decimals="-6" id="f-1418" unitRef="usd">264000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:CompensationRelatedCostsGeneralTextBlock contextRef="c-1" id="f-1419">Employee related obligations&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;At the end of fiscal 2024 and fiscal 2023, employee related obligations recorded on the Consolidated Balance Sheets were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.685%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Pension benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$2,968&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,129&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Postretirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,920&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,963&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Postemployment benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,910&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,527&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;68&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total employee obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,847&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,687&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less current benefits payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;592&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;538&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Employee related obligations&#160;&#x2014; non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$7,255&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,149&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Prepaid employee related obligations of $6,046 million and $4,992 million for 2024 and 2023, respectively, are included in Other assets on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsGeneralTextBlock>
    <jnj:EmployeeRelatedObligationsTableTextBlock contextRef="c-1" id="f-1420">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;At the end of fiscal 2024 and fiscal 2023, employee related obligations recorded on the Consolidated Balance Sheets were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.685%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Pension benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$2,968&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,129&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Postretirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,920&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,963&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Postemployment benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,910&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,527&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;68&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total employee obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,847&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,687&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less current benefits payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;592&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;538&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Employee related obligations&#160;&#x2014; non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$7,255&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,149&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</jnj:EmployeeRelatedObligationsTableTextBlock>
    <us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities contextRef="c-10" decimals="-6" id="f-1421" unitRef="usd">2968000000</us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities>
    <us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities contextRef="c-11" decimals="-6" id="f-1422" unitRef="usd">3129000000</us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities>
    <us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent contextRef="c-10" decimals="-6" id="f-1423" unitRef="usd">1920000000</us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent contextRef="c-11" decimals="-6" id="f-1424" unitRef="usd">1963000000</us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent contextRef="c-10" decimals="-6" id="f-1425" unitRef="usd">2910000000</us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent contextRef="c-11" decimals="-6" id="f-1426" unitRef="usd">2527000000</us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent contextRef="c-10" decimals="-6" id="f-1427" unitRef="usd">49000000</us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent contextRef="c-11" decimals="-6" id="f-1428" unitRef="usd">68000000</us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent>
    <jnj:EmployeeObligations contextRef="c-10" decimals="-6" id="f-1429" unitRef="usd">7847000000</jnj:EmployeeObligations>
    <jnj:EmployeeObligations contextRef="c-11" decimals="-6" id="f-1430" unitRef="usd">7687000000</jnj:EmployeeObligations>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities contextRef="c-10" decimals="-6" id="f-1431" unitRef="usd">592000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities contextRef="c-11" decimals="-6" id="f-1432" unitRef="usd">538000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent contextRef="c-10" decimals="-6" id="f-1433" unitRef="usd">7255000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent contextRef="c-11" decimals="-6" id="f-1434" unitRef="usd">7149000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent contextRef="c-10" decimals="-6" id="f-1435" unitRef="usd">6046000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent contextRef="c-11" decimals="-6" id="f-1436" unitRef="usd">4992000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c-1" id="f-1437">Pensions and other benefit plans&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. The Company also provides post-retirement benefits, primarily healthcare, to all eligible U.S.&#160;retired employees and their dependents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Many international employees are covered by government-sponsored programs and the cost to the Company is not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In the U.S., non-union pension benefits for employees hired before January 1, 2015 are primarily based on the employee&#x2019;s compensation during the last five years before retirement and the number of years of service (the Final Average Pay formula). U.S. pension benefits for employees hired after 2014, are calculated using a different formula based on employee compensation over total years of service (the Retirement Value formula).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees, regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits accrued under the Final Average Pay formula for service before January 1, 2026. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;International subsidiaries have plans under which funds are deposited with trustees, annuities are purchased under group contracts, or reserves are provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company does not fund retiree healthcare benefits in advance and has the right to modify these plans in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In 2024 and 2023 the Company used December 31, 2024 and December 31, 2023, respectively, as the measurement date for all U.S.&#160;and international retirement and other benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Net periodic benefit costs for the Company&#x2019;s defined benefit retirement plans and other benefit plans for 2024, 2023 and 2022 include the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.114%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.792%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$948&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;893&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,319&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;277&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;264&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;320&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,402&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,437&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;908&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;209&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;214&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;104&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,560)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,716)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,756)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization of prior service cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Recognized actuarial losses (gains)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;174&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(199)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;122&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Curtailments and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net periodic benefit cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$(222)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(676)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;530&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;487&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;533&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, Selling, marketing and administrative expenses, and Net earnings from discontinued operations, net of taxes if related to the separation of Kenvue. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings, with the exception of certain amounts for curtailments and settlements, which are reported in Net earnings from discontinued operations, net of taxes if related to the separation of Kenvue (as noted above).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Unrecognized gains and losses for the U.S.&#160;pension plans are amortized over the average remaining future service for each plan. For plans with no active employees, they are amortized over the average life expectancy. The amortization of gains and losses for the other U.S.&#160;benefit plans is determined by using a 10% corridor of the greater of the market value of assets or the accumulated postretirement benefit obligation. Total unamortized gains and losses in excess of the corridor are amortized over the average remaining future service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Prior service costs/benefits for the U.S.&#160;pension plans are amortized over the average remaining future service of plan participants at the time of the plan amendment. Prior service cost/benefit for the other U.S.&#160;benefit plans is amortized over the average remaining service to full eligibility age of plan participants at the time of the plan amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table represents the weighted-average actuarial assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.114%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.792%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Worldwide Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;Net Periodic Benefit Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Service cost discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest cost discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Rate of increase in compensation levels&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected long-term rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Rate of increase in compensation levels&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company&#x2019;s discount rates are determined by considering current yield curves representing high quality, long-term fixed income instruments. The resulting discount rates are consistent with the duration of plan liabilities. The Company's methodology in determining service and interest cost uses duration specific spot rates along that yield curve to the plans' liability cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The expected rates of return on plan asset assumptions represent the Company's assessment of long-term returns on diversified investment portfolios globally. The assessment is determined using projections from external financial sources, long-term historical averages, actual returns by asset class and the various asset class allocations by market. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table displays the assumed healthcare cost trend rates, for all individuals:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.685%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Healthcare Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Healthcare cost trend rate assumed for next year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Rate to which the cost trend rate is assumed to decline (ultimate trend)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Year the rate reaches the ultimate trend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2024 and 2023 for the Company&#x2019;s defined benefit retirement plans and other post-retirement plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.087%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Change in Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Projected benefit obligation&#160;&#x2014; beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$31,744&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;29,390&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,108&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,192&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;948&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;893&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;277&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;264&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,402&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,437&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;209&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;214&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Plan participant contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;73&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amendments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Actuarial (gains) losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,245)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,068&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;398&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;469&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Divestitures&#160;&amp;amp; acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(352)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Curtailments, settlements&#160;&amp;amp; restructuring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(238)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Benefits paid from plan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,801)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,122)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(556)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(702)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Effect of exchange rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(685)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;601&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Projected benefit obligation&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$30,317&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;31,744&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,425&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,108&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.087%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Change in Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Plan assets at fair value&#160;&#x2014; beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$33,607&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,496&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;78&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Actual return (loss) on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,113&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,951&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Company contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;229&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;268&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;548&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;694&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Plan participant contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;73&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Divestitures &amp;amp; acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(509)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Benefits paid from plan assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,801)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,122)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(556)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(702)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Effect of exchange rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(714)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;626&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Plan assets at fair value&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$33,395&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;33,607&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;86&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Funded status &#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$3,078&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,863&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(4,332)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(4,022)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Amounts Recognized in the Company&#x2019;s Balance Sheet consist of the&#160;following:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$6,046&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,992&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(453)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(416)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,832)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,010)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,879)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,606)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total recognized in the consolidated balance sheet&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$3,078&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,863&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(4,332)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(4,022)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Amounts Recognized in Accumulated Other Comprehensive Income consist&#160;of the following:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$3,903&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,962&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;691&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;354&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Prior service cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,051)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,236)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Unrecognized net transition obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total before tax effects&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$2,852&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,726&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;687&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;348&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Accumulated Benefit Obligations&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$28,883&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;30,139&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt"&gt;The actuarial (gains)/losses for retirement plans in 2024 and 2023 were primarily driven by changes in the discount rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt"&gt;Driven by the Kenvue separation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt"&gt;The fiscal years 2024 and 2023 includes approximately $400 million and $800&#160;million, respectively, transferred to a group annuity contract issued by a third-party insurer for the U.S. Salaried Pension&#160;Plan.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive&#160;Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net periodic benefit cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$(222)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(676)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;530&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;487&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(807)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;711&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;389&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;136&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization of net actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(172)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;199&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Prior service cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization of prior service (cost) credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;184&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;185&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Effect of exchange rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;103&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total loss/(income) recognized in other comprehensive income, before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$(874)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,195&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;339&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;116&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total recognized in net periodic benefit cost and other comprehensive&#160;income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$(1,096)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;519&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;869&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;603&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company plans to continue to fund its U.S. Qualified Plans to comply with the Pension Protection Act of 2006. International Plans are funded in accordance with local regulations. Additional discretionary contributions are made when deemed appropriate to meet the long-term obligations of the plans. For certain plans, funding is not a common practice, as funding provides no economic benefit. Consequently, the Company has several pension plans that are not funded. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In 2024, the Company contributed $122 million and $107 million to its U.S.&#160;and international pension plans, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table displays the funded status of the Company's U.S. Qualified &amp;amp; Non-Qualified pension plans and international funded and unfunded pension plans at December&#160;31, 2024 and December&#160;31, 2023, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.685%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.688%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;International Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Qualified Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Non-Qualified Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Funded Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unfunded Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$22,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,298&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,145&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,309&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Projected Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,146&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19,152&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,990&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,037&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,069&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,431&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;112&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;124&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accumulated Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17,726&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,557&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,949&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,982&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,115&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,498&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;102&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Over (Under) Funded Status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Projected Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$4,104&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,146&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,990)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,037)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,076&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;878&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(112)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accumulated Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,524&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,741&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,949)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,982)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,811&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Plans with accumulated benefit obligations in excess of plan assets have an accumulated benefit obligation, projected benefit obligation and plan assets of $5.8 billion, $6.1 billion and $3.2 billion, respectively, at the end of 2024, and $5.8 billion, $6.1 billion and $3.1 billion, respectively, at the end of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table displays the projected future benefit payments from the Company&#x2019;s retirement and other benefit plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.286%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2030-2034&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Projected future benefit payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Retirement plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$1,480&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,503&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,604&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,702&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,797&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,401&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other benefit plans&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$464&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;478&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;432&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;445&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;462&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,537&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table displays the projected future minimum contributions to the unfunded retirement plans. These amounts do not include any discretionary contributions that the Company may elect to make in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.286%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2030-2034&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Projected future contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$133&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;135&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;140&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;145&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;150&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;815&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Each pension plan is overseen by a local committee or board that is responsible for the overall administration and investment of&#160;the pension plans. In determining investment policies, strategies and goals, each committee or board considers factors including, local pension rules and regulations; local tax regulations; availability of investment vehicles (separate accounts, commingled accounts, insurance funds, etc.); funded status of the plans; ratio of actives to retirees; duration of liabilities; and&#160;other relevant factors including: diversification, liquidity of local markets and liquidity of base currency. A majority of the Company&#x2019;s pension funds are open to new entrants and are expected to be on-going plans. Permitted investments are primarily liquid and/or listed, with little reliance on illiquid and non-traditional investments such as hedge funds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company&#x2019;s retirement plan asset allocation at the end of 2024 and 2023 and target allocations for 2025 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.078%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Percent of&lt;br/&gt;Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Target&lt;br/&gt;Allocation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Worldwide Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Determination of fair value of plan assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Plan has an established and well-documented process for determining fair values. Fair value is based upon quoted market prices, where available. If listed prices or quotes are not available, fair value is based upon models that primarily use, as inputs, market-based or independently sourced market parameters, including yield curves, interest rates, volatilities, equity or debt prices, foreign exchange rates and credit curves.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;While the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Valuation hierarchy&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described in the table below with Level&#160;1 having the highest priority and Level&#160;3 having the lowest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Net Asset Value (NAV) is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;A financial instrument&#x2019;s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Following is a description of the valuation methodologies used for the investments measured at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%;padding-left:7.83pt"&gt;Short-term investment funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&#x2014; Cash and quoted short-term instruments are valued at the closing price or the amount held on deposit by the custodian bank. Other investments are through investment vehicles valued using the NAV provided by the administrator of the fund. The NAV is a quoted price in a market that is not active and classified as Level&#160;2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%;padding-left:7.83pt"&gt;Government and agency securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&#x2014; A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified within Level&#160;1 of the valuation hierarchy. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows. When quoted market prices for a security are not available in an active market, they are classified as Level&#160;2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%;padding-left:7.83pt"&gt;Debt instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&#x2014; A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified as Level&#160;1. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows and are classified as Level&#160;2. Level&#160;3 debt instruments are priced based on unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%;padding-left:7.83pt"&gt;Equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&#x2014; Equity securities are valued at the closing price reported on the major market on which the individual securities are traded. Substantially all equity securities are classified within Level&#160;1 of the valuation hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%;padding-left:7.83pt"&gt;Commingled funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&#x2014; These investment vehicles are valued using the NAV provided by the fund administrator. Assets in the Level&#160;2 category have a quoted market price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%;padding-left:7.83pt"&gt;Other assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#160;&#x2014; Other assets are represented primarily by limited partnerships. These investment vehicles are valued using the NAV provided by the fund administrator. Other assets that are exchange listed and actively traded are classified as Level&#160;1, while inactively traded assets are classified as Level&#160;2. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table sets forth the Retirement Plans' investments measured at fair value as of December&#160;31, 2024 and December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.840%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Quoted Prices&lt;br/&gt;in Active&lt;br/&gt;Markets for&lt;br/&gt;Identical Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Inputs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Investments&lt;br/&gt;Measured at Net&lt;br/&gt;Asset Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Short-term investment funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;511&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;829&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;511&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;841&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,885&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,985&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,885&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,985&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Debt instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,321&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,899&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,321&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,899&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,144&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,764&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,144&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,764&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commingled funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,004&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,967&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,190&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,672&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,231&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,682&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;128&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,087&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,295&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,303&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,436&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Investments at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$7,144&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,776&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;15,809&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;15,729&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;165&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;135&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;10,277&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;9,967&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;33,395&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;33,607&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt"&gt;The activity for the Level 3 assets is not significant for all years presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company's Other Benefit Plans are unfunded except for U.S.&#160;commingled funds (Level 2) of $93 million and $86 million at December&#160;31, 2024 and December&#160;31, 2023, respectively. &lt;/span&gt;&lt;/div&gt;The fair value of Johnson&#160;&amp;amp; Johnson Common Stock directly held in plan assets was $13 million at December&#160;31, 2024 and $14 million at December&#160;31, 2023.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <jnj:EmployeeCompensationPeriod contextRef="c-290" id="f-1438">P5Y</jnj:EmployeeCompensationPeriod>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock contextRef="c-1" id="f-1439">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Net periodic benefit costs for the Company&#x2019;s defined benefit retirement plans and other benefit plans for 2024, 2023 and 2022 include the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.114%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.792%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$948&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;893&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,319&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;277&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;264&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;320&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,402&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,437&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;908&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;209&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;214&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;104&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,560)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,716)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,756)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization of prior service cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Recognized actuarial losses (gains)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;174&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(199)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;122&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Curtailments and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net periodic benefit cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$(222)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(676)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;530&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;487&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;533&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-291" decimals="-6" id="f-1440" unitRef="usd">948000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-292" decimals="-6" id="f-1441" unitRef="usd">893000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-293" decimals="-6" id="f-1442" unitRef="usd">1319000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-294" decimals="-6" id="f-1443" unitRef="usd">277000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-295" decimals="-6" id="f-1444" unitRef="usd">264000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-296" decimals="-6" id="f-1445" unitRef="usd">320000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-291" decimals="-6" id="f-1446" unitRef="usd">1402000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-292" decimals="-6" id="f-1447" unitRef="usd">1437000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-293" decimals="-6" id="f-1448" unitRef="usd">908000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-294" decimals="-6" id="f-1449" unitRef="usd">209000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-295" decimals="-6" id="f-1450" unitRef="usd">214000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-296" decimals="-6" id="f-1451" unitRef="usd">104000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets contextRef="c-291" decimals="-6" id="f-1452" unitRef="usd">2560000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets contextRef="c-292" decimals="-6" id="f-1453" unitRef="usd">2716000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets contextRef="c-293" decimals="-6" id="f-1454" unitRef="usd">2756000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets contextRef="c-294" decimals="-6" id="f-1455" unitRef="usd">7000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets contextRef="c-295" decimals="-6" id="f-1456" unitRef="usd">7000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets contextRef="c-296" decimals="-6" id="f-1457" unitRef="usd">8000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit contextRef="c-291" decimals="-6" id="f-1458" unitRef="usd">-184000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit contextRef="c-292" decimals="-6" id="f-1459" unitRef="usd">-184000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit contextRef="c-293" decimals="-6" id="f-1460" unitRef="usd">-184000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit contextRef="c-294" decimals="-6" id="f-1461" unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit contextRef="c-295" decimals="-6" id="f-1462" unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit contextRef="c-296" decimals="-6" id="f-1463" unitRef="usd">-5000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses contextRef="c-291" decimals="-6" id="f-1464" unitRef="usd">-174000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses contextRef="c-292" decimals="-6" id="f-1465" unitRef="usd">199000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses contextRef="c-293" decimals="-6" id="f-1466" unitRef="usd">-650000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses contextRef="c-294" decimals="-6" id="f-1467" unitRef="usd">-53000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses contextRef="c-295" decimals="-6" id="f-1468" unitRef="usd">-23000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses contextRef="c-296" decimals="-6" id="f-1469" unitRef="usd">-122000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1 contextRef="c-291" decimals="-6" id="f-1470" unitRef="usd">2000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1 contextRef="c-292" decimals="-6" id="f-1471" unitRef="usd">-93000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1 contextRef="c-293" decimals="-6" id="f-1472" unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1 contextRef="c-294" decimals="-6" id="f-1473" unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1 contextRef="c-295" decimals="-6" id="f-1474" unitRef="usd">5000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1 contextRef="c-296" decimals="-6" id="f-1475" unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-291" decimals="-6" id="f-1476" unitRef="usd">-222000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-292" decimals="-6" id="f-1477" unitRef="usd">-676000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-293" decimals="-6" id="f-1478" unitRef="usd">-62000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-294" decimals="-6" id="f-1479" unitRef="usd">530000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-295" decimals="-6" id="f-1480" unitRef="usd">487000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-296" decimals="-6" id="f-1481" unitRef="usd">533000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <jnj:PercentageOfCorridorOfGreaterOfMarketValueOfAssets contextRef="c-10" decimals="2" id="f-1482" unitRef="number">0.10</jnj:PercentageOfCorridorOfGreaterOfMarketValueOfAssets>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock contextRef="c-1" id="f-1483">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table represents the weighted-average actuarial assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.114%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.792%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Worldwide Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;Net Periodic Benefit Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Service cost discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest cost discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Rate of increase in compensation levels&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected long-term rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Rate of increase in compensation levels&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-291"
      decimals="4"
      id="f-1484"
      unitRef="number">0.0439</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-292"
      decimals="4"
      id="f-1485"
      unitRef="number">0.0485</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-293"
      decimals="4"
      id="f-1486"
      unitRef="number">0.0246</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-294"
      decimals="4"
      id="f-1487"
      unitRef="number">0.0509</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-295"
      decimals="4"
      id="f-1488"
      unitRef="number">0.0540</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-296"
      decimals="4"
      id="f-1489"
      unitRef="number">0.0259</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-291"
      decimals="4"
      id="f-1490"
      unitRef="number">0.0495</jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-292"
      decimals="4"
      id="f-1491"
      unitRef="number">0.0525</jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-293"
      decimals="4"
      id="f-1492"
      unitRef="number">0.0280</jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-294"
      decimals="4"
      id="f-1493"
      unitRef="number">0.0512</jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-295"
      decimals="4"
      id="f-1494"
      unitRef="number">0.0543</jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="c-296"
      decimals="4"
      id="f-1495"
      unitRef="number">0.0264</jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="c-291"
      decimals="4"
      id="f-1496"
      unitRef="number">0.0370</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="c-292"
      decimals="4"
      id="f-1497"
      unitRef="number">0.0371</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="c-293"
      decimals="4"
      id="f-1498"
      unitRef="number">0.0402</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="c-294"
      decimals="4"
      id="f-1499"
      unitRef="number">0.0422</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="c-295"
      decimals="4"
      id="f-1500"
      unitRef="number">0.0422</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="c-296"
      decimals="4"
      id="f-1501"
      unitRef="number">0.0421</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="c-291"
      decimals="4"
      id="f-1502"
      unitRef="number">0.0725</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="c-292"
      decimals="4"
      id="f-1503"
      unitRef="number">0.0721</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="c-293"
      decimals="4"
      id="f-1504"
      unitRef="number">0.0725</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-297"
      decimals="4"
      id="f-1505"
      unitRef="number">0.0495</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-298"
      decimals="4"
      id="f-1506"
      unitRef="number">0.0458</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-299"
      decimals="4"
      id="f-1507"
      unitRef="number">0.0501</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-300"
      decimals="4"
      id="f-1508"
      unitRef="number">0.0554</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-301"
      decimals="4"
      id="f-1509"
      unitRef="number">0.0511</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-302"
      decimals="4"
      id="f-1510"
      unitRef="number">0.0542</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="c-297"
      decimals="4"
      id="f-1511"
      unitRef="number">0.0370</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="c-298"
      decimals="4"
      id="f-1512"
      unitRef="number">0.0369</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="c-299"
      decimals="4"
      id="f-1513"
      unitRef="number">0.0400</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="c-300"
      decimals="4"
      id="f-1514"
      unitRef="number">0.0422</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="c-301"
      decimals="4"
      id="f-1515"
      unitRef="number">0.0422</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="c-302"
      decimals="4"
      id="f-1516"
      unitRef="number">0.0421</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock contextRef="c-1" id="f-1517">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table displays the assumed healthcare cost trend rates, for all individuals:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.685%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Healthcare Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Healthcare cost trend rate assumed for next year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Rate to which the cost trend rate is assumed to decline (ultimate trend)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Year the rate reaches the ultimate trend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock>
    <us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear contextRef="c-10" decimals="4" id="f-1518" unitRef="number">0.0933</us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
    <us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear contextRef="c-11" decimals="4" id="f-1519" unitRef="number">0.1390</us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
    <us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1 contextRef="c-10" decimals="4" id="f-1520" unitRef="number">0.0402</us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1>
    <us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1 contextRef="c-11" decimals="4" id="f-1521" unitRef="number">0.0400</us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1>
    <us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate contextRef="c-1" id="f-1522">2048</us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate>
    <us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate contextRef="c-12" id="f-1523">2048</us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate>
    <us-gaap:ScheduleOfNetFundedStatusTableTextBlock contextRef="c-1" id="f-1524">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2024 and 2023 for the Company&#x2019;s defined benefit retirement plans and other post-retirement plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.087%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Change in Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Projected benefit obligation&#160;&#x2014; beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$31,744&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;29,390&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,108&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,192&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;948&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;893&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;277&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;264&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,402&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,437&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;209&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;214&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Plan participant contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;73&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amendments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Actuarial (gains) losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,245)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,068&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;398&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;469&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Divestitures&#160;&amp;amp; acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(352)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Curtailments, settlements&#160;&amp;amp; restructuring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(238)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Benefits paid from plan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,801)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,122)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(556)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(702)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Effect of exchange rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(685)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;601&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Projected benefit obligation&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$30,317&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;31,744&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,425&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,108&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.087%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Change in Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Plan assets at fair value&#160;&#x2014; beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$33,607&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,496&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;78&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Actual return (loss) on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,113&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,951&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Company contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;229&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;268&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;548&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;694&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Plan participant contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;73&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Divestitures &amp;amp; acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(509)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Benefits paid from plan assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,801)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,122)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(556)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(702)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Effect of exchange rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(714)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;626&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Plan assets at fair value&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$33,395&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;33,607&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;86&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Funded status &#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$3,078&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,863&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(4,332)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(4,022)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Amounts Recognized in the Company&#x2019;s Balance Sheet consist of the&#160;following:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$6,046&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,992&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(453)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(416)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,832)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,010)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,879)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,606)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total recognized in the consolidated balance sheet&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$3,078&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,863&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(4,332)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(4,022)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Amounts Recognized in Accumulated Other Comprehensive Income consist&#160;of the following:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$3,903&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,962&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;691&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;354&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Prior service cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,051)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,236)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Unrecognized net transition obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total before tax effects&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$2,852&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,726&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;687&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;348&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Accumulated Benefit Obligations&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$28,883&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;30,139&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt"&gt;The actuarial (gains)/losses for retirement plans in 2024 and 2023 were primarily driven by changes in the discount rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt"&gt;Driven by the Kenvue separation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt"&gt;The fiscal years 2024 and 2023 includes approximately $400 million and $800&#160;million, respectively, transferred to a group annuity contract issued by a third-party insurer for the U.S. Salaried Pension&#160;Plan.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive&#160;Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net periodic benefit cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$(222)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(676)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;530&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;487&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(807)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;711&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;389&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;136&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization of net actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(172)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;199&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Prior service cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization of prior service (cost) credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;184&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;185&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Effect of exchange rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;103&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total loss/(income) recognized in other comprehensive income, before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$(874)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,195&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;339&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;116&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total recognized in net periodic benefit cost and other comprehensive&#160;income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$(1,096)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;519&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;869&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;603&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetFundedStatusTableTextBlock>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-298" decimals="-6" id="f-1525" unitRef="usd">31744000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-299" decimals="-6" id="f-1526" unitRef="usd">29390000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-301" decimals="-6" id="f-1527" unitRef="usd">4108000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-302" decimals="-6" id="f-1528" unitRef="usd">4192000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-291" decimals="-6" id="f-1529" unitRef="usd">948000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-292" decimals="-6" id="f-1530" unitRef="usd">893000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-294" decimals="-6" id="f-1531" unitRef="usd">277000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-295" decimals="-6" id="f-1532" unitRef="usd">264000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-291" decimals="-6" id="f-1533" unitRef="usd">1402000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-292" decimals="-6" id="f-1534" unitRef="usd">1437000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-294" decimals="-6" id="f-1535" unitRef="usd">209000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-295" decimals="-6" id="f-1536" unitRef="usd">214000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant contextRef="c-291" decimals="-6" id="f-1537" unitRef="usd">75000000</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant contextRef="c-292" decimals="-6" id="f-1538" unitRef="usd">73000000</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant contextRef="c-294" decimals="-6" id="f-1539" unitRef="usd">0</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant contextRef="c-295" decimals="-6" id="f-1540" unitRef="usd">0</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAmendments contextRef="c-291" decimals="-6" id="f-1541" unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments contextRef="c-292" decimals="-6" id="f-1542" unitRef="usd">-6000000</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments contextRef="c-294" decimals="-6" id="f-1543" unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments contextRef="c-295" decimals="-6" id="f-1544" unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss contextRef="c-291" decimals="-6" id="f-1545" unitRef="usd">1245000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss contextRef="c-292" decimals="-6" id="f-1546" unitRef="usd">-2068000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss contextRef="c-294" decimals="-6" id="f-1547" unitRef="usd">-398000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss contextRef="c-295" decimals="-6" id="f-1548" unitRef="usd">-469000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease contextRef="c-291" decimals="-6" id="f-1549" unitRef="usd">0</jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease>
    <jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease contextRef="c-292" decimals="-6" id="f-1550" unitRef="usd">-352000000</jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease>
    <jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease contextRef="c-294" decimals="-6" id="f-1551" unitRef="usd">0</jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease>
    <jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease contextRef="c-295" decimals="-6" id="f-1552" unitRef="usd">1000000</jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease>
    <jnj:CurtailmentsAndSettlementsAndRestructuring contextRef="c-291" decimals="-6" id="f-1553" unitRef="usd">121000000</jnj:CurtailmentsAndSettlementsAndRestructuring>
    <jnj:CurtailmentsAndSettlementsAndRestructuring contextRef="c-292" decimals="-6" id="f-1554" unitRef="usd">238000000</jnj:CurtailmentsAndSettlementsAndRestructuring>
    <jnj:CurtailmentsAndSettlementsAndRestructuring contextRef="c-294" decimals="-6" id="f-1555" unitRef="usd">0</jnj:CurtailmentsAndSettlementsAndRestructuring>
    <jnj:CurtailmentsAndSettlementsAndRestructuring contextRef="c-295" decimals="-6" id="f-1556" unitRef="usd">332000000</jnj:CurtailmentsAndSettlementsAndRestructuring>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid contextRef="c-291" decimals="-6" id="f-1557" unitRef="usd">1801000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid contextRef="c-292" decimals="-6" id="f-1558" unitRef="usd">2122000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid contextRef="c-294" decimals="-6" id="f-1559" unitRef="usd">556000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid contextRef="c-295" decimals="-6" id="f-1560" unitRef="usd">702000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation contextRef="c-291" decimals="-6" id="f-1561" unitRef="usd">685000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation contextRef="c-292" decimals="-6" id="f-1562" unitRef="usd">-601000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation contextRef="c-294" decimals="-6" id="f-1563" unitRef="usd">11000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation contextRef="c-295" decimals="-6" id="f-1564" unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-297" decimals="-6" id="f-1565" unitRef="usd">30317000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-298" decimals="-6" id="f-1566" unitRef="usd">31744000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-300" decimals="-6" id="f-1567" unitRef="usd">4425000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-301" decimals="-6" id="f-1568" unitRef="usd">4108000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-298" decimals="-6" id="f-1569" unitRef="usd">33607000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-299" decimals="-6" id="f-1570" unitRef="usd">31496000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-301" decimals="-6" id="f-1571" unitRef="usd">86000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-302" decimals="-6" id="f-1572" unitRef="usd">78000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets contextRef="c-291" decimals="-6" id="f-1573" unitRef="usd">2113000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets contextRef="c-292" decimals="-6" id="f-1574" unitRef="usd">3951000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets contextRef="c-294" decimals="-6" id="f-1575" unitRef="usd">15000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets contextRef="c-295" decimals="-6" id="f-1576" unitRef="usd">16000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="c-291" decimals="-6" id="f-1577" unitRef="usd">229000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="c-292" decimals="-6" id="f-1578" unitRef="usd">268000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="c-294" decimals="-6" id="f-1579" unitRef="usd">548000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="c-295" decimals="-6" id="f-1580" unitRef="usd">694000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant contextRef="c-291" decimals="-6" id="f-1581" unitRef="usd">75000000</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant contextRef="c-292" decimals="-6" id="f-1582" unitRef="usd">73000000</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant contextRef="c-294" decimals="-6" id="f-1583" unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant contextRef="c-295" decimals="-6" id="f-1584" unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets contextRef="c-291" decimals="-6" id="f-1585" unitRef="usd">114000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets contextRef="c-292" decimals="-6" id="f-1586" unitRef="usd">176000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets contextRef="c-294" decimals="-6" id="f-1587" unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets contextRef="c-295" decimals="-6" id="f-1588" unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease contextRef="c-291" decimals="-6" id="f-1589" unitRef="usd">0</jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease>
    <jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease contextRef="c-292" decimals="-6" id="f-1590" unitRef="usd">-509000000</jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease>
    <jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease contextRef="c-294" decimals="-6" id="f-1591" unitRef="usd">0</jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease>
    <jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease contextRef="c-295" decimals="-6" id="f-1592" unitRef="usd">0</jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid contextRef="c-291" decimals="-6" id="f-1593" unitRef="usd">1801000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid contextRef="c-292" decimals="-6" id="f-1594" unitRef="usd">2122000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid contextRef="c-294" decimals="-6" id="f-1595" unitRef="usd">556000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid contextRef="c-295" decimals="-6" id="f-1596" unitRef="usd">702000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss contextRef="c-291" decimals="-6" id="f-1597" unitRef="usd">-714000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss contextRef="c-292" decimals="-6" id="f-1598" unitRef="usd">626000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss contextRef="c-294" decimals="-6" id="f-1599" unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss contextRef="c-295" decimals="-6" id="f-1600" unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-297" decimals="-6" id="f-1601" unitRef="usd">33395000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-298" decimals="-6" id="f-1602" unitRef="usd">33607000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-300" decimals="-6" id="f-1603" unitRef="usd">93000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-301" decimals="-6" id="f-1604" unitRef="usd">86000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="c-297" decimals="-6" id="f-1605" unitRef="usd">3078000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="c-298" decimals="-6" id="f-1606" unitRef="usd">1863000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="c-300" decimals="-6" id="f-1607" unitRef="usd">-4332000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="c-301" decimals="-6" id="f-1608" unitRef="usd">-4022000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent contextRef="c-297" decimals="-6" id="f-1609" unitRef="usd">6046000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent contextRef="c-298" decimals="-6" id="f-1610" unitRef="usd">4992000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent contextRef="c-300" decimals="-6" id="f-1611" unitRef="usd">0</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent contextRef="c-301" decimals="-6" id="f-1612" unitRef="usd">0</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities contextRef="c-297" decimals="-6" id="f-1613" unitRef="usd">136000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities contextRef="c-298" decimals="-6" id="f-1614" unitRef="usd">119000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities contextRef="c-300" decimals="-6" id="f-1615" unitRef="usd">453000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities contextRef="c-301" decimals="-6" id="f-1616" unitRef="usd">416000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent contextRef="c-297" decimals="-6" id="f-1617" unitRef="usd">2832000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent contextRef="c-298" decimals="-6" id="f-1618" unitRef="usd">3010000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent contextRef="c-300" decimals="-6" id="f-1619" unitRef="usd">3879000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent contextRef="c-301" decimals="-6" id="f-1620" unitRef="usd">3606000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet contextRef="c-297" decimals="-6" id="f-1621" unitRef="usd">3078000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet contextRef="c-298" decimals="-6" id="f-1622" unitRef="usd">1863000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet contextRef="c-300" decimals="-6" id="f-1623" unitRef="usd">-4332000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet contextRef="c-301" decimals="-6" id="f-1624" unitRef="usd">-4022000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax contextRef="c-297" decimals="-6" id="f-1625" unitRef="usd">-3903000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax contextRef="c-298" decimals="-6" id="f-1626" unitRef="usd">-4962000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax contextRef="c-300" decimals="-6" id="f-1627" unitRef="usd">-691000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax contextRef="c-301" decimals="-6" id="f-1628" unitRef="usd">-354000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax contextRef="c-297" decimals="-6" id="f-1629" unitRef="usd">-1051000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax contextRef="c-298" decimals="-6" id="f-1630" unitRef="usd">-1236000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax contextRef="c-300" decimals="-6" id="f-1631" unitRef="usd">-4000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax contextRef="c-301" decimals="-6" id="f-1632" unitRef="usd">-6000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax contextRef="c-297" decimals="-6" id="f-1633" unitRef="usd">0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax contextRef="c-298" decimals="-6" id="f-1634" unitRef="usd">0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax contextRef="c-300" decimals="-6" id="f-1635" unitRef="usd">0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax contextRef="c-301" id="f-1636" unitRef="usd" xsi:nil="true"/>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax contextRef="c-297" decimals="-6" id="f-1637" unitRef="usd">2852000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax contextRef="c-298" decimals="-6" id="f-1638" unitRef="usd">3726000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax contextRef="c-300" decimals="-6" id="f-1639" unitRef="usd">687000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax contextRef="c-301" decimals="-6" id="f-1640" unitRef="usd">348000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation contextRef="c-297" decimals="-6" id="f-1641" unitRef="usd">28883000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation contextRef="c-298" decimals="-6" id="f-1642" unitRef="usd">30139000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <jnj:DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract contextRef="c-1" decimals="-6" id="f-1643" unitRef="usd">400000000</jnj:DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract>
    <jnj:DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract contextRef="c-12" decimals="-6" id="f-1644" unitRef="usd">800000000</jnj:DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-291" decimals="-6" id="f-1645" unitRef="usd">-222000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-292" decimals="-6" id="f-1646" unitRef="usd">-676000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-294" decimals="-6" id="f-1647" unitRef="usd">530000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-295" decimals="-6" id="f-1648" unitRef="usd">487000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax contextRef="c-291" decimals="-6" id="f-1649" unitRef="usd">807000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax contextRef="c-292" decimals="-6" id="f-1650" unitRef="usd">-711000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax contextRef="c-294" decimals="-6" id="f-1651" unitRef="usd">-389000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax contextRef="c-295" decimals="-6" id="f-1652" unitRef="usd">-136000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax contextRef="c-291" decimals="-6" id="f-1653" unitRef="usd">-172000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax contextRef="c-292" decimals="-6" id="f-1654" unitRef="usd">199000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax contextRef="c-294" decimals="-6" id="f-1655" unitRef="usd">-53000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax contextRef="c-295" decimals="-6" id="f-1656" unitRef="usd">-22000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax contextRef="c-291" decimals="-6" id="f-1657" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax contextRef="c-292" decimals="-6" id="f-1658" unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax contextRef="c-294" decimals="-6" id="f-1659" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax contextRef="c-295" decimals="-6" id="f-1660" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax contextRef="c-291" decimals="-6" id="f-1661" unitRef="usd">-184000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax contextRef="c-292" decimals="-6" id="f-1662" unitRef="usd">-185000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax contextRef="c-294" decimals="-6" id="f-1663" unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax contextRef="c-295" decimals="-6" id="f-1664" unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <jnj:EffectOfExchangeRates contextRef="c-291" decimals="-6" id="f-1665" unitRef="usd">-79000000</jnj:EffectOfExchangeRates>
    <jnj:EffectOfExchangeRates contextRef="c-292" decimals="-6" id="f-1666" unitRef="usd">103000000</jnj:EffectOfExchangeRates>
    <jnj:EffectOfExchangeRates contextRef="c-294" decimals="-6" id="f-1667" unitRef="usd">1000000</jnj:EffectOfExchangeRates>
    <jnj:EffectOfExchangeRates contextRef="c-295" decimals="-6" id="f-1668" unitRef="usd">0</jnj:EffectOfExchangeRates>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax contextRef="c-291" decimals="-6" id="f-1669" unitRef="usd">-874000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax contextRef="c-292" decimals="-6" id="f-1670" unitRef="usd">1195000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax contextRef="c-294" decimals="-6" id="f-1671" unitRef="usd">339000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax contextRef="c-295" decimals="-6" id="f-1672" unitRef="usd">116000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax contextRef="c-291" decimals="-6" id="f-1673" unitRef="usd">-1096000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax contextRef="c-292" decimals="-6" id="f-1674" unitRef="usd">519000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax contextRef="c-294" decimals="-6" id="f-1675" unitRef="usd">869000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax contextRef="c-295" decimals="-6" id="f-1676" unitRef="usd">603000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:PensionContributions contextRef="c-303" decimals="-6" id="f-1677" unitRef="usd">122000000</us-gaap:PensionContributions>
    <us-gaap:PensionContributions contextRef="c-304" decimals="-6" id="f-1678" unitRef="usd">107000000</us-gaap:PensionContributions>
    <jnj:InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock contextRef="c-1" id="f-1679">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table displays the funded status of the Company's U.S. Qualified &amp;amp; Non-Qualified pension plans and international funded and unfunded pension plans at December&#160;31, 2024 and December&#160;31, 2023, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.685%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.688%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;International Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Qualified Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Non-Qualified Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Funded Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unfunded Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$22,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,298&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,145&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,309&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Projected Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,146&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19,152&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,990&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,037&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,069&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,431&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;112&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;124&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accumulated Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17,726&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,557&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,949&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,982&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,115&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,498&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;102&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Over (Under) Funded Status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Projected Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$4,104&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,146&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,990)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,037)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,076&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;878&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(112)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accumulated Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,524&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,741&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,949)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,982)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,811&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</jnj:InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-305" decimals="-6" id="f-1680" unitRef="usd">22250000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-306" decimals="-6" id="f-1681" unitRef="usd">22298000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-307" decimals="-6" id="f-1682" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-308" decimals="-6" id="f-1683" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-309" decimals="-6" id="f-1684" unitRef="usd">11145000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-310" decimals="-6" id="f-1685" unitRef="usd">11309000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-311" decimals="-6" id="f-1686" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-312" decimals="-6" id="f-1687" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-305" decimals="-6" id="f-1688" unitRef="usd">18146000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-306" decimals="-6" id="f-1689" unitRef="usd">19152000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-307" decimals="-6" id="f-1690" unitRef="usd">1990000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-308" decimals="-6" id="f-1691" unitRef="usd">2037000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-309" decimals="-6" id="f-1692" unitRef="usd">10069000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-310" decimals="-6" id="f-1693" unitRef="usd">10431000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-311" decimals="-6" id="f-1694" unitRef="usd">112000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-312" decimals="-6" id="f-1695" unitRef="usd">124000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation contextRef="c-305" decimals="-6" id="f-1696" unitRef="usd">17726000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation contextRef="c-306" decimals="-6" id="f-1697" unitRef="usd">18557000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation contextRef="c-307" decimals="-6" id="f-1698" unitRef="usd">1949000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation contextRef="c-308" decimals="-6" id="f-1699" unitRef="usd">1982000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation contextRef="c-309" decimals="-6" id="f-1700" unitRef="usd">9115000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation contextRef="c-310" decimals="-6" id="f-1701" unitRef="usd">9498000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation contextRef="c-311" decimals="-6" id="f-1702" unitRef="usd">93000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation contextRef="c-312" decimals="-6" id="f-1703" unitRef="usd">102000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="c-305" decimals="-6" id="f-1704" unitRef="usd">4104000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="c-306" decimals="-6" id="f-1705" unitRef="usd">3146000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="c-307" decimals="-6" id="f-1706" unitRef="usd">-1990000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="c-308" decimals="-6" id="f-1707" unitRef="usd">-2037000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="c-309" decimals="-6" id="f-1708" unitRef="usd">1076000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="c-310" decimals="-6" id="f-1709" unitRef="usd">878000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="c-311" decimals="-6" id="f-1710" unitRef="usd">-112000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="c-312" decimals="-6" id="f-1711" unitRef="usd">-124000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO contextRef="c-305" decimals="-6" id="f-1712" unitRef="usd">4524000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO contextRef="c-306" decimals="-6" id="f-1713" unitRef="usd">3741000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO contextRef="c-307" decimals="-6" id="f-1714" unitRef="usd">-1949000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO contextRef="c-308" decimals="-6" id="f-1715" unitRef="usd">-1982000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO contextRef="c-309" decimals="-6" id="f-1716" unitRef="usd">2030000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO contextRef="c-310" decimals="-6" id="f-1717" unitRef="usd">1811000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO contextRef="c-311" decimals="-6" id="f-1718" unitRef="usd">-93000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO contextRef="c-312" decimals="-6" id="f-1719" unitRef="usd">-102000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation contextRef="c-10" decimals="-8" id="f-1720" unitRef="usd">5800000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation contextRef="c-10" decimals="-8" id="f-1721" unitRef="usd">6100000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets contextRef="c-10" decimals="-8" id="f-1722" unitRef="usd">3200000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation contextRef="c-11" decimals="-8" id="f-1723" unitRef="usd">5800000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation contextRef="c-11" decimals="-8" id="f-1724" unitRef="usd">6100000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets contextRef="c-11" decimals="-8" id="f-1725" unitRef="usd">3100000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock contextRef="c-1" id="f-1726">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table displays the projected future benefit payments from the Company&#x2019;s retirement and other benefit plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.286%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2030-2034&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Projected future benefit payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Retirement plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$1,480&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,503&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,604&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,702&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,797&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,401&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other benefit plans&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$464&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;478&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;432&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;445&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;462&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,537&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths contextRef="c-297" decimals="-6" id="f-1727" unitRef="usd">1480000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo contextRef="c-297" decimals="-6" id="f-1728" unitRef="usd">1503000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree contextRef="c-297" decimals="-6" id="f-1729" unitRef="usd">1604000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour contextRef="c-297" decimals="-6" id="f-1730" unitRef="usd">1702000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive contextRef="c-297" decimals="-6" id="f-1731" unitRef="usd">1797000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter contextRef="c-297" decimals="-6" id="f-1732" unitRef="usd">10401000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths contextRef="c-300" decimals="-6" id="f-1733" unitRef="usd">464000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo contextRef="c-300" decimals="-6" id="f-1734" unitRef="usd">478000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree contextRef="c-300" decimals="-6" id="f-1735" unitRef="usd">432000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour contextRef="c-300" decimals="-6" id="f-1736" unitRef="usd">445000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive contextRef="c-300" decimals="-6" id="f-1737" unitRef="usd">462000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter contextRef="c-300" decimals="-6" id="f-1738" unitRef="usd">2537000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <jnj:ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock contextRef="c-1" id="f-1739">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table displays the projected future minimum contributions to the unfunded retirement plans. These amounts do not include any discretionary contributions that the Company may elect to make in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.286%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2030-2034&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Projected future contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$133&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;135&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;140&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;145&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;150&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;815&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</jnj:ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock>
    <jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne contextRef="c-10" decimals="-6" id="f-1740" unitRef="usd">133000000</jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne>
    <jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo contextRef="c-10" decimals="-6" id="f-1741" unitRef="usd">135000000</jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo>
    <jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree contextRef="c-10" decimals="-6" id="f-1742" unitRef="usd">140000000</jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree>
    <jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour contextRef="c-10" decimals="-6" id="f-1743" unitRef="usd">145000000</jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour>
    <jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive contextRef="c-10" decimals="-6" id="f-1744" unitRef="usd">150000000</jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive>
    <jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter contextRef="c-10" decimals="-6" id="f-1745" unitRef="usd">815000000</jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter>
    <us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock contextRef="c-1" id="f-1746">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company&#x2019;s retirement plan asset allocation at the end of 2024 and 2023 and target allocations for 2025 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.078%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Percent of&lt;br/&gt;Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Target&lt;br/&gt;Allocation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Worldwide Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="c-313"
      decimals="2"
      id="f-1747"
      unitRef="number">0.55</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="c-314"
      decimals="2"
      id="f-1748"
      unitRef="number">0.58</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="c-313"
      decimals="2"
      id="f-1749"
      unitRef="number">0.54</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="c-315"
      decimals="2"
      id="f-1750"
      unitRef="number">0.45</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="c-316"
      decimals="2"
      id="f-1751"
      unitRef="number">0.42</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="c-315"
      decimals="2"
      id="f-1752"
      unitRef="number">0.46</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations contextRef="c-10" decimals="2" id="f-1753" unitRef="number">1</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations contextRef="c-11" decimals="2" id="f-1754" unitRef="number">1</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage contextRef="c-10" decimals="2" id="f-1755" unitRef="number">1</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock contextRef="c-1" id="f-1756">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table sets forth the Retirement Plans' investments measured at fair value as of December&#160;31, 2024 and December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.840%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Quoted Prices&lt;br/&gt;in Active&lt;br/&gt;Markets for&lt;br/&gt;Identical Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Inputs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Investments&lt;br/&gt;Measured at Net&lt;br/&gt;Asset Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Short-term investment funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;511&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;829&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;511&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;841&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,885&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,985&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,885&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,985&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Debt instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,321&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,899&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,321&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,899&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,144&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,764&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,144&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,764&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commingled funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,004&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,967&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,190&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,672&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,231&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,682&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;128&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,087&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,295&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,303&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,436&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Investments at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$7,144&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,776&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;15,809&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;15,729&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;165&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;135&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;10,277&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;9,967&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;33,395&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;33,607&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt"&gt;The activity for the Level 3 assets is not significant for all years presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-317" decimals="-6" id="f-1757" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-318" decimals="-6" id="f-1758" unitRef="usd">12000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-319" decimals="-6" id="f-1759" unitRef="usd">511000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-320" decimals="-6" id="f-1760" unitRef="usd">829000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-321" decimals="-6" id="f-1761" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-322" decimals="-6" id="f-1762" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-323" decimals="-6" id="f-1763" unitRef="usd">511000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-324" decimals="-6" id="f-1764" unitRef="usd">841000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-325" decimals="-6" id="f-1765" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-326" decimals="-6" id="f-1766" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-327" decimals="-6" id="f-1767" unitRef="usd">7885000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-328" decimals="-6" id="f-1768" unitRef="usd">5985000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-329" decimals="-6" id="f-1769" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-330" decimals="-6" id="f-1770" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-331" decimals="-6" id="f-1771" unitRef="usd">7885000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-332" decimals="-6" id="f-1772" unitRef="usd">5985000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-333" decimals="-6" id="f-1773" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-334" decimals="-6" id="f-1774" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-335" decimals="-6" id="f-1775" unitRef="usd">2321000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-336" decimals="-6" id="f-1776" unitRef="usd">3899000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-337" decimals="-6" id="f-1777" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-338" decimals="-6" id="f-1778" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-339" decimals="-6" id="f-1779" unitRef="usd">2321000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-340" decimals="-6" id="f-1780" unitRef="usd">3899000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-341" decimals="-6" id="f-1781" unitRef="usd">7144000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-342" decimals="-6" id="f-1782" unitRef="usd">7764000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-343" decimals="-6" id="f-1783" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-344" decimals="-6" id="f-1784" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-345" decimals="-6" id="f-1785" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-346" decimals="-6" id="f-1786" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-347" decimals="-6" id="f-1787" unitRef="usd">7144000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-348" decimals="-6" id="f-1788" unitRef="usd">7764000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-349" decimals="-6" id="f-1789" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-350" decimals="-6" id="f-1790" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-351" decimals="-6" id="f-1791" unitRef="usd">5004000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-352" decimals="-6" id="f-1792" unitRef="usd">4967000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-353" decimals="-6" id="f-1793" unitRef="usd">37000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-354" decimals="-6" id="f-1794" unitRef="usd">43000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets contextRef="c-355" decimals="-6" id="f-1795" unitRef="usd">6190000000</jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets>
    <jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets contextRef="c-356" decimals="-6" id="f-1796" unitRef="usd">6672000000</jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-355" decimals="-6" id="f-1797" unitRef="usd">11231000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-356" decimals="-6" id="f-1798" unitRef="usd">11682000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-357" decimals="-6" id="f-1799" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-358" decimals="-6" id="f-1800" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-359" decimals="-6" id="f-1801" unitRef="usd">88000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-360" decimals="-6" id="f-1802" unitRef="usd">49000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-361" decimals="-6" id="f-1803" unitRef="usd">128000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-362" decimals="-6" id="f-1804" unitRef="usd">92000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets contextRef="c-363" decimals="-6" id="f-1805" unitRef="usd">4087000000</jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets>
    <jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets contextRef="c-364" decimals="-6" id="f-1806" unitRef="usd">3295000000</jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-363" decimals="-6" id="f-1807" unitRef="usd">4303000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-364" decimals="-6" id="f-1808" unitRef="usd">3436000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-365" decimals="-6" id="f-1809" unitRef="usd">7144000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-366" decimals="-6" id="f-1810" unitRef="usd">7776000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-367" decimals="-6" id="f-1811" unitRef="usd">15809000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-368" decimals="-6" id="f-1812" unitRef="usd">15729000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-369" decimals="-6" id="f-1813" unitRef="usd">165000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-370" decimals="-6" id="f-1814" unitRef="usd">135000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets contextRef="c-371" decimals="-6" id="f-1815" unitRef="usd">10277000000</jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets>
    <jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets contextRef="c-372" decimals="-6" id="f-1816" unitRef="usd">9967000000</jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-371" decimals="-6" id="f-1817" unitRef="usd">33395000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-372" decimals="-6" id="f-1818" unitRef="usd">33607000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-373" decimals="-6" id="f-1819" unitRef="usd">93000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-374" decimals="-6" id="f-1820" unitRef="usd">86000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <jnj:FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets contextRef="c-10" decimals="-6" id="f-1821" unitRef="usd">13000000</jnj:FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets>
    <jnj:FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets contextRef="c-11" decimals="-6" id="f-1822" unitRef="usd">14000000</jnj:FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets>
    <jnj:SavingsPlanTextBlock contextRef="c-1" id="f-1823">Savings plan&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company has voluntary 401(k) savings plans designed to enhance the existing retirement programs covering eligible employees. The Company matches a percentage of each employee&#x2019;s contributions consistent with the provisions of the plan for which the employee is eligible. Total Company matching contributions to the plans were $282 million, $263 million and $257 million in fiscal years 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</jnj:SavingsPlanTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-1" decimals="-6" id="f-1824" unitRef="usd">282000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-12" decimals="-6" id="f-1825" unitRef="usd">263000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-13" decimals="-6" id="f-1826" unitRef="usd">257000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:TreasuryStockTextBlock contextRef="c-1" id="f-1827">Capital and treasury stock&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Changes in treasury stock were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.685%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Treasury Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Amounts in Millions Except Treasury Stock Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance at January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;490,878&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$39,099&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Employee compensation and stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(20,007)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,440)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Repurchase of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;35,375&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,035&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;506,246&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;41,694&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Employee compensation and stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(15,521)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,529)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Repurchase of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,085&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,079&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Kenvue share exchange (Note 21)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;190,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;31,418&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;712,765&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;75,662&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Employee compensation and stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(15,027)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,389)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Repurchase of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,183&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,407&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance at December 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;712,921&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$75,680&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Aggregate shares of common stock issued were approximately 3,119,843,000&#160;shares at the end of fiscal years 2024, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Cash dividends paid were $4.91 per share in fiscal year 2024, compared with dividends of $4.70 per share in fiscal year 2023, and $4.45 per share in fiscal year 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;On January 2, 2025, the Board of Directors declared a regular cash dividend of $1.24 per share, payable on March 4, 2025 to shareholders of record as of February 18, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;On September 14, 2022, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company's shares of common stock. The repurchase program was completed during the fiscal first quarter of 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:TreasuryStockTextBlock>
    <jnj:ChangesInTreasuryStockTableTextBlock contextRef="c-1" id="f-1828">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Changes in treasury stock were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.685%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Treasury Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Amounts in Millions Except Treasury Stock Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance at January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;490,878&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$39,099&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Employee compensation and stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(20,007)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,440)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Repurchase of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;35,375&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,035&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;506,246&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;41,694&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Employee compensation and stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(15,521)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,529)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Repurchase of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,085&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,079&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Kenvue share exchange (Note 21)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;190,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;31,418&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;712,765&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;75,662&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Employee compensation and stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(15,027)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,389)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Repurchase of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,183&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,407&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance at December 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;712,921&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$75,680&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</jnj:ChangesInTreasuryStockTableTextBlock>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-14"
      decimals="-3"
      id="f-1829"
      unitRef="shares">490878000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue contextRef="c-14" decimals="-6" id="f-1830" unitRef="usd">39099000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c-13"
      decimals="-3"
      id="f-1831"
      unitRef="shares">20007000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c-13" decimals="-6" id="f-1832" unitRef="usd">3440000000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-20"
      decimals="-3"
      id="f-1833"
      unitRef="shares">35375000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-20" decimals="-6" id="f-1834" unitRef="usd">6035000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-22"
      decimals="-3"
      id="f-1835"
      unitRef="shares">506246000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue contextRef="c-22" decimals="-6" id="f-1836" unitRef="usd">41694000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c-12"
      decimals="-3"
      id="f-1837"
      unitRef="shares">15521000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c-12" decimals="-6" id="f-1838" unitRef="usd">2529000000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-28"
      decimals="-3"
      id="f-1839"
      unitRef="shares">31085000</us-gaap:TreasuryStockSharesAcquired>
    <jnj:TreasuryStockValueAcquiredCostMethodNetOfTax contextRef="c-28" decimals="-6" id="f-1840" unitRef="usd">5079000000</jnj:TreasuryStockValueAcquiredCostMethodNetOfTax>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-33"
      decimals="-3"
      id="f-1841"
      unitRef="shares">190955000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue contextRef="c-33" decimals="-6" id="f-1842" unitRef="usd">31418000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-11"
      decimals="-3"
      id="f-1843"
      unitRef="shares">712765000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue contextRef="c-11" decimals="-6" id="f-1844" unitRef="usd">75662000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c-1" decimals="-3" id="f-1845" unitRef="shares">15027000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c-1" decimals="-6" id="f-1846" unitRef="usd">2389000000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-35"
      decimals="-3"
      id="f-1847"
      unitRef="shares">15183000</us-gaap:TreasuryStockSharesAcquired>
    <jnj:TreasuryStockValueAcquiredCostMethodNetOfTax contextRef="c-35" decimals="-6" id="f-1848" unitRef="usd">2407000000</jnj:TreasuryStockValueAcquiredCostMethodNetOfTax>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-10"
      decimals="-3"
      id="f-1849"
      unitRef="shares">712921000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue contextRef="c-10" decimals="-6" id="f-1850" unitRef="usd">75680000000</us-gaap:TreasuryStockValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-10"
      decimals="-3"
      id="f-1851"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-22"
      decimals="-3"
      id="f-1852"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-11"
      decimals="-3"
      id="f-1853"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-1"
      decimals="2"
      id="f-1854"
      unitRef="usdPerShare">4.91</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-12"
      decimals="2"
      id="f-1855"
      unitRef="usdPerShare">4.70</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-13"
      decimals="2"
      id="f-1856"
      unitRef="usdPerShare">4.45</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-375"
      decimals="INF"
      id="f-1857"
      unitRef="usdPerShare">1.24</us-gaap:CommonStockDividendsPerShareDeclared>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-376" decimals="-8" id="f-1858" unitRef="usd">5000000000.0</srt:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="c-1" id="f-1859">Accumulated other comprehensive income (loss)&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Components of other comprehensive income (loss) consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.334%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.436%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gain/&lt;br/&gt;(Loss) On&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Employee&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gain/&lt;br/&gt;(Loss) On&lt;br/&gt;Derivatives&lt;br/&gt;&amp;amp; Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;br/&gt;Accumulated&lt;br/&gt;Other&lt;br/&gt;Comprehensive&lt;br/&gt;Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$(10,017)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,702)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(336)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(13,058)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net 2022 changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,796)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,805&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;106&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;91&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(11,813)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(897)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(12,967)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net 2023 changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,221)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,399)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,741)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Kenvue Separation/IPO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,885&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;296&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,181&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(10,149)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,000)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(377)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(12,527)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net 2024 changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,708&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;449&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,373)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;786&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$(8,441)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,551)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,750)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(11,741)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For&#160;additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Details on reclassifications out of Accumulated Other Comprehensive Income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 10 for additional details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Gain/(Loss) On Derivatives &amp;amp; Hedges - reclassifications to earnings are recorded in the same account as the hedged transaction. See Note 6 for additional details.&lt;/span&gt;&lt;/div&gt;*&#160;&#160;&#160;&#160;Includes impact of curtailments and settlements in connection with separation from Kenvue.</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-1860">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Components of other comprehensive income (loss) consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.334%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.436%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gain/&lt;br/&gt;(Loss) On&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Employee&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gain/&lt;br/&gt;(Loss) On&lt;br/&gt;Derivatives&lt;br/&gt;&amp;amp; Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;br/&gt;Accumulated&lt;br/&gt;Other&lt;br/&gt;Comprehensive&lt;br/&gt;Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$(10,017)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,702)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(336)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(13,058)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net 2022 changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,796)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,805&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;106&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;91&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(11,813)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(897)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(12,967)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net 2023 changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,221)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,399)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,741)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Kenvue Separation/IPO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,885&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;296&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,181&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(10,149)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,000)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(377)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(12,527)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net 2024 changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,708&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;449&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,373)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;786&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$(8,441)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,551)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,750)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(11,741)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-377" decimals="-6" id="f-1861" unitRef="usd">-10017000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-378" decimals="-6" id="f-1862" unitRef="usd">-3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-379" decimals="-6" id="f-1863" unitRef="usd">-2702000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-380" decimals="-6" id="f-1864" unitRef="usd">-336000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-16" decimals="-6" id="f-1865" unitRef="usd">-13058000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-381" decimals="-6" id="f-1866" unitRef="usd">-1796000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-382" decimals="-6" id="f-1867" unitRef="usd">-24000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-383" decimals="-6" id="f-1868" unitRef="usd">1805000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-384" decimals="-6" id="f-1869" unitRef="usd">106000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-21" decimals="-6" id="f-1870" unitRef="usd">91000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-385" decimals="-6" id="f-1871" unitRef="usd">-11813000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-386" decimals="-6" id="f-1872" unitRef="usd">-27000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-387" decimals="-6" id="f-1873" unitRef="usd">-897000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-388" decimals="-6" id="f-1874" unitRef="usd">-230000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-24" decimals="-6" id="f-1875" unitRef="usd">-12967000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-389" decimals="-6" id="f-1876" unitRef="usd">-3221000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-390" decimals="-6" id="f-1877" unitRef="usd">26000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-391" decimals="-6" id="f-1878" unitRef="usd">-1399000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-392" decimals="-6" id="f-1879" unitRef="usd">-147000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-29" decimals="-6" id="f-1880" unitRef="usd">-4741000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation contextRef="c-389" decimals="-6" id="f-1881" unitRef="usd">4885000000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation contextRef="c-391" decimals="-6" id="f-1882" unitRef="usd">296000000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation contextRef="c-29" decimals="-6" id="f-1883" unitRef="usd">5181000000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-393" decimals="-6" id="f-1884" unitRef="usd">-10149000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-394" decimals="-6" id="f-1885" unitRef="usd">-1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-395" decimals="-6" id="f-1886" unitRef="usd">-2000000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-396" decimals="-6" id="f-1887" unitRef="usd">-377000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-6" id="f-1888" unitRef="usd">-12527000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-397" decimals="-6" id="f-1889" unitRef="usd">1708000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-398" decimals="-6" id="f-1890" unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-399" decimals="-6" id="f-1891" unitRef="usd">449000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-400" decimals="-6" id="f-1892" unitRef="usd">-1373000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-36" decimals="-6" id="f-1893" unitRef="usd">786000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-401" decimals="-6" id="f-1894" unitRef="usd">-8441000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-402" decimals="-6" id="f-1895" unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-403" decimals="-6" id="f-1896" unitRef="usd">-1551000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-404" decimals="-6" id="f-1897" unitRef="usd">-1750000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-38" decimals="-6" id="f-1898" unitRef="usd">-11741000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ForeignCurrencyDisclosureTextBlock contextRef="c-1" id="f-1899">International currency translation&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;For translation of its subsidiaries operating in non-U.S.&#160;Dollar currencies, the Company has determined that the local currencies of its international subsidiaries are the functional currencies except those in highly inflationary economies, which are defined as those which have had compound cumulative rates of inflation of 100% or more during the past three years, or where a substantial portion of its cash flows are not in the local currency. For the majority of the Company's subsidiaries the local currency is the functional currency. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive income. The other current and non-current assets line within the Statement of Cash flows includes the impact of foreign currency translation. This equity account includes the results of translating certain balance sheet assets and liabilities at current exchange rates and some accounts at historical rates, except for those located in highly inflationary economies (Argentina, Turkey and Venezuela). Beginning in the fiscal fourth quarter of 2024, the Company also accounted for operations in Egypt as highly inflationary. The translation of balance sheet accounts for highly inflationary economies are reflected in the operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;A rollforward of the changes during fiscal years 2024, 2023 and 2022 for foreign currency translation adjustments is included in Note&#160;13. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Net currency transaction gains and losses included in Other (income) expense were losses of $214 million, $366 million and $286 million in fiscal years 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyDisclosureTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-1" decimals="-6" id="f-1900" unitRef="usd">-214000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-12" decimals="-6" id="f-1901" unitRef="usd">-366000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-13" decimals="-6" id="f-1902" unitRef="usd">-286000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-1903">Earnings per share&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended December&#160;29, 2024, December&#160;31, 2023 and January&#160;1, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.096%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In Millions Except Per Share Amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic net earnings per share from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$5.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.23&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic net earnings per share from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.60&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total net earnings per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13.88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.83&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Average shares outstanding&#160;&#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,407.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,533.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,625.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Potential shares exercisable under stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;77.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;94.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;140.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less: shares repurchased under treasury stock method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(55.6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(67.2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(101.4)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Adjusted average shares outstanding&#160;&#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,429.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,560.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,663.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Diluted net earnings per share from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Diluted net earnings per share from discontinuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.59&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total net earnings per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$5.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.73&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Shares in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The diluted net earnings per share calculation excluded the following number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Company&#x2019;s stock. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;54.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-1904">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended December&#160;29, 2024, December&#160;31, 2023 and January&#160;1, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.096%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In Millions Except Per Share Amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic net earnings per share from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$5.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.23&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic net earnings per share from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.60&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total net earnings per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13.88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.83&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Average shares outstanding&#160;&#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,407.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,533.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,625.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Potential shares exercisable under stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;77.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;94.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;140.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less: shares repurchased under treasury stock method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(55.6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(67.2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(101.4)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Adjusted average shares outstanding&#160;&#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,429.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,560.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,663.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Diluted net earnings per share from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Diluted net earnings per share from discontinuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.59&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total net earnings per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$5.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.73&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Shares in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The diluted net earnings per share calculation excluded the following number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Company&#x2019;s stock. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;54.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-1905"
      unitRef="usdPerShare">5.84</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-12"
      decimals="2"
      id="f-1906"
      unitRef="usdPerShare">5.26</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-13"
      decimals="2"
      id="f-1907"
      unitRef="usdPerShare">6.23</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-1908"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="c-12"
      decimals="2"
      id="f-1909"
      unitRef="usdPerShare">8.62</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="c-13"
      decimals="2"
      id="f-1910"
      unitRef="usdPerShare">0.60</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-1911"
      unitRef="usdPerShare">5.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-12"
      decimals="2"
      id="f-1912"
      unitRef="usdPerShare">13.88</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-13"
      decimals="2"
      id="f-1913"
      unitRef="usdPerShare">6.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-1914" unitRef="shares">2407300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-12"
      decimals="-5"
      id="f-1915"
      unitRef="shares">2533500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-13"
      decimals="-5"
      id="f-1916"
      unitRef="shares">2625200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-1" decimals="-5" id="f-1917" unitRef="shares">77700000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-12"
      decimals="-5"
      id="f-1918"
      unitRef="shares">94100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-13"
      decimals="-5"
      id="f-1919"
      unitRef="shares">140100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod contextRef="c-1" decimals="-5" id="f-1920" unitRef="shares">55600000</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="c-12"
      decimals="-5"
      id="f-1921"
      unitRef="shares">67200000</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="c-13"
      decimals="-5"
      id="f-1922"
      unitRef="shares">101400000</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-1923" unitRef="shares">2429400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-12"
      decimals="-5"
      id="f-1924"
      unitRef="shares">2560400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-13"
      decimals="-5"
      id="f-1925"
      unitRef="shares">2663900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-1926"
      unitRef="usdPerShare">5.79</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-12"
      decimals="2"
      id="f-1927"
      unitRef="usdPerShare">5.20</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-13"
      decimals="2"
      id="f-1928"
      unitRef="usdPerShare">6.14</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-1929"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="c-12"
      decimals="2"
      id="f-1930"
      unitRef="usdPerShare">8.52</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="c-13"
      decimals="2"
      id="f-1931"
      unitRef="usdPerShare">0.59</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-1932"
      unitRef="usdPerShare">5.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-12"
      decimals="2"
      id="f-1933"
      unitRef="usdPerShare">13.72</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-13"
      decimals="2"
      id="f-1934"
      unitRef="usdPerShare">6.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="2" id="f-1935" unitRef="shares">54.1</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-12" decimals="2" id="f-1936" unitRef="shares">43.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-405"
      decimals="2"
      id="f-1937"
      unitRef="shares">0.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-1938">Common stock, stock option plans and stock compensation agreements&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;At December&#160;29, 2024, the Company had one active stock-based compensation plan, the 2022 Long-Term Incentive Plan. The shares outstanding are for contracts under the Company's 2012 Long-Term Incentive Plan and 2022 Long-Term Incentive Plan. The 2012 Long-Term Incentive Plan expired on April 26, 2022. All awards (stock options, restricted shares units and performance share units) granted subsequent to that date were under the 2022 Long-Term Incentive Plan. Under the 2022 Long-Term Incentive Plan, the Company may issue up to 150&#160;million shares of common stock, of which up to 110&#160;million shares of common stock may be issued subject to stock options or stock appreciation rights and up to 40&#160;million shares of common stock may be issued subject to full value awards. Awards will generally be counted on a 1-for-1 basis against the share reserve, provided that if more than 40&#160;million full value awards are granted, each full value award in excess of 40&#160;million will be counted on a 5-for-1 basis against the share reserve. Shares available for future grants under the 2022 Long-Term Incentive Plan were 111 million at the end of fiscal&#160;year&#160;2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The compensation cost that has been charged against income for these plans was $1,176 million, $1,087 million and $1,028 million for fiscal years 2024, 2023 and 2022, respectively. The total income tax benefit recognized in the income statement for share-based compensation costs was $251 million, $221 million and $177 million for fiscal years 2024, 2023 and 2022, respectively. The Company also recognized additional income tax benefits of $94&#160;million, $126&#160;million and $267&#160;million for fiscal years 2024, 2023 and 2022, respectively, for which options were exercised or restricted shares were vested. The total unrecognized compensation cost was $1,002 million, $907 million and $866 million for fiscal years 2024, 2023 and 2022, respectively. The weighted average period for this cost to be recognized was 1.81&#160;years, 1.80&#160;years and 1.80&#160;years for fiscal years 2024, 2023, and 2022, respectively. Share-based compensation costs capitalized as part of inventory were insignificant in all periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company settles employee benefit equity issuances with treasury shares. Treasury shares are replenished through market purchases throughout the year for the number of shares used to settle employee benefit equity issuances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Stock options expire 10 years&#160;from the date of grant and vest over service periods that range from 6 months to 4 years. Options granted under the 2012 Long-Term Incentive Plan were granted at the average of the high and low prices of the Company&#x2019;s Common Stock on the New York Stock Exchange on the date of grant. Options granted under the 2022 Long-Term incentive Plan were granted at the closing price of the Company&#x2019;s Common Stock on the New York Stock Exchange on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. For 2024, 2023, and 2022 grants, expected volatility represents a blended rate of 10-year weekly historical overall volatility rate, and a 5-week average implied volatility rate based on at-the-money traded Johnson&#160;&amp;amp; Johnson options with a life of 2&#160;years. For all grants, historical data is used to determine the expected life of the option. The risk-free rate was based on the U.S.&#160;Treasury yield curve in effect at the time of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The average fair value of options granted was $27.67, $27.85 and $23.23, in fiscal years 2024, 2023 and 2022, respectively. The fair value was estimated based on the weighted average assumptions of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;A summary of option activity under the Plan as of December&#160;29, 2024, is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.780%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.780%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(Dollars in Millions) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Shares at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;112,238&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$139.88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$2,239&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,917&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;157.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(10,771)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;107.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Options canceled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,755)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;162.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Shares at December 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;112,629&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$144.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$1,129&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The total intrinsic value of options exercised was $560 million, $729 million and $1,228 million in fiscal years 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table summarizes stock options outstanding and exercisable at December&#160;29, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.590%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.593%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise Price Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average Life&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$100.06 - $101.87&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$101.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$101.29&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$115.67 - $129.51&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,252&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;122.49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,252&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;122.49&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$131.94 - $151.41&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;25,624&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;142.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;25,624&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;142.87&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$157.92 - $162.75&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26,391&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;160.33&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,269&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;162.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$164.62 - $165.89&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;29,346&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;165.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,522&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;164.64&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;112,629&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$144.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;74,683&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$135.72&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt"&gt;Average contractual life remaining in years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Stock options outstanding at December&#160;31, 2023 and January&#160;1, 2023 were 112,238 and an average life of 5.5 years and 118,672 and an average life of 5.8&#160;years, respectively. Stock options exercisable at December&#160;31, 2023 and January&#160;1, 2023 were 66,998 at an average price of $123.39 and 63,661 at an average price of $113.06, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Restricted share units and performance share units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company grants restricted share units which vest over service periods that range from 6 months to 3 years. The Company also grants performance share units, which are paid in shares of Johnson &amp;amp; Johnson Common Stock after the end of a three-year performance period. Performance shares were granted with two equally-weighted goals that directly align with or help drive long-term total shareholder return: adjusted operational earnings per share and relative total shareholder return. The&#160;number of shares actually earned at the end of the three-year period will vary, based only on actual performance, from 0% to 200% of the target number of performance share units granted. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;A summary of the restricted share units and performance share units activity under the Plans as of December&#160;29, 2024 is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding&lt;br/&gt;Restricted Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding&lt;br/&gt;Performance Share Units&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Shares at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,938&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,037&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,331&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;906&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,454)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(808)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Canceled/forfeited/adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(774)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Shares at December 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,013&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The average fair value of the restricted share units granted was $147.51, $152.63 and $153.67 in fiscal years 2024, 2023 and 2022, respectively, using the fair market value at the date of grant. The fair value of restricted share units was discounted for dividends, which are not paid on the restricted share units during the vesting period. The fair value of restricted share units issued was $833 million, $605 million and $591 million in 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The weighted average fair value of the performance share units granted was $133.76, $145.17 and $170.46 in fiscal years 2024, 2023 and 2022, calculated using the weighted average fair market value for each of the component goals at the date of&#160;grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The fair values for the earnings per share goals of each performance share unit were estimated on the date of grant using the fair market value of the shares at the time of the award discounted for dividends, which are not paid on the performance share units during the vesting period.&#160;The fair value for the relative total shareholder return goal of each performance share unit was estimated on the date of grant using the Monte Carlo valuation model.&#160;The fair value of performance share units issued was $146 million, $140 million and $94 million in fiscal years 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <jnj:NumberOfStockBasedCompensationPlans
      contextRef="c-10"
      decimals="0"
      id="f-1939"
      unitRef="stockbasedcompensationplans">1</jnj:NumberOfStockBasedCompensationPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-406"
      decimals="-6"
      id="f-1940"
      unitRef="shares">150000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights
      contextRef="c-406"
      decimals="-6"
      id="f-1941"
      unitRef="shares">110000000</jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights>
    <jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards
      contextRef="c-406"
      decimals="-6"
      id="f-1942"
      unitRef="shares">40000000</jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards>
    <jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards
      contextRef="c-406"
      decimals="-6"
      id="f-1943"
      unitRef="shares">40000000</jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards>
    <jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess
      contextRef="c-406"
      decimals="-6"
      id="f-1944"
      unitRef="shares">40000000</jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-406"
      decimals="-6"
      id="f-1945"
      unitRef="shares">111000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-6" id="f-1946" unitRef="usd">1176000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-12" decimals="-6" id="f-1947" unitRef="usd">1087000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-13" decimals="-6" id="f-1948" unitRef="usd">1028000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-1" decimals="-6" id="f-1949" unitRef="usd">251000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-12" decimals="-6" id="f-1950" unitRef="usd">221000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-13" decimals="-6" id="f-1951" unitRef="usd">177000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-1" decimals="-6" id="f-1952" unitRef="usd">94000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-12" decimals="-6" id="f-1953" unitRef="usd">126000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-13" decimals="-6" id="f-1954" unitRef="usd">267000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-10" decimals="-6" id="f-1955" unitRef="usd">1002000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-11" decimals="-6" id="f-1956" unitRef="usd">907000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-22" decimals="-6" id="f-1957" unitRef="usd">866000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-1958">P1Y9M21D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-12" id="f-1959">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-13" id="f-1960">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-407" id="f-1961">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-408" id="f-1962">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-409" id="f-1963">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-1964">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The average fair value of options granted was $27.67, $27.85 and $23.23, in fiscal years 2024, 2023 and 2022, respectively. The fair value was estimated based on the weighted average assumptions of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-1965"
      unitRef="usdPerShare">27.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-12"
      decimals="2"
      id="f-1966"
      unitRef="usdPerShare">27.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-13"
      decimals="2"
      id="f-1967"
      unitRef="usdPerShare">23.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-1" decimals="4" id="f-1968" unitRef="number">0.0415</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-12" decimals="4" id="f-1969" unitRef="number">0.0374</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-13" decimals="4" id="f-1970" unitRef="number">0.0198</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-1" decimals="4" id="f-1971" unitRef="number">0.1785</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-12" decimals="4" id="f-1972" unitRef="number">0.1769</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-13" decimals="4" id="f-1973" unitRef="number">0.1800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-1" id="f-1974">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-12" id="f-1975">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-13" id="f-1976">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="4" id="f-1977" unitRef="number">0.0310</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-12" decimals="4" id="f-1978" unitRef="number">0.0290</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-13" decimals="4" id="f-1979" unitRef="number">0.0270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-1980">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;A summary of option activity under the Plan as of December&#160;29, 2024, is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.780%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.780%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(Dollars in Millions) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Shares at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;112,238&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$139.88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$2,239&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,917&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;157.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(10,771)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;107.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Options canceled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,755)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;162.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Shares at December 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;112,629&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$144.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$1,129&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-11"
      decimals="-3"
      id="f-1981"
      unitRef="shares">112238000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-11"
      decimals="2"
      id="f-1982"
      unitRef="usdPerShare">139.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-11" decimals="-6" id="f-1983" unitRef="usd">2239000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c-1" decimals="-3" id="f-1984" unitRef="shares">13917000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-1985"
      unitRef="usdPerShare">157.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="-3" id="f-1986" unitRef="shares">10771000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-1987"
      unitRef="usdPerShare">107.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="-3" id="f-1988" unitRef="shares">2755000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-1989"
      unitRef="usdPerShare">162.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-10"
      decimals="-3"
      id="f-1990"
      unitRef="shares">112629000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-10"
      decimals="2"
      id="f-1991"
      unitRef="usdPerShare">144.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-10" decimals="-6" id="f-1992" unitRef="usd">1129000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-6" id="f-1993" unitRef="usd">560000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-12" decimals="-6" id="f-1994" unitRef="usd">729000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-13" decimals="-6" id="f-1995" unitRef="usd">1228000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="c-1" id="f-1996">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table summarizes stock options outstanding and exercisable at December&#160;29, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.590%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.593%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise Price Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average Life&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$100.06 - $101.87&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$101.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$101.29&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$115.67 - $129.51&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,252&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;122.49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,252&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;122.49&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$131.94 - $151.41&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;25,624&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;142.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;25,624&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;142.87&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$157.92 - $162.75&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26,391&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;160.33&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,269&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;162.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$164.62 - $165.89&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;29,346&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;165.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,522&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;164.64&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;112,629&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$144.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;74,683&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$135.72&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt"&gt;Average contractual life remaining in years.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-410"
      decimals="2"
      id="f-1997"
      unitRef="usdPerShare">100.06</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-410"
      decimals="2"
      id="f-1998"
      unitRef="usdPerShare">101.87</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-411"
      decimals="-3"
      id="f-1999"
      unitRef="shares">13016000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-410" id="f-2000">P0Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-411"
      decimals="2"
      id="f-2001"
      unitRef="usdPerShare">101.29</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-411"
      decimals="-3"
      id="f-2002"
      unitRef="shares">13016000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-411"
      decimals="2"
      id="f-2003"
      unitRef="usdPerShare">101.29</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-412"
      decimals="2"
      id="f-2004"
      unitRef="usdPerShare">115.67</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-412"
      decimals="2"
      id="f-2005"
      unitRef="usdPerShare">129.51</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-413"
      decimals="-3"
      id="f-2006"
      unitRef="shares">18252000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-412" id="f-2007">P2Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-413"
      decimals="2"
      id="f-2008"
      unitRef="usdPerShare">122.49</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-413"
      decimals="-3"
      id="f-2009"
      unitRef="shares">18252000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-413"
      decimals="2"
      id="f-2010"
      unitRef="usdPerShare">122.49</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-414"
      decimals="2"
      id="f-2011"
      unitRef="usdPerShare">131.94</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-414"
      decimals="2"
      id="f-2012"
      unitRef="usdPerShare">151.41</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-415"
      decimals="-3"
      id="f-2013"
      unitRef="shares">25624000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-414" id="f-2014">P4Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-415"
      decimals="2"
      id="f-2015"
      unitRef="usdPerShare">142.87</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-415"
      decimals="-3"
      id="f-2016"
      unitRef="shares">25624000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-415"
      decimals="2"
      id="f-2017"
      unitRef="usdPerShare">142.87</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-416"
      decimals="2"
      id="f-2018"
      unitRef="usdPerShare">157.92</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-416"
      decimals="2"
      id="f-2019"
      unitRef="usdPerShare">162.75</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-417"
      decimals="-3"
      id="f-2020"
      unitRef="shares">26391000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-416" id="f-2021">P8Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-417"
      decimals="2"
      id="f-2022"
      unitRef="usdPerShare">160.33</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-417"
      decimals="-3"
      id="f-2023"
      unitRef="shares">4269000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-417"
      decimals="2"
      id="f-2024"
      unitRef="usdPerShare">162.75</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-418"
      decimals="2"
      id="f-2025"
      unitRef="usdPerShare">164.62</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-418"
      decimals="2"
      id="f-2026"
      unitRef="usdPerShare">165.89</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-419"
      decimals="-3"
      id="f-2027"
      unitRef="shares">29346000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-418" id="f-2028">P6Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-419"
      decimals="2"
      id="f-2029"
      unitRef="usdPerShare">165.29</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-419"
      decimals="-3"
      id="f-2030"
      unitRef="shares">13522000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-419"
      decimals="2"
      id="f-2031"
      unitRef="usdPerShare">164.64</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-10"
      decimals="-3"
      id="f-2032"
      unitRef="shares">112629000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-2033">P5Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-10"
      decimals="2"
      id="f-2034"
      unitRef="usdPerShare">144.69</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-10"
      decimals="-3"
      id="f-2035"
      unitRef="shares">74683000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-10"
      decimals="2"
      id="f-2036"
      unitRef="usdPerShare">135.72</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-11"
      decimals="-3"
      id="f-2037"
      unitRef="shares">112238000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-12" id="f-2038">P5Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-22"
      decimals="-3"
      id="f-2039"
      unitRef="shares">118672000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-13" id="f-2040">P5Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-11"
      decimals="-3"
      id="f-2041"
      unitRef="shares">66998000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-11"
      decimals="2"
      id="f-2042"
      unitRef="usdPerShare">123.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-22"
      decimals="-3"
      id="f-2043"
      unitRef="shares">63661000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-22"
      decimals="2"
      id="f-2044"
      unitRef="usdPerShare">113.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-420" id="f-2045">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-421" id="f-2046">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-422" id="f-2047">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-422" id="f-2048">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-423"
      decimals="INF"
      id="f-2049"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-424"
      decimals="INF"
      id="f-2050"
      unitRef="number">2</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="c-1" id="f-2051">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;A summary of the restricted share units and performance share units activity under the Plans as of December&#160;29, 2024 is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding&lt;br/&gt;Restricted Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding&lt;br/&gt;Performance Share Units&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Shares at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,938&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,037&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,331&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;906&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,454)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(808)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Canceled/forfeited/adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(774)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Shares at December 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,013&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-425"
      decimals="-3"
      id="f-2052"
      unitRef="shares">12938000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-426"
      decimals="-3"
      id="f-2053"
      unitRef="shares">2037000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-427"
      decimals="-3"
      id="f-2054"
      unitRef="shares">6331000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-422"
      decimals="-3"
      id="f-2055"
      unitRef="shares">906000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-427"
      decimals="-3"
      id="f-2056"
      unitRef="shares">5454000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-422"
      decimals="-3"
      id="f-2057"
      unitRef="shares">808000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod
      contextRef="c-427"
      decimals="-3"
      id="f-2058"
      unitRef="shares">774000</jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod>
    <jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod
      contextRef="c-422"
      decimals="-3"
      id="f-2059"
      unitRef="shares">122000</jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-428"
      decimals="-3"
      id="f-2060"
      unitRef="shares">13041000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-429"
      decimals="-3"
      id="f-2061"
      unitRef="shares">2013000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-427"
      decimals="2"
      id="f-2062"
      unitRef="usdPerShare">147.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-430"
      decimals="2"
      id="f-2063"
      unitRef="usdPerShare">152.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-431"
      decimals="2"
      id="f-2064"
      unitRef="usdPerShare">153.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-427" decimals="-6" id="f-2065" unitRef="usd">833000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-430" decimals="-6" id="f-2066" unitRef="usd">605000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-431" decimals="-6" id="f-2067" unitRef="usd">591000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-422"
      decimals="2"
      id="f-2068"
      unitRef="usdPerShare">133.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-432"
      decimals="2"
      id="f-2069"
      unitRef="usdPerShare">145.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-433"
      decimals="2"
      id="f-2070"
      unitRef="usdPerShare">170.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-422" decimals="-6" id="f-2071" unitRef="usd">146000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-432" decimals="-6" id="f-2072" unitRef="usd">140000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-433" decimals="-6" id="f-2073" unitRef="usd">94000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-2074">Segments of business and geographic areas&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Following the separation of the Consumer Health business in the fiscal third quarter of 2023, the Company is now organized into two reportable segments: Innovative Medicine and MedTech. The segment results have been recast for all periods to reflect the continuing operations of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company&#x2019;s chief operating decision maker (CODM) is the Chief Executive Officer (Principal Executive Officer). For the Innovative Medicine and MedTech segments, the CODM uses segment income before tax to allocate resources (including employees, financial, and capital resources) for each segment predominantly in the annual forecasting process. The CODM considers planning-to-actual variances on a quarterly basis to assess performance and make decisions about allocating resources to the segments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.358%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Sales to Customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;% Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2019;24 vs. &#x2019;23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2019;23 vs. &#x2019;22&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;INNOVATIVE MEDICINE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$11,355&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,539&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,473&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,513&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,899&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17,828&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,052&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,935&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;REMICADE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,009&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,143&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,417&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(11.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(19.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Exports&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;147&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;204&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(33.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(28.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;497&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;549&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;722&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(9.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(23.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,605&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,839&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,343&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(21.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;SIMPONI / SIMPONI ARIA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,082&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,124&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,166&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,108&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,073&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,190&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,197&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,184&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;STELARA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,720&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,966&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,388&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,641&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,892&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,335&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,361&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,858&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,723&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;TREMFYA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,443&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,147&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,844&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,227&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;999&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;824&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,670&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,147&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,668&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;OTHER IMMUNOLOGY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(74.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(33.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(74.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(33.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Infectious Diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,354&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,680&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(9.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(10.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,042&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,918&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,769&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(30.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(22.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,396&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,418&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,449&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(23.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(18.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;COVID-19 VACCINE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;120&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;198&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,117&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2,059&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(82.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(45.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.358%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Sales to Customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;% Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2019;24 vs. &#x2019;23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2019;23 vs. &#x2019;22&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;198&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,117&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2,179&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(82.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(48.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;EDURANT / rilpivirine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,241&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,115&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;972&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,272&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,150&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,008&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;PREZISTA / PREZCOBIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; /&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;REZOLSTA / SYMTUZA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,311&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,446&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,494&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;401&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;408&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;449&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,712&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,854&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,943&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;OTHER INFECTIOUS DISEASES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(41.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(34.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;203&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;278&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;289&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(26.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;214&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;297&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;318&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(27.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4,398&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4,065&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3,570&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2,718&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3,076&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3,323&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(11.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;7,115&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;7,140&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;6,893&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;CONCERTA / methylphenidate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;134&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;230&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;151&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(41.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;52.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;507&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;554&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;493&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;641&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;783&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;644&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(18.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3,125&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2,897&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2,714&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,097&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,218&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,426&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(14.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4,222&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4,115&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4,140&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;SPRAVATO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;929&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;589&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;328&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;57.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;79.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;148&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;46&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;48.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,077&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;689&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;374&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;56.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;84.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;OTHER NEUROSCIENCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;210&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;349&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;376&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(39.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;965&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,204&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,358&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(19.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(11.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,175&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,553&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,734&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(24.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(10.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;10,854&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;8,462&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;6,930&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;22.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;9,926&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;9,199&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;9,052&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;20,781&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;17,661&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;15,983&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;CARVYKTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;869&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;469&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;133&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;85.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.358%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Sales to Customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;% Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2019;24 vs. &#x2019;23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2019;23 vs. &#x2019;22&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;963&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;133&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;92.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;DARZALEX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,588&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,277&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,210&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;25.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,082&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,467&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,767&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,670&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,744&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,977&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;ERLEADA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,282&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,065&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;968&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,717&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,322&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;913&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,999&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,387&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,881&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;IMBRUVICA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,051&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,390&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(24.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,214&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,394&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,038&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,264&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,784&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(13.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;TECVAYLI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;418&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;334&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;131&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;549&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;395&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;ZYTIGA /abiraterone acetate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(32.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(32.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;597&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;837&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,696&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(28.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(50.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;631&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;887&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,770&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(28.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(49.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;OTHER ONCOLOGY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;643&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;215&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;144&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;49.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;288&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;269&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;280&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;931&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;484&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;423&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;92.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Pulmonary Hypertension&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,143&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,697&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,346&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,140&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,117&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,071&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,282&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,815&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,417&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:underline"&gt;OPSUMIT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,520&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,292&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,132&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;664&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;681&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;651&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,184&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,973&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,783&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;UPTRAVI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,511&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,326&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,104&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;307&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;255&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;218&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,817&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,582&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,322&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;OTHER PULMONARY HYPERTENSION&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;112&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;110&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;41.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(28.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;169&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;182&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;202&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(10.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;281&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;260&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;313&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(16.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.358%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Sales to Customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;% Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2019;24 vs. &#x2019;23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2019;23 vs. &#x2019;22&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cardiovascular / Metabolism / Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,866&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,906&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,042&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;696&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;765&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;845&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,562&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,671&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,887&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;XARELTO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,373&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,365&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,473&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,373&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,365&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,473&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;OTHER&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;494&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;541&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;569&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;696&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;765&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;845&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,189&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,306&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,414&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(8.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;TOTAL INNOVATIVE MEDICINE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;33,970&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,169&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;28,604&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,994&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;23,590&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;23,959&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;56,964&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;54,759&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;52,563&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;MEDTECH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cardiovascular &lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,513&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,633&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,169&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;67.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,194&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,717&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,131&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,707&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,350&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,300&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;47.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;ELECTROPHYSIOLOGY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,738&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,458&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,529&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,230&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,901&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,267&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,688&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,937&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;ABIOMED&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,213&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,066&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;284&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;240&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,496&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,306&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;SHOCKWAVE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;442&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;122&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;564&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;OTHER CARDIOVASCULAR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;120&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;109&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;102&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;260&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;247&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;230&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;380&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;356&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;332&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Orthopaedics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,689&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,525&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,321&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,470&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,417&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,267&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,158&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,942&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,587&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.358%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Sales to Customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;% Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2019;24 vs. &#x2019;23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2019;23 vs. &#x2019;22&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;HIPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,057&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;996&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;943&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;581&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;564&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;571&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,638&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,560&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,514&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;KNEES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;922&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;896&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;851&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;623&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;559&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;508&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,545&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,456&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,359&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;TRAUMA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,949&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,882&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;989&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,049&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,979&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,871&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;SPINE, SPORTS &amp;amp; OTHER&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,696&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,684&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,645&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,230&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,263&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,198&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,926&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,947&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,843&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Surgery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,003&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,897&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,842&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,006&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,793&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,845&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,037&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,690&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;ADVANCED&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,838&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,833&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,784&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,837&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,785&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,488&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,671&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,569&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;GENERAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,165&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,198&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,113&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,192&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,168&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,008&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,358&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,366&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,121&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Vision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,128&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,086&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,990&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,986&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,859&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,146&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,072&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,849&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;CONTACT LENSES / OTHER&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,684&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,626&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,522&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,049&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,076&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,733&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,702&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,543&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;SURGICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;444&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;460&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;468&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;969&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;910&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;837&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,413&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,370&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,306&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.358%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Sales to Customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;% Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2019;24 vs. &#x2019;23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2019;23 vs. &#x2019;22&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;TOTAL MEDTECH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,332&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,275&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,377&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,525&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,125&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,857&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;30,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;27,427&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;WORLDWIDE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50,302&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;46,444&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;41,981&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,519&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,715&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,009&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$88,821&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;85,159&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;79,990&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;*&#160;&#160;&#160;&#160;percentage greater than 100% or not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt"&gt;Previously referred to as Interventional Solutions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt"&gt;Acquired on December 22, 2022&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt"&gt;Acquired on May 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.750%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Income Before Tax by Segment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Innovative&lt;br/&gt;Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;MedTech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Innovative&lt;br/&gt;Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;MedTech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Innovative&lt;br/&gt;Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;MedTech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Sales to customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$56,964&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,857&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;54,759&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;30,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;52,563&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;27,427&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,345&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,715&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,722&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,066&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,397&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Selling, marketing and administrative &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,906&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,812&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,842&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,476&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,714&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,537&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,529&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,703&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,963&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,122&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,642&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,493&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other segment items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(426)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;257&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;993&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(589)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,494&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;553&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Segment income before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$18,919&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,740&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,659&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,246&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,669&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,915&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,647&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,447&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,094&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less: Expense not allocated to segments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,972&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,853&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;735&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Worldwide total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$16,687&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;15,062&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;19,359&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Identifiable Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Innovative Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$57,070&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;58,324&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;MedTech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;84,322&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;74,710&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;141,392&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;133,034&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,712&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;34,524&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Worldwide total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$180,104&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;167,558&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.465%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.873%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Additions to Property,&lt;br/&gt;Plant &amp;amp; Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Depreciation and&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Innovative Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$1,710&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,653&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,374&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$3,760&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,847&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,687&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;MedTech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,443&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,372&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,120&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,237&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,943&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,302&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Segments total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,153&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,494&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,997&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,790&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,989&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;162&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;303&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;641&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;271&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;356&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;212&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;342&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;313&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;340&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Worldwide total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$4,424&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,543&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,009&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$7,339&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,486&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;6,970&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.614%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Sales to Customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Long-Lived Assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$50,302&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;46,444&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;41,981&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$70,670&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;54,832&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,212&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,410&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,664&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;27,267&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,616&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Western Hemisphere excluding U.S.&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,714&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,549&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,108&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,728&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,491&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Asia-Pacific, Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,593&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,756&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,237&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,454&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,500&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Segments total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;88,821&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;85,159&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;79,990&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;101,119&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;89,439&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,217&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,192&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other non long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;77,768&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;76,927&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Worldwide total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$88,821&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;85,159&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;79,990&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$180,104&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;167,558&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;See Note&#160;1 for a description of the segments in which the Company operates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;Export sales are not significant. In fiscal year 2024, the Company utilized three wholesalers distributing products for both segments that represented approximately 20.5%, 15.6% and 12.3% of the total gross revenues. In fiscal year 2023, the Company had three wholesalers distributing products for both segments that represented approximately 18.2%, 15.1% and 14.2% of the total gross revenues. In fiscal year 2022, the Company had three wholesalers distributing products for all three segments that represented approximately 18.9%, 15.0%, and 13.8% of the total gross revenues. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.64pt"&gt;&lt;span style="-sec-ix-hidden:f-2949"&gt;Other segment expenses&lt;/span&gt; for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:7.29pt"&gt;Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal years 2024 and 2023 include charges for talc matters of approximately $5.1&#160;billion and $7&#160;billion, respectively (See Note 19, Legal proceedings, for additional details). The fiscal year 2024 includes a loss of approximately $0.4&#160;billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock. The fiscal year 2023 includes the unfavorable change in the fair value of the retained stake in Kenvue of approximately $0.4&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:7.19pt"&gt;Innovative Medicine segment income before tax includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt"&gt;Acquired in-process research &amp;amp; development expense of $1.25&#160;billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt"&gt;Monetization of royalty rights of $0.3&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt"&gt;Litigation expense of $0.3&#160;billion primarily related to Risperdal Gynecomastia&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt"&gt;An intangible asset impairment charge of approximately $0.2&#160;billion associated with the M710 (biosimilar) asset acquired as part of the acquisition of Momenta Pharmaceuticals in 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt"&gt;A restructuring related charge of $0.1&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt"&gt;One-time COVID-19 Vaccine manufacturing exit related costs of $0.1&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt"&gt;Favorable changes in the fair value of securities of $0.1&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;MedTech segment income before tax includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt"&gt;Acquisition and integration related costs of $1.0&#160;billion primarily related to the acquisition of Shockwave &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt"&gt;Acquired in-process research and development expense of $0.5&#160;billion from the V-Wave acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt"&gt;A gain of $0.2&#160;billion related to the Acclarent divestiture&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt"&gt;A Medical Device Regulation charge of $0.2&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt"&gt;A restructuring related charge of $0.2&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.07pt"&gt;Innovative Medicine segment income before tax includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;One-time COVID-19 Vaccine manufacturing exit related costs of $0.7&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;A restructuring related charge of $0.5&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;Unfavorable changes in the fair value of securities of $0.4&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;Favorable litigation related items of $0.1&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;Loss on divestiture of $0.2&#160;billion. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;An intangible asset impairment charge of approximately $0.2&#160;billion related to market dynamics associated with a non-strategic asset (M710) acquired as part of the acquisition of Momenta Pharmaceuticals in 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;MedTech segment income before tax includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;Acquired in-process research and development expense of $0.4&#160;billion related to the Laminar acquisition in 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;A restructuring related charge of $0.3&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;Acquisition and integration related costs of $0.2&#160;billion primarily related to the acquisition of Abiomed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;A Medical Device Regulation charge of $0.3&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;Income from litigation settlements of $0.1&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:7.17pt"&gt;Innovative Medicine segment income before tax includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;One-time COVID-19 Vaccine manufacturing exit related costs of $1.5&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;An intangible asset impairment charge of approximately $0.8&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;Litigation expense of $0.1&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;Unfavorable changes in the fair value of securities of $0.7&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;A restructuring related charge of $0.1&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;MedTech segment income before tax includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;Litigation expense of $0.6&#160;billion primarily for pelvic mesh related costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;A restructuring related charge of $0.3&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;Acquisition and integration related costs of $0.3&#160;billion primarily related to the acquisition of Abiomed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt"&gt;A Medical Device Regulation charge of $0.3&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;   General corporate includes cash, cash equivalents, marketable securities and other corporate assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.64pt"&gt;Long-lived assets include property, plant and equipment, net for fiscal years 2024, and 2023 of $20,518 and $19,898, respectively, and intangible assets and goodwill, net for fiscal years 2024 and 2023 of $81,818 and $70,733, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-2075"
      unitRef="segment2">2</us-gaap:NumberOfOperatingSegments>
    <jnj:SalesBySegmentOfBusinessTableTextBlock contextRef="c-1" id="f-2076">&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.358%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Sales to Customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;% Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2019;24 vs. &#x2019;23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2019;23 vs. &#x2019;22&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;INNOVATIVE MEDICINE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$11,355&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,539&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,473&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,513&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,899&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17,828&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,052&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,935&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;REMICADE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,009&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,143&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,417&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(11.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(19.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Exports&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;147&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;204&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(33.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(28.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;497&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;549&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;722&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(9.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(23.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,605&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,839&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,343&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(21.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;SIMPONI / SIMPONI ARIA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,082&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,124&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,166&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,108&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,073&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,190&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,197&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,184&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;STELARA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,720&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,966&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,388&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,641&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,892&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,335&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,361&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,858&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,723&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;TREMFYA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,443&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,147&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,844&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,227&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;999&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;824&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,670&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,147&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,668&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;OTHER IMMUNOLOGY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(74.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(33.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(74.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(33.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Infectious Diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,354&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,680&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(9.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(10.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,042&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,918&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,769&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(30.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(22.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,396&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,418&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,449&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(23.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(18.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;COVID-19 VACCINE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;120&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;198&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,117&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2,059&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(82.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(45.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.358%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Sales to Customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;% Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2019;24 vs. &#x2019;23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2019;23 vs. &#x2019;22&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;198&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,117&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2,179&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(82.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(48.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;EDURANT / rilpivirine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,241&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,115&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;972&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,272&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,150&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,008&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;PREZISTA / PREZCOBIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; /&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;REZOLSTA / SYMTUZA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,311&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,446&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,494&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;401&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;408&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;449&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,712&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,854&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,943&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;OTHER INFECTIOUS DISEASES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(41.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(34.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;203&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;278&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;289&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(26.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;214&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;297&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;318&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(27.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4,398&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4,065&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3,570&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2,718&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3,076&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3,323&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(11.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;7,115&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;7,140&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;6,893&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;CONCERTA / methylphenidate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;134&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;230&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;151&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(41.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;52.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;507&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;554&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;493&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;641&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;783&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;644&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(18.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3,125&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2,897&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2,714&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,097&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,218&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,426&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(14.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4,222&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4,115&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4,140&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;SPRAVATO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;929&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;589&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;328&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;57.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;79.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;148&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;46&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;48.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,077&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;689&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;374&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;56.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;84.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;OTHER NEUROSCIENCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;210&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;349&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;376&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(39.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;965&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,204&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,358&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(19.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(11.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,175&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,553&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,734&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(24.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(10.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;10,854&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;8,462&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;6,930&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;22.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;9,926&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;9,199&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;9,052&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;20,781&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;17,661&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;15,983&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;CARVYKTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;869&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;469&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;133&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;85.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.358%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Sales to Customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;% Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2019;24 vs. &#x2019;23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2019;23 vs. &#x2019;22&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;963&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;133&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;92.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;DARZALEX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,588&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,277&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,210&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;25.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,082&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,467&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,767&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,670&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,744&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,977&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;ERLEADA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,282&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,065&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;968&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,717&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,322&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;913&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,999&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,387&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,881&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;IMBRUVICA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,051&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,390&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(24.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,214&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,394&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,038&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,264&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,784&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(13.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;TECVAYLI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;418&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;334&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;131&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;549&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;395&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;ZYTIGA /abiraterone acetate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(32.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(32.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;597&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;837&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,696&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(28.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(50.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;631&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;887&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,770&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(28.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(49.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;OTHER ONCOLOGY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;643&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;215&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;144&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;49.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;288&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;269&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;280&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;931&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;484&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;423&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;92.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Pulmonary Hypertension&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,143&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,697&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,346&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,140&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,117&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,071&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,282&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,815&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,417&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:underline"&gt;OPSUMIT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,520&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,292&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,132&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;664&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;681&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;651&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,184&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,973&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,783&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;UPTRAVI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,511&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,326&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,104&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;307&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;255&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;218&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,817&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,582&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,322&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;OTHER PULMONARY HYPERTENSION&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;112&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;110&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;41.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(28.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;169&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;182&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;202&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(10.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;281&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;260&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;313&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(16.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.358%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Sales to Customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;% Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2019;24 vs. &#x2019;23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2019;23 vs. &#x2019;22&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cardiovascular / Metabolism / Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,866&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,906&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,042&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;696&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;765&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;845&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,562&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,671&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,887&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;XARELTO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,373&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,365&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,473&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,373&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,365&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,473&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;OTHER&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;494&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;541&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;569&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;696&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;765&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;845&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,189&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,306&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,414&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(8.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;TOTAL INNOVATIVE MEDICINE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;33,970&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,169&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;28,604&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,994&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;23,590&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;23,959&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;56,964&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;54,759&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;52,563&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;MEDTECH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cardiovascular &lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,513&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,633&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,169&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;67.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,194&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,717&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,131&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,707&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,350&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,300&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;47.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;ELECTROPHYSIOLOGY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,738&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,458&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,529&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,230&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,901&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,267&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,688&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,937&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;ABIOMED&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,213&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,066&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;284&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;240&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,496&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,306&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;SHOCKWAVE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;442&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;122&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;564&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;OTHER CARDIOVASCULAR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;120&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;109&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;102&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;260&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;247&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;230&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;380&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;356&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;332&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Orthopaedics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,689&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,525&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,321&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,470&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,417&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,267&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,158&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,942&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,587&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.358%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Sales to Customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;% Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2019;24 vs. &#x2019;23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2019;23 vs. &#x2019;22&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;HIPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,057&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;996&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;943&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;581&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;564&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;571&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,638&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,560&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,514&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;KNEES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;922&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;896&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;851&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;623&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;559&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;508&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,545&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,456&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,359&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;TRAUMA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,949&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,882&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;989&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,049&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,979&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,871&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;SPINE, SPORTS &amp;amp; OTHER&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,696&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,684&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,645&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,230&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,263&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,198&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,926&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,947&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,843&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Surgery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,003&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,897&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,842&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,006&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,793&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,845&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,037&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,690&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;ADVANCED&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,838&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,833&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,784&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,837&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,785&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,488&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,671&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,569&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;GENERAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,165&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,198&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,113&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,192&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,168&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,008&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,358&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,366&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,121&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Vision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,128&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,086&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,990&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,986&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,859&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,146&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,072&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,849&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;CONTACT LENSES / OTHER&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,684&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,626&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,522&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,049&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,076&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,733&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,702&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,543&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;SURGICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;444&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;460&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;468&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;969&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;910&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;837&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,413&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,370&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,306&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.358%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Sales to Customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;% Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2019;24 vs. &#x2019;23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2019;23 vs. &#x2019;22&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;TOTAL MEDTECH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,332&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,275&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,377&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,525&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,125&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,857&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;30,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;27,427&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;WORLDWIDE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50,302&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;46,444&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;41,981&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,519&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,715&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,009&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$88,821&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;85,159&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;79,990&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;*&#160;&#160;&#160;&#160;percentage greater than 100% or not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt"&gt;Previously referred to as Interventional Solutions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt"&gt;Acquired on December 22, 2022&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt"&gt;Acquired on May 31, 2024&lt;/span&gt;&lt;/div&gt;</jnj:SalesBySegmentOfBusinessTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-434" decimals="-6" id="f-2077" unitRef="usd">11355000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-435" decimals="-6" id="f-2078" unitRef="usd">11539000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-436" decimals="-6" id="f-2079" unitRef="usd">11036000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-434"
      decimals="3"
      id="f-2080"
      unitRef="number">-0.016</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-435"
      decimals="3"
      id="f-2081"
      unitRef="number">0.046</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-437" decimals="-6" id="f-2082" unitRef="usd">6473000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-438" decimals="-6" id="f-2083" unitRef="usd">6513000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-439" decimals="-6" id="f-2084" unitRef="usd">5899000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-437"
      decimals="3"
      id="f-2085"
      unitRef="number">-0.006</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-438"
      decimals="3"
      id="f-2086"
      unitRef="number">0.104</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-440" decimals="-6" id="f-2087" unitRef="usd">17828000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-441" decimals="-6" id="f-2088" unitRef="usd">18052000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-442" decimals="-6" id="f-2089" unitRef="usd">16935000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-440"
      decimals="3"
      id="f-2090"
      unitRef="number">-0.012</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-441"
      decimals="3"
      id="f-2091"
      unitRef="number">0.066</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-443" decimals="-6" id="f-2092" unitRef="usd">1009000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-444" decimals="-6" id="f-2093" unitRef="usd">1143000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-445" decimals="-6" id="f-2094" unitRef="usd">1417000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-443"
      decimals="3"
      id="f-2095"
      unitRef="number">-0.117</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-444"
      decimals="3"
      id="f-2096"
      unitRef="number">-0.193</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-446" decimals="-6" id="f-2097" unitRef="usd">98000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-447" decimals="-6" id="f-2098" unitRef="usd">147000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-448" decimals="-6" id="f-2099" unitRef="usd">204000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-446"
      decimals="3"
      id="f-2100"
      unitRef="number">-0.330</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-447"
      decimals="3"
      id="f-2101"
      unitRef="number">-0.280</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-449" decimals="-6" id="f-2102" unitRef="usd">497000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-450" decimals="-6" id="f-2103" unitRef="usd">549000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-451" decimals="-6" id="f-2104" unitRef="usd">722000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-449"
      decimals="3"
      id="f-2105"
      unitRef="number">-0.095</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-450"
      decimals="3"
      id="f-2106"
      unitRef="number">-0.239</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-452" decimals="-6" id="f-2107" unitRef="usd">1605000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-453" decimals="-6" id="f-2108" unitRef="usd">1839000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-454" decimals="-6" id="f-2109" unitRef="usd">2343000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-452"
      decimals="3"
      id="f-2110"
      unitRef="number">-0.128</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-453"
      decimals="3"
      id="f-2111"
      unitRef="number">-0.215</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-455" decimals="-6" id="f-2112" unitRef="usd">1082000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-456" decimals="-6" id="f-2113" unitRef="usd">1124000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-457" decimals="-6" id="f-2114" unitRef="usd">1166000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-455"
      decimals="3"
      id="f-2115"
      unitRef="number">-0.038</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-456"
      decimals="3"
      id="f-2116"
      unitRef="number">-0.036</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-458" decimals="-6" id="f-2117" unitRef="usd">1108000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-459" decimals="-6" id="f-2118" unitRef="usd">1073000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-460" decimals="-6" id="f-2119" unitRef="usd">1017000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-458"
      decimals="3"
      id="f-2120"
      unitRef="number">0.033</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-459"
      decimals="3"
      id="f-2121"
      unitRef="number">0.054</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-461" decimals="-6" id="f-2122" unitRef="usd">2190000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-462" decimals="-6" id="f-2123" unitRef="usd">2197000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-463" decimals="-6" id="f-2124" unitRef="usd">2184000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-461"
      decimals="3"
      id="f-2125"
      unitRef="number">-0.003</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-462"
      decimals="3"
      id="f-2126"
      unitRef="number">0.006</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-464" decimals="-6" id="f-2127" unitRef="usd">6720000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-465" decimals="-6" id="f-2128" unitRef="usd">6966000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-466" decimals="-6" id="f-2129" unitRef="usd">6388000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-464"
      decimals="3"
      id="f-2130"
      unitRef="number">-0.035</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-465"
      decimals="3"
      id="f-2131"
      unitRef="number">0.090</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-467" decimals="-6" id="f-2132" unitRef="usd">3641000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-468" decimals="-6" id="f-2133" unitRef="usd">3892000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-469" decimals="-6" id="f-2134" unitRef="usd">3335000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-467"
      decimals="3"
      id="f-2135"
      unitRef="number">-0.064</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-468"
      decimals="3"
      id="f-2136"
      unitRef="number">0.167</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-470" decimals="-6" id="f-2137" unitRef="usd">10361000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-471" decimals="-6" id="f-2138" unitRef="usd">10858000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-472" decimals="-6" id="f-2139" unitRef="usd">9723000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-470"
      decimals="3"
      id="f-2140"
      unitRef="number">-0.046</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-471"
      decimals="3"
      id="f-2141"
      unitRef="number">0.117</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-473" decimals="-6" id="f-2142" unitRef="usd">2443000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-474" decimals="-6" id="f-2143" unitRef="usd">2147000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-475" decimals="-6" id="f-2144" unitRef="usd">1844000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-473"
      decimals="3"
      id="f-2145"
      unitRef="number">0.137</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-474"
      decimals="3"
      id="f-2146"
      unitRef="number">0.165</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-476" decimals="-6" id="f-2147" unitRef="usd">1227000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-477" decimals="-6" id="f-2148" unitRef="usd">999000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-478" decimals="-6" id="f-2149" unitRef="usd">824000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-476"
      decimals="3"
      id="f-2150"
      unitRef="number">0.228</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-477"
      decimals="3"
      id="f-2151"
      unitRef="number">0.212</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-479" decimals="-6" id="f-2152" unitRef="usd">3670000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-480" decimals="-6" id="f-2153" unitRef="usd">3147000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-481" decimals="-6" id="f-2154" unitRef="usd">2668000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-479"
      decimals="3"
      id="f-2155"
      unitRef="number">0.166</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-480"
      decimals="3"
      id="f-2156"
      unitRef="number">0.179</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-482" decimals="-6" id="f-2157" unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-483" decimals="-6" id="f-2158" unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-484" decimals="-6" id="f-2159" unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-482"
      decimals="3"
      id="f-2160"
      unitRef="number">-0.741</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-483"
      decimals="3"
      id="f-2161"
      unitRef="number">-0.338</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-485" decimals="-6" id="f-2162" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-486" decimals="-6" id="f-2163" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-487" decimals="-6" id="f-2164" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-485"
      decimals="3"
      id="f-2165"
      unitRef="number">0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-488" decimals="-6" id="f-2166" unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-489" decimals="-6" id="f-2167" unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-490" decimals="-6" id="f-2168" unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-488"
      decimals="3"
      id="f-2169"
      unitRef="number">-0.741</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-489"
      decimals="3"
      id="f-2170"
      unitRef="number">-0.338</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-491" decimals="-6" id="f-2171" unitRef="usd">1354000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-492" decimals="-6" id="f-2172" unitRef="usd">1500000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-493" decimals="-6" id="f-2173" unitRef="usd">1680000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-491"
      decimals="3"
      id="f-2174"
      unitRef="number">-0.098</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-492"
      decimals="3"
      id="f-2175"
      unitRef="number">-0.107</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-494" decimals="-6" id="f-2176" unitRef="usd">2042000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-495" decimals="-6" id="f-2177" unitRef="usd">2918000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-496" decimals="-6" id="f-2178" unitRef="usd">3769000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-494"
      decimals="3"
      id="f-2179"
      unitRef="number">-0.300</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-495"
      decimals="3"
      id="f-2180"
      unitRef="number">-0.226</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-497" decimals="-6" id="f-2181" unitRef="usd">3396000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-498" decimals="-6" id="f-2182" unitRef="usd">4418000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-499" decimals="-6" id="f-2183" unitRef="usd">5449000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-497"
      decimals="3"
      id="f-2184"
      unitRef="number">-0.231</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-498"
      decimals="3"
      id="f-2185"
      unitRef="number">-0.189</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-500" decimals="-6" id="f-2186" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-501" decimals="-6" id="f-2187" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-502" decimals="-6" id="f-2188" unitRef="usd">120000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-500"
      decimals="3"
      id="f-2189"
      unitRef="number">0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-503" decimals="-6" id="f-2190" unitRef="usd">198000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-504" decimals="-6" id="f-2191" unitRef="usd">1117000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-505" decimals="-6" id="f-2192" unitRef="usd">2059000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-503"
      decimals="3"
      id="f-2193"
      unitRef="number">-0.824</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-504"
      decimals="3"
      id="f-2194"
      unitRef="number">-0.458</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-506" decimals="-6" id="f-2195" unitRef="usd">198000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-507" decimals="-6" id="f-2196" unitRef="usd">1117000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-508" decimals="-6" id="f-2197" unitRef="usd">2179000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-506"
      decimals="3"
      id="f-2198"
      unitRef="number">-0.824</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-507"
      decimals="3"
      id="f-2199"
      unitRef="number">-0.488</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-509" decimals="-6" id="f-2200" unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-510" decimals="-6" id="f-2201" unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-511" decimals="-6" id="f-2202" unitRef="usd">36000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-509"
      decimals="3"
      id="f-2203"
      unitRef="number">-0.100</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-510"
      decimals="3"
      id="f-2204"
      unitRef="number">-0.037</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-512" decimals="-6" id="f-2205" unitRef="usd">1241000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-513" decimals="-6" id="f-2206" unitRef="usd">1115000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-514" decimals="-6" id="f-2207" unitRef="usd">972000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-512"
      decimals="3"
      id="f-2208"
      unitRef="number">0.112</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-513"
      decimals="3"
      id="f-2209"
      unitRef="number">0.148</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-515" decimals="-6" id="f-2210" unitRef="usd">1272000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-516" decimals="-6" id="f-2211" unitRef="usd">1150000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-517" decimals="-6" id="f-2212" unitRef="usd">1008000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-515"
      decimals="3"
      id="f-2213"
      unitRef="number">0.106</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-516"
      decimals="3"
      id="f-2214"
      unitRef="number">0.141</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-518" decimals="-6" id="f-2215" unitRef="usd">1311000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-519" decimals="-6" id="f-2216" unitRef="usd">1446000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-520" decimals="-6" id="f-2217" unitRef="usd">1494000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-518"
      decimals="3"
      id="f-2218"
      unitRef="number">-0.094</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-519"
      decimals="3"
      id="f-2219"
      unitRef="number">-0.032</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-521" decimals="-6" id="f-2220" unitRef="usd">401000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-522" decimals="-6" id="f-2221" unitRef="usd">408000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-523" decimals="-6" id="f-2222" unitRef="usd">449000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-521"
      decimals="3"
      id="f-2223"
      unitRef="number">-0.017</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-522"
      decimals="3"
      id="f-2224"
      unitRef="number">-0.092</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-524" decimals="-6" id="f-2225" unitRef="usd">1712000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-525" decimals="-6" id="f-2226" unitRef="usd">1854000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-526" decimals="-6" id="f-2227" unitRef="usd">1943000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-524"
      decimals="3"
      id="f-2228"
      unitRef="number">-0.077</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-525"
      decimals="3"
      id="f-2229"
      unitRef="number">-0.046</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-527" decimals="-6" id="f-2230" unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-528" decimals="-6" id="f-2231" unitRef="usd">19000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-529" decimals="-6" id="f-2232" unitRef="usd">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-527"
      decimals="3"
      id="f-2233"
      unitRef="number">-0.410</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-528"
      decimals="3"
      id="f-2234"
      unitRef="number">-0.345</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-530" decimals="-6" id="f-2235" unitRef="usd">203000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-531" decimals="-6" id="f-2236" unitRef="usd">278000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-532" decimals="-6" id="f-2237" unitRef="usd">289000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-530"
      decimals="3"
      id="f-2238"
      unitRef="number">-0.267</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-531"
      decimals="3"
      id="f-2239"
      unitRef="number">-0.038</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-533" decimals="-6" id="f-2240" unitRef="usd">214000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-534" decimals="-6" id="f-2241" unitRef="usd">297000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-535" decimals="-6" id="f-2242" unitRef="usd">318000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-533"
      decimals="3"
      id="f-2243"
      unitRef="number">-0.276</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-534"
      decimals="3"
      id="f-2244"
      unitRef="number">-0.067</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-536" decimals="-6" id="f-2245" unitRef="usd">4398000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-537" decimals="-6" id="f-2246" unitRef="usd">4065000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-538" decimals="-6" id="f-2247" unitRef="usd">3570000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-536"
      decimals="3"
      id="f-2248"
      unitRef="number">0.082</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-537"
      decimals="3"
      id="f-2249"
      unitRef="number">0.139</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-539" decimals="-6" id="f-2250" unitRef="usd">2718000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-540" decimals="-6" id="f-2251" unitRef="usd">3076000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-541" decimals="-6" id="f-2252" unitRef="usd">3323000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-539"
      decimals="3"
      id="f-2253"
      unitRef="number">-0.116</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-540"
      decimals="3"
      id="f-2254"
      unitRef="number">-0.075</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-542" decimals="-6" id="f-2255" unitRef="usd">7115000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-543" decimals="-6" id="f-2256" unitRef="usd">7140000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-544" decimals="-6" id="f-2257" unitRef="usd">6893000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-542"
      decimals="3"
      id="f-2258"
      unitRef="number">-0.004</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-543"
      decimals="3"
      id="f-2259"
      unitRef="number">0.036</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-545" decimals="-6" id="f-2260" unitRef="usd">134000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-546" decimals="-6" id="f-2261" unitRef="usd">230000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-547" decimals="-6" id="f-2262" unitRef="usd">151000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-545"
      decimals="3"
      id="f-2263"
      unitRef="number">-0.417</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-546"
      decimals="3"
      id="f-2264"
      unitRef="number">0.525</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-548" decimals="-6" id="f-2265" unitRef="usd">507000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-549" decimals="-6" id="f-2266" unitRef="usd">554000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-550" decimals="-6" id="f-2267" unitRef="usd">493000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-548"
      decimals="3"
      id="f-2268"
      unitRef="number">-0.084</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-549"
      decimals="3"
      id="f-2269"
      unitRef="number">0.122</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-551" decimals="-6" id="f-2270" unitRef="usd">641000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-552" decimals="-6" id="f-2271" unitRef="usd">783000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-553" decimals="-6" id="f-2272" unitRef="usd">644000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-551"
      decimals="3"
      id="f-2273"
      unitRef="number">-0.181</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-552"
      decimals="3"
      id="f-2274"
      unitRef="number">0.216</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-554" decimals="-6" id="f-2275" unitRef="usd">3125000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-555" decimals="-6" id="f-2276" unitRef="usd">2897000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-556" decimals="-6" id="f-2277" unitRef="usd">2714000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-554"
      decimals="3"
      id="f-2278"
      unitRef="number">0.079</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-555"
      decimals="3"
      id="f-2279"
      unitRef="number">0.067</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-557" decimals="-6" id="f-2280" unitRef="usd">1097000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-558" decimals="-6" id="f-2281" unitRef="usd">1218000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-559" decimals="-6" id="f-2282" unitRef="usd">1426000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-557"
      decimals="3"
      id="f-2283"
      unitRef="number">-0.099</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-558"
      decimals="3"
      id="f-2284"
      unitRef="number">-0.146</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-560" decimals="-6" id="f-2285" unitRef="usd">4222000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-561" decimals="-6" id="f-2286" unitRef="usd">4115000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-562" decimals="-6" id="f-2287" unitRef="usd">4140000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-560"
      decimals="3"
      id="f-2288"
      unitRef="number">0.026</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-561"
      decimals="3"
      id="f-2289"
      unitRef="number">-0.006</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-563" decimals="-6" id="f-2290" unitRef="usd">929000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-564" decimals="-6" id="f-2291" unitRef="usd">589000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-565" decimals="-6" id="f-2292" unitRef="usd">328000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-563"
      decimals="3"
      id="f-2293"
      unitRef="number">0.578</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-564"
      decimals="3"
      id="f-2294"
      unitRef="number">0.797</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-566" decimals="-6" id="f-2295" unitRef="usd">148000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-567" decimals="-6" id="f-2296" unitRef="usd">100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-568" decimals="-6" id="f-2297" unitRef="usd">46000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-566"
      decimals="3"
      id="f-2298"
      unitRef="number">0.482</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-569" decimals="-6" id="f-2299" unitRef="usd">1077000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-570" decimals="-6" id="f-2300" unitRef="usd">689000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-571" decimals="-6" id="f-2301" unitRef="usd">374000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-569"
      decimals="3"
      id="f-2302"
      unitRef="number">0.564</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-570"
      decimals="3"
      id="f-2303"
      unitRef="number">0.841</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-572" decimals="-6" id="f-2304" unitRef="usd">210000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-573" decimals="-6" id="f-2305" unitRef="usd">349000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-574" decimals="-6" id="f-2306" unitRef="usd">376000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-572"
      decimals="3"
      id="f-2307"
      unitRef="number">-0.398</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-573"
      decimals="3"
      id="f-2308"
      unitRef="number">-0.073</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-575" decimals="-6" id="f-2309" unitRef="usd">965000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-576" decimals="-6" id="f-2310" unitRef="usd">1204000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-577" decimals="-6" id="f-2311" unitRef="usd">1358000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-575"
      decimals="3"
      id="f-2312"
      unitRef="number">-0.198</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-576"
      decimals="3"
      id="f-2313"
      unitRef="number">-0.113</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-578" decimals="-6" id="f-2314" unitRef="usd">1175000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-579" decimals="-6" id="f-2315" unitRef="usd">1553000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-580" decimals="-6" id="f-2316" unitRef="usd">1734000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-578"
      decimals="3"
      id="f-2317"
      unitRef="number">-0.243</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-579"
      decimals="3"
      id="f-2318"
      unitRef="number">-0.104</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-581" decimals="-6" id="f-2319" unitRef="usd">10854000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-582" decimals="-6" id="f-2320" unitRef="usd">8462000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-583" decimals="-6" id="f-2321" unitRef="usd">6930000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-581"
      decimals="3"
      id="f-2322"
      unitRef="number">0.283</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-582"
      decimals="3"
      id="f-2323"
      unitRef="number">0.221</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-584" decimals="-6" id="f-2324" unitRef="usd">9926000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-585" decimals="-6" id="f-2325" unitRef="usd">9199000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-586" decimals="-6" id="f-2326" unitRef="usd">9052000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-584"
      decimals="3"
      id="f-2327"
      unitRef="number">0.079</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-585"
      decimals="3"
      id="f-2328"
      unitRef="number">0.016</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-587" decimals="-6" id="f-2329" unitRef="usd">20781000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-588" decimals="-6" id="f-2330" unitRef="usd">17661000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-589" decimals="-6" id="f-2331" unitRef="usd">15983000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-587"
      decimals="3"
      id="f-2332"
      unitRef="number">0.177</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-588"
      decimals="3"
      id="f-2333"
      unitRef="number">0.105</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-590" decimals="-6" id="f-2334" unitRef="usd">869000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-591" decimals="-6" id="f-2335" unitRef="usd">469000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-592" decimals="-6" id="f-2336" unitRef="usd">133000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-590"
      decimals="3"
      id="f-2337"
      unitRef="number">0.852</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-593" decimals="-6" id="f-2338" unitRef="usd">94000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-594" decimals="-6" id="f-2339" unitRef="usd">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-595" decimals="-6" id="f-2340" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-596" decimals="-6" id="f-2341" unitRef="usd">963000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-597" decimals="-6" id="f-2342" unitRef="usd">500000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-598" decimals="-6" id="f-2343" unitRef="usd">133000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-596"
      decimals="3"
      id="f-2344"
      unitRef="number">0.927</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-599" decimals="-6" id="f-2345" unitRef="usd">6588000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-600" decimals="-6" id="f-2346" unitRef="usd">5277000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-601" decimals="-6" id="f-2347" unitRef="usd">4210000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-599"
      decimals="3"
      id="f-2348"
      unitRef="number">0.248</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-600"
      decimals="3"
      id="f-2349"
      unitRef="number">0.254</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-602" decimals="-6" id="f-2350" unitRef="usd">5082000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-603" decimals="-6" id="f-2351" unitRef="usd">4467000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-604" decimals="-6" id="f-2352" unitRef="usd">3767000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-602"
      decimals="3"
      id="f-2353"
      unitRef="number">0.138</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-603"
      decimals="3"
      id="f-2354"
      unitRef="number">0.186</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-605" decimals="-6" id="f-2355" unitRef="usd">11670000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-606" decimals="-6" id="f-2356" unitRef="usd">9744000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-607" decimals="-6" id="f-2357" unitRef="usd">7977000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-605"
      decimals="3"
      id="f-2358"
      unitRef="number">0.198</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-606"
      decimals="3"
      id="f-2359"
      unitRef="number">0.222</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-608" decimals="-6" id="f-2360" unitRef="usd">1282000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-609" decimals="-6" id="f-2361" unitRef="usd">1065000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-610" decimals="-6" id="f-2362" unitRef="usd">968000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-608"
      decimals="3"
      id="f-2363"
      unitRef="number">0.203</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-609"
      decimals="3"
      id="f-2364"
      unitRef="number">0.100</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-611" decimals="-6" id="f-2365" unitRef="usd">1717000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-612" decimals="-6" id="f-2366" unitRef="usd">1322000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-613" decimals="-6" id="f-2367" unitRef="usd">913000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-611"
      decimals="3"
      id="f-2368"
      unitRef="number">0.298</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-612"
      decimals="3"
      id="f-2369"
      unitRef="number">0.448</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-614" decimals="-6" id="f-2370" unitRef="usd">2999000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-615" decimals="-6" id="f-2371" unitRef="usd">2387000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-616" decimals="-6" id="f-2372" unitRef="usd">1881000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-614"
      decimals="3"
      id="f-2373"
      unitRef="number">0.256</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-615"
      decimals="3"
      id="f-2374"
      unitRef="number">0.269</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-617" decimals="-6" id="f-2375" unitRef="usd">1020000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-618" decimals="-6" id="f-2376" unitRef="usd">1051000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-619" decimals="-6" id="f-2377" unitRef="usd">1390000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-617"
      decimals="3"
      id="f-2378"
      unitRef="number">-0.030</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-618"
      decimals="3"
      id="f-2379"
      unitRef="number">-0.244</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-620" decimals="-6" id="f-2380" unitRef="usd">2018000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-621" decimals="-6" id="f-2381" unitRef="usd">2214000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-622" decimals="-6" id="f-2382" unitRef="usd">2394000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-620"
      decimals="3"
      id="f-2383"
      unitRef="number">-0.088</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-621"
      decimals="3"
      id="f-2384"
      unitRef="number">-0.075</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-623" decimals="-6" id="f-2385" unitRef="usd">3038000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-624" decimals="-6" id="f-2386" unitRef="usd">3264000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-625" decimals="-6" id="f-2387" unitRef="usd">3784000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-623"
      decimals="3"
      id="f-2388"
      unitRef="number">-0.069</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-624"
      decimals="3"
      id="f-2389"
      unitRef="number">-0.137</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-626" decimals="-6" id="f-2390" unitRef="usd">418000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-627" decimals="-6" id="f-2391" unitRef="usd">334000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-628" decimals="-6" id="f-2392" unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-626"
      decimals="3"
      id="f-2393"
      unitRef="number">0.253</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-629" decimals="-6" id="f-2394" unitRef="usd">131000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-630" decimals="-6" id="f-2395" unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-631" decimals="-6" id="f-2396" unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-632" decimals="-6" id="f-2397" unitRef="usd">549000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-633" decimals="-6" id="f-2398" unitRef="usd">395000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-634" decimals="-6" id="f-2399" unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-632"
      decimals="3"
      id="f-2400"
      unitRef="number">0.388</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-635" decimals="-6" id="f-2401" unitRef="usd">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-636" decimals="-6" id="f-2402" unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-637" decimals="-6" id="f-2403" unitRef="usd">74000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-635"
      decimals="3"
      id="f-2404"
      unitRef="number">-0.322</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-636"
      decimals="3"
      id="f-2405"
      unitRef="number">-0.321</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-638" decimals="-6" id="f-2406" unitRef="usd">597000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-639" decimals="-6" id="f-2407" unitRef="usd">837000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-640" decimals="-6" id="f-2408" unitRef="usd">1696000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-638"
      decimals="3"
      id="f-2409"
      unitRef="number">-0.286</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-639"
      decimals="3"
      id="f-2410"
      unitRef="number">-0.507</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-641" decimals="-6" id="f-2411" unitRef="usd">631000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-642" decimals="-6" id="f-2412" unitRef="usd">887000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-643" decimals="-6" id="f-2413" unitRef="usd">1770000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-641"
      decimals="3"
      id="f-2414"
      unitRef="number">-0.288</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-642"
      decimals="3"
      id="f-2415"
      unitRef="number">-0.499</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-644" decimals="-6" id="f-2416" unitRef="usd">643000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-645" decimals="-6" id="f-2417" unitRef="usd">215000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-646" decimals="-6" id="f-2418" unitRef="usd">144000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-645"
      decimals="3"
      id="f-2419"
      unitRef="number">0.493</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-647" decimals="-6" id="f-2420" unitRef="usd">288000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-648" decimals="-6" id="f-2421" unitRef="usd">269000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-649" decimals="-6" id="f-2422" unitRef="usd">280000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-647"
      decimals="3"
      id="f-2423"
      unitRef="number">0.071</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-648"
      decimals="3"
      id="f-2424"
      unitRef="number">-0.039</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-650" decimals="-6" id="f-2425" unitRef="usd">931000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-651" decimals="-6" id="f-2426" unitRef="usd">484000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-652" decimals="-6" id="f-2427" unitRef="usd">423000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-650"
      decimals="3"
      id="f-2428"
      unitRef="number">0.925</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-651"
      decimals="3"
      id="f-2429"
      unitRef="number">0.144</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-653" decimals="-6" id="f-2430" unitRef="usd">3143000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-654" decimals="-6" id="f-2431" unitRef="usd">2697000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-655" decimals="-6" id="f-2432" unitRef="usd">2346000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-653"
      decimals="3"
      id="f-2433"
      unitRef="number">0.165</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-654"
      decimals="3"
      id="f-2434"
      unitRef="number">0.150</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-656" decimals="-6" id="f-2435" unitRef="usd">1140000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-657" decimals="-6" id="f-2436" unitRef="usd">1117000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-658" decimals="-6" id="f-2437" unitRef="usd">1071000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-656"
      decimals="3"
      id="f-2438"
      unitRef="number">0.020</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-657"
      decimals="3"
      id="f-2439"
      unitRef="number">0.043</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-659" decimals="-6" id="f-2440" unitRef="usd">4282000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-660" decimals="-6" id="f-2441" unitRef="usd">3815000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-661" decimals="-6" id="f-2442" unitRef="usd">3417000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-659"
      decimals="3"
      id="f-2443"
      unitRef="number">0.123</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-660"
      decimals="3"
      id="f-2444"
      unitRef="number">0.116</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-662" decimals="-6" id="f-2445" unitRef="usd">1520000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-663" decimals="-6" id="f-2446" unitRef="usd">1292000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-664" decimals="-6" id="f-2447" unitRef="usd">1132000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-662"
      decimals="3"
      id="f-2448"
      unitRef="number">0.177</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-663"
      decimals="3"
      id="f-2449"
      unitRef="number">0.141</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-665" decimals="-6" id="f-2450" unitRef="usd">664000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-666" decimals="-6" id="f-2451" unitRef="usd">681000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-667" decimals="-6" id="f-2452" unitRef="usd">651000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-665"
      decimals="3"
      id="f-2453"
      unitRef="number">-0.024</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-666"
      decimals="3"
      id="f-2454"
      unitRef="number">0.046</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-668" decimals="-6" id="f-2455" unitRef="usd">2184000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-669" decimals="-6" id="f-2456" unitRef="usd">1973000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-670" decimals="-6" id="f-2457" unitRef="usd">1783000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-668"
      decimals="3"
      id="f-2458"
      unitRef="number">0.107</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-669"
      decimals="3"
      id="f-2459"
      unitRef="number">0.106</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-671" decimals="-6" id="f-2460" unitRef="usd">1511000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-672" decimals="-6" id="f-2461" unitRef="usd">1326000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-673" decimals="-6" id="f-2462" unitRef="usd">1104000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-671"
      decimals="3"
      id="f-2463"
      unitRef="number">0.139</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-672"
      decimals="3"
      id="f-2464"
      unitRef="number">0.201</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-674" decimals="-6" id="f-2465" unitRef="usd">307000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-675" decimals="-6" id="f-2466" unitRef="usd">255000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-676" decimals="-6" id="f-2467" unitRef="usd">218000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-674"
      decimals="3"
      id="f-2468"
      unitRef="number">0.201</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-675"
      decimals="3"
      id="f-2469"
      unitRef="number">0.173</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-677" decimals="-6" id="f-2470" unitRef="usd">1817000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-678" decimals="-6" id="f-2471" unitRef="usd">1582000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-679" decimals="-6" id="f-2472" unitRef="usd">1322000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-677"
      decimals="3"
      id="f-2473"
      unitRef="number">0.149</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-678"
      decimals="3"
      id="f-2474"
      unitRef="number">0.197</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-680" decimals="-6" id="f-2475" unitRef="usd">112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-681" decimals="-6" id="f-2476" unitRef="usd">79000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-682" decimals="-6" id="f-2477" unitRef="usd">110000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-680"
      decimals="3"
      id="f-2478"
      unitRef="number">0.418</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-681"
      decimals="3"
      id="f-2479"
      unitRef="number">-0.286</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-683" decimals="-6" id="f-2480" unitRef="usd">169000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-684" decimals="-6" id="f-2481" unitRef="usd">182000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-685" decimals="-6" id="f-2482" unitRef="usd">202000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-683"
      decimals="3"
      id="f-2483"
      unitRef="number">-0.069</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-684"
      decimals="3"
      id="f-2484"
      unitRef="number">-0.103</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-686" decimals="-6" id="f-2485" unitRef="usd">281000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-687" decimals="-6" id="f-2486" unitRef="usd">260000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-688" decimals="-6" id="f-2487" unitRef="usd">313000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-686"
      decimals="3"
      id="f-2488"
      unitRef="number">0.079</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-687"
      decimals="3"
      id="f-2489"
      unitRef="number">-0.167</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-689" decimals="-6" id="f-2490" unitRef="usd">2866000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-690" decimals="-6" id="f-2491" unitRef="usd">2906000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-691" decimals="-6" id="f-2492" unitRef="usd">3042000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-689"
      decimals="3"
      id="f-2493"
      unitRef="number">-0.014</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-690"
      decimals="3"
      id="f-2494"
      unitRef="number">-0.045</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-692" decimals="-6" id="f-2495" unitRef="usd">696000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-693" decimals="-6" id="f-2496" unitRef="usd">765000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-694" decimals="-6" id="f-2497" unitRef="usd">845000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-692"
      decimals="3"
      id="f-2498"
      unitRef="number">-0.091</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-693"
      decimals="3"
      id="f-2499"
      unitRef="number">-0.094</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-695" decimals="-6" id="f-2500" unitRef="usd">3562000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-696" decimals="-6" id="f-2501" unitRef="usd">3671000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-697" decimals="-6" id="f-2502" unitRef="usd">3887000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-695"
      decimals="3"
      id="f-2503"
      unitRef="number">-0.030</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-696"
      decimals="3"
      id="f-2504"
      unitRef="number">-0.055</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-698" decimals="-6" id="f-2505" unitRef="usd">2373000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-699" decimals="-6" id="f-2506" unitRef="usd">2365000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-700" decimals="-6" id="f-2507" unitRef="usd">2473000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-698"
      decimals="3"
      id="f-2508"
      unitRef="number">0.003</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-699"
      decimals="3"
      id="f-2509"
      unitRef="number">-0.044</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-701" decimals="-6" id="f-2510" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-702" decimals="-6" id="f-2511" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-703" decimals="-6" id="f-2512" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-701"
      decimals="3"
      id="f-2513"
      unitRef="number">0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-702"
      decimals="3"
      id="f-2514"
      unitRef="number">0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-704" decimals="-6" id="f-2515" unitRef="usd">2373000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-705" decimals="-6" id="f-2516" unitRef="usd">2365000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-706" decimals="-6" id="f-2517" unitRef="usd">2473000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-704"
      decimals="3"
      id="f-2518"
      unitRef="number">0.003</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-705"
      decimals="3"
      id="f-2519"
      unitRef="number">-0.044</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-707" decimals="-6" id="f-2520" unitRef="usd">494000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-708" decimals="-6" id="f-2521" unitRef="usd">541000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-709" decimals="-6" id="f-2522" unitRef="usd">569000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-707"
      decimals="3"
      id="f-2523"
      unitRef="number">-0.088</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-708"
      decimals="3"
      id="f-2524"
      unitRef="number">-0.050</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-710" decimals="-6" id="f-2525" unitRef="usd">696000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-711" decimals="-6" id="f-2526" unitRef="usd">765000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-712" decimals="-6" id="f-2527" unitRef="usd">845000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-710"
      decimals="3"
      id="f-2528"
      unitRef="number">-0.091</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-711"
      decimals="3"
      id="f-2529"
      unitRef="number">-0.094</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-713" decimals="-6" id="f-2530" unitRef="usd">1189000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-714" decimals="-6" id="f-2531" unitRef="usd">1306000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-715" decimals="-6" id="f-2532" unitRef="usd">1414000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-713"
      decimals="3"
      id="f-2533"
      unitRef="number">-0.089</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-714"
      decimals="3"
      id="f-2534"
      unitRef="number">-0.076</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-716" decimals="-6" id="f-2535" unitRef="usd">33970000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-717" decimals="-6" id="f-2536" unitRef="usd">31169000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-718" decimals="-6" id="f-2537" unitRef="usd">28604000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-716"
      decimals="3"
      id="f-2538"
      unitRef="number">0.090</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-717"
      decimals="3"
      id="f-2539"
      unitRef="number">0.090</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-719" decimals="-6" id="f-2540" unitRef="usd">22994000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-720" decimals="-6" id="f-2541" unitRef="usd">23590000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-721" decimals="-6" id="f-2542" unitRef="usd">23959000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-719"
      decimals="3"
      id="f-2543"
      unitRef="number">-0.025</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-720"
      decimals="3"
      id="f-2544"
      unitRef="number">-0.015</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-114" decimals="-6" id="f-2545" unitRef="usd">56964000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-110" decimals="-6" id="f-2546" unitRef="usd">54759000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-722" decimals="-6" id="f-2547" unitRef="usd">52563000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-114"
      decimals="3"
      id="f-2548"
      unitRef="number">0.040</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-110"
      decimals="3"
      id="f-2549"
      unitRef="number">0.042</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-723" decimals="-6" id="f-2550" unitRef="usd">4513000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-724" decimals="-6" id="f-2551" unitRef="usd">3633000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-725" decimals="-6" id="f-2552" unitRef="usd">2169000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-723"
      decimals="3"
      id="f-2553"
      unitRef="number">0.242</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-724"
      decimals="3"
      id="f-2554"
      unitRef="number">0.675</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-726" decimals="-6" id="f-2555" unitRef="usd">3194000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-727" decimals="-6" id="f-2556" unitRef="usd">2717000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-728" decimals="-6" id="f-2557" unitRef="usd">2131000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-726"
      decimals="3"
      id="f-2558"
      unitRef="number">0.176</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-727"
      decimals="3"
      id="f-2559"
      unitRef="number">0.275</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-729" decimals="-6" id="f-2560" unitRef="usd">7707000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-730" decimals="-6" id="f-2561" unitRef="usd">6350000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-731" decimals="-6" id="f-2562" unitRef="usd">4300000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-729"
      decimals="3"
      id="f-2563"
      unitRef="number">0.214</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-730"
      decimals="3"
      id="f-2564"
      unitRef="number">0.477</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-732" decimals="-6" id="f-2565" unitRef="usd">2738000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-733" decimals="-6" id="f-2566" unitRef="usd">2458000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-734" decimals="-6" id="f-2567" unitRef="usd">2036000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-732"
      decimals="3"
      id="f-2568"
      unitRef="number">0.114</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-733"
      decimals="3"
      id="f-2569"
      unitRef="number">0.207</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-735" decimals="-6" id="f-2570" unitRef="usd">2529000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-736" decimals="-6" id="f-2571" unitRef="usd">2230000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-737" decimals="-6" id="f-2572" unitRef="usd">1901000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-735"
      decimals="3"
      id="f-2573"
      unitRef="number">0.134</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-736"
      decimals="3"
      id="f-2574"
      unitRef="number">0.173</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-738" decimals="-6" id="f-2575" unitRef="usd">5267000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-739" decimals="-6" id="f-2576" unitRef="usd">4688000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-740" decimals="-6" id="f-2577" unitRef="usd">3937000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-738"
      decimals="3"
      id="f-2578"
      unitRef="number">0.123</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-739"
      decimals="3"
      id="f-2579"
      unitRef="number">0.191</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-741" decimals="-6" id="f-2580" unitRef="usd">1213000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-742" decimals="-6" id="f-2581" unitRef="usd">1066000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-743" decimals="-6" id="f-2582" unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-741"
      decimals="3"
      id="f-2583"
      unitRef="number">0.137</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-744" decimals="-6" id="f-2584" unitRef="usd">284000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-745" decimals="-6" id="f-2585" unitRef="usd">240000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-746" decimals="-6" id="f-2586" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-744"
      decimals="3"
      id="f-2587"
      unitRef="number">0.182</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-747" decimals="-6" id="f-2588" unitRef="usd">1496000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-748" decimals="-6" id="f-2589" unitRef="usd">1306000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-749" decimals="-6" id="f-2590" unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-747"
      decimals="3"
      id="f-2591"
      unitRef="number">0.145</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-750" decimals="-6" id="f-2592" unitRef="usd">442000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-751" decimals="-6" id="f-2593" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-752" decimals="-6" id="f-2594" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-753" decimals="-6" id="f-2595" unitRef="usd">122000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-754" decimals="-6" id="f-2596" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-755" decimals="-6" id="f-2597" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-756" decimals="-6" id="f-2598" unitRef="usd">564000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-757" decimals="-6" id="f-2599" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-758" decimals="-6" id="f-2600" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-759" decimals="-6" id="f-2601" unitRef="usd">120000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-760" decimals="-6" id="f-2602" unitRef="usd">109000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-761" decimals="-6" id="f-2603" unitRef="usd">102000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-759"
      decimals="3"
      id="f-2604"
      unitRef="number">0.107</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-760"
      decimals="3"
      id="f-2605"
      unitRef="number">0.067</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-762" decimals="-6" id="f-2606" unitRef="usd">260000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-763" decimals="-6" id="f-2607" unitRef="usd">247000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-764" decimals="-6" id="f-2608" unitRef="usd">230000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-762"
      decimals="3"
      id="f-2609"
      unitRef="number">0.053</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-763"
      decimals="3"
      id="f-2610"
      unitRef="number">0.073</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-765" decimals="-6" id="f-2611" unitRef="usd">380000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-766" decimals="-6" id="f-2612" unitRef="usd">356000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-767" decimals="-6" id="f-2613" unitRef="usd">332000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-765"
      decimals="3"
      id="f-2614"
      unitRef="number">0.069</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-766"
      decimals="3"
      id="f-2615"
      unitRef="number">0.071</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-768" decimals="-6" id="f-2616" unitRef="usd">5689000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-769" decimals="-6" id="f-2617" unitRef="usd">5525000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-770" decimals="-6" id="f-2618" unitRef="usd">5321000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-768"
      decimals="3"
      id="f-2619"
      unitRef="number">0.030</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-769"
      decimals="3"
      id="f-2620"
      unitRef="number">0.038</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-771" decimals="-6" id="f-2621" unitRef="usd">3470000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-772" decimals="-6" id="f-2622" unitRef="usd">3417000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-773" decimals="-6" id="f-2623" unitRef="usd">3267000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-771"
      decimals="3"
      id="f-2624"
      unitRef="number">0.015</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-772"
      decimals="3"
      id="f-2625"
      unitRef="number">0.046</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-774" decimals="-6" id="f-2626" unitRef="usd">9158000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-775" decimals="-6" id="f-2627" unitRef="usd">8942000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-776" decimals="-6" id="f-2628" unitRef="usd">8587000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-774"
      decimals="3"
      id="f-2629"
      unitRef="number">0.024</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-775"
      decimals="3"
      id="f-2630"
      unitRef="number">0.041</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-777" decimals="-6" id="f-2631" unitRef="usd">1057000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-778" decimals="-6" id="f-2632" unitRef="usd">996000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-779" decimals="-6" id="f-2633" unitRef="usd">943000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-777"
      decimals="3"
      id="f-2634"
      unitRef="number">0.062</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-778"
      decimals="3"
      id="f-2635"
      unitRef="number">0.056</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-780" decimals="-6" id="f-2636" unitRef="usd">581000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-781" decimals="-6" id="f-2637" unitRef="usd">564000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-782" decimals="-6" id="f-2638" unitRef="usd">571000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-780"
      decimals="3"
      id="f-2639"
      unitRef="number">0.030</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-781"
      decimals="3"
      id="f-2640"
      unitRef="number">-0.012</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-783" decimals="-6" id="f-2641" unitRef="usd">1638000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-784" decimals="-6" id="f-2642" unitRef="usd">1560000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-785" decimals="-6" id="f-2643" unitRef="usd">1514000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-783"
      decimals="3"
      id="f-2644"
      unitRef="number">0.050</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-784"
      decimals="3"
      id="f-2645"
      unitRef="number">0.030</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-786" decimals="-6" id="f-2646" unitRef="usd">922000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-787" decimals="-6" id="f-2647" unitRef="usd">896000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-788" decimals="-6" id="f-2648" unitRef="usd">851000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-786"
      decimals="3"
      id="f-2649"
      unitRef="number">0.029</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-787"
      decimals="3"
      id="f-2650"
      unitRef="number">0.053</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-789" decimals="-6" id="f-2651" unitRef="usd">623000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-790" decimals="-6" id="f-2652" unitRef="usd">559000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-791" decimals="-6" id="f-2653" unitRef="usd">508000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-789"
      decimals="3"
      id="f-2654"
      unitRef="number">0.113</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-790"
      decimals="3"
      id="f-2655"
      unitRef="number">0.102</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-792" decimals="-6" id="f-2656" unitRef="usd">1545000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-793" decimals="-6" id="f-2657" unitRef="usd">1456000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-794" decimals="-6" id="f-2658" unitRef="usd">1359000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-792"
      decimals="3"
      id="f-2659"
      unitRef="number">0.061</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-793"
      decimals="3"
      id="f-2660"
      unitRef="number">0.071</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-795" decimals="-6" id="f-2661" unitRef="usd">2013000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-796" decimals="-6" id="f-2662" unitRef="usd">1949000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-797" decimals="-6" id="f-2663" unitRef="usd">1882000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-795"
      decimals="3"
      id="f-2664"
      unitRef="number">0.033</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-796"
      decimals="3"
      id="f-2665"
      unitRef="number">0.036</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-798" decimals="-6" id="f-2666" unitRef="usd">1036000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-799" decimals="-6" id="f-2667" unitRef="usd">1030000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-800" decimals="-6" id="f-2668" unitRef="usd">989000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-798"
      decimals="3"
      id="f-2669"
      unitRef="number">0.006</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-799"
      decimals="3"
      id="f-2670"
      unitRef="number">0.041</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-801" decimals="-6" id="f-2671" unitRef="usd">3049000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-802" decimals="-6" id="f-2672" unitRef="usd">2979000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-803" decimals="-6" id="f-2673" unitRef="usd">2871000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-801"
      decimals="3"
      id="f-2674"
      unitRef="number">0.023</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-802"
      decimals="3"
      id="f-2675"
      unitRef="number">0.038</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-804" decimals="-6" id="f-2676" unitRef="usd">1696000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-805" decimals="-6" id="f-2677" unitRef="usd">1684000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-806" decimals="-6" id="f-2678" unitRef="usd">1645000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-804"
      decimals="3"
      id="f-2679"
      unitRef="number">0.007</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-805"
      decimals="3"
      id="f-2680"
      unitRef="number">0.024</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-807" decimals="-6" id="f-2681" unitRef="usd">1230000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-808" decimals="-6" id="f-2682" unitRef="usd">1263000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-809" decimals="-6" id="f-2683" unitRef="usd">1198000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-807"
      decimals="3"
      id="f-2684"
      unitRef="number">-0.026</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-808"
      decimals="3"
      id="f-2685"
      unitRef="number">0.054</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-810" decimals="-6" id="f-2686" unitRef="usd">2926000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-811" decimals="-6" id="f-2687" unitRef="usd">2947000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-812" decimals="-6" id="f-2688" unitRef="usd">2843000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-810"
      decimals="3"
      id="f-2689"
      unitRef="number">-0.007</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-811"
      decimals="3"
      id="f-2690"
      unitRef="number">0.037</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-813" decimals="-6" id="f-2691" unitRef="usd">4003000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-814" decimals="-6" id="f-2692" unitRef="usd">4031000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-815" decimals="-6" id="f-2693" unitRef="usd">3897000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-813"
      decimals="3"
      id="f-2694"
      unitRef="number">-0.007</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-814"
      decimals="3"
      id="f-2695"
      unitRef="number">0.034</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-816" decimals="-6" id="f-2696" unitRef="usd">5842000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-817" decimals="-6" id="f-2697" unitRef="usd">6006000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-818" decimals="-6" id="f-2698" unitRef="usd">5793000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-816"
      decimals="3"
      id="f-2699"
      unitRef="number">-0.027</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-817"
      decimals="3"
      id="f-2700"
      unitRef="number">0.037</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-819" decimals="-6" id="f-2701" unitRef="usd">9845000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-820" decimals="-6" id="f-2702" unitRef="usd">10037000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-821" decimals="-6" id="f-2703" unitRef="usd">9690000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-819"
      decimals="3"
      id="f-2704"
      unitRef="number">-0.019</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-820"
      decimals="3"
      id="f-2705"
      unitRef="number">0.036</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-822" decimals="-6" id="f-2706" unitRef="usd">1838000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-823" decimals="-6" id="f-2707" unitRef="usd">1833000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-824" decimals="-6" id="f-2708" unitRef="usd">1784000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-822"
      decimals="3"
      id="f-2709"
      unitRef="number">0.002</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-823"
      decimals="3"
      id="f-2710"
      unitRef="number">0.028</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-825" decimals="-6" id="f-2711" unitRef="usd">2650000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-826" decimals="-6" id="f-2712" unitRef="usd">2837000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-827" decimals="-6" id="f-2713" unitRef="usd">2785000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-825"
      decimals="3"
      id="f-2714"
      unitRef="number">-0.066</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-826"
      decimals="3"
      id="f-2715"
      unitRef="number">0.019</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-828" decimals="-6" id="f-2716" unitRef="usd">4488000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-829" decimals="-6" id="f-2717" unitRef="usd">4671000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-830" decimals="-6" id="f-2718" unitRef="usd">4569000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-828"
      decimals="3"
      id="f-2719"
      unitRef="number">-0.039</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-829"
      decimals="3"
      id="f-2720"
      unitRef="number">0.022</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-831" decimals="-6" id="f-2721" unitRef="usd">2165000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-832" decimals="-6" id="f-2722" unitRef="usd">2198000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-833" decimals="-6" id="f-2723" unitRef="usd">2113000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-831"
      decimals="3"
      id="f-2724"
      unitRef="number">-0.015</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-832"
      decimals="3"
      id="f-2725"
      unitRef="number">0.040</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-834" decimals="-6" id="f-2726" unitRef="usd">3192000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-835" decimals="-6" id="f-2727" unitRef="usd">3168000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-836" decimals="-6" id="f-2728" unitRef="usd">3008000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-834"
      decimals="3"
      id="f-2729"
      unitRef="number">0.008</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-835"
      decimals="3"
      id="f-2730"
      unitRef="number">0.053</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-837" decimals="-6" id="f-2731" unitRef="usd">5358000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-838" decimals="-6" id="f-2732" unitRef="usd">5366000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-839" decimals="-6" id="f-2733" unitRef="usd">5121000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-837"
      decimals="3"
      id="f-2734"
      unitRef="number">-0.002</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-838"
      decimals="3"
      id="f-2735"
      unitRef="number">0.048</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-840" decimals="-6" id="f-2736" unitRef="usd">2128000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-841" decimals="-6" id="f-2737" unitRef="usd">2086000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-842" decimals="-6" id="f-2738" unitRef="usd">1990000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-840"
      decimals="3"
      id="f-2739"
      unitRef="number">0.020</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-841"
      decimals="3"
      id="f-2740"
      unitRef="number">0.048</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-843" decimals="-6" id="f-2741" unitRef="usd">3018000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-844" decimals="-6" id="f-2742" unitRef="usd">2986000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-845" decimals="-6" id="f-2743" unitRef="usd">2859000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-843"
      decimals="3"
      id="f-2744"
      unitRef="number">0.011</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-844"
      decimals="3"
      id="f-2745"
      unitRef="number">0.045</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-846" decimals="-6" id="f-2746" unitRef="usd">5146000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-847" decimals="-6" id="f-2747" unitRef="usd">5072000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-848" decimals="-6" id="f-2748" unitRef="usd">4849000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-846"
      decimals="3"
      id="f-2749"
      unitRef="number">0.015</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-847"
      decimals="3"
      id="f-2750"
      unitRef="number">0.046</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-849" decimals="-6" id="f-2751" unitRef="usd">1684000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-850" decimals="-6" id="f-2752" unitRef="usd">1626000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-851" decimals="-6" id="f-2753" unitRef="usd">1522000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-849"
      decimals="3"
      id="f-2754"
      unitRef="number">0.036</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-850"
      decimals="3"
      id="f-2755"
      unitRef="number">0.068</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-852" decimals="-6" id="f-2756" unitRef="usd">2049000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-853" decimals="-6" id="f-2757" unitRef="usd">2076000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-854" decimals="-6" id="f-2758" unitRef="usd">2022000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-852"
      decimals="3"
      id="f-2759"
      unitRef="number">-0.013</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-853"
      decimals="3"
      id="f-2760"
      unitRef="number">0.027</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-855" decimals="-6" id="f-2761" unitRef="usd">3733000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-856" decimals="-6" id="f-2762" unitRef="usd">3702000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-857" decimals="-6" id="f-2763" unitRef="usd">3543000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-855"
      decimals="3"
      id="f-2764"
      unitRef="number">0.008</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-856"
      decimals="3"
      id="f-2765"
      unitRef="number">0.045</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-858" decimals="-6" id="f-2766" unitRef="usd">444000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-859" decimals="-6" id="f-2767" unitRef="usd">460000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-860" decimals="-6" id="f-2768" unitRef="usd">468000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-858"
      decimals="3"
      id="f-2769"
      unitRef="number">-0.034</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-859"
      decimals="3"
      id="f-2770"
      unitRef="number">-0.018</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-861" decimals="-6" id="f-2771" unitRef="usd">969000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-862" decimals="-6" id="f-2772" unitRef="usd">910000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-863" decimals="-6" id="f-2773" unitRef="usd">837000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-861"
      decimals="3"
      id="f-2774"
      unitRef="number">0.065</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-862"
      decimals="3"
      id="f-2775"
      unitRef="number">0.086</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-864" decimals="-6" id="f-2776" unitRef="usd">1413000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-865" decimals="-6" id="f-2777" unitRef="usd">1370000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-866" decimals="-6" id="f-2778" unitRef="usd">1306000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-864"
      decimals="3"
      id="f-2779"
      unitRef="number">0.032</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-865"
      decimals="3"
      id="f-2780"
      unitRef="number">0.049</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-867" decimals="-6" id="f-2781" unitRef="usd">16332000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-868" decimals="-6" id="f-2782" unitRef="usd">15275000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-869" decimals="-6" id="f-2783" unitRef="usd">13377000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-867"
      decimals="3"
      id="f-2784"
      unitRef="number">0.069</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-868"
      decimals="3"
      id="f-2785"
      unitRef="number">0.142</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-870" decimals="-6" id="f-2786" unitRef="usd">15525000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-871" decimals="-6" id="f-2787" unitRef="usd">15125000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-872" decimals="-6" id="f-2788" unitRef="usd">14050000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-870"
      decimals="3"
      id="f-2789"
      unitRef="number">0.026</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-871"
      decimals="3"
      id="f-2790"
      unitRef="number">0.077</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-115" decimals="-6" id="f-2791" unitRef="usd">31857000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-111" decimals="-6" id="f-2792" unitRef="usd">30400000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-873" decimals="-6" id="f-2793" unitRef="usd">27427000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-115"
      decimals="3"
      id="f-2794"
      unitRef="number">0.048</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-111"
      decimals="3"
      id="f-2795"
      unitRef="number">0.108</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-874" decimals="-6" id="f-2796" unitRef="usd">50302000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-875" decimals="-6" id="f-2797" unitRef="usd">46444000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-876" decimals="-6" id="f-2798" unitRef="usd">41981000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-874"
      decimals="3"
      id="f-2799"
      unitRef="number">0.083</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-875"
      decimals="3"
      id="f-2800"
      unitRef="number">0.106</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-877" decimals="-6" id="f-2801" unitRef="usd">38519000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-878" decimals="-6" id="f-2802" unitRef="usd">38715000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-879" decimals="-6" id="f-2803" unitRef="usd">38009000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-877"
      decimals="3"
      id="f-2804"
      unitRef="number">-0.005</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="c-878"
      decimals="3"
      id="f-2805"
      unitRef="number">0.019</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-6" id="f-2806" unitRef="usd">88821000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-6" id="f-2807" unitRef="usd">85159000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-6" id="f-2808" unitRef="usd">79990000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness contextRef="c-1" decimals="3" id="f-2809" unitRef="number">0.043</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness contextRef="c-12" decimals="3" id="f-2810" unitRef="number">0.065</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="c-1" id="f-2811">&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.679%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.750%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Income Before Tax by Segment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Innovative&lt;br/&gt;Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;MedTech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Innovative&lt;br/&gt;Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;MedTech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Innovative&lt;br/&gt;Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;MedTech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Sales to customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$56,964&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,857&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;54,759&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;30,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;52,563&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;27,427&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,345&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,715&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,722&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,066&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,397&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Selling, marketing and administrative &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,906&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,812&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,842&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,476&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,714&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,537&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,529&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,703&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,963&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,122&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,642&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,493&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other segment items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(426)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;257&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;993&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(589)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,494&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;553&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Segment income before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$18,919&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,740&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,659&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,246&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,669&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,915&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,647&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,447&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,094&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less: Expense not allocated to segments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,972&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,853&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;735&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Worldwide total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$16,687&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;15,062&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;19,359&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-880" decimals="-6" id="f-2812" unitRef="usd">56964000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-881" decimals="-6" id="f-2813" unitRef="usd">31857000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-882" decimals="-6" id="f-2814" unitRef="usd">54759000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-883" decimals="-6" id="f-2815" unitRef="usd">30400000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-884" decimals="-6" id="f-2816" unitRef="usd">52563000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-885" decimals="-6" id="f-2817" unitRef="usd">27427000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-880" decimals="-6" id="f-2818" unitRef="usd">14036000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-881" decimals="-6" id="f-2819" unitRef="usd">13345000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-882" decimals="-6" id="f-2820" unitRef="usd">13715000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-883" decimals="-6" id="f-2821" unitRef="usd">12722000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-884" decimals="-6" id="f-2822" unitRef="usd">14066000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-885" decimals="-6" id="f-2823" unitRef="usd">10397000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-880" decimals="-6" id="f-2824" unitRef="usd">10906000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-881" decimals="-6" id="f-2825" unitRef="usd">10812000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-882" decimals="-6" id="f-2826" unitRef="usd">9842000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-883" decimals="-6" id="f-2827" unitRef="usd">10476000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-884" decimals="-6" id="f-2828" unitRef="usd">9714000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-885" decimals="-6" id="f-2829" unitRef="usd">9537000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-880" decimals="-6" id="f-2830" unitRef="usd">13529000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-881" decimals="-6" id="f-2831" unitRef="usd">3703000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-882" decimals="-6" id="f-2832" unitRef="usd">11963000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-883" decimals="-6" id="f-2833" unitRef="usd">3122000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-884" decimals="-6" id="f-2834" unitRef="usd">11642000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-885" decimals="-6" id="f-2835" unitRef="usd">2493000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-880" decimals="-6" id="f-2836" unitRef="usd">-426000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-881" decimals="-6" id="f-2837" unitRef="usd">257000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-882" decimals="-6" id="f-2838" unitRef="usd">993000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-883" decimals="-6" id="f-2839" unitRef="usd">-589000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-884" decimals="-6" id="f-2840" unitRef="usd">1494000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-885" decimals="-6" id="f-2841" unitRef="usd">553000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-880" decimals="-6" id="f-2842" unitRef="usd">18919000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-881" decimals="-6" id="f-2843" unitRef="usd">3740000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-886" decimals="-6" id="f-2844" unitRef="usd">22659000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-882" decimals="-6" id="f-2845" unitRef="usd">18246000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-883" decimals="-6" id="f-2846" unitRef="usd">4669000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-887" decimals="-6" id="f-2847" unitRef="usd">22915000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-884" decimals="-6" id="f-2848" unitRef="usd">15647000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-885" decimals="-6" id="f-2849" unitRef="usd">4447000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-888" decimals="-6" id="f-2850" unitRef="usd">20094000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-1" decimals="-6" id="f-2851" unitRef="usd">5972000000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-12" decimals="-6" id="f-2852" unitRef="usd">7853000000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-13" decimals="-6" id="f-2853" unitRef="usd">735000000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-2854" unitRef="usd">16687000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-12" decimals="-6" id="f-2855" unitRef="usd">15062000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-13" decimals="-6" id="f-2856" unitRef="usd">19359000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-2857">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Identifiable Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Innovative Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$57,070&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;58,324&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;MedTech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;84,322&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;74,710&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;141,392&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;133,034&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,712&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;34,524&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Worldwide total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$180,104&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;167,558&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.465%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.873%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Additions to Property,&lt;br/&gt;Plant &amp;amp; Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Depreciation and&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Innovative Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$1,710&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,653&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,374&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$3,760&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,847&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,687&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;MedTech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,443&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,372&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,120&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,237&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,943&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,302&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Segments total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,153&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,494&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,997&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,790&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,989&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;162&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;303&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;383&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;641&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;271&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;356&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;212&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;342&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;313&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;340&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Worldwide total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$4,424&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,543&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,009&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$7,339&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,486&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;6,970&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Assets contextRef="c-889" decimals="-6" id="f-2858" unitRef="usd">57070000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-890" decimals="-6" id="f-2859" unitRef="usd">58324000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-891" decimals="-6" id="f-2860" unitRef="usd">84322000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-892" decimals="-6" id="f-2861" unitRef="usd">74710000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-893" decimals="-6" id="f-2862" unitRef="usd">141392000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-894" decimals="-6" id="f-2863" unitRef="usd">133034000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-895" decimals="-6" id="f-2864" unitRef="usd">38712000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-896" decimals="-6" id="f-2865" unitRef="usd">34524000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-10" decimals="-6" id="f-2866" unitRef="usd">180104000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-11" decimals="-6" id="f-2867" unitRef="usd">167558000000</us-gaap:Assets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-880" decimals="-6" id="f-2868" unitRef="usd">1710000000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-882" decimals="-6" id="f-2869" unitRef="usd">1653000000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-884" decimals="-6" id="f-2870" unitRef="usd">1374000000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-880" decimals="-6" id="f-2871" unitRef="usd">3760000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-882" decimals="-6" id="f-2872" unitRef="usd">3847000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-884" decimals="-6" id="f-2873" unitRef="usd">3687000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-881" decimals="-6" id="f-2874" unitRef="usd">2443000000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-883" decimals="-6" id="f-2875" unitRef="usd">2372000000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-885" decimals="-6" id="f-2876" unitRef="usd">2120000000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-881" decimals="-6" id="f-2877" unitRef="usd">3237000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-883" decimals="-6" id="f-2878" unitRef="usd">2943000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-885" decimals="-6" id="f-2879" unitRef="usd">2302000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-897" decimals="-6" id="f-2880" unitRef="usd">4153000000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-898" decimals="-6" id="f-2881" unitRef="usd">4025000000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-899" decimals="-6" id="f-2882" unitRef="usd">3494000000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-897" decimals="-6" id="f-2883" unitRef="usd">6997000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-898" decimals="-6" id="f-2884" unitRef="usd">6790000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-899" decimals="-6" id="f-2885" unitRef="usd">5989000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-900" decimals="-6" id="f-2886" unitRef="usd">0</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-901" decimals="-6" id="f-2887" unitRef="usd">162000000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-902" decimals="-6" id="f-2888" unitRef="usd">303000000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-900" decimals="-6" id="f-2889" unitRef="usd">0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-901" decimals="-6" id="f-2890" unitRef="usd">383000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-902" decimals="-6" id="f-2891" unitRef="usd">641000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-903" decimals="-6" id="f-2892" unitRef="usd">271000000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-904" decimals="-6" id="f-2893" unitRef="usd">356000000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-905" decimals="-6" id="f-2894" unitRef="usd">212000000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-903" decimals="-6" id="f-2895" unitRef="usd">342000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-904" decimals="-6" id="f-2896" unitRef="usd">313000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-905" decimals="-6" id="f-2897" unitRef="usd">340000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-1" decimals="-6" id="f-2898" unitRef="usd">4424000000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-12" decimals="-6" id="f-2899" unitRef="usd">4543000000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-13" decimals="-6" id="f-2900" unitRef="usd">4009000000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-6" id="f-2901" unitRef="usd">7339000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-12" decimals="-6" id="f-2902" unitRef="usd">7486000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-13" decimals="-6" id="f-2903" unitRef="usd">6970000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock contextRef="c-1" id="f-2904">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.614%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Sales to Customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Long-Lived Assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$50,302&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;46,444&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;41,981&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$70,670&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;54,832&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,212&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,410&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,664&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;27,267&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,616&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Western Hemisphere excluding U.S.&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,714&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,549&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,108&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,728&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,491&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Asia-Pacific, Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,593&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,756&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,237&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,454&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,500&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Segments total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;88,821&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;85,159&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;79,990&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;101,119&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;89,439&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,217&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,192&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other non long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;77,768&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;76,927&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Worldwide total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$88,821&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;85,159&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;79,990&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$180,104&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;167,558&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;See Note&#160;1 for a description of the segments in which the Company operates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;Export sales are not significant. In fiscal year 2024, the Company utilized three wholesalers distributing products for both segments that represented approximately 20.5%, 15.6% and 12.3% of the total gross revenues. In fiscal year 2023, the Company had three wholesalers distributing products for both segments that represented approximately 18.2%, 15.1% and 14.2% of the total gross revenues. In fiscal year 2022, the Company had three wholesalers distributing products for all three segments that represented approximately 18.9%, 15.0%, and 13.8% of the total gross revenues. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.64pt"&gt;&lt;span style="-sec-ix-hidden:f-2949"&gt;Other segment expenses&lt;/span&gt; for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:7.29pt"&gt;Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal years 2024 and 2023 include charges for talc matters of approximately $5.1&#160;billion and $7&#160;billion, respectively (See Note 19, Legal proceedings, for additional details). The fiscal year 2024 includes a loss of approximately $0.4&#160;billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock. The fiscal year 2023 includes the unfavorable change in the fair value of the retained stake in Kenvue of approximately $0.4&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:7.19pt"&gt;Innovative Medicine segment income before tax includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt"&gt;Acquired in-process research &amp;amp; development expense of $1.25&#160;billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt"&gt;Monetization of royalty rights of $0.3&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt"&gt;Litigation expense of $0.3&#160;billion primarily related to Risperdal Gynecomastia&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt"&gt;An intangible asset impairment charge of approximately $0.2&#160;billion associated with the M710 (biosimilar) asset acquired as part of the acquisition of Momenta Pharmaceuticals in 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt"&gt;A restructuring related charge of $0.1&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt"&gt;One-time COVID-19 Vaccine manufacturing exit related costs of $0.1&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt"&gt;Favorable changes in the fair value of securities of $0.1&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;MedTech segment income before tax includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt"&gt;Acquisition and integration related costs of $1.0&#160;billion primarily related to the acquisition of Shockwave &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt"&gt;Acquired in-process research and development expense of $0.5&#160;billion from the V-Wave acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt"&gt;A gain of $0.2&#160;billion related to the Acclarent divestiture&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt"&gt;A Medical Device Regulation charge of $0.2&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt"&gt;A restructuring related charge of $0.2&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.07pt"&gt;Innovative Medicine segment income before tax includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;One-time COVID-19 Vaccine manufacturing exit related costs of $0.7&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;A restructuring related charge of $0.5&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;Unfavorable changes in the fair value of securities of $0.4&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;Favorable litigation related items of $0.1&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;Loss on divestiture of $0.2&#160;billion. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;An intangible asset impairment charge of approximately $0.2&#160;billion related to market dynamics associated with a non-strategic asset (M710) acquired as part of the acquisition of Momenta Pharmaceuticals in 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;MedTech segment income before tax includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;Acquired in-process research and development expense of $0.4&#160;billion related to the Laminar acquisition in 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;A restructuring related charge of $0.3&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;Acquisition and integration related costs of $0.2&#160;billion primarily related to the acquisition of Abiomed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;A Medical Device Regulation charge of $0.3&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;Income from litigation settlements of $0.1&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:7.17pt"&gt;Innovative Medicine segment income before tax includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;One-time COVID-19 Vaccine manufacturing exit related costs of $1.5&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;An intangible asset impairment charge of approximately $0.8&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;Litigation expense of $0.1&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;Unfavorable changes in the fair value of securities of $0.7&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;A restructuring related charge of $0.1&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;MedTech segment income before tax includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;Litigation expense of $0.6&#160;billion primarily for pelvic mesh related costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;A restructuring related charge of $0.3&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt"&gt;Acquisition and integration related costs of $0.3&#160;billion primarily related to the acquisition of Abiomed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt"&gt;A Medical Device Regulation charge of $0.3&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;   General corporate includes cash, cash equivalents, marketable securities and other corporate assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.64pt"&gt;Long-lived assets include property, plant and equipment, net for fiscal years 2024, and 2023 of $20,518 and $19,898, respectively, and intangible assets and goodwill, net for fiscal years 2024 and 2023 of $81,818 and $70,733, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-906" decimals="-6" id="f-2905" unitRef="usd">50302000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-907" decimals="-6" id="f-2906" unitRef="usd">46444000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-908" decimals="-6" id="f-2907" unitRef="usd">41981000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NoncurrentAssets contextRef="c-909" decimals="-6" id="f-2908" unitRef="usd">70670000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-910" decimals="-6" id="f-2909" unitRef="usd">54832000000</us-gaap:NoncurrentAssets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-911" decimals="-6" id="f-2910" unitRef="usd">20212000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-912" decimals="-6" id="f-2911" unitRef="usd">20410000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-913" decimals="-6" id="f-2912" unitRef="usd">20664000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NoncurrentAssets contextRef="c-914" decimals="-6" id="f-2913" unitRef="usd">27267000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-915" decimals="-6" id="f-2914" unitRef="usd">31616000000</us-gaap:NoncurrentAssets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-916" decimals="-6" id="f-2915" unitRef="usd">4714000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-917" decimals="-6" id="f-2916" unitRef="usd">4549000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-918" decimals="-6" id="f-2917" unitRef="usd">4108000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NoncurrentAssets contextRef="c-919" decimals="-6" id="f-2918" unitRef="usd">1728000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-920" decimals="-6" id="f-2919" unitRef="usd">1491000000</us-gaap:NoncurrentAssets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-921" decimals="-6" id="f-2920" unitRef="usd">13593000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-922" decimals="-6" id="f-2921" unitRef="usd">13756000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-923" decimals="-6" id="f-2922" unitRef="usd">13237000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NoncurrentAssets contextRef="c-924" decimals="-6" id="f-2923" unitRef="usd">1454000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-925" decimals="-6" id="f-2924" unitRef="usd">1500000000</us-gaap:NoncurrentAssets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-886" decimals="-6" id="f-2925" unitRef="usd">88821000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-887" decimals="-6" id="f-2926" unitRef="usd">85159000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-888" decimals="-6" id="f-2927" unitRef="usd">79990000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NoncurrentAssets contextRef="c-926" decimals="-6" id="f-2928" unitRef="usd">101119000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-927" decimals="-6" id="f-2929" unitRef="usd">89439000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-895" decimals="-6" id="f-2930" unitRef="usd">1217000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-896" decimals="-6" id="f-2931" unitRef="usd">1192000000</us-gaap:NoncurrentAssets>
    <jnj:OtherNonLongLivedAssets contextRef="c-928" decimals="-6" id="f-2932" unitRef="usd">77768000000</jnj:OtherNonLongLivedAssets>
    <jnj:OtherNonLongLivedAssets contextRef="c-929" decimals="-6" id="f-2933" unitRef="usd">76927000000</jnj:OtherNonLongLivedAssets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-6" id="f-2934" unitRef="usd">88821000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-6" id="f-2935" unitRef="usd">85159000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-6" id="f-2936" unitRef="usd">79990000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Assets contextRef="c-10" decimals="-6" id="f-2937" unitRef="usd">180104000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-11" decimals="-6" id="f-2938" unitRef="usd">167558000000</us-gaap:Assets>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-930"
      decimals="3"
      id="f-2939"
      unitRef="number">0.205</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-931"
      decimals="3"
      id="f-2940"
      unitRef="number">0.156</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-932"
      decimals="3"
      id="f-2941"
      unitRef="number">0.123</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-933"
      decimals="3"
      id="f-2942"
      unitRef="number">0.182</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-934"
      decimals="3"
      id="f-2943"
      unitRef="number">0.151</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-935"
      decimals="3"
      id="f-2944"
      unitRef="number">0.142</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-13"
      decimals="INF"
      id="f-2945"
      unitRef="segment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-936"
      decimals="3"
      id="f-2946"
      unitRef="number">0.189</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-937"
      decimals="3"
      id="f-2947"
      unitRef="number">0.150</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-938"
      decimals="3"
      id="f-2948"
      unitRef="number">0.138</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:LossContingencyLossInPeriod contextRef="c-939" decimals="-8" id="f-2950" unitRef="usd">5100000000</us-gaap:LossContingencyLossInPeriod>
    <us-gaap:LossContingencyLossInPeriod contextRef="c-940" decimals="-8" id="f-2951" unitRef="usd">7000000000</us-gaap:LossContingencyLossInPeriod>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-1" decimals="-8" id="f-2952" unitRef="usd">-400000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-12" decimals="-8" id="f-2953" unitRef="usd">-400000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="c-65" decimals="-6" id="f-2954" unitRef="usd">1250000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:ProceedsFromRoyaltiesReceived contextRef="c-1" decimals="-6" id="f-2955" unitRef="usd">300000000</us-gaap:ProceedsFromRoyaltiesReceived>
    <us-gaap:LitigationSettlementExpense contextRef="c-115" decimals="-8" id="f-2956" unitRef="usd">300000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-941" decimals="-8" id="f-2957" unitRef="usd">200000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:RestructuringCharges contextRef="c-880" decimals="-8" id="f-2958" unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:SuppliesExpense contextRef="c-880" decimals="-8" id="f-2959" unitRef="usd">100000000</us-gaap:SuppliesExpense>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss contextRef="c-114" decimals="-8" id="f-2960" unitRef="usd">100000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-115" decimals="-8" id="f-2961" unitRef="usd">1000000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="c-942" decimals="-8" id="f-2962" unitRef="usd">500000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-115" decimals="-8" id="f-2963" unitRef="usd">200000000</us-gaap:GainLossOnSaleOfBusiness>
    <jnj:RegulationCharge contextRef="c-115" decimals="-8" id="f-2964" unitRef="usd">200000000</jnj:RegulationCharge>
    <us-gaap:RestructuringCharges contextRef="c-881" decimals="-8" id="f-2965" unitRef="usd">200000000</us-gaap:RestructuringCharges>
    <us-gaap:SuppliesExpense contextRef="c-882" decimals="-8" id="f-2966" unitRef="usd">700000000</us-gaap:SuppliesExpense>
    <us-gaap:RestructuringCharges contextRef="c-882" decimals="-8" id="f-2967" unitRef="usd">500000000</us-gaap:RestructuringCharges>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss contextRef="c-110" decimals="-8" id="f-2968" unitRef="usd">-400000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:GainLossRelatedToLitigationSettlement contextRef="c-110" decimals="-8" id="f-2969" unitRef="usd">100000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-110" decimals="-8" id="f-2970" unitRef="usd">-200000000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-943" decimals="-8" id="f-2971" unitRef="usd">200000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="c-944" decimals="-8" id="f-2972" unitRef="usd">400000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:RestructuringCharges contextRef="c-883" decimals="-8" id="f-2973" unitRef="usd">300000000</us-gaap:RestructuringCharges>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-111" decimals="-8" id="f-2974" unitRef="usd">200000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <jnj:RegulationCharge contextRef="c-111" decimals="-8" id="f-2975" unitRef="usd">300000000</jnj:RegulationCharge>
    <us-gaap:GainLossRelatedToLitigationSettlement contextRef="c-12" decimals="-8" id="f-2976" unitRef="usd">100000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:SuppliesExpense contextRef="c-884" decimals="-8" id="f-2977" unitRef="usd">1500000000</us-gaap:SuppliesExpense>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-945" decimals="-8" id="f-2978" unitRef="usd">800000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:LitigationSettlementExpense contextRef="c-722" decimals="-8" id="f-2979" unitRef="usd">100000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss contextRef="c-722" decimals="-8" id="f-2980" unitRef="usd">-700000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:RestructuringCharges contextRef="c-722" decimals="-8" id="f-2981" unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:LitigationSettlementExpense contextRef="c-873" decimals="-8" id="f-2982" unitRef="usd">600000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:RestructuringCharges contextRef="c-873" decimals="-8" id="f-2983" unitRef="usd">300000000</us-gaap:RestructuringCharges>
    <us-gaap:AcquisitionCosts contextRef="c-873" decimals="-8" id="f-2984" unitRef="usd">300000000</us-gaap:AcquisitionCosts>
    <jnj:RegulationCharge contextRef="c-873" decimals="-8" id="f-2985" unitRef="usd">300000000</jnj:RegulationCharge>
    <us-gaap:NoncurrentAssets contextRef="c-946" decimals="-6" id="f-2986" unitRef="usd">20518000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-947" decimals="-6" id="f-2987" unitRef="usd">19898000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-948" decimals="-6" id="f-2988" unitRef="usd">81818000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-949" decimals="-6" id="f-2989" unitRef="usd">70733000000</us-gaap:NoncurrentAssets>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-2990">Acquisitions and divestitures&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Subsequent to the fiscal year end 2024, the Company announced it has entered into a definitive agreement to acquire Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, for $132.00 per share in cash for a total equity value of approximately $14.6&#160;billion. The Company expects to fund the transaction through a combination of cash on hand and debt. The closing of the transaction is expected to occur later this year subject to applicable regulatory approvals, approval by Intra-Cellular Therapies&#x2019; stockholders and other customary closing conditions for a transaction of this type. The results of operations will be included in the Innovative Medicine segment beginning on the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:112%"&gt;Business combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Acquisitions of a business are accounted for as business combinations applying the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed are recorded at their respective fair values as of the acquisition date in the Company&#x2019;s consolidated financial statements. The excess of the purchase price over the fair value of the acquired net assets, where applicable, is recorded as goodwill. The results of operations of these acquisitions have been included in the Company&#x2019;s financial statements from their respective dates of acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;During the fiscal year 2024, certain businesses were acquired for $15.1&#160;billion, net of cash acquired. The fiscal year 2024 acquisitions primarily included; Ambrx Biopharma, Inc., Shockwave Medical Inc., and Proteologix, Inc. The remaining acquisitions were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;On June 20, 2024, the Company completed the acquisition of Proteologix, Inc., a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for approximately $0.8&#160;billion net of cash acquired, with potential for an additional milestone payment. The results of operations are included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $1.2&#160;billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&amp;amp;D, for $0.9&#160;billion, goodwill for $0.3&#160;billion, and $0.3&#160;billion of liabilities assumed which included $0.1&#160;billion related to a contingent consideration. The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period. A probability of success factor ranging from 30% to 45% was used in the fair value calculation to reflect inherent regulatory and commercial risk of the IPR&amp;amp;D. The discount rate applied was approximately 16%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. Acquisition related costs before tax for the fiscal 2024 were not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;On May 31, 2024, the Company completed the acquisition of Shockwave Medical Inc. (SWAV)(Shockwave), a leading, first-to-market provider of innovative intravascular lithotripsy (IVL) technology for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD) in an all-cash merger transaction. The Company acquired all the outstanding shares of Shockwave&#x2019;s common stock for $335.00 per share through a merger of Shockwave with a subsidiary of the Company. The results of operations were included in the MedTech segment as of the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Details of the fair value amounts recognized for assets acquired and liabilities assumed as of the purchase date and at the end of fiscal year 2024, which includes measurement period adjustments, are included in the table below. As the acquisition occurred in May 2024, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.060%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Billions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;May 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;Assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$1.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$1.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortizable intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$15.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$15.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$1.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$1.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Notes payable*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accrued liabilities**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$2.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$2.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$12.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$12.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net assets acquired as of May 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$12.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less: Cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Equity awards settled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Settlement of Note payable*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total enterprise value as of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$13.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;*&#160;&#160;&#160;&#160;Represents the convertible debt which was subsequently paid in the fiscal second quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;**&#160;&#160;&#160;&#160;Includes $0.2&#160;billion of equity awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. Acquisition related costs before tax for the fiscal 2024 were $0.9&#160;billion of which $0.4&#160;billion was related to the fair value of the inventory step-up and was recorded in Cost of products sold and $0.5&#160;billion primarily related to equity awards and was recorded in Other (income) expense. The amortizable intangible assets were primarily comprised of already in-market CAD and PAD IVL products with the average weighted lives of 14 years. The IPR&amp;amp;D assets were valued for technology programs for unapproved products. The value of the IPR&amp;amp;D was calculated using a probability-adjusted cash flow projection discounted for the risk inherent in such projects with the weighted average probability of success factors of approximately 50%. The discount rate applied was 9.0%.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;On March 7, 2024, the Company completed the acquisition of Ambrx Biopharma, Inc., (Ambrx), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of approximately $2.0&#160;billion, or $1.8&#160;billion net of cash acquired. The Company acquired all of the outstanding shares of Ambrx&#x2019;s common stock for $28.00 per share through a merger of Ambrx with a subsidiary of the Company. The results of operations were included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $2.3&#160;billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&amp;amp;D, for $1.9&#160;billion, goodwill for $0.3&#160;billion and liabilities assumed of $0.5&#160;billion, which includes deferred taxes of $0.4&#160;billion. The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period. A probability of success factor ranging from 40% to &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;70% was used in the fair value calculation to reflect inherent regulatory and commercial risk of the IPR&amp;amp;D. The discount rate applied was approximately 17%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. Acquisition related costs before tax for the fiscal year 2024 were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;During the fiscal year 2023, the Company did not make any acquisitions that qualified as a business combination. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;During the fiscal year 2022, certain businesses were acquired for $17.7&#160;billion, net of cash acquired. The fiscal year 2022 acquisitions primarily included Abiomed, Inc. (Abiomed). The remaining acquisitions were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;On December 22, 2022, the Company completed the acquisition of Abiomed, a leading, first-to-market provider of cardiovascular medical technology with a first-in-kind portfolio for the treatment of coronary artery disease and heart failure which also has an extensive innovation pipeline of life-saving technologies. The transaction broadens the Company&#x2019;s position as a growing cardiovascular innovator, advancing the standard of care in heart failure and recovery, one of healthcare&#x2019;s largest areas of unmet need. The results of operations were included in the MedTech segment as of the date of the acquisition. The acquisition was completed through a tender offer for all outstanding shares. The consideration paid in the acquisition consisted of an upfront payment of $380.00 per share in cash, amounting to $17.1&#160;billion, net of cash acquired, as well as a non-tradeable contingent value right (&#x201c;CVR&#x201d;) entitling the holder to receive up to $35.00 per share in cash (which with respect to the CVRs total approximately $1.6&#160;billion in the aggregate) if certain commercial and clinical milestones are achieved. The corresponding enterprise value (without taking into account the CVRs) of approximately $16.5&#160;billion includes cash, cash equivalents and marketable securities acquired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The milestones of the CVR consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.65pt"&gt;$17.50 per share, payable if net sales for Abiomed products exceeds $3.7&#160;billion during Johnson &amp;amp; Johnson&#x2019;s fiscal second quarter of 2027 through fiscal first quarter of 2028, or if this threshold is not met during this period and is subsequently met during any rolling four quarter period up to the end of Johnson &amp;amp; Johnson&#x2019;s fiscal first quarter of 2029, $8.75 per&#160;share;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;b.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.23pt"&gt;$7.50 per share payable upon FDA premarket application approval of the use of Impella&#xae; products in ST-elevated myocardial infarction (STEMI) patients without cardiogenic shock by January 1, 2028; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;c.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.49pt"&gt;$10.00 per share payable upon the first publication of a Class I recommendation for the use of Impella&#xae; products in high risk PCI or STEMI with or without cardiogenic shock within four years from their respective clinical endpoint publication dates, but in all cases no later than December 31, 2029.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;During the fiscal fourth quarter of 2023, the Company finalized the purchase price allocation. In fiscal 2023, there were purchase price allocation adjustments netting to approximately $0.2&#160;billion with an offsetting increase to goodwill. The fair value of the acquisition was allocated to assets acquired of $20.1&#160;billion (net of $0.3&#160;billion cash acquired), primarily to goodwill for $11.1&#160;billion, amortizable intangible assets for $6.6&#160;billion, IPR&amp;amp;D for $1.1&#160;billion, marketable securities of $0.6&#160;billion and liabilities assumed of $3.0&#160;billion, which includes the fair value of the contingent consideration mentioned above for $0.7&#160;billion and deferred taxes of $2.0&#160;billion. The goodwill is primarily attributable to the commercial acceleration and expansion of the portfolio and is not expected to be deductible for tax purposes. The contingent consideration was recorded in Other Liabilities and adjusted to fair value through the fiscal year end 2024 on the Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The amortizable intangible assets were primarily comprised of already in-market products of the Impella&#xae; platform with an average weighted life of 14 years. The IPR&amp;amp;D assets were valued for technology programs for unapproved products. The value of the IPR&amp;amp;D was calculated using probability-adjusted cash flow projections discounted for the risk inherent in such projects. The probability of success factor ranged from 52% to 70%. The discount rate applied was 9.5%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In the fiscal years 2024, 2023 and 2022, the Company recorded acquisition related costs before tax of approximately $0.3&#160;billion, $0.2&#160;billion and $0.3&#160;billion, which was primarily recorded in Other (income)/expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In accordance with U.S.&#160;GAAP standards related to business combinations, and goodwill and other intangible assets, supplemental pro forma information for fiscal years 2024, 2023 and 2022 is not provided, as the impact of the aforementioned acquisitions did not have a material effect on the Company&#x2019;s results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Asset acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Acquired In-process research and development (IPR&amp;amp;D) in an asset acquisition is immediately expensed as research and development expense in the Company's consolidated financial statements. Milestone payments incurred prior to regulatory approval are expensed as research and development expense when the milestone event occurs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The fiscal year 2024 asset acquisitions expensed as research and development included V-Wave Ltd. and the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition). The remaining activity was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;On October 8, 2024, the Company completed the acquisition of V-Wave Ltd, a privately-held company focused on developing innovative treatment options for patients with heart failure, for an upfront payment of $0.6&#160;billion, with the potential for additional regulatory and commercial milestone payments up to approximately $1.1&#160;billion. The Company recorded an IPR&amp;amp;D charge of approximately $0.5&#160;billion, net of a gain recorded on the Company's existing investment in V-Wave and the results of operations are included in the MedTech segment as of the acquisition date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;On July 11, 2024, the Company completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics AG, to secure the global rights to NM26, a novel, investigational first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD), in an all-cash transaction for approximately $1.25&#160;billion. The Company recorded an IPR&amp;amp;D charge of approximately $1.25&#160;billion, and the results of operations are included in the Innovative Medicine segment as of the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The fiscal year 2023 asset acquisitions expensed as research and development included Laminar Inc. The remaining activity was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;During the fiscal year 2023, the Company completed the acquisition of Laminar Inc., a privately-held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib), for an upfront payment of $0.4&#160;billion. The Company recorded an IPR&amp;amp;D charge of approximately $0.4&#160;billion and the results of operations are included in the MedTech segment as of the acquisition date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;There were no significant asset acquisitions in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:112%"&gt;Divestitures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;During the fiscal year 2024, the Company completed the divestiture of Acclarent resulting in approximately $0.3&#160;billion in proceeds and the divestiture of Ponvory outside of the U.S. resulting in approximately $0.2&#160;billion in proceeds. All other divestitures were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;During the fiscal year 2023, the Company executed divestitures resulting in approximately $0.2&#160;billion in proceeds resulting in gains or losses that were not material. At fiscal year end 2023, the Company held assets, primarily intangibles, on its Consolidated Balance Sheet of approximately $0.3&#160;billion, primarily related to Acclarent and Ponvory, that were subsequently divested in fiscal 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;During fiscal year 2022, the Company did not make any material divestitures.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="c-950"
      decimals="2"
      id="f-2991"
      unitRef="usdPerShare">132.00</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-951" decimals="-8" id="f-2992" unitRef="usd">14600000000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-1" decimals="-8" id="f-2993" unitRef="usd">15100000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-952" decimals="-8" id="f-2994" unitRef="usd">800000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="c-953" decimals="-8" id="f-2995" unitRef="usd">1200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-953" decimals="-8" id="f-2996" unitRef="usd">900000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-952" decimals="-8" id="f-2997" unitRef="usd">300000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-953" decimals="-8" id="f-2998" unitRef="usd">300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-953" decimals="-8" id="f-2999" unitRef="usd">100000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <jnj:BusinessCombinationProbabilityOfSuccessFactor
      contextRef="c-954"
      decimals="2"
      id="f-3000"
      unitRef="number">0.30</jnj:BusinessCombinationProbabilityOfSuccessFactor>
    <jnj:BusinessCombinationProbabilityOfSuccessFactor
      contextRef="c-955"
      decimals="2"
      id="f-3001"
      unitRef="number">0.45</jnj:BusinessCombinationProbabilityOfSuccessFactor>
    <jnj:BusinessAcquisitionDiscountRate
      contextRef="c-953"
      decimals="3"
      id="f-3002"
      unitRef="number">0.16</jnj:BusinessAcquisitionDiscountRate>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-956" decimals="-8" id="f-3003" unitRef="usd">0</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="c-957"
      decimals="2"
      id="f-3004"
      unitRef="usdPerShare">335.00</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="c-1" id="f-3005">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Details of the fair value amounts recognized for assets acquired and liabilities assumed as of the purchase date and at the end of fiscal year 2024, which includes measurement period adjustments, are included in the table below. As the acquisition occurred in May 2024, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.060%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Billions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;May 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;Assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$1.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$1.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortizable intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$15.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$15.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$1.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$1.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Notes payable*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accrued liabilities**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$2.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$2.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$12.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$12.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net assets acquired as of May 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$12.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less: Cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Equity awards settled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Settlement of Note payable*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total enterprise value as of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$13.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;*&#160;&#160;&#160;&#160;Represents the convertible debt which was subsequently paid in the fiscal second quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt;**&#160;&#160;&#160;&#160;Includes $0.2&#160;billion of equity awards&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-957" decimals="-8" id="f-3006" unitRef="usd">1100000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-958" decimals="-8" id="f-3007" unitRef="usd">1100000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:Goodwill contextRef="c-957" decimals="-8" id="f-3008" unitRef="usd">7500000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-958" decimals="-8" id="f-3009" unitRef="usd">7600000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-957" decimals="-8" id="f-3010" unitRef="usd">5300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-958" decimals="-8" id="f-3011" unitRef="usd">5300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-957" decimals="-8" id="f-3012" unitRef="usd">600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-958" decimals="-8" id="f-3013" unitRef="usd">600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="c-957" decimals="-8" id="f-3014" unitRef="usd">500000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="c-958" decimals="-8" id="f-3015" unitRef="usd">500000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets contextRef="c-957" decimals="-8" id="f-3016" unitRef="usd">500000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets contextRef="c-958" decimals="-8" id="f-3017" unitRef="usd">400000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="c-957" decimals="-8" id="f-3018" unitRef="usd">15500000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="c-958" decimals="-8" id="f-3019" unitRef="usd">15500000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-957" decimals="-8" id="f-3020" unitRef="usd">1500000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-958" decimals="-8" id="f-3021" unitRef="usd">1500000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt contextRef="c-957" decimals="-8" id="f-3022" unitRef="usd">1000000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt contextRef="c-958" decimals="-8" id="f-3023" unitRef="usd">1000000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt>
    <jnj:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities contextRef="c-957" decimals="-8" id="f-3024" unitRef="usd">400000000</jnj:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities>
    <jnj:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities contextRef="c-958" decimals="-8" id="f-3025" unitRef="usd">400000000</jnj:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-957" decimals="-8" id="f-3026" unitRef="usd">2900000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-958" decimals="-8" id="f-3027" unitRef="usd">2900000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-957" decimals="-8" id="f-3028" unitRef="usd">12600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-958" decimals="-8" id="f-3029" unitRef="usd">12600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-957" decimals="-8" id="f-3030" unitRef="usd">12600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-957" decimals="-8" id="f-3031" unitRef="usd">1100000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <jnj:BusinessCombinationSettlementOfEquityAwards contextRef="c-959" decimals="-8" id="f-3032" unitRef="usd">600000000</jnj:BusinessCombinationSettlementOfEquityAwards>
    <jnj:BusinessCombinationSettlementOfNotesPayable contextRef="c-959" decimals="-8" id="f-3033" unitRef="usd">1000000000.0</jnj:BusinessCombinationSettlementOfNotesPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-960" decimals="-8" id="f-3034" unitRef="usd">13100000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-961" decimals="-8" id="f-3035" unitRef="usd">200000000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-962" decimals="-8" id="f-3036" unitRef="usd">900000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss contextRef="c-962" decimals="-8" id="f-3037" unitRef="usd">400000000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss>
    <jnj:BusinessCombinationAcquisitionRelatedCostsEquityAwards contextRef="c-962" decimals="-8" id="f-3038" unitRef="usd">500000000</jnj:BusinessCombinationAcquisitionRelatedCostsEquityAwards>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-961" id="f-3039">P14Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <jnj:BusinessCombinationProbabilityOfSuccessFactor
      contextRef="c-963"
      decimals="2"
      id="f-3040"
      unitRef="number">0.50</jnj:BusinessCombinationProbabilityOfSuccessFactor>
    <jnj:BusinessAcquisitionDiscountRate
      contextRef="c-957"
      decimals="3"
      id="f-3041"
      unitRef="number">0.090</jnj:BusinessAcquisitionDiscountRate>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-964" decimals="-8" id="f-3042" unitRef="usd">2000000000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-964" decimals="-8" id="f-3043" unitRef="usd">1800000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="c-965"
      decimals="2"
      id="f-3044"
      unitRef="usdPerShare">28.00</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="c-965" decimals="-8" id="f-3045" unitRef="usd">2300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-965" decimals="-8" id="f-3046" unitRef="usd">1900000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-964" decimals="-8" id="f-3047" unitRef="usd">300000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-965" decimals="-8" id="f-3048" unitRef="usd">500000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-965" decimals="-8" id="f-3049" unitRef="usd">400000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <jnj:BusinessCombinationProbabilityOfSuccessFactor
      contextRef="c-966"
      decimals="2"
      id="f-3050"
      unitRef="number">0.40</jnj:BusinessCombinationProbabilityOfSuccessFactor>
    <jnj:BusinessCombinationProbabilityOfSuccessFactor
      contextRef="c-967"
      decimals="2"
      id="f-3051"
      unitRef="number">0.70</jnj:BusinessCombinationProbabilityOfSuccessFactor>
    <jnj:BusinessAcquisitionDiscountRate
      contextRef="c-965"
      decimals="3"
      id="f-3052"
      unitRef="number">0.17</jnj:BusinessAcquisitionDiscountRate>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-12" decimals="-8" id="f-3053" unitRef="usd">17700000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="c-968"
      decimals="2"
      id="f-3054"
      unitRef="usdPerShare">380.00</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-969" decimals="-8" id="f-3055" unitRef="usd">17100000000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight
      contextRef="c-970"
      decimals="2"
      id="f-3056"
      unitRef="usdPerShare">35.00</jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight>
    <jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight contextRef="c-970" decimals="-8" id="f-3057" unitRef="usd">1600000000</jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-968" decimals="-8" id="f-3058" unitRef="usd">16500000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="c-968"
      decimals="2"
      id="f-3059"
      unitRef="usdPerShare">17.50</us-gaap:DividendsPayableAmountPerShare>
    <jnj:RevenuesContingentConsideration contextRef="c-970" decimals="-8" id="f-3060" unitRef="usd">3700000000</jnj:RevenuesContingentConsideration>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="c-971"
      decimals="2"
      id="f-3061"
      unitRef="usdPerShare">8.75</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="c-972"
      decimals="2"
      id="f-3062"
      unitRef="usdPerShare">7.50</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="c-973"
      decimals="2"
      id="f-3063"
      unitRef="usdPerShare">10.00</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-1" decimals="-8" id="f-3064" unitRef="usd">200000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="c-974" decimals="-8" id="f-3065" unitRef="usd">20100000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:CashAcquiredFromAcquisition contextRef="c-975" decimals="-8" id="f-3066" unitRef="usd">300000000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-975" decimals="-8" id="f-3067" unitRef="usd">11100000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c-975" decimals="-8" id="f-3068" unitRef="usd">6600000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <jnj:ResearchAndDevelopmentInProcess1 contextRef="c-975" decimals="-8" id="f-3069" unitRef="usd">1100000000</jnj:ResearchAndDevelopmentInProcess1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities contextRef="c-974" decimals="-8" id="f-3070" unitRef="usd">600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-974" decimals="-8" id="f-3071" unitRef="usd">3000000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-974" decimals="-8" id="f-3072" unitRef="usd">700000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-974" decimals="-8" id="f-3073" unitRef="usd">2000000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-971" id="f-3074">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <jnj:BusinessCombinationProbabilityOfSuccessFactor
      contextRef="c-976"
      decimals="2"
      id="f-3075"
      unitRef="number">0.52</jnj:BusinessCombinationProbabilityOfSuccessFactor>
    <jnj:BusinessCombinationProbabilityOfSuccessFactor
      contextRef="c-977"
      decimals="2"
      id="f-3076"
      unitRef="number">0.70</jnj:BusinessCombinationProbabilityOfSuccessFactor>
    <jnj:BusinessAcquisitionDiscountRate
      contextRef="c-968"
      decimals="3"
      id="f-3077"
      unitRef="number">0.095</jnj:BusinessAcquisitionDiscountRate>
    <us-gaap:AcquisitionCosts contextRef="c-115" decimals="-8" id="f-3078" unitRef="usd">300000000</us-gaap:AcquisitionCosts>
    <us-gaap:AcquisitionCosts contextRef="c-111" decimals="-8" id="f-3079" unitRef="usd">200000000</us-gaap:AcquisitionCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-13" decimals="-8" id="f-3080" unitRef="usd">300000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c-978" decimals="-8" id="f-3081" unitRef="usd">600000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c-979" decimals="-8" id="f-3082" unitRef="usd">1100000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <jnj:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill contextRef="c-980" decimals="-8" id="f-3083" unitRef="usd">500000000</jnj:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c-981" decimals="-7" id="f-3084" unitRef="usd">1250000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <jnj:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill contextRef="c-982" decimals="-7" id="f-3085" unitRef="usd">1250000000</jnj:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c-983" decimals="-8" id="f-3086" unitRef="usd">400000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <jnj:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill contextRef="c-984" decimals="-8" id="f-3087" unitRef="usd">400000000</jnj:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill>
    <us-gaap:ProceedsFromDivestitureOfBusinesses contextRef="c-985" decimals="-8" id="f-3088" unitRef="usd">300000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses contextRef="c-986" decimals="-8" id="f-3089" unitRef="usd">200000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses contextRef="c-12" decimals="-6" id="f-3090" unitRef="usd">200000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup contextRef="c-11" decimals="-6" id="f-3091" unitRef="usd">300000000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup>
    <us-gaap:ProceedsFromDivestitureOfBusinesses contextRef="c-13" decimals="-8" id="f-3092" unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="c-1" id="f-3093">Legal proceedings&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Johnson &amp;amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of December 29, 2024, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In the Company&#x2019;s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company&#x2019;s balance sheet, is not expected to have a material adverse effect on the Company&#x2019;s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company&#x2019;s results of operations and cash flows for that period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Matters concerning talc&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;A significant number of personal injury claims alleging that talc causes cancer have been asserted against the Company and its affiliates arising out of the use of body powders containing talc, primarily JOHNSON&#x2019;S Baby Powder. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In talc cases that have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7&#160;billion in Ingham v. Johnson &amp;amp; Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $2.1&#160;billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied, and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $2.5&#160;billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company&#x2019;s confidence in the safety of its talc products, in certain circumstances the Company has settled cases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In June 2014, the Mississippi Attorney General filed a complaint against the Company alleging violation of the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers&#x2019; use of talc contained in JOHNSON&#x2019;S Baby Powder and JOHNSON&#x2019;S Shower to Shower (a product divested in 2012). The Company has reached an agreement to resolve this matter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The Company has reached an agreement to resolve this matter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Forty-two states and the District of Columbia commenced a joint investigation into the Company&#x2019;s marketing of its talcum powder products. In January 2024, the Company reached an agreement in principle with the multi-state group of state Attorneys General, subject to ongoing negotiation of non-monetary terms. In June 2024, the settlements were finalized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In October 2021, Johnson &amp;amp; Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&amp;amp;M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor&#x2019;s direct parent, Johnson &amp;amp; Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI&#x2019;s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers&#x2019; compensation statute or act (the Talc-Related Liabilities).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In October 2021, notwithstanding the Company&#x2019;s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under Chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). All litigation against LTL, Old JJCI, New JJCI, the Company, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties) was stayed. The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions in March 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss the LTL Bankruptcy Case and the extension of the stay to the Protected Parties. On January 30, 2023, the Third Circuit reversed the Bankruptcy Court&#x2019;s ruling and remanded to the Bankruptcy Court to dismiss the LTL bankruptcy. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to all parties and returning the talc litigation to the tort system. LTL re-filed in the United States Bankruptcy Court for the District of New Jersey seeking relief under Chapter 11 of the Bankruptcy Code (the LTL 2 Bankruptcy Case). As a result of the new filing, all talc claims against LTL were again automatically stayed pursuant to section 362 of the Bankruptcy Code. Additionally, the New Jersey Bankruptcy Court issued a temporary restraining order staying all litigation as to LTL, Old JJCI, New JJCI, the Company, identified retailers, and certain other parties (the New Protected Parties). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Also in April 2023, the New Jersey Bankruptcy Court issued a decision that granted limited injunctive relief to the Company and the New Protected Parties (the LTL 2 Preliminary Injunction). The LTL 2 Preliminary Injunction remained in force until late August 2023, following the Bankruptcy Court&#x2019;s extension of the initial LTL 2 Preliminary Injunction in June 2023. Under the LTL 2 Preliminary Injunction, except for those cases filed in the federal court ovarian cancer multi-district litigation, discovery in all personal injury and wrongful death matters was permitted to proceed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Furthermore, in April 2023, the Talc Claimants' Committee filed a motion to dismiss the LTL 2 Bankruptcy followed by similar motions from other claimants. Hearings on the motions to dismiss occurred in June 2023. In July 2023, the court dismissed the LTL 2 Bankruptcy case and, the same day, the Company stated its intent to appeal the decision and to continue its efforts to obtain a resolution of the talc claims. In September 2023, the Bankruptcy Court entered an order granting LTL leave to seek a direct appeal to the Third Circuit Court of Appeals. In October 2023, the Third Circuit granted LTL&#x2019;s petition for a direct appeal. In July 2024, the Third Circuit issued a non-precedential opinion affirming the Bankruptcy Court's decision to dismiss the LTL Bankruptcy case.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In October 2023, the Company stated that it was pursuing the following four parallel and alternative pathways to achieve a comprehensive and final resolution of the talc claims: (i) the appeal of the LTL 2 dismissal decision; (ii) pursuing a consensual &#x201c;prepackaged&#x201d; bankruptcy case, as &#x201c;strongly encouraged&#x201d; by the Bankruptcy Court in its dismissal decision; (iii) aggressively litigating the talc claims in the tort system; and (iv) pursuing affirmative claims against experts for false and defamatory narratives regarding the Company&#x2019;s talc powder products. In December 2023, LTL changed its state of formation to Texas and its name to LLT Management LLC ("LLT").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Following the dismissal of LTL 2, new lawsuits were filed, cases across the country that had been stayed were reactivated, and trials have commenced. The majority of the cases are pending in federal court, organized in a multi-district litigation (MDL) in the United States District Court for the District of New Jersey. In the MDL, case-specific discovery proceeded. The MDL proceedings have been stayed by order of the bankruptcy court in the Red River Bankruptcy case discussed below. In March 2024, the court granted the Company's motion for a renewed Daubert hearing prior to the trial. The briefing on the renewed Daubert issues was completed in August 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In May 2024, the Company commenced a three-month solicitation period of its proposed consensual &#x201c;prepackaged&#x201d; Chapter 11 bankruptcy plan (the &#x201c;Proposed Plan&#x201d;) for the comprehensive and final resolution of all current and future claims related to cosmetic talc in the United States, excluding claims related to mesothelioma or State consumer protection claims, in exchange for the payment by the Company of present value of approximately $6.475&#160;billion payable over 25 years (nominal value of approximately $8.0&#160;billion, discounted at a rate of 4.4%). The claims encompassed by the Proposed Plan constitute 99.75% of pending lawsuits against the Company relating to its talc powder products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In August 2024, LLT engaged in a restructuring that resulted in the creation of three new Texas limited liability companies: (a) Red River Talc, LLC ("Red River"); (b) Pecos River Talc LLC ("Pecos River"); and (3) New Holdco (Texas) LLC. As a result of this restructuring, all claims related to ovarian and other gynecological cancers were separated and allocated to Red River, and mesothelioma, governmental unit and certain other claims were allocated to Pecos River.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In September 2024, while reiterating the Company's continued confidence in the safety of its talc products, Red River filed a voluntary petition with the United States Bankruptcy Court for the Southern District of Texas, seeking relief under Chapter 11 of the Bankruptcy Code (the Red River Bankruptcy Case), in furtherance of the Company's consensual "prepackaged" Proposed Plan. Red River also filed a motion for a temporary restraining order, seeking to extend the automatic stay to additional non-debtor entities. Prior to filing, the initial proposed plan was amended to, among other things, increase the proposed resolution by $1.75&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Shortly after Red River filed its Chapter 11 petition, the U.S. Trustee's office filed a motion to transfer venue in the New Jersey Bankruptcy Court, and thereafter, a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. A coalition of six plaintiff law firms also filed a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. In September 2024, the Texas Bankruptcy Court entered a temporary order enjoining the commencement or prosecution of all claims against Red River and certain non-debtor entities, including the Company, until October 11, 2024. The temporary order was extended in October 2024 and again in December 2024. The commencement and prosecution of all claims against Red River and certain non-debtor entities are currently enjoined until March 15, 2025. Also in September 2024, the New Jersey Bankruptcy Court denied the U.S. Trustee's motion to transfer venue without prejudice. In October 2024, the Texas Bankruptcy Court denied the motion to transfer venue from Texas to New Jersey Bankruptcy Court. A consolidated hearing to address, among other things, the motions to dismiss and plan confirmation is currently scheduled to begin on February&#160;18,&#160;2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Mesothelioma and State consumer protection claims are being addressed outside the Proposed Plan. The Company separately has resolved 95% of the mesothelioma lawsuits filed to date and has resolved the State claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;To account for these settlements and the contemplated comprehensive resolution through the Proposed Plan, the Company recorded a cumulative incremental charge of approximately $5.0&#160;billion, through the fourth fiscal quarter 2024. As of December 29, 2024, the total present value of the reserve is approximately $11.6&#160;billion (or nominal value of approximately $13.5&#160;billion), net of payments made in fiscal 2024. Approximately ten percent of the reserve is recorded as a current liability. The recorded amount remains the Company's best estimate of probable loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In February 2019, the Company&#x2019;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition for relief under Chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#x2019;s potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In its bankruptcy, Imerys proposed a Chapter 11 plan (the Imerys Plan) that contemplated all talc-related claims against it being channeled to a trust along with its alleged indemnification rights against the Company. Following confirmation and consummation of the plan, the trust would pay talc claims pursuant to proposed trust distribution procedures (the TDP) and then seek indemnification from the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In February 2021, Cyprus Mines Corporation (Cyprus), which had owned certain Imerys talc mines, filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan (the Cyprus Plan). The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain affiliated parties. Cyprus also asserts it has claims for indemnity against the Company arising out of talc personal injury claims. Under the Cyprus Plan, Cyprus would also contribute its alleged indemnification rights to the trust. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In September 2023, Imerys and Cyprus filed amended plans of reorganization. The amended plans contemplate a similar construct as the prior Imerys and Cyprus Plans, including all talc claims against Imerys and Cyprus (and certain other protected parties) being channeled to a trust along with Imerys&#x2019;s and Cyprus&#x2019;s alleged indemnification rights against the Company. The Company opposed both plans on the basis that the plans inflated Imerys&#x2019;s and Cyprus&#x2019;s liability for talc claims and had the potential effect of imposing those inflated liabilities on the Company through the Company&#x2019;s alleged indemnification&#160;obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In July 2024, the Company, Imerys, and Cyprus and certain of their affiliates (including their parent entities), and the tort claimants' committees and future claimants' representatives appointed in their respective Chapter 11 cases entered into a global settlement agreement (the Imerys Settlement Agreement) to resolve their ongoing disputes, including disputes raised in the Imerys and Cyprus bankruptcies. In August 2024, Imerys and Cyprus filed amended Chapter 11 plans and disclosure statements incorporating the terms of the settlement with the Company. In October 2024, the Imerys Bankruptcy Court entered an order approving the Imerys Settlement Agreement (the Settlement Order). The effectiveness of certain provisions of the settlement, including mutual releases, are subject to certain conditions, including the Imerys and Cyprus Plans being accepted by a sufficient number and amount of voting creditors to be confirmed under the Bankruptcy Code. Certain insurers have appealed the Settlement Order and sought a stay of the order pending appeal, which the Court denied on January 13, 2025.  The briefing of the appeal in the District Court is scheduled to be completed in April 2025. On January 5, 2025, Imerys and Cyprus each filed a certification of voting results, indicating that their respective plan had been accepted by each voting class of creditors. A joint confirmation hearing for the plans is scheduled for April 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%"&gt;In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#x2019;S Baby Powder, and that purchasers of the Company&#x2019;s shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. The case was stayed in May 2022 pursuant to the LTL Bankruptcy Case and was reopened in May 2023. In December 2023, the Court granted Plaintiff&#x2019;s motion for class certification. In January 2024, Defendants filed a petition with the Third Circuit under Federal Rule of Civil Procedure 23(f) for permission to appeal the Court&#x2019;s order granting class certification, and in February 2024, the Third Circuit granted Defendants' petition. In February 2024, fact discovery closed, the Court ordered the parties to mediate, and stayed the case pending mediation. In May 2024, the parties participated in an unsuccessful mediation. In June 2024, at the parties' request, the Court lifted the stay for certain limited discovery, but otherwise kept the stay in place pending a decision from the Third Circuit on the 23(f) petition. Briefing on the 23(f) petition was completed in September 2024. In January 2025, the Third Circuit listed the appeal for oral argument in March 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:129%"&gt;Matters concerning opioids&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%"&gt;Beginning in 2014 and continuing to the present, the Company and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children born with Neonatal Abstinence Syndrome (NAS); hospitals; and health insurers/payors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%"&gt;To date, the Company and JPI have litigated two of the cases to judgment and have prevailed in both, either at trial or on&#160;appeal. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%"&gt;In July 2021, the Company announced finalization of an agreement to settle the state and subdivision claims for up to $5.0&#160;billion. Approximately 70% of the all-in settlement was paid by the end of fiscal fourth quarter 2024. A few government entities opted out of the settlement. In September 2024, the Company reached an agreement to resolve the hospital cases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%"&gt;The Company and JPI continue to defend the cases brought by the remaining government entity litigants as well as the cases brought by private litigants. In total, there are approximately 35 remaining opioid cases against the Company and JPI in various state courts, 390 remaining cases in the Ohio multi-district litigation (MDL), and 4 additional cases in other federal courts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%"&gt;In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate Janssen Inc., and many other industry members, in Canada. That action was certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada in January 2025. Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. The proposed class action in Quebec on behalf of residents diagnosed with opioid use disorder was authorized to proceed against Janssen Inc. and other industry members in April 2024; and leave to appeal was denied in October 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%"&gt;Starting in November 2019, a series of shareholder derivative complaints were filed against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches. As of September 2024, all the complaints had been dismissed, and all appeals&#160;exhausted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Product liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%"&gt;The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25, Contingencies. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The table below contains the most significant of these cases and provides the approximate number of plaintiffs in the United States with direct claims in pending lawsuits regarding injuries allegedly due to the relevant product or product category as of December&#160;29, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.340%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Product or product category&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of plaintiffs &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Body powders containing talc, primarily JOHNSON&#x2019;S Baby Powder&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;62,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;PINNACLE Acetabular Cup System&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Pelvic meshes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ETHICON PHYSIOMESH Flexible Composite Mesh&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;RISPERDAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ELMIRON&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. There may be additional claims that have not yet been filed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;MedTech&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;DePuy ASR XL Acetabular System and ASR Hip Resurfacing System&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Ireland, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;DePuy PINNACLE Acetabular Cup System &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;Ethicon Pelvic Mesh &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicon&#x2019;s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company&#x2019;s accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon&#x2019;s pelvic mesh devices have been commenced in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, and Ireland, and class actions in Israel, Australia, Canada and South Africa. The vast majority of these actions are now resolved. The Company has established accruals with respect to product liability litigation associated with Ethicon&#x2019;s pelvic mesh products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Ethicon Physiomesh&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. Other than a small number of cases still pending in the MDL, all Physiomesh matters in the United States have been resolved or are undergoing formal review for purposes of settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Claims have also been filed against Ethicon and the Company alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Ethicon and the Company also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In October 2022, an agreement in principle, subject to various conditions, was reached to settle the majority of the pending cases involving Proceed, Proceed Ventral Patch, Prolene Hernia System and related multi-layered mesh products, as well as a number of unfiled claims. All litigation activities in the two New Jersey MCLs are stayed pending effectuation of the proposed settlement. Future cases that are filed in the New Jersey MCLs will be subject to docket control orders requiring early expert reports and discovery requirements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company has established accruals with respect to product liability litigation associated with Ethicon Physiomesh Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Innovative Medicine&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;RISPERDAL&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and the Company arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. The Company continues to defend RISPERDAL product liability lawsuits, and continues to evaluate potential costs related to those claims. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0&#160;billion of punitive damages related to one plaintiff, which the trial judge reduced to $6.8&#160;million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company's accruals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;ELMIRON&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Claims for personal injury have been made against a number of Johnson &amp;amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Jersey (MDL). In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. The Company continues to defend ELMIRON product liability lawsuits and continues to evaluate potential costs related to those claims. All U.S. based ELMIRON matters have been resolved or are undergoing formal review for purposes of settlement. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Intellectual property&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Certain subsidiaries of the Company are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the scope and/or validity of patents that relate to various products and allegations that certain of the Company&#x2019;s products infringe the intellectual property rights of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Innovative Medicine - litigation against filers of abbreviated new drug applications (ANDAs)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company&#x2019;s subsidiaries have brought lawsuits against generic companies that have filed ANDAs with the U.S. FDA (or similar lawsuits outside of the United States) seeking to market generic versions of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These lawsuits typically include allegations of non-infringement and/or invalidity of patents listed in FDA&#x2019;s publication &#x201c;Approved Drug Products with Therapeutic Equivalence Evaluations&#x201d; (commonly known as the Orange Book). In each of these lawsuits, the Company&#x2019;s subsidiaries are seeking an order enjoining the defendant from marketing a generic version of a product before the expiration of the relevant patents (Orange Book Listed Patents). In the event the Company&#x2019;s subsidiaries are not successful in an action, or any automatic statutory stay expires before the court rulings are obtained, the generic companies involved would have the ability, upon regulatory approval, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company&#x2019;s subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Inter Partes Review (IPR) process with the United States Patent and Trademark Office (USPTO), created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits to challenge the applicable patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;XARELTO&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Beginning in March 2021, Janssen Pharmaceuticals, Inc.; Bayer Pharma AG; Bayer AG; and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddy&#x2019;s Laboratories, Inc.; Dr. Reddy&#x2019;s Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mankind Pharma Limited; Apotex Inc.; Apotex Corp.; Auson Pharmaceuticals Inc.; Shanghai Auson Pharmaceuticals Co. Ltd.; Cipla Ltd.; Cipla USA Inc.; InvaGen Pharmaceuticals, Inc.; Prinston Pharmaceuticals, Inc.; Ascent Pharmaceuticals, Inc.; and Hetero Labs Limited. In October 2024, the Company entered into a confidential settlement agreement with Auson Pharmaceuticals Inc. and Shanghai Auson Pharmaceuticals Co., Ltd. and the case was dismissed. In November 2024, the Company entered into confidential settlement agreements with Ascent Pharmaceuticals Inc. that resulted in dismissal of litigation against Ascent Pharmaceuticals, Inc. and Hetero Labs Limited. In January 2025, the Company entered into a confidential settlement agreement with Prinston Pharmaceutical, Inc. (as to U.S. Patent No. 9,539,218). The following U.S. patents are included in one or more cases: 9,539,218 and 10,828,310. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;U.S. Patent No. 10,828,310 was also under consideration by the USPTO in an IPR proceeding. In July 2023, the USPTO issued a final written decision finding the claims of the patent invalid. In September 2023, Bayer Pharma AG filed an appeal to the U.S. Court of Appeals for the Federal Circuit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;INVEGA SUSTENNA &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; Accord Healthcare, Inc.; Qilu Pharmaceutical Co. Ltd.; and Qilu Pharma Inc. The following U.S. patent is included in one or more cases: 9,439,906. In October 2020, the district court issued a decision in the case against Teva Pharmaceuticals USA, Inc., finding that United States Patent No. 9,439,906 is not invalid. Teva previously stipulated to infringement. Teva appealed the decision, and, in April 2024, the United States Court of Appeals for the Federal Circuit vacated and remanded the case to the district court for further proceedings. In November 2024, the district court issued its decision on remand, finding that United States Patent No. 9,439,906 is not invalid. Teva appealed to the Court of Appeals for the Federal Circuit, and oral argument is scheduled for April 2025. In February 2024, the district court issued a decision in the case against Tolmar Inc. finding that United States Patent No. 9,439,906 is not invalid. Tolmar previously stipulated to infringement. Tolmar has appealed the&#160;decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Beginning in February 2018, Janssen Inc. and Janssen Pharmaceutica NV initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the listed patent. The following entities are named defendants: Pharmascience Inc. and Apotex Inc. The following Canadian patent is included in one or more cases: 2,655,335. In June 2024, the Supreme Court dismissed the Apotex case. In September 2024, the Supreme Court granted Pharmascience's motion to appeal the Federal Court's decision that the 2,655,335 Patent is not invalid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;INVEGA TRINZA &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Beginning in September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp;amp; Development, LLC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA TRINZA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Mylan Laboratories Limited; Mylan Pharmaceuticals Inc.; and Mylan Institutional LLC. The following U.S. patent is included in one or more cases: 10,143,693. In May 2023, the District Court issued a decision finding that Mylan&#x2019;s proposed generic product infringes the asserted patent and that the patent is not invalid. Mylan has appealed the decision. Oral argument before the Court of Appeals for the Federal Circuit was held in February 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;SYMTUZA &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Beginning in November 2021, Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company, Gilead Sciences, Inc. and Gilead Sciences Ireland UC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SYMTUZA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; MSN Laboratories Private Ltd.; MSN Life Sciences Private Ltd.; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 10,039,718 and 10,786,518. A trial is scheduled to begin in February 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;ERLEADA &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Beginning in May 2022, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc. (collectively, Janssen), Sloan Kettering Institute for Cancer Research (SKI) and The Regents of the University of California filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of ERLEADA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Zydus Worldwide DMCC; Zydus Pharmaceuticals (USA), Inc.; Zydus Lifesciences Limited; Hetero Labs Limited Unit V; and Hetero USA, Inc. The following U.S. patents are included in one or more cases: 9,481,663; 9,884,054; 10,052,314 (which reissued as RE49,353); 10,702,508; 10,849,888; 8,445,507; 8,802,689; 9,388,159; 9,987,261; RE49,353; and 11,963,952. In October 2024, Janssen, The Regents of the University of California, SKI, Hetero Labs Limited Unit V, and Hetero USA, Inc. entered into a confidential settlement, and the case was dismissed. In November 2024, Janssen, The Regents of the University of California, Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA), Inc., and Zydus Lifesciences Limited entered into confidential settlements, and the cases were dismissed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;SPRAVATO &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Beginning in May 2023, Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SPRAVATO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sandoz &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Inc.; Hikma Pharmaceuticals Inc. USA; Hikma Pharmaceuticals PLC; and Alkem Laboratories Ltd. The following U.S. patents are included in one or more cases: 10,869,844; 11,173,134; 11,311,500; and 11,446,260. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;INVOKANA &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Beginning in January 2024, Janssen Inc. and Mitsubishi Tanabe Pharma Corporation initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who filed ANDSs seeking approval to market generic versions of INVOKANA before expiration of the listed patents. The following entities are named defendants: Jamp Pharma Corporation and Apotex Inc. The following Canadian patents are included in one or more cases: 2,534,024 and 2,671,357. Trial in the Jamp action is scheduled for September 2025, and trial in the Apotex action is scheduled for December 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;MedTech &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In March 2016, Abiomed, Inc. (Abiomed) filed a declaratory judgment action against Maquet Cardiovascular LLC (Maquet) in U.S. District Court for the District of Massachusetts seeking a declaration that the Impella does not infringe certain Maquet patents, currently U.S. Patent Nos. 7,022,100 (&#x2019;100); 8,888,728; 9,327,068; 9,545,468; 9,561,314; and 9,597,437. Maquet counterclaimed for infringement of each of those patents. After claim construction, Maquet alleged infringement of only the &#x2019;100 patent. In September 2021, the court granted Abiomed&#x2019;s motion for summary judgment of non-infringement of the &#x2019;100 patent, and in September 2023, the district court entered final judgment in favor of Abiomed on all patents-in-suit. Maquet&#160;appealed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:142%"&gt;Government proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Like other companies in the pharmaceutical and medical technologies industries, the Company and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;MedTech&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In July 2018, the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp;amp; Johnson do Brasil Ind&#xfa;stria e Com&#xe9;rcio de Produtos para Sa&#xfa;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice (DOJ) and the United States Securities and Exchange Commission. The Company has been informed DOJ has closed its investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In July 2023, the DOJ issued Civil Investigative Demands to the Company, Johnson &amp;amp; Johnson Surgical Vision, Inc., and Johnson &amp;amp; Johnson Vision Care, Inc. (collectively, J&amp;amp;J Vision) in connection with a civil investigation under the False Claims Act relating to free or discounted intraocular lenses and equipment used in eye surgery, such as phacoemulsification and laser systems. J&amp;amp;J Vision has begun producing documents and information responsive to the Civil Investigative Demands. J&amp;amp;J Vision is in ongoing discussions with the DOJ regarding its inquiry.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:139%"&gt;Innovative Medicine&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and trial commenced in May 2024. On June 13, 2024, a jury found no liability regarding the anti-kickback violations but found liability for a portion of the off-label promotion claims. The Company is pursuing post-trial briefing challenging the verdict on the off-label claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;General litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The Company or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the Company&#x2019;s agreement to implement remediation activities at designated hazardous waste sites or to reimburse the government or third parties for the costs they have incurred in performing remediation as such&#160;sites.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp;amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Court&#x2019;s decision. In June 2023, defendants filed a petition for a writ of certiorari to the United States Supreme Court. In June 2024, the Supreme Court vacated the D.C. Circuit's decision and remanded the case to the D.C. Circuit. Oral argument was held in November 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In February 2024, a putative class action was filed against the Company, the Pension &amp;amp; Benefits Committee of Johnson &amp;amp; Johnson (Committee), and certain named officers and employees, in United States District Court for the District of New Jersey. In May 2024, the plaintiff filed an amended complaint against the Company and the Committee. The complaint alleges that defendants breached fiduciary duties under the Employee Retirement Income Security Act (ERISA) by allegedly mismanaging the Company&#x2019;s prescription-drug benefits program. The complaint seeks damages and other relief. In January 2025, the Court granted in part and denied in part defendants&#x2019; motion to dismiss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;MedTech&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#x2019;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants&#x2019; motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial occurred in January 2024. In September 2024, the court found liability with respect to certain claims and no liability with respect to other claims. The Company has appealed the decision. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc (BWI) in the United States District Court for the Central District of California. The complaint alleges that certain of BWI's business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. Trial is scheduled for April 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Innovative Medicine&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to the Company and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssen&#x2019;s REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand. Janssen is in ongoing discussions with the FTC staff regarding its inquiry. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;In February 2022, the United States Federal Trade Commission (FTC) issued Civil Investigative Demands to Johnson &amp;amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether advertising practices for REMICADE violate federal law. Janssen has produced documents and information responsive to the Civil Investigative Demands. In January 2025, the FTC Bureau of Consumer Protection informed Janssen that it was closing its investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In September 2024, the district court granted plaintiff's motion for class certification. Trial is scheduled for March 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;In December 2023, a putative class action lawsuit was filed against the Company and Janssen Biotech Inc. (collectively Janssen) in the United States District Court for the Eastern District of Virginia. The complaint alleges that Janssen violated federal and state antitrust laws and other state laws by delaying biosimilar competition with STELARA through Janssen's enforcement of patent rights covering STELARA. The complaint seeks damages and other relief. In February 2024, plaintiffs filed an amended complaint, which Janssen moved to dismiss in March 2024. In August 2024, the court granted in part and denied in part Janssen's motion to dismiss. &lt;/span&gt;&lt;/div&gt;In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc., Janssen Research &amp;amp; Development, LLC, and Johnson &amp;amp; Johnson (collectively, Janssen) were served with a qui tam complaint on behalf of the United States, certain states, and the District of Columbia. The complaint alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct sales and reimbursement programs. At this time, the federal and state governments have declined to intervene. In December 2021, the United States District Court for the District of New Jersey denied Janssen's motion to dismiss.</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LossContingencyDamagesAwardedValue contextRef="c-987" decimals="-8" id="f-3094" unitRef="usd">4700000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue contextRef="c-988" decimals="-8" id="f-3095" unitRef="usd">2100000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesPaidValue contextRef="c-989" decimals="-8" id="f-3096" unitRef="usd">2500000000</us-gaap:LossContingencyDamagesPaidValue>
    <jnj:LossContingencySolicitationPeriod contextRef="c-990" id="f-3097">P3M</jnj:LossContingencySolicitationPeriod>
    <us-gaap:LossContingencyDamagesSoughtValue contextRef="c-990" decimals="-6" id="f-3098" unitRef="usd">6475000000</us-gaap:LossContingencyDamagesSoughtValue>
    <jnj:LossContingencyPaymentPeriod contextRef="c-990" id="f-3099">P25Y</jnj:LossContingencyPaymentPeriod>
    <jnj:LossContingencyDamagesSoughtNominalValue contextRef="c-990" decimals="-8" id="f-3100" unitRef="usd">8000000000</jnj:LossContingencyDamagesSoughtNominalValue>
    <jnj:LossContingencyDiscountRate
      contextRef="c-991"
      decimals="3"
      id="f-3101"
      unitRef="number">0.044</jnj:LossContingencyDiscountRate>
    <jnj:TotalClaimsAgainstCompanyPercent
      contextRef="c-990"
      decimals="4"
      id="f-3102"
      unitRef="number">0.9975</jnj:TotalClaimsAgainstCompanyPercent>
    <jnj:LossContingencyDamagesSoughtValueIncrease contextRef="c-992" decimals="-7" id="f-3103" unitRef="usd">1750000000</jnj:LossContingencyDamagesSoughtValueIncrease>
    <jnj:LossContingencyClaimsSettledPercent
      contextRef="c-993"
      decimals="2"
      id="f-3104"
      unitRef="number">0.95</jnj:LossContingencyClaimsSettledPercent>
    <us-gaap:LossContingencyAccrualProvision contextRef="c-994" decimals="-8" id="f-3105" unitRef="usd">5000000000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-995" decimals="-8" id="f-3106" unitRef="usd">11600000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <jnj:LossContingencyAccrualNominalValue contextRef="c-995" decimals="-8" id="f-3107" unitRef="usd">13500000000</jnj:LossContingencyAccrualNominalValue>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="c-996"
      decimals="INF"
      id="f-3108"
      unitRef="claimant">3500</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-997" decimals="-8" id="f-3109" unitRef="usd">5000000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <jnj:LossContingencyAccrualPaymentPercentage
      contextRef="c-997"
      decimals="2"
      id="f-3110"
      unitRef="number">0.70</jnj:LossContingencyAccrualPaymentPercentage>
    <us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock contextRef="c-1" id="f-3111">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The table below contains the most significant of these cases and provides the approximate number of plaintiffs in the United States with direct claims in pending lawsuits regarding injuries allegedly due to the relevant product or product category as of December&#160;29, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.340%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Product or product category&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of plaintiffs &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Body powders containing talc, primarily JOHNSON&#x2019;S Baby Powder&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;62,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;PINNACLE Acetabular Cup System&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Pelvic meshes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ETHICON PHYSIOMESH Flexible Composite Mesh&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;RISPERDAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ELMIRON&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="c-998"
      decimals="0"
      id="f-3112"
      unitRef="claimant">62830</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="c-999"
      decimals="0"
      id="f-3113"
      unitRef="claimant">60</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="c-1000"
      decimals="0"
      id="f-3114"
      unitRef="claimant">910</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="c-1001"
      decimals="0"
      id="f-3115"
      unitRef="claimant">5990</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="c-1002"
      decimals="0"
      id="f-3116"
      unitRef="claimant">130</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="c-1003"
      decimals="0"
      id="f-3117"
      unitRef="claimant">7</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="c-1004"
      decimals="0"
      id="f-3118"
      unitRef="claimant">2170</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:Numberofpatientsinsettlement
      contextRef="c-1005"
      decimals="0"
      id="f-3119"
      unitRef="claimant">10000</jnj:Numberofpatientsinsettlement>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="c-1006"
      decimals="0"
      id="f-3120"
      unitRef="cases">3600</us-gaap:LossContingencyPendingClaimsNumber>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="c-1006"
      decimals="0"
      id="f-3121"
      unitRef="claimant">4300</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:LossContingencyNumberOfClaimsWithinSettlementAgreement
      contextRef="c-1007"
      decimals="0"
      id="f-3122"
      unitRef="cases">3729</jnj:LossContingencyNumberOfClaimsWithinSettlementAgreement>
    <us-gaap:LossContingencyDamagesAwardedValue contextRef="c-1008" decimals="-8" id="f-3123" unitRef="usd">8000000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue contextRef="c-1009" decimals="-5" id="f-3124" unitRef="usd">6800000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-3125">Restructuring&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;In fiscal 2023, the Company commenced restructuring actions within its Innovative Medicine and MedTech segments. The amounts and details of the current year programs are included below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;In fiscal 2023, the Company completed a prioritization of its research and development (R&amp;amp;D) investment within its Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within certain therapeutic areas. The R&amp;amp;D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. Pre-tax Restructuring expenses of $0.1&#160;billion in the fiscal year 2024, included the termination of partnered and non-partnered development program costs, asset impairments and asset divestments. Pre-tax Restructuring expenses of $0.5&#160;billion in the fiscal year 2023, included the termination of partnered and non-partnered development program costs and asset impairments. Total project costs of approximately $0.6&#160;billion have been recorded since the restructuring was announced. The program was completed in the fiscal fourth quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense of $0.2&#160;billion in the fiscal year 2024 primarily included costs related to market and product exits. The pre-tax restructuring expense of $0.3&#160;billion in the fiscal year 2023 primarily included inventory and instrument charges related to market and product exits. Total project costs of approximately $0.5&#160;billion have been recorded since the restructuring was announced. The estimated costs of the total program are between $0.7&#160;billion - $0.8&#160;billion and is expected to be completed by the end of fiscal year 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;The following table summarizes the restructuring expenses for the fiscal years 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.173%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Pre-tax Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Innovative Medicine Segment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$102&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;479&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;MedTech Segment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;167&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;319&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total Programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$269&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$798&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt"&gt;The fiscal year of 2024 included $102&#160;million in Restructuring on the Consolidated Statement of Earnings. The fiscal year of 2023 included $449&#160;million in Restructuring and $30&#160;million in Cost of products sold on the Consolidated Statement of Earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt"&gt;The fiscal year of 2024 included $132&#160;million in Restructuring and $35&#160;million in Cost of products sold on the Consolidated Statement of Earnings. The fiscal year of 2023 Included $40&#160;million in Restructuring and $279&#160;million in Cost of products sold on the Consolidated Statement of Earnings.&lt;/span&gt;&lt;/div&gt;Restructuring reserves as of December 29, 2024 and December 31, 2023 were insignificant.</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringCharges contextRef="c-1010" decimals="-8" id="f-3126" unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-1011" decimals="-8" id="f-3127" unitRef="usd">500000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 contextRef="c-1012" decimals="-8" id="f-3128" unitRef="usd">600000000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringCharges contextRef="c-1013" decimals="-8" id="f-3129" unitRef="usd">200000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-1014" decimals="-8" id="f-3130" unitRef="usd">300000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 contextRef="c-1015" decimals="-8" id="f-3131" unitRef="usd">500000000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-1016" decimals="-8" id="f-3132" unitRef="usd">700000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-1017" decimals="-8" id="f-3133" unitRef="usd">800000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="c-1" id="f-3134">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%"&gt;The following table summarizes the restructuring expenses for the fiscal years 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.173%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Pre-tax Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Innovative Medicine Segment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$102&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;479&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;MedTech Segment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;167&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;319&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total Programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$269&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$798&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt"&gt;The fiscal year of 2024 included $102&#160;million in Restructuring on the Consolidated Statement of Earnings. The fiscal year of 2023 included $449&#160;million in Restructuring and $30&#160;million in Cost of products sold on the Consolidated Statement of Earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt"&gt;The fiscal year of 2024 included $132&#160;million in Restructuring and $35&#160;million in Cost of products sold on the Consolidated Statement of Earnings. The fiscal year of 2023 Included $40&#160;million in Restructuring and $279&#160;million in Cost of products sold on the Consolidated Statement of Earnings.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringCharges contextRef="c-880" decimals="-6" id="f-3135" unitRef="usd">102000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-882" decimals="-6" id="f-3136" unitRef="usd">479000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-881" decimals="-6" id="f-3137" unitRef="usd">167000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-883" decimals="-6" id="f-3138" unitRef="usd">319000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-886" decimals="-6" id="f-3139" unitRef="usd">269000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-887" decimals="-6" id="f-3140" unitRef="usd">798000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-114" decimals="-6" id="f-3141" unitRef="usd">102000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-1018" decimals="-6" id="f-3142" unitRef="usd">449000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-1019" decimals="-6" id="f-3143" unitRef="usd">30000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-1020" decimals="-6" id="f-3144" unitRef="usd">132000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-1021" decimals="-6" id="f-3145" unitRef="usd">35000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-1022" decimals="-6" id="f-3146" unitRef="usd">40000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-1023" decimals="-6" id="f-3147" unitRef="usd">279000000</us-gaap:RestructuringCharges>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="c-1" id="f-3148">Kenvue separation and discontinued operations&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The results of the Consumer Health business (previously reported as a separate business segment) have been reflected as discontinued operations in the Company&#x2019;s consolidated statements of earnings as Net earnings from discontinued operations, net of taxes through August 23, 2023, the date of the exchange offer. Prior periods have been recast to reflect this&#160;presentation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;On May 15, 2024, the Company issued $3.6&#160;billion aggregate principal amount of commercial paper and received $3.6&#160;billion of net cash proceeds to be used for general corporate purposes. On May 17, 2024, the Company completed a Debt-for-Equity Exchange of its remaining 182,329,550 shares of Kenvue Common Stock for the outstanding Commercial Paper. Upon completion of the Debt-for-Equity Exchange, the Commercial Paper was satisfied and discharged and the Company no longer owns any shares of Kenvue Common Stock. This exchange resulted in a loss of approximately $0.4&#160;billion recorded in Other (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of 198,734,444 shares of its common stock, par value $0.01 per share (the &#x201c;Kenvue Common Stock&#x201d;), at an initial public offering of $22.00 per share for net proceeds of $4.2&#160;billion. The excess of the net proceeds from the IPO over the net book value of the Johnson &amp;amp; Johnson divested interest was $2.5&#160;billion and was recorded to additional paid-in capital. As of the closing of the IPO, Johnson &amp;amp; Johnson owned approximately 89.6% of the total outstanding shares of Kenvue Common Stock and at July 2, 2023, the non-controlling interest of $1.3&#160;billion associated with Kenvue was reflected in equity attributable to non-controlling interests in the consolidated balance sheet in the fiscal second quarter of 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;On August 23, 2023, Johnson &amp;amp; Johnson completed the disposition of an additional 80.1% ownership of Kenvue Common Stock through an exchange offer, which resulted in Johnson &amp;amp; Johnson acquiring 190,955,436 shares of the Company&#x2019;s common stock in exchange for 1,533,830,450 shares of Kenvue Common Stock. The $31.4&#160;billion of Johnson &amp;amp; Johnson common stock received in the exchange offer is recorded in Treasury stock. Following the exchange offer, the Company owned 9.5% of the total outstanding shares of Kenvue Common Stock that was recorded in other assets within continuing operations at the fair market value of $4.3&#160;billion as of August 23, 2023. Subsequent changes are reflected in other income/expense and amounted to $0.4&#160;billion expense through December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Johnson &amp;amp; Johnson divested net assets of $11.6&#160;billion as of August 23, 2023, and the accumulated other comprehensive loss attributable to the Consumer Health business at that date was $4.3&#160;billion. Additionally, at the date of the exchange offer, Johnson &amp;amp; Johnson decreased the non-controlling interest by $1.2&#160;billion to record the deconsolidation of Kenvue. This resulted in a non-cash gain on the exchange offer of $21.0&#160;billion that was recorded in Net earnings from discontinued operations, net of taxes in the consolidated statements of earnings for the fiscal third quarter of 2023. This one-time gain includes a gain of $2.8&#160;billion on the Kenvue Common Stock retained by Johnson &amp;amp; Johnson. The gain on the exchange offer qualifies as a tax-free transaction for U.S. federal income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Also in connection with the separation, Johnson &amp;amp; Johnson and Kenvue entered into a separation agreement and also entered into various other agreements that provide for certain transactions to effect the transfer of the assets and liabilities of the Consumer Health business to Kenvue and to govern various interim and ongoing relationships between Kenvue and Johnson &amp;amp; Johnson following the completion of the Kenvue IPO, including transition services agreements (TSAs), transition manufacturing agreements (TMAs), trademark agreements, intellectual property agreements, an employee matters agreement, and a tax matters agreement. Under the TSAs, Johnson &amp;amp; Johnson will provide Kenvue various services and, similarly, Kenvue will provide Johnson &amp;amp; Johnson various services. The provision of services under the TSAs generally will terminate within 24 months following the Kenvue IPO. Additionally, Johnson &amp;amp; Johnson and Kenvue entered into TMAs pursuant to which Johnson &amp;amp; Johnson will manufacture and supply to Kenvue certain products and, similarly, Kenvue will manufacture and supply to Johnson &amp;amp; Johnson certain products. The terms of the TMAs range in initial duration from 3 months to 5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Amounts related to the TSAs and TMAs included in the consolidated statements of earnings were immaterial for both fiscal years 2024 and 2023. Additionally, the amounts due to and from Kenvue for the above agreements was not material as of December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The results of the Consumer Health business (previously reported as a separate business segment), as well as the associated gain, have been reflected as discontinued operations in the Company&#x2019;s consolidated statements of earnings as Net earnings from discontinued operations, net of taxes. As a result of the separation of Kenvue, Johnson &amp;amp; Johnson incurred separation costs of $145&#160;million in the fiscal year 2024, which was included in Net Earnings and incurred separation costs of $986&#160;million and $1,089&#160;million in the fiscal years 2023 and 2022, respectively, which were included in Net earnings from discontinued operations, net of taxes. These costs were primarily related to external advisory, legal, accounting, contractor and other &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;incremental costs directly related to separation activities. In the fiscal 2022, as part of the planned separation of the Company&#x2019;s Consumer Health business, the Company recognized approximately $0.5&#160;billion in net incremental tax costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Details of Net Earnings from Discontinued Operations, net of taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Sales to customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$10,036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;14,953&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4,369&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;6,494&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;5,667&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;8,459&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Selling, marketing and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3,085&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4,519&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;258&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;468&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest expense, net of portion capitalized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;199&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,092&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,060&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(Gain) on separation of Kenvue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(20,984)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Restructuring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;46&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Earnings from Discontinued Operations Before Provision for Taxes on Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;22,134&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2,366&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Provision for taxes on income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;307&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;795&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net earnings from Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;$21,827&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;1,571&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt"&gt;The Company ceased consolidating the results of the Consumer Health business on August 23, 2023, the date of the exchange offer, but continued to reflect any separation costs incurred as part of discontinued operations through the end of the fiscal fourth quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table presents depreciation, amortization and capital expenditures of the discontinued operations related to&#160;Kenvue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.173%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation and Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$383&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;641&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$162&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;303&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:CommercialPaper contextRef="c-184" decimals="-8" id="f-3149" unitRef="usd">3600000000</us-gaap:CommercialPaper>
    <us-gaap:ProceedsFromIssuanceOfCommercialPaper contextRef="c-185" decimals="-8" id="f-3150" unitRef="usd">3600000000</us-gaap:ProceedsFromIssuanceOfCommercialPaper>
    <jnj:DebtForEquityExchangeSharesExchanged
      contextRef="c-186"
      decimals="INF"
      id="f-3151"
      unitRef="shares">182329550</jnj:DebtForEquityExchangeSharesExchanged>
    <jnj:DebtForEquityExchangeLossOnSharesExchanged contextRef="c-187" decimals="-8" id="f-3152" unitRef="usd">400000000</jnj:DebtForEquityExchangeLossOnSharesExchanged>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-41"
      decimals="INF"
      id="f-3153"
      unitRef="shares">198734444</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-42"
      decimals="INF"
      id="f-3154"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-42"
      decimals="2"
      id="f-3155"
      unitRef="usdPerShare">22.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c-41" decimals="-8" id="f-3156" unitRef="usd">4200000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal contextRef="c-43" decimals="-8" id="f-3157" unitRef="usd">2500000000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction contextRef="c-44" decimals="3" id="f-3158" unitRef="number">0.896</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:CommonStockValueOutstanding contextRef="c-45" decimals="-8" id="f-3159" unitRef="usd">1300000000</us-gaap:CommonStockValueOutstanding>
    <jnj:OwnershipPercentageSplitOffPercent contextRef="c-46" decimals="3" id="f-3160" unitRef="number">0.801</jnj:OwnershipPercentageSplitOffPercent>
    <jnj:StockIssuedDuringPeriodSharesExchangeOffer
      contextRef="c-1024"
      decimals="0"
      id="f-3161"
      unitRef="shares">190955436</jnj:StockIssuedDuringPeriodSharesExchangeOffer>
    <jnj:StockIssuedDuringPeriodSharesExchangeOffer
      contextRef="c-1025"
      decimals="0"
      id="f-3162"
      unitRef="shares">1533830450</jnj:StockIssuedDuringPeriodSharesExchangeOffer>
    <jnj:ExchangeOfStockCommonStockValueReceived contextRef="c-1026" decimals="-8" id="f-3163" unitRef="usd">31400000000</jnj:ExchangeOfStockCommonStockValueReceived>
    <jnj:ExchangeOfStockPercentageOwnershipAfterTransaction contextRef="c-47" decimals="3" id="f-3164" unitRef="number">0.095</jnj:ExchangeOfStockPercentageOwnershipAfterTransaction>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-1027" decimals="-8" id="f-3165" unitRef="usd">4300000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-1028" decimals="-8" id="f-3166" unitRef="usd">400000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-1029" decimals="-8" id="f-3167" unitRef="usd">11600000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-1029" decimals="-8" id="f-3168" unitRef="usd">-4300000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation contextRef="c-1030" decimals="-8" id="f-3169" unitRef="usd">1200000000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <jnj:NoncashOrPartNoncashTransactionGainOnExchangeOfStock contextRef="c-1029" decimals="-8" id="f-3170" unitRef="usd">21000000000</jnj:NoncashOrPartNoncashTransactionGainOnExchangeOfStock>
    <jnj:NoncashOrPartNoncashTransactionGainOnExchangeOfStock contextRef="c-1031" decimals="-8" id="f-3171" unitRef="usd">2800000000</jnj:NoncashOrPartNoncashTransactionGainOnExchangeOfStock>
    <jnj:DiscontinuedOperationsTransitionServiceAgreementTerm contextRef="c-1032" id="f-3172">P24M</jnj:DiscontinuedOperationsTransitionServiceAgreementTerm>
    <jnj:DiscontinuedOperationTransitionManufacturingAgreementTerm contextRef="c-1033" id="f-3173">P3M</jnj:DiscontinuedOperationTransitionManufacturingAgreementTerm>
    <jnj:DiscontinuedOperationTransitionManufacturingAgreementTerm contextRef="c-1034" id="f-3174">P5Y</jnj:DiscontinuedOperationTransitionManufacturingAgreementTerm>
    <jnj:DiscontinuedOperationsSeparationCostsIncurred contextRef="c-1" decimals="-6" id="f-3175" unitRef="usd">145000000</jnj:DiscontinuedOperationsSeparationCostsIncurred>
    <jnj:DiscontinuedOperationsSeparationCostsIncurred contextRef="c-12" decimals="-6" id="f-3176" unitRef="usd">986000000</jnj:DiscontinuedOperationsSeparationCostsIncurred>
    <jnj:DiscontinuedOperationsSeparationCostsIncurred contextRef="c-405" decimals="-6" id="f-3177" unitRef="usd">1089000000</jnj:DiscontinuedOperationsSeparationCostsIncurred>
    <jnj:DiscontinuedOperationIncrementalTaxCost contextRef="c-13" decimals="-8" id="f-3178" unitRef="usd">500000000</jnj:DiscontinuedOperationIncrementalTaxCost>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="c-1" id="f-3179">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;Details of Net Earnings from Discontinued Operations, net of taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Sales to customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;$10,036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;14,953&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4,369&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;6,494&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;5,667&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;8,459&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Selling, marketing and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;3,085&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;4,519&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;258&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;468&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest expense, net of portion capitalized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;199&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,092&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;1,060&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(Gain) on separation of Kenvue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;(20,984)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Restructuring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;46&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Earnings from Discontinued Operations Before Provision for Taxes on Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;22,134&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;2,366&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Provision for taxes on income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;307&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;795&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net earnings from Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;$21,827&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"&gt;1,571&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt"&gt;The Company ceased consolidating the results of the Consumer Health business on August 23, 2023, the date of the exchange offer, but continued to reflect any separation costs incurred as part of discontinued operations through the end of the fiscal fourth quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"&gt;The following table presents depreciation, amortization and capital expenditures of the discontinued operations related to&#160;Kenvue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.173%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation and Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$383&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;641&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$162&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;303&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="c-12" decimals="-6" id="f-3180" unitRef="usd">10036000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="c-13" decimals="-6" id="f-3181" unitRef="usd">14953000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="c-12" decimals="-6" id="f-3182" unitRef="usd">4369000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="c-13" decimals="-6" id="f-3183" unitRef="usd">6494000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss contextRef="c-12" decimals="-6" id="f-3184" unitRef="usd">5667000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss contextRef="c-13" decimals="-6" id="f-3185" unitRef="usd">8459000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense contextRef="c-12" decimals="-6" id="f-3186" unitRef="usd">3085000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense contextRef="c-13" decimals="-6" id="f-3187" unitRef="usd">4519000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <jnj:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense contextRef="c-12" decimals="-6" id="f-3188" unitRef="usd">258000000</jnj:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense>
    <jnj:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense contextRef="c-13" decimals="-6" id="f-3189" unitRef="usd">468000000</jnj:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome contextRef="c-12" decimals="-6" id="f-3190" unitRef="usd">117000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome contextRef="c-13" decimals="-6" id="f-3191" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense contextRef="c-12" decimals="-6" id="f-3192" unitRef="usd">199000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense contextRef="c-13" decimals="-6" id="f-3193" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <jnj:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet contextRef="c-12" decimals="-6" id="f-3194" unitRef="usd">-1092000000</jnj:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet>
    <jnj:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet contextRef="c-13" decimals="-6" id="f-3195" unitRef="usd">-1060000000</jnj:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax contextRef="c-12" decimals="-6" id="f-3196" unitRef="usd">20984000000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax contextRef="c-13" decimals="-6" id="f-3197" unitRef="usd">0</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <jnj:DisposalGroupIncludingDiscontinuedOperationRestructuringExpense contextRef="c-12" decimals="-6" id="f-3198" unitRef="usd">0</jnj:DisposalGroupIncludingDiscontinuedOperationRestructuringExpense>
    <jnj:DisposalGroupIncludingDiscontinuedOperationRestructuringExpense contextRef="c-13" decimals="-6" id="f-3199" unitRef="usd">46000000</jnj:DisposalGroupIncludingDiscontinuedOperationRestructuringExpense>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax contextRef="c-12" decimals="-6" id="f-3200" unitRef="usd">22134000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax contextRef="c-13" decimals="-6" id="f-3201" unitRef="usd">2366000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation contextRef="c-12" decimals="-6" id="f-3202" unitRef="usd">307000000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation contextRef="c-13" decimals="-6" id="f-3203" unitRef="usd">795000000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest contextRef="c-12" decimals="-6" id="f-3204" unitRef="usd">21827000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest contextRef="c-13" decimals="-6" id="f-3205" unitRef="usd">1571000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization contextRef="c-12" decimals="-6" id="f-3206" unitRef="usd">383000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization contextRef="c-13" decimals="-6" id="f-3207" unitRef="usd">641000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <us-gaap:CapitalExpenditureDiscontinuedOperations contextRef="c-12" decimals="-6" id="f-3208" unitRef="usd">162000000</us-gaap:CapitalExpenditureDiscontinuedOperations>
    <us-gaap:CapitalExpenditureDiscontinuedOperations contextRef="c-13" decimals="-6" id="f-3209" unitRef="usd">303000000</us-gaap:CapitalExpenditureDiscontinuedOperations>
    <dei:AuditorName contextRef="c-1" id="f-3210">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-3211">Florham Park, New Jersey</dei:AuditorLocation>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1035" id="f-3212">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-1035" id="f-3213">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1035" id="f-3214">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-1035" id="f-3215">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-3216">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
